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Preface
The third edition of Current Diagnosis & Treatment: Critical Care is designed to serve as a single-source reference for the adult
critical care practitioner. The diversity of illnesses encountered in the critical care population necessitates a well-rounded and
thorough knowledge of the manifestations and mechanisms of disease. In addition, unique to the discipline of critical care is
the integration of an extensive body of medical knowledge that crosses traditional specialty boundaries. This approach is
readily apparent to intensivists, whose primary background may be in internal medicine or one of its subspecialties, surgery,
or anesthesiology. Thus a central feature of this book is a unified and integrated approach to the problems encountered in
critical care practice. Like other books with the Lange imprint, this book emphasizes recall of major diagnostic features,
concise descriptions of disease processes, and practical management strategies based on often recently acquired evidence.
INTENDED AUDIENCE
Planned by two internists and a surgeon to meet the need for a concise but thorough source of information, Current Diagnosis
& Treatment: Critical Care is intended to facilitate both teaching and practice of critical care. Students will find its consid-
eration of basic science and clinical application useful during clerkships on medicine, surgery, and intensive care unit electives.
House officers will appreciate its descriptions of disease processes and organized approach to diagnosis and treatment. Fellows
and those preparing for critical care specialty examinations will find those sections outside their primary disciplines particu-
larly useful. Clinicians will recognize this succinct reference on critical care as a valuable asset in their daily practice.
Because this book is intended as a reference on various aspects of adult critical care, it does not contain chapters on
pediatric or neonatal critical care. These areas are highly specialized and require entire monographs of their own. Further, we
have not included detailed information on performing bedside procedures such as central venous catheterization or arterial line
insertion. Well-illustrated pocket manuals are available for readers who require basic technical information. Finally, we have
chosen not to include a chapter on nursing or administrative topics, details of which can be found in other works.
ORGANIZATION
Current Diagnosis & Treatment: Critical Care is conceptually organized into three major sections: (1) fundamentals of crit-
ical care applicable to all patients, (2) topics related primarily to critical care of patients with medical diseases, and (3) essentials of
care for patients requiring care for surgical problems. Early chapters provide information about the general physiology and
pathophysiology of critical illness. The later chapters discuss pathophysiology using an organ system– or disease-specific
approach. Where appropriate, we have placed the medical and surgical chapters in succession to facilitate access to information.
OUTSTANDING FEATURES
 Concise, readable format, providing efficient use in a variety of clinical and academic settings
 Edited by both surgical and medical intensivists, with contributors from multiple subspecialties
 Illustrations chosen to clarify basic and clinical concepts
 Careful evaluation of new diagnostic procedures and their usefulness in specific diagnostic problems
 Updated information on the management of severe sepsis and septic shock, including hydrocortisone therapy
 New information on the serotonin syndrome
 Carefully selected key references in Index Medicus format, providing all information necessary to allow electronic retrieval
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Philosophy & Principles
of Critical Care
Darryl Y. Sue, MD
Frederic S. Bongard, MD
Critical care is unique among the specialties of medicine.
While other specialties narrow the focus of interest to a sin-
gle body system or a particular therapy, critical care is
directed toward patients with a wide spectrum of illnesses.
These have the common denominators of marked exacerba-
tion of an existing disease, severe acute new problems, or
severe complications from disease or treatment. The range
of illnesses seen in a critically ill population necessitates
well-rounded and thorough knowledge of the manifesta-
tions and mechanisms of disease. Assessing the severity of
the patient’s problem demands a simultaneously global and
focused approach, depends on accumulation of accurate
data, and requires integration of these data. Although prac-
titioners of critical care medicine—sometimes called
intensivists—are often specialists in pulmonary medicine,
cardiology, nephrology, anesthesiology, surgery, or critical
care, the ability to provide critical care depends on the basic
principles of internal medicine and surgery. Critical care
might be considered not so much a specialty as a “philoso-
phy” of patient care.
The most important development in recent years has
been an explosion of evidence-based critical care medicine
studies. For the first time, we have evidence for many of the
things that we do for patients in the ICU. Examples include
low tidal volume strategies for acute respiratory distress
syndrome, tight glycemic control, prevention of ventilator-
associated pneumonia, and use of corticosteroids in septic
shock (Table 1–1). The resulting improvement in outcome
is gratifying, but even more surprising is how often evi-
dence contradicts long-held beliefs and assumptions.
Probably the best example is recent studies that conclude
that the routine use of pulmonary artery catheters in ICU
patients adds little or nothing to management. Much more
needs to be studied, of course, to address other unresolved
issues and controversies.
Do intensivists make a difference in patient outcome?
Several studies have shown that management of patients by
full-time intensivists does improve patient survival. In fact,
several national organizations recommend strongly that full-
time intensivists provide patient care in all ICUs. It can be
argued, however, that local physician staffing practices;
interactions among primary care clinicians, subspecial-
ists, and intensivists; patient factors; and nursing and
ancillary support play large roles in determining out-
comes. In addition, recent studies show that patients do
better if an ICU uses protocols and guidelines for routine
care, controls nosocomial infections, and provides feed-
back to practitioners.
The general principles of critical care are presented in this
chapter, as well as some guidelines for those who are respon-
sible for leadership of ICUs.
GENERAL PRINCIPLES OF CRITICAL CARE
 Early Identification of Problems
Because critically ill patients are at high risk for developing
complications, the ICU practitioner must remain alert to
early manifestations of organ system dysfunction, complica-
tions of therapy, potential drug interactions, and other pre-
monitory data (Table 1–2). Patients with life-threatening
illness in the ICU commonly develop failure of other
organs because of hemodynamic compromise, side effects
of therapy, and decreased organ function reserve, espe-
cially those who are elderly or chronically debilitated. For
example, positive-pressure mechanical ventilation is asso-
ciated with decreased perfusion of organs. Many valuable
drugs are nephro- or hepatotoxic, especially in the face of
preexisting renal or hepatic insufficiency. Older patients
are more prone to drug toxicity, and polypharmacy pres-
ents a higher likelihood of adverse drug interactions. Just as
patients with acute coronary syndrome and stroke benefit
from early intervention, an exciting finding is the evidence
that the first 6 hours of management of septic shock are very
important.
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Identifying and acting on new problems and complica-
tions in the ICU demands frequent and regular review of all
information available, including changes in symptoms, phys-
ical findings, and laboratory data and information from mon-
itors. In some facilities, early identification and treatment are
provided by rapid-response teams. Once notified that a patient
outside the ICU may be deteriorating, the team is mobilized
to provide a mini-ICU environment in which critical care can
be delivered early, even before the patient is actually
transferred.
 Effective Use of the Problem-Oriented
Medical Record
The special importance of finding, tracking, and being aware
of ICU issues demands an effective problem-oriented med-
ical record. In order to define and follow problems effec-
tively, each problem should be reviewed regularly and
characterized at its current state of understanding. For exam-
ple, if the general problem of “renal failure” subsequently has
been determined to be due to aminoglycoside toxicity, it
should be described in that way in an updated problem list.
However, even the satisfaction of identifying a cause of the
renal failure may be short-lived. The same patient subse-
quently may develop other related or unrelated renal prob-
lems, thereby forcing reassessment.
In our opinion, ICU problems must not be restricted to
“diagnoses.” We list intravascular catheters and the date they
Table 1–1. Recent developments in evidence-based
critical care medicine.
Table 1–2. Recommendations for routine patient care in
the ICU.
• Assess current status, interval history, and examination.
• Review vital signs for interval period (since last review).
• Review medication record, including continuous infusions:
Duration and dose
Changes in dose or frequency based on changes in renal, hepatic,
or other pharmacokinetic function
Changes in route of administration
Potential drug interactions
• Correlate changes in vital signs with medication administration and
other changes by use of chronologic charting.
• Integrate nursing, respiratory therapists, patient, family, and other
observations.
• Review, if indicated:
Respiratory therapy flow chart
Hemodynamics records
Laboratory flowsheets
Other continuous monitoring
• Review all problems, including adding, updating, consolidating, or
removing problems as indicated.
• Periodically, review supportive care:
Intravenous fluids
Nutritional status and support
Prophylactic treatment and support
Duration of catheters and other invasive devices
• Review and contrast risks and benefits of intensive care.
• Corticosteroids improve outcome in exacerbations of chronic obstruc-
tive respiratory disease (COPD).
• A low tidal volume strategy decreases mortality in acute respiratory
distress syndrome (ARDS).
• A lower hemoglobin decision point for transfusion of red blood cells
in many ICU patients results in similar outcome and greatly reduced
use of blood products.
• Tight glycemic control in postoperative surgical patients, most of
whom did not have diabetes, resulted in less mortality and fewer
complications.
• Elevating the head of the bed to 30–45 degrees in ICU patients
reduces the incidence of nosocomial pneumonia.
• Daily withholding of sedation in the ICU decreases the number of
ICU days and results in fewer evaluations for altered level of
consciousness.
• Daily spontaneous breathing trials lead to faster weaning from
mechanical ventilation and shorter duration of ICU stay.
• Low-dose (physiologic) vasopressin may reduce the need for pres-
sors in septic shock.
• Fluid resuscitation using colloid-containing solutions is not more ben-
eficial than crystalloid fluids.
• Low-dose dopamine does not improve renal function or diuresis and
does not protect against renal dysfunction.
• Acetylcysteine or sodium bicarbonate protect against radiocontrast
material–induced acute renal failure.
• Patients with bleeding esophageal varices have a higher rebleeding
risk if they have infection, especially spontaneous bacterial peritonitis.
• Noninvasive positive-pressure ventilation decreases the need for
intubation in patients with COPD exacerbation.
• Noninvasive positive-pressure ventilation is associated with fewer
respiratory infections than conventional ventilation.
• Early goal-directed therapy for sepsis (specific targets for central
venous pressure, hemoglobin, and central venous oxygen content
during the first 6 hours of care) decreases mortality.
PHILOSOPHY & PRINCIPLES OF CRITICAL CARE 3
were inserted on the problem list. This helps us to remember
to consider the catheter as a site of infection if the patient
has a fever. Other “nondiagnoses” on our problem list
include nutritional support, prevention of deep vein
thrombosis and decubitus ulcers, drug allergies, patient
positioning, and prevention of stress ulcers. It may be use-
ful to include nonmedical issues as well so that they can be
discussed routinely. Examples are psychosocial difficul-
ties, unresolved end-of-life decisions, and other questions
about patient comfort. Finally, we share the patient’s
problem-oriented record with nonphysicians caring for the
patient, a process that enhances communication, simplifies
interactions between staff members, and furthers the goals
of patient care.
 Monitoring & Data Display
A tremendous amount of patient data is acquired in the
ICU. Although ICU monitoring is often thought of as
electrocardiography, blood pressure measurements, and
pulse oximetry, ICU data include serial plasma glucose
and electrolyte determinations, arterial blood gas deter-
minations, documentation of ventilator settings and
parameters, and body temperature determinations. Taking
a daily weight is invaluable in determining the net fluid
balance of a patient.
Flowcharts of laboratory data and mechanical ventilator
activity, 24-hour vital signs, graphs of hemodynamic data, and
lists of medications are indispensable tools for good patient
care, and efforts should be made to find the most effective and
efficient ways of displaying such information in the ICU.
Methods that integrate the records of physicians, nurses, respi-
ratory therapists, and others are particularly useful.
Computer-assisted data collection and display systems
are found increasingly in ICUs. Some of these systems
import data directly from bedside monitors, mechanical
ventilators, intravenous infusion pumps, fluid collection
devices, clinical laboratory instruments, and other devices.
ICU practitioners may enter progress notes, medications
administered, and patient observations. Advantages of these
systems include decreased time for data collection and the
ability to display data in a variety of formats, including flow-
charts, graphs, and problem-oriented records. Such data can
be sent to remote sites for consultation, if necessary.
Computerized access to data facilitates research and quality
assurance studies, including the use of a variety of prognos-
tic indicators, severity scores, and ICU decision-making
tools. Computerized information systems have the potential
for improving patient care in the ICU, and their benefit to
patient outcome continues to be studied.
The next step is to integrate ICU data with treatment,
directly and indirectly. One excellent example is glycemic
control so that up-to-date blood glucose measurements
will be linked closely to insulin protocols—at first with
the nurse and physician “in the loop” but potentially with
real-time feedback and automated adjustment of insulin
infusions.
 Supportive & Preventive Care
Many studies have pointed out the high prevalence of gas-
trointestinal hemorrhage, deep venous thrombosis, decu-
bitus ulcers, inadequate nutritional support, nosocomial
and ventilator-associated pneumonias, urinary tract infec-
tions, psychological problems, sleep disorders, and other
untoward effects of critical care. Efforts have been made to
prevent, treat, or otherwise identify the risks for these
complications. As outlined in subsequent chapters, effec-
tive prevention is available for some of these risks (Table 1–3);
for other complications, early identification and aggres-
sive intervention may be of value. For example, aggressive
nutritional support for critically ill patients is often indi-
cated both because of the presence of chronic illness and
malnutrition and because of the rapid depletion of
nutritional reserves in the presence of severe illness.
Nutritional support, prevention of upper gastrointestinal
bleeding and deep venous thrombosis, skin care, and other
supportive therapy should be included on the ICU
patient’s problem list. To these, we have added glycemic
control because of recent data indicating reduced morbid-
ity and mortality in medical and surgical patients whose
plasma glucose concentration is maintained in a relatively
narrow range.
Because of expense and questions of effectiveness and
safety, studies of preventive treatment of ICU patients con-
tinue. For example, a multicenter study reported that clini-
cally important gastrointestinal bleeding in critically ill
patients was seen most often only in those with respiratory
failure or coagulopathy (3.7% for one or both factors).
Otherwise, the risk for significant bleeding was only 0.1%.
The authors suggested that prophylaxis against stress ulcer
could be withheld safely from critically ill patients unless
they had one of these two risk factors. On the other hand,
about half the patients in this study were post–cardiac sur-
gery patients, and the majority of patients in many ICUs have
one of the identified risk factors. Thus there may not be suf-
ficient compelling evidence to discontinue the practice of
providing routine prophylaxis for gastrointestinal bleeding
in all ICU patients.
Other routine practices have been challenged. For exam-
ple, several studies show that routine transfusion of red
blood cells in ICU patients who reached an arbitrary hemo-
globin level did not change outcome when compared with
allowing hemoglobin to fall to a lower value. Further studies
are needed to define the role of other preventive strategies.
Important questions include differences in the need for
glycemic control, critical differences in the intensity and type
of therapy needed to prevent thrombosis, the optimal hemo-
globin for patients with myocardial infarction, and the bene-
fit of tailored nutritional support.
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(continued )
Things To Think About Reminders 
General ICU Care
1. Nosocomial infections, especially line- and catheter-related.
2. Stress gastritis.
3. Deep venous thrombosis and pulmonary embolism.
4. Exacerbation of malnourished state.
5. Decubitus ulcers.
6. Psychosocial needs and adjustments.
7. Toxicity of drugs (renal, pulmonary, hepatic, CNS).
8. Development of antibiotic-resistant organisms.
9. Complications of diagnostic tests.
10. Correct placement of catheters and tubes.
11. Need for vitamins (thiamine, C, K).
12. Tuberculosis, pericardial disease, adrenal insufficiency, fungal sepsis,
rule out myocardial infarction, pneumothorax, volume overload or
volume depletion, decreased renal function with normal serum crea-
tinine, errors in drug administration or charting, pulmonary vascular
disease, HIV-related disease.
1. Discontinue infected or possibly infected lines.
2. Need for H2 blockers, antacids, or sucralfate.
3. Provide enteral or parenteral nutrition.
4. Change antibiotics?
5. Chest x-ray for line placement.
6. Review known drug allergies (including contrast agents).
7. Check for drug dosage adjustments (new liver failure or renal failure).
8. Need for deep venous thrombosis prophylaxis?
9. Pain medication and sedation.
10. Weigh patient.
11. Give medications orally, if possible.
12. Does patient really need an arterial catheter?
13. Give thiamine early.
Nurition
1. Set goals for appropriate nutrition support.
2. Avoid or minimize catabolic state.
3. Acquired vitamin K deficiency while in ICU.
4. Avoidance of excessive fluid intake.
5. Diarrhea (lactose intolerance, low serum protein, hyperosmolarity,
drug-induced, infectious).
6. Minimize and anticipate hyperglycemia during parenteral nutritional
support.
7. Adjustment of rate or formula in patients with renal failure or liver
failure.
8. Early complications of refeeding.
9. Acute vitamin insufficiency.
1. Calculate estimated basic caloric and protein needs. Use 30 kcal/kg
and 1.5 g protein/kg for starting amount.
2. Regular food preferred over enteral feeding; enteral feeding preferred
over parenteral in most patients.
3. Increased caloric and protein requirements if febrile, infected, agitated,
any inflammatory process ongoing, some drugs.
4. Adjust protein if renal or liver failure is present. Adjust again if dialysis
is used.
5. Measure serum albumin as primary marker of nutritional status.
6. Give vitamin K, especially if malnourished and receiving antibiotics.
7. Consider volume restriction formulas (both enteral and parenteral).
8. Give phosphate early during refeeding.
9. Control hyperglycemia (glucose <110–120 mg/dL).
Acute Renal Failure
1. Volume depletion, hypoperfusion, low cardiac output, shock.
2. Nephrotoxic drugs.
3. Obstruction of urine outflow.
4. Interstitial nephritis.
5. Manifestation of systemic disease, multiorgan system failure.
6. Degree of preexisting chronic renal failure.
1. Measure urine Na+, Cl–, creatinine, and osmolality.
2. Volume challenge, if indicated.
3. Discontinue nephrotoxic drugs if possible.
4. Adjust all renally excreted drugs.
5. Renal medicine consultation for dialysis, other management.
6. Renal ultrasound if indicated for obstruction.
7. Check catheter and replace if indicated.
8. Stop potassium supplementation if necessary.
9. Adjust diet (Na+, protein, etc.).
10. If dialytic therapy is begun, adjust drugs if necessary.
11. Weigh patient daily.
Table 1–3. Things to think about and reminders for ICU patient care.
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Things To Think About Reminders 
Acute Respiratory Failure, COPD
1. Adequacy of oxygenation.
2. Exacerbation due to infection, malnutrition, congestive heart failure.
3. Airway secretions.
4. Other medical problems (coexisting heart failure).
5. Hypotension and low cardiac output response to positive-pressure
ventilation.
6. Hyponatremia, SIADH.
7. Severe pulmonary hypertension.
8. Sleep deprivation.
9. Coexisting metabolic alkalosis.
1. Should patient be intubated or mechanically ventilated?
Noninvasive mechanical ventilation?
2. Bronchodilators.
3. Consider corticosteroids, ipratropium.
4. Sufficient supplemental oxygen.
5. Antibiotic coverage for common bacterial causes of exacerbations.
Evaluate for pneumonia as well as acute bronchitis.
6. Early nutrition support.
7. Check theophylline level, if indicated.
8. Ventilator management: low tidal volume, long expiratory time, high
inspiratory flow, watch for auto-PEEP. 
9. Think about weaning early.
Acute Respiratory Failure, ARDS
1. Sepsis as cause, from pulmonary or nonpulmonary site (abdominal,
urinary).
2. Possible aspiration of gastric contents.
3. Fluid overload or contribution form congestive heart failure.
4. Anticipate potential multiorgan system failure.
5. Assess the risks of oxygen toxicity versus complications of PEEP.
6. Consider the complications of high airway pressure or large tidal vol-
ume in selection of type of mechanical ventilatory support.
7. Low serum albumin (contribution from hypo-oncotic pulmonary
edema).
1. Early therapeutic goal of Fi02 <0.50 and lowest PEEP (<5–10 cm H2O),
resulting in acceptable O2 delivery.
2. Directed (if possible) or broad-spectrum antibiotics.
3. Evaluate for soft tissue or intra-abdominal infection source.
4. Diuretics, if necessary. Assess need for fluid intake to support O2 delivery.
5. Evaluate intake and output daily; weigh patient daily.
6. Use low tidal volume, ≤6 ml/kg to keep plateau pressure <30 cm H2O.
7. Follow renal function, electrolytes, liver function, mental status to
assess organ system function.
Asthma
1. Airway inflammation is the primary cause of status asthmaticus.
2. Auto-PEEP or hyperinflation dominates gas exchange when using
mechanical ventilation.
3. Potentially increased complication rate of mechanical ventilation.
1 High-dose corticosteroids are primary treatment.
2. Aggressive inhaled aerosolized β2 agonists (hourly, if needed).
3. Early intubation if necessary.
4. Adequate oxygen to inhibit respiratory drive.
5. Use low tidal volume, high inspiratory flow, low respiratory frequency
with mechanical ventilation to avoid barotrauma and auto-PEEP.
6. May need to sedate or paralyze to reduce hyperinflation.
7. Measure peak flow or FEV, as a guide to therapeutic response.
Diabetic Ketoacidosis
1. Evaluate degree of volume depletion and relationship of water to
solute balance (hyperosmolar component).
2. Avoid excessive volume replacement.
3. Look for a trigger for diabetic ketoacidosis (infection, poor compliance,
mucormycosis, other).
4. Avoid hypoglycemia during correction phase.
5. Identify features of hyperosmolar complications.
6. Calculate water and volume deficits.
7. Evaluate presence of coexisting acid-base disturbances (lactic acidosis,
metabolic alkalosis).
8. Avoid hypokalemia and hypophosphatemia during correction phase.
1. Give adequate insulin to lower glucose at appropriate rate (increase
aggressively if no response). Use continuous insulin infusion.
2. Give adequate volume replacement (normal saline) and water replace-
ment, if needed (half normal saline, glucose in water).
3. Follow glucose and electrolytes frequently.
4. Consider stopping insulin infusion when glucose is about 250 mg/dL
and HCO3
– is >18 meq/L.
5. Avoid hypoglycemia; if you continue insulin drip with glucose <250mg/dL,
then give D5W. If glucose continues to fall, lower insulin drip rate.
6. Monitor serum potassium, phosphorus.
7. Calculate water deficit, if any.
8. Urine osmolality, glucose, etc.
9. Check sinuses, nose, mouth, soft tissue, urine, chest x-ray, abdomen for
infection.
(continued )
Table 1–3. Things to think about and reminders for ICU patient care. (continued)
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Table 1–3. Things to think about and reminders for ICU patient care. (continued)
(continued )
Things To Think About Reminders
Hyponatremia
1. Consider volume depletion (nonosmolar stimulus for ADH secretion).
2. Consider edematous state with hyponatremia (cirrhosis, nephrotic
syndrome, congestive heart failure).
3. SIADH with nonsuppressed ADH.
4. Drugs (thiazide diuretics).
5. Adrenal insuffieiency, hypothyroidism.
1. Measure urine Na+, Cl–, creatinine, and osmolality.
2. Calculate or measure serum osmolality.
3. Volume depletion? Give volume challenge?
4. Ask if patient is thirsty (may be volume-depleted).
5. Review medication list.
6. Primary treatment may be water restriction.
7. Consider need for hypertonic saline (carefully calculate amount)
and furosemide.
8. Other treatment (demeclocycline).
Hypernatremia
1. Diabetes insipidus (CNS or renal disease, lithium?) 
2. Diabetes mellitus.
3. Has patient been water-depleted for a long-time?
4. Concomitant volume depletion?
5. Is the urine continuing to be poorly concentrated?
1. Calculate water deficit and ongoing water loss.
2. Replace with hypotonic fluids (0.45% NaCl, D5W) at calculated rate.
3. Replace volume deficit, if any, with normal saline.
4. Measure urine osmolality, Na+, Cl–, creatinine.
5. Does patient need desmopressin acetate (central diabetes insipidus)?
Hypotension
1. Volume depletion.
2. Sepsis. (Consider potential sources; may need to treat empirically.)
3. Cardiogenic. (Any reason to suspect?)
4. Drugs or medications (prescribed or not).
5. Adrenal insufficiency.
6. Pneumothorax, pericardial effusion or tamponade, fungal sepsis,
tricyclic overdose, amyloidosis.
1. Volume challenge; decide how and what to give and how to monitor.
2. If volume-depleted, correct cause.
3. Gram-positive or gram-negative sepsis (or candidemia) may also cause
hypotension and shock.
4. Give naloxone if clinically indicated.
5. Echocardiogram (left ventricular and right ventricular function, pericardial
disease, acute valvular disease) may be helpful.
6. Does the patient need a Swan-Ganz catheter?
7. Cosyntropin stimulation test or empiric corticosteroids.
Swan-Ganz Catheters
1. Site of placement (safety, risk, experience of operator).
2. Coagulation times, platelet count, bleeding time, other
bleeding risks.
3. Document in medical record.
4. Estimate need for monitoring therapy.
5. Predict whether interpretation of data may be difficult (mechanical
ventilation, valvular insufficiency, pulmonary hypertension).
1. Check for contraindications.
2. Write a procedure note.
3. Make measurements and document immediately after placement.
4. Obtain chest x-ray afterward.
5. Level transducer with patient before making measurement; eliminate
bubbles in lines or transducer.
6. Discontinue as soon as possible.
7. Use Fick calculated cardiac output to confirm thermodilution 
measurements.
8. Send mixed venous blood for O2 saturation. 
Upper Gastrointestinal Bleeding
1. Rapid stabilization of patient (hemoglobin and hemodynamics).
2. Identification of bleeding site.
3. Does patient have a nonupper GI bleeding site?
4. Consider need for early operation.
5. Review for bleeding, coagulation problems.
6. Determine when “excessive” amounts of blood products given.
7. Do antacids, H2 blockers, PPIs play a role?
8. Reversible causes or contributing causes.
1. Monitor vital signs at frequent intervals.
2. Monitor hematocrit at frequent intervals.
3. Choose hematocrit to maintain.
4. Consider need and timing of endoscopy.
5. Consult surgery.
6. Patients with abnormally long coagulation time may benefit from fresh-
frozen plasma (calculate volume of replacement needed).
7. Platelet transfusions needed?
8. Desmopressin acetate (renal failure).
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 Attention to Psychosocial
& Other Needs of the Patient
Psychosocial needs of the patient must be a major considera-
tion in the ICU. The psychological consequences of critical
illness and its treatment have a profound impact on patient
outcome. Leading factors include the patient’s lack of control
over the local environment, severe disruption of the sleep-
wake cycle, inability to communicate easily and quickly with
critical care providers, and pain and other types of physical
discomfort. Inability to communicate with family members,
as well as concern about employment status, activities of daily
living, finances, and other matters, further inflates the emo-
tional costs of being seriously ill. The intensivist and other
staff members must pay close attention to these problems
and issues and consider psychological problems in the differ-
ential diagnosis of any patient’s altered mental status.
Adequate yet appropriate sedation and analgesia are manda-
tory to preserve the balance of comfort with patient assess-
ment and interaction needs.
There is increased awareness of the potential harm to
patients and caregivers from the ICU environment. The
noise level is high (reported to exceed 60–84 dB, where a
busy office might have 70 dB and a pneumatic drill at 50 feet
might be as loud as 80 dB), notably from mechanical venti-
lators, conversations, and telephones but especially from
audio alarms on ICU equipment. One study found that care-
givers were unable to discern and identify alarms accurately,
including alarms that indicated critical patient or equipment
conditions.
Sleep disruption deserves much more attention. Very dis-
ruptive sleep architecture has been identified in patients in
the ICU. Frequent checking of vital signs and phlebotomy
were most disruptive to patients, and environmental factors
were less of a problem to patients surveyed. Most recently, in
addition, the impact of duty hours, sleep, and time off on the
cognitive and patient care ability of house officers is being
studied and reported.
 Understand the Limits of Critical Care
All physicians involved with critical care must be familiar
with the limitations of such care. Interestingly, physicians
and other care providers may have to be reminded that
Things To Think About Reminders
Fever, Recurrent or Persistent
1. New, unidentified source of infection.
2. Lack of response of identified or presumed source of infection.
3. Opportunistic organism (drug-resistant, fungus, virus, parasite, 
acid-fast bacillus).
4. Drug fever.
5. Systemic noninfectious disease.
6. Incorrect empiric antibiotics.
7. Slow resolution of fever (deep-seated infection: endocarditis,
osteomyelitis).
8. Infected catheter site or foreign body (medical appliance).
9. Consider infections of sinuses, CNS, decubitus ulcers; septic arthritis.
1. Examine catheter sites (old and new), surgical wounds, sinuses, back
and buttocks, large joints, pelvic organs, catheters and tubes, skin
rashes, hands and feet.
2. Consider pleural, pericardial, subphrenic spaces; perinephric infection;
spleen, prostate, intra-abdominal abscess; bowel infarction or necrosis.
3. Abscess in area of previous known infection.
4. Review prior culture results and antibiotic use.
5. Consider change in empiric antibiotics.
6. Culture usual locations plus any specific areas.
7. Discontinue or change catheters.
8. Consider candidemia or disseminated candidiasis.
9. Discontinue antibiotics?
10. Abdominal ultrasound, CT scan, gallium, leukocyte scans.
Pancytopenia (After Chemotherapy)
1. Fever, presumed infection, response to antimicrobials.
2. Thrombocytopenia and spontaneous bleeding.
3. Drug fever.
4. Transfusion reactions.
5. Staphylococcus, candida, other opportunistic infections.
6. Infection sites in patient without granulocytes may have induration,
erythema, without fluctuance.
7. Pulmonary infiltrates and opportunistic infection.
1. Fever workup; see above.
2. Special sites: soft tissues, perirectal abscess, urine fungal cultures,
lungs.
3. Bronchoscopy with bronchoalveolar lavage.
4. Empiric antibiotics, continue until afebrile, doing well, granulocytes
>1000/μL.
5. Empiric or directed vancomycin, antifungal drugs, antiviral drugs, antitu-
berculous drugs.
6. Check intravascular catheters, bladder, catheter.
7. Platelet transfusions, prophylaxis for spontaneous bleeding (or if
already bleeding).
Table 1–3. Things to think about and reminders for ICU patient care. (continued)
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critical illness is and always will be associated with high
morbidity and mortality rates. The outcome of some dis-
ease processes simply cannot be altered despite the avail-
ability of modern comprehensive treatment. On the basis
of medical evidence and after consultation with the
patient and family, some patients will continue to receive
aggressive treatment; for others, withdrawal or withhold-
ing of ICU care may be the most appropriate and correct
decision.
It is not surprising that critical care physicians, together
with medical ethicists, have played a major role in devel-
oping a body of ethical constructs concerned with such
issues as forgoing of care, determination of brain death,
and withholding feeding and hydration. The critical care
physician must be familiar with ethical and legal concepts
of patient autonomy, informed consent and refusal, appli-
cation of advanced directives for health care, surrogate
decision makers, and the legal consequences of decisions
made in this context. The cost of care in the ICU will be
scrutinized increasingly because of economic constraints
on health care.
There is evidence that care in the ICU improves outcome
in only a small subgroup of patients admitted. Some patients
may be so critically ill with a combination of chronic and
acute disorders that no intervention will reverse or even ame-
liorate the course of disease. Others may be admitted with
very mild illness, and admission to the ICU rather than a
non-ICU area does not improve the outcome. On the other
hand, two other subgroups emerge from this analysis of ICU
patients. First, a small subgroup with a predictably poor out-
come may have an unexpectedly successful result from ICU
care. A patient with cardiogenic shock with a predicted mor-
tality rate of over 90% who survives because of aggressive
management and reversal of myocardial dysfunction would
fall into this group. The other small group consists of
patients admitted for monitoring purposes only or for minor
therapeutic interventions who develop severe complications
of treatment. In these patients with predicted favorable out-
comes, unanticipated adverse effects of care may result in
severe morbidity or death.
Areas of critical care outcome research have, for example,
focused on the elderly, those with hematologic and other
malignancies, patients with complications of AIDS, and
those with very poor lung function from chronic obstructive
pulmonary disease, interstitial lung disease, acute respiratory
distress syndrome, multiorgan failure, or pancreatitis. Much
more needs to be learned about prognosis and factors that
determine outcome, but it is essential that data be used
appropriately and not applied indiscriminately for individual
patient decisions.
Alternatives to current care should be reviewed periodi-
cally and considered in every patient in the ICU. Some
patients may no longer require the type of care available in
the ICU; transfer to a lower level of care may benefit the
patient medically and emotionally and may decrease the
risk of complications and the costs of treatment. Admission
criteria should be reviewed regularly by the medical staff.
Similarly, ongoing resource utilization efforts should be
directed at determining which types of patients are best
served by continued ICU care.
ROLE OF THE MEDICAL DIRECTOR
OF THE INTENSIVE CARE UNIT
The medical director of the ICU has administrative and
regulatory responsibilities for this patient care area. As
medical director, leadership is vital in establishing policies
and procedures for patient care, maintaining communica-
tion across health care disciplines, developing and ensuring
quality care, and helping to provide education in a rapidly
and constantly changing medical field. The medical direc-
tor and the ICU staff may choose to coordinate care in a
number of areas.
 Protocols, Practice Guidelines,
& Order Sets
A survey of outcomes from ICUs concluded that established
protocols for management of specific critical illnesses con-
tribute to improved results. The medical director and medical
staff, nursing staff, and other health care practitioners may
choose to develop protocols that define uniformity of care or
ensure that complete orders are written. Some protocols may
be highly detailed, complete, and focused on a single clinical
condition. An example might be a protocol for treatment of
patients with suspected acute myocardial infarction—the
protocol could specify the frequency, timing, and types of car-
diac enzyme or troponin determination and the timing for
ECGs and other diagnostic tests. Certain standardized med-
ications, such as aspirin, heparin, angiotensin-converting
enzyme inhibitors, and beta-adrenergic blockers, might be
included in such a protocol, and the physician could choose
to give these or not depending on the particular clinical situ-
ation. Protocols are used by many ICUs for community-
acquired pneumonia, ventilator-associated pneumonia,
sepsis, ventilator weaning, and other clinical situations.
Another type of protocol can be “driven” by critical care
nurses or respiratory therapists. In these protocols, nurses or
therapists are given orders to assess the effectiveness and side
effects of therapy and are given freedom to adjust therapy
based on these results. A protocol for aerosolized bronchodila-
tor treatment might specify administration of albuterol by
metered-dose inhaler, but the respiratory therapist would
determine the optimal frequency and dose on the basis of how
much improvement in peak flow or FEV1 was obtained and
how much excessive tachycardia was encountered.
The ICU medical director may consider limiting the use
of certain medications based on established protocols. For
example, some antibiotics may be restricted because of cost,
toxicity, or potential for development of microbial resistance.
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Neuromuscular blocking agents may be restricted to use only
by certain qualified personnel because of need for special
expertise in dosing or patient support. Protocols can take
several different forms, and patient care in the ICU may ben-
efit from their development.
Physician practice guidelines are being developed for
many aspects of medical practice. Although some critics of
guidelines argue that these are unnecessarily restrictive and
that elements of medical practice cannot be rigidly defined,
practice guidelines may be useful for diagnosing and treating
patients in the ICU. Guidelines may vary from recommenda-
tions for dose and adjustment of heparin infusion for antico-
agulation to specific minimum standards of care for status
asthmaticus, unstable angina, heart failure, or malignant
hypertension. Practice guidelines will be found commonly in
the ICU of the near future, and ICU directors will be called
on to develop, review, accept, or modify guidelines for indi-
vidual ICUs.
The next step beyond practice guidelines is ICU order
sets. Order sets, either paper or paperless, can streamline
practice guidelines accepted by the ICU staff. Highly recom-
mended orders can be preselected, whereas guidance may be
given for other choices. A major feature of order sets will be
reduction of errors because the order sets include preprinted
medication names, recommended dosages, and potential
drug interactions. Computerized order entry goes beyond
the ICU order set, permitting immediate dosage calculations,
for example, or other real-time recommendations. Although
some have questioned the “one size fits all” nature of order
sets, evidence suggests that there is an increase in the correct
application of evidence-based treatment with implementa-
tion of ICU order sets.
 Quality Assurance
The ICU medical director participates in quality-of-care
evaluation. Quality of care may be assessed by measure-
ment of patient satisfaction, analyzing frequency of deliv-
ery of care, monitoring of complications, duration of
hospitalization, analysis of mortality data, and other ways.
Patient outcome eventually may emerge as the most effec-
tive global determination of the quality of care, but such
measures suffer from the difficulty in stratifying severity in
very complex patients with multiple medical problems. The
development of protocols and programs to measure and
enhance the quality of care is beyond the scope of this pres-
entation. However, the medical and nursing leadership of the
ICU must play key roles in any such projects.
The medical director also plays an important role in
granting privileges to practice in the ICU. Competence in
and experience with medical procedures must be investi-
gated, documented, and maintained for all physicians who
use the service. While this is especially important for invasive
procedures such as placement of pulmonary artery catheters
and endotracheal intubation, consideration also should be
given to developing and granting privileges for mechanical
ventilator management, management of shock, and other
nonprocedural care. Similarly, the skills and knowledge of
nurses, respiratory therapists, and other professionals in the
ICU should be determined, documented, and matched to
their duties. The ICU medical director has the responsibility
to develop standards for those who care for the patients in
that unit.
Effective quality improvement activities go far beyond
simple data collection and reporting. A dedicated group of
health care providers should meet regularly to review the
data, establish trends, and suggest methods for improve-
ment. The importance of “closing the loop” in the quality
improvement process cannot be overstated. Monitoring of
outcomes after instituting change is an important part of this
activity and is mandatory if patient care is to be effectively
and expeditiously improved.
 Infection Control
Nosocomial infections are important problems in the ICU,
and their prevention and management can provide insight
into the effectiveness of protocols and quality assurance
functions. Infection control is particularly important
because of increased antimicrobial resistance of organisms
such as methicillin-resistance Staphylococcus aureus (MRSA),
multidrug-resistant Acinetobacter, vancomycin-resistant
enterococci (VRE), and Clostridium difficile. As described
elsewhere, nosocomial infections are often preventable by
adherence to procedures and policies designed to limit
spread of infection between patients and between ICU staff
and patients. The ICU medical director must take the lead in
establishing infection control protocols, including proce-
dures for aseptic technique for invasive procedures, stan-
dards for universal precautions, duration of invasive catheter
placement, suctioning of endotracheal tubes, appropriate use
of antibiotics, procedures in the event of finding antibiotic-
resistant microorganisms, and the need for isolation of
patients with communicable diseases. Consequently, an
important measure of the quality of care being provided is
the nosocomial infection rate in the ICU, especially intravas-
cular infections secondary to indwelling catheters. The ICU
medical director should work closely with the nursing staff
and hospital epidemiologist in the event of excessive nosoco-
mial infections. Often a breach in procedures can be identi-
fied and corrected. Importantly, it has been demonstrated
that simple measures to prevent infection at the time of
placement of intravenous catheters is highly effective.
 Education & Errors
The ICU medical director is required to provide educational
resources for the staff of the ICU, including critical care
nurses, respiratory therapists, occupational therapists, and
other physicians. This may be in the form of lectures, small
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group discussions, audiovisual presentations, or prepared
handouts or directed readings. An effective strategy is to
focus presentations on problems recently or commonly
encountered; recent experience may help to clarify and
amplify the more didactic portion. Very often in critical care
areas there is a need for personnel to develop skills for using
new equipment such as monitors, catheters, and ventilators.
Appropriate time and feedback should be planned with the
introduction of such equipment before it can be assumed
that it can be used for patient care.
In the teaching hospital, the faculty and attending staff not
only must convey the principles of critical care practice but
also must foster an attitude of rigorous critical review of data,
cooperation between medical and other personnel, and atten-
tion to detail. The new focus on reduction of medical errors
has greatly changed the way critical care medicine is prac-
ticed. The potential for errors is enormous in the ICU. Data
show that changing error reporting from a potentially puni-
tive system to one in which future errors are prevented is key.
 Communication
The ICU medical director serves as a communication link
between physician staff, including primary care and consult-
ing physicians, and the nursing and other health care profes-
sional staff in the ICU. Most of this communication will
occur naturally as a result of interaction during patient care,
quality assurance activities, and other administrative meet-
ings. On occasion, further communication is needed to
address specific complaints, procedures, or policies.
Depending on the organization of the hospital, the ICU also
may be served by a multidisciplinary committee that can
participate in development of protocols and policies. This
committee may function with respect to a single ICU in a
hospital or may have responsibility for standardization of
activities in several ICUs in the area.
 Burnout
A different topic is burnout among ICU physicians, nurses,
and other health care workers. Valuable data are now avail-
able about the risks of burnout and its effects on patient
care, productivity, and career planning. Burnout is one
effect of psychosocial stress and is related to duration of
work hours, the impact of taking care of patients with criti-
cal illness, the effects of poor patient outcome despite max-
imal effort, and organizational issues. Intensivists, ICU
nurses, and respiratory therapists may experience occupa-
tional burnout.
 Outcomes & Alternatives
In many facilities, ICU beds are limited in number, and
incoming patients with varying degrees of morbidity
often must be evaluated and compared to determine who
might best be treated in the ICU. A number of published
studies have confirmed that a good proportion of patients
admitted to ICUs receive diagnostic studies and monitor-
ing of physiologic variables only—ie, no therapy that could
not be given outside the ICU. On the other hand, other
patients admitted to the ICU do receive such “intensive”
therapy, and some of these have better outcomes. Because
ICU beds are a limited resource in all hospitals, ICU med-
ical directors must develop familiarity with the overall out-
comes and results of patients admitted to their ICU beds.
They will be called on not infrequently to make decisions
about admissions, discharge, and transfer from the ICU,
and these decisions at times may be arrived at painfully. As
with all decisions affecting patient care, the medical direc-
tor must weigh the body of medical knowledge available;
the wishes of patients, families, and physicians; and the
likelihood or not that intensive care will benefit the patient.
At times, these decisions will involve only “medical judg-
ment”; at other times, the choice will reflect an ethical,
legal, or philosophical perspective.
Specific practice guidelines for individual diseases have
been developed for the purpose of identifying particular
patients. Recognition that many patients previously admitted
to ICUs did not require or receive major diagnostic or thera-
peutic interventions led to the design of progressive care,
“step-down,” or noninvasive monitoring units in some hos-
pitals. Equipped and staffed generally for electrocardiogra-
phy, pulse oximetry, and sometimes for noninvasive
respiratory impedance plethysmography—but not for
intravascular instrumentation—these units have potential as
highly effective, less costly alternatives to ICUs. A number of
studies have provided justification for intermediate care
units either as an area for patients leaving the ICU or as an
area devoted to care of certain kinds of medical problems—
primarily mild respiratory failure, cardiac arrhythmias, or
moderately severe electrolyte disorders.
CRITICAL CARE SCORING
The combination of an increasing patient population and
diminished funding for hospital services is creating a need
for optimized distribution of medical resources. This chal-
lenge is being met in a number of ways, including regional-
ization of care, specialization of critical care facilities (both
between and within hospitals), and better allocation of avail-
able personnel and equipment. To this end, the intensivist
must be prepared to make both administrative and medical
decisions about which patients will benefit most from admis-
sion to a critical care unit. Data in 1987 indicated that up to
40% of patients in ICUs were inappropriately admitted
either because they probably would have died regardless of
the care provided or because their illnesses were not life-
threatening enough to require ICU care. Indeed, a substantial
number of patients treated in critical care units at teaching
hospitals are admitted for “observation and monitoring”
only.
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Illness scoring has become a popular method for triage
within and between hospitals. Many such scores have been
introduced over the past two decades in an attempt to prior-
itize illness and injury for ICU admission purposes. Such
scores must be used with full appreciation of their limita-
tions. While they are useful for comparing institutional per-
formances and outcomes in studies of certain groups of
patients, great caution must be exercised when applying
these protocols to individual patients.
The most commonly used trauma and critical care scores
are discussed below and are illustrated in the accompanying
tables.
Glasgow Coma Scale
The Glasgow Coma Scale assesses the extent of coma in patients
with head injuries (Table 1–4). The scale is based on eye open-
ing, verbal response, and motor response. The total is the sum
of each of the individual responses and varies between 3 points
and 15 points. Mortality risk is correlated with the total score
and with a similar Glasgow Outcome Scale. Examination of the
patient and calculation of the score can be accomplished in less
than 1 minute. The scale is easy to use and highly reproducible
between observers. It has been incorporated into several other
scoring systems. The Glasgow Coma Scale is useful for prehos-
pital trauma triage as well as for assessment of patient progress
after arrival and during critical care admission.
Trauma Score and Revised Trauma Score
Because of the increasing number of trauma patients admitted
to critical care facilities, familiarity with trauma scales is impor-
tant. The Trauma Score is based on the Glasgow Coma Scale
and on the status of the cardiovascular and respiratory systems.
Weighted values are assigned to each parameter and summed
to obtain the total Trauma Score, which ranges from 1 to 16
(Table 1–5). Mortality risk varies inversely with this score.
After extensive use and evaluation of the Trauma Score, it
was found to underestimate the importance of head injuries.
In response to this, the Revised Trauma Score (RTS) was intro-
duced and is now the most widely used physiologic trauma
scoring tool. It is based on the Glasgow Coma Scale, systolic
blood pressure, and respiratory rate. For evaluation of in-
hospital outcome, coded values of the Glasgow Coma Scale,
blood pressure, and respiratory rate are weighted and summed
(Table 1–6). Better prognosis is associated with higher values.
CRAMS Scale
The Circulation, Respiration, Abdomen, Motor, Speech
(CRAMS) Scale is another trauma triage scale that has found
A. Systolic blood pressure B. Respiratory rate C. Respiratory effort D. Capillary refill 
>90 4
70–90 3
59–69 2
<50 1
0 0
10–24 4
25–35 3
>35 2
10 1
0 0
Normal 1
Shallow or retractions 0
Normal 2
Delay 1
None 0
E. 4 GCS points
1. Eye opening
Spontaneous 4
To voice 3
To pain 2
None 1
2. Motor response 
Obedient 6
Purposeful 5
Withdrawal 4
Flexion 3
Extension 2
None 1
3. Verbal response 
Oriented 5
Confused 4
Inappropriate 3
Incomprehensible 2
None 1
(1 + 2 + 3)
14–15 5
11–13 4
8–10 3
5–7 2
3–4 1
TRAUMA SCORE (A + B + C + D + E) ______
Table 1–5. Trauma Score.
Eye Motor Verbal 
4 = Spontaneous 6 = Obedient 5 = Oriented 
3 = To Voice 5 = Purposeful 4 = Confused 
2 = To pain 4 = Withdrawal 3 = Inappropriate 
1 = None 3 = Flexion 2 = Incomprehensible 
2 = Extension 1 = None 
1 = None 
Table 1–4. The Glasgow Coma Scale.
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regional acceptance (Table 1–7). It is frequently used to
decide which patients require triage to a trauma center.
Patients with lower CRAMS Scale scores would be expected
to require critical care unit admission.
Injury Severity Score (ISS)
The ISS attempts to quantitate the extent of multiple injuries
by assignment of numerical scores to different body regions
(head and neck, face, thorax, abdomen, pelvic contents,
extremities, and external). A book of codes is available that
provides information on the scoring of each injury. The worst
injury in each region is assigned a numerical value, which is
then squared and added to those from each of the other areas.
The total score ranges from 1 to 75 and correlates with mor-
tality risk. The major limitation of the ISS is that it considers
only the highest score from any body region and considers
injuries with equal scores to be of equal importance irrespec-
tive of body region. Similarly, since the ISS is an anatomic
score, a small injury with a significant potential for deleterious
outcome (closed head injury) may lead to the false impression
of a minimally injured patient. ISS is the most commonly used
measure of the severity of anatomic injury and provides a
rough survival estimate for the severely injured patient.
Acute Physiology, Age, Chronic Health
Evaluation (APACHE)
The APACHE scoring system (APACHE III) is probably the
most widely used critical care scale. It permits comparisons
between groups of patients and between facilities. It was not
designed to evaluate individual patient outcomes. To this
end, APACHE III was introduced to objectively estimate
patient risk for mortality and other important outcomes
related to patient stratification. While some centers have
adopted the APACHE III score, it is not used widely except
for study of trends in patient groups.
CURRENT CONTROVERSIES
& UNRESOLVED ISSUES
The usefulness of scales such as the APACHE III scoring sys-
tem remains to be determined long after their introduction.
Furthermore, the ability of experienced physicians to make
such management decisions may be as good as such scales
and perhaps often better. Some authors have concluded that
ICU scoring systems can be used to compare outcomes
within and between ICUs and can provide adequate adjust-
ment of mortality rates based on preadmission severity for
the purpose of assessing quality of care.
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2
1
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1
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DISORDERS OF FLUID VOLUME
In normal persons, water, distributed between the intracellu-
lar and extracelluar spaces, makes up 50–60% of total body
weight. Critical illness not only can result from abnormalities
in the amount and distribution of water but also can cause
strikingly abnormal disorders of water and solutes.
Distribution of Body Water
Total body water is distributed freely throughout the body
except for a very few areas in which movement of water is lim-
ited (eg, parts of the renal tubules and collecting ducts). Water
diffuses freely between the intracellular space and the extra-
cellular space in response to solute concentration gradients.
Therefore, the amount of water in different compartments
depends entirely on the quantity of solute present in that
compartment.
The two major fluid compartments of the body are the
intracellular space, in which the major solutes are potassium
and various anions, and the extracellular space, for which
sodium and other anions are the major solutes. Sodium moves
into and potassium out of cells passively along concentration
gradients. Thus active transport of sodium and potassium by
Na+,K+-ATP-dependent pumps on the cell membrane deter-
mines the relative quantities of these cations on the inside and
outside of each cell. The distribution of Na+ and K+ determines
the relative volumes. In normal individuals, about two-thirds of
total body water is intracellular and one-third is extracellular.
Addition of solute to either compartment will increase the
volume of that compartment by redistribution of water from
the compartment of lower solute (higher water) concentration
into the compartment to which the solute was added. Thus
the solute concentration in both compartments will increase
(see “Water Balance”). To restore normal volumes, the body
will seek to eliminate or redistribute the added solute and cor-
rect the increased solute concentration (eg, stimulation of thirst
or conservation of water). Similarly, the loss of solute from a
compartment results in a shrinkage of that compartment. The
body then tries to restore the lost solute to reestablish the
original volume and distribution of solute and water.
Distribution of Extracellular Volume
Extracellular volume is divided into the interstitial and the
intravascular space. The distribution of water between these
two compartments is complex in normal subjects and more
so during disease states in which edema (increase in intersti-
tial volume) or accumulation of fluid in normally nearly dry
spaces (eg, peritoneal cavity or pleural space) is present.
Normally, intravascular volume is maintained by the oncotic
pressure of large molecules that are confined to the intravas-
cular space, by movement of lymph from the interstitial to
the intravascular space, and by forces that maintain extracel-
lular volume. Countering these are the hydrostatic pressure
developed by the heart and circulation and interstitial fluid
oncotic pressure, which tend to push fluid out of the
intravascular space. The volume of the intravascular com-
partment determines the adequacy of the circulation; this, in
turn, determines the adequacy of delivery of oxygen, nutri-
ents, and other substances needed for organ function.
Hypovolemia and Hypervolemia
Because sodium is the predominant extracellular solute, extra-
cellular volume is determined primarily by the sodium content
of the body and the mechanisms responsible for maintaining
sodium content (Table 2–1). However, the term hypovolemia
generally refers only to decreased intravascular volume and not
decreased extracellular volume, and this disorder results from
inadequate intravascular volume maintenance. On the other
hand, the term hypervolemia generally denotes increased extra-
cellular volume with or without increased intravascular vol-
ume. Thus patients with edema or ascites have hypervolemia
(frequently  with decreased intravascular volume), but so do
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patients with congestive heart failure (who have increase in
both intravascular and extracellular volumes).
Normally, daily sodium excretion equals intake, so sodium
excretion varies with dietary or other intake. The average diet
contains 4–8 g of sodium daily, and this quantity must be
excreted. With severe limitation of dietary sodium, normal kid-
neys can vigorously reabsorb sodium, so as little as 1–5 meq
Na+/L of urine appears, and only 1–2 meq of Na+ is excreted
daily. A daily sodium intake and excretion of approximately
40–65 meq (about 1–1.5 g) is sufficient in normal individuals.
 Hypovolemia
ESSENT IALS  OF  D IAGNOS I S
 Evidence of decreased intravascular volume: hypoten-
sion, low central venous or pulmonary artery wedge
pressures
 Indirect evidence of decreased effective intravascular vol-
ume: tachycardia, oliguria, avid renal sodium reabsorption
 Circumstantial evidence of depleted effective intravas-
cular volume: end-organ dysfunction, peripheral
vasoconstriction
 Potential source of loss of extracellular volume or
evidence of inadequate repletion 
General Considerations
A. Definition—Hypovolemia is decreased volume of the
intravascular space. Although extracellular volume, of which
the intravascular space is a part, is often diminished, hypov-
olemia can occur even in the presence of normal or increased
extracellular volume (Table 2–2). The assessment of ade-
quacy of intravascular volume in the presence of normal or
increased extracellular volume is often difficult, especially in
critically ill patients. It is central to the concept of hypov-
olemia that total intravascular volume need not be dimin-
ished but that effective intravascular volume is low, such that
there is insufficient volume in the circulation to provide cir-
culatory adequacy. The term effective arterial volume is some-
times used to characterize the physiologically effective part of
the intravascular volume.
Some clinicians use the term dehydration as a substitute
for hypovolemia. This is incorrect, and this term should be
reserved to mean insufficient water relative to total body
solute (see below).
B. Pathophysiology—Decreased effective intravascular vol-
ume can occur with decreased, normal, or increased extracel-
lular volume. Decreased extracellular volume leading to
depletion of intravascular volume is most common and can
arise from increased loss of extracellular fluid, failure to
replete normal losses, or a combination of both. Bleeding,
diarrhea, vomiting, and excessive skin loss of fluid (sweating,
burns) can quickly deplete extracellular volume. Abnormally
large urinary losses of sodium and water from renal disease,
adrenal insufficiency, diuretics, or hyperglycemia (osmotic
diuresis) also should be considered as sources of volume
depletion. Decreased extracellular volume also can arise
Table 2–1. Factors affecting body sodium balance.
Increased body sodium content (increased extracellular volume)
• Increased sodium intake (in absence of increased sodium excretion)
• Decreased sodium excretion by kidneys
Decreased glomerular filtration
Increased renal tubular sodium reabsorption 
Increased renin, angiotensin, aldosterone 
Excessive mineralocorticoid activity 
Decreased body sodium content (decreased extracellular volume)
• Decreased sodium intake (in presence of normal sodium excretion)
• Increased sodium excretion
Renal: 
Renal failure  
Salt-losing nephropathy  
Osmotic diuresis 
Diuretic drugs 
Atrial natriuretic peptide 
Decreased renin, angiotensin, aldosterone, or cortisol 
Extrarenal:  
Diarrhea  
Vomiting 
Sweating 
Surgical drainage 
Table 2–2. Hypovolemia (decreased effective intravascular
volume).
With decreased extracellular volume
• Increased fluid losses
Gastrointestinal tract (diarrhea, vomiting, fistulas, nasogastric suction)
Renal (polyuria with renal sodium wasting, osmotic diuresis)
Skin or wound losses (sweating, burns) 
Hemorrhage (trauma, other bleeding site) 
• Decreased intake of sodium and water
• Impaired normal capacity to retain sodium and water
Renal sodium wasting (polycystic kidneys, diuretics) 
Adrenal insufficiency 
Osmotic diuresis (hyperglycemia) 
With increased or normal extracellular volume
• Cirrhosis with ascites
• Protein-losing enteropathy
• Congestive heart failure
• Increased vascular permeability (sepsis, shock, trauma, burns)
 CHAPTER 216
from inadequate replacement; this is particularly likely to
occur in ill patients who do not eat or drink appropriately or
who do not have access to adequate amounts of water and
solutes.
Hypovolemia with normal extracellular volume results
from any disorder that alters the balance between intravascu-
lar and extravascular fluid compartments. Intravascular
oncotic pressure and intact vascular integrity largely main-
tain intravascular volume, whereas hydrostatic pressure
tends to push fluid out of the circulation. Sepsis, acute respi-
ratory distress syndrome (ARDS), shock, and other critical
illnesses alter this balance by increasing the permeability of
the vasculature, thereby raising nonintravascular fluid vol-
ume (ie, interstitial compartment, pleural effusions, or
ascites) at the expense of the intravascular volume. Although
decreased vascular oncotic pressure and increased hydro-
static pressure also should shift fluid balance in this direc-
tion, these rarely develop rapidly enough to be seen with
unchanged total extracellular fluid volume.
Disorders that increase hydrostatic pressure in certain
vascular beds or reduce intravascular oncotic pressure also
can deplete intravascular volume. Reduced intravascular vol-
ume stimulates increased renal sodium reabsorption, which
causes an increase in total extracellular volume. Thus cirrho-
sis with hypoalbuminemia results in ascites from a combina-
tion of portal hypertension and decreased oncotic pressure,
heart failure leads to edema as a result of increased hydro-
static pressure, and edema in nephrotic syndrome results
from severely reduced oncotic pressure. The paradox in these
clinical situations is that effective intravascular volume may
be severely reduced even though the extracellular volume is
greatly increased.
Clinical Features
The diagnosis of volume depletion in the critically ill patient
is often difficult largely because of the confounding effects of
organ system dysfunction and the frequency with which
drugs, edematous states, altered cardiovascular and renal
function, and other factors interfere with assessment of vol-
ume status.
A. Symptoms and Signs—Symptoms and signs suggesting
hypovolemia in the critically ill patient may or may not be
helpful. Volume depletion causing inadequate systemic per-
fusion leads to altered mental status, confusion, lethargy, and
coma; cold skin and extremities from vasoconstriction; car-
diac ischemia and dysfunction; and liver and kidney failure.
None of these are specific for hypovolemia, but all are com-
mon to hypotension and shock from any cause. A potentially
important symptom is thirst in a patient with hyponatremia;
lack of an osmotic stimulus leaves volume depletion as the
only physiologic reason for thirst. In the patient with hypov-
olemia with increased extracellular fluid volume, edema, and
ascites make determination of effective intravascular volume
even more difficult.
Symptoms and signs do not have sufficiently high sensi-
tivity and high specificity to be of strong clinical value.
Postural lightheadedness increases the likelihood of volume
depletion, but an increase in heart rate from supine to stand-
ing must be greater than 30 beats/min to be specific for
hypovolemia. Orthostatic blood pressure changes lack sensi-
tivity and specificity, but these should be part of the evalua-
tion of potential hypovolemia. Dry axillae, longitudinal
furrows on the tongue, and sunken eyes have some slight pre-
dictive value for hypovolemia.
A source of volume loss or an explanation for inadequate
volume repletion strongly supports the diagnosis of hypov-
olemia. In the ICU patient, blood loss, diarrhea, and polyuria
are usually obvious; less easily identified are heavy sweating
during fever, fluid losses from extensive burns, volume
changes during hemodialysis or ultrafiltration, and drainage
from surgical incisions or wounds. Review of intravenous
and enteral fluid intake is often helpful, along with compari-
son of patient weights on a daily basis or more often.
Indirect evidence of hypovolemia can come from the
response of the cardiovascular and renal systems. Depleted
intravascular volume leads to decreased venous return to the
heart; the normal response is a lower stroke volume and
sinus tachycardia to maintain cardiac output.
B. Laboratory Findings—Intravascular volume depletion
may lead to avid retention of water because of increased
antidiuretic hormone (ADH) release and, if there is sufficient
water intake, hyponatremia. Decreased intravascular volume
causes prerenal azotemia with elevation of plasma creatinine
and urea nitrogen concentrations.
Except in the case of a primary renal cause of hypov-
olemia, decreased renal blood flow, even if glomerular filtra-
tion is maintained, increases renal tubular sodium
reabsorption. Urine volume diminishes, and urine becomes
highly concentrated under the influence of ADH and other
factors. Urine sodium and chloride concentrations may
become very low (<5–10 meq/L) with correspondingly low
fractional excretion of sodium (FENa <1%), chloride, and urea
(<35%). Because of decreased renal tubular flow, urea is reab-
sorbed more readily, and the plasma urea nitrogen:plasma cre-
atinine ratio increases, often greater than 30:1. In some
patients, avid sodium reabsorption comes at the expense of
increased potassium losses in the urine and hypokalemia.
Potassium depletion and increased sodium reabsorption in
the distal tubule enhance hydrogen ion excretion, leading to
metabolic alkalosis (contraction alkalosis); this is especially
common in volume depletion owing to vomiting.
On the other hand, if there is a primary renal-mediated
mechanism of hypovolemia, urine sodium concentration
and FENa may not decrease in the face of decreased intravas-
cular volume. Urinary indices of volume depletion may be
misleading, and paradoxical polyuria and high urine sodium
may be found. For patients taking diuretics, the fractional
excretion of urea may be low (<35%) in the face of hypov-
olemia even though the fractional excretion of sodium is
misleadingly high. Some patients will have mild to severe
renal insufficiency. Excessive and inappropriate renal sodium
loss is also seen in adrenal insufficiency; these patients also
may have hyponatremia, hyperkalemia, hyperchloremic
metabolic acidosis, and other features of inadequate adreno-
cortical hormone production. Osmotic diuresis (eg, from
hyperglycemia or administration of mannitol) and diuretic
drugs also cause hypovolemia with paradoxically increased
urine sodium and water.
C. ICU Monitoring—Pressure measurements provide evi-
dence of volume depletion but must be interpreted with
caution. The volume of the intravascular space determines
“pressure” as a function of the physical properties, size, and
character of the vessels—whether arteries or veins—along
with the amount of propulsive force imparted to the blood
by the heart. In a patient with “normal” vessels and a normal
heart, hypotension indicates that the volume of fluid is
insufficient to fill the arterial vessels. Hypotension of the
venous system can be assessed in the same way, using central
venous pressure (CVP) or pulmonary capillary wedge pres-
sure (PCWP).
Differential Diagnosis
Hypotension from cardiogenic shock results from decreased
systolic function of the heart, and septic shock arises largely
from extreme dilation of the vascular space, causing relative
hypovolemia. Orthostatic changes in blood pressure in the
absence of hypovolemia may be seen with autonomic dysfunc-
tion, peripheral neuropathy, diabetes mellitus, or hypokalemia
and in response to antihypertensive medications.
Treatment
A. Estimate Magnitude of Hypovolemia—The amount of
volume depletion in the hypovolemic patient in the ICU can-
not be easily estimated. In a normal-sized adult, extracellular
volume depletion of 15–25%, or 2–4 L, is needed before
orthostatic blood pressure and pulse changes occur. During
acute blood loss, changes in blood pressure and heart rate are
seen only when more than 2 units of blood (about 1 L, or
20%, of normal blood volume) are lost.
CVP and PCWP measurements are most useful for iden-
tifying volume depletion, but their magnitudes provide only a
rough guide to the degree of hypovolemia. The response to a
trial of fluid administration is often the best evidence for
hypovolemia and gives a useful (albeit retrospective) measure
of the amount of volume depletion originally present.
Acutely, such as during hemodialysis or ultrafiltration, the
change in weight is an accurate measure of extracellular fluid
change, but this may not be true in other circumstances.
Further confounding the assessment of hypovolemia is the
highly variable speed of mobilization of interstitial fluid
(edema) or pleural or peritoneal fluid as intravascular volume
decreases. In general, an adult ICU patient in whom hypov-
olemia is strongly suspected is likely to be depleted by about
1–4 L of extracellular volume, but correction of severe volume
depletion may require considerably more.
B. Determine Rate of Correction of Hypovolemia—
Hypovolemic shock with severe organ dysfunction, hypoten-
sion, and oliguria requires immediate and rapid correction of
hypovolemia. Under less severe circumstances, repletion of
extracellular and intravascular volume can be undertaken
more slowly and carefully to avoid overcorrection with subse-
quent pulmonary or peripheral edema. In all cases, the vol-
ume of replacement should be estimated and some
proportion of this quantity given over a defined period of
time. Evidence of continued volume depletion should be
reviewed regularly, and volume repletion should be halted as
soon as there is no longer evidence of hypovolemia or when
complications of therapy (pulmonary edema) are discovered.
About 50–80% of the estimated fluid replacement vol-
ume should be given over 12–24 hours if the patient is not
acutely hypotensive. This generally puts the rate of fluid
intake in the range of 50–150 mL/h above maintenance fluid
administration, depending on the estimated degree of vol-
ume depletion. In other patients—especially those in whom
the diagnosis of hypovolemia is less certain or those who
have known or suspected heart disease—a “fluid challenge”
may be more appropriate, that is, giving 100–300 mL (less in
smaller persons) of intravenous fluid over 1–2 hours and
then making a careful reassessment and checking urine out-
put, CVP or PCWP, blood pressure, and other signs. At this
point, a decision can be made about whether to repeat the
challenge, start a continuous infusion, or consider other
issues. Patients with severe volume depletion and organ dys-
function should be given fluid rapidly (200–300 mL/h) for
short periods and reassessed frequently.
C. Type of Fluid Replacement—Because hypovolemia is
depletion of the volume of the intravascular space, replacement
fluid should predominantly fill and remain in the intravascular
space. In practice, replacement fluids given intravenously con-
sist of crystalloid solutions, made of water and small solutes,
and colloid solutions, consisting of water, electrolytes, and
higher-molecular-weight proteins or polymers (Table 2–3).
At first glance, crystalloid solutions would appear to be
inefficient for intravascular fluid repletion because the small
solutes and water distribute quickly into both the interstitial
and the intrasvascular spaces. Nevertheless, repletion of the
total extracellular volume is essential in patients with hypov-
olemia and extracellular fluid depletion (eg, blood loss, gas-
trointestinal tract losses, polyuria, and sweating), and
intravascular volume will be corrected along with correction
of extracellular volume. In theory, large volumes of crystalloid
would be undesirable in patients with hypovolemia and
increased extracellular volume (ie, ascites and/or edema), but
this does not present serious problems in most patients.
Solutions containing only dextrose and water (eg, 5% dextrose
in water) are poor volume replacement solutions because the
glucose is rapidly taken up by cells (with water subsequently
distributed freely into both the intracellular and extracellular
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compartments). Although sometimes used to replace extracel-
lular volume deficits, Ringer’s lactate (containing Na+, K+, Cl–,
Ca2+, and lactate) is no more effective than 0.9% NaCl in most
clinical situations. However, evidence suggests that large vol-
umes of NaCl-containing fluids are likely to cause mild hyper-
chloremic acidosis, the consequences of which are unclear.
Therefore, some practitioners advocate crystalloid replace-
ment with Ringer’s lactate, especially in hemorrhagic shock
before blood replacement is available.
For years, colloid solutions have been advocated for more
efficient repletion of intravascular volume, especially in states
of normal or elevated extracellular volume and in hypov-
olemic shock. In theory, colloids are restricted at least tran-
siently to the intravascular space and thereby exert an
intravascular oncotic pressure that draws fluid out of the inter-
stitial space and expands the intravascular space by an amount
out of proportion to the volume of colloid solution adminis-
tered. A theoretical disadvantage is that the interstitial space
would be depleted of water, leading to an increase in intersti-
tial oncotic pressure that would draw water back out.
Nevertheless, studies have failed to identify clear-cut advan-
tages of colloid-containing solutions over crystalloid solutions
in critically ill patients. This is probably because increased cap-
illary permeability in patients with sepsis, shock, and other
problems negates the potential benefit of retaining colloid
within the vascular space. Furthermore, some investigators
have suspected that leakage of colloid into the interstitial space
of the lungs and other organs can contribute to persistent
organ system dysfunction and edematous states. In hypov-
olemia associated with ascites, rapid movement of colloid into
the ascitic fluid may occur, resulting in only a transient
increase in intravascular volume. In patients with nephrotic
syndrome or protein-losing enteropathies, albumin and other
colloids may be lost fairly rapidly.
Colloid solutions for intravenous replacement include
human serum albumin (5% and 25% albumin, heat-treated to
reduce infectious risk) and hetastarch (6% hydroxyethyl
starch). Albumin is considered nonimmunogenic, but it is
expensive, offers few advantages over other solutions, and has
not been shown to improve outcome. Hetastarch is a synthetic
colloid solution used for volume expansion. Clinical benefit of
the use of this solution is unclear. Fresh frozen plasma is an
expensive and inefficient volume expander and should be
reserved for correction of coagulation factor deficiencies. There
is little rationale for the use of whole blood; red blood cells and
other blood components should be given for specific indica-
tions, along with crystalloid or colloid supplements as needed.
Meta-analyses have found either no difference or a trend
toward increased mortality in critically ill patients given
albumin. In a large prospective trial comparing albumin or
isotonic crystalloid, however, there was no difference in mor-
tality. A few clinical conditions have been shown to benefit
from albumin infusions. Antibiotics and intravenous albu-
min, 1.5 g/kg on day 1 and 1 g/kg on day 3, significantly
reduced mortality and renal failure in patients with cirrhosis
and spontaneous bacterial peritonitis. Albumin may be help-
ful after large-volume paracentesis and to correct dialysis-
related hypotension.
D. Complications—Complications of fluid replacement
include excessive fluid repletion owing to overestimation of
the hypovolemia or inadvertent excessive fluid administration.
Patients with renal and cardiac dysfunction are especially
prone to fluid overload, and pulmonary edema may be the
first manifestation. Pulmonary edema is also likely—and may
occur without excessive fluid repletion—in patients who have
increased lung permeability or ARDS. During fluid repletion,
worsening of peripheral edema or ascites may occur. Large
[Na+] (meq/L) [Cl–] (meq/L) [osm] (mosm/L) Other
Crystalloids
0.9% NaCl (normal saline) 154 154 308
5% dextrose in 0.9% NaCl 154 154 560 Glucose, 50 g/L 
Ringer’s lactate 130 109 273 K+, Ca2+, lactate1
5% dextrose in water2 0 0 252 Glucose, 50 g/L 
0.45% NaCl 77 77 154
5% dextrose in 0.45% NaCl 77 77 406 Glucose, 50 g/L
Colloids
Albumin (5%) 
Albumin (25%)
6% hetastarch in 0.9% NaCl 
1K+ 4 meq/L, Ca2+ 3 meq/L, lactate 28 meq/L.
2Not recommended for rapid correction of intravascular or extracellular volume deficit.  
Table 2–3. Fluids for intravenous replacement of extracellular volume or water deficit.
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amounts of isotonic saline may contribute to expansion
acidosis—a hyperchloremic metabolic acidosis owing largely
to dilution of plasma bicarbonate—but this is uncommon.
E. Maintenance Fluid Requirements—Normal mainte-
nance fluids to prevent hypovolemia should provide
1.5–2.5 L of water per day for normal-sized adults, adjusted
to account for other sources of water intake (eg, medications
and/or food intake) and the ability of the kidneys to concen-
trate and dilute the urine. Sodium intake in the ICU gener-
ally should be limited to a total of 50–70 meq/day, but many
critically ill patients avidly retain sodium, and they may have
a net positive sodium balance with even a smaller sodium
intake. Patients are frequently given much more sodium than
needed. For example, 0.9% NaCl has 154 meq/L of sodium
and chloride, and some patients are inadvertently given as
much as 3–4 L/day. Although it is sometimes necessary,
it is difficult to rationalize giving diuretics to a patient
simply to enhance removal of sodium given as part of replace-
ment fluids. On the other hand, diuretics are useful when
needed to facilitate excretion of the sodium ingested from
an appropriate diet. In states of ongoing losses of extracellu-
lar volume, appropriate fluid replacement in addition to
maintenance water and electrolytes should be given as needed
(Table 2–4).
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 Hypervolemia
ESSENT IALS  OF  D IAGNOS I S
 Edema, ascites, or other evidence of increased extracel-
lular volume
 Intravascular volume may be normal, low (hypovolemia),
or high
 Potential causes of increased extracellular volume:
renal insufficiency, congestive heart failure, liver dis-
ease, or other mechanism of sodium retention or exces-
sive sodium administration
General Considerations
In contrast to hypovolemia, in which there is always decreased
volume of the intravascular space, in hypervolemia the
intravascular volume may be high, normal, or paradoxically
low. Peripheral or pulmonary edema, ascites, or pleural effu-
sions are the evidence for increased extracellular volume.
Increased extracellular volume may not be an emergency in
ICU patients, but this depends on how much and where the
excess fluid accumulates. If associated with decreased intravas-
cular volume (eg, hypovolemia), increased intravascular vol-
ume (eg, pulmonary edema), or severe ascites (with respiratory
compromise), rapid intervention may be indicated.
A. Hypervolemia with Decreased Intravascular
Volume—Because sodium—along with anions—is the pre-
dominant solute in the extracellular space, increased extra-
cellular volume is an abnormally increased quantity of
sodium and water. The body normally determines whether
sodium and water should be retained by sensing the ade-
quacy of intravascular volume, and the nonvascular com-
ponent does not play a role in stimulating or inhibiting
sodium and water retention. Thus excessive sodium reten-
tion resulting in hypervolemia may occur in states of inade-
quate effective circulation, such as heart failure, or
suboptimal filling of the vascular space resulting from loss of
fluid into other compartments, such as occurs with hypoal-
buminemia, portal hypertension, or increased vascular per-
meability to solute and water.
Table 2–4. Guidelines for replacement of fluid losses
from the gastrointestinal tract.
Replace mL
per mL with
Add
Gastric (vomiting or
nasogastric aspiration)
5% dextrose in
0.45% NaCl
KCl, 20 meq/L
Small bowel 5% dextrose in
0.45% NaCl
KCl, 5 meq/L
NaHCO3, 22 meq/L
Biliary 5% dextrose in
0.90% NaCl
NaHCO3, 45 meq/L
Large bowel (diarrhea) 5% dextrose in
0.45 NaCl
KCl, 40 meq/L
NaHCO3, 45 meq/L
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Ascites owing to liver disease arises from a combination
of portal hypertension and hypoalbuminemia, as seen in
severe hepatic disease, but occasionally it occurs as a result of
pre- or posthepatic portal obstruction. Decreased plasma
albumin by itself, though a cause of edema, is an unusual
cause of severe ascites or pleural effusions. Ascites also may
be a marker of local inflammatory or infectious disorders.
Pleural effusions may indicate hypervolemia if associated
with heart failure or hypoalbuminemia, but they also may be
associated with pneumonia or other local causes.
B. Hypervolemia with Primary Increased Sodium
Retention—The other major mechanism of hypervolemia is
excessive function of the normal mechanisms that ensure
sodium and water balance. Normal extracellular volume is
maintained by an interactive system that includes renin,
angiotensin, aldosterone, glomerular filtration, renal tubular
handling of sodium and water, atrial natriuretic factor, and
ADH, along with the intake of sodium and water in the diet.
Hyperfunction of some of these mechanisms, such as hyper-
aldosteronism or excessive intake of sodium, or renal dys-
function causes net positive sodium balance with inevitable
expansion of the extracellular volume. Although due in some
degree to hypoalbuminemia with decreased effective
intravascular volume, nephrotic syndrome with renal dys-
function is considered a state in which there is also impaired
renal sodium excretion. While not a dysfunction of normal
sodium balance, excessive administration of sodium, espe-
cially from hypertonic fluid or dietary sources, may expand
the extracellular volume. Administration of drugs that
impair sodium excretion also may contribute, including cor-
ticosteroids, mineralocorticoids, and some antihypertensive
agents.
Clinical Features
A. Symptoms and Signs—Increased extracellular volume
may be localized to certain compartments (eg, ascites) or
generalized. Edema is often a major feature of increased
extracellular volume, collecting in dependent areas of the
body, and the lower back and sacral areas may demonstrate
edema in the absence of edema of the lower extremities in
ICU patients. Edema always indicates increased extracellular
volume except when there is a localized mechanism of fluid
transudation or exudation, for example, local venous insuffi-
ciency, cellulitis, lymphatic obstruction, or trauma. The pres-
ence of edema may or may not signify that the intravascular
volume is increased.
Abdominal distention and other findings consistent with
ascites may be present. Pleural effusions indicate hyperv-
olemia when associated with congestive heart failure.
Other clinical features depend on the mechanism of hyper-
volemia. Intravascular volume may be low, high, or normal in
the face of increased extracellular volume. If low, evidence of
inadequate circulation may be found, including tachycardia,
peripheral cyanosis, and altered mental status. If extracellular
volume is high, signs of pulmonary edema may be present.
Patients with hypervolemia owing to endocrine disorders or
renal failure may have findings specific to the underlying cause.
As shown in Table 2–5, the associated conditions leading to
hypervolemia can be divided according to the presumed patho-
genesis into those associated with decreased effective intravas-
cular volume (eg, heart failure, liver disease, or increased
vascular permeability) and those associated with increased or
normal intravascular volume (eg, primary disorder of sodium
excretion or excessive administration of sodium).
B. Laboratory Findings—Except in a few instances, lab-
oratory findings in hypervolemia are nonspecific.
Hypoalbuminemia is seen in patients with nephrotic syn-
drome, protein-losing enteropathy, malnutrition, and liver
disease. Urine sodium is usually very low in the face of avid
sodium retention in the untreated patient. Nephrotic syn-
drome patients have moderate to severe proteinuria.
Decreased glomerular filtration (increased plasma creatinine
and urea nitrogen) is seen in patients with severely decreased
intravascular volume.
Despite the increased extracellular quantity of sodium,
plasma sodium concentrations are often low (120–135
meq/L) in patients with decreased effective intravascular vol-
ume because of strong stimulation of ADH release. Plasma
potassium is often low as well. Patients with excess endoge-
nous or administered corticosteroids (Cushing’s syndrome)
or mineralocorticoids may have hypokalemic metabolic alka-
losis; those with cirrhosis often have respiratory alkalosis.
Treatment
The need for treatment and the treatment approach depend
on the mechanism of hypervolemia. Hypervolemia associated
with severely decreased or markedly increased intravascular
volume requires rapid and aggressive treatment.
Table 2–5. Hypervolemia (increased extracellular
volume).
With decreased effective intravascular volume
• Cirrhosis with ascites
• Pre- and posthepatic portal hypertension with ascites
• Hypoalbuminemia from protein-losing enteropathy, malnutrition,
nephrotic syndrome 
• Congestive heart failure
• Excess sodium intake 
With increased intravascular volume
• Increased sodium retention
Renal insufficiency (especially glomerular disease)
Hyperaldosteronism, hypercortisolism 
Increased renin and angiostensin  
Drugs (corticosteroids, some antihypertensives)
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A. Hypervolemia with Decreased Intravascular Volume—
The critically ill patient with decreased intravascular volume
and increased extracellular volume may have an acute increase
in permeability of the vascular system with leakage of fluid
into the interstitial space (eg, sepsis). More commonly, the
patient may have a chronic condition leading to edema or
ascites accompanied by a subtle and gradual decrease in
intravascular volume. Diuretic treatment should be delayed
until the intravascular fluid deficit is corrected to avoid further
deterioration. Treatment of decreased intravascular volume
was described earlier (in the section “Hypovolemia”), but with
preexisting hypervolemia, necessary fluid replacement may
worsen edema, ascites, or other fluid accumulations. In some
patients, some worsening of hypervolemia (edema) may be
accepted for a time until intravascular volume is repleted.
Then, by improving renal perfusion, there may be appropriate
natriuresis with mobilization of edema fluid. A special situa-
tion is the patient with cor pulmonale who develops edema
secondary to impaired right ventricular function and who
may have low effective intravascular volume. These patients
may benefit from reduction of pulmonary hypertension fol-
lowing administration of oxygen.
B. Hypervolemia with Increased Intravascular Volume—
In these patients, severely increased intravascular volume
may be manifested by pulmonary edema, hypoxemia, and
respiratory distress. If intravenous fluids are being adminis-
tered, these should be discontinued unless blood transfusions
are necessary for severe anemia. Intravenous furosemide
(10–80 mg) is given, with repeated doses every 30–60 minutes
depending on the diuretic response. Supportive care includes
oxygen, changes in the patient’s position, and mechanical
ventilation if necessary. Cardiogenic pulmonary edema
also may benefit from morphine, vasodilators (eg, nitroprus-
side or angiotensin-converting enzyme [ACE] inhibitors),
venodilators (nitrates), or nesiritide. Mechanical ventilatory
support, either intubation or noninvasive positive-pressure
ventilation, may be necessary.
In some critically ill patients, sodium excretion is impaired,
and diuretics must be given in larger than usual doses. Patients
with previous diuretic use, those with severe cardiac failure,
and those with renal insufficiency may require furosemide in
doses up to 400 mg given slowly. Metolazone, which acts in the
distal renal tubule, may facilitate the response to furosemide.
There is no role for osmotic diuretics such as mannitol
because these will further expand the intravascular volume,
especially if they are ineffective in producing diuresis.
Potassium-sparing collecting tubule diuretics, such as tri-
amterene, amiloride, and spironolactone, usually have little
acute effect in these patients. Failure to induce appropriate
diuresis in the situation of expanded intravascular volume
may require acute hemodialysis or ultrafiltration.
For critically ill patients, rapid decreases in intravascular
volume may be particularly hazardous in those with chronic
hypertension (associated with hypertrophic, poorly compliant
ventricles), pulmonary hypertension, pericardial effusion, sep-
sis, diabetes mellitus, autonomic instability, electrolyte distur-
bances, or recent blood loss. Patients receiving alpha- or
beta-adrenergic blockers, arterial or venous dilators (including
hydralazine, nitroprusside, and nitroglycerin), and mechanical
ventilation may be very sensitive to rapid depletion of intravas-
cular volume. Severe hypotension and hypovolemic shock may
be induced by diuretics or other fluid removal.
C. Increased Extracellular Volume without Change in
Intravascular Volume—Conditions such as this are usually
chronic. Edema and ascites do not by themselves cause
immediate problems, but edema may impair skin care and
lead to immobility, whereas ascites may become uncomfort-
able, may cause respiratory distress and hypoxemia, and may
become infected (spontaneous bacterial peritonitis).
1. Sodium restriction—Treatment centers around net
negative sodium balance. Urine sodium concentration can
provide a guide to the degree of sodium intake restriction
and diuretics needed. In severe states, urine sodium concen-
tration may be as low as 1–2 meq/L, but more often it is 5–20
meq/L. With daily urine volumes of 1–2 L, only a total of
1–40 meq of Na+ may be excreted daily. In contrast, moder-
ate dietary sodium restriction is often considered to be 2 g
(87 meq) of sodium per day and therefore unlikely to be suc-
cessful alone. Nevertheless, most patients should be
restricted to 1–2 g of sodium daily, although only 10–15% of
patients with severe fluid retention will respond.
2. Diuretics—Ascites and edema often will respond best to a
combination of furosemide and spironolactone. Furosemide is
usually started at 40 mg daily; spironolactone’s starting dose
is 100 mg daily. If needed, furosemide can be increased to
160 mg/day and spironolactone up to 400 mg/day.
Diuretics should be used cautiously if there is concomi-
tant marginal or decreased effective intravascular volume
(eg, ascites, heart failure, or nephrotic syndrome). Too-rapid
depletion of extracellular volume not only may worsen circu-
latory dysfunction but also will sometimes further enhance
sodium retention, perhaps inducing a state of “escape” from
diuretic responsiveness. Concern has been expressed about
the possibility of an increased incidence of hepatorenal syn-
drome in patients with severe liver disease who are given
large doses of diuretics.
Complications of diuretics depend somewhat on their
effectiveness in inducing natriuresis and volume depletion.
Furosemide may cause severe hypokalemia and contributes
to metabolic alkalosis, and hypomagnesemia and hyperna-
tremia are occasionally significant problems. Spironolactone
and triamterene should not be used in patients with hyper-
kalemia, and patients receiving potassium supplementation
should be monitored carefully when these agents are given.
Patients may have allergic or other unpredictable reactions to
any of these drugs.
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3. Increased elimination of extracellular fluid—
Removal of ascites by paracentesis in patients with chronic
liver disease has some advocates. Although earlier studies
found an association of excessive depletion of intravascular
volume following removal of more than 800–1500 mL of
ascitic fluid, recent investigations have suggested that large-
volume paracentesis (>1500 mL) may be safe—usually if
intravenous albumin is given to maintain intravascular vol-
ume immediately after fluid removal. Paracentesis is indi-
cated in patients with severe respiratory distress or
discomfort from their ascites, but the exact amount of fluid
that can be removed safely remains unclear.
Patients with congestive heart failure with hypervolemia
are often treated with a combination of diuretics, inotropic
agents such as digitalis, and systemic vasodilators. Vasodilators
that reduce left ventricular afterload and improve cardiac out-
put are very effective in decreasing hypervolemia without
compromising organ system perfusion. These agents, prima-
rily ACE inhibitors and angiotensin-receptor blockers, have
been particularly useful in reversing the consequences of
decreased effective intravascular volume.
Extracellular volume can be readily removed in most ICU
patients by ultrafiltration, especially using continuous ven-
ovenous hemofiltration. This can be accomplished rapidly or
slowly depending on the method chosen. Hypotension may
accompany too-rapid intravascular fluid removal.
Carvounis CP, Nisar S, Guro-Razuman S: Significance of the frac-
tional excretion of urea in the differential diagnosis of acute
renal failure. Kidney Int 2002;62:2223–9. [PMID: 12427149]
Cho S, Atwood JE: Peripheral edema. Am J Med 2002;113:580–6.
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DISORDERS OF WATER BALANCE
The term water balance refers to the normally closely regu-
lated relationship between total body water and total body
solute that determines solute concentration throughout the
body. With the exception of a few special areas such as the renal
medulla and collecting ducts, water moves freely between all
body compartments—intracellular and extracellular—by
way of osmotic gradients. Therefore, solute concentration is
equal everywhere, but the amount of water in a given body
space is determined by the quantity of solute contained
within that space.
Clinical disorders of water balance are estimated from
plasma sodium [Na+] because the concentration of that pre-
dominantly extracellular cation is inversely proportional to the
quantity of total body water relative to total solute. There is one
caveat, however. Hypernatremia always denotes hypertonicity
(increased solute relative to total body water), but hyponatremia
may be seen with hypotonicity, normotonicity, or hypertonicity.
This is so because solutes other than sodium may be present in
high enough quantity to exert an osmotic effect.
Solute concentration can be expressed as osmolarity
(mOsm/L) or osmolality (mOsm/kg). For clinical purposes,
these are generally interchangeable, and osmolality will be
used. The term tonicity is often considered synonymous with
osmolality but should be used to express “effective osmolality.”
This is so because some solutes, notably urea, move freely
into and out of cells. Thus urea contributes to the osmolality
of plasma but does not add to plasma tonicity.
Total Body Water and Plasma Sodium
Concentration
If total body exchangeable solute is dissolved hypothetically
in a volume equal to total body water (TBW), the osmolality
of the solution will be as shown in the following equation:
If water moves freely between body compartments, then
water will move from compartments with low osmolality to
those with high osmolality, equalizing solute concentrations.
Therefore, for the plasma compartment,
Plasma osmolality is approximately the sum of cation
plus anion concentrations, often expressed as milliequiva-
lents per liter (meq/L) rather than milliosmols per kilogram
(mosm/kg) for monovalent solutes. Since sodium is the most
abundant extracellular cation, the sum of cation and anion
concentrations is approximately 2 × [Na+]. Therefore,
A useful form of this equation relates TBW and [Na+]
under abnormal conditions to normal TBW and [Na+],
assuming that total body solute does not change:
This equation estimates TBW from plasma [Na+], and the
difference between TBW and normal TBW is the water
TBW (L) normal  TBW (L)
normal [Na
Na
+
+
= ×
]
[ ]
2   [Na ]
total solute (mOsm)
TBW (L)
or  +× =      [Na ]  
1
TBW (L)
+ ∞ 
Plasma osmolality (mOsm/kg)
total solute (m
=
Osm)
TBW (kg)
Body osmolality (mOsm/kg)
total solute (mOs
=
m)
TBW (kg)
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deficit or water excess. Normal TBW is approximately 60% of
body weight in men and 50% of body weight in women who
are near ideal body weight. The TBW as a proportion of body
weight decreases with obesity and in the elderly to as low as
45–50% of body weight.
It should be understood that this analysis is an oversim-
plied model that does not account entirely for changes in
exchangeable solute, all shifts in water between different
compartments, and solute and water gains and losses.
Regulation of Water Balance
Water balance is maintained primarily by water intake (water
consumption mediated by thirst plus water produced from
metabolism) and water excretion by the kidneys. Other
sources of water loss such as intestinal secretions and sweat-
ing are unregulated. Normally, enough excess water is taken
in to allow the kidneys to control body osmolality by increas-
ing or decreasing water excretion as necessary. Although nor-
mal persons filter as much as 150 L/day through the
glomeruli, about 99% of the water is reabsorbed in the renal
tubules. The amount of water that can be excreted in 24 hours
depends on renal concentrating and diluting ability (depend-
ing on renal function) and the quantity of solute excreted per
day. Solutes consist of electrolytes and urea (Table 2–6), and
the latter depends on the dietary protein intake and catabolic
rate. Healthy normal subjects are theoretically able to main-
tain water balance with as little as 670 mL or as much as
12,000 mL water intake per day. This wide range depends on
normal glomerular filtration rate, normal urinary concen-
trating and diluting ability, and normal solute excretion rate.
Patients with abnormal renal function are consequently
much more limited in their ability to tolerate and correct
water imbalances.
A. Urine Concentration—The urine concentration
depends on the amount of ADH present and renal tubular
function. ADH, also known as arginine vasopressin (AVP), is
secreted by the posterior pituitary in response to changes in
plasma osmolality sensed by the hypothalamic supraoptic
and paraventricular nuclei. Increased plasma osmolality
increases ADH secretion; decreased osmolality inhibits ADH
secretion. ADH also is released in response to decreased
extracellular volume, sensed by receptors in the atria.
Extracellular volume status and osmolality interact to deter-
mine plasma ADH levels. For example, with hypovolemia
plus hyponatremia, ADH release may continue despite inhi-
bition by low plasma osmolality.
Maximum urine concentrating capacity requires sufficient
solute delivery to the distal nephrons, maintenance of a high
solute concentration in the renal medulla, and high levels of
ADH. Active transport of sodium out of the thick ascending
limb of the loop of Henle generates high solute concentration
in the renal medullary interstitium, whereas tubular fluid
becomes progressively more dilute because water is kept in
the tubules. In the distal tubules and collecting ducts, the
tubular fluid is exposed to the medullary concentration gra-
dient, and—in the presence of ADH—water moves freely out
of the lumen, thereby concentrating the urine. Maximum
urine concentration, when needed to conserve water excre-
tion, may be limited if there is insufficient sodium presented
to the loop of Henle (renal insufficiency), inhibition of active
transport in the thick ascending limb (loop diuretics), inade-
quate response to ADH (nephrogenic diabetes insipidus), or
absence of ADH (central diabetes insipidus).
Maximum urine diluting capacity also depends on func-
tion of the ascending loop of Henle and the distal convoluted
tubule, as well as maintenance of an impermeable collecting
duct and suppression of ADH release. Excess water in the
body should be countered by increased volume of maximally
diluted urine. Failure to dilute urine maximally may result
from renal insufficiency, especially with tubulointerstitial
diseases, inappropriate secretion of ADH, and abnormally
increased permeability of the collecting ducts to water (adre-
nal insufficiency). In addition, sedative-hypnotic drugs, anal-
gesics, opioids, and antipsychotic drugs may interfere with
renal diluting ability.
Table 2–6. Range of urinary water excretion with normal solute load.
• Minimum urine concentration: 50 mosm/L 
• Maximum urine concentration: 1200 mosm/L
• Normal urine solute excretion: 800 mosm/d 
• Minimum urine volume (water excretion) per day =
• Maximum urine volume (water excretion) per day =
800 mosm/d
1200 mosm/L 
= 0.67 L/d
800 mosm/d
50 mosm/L   
= 16 L/d
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B. Solute Excretion and Water Excretion Rate—The
quantity of solute excreted also determines the maximum
and minimum water excretion rates. In normal subjects,
there is an obligate solute loss of about 800 mOsm/day,
including sodium, potassium, anions, ammonium, and urea.
Urea, from breakdown of amino acids, makes up about 50%
of the solute excreted. In the presence of severely limited pro-
tein intake, 24-hour urine urea excretion is reduced. This
decrease in urine solute excretion limits maximum water
excretion even if urine is maximally diluted. A fall in the total
24-hour urine solute excretion to 300 mOsm/day, for exam-
ple, means that even if urine concentration is 50 mOsm/kg,
only 6 L of water can be excreted per day. In contrast, if there
is 800 mOsm/day of solute to excrete, 16 L of water per day
could have been excreted with maximum urinary dilution.
 Hyponatremia
ESSENT IALS  OF  D IAGNOS I S
 Plasma sodium <135 meq/L
 Altered mental status (confusion, lethargy) or new onset
of seizures
 Most cases discovered by review of routinely obtained
plasma electrolytes
General Considerations
Hyponatremia is encountered commonly in the ICU. It has
been estimated that 2.5% of hospitalized patients have hypona-
tremia. Low plasma sodium is associated with a variety of
endocrine, renal, neurologic, and respiratory disorders; medica-
tions and other treatment; and other medical conditions. Severe
hyponatremia is manifested by altered mental status (hypona-
tremic encephalopathy), seizures, and high mortality.
Hyponatremia is particularly dangerous in patients with acute
neurologic disorders, especially head injury, stroke, and hemor-
rhage. Severe hyponatremia must be corrected rapidly, carefully,
and in a controlled fashion to avoid further complications.
In the absence of hyponatremia associated with normal
or increased tonicity (see below), low plasma sodium indi-
cates excess total body water for the amount of solute (dilu-
tional hyponatremia). In normal subjects, this condition
would initiate compensatory mechanisms that facilitate rapid
excretion of water, correcting the imbalance. Therefore, in
states of persistent hyponatremia, there is physiologic or patho-
logic inability to excrete water normally.
Hyponatremia (dilutional hyponatremia) is seen in three
distinct clinical situations in which extracellular volume is low,
high, or normal (Table 2–7).
A. Hyponatremia with Decreased Extracellular Volume—
Decreased extracellular volume leads to vigorous water
conservation, primarily mediated by increased ADH release
stimulated by atrial receptors and increased thirst leading to
increased water intake. Generally, urinary sodium excretion is
very low, and water intake and retention lead to increased
TBW relative to the reduced amount of solute. However, in
conditions in which the hypovolemic state is due to sodium
and water loss in the urine, such as adrenal insufficiency,
diuretic use, and salt-losing nephropathies, urine sodium
excretion may be normal or high. In adrenal insufficiency,
hyponatremia is facilitated because lack of cortisol causes col-
lecting ducts to be excessively permeable to water reabsorp-
tion, and ADH fails to be suppressed normally by low plasma
osmolality. A frequently seen form of hypovolemic hypona-
tremia occurs with thiazide diuretics. Chronic volume deple-
tion leading to stimulation of ADH release is an important
factor. In addition, thiazides impair urinary dilution by block-
ing sodium and chloride transport in the diluting segment of
the distal nephron and potentiate the effect of ADH. Finally,
thiazide-induced renal potassium excretion further reduces
total body solute content, also contributing to hyponatremia.
B. Hyponatremia with Increased Extracellular Volume—
Hyponatremia in the presence of increased extracellular vol-
ume is seen in congestive heart failure, nephrotic syndrome,
Normal plasma osmolality 
Pseudohyponatremia (hyperlipidemia); rare if measured with
ion-specific Na+ electrode 
Elevated plasma osmolality 
Hyperglycemia  
Mannitol, glycerol, radiocontrast agents  
Decreased plasma osmolality 
Urine maximally diluted:
1. Decreased solute excretion (low protein intake) 
2. Excessive water ingestion or intake 
Urine not maximally diluted:
1. Normal extracellular volume  
a. SIADH  
Lung disease  
CNS disease  
Drugs  
Anxiety  
b. Adrenal insufficiency (may also have volume depletion)  
c. Hypothyroidism  
2. Low extracellular volume  
a. Extrarenal loss  
b. Renal loss: diuretics, sodium-losing nephropathy  
3. Increased extracellular volume  
a. Congestive heart failure  
b. Cirrhosis  
c. Nephrotic syndrome  
Table 2–7. Disorders of water balance: Hyponatremia. 
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cirrhosis, protein-losing enteropathy, and pregnancy. These
disorders have in common edema, ascites, pulmonary
edema, or other evidence of increased extracellular volume.
However, these patients appear to have an inability to main-
tain normal intravascular volume because of forces generat-
ing excessive venous and extravascular volume. Hyponatremia
is a consequence of ADH release in response to decreased
intravascular volume, even though extracellular volume and
TBW are high. Some patients with hypothyroidism have
hyponatremia owing primarily to heart failure, but hypothy-
roidism also interferes directly with the ability to dilute urine
maximally.
C. Hyponatremia with Normal Extracellular Volume—
Hyponatremia in association with normal extracellular vol-
ume is seen with psychogenic water ingestion, decreased
solute intake, and, most commonly, the syndrome of inap-
propriate secretion of ADH (SIADH). Massive intake of
water rarely results in severe hyponatremia if the ability to
excrete water is unimpaired. However, decreased solute
intake as described earlier limits the maximum volume of
water that can be excreted even when urine is maximally
diluted. The syndrome of “beer-drinker’s potomania” results
from heavy consumption of beer and other low-solute fluids
that limit the quantity of solute available for excretion. A very
low protein diet also generates very little urea for excretion.
The majority of patients with normovolemic hypona-
tremia have SIADH, resulting from release of ADH in
response to a variety of disorders but primarily from lung
and CNS problems. Lung diseases include lung cancer, tuber-
culosis, pneumonia, chronic obstructive pulmonary disease
(COPD), asthma, respiratory failure from any cause, and use
of mechanical ventilation. SIADH is also associated with
encephalitis, status epilepticus, brain tumors, meningitis,
head trauma, and strokes. The mechanism of ADH release in
these disorders is unclear. Some cancer chemotherapeutic
drugs, chlorpropamide, nicotine, tricyclics, serotonin reup-
take inhibitors, and some opioids are associated with SIADH.
Some patients with septic shock are thought to have phys-
iologic vasopressin deficiency, which contributes to refractory
hypotension. Thus these patients are treated with physiologic
replacement doses of vasopressin (ADH). While these physi-
ologic doses should not be associated with hyponatremia,
hyponatremia is reported to be a side effect.
D. Hyponatremia without Hypotonicity—Hyponatremia
without hypotonicity was seen in patients with severe hyper-
triglyceridemia or hyperproteinemia (>10 g/dL) when
plasma sodium was measured by flame photometry. This
should no longer be a problem with the use of ion-specific
sodium electrodes.
E. Hyponatremia with Hypertonicity—In this seemingly
paradoxical situation, hyponatremia is not associated with
increased TBW but with decreased TBW. It is seen com-
monly with hyperglycemia and occasionally with administra-
tion of mannitol. Enhanced gluconeogenesis or glycogenolysis
in diabetics—or exogenous glucose administration—adds a
large quantity of osmotically active molecules to the extracel-
lular compartment. Water moves from the intracellular space
to the extracellular space to equalize osmotic gradients.
Osmolality increases throughout the body, but plasma
sodium falls because of the additional water moving out of
the cells into the extracellular space. The hyponatremia may
be mistakenly thought to be evidence for excessive TBW
when instead there is a TBW deficit.
Hyponatremia in the presence of hyperglycemia can be
addressed in several ways. First, laboratory measurement of
plasma osmolality will give a correct assessment of water bal-
ance; plasma osmolality will be higher than estimated from
plasma sodium. Another way is to “correct” the plasma sodium
for the degree of hyperglycemia. One empirical correction is to
add to the measured plasma sodium 1 meq/L for every
60 mg/dL the plasma glucose is increased above 100 mg/dL. For
example, if plasma sodium is 130 meq/L and plasma glucose is
1300 mg/dL (1200 mg/dL above 100 mg/ dL), the “corrected”
plasma sodium will be 130 + 20 = 150 meq/L. The corrected
plasma sodium is a valid estimate of the increase or decrease of
TBW relative to solute. Although glucose is the most commonly
encountered solute that causes this phenomenon, other extra-
cellular solutes such as mannitol and radiopaque contrast agents
can cause hyponatremia with decreased TBW.
Clinical Features
Figure 2–1 shows a clinical and laboratory approach to the
diagnosis of hyponatremia and identification of the cause of
low plasma sodium.
A. Symptoms and Signs—Hyponatremia associated with
decreased osmolality is often asymptomatic until plasma
sodium falls below 125 meq/L, but the rate of change is
clearly important. Rapid development is associated with more
severe acute changes. Subtle neurologic findings sometimes
can be identified, such as decreased ability to concentrate or
perform mental arithmetic. Severe symptoms—including
altered mental status, seizures, nausea, vomiting, stupor, and
coma—occur when plasma sodium is less than 115 meq/L,
when hyponatremia develops acutely, or when plasma
sodium is  less than 105–110 meq/L during chronic hypona-
tremia. A syndrome of opisthotonos, respiratory depression,
impaired responsiveness, incontinence, hallucinations,
decorticate posturing, and seizures has been termed hypona-
tremic encephalopathy. Occasionally, patients with chronic
hyponatremia may be awake, alert, and oriented even with
the plasma sodium as low as 100 meq/L; these patients are
almost always found to have slowly developed hyponatremia.
Symptoms and signs of any underlying disorder should
be sought. Medications that can affect urinary water excre-
tion should be identified and discontinued. These include
thiazide diuretics and drugs that impair renal function.
Thiazide-induced hyponatremia has been reported to be
more common in women, but advanced age was not a risk
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factor. Enalapril given to elderly patients is reported to cause
hyponatremia. Excessive water drinking can be identified
from the history and the presence of polyuria, but large vol-
umes of water may be given inadvertently in the ICU.
Adrenal insufficiency and hypothyroidism should be consid-
ered in critically ill patients. Hyponatremia has been associ-
ated with hospitalized AIDS patients; volume depletion from
gastrointestinal fluid losses and SIADH were the most com-
mon causes, and there was an increase in morbidity and
mortality in those with hyponatremia. For unclear reasons,
young women recovering from surgery can have particularly
severe symptoms and a poor prognosis from hyponatremia.
Although previously thought to be caused by excessive hypo-
tonic fluid replacement, hyponatremia results from genera-
tion of inappropriately concentrated urine, high ADH levels,
and possibly estrogen-induced sensitivity to ADH.
Patients with hypovolemic hyponatremia may have evi-
dence of volume depletion such as hypotension, tachycardia,
decreased skin turgor, or documented weight loss, but these
findings may be subtle or absent; those with hypervolemia
have edema and weight gain. SIADH is confirmed by lack of
evidence of abnormal extracellular volume and is sometimes
accompanied by clinical findings suggesting pulmonary or
CNS disease.
 Figure 2–1. Clinical and laboratory approach to the diagnosis of hyponatremia.
mOsm/L?
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Hyponatremic encephalopathy is thought to be due to
cerebral edema from water shifts into the brain and increased
intracranial pressure. Decreased cerebral blood flow plays a
role. Movement of solute out of brain cells—given sufficient
time—minimizes the effects, probably explaining the lack of
symptoms of slowly evolving hyponatremia. On the other
hand, evidence has linked a specific neurologic syndrome,
osmotic demyelination syndrome (central pontine and
extrapontine myelinolysis), with both severe hyponatremia
and rapid correction of hyponatremia. It is speculated that
adaptation to hyponatremia may be the cause of demyelina-
tion in susceptible regions of the brain. A firm conclusion
cannot be made about whether osmotic demyelination syn-
drome is due to the severity of hyponatremia or to exces-
sively fast correction. Osmotic demyelination syndrome is
reported to occur about 3 days after the start of correction of
hyponatremia, but findings may be seen before, during, or
after plasma sodium has been corrected. Corticospinal and
corticobulbar signs are reported most often, including weak-
ness, spastic quadriparesis, dysphonia, and dysphagia, but
impaired level of consciousness is common. Radiolucent
areas on CT scan or decreased T1-weighted MRI intensity
provides evidence of myelinolysis in the central pons and
elsewhere.
B. Laboratory Findings—Plasma electrolytes; glucose, crea-
tinine, and urea nitrogen; plasma osmolality; urine osmolal-
ity; urine Na+; and urine creatinine (to calculate fractional
excretion of Na+) should be measured. Low plasma osmolal-
ity (<280 mOsm/kg) confirms hyponatremia owing to
increased water relative to solute. The corrected plasma
sodium should be used if there is hyperglycemia. An associa-
tion has been found between hyponatremia with hypokalemia
and severe body potassium depletion. Hypokalemia also may
predispose patients with hyponatremia to osmotic demyelina-
tion syndromes and encephalopathy. Particularly high mortal-
ity has been found when hyponatremia is associated with
hypoxemia.
In patients with excessive water intake as the cause of
hyponatremia, urine osmolality will be low (<300
mOsm/kg). Patients with hypovolemia will have low urine
sodium (<20 meq/L), fractional excretion of sodium (<1%),
and fractional excretion of urea (<35%), and these also may
be seen in patients with increased extracellular volume but
low intravascular volume. If, however, hypovolemia is caused
by a renal mechanism, urine sodium may not be appropri-
ately conserved.
The diagnosis of SIADH is made by finding inappropri-
ately high urine osmolality (usually 300–500 mOsm/kg) in
the presence of low plasma osmolality and the absence of low
urinary sodium concentration. It should be noted that in
SIADH, urine osmolality may be less than plasma osmolal-
ity but not as low as it should be because urine should be
maximally diluted in the presence of severe hypona-
tremia. For example, in SIADH, plasma osmolality may be
240 mOsm/kg, indicating severe water excess, whereas urine
osmolality is 200 mOsm/kg. Because maximally dilute urine
can be as low as 50 mOsm/kg in young healthy persons, these
findings are consistent with SIADH. Patients with renal dis-
ease may be limited in their maximum urinary diluting abil-
ity to 100–200 mOsm/kg.
Treatment
Severity of hyponatremia ([Na+] <120 meq/L), acuteness of
onset, and the presence of neurologic symptoms (ie, confu-
sion, stupor, coma, or seizures) determine how quickly treat-
ment should be instituted and how aggressively it should be
pursued. If the patient is asymptomatic and hyponatremia is
mild and chronic, the need to treat is less emergent, and
aggressive treatment is not needed.
A. Estimation of Water Excess—Water excess can be esti-
mated by relating current measured [Na+] to TBW and sub-
stituting 140 meq/L for normal [Na+]:
For a 70-kg man with a normal TBW of 0.6 L/kg, normal
TBW would be 42 L. If [Na+] is 110 meq/L, TBW would be
estimated as 42 × 140 ÷ 110 = 53.5 L. The water excess would
be 53.5 L – 42 L = 11.5 L. If it is desired to correct [Na+] to 125
meq/L because of concern about too-rapid correction to nor-
mal in a patient with chronic hyponatremia, the estimated
water excess to be corrected would be 53.5 L – (42 × 125 ÷
110) = 5.8 L.
B. Determine Need for Rapid or Aggressive Correction—
Patients with hyponatremia who have altered mental status
or seizures attributed to hyponatremia require rapid treat-
ment. Most patients with severely reduced [Na+] (<105 meq/L)
are also a concern even if asymptomatic. Symptomatic
hyponatremia is usually associated with severely reduced
[Na+], and only rarely do these patients have water intoxica-
tion from psychogenic water ingestion, thiazide diuretics,
decreased solute excretion, or conditions of hypo- or hyper-
volemia. SIADH is the most commonly encountered problem
requiring aggressive and rapid correction of hyponatremia.
Patients with neurologic disorders, including stroke, hemor-
rhage, and head injury, are at particularly high risk for com-
plications of hyponatremia.
C. Correct the Underlying Problem—Of the underlying
problems leading to hyponatremia, the most straightforward
and easily corrected is hypovolemia. Administration of normal
saline repletes the intravascular volume and inhibits ADH
release by reducing the hypovolemic stimulus. Water excretion
is enhanced by the increased glomerular filtration rate, and
urine should become quickly and near maximally dilute, facil-
itating water excretion. Patients with psychogenic water intox-
ication and those being given large volumes of intravenous
fluid already should be maximally excreting water; removing
TBW (L) normal TBW (L)
140
[Na ]
= ×
+
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the intake of water leads to rapid restoration of normal [Na+]
if there are no other medical problems. Discontinuation of
thiazide diuretics results in rapid restoration of maximum uri-
nary dilution in most patients. Hypokalemia should be cor-
rected because this has been associated with complications of
hyponatremia and its treatment.
Hypervolemia (edematous states) with hyponatremia rep-
resents a more difficult problem of management, but severe
hyponatremia is unusual. It is especially important to avoid
“correcting” a low plasma [Na+] in congestive heart failure by
giving more sodium and chloride. Although effective arterial
volume is diminished, additional volume expansion will have
only a transient effect on ADH release and can worsen
peripheral edema, ascites, or pulmonary edema. In patients
with congestive heart failure, improvement of hyponatremia
has followed successful treatment with afterload reduction.
Patients with nephrotic syndrome and cirrhosis have a tem-
porary response to albumin infusions, but longer-term ther-
apy depends on improving the underlying disease.
Adrenal insufficiency, hypothyroidism, and other specific
causes of hyponatremia will respond to correction of the
underlying problem. SIADH occasionally responds to treat-
ment of the condition leading to this syndrome, but therapy
is usually directed toward correction of the hyponatremia
itself.
If vasopressin is being administered for refractory septic
shock, it should be discontinued unless absolutely necessary
to help maintain blood pressure.
D. Specific Treatment of Normovolemic Hyponatremia
(SIADH)—There is not yet agreement on the rate of correc-
tion of hyponatremia that minimizes the risk from low
plasma tonicity and the risk of excessively rapid correction
with osmotic demyelination syndrome. Because symptomatic
hyponatremia almost always will respond to a small increase
in [Na+] (~5 meq/L) and the risk of osmotic demyelination
appears to be minimal when [Na+] increases at less than
12 meq/L per day, a compromise target of about 8 meq/L per
day is often recommended. In general, rapid correction of
hyponatremia is not indicated after the patient’s [Na+] is
greater than 125 meq/L or symptoms have abated.
The specific treatment of hypotonic hyponatremia is a
combination of water restriction and efforts to enhance
water excretion. Water restriction is usually sufficient for
asymptomatic or mild hyponatremia; hypertonic saline and
furosemide are indicated for symptomatic hyponatremia
and asymptomatic hyponatremia in which [Na+] is less than
105 meq/L.
1. Restriction of water intake—Restriction of water
intake, both oral and parenteral, will improve hyponatremia
from any cause and should be considered in all patients
except those with hypovolemia. Most patients with hypona-
tremia have decreased ability to excrete water, but water
restriction to a volume the kidneys can eliminate adequately
will lead to net water loss and correction of hyponatremia.
Water restriction to less than 1000–1500 mL/day is usually
successful in reversing hyponatremia when [Na+] is
between 125 and 135 meq/L and patients are asympto-
matic. More severe water restriction may be useful in some
patients. It is a mistaken belief that only electrolyte-free
water must be restricted and that solute-containing fluids
(eg, normal saline) can be given safely. Normal saline
(osmolality 308 mOsm/kg) may be hyperosmolal relative to
the plasma but is frequently hypoosmolal relative to the
more concentrated urine of patients with SIADH. Thus
administration of normal saline may result in a net gain of
water and worsening of hyponatremia.
2. Hypertonic saline and furosemide—The most potent
combination therapy for treating symptomatic hypona-
tremia is hypertonic saline (usually 3% NaCl) and
furosemide. Furosemide alone (40–80 mg given frequently
enough to maintain a brisk diuresis) will increase sodium
and chloride excretion and, by inhibiting solute transport
from the ascending loop of Henle, produce urinary dilution.
Although this will promote water loss, sodium and chloride
will be lost. Therefore, the goal is to replace urinary solute
losses but with a more concentration solution than the urine
so that there is a net loss of water from the body.
Ideally, the amount of sodium in the urine can be meas-
ured hourly, and the exact amount of sodium and chloride can
be replaced using hypertonic saline. However, a more practical
approach assumes that urine osmolality will be about 280–300
mOsm/kg in the presence of furosemide. Furosemide should
be given to achieve a urine output of 200–300 mL/h. If the
urine contains approximately 280 mOsm/kg, then about
70 mOsm/h is lost if urine output is 250 mL/h. Replacing
70 mOsm/h using 3% NaCl (1026 mOsm/L) requires only
68 mL/h. This causes a net water excretion rate of 182 mL/h
(250 mL/h – 68 mL/h) with a rise in plasma [Na+] of about
1 meq/L per hour. In practice, replacing about 25–30% of
urine volume each hour with 3% NaCl will approximate the
solute replacement required. As recommended earlier,
furosemide and 3% NaCl solution should be discontinued
when [Na+] is above 120–125 meq/L. Furthermore, [Na+]
must not exceed 130 meq/L in the first 48 hours. Excessive vol-
ume or rate of hypertonic saline should not be given because
acute volume overload and pulmonary edema may occur.
Calculation of the amount of hypertonic saline needed should
be double-checked, and it is unlikely that the total amount of
hypertonic saline will exceed 1000 mL or a rate greater than
60–75 mL/h. Plasma sodium should be followed closely and
appropriate adjustments made in the rate of correction.
A very useful formula can be derived from the preceding
relationship between plasma [Na+] and TBW. This formula
estimates the amount of change in plasma [Na+] when 1 L of
any fluid is administered:
ΔPlasma [Na ] f luid [Na ] plasma [Na ]
TBW 1
+
+ +
=
−
+
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where TBW is the calculated estimate of total body water (see
earlier). This formula is useful for determining how much the
plasma [Na+] will change in response to administration of 1 L
of hypertonic or normal saline. It does not take into account
fluid losses, however. To calculate the change for more than 1
L of fluid administration, you must calculate for each liter
incrementally—that is, calculate the change in plasma [Na+]
for the first liter and then enter the new value for [Na+] into
the formula to calculate the change for the next liter.
3. Vasopressin antagonism—Conivaptan, an arginine
vasopressin receptor antagonist, is approved for treatment of
euvolemic hyponatremia, such as SIADH, in which inappro-
priate levels of vasopressin are present. It should not be used
for hypovolemic hyponatremia. It works by antagonizing the
action of endogenous vasopressin at both V1A and V2 recep-
tors. Conivaptan is given as an intravenous loading dose of
20 mg followed by a continuous infusion of 20 mg/day for
1–3 days. Since the effect will vary among patients, careful
monitoring of urine output and plasma sodium is indicated.
E. Other Treatment for Chronic Hyponatremia—Patients
with reversible CNS or lung disease generally will respond
after correction or resolution of the underlying problem.
Mild to moderate water restriction may be necessary. A few
patients will need additional help to facilitate water excre-
tion; demeclocycline induces a mild nephrogenic diabetes
insipidus–like condition and may be useful in the manage-
ment of chronic hypotonic hyponatremia.
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 Hypernatremia
ESSENT IALS  OF  D IAGNOS I S
 Plasma sodium >145 meq/L 
 Serum osmolality >300 mOsm/kg
 Evidence of increased solute administration, polyuria
with dilute urine (diabetes insipidus), or inadequate
water intake
 Altered mental status
General Considerations
In contrast to hyponatremia, for which hypotonicity is often
but not always present, hypernatremia, defined as [Na+] greater
than 145 meq/L, is always associated with hypertonicity,
defined as plasma osmolality greater than 300 mOsm/kg.
Severe hypernatremia must be treated vigorously but carefully
to avoid excessively rapid correction and further complications.
Hypernatremia indicates a deficit of TBW relative to total
body solute (Table 2–8). This condition occasionally develops
when a large amount of solute is given in concentrated form,
but hypernatremia is much more commonly associated with
either insufficient water intake or excessive water loss.
A. Addition of Solute—Addition of solute to the body with-
out a corresponding addition of water results in an increase in
plasma osmolality. The source of solute may be exogenous,
such as administration of hypertonic saline or sodium bicar-
bonate, glucose, mannitol, or other solutes. The only com-
mon endogenous mechanism is gluconeogenesis and
glycogenolysis causing hyperglycemia. As discussed earlier,
hyperglycemia increases plasma osmolality without causing
hypernatremia. Increased plasma urea increases plasma
osmolality but does not increase tonicity because urea con-
centration also increases within cells. When solute is added,
increased plasma osmolality stimulates maximum ADH
release to minimize water excretion (urine osmolality
increases). Correction of the hyperosmolal state results when
the excess solute is disposed of or, in the case of glucose,
excreted or taken into the cells as glycogen. However, the obli-
gate loss of water needed to excrete solute requires that water
be given to the patient to achieve appropriate correction.
B. Inadequate Water Intake—Insufficient water intake
results in hypernatremia because of obligatory renal and non-
renal water losses. Daily insensible loss of water amounts to
about 500 mL, increasing somewhat with body temperature
and sweating. Because most insensible loss is through the air-
ways, intubation and mechanical ventilation with humidified
air decrease insensible losses to minimal amounts.
Minimum urine volume is determined by maximum
urine concentration and obligate solute excretion. As calcu-
lated in Table 2–6, the normal urinary solute excretion of
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800 mOsm/day necessitates a mandatory loss of 670 mL of
water per day if urine is maximally concentrated (to 1200
mOsm/L). Thus minimal water loss in adults of normal size
is approximately 1170 mL/day (670 mL urine plus 500 mL
insensible loss). Because metabolism generates about
500–600 mL water per day, there is a mandatory intake of
600–700 mL water per day. Failure to take in at least this
much water predictably results in hypernatremia.
C. Excessive Water Loss—The final major mechanism of
hypernatremia is excessive water loss with inadequate replace-
ment. Some patients are unable to concentrate urine maxi-
mally, thereby making mandatory an increased intake of water
to avoid development of hyperosmolality. Maximum urine
concentration in normal subjects is 1200 mOsm/L but
depends on having normal renal tubular function, normal
solute load, and normal ADH release and response. Renal
tubulointerstitial disease such as seen in sickle cell anemia,
urate nephropathy, and renal cystic disease; use of loop diuret-
ics such as furosemide; and use of drugs such as demeclocy-
cline and lithium interfere with urine concentrating ability. An
increase in renal tubular solute load forces the tubules to
produce a urine that is isosmotic with plasma (isosthenuria).
Glucose, mannitol, and urea are the most likely encountered
poorly reabsorbable solutes that contribute to such an
“osmotic diuresis,” limiting maximum urine concentration.
Patients who lack appropriate ADH release from the poste-
rior pituitary or whose kidneys do not respond properly to
ADH have impaired urine concentrating ability and polyuria
and will develop hypernatremia in the absence of increased
water intake. Lack of ADH production (central diabetes
insipidus) results from head trauma, pituitary tumors, tumors
adjacent to the pituitary, granulomatous diseases such as
tuberculosis and sarcoidosis, meningitis, and vascular anom-
alies near the hypothalamus. Occasionally, diabetes insipidus
is idiopathic. If ADH is present but the kidneys do not respond
by increasing urine concentration, a diagnosis of nephrogenic
diabetes insipidus is made. This relative or absolute resistance
to ADH is seen in a familial form, may be due to drugs such as
demeclocycline or lithium, or may be found in conjunction
with tubulointerstitial diseases of the kidneys.
Sweating increases water loss greatly, especially during
hot weather and with high fever, and gastrointestinal tract
losses may be marked in patients with diarrhea or vomiting.
Clinical Features
Hypernatremia and hyperosmolality should be suspected in
patients with decreased access to water, especially with
altered mental status, or those with a history of polyuria. The
elderly patient living in a chronic care facility is especially
susceptible. However, many patients are identified through
routine electrolyte determinations. The severity of water
deficit is estimated from the plasma electrolytes and body
weight. Figure 2–2 shows a clinical and laboratory approach
to patients with hypernatremia.
A. Symptoms and Signs—As with hyponatremia, hyperna-
tremia and hypertonicity affect primarily the brain. Both the
addition of solute to the extracellular compartment (causing
water to move out of cells) and the net loss of water from the
body acutely decrease the size of brain cells. Shrinkage of
brain cells can lead to altered mental status, impaired think-
ing, and loss of consciousness. Cerebral hemorrhage, thought
to be due to tearing of blood vessels owing to brain shrinkage,
is a rare complication. In patients who can respond, thirst is
an important clue to both hypovolemia and hypertonicity. A
history of polyuria and nocturia is important in establishing
the cause of hypernatremia as diabetes insipidus.
The clinical situation, symptoms, and signs may provide
clues to the cause of hypernatremia. Addition of large quanti-
ties of solute is a rare cause. Saltwater near-drowning is said
to cause hypernatremia by absorption of Na+ and Cl– through
the lungs, but this is rare in those who survive asphyxiation.
Others will have a history of receiving hypertonic saline, man-
nitol, glucose, or sodium bicarbonate. Volume overload may
cause pulmonary and peripheral edema in these patients.
A history of decreased water intake may be obtained in
patients who have not had access to water at home or in the
Increased sodium load 
Hypertonic sodium chloride infusion 
Hypertonic sodium bicarbonate infusion  
Increased net water loss (nonrenal)  
Sweating  
Diarrhea  
Exertion during hot weather  
Associated with polyuria  
Osmotic diuresis:
1. Sodium diuresis  
Loop diuretics  
2. Nonsodium diuresis  
a. Mannitol  
b. Glucose  
c. Urea (postobstructive diuresis)  
Water diuresis:  
1. Decreased ADH release (central diabetes insipidus) 
a. Head trauma  
b. Surgery  
c. Pituitary tumor  
d. Infection, granulomatous diseases  
e. Vascular (aneurysms)  
2. Decreased ADH effectiveness (nephrogenic diabetes insipidus)  
a. Tubulointerstitial disease 
b. Lithium  
c. Demeclocycline  
d. Hypokalemia  
e. Hypercalcemia  
Table 2–8. Disorders of water balance: Hypernatremia. 
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hospital (eg, acute illness, altered mental status, or trauma)
or who have had increased normal losses of water from
extrarenal mechanisms (eg, exertion in hot weather or diar-
rhea). Features suggestive of decreased extracellular volume
status include hypotension, tachycardia, and oliguria.
If the patient has hypernatremia, polyuria with dilute
urine suggests that the excessive water loss is due to inability to
concentrate the urine appropriately (central or nephrogenic
diabetes insipidus). Hypernatremia with polyuria and isos-
thenuric urine suggests solute diuresis.
B. Laboratory Findings—Laboratory studies are needed to
make the diagnosis of hypernatremia, confirm plasma hyper-
osmolality, and determine the cause. In general, plasma elec-
trolytes and osmolality; glucose, creatinine, and urea nitrogen;
urine osmolality; urine Na+ and creatinine; and urine volume
(UOsm high)
(UOsm = SOsm)
(UOsm
 Figure 2–2. Clinical and laboratory approach to the diagnosis of hypernatremia.
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should be measured. Plasma sodium greater than 145 meq/L
makes the diagnosis of hypernatremia, and this will be accom-
panied by plasma osmolality greater than 300 mOsm/kg.
1. Hypernatremia without polyuria—In the absence of
renal disease and with normal ADH response, patients in
whom addition of solute is the cause of hypernatremia will
excrete small amounts of concentrated urine. Urine osmolal-
ity is greater than 300 mOsm/kg and usually much higher
(up to 1200 mOsm/kg in normal young adults). Patients with
decreased water intake relative to nonrenal water losses with
normal renal function also will have maximum conservation
of urine volume with oliguria, plasma urea nitrogen:plasma
creatinine ratio greater than 30, low urine Na+, and low frac-
tional excretion of Na+.
2. Hypernatremia with polyuria—In the presence of
hypernatremia, polyuria with dilute urine suggests that the
mechanism of water loss is inability to concentrate the urine
appropriately, but the driving force for polyuria may be either
solute (osmotic) diuresis or water diuresis. Water diuresis and
solute diuresis can be distinguished by the ratio of urine to
plasma osmolality (UOsm/POsm). UOsm/POsm in solute diuresis
(osmotic diuresis) is greater than 0.9; UOsm/POsm in water diure-
sis is less than 0.9. Thus solute diuresis generally is associated
with isosthenuria, whereas water diuresis is associated with
excretion of dilute urine. Solute diuresis can be further subdi-
vided into electrolyte diuresis or nonelectrolyte diuresis. If 2 ×
(U[Na+] + U[K+]) >0.6 × UOsm, then the majority of solute in the
urine consists of electrolytes such as sodium and potassium; if it
is less than 0.6 × UOsm, then urea, glucose, mannitol, or other
nonelectrolyte solute is the cause of the diuresis. Electrolyte
diuresis is seen with administration of diuretics and is the nor-
mal response to correction of increased extracellular volume.
Patients in the ICU who are receiving excessive amounts of nor-
mal saline have increased urine output and NaCl diuresis. Urea-
induced diuresis occurs after relief of obstructive nephropathy
and in the diuretic phase of acute tubular necrosis.
The polyuria with water diuresis may be normal (eg, if
the patient has hyponatremia) but is abnormal during
hypernatremia, suggesting diabetes insipidus.
3. Diabetes insipidus—Diabetes insipidus is usually charac-
terized by hypernatremia, polyuria, and decreased ability to
concentrate urine maximally, but some mild cases may be dif-
ficult to identify, and in other cases, earlier treatment may
confuse the diagnosis. A water deprivation test may be neces-
sary. In this test, a patient with normal or near-normal plasma
osmolality is deprived of water for a scheduled interval while
weight, plasma sodium and osmolality, and urine volume and
osmolality are measured. If polyuria continues and urine con-
centration fails to increase into an appropriately high range
(>800 mOsm/kg) despite a plasma osmolality greater than
290–300 mOsm/kg, a diagnosis of diabetes insipidus is made.
Water deprivation is allowed to continue until the patient loses
3–5% of body weight. For safety when designing the water depri-
vation test, patients should be anticipated to continue to maintain
urine output at the starting rate. Thus, for example, if urine vol-
ume is initially 600 mL/h, a 60-kg patient could be expected to
lose 3% of body weight in just 3 hours; if this urine is maximally
dilute (eg, severe central diabetes insipidus), the expected
increase in plasma osmolality also can be calculated. Actual
weight loss and urine volume should be used to make the deci-
sion to stop the test. Five units of aqueous vasopressin is admin-
istered at the end of the test if urine concentration fails to rise.
Lack of response to vasopressin indicates that the cause is
nephrogenic rather than failure of release of ADH. Lack of
ADH or of response to ADH can be complete or partial.
Identification of intermediate response may be important in
deciding treatment, and this usually can be concluded from the
degree of urine concentration achieved during the water depri-
vation test.
Treatment
A. Calculation of Water Deficit—All patients with hyper-
natremia have increased plasma osmolality, and the amount
of water needed to correct this state can be calculated from
the following equation:
If [Na+] is 170 meq/L and normal TBW is 0.6 L/kg, the TBW
for a man whose customary weight is 70 kg is approximately
42 L × 140 ÷ 170 = 35 kg (L), and the water deficit is 42 – 35
= 7 L. Note that this is the amount of water needed to correct
[Na+] to 140 meq/L. In practice, the patient’s normal body
weight may not be known, but only the current body weight.
Using current weight is acceptable as an estimate, but it is
potentially misleading because the water deficit may con-
tribute to the weight difference.
B. Rate of Correction of Hypernatremia—Just as with
hyponatremia, too-rapid correction of hypernatremia may be
harmful. Cerebral edema with neurologic complications has
occurred during correction as a result of a compensatory
mechanism intended to maintain normal brain cell volume.
In response to development of hypertonicity, brain cells fairly
rapidly increase the amount of inorganic ions; this restores
cell volume to near normal, but at the expense of disrupted
cellular function. With persistence of hypertonicity, brain
cells generate and take up idiogenic osmoles, sometimes
called organic osmolytes. Since cell volume is determined from
the amount of solute contained within the cell, organic
osmolytes resist the movement of water out of the cells and
maintain brain volume close to normal. Many of the organic
osmolytes are taken up from the extracellular space by the
formation of specific membrane channels. These channels do
not disappear quickly or reverse function when hyperna-
tremia is corrected. Therefore, rapid restoration of water to
the body theoretically may cause overexpansion of these cells,
resulting in cerebral edema. Although mild controversy exists,
TBW (L) normal TBW (L)
140
[Na ]+
= ×
FLUIDS, ELECTROLYTES, & ACID-BASE  33
conservative recommendations are to correct hypernatremia
by no more than 10 meq/L per day to allow elimination of
organic osmolytes and avoid cerebral edema. This slow rate of
correction may not be necessary in patients who develop
hypernatremia over the course of a few hours, however.
The following formula is very helpful in calculating the
anticipated changes in plasma [Na+] in the hypernatremic
patient given intravenous fluids. The rate of correction of
plasma [Na+] can be estimated. This formula estimates the
amount of change in plasma [Na+] when 1 L of any fluid is
administered:
where TBW is the calculated estimate of total body water
(see above). This formula demonstrates how little the
plasma [Na+] changes when normal saline ([Na+] = 154
meq/L) is given to a hypernatremic patient. In order to
determine how much hypotonic fluid is needed to achieve a
10 meq/L decrease in plasma [Na+] in 24 hours, begin by
calculating the change for 1 L of fluid administered, and
then calculate for the next liter, etc., until the desired change
is reached. The total number of liters of fluid divided by
24 hours will be the hourly infusion rate. Serial measure-
ments of plasma [Na+] are essential because the formula
does not account for other fluid sources, urinary losses, or
insensible water loss.
C. Hypernatremia Associated with Increased Solute—
These patients should have facilitation of solute excretion—
if possible, with diuretics and administration of water or 5%
dextrose in water. Diuretics will speed removal of sodium
and chloride, but the obligate loss of water with the solute
will increase the amount of water that must be given. If
patients have renal insufficiency, removal of solute may
require hemodialysis or ultrafiltration with replacement of
water. A few patients have been treated by hemodialysis with
dialysate containing hypotonic solution, facilitating water
replacement. Peritoneal dialysis using hypotonic solutions
should be efficacious in removing extracellular solute and
increasing water replenishment.
Patients with hyperosmolality owing to severe hyper-
glycemia are treated with intravenous insulin to lower blood
glucose, but normal saline (0.9% NaCl) is the preferred ini-
tial fluid replacement. Movement of glucose into cells is
accompanied by movement of water out of the intravascular
space, resulting in severe volume depletion. After adequate
normal saline is given, hypotonic fluid (5% dextrose in
water) is used to correct net water deficits.
D. Hypernatremia with Diminished Extracellular
Volume—These patients have either an extrarenal or renal
loss of hypotonic fluid. Therefore, both solute and water have
to be replaced. Extracellular volume should be replaced with
normal saline first, but it should be remembered that even
large volumes of normal saline, despite being hypotonic to
plasma in most hypernatremic patients, correct the water
deficit only very slightly. For example, if [Na+] = 170 meq/L
for a normally 70-kg patient, 1 L of 0.9% NaCl will add 308
mOsm of solute and 1 L of water, predictably decreasing
[Na+] to only about 169.5 meq/L. Therefore, if more rapid
correction of hypernatremia is desired, hypotonic fluid (5%
dextrose in water or 0.45% NaCl) should be given as well. In
practice, volume repletion is generally a higher priority, but
after some correction of the volume deficit, the water deficit
should be addressed directly.
E. Hypernatremia Associated with Diabetes Insipidus—
Hypernatremia in diabetes insipidus will respond to admin-
istration of water orally or 5% dextrose in water
intravenously, but correction of hypernatremia depends on
giving enough water both to overcome the water deficit and
to compensate for continued urine water losses. In severe
diabetes insipidus, urine volume can exceed 500 mL/h, and
with a severe water deficit, water may have to be given at rates
exceeding 600–700 mL/h.
Central diabetes insipidus should respond to synthetic
ADH compounds. Aqueous vasopressin (5–10 units two or
three times daily) can be given subcutaneously, or desmo-
pressin acetate, which lacks vasopressor effects but retains
ADH activity, can be given intravenously or subcutaneously
(2–4 μg/day) or by nasal spray. The dose should be adjusted
on the basis of plasma [Na+], urine output, and urine osmo-
lality. Ideally, urine output should be reduced to 3–4 L/day,
an amount that can be replaced readily by oral or intra-
venous administration.
Nephrogenic diabetes insipidus is rarely as severe as
complete central diabetes insipidus, and during water dep-
rivation, urine osmolality is sometimes as high as 300–400
mOsm/kg. Administration of enough water to maintain
normal plasma [Na+] usually can be achieved. If a reversible
cause such as lithium toxicity is found, the offending agent
can be discontinued, although the effect on renal concen-
trating ability may persist for days. Thiazide diuretics
induce mild volume depletion, leading to increased proxi-
mal tubular sodium reabsorption and decreased delivery of
sodium and water to the distal diluting segment, so that less
water is lost.
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DISORDERS OF POTASSIUM BALANCE
Potassium is the most abundant intracellular cation and the
second most common cation in the body. The ratio of intra-
cellular to extracellular potassium concentration is normally
about 35:1, whereas sodium is much higher in the extracellu-
lar space. The importance of these distributions is reflected
in the ubiquitous Na+,K+-ATPase pumps on the cell mem-
branes that continuously move K+ into and Na+ out of the
cells to maintain these gradients. The intracellular:extracel-
lular ratios for Na+ and K+ determine the electrical potential
across the cell membrane and are responsible for initiating
and transmitting electrical signals in nerves, skeletal muscle,
and myocardium. The two major mechanisms that deter-
mine plasma [K+] are renal potassium handling and the dis-
tribution of potassium between the intracellular and
extracellular compartments.
Plasma Potassium and Total Body Potassium
Laboratory determinations of potassium are made on either
serum or plasma. There is no appreciable difference between
the two in the absence of thrombocytosis (which can cause
elevated serum potassium but has minimal effect on plasma
potassium), and plasma potassium will be used in this dis-
cussion. Plasma potassium [K+] is closely regulated, but
hyper- and hypokalemia do not necessarily indicate
increased and decreased total body potassium because of the
high proportion of intracellular potassium. For example,
movement of K+ out of the cells and into the extracellular
space can mask severe depletion of total body K+; similarly,
hypokalemia may be seen despite increase in total body K+.
The use of plasma [K+] to estimate the need to administer or
remove potassium from a patient always must take into
account factors that alter the intracellular:extracellular distri-
bution of potassium.
Renal Potassium Handling
In the normal steady state, dietary potassium intake is
excreted almost entirely by the kidneys, although small
amounts of potassium are lost in sweat and gastrointestinal
fluids. Large amounts of potassium can be excreted by the
kidneys as long as sufficient time to adapt is given, and potas-
sium can be conserved with moderate efficiency in normal
individuals, although not to the same extent as sodium.
Almost all potassium in the glomerular filtrate is reab-
sorbed. Therefore, urinary potassium comes from secretion
of potassium into the tubular fluid through potassium chan-
nels on distal renal tubular cells, especially those of the corti-
cal collecting tubules. Increased concentration of tubular cell
potassium and a greater degree of electronegativity of adja-
cent tubular fluid increase the rate of potassium secretion.
The strongest impetus to potassium secretion, though, is
sodium reabsorption. The aldosterone-regulated Na+,K+-
ATPase pump on the blood side of the tubular cell transports
potassium into the cell against its concentration gradient and
moves Na+ out of the cell into the blood. This creates a
sodium gradient from the tubular lumen into the cell caus-
ing passive movement of sodium through epithelial sodium
channels (enhanced by aldosterone) and generating an elec-
tronegative luminal fluid as anions such as chloride and
bicarbonate remain in the lumen. In turn, potassium moves
passively from a high concentration inside the cell into the
tubule both because of the lower tubular potassium concen-
tration and because of the more electronegative fluid.
Potassium excretion is facilitated by increased aldosterone
(increased Na+,K+-ATPase pump activity and opening of
luminal Na channels), increased distal tubular Na+ delivery
(larger quantity of Na+ to draw out of tubule), the presence
of poorly reabsorbable tubular anions, and increased intra-
cellular potassium concentration. Clinical correlates of each
of these factors can be shown in Table 2–9, by which normal
and abnormally excessive potassium excretion can be
explained. Failure of these mechanisms for potassium excre-
tion potentially leads to increased total body potassium in
the face of continued potassium intake.
Distribution of Total Body Potassium
The other major mechanism determining potassium balance
and plasma [K+] is the intracellular-extracellular distribution
of potassium. Only a small quantity of potassium is found in
the extracellular space. If plasma [K+] is 4 meq/L and potas-
sium is freely distributed throughout the estimated 12 L of
extracellular water in a normal 60-kg subject, then only
48 meq of K+ is present in this space. The intracellular com-
partment has a concentration of 130 meq K+/L × 24 L intra-
cellular volume, or 3120 meq K+ within cells. The main
mechanisms for maintaining this distribution are the Na+,K+-
ATPase membrane pumps that draw K+ into the cells and
move Na+ out of cells. These pumps are subject to control by
insulin and epinephrine, each stimulating increased Na+ and
K+ exchange by different mechanisms. Insulin has in fact been
considered by some to have plasma potassium regulation as
its major role. Clinically, exogenous insulin administration is
associated with potential for hypokalemia despite no change
in total body potassium. In addition, insulin-dependent dia-
betics with renal insufficiency (inability to excrete potassium
readily) are prone to severe hyperkalemia unless adequate
insulin therapy is given. Beta-adrenergic agonists also can
cause hypokalemia by an epinephrine-like effect, and beta-
adrenergic antagonists prolong and amplify the rise in plasma
potassium after administration of potassium.
Blood pH also has an effect on the intracellular-
extracellular potassium distribution but does not act
through the Na+,K+-ATPase pump. However, acid-base dis-
turbances have less effect on plasma [K+] than is generally
assumed. Of the acid-base disturbances, metabolic acidosis in
which the acid is predominantly extracellular and inorganic—
that is, hyperchloremic acidosis—causes the largest increase in
plasma potassium, potentially with severe life-threatening
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hyperkalemia. The mechanism is thought to be exchange of
extracellular hydrogen ion for intracellular potassium in the
absence of simultaneous movement of chloride into the cell.
Metabolic acidosis in which an organic anion is largely
intracellular—for example, lactic acidosis or ketoacidosis—
results in little or no change in plasma [K+]. Metabolic alka-
losis often causes hypokalemia, but its major effect is to
increase the quantity of bicarbonate in the distal tubule,
resulting in severe renal potassium losses.
 Hypokalemia
ESSENT IALS  OF  D IAGNOS I S
 Plasma [K+] <3.5 meq/L.
 Usually asymptomatic, but there may be muscular
weakness.
 Severe hypokalemia affects neuromuscular function and
electrical activity of the heart: arrhythmias, ventricular
tachycardia, increased likelihood of digitalis toxicity.
General Considerations
Hypokalemia is a potentially hazardous electrolyte distur-
bance in many critically ill patients. Because the intracellular
potassium concentration is so much larger, and because it is
the ratio of intracellular to extracellular potassium that
determines cell membrane potential, small changes in extra-
cellular potassium can have serious effects on cardiac
rhythm, nerve conduction, skeletal muscles, and metabolic
function. Patients in the ICU may have a number of disor-
ders that are associated with hypokalemia, including diar-
rhea, solute diuresis, vomiting, metabolic alkalosis, and
malnutrition. Treatment with insulin, beta-adrenergic ago-
nists, diuretics, some antibiotics, and other drugs increases
the likelihood of potassium depletion and hypokalemia.
Hypokalemia may or may not be associated with deple-
tion of total body potassium. Thus mechanisms of
hypokalemia can be divided into those in which total body
potassium is low (eg, decreased intake or increased loss) or
those in which total body potassium is normal or high (eg,
redistribution of extracellular potassium into cells).
A. Depletion of Body Potassium—Normal subjects require
at least 30–40 meq/day to replace obligate losses of potassium,
Mechanism of Regulation Examples 
Renal potassium excretion 
Facilitated by:
Increased Na+ reabsorption in distal nephron 
Increased Na+ delivery to distal nephron
Increase in poorly reabsorbable tubular anions
Increased intracellular K+ concentration
Magnesium depletion
Volume depletion, aldosterone
Loop diuretics, thiazides
Carbenicillin, bicarbonate, keto acids, inorganic anions 
Increased intracellular K+ distribution 
Amphotericin B, cisplatin, aminoglycosides 
Impaired by: 
Decreased K+ filtration 
Decreased Na+ delivery to distal nephron 
Inhibition of K+ secretion 
Renal insufficiency 
Volume depletion with proximal Na+ reabsorption 
Amiloride, spironolactone, triamterene, trimethoprim, decreased
aldosterone  
Decreased extracellular:intracellular K+ ratio (hypokalemia)
Increased plasma insulin level
Catecholamines (beta-adrenergic agonists) 
Metabolic alkalosis 
Exogenous insulin, hyperalimentation
Bronchodilators, decongestants, theophylline 
Vomiting, volume depletion 
Increased extracellular:intracellular K+ ratio (hyperkalemia)
Decreased plasma insulin level 
Beta-adrenergic blockade 
Metabolic acidosis (hyperchloremic) 
Depolarizing neuromuscular blockade 
Diabetes mellitus 
Propranolol 
Ammonium chloride, lysine hydrochloride, arginine hydro-
chloride, parenteral nutrition 
Succinylcholine 
Table 2–9. Plasma and total body potassium regulation by renal excretion and extracellular-intracellular
distribution. 
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but decreased intake of potassium alone is very rarely a
cause of hypokalemia except in critically ill patients who
are not being fed or given potassium. More commonly,
potassium depletion results from increased potassium
loss without adequate replacement. One classification is
to divide potassium loss into nonrenal and renal sources
(see Table 2–9).
Nonrenal potassium losses can result from severe diarrhea
and excessive sweating (although vomiting and nasogastric
suction stimulate renal potassium excretion), but increased
renal potassium loss that results from increased secretion of
potassium is found more commonly in ICU patients. Almost
all filtered potassium is reabsorbed, and renal tubular dys-
function rarely leads to impaired reabsorption.
Several factors facilitate renal potassium secretion. First,
any cause of increased mineralocorticoids contributes to
renal loss of potassium—including volume depletion, in
which aldosterone increase is compensatory, and primary
hyperaldosteronism. Cushing’s syndrome and pharmaco-
logic administration of hydrocortisone, prednisone, or
methylprednisolone often lead to decreased [K+] owing to the
mineralocorticoid activity of these corticosteroids. Unusual
causes of increased mineralocorticoid activity include licorice
ingestion (inhibits 11β-hydroxysteroid dehydrogenase) and
administration of potent synthetic mineralocorticoids such as
fludrocortisone. Second, increased delivery of sodium to the
distal nephron enhances potassium secretion. Solute diuresis
from glucose, mannitol, or urea increases distal sodium deliv-
ery by interfering with proximal sodium reabsorption.
Furosemide and other loop diuretics, which also increase
potassium loss because of volume depletion, increase distal
tubular sodium delivery by inhibiting sodium reabsorption in
the ascending loop of Henle. Thiazide diuretics increase
potassium exchange for sodium in the distal tubules. Rarely,
Bartter’s syndrome (a congenital defect of one of several
mechanisms of Na-Cl reabsorption in the ascending limb of
the loop of Henle) and Gitelman’s syndrome (a defect of the
thiazide-sensitive Na-Cl cotransporter in the distal nephron)
cause hypokalemia by renal salt wasting.
Any increased quantity of poorly reabsorbed anions in the
tubular lumen increases the electronegative gradient, drawing
potassium out of the distal tubular cells. Bicarbonate is less
easily absorbed than chloride, and increased distal tubular
bicarbonate is found in proximal renal tubular acidosis, dur-
ing compensation for respiratory alkalosis, and in metabolic
alkalosis. Other anions include those of organic acids such as
keto acids and antibiotics such as sodium penicillin.
Hypomagnesemia reduces Na+,K+-ATPase pump activity,
impairing intracellular potassium movement and impairing
repletion of total body potassium. Hypokalemia is seen in
about 40% of patients with magnesium deficiency; renal
potassium loss paradoxically increases during repletion of
potassium in this condition because of failure of cellular
uptake. Amphotericin B can cause renal potassium wasting by
acting as a potassium channel in the distal tubular cell.
Aminoglycosides are associated with hypokalemia by a similar
mechanism, but clinically significant hypokalemia attributed
to aminoglycosides is uncommon.
B. Abnormal Distribution of Potassium—Hypokalemia in
the face of normal or increased total body potassium must be
due to abnormal distribution of potassium between the
extracellular and intracellular spaces. Common causes of
decreased [K+] from potassium redistribution in ICU patients
include drugs and acid-base disturbances. Insulin has a major
role in transmembrane potassium transport. Either endoge-
nous insulin, increased after glucose administration, or the
combination of exogenous insulin and glucose can lead to
hypokalemia by this mechanism. Beta-agonists increase the
activity of the Na+,K+-ATPase pump, so beta-adrenergic
bronchodilators, sympathomimetic vasopressors, and theo-
phylline are causes of decreased [K+]. Metabolic and respira-
tory alkaloses do result in some shift of potassium into cells in
exchange for hydrogen ion; the major effect of metabolic
alkalosis, however, is to increase renal potassium secretion.
Clinical Features
Figure 2–3 shows a clinical and laboratory approach to the
diagnosis of hypokalemia.
A. Symptoms and Signs—Most hypokalemic patients are
asymptomatic, but mild muscle weakness may be missed in
critically ill patients. More severe degrees of hypokalemia
may result in skeletal muscle paralysis, and respiratory failure
has been reported owing to weakness of respiratory muscles.
Cardiovascular complications include electrocardiographic
changes, arrhythmias, and postural hypotension. Cardiac
arrhythmias include premature ventricular beats, ventricular
tachycardia, and ventricular fibrillation. Rhythm distur-
bances are seen more commonly in association with myocar-
dial ischemia, hypomagnesemia, or when drugs such as
digitalis and theophylline have been given. Hypokalemia may
exacerbate hepatic encephalopathy by stimulating ammonia
generation. The combination of severe hypokalemia, meta-
bolic alkalosis, and hyponatremia is often seen in patients
with evidence of volume depletion such as tachycardia,
hypotension, and mild renal insufficiency.
Although hypokalemia is most often a laboratory diagnosis,
it should be suspected in patients at risk. In the ICU,
hypokalemia is found commonly because many critical ill-
nesses and their treatments contribute to renal and nonrenal
potassium wasting. Patients being given diuretics (eg, thi-
azides, loop diuretics, acetazolamide, or osmotic diuretics),
beta-adrenergic bronchodilators, theophylline, corticos-
teroids, insulin, large amounts of glucose, total parenteral
nutrition, aminoglycosides, high-dose sodium penicillin, and
amphotericin B are among those who should have particular
attention paid to monitoring plasma [K+]. Toxic levels of theo-
phylline in particular can cause profoundly reduced plasma
[K+]. Patients with volume depletion, especially from diarrhea,
vomiting, or nasogastric suctioning (which induces both vol-
ume depletion and metabolic alkalosis), and osmotic diuresis
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should be watched carefully for development of hypokalemia.
In patients with renal failure undergoing dialysis, excessive
potassium losses are unusual, although they may occur.
B. Laboratory Findings—A plasma potassium concentration
of less than 3.5 meq/L makes the diagnosis of hypokalemia.
However, there is some evidence that complications of
hypokalemia may occur even when plasma potassium is in the
low end of the normal range. The electrocardiogram may show
nonspecific ST- and T-wave changes, although flattening of the
T wave with development of a U wave is considered character-
istic with more severe hypokalemia. Plasma [Na+] may be low
as a consequence of total body potassium depletion.
 Figure 2–3. Clinical and laboratory approach to the diagnosis of hypokalemia.
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Other laboratory findings are helpful for identifying the
cause of hypokalemia. Finding the mechanism of hypokalemia
is important because inappropriate replacement with large
amounts of potassium may lead to hyperkalemia if redistri-
bution rather than depletion of potassium is the cause of
hypokalemia. Confirmation of renal potassium wasting can
be useful. In the presence of hypokalemia, a urinary potas-
sium concentration of less than 20 meq/L suggests nonrenal
potassium wasting, whereas a urinary potassium concentra-
tion of greater than 20 meq/L increases the likelihood of
renal potassium wasting.
The transtubular potassium gradient (or ratio) can be
helpful in diagnosing renal potassium wasting:
where [UOsm] is urine osmolality and [POsm] is plasma osmo-
lality. This formula estimates the potassium concentration in
the distal nephron by multiplying the urine [K+] by the ratio
of urine osmolality to plasma osmolality to account for the
change in water concentration through the collecting ducts.
A ratio of distal tubular [K+] (numerator) to plasma [K+]
(denominator) of less than 2 indicates appropriate renal con-
servation of potassium in the face of hypokalemia. A ratio
greater than 4 suggests renal tubular potassium wasting. Even
if it is known that the mechanism of hypokalemia is excessive
urinary loss, urinary potassium determination can be a use-
ful guide to the amount of potassium replacement needed to
maintain normal levels or to correct hypokalemia.
Identification of a poorly absorbable anion in the urine is
usually not feasible, but an increased quantity of unmeasured
anions can be inferred if the sum of urine sodium and potas-
sium exceeds urine chloride concentration by greater than
40 meq/L. Redistribution of potassium leading to hypokalemia
cannot be definitely diagnosed by laboratory studies, although
metabolic or respiratory alkalosis can be identified by arterial
blood gases. Measurement of drug level may confirm theo-
phylline toxicity as a factor contributing to hypokalemia.
Treatment 
A. Estimating Total Body Potassium Deficit—Plasma
[K+] reflects only extracellular potassium. Although normal
intracellular potassium concentration is 35 times extracellu-
lar and normal intracellular volume is twice extracellular,
there is no simple relationship between plasma [K+] and total
body potassium. Nomograms and formulas for estimating
total body potassium deficit based on plasma [K+], pH, and
plasma osmolality are available, but these should not be
relied on heavily. However, in general, patients with severe
hypokalemia ([K+] <2.5 meq/L) and severe metabolic alkalosis
have the largest potassium deficits—up to 400 or 500 meq—
whereas those with hyperchloremic acidosis and mild
hypokalemia have milder deficits.
The magnitude of the potassium deficit has implications for
the amount of potassium needed to correct the deficit but not
necessarily for the urgency or amount immediately needed.
Because the clinical manifestations of hypokalemia are deter-
mined by the ratio of extracellular and intracellular [K+], any
degree of moderate to severe hypokalemia, regardless of the size
of the potassium deficit, may impose the same risk to the patient.
B. Severe Hypokalemia—The oral route is preferred for
potassium replacement, except in those patients whose oral
intake is restricted or whose hypokalemia is life-threatening.
The rate of administration and the amount of potassium
that can be given are limited by local complications
(irritation at the intravenous site) and because potassium is
distributed initially only into the extracellular space. Too-
rapid administration can result in large and dangerous
increases in extracellular and plasma [K+] before potassium
can be taken into cells. Special care should be taken in patients
receiving beta-adrenergic blockers, in type 1 diabetics, and in
patients with oliguric acute or chronic renal failure.
Potassium chloride and potassium phosphate are
available for intravenous use. Potassium chloride should
be given unless there is hypophosphatemia (see
“Hypophosphatemia” below). Intravenous potassium chlo-
ride can be given in concentrations as high as 60 meq/L.
The total amount of potassium in a single intravenous bag
should be restricted, however, to 20–40 meq to avoid the
risk of inadvertent rapid administration of excessive
amounts, and these amounts should be administered over
at least 1 hour into a peripheral vein. Because of the size of
the extracellular space into which potassium is initially dis-
tributed, 20–40 meq of potassium can cause the potassium
to rise as much as of 2–4 meq/L if it is not distributed
quickly to the intracellular compartment.
Intravenous potassium into central venous catheters
must be given cautiously and only when absolutely necessary.
Very high plasma [K+] levels can be achieved within the
heart, resulting in conduction system disturbances. However,
the large volume of blood into which the potassium mixes
generally dilutes [K+] rapidly. Large quantities of potassium
may be needed in special circumstances to counteract
hypokalemia, such as after open heart surgery. It is recom-
mended that each ICU develop a protocol to ensure safety in
giving potassium into central venous sites. In any patient
receiving intravenous potassium, frequent (every 1–2 hours)
serial monitoring of plasma [K+] is mandatory.
C. Potassium Replacement—Potassium needs should be
anticipated in ICU patients to avoid hypo- and hyperkalemia.
Patients receiving potent diuretics, those on continuous
nasogastric suction, those starting intravenous glucose for
parenteral nutrition, and those receiving digitalis should be
considered for increased potassium supplementation.
Patients with acute myocardial ischemia and infarction may
be more prone to arrhythmias, which can be prevented by care-
ful attention to plasma potassium levels. Other patients with a
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potential for hypokalemia include those prescribed beta-
adrenergic agonists (bronchodilators) or theophylline and
patients with hypomagnesemia. A special case is the treatment
of diabetic ketoacidosis. Insulin is expected to drive potas-
sium into cells along with glucose. Although potassium
should be withheld in those presenting with hyperkalemia,
patients with normal plasma [K+] generally can be expected
to require potassium supplementation during insulin treat-
ment because most patients have moderate to severe potas-
sium deficits from earlier solute diuresis. In many patients
with diabetic ketoacidosis, moderate to severe hypophos-
phatemia develops, and potassium phosphate is indicated.
D. Correct Underlying Disorder—The underlying disorder
contributing to hypokalemia may or may not be correctable.
Correction of magnesium deficiency may correct a state of
refractory potassium deficiency. Efforts should be made to
control extrarenal losses of potassium and fluid. Diuretics
causing hypokalemia generally must be continued for treat-
ment of volume overload states, but benefit sometimes can
obtained from potassium-sparing diuretics such as spirono-
lactone, triamterene, or amiloride, although these are less
potent natriuretic agents than furosemide. In critically ill
patients, potassium replacement plus furosemide is gener-
ally preferred over potassium-sparing diuretics, especially if
there is renal insufficiency, hypokalemia requiring simulta-
neous potassium supplementation, and a severe edematous
state. Similarly, amphotericin B, aminoglycosides, corticos-
teroids, and other drugs associated with hypokalemia used
in critically ill patients may not be avoidable and must be
continued.
Gennari FJ: Disorders of potassium homeostasis: Hypokalemia and
hyperkalemia. Crit Care Clin 2002;18:273–88. [PMID: 12053834]
Lin SH et al: Laboratory tests to determine the cause of
hypokalemia and paralysis. Arch Intern Med 2004;164:1561–6.
[PMID: 15277290]
Sedlacek M, Schoolwerth AC, Remillard BD: Electrolyte distur-
bances in the intensive care unit. Semin Dial 2006;19:496–501.
[PMID: 17150050]
Weiss-Guillet EM, Takala J, Jakob SM: Diagnosis and management
of electrolyte emergencies. Best Pract Res Clin Endocrinol
Metab 2003;17:623–51. [PMID: 14687593]
 Hyperkalemia
ESSENT IALS  OF  D IAGNOS I S
 Plasma [K+] >5 meq/L.
 Severe hyperkalemia affects neuromuscular function
and electrical activity of the heart, with abnormal ECG.
May develop heart block, ventricular fibrillation, or
asystole.
General Considerations
While hypokalemia is more common in ICU patients, renal
failure, metabolic acidosis, potassium-sparing diuretics, adre-
nal insufficiency, drugs, and iatrogenic administration of
potassium may lead to hyperkalemia. Hyperkalemia has seri-
ous effects on myocardial conduction, and most life-
threatening emergencies from hyperkalemia involve the heart.
The mechanisms of hyperkalemia can be divided into
those in which increased addition of potassium to the extra-
cellular space overwhelms the normal mechanisms of potas-
sium disposal and those in which the capacity for potassium
disposal is impaired. Because hyperkalemia reflects plasma
[K+] and not total body potassium, impaired disposal may be
due to impaired redistribution of potassium into the cell or
impaired excretion of potassium.
A. Addition of Potassium to Extracellular Space—
Exogenous potassium can lead to hyperkalemia if enough
potassium is given rapidly enough to raise potassium con-
centration in the extracellular space. Both exogenous and
endogenous sources cause hyperkalemia. Impaired insulin
release or beta-adrenergic blockade facilitate hyperkalemia,
and because the normal extracellular potassium store is only
as little as 40–60 meq, rapid potassium administration can
easily overwhelm normal redistribution mechanisms. If
potassium is given more slowly, however, normal renal excre-
tion makes development of hyperkalemia much less likely.
Endogenous sources of large potassium loads are not infre-
quent in the ICU from rhabdomyolysis owing to infection,
trauma, or drugs; tumor lysis of lymphoma or leukemia; and
severe hemolysis or other tissue breakdown.
A special case of endogenous potassium leading to a false
diagnosis of hyperkalemia results from hemolysis of red
blood cells after blood has been drawn. Pseudohyperkalemia
also can be seen in patients with extreme thrombocytosis or
leukocytosis.
B. Impaired Disposal of Potassium—Redistribution of
potassium from the intracellular to the extracellular space or
impaired potassium disposal can cause hyperkalemia.
Metabolic acidosis, insulin deficiency, and beta-adrenergic
blockade may redistribute potassium out of cells and cause
hyperkalemia. Administration of acids with chloride anion
(eg, hydrochloric acid, lysine hydrochloride, or arginine
hydrochloride) is associated with hyperkalemia because of
exchange of hydrogen ion for potassium inside the cell.
Organic acidoses affect plasma potassium much less. Muscle
paralysis with succinylcholine, a depolarizing muscle relax-
ant, releases potassium from muscle cells and prevents reup-
take. Type 1 diabetic patients are prone to hyperkalemia
because they lack the ability to increase insulin secretion in
the face of increased plasma potassium.
1. Renal insufficiency—The kidneys are largely responsi-
ble for excretion of potassium and can greatly increase potas-
sium excretion in response to hyperkalemia. Potassium is
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filtered and then almost completely reabsorbed; this is true
even in the face of hyperkalemia. However, in contrast to
hypokalemia, in which increased filtration does not cause
potassium depletion, decreased filtration does contribute to
hyperkalemia. As with hypokalemia, aldosterone plays an
important role in renal potassium handling.
Acute renal insufficiency more commonly causes hyper-
kalemia than chronic renal insufficiency, in the absence of
increased intake of potassium. Chronically, aldosterone is
released in direct response to hyperkalemia and facilitates
secretion of potassium in the distal nephron. Decreased
glomerular filtrate affects potassium secretion primarily by
decreasing the amount of sodium available for lumen–tubular
cell exchange, thereby limiting generation of the electroneg-
ative gradient that drives potassium secretion.
2. Aldosterone deficiency—Deficiency of aldosterone
predictably causes hyperkalemia. Diseases that destroy the
adrenal glands result in loss of endogenous glucocorticoids
and aldosterone (Addison’s disease), but isolated cases of
hypoaldosteronism are also seen. In long-standing diabetes,
hyporeninemic hypoaldosteronism causes hyperkalemia and
hyperchloremic metabolic acidosis (type 4 renal tubular aci-
dosis). Spironolactone, an aldosterone antagonist, causes
hyperkalemia in susceptible patients.
C. Drugs Associated with Hyperkalemia—Drugs associated
with hyperkalemia are classified according to their mechanism
of hyperkalemia. Those that impair intracellular potassium dis-
tribution include beta-adrenergic blockers, succinylcholine,
hydrochloric acid, and other acidifying agents. Some earlier
formulations of total parenteral nutrition solutions contained
excess chloride salts of amino acids that contributed to hyper-
kalemia. Drugs that interfere with renal potassium secretion
include aldosterone antagonists (eg, spironolactone),
potassium-sparing diuretics (eg, triamterene and amiloride),
ACE inhibitors, and drugs that decrease renal function (nons-
teroidal anti-inflammatory drugs [NSAIDs]). Patients with
heart failure are at risk for both hypokalemia and hyper-
kalemia because they may be prescribed potent loop diuretics,
aldosterone, beta-adrenergic blockers, and ACE inhibitors
simultaneously. Heparin and, to a lesser extent, low-
molecular-weight heparin suppress aldosterone synthesis and
can result in hyperkalemia in patients with diabetes mellitus
and renal failure.
A number of patients receiving high doses of
trimethoprim-sulfamethoxazole may have hyperkalemia.
Trimethoprim has an amiloride-like effect, blocking distal
tubular sodium channels and inhibiting potassium secretion
because of decreased tubular electronegativity. Small amounts
of potassium in potassium penicillin G (1.7 meq per million
units) and transfused blood can cause hyperkalemia but usu-
ally only in patients with impaired potassium handling.
Clinical Features
A clinical and laboratory approach to the diagnosis of hyper-
kalemia is shown in Figure 2–4.
A. Symptoms and Signs—Hyperkalemia is usually identi-
fied by routine measurement of electrolytes in the ICU. In
critically ill patients, hyperkalemia may present acutely with-
out warning. The most serious concern is cardiac rhythm
disturbances, but weakness also may be present.
The medical history should be reviewed for medications
that cause hyperkalemia, recently transfused blood, potential
for tumor lysis syndrome, diabetes, renal failure, and other
disorders. Intravenous solutions should be checked for inad-
vertent potassium administration. For critically ill patients,
consideration of acute adrenal insufficiency is mandatory,
especially if the patient had been receiving corticosteroids or
has hypotension and hyponatremia.
Those at high risk for development of hyperkalemia
include any patient receiving potassium supplementation or
potassium-sparing diuretics, digitalis, beta-adrenergic block-
ers, trimethoprim, or ACE inhibitors. Patients with renal
insufficiency (especially acute renal failure) or diabetes mel-
litus (especially type 1 diabetes) may develop hyperkalemia.
Hyperkalemia sometimes can occur in patients who are
sodium-restricted if they are allowed to use salt substitutes
that contain primarily potassium chloride.
The most common associations of hyperkalemia in hos-
pitalized patients are renal failure, drugs, and hyperglycemia.
In one study, administration of potassium to correct
hypokalemia was the most frequent cause of hyperkalemia.
B. Laboratory Findings—Hyperkalemia is diagnosed when
plasma potassium concentration is greater than 5 meq/L. The
ECG is an important indicator of severity of hyperkalemia, but
electrocardiographic abnormalities were seen in only 14% of
hospitalized patients with hyperkalemia in one study.
Asymptomatic electrocardiographic changes occur as plasma
[K+] rises, with increased height and sharper peaks of T waves
seen first. The QRS duration then lengthens, and the P wave
decreases in amplitude before disappearing as plasma [K+] rises.
At very high plasma [K+], electrical activity becomes a broad
sinelike wave preceding ventricular fibrillation or asystole.
Plasma sodium, chloride, glucose, and creatinine; urea nitro-
gen; arterial blood pH; PaCO2; hematocrit; and platelet count
should be determined to aid in establishing the cause of hyper-
kalemia. If the platelet count exceeds 1,000,000/μL, serum
potassium may be falsely elevated as the blood clots and potas-
sium is released from platelets; in such cases, plasma rather than
serum potassium will reflect the true value in the body. In renal
insufficiency, plasma creatinine and urea nitrogen are elevated.
Urine potassium determination may be helpful in deciding
whether renal potassium elimination is appropriate. The
transtubular potassium gradient (see “Hypokalemia” above)
can determine if the kidneys are contributing to hyperkalemia;
a nonrenal cause is more likely if the gradient is greater than 10.
Plasma sodium and chloride may provide evidence of adrenal
insufficiency, but other tests of adrenocortical function should
be performed. A very low plasma cortisol, for example, in the
presence of hyperkalemia can be diagnostic of adrenal insuffi-
ciency. Arterial blood pH and plasma glucose are helpful in
deciding on the approach to treatment of hyperkalemia.
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Treatment
Arrhythmias suspected of being due to hyperkalemia or elec-
trocardiographic changes with plasma [K+] above the nor-
mal range (ie, >5 meq/L) should be treated aggressively, and
the same is true if plasma [K+] is greater than 6 meq/L even
if the ECG shows no evidence of hyperkalemia.
A. Calcium—Combination therapy is usually given to
counter the effects of hyperkalemia on the heart and redistribute
potassium into cells. Calcium directly reverses the effects of
potassium on the cardiac conduction system, although intra-
venous calcium chloride or calcium gluconate does not affect
plasma potassium levels. One recommendation is to give
slowly 5 mL of 5% calcium chloride (or 10 mL of calcium glu-
conate) intravenously every 1–2 hours as long as [K+] exceeds
6 meq/L and there are electrocardiographic abnormalities, but
the number of doses should not exceed two or three. Calcium
should be given cautiously in the presence of digitalis toxicity.
 Figure 2–4. Clinical and laboratory approach to the diagnosis of hyperkalemia.
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B. Redistribution of Potassium—Insulin has an immedi-
ate plasma [K+] lowering effect, but hypoglycemia ensues
unless glucose is given simultaneously. Insulin can be given
subcutaneously or by intravenous bolus or continuous infu-
sion. One method is to give 1–2 ampules of 50% dextrose in
water along with 5–10 units of intravenous insulin. Another
method for severe hyperkalemia is to administer regular
insulin intravenously at a rate of 1–2 units/h while 5% dex-
trose in water is given at a rate of 125 mL/h (8–10 units
insulin in each liter of 5% dextrose in water). One should
monitor electrolytes and glucose hourly and watch closely
for hypoglycemia. The rate of administration of insulin and
glucose can be adjusted accordingly.
Metabolic acidosis contributing to hyperkalemia, if pres-
ent, can be ameliorated with sodium bicarbonate given intra-
venously. This treatment is not without hazard, with volume
overload and hyperosmolality possible complications. Only
enough NaHCO3 should be given to reverse hyperkalemia, not
completely correct acidemia. Treatment should begin with one
ampule (about 44 meq NaHCO3) given over several minutes.
Another ampule can be given if needed in 15–30 minutes.
Alternatively, two ampules can be added to 1 L of 5% dextrose
in water for continuous intravenous administration (final
sodium concentration about 90 meq/L) at 50–150 mL/h. This
infusion can be stopped as soon as the plasma potassium con-
centration normalizes or in the event of fluid overload.
A few patients with hyperkalemia and renal failure have
been treated with the beta-adrenergic agonist albuterol by
nebulization. A modest transient reduction in plasma [K+] can
be achieved even with standard bronchodilator doses, but the
risks of arrhythmias and other potential problems suggest that
this form of therapy should be used only when conventional
therapy has failed or fluid overload is a concern.
C. Increased Excretion of Potassium—Facilitation of renal
excretion mechanisms can help rid the body of excess potas-
sium, but this route of excretion is usable only in patients
whose renal potassium excretion is unimpaired. Furosemide
increases distal tubule sodium delivery and promotes potas-
sium secretion.Volume replacement with normal saline may be
necessary if the patient begins with normal extracellular fluid
volume. Mineralocorticoids increase renal potassium excre-
tion, but in patients with a normal adrenal response, aldos-
terone levels are maximal. Therefore, mineralocorticoids such
as fludrocortisone are useful only in patients with adrenal
insufficiency or some other cause of depressed aldosterone.
In patients with impaired renal potassium excretion or to
increase potassium elimination in any patient with hyper-
kalemia, increased nonrenal potassium excretion is indicated.
A cation exchange resin designed for oral or rectal adminis-
tration (eg, sodium polystyrene sulfonate) binds potassium in
exchange for sodium. If the gastrointestinal tract is func-
tional, 15–60 g mixed in 20–100 mL of water or sorbitol solu-
tion can be given orally; the dose can be repeated every 4–6
hours. The suspension also can be given as a retention enema.
Hemodialysis is an effective way of decreasing plasma
potassium concentration, but hyperkalemia may return rapidly
after dialysis as potassium diffuses back out of the cells.
Therefore, as much potassium removal as possible is indi-
cated during hemodialysis if it is concluded that a large
increase in total body potassium is present. Plasma potas-
sium concentration should be carefully monitored during
dialysis. Continuous venovenous hemofiltration and dialysis
(CVVHD) is very effective, or peritoneal dialysis with dialysate
containing no potassium can be used.
D. Other Treatment—Dietary potassium intake should be
restricted. In practice, the diet should avoid high-potassium
foods, but in ICU patients in whom sparing of body protein is
a goal, at least 2.5 g (64 meq) of potassium daily is usually nec-
essary to maintain acceptable protein intake. All intravenous
infusions should be double-checked to make sure that potas-
sium (sometimes in the form of phosphate as well as chloride)
is not being given inadvertently. Potassium penicillin should be
switched to sodium penicillin. The need for drugs contributing
to potassium maldistribution, impaired excretion, metabolic
acidosis, and renal insufficiency should be reevaluated and the
drugs discontinued, if possible. These include ACE inhibitors,
beta-adrenergic blockers, and potassium-sparing diuretics.
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DISORDERS OF PHOSPHORUS BALANCE
Phosphorus is found in both inorganic (phosphate) and
organic forms. Most of the body’s store of phosphorus is in
the bones (80%), and the vast majority of the remainder is,
like potassium, distributed inside cells (muscles 10%) as
organic phosphates. Only 1% is in the blood, and plasma
phosphorus does not reflect the total body phosphorus.
Organic phosphates play a major role in metabolic functions,
especially in energy-producing reactions, as part of ATP and
other cofactors. In the erythrocyte, 2,3-diphosphoglycerate
(2,3-DPG) levels decrease with decreased plasma phosphorus
concentration, leading to impaired tissue oxygen delivery. In
the ICU, hypophosphatemia is associated with dysfunction of
red blood cells, respiratory muscles, the heart, platelets, and
white blood cells and is often due to acute ICU interventions
in susceptible patients. Patients with hypophosphatemia may
have heart failure, hemolysis, respiratory failure, and
impaired oxygen delivery.
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Plasma phosphorus is reported by the laboratory in mil-
ligrams of elemental phosphorus per deciliter, but phospho-
rus is largely in the form of inorganic phosphate in the
divalent (HPO4
–2) and monovalent forms (H2PO4
–). There
are two major determinants of phosphorus balance in the
body: the distribution of phosphorus compounds between
intracellular and extracellular spaces and the daily intake
compared with excretion. The total body store of phospho-
rus is great, and only a small proportion of total body phos-
phorus participates in intracellular reactions and shifts
between cells and extracellular spaces.
The intracellular phosphorus concentration is consider-
ably larger than the extracellular concentration. Factors
that determine the distribution of phosphorus between the
two compartments include the rate of glucose entry into
cells and the presence of respiratory alkalosis. Glucose
movement into cells, facilitated by insulin, traps phosphate
intracellularly through phosphorylation of glucose and
glycolytic intermediates. Acute respiratory alkalosis facili-
tates glycolysis, thereby reducing extracellular phospho-
rus concentration.
Phosphorus intake depends on the type of diet and the
presence of active 1,25(OH)2-vitamin D3, which facilitates
both calcium and phosphorus absorption in the gastroin-
testinal tract. Corticosteroids, dietary magnesium, hypothy-
roidism, and intestinal phosphate-binding drugs (eg,
aluminum hydroxide and calcium carbonate) decrease
phosphorus absorption. Net phosphate excretion is prima-
rily through the kidneys by filtration and reabsorption.
Because filtration is unregulated, reabsorption in the proxi-
mal tubules determines phosphorus excretion, and this
mechanism is driven by proximal tubular sodium reabsorp-
tion. Thus there is enhanced phosphorus reabsorption in
the face of increased proximal sodium reabsorption in
volume-depleted states. However, proximal phosphorus
reabsorption is also independently regulated by the parathy-
roid hormone level. This can lead to dissociation between
sodium reabsorption and phosphorus reabsorption, as in
hyperparathyroidism.
 Hypophosphatemia
ESSENT IALS  OF  D IAGNOS I S
 Plasma phosphorus <2.5 mg/dL; severe, <1.0 mg/dL.
 May have muscle weakness, including respiratory mus-
cle weakness (failure to wean from respirator) and
myocardial dysfunction.
 Evidence of impaired oxygen transport.
 Impaired platelet and leukocyte function. Hemolysis
and rhabdomyolysis may occur with plasma phosphorus
<1 mg/dL.
General Considerations
Hypophosphatemia is associated in the ICU mostly with a
shift of extracellular phosphorus into cells and is seen as a
consequence of acid-base disturbances and as a complication
of drugs and nutritional support more often than as a pri-
mary problem. Acute hypophosphatemia should be antici-
pated in postoperative patients; in patients with chronic or
acute alcoholism, diabetic ketoacidosis, or head trauma; and
in patients receiving total parenteral nutrition or mechanical
ventilation.
In theory, hypophosphatemia always results from a prob-
lem of maldistribution of total body phosphorus. This is so
because of the very large quantity of phosphorus in the intra-
cellular space plus the amount of phosphorus in bone, even
in those with hypophosphatemia (ie, decreased plasma phos-
phorous and extracellular phosphorus). Thus even a state of
“phosphate depletion” from increased losses and decreased
intake is a problem of distribution because there must be
decreased ability to mobilize and transfer phosphorus to the
extracellular space coincident with depletion. Nevertheless, it
is helpful to think of the pathophysiology of hypophos-
phatemia as being primarily redistribution, decreased intake,
or increased excretion of phosphorus.
A. Redistribution of Phosphorus—In the ICU, the most
common causes of hypophosphatemia are administration of
insulin and glucose or acute hyperventilation. Glucose
movement into cells (facilitated by insulin) and subsequent
glycolysis produce phosphorylated intermediates that are
trapped intracellularly. The most striking examples of rapid,
severe falls in plasma phosphorus are seen in the treatment
of diabetic ketoacidosis and in the refeeding syndrome.
Diabetic ketoacidosis is associated with pretreatment extra-
cellular phosphate loss from solute diuresis. The administra-
tion of insulin results predictably in hypophosphatemia as
glucose and phosphate move into cells. The marked fall in
plasma phosphate during enteral or parenteral refeeding of
chronically malnourished individuals, including alcoholics,
reflects low extracellular phosphorus from decreased intake
followed by rapid movement of phosphate and glucose
intracellularly.
Respiratory alkalosis also causes a shift of extracellular
phosphorus into cells. This has been attributed to enhanced
activity of the glycolytic enzyme phosphofructokinase at
high pH, but this mechanism has been called into question
because metabolic alkalosis of comparable degree has little
effect on plasma phosphorus. Hypophosphatemia seen in
salicylate toxicity, sepsis, and hepatic encephalopathy is prob-
ably secondary to hyperventilation.
B. Decreased Phosphorus Intake—Decreased intake of
phosphorus is usually a chronic problem and is seen in ICU
patients with preexisting diseases leading to decreased
dietary intake of calcium, phosphorus, and vitamin D. In
addition, binding of phosphorus in the gastrointestinal tract
by antacids and specific phosphate-binding compounds pre-
vents absorption and can lead to hypophosphatemia, especially
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when the diet is limited in phosphorus content. Because
most diets contain adequate phosphorus, low dietary intake
of phosphorus is seen almost exclusively in patients who are
not being fed at all.
C. Increased Excretion of Phosphorus—Among all
patients, increased renal tubular excretion of phosphate is
the most common cause of hypophosphatemia, primarily
from subclinical hyperparathyroidism. In critically ill
patients, renal phosphate excretion increases with solute
diuresis and with the use of acetazolamide, a carbonic anhy-
drase inhibitor. Metabolic acidosis increases the release of
inorganic phosphate into the extracellular space, resulting in
increased renal excretion of phosphate, but this is not usually
a cause of hypophosphatemia because phosphorus can be
mobilized easily from the intracellular stores. Hemodialysis
is a relatively inefficient way of removing phosphate; there-
fore, hypophosphatemia is an unusual complication of renal
replacement therapy.
D. Physiologic Effects of Hypophosphatemia—
Phosphorus in the form of phosphate plays an important
role in intermediary metabolism, especially in intracellular
energy production. Clinical consequences of hypophos-
phatemia are due to decreased production of ATP and ery-
throcyte 2,3-DPG. Erythrocyte inorganic phosphate
concentration is directly related to plasma phosphorus, and
inorganic phosphate is required for the conversion of glycer-
aldehyde 3-phosphate to 1,3-diphosphoglyceric acid, a key
step in glycolysis. In hypophosphatemia, glycolytic interme-
diates preceding this enzymatic step accumulate and those
following, including ATP and 2,3-DPG, decrease in concen-
tration. Low 2,3-DPG increases the O2 affinity of hemoglo-
bin (left-shifted oxyhemoglobin curve), potentially
impairing O2 delivery to the tissues. Hemolysis is due to
impaired ATP generation, probably in a way similar to ery-
throcyte glycolytic enzyme deficiencies such as pyruvate
kinase deficiency. Impaired function of skeletal muscles,
including respiratory muscles, and myocardium have been
related to both decreased 2,3-DPG and decreased availability
of phosphorus to the muscles. In one study, decreased respi-
ratory and peripheral muscle phosphate concentrations were
found in 50% of patients with COPD and respiratory failure
compared with normal control individuals.
Clinical Features
Although most patients with hypophosphatemia are identi-
fied by routine monitoring of electrolytes, hypophosphatemia
should be suspected in certain high-risk ICU patients, that is,
those with preexisting total body or extracellular phosphorus
depletion or a severe acute disorder causing redistribution of
extracellular phosphorus (Table 2–10). The most likely candi-
dates for symptomatic hypophosphatemia are those with
combinations of mechanisms, such as patients with diabetic
ketoacidosis with solute diuresis who are receiving insulin
and malnourished alcoholics given glucose, insulin, and
phosphate-binding antacids. Severely burned patients may
have a combination of respiratory alkalosis, pain, sepsis, and
increased tissue uptake of phosphate. Patients with severe
head injury are reported to have hypophosphatemia and
hypomagnesemia owing to excessive urinary losses.
A. Symptoms and Signs—Mild to moderate hypophos-
phatemia is usually asymptomatic. When hypophosphatemia
is severe (plasma phosphorus <1.0 mg/dL), patients may
complain of muscle weakness. Skeletal and cardiac muscles
are involved primarily, and signs of weakness may be present
in the respiratory muscles. Patients may have difficulty wean-
ing from mechanical ventilation or may present with symp-
toms and signs of congestive heart failure. Rhabdomyolysis
and hemolysis are uncommon features of severe hypophos-
phatemia. Although unusual, leukocyte dysfunction may
result in an increased tendency to infection, and platelet dys-
function may contribute to bleeding.
CNS dysfunction has been attributed to hypophos-
phatemia, but consistent features have not been found.
Findings have included changes in mental status, seizures,
and neuropathy. Changes may be related to direct effects or
may occur because of reduced CNS oxygen delivery.
B. Laboratory Findings—The diagnosis of hypophos-
phatemia is made when plasma phosphorus concentration is
less than 2.5 mg/dL, but symptoms are not likely to appear
until the plasma phosphorus concentration is less than
1.5 mg/dL. Other laboratory findings may include features
of hemolysis, elevated creatine kinase, and qualitative
platelet dysfunction (prolonged bleeding time) when
plasma phosphorus is 0.5–1 mg/dL. For determining the
Table 2–10. ICU patients at risk for hypophosphatemia.
Preexisting total body or extracellular phosphorus depletion
Malnutrition 
Chronic increased renal phosphate loss
Diabetic ketoacidosis (osmotic diuresis)
Alcoholism
Vitamin D deficiency
Fat malabsorption 
Chronic antacid use
Acute redistribution of extracellular phosphorus
Respiratory alkalosis 
Sepsis 
Salicylate toxicity  
Hepatic encephalopathy  
Toxic shock syndrome  
Glucose-insulin administration  
Diabetic ketoacidosis  
Refeeding syndrome  
Hyperalimentation  
Treatment of hyperkalemia
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specific cause of hypophosphatemia, the clinical history
is most useful; arterial blood gases and plasma glucose,
electrolytes, and calcium may be helpful. Although useful in
evaluation of chronic hypophosphatemia, urinary phospho-
rus measurement is seldom necessary in ICU patients.
Treatment
A. Assess Urgency of Treatment—In critically ill
patients, development of severe hypophosphatemia may
require immediate treatment if weakness involving the
respiratory muscles precipitates respiratory failure.
Generally, a plasma phosphorus concentration of less than
1–1.5 mg/dL should be treated immediately. This is espe-
cially important when a further decrease in phosphorus is
anticipated, such as in the treatment of diabetic ketoacido-
sis. Supportive care is essential while severe hypophos-
phatemia is corrected.
B. Phosphorus Replacement—Recommendations for
phosphorus repletion are often confusing because of the way
elemental phosphorus and phosphate concentrations and
amounts are expressed. At physiologic pH, inorganic phos-
phate anion exists almost entirely in the monovalent
(H2PO4
–) and divalent (HPO4
–2) forms (about 1:4 monova-
lent:divalent). This means that the use of milliequivalents is
potentially misleading. Laboratories report plasma phospho-
rus as milligrams of elemental phosphorus per deciliter. To
avoid confusion, calculations for repletion should be based
on milligrams of elemental phosphorus or millimoles of
phosphorus or phosphate (these are the same because there
is one phosphorus atom for each phosphate regardless of
valence). One millimole of phosphate or phosphorus is the
same as 31 mg phosphorus.
Intravenous phosphate is given as sodium or potassium
phosphate, available usually at a concentration of 93 mg
phosphorus/mL (3 mmol/mL). The amount of phosphorus
to be given is difficult to estimate because total body phos-
phorus may not be decreased (redistribution), and rapid
phosphate shifts during treatment may resolve or worsen the
problem. Therefore, close monitoring of plasma phosphorus
and other electrolytes is necessary during repletion, espe-
cially if phosphate is given as the potassium salt.
In severe cases (plasma phosphorus <1.0 mg/dL), give
5–7 mg phosphorus/kg of body weight intravenous in 1 L of
5% dextrose in water (D5W) over 4–6 hours. For a 60-kg
adult, this would be approximately 400 mg phosphorus, or
about 4 mL of sodium or potassium phosphate solution
(3 mmol/mL) in the 1-L infusion. Alternatively, 1 g phosphorus
(~10 mL of sodium or potassium phosphate [3 mmol/mL]) is
added to 1 L D5W and infused over 12–24 hours or until the
serum phosphorus concentration is greater than 1.5 mg/dL.
In less severe hypophosphatemia, an appropriate starting
dose would be 2–4 mg/kg intravenously over 8 hours. Oral
supplementation can be provided using potassium phosphate
or mixtures of sodium and potassium phosphate.
Prevention of hypophosphatemia is important. In
patients receiving intravenous glucose, phosphorus supple-
mentation should be considered. Adult patients receiving
parenteral hyperalimentation generally require about 1 g
phosphorus daily, or approximately 12 mmol (372 mg) for
every 1000 kcal provided.
Routine repletion of phosphorus in patients with diabetic
ketoacidosis has been recommended because of the high fre-
quency of hypophosphatemia reported during treatment
with insulin infusions. It has been proposed that hypophos-
phatemia contributes to decreased oxygen delivery, insulin
resistance, hyperchloremic acidosis, and other complications
of diabetic ketoacidosis. However, improvement in interme-
diate or final outcome from routine phosphate replacement
has not been demonstrated.
C. Complications of Treatment—Complications of exces-
sive phosphate repletion include volume overload from
sodium phosphate, hyperkalemia from potassium phos-
phate, precipitation of calcium phosphate in the face of
hypercalcemia, and hypocalcemia. In older patients with
renal insufficiency and small children, especially with fluid
restriction, phosphate salts given for bowel preparation are
associated with severe hyperphosphatemia, marked anion
gap metabolic acidosis, and hypocalcemia.
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 Hyperphosphatemia
ESSENT IALS  OF  D IAGNOS I S
 Plasma phosphorus >5 mg/dL.
 Usually no acute symptoms.
 Cardiac conduction system disturbances and features of
hypocalcemia may occur.
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General Considerations
Hyperphosphatemia as a clinical problem is most often the
result of long-standing elevation of plasma phosphorus con-
centration to greater than 5 mg/dL, but acute elevation can
have consequences owing to precipitation of calcium phos-
phate salts in the heart, kidneys, and lungs; rarely, acute car-
diac conduction disturbances can occur. In addition, calcium
phosphate precipitation results in acute hypocalcemia and its
consequences.
Severe hyperphosphatemia is associated in the ICU with
a shift of intracellular phosphorus out of cells and is seen
when there is massive tissue breakdown. Rarely, in patients
given large amounts of sodium phosphate as a cathartic or
enema, severe anion gap metabolic acidosis may result.
Patients in whom this has been reported are elderly or very
young and often have renal insufficiency. More commonly,
hyperphosphatemia is seen in chronic renal failure, where
there is decreased ability to excrete phosphorus.
Hyperphosphatemia results from impaired excretion of
phosphorus or increased addition of phosphorus to the
extracellular space.
A. Impaired Phosphate Excretion—There is a large
quantity of phosphorus in the intracellular space, as well as
the phosphorus stored in bone, but the quantity of extracel-
lular phosphorus is small. Normal cell turnover releases a
steady quantity of phosphorus into the extracellular space
that is taken back up into the cells or bone or excreted by
the kidney. Impaired excretion primarily results from
chronic renal insufficiency, and because parathyroid hor-
mone facilitates renal phosphate excretion, hypoparathy-
roidism impairs renal phosphorus excretion even with
normal renal function.
B. Redistribution of Phosphorus—A cause of hyper-
phosphatemia unique to critically ill patients is massive tis-
sue breakdown, a form of “redistribution” of a large
amount of intracellular phosphorus into the extracellular
space. The most common form of tissue injury seen in the
ICU is rhabdomyolysis from trauma or other muscle injury
from infection, drugs, seizures, or metabolic problems.
Tumor lysis syndrome, seen after chemo- or radiotherapy
of highly responsive tumors (eg, lymphoma), releases large
quantities of phosphorus as well as purines (to become
uric acid) and potassium. Tumor lysis syndrome is seen
uncommonly in patients with solid tumors, except those
with extensive necrosis. Bowel necrosis from ischemia also
may be associated with hyperphosphatemia. Renal insuffi-
ciency exacerbates hyperphosphatemia caused by redistri-
bution of phosphorus. Because insulin and glucose drive
phosphorus into cells, diabetics with insulin deficiency
also may be more prone to hyperphosphatemia, but this is
rarely significant.
C. Excessive Replacement of Phosphorus—Excessive
replacement of phosphorus in patients with hypophosphatemia
may cause hyperphosphatemia. Factors that may lead to this
situation include renal insufficiency and continued replace-
ment of phosphorus after reversal of the cause of hypophos-
phatemia. Patients receiving total parenteral nutrition should
be monitored closely because standard solutions may con-
tain 300–500 mg phosphorus per liter. Enemas or oral bowel
preparation products used prior to radiographic procedures
or colonoscopy may contain a large quantity of sodium
phosphate as an osmotic agent. If patients absorb some of
this phosphate, severe hyperphosphatemia (plasma phos-
phorus >20 mg/dL) and anion gap metabolic acidosis have
been reported.
Clinical Features
Patients at high risk for development of hyperphosphatemia
are those with tissue injury and renal insufficiency (Table 2–11),
especially in combination. Other patients in the ICU who
may develop hyperphosphatemia include those receiving
intravenous or oral phosphorus supplementation for treat-
ment of hypophosphatemia, patients with decreased
glomerular filtration because of extracellular volume deple-
tion, those with chronic renal failure, and those given large
amounts of oral phosphate salts.
A. Symptoms and Signs—Most patients with hyperphos-
phatemia of mild to moderate degree are asymptomatic. In
more severe cases, if the calcium × phosphorus product is
greater than 60, the risk of ectopic calcification in various
organs increases, including the heart, lungs, and kidneys.
Acute problems from precipitation of calcium phosphate are
mainly restricted to the development of cardiac conduction
system disturbances such as heart block.
Acute hyperphosphatemia also can lead to hypocalcemia
with development of tetany, seizures, cardiac arrhythmias,
and hypotension. Plasma calcium should be monitored dur-
ing treatment of both hypo- and hyperphosphatemia.
Table 2–11. ICU patients at risk for hyperphosphatemia.
Impaired excretion of phosphate 
Chronic renal failure 
Acute renal failure 
Extracellular volume depletion 
Hypoparathyroidism 
Acute redistribution of intracellular phosphorus  
Massive tissue breakdown 
Rhabdomyolysis 
Tumor lysis syndrome (lymphoma)
Exogenous phosphorus intake 
Excessive treatment of hypophosphatemia  
Increased dietary phosphorus (with renal insufficiency)  
Excessive sodium phosphate enema or laxative use
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Hypocalcemia results both from precipitation of calcium
phosphate and from inhibition of renal 1a-hydroxylase nec-
essary for vitamin D activation.
B. Laboratory Findings—The diagnosis of hyperphos-
phatemia is most often made only by the laboratory finding
of a plasma phosphorus concentration of greater than 5 mg/dL.
The specific cause of hyperphosphatemia usually can be
determined from the clinical history, but plasma creatinine
and electrolytes should be obtained. Plasma uric acid and
potassium are expected to be elevated in tumor lysis syn-
drome. In rhabdomyolysis, plasma creatine kinase and
aldolase are elevated, and myoglobinuria may be present. In
patients who have hyperphosphatemia from administration
of phosphate salts, metabolic acidosis with a large anion gap
can be found.
Treatment
A. Assess Urgency of Treatment—There is no absolute
elevated plasma concentration of phosphorus that requires
immediate treatment. Rapid treatment should be consid-
ered if there is evidence of a cardiac conduction distur-
bance such as heart block or evidence of symptomatic or
severe hypocalcemia. Hypocalcemia in the presence of
hyperphosphatemia should be treated by lowering the
plasma phosphorus concentration rather than by adminis-
tration of calcium because the latter action may worsen
ectopic calcification.
B. Remove Phosphorus from the Body—Renal excretion
of phosphorus depends on having an adequate glomerular
filtration rate. Because phosphate reabsorption depends on
proximal tubular sodium reabsorption, normal saline infu-
sion in patients who can tolerate this treatment will enhance
phosphate excretion. This should be avoided in patients with
preexisting increased extracellular volume, congestive heart
failure, and renal insufficiency.
Hemodialysis is effective in removing extracellular phos-
phate but has only a transient effect because of the small pro-
portion of phosphorus in the extracellular fluid. Orally
administered phosphate binders have only a mild acute effect,
especially if patients are not being fed enterally. Calcium car-
bonate should be avoided in acute hyperphosphatemia
because of the potential for raising the calcium × phosphorus
product. Non-calcium-, non-aluminum-containing phos-
phate binders are used acutely. For chronic administration,
calcium carbonate or non-aluminum-containing phosphate
binders are preferred.
C. Minimize Phosphorus Intake—Exogenous sources of
phosphate should be discontinued, including total parenteral
nutrition solutions and supplemental phosphorus given
orally or intravenously. Dietary phosphorus can be mini-
mized by prescribing a low-protein diet and avoiding dairy
products that contain both calcium and phosphorus, but this
may conflict with nutritional goals.
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DISORDERS OF MAGNESIUM BALANCE
Magnesium is the most abundant intracellular divalent cation
and, after calcium, the most common divalent cation in the
body. The distribution of magnesium is similar to that of
potassium, with the vast majority (99%) of magnesium resid-
ing inside cells. Consequently, plasma magnesium concentra-
tion does not reflect total body magnesium. Magnesium plays
an important role in neuromuscular coupling, largely
through its interaction with calcium. In the ICU, disorders of
magnesium primarily reflect hypomagnesemia, with cardiac
arrhythmias and other features similar to those of hypocal-
cemia. Among the causes of hypomagnesemia are drugs fre-
quently used in critically ill patients such as amphotericin B,
diuretics, and aminoglycoside antibiotics, but hypomagne-
semia is also seen in malnutrition, chronic alcoholism, and
malabsorption. In contrast, hypermagnesemia in ICU
patients is relatively uncommon and almost always results
from a combination of renal insufficiency and increased mag-
nesium intake. On occasion, hypermagnesemia results from
overzealous repletion of hypomagnesemia.
Magnesium Intake and Distribution
Magnesium is found in many foods, including green vegetables
and meat products, and the normal diet is usually more than
ample. Approximately 5 mg/kg per day of magnesium is
required for normal magnesium balance. Magnesium is sup-
plied as part of enteral feedings and is added to parenteral
nutrition formulations. Factors that control gastrointestinal
magnesium absorption are unclear, but about one-third of
ingested magnesium is absorbed. The absorbed fraction
decreases with increased ingestion, suggesting an active trans-
port mechanism. Magnesium binds to fatty acids and oxalate in
the gut, decreasing absorption. Like potassium, magnesium is
distributed largely within cells, but the mechanisms controlling
distribution do not seem to be controlled by circulating levels
of hormones such as insulin or epinephrine or by acid-base sta-
tus. About 25% of plasma magnesium is protein-bound.
Magnesium Excretion
Free magnesium is filtered and largely reabsorbed under
steady-state conditions in the proximal nephron (a minor
role), ascending loop of Henle (accounting for about 60–70%
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of reabsorption), and the distal nephron (about 10%). The
distal nephron, however, is the major site of fine regulation of
magnesium excretion. Only about 100 mg magnesium is
excreted per day even though as much as 2400 mg is filtered
by the glomeruli, and reabsorption is increased in the face of
magnesium deficiency. The driving force for magnesium
reabsorption is the reabsorption of Na+ and K+. As would be
expected, drugs that interfere with sodium reabsorption
interfere with magnesium reabsorption. Because the ascend-
ing portion of the loop of Henle accounts for a large fraction
of magnesium reabsorption, loop-acting diuretics predictably
have a potent magnesium-wasting effect.
Excess magnesium is excreted renally by decreased reab-
sorption. When plasma magnesium levels are elevated—as
happens, for example, shortly after intravenous administra-
tion of a large quantity of magnesium salt—renal magne-
sium excretion increases. This is so in part because a lower
proportion is protein-bound and in part because only a fixed
amount rather than a fixed proportion of the larger filtered
load is reabsorbed. Maximum magnesium excretion is lim-
ited by glomerular filtration, as would be expected from its
renal handling.
Role of Magnesium
The major role of magnesium is as a cofactor for hundreds of
identified enzymes that produce or require ATP, such as
kinases, ATPase, and adenylyl cyclase. Disorders of magne-
sium may lead to impaired energy production, substrate uti-
lization, and synthetic processes.
 Hypomagnesemia
ESSENT IALS  OF  D IAGNOS I S
 Plasma [Mg2+] <1.7 mg/dL.
 Cardiac arrhythmias, refractory potassium deficiency.
 Features suggestive of hypocalcemia: tetany, weakness,
increased deep tendon reflexes, altered mental status,
and seizures. 
General Considerations
Decreased plasma magnesium has serious consequences in
critically ill patients, potentiating arrhythmias, interfering
with potassium repletion, and causing neuromuscular weak-
ness. However, mild to moderate hypomagnesemia is fre-
quently unrecognized because routine plasma [Mg2+] levels
are not always obtained. Some investigators have recom-
mended that this test be included as part of daily electrolyte
determinations whenever these are deemed necessary for
patient care. The prevalence of hypomagnesemia in ICU
patients has been estimated to be about 20–65%, and most of
these patients are on the medical rather than surgical services.
Hypomagnesemia is defined as a plasma magnesium concen-
tration of less than 1.7 mg/dL, but about 25% of plasma mag-
nesium is bound to albumin. While the plasma level reflects
both bound and unbound magnesium, the clinical effects of
magnesium, like those of calcium, are due to the unbound ion.
The mechanisms of hypomagnesemia can be divided into
decreased intake and increased losses of magnesium, both
renal and extrarenal in nature (Table 2–12).
A. Decreased Magnesium Intake—Decreased intake is an
unusual cause of decreased [Mg2+], but patients with no oral
intake who receive parenteral nutrition without magnesium
supplementation can develop hypomagnesemia. More com-
monly, the diet contains sufficient magnesium, but intestinal
causes of malnutrition interfere with its absorption.
Alcoholism is often associated with hypomagnesemia, but it
is likely that factors in addition to malnutrition play roles in
causing low [Mg2+] in these patients, such as increased renal
losses, vomiting, and diarrhea. In malabsorption syndromes,
increased levels of free fatty acids in the intestinal lumen may
bind magnesium in a poorly absorbable state.
B. Increased Loss of Magnesium—Increased losses of
magnesium are most commonly due to renal magnesium
wasting. Intrinsic renal parenchymal diseases primarily lead
to hypermagnesemia, but relief of acute obstructive
nephropathy (postobstructive diuresis), solute diuresis, and
the diuretic phase of acute tubular necrosis sometimes lead
to large amounts of magnesium excretion. In the ICU, renal
magnesium wasting is most commonly secondary to drugs,
including loop diuretics, cyclosporine, cisplatin, aminoglyco-
sides, amphotericin B, pentamidine, and poorly absorbable
anionic antibiotics such as ticarcillin and carbenicillin in
large doses. These drugs, along with ethanol, decrease tubu-
lar magnesium reabsorption. Nonrenal losses of magnesium
occur in association with intestinal bypass, sprue, malabsorp-
tion, severe diarrhea, short bowel syndrome, biliary fistulas,
Table 2–12. Risks for hypomagnesemia in ICU patients. 
Increased loss of magnesium  
Renal loss 
Volume expansion  
Osmotic diuresis  
Diuretics  
Amphotericin B 
Aminoglycosides 
Cyclosporine  
Diuretic phase of acute tubular necrosis
Extrarenal loss  
Diarrhea  
Nasogastric suction or vomiting  
Pancreatitis  
Intestinal fistulas with external drainage 
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and other mechanisms of fluid loss from the gastrointestinal
tract. Hypomagnesemia is also found in association with dia-
betes mellitus, phosphate depletion, hyperparathyroidism,
and thyrotoxicosis.
Several specific primary renal magnesium-wasting disor-
ders are described. Gitelman’s syndrome is due to a defect in
the thiazide-sensitive sodium-chloride cotransporter and
presents with hypocalciuria, hypomagnesemia, and
hypokalemic metabolic alkalosis. Another is a syndrome of
primary hypercalciuria, nephrocalcinosis, and renal tubular
acidification defects.
Whether abnormally low plasma [Mg2+] can result from
maldistribution of this cation between extracellular and
intracellular spaces is debated. One possible cause of hypo-
magnesemia is vigorous refeeding after starvation. Both
hypomagnesemia and hypocalcemia may be seen during
acute pancreatitis, primarily from deposition of these cations
into the tissue.
C. Hypomagnesemia and Acute Myocardial Infarction—
There is an association between hypomagnesemia and acute
myocardial infarction that is not explicable by renal or other
increased excretion of magnesium. Hypomagnesemia occur-
ring with acute myocardial infarction persists for 5–12 days,
and [Mg2+] then generally returns to normal. The association
is strengthened by the finding that treatment with magne-
sium has a beneficial effect in such patients found to have
decreased [Mg2+] by reducing the frequency and conse-
quences of ventricular arrhythmias. The mechanism of
hypomagnesemia is likely a shift in magnesium from the
extracellular space.
Clinical Features
A. Symptoms and Signs—Hypomagnesemia has its own
effects, but because it may be accompanied by hypokalemia,
hypocalcemia, acid-base disturbances, clinical features may
result from a composite of abnormalities. Cardiac arrhyth-
mias are the most important complications of hypomagne-
semia. Ventricular rhythms such as torsade de pointes,
ventricular tachycardia, and ventricular fibrillation, as well as
atrial tachycardia and atrial premature beats, can be seen.
There is an association of increased arrhythmias with digi-
talis toxicity and hypomagnesemia. Acute myocardial infarc-
tion imposes a further arrhythmia risk when decreased
plasma [Mg2+] is found. Hypocalcemia is strongly associated
with hypomagnesemia. Tetany, positive Chvostek and
Trousseau signs, seizures, weakness, and altered mental status
may be seen.
Most patients with hypomagnesemia are identified by
routine plasma [Mg2+] determinations, but the disorder
should be anticipated in certain high-risk groups, that is,
patients with hypocalcemia, acute myocardial infarction,
congestive heart failure, alcoholism, acute pancreatitis, mal-
nutrition, diarrhea, or seizures and those receiving diuretics,
amphotericin B, or aminoglycosides.
B. Laboratory Findings—Hypomagnesemia is diagnosed
when the plasma [Mg2+] is less than 1.7 mg/dL. In critically
ill patients, [Mg2+] levels should be obtained when routine
plasma electrolytes are needed. This probably means at least
daily for most high-risk patients. In patients with hypomag-
nesemia, other electrolytes, plasma calcium and phosphorus,
and urinary magnesium determinations may be helpful for
diagnostic purposes.
Because magnesium is largely intracellular, plasma
[Mg2+] may not reflect total body magnesium depletion. Red
blood cell and leukocyte [Mg2+] concentrations do not offer
much better sensitivity or specificity. Some studies have
shown that a functional magnesium loading test can identify
patients who may benefit from supplemental magnesium,
including those with normal [Mg2+] levels. These patients
may be identified by greater retention of magnesium (>70%
of a loading dose of 30 mmol magnesium sulfate).
Two electrolyte disturbances are closely tied to hypomag-
nesemia and total body magnesium depletion: hypokalemia
and hypocalcemia. Hypomagnesemia is seen in a large per-
centage of those with hypokalemia (40%). Although this
may be due to similar renal handling of these cations or
coincidental gastrointestinal losses, magnesium deficiency
may be responsible for refractory potassium deficiency.
Hypomagnesemia interferes with potassium movement into
cells, leading to net potassium leakage out of cells, by inhibit-
ing Na+,K+-ATPase pumps. Intracellular potassium falls
while intracellular sodium concentration rises. Refractory
potassium deficiency results because administered potas-
sium is unable to enter cells readily and therefore is excreted
in the urine. Hypomagnesemia also stimulates renin release
and thereby increases aldosterone, further enhancing potas-
sium excretion.
Hypomagnesemia is also strongly linked with hypocal-
cemia and inappropriately low levels of parathyroid hor-
mone. Parathyroid hormone release is impaired by
hypomagnesemia, and the hormone has a reduced effect in
the presence of hypomagnesemia. In fact, plasma [Ca2+] has
been used to estimate the effective [Mg2+] concentration.
Clinical findings of severe hypocalcemia, including
Chvostek’s sign and tetany, can be due both to hypomagne-
semia and to the resulting hypocalcemia.
The ECG may show arrhythmias, but flattened T waves,
widening of the QRS complex, PR-interval prolongation,
and U waves may be seen in moderate to severe magnesium
deficiency.
Treatment
Plasma magnesium measures both protein-bound and
unbound magnesium, but more than 95% of magnesium in
the body is found in the bones and intracellularly. In contrast
to potassium, however, rarely are there instances of normal
or high plasma [Mg2+] in patients with depletion of total
body magnesium. This suggests that plasma [Mg2+] is a rea-
sonable guide to deciding that total body magnesium is low
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but perhaps not ideal for determining the degree of deple-
tion. Fortunately, in the absence of decreased glomerular fil-
tration, administered magnesium is readily excreted when
plasma [Mg2+] is greater than 2 mg/dL, suggesting that reple-
tion of magnesium is apt to be indicated and safe in almost
all patients with [Mg2+] less than 1.5–1.7 mg/dL.
A. Assess Urgency of Treatment—Replacement of magne-
sium is indicated in patients having or anticipated to have
serious cardiac arrhythmias owing to or contributed to by
hypomagnesemia. Seizures, especially if not responsive to
seizure medications, should receive immediate treatment
with magnesium if hypomagnesemia is suspected. In high-
risk groups, plasma [Mg2+] should be used as a guide, but
even a mildly reduced plasma [Mg2+] may call for aggressive
magnesium replacement therapy, especially for patients with
myocardial infarction, digitalis toxicity, or congestive heart
failure. If hypocalcemia is symptomatic and due to hypo-
magnesemia, repletion of magnesium may be more effective
and safer than administration of calcium. Hypokalemia
refractory to potassium administration may respond to mag-
nesium replacement; an arrhythmia owing to hypokalemia
or hypomagnesemia is an indication for urgent magnesium
therapy.
B. Estimate Replacement Requirements—Estimation of
total body magnesium deficiency is often inaccurate. In mag-
nesium deficiency, the deficit ranges between 6 and 24 mg/kg
of body weight. For a 60-kg adult with moderate magnesium
deficiency (12 mg/kg), the deficit is about 720 mg. Because
plasma levels may not reflect the magnitude of the deficit,
replacement is usually initiated, and plasma [Mg2+] is fol-
lowed with repeated measurements.
C. Magnesium Replacement—Intravenous magnesium
sulfate (MgSO4) can be given as 50% solution added to D5W
or normal saline. Each 1 mL of 50% solution contains 500 mg
MgSO4, or about 2 mmol (48 mg) of elemental magnesium.
In severe hypomagnesemia, 1–2 g of MgSO4 (4–8 mmol)
can be given over 20–30 minutes (2–4 mL of 50% solution of
MgSO4 in 50–100 mL of D5W). This can be followed by 4–8
mmol magnesium over 6–8 hours and repeated as needed. It
is not uncommon to find that patients need 25–50 mmol in
24 hours. It has been recommended that one should limit
intravenous magnesium replenishment to 50 mmol in
24 hours except in severe life-threatening hypomagnesemia,
although about 50% of intravenous magnesium will be
excreted into the urine even in the presence of magnesium
deficiency. Although plasma levels of Mg2+, Ca2+, and K+ are
useful for following replacement, some clinicians recom-
mend following deep tendon reflexes. These reflexes disap-
pear with hypermagnesemia, but usually only at very high
toxic levels. Replacement doses of magnesium in patients
with renal insufficiency should be reduced, and plasma
[Mg2+] must be watched carefully.
Dietary intake of approximately 5 mg/kg per day (about
300 mg) of magnesium is required for normal magnesium
balance. Magnesium supplementation is not usually required
in patients eating a reasonable diet or who are receiving enteral
feeding formulas. Parenteral nutrition solutions should pro-
vide about 12 mmol/day (about 300 mg/day) of magnesium.
D. Correction of Cause of Hypomagnesemia—Patients
with self-limited gastrointestinal tract losses will not require
continued magnesium therapy, but renal magnesium wast-
ing may be caused by required medications such as antibi-
otics, amphotericin B, and diuretics. In these patients,
continued magnesium supplementation may be necessary.
Dacey MJ: Hypomagnesemic disorders. Crit Care Clin 2001;17:
155–73. [PMID: 11219227]
Escuela MP et al : Total and ionized serum magnesium in critically ill
patients. Intensive Care Med 2005;31:151–6. [PMID: 15605229]
Soliman HM et al: Development of ionized hypomagnesemia is asso-
ciated with higher mortality rates. Crit Care Med 2003;31:1082–7.
[PMID: 12682476]
Tong GM, Rude RK: Magnesium deficiency in critical illness.
J Intensive Care Med 2005;20:3–17. [PMID: 15665255]
Topf JM, Murray PT: Hypomagnesemia and hypermagnesemia.
Rev Endocr Metab Disord 2003;4:195–206. [PMID: 12766548]
 Hypermagnesemia
ESSENT IALS  OF  D IAGNOS I S
 Plasma [Mg2+] >2.7 mg/dL: usually asymptomatic.
 Plasma [Mg2+] >7 mg/dL: weakness, loss of deep ten-
don reflexes, and paralysis.
 Plasma [Mg2+] >10 mg/dL: hypotension and cardiac
arrhythmias.
General Considerations
In contrast to hypomagnesemia, increased [Mg2+] is seen in
a limited number of disorders. The normal kidney’s gener-
ous magnesium excretion capacity suggests that both
increased intake of magnesium and decreased glomerular fil-
tration rate are necessary for hypermagnesemia to develop.
Hypermagnesemia in critically ill patients occurs occasionally,
and impaired neuromuscular and cardiac function may result.
A. Increased Magnesium Intake—Increased intake alone
is a rare cause of increased plasma [Mg2+]. High intake of
magnesium by the oral route is unusual and is almost never
from dietary sources. Magnesium-containing antacids (eg,
magnesium hydroxide) and laxatives (eg, magnesium citrate)
provide the only likely sources of increased oral magnesium
ingestion, but fatal cases of hypermagnesemia have resulted
from these agents, especially in the elderly and those with
renal failure. Excessive amounts of intravenous magnesium
sulfate can be given inadvertently in the course of parenteral
FLUIDS, ELECTROLYTES, & ACID-BASE  51
nutrition or during replacement therapy, making close mon-
itoring of plasma [Mg2+] mandatory. In the treatment of
preeclampsia-eclampsia, large amounts of intravenous mag-
nesium sulfate are sometimes given, with the goal of achiev-
ing a plasma [Mg2+] well above the usual normal range.
Rarely, tissue breakdown (tumor lysis syndrome) can cause
hypermagnesemia as intracellular magnesium is released.
B. Decreased Magnesium Excretion—Unbound magne-
sium is filtered, and the amount appearing in the urine repre-
sents what is not reabsorbed. In the presence of increased
plasma [Mg2+], a larger quantity is non-protein-bound,
increasing the amount filtered relative to the glomerular filtra-
tion rate. Magnesium is reabsorbed as a result of sodium reab-
sorption in proximal, loop of Henle, and distal sites. In the
absence of enhanced sodium reabsorption, there is no change
in the quantity of reabsorbed magnesium, and the net result in
hypermagnesemia is increased renal excretion. However, any
disorder impairing glomerular filtration has the potential for
causing hypermagnesemia, including acute and chronic renal
failure. An increase in sodium reabsorption, such as seen in
volume-depleted states, may impair renal magnesium excre-
tion by facilitating magnesium reabsorption.
Clinical Features
A. Symptoms and Signs—Effects of hypermagnesemia are
nonspecific and include lethargy, weakness, and hypore-
flexia. More severely increased Mg2+ levels are associated
with loss of deep tendon reflexes, refractory hypotension
(from interference with membrane calcium transport), car-
diac arrhythmias, respiratory depression, and drowsiness.
Hypermagnesemia should be suspected in patients with
renal insufficiency who are receiving magnesium-containing
medications or oral or parenteral magnesium supplementation
or replacement. Other high-risk critically ill patients include
those receiving nephrotoxic drugs, those with hypotension or
hypovolemia and oliguria, and those with preeclampsia-
eclampsia or preterm labor receiving large doses of intravenous
magnesium. Patients with chronic renal failure should have
antacids containing magnesium restricted. Elderly patients with
diminished renal function who use magnesium-containing
antacids and laxatives or vitamins containing magnesium salts
may have an increased incidence of hypermagnesemia.
B. Laboratory Findings—A plasma magnesium level over
2.7 mg/dL makes the diagnosis of hypermagnesemia. Other
laboratory studies that should be obtained include other
plasma electrolytes and plasma creatinine and urea nitrogen.
Urinary magnesium may be of value in confirming that
hypermagnesemia is due to increased intake of magnesium
rather than decreased renal excretion.
Treatment
A. Hypermagnesemia Requiring Urgent Treatment—
Patients who are symptomatic and who have plasma [Mg2+]
greater than 8–10 mg/dL should be treated urgently. Most
commonly they will have muscle weakness or paralysis and
hypotension, prompting evaluation and treatment.
Intravenous calcium gluconate or calcium chloride will
counter the effects of excessively high [Mg2+]. The amount of
calcium should be limited in the presence of renal failure if
the plasma phosphorus concentration is elevated.
B. Decrease Intake of Magnesium—Magnesium-containing
antacids and other agents should be discontinued. Intravenous
fluids, especially parenteral nutrition fluids, should have
magnesium removed.
C. Increase Magnesium Excretion—In patients with normal
renal function who develop hypermagnesemia, even a large
excess of magnesium will be excreted rapidly without inter-
vention. The majority of patients with decreased glomerular
filtration will not be able to increase excretion appreciably
because they are limited by decreased filtration. Nevertheless,
inhibition of ascending loop of Henle sodium reabsorption
with furosemide may impair magnesium reabsorption some-
what. Patients who can tolerate volume expansion also should
be given normal saline to facilitate magnesium excretion. In
patients who have severe hypermagnesemia, greatly enhanced
magnesium removal requires hemodialysis.
Topf JM, Murray PT: Hypomagnesemia and hypermagnesemia.
Rev Endocr Metab Disord 2003;4:195–206. [PMID: 12766548]
DISORDERS OF CALCIUM BALANCE
Calcium is the most abundant divalent cation in the body.
The vast majority (98%) of calcium is in the form of hydrox-
yapatite in the bone, and only a very small amount is in the
extracellular fluid. Nevertheless, plasma and extracellular
calcium has a major role in the control of neuromuscular
coupling and contraction. Plasma calcium is regulated by a
complex system of hormones, vitamins, and organ function
and is closely tied to phosphorus and magnesium regulation.
In the ICU, both hyper- and hypocalcemia are seen. Severe
hypercalcemia is due primarily to malignant disorders; there
are fewer patients who have severe hypercalcemia from
hyperparathyroidism, vitamin D toxicity, sarcoidosis, and
other disorders. Hypocalcemia is seen in patients with
chronic or acute renal failure, hyperphosphatemia, hypo-
magnesemia, and drug treatment.
Physiologic Considerations
A. Calcium Intake—Dietary calcium has a wide range in
adult patients. Calcium absorption from the intestinal tract
is influenced by 1,25-dihydroxyvitamin D, but calcium
uptake is also proportionate to calcium intake. Calcium is
taken up primarily in the duodenum and jejunum. Calcium
binding to phosphate and free fatty acids in the lumen to
form insoluble salts will interfere with absorption.
B. Plasma Calcium—Plasma calcium is about 40% protein-
bound to albumin and other plasma proteins, and a smaller
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fraction (10%) is attached to various anions. Total plasma
calcium concentration is normally about 9–10 mg/dL;
therefore, ionized calcium concentration is normally about
4.5–5 mg/dL. An important cause of decreased total plasma
calcium is hypoalbuminemia, but ionized calcium, the com-
ponent important in symptomatic hypocalcemia, may not be
reduced. One approximation is that for each decrease of
1 g/dL of albumin from normal, 0.2 mmol/L (0.8 mg/dL) is
added to the plasma calcium as a correction factor for inter-
pretation of the level. The degree of protein binding of cal-
cium to plasma proteins is affected by plasma pH; acidosis
increases and alkalosis decreases ionized calcium.
C. Renal Calcium Excretion—Free calcium is filtered and
largely reabsorbed (>95%) under steady-state conditions in
the proximal nephron (accounting for about 60% of reab-
sorption), the ascending loop of Henle, and the distal
nephron. Although passive movement of calcium is largely
responsible for calcium uptake in the proximal tubule, there
is some active transport. In the loop of Henle, the driving
force for calcium reabsorption is the reabsorption of Na+ and
K+, causing an electropositive gradient from lumen to extra-
cellular space. Drugs that interfere with sodium reabsorption
here, such as loop diuretics, interfere with calcium reabsorp-
tion and lead to increased calcium excretion. On the other
hand, the action of thiazide diuretics in the distal tubule
favors calcium reabsorption, increasing plasma calcium and
decreasing calciuria. Under physiologic conditions, the nor-
mal kidneys can conserve calcium extremely well (<100
mg/day) and can increase excretion to very high levels in the
face of hypercalcemia.
D. Regulation of Plasma Calcium—In contrast to magne-
sium, which does not appear to be under hormonal control,
plasma calcium is regulated primarily by two interacting
hormones: parathyroid hormone (PTH) and vitamin D
(1,25[OH]2D3). These two hormones control the complex
cycle of calcium between the intestinal lumen (dietary cal-
cium), the large reserve of calcium in the bone, and renal
excretion. They also play important roles in the regulation of
phosphorus distribution, absorption, and excretion.
1. Parathyroid hormone—Hypocalcemia stimulates
release of PTH from the parathyroid glands. PTH binds to
transmembrane receptors in bone and renal tubular cells and
stimulates adenylyl cyclase, resulting in increased intracellu-
lar cAMP levels. The effect of PTH is to mobilize calcium by
bone resorption and, in the kidneys, to decrease calcium
excretion, increase phosphate excretion, and stimulate
increased synthesis of active vitamin D (1,25[OH]2D3). In
the absence of PTH, patients can have severe hypocalcemia
and hyperphosphatemia; in states of excess PTH from hyper-
plasia of the parathyroid glands, hypercalcemia and
hypophosphatemia are noted.
2. Vitamin D—Vitamin D3 is a fat-soluble vitamin that is
found in various amounts in the diet. Ultraviolet light stim-
ulates some conversion of precursor substances to vitamin
D3 in the skin. The most active vitamin D compound is
1,25(OH)2D3, which is synthesized by conversion of vitamin
D3 in two stages to 25(OH)D3 by the liver and to 1,25(OH)2
D3 by the kidneys. The rate of conversion of 25(OH)D3 to
1,25(OH)2D3 is indirectly accelerated by hypocalcemia
through the action of PTH on the kidneys. Active 1,25(OH)2
D3 increases calcium and phosphorus absorption from the
gastrointestinal tract and helps PTH mobilize calcium from
the bone.
 Hypocalcemia (See Table 2–13)
ESSENT IALS  OF  D IAGNOS I S
 Plasma [Ca2+] <8.5 mg/dL.
 Nervous system irritability, including altered mental
status, focal and grand mal seizures, paresthesias,
tetany, hyperreflexia, muscle weakness.
 Prolonged QT interval, cardiac arrhythmias.
General Considerations
Decreased plasma calcium can have serious consequences in
critically ill patients, potentiating arrhythmias and seizures.
However, most patients in the ICU with hypocalcemia (total
[Ca2+] <8.5 mg/dL) are asymptomatic. This is so because
these patients have low plasma albumin levels, and the non-
albumin-bound or ionized fraction of Ca2+ that participates
in neuromuscular coupling is normal. Total plasma [Ca2+]
can be “corrected” for hypoalbuminemia by adding 0.8 mg/dL
to the measured total [Ca2+] for every 1 g/dL decrease in
plasma albumin below 3.5 g/dL. If the value is above 8.5 mg/dL,
ionized calcium is likely to be normal, except with extreme
changes in pH. Ionized plasma calcium measurements can
confirm this correction, if indicated.
Table 2–13. Risks for hypocalcemia in ICU patients.
Decreased intake of calcium 
Malabsorption of calcium or vitamin D 
Steatorrhea  
Decreased PTH or decreased PTH effectiveness 
Hypoparathyroidism, parathyroidectomy 
Hypomagnesemia 
Acute pancreatitis  
Vitamin D deficiency  
Chronic renal insufficiency
Other  
Septic shock  
Rhabdomyolysis  
Acute hyperphosphatemia 
Treatment of hypercalcemia 
Hypoalbuminemia 
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There is an abundance of calcium in the body, but much
of it is in poorly mobilized forms. When hypocalcemia
occurs, there is failure of normal plasma calcium regulation.
Calcium can leave the extracellular space when driven by
reactions that deposit calcium in the bones and soft tissues or
when there is insufficient PTH or 1,25(OH)2D3 to mobilize
calcium from the bone. In the ICU, a few other factors may
also lead to hypocalcemia—notably drugs and hyperphos-
phatemia.
A. Calcium Deposition—Hypocalcemia may be due to loss
of plasma calcium by deposition of calcium salts in tissues. In
critically ill patients, this may be seen in acute pancreatitis
and rhabdomyolysis. Calcium is deposited in the form of cal-
cium soaps (ie, poorly soluble salts of Ca2+ and fatty acids) in
the case of pancreatitis or in other forms in damaged skeletal
muscle. Most other patients with hypocalcemia from calcium
deposition have hyperphosphatemia. In these patients, when
the product of calcium × phosphorus is greater than 60, cal-
cium phosphate tends to deposit in soft tissues. An impor-
tant cause of hypocalcemia is the tumor lysis syndrome, in
which there is massive release of phosphorus into the blood.
Hyperphosphatemia also may be seen in ICU patients in
whom excessive phosphorus repletion is given to correct
hypophosphatemia or from absorption of bowel preparation
solutions containing sodium phosphate. Most patients with
chronic renal failure will have some degree of hyperphos-
phatemia that facilitates hypocalcemia unless they are effec-
tively treated with oral phosphate-binding agents and
vitamin D supplementation. Rarely—less commonly than at
one time believed—large amounts of blood transfusions
have been associated with hypocalcemia, probably from
chelation of Ca2+ by citrate used as an anticoagulant.
B. Decreased PTH or PTH Effect—Hypoparathyroidism is
seen occasionally in the ICU but is rarely undiagnosed or
unsuspected prior to admission. Low PTH levels are still seen
occasionally after thyroid surgery when parathyroid glands
are not preserved adequately. On the other hand, hypomag-
nesemia has an important effect of decreasing PTH release
from parathyroids, contributing to hypocalcemia. There are
rare congenital forms of PTH resistance.
In critically ill patients, hypocalcemia also may be due to
a decreased effect of PTH action. Hypomagnesemia
decreases the action of PTH on bone. Pancreatitis usually is
thought to cause hypocalcemia from soft tissue deposition,
but there also may be resistance to PTH in this disease.
Vitamin D deficiency also interferes with the action of PTH.
C. Other Causes—Loop-acting diuretics such as furosemide
may cause excessive calcium excretion by the kidneys, but
this is rarely a cause of hypocalcemia alone because of effec-
tive counterregulatory mechanisms. Treatment of hypercal-
cemia with bisphophonates, plicamycin, or calcitonin may
lead to excessively low [Ca2+]—but again, this is rarely seen.
Finally, patients with renal failure have hypocalcemia from a
combination of mechanisms, including hyperphosphatemia
and decreased conversion of 1,25(OH)2D3.
Clinical Features
A. Symptoms and Signs—Central and peripheral nervous
system effects are the most common features of hypocal-
cemia. Altered mental status, including lethargy and coma,
may be present. Seizures may be focal or generalized, and
hypocalcemia may complicate a known seizure disorder.
More often, hypocalcemia is manifested by tetany, paresthe-
sias, and hyperreflexia. The Chvostek and Trousseau signs
may be positive. When severe, hypocalcemia may result in
muscle weakness. Hypocalcemia prolongs the QT interval on
the ECG. Ventricular arrhythmias may be seen, including
ventricular fibrillation.
Patients with chronic hypocalcemia may have manifesta-
tions of bone resorption of calcium and have features of the
underlying disease leading to decreased plasma [Ca2+]. For ICU
patients, review of medications and recent conditions that may
affect plasma [Ca2+] should be undertaken. Medications con-
tributing to hypocalcemia include furosemide, phenytoin,
calcium-lowering drugs such as plicamycin and bisphospho-
nates, blood transfusions, and phosphate therapy. Patients with
renal failure (acute or chronic), rhabdomyolysis, pancreatitis,
tumors, malnutrition, and gastrointestinal disorders are at risk.
B. Laboratory Findings—Hypocalcemia is diagnosed when
the plasma [Ca2+] is less than 8.5 mg/dL after appropriate
correction for low plasma albumin levels. In critically ill
patients, [Ca2+] should be measured when routine plasma
electrolyte determinations are needed. This probably means
at least daily for most high-risk patients. In patients with
hypocalcemia, plasma sodium, potassium, chloride, magne-
sium, phosphorus, amylase, and creatine kinase may be help-
ful for making a specific diagnosis.
Vitamin D levels in the blood can be measured, including
1,25(OH)2D3, if necessary. The PTH level can be interpreted
properly only when compared with the normal range for the
[Ca2+]. In most cases of hypocalcemia in the ICU, these
measurements are not necessary.
Treatment
A. Need for Treatment—Low plasma [Ca2+] calls for treat-
ment if the patient is symptomatic, especially with very low
[Ca2+] and tetany, arrhythmias, or seizures. Hypomagnesemia,
because of multiple effects leading to hypocalcemia, is also a
treatment priority and usually can be corrected with little risk
of complications, except in patients with renal insufficiency.
Patients with decreased total plasma calcium but with
hypoalbuminemia or pH changes sufficient to maintain a nor-
mal estimated ionized calcium do not require calcium replace-
ment. Patients with both acute severe hyperphosphatemia and
hypocalcemia represent a problem. Raising plasma calcium in
the face of hyperphosphatemia may cause widespread calcium
phosphate deposition. Only enough calcium to prevent or
reverse cardiovascular complications should be given. It may
be advisable to determine plasma ionized calcium in this situ-
ation for guidance. Acute hemodialysis to lower the plasma
phosphorus concentration could be helpful.
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B. Treatment of Severe Hypocalcemia—Treatment with
intravenous calcium gluconate or calcium chloride is indicated.
Calcium chloride may be less well tolerated than calcium glu-
conate, and calcium gluconate is recommended except during
cardiac arrest or severe arrhythmias. Each compound is avail-
able in ampules containing 10 mL of 10% solution containing
93 mg Ca2+ for calcium gluconate and 273 mg Ca2+ for calcium
chloride. For rapid intravenous infusion, give 1 ampule over
10–30 minutes. For persistent severe hypocalcemia, intra-
venous calcium gluconate can be given as 8–12 mg/kg (about
6–8 ampules of calcium gluconate) of Ca2+ over 6–8 hours.
During treatment, plasma [Ca2+] should be followed,
along with phosphorus and magnesium. The physical exam-
ination and ECG may be helpful in deciding when treatment
should be slowed or changed to oral supplementation.
C. Correction of Cause of Hypocalcemia—Patients with
pancreatitis and rhabdomyolysis may have transient
hypocalcemia of varying duration followed by release of Ca2+
back into the extracellular space. Therefore, these patients
should be monitored closely for development of normocal-
cemia or even rebound hypercalcemia. Patients with chronic
renal failure with hypocalcemia may respond to vitamin D
supplementation and dialysis. Hypoparathyroidism is
treated with calcium supplementation and vitamin D.
Ariyan CE, Sosa JA: Assessment and management of patients with
abnormal calcium. Crit Care Med 2004;32:S146–54. [PMID:
15064673]
Dickerson RN et al: Treatment of moderate to severe acute
hypocalcemia in critically ill trauma patients. J Parenter Enteral
Nutr 2007;31:228–33. [PMID: 17463149]
Tiu RV et al: Tumor lysis syndrome. Semin Thromb Hemost
2007;33:397–407. [PMID: 17525897]
Zivin JR et al: Hypocalcemia: A pervasive metabolic abnormality
in the critically ill. Am J Kidney Dis 2001;37:689–98. [PMID:
11273867]
 Hypercalcemia (See Table 2–14)
ESSENT IALS  OF  D IAGNOS I S
 Plasma [Ca2+] >10.5 mg/dL.
 Altered mental status with confusion, lethargy, psy-
chosis, and coma.
 Hyporeflexia and muscle weakness.
 Constipation, shortening of QT interval, and pancreatitis.
 Features of chronic hypercalcemia may be seen: bone
changes, band keratopathy.
 May have features of underlying disease: hyperparathy-
roidism, malignancy, sarcoidosis, vitamin A toxicity.
General Considerations
Hypercalcemia is a frequent cause of admission to the ICU,
as well as a complication of a variety of disorders. Most often
hypercalcemia is identified by a routine plasma calcium level
([Ca2+] >10.5 mg/dL), but severe hypercalcemia with altered
mental status is a medical emergency. Patients may be
admitted to the ICU for management, especially for close
monitoring of intravascular fluid therapy. Severe hypercal-
cemia is almost always due to malignancy, including solid
tumors, lymphoma, and multiple myeloma. Causes of
more mild hypercalcemia include granulomatous diseases
such as sarcoidosis, tuberculosis, and fungal diseases and
hyperparathyroidism.
The mechanisms of hypercalcemia, like hypocalcemia,
reflect the large amount of Ca2+ flux between the gastrointesti-
nal tract, bone, kidneys, and extracellular space. Hypercalcemia
is the result of failure of the regulatory mechanisms for cal-
cium, including inability to suppress PTH normally, or exces-
sive mobilization of calcium by an abnormally produced
PTH-like compound or vitamin D. PTH activates or stimulates
osteoclasts that mobilize calcium from bone.Vitamin D prima-
rily increases calcium absorption from the gastrointestinal
tract.
A. Primary Elevation of Parathyroid Hormone—
Hypercalcemia in primary hyperparathyroidism is caused by
unregulated PTH secretion from parathyroid adenoma or
hyperplasia. In the past, patients were identified when symp-
tomatic from renal stones, bone pain, or symptoms of hyper-
calcemia. These patients are now identified most often from
routine screening laboratory tests that include plasma [Ca2+].
Diagnosis is made by the finding of PTH levels that are inap-
propriately high in the presence of elevated plasma [Ca2+].
Table 2–14. Risks for hypercalcemia in ICU patients.
Increased intake of calcium 
Calcium-containing antacids 
Milk-alkali syndrome 
Increased PTH or PTH effectiveness  
Hyperparathyroidism  
Vitamin D intoxication  
Hypercalcemia of malignancy  
PTH-related peptide 
Increased vitamin D conversion 
Bone destruction 
Cytokines
Others  
Thiazide diuretics  
Immobilization  
Thyrotoxicosis 
Granulomatous diseases (vitamin D conversion)  
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B. Abnormal PTH-like Substance—Malignancy is the most
frequent cause of severe hypercalcemia. Although several
mechanisms of tumor hypercalcemia have been identified,
the most important is release by the tumor of a peptide that
has structural homology with PTH, called parathyroid
hormone–related peptide (PTHrP). The effects of PTHrP are
similar to those of PTH, causing increased plasma calcium
and decreased plasma phosphorus. Hypercalcemia from this
substance is seen in bronchogenic carcinoma and many
other malignancies. Hypercalcemia in malignant disease is
also caused by other factors, including bony metastases with
bone destruction and the effects of cytokines, including
interleukins and transforming growth factor β (TGF-β).
C. Abnormal Production of Vitamin D—Excessive admin-
istration or ingestion of vitamin D can cause hypercalcemia,
but this does not occur immediately. Toxic doses of vitamin
A also may cause hypercalcemia. Macrophages within granu-
lomas may synthesize 1,25(OH)2D3. Although sarcoidosis is
the best known entity associated with hypercalcemia, tuber-
culosis, berylliosis, and fungal diseases may behave similarly.
In some patients with granulomatous diseases, hypercalciuria
is more common than hypercalcemia. This is probably so
because both elevated Ca2+ and vitamin D inhibit PTH
release. In the absence of elevated PTH, renal calcium excre-
tion is high, resulting in hypercalciuria without hypercal-
cemia. Both Hodgkin’s and non-Hodgkin’s lymphoma can
produce 1,25(OH)2D3.
D. Other Causes—Patients recovering from acute pancreati-
tis or rhabdomyolysis can have a rebound of plasma Ca2+ lev-
els as Ca2+ is released back into the extracellular space.
Milk-alkali syndrome results from ingestion of calcium and
antacids by a patient with renal failure and is associated with
the unusual combination of hypercalcemia and hyperphos-
phatemia. Hypercalcemia can be seen rarely as a manifestation
of hyperthyroidism. Thiazide diuretics decrease renal calcium
excretion. Immobilization does not cause hypercalcemia but
exacerbates hypercalcemia owing to other mechanisms.
Clinical Features
Most patients with hypercalcemia of mild degree are identi-
fied by routine plasma [Ca2+] determinations on screening
laboratory tests.
A. Symptoms and Signs—Hypercalcemia affects mental
status, including lethargy, confusion, and psychosis.
Patients may have absent deep tendon reflexes and muscle
weakness. A major complaint may be constipation, and
bowel sounds usually are decreased. Polyuria and impaired
urinary concentrating ability (nephrogenic diabetes
insipidus) are consequences of hypercalcemia. The ECG
may show a shortened QT interval. Arrhythmias may be
precipitated in patients receiving digitalis. Hypercalcemia is
associated with and may be a causal factor in peptic ulcer
disease and pancreatitis.
Hypercalcemia should be suspected in patients with
malignancies of the breast, prostate, lung, kidney, liver, and
head and neck. Patients with multiple myeloma may have
hypercalcemia as well. Sarcoidosis, tuberculosis, fungal infec-
tions, and other granulomatous diseases may be associated
with significant hypercalcemia, but rarely is plasma [Ca2+]
high enough to cause severe symptoms.
Other symptoms and signs are related to the underlying
disease, especially with long-standing hyperparathyroidism
(eg, renal stones, fractures, bony deformities, band keratopathy,
and conjunctivitis). Patients with hypercalcemia of malignancy
usually do not have evidence of long-term hypercalcemia but
may have findings related to the primary or metastatic tumor.
B. Laboratory Findings
A plasma calcium concentration over 10.5 mg/dL makes the
diagnosis of hypercalcemia. Other laboratory studies that
should be obtained include plasma phosphorus, other elec-
trolytes, and creatinine and urea nitrogen. In hypercalcemia,
polyuria may result from inability to concentrate the urine.
Renal calcification and obstructive uropathy from renal
stones may lead to renal insufficiency.
For severe hypercalcemia, treatment can be initiated
without knowledge of the underlying cause. However, spe-
cific diagnosis may be helped by obtaining a PTH level.
Assays for PTH and PTHrP are available to distinguish pri-
mary hyperparathyroidism from hypercalcemia of malig-
nancy mediated by PTHrP. Vitamin D levels are rarely
needed for work-up of hypercalcemia.
Treatment
A. Need for Treatment—Patients with mild hypercalcemia
need not be treated immediately or aggressively unless
symptomatic. Severe hypercalcemia ([Ca2+] >12–13 mg/dL)
should be treated even if asymptomatic, and hypercalcemia
of any degree with symptoms, especially altered mental sta-
tus or seizures, should be treated vigorously. Treatment is
directed at lowering plasma [Ca2+] by increased renal excre-
tion and by decreasing mobilization from the bone stores.
In patients with symptomatic or severe hypercalcemia, a
four-pronged approach is used: expansion of extracellular
volume, furosemide, calcitonin, and pamidronate.
B. Increased Excretion of Calcium—Unbound plasma cal-
cium is filtered and largely reabsorbed. Calcium reabsorption
is closely tied to sodium reabsorption in the proximal nephron
and loop of Henle. Expansion of extracellular volume with
0.9% NaCl decreases passive proximal reabsorption of calcium.
Loop diuretics are given both to prevent volume overload
and to inhibit active sodium and passive calcium reabsorp-
tion in the loop of Henle. In severe hypercalcemia, intra-
venous 0.9% NaCl should be given at a rate of 200–300 mL/h
or more. Patients with cardiac disease and the elderly may be
unable to tolerate these large volumes, and pulmonary edema
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may develop. In such patients, central venous pressure or
pulmonary artery wedge pressure measurements may be
necessary.
Because calcium absorption is coupled with sodium reab-
sorption in the ascending loop of Henle, furosemide
increases calcium excretion. Furosemide can be given in a
dosage of 20–60 mg intravenously every 2–6 hours as needed
to maintain urine output. Furosemide is also useful to main-
tain natriuresis in patients given large volumes of intra-
venous NaCl. In patients given large doses of furosemide,
hypokalemia and hypomagnesemia may be problems.
Thiazide diuretics should not be given because these drugs
inhibit renal calcium excretion in the distal tubule.
Plasma calcium concentration usually will begin to
decline within a few hours with the combination of
furosemide and normal saline, as long as 0.9% NaCl is given
at a sufficient rate.
C. Decreased Mobilization of Calcium from Bone—
Bisphosphonates are very effective agents used for the man-
agement of hypercalcemia and have low toxicity. These drugs
bind to bone hydroxyapatite and inhibit osteoclast activity
for a prolonged period. Their action is moderately rapid,
with onset within 2 days and maximum effect at about 1
week. Plasma [Ca2+] falls even while urinary [Ca2+]
decreases. With bisphosphonates, a large proportion of
patients will have return of [Ca2+] to the normal range
regardless of the cause of hypercalcemia.
Pamidronate is given as a single dose of 60 or 90 mg intra-
venous over 24 hours, with 60–100% of patients having a
normal plasma [Ca2+] 10–13 days later. The higher dose is
given for more severe hypercalcemia (>13.5 mg/dL). Patients
with renal insufficiency should be given a smaller dose of
pamidronate. Side effects of pamidronate are minor.
However, in fewer than 2% of patients, systemic inflamma-
tory reactions, ocular inflammation, and osteonecrosis of the
maxilla and mandible may occur. The calcium-lowering
effect may last 2–4 weeks, although the effect may be shorter
and less pronounced when treating malignant hypercal-
cemia. Newer bisphosphonates, including oral agents, are
used mostly for mild hypercalcemia or to prevent osteoporo-
sis or hypercalcemia.
Calcitonin (calcitonin-salmon, 4 IU/kg IM as a starting
dosage) has a slight and short-term effect but can be used in
the initial phase of therapy. It is nontoxic and acts most
quickly of all these agents. Calcitonin promotes renal excre-
tion of calcium, inhibits bone resorption, and inhibits gut
absorption of calcium. The effect of calcitonin diminishes
within a few days, but other treatments are likely to be effec-
tive by then.
Plicamycin blocks bone resorption of calcium. It can
be given to any patient with hypercalcemia but is used
most often in hypercalcemia of malignancy. The usual dose
is 25 μg/kg in 50 mL D5W intravenous over 3–6 hours.
[Ca2+] begins to decline at about 24 hours and normalizes
in about 60% of patients. Plicamycin should not be used in
the presence of severe renal or liver failure or thrombocy-
topenia. It is much less often used since the advent of the
bisphosphonates.
There are some limited data on gallium nitrate for the
treatment of hypercalcemia of malignancy. Studies indicate
that it is as effective as pamindronate and has few side
effects. It may be particularly useful in specific kinds of
tumors or in those whose hypercalcemia is refractory to
other treatment.
D. Other Therapy—Hemodialysis is very effective in lower-
ing plasma [Ca2+] in patients who have inadequate renal
function or who cannot tolerate forced diuresis.
Corticosteroids have a role in hypercalcemia mediated by ele-
vated vitamin D (in granulomatous disorders) and in multiple
myeloma. The effect is not immediate because corticosteroids
probably decrease absorption of calcium from the gut by
interfering with vitamin D activation. While intravenous
sodium phosphate has a predictable calcium-lowering effect,
this treatment is used rarely at present because of the precip-
itation of calcium phosphate in soft tissues. On the other
hand, oral sodium phosphate therapy is effective in forming
insoluble calcium phosphate deposits in the gut.
Ariyan CE, Sosa JA: Assessment and management of patients with
abnormal calcium. Crit Care Med 2004;32:S146–54. [PMID:
15064673]
Body JJ, Bouillon R: Emergencies of calcium homeostasis. Rev
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ACID-BASE HOMEOSTASIS & DISORDERS
 Pathophysiology
Arterial pH is reflected by the relative concentrations of bicar-
bonate (HCO3
–) and carbon dioxide (CO2) in the blood.
While this system does not provide very strong buffering, the
ability to adjust these variables makes this system an impor-
tant component of acid-base regulation. Plasma bicarbonate
is controlled principally by renal conservation or excretion of
bicarbonate and hydrogen ion; CO2, largely by pulmonary
ventilation. Decreased arterial pH is called acidemia, and
increased arterial pH is called alkalemia. The disturbances
responsible for these changes are acidosis and alkalosis,
respectively, and these changes are defined as “metabolic”
(owing to primary increase or decrease in HCO3
–) or “respi-
ratory” (owing to primary increase or decrease in CO2).
Acid-Base Buffering Systems
The major acid-base buffering system in the blood involves
carbon dioxide and bicarbonate. Carbon dioxide, bicarbon-
ate, and carbonic acid are interconverted according to the
following reaction:
H+ + HCO3
– ↔ H2CO3 ↔ CO2 + H2O
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The relationship between the species that define pH is
known as the Henderson-Hasselbalch equation:
Under normal conditions, the balance between these
components is tightly controlled. Within 95% confidence
limits, the pH of the arterial blood is between 7.35 and 7.43.
For PaCO2, the limits are 37 and 45 mm Hg. Bicarbonate con-
centration normally varies between 22 and 26 meq/L. If
hydrogen ions are added to the blood, the reaction shifts
rightward, with production of CO2 and water. Normally, the
CO2 so produced is eliminated rapidly by the lungs.
The bicarbonate–carbon dioxide buffering system is the
major extracellular buffer. Other minor extracellular buffer
systems also contribute to stabilization of the pH. After
extracellular buffering occurs, a second intracellular phase
takes place over the next several hours. The main intracellu-
lar buffer systems include hemoglobin, protein, dibasic phos-
phate, and carbonate in bone. The ratio of extracellular to
intracellular buffering is approximately 1:1 unless the acid
load is very large or continues over a long period of time.
Contribution by both the extracellular and intracellular
buffers means that an exogenous acid load (or deficit) has a
volume of distribution approximately equal to that of the
total body water (50–60% of ideal body weight).
Finally, both bicarbonate and CO2 act as a “dynamic”
buffering system. For usual buffers, the addition or removal
of hydrogen ion, for example, is countered by corresponding
opposite effects of the buffer components. This minimizes
pH change at the expense of consumption of some of the
buffer components, limiting the maximum buffering capac-
ity. For the bicarbonate-CO2 system, however, physiologic
mechanisms greatly increase the buffer capacity. Metabolic
acidosis can be countered by decreased arterial PaCO2,
whereas a respiratory acidosis is countered by increased
plasma bicarbonate. Because the lungs can eliminate a vast
amount of CO2 per day, this is a very powerful buffering
component. Similarly, the kidneys can eliminate bicarbonate
if necessary or can regenerate bicarbonate at quite high rates.
Renal Handling of Bicarbonate
The kidneys perform two major functions in acid-base
homeostasis. First, they reclaim filtered bicarbonate by
secreting hydrogen ions. Within the cells of the proximal
tubule, carbonic anhydrase facilitates conversion of CO2 and
water into protons and bicarbonate ions. The bicarbonate is
returned to the blood, whereas the hydrogen is secreted into
the proximal tubule, where it combines with tubular bicar-
bonate to re-form CO2 and water. The result is a net reclama-
tion of bicarbonate; 80–85% is reabsorbed in the proximal
convoluted tubule, with lesser amounts in the loop of Henle
(5%), the distal tubule (5%), and the collecting system (5%).
In addition to bicarbonate, the anions of other acids are
filtered by the glomeruli. The formation of these acids in the
body results in an equimolar decrease in bicarbonate. The
most important of these anions is monohydrogen phos-
phate. When hydrogen ion, secreted by the proximal tubules,
combines with monohydrogen phosphate, it forms dihydro-
gen phosphate (H2PO4
–), which is a weak acid with a pKa of
6.8. The lowest pH attainable in the proximal tubule is
approximately 4.5. Because the pKa of this acid is within the
tubular physiologic range for pH, it can be re-formed and
excreted. When acids can be excreted by this process, they are
referred to as titratable acids. The net effect is the regenera-
tion of a bicarbonate anion to be added to the blood.
On the other hand, acids with pKa values lower than 4.5
(such as sulfuric acid, which is formed as a metabolic prod-
uct of some amino acids) cannot be regenerated in this way.
Therefore, excess hydrogen ions secreted into the proximal
tubule must be excreted bound to another buffer to permit
the continued formation of bicarbonate by the tubular
cells. Tubular cells deaminate glutamine, and ammonia dif-
fuses into the proximal tubules. Ammonia reacts with
hydrogen ion produced in the distal tubule to form ammo-
nium ion (NH4·), which is excreted as NH4Cl. Ammonium
excretion can increase from its normal level of 35 meq/day
to over 300 meq/day in the face of severe acidemia. Three to
five days are required before maximum excretion of ammo-
nium is achieved. As ammonium excretion increases,
plasma bicarbonate concentration rises, as does urinary
pH. Because a greater absolute quantity of hydrogen ions
can be excreted in buffered (ammonium-rich) urine, uri-
nary pH does not always reflect the extent of renal acidifi-
cation. Both ammonia production and proton secretion in
the proximal tubules are increased by acidemia and
decreased by alkalemia.
Loss of acidic fluids (eg, in vomiting) or increase in alkali
(eg, antacid ingestion) in the body causes a reduction in
hydrogen ion concentration and an increase in plasma bicar-
bonate and pH. About two-thirds of the alkaline load is
buffered in the extracellular space, whereas only one-third
enters the intracellular compartment. At the same time, there
is a modest shift of potassium into the cells, resulting in a
decline in potassium concentration of approximately 0.4–0.5
meq/L for each 0.1 unit increase in pH. The acute response
to an infusion of bicarbonate is an increase in PaCO2, which
results from combination with H+, and the release of CO2.
The pulmonary response to chronic alkalemia is inhibition
of the respiratory drive. This causes a rise in PaCO2 of about
0.5 mm Hg for each 1 meq/L increase in the plasma bicar-
bonate concentration.
The kidney is able to excrete large amounts of excess
bicarbonate under normal physiologic conditions. Increased
concentration of bicarbonate in the glomerular ultrafiltrate,
in combination with elevated pH of the blood perfusing the
cells of the proximal tubules, decreases renal reabsorption
and creates alkaline urine. Titratable acid and ammonia
excretion are rapidly reduced.
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However, both hypovolemia (volume-contraction alkalo-
sis) and hypokalemia can compromise the kidney’s ability to
excrete bicarbonate. Three mechanisms are responsible:
(1) Decreased glomerular filtration rate (GFR) caused by
hypovolemia, despite an elevated plasma bicarbonate,
decreases the amount of filtered bicarbonate, (2) proximal
tubular reabsorption of HCO3
– is stimulated by hypovolemia
and hypokalemia, and (3) increased aldosterone concentra-
tion, produced by hypovolemia, encourages paradoxically
increased bicarbonate reabsorption.
Respiratory Acid-Base Changes
Chemoreceptors normally maintain the PaCO2 between 37
and 45 mm Hg as long as pH is near normal. Lung disease,
chest wall abnormalities, neurologic disease, or trauma may
interfere with pulmonary excretion of CO2 and cause hyper-
capnia. Both stimulation of ventilation and other mecha-
nisms cause hypocapnia. An acute change in PaCO2 produces
a change in blood pH within several minutes.
Because of “mass action,” plasma bicarbonate falls by about
0.25 meq/L for each 1 mm Hg decrease in PaCO2 (acute respi-
ratory alkalosis) and increases by 0.1 meq/L for each 1 mm Hg
increase in PaCO2 during acute respiratory acidosis. Eventually,
the kidneys respond to the change in PaCO2 by increasing
bicarbonate reabsorption from the proximal tubules, compen-
sating for a rise in PaCO2, or decreasing bicarbonate reabsorp-
tion if PaCO2 is low. Plasma bicarbonate concentration
increases by an average of 0.5 meq/L for each 1 mm Hg
increase in PaCO2 during chronic hypercapnia. Chronic hyper-
capnia stimulates ammonia production and increases urinary
ammonium excretion. Occasionally, pH becomes slightly alka-
line owing to excessive renal bicarbonate production and
retention. Hypocapnia appropriately increases urinary bicar-
bonate excretion and transiently reduces urinary net acid
secretion. The increased excretion of bicarbonate also results
in kaliuresis and a decline in plasma potassium concentration.
In the steady state, the plasma bicarbonate concentration falls
by about 0.5 meq/L for each 1 mm Hg decrease in PaCO2.
Classification of Acid-Base Disorders
Acid-base disorders are classified according to whether there
is a primary abnormality in plasma bicarbonate concentra-
tion, plasma PaCO2, or both. Abnormal pH owing to altered
bicarbonate concentration with PaCO2 changes in response to
the primary disorder is referred to as either metabolic acidosis
or metabolic alkalosis. When the defect in pH is due primarily
to altered PaCO2, the condition is referred to as either respira-
tory acidosis or respiratory alkalosis. A change in HCO3
– brings
about a compensatory change in PaCO2, and a primary change
in PaCO2 stimulates a compensatory adjustment in plasma
HCO3
–. The compensatory changes may take minutes
(PaCO2) or hours to days (HCO3
–) to reach a steady state.
Simple acid-base disorders occur when there is a primary
change either in the bicarbonate concentration or in the PaCO2
with an appropriate (normal) secondary change in the other
parameter (Table 2–15 and Figure 2–5). When values do not
follow these rules, a complex (mixed) acid-base disorder exists.
Mixed acid-base disorders include all possible combinations.
For example, a patient may develop metabolic acidosis and res-
piratory acidosis simultaneously. Another patient may have a
combination of respiratory alkalosis and metabolic acidosis.
Some patients who have toxicity from excessive salicylates will
develop metabolic acidosis along with respiratory alkalosis.
It is helpful in evaluating acid-base disorders to follow
some general rules. First, disorders are identified by the
direction of the pH change. That is, any patient with a low pH
(acidemia) must have at least metabolic acidosis, respiratory
acidosis, or both. If both PaCO2 and HCO3
– contribute to
either acidemia or alkalemia, then the patient must have two
(or more) problems. Third, because compensatory mecha-
nisms are never sufficient to restore the pH to normal, any
patient with a normal pH (about 7.40) and appreciably
abnormal PaCO2 and HCO3
– must have at least two primary
acid-base disturbances. For example, acidemia with a
decreased HCO3
– concentration and a reduced PaCO2 is most
often a simple metabolic acidosis with respiratory compensa-
tion. However, if the pH is very close to 7.40, then respiratory
compensation is abnormally excessive, and a second primary
disturbance, respiratory alkalosis, should be suspected.
Figure 2–5 will help in determining whether appropriate
compensation is present. Location of a patient’s position on
the diagram will suggest if a mixed acid-base problem is pres-
ent. The areas shown represent 95% confidence intervals for
single acid-base problems (labeled). If a point falls outside an
area, then it is less likely to be a single acid-base problem, and
a mixed acid-base disturbance (with two or more processes)
should be suspected. General rules for the identification and
verification of disorders are listed in Tables 2–15 and 2–16.
Current Controversies and Unresolved Issues
Most clinicians currently understand and manage acid-base
disorders in what have been termed traditional frameworks.
The two most commonly used are either the PaCO2–plasma
HCO3
– system or, recognizing that plasma HCO3
– reflects both
Table 2–15. Identification of acid-base disorders. 
I. Confirm that pH, PaCO2, and [HCO3
–] are compatible: 
Henderson-Hasselbalch equation 
Acid-based nomogram 
II. Identify the primary disturbance:  
1. Arterial pH to identify acidemia or alkalemia
2. Change in PaCO2, HCO3
−, or both to determine whether respiratory,
metabolic or both.
III. Determine whether the disorder is simple or complex:  
Acid-base nomogram  
Anion gap 
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“metabolic” and “respiratory” changes, systems that express
plasma HCO3
– changes as base excess or deficit or standard
bicarbonate. In recent years, these frameworks have been
challenged by a physical-chemical approach that reaches sim-
ilar clinical conclusions but suggests different mechanisms for
acid-base disorders. This approach, sometimes called the
strong ion difference, may have important implications for
such entities as dilutional acidosis, correction of metabolic
alkalosis, detection of subtle metabolic acidosis, and progno-
sis in the ICU. Some studies have shown that the strong ion
difference concept improves diagnosis and therapy of acid-
base disorders, but this remains unresolved.
 Figure 2–5. Acid-base nomogram showing the relationship between pH and HCO3
–. The curved lines are isopleths of
PCO2. The shaded areas represent the approximate 95% confidence limits of the normal respiratory and metabolic com-
pensations for a single primary acid-base disturbance (MetAcid = metabolic acidosis; MetAlk = metabolic alkalosis;
ARespAcid = acute respiratory acidosis; ARespAlk = acute respiratory alkalosis; CRespAcid = chronic respiratory acidosis;
CRespAlk = chronic respiratory alkalosis. Points in the center area show normal pH, PCO2, and HCO3
–. Points with an abnor-
mal pH, PCO2, or HCO3
– outside the shaded areas are more likely to be compatible with mixed acid-base disturbances.
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Table 2–16. Approximate expected response for a single acid-base disturbance.
For Each Expected Change
Acute respiratory acidosis
Increase in Paco2 by 1 mm Hg
[HCO3
–] increases by 0.1 mmol/L
Chronic respiratory acidosis [HCO3
–] increases by 0.5 mmol/L
Acute respiratory alkalosis
Decrease in Paco2 by 1 mm Hg
[HCO3
–] decreases by 0.25 mmol/L
Chronic respiratory alkalosis [HCO3
–] decreases by 0.5 mmol/L
Metabolic acidosis Decrease in [HCO3
–] by 1 mmol/L Paco2 decreases by 1.25 mm Hg
Metabolic alkalosis Increase in [HCO3
–] by 1 mmol/L Paco2 increases by 0.5 mm Hg
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 Metabolic Acidosis
ESSENT IALS  OF  D IAGNOS I S
 Decreased plasma [HCO3
–] with appropriately decreased
PaCO2 (simple metabolic acidosis), but metabolic acido-
sis may be part of a mixed acid-based disturbance.
 Evidence that low plasma [HCO3
–] is primary problem
(and not due to compensation for hypocapnia).
 May present with peripheral vasodilation, depressed
cardiac contractility in severe acidosis, fatigue, weak-
ness, stupor, and coma.
General Considerations
Metabolic acidosis results from a primary reduction in
plasma bicarbonate concentration, usually accompanied by a
compensatory decrease in PaCO2. Compared with respiratory
acid-base disorders, the degree of PaCO2 compensation in
metabolic acidosis depends only slightly on whether the con-
dition is acute or chronic. The normal compensatory
response is to maximize renal reabsorption of bicarbonate. In
a recent study, ICU patients with metabolic acidosis regard-
less of etiology had a poorer outcome than those without.
A useful classification for metabolic acidosis uses the
anion gap. The anion gap is calculated as
Anion gap = [Na+] – ([HCO3
–] + [Cl–])
The normal value for the anion gap is 12 ± 4 meq/L. The
anion gap is equal to the difference between “unmeasured”
anions and “unmeasured” cations. In normal subjects,
unmeasured anions include albumin (2 meq/L), phosphate
(2 meq/L), sulfate (1 meq/L), lactate (1–2 meq/L), and the
anions of weak acids (3–4 meq/L). The predominant unmea-
sured cations include calcium (5 meq/L), magnesium (2 meq/L),
and certain cationic immunoglobulins. Some clinicians rec-
ommend making a correction to the calculated anion gap
by correcting for plasma albumin (add to calculated anion
gap 2.8 times [4 – plasma albumin in g/dL]).
The anion gap widens most commonly because of
increased unmeasured anions, but occasionally widening is
due to decreased unmeasured cations. In metabolic acidosis,
an increased anion gap indicates that a strong acid is present
that dissociates into hydrogen ion and an “unmeasured”
anion. On the other hand, failure of the kidneys to generate
sufficient bicarbonate results in metabolic acidosis in which
chloride, a “measured” anion, is the predominant anion.
Therefore, the anion gap does not widen. This classification
divides metabolic acidosis, therefore, into those with an
increased anion gap and those without an increase in the
anion gap. The latter are often called hyperchloremic meta-
bolic acidosis.
While challenged by some investigators, an additional cal-
culation may be helpful. Because an increase in anion gap
must be due to the addition of a strong acid, the increase in
the anion gap must be equal to the fall in plasma bicarbon-
ate. Thus, adding the numerical increase in anion gap to the
measured plasma bicarbonate estimates the plasma bicar-
bonate “before” the anion gap acidosis occurred. If the sum
is below normal (22–26 meq/L), then a preexisting low
plasma bicarbonate can be assumed (ie, metabolic acidosis
or chronic respiratory alkalosis). On the other hand, if the
calculated sum is greater than 26 meq/L, then the preexisting
plasma bicarbonate can be assumed to be high (ie, chronic
respiratory acidosis or metabolic alkalosis). This estimate is
not perfect, but if the clinical situation fits, it may allow the
identification of mixed acid-base disturbances that otherwise
might be missed.
Normal Anion Gap Metabolic Acidosis
Hyperchloremic metabolic acidosis occurs from one of four
mechanisms: (1) dilution of extracellular buffer (bicarbon-
ate) by bicarbonate-free solutions, (2) addition of net
hydrochloric acid, (3) a defect in renal acidification, or (4) renal
excretion of large quantities of nonchloride anions with
reabsorption of chloride. Dilutional acidosis occurs when
patients are rapidly infused with a solution devoid of buffer-
ing compounds. For example, a large volume of normal
saline is given to resuscitate a trauma victim or patient with
hypovolemic shock. Dilutional acidosis is usually mild;
plasma bicarbonate is rarely less than 15 meq/L. In response,
the kidneys correct the situation by maximizing urine acidi-
fication and natriuresis to normalize the extracellular vol-
ume. Saline-based crystalloids are avoided by some clinicians
who favor lactated Ringer’s solution for large volume
replacement. In some trials, small differences in hemody-
namic variables and degree of acidemia have been noted.
Administration of dilute hydrochloric acid for treatment
of severe metabolic alkalosis is rarely needed, but excess
hydrochloric acid will result in hyperchloremic metabolic
acidosis. More commonly, bicarbonate is lost as a result of
gastrointestinal losses from diarrhea or fluids from fistulas.
Regeneration of bicarbonate in the lower gastrointestinal
tract accounts for net addition of hydrogen ion to blood with-
out adding an unmeasured anion. When loss of bicarbonate is
severe, extracellular volume depletion, electrolyte imbalances,
and stimulation of aldosterone and renin ensues. In response
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to such conditions, net renal acid excretion increases, with a
tendency for urine pH to rise because of ammonium pro-
duction.
Failure of normal urinary acidification increases bicarbon-
ate losses. This condition, called renal tubular acidosis, leads to
metabolic acidosis because the kidneys are unable to compen-
sate for normal acid production or fail to reabsorb normal
amounts of filtered bicarbonate. At least four subtypes of renal
tubular acidosis exist, differentiated on the basis of the primary
tubular abnormality. These differ in the site of abnormality
(proximal or distal tubule), mechanism, and ease of correction
with alkali therapy. In the absence of renal failure, these are rel-
atively rare disorders, except for type 4 renal tubular acidosis.
This disorder, commonly seen in diabetics, is caused by defi-
ciency of aldosterone and is identified by mild metabolic acido-
sis in association with hyperkalemia. Treatment is not always
needed and involves replacement of mineralocorticoid func-
tion with fludrocortisone. Hyperchloremic metabolic acidosis
can be caused by acetazolamide, a carbonic anhydrase inhibitor
and diuretic. Acetazolamide inhibits proximal tubular bicar-
bonate reabsorption; the result is metabolic acidosis with inap-
propriate loss of renal tubular bicarbonate, a drug-induced
renal tubular acidosis.
Patients with diabetic ketoacidosis (DKA) almost always
will present with an anion gap metabolic acidosis. Because,
however, the anions of the keto acids β-hydroxybutyrate
and acetoacetate are readily excreted in the urine, the
anion gap may not persist in patients who are able to maintain
adequate glomerular filtration. Thus a small fraction of those
with DKA will present with an anion gap increase that is
smaller than the decrease in plasma bicarbonate. That is,
there is both anion gap and non–anion gap metabolic aci-
doses. While unusual at the start of DKA, this feature is seen
in as many as 80% of patients during treatment. The mecha-
nism is the urinary loss of anions of the keto acids while
bicarbonate regeneration is too slow to correct for the earlier
loss of bicarbonate. Several days are sometimes required for
the bicarbonate to return to normal.
Anion Gap Metabolic Acidosis
The major causes of metabolic acidosis with elevated anion
gap are listed in Table 2–17. Except for uremia, they all occur
acutely and are due to overproduction or administration of a
strong acid that dissociates into a hydrogen ion and an
“unmeasured” anion. Unlike renal tubular acidosis, renal
mechanisms for acid handling are intact but are unable to
keep pace with the extent of acid production.
A. Lactic Acidosis—Lactic acidosis occurs in a number of
situations in critically ill patients, including shock, diabetes,
renal failure, liver disease, sepsis, drug intoxication, severe
volume depletion, and hereditary metabolic abnormali-
ties. Transient lactic acidosis is a feature of grand mal
seizures. Patients with liver disease have difficulty remov-
ing lactate. An uncommon complication of nonnucleoside
reverse transcriptase inhibitors is lactic acidosis with hepatic
Table 2–17. Common metabolic acidoses with increased anion gap.
Type Mechanism Unmeasured Anion Treatment Apporach
Lactic acidosis Decreased perfusion (shock)
Drugs
Seizures
Exercise
Lactate Treat underlying disorder
Diabetic ketoacidosis Diabetes (type 1 or type 2),
insufficient insulin
β-Hydroxybutyrate,
acetoacetate
Insulin, fluid replacement
Alcoholic ketoacidosis Acute ethanol ingestion Fluid replacement, glucose
Salicylate Ingestion Salicylate, lactate Alkaline diuresis, hemodialysis
Ethylene glycol Ingestion Glycolate Hemodialysis, alcohol dehydrogenase
inhibitors, ethanol
Methanol Ingestion Formate Hemodialysis, alcohol dehydrogenase
inhibitors, ethanol
Uremia Renal failure Inorganic acid anions (sulfate,
phosphate)
NaHCO3, dialysis
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steatosis. A proposed mechanism is inhibition of mitochon-
drial DNA synthesis with impaired oxidative phosphoryla-
tion and resulting lactic acidosis. Metformin is reported to be
a rare cause of lactic acidosis. Identification and correction of
the underlying process are essential to the management of this
disorder. Specific therapy for this and other causes of meta-
bolic acidosis will be discussed subsequently.
B. Ketoacidosis—Ketoacidosis is most commonly due to
poorly controlled diabetes mellitus, occasionally in those
with heavy ethanol consumption in the absence of food
intake (alcoholic ketoacidosis), and during starvation. In all
cases, keto acids (β-hydroxybutyrate and acetoacetate)
derived from oxidation of fatty acids in the liver accumulate.
In alcoholic ketoacidosis, β-hydroxybutyrate and lactate lev-
els rise more than acetoacetate, and blood glucose concentra-
tions are usually only minimally elevated. Starvation
produces mild ketoacidosis accompanied by mild renal wast-
ing of sodium, chloride, potassium, calcium, phosphate, and
magnesium. In all three conditions, unmeasured anions ele-
vate the anion gap.
C. Uremia—In chronic renal insufficiency, hyperchloremic
metabolic acidosis may occur initially owing to impaired
ammonia generation and decreased ammonium excretion.
When the GFR falls below 20 mL/min, excretion of fixed
acids is impaired, adding an anion gap acidosis. Usually a
mixed anion gap/non–anion gap metabolic acidosis is seen
in chronic renal failure.
D. Poisons—Ingestion of ethylene glycol (radiator antifreeze),
methanol, and excessive salicylic acid may give rise to anion
gap metabolic acidosis. Ethylene glycol is oxidized by alco-
hol dehydrogenase to glycolic acid, which is the major acid
found in the blood. Further oxidation produces oxalic
acid, with resulting sodium oxalate crystals precipitating in
the urine. Lactic acid may be present if circulatory shock
develops. Methanol is oxidized to formaldehyde and formic
acid. Although salicylate is itself a weak acid, it probably pro-
duces its major effect by inducing simultaneous lactic acido-
sis. Isopropyl alcohol ingestion is sometimes thought to
cause an anion gap metabolic acidosis, but oxidation of
this alcohol produces acetone and no strong acid. The man-
agement of poisoning is discussed in greater detail in
Chapter 36.
Clinical Features
A. Symptoms and Signs—The physical findings associated
with mild acidemia are nonspecific and may reflect the
underlying disease or associated conditions. As acidosis
worsens, increased respiratory rate and tidal volume
(Kussmaul respiration) provide partial respiratory compen-
sation. Peripheral vasodilation occurs and produces palpable
cutaneous warmth. Paradoxical venoconstriction increases
central pooling and may result in pulmonary edema. Cardiac
contractility may decrease below a pH of 7.10 and may result
in reduced blood pressure or shock. CNS depression produces
fatigue, weakness, lethargy, and ultimately stupor and coma,
but CNS disturbances are much more common with respira-
tory acidosis at similar pH.
Metabolic acidosis is associated with poorer prognosis in
the ICU possibly because it is now recognized that low pH
induces release of nitric oxide and inflammatory mediators
regardless of the cause of acidemia.
B. Laboratory Findings—The anion gap calculation sepa-
rates those with anion gap metabolic acidosis from those
with non–anion gap acidosis, so plasma sodium, chloride,
and bicarbonate must be measured. Because pH determines
the severity of metabolic acidosis and not plasma bicarbon-
ate, an arterial blood gas determination is essential.
In patients with an increased anion gap, the unmeasured
anion sometimes can be identified. Serum lactate levels are
elevated (>2–3 meq/L) when lactic acidosis is the cause of a
high anion gap acidosis. DKA is often accompanied by
hypokalemia, hypomagnesemia, and hypophosphatemia,
along with hyperglycemia. The ratio of keto acids present
depends on the intracellular redox potential (NADH:NAD
ratio). Because the commonly used nitroprusside reaction
measures only the acetoacetate, tests for ketones may be nega-
tive if the β-hydroxybutyrate:acetoacetate ratio is very high.
Alcoholic ketoacidosis presents with similar laboratory find-
ings to DKA, except that glucose is only minimally elevated.
Because β-hydroxybutyrate is the predominant keto acid, test-
ing for ketones may be negative. With starvation, decreased
serum concentrations of sodium, chloride, potassium, cal-
cium, phosphate, and magnesium may be present. Ingestion of
ethylene glycol or methanol causes an increased osmolal gap
that persists until the toxic alcohol is metabolized.
Laboratory tests in a patient with hyperchloremic
non–anion gap acidosis may help to distinguish renal causes
from a nonrenal cause such as diarrhea. Calculation of the
urine anion gap ([Na+] + [K+] – [Cl–]) may be helpful. The
normal urine anion gap is negative because of the presence
of ammonium, an unmeasured cation. The urine anion gap
becomes more negative as the ammonium concentration
increases, which is seen in hyperchloremic metabolic acido-
sis caused by diarrhea or some other extrarenal mechanism.
On the other hand, the urine anion gap becomes positive
when ammonium excretion fails to increase or if there is
bicarbonaturia indicative of renal tubular acidosis. Findings
associated with ingestions are specific to the toxin and are
discussed in Chapter 36. The specific anion is usually not
measured when, for example, one of the commonly ingested
toxic alcohols is present. Of note, isopropyl alcohol ingestion
is associated with ketonemia but does not cause metabolic
acidosis. When uremia is the cause, increases in serum potas-
sium, serum urea nitrogen, and serum creatinine are typi-
cally observed.
Differential Diagnosis
The history and careful questioning regarding drug intake
and use are essential in determining the cause of the acidosis.
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When ingestion is suspected, microscopic examination of the
urine looking for oxalate crystals may aid in the diagnosis of
ethylene glycol ingestion. Similarly, visual impairment, nau-
sea and vomiting, and disordered CNS functioning are char-
acteristic of methanol ingestion. A history of insulin
requirement and use—along with the blood glucose con-
centration—aids in the diagnosis of DKA. Differentiation
between hyperchloremic acidosis and renal tubular acidosis
is aided by calculation of the urine anion gap and the pres-
ence or absence of diarrhea.
Treatment
A. Assessment of the Need for Therapy—Whenever
metabolic acidosis is present, a diligent search should be
made for its underlying cause. Therapy directed toward
treatment of the primary disorder is instituted. Correction of
fluid and electrolyte disturbances is key in patients with DKA
or with lactic acidosis owing to hypovolemic, septic, or car-
diogenic shock and in patients with various toxic ingestions.
There are few data supporting improved patient outcome
with treatment directed specifically at the metabolic acidosis
in patients with anion gap acidosis, including DKA and lactic
acidosis. However, there are few or no randomized trials in
patients with severe acidemia. Thus, when acidemia is acute
and the pH falls below 7.00, directed therapy should be
considered. For pH values between 7.00 and 7.20, the need to
treat should be individualized based on such considerations as
the patient’s level of stability and the presumed cause of the
disturbance. There is experimental evidence that bicarbonate
therapy of acute lactic acidosis may promote further lactate
production and actually worsen the situation. Furthermore,
bicarbonate buffering yields considerable carbon dioxide that
produces severe local respiratory acidosis. However, because
severe acidosis acts as a myocardial and circulatory depressant,
treatment should be considered if there is evidence of circula-
tory impairment and other factors have been addressed.
When acidosis is chronic, as with uremia or the renal
tubular acidosis syndromes, the need for treatment should be
based on the patient’s overall status and the presence of signs
and symptoms related to the acidosis, as well as the absolute
arterial pH itself.
B. Treatment—If treatment is indicated for severe metabolic
acidosis, intravenous sodium bicarbonate is the preferred
agent. It is most commonly supplied in 50-mL ampules con-
taining 44.6 meq of HCO3
–. The amount of bicarbonate
required is based on the degree of acidemia. Because the
administered base will partition equally between intracellular
and extracellular spaces, dosing is based on total body water
(approximately one-half the total body weight) and the extent
of the acidemia. Typically, one-half the bicarbonate required
to completely correct the deficit is administered acutely, with
the rest given by slow intravenous infusion over the ensuing
8–12 hours. For example, if a 70-kg patient has a bicarbonate
concentration of 14 meq/L, the amount of bicarbonate
administered acutely can be calculated as follows:
[HCO3
–] deficit = normal concentration – present
concentration = (24 – 14) = 10 meq/L 
Distribution volume = total body water × 0.5
= 70 × 0.5 = 35 L
Dose = deficit × distribution × 0.5 (to correct half
the deficit) = 10 × 35 × 0.5 = 175 meq
Some laboratories calculate base deficit from blood gas
values. The base deficit is an approximation of base (or bicar-
bonate) depletion secondary to metabolic causes. The base
deficit usually is reported as a positive number. It is negative
when a base excess is present. The base deficit can be used to
calculate the amount of bicarbonate required according to
the following equation:
[HCO3
–] required = base deficit × 0.4
× body weight (kg)
The amount of sodium bicarbonate required to completely
correct the deficit is then halved to arrive at an appropriate
dose.
Because of the considerable intracellular buffering of
hydrogen ion in severe acidosis, the bicarbonate volume of
distribution can be underestimated. Thus the improvement
in pH may be less than expected. However, because of the
risks of excessive bicarbonate therapy and the greatest
benefit seen in correcting severe acidosis, the goal is to
correct pH to more than 7.20 and often to much less than
that (see below).
Bicarbonate must be administered with extreme care in
patients with potentially compromised respiratory status
because the combination of HCO3
– with excess H+ will yield
H2O and CO2. Acute respiratory acidosis may occur. On the
other hand, if the metabolic acidosis is chronic or well com-
pensated by respiratory mechanisms, rebound alkalosis can
follow bicarbonate administration. Because bicarbonate is
administered as the sodium salt and given in high concentra-
tion, both volume overloading and hyperosmolality can result.
Current Controversies and Unresolved Issues
No issue in critical care medicine remains more controversial
and less resolved than the administration of bicarbonate in
acute metabolic acidosis. Animal studies support both a ben-
efit of bicarbonate in severe acidosis and numerous compli-
cations of such therapy. Human studies are limited because,
although inconclusive, they have not randomized patients
with severe acidosis. It is very likely that the outcome of
patients with metabolic acidosis is more closely linked to the
underlying disease than to the severity of acidemia. In the
words of some investigators, there is no evidence that bicar-
bonate therapy improves the outcome for any patient with an
acute anion gap metabolic acidosis (DKA or lactic acidosis).
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A small increase in pH in patients with severe metabolic
acidosis can be associated with significant improvement in
the function of physiologic systems. Because a patient with a
very low serum bicarbonate (2–4 meq/L) will have a substan-
tial increase in pH when the bicarbonate reaches 6–8 meq/L,
one approach is to treat only those who have very severe meta-
bolic acidosis and administer only a relatively small amount of
sodium bicarbonate. In theory, this patient will have the great-
est potential benefit, less generation of carbon dioxide, and
minimal risks of volume overload and hyperosmolality.
Another approach has been to use non-CO2-generating
buffering agents. A mixture of carbonate and bicarbonate
has been given experimentally. This product, called carbicarb,
generates a smaller amount of CO2 for the degree of buffer-
ing, but clinical experience is limited. There are studies using
tris(hydroxymethyl)aminomethane (THAM) as a buffering
agent. This compound, which also does not produce CO2
during use, may be a useful alkalizing agent if further studies
demonstrate its value.
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 Metabolic Alkalosis
ESSENT IALS  OF  D IAGNOS I S
 Alkalemia with increased plasma [HCO3
–].
 Lethargy and confusion progressing to seizures in
severe cases.
 Ventricular and supraventricular arrhythmias.
 Impaired oxygen delivery because of increased hemo-
globin affinity for oxygen. 
General Considerations
Metabolic alkalosis consists of the triad of increased [HCO3
–],
increased pH, and decreased plasma chloride concentration.
The principal mechanisms leading to metabolic alkalosis
include (1) addition of bicarbonate to the plasma, (2) loss of
hydrogen ion, (3) volume depletion, (4) chronic use of
chloruretic diuretics, and (5) potassium depletion.
Pathophysiology
A. Addition of Bicarbonate—Addition of bicarbonate is
an unusual cause of metabolic alkalosis but may occur
with prolonged administration of high amounts of alkali
(milk-alkali syndrome) or after therapy with solutions
that contain bicarbonate, carbonate, acetate, lactate, or
citrate. In normal adults, up to 20 meq/kg per day of
bicarbonate may be administered without significantly
altering plasma pH.
When calcium and vitamin D intakes are high, as in the
milk-alkali syndrome, nephrocalcinosis causes renal insuffi-
ciency and diminishes GFR. This reduced renal capacity
permits the retention of bicarbonate and increases pH. High
concentrations of acetate in hyperalimentation fluids may
be an unsuspected cause in critically ill patients. When the
GFR is normal, elevated plasma bicarbonate results in the
presentation of increased bicarbonate to the proximal
tubules, which reduces bicarbonate reabsorption and causes
bicarbonaturia.
B. Vomiting—Prolonged emesis and nasogastric suction are
the most common causes of loss of hydrogen ion leading of
metabolic alkalosis in critically ill patients. Parietal cells pro-
duce hydrochloric acid from carbonic acid, and for each pro-
ton secreted into the gastric lumen, one molecule of
bicarbonate is returned to the blood. Reduction in intravas-
cular volume stimulates renal sodium reabsorption with loss
of potassium. Avid sodium reabsorption is accompanied by
chloride reabsorption, and when chloride is depleted, bicar-
bonate is reabsorbed. This counterproductive response
results in a paradoxical aciduria when urine should be max-
imally alkaline in response to metabolic alkalosis.
C. Volume Depletion—Volume depletion accompanies
many types of chronic metabolic alkalosis. Volume depletion
may generate and certainly maintains metabolic alkalosis. In
response to volume depletion, renin and aldosterone pro-
duction are increased, and these stimulate renal tubular
sodium reabsorption and potassium secretion. Furthermore,
because hydrogen ion secretion by the α-intercalated cells of
the collecting tubules is sensitive to the concentration of
aldosterone, hyperreninemia also increases bicarbonate reab-
sorption in the distal tubules.
Thiazide and loop diuretics are important causes of vol-
ume depletion and metabolic alkalosis, but there are impor-
tant additional factors with these drugs. Sodium delivery to
the distal tubule is increased, stimulating increased hydrogen
and potassium secretion. As extracellular volume falls, renin
secretion further enhances renal hydrogen and potassium
losses. Hypokalemia stimulates ammoniagenesis and
increases ammonium excretion with further loss of hydrogen
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ion. Thus additional bicarbonate is generated, and metabolic
alkalosis is created and sustained by the combined effects of
increased distal tubular sodium delivery, elevated aldos-
terone levels, and hypokalemia. Administration of saline and
potassium increases GFR and repairs the hypokalemia, per-
mitting excretion of the accumulated bicarbonate.
There has been ongoing debate about the specific role of
chloride ion compared with volume repletion alone. Earlier
experiments seemed to demonstrate that replacement of
volume deficit with non-chloride-containing solutions led
to prompt bicarbonaturia and resolution of the metabolic
alkalosis. However, more recently, administration of
chloride-containing solutions corrected the alkalosis (bicar-
bonaturia) despite insufficient volume replacement, sug-
gesting a key role for chloride. This is why some patients
with metabolic alkalosis who have volume depletion and
hypokalemia are variably termed volume-responsive or
chloride-responsive.
D. Potassium Depletion—Potassium depletion results in
a shift of hydrogen ions into the cells, raising pH. However,
potassium depletion increases renal ammonia generation
and reduces potassium secretion in the distal nephron,
stimulating bicarbonate generation and reabsorption. A
combination of potassium depletion and mineralocorti-
coid excess is associated with marked refractory metabolic
alkalosis.
E. Other Causes—Some nonreabsorbable anions (eg, peni-
cillin and carbenicillin anion) promote tubular secretion of
hydrogen and potassium by increasing luminal electronega-
tivity. The metabolic alkalosis produced can be repaired
readily by administering NaCl and potassium. A related
cause is seen in the ICU and follows carbohydrate refeeding
after starvation ketoacidosis. During the period of starva-
tion, renal production of bicarbonate in response to the
acidemia helps to maintain pH. However, when refeeding is
instituted, ketones are converted into bicarbonate, thereby
producing metabolic alkalosis. Coexisting potassium and
volume depletion will maintain the alkalosis unless sodium
chloride and potassium are provided.
Other common causes of metabolic alkalosis, categorized
by physiology and response to NaCl or KCl infusion, are
listed in Table 2–18. On rare occasions, a patient requiring
critical care will present with hypervolemia, mild to moder-
ate hypertension, hypokalemia, metabolic alkalosis, and pri-
mary hypersecretion of aldosterone. A similar situation may
be seen with administration of mineralocorticoids or corti-
costeroids with mineralocorticoid activity. These metabolic
alkalosis states are associated with hypervolemia, so they are
not volume- or chloride-responsive. Rarely, adult patients
with Gitelman’s syndrome will be seen in the ICU. The defect
is located in the thiazide-sensitive NaCl cotransporter in the
distal tubule, resulting in a thiazide diuretic–like syndrome
of hypokalemia, metabolic alkalosis, hypocalciuria, and
hypomagnesemia.
Clinical Features
A. Symptoms and Signs—Symptoms and physical findings
with mild metabolic alkalosis are nonspecific and usually are
related more closely to the underlying disorder than to the
acid-base disturbance itself. Review of the patient’s medical
record with particular attention to medications received
and fluid balance will often aid in determining the origin of
alkalemia. On physical examination, a difference between
supine and sitting blood pressures may reveal hypovolemia.
Hypertension suggests hypervolemia. When both hyperten-
sion and metabolic alkalosis are present, a history of gluco-
corticoid or mineralocorticoid use or endogenous aldosterone
production should be considered.
A decrease in minute ventilation is usually noted in mod-
erate cases of metabolic alkalosis. If preexisting pulmonary
disease is present, CO2 retention may result in severe hyper-
capnia. As alkalemia progresses, the ionized calcium concen-
tration decreases and produces neuromuscular findings
similar to those of hypocalcemia. Initial lethargy and confu-
sion give way to obtundation and seizures as the alkalemia
worsens. Patients may complain of paresthesias and muscle
cramps. The Chvostek and Trousseau signs may be present.
In severe cases, respiratory muscle paralysis may develop.
Alkalemia acts as a negative inotrope, with the change in
blood pressure depending on the degree of hypo- or hyperv-
olemia. Furthermore, the increase in pH lowers the arrhyth-
mia threshold, with supraventricular and ventricular
arrhythmias predominating. There are no electrocardio-
graphic abnormalities specific for alkalemia, although the
presence of arrhythmias should alert the clinician to the
potential severity of the acid-base disturbance.
B. Laboratory Findings—An increase in plasma [HCO3
–]
may be present with either chronic respiratory acidosis or
Table 2–18. Causes of metabolic alkalosis. 
I. Exogenous bicarbonate administration:
Bicarbonate, citrate, acetate, lactate
Milk-alkali syndrome
II. Volume contraction + potassium depletion (saline-responsive)  
Gastrointestinal loss (emesis, gastric suction, villous adenoma)
Renal loss (loop and thiazide diuretics)  
Posthypercapnic states
Nonreabsorbable anions (ketones, penicillin, carbenicillin) 
After treatment for lactic acidosis or ketoacidosis 
Carbohydrate refeeding after starvation
Hypokalemia, hypomagnesemia 
III. Volume expansion + potassium deficiency (not saline-responsive)
High renin (malignant hypertension, renin-secreting tumor)
Low renin (primary hyperaldosteronism, adrenal enzymatic defects, 
Cushing’s disease) 
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metabolic alkalosis. The arterial pH is essential to make the
distinction. Comparison of the PaCO2 with the nomogram in
Figure 2–5 will aid in determining whether any respiratory
compensation is appropriate or whether a mixed acid-base
disorder is present.
Once it has been determined that simple metabolic alka-
losis is present, further evaluation will determine the cause of
the disorder. Plasma potassium is almost always decreased.
The magnitude of total body potassium depletion cannot be
estimated precisely from the plasma potassium. Hyponatremia
is common in hypovolemic disorders, which are ultimately
responsive to saline infusion.
A useful distinction can be made by separating meta-
bolic alkaloses into those that are chloride-sensitive (some-
times called volume- or saline-responsive) and those that are
non-chloride-sensitive. Chloride- or volume-sensitive
patients are volume-depleted, hypokalemic, and will
respond to chloride or volume administration (see above).
The latter group is usually volume overloaded and will
worsen or fail to improve with chloride-containing solu-
tions or volume repletion.
These groups can be distinguished by measurement of
urine chloride. Volume contraction usually is accompanied
by concentrated urine with a low sodium concentration.
However, if metabolic alkalosis develops, high renal tubular
bicarbonate concentrations may encourage sodium to be
spilled into the urine. Thus there is a paradoxically high urine
sodium and fractional excretion of sodium despite volume
depletion. However, urine chloride can be relied on in this sit-
uation. A low urine [Cl–] (<10 meq/L) indicates potential
volume-responsive or chloride-responsive metabolic alkalosis.
On the other hand, diuretics will confuse this picture
because both urine sodium and urine chloride will be
increased despite the hypovolemia. Hypomagnesemia from
gastrointestinal and renal losses is observed occasionally in
this situation.
When primary hyperaldosteronism is the cause of meta-
bolic alkalosis, urinary sodium and chloride outputs are
approximately equal to intake and in the range of 100–200
meq/L. Volume expansion and hypertension are usually
present.
Differential Diagnosis
Once a high plasma bicarbonate is identified, the most
important distinction must be made between metabolic
alkalosis and chronic respiratory acidosis with renal com-
pensation. Diuretic therapy may superimpose additional
metabolic alkalosis on top of chronic respiratory acidosis,
which further increases the [HCO3
–] and actually may
result in an alkaline pH. Noting increased concentrations
of sodium and chloride in the urine prior to discontinua-
tion of diuretic therapy is a useful tool. When simple meta-
bolic alkalosis is present, the distinction between
chloride-responsive and chloride-unresponsive disorders
should be made.
Treatment
It has become clear that alkalemia in critically ill patients is
associated with poor outcome, just as acidemia is linked to
decreased survival. The underlying disease in all situations
must be addressed to slow or reverse the cause of metabolic
alkalosis. The decision to treat is based on both the severity
of alkalemia and the risks of complications.
A. Saline-Responsive Metabolic Alkalosis—Mild alka-
lemia (pH 7.40–7.50) is well tolerated and does not require
treatment unless preexisting cardiac or pulmonary disease
complicates the situation. If the alkalemia worsens (pH >7.60),
or if findings consistent with cardiac, pulmonary, or neuro-
muscular complications appear, treatment is indicated.
The key to therapy is restoration of normal circulating
blood volume and repair of the associated hypokalemia.
Potassium replacement can be estimated from the extent of the
potassium deficit. The volume of normal saline required
should be infused so that one-half the deficit is replaced within
8 hours and the remainder within the ensuing 16 hours. As dis-
cussed earlier, there is evidence that chloride-containing solu-
tions stimulate a more marked bicarbonaturia, leading to more
rapid correction of the alkalosis. Therefore, volume repletion
preferentially should be with NaCl and KCl solutions.
In unusual situations, acetazolamide, an inhibitor of car-
bonic anhydrase, can be used to correct metabolic alkalosis
as long as the patient is not volume-depleted. This situation
is encountered rarely, and the drug will exacerbate both vol-
ume depletion and hypokalemia. Acetazolamide, 250–500 mg,
can be given orally and repeated if necessary with close mon-
itoring of plasma potassium. Very rarely, if alkalemia is
extremely severe, dilute hydrochloric acid (0.1 mol/L) can be
infused into a central vein. The quantity required can be cal-
culated from the plasma bicarbonate concentration.
Assuming that the volume of distribution of bicarbonate is
that of total body water (one-half body weight), the amount
of HCl required is calculated as follows:
HCl required (meq) = ([HCO3
–] – 24) × 0.5
× weight (kg)
One-half the calculated dose should be given over the first 4–8
hours, with the remainder infused over the next day.
Hyperkalemia is a major potential complication of this therapy.
Several other acidifying agents have been used, including
ammonium chloride, arginine monohydrochloride, and lysine
monohydrochloride. The latter two should not be given because
of the very high risk of hyperkalemia, sometimes fatal, associ-
ated with large and rapid shifts of potassium out of the cells.
B. Saline-Resistant Metabolic Alkalosis—These disorders
are encountered rarely and may result from reversible (drug-
induced) causes or abnormal endogenous secretion of aldos-
terone. In both cases, mineralocorticoids lead to sodium
retention and potassium excretion despite elevated extracel-
lular volume and hypokalemia.
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Therapy of these disorders should be aimed at identifying
the source of the aldosterone or other mineralocorticoid.
When the condition follows excessive administration of min-
eralocorticoids, their use should be stopped. If the patient
has excessive aldosterone secretion from an adrenal ade-
noma, medical management with an inhibitor of aldosterone
(eg, spironolactone) may play a role until more definitive
therapy can be planned.
Galla JH: Metabolic alkalosis. J Am Soc Nephrol 2000;11:369–75.
[PMID: 10665945]
Khanna A, Kurtzman NA: Metabolic alkalosis. J Nephrol 2006;19:
S86–96. [PMID: 16736446]
 Respiratory Acidosis
ESSENT IALS  OF  D IAGNOS I S
 Acidemia with increased PaCO2 and near-normal (acute)
or appropriately elevated [HCO3
–] (chronic).
 Fatigue, weakness, confusion, and headaches.
 If severe, lethargy, stupor, and coma.
 Decreased cardiac contractility, pulmonary artery hyper-
tension, and splanchnic vasodilation.
General Considerations
Elevated PaCO2 (hypercapnia) with resulting acidemia is
termed respiratory acidosis. After going into solution, dis-
solved CO2 turns into hydrogen ion and bicarbonate. The
major problem in acute hypercapnia is that dissolved CO2
can rapidly produce tissue acidosis because CO2 diffuses eas-
ily into tissues and cells. This is particularly important at the
blood-brain barrier, such that the pH of CSF falls rapidly
after an acute increase in PaCO2.
Hypercapnia is usually attributed to lung disease, such as
COPD. However, hypercapnia can be produced either by an
increase in the production of CO2 without compensatory
elimination or by constant production with decreased elimi-
nation. The second mechanism is usually seen in patients with
COPD or restrictive pulmonary disease, in those with a
severely deformed chest wall or neuromuscular weakness, after
trauma, and following anesthesia, where either the respiratory
mechanics or the drive for CO2 elimination are compromised.
Increased CO2 production is not uncommon because
CO2 output follows metabolic rate, and patients in the ICU
are frequently hypermetabolic. What is unusual, however, is
failure of the ventilatory control mechanisms to respond to
the increase in CO2 production by stimulating ventilation
and maintaining PaCO2 at a constant value.
Common causes of respiratory acidosis among criti-
cally ill patients are listed in Table 2–19, and there is
additional discussion of hypercapnic respiratory failure in
Chapter 12.
An acute change in PaCO2 produces a blood pH change
within minutes. There is a small rise in plasma bicarbonate
concentration owing to acute “mass action” shifts. The pre-
dicted response of [HCO3
–] is an increase of approximately
0.25 meq/L for each 1 mm Hg increase in PaCO2. More
marked changes in plasma bicarbonate concentration sug-
gest that a mixed acid-base disturbance is present.
Hypercapnia stimulates renal ammonia production and
increases urinary ammonium excretion because of an increase
in local PaCO2 and because of the fall in pH. Urine pH decreases
appropriately as newly generated bicarbonate is added to the
blood in exchange for acidifying the urine. An increase in bicar-
bonate absorptive capacity also occurs so that increased quanti-
ties of filtered bicarbonate can be reabsorbed completely. Once
equilibrium has been reached after several days, the plasma
bicarbonate concentration should increase by about 0.5 meq/L
for each 1 mm Hg increase in PaCO2. Arterial pH actually may
become slightly alkalemic because of the avid retention of bicar-
bonate; this is one situation in which “complete”correction may
occur and may not represent a mixed acid-base disturbance.
Clinical Features
A. Symptoms and Signs—There are no symptoms or signs
specific to mild respiratory acidosis. Findings are usually
Acute Chronic 
Airway obstruction 
Emesis with aspiration 
Bronchospasm 
Laryngospasm 
Airway obstruction 
Chronic obstructive pulmonary
disease 
Respiratory center depression 
General anesthesia 
Sedative or narcotic over-dose 
Head injury 
Respiratory center depression 
Chronic sedative overdose 
Obesity (Picwickian syndrome)
Brain tumor 
Circulatory collapse 
Cardiac arrest 
Pulmonary edema
Neurogenic causes 
Cervical spine injury 
Guillain-Barré syndrome 
Myasthenic crisis
Drugs (paralytic agents, 
organophosphates) 
Neurogenic causes 
Multiple sclerosis 
Muscular dystrophy 
Amyotrophic lateral sclerosis
Myxedema
Posttraumatic diaphragmatic
paralysis
Phrenic nerve injury 
Restrictive defects 
Hemothorax or pneumothorax
Flail chest
ARDS
Restrictive defects 
Hydrothorax or fibrothorax 
Ascites 
Obesity 
Table 2–19. Causes of respiratory acidosis. 
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related to the underlying cause, such as COPD, obesity-
hypoventilation syndrome, CNS disease, or severe hypothy-
roidism. When airway obstruction is the cause, patients may
present with shortness of breath and labored breathing. If
respiratory center depression is the cause, slow and shallow
or even apneustic breathing may be noted. As discussed in
Chapter 12, patients may have tachypnea or hyperpnea
(increased minute ventilation) despite hypercapnia (alveolar
hypoventilation).
In cases of marked respiratory acidosis, fatigue, weakness,
and confusion are present. In milder cases, patients may
complain of headache. Physical findings are nonspecific and
include tremor, asterixis, weakness, incoordination, cranial
nerve signs, papilledema, retinal hemorrhages, and pyram-
idal tract findings. The syndrome of pseudotumor cerebri
(increased CSF pressure and papilledema) may be simu-
lated by respiratory acidosis. Coma begins at levels of CO2
that vary from 70–100 mm Hg depending on arterial pH
(pH <7.25) and the rate of increase of PaCO2. It is critical to
remember that almost all patients with hypercapnia will have
concomitant hypoxemia unless they are receiving supple-
mental oxygen.
B. Laboratory Findings—Respiratory acidosis is manifested
by acidemia and elevated PaCO2 in the presence of an appro-
priate [HCO3
–] (see Figure 2–5). Because renal ammonia
production and hydrogen ion secretion are stimulated, urine
pH falls. In chronic respiratory acidosis, plasma pH may be
very close to normal as bicarbonate concentration rises in
compensation. A mild increase in potassium secretion
occurs, although hypokalemia is not inevitable.
Treatment 
The key to management of respiratory acidosis is correction
of its primary cause (see Chapter 12). For some patients, this
will require endotracheal intubation and mechanical ventila-
tion or noninvasive positive-pressure ventilation.
Restoration of pH and PaCO2 should take place over sev-
eral hours if the respiratory acidosis is chronic to prevent
alkalemia. The compensatory increase in plasma bicarbonate
in response to hypercapnia may take hours to days to be
eliminated if the PaCO2 is immediately corrected to normal.
This results in a form of “metabolic alkalosis” that requires
renal elimination of bicarbonate to a normal value. In many
patients, overcorrection of chronic hypercapnia to normal is
not advised because these patients have poor lung or ventila-
tory function. When mechanical ventilation is removed, they
will be unable to maintain sufficient ventilation to keep the
PaCO2 at the lower level, resulting in recurrence of severe
acute respiratory acidosis.
In general, there is no role for respiratory stimulant drugs
except in a few circumstances. Administration of antagonists
to opiates or benzodiazepines may be helpful if respiratory
depression from these agents is suspected.
Current Controversies and Unresolved Issues
Acute hypercapnia and respiratory acidosis almost always
can be reversed effectively by increasing minute ventilation
until the underlying disorder can be treated (eg, COPD, neu-
romuscular weakness, etc.). It is now recognized that exces-
sively high tidal volume may be associated with damage to
the lungs, prolonged hospitalization, and increased mortal-
ity. Therefore, low tidal volume strategies are recommended
(see Chapter 12). The consequence is mild to moderate
hypercapnia in some of these patients. The bulk of the evi-
dence from large studies suggests that such hypercapnia is
well tolerated and rarely associated with complications. In
fact, some studies have suggested that hypercapnia is not
merely a consequence that must be tolerated but that it actu-
ally may be instrumental in improving outcomes of patients
with acute lung injury (eg, ARDS). For example, in ARDS, a
tidal volume of 6 mL/kg was associated with lower mortality
than 12 mL/kg. However, in the patients randomized to
12 mL/kg, the odds ratio for mortality was 0.14 in those who
were hypercapnic compared with those with a normal PaCO2.
While there have been limited studies of the effects of
ameliorating the fall in pH during so-called permissive
hypercapnia, it remains to be seen if preventing the fall in pH
with bicarbonate or other buffers is beneficial, hazardous, or
neither. Nonbicarbonate buffers may be preferred to avoid
generation of additional CO2.
Kallet RH, Liu K, Tang J: Management of acidosis during lung-
protective ventilation in acute respiratory distress syndrome.
Respir Care Clin North Am 2003;9:437–56. [PMID: 14984065]
Kregenow DA et al: Hypercapnic acidosis and mortality in acute
lung injury. Crit Care Med 2006;34:1–7. [PMID: 16374149]
Laffey JG, Engelberts D, Kavanagh BP: Buffering hypercapnic aci-
dosis worsens acute lung injury. Am J Respir Crit Care Med
2000;161:141–6. [PMID: 10619811]
 Respiratory Alkalosis
ESSENT IALS  OF  D IAGNOS I S
 Alkalemia with decreased PaCO2 and normal or appro-
priately decreased [HCO3
–].
 Anxiety, irritability, vertigo, and syncope.
 Flattened ST segments or T waves.
 Tetany in severe cases.
General Considerations
A primary decrease in arterial PCO2 (hypocapnia) indicates
respiratory alkalosis. By definition, alveolar hyperventilation
is synonymous with hypocapnia. The most common causes
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of hyperventilation include hypoxemia, CNS disorders,
pulmonary disease, and excessive mechanical ventilation.
Patients who are anxious, pregnant, have liver failure, or are
toxic from salicylates often will hyperventilate. A few patients
seem to have primary hyperventilation of unknown mecha-
nism. In the ICU, hyperventilation may be an early feature of
sepsis. Hyperventilation resulting in respiratory alkalosis
must be distinguished from the low PaCO2 seen as compen-
sation for metabolic acidosis. In both, PaCO2 is reduced and
plasma HCO3
– is low. The difference is that in respiratory
alkalosis, low PaCO2 is primary and pH is above normal,
whereas in metabolic acidosis, pH is in the acidic range and
low HCO3
– is the primary disturbance.
The principal compensatory response for respiratory
alkalosis is renal elimination of bicarbonate, which takes sev-
eral hours to days to complete. Hypocapnia itself reduces
bicarbonate reabsorption from the proximal tubule, but
hydrogen ion secretion in the distal nephron is also
decreased, resulting in loss of tubular bicarbonate. Increased
delivery of bicarbonate from the proximal tubule stimulates
a marked kaliuresis. In the steady state, plasma bicarbonate
concentration falls by about 0.5 meq/L for each 1 mm Hg
decrease in PaCO2 during chronic respiratory alkalosis, and
there is a smaller decreased in plasma bicarbonate with acute
respiratory alkalosis. The arterial pH therefore is corrected
toward normal but not to normal.
Clinical Features
A. Symptoms and Signs—Severe hyperventilation may
result in tetany that is clinically indistinguishable from the
hypocalcemic variety except that total plasma calcium and
the ionized fraction of calcium are normal. Hyperventilation
also may decrease blood pressure and cerebral perfusion,
which can cause increased irritability, anxiety, and inability
to concentrate. Occasionally, awake patients will complain of
vertigo and experience syncope. Other features are those of
the underlying disorder leading to respiratory alkalosis.
Patients with severe damage to the midbrain may have cen-
tral neurogenic hyperventilation. Prolonged respiratory alka-
losis may have adverse effects on patients with head injury
despite transient reduction in intracranial pressure acutely
largely because of decreased oxygen delivery and unloading
in the brain. Interestingly, respiratory but not metabolic
alkalosis may impair fluid resorption from lungs with pul-
monary edema.
B. Laboratory Findings—The hallmark of respiratory alka-
losis is the presence of alkalemia (pH >7.44) and decreased
PaCO2 in the presence of normal or decreased HCO3
–. The
extent of plasma bicarbonate reduction depends on the
duration of the respiratory disorder and the effectiveness of
the kidneys. The nomogram in Figure 2–5 may aid in deter-
mining whether the respiratory alkalosis is occurring alone
or is a mixed disorder. Most patients with chronic respira-
tory alkalosis will have a decline in plasma bicarbonate of
0.5 meq/L for each 1 mm Hg decrease in PaCO2. Mild
hyponatremia and hypochloremia often are present.
Hypophosphatemia owing to excess renal phosphate wasting
seems to be more marked with respiratory alkalosis than in
metabolic alkalosis.
For patients with central neurogenic hyperventilation,
evaluation may include CT scan or MRI of the head. Drug
ingestions (particularly salicylates) can be investigated with a
toxicology screen or blood salicyate determination.
Because hypoxemia appropriately may stimulate respira-
tory drive and cause respiratory alkalosis, the adequacy of
arterial oxygenation must be assessed.
C. Electrocardiography and Electroencephalography—
Electrocardiographic changes may include ST-segment or T-
wave flattening or inversion. Alterations in the QRS complex
also have been reported. Electroencephalographic studies are
usually normal but may show an increase in the number of
slow high-voltage waves.
Differential Diagnosis
The most important differential is metabolic acidosis with
respiratory compensation. As described earlier, in metabolic
acidosis, the blood pH is less than 7.38, whereas respiratory
alkalosis is associated with alkalemia. Mixed or combined dis-
turbances are often seen with respiratory alkalosis—notably
salicylate overdose, which may cause primary metabolic aci-
dosis and primary respiratory alkalosis simultaneously.
Treatment
A. Correction of Underlying Disorder—The key to treat-
ment is identification and management of underlying disor-
ders. If the patient is hypoxemic, the inspired oxygen
concentration may need to be increased. Anemia also may be
contributory and may be helped by blood transfusion. Other
potentially reversible causes include sepsis and liver failure.
Severe CNS disorders may cause respiratory alkalosis.
B. Mechanical Ventilation—Probably the most common
cause of respiratory alkalosis among critically ill patients is
iatrogenic hyperventilation owing to excessive mechanical
ventilation. Strict attention to blood gases and examination
of trends over several days usually will disclose this problem.
If the ventilator has been set to deliver too much minute ven-
tilation and the patient is not triggering, reducing the respi-
ratory rate and tidal volume will cause a marked and
predictable fall in pH. One reasonable goal is to reduce
minute ventilation just until the patient begins to trigger
spontaneous ventilation. At this point, pH is likely to be near
normal.
On the other hand, if the patient is already triggering the
mechanical ventilator, that is, choosing the respiratory rate,
then he or she is generating the primary drive for hyperventi-
lation. In most of these cases, changing the settings on the
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ventilator will not affect the patient’s spontaneous respiratory
rate. Hyperventilation sometimes can be moderated by
increasing paradoxically the inspiratory flow rate or tidal
volume.
Clinicians often opt for intermittent mandatory ventila-
tion to treat respiratory alkalosis; controlled trials have
shown that this is ineffective. Adding dead space to the ven-
tilator circuit tubing should not be done. In rare circum-
stances, severe respiratory alkalosis that cannot be managed
in any other way may require paralyzing the patient and con-
trolling the PaCO2 and pH.
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10520649]
Myrianthefs PM et al: Hypocapnic but not metabolic alkalosis
impairs alveolar fluid reabsorption. Am J Respir Crit Care Med
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The discovery of the ABO and Rh blood groups and the
development of nontoxic anticoagulant-preservative solu-
tions for blood storage during the first half of the 20th cen-
tury made it possible for human blood to be widely used as
lifesaving therapy in critically ill patients. Subsequent refine-
ments in cross-matching and the development of sophisti-
cated screening tests for transmissible diseases have made
blood transfusion a safe and often lifesaving form of therapy.
Because of the wide range of potential adverse effects of
transfusion therapy, however, the clinician must have a clear
understanding of the indications, efficacy, and complications
of blood component therapy.
BLOOD COMPONENTS
In modern transfusion practice, blood is separated into vari-
ous components (see Table 3–1), and individual components
are selected for transfusion based on the needs of the patient.
Blood component therapy is superior to whole blood
replacement because it concentrates those portions of blood
a patient needs, thereby increasing efficiency and minimizing
volume and subsequent transfusion requirements—as well
as increasing the efficiency of blood banking by putting
donated blood to maximal and optimal use.
 Red Blood Cells
The products available for replacement of red blood cells are
listed in Table 3–1. Homologous packed red blood cells from
volunteer donors are transfused most often. Leukocyte-poor
red blood cells are prepared by a variety of techniques to
remove at least 70% of leukocytes. Washing red blood cells
in saline removes most plasma proteins and some leukocytes
and platelets. Red blood cells frozen in liquid nitrogen with
glycerol as a cryoprotective agent can be stored for up to
10 years. Extensive washing after thawing removes most
plasma proteins and cellular debris. Neocytes (young red blood
cells) can be prepared by differential centrifugation or cell
separators and have a longer circulating life span than stan-
dard red cells, but they are rarely used. Directed donations of
red blood cells from ABO- and Rh-compatible individuals
who are appropriately screened may be substituted for
homologous red blood cells at the patient’s request.
Autologous red blood cells may be collected preoperatively,
by perioperative blood salvage, or by acute normovolemic
hemodilution to decrease homologous red blood cell use.
Indications
Red blood cell transfusions are indicated to promote oxygen
delivery in patients who are actively bleeding, for sympto-
matic anemia unresponsive to conservative management, or
when time does not permit alternative treatment. Red blood
cell transfusions also may be useful for improving the bleed-
ing tendency of a severely anemic patient with platelet dys-
function (eg, uremia) or severe thrombocytopenia.
The decision to transfuse red blood cells should be made
only after consideration of several factors. The age and gen-
eral condition of the patient and the presence of coexisting
cardiac, pulmonary, or vascular conditions will influence the
patient’s ability to tolerate acute blood loss or chronic ane-
mia. The degree and chronicity of the anemia are also impor-
tant determinants of the physiologic responses to anemia.
Finally, the cause of the anemia must be considered because
alternative therapy (eg, iron sulfate, vitamin B12, folate, or
epoetin alfa [erythropoietin]) may eliminate the need for
transfusions altogether.
A. Chronic Hypoproliferative Anemia—Chronic anemia is
accompanied by several physiologic adaptations that enhance
oxygen delivery despite a reduced red blood cell oxygen-
carrying capacity. Increased cardiac output, increased
intravascular volume, and redistribution of blood flow to vital
organs maintain organ function. Tissue extraction of oxygen
occurs over a wide range of hemoglobin concentrations and is
3
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Table 3–1. Blood component therapy.
enhanced by a rightward shift in the oxyhemoglobin dissoci-
ation curve (owing to increased erythrocyte 2,3-DPG produc-
tion and the Bohr effect). Additional responses to anemia
include increased erythropoietin production and early release
of young red blood cells into the circulation. These adaptive
responses allow most individuals to tolerate severe decreases
in oxygen-carrying capacity. Therefore, red blood cell transfu-
sions are rarely necessary for patients with chronic anemia
who have hemoglobin concentrations above 7 g/dL unless
significant cardiopulmonary disease is present, and transfu-
sions may result in circulatory overload if given rapidly or in
excessive quantity.
 CHAPTER 372
Products Available Indications for Transfusion 
Red Blood Cells (RBC) 
Homologous packed RBC Promote oxygen delivery for patients with active bleeding or severe anemia; improve bleeding tendency in
severely anemic patients with platelet dysfunction; replace sickle RBC with normal RBC by exchange transfusion. 
Leukocyte-poor RBC Reduce febrile reactions; prevent HLA alloimmunization and CMV infection in potential transplant recipients or
those requiring chronic platelet transfusions.
Irradiated RBC Reduce graft-versus-host disease.
Washed RBC Substitute for homologous RBC in patients sensitive to a plasma component; avoid transfusion of anti-A and
anti-B antibodies when O-negative blood is used in patients who are type A, B, or AB. 
Frozen RBC Preserve autologous RBC; maintain store of rare blood types. 
Neocytes Increase efficacy of individual transfusion for patients with transfusion-dependent anemia. 
Directed donor RBC After screening and informed consent, may be substituted for volunteer RBC at patient request.
Autologous RBC Decrease or eliminate need for homologous RBC in patients undergoing elective surgical procedures or obstetric
delivery.
Platelets 
Random donor platelets Treat or prevent bleeding associated with severe thrombocytopenia or platelet dysfunction; replace platelets
lost with massive bleeding; treat excessive bleeding associated with cardiopulmonary bypass. 
Platelet pheresis Decrease exposure to infectious agents.  
Leukocyte-poor platelets Reduce febrile reactions; reduce HLA alloimmunization for patients requiring chronic platelet transfusions.
Irradiated platelets Reduce graft-versus-host disease.
HLA-matched platelets Treat bleeding associated with thrombocytopenia in patients who are refractory to platelet transfusions due to
HLA sensitization. 
Plasma and Derivatives 
Fresh frozen plasma (FFP) Correct coagulation factor deficiencies in bleeding patients or those who require invasive procedures if
concentrated or recombinant product not available; treat TTP/HUS, protein-losing enteropathy in infants;
antithrombin III deficiency; C-1 esterase inhibitor deficiency. 
Fresh plasma (liquid plasma) Same as FFP, except does not contain factors V and VIII.
Cryoprecipitate-poor plasma Correct coagulation factor deficiencies other than VIII, XIII, fibrinogen, vWF; may be indicated for treatment of
refractory TTP. 
Cryoprecipitate Correct severe hypofibrinogenemia; may be useful for treatment of bleeding associated with uremia; provides
factors VIII and XIII, fibrinogen, and vWF.
Granulocytes 
Stimulated leukapheresis Treat severe bacterial infections unresponsive to antibiotics in patients with prolonged, severe neutropenia or
congenital neutrophil dysfunction; may be indicated in the management of neonatal sepsis. 
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B. Acute Blood Loss—In contrast, physiologic responses
may be inadequate to maintain organ function and hemody-
namic stability following acute blood loss, even with appar-
ently normal hemoglobin concentration, because it takes time
for mobilization of extracellular fluid into the intravascular
space and for increased production of erythrocyte 2,3-DPG.
However, a healthy young person generally tolerates
500–1000 mL of acute blood loss without red blood cell
transfusion, and intravascular volume can be repleted with
crystalloid solutions. Acute blood loss of 1000–2000 mL usu-
ally can be managed with volume replacement alone, but red
blood cell transfusions are necessary occasionally. More than
2 L of acute blood loss usually will require red blood cell
transfusion. Other clinical factors are important. For exam-
ple, because of the vasodilatory effects of anesthesia, intraop-
erative blood loss of more than 500 mL may require red blood
cell transfusion to maintain hemodynamic stability, and burn
patients often require vigorous blood product support
because of volume depletion through denuded body surfaces.
C. High-Risk Patients—Any condition that impairs the
patient’s ability to increase intravascular volume, heart rate,
stroke volume, or blood flow can result in poor tolerance of
chronic anemia or acute blood loss (eg, patients with cardio-
vascular disease, volume depletion from diuretics or gas-
trointestinal losses, vascular fluid redistribution, and elderly
patients). In these circumstances, transfusion may be neces-
sary in patients with physiologic signs of inadequate oxy-
genation despite higher hemoglobin concentrations than in
normal individuals with adequate physiologic reserves. The
use of objective scoring systems (such as the APACHE II
[Acute Physiology and Chronic Health Evaluation II] and the
multiorgan dysfunction scores) to stratify patients according
to severity of illness may be useful for determining which
critically ill patients may benefit from a restrictive transfu-
sion approach.
Studies have demonstrated that patients younger than
55 years of age with less severe illness may have improved
outcomes using a lower hemoglobin threshold (<7 g/dL) for
transfusion compared with more liberal use of transfusion
(<10 g/dL). This lower threshold for transfusion appears to
be at least as safe in older patients and those with more severe
disease as well.
Exceptions include those with acute bleeding (discussed
earlier) or myocardial ischemia. Although baseline anemia in
patients with acute myocardial infarction is associated with
adverse outcomes, including increased mortality, there is no
clear evidence that a liberal blood transfusion strategy (ie,
hemoglobin <10 g/dL as a trigger for transfusion) improves
outcomes. Available clinical data are inadequate to make a
firm recommendation regarding the hemoglobin threshold
for transfusion for these patients; therefore, decisions about
red blood cell transfusions must be individualized.
D. Hemolytic Anemia—Red blood cell transfusions are
indicated in the management of some patients with a variety
of severe and symptomatic hemolytic anemias. Patients with
markedly symptomatic antibody-mediated hemolytic ane-
mias may require red blood cell transfusion until definitive
therapy is effective. Autoantibodies are often reactive with all
donor red blood cells in vitro such that cross-matching is
impossible. Transfusion of ABO- and Rh-compatible red
blood cells is usually safe in these patients; the blood bank
can perform an extended cross-match to identify units with
the least degree of in vitro hemolysis. Patients with cold-
reacting antibodies (usually IgM) should receive blood
through a blood warmer if transfusion is necessary.
E. Sickle Cell Anemia—Patients with sickle cell anemia may
require red blood cell transfusion (and, in selected cases, par-
tial or complete exchange transfusion) for management of
specific complications, including splenic sequestration and
aplastic crises (with rapidly falling hemoglobin concentra-
tion), recurrent priapism, chronic unremitting osteomyelitis,
severe leg ulcers, pneumonia, or pulmonary sequestration
crises. Red blood cell transfusion is also indicated for such
patients undergoing major surgery, particularly those under-
going orthopedic procedures. Simple preoperative transfu-
sion to achieve hematocrit levels of about 30% appears to be
as effective as regimens aimed at reducing the fraction of
hemoglobin S to 30% of total hemoglobin (by exchange
transfusion or multiple transfusions over time) and is associ-
ated with fewer transfusion-related complications. Patients
with sickle cell anemia are not candidates for autologous
donation and transfusion.
Exchange transfusion is also indicated in the manage-
ment of acute central nervous system infarction or hemor-
rhage (followed by chronic transfusion therapy to prevent
recurrent strokes). Chronic prophylactic transfusion reduces
the risk of initial stroke in children with sickle cell disease
who have abnormal cerebrovascular blood flow on Doppler
ultrasonography; however, alloimmunization (even with
phenotypically matched, leukocyte-depleted red blood cells),
iron overload, and infections complicating chronic transfu-
sion programs have limited the acceptance of this approach.
Furthermore, the duration of transfusion required to prevent
stroke is unclear. Recent studies demonstrate that the risk of
stroke increases once chronic transfusions are stopped.
Routine transfusion during pregnancy should be avoided.
Patients with severe, symptomatic sickle cell anemia or those
suffering recurrent painful crises may require periodic trans-
fusion during pregnancy. Likewise, routine transfusion is not
indicated in the management of painful vaso-occlusive sickle
cell crises and should be reserved for patients with sympto-
matic anemia. Patients with sickle cell anemia appear to be
unusually susceptible to the development of alloantibodies
(see “Complications of Transfusion”), which limits the utility
of chronic transfusion programs. The use of blood from
racially matched donors that has been screened for selected
minor blood group antigens may prevent alloimmunization
in patients requiring chronic transfusion therapy, but this
approach awaits confirmation.
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F. Perioperative Transfusion—Transfusion is rarely indi-
cated for patients undergoing noncardiac surgery who have
hemoglobin values greater than 7–8 g/dL and no risk factors
for myocardial ischemia. However, elderly patients with hema-
tocrits less than 28% (hemoglobin of approximately 9 g/dL)
may be at risk for myocardial ischemia during surgery, espe-
cially if tachycardia is present. In these patients—and others at
risk for myocardial ischemia—a hemoglobin value of less than
10 g/dL probably warrants transfusion. The threshold for
intraoperative transfusion depends on many factors, such as
the presence of hemorrhage or coagulopathy, hemodynamic
instability, and ischemic electrocardiographic changes.
G. Unacceptable Indications—Red blood cell transfusions
should not be used to enhance a patient’s general sense of
well-being, to promote wound healing, or to expand vascular
volume when oxygen-carrying capacity is adequate.
 Red Blood Cell Transfusion Requirements
There is no single hemoglobin threshold that is universally
appropriate for determining transfusion requirements. The
amount of red blood cells to be transfused should be deter-
mined by the clinical status of the patient rather than by the
hemoglobin concentration. In patients who are actively
bleeding, crystalloid volume repletion is essential.
Hemodynamic instability, symptoms and signs of impaired
organ function, rate of blood loss, and response to transfu-
sion should be used to determine how much blood should be
transfused. Patients with chronic anemia should receive only
the amount of red blood cells necessary to reverse symptoms
and signs. Patients with self-limited anemia (eg, transient
blood loss, hemolysis, or marrow suppression) or those for
whom alternative therapy is available (eg, nutritional defi-
ciencies, anemia of renal failure) should receive red blood
cells only when an immediate need for increased oxygen-
carrying capacity is present, such as during myocardial
ischemia, heart failure, impaired central nervous system oxy-
genation, hypotension, or other evidence of tissue hypoxia.
The patient should be reevaluated after each unit of red
blood cells is transfused rather than giving an arbitrary or
predetermined number of units. Volume overload following
red blood cell transfusion in patients with chronic severe
anemia may eliminate any benefit of increasing the oxygen-
carrying capacity and must be monitored carefully.
When untreatable chronic anemia is present (eg, bone
marrow failure or chronic severe hemolytic anemia), red
blood cell transfusions must be given conservatively to delay
long-term treatment complications such as alloimmuniza-
tion, infections, and iron overload. Red blood cell transfu-
sions may be administered more liberally in the treatment of
anemia associated with severe thrombocytopenia or platelet
dysfunction (eg, acute leukemia or uremic bleeding
episodes) because the salutary effect of increased hematocrit
on platelet function may decrease platelet transfusion
requirements and lessen clinical bleeding.
 Platelets
Platelet products available are listed in Table 3–1. The choice
of platelet product depends on the underlying condition of
the patient (eg, acute reversible thrombocytopenia versus
chronic thrombocytopenia) as well as the local availability of
supplies. Pooled random-donor platelets or single-donor
platelets obtained by apheresis are the usual products trans-
fused for correction of severe thrombocytopenia. Filtration
or irradiation with ultraviolet B depletes donor platelets of
leukocytes, and these are equally effective strategies for pre-
venting alloantibody-mediated refractoriness to platelet
transfusions. Such leukodepletion is appropriate for patients
likely to require repeated platelet transfusions (eg, acute
leukemia, aplastic anemia, and other bone marrow failure
states). Leukocyte depletion performed shortly after collec-
tion of platelets also may decrease the risk of febrile reactions
by preventing in vitro accumulation of cytokines, which are
released during storage. Single-donor platelets decrease the
total number of donor exposures and may reduce the risk of
transfusion-transmitted infections but do not appear to offer
additional benefit over filtration or irradiation for preven-
tion of alloimmunization.
Product availability often will determine whether pooled
platelets or single-donor platelets are transfused. Whenever
possible, ABO type–specific platelets should be used; how-
ever, because platelets have a limited storage period, they are
not always available. A decreased response to platelet trans-
fusion may result from the use of ABO-incompatible
platelets, but the most significant risk occurs when ABO-
incompatible plasma is infused (ie, type O donor, type A or
B recipient), resulting in hemolysis (estimated risk
1:9000–1:6600). Apheresis units may increase this risk by
increasing the dose of incompatible plasma. If type-specific
platelets are not available, pooled platelets are preferable to
single-donor platelets. Washing the platelets to remove
plasma may help to minimize exposure to incompatible
plasma. Although platelets do not carry Rh antigens, platelets
from Rh-negative donors should be used for transfusion in
Rh-negative women of childbearing years to prevent sensiti-
zation from contaminating red blood cells.
Indications
Platelet transfusions are indicated for treatment of bleeding
associated with thrombocytopenia or intrinsic platelet dys-
function. Platelet transfusions are also indicated in the man-
agement of massive bleeding if severe thrombocytopenia
develops. Patients undergoing cardiopulmonary bypass may
require platelet transfusions if excessive bleeding occurs
because of thrombocytopenia and decreased platelet function
induced by the bypass procedure. Other surgical procedures
in thrombocytopenic patients generally require prophylactic
platelet transfusions to maintain adequate perioperative
platelet counts for at least 3 days (>50,000/μL for major pro-
cedures; >30,000/μL for minor procedures). Prophylactic
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platelet transfusions are also indicated for severely thrombo-
cytopenic (eg, <10,000/μL platelets) patients undergoing
intensive chemotherapy for acute leukemia; the threshold for
transfusion may be higher in the presence of fever, infection,
or drugs that cause platelet dysfunction.
Factors that determine the risk of serious bleeding owing
to thrombocytopenia include the cause and severity of
thrombocytopenia, the presence of vascular defects, the
functional status of the patient’s platelets, and the presence of
other hemostatic defects. Severe anemia also may contribute
to bleeding in patients with thrombocytopenia or platelet
dysfunction. Because of the increased functional capacity of
younger platelets in patients with decreased platelet survival,
decreased production of platelets carries a higher risk of seri-
ous bleeding at any given platelet count than thrombocy-
topenia owing to destruction, consumption, or hypersplenism.
Typical bleeding manifestations related to the level of throm-
bocytopenia are shown in Table 17–8. If bleeding is out of
proportion to a given platelet count, other contributing factors
to bleeding should be investigated.
The risk of bleeding in patients with disorders of platelet
function likewise depends on the cause and severity of the dis-
order and whether vascular defects, other hemostatic abnor-
malities, or severe anemia is present. Bleeding time is the most
widely used test of platelet function, and although it is useful in
the diagnosis of certain disorders (eg, von Willebrand’s disease,
hereditary platelet disorders), prolonged bleeding time in the
absence of a history of bleeding is not a reliable predictor of
subsequent bleeding. A prolonged bleeding time in the absence
of thrombocytopenia or severe anemia in a bleeding patient,
however, may indicate the presence of platelet dysfunction.
The efficacy of platelet transfusions can be assessed by
observing a sustained rise in platelet count in a patient who
has stopped bleeding. Patients with thrombocytopenia
owing to decreased production of platelets are most likely to
experience a significant, sustained increase in platelet count
following platelet transfusion. Patients with increased
destruction of platelets and those who have hypersplenism
usually do not achieve a significant increase in platelet count
after transfusion, and any increase that occurs is usually tran-
sient. Similarly, patients with massive platelet consumption
owing to bleeding will have a suboptimal increase in platelet
count following transfusion. Hemorrhage owing to platelet
dysfunction can be controlled with platelet transfusions only
if the defect is intrinsic to the platelet (eg, aspirin ingestion,
cardiopulmonary bypass, inherited platelet disorders) rather
than extrinsic (eg, von Willebrand’s disease or uremia).
Platelet transfusions are minimally useful in the treatment
of thrombocytopenia owing to decreased platelet survival and
should not be given unless severe life-threatening bleeding
occurs. Platelet transfusions may be harmful in patients with
thrombotic thrombocytopenic purpura–hemolytic uremic
syndrome (TTP-HUS) despite the presence of thrombocy-
topenia, presumably owing to accelerated thrombosis in vital
organs. Because platelet survival is short in this disorder,
platelet transfusions usually are ineffective in controlling
hemorrhage. The diagnosis of TTP-HUS should be suspected
in a patient with severe thrombocytopenia and hemolysis with
schistocytes on peripheral blood smear (microangiopathic
hemolytic anemia) with or without associated central nervous
system dysfunction, renal dysfunction, or fever. Patients with
heparin-associated thrombocytopenia also may suffer
increased thrombotic complications if platelets are transfused.
Platelet transfusions should be administered to these patients
only when the risk of death from bleeding outweighs the
potential risk of clinical deterioration from transfusion.
Platelet Transfusion Requirements
The quantity of platelets to be transfused depends on the
source of the platelets, the cause and degree of thrombocytope-
nia, and the observed response to transfusions. The usual ini-
tial amount transfused is 6–8 units of random-donor platelets
or 1 unit of single-donor apheresis product. Platelet packs
should contain a minimum of 5.5 × 109 platelets per unit.
The response to platelet transfusions should be deter-
mined by obtaining a platelet count 1 hour after transfusion
and daily thereafter and by observing the effect on control of
bleeding. The 1-hour count should increase by about
5000–10,000 per unit of random-donor platelets or
30,000–50,000 per unit of single-donor platelets. Stored
homologous platelets survive about 3 days in thrombocy-
topenic patients. The 1-hour count and subsequent platelet
survival will be reduced in patients with increased destruc-
tion or hypersplenism. These measurements will help to
determine the magnitude of the benefit to be expected from
subsequent transfusions. If only a minimal response occurs,
or if the platelet rise is short-lived, subsequent prophylactic
transfusions should be withheld. However, in patients with
severe thrombocytopenia owing to destruction or hyper-
splenism who have serious bleeding, platelet transfusions
may be warranted. In any patient, if clinical bleeding does
not improve despite platelet transfusion, other causes of
bleeding should be evaluated and the utility of subsequent
platelet transfusions in such patients reassessed.
The underlying cause of thrombocytopenia or platelet
dysfunction should be determined so that specific therapy
to reverse the process can be given if available. Alternatives
to platelet transfusions in bleeding patients with thrombo-
cytopenia or platelet dysfunction are set forth in Table 3–2.
 Plasma
Plasma products available are listed in Table 3–1. Fresh
frozen plasma (FFP) is prepared by separating plasma from
red blood cells (after collection of whole blood or during
plasmapheresis) and freezing it within 6 hours after collec-
tion at –18°C or colder. It can be stored for up to 1 year and
is thawed over 20–30 minutes prior to administration.
Activities of coagulation factors are adequate for 24 hours
after thawing. Fresh plasma and plasma recovered from out-
dated blood products are used for preparation of plasma
derivatives (eg, immunoglobulin, cryoprecipitate, albumin,
coagulation factor concentrates). Fresh plasma may be used
as an alternative to FFP for replacement of coagulation fac-
tors other than factors VIII and V.
Cryoprecipitate-poor plasma is the supernatant plasma
remaining after preparation of cryoprecipitate and contains
adequate quantities of all coagulation factors except fibrino-
gen, factors VIII and XIII, and von Willebrand factor.
Solvent-detergent treatment of plasma (S/D plasma) inac-
tivates lipid-enveloped viruses and has been licensed
recently by the Food and Drug Administration (FDA) to
minimize the risk of transfusion-transmitted infections
and allergic reactions in the management of coagulopathies
and thrombotic thrombocytopenic purpura (TTP). The
highest-molecular-weight von Willebrand factor multimers
are reduced in S/D plasma, enhancing its efficacy in the
treatment of TTP, but protein S and plasmin inhibitor levels
are also variably reduced, potentially causing venous throm-
boembolism (low protein S) or excessive bleeding (low plas-
min inhibitor). Numerous other derivatives of plasma are
now available; Table 3–3 outlines some of these products and
their therapeutic uses.
Alternative Possible Indications 
High-dose IgG Life-threatening bleeding in immune-
mediated thrombocytopenia (ITP). 
Anti-D immune
globulin  
Treatment of bleeding in ITP in Rh-positive
patients. 
Desmopressin
(DDAVP) 
Bleeding associated with platelet dysfunction,
uremia, von Willebrand’s disease. 
Antifibrinolytic agents
(eg, aminocaproic
acid) 
Excessive bleeding without evidence of throm-
botic diathesis or hematuria. 
Estrogens Bleeding associated with uremic platelet
dysfunction. 
Red cell transfusions Severe anemia associated with thrombocy-
topenia or platelet dysfunction. 
Erythropoietin Bleeding in anemic, uremic patients.
Corticosteroids ITP, possibly thrombotic thrombocytopenic
purpura-hemolytic uremic syndrome (TTP-HUS).
Splenectomy Refractory ITP, severe hypersplenism,
possibly TTP.
Immunosuppressives, 
chemotherapy,
danazol, vinca
alkaloids, interferon
alpha, protein-A
immunoadsorption,
rituximab
Refractory ITP.
Plasma infusion or
exchange 
TTP-HUS.
Table 3–2. Alternatives to platelet transfusions.
Table 3–3. Therapeutic products derived from plasma.  
Plasma Derivative Therapeutic Use 
Fibrin glue (human fibrinogen
combined with bovine
thrombin) 
Prevent surgical oozing with
topical use 
Albumin (heat-treated) Hypoalbuminemia in nephrotic
syndrome 
Plasma-derived factor VIII
concentrate 
Hemophilia A* 
Humate-P von Willebrand’s disease 
Prothrombin complex concentrate Coagulation inhibitors, factor X
and prothrombin deficiencies
Activated factor IX concentrates
(Autoplex, FEIBA) 
Factor VIII inhibitors 
Plasma-derived factor IX
concentrate 
Hemophilia B* 
Fibrinogen concentrate Hypofibrinogenemia
Factor VII concentrate Factor VII deficiency
Factor XI concentrate Factor XI deficiency
Factor XIII concentrate Factor XIII deficiency 
Antithrombin III concentrate Thrombosis in antithrombin III
deficiency 
C1 esterase inhibitor concentrate Angioedema 
α1-Antitrypsin concentrate Prevent lung damage in
α1-antitrypsin deficiency 
Protein C and S concentrate Severe protein C or S deficiency 
Intravenous immunoglobulin Immunodeficiency states; immune
cytopenias, Kawasaki syndrome,
Guillain-Barré syndrome,
dermatomyositis 
Immune serum globulin Passive immunization against hep-
atitis A, measles, poliomyelitis,
varicella, rubella 
*Recombinant products are available as an alternative to plasma-
derived product; see Chapter 17.
 CHAPTER 376
TRANSFUSION THERAPY  77
Indications
The major indication for plasma transfusion is correction of
coagulation factor deficiencies in patients with active bleeding
or in those who require invasive procedures. Isolated congen-
ital factor deficiencies (eg, factor II, V, VII, X, XI, or XIII) may
be treated with plasma (FFP for factor V deficiency, FFP or
fresh plasma for the remainder) if factor-specific concentrate
is unavailable. Multiple acquired factor deficiencies compli-
cating severe liver disease and disseminated intravascular
coagulation (DIC) and, if associated with significant bleed-
ing, may be treated with FFP. However, excessive volume
expansion or decreased survival of coagulation factors may
decrease the usefulness of FFP in these conditions. Vitamin K
deficiency and warfarin therapy result in a functional defi-
ciency of factors II, VII, IX, and X, and parenteral vitamin K
administration will reverse these deficiencies within about
24 hours. If immediate correction is necessary because of
active bleeding, plasma can be given. Massively bleeding
patients requiring transfusion of red blood cells greater than
100% of normal blood volume in less than 24 hours may
become deficient in multiple coagulation factors, and plasma
is indicated if a demonstrable coagulopathy develops follow-
ing massive transfusion and bleeding continues. However,
bleeding in such patients is more often due to thrombocy-
topenia than coagulation factor deficiencies, so prophylactic
administration of plasma usually is not indicated.
Other indications for treatment with plasma include
antithrombin III deficiency in patients at high risk for throm-
bosis or who are unresponsive to heparin therapy, severe
protein-losing enteropathy in infants, severe C1 esterase
inhibitor deficiency with life-threatening angioedema, and
TTP-HUS.
Plasma exchange therapy, with removal of undesirable
plasma substances and reinfusion of normal plasma,
appears to be effective alone or as an adjunct in the manage-
ment of TTP-HUS, cryoglobulinemia, Goodpasture’s syn-
drome, Guillain-Barré syndrome, homozygous familial
hypercholesterolemia, and posttransfusion purpura. Plasma
exchange may be of value in some patients with chronic
inflammatory demyelinating polyneuropathy, cold agglu-
tinin disease, autoimmune thrombocytopenia, rapidly pro-
gressive glomerulonephritis, and systemic vasculitis. Rarely,
patients with alloantibodies, pure red blood cell aplasia,
warm autoimmune hemolytic anemia, multiple sclerosis, or
maternal-fetal incompatibility may benefit from therapeutic
plasma exchange.
Plasma should not be administered for reversal of volume
depletion or to counter nutritional deficiencies (except severe
protein-losing enteropathy in infants) because effective alter-
natives are available. Purified human immunoglobulin has
replaced plasma in the treatment of humoral immunodefi-
ciency. Patients with coagulation factor deficiencies who are
not bleeding or not in need of invasive procedures likewise
should not be treated with plasma. Patients with mild coagu-
lation factor deficiencies (ie, prothrombin time <16–18 s,
partial thromboplastin time <55–60 s) are unlikely to have
bleeding in the absence of an anatomic lesion, and even with
surgery or other invasive procedures, these patients may not
have excessive bleeding. Therefore, prophylactic administra-
tion of plasma should be discouraged in such patients.
Plasma Transfusion Requirements
ABO type–specific plasma should be used to prevent trans-
fusion of anti-A or anti-B antibodies. Rh-negative donor
plasma should be administered to Rh-negative patients to
prevent Rh sensitization from contaminating red blood cells
(particularly important for women of childbearing years).
The amount of plasma must be individualized. In the
treatment of coagulation factor deficiencies, the appropriate
dose of plasma must take into account the plasma volume of
the patient, the desired increase in factor activity, and the
expected half-life of the factors being replaced. The average
adult patient with multiple factor deficiencies requires 2 to
9 units (about 400–1800 mL) of plasma acutely to control
bleeding, with smaller quantities given at periodic intervals
as necessary to maintain adequate hemostasis. Control of
bleeding and measurement of coagulation times (prothrom-
bin time and partial thromboplastin time) should be used to
determine when and if to give repeated doses of plasma.
Smaller amounts of plasma usually are sufficient for treat-
ment of isolated coagulation factor deficiencies.
Plasma infusion and plasma exchange for treatment of
TTP-HUS usually necessitate very large quantities of
plasma—up to 10 units per day (or even more)—for several
days until the desired clinical response is achieved. The pre-
cise dose of plasma required to treat hereditary angioedema
is unknown; 2 units is probably adequate, and a concentrate
is now available to treat C1 esterase inhibitor deficiency.
 Cryoprecipitate
Preparation
When FFP is thawed at 4°C, a precipitate is formed. This cry-
oprecipitate is separated from the supernatant plasma and
resuspended in a small volume of plasma. It is then refrozen
at –18°C and kept for up to 1 year. The supernatant plasma
is used for preparation of other plasma fractions (eg, coagu-
lation factor concentrates, albumin, and immunoglobulin).
Each bag of cryoprecipitate (about 50 mL) contains approx-
imately 100–250 mg of fibrinogen, 80–100 units of factor
VIII, 40–70% of the plasma von Willebrand factor concen-
tration, 50–60 mg of fibronectin, and factor XIII at one and
one-half to four times the concentration in FFP.
Indications
Cryoprecipitate is indicated in patients with severe hypofib-
rinogenemia (<100 mg/dL) for treatment of bleeding
episodes or as prophylaxis for invasive procedures. It may be
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useful in the treatment of severe bleeding in uremic patients
unresponsive to desmopressin and dialysis. Cryoprecipitate
also can be used to make a topical fibrin glue for use intraop-
eratively to control local bleeding and has been used in the
removal of renal stones when combined with thrombin and
calcium.
Purified factor VIII concentrates or recombinant factor
VIII products are preferred over cryoprecipitate in the man-
agement of hemophilia A because of the lower risk of infec-
tious disease transmission, as well as fewer other complications
(eg, allergic reactions to other plasma or cryoprecipitate con-
stituents). Antihemophilic factor–von Willebrand factor com-
plex (human), dried, pasteurized (Humate-P), a concentrate
rich in von Willebrand factor, is now preferred over cryoprecip-
itate in the treatment of von Willebrand’s disease when treat-
ment with desmopressin is inadequate or unsuitable.
Likewise, factor XIII concentrate is available for treatment of
bleeding owing to factor XIII deficiency.
Cryoprecipitate is not indicated for bleeding owing to
thrombocytopenia, for bleeding owing to multiple coagula-
tion factor deficiencies unless severe hypofibrinogenemia is
present, or for bleeding owing to unknown cause. It is not
indicated for treatment of patients with deficiencies of fac-
tors VIII and XIII or von Willebrand factor in the absence of
bleeding or the need for invasive procedures.
Administration 
ABO type–specific cryoprecipitate is thawed and pooled into
the desired quantity and administered intravenously by infu-
sion or syringe. In treatment of bleeding owing to hypofib-
rinogenemia, the goal of therapy is to maintain the
fibrinogen concentration above 100 mg/dL. Two to three
bags per 10 kg of body weight will increase the fibrinogen
concentration by about 100 mg/dL. Maintenance doses of
one bag per 15 kg of body weight can be given daily until
adequate hemostasis is achieved. When hypofibrinogenemia
is due to increased consumption (eg, DIC), larger and more
frequent doses may be required to control bleeding.
 Granulocytes
Granulocyte concentrates (see Table 3–1) are prepared by
automated leukapheresis from ABO-compatible donors
stimulated several hours before collection with corticos-
teroids. Granulocytes have decreased function if refrigerated
or agitated, so these concentrates should be given as soon as
possible after collection (preferably within 6 hours; never
after 24 hours). Granulocytes do not survive prolonged stor-
age and so must be prepared before each transfusion.
Indications
The indications for granulocyte transfusions are controver-
sial. Severe neutropenia (<500/μL) is associated with a
marked increase in the risk of bacterial and fungal infections.
Most authorities agree that granulocyte transfusions are
most likely to be helpful in patients with documented bacte-
rial or fungal infections unresponsive to antibiotics accom-
panied by prolonged severe neutropenia when bone marrow
recovery is expected in 7–10 days or in patients with congen-
ital severe granulocyte dysfunction complicated by life-
threatening fungal infections. Granulocyte transfusions also
may be of value in the treatment of neonatal sepsis, although
this remains controversial.
Granulocyte transfusions are not helpful for preventing
infections in neutropenic patients, in treating infections
associated with transient neutropenia, or in treating fevers
and neutropenia not associated with documented infection.
Patients who are unlikely to recover bone marrow function
(eg, those with aplastic anemia or refractory acute leukemia)
appear to derive less benefit than patients who will recover
ultimately (eg, those with acute leukemia following success-
ful chemotherapy). Granulocyte transfusions should be used
with caution in patients receiving amphotericin B and in
those with pulmonary infiltrates because of the potential for
adverse pulmonary events.
Administration
Granulocytes should be administered as soon as possible after
collection from a corticosteroid-stimulated ABO-compatible
donor. The minimal dose recommended is 2–3 × 1010 granu-
locytes per transfusion, infused slowly under constant super-
vision. Daily transfusions should be administered for at least
4 days and perhaps longer until the infection is controlled.
Complications
Granulocyte transfusions are associated with numerous
adverse effects, including febrile reactions (25–50%),
alloantibodies (human leukocyte antigen [HLA] and
neutrophil-specific), cytomegalovirus (CMV) infections if
granulocytes from seropositive donors are given to seroneg-
ative patients, pulmonary reactions, and graft-versus-host
disease (preventable with irradiation of the product). These
complications—as well as the development of more effective
antibiotics and more effective antileukemic therapy—have
diminished the occasions for use of granulocyte transfusions
over the last decade. Human recombinant cytokines, such as
granulocyte colony-stimulating factor (Filgrastim; G-CSF)
and granulocyte-macrophage colony-stimulating factor
(Sargramostim; GM-CSF) can be used to decrease the sever-
ity and duration of neutropenia in patients receiving
chemotherapy for nonmyeloid malignancies and even in
selected patients with myeloid malignancies.
 Coagulation Factors
Available coagulation factor products, indications, dosing,
alternatives, and complications are discussed in Chapter 17.
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BLOOD COMPONENT ADMINISTRATION
 Informed Consent
Before elective transfusion of any blood component is under-
taken, the patient should be informed of the benefits of trans-
fusion, the potential risks of transfusion, and the alternatives
to transfusion. The patient should be given the opportunity to
ask questions about the recommended transfusion, and con-
sent should be obtained before proceeding. Informed consent
also should be obtained from competent patients in emer-
gency situations. Many states have passed laws requiring
informed consent prior to elective transfusion, including pro-
viding the patient with the option of autologous donation,
where appropriate (usually for elective surgical procedures).
 Patient Identification
The identity of the patient should be verified when obtaining
specimens for cross-match, and blood collected should be
labeled immediately with the patient’s name and hospital
identification number, dated, and signed by the phle-
botomist. At the time of transfusion, the label on the unit
should be compared with the name and identification num-
ber on the patient’s bracelet. There should be no discrepan-
cies in spelling or medical record number. Rigid adherence to
these practices eliminates the great majority of major acute
hemolytic transfusion reactions.
 Preparation of Blood Components
Potential donors are screened with a questionnaire prior to
donation to eliminate donors with identifiable risk factors
for complications in both the donor and the recipient. After
collection, donor blood is screened for the presence of infec-
tious diseases or their markers, including VDRL, hepatitis B
surface antigen and core antibody, hepatitis C, HIV-1 and -2,
HTLV-1 and -2 antibodies, hepatitis C and HIV-1 RNA, and
occasionally, CMV antibody. The ABO and Rh types of
donor and recipient red blood cells are determined, and the
sera of both donor and recipient are screened for clinically
significant alloantibodies to the major red blood cell anti-
gens. If donor red blood cells appear to be Rh-negative, they
are typed further to exclude a weakly reactive Rh-positive
variant (weak D, Du). Recipient serum is incubated with
donor red blood cells to detect antibodies that may react with
donor red cells (the “cross-match”). Some patients have
autoantibodies that react with virtually all red blood cells. In
these situations, the in vitro cross-match should be per-
formed with multiple type-specific donor samples to find
red blood cells with the least in vitro incompatibility.
 Administration
All blood components should be administered through a
standard blood filter to trap clots and other large particles
into any accessible vein or central venous catheter. When
leukocyte-depleted red blood cells or platelets are desired,
third-generation leukoreduction filters may be used if filtra-
tion has not been performed in the laboratory. Red blood
cells should not be administered by syringe or by automatic
infusion pump because forcible administration may cause
mechanical hemolysis, but other cellular components and
plasma derivatives may be administered by pumps. Nothing
should be added to the blood component (eg, medications,
hyperalimentation) or administered through the same line as
the component. Only physiologic saline solution should be
administered through the same line and may be used to
dilute red blood cells and thus promote easier flow.
Hypotonic solutions (5% dextrose in water) may cause
hemolysis, and solutions containing calcium (Ringer’s lac-
tate) may initiate coagulation. These should not be adminis-
tered through the same line with blood components.
Blood components should be administered slowly for the
first 5–10 minutes while the patient is under observation,
and the patient should be reassessed periodically throughout
the transfusion process for adverse effects. Blood compo-
nents should not be kept at room temperature for more than
4 hours after the blood bag has been opened. If a slower infu-
sion rate is necessary to avoid circulatory overload, the unit
may be divided into smaller portions. Each portion should
be refrigerated until used, and each then can be administered
over 4 hours. Catheter size should be sufficiently large to
allow blood to be administered within the 4-hour time
period (generally 20 gauge or larger). Use of very small gauge
catheters will impede flow, especially of packed red blood
cells, and should be reserved for pediatric patients, who
require much smaller volumes of blood. A blood warmer
should be used for transfusion of patients with cold-reacting
antibodies to prevent acute hemolysis.
COMPLICATIONS OF TRANSFUSION
 Red Cell Antibody-Mediated Reactions
Acute Reactions
Acute hemolytic transfusion reactions are almost always due to
human error, resulting in transfusion of incompatible blood,
and are preventable by rigid adherence to a standardized pro-
tocol for collecting, labeling, storing, and releasing all blood
involved in transfusion. When incompatible red blood cells are
transfused, recipient antibodies directed against donor red
blood cells may cause acute intravascular hemolysis. ABO
incompatibility is most common because anti-A and anti-B
antibodies are naturally occurring, but other antibodies owing
to prior sensitization can cause acute hemolytic reactions.
Acute hemolytic transfusion reactions range in severity from
mild, clinically undetected hemolysis to fulminant, fatal events.
Back pain, chest tightness, chills, and fever are the most com-
mon complaints in conscious patients. If the patient is uncon-
scious (eg, under general anesthesia), hypotension, tachycardia,or
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fever may be the first clue, followed by generalized oozing from
venipuncture and surgical sites. Since the severity of acute
hemolytic transfusion reactions is related to the amount of
incompatible blood given, it is vital to recognize early warning
symptoms and signs to minimize sequelae of such a transfusion.
Complications of acute hemolytic transfusion reactions
include cardiovascular collapse, oliguric renal failure, and
DIC. Massive immune-complex deposition, stimulation of
the coagulation cascade, and activation of vasoactive sub-
stances are the main pathophysiologic mechanisms underly-
ing these complications, with subsequent decreased perfusion
and hypoxia resulting in tissue damage. The degree of dam-
age is related to the dose of incompatible blood received.
Any transfusion complicated by even apparently mild
findings such as fever or allergic symptoms should be
stopped. The identity of the patient and the label on the unit
should be verified quickly. If the patient has never been
transfused or has never had any adverse reaction to prior
transfusions, even a minor febrile reaction should prompt an
evaluation for incompatibility. The remainder of the unit of
blood and additional samples (anticoagulated and coagu-
lated) from the patient should be sent to the blood bank for
repeat cross-match and direct antiglobulin testing. Patient
plasma and urine should be examined for hemoglobin. It
may be useful to check serum bilirubin and haptoglobin lev-
els for evidence of hemolysis.
If acute hemolysis has occurred, the patient should be
managed with aggressive supportive care. Vital signs should be
monitored and intravenous volume support provided to
maintain adequate blood pressure and renal perfusion for at
least 24 hours following acute hemolysis. Loop or osmotic
diuretics may be used in combination with intravenous fluids
to maintain renal perfusion and urine output over 100 mL/h.
Renal and coagulation status should be monitored clinically
and with appropriate laboratory tests. DIC may occur and
occasionally requires treatment with factor replacement. It is
important to remember that an adverse reaction to an incom-
patible unit of red blood cells does not obviate the initial need
for the transfusion. Therefore, transfusion with compatible
red blood cells should be undertaken to provide the oxygen-
carrying capacity the patient required prior to the transfusion.
In a patient who had been transfused previously and has
had prior febrile reactions, the decision to evaluate each
subsequent febrile reaction may be difficult. At a minimum,
verification of the identity of the unit and the patient always
should be performed. Whether to initiate the entire evalua-
tion for hemolysis will depend on the clinical circumstances.
When in doubt, it is safer to stop the transfusion and perform
a complete evaluation before continuing. Alternatively, if
judged safe to continue without further evaluation, antipyret-
ics may be used to lessen or prevent subsequent reactions.
Delayed Reactions
Hemolysis occurring about 1 week after red blood cell trans-
fusion may occur when the initial cross-match fails to detect
recipient antibodies to donor red blood cell antigens. Prior
sensitization by transfusion or pregnancy to red blood cell
antigens other than ABO may result in a transient rise in
antibodies directed against those antigens. The antibody titer
may wane to undetectable levels in as little as a few weeks. A
second exposure prompts an anamnestic rise in antibody
titer to a level sufficient to cause hemolysis.
The clinical manifestations of delayed hemolytic transfu-
sion reactions are generally mild, with a fall in hematocrit
accompanied by a slight increase in indirect bilirubin and lac-
tic dehydrogenase levels about 1 week after transfusion. A
repeat cross-match will demonstrate a “new” antibody. With
some exceptions, hemolysis is extravascular and mild, without
the serious sequelae that may follow acute hemolytic reactions.
No specific therapy is necessary, but if indicated clinically, fur-
ther transfusion should be given with red blood cells negative
for the antigen. The blood bank should maintain a permanent
record of the antibody, and all future red blood cell transfu-
sions should be with antigen-negative blood. The patient
should be informed of the antibody and of the need for screen-
ing of all future transfused red blood cells to avoid another such
reaction. The patient also should be monitored for the develop-
ment of other antibodies following subsequent transfusions.
Alloimmunization
Alloantibodies to red blood cell antigens other than ABO
may occur in some recipients of red blood cell transfusions.
Since there are over 300 red blood cell antigens, virtually all
red blood cell transfusions expose the recipient to foreign
antigens. Most antigens are not immunogenic, however, and
rarely result in development of alloantibodies. Factors that
influence the development of alloantibodies include the
immunogenicity of the antigen, the frequency of the antigen
in the population, the number of transfusions given, and the
tendency of the recipient to form antibodies.
Because of the time required for the primary antibody
response, alloantibodies do not complicate the sensitizing
transfusion. Subsequent cross-match procedures will detect
most clinically significant alloantibodies, but the develop-
ment of multiple alloantibodies may make it difficult to find
compatible units for transfusion-dependent recipients.
Delayed hemolytic transfusion reactions may occur if the
antibody is not detectable at the time of subsequent cross-
match procedures. Red blood cell phenotyping may be useful
for transfusion-dependent patients who demonstrate a ten-
dency for antibody formation. When significant differences
in the frequency of antigens exist between donor and recip-
ient populations, empiric transfusion of red blood cells
negative for certain antigens may be useful (eg, Duffy antigen–
negative red blood cells for sickle cell patients) to prevent
alloimmunization.
 Infectious Complications of Transfusions
Current transfusion techniques minimize the risk of trans-
mission of many potential pathogens (Table 3–4). The major
factors that decrease the risk of transmission of disease
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Infection  Clinical Significance/Incidence
Viruses
Hepatitis A Rarely transmitted because of short period of viremia and lack of carrier state (1 in 1,000,000 units transfused)
Parvovirus B19 Estimated risk is 1 in 10,000 units transfused. Infection clinically insignificant except in pregnant women, patients
with hemolytic anemia or who are immunocompromised.
Esptein-Barr virus Rarely transmitted because of immunity acquired early in life.
Cytomegalovirus Clinically significant transfusion complication in low-birth-weight neonates or immunocompromised hosts.
Markedly reduced by use of CMV-seronegative donors for all blood component therapy or by leukodepletion of
blood products for CMV-negative recipients at high risk. 
HTLV-1, HTLV-2 Estimated risk is 1 in 250,000 to 1 in 2,000,000 units transfused. Blood stored for more than 14 days and noncel-
lular components are not infectious. Twenty to forty percent of recipients receiving infected blood become
infected with virus; infection may lead to T cell lymphoproliferative disorder or myelopathy after long latency
period. Donors are screened for both viruses.
Hepatitis B Estimated risk is 1:50,000 to 1:150,000 units transfused. Usually causes anicteric and asymptomatic hepatitis
6 weeks to 6 months after transfusion. Ten percent become chronic carriers at risk for cirrhosis. All donors screened
with surface antigen and core antibody.
Delta agent Cotransmitted with hepatitis B, found primarily in drug abusers or patients who have received multiple transfu-
sions. Superinfection of hepatitis B surface antigen carriers may result in fulminant hepatitis or chronic infectious
state. Screening for hepatitis B eliminates the majority of infectious donors.
Hepatitis C Previously the leading cause of posttransfusion hepatitis; donors are now screened, with estimated risk
1:600,000. Infection may be asymptomatic but 85% become chronic, 20% develop cirrhosis, and 1–5% develop
hepatocellular carcinoma.
Hepatitis G (GB virus C) Viremia may be present in 1–2% of donors, but no clear evidence that virus causes disease. Coinfection with HIV
associated with prolonged survival. No approved screening test.
HIV Screening program has been highly successful in eliminating transfusion-associated HIV disease; high risk donors
excluded from donation; all donors tested for HIV antibody and p24 antigen. Estimated risk is 1:1,900,000 units
transfused. Most recipients of infected blood develop HIV infection.
West Nile virus Most infections mild but 1:150 infected will have severe illness with CNS involvement. Rare (146–1233:1,000,000
donations).
Bacteria 
Environmental contaminants Closed, sterile collection techniques, use of preservatives and refrigeration, and natural bactericidal action of
blood ensures extremely low risk, but improper storage or contamination with pathogens that survive refrigera-
tion may result in serious bacterial infection. 
Donor-transmitted Asymptomatic carriers of certain bacteria may transmit infection; Yersinia enterocolitica is most common
(<1:1,000,000) and is highly fatal. Other organisms (salmonella, brucella) associated with chronic carrier state
are transmitted less often. Platelet concentrates carry higher risk (1:1000–1:2000) due to high storage tempera-
ture (most common organisms are staphylococcus, klebsiella, serratia); pooled platelets have greater risk than
single-donor apheresis units. New standards to detect bacterial contamination of stored platelets should reduce
this risk.
Spirochetes
Syphilis Short viability period (96 hours) in storage and donor screening with VDRL/RPR virtually eliminates possibility of
transmission.
Lyme disease Borrelia burgdorferi viable much longer than Treponema pallidum, but the period of blood culture positivity
is associated with symptoms that preclude donation. No reported cases from transfusion.
Table 3–4. Infectious complications of transfusion therapy.
(continued )
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include a closed, sterile system of collection of blood, proper
storage and preservation of blood products, and screening.
Standards for detecting bacterial contamination of platelets
have been adopted recently by the American Association of
Blood Banks. Screening includes obtaining historical infor-
mation from potential donors to identify risk factors for
infectious diseases and performing tests to identify carriers
of known transmissible agents (see above) and those at high
risk of being carriers. Current screening practices reduce the
incidence of but do not eliminate entirely the transmission of
infectious disease by blood transfusion. Characteristics of agents
transmissible by blood include the ability to persist in blood
for a prolonged period in an asymptomatic potential donor
and stability in blood stored under refrigeration. Table 3–4
sets forth the major clinical features of transfusion-transmitted
infectious diseases.
 Nonhemolytic, Noninfectious
Complications
Nonhemolytic, noninfectious transfusion reactions account
for more than 90% of adverse effects of transfusions and
occur in approximately 7% of recipients of blood compo-
nents. Major features of these unwanted complications are
listed in Table 3–5.
Of particular importance in the critical care setting is
transfusion-related acute lung injury (TRALI), which has
emerged as the leading cause of transfusion-related death in
the United States. This syndrome occurs within 4–6 hours of
transfusion and is very similar clinically to the acute respira-
tory distress syndrome (ARDS). The pathophysiology of
TRALI is not known but is suspected to be related to donor
antineutrophil antibodies or to transfusion of substances
that activate recipient neutrophils in susceptible patients.
TRALI appears to be more common after cardiac bypass sur-
gery, during initial treatment for hematologic malignancies,
following massive transfusion in organ recipients, and in
patients receiving plasma for warfarin reversal or thrombotic
thrombocytopenic purpura. Treatment with aggressive
supportive care results in recovery in most patients within
72 hours, but the reported mortality rates of 5–25% under-
score the need for selecting patients appropriately for trans-
fusion therapy.
CURRENT CONTROVERSIES
& UNRESOLVED ISSUES
 Perioperative Transfusion
The need for transfusion in the perioperative period should
be determined by individual patient characteristics and by
the type of surgical procedure rather than by hemoglobin
level alone. Chronic mild to moderate anemia does not
increase perioperative morbidity and by itself is not an indi-
cation for preoperative red blood cell transfusion. Intraoperative
and postoperative blood loss should be managed first with
crystalloids to maintain hemodynamic stability. Red blood
cells should not be administered unless there is hemody-
namic instability or the patient is at high risk for compli-
cations of acute blood loss (eg, coronary or cerebral
vascular disease, congestive heart failure, or significant
valvular heart disease). Patients who are at high risk or are
Infection  Clinical Significance/Incidence
Parasites 
Malaria Rare complication in USA (<0.25:1,000,000 units collected) because of exclusion from donation of asymptomatic
individuals who have traveled to endemic areas within 1 year, or who have history of malaria or use of anti-
malarial prophylaxis, or who are former residents of endemic areas for 3 years. Unexplained fever 7–50 days
after transfusion should prompt consideration of posttransfusion malaria.
Chagas’ disease Trypanosoma cruzi mainly a transfusion hazard in Central and South America, but immigration to the USA
may result in increased incidence. No screening test currently available.
Babesiosis Endemic to northeastern USA. Causes mild malaria-like illness. Major risk to asplenic or immunocompromised
recipients. No screening test currently available.
Toxoplasmosis Infrequent hazard of granulocyte transfusion in immunosuppressed hosts.
Prions
Variant Creutzfeldt-Jakob disease
(vCJD, “mad cow disease”)
Two possible cases of transfusion–associated v-CJD have been reported in the United Kingdom. The FDA has rec-
ommended excluding from donation individuals who spent a significant amount of time or received blood trans-
fusions in endemic areas (United Kingdom, France, certain other parts of Northern Europe) between 1980 and
1986; or those who used bovine insulin during this time period.
Table 3–4. Infectious complications of transfusion therapy. (continued)
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Complication Clinical Manifestations, Pathogenesis, Prevention, and Treatment Strategies 
Febrile-associated transfusion
reaction (FATR)
Occurs in 0.5–3% of transfusion. Rigors or chills followed by fever during or shortly after transfusion due to prior
sensitization to WBC or platelet antigens, or to pyrogenic cytokines released during storage. Prevent with
antipyretics or leukocyte depletion of blood components.
Transfusion-related acute
lung injury (TRALI) 
Noncardiogenic pulmonary edema with fevers, chills, tachycardia, and diffuse pulmonary infiltrates shortly after
transfusion, due to leukocyte incompatibility. Resolves in 1–4 days; rarely results in respiratory failure. Occurs in
1:5000–1:1323 transfusions.
Allergic reactions Occurs in 1–3% of transfusions. Urticaria, pruritus, bronchospasm, or frank anaphylaxis due to recipient sensitiza-
tion to a cellular or plasma element. Rarely, due to allergy to medication donor is taking. If severe, evaluate
recipient for IgA deficiency (2% of population). Leukocyte depletion or washed red cells may be necessary for
subsequent transfusions.
Transfusion–associated circulatory
overload (TACO)
Common following transfusion for chronic anemia or when patient has impaired cardiovascular reserve. Prevent
by transfusing only when clearly indicated, using the minimum amount of blood required to reverse symptoms,
and carefully reassessing patient after each unit. Treat with oxygen, diuretics, and, rarely, phlebotomy (save
units for reinfusion if necessary).
Dilutional effects Transfusing with more than one blood volume or red blood cells with dilute platelets and coagulation factors.
Replacement indicated only for clinical bleeding.
Hypocalcemia Due to citrate intoxication following massive transfusion. Treat only if symptomatic.
Hyperkalemia May occur in patients with preexisting renal insufficiency and hyperkalemia or in neonates. Use of fresh blood
or washed red cells decreases potassium load for these patients.
Hypothermia After massive transfusion of refrigerated blood, hypothermia may cause cardiac arrhythmias.
Refrigerated blood may accelerate hemolysis in patients with cold agglutinin disease.
Prevent by warming blood.
Immune modulation Mechanisms and clinical significance unclear for immunosuppression that follows transfusion; enhances results
following renal transplantation; possible deleterious effect on outcome after colorectal cancer surgery; possible
increased susceptibility to bacterial infections.
Graft-versus-host disease Immunocompetent donor T lymphocyctes may engraft if the recipient is markedly immunosuppressed or if
closely HLA-related. Symptoms and signs include high fever, maculopapular erythematous rash, hepatocellular
damage, and pancytopenia 2–30 days after transfusion. Usually fatal despite treatment with immunosuppres-
sives. Prevent by irradiating all blood components with 2500 cGy for immunocompromised recipients or when
donor is first-degree relative.
Iron overload Multiple transfusions in the absence of blood loss lead to excess accumulation of body iron with cirrhosis, heart
failure, and endocrine organ failure. Prevent by decreasing total amount of red cells given, using alternatives to
red cells whenever possible, using neocytes, and modifying diet to decrease iron absorption. Iron chelation indi-
cated for patients with chronic transfusion dependence if prognosis is otherwise good.
Posttransfusion purpura Acute severe thrombocytopenia about 1 week after transfusion due to alloantibodies to donor platelet antigen
(usually P1A1). Self-limited, but treatment with steroids, high-dose IgG, plasmapheresis, or exchange transfu-
sion recommended to prevent central nervous system hemorrhage. Platelet transfusions are ineffective even
with compatible platelets. Pathogenesis poorly understood.
Miscellaneous Increased supply of complement may accelerate hemolysis in paroxysmal nocturnal hemoglobinuria or make
angioedema worse in patient with C1 esterase inhibitor deficiency. Increased blood viscosity may occur in patients
with Waldenström’s macroglobulinemia, polycythemia, or leukemia with high white blood cell count. Sudden dete-
rioration may follow platelet transfusion in patients with TTP-HUS or heparin-induced thrombocytopenia. 
Table 3–5. Noninfectious complications of transfusion.
unstable should be transfused on a unit-by-unit basis to
maintain adequate perfusion of vital organs and to stabilize
vital signs. It is reasonable to transfuse stable perioperative
patients who have hemoglobin values around 7–8 g/dL if
there are no significant risk factors for ischemia; in patients
who are elderly, unstable, or at higher risk for ischemia, a
higher threshold (eg, 10 g/dL) is probably safer.
Alternatives to homologous red blood cell transfusions in
the perioperative period include autologous red blood cells
donated in advance of elective surgery, acute normovolemic
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hemodilution, and intraoperative blood salvage. Preoperative
autologous red blood cell donations are desirable whenever
elective surgery likely to require red blood cell transfusion is
planned and the patient is medically suitable for donation.
Epoetin alfa (erythropoietin) use may enhance collection in
patients with anemia or those likely to require large amounts
of red blood cell transfusions. However, autologous donation
is not without problems. Although autologous donation may
decrease the use of allogeneic blood from an ever decreasing
donor pool, thus reserving it for emergencies, about half the
autologous blood collected is discarded, which is both waste-
ful and costly. Preoperative autologous donation may
increase the risk of ischemic events, thereby outweighing the
potential decrease in infectious risks, particularly in patients
undergoing cardiovascular bypass surgery. In addition, col-
lection of autologous blood preoperatively increases the risk
of postoperative anemia and actually may increase the need
for perioperative transfusion. Transfusion of autologous
blood is also associated with some of the same risks as allo-
geneic blood (eg, administrative errors leading to ABO mis-
match and hemolysis, bacterial contamination, volume
overload, and reactions to preservatives). Therefore, criteria
for transfusion of autologous units should be the same as
those for transfusion of homologous red blood cells to avoid
these unnecessary potential complications.
Acute normovolemic hemodilution may be suitable for
patients undergoing surgical procedures with a significant
risk of intraoperative bleeding (>20% of blood volume) who
have baseline hemoglobin levels greater than 10 g/dL and
who do not have severe ischemic heart disease or critical aor-
tic stenosis. Phlebotomy with volume replacement by crys-
talloid is performed immediately after anesthetic induction.
Blood lost intraoperatively results in loss of fewer red blood
cells because of the lowered hematocrit, and subsequent
reinfusion of the phlebotomized blood can restore oxygen-
carrying capacity, if necessary. Perioperative allogeneic trans-
fusion requirements following acute normovolemic
hemodilution or preoperative autologous donation appear
to be about the same when compared directly in certain
types of surgery, but there are some advantages favoring
hemodilution. It is less costly because no testing is performed
on the blood, the risks of bacterial contamination related to
storage or ABO mismatch owing to administrative error are
reduced because the blood never leaves the operating room,
and surgery does not have to be delayed to allow time for
autologous donation.
Intraoperative blood salvage may be indicated for
patients undergoing procedures with substantial blood loss
or when transfusion is impossible (eg, patients who refuse
blood transfusions and patients with rare blood groups or
multiple red blood cell alloantibodies). Reinfusion of blood
salvaged from the surgical field can reduce the requirement
for standard homologous and autologous blood transfu-
sions. Relative contraindications include the presence of
infection, amniotic fluid or ascites in the operative field,
malignancy, or the use of topical hemostatic agents in the
field from which blood is salvaged. It has not been demon-
strated, however, that use of salvaged blood decreases the
need for allogeneic transfusion, and it may be expensive if
automated cell-washing devices are used. The main value of
intraoperative salvage is that blood is immediately available
if rapid blood loss occurs.
Postoperative salvage from chest or pericardial tubes or
from drains also may provide blood for autologous transfu-
sion if persistent bleeding occurs. However, because the
fluid collected is dilute (therefore providing a small volume
of red blood cells for reinfusion), depleted of coagulation
factors, and may contain cytokines, it is not clear how effec-
tive or safe reinfusion of recovered fluid is. Clinical trials
have yielded conflicting results about the benefits of this
procedure.
 Directed Donations
Transfusions from ABO- and Rh-compatible family mem-
bers or friends are frequently requested because of concerns
about the safety of homologous transfusion. There is no evi-
dence that directed donations are safer than volunteer dona-
tions, however, and some evidence exists that they may be
less safe because blood from directed donors has a higher
prevalence of serologic markers of infections than blood
from volunteer donors. The patient and potential directed
donors should be informed of the increased risk of transmis-
sion of infectious disease when directed donations are used.
If the patient accepts this risk, potential donors should be
given every opportunity to inform the blood bank of any
conditions that would preclude use of their blood. Directed
donations are not available immediately for transfusion
because laboratory screening procedures are the same as for
volunteer donor blood and require about 72 hours to com-
plete. Blood donated from first-degree relatives should be
irradiated prior to transfusion to prevent graft-versus-host
disease, which can occur when the donor and recipient are
closely HLA-matched.
 Increasing Blood Product Safety
Several strategies have been proposed and implemented to
further decrease the risk of transfusion-related infections.
Solvent/detergent-treated pooled plasma is now available
commercially for treatment of coagulopathies and thrombotic
thrombocytopenic purpura. Viruses with lipid envelopes are
inactivated; however, there is concern that use of these prod-
ucts will result in transmission of viruses that do not have
lipid envelopes. Plasma can be frozen and stored for a year,
allowing for retesting beyond the window period between
infection and serologic conversion of plasma donors prior to
releasing the units for transfusion. Inactivation of viruses by
exposure to psoralen and ultraviolet A irradiation (PUVA)
can reduce the levels of HIV and hepatitis viruses, inactivate
bacteria, and eliminate the problem of immunomodulation  
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owing to transfused lymphocytes. However, any toxicity
from exposure of blood products to psoralen derivatives
must be determined before this approach can be recom-
mended. In addition, viability of platelets may be affected by
PUVA.
Exposure of blood products to gamma irradiation
(2500 cGy) results in inactivation of donor leukocytes, ren-
dering them incapable of participation in the immune
response. Graft-versus-host disease, a rare complication of
blood transfusion that can occur in immunocompromised
hosts or when the donor and recipient are closely related, can
be prevented by irradiation of cellular blood components
prior to transfusion. Alloimmunization, which can lead to
poor response to subsequent platelet transfusions, also can
be prevented with irradiation.
 Patients Who Refuse Blood Transfusion
Even after extensive counseling regarding the risks and ben-
efits of transfusion, some patients refuse some or all blood
products even under life-threatening circumstances. Courts
have affirmed the right of individuals to refuse medical care
in part (eg, transfusions) without relinquishing the right to
receive other care. This is true also for surrogate decision
makers for adults who are not competent to make their own
medical decisions. In such situations, it is important to deter-
mine how adamant the patient is in refusing to accept blood
products and to have the patient affirm that refusal in writ-
ing, if possible, even if death is imminent. Patients who have
previously refused blood products should not be transfused
if subsequently unable to give consent (eg, under general
anesthesia). In an emergency, courts generally have granted
permission to physicians to transfuse a patient over a family
member’s objections if no prior refusal by the patient has
been documented and the patient is incompetent to give
consent. It is preferable to avoid transfusions, however, rather
than to obtain court permission to transfuse against a
patient’s or the family’s wishes. Every effort should be made
to treat existing anemia or acute blood loss with alternative
therapy—volume expansion, erythropoietin (epoetin alfa),
and (hematinics, iron, vitamins)—whenever possible.
Careful surgical technique, meticulous hemostasis, and
reliance on aggressive volume support have eliminated the
need for transfusion during many major surgical procedures
in patients who refuse blood transfusion therapy.
 Epoetin Alfa (Erythropoietin)
Recombinant human erythropoietin is available as epoetin
alfa for the treatment of anemia owing to renal disease, for
AIDS patients on zidovudine therapy with transfusion-
dependent anemia, and for anemia associated with cancer or
cancer chemotherapy. It also may be useful in the treatment
of the anemia of chronic disease. Erythropoietin may be
useful to augment autologous donations of red blood cells
preoperatively even in the absence of anemia and may
decrease the need for transfusion perioperatively when
autologous blood is not collected. Because the cost of the
drug is substantial, patient selection and modification of
dosage will improve cost-effectiveness of this therapy. Those
who will benefit most from preoperative erythropoietin
treatment have baseline hematocrits between 33% and 39%,
with expected blood loss of 1000–3000 mL. If more blood
loss is anticipated, autologous donation in addition to ery-
thropoietin may be needed to prevent preoperative poly-
cythemia. Erythropoietin therapy also may improve the
efficacy of acute normovolemic hemodilution.
Data on whether erythropoietin reduces the need for red
blood cell transfusion and decreases the total amount of
blood transfused in critically ill patients with anemia are
inconclusive. Its use does not appear to reduce mortality or
other serious events. Treatment with erythropoietin is asso-
ciated with an increase in thromboembolic events in ICU
patients, even among those who are not considered high risk
(eg, renal failure, prior thromboembolic disease), and in
those who reach excessively high hemoglobin concentrations
(>12 g/dL).
 Massive Transfusion
Administration of a volume of blood and blood components
equal to or exceeding the patient’s estimated blood volume
within a 24-hour period is accompanied by complications
not often seen during transfusion of smaller volumes.
Deficiencies of platelets and clotting factors may occur,
especially if extensive tissue injury or DIC is present.
However, prophylactic replacement with platelets or plasma
results in unnecessary transfusions for many patients. It is
preferable to base the decision to replace platelets and clot-
ting factors on clinical criteria such as a generalized bleeding
diathesis and laboratory abnormalities (platelet count and
clotting times).
Clinically significant citrate (anticoagulant) intoxication
is rare even with massive transfusions. Prophylactic calcium
administration is not indicated, with the possible exception
of patients with severe hepatic dysfunction or heart failure in
whom citrate metabolism may be impaired. Hyperkalemia
occurs rarely following even massive blood transfusion. In
fact, hypokalemia occurs more frequently as a result of meta-
bolic alkalosis, which occurs as citrate is metabolized to
bicarbonate. Interventions should be based on serum potas-
sium levels. Although banked blood is acidic, massive transfu-
sion does not complicate the lactic acidosis present in a patient
with severe blood loss because improved tissue oxygenation
results in metabolism of lactate and citrate to bicarbonate.
Therefore, prophylactic administration of sodium bicarbon-
ate is inadvisable in the massively transfused patient. The
clinical significance of the low 2,3-DPG found in stored red
blood cells appears to be minor because many other factors
determine tissue oxygenation, including pH, tissue perfu-
sion, hemoglobin concentration, and temperature. There
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appears to be no advantage in transfusing fresh red blood
cells over stored cells.
Hypothermia may result from massive transfusion of
refrigerated blood and may impair cardiac function.
Warming of blood prior to transfusion is recommended to
prevent this complication. Microembolization of particulate
debris in stored blood probably does not have any clinical
significance. The use of microaggregate filters rather than
standard blood filters has not been proven to be beneficial.
A significant potential hazard of massive transfusion is
unrecognized acute hemolytic transfusion reaction. Many of
the clinical signs and symptoms observed in the acutely
bleeding patient are identical to those of an acute hemolytic
event. Most fatal hemolytic transfusion reactions occur in
emergency settings both because of the difficulty in recog-
nizing such reactions and because of the higher potential for
human error in emergency situations. Strict attention to
details of specimen labeling and patient identification and
recognition of signs such as hemoglobinuria, fever, and gen-
eralized oozing from DIC can minimize the risks and com-
plications of such reactions.
Emerging Technologies
Several biotechnology products are under development as
potential alternatives to blood products. Blood substitutes
(eg, cell-free hemoglobin solutions and perfluorocarbon
emulsions) may serve as alternative oxygen carriers in
patients undergoing surgery, following massive trauma, or
for patients who refuse blood products. New erythropoiesis
stimulants may offer more rapid correction of anemia.
Recombinant coagulation factors can reduce exposure of
patients with severe clotting disorders or inhibitors to infec-
tious agents. Synthesis of important molecules in blood
eventually may offer specific therapy for disorders currently
treated with blood products (eg, the metalloprotease impli-
cated in the pathogenesis of thrombotic thrombocytopenic
purpura could offer targeted therapy in place of the massive
plasma infusion that is currently the mainstay of treatment).
Embryonic stem cells have the capacity to produce all blood
cells and eventually may lead to a new source of cells for
blood transfusion. All these biotechnologic approaches hold
the promise of decreasing our dependence on blood prod-
ucts, therefore conserving this resource and decreasing seri-
ous complications associated transfusion, but considerations
of cost and safety must be balanced against their potential
benefits.
 Pretransplant Transfusion Therapy
Use of HLA-related blood donors may induce immune toler-
ance to donor antigens following organ transplant, therefore
improving allograft survival. However, better methods of
immunosuppression have decreased the clinical importance
of pretransplant blood transfusion. In contrast, blood trans-
fusion prior to bone marrow transplantation—particularly
in patients with aplastic anemia—appears to decrease its suc-
cess, especially if HLA-related donors are the source of
blood.
 Use of Non-Cross-Matched Blood
in Emergency Situations
In the absence of unusual antibodies, complete cross-
matching takes approximately 30–60 minutes. In most cases
of acute hemorrhage, initial management with crystalloid is
sufficient to maintain perfusion and hemodynamic stabil-
ity. Occasionally, a delay in red blood cell transfusion poses
a substantial risk to the patient, as in sudden massive blood
loss or less massive blood loss occurring in a patient with
myocardial or cerebral ischemia. In these circumstances,
transfusion with non-cross-matched type O, Rh-negative
blood or ABO-compatible blood tested with an abbreviated
cross-match (5–20 minutes) may be necessary. Since Rh-
negative blood is often in short supply, Rh-positive blood
may be given to women beyond childbearing years or to
males if emergent transfusion is required. If the recipient’s
blood type is known, unmatched blood of the same group
may be used. Patients with group AB blood may receive
either group A or group B cells. Type-specific plasma is pre-
ferred when plasma transfusion is necessary because natu-
rally occurring anti-A or anti-B antibodies (or both) are
present in plasma from all donors except those with type
AB red cells, independent of prior sensitization. When
type-specific plasma is not available, patients with type O
blood can receive plasma of any type, but patients with
types A and B can receive plasma only from AB donors.
Patients with type AB blood can receive type-specific
plasma only.
The disadvantages of using non-cross-matched blood
include the possible transfusion of incompatible blood
owing to clinically significant antibodies to blood groups
other than ABO, transfusion of anti-A and anti-B antibodies
from plasma accompanying type O, Rh-negative red blood
cells, and depletion of the supply of group O blood.
Whenever possible, transfusion of cross-matched, type-
specific blood should be used. ABO group–specific partially
cross-matched blood is preferred over type O blood to avoid
transfusion of ABO-incompatible plasma. Non-cross-
matched type O blood should be reserved for truly extreme
emergencies. A blood sample from the patient always should
be obtained prior to any transfusion for complete cross-
matching for subsequent transfusions and to aid in the eval-
uation of transfusion reactions.
 Conservation of Blood Resources
Conserving blood resources is one of the goals of the
National Blood Resource Education Program of the National
Institutes of Health. Recently, several controlled clinical trials
examining the impact of transfusion on outcomes in a wide-
variety of clinical settings have been performed. These trials
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serve to promote rational use of blood products for the ben-
efit of patients as well as protecting the limited supply of
blood from waste. These trials have clearly influenced trans-
fusion practices in well-defined clinical situations. There are
many situations, however, where no empirical data exist, and
the clinician must determine the benefits of transfusion on
an individualized basis. Massive repeated transfusion in
patients with uncorrectable vascular defects or who are ter-
minally ill—and platelet and plasma transfusions for
patients without demonstrated response to such
transfusions—may deplete the blood supply without sub-
stantially improving the outcome for those patients.
The medical team caring for a patient with massive
uncontrollable bleeding or a terminal illness should make
every effort to discuss the limits of care with the patient and
family members, to establish long-term treatment goals and
expectations, and to decide when continued blood transfu-
sion is no longer of benefit to the patient. In addition, family
members should be strongly encouraged to donate blood to
help replace some of the units used. Ineffective therapy
should not be given prophylactically (eg, daily platelet trans-
fusions in patients with consumptive thrombocytopenia
without bleeding or plasma therapy in patients with multiple
severe coagulation deficiencies not corrected with large doses
of plasma).
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Critically ill patients are almost always given many different
drugs. For example, patients may require broad-spectrum
antibiotics, vasopressor agents, and antiarrhythmics. At the
same time, clinicians often must give sedatives and muscle
relaxants to patients in order to tolerate mechanical ventila-
tion, and there is strong evidence that ICU outcome is
improved by empirical prophylaxis for GI bleeding with pro-
ton pump inhibitors or other antacids and prophylaxis for
deep venous thrombosis with heparin.
One estimate is that ICU patients receive twice as many
different drugs as other hospitalized patients. It is no wonder,
therefore, that medication errors, a major focus of hospital
safety improvement, are increased in ICU patients. In fact, an
error in preparation, dosage, or rate of infusion has been
found in as many as 10% of intravenous medications.
Furthermore, complex changes in pharmacokinetics and
pharmacodynamics are seen frequently in these patients,
necessitating consideration of dosage, interaction, and organ
function.
Pharmacokinetics is the movement of a drug through the
body over time and is defined by the following: absorption,
distribution, metabolism, and elimination—basically, how
the patient affects a drug. Pharmacodynamics is the relation-
ship between drug concentration and drug effect—or how a
drug affects the patient. Both pharmacokinetic and pharma-
codynamic changes compared with baseline occur in critical
illness and the management of patients in the ICU.
PHARMACOKINETIC PARAMETERS
The most important pharmacokinetic parameters are clear-
ance and volume of distribution. The disposition of a drug,
once it has entered the body, depends on both clearance (CL)
and the volume of distribution (Vd). Clearance is propor-
tional to the rate at which a drug is eliminated from the body.
Volume of distribution is a theoretical volume that relates
the concentration in the plasma to the total amount of drug
in the body. The elimination half-life (t1/2) depends on the
preceding independent variables and is described by the fol-
lowing mathematical relationship:
t1/2 = (0.693 × Vd/CL)
Hence either decreased clearance or an expanded volume
of distribution will result in an increased pharmacologic
half-life. A practical understanding of this mathematical
relationship is essential for developing optimal dosing regi-
mens in the critically ill patient.
PHARMACOKINETIC CONSIDERATIONS
 Absorption
Drug absorption is influenced by a variety of factors, includ-
ing the site of absorption, the amount metabolized before
reaching the systemic circulation (“first-pass” effect for orally
administered drugs), and drug interactions. In critical illness,
the site of absorption is of utmost importance. The extent of
oral absorption—bioavailability—may be diminished as a
result of low cardiac output or shunting of blood from the
mesentery to the peripheral circulation. In patients who are in
the ICU for a longer duration, intestinal atrophy and motility
dysfunction may play a role. While highly encouraged in suitable
patients, enteral nutritional support may cause inadvertent mal-
absorption of some orally administered medications. Therefore,
therapeutic “failures” may be due to inadequate bioavailability
rather than absence of effect at the intended receptor site.Acutely
ill patients may have decreased perfusion of sites of parenteral
administration of drugs. These patients may have poor or unreli-
able absorption of subcutaneously or intramuscularly adminis-
tered medications. In general, the intravenous route is preferred
for critical medications, and oral, subcutaneous, or intramuscu-
lar administration should be avoided.
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 Distribution
The distribution of drugs in the body depends on factors such
as blood flow, body composition, and plasma protein binding
(Table 4–1). For a single-compartment model, initial plasma
concentration (before elimination) equals the dose of drug
given divided by the apparent volume of distribution. In nor-
mal subjects, the volume of distribution of a drug is generally
well described and usually is related to some measure of
patient size (eg, total body water for a water-soluble drug and
extravascular volume for a large molecule). However, volume
of distribution is strongly influenced by drug lipid solubility,
protein binding, and intra- versus extracellular partitioning.
In critical illness, fluid overload can increase a patient’s
volume of distribution significantly, and insufficiently
effective drug concentrations may result. For drugs with
extensive tissue distribution (eg, digoxin), the volume of
distribution is approximately 500 L, or several times actual
body weight. Thus it is unlikely that changes in fluid status
can affect the distribution of digoxin significantly. For
drugs apparently distributed largely into extracellular
water, however, drug concentrations can be affected. It is
not uncommon for a critically ill patient to gain several
kilograms of extracellular water (ECW). Because this space
is roughly 20% of body weight, or about 12 L in a 60 kg
adult, gaining even 2 L of ECW would reduce expected con-
centration of such a drug by 15–20%. A drug such as gen-
tamicin exhibits concentration-dependent killing of
bacteria. A peak level of 25 μg/kg (dose = 5–7 mg/kg, nor-
mal Vd = 0.25 L/kg) is expected. However, Vd in critically ill
patients may be as high as 0.6 L/kg, resulting in a much
lower than expected serum level.
Body composition and the lipophilicity of a given drug
are also important factors to consider. In general, lipophilic
agents such as diazepam readily distribute into fat. For these
agents, dosing should be based on total body weight. Since
most agents used in the ICU setting are not lipophilic, such
as pressors and most antimicrobials, it may be more accu-
rate to use ideal body weight in dosing calculations.
However, an increasingly important question is how to
adjust medication dosages for obese patients because the
volume of distribution likely will change. Considerations
include unexpected changes in the proportion of adipose
tissue compared with total body weight, thereby changing
estimates of total body and extracellular water, and some-
times the difficulty in obtaining accurate scaled weights.
Analgesics, including opiates, and sedatives should be
titrated to desired clinical effect in the absence of studies of
weight-adjusted dosing. Antibiotic dosing should be guided
by therapeutic drug monitoring when possible, adjusting for
both desired antimicrobial effect and toxicity. Low-
molecular-weight heparin is a special situation because the
effect when dosed as milligrams per kilogram is no longer
predictable in the obese patient; in this case, measurement
of factor Xa activity may be useful.
Protein binding is another important determinant of dis-
tribution. Only the unbound fraction of a drug can diffuse or
be transported into tissues. Thus the influence of protein
binding is a limiting factor in drug distribution for highly
bound drugs (see Table 4–1). Serum pH, often abnormal in
critically ill patients, also may affect the degree of protein
binding of drugs. Phenytoin is a highly protein-bound drug
(~90%). The remaining 10% circulates as unbound or “free”
drug and is the fraction responsible for the pharmacologic
effect. If a patient with normal albumin has a phenytoin level
of 12 mg/L, the free fraction would be approximately 1.2 mg/L.
However, with decreased serum albumin, as is found in
patients with CNS trauma or those with end-stage liver dis-
ease, less serum protein is available to bind phenytoin. The
laboratory reports total phenytoin concentrations, which
includes bound and unbound drug. In a patient with hypoal-
buminemia, the total phenytoin level will be unchanged, but
the percentage of “free” drug (ie, pharmacologically avail-
able) will increase. For example, a patient with a serum albu-
min of 2 g/dL and a measured phenytoin plasma concentration
(Cmeas) of 12 mg/L has more free drug, resulting in an adjusted
phenytoin plasma concentration (Cadj) of 24 mg/L.
Drug Protein-Bound 
Amphotericin B 90–95% 
Ceftriaxone 93–96% 
Chlordiazepoxide 94–97% 
Clindamycin 93% 
Diazepam 84–98% 
Erythromycin 96% 
Ethacrynic acid 95% 
Furosemide 91–99% 
Haloperidol 90–92% 
Heparin >90% 
Hydralazine 90%  
Lorazepam 90% 
Midazolam 94–97% 
Nafcillin 70–90% 
Nifedipine 89–92% 
Oxacillin 89–94% 
Phenytoin 90% 
Prochlorperazine 90% 
Rifampin 84–91% 
Vecuronium 60–90% 
Verapamil 90% 
Table 4–1. Protein binding. 
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The uremia accompanying renal failure also displaces
phenytoin from its binding sites because endogenous com-
petitors for binding accumulate. It is important to recognize
that malnourished patients and those with renal failure
will have a lower than normal “therapeutic range” for
phenytoin. For this reason, it is clinically more relevant to
monitor free phenytoin concentrations or to use these values
in calculation of dosage adjustments.
 Drug Clearance (Elimination)
With limited exceptions, most pharmacologic agents are
eliminated either renally or hepatically, but drug clearance is
considered the effect of all pathways of elimination taken
together. Since multiorgan dysfunction is commonly
encountered in critically ill patients, drug accumulation and
toxicity are of concern. Specific dosage adjustment is often
required in the setting of renal or hepatic impairment. Some
of the most frequently used agents with predominantly renal
elimination are listed in Table 4–2. Most antimicrobials,
including aminoglycosides, vancomycin, beta-lactams, and
fluoroquinolones, are eliminated primarily via the kidneys.
Although some dosage adjustment is needed when these
antimicrobials are used in critically ill patients with renal
failure, studies have found both under- and overdosing of
antimicrobial agents because of renal function considera-
tions. Importantly, the initial concentration of an antimicro-
bial drug is related to its dose and volume of distribution, not
its elimination. Therefore, the “first dose” of an antimicrobial
need not be adjusted for renal failure, only subsequent doses.
Failure to recognize this concept leads to a delay in achieving
desired therapeutic levels.
Other drugs with primarily renal elimination used in the
critical care setting are the low-molecular-weight heparins.
Currently, dosage of enoxaparin is reduced 25–50% for
patients with a creatinine clearance of less than 30 mL/min,
but not for mild or moderate renal insufficiency. Some prac-
titioners advocate monitoring factor Xa activity for these
patients. Some drugs have mixed routes of elimination and
require adjustment for both renal and hepatic function for
proper dosing.
Renal Dysfunction
Medications used in the ICU are often eliminated by the kid-
neys, and dosages are adjusted in the face of renal insuffi-
ciency. Common causes of renal insufficiency in the ICU
include chronic kidney disease, acute renal failure from
shock or hypoperfusion, exposure to nephrotoxic drugs, and
obstructive uropathy.
Several studies have demonstrated that dosing of renally
excreted drugs (cleared by glomerular filtration) is
improved when creatinine clearance rather than serum cre-
atinine concentration alone is used to estimate renal func-
tion. This is especially true in the elderly and those who are
underweight, in whom a “normal” serum creatinine concen-
tration (0.8–1 mg/dL) may be associated with significantly
reduced renal function. Less commonly, patients with rhab-
domyolysis produce more than the expected amount of cre-
atinine; in these patients, elevated serum creatinine may not
indicate decreased glomerular filtration rate (GFR). Rarely,
some medications interfere with creatinine secretion, fur-
ther dissociating the relationship between serum creatinine
and GFR.
When the serum creatinine level is known, an estimate of
creatinine clearance can be obtained to assist with dosage
adjustment using the Cockroft-Gault equation:
(For females, multiply the numerator by a factor of 0.85.)
Although this equation and several others are used fre-
quently in ICU patients and generally are better estimates
than serum creatinine alone, some studies demonstrate that
they are far from perfect. In fact, even short-term collections
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Table 4–2. Drugs with primarily renal elimination.
Antimicrobials  
Acyclovir Ciprofloxacin Meropenem 
Amikacin Fluconazole Penicillin G  
Ampicillin Flucytosine Piperacillin  
Cefazolin Ganciclovir Ticarcillin-clavulanate 
Cefepime Gatifloxacin  Tobramycin 
Cefotetan Gentamicin Trimethoprim-sulfamethoxazole
Cefoxitin Imipenem-cilastatin Vancomycin
Ceftazidime Levofloxacin
Ceftizoxime
Antihypertensives  
Diazoxide  
Methyldopa  
Nitroprusside  
Antiarrhythmic agents  
Bretylium  
Digoxin  
Procainamide  
Miscellaneous drugs 
Ranitidine  
Pancuronium 
of urine for calculation of creatinine clearance are less accu-
rate than 12- or 24-hour collections, probably because of
variability in GFR over time.
For patients requiring hemodialysis, it is essential to
know the extent to which drugs can be removed by dialysis.
Knowledge of pharmaceutical properties such as
hydrophilicity, molecular weight, plasma protein binding,
and volume of distribution (Table 4–3) can help to distin-
guish agents that are dialyzable. Low-molecular-weight,
water-soluble drugs with low protein binding are highly
dialyzable. If they have a small volume of distribution, then
an appreciable amount of the drug can be eliminated by
dialysis. Conversely, drugs with extensive tissue distribution
such as digoxin or the calcium channel blockers and highly
lipophilic drugs are not affected by dialysis. Other impor-
tant considerations for drug clearance include the duration
and type of dialysis. Short dialysis sessions are less likely to
remove significant amounts of drug. New forms of dialysis
are more efficient and remove drugs previously thought
to be minimally dialyzable. Hemodialysis with high-flux
filters removes significant amounts of vancomycin, previ-
ously considered not to require replacement for drug lost to
dialysis. Continuous renal replacement therapy is a much
more efficient process than conventional hemodialysis
and equates to a clearance of approximately 30 mL/min for
creatinine, but not clearly comparable for other drugs. It
is essential to review the medication regimen closely
when patients are dialyzed with high-flux filters or are
switched from hemodialysis to continuous renal replace-
ment because the dosages of some drugs will have to be
increased.
Hepatic Dysfunction 
Liver failure is a common problem in the ICU and may be
due to chronic liver disease (eg, cirrhosis or hemochromato-
sis) or acute liver disease (eg, acute hepatitis, drug-induced
hepatitis, alcohol, or toxins). Some drugs require dosage
adjustment in hepatic insufficiency (Table 4–4). However,
most commonly used tests of “liver function” describe the
degree of liver damage and not the liver’s capacity for drug
elimination. Determining the degree of hepatic dysfunction
is difficult because no quantitative equations exist.
Laboratory tests of hepatic synthetic function (eg, prothrom-
bin time, serum albumin, and conjugated bilirubin) are most
predictive of drug elimination. For drugs metabolized by the
liver, the route of metabolism is important in determining
the effects of liver disease on drug clearance. Some enzyme
systems are remarkably well preserved even in end-stage liver
disease. Drugs such as lorazepam that are metabolized pri-
marily by conjugation with glucuronic acid are minimally
affected in cirrhosis, so little dosage adjustment is required.
For drugs whose clearance depends on oxidative metabolism
(eg, metronidazole, theophylline, opioids, and sedative-
hypnotics), cirrhosis reduces their elimination. Generally
speaking, acute liver disease (eg, hepatitis) does not alter
drug clearance significantly.
Congestive heart failure may cause hepatic congestion
and decreased hepatic blood flow and decrease hepatic elim-
ination of drugs. The hepatic clearance of theophylline, for
example, is markedly reduced in patients with congestive
heart failure (CHF). Patients with chronic liver disease fre-
quently have hypoalbuminemia, thereby reducing the
amount of drug protein binding. For such highly protein-
bound drugs as phenytoin, the proportion of free unbound
drug rises with hypoalbuminemia.
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Table 4–3. Drugs significantly removed by hemodialysis.
Antimicrobials 
Aminoglycosides Ceftizoxime Meropenem  
Ampicillin Chloramphenicol Metronidazole  
Cefazolin Ciprofloxacin Penicillin G  
Cefepime Gatifloxacin Piperacillin  
Cefotaxime Imipenem-cilastatin Quinupristin- 
Cefotetan Levofloxacin dalfopristin  
Cefoxitin Linezolid Trimethoprim-
Ceftazidime sulfamethoxazole 
Antihypertensives 
Diazoxide  
Methyldopa  
Nitroprusside  
Antiarrhythmic agents  
Bretylium  
Digoxin  
Procainamide 
Miscellaneous drugs 
Ranitidine  
Pancuronium 
Table 4–4. Drugs requiring dosage adjustment in severe
hepatic insufficiency.
Analgesics Antimicrobials  
Acetaminophen Cefoperazone  
Opioids Ceftriaxone  
Salicylates Chloramphenicol 
Antiarrhythmics Clindamycin  
Lidocaine Erythromycin 
Quinidine Isoniazid  
Verapamil Metronidazole
Anticonvulsants Nafcillin 
Phenobarbital Rifampin  
Phenytoin Sedative-hypnotics  
Antihypertensives Chlordiazepoxide  
Hydralazine Diazepam  
Labetalol Midazolam 
Nitroprusside Miscellaneous 
Haloperidol 
Theophylline  
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 Therapeutic Drug Monitoring
Agents with a narrow therapeutic index have only a small dif-
ference between serum drug concentrations that produce
therapeutic and toxic effects, and monitoring of serum drug
concentrations is recommended (Table 4–5). Examples of
agents with low therapeutic indices are the aminoglycosides,
digoxin, theophylline, and phenytoin.
In many ICUs, routine blood samples are collected at a set
time. For therapeutic drug monitoring, this may not be
acceptable because the time the sample is drawn must be
related to the time since the last dose of the drug was given.
First, for some drugs, an estimate of peak concentration is
desired. This level should be obtained after distribution of the
dose into the volume of distribution is achieved. For example,
digoxin levels should be drawn about 4–6 hours after admin-
istration in order to distribute into its very large Vd. If peak
aminoglycoside or vancomycin levels are sought, these are
usually reached at 30 minutes to 1 hour after administration.
Second, sometimes the “trough,” or lowest, value before
administration of the next dose is wanted. Obviously, the
sample is drawn just prior to administration. Finally, for
many drugs, dosing is predicted by formulas or nomograms
that use serum levels at designated times (eg, aminoglycosides
and vancomycin), such as 4–10 hours after dosing. Drug dis-
tribution is also of concern following dialysis. It is important
to allow at least 3 hours to elapse after dialysis to obtain drug
levels to allow for redistribution of drug from other tissues
into the main compartment (eg, intravascular space). This
is illustrated also in the case of hemodialysis for a toxic
ingestion of lithium. A lithium level of 10 meq/L (therapeutic
level is 0.5–2 meq/L) obtained before dialysis may decrease to
1 meq/L immediately after hemodialysis. However, a third
level obtained 3–4 hours after dialysis may rebound to a toxic
level of 5 meq/L, showing evidence of redistribution from the
CNS back into the main compartment. This indicates the
need for longer or more frequent hemodialysis.
Phenytoin serum levels are often used to adjust dosing.
Phenytoin is eliminated by first-order kinetics at low serum
levels, but elimination is saturable at higher levels, even
within the therapeutic range. Therefore, at these levels, small
increases in dosing may result in unexpectedly high levels.
Ethanol is eliminated by alcohol dehydrogenase and obeys
zero-order kinetics; thus a constant fall in serum level with
time is expected, usually 30-40 mg/dL per hour.
 Drug Interactions
Given the number of drugs prescribed for critically ill
patients, the potential for drug interactions is high. Drug
interactions may occur as a result of pharmacodynamic, phar-
maceutical, or pharmacokinetic effects. Pharmacodynamic
interactions result from the drugs actions and may enhance or
antagonize a drug’s effects. Pharmaceutical interactions can
result from a number of causes, one of which is the relationship
between two drugs. The most striking interactions are phar-
macokinetic, which occur when one drug affects the absorp-
tion, distribution, or clearance of another.
Pharmacodynamic Interactions 
Pharmacodynamic drug interactions can result in synergis-
tic, additive, or antagonistic pharmacologic effects. A benefi-
cial additive effect would be observed in a patient with
poorly controlled hypertension who receives a second anti-
hypertensive agent from a different class and then achieves
optimal blood pressure control. Synergistic combinations are
noted when the resulting pharmacologic effect with combi-
nation therapy is greater than the expected sum of drug
effects. This phenomenon occurs infrequently and is best
described for antimicrobial combinations. A beta-lactam
antimicrobial (eg, piperacillin or ceftazidime) in combina-
tion with an aminoglycoside may be more effective than a
beta-lactam alone and results in a lower incidence of
acquired bacterial resistance in the treatment of infections
with aerobic gram-negative organisms. On the other hand,
antagonism may be encountered when beta-blockers reverse
the pharmacologic benefit of beta-agonists in patients with
chronic obstructive pulmonary disease (COPD). While some
beta-blockers such as atenolol are more cardioselective at
lower doses, they still have the potential to antagonize bron-
chodilators such as albuterol and salmeterol. The concomitant
use of antimicrobials from the same class also carries the
potential for antagonism. For example, some beta-lactams
induce production of beta-lactamase. The combination of a
strongly inducing beta-lactam with a labile compound
Drug Therapeutic Range
Amikacin Peak: 25–35 mg/L
Trough: <10 mg/L
Amiodarone 0.8–2.8 mg/L 
Gentamicin, tobramycin Peak: 8–12 mg/L 
Trough: <1 mg/L
Digoxin 1–2 μg/L 
Lidocaine 1–5 mg/L
Phenobarbital 10–30 mg/L 
Phenytoin 10–20 mg/L
Procainamide 4–8 mg/L
N-Acetylprocainamide <30 mg/L 
Salicylates 100–300 mg/L 
Theophylline (in COPD) 8–10 mg/L 
Vancomycin Trough: 5–15 mg/L 
Table 4–5. Therapeutic ranges for drugs commonly used
in critical care.
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(eg, piperacillin) for the treatment of infections owing to
Enterobacter species has been shown to produce antagonism
in vitro and in animal models of infection. Hence double
beta-lactam combinations that include a strong inducer
should be avoided.
Pharmaceutical Interactions
Pharmaceutical interactions may be caused by drug incompat-
ibilities or drug adsorption to catheters and to intravenous
administration materials. For example, intravenous adminis-
tration of nitroglycerin requires special equipment to decrease
the likelihood of adsorption. The complexity of drug regimens
in the critically ill patient coupled with limited intravenous
access makes intravenous drug compatibility a significant
issue. Although a great deal is known about the compatibility
of drug combinations, there are still many potential combina-
tions for which no such information is available.
Pharmacokinetic Interactions
Although pharmacokinetic interactions occur as a result of
alterations in drug absorption, distribution, metabolism, or
elimination, the effects on drug metabolism are the most
clinically significant. A commonly seen absorption interac-
tion occurs when fluoroquinolones are administered con-
comitantly with antacids, causing decreased quinolone
bioavailability. Similarly, enteral feeding should be withheld
2 hours before and after the administration of oral phenytoin
formulations because of the decreased and delayed absorp-
tion of phenytoin that occurs.
Drug interactions owing to altered distribution also may
occur. When two drugs compete for binding sites on plasma
proteins or tissues, the unbound or free serum concentration
of one or both drugs may increase. Although this theoreti-
cally may increase a drug’s effect, the enhanced pharmaco-
logic effect is usually transient because more unbound drug
is now available for elimination by the liver and kidney. Thus
the clinical significance of protein-binding displacement
interactions is minimal unless there is concomitant hepatic
or renal disease. However, warfarin and phenytoin may be
transiently displaced by a number of drugs.
Pharmacokinetic drug interactions are frequently due to
altered metabolism involving the cytochrome P450 (CYP)
enzyme system, which is largely responsible for oxidative
metabolism of drugs by the liver. These enzymes are a super-
family of microsomal drug-metabolizing enzymes that
degrade endogenous substances, chemicals, toxins, and med-
ications. The primary ones responsible for drug metabolism
are CYP3A4, CYP2D6, CYP1A2, and CYP2C. Examples of
commonly used drugs that are inducers and inhibitors of
CYP are shown in Table 4–6. The most potent drugs likely to
be encountered are phenobarbital, phenytoin, and rifampin,
with subsequently more rapid metabolism and lower serum
levels for cimetidine, phenytoin, theophylline, warfarin, cor-
ticosteroids, and quinidine. Cigarette smoking and chronic
ethanol use also increase CYP activity. This explains why
alcoholics may require surprisingly high doses of sedatives
(eg, diazepam and midazolam) or analgesics. CYP induction
does not occur immediately, but usually takes at least several
days. Therefore, effects of CYP may be immediate (eg, in a
Drug Affected CYP Inducer/Inhibitor Effect
Benzodiazepines (alprazolam) Inhibitor
Azole antifungal (fluconazole, itracona
zole, ketoconazole)
Increased benzodiazepine concentration
Cyclosporine Inducer
Rifampin, rifabutin, phenobarbital,
phenytoin
Inhibitor
Erythromycin, azole antifungal
Decreased cyclosporine levels
Increased cyclosporine levels
Theophylline Inhibitor
Fluoroquinolone
Inducer
Cigarette smoking
Increased theophylline levels
Decreased theophylline levels
Warfarin Inducer
Phenobarbital
Inhibitor
Cimetidine
Decreased warfarin levels
Increased warfarin levels
Table 4–6. Examples of cytochrome P450 (CYP) induction or inhibition by drugs. 
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chronic smoker) or delayed (eg, after starting a potential
CYP inducer in the hospital). Drugs that inhibit CYP systems
may behave differently than those that are inducers because
the former can act immediately on CYP. The most common
CYP inhibitors in the ICU are allopurinol, amiodarone,
cimetidine, erythromycin, and fluconazole.
The importance of CYP induction and inhibition depend
on the therapeutic indices of the drugs whose metabolism
are affected. The narrower the therapeutic window (level
providing therapeutic effect compared with the level result-
ing in toxic effect), the greater is the likelihood that a CYP
inhibitor will lead to toxicity or an inducer will cause sub-
therapeutic levels.
 Adverse Effects & Drug Toxicities
Drugs may adversely affect all organ systems, but the kidney,
liver, heart, CNS, and vascular system are most frequently
affected. In critically ill patients with multiple medical prob-
lems, it can be quite difficult to isolate drug toxicity as the
sole cause of organ failure. Some drug toxicities are dose-
dependent, so attention to dosing and elimination is impor-
tant, as well as to drug interactions that may increase drug
levels (eg, inhibition of cytochrome P450 enzymes). Other
adverse effects are allergic and depend on the host response
and prior exposure. For some adverse effects, the patient may
be more susceptible for genetic or other reasons (long QT
syndrome).
Nephrotoxicity
The most common causes of drug-induced nephrotoxicity
are listed in Table 4–7. Nephrotoxicity in critically ill patients
may be due to drug-induced causes or to hypoperfusion.
Because the mortality rate for ICU patients with acute renal
failure approaches 80%, efforts should be directed at remov-
ing all potential causes of nephrotoxicity. Adequate fluid
resuscitation and maintenance of renal perfusion are of
paramount importance for preventing prerenal acute renal
failure. Appropriate intravascular volume status and pre-
treatment with N-acetylcysteine or sodium bicarbonate
decrease the risk of nephrotoxicity from radiocontrast
agents.
Despite adequate preventive measures, up to 20% of all
cases of acute renal failure may be associated with drug toxi-
city. Drug-induced toxicity may take the form of acute tubu-
lar necrosis, interstitial nephritis, or glomerulonephritis. Of
those drugs associated with acute tubular necrosis, the most
notable are the aminoglycosides and amphotericin B. With
once-daily dosing of aminoglycosides (5–7 mg/kg per day)
and proper therapeutic drug monitoring, the incidence of
acute tubular necrosis is reduced significantly. Novel ampho-
tericin B formulations as well as the increased use of other
antifungals (eg, azoles and echinocandins) reduce the risk of
nephrotoxicity. Interstitial nephritis and glomerulonephritis
are due to hypersensitivity reactions or immune-complex
formation. The most common drugs leading to interstitial
nephritis are antibiotics, even though the most likely culprit,
methicillin, is no longer used.
Hepatotoxicity
While a number of drugs have been associated with altered
liver function tests, these changes are usually reversible on
discontinuation of the offending agent. Since acute hepatic
injury is classified according to morphology, drug-induced
hepatic injury may cause either direct hepatocellular necro-
sis, cholestasis, or a mixed presentation of both (Table 4–8).
Some drug combinations such as rifampin and isoniazid,
amoxicillin and clavulanic acid, and trimethoprim and sul-
famethoxazole also may increase the possibility of hepato-
toxic reactions. This may occur because one agent alters the
metabolism of the other, leading to the production of toxic
metabolites. Phenytoin induces both hepatic necrosis and
cholestasis in association, producing an immune response
manifested by a rash, eosinophilia, atypical lymphocytosis,
and serum IgG antibodies against phenytoin.
An increasingly important source of drug-induced hepa-
totoxicty is the use of herbal drugs. These may not be disclosed
Acute tubular necrosis  
Acyclovir  
Aminoglycosides  
Amphotercin B  
Iodinated contrast dyes  
Foscarnet  
Pentamidine  
Interstitial nephritis  
Allopurinol  
Cimetidine  
Furosemide  
Methicillin  
Phenytoin  
Rifampin  
Thiazides  
Trimethoprim-sulfamethoxazole  
Vancomycin  
Glomerulonephritis  
ACE inhibitors  
Gold salts  
Hydralazine  
Penicillamine  
Rifampin  
Renal hemodynamics  
ACE inhibitors  
Cyclosporine  
NSAIDs  
Tacrolimus 
Table 4–7. Nephrotoxic drugs.
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by patients without specific questioning. Toxicity may be
hepatocellular or cholestatic in nature. Some herbs may
inhibit or induce the CYP system (eg, St. John’s wart induces
CYP3A4, reducing concentrations of cyclosporine A), and
several herbal drugs affect metabolism of warfarin.
Cardiac Toxicity
Many drugs used in the ICU have potentially adverse cardiac
effects. These include drugs that cause tachycardia (eg, beta-
adrenergic agonists, dopamine, and theophylline), bradycardia
(eg, beta-adrenergic blockers and certain calcium channel
blockers), myocardial depression, and arrhythmias (eg,
digoxin, theophylline, and, surprisingly, antiarrhythmic drugs).
An important but unusual adverse effect is drug-induced
prolonged QT interval syndrome, sometimes associated with
a chaotic ventricular tachycardia (torsade de points). Both
cardiac and noncardiac drugs have been associated with this
syndrome, including quinindine and procaineamide;
antipsychotic drugs; antibiotics such as macrolides, fluoro-
quinolones, and ketoconazole; histamine-1-antihistamines;
and other drugs. In some cases, patients receiving multiple
drugs develop interactions that increase serum levels of the
contributing agent. It should be noted that some such drugs
have been withdrawn from the market because of the risk of
prolonging the QT interval. Drug-induced prolonged QT
syndrome and torsade de points are more common in
women, those with heart disease and electrolyte disorders,
and those with familial long QT syndrome. In one study, one
or more of these risk factors were present in the majority of
patients who had drug-induced torsade de points.
Electrolyte Abnormalities
Drugs may be associated with a variety of electrolyte and
acid-base abnormalities. Some of the effects are predictable,
such as hypokalemia induced by thiazide diuretics,
furosemide, glucocorticoids, insulin, and beta-adrenergic
agonists and hyperkalemia from spironolactone, tri-
amterene, or angiotensin-converting enzyme (ACE)
inhibitors. On the other hand, less often expected are hyper-
kalemia with heparin, potassium penicillin G, and trimetho-
prim. Hyponatremia may be a feature of thiazide diuretic
administration. Amphotericin B is associated with
hypokalemia, hypomagnesemia, and renal tubular acidosis.
MEDICATION ERRORS & PREVENTION
IN THE ICU
Reduction of medical errors is the focus of many hospital
quality improvement plans, and medication errors usually
make up the vast majority of medical errors. In the ICU,
attention to medication administration is very important,
and systems to reduce errors have been shown to be effective.
Medication errors arise at any point—from ordering to
administration. The most common errors are those of dosing
without due consideration for the patient’s age, size, renal or
hepatic function, or drug interactions. More rare is adminis-
tration of the wrong medication; this can result from tran-
scription errors or failure to match the medication with the
patient. Because critically ill patients often have multiple clini-
cians participating in their care and multiple medications
Table 4–8. Hepatotoxic drugs.
Type of Hepatic Injury Drug
Hepatocellular Acetaminophen
Allopurinol
Amiodarone
Isoniazid
Ketoconazole
Lisinopril
Losartan
Nevirapine
Paroxetine
Pyrazinamide
Rifampin
Risperidone
Ritonavir
Salicylates
Sertraline
HMG-CoA reductase inhibitors (“statins”)
Tetracycline
Trazodone
Valproic acid
Cholestatic Amoxicillin ⁄ clavulanate
Anabolic steroids
Azathioprine
Chlorpromazine
Clopidogrel
Cytarabine
Erythromycin
Estrogens
Oxacillin
Phenothiazines
Sulindac
Tricyclic antidepressants
Mixed Amitryptilline
Azathioprine
Captopril
Carbamazepine
Clindamycin
Cyprohepatadine
Enalapril
Ibuprofen
Nitrofurantoin
Phenobarbital
Phenytoin
Sulfonamides
Trazodone
Trimethoprim-sulfamethoxazole
Verapamil
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prescribed, it is not surprising that there may be duplication of
medication orders, inadvertent administration of two drugs
for the same purpose, and unrecognized drug interactions.
Systems for minimizing medication errors in the ICU
depend on careful, timely, and regular review of medications
and reconciliation of orders with administered medications.
Standardized intravenous mixtures, protocols for drug
administration (eg, sedation guidelines and IV insulin and
heparin protocols), computerized order entry, and auto-
mated review of potential drug interactions are effective
tools.
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PHYSIOLOGIC EFFECTS OF ANESTHESIA
IN THE CRITICALLY ILL
Many critically ill patients undergo surgery and anesthesia
before or after admission to the ICU. To take care of these
patients perioperatively, an understanding of the physiologic
effects of anesthesia is essential.
Anesthetics produce their primary effects by acting on the
CNS. They also elicit a variety of physiologic changes through-
out the body. The physiologic reserve of critically ill patients is
limited because of concurrent or preexisting pathophysiologic
disorders. Such individuals thus are more susceptible to phys-
iologic derangements than normal and more apt to develop
complications during the recovery period.
Recovery from the influences of anesthesia requires care-
ful observation and specialized management. Since patients
may be labile and vulnerable during this stage, they may stay
in the postanesthetic care unit (PACU) until they have
regained consciousness. The function of the PACU is to pro-
vide close monitoring of vital functions and to ensure
prompt recognition of problems owing to anesthesia and
surgery. The same functions can be served in the ICU as well.
 Anesthesia & the Airway 
Soft Tissue Obstruction 
Under the influence of residual anesthesia and muscle relax-
ant effects, airway obstruction is a common and potentially
catastrophic complication in the immediate postanesthesia
period. It usually results from soft tissue obstruction by the
tongue and laryngopharyngeal structures when recovery
from neuromuscular function is incomplete. It can be
detected by physical signs and symptoms with or without
abnormal blood gas measurements. Management includes
hyperextension of the head, chin lift–jaw thrust maneuvers,
insertion of an oropharyngeal or nasopharyngeal airway, or
positive-pressure ventilation.
Laryngospasm  
As the patient is emerging from anesthesia, the vocal cords
are sensitive and prone to develop spasms if blood or secre-
tions accumulate in the area of the larynx. This may result in
hypoxia, hypercapnia, and respiratory arrest if not corrected
promptly. Suctioning corrects the problem in most cases. If
spasms persist, positive-pressure ventilation by mask with or
without small doses (10–20 mg) of succinylcholine may be
necessary. Endotracheal reintubation is seldom required.
Laryngoedema 
Edema of the laryngeal structures may occur following extu-
bation after anesthesia. It is usually due to use of an oversized
endotracheal tube or traumatic intubation, fluid overload, or
allergic reaction. In women, it may be caused by preeclamp-
sia. It usually responds best to high humidity and nebulized
racemic epinephrine. Corticosteroids may be beneficial.
Aspiration 
Recovery of laryngopharyngeal function may be incomplete
after anesthesia with muscle relaxant drugs. Prolonged place-
ment of the endotracheal tube may further aggravate the sit-
uation. With an incompetent larynx, aspiration may occur
following vomiting or regurgitation.
 Cardiovascular Effects of Anesthesia 
Anesthesia may disrupt homeostatic regulation of the car-
diovascular system by a variety of mechanisms.
Inhalation Anesthesia 
A. Blood Pressure Response—All currently used inhala-
tion anesthetics (ie, halothane, enflurane, isoflurane, desflu-
rane, and sevoflurane) cause dose-dependent reduction in
mean arterial blood pressure. The decrease in blood pres-
sure is due primarily to a decrease in cardiac output by
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myocardial depression with halothane and enflurane and a
decrease in peripheral vascular resistance with isoflurane,
desflurane, and sevoflurane.
B. Cardiac Effects—All inhalation anesthetics shift the left
ventricular function curve downward and to the right, indi-
cating depression of myocardial contractility. This may be
due to a direct action of anesthetics on cardiac cells or on
postganglionic receptors on the myocytes. The drugs may
inhibit the slow Na+-Ca2+ channels and reduce Ca2+ influx.
The degree of depression varies with different agents and
concentrations. There is a consistent decrease in stroke vol-
ume as well as cardiac output, whereas the heart rate
response may vary. All agents decrease the slope of phase 4
and phase 0 depolarizations and increase the action potential
duration at minimum alveolar concentrations.
C. Peripheral Resistance Effects—All inhalation agents
cause vasodilation and decrease peripheral resistance, but to
different degrees. This effect may be due to the direct vasodi-
lating effects on vascular smooth muscle as well as the result
of decrease in sympathetic vasoconstrictor tone. Anesthetics
may interfere with the movement of Ca2+ across the vascular
endothelial membranes and within the smooth muscle cells.
D. Cardiovascular Reflexes—Inhalation anesthetic agents
depress homeostatic reflex regulation of the cardiovascular
system. The baroreceptor reflex is attenuated or blocked via
either a central or a peripheral effect. The cardiac chronotropic
response is also blunted by higher anesthetic doses.
Narcotic Anesthesia 
A. Cardiac Effects—Depression in myocardial contractility
has been demonstrated in a variety of isolated heart muscle
preparations using different opioids in concentrations much
higher than those attained clinically. Opioid receptors may
not be involved in this effect. It is not preventable with nalox-
one pretreatment.
With the exception of meperidine, opioids cause brady-
cardia by stimulation of vagal preganglionic neurons in the
medulla oblongata. They also may cause direct depression of
the sinoatrial node at very high doses. Bradycardia can be
reversed by naloxone or atropine.
B. Peripheral Resistance Effects—Aside from histamine
release, morphine may cause vasodilation of both resistance
and capacitance vessels through direct local effects on vascu-
lar smooth muscle or the central vasomotor center. The
degree of this effect is determined by the specific opioid, the
rate of injection, the baseline status of the patient, and com-
pensatory responses. The vascular effects of morphine may
not involve opioid receptors or narcotic action. Clinically,
opioid-induced vasodilation occurs predominantly in
patients who are critically ill or in those with underlying car-
diac disease with elevated sympathetic tone.
Anesthesia with opioids in high doses (morphine, 1–3 mg/kg;
fentanyl, 50–150 μg/kg) normally causes little hemodynamic
change and is well tolerated by patients with poor cardiovas-
cular function. However, the potential risk of myocardial
depression and peripheral vasodilation with opioids should
not be underestimated. Adding nitrous oxide or benzodi-
azepines to high doses of fentanyl may produce hypotension
owing to myocardial depression or peripheral vasodilation.
Regional Anesthesia 
Local anesthetic agents inhibit the excitation-conduction
process in peripheral nerves. In sufficient tissue concentra-
tion, they may affect the heart and smooth muscles of blood
vessels, resulting in hemodynamic depression.
A. Direct Effects—All local anesthetics produce a dose-
related decrease in velocity of atrial conduction, atrioventric-
ular conduction, and ventricular conduction. Lidocaine
decreases the maximum rate of depolarization, action poten-
tial duration, and effective refractory period. Bupivacaine,
etidocaine, and tetracaine, which are highly potent local
anesthetics, tend to decrease conduction velocity through
various parts of the heart at relatively low concentrations. An
extremely high concentration of local anesthetics will
depress spontaneous pacemaker activity in the sinus node,
resulting in sinus bradycardia and sinus arrest.
All local anesthetics essentially exert a dose-dependent
negative inotropic action. High doses of bupivacaine are car-
diotoxic. A biphasic peripheral vascular effect of local anes-
thetic agents may be observed, with vasoconstriction
followed by vasodilation in high concentration.
B. Indirect Effects—Spinal or epidural anesthesia is asso-
ciated with sympathetic blockade that may result in pro-
found hypotension owing to peripheral vasodilation. The
higher the spinal level of the blockade, the lower is the
blood pressure.
Below the T5 dermatomal level, epidural anesthesia is not
usually associated with significant cardiovascular changes.
From T5 to T1, it produces about a 20% decrease in blood
pressure. At T1 or above, bradycardia and a fall in cardiac
output may develop as a result of blockade of cardiac sympa-
thetic accelerator nerves. In addition to peripheral vasodila-
tion, myocardial contractility is depressed. Hypovolemic
patients are more susceptible to sympathetic blockade; pro-
found hypotension may occur when the preload is too low.
High epidural anesthesia may decrease coronary and hepatic
blood flow and may alter normal autoregulation of cerebral
and renal blood flow as well.
 Anesthesia & the Respiratory System 
Inhalation Anesthesia 
A. Control of Ventilation—In general, all volatile anesthet-
ics decrease ventilation in a dose-related manner. When the
patient is allowed to breathe spontaneously, the decrease in
tidal volume reflects the depth of anesthesia. Although
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anesthesia reduces metabolism and thus CO2 production, it
also increases dead space. Postoperative hypoventilation may
occur under the residual effect of anesthesia on the respira-
tory center with resulting hypercapnia and hypoxemia.
With the exception of ether, all inhalation anesthetics
cause not only a rise in resting PaCO2 but also a diminished
responsiveness of ventilation to added CO2. This shifts the
CO2 response curve downward and to the right, causing
hypoventilation in the immediate postanesthesia period.
Doxapram, which produces respiratory stimulation via
peripheral carotid chemoreceptors, may be useful, but
mechanical ventilation until the residual anesthesia effect
completely wears off is the best treatment.
In general, inhalation anesthetics depress the hyperventi-
lation response to hypoxemia by acting directly on the
carotid body. This hypoxic ventilatory response is impaired
in a dose-related manner; however, the dose required is
much smaller than that required for depressing the hyper-
capnic ventilatory response. In the immediate postoperative
period, the patient may fail to respond to hypoxemia by
increasing ventilation because of impairment of this defense
mechanism by residual anesthetic agent.
1. Response to loading and stimulations—In a con-
scious person, inspiratory effort increases when external
resistance is imposed. This response is markedly depressed by
anesthesia. Under the influence of anesthetics, patients with
chronic obstructive pulmonary disease in particular may fail
to increase ventilation when airway resistance is increased.
Ventilation increases with surgical stimulation during
anesthesia. When all stimulation ceases at the conclusion of
the procedure, spontaneous breathing may diminish or stop.
2. Apnea threshold—The apnea threshold is the PaCO2
level at which spontaneous ventilatory effort ceases. The dif-
ference between the PaCO2 during spontaneous breathing
and during apnea is generally a constant value of 5–9 mm Hg,
independent of anesthetic depth. When PaCO2 is too low as
a result of prolonged hyperventilation during anesthesia,
postoperative hypoventilation or apnea can occur and lead to
hypoxemia.
3. Posthyperventilation hypoxemia—Following pro-
longed anesthesia with hyperventilation, the body stores of
CO2 are depleted. Refilling CO2 stores leads to low PaCO2 and
hypoventilation. Hypoxemia may occur if supplemental oxy-
gen is not provided.
B. Mechanics of Respiration—General anesthesia and
muscle paralysis have a significant impact on respiratory
mechanics that may lead to impaired gas exchange.
1. Functional residual capacity—With induction of gen-
eral anesthesia, functional residual capacity is reduced by
about 500 mL within 30 seconds. The mechanisms of this
effect remain unclear. Increased elastic recoil of the lung,
decreased outward recoil of the chest wall, and peripheral
alveolar atelectasis owing to absorption or hypoventilation
in the dependent portions of the lung are the most likely
underlying mechanisms. Other possibilities include trapping
of gas distal to the closed airways, increased activity of expira-
tory or decreased activity of inspiratory muscles, and increased
thoracic or abdominal blood volume, alone or in combination.
Twenty-four hours after recovery from anesthesia—
particularly following upper abdominal surgery—functional
residual capacity continues to fall to the lowest value
(70–80% of the preoperative level). It takes about 7–10 days
to return to the preoperative volume. When closing capac-
ity exceeds functional residual capacity, regions with a low
ventilation-perfusion (
.
V/
.
Q) ratio develop, leading to atelec-
tasis, shunting, and impaired gas exchange. Widening of the
alveolar-arterial PO2 gradient and some degree of hypox-
emia are not uncommon in the immediate postoperative
period.
2. Compliance of the lung and chest wall—The com-
pliance of the total respiratory system and lungs is reduced.
The pressure-volume curve shifts rightward, following
induction of general anesthesia. This may be due to a
decrease in functional residual capacity, an increase in recoil
of the lung, and paralysis of the diaphragm. The reduction in
total compliance results in a need for greater airway pressures
to inflate the lungs to a given volume under anesthetic influ-
ence. A restrictive ventilatory pattern with impaired gas
exchange may occur during the recovery period.
3. Airway resistance—Following induction of general
anesthesia and endotracheal intubation, pulmonary resist-
ance may be doubled. The size of the airway may be altered
by the decrease of lung recoil, and bronchial smooth muscle
tone may be diminished by some anesthetics. The pressure-
flow relationship is affected, and dynamic compliance is also
decreased.
4. Intrapulmonary gas distribution—Changes in the
vertical pleural pressure gradient secondary to alterations in
the shape or pattern of chest wall motion during anesthesia
may influence the intrapulmonary distribution of inspired
gas. In contrast to the awake state, preferential ventilation of
the nondependent lung occurs in patients under general
anesthesia. This redistribution does not depend on the use of
muscle paralytic agents. Abnormal gas distribution and 
.
V/
.
Q
mismatching may exist when there is a residual effect of
anesthetics or muscle relaxant.
5. Postoperative vital capacity—The characteristic pul-
monary function profile following abdominal or thoracic
surgery is a restrictive pattern with markedly reduced
inspiratory capacity and vital capacity. Patients usually
breathe with a shallow volume at a higher rate and cough
ineffectively. The vital capacity is reduced by 50–70% of
preoperative values immediately after upper abdominal sur-
gery and remains depressed for 7–10 days. Only moderate or
minimal reduction in vital capacity is observed following
extremity surgery. If not improved, this defect of pul-
monary mechanics may lead to atelectasis and pneumonia
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during the postoperative period. Although residual effects
of anesthetics and muscle relaxants may have some contribu-
tion during the immediate postoperative period, the reduc-
tion of vital capacity appears to be more related to surgical
pain and the noxious reflex, which limit excursion of the
diaphragm more than the anesthesia itself.
6. Diaphragmatic function—Normally, the muscles of
the chest wall, the diaphragm, and the abdominal muscles
have important roles in the regional distribution of inhaled
gases. Anesthesia and muscle paralysis have a significant
impact on the mechanics of the chest wall, particularly the
diaphragm, causing irregularities of gas distribution and
exchange. Both anesthesia and muscle paralysis move the
diaphragm cephalad in the recumbent and decubitus posi-
tions at the end of expiration. This is of greatest significance
for the dependent parts of the diaphragm, for which abdom-
inal pressure has the greatest influence. While displacement
of the diaphragm during spontaneous inspiration is maxi-
mal in dependent regions and minimal in nondependent
regions, the relationship is reversed during paralysis with
mechanical ventilation. Regional gas volume and distribu-
tion are in proportion to diaphragmatic movement. In states
of anesthesia and paralysis, the anteroposterior diameters of
both the rib cage and the abdomen decrease while the trans-
verse diameters increase. Compliance of the rigid thoracic
compartment increases, and that of the abdomen and
diaphragm decrease. The persistent tonic activity of the
diaphragm throughout expiration is also abolished, and the
motion of the diaphragm becomes passive. In contrast to
active breathing, displacement of the diaphragm and the
associated gas distribution will be different. Mismatch of
ventilation and perfusion may be exaggerated.
C. Pulmonary Gas Exchange—Under general anesthesia,
oxygen consumption normally decreases by approximately
10%. This may decline to 25% of normal depending on the
fall in body temperature. It is raised substantially if shivering
occurs. The production of CO2 fluctuates with oxygen con-
sumption. While it is not uncommon to mechanically hyper-
ventilate a paralyzed patient, hypoventilation usually occurs
during anesthesia with spontaneous breathing. Diffusing
capacity for carbon monoxide remains unaltered, indicating
that transfer across the alveolar-capillary membrane is not
affected. Studies on gas exchange indicate the occurrence of
ventilation-perfusion mismatching during anesthesia. The
increase in P(A–a)O2 gradient may be due to increased perfu-
sion of regions with low 
.
V/
.
Q ratio or increased shunt (or
both). The increase in alveolar dead space appears to be a
result of the relative maldistribution of ventilation.
D. Pulmonary Circulation—Normally, hypoxic pulmonary
vasoconstriction is a powerful physiologic response. The
mechanism is triggered by regional alveolar hypoxia (low
PAO2 or low P
–vO2), which causes precapillary pulmonary
arterial constriction. The increase of vascular tone in the
hypoxic area diverts blood flow to areas of higher oxygen
tension. This optimizes ventilation-perfusion matching in
the lung and thus reduces venous admixture and maintains
better gas exchange. All three currently used inhalation anes-
thetics inhibit hypoxic pulmonary vasoconstriction in a
dose-dependent manner. This special effect of volatile agents
may contribute to the inefficiency of oxygen exchange during
anesthesia.
E. Diffusion Hypoxemia and Absorption Atelectasis—At
the conclusion of inhalation anesthesia, when the patient
starts to breathe spontaneously, diffusion hypoxemia may
occur. Since nitrous oxide is 30 times more soluble than
nitrogen, it will rapidly diffuse from the pulmonary capillary
blood and dilute the inspired alveolar air. This causes a
reduction in PaO2 that can be corrected with supplemental
oxygen.
When high concentrations of oxygen are used during
anesthesia, the lung units with low ventilation-perfusion
ratios may become unstable and collapse. This absorption
atelectasis may widen the PAO2–PaO2 gradient, particularly
when ventilation is shallow and inadequate.
Narcotic Anesthesia 
All opioid agonists produce a dose-dependent depression of
ventilation by acting on the central respiratory center. The
ventilatory effects of opioids include a decreased respiratory
rate, decreased minute ventilation, increased arterial CO2 ten-
sion, and decreased ventilatory response to CO2. Although
equianalgesic doses of opioids are likely to produce equivalent
depression of ventilation, the peak effects and durations are
determined by the pharmacokinetics of each drug.
Depression of ventilation is augmented and prolonged in eld-
erly and debilitated patients and in the presence of other CNS
depressants. Airway reflexes are blunted, as is the hypoxic ven-
tilatory response. Additionally, fentanyl may cause chest wall
rigidity and compromise ventilatory function.
Regional Anesthesia 
Diaphragmatic function is usually preserved even with high
spinal anesthesia as long as the cervical portion of the spinal
cord is not involved. With paralysis of the thoracic cage, the
patient may appear to experience an incoordinate breathing
pattern with paradoxical abdominal respiration even though
ventilatory function is well maintained at the 75–85% level.
The blockade of intercostal nerves leads to abdominal mus-
cle paralysis that may limit the ability to cough and clear
secretions. When anesthetics reach the cervical region or
fourth ventricle, total apnea develops.
 Anesthesia & Body Temperature 
Hypothermia may occur with general anesthesia. Not only
are the thermoregulatory centers depressed by anesthetic
agents, but the interior and exterior of the body are also
exposed to a cool environment for hours. In addition, the
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peripheral vasodilatory effect associated with most types of
anesthesia can aggravate heat loss and further decrease body
temperature. Although hypothermia lowers total body oxy-
gen consumption, severe depression may be fatal. Other
complications of hypothermia include myocardial dysfunc-
tion, cardiac dysrhythmia, coagulopathy, and acidosis.
Shivering during recovery may increase oxygen consumption
as much as fourfold. During rewarming, circulatory collapse
can occur if adequate fluid replacement is not provided to
offset increased vascular capacitance.
 Effects of Neuromuscular Blockade 
Neuromuscular blocking agents are used commonly in anes-
thesia to facilitate surgical procedures. Because of paralysis or
weakness of skeletal muscles, such blockade has a significant
influence on ventilation and airway maintenance if a residual
effect persists during the recovery period. Neuromuscular
blocking agents are classified as depolarizing or nondepolar-
izing depending on their effects at the neuromuscular junc-
tion. Depolarizing agents form strong attachments to the
postsynaptic cholinergic receptor and result in persistent
depolarization and paralysis. Nondepolarizing drugs bind
competitively to postsynaptic cholinergic receptors and pre-
vent acetylcholine from activating sodium channels. Residual
neuromuscular blockade must be antagonized before
extubation—otherwise, airway patency as well as respiratory
function may be compromised postoperatively. If not
reversed completely, residual neuromuscular blockade may
persist into the recovery period. Recovery is monitored by
peripheral nerve stimulators using a train-of-four test. There
are essentially two patterns of blockade: (1) Phase 1 (depolar-
izing) block is produced by succinylcholine and is associated
with sustained tetanus, equal train-of-four responses (muscle
responses to four consecutive 2-Hz electrical nerve stimuli),
and absence of posttetanic potentiation, which refers to
enhanced twitch responses after tetanic stimulation. (2) Phase 2
block is caused by nondepolarizing agents or the prolonged
use of succinylcholine and is characterized by tetanic fade and
fade of the train-of-four responses and posttetanic potentia-
tion. Both can recover spontaneously. Nondepolarizing
agents may be reversed with anticholinesterases such as edro-
phonium, neostigmine, or pyridostigmine. Persistent phase 1
block requires continuous ventilatory support.
AIRWAY MANAGEMENT 
In the ICU, airway management is a common challenge in
daily practice. For critical care physicians, its importance
cannot be overemphasized. A number of techniques must be
mastered, ranging from merely lifting the chin to emergency
tracheostomy. Physicians confronted with airway problems
must decide whether to intervene. This requires rapid assess-
ment of several factors such as the duration of hypoxia, the
current status of the airway and ventilation, the presence of
jaw clenching, cervical spine stability, prior difficulties with
intubation, and available equipment and skills. Contingency
plans for various potential airway emergencies must be in
place and familiar to all ICU personnel. The risk of irre-
versible hypoxic damage always should dictate priorities in
the decision algorithm. Gloves and goggles are indicated for
personal protection during manipulations of the airway.
 Secure a Patent Airway 
Partial or complete obstruction of the airway results in ven-
tilatory failure, hypoxemia, hypercapnia, and death. The first
priority in management of any critically ill patient is estab-
lishment of airway patency. In the ICU, this may be accom-
plished urgently for cardiopulmonary resuscitation or
electively for mechanical ventilation.
Mechanical Maneuvers 
Whenever the airway is compromised at the pharyngolaryn-
geal area owing to tongue or soft tissue occlusion, the chin
lift–jaw thrust maneuver is useful initially to maintain
patency, particularly in conjunction with insertion of oral or
nasal airways. These techniques for temporary opening of
the airway can be performed easily in any unconscious
patient. They are commonly followed by mask ventilation
and endotracheal intubation.
It is essential to exclude cervical spine injury by appropri-
ate x-rays at the time of a patient’s arrival in the unit so that
further neurologic damage can be avoided in case emergent
intubation is required. Neck lift and head tilt maneuvers are
contraindicated in patients with cervical spine injury. Chin
lifting or jaw thrusting may be performed while the neck is
maintained in the neutral position.
Clearing of vomitus, secretions, blood, and foreign bodies
should be done immediately when necessary to ensure an
open airway. If the risk of aspiration is high and the spine is
stable, the patient should be placed in the lateral position.
Adequate suction devices, including large-bore rigid and
flexible cannulas, always should be available.
Artificial Airways 
Artificial airways are useful when the obstruction is above the
laryngopharynx. They keep the tongue from falling back and
aid in removal of secretions from the posterior pharynx.
Oropharyngeal and nasopharyngeal airways are used com-
monly. Selection of an airway of appropriate size is required
to achieve optimal effect. Oral airways may prevent undesir-
able clenching of the teeth. Nasal airways usually are better
tolerated by agitated and semiconscious patients. Lubrication
with local anesthetics prior to airway insertion can be helpful.
Nasal airways are contraindicated in patients with suspected
basilar skull fractures or coagulopathies because they may
cause severe bleeding from the nasal mucosa.
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Intermediate Airways 
Intermediate airways include the esophageal obturator air-
way, the esophageal gastric tube airway, the pharyngeal-
tracheal lumen airway, and the esophageal-tracheal
combitube. The first two are designed to occlude only the
esophagus, whereas the latter two can be inserted into either
the trachea or the esophagus. These devices are designed to
establish an airway rapidly, but they fail to control the airway
completely. Because of the latter shortcoming, they are not
often used in the ICU.
Laryngeal Mask Airway (LMA)
The laryngeal mask airway (LMA) is designed to provide a
secured patent airway by inserting variable sizes of cuffed
tubes into the larynx. It has the advantages of not requiring
laryngoscope and easy insertion. However, it is contraindi-
cated in patients with risk of aspiration. It has been used
widely for anesthesia in spontaneously breathing patients. It
also has proved to be useful in emergency airway manage-
ment during difficult airway and cardiopulmonary resuscita-
tion (CPR) situations. The practical use of an LMA in critical
care unit is not well evaluated yet.
Brain A et al: The intubating laryngeal mask: Development of new
device for intubation of the trachea. Br J Anaesth 1997;79:
699–703. [PMID: 9496198]
 Endotracheal Intubation 
Endotracheal intubation is indicated if the chin lift–jaw
thrust maneuver fails to establish or secure a patent airway,
if the patient is obtunded and aspiration is a concern, if
positive-pressure mechanical ventilation is required, if tra-
cheobronchial secretions cannot be cleared, or if complete
control of the airway is desirable. In critically ill patients,
use of the esophageal obturator airway and its variants
should be limited to situations in which endotracheal intu-
bation has been unsuccessful and no other methods are
available.
Any maneuver involving movement of the neck should be
avoided in cases of confirmed or suspected cervical spine
injury. However, if the patient sustains apnea or severe
hypoxemia despite conservative management, immediate
endotracheal intubation may become necessary. Oral endo-
tracheal intubation may be attempted if stability of the neck
can be maintained. The risk of further damage must be bal-
anced by the overall risk to the patient’s life owing to failure
to secure an airway. If time permits, fiberoptic nasotracheal
intubation should be the first choice in such situations. Blind
nasotracheal intubation is the alternative when a skilled oper-
ator with the necessary equipment for fiberoptic intubation is
not available or when the oral approach is contraindicated,
impossible, or difficult. Nevertheless, a careful orotracheal
approach is common practice.
 Special Considerations in Airway
Management 
Neuromuscular Blocking Agents 
At the time of intubation, jaw clenching induced by neuro-
logic dysfunction in various disease states can obstruct the
oral passage and prevent not only access to the larynx but
also clearing of secretions, vomitus, blood, and foreign bod-
ies. Even though jaw clenching usually will subside when
severe hypoxia develops, the risk of irreversible cerebral
damage is very high if a patent airway cannot be established
immediately. Rather than attempting intubation with force,
neuromuscular blocking agents are indicated to overcome
jaw clenching and facilitate intubation.
Time Factors 
Irreversible brain damage can result within minutes if apnea
is not corrected. The period of apnea that can be sustained
without brain damage depends on the degree of preoxygena-
tion and the patient’s oxygen consumption, hemoglobin con-
centration, cardiac output, and functional residual capacity.
Patients with low reserves can tolerate only brief periods of
apnea. Without preoxygenation, the customary maximum
interval of allowable apnea during intubation is 30 seconds.
The interval can be extended to minutes in a healthy young
person who has been preoxygenated. Ventilation with a mask
that provides 100% oxygen is strongly recommended before
attempts at intubation are repeated. Prolonged and multiple
attempts at intubation can injure the airway and cause
decompensation of the cardiorespiratory system, including
hypoxemia, arrhythmia, bradycardia, asystole, laryngospasm,
bronchospasm, and apnea. An oxygen saturation monitor
(pulse oximeter) and atropine should be available.
Endotracheal Tube Size 
In adults, cuffed endotracheal tubes of different internal
diameters (6.5–9 mm) should be available. Tubes with diam-
eters of 7–8 mm are usually appropriate for females, whereas
slightly larger tubes (7.5–8.5 mm) are appropriate for males.
A slightly smaller tube (by 0.5 mm in each case) is usually
adequate for nasal intubation. Tubes that are too large will
cause laryngeal injury, particularly after prolonged intuba-
tion; tubes that are too small will increase airway resistance
and the work of breathing. An endotracheal tube with a min-
imum internal diameter of 8 mm is advisable if bron-
choscopy is anticipated. The cuff should be checked for any
leak beforehand. After tube placement, the cuff should be
inflated with the minimum volume necessary to prevent air
leak around the tube. Breath sounds should be checked bilat-
erally immediately after tube placement, and the position of
the tube should be checked by x-ray. When the tube is placed
correctly, it is secured with tape and a bite block or oral air-
way to protect it from damage or crimping.
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Improper Positioning 
Esophageal placement of the endotracheal tube, if unrecog-
nized, is a lethal complication. Unfortunately, esophageal
intubation may not be detected immediately. Auscultation of
breath sounds bilaterally is useful but not always reliable.
Absence of breath sounds, increasing abdominal girth, or
gurgling during ventilation in conjunction with desaturation
and cyanosis should alert one to the possibility of esophageal
intubation. End-tidal CO2 measurement has become the best
means of confirming proper placement of the endotracheal
tube in most instances. The colorimetric end-tidal carbon
dioxide detector is used frequently in non-OR facilities to
confirm the right placement of endotracheal tube by color
changes. However, its use in arrested patients, who have no
blood circulation to the lung, is not valid. A flexible fiberop-
tic bronchoscope, if available, is also helpful to ensure proper
positioning under direct vision.
If a tube that is too long is inserted, main stem bronchus
intubation results. This occurs most commonly on the right
side. If unrecognized, one-sided intubations can cause atelec-
tasis of the opposite lung, hypoxemia owing to shunting, and
an increased risk of barotrauma of the ipsilateral lung.
Asymmetric breath sounds and chest movements are com-
mon findings. The tube should be withdrawn about 2–3 cm
beyond the point where equal breath sounds are first heard.
Chest radiographs are useful to confirm tube placement but
do not always exclude main stem intubations.
Other than esophageal and main stem bronchus intuba-
tions, complications following nasal endotracheal intubation
include epistaxis, nasal necrosis, retropharyngeal laceration,
mediastinal emphysema, and intracranial placement of the
tube. Nasal sinusitis is common and may be a cause of sepsis.
Persistent Air Leak 
Persistent air leak around an endotracheal tube may result
in hypercapnia and hypoxemia secondary to inadequate
ventilation. The leak may be due to damage to the balloon
itself or to the pilot balloon. Other causes include tracheo-
malacia or malposition of the cuff at or above the vocal
cords. Repositioning the tube or replacement with a tube of
appropriate size is required.
Surgical Airway 
When endotracheal intubation is impossible or has failed
after several attempts, operative creation of an airway
becomes imperative. Options include needle cricothyrotomy,
surgical cricothyrotomy, and tracheostomy. Jet ventilation
may be used initially with needle cricothyrotomy; however,
adequate alveolar ventilation is not ensured, and a formal
airway is usually required in less than 45 minutes. Surgical
cricothyrotomy will rapidly stabilize and secure the airway,
but pressure effects will lead to necrosis if the endotracheal
tube is not removed within several days.
Airway Management in Patients Requiring
Prolonged Ventilation 
The use of high-volume, low-pressure cuffs has greatly
reduced the incidence of tracheal injury from intubation.
However, damage to the laryngeal area has been a continuing
problem. Tubes with high-pressure, low-compliance cuffs
should be avoided or replaced. Monitoring of the cuff pres-
sure is useful but not reliable because it does not reflect the
lateral tracheal wall pressure and may fluctuate when high
pressures are used to overcome poor lung compliance.
Conversion to a tracheostomy is indicated when endotra-
cheal intubation is prolonged and laryngeal damage is a con-
cern. Other relative indications include patient comfort,
easier nursing care, and facilitation of suction.
The time limit for change is debated. Three weeks is the
empirical limit. Recently, earlier tracheostomy has been
advocated.
PAIN MANAGEMENT IN THE ICU 
Pain control in the ICU has improved significantly over the
last decade with greater understanding of neurophysiologic
mechanisms, anatomic pathways, causes of pain perception,
and clinical pharmacology. In a sense, pain serves as a means
for detection of tissue damage, for prevention of further
harm, and for promotion of healing through rest.
Postoperative or posttraumatic pain, however, may have no
such useful purpose and may in fact be detrimental and
cause complications in many organ systems. The goal of pain
management in the ICU is to minimize discomfort and pro-
mote faster recovery of normal function.
 Anatomic Pathways & Physiology of Pain 
Pain is perceived through the nociceptors at nerve endings
throughout the body. The impulses in response to mechani-
cal, thermal, and certain chemical stimuli are transmitted
through A, δ, and C fibers to the neuraxis at the dorsal horn
of the spinal cord. The marginal layer cells in lamina I and
the wide-dynamic-range neurons in lamina V are activated
and send projections to the nociceptive areas of the thala-
mus. The spinothalamic tract is the predominant but not the
only pathway. Others project to the reticular formation, mid-
brain, hypothalamus, and limbic forebrain structures.
Impulses finally reach the cortex, where perception of pain is
completed. Cells in the substantia gelatinosa modulate both
segmental and descending input and exert an inhibitory
effect on thalamic projection cells in the dorsal horn. Some
visceral pain may pass through visceral afferents.
 Pathophysiology of Pain  
Perception of pain at the neuraxis provokes both segmental
reflexes and central responses. Segmentally, it causes a
marked increase in local skeletal muscle tension, which not
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only impairs normal function but also intensifies pain.
Centrally, the sympathetic nervous system is activated, and
this leads to an increase in overall sympathetic tone, thereby
increasing cardiac output, blood pressure, and cardiac work
load. Cardiac metabolism—as well as whole body metabolism—
and oxygen consumption are augmented. Tachypnea, ileus,
nausea, bladder hypotonicity, and urinary retention are not
uncommon.
Pain itself—as well as the associated anxiety and appre-
hension—also aggravates the hypothalamic neuroendocrine
response. There are increased secretions of catabolic hor-
mones such as catecholamines, adrenocorticotropic hor-
mone (ACTH), cortisol, antidiuretic hormone (ADH),
aldosterone, and glucagon. Secretion of anabolic hormones
such as insulin and testosterone is decreased. Persistent pain,
if uncorrected, will result in a catabolic state and negative
nitrogen balance.
 Pain & Respiratory Dysfunction 
The incidence of postoperative pulmonary complications
varies from 5–28%. Most of these complications are related
to inappropriate control of postoperative pain. Pulmonary
function can be affected significantly depending on the site
and extent of surgery or trauma. Derangement of
ventilation-perfusion relationships occurs, followed by
abnormal gas exchange and hypoxemia. Surgery and postop-
erative pain cause involuntary splinting and reflex muscle
spasm of the abdominal and thoracic muscles. Excursions of
the diaphragm are markedly limited, particularly when ileus
develops. Furthermore, in an attempt to minimize pain, the
patient refrains from deep breathing and coughing.
Pulmonary status deteriorates, and some patients progress to
atelectasis and pneumonia. When narcotics are given in suf-
ficient quantity, respiratory depression results. Apnea can
occur in severe cases. Adequate monitoring and therapeutic
facilities always should be available.
 Analgesia with Opioids  
Intravenous Opioid Analgesia 
Opioid analgesics alone or in combination with adjuvant
agents such as nonsteroidal anti-inflammatory drugs
(NSAIDs) have been used conventionally for pain relief.
They are effective if prescribed properly. However, patients
are frequently undertreated. The minimum effective anal-
gesic dosage varies widely in different patients. Therefore,
the dose of opioid should be individualized and titrated as
needed.
The absorption of opioids following intramuscular or
oral administration is variable. The intravenous route is usu-
ally appropriate for patients in the ICU because an effective
plasma concentration level can be achieved promptly. Not
uncommonly, small doses (3–5 mg) of morphine or other
equally potent opioids are given for pain relief. Continuous
infusion of small doses of morphine (0.1 mg/min) avoids
peaks and valleys in plasma concentration and provides
effective relief of pain in most instances.
Patient-controlled analgesia (PCA) allows the patient to
self-administer a preset amount of opioid intravenously as
needed. A lock-out interval can be set to prevent overdosage.
PCA permits the patient to titrate his or her own analgesic
requirements and maintains a relatively steady level of min-
imum effective analgesic concentration. PCA is generally
well accepted by patients. Overall, it provides smoother and
more adequate analgesia accompanied by relief of fear and
anxiety. It improves pulmonary function in postoperative
patients, reduces nocturnal sleep disturbances, and decreases
the overall drug requirement. The patient must be thor-
oughly instructed about the device in order to maximize its
advantages.
The ideal agent for PCA in the ICU should have a rapid
onset, a predictable efficacy, a relatively short duration of
action with minimal side effects (particularly on cardiopul-
monary function), and no tendency to cause tolerance or
dependency. A typical prescription of PCA with morphine is
a loading dose of 2–10 mg over 15–30 minutes, followed by a
patient-triggered bolus (1–2 mg) via the PCA pump pro-
grammed with a lock-out interval of 5–15 minutes. This reg-
imen may be changed based on the patient’s responses. Total
doses and effective therapeutic concentrations cannot be
predicted. Individualization is necessary.
The combination of PCA with continuous infusion has
the advantage of providing a baseline plasma level of anal-
gesic while allowing titration of boluses to overcome varying
acute changes in the threshold of pain perception.
Epidural and Intrathecal Opioids 
The use of epidural and intrathecal opioids for pain relief in
the ICU has increased recently. Epidural and intrathecal nar-
cotics act mainly on spinal receptors and produce long-
lasting pain relief with relatively small amounts of drug. The
major advantage of this modality over local anesthesia is that
sympathetic and motor nerves are not blocked.
Morphine, a highly hydrophilic drug, has been shown to
spread rostrally to reach the fourth ventricle and brain stem
in about 6 hours following epidural administration. There
are two phases of respiratory depression. The earlier phase
reflects the rise of serum levels through absorption from
epidural veins. It commonly occurs 20–45 minutes after an
injection. The second phase coincides with rostral spread and
appears approximately 6–10 hours after injection. It causes a
decrease in respiratory rate. The risk of delayed respiratory
depression rises greatly if opioid is given systemically at the
same time.
Fentanyl, a lipophilic agent, also travels cephalad
through the cerebrospinal fluid (SCF) but extends less than
morphine. When given by lumbar epidural catheter, it may
not be equianalgesic with morphine for thoracic pain. It
tends to have fewer side effects than morphine, and most
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can be reversed with naloxone. These include nausea and
vomiting (17–34%), pruritus (11–24%), and urinary reten-
tion (22–50%).
Epidural morphine has a relatively slow onset, prolonged
action, and delayed occurrence of respiratory depression.
Fentanyl has a rapid onset and short duration of action and
is not uncommonly used for continuous epidural infusion.
The addition of epinephrine to epidural narcotics is not rec-
ommended because of the increased incidence of side
effects.
Intermittent epidural administration of opioids has the
drawback of peak and trough concentrations, so patients
may suffer unacceptable pain before adequate analgesia is
restored. Continuous infusion, PCA, or a combination of
both may provide better pain control in certain situations.
The epidural route has been used more commonly than
the intrathecal route for postoperative pain control. Potential
risks, complications, and monitoring requirements are simi-
lar for the two techniques. Because of spinal cord toxicity, not
all drugs used epidurally are safe for intrathecal use.
Compared with regional anesthesia, epidural or intrathecal
narcotics provide highly effective pain relief with no direct
effects on hemodynamics and motor function. However,
they may be less effective than regional anesthesia in block-
ing nociceptive perception and the associated metabolic and
neuroendocrine reactions.
 Local Anesthetic Analgesia  
Postoperative or posttraumatic pain control also can be
managed with long-acting local anesthetics. Brachial plexus
block, intercostal block, other peripheral nerve blocks,
intrapleural block, and local infiltration of the wound area
are available. When feasible, continuous infusion may be
more effective and reliable.
Regional Analgesia 
Regional analgesia with local anesthetic agents generally pro-
vides better pain relief than opioids because anesthetic
agents block both the afferent and the efferent pathways of
the reflex arc. This minimizes neuroendocrine and metabolic
responses to noxious stimuli. Nevertheless, when local anes-
thetics are administered epidurally or intrathecally, care must
be exercised to minimize side effects such as hypotension and
limb paralysis or weakness secondary to sympathetic and
somatic nerve blockade. A proper combination of opioids
and local anesthetics may achieve the ideal goal of adequate
analgesia with minimum metabolic and physiologic changes.
Local Anesthetic Agents
Local anesthetics produce both sensory and motor block when
a sufficient quantity is deposited near neural tissue. They are
used in the ICU to provide anesthesia and analgesia through
spinal, epidural, field, nerve block, or intravenous techniques.
Local anesthetics are classified as esters (eg, tetracaine,
chloroprocaine, and procaine) or amides (eg, lidocaine, bupi-
vacaine, and ropivacaine) depending on the chemical bond of
their alkyl chain. The ester local anesthetics are metabolized
by plasma cholinesterase, and the amide local anesthetics are
metabolized by the liver. The actions of local anesthetics are
affected by multiple factors, including lipid solubility, pKa,
protein binding, metabolism, and local vasoactivity. Onset of
block depends on the availability of the nonionized form of
the drug, which is determined by its pKa and the tissue pH.
The extent of binding to membrane protein and the time of
direct contact with the nerve fiber affect its duration of
action. Epinephrine (1:200,000) is frequently added to local
anesthetic solutions to reduce their absorption and prolong
the duration of action through local vasoconstriction.
Allergic reactions to local anesthetics are rare and more
likely to occur with esters than with amides. High plasma
concentrations of local anesthetics from either excessive
absorption or inadvertent overdose lead to severe side effects.
Hypotension, direct myocardial depression, arrhythmias,
and cardiac arrest are potentially lethal complications.
Perioral numbness, restlessness, vertigo, tinnitus, twitching,
and seizures are common manifestations that involve the
nervous system.
A. Lidocaine—Lidocaine is currently the most widely used
local anesthetic in the ICU because it has a low incidence of
side effects, a rapid onset of action, and an intermediate
duration of action. It has a volume of distribution of 90 L, a
clearance rate of 60 L/h, a distribution half-life of 57 seconds,
and an elimination half-life of 1.6 hours. It is metabolized in
the liver by oxidative dealkylation.
Lidocaine is used to provide pain control in spinal,
epidural, caudal, nerve, and field blocks, as well as in Bier
block anesthesia (IV regional block). Lidocaine in concentra-
tions of 2–4% has been used topically in the nose, mouth,
laryngotracheobronchial tree, esophagus, and urethra.
Lidocaine concentrations of 0.5–1.5% are used for local infil-
tration. An intravenous bolus of lidocaine (1.5 mg/kg) is use-
ful to attenuate the increase of intracranial pressure and blood
pressure during laryngoscopy and endotracheal intubation.
Systemic toxicity occurs when plasma concentrations of
lidocaine are above 5–10 μg/mL. Doses of 6.5 mg/kg can
cause CNS toxicity.
B. Bupivacaine—Bupivacaine, commonly used in obstetric
epidural and spinal anesthesia, is highly protein-bound and
produces intense analgesia of prolonged duration but is rel-
atively slow in onset. It has a volume of distribution of 72 L,
a clearance rate of 28 L/h, a distribution half-life of 162 sec-
onds, and an elimination half-life of 3.5 hours. It is metabo-
lized primarily in the liver.
Bupivacaine is used commonly in neuraxial anesthesia
and for nerve blocks. CNS toxicity occurs with plasma con-
centrations of 1.5 μg/mL. Clinically, doses exceeding 2 mg/kg
may cause systemic toxicity. Cardiac toxicity owing to severe
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myocardial depression may be fatal. Levobupivacaine, an iso-
mer of bupivacaine, causes less cardiotoxicity. Other less
commonly used agents include etidocaine, mepivacaine,
chloroprocaine, and procaine (Table 5–1).
C. Ropivacaine—Ropivacaine is one of the amide group of
local anesthetics. It is 94% protein bound with a steady-state
volume of distribution of 41 ± 7 L and is metabolized exten-
sively in the liver. Approximately 37% of the total dose is
excreted in the urine. Unlike most other local anesthetics, the
presence of epinephrine has no major effect on either the
time of onset or the duration of action. At blood concentra-
tions achieved with therapeutic doses, changes in cardiac
conduction, excitability, refractoriness, contractility, and
peripheral vascular resistance are minimal. Ropivacaine may
cause depression of cardiac contractility. Although both are
considerably more toxic than lidocaine, the cardiac toxicity
of ropivacaine is less than that of bupivacaine.
 Nonsteroidal Anti-Inflammatory Drugs 
NSAIDs are a group of compounds with heterogeneous
structures that relieve pain, lower fever, and decrease inflam-
matory reactions. The mechanism of their actions remains
unclear but may involve an inhibitory effect on prostaglandin
synthesis. They are useful for management of mild to moder-
ate pain. Compared with opioids, they have both the advan-
tages and the disadvantages of analgesia but without
producing changes in sensorium or ventilatory depression
and without the possibility of dependency. NSAIDs cause
platelet dysfunction and prolong bleeding time. They may
produce gastric erosions and hemorrhage. Other adverse
effects include interstitial nephritis, renal hypoperfusion,
somnolence, nausea and vomiting, and palpitations.
Until recently, because of a lack of parenteral formula-
tions, the use of NSAIDs in the ICU was limited. The advent
of ketorolac tromethamine, which can be given parenterally,
has made this class of agents more conveniently available for
critically ill patients.
Ketorolac tromethamine has no direct effect on opiate
receptors. It is a potent analgesic with a ceiling effect. IM
doses of 30–90 mg have analgesic efficacy comparable with
that of 10 mg of morphine. After IM injection, maximum
plasma concentrations are achieved within 45–60 minutes.
Ketorolac tromethamine is highly protein bound and
metabolized primarily by hepatic conjugation. Excretion is
through the kidney. It is nonaddicting and has no effect on
ventilation. Its side effects are similar to those of other
NSAIDs. It should be avoided in patients with renal dysfunc-
tion and bleeding tendencies.
 Analgesia & Anesthesia for Bedside
Procedures 
Excision of Eschar in Burn Patients; Wound
Debridement and Dressing Changes 
The first excision may be performed without anesthesia on the
fifth or sixth day following the burn. This is carried to the point
of pain or bleeding and identifies the areas of second- and third-
degree burn.Anesthesia with IM ketamine at up to 3–4 mg/kg or
intravenous ketamine at up to 1–2 mg/kg is satisfactory for sub-
sequent excisions. The patient is usually semiresponsive, whereas
respiratory function and the gag and cough reflexes are pre-
served. Emergence nightmares may occur and can be reduced by
giving diazepam or midazolam (IM or IV) during induction of
and emergence from ketamine anesthesia. Increased sympathetic
activity following ketamine administration may be beneficial in
critically ill patients with circulatory depression.
Cardioversion 
In cases of elective cardioversion such as atrial flutter or atrial
fibrillation, there is usually sufficient time to premedicate the
patient to provide a period of amnesia or hypnosis. Intravenous
diazepam, 5–10 mg, or midazolam, 2–3 mg, is effective and
safe. Methohexital, a short-acting barbiturate, 1 mg/kg intra-
venous, is also useful. Thiopental (50–100 mg) and propofol
(0.5–1 mg/kg) also have been used. Narcotics alone are not
sufficient. Supplemental oxygen and equipment for intuba-
tion and ventilation should be available.
MUSCLE RELAXANTS IN INTENSIVE CARE 
Neuromuscular blocking agents (Table 5–2) are used fre-
quently in the ICU. Their major drawbacks are the lack of
titratable agents and the difficulty with bolus techniques.
Table 5–1. Commonly used local anesthetics.
Agent 
Half-Life
(hours) Use 
Maximum
Single Dose
Amides
Bupivacaine
Ropivacaine
Etidocaine 
Lidocaine 
Mepivacaine 
Esters
Procaine
3.5
3.5
2.6
1.6
1.9 
0.14 
Epidural, spinal
infiltration 
Epidural, spinal,
caudal, infiltration
nerve block
Epidural, caudal,
infiltration, nerve
block
Epidural, caudal,
infiltration, nerve
block
Epidural, caudal,
infiltration, nerve
block
Spinal, infiltration,
nerve block
3 mg/kg
NA
3 (4)1 mg/kg
4.5 (7)1 mg/kg
4.5 (7)1 mg/kg
12 mg/kg 
1Maximum dose with epinephrine.
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This, coupled with inadequate monitoring, may result in
inappropriate blockade and markedly delayed recovery.
Nowadays, the availability of bedside intravenous pumps,
nerve stimulator monitors, and intermediate-acting nonde-
polarizing agents has redefined their role in ICU manage-
ment. Recent reports of prolonged paralysis, muscle
weakness from neuromuscular junction dysfunction, and
muscle atrophy following long-term treatment with neuro-
muscular blocking agents should alert the clinician to serious
potential consequences. Whenever prolonged use of neuro-
muscular blocking agents is planned, the balance of benefits
and complications should be carefully assessed.
There are some circumstances in critical care in which
neuromuscular blocking agents are indicated but not indis-
pensable. These include endotracheal intubation, postopera-
tive rewarming with shivering, the presence of delicate
vascular anastomoses, the need for protection of wounds with
tension, tracheal anastomosis, increased intracranial pressure,
insertion of invasive vascular catheters in agitated patients,
and facilitation of mechanical ventilation. In other specific
areas (eg, neurosurgical intensive therapy, management of
tetanus, and severe status epilepticus), neuromuscular agents
can either provide protection of the patient or facilitate pro-
cedures and management. Neuromuscular blocking agents in
these situations are beneficial but not essential. If adequate
sedation and analgesia are provided, the need for relaxants is
frequently diminished. In most instances, muscle relaxation is
required only when sedation and analgesia fail to achieve ade-
quate ventilation or other therapeutic goals.Anxiety, apprehen-
sion, and confusion, together with pain and discomfort, often
make patients agitated, combative, and more apt to fight
against the ventilator. It is essential to provide appropriate
levels of sedation and pain relief before and after a trial of neu-
romuscular blocking agents. Adequate intravenous administra-
tion of narcotics, either by bolus or by continuous infusion,
accompanied by benzodiazepines, usually obviates the need
for neuromuscular blocking agents.
Once paralysis is induced, the feeling of total dependency
and helplessness can lead to extreme anxiety and fear. This
psychosomatic impact must not be ignored. Sedation with
narcotics or benzodiazepines is mandatory.
 Muscle Relaxants in Mechanical
Ventilation 
Only rarely does a mechanically ventilated patient require
neuromuscular blockade. Therapy should be instituted to
make certain that the patient is properly sedated and free
from pain before blockade is considered. The use of muscle
relaxants is indicated for patients who have very poor tho-
racic or lung compliance, those who are fighting the ventila-
tor, and those at increased risk of barotrauma from high
airway pressures. If total control of ventilation is required
with modalities such as an inverted I:E ratio or high-minute-
volume ventilation or hypoventilation with permissive
hypercarbia, muscle relaxants may be required.
Before initiating neuromuscular blockade, the patient-
ventilator system should be thoroughly reviewed and evalu-
ated. Any sudden development such as pulmonary edema,
pneumothorax, or an obstructed endotracheal tube can
cause contraction of the respiratory muscles, resulting in
uncoordinated, asynchronous breathing. On the other hand,
the ventilator settings may no longer be appropriate.
Adjustments in tidal volume, inspiratory flow rate, ventilator
triggering sensitivity, or mode of ventilation often can avoid
the need for neuromuscular blockade.
If there is no apparent change in the patient’s clinical sta-
tus, and if adjustments in the mechanical ventilator fail to
improve the situation, attention should be directed to the
need for adequate sedation and analgesia.
Drug Loading Dose Maintenance Dose  Time of Onset Duration of Action Complications 
Succinylcholine 1–2 mg/kg Not recommended 0.5–1 min 5–10 min Vagolytic, prolonged 
Pancuronium 0.1 mg/kg 0.3–0.5 μg/kg/min 3 min 45–60 min Minimal histamine release 
Atracurium 0.5 mg/kg 3–10 μg/kg/min 1.5–2 min 20–60 min Weak histamine release 
Vecuronium 0.1 mg/kg 1–2 μg/kg/min 2–3 min 25–30 min None 
Cisatracurium 0.2–0.3 mg/kg 2–3 min 30–40 min None
Doxacurium 0.05 mg/kg 
Supplemental dose guided
by twitch monitor 
4 min 30–160 min None 
Pipecuronium 0.15 mg/kg 3 min 45–120 min None 
Mivacurium 0.15 mg/kg 2 min 15–20 min Weak histamine release 
Rocuronium 0.6 mg/kg 0.075–0.225 mg/kg 1–1.5 min 20–30 min None
Table 5–2. Commonly used muscle relaxants. 
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 Depolarizing Agents 
Succinylcholine 
Succinylcholine is the only clinically available depolarizing
neuromuscular blocking agent in the United States. It has a
uniquely rapid onset (30–60 seconds) and a short duration
of action (5–10 minutes). It acts as a false transmitter of
acetylcholine by avidly binding to postsynaptic cholinergic
receptors, resulting in persistent depolarization and muscle
paralysis. Succinylcholine also stimulates all cholinergic
receptors, including autonomic ganglia, postganglionic
cholinergic nerve endings, and the acetylcholine receptors of
the vascular system, which causes changes in blood pressure
and heart rate. A peculiar bradycardia may occur after
repeated bolus doses of succinylcholine, especially in chil-
dren, when the interval of injections is shorter than 4–5 minutes.
Use of succinylcholine in a hypoxic patient may cause irre-
versible sinus arrest. Muscle fasciculations from sustained
depolarization following succinylcholine can increase serum
K+ by 0.5–1 meq/L and produce arrhythmias. This induced
hyperkalemia is enhanced 24 hours after burns or with long-
term paraplegia or hemiplegia. Succinylcholine should be
avoided in these situations. Otherwise, succinylcholine
remains the preferred choice of muscle relaxant for intuba-
tion in acute trauma patients.
Based on the fact that succinylcholine causes hyper-
kalemic cardiac arrhythmia and even arrest more frequently
in pediatric patients with undiagnosed myopathy, the Food
and Drug Administration (FDA) issued a warning on the
succinylcholine package insert. Now the use of succinyl-
choline in children is only by indications, such as immediate
airway security, by most anesthesiologists. Severe fascicula-
tions also may increase intragastric pressure, resulting in
regurgitation and aspiration. Succinylcholine also may trig-
ger malignant hyperthermia.
Succinylcholine is rapidly hydrolyzed by pseudo-
cholinesterase in the plasma to succinylmonocholine, a rela-
tively inactive metabolite. In patients with low levels of
pseudocholinesterase or atypical cholinesterase enzyme, pro-
longed relaxation can occur. Furthermore, when very large
doses of succinylcholine are used, a phase 2 competitive
block, which is similar to nondepolarizer block, may develop.
Succinylcholine is used in the ICU mainly for endotra-
cheal intubation, especially when jaw clenching or muscle
tone makes laryngoscopy difficult or impossible. The usual
dose of succinylcholine is 1–2 mg/kg IV. This drug is partic-
ularly useful in critically ill patients with a full stomach, for
whom a rapid-sequence intubation technique is needed.
 Nondepolarizing Neuromuscular Blocking
Agents 
Nondepolarizing neuromuscular blocking agents bind in a
competitive manner principally to postsynaptic choliner-
gic receptors at the neuromuscular junctions, where they
prevent depolarization by acetylcholine.
Pancuronium 
Pancuronium bromide, a bisquaternary aminosteroid, used to
be the principal muscle relaxant in critical care. It is a long-
acting nondepolarizing agent, water-soluble, highly ionized,
and excreted mainly through the kidney. Its clearance depends
on the glomerular filtration rate. It is also metabolized and
broken down into less active hydroxyl metabolites in the liver.
The elimination half-life of pancuronium is 90–160 minutes,
which is greatly prolonged by hepatic or renal failure.
Pancuronium is administered intravenously as a bolus of 0.1
mg/kg. Onset of complete relaxation is 3–5 minutes, and the
duration of action is 45–60 minutes. Unlike monoquaternary
relaxants, pancuronium causes histamine release. In large doses,
because of vagolytic and sympathomimetic effects, it may cause
increases in heart rate and blood pressure. Prolonged paralysis
can occur after relatively large doses of pancuronium, particu-
larly in patients with renal or hepatic dysfunction.
Atracurium 
Atracurium is a nondepolarizing muscle relaxant with an
intermediate duration of action. It has the unique property of
being hydrolyzed through the Hoffman degradation mecha-
nism. Renal or hepatic disease does not prolong its short
elimination half-life (19 minutes). Laudanosine, its metabo-
lite, causes cerebral irritation in high doses in several animal
species. This has not been noted clinically, however, even after
prolonged use of atracurium. The route of laudanosine elim-
ination is not known for certain, but it seems that renal fail-
ure itself will not affect metabolic accumulation significantly.
For intravenous administration, 0.5 mg/kg is given in
adults. The onset of action is 1.5–2 minutes, with peak relax-
ation in 3–5 minutes. The duration of action is 20–60 min-
utes. There are no cumulative effects.
Administration of atracurium should be slow and ade-
quate in amount because rapid intravenous injection with a
large bolus may result in histamine release and hypotension.
Clinically, in most instances, recovery is rapid and complete
once the infusion is stopped. Because of its relatively mild
cardiovascular and cumulative effects, atracurium by contin-
uous infusion appears to be useful when prolonged neuro-
muscular blockade is required.
Cisatracurium
Cisatracurium is a stereoisomer of atracurium with higher
potency and no histamine release and thus more cardiovas-
cular stability. It has replaced the original atracurium
because of these advantages. Like atracurium, it is particu-
larly indicated in patients with compromised hepatic and/or
renal functions. The dose for intubation is 0.2–0.3 mg/kg,
with onset in 3 minutes.
Mivacurium
Mivacurium is the only short-acting nondepolarizing muscle
relaxant currently available. It is metabolized by plasma
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cholinesterase. In some procedures, mivacurium can
replace succinylcholine if short duration of muscle relax-
ation is needed and succinylcholine is contraindicated.
Renal and hepatic patients have prolonged action of
mivacurium because of decreased plasma cholinesterase
in those patients. It can cause histamine release and thus
is not suitable for hemodynamically unstable patients.
The dose for intubation is 0.1–0.15 mg/kg, with recovery
in 15 minutes.
Vecuronium 
Vecuronium is a shorter-acting monoquaternary steroidal
analogue of pancuronium. It is classified as an intermediate-
duration nondepolarizing muscle relaxant. Because it causes
no vagolytic effects and does not provoke histamine release,
its use is associated with marked cardiovascular stability. The
metabolism and excretion of vecuronium are mainly
through the liver, although about 15–25% is excreted by the
kidneys. The elimination half-life is 70 minutes. The metabo-
lite 3-desacetyl vecuronium has about half the potency of the
parent compound.
The intravenous dose of vecuronium for adults is 0.1 mg/kg.
Onset of action is 2–3 minutes, peak relaxation occurs within
3–5 minutes, and the duration of action is 25–30 minutes.
Continuous infusion of vecuronium is recommended for
prolonged paralysis in patients with cardiovascular insta-
bility. A lower dose should be used in patients with hepatic
or renal failure. In patients with cardiac failure, modification
of the dose is not required.
In patients with normal renal and liver function, recovery
of neuromuscular function occurs rapidly when the infusion
is stopped, even after large doses. However, in patients with
renal and hepatic failure, the effect may be more variable and
the duration of action unpredictable.
Rocuronium 
Depending on the dose, rocuronium is a nondepolarizing
neuromuscular blocking agent with a rapid to intermediate
onset. With rocuronium 0.6 mg/kg, good to excellent intu-
bating conditions can be achieved within 2 minutes in
most patients. The duration of action of rocuronium at
this dose is approximately equivalent to the duration of
other intermediate-acting neuromuscular blocking drugs.
Generally, there are no dose-related changes in mean arterial
pressure or heart rate associated with injection. The rapid-
distribution half-life is 1–2 minutes, and the slower-
distribution half-life is 14–18 minutes. Rocuronium is
eliminated primarily by the liver. Patients with liver cirrhosis
have a marked increase in volume of distribution, resulting
in a plasma half-life that is approximately twice that of
patients with normal liver function. Currently, rocuronium
is used commonly to replace succinylcholine when rapid-
sequence intubation is needed or when succinylcholine is
contraindicated.
Doxacurium and Pipecuronium
Doxacurium and pipecuronium are as long-acting as pan-
curonium but are associated with better cardiovascular sta-
bility. Clinical experience with their use in the ICU is
limited. Both doxacurium and pipercuronium are obsolete
in clinical use owing to their lack of titratability compared
with other relaxants.
 Complications of Use of Muscle Relaxants 
Psychosomatic Effects 
When paralysis is imposed without adequate explanation
and sedation, severe psychosomatic stress and crisis may
result. If both muscle relaxants and sedatives are appropri-
ately titrated, the goal of management can be maintained in
a cooperative and well-sedated but easily arousable patient.
Suppression of Cough Reflex 
When all the respiratory muscles are paralyzed, the cough
reflex is suppressed. Endotracheal suctioning may provoke
no response or only an ineffective cough. Retention of secre-
tions can precipitate atelectasis and lead to pneumonia.
Neuromuscular Dysfunction and Prolonged
Paralysis
When controlled ventilation is indicated, prolonged use
(>48 hours) of neuromuscular blocking agents is often nec-
essary. Aside from delayed recovery from paralysis, there is
evidence that some degree of neuromuscular dysfunction
can occur. Clinically, these types of neuromuscular dysfunc-
tion range from generalized weakness, paresis, and areflexia
to persistent flaccid paralysis for days or months. There are
generally no sensory disturbances after discontinuation of
relaxants.
Long periods of iatrogenic immobilization lead to disuse
atrophy. Pathologic changes of motor endplates and muscle
fibers have been demonstrated. Electrodiagnostic studies
show evidence of neurogenic and myopathic abnormalities,
as well as transmission disturbances at the neuromuscular
junction. Unless strongly indicated, the duration of relax-
ation should be as short as possible. Range-of-motion exer-
cises may help to prevent atrophy and contracture.
 Monitoring with a Peripheral Nerve
Stimulator 
Without objective monitoring of responses, overdosing of
muscle relaxants is not uncommon. During surgical anesthe-
sia, train-of-four stimuli are used to detect the degree of
muscle relaxation. In the ICU, paralysis with total ablation
of twitches of a train-of-four is usually not necessary. The
use of peripheral nerve stimulators is helpful to titrate the
requirement of neuromuscular blocking agents.
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 Reversal of Neuromuscular Blockade 
While there is no specific antagonist for depolarizing agents,
nondepolarizing neuromuscular blockade can be reversed
with intravenously administered anticholinesterase drugs.
The commonly used anticholinesterases include edrophonium
(0.5 mg/kg), neostigmine (0.05 mg/kg), and pyridostigmine
(0.2 mg/kg). Anticholinergic agents such as atropine (0.01 mg/kg)
or glycopyrrolate (0.008 mg/kg) are usually given simultaneously
to offset the stimulation of muscarinic receptors.
A new reversal agent, cyclodextrin (Sugammadex), a large-
molecule sugar derivative, has proven significant reversibility
immediately after even large doses of steroid nondepolarizer
(eg, rocuronium and vecuronium) and will come to clinical
use soon. The need for succinylcholine will be decreased sig-
nificantly if cyclodextrin is available clinically.
Naguib M: Sugammadex: Another milestone in clinical pharma-
cology. Anesth Analg 2007;104:575–81. [PMID: 17312211]
SEDATIVE-HYPNOTICS FOR THE CRITICALLY ILL 
Critically ill patients are constantly exposed to an unusual
and frequently noxious environment that includes pain,
noise, tracheal suctioning, sensory overload or deprivation,
isolation, immobilization, physical restraints, lack of com-
munication, and sleep deprivation. These unpleasant experi-
ences can lead to anger, frustration, anxiety, and mental
stress. This may result in a diagnosis of ICU psychosis unless
organic and pharmacologic causes are excluded.
Sedative-hypnotic medications are used frequently to
calm the patient or induce sleep for therapeutic or diagnostic
purposes. Because of associated side effects, stable cardiopul-
monary function must be ensured prior to administration.
Furthermore, because individual responses may vary greatly
among patients—and even in the same patient at different
stages of illness—dosage should be adjusted carefully. The
conventional categories of sedative-hypnotic agents are the
benzodiazepines, barbiturates, and narcotics. The ideal agent
for use in the ICU should have a rapid onset of action, a pre-
dictable duration of action, no adverse effects on cardiovascu-
lar stability or respiratory function, a favorable therapeutic
index, no tendency toward accumulation in the body, ease of
administration, and available antagonists.
 Benzodiazepines 
Benzodiazepines (Table 5–3) produce sedation, anxiolysis, and
muscle relaxation. They also have anticonvulsant activity.
Flumazenil is the specific antagonist for benzodiazepines at a
dosage of 1 mg slowly intravenously up to a total dose of 3 mg.
Diazepam 
Diazepam binds to specific benzodiazepine receptors in cortical
limbic, thalamic, and hypothalamic areas of the CNS, where it
enhances the inhibitory effects of γ-aminobutyric acid (GABA)
and other neurotransmitters. Following an intravenous dose,
its onset of action is within 1–2 minutes. Maximum effect
is achieved in 2–5 minutes, and the duration of action is
4–6 hours. Diazepam is redistributed initially into adipose tis-
sue and is metabolized in the liver by microsomal oxidation
and demethylation. Its active metabolites are excreted by the
kidney with a half-life of 45 hours. The IM route should not
be used because of poor bioavailability from unpredictable
absorption. Abscesses may form at the injection site.
Diazepam is used to produce sedation and amnesia for
reduction of anxiety and unpleasant stress. It is also useful
for anticonvulsion, muscle relaxation, cardioversion,
endoscopy, and management of drug or alcohol withdrawal.
For relief of anxiety in adults, an intravenous bolus injec-
tion of 2–10 mg is given slowly. This can be repeated every
3–4 hours if necessary. When used for cardioversion, 5–15 mg
is administered intravenously 5–10 minutes before the pro-
cedure. For status epilepticus, 5–10 mg is administered intra-
venously and repeated every 10–15 minutes up to a
maximum dose of 30 mg. For acute alcohol withdrawal,
5–10 mg is given intravenously every 3–4 hours as necessary.
Diazepam can cause prolonged dose-related drowsiness,
confusion, and impairment of psychomotor and intellectual
functions. Paradoxical excitement can occur. Hypotension,
bradycardia, cardiac arrest, respiratory depression, and apnea
have been associated with rapid parenteral injection, partic-
ularly in elderly and debilitated patients. Allergic reactions
have been reported. Irritation at the infusion site and throm-
bophlebitis may occur.
Lorazepam 
Lorazepam acts on benzodiazepine receptors in the CNS and
enhances the chloride channel gating function of GABA by
promoting binding to its receptors. The resulting increase in
resistance to neuronal excitation leads to anxiolytic, hypnotic,
and anticonvulsant effects. Lorazepam is highly lipid soluble
and protein bound. It can be administered both intravenously
and intramuscularly. The onset of action following intra-
venous injection is within 1–5 minutes, with a peak at 60–90
minutes. The duration of action is 6–10 hours. Seventy-five per-
cent of the dose is conjugated in the liver and excreted in the
urine. The elimination half-life is 12–20 hours.
Lorazepam is useful for the management of anxiety with
or without depression, stress, and insomnia. It can be used
for preoperative sedation as well as status epilepticus.
Agent Intravenous Dose Duration of Action
Diazepam 2–10 mg 4–6 hours
Lorazepam 0.04 mg/kg 6–10 hours
Midazolam 0.1 mg/kg 0.5–2 hours
Table 5–3. Commonly used benzodiazepines.
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The common dosage for IV or IM administration is
0.04 mg/kg. Normal maximum doses are 2 mg intravenously
and 4 mg intramuscularly. The dose needs to be individual-
ized to minimize adverse effects. For status epilepticus, 0.5–2 mg
may be given intravenously every 10 minutes until seizures stop.
Side effects of drowsiness, ataxia, confusion, and hypoto-
nia are extensions of the drug’s pharmacologic effects.
Cardiovascular depression, hypotension, bradycardia, car-
diac arrest, and respiratory depression have been associated
with parenteral use of lorazepam, especially in elderly and
debilitated patients. Caution and adjustment of doses are
required when administering this drug to patients with liver
or kidney dysfunction.
Midazolam 
Midazolam, an imidazole benzodiazepine derivative, exerts
its sedative and amnestic effect through binding of benzodi-
azepine receptors. It is two to three times as potent as
diazepam. Its onset of action begins within 1–2 minutes after
an IV or IM dose. Its duration of action is 0.5–2 hours.
Midazolam reaches its peak of action rapidly (3–5 minutes)
and has a plasma half-life of 1.5–3 hours. Its high lipid solu-
bility results in rapid redistribution from the brain to inactive
tissue sites, yielding a short duration of action. Metabolism is
by hepatic microsomal oxidation with renal excretion of glu-
curonide conjugates. The drug’s half-life can be extended up
to 22 hours in patients with liver failure. It is water soluble
and can be administered intravenously or intramuscularly.
Pain and phlebitis at injection sites are seen less frequently
than with other benzodiazepines.
Midazolam is indicated for sedation, to creation of an
amnesia state, for anesthesia induction, and for anticonvul-
sant treatment. It has become the benzodiazepine of choice
for sedation in the ICU. Midazolam can be administered
intravenously or intramuscularly at a rate of 0.1 mg/kg to a
maximum dose of 2.5 mg/kg. Alternatively, intermittent
doses of 2.5–5 mg may be given every 2–3 hours. A rate of
1–20 mg/h or 0.5–10 μg/kg per minute can be used for con-
tinuous intravenous infusion.
Midazolam may cause unexpected respiratory depression or
apnea, particularly in elderly and debilitated patients. In combi-
nation with some narcotics, midazolam may cause myocardial
depression and hypotension in relatively hypovolemic patients.
Monitoring of cardiopulmonary function is required.
 Barbiturates 
The barbiturates possess sedative-hypnotic activities without
analgesia.
Thiopental 
This ultra-short-acting barbiturate is a potent coma-inducing
agent. It blocks the reticular activating system and depresses
the CNS to produce anesthesia without analgesia. It quickly
crosses the blood-brain barrier and has an onset of action
within 10–15 seconds after an intravenous bolus, a peak effect
within 30–40 seconds, and a duration of action of only 5–10
minutes. This initial effect on the CNS disappears rapidly as a
result of drug redistribution. Thiopental is metabolized by
hepatic degradation, and the inactive metabolites are excreted
by the kidney. The elimination half-life is 5–12 hours but can
be as long as 24–36 hours after prolonged continuous infu-
sion. In sufficient doses, thiopental can cause deep coma and
apnea but poor analgesia. It also produces a dose-related
depression of myocardial contractility, venous pooling, and
an increase in peripheral vascular resistance. Thiopental
reduces cerebral metabolism and oxygen consumption.
Thiopental is used for induction of general anesthesia but
is also useful for sedation, particularly in patients with high
intracranial pressures or seizures. It is also useful for short pro-
cedures such as cardioversion and endotracheal intubation.
For induction of anesthesia, an intravenous bolus of 3–5
mg/kg is given over 1–2 minutes. Individual responses are
sufficiently variable that the dose should be titrated to
patient requirements as guided by age, sex, and body weight.
In patients with cardiac, hepatic, or renal dysfunction, dose
reduction is required. Slow injection is recommended to
minimize respiratory depression. Convulsions usually can be
controlled with a dose of 75–150 mg. When continuous infu-
sion is required, the maintenance dose is 1–5 mg/kg per hour
of 0.2% or 0.4% concentration. After prolonged continuous
use, thiopental will become a long-acting drug.
Side effects of thiopental include respiratory depression,
apnea, myocardial depression with hypotension, laryn-
gospasm, bronchospasm, arrhythmias, and tissue necrosis
with extravasation. Thiopental is contraindicated in patients
with porphyria or status asthmaticus and in those with
known hypersensitivity to barbiturates.
 Opioids (Narcotics) 
Opioids (Table 5–4) have the advantage of possessing both
analgesic and sedative effects.
Table 5–4. Commonly used intravenous opioids. 
Agent
Usual Initial
Intravenous Dose Duration of Action
Morphine 3–5 mg 2–3 hours
Meperidine 25–50 mg 2–4 hours
Fentanyl 2–3 μg/kg 0.5–1 hours
Sufentanil 0.1–0.4 μg/kg 20–45 minutes
Alfentanil 10–15 μg/kg 30 minutes
Remifentinal 1–2 μg/kg <10 minutes
 CHAPTER 5112
Opioid Agonists
Opioid agonists acting at stereospecific opioid receptors at the
level of the CNS are associated with dose-related sedation in
addition to their pain-relieving effects. Titration to patient
response is advisable. Alterations in sensorium such as
nervousness, disorientation, delirium, and hallucinations can
occur. It is essential to maintain a balance between the patient’s
comfort and level of awareness. Opioids can cause peripheral
vasodilation, but their use has rarely been associated with clin-
ically significant cardiovascular effects. Unlike local anesthet-
ics, opioids do not block noxious stimuli via the afferent nerve
endings or nerve conduction along peripheral nerves.
Opioid agonists include morphine, meperidine,
methadone, fentanyl, sufentanil, alfentanil, and  remifentanil,
as well as other drugs. Each produces particular pharmaco-
logic effects depending on the types of receptors stimulated.
A. Morphine—Morphine, a pure agonist of opioid recep-
tors, produces analgesia through its action on the CNS. It
also can induce a sense of sedation and euphoria. Its volume
of distribution is 3.2–3.4 L/kg, its distribution half-life is
1.5 minutes, and its elimination half-life is 1.5 hours in
young adults. Elimination is prolonged up to 4–5 hours in
the elderly. It has an onset of action within 1–2 minutes, a
peak action at 30 minutes, and a duration of action of 2–3
hours. Morphine is metabolized primarily in the liver by
conjugation with glucuronic acid. It is excreted principally
through glomerular filtration. Only 10–50% is excreted
unchanged in the urine or in conjugated form in the feces.
Morphine is used widely for the management of moder-
ate to severe pain. A number of administration routes are
available. These include the epidural, intrathecal, IM, and IV
routes (by bolus injection such as PCA). Morphine is also
very useful for sedation, particularly in patients with some
pain. Other indications are myocardial infarction and pul-
monary edema.
Since absorption following IM or SQ administration is
unpredictable, the intravenous route is preferable in critically
ill patients. The initial intravenous dose is 3–5 mg. This may
be repeated every 2–3 hours as necessary to titrate effect. For
maintenance, it can be given by continuous infusion at a rate
of 1–10 mg/h.
Morphine causes respiratory depression through direct
action on the pontine and medullary respiratory centers. It
decreases the response to CO2 stimulation. Respiratory depres-
sion, which is dose-dependent, occurs shortly after intravenous
injection but may be delayed following IM or SQ administra-
tion. In therapeutic doses, morphine produces little change in
the cardiovascular system other than occasional bradycardia
and mild venodilation. It also causes nausea and vomiting,
bronchial constriction, spasm at the sphincter of Oddi, constipa-
tion, and urinary urgency and retention. In patients with renal,
hepatic, or cardiac failure, smaller doses at less frequent intervals
may be necessary. Respiratory depression can be treated with
naloxone, 0.4–2 mg intramuscularly or intravenously.
B. Meperidine—Meperidine, a phenylpiperidine derivative opi-
oid agonist, is one-tenth as potent as morphine and has a slightly
faster onset and shorter duration of action. Meperidine is metab-
olized in the liver by demethylation to normeperidine, which is an
active metabolite. It has a distribution half-life of 5–15 minutes,
an elimination half-life of 3–4 hours, and a duration of action
of 2–4 hours. Meperidine can cause direct myocardial depres-
sion and histamine release. It may increase the heart rate via a
vagolytic effect. Overdosage of meperidine may depress venti-
lation. Compared with morphine, meperidine produces less
biliary tract spasm, less urinary retention, and less constipation.
It is useful as an analgesic for short procedures that produce
moderate to severe pain. It is also used to induce sedation.
For intravenous administration, the initial dose is 25–50
mg every 2–3 hours as necessary. For IM injection, 50–200
mg is given initially and repeated every 2–3 hours if required.
Ventilatory depression can be reversed with naloxone. Other
side effects include histamine release, hypotension, nausea
and vomiting, hallucinations, psychosis, and seizures.
C. Methadone—Methadone is a synthetic mu-agonist opi-
oid. Absorption from the stomach is fast, but the onset is
slow. It is metabolized by the liver without active metabolites,
so there is no need to reduce dose in renal failure patients.
The elimination half-life is about 22 hours, but metabolism
varied in each person, requiring careful titration to avoid
accumulation and side effects. The initial dose is 5–10 mg PO
bid to tid. Methadone is used initially for detoxication of opi-
oid addiction, but now its use is emerging for the treatment
of chronic pain and cancer pain. Respiratory depression is
the most serious complication, especially when it is com-
bined with benzodiazepines.
D. Fentanyl—Fentanyl, a highly lipid-soluble synthetic opioid
agonist, crosses the blood-brain barrier easily. It is 75–125
times more potent than morphine as an analgesic. It has a
rapid onset of action (<30 seconds), a short duration of effect,
a plasma half-life of 90 minutes, and an elimination half-time
of 180–220 minutes. Initially, fentanyl is redistributed to inac-
tive tissue sites such as fat and muscle. It is eventually metabo-
lized extensively in the liver and excreted by the kidneys.
When fentanyl is administered in repeated doses or by
continuous infusion, progressive saturation occurs. As a
result, the duration of analgesia—as well as ventilatory
depression—may be prolonged. Fentanyl does not cause his-
tamine release and is associated with a relatively low inci-
dence of hypotension and myocardial depression. It has been
used widely in balanced anesthesia for cardiac patients.
Fentanyl is indicated for short, painful procedures such as
orthopedic reductions and laceration repair. The initial intra-
venous dose is 2–3 μg/kg over 3–5 minutes for analgesia. The
dosing interval is 1–2 hours. A reduced dose and an increase
in dosing interval may be necessary in hepatic or renal disease.
Ventilatory depression is a potential complication follow-
ing fentanyl. Muscle rigidity, difficult ventilation, and respira-
tory failure can develop and call for administration of naloxone.
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E. Sufentanil—Sufentanil, a thienyl analogue of fentanyl, has
high affinity for opioid receptors and an analgesic potency
5–10 times that of fentanyl. Its lipophilic nature permits rapid
diffusion across the blood-brain barrier followed by quick
onset of analgesic effect. The effect is terminated by rapid
redistribution to inactive tissue sites. Repeated doses of sufen-
tanil can cause a cumulative effect. Sufentanil has an interme-
diate elimination half-time of 150 minutes and a smaller
volume of distribution. It is metabolized rapidly by dealkyla-
tion in the liver. Metabolites are excreted in urine and feces.
Sufentanil is given intravenously in doses of 0.1–0.4 μg/kg
to produce a longer period of analgesia and less depression of
ventilation than a comparable dose of fentanyl. Sufentanil
may cause bradycardia, decreased cardiac output, and delayed
depression of ventilation.
F. Alfentanil—Alfentanil, a highly lipophilic narcotic, has a
more rapid onset and a shorter duration of action than fen-
tanyl. The onset of action after intravenous administration is
1–2 minutes. Because of the agent’s low pH, more of the nonion-
ized fraction is available to cross the blood-brain barrier. The
serum elimination half-life of alfentanil is about 30 minutes
because of redistribution to inactive tissue sites and metabolism.
The drug is metabolized in the liver and excreted by the kidney.
Continuous intravenous infusion of alfentanil does not
lead to a significant cumulative effect. Alfentanil does not
cause histamine release and thus tends not to cause hypoten-
sion and myocardial depression. It can be used in patients
with chronic obstructive pulmonary disease or asthma.
Respiratory depression can occur with large doses.
The initial dose for intravenous injection is 10–15 μg/kg
over 3–5 minutes, repeated every 30 minutes as needed. For
maintenance, continuous infusion is given at a rate of
25–150 μg/kg per hour. Reduction of dosage and increase in
dosing interval are required in hepatic and renal dysfunction.
Muscle rigidity and respiratory depression may develop fol-
lowing administration of alfentanil.
G. Remifentanil—Remifentanil is an ultra-short-acting syn-
thetic opioid. It is metabolized by hydrolysis of blood and tissue
cholinesterase. Because of its rapid metabolism, the administra-
tion of remifentanil has to use continuous infusion. It has very
little accumulative effect even after prolonged infusion.
Combination of propofol and remifentanil infusion provides a
controllable and rapid-recovery regimen for either anesthesia or
sedation in the OR as well as in the ICU. Hypotension can occur
if remifentanil is given in a large dose or too fast.
Opioid Agonist-Antagonists 
Opioid agonist-antagonists bind to opioid receptors and
produce limited pharmacologic responses to opioids. They
are effective analgesics but lack the efficacy of subsequently
administered opioid agonists. The advantage of this group of
drugs is the ability to provide analgesia with limited side effects,
including ventilatory depression and physical dependence.
A. Butorphanol—Butorphanol, acting on different opioid
receptors, has agonist and antagonist effects. It may be used
for control of acute pain. However, in comparison with
equianalgesic doses of morphine, it may cause similar venti-
latory depression. It is metabolized in the liver to an inactive
form that is largely eliminated in the bile. The onset of anal-
gesia is within 10 minutes following IM injection, peak activ-
ity is within 30–60 minutes, and the elimination half-life is
2.5–3.5 hours. Following intravenous doses, butorphanol
may increase mean arterial pressure, pulmonary wedge pres-
sure, and pulmonary vascular resistance. It is useful for post-
operative or traumatic pain of moderate or severe degree.
For the average adult, the usual intravenous dose is 0.5–2
mg every 3–4 hours as required. Butorphanol also may be given
by IM injection at dosage of 1–4 mg every 3–4 hours as indi-
cated. Side effects include dizziness, lethargy, confusion, and
hallucinations. Butorphanol may increase the cardiac work-
load, which limits its usefulness in acute myocardial infarction
or coronary insufficiency and congestive heart failure.
B. Buprenorphine—Buprenorphine is derived from the
opium alkaloid thebaine. It has 50 times the affinity of mor-
phine for the mu receptors and is a powerful analgesic drug.
It is highly lipid soluble and dissociates slowly from its recep-
tors. After IM administration, analgesia occurs within 15–30
minutes and persists for 6–8 hours, with a plasma half-life of
2–3 hours. Two-thirds of the drug is excreted unchanged in
the bile and one-third in the urine as inactive metabolites. A
buprenorphine dose of 0.3–0.4 mg is equivalent to 10 mg
morphine.
Buprenorphine is indicated for the control of moderate
to severe pain such as that of myocardial infarction, cancer,
renal colic, and postoperative or posttraumatic discomfort.
For IM or IV administration, 0.3–0.4 mg buprenorphine is
given every 6–8 hours as needed. Drowsiness, nausea, vomit-
ing, and depression of ventilation are common side effects.
The duration of ventilatory depression may be prolonged
and resistant to antagonism with naloxone.
Toombs JD, Kral LA: Methadone treatment for pain states. Am
Fam Physician 2005;71:1353–8. [PMID: 15832538]
 Opioid Antagonists
Pure opioid antagonists act by a competitive mechanism in
which they bind to receptors, making them unavailable to the
agonist. Naloxone is the single agent used clinically.
Naloxone 
Naloxone, a synthetic congener of oxymorphone, competi-
tively displaces opioid agonists from the mu receptors and thus
reverses opioid-induced analgesia and ventilatory depres-
sion. Following intravenous administration, naloxone has a
rapid onset of effect (within 2 minutes) and a relatively short
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duration of action (30–45 minutes). For this reason,
repeated doses or continuous infusions are usually required
for sustained antagonist effects. Naloxone is metabolized in the
liver by conjugation, with an elimination half-life of 60–90 min-
utes. Naloxone is used most commonly for the treatment of
opioid-induced ventilatory depression and opioid overdosage.
Intravenous doses of 1–4 μg/kg are given to reverse
opioid-induced ventilatory depression. Boluses of 0.4–2 mg
(intravenously, intramuscularly, or subcutaneously) may be
repeated every 2–3 minutes up to a total dose of 10 mg.
Continuous infusion of 5 μg/kg per hour may reverse venti-
latory depression without affecting analgesia.
Reversal of analgesia, nausea, and vomiting can occur fol-
lowing naloxone administration when it is given to antago-
nize ventilatory depression. Larger doses of naloxone have
been associated with increased sympathetic activity mani-
fested by tachycardia, hypertension, pulmonary edema, and
cardiac arrhythmias.
 Haloperidol 
Haloperidol, a butyrophenone antipsychotic agent, produces
rapid tranquilization and sedation of agitated or violent
patients. The mechanism of action is unclear, although it
may be related to antidopaminergic activity. Onset of action
is 5–20 minutes when haloperidol is given intravenously or
intramuscularly. Peak action is at 15–45 minutes, although
the duration of effect is highly variable (4–12 hours).
Haloperidol is metabolized in the liver and excreted through
the kidneys. The plasma half-life is 20 hours. Haloperidol
causes few hemodynamic or respiratory changes.
For control of agitated patients, administration begins
with IV or IM doses of 1–2 mg. This dosage can be increased
to 2–5 mg every 8 hours. The dose may be doubled every
30 minutes until the patient is calmed. Maintenance dosage
depends on individual response. As much as 50 mg over 1–2
hours has been used.
Haloperidol can cause extrapyramidal reactions and is
absolutely contraindicated in patients with Parkinson’s dis-
ease. Other complications include neuroleptic malignant
syndrome, hypotension, seizures, and cardiac arrhythmias.
Haloperidol also may antagonize the renal diuretic effect of
dopamine.
 Intravenous Anesthetics 
Propofol 
Propofol, an isopropylphenol, is used increasingly for sedation
and induction of general anesthesia. Following intravenous
administration, it produces unconsciousness within 30 seconds.
In most cases, recovery is more prompt and complete than
recovery from thiopental and without residual effect.
Redistribution and liver metabolism are responsible for
rapid clearance of propofol from the plasma. Elimination
seems not to be affected by renal or hepatic dysfunction. The
plasma half-life is 0.5–1.5 hours. Propofol has been used by
continuous infusion without excessive cumulative effect.
Hemodynamically, it may cause hypotension, especially in
hypovolemic or elderly patients or those with heart failure.
Propofol can produce transient ventilatory depression or
apnea following rapid intravenous boluses.
In the ICU, propofol may be used for brief procedures
such as cardioversion, endoscopy, and endotracheal intuba-
tion and for sedation of agitated, anxious patients. The
dosage for sedation is 1–3 mg/kg per hour; for anesthesia, the
dosage is 5–15 mg/kg per hour.
Propofol may cause ventilatory and cardiovascular
depression, particularly if given rapidly or in large amounts.
It has been noted to increase the prothrombin time. After
high-dose and long-term infusion, rhabdomyolysis, meta-
bolic acidosis, and renal failure had been reported.
Hypertriglyceridemia had been mentioned but has not been
substantially related to propofol infusion.
Ketamine 
Ketamine, a phencyclidine derivative, produces dissociative
anesthesia with profound analgesia and hypnosis. In contrast
to inhalation anesthetics, ketamine is characterized by
slightly increased skeletal muscle tone, normal pharyngeal
and laryngeal reflexes with a patent airway, and cardiovascu-
lar stimulation secondary to sympathetic discharge. It has a
rapid onset of action (intravenously, less than 1 minute;
intramuscularly, 15–30 minutes). Its volume of distribution
is 3 L/kg, and its distribution half-life is 15–45 minutes.
Ketamine is eliminated by hepatic biotransformation, with a
plasma half-life of 2–3 hours. With doses lower than those
needed for dissociative anesthesia, ketamine induces analge-
sia comparable with that achieved with the opioids. It also
produces bronchodilation.
In the ICU, ketamine is useful as a sole anesthetic or anal-
gesic agent for relatively short diagnostic and surgical proce-
dures that do not require muscle relaxation. It has been used
for treatment of persistent status asthmaticus. It is one of the
agents of choice for the care of burn patients. An IV dose of
2 mg/kg or an IM dose of 10 mg/kg may be used to produce
surgical anesthesia. For maintenance, 10–30 μg/kg per minute
is given by continuous infusion. Ketamine at a dosage of
0.2–0.3 mg/kg produces analgesia with little change in the level
of consciousness. It is particularly useful in patients who have
cardiovascular depression and are in constant pain.
Transient emergence hallucinations, excitement, and delir-
ium have been associated with ketamine administration in
5–30% of patients. Stimulation of the cardiovascular system
may cause tachycardia, hypertension, and increased myocar-
dial oxygen consumption. Other side effects include nystag-
mus, nausea, paralytic ileus, increased skeletal muscle tone,
and slight elevation in intraocular pressure. Severe respiratory
depression or apnea may occur following rapid intravenous
administration of high doses. Ketamine is contraindicated in
patients with increased intracranial pressure because it aug-
ments cerebral blood flow and oxygen consumption.
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MALIGNANT HYPERTHERMIA 
ESSENT IALS  OF  D IAGNOS I S
 History of exposure to agents known to trigger malig-
nant hyperthermia.
 Development of muscle rigidity.
 Signs of hypermetabolic activity with hyperthermia.
 Confirmation by muscle biopsy with caffeine-halothane
contracture test.
General Considerations 
Malignant hyperthermia is a syndrome characterized by a
paroxysmal fulminant hypermetabolic crisis in both skeletal
and heart muscle. Massive heat is generated and overwhelms
the body’s normal dissipation mechanisms. It is a complica-
tion uniquely associated with anesthesia. Almost any anes-
thetic agent or muscle relaxant may trigger malignant
hyperthermia. Halothane and succinylcholine are the most
common offenders. Malignant hyperthermia can occur at
any time perioperatively—before, during, or after the induc-
tion of anesthesia.
The incidence of malignant hyperthermia is difficult to
assess because of various regional distributions. It is esti-
mated to occur in 1:50,000 adults and 1:15,000 children
undergoing general anesthesia.
Pathophysiology 
Malignant hyperthermia is a genetically predisposed syn-
drome transmitted as an autosomal dominant trait with
reduced penetrance and variable expressivity. The precise
cause has not been fully elucidated. The central pathophysi-
ologic event is a sudden increase in intracellular Ca2+ con-
centration in skeletal and perhaps also cardiac muscles
triggered by causative agents. This may be due to any of the
following mechanisms singly or in combination: increased
release of Ca2+ from the sarcoplasmic reticulum, inhibition
of calcium uptake in the sarcoplasmic reticulum, defective
accumulation of calcium in mitochondria, excessive calcium
influx via a fragile sarcolemma, and exaggeration of adrener-
gic activity.
The excessive myoplasmic calcium activates ATPase and
phosphorylase, thus causing muscle contracture and a mas-
sive increase in oxygen consumption, CO2 production, and
heat generation. The toxic concentrations of calcium within
mitochondria uncouple oxidative phosphorylation that
leads to increased anaerobic metabolism. The production of
lactate, CO2, and heat is accelerated. Membrane permeability
increases when the ATP level eventually falls. This allows K+,
Mg2+, and PO4
2– to leak from and calcium to flow into
myoplasm. As a result, severe respiratory and metabolic aci-
dosis develops, followed by dysrhythmias and cardiac arrest.
Rhabdomyolysis, hyperkalemia, and myoglobinuria are
common consequences of muscle damage.
Clinical Features 
A. Symptoms and Signs—Unexplained tachycardia (96%)
and tachypnea (85%) are usually the earliest and most
consistent—but nonspecific—signs of malignant hyperther-
mia. The patient also may present with profuse sweating, hot
and flushed skin, mottling and cyanosis, arrhythmias, and
hypertension or hypotension. During anesthesia, the canister
of CO2 absorbent is overheated. Evidence of increased mus-
cle tone may appear in the form of marked fasciculations or
sustained muscle rigidity.
A rapid rise of body temperature (1°C per 5 minutes) is a
classic but relatively late sign. The magnitude and duration
of fever directly affect the mortality rate. Conventionally, the
diagnosis of malignant hyperthermia is based on the clinical
triad of (1) a history of exposure to an agent or stress known
to trigger the episode, (2) development of muscle rigidity,
and (3) signs of hypermetabolic activity with hyperthermia.
However, 20% of patients may never manifest any percepti-
ble hyperthermia or muscle rigidity. Signs of pulmonary
edema, acute renal failure, myoglobinuria, disseminated
intravascular coagulation, and cardiovascular collapse may
occur subsequently.
B. Laboratory Findings—Respiratory and metabolic acido-
sis with hypercapnia is the characteristic finding on arterial
blood gas analysis. Clinically, a sudden marked increase in
end-tidal CO2 is the best early clue to the diagnosis.
Hypoxemia, hyperkalemia, hypermagnesemia, myoglobine-
mia, hemoglobinemia, and increases in lactate, pyruvate, and
creatine kinase may be seen.
C. Special Tests—The diagnosis can be confirmed by mus-
cle biopsy with the caffeine-halothane contracture test.
Clinically, rapid resolution after treatment with dantrolene is
highly suggestive.
Genetic testing for a ryanodine receptor on chromosome
19q13.2 is the major locus of malignant hyperthermia sus-
ceptibility, but there are several other loci, and a high muta-
tion rate has been identified.
Currently, there are six malignant hyperthermia diagnos-
tic centers in the United States for performing contracture
and genetic testing. The Malignant hyperthermiathe Hotline
(1-800-644-9737) is available 24 hours a day for consultation.
Complications 
Late complications of malignant hyperthermia involve mul-
tiple organ systems (Table 5–5).
Treatment 
Early diagnosis and prompt drug treatment cannot be
overemphasized. To be effective, dantrolene must be given
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before tissue ischemia occurs. Hyperthermia must be con-
trolled as quickly as possible. Standard supportive and cool-
ing measures should be started immediately and
simultaneously with the administration of dantrolene.
The treatment of malignant hyperthermia should pro-
ceed as follows:
1. Immediately discontinue all possible triggering agents if
any are still in use.
2. Perform intubation and start hyperventilation with 100%
oxygen.
3. Initiate active cooling by internal and external measures;
use intravenous refrigerated saline, iced saline lavage of
the stomach or rectum, surface cooling with a thermal
blanket, ice or alcohol, and fans.
4. Dantrolene sodium is the only specific drug for treatment
of malignant hyperthermia. A hydantoin derivative, it
acts by inhibiting the release of calcium from the sarcoplas-
mic reticulum. Intravenous dantrolene should be started at
a rate of 1–2 mg/kg. Warming the preservative-free sterile
water to fasten dissolving dantrolene is recommended.
Repeat the same dose every 15–30 minutes up to 10–20
mg/kg, if necessary, until signs of improvement become evi-
dent. Response is indicated by slowing of the heart rate, res-
olution of arrhythmia, relaxation of muscle tone, and
decline in body temperature. Because retriggering may
occur, dantrolene should be continued for 24–48 hours.
5. Fluid resuscitation, diuretics, procainamide, and bicar-
bonate should be used as indicated.
6. Continue to monitor the patient closely.
Prognosis 
The mortality and morbidity rate, high 2 decades ago (70%),
is now much lower (10%) because of earlier diagnosis and
effective treatment.
Ruffert H et al: [Current aspects of the diagnosis of malignant
hyperthermia] (in German). Anaesthesist 2002;51:904–13.
[PMID: 12434264]
Urwyler A et al: Guildlines for the molecular detection of suscepti-
bility to malignant hyperthermia. Br J Anaesth 2001;86:283–7.
[PMID: 11573677] 
Sei Y et al: Malignant hyperthermia in North America: Genetic
screening of the three hot spots in the type I ryanodine receptor
gene mutations. Anesthesiology 2004;101:824–30.
Site Complication
Heart Increase in myocardial oxygen consump-
tion, decrease in myocardial contractility,
decrease in cardiac output, hypotension,
dysrhythmia, and cardiac arrest.
Lungs Pulmonary edema.
Central nervous system Cerebral edema and hypoxia, convulsion,
of, coma, brain death, and increased sym-
pathetic activity.
Kidneys Acute renal failure, myoglobinuria, and
hemoglobinuria.
Hematologic system Disseminated intravascular coagulopathy,
hemolysis.
Liver Increased hepatic enzyme activity. 
Musculoskeletal system Muscle edema and necrosis.
Table 5–5. Late complications of malignant hyperthermia.
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Nutrition
John A. Tayek, MD
NUTRITION & MALNUTRITION IN THE
CRITICALLY ILL PATIENT
In the critically ill patient, nutritional status plays a key role
in recovery. The extent of muscle wasting and weight loss in
the ICU is inversely correlated with long-term survival.
However, because conventional nutritional therapy of mal-
nourished critically ill patients has not been demonstrated to
produce anabolism, blunting of the catabolic state may be
the more effective strategy. The use of conventional nutri-
tional support and the role of newer nutritional adjunctive
techniques used in the critical care setting will be discussed
in this chapter.
 Metabolic & Nutritional Changes During
Critical Illness
Acute-Phase Response
The acute-phase response to sudden illness or trauma is one
of the most basic features of the body’s defenses against
injury. Phylogenetically, this response could be considered
the most primitive one that occurs, and it is similar for
insults owing to trauma, burns, or infections. It includes
alterations in amino acid distribution and metabolism, an
increase in acute-phase protein synthesis, increased gluco-
neogenesis, reductions in serum iron and zinc levels, and
increased serum copper and ceruloplasmin levels. Fever and
negative nitrogen balance follow as a consequence of these
changes.
Changes in levels of cytokines and hormones occur as
part of the acute-phase response. For example, an infectious
process in the lung will attract monocytes that will be trans-
formed into macrophages at the site of infection. These
macrophages will secrete proteins known as cytokines and
other peptides that attract other white blood cells and initi-
ate the inflammatory response common to many types of
injury. These cytokines include tumor necrosis factor-α
(TNF-α) and interleukins 1–32. TNF-α and other cytokines
circulate to the liver, where they inhibit albumin synthesis
and stimulate the synthesis of acute phase proteins, including
(1) C-reactive protein, which promotes phagocytosis and
modulates the cellular immune response, (2) α1-antichy-
motrypsin, which minimizes tissue damage from phagocytosis
and reduces intravascular coagulation, and (3) α2-
macroglobulin, which forms complexes with proteases and
removes them from circulation, maintains antibody produc-
tion, and promotes granulopoiesis. TNF-α and some of the
interleukins also circulate to the brain, where they are
responsible for induction of fever and initial stimulation of
adrenocorticotropic hormone release with a subsequent rise
in serum cortisol.
Hormonal Changes
A. Insulin Resistance—As a result of severe injury, many
patients develop the syndrome of insulin resistance with
hyperglycemia even though they had no history of diabetes
prior to the injury. Patients with new-onset diabetes, defined
as two random blood glucose determinations greater than
199 mg/dL or two fasting blood glucose determinations
greater than 125 mg/dL, have an increased hospital and ICU
mortality compared to known diabetics. Hospital mortality
increased 3–16% in new-onset diabetic patients compared
with known hospitalized diabetic patients. ICU mortality is
increased threefold in this group of patients (30% versus
10%). New-onset diabetic patients had the same level of
injury as the known diabetics. The higher mortality may be
due to the proinflammatory effect of an elevated glucose
concentration.
Both the injury response and the septic state are associ-
ated with a decrease in whole body glucose oxidation and an
increase in the fasting hepatic glucose production rate.
Recently, it has been demonstrated that the elevated blood
glucose in sepsis and injury is due to an overproduction of
glucose by the liver.
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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The rise in serum cortisol is one of the many factors
responsible for the development of insulin resistance. Insulin
resistance is easy to diagnose because the injured patient will
develop an elevated blood glucose level (fasting >125 mg/dL
or nonfasting >199 mg/dL). In addition to cortisol, eleva-
tions in catecholamines, glucagon, and growth hormone in
the injured patient also contribute to the development of
insulin resistance. All these hormones increase the rate of
hepatic glucose production.
Increased catecholamine levels are a direct response to the
injury via secretion of these hormones by the adrenal gland
and sympathetic ganglia throughout the body. Glucagon and
growth hormone levels increase in response to the injury.
Both hormones are known to increase hepatic glucose
production.
B. Thyroid Hormones—As a normal response to injury, the
body’s ability to convert the stored form of thyroid hormone,
thyroxine (T4), into the active form, triiodothyronine (T3),
becomes impaired. There is increased conversion of T4 to an
inactive thyroid hormone known as reverse T3 (rT3) rather
than T3. This may have evolved as an energy-saving response
during severe injury or illness to reduce the known contribu-
tion of T3 to increased resting energy expenditure. Thus the
syndrome of low T3 (sick euthyroid syndrome) seen in acute
illness is an adaptive strategy that reduces the normal effects
of T3 on resting energy expenditure.
In clinical trials, normalization of T3 values by replace-
ment of thyroid hormone in cardiovascular surgery patients
has been accomplished without noted harm. However, in
critically ill patients, the administration of T3 should not be
provided until clinical trials are performed to document an
improved clinical outcome.
Catabolism and Urine Urea Nitrogen
As part of the injury response resulting in protein break-
down, critically ill adult patients may lose about 16–20 g of
nitrogen (in the form of urea) in the urine per day—
compared with about 10–12 g/day in normal individuals.
In some septic patients, losses have been noted to be
as high as 24 g of urinary urea nitrogen per day. The loss
of 1 g of urinary urea nitrogen is equal to the nitrogen con-
tained in 6.25 g protein. This amount of protein is equal to
approximately 1 oz of lean body mass. As one can calcu-
late, the loss of 16 g nitrogen as urinary urea therefore is
equal to the loss of about 1 lb of skeletal muscle or lean
body mass per day.
Specific areas of loss of lean body mass loss may result in
functional impairment of the respiratory muscles (including
the diaphragm), heart muscle, and gastrointestinal mucosa,
thus contributing to the development of respiratory failure,
heart failure, and diarrhea. Rapid development of malnutri-
tion can occur in the critically ill patient as a result of these
large daily losses of lean body mass. The patient who enters
the ICU at 100% of ideal body weight (IBW) usually will not
survive a weight loss greater than 30%. However, because
large changes in intravascular and extravascular fluid may
occur in critically ill patients, body weight needs to be corre-
lated with loss in lean body mass (estimated from urinary
creatinine) to confirm that any weight changes are not just
due to changes in fluid volume.
The injury response is associated with an increase in both
protein synthesis and protein degradation, as determined by
either stable or radioactive amino acid tracer infusion stud-
ies. In contrast to increased whole body protein synthesis,
skeletal muscle protein synthesis is usually reduced, so the
increased whole body protein synthesis may be due to pro-
duction of acute-phase proteins, leukocytes, complement,
and immunoglobulins. Leukocytes have a 4–6-hour half-life
during infection, so adequate nutritional support is impor-
tant for their replacement and function. It has been esti-
mated that the average adult can break down and
resynthesize up to 400 g protein per day.
Conventional Total Parenteral Nutrition and Loss
of Lean Body Mass
It has been demonstrated that conventional total parenteral
nutrition (TPN) given at a rate of 39 kcal/kg per day and
1.8 g/kg per day of protein did not stop the loss of lean body
mass in acute illness. Despite this aggressive feeding regimen,
critically ill patients lost an average of 24 g nitrogen (1.5 lb of
lean body mass) per day over a 10-day period, resulting in a
15-lb loss of lean body mass. These patients were able to
increase the fat content of their bodies by about 5 lb over this
same period, but they were unable to increase lean body
mass. It was concluded that conventional TPN in this study
was able to ameliorate the overall nitrogen and lean body
mass loss but was not able to produce a net protein
anabolism. Because of the inability of conventional TPN to
stop progressive loss of lean body mass in acute illness, sev-
eral anabolic agents (eg, insulin, anabolic steroids, and
growth hormone) have been or may be studied in the future
to see if they can prevent the loss of lean body mass and its
functional consequences.
 Nutritional Assessment & Prediction
of Outcome
Nutritional Markers
Conventional nutritional assessment in the critically ill
patient is of limited value. Daily weights in critically ill
patients are helpful more for the determination of fluid
changes and less for the determination of actual loss of lean
body mass. The 24-hour urine urea nitrogen measurement is
the single best determination of the severity of the injury
response, but it cannot be used in those who have oliguric
renal failure. Daily measurement of urine urea nitrogen is
inexpensive and provides a good marker of catabolism that
may not be detected from systemic signs such as tachycar-
dia, tachypnea, or fever. Unfortunately, the severity of the
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catabolic response to injury is the same in malnourished and
nonmalnourished patients. Therefore, the absolute urine
urea nitrogen content does not indicate who is initially more
malnourished.
Protein requirements for critically ill patients can be esti-
mated by the use of the 24-hour urinary urea loss. Add 4 g to
the quantity of urinary urea (in grams) to get an estimate of
total nitrogen losses (in grams). For example, if the urine
urea nitrogen is 12 g per day, add 4 g to equal 16 g of nitro-
gen loss per day. Multiply this amount by 6.25 to determine
the protein requirement per day (16 g nitrogen × 6.25 g
protein/g of nitrogen = 100 g of protein per day). Adjustments
should be made based on the urinary urea loss + 4 g +
additional nitrogen losses estimated if there are severe stool,
skin, or fistula losses.
Serum Albumin
The serum albumin level is one of the best predictors of mal-
nutrition because it provides the clinician with an index of
visceral and somatic protein stores in most medical illnesses.
Exceptions include anorexia nervosa and congenital analbu-
minemia (rare). Serum albumin level rarely increases during
most hospital stays because of albumin’s 21-day half-life.
Thus, while serum albumin is a marker of initial nutritional
status, serum transferrin (7-day half-life) or, better yet, pre-
albumin (1-day half-life) responds more rapidly to nutri-
tional support. Either one can be used to monitor sequential
measurements, which would reflect improvements in nutri-
tional intake and status.
Albumin is a 584-amino-acid protein with a net negative
charge of 19, permitting transport of many compounds.
Large portions of the plasma’s calcium, magnesium, zinc,
bilirubin, many drugs (eg, anticoagulants, antibiotics, etc.),
and free fatty acids are transported bound to albumin.
Approximately 40% of whole body albumin reserves (4–5 g/kg)
are intravascular, and albumin is responsible for about 76%
of the colloid oncotic pressure of the plasma. Patients with
normal serum albumin levels have less wound edema, and
the inflammatory phase of wound healing is shortened.
A. Causes of Hypoalbuminemia—Except for the rare
patient with analbuminemia, hypoalbuminemia results from
an increase in plasma volume; an increase in skin, urine, or
stool losses of albumin; an increase in albumin degradation;
loss into ascites; or a reduction in albumin synthesis. Bed rest
is associated with an approximately 7% increase in plasma
volume and an equal reduction in serum albumin. In
patients who are hypoalbuminemic, plasma volume can
increase by 18% with bed rest. Because the skin stores
approximately 20% of the total albumin mass, excessive
losses of albumin occur with burns and subsequent exuda-
tive losses. Massive losses of protein can occur in the
nephrotic syndrome, in which 60% to as much as 90% of the
protein lost in the urine is albumin. Gastrointestinal losses of
protein can vary markedly, and the amount of albumin nor-
mally degraded and lost in the stool is not known. In addition,
large amounts can be lost into ascites fluid. A third factor
contributing to the development of hypoalbuminemia is
impaired albumin synthesis in the liver. Albumin is synthe-
sized in the hepatocyte as a larger precursor, preproalbumin,
containing 24 additional amino-terminal amino acids
referred to as the signal peptide. The preproalbumin under-
goes two sequential cleavages within the rough endoplasmic
reticulum within 3–6 minutes of initial formation and is
transported to the Golgi apparatus within 15–20 minutes for
subsequent vesicular release. Albumin synthesis is inhibited
by severe protein and calorie deprivation, ethanol, severe
liver disease, malabsorption, early forms of injury, burns,
infections, cancer cachexia, and aging.
B. Albumin Synthesis—The rate of albumin synthesis (nor-
mally 150 mg/kg per day) is stimulated by (1) reduction in
colloid oncotic pressure, (2) antibiotic treatment, (3) gluco-
corticoid therapy in cirrhosis, and (4) amino acid adminis-
tration. Albumin synthesis was increased to 350 mg/kg per
day in a small group of patients with idiopathic tropical diar-
rhea following 2 weeks of tetracycline therapy. In a small
group of patients with cirrhosis, prednisolone, 60 mg daily
for 2 weeks, was associated with an increase of albumin syn-
thesis from 130 to 260 mg/kg per day.
In one study, albumin synthesis is more stimulated (240
mg/kg per day) after 300 kcal of amino acid administration
than after 400 kcal of glucose administration (160 mg/kg per
day). Furthermore, albumin synthesis is higher (360 mg/kg
per day) when providing a total of 700 kcal/day rather than
only 300 kcal/day (albumin synthesis rate 240 mg/kg per
day) for the same protein intake (1 g/kg per day).
There is a positive correlation between albumin synthesis
rate and serum concentrations of leucine, isoleucine, valine,
and tryptophan. It appears that the albumin synthesis rate in
cancer cachexia is also responsive to isonitrogenous amounts
of a branched-chain-enriched amino acid solution. In one
study, cancer patients increased albumin synthesis from 100
to 190 mg/kg per day as a result of increased administration
of leucine, isoleucine, and valine (branched-chain amino
acids). These observations imply that providing a diet rich in
tryptophan, leucine, isoleucine, and valine may stimulate
albumin synthesis.
Nutritional Predictors of Outcome
Serum albumin is an excellent predictor of survival (Table 6–1).
At least 22 studies to date have shown that a below-normal
serum albumin level can be used to predict disease outcome
in many groups of patients. Thirty-day mortality rates for a
total of 2060 consecutive medical and surgical admissions
were reported at a Veterans Affairs hospital. The investigators
found that 24.7% of the patient population had a low albu-
min, defined as less than 3.4 g/dL. The 30-day mortality rate
for hypoalbuminemic patients was 24.6% compared with
1.7% in patients with normal serum albumin levels. The
investigators also demonstrated an excellent correlation
between serum albumin levels and 30-day mortality rates. In
a recent meta-analysis, for each 1.0-g decrease in serum albu-
min concentration, the odds ratio for mortality increased by
137%. However, the relationship between albumin concen-
tration and mortality is not linear. In 13,473 patients on
hemodialysis, for example, mortality increased in an expo-
nential fashion as serum albumin decreased. If one sets the
risk for death equal to 1 at an albumin level of 4.25 g/dL, then
the risk for death drops to 0.47 if the serum albumin is
greater than 4.4 g/dL. In contrast, the odds ratio for mortal-
ity increases 12.8-fold for patients with an albumin level less
than 2.5 g/dL as compared with baseline.
A simplified formula for estimating the relative risk of
death in patients with chronic renal insufficiency is
128/(albumin3), where albumin is in grams per deciliter. A
serum albumin level of 4 g/dL has a twofold risk of death,
and a serum albumin level of 2 g/dL has a 16-fold risk of
death (Figure 6–1).
In a large group (54,215) of surgical patients, there also
was an exponential increase in 30-day mortality as albumin
decreased. For example, 30-day mortality was 1% in patients
with a normal concentration (albumin >4.6 g/dL), and
mortality increased to 29% with an albumin concentration
of less than 2.1 g/dL. The relationship between surgical
mortality and serum albumin concentration also was
exponential. A simplified equation to estimate the risk of
morality could be used, where mortality is equal to
60/albumin2. Surgical patients with an albumin level of
1 g/dL have an approximate 60% mortality. In comparison,
surgical patients with an albumin level of 4.5 g/dL have a 3%
mortality.
 CHAPTER 6120
Diagnosis or Study Group n
Normal Serum
Albumin (g/dL)1
Mortality,Normal
Serum Albumin
Mortality
Low Serum
Albumin
Relative Mortality
Risk of Low Serum
Albumin
Medical and surgical patients 500 3.5 1.3% 7.9% 6.1 
Critically ill 55 3.0 10.0% 76.0% 7.6 
Surgical patients 243 3.5 4.7% 23.0% 4.9 
Hodgkin’s disease 586 3.5 1.0% 10.0% 10.0 
Malnutrition 92 3.5 8.0% 40.0% 5.0 
Colorectal surgery 83 3.5 3.0% 28.0% 9.3 
Alcoholic hepatitis 352 3.5 2.0% 19.8% 9.9 
Cirrhosis 139 2.9 32.0% 52.0% 1.6 
Lung cancer 59 3.4 49.0% 85.0% 1.7 
Heart disease 7,735 4.0 0.4% 2.3% 6.1 
Multiple myeloma 23 3.0 25.0% 50.0% 2.0 
Trauma 34 3.5 15.4% 28.6% 1.9 
Sepsis 199 2.9 0.7% 15.9% 22.7 
Pneumonia 456 3.5 2.1% 8.3% 4.0 
Pneumonia 38 3.0 0.0% 10.0% — 
VA Hospital 152 3.5 3.3% 7.8% 7.8 
VA Hospital 2,060 3.5 1.7% 14.5% 14.5 
CABG/Cardiac valve surgery 5,156 2.5 0.2% 0.9% 5.7 
Preoperative (VA hospital) 54,215 3.5 2.0% 10.3% 5.1 
Beth Israel Hospital 15,511 3.4 4.0% 14.0% 3.5 
Hemodialysis 13,473 4.0 8.0% 16.6% 2.1 
Stroke 225 3.5 20.0% 55.0% 2.7 
1Serum albumin, g/dL, separating normal and low albumin groups for each study.
Table 6–1. Serum albumin and increased mortality risk in various published studies.
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In addition to the use of serum albumin, the patient’s caloric
intake predicts survival. Patients provided with an adequate
caloric intake (1632 versus 671 kcal/d) have an eightfold reduc-
tion in mortality (11.8% versus 1.5%). At the same albumin
concentration (<3.0 g/dL), survival is longer in those who have
a normal energy and protein intake. This is also true for patients
with advanced liver cirrhosis. In comparison, a recent, very large
study in which additional calories were provided to patients
with stroke failed to demonstrate reduced mortality. However,
in a recent meta-analysis, all-cause mortality was reduced from
13.7% to 9.7% when patients received supplement feeding.
In summary, serum albumin concentration and energy
intake in critically ill patients provide the clinician with tools
to help predict recovery or demise. Albumin levels should be
monitored at regular intervals (weekly) and caloric intake
should be determined daily in patients who are ill and at risk
for malnutrition. Once hypoalbuminemia is documented,
albumin measurement is not an ideal indicator of nutritional
repletion because it returns to normal slowly (half-life
21 days) and lags behind other laboratory indices of nutri-
tional status such as transferrin (half-life 7 days), prealbumin
(half-life 1 day), insulin-like growth factor-1 (IGF-1; half-
life 20 hours), and retinol-binding protein (half-life 4
hours). Albumin replacement itself does not reverse the
metabolic process that the hypoalbuminemic state repre-
sents. The reduced level of protein reserves in the patient and
the severity of the metabolic injury are the two most impor-
tant determinants of serum albumin level.
 Features of Malnutrition in Critical Illness
Symptoms and Signs
It is important to ask patients if they have been able to main-
tain appetite and body weight over the last several months. A
history of recent hospitalization is important because of the
common development of protein malnutrition during a hos-
pital stay. Physical examination should include an estimate of
muscle mass, noting especially a loss of temporalis muscle
mass, “squaring off” of the deltoid muscle, and loss of thigh
muscle mass. Measurement of body weight should be stan-
dard on all ICU admissions, and weight should be followed
on a daily basis. Daily weights are facilitated in the ICU by
use of beds with built-in scales. Although it can be argued
that body weight is not a good marker of nutritional status
in the ICU—and this may be true for many patients—body
weight is also useful as a marker of changes in fluid status.
Laboratory Findings
Up to 50% of hospitalized surgical and medical patients have
either hypoalbuminemic malnutrition or marasmic-type
malnutrition. Hypoalbuminemic (protein) malnutrition is
diagnosed by finding reduced serum albumin or other pro-
tein (eg, transferrin, prealbumin, etc.) level. Serum albumin
is used most commonly. Marasmic malnutrition is identified
in anyone who has lost 20% or more of usual body weight
over the preceding 3–6 months or who is at less than 90% of
ideal body weight. Marasmic malnutrition is starvation with-
out injury; protein malnutrition always accompanies injury
(eg, trauma, sepsis, inflammation, or cancer). Of these two
types of malnutrition, hypoalbuminemic malnutrition is
the most common. Hypoabluminemia was associated with a
4-fold increase in dying and a 2.5-fold increased risk of
developing a nosocomial infection and sepsis. Table 6–1
shows that a low serum albumin level predicts a significant
increase in mortality rate in a variety of types of patients
and diseases.
Delayed Hypersensitivity
Delayed hypersensitivity, as measured by skin testing, is fre-
quently abnormal or absent (anergic) in patients with
hypoalbuminemic malnutrition. When five appropriate anti-
gens are used for testing delayed hypersensitivity in such
patients, failure to respond to more than one antigen was
associated with an 80% 2-year mortality rate compared with
an overall 35% mortality rate. In another study of over 500
patients, anergy was associated with a fivefold increase in
numbers of deaths in trauma patients and a sixfold increase
in septic patients.
Lean Body Mass
The use of body weight as an index of muscle mass in ICU
patients is very difficult because of fluid shifts that occur in
the extracellular compartment. Body weight can be divided
into three compartments: extracellular mass, lean body mass,
and fat mass. Extracellular fluid is known to increase as a
result of critical illness even in well-nourished individuals,
but the degree of increase in extracellular fluid is greater in
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 Figure 6–1. In patients undergoing hemodialysis,
lower serum albumin is a predictor of increased mortal-
ity. The risk of death (odds ratio) is increased 12.5-fold
in the group with the lowest albumin concentration.
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the malnourished. Much of this is accounted for by fluid
shifts into the extracellular space because of reduced plasma
colloid oncotic pressure.
Lean body mass is the sum of skeletal muscle, plasma pro-
teins, skin, skeleton, and visceral organs, with the skin and
skeleton accounting for 50% of the total. There are no con-
venient markers to determine loss of nitrogen from skin or
skeleton. The plasma proteins account for only 2% of the
lean body mass, but measurement of plasma proteins can
reflect the overall status of the lean body mass compartment.
The viscera account for about 12% of the lean body mass,
and decreases in size of some organs (ie, gut atrophy and
cardiac atrophy) are noted in critically ill patients.
Unfortunately, there is no convenient marker of loss of lean
body mass from the visceral organs.
The skeletal muscles account for 35% of lean body mass
and provide the major storage area for amino acids needed
during illness. Urinary creatinine is related to the size of the
skeletal muscle mass. A standard way to assess the size of the
skeletal muscle mass is to determine the creatinine-height
index by collecting a 24-hour urine and comparing the value
against normal tables of creatinine excretion for age, sex, and
height. A simpler way is to divide the 24-hour creatinine
excretion by the patient’s usual body weight obtained from
the history. The normal value for an adult man is 23 mg/kg of
ideal body weight; the normal value for a woman is 18
mg/kg. A creatinine-weight index 10% less than normal
would be consistent with a 10% loss in muscle mass. For
example, if the usual weight for a woman was 50 kg, her 24-
hour urine collection should contain 900 mg creatinine. A
value of 810 mg/24 hours would reflect minimal loss of mus-
cle mass. A value of 20% less than normal would classify
patients as having mild muscle loss, a 20–30% loss would
classify them as having moderate loss, and a 30% or greater
reduction in the 24-hour urinary creatinine would document
severe muscle loss. The most accurate estimates result from
measuring urinary creatinine over a 3-day period and repeat-
ing the measurements at intervals to document the loss of
muscle mass over an extended period of time. Dietary crea-
tine and creatinine intakes have only a minor influence
(<20%) on urinary creatinine in the normally fed individual,
and dietary influences will be very small in most critically ill
patients. However, impairment of renal function reduces
normal creatinine excretion and excludes the creatinine-
height or creatinine-weight index as a marker of muscle mass.
Vitamins and Minerals
Many of the vitamins and minerals act as cofactors for essen-
tial processes in health and illness. The requirements for
health have been well established and are published as the
recommended daily requirements (Tables 6–2 and 6–3).
The exact needs for the critically ill patient are not well
documented.
Reduced levels of vitamin C, vitamin A, copper, man-
ganese, and zinc are associated with poor wound healing.
Abnormally low levels of minerals are known to occur as part
of the cytokine-mediated inflammatory response and also
may occur secondary to poor oral intake, increased require-
ments, and excessive urinary and stool losses in the critically
ill patient.
A. Folate—In large studies of critically ill patients, 12–52%
have been noted to have a reduced folate level. Not all of
these will have folate deficiency because serum levels fall rap-
idly, despite normal tissue stores, when folate intake is
restricted. Alcohol intake has a similar effect of falsely lower-
ing folate levels. A prospective, randomized clinical trial
demonstrated that critically ill patients given only replace-
ment doses of approximately 0.3 mg/day of folate continued
to demonstrate decreased serum and red blood cell folate
levels. A few of these patients developed severe hematologic
disturbances that were reversed with administration of larger
amounts (50 mg/week or 5 mg/day of folate).
Nutrient Oral Intravenous
Special
Requirements
Vitamin A 3300 IU 3300 IU (1 mg) 5000 + IU (serious
infections) 
Vitamin B1,
thiamine 
1.5 mg 3 mg 50 mg (alcoholics,
Wernicke-Korsakoff) 
Vitamin B2,
riboflavin 
1.8 mg 3.6 mg 
Vitamin B3, niacin 20 mg 40 mg 
Vitamin B6,
pyridoxine 
2 mg 4 mg 
Vitamin B12 2 μg 5 μg 
Biotin 100 μg 60 μg 
Vitamin C 60 mg 100 mg
Vitamin D 400 IU 200 IU (5 μg)
Vitamin E 10 mg 10 mg 
Folic acid 0.2 mg 0.4 mg 5 mg (ICU patient;
thrombocytopenia) 
Vitamin K  80 μg See note 1. 
Pantothenic acid 7 mg 15 mg 
1Vitamin K is routinely given as 10 mg subcutaneously on admission
and then weekly.
Table 6–2. Adult daily nutritional requirements
(RDA, 1989).
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B. Vitamin A and Vitamin C—Critically ill patients, espe-
cially those with sepsis, can have significant reductions in
plasma levels of vitamins A and C. A recent study in healthy
elderly patients demonstrated that approximately 20% have
reduced vitamin C levels (<0.5 mg/dL), and 10% have a
reduced serum vitamin A level (<33 μg/dL). The administra-
tion of multiple vitamins and minerals containing 80 mg vita-
min C and 15,000 IU vitamin A daily for 1 year resulted in a
significant reduction in the number of days of infection-
related illnesses (48 ± 7 to 23 ± 5 days per year; mean ± SEM).
The multiple vitamin and mineral supplement improved the
lymphocyte response to phytohemagglutinin and the natural
killer cell activity. Providing vitamins C and E in a double-
blind clinical trial of critically ill patients significantly reduced
28-day mortality (67.5% versus 45.7% mortality). In a second
study, additional vitamin C and vitamin E reduced the devel-
opment of end-organ failure (p <0.05) but had no significant
effect on 28-day mortality (2.4% versus 1.3%, vitamins versus
placebo, respectively). While plasma levels of vitamin C do
reflect whole body stores, plasma levels of vitamin A may not
be the best marker of actual deficiency states.
Liver vitamin A measurements may be a better marker.
Patients who die of infectious diseases have an 18–35%
incidence of severe reduction of liver vitamin A. In other
studies, serum vitamin A (retinol) levels are low in 30–92%
of patients with serious infections. The mechanism for this
loss may be via excessive urinary losses of vitamin A.
Patients with pneumonia, sepsis, and severe injury can lose
vitamin A (retinol) in the urine on a daily basis in an
amount greater than the recommended dietary intake of
vitamin A (5000 IU). In contrast to what is noted in serious
infections, trauma patients who die within 7 days of hospi-
talization have only a 2% incidence of severe liver vitamin A
deficiency.
Several prospective, randomized clinical trials have
demonstrated that the administration of vitamin A to children
who have measles or other infectious illnesses can reduce the
mortality rate by up to 50%. Similar data are not available for
adults. Nevertheless, because serum vitamin A levels are fre-
quently reduced in critically ill patients who have serious
infections, critically ill patients should start receiving the rec-
ommended daily allowance (RDA) of vitamin A on admission.
Nutrient Oral Intravenous Special Requirements
Macronutrients
Protein 1.5 g/kg 1.5 g/kg 2–3 g/kg (thermal injury)
Glucose 20–25 kcal/kg 20–25 kcal/kg Fasting blood glucose >139 mg/dL, reduce to 10 kcal/kg
Lipid 4% of kcal 4% of kcal May provide up to 60% of caloric needs as lipid
Micronutrients
Sodium 60–150 meq 60–150 meq Severely reduce if ascites or heart failure present 
Potassium 40–80 meq 40–80 meq
Chloride 40–100 meq 40–100 meq
Acetate 10–40 meq 10–40 meq
Phosphorus 10–60 mmol 10–60 mmol Large amounts (100 mmol+) may be needed with early refeeding
period, days 2–4 of refeeding
Calcium 5–20 meq 5–20 meq
Magnesium 10–20 meq 10–20 meq 50–100 meq (cardiac arrhythmias, diarrhea)
Zinc 3 mg 2.5–4 mg 10–50 mg (diarrhea, fistula, wounds)
Copper 1.5–3 mg 1–1.5 mg
Chromium 50–200 μg 10–15 μg Additional amounts may be needed if diarrhea, GI losses
Molybdenum 75–250 μg 100–200 μg
Manganese 2–5 mg 150–800 μg
Selenium 40–120 μg 40–120 μg 120–200 μg (thermal injury, wounds)
Table 6–3. Adult daily nutritional requirement.
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Vitamin A treatment of premature infants reduces the
development of chronic lung disease or death from 62% to
55%. Additional vitamin A treatment of infants who
were likely vitamin A deficient reduced mortality com-
pared with placebo-treated infants (6.9% versus 5.4% mor-
tality, p <0.05).
In addition to the changes in folate, vitamin A, and vita-
min C, excessive losses of several other vitamins have been
observed in patients receiving medications that interfere
with normal utilization or elimination (Table 6–4).
C. Magnesium—Hypomagnesemia occurs in 34–44% of
patients receiving TPN. Severe depletion is associated with
cardiac arrhythmias and sudden death. Alcoholics are com-
monly found to have poor magnesium intake and also to
have excessive urinary magnesium losses. For this reason and
because of recent data on the antiarrhythmic effects of mag-
nesium, the commonly used normal values for serum mag-
nesium levels probably should be increased from 1.7–2.3 to
2.0–2.6 mg/dL. Isolated bacteremia in otherwise healthy men
is associated with a 60-mg (5-meq) magnesium loss in the
urine per day. Large losses can occur in conditions such as
ulcerative colitis, where the stool can contain up to 12 meq/L
and urinary losses can be as much as 25 meq/day. Large uri-
nary losses also can be seen in patients receiving aminoglyco-
sides, diuretics, and amphotericin B, to mention a few
medications commonly used in the ICU. Furthermore, large
quantities of magnesium can be found in some of the intes-
tinal fluids (Table 6–5). The effects of magnesium depletion
and hypomagnesemia are discussed in the section on hypo-
magnesemia in Chapter 2.
D. Phosphate—Hypophosphatemia occurs in 35–45% of
patients receiving TPN. Severe hypophosphatemia results in
cardiac standstill and sudden death. Recent data have
demonstrated rapid and life-threatening reductions in serum
phosphate associated with live-donor liver transplantation.
Phosphate is an intracellular anion that must be adminis-
tered in very large quantities to both the donor and the recip-
ient. The profound hypophosphatemia is probably due to the
rapid regeneration of the liver that is known to occur over
the first few weeks after transplantation.
In a recent study, the mortality rate of children with
severe hypophosphatemia was 33%. The refeeding syn-
drome (ie, severe hypophosphatemia) occurs commonly in
patients who have had poor or no food intake for 2 or more
days. Hypophosphatemia occurs when there is administra-
tion of glucose without adequate phosphate intake. Patients
at high risk for the refeeding syndrome have a low prealbu-
min level (<11 mg/dL) level. Other patients at risk include
those with a history of alcoholism, diabetes, vitamin D defi-
ciency, or chronic renal failure. In chronic renal failure,
patients are frequently malnourished, and refeeding is asso-
ciated with a high risk for severe hypophosphatemia. This
can be due to the fact that these patients are frequently
given phosphate binders, and when they are refed, the rapid
anabolism quickly reduces serum phosphorus to dangerous
levels.
In addition, there are many medications that can increase
urinary phosphate loss to greater than 200 mg/L. Common
medications that increase urinary loss include beta-agonists,
diuretics, theophylline, and glucocorticoids. The normal
dietary intake of phosphorus is approximately 1000–1500
mg/day. Approximately 70% of phosphorus is absorbed per
day, and stool output may represent 30% of the intake.
However, in patients with malabsorption, stool phosphorus
losses can be much greater.
Serum phosphorus should be monitored three times a
day when beginning to refeed patients to prevent the syn-
drome and its 33% mortality rate. When the serum phos-
phorus level is less than 2.5 mg/dL (<0.8 mmol), phosphate
repletion should be given at 2 mmol/h over 6 hours to pro-
vide 24 mmol phosphate. When the phosphate level is less
than 1.0 mg/dL, it is a medical emergency, and phosphate
repletion should be given at 8 mmol/h for 6 hours to total
48 mmol. Renal failure patients may require a smaller dose.
Drug Nutrients Affected
Aminoglycosides Magnesium, zinc
Ammonium chloride Vitamin C
Antacids Phosphorus, phosphates
Aspirin Vitamin C
Cholestyramine Triglycerides, fat-soluble vitamins
Cisplatin Magnesium, zinc
Corticosteroids Vitamin A, potassium
Diuretics Sodium, potassium, magnesium, zinc
Estrogen and progesterone
compounds 
Folic acid, vitamin B6
Hydralazine Vitamin B6
Isoniazid Vitamin B6, niacin
Laxatives Sodium, potassium, magnesium
Penicillamine Vitamin B6
Phenobarbital Vitamin C, vitamin D
Phenothiazines Riboflavin
Phenytoin Vitamin C, vitamin D, niacin
Tetracycline Vitamin C
Tricyclic antidepressants Riboflavin
Warfarin Vitamin K
Table 6–4. Drug-induced nutrient deficiencies.
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Rechecking serum phosphorus and adjusting the repletion
rate should be done frequently, similar to management of a
reduced potassium level in an ICU setting.
E. Zinc—Serum zinc levels drop as an early response to infec-
tion and injury. There are minor tissue stores of zinc in skin,
bone, and intestine, but zinc is redistributed to liver, bone mar-
row, thymus, and the site of injury or inflammation in the crit-
ically ill patient. This redistribution is mediated by interleukin
1 (IL-1) and other cytokines secreted from macrophages.
Approximately 60–70% of burn patients have a reduced serum
zinc level, and in septic patients it may be 100%. Zinc adminis-
tration (50 mg/day) to these patients was associated with nor-
malization of the zinc level after 3 weeks of feeding. In elderly
patients, 14 mg/day of zinc for 1 year resulted in a significant
reduction in the number of days of infection-related illnesses
(48 ± 7 to 23 ± 5 days per year; mean ± SEM).
Zinc supplementation in the critically ill patient is needed
for cell mitosis and cell proliferation in wound repair. It also
has been demonstrated that 600 mg zinc sulfate (136 mg ele-
mental zinc) orally daily will improve wound healing in
patients who had a serum zinc level on admission of less than
100 μg/dL. In this double-blind study, the healing rate
increased more than twofold in those randomized to receive
zinc supplementation. As little as 20 mg/day of zinc supple-
mentation in very young children reduces the length of hos-
pital stay by 25%.
Zinc supplementation is important in patients in whom
there are intestinal losses, such as seen with severe diarrhea
or fistula. Large losses of zinc can occur via intestinal losses
(see Table 6–5) because intestinal fluids contain up to 17 mg
of zinc per liter.
F. Copper—Serum copper and ceruloplasmin increase with
severe injury or sepsis. Cytokines are believed to be responsi-
ble for these changes. The reasons for these increases are not
known.
G. Iron—Serum iron levels fall as a result of the cytokine-
mediated response to infection or injury. The iron is stored
in the Kupffer cells of the liver until the inflammation wanes.
This is a beneficial effect because many microbes use iron as
a cofactor for energy production. Therefore, iron administra-
tion should be restricted in patients with serious infections
because iron therapy in one double-blind study was associ-
ated with an increase in infectious episodes by approxi-
mately 50% compared with only 10% in placebo-treated
control individuals. Lastly, iron administration has been
demonstrated to cause harm in liver transplant patients. In
liver transplantation, patients who receive a liver high in
iron concentration have an increased incidence of fatal infec-
tions (24% versus 7%) and reduced 5-year survival rates
(48% versus 77%).
Bianchi G et al: Update on branched-chain amino acid supple-
mentation in liver diseases. Curr Opin Gastroenterol
2005;21:197–200. [PMID: 15711213]
Gibbs J et al: Preoperative serum albumin level as a predictor
of operative mortality and morbidity: Results from a
national VA surgical risk study. Arch Surg 1999;134:36–42.
[PMID: 9927128]
Marchesini G et al: Nutritional supplementation with branched-
chain amino acids in advanced cirrhosis: A double-blind, ran-
domized trial. Gastroenterology 2003:124:1980–2. [PMID:
12806613]
Body Fluid Na+ K+ Cl− HCO3
− Mg2+ Zn2+ (mg/L)
Saliva 10 20–30 15 50 — —
Stomach fluids 100 10 120 0 — —
Duodenal fluid 100–130 5–10 90 10 1–2 12
Ileal fluids 100–140 10–20 100 20–30 6–12 17
Colonic fluids 50 30–70 15–40 30 6–12 17
Diarrheal fluids 50 35 40 45 1–13 17
Pancreatic juice 140 5 75 70–115 0.5 —
Bile 145 5 100 15–60 1–2 —
Urine 60–120 30–70 60–120 — 5 0.1–0.5
Urine (post furosemide) 10 times normal 2 times normal — — 20 times normal —
Table 6–5. Electrolyte and mineral content (meq/L) of body fluids.
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NUTRITIONAL THERAPY
 Assessment of Nutritional Needs
Catabolism in Critical Illness
The best marker of catabolism is the determination of urine
urea nitrogen loss. Approximately 80% of the total urine
nitrogen appears as urinary urea nitrogen, and this test can
be performed at the cost of a single urea determination. A
classification of catabolism is based on the urine urea nitro-
gen loss over a 24-hour period plus approximately 2 g of
nitrogen lost as creatinine, creatine, ammonia, and amino
acids and approximately 2 g in skin, stool, and respiratory
losses (although losses greater than 2 g can occur in thermal
injury and severe diarrhea). Urinary loss of less than 6 g urea
nitrogen is normal; loss of 6–12 g/day is mild, 12–18 g/day is
moderate, and more than 18 g/day is severe catabolism. As
mentioned earlier, 1 g urea nitrogen in the urine is equal to
6.25 g nonhydrated protein or 1 oz of lean body mass.
Therefore, the loss of 16 g urea nitrogen  per day is roughly
equal to the loss of 1 lb of skeletal muscle per day. Although
the mobilized amino acids that are broken down into urea do
not all come from the skeletal muscles, those muscles are the
major source of the amino acids used during the catabolic
process that occurs in all critically ill patients because they
represent 50% of the fat-free body weight. In a patient with
mild to moderate catabolism, 12 g urinary urea nitrogen loss
plus 4 g nitrogen loss from other sources calls for replace-
ment of about 100 g nitrogen daily to maintain nitrogen bal-
ance. For a 70-kg adult, this is approximately 1.5 g/kg protein
(or amino acid) per day. In severely catabolic patients, losses
as much as 24 g urea nitrogen per day (28 g total) requires
approximately 175 g of protein intake per day (2.5 g/kg per
day) to maintain “nitrogen balance.” Nitrogen losses can be
even higher in thermal injury.
Energy Expenditure in the Critically Ill Patient
Resting energy expenditure (REE) is directly linked to lean
body mass. REE is difficult to determine precisely in the ICU
without measuring oxygen consumption and carbon dioxide
production rates and without performing appropriate calcu-
lations for estimation of energy expenditure. Various equa-
tions used to estimate REE without actual measurements are
not very accurate in critically ill patients. These equations,
based on REEs in healthy individuals, do, however, provide
an approximation of the energy requirements. Using these
estimates, several authors have suggested that energy expen-
diture is increased by 30–100% above REE in critically ill
patients. However, recent data based on direct measurements
of energy expenditure in critically ill patients do not support
the need for higher estimates of energy requirements. Thus
more appropriate estimates would be between 20% and 50%
above predicted needs. A convenient estimate that takes REE
and added energy expenditure into account is to provide
30–35 kcal/kg per day (based on ideal body weight) to patients
with mild to moderately severe critical illness. In those with
severe pancreatitis, closed head injury, or thermal injury,
caloric requirements may be close to 40 kcal/kg per day.
Vitamins and Minerals
The recommended oral and intravenous vitamin intakes are
listed in Table 6–2. The mineral and trace element require-
ments are listed in Table 6–3. Also included are the few excep-
tions to the routine intravenous amounts for both tables. These
vitamin, mineral, and trace mineral recommendations are for
critically ill patients who do not have oliguric renal failure or
cholestatic liver disease. In acute oliguric renal failure, vitamins
A and D should be reduced or eliminated from the enteral or
parenteral solutions. Potassium, phosphorus, magnesium, zinc,
and selenium should be reduced or eliminated. Iron and
chromium are known to accumulate in renal failure and should
be removed from parenteral or enteral formulations.
Copper and manganese are excreted via the biliary tree,
and intake should be reduced or eliminated in patients with
cholestatic liver disease to prevent toxicity. In comparison,
large amounts of electrolytes and minerals can be lost in gas-
trointestinal fluids and in urine (see Table 6–5). It is essential
to replace the estimated amounts lost on a daily basis by
appropriate supplementation of the parenteral nutrition
fluid.
 Enteral & Parenteral Nutrition
Choice of Enteral or Parenteral Feeding
In all clinical situations, if the gut is functional, then the gut
should be used as the route of feeding. Gut atrophy predis-
poses to bacterial and fungal colonization and subsequent
invasion associated with bacteremia. Sepsis owing to micro-
bial translocation or endotoxin translocation from the gut
into the portal system is a frequent source of fever in those
who do not have an obvious source of infection. Use of the
gastrointestinal tract for feeding can reduce the incidence of
bacterial translocation.
A study of over 200 abdominal trauma patients compared
mortality rates of parenterally and enterally fed ICU patients
who had similar illness severity at admission. The group that
could not tolerate enteral feeding received TPN that averaged
35 kcal/kg per day and 1.2 g/kg of protein per day. The other
group tolerated enteral feedings and received 30 kcal/kg per
day and 1.1 g/kg of protein per day. The overall mortality rate
was significantly lower (51% versus 25%) in patients who
tolerated enteral nutritional support. It appears that patients
with gastrointestinal intolerance may have a poorer clinical
outcome, even though they are given appropriate parenteral
nutritional support.
The indications for TPN are listed in Table 6–6.
Preoperative TPN should not be used routinely because most
NUTRITION 127
prospective studies have shown no benefit, and one has
shown harm. However, recent evidence in malnourished
cancer patients demonstrated that preoperative TPN reduces
complications and may reduce mortality. Likewise, postoper-
ative TPN should not be used routinely because most
prospective trials have shown no benefit, and some have
shown an increased rate of complications. This lack of bene-
fit and increased harm may be due to failure to maintain
tight glucose control (<110 mg/dL) in critically ill patients
receiving TPN.
Enteral Nutrition
The feeding tube should be positioned in the small bowel up
to the ligament of Treitz. This is best achieved with the aid of
fluoroscopy but also can be achieved by passage of the feed-
ing tube into the small bowel by a “corkscrew” technique
after bending the distal tip of the feeding tube to about
30 degrees with the wire stylet in place. On placement in the
stomach, the tube is rotated so that the tip can pass via the
pylorus into the duodenum. The infusion of enteral products
into the small bowel will reduce the incidence of aspiration
because the infusion is below the pylorus. Patients with a
cuffed endotracheal tube have a smaller risk of aspiration, so
placement of a feeding tube into the small bowel is less
essential.
Supine patients had a 34% incidence of aspiration pneu-
monia, but the risk was only 8% when patients were kept
semirecumbent. The Centers for Disease Control and
Prevention (CDC) recommends that ICU patients be man-
aged in this position to reduce the risk for nosocomial
infections.
A. Protein—Protein is better absorbed in the peptide form
than as free amino acids because of specific transporters in
the small intestines for amino acids, dipeptides, and tripep-
tides. Supplementation of standard enteral feeding products
with increased amounts of arginine has been shown to
enhance immune function, although published data in
humans are very limited. It is also important to point out
that arginine is a precursor of nitric oxide, a vasodilator sub-
stance that may be involved in mediating some of the effects
of sepsis. Branched-chain amino acid–enriched enteral
products have been shown to improve mental function and
reduce mortality rates in patients with hepatic encephalopa-
thy and advanced cirrhosis. Albumin synthesis is nearly dou-
bled by branched-chain-enriched amino acids. However,
data to date do not demonstrate decreased morbidity or
mortality rates in trauma or sepsis patients randomized to
receive branched-chain-enriched amino acids as opposed to
conventional feeding.
B. Lipid—The lipid composition of enteral feeding products
is becoming an important consideration depending on the
type of disease. The use of omega-3 (fish oil)–enriched fatty
acids in the enteral product has been associated with modifi-
cation of the inflammatory response. This effect may be
related to increased arachidonic acid metabolism and
decreased omega-6 pathway fatty acid metabolism. Because
most commercially available enteral products that contain
omega-3 fatty acids also have other additives such as argi-
nine, glutamine, and nucleotides, the benefits attributed to
the use of an omega-3-enriched fatty acid enteral diet await
confirmation. At this time, caution with the use of so-called
immunonutrition products is recommended because
recently published data suggest a fourfold increase in mortal-
ity in patients with severe sepsis.
C. Enteral Feeding Products—A large number of enteral
feeding products are manufactured for use in the ICU and
acute medical care settings, including elemental formulas
(eg, amino acids, mono- and oligosaccharides, and lipids),
specialized products for certain critical care situations (eg,
renal failure and liver failure), products containing fiber, and
lactose-free nonelemental products containing 1–2 kcal/mL.
These formulations vary in terms of the ratio of nitrogen to
nonnitrogen calories, protein source, and concentration.
They also vary in the amount and source of fat, electrolyte
concentration, and other constituents. Most hospitals select a
limited number of enteral feeding products for their formu-
laries and have recommended products for each clinical
situation.
D. Recommended Enteral Feeding Formulas—Lactose-
free formulas should be used for ICU patients. The infusion
rate should not exceed 30 kcal/h for the first 6–12 hours, and
the rate then should be advanced as tolerated. If the patient
has a serum albumin concentration of less than 2.5 g/dL,
the enteral infusion rate should be increased slowly (ie,
every 24 hours).
The source of carbohydrate or protein appears not to be
important except in patients with hepatic encephalopathy, in
whom a formula high in the branched-chain amino acids
would be indicated. The addition of moderate amounts of
glutamine may be helpful because only a few formulas have
added glutamine. Until additional data become available,
there are no specific recommendations for the source of fat
calories in the enteral feeding formula, such as changing
omega-3 fatty acids, omega-6 fatty acids, medium-chain
triglycerides, or structured lipids.
Short bowel syndrome
High output gastrointestinal fistula
Hyperemesis gravidarum
Bone marrow transplantation
Table 6–6. Indications for total parenteral nutrition (TPN).
Note: If the gastrointestinal tract is functional, do not use TPN.
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Parenteral Nutrition
A. Central versus Peripheral Parenteral Nutrition—The
route of parenteral nutrition should be secondary to the
principle of meeting the individual patient’s calorie and pro-
tein goals. Peripheral parenteral nutrition (ie, given through
a peripheral vein) can be used in patients who can tolerate
the daily 3-L fluid requirement necessary to obtain adequate
calorie administration or in patients in the early phase of
enteral alimentation as a supplement. Currently, the permis-
sible concentrations of glucose, amino acids, and other nutri-
ents delivered via peripheral vein alimentation are limited by
phlebitis caused by the high osmolality of the alimentation
solution. Advances in catheter technology may allow for
peripheral administration of solutions of greater than
600 mOsm/L without damage to the vein. A solution of
900 mOsm/L may be well tolerated and could reduce the
volume of peripheral alimentation fluid to 2 L/day. Even with
this new technology, patients requiring severe fluid restric-
tion should receive central parenteral nutrition (via a central
venous catheter) using one of several fluid-restricted formu-
las (Table 6–7).
B. Placement of Catheters for Total Parenteral
Nutrition—Central and peripheral venous catheters are
composed of scarified polyvinylchloride, standard
polyvinylchloride, polyethylene, silicone, hydromer-coated
polyurethane, standard polyurethane, fluoroethylene,
propylene, or Teflon. The lowest rate of thrombogenicity is
seen with the hydromer-coated polyurethane. The rate of
thrombophlebitis is relatively low when catheters are used in
a central vein owing to the rapid rate of dilution of the
hyperosmolal solution. Peripheral venous access is associated
with a higher rate of thrombophlebitis, which is secondary to
the high-osmolality solution infused into a small vein. The
size of the peripheral catheter is important, with the larger
catheters having a more frequent rate of thrombophlebitis.
Recent data would suggest that the use of a small silicone-
coated catheter may increase the life span from 2–5 days
when infusing a fluid of very high osmolality through a
peripheral vein. Osmolality above 900 mOsm/kg is not rec-
ommended for peripheral infusion.
Traditional aseptic technique is required for placement of
central venous catheters. The subclavian vein is the most
commonly used site, followed by the internal jugular vein.
Central venous access also can be obtained by the use of a
long venous catheter placed in the upper arm vein and
passed up near but not into the right atrium. Central
catheters also can lead to thrombosis as a result of improper
placement in the subclavian vein. The tip of the catheter
should be positioned at the entry of the right atrium.
Heparin (1000 units/L) or hydrocortisone (5 mg/L)
added to the TPN solution can reduce the occurrence of
thrombophlebitis resulting from peripheral administration
of hyperosmolar solutions. A nitroglycerin patch on the skin
(5 mg) acts as a local vasodilator and also has been associated
Name1 Amino Acids (g/L) Dextrose (g/L) Calories (kcal/L) Osmolarity (mosm/L) BCAA2 (%)
Central A5% D15% 50 150 710 1250 19
Peripheral A3.5% D5% 35 50 310 760 19
Peripheral high BCAA 3.5% D5% L3% 35 50 310 800 41
Fluid-restricted (central) A10% D21% 100 210 1114 2108 19
Severe fluid restriction (central) A12%
D15%3
120 150 910 1950 19
High branched-chain amino acids (central)
A3.5% D20% 
35 200 820 1476 46
Renal failure (central) A2.7% D35% 27 350 1292 2426 39
Key: Dextrose (D) = 3.4 kcal/g, amino acids (A) = 4.0 kcal/g
Note: All formulas can have 3% lipid added to them to provide 30 g of lipid per liter; 270 additional calories.
Each 1 g amino acids = 10 mosm; each 1 g dextrose = 5 mosm
Each 1% amino acids = 100 mosm; each 1% dextrose = 50 mosm
1Lipids are included in many of these formulas at 10–60% of total calories; these formulations are called “3 in 1;” 3% is 3 g lipid per 100 mL
2Branched-chain amino acids
3Contraindicated in renal failure and hepatic encephalopathy
Table 6–7. Some selected typical parenteral nutrition formulas.
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with a reduction in thrombophlebitis. Subcutaneous tunnel-
ing may help to reduce the rate of catheter infection, but the
best precaution is optimal nursing care and the use of
chlorhexidine as an antiseptic for skin preparation.
Catheter-related infection is a major concern. The two
most likely causes for catheter-related infections are migration
of bacteria down the catheter sheath and trapping and growth
of bacteria that accumulates on the fibrin tip at the distal end of
the catheter. Replacement of the catheter involves either
exchange over a guidewire or selection of a new site. If obvious
infection is present at the original site, a new site must be
selected. If there is no obvious infection at the catheter site, the
catheter may be exchanged aseptically over a guidewire. The
removed catheter tip should be sent for culture, and if bacteria
grow over the next 24–72 hours, the exchanged catheter
should be discontinued and a new site selected. Central line
placement has a 3–5% likelihood of causing pneumothorax or
some other serious complication. Changes of catheter sites
reserved solely for TPN usage are not needed on a regular basis
but only when there is evidence of local or systemic infection
or other complication of the catheter.
The most common complication of TPN is catheter-
related infection. In a pediatric setting, 15% of patients may
develop bacteremia or candidemia. Patients at highest risk
are those with diabetes mellitus. It has been estimated that
catheter-related infections occur in 3% of nondiabetic adults
and in 17% of diabetic adults. The most serious infections
are due to Candida species, with mortality rates as high as
34% despite antifungal treatment.
C. Carbohydrate and Protein—Since the intravenous route
is not the natural route for nutritional substrate administra-
tion, it is important to provide adequate but not excessive
amounts of protein, carbohydrate, and fat on a daily basis.
Most critically ill patients need 1.5–2.5 g/kg per day of pro-
tein. The ideal body weight value should be used in calculat-
ing the daily protein requirements. Dextrose administration
to most critically ill patients should not exceed 3.0 mg/kg per
minute (4.3 g/kg per day). This generally translates into
about 300 g dextrose, or 2 L of 15% dextrose, in a 70-kg
adult. Administration of greater amounts of dextrose can
result in glucose intolerance, abnormal liver function tests,
and fatty infiltration of the liver.
D. Lipid—Currently available intravenous fat emulsion prod-
ucts are derived from soybean or a mixture of soybean and
safflower oil. The products vary slightly in the amount of
linoleic, linolenic, and oleic acids. Each product is available
in 10% and 20% concentrations, but the 20% product is
the best choice because of its caloric density and the lack of
imbalance in the phospholipid-to-lipid ratio. Intravenous
lipid can be administered as a separate 20% concentration
over 20–24 hours or—more commonly—as part of the
TPN called “3 in 1” with dextrose and amino acids.
Maximum fat administration can be estimated at 2 g/kg
per day or 140 g/day (1260 kcal).
The use of intravenous fat administration in critically ill
patients initially was very controversial. Some of the early stud-
ies did not demonstrate any improvement in nitrogen reten-
tion when glucose calories were exchanged for fat calories.
The septic patient has a reduced ability to use calories
provided as dextrose, so any amount of dextrose in excess of
300 g/day (1020 kcal) may not be used as energy and could
contribute to the development of fatty liver infiltration and
mild elevations in liver function tests. Because septic
patients have an approximately threefold increase in fat oxi-
dation rate, fat calories may be readily used in these
patients. As a precaution, however, and because excessive
amounts of intravenous lipids in animals contribute to an
increased incidence of sepsis and associated morbidity, a
maximum of 60% of total calories as intravenous fat is
acceptable in most critically ill patients.
There is some interest in the use of peripheral adminis-
tration of lipid, amino acids, and dextrose in a single 3-L bag
via a very small catheter. In theory, the catheter floats in the
vein, causing less luminal damage. An option used by some is
to administer the peripheral infusion of lipid emulsion for 18
of the 24 hours and to run in 5% dextrose over the 6-hour
resting period. This makes physiologic sense because fasting
will permit clearance of very low-density lipoprotein
(VLDL) particles and allow for adaptation to the nonfed
state.
Essential fatty acid requirements are estimated to be
approximately 1–4% of total energy requirements and
should be in the form of linoleic acid. An elevation of the
eicosatrienoic acid (triene) to arachidonic acid (tetrane)
ratio to 0.4 is indicative of essential fatty acid deficiency.
Treatment of essential fatty acid deficiency requires
approximately 10–20% of total energy to be in the form of
linoleic acid.
E. Parenteral Nutrition Solutions—Some standard par-
enteral nutritional formulas and those containing higher
amounts of branched-chain-enriched amino acid formulas
are listed in Table 6–7. Most formulas provide approximately
1 kcal/mL of TPN. Standard parenteral nutrition solutions
do not contain glutamine owing to the instability of this
amino acid in solution. Standard parenteral formulas also do
not contain large amounts of arginine. Both glutamine and
arginine can be added to the parenteral formulas before
administration, but there is no convincing evidence that
added arginine is helpful. Recent data suggest that glutamine
may be a preferred fuel for enterocytes and lymphocytes. The
use of glutamine-enriched formulas can prevent postinjury
expansion of the extracellular water compartment in bone
marrow transplant patients. There also may be a slight reduc-
tion in the incidence of infection.
F. Recommendations for Ordering Central Parenteral
Nutrition—Each hospital should have standard formulas for
parenteral nutrition. Consider using a central parenteral
nutrition formula with 15% dextrose, 5% amino acids, and
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5% lipid containing 1160 kcal/L with osmolarity of
1250 mosm/L (see Table 6–7). Fluid-restricted formulas are
often required in critically ill patients. These solutions con-
tain more concentrated mixtures of amino acids. Special for-
mulas may be useful in patients with hepatic and/or renal
failure.
G. Recommendations for Peripheral Parenteral
Nutrition—A standard solution is 3–5% amino acid and 5%
dextrose for peripheral vein administration, for example,
3.5% amino acid and 5% dextrose. Each milliliter provides
approximately 0.3 kcal. Therefore, 3 L of this solution pro-
vide 105 g protein (amino acids), 150 g dextrose, and about
900 kcal.
Using a microcatheter that allows for a higher-osmolarity
solution to be infused safely, more calories can be given via a
peripheral vein by adding 20% lipid. For ICU patients, a
solution of 5% amino acid, 5% dextrose, and 5% lipid has
900 mOsm/L. Two liters of this formula provides 100 g pro-
tein and 1640 kcal (55% of calories from lipid).
NUTRITIONAL SUPPORT IN SPECIFIC
DISEASES
 Malnutrition
Patients with a serum albumin level of less than 2.8 g/dL, a
20% weight loss over the preceding 3 months, or an ideal
body weight less than 90% for height should be provided
nutritional support on entry to the ICU. Other patients
should be evaluated for the likelihood of being able to ingest
a minimum of 1500 kcal by the fifth day in the ICU. If this
seems unlikely, it would be appropriate to provide nutri-
tional support early in the ICU stay.
 Cardiopulmonary Disorders
Hypooncotic Pulmonary Edema
Albumin accounts for about 78% of the total oncotic pres-
sure in the plasma compartment, and hypooncotic edema
can be misdiagnosed as acute respiratory distress syndrome
(ARDS). In conformity with Starling’s law, pulmonary
edema may evolve as (1) hydrostatic edema (fluid overload),
(2) increased permeability of the epithelium, (3) hypoon-
cotic edema (low plasma oncotic pressure from decreased
plasma protein), and (4) lymphedema. Capillary fluid
exchange is based on the balance of forces moving fluid out-
ward (ie, hydrostatic pressure, negative interstitial pressure,
and interstitial colloid pressure) and the only force moving
fluid inward (ie, plasma oncotic pressure). Therefore, plasma
proteins are the only force holding fluid inside the capillar-
ies. If a patient has isolated hypooncotic edema, with serum
albumin level of less than 2.5 g/dL, then a 25–50-g infusion
of albumin over 24 hours may resolve the edema.
Pneumonia
Both lymphopenia (<1000/μL) and hypoalbuminemia
(serum albumin <2.5 g/dL) are predictors of poor prognosis
in patients with pneumonia. In hospitalized patients, the use
of antacids or H2 blockers is associated with an increased
incidence of nosocomial pneumonia, and use of sucralfate in
place of antacids or H2 blockers has been associated with a
significantly lower rate of nosocomial infection. The reduced
incidence of nosocomial infections also was associated with
a significant reduction in mortality rate (from 46–24%). The
decrease has been thought to be due to maintenance of gas-
tric acidity to support the stomach’s overall bactericidal
activity. Although there is some controversy about increased
risks of infection in patients receiving H2 blockers in the
ICU, current data also suggest that the rate of spontaneous
gastritis or gastrointestinal ulceration in ICU patients actu-
ally was falling prior to the increased use of these drugs for
prophylaxis against upper gastrointestinal bleeding.
Emphysema
In malnourished patients with emphysema, energy expendi-
ture is increased by as much as 23–26% above that in weight-
matched controls. Unlike the preferred fat oxidation seen in
sepsis, patients with emphysema have an increase in protein
and carbohydrate oxidation in the fasting and fed states.
Forced vital capacity and diaphragmatic mass and strength
are reduced in malnourished patients. Even though there are
no prospective studies demonstrating improved survival in
patients with emphysema given aggressive nutritional sup-
port, the ability to maintain respiratory muscle strength and
mass during acute illness should be beneficial.
Enteral nutrition should be used with caution, however,
in patients with chronic obstructive pulmonary disease
(COPD) owing to increased mortality. This may be due in
part to the common practice of nursing patients in the
supine position (increased risk of aspiration pneumonia)
instead of the safer 45-degree upright position. Another risk
may be due to the elevated blood glucose level and morbid-
ity and mortality associated with patients on mechanical
ventilators. If nutritional support is provided, it must be
done safely. Recent evidence suggests that weight loss during
hospitalization and a low body mass index increase the risk
for unplanned readmission to hospital.
Congestive Heart Failure
Many patients awaiting heart valve replacement have a com-
bination of marasmic and hypoalbuminemic malnutrition,
placing them at a higher postoperative risk for subsequent
morbidity and mortality. Feeding these patients can improve
cardiac function, but certain precautions are necessary. A
low-sodium intake is essential owing to the association of
sodium administration and fluid retention resulting in car-
diac failure. Because fatty acids are used as cardiac muscle
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fuel, mixed-fuel nutritional support (ie, lipid, carbohydrate,
and protein) may be preferable. Ischemic cardiac muscle
derives all its energy from anaerobic metabolism, so TPN
with adequate glucose, potassium, phosphate, and insulin
may optimize substrate delivery to areas limited to anaerobic
glycolysis. Patients with severe calorie or protein malnutri-
tion (albumin <2.5 g/dL) should be given adequate calories
and protein for about 1 week before cardiac surgery to opti-
mize the recovery period. Patients treated with diuretics
(eg, furosemide) are at an increased risk for thiamine defi-
ciency. The loss of thiamine in the urine can increase the risk
for high-output congestive heart failure (ie, wet cardiac
beriberi).
 Gastrointestinal Disorders
Pancreatitis
Earlier work suggested that the benefits of parenteral nutri-
tion were especially important for patients with acute pan-
creatitis who were malnourished on entry into the ICU.
However, nutritional status may be difficult to determine
because weight history and actual weights are frequently not
accurate owing to fluid accumulation in this disorder. Several
studies have evaluated the benefits of parenteral nutritional
support in patients with acute pancreatitis. In one study, the
overall mortality rate was decreased from 21% to 3% in
patients who were able to receive an average of 37 ± 1 (mean
± SEM) versus 26 ± 4 kcal/kg per day over a 29-day period.
In a second report, the mortality rate in 67 patients was
reduced from 38% to 13% if patients with acute pancreati-
tis received parenteral nutritional support within 72 hours
of admission. Other studies have not demonstrated
decreased mortality rates with administration of parenteral
nutrition. Septic complications are reduced in patients with
acute necrotizing pancreatitis provided enteral nutritional
support as compared with those given TPN (28% versus
50%). Mortality in this study was similar with TPN and
enteral nutrition.
Hepatic Encephalopathy
A branched-chain amino acid–enriched formula has been
shown to improve mental recovery in almost all studies to
date. A meta-analysis of six large studies demonstrated that
there was an improvement in overall survival if patients with
liver disease were fed a parenteral formula containing
increased amounts of branched-chain amino acids. The
mortality rate in the branched-chain-enriched amino acid
treatment group averaged 24%, and in the control group it
was 43%. In a recent study, the benefits were confirmed for
the use of branched-chain amino acids in patients with
advanced cirrhosis. In contrast to the beneficial effects noted
in hepatic encephalopathy and cirrhosis, there is no evidence
that high branched-chain-enriched nutritional regimens
reduce the mortality rate in trauma or sepsis.
Alcoholic Hepatitis
One of the earliest studies of protein administration to
patients with alcoholic hepatitis was performed in 1948, and
this study demonstrated an improved survival rate in
patients given protein and calories. One study has evaluated
patients with alcoholic hepatitis who were prospectively ran-
domized to receive parenteral nutritional support with
amino acid solutions or the regular hospital diet. This small
study demonstrated that morbidity and mortality rates were
reduced in patients given parenteral nutrition support. A
more recent study of enteral feeding versus steroid therapy
demonstrated a reduced 1-year mortality in the enteral feed-
ing group (37% versus 53%; P <0.05). Survival in alcoholic
hepatitis was linked to the level of protein malnutrition.
Thirty-day mortality rates ranged from 2% in mild malnu-
trition to 15% in moderate malnutrition and up to 52% in
severe malnutrition. Contrary to what is still written in most
textbooks, the administration of 1.5 g/kg of protein is not
associated with deterioration in mental status in patients
with alcoholic hepatitis. Increased nutritional intake with
calories as high as 3000 kcal/day has been associated with
prolonged survival.
Gastrointestinal Dysfunction
Absolute indications for parenteral nutrition include pseudo-
obstruction, radiation enteritis, massive small bowel obstruc-
tion, prolonged ileus, prolonged diarrhea, short bowel
syndrome, and hyperemesis gravidarum. Parenteral or enteral
nutritional support may be indicated for Crohn’s disease,
Whipple’s disease, abetalipoproteinemia, and diarrhea associ-
ated with scleroderma. The benefits of parenteral nutrition in
ulcerative colitis are no greater than the use of bowel rest and
hydrocortisone. However, the potential benefit of parenteral
nutrition is that the patient may be better nourished and thus
better able to tolerate colectomy if needed. Dysfunctional
bowel, as mentioned earlier, is predictive of a poor outcome.
Methods to improve gastrointestinal function should be used
when absolute contraindications to bowel utilization are not
present. Osmotic diarrhea sometimes can be improved with
the use of intravenous albumin supplementation when serum
albumin levels are less than 2.5 g/dL.
Gastrointestinal Fistulas
Fistulas with a fluid output of at least 500 mL/day have been
treated routinely with parenteral nutrition and bowel rest. A
recent study suggests that enteral nutrition can be successful
in patients with high-output fistulas but that these patients
should be cared for in a specialized unit where optimal con-
ditions for artificial nutrition and local management are in
place.
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 Renal Disorders
Acute Renal Failure
Although early studies of parenteral nutrition (amino acids
and vitamins) compared with dextrose infusion alone (no
vitamins or amino acids) demonstrated better recovery in
patients with acute renal failure, subsequent studies have not
consistently demonstrated a clear benefit. The patient who
develops acute renal failure with malnutrition should receive
enteral nutrition if the gut is functional and parenteral nutri-
tion if it is not. The combination of acute renal failure and
severe malnutrition is associated with a 7.2-fold increase in
mortality.
Chronic Renal Failure
In chronic renal failure, the relative risk for mortality
increases logarithmically as albumin decreases (see Figure
6–1). The risk increases to 12.8-fold for a serum albumin
level of less than 2.5 mg/dL. In contrast, the relative risk for
mortality decreases to 0.47 when the serum albumin level is
greater than 4.4 g/dL. In addition to serum albumin, serum
ferritin is a marker of increased morbidity. Chronic renal
failure patients with serum ferritin levels of greater than
500 ng/mL have a 19-fold increase in septic episodes com-
pared with chronic renal failure patients who do not have as
high an iron load. Treatment with deferoxamine mesylate, an
iron-chelating agent, reduces the sepsis rate 24-fold. Selected
renal failure patients and those with iron overload should be
watched carefully for a higher than expected incidence of
infection. The increased use of epoetin alfa (erythropoietin)
has virtually eliminated the iron-overload problem seen in
patients with chronic renal failure. However, methods to
remove the excess iron storage may be indicated to reduce
the incidence of serious infections.
 Hematologic Disorders & Cancer
Bone Marrow Transplantation
Conventional nutritional therapy in bone marrow transplant
patients in some studies can increase the engraftment rate of
the donor’s cells in the recipient’s bone marrow but in some
studies has shown no benefit. Early parenteral nutritional
support rather than a hospital diet in well-nourished bone
marrow recipients can increase overall survival. Recent evi-
dence suggests that the use of glutamine-enriched parenteral
nutritional support after bone marrow transplantation
improves nitrogen balance, reduces the incidence of infec-
tion, and shortens the hospital stay by about 7 days.
Cancer Cachexia
A meta-analysis concluded that parenteral nutritional sup-
port does not improve survival and may in fact increase
the risk for infection in nonmalnourished cancer patients.
A possible source of error in interpretation of these results is
that many of the studies did not control for the severity of
the malnutrition. In a few studies, the more severely ill and
malnourished patients were selected to receive parenteral
nutritional support. Those who were less ill or who could tol-
erate a hospital diet were given enteral support. Aggressive
nutritional support should be provided as routine care to the
cancer cachexia patient using the gastrointestinal route if
available.
Iron Deficiency Anemia
Critically ill patients are often found to be anemic. This is most
often found to be anemia of chronic infection (or illness). If
iron deficiency anemia is diagnosed, the standard of care has
been to provide the patient with iron replacement after causes
of iron deficiency anemia are evaluated. Data from a prospec-
tive clinical trial have demonstrated, however, that iron
replacement is associated with a significant increase in rates of
infection or reactivation of malaria, brucellosis, schistosomia-
sis, and tuberculosis. Iron replacement therefore should be
confined to those who do not have a high risk for subsequent
infection and who do not have a current serious infection.
Thrombocytopenia
Sepsis and disseminated intravascular coagulation are the
most common causes of thrombocytopenia in ICU patients.
Folate deficiency can occur in the ICU population. Patients
who are not eating should be given 5 mg/day of folate to pre-
vent thrombocytopenia.
 Trauma & Postsurgery
Severe Head Injury and Spinal Trauma
Closed head injury is one of the most highly catabolic ill-
nesses in ICU patients. Urinary urea nitrogen excretion can
approach that seen in thermal injury. Several prospective tri-
als have evaluated the risks and benefits of parenteral and
enteral nutritional support in these patients. One early study
demonstrated improved survival in parenterally fed patients
compared with nonfed controls. A second trial failed to
demonstrate improvement in survival over that of enterally
fed patients. A clinical trial demonstrated that TPN could
improve morbidity but that the improvement in mortality
was not significant. Recently, patients given enteral feeding
for nontraumatic coma were shown to have improved sur-
vival. Enteral diets containing glutamine reduced the inci-
dence of pneumonia (17% versus 45%), bacteremia (7%
versus 42%), and sepsis (3% versus 26%).
Abdominal Trauma
Enteral nutritional support compared with parenteral nutri-
tional support is associated with maintenance of serum
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albumin levels and a significant reduction in major infec-
tions from 20% to 3%. Patients who tolerate enteral feedings
have better survival rates than those who cannot tolerate
enteral feeding and therefore must receive parenteral feeding.
Abdominal Wound Dehiscence and Wound
Healing
Appropriate nutrient administration is important for rapid
and safe wound closure. Parenteral nutrition increases
hydroxyproline levels and tensile strength in wounds.
Wound dehiscence is eight times more common with
decreased vitamin C levels. This is probably because vitamin C
enhances capillary formation and decreases capillary
fragility and is essential for hydroxylation of proline and
lysine in collagen synthesis. Vitamin A enhances collagen
synthesis and cross-linking of new collagen, enhances
epithelialization, and antagonizes the inhibitory effects of
glucocorticoids on cell membranes. Manganese is a cofactor
in the glycosylation of hydroxylysine in procollagen. Copper
acts as a cofactor in the polymerization of the collagen mol-
ecule and in the formation of collagen cross-links. Zinc sup-
plementation also speeds up the wound healing rate.
Vitamin, mineral, and nutritional support are essential for
prompt wound repair.
Burns
Parenteral nutrition may be indicated in the early manage-
ment of burn patients who develop burn-related ileus. After
that time, the gut is the preferred route of feeding. In a small
study of 18 burned children, providing 4.9 g/kg per day of
protein versus 3.9 g/kg per day reduced the mortality rate
from 44% to nil.
 Sepsis & Multiple Organ Failure
Syndrome
Preoperative nutritional support of malnourished and non-
malnourished patients reduces the rate of septic complica-
tions (eg, wound infections, pneumonia, intraabdominal
abscess, and sepsis), but the overall mortality rate has not
been consistently affected. A study of blunt abdominal
trauma patients who were prospectively randomized to
receive either enteral or parenteral nutritional support has
demonstrated a significant reduction in the incidence of
pneumonia (from 31% to 12%), intraabdominal abscesses
(from 13% to 2%), and catheter sepsis (from 13% to 2%) in
the group receiving enteral nutritional support.
The ability to provide adequate protein and calories to
septic ICU patients has been associated with adequate IL-1
production and a significant improvement in hospital sur-
vival rates. However, early enteral nutrition during sepsis
does not prevent the development of multiple organ failure.
Treatment for this disorder remains supportive.
Stroke
Recent data would suggest that nutritional supplements do
not reduce mortality in stroke patients. In stroke patients with
dysphagia, early enteral feeding was associated with a non-
significant (5.8%; p = 0.09) reduction in death. In fact, the use
of percutaneous endoscopic gastrotomy (PEG) feeding
increased the risk of death by 7.8%. Therefore, unlike what
has been seen in head trauma patients, there appears little
benefit for early aggressive feeding in patients with strokes.
 Endocrine & Metabolic Disorders
Diabetes Mellitus
Impaired fasting glucose (IFG) syndrome is a condition of
elevated blood glucose (>109 mg/dL) in the ICU setting. The
incidence of IFG ranges from 45–50% in patients receiving
TPN to 99% of patients on mechanical ventilation. Patients
with IFG have a 3.9-fold increase risk of death. IFG is prob-
ably not due to caloric intake alone but to elevated counter-
regulatory hormones and insulin resistance. Reducing
caloric intake from 1400 to 1000 kcal/day does not reduce the
incidence of the syndrome. Aggressive regular insulin
administration to maintain the blood glucose concentration
under 110 mg/dL in 765 mechanically ventilated (mostly sur-
gical) patients reduced mortality by 43%. In this prospective,
randomized trial, patients were randomized to either inten-
sive insulin therapy or standard therapy. The goal in the
intensive therapy group was to maintain blood glucose con-
centrations under 110 mg/dL. This was obtained with the
intravenous administration of insulin. Ninety-nine percent
of patients required insulin at an average dose of 71 units/day.
Both groups were equally randomized according to age, gen-
der, body mass index, injury score, incidence of type 2 dia-
betes (13%), and incidence of cancer. The intensive
treatment group had a significant reduction in mean early
morning blood glucose (103 ± 18 mg/dL versus 173 ± 32
mg/dL; P <0.001). Improved blood glucose control reduced
the incidence of bacteremia by 50%, the need for hemodial-
ysis by 42%, and the need for prolonged mechanical ventila-
tion by 37% (P <0.01). ICU mortality was reduced by 43%
(from 8.1% to 4.6%), and hospital mortality was reduced by
34% (from 10.9% to 7.2%; P <0.01).
Both type 1 and type 2 diabetic patients frequently have
low levels of vitamin C. Type 1 diabetics also have a lower
serum retinol (vitamin A) level than normal volunteers. The
exact mechanisms responsible for reduced serum vitamin C
and vitamin A levels in these patients are not known. In dia-
betic animals treated with vitamin A, abnormally low
hydroxyproline levels and decreased wound breaking
strength return to normal. Type 1 diabetics also have reduced
serum and white blood cell zinc levels and excessive losses of
zinc in the urine. Both type 1 and type 2 diabetics can have
increased magnesium losses in the urine and reduced serum
magnesium levels.
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Diabetics also have alterations in neutrophil function,
putting them at an increased risk of infection, including
decreased adhesiveness, poor chemotaxis, decreased
opsonization, decreased phagocytosis, and decreased intra-
cellular killing. The lymphocyte also behaves differently in
diabetics, especially if the patient is malnourished, and the
lymphocyte count is decreased in proportion to the degree of
malnutrition. Diabetics have decreased cell-mediated immu-
nity with decreased lymphocyte transformation, reduced
macrophage-lymphocyte interaction, and an impaired
delayed-type hypersensitivity. One may be able to improve
leukocyte dysfunction by maintaining excellent glucose con-
trol in the diabetic patient wit a blood glucose concentration
of less than 200 mg/dL at all times. A blood glucose level
below 250 mg/dL improves but does not correct white blood
cell phagocytic function, improves but does not correct gran-
ulocyte adherence, and improves but does not correct leuko-
cyte bacterial killing.
Diabetic patients receiving TPN frequently have serum
electrolyte and glucose levels that are difficult to control.
TPN should be initiated in the diabetic patient with only
150 g of dextrose over the first 24 hours (eg, as 1 L of 15%
dextrose at 40 mL/h). Approximately one-third to one-half
the patient’s usual total daily subcutaneous insulin dose
should be added to the TPN solution. Additional subcuta-
neous insulin should be administered using a “sliding scale”
regimen written as a standing order, with the dose of insulin
based on bedside glucose measurements and serum glucose
concentrations from venous blood measured every 3–4
hours. After the first 24 hours, approximately half the addi-
tional subcutaneous regular insulin administered over the
24-hour period then is added to the TPN solution prior to
increasing the rate of TPN administration or the concentra-
tion of dextrose.
The optimal intravenous insulin infusion rate may take
2–3 days to determine because of the variable loss of insulin
to different types of plastic and glass bottles used in hospi-
tals. However, once the serum glucose concentration is less
than 140 mg/dL over a 24-hour period, the overall rate of the
TPN infusion or the dextrose concentration can be
increased. If the rate of the infusion is increased, there should
be no need to alter the dextrose:insulin ratio in the TPN
solution. If the concentration of the dextrose is increased, the
original ratio of dextrose to insulin should be maintained in
the TPN solution by adding insulin to the bottle. To prevent
hypoglycemia, it is advisable not to add excessive amounts of
insulin to the TPN solution. Insulin must be added to the
TPN solution for any patient who has a blood glucose con-
centration of greater than 140 mg/dL. The use of separate
intravenous infusions of insulin and TPN solution has been
associated with severe hypoglycemia and death.
Lastly, as mentioned earlier, new-onset diabetic patients
have a fivefold increase in hospital mortality compared with
hospitalized known diabetic patients. Likely the new-onset
hyperglycemia is proinflammatory and contributes to more
tissue inflammation and injury. While all diabetic patients
are provided insulin during their hospital stay, it is possible
that the routine medications that known diabetics are given
(eg, statin, angiotension-converting enzyme [ACE] inhibitor,
beta-blocker, and aspirin [ASA]) are not provided in the hos-
pital to the new-onset diabetics, and this may be a factor in
the severe difference in hospital survival.
Immune-Enhancing Diet
The use of an immune-enhancing diet in severe trauma
patients can reduce major infectious complications (6%
versus 41%) and hospital stay (18 versus 33 days). However,
in none of the surgical studies has mortality been improved.
In contrast, the use of immune-enhancing diets in a ran-
domized clinical trial was seen to increase ICU mortality
threefold (from 14% to 44%). The use of this specific form
of immunonutrition was stopped because of harm to
patients with septic shock and severe sepsis. Therefore, these
agents should be used only in nonseptic surgical patients
until safety can be established.
Acute Hepatic Porphyria
This rare cause of abdominal pain is treated with dextrose,
500 g/day (2 L of 25% dextrose at a rate of 80 mL/h).
NEW TREATMENT STRATEGIES FOR THE
MALNOURISHED CRITICALLY ILL PATIENT
Insulin
There have been many recent recommendations concerning
tighter glycemic control in ICU patients. Patients in the ICU
should have an upper limit for glucose at 110 mg/dL. This
recommendation has been established based on the clinical
trials of van den Berghe and others and has increased the
need for aggressive administration of insulin. Careful moni-
toring of the serum phosphorus level over the first 48 hours
of insulin therapy is important to prevent hypophos-
phatemia (refeeding syndrome), which has a mortality of up
to 33%. Respiratory failure and cardiac dysfunction can be
seen at serum phosphorus levels below 2.5 mg/dL. A severely
reduced serum phosphate concentration of less than 1 mg/dL
is often lethal.
Critically ill patients without diabetes frequently have ele-
vated blood glucose concentrations owing to metabolic stress
syndrome. Some of these patient who also have insulin
resistance develop new-onset diabetes, as defined by two ran-
dom blood glucose values greater than 199 mg/dL on two
separate days or a fasting blood glucose concentration of
greater than 125 mg/dL on two separate days. The new-onset
diabetes is due to insulin resistance and elevations in coun-
terregulatory hormones. It has been demonstrated recently
that the major reason why the blood glucose level is elevated
NUTRITION 135
is the increased rate of hepatic glucose production and not
reduced tissue uptake of glucose. This response may interfere
with nutritional therapy. The metabolic abnormalities of
insulin resistance include glucose intolerance, increased
hepatic glucose production, increased whole body amino
acid flux, and decreased whole body glucose utilization.
Insulin resistance resulting in the metabolic stress syndrome
is type 2 diabetic in character because patients are not
insulinopenic but are insulin-resistant. The more severe the
malnutrition or illness, the greater is the hepatic glucose pro-
duction. Amino acid flux is also greater the more severe the
malnutrition or illness. Recognizing the presence of new-
onset diabetes or the milder metabolic stress syndrome in
patients is important because insulin administration appears
to be protein-sparing in catabolic postinjury patients and
reduces mortality in ICU patients when the blood glucose
level is maintained under 110 mg/dL. The use of insulin or
other agents that reduce hepatic glucose production in criti-
cal illness may be helpful in reducing protein breakdown
from the lean body mass for amino acid gluconeogenic pre-
cursors. A randomized study of tight glycemic control with
intravenous insulin intended to keep the blood glucose level
between 80 and 100 mg/dL (compared with conventional
therapy with a target blood glucose level of 180–215 mg/dL)
in postoperative cardiac surgery patients resulted in lower
mortality (4.6% compared with 8%), fewer bloodstream
infections, less need for hemodialysis, and shorter duration
of mechanical ventilation. Of note is that only a small pro-
portion of patients had a history of diabetes. Hypoglycemia
(blood glucose <40 mg/dL) occurred in 5% of the intensively
treated group and fewer than 1% of the conventionally
treated patients. While this study was on surgical patients,
these data support the beneficial effect of insulin and a target
blood glucose level (<110 mg/dL) for surgical ICU patients.
Similar findings have been seen in medical ICU patients and
in those with stroke and myocardial infarction. While there
were small differences in outcome in these studies, the over-
all benefit of more stringent glycemic control is generally
apparent.
Growth Hormone
In a prospective, blinded study, administration of growth
hormone to burned children was associated with an
improved healing time. In a retrospective state, growth hor-
mone treatment increased survival in adults with severe
burns. However, the use of growth hormone also was associ-
ated with an increase in insulin resistance and the need to
administer an increased insulin dose. Growth hormone
probably improves wound healing by increasing protein syn-
thesis without increasing protein oxidation, so there is a net
protein deposition in the body, likely in the liver.
At present, use of growth hormone is restricted to chil-
dren who are deficient in growth hormone. Growth hor-
mone should not be used in critically ill patients because
mortality can increase 1.9- to 2.4-fold. Additional studies
that support the use of growth hormone are needed prior to
the use of growth hormone in patients who are seriously ill.
Anabolic Steroids
Anabolic steroids have been used in several clinical trials of
malnourished patients with mixed results. Nitrogen balance
has been shown to be improved in some but not all the clin-
ical trials. The improved nitrogen balance generally was
seen in patients with benign diseases (eg, hip replacement
surgery, vagotomy, or pyloroplasty). In a prospective study
of burns, oxandrolone 20 mg/day reduced weight loss (3 ver-
sus 8 kg), nitrogen loss (4 versus 13 g/day), and healing time
(9 versus 13 days). On the other hand, oxandrolone treat-
ment in trauma patients failed to reduce nitrogen loss,
length of hospital stay (31 versus 27 days), or length of ICU
stay. In fact, recent data suggest that their use is associated
with a prolongation of the time on the ventilator (22 versus
16 days).
Albumin
Normal serum albumin is associated with a shorter inflam-
matory phase of wound healing and normal angiogenesis,
collagen synthesis, and wound remodeling. Albumin levels of
less than 2.5 g/dL represent a 50% loss in the normal plasma
colloid oncotic pressure and may contribute to gastrointesti-
nal mucosal edema and diarrhea. Several authors have found
that close to 100% of patients with a serum albumin below
1.5 g/dL develop diarrhea when given enteral feeding.
Limited clinical trials have demonstrated some benefit
from albumin administration and nutritional support in
critically ill patients with noninfectious causes of diarrhea
and in nontraumatic hypovolemic shock such as septic
shock. Less convincing evidence exists for a beneficial effect
of albumin administration in primary lung injury, such as
acute respiratory distress syndrome (ARDS). A few cases of
what appeared to be ARDS with low serum albumin levels
have resolved following restoration of a normal colloid
oncotic pressure by continuous administration of albumin
until a normal level is reached. However, the use of albumin
should be restricted to specific indications.
If intravenous albumin is administered, it is advisable to
administer it with the TPN fluid or over a prolonged period
of time. Even though the 50-mL vial of 25% human albumin
can be given as a rapid intravenous infusion, one 50-mL vial
of 25% albumin can rapidly expand the plasma compart-
ment by as much as 300 mL, which may be enough to cause
a sudden onset of pulmonary edema in susceptible patients.
Beta-Adrenergic Blockade
A small study showed that 2 weeks of propranolol given to
children with 40% or more third-degree burns resulted in
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lower heart rate, oxygen consumption, and energy expenditure
by about 20%. Propranolol increased protein synthesis and
prevented net whole body protein loss by approximately 10%
over a 1-month period. In adults, the administration of
atenolol or propranolol or atenolol resulted in a 50–80-kcal
reduction in energy expenditure. Beta-adrenergic blockade
may be useful in decreasing metabolic demands, but this
possibility awaits confirmation in larger trials.
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An unprecedented array of imaging options is now avail-
able to the physician in the ICU. The choice of a particular
imaging modality is occasionally difficult and should be
based on recommendations in the literature, local expert-
ise, type of equipment available, and the experience of the
radiologists. Given the increasing emphasis on cost-
effective practice, clinicians and radiologists must maxi-
mize the diagnostic and therapeutic yield of procedures
while minimizing costs. Optimal management of critically
ill patients also requires close communication between the
critical care team and the diagnostic and interventional
radiologist. An established practice of daily ICU radiology
rounds with the participation of the radiologist facilitates
this level of communication.
In a traditional model, all ICU films would be placed on
a designated mechanical film alternator within either the
ICU or the radiology department. With rapid advances in
imaging options and telecommunications feasibility, new
models for ICU imaging are being developed. In one model,
films are acquired electronically and displayed in a patient
archival and communications system (PACS) or on Web-
based servers. The PACS unit is able to display plain radi-
ographs, ultrasound and nuclear medicine studies, computed
tomography (CT), and magnetic resonance images (MRI).
Suboptimal exposures may be corrected in part by adjusting
contrast and window levels. High-resolution monitors may
be placed at designated sites in the ICU and throughout the
hospital. An ideal system integrates PACS with the hospital
information system (HIS) and the radiology information
system (RIS) to display clinical and radiologic information.
These systems may greatly improve the efficiency of clini-
cians, nurses, and support staff.
Although neurologic and musculoskeletal imaging stud-
ies play an important role in the care of the critically ill
patient, this chapter will limit discussion to imaging of the
chest and abdomen, with a focus on adult ICU patients.
IMAGING TECHNIQUES
Most radiographic examinations in the ICU are obtained at
the bedside utilizing conventional analog or digital equip-
ment. In most facilities, ultrasound and portable gamma
cameras for planar nuclear medicine studies are useful and
critical adjuncts for bedside examinations in the ICU. Other
imaging methods, including high-quality ultrasound, CT,
nuclear medicine techniques, and MRI, are used selectively
due to cost and transport issues. Interventional procedures,
either at the bedside or in the radiology suite, are also fre-
quently performed under imaging guidance.
Plain Radiography 
Digital systems are being used increasingly in the ICU for
portable radiography. With these systems, images are
obtained using a photo-stimulable phosphor imaging plate
instead of film. The exposed imaging plate is scanned, read,
and processed by computer, and the image can be transmit-
ted to an ICU console or viewed as a hard copy on a conven-
tional view box. Chest radiographs are the most common
imaging examination, accounting for approximately 40% of
the volume in a radiology department. As many as one-third
of these chest radiographs may be obtained at the bedside
(portable radiographs), and in the ICU almost all chest radi-
ographs are taken using the portable technique. The utility
and effectiveness of routine daily portable chest radiographs
have been studied, and—despite limitations of the technique—
these films play an important role in identifying and follow-
ing pulmonary and cardiac disorders in ICU patients. Chest
radiographs are also used to evaluate the positions of and
complications from catheters and support devices used in
the care of critically ill patients.
Likewise, imaging of the abdomen generally should begin
with plain radiographs, which provide a readily accessible
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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means of diagnosing perforation, bowel obstruction, and
ileus. However, because the overall sensitivity of plain radi-
ographs remains low, further imaging with CT may be nec-
essary to confirm suspected perforation and related
complications (eg, abscess) and to inspect the features of the
bowel walls and surrounding fat. Supine radiographs are most
appropriate for verifying nasogastric or feeding tube place-
ment and for investigation of renal stones and possible ileus
or bowel obstruction. Additional views (ie, semiupright, left
lateral decubitus, and cross-table lateral) may be helpful in
cases of bowel perforation, ileus, or obstruction.
Ultrasound
Ultrasound examination at the bedside in the ICU is relatively
inexpensive and does not use ionizing radiation. In the thorax,
ultrasound is used most often to evaluate and localize pleural
fluid collections, to determine whether such collections are
free or loculated, and as a guide to thoracentesis. Ultrasound is
also helpful in clarifying peridiaphragmatic processes because
the diaphragm is easily visualized, allowing differentiation of
supradiaphragmatic and infradiaphragmatic fluid collections.
The greatest utility of ultrasound, however, is in the evalua-
tion of abdominal disease. Ultrasound provides rapid assess-
ment of hepatobiliary and genitourinary disease and may be
used to guide percutaneous drainage of intraabdominal
abscesses. It allows rapid evaluation of the hepatobiliary sys-
tem, gallbladder, kidneys, pelvic organs, and scrotal disorders.
Visualization of vascular perfusion and parenchymal flow is
a useful feature, especially in transplanted organs.
Ultrasound is also indispensable for guidance of bedside pro-
cedures such as central line placement, cholecystostomies,
biopsies, and drainage of fluid collections.
Computed Tomography
By virtue of multiplanar imaging capabilities and improved
contrast resolution, multidetector CT (MDCT) has been
shown to be very valuable in increasing diagnostic accuracy
and guiding therapeutic procedures for critically ill patients.
MDCT allows for more rapid scanning of patients, with
imaging of the entire chest, abdomen, and pelvis with thin
sections during a single breath-hold. Such short acquisition
times have facilitated the use of CT for evaluation of vascu-
lar disorders such as aortic dissection and pulmonary
embolism. CT also allows for improved characterization of
pulmonary diseases, particularly acute respiratory distress
syndrome (ARDS), and is a critical diagnostic tool for the
evaluation of an acute abdomen.
Transportation of the ICU patient to the CT scanner
requires a coordinated effort from hospital personnel, includ-
ing ICU physicians and nurses, respiratory therapists, radiol-
ogy technologists, and radiologists. Careful monitoring
during transport and during the procedure is essential and
must include arrhythmia monitoring and pulse oximetry.
Nuclear Scintigraphy
Nuclear scintigraphy has a number of applications in the
critically ill patient. Myocardial perfusion and infarct scan-
ning in cardiac disease, ventilation-perfusion scanning in
patients with suspected pulmonary embolism, evaluation of
gastrointestinal hemorrhage and acute cholecystitis, and
localization of occult infection are among the most common
indications for radionuclide imaging in the ICU patient.
Magnetic Resonance Imaging
MRI has supplanted CT in the evaluation of many disorders
because it does not employ ionizing radiation, because it pro-
vides excellent differentiation of vascular and nonvascular
structures without the use of intravenous contrast material, and
because it provides cross-sectional images in multiple planes. It
is generally considered the single best imaging method for eval-
uation of the CNS, head and neck, liver, and musculoskeletal
system. However, in many cases, MRI is not feasible in the eval-
uation of the critically ill patient because of interference caused
by ferromagnetic monitoring devices, the difficulty of ade-
quately ventilating and monitoring patients within the narrow
MRI gantry, and long scan times. MRI may be appropriate in
selected diagnostic dilemmas if MR-compatible equipment and
coordinated effort among caregivers can be arranged.
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IODINATED CONTRAST AGENTS
Adverse reactions to iodinated contrast agents occur at low
rates but are encountered not infrequently given their wide-
spread use. Older ionic agents, newer nonionic agents, and
the newest nonionic isoosmolar agents are available, with
the oldest agents having the highest incidence of adverse
reactions and the newest agents having a significantly lower
incidence. Idiosyncratic reactions range from benign
urticaria to, very rarely, life-threatening hypotension, laryn-
geal edema, and bronchospasm. These events are not consid-
ered truly allergic in nature because they are not
antibody-mediated and are inconsistently reproducible with
subsequent administrations. Pretreatment with corticos-
teroids appears to be effective for mild events, but corticos-
teroids should not be used in patients with a history of severe
reaction. In the latter situation, an alternative such as MRI with
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gadolinium contrast or carbon dioxide angiography should
be considered. Contrary to popular belief, allergy to shellfish
is not predictive of reactions to iodinated contrast agents.
Contrast nephropathy is another important complication
of intravascular iodinated contrast use and occurs in the setting
of preexisting renal compromise, most often due to dehydra-
tion, surgery, nephrotoxic drugs, or long-standing diabetes.
Again, the incidence is highest with the oldest agents and low-
est with the isoosmolar nonionic agents. Although the serum
creatinine level is a convenient measure of renal function, cre-
atinine clearance should be calculated for a more reliable
estimation—less than 25 mL/min or 25–50 mL/min with risk
factors identifying high-risk patients. Potentially effective pre-
ventive strategies include adequate intravenous hydration with
normal saline or sodium bicarbonate solution and administra-
tion of N-acetylcysteine. Metformin should be stopped until
48 hours following contrast use to avoid possible lactic acidosis
in the event of contrast nephrotoxicity. Rather than using a uni-
versal creatinine level cutoff, the decision to use contrast agents
should be made on a case-by-case basis, carefully weighing the
need for the study in high-risk patients. In affected patients, the
serum creatinine level peaks at 4–7 days and gradually normal-
izes. Progression to end-stage renal disease is exceptionally rare.
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Merten GJ et al: Prevention of contrast-induced nephropathy with
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USE OF CENTRAL VENOUS CATHETERS
FOR CONTRAST INJECTION
Peripheral veins are the preferred routes of contrast agent
administration in imaging. When peripheral access is diffi-
cult, existing central venous catheters (CVCs) may be consid-
ered, with a few caveats. Intraluminal pressure limitations
may result in low contrast flow rates, producing a suboptimal
study, or catheter rupture may occur during rapid power
injection of the relatively viscous contrast material. While
most catheter manufacturers do not provide specific instruc-
tions in this regard and practice standards have not been
established, the following general precautions may be useful:
(1) High flow rates (>2 mL/s) should be avoided in most
temporary or tunneled CVCs, (2) silicone-type peripherally
inserted central catheters (PICCs) should not be used, (3) for
multilumen catheters, the largest-caliber port should be used
when possible, (4) Groshong-valve lines should not be used,
(5) pulmonary or systemic arterial lines should not be used,
and (6) catheter integrity and patency should be checked
before and after injection. Since no established guidelines are
available, hospital personnel should be knowledgeable about
the specific catheters used at their institution.
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IMAGING OF SUPPORT & MONITORING
DEVICES IN THE ICU
 Endotracheal & Tracheostomy Tubes
Both endotracheal intubation and tracheostomy may cause
potentially serious complications. Malpositioning of the
endotracheal tube into the right main stem bronchus occurs
in approximately 9% of endotracheal intubations. Such mal-
positioning may lead to atelectasis of the left lung, hyperin-
flation of the right lung, and possible pneumothorax. The
clinical assessment of tube location is frequently inaccurate,
and a chest radiograph should be obtained immediately fol-
lowing intubation. Tubes currently in use are usually radi-
ographically visible by virtue of a metallic wire or barium
marker in the wall of the tube. Periodic radiographs are
required to exclude inadvertent displacement of the tube by
cough, suctioning, or the weight of the respiratory apparatus.
Since endotracheal tubes are typically fixed in position at
the nose or mouth, flexion and extension of the neck may result
in motion of the tube relative to the carina, with the tube
descending during flexion and ascending during extension.
With the neck in neutral position, the ideal position of the tube
tip is 5–7 cm above the carina, which allows for a tolerable
change in tube position during flexion and extension. In 90%
of patients, the carina projects between the fifth and seventh
thoracic vertebrae on the portable radiograph; when the carina
cannot be clearly seen, the ideal positioning of the endotracheal
tube is at the T2–T4 level. The aortic arch also may be used to
estimate tube location because the carina is typically at the level
of the undersurface of the aortic arch. The balloon cuff should
not be greater in diameter than the trachea because cuff over-
inflation can cause pressure necrosis of the tracheal wall.
Inadvertent placement of the endotracheal tube into the
esophagus is uncommon but may be catastrophic when it
does occur. Esophageal intubation may be difficult to diag-
nose on the portable chest film because the esophagus fre-
quently projects over the tracheal air column. Gastric or
distal esophageal distention, location of the tube lateral to
the tracheal air column, and deviation of the trachea sec-
ondary to an overinflated intraesophageal balloon cuff are
radiographic signs of esophageal intubation. The right posterior
oblique view with the patient’s head turned to the right
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allows ease of separation of the esophagus and trachea and
should be obtained in equivocal cases.
Intubation may result in injury to the trachea, with tra-
cheal stenosis developing in approximately 19% of patients
following endotracheal intubation and approximately 65%
of patients with tracheostomy. In patients with translaryn-
geal intubation, the most frequent sites of stenosis are the
cuff site and the subglottic region.
Tracheostomy is typically performed in the patient who
requires relatively long-term ventilatory support. Although
the surgical mortality rate is less than 2%, the long-term
complication rate may be as high as 60%. Pneumothorax,
pneumomediastinum, subcutaneous emphysema, hemor-
rhage, and tube malposition may occur as early complica-
tions, whereas late complications include tracheal stenosis,
tracheo-innominate artery fistula, tracheoesophageal fistula,
stomal infection, aspiration, and tube occlusion. In addition,
the incidence of nosocomial pneumonia is increased second-
ary to airway bacterial colonization.
 Central Venous Catheters 
Central venous catheters are used frequently in the ICU patient
for venous access, especially for purposes of parenteral alimen-
tation, monitoring central venous pressure, and hemodialysis.
Such catheters are visible on the chest radiograph, and knowl-
edge of normal thoracic venous anatomy is required to assess
catheter location. The subclavian vein, the internal jugular vein,
and the femoral veins are the sites of venous access used most
commonly. Central venous lines inserted via a thoracic vein are
optimally positioned when the tip is past the valves in the sub-
clavian or brachiocephalic veins within the superior vena cava.
The preferred location for hemodialysis or pheresis catheters is
subject to debate, however, because some physicians believe
that catheter durability and performance are improved by
placement of the catheter tip within the upper right atrium.
Union of the subclavian and internal jugular veins to form
the brachiocephalic vein usually occurs behind the sternal end
of the corresponding clavicle. Whereas the right brachio-
cephalic vein has a vertical course as it forms the superior vena
cava, the left brachiocephalic vein crosses the mediastinum
from left to right in a retrosternal position to enter the superior
vena cava. The radiographic location of the superior vena cava
may be assessed relative to the tracheobronchial angle, with the
upper border of the superior vena cava usually just superior to
the angle of the right main stem bronchus and the trachea. The
junction of the superior vena cava and right atrium is at the
approximate level of the lower aspect of the bronchus inter-
medius. Changes in catheter location may occur with change in
patient position and changes in respiration.
Approximately one-third of catheters are incorrectly
positioned at the time of the initial chest radiograph. The
malpositioned catheter tip may result in venous thrombosis
or perforation as well as inaccurate venous pressure readings.
Positioning of the catheter tip within the right atrium may
result in cardiac perforation and tamponade, whereas a right
ventricular location may result in arrhythmias secondary to
irritation of the endocardium or interventricular septum.
Complications of central venous catheterization include
pneumothorax, hemothorax, and perforation, which may
result in pericardial effusion, hydrothorax, mediastinal
hemorrhage, or ectopic infusion of intravenous solutions
(Figure 7–1). Less common complications include air
A B
 Figure 7–1. Mediastinal hematoma following attempted central venous catheterization. A. Mediastinum appears
unremarkable prior to catheter placement. B. Following attempted central line placement, there is widening of the
superior mediastinum secondary to mediastinal hemorrhage due to a lacerated subclavian artery.
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embolism and catheter fracture or embolism. The incidence of
pneumothorax ranges between 1% and 12% and is higher with
a subclavian approach than with an internal jugular approach.
Pneumothorax may be clinically occult, and a chest radiograph
should be obtained to exclude a pneumothorax following line
placement. A radiograph should be obtained even following an
unsuccessful attempted line placement and is more critical
when contralateral venous cannulation is anticipated to avoid
the development of bilateral pneumothoraces. Although sel-
dom obtained in ICU patients, the cross-table lateral view may
be helpful to localize catheters malpositioned in the internal
mammary or azygos vein or in extravascular positions.
Venous air embolism is an uncommon complication of
central venous catheterization. Radiographically, air in the
main pulmonary artery is diagnostic, but other features include
focal oligemia, pulmonary edema, and atelectasis. Intracardiac
air or air within the pulmonary artery is seen easily on CT.
Long-term complications of venous access devices include
delayed perforation, pinch-off syndrome, thrombosis,
catheter knotting, and catheter fragmentation. Left-sided
catheters have a greater risk for perforation, with increased
risk in catheters abutting the right lateral wall of the superior
vena cava. In pinch-off syndrome, the catheter lumen is com-
promised by compression between the clavicle and the first
rib, leading to catheter malfunction and possible catheter
fracture. This is frequently first observed as subtle focal nar-
rowing of the catheter as it crosses the intersection of clavicle
and rib. As increasing numbers of chronically ill patients with
long-term venous catheters—including liver and bone mar-
row transplant recipients—are transferred to the ICU during
their hospital course, more such complications may be seen.
Access to the central venous system may be achieved
through a peripherally inserted central catheter (PICC)
placed via the antecubital fossa. These smaller catheters
course to the superior vena cava and may be associated with
fewer complications than catheters inserted via the internal
jugular or subclavian approach.
 Pulmonary Artery Catheters
The pulmonary artery catheter has enhanced the manage-
ment of the ICU patient, allowing monitoring of left atrial
and left ventricular end-diastolic pressures and calculation of
vital data such as cardiac output and vascular resistance. The
catheter tip should lie within a large central pulmonary
artery; the ideal position for the pulmonary artery catheter is
within the right or left main pulmonary artery, below the
level of the left atrium. The catheter tip when deflated should
not be peripheral to the proximal interlobar arteries.
Complications associated with their use include arrhyth-
mias, pneumothorax, vascular perforation, venous air
embolism, and catheter-related sepsis. Knotting, kinking,
and coiling of the catheter also occur.
Pulmonary infarction, thrombosis, pulmonary artery rup-
ture, and infection represent other major complications asso-
ciated with indwelling pulmonary artery catheters. There is a
7% incidence of pulmonary ischemic lesions due to direct
injury from the use of pulmonary artery catheters. The major-
ity of these lesions are thought to be due to vascular occlusion
by the catheter itself. Continuous wedging of the catheter tip
in a peripheral pulmonary artery and central pulmonary
artery obstruction by the inflated balloon have been cited as
precipitating causes. In a smaller number of cases, emboli
arose from peripheral thrombosis around the catheter.
Pulmonary infarction secondary to a pulmonary artery
catheter has a radiographic appearance like that of infarction
from other causes. Typically, a wedge-shaped parenchymal
opacity is seen in the distribution of the vessel distal to the
catheter (Figure 7–2). The presence of a pleural effusion is
variable. Management consists of removal of the catheter;
anticoagulation is generally not required. Resolution of con-
solidation usually occurs in 2–4 weeks.
Pulmonary artery rupture is a catastrophic complication
of pulmonary artery catheterization, with a reported mortal-
ity rate of 46%. The incidence is low—no more than 0.2% of
catheter placements. Risk factors include pulmonary hyper-
tension, advanced age, and improper balloon location or
inflation. The mortality rate increases in anticoagulated
patients. Pseudoaneurysm formation has been reported sec-
ondary to rupture or dissection by the balloon catheter tip.
This appears radiographically as a well-defined nodule at the
site of the aneurysm, but it may be obscured initially by
extravasation of blood into the adjacent air spaces. Chest
radiographic findings often precede clinical manifestations,
and death due to rupture of pseudoaneurysm may occur
weeks following catheterization. The CT appearance of a
pulmonary artery pseudoaneurysm has been described as a
sharply defined nodule with a surrounding halo of faint
parenchymal density. Pulmonary artery pseudoaneurysm
now may be treated in some patients with transcatheter
embolization rather than surgical resection.
Location of the catheter tip should be monitored with
serial radiographs. Softening of the catheter over time may
result in migration of the catheter tip peripherally.
Redundancy of the catheter within the right heart favors
peripheral migration, and the intracardiac loop gradually
becomes smaller (see Figure 7–2).
 Intraaortic Balloon Counterpulsation
Intraaortic balloon counterpulsation is used to improve car-
diac function in patients with cardiogenic shock and in the
perioperative period in cardiac surgery patients. The device
consists of a fusiform inflatable balloon surrounding the
distal portion of a catheter that is placed percutaneously
from a femoral artery into the proximal descending thoracic
aorta. The balloon is inflated during diastole, thereby
increasing diastolic pressure in the proximal aorta and
increasing coronary artery perfusion. During systole, the
balloon is forcibly deflated, allowing aortic blood to move
distally and decreasing the afterload against which the left
ventricle must contract, thus decreasing left ventricular
workload. The timing of inflation and deflation is controlled
by the ECG.
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The tip of the balloon ideally should be positioned just dis-
tal to the origin of the left subclavian artery at the level of the
aortic knob, maximizing the effect on the coronary arteries
while reducing the possibility of occlusion of the left subclavian
artery, embolization to cerebral vessels, or occlusion of the
abdominal vessels by the balloon. Complications associated
with the device are most often secondary to malpositioning of
the catheter and include obstruction of the subclavian artery
and cerebral embolism. Aortic dissection has been described,
and an indistinct aorta on chest radiographs has been suggested
as an early clue to intramural location, requiring confirmation
by angiography. Balloon leak or rupture also has been described.
A B
C
 Figure 7–2. Lung infarction secondary to pulmonary artery catheterization. A. Initial radiograph after catheterization
shows the tip of the catheter at the level of the right interlobar pulmonary artery. Mild redundancy of the catheter is present
within the dilated heart. B. At 24 hours, the patient developed hemoptysis. Radiograph now shows migration of the catheter
into a segmental arterial branch with increased density in the right lower lobe. C. Follow-up film demonstrates dense consol-
idation of the right middle and lower lobes secondary to infarction. (Reproduced, with permission, from Aberle DA, Brown K:
Radiologic considerations in the adult respiratory distress syndrome. Clin Chest Med 1990;2:737–54. Copyright 1990 Elsevier.)
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 Cardiac Pacemakers and Automatic
Implantable Cardioverter Defibrillators
Cardiac pacemakers can be inserted by three approaches:
transvenous, epicardial, and subxiphoid. Most often the
transvenous approach is used, whereby wires are introduced
via the subclavian or jugular vein and fluoroscopically
guided into the right atrium and ventricle.
When viewed on a chest radiograph, the pacemaker lead
should curve gently throughout its course; regions of sharp
angulation will have increased mechanical stress and
enhance the likelihood of lead fracture. Excessive lead length
may predispose to fracture secondary to sharp angulation or
may perforate the myocardium, and a short lead can become
dislodged and enter the right atrium. Leads also may
become displaced and enter the pulmonary artery, coronary
sinus, or inferior vena cava. When possible, a lateral chest
radiograph is recommended to confirm pacemaker lead
location, with the electrodes located at least 3 mm deep to
the epicardial fat stripe. Other complications include venous
thrombosis or infection, either at the pulse generator pocket
or within the vein. Myocardium perforation may result in
hemopericardium and cardiac tamponade.
Biventricular pacing or cardiac resynchronization therapy is
a relatively new treatment for severe chronic heart failure. In
patients with dilated cardiomyopathy and intraventricular con-
duction delay, biventricular or left ventricular pacing can syn-
chronize contraction and increase cardiac output and exercise
tolerance. Percutaneous lead placement into a coronary vein via
the coronary sinus allows for left ventricular pacing. Many of
these patients also will have intravascular defibrillators because
of the risk of ventricular arrhythmias. The automatic
implantable cardioverter defibrillator (AICD) is used for treat-
ment of ventricular tachyarrhythmias unresponsive to conven-
tional antiarrhythmic drugs. Earlier devices consisted of a fine
titanium mesh placed on the cardiac surface and attached to a
generator source that provided an electrical output in the event
of ventricular arrhythmia. Devices currently in use typically are
combined with a cardiac pacemaker. Radiographs are used to
assess the location of wires.
 Nasogastric Tubes
Nasogastric tubes are used frequently to provide nutrition
and administer oral medications as well as for suctioning gas-
tric contents. Ideally, the tip of the tube should be positioned
at least 10 cm beyond the gastroesophageal junction. This
ensures that all sideholes are located within the stomach and
decreases the risk of aspiration. Complications of nasogastric
intubation include esophagitis, stricture, and perforation.
Small-bore flexible feeding tubes have been developed
to facilitate insertion and improve patient comfort.
However, inadvertent passage of the nasogastric tube into
the tracheobronchial tree is not uncommon, most often
occurring in the sedated or neurologically impaired
patient. In patients with endotracheal tubes in place, low-
pressure, high-volume balloon cuffs do not prevent passage
of a feeding tube into the lower airway. If sufficient feeding
tube length is inserted, the tube actually may traverse the
lung and penetrate the visceral pleura (Figure 7–3).
 Figure 7–3. Malpositioned feeding tube. A. Feeding tube courses via the right main stem bronchus with the tip
(arrow) overlying the right costophrenic angle. An endotracheal tube is present. B. Following removal of the feeding
tube, a pneumothorax is seen (arrow).
A B
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Removal of the tube from an intrapleural location may
result in tension pneumothorax, and preparations should
be made for potential emergent thoracostomy tube place-
ment at the time of removal.
In addition to feeding tubes, balloon tamponade tubes
occasionally are used for nasogastric intubation in the treat-
ment of bleeding esophageal and gastric varices. The balloon
can be easily recognized when distended, and correct posi-
tioning can be evaluated radiographically. Esophageal rup-
ture complicates approximately 5% of cases in which balloon
tamponade tubes are used.
 Chest Tubes
Thoracostomy tubes (“chest tubes”) are used for the evacua-
tion of air or fluid from the pleural space. When chest tubes
are used for relief of pneumothorax, apical location of the tip
of the tube is most effective, whereas a tube inserted to drain
free-flowing effusions should be placed in the dependent
portion of the thorax. Chest radiographs, ultrasound, or CT
should be used to guide correct placement of the tube for
adequate drainage of a loculated effusion. Failure of the chest
tube to decrease the pneumothorax or the effusion within
several hours should arouse suspicion of a malpositioned
tube. Tubes located within the pleural fissures are usually less
effective in evacuating air or fluid collections. An interfis-
sural location is suggested by orientation of the tube along
the plane of the fissure on frontal radiographs and by lack of
a gentle curvature near the site of penetration of the pleura,
indicating failure of the tube to be deflected anteriorly or
posteriorly in the pleural space. The lateral view may be con-
firmatory. Uncommonly, thoracostomy tubes may penetrate
the lung, resulting in pulmonary laceration and bron-
chopleural fistula. Unilateral pulmonary edema may occur
following rapid evacuation of a pneumothorax or pleural
effusion that is of long standing or has produced significant
compression atelectasis of lung.
Cascade PN et al: Radiographic appearance of biventricular pacing
for the treatment of heart failure. AJR 2001;177:1447–50.
[PMID: 11717105]
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IMAGING IN PULMONARY DISEASES
 Routine Daily Chest Radiographs:
Technical Considerations & Utility  
Portable chest radiographs are frequently obtained on a daily
basis on ICU patients and as indicated by changes in their
clinical situation. Several factors related to portable radiog-
raphy may lead to difficulty in evaluation of radiographs in
a critically ill patient. The equipment used for portable
radiographs requires longer exposure time than standard
radiographs obtained in the radiology department, some-
times resulting in artifacts due to respiratory, cardiac, and
gross patient motion. Inadequate exposure may result
from the limited power output of portable equipment.
Special attention must be paid to the multiple monitoring
devices required by the ICU patient, and considerable physical
effort by the technologists is required to transport portable
equipment.
Limitations imposed by the portable technique often
complicate image interpretation. Almost all portable chest
radiographs are taken with the patient supine and with the
film placed behind the back of the patient (anteroposterior)
rather than in the conventional upright, posteroanterior
position used in the radiology department. Supine chest
radiographs result in decreases in lung volume and can alter
the size and appearance of the lungs, the pulmonary vascula-
ture, and the mediastinum. Anteroposterior chest radi-
ographs cause cardiac magnification, making evaluation of
true cardiac size more difficult. Inspiratory films may be dif-
ficult to obtain because of respiratory distress, pain, sedation,
or alterations in mental status. These technical limitations
complicate diagnostic interpretation. Nonetheless, portable
radiography continues to be a primary method of imaging
critically ill patients.
The utility of daily radiographs may depend on the
underlying disease process. Routine daily radiographs are
of greatest utility in patients with pulmonary or compli-
cated cardiac disease. The American College of Radiology
Thoracic Expert Panel concluded that daily chest radi-
ographs are indicated for patients with acute cardiopul-
monary problems and those receiving mechanical
ventilation. In patients requiring cardiac monitoring or
stable patients admitted for extrathoracic disease, an ini-
tial admission film is recommended. Additional radi-
ographs are indicated when new support devices are
placed or a specific question arises regarding cardiopul-
monary status.
Krivopal M et al: Utility of daily routine portable chest radiographs
in mechanically ventilated patients in the medical ICU. Chest
2003;123:1607–14. [PMID: 12740281] 
Tocino I et al: Routine daily portable x-ray. American College of
Radiology. ACR Appropriateness Criteria. Radiology 2000;215:
S621–6. [PMID: 11037473]
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 Atelectasis
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Shift in position of a fissure or change in position of hila
or mediastinum.
 Elevation of hemidiaphragm.
 Compensatory hyperexpansion of uninvolved lobes.
 Increased opacity of the atelectatic lung.
 Air bronchograms.
 Narrowing of rib interspaces.
General Considerations
Atelectasis is the most common pulmonary parenchymal
abnormality seen in ICU patients. Signs and symptoms of
atelectasis are nonspecific, and atelectasis may coexist with
other pulmonary diseases. Multiple factors contribute to the
development of atelectasis. In the bedridden patient,
hypoventilation results in atelectasis of the dependent lung.
Central neurogenic depression, anesthesia, or splinting may
decrease alveolar volume, reducing surfactant and promot-
ing diffuse microatelectasis. Bronchial obstruction from
retained secretions and mucous plugging may lead to post-
obstructive collapse of the distal lung, particularly in patients
with pulmonary infection or chronic airway disorders. In the
intubated or postoperative patient, other factors are contrib-
utory. A malpositioned endotracheal tube with right main
stem bronchial intubation can cause atelectasis of the non-
ventilated left lung. Following cardiac surgery, left lower lobe
collapse occurs frequently due in part to the weight of the
heart unsupported by pericardium, which compresses the
left lower lobe bronchus. Phrenic nerve paresis secondary to
intraoperative cold cardioplegia results in diaphragmatic ele-
vation and is also thought to contribute to lower lobe atelec-
tasis. Pleural processes, including pneumothorax and pleural
effusion, may also result in atelectasis.
Radiographic Features
The radiographic appearance of atelectasis depends largely on
the degree and cause of lung collapse. Findings noted on the
chest radiograph in atelectasis range from subtle diminution in
lung volume without visible opacification to complete opacifi-
cation of a segment, lobe, or lung. Dependent atelectasis occur-
ring in supine patients may be demonstrated on thoracic CT
even in healthy individuals but is usually not appreciated on
plain chest radiography. Linear bands of opacity may be seen in
“discoid” or “platelike” atelectasis, whereas a patchy opacity is
seen with atelectasis of lung subtended by a segmental or sub-
segmental bronchus. With more extensive volume loss such as
collapse of an entire lobe or lung, radiographic signs include an
increase in opacity of the atelectatic lung; shift in the position
of a fissure; change in the position of the mediastinum, hila, or
diaphragm; and hyperexpansion of the uninvolved lung
(Figure 7–4). In some cases, signs of volume loss may be absent
because of exudation of fluid into the atelectatic lung.
Air bronchograms are linear lucencies coursing through
opacified lung and represent patent bronchi and bronchi-
oles surrounded by opacified air spaces. Air bronchograms
are radiographically nonspecific and occur in any disorder
in which patent air-containing bronchi are situated within
consolidated lung, including atelectasis, pulmonary edema,
pneumonia, and hemorrhage. The presence of air bron-
chograms is also variable in atelectasis and depends on the
patency of the major airways and the cause of atelectasis.
Air bronchograms may be useful predictors of the effective-
ness of bronchoscopy in patients with lobar collapse.
Patients without air bronchograms are more likely to
demonstrate improvement following fiberoptic bron-
choscopy than those with air bronchograms. The absence of
air bronchograms in lobar collapse suggests that central
 Figure 7–4. Atelectasis in a 22-year-old man with
status asthmaticus. The right upper lobe is opaque, and
there is elevation of the minor fissure consistent with
right upper lobe collapse. Areas of increased density in
the left lung are also due to atelectasis. Lucency adjacent
to the left heart border secondary to pneumomedi-
astinum is present (arrow), and there is subcutaneous
emphysema in the right supraclavicular region.
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airways may be plugged by secretions which by virtue of
their proximal location are amenable to bronchoscopic
removal. In contrast, the presence of air bronchograms sug-
gests that the collapse is more apt to be due to small airway
collapse or peripheral mucous plugs that are not effectively
treated by therapeutic fiberoptic bronchoscopy.
The left lower lobe is the most frequent location of lobar
atelectasis, with collapse occurring two to three times more
often in the left lower than in the right lower lobe. The cause
is uncertain, although many of the factors cited earlier are
contributory. The radiographic features of left lower lobe col-
lapse include a triangular opacity in the retrocardiac region
and loss of definition of the descending aorta and left hemidi-
aphragm—as well as other signs of volume loss outlined ear-
lier (Figure 7–5). Adequate penetration and patient
positioning are important in assessing left lower lobe disease.
Left lower lobe collapse may be falsely diagnosed secondary
to faulty radiologic technique. Cephalic angulation of the
radiographic beam by 10–15 degrees (lordotic positioning)
may cause projection of extrapleural fat onto the base of the
left lung and result in loss of tangential imaging of the apex of
the hemidiaphragm and subsequent loss of definition of the
diaphragm in the absence of left lower lobe disease. In
instances in which patients are examined radiographically
with even a small degree of lordosis, loss of definition of the
diaphragm therefore cannot be assumed to be secondary to
left lower lobe collapse. Ancillary findings, including depres-
sion of the hilum, crowding of vessels, and air bronchograms,
must be used to diagnose true left lower lobe disease.
Unusual appearances of lobar atelectasis may occur and
make diagnosis difficult. Atelectasis with marked volume
loss may be caused by peripheral airway obstruction and is
frequently chronic and easily missed. Atelectasis also may
present as a mass and be confused with tumor. Recognition
of the anatomic alterations described earlier is required for
differentiation.
Many other causes of parenchymal opacification may be
confused with atelectasis, including pneumonia and pul-
monary infarction. In addition to other features previously
discussed, temporal sequence may be helpful in distinguish-
ing atelectasis from other causes of focal parenchymal opaci-
fication. Whereas atelectasis may appear within minutes to
hours and also may clear rapidly, pneumonia and infarction
typically resolve over days to weeks.
Ashizawa K et al: Lobar atelectasis: Diagnostic pitfalls on chest
radiography. Br J  Radiol 2001;74:89–97. [PMID: 11227785]
Tsai KL, Gupta E, Haramati LB: Pulmonary atelectasis: A frequent
alternative diagnosis in patients undergoing CT-PA for sus-
pected pulmonary embolism. Emerg Radiol 2004;10:282–6.
[PMID: 15290480]
 Pneumonia
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 May present as lobar pneumonia, bronchopneumonia,
or interstitial pneumonia.
 Parapneumonic effusions and cavitation may be present.
 Hilar or mediastinal densities may lead to suspicion of
obstruction secondary to underlying malignancy.
 In ICU patients, development of new or worsening
parenchymal pulmonary infiltrates may indicate nosoco-
mial pneumonia, especially if accompanied by cavitation.
General Considerations
Patients with severe pneumonia complicated by sepsis, respira-
tory failure, hypotension, or shock are seen frequently in the
ICU. Some patients will have acquired pneumonia outside of
the hospital (community-acquired), but an important problem
is that of nosocomial pneumonia, defined as lower respiratory
tract infection occurring more than 72 hours after admission.
Nosocomial pneumonia is the most common infection leading
to death among hospitalized patients. Factors contributing to
the high incidence of hospital-acquired pneumonias include
endotracheal intubation or tracheostomy, aspiration, and
impaired host defenses. Prior antibiotic therapy promotes col-
onization of the tracheobronchial tree.
Most radiologists sort the radiographic appearance of
pneumonias into three categories that may aid in differenti-
ation: lobar (alveolar or air space) pneumonia, lobular
 Figure 7–5. Left lower lobe collapse in a 20-year-old
man with head trauma sustained in a motor vehicle acci-
dent. A triangular region of increased opacity is present
in the retrocardiac region secondary to left lower lobe
collapse. The major fissure is displaced inferiorly (arrow).
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pneumonia (bronchopneumonia), and interstitial pneumo-
nia. Lobar pneumonia is characterized on x-ray by relatively
homogeneous regions of increased lung opacity and air
bronchograms. The entire lobe need not be involved, and in
fact, with early therapy, consolidation does not usually affect
the entire lobe. Pathologically, the infecting organism reaches
the distal air spaces, resulting in edema filling the alveoli. The
infected edema fluid spreads centripetally throughout the
lobe via communicating channels to adjacent segments. Air
bronchograms are common. Streptococcus pneumoniae
(pneumococcal) pneumonia is the classic lobar pneumonia,
although other organisms, including Klebsiella pneumoniae
and Legionella pneumophila, may produce an identical pat-
tern. Since the airways are not primarily involved, volume
loss is not conspicuous. Indeed, expansion of the lobe may
occur in Klebsiella or pneumococcal pneumonia.
Bronchopneumonia (lobular pneumonia) results from
inflammation involving the terminal and respiratory bron-
chioles rather than the distal air spaces. Since the process
focuses in the airways, the distribution is more segmental
and patchy, affecting some lobules while sparing others.
Pathologically, there is less edema fluid and more inflamma-
tion of the mucosa of bronchi and bronchioles. Patchy con-
solidation is seen radiographyically. Mild associated volume
loss may also be present. Air bronchograms are not as com-
mon a feature in bronchopneumonia as in lobar pneumonia.
The most common organisms producing classic bronchop-
neumonia are Staphylococcus aureus and Pseudomonas
species.
Interstitial pneumonia is typically caused by viruses or
Mycoplasma pneumoniae. In the immunocompromised
patient, Pneumocystis carinii (now known as Pneumocystis
jerovicii) is an important cause of interstitial pneumonia.
The pathologic process is located primarily in the intersti-
tium, and the classic radiograph reflects the interstitial
process and demonstrates an increase in linear or reticular
markings in the lung parenchyma with peribronchial
thickening and occasionally septal lines (Kerley A and B
lines). Although the pathologic process is primarily
located in the interstitium, proteinaceous fluid is exuded
into the air spaces and consequently may progress to a
pneumonia that radiographically appears alveolar.
Radiographic Features
A. Plain Films—Although plain films cannot provide a spe-
cific microbial diagnosis in a patient with pneumonia, radi-
ology has a central role in both initial evaluation and
treatment. The chest radiograph documents the presence
and extent of disease. Associated parapneumonic effusions,
mediastinal or hilar adenopathy, cavitation, and abscess
formation—as well as predisposing conditions such as cen-
tral bronchogenic carcinoma—may be identified. Such
information can guide the clinician to a high-yield diagnos-
tic procedure such as thoracentesis or bronchoscopy, which
may be necessary in a patient who cannot produce adequate
sputum for bacteriologic culture. The chest radiograph is
also critical in evaluating the patient’s response to therapy.
Antibiotic therapy is frequently empirical, and the chest radi-
ograph may be the first indicator of failure of antibiotics and
a need for change in management. A pneumonia that does
not clear despite antibiotic therapy should raise the suspicion
of central airway obstruction by a mass or foreign body or
may represent a bronchoalveolar carcinoma mimicking
pneumonia.
Localization of the consolidation to a specific lobe is
important not only to correlate with the physical examina-
tion but also to guide the bronchoscopist when necessary.
In addition, different types of pneumonia may be more
likely to occur in specific regions. For example, reactivation
tuberculosis occurs most commonly in the apical and pos-
terior segments of the upper lobes and the superior seg-
ment of the lower lobes. The silhouette sign is useful in
determining the site of pneumonia. When consolidation is
adjacent to a structure of soft tissue density (eg, the heart or
the diaphragm), the margin of the soft tissue structure will
be obliterated by the opaque lung. For example, right mid-
dle lobe consolidation may cause loss of the margin of the
right heart border, lingular consolidation may cause loss of
the left heart border, and lower lobe pneumonia may oblit-
erate the diaphragmatic contour.
Intrathoracic nodal enlargement may be a useful diag-
nostic feature. Enlargement of the hilar or mediastinal lymph
nodes is uncommon in bacterial pneumonia and most viral
pneumonias. Tuberculosis, atypical mycobacterial infections,
fungal infections such as coccidioidomycosis and histoplas-
mosis, and viral infections such as measles and Epstein-Barr
virus may be associated with adenopathy.
Pleural effusions occur in up to 40% of patients with bac-
terial pneumonia. A parapneumonic effusion consists of
intrapleural fluid in association with pneumonia or lung
abscess. Empyema is defined as pus in the pleural space.
Thoracentesis is required for differentiation between a sim-
ple parapneumonic effusion and an empyema, and the deci-
sion to place a chest tube depends on the characteristics and
the quantity of the effusion. A pleural effusion usually is
identified radiographically on a plain film, although ultra-
sound or CT may be necessary in some cases.
1. Lung abscess and cavitation—Cavitation of pneumo-
nia results from destruction of lung tissue by the inflamma-
tory process, leading to lung abscess formation (Figure 7–6).
Although often seen in pneumonias due to gram-negative
organisms such a Pseudomonas and Klebsiella, cavitation is
rare in pneumococcal pneumonia. Pneumonias due to
Mycobacterium tuberculosis, atypical mycobacteria, and fungi
and those due to anaerobes and staphylococci also frequently
cavitate. Cavitary lung abscesses must be distinguished from
bullae, pneumatoceles, cavitary lung cancers, and other
lucent lesions. Most abscesses have a wall thickness between
5 and 15 mm, allowing differentiation from bullae and pneu-
matoceles, which usually have thin, smooth walls. A lung
abscess is usually surrounded by adjacent parenchymal con-
solidation, which may serve to differentiate an abscess from a
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cavitary bronchogenic carcinoma. Complications of lung
abscess include sepsis, cerebral abscess, hemorrhage, and
spillage of contents of the cavity into uninfected lung or
pleural space.
In one review, 18% of lung abscesses were radiographi-
cally occult, with only nonspecific lung opacities or nod-
ules identified. In these patients, the diagnosis was made at
surgery or at postmortem examination. One reason lung
abscesses were not identified was probably failure to use a
horizontal beam in obtaining the chest radiographs. With
semierect or supine positioning, air-fluid levels within the
cavity were obscured. In cases where erect chest films are
unobtainable, decubitus or cross-table lateral views can be
obtained with a horizontal beam and may be diagnostic.
2. Nosocomial pneumonia—Definitive diagnosis of noso-
comial pneumonia is difficult because both the clinical fea-
tures and the chest radiographic findings may be present in
other disease processes and because abnormalities on chest
radiographs are often present prior to development of noso-
comial pneumonia. Clinical suspicion in patients with
underlying heart and lung disease is important. For example,
the incidence of nosocomial pneumonia is increased in
patients with ARDS as well as in other patients with respira-
tory failure.
Radiographically, nosocomial pneumonia is heralded
by the development of new or worsening parenchymal
opacities, usually multifocal. Since nosocomial pneumonias
are most often due to aerobic gram-negative organisms or
staphylococci, abscesses and pleural effusions may develop.
Development of cavitation helps to distinguish nosocomial
pneumonia from other causes of parenchymal opacification
such as atelectasis, lung contusion, or pulmonary edema.
B. Computed Tomography—The cross-sectional imaging
plane and superior contrast resolution make CT useful in
the evaluation of complicated inflammatory diseases.
Cavitation, which may be obscured on plain films, is easily
identified on CT. Localization of parenchymal diseases
facilitates the direction of invasive studies such as bron-
choscopy or open lung biopsy. Superimposed pleural and
parenchymal processes are more easily differentiated on CT
than on plain films (Figure 7–7). Loculated pleural effusion
or empyema associated with pneumonia may be difficult to
evacuate, and CT may serve to guide thoracentesis, chest
tube placement, or percutaneous drainage of large lung
abscesses.
Empyema and lung abscess are more easily distinguished
on CT than on conventional radiographs. Separation of
thickened visceral and parietal pleural surfaces (“split pleura
sign”) may be seen in empyema. Other useful findings
included wall characteristics, with smooth, uniform walls
seen in empyema and thick, irregular walls more commonly
seen in lung abscess. The size and shape of the lesion are less
helpful; lung abscesses generally tend to be round—as
opposed to lenticular in empyemas. The administration of
A B
 Figure 7–6. Cavitary pneumonia. Posteroanterior (A) and lateral (B) chest radiographs demonstrate consolidation
with cavitation (arrows) in the superior segment of the left lower lobe secondary to Pseudomonas aeruginosa. A small
left pleural effusion is present, best seen on the lateral view (arrowhead). Changes of chronic obstructive pulmonary
disease are also present.
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intravenous contrast material facilitates differentiation of
pleural and parenchymal disease because the lung
parenchyma will enhance with contrast, whereas the pleural
effusion will retain its low attenuation.
Franquest T: Imaging of pneumonia: Trends and algorithms. Eur
Respir J 2001;18:196–208. [PMID: 11510793]
Sharma S et al: Radiological imaging in pneumonia: recent innova-
tions. Curr Opin Pulm Med 2007;13:159–69. [PMID: 17414122]
Vilar J et al: Radiology of bacterial pneumonia. Eur J Radiol
2004;51:102–13. [PMID: 15246516] 
 Aspiration Pneumonia
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Consolidation in dependent regions of the lung, varying
with position of patient at time of aspiration, but may
be multilobar and bilateral.
 Cavitation and abscess formation may be seen, but
pleural effusions are infrequent.
 May lead to necrotizing pneumonia and lung abscess.
 Aspiration of gastric contents may result in noncardio-
genic pulmonary edema, cavitation, and atelectasis.
General Considerations
Aspiration pneumonia results from endotracheal aspiration
of oropharyngeal or gastric secretions. Aspiration is thought
to be a common occurrence in the healthy adult, with the
incidence during sleep estimated to be as high as 45%.
Small-volume aspirates are cleared by physical entrapment
and coughing along with the mucociliary elevator action of
the respiratory epithelium. Inactivation by IgA antibodies
and opsonization and ingestion of bacteria by phagocytic
cells play a role as well. Although organisms are present in
pathogenic numbers even in small-volume aspirates, nor-
mal individuals are able to clear these organisms without
sequelae.
Several clinical conditions predispose patients to aspira-
tion. Depressed levels of consciousness secondary to medica-
tions, alcohol intoxication, seizures, anesthesia, or neurologic
disease result in impaired upper airway reflexes.
Endotracheal intubation increases the rate of aspiration,
with both high-volume, low-pressure cuffs and uncuffed or
low-volume, high-pressure tubes implicated. The incidence
of aspiration is even higher in patients with tracheostomies
as compared with endotracheal tubes. Nasogastric and feed-
ing tubes, gastric distention, gastroesophageal reflux, hiatal
hernia, decreased esophageal mobility, and vomiting have all
been cited as predisposing factors for aspiration. Severe peri-
odontal disease is also a risk factor for aspiration pneumonia.
Bacterial colonization of gastric secretions also plays a role in
the development of aspiration pneumonia. Although gastric
acidity prevents significant bacterial colonization, antacid
therapy for prophylaxis for stress ulcers may change gastric
pH, resulting in increased bacterial colonization of gastric
contents.
Aspiration pneumonia occurs when a normal host aspi-
rates a large amount of contaminated matter, overwhelming
host defenses, or when smaller amounts are aspirated in a
patient with impaired defenses. Aspiration pneumonia is
caused by mixed anaerobic and aerobic organisms, with up
to 80% of cases caused by multiple strains of bacteria. The
A
B
 Figure 7–7. Pneumonia with loculated empyema. A. CT
shows a loculated pleural effusion in the left hemithorax
(arrows). B. More caudally, dense consolidation with air bron-
chograms secondary to pneumonia is present in the left
lower lobe. The consolidated lung enhances with contrast and
is easily distinguished from the surrounding pleural effusion.
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organisms responsible for the pneumonia vary with the
clinical setting—community-acquired, nursing home, or
hospitalized patients—and reflect colonization of the upper
airway. Aerobic bacteria associated with community-
acquired aspiration pneumonia are mostly streptococci,
whereas gram-negative organisms, particularly Klebsiella and
Escherichia coli, are seen more often in nosocomial infection.
The major anaerobic organisms include Fusobacterium
nucleatum, Peptostreptococcus, Bacteroides melaninogenicus,
and Bacteroides intermedius.
There are three general clinical patterns that may be seen
following aspiration: (1) respiratory compromise followed
by rapid clinical and radiographic improvement, (2) rapid
clinical and radiographic progression, and (3) transient sta-
bilization followed by protracted worsening of clinical and
radiographic status, with bacterial superinfection or ARDS.
Aspiration of acidic gastric contents resulting in an acute
pulmonary reaction with pulmonary edema is sometimes
referred to as Mendelson’s syndrome. Manifestations depend
on the volume, pH, and distribution of the aspirate. The
absorption of acid by the pulmonary vasculature and subse-
quent pulmonary injury are almost immediate and lead to
consolidation, alveolar hemorrhage, and collapse with tran-
sudation of fibrin and plasma into the alveoli. Aspiration of
a combination of acid and gastric particulate material pro-
duces a more severe injury pattern than either acid or gastric
particulate matter alone.
Radiographic Features
Aspiration pneumonia results in consolidation in dependent
regions of the lung. The location of the consolidation will
vary according to the patient’s position at the time of aspira-
tion. In the supine patient, the superior segments of the
lower lobes, the posterior segment of the right upper lobe,
and the posterior subsegment of the left upper lobe are
involved—whereas in the upright patient, the basal segments
of the lower lobes are more often affected, particularly on the
right. The more obtuse angle between the trachea and the
right main stem bronchus compared with the angle of the
trachea and the left main stem bronchus results in a higher
percentage of right-sided abnormalities in the supine patient.
Consolidation is usually multilobar and bilateral (Figure 7–8).
Because of frequent infection with anaerobes, cavitation and
abscess formation may be seen. Effusions are infrequent.
CT is useful in the evaluation of aspiration disease and to
differentiate aspiration from other parenchymal diseases. CT
is also more sensitive than chest radiographs for the detec-
tion of aspirated foreign bodies.
Complications of simple aspiration pneumonia include
necrotizing pneumonitis and lung abscess. Necrotizing pneu-
monia results in multiple small cavities within the involved
lung and may extend into the pleural space, leading to
empyema formation. Lung abscess radiographically appears
as a cavitary lesion within a focus of consolidation, usually
solitary. Empyema is less likely in lung abscess since extension
of infection into the pleural space is usually impeded by the
barrier effect of the fibrous wall of the abscess cavity.
Patients who aspirate gastric contents may develop a
chemical pneumonitis that shows characteristics consistent
with noncardiogenic pulmonary edema. ARDS and features
of secondary bacterial infection may follow, including lung
necrosis and cavitation. Atelectasis may be a feature of airway
obstruction with food particles.
Franquet T et al: Aspiration diseases: Findings, pitfalls, and differen-
tial diagnosis. Radiographics 2000;20:673–85. [PMID: 10835120]
 Chronic Obstructive Pulmonary Disease
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Hyperinflation.
 Bullae or blebs.
 Pulmonary arterial deficiency pattern (areas of decreased
pulmonary vasculature).
 Features of pulmonary hypertension.
General Considerations
Chronic obstructive pulmonary disease (COPD) is any pul-
monary disorder characterized by airflow obstruction.
Emphysema and chronic bronchitis are the most com-
mon examples. Emphysema is defined as a lung condition
characterized by enlargement of the air spaces distal to the
 Figure 7–8. Aspiration pneumonia. Multiple areas of
pulmonary opacification are present bilaterally—secondary
to aspiration pneumonia following drug overdose.
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terminal bronchiole, accompanied by destruction of the
walls without obvious fibrosis. Four principal types of
emphysema are described: centrilobular, panlobular,
paraseptal, and paracicatricial. Chronic bronchitis is usually
defined in clinical terms, manifested by chronic productive
cough for at least 3 months for a minimum of 2 consecutive
years and characterized by excessive secretion of mucus in
the bronchi. Emphysema and chronic bronchitis frequently
coexist.
Radiographic Features
There is considerable controversy regarding the utility of the
chest radiograph in the evaluation of emphysema. Although
moderate to severe emphysema is usually apparent on the
chest radiograph, mild disease is difficult to appreciate.
Hyperinflation results from obstruction of small airways,
resulting in air trapping. Radiographic features include an
increase in size of the retrosternal clear space, flattening of
the hemidiaphragms, increased height of the lung, and
increased radiolucency (Figure 7–9). Measurements
obtained from chest x-rays have shown that the height of the
lung and the height of the arc of the right hemidiaphragm
correlate best with spirometric measures such as the forced
expiratory volume in 1 second (FEV1) and forced vital capac-
ity (FVC). A lung height of 29.9 cm or greater, as measured
from the tubercle of the first rib to the dome of the right
hemidiaphragm, will identify 70% of patients with abnormal
pulmonary function tests. A height of the right hemidi-
aphragm of less than 2.6 cm on the lateral projection identi-
fies 68% of patients with abnormal pulmonary function tests.
Bullae and blebs appear as focal regions of hyperlucency.
Although good indicators of emphysema, they also may be
seen in patients without COPD. Bullae are recognized as
hyperlucent or avascular regions and occasionally are demar-
cated peripherally by a fine curvilinear wall. The lung adja-
cent to large bullae may be compressed, and redistribution of
pulmonary blood flow away from areas of extensive bullous
disease may occur. The arterial deficiency pattern refers to
regions of radiolucent, hypovascular pulmonary
parenchyma characterized by a decrease in the size and num-
ber of vessels. This appearance may be due to multiple bul-
lae. Emphysema eventually can lead to pulmonary arterial
hypertension, manifested radiographically by disproportion-
ate enlargement of the central pulmonary arteries and right
heart chambers.
The radiographic appearance of the lungs in chronic
bronchitis is even less specific. Unlike that of emphysema, the
diagnosis of chronic bronchitis is based on clinical symp-
toms and not morphologic appearance. In addition, chronic
bronchitis and emphysema frequently coexist, making pure
chronic bronchitis difficult to characterize. Radiographic
findings suggesting chronic bronchitis include thickening of
bronchial walls and increased linear markings (“dirty
lungs”). Hyperinflation and hypovascularity have been
described but are probably due to concomitant emphysema.
A
B
 Figure 7–9. Chronic obstructive pulmonary disease.
Posteroanterior (A) and lateral (B) chest radiographs show
hyperinflated lungs with increased anteroposterior diame-
ters, flattening of the diaphragm, and increased retroster-
nal clear space.
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High-resolution CT (HRCT) is more sensitive than plain
radiographs in the detection of emphysema. On HRCT,
emphysema appears as regions of low attenuation, lung
destruction, or simplification of the pulmonary vasculature.
The type of emphysema can often be defined by its pattern
and distribution on CT, with centrilobular CT predominantly
upper zone in distribution and panlobular emphysema more
diffuse or more severe within the lower lobes. The CT
appearance of chronic bronchitis may be overshadowed by
coexisting emphysema. Bronchial wall thickening and cen-
trilobular abnormalities have been described.
Cleverley JR, Muller NL: Advances in radiologic assessment of
chronic obstructive pulmonary disease. Clin Chest Med
2000;21:653–63. [PMID: 11194777]
Goldin JG: Quantitative CT of emphysema and the airways.
J Thorac Imaging 2004;19:235–40. [PMID: 15502610]
Shaker SB et al: Imaging in chronic obstructive pulmonary disease.
COPD 2007;4:143–61. [PMID 17530508]
Webb WR: Radiology of obstructive pulmonary disease. AJR
1997;169:637–47. [PMID: 9275869]
 Asthma
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Hyperinflation.
 Peribronchial thickening.
 Increased lung markings centrally.
 Subsegmental atelectasis.
General Considerations
Asthma is a disease characterized by widespread narrowing
of the airways that fluctuates in severity over short periods of
time either spontaneously or following therapy.
Hyperactivity of airways may be induced by a variety of stim-
uli, and asthma is usually divided into two types: intrinsic
and extrinsic. Pathologic changes include smooth muscle
hypertrophy, mucosal edema, mucous hypersecretion, and
plugging of airways by thick, viscid mucus. The result is nar-
rowing of the airway diameter.
Radiographic Features
The radiographic manifestations of asthma vary from a normal
radiograph to hyperinflation, atelectasis, or barotrauma.
Radiographic findings may be categorized as (1) those common
features of asthma that do not affect management and are there-
fore not unanimously considered abnormalities and (2) find-
ings that influence patient management. The incidence of
radiographic abnormalities depends on the age of the patient
and the definition of abnormal by the investigator.
A. Uncomplicated Asthma—Hyperinflation, bronchial wall
thickening, and prominent perihilar vascular markings are all
features commonly seen in uncomplicated asthma that do not
alter patient management. Hyperinflation, characterized by
flattening of the hemidiaphragms and an increase in the ret-
rosternal clear space, results from air trapping. Bowing of the
sternum, another sign of hyperinflation, is seen more fre-
quently in the pediatric population, probably secondary to
more pliable osseous structures. Hyperinflation is not specific
for asthma and occurs in other pulmonary diseases associated
with air trapping, including emphysema and cystic fibrosis.
Bronchial wall thickening results from edema of the
bronchial wall and can be diagnosed when the walls of sec-
ondary bronchi peripheral to the central bronchi appear
abnormally thickened. Identification of bronchial wall thick-
ening may be difficult and is best made when serial films are
compared. Mucous plugs may be identified as tubular or
branching soft tissue densities; plugging of large airways may
result in atelectasis. Prominent perihilar vascular shadows
and prominence of the main pulmonary artery segment are
probably due to transient pulmonary arterial hypertension
and are more often seen in children.
B. Complications of Asthma—Radiographic findings that
alter medical management and therefore are considered
manifestations of complicated asthma consist of pneumonia,
segmental or lobar atelectasis, and barotrauma, including
pneumomediastinum and pneumothorax. Exacerbation of
asthma secondary to pneumonia is usually secondary to viral
infection. Although subsegmental atelectasis from mucous
plugging is common in uncomplicated asthma, plugging of
large airways may result in lobar collapse (see Figure 7–4).
Lobar atelectasis occurs more often in children, with an inci-
dence between 5% and 10%.
Pneumomediastinum complicating asthma is uncom-
mon but has been reported in 1–5% of cases of acute asthma.
This complication occurs primarily in children; the pre-
sumed mechanism is an increase in intraalveolar pressure
and subsequent alveolar rupture secondary to mucous plug-
ging, giving rise to pulmonary interstitial emphysema.
Central dissection of air along the perivascular sheaths
results in pneumomediastinum and may eventuate in subcu-
taneous emphysema and pneumothorax. In aerated lung,
pulmonary interstitial emphysema is usually not identifiable,
but the sequelae of pneumomediastinum and pneumotho-
rax may be recognized.
C. Assessment of Asthma Severity—Several studies have
addressed the usefulness of chest radiography in acute asthma.
Although the findings of hyperinflation, increased perihilar
markings, bronchial wall thickening, and subsegmental atelec-
tasis are seen frequently, identification of these abnormalities
does not change medical management. Most investigators
agree that a chest radiograph should be obtained when asthma
is diagnosed initially to rule out other causes of wheezing such
as airway obstruction by tumor or foreign body, congestive
heart failure, bronchiectasis, or pulmonary embolism.
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D. High-Resolution CT—HRCT is rarely used to evaluate
patients with asthma. Bronchial wall thickening with narrowing
of the bronchial lumen is identified. Mild bronchiectasis also
may be seen with mucous plugging of small centrilobular
bronchioles, resulting in a tree-in-bud appearance. Air trap-
ping may be identified with focal or diffuse hyperlucency,
accentuated on expiratory images.
Grenier PA et al: New frontiers in CT imaging of airway disease.
Eur Radiol 2002;12:1022–44. [PMID: 11976844]
Lynch DA: Imaging of asthma and allergic bronchopulmonary
mycoses. Radiol Clin North Am 1998;36:129–42. [PMID: 9465871]
Mitsunobu F, Tanizaki Y: The use of computed tomography to
assess asthma severity. Curr Opin Allergy Clin Immunol.
2005;5:85–90. [PMID: 15643349]
Silva CI et al: Asthma and associated conditions: High-resolution
CT and pathologic findings. AJR 2004;183:817–24. [PMID:
15333375]
Sung A et al: The role of chest radiography and computed tomog-
raphy in the diagnosis and management of asthma. Curr Opin
Pulm Med 2007;13:31–6. [PMID: 17133122]
 Epiglottitis
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Enlargement of the epiglottis and thickening of the
aryepiglottic folds on lateral radiographs of the neck.
 Ballooned hypopharynx, narrowed tracheal air column,
prevertebral soft tissue swelling, and obliteration of the
vallecula and piriform sinuses.
General Considerations
Epiglottitis is a potentially lethal infection of the epiglottis and
larynx resulting in supraglottic airway obstruction. Although
usually a disorder of children aged 3–6 years, epiglottitis can
occur in adults as well. In the pediatric patient, the causative
organism is usually Haemophilus influenzae, whereas in adults
the etiologic agents also include H. parainfluenzae, pneumo-
cocci, group A streptococci, and S. aureus. Epiglottitis results
in edema of the epiglottis, aryepiglottic folds, false cords, and
subglottic region and may involve the entire pharyngeal wall.
The clinical presentation differs somewhat in children and
adults, with fever more common in the pediatric patient.
Radiographic Features
The radiologic examination may be diagnostic. However, sud-
den death from airway obstruction is known to occur, and
patients should be accompanied by a physician during the
examination in the event that emergency endotracheal intuba-
tion or tracheostomy is necessary. Films should be obtained in
the erect position to minimize respiratory distress; manipula-
tion of the neck should be avoided. A single lateral radiograph
of the neck should be confirmatory. In the patient with obvi-
ous (classic) epiglottitis, roentenographic diagnosis is not nec-
essary, and airway management is started immediately.
In acute epiglottitis, enlargement of the epiglottis and
thickening of the aryepiglottic folds are noted in 80–100% of
patients. The normal epiglottis has a shape like a little finger,
whereas the enlarged epiglottis has been likened to a thumb
(“thumb sign”). Other radiographic features of acute epiglot-
titis include a ballooned hypopharynx, narrowed tracheal air
column, prevertebral soft tissue swelling, and obliteration of
the vallecula and the piriform sinuses. In one report of an
affected adult, CT examination demonstrated enlargement of
the epiglottis and aryepiglottic folds as well as induration of
preepiglottic fat. CT is not appropriate in children with sus-
pected epiglottitis and is rarely required in an adult.
Radiography may be useful in distinguishing epiglottitis
from other causes of upper airway obstruction in the pedi-
atric patient such as croup, retropharyngeal abscess, or for-
eign body aspiration.
 Pulmonary Embolism
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Chest radiograph usually abnormal but nonspecific, showing
atelectasis. Useful to exclude other causes of symptoms
such as pneumonia, pneumothorax, and pulmonary edema.
 In pulmonary embolism, chest radiograph may show
focal oligemia and radiolucency. In pulmonary infarc-
tion, may show peripheral parenchymal opacities.
 Pleural effusions occur frequently.
 Ventilation-perfusion lung scan can be used to assess
probability of pulmonary embolism in a given patient.
 Spiral or multidetector CT allows for direct visualization
of thrombus and parenchymal and pleural changes sec-
ondary to pulmonary embolism.
 Pulmonary angiography considered the “gold standard”
for the diagnosis of pulmonary embolism, but is rarely
performed. If clinical suspicion of pulmonary embolism is
high but the patient has an indeterminate, intermediate,
or low-probability ventilation-perfusion scan or an inde-
terminate CT angiogram, pulmonary angiography is nec-
essary for diagnosis.
General Considerations
Pulmonary embolism is a common life-threatening disorder
that results from venous thrombosis, usually arising in the
deep veins of the lower extremities. In situ pulmonary arterial
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thrombosis is exceedingly rare. The signs and symptoms of
pulmonary embolism are nonspecific, and can be seen in a
variety of pulmonary and cardiovascular diseases. The clini-
cian must stay alert to the possibility of pulmonary embolism
in any patient at risk for Virchow’s triad of venous stasis, inti-
mal injury, and hypercoagulable state. The high morbidity
and mortality rates of pulmonary embolism and the not
inconsequential risk of anticoagulant therapy make accurate
diagnosis of venous thromboembolism crucial. A variety of
imaging resources, including chest radiography, ventilation-
perfusion scans, pulmonary angiography, and spiral or helical
CT, play a role in the diagnosis of pulmonary embolism.
Radiographic Features
A. Chest Radiograph—Although the chest x-ray is abnor-
mal in 80–90% of cases, findings are nonspecific. Despite its
low sensitivity and specificity, the chest radiograph may
exclude other diseases that can mimic pulmonary embolism,
such as pneumonia, pneumothorax, or pulmonary edema. In
addition, the chest radiograph is necessary for proper inter-
pretation of the ventilation-perfusion radionuclide scan.
Radiographic findings include atelectasis, pleural effusion,
alterations in the pulmonary vasculature, or consolidation.
Linear opacities (discoid or plate atelectasis) occur commonly
in pulmonary embolism as well as in several other disorders in
which ventilation is impaired. These linear shadows are most
prevalent in the lung bases and are presumed to be secondary
to regions of peripheral atelectasis from small mucous plugs.
Some investigators have suggested that these linear opacities
are caused by infolding of subpleural lung in low-volume
states with hypoventilation, distal airway closure, and
decreased surfactant production. Linear shadows also may
occur secondary to regions of fibrosis due to pulmonary
infarction or prior inflammatory disease. Pleural effusions are
a frequent finding, occurring in up to 50% of patients. The
effusions are usually small and unilateral. Effusions may be
present with or without pulmonary infarction, although
patients with lung infarction tend to have larger, more slowly
resolving effusions that are often hemorrhagic. Alterations in
the pulmonary vasculature are manifested radiographically by
focal oligemia and radiolucency (Westermark’s sign). These
findings result from obstruction of pulmonary vessels either
by thrombus or by reflex vasoconstriction. Focal oligemia usu-
ally requires occlusion of a large portion of the vascular bed
and is uncommonly observed. Associated enlargement of the
central pulmonary artery may be seen secondary to a large
central embolus or acute pulmonary hypertension.
It is estimated that approximately 10–15% of pulmonary
thromboemboli cause pulmonary infarction. By virtue of
dual blood supply via the pulmonary and bronchial arterial
circulations, infarcts are relatively uncommon, occurring
more often peripherally, where collateral flow via bronchial
arteries is reduced. The incidence of pulmonary infarction is
also greater in patients with left ventricular failure, in whom
there is compromise of the bronchial circulation. Infarcts are
more common in the lower lobes and vary in size from less
than 1 cm to an entire lobe. Radiographically, they appear as
regions of parenchymal opacity adjacent to the pleura, typi-
cally developing 12–24 hours following the onset of symp-
toms. Initially ill-defined, the lesion becomes more discrete
and well-demarcated over several days. Air bronchograms
are uncommon, presumably because the bronchi are filled
with blood. Hampton and Castleman described the classic
appearance of a pulmonary infarct as a wedge-shaped, well-
defined opacity abutting the pleura (Hampton’s hump), but
this is observed in a minority of cases.
Infarcts may resolve entirely or may clear with residual lin-
ear scars or pleural thickening. The appearance of a resolving
infarct has been likened to a melting ice cube in that the
infarct shrinks in size while maintaining its basic configura-
tion. This is in contrast to infectious processes, which show
gradual resolution or fading of the entire involved area.
B. Ventilation-Perfusion Lung Scan—The ventilation-
perfusion (
.
V/
.
Q) scintigraphic lung scan was previously fre-
quently performed in the patient with suspected pulmonary
embolism before the advent of CT pulmonary angiography
and still has a role in the diagnosis of this disease today. A nor-
mal perfusion scan virtually excludes pulmonary embolism.
Interpretation of
.
V/
.
Q scans is complex, and an abnormal 
.
V/
.
Q
scan does not make a definitive diagnosis of pulmonary
embolism. Instead, the 
.
V/
.
Q scan in conjunction with the chest
radiograph may be used to determine the probability of pul-
monary embolism in a given patient. The results of a 
.
V/
.
Q scan
in an individual patient then must be evaluated in conjunction
with the clinical data to determine the course of action for that
specific patient. Based on these combined data, the decision to
treat the patient or not or to perform additional diagnostic
procedures is made.
Ventilation-perfusion scans are based on the premise
that pulmonary thromboembolism results in a region of
lung that is ventilated but not perfused. The study consists
of two scans—the perfusion scan and the ventilation scan—
that are compared for interpretation. The perfusion scan
involves injection of an agent such as macroaggregated albu-
min labeled with technetium-99m (99mTc). This agent is
trapped via the precapillary arterioles and identifies areas of
normal lung perfusion. Following injection, the patient is
immediately scanned in multiple projections. Regions of the
lung with absent perfusion will appear photon-deficient.
The ventilation scan is performed by having the patient
inhale a radionuclide, usually xenon (133Xe), krypton
(81mKr), or 99mTc. Images are obtained during an initial
breath-hold of approximately 15 seconds while breathing in
a closed system (equilibrium) and during a “washout”
phase. Most images are obtained in a posterior projection,
allowing for evaluation of the largest lung volume.
Ventilation scans can also be performed using a radionu-
clide aerosol. This has the advantage of allowing multiple
images to be acquired with the patient in the same positions
as during the perfusion scan.
Although the concept behind 
.
V/
.
Q scanning is simple,
image interpretation is quite complex. Perfusion scans are
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quite sensitive in the detection of perfusion abnormalities.
However, several disorders other than pulmonary
thromboembolism may cause perfusion defects, including
COPD, pulmonary edema, lung cancer, pneumonia, atelecta-
sis, and vasculitis. In an attempt to increase the specificity of
radionuclide lung scans, ventilation scans were added to per-
fusion scans. Whereas pulmonary embolism results in a
region of nonperfused lung, ventilation to this region is
maintained, resulting in a perfusion defect without an asso-
ciated ventilation defect (mismatch). In obstructive pul-
monary disease, both perfusion and ventilation are impaired,
resulting in a matched perfusion and ventilation defect.
There has been considerable controversy regarding the effi-
cacy, reliability, and interpretation of
.
V/
.
Q scans. The majority of
these studies were retrospective, resulting in bias secondary to
patient selection. Standardized criteria have been established
that are used most often in the interpretation of the 
.
V/
.
Q scan.
The chest radiograph, the size and number of perfusion
defects, and the match or mismatch of ventilation defects are all
taken into consideration in assigning probability categories for
pulmonary embolism. There are four probability categories:
normal, low, indeterminate or intermediate, and high. Fewer
than 8% of patients in the low-probability category had pul-
monary embolism documented by angiography, whereas those
in the high-probability category had pulmonary embolism
documented in approximately 90% of cases. Of the
intermediate-probability group, 20–33% had pulmonary
embolism documented angiographically. In a multicenter
prospective study (PIOPED) of the value of the ventilation-
perfusion study in acute pulmonary embolism, 88% of patients
with high-probability scans had pulmonary embolism,
whereas 33% of those with intermediate-probability scans and
12% of those with low-probability scans had pulmonary
embolism. However, only a minority of patients with pul-
monary embolism had high-probability scans. Angiography
was required for a substantial number of patients to make a
definitive diagnosis of pulmonary embolism in this study.
C. CT Pulmonary Angiography—The search for a noninva-
sive study that can detect thrombus rather than the second-
ary effects of thrombi has lead to the use of CT scanning for
the evaluation of pulmonary embolism. Contrast-enhanced
helical (spiral) or electron beam CT has sensitivities and
specificities of approximately 90% in the diagnosis of pul-
monary embolism involving segmental or larger pulmonary
arteries. Although subsegmental thrombi may be missed, the
clinical significance as well as the incidence of an isolated
subsegmental clot remains uncertain. Multidetector CT
(MDCT) demonstrates subsegmental pulmonary artery
embolism with greater frequency. Given the relatively nonin-
vasive nature of the technique and its high sensitivity and
specificity for central clot, many institutions have chosen to
perform CT pulmonary angiography as the initial study in
the investigation of suspected pulmonary embolism, bypass-
ing the ventilation-perfusion scan. Using CT venography, the
deep veins of the pelvis and lower extremities also may be
evaluated. Scanning of the lower extremities may be performed
3–4 minutes after scanning the pulmonary arteries, without
additional contrast material.
CT findings of pulmonary embolism include partial or
complete filling defects within the pulmonary artery due to
nonocclusive or occlusive thrombi, contrast material stream-
ing around a central thrombus, complete cutoff of vascular
enhancement, enlargement of an occluded vessel, and mural
defects (Figure 7–10). Parenchymal and pleural changes that
occur with pulmonary emboli are also easily detected on CT.
Oligemia of lung parenchyma distal to the occluded vessel
may be present. Pulmonary embolism may result in hemor-
rhage that is visible as ground-glass opacification or consoli-
dation on CT. An infarct may appear as a peripheral region of
consolidation, typically wedge-shaped with a central region of
lower attenuation due to uninfarcted lobules. Pleural effu-
sions are seen commonly. Acute right-sided heart failure may
occur secondary to pulmonary embolism and is suggested on
CT by right ventricular dilatation and deviation of the inter-
ventricular septum toward the left ventricle. On non-
contrast-enhanced CT, a region of increased attenuation
within the pulmonary artery may suggest acute central pul-
monary embolism. CT also may provide an alternative diag-
nosis in patients with suspected pulmonary embolism and
may demonstrate pulmonary edema, pneumonia, pericardial
disease, aortic dissection, or pneumothorax.
Pitfalls in the interpretation of CT pulmonary angiogra-
phy include breathing artifacts in patients unable to breath-
hold, inadequate contrast opacification of the pulmonary
arteries, and suboptimal visualization of vessels that are
obliquely oriented relative to the transverse imaging plane
(eg, the segmental branches of the right middle lobe and
lingula). Partially opacified veins may be confused with
thrombosed arteries, and hilar lymph nodes and mucus-
filled bronchi may be misinterpreted as thrombi.
 Figure 7–10. Acute pulmonary embolism. CT pul-
monary angiogram demonstrates low-attenuation filling
defects within the right pulmonary artery and within the
left lower lobe pulmonary artery. There is distention of
the left lower lobe pulmonary artery.
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D. Pulmonary Angiography—Pulmonary angiography is gen-
erally considered the most sensitive and specific imaging method
for the diagnosis of pulmonary embolism. Angiography is indi-
cated when there is disagreement between the results of the  CT
angiogram or 
.
V/
.
Q scan and the clinical suspicion of pulmonary
embolism; when the CT angiography is indeterminate or the   
.
V/
.
Q
scan is indeterminate or is of intermediate probability, when
there is a contraindication to anticoagulant therapy, or when
other studies are indeterminate, therapy involves more compli-
cated treatment such as an inferior vena cava filter, surgical
embolectomy, or thrombolytic therapy. Complications of pul-
monary angiography are related to the catheter and its manipu-
lation through the heart and to reactions to intravenous contrast
material. Dysrhythmias, heart block, cardiac perforation, cor
pulmonale, and cardiac arrest may occur. Relative contraindica-
tions to pulmonary angiography include elevated right ventricu-
lar and pulmonary arterial pressures, bleeding diathesis, renal
insufficiency or failure, left-sided heart block, and a history of
contrast material allergy. Pulmonary angiography can be per-
formed in all these settings if appropriate measures are taken to
reduce the risk of the procedure.
At angiography, the diagnosis of pulmonary embolus is
made when an intraluminal filling defect or an occluded pul-
monary artery is identified. Secondary findings include
decreased perfusion, delayed venous return, abnormal
parenchymal stain, and crowded vessels, which, though sug-
gestive, may be seen in other pulmonary disorders.
E. MRI—The role of MRI and MR angiography (MRA) in the
diagnosis of pulmonary embolism remains unclear.
Although central and peripheral emboli have been detected
on MRA, and physiologic information on ventilation and
perfusion may be provided, CT is more readily accessible and
suitable for imaging of the critically ill patient.
F. Imaging Techniques in Chronic Pulmonary Embolism—
Chronic pulmonary embolism may lead to right ventricular
failure and pulmonary arterial hypertension. Radiographic
findings include enlargement of the right side of the heart and
of the main and proximal pulmonary arteries and decreased
peripheral vascularity. Bronchial arteries distal to the occluded
pulmonary artery may become dilated. As in patients with
acute pulmonary embolism, evaluation of the patient with sus-
pected chronic pulmonary embolism includes 
.
V/
.
Q scanning,
CT pulmonary angiography, and pulmonary angiography. In
addition to direct visualization of clot, other signs of chronic
pulmonary embolism seen on CT angiography include abrupt
narrowing of the vessel diameter, cutoff of distal lobar or seg-
mental arterial branches, webs and bands, and an irregular or
nodular arterial wall. Calcification within the vessel is uncommon
but may be present. Recanalization and eccentric location of
thrombi also suggest chronicity. Direct pulmonary angiography
may demonstrate similar findings. Findings indicative of pul-
monary arterial hypertension, such as enlargement of the main
pulmonary artery, pericardial fluid, and right ventricular enlarge-
ment, also may be seen on CT. Abnormalities of the lung
parenchyma may include local regions of decreased lung atten-
uation and perfusion.
Han D et al: Thrombotic and nonthrombotic pulmonary arterial
embolism: Spectrum of imaging findings. Radiographics
2003;23:1521–39. [PMID: 14615562]
The PIOPED Investigators: Value of the ventilation-perfusion scan
in acute pulmonary embolism. JAMA 1990;263:2753–9.
[PMID: 2332918]
Quiroz R et al: Clinical validity of a negative computed tomogra-
phy scan in patients with suspected pulmonary embolism: A
systematic review. JAMA 2005;293:2012–7. [PMID: 15855435]
Stein PD et al: Diagnostic pathways in acute pulmonary embolism:
Recommendations of the PIOPED II investigators. Radiology
2007;242:15–21. [PMID: 17185658]
Stein PD et al: Multidetector computed tomography for acute pul-
monary embolism. N Engl J Med 2006;354:2317–27. [PMID:
16738268]
Swensen SJ et al: Outcomes after withholding anticoagulation
from patients with suspected acute pulmonary embolism and
negative computed tomographic findings: A cohort study. Mayo
Clin Proc 2002;77:130–8. [PMID: 11838646]
Winer-Muram HT et al: Suspected acute pulmonary embolism:
Evaluation with multi-detector row CT versus digital subtrac-
tion pulmonary arteriography. Radiology 2004;233:806–15.
[PMID: 15564410]
Wittram C et al: CT angiography of pulmonary embolism:
Diagnostic criteria and causes of misdiagnosis. Radiographics
2004;24:1219–38. [PMID: 15371604]
 Septic Pulmonary Emboli
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Wedge-shaped or rounded peripheral opacities of vary-
ing size, usually multiple and more numerous in the
lower lobes.
 Thin-walled cavities, sometimes with necrotic debris,
are common.
 On CT scan, peripheral nodules, wedge-shaped periph-
eral opacities, and cavitation.
General Considerations
Infections of the right side of the heart or of the peripheral
veins may give rise to septic pulmonary emboli. Risk factors
include intravenous drug use, indwelling catheters, pelvic
inflammatory disease, organ transplantation, and immuno-
logic deficiencies such as lymphoma or AIDS. Infectious
thrombophlebitis also may result from infection of the phar-
ynx extending to the parapharyngeal space and internal jugular
venous system (Lemierre’s syndrome or postanginal sepsis).
Tricuspid valve endocarditis is the most common source of
septic emboli in the intravenous drug user. S. aureus is the most
commonly isolated organism, followed by streptococci.
IMAGING PROCEDURES 157
Radiographic Features
Septic pulmonary emboli appear radiographically as wedge-
shaped or rounded peripheral opacities. Septic emboli are
usually multiple and are more numerous in the lower lobes,
reflecting increased blood flow to the dependent lung. The
lesions may vary in size by virtue of variations in the timing
of embolization. Cavitation, typically thin-walled, is com-
mon, and necrotic debris may be identified within the cavity.
Hilar and mediastinal adenopathy can occur, and empyema
may occur.
The CT features of septic emboli have been described.
Peripheral nodules with identifiable feeding vessels, wedge-
shaped peripheral opacities, and cavitation are the most diag-
nostic features. Peripheral enhancement along the margins of
the wedge-shaped densities has been reported following
administration of intravenous contrast material (Figure 7–11).
It has been suggested that CT can detect disease earlier than the
plain radiograph and that it better characterizes the extent of
disease. Moreover, the cross-sectional perspective of CT affords
better identification of embolic lesions that may be obscured
on chest radiographs by edema or other diffuse consolidations.
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 Pulmonary Edema
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
Interstitial edema:
 Kerley B (most common), A, and C lines.
 Peribronchial cuffing.
 Indistinct pulmonary vessels.
 Hilar haze.
Alveolar edema:
 Poorly marginated, coalescent opacities.
 Air bronchograms.
 “Butterfly” pattern.
General Considerations
Pulmonary edema—an excess of water in the extravascular space
of the lung—is a frequent cause of respiratory distress in the crit-
ically ill patient. The three main categories of pulmonary edema
are cardiac edema secondary to myocardial or endocardial dis-
ease, volume overloaded state due to renal failure or excess
administration of fluid, and increased capillary permeability,
which may result from a variety of insults to the microvascula-
ture of the lung. In the ICU patient, more than one mechanism
may contribute to the formation of edema, increasing the diffi-
culty of diagnostic interpretation on radiographs.
There are four principal mechanisms that result in the
development of edema: elevated capillary hydrostatic pressure,
decreased plasma oncotic pressure, increased capillary perme-
ability, and obstruction of lymphatic drainage. Decreased
plasma oncotic pressure and obstruction to lymphatic drainage
only rarely lead to pulmonary edema but may be contributing
factors in the setting of increased hydrostatic pressure. The
A
B
 Figure 7–11. Young woman with septic emboli second-
ary to intravenous drug abuse. Blood cultures were positive
for Staphylococcus aureus. A. Peripheral nodular opacities
are present with evidence of cavitation (arrow). A feeding
vessel is identified leading to a pulmonary nodule, consis-
tent with hematogenous dissemination (arrowhead).
B. Wedge-shaped subpleural lesion is noted with periph-
eral enhancement after administration of intravenous contrast
material.
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most common cause of pulmonary edema is hydrostatic pres-
sure elevation due to cardiac disease. Acute myocardial infarc-
tion, acute volume overload of the left ventricle, and mitral
stenosis are common causes of cardiogenic edema.
Radiographic Features
The chest radiograph is the most commonly used noninva-
sive test in the evaluation of a patient with pulmonary
edema. Interstitial edema may be present radiographically in
the absence of clinical signs and symptoms, and the chest
radiograph may be the first indication of pulmonary edema.
A. Cardiogenic Pulmonary Edema—In the patient with heart
failure, pulmonary edema is preceded by pulmonary venous
hypertension. In patients with left ventricular failure, elevated left
ventricular end-diastolic pressure (pulmonary venous hyperten-
sion) is reflected in the pulmonary vasculature by dilation and
redistribution of pulmonary blood flow to the upper lobes. In the
normal erect patient, the upper zone vessels are smaller than the
lower zone vessels, and a significant fraction of the pulmonary
circulation, particularly to the upper lobes, is not perfused. In
conditions of increased pulmonary blood volume or left ventric-
ular failure, there is recruitment of these nonperfused reserve ves-
sels in the upper lobes, while reflex hypoxic vasoconstriction of
lower lobe vessels occurs. These and other pathophysiologic fac-
tors contribute to the phenomenon of upper lobe arterial and
venous redistribution. Vascular redistribution is often difficult to
observe on radiographs,particularly in critically ill patients imaged
in the semierect or supine position. As the pulmonary venous
pressure continues to increase, pulmonary edema develops.
Pulmonary edema may be present within the pulmonary
interstitium, the alveoli, or both. Radiographic evidence of inter-
stitial edema includes Kerley A, B, and C lines; peribronchial cuff-
ing; hilar haze; indistinct vascular markings; and subpleural
edema. Kerley lines represent thickened interlobular septa, with
Kerley B lines being the most easily and most frequently seen.
These lines are horizontal linear densities measuring 1–2 cm in
length and 1–2 mm in width. They are located peripherally,
extend to the pleural surface, and are best seen at the lung bases on
the frontal film (Figure 7–12). Kerley A lines are longer and more
randomly oriented and are best seen in the upper lobes, directed
toward the hila. Kerley C lines are presumably a superimposition
of many thickened interlobular septa and appear as a fine reticu-
lar pattern. Other signs of interstitial edema, including peri-
bronchial cuffing, hilar haze, and indistinct vascular markings,
result from accumulation of fluid in the perivascular and peri-
bronchial interstitium. Accumulation of fluid in the subpleural
interstitium is best demonstrated along the pleural fissures.
Alveolar edema occurs as fluid fills the air spaces of the
lungs (Figure 7–13). Although interstitial edema precedes alve-
olar edema and continues to be present in the alveolar filling
stage, the interstitial component is frequently obscured by
concomitant air space edema. With filling of the air spaces, the
lung becomes opaque, with poorly defined confluent opacity.
Air bronchograms are identified as tubular lucencies repre-
senting normal patent bronchi surrounded by fluid-filled air
spaces. The butterfly pattern, appearing as a dense perihilar
opacification, has been described in volume overloaded states
and cardiogenic edema.
In general, cardiogenic pulmonary edema is bilateral and
symmetric. Atypical edema patterns may be seen in patients
with underlying acute or chronic lung disease or as a conse-
quence of gravitational forces related to patient positioning.
Destruction of the lung due to emphysema may cause a
patchy, asymmetric distribution of edema that spares regions
of bullous disease. Gravitational forces also affect the distribu-
tion of edema, with increased edema in the dependent lung.
Shifting the patient’s position can change the appearance of
 Figure 7–12. Interstitial edema. Kerley B lines are
identified at the lung bases (arrows).
 Figure 7–13. Alveolar edema. Air space opacities
with vascular redistribution, perihilar haze, cardiomegaly,
and bilateral pleural effusions are secondary to cardio-
genic edema. A pulmonary artery catheter and nasogas-
tric tube are present.
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edema. Such maneuvers may help to distinguish atypical
edema from other air space processes such as pneumonia.
The temporal sequence of parenchymal opacification is also
crucial because the onset and resolution of hydrostatic
edema may be rapid, whereas in other conditions such as
pneumonia and ARDS, changes are more gradual.
The CT findings in heart failure have been studied and, as
predicted by the chest radiograph, include “ground glass” opac-
ities, interstitial and alveolar edema, and pleural effusions.
Small pulmonary nodules also have been described and likely
represent pulmonary vessels and regions of edema. Mediastinal
adenopathy may be present, with 35% of patients with chronic
heart failure demonstrating nodal enlargement on CT.
B. Distinguishing Cardiogenic from Noncardiogenic
Pulmonary Edema—Three principal features have been pro-
posed to distinguish cardiogenic from noncardiogenic pul-
monary edema radiographically: distribution of pulmonary
flow, distribution of pulmonary edema, and width of the vas-
cular pedicle. Ancillary features include pulmonary blood vol-
ume, peribronchial cuffing, septal lines, pleural effusions, air
bronchograms, lung volume, and cardiac size. The vascular
pedicle width is defined as the width of the mediastinum just
above the aortic arch, with normal width ranging from 43 to
53 mm in an erect patient. The vascular pedicle is enlarged in
60% of patients with cardiac failure and in 85% of patients
with renal failure or volume overload. This is in contrast to
patients with  noncardiogenic capillary permeability edema,
who have a normal or narrowed vascular pedicle in 70% of
cases. The distribution of flow is also a discriminating feature
in that patients with hydrostatic edema more typically have bal-
anced flow or vascular redistribution. In contrast, patients with
capillary permeability edema usually demonstrate a normal or
balanced distribution of flow. Finally, the distribution of edema
is symmetric and perihilar or basilar in patients with cardio-
genic edema or volume overloaded states, whereas capillary
permeability edema appears patchy and peripheral.
Heart size and the presence or absence of septal lines also
may be useful criteria for differentiating cardiogenic from per-
meability edema with an accuracy of 83%. Thus, if the heart is
enlarged or of normal size and septal lines are present, cardio-
genic edema is likely, but if the heart size is of normal and sep-
tal lines are absent, permeability edema is more likely. There
may be considerable overlap. In one study, a classic hydro-
static pattern occurred in 90% of patients with hydrostatic
edema, but 40% of patients with increased permeability
edema had radiographic features consistent with hydrostatic
edema. A peripheral or patchy air space pattern was relatively
specific for capillary permeability edema. Overlapping features
may arise from differences in patient populations, including
differences in the severity of edema, underlying heart or lung
disease, and radiologic technique and patient positioning.
The radiographic diagnosis of edema may be complicated
by several factors. However, general guidelines can be suggested.
In general, noncardiogenic edema typically demonstrates nor-
mal cardiac size with air space opacities (Figure 7–14) and
A B
 Figure 7–14. Noncardiogenic pulmonary edema secondary to near-drowning. A. Anteroposterior chest radiograph
demonstrates asymmetric air space opacities bilaterally. Heart size is normal, and there are no pleural effusions.
Endotracheal tube is high in position, and a nasogastric tube is present. B. Radiograph 48 hours after admission shows het-
erogeneous parenchymal opacification with worsening at the lung bases. A left thoracostomy tube and pulmonary artery
catheter are now present, and the endotracheal tube is in satisfactory position. There is evidence of barotrauma with pneu-
momediastinum (arrow). 
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infrequent Kerley lines, peribronchial cuffing, or pleural effu-
sions. In contrast, hydrostatic edema is associated with cardiac
enlargement, septal lines, and frequent pleural effusions. The
accuracy of chest radiographic diagnosis depends on the inte-
gration of all available clinical and physiologic data.
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 Acute Respiratory Distress Syndrome
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Early ARDS: Decrease in lung volumes, but lungs are
generally clear. If ARDS is caused by aspiration or pneu-
monia, parenchymal opacifications may be present.
 Later: Air space opacification is usually bilateral but may
be asymmetric and patchy and may progress later to
more uniform consolidation. Air bronchograms are usu-
ally present.
 Late ARDS associated with collagen deposition shows
less dense parenchymal consolidations with interstitial
or “ground glass” opacities.
 Complications include pulmonary interstitial emphy-
sema, pneumomediastinum, and pneumothorax.
General Considerations
ARDS is a catastrophic consequence of acute lung injury,
with damage to the alveolar epithelium and pulmonary vas-
culature resulting in increased capillary permeability edema.
Despite numerous attempts at clarification in the literature,
there is still disagreement about the best way to describe this
disorder. It is usually characterized clinically by refractory
hypoxemia, decreased lung compliance, severe acute respi-
ratory distress, and pulmonary parenchymal consolidations
on chest radiographs. A number of disorders are associated
with ARDS, including both direct insults to the lungs and
nonpulmonary systemic conditions.
Radiographic Features
A. Chest Radiographs—The radiographic manifestations
correlate with the pathologic changes seen in the lungs and
vary with the stage of lung injury. Three stages have been
described in ARDS. Stage I (also known as the acute exuda-
tive phase) is the earliest and most transient stage of lung
injury and occurs during the first hours after the insult.
Pathologically, this stage is characterized by pulmonary cap-
illary congestion, endothelial cell swelling, and extensive
microatelectasis. Fluid leakage is confined to the intersti-
tium and is limited. Clinically, respiratory distress with
tachypnea and hypoxemia is present. In patients with ARDS
secondary to systemic insults, diffuse microatelectasis and
diminished lung compliance may result in a decrease in lung
volumes, but the lungs are generally clear. Interstitial fluid is
usually too mild to be radiographically apparent (Figure 7–15).
In primary pulmonary insults causing ARDS, such as aspira-
tion or pneumonia, parenchymal opacifications may be pres-
ent (Figure 7–16). Physiologic changes due to therapy are also
reflected on the radiograph, including volume overload and
barotrauma. The use of positive end-expiratory pressure
(PEEP) may cause improvement in aeration on the chest
radiograph without physiologic or clinical improvement. In
fact, occasionally there is paradoxical worsening of oxygena-
tion from alveolar overdistention with subsequent diversion
of pulmonary flow to poorly ventilated regions.
In stage II (also referred to as the fibroproliferative phase),
the pathologic features of hemorrhagic fluid leakage, fibrin
deposition, and hyaline membrane formation result in radi-
ographic consolidation. Air space opacification is usually bilat-
eral but may be asymmetric and patchy and may progress later
to more uniform consolidation. Air bronchograms are usually
present and become more conspicuous with severe consolida-
tion. The transition to stage II may occur 1–5 days following
the pulmonary insult depending on its type and severity. More
severe injuries result in a more rapid transition. Pleural effu-
sions are uncommon and, when present, are small.
Stage III (also referred as the fibrotic or recovery phase) is
characterized by hyperplasia of type II alveolar epithelial cells
and collagen deposition. Decreased lung compliance,
ventilation-perfusion imbalance, diffusion impairment, and
destruction of the microvascular bed result in abnormal gas
exchange and lung mechanics. Radiographically, parenchy-
mal consolidations become less dense and confluent.
Interstitial or “ground glass” opacities develop as fluid is
replaced by the deposition of collagen. Subpleural lucencies
may develop in regions of peripheral ischemia and ischemic
necrosis. The treatment of ARDS, including positive-pressure
ventilation, sometimes results in barotrauma that is mani-
fested as pulmonary interstitial emphysema, pneumomedi-
astinum, and pneumothorax (Figure 7–17).
Long-term sequelae of ARDS are variable. The overall mor-
tality rate is approximately 50%. Although long-term survivors
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may have complete recovery of pulmonary function, respiratory
impairment may result from pulmonary fibrosis and microvas-
cular damage. Improvement in lung function is relatively rapid
during the first 3–6 months, reaching maximum recovery
within 6–12 months following the onset of ARDS. The chest
radiograph may continue to show hyperinflation and some
residual lung opacities, but most often it returns to normal.
B. CT Scans—The CT appearance of ARDS has been
described by numerous investigators. In general, CT demon-
strates a variable and patchy distribution, with most marked
involvement in the dependent lung regions. These opacities
probably represent severe diffuse microatelectasis as well as
edema fluid and have been observed to migrate under the
influence of gravity. Air bronchograms are frequent, and
pleural effusions, typically small, occur in approximately
one-half of patients. The distribution of consolidation may
depend on the stage of ARDS. Early changes may show
patchy areas of “ground glass” opacity or consolidation dif-
fusely but not uniformly, without central or gravity depend-
ence. Later changes show more homogeneity as the lung
becomes more edematous, and gravity-dependent atelectasis
increases. On CT, barotraumatic lung cysts and infectious
complications such as cavitation or empyema are better
identified than on projectional radiographs (Figure 7–18).
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IMAGING IN PLEURAL DISORDERS
 Pleural Effusions
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Blunting of the lateral costophrenic angle (meniscus sign).
 Elevation of the apparent level of the diaphragm. Increased
separation between the lung and the stomach bubble.
 Homogeneous increased density of the involved
hemithorax.
 Fluid capping the lung apex.
 Decreased visibility of pulmonary vessels below the
diaphragm.
 Increased density within the pleural fissures (“pseudo-
tumor”).
General Considerations
Pleural fluid is primarily formed on the parietal pleural sur-
face and absorbed on the visceral pleural surface, with
approximately 25 mL of fluid present normally in the pleural
space. Pleural effusion is an excess accumulation of
intrapleural fluid. A wide variety of disorders result in excess
pleural fluid. Although the chest radiograph is useful for
detecting and estimating the amount of pleural effusion, the
differentiation between transudate, exudate, empyema, and
hemorrhagic pleural effusion requires a thoracentesis.
Congestive heart failure is the most common cause of pleu-
ral effusion in the ICU population.
A B
 Figure 7–15. ARDS secondary to sepsis in an immunocompromised patient following bone marrow transplantation.
A. Stage I ARDS. The lungs are clear, despite marked dyspnea and hypoxemia. Lung volumes are slightly decreased.
B. Stage II ARDS. Within 24 hours, the chest radiograph shows diffuse parenchymal opacification consistent with ARDS.
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Radiographic Features
The distribution of fluid within the pleural space is greatly
affected by lung elastic recoil and gravity. On erect frontal and
lateral radiographs, free pleural effusions typically have a con-
cave, upward-sloping contour (the meniscus appearance). Since
the posterior costophrenic angles are usually deeper than the
lateral costophrenic angles, small pleural effusions are typically
best seen on the lateral view. Blunting of the lateral costophrenic
angle—detectable on an erect posteroanterior chest radi-
ograph—may occur with as little as 175 mL of fluid, although in
some cases as much as 525 mL will be present before blunting is
noted. Pleural effusion also may accumulate in a subpulmonary
location between the lung base and diaphragm without causing
A B
C
 Figure 7–16. ARDS secondary to pneumococcal pneumonia in a patient with a history of Hodgkin’s disease and
splenectomy several years earlier. A. Initial chest radiograph demonstrates patchy bilateral consolidation. B. Within
12 hours of admission, dense air space consolidation is present, necessitating intubation. Clinical course was consistent
with ARDS. C. Follow-up radiograph 5 weeks after admission to the ICU shows a coarse reticular pattern bilaterally.
Lung volumes are slightly decreased in comparison with the admission radiograph.
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blunting of the lateral costophrenic sulcus. These subpul-
monary collections simulate elevation of the diaphragm; on the
left, the distance between the gastric air bubble and the “pseu-
dodiaphragm” will be increased. The pulmonary vessels are not
seen through the basilar pulmonary parenchyma. The pseudo-
diaphragm is elevated and flattened, with the dome appearing
more lateral than normal.
Pleural effusions may extend into the fissures, with the
radiographic appearance depending on the shape and orientation
of the fissure, the location of the fluid, and the direction of the
radiographic beam. Collections of fluid in the fissures may
mimic a mass, resulting in a “pseudotumor” appearance.
Although the preceding radiographic appearances of
pleural effusion are well known and easily recognized on pos-
teroanterior and lateral chest radiographs, these projections
are infrequently obtained in the ICU patient, and recognition
of pleural effusion in the supine patient may be difficult. In
supine patients, the most dependent regions of the pleural
A B
C
 Figure 7–17. Barotrauma in ARDS. A. Chest radiograph demonstrates diffuse lung consolidation secondary to ARDS.
Parenchymal stippling is present with lucent perivascular halos secondary to pulmonary interstitial emphysema. B. On
chest radiograph 4 days later, pneumomediastinum is now identified with extensive subcutaneous emphysema. C. In
another patient with ARDS, subpleural cysts (arrow) and parenchymal stippling due to pulmonary interstitial emphy-
sema are present.
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space are the posterior aspects of the bases and the lung apex.
Free pleural effusions layer posteriorly, resulting in a homoge-
neous increased density of the lower involved hemithorax.
Fluid also may accumulate at the apex of the thorax, resulting
in apical capping. These findings, however, are seen frequently
only in moderate or large pleural effusions, and small effu-
sions may not be detected on supine radiographs. Although
very small accumulations of pleural effusion can be detected
on lateral decubitus views, this projection is logistically diffi-
cult to obtain in the ICU patient.
Atelectasis and lung consolidation may be difficult to dis-
tinguish from a pleural effusion because they too may result
in elevation of the hemidiaphragm and decreased visibility of
lower lobe vessels. Cross-sectional imaging using ultrasound or
CT is very helpful in detecting small amounts of pleural effu-
sion and in distinguishing complicated pleural and parenchy-
mal processes. These imaging methods are also used frequently
to guide interventional procedures, including diagnostic thora-
centesis, drainage of empyema or malignant pleural effusions,
intracavitary fibrinolytic therapy, and sclerotherapy.
Ultrasound can be performed at the bedside and can easily
detect both free pleural effusions and loculated collections
(Figure 7–19). In most situations, ultrasound is the imaging
method of choice for guiding thoracentesis and may decrease
the incidence of iatrogenic pneumothorax. The percutaneous
drainage of pleural fluid collections with small catheters
instead of large-bore thoracostomy tubes has been shown to be
effective in treating both sterile and infected effusions.
Intracavitary fibrinolytic therapy, the installation of fibrinolytic
enzymes into the pleural space, has greatly improved the effec-
tiveness of pleural fluid drainage with smaller catheters.
CT is extremely sensitive in detecting even small amounts
of free pleural effusion, demonstrating loculations, and evalu-
ating the underlying lung parenchyma. The excellent contrast
resolution of CT allows demonstrations of regions of high atten-
uation secondary to blood or proteinaceous collections and
shows calcifications that are not apparent on chest radiographs.
By virtue of the cross-sectional perspective, air-fluid levels are
easily identified. In complicated cases, intravenous contrast
administration will help to differentiate pulmonary and pleural
processes in that perfused, consolidated lung will be enhanced,
whereas pleural processes will not (see Figure 7–7). The disad-
vantages of CT are its relatively high cost and the need for trans-
porting the critically ill patient to the radiology department.
Emamian SA et al: Accuracy of the diagnosis of pleural effusion on
supine chest x-ray. Eur Radiol 1997;7:57–60. [PMID: 9000398] 
Ruskin JA et al: Detection of pleural effusions on supine chest radi-
ographs. AJR 1987;148:681–3. [PMID: 3493648]
Moulton JS: Image-guided management of complicated pleural
fluid collections. Radiol Clin North Am 2000;38:345–74. [PMID:
10765394]
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 Pneumothorax
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Identification of a visceral pleural line.
 Absence of pulmonary vessels peripheral to visceral
pleural line.
 Basilar hyperlucency in the supine patient.
 Deep sulcus sign (supine patient).
 Figure 7–18. Adult respiratory distress syndrome. CT
shows heterogeneous consolidation with subpleural air
cyst secondary to barotrauma.
 Figure 7–19. Pleural effusion on ultrasound. Right
pleural effusion is seen as a region of low echogenicity
(asterisk) above the hyperechoic diaphragm (arrow).
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General Considerations
Pneumothorax is a frequent and serious complication in
the ICU. Iatrogenic pneumothorax may develop as a
sequela of invasive diagnostic or therapeutic procedures,
including central venous catheterization, endotracheal
intubation, tracheostomy, thoracentesis, pleural biopsy,
percutaneous lung biopsy, bronchoscopy, cardiothoracic or
abdominal surgery, and interventional abdominal proce-
dures to the liver and upper abdominal viscera.
Pneumothorax also may result from blunt chest trauma or
underlying lung diseases such as COPD, asthma, cystic fibro-
sis, and interstitial lung disease. Pneumothorax can compli-
cate the course of cavitary pneumonias due to infections
with M. tuberculosis, staphylococci, Klebsiella and other
gram-negative organisms, or fungi; similarly, there is an
increased incidence of pneumothorax in patients with AIDS
who develop Pneumocystis pneumonia. Finally, in patients
receiving positive-pressure mechanical ventilation, pneu-
mothorax may result from pulmonary interstitial emphy-
sema due to barotrauma.
In a recent study of pneumothorax in ICU patients, 35 of 60
patients (58%) who developed a pneumothorax during the
study period had procedure-related pneumothoraces. Patients
with pneumothoraces due to barotrauma or who had concur-
rent septic shock or a tension pneumothorax had a higher risk of
mortality than patients with postprocedural pneumothoraces.
Radiographic Features
A. Simple Pneumothorax—As with fluid in the pleural
space, the distribution of a pneumothorax is influenced by
gravity, lung elastic recoil, potential adhesions in the pleural
space, and the anatomy of the pleural recesses. In the upright
patient, air accumulates in the nondependent region of the
pleural space, the apex. Radiographically, a pneumothorax is
identified by separation of the visceral pleural surface from the
chest wall and the absence of pulmonary vessels peripheral
to the pleural line. A pneumothorax typically is better seen
on expiratory images because of a relative decrease in lung
volumes compared with the air in the pleural space.
Imaging in the supine position alters the radiographic
appearance of pneumothorax. In this position, the least
dependent regions of the pleural space are the anteromedial
and subpulmonary regions. Pleural air in the anteromedial
space results in sharp delineation of mediastinal contours,
including the superior vena cava, the azygos vein, the heart
border, the inferior vena cava, and the left subclavian artery.
The accumulation of air in the subpulmonary region is seen as
a hyperlucent upper quadrant of the abdomen; a deep, hyper-
lucent lateral costophrenic sulcus (“deep sulcus sign”); sharp
delineation of the ipsilateral diaphragm; and visualization of
the inferior surface of the lung (Figure 7–20). Air can accumu-
late in the apicolateral pleural space in the supine patient just
as in the erect patient, especially when a large pneumothorax
is present. In the presence of lower lobe collapse, air can
accumulate in the posteromedial pleural recess. This results in
a sharp delineation of the posterior mediastinal structures,
including the descending aorta and the costovertebral sulcus.
Subtle pneumothoraces may require other projections for
detection, such as decubitus or cross-table lateral views. CT
is an excellent method for diagnosing a pneumothorax not
demonstrated on plain chest radiographs.
Several conditions may be confused with a pneumothorax.
Pneumoperitoneum may result in a hyperlucent upper
abdomen, mimicking pneumothorax. Skin folds can be con-
fused with apicolateral pneumothorax but should be recog-
nized when they extend outside the bony thorax or are traced
bilaterally. Pneumomediastinum may simulate medial pneu-
mothorax, but pneumomediastinum may cross the midline
and extend into the retroperitoneum.
B. Tension Pneumothorax—Recognition of even small
pneumothoraces is crucial to prevention of progressive accu-
mulation of pleural air collections, particularly in patients
being maintained on mechanical ventilation. Tension pneu-
mothorax occurs when the pressure of air in the pleural space
exceeds ambient pressure during the respiratory cycle. With
this pressure gradient, air enters the pleural space on inspi-
ration but is prevented from exiting the pleural space during
expiration due to a check-valve mechanism. A tension
 Figure 7–20. Pneumothorax in a supine patient with
ARDS. Chest radiograph demonstrates a large right pneu-
mothorax with intrapleural air adjacent to the diaphragm
and evidence of a deep sulcus (arrow). The margin of the
right hemidiaphragm is obliterated by adjacent adhesions.
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pneumothorax may result in acute respiratory distress and, if
untreated, cardiopulmonary arrest and death. The diagnosis
of tension pneumothorax is made clinically, reflecting the
hemodynamic sequelae of impaired venous return to the
right side of the heart. Radiographic signs include displace-
ment of the mediastinum toward the contralateral thorax,
inferior displacement or inversion of the diaphragm, and
total lung collapse (Figure 7–21). However, significant hemo-
dynamic compromise can exist in the absence of these find-
ings. Adhesions may prevent mediastinal shift, and lung
collapse may not occur in patients with stiff lungs such as
those with ARDS. A small pneumothorax may convert to a
tension pneumothorax, particularly in patients receiving
mechanical ventilatory support. In patients with ARDS,
poorly compliant lungs and pleural adhesions may result in
difficulty identifying a pneumothorax on portable chest
radiographs, and CT may be particularly useful in the diag-
nosis of loculated pneumothorax and in guiding appropriate
chest tube placement.
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 Pulmonary Interstitial Emphysema
& Pneumomediastinum
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Pulmonary interstitial emphysema: Perivascular “halo”
(air surrounding pulmonary vessels seen on end), linear
radiolucencies radiating toward the hila, irregular radi-
olucent mottling, parenchymal cysts, or collections of
air along visceral pleural surface.
 Pneumomediastinum: Linear lucencies adjacent to the
heart and aortic arch, descending aorta, and great ves-
sels. May have subcutaneous emphysema with linear
radiolucencies extending along tissue planes in the
chest wall and neck.
General Considerations
Barotrauma is a serious and frequent complication in the
ICU patient. Defined as damage secondary to the presence
of extraalveolar or extraluminal air, the incidence is highest
in patients being supported by mechanical ventilation.
Alveolar overdistention and an increased intraalveolar pres-
sure gradient from alveolus to vascular sheath allow rupture
of air into the interstitial space along the perivascular
sheaths, resulting in pulmonary interstitial emphysema.
Reduction in the caliber of pulmonary vessels—as well as
general and local alveolar overinflation—contributes to the
pressure gradient, causing alveolar rupture. Although com-
monly associated with mechanical ventilation, barotrauma
may also result from coughing, straining, trauma, pneumo-
nia, a Valsalva maneuver, anesthesia or resuscitation, partu-
rition, positive-pressure breathing, and asthma. Other
manifestations of barotraumas develop because air from
ruptured alveoli follows the path of least resistance. Air dis-
sects centrally to cause pneumomediastinum and dissects
via the cervical fascial planes, resulting in subcutaneous
emphysema in the neck and chest wall. Air also can dissect
from the mediastinum into the abdomen, leading to
retroperitoneal air and pneumoperitoneum or into the
pleural space resulting in a pneumothorax.
Barotrauma has a high incidence in patients with ARDS. In
one study of 15 patients with ARDS—all requiring positive-
pressure ventilation—radiographic evidence of pulmonary inter-
stitial emphysema was found in 87%. Although there was no
correlation with positive end-expiratory pressure or mean airway
 Figure 7–21. Spontaneous tension pneumothorax. The
left lung is completely collapsed, with visualization of a vis-
ceral pleural line and hyperlucency of the thorax. The medi-
astinum is shifted to the right, and there is depression of the
left hemidiaphragm consistent with tension pneumothorax.
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pressure, in all but one of the patients barotrauma was noted
when peak airway pressure was greater than 40 cm H2O. Other
studies report an incidence of about 50% and suggest that
PEEP does contribute to the development of barotrauma.
Decreased compliance of the lungs in patients with ARDS
necessitates higher ventilatory pressures to maintain adequate
oxygenation, which results in an increased risk of barotrauma.
Pulmonary diseases that increase lung compliance also may
promote barotrauma because there is greater overdistention of
the lung.
Radiographic Features
Radiographic findings of pulmonary interstitial emphy-
sema include visualization of perivascular air along pul-
monary vessels seen on end (producing a perivascular
“halo”), linear radiolucencies radiating toward the hila,
irregular radiolucent mottling, parenchymal cysts (pneu-
matoceles), and linear or rounded collections of air along
the visceral pleural surface (subpleural air cysts).
Pulmonary interstitial emphysema may be difficult to
detect and to distinguish from air bronchograms.
Moreover, pulmonary interstitial emphysema is usually not
apparent radiographically unless present in conjunction
with pulmonary opacification.
Pneumomediastinum may be recognized radiographi-
cally by linear lucencies adjacent to the heart and aortic arch,
descending aorta, and great vessels. Visibility of the wall of a
main bronchus, air outlining the thymus, and air between
the parietal pleura and diaphragm also have been described.
Pneumomediastinum is usually easier to identify than pul-
monary interstitial emphysema and is often the first evidence
of barotrauma. Subsequent dissection of air from the medi-
astinum along fascial planes may result in subcutaneous
emphysema, with linear radiolucencies extending along tis-
sue planes in the chest wall and neck (see Figure 7–17). Less
often, dissection of air along the descending aorta into the
retroperitoneum will occur, with rare rupture into the
abdomen giving rise to pneumoperitoneum. In such
instances, clinical correlation is essential to exclude a perfo-
rated abdominal viscus. Early diagnosis of pulmonary inter-
stitial emphysema may alert clinicians to pneumothorax, a
potentially catastrophic consequence of barotrauma.
Although other manifestations of barotrauma are usually
self-limited, even a small pneumothorax may progress to
tension pneumothorax in critically ill patients, particularly
in patients being maintained with mechanical ventilators. As
previously discussed, pneumothorax in the supine patient
may be difficult to diagnose and must be considered or it will
be missed. Occasionally, tension pneumomediastinum may
occur, although this is usually of greater clinical likelihood in
pediatric patients. Concomitant pulmonary interstitial
emphysema will result in further respiratory embarrassment
secondary to compression of lung parenchyma by interstitial
air and decreases in both ventilation and perfusion.
Pneumopericardium arises infrequently secondary to
barotrauma but may progress to tension, in which there is
increased intrapericardial pressure and impairment in
venous return and cardiac function.
Kemper AC, Steinberg KP, Stern EJ: Pulmonary interstitial emphy-
sema: CT findings. AJR 1999;172:1642. [PMID: 10350307]
Trotman-Dickenson B: Radiology in the intensive care unit (part 2).
J Intensive Care Med 2003;18:239–52. [PMID: 15035758]
Webb WR, Higgins CB: Thoracic Imaging: Pulmonary and
Cardiovascular Radiology. Philadelphia: Lippincott Williams &
Wilkins, 2005.
IMAGING OF THE ABDOMEN & PELVIS
General Principles
Imaging of the gastrointestinal tract generally should begin
with plain radiographs because these are readily obtained
and provide useful information regarding perforation,
bowel obstruction, and ileus. However, because the overall
sensitivity of plain radiographs remains low, further imag-
ing with CT may be necessary to confirm suspected pneu-
moperitoneum or intraabdominal abscess and to inspect
the features of the small and large bowel walls and sur-
rounding fat. Imaging of abdominal and pelvic solid
organs, including the gallbladder and urinary bladder,
should begin with ultrasound because it is nonionizing and
portable to the ICU.
 Gastrointestinal Perforation
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Lucency over the liver or abdomen.
 Lucency under a hemidiaphragm on upright views.
 “Double-wall sign.”
 Visualization of the falciform ligament.
 “Football sign.”
 “Inverted-V sign.”
 “Triangle sign.”
General Considerations
In the ICU, bowel perforation usually results from an upper
abdominal source, such as a penetrating gastric or duodenal
ulcer; a lower gastrointestinal tract source, such as diverticulitis
or toxic megacolon; or from complications of upper and
lower endoscopic procedures. Other causes of perforation
include severe intestinal inflammation, bowel obstruction,
bowel infarction, or neoplasm.
 CHAPTER 7168
Radiographic Features
An experienced abdominal radiologist may identify even small
amounts of free air on a supine abdominal radiograph, finding
small bubbles or generalized increased lucency over the abdomen,
right upper quadrant, or subhepatic space. Other signs include
the “double-wall sign” of Rigler, the “triangle sign,” the “football
sign,” or the falciform ligament sign (Figure 7–22). For less expe-
rienced readers, a second view must be added to the supine radi-
ograph to increase sensitivity. Most commonly, this is an upright
abdominal film in which air rises to outline the thin curvilinear
hemidiaphragm. However, to obtain this view properly is nearly
impossible in the ICU. Useful alternatives include the left lateral
decubitus view (where the patient maintained in the left-side-
down position for at least 5–10 minutes), allowing free air to rise
toward the right subphrenic space. A right lateral decubitus view
is usually nondiagnostic because of confusion arising from the
adjacent stomach bubble. In immobile patients, a cross-table lat-
eral view may be obtained, in which the patient remains supine,
but the x-ray beam is tangential to the anterior abdominal wall.
However, small amounts of free air may be missed on this view. If
plain films are equivocal and perforation is suspected, an abdom-
inal CT (Figure 7–23) offers an excellent means of detecting even
tiny amounts of free air and possibly localizing a source.
Differential Diagnosis
Pneumoperitoneum has a variety of causes and is not synony-
mous with bowel perforation, its most serious and surgically
urgent cause. In the ICU, the most common reason for pneu-
moperitoneum is probably the postoperative state.
Pneumoperitonem may persist for up to 14 days after surgery,
the amount of air decreasing progressively and never increasing
over time. Other forms of pneumoperitoneum requiring urgent
attention include peritonitis caused by gas forming microorgan-
isms. Benign causes include dissection of gas from the thoracic
cavity in patients with COPD receiving mechanical ventilation.
Bhalla S, Menias CO, Heiken JP: CT of acute abdominal aortic disor-
ders. Radiol Clin North Am 2003;41:1153–69. [PMID: 14661663] 
Gore RM et al: Helical CT in the evaluation of the acute abdomen.
AJR 2000;174;901–13. [PMID: 10749221]
Grassi R et al: Gastro-duodenal perforations: Conventional plain
film, US and CT findings in 166 consecutive patients. Eur J
Radiol 2004;50:30–6. [PMID: 15093233]
Pinto A et al: Comparison between the site of multislice CT signs
of gastrointestinal perforation and the site of perforation
detected at surgery in forty perforated patients. Radiol Med
(Torino) 2004;108:208–17. [PMID: 15343135]
A B
 Figure 7–22. A: Pneumoperitoneum in a 72-year-old man with perforated sigmoid diverticulitis. On a supine radi-
ograph, there is lucency over the right upper quadrant with visualization of falciform ligament. Both sides of small
bowel wall are visualized (Rigler’s sign) with characteristic triangles. B. Pneumoperitoneum in an 80-year-old man
after recent abdominal surgery. Supine radiograph demonstrates a more subtle example of Rigler’s sign.
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 Bowel Obstruction
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Asymmetric dilation of proximal bowel loops. 
 Normal or collapsed distal bowel loops.
 Small bowel obstruction: Dilated U-shaped loops with
air-fluid levels (upright or decubitus films) or a single
loop with air-fluid levels at different heights.
 Large bowel obstruction: Cecal distention, absence of
rectal gas, or “triple flexure” and “coffee bean” signs of
sigmoid volvulus.
 CT scan: Excellent for detecting bowel obstruction and
confirming the cause.
General Considerations
Mechanical obstruction of the bowel is a relatively common
occurrence in hospitalized patients. In the general population,
bowel obstructions account for approximately 20% of acute
abdominal conditions. Obstruction usually results from extrin-
sic compression but can occur from luminal obstruction.
Without prompt attention, bowel obstruction may progress to
bowel infarction because of disruption of venous outflow and
subsequent arterial blood supply. Bowel infarction may progress
to mucosal ulceration, necrosis, and perforation. Mortality rates
for untreated obstruction have been as high as 60%.
Approximately three-fourths of bowel obstructions are
related to the small bowel (enteric) and one-fourth to the
colon. Small bowel obstructions are most commonly due to
adhesions from prior abdominal surgery. Adhesions can
form rapidly, sometimes within 4–10 days after surgery, or
may develop manifestations many years later. Other causes of
small bowel obstruction include hernias (external and internal),
primary and metastatic tumors, intussusception, inflamma-
tory bowel disease, abscesses, and trauma.
Large bowel obstructions are most often (60%) caused by
primary carcinomas of the distal (left) colon. Metastatic
tumor or invasion from cancers of surrounding organs,
diverticulitis, sigmoid volvulus, and fecal impaction also may
cause a distal colonic obstruction.
Radiographic Features
A. Plain Abdominal Radiographs—An abdominal series that
includes supine plus upright or decubitus views of the
abdomen is only 50–60% sensitive for small bowel obstruction.
Objective evidence of small bowel obstruction includes asym-
metric dilation (luminal diameter >3 cm) of small bowel prox-
imal to the site of obstruction, with normal or decompressed
A
B
 Figure 7–23. A. Pneumoperitoneum and pneu-
moretroperitoneum in a 76-year-old man after biliary
stent placement because of obstruction from pancre-
atic cancer. A supine radiograph shows characteristic
air under the diaphragm and surrounding liver. The
psoas muscles and kidneys are also outlined by gas,
confirming the presence of pneumoretroperitoneum.
B. Abdominal CT demonstrates ectopic gas and confirms
the diagnosis of pneumoperitoneum in the patient in
Figure 7–21.
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small bowel loops distally and normal to absent colonic gas.
However, these findings may not be seen in all patients who
present  with a small bowel obstruction. More valuable is the
relative change in distention over time, and for this reason,
comparison of a series of studies is prudent. Other radi-
ographic signs include an inverted U-shaped loop of dilated
small bowel with air-fluid levels, multiple air-fluid levels, and
dynamic loops (air-fluid levels at varying heights in different
limbs of a loop). In some cases, a “string of pearls sign” can be
seen (Figure 7–24).
On a single supine film of the abdomen, dilated small
bowel loops may be mostly fluid-filled, with a minimal
amount of gas, or may be completely devoid of gas. In this
case, the film will be nonspecific, and additional views or CT
may be required. Diagnosis of small bowel obstruction may
be difficult because the presence of radiographic signs will
depend on the site, duration, and degree of obstruction.
Bowel distal to a complete obstruction takes 12–48 hours to
evacuate all its gas. Serial plain films sometimes are required
to capture these changes because films may be nonspecific if
imaging is performed too early.
Because of the limited utility of plain radiographs, helical
CT is now the preferred method for evaluating suspected
small bowel obstruction (Figure 7–25). In patients who can-
not undergo CT or if CT is unavailable, serial radiographs
may be taken after ingestion of enteric contrast material.
Although water-soluble contrast agents are preferred, espe-
cially for patients who are surgical candidates, they are
hypertonic and become progressively more dilute, limiting
the ability of the study to accurately identify the site of
obstruction. Barium is preferred in nonsurgical patients
because progressive dilution does not occur, and the site of
obstruction is more easily identified. However, in high-grade
obstructions, barium may thicken and become difficult to
evacuate. The high density of retained barium also degrades
CT images because of a beam-hardening artifact that results
in a nondiagnostic CT examination. Given these problems,
CT is the initial imaging procedure of choice if small bowel
obstruction is suspected.
In general, colonic obstruction (Figure 7–26) tends to occur
distally because most obstructing colon cancers occur in the dis-
tal large bowel. A single supine radiograph often fails to identify
the site of obstruction, and supplementary views—an upright
view, a right lateral decubitus view, or a prone view—may be
necessary to work up a possible obstruction and distinguish it
from an ileus. In large bowel obstruction, the cecum distends to
a greater degree than does the remainder of the colon regardless
of the site of obstruction. This follows from Laplace’s law, which
states that the pressure required to distend the walls of a hollow
structure is inversely proportional to its radius. The cecum has
the largest radius of any part of the large bowel. Generally, the
upper limits of normal for the transverse diameter of a large
bowel loop is 6 cm; for the cecum, it is 9 cm. However, these are
rough estimates only and may not hold true for a given patient.
Again, one must interpret, if possible, the relative change in dis-
tention with comparison studies over time. Perforation is a
dreaded complication of obstruction. The overall risk of cecal
perforation is low—approximately 1.5%—but may increase to
14% with delay in diagnosis. There is an increased risk of cecal
perforation if the luminal diameter exceeds 9 cm and persists
for more than 2–3 days.
B. Computed Tomography—Over the last 10 years, several
investigators have emphasized the value of CT scanning in
detecting bowel obstruction. Helical and multidetector CT
can produce multiplanar images to help determine whether
obstruction is present, the severity and level of obstruction,
the cause of obstruction, and whether strangulation or
ischemia is present. Current helical and multidetector tech-
nology permits evaluation of the abdomen and pelvis in 20
seconds to 2 minutes. Oral and intravenous contrast material
may not be required if experienced radiologists interpret the
scans. In most cases of small bowel obstruction, a transition
point between dilated and nondilated bowel can be demon-
strated. Identification of the transition zone and the cause of
obstruction, when not apparent on axial images, may be
aided by the multiplanar reformatting possible on current
CT scanners and image-processing workstations. Although
adhesions themselves are too thin to be imaged, most other
common causes of small bowel obstruction—including her-
nia, tumor, intussusception, postradiation fibrosis, and gall-
stone ileus—may be identified. The accuracy of CT is
90–95% in high-grade bowel obstruction but somewhat less
in low-grade obstruction.
Furukawa A et al: Helical CT in the diagnosis of small bowel
obstruction. Radiographics 2001;21:341–55. [PMID: 11259698]
Lappas JC, Reyes BL, Maglinte DD: Abdominal radiography
findings in small-bowel obstruction: Relevance to triage for
additional diagnostic imaging. AJR 2001;176:167–74.
[PMID:11133561]
Mak SY et al: Small bowel obstruction: Computed tomography
features and pitfalls. Curr Probl Diagn Radiol 2006;35:65–74.
[PMID: 16517290]
Nicolaou S et al: Imaging of acute small-bowel obstruction. AJR
2005;185:1036–44. [PMID: 16177429]
Thompson WM et al: Accuracy of abdominal radiography in acute
small-bowel obstruction: Does reviewer experience matter? AJR
2007;188:W233–8. [PMID: 17312028]
 Ileus
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Diffuse symmetric dilation of small and large bowel.
 May be focal when adjacent to an inflammatory source.
 Colonic ileus (Ogilvie’s syndrome) may be seen alone or
in conjunction with small bowel ileus.
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 Figure 7–24. A. Small bowel obstruction. Because of their widespread availability, conventional upright and supine
radiographs are a good first step in suspected small bowel obstruction, although sensitivity and specificity are low.
A supine radiograph demonstrates asymmetric dilation of the proximal small bowel (note plicae circulares) without
significant gas in the colon. B. In the same patient, an upright abdominal radiograph demonstrates a prominent
air-fluid level from proximal small bowel obstruction. C. The “string of pearls sign” in small bowel obstruction; an
upright radiograph demonstrates numerous air-fluid levels.
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General Considerations
Ileus is generalized dysfunction of bowel related to an
underlying disorder, usually most severe in the 2–4 days
following abdominal surgery with extensive bowel manip-
ulation. Dysfunction due to humoral, metabolic, and neu-
ral factors contributes to the overall process. Other
common causes include abdominal infections, peritonitis,
active inflammatory bowel disease, opioid or chemother-
apy use, electrolyte imbalances, visceral pain syndrome
(biliary or ureteral colic, ovarian torsion), and myocardial
infarction.
Radiographic Features
In the generalized form of ileus, the small and large
bowel are dilated but generally to a lesser degree than
seen in moderate to severe bowel obstruction (Figure 7–27).
In many cases, there is a significant overlap with clinical
and radiologic features of small bowel obstruction, and
differentiation on the basis of a single study may not be
possible. Serial radiographs, contrast studies with water-
soluble contrast agents or barium, or CT may be
required.
An intraabdominal inflammatory event (acute pancreatitis)
or trauma may produce a focal form of ileus. The dysfunc-
tional segment of bowel may lose peristaltic activity and
enlarge. This is known as a sentinel loop.
Colonic ileus—also known as intestinal pseudo-
obstruction or Ogilvie’s syndrome—usually presents in
elderly, debilitated, or bedridden patients with major
underlying systemic abnormalities, severe infection,
cardiac disease, or recent surgery. Progressive large
bowel distention is variably accompanied by small bowel
distention. Massive cecal distention compromises blood
flow and may be complicated by perforation, with a
mortality rate of 30–45%. As in the small bowel, colonic
ileus is not always diffuse and may be segmental, typi-
cally in the cecum. In cecal ileus, there is massive dila-
tion of the cecum. If the cecum is mobile, this condition
may be difficult to distinguish from cecal volvulus, and
a contrast examination may be necessary to make the
differentiation.
Conservative treatment, consisting of nasogastric tube,
rectal tube, or colonoscopic decompression, is successful in
78% of patients. Alternatively, surgical cecostomy may be
necessary. Percutaneous cecostomy may be offered to high-
risk patients.
Nunley JC, FitzHarris GP: Postoperative ileus. Curr Surg
2004;61:341–5. [PMID: 15276337]
Saunders MD, Kimmey MB: Colonic pseudo-obstruction: The
dilated colon in the ICU. Semin Gastrointest Dis 2003;14:20–7.
[PMID: 12610851]
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 Figure 7–25. A. CT is excellent for diagnosing small
bowel obstruction and for detecting a cause (eg, mass,
intussusception, or hernia). In this patient, a large
leiomyosarcoma caused a high-grade small bowel
obstruction. B. In certain situations, following luminal
contrast material through the small bowel (small bowel
follow-through) may be helpful for detecting small
bowel obstruction. This study from the same patient
demonstrates an abrupt tapering of the bowel lumen
with dilated proximal bowel due to the mass.
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 Figure 7–26. Large bowel obstruction. A. Most large bowel obstructions occur distally and are due to tumors or
diverticulitis. In this patient, the large bowel is diffusely dilated and filled with stool. B. A single-contrast barium
enema depicts a short segment annular carcinoma causing sigmoid colon obstruction. C. Sigmoid volvulus. On plain
radiograph, the dilated sigmoid colon may project over the right upper quadrant with a “coffee bean” appearance. The
remainder of the colon is dilated. D. Cecal volvulus. On plain radiographs, the dilated cecum is filled with stool and
projects over the midabdomen or sometimes the left upper quadrant. The small bowel is diffusely dilated.
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 Intestinal Ischemia
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Plain films: Early: normal or nonspecific dilation of
bowel; later: focal, edematous, thick-walled bowel
loops, gas in the superior mesenteric and portal veins,
pneumatosis intestinalis, ileus, and gasless abdomen.
 Abdominal CT: bowel wall thickening, pneumatosis;
portal venous gas usually sign of infarction.
 CT or MRA provides excellent evaluation of the larger
mesenteric arteries and veins.
 Conventional angiography is infrequently needed but
may be confirmatory in some situations.
General Considerations
Early diagnosis of bowel ischemia and infarction remains diffi-
cult because of limited clinical and radiologic sensitivity.
Vascular insufficiency must be considered in elderly patients or
for any patient with atherosclerotic vascular disease, hypoten-
sion, cardiac failure, or arteritis. In young patients, vasculitis, a
hypercoagulable state, pregnancy, illicit use of cocaine, or
embolic sources (eg, patent foramen ovale) must be suspected.
Morbidity and mortality rates remain high (30–80%).
Ischemia has a variety of underlying causes, including
mesenteric arterial occlusion (ie, thrombus, embolus, or dis-
section), venous occlusion (ie, hypercoagulable states or
malignancy), nonocclusive mesenteric ischemia (ie,
vasospasm, myocardial infarction, or shock), and mechanical
obstruction, including colonic pseudo-obstruction. Any por-
tion of the small bowel may be affected; the cecum and dis-
tal left colon are the large bowel segments affected most
commonly. Rectal ischemia is infrequent because of the rec-
tum’s dual blood supply, but it may be seen in patients who
have had prior radiation therapy to that area.
Clinical symptoms are variable. Generally, abdominal
pain out of proportion to physical findings, and bloody
diarrhea may be suggestive of ischemic colitis. Segmental
ischemia often resolves spontaneously, but fibrotic strictures
may develop. Infarcted bowel must be surgically resected. In
selected patients, clots identified on IV contrast-enhanced
CT may be treated with angiographic interventional tech-
niques, including thrombolysis or stent placement.
Radiographic Features
A. Plain Radiographs—Edematous, thick-walled bowel,
pneumatosis intestinalis, and portal venous gas are the most
specific signs of ischemia and infarction but are insensitive.
More commonly, plain films are normal, show lack of
abdominal gas, or suggest focal ileus or small bowel obstruc-
tion (Figure 7–28).
B. Computed Tomography—Helical CT is important for
detecting early changes of ischemia. A high-quality helical CT
is usually performed with oral contrast material to opacify
and distend the small bowel along with rapid IV contrast
material injection (3 mL/s) to optimize opacification of the
superior mesenteric artery and vein. The CT features of
intestinal ischemia vary with its cause, chronicity, and sever-
ity. Bowel wall thickening is a sensitive but nonspecific early
finding and may be accompanied by a “target sign” appear-
ance of bowel caused by submucosal edema. Indirect signs of
ischemia include focal ascites, bowel distention, and mesen-
teric edema. In more advanced stages of bowel ischemia, the
presence of gas within the bowel wall or within the superior
mesenteric or portal vein makes the prognosis more grave.
Colonic ischemia generally results from hypoperfusion or
hypotension, and mesenteric thrombosis is rare. CT angiog-
raphy using newer-generation multidetector helical scanners
∂174
 Figure 7–27. Ileus. Plain abdominal radiograph
demonstrates mild diffuse gaseous dilation of both the
small and the large bowel. No transition point is present.
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allows excellent vascular and intestinal wall assessment, aided
by three-dimensional image processing (eg, multiplanar,
volume-rendered, and maximum-intensity projection views).
Thrombus in the major mesenteric vessels may be detected.
However, a normal CT does not exclude ischemia, and if a
strong clinical suspicion is present—especially in patients
with vasculitis—angiography or surgery may be required.
C. Catheter Angiography—Angiography may be both diag-
nostic and therapeutic. Vasodilators may be used in conjunc-
tion with thrombolytic agents in certain patients. While
angiography remains the diagnostic standard in patients
with vasculitides given its unparalleled spatial resolution,
multidetector CT and modern MR scanners have narrowed
the resolution gap. Angiography has a limited role in colonic
ischemia because low-blood-flow states rather than occlu-
sion of the vasculature are most often the cause.
Bradbury MS et al: Mesenteric venous thrombosis: Diagnosis and
noninvasive imaging. Radiographics 2002;22:527–41. [PMID:
12006685]
Horton KM, Fishman EK: Multidetector CT angiography in the
diagnosis of mesenteric ischemia. Radiol Clin North Am
2007;45:275–88. [PMID: 17502217]
Kirkpatrick ID, Kroeker MA, Greenberg HM: Biphasic CT with mesen-
teric CT angiography in the evaluation of acute mesenteric ischemia:
Initial experience. Radiology 2003;229:91–8. [PMID: 12944600]
Nehme OS, Rogers AI: New developments in colonic ischemia.
Curr Gastroenterol Rep 2001;3:416–9. [PMID: 11560800]
Shih MC, Hagspiel KD: CTA and MRA in mesenteric ischemia: 1.
Role in diagnosis and differential diagnosis. AJR 2007;
188:452–61. [PMID: 17242255]
 Colitis
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Colonic wall thickening and nodularity associated with
paralytic ileus.
 Infiltration of pericolonic fat, often seen on CT.
 Plaque-like filling defects are suggestive of pseudomem-
branous colitis.
General Considerations
Inflammatory bowel disease, ischemia, and infections are the
most common causes of colitis. Patients present with pain,
bloody diarrhea, cramping, fever, and leukocytosis.
Infectious colitis may be bacterial, viral, fungal, or parasitic.
Stool cultures, serologic tests, or colonic biopsy may be
required.
Pseudomembranous colitis—the most common cause of
colitis in hospitalized populations—is a complication of
antibiotic therapy. Clostridium difficile produces an entero-
toxin that causes mucosal ulceration and edema and the
development of pseudomembranes. The process may be
focal or diffuse.
 Figure 7–28. Colonic ischemia. A. Plain radiograph
demonstrates mottled lucency of the wall of the ascend-
ing colon consistent with pneumatosis. B. Abdominal CT
is excellent for confirmation of pneumatosis.
A
B
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Neutropenic colitis is typically seen in patients undergo-
ing chemotherapy or bone marrow transplantation with
myelosuppression. Although involvement can be diffuse, it
typically affects the ascending colon, cecum, appendix, and
terminal ileum. If cecal inflammation is present, then the
term typhlitis (or necrotizing enterocolitis) is used.
Radiographic Features
Although usually normal or nonspecific, plain radiographs
may reveal colonic fold thickening and nodularity. Features
of paralytic ileus may be present. Contrast studies such as a
barium enema should be avoided but can be performed care-
fully with water-soluble agents only if absolutely necessary
(Figure 7–29). Although abdominal CT is an excellent test, it
may be normal in early infectious colitis. In more advanced
cases of infectious colitis and in pseudomembranous colitis,
mural thickening is more severe, averaging 15–20 mm, with
a target or halo pattern. An accordion-like pattern reflecting
haustral thickening may be produced in addition to peri-
colonic inflammatory changes and lymphadenopathy. In
neutropenic colitis (typhlitis), similar features are present,
but most commonly in the right colon. Occasionally in
advanced cases, pneumatosis intestinalis and frank perfora-
tion may develop.
Horton KM, Corl FM, Fishman EK: CT evaluation of the colon:
Inflammatory disease. Radiographics 2000;20:399–418. [PMID:
10715339]
Kawamoto S et al: Pseudomembranous colitis: Spectrum of imag-
ing findings with clinical and pathologic correlation.
Radiographics 1999;19:887–97. [PMID: 10464797]
Ramachandran I et al: Pseudomembranous colitis revisited:
Spectrum of imaging findings. Clin Radiol 2006;61:535–44.
[PMID: 16784938]
Thoeni RF, Cello JP: CT imaging of colitis. Radiology
2006;240:623–38. [PMID: 16926320]
Zalis M, Singh AK: Imaging of inflammatory bowel disease: CT
and MR. Dig Dis 2004;22:56–62. [PMID: 15292695]
 Toxic Megacolon
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Gaseous colonic distention, which may be diffuse or
segmental. 
 Effacement of haustra, edematous folds (thumbprinting),
relative paucity of feces.
 Common complication of a number of inflammatory
conditions, notably ulcerative colitis.
 Figure 7–29. A. Colitis. Plain radiograph demon-
strates mild dilation and severe fold thickening
(thumbprinting) of transverse colon in this case of
pseudomembranous colitis. B. Abdominal CT also
demonstrates mural colonic thickening with associated
infiltration of the pericolonic fat.
A
B
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General Considerations
Toxic megacolon is a complication of many different types of
ischemic, inflammatory, or infectious conditions of the colon
but is most closely associated with ulcerative colitis. Patients
are usually in extremis, complaining of fever and bloody diar-
rhea. Tachycardia and abdominal pain may be present.
Clinical features are accompanied by thickened colonic haus-
tra on plain radiographs. Due to the transmural nature of the
inflammation, the neuromuscular and neurohumoral tone of
the colon is disrupted. Without treatment, the mortality rate
is nearly 20%.
Radiographic Features
Generally, plain radiographs will reveal varying degrees of
colonic dilation (generally >6.5 cm) with or without associated
fold thickening. Thickened or effaced haustra are present, with
edematous or inflamed folds, and there is a paucity of feces. An
enema is contraindicated if toxic megacolon is suspected
(Figure 7–30). These features are more clearly seen on abdom-
inal CT imaging, and complications such as perforation and
gas within the colonic wall are easier to detect. The pericolonic
fat is usually infiltrated, and both colon and fat are sometimes
hyperemic.
 Intraabdominal Abscess
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Plain film: Usually invisible except when abscess is gas-
filled or produces a mass effect.
 Ultrasound: Well-circumscribed collection of variably
echogenic fluid. 
 Abdominal CT: Well-circumscribed fluid-filled mass,
which may contain gas. Wall is of variable thickness and
enhancement.
 Radionuclide scintigraphy: Radionuclide-tagged white
blood cell scan may be useful in search of occult abscess
or other sources of infection.
General Considerations
Over the past 25 years, imaging has revolutionized the diag-
nosis and management of abdominal and pelvic abscesses,
often precluding the need for laparotomy and for incision
and drainage in the vast majority of patients.
Intraabdominal abscesses typically are caused by perfo-
rated appendicitis in the young and diverticulitis in the
elderly. Overall, most cases are iatrogenic, occurring after
intraabdominal surgery. Hematogenous seeding of bacteria
may be responsible for liver and, especially, splenic abscesses.
The mortality remains high, ranging from 80% to 100% with-
out treatment and up to 30% in patients receiving appropri-
ate therapy.
Radiographic Features
A. Plain Radiographs—These may be helpful in evaluating
the gastrointestinal tract but are not generally able to localize
an abscess. On occasion, the abscess will appear as a gasless
fluid collection mimicking a mass with defined radiodense
contours that displaces bowel or bladder.
B. Ultrasound—Ultrasound is an excellent means for bed-
side evaluation of defined areas such as the upper quadrants,
 Figure 7–30. Toxic megacolon. Plain radiograph demon-
strates diffuse dilation and severe thickening of mucosal folds
(thumbprinting) of the colon. There is no stool. The patient
was in extremis with a severe flare of ulcerative colitis.
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the paracolic gutters, and the pelvis. Features that suggest
an infected fluid accumulation on sonography include
rounded or ovoid collections with thick walls, with variable
internal echoes and without evidence of central vascularity,
as demonstrated by color, power, or spectral Doppler sig-
nals. Focal bright echoes with variable shadowing within
collections may suggest the presence of gas. However, these
signs are not specific for infected fluid; a hematoma or
seroma may appear identical. On the other hand, nonin-
fected collections generally have angular margins, conform
to anatomic spaces, and tend to lack significant internal
echogenicity.
Ultrasound is especially valuable for evaluating the sub-
diaphragmatic regions or the low pelvis. However, one
should bear in mind its limitations. Ultrasound will not
reliably evaluate the retroperitoneum and retroperitoneal
organs such as the pancreatic body and tail. Evaluation of
complex collections in postoperative patients or in patients
with open abdominal incisions or surgical dressings is likely
to be suboptimal. Imaging of abscesses within organs may
be difficult.
C. Computed Tomography—CT is the method of
choice for evaluation of an intraabdominal abscess
(Figure 7–31). Although preparation with oral and IV
contrast agents is preferred for optimal diagnosis in most
patients, contrast material is not always required when
using the latest-generation equipment. This is especially
true in obese patients because of inherent contrast pro-
vided by intraabdominal fat. Actual scanning time with a
multidetector helical scanner is typically on the order of
20–40 seconds.
Abscesses generally appear as round or ovoid collections
with thick surrounding rims. Intraluminal gas due to
anaerobic bacterial infection may be present in up to 50%
of collections. If IV contrast material is given, enhancement
of the surrounding rim may be noted in up to 50% of
abscesses. Abscesses under the diaphragm and surrounding
the liver or kidney may have crescentic margins. However,
in many cases, the CT signs of an abscess are nonspecific.
Necrotic tumors may have an identical appearance, and
percutaneous aspiration may be required to distinguish
between them.
D. Radionuclide Scintigraphy—Although unnecessary in
the vast majority of patients, nuclear medicine studies with
indium (111In)–labeled or gallium citrate (67Ga)–labeled
white blood cells are useful for the detection of occult
abscesses, especially in patients with fever of unknown origin.
Both indium oxine–labeled and gallium citrate–labeled cells
are injected intravenously, and scans are typically obtained
48–72 hours later. Although gallium is highly sensitive for
the detection of intraabdominal abscess (80–90%), speci-
ficity is limited by intestinal secretion at 48–72 hours.
Overall, indium-labeled white blood cell scans are more
accurate for abdominal applications.
E. Algorithm for Imaging the Patient with Suspected
Abdominal Abscess—In patients without localizing signs
or symptoms and varying degrees of suspicion of abdominal
abscess, the test of choice is helical or multidetector CT with
IV and oral contrast. This study helps to exclude potential
peritoneal and retroperitoneal sources of infection. CT is
necessary for adequate visualization of the pancreas, psoas
muscles, other retroperitoneal structures and complex col-
lections. CT is superior to other imaging methods in patients
A
B
 Figure 7–31. Psoas abscess. Young woman with pain
and fever 1 month after renal and pancreas transplanta-
tion. A. CT demonstrates a multiloculated right psoas
abscess with air and gas tracking into the right psoas
sheath. B. Air in the right abdominal wall is from a
recent biopsy.
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with ileus, open incisions, dressings, indwelling catheters,
and drains. If symptoms are localized to the upper abdomi-
nal quadrants or to the pelvis, ultrasound is an excellent
choice for diagnosis and can be performed quickly at the
bedside. Furthermore, bedside percutaneous incision and
drainage may be performed with sonographic guidance.
Scintigraphy has a limited role in diagnosing abscess in an
acutely ill patient.
F. Percutaneous Image-Guided Drainage—Percutaneous
drainage has revolutionized the management of infected
fluid collections. Expanded criteria render only a small
minority of collections unsuitable for such drainage.
General criteria include a fluid collection at least 2–3 cm in
diameter and safe access to the collection without inter-
vening blood vessels, pleura, bladder, or bowel. One should
confirm with CT or sonographic Doppler that the collec-
tion in question is not a pseudoaneurysm. Fluid collections
may be multiloculated or communicate with the gastroin-
testinal, biliary, or genitourinary tracts. Solid organ and
tubo-ovarian abscesses may be drained safely, although the
latter frequently respond to antibiotics and needle aspira-
tion alone.
A number of catheter types and sizes are available.
Noninfected serous collections usually can be drained with
6–8F catheters, whereas infected, thick purulent collections
may be drained with 10–14F catheters. Multiple catheters or
larger catheters (16–18F) occasionally may be needed for
multiloculated noncommunicating thick-walled collections.
Guidance for drainage procedures includes ultrasound, fluo-
roscopy, or CT. Ultrasound is especially versatile because cav-
itary probes (endovaginal or endorectal) can help diagnose
deep pelvic abscesses and guide transrectal or transvaginal
drainage. Catheters should be left to gravity drainage and
flushed gently with 5 mL of normal saline at 8-hour intervals
to ensure patency. Drainage output should be recorded on
the nursing flow sheet.
Catheter position may be confirmed by fluoroscopic
injection of contrast material or by ultrasound or CT.
General criteria for catheter removal include resolution of
symptoms and signs, decrease in net catheter output to
under 10 mL/day, and closure of the cavity as determined by
follow-up imaging studies.
Gerzof SG et al: Percutaneous catheter drainage of abdominal
abscesses: A five year experience. N Engl J Med 1981;305:653–7.
[PMID: 7266601]
Gerzof SG et al: Expanded criteria for percutaneous abscess
drainage. Arch Surg 1985;120:227–32. [PMID: 3977590]
VanSonnenberg E et al: Percutaneous abscess drainage: Update.
World J Surg 2001;25:362. [PMID: 11343195]
Yu SC et al: Treatment of pyogenic liver abscess: Prospective, ran-
domized comparison of catheter drainage and needle aspira-
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 Acute Pancreatitis
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Plain radiographs: Gallstones, ileus of regional bowel (sen-
tinel loop), transverse colon ileus (colon cutoff), pancreatic
calcifications (chronic pancreatitis), and pleural effusion.
 Ultrasound: Peripancreatic fluid, enlarged pancreas with
variable echogenicity, localized fluid collections,
cholelithiasis, choledocholithiasis, biliary tract obstruction.
 Helical CT: Pancreatic enlargement, necrosis, or hemor-
rhage; thoracic and intraabdominal fluid or fluid collec-
tions; cholelithiasis; choledocholithiasis.
General Considerations
Imaging studies in acute pancreatitis help to confirm the
diagnosis, suggest possible causes (eg, choledocholithiasis or
pancreas divisum), detect features suggesting chronicity, and
demonstrate the extent of complications, such as abscess,
pseudocyst, hemorrhage, and necrosis. Imaging findings may
add to prognostic information derived from clinical and
serum laboratory parameters.
Acute pancreatitis is caused mainly by alcohol abuse or
choledocholithiasis. In the ICU, iatrogenic causes such as
postoperative state, medications (eg, antiretrovirals,
chemotherapeutic agents), or endoscopic retrograde cholan-
giopancreatography may cause acute pancreatitis. Other
causes include trauma, hypercalcemia, hypertriglyceridemia,
peptic ulcer disease, and structural congenital anomalies.
By imaging criteria, acute pancreatitis may be subdivided
broadly into acute interstitial (edematous) pancreatitis and
acute necrotizing or hemorrhagic pancreatitis. While acute
interstitial pancreatitis is usually self-limited and requires
supportive care, acute necrotizing pancreatitis is difficult to
manage and carries a significant risk of high morbidity and
mortality. In up to 60% of patients, peripancreatic and pan-
creatic fluid collections are present. Pseudocysts, which are
collections of pancreatic juice and debris, are lined by a
fibrous capsule and by definition have been present for at
least 4 weeks. In the acute phase, the behavior of a phlegmon
or nonliquified inflammatory pancreatic tissue is difficult to
predict, although most resolve. If a pancreatic abscess is
detected, prompt percutaneous or surgical debridement must
be performed because it is associated with a high mortality.
Radiographic Features
A. Plain Abdominal Radiographs—Several indirect signs in a
patient with acute back or epigastric pain suggest acute
pancreatitis (Figure 7–32). However, none of the following are
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specific for pancreatitis: (1) duodenal ileus—gas in the second
portion of the duodenum—reported in up to 50% of patients,
(2) jejunal ileus—focal gaseous distention of a jejunal loop
(“sentinel-loop sign”), (3) transverse colon ileus—gaseous dis-
tention of the transverse colon with a paucity of gas in the
descending colon—compatible with the “colon cutoff sign,” and
(4) left-sided pleural effusion, reported in 10–15% of patients.
B. Fluoroscopic Contrast Studies—Upper gastrointestinal
studies may be indicated to look for peptic ulcer disease.
Although they are not indicated for the diagnosis of acute
pancreatitis, one sometimes may observe a widening of the C-
loop with thickening of the duodenal folds due to edema.
C. Ultrasound—An ultrasound examination may be neces-
sary to confirm or exclude the presence of gallstones within
the gallbladder or common duct. Sonographic imaging of
the pancreas may reveal diffuse edema.
D. Abdominal CT—Current CT techniques allow detailed
pancreatic imaging tailored to the particular clinical situation.
In the setting of acute pancreatitis, a single or multidetector
helical CT may be performed, imaging the pancreas with a
minimum of 3-mm collimation with IV contrast enhance-
ment in the “pancreatic phase,” approximately 40 seconds
after bolus contrast material injection in patients with normal
cardiac output. In addition to highly detailed pancreatic
images, the remainder of the abdomen and pelvis should be
imaged to exclude distant complications, including fluid col-
lections and phlebitis. CT is the single best imaging method
for pancreatic evaluation because it provides excellent evalua-
tion and the ability to treat complications percutaneously.
Uncomplicated acute pancreatitis has an extremely vari-
able presentation. The pancreas may be normal or edema-
tous, increasing the attenuation of the intrapancreatic fat. The
peripancreatic fat planes may become infiltrated by edema
and products of the nonspecific inflammatory response. In
patients with severe pancreatitis, sections of the gland
undergo necrosis and may become hemorrhagic or infected.
On CT, lack of diffuse and homogeneous pancreatic enhance-
ment with IV contrast material reflects poor parenchymal
perfusion and is typical of necrotizing pancreatitis. In areas of
necrosis, the pancreas becomes ill-defined, with a severe peri-
pancreatic inflammatory response and local and distant free
and contained fluid. Splenic vein thrombosis may be present,
and other complications such as pseudoaneurysm formation
and pseudocyst formation may be seen at local and distant
sites (Figure 7–33). A proposed CT grading system is used in
some centers to estimate the amount of pancreatic injury and
to predict outcome. Hemorrhagic complications are well seen
because recent hemorrhage (<1 week) is usually of high
attenuation compared with surrounding tissue. Over time as
the hematoma ages, its attenuation gradually decreases.
A pancreatic abscess, which may complicate acute pancre-
atitis in up to 9% of patients, implies a poor prognosis, with
reported mortality rates of 40–70% in the pre-CT era. Prompt
CT diagnosis and treatment have reduced the mortality rate to
20%. CT appearance of a pancreatic abscess can be variable
and can range from a contained fluid collection to a more typ-
ical rim-enhancing lesion with central low attenuation and gas
collection. The latter findings are present in only 20–30% of all
pancreatic abscesses, and percutaneous aspiration is usually
necessary for confirmation. The presence of gas bubbles also
may suggest a fistulous communication with bowel.
 Figure 7–32. Acute pancreatitis. A. Plain film demon-
strates focal dilated “sentinel loops” resulting from localized
ileus. B. Abdominal CT in the same patient shows peripan-
creatic stranding and a fatty liver from recent ethanol abuse.
A
B
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Treatment
Acute pancreatitis complicated by necrosis or infection often
can be treated successfully by aggressive percutaneous catheter
drainage with large-bore catheters. In more complex or severe
cases, percutaneous management may help to temporize a
critically ill patient until surgical debridement is possible.
The management of pseudocysts is complex. Generally,
pseudocysts may be managed expectantly because most will
regress over time. By definition, a true pseudocyst has a
mature fibrous wall developed over at least 4 weeks.
Indications for percutaneous drainage or internal drainage
into the stomach are the following: infection; enlargement;
pain; bowel, bile, or urinary obstruction; and diameter greater
than 5 cm. For noninfected pseudocysts, success rates for
internal or external drainage are high. For the 20–30% of
pseudocysts communicating with the pancreatic duct, external
drainage will be difficult, and a cyst gastrostomy performed
percutaneously, surgically, or laparoscopically may be better.
Superinfection of a previously sterile pseudocyst occurs
in less than 5% of cases. As with most fluid collections, iden-
tification of infection within a pseudocyst requires clinical
suspicion and confirmation by percutaneous aspiration.
Successful drainage of an infected pseudocyst uses the same
principles of drain placement and management as for most
intraabdominal abscesses.
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IMAGING OF ACUTE GALLBLADDER & BILIARY
TRACT DISORDERS
 Acute Calculous Cholecystitis
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Plain films: 15–20% of gallstones are radiopaque; dis-
tended gallbladder may be present in the right abdomen
and produce a rounded radiodensity; gas may be present
in the lumen or wall in emphysematous cholecystitis.
 Ultrasound: Thickening of gallbladder wall (>3 mm),
intraluminal gallstones and sludge, pericholecystic
fluid and focal tenderness over gallbladder (sono-
graphic Murphy’s sign).
 CT: Nearly 100% of gallstones visualized. Distended
gallbladder with thickened wall, rim enhancement,
pericholecystic fat stranding, gas in lumen or wall in
emphysematous cholecystitis.
 Hepatobiliary scintigraphy: Uptake of iminodiacetic acid
analogues into liver but nonvisualization of gallbladder
within 60 minutes of injection.
General Considerations
In acute calculous cholecystitis, cystic duct obstruction
results from a lodged gallstone in almost 95% of cases. The
gallbladder distends, with resulting mucosal inflammation
and edema from bile stasis. Both distention and mural edema
may lead to venous obstruction and subsequent mural
ischemia and possible perforation.
Clinical parameters are of limited utility in the critical
care setting. There is a significant clinical overlap among a
variety of conditions, such as acute pancreatitis, perforated
peptic ulcer, pyelonephritis, and thoracic abnormalities such
as pneumonia and myocardial infarction.
 Figure 7–33. Complicated pancreatitis. CT demon-
strates a large pseudocyst in the head of the pancreas.
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Radiographic Features
A. Plain Abdominal Radiographs—Plain radiographs can
detect the 15% of gallstones that are radiopaque. In emphy-
sematous cholecystitis, typically seen in diabetics, gas within
the gallbladder wall and lumen may be seen. Plain films also
may be useful to distinguish other causes of right upper
quadrant pain, such as a perforated viscus or pneumonia.
B. Ultrasound—Ultrasound should be the test of choice for
rapid diagnosis of acute cholecystitis at the bedside. Features
highly suggestive of acute calculous cholecystitis include a
thick-walled, distended gallbladder with gallstones, perichole-
cystic fluid, and focal tenderness overlying the gallbladder
(sonographic Murphy’s sign)(Figure 7–34). However, in
patients who have been in the ICU for a few days or longer,
the gallbladder tends to look abnormal on sonography, usu-
ally having a thickened wall and internal echoes. In these
patients, a reliable sonographic Murphy’s sign should be
absent. Sonography also may be limited by body habitus,
overlying bowel gas, gangrenous cholecystitis, or overlying
dressings. Pericholecystic fluid is an unreliable sign in patients
with ascites. Gallbladder wall thickening alone in the absence
of other findings may have many causes, including acute hep-
atitis, HIV cholangiopathy, IL-2 therapy, and anasarca.
C. Scintigraphy—In patients with equivocal signs and
sonography, scintigraphy may provide complementary infor-
mation in acute calculous cholecystitis. Technetium (99mTc)
iminodiacetic acid–derived agents have been shown to have
high sensitivity and specificity for the diagnosis of acute
cholecystitis. These agents are injected intravenously, and
sequential imaging is performed over the liver with a SPECT
camera. Sequential liver uptake and excretion into the biliary
tree and intestine are imaged for up to 1 hour after injection.
Normally, the gallbladder should fill with the radiotracer
within 1 hour. Lack of filling confirms the diagnosis of acute
calculous cholecystitis. However, lack of filling is also seen
with intrinsic gallbladder dysfunction.
Although scintigraphy is an excellent test, it is cumber-
some to perform at the bedside in the ICU compared with
sonography. An accurate test requires that the patient fast
for at least 2–4 hours prior to the procedure, and delayed
images up to 4 hours may be needed. Scintigraphy has high
negative predictive value; filling of the gallbladder within
1 hour excludes the diagnosis of acute calculous cholecystitis.
However, many causes can prevent radiotracer flow into the
cystic duct, and false-positive examinations have been
reported in up to 40% of severely ill or debilitated patients.
The most common causes of false-positive tests are bile sta-
sis, bile hyperviscosity, and gallbladder distention. Specific
causes include chronic cholecystitis, hyperalimentation,
severe jaundice, hepatic dysfunction, pancreatitis, prolonged
fasting, and recent nonfasting state. Causes of false-negative
tests include pancreatitis and poor hepatic function.
Hepatobiliary scintigraphic agents also may be used to con-
firm complications such as total common duct obstruction
or bile leak.
 Acalculous Cholecystitis
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Ultrasound: Gallbladder wall is thickened; no intralumi-
nal stones; sonographic Murphy’s sign usually present.
 CT: Mural thickening and inflammatory infiltration of
the pericholecystic fat.
A
B
 Figure 7–34. Acute cholecystitis. A. Ultrasound demon-
strates a stone at the gallbladder neck with thickening of
the gallbladder wall, pericholecystic fluid, and tenderness
on compression (sonographic Murphy’s sign). In combination,
these features are highly specific for acute cholecystitis. B. In
another patient, abdominal CT shows distended gallbladder
with gallstones and surrounding infiltration of the fat.
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General Considerations
Acalculous cholecystitis is associated with a variety of clinical
conditions, including chronic debilitation, prolonged intuba-
tion, nasogastric suction and hyperalimentation, burns, and
pancreatitis. Although comprising 10–15% of all cases of chole-
cystitis, acalculous cholecystitis predominates in the postopera-
tive and posttraumatic patient population, accounting for up to
90% of all cholecystitis cases seen in that group. Mechanisms are
poorly understood and probably multifactorial. Bile stasis, bile
hyperconcentration, and edema with pressure in the gallbladder
wall leading to progressive ischemia have been linked to the
pathogenesis of this disorder. In addition, reflux of pancreatic
juices through biliary enteric anastomoses and pancreatitis have
been suggested. The clinical presentation of acalculous chole-
cystitis is similar to that of calculous cholecystitis. However, typ-
ical symptoms may be masked by concomitant problems.
Radiographic Features
As with the clinical diagnosis, the radiologic diagnosis is also
difficult. In the patient population most prone to acalculous
cholecystitis, intrinsic functional and morphologic abnor-
malities of the gallbladder limit the specificity of both scintig-
raphy and sonography (Figure 7–35). Scintigraphy relies on
technetium (99mTc) iminodiacetic acid to fill the gallbladder,
and scans often are done with pharmacologic intervention to
improve accuracy. Morphine may cause contraction of the
sphincter of Oddi, resulting in increased back pressure; chole-
cystokinin can be used to first empty the gallbladder. Although
the sensitivity of scintigraphy has been reported to be as high
as 95%, specificity is significantly lower than in calculous
cholecystitis. This is so because of the high number of false neg-
atives resulting from coexisting conditions such as prolonged
intubation, nasogastric suction, and hyperalimentation.
Sonographic features suggesting cholecystitis are simi-
larly compromised in these patients. They may have mild
wall thickening from edema and mild contraction. Often,
right upper quadrant tenderness mimicking a sonographic
Murphy sign is present in these patients in the absence of
acalculous cholecystitis. Although the sensitivity of sonogra-
phy is high, specificity is poor.
If results are equivocal, both scintigraphy and ultrasound
may be necessary, or a CT scan may be performed. Using IV
contrast–enhanced CT, mural thickening, mucosal enhance-
ment, and subtle pericholecystic inflammatory changes may
improve specificity.
Treatment
In patients with uncomplicated acute cholecystitis, IV antibi-
otics contain the inflammatory response and suppress further
inflammation, allowing patients to undergo less invasive surgery
with fewer complications. Although percutaneous aspiration
usually can be performed in patients with acute cholecystitis, its
role is debated because there is a high incidence of false-negative
sterile aspirates resulting from effective antibiotic treatment.
Temporary gallbladder decompression by percutaneous
cholecystostomy is beneficial in patients with acute cholecys-
titis who are at high surgical risk. The procedure is performed
with sonographic and fluoroscopic guidance in most institu-
tions, but it may be performed with CT guidance. It also can
be performed with sonographic guidance alone at the bed-
side. Complications, including bile leak, hemobilia, and vagal
reaction, have been reported in 5–10% of patients—less than
the complication rate associated with surgery (24%). Other
A
B
 Figure 7–35. Acalculous cholecystitis. A. Ultrasound
demonstrates diffuse echoes throughout the gallbladder,
a marginally thickened wall, and positive sonographic
Murphy’s sign. B. HIDA (hepatobiliary iminodiacetic acid)
scan. The gallbladder does not fill with tracer by 60 minutes
despite provocative maneuvers.
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indications for percutaneous drainage include decompres-
sion of the biliary tract in cases of distal common duct
obstruction with only mild dilation of the intrahepatic ducts.
Some have advocated performing percutaneous cholecys-
tostomy in critically ill patients as a means of diagnosing and
treating acute cholecystitis. With this approach, in one study,
58% of critically ill patients improved.
Akhan O, Akinci D, Ozmen MN: Percutaneous cholecystostomy.
Eur J Radiol 2002;43:229–36. [PMID: 12204405]
Bennett GL, Balthazar EJ: Ultrasound and CT evaluation of emer-
gent gallbladder pathology. Radiol Clin North Am
2003;41:1203–16. [PMID: 14661666]
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IMAGING IN EMERGENT & URGENT
GENITOURINARY CONDITIONS
 Acute Renal Failure
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Ultrasound: In obstructive uropathy, dilation of the calices
and renal pelvis with visualization of echogenic calculi; in
intrinsic renal disease, increased cortical echogenicity
correlates with chronic medical renal disease.
 CT: In obstructive uropathy, signs of acute obstruction
on CT include dilation of the collecting system, a source
of obstruction such as stone, swollen kidney with
increased stranding in the perinephric space; CT urogra-
phy (noncontrast helical CT) provides a rapid method of
detecting renal calculi and obstructive nephropathy
from a passing stone.
 MR urography: Rapid assessment of cause and level of
obstruction; with gadolinium enhancement, differential
rates of enhancement permit assessment of renal
perfusion.
 Renal scintigraphy: Technetium-99m MAG 3 scan per-
mits rapid assessment of differential renal function,
including flow, uptake, and excretion. Especially valuable
in transplanted kidneys to assess for a vascular occlusion
from intrinsic renal abnormality.
General Considerations
The workup of acute renal failure traditionally has been
focused on identifying prerenal, intrinsic renal, and postre-
nal causes. Prerenal causes (eg, cardiac or liver failure) and
systemic hypotension account for 75% of all causes of renal
failure. Intrinsic causes such as acute tubular necrosis and
glomerulonephritis account for 20%, and postrenal causes
such as obstructive nephropathy account for less than 5% of
cases. Imaging is used mainly to exclude an obstructive cause
of acute renal failure. These causes include obstruction from
a lower urinary tract source such as bladder tumor, prostatic
enlargement, or urethral stricture. Concomitant reflux also
may decrease renal function. Ureteral causes of obstruction
include luminal stones, tumors, blood clots, fungus balls, and
sloughed papillae, as well as extraluminal causes such as
mural strictures or extramural causes such as retroperitoneal
fibrosis, lymphadenopathy, or inadvertent ureteral ligation.
Radiographic Features
Azotemia due to obstruction is usually easily and rapidly
treatable. Cross-sectional imaging allows rapid identification
of hydronephrosis and its causes, as well as clues to evaluate
pyonephrosis, pyelonephritis, or abscess.
Sonography is the imaging method of choice to evaluate
hydronephrosis in the critically ill patient. It may be per-
formed at the bedside. Since it detects the presence of a
dilated collecting system, pitfalls in interpretation may be
present. In acute hydronephrosis, sonography may be normal
in 50% of patients because dilation is suboptimal, especially
in the first 72 hours. In subacute situations, a ruptured calix
may decompress the collecting system, leading to a false-
negative diagnosis if perinephric fluid is minimal or absent. A
volume-depleted patient may also have poor distention of the
collecting system due to low urine output. Patients with
retroperitoneal fibrosis or neoplastic encasement of the
ureters may have only minimally distended collecting sys-
tems. Conversely, patients with vesicoureteral reflux, para-
pelvic cysts, or prior episodes of inflammation may receive a
false-positive diagnosis of hydronephrosis. Sonography may
suggest the diagnosis of pyonephrosis or renal bleeding by the
presence of echoes in the collecting system.
In a large series of patients with azotemia undergoing renal
sonography, hydronephrosis was detected in 29% of those
known to be at high risk (ie, pelvic malignancy, palpable
abdominal or pelvic mass, renal colic, known nephrolithiasis,
bladder outlet obstruction, recent pelvic surgery, or sepsis).
However, in patients without these risk factors, hydronephro-
sis was detected in only 1%. Sixty-five percent of patients in
the low-risk group had medical renal disease compared with
36% of high-risk patients. The simplicity and relatively low
cost of a sonogram must be weighed against a typically nega-
tive result in the vast majority of patients and the risk of miss-
ing an obstructive cause of renal failure.
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Helical noncontrast CT has emerged over the past few
years as the imaging procedure of choice for the evaluation
of renal colic (Figure 7–36). Helical CT detects over 99% of
all types of calculi—with the exception of the stones caused
by crystallization of the antiretroviral protease inhibitor
indinavir. Helical CT images stones not only in the renal col-
lecting system but also in the ureters, bladder, and posterior
urethra. CT also images the retroperitoneum and pelvis,
allowing detection of processes such as retroperitoneal fibro-
sis and lymphadenopathy. CT is excellent for the detection of
perirenal abscesses and abscesses in other areas of the
abdomen and pelvis.
When a potentially obstructing stone is found in the uri-
nary tract, the specific signs of obstruction include
hydronephrosis and hydroureter to the level of obstruction,
unilateral infiltration of perirenal and periureteral fat, and a
swollen kidney. Hydronephrosis may not be distinguishable
from pyonephrosis. However, high-density debris or, espe-
cially, gas within the collecting system suggests pyonephrosis.
MRI is emerging as a tool for evaluating urinary tract dis-
ease. However, it is currently impractical in critically ill
patients.
 Urinary Tract Infection
ESSENT IALS  OF  RAD IOLOG IC
D IAGNOS I S
 Ultrasound: Usually normal in uncomplicated pyelonephri-
tis. However, the kidneys may be enlarged, with variable
echogenicity. Focal nephritis may appear as a solid renal
mass. A renal abscess appears as a complex cystic or
hypoechoic mass.
 CT: Pyelonephritis is typically associated with nonspe-
cific findings. Kidneys may be enlarged, with peri-
nephric stranding. With IV contrast material, a striated
nephrogram may be seen with delayed function in
infected areas. Focal nephritis appears as an ill-
defined region of low attenuation in a lobar distribu-
tion. Renal abscesses are well-defined masses, often
with an enhancing rim, increased attenuation of the
adjacent perirenal fat, and thickening of the renal
fascia.
General Considerations
Pyelonephritis is typically a clinical diagnosis. Imaging is
helpful to detect complications of pyelonephritis or urosep-
sis or in patients who have failed to respond to standard
medical therapy. Complications of pyelonephritis include
pyonephrosis, renal or perirenal abscess, or other conditions
requiring surgical or percutaneous intervention.
A
B
C
 Figure 7–36. Obstructive uropathy. A. Ultrasound shows
moderate hydronephrosis of the left kidney. B. CT scan
demonstrates moderate left hydronephrosis with
hydroureter. C. There is a tiny calculus obstructing the left
ureterovesical junction.
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Radiographic Features
Sonography is relatively insensitive and nonspecific in diag-
nosing acute pyelonephritis. It is useful to exclude
hydronephrosis and possibly pyonephrosis, as well as renal or
perirenal abscess. However, sonography cannot diagnose
changes in the perinephric fat or inflammatory thickening of
the perirenal fascia.
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Physiologic monitoring is available for appropriate indica-
tions in the ICU. Monitoring should be selected and applied
to detect pathophysiologic abnormalities in patients at high
risk of developing them and to aid in the titration of therapy
to appropriate physiologic end points.
 Electrocardiography
Continuous electrocardiography permits monitoring of heart
rate, detection of arrhythmias, and evaluation of pacemaker
function. It also may help detect myocardial ischemia or elec-
trolyte abnormalities. Continuous electrocardiographic mon-
itoring is indicated for patients with potential for developing
arrhythmias—particularly those with acute myocardial
infarction, traumatic cardiac contusion, following cardiac
surgical procedures, and those with a prior history of arrhyth-
mia. It is also useful for those in whom heart rate monitoring
is indicated, such as patients at risk of hemorrhage or those
undergoing fluid resuscitation. Monitoring of the ST seg-
ments is indicated for patients at risk of myocardial ischemia,
such as those with coronary artery disease who have an injury,
illness, or operation. Monitoring of the ECG also may be use-
ful to detect certain electrolyte abnormalities such as
hypokalemia during treatment of diabetic ketoacidosis.
The cardiac electrical potential available for skin surface
monitoring is between 0.5 and 2.0 mV. Because of this low
signal level, electrocardiographic systems must have good
sensing, amplifying, and display capabilities. The electrodes
used for  electrocardiographic monitoring are usually com-
posed of silver–silver chloride gel (Ag/AgCl) inside an adhe-
sive pad. Prior to placement, the skin should be clean and
dry. The stratum granulosum has an electrical resistance of
50,000 Ω/cm3, which can be reduced to 10,000 Ω/cm3 simply
by cleansing, which removes oils and dead cells. Difficulties
with a low signal are often remedied by reapplying the elec-
trode after cleaning the skin.
Optimal electrode placement (Figure 8–1) allows proper
detection of the electrocardiographic signals with a minimum
of extraneous noise. A “modified lead II” configuration is
appropriate for routine monitoring, with limb leads
extended proximally to lie over the shoulders. Placing them
over bony prominences reduces electrical noise from muscle
contractions.
Most electrocardiographic amplifiers and display modules
can be used for both diagnostic and monitoring applications.
The diagnostic setting permits greater amplifier bandwidth
(0.05–100 Hz) when compared with the monitor setting
(0.5–50 Hz). For routine rate and arrhythmia detection, the
monitor setting is preferred because it decreases baseline
wander, reduces unwanted interference, and improves overall
trace quality. However, because it may falsely elevate or
depress ST segments, the diagnostic mode should be selected
when myocardial ischemia is the primary concern.
Clinical Applications
A. Electrocardiographic Monitoring—Lead placement at
the shoulders and in the lead II position parallels the atria
and results in the greatest P-wave voltage of any surface lead
configuration. This facilitates recognition of arrhythmias
and inferior wall ischemia. When placed in the V5 position
along the anterior axillary line, both anterior and lateral wall
ischemia can be detected. Because patient positioning may
make a true lead V5 position difficult, a modified arrange-
ment (CS5), in which the left arm lead is placed just lateral to
the left nipple and the lower limb lead is placed over the iliac
crest, is a good alternative. When possible, leads II and V5
should be monitored simultaneously. Esophageal leads are
better than lead II for the detection of arrhythmias, but their
use is difficult in patients who are not paralyzed and sedated,
and they are rarely used in the ICU setting.
B. Complications—Difficulties associated with electrocardio-
graphy are usually due to technical error or equipment mal-
function. Electrodes may not function properly when they are
old and dry or if they are not attached securely. Electrical noise
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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accompanying the displayed electrocardiogram is usually due
to loose electrodes, broken wires, or poorly fitting contacts or
problems with associated electrical equipment. Proximity of
the patient to electrical lines (ie, power cords, etc.) produces a
potential difference through capacitive coupling known as
common-mode voltage. Typically as low as a few millivolts, cou-
pling can cause voltages as high as 20 V. Common-mode volt-
age interference usually presents as 60-Hz interference and
often can be reduced by using properly placed shielded wires,
good skin preparation, and an electrocardiographic amplifier
that offers common-mode rejection.
Proper sensitivity setting of the amplifier and recorder
is essential to make certain that large T waves are not
“double-counted” in the rate determination. Additional fil-
tering is occasionally required for patients who have
pacemakers—in whom the pacer spike is interpreted as a
QRS complex.
Goodman S, Shirov T, Weissman C: Supraventricular arrhythmias
in intensive care unit patients: Short and long-term conse-
quences. Anesth Analg 2007;104:880–6. [PMID: 17377100]
Reinelt P et al: Incidence and type of cardiac arrhythmias in criti-
cally ill patients: A single-center experience in a medical-
cardiological ICU. Intensive Care Med 2001;27:1466–73.
[PMID: 11685339]
 Blood Pressure Monitoring
Because systemic blood pressure is related to both cardiac
function and the peripheral circulation, blood pressure mon-
itoring provides information related to the overall circula-
tory condition. While blood pressure monitoring is standard
and universal for critically ill patients, the type of blood pres-
sure monitoring and its frequency should be chosen based
on the individual patient’s diagnosis and condition.
 Figure 8–1. Locations of the unipolar precordial leads on the body surface. (Reproduced, with permission, from
Goldschlager N, Goldman MJ: Principles of Clinical Electrocardiography, 13th ed. Originally published by Appleton
& Lange. Copyright © 1989 by The McGraw-Hill Companies, Inc.)
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Blood pressure represents lateral force exerted on the vas-
culature by flowing blood. Pressure is maximal shortly after
ventricular systole (SBP). The diastolic pressure (DBP) fol-
lows cardiac diastole and is the lowest pressure in the cycle.
The mean arterial pressure (MAP) represents the standing
pressure in the arterial circuit and is calculated as follows:
Pulse pressure is the arithmetic difference between the sys-
tolic and diastolic pressures. Pulse pressures vary with stroke
volume or vascular compliance. Pulse pressures less than
30 mm Hg are common with hypovolemia, tachycardia, aor-
tic stenosis, constrictive pericarditis, pleural effusions, and
ascites. Widened pulse pressures may be due to aortic regur-
gitation, thyrotoxicosis, patent ductus arteriosus, arteriove-
nous fistula, and coarctation of the aorta. Variability of pulse
pressure and systolic pressure during the respiratory cycle has
been correlated with response to intravascular fluid repletion.
The initial upstroke and peak of the arterial waveform are
produced by left ventricular ejection. The end of systole is
marked by a brief decline in pressure until the aortic valve
closes and redirects backflowing blood into the aorta. The
“dicrotic notch” so created may be detected on recordings
obtained from aortic or proximal arterial sites. The waveform
becomes more peaked and of higher amplitude as it progresses
distally. The initial upstroke is prolonged, producing a higher
systolic and a lower diastolic pressure (Figure 8–2).
The velocity of blood flow is slowest in the largest arter-
ies because they are distensible and absorb energy from the
pressure wave front. The pulse wave travels at a rate of 7–10 m/s
in large arteries such as the subclavian artery and increases to
15–30 m/s in smaller distal arteries.
When a pressure wave front enters a small, nondistensible
artery, part of the wave may be reflected back proximally. If a
reflected wave strikes an oncoming wave, the two summate,
causing a higher pressure than would occur otherwise. This
phenomenon produces pressures in the distal peripheral
arteries that paradoxically may be more than 20–30 mm Hg
above those recorded in the aorta.
Arterial pressure depends on cardiac output (CO) and
systemic vascular resistance (SVR). The latter is calculated as
follows:
When MAP and CVP (central venous pressure) are in
millimeters of mercury and CO is in liters per minute, SVR
is expressed in dynes × seconds × cm–5. Evaluation of the
equation indicates that an increase in either SVR or CO will
increase mean arterial pressure.
Clinical Applications
Arterial blood pressure can be assessed either by direct
instrumentation of the vascular tree or by indirect means.
The indirect technique usually involves inflating a cuff to
occlude an artery. As the cuff is deflated and inflow resumes,
arterial pressure can be determined.
A. Noninvasive Arterial Pressure Monitoring—
1. Palpation—A blood pressure cuff is placed above an eas-
ily palpated artery and inflated until pulsation ceases. On
cuff deflation, systolic pressure is estimated as that pressure
at which pulsation resumes. This method is limited because
it underestimates true arterial pressure and does not provide
a diastolic pressure.
2. Auscultation (Riva-Rocci method)—When an occlud-
ing proximal cuff is deflated below systolic pressure, flow
begins through the compressed artery. The turbulent flow thus
created strikes the walls of the vessel, causing them to reverber-
ate (Korotkoff sounds). As long as the cuff pressure is higher
than diastolic pressure, no flow will occur during diastole. The
sound thus produced is rhythmic in nature. Once the pressure
in the cuff is below diastolic pressure, flow occurs throughout
the cardiac cycle, and the sounds disappear. A cuff 20% wider
than the diameter of the limb must be used to obtain correct
sphygmomanometric pressures. If the cuff is too narrow, the
systolic and diastolic pressures will be artificially increased,
and vice versa. Other sources of error include too-tight or too-
loose cuff application and too-rapid or too-slow cuff deflation.
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 Figure 8–2. The shape of the arterial pressure wave
front changes as it progresses distally. The systolic peak
becomes more pronounced, as does the dicrotic notch.
(Reproduced, with permission, from Morgan GE, Mikhail
MS: Clinical Anesthesiology. Originally published by
Appleton & Lange. Copyright © 1992 by The McGraw-Hill
Companies, Inc.)
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Unduly slow deflation produces venous congestion, which
decreases the amplitude of the Korotkoff sounds as the cuff
pressure nears the diastolic pressure.
When compared with intraarterial pressure measure-
ments, those obtained by auscultation differ by 1–8 mm Hg
systolic and 8–10 mm Hg diastolic. At intraarterial pressures
below 120 mm Hg systolic, auscultation tends to overesti-
mate pressure, whereas above 120 mm Hg, auscultation
underestimates arterial pressure.
3. Oscillometry—The oscillometer uses two cuffs in series;
one occludes the artery proximally, whereas the other detects
the onset of pulsations. Slow deflation of the proximal cuff
produces aneroid needle oscillation or mercury column vari-
ation at systolic pressure. Oscillometry is the only noninva-
sive technique capable of indicating mean arterial pressure,
which coincides with maximum deflection of the manome-
ter. Although diastolic pressure is defined as that point at
which oscillation ceases, measurement of diastolic pressure is
in fact inaccurate. Oscillometry requires several cardiac
cycles to measure blood pressure accurately.
Automated oscillometry devices generally use single-
bladder cuffs that are alternately inflated and deflated. On
deflation, alterations in cuff pressure are sensed by a trans-
ducer inside the instrument. Pairs of oscillations and corre-
sponding cuff pressures are stored electronically to permit
measurement of the systolic and diastolic pressures. Use of
these automated devices is limited in those with irregular
rhythms or when motion cannot be minimized. In addition,
measurements tend to be unreliable in low-flow states.
4. Plethysmography—Arterial pulsations produce minute
changes in the volume of an extremity. Such alterations in
finger volume can be detected photometrically with a
plethysmograph. These devices tend to be less accurate than
alternative pressure monitoring techniques, particularly dur-
ing low-flow and stress conditions.
5. Doppler—The Doppler principle states that any moving
object in the path of a sound beam will alter the frequency of the
transmitted signal. The sound beam used to “insonate” tissue is
created by applying an electrical potential to a crystal that causes
it to oscillate in the radiofrequency spectrum. This sound is cou-
pled to the tissue of interest through an acoustic gel.
When the beam strikes moving blood cells, the frequency
of the reflected beam is altered in a manner proportionate to
the velocity of the reflecting surface. Continuous- and pulsed-
wave Doppler equipment is currently available. Continuous-
wave transducers have two crystals mounted together in a
single probe. One is continuously transmitting, and the other
is continuously receiving. Only the velocity of flow and its
direction can be determined by a continuous-wave device.
Because a Doppler shift occurs only when blood moves rela-
tive to the transducer, an angle correction must be applied:
where Δf is the frequency shift, fe is the frequency of the
insonating beam, V is blood velocity, θ is the incident angle
of insonation, and C is the velocity of sound in tissue.
The depth of tissue penetration by the sound beam is
inversely proportional to the frequency of insonation.
Because arteries of interest are typically superficial, a 10-
MHz probe can be used. As can be seen from the equation,
the largest frequency shift is obtained when the probe is held
parallel to the artery. Perpendicular positioning decreases the
frequency shift (cos θ → 0). Doppler blood pressure meas-
urements are obtained by placing an ultrasonic probe on an
artery distal to a compressing cuff.
Doppler sounds become apparent when cuff pressure falls
below arterial pressure. Arterial pressures obtained using a
Doppler probe usually are higher than those obtained by pal-
pation and lower than those obtained by direct measurement,
although the overall correlation is excellent. An automated
device (Arteriosonde) is available for Doppler measurements.
It uses a 2-MHz insonation frequency directed at the brachial
artery. Overall accuracy is very good—especially at low pres-
sures, when ultrasonic and palpatory techniques are more
accurate than auscultation. Disadvantages include motion
sensitivity, requirement for accurate placement, and the need
to use a sonic transmission gel.
B. Invasive Pressure Monitoring—Insertion of a catheter
into an artery is the most accurate technique for pressure
monitoring. Such catheters are connected by tubing to pres-
sure transducers that convert pressure into electrical signals.
Because arterial pressure waves are themselves too weak to
generate electrical impulses, most transducers actually meas-
ure the displacement of an internal diaphragm. This
diaphragm is connected to a resistance bridge such that
motion of the diaphragm modulates an applied current. The
transducer’s sensitivity is the change in applied current for a
given pressure change.
Because transducers are ultimately mechanical, they
absorb energy from the systems they monitor. If absorbed
energy in the transducer’s diaphragm is suddenly released, it
will begin to vibrate at its natural (resonant) frequency. The
tendency for this oscillation to stop depends on the damping
of the system. Oscillating frequency increases as damping
decreases. The resonant frequency is a function of the natu-
ral frequency and the damping coefficient. Classically, a sys-
tem’s damping coefficient is determined by applying and
releasing a square pressure wave (Figure 8–3).
Damping increases when compliance increases. Soft
(compliant) connecting tubing absorbs transmitted pressure
waves and damps the system. Other factors that increase
damping include air in the transducer dome or tubing, exces-
sively long or coiled tubing, connectors containing
diaphragms, and the use of stopcocks. Because air is more
compressible than water, even small bubbles increase the sys-
tem damping. Excessive damping results in underestimation
of systolic pressure and overestimation of diastolic pressure.
There is little effect on mean pressure. Underdamped systems
produce the opposite effects. Additionally, systems with
Δf = 2feV
C
(cos  )θ
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 Figure 8–3. The amplitude ratio obtained by measuring the amplitude of oscillations after pressure release. Either
the listed formula or the tables then can be used to calculate the damping coefficient. (Reproduced, with permission,
from Morgan GE, Mikhail MS: Clinical Anesthesiology. Originally published by Appleton & Lange. Copyright © 1992 by The
McGraw-Hill Companies, Inc.)
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insufficient compliance tend to “ring” when rapid pressure
changes cause oscillations within the system. Conversely,
overdamping decreases the frequency response to the point
that rapid changes in pressure may not occur. The effect of
damping on the natural frequency of the system is illustrated
in Figure 8–4. The optimal damping coefficient is near 0.7
because there is essentially no effect on amplitude until the
measured frequency approaches the natural frequency of the
measuring system.
Clinical Applications
The arteries commonly used for invasive blood pressure
monitoring, in order of usual preference, are the radial,
ulnar, dorsalis pedis, posterior tibial, femoral, and axillary
arteries. The radial artery is preferred because of its ease of
cannulation and relatively low incidence of serious compli-
cations. The ulnar artery is the dominant artery to the hand
in 90% of patients. It connects with the radial artery through
the palmar arches in 95% of patients. Because vascular
insufficiency may result from occlusion of the dominant
artery, all patients should undergo an Allen test prior to
catheter insertion, and the results should be entered into the
medical record. However, one prospective study has demon-
strated that vascular complications were not reliably related
to results of the Allen test. Overall, there is a 10% incidence
of arterial occlusion in adults cannulated with 20-gauge
Teflon catheters for a period of 1–3 days. The use of 22-gauge
catheters seems to reduce this incidence.
For unknown reasons, women have a lower incidence of
arterial thrombosis than men. When thromboses do occur in
women, occlusions are usually temporary. Distal occlusion of
the radial artery may cause overestimation of systolic pres-
sure because of increased wave reflection, whereas proximal
occlusion usually causes reduction in pressure owing to
overdamping. Another complication of arterial catheters is
infection, most commonly limited to the skin but some-
times involving the artery as well; distal septic emboli rarely
occur. The incidence and severity of such infections can be
minimized by strict adherence to policies of daily catheter
 Figure 8–4. The amplitude ratio depends on the natural frequency of the system and the damping ratio (h). A sys-
tem that operates below its natural frequency and with a damping ratio near 0.7 is desirable. (Reproduced, with
permission, from Fry DL: Physiologic recording by modern instruments with particular reference to pressure recording.
Physiol Rev 1960;40.)
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inspection, sterile dressing changes, and limiting catheteriza-
tion to 5 days or less at any single site. Pseudoaneurysm for-
mation may be a late complication of arterial catheters. The
incidence of pseudoaneurysms may be minimized by using
smaller catheters, minimizing the duration of catheteriza-
tion, and preventing catheter infections.
Physiologic pressures are measured with reference to the
tricuspid valve, where intravascular pressure is defined as
zero. This phlebostatic axis is independent of changes in
body habitus. Postural changes affect the reference pressure
by less than 1 mm Hg. The phlebostatic point is identified as
(1) 61% of the way from the back to the front, (2) exactly in
the midline, and (3) one-quarter of the distance above the
inferior tip of the xiphoid process. A convenient method of
system calibration is to move an open stopcock attached by
fluid-filled connecting tubing to the transducer up against
the patient’s midaxillary line. The digital display on the mon-
itor indicates whether the midaxillary line is above (positive
pressure) or below (negative pressure) the transducer. The
bed is then moved up or down until the pressure reads zero
(Figure 8–5).
Calibration of the monitor for nonzero pressure can be
done internally or externally. External calibration can be
done with a mercury manometer for systemic arterial pres-
sures. A convenient method adequate for the lower pressure
range required for a pulmonary artery catheter (up to 60 cm
H2O) takes advantage of the fluid-filled connecting tubing.
After establishing the zero reference, move an open stopcock
connected to the transducer above the transducer a meas-
ured amount. The height above the transducer in centimeters
(cm H2O pressure) should be read by the monitor system in
millimeters of mercury as height in centimeters divided
by 1.36. Therefore, if the system is calibrated accurately, the
pressure reading should be about 14.8 mm Hg when the
stopcock is raised 20 cm above the transducer.
An additional use of arterial catheterization is to provide
access for arterial blood sampling. This is often indicated in
patients who require frequent sampling of blood for arterial
blood gases or other blood tests.
Araghi A, Bander JJ, Guzman JA: Arterial blood pressure monitor-
ing in overweight critically ill patients: Invasive or noninvasive?
Crit Care 2006;10:R64. [PMID: 16630359]
Bur A et al: Factors influencing the accuracy of oscillometric blood
pressure measurement in critically ill patients. Crit Care Med
2003;31:793–9. [PMID: 12626986]
Gibbs NC, Gardner RM: Dynamics of invasive pressure monitor-
ing systems: Clinical and laboratory evaluation. Heart Lung
1988;17:43–51. [PMID: 3338943]
Gunn SR, Pinsky MR: Implications of arterial pressure variation in
patients in the intensive care unit. Curr Opin Crit Care
2001;7:212–7. [PMID: 11436530]
Mignini MA, Piacentini E, Dubin A: Peripheral arterial blood pres-
sure monitoring adequately tracks central arterial blood pres-
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 Central Venous Catheters
Central venous (CV) catheters are inserted via the subcla-
vian, internal jugular, or a peripheral vein in the arm.
Femoral venous catheters are not long enough to reach
“central” veins but provide similar access for intravenous
 Figure 8–5. The height of the transducer must be adjusted to the phlebostatic axis to ensure accuracy of the
pressure measurements.
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infusions. For monitoring purposes, CV catheters provide
estimates of central venous pressure (CVP) and measure-
ment of central venous oxygen saturation (ScvO2). Central
venous pressure (CVP) reflects the balance between systemic
venous return and cardiac output. In the normal heart, the
right ventricle is more compliant than the left. This differ-
ence in compliance accounts for the slope of their correspon-
ding Frank-Starling curves. The use of CVP to assess
left-sided preload causes difficulty because CVP primarily
reflects changes in right ventricular end-diastolic pressure
and only secondarily reflects changes in pulmonary venous
and left-sided pressures. The relationship between CVP and
venous return is shown in Figure 8–6A. Decreasing right
atrial pressure below zero does not significantly increase
CVP because of collapse of the vasculature leading to the
chest. The figure also demonstrates that changes in mean sys-
temic pressure cause a parallel change in venous return.
Alterations in vascular resistance (decreased by anemia, arte-
riovenous fistulas, pregnancy, or thyrotoxicosis) change the
slope of the respective curves (Figure 8–6B).
A water manometer may be used to measure CVP. The
normal range of CVP is between –4 and +10 mm Hg (–5.4
and +13.6 cm H2O).
An electronic transducer also displays the pressure wave-
form. The bandwidth of a catheter-transducer system used to
monitor CVP can be significantly narrower than that used
for arterial pressure.
A typical CVP waveform has three positive deflections
(a, c, and v) and two descents (x and y) (Figure 8–7). The
increase in venous pressure caused by atrial contraction pro-
duces the a wave. The c wave is created when the tricuspid valve
is displaced into the right atrium during initial ventricular
contraction. The x descent corresponds to the period of ven-
tricular ejection, when blood empties from the heart; it is
inscribed when the ventricle draws down on the floor of the
atrium and decreases the CVP. The v wave is produced by the
increase in atrial pressure that takes place as venous return
continues while the tricuspid valve is closed. The y descent
occurs when the tricuspid valve opens at the conclusion of
ventricular contraction, and blood enters the right ventricle.
The a wave is absent during atrial fibrillation and is magni-
fied by tricuspid stenosis (cannon wave). The x descent also
may be absent with atrial fibrillation. The x and y descents
are both exaggerated by constrictive pericarditis. Cardiac
tamponade magnifies the x descent while abolishing the y
descent. When tricuspid regurgitation occurs, the c wave and
the x descent are replaced by a large single regurgitant wave.
Pulmonary hypertension decreases right ventricular compli-
ance and accentuates the v wave.
Clinical Applications
A. CVP Monitoring—CVP monitoring is best used for
patients without preexisting cardiac disease as one indicator
of the adequacy of venous return and cardiac filling. An
intravenous fluid challenge is employed to aid in determin-
ing whether decreased blood pressure is due to hypovolemia
or to cardiogenic failure. Measurements of CVP are affected
by ventilation because transthoracic pressure is transmitted
through the pericardium and the thin-walled venae cavae.
During spontaneous ventilation, inspiration lowers CVP, and
exhalation increases it. The situation is reversed in patients
being mechanically ventilated, in whom inspiration increases
intrathoracic pressure and elevates CVP.
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 Figure 8–6. A. Effect of mean systemic pressure on venous return. B. Effect of systemic vascular resistance on
venous return. (Reproduced, with permission, from Otto CW: Central venous pressure monitoring. In: Blitt CD (ed),
Monitoring in Anesthesia and Critical Care. New York: Churchill Livingstone, 1985. Copyright 1985 Elsevier.)
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The degree of this elevation depends on the compliance
of the lungs and intravascular volume and will vary among
patients. For this reason, CVP measurements are best made
and compared at end expiration. When positive end-
expiratory pressure (PEEP) is applied, the positive pressure is
transmitted through to the right atrium, causing a decrease
in venous return and a rise in CVP. Again, the magnitude of
this effect of PEEP on CVP varies with pulmonary compli-
ance and blood volume. Some argue that the patient should
be temporarily removed from PEEP while the measurement
is taken. This is both impractical and potentially dangerous.
In critical situations, an esophageal probe can be inserted to
estimate transthoracic pressure. Subtracting the transtho-
racic pressure from the CVP provides transmural pressure,
which is a better estimate of right atrial pressure in the pres-
ence of elevated transthoracic pressure.
B. Central Venous O2 Saturation—Mixed venous oxygen
saturation (S–vO2) reflects the relative delivery of O2 to the tis-
sues compared with consumption. If lower than normal,
concern should be raised about tissue hypoxia. True S–vO2
must be measured in the pulmonary artery. Central venous
O2 saturation (ScvO2) does not require a pulmonary artery
catheter, but theoretically, the value will differ from S–vO2
because ScvO2 obtained from a subclavian or internal jugular
vein does not reflect venous blood returning via the inferior
vena cava or coronary sinus. Generally, ScvO2 is about 5%
higher than S–vO2.
In practice, however, ScvO2 appears to have similar predic-
tive value for end-organ hypoxia as S–vO2. Recent studies
emphasizing early goal-directed therapy in sepsis have
emphasized a target ScvO2 of greater than 70% by giving
blood transfusion and cardiac inotropic drugs. ScvO2 can be
obtained from a small sample of blood drawn back through
the catheter or by using an oximeter-tipped CVP catheter.
C. Complications—Inadvertent arterial insertion occurs
about 2% of the time; such insertion is particularly dangerous
if large, rigid “introducer” catheters are inserted. Perforation
of the superior vena cava is associated with a 67% mortality
rate, whereas the rate associated with laceration of the right
ventricle approaches 100%. Such perforations may occur
either from guidewires or from catheter erosion—again, par-
ticularly with introducer catheters. Other structures that may
be injured on insertion include the brachial plexus, the stel-
late ganglion, and the phrenic nerve. Air emboli are uncom-
mon at insertion but more often during use or at the time of
removal when the patient is not positioned properly. Late
complications are due to catheter migration, embolization,
and infection. The incidence of cannula-related thrombosis
of the axillary and subclavian veins varies between 16.5% and
46%. Central venous catheter infections occur in approxi-
mately 5% of insertions. The organisms most commonly
involved are Staphylococcus epidermidis, 30%; Staphylococcus
aureus, 8%; streptococci, 3%; gram-negative rods, 18%; diph-
theroids, 2%; Candida species, 24%; and other pathogens, 15%.
Both colonization of central venous catheters and systemic
sepsis are reduced by routine catheter care and periodic
removal and reinsertion.
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 Figure 8–7. Effect of mechanical ventilation on central venous pressure. The a, c, and v waves along with the
x and y descents are shown. (Reproduced, with permission, from Otto CW: Central venous pressure monitoring. In: Blitt CD
(ed), Monitoring in Anesthesia and Critical Care. New York: Churchill Livingstone, 1985. Copyright 1985 Elsevier.)
 CHAPTER 8196
Rivers EP, Ander DS, Powell D: Central venous oxygen saturation
monitoring in the critically ill patient. Curr Opin Crit Care
2001;7:204–211. [PMID: 11436529]
Taylor RW, Palagiri AV: Central venous catheterization. Crit Care
Med 2007;35:1390–6. [PMID: 17414086]
 Pulmonary Artery Catheterization
Catheterization of the pulmonary artery is a useful addition
to CVP monitoring. It provides information related to left
heart filling pressures and allows sampling of pulmonary
artery blood for determination of mixed venous oxygen sat-
uration. Thermodilution cardiac output measurements are
made using a thermistor-tipped catheter.
As the balloon flotation catheter is advanced through the
heart, characteristic pressure waveforms are obtained that
indicate the position of the catheter’s distal port (Figure 8–8).
Simultaneous electrocardiographic monitoring ensures that
ventricular tachyarrhythmias will be detected as the
catheter traverses the right ventricle. After a pulmonary
capillary wedge tracing is obtained, the catheter should be
deflated and withdrawn until only 1 mL of inflation is
required to advance from a pulmonary artery to a capillary
wedge tracing. Insertion of excessive catheter length con-
tributes to intracardiac knotting. If subsequent pressure
tracings are not obtained within 15 cm of additional inser-
tion, looping should be suspected. When the catheter is
placed through either the subclavian or the jugular vein, the
typical distances required are as follows: right atrium, 10–15
cm; right ventricle, 20–30 cm; pulmonary artery, 45–50 cm;
and pulmonary capillary wedge, 50–55 cm. As the catheter
passes through the right ventricle, a wedgelike pressure trac-
ing may be obtained. This “pseudowedge” is due to engage-
ment of the catheter tip beneath the pulmonary valve or
within trabeculations. Withdrawal of 10 cm of the catheter
will solve the problem. Overinflation of the balloon, causing
it to herniate over the tip of the catheter, results in a pressure
tracing that continues to rise to high levels. The balloon
should be deflated and a short length of catheter withdrawn
before further advancement is attempted.
The final position of the catheter tip within the pul-
monary artery is critical. This may be described with refer-
ence to three lung zones that depend on the relationship of
airway and vascular pressures (Figure 8–9). In zones I and II,
mean airway pressure is intermittently greater than pul-
monary venous pressure, which results in collapse of the vas-
culature between the catheter tip and the left atrium. In this
position, observed pressures will be more indicative of air-
way pressure than of left atrial pressure. Only in zone III is
there an uninterrupted column of blood between the
catheter and the left atrium. In the supine position, zone III
assumes a more dependent position, caudal to the atrium.
Decreased airway pressures change the ventilation-perfusion
relationship, producing a relative increase in zone III.
Hypovolemia decreases vascular pressures and decreases
zone III.
Correct catheter position should be ensured by chest x-
ray. Although most catheters migrate caudally and to the
right, an occasional catheter will become wedged anterior to
the vena cava. In this position, true pulmonary capillary
pressures may be less than alveolar pressures, resulting in
spuriously elevated measurements. A lateral chest x-ray will
m
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 Figure 8–8. Normal pressures and waveforms obtained as a pulmonary artery flotation catheter is advanced from
the right atrium to a pulmonary artery wedge position. (Reproduced, with permission, from Morgan GE, Mikhail MS:
Clinical Anesthesiology. Originally published by Appleton & Lange. Copyright © 1992 by The McGraw-Hill Companies, Inc.)
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demonstrate when the catheter has assumed this position.
Indicators of proper tip placement include (1) a decline in
pressure as the catheter moves from the pulmonary artery
into the “wedged” position, (2) ability to aspirate blood from
the distal port (eliminating the possibility of overwedging),
and (3) a decline in end-tidal CO2 concentration with infla-
tion of the balloon (produced by a rise in alveolar dead
space). In a patient receiving positive end-expiratory pres-
sure (PEEP), another indicator of correct positioning is an
increase pulmonary capillary wedge pressure less than 50%
of any increase in PEEP. This is so because normal lung and
chest wall compliances are approximately equal at end expi-
ration. Therefore, intrathoracic pressure will increase by 50%
of PEEP, and pulmonary capillary wedge pressure also will
increase by at most 50%. Lung disease (decreased lung com-
pliance generally) will distort this relationship, but almost
always to less than 50%. If the pulmonary capillary wedge
pressure rises more than 50% of the PEEP, repositioning
must be considered.
The pulmonary capillary wedge (pulmonary capillary
occlusion) pressure (PCWP) estimates left ventricular end-
diastolic pressure and thus serves as an estimate of left ven-
tricular preload. Because the pulmonary vasculature is a
low-resistance circuit, the pulmonary artery end-diastolic
pressure in normals is usually only 1–3 mm Hg higher than
the mean pulmonary capillary wedge pressure and has been
used to estimate left ventricular pressure when the pul-
monary capillary wedge pressure is not available—but this is
unreliable and inconsistent in the case of lung disease, pul-
monary hypertension, or tachycardia. Normal values for pul-
monary artery catheter pressures are shown in Figure 8–8.
Pulmonary capillary filtration pressure (Pcap) is a measure
of the potential difference that drives fluid from the pulmonary
vasculature into the perivascular interstitial and alveolar spaces.
The contribution of hydrostatic and osmotic pressure differ-
ences to fluid filtration is described by Starling’s law. The equa-
tion relating mean PA pressure, PCWP, and Pcap is
Pcap = PCWP + 0.4 × (PA – PCWP)
Adult respiratory distress syndrome (ARDS) widens the
PA-to-PCWP gradient and increases Pcap, contributing to
pulmonary edema.
Clinical Applications
A. Pressure Measurements—In most instances, PCWP is
an accurate indicator of left ventricular end-diastolic pres-
sure. Correlation between CVP and PCWP may be poor in
critically ill patients with cardiopulmonary disease because
 Figure 8–9. The effect of airway pressure on the pulmonary vasculature is divided into three zones. A pulmonary
artery flotation catheter should wedge in zone III, where there is a continuous column of blood between the pul-
monary capillary and the left atrium. (Reproduced, with permission, from West JB, Dollery CT, Naimark A: Distribution of
blood flow in isolated lung: Relation to vascular and alveolar pressures. J Appl Physiol 1964;19:713.)
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of differences between right and left ventricular function. In
this group, both absolute values and relative changes in CVP
are unreliable because alterations in the pulmonary vascular
bed affecting the right side of the heart do not equally affect
the left ventricle. This is of particular importance following
pulmonary embolization, which increases right ventricular
afterload without affecting left ventricular end-diastolic
pressure. CVP and pulmonary systolic and diastolic pres-
sures are all elevated, whereas PCWP is decreased because of
the decline in forward flow.
PCWP correlates best with left atrial pressure (LAP) when
the latter is less than 25 mm Hg. However, PCWP will be
lower than LAP in hypovolemic patients, whose pulmonary
vasculature collapses during peak inspiration. When LAP
increases to more than 25 mm Hg—which may occur after
acute myocardial infarction with decreased left ventricular
compliance—PCWP tends to underestimate left-ventricular
end-diastolic pressure (LVEDP). As left ventricular function
deteriorates, the contribution that atrial contraction makes to
left ventricular filling is increased, and LVEDP can be signifi-
cantly higher than PCWP. Several conditions affect the accu-
racy of PCWP as an indicator of LVEDP. In mitral stenosis,
left atrial pressure at end diastole may be significantly higher
than left ventricular pressure. This is diagnosed by the pres-
ence of large v waves on a PCWP tracing. Large left atrial
myxomas also elevate PCWP. Aortic regurgitation produces
an underestimation of LVEDP by PCWP because the mitral
valve closes early despite increasing left ventricular pressure.
Mitral regurgitation results in accentuation of LVEDP
because of backward flow during systole. Pericardial tampon-
ade restricts filling of all four cardiac chambers and results in
an equalization of CVP and PCWP because all such pressures
are under the restrictive influence of the tamponade. Positive
end-expiratory pressure (PEEP) adversely affects the ability of
PCWP to monitor left ventricular preload. High positive air-
way pressures (PEEP >15 mm Hg) can result in pulmonary
vascular collapse, causing PCWP to reflect airway pressure
instead of left atrial pressure (conversion from zone III to
zone I). As with CVP, an esophageal pressure transducer per-
mits calculation of transmural rather than transthoracic pres-
sures. However, because pulmonary compliance is not
disturbed uniformly, the pressure obtained through the
esophageal probe may not correctly reflect the pressure that
surrounds the pericardium.
While PCWP often closely estimates LVEDP, these values
may not accurately reflect true LV preload, which is a func-
tion of LV end-diastolic volume and stretch of myocardium.
Patients with LV hypertrophy, diastolic heart failure, and LV
ischemia have distorted relationships between LVEDP and
ventricular preload. Consequently, a single PCWP measure-
ment may be less helpful than therapeutic trials of volume
loading or diuretics with serial measurements.
B. Mixed Venous Oxygen Saturation—Mixed venous oxy-
gen saturation (S–vO2) is obtained from blood from the pul-
monary artery drawn out of the distal port of the catheter.
Pulmonary artery blood should be withdrawn slowly to
avoid inadvertently pulling “pulmonary capillarized” blood
with a misleadingly higher O2 saturation.
Mixed venous oxygen saturation is an indicator of sys-
temic oxygen utilization. Normally, peripheral oxygen con-
sumption (
.
VO2) is independent of oxygen delivery (DO2).
Therefore, as cardiac output and oxygen delivery decline,
peripheral oxygen extraction increases to keep consumption
constant. This results in decreased mixed venous oxygen sat-
uration. Conversely, sepsis may cause a reduction in periph-
eral oxygen consumption, thereby increasing mixed venous
oxygen saturation.
The partial pressure of oxygen in mixed venous blood is
normally about 40 mm Hg, resulting in a hemoglobin satu-
ration of 75%. Oxygen content can be calculated for both
arterial and venous hemoglobin saturations (%Sat Hb) using
the following formula:
CXO2 = 1.34 × Hb × %Sat + (0.0031 × PXO2)
If hemoglobin concentration is in grams per deciliter,
oxygen content is expressed in milliliters per deciliter.
Dissolved oxygen (0.0031 × PO2) contributes minimally to
oxygen content but may become significant in patients who
are profoundly anemic. The normal arteriovenous oxygen
content difference—C(a–v)O2—is 5 mL/dL. Hypovolemia and
cardiogenic shock both increase the difference (>7 mL/dL),
whereas sepsis decreases it (<3 mL/dL). Left-to-right intrac-
ardiac shunts produce a significant step-up in hemoglobin
saturation in the right ventricle and therefore decrease the
C(a–v)O2 gradient.
Mixed venous saturation can be obtained continuously
from pulmonary artery catheters with integral fiberoptic
oximetry capabilities. Dual oximetry combines mixed
venous and arterial pulse oximetry (SpaO2) to provide con-
tinuous estimates of oxygen extraction and intrapulmonary
shunting. From continuous oximetry data, the ventilation-
perfusion index (
.
V/
.
QI) can be calculated by the following
equation:
where PAO2 is alveolar oxygen tension, calculated from the
alveolar gas equation.
.
V/
.
QI correlates well with shunt (
.
Qs/
.
Qt)
over a wide range of parameters and clinical conditions.
C. Complications—Complications of pulmonary arterial
catheterization may occur both on insertion and subse-
quently. The incidence of a pneumothorax with either the
subclavian or internal jugular approach is 2–3%. Catheter
knotting is related to the size of the catheter and the insertion
length. Smaller catheters knot more frequently, as do those
with excessive redundancy in the ventricle. The incidence of
catheter-induced transient right bundle branch block is
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between 0.1% and 0.6% and is thought to be caused by direct
trauma to the bundle of His. The incidence increases to as
high as 23% in patients with preexisting left bundle branch
block. Ventricular arrhythmias also may occur, although they
are usually transient and do not require treatment. Other
complications that may occur during insertion include tra-
cheal laceration, innominate artery injury, and bleeding.
Pulmonary artery rupture may occur at the time of place-
ment, as a result of laceration by the catheter tip, or subse-
quently, from overinflation of the balloon in the distal
pulmonary artery. The overall incidence of rupture is sub-
stantially less than 1%. Contributory factors include distal
position of the catheter, decreased vessel diameter (primary
pulmonary hypertension), systemic anticoagulation, and
prolonged balloon inflation. Hemoptysis is usually the pre-
senting sign. The need for complete removal of the catheter
is debatable because the requirements for monitoring are
compounded by the complication. The catheter should be
withdrawn to a more proximal site and the patient posi-
tioned with the affected side down to optimize ventilation-
perfusion relationships. Emergency thoracotomy is required
in rare cases when uncontrolled bleeding occurs.
Air embolism occurs most commonly with tubing
changes and transducer calibrations. Approximately 20 mL/s
of air is required in adults before symptoms appear, with
75 mL/s required to produce hemodynamic collapse and
death. The precipitating cause is mechanical obstruction of
right ventricular outflow by the air embolus. Patients should
be placed in the left decubitus and steep Trendelenburg posi-
tion. This puts the outflow tract in a dependent location and
allows the air to rise in the ventricle. Aspiration of air through
the pulmonary artery catheter has been reported with varying
results. Obstruction of the pulmonary vasculature by the
embolus results in hypoxemia, increased pulmonary artery
pressure, and right ventricular dysfunction. Passage of air
through a patent foramen ovale may cause cerebral emboliza-
tion and stroke.
Thromboemboli may originate from the tip or body of
the catheter and can result in pulmonary emboli. Catheters
left in place for long periods may cause subclavian or jugular
venous thrombosis. Other complications include infective
endocarditis, sepsis, aseptic thrombotic endocarditis, and
rupture of the chordae tendineae.
The avoidance of sepsis from pulmonary arterial
catheters is identical to the protocols for central venous
catheters. Daily sterile catheter care, dressing changes, and
regular rotation of insertion sites are critical to minimize
catheter-related infections.
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 Cardiac Output
The bedside technique of measuring cardiac output by ther-
modilution added a new dimension to ICU monitoring.
When a known quantity of hot (or cold) solution (indicator)
is injected into the circulation, a time-temperature curve
may be produced that allows calculation of flow. The area
under the time-temperature curve is inversely proportional
to cardiac output. This is calculated using the Stewart-
Hamilton indicator dilution equation:
where VI is the volume of injectate (mL) and TB, TI, SI, SB, CB,
and CI are temperature, specific gravity, and specific heat of
blood (B) and indicator (I), respectively.
Either iced or room-temperature thermal boluses can be
used, although the use of iced fluid slightly improves the
signal-to-noise ratio. Room-temperature boluses generally
are adequate except when cardiac output is very low. For best
results, the difference between the blood’s temperature and
that of the injectate should be at least 12°C, which is easily
achieved with room-temperature injectate. Bolus injection
speed and warming of the indicator as it passes through the
catheter have only minimal effects (±3%). When technique is
optimal, measurement repeatability is within 10%. Severe
cardiac arrhythmias may reduce repeatability and yield
results that may not accurately reflect average cardiac output.
Timing of injection with a particular phase of respiration
(end expiration) improves consistency of measurements.
Excessive patient movement also may produce erratic results.
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Continuous thermodilution cardiac output measure-
ments can be obtained using special pulmonary artery
catheters. In one type, the right ventricular segment of the
catheter warms the blood by a small amount above body
temperature. A sensitive downstream thermistor records the
change in temperature. In another type, blood flow is esti-
mated by how much electric current is needed to maintain a
segment of the catheter at a temperature slightly above body
temperature. Blood flow is directly related, but in a complex
manner, to the amount of energy needed for a constant tem-
perature. These methods correlate well with conventional
bolus thermodilution but may differ in systematic or nonsys-
tematic fashion.
Other Methods to Measure Cardiac Output
A. Indicator Dilution Cardiac Output—This technique
relies on dilution of a colored dye. A bolus of dye is injected
intravenously through a central venous catheter while
peripheral arterial blood is withdrawn. The arterial sample is
continuously passed through a densitometer. The area under
the dye curve is calculated, and a modification of the
Stewart-Hamilton equation is applied. This techniques is
rarely used in the ICU.
B. Doppler Ultrasound—Doppler devices measure ascend-
ing aortic flow and calculate cardiac output. A continuous-
wave Doppler probe is placed in the sternal notch to measure
the velocity of aortic blood flow. A separate A-mode pulsed
Doppler probe is centered in the third or fourth anterior
intercostal space to measure the cross-sectional diameter of
the aortic root. The stroke volume is the product of the
cross-sectional area and the average blood velocity. Cardiac
output is calculated by multiplying the heart rate and the
stroke volume. Potential sources of error include (1) mis-
alignment of the Doppler beam, which produces errors in
measurement of blood velocity, (2) the assumption that the
aorta is circular, and (3) the assumption that aortic blood
flow is laminar. Each of these factors accounts for a cardiac
output error that approaches 15% when compared with
determinations obtained by other means. The difference
between suprasternal Doppler ultrasound cardiac output
and standard thermodilution has been reported to range
from –4.9 to +5.8 L/min. An esophageal probe is now avail-
able that measures descending aortic flow. An insertion
depth of about 30 cm is required to reach the esophageal
“window.” The aortic root is sized using an A-mode pulsed
Doppler, and a single measurement of ascending aortic flow
is performed with a continuous-mode suprasternal probe.
The esophageal probe is then calibrated against the cardiac
output obtained by the suprasternal technique. This method
yields results as good as those obtained with the suprasternal
technique and offers the added advantage of providing data
continuously. A recently developed transtracheal probe uses
a pulsed Doppler probe attached to the distal end of an endo-
tracheal tube. Controlled studies have shown good accuracy,
but extensive clinical experience is wanting.
C. Thoracic Bioimpedance—This noninvasive technique
measures stroke volume by passing a small alternating cur-
rent (2.5–4.0 mA) through the chest at radiofrequency
70–100 kHz. Four pairs of electrodes (one transmitter and
one sensor) are required. Two pairs are placed at the base of
the neck and two at the level of the xiphoid process in the
midcoronal plane. The change in thoracic impedance is due
to blood flow, ventilation, and body movement. Respiratory
variations occur much more slowly than those associated
with blood flow and can be eliminated by the computer algo-
rithm. Similarly, motion artifacts can be rejected by special
circuitry. The majority of systolic blood flow is due to pul-
satile blood flow in the descending thoracic aorta. Stroke vol-
ume is obtained by analyzing the impedance change over a
cardiac cycle. Heart rate is determined at the same time and
multiplied by stroke volume to yield cardiac output. Other
parameters obtained include ejection velocity index, thoracic
fluid index, and ventricular ejection time. The thoracic fluid
index is thought to correlate with extravascular lung water,
whereas ejection time has been used as a parameter of car-
diac function.
Because bioimpedance cardiac output measurements are
noninvasive, they can be repeated frequently. The volume of
electrically participating tissue (VEPT) is critical in determi-
nation of the stroke volume. Although changes in body habi-
tus are included in the nomogram used to calculate VEPT,
small changes can produce significant error. Similarly, elec-
trode placement is important. A 2-cm change in the distance
between the sensing electrodes will produce a 20% variation
in recorded cardiac output. Overall correlation with ther-
modilution in adults has been only fair. The method is fur-
ther limited by inaccuracies caused by dysrhythmias.
Furthermore, readings are difficult during patient move-
ment, including shivering. Cardiac output is overestimated
when preload is reduced; in low-flow states, when inotropes
are required; and with aortic insufficiency. Underestimation
is produced by hyperdynamic sepsis, hypertension, and
intracardiac shunts.
D. Fick Method—Cardiac output may be calculated by relat-
ing oxygen consumption to arterial and mixed venous oxy-
gen saturation using Fick’s equation:
Calculation of cardiac output using Fick’s equation is the
reference with which all other techniques are compared. The
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arteriovenous oxygen content difference requires that a pul-
monary artery catheter be placed to obtain mixed venous
blood. Oxygen consumption is calculated by measuring the
oxygen content difference between inspired and exhaled gas.
A modification of this technique substitutes mixed venous
CO2 (rebreathing), arterial PCO2, and expired volume of CO2
for the corresponding oxygen values in the Fick equation.
E. Pulse Waveform Analysis—A noninvasive method that
shows some promise despite varying reported accuracy uses
algorithmic analysis of the arterial pulse waveform. The
waveform bears a certain relationship with stroke volume
but is modified a great deal by the capacitance, impedance,
and other characteristics of upstream and downstream arte-
rial beds. The aortic impedance plays a major role in this
relationship and is likely to differ between patients. Thus
“calibration” of a noninvasive system (or one using an arte-
rial catheter) using the arterial waveform with thermodilu-
tion cardiac output has been necessary. Recently, several
commercially available systems have been reported to have
adequate agreement with conventional measurements.
Sources of Error
Use of correct temperatures and volumes is the most impor-
tant factor contributing to accurate thermodilution cardiac
output results. If the amount of indicator injected is less than
the amount used in calculation, the fall in indicator temper-
ature will be less than anticipated, and the cardiac output
will be falsely elevated. Cardiac output also will be falsely
elevated if the injectate is warmer than that used in the cal-
culation. The latter problem has been largely overcome with
the introduction of new cardiac output computers that
measure the injectate’s temperature and automatically enter
the value into the calculation.
Right-to-left intracardiac shunt will result in loss of the
indicator, causing a falsely elevated cardiac output. Left-to-
right shunts permit recirculation of indicator that has
already passed through the lungs. This produces multiple
peaks in the time-temperature curve that cannot be inter-
preted by the cardiac output computer, resulting in a bad
curve alert. When tricuspid regurgitation occurs, blood and
indicator mix, resulting in prolongation of transit time. The
curve produced has a slow upstroke and decay, thereby
increasing the area underneath it. This causes sporadic read-
ings and underestimation of the true cardiac output.
Derived Parameters 
Cardiac output measurements may be combined with sys-
temic arterial, venous, and pulmonary artery pressure deter-
minations to calculate a number of hemodynamic variables
useful in assessing the overall hemodynamic status of the
patient (Table 8–1). Oxygen transport parameters also may
be calculated (see below).
Cholley BP, Payen D: Noninvasive techniques for measurements of
cardiac output. Curr Opin Crit Care 2005;11:424–9. [PMID:
16175028]
 Pulse Oximetry
Pulse oximetry affords a noninvasive estimate of arterial oxy-
gen saturation using the change in light absorption across a
Table 8–1. Hemodynamic calculations and normal ranges.
Formula Normal Range
Stroke volume, mL 60–90 ml
Stroke volume index, mL/m2 30–65 ml
Cardiac index, L/min/m2 2.8–4.2 L/min/m2
Systemic vascular resistance, dyne-s/cm5 1200–1500 dyn-s/cm5
Pulmonary vascular resistance, dyne-s/cm5 100–300 dyn-s/cm5
CO = cardiac output; BSA = body surface area; BP = systemic blood pressure; CVP = central venous pressure; PAP = pul-
monary artery pressure; PAWP = pulmonary artery wedge pressure.
1000 × CO (L/min)
HR (beats/min) 
Stroke volume (mL/beat)
BSA (m2)
CO (L/min)
BSA (m2)
[Mean BP (mm Hg) – CVP (mm Hg)] 
× 80
CO (L/min)
[Mean PAP (mm Hg) – PAWP (mm Hg)] 
× 80
CO (L/min)
 CHAPTER 8202
vascular bed during the arterial pulse. In the ICU, pulse
oximetry has important uses and has become a standard of
care in many institutions. There are, however, a number of
issues that should be understood and considered with this
monitoring technique. In particular, the reliability of this
method may be limited in patients with severe hypoxemia,
abnormal arterial pulsations, and hypoperfusion of the site
of measurement.
When light of a particular wavelength is transmitted
through a clear solvent containing solute that absorbs light at
that wavelength, the amount of light absorbed is the product
of solute concentration, path length, and the extinction coef-
ficient (determined by the solute and the wavelength). For a
hemoglobin solution, the relative concentrations of oxy- and
deoxyhemoglobin can be determined in a spectrophotome-
ter because the extinction coefficients are different for these
two hemoglobin species at certain wavelengths.
Pulse oximetry uses the beat-to-beat changes in light
absorption through a vascular bed to estimate arterial O2 sat-
uration, discarding any nonvariable light absorption by con-
sidering only the difference between peak and nadir light
intensities. The method determines O2 saturation by a com-
plex calculation that includes several important assump-
tions. With the use of two light-emitting diodes (LEDs)
producing light in the red and infrared ranges, pulse oxime-
try is able to estimate oxyhemoglobin as a proportion of the
sum of oxyhemoglobin plus deoxyhemoglobin—the so-
called functional oxyhemoglobin saturation. Pulse oximeters
are “calibrated” by comparison of arterial blood oxygen sat-
uration in volunteers to calculated values; the devices use a
“look-up table” to translate the measured proportion to the
displayed saturation. Pulse oximetry is subject to artifact-
caused errors. Movement of the oximeter probe, extraneous
incident light (especially if pulsatile), variations in arterial
pulsation, dependent position, venous pulsations, and other
factors may result in incorrect O2 saturation readings. Pulse
oximeters are most commonly transmission pulse oximeters,
in which light is passed through tissue (ear or fingertip) to a
sensor on the opposite side, but they may be reflectance pulse
oximeters, in which light passes through tissue but is
reflected back to a sensor on the same side as the light source.
Validity
The accuracy of pulse oximetry is generally considered good
in the range of normoxia to mild hypoxemia. However, accu-
racy may be suspect during more severe hypoxemia, such as
when arterial O2 saturation is below 75%. In this range, dif-
ferences between measured O2 saturation and pulse oximetry
saturation range from 5–12%.
A. Patient Factors—Patients in the ICU frequently have
hypotension, poor distal extremity perfusion, and impaired
oxygen delivery—or are being given pharmacologic vasopres-
sors or vasodilators. These factors affect blood flow to the site
of pulse oximetry and vary the contour and intensity of the
beat-to-beat pulse used to calculate O2 saturation. Most
devices are programmed to avoid reporting O2 saturation
when low perfusion or a poor pulse signal is being measured.
In some of the few studies considering these issues in the ICU,
failure of the pulse oximeter to measure O2 saturation was not
infrequent in patients with hemodynamic instability
(12–15%). However, other studies have demonstrated that
some pulse oximeters continue to measure and report O2 sat-
uration despite very poor blood flow and severe hypotension.
These results may not be reliable, and there is concern that
pulse oximeter O2 saturation under these conditions may be
misleadingly high. Pulse oximeter technology continues to
evolve. The latest-generation devices have improved resist-
ance to motion artifact and low perfusion. These are expected
to be more reliable and accurate in the ICU setting.
B. Abnormal Hemoglobins—The pulse oximeter cannot
measure carboxyhemoglobin nor accurately measure oxyhe-
moglobin in the presence of carboxyhemoglobin. The oxy-
gen saturation displayed is essentially equal to the difference
between total hemoglobin and deoxygenated hemoglobin
(100% – the percentage of deoxyhemoglobin), but the relative
concentrations of oxy- and carboxyhemoglobin are
unknown. Other substances in the blood may or may not
affect pulse oximetry. Bilirubin has little effect on pulse
oximetry; methemoglobin, generated in the presence of oxi-
dizing agents such as nitrites and sulfonamides, usually
increases the difference between functional O2 saturation and
oxyhemoglobin, but a sufficiently high methemoglobin con-
centration also may have the peculiar effect of causing the
pulse oximeter to read 85% regardless of other conditions. A
number of dyes such as indocyanine green and methylene
blue also have effects on the accuracy of measurement.
Clinical Applications
Pulse oximetry has widespread usefulness in the ICU, espe-
cially in adjusting inspired oxygen, during weaning from
mechanical ventilation, and in testing different levels of
PEEP, inverse I:E ratio, or other mechanical ventilator adjust-
ments. Other uses include monitoring during procedures
such as bronchoscopy, gastrointestinal endoscopy, cardiover-
sion, hemodialysis, and radiography. Pulse oximetry is par-
ticularly accurate in following O2 saturation in patients who
have mild to moderate hypoxemia (O2 saturation >75%) but
without severe hypoperfusion or hypotension. It cannot be
regarded as a complete substitute for arterial blood gas deter-
minations partly because of the lack of PO2 and pH determi-
nations but also because of the relationship between PO2 and
O2 saturation when the latter is above 90–95%. Results of
pulse oximetry should be interpreted cautiously in patients
with carboxyhemoglobinemia or methemoglobinemia.
Keogh BF, Kopotic RJ: Recent findings in the use of reflectance
oximetry: A critical review. Curr Opin Anaesthesiol
2005;18:649–54. [PMID: 16534307]
McMorrow RC, Mythen MG: Pulse oximetry. Curr Opin Crit Care
2006;12:269–71. [PMID: 16672788]
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 Airway CO2 Monitoring
A disposable colorimetric device that detects CO2 can con-
firm endotracheal tube placement and position. When the
device tests positively for CO2, this confirms that the endo-
tracheal tube is in the trachea. However, a negative result is
not as reliable, and alternative means for checking tube
placement must be used.
Continuous airway CO2 monitoring uses a rapidly
responding infrared CO2 analyzer. Capnography is a continu-
ous display or recording of CO2 concentration during each
breath. Other devices may display the end-tidal CO2 fraction
or partial pressure (PETCO2).
The infrared analyzer uses an appropriate wavelength of
infrared light for which the CO2 concentration is propor-
tionate to the absorption of the light. It has the advantage of
relatively low cost, real-time sampling, reliability, ease of cal-
ibration, and acceptable response time.
Capnography shows a continuous display of expired and, if
desired, inspired CO2 concentration or partial pressure. The
expired CO2 waveform can give a qualitative assessment of the
degree of ventilation-perfusion mismatching. For example,
the steepness of the slope of the “alveolar plateau” indicates
more severe 
.
V/
.
Q mismatching because it demonstrates empty-
ing of progressively less well ventilated lung units compared
with a waveform showing a flatter alveolar plateau in a patient
with less severe 
.
V/
.
Q mismatching. The inspiratory segment
also should be inspected to confirm that the inspired gas is free
of CO2 as a result of malfunction of the ventilator’s expiratory
valve or some other component.
End-Tidal and Mixed Expired PCO2
In normal subjects at rest and breathing at a normal tidal vol-
ume and respiratory rate, PETCO2 is close numerically to arte-
rial PCO2, with the usual difference between PaCO2 and
PETCO2 0–4 mm Hg (P[a–ET]CO2). In patients with respira-
tory failure, contribution to expired gas from dead space and
high 
.
V/
.
Q lung units decreases CO2 concentration during
expiration and at end expiration. The P(a–ET)CO2 becomes
increasingly large, with a strong correlation between
P(a–ET)CO2 and the dead space–tidal volume ratio. The
PETCO2 should not be used as a substitute for PaCO2 in
patients with lung disease. Furthermore, P(a–ET)CO2 cannot
be assumed to remain constant in the face of lung disease
and mechanical ventilation.
The mixed expired CO2 fraction or partial pressure (P
–ECO2)
is usually determined from collection of expired gas for several
minutes. This should be distinguished from PETCO2 sampled at
the end of a single breath. The mixed expired CO2 fraction can
be used with PaCO2 to calculate the dead space–tidal volume
ratio (VD/VT) using the modified Bohr equation:
In addition, if minute ventilation is measured,
where PB is barometric pressure.
Volumetric Capnography
Capnography records CO2 concentration against time dur-
ing expiration. If CO2 is plotted against expired volume, then
a semiquantative estimate of dead space:tidal volume ratio is
obtained. Equipment for doing volumetric capnography can
be built into mechanical ventilators. Volumetric capnogra-
phy has been used to help diagnose pulmonary embolism
and theoretically should be applicable to other situations
where dead space:tidal volume ratio is useful (eg, weaning,
ARDS, and asthma).
Validity
As described earlier, end-tidal PCO2 should not be used as an
accurate estimate of PaCO2. Patients with either worsening of
gas exchange function (increased PaCO2) or improvement in
function (decreased PaCO2) can have a fall in PETCO2. The
former occurs because of an increase in P(a–ET)CO2; the lat-
ter represents a parallel fall in both PETCO2 and PaCO2.
However, among the relatively few reports involving ICU
patients—most of whom were receiving mechanical ventila-
tion—some indicate that PaCO2 and PETCO2 track together rel-
atively well, with mean differences less than 5 mm Hg and no
change in difference during weaning or extubation. In COPD
patients, the difference was considerably higher (as much as 9
mm Hg) but, again, relatively constant. In contrast, other stud-
ies have found that P(a–ET)CO2 varies considerably, and while
there was correlation with VD/VT, there was a lack of a con-
stant value for P(a–ET)CO2 that would allow “tracking” of
PaCO2 from PETCO2 alone. In particular, one study demon-
strated that both increases and decreases in P(a–ET)CO2 may
result from mechanical ventilator adjustments.
Clinical Applications
Airway CO2 monitoring has the advantage of being nonin-
vasive, and studies are available that indicate a decrease in
the number of arterial blood gases obtained when this
modality is used. However, it is clear that the critically ill
patient with respiratory failure will have the largest and
most unpredictable difference between PaCO2 and PETCO2;
in these patients, PETCO2 is an unreliable estimate of PaCO2.
On the other hand, the difference between PaCO2 and
PETCO2 can be used as a measure of dead space:tidal volume
ratio and therefore as a measure of the severity of gas
exchange derangement.
Although studies are lacking on the benefit of routine mon-
itoring of airway CO2, capnography and PETCO2 monitoring
V L/min STPD V L/min, BTPS
P
CO E
2
0 826( ,  ) .  ( )= × ×
ECO
B
2
P
V
V
Pa P
Pa
D
T
CO ECO
CO
=
−
2 2
2
 CHAPTER 8204
have been used in several clinical situations. First, airway CO2
monitoring can provide rapid noninvasive assurance of correct
endotracheal tube placement. The capnogram should show
increasing CO2 concentration during expiration, and PETCO2
should be a plausible value. Second, PETCO2 has been used dur-
ing cardiopulmonary resuscitation as a measure of the effec-
tiveness of artificial circulatory assistance; a very low PETCO2
suggests that venous blood is not adequately returning to the
central circulation. Third, the combination of arterial and end-
tidal PCO2 provides an estimate of the inefficiency of ventila-
tion (VD/VT). Some researchers have suggested that
P(a–ET)CO2 can be used to titrate the optimal amount of PEEP.
While the smallest difference in P(a–ET)CO2 has correlated with
the highest degree of tissue oxygen delivery, this measurement
has not proved ideal in all studies. Finally, it has been suggested
that capnography can help in weaning patients from mechani-
cal ventilation, but the predictive value of airway CO2 monitor-
ing in this clinical situation is unclear.
Belpomme V et al: Correlation of arterial PCO2 and PETCO2 in pre-
hospital controlled ventilation. Am J Emerg Med 2005;
23:852–9. [PMID: 16291440]
Kallet RH et al: Accuracy of physiologic dead space measure-
ments in patients with acute respiratory distress syndrome
using volumetric capnography: Comparison with the meta-
bolic monitor method. Respir Care 2005;50:462–7. [PMID:
15807908]
Moon SW et al: Arterial minus end-tidal CO2 as a prognostic fac-
tor of hospital survival in patients resuscitated from cardiac
arrest. Resuscitation 2007;72:219–25. [PMID: 17101205]
Verschuren F et al: Volumetric capnography as a screening test for
pulmonary embolism in the emergency department. Chest
2004;125:841–50. [PMID: 16117730]
 Transcutaneous Blood Gases
Using transcutaneous blood gas monitors, partial pressures
of oxygen and carbon dioxide may be measured in the tissue
beneath heated skin electrodes. This monitoring technique
has value because it reflects tissue levels, but it cannot yet be
employed as a substitute for blood gas monitoring.
Principle
The Clark electrode, similar to that used in blood gas analyz-
ers, has been modified to be used on the skin surface. The
skin in the area of the electrode is heated to 43–45°C. This
heating is necessary to make the skin permeable to oxygen,
but it has the additional effect of increasing perfusion in the
tissues beneath the probe. Since transcutaneous PO2 (PtcO2)
reflects the oxygen tension level of the tissue beneath the
probe, values may be affected either by arterial oxygenation
or by systemic and regional perfusion. At relatively normal
cardiac output and with normal regional blood flow, PtcO2
values reflect arterial PO2 values. In adults, the ratio of
transcutaneous-to-arterial PO2 is normally about 0.8,
whereas in children it tends to be higher. (Values in neonates
may be very close to equal.) However, when either cardiac
output or regional perfusion is decreased, the ratio of
transcutaneous-to-arterial PO2 is decreased in proportion to
the level of decreased perfusion. Hence transcutaneous oxy-
gen monitoring may be used as a monitor of both oxygena-
tion and perfusion. A low PtcO2 value is an indicator that the
patient is either hypoxemic or in a low-flow state (or has
reduced regional perfusion).
Transcutaneous PCO2 (PtcCO2) has been measured using
a modified PCO2 electrode attached to the skin surface. In
contrast to PtcO2, however, CO2 is more soluble than O2, so
tissue stores of CO2 act as a buffer, reducing the dependence
of PtcCO2 on blood flow and metabolism. In theory, PtcCO2
should mirror PaCO2 more closely than PtcO2 reflects PaO2,
and there is no need to heat the skin at the monitoring site.
Newly designed sensors with heaters have been studied
recently. Results have been variable.
Both PtcO2 and PtcCO2 devices should be calibrated
against known PO2 and PCO2. Because of the heating of the
PtcO2 electrode site, the location must be changed every 4–6
hours to minimize the risk of thermal injury.
Clinical Applications
Many neonatal ICUs routinely employ PtcO2 monitoring and
have found good correlation with arterial blood gases except in
patients with severe cardiac compromise. In adults, PtcO2
measurement is best used as a measure of tissue hypoperfusion.
A reduction of PtcO2 may be an early indicator of low flow, par-
ticularly if pulse oximetry does not indicate severe hypoxemia.
Kagawa S, Severinghaus JW: Errors in monitoring transcutaneous
PCO2 on the ear. Crit Care Med 2005;33:2414–5. [PMID:
16215403]
Kagawa S et al: Initial transcutaneous PCO2 overshoot with ear
probe at 42ºC. J Clin Monit Comput 2004;18:343–5. [PMID:
15957625]
 Respiratory Mechanics
Measured parameters are tidal volume, vital capacity, airway
pressure, and intrathoracic pressure. From these, respiratory
system and lung compliance, airway resistance, and work of
breathing can be estimated. Modern mechanical ventilators
often are equipped to measure airway pressure, tidal volume,
inspiratory flow, and other derived values. They may be able
to display in real time flow-volume or pressure-volume
loops. A discussion of respiratory compliance and resistance
is found in Chapter 12.
Tidal Volume
In the ICU, tidal volume is measured most commonly in
patients who have endotracheal tubes and require mechanical
ventilation. Respiratory inductive plethysmography provides
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a noninvasive estimate of tidal volume. Tidal volume should
be monitored frequently in patients receiving mechanical
ventilation. When volume-preset modes are used, a difference
in expired volume compared with preset volume indicates
that there is a leak in the ventilator circuit, that inspiratory
flow demand is extremely high, or that inspiratory peak pres-
sure exceeds the preset limit. In pressure-controlled ventila-
tion, tidal volume is used to adjust the level of set airway
pressure, and any change in expired tidal volume indicates a
change in lung or chest wall compliance or airway resistance.
During spontaneous respiration, tidal volume monitoring
using noninvasive measurement can be employed to help
identify patients with obstructive sleep apnea or abnormal
breathing patterns (Cheyne-Stokes respiration).
Maximum Inspiratory and Expiratory Airway
Pressure
Inspiratory and expiratory maximum pressures are deter-
mined by a manometer connected either to a mouthpiece or
to tubing adapted to fit onto the endotracheal tube. These
pressures are measured correctly starting at functional resid-
ual volume so that lung and chest wall elastic recoils are
neutralized, and the pressures reflect only respiratory mus-
cle strength. In practice, this detail is often omitted. Normal
maximum inspiratory pressure is more than –80 to –100 cm
H2O; maximum expiratory pressure in normal individuals
exceeds 120–150 cm H2O. Maximum negative inspiratory
and positive expiratory pressures are useful in assessment of
respiratory failure in patients with neuromuscular disor-
ders. Studies support the use either of the average of maxi-
mum inspiratory and expiratory pressures or of vital
capacity in roughly predicting the onset of hypercapnia in
these patients when pressures fall by about 70% or when
vital capacity is less than about 55% of predicted. These
direct measures are notably better than extrapolations of
respiratory muscle strength from measurements of the
strength of the extremities.
Intrathoracic (Intraesophageal) Pressure
Intrathoracic pressure requires a pressure sensor within the
chest—almost always a balloon placed in the lower third of the
esophagus and connected to a suitable manometer. The bal-
loon must be filled carefully with a small amount of air so that
the changes in intrathoracic pressure are faithfully recorded
without the confounding effects of the balloon’s compliance.
Care must be taken to position the balloon within the chest
and not in the stomach. Systems for measuring esophageal
pressure are available commercially. Esophageal pressure is
used most often to determine lung or chest wall compliance or
work of breathing, but it also can be helpful in identifying
auto-PEEP. A potential use is to “correct” pulmonary artery or
pulmonary artery wedge pressures for large swings in
intrathoracic pressure during the respiratory cycle.
Lung and Chest Wall Compliance
Calculation of compliance of the respiratory system (chest
wall and lungs together) is reviewed in Chapter 12. The com-
ponents of respiratory system compliance can be subdivided
into chest wall and lung compliances. Lung compliance (CL)
is calculated as the ratio of change in volume (ΔV) to change
in pressure (ΔP), where ΔV is usually the tidal volume and
ΔP is the difference between end-inspiratory and end-
expiratory transpulmonary pressure. Transpulmonary pres-
sure is the pressure difference between the pressure in the
airway and the esophageal pressure. Normal lung compliance
is about 200 mL/cm H2O at end-expiratory volume. If chest
wall compliance (CCW) is desired, the formula 1/CRS = 1/CL
+ 1/CCW can be used, where RS is the respiratory system).
Decreased lung compliance has been used as a criterion of
ARDS in some clinical studies but is not usually required for
its clinical diagnosis. Low lung or chest wall compliance sug-
gests increased work of breathing  and could suggest that
weaning would be difficult or inappropriate. On occasion,
abnormal chest wall compliance as a cause of respiratory fail-
ure is not identified unless measured. If low chest wall com-
pliance is found to contribute to respiratory failure, a very
different approach to treatment may be warranted.
Work of Breathing
The work required for breathing is derived from the for-
mula for mechanical work: W = force × distance. For
breathing in which the force is applied over a predeter-
mined volume, substitute pressure for work, and for dis-
tance, substitute change in volume. Thus work of
breathing is the product of ΔP × ΔV. Work of breathing can
be calculated for the patient-ventilator system, with the
result indicating the work being done by the mechanical
ventilator for a particular tidal volume. The same work, of
course, would be done by the patient breathing sponta-
neously, but this is usually not relevant because the patient
is unlikely to breathe at the same rate, tidal volume, and I:E
ratio. For spontaneous breathing, tidal volume should be
measured nonintrusively, and the pressure difference
between end expiration and end inspiration is measured
inside the thorax (esophageal pressure). Thus a setup for
measuring mechanical work of breathing generally meas-
ures tidal volume (noninvasive or through the endotra-
cheal tube) and esophageal pressure.
Work of breathing calculated from tidal volume and
esophageal pressure may underestimate actual work being
performed by a significant amount. Some of the difference
arises from nonuniform expansion of the lung or chest wall
or compression of intrathoracic gas, and the calculation does
not consider the expiratory work of breathing. In practice,
work of breathing is rarely measured for clinical purposes.
Theoretically, increased work of breathing should be a good
predictor of the success of weaning from mechanical ventila-
tion and could provide a guide to maximizing respiratory
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muscle strength, maximizing lung and chest wall compliance,
and minimizing airway resistance. In the area of research in
critically ill patients, work of breathing has been used to
characterize an excessive burden on the respiratory muscles
from high resistance in the ventilator circuit, poorly func-
tioning expiratory and inspiratory valves, development of
auto-PEEP, and other factors.
Bigatello LM, Davignon KR, Stelfox HT: Respiratory mechanics
and ventilator waveforms in the patient with acute lung injury.
Respir Care 2005;50:235–45. [PMID: 15691393]
Durbin CG Jr: Applied respiratory physiology: Use of ventilator
waveforms and mechanics in the management of critically ill
patients. Respir Care 2005;50:287–93. [PMID: 15691397]
Gattinoni L, Eleonora C, Caironi P: Monitoring of pulmonary
mechanics in acute respiratory distress syndrome to titrate ther-
apy. Curr Opin Crit Care 2005;11:252–8. [PMID: 15928475]
Haitsma JJ: Physiology of mechanical ventilation. Crit Care Clin
2007;23:117–34. [PMID: 17368160]
Jonson B: Elastic pressure-volume curves in acute lung injury and
acute respiratory distress syndrome. Intensive Care Med
2005;31:205–12. [PMID: 15605228]
Stahl CA et al: Dynamic versus static respiratory mechanics in
acute lung injury and acute respiratory distress syndrome. Crit
Care Med 2006;34:2090–8. [PMID: 16755254]
 Respired Gas Analysis
Measurement of respired gases includes determination of
CO2 output (
.
VCO2) and O2 uptake (
.
VO2). In the steady state,
these are considered equivalent to CO2 production and O2
consumption. The ratio 
.
VCO2/
.
VO2 is the respiratory gas
exchange ratio, which is equal to the respiratory quotient
(RQ) in the steady state..
VCO2 and
.
VO2 are measured by comparing inspired and
expired gas concentrations of O2 and CO2 and knowing the
inspired or expired minute ventilation. Gas concentrations
are measured using O2 and CO2 analyzers. Oxygen analyzers
measure PO2 using an electrochemical method to generate
current proportionate to PO2. Infrared CO2 analyzers are
highly reliable and accurate. Both inspired and expired gas
concentrations are needed.
The product of mixed expired CO2 fraction (F
–
ECO2) and
expired minute ventilation is  
.
VCO2 (L/min) expressed at stan-
dard temperature and pressure, dry (STPD). For 
.
VO2
(L/min), the calculation is more complex, having to take into
account the inspired oxygen fraction and the small but sig-
nificant difference between inspired and expired minute ven-
tilation owing to the gas exchange ratio.
Automated instruments allow for continuous measure-
ment of
.
VCO2 and
.
VO2 and often report these results in tables
or graphs. Indirect calorimetry uses 
.
VO2 and an estimate of
the substrate mix being used for energy production (RQ) to
estimate the energy expenditure or caloric requirement of
the patient:
.
VO2 and
.
VCO2 also can be measured using the Fick equa-
tion with knowledge of arterial and mixed venous O2 and
CO2 contents (mL/dL or mL/L of blood) and cardiac output
(thermodilution or other technique). For critically ill
patients, this requires a pulmonary artery catheter, and most
commonly it has been an intermittent calculation. However,
with continuous cardiac output technology, continuous
mixed venous oximetry, and arterial pulse oximetry, a con-
tinuously calculated oxygen consumption is now possible.
Validity
Carbon dioxide output (
.
VCO2) determination is generally
satisfactory in the ICU, including patients receiving mechan-
ical ventilation. With high inspired O2, CO2 analyzers require
adjustment according to the manufacturer’s instructions, but
this does not detract from accuracy.
On the other hand,
.
VO2 is calculated most often using the
difference between inspired and expired fraction of O2 and
an adjustment that accounts for the small difference between
inspired and expired minute ventilation. This formula is very
sensitive to inspired O2 concentration, especially when FIO2 >
0.50. In fact, some investigators are suspicious of
.
VO2 deter-
minations from expired gas when FIO2 exceeds 0.21, and
many commercial systems are not reliable when FIO2 is
greater than 0.30–0.40.
Calculation of oxygen consumption by the Fick equation
also has significant inherent inexactness. Intermittent ther-
modilution measurements of cardiac output have signifi-
cant variance, as do measurements of arterial and venous
saturation, as well as hemoglobin. Any errors in these
measurements are increased geometrically during calcula-
tion of oxygen consumption—so-called mathematical cou-
pling. However, the importance of this limitation to the
accuracy of this methodology in clinical practice is a matter
of controversy.
 Clinical Applications
Monitoring of oxygen delivery and oxygen consumption
allows titration of ICU interventions to specific physiologic
end points for individual patients. However, it is not clear
that providing “supranormal” oxygen delivery improves out-
come for critically ill patients with shock, sepsis, trauma, or
hemorrhage. One important exception is during the early
phase of sepsis and septic shock, in which attention to oxy-
gen delivery (assessed using central venous oxygen satura-
tion) increases survival.
Oxygen uptake by indirect calorimetry in the ICU also
may be used to determine metabolic requirements so that
appropriate caloric requirements as well as substrate
kcal/day V (L/min) 1440 min/dayO
2
= ×
                 × + ×(3.82 1.23 RQ) kcal/L VO
2
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utilization may be monitored. There are insufficient out-
come data supporting routine use of indirect calorimetry,
but numerous studies have pointed out that, without direct
measurements, patients are often under- or overfed in com-
parison with their actual needs.
As indicated earlier, precise determination of dead
space:tidal volume ratio requires measurement of expired
CO2 rather than estimation. Respired gas measurements
therefore may be useful in predicting weaning from mechan-
ical ventilation or for estimating prognosis in ARDS or
COPD exacerbations.
Boullata J et al: Accurate determination of energy needs in hospi-
talized patients. J Am Diet Assoc 2007;107:393–401. [PMID:
17324656]
Davis KA et al: Nutritional gain versus financial gain: The role of
metabolic carts in the surgical ICU. J Trauma 2006;61:1436–40.
[PMID: 17159687]
Heyland DK et al: Canadian clinical practice guidelines for nutri-
tion support in mechanically ventilated, critically ill adult
patients. J Parent Ent Nutr 2003;27:355–73. [PMID: 12971736]
Petros S, Engelmann L: Enteral nutrition delivery and energy
expenditure in medical intensive care patients. Clin Nutr
2006;25:51–9. [PMID: 16216393]
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This chapter will describe and discuss interfacility transport
of the critically ill. As technology advances and as fiscal real-
ities increase the incentive to control health care spending,
increased regionalization will result in transport of the criti-
cally ill to the hospital that can best manage the patient.
Lessening the need for duplicate resources by regionalization
of specialized health care services may achieve optimal
patient outcomes at minimal costs. Repatriation of health
plan participants with their primary care providers has led to
a dramatic increase in interfacility transport of persons
requiring hospitalization or extended emergency evaluation.
Management of resource-intensive critical illness in  spe-
cialized regional centers has been shown to improve medical
outcomes and cost-effectiveness. Most studies support the
concept that patient volume in tertiary care centers
(Table 9–1) leads to better patient outcomes because staffs
of these centers maintain high experience and proficiency
levels. With medical evidence strongly supporting regional-
ized medical specialty centers, methods for transport of
patients to these centers must be developed using practices
based on the best scientific and management evidence.
Alter DA et al: Long-term MI outcomes at hospitals with or with-
out on-site revascularization. JAMA 2001;285:2101–8. [PMID:
11311099]
Frankema SP et al: Beneficial effect of helicopter emergency med-
ical services on survival of severely injured patients. Br J Surg
2004;91:1502–6.
Clark DE et al: Evaluating an inclusive trauma system using linked
population-based data. J Trauma 2004;57:501–9. [PMID:
15454794]
 Interhospital Transport
Composition of the Transport Team
Once the referring physician decides that a patient needs
a higher level of care, the mode of transport must be cho-
sen as well as the composition of the transporting crew.
For interfacility transfers, there are no standard guidelines
regarding which patients may be transferred solely with
paramedics, which require a nurse in attendance, and
which require a physician in attendance. Local regulations
may restrict the role of paramedics, who should not, for
example, give medications or manipulate unfamiliar
equipment such as ventilators unless they have docu-
mented evidence of training and competence. The scope of
such training may be limited by the paramedic licensing or
certification board.
There are no national data on overall transport volumes
or team composition within transport systems. Published
guidelines recommend that a minimum of two medically
qualified people in addition to vehicle operators accom-
pany a critically ill patient. The two medical attendant
teams usually consist of combinations of ambulance atten-
dants, emergency medical technicians (EMTs) who receive
100–300 hours of initial education, paramedics who
receive 1000–3000 hours of initial education, respiratory
therapists, critical care technicians, licensed registered
nurses, and physicians. In urban areas, ground transport is
most common; in rural areas, air transport is more often
required because of the distances and the difficulties of
road travel. In most settings, the EMT is the highest-level
care provider on the interfacility transport team, but for
critical care transports, a physician, nurse, or paramedic is
most often  the highest-level provider. EMTs, paramedics,
respiratory therapists, critical care technicians, and nurses
usually have defined scopes of practice in the jurisdiction
where they are licensed. This scope of practice limits what
the individual may or may not do during the transport
process. Many critical care transport programs  that  have
physicians on board transport vehicles are using physi-
cians who are still in training—there is little information
about whether the level of experience of the physicians is a
factor in outcome. Many programs ascribe considerable
value to the presence of physicians; this despite the fact
that only 11% of programs fly with physicians on board.
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Appropriately educated and monitored nonphysicians can
use paralytic pharmacologic agents and perform intuba-
tion, cricothyrotomy, and tube thoracostomy safely; nurses
or respiratory therapists may be more familiar with venti-
lators than a  physician.
Current standards for interfacility transport dictate that
the decision on transport mode and team composition is
based on individual patient requirements for minimization
of transport time and monitoring and anticipated treatment
requirements during transport. For example, a patient who
requires advanced airway monitoring and skills should be
transported in a vehicle with airway monitoring equipment,
accompanied by an individual trained and qualified in
advanced airway management.
Mode of Transport
Current options for mode of transport are the ground ambu-
lance, either a helicopter or a fixed-wing aircraft, and water-
craft. In many urban centers, all options are available, and in
rural areas—Alaska, for example—the airplane is essential.
Decisions that will influence the mode of transport (if all
options are available) include the distance and thus the dura-
tion of transport, the diagnosis and thus the complications
that may arise during transport, the level of training and
techniques the transporting personnel can provide, the
urgency of access to tertiary care, and local weather condi-
tions and geography. In general terms, ground ambulances
are more available than air vehicles; ground ambulances may
be dispatched from a local facility, although an outreach
team from the tertiary care center may be requested; mobi-
lization time of such a team and their arrival will have to be
taken into consideration (Table 9–2).
A. Ground Ambulance—Ground ambulance vehicles are
usually the most readily available and may be categorized as
vehicles for basic life support (BLS) or advanced life support
(ALS). BLS ambulances are most often staffed with two EMTs
and can provide basic first aid, monitoring of vital signs, basic
airway management and intervention, automatic external
defibrillation, monitoring of maintenance intravenous fluid
infusions, and oxygen without cardiac monitoring. ALS
ambulances are staffed with a paramedic, nurse, or physician
as the highest-level provider. ALS ambulance personnel can
provide cardiac monitoring and advanced airway manage-
ment and can deliver the drugs and intravenous fluids com-
monly used for resuscitation and stabilization of medical and
trauma patients. ALS ambulances  must have the necessary
outlets for managing ventilators or balloon pumps for inter-
facility critical transfers. However, if the ambulance belongs
to the local Emergency Medical Services (EMS) jurisdiction,
the administrators may not allow the vehicle to be out of serv-
ice for a long trip to a tertiary center. In many urban areas,
ambulance companies maintain some ALS ambulances for
interfacility transports so that the primary EMS system is not
affected. Ground ambulances are limited by surface condi-
tions or traffic congestion. Equipment used to support
patients during transport should have a backup supply (ie,
batteries or extra oxygen tanks) in case of need. The U.S.
Table 9–1. Medical services most effectively delivered
in specialized referral centers.
Burn injuries 
Trauma  
High-risk blunt and penetrating injuries  
Neurologic injuries 
Vascular injuries 
Complex orthopedic injuries 
Pediatric-age trauma 
Oro-maxillary-facial injuries 
Obstetric, high-risk 
Neonatal care 
Pediatric critical care 
Cardiac 
Invasive coronary revascularization 
High-risk cardiac care 
Cerebrovascular (“stroke”) management
Rehabilitation, intensive
Favoring ground ambulance
Ambulance staffed by critical care team 
Ambulance equipped appropriately
Patient location accessible to ground transport
Ambulance can be spared for use within the local system
Geography allows ground transport 
Favoring helicopter transport
Transport distance 30–180 miles
Important to minimize transport time 
Helicopter staffed by critical care team 
Helicopter equipped appropriately
Patient location and receiving location accessible to helicopter
landing and takeoff
Allowable weather conditions
Patient/equipment weight allows use of available helicopter
Favoring fixed-wing aircraft
Transport distance over 100–150 miles
Important to minimize transport time 
Aircraft staffed by critical care team 
Aircraft equipped appropriately
Patient location and receiving location accessible to an airport
Allowable weather conditions
Patient/equipment weight allows use of available aircraft
Critical care transport available for moving patient to and from
landing sites 
Table 9–2. Factors that favor a specific mode of critical
care transport.
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Department of Transportation (DOT) has published stan-
dards that have been adopted by most states that relate to
minimum ambulance configuration and equipment require-
ments. Communication between the ground ambulance and
the receiving facility or designated medical control center can
be a consideration during  transport. The ground ambulance
is the most widely used and least expensive mode of interfa-
cility transfer. This method should be considered for trans-
port distances of 30 miles or less.
B. Helicopter—Helicopters should be considered for trans-
ports over distances of 30–150 miles. They travel at ground
speeds of 120–180 miles per hour and often are dispatched
from the receiving tertiary facility or urban area emergency
service providers. The physical location of the helicopter at
the time of dispatch is important to consider because an in-
flight round trip to transport a patient may not offer advan-
tages over a one-way trip by an available ground vehicle.
Helicopters usually require a warmup time of 2–3 minutes
before liftoff and—allowing for communication time—can
be launched within 5–6 minutes after the flight request is
received. Medical transport helicopters are usually staffed by
critical care (ALS) crews. Under normal weather conditions,
helicopters can fly point to point and land at accident scenes
or sending facilities; the liftoff capability depends on the type of
helicopter used. Helicopter transports are limited by adverse
weather conditions and available landing sites (often a prob-
lem in densely populated areas). Helicopters are expensive—
the capital cost is between $ 2.5 million and $ 15 million
depending on whether a single- or dual-engine model is
selected; likewise, the number of patients that can be trans-
ported is determined by aircraft selection and configuration.
Helicopters can fly from point to point under visual flight
rules (VFR). In inclement weather, several helicopter pro-
grams can fly under instrument flight rules (IFR). This, how-
ever, requires that they take off and land at an airport with
appropriate instrumentation. Helicopters cannot fly in freez-
ing rain or dense fog.
C. Fixed-Wing Aircraft—Fixed-wing aircraft should be con-
sidered for transport over distances exceeding 100–150 miles.
Fixed-wing aircraft will have IFR capability and can fly from
airport to airport, with ground transportation required at
both ends. Fixed-wing aircraft are less susceptible to adverse
weather in comparison with helicopters. Aircraft cabins nor-
mally are pressurized between 6000 and 8000 feet, and this
may have effects not only on the patient’s clinical condition
but also on apparatus such as endotracheal tubes or Swan-
Ganz catheters; in addition, ventilators may need to be recal-
ibrated. Some patients—for example, those being transferred
to hyperbaric facilities for treatment of decompression
sickness—may require pressurization at ground level. Fixed-
wing aircraft are being used more often as long distant trans-
ports across states and regions occur. Fixed-wing aircraft are
used commonly for international transports. When national
borders are crossed by transport craft, international rules and
national immigration and visa requirements must be met.
D. Watercraft—Watercraft are used rarely for interfacility
critical care transport. In special environments, such as off-
shore islands and oil platforms, watercraft do play a role in
medical transport. The use of watercraft for critical care
transport is usually in a situation where inclement weather
does not allow for helicopter transport. Because of problems
with water damage to electrical equipment and dangers of
staff electrical shock from defibrillators, the monitoring and
ALS activities that can be supported on watercraft are limited.
Liability and Legal Issues
A. Interfacility Transfer—Interfacility transport of patients
received increased legal visibility by the passage in 1986 of
COBRA 1985, Section 9121, Amendments to the Social
Security Law, and Section 1867, Special Responsibilities for
Hospitals in Emergency Cases. These rules have undergone
repeated emendation, and the regulations have been renamed
the Emergency Treatment and Active Labor Act (EMTALA),
further amending Section 1867. Briefly, these laws refer to
emergency transfers of unstable patients and were drafted to
address the problem of transfers of uninsured patients.
Indeed, the EMTALA regulations are often referred to as
“antidumping legislation.” EMTALA provides a framework
of legal liability under which the sending facility is responsi-
ble for initiating the transfer and selecting the mode of trans-
portation (including the level of expertise of transferring
personnel) and thus indirectly the equipment on the trans-
porting vehicle. The sending facility is responsible for ensur-
ing that the receiving facility has space and personnel
available for care of the patient, and the sending physician is
responsible for the risks of transfer and for deciding that the
benefits to the patient following successful transfer outweigh
the risks. A receiving facility that has specialized units such  as
burn units, shock trauma units, cardiac catheterization units,
and neonatal ICUs shall not refuse to accept an appropriate
transfer if that hospital has the capability to treat the individ-
ual. This is a nondiscrimination clause and is an attempt to
prevent receiving facilities from accepting only funded
patients. All emergency critical care and transferring person-
nel should understand the implications of these statutes.
B. Confidentiality—All ambulance and transport providers
who engage in transactions that transmit protected health
information in electronic form  are required to comply with
the U.S. Health Insurance Portability and Accountability Act
(HIPAA). Protected health information includes any infor-
mation identifiable to a specific person that relates to that
individual’s past, present, or future physical or mental health.
HIPAA provides criminal and civil penalties for the improper
use of protected health information, requiring that consent be
given to obtain health information and that safeguards are in
place to protect such information. Records pertaining to the
use and disclosure of protected health information must be
maintained for inspection by appropriate parties.
In addition to the legal requirements of transfer, the
transferring personnel have certain liability concerns—
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particularly if they perform air medical transport. The high
degree of acuteness of these patients and the potential for
adverse outcomes mandate medical malpractice coverage for
the transferring personnel; the premiums will vary according
to the staffing pattern selected. Medical directors also may
need to make certain that they are appropriately covered for
giving offline medical direction and may find that although
some of their responsibilities are covered by medical mal-
practice insurance, directors’ and officers’ insurance may be
needed to cover their management decisions.
Outcome
The data that support the validity of transfer of the critically
ill emphasize five recurring themes:
1. Outcomes of the critically ill in tertiary centers are better
than outcomes in other facilities (matched for severity).
2. Transport of the critically ill does not adversely affect the
patient during transport—and therefore, by implication,
the patient receives the benefit of theme 1.
3. Transport of critically ill patients improves outcome
when compared with national norms.
4. Established systems of care (encompassing critical trans-
port as a component) have societal outcomes better than
those of comparable communities without such a system
and better than those in the same community before the
system was in place.
5. Regionalization of specialized care is cost-effective and
improves utilization of community resources.
An outcome study of all critically injured children with
respiratory failure and head trauma in Oregon for 6 months
compared mortality in 71 nontertiary and 3 tertiary facilities.
Using the pediatric risk of mortality score, the study found
that outcomes in the nontertiary facilities were lower than
those in tertiary facilities—and further, that the difference in
outcome was more pronounced the higher the expected
mortality. For the most critical group (mortality risk >30%),
the odds ratio of dying in a nontertiary versus a tertiary facil-
ity was 8:1. The study concluded that “pediatric survival
from a broad range of disorders might be improved by
regional organization of pediatric care.”
Improved outcome of the critically ill has been related to
the volume of patients. This has been shown for coronary
artery bypass surgery, trauma management, acute cardiac
disease, abdominal aortic aneurysm, and stroke. For exam-
ple, using the Trauma and Injury Severity Score (TRISS)
methodology, it has been shown that rapid transport or
transfer by helicopter of trauma patients to a specialized
trauma center resulted in a 13% reduction in mortality when
compared with the outcome expected from the benchmark
Multiple Trauma Outcome Study database. Studies demon-
strating improved outcomes of the critically ill in regional-
ized specialty centers are in strong support of critical patient
transport systems that facilitate movement of patients to
these centers.
Transfer of the critically ill has been shown to be safe in
cardiac patients, patients with respiratory distress, and pedi-
atric patients. Transfer of patients sustaining acute myocar-
dial infarction by air does not appear to be detrimental to
patient outcome. Currently, critical care regionalization is
becoming more common in developed countries throughout
the world, and  interfacility critical care transport is an essen-
tial component of this move to regionalization.
Thomson DP et al: Guidelines for air medical dispatch. Prehosp
Emerg Care 2003;7:265–71.
De Wing MD et al: Cost-effective use of helicopters for the trans-
portation of patients with burn injuries. J Burn Care Rehabil
2000;21:535.
Pollack NM et al: Improved outcomes from tertiary center pedi-
atric intensive care: A statewide comparison of tertiary and
non-tertiary care facilities. Crit Care Med 1991;19:50.
Post GB: Building the Tower of Babel: Cross-border urgent med-
ical assistance in Belgium, Germany, and the Netherlands.
Prehosp Disaster Med 2004;19:235–44.
Muhm JM: Predicting arterial oxygenation at commercial aircraft
cabin altitudes. Aviat Space Environ Med 2004;75:905–12.
Thomas SH: Helicopter emergency medical services transport out-
comes literature: Annotated review of articles published
2000–2003. Prehosp Emerg Care 2004;8:322–33.
 Equipment & Monitoring
Interfacility critical care transport requires continuous mon-
itoring and clinical management of the patient throughout
the transport environment. The transporting vehicle should
have the necessary power converters for all equipment that
could be needed during a transfer; in addition, much of the
equipment needs battery backup in case of electrical failure
and backup oxygen supply in case of vehicle breakdown. In
cold climates, provision must be made for maintenance of a
warm environment in case of vehicle failure. In 2004, the
American College of Critical Care Medicine, the Society of
Critical Care Medicine, and the American Association of
Critical Care Nurses published a consensus document that
details minimum equipment and medications recommended
for critical care transport units.
Airway Management
Critical care transport often involves patients who require
advanced airway management. Often patients have had an
endotracheal tube placed prior to transport, but transport
team members always must be prepared to reintubate or
establish an advanced airway should the need arise. In addi-
tion to standard endotracheal intubation equipment, a
backup system such as the laryngeal mask or pharyngotra-
cheal lumen tube should be available for those in whom
intubation cannot be accomplished. Emergency transtra-
cheal jet ventilation by means of needle cricothyrotomy and
airway tube placement by cricothyrotomy have been success-
ful in establishing a temporary airway during transport when
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performed by properly trained personnel. The effectiveness
of transtracheal jet ventilation at the higher altitudes encoun-
tered in fixed-wing aircraft is not established. In addition to
advanced airway management, ALS transport crews should
have equipment available for decompression of tension pneu-
mothorax (ie, either needle or chest tube thoracostomy).
Medications
Medication lists have been published for the management of
the obstetric patient, the neonatal patient, the pediatric
patient, and the adult patient during transport. Additional
medications may be required that depend on patient profiles,
and protocols should be prepared for the use of these med-
ications. Care must be taken to ensure that expiration dates
on medications are recognized, and guidelines should be in
place beforehand for authorization to use them. Use of criti-
cal care transport under these circumstances allows a higher
level of pharmacologic intervention—for example, many
flight programs routinely use paralytic agents to facilitate
endotracheal intubation.
The use of thrombolytic agents for acute cardiac and
stroke patients during interfacility transport is controversial.
Observational studies have shown that thrombolytic use
during transport of acute myocardial infarction patients has
acceptable risk profiles, but with cardiac catheterization
becoming a primary reason for transport, interest in trans-
port thrombolytics has decreased.
Blood Utilization
Blood product transfusion during interfacility transport is
controversial. It has been shown that in rotor-wing programs
using flight nurses, the transfusion of blood can be per-
formed safely and is feasible during transport. Use of blood
product transfusions is limited to lengthy transports during
which crystalloid infusion alone will not stabilize a patient.
Use of blood products during transport requires adherence
to strict standard blood transfusion protocols, with blood
administered by properly trained transport personnel.
Ventilators
Several types of ventilators are available for the transport
environment. The choice of ventilator will depend on the
mission profile, compatibility with sponsoring ICUs, and the
preferences of the medical director. Mechanical ventilation of
intubated patients during transport has been shown to be
optimal in comparison with manual ventilation. Food and
Drug Administration (FDA)–approved transport ventilators
have performance indexes comparable with those of ICU
ventilators. Transport ventilators must be monitored contin-
uously during transport and, because of the unique transport
environment, are subject to problems such as power failure
and disconnection. Pressure-controlled ventilators are used
most commonly during transport and in aircraft must be
adjusted to for altitude changes. Most critical care transport
programs  monitor their patients continuously by oximetry
and continuous end-tidal carbon dioxide monitoring; in one
study, continuous oximetry monitoring identified clinically
unrecognized hypoxia.
Monitoring
The ECG, blood pressure, oxygen saturation, and, if neces-
sary, end-tidal carbon dioxide level, pulmonary artery pres-
sure, intraarterial pressure, and intracranial pressure should
be monitored during transport. Successful defibrillation has
been performed during flight, and use of this equipment
does not interfere with other systems on helicopters and
fixed-wing aircraft. If the patient does not have an intraarte-
rial line, occlusion oscillometry or Doppler measurement
will give a satisfactory indication of blood pressure; normal
auscultation of the blood pressure using a sphygmo-
manometer cuff is difficult in the transport environment
because ambient noise may exceed 110 dB.
Medications should be administered by infusion pump
throughout transport to ensure smooth and accurate dosing.
Many small, rugged infusion pumps are available and can be
reprogrammed rapidly to manage unstable patients. In addi-
tion, portable intraaortic balloon pumps and left ventricular
assist devices are now available commercially that weigh less
than 150 lb and can be transported on most ambulances, hel-
icopters, and airplanes.
Warren J et al: Guidelines for the inter- and intrahospital transport
of critically ill patients. Crit Care Med 2004;32:256–62.
Davey AL, Macnab AJ, Green G: Changes in PCO2 during air med-
ical transport of children with closed head injuries. Air Med J
2001;20:27.
Sumida MP et al: Prehospital blood transfusion versus crystalloid
alone in the air medical transport of trauma patients. Air Med J
2000;19:104.
 Education & Training
Crew Composition Decisions
Once the mission profile of the transport program has been
specified, decisions must be made concerning the qualifica-
tions of the personnel. The mission profile also may dictate
the qualifications of the medical director.
Physicians: On- and Offline
In addition to their duties in off-line medical control (eg,
supervising training, development of medical protocols and
standing orders, and quality assurance), physicians must be
available online 24 hours a day (by cellular phone or radio)
to help manage critical situations. Most online medical con-
trol is provided by emergency physicians. These individuals
have experience conveying instruction by radio to para-
medics, are immediately available 24 hours a day, and are
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familiar with radio equipment and the rules and regulations
covering their use. Occasionally, online medical direction
may be obtained through an ICU or from a neonatologist at
a tertiary care facility.
Crew Qualifications
Training modules for all transporting personnel should be
developed in such a way that it is consistent with the policies
and practices of the local emergency medical services and
critical care community. The facilities and the crew should be
subjected to ongoing curriculum development and quality
assurance by the medical director.
A. The Emergency Medical Technician—Emergency med-
ical technicians (EMTs) have completed a course of training
outlined by the DOT and are required to recertify every 2–4
years, usually by means of taking a nationally standardized
skills and knowledge test. EMTs are taught first aid and basic
rescue skills in programs composed of 100–300 contact
hours. EMTs receive training in the basic management of
trauma and medical, pediatric, obstetric, and psychiatric
emergencies. Many EMTs are proficient in the use of auto-
matic external defibrillators. EMTs know basic noninvasive
airway techniques and are often certified to monitor continu-
ous maintenance intravenous infusions. Generally, EMTs do
not have training in cardiac rhythm recognition, intravenous
access, or invasive procedures.
B. The Paramedic—Paramedics have completed a course
curriculum outlined by the DOT and usually are required to
pass a state licensing examination and to seek recertification
every 2 or 4 years. Most U.S. paramedics obtain initial certi-
fication by participating in a nationally recognized testing
program. In the United States, paramedic training programs
vary from 1000–3000 contact hours. Paramedics have knowl-
edge of all emergency situations, including the acute man-
agement of trauma and of cardiac arrhythmias. Under state
or regional guidelines, they usually can perform defibrilla-
tion and are able to recognize and treat lethal dysrhythmias.
They are trained in endotracheal intubation and cricothyro-
tomy, interosseous lines, needle thoracostomy, and transtho-
racic cardiac pacing, although not all of these skills are
sanctioned for performance by paramedics in all states.
Paramedic training corresponds to what is required for
Aeromedical Crew Level 2 personnel by the American
College of Surgeons.
C. The Critical Care Transport RN—A standard curriculum
and certification program for critical care nurses has been
developed by the American Association of Critical Care
Nurses. Schools for flight nursing have been developed, along
with a generally recognized curriculum. In addition to other
nursing skills, transport nurses should be trained to perform
endotracheal intubation, needle thoracostomy, and
cricothyrotomy and to insert and maintain interosseous
lines and central venous lines. They are also expected to be
familiar with the operation of transport ventilators and, if
the mission profile includes intraaortic balloon pumping, the
management of a balloon pumps (although many programs
use pump technicians for this function). They should have
knowledge of the critical care management of obstetric,
neonatal, pediatric, and burn patients as well as cardiac,
CNS, and psychiatric patient management. Transport teams
involved in aerospace medicine should have knowledge
about altitude physiology, aircraft safety, aviation communi-
cations, and emergency aeromedical procedures such as
crash response and survival. Training guidelines have been
developed and are in concert with the suggestions outlined in
the ACS publication cited below.
Adams K et al: Comparison of intubation skills between interfacil-
ity transport team members. Pediatr Emerg Care 2000;16:5.
Committee on Trauma: Resources for Optimal Care of the Injured
Patient. Chicago: American College of Surgeons, 1999.
Jones AE et al: A national survey of the air medical transport of
high-risk obstetric patients. Air Med J 2001;20:17.
 Reimbursement Standards & Costs
Standards
Any medical interfacility aeroground transport vehicle will
have to be licensed by the designating agency as a transfer-
ring ambulance. Ambulance licensing varies considerably
from state to state but may depend on minimal equipment
requirements, staffing availability, staff licensing, and record
keeping. Non-public-sector aeromedical programs also are
required to comply with Federal Aviation Administration
regulations with respect to equipment, qualifications, and
hours of pilot duty. If transport vehicles cross state lines,
licensing of both staff and vehicles in neighboring states may
be required unless an interstate agreement has been reached
covering medical practice and emergency response contin-
gencies. Voluntary standards have been developed by the
Society of Aeromedical Systems, the Commission on
Accreditation of Medical Transport Systems, and the
Commission on Accreditation of Ambulance Services, and
accreditation tracks are available.
Reimbursement
For hospital-based transport teams involving ground ambu-
lances, the sponsoring facilities often support the medical
crew and contract with an ambulance company for the ambu-
lances, drivers, and in some cases the services of paramedical
personnel. Ground ambulance services may be covered by
third-party insurers. A medical necessity form is usually
required justifying the transfer before payment is made.
Helicopter programs  often lease the helicopter together
with pilots, support mechanics, and a backup for service
during scheduled or unscheduled maintenance proce-
dures. Hospital support is provided by the medical crew.
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Most programs bill third-party payers for the transport serv-
ice. Both fixed-wing and helicopter rates and reimbursement
vary widely nationally, and most continue to require support
by sponsoring institutions in order to maintain financial via-
bility. Charges and reimbursements are variable—and
indeed, charge structure may vary from one program to
another because the medical costs such as crew salaries and
equipment may be part of the hospital’s or the flight pro-
gram’s cost base. Third-party payer reimbursement also
varies nationally and usually requires utilization review.
Medicare traditionally reimburses for transport only to the
closest medical facility capable of managing the patient, and
this policy may not be congruent with the emergency med-
ical services plan for the state or region. Medicare reimburse-
ment is made by a prospective payment system similar to
what is used for hospital ambulatory care billing.
Cummings G: Scene disposition and mode of transport following
rural trauma prospective cohort study comparing patient costs.
J Emerg Med 2000;18:349–54.
 Current Controversies & Unresolved Issues
The beneficial and cost-effective use of air transport has been
and remains controversial. Studies now question the use of
more expensive air transport modalities in rural areas. Air
transport is a strong consideration for long-range (>50–60
miles [80.5–96 km]) transport. With regard to intermediate
transport distances of about 50 miles (80.5 km), data are
conflicting with regard to the benefit of air transport versus
ground transport. Recent evidence has shown no advantage
to air transport of trauma or burn patients when there is an
intermediate (80 km) or less transport distance. In urban
areas, a large number of variables determine the risks and
benefits of a particular mode of transport, and because of
population density with resulting loss of landing sites and
safety, ground transport is often preferred.
Chemical restraint for combative or agitated patients has
been reported to be appropriate, particularly during air
transport. Benzodiazepines are used most commonly. As
with opioid analgesic use, patients must be closely monitored
when chemical restraint is used.
Although critical care transport is a common practice,
truly comparative studies that address controversial practices
are not yet available. Because of the nature of transport and
the large number of variables to consider in transport
research, most of the published literature is qualitative and
descriptive. Qualitative research methods are appropriate for
addressing many of the issues of critical care transport and
should be done in conformity with proper research design
techniques.
The role of physician staffing of air transport units has
been questioned in recent literature. While physicians have a
broad skill set that may be an advantage during a long trans-
port, the opportunity and means to fully apply the physician
skill set during transport are severely limited. Further, with
advanced telemetry and telecommunications, physician
input and backup can be readily available.
Garner AA: The role of physician staffing of helicopter emergency
medical services in prehospital trauma response. Emerg Med
Australas 2004;16:318–23.
Berns KS et al: Comparison of air and ground transport of cardiac
patients. Air Med J 2001;20:33–6.
Slater H et al: Helicopter transportation of burn patients. Burns
2002;28:70–2.
Chappell VL et al: Impact of discontinuing a hospital-based air
ambulance service on trauma patient outcomes. J Trauma
2002;52:486–91.
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Ethical, Legal, & Palliative/
End-of-Life Care
Considerations
Paul A. Selecky, MD
Advances in modern medicine have increased the ability of
the physician and the health care team to prolong life by
using a wide variety of life support modalities, including
medications, mechanical devices, and the transplantation of
vital organs. Despite their scientific success, these treatments
can prolong life of a quality that in many cases is not mean-
ingful or rewarding to the patient. The result has been that
the physician and the health care team sometimes must help
their patients make decisions about whether to withhold or
withdraw life support medications or mechanical devices—
and sometimes whether even to withhold basic life support
measures such as nutrition and hydration.
Life support decision making in the ICU often presents
ethical or legal dilemmas that must be resolved by staff and
patients and the patients’ families or surrogates. This chapter
will attempt to review the basic principles that form the eth-
ical framework of the modern practice of medicine. The pur-
pose of this discussion will not be to erect standards of
practice or to give legal advice but to offer a system for apply-
ing ethical principles in an effort to avoid or resolve conflicts.
These principles are also applied in the light of the health
care worker’s personal and professional values, institutional
policies and statutory mandates, and the published state-
ments of professional bodies.
 Ethical Principles
The principles of medical ethics are rooted in religious and
philosophical traditions, which include the absolute values of
good and evil, right and wrong, and that human life is of infi-
nite worth and sanctity. Ethics is the system of principles by
which these beliefs govern our behavior and our interaction
with others. The application of these beliefs may therefore
change over time to adapt to the needs of society, but the
boundaries of the absolute values are maintained.
Four basic ethical principles flowing from these absolute
values strongly influence the practice of medicine, particularly
in critical care medicine. The first is beneficence, which directs
the physician and health care worker to do good, specifically by
restoring health and relieving suffering. This has been a funda-
mental goal of medical practice since the time of Hippocrates
in the fourth century BC, but it is not the only goal.
The ethical companion of beneficence is nonmaleficence,
compelling health care workers first of all to do no harm
(primum non nocere). Nonmaleficence is not merely a corol-
lary of beneficence because these two principles must some-
times be in conflict. For example, it is considered ethically
justified to administer morphine to relieve pain (benefi-
cence) in the terminally ill patient even though the morphine
might increase the risk of death, an act that may violate the
principle of nonmaleficence. This has been described as the
principle of double effect, one act having two opposing effects.
The third ethical principle is autonomy, which dictates that
any competent adult patient who has been appropriately
informed has the right to accept or refuse medical treatment,
including life-sustaining measures—that is, the right of self-
determination. This does not include the right to commit sui-
cide or to require a physician to assist in suicide or perform
euthanasia. Although Oregon legalized physician-assisted sui-
cide under limited circumstances in 1997, physicians’ partici-
pation remains voluntary. The physician and the health care
team have a mandate to preserve patient autonomy, however,
by being honest and truthful in providing clinical informa-
tion to the patient in order to obtain informed consent to
treatment. Table 10–1 lists the patient’s rights adopted by the
American Hospital Association. The Joint Commission has
drawn up a similar list of patient rights.
The fourth ethical principle is justice, dictating that indi-
viduals be treated fairly in relation to other patients and the
overall distribution of medical resources. When medical
resources are limited, this principle states that treatment
should be administered to patients who are most likely to
benefit from them. The overriding consideration for the
physician is an obligation to care for the individual patient at
hand. Thus ethicists have argued that physicians involve
themselves in the process of providing medical care to society
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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in general but not use arguments about limited resources in
making decisions about an individual patient.
 Conflicts Between Ethical Principles
The practice of medicine often generates conflicts among
these fundamental principles. Efforts have been made to pri-
oritize them, often putting autonomy first as the most
important ethical guideline, but the matter is controversial.
Nonetheless, the physician and health care team are required
to address any conflicts among these principles in the light of
the circumstances presented in each individual case.
Patient autonomy must be preserved, but the physician
sometimes may find that the patient’s wishes are in conflict
with the physician’s own professional, personal, or religious
values. In these situations, the patient’s wishes take prece-
dence while the physician attempts to transfer the responsi-
bility for the patient’s care to another physician.
Medical Futility 
A conflict also may arise if the physician feels that the ther-
apy requested by the patient is medically futile—particularly
if it is a life support measure. A method of treatment is
judged to be futile if reason and experience indicate that it
would be highly unlikely to result in meaningful survival.
One need not conclude that success of the treatment is
impossible—it is enough to decide that a good result would
be highly unlikely; for example, one proposed working def-
inition of futility is no successful outcomes in the last 100
reported or observed attempts of that treatment. The physi-
cian is best qualified to judge whether the treatment is med-
ically futile, but only the patient can decide whether
continued survival would be personally acceptable. An
example might be the decision whether or not to initiate
ventilatory support for a patient with severe progressive
chronic lung disease. Ideally, the treatment goals of the
physician and the patient should be identical and consensu-
ally derived.
The current consensus among ethicists holds that the
physician has no ethical obligation to provide life-sustaining
treatment he or she considers to be futile but does have the
responsibility to inform the patient of the reasons for that
opinion. If the patient requests the treatment nonetheless,
the physician is required to take measures necessary to trans-
fer the patient’s care to another physician or institution that
would follow the patient’s wishes. At the same time, all other
care that is both medically indicated and agreed to by the
patient must be continued.
 Ethical Decision Making
Assessing Decision-Making Capacity
Medical decisions made in the ICU are governed by the prin-
ciple of patient autonomy, but the patient’s illness may have
significantly diminished his or her decision-making capacity.
This capacity is generally defined as the patient’s ability to
(1) receive and understand pertinent information, (2) reflect
on this information in an appropriate way, and (3) communicate
decisions and desires to the caregivers.
Surrogate Decision Makers
When this decision-making capacity is diminished or lost, a
surrogate decision maker can be sought. Ideally, this will be
an individual previously so designated by the patient in a
written advance directive. Alternatively, it may be an appro-
priate family member in an order of authority and responsi-
bility identified by local institutional or legal guidelines. A
common hierarchy progresses from the patient’s spouse to an
adult child, then to a parent, then to an adult sibling, and
then to a grandparent. Rarely, a court-appointed individual
(conservator) undertakes this role.
In the absence of specific decisions about health care pre-
viously made by the patient, the surrogate is obliged to act in
the patient’s best interests, weighing the potential benefits
and burdens of treatment—that is, applying the concept of
proportionality. The surrogate ideally therefore should be
someone who (1) is willing to accept these duties, (2) under-
stands and accepts the personal values of the patient, (3) has
no major emotional opposition to fulfilling the role, and (4) has
no conflict of interest.
For circumstances when an appropriate surrogate decision
maker cannot be identified (eg,“patient John Doe”), the health
care institution should have a mechanism in place for naming
someone to act in the patient’s best interests. Such a mecha-
nism should be governed by factors such as local medical prac-
tice, legal precedents, and institutional policies. Consultation
might be sought from an appropriate resource, such as a
bioethicist or a hospital health care ethics committee.
Table 10–1. A patient’s bill of rights.1
The patient has a right to—  
Considerate and respectful care  
Information about diagnosis, treatment, and prognosis 
Make decisions about treatment  
Have an advance directive  
Consideration of privacy  
Expect confidentiality  
Review medical records  
Request medical services  
Be informed about health care business practices
Consent or decline to participate in research 
Expect reasonable continuity of care  
Be informed of hospital policies on patient care, including resources
for conflict resolution 
1With permission from the American Hospital Association. 
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Although rarely necessary, a legal decision can be sought
from the courts, such as in situations in which (1) the state
of the patient’s decision-making capacity is in doubt, or
(2) the surrogate decision maker cannot make or refuses to
make the decision, or (3) the health care team feels that the
surrogate’s decision is not in the patient’s best interests, or
(4) the surrogate’s decision is contrary to the patient’s
advance directive.
Shared Decision Making
Decision making in the ICU should be a shared responsibil-
ity between the physician and the patient or surrogate deci-
sion maker. The physician should avoid making
independent paternalistic medical decisions for the patient
involving life support measures even though doing so might
seem to be in the patient’s best interests. The physician is
singularly qualified to determine the medical futility of a
specific treatment, but only the patient or surrogate decision
maker can decide quality-of-life issues, that is, whether pro-
longation of life would be meaningful and valuable to the
patient. The physician should seek input from other mem-
bers of the patient’s health care team, including nurses and
other care providers.
 Advance Care Planning
In an attempt to support the fundamental ethical principle of
patient autonomy, legislation has been enacted to facilitate
the process by which the patient’s wishes may be carried out
when he or she is no longer able to make decisions. That is, a
legal declaration by the patient gives the physician and health
care team advance notice of what he or she wants to be done
or not done under various future circumstances. Federal leg-
islation requires hospitals and skilled nursing facilities that
receive Medicare or Medicaid funding to inform all patients
of their right to complete such an advance directive. These
documents exist in most states, but the legal requirements
and implications vary in different jurisdictions.
The living will is the most common document by which
the patient may request or refuse life-sustaining treatment if
he or she becomes terminally ill and no longer able to make
medical decisions or becomes permanently unconscious.
Such documents are not legally binding in all states but
serve as guides for the physician and surrogate decision
maker. A legally binding natural advance death declaration
health care directive can include the decision to forego basic
life support measures of artificially administered nutrition
and hydration.
The advance health care directive appoints a health care
agent (“attorney-in-fact”) to act in the patient’s best interests
when the patient can no longer do so. Such an advance direc-
tive is most helpful when the patient has expressed his or her
wishes in writing in some detail rather than merely using
general terms such as “no heroic measures.” Ideally, individ-
uals executing these directives should discuss their intentions,
beliefs, and value systems with their health care agent, family,
and physician, in addition to completing the advance direc-
tive document. It is also important that these wishes and the
directive be reviewed on a regular basis, particularly each
time the patient is hospitalized.
 Medicolegal Aspects of Decision Making
Critical care practices have been influenced by court actions
that were pursued to resolve ethical conflicts regarding
individual patients. While the actions are not legally bind-
ing outside those jurisdictions, they are used as legal prece-
dents to guide behavior and to aid in arriving at future
court decisions.
A number of cases have strengthened the ethical principle
of patient autonomy and have helped to clarify the role of the
surrogate decision maker in exercising the process of “substi-
tuted judgment” when acting for the patient. For example, in
1976, the New Jersey Supreme Court allowed the family of
Karen Quinlan to withdraw her from mechanical ventilation
because it agreed with her parents that this treatment would
not allow her to return to a cognitive and sapient life but
would merely keep her in a persistent vegetative state.
Similarly, legal decisions surrounding the care of Nancy
Cruzan in Missouri in 1990 ultimately acknowledged that
her parents as surrogate decision makers, based on past com-
ments the patient had made, could refuse life-sustaining
treatment, including nutrition and hydration.
Patient autonomy was further strengthened by the legal
determination in 1991 concerning the care of Helga Wanglie,
who was in a persistent vegetative state on a ventilator in
Minneapolis. The hospital had requested permission from
her husband to discontinue life support treatment based on
the medical decision that Ms Wanglie had no chance for
recovery, that is, that the treatment was futile. Her husband
refused, deciding that based on her religious beliefs,
Ms Wanglie would have wished to continue living. The court
affirmed Mr. Wanglie’s decision and refused to appoint an
independent conservator to replace him as decision maker.
More recently, the decision to withdraw nutrition and
hydration from Terri Schiavo, a woman in a persistent vege-
tative state following a cardiac arrest, was marked by pro-
tracted conflict between the patient’s husband and her
parents that went on for 15 years. The decision to withdraw
treatment was contested in the local, state, and federal judi-
cial systems, and even by Congress, before the treatment was
finally withdrawn, allowing the patient to die according to
her wishes shared in the past with her husband. This case
illustrates the value of advance care planning for everyone
and making one’s wishes in end-of-life care known to the
family rather than debating them later in the courts.
These precedents reaffirm the principle of patient auton-
omy, but ethical conflicts nonetheless remain, particularly
for individuals who stress the principle of justice and the fair
allocation of medical resources.
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 Withholding & Withdrawing Life Support
Based on the ethical principles discussed in the preceding
paragraphs, the patient or the surrogate decision maker can
request that life support treatments be withheld or with-
drawn. Current judgment does not distinguish an ethical or
legal difference between the act of withholding and the act of
withdrawing life support measures. Nevertheless, the patient,
the family, and the health care team may find it more diffi-
cult to withdraw life support than to withhold it. In addition,
Orthodox Jewish tradition does not permit the withdrawing
of life support measures, including nutrition or hydration,
feeling that this would be equivalent to suicide. There is usu-
ally less concern about the more passive act of withholding
treatment.
Decisions to withhold or withdraw treatment are best
made in advance of a life-threatening situation, allowing the
patient and family to consider the potential outcome of life
support measures. This is particularly important in patients
who are terminally ill or who have an illness that is severe
and irreversible.
“Do Not (Attempt) Resuscitate (Resuscitation)”
(DNR/DNAR) Orders
In the event of cardiac or respiratory arrest in a hospitalized
patient, cardiopulmonary resuscitation (CPR) is initiated
automatically. In some cases, it may be desired to forgo CPR,
in which case a “do not resuscitate” order is written. This
decision is made jointly by the patient (or surrogate) and the
physician, but either party may initiate discussion about the
decision. In general, physicians should initiate discussions
about CPR and DNR/DNAR—ideally, before the patient
becomes critically ill and before the disease progresses to a
life-threatening stage despite optimal therapy. Some writers
have advocated use of the term “allow natural death” (AND)
as more descriptive of the intent of this order.
The physician should choose an appropriate setting for
this discussion with the patient and family, allowing ample
time for discussion. The DNR/DNAR order should be pre-
sented in a positive light, emphasizing the continuation of
supportive treatment, relief of physical suffering such as pain
and dyspnea, and support for emotional suffering. It should
be made clear that such a decision does not mean that the
health care team is “giving up” but that the focus of therapy
is altered, emphasizing comfort while avoiding futile or
unnecessary treatment.
When the outcome is bleak, the discussion should focus
not only on whether CPR should be initiated but also on
whether life support measures should be withheld or with-
drawn. The “do not resuscitate” decision does not, by itself,
imply any decisions about other medical treatment, includ-
ing ICU admission, surgery, or other treatment. Thus, if the
patient’s outcome is likely to be poor, offering CPR may give
the patient and family false hope about the likelihood of a
good outcome. A better approach is to discuss whether to
withhold or withdraw life support measures when a crisis
develops if such measures are judged to be futile. The treat-
ment plan thus should be presented in an atmosphere that
will allow the patient, family, and health care team to “hope
for the best, but prepare for the worst.”
There may be situations in which a physician recom-
mends that a DNR order be written, but the patient or fam-
ily disagrees and wishes CPR to be initiated at the time of
cardiac or respiratory arrest. In this situation, several steps
can be taken. First, the physician and patient (or surrogate)
should continue the discussion, with clarification about the
reasons for each person’s decision, misconceptions about
CPR, and the continuation or discontinuation of other med-
ical care. Second, the American Medical Association (AMA)
Council on Ethical and Judicial Affairs has decided that a
physician who determines that CPR may be futile may initi-
ate a DNR order against the patient’s wishes. In this situa-
tion, the patient must be informed of the decision and its
reasons. Third, in the event of disagreement, the patient
should be transferred to the care of another physician able to
reconcile the wishes of the patient with his or her own med-
ical judgment.
Once the decision for a DNR order is made by the patient
or physician, institutional policies and procedures should
govern how such an order should be written in order to avoid
miscommunication. Major points of the discussion with the
patient and family should be documented in the medical
record, including who participated, the decision-making
capacity of the patient, the medical diagnosis and prognosis,
and the reasons for the DNR decision.
Withholding or Withdrawing Treatment
A. A Stepwise Approach—Decisions to withhold or with-
draw life support treatment must not be made hastily.
Several steps are recommended: (1) The physician should
have a clear understanding of the patient’s diagnosis, physio-
logic and functional status, and any coexisting morbid states.
(2) The physician should seek unanimity among the health
care team for the decision to withhold or withdraw life sup-
port measures. (3) The next step is to seek informed consent
from a legally competent patient. If the patient is not legally
competent, the surrogate decision maker must be contacted.
It is wise to include the family and the patient’s referring or
primary care physician in the process, although the patient
or the surrogate decision maker holds responsibility for the
ultimate decision. (4) If a decision cannot be made in a
timely fashion and life support measures are imminently
required, the physician might consider recommending a lim-
ited trial of the life support measure—for example, ventila-
tory support for the next 72 hours, with reassessment at that
time. In the absence of a firm decision, life support measures
should be initiated or continued.
Physicians and other health care workers may fear that
their actions in withholding or withdrawing life support may
subject them to litigation or even criminal prosecution.
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While no one is immune from criticism or challenge, health
care workers who act thoughtfully and rationally, with con-
cern for the patient and in the open company of their peers,
should not fear legal retribution.
B. Establish a Treatment Plan—Once a decision has been
made to withhold life support measures, a specific treatment
plan should be formulated with emphasis on providing com-
fort and support and continually adjusting the plan to meet
the changing needs of the patient. A DNR order should not
automatically preclude care for a patient in the ICU. All
efforts should be made to avoid giving the patient and fam-
ily a feeling of abandonment. Forgoing treatment does not
mean forgoing care. It may be helpful to involve the services
of a medical social worker or chaplain to make certain that
the patient and family receive appropriate emotional and
spiritual support and attention to their physical comfort.
C. Withdraw Life Support—When a decision to withdraw
life support measures has been made, the order should be
executed in a timely manner, paying close attention to the
emotional needs of the patient and family.
After the life support measure is discontinued—for
example, disconnecting the patient from mechanical
ventilation—the family should be allowed access to the
patient to the extent possible, and attention should be given
to their emotional and physical needs. If the dying process is
prolonged, the patient may be transferred to a separate room
for more privacy. Medications appropriate to control pain,
dyspnea, and other symptoms should be administered liber-
ally. Nursing care and physician attention should be as dili-
gent as before the decision was made. The primary training
and practice of critical care clinicians are to prevent and treat
life-threatening medical crises, but they also must be pre-
pared to provide palliative care, administering to the dying
patient and his or her family. A large body of educational
resources is available to assist the health care team in provid-
ing palliative care in the critical care setting.
 Organ Donation
Organ transplantation has progressed rapidly in recent years
and now offers hope to patients who otherwise would die
because of failure of a vital organ. One of the limiting factors,
however, is the short supply of donor organs from individu-
als who have suffered irreversible cessation of brain stem
function.
In order to establish the diagnosis of death by neurologic
criteria, that is,“brain death,” a physician who has no conflict
of interest must verify by appropriate clinical evaluation that
the patient has suffered irreversible cessation of all brain
function. Such a diagnosis must be made in the absence of
hypothermia, drug effect, or metabolic intoxication that can
temporarily suppress the CNS. It also must be made with
caution in patients in shock because reduced brain perfusion
may make the examination unreliable. Guidelines have been
published by the American Academy of Neurology.
Because of the possibility that some patients may become
candidates for organ donation, physicians and health care
professionals in the ICU should be aware of the processes by
which donations can be made. Some patients already may
have disclosed in an advance directive that they wish to
donate body organs or tissues under these circumstances.
Otherwise, authorization for such organ donation must be
obtained from the surrogate decision maker or appropriate
family member unless the religious beliefs of the patient pre-
clude such donation (eg, Christian Science, Orthodox
Judaism, or Jehovah’s Witnesses).
Organ donation is a sensitive issue that health care
providers are often reluctant to raise, particularly at a time
when the potential donor patient’s family is suffering the
impending loss of their loved one. It is therefore necessary to
discuss these issues in a sensitive and timely manner once the
family has accepted the irreversibility of the brain damage.
Legislation in some states requires that such a discussion take
place. In the absence of any known family members or other
appropriate surrogate decision maker, the institution may be
permitted to arrange a donation in accordance with statutory
guidelines. It is important that all health care personnel be
familiar with the policies and procedures for organ donation
in order to identify potential transplant donors.
 Role of the Health Care Professional
Education
All health care professionals who work in the critical care set-
ting should be intimately familiar with the ethical and legal
principles that influence their medical decision making. A
number of professional bodies have published position state-
ments on the ethical implications of critical care, and some
of these resources are listed in the references at the end of this
chapter and in the appendix of Web sites. Copies of these
statements should be readily available to critical care person-
nel. Skilled legal resources also should be available.
Discussions with patients concerning life support meas-
ures are potentially within the purview of all health care
workers, so this education should be offered to the entire
medical staff and all hospital medical personnel. The
patient’s primary physician ideally should initiate discussion
about advance directives and decisions concerning treatment
long before a crisis occurs. Such discussions can be encour-
aged through public education and by taking advantage of
opportunities to document decisions such as when preparing
wills and other estate planning instruments.
Communication Skills
In addition to possessing knowledge about the ethics of crit-
ical care medicine, health care workers should be skilled in
communicating these principles and their conflicts to
patients and families as well as among the health care team.
The physician traditionally assumes the role of the leader of
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that team, but critical care nurses and respiratory care prac-
titioners often develop close relationships with patients and
their families as well and can aid in the process.
Communication is aided by allowing ample time for dis-
cussing these issues in an appropriate setting—ideally, long
before a critical decision must be made. This would allow
general discussion of such sensitive issues as whether to ini-
tiate or withhold CPR or other life support measures and
other decisions about which the patient may wish to express
a preference.
Medical institutions should establish mechanisms by
which ethical conflicts can be resolved satisfactorily. This
might include the availability of ethics and/or palliative care
consultations, patient care conferences, and resources such as
patient advocates, medical social workers, and the hospital’s
retained legal advisers or others who are knowledgeable
about critical care and ethical issues.
Compassion Fatigue
Critical care professionals, by the nature of their work, are
subject to significant emotional distress in the care of criti-
cally ill and/or dying patients. This can result in compassion
fatigue, by which the emotional strain on the professional
caregivers begins to affect their decision making, care deliv-
ery, and sometimes their personal lives. Signs and symptoms
of compassion fatigue can include feelings of anger toward
the patient and family resulting in avoiding them and thus
stifling communication and empathy. This is best addressed
and/or avoided by providing an open and collegial atmos-
phere within the health care team, allowing members to dis-
cuss their feelings about caring for the patient and family.
Development of Institutional Policies
Institutional policies and procedures should be drafted to aid
the health care worker in responding to ethical issues in the
critical care arena and other areas of the hospital. A number
of such policies are listed in Table 10–2. They are designed as
much to prevent ethical conflicts as to aid in resolving them.
Guidelines for formulating these policies may be found in
the references listed below. Some state hospital associations
are also a resource for such policies.
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Table 10–2. Institutional policies to help prevent or
resolve ethical conflicts in critical care.
Intensive care unit admission and discharge criteria 
Methods for resolving ethical conflicts 
Do not resuscitate orders 
Guidelines for withholding and withdrawing life support  
Care of the dying patient 
Definition of and procedure for determining brain death  
Requesting organ or tissue donation 
Organizational ethics 
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APPENDIX 10A
 Web Sites for Health Care Ethics
Information & Policies
These Web sites were operational as of April 7, 2008:
American Medical Association: www.ama-assn.org
The Hastings Center for Bioethics: www.thehastingscenter
.org
Medical College of Wisconsin Center for the Study of Ethics:
www.mcw.edu/bioethics
University of Pennsylvania Center for Bioethics, American
Journal of Bioethics Online: www.ajobonline.com
University of Pittsburgh Consortium Ethics Program:
www.pitt.edu/~cep
University of Toronto Joint Center for Bioethics: www.
utoronto.ca/jcb
University of Washington School of Medicine Ethics in
Medicine: http://depts.washington.edu/bioethx/toc.html
Center to Advance Palliative Care (CAPC): www.capc.org
Center for Ethics in Health Care: www.ohsu.edu/ethics
StopPain.org: www.stoppain.org
The EPEC Project: www.epec.net
End-of-Life Physician Education Resource Center:
www.eperc.mcw.edu
Five Wishes (advance care planning): www.agingwithdignity
.com
Southern California Cancer Pain Initiative: http://
sccpi.coh.org
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The diagnosis and management of shock are among the
most common challenges the intensivist must deal with.
Shock may be broadly grouped into three pathophysiologic
categories: (1) hypovolemic, (2) distributive, and (3) car-
diac. Failure of end-organ cellular metabolism is a feature
of all three. Hemodynamic patterns vary greatly and consti-
tute the diagnostic features of the three types of shock.
HYPOVOLEMIC SHOCK
ESSENT IALS  OF  D IAGNOS I S
 Tachycardia and hypotension.
 Cool and frequently cyanotic extremities. 
 Collapsed neck veins.
 Oliguria or anuria.
 Rapid correction of signs with volume infusion.
General Considerations
Hypovolemic shock occurs as a result of decreased circulat-
ing blood volume. The most common cause is trauma result-
ing in either external hemorrhage or concealed hemorrhage
from blunt or penetrating injury. Hypovolemic shock also
may occur as a result of sequestration of fluid within the
abdominal viscera or peritoneal cavity.
The severity of hypovolemic shock depends not only on
the volume deficit but also on the age and premorbid status
of the patient. The rate at which the volume was lost is a crit-
ical factor in the compensatory response. Volume loss over
extended periods, even in older, more severely compromised
patients, is better tolerated than rapid loss. Clinically, hypov-
olemic shock is classified as mild, moderate, or severe
depending on the blood volume lost (Table 11–1). While
these classifications are useful generalizations, the severity of
preexisting disease may create a critical situation in a patient
with only minimal hypovolemia.
Hypovolemic shock produces compensatory responses in
virtually all organ systems.
A. Cardiovascular Effects—The cardiovascular system
responds to volume loss through homeostatic mechanisms
for maintenance of cardiac output and blood pressure. The
two primary responses are increased heart rate and periph-
eral vasoconstriction, both mediated by the sympathetic
nervous system. The neuroendocrine response, which pro-
duces high levels of angiotensin and vasopressin, enhances
the sympathetic effects. Adrenergic discharge results in
constriction of large capacitance venules and small veins,
which reduces the capacitance of the venous circuit.
Because up to 60% of the circulating blood volume resides
in the venous reservoir, this action displaces blood toward
the heart to increase diastolic filling and stroke volume. It
is probable that venular constriction is the single most
important circulatory compensatory mechanism in hypo-
volemic shock.
Precapillary sphincter and arteriolar vasoconstriction
results in redirection of blood flow. The greatest decrease
occurs in the visceral and splanchnic circuits. Flow to bowel
and liver decreases early in experimental shock. Intestinal
perfusion is depressed out of proportion to reductions in
cardiac output. Reduction in flow to the kidneys accounts for
the decline in glomerular filtration and urine output,
whereas decreased skin flow is responsible for the cutaneous
coolness associated with hypovolemia. The cutaneous vaso-
constrictive response diverts flow to critical organs and has
the further effect of reducing heat loss through the skin. The
reduced diameter of the small, high-resistance vessels
increases the velocity of flow and decreases the viscosity of
blood as it reaches the ischemic vascular beds, thus permit-
ting more efficient microcirculatory flow.
Increased flow velocity in the microcirculation may
have the additional benefit of improving oxygen delivery
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while reducing tissue acidosis. A countercurrent exchange
mechanism has been postulated in which oxygen diffuses
from arterioles into adjacent venules. Normally, the
amount of arterial oxygen lost by this mechanism is
small. However, as flow decreases through dilated arteri-
oles, more oxygen can leave the slowly flowing arterial
blood and diffuse to the venous circuit. Arteriolar con-
striction increases flow velocity and decreases blood resi-
dence time. This effectively reduces the peripheral oxygen
shunt. In a similar fashion, CO2 diffuses from the post-
capillary venules into the arterioles. In the absence of
arteriolar vasoconstriction, such diffusion could increase
the volume of CO2 reaching the tissues and result in
worsening of tissue acidosis.
The balance of fluid shifts between the intravascular and
extravascular spaces is governed by Starling’s law, which
relates net transvascular flux to differences in hydrostatic and
osmotic pressure:
.
Q = K[(Pc − Pi) − σ(Πc − Πi)]
where Q is fluid flux, (Pc – Pi) is the hydrostatic pressure gra-
dient, (Πc – Πi) is the osmotic pressure gradient, K is the per-
meability coefficient, and σ is the reflection coefficient.
Under normal circumstances, intravascular hydrostatic
pressure (Pc) is greater than interstitial hydrostatic pres-
sure (Pi), and fluid tends to move from the capillaries into
the interstitium. Interstitial osmotic pressure (Πi) is usu-
ally less than the intravascular osmotic pressure (Πc),
favoring the movement of fluid back into the capillary.
This results in a small net movement of water, Na+, and K+
out of the capillaries. When hypovolemia occurs, intravas-
cular pressure falls, facilitating the movement of fluid and
electrolytes from the interstitium back into the vascular
space. The degree of this translocation is limited because as
fluid moves back into the capillaries, the albumin remain-
ing in the interstitium exerts an increased extravascular
osmotic pressure. Compensatory vasoconstriction facili-
tates this process because fluid can be recovered more
easily if the vascular space is collapsed than if it is dilated.
The degree of such translocation is probably limited to a
total of 1–2 L. This vascular refill accounts not only for
the decrease in intravascular osmotic pressure, but it is also
primarily responsible for the decline in hematocrit
observed in hypovolemic patients before resuscitation is
started.
Increased heart rate and contractility are important
homeostatic responses to hypovolemia. Both the direct
adrenergic response and the epinephrine secreted by the
adrenal medulla are responsible for these reflexes. Cardiac
output is the product of heart rate and stroke volume. It is
supported both by tachycardia and by translocated fluid.
Because blood pressure is the product of systemic vascular
resistance and cardiac output, peripheral vasoconstriction is
an essential factor in supporting blood pressure.
B. Metabolic Effects—Tissue metabolic pathways require
ATP as an energy source. Normally, ATP is produced
through the Krebs cycle via the aerobic metabolism of
glucose. Six molecules of oxygen are consumed when six
molecules of glucose are used to convert six molecules of
ADP into six molecules of ATP, CO2, and water. When
oxygen is not available, ATP is generated through anaero-
bic glycolysis, which not only yields smaller quantities of
ATP for the amount of glucose consumed but also pro-
duces lactic acid. This latter product is largely responsible
for the acidosis of ischemia. The point at which tissues
change from aerobic to anaerobic metabolism is defined
as the anaerobic threshold. This theoretic point varies
between tissues and clinical situations. .The most impor-
tant factor influencing the conversion to anaerobic gly-
colysis is oxygen availability.
The delivery of oxygen depends on the quantity of oxygen
present in the blood and the cardiac output. The former,
defined as the oxygen content, is calculated as follows:
CaO2 = 1.34 × Hb × SaO2 + (0.0031 × PaO2)
Pathophysiology Clinical Features 
Mild (<20% of
blood volume) 
Decreased perfusion of
organs that are able to
tolerate ischemia (skin,
fat, skeletal muscle,
bone). Redistribution of
blood flow to critical
organs. 
Subjective complaints
of feeling cold. Postural
changes in blood pres-
sure and pulse. Pale,
cool, clammy skin. Flat
neck veins.
Concentrated urine. 
Moderate (deficit =
20–40% of blood
volume) 
Decreased perfusion of
organs that withstand
ischemia poorly (pan-
creas, spleen, kidneys). 
Subjective complaint of
thirst. Blood pressure is
lower than normal in
the supine position.
Oliguria. 
Severe (deficit >
40% of blood
volume)
Decreased perfusion of
brain and heart.
Patient is restless, agi-
tated, confused, and
often obtunded. Low
blood pressure with a
weak and often thready
pulse. Tachypnea may
be present. If allowed
to progress, cardiac
arrest results.
From Holcroft JW, Wisner DH: Shock and acute pulmonary failure
in surgical patients. In: Current Surgical Diagnosis and
Treatment, 9th ed. Way LW (editor). Originally published by
Appleton & Lange. Copyright © 1991 by the McGraw-Hill
Companies, Inc. 
Table 11–1. Pathophysiology and clinical features of
hypovolemia.
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where CaO2 is arterial oxygen content (in milliliters per
deciliter), Hb is hemoglobin concentration (in grams per
deciliter), SaO2 is hemoglobin saturation of arterial blood (in
percent), and PaO2 is partial pressure of dissolved oxygen in
arterial blood (in millimeters of mercury).
The principal determinants of oxygen content are the
concentration of hemoglobin and its saturation. Although
PaO2 is the most commonly used indicator of oxygenation,
the dissolved oxygen component contributes only minimally
to oxygen content in patients with normal hemoglobin con-
centration and saturation. When anemia is profound, the rel-
ative contribution of dissolved oxygen increases. Systemic
oxygen delivery is defined as follows:
DO2 = CaO2 × CO × 10
where DO2 is systemic oxygen delivery (in milliliters per
minute), CaO2 is arterial oxygen content (in milliliters per
deciliter), and CO is cardiac output (in liters per minute).
Normally, DO2 is in excess of 1000 mL/min. When cardiac
output falls with hypovolemic shock, DO2 declines as well.
The extent depends not only on the cardiac output but also
on the fall in hemoglobin concentration. As oxygen delivery
declines, most organs increase their extraction of oxygen
from the blood they receive and return relatively desaturated
blood to the venous circuit. Systemic oxygen consumption is
calculated by rearranging Fick’s equation:
.
VO2 = (a − v)DO2 × CO × 10
Systemic oxygen consumption is typically 200–260 mL O2
per minute for a 70-kg patient under baseline conditions. The
arteriovenous oxygen content difference—(a – v)DO2—is
approximately 5 ± 1 mL/dL under these conditions. With
hypovolemia, oxygen consumption remains remarkably con-
stant, although peripheral oxygen extraction increases, result-
ing in an increase in (a – v)DO2 to values typically greater than
7 mL/dL. The oxygen extraction ratio (O2ER), which is defined
as
.
VO2/DO2, is also augmented. Increased (a – v)DO2 and O2ER
are metabolic hallmarks of hypovolemic shock.
Tissues vary greatly in their ability to increase oxygen
extraction. The normal extraction ratio is near 0.3 and may
increase to as much as 0.8 in conditioned athletes. The heart
and brain maximally extract oxygen under normal circum-
stances, making them extremely flow-dependent. Peripheral
oxygen consumption (
.
VO2) remains essentially constant dur-
ing hypovolemia until a critical threshold is reached, at
which point increased extraction can no longer keep pace
with delivery. There is conflicting evidence about whether
oxygen consumption decreases in the face of reduced oxygen
delivery in humans. This so-called pathologic supply
dependence may, however, occur in patients with distributive
shock and with acute respiratory distress stndrome (ARDS).
When circulating blood volume falls sufficiently, oxygen
delivery declines, and death occurs below a critical DO2 of
less than 8–10 mL O2 per minute.
Compensated shock occurs when system oxygen delivery
falls below DO2,crit, and anaerobic metabolism becomes more
prevalent. Cell function is maintained as long as the combina-
tion of aerobic and anaerobic metabolism provides adequate
ATP. Tissues vary greatly in their resistance to hypoxia. While
the brain may tolerate only brief intervals, skeletal histiocytes
may withstand up to 2.5 hours of ischemia. Significantly, the
gut appears to be very sensitive to decreased perfusion.
Uncompensated shock, which results in tissue damage, occurs
when combined aerobic and anaerobic metabolism is not
adequate to sustain cellular function. Loss of cellular mem-
brane integrity results in cell swelling and ultimate cell death.
C. Neuroendocrine Effects—Adrenergic discharge and the
secretion of vasopressin and angiotensin are neuroendocrine
compensatory mechanisms that together produce vasocon-
striction, translocation of fluid from the interstitium into the
vascular space, and maintenance of cardiac output.
1. Secretion of aldosterone and vasopressin—
Together these hormones increase renal retention of salt and
water to assist in maintaining circulating blood volume.
2. Secretion of epinephrine, cortisol, and glucagon—
These hormones increase the extracellular concentration of
glucose and make energy stores available for cellular metab-
olism. Fat mobilization is increased. Serum insulin levels are
decreased.
3. Endorphins—Although their exact role is unclear, these
endogenously occurring opioids are known to decrease pain.
They promote deep breathing, which might increase venous
return by decreasing intrathoracic vascular resistance.
Endorphins have a vasodilatory effect and actually may
counteract the sympathetic influence.
D. Cellular and Immunologic Effects—Although sepa-
ration of shock and resuscitation into cellular and
immunologic effects is somewhat artificial, the distinction
provides a useful framework for the subsequent discus-
sion of resuscitation.
1. Cellular effects—Injured cells die by either apoptosis
or necrosis. Apoptosis requires energy and is a more con-
trolled than simple necrosis. Although apoptosis is required
for homeostasis, an increase in apoptosis may indicate cellu-
lar injury and organ dysfunction. Recent research has shown
that the type of resuscitation fluid used may have a signifi-
cant effect on the extent of apoptosis. Additionally, the extent
of apoptosis varies between cell types and may be particu-
larly significant in the CNS and brain.
Recent research has shown that the fluid used for resus-
citation also has an effect on cellular function. Some of the
factors thought to exert an influence include (1) the elec-
trolyte composition of the fluid used, (2) tonicity, (3) duration
of resuscitation, (4) type of cells exposed, (5) concurrent
inflammation or infection, (6) presence of additional
periods of shock or infection/contamination (“second hit”),
and (7) timing of resuscitation.
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2. Immunologic effects—Hypovolemic shock initiates a
series of inflammatory responses that may have deleterious
effects. Stimulation of circulating and fixed macrophages
induces the production and release of tumor necrosis factor
(TNF), which, in turn, leads to production of neutrophils,
inflammation, and activation of the clotting cascade.
Neutrophils are known to release free oxygen radicals, lyso-
somal enzymes, and leukotrienes C4 and D4. These mediators
may disrupt the integrity of the vascular endothelium and
result in vascular leaks into the interstitial space. Activated
complement and products of the arachidonic acid pathway
serve to augment these responses.
Adhesion molecules are glycoproteins that cause leuko-
cyte recruitment and migration after hemorrhagic shock.
The most frequently involved cell adhesion molecules are the
selectins, integrins, and immunoglobulins. Although the
roles of the adhesion molecules are still under investigation,
some authorities have reported a correlation between the
severity of injury and the release of soluble cell adhesion
molecules (SCAMs). Others also have noted a relationship
between the development of multiple-organ failure and the
expression of SCAMs. The feasibility of using monoclonal
antibodies to SCAMs—as well as pathway blockade—is
under study. Isotonic crystalloid resuscitation fluids, as well
as some artificial colloids, have been demonstrated to pro-
duce an oxidative burst and the expression of adhesion mol-
ecules on neutrophils in a dose-dependent manner. Natural
colloids, such as albumin, did not create such a burst, and the
use of hypertonic saline has been shown to suppress some
neutrophil functions.
Oxygen metabolites, including superoxide anions, hydro-
gen peroxide, and hydroxyl-free radicals, are produced when
oxygen is incompletely reduced to water. These radical inter-
mediates are extremely toxic because of their effects on lipid
bilayers, intracellular enzymes, structural proteins, nucleic
acids, and carbohydrates. Phagocytes normally generate oxy-
gen radicals to assist in killing ingested material.
Antioxidants protect surrounding tissue if these compounds
leak from the phagocytes. Ischemia, followed by reperfusion,
has been shown to accelerate the production of toxic oxygen
metabolites independently of the activity of inflammatory
cells. This ischemia-reperfusion syndrome may lead to exten-
sive destruction of surrounding tissue and may play a signif-
icant role in determining the ultimate outcome of an episode
of hypovolemic shock.
Animal experiments have identified a number of other
potentially important immunologic responses to hypov-
olemia, including failure of antigen presentation by Kupffer
cells in the liver and translocation of bacteria from the gut
into the systemic circulation. This latter mechanism may
explain the occurrence of sepsis after hypotension without
other sources of infection.
E. Renal Effects—Blood flow to the kidneys decreases
quickly with hypovolemic shock. The decline in afferent flow
causes glomerular filtration pressure to fall below the critical
level required for filtration into Bowman’s capsule. The kid-
ney has a high metabolic rate and requires substantial blood
flow to maintain its metabolism. Therefore, sustained
hypotension may result in tubular necrosis.
F. Hematologic and Thrombotic Effects—When hypov-
olemia is due to loss of fluid volume without loss of red
blood cells, which occurs with emesis, diarrhea, or burns, the
intravascular space becomes concentrated, with increased
viscosity. This sludging may lead to microvascular thrombo-
sis with ischemia of the distal bed.
G. Neurologic Effects—Sympathetic stimulation does not
cause significant vasoconstriction of the cerebral vessels.
Autoregulation of the brain’s blood supply keeps flow con-
stant as long as arterial pressure does not decrease to less
than 70 mm Hg. Below this level, consciousness may be lost
rapidly, followed by decline in autonomic function.
H. Gastrointestinal Effects—Hypotension causes a decrease
in splanchnic blood flow. Animal models have shown a rapid
decrease in gut tissue oxygen tension, which may lead to the
ischemia-reperfusion syndrome or to translocation of intes-
tinal bacteria. Increased concentrations of xanthine oxidase
occur within the mucosa and also may be responsible for
bacterial translocation. Pentoxifylline has aroused recent
interest as a potential agent for increasing intestinal
microvascular blood flow after periods of ischemia.
Clinical Features
A. Symptoms and Signs—The findings associated with
hypovolemic shock vary with the age of the patient, the pre-
morbid condition, the extent of volume loss, and the time
period over which such losses occur. The physical findings
associated with different degrees of volume loss are summa-
rized in Table 11–1. Heart rate and blood pressure measure-
ments are not always reliable indicators of the extent of
hypovolemia. Younger patients can easily compensate for
moderate volume loss by vasoconstriction and only minimal
increases in heart rate. Furthermore, severe hypovolemia can
result in bradycardia as a preterminal event. Orthostatic
blood pressure testing is often helpful. Normally, transition
from the supine to the sitting position will decrease blood
pressure by less than 10 mm Hg in a healthy person. When
hypovolemia is present, the decline is greater than 10 mm Hg,
and the pressure does not return to normal within several
minutes. Older patients who present with apparently normal
blood pressures while supine often become hypotensive
when brought to an upright position. Such testing must be
used with caution in patients who have sustained multiple
injuries because potentially unstable vertebral injuries may
be present.
Decreased capillary refilling, coolness of the skin, pallor,
and collapse of cutaneous veins are all associated with
decreased perfusion. The extent of each depends on the
severity of the underlying shock. These findings are not spe-
cific to hypovolemic shock and may occur with cardiac shock
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or shock from pericardial tamponade or tension pneumoth-
orax. Collapsed jugular veins are commonly found in hypo-
volemic shock, although they also may occur with cardiac
compression in a patient who is not adequately fluid-
resuscitated. Examination of the jugular veins is best per-
formed with the patient’s head elevated to 30 degrees. A
normal right atrial pressure will distend the neck veins
approximately 4 cm above the manubrium.
Urine output is usually markedly decreased in patients
with hypovolemic shock. Oliguria in adults is defined as
urine output of less than 0.5 mL/kg per hour. If oliguria is
not present in the face of clinical shock, the urine should be
examined for the presence of osmotically active substances
such as glucose and radiographic dyes.
B. Laboratory Findings—Laboratory studies may be useful
in determining the cause of hypotension. However, resuscita-
tion of a patient in shock should never be withheld pending
the results of laboratory determinations.
The hematocrit of a patient in hypovolemic shock may be
low, normal, or high depending on the cause and duration of
shock. When blood loss has occurred, evaluation prior to
capillary refill by interstitial fluid will yield a normal hemat-
ocrit. On the other hand, if the patient has bled slowly, if
recognition is delayed, or if fluid resuscitation has been insti-
tuted, the hematocrit will be low. When hypovolemia results
from loss of nonsanguineous fluid (eg, emesis, diarrhea, or
fistulas), the hematocrit is usually high. A crude way to esti-
mate the extent of blood loss is to assume that the intravas-
cular space is a single compartment and that the change in
hemoglobin concentration is proportional to the extent of
blood loss and fluid replacement with nonsanguineous flu-
ids. Where Hi is the (presumed) initial hematocrit, Hf is the
final hematocrit, and EBV is the approximate circulating
blood volume (approximately 70% of the body weight in an
adult), the estimated blood loss (EBL) may be calculated as
EBL = EBV × ln(Hi/Hf).
Lactic acid accumulates in patients with shock that is
severe enough to cause anaerobic metabolism. Both the extent
of elevation of arterial lactic acid and the rate at which it is
cleared with volume resuscitation and control of bleeding are
useful markers of the presence of ischemia and its resolution.
Failure to clear elevated arterial lactic acid is an indication of
inadequate resuscitation. If arterial lactic acid concentration
remains elevated despite seemingly appropriate fluid resusci-
tation, other causes of hypoperfusion should be sought.
Other nonspecific findings include decreased serum
bicarbonate and a minimally increased white blood cell
count. Base excess, calculated from an arterial blood gas
determination, indicates that portion on an acidosis that is
metabolic in nature. Some laboratories use the term base
deficit, which is simply the negative absolute value of the base
excess. Like lactic acid, base deficit should resolve with ade-
quate resuscitation.
C. Hemodynamic Monitoring—Assessment of central
venous pressure is seldom required to make the diagnosis of
hypovolemic shock. Because the decreased volume allows
venous collapse, insertion of central venous monitoring
catheters can be particularly hazardous. If the patient’s blood
pressure and mental status do not respond to fluid adminis-
tration, a continued source of bleeding should be suspected.
Central venous pressure monitoring may be useful in older
patients with a known or suspected history of congestive
heart failure because excessive fluid administration may rap-
idly result in pulmonary edema. In extreme cases, a pul-
monary artery flotation catheter may be required to optimize
fluid status.
Capnographic monitoring will reflect a decrease in end-
tidal CO2. This is produced by a decrease in blood flow to the
lungs. When compared with arterial blood gases, a widening
of the arterial–end-tidal CO2 gradient is apparent. If pul-
monary function is normal, only minimal changes in arterial
hemoglobin saturation will be present. Hence pulse oximetry
indicates normal saturation. The introduction of noninvasive
transcutaneous tissue oxygen probes, which use near-infrared
spectroscopy to measure subcutaneous tissue oxygen tension
(StO2), holds promise as a simple bedside method for deter-
mining the adequacy of resuscitation. A pilot study showed
that trauma patients who maintained StO2 above 75% within
the first hour of ED arrival had an 88% chance of surviving
without multiple-organ dysfunction.
Differential Diagnosis
Shock owing to hypovolemia may be confused with shock
from other causes (Table 11–2). Cardiac shock produces
signs similar to those found with hypovolemia, with the
exception that neck veins are usually distended. Absence of
such distention may be due to inadequate fluid resuscitation.
Central venous pressure monitoring will help to make the
differentiation. Following trauma, peripheral vasodilation
owing to spinal cord injury may produce shock that is rela-
tively resistant to fluid administration. Hypovolemia is the
primary cause of shock in trauma victims, and it should
never be assumed that other causes are responsible until fluid
in adequate amounts has been administered.
Alcoholic intoxication may make the diagnosis of hypov-
olemia difficult. Serum ethanol elevation causes the skin to be
warm, flushed, and dry. The patient usually makes dilute
urine. These patients may be hypotensive when supine, with
exaggerated postural blood pressure changes. Hypoglycemic
shock owing to excessive insulin administration is not uncom-
mon in the ICU. The patients are cold, clammy, oliguric, and
tachycardiac. A history of recent insulin administration should
arouse suspicion of hypoglycemic shock. After samples have
been taken for blood glucose determinations, intravenous
administration of 50 mL 50% glucose should improve the
situation.
Treatment
A. General Principles—Unlike acute posttraumatic situa-
tions, resuscitation of patients with hypovolemic shock in
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the ICU typically proceeds from a more controlled baseline.
As in any emergent situation, the priorities of airway, breath-
ing, and circulation must be addressed sequentially.
Although many ICU patients will already have an established
airway, attention to this area of concern is always the first pri-
ority. Techniques to control the airway and reestablish ade-
quate breathing are discussed in Chapter 11.
Intravenous access through at least two large-bore
(16-gauge) catheters is mandatory. The relatively small
ports on pulmonary artery and triple-lumen catheters are
inadequate for rapid fluid resuscitation and should be used
only until larger catheters can be placed. Central venous
catheters inserted in the internal jugular or subclavian vein
generally should not be inserted in hypovolemic patients
for emergent resuscitation because of the risk of a pneumoth-
orax associated with attempts to place a cather into a col-
lapsed overlying vein.A quick search should be made for
sources of blood and fluid loss. Potential sources include gas-
trointestinal bleeding, accelerated fluid loss through fistulas,
disconnection of intravenous access lines with retrograde
bleeding, and disruption of vascular suture lines. When exter-
nal bleeding is present, direct pressure over the site should be
applied until definitive surgical control can be secured. Blind
probing of a bleeding wound with clamps almost invariably
fails to control the bleeding and may cause further injury.
B. Fluid Resuscitation—Rapid fluid resuscitation is the cor-
nerstone of therapy for hypovolemic shock. Fluid should be
infused at a rate sufficient to rapidly correct the deficit. In
younger patients, infusion is typically at the maximum rate
sustainable by the delivery equipment and the access vein. In
older patients or those with prior cardiac disease, infusion
should be slowed once a response is detected to prevent com-
plications associated with hypervolemia.
Parenteral solutions for the intravenous resuscitation of
hypovolemic shock generally are classified as crystalloids or
colloids depending on the highest molecular weight of the
species they contain.
1. Crystalloids—Crystalloid solutions have no species with
a molecular weight greater than 6000. Although a large num-
ber of crystalloids are available, only those isotonic with
human plasma that have sodium as their principal osmoti-
cally active particle should be used for resuscitation.
Commonly available solutions are listed in Table 11–3.
Because they have low viscosity, crystalloids can be adminis-
tered rapidly through peripheral veins.
Because isotonic fluids have the same osmolality as
body fluids, there are no net osmotic forces tending to
move water into or out of the intracellular compartment.
Therefore, the electrolytes and water partition themselves
in a manner similar to the body’s extracellular water con-
tent: 75% extravascular and 25% intravascular. When iso-
tonic crystalloids are used for resuscitation, administration
of approximately three to four times the vascular deficit is
required to account for the distribution between the intra-
and extravascular spaces. This partitioning typically occurs
within 30 minutes after the fluid is given. Within 2 hours,
less than 20% of the infused fluid remains within the
intravascular space.
Cardiogenic
Shock 
Cardiac
Compressive
Shock 
Hypovolemic or Traumatic  Shock 
Mild Moderate Severe
Low-Output
Septic Shock 
High-Output
Septic Shock 
Neurogenic
Shock 
Skin perfusion Pale Pale Pale Pale Pale Pale Pink Pink 
Urine output Low Low Normal Low Low Low Low Low 
Pulse rate High High Normal Normal High High High Low 
Mental status Anxious Anxious Normal Thirsty Anxious Anxious Anxious Anxious 
Neck veins Distended Distended Flat Flat Flat Flat Flat Flat 
Oxygen consumption Low Low Low Low Low Low Low Low 
Cardiac index Low Low Low Low Low Low High Low 
Cardiac filling pressures High High Low Low Low Low Low Low 
Systemic vascular
resistance 
High High High High High High Low Low 
From Holcroft J, Robinson MK: Shock: Identification and management of shock states. In: Care of the Surgical Patient. Scientific
American, 1992.
Table 11–2. Clinical findings associated with shock.
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Crystalloid solutions are safe and effective for resuscita-
tion of patients in hypovolemic shock. The major complica-
tions associated with their use are undertreatment and
overtreatment. Clinical parameters such as restoration of
urine output, decreased heart rate, and increased blood pres-
sure should be used to determine when a sufficient quantity
of fluid has been given. Restoration of mental status, skin
turgor, and capillary refill are also useful parameters. Central
venous or pulmonary artery pressure monitoring is useful in
patients with preexisting cardiopulmonary disease.
Excessive administration of crystalloids is associated with
generalized edema. Unless quantities sufficient to increase the
pulmonary hydrostatic pressure to very high levels are given
(typically >25–30 mm Hg), pulmonary edema does not occur.
Subcutaneous edema may be a significant problem because it
limits patient mobility, increases the potential for decubitus
ulcers, and potentially restricts respiratory excursions.
It has been shown recently that the type of crystalloid used
may exert an important effect on the cellular injury caused by
hemorrhagic shock. Investigation of this “resuscitation injury”
has shown that the D-isomer found in traditional lactated
Ringer’s solution (a racemic mixture along with the L-isomer)
may have adverse immunoinflammatory properties.
Additional work has shown that both pulmonary and hepatic
apoptosis may be reduced if lactate in the solution is
replaced with either sodium pyruvate, ethylpyruvate, or β-
hydroxybutyrate. It is believed that the modified Ringer’s
solutions exert their protective effect through posttranslational
modification of important regulatory proteins and by selective
acetylation of histones. Presently, however, the choice of the
specific crystalloid for resuscitation remains  largely a matter
of individual preference. Normal saline has the advantages of
being universally available and being the only crystalloid that
can be mixed with blood. Because its chloride concentration is
significantly higher than that of plasma, patients resuscitated
with normal saline often develop a fixed hyperchloremic
metabolic acidosis that requires renal chloride excretion for
correction. Lactated Ringer’s solution has the advantage of a
more physiologic electrolyte composition. The added lactate is
converted to bicarbonate in the liver. Such conversion occurs
readily in all but the sickest of patients.
Hypertonic saline solutions are crystalloids that contain
sodium in supraphysiologic concentrations. They expand the
extracellular space by exerting an osmotic effect that dis-
places water from the intracellular compartment. They also
may exert a mild positive inotropic effect as well as produc-
ing systemic and pulmonary vasodilation. In comparison
with isotonic crystalloids, hypertonic saline decreases wound
and peripheral edema. Recent studies have indicated, how-
ever, that hypertonic saline resuscitation may increase the
incidence of bleeding. Animal models indicate that this may
be due to decreased ADP-mediated platelet aggregation.
Hypertonic saline solutions have received recent attention,
particularly with regard to resuscitation of battlefield casualties,
Solutions fluid
Glucose
(g/L) N+ Cl– HCO3
–
K+ Ca2+ Mg2+ HPO4
– NH4
+
(meq/L)
Extracellular fluid 1000 140 102 27 4.2 5 3 3 0.3
5% dextrose and water 50
10% dextrose and water 100
0.9% sodium chloride
(normal saline)
154 154
0.45% sodium chloride
(0.5 normal saline)
77 77
0.21% sodium chloride
(0.25 normal saline)
34 34
3% sodium chloride
(hypertonic saline)
513 513
Lactated Ringer’s solution 130 109 28∗ 4 2.7
0.9% ammonium chloride 168 168
From Miller TA, Duke JH: Fluid and electrolyte management. In: Manual of Preoperative and Postoperative Care. Dudrick SJ et al (editors).
Saunders, 1983.
∗Present in solution as lactate but is metabolized to bicarbonate. 
Table 11–3. Composition of balanced salt solutions.
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because small volumes may produce large effects.
Additionally, hypertonic saline may suppress neutrophil func-
tion through the modulation of chemoattractant receptor sig-
naling pathways. Recent clinical work has found no increase
in the incidence of hypernatremic seizures, increased bleeding
or blood transfusion requirement, coagulopathies, renal fail-
ure, cardiac arrhythmias, or central pontine myelinosis.
Hypertonic saline also has been shown to be advantageous
when mixed with artificial colloids such as dextran.
2. Colloids—As a group, colloids are solutions that rely on
high-molecular-weight species for their osmotic effect.
Because the barrier between the intra- and extravascular
spaces is only partially permeable to the passage of these
molecules, colloids tend to remain in the intravascular space
for longer periods than do crystalloids. Smaller quantities of
colloids are required to restore circulating blood volume.
Because of their oncotic pressure, colloids tend to draw fluid
from the extravascular to the intravascular space. They are
significantly more expensive to use than crystalloids, even
though smaller absolute volumes are required. The use of
albumin solutions in the initial resuscitation stages of hypo-
volemic shock has not been shown to be more effective than
the use of crystalloid. Rather, a meta-analysis of 26 prospec-
tive, randomized trials found an increased absolute risk for
death of 4% when colloids were used for resuscitation.
a. Albumin—Albumin (normal serum albumin) is the
most commonly used colloid. It has a molecular weight of
66,000–69,000 and is available as a 5% or 25% solution.
Normal serum albumin is approximately 96% albumin,
whereas plasma protein fraction is 83% albumin. Each gram
of albumin can hold 18 mL of fluid in the intravascular
space. The serum half-life of exogenous albumin is less than
8 hours although less than 10% leaves the vascular space
within 2 hours after administration. When 25% albumin is
administered, it results in increased intravascular volume
approaching five times the administered quantity.
Like crystalloid infusion, the endpoints for the adminis-
tration of colloid to patients in hypovolemic shock are
largely subjective. Because albumin has been implicated as a
cause of decreased pulmonary function, strict attention to
resuscitation endpoints is required. Other reported compli-
cations include depressed myocardial function, decreased
serum calcium concentration, and coagulation abnormali-
ties. The latter two may be due simply to volume effects.
b. Hetastarch—Hetastarch (hydroxyethyl starch) is a syn-
thetic product available as a 6% solution dissolved in normal
saline. It has an average molecular weight of 69,000. Forty-six
percent of an administered dose is excreted by the kidneys
within 2 days, and 64% is eliminated within 8 days. Detectable
starch concentrations may be found 42 days after infusion.
Hetastarch is an effective volume expander, with effects that
typically last between 3 and 24 hours. Intravascular volume
increases by more than the volume infused. Most patients
respond to between 500 and 1000 mL. Renal, hepatic, and
pulmonary complications may occur when dosing exceeds
20 mL/kg per day.
Hetastarch may cause a decreased platelet count and pro-
longation of the partial thromboplastin time owing to its
anti–factor VIII effect. Anaphylaxis is rare. A combination
product containing 6% hetastarch in a balanced salt solution
is now available. Because it may cause inhibition of factor
VIII, its use for large-volume resuscitation requires further
review. When used, it is typically administered at doses of
500–1000 mL.
A similar five-carbon preparation (pentastarch) is cur-
rently available only for leukapheresis but is also a useful vol-
ume expander. It may have fewer effects on the coagulation
cascade than does hetastarch.
c. Dextrans—Two forms of dextran are generally available:
dextran 70 (90% of molecules have MW 25,000–125,000) and
dextran 40 (90% of molecules have MW 10,000–80,000). Both
may be used as volume expanders. The extent and duration of
expansion are related to the type of dextran used, the quantity
infused, the rate of administration, and the rate of clearance
from the plasma. The lower-molecular-weight molecules are
filtered by the kidney and produce diuresis; the heavier ones
are metabolized to CO2 and water. The higher-molecular-
weight dextrans remain in the intravascular space longer than
do the lighter compounds. Dextran 70 is preferred for volume
expansion because it has a half-life of several days. A 10% solu-
tion of dextran 40 has a greater colloid oncotic pressure than
the 70% solution but is cleared from the plasma rapidly.
Several complications are associated with dextran admin-
istration, including renal failure, anaphylaxis, and bleeding.
Dextran 40 is filtered by the kidney and may result in an
osmotic diuresis that actually decreases plasma volume. It
should be avoided in patients with known renal dysfunction.
Dextran 70 infrequently has been associated with renal fail-
ure. Anaphylactic reactions occur in patients with high
anti–dextran antibody titers. The incidence of reactions is
between 0.03% and 5%.
Both dextrans inhibit platelet adhesion and aggregation
probably via factor VIIIR:ag activity. The clinical effect is simi-
lar to von Willebrand’s disease. The effect is greater with dex-
tran 70 than with dextran 40. Both preparations may interfere
with serum glucose determinations and blood cross-matching.
d. Other colloids—Modified fluid gelatin (MFG) and
urea-bridged gelatins are prepared as 3.5% and 4% solutions
in normal saline, respectively. Both are effective plasma vol-
ume expanders. Their low molecular weight leads to rapid
renal excretion. Anaphylactoid reactions (0.15%) are the
most common complication. Rapid infusion of the urea-
bridged formulation causes histamine release from mast cells
and basophils. The incidence of allergic reactions is less for
MFG. Gelatins may cause depression of serum fibronectin.
They are not associated with renal failure and do not inter-
fere with blood banking techniques. These preparations are
used widely in Europe and in the military for mass casualties.
They are currently unavailable in the United States.
Oxygen-carrying solutions such as stroma-free hemoglo-
bin and perfluorocarbons are the subjects of active research.
At present, however, they are available only for limited use
and in clinical trials.
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3. Blood—The hemoglobin concentration at which blood
should be transfused is still hotly debated. The so-called trans-
fusion trigger depends on a number of factors, including age,
comorbid factors, presence of ongoing bleeding, etc. In healthy
human volunteers, isovolemic hemodilution is tolerated at
concentrations as low as 5 g/dL, whereas the National
Institutes of Health recommend a concentration of greater
than 7 g/dL. Traditionally, the transfusion trigger was set at
10 g/dL, but epidemiologic studies have shown that early
transfusion is a strong independent risk factor for multiple-
organ failure. While the exact mechanism is not known, neu-
trophil priming may play a role. This occurs when passenger
leukocytes accompanying stored red blood cells generate proin-
flammatory agents. Such agents increase at between 14 and 42
days of blood storage. Additional factors such as decreased red
cell deformability and cytokine production also have been cited.
Current Controversies and Unresolved Issues
A. Crystalloids versus Colloids—The crystalloid versus col-
loid debate has emerged anew, fueled by the findings that the
traditional lactated Ringer’s solution may be proinflamma-
tory and that hypertonic saline may suppress disadvanta-
geous immune responses. Presently, there is no clear
indication that the current use of lactated Ringer’s or normal
saline as the resuscitation fluid of choice should be changed.
Additional studies on the use of single-isomer solutions and
hypertonic saline will be required. A meta-analysis of colloid
use found an increase in the absolute number of deaths when
compared with crystalloid, thus discouraging the use of
high-molecular-weight solutions.
B. Ischemia-Reperfusion—Ischemia-reperfusion is an area
of critical investigation. Clarification of the mechanism of
oxygen radical tissue destruction with tissue reperfusion may
help to prevent some of the complications of ischemia. A
number of compounds, including diltiazem, amiloride, and
pentoxifylline, have been explored in an effort to improve car-
diac, peripheral vascular, and renal function after reperfusion.
C. Endpoints—The endpoints of resuscitation are parame-
ters such as blood pressure, heart rate, and urine output.
Tissue-specific monitors such as tissue oxygen tension
(TPO2) and intramucosal pH (pHi) have received recent
attention as objective indices. Because of the time required
for pHi sample collection, it is unlikely to become a clinically
useful tool for resuscitation. It may, however, be valuable for
monitoring patients after they have stabilized. Tissue oxygen
measurements use several modalities, including electrodes
and fluorescence-quenching optodes. The latter has proved
to be a reliable indicator of oxygen tension in the subcutaneous
and visceral tissues during shock and resuscitation. Its clini-
cal usefulness remains to be demonstrated.
D. Bacterial Translocation—The anomalous appearance of
sepsis in patients who develop hypovolemic shock has raised
the question of intestinal bacterial translocation. This theory
proposes that ischemia of the intestinal mucosa allows
luminal bacteria to pass through or between cells and into
the portal venous system. The mechanism has been clearly
demonstrated in animals, but definitive evidence in humans
is lacking. Elucidation of this mechanism may provide infor-
mation on the prevention of sepsis in this setting.
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DISTRIBUTIVE SHOCK
Distributive shock is so named because of the redistribution
of blood flow to the viscera. The three types of distributive
shock commonly treated in ICUs are septic, anaphylactic,
and neurogenic shock.
 Septic Shock
ESSENT IALS  OF  D IAGNOS I S
 Increased cardiac output in the face of decreased blood
pressure.
 Decreased peripheral oxygen consumption.
 Decreased systemic vascular resistance.
 Decreased ventricular ejection fraction.
 Associated multiple organ system failure.
General Considerations
The incidence of septic shock has been increasing in the United
States over the past several years. Approximately
100,000–300,000 people develop bacteremia each year, and
one-half of these patients progress to septic shock. The overall
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mortality rate from septic shock is between 40% and 60%.
Higher death rates occur in the aged and in those with compro-
mised immune status as a result of trauma, diabetes, malignancy,
burns, cirrhosis, or treatment with antitumor chemotherapeutic
agents. Aerobic gram-negative bacillary infections are the most
common cause. The predominant organisms are Escherichia coli
and Klebsiella. Gram-positive organisms such as staphylococci
and fungi also may cause septic shock.
A. Pathogenesis—It is unlikely that bacteria per se are
responsible for septic shock. Rather, interactions between their
products and normal host defenses probably elicit the usual
reactions. Gram-negative organisms have complex walls com-
posed of lipopolysaccharides and proteins. Endotoxin is a
lipopolysaccharide component of the outer membrane. It is
composed of oligosaccharide side chains, a core polysaccha-
ride, and lipid A. The chemical and physical structure of the lat-
ter is highly conserved between different bacterial species and is
highly antigenic. In both animal and human studies it has been
shown that infusion of lipid A causes many of the same effects
observed in clinical sepsis. Endotoxin has effects on multiple
regulatory systems, including complement, kinins, coagulation,
plasma phospholipases, cytokines, β-endorphins, leukotrienes,
platelet-activating factor (PAF), and prostaglandins.
Cytokines are a group of proteins produced by white blood
cells in response to a number of stimulating factors. Although
multiple cytokines have been identified, those known to
be involved in the human septic response are TNF and
interleukin-1 (IL-1), IL-2, and IL-6. These agents are likely to
have both beneficial and deleterious effects. Increased levels of
TNF, IL-1, and IL-6 have been correlated with a poor outcome.
TNF produces hypotension and decreased ventricular func-
tion in animal studies. The cytokines are known to induce the
release of counterregulatory hormones such as glucagon, epi-
nephrine, and cortisol, which are necessary to support the
response to sepsis. Cytokines responsible for modulation of
the immune response include IL-4, IL-6, IL-10, IL-11, IL-13,
and IL-1Ra (receptor antagonist). Compounds responsible for
amplification of the immune response include IL-8, IL-12, IL-
18, PAF, serotonin, and the eicosanoids.
Circulating endotoxin induces the production of a num-
ber of white blood cell products that arise from the release
of arachidonic acid from leukocyte cell membranes medi-
ated by phospholipase A2. The mobilized arachidonic acid
then can follow one of two pathways: conversion to
leukotrienes via the lipoxygenase pathway or creation of
prostaglandins and thromboxanes via the cyclooxygenase
pathway (Figure 11–1). The lipoxygenase and cyclooxygenase
 Figure 11–1. Pathways of arachidonic acid. (Adapted from Holcroft J, Robinson MK: Shock: Identification and management
of shock states. In: Care of the Surgical Patient. Scientific American, 1992.)
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compounds have distinct actions (Table 11–4). Phospholipase
A2 also releases membrane-bound alkyl phospholipids that
may be converted into PAF, the most potent lipid mediator
known. The actions of PAF include activation of phagocytes
as well as of platelets, production of oxygen-free radicals,
increase of vascular permeability, and decrease of cardiac
output and blood pressure. Cells known to produce PAF
include neutrophils, basophils, endothelial cells, and
platelets.
Several plasma proteases are activated in septic shock.
These include the kinin system, the clotting cascade, and the
complement system. Endotoxin and gram-positive bacteria
both activate the complement cascade via the extrinsic path-
way. The effects of complement activation include (1)
increased vascular permeability, (2) release of toxic oxygen
metabolites by activated phagocytes, and (3) increased
opsonization and phagocytosis by neutrophils and
macrophages. It is likely that the increased vascular perme-
ability so produced plays an important role in the hemody-
namic picture characteristic of septic shock. A correlation
has been demonstrated between increased concentration of
activated complement and mortality rates. Concomitant
activation of Hageman factor (XIIa) may be responsible for
the disseminated intravascular coagulopathy associated with
sepsis. Factor XIIa also may lead to the conversion of
prekallikrein to kallikrein and ultimately to the release of
bradykinin, which causes severe hypotension.
Recent interest has focused on the roles of toxic oxygen
metabolites and nitric oxide. Activated phagocytes produce
oxygen radicals that kill ingested bacteria. When these prod-
ucts leak from the cell, they may cause severe tissue damage.
Endothelium-derived relaxing factor (EDRF) is another
toxic-free radical species. Chemically, it is nitric oxide (NO).
While small quantities of NO may improve blood flow in the
microcirculation, higher concentrations produce vasodila-
tion and hypotension. NO may arise from several cell lines,
including neutrophils, the vascular endothelium, and
Kupffer cells. NO synthetase is induced by both endotoxin
and TNF. It produces NO from L-arginine.
B. Hemodynamic Effects—The distinguishing hemody-
namic features of septic shock are elevated cardiac output,
decreased systemic vascular resistance, and decreased blood
pressure. Tachycardia is partially responsible for maintain-
ing the blood pressure. Earlier investigators described
hyperdynamic and hypodynamic phases of septic shock.
More recent investigations have shown, however, that car-
diac output remains elevated until decreased output devel-
ops as a preterminal event. It is likely that the earlier
observations were made in patients who were inadequately
fluid-resuscitated.
Right and left ventricular ejection fractions are decreased
in septic shock, as is left ventricular stroke work. In contrast
to hypovolemic shock, increasing preload by administering
volume only minimally increases left ventricular stroke
work. This may be due to altered compliance characteristics
of the ventricles. Pulmonary artery hypertension, which fre-
quently develops early, also may be partially responsible for
right ventricular dysfunction. Cardiac adrenergic downreg-
ulation also occurs. The number of receptors and their
affinities are reduced. Patients who recover from septic
shock increase their left ventricular stroke work index,
whereas those who succumb do not. Radionuclide scans
have shown that left ventricular dilation occurs within
1–2 days of the onset of shock. This increased end-diastolic
volume permits a greater stroke volume in the face of
decreased ejection fraction. Left ventricular dilation
improves as patients recover. Despite the ventricular abnor-
malities, the coronary circulation exhibits above-normal
flow, normal myocardial oxygen consumption, and net
myocardial lactate extraction.
The myocardial depressant factor (MDF) of sepsis has
been characterized as a low-molecular-weight protein
(<1000). Patients with cardiac disease and sepsis without
shock fail to exhibit such activity. MDF may originate from
the intestinal tract in patients with hypovolemic shock. The
cytokines and endotoxin have been suspected as the origin of
MDF. However, TNF has a molecular weight of 17,000.
Lipopolysaccharide, IL-1, and IL-2 in high concentrations
Mediator Actions 
Prostacyclin (PGI2) Vasodilation
Decreased platelet aggregation 
PGE2 Vasodilation
Immunomodulation
Platelet aggregation 
PGF2 Vasodilation 
PGD2 Vasodilation 
Thromboxane A2 Vasoconstriction
Increased platelet aggregation 
LTB4 Chemotaxis
Leukocyte–endothelial cell adhesion 
LTC4 Immunomodulation
Vasoconstriction
Bronchoconstriction
Increased vascular permeability 
LTD4 Vasoconstriction
Bronchoconstriction
Increased vascular permeability
LTE4 Vasoconstriction
Bronchoconstriction
Increased vascular permeability
Table 11–4. Actions of arachidonic acid mediators. 
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fail to duplicate the effect of MDF. The decrease in circulat-
ing plasma volume owing to increased capillary permeability
is a major influence in the hemodynamic pathophysiology of
sepsis. In addition to actual transudation of fluid from the
intravascular into the interstitial space, peripheral pooling,
hepatosplanchnic venous pooling, and gastrointestinal and
wound losses—along with idiopathic polyuria—also reduce
cardiac preload.
Changes in the pattern of blood flow distribution are
characteristic of septic shock. It was once thought that shunt-
ing of blood through cutaneous arteriovenous pathways was
responsible for decreased peripheral oxygen extraction, but
the anatomic presence of such shunts has not been demon-
strated. Rather, it is likely that a mismatching of blood flow
and metabolic demand occurs. Thus some organs receive
supranormal oxygen delivery, whereas others are rendered
ischemic. This is of particular importance in the splanchnic
circulation, where hepatic venous desaturation has been
reported in septic patients. Oxygen extraction is also
affected, resulting in flow-dependent oxygen consumption. A
normal or elevated mixed venous oxygen saturation and
decreased arterial-venous oxygen content difference is pres-
ent. Lactic acidosis may indicate the presence of pathologic
oxygen delivery-dependent consumption. It is unlikely that
oxygen utilization is limited by mitochondrial dysfunction.
C. Metabolic Abnormalities—The extent of the metabolic
response to sepsis depends not only on the duration and
severity of the illness but also on the premorbid nutritional
and immunologic status. Even though systemic oxygen con-
sumption is decreased, the metabolic rate in sepsis is
markedly elevated. Mixed fuels serve as the energy source,
with an increase in the respiratory quotient (RQ) to between
0.78 and 0.82. Hepatic glucose production is markedly
increased, with lactate and alanine serving as the major glu-
coneogenic precursors. Hyperglycemia is common, as is
insulin resistance. The elaboration of catechols in
response to the cytokines induces lipolysis, although
ketosis is reduced as a result of decreased hepatic production.
Hypertriglyceridemia may occur as a result of increased
hepatic synthesis and decreased lipoprotein lipase activity.
Protein turnover is greatly increased as a result of the break-
down of skeletal muscle, connective tissue, and visceral pro-
teins as acid sources. Branched-chain amino acids serve as
the preferred fuel source for skeletal muscle. Production of
acute-phase reactants is increased, whereas production of
albumin and transferrin is decreased.
D. Multiple-Organ Failure—Septic shock affects virtually
all organ systems (Table 11–5). Although the exact mecha-
nism responsible is not clear, this may result from microvas-
cular injury and local inflammatory responses. Ischemia
results from tissue hypoperfusion as blood flow is redistrib-
uted away from tissues with high metabolic demands.
The usual progression of organ system failures is pul-
monary, hepatic, and renal. The mortality rate is propor-
tionate to the number of organ systems that fail and reaches
80–100% when three or more systems are involved.
Respiratory failure occurs in 30–80% of patients with sep-
tic shock and usually is in the form of ARDS. Hypoxemia
refractory to increasing levels of support is characteristic.
An elevated intrapulmonary shunt (
.
Qs/
.
Qt) makes the
hypoxia resistant to increased concentrations of inspired
oxygen. Pulmonary hypertension, increased extravascular
lung water, and decreased pulmonary compliance accom-
pany the syndrome. Respiratory muscle fatigue and
depressed diaphragmatic contractility further complicate
the situation.
Liver failure is manifested as hyperbilirubinemia and ele-
vation of the aminotransferase and alkaline phosphatase
concentrations. Decreased hepatic amino acid clearance and
an elevation of serum amino acid concentrations are preter-
minal events. Histologic examination reveals intrahepatic
cholestasis with minimal necrosis.
Renal failure may occur as a consequence of hypotension,
from nephrotoxic drug administration (eg, aminoglycosides
and amphotericin B), or from intrarenal corticomedullary
shunting.
Clinical Features
A. Symptoms and Signs—Septic shock is classically defined
as a mean blood pressure of less than 60 mm Hg (systolic
pressure <90 mm Hg)—or a decrease in systolic blood pres-
sure of more than 40 mm Hg from baseline—in a patient
with clinical evidence of infection. Accompanying findings
include fever or hypothermia, tachycardia, and tachypnea.
Patients are frequently obtunded. The skin may be warm if
hypovolemia is not present.
If a pulmonary artery catheter is placed for monitor-
ing, an elevated cardiac output in the face of decreased
systemic vascular resistance will be found. When
decreased cardiac output is noted, hypovolemia should be
suspected. Increased pulmonary artery pressures are com-
mon as a result of vascular reactivity and increased pul-
monary vascular resistance. A pulmonary artery catheter
capable of ejection fraction measurement will indicate a
decrease in right ventricular ejection fraction and stroke
volume. The left ventricular stroke work index is similarly
depressed. Pulmonary capillary wedge pressure (PCWP) is
usually low or normal. Volume infusion to increase the
PCWP generally produces only minimal increases in car-
diac output.
B. Laboratory Findings—Leukocytosis with an increased
percentage of juvenile band forms is the usual finding.
Neutropenia occurs in a small percentage of patients and
portends a poor outcome. Disseminated intravascular coag-
ulation (DIC) with increased prothrombin time, elevated
fibrin split products, and decreased fibrinogen concentration
are also common. Thrombocytopenia occurs in 50% of
patients and may be due to endothelial adherence of platelets
to reactive vascular endothelium. Overt bleeding is noted in
less than 5% of patients.
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Indicators of Dysfunction
Degree of Dysfunction
Mild Moderate Severe 
Respiratory tract PaO2, FIO2, PaO2/FIO2, PEEP number of
days on ventilator; peaks airway pres-
sure; use of high-frequency
ventilation or extra-corporeal
membrane oxygenation
PaO2/FIO2 >250 PaO2/FIO2 150–250 PaO2/FIO2 <150 
Kidneys Creatinine level, creatinine clearance, 
BUN, need for dialysis to regulate
serum potassium and bicarbonate
Creatinine <1.5 mg/dL Creatinine 1.5–3.0 mg/dL Creatinine >3.0 mg/dL; need
for dialysis
Liver Bilirubin, albumin, cholesterol, ALT,
AST, γ-glutamyltransferase, alkaline
phosphatase, ammonia
Bilirubin <3 mg/dL Bilirubin 3–8 mg/dL;
elevation of transami-
nases or alkaline phos-
phatase to twice normal
values
Bilirubin >8.0 mg/dL; 
elevation of serum ammonia
Gastrointestinal tract Stress-related mucosal ulceration and
bleeding, mucosal acidosis, failure of
pH regulation, volume of nasogastric
drainage, ileus, diarrhea, intolerance
of enteral feeding, acalculous
cholecystitis, pancreatitis 
Nasogastric drainage
<300 mL/24 h, diarrhea
in response to enteral
feeding
Nasogastric drainage
300–1000 mL/24 h,
visible blood in drainage
fluid
Nasogastric drainage >1000
mL/24 h, upper GI bleeding
necessitating transfusion,
acalculous cholecystitis,
pancreatitis
Heart Supraventricular arrhythmias, elevated
pulmonary artery wedge pressure and
mean arterial pressure, reduced ven-
tricular stroke-work index, requirement
for inotropes or vasopressors to main-
tain adequate mean arterial pressure 
Development of super-
ventricular tachycardias
with heart rate <140
beats/min and no fall in
mean arterial pressure 
PAWP 16–30 mm Hg;
requirement for dopamine
or dobutamine at dosage
of <10 μg/kg/min to
maintain satisfactory car-
diac output and PAWP
Requirement for vasopres-
sors (eg, dopamine, epi-
nephrine, norepinephrine,
phenylephrine, vasopressin)
to maintain mean arterial
pressure >80 mm Hg
Central nervous
system
Glasgow Coma Scale score, especially
on components reflecting level of
consciousness
Glasgow score 13–14 Glasgow score 10–12 Glasgow score ≤9
Hematologic system Thrombocytopenia, elevated PT and
PTT, elevated fibrin degradation
products
Platelet count
>60,000/mL
Platelet count
20,000–60,000/mL;
mild elevation of PT or
PTT in absence of
anticoagulation 
Platelet count 
<20,000/mL
Metabolic and
endocrine systems
Insulin requirements, levels of T4 and
reverse T3
Insulin requirement ≤1
unit/h
Insulin requirement
2–4 units/h
Insulin requirement
≥5 units/h
Immunologic system Impaired DTH responsiveness, reduced
in vitro lymphocyte proliferation,
infection with ICU pathogens
(eg, S. epidermidis, candida,
pseudomonas, enterococcus)
Reduced delayed type
hypersensitivity reactivity
Cutaneous anergy Cutaneous anergy, recurrent
infection with ICU pathogens
Wound healing Wound infection, impaired formation
of granulation tissue, would
dehiscence
Wound infection Impaired formation of
granulation tissue
Decubitus ulcers wound
dehiscence
From Holcroft J, Robinson MK: Shock: Identification and management of shock states. In: Care of the Surgical Patient. Scientific American,
1992.
Table 11–5. Recognition and assessment of organ system dysfunction.
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Hyperglycemia is common and probably reflects the
action of counterregulatory hormones such as epinephrine,
cortisol, and glucagon. Elevation of the serum glucose con-
centration in a patient receiving intravenous hyperalimenta-
tion may be the first indicator of impending sepsis.
Hypoglycemia is frequently a preterminal event. Increased
lactate concentration is common and reflects cellular hypop-
erfusion. Liver chemistries reveal an increase in bilirubin,
aminotransferase, and alkaline phosphatase concentrations.
Mixed substrate fuel consumption increases the respira-
tory quotient to near 0.8. Hypermetabolic protein turnover is
reflected by a negative nitrogen balance. Total serum amino
acid levels are increased with the exception of branched-
chain amino acids (eg, leucine, isoleucine, and valine), which
are decreased.
Arterial blood gas determinations typically indicate mod-
erate hypoxemia and metabolic acidosis. Unless severe respira-
tory muscle weakness is present, PaCO2 is usually normal or
only minimally elevated. The extent of arterial hypoxemia is
related to the severity of the accompanying respiratory distress
syndrome. The decrease in bicarbonate concentration may
be greater than the increase in lactic acid level, which may be
increased owing to both cellular metabolic failure and failure
of the liver to clear excess production. Blood lactate levels have
been shown to have greater prognostic value than oxygen-
derived variables. Venous blood gases reveal an increased
hemoglobin saturation. Although peripheral oxygen delivery
is elevated, peripheral oxygen consumption and oxygen
extraction are depressed. The arterial-venous oxygen content
gradient is narrowed and may be less than 3 mL/dL. As volume
is administered and oxygen delivery is increased, a correspon-
ding increase in 
.
VO2 also may be noted. This supply depend-
ency of oxygen consumption is characteristic of sepsis.
C. Microbiology—Positive blood cultures are present in
about 45% of patients with the septic syndrome and septic
shock. The frequency of organisms present varies in different
studies, although gram-negative aerobic species usually pre-
dominate. A study found that 26% of patients with aerobic
gram-negative bacteremia developed shock, whereas only
12% of those with gram-positive bacteremia went on to
shock. There are no consistent differences in the laboratory
findings of those with and without positive blood cultures.
Furthermore, the mortality rates in the two groups are about
the same (30% without versus 36% with). Other infecting
organisms include Candida albicans and Bacteroides fragilis.
Fungal infections are particularly common in patients with
disorders associated with systemic immunocompromise
such as diabetes. The prolonged use of antimicrobials and a
history of polymicrobial bacterial infections also predispose
to fungal sepsis.
Differential Diagnosis
The difference between true septic shock and the septic syn-
drome is a matter of degree. The major differential factor is
that hypotension is not part of the septic syndrome. Other
forms of distributive shock include anaphylaxis and neurogenic
shock. A history of recent drug administration in the former
and trauma in the latter should aid in diagnosis.
Hemodynamic and cardiac shock rarely cause differential
problems.
Treatment
A. Early Goal-Directed Therapy—Because of the numerous
strategies available for the treatment of septic shock (BP <90
mm Hg), increased emphasis has been placed on evidence-
based management. To this end, a protocol was developed as
part of an international effort to create guidelines for the
treatment of severe sepsis. The general protocol for such
treatment is outlined in Figure 11-2.
B. Fluid Resuscitation—Restoration of adequate circulating
blood volume is the first and most important therapy for
septic shock. Loss of intravascular volume may be through
capillary leaks, fistulas, diarrhea, or emesis. Patients may not
Transfusion of
red cells until
hematocrit ≥30%
Colloid
Supplemental oxygen ±
endotracheal intubation
and mechanical ventilation
Central venous and
arterial catheterization
Sedation, paralysis
(if intubated), or both
CVP
MAP
ScvO2
Goals
achieved
Transfer from
ICU
8–12 mm Hg
≥65 and
≤90 mm Hg
≥70%
Yes
No
Crystalloid
Vasoactive agents
Inotropic agents
<65 mm Hg
>90 mm Hg
<8 mm Hg
<70%
≥70%
<70%
 Figure 11-2. A general protocol for early goal-directed
therapy in the management of severe sepsis and septic
shock.
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have been receiving adequate oral intake or may have
received insufficient maintenance intravenous fluid.
Crystalloid is preferred by most physicians as the initial fluid
for resuscitation. Rather than simply increase the infusion
rate, patients should receive boluses of 500–1000 mL of fluid
at a time. Because the extent of peripheral vasodilation may
be massive, these patients may require large amounts of fluid.
A central venous pressure catheter may be inserted to guide
therapy. Bolus administration of volume should be titrated
to maintain central venous pressure between 8 and 12 mm Hg.
If a pulmonary artery flotation catheter is used, PCWP needs
to be elevated to higher than normal levels before an ade-
quate cardiac output and blood pressure are achieved.
Typically, a PCWP of between 10 and 15 mm Hg will be
required. This may call for the administration of several liters
of balanced salt solution. Ongoing capillary leakage calls for
continuing aggressive fluid replacement. Infusion should be
monitored by watching for signs of pulmonary edema and
congestive heart failure. Peripheral edema may be noted and
is a normal consequence of the capillary leak that accompa-
nies the systemic inflammatory response syndrome. The
choice of crystalloid or colloid resuscitation remains contro-
versial. Two meta-analyses that compared albumin and crys-
talloid found that mortality was higher among those who
received albumin. However, some studies have found a trend
toward reduced mortality when albumin was used. Because
there is no clear benefit of either solution at this time, most
clinicians prefer crystalloid solutions because of their
reduced choice and universal availability.
C. Respiratory Support—Many patients with septic shock
will have severe respiratory distress syndrome. They also may
be unable to meet the increased demands of the work of
breathing. Semielective endotracheal or orotracheal intuba-
tion is recommended prior to the development of respiratory
arrest. After intubation, mechanical ventilation always
should be instituted to decrease the work of breathing. Many
patients will require high inspired oxygen concentrations
and positive end-expiratory pressures (PEEP). Inverse I:E
ratio, pressure-controlled, and/or pressure-regulated
volume-control ventilation may be required if pulmonary
compliance is severely compromised. Airway pressure-
release ventilation (APRV) is also useful in those with ARDS
and poor oxygenation. The great advantage of APRV is that
patients can be weaned from it directly without having to
employ other modes. Treatment of respiratory failure is dis-
cussed in Chapter 3.
D. Pharmacologic Support—If intravascular volume resus-
citation fails to restore blood pressure toward normal, phar-
macologic support with pressor drugs is indicated. Target
mean arterial pressure is between 60 and 65 mm Hg,
although the optimal pressure is still debated. It is important
not only to measure arterial pressure but also to evaluate
overall perfusion based on SvO2, urine output, and resolution
of increased arterial lactate. Both peripheral and cardiac
adrenergic receptors appear to be downregulated in sepsis,
making the required dose of pressors higher than otherwise
might be expected. Dopamine and norepinephrine are the
most common pressors used for the treatment of septic
shock. Although dopamine was used often initially in the
past, there has been a trend toward the use of norepinephrine
as the first-choice pressor (see below). Although no large-
scale trials have been completed to determine which agents
are associated with better outcomes, there is some evidence
to suggest that patients who have not received dopamine
have a lower 30-day mortality than those who have.
1. Dopamine—Dopamine is the immediate precursor of
endogenous norepinephrine. Dopamine’s hemodynamic
effects are due to the release of norepinephrine from sympa-
thetic nerves and the direct stimulation of alpha, beta, and
dopaminergic receptors. Approximately 50% of dopamine’s
effect is due to the release of norepinephrine. When com-
pared with dobutamine, dopamine’s effect is less pro-
nounced after endogenous norepinephrine stores have been
depleted. At lower doses (2–5 μg/kg per minute), dopamine
increases cardiac contractility and cardiac output without
increasing heart rate, blood pressure, or systemic vascular
resistance. Renal blood flow and urine output increase in
response to doses of 0.5-2 μg/kg per minute as a result of
selective stimulation of dopaminergic receptors. When doses
reach 10 μg/kg per minute, dopamine has both a
chronotropic and an inotropic effect. At infusion rates in
excess of 10 μg/kg per minute, alpha-adrenergic stimulation
occurs, along with an increase in systemic vascular resistance.
The metabolic effects of dopamine administration include
decreased aldosterone secretion, inhibition of thyroid-
stimulating hormone and prolactin release, and inhibition of
insulin secretion. Because it increases cardiac output,
dopamine can increase pulmonary shunting by augmenting
flow to poorly ventilated lung regions.
After ensuring adequate fluid resuscitation, dopamine
infusion is usually started at a dose of 5 μg/kg per minute
and advanced until blood pressure increases. Used in low
doses with norepinephrine, dopamine’s selective effect on
the renal vasculature may continue to allow adequate urine
production while norepinephrine supports the blood pres-
sure by its vasoconstrictive effect.
2. Dobutamine—Dobutamine has predominantly β-
adrenergic inotropic effects. It has a relatively minor
chronotropic effect. Unlike dopamine, it does not cause the
release of endogenous norepinephrine. It produces less
increase in heart rate and peripheral vascular resistance than
an equally inotropic dose of isoproterenol. It is the pressor of
choice in patients with adequate blood pressure but depressed
cardiac output. Onset of action is within 1–2 minutes, although
the peak effect may not be reached until 10 minutes after
administration. The plasma half-life is 2 minutes. The drug is
methylated and excreted in the urine. Dobutamine tends to
lose its hemodynamic effect after prolonged administration
probably because of downregulation of receptors. However,
dobutamine is a better choice for long-term infusion than
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dopamine because the latter depletes myocardial norepineph-
rine stores. Dosage typically ranges from 5–15 μg/kg per
minute. Increased urine output also may be achieved after
dobutamine administration because of increased renal perfu-
sion from elevated cardiac output. Infusion is begun at a rate
of 2–5 μg/kg per minute and titrated to the desired effect.
Maximal benefit is usually achieved at levels between 10 and
15 μg/kg per minute.
3. Alpha-adrenergic agents—Despite adequate volume
resuscitation and improved cardiac output, blood pressure
may remain depressed. Phenylephrine and norepinephrine
are two agents commonly used to increase systemic vascular
resistance.
Norepinephrine is the biosynthetic precursor of epineph-
rine, and as such posses both α- and β-adrenergic activity. In
low doses, its major effect is β-adrenergic. It increases cardiac
contractility, conduction velocity, and heart rate. At higher
doses, both α- and β-adrenergic effects occur, which include
peripheral vasoconstriction, increased cardiac contractility, car-
diac work, and stroke volume. Norepinephrine causes splanch-
nic vasoconstriction, which may lead to end-organ ischemia.
The drug is cleared rapidly from the plasma with a half-life of
approximately 2 minutes. Initial infusion rates are 0.5–1
μg/min. The usual maximum dose is 1 μg/kg per minute.
4. Vasopressin—Vasopressin (antidiuretic hormone) is nor-
mally released by the hypothalamus and produces vasocon-
striction of vascular smooth muscle in addition to its
antidiuretic effect on the renal collecting system. At low plasma
concentrations it causes vasodilation of the coronary, cerebral,
and pulmonary vessels. Vasopressin levels increase in early sep-
tic shock and later fall as sepsis worsens. When given in doses
of 0.01–0.04 units/min, vasopressin infusion increases serum
vasopressin levels and decreases the need for other vasopres-
sors. At this dose, urinary output may increase, and pulmonary
vascular resistance may decrease. Doses higher than 0.04
units/min can cause undesirable vasoconstrictive effects.
5. Vasodilators—Because decreased vascular resistance is
the primary cause of hypotension in septic shock, further
pharmacologic vasodilation is contraindicated. Occasionally,
severe myocardial depression is accompanied by an increase
in systemic vascular resistance. This preterminal event puts
further strain on the left ventricle and may cause complete
hemodynamic collapse. Judicious use of vasodilators such as
nitroprusside may be tried. Nitroglycerin is probably an infe-
rior choice because it also reduces preload.
E. Antimicrobial Agents—Identification of the source of
sepsis is imperative. If the offending tissue bed is not drained
or if bacteremia is not treated, outcome will be adversely
affected. Evaluation of the patient’s history is essential to deter-
mine likely sources. Once the probable origin has been identi-
fied, appropriate antimicrobial therapy can be instituted to
provide coverage for organisms commonly encountered. The
details of diagnosis and therapy of infections are presented in
Chapters 15 and 16. When a likely source cannot be identified,
empirical broad-spectrum therapy should be instituted with
drugs known to be effective against gram-positive, gram-
negative, and anaerobic organisms. In surgical patients who
have had abdominal procedures, enteric gram-negative and
anaerobic organisms are of particular concern. Attention must
be given to dosing in these patients because alterations in renal
function may affect degradation and because an expanded
plasma volume affects the volume of distribution and there-
fore the size of the loading dose that must be given.
F. Glycemic Control—Hyperglycemia is defined as a blood
glucose concentration of greater than 110 mg/dL and is com-
mon in critically ill patients. Multiple factors contribute to
hypergylcemia, including increased levels of stress hor-
mones, peripheral insulin resistance, drugs, and exogenous
dextrose infusion. Hyperglycemia has a number of detrimen-
tal effects, including decreased leukocyte adhesion, impaired
neutrophil chemotaxis, and phagocytosis. Hypergylcemia
also may be prothrombotic.
Rigid control of hyperglycemia has been shown to
improve outcome, likely by reducing the incidence of sepsis-
induced multiple-organ failure. Additionally, tight control
has been shown to reduce the length of stay in the ICU, atten-
uate the inflammatory response, decrease antibiotic use,
reduce the incidence and duration of critical-illness polyneu-
ropathy, and reduce the number of ventilator days.
Glucose control may be provided with either a glucose
concentration–dependent dose (“sliding scale”) or a con-
stant infusion for higher serum glucose levels. Typically, glu-
cose levels should remain below 130 mg/dL.
G. Corticosteroids—While older studies demonstrated no
benefit to the use of supraphysiologic doses of corticos-
teroids, more recent work has found that lower physiologic
doses for longer periods of time may be beneficial. Patients
should undergo a Cortrosyn stimulation test. After obtaining
blood for a baseline concentration of serum cortisol, 250 μg
Cortrosyn is given intravenously, and blood for a repeat
serum cortisol assay is collected 30–60 minutes later. If there
is concern that the patients is hypoadrenal, 4 mg dexametha-
sone can be given prior because it does not interfere with the
test. If the increase after Cortrosyn is less than 9 μg/dL, there
is insufficient adrenal reserve, and 50 mg hydrocortisone
should be given every 6 hours for 7 days. This should be sup-
plemented with fludrocortisone 50 μg orally every day. It is
likely that all patients should be started on replacement cor-
ticosteroid until the results of the stimulation study are
known, at which time supplementation can be withdrawn
from those who responded to the stimulation test.
H. Drotrecogin Alfa—Drotrecogin alfa is a glycoprotein ana-
logue of protein C that is activated by thrombin. Activated
protein C inhibits coagulation, increases fibrin breakdown,
and possibly inhibits the synthesis of TNF. A large clinical
study of drotrecogin alfa found a reduction in mortality from
30.8% in patients treated with placebo to 24.7% in those
treated with the drug. The most important adverse effect of
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the drug is bleeding, which occurred in 3.5% of those treated
with the drug compared with 2% treated with placebo.
Although the incidence of bleeding did not reach statistical
significance, the drug is contraindicated in patients with active
or recent bleeding or a high risk of bleeding, an epidural
catheter, or intracranial hemorrhage. It should be used cau-
tiously in those at risk for bleeding. Drotrecogin alfa is admin-
istered intravenously at a continuous dose of 24 μg/kg per
hour for 96 hours. No alteration in the dose is required for
those with renal or hepatic compromise. The drug’s cost is
approximately $8000 for a 4-day regimen in a 70-kg patient.
I. Transfusion—The traditional transfusion threshold of 10
mg/dL has been challenged by the finding that patients are
not adversely affected by withholding transfusion until
hemoglobin concentration drops to between 7 and 9 g/dL.
Further, there may be some advantage to lower hemoglobin
concentrations in patients older than age 55. Such data come
from broad groups of patients, and specific conclusions can-
not be drawn. It is likely, however, that more restrictive
thresholds are not harmful and actually may reduce mortal-
ity. The availability of recombinant human erythropoietin
may be a useful adjunct to reducing the need for transfusion
in critically ill patients.
J. Other Modalities—Septic patients require multimodality
support, including gastrointestinal and renal. To this end,
proper prophylaxis against gastric stress ulceration should be
provided with either H2-receptor blockade or proton pump
inhibitors. Additionally, renal function must be monitored
closely, and appropriate support with either hemofiltration
and/or dialysis should be provided. Adequate prophylaxis
against deep venous thrombosis includes either unfraction-
ated or low-molecular-weight heparin. The dose of some
low-molecular-weight heparins needs to be adjusted or with-
held in patients with renal failure. Lower extremity compres-
sion stockings are valuable adjuncts.
Current Controversies and Unresolved Issues
A. Fluid Resuscitation—The choice of fluid for the initial
and continued resuscitation of septic patients is widely
debated. Proponents of balanced salt solutions claim that pul-
monary dysfunction is not worsened by judicious administra-
tion guided by endpoints such as ventricular filling pressure
and cardiac output. Colloids increase the circulating plasma
volume more effectively than do crystalloids, but they are
expensive. When pulmonary microvascular permeability is
increased, colloids actually may worsen respiratory function
by increasing the osmotic gradient favoring translocation of
fluid into the alveolar and pulmonary interstitial spaces.
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 Anaphylactic Shock & Anaphylactoid
Reactions
ESSENT IALS  OF  D IAGNOS I S
 Cutaneous flushing, pruritus.
 Abdominal distention, nausea, vomiting, diarrhea.
 Airway obstruction owing to laryngeal edema. 
 Bronchospasm, bronchorrhea, pulmonary edema. 
 Tachycardia, syncope, hypotension. 
 Cardiovascular collapse. 
General Considerations
Anaphylactic shock and anaphylactoid reactions are due to
the sudden release of preformed inflammatory mediators
from mast cells and basophils. After exposure to the offend-
ing stimulus, initial symptoms may appear within seconds to
minutes or may be delayed as long as 1 hour. Anaphylactic
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shock is differentiated from anaphylactoid reactions in that
the former is a true anamnestic response in which a sensi-
tized individual comes in contact with an antigenic sub-
stance. This reaction stimulates membrane-bound IgE,
causing mast cells and basophils to release histamine and
PAF into the circulation. These mediators result in vasodila-
tion, bronchoconstriction, pruritus, bronchorrhea, platelet
aggregation, and increased vascular permeability. The latter
may lead to laryngeal edema that culminates in airway
obstruction. The frequency and outcome of anaphylactic
reactions are summarized in Table 11–6. Anaphylactoid reac-
tions occur when the offending agent causes the direct release
of these substances without mediation by IgE. This may
involve a number of pathways, including complement-
mediated reactions, nonimmunologic activation of mast
cells, and production of arachidonic acid mediators.
Reactions to nonsteroidal anti-inflammatory drugs
(NSAIDs) are particularly dangerous because NSAID inhibi-
tion of the cyclooxygenase pathway favors the formation of
lipoxygenase pathway mediators from arachidonic acid.
Some of these include leukotrienes C4, D4, E4 (slow-reacting
substance of anaphylaxis), and B4. These leukotrienes and
their intermediate products (5-HETE and 5-HPETE)
increase vascular permeability and produce bronchocon-
striction. Leukotriene B4 is an eosinophilic and neutrophilic
chemoattractant. If the cyclooxygenase pathway is activated
by the inciting agent, the production of prostaglandin D2
furthers bronchoconstriction. The most common agents
causing anaphylactic shock and anaphylactoid reactions are
listed in Tables 11–7 and 11–8. Anaphylactoid reactions may
occur in up to 10% of patients. When an initial reaction
occurs after the infusion of radiocontrast agents, the risk of a
similar reaction on reexposure approaches 35%.
Clinical Features
A. Symptoms and Signs—The initial symptoms are often
complaints of pruritus and a sense of impending doom.
These can progress to overt signs over several seconds or may
be delayed for up to an hour. Respiratory symptoms may
start with complaints of a lump in the throat, progressing to
dyspnea, dysphonia, hoarseness, and cough. If pulmonary
edema develops as a result of increased capillary permeability,
dyspnea and cyanosis result. Cardiovascular findings begin
with symptoms of weakness and faintness that may be accom-
panied by palpitations. As shock progresses, tachycardia
Agent 
Frequency of Events
Mild Severe
Deaths per Year
(USA) 
Penicillin 0.5–1% 0.04% 400–800 
Hymenoptera stings 0.5% 0.05% ≥100 
Contrast media 5% 0.10% 250–1000 
From Lavine SJ, Shelhamer JH: Anapyhlaxis. In: Critical Care.
Civetta JM, Raylor RW, Kirby RR (editors). Lippincott, 1992.
Table 11–6. Frequency of anaphylactic events and
deaths.
Haptens Foods Venoms 
Beta-lactam antibiotics Nuts Stinging insects, 
Sulfonamides Shellfish especially 
Nitrofurantoin Buckwheat Hymenoptera, 
Demeclocycline Egg white fire ants
Streptomycin Cottonseed Hormones
Vancomycin Milk Insulin  
Local anesthetics Corn Adrenocortico-tropic
Others  Potato hormone 
Serum products Rice Thyroid-stimulating
Immune globulin Legumes hormone
Immunotherapy for allergic Citrus fruits Enzymes  
diseases Chocolate Chymopapain  
Heterologous serum Others L-Asparaginase 
Miscellaneous 
Seminal fluid 
Others 
Modified from Austen KF: Systemic anaphylaxis in man. JAMA
1965;192:108; and from Kaliner M: Anaphylaxis. NER Allergy
Proceedings 1984;5:324.
Table 11–7. Etiologic agents responsible for anaphylactic
shock.
Complement-mediated reactions
Blood
Serum
Plasma
Plasmanate (not albumin)
Immunoglobulins
Nonimmunologic mast cell activators
Opioids
Radiocontrast media
Dextrans
Neuromuscular blocking agents
Others
Arachidonic acid modulators
Nonsteroidal anti-inflammatory drugs
Tartrazine (possibly)
Idiopathic
Most common conclusion after thorough evaluation 
Adapted from Kaliner M: Anaphylaxis. NER Allergy Proceedings
1984;5:324. 
Table 11–8. Etiologic agents for anaphylactoid reactions.
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appears along with arrhythmias, conduction disturbances, and
myocardial ischemia. Cutaneous symptoms include flushing
and pruritus that progress to urticaria, angioedema, and
diaphoresis. Patients may complain of abdominal pain or
bloating, cramps, and nausea. These progress to emesis, diar-
rhea, and occasionally hematemesis and hematochezia.
Other signs include syncope, seizures, conjunctival injection,
lacrimation, rhinorrhea, and nasal congestion.
B. Laboratory Findings—An increased hematocrit is found
commonly as a result of hemoconcentration from vascular
permeability. Serum mast cell tryptase is usually elevated.
Differential Diagnosis
Several common disorders seen in the ICU may be confused
with anaphylactic shock and anaphylactoid reactions:
myocardial ischemia and infarction, cardiac arrhythmias,
hypovolemic shock, septic shock, pulmonary embolism, aspi-
ration of feedings, bronchitis, acute exacerbation of chronic
obstructive pulmonary disease (COPD), seizure disorder,
hypoglycemia, and cerebrovascular accidents. Relationship to
administration of medications, blood, and new intravenous
solutions should suggest the possibility of anaphylaxis.
Treatment
A. Airway—The first mandate is to ensure a secure airway. If
the patient was intubated prior to the reaction, one should
take care that the endotracheal or nasotracheal tube does not
become dislodged during resuscitation. If the patient was not
intubated, emergency airway control by bag and mask or
intubation probably will be necessary. It is far better to intu-
bate these patients before laryngeal edema develops because
subsequent intubation is extremely difficult. Some clinicians
recommend the use of inhaled racemic epinephrine (0.3 mL
in 3 mL of saline administered by nebulizer) if upper airway
compromise occurs because of edema. It is far safer to intu-
bate the patient.
B. Circulatory Support—Most patients who develop ana-
phylactic shock or an anaphylactoid reaction in the ICU will
already have intravenous access. However, this catheter may
be small and will not permit the administration of large vol-
umes of fluid over a short period of time. Large-bore peripheral
intravenous lines are mandatory for fluid and drug adminis-
tration. Do not attempt central line placement in a hypoten-
sive patient who is hypovolemic. Collapse of the large veins
normally used for central catheter placement increases the
risk of a life-threatening complication.
1. Epinephrine—Drug therapy should begin with epineph-
rine (1:1000), 0.3–0.5 mL subcutaneously. The dose of epi-
nephrine may be repeated every 5–10 minutes as needed. If
the patient does not respond to the initial dose—or if severe
laryngospasm or frank cardiovascular collapse is present—
5–10 mL of epinephrine (1:10,000) may be administered
intravenously. If intravenous access is not available, either
0.5 mL of a 1:1000 dilution may be given intramuscularly or
10 mL of a 1:10,000 dilution may be instilled into the endo-
tracheal tube. When epinephrine is given intravenously,
severe tachycardia, myocardial ischemia, vasospasm, and
hypertension may result. Epinephrine decreases mediator
synthesis by increasing intracellular concentrations of cAMP.
Furthermore, it counteracts many of the deleterious effects of
the mediators of anaphylaxis.
2. Histamine antagonists—Histamine antagonists should
be administered as early as possible. Diphenhydramine
(1 mg/kg intravenously) and ranitidine (50 mg intravenously
over 5 minutes) are the preferred drugs. Cimetidine must be
used with extreme caution because rapid intravenous admin-
istration may result in hypotension or asystole.
3. Pressors—If hypotension persists after the repeated
administration of epinephrine and histamine antagonists,
aggressive fluid resuscitation is required. If this fails,
dopamine may be started at an initial dose of 5 μg/kg per
minute and increased until the dose reaches 20 μg/kg per
minute. A plateau effect occurs above this dose, requiring
that a second pressor be used if an adequate response has not
yet been achieved. Because of the extreme vasodilation, nor-
epinephrine should be started in the range of 3–4 μg/min
and titrated until a mean arterial pressure between 60 and
80 mm Hg is reached. The patient should be weaned from
pressors as quickly as possible.
C. Other Measures—Continued observation in the ICU is
indicated. An arterial catheter should be inserted for pressure
monitoring and to aid in securing blood gas samples for ven-
tilator management. In patients who remain unstable or who
require continuing pressor infusion, a pulmonary artery
catheter should be placed. Biphasic anaphylaxis may occur in
up to 25% of patients. Life-threatening reactions reappear
after an asymptomatic interval of up to 8 hours following
resuscitation. Hydrocortisone, 100–250 mg intravenously
every 6 hours, may help to prevent the late manifestations of
biphasic anaphylaxis. Steroids probably have no role in the
immediate treatment of acute anaphylaxis.
Patients who are receiving beta-blockers at the time of an
anaphylactic reaction may be resistant to the effects of
administered epinephrine. Atropine and glucagon may be
useful adjuncts to reverse the cardiac manifestations of
anaphylaxis in these patients.
Prognosis
The patient’s overall medical condition, the delay between
exposure to the antigen and the onset of anaphylaxis, and the
severity of symptoms all influence the outcome.
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 Neurogenic Shock
ESSENT IALS  OF  D IAGNOS I S
 Preceded by trauma or spinal anesthesia. 
 Hypotension with tachycardia. 
 Cutaneous warmth and flushing in the denervated area. 
 Venous pooling.
General Considerations
Neurogenic shock is produced by loss of peripheral vasomo-
tor tone as a result of spinal cord injury, regional anesthesia,
or administration of autonomic blocking agents. Blood
becomes pooled in the periphery, venous return is decreased,
and cardiac output falls. If the level of interruption is below
the midthorax, the remaining adrenergic system above the
level of injury is activated, resulting in increased heart rate
and contractility. If the cardiac sympathetic outflow is
affected, bradycardia results. Blood pressure can decrease to
extremely low levels as blood pools peripherally in the
venous reservoir. All patients who have sustained spinal
trauma should be assumed to have hypovolemic shock from
associated injuries until proved otherwise.
Clinical Features
A. Symptoms and Signs—Patients may be alert and
responsive if head injuries are absent. Extremities are warm
above the level of injury and cool below. Blood pressure may
be extremely low, with a very rapid heart rate. Skeletal mus-
culature is affected after trauma. Loss of the peripheral
venous muscular pump may further decrease venous return.
Signs and symptoms of spinal cord injury and spinal shock
will be present.
B. Laboratory Findings—Laboratory studies are not helpful
in diagnosis. Because capillary permeability is normal,
plasma leaks do not occur. Prior to volume resuscitation,
hematocrit is usually normal.
C. Imaging Studies—Radiographs of the cervical, thoracic,
and lumbosacral spine are important to determine whether
fractures are present that may be unstable. These typically
will have been completed before the patient was admitted to
the ICU, but the intensivist must review the films so that
patient manipulations will not cause further spinal cord
injury. CT and MRI may be useful to determine whether
fragments within the spinal canal may be causing cord com-
pression. When present, they may be amenable to neurosur-
gical decompression.
Differential Diagnosis
Trauma patients considered for admission to a critical care
unit after spinal injury must have thorough surgical and neu-
rosurgical evaluation before transfer. The presence of con-
comitant hypovolemic shock from unrecognized bleeding
sites within the abdomen, chest, and extremities must be
excluded. Isolated head injury does not cause shock. Rather,
it may increase the blood pressure while slowing the heart
rate (Cushing’s reflex).
Treatment
A. Supportive Measures—A secure airway and adequate
intravenous access are urgent priorities. If intubation is
required and there is concern regarding the stability of the
cervical spine, fiberoptic or nasotracheal intubation may be
required. A diligent search must be made for other injuries in
trauma patients. When neurogenic shock arises from a spinal
anesthetic procedure in which the level of blockade has
become too high, intubation also may be necessary because
of compromise of the muscles of respiration.
Depending on the level of the injury, patients may have
loss of bladder function. A Foley catheter should be
inserted to decompress the bladder and aid in monitoring
urine output.
B. Fluid Resuscitation—Effective circulating blood volume
decreases dramatically because of venous pooling. Fluid
resuscitation is usually necessary and typically begins with
several liters of balanced salt solution. In some patients, this
may be all that is required to increase blood pressure.
C. Pharmacologic Support—If volume infusion fails to
restore the blood pressure, infusion of an alpha-adrenergic
agent is required to provide direct vasoconstriction. Either
phenylephrine or norepinephrine may be used. These drugs
are started in low doses and increased slowly until just suffi-
cient to restore blood pressure to a mean between 60 and
80 mm Hg. Weaning usually can be achieved fairly quickly, so
central venous or pulmonary artery catheterization is not
often required.
D. Surgery—If spinal cord transection is complete, the only
role for surgery is stabilization of vertebral fractures to pre-
vent further injury. If a foreign body is present, removal may
promote return of function if the cord is intact.
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E. Rehabilitation—After the acute stage has passed and the
patient has been stabilized, planning should be undertaken
to provide long-term care. This is the most difficult part of
the management of these patients. Demands on nursing and
support personnel are extreme in order to prevent pressure
ulcers and urinary and respiratory tract infections and to
provide nutritional support. Early consultation with a psy-
chiatrist is recommended to help the patient adjust to com-
plete and permanent loss of function.
CARDIAC SHOCK
Cardiac shock occurs when the heart fails to adequately
pump the blood volume presented to it. There are two gen-
eral categories: cardiogenic shock and cardiac compressive
shock. Cardiogenic shock develops when the heart loses its
ability to function as a pump. Cardiocompressive shock is
due to compression of the great veins and cardiac chambers,
restricting their normal filling and emptying.
 Cardiogenic Shock
ESSENT IALS  OF  D IAGNOS I S
 Decreased urine output.
 Impaired mental function. 
 Cool extremities. 
 Distended neck veins. 
 Hypotension with evidence of peripheral and pul-
monary venous congestion.
General Considerations
Cardiogenic shock occurs most commonly either after
relentless progression of cardiac disease or after an acute
event such as myocardial infarction or rupture of a cardiac
valve or septum. These causes are summarized in Table 11–9.
The absolute amount of myocardium involved is probably
the most important prognostic factor. When more than 45%
of the left ventricular myocardium is necrotic, cardiogenic
shock becomes evident clinically.
Bradycardia and arrhythmias may underlie cardiogenic
shock. Heart rates less than about 50 beats/min may be inad-
equate to support cardiac output. Similarly, arrhythmias may
significantly alter cardiac filling patterns and prevent ade-
quate pumping.
A staging system has been developed for the classification
of cardiogenic shock that develops on a chronic basis.
A. Stage I (Compensated Hypotension)—The decreased
cardiac output and resulting hypotension invoke compensa-
tory mechanisms able to restore blood pressure and tissue
blood flow to normal levels. These reflexes are mediated by
the arterial baroreceptors, which increase the systemic vascu-
lar resistance.
B. Stage II (Decompensated Hypotension)—Cardiac
output falls below that which enables the peripheral vascula-
ture to maintain blood pressure by vasoconstriction. Blood
pressure and tissue perfusion fall.
C. Stage III (Irreversible Shock)—Profound reduction in
flow activates ischemic mediators such as the complement
cascade. Membrane injury develops that further aggravates
the ischemic insult. Irreversible myocardial and peripheral
tissue damage occur.
Clinical Features
A. Symptoms and Signs—When cardiogenic shock occurs
as a result of an acute event, pain may be a prominent find-
ing. Details of diagnosis and management of acute myocar-
dial infarction are presented in Chapter 22. When shock is an
acute exacerbation of a relentless process or the result of
another disease, symptoms may be less pronounced.
Physical examination will reveal signs consistent with the
underlying pathophysiologic mechanism of decreased car-
diac output and absolute hypervolemia. Blood pressure is
less than 90 mm Hg. The heart rate may be extremely high
and exceed the maximum aerobic limit (230––the patient’s
age in years). When decompensation occurs, bradycardia
usually develops. Neck veins are distended, and pulsations
frequently can be observed more than 4 cm above the clavi-
cle with the patient in the semierect position. Peripherally,
the extremities are cool, reflecting inadequate perfusion.
Abdominal examination may reveal a congested and dis-
tended liver that is tender to palpation. Rales are detected on
auscultation of the lungs in a patient who has a normal right
ventricle. With biventricular failure or pulmonary hyperten-
sion, pulmonary auscultation may be normal. Cardiac exam-
ination typically reveals a third heart sound, and there may
be a murmur characteristic of valvular disease.
B. Hemodynamic Effects—Virtually all patients with car-
diogenic shock will require a pulmonary artery catheter for
monitoring and evaluation of the response to therapy. The
Nonmechanical Causes Mechanical Causes
Acute myocardial infarction 
Low cardiac output syndromes 
Right ventricular infarction 
End-stage cardiomyopathy
Rupture of septum or free wall
Mitral or aortic insufficiency
Papillary muscle rupture or
dysfunction
Critical aortic stenosis
Pericardial tamponade
From Farmer JA: Cardiogenic Shock. In: Critical Care. Civetta JM,
Taylor RW, Kirby RR (editors). Lippincott, 1992. 
Table 11–9. Causes of cardiogenic shock.
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usual findings are elevation of central venous and pul-
monary capillary wedge pressures and a cardiac index less
than about 1.8 L/min/m2.
C. Laboratory Findings—If acute myocardial infarction is
the precipitating cause, elevated cardiac bands of creatine
kinase will be observed. Plasma drug levels of medications
the patient has been receiving should be measured to deter-
mine whether they are in the toxic or subtherapeutic ranges.
A routine chemistry panel is required to evaluate K+ and
HCO3
–. Serum lactate may be elevated when shock has been
prolonged. Hematocrit and hemoglobin should be deter-
mined to evaluate the need for transfusion.
D. Imaging Studies—Chest radiography often will reveal a
pattern of pulmonary edema. Radionuclide ventriculogra-
phy may be helpful in evaluating ventricular ejection frac-
tion. Echocardiography is also useful in the evaluation of
valvular and ventricular function. If pericardial tamponade
is suspected, echocardiography is the examination of choice
to establish that diagnosis.
Differential Diagnosis
Cardiogenic shock should be suspected in patients with
chronic myocardial disease who experience a sudden wors-
ening of symptoms. Acute myocardial infarction may be
complicated by ventricular septal rupture, papillary muscle
rupture, and papillary muscle dysfunction, which can lead to
cardiogenic shock. Constrictive pericarditis and rupture of a
cardiac ventricular aneurysm may lead to cardiac compres-
sive shock. Rupture of an abdominal aortic aneurysm in a
patient with coronary artery disease may cause diagnostic
confusion. Abdominal pain owing to rupture of the
aneurysm may simulate the pain of acute myocardial infarc-
tion. Electrocardiography typically reveals myocardial
ischemia. The absence of distended neck veins is the critical
distinguishing feature. Myocardial contusion after blunt
trauma may cause severe cardiogenic shock.
Treatment 
A. General Measures—Patient comfort and relief of anxi-
ety should be addressed immediately. Opioids not only
relieve pain and provide sedation—but they also block
adrenergic discharge and lessen cardiac stress. Intravenous
morphine should be given starting with a bolus of 2–4 mg.
Dosing should be titrated to both subjective response and
effect on blood pressure. Because morphine is a vasodilator,
it may decrease right ventricular filling and adversely affect
blood pressure in a hypovolemic patient. An arterial catheter
and a pulmonary artery flotation catheter usually are
mandatory to manage these patients effectively.
When cardiogenic shock is the result of acute myocardial
infarction, early efforts should be directed at controlling the
infarct size. An imbalance between oxygen delivery and
increased oxygen consumption prompted by changes in
heart rate, blood pressure, and contractility may extend the
size of the infarction. If therapy is begun within 3 hours of
myocardial infarction, the incidence of cardiogenic shock is
4%. However, if therapy is delayed, cardiogenic shock occurs
in up to 13% of patients. Intravenous nitroglycerin and beta-
blockers are the main features of early treatment.
Nitroglycerin reduces right ventricular preload and
decreases left ventricular afterload. The reduction in after-
load decreases end-diastolic pressure and reduces wall stress
and myocardial oxygen consumption. Furthermore, it dilates
epicardial vessels and may improve oxygen delivery to
ischemic areas. The early use of nitroglycerin both decreases
infarct size and reduces early mortality. The possibility of
right ventricular infarction and pericardial tamponade must
be excluded before therapy with nitroglycerin is begun.
Beta-blockers decrease myocardial oxygen demand,
antagonize circulating catechols, and have antiarrhythmic
activity. A particular benefit may accrue when beta-blockers
are combined with thrombolytic agents. Beta-blockers are
best started within 2 hours of infarction. Calcium channel
blockers also have been investigated for this purpose but have
failed to demonstrate efficacy in acute situations. The mor-
tality rate may be increased if calcium channel blockers are
used in patients with pulmonary edema.
B. Resuscitation—Although cardiogenic shock may occur
in patients with whole body fluid overload, they may be
effectively hypovolemic. If PCWP is less than 10–12 mm Hg,
balanced salt solution should be administered in an attempt
to increase filling pressures. Cardiac output should be meas-
ured after each change of 2–3 mm Hg in PCWP. Filling pres-
sures near 20 mm Hg may be required before cardiac output
increases.
If laboratory studies reveal that the patient is hypoxemic,
supplemental oxygen should be provided. Oxygen delivery
should be maximized by ensuring complete arterial hemo-
globin saturation. Intubation with PEEP may be required to
accomplish this when pulmonary edema is present. Judicious
use of PEEP is required because it adversely affects ventricu-
lar preload and cardiac output.
C. Pharmacologic Support—Once volume status has been
optimized, support of the failing myocardium is often neces-
sary. Inotropes, vasodilators, and diuretics all may be used.
1. Inotropes—
a. Dobutamine—Dobutamine is the inotropic drug of
choice for the management of congestive heart failure and
cardiogenic shock. It is a β1-adrenergic agonist that has min-
imum chronotropic and peripheral vasoconstrictive effects.
It has a significant advantage over dopamine in that it does
not cause the release of norepinephrine. Furthermore, it does
not require the presence of norepinephrine at the nerve ter-
minals for effect. Because of its minimum chronotropic
effect, dobutamine can improve ventricular performance
without significantly increasing myocardial oxygen demand.
Dobutamine’s greatest potential is realized in patients with
reduced cardiac indices and increased filling pressures.
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Because it is a vasodilator, dobutamine reduces filling pres-
sures and wall tensions in patients with dilated ventricles.
This permits better myocardial nutrient flow during diastole.
A recent study found a 33% improvement in cardiac index, a
decrease in systemic vascular resistance, and no change in
heart rate or systemic blood pressure when dobutamine was
given in doses that averaged 8.5 μg/kg per minute. The drug
may be given in doses up to 40 μg/kg per minute without sig-
nificantly increasing heart rate. When three-vessel coronary
artery disease is present, dobutamine may create a steal and
direct blood away from ischemic areas.
b. Dopamine—The effects of dopamine depend on the
dose administered. In lower doses (<4 μg/kg per minute),
dopamine increases renal blood flow by stimulating
dopaminergic (D1) receptors in the kidney and causes
peripheral vasodilation through D2 receptors that inhibit the
release of norepinephrine. At intermediate dosages (5–10
μg/kg per minute), dopamine improves cardiac function and
increases blood pressure without elevating myocardial oxy-
gen consumption. Systemic vascular resistance is usually not
increased. At higher doses (>10 μg/kg per minute),
dopamine elevates systemic vascular resistance by stimulat-
ing alpha-adrenergic receptors and heart rate by stimulating
beta-adrenergic receptors. A recent study found that an aver-
age dose of 17 μg/kg per minute was needed to optimize
coronary perfusion pressure in a group of patients that
developed cardiogenic shock after myocardial infarction.
Dopamine at such high levels increases myocardial oxygen
demand, produces tachycardia, and may limit renal perfusion.
It should be used with caution in patients with cardiogenic
shock because it may adversely influence the balance of
myocardial oxygen delivery and consumption.
c. Digoxin—Although digitalis preparations have modest
inotropic effects, they are probably of little importance in the
treatment of cardiogenic shock except for the treatment of
atrial fibrillation with rapid ventricular response. Small
intravenous doses of digoxin may improve diastolic filling
time and increase cardiac output in these situations.
d. Isoproterenol—This agent causes tachycardia, increased
myocardial contractility, and decreased peripheral vascular
resistance through its stimulation of both α1 and β2 receptors.
Myocardial oxygen consumption is increased dramatically.
Although isoproterenol increases coronary blood flow, it actu-
ally may shunt blood away from ischemic areas and increase
the infarct size. Highly restricted indications include the pres-
ence of bradycardia and severe aortic valvular insufficiency.
Intravenous administration is started at a dose of 0.01 μg/kg
per minute and increased until the desired effect is obtained.
e. Norepinephrine—Norepinephrine has both alpha- and
beta-adrenergic effects. At low doses, it causes beta stimula-
tion of the heart and increases blood pressure and cardiac
output. At higher doses, it primarily affects the alpha-
adrenergic receptors and supports blood pressure by increas-
ing systemic vascular resistance. At higher doses it also tends
to produce tachycardia, arrhythmias, and peripheral visceral
ischemia. Norepinephrine should be used with extreme caution
because at higher doses it increases left ventricular afterload
and may worsen myocardial ischemia. If cardiogenic shock
proves resistant to both dobutamine and dopamine, norepi-
nephrine may be started at doses of 1–2 μg/min and
increased until blood pressure increases. Of particular con-
cern are the visceral and renal vasoconstrictive effects that
may produce end-organ ischemia in the face of apparently
satisfactory blood pressure.
f. Other agents—Amrinone is a weak inotrope that increases
contractility independently of the catechol pathways. Although
its exact mechanism of action is not known, it increases intra-
cellular cAMP and calcium concentrations. The increased
cAMP concentration in smooth muscle decreases peripheral
and pulmonary vascular resistance and dilates coronary arter-
ies. Amrinone increases stroke volume without increasing heart
rate. The usual loading dose is 0.75 mg/kg over 3–5 minutes,
followed by a second bolus 30 minutes later. The boluses are
followed by a continuous intravenous infusion of 5–10 μg/kg
per minute. The total daily dose should not exceed 10 mg/kg.
After the bolus is given, effects are seen within several minutes.
Glucagon increases cardiac contractility and decreases
peripheral vascular resistance. The onset of action is
extremely rapid. A test dose of 4–6 mg should be given intra-
venously to determine whether any effect is produced. If suc-
cessful, this is followed by a constant infusion of 4–12 mg/h.
The agent appears to be useful for the treatment of cardio-
genic shock and left ventricular failure. It probably merits
consideration in patients who have failed to respond to other
agents or when dysrhythmias develop. It may be helpful when
left ventricular dysfunction is a result of treatment with beta-
blockers. Hyperglycemia is a side effect of the drug.
2. Vasodilators—Vasodilators are used to lower left ven-
tricular afterload, which decreases myocardial oxygen con-
sumption. Their use is limited by their hypotensive effect,
which may compound the difficulties associated with
peripheral oxygen delivery.
a. Nitroprusside—Nitroprusside decreases both afterload
and preload. When nitroprusside is used optimally, the
increase in left ventricular ejection fraction partially offsets
the decrease in systemic vascular resistance. Therapy begins
with a dose of 5–10 μg/min and is advanced in increments of
2.5–5 μg/min every 10 minutes until an increase in cardiac
output is noted. The dose should be reduced if systolic blood
pressure falls below 90 mm Hg. Nitroprusside may produce
an intracoronary steal that may aggravate areas of ischemia.
The drug is metabolized to cyanide and subsequently to thio-
cyanate. Doses above 3 μg/min may lead to toxicity, especially
when the drug is used for more than 3 days. Free cyanide ions
combine with cytochromes, leading to anaerobic metabolism
and increased lactate levels. This results in a metabolic acido-
sis that eventually culminates in confusion, hyperreflexia,
and coma. Thiocyanate levels should be monitored and not
permitted to rise above 10 mg/dL. Prophylactic infusion of
hydroxocobalamin may avert toxicity by combining with
cyanide to form cyanocobalamin.
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b. Nitroglycerin—Nitroglycerin is a nitrate derivative
whose greatest effect is preload reduction, which reflexly
decreases left ventricular filling. It has the additional advan-
tage of dilating the coronary vasculature and is the drug of
choice when cardiogenic shock is due to ischemia.
Nitroglycerin is also effective in the treatment of acute valvu-
lar incompetence. Care must be exercised to ensure that
patients are not hypovolemic prior to its administration
because the increased venous capacity will decrease venous
return and further lower the cardiac output. The normal
starting dose is 10 μg/min, which can be increased by 10 μg/min
every 5–10 minutes to a total dose of 50–100 μg/min. Doses
as high as 400 μg/min can be tolerated for several days.
D. Other Modalities—The management of acute myocar-
dial infarction is discussed in Chapter 22. Newer modalities
available to improve cardiac function after infarction include
thrombolytic therapy, percutaneous angioplasty, balloon
pumping, and left ventricular assist devices. Emergency
coronary artery bypass grafting is an option for patients who
fail to respond to other forms of treatment.
Prognosis
Fulminant cardiogenic shock continues to carry a mortality
rate of 90% when only pharmacologic therapy is used.
Application of percutaneous transluminal coronary angio-
plasty, left ventricular assist devices, and early surgical revas-
cularization may help to improve this outcome.
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 Cardiac Compressive Shock 
ESSENT IALS  OF  D IAGNOS I S
 Hypotension with tachycardia. 
 Oliguria. 
 Mental status changes. 
 Distended neck veins. 
General Considerations
Cardiac compressive shock is a low-output state that occurs
when the heart or great veins are compressed. Compression
either impedes the return of blood to the heart or prevents
effective pumping action of the heart itself. Pericardial tam-
ponade is due to fluid within the pericardial sac that con-
stricts the cardiac chambers and prevents them from filling
properly. This may occur acutely after penetrating trauma
with laceration of a coronary artery, or it may be progressive
with chronic diseases such as uremia and connective tissue
disorders. Distention of the abdomen with elevation of the
diaphragm compresses the heart and may produce a form of
shock. PEEP used with mechanical ventilation increases the
intrathoracic pressure, which both collapses the superior and
inferior venae cavae and reduces the transmural pressure
gradient, thereby decreasing cardiac filling. In similar fash-
ion, tension pneumothorax increases the intrathoracic pres-
sure and decreases venous return.
Clinical Features
A. Symptoms and Signs—Signs associated with poor
peripheral perfusion such as hypotension, tachycardia, cool
extremities, oliguria, and altered mental status are usually
present. The presence of distended neck veins is central to the
diagnosis, although they may be absent if the patient is hypo-
volemic. When tension pneumothorax is the cause, hyperres-
onance is noted on thoracic percussion, breath sounds are
absent on the affected side, and the mediastinum is shifted
away from the involved chest. Displacement of the trachea in
association with distended neck veins is pathognomonic of
tension pneumothorax. For patients who are breathing spon-
taneously, inspiration increases the degree of venous disten-
tion (Kussmaul’s sign). Paradoxic pulse also may occur with
spontaneous breathing and consists of a decrease in systolic
pressure of more than 10 mm Hg with inspiration.
When cardiac compressive shock occurs after injury, pen-
etrating trauma to the chest is usually present. Pericardial
tamponade is uncommon after blunt injuries. Patients
admitted for exacerbations of chronic disease often have a
history of pericardial effusion. When mechanical ventilation
is used, cardiac compressive shock occurs because (1) the
inflated lungs compress the superior and inferior venae
cavae, (2) the right atrium and ventricle are compressed, and
(3) expansion of the lungs compresses the pulmonary vascu-
lature and increases the resistance to right ventricular ejec-
tion. Hypotension and tachycardia worsen in these patients
as PEEP is increased. The correlation between the two may
not be apparent at first, although careful examination of the
patient’s flowsheet will reveal changes in hemodynamics that
correspond to ventilator manipulations.
B. Hemodynamic Monitoring—Central venous pressure is
increased, as are pulmonary artery and pulmonary capillary
wedge pressures. Equalization of central venous pressure,
pulmonary artery, and pulmonary capillary wedge pressures
strongly suggests pericardial tamponade.
C. Imaging Studies—Upright posteroanterior chest radi-
ographs may show an enlarged cardiac shadow, but this is
nonspecific. If tension pneumothorax is suspected, treatment
 CHAPTER 11246
must not be delayed while x-rays are obtained. If an inciden-
tal chest radiograph is available, it will reveal hyperlucency of
one or both hemithoraces with displacement of the mediasti-
nal structures to the contralateral side. Transesophageal two-
dimensional echocardiography is very sensitive and can be
used to establish the diagnosis in nonemergent situations.
Treatment of suspected decompensated traumatic pericar-
dial tamponade should never be postponed while awaiting
imaging studies.
Differential Diagnosis
Primary cardiogenic shock without compression presents
the major differential dilemma because both types present
with low cardiac output and high venous pressure. An acute
myocardial infarction or progressive deterioration in a criti-
cally ill patient suggests cardiogenic shock. Most patients
who develop tension pneumothorax or pericardial tampon-
ade after injury will have had the diagnosis established and
therapy instituted before arrival in the critical care unit.
Missed injuries occur occasionally and must be differentiated
from traumatic air embolism to the coronary arteries. The
latter usually causes severe dysrhythmias and a rapid down-
hill course.
Treatment
A. Fluid Resuscitation—Rapid fluid infusion may tran-
siently compensate for the decrease in ventricular filling.
Central venous pressure cannot be used to guide such infu-
sion because central venous pressure always will be elevated
prior to the administration of fluid.
B. Operative Treatment—Surgical decompression of the
offending site is indicated. For tension pneumothorax,
immediate insertion of a large-bore intravenous catheter into
the affected hemithorax will rapidly release the increased
pressure. After pulse and blood pressure return to normal,
this small catheter can be replaced with a larger tube thora-
costomy connected to a chest evacuation device. Placement
of the smaller catheter never should be delayed pending pro-
curement and placement of a more definitive thoracostomy
tube. If cardiac compression is due to gastric distention,
placement of a nasogastric tube may be helpful. When dis-
tention is due to other causes, surgical exploration is usually
warranted. Pericardial decompression should be performed
for pericardial tamponade. Reduction of ventilatory pres-
sures and augmentation of the circulating blood volume, if
possible, usually correct compression resulting from the use
of PEEP.
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Respiratory Failure
Darryl Y. Sue, MD
Janine R. E. Vintch, MD
PATHOPHYSIOLOGY OF RESPIRATORY FAILURE
Respiratory failure is inability of the respiratory system to
maintain a normal state of gas exchange from the atmos-
phere to the cells as required by the body. Simply, the role of
the respiratory system is to maintain normal arterial blood
PO2, PCO2, and pH. Respiratory failure can result from disor-
ders of the lungs, heart, chest wall, respiratory muscles, and
central ventilatory control mechanisms. In addition, dys-
functions of the heart, the pulmonary and systemic circula-
tions, the oxygen-carrying capacity of the blood, and
systemic capillaries have important implications for patients
with respiratory failure.
Definition
Respiratory failure is present (1) if arterial PO2 (PaO2) is less
than 60 mm Hg or (2) if arterial PCO2 (PaCO2) is greater than
45 mm Hg. A PaO2 of less than 60 mm Hg, indicating hypox-
emic respiratory failure, is valid during room air breathing
(inspired O2 fraction [FIO2] = 0.21), but hypoxemia while
breathing supplemental oxygen also indicates respiratory
failure. An exception to the rule that PaCO2 greater than
45 mm Hg defines hypercapnic respiratory failure is meta-
bolic acidosis. Patients with metabolic acidosis normally
decrease PaCO2 to compensate for low pH, but if PaCO2 is
abnormally elevated even though below 45 mm Hg during
metabolic acidosis, respiratory failure is present.
Effectiveness and Efficiency of the Respiratory
System
It is useful to distinguish between the effectiveness and the effi-
ciency of the respiratory system in maintaining arterial blood
gases. An arterial PO2 of 100 mm Hg, for example, indicates
effective oxygenation (more than adequate). Effective elimi-
nation of CO2 is evidenced by an arterial PCO2 of 40 mm Hg
if this PaCO2 is consistent with an acceptable acid-base status.
On the other hand, there is an obvious difference between two
patients who each have a PaO2 of 100 mm Hg if the first
patient is breathing room air (FIO2 = 0.21) and the other is
breathing 100% O2 (FIO2 = 1.0). The first patient is exchanging
oxygen more efficiently from the atmosphere to the arterial
blood than the latter. PaO2 determines the effectiveness of oxy-
genation; the relationship between inspired oxygen concentra-
tion and PaO2 is a marker of efficiency.
PaCO2 measures the effectiveness of ventilation. Two
patients with PaCO2 of 40 mm Hg have equally effective ven-
tilation. If one of them needs a higher minute ventilation
(respired gas volume in 1 minute) than the other, however,
the patient requiring the higher minute ventilation is less
efficiently eliminating CO2 than the one with the lower
minute ventilation. Thus the relationship between PaCO2 and
minute ventilation (
.
VE) reflects the efficiency of ventilation.
Measurement of the degree of inefficiency of oxygenation
and ventilation is discussed below.
Classification of Respiratory Failure
One classification of respiratory failure separates disorders
that affect the lungs (airways, alveolar spaces, interstitium,
and pulmonary circulation) from those that affect primarily
the nonlung components of the respiratory system.
Respiratory failure from diseases that directly affect the
lungs almost always has hypoxemia, but these patients may
or may not have hypercapnia depending on the type of dis-
ease and its severity. Examples include pneumonia, aspira-
tion of gastric contents, acute respiratory distress syndrome
(ARDS), pulmonary embolism, asthma, and interstitial lung
diseases.
Disorders of the nonpulmonary respiratory system usu-
ally cause hypercapnia plus hypoxemia. Examples include
diseases that cause weakness of the respiratory muscles, CNS
diseases that disrupt ventilatory control, and conditions that
affect chest wall shape or size, such as kyphoscoliosis. In
hypercapnic respiratory failure, the lungs may in fact be nor-
mal, so hypoxemia out of proportion to hypercapnia most
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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likely indicates additional lung disease. An example might be
a patient with neuromuscular weakness from myasthenia
gravis who initially presents with hypercapnic respiratory
failure but who subsequently develops pneumonia from an
inability to clear tracheal secretions. At this point, the patient
may be considered to have hypoxemic respiratory failure in
addition to hypercapnia.
 Hypercapnic Respiratory Failure
Patients with hypercapnic respiratory failure have an
abnormally high PaCO2. Because CO2 is elevated in the alve-
olar spaces, O2 is displaced from the alveoli, and PaO2
decreases. Thus these patients usually have both hypercap-
nia and hypoxemia unless the inspired gas is enriched with
oxygen. The lungs themselves may or may not be abnormal,
especially if the primary disease affects nonlung parts of the
respiratory system such as the chest wall, respiratory mus-
cles, or brain stem. On the other hand, chronic obstructive
lung disease not infrequently leads to hypercapnic respira-
tory failure, and some patients with severe asthma, end-
stage pulmonary fibrosis, and severe ARDS can develop
hypercapnia.
 Physiologic Considerations
A. Alveolar Hypoventilation—In the steady state, a patient
produces CO2 from metabolic processes each minute and
must eliminate that  CO2 from the lungs each minute. If the
minute output of CO2 (
.
VCO2) exchanges into the gas-
exchanging spaces of the lungs, the fractional concentration
of CO2 in the alveolar space is:
where FACO2 is the fractional concentration of CO2 in the
alveoli,
.
VA is the volume of air exchanging in the alveoli dur-
ing that minute (alveolar ventilation), and 0.826 adjusts for
temperature and water vapor. The sum of partial pressures of
individual gases equals the total pressure, so the fraction of
alveolar gas that is CO2 also can be written as
where PACO2 is the alveolar partial pressure of CO2 and PB is
barometric pressure. Because PACO2 cannot be measured,
PaCO2 is usually substituted. Substituting and rearranging
the preceding equation gives
where 863 includes factors that adjust for 
.
VCO2 at standard
temperature and pressure, dry (STPD); for  
.
VA at body tem-
perature and pressure, saturated (BTPS); and for PaCO2 in mil-
limeters of mercury. For constant CO2 output, the relationship
between PaCO2 and
.
VA describes a “ventilatory hyperbola” in
which PaCO2 and
.
VA are inversely related. Thus hypercapnia is
always means alveolar hypoventilation, and hypocapnia is syn-
onymous with alveolar hyperventilation. Because alveolar ven-
tilation cannot be measured, estimation of alveolar ventilation
can be made only by using PaCO2 and this formula.
B. Minute Ventilation—In a patient with alveolar hypoven-
tilation,
.
VA is reduced and PaCO2 is increased. Although 
.
VA
cannot be measured directly, the total amount of gas moving
into and out of the lungs each minute can be measured eas-
ily. This is defined as the minute ventilation (
.
VE, L/min).
.
VE is
the sum of the 
.
VA (the portion participating in gas exchange)
and any wasted or dead-space ventilation (
.
VD):
.
VE =
.
VA +
.
VD and
.
VA =
.
VE – 
.
VD
Substituting,
.
VA = f × VA;
.
VE = f × VT; and 
.
VD = f × VD—
where f is the respiratory frequency, VT is tidal volume, and
VD is dead-space volume:
where VD/VT is the dead space:tidal volume ratio.
Substituting and rearranging gives
VD/VT reflects the degree of ventilatory inefficiency of
the lungs. In a normal subject, VD/VT is about 0.30, meaning
that about 30% of the minute ventilation is not participating
in gas exchange. In most lung diseases, the wasted proportion
of
.
VE increases, so VD/VT rises. From the preceding formula
for a constant VD/VT and
.
VCO2, the relationship of PaCO2
and
.
VE is described by a hyperbola transposed upward from
the hyperbola described by the relationship between PaCO2
and
.
VA. For different values of VD/VT, these relationships are
described by a family of hyperbolic curves (Figure 12–1).
These curves are useful in estimating VD/VT from measure-
ment of PaCO2 and
.
VE, or they can be used to determine the
change in  
.
VE needed to cause a desired change in PaCO2.
C. Mechanisms of Hypercapnia—Hypercapnia (alveolar
hypoventilation) occurs when 
.
VE is abnormally low or when.
VE is normal or high but VD/VT is abnormally increased. It is
emphasized that hypoventilation refers to alveolar


V
V
Pa
V
V
E
CO
CO
D
T
2
2
=
×
× −
⎛
⎝⎜
⎞
⎠⎟
863
1
 V V 1
V
V
A E
D
T
= × −
⎛
⎝⎜
⎞
⎠⎟
 V L/min Pa mm Hg V  (L/min)CO CO A
2 2
1
863
( ) ( )= × ×
F
P (mm Hg)
P (mm Hg)
ACO
ACO
B
2
2
=
F
V L/min STPD)
V (L/min BTPS) 0.
ACO
CO
A
2
2
=
×


(
826
248
RESPIRATORY FAILURE 249
hypoventilation, and for this reason, hypercapnia may be
present even though the patient’s 
.
VE is greater than normal if
VD/VT is abnormally high or CO2 output is increased (exer-
cise or other increased metabolic rate).
Alveolar dead space and VD/VT are useful physiologic
concepts that may or may not have anatomic counterparts.
The trachea and airways are conduits for gas moving into
and out of the lungs during the respiratory cycle but do not
participate in gas exchange with the pulmonary capillary
blood. These spaces make up the anatomic dead space. An
artificial airway or part of a mechanical ventilator circuit that
is common to both inspiratory and expiratory pathways also
contributes to anatomic dead space. However, in patients
with lung disease, most of the increase in total dead space
consists of “physiologic dead space,” in which regional venti-
lation exceeds regional blood flow (ventilation-perfusion
[
.
V/
.
Q] mismatching). While 
.
V/
.
Q mismatching usually is con-
sidered as a mechanism of hypoxemia rather than hypercap-
nia, it theoretically should cause elevated PaCO2 as well.
However, in all but severe instances of
.
V/
.
Q mismatching,
hypercapnia stimulates increased ventilation, returning
PaCO2 to normal. Thus 
.
V/
.
Q mismatching does not usually
result in hypercapnia but in normocapnia with increased 
.
VE.
As can be seen in Figure 12–1, increased 
.
VE in the face of nor-
mal PaCO2 indicates increased VD/VT—in this case an
increase in physiologic dead space.
Clinical Features
Acute hypercapnia acts largely on the CNS (Table 12–1).
Increased PaCO2 depresses the CNS, and the mechanism is
primarily through a fall of pH in the cerebrospinal fluid
(CSF) resulting from acute elevation of PaCO2. Because CO2
rapidly diffuses into the CSF, pH falls rapidly and severely
with acute hypercapnia. With chronic elevation of PaCO2,
however, the increase in PaCO2 is present long enough for
plasma and CSF bicarbonate to increase in compensation for
the chronic respiratory acidosis. This explains why low pH
rather than absolute level of PaCO2 best correlates with
altered mental status and other clinical changes.
Symptoms of hypercapnia may overlap those of hypox-
emia. In addition, while hypercapnia stimulates ventilation in
normal subjects, hypercapnic patients may have either
decreased or increased minute ventilation depending on the
primary disorder leading to respiratory failure. Dyspnea,
tachypnea, and hyperpnea may be associated with hypercapnic
respiratory failure just as often as bradypnea and hypopnea.
The major differential distinguishing point is between
hypercapnic respiratory failure owing to lung disease and that
resulting from nonlung disorders. Patients with lung disease
often will have hypoxemia out of proportion to the degree of
hypercapnia. This can be assessed using the alveolar-arterial
PO2 difference. However, patients with nonlung problems
may have secondary hypoxemia because the effects of neuro-
muscular weakness, for example, contribute to  atelectasis or
aspiration pneumonia. Disorders of the lungs—in contrast to
disorders of other components of the respiratory system—are
associated with increased VD/VT, elevated  
.
VE, and respira-
tory frequency. Patients with respiratory muscle weakness also
may be tachypneic. The effects of hypercapnia and hypoxemia
may mask neurologic disorders, overmedication with seda-
tives, myxedema, or head trauma. Alteration of mental status
may make it difficult to assess muscle strength, and the
strength of muscles in the extremities may not correlate with
respiratory muscle strength.
 Figure 12–1. Alveolar ventilation (
.
VA) or minute ventila-
tion (
.
VE) as a function of PaCO2 for a constant CO2 output of
200 mL/min. Increased PaCO2 (hypercapnia) is due to alve-
olar hypoventilation; decreased PaCO2 (hypocapnia) is the
same as alveolar hyperventilation. The other two curves
show the relationship of 
.
VE and PaCO2 for normal dead
space:tidal volume ratio (VD/VT = 0.3) and abnormal
dead space:tidal volume ratio (VD/VT = 0.6).
Hypercapnia Hypoxemia
Somnolence 
Lethargy 
Coma 
Asterixis 
Restlessness 
Tremor
Slurred speech
Headache
Papilledema 
Anxiety 
Tachycardia 
Tachypnea 
Diaphoresis
Arrhythmias 
Altered mental status
Confusion 
Cyanosis 
Hypertension
Hypotension 
Seizures
Lactic acidosis
Table 12–1. Clinical manifestations of hypercapnia and
hypoxemia.
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 Hypoxemic Respiratory Failure
Hypoxemic respiratory failure is much more commonly
encountered than hypercapnic respiratory failure. These
patients have abnormally low PaO2 but normal or low PaCO2.
The latter distinguishes them from hypercapnic respiratory
failure, in which the primary problem is alveolar hypoventila-
tion. Outside of unusual environments in which the atmos-
phere has a severely reduced amount of oxygen, such as high
altitude or when oxygen has been replaced with other gases,
hypoxemic respiratory failure indicates disease affecting
the lung parenchyma or pulmonary circulation. Common
situations in which hypoxemia without elevated PaCO2 are
seen include pneumonia, aspiration of gastric contents, pul-
monary embolism, asthma, and acute respiratory distress
syndrome (ARDS).
Physiologic Considerations
A. Hypoxemia and Hypoxia—The term hypoxemia most
often denotes low PO2 in arterial blood (PaO2), but it can be
used to mean low capillary, venous, or pulmonary capillary
PO2 as well. It also may be used to signify low blood O2 con-
tent or reduced saturation of hemoglobin with oxygen.
Hypoxemia should be distinguished from hypoxia, which is
decreased O2 delivery to the tissues or the effects of
decreased tissue O2 delivery. While hypoxia will result from
severe hypoxemia, hypoxia also can be a consequence of
decreased O2 delivery owing to low cardiac output, anemia,
septic shock, or carbon monoxide poisoning, in which the
PaO2 may be normal or even elevated.
B. Mechanisms of Hypoxemia—The physiologic mecha-
nism of arterial hypoxemia has important implications for
identifying the type of lung disease and the response to ther-
apy with oxygen or other treatment. Five distinct mecha-
nisms of hypoxemia can be identified, but these five can be
divided conceptually into two major groups (Table 12–2):
(1) decreased alveolar PO2 (PAO2) and (2) increased influence
of venous admixture.
Mechanisms of arterial hypoxemia can be demonstrated
by analysis of the possible extremes of oxygenation of the
arterial blood. If desaturated systemic venous blood return-
ing to the lungs gained no oxygen during transit through the
lungs, the arterial blood would have the same oxygen con-
tent and partial pressure as the systemic venous blood (obvi-
ously a situation incompatible with life). Systemic venous
blood PO2 (P
–vO2) determines the lower limit for arterial PO2.
On the other hand, if all the desaturated venous blood pass-
ing through the lungs reaches equilibrium with gases in the
alveolar space, then PaO2 equals PAO2. Thus alveolar PAO2
determines the hypothetical upper limit for arterial PO2.
Therefore, all possible values of PaO2 must be between P
–vO2
and PAO2.
Arterial hypoxemia is always the result either of decreased
PAO2 or of a greater quantity of desaturated venous blood
(venous admixture) mixing with pulmonary capillary blood
(see Table 12–2). In some patients with hypoxemic respira-
tory failure, both these mechanisms play a role.
C. Decreased PAo2—The total pressure in the alveolar space
is the sum of PO2, PCO2, PH2O, and PN2. Because PH2O and
PN2 do not change appreciably, any increase in PACO2 must
cause a fall in PAO2. Thus alveolar hypoventilation causes
decreased PAO2, which must result in decreased PaO2. The
alveolar gas equation, in simplified form, shows the relation-
ship between alveolar PO2 and PCO2:
Mechanism PaCO2 (PACO2) PAO2 P(A–a)O2* 
PO2 on 100% O2
(mm Hg)† Example 
Alveolar PO2↓ Inspired PO2
Hypoventilation 
↓
↑
↓
↓
Normal‡
Normal 
>550
>550
High altitude. 
Neuromuscular disease, obesity-
hypoventilation syndrome.
Venous admixture
Right-to-left shunt .
V/
.
Q mismatching
Diffusion limitation  
Normal or low 
Normal or low 
Normal or low 
Normal 
Normal 
Normal 
Increased
Increased
Increased 
<550
>550
>550
ARDS, septal defect. 
Pneumonia, asthma, COPD. 
Alveolar proteinosis. 
∗P(A–a)o2 on room air. Normal <15–20 mm Hg.
†Pao2 while breathing 100% O2 distinguishes right-to-left shunt from other mechanisms.
‡P(A–a)o2 calculated using PAO2 from alveolar gas equation.  
Table 12–2. Mechanisms of hypoxemia. 
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where FIO2 is the oxygen fraction of the inspired gas, PB is the
barometric pressure, and R is the respiratory gas exchange
ratio, the steady-state ratio of CO2 entering and O2 leaving
the alveolar space. In practice, PaCO2 substitutes for PACO2.
Because PAO2 decreases with increased PACO2, alveolar
hypoventilation is a cause of hypoxemia (reduced PaO2).
The alveolar gas equation also indicates that hypoxemia
occurs if total barometric pressure is reduced, such as at high
altitude or if FIO2 is low (such as when breathing a gas in
which some of the oxygen has been replaced by another gas).
In hypoxemia owing to reduced PAO2 alone, the decrease in
PaO2 approximately equals the fall in PAO2, and the alveolar-
arterial PO2 difference is normal.
D. Venous Admixture—The other causes of hypoxemia
result from increased amounts of deoxygenated venous
blood reaching the arterial blood without becoming fully
oxygenated by exposure to the alveolar gas. The alveolar-
arterial PO2 difference (P[A–a]O2) is increased because
of increased venous admixture. During room air breath-
ing, P(A–a)O2 is normally between 10 and 20 mm Hg,
increasing with age and when the subject is in the
upright position.
During room air breathing, FIO2 = 0.21; if R = 0.8, PaCO2
= 40 mm Hg, and PaO2 = 55 mm Hg, then
PAO2 = (0.21 × 713) – (40/0.8)
= 150 – 50 = 100 mm Hg
and
P(A–a)O2 = 100 – 55 = 45 mm Hg
In this example, arterial hypoxemia is present (PaO2 <60
mm Hg), and P(A–a)O2 is increased (>20 mm Hg). It should
be concluded that hypoxemia is due to one of the causes of
increased venous admixture.
1. Right-to-left shunt—If some systemic venous blood
bypasses the alveoli and then mixes with blood that did go
through the lungs, the resulting arterial mixture must have a
PO2 between PAO2 and P
–vO2. The exact PO2 depends on the
proportion of blood that bypassed the lungs and the values of
PAO2 and P
–vO2. This mechanism of hypoxemia is known as
right-to-left shunt, one of the mechanisms of hypoxemia
owing to increased venous admixture. Right-to-left shunt may
occur because of complete atelectasis of a lung or lobe in
which blood flow is maintained, or may be seen in patients
with congenital heart disease in which there is a right-to-left
shunt through a cardiac septal defect. Patients with ARDS may
have such severe pulmonary edema, localized atelectasis, or
alveolar collapse that right-to-left shunt occurs. Clues to the
presence of right-to-left shunt include severe hypoxemia while
breathing room air, only very small increases in PaO2 when
supplemental oxygen is administered, a need to give an FIO2
greater than 0.6 to achieve an acceptable PaO2, and a PaO2 of
less than 550 mm Hg while breathing 100% O2. By conven-
tion, when PaO2 is less than 550 mm Hg while breathing 100%
O2, right-to-left shunt is confirmed.
2. Ventilation-perfusion mismatching—A second cause
of hypoxemia owing to venous admixture is ventilation-
perfusion (
.
V/
.
Q) mismatching. This mechanism, sometimes
termed
.
V/
.
Q inequality, is the most frequent cause of hypox-
emia. In contrast to right-to-left shunt, hypoxemia in 
.
V/
.
Q
mismatching does not result from venous blood completely
bypassing ventilated areas of lung. Rather, some regions of
the lungs have insufficient ventilation for the amount of
blood flow, whereas others have excessive ventilation for the
amount of regional blood flow. Pulmonary capillary blood
draining those parts of the lungs that have relative “hypoven-
tilation” is less well oxygenated and contributes to hypox-
emia. The effects of
.
V/
.
Q mismatching on gas exchange are
often quite complicated, but practically any lung disease that
alters the distribution of ventilation or blood flow can result
in
.
V/
.
Q mismatching. Thus hypoxemia owing to 
.
V/
.
Q mis-
matching is seen in asthma and other chronic obstructive
lung diseases in which variations in airway resistance distrib-
ute ventilation unevenly.
.
V/
.
Q mismatching also contributes
to hypoxemia in pulmonary vascular diseases such as pul-
monary thromboembolism, in which the distribution of per-
fusion is altered. In contrast to right-to-left shunt, most
patients with  
.
V/
.
Q mismatching respond dramatically to sup-
plemental oxygen therapy. A clue to 
.
V/
.
Q mismatching, there-
fore, is that the PaO2 can be relatively easily brought up to
acceptable values with the administration of supplemental
oxygen.
3. Diffusion limitation—The third mechanism of hypox-
emia owing to venous admixture is diffusion limitation of O2
transfer. This is an unusual cause of hypoxemia, and the basis
for this mechanism is often misunderstood. Normally, there
is more than sufficient time for blood passing through the
lungs to become fully equilibrated with the gases in the alve-
oli. Rarely, however, pulmonary capillary blood passes so
quickly through the lungs that there is insufficient time for
pulmonary capillary PO2 to equilibrate with PAO2, resulting
in hypoxemia. This is a form of venous admixture because
the hypoxemia results from the influence of deoxygenated
venous blood. Diffusion limitation resulting in hypoxemia
theoretically can occur if PAO2 is very low—so that the diffu-
sion of oxygen is slowed—or if the transit time for pul-
monary capillary blood is very short. There are few diseases
in which diffusion limitation for oxygen transfer is thought
to be a major cause of hypoxemia. For example, hypoxemia
in patients with pulmonary vascular disease may be due to
diffusion limitation because of decreased mean transit time,
especially if cardiac output is increased. Pulmonary alveolar
proteinosis—a disease in which the alveolar spaces are filled
with a homogeneous protein and lipid fluid—may slow dif-
fusion of oxygen sufficiently to cause hypoxemia. In
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most other lung diseases presenting with hypoxemia,.
V/
.
Q mismatching and right-to-left shunt explain hypoxemia
more often than diffusion limitation.
Clinical Features
Manifestations of hypoxemic respiratory failure are the result
of a combination of features of arterial hypoxemia and tissue
hypoxia (see Table 12–1). Arterial hypoxemia increases ven-
tilation by stimulation of carotid body chemoreceptors, lead-
ing to dyspnea, tachypnea, hyperpnea, and usually,
hyperventilation. The degree of ventilatory response depends
on the ability to sense hypoxemia and the capacity of the res-
piratory system to respond. In hypoxemic patients with
severe lung disease or ventilatory limitation, there may be lit-
tle or no increase in ventilation and absence of hyperventila-
tion. In patients who lack carotid body function, there will be
no ventilatory response to hypoxemia. There may be
cyanosis, especially marked in the distal extremities but also
centrally prominent around the mucous membranes and
lips. The degree of cyanosis depends on the hemoglobin con-
centration and the patient’s state of perfusion.
Other effects attributable to hypoxemia are due to inade-
quate supply of oxygen to the tissues, or hypoxia. Hypoxia
causes a shift to anaerobic metabolism, which is accompa-
nied by generation of lactic acid. Increased blood lactic acid
may further stimulate ventilation. Mild early hypoxia may
cause impaired mental performance, especially for complex
tasks or abstract thinking. More severe hypoxia can cause
much more severe alteration of mental status, including
somnolence, coma, seizures, and permanent hypoxic brain
damage. Sympathetic nervous system activity is increased,
and this contributes to tachycardia, diaphoresis, and systemic
vasoconstriction, leading to hypertension. More severe
hypoxia, however, can lead to bradycardia, vasodilation, and
hypotension as well as myocardial ischemia, infarction,
arrhythmias, and cardiac failure.
Manifestations of hypoxemic respiratory failure are mag-
nified in the presence of impaired tissue oxygen delivery.
Patients with reduced cardiac output, anemia, or circulatory
abnormalities  can be expected to have global and regional
tissue hypoxia at less severe degrees of hypoxemia. Examples
include the increased risk of myocardial ischemia from
hypoxemia in a patient with coexisting coronary atheroscle-
rosis or a patient with hypovolemic shock who shows evi-
dence of lactic acidosis in the presence of mild arterial
hypoxemia.
 Oxygen Delivery & Tissue Hypoxia
Adequate O2 delivery to the tissues is the most important
function of the respiratory system, and this aspect requires
normal function of the lungs, heart, and circulation.
Recognition and treatment of compromised systemic O2
delivery should be primary goals in management of respira-
tory failure in addition to correcting abnormalities of arterial
blood gases.
Physiologic Considerations
A. Oxygen Delivery—Systemic O2 delivery is the product of
arterial O2 concentration (mL O2/L blood) and cardiac out-
put (L/min). This calculation does not help to determine
whether the blood and O2 are distributed to organs in pro-
portion to their needs, so even normal or high O2 delivery
may be insufficient under certain conditions such as shock,
sepsis, or end-stage liver disease.
O2 delivery (mL/min) = arterial O2 content (CaO2,
mL O2/L blood) × cardiac output (
.
Q, L/min)
where CaO2, mL O2/L blood = [O2 saturation × hemoglobin
(g/dL) × 1.34 mL O2/g hemoglobin + PaO2 (mm Hg) × 0.003
mL O2/mm Hg/dL] × 10.
In normal subjects at rest, normal arterial O2 concentra-
tion is about 200 mL O2/L blood (O2 saturation 97%, hemo-
globin 15 g/dL of blood, PaO2 100 mm Hg). Resting cardiac
output is about 5 L/min, resulting in normal O2 delivery =
1000 mL O2/min.
B. Causes of Decreased Oxygen Delivery—Factors
included in the formula for O2 delivery can be examined to
identify pathologic states that result in potentially decreased
O2 delivery. First, arterial O2 concentration can be reduced as
a result of decreased O2 saturation of hemoglobin from arte-
rial hypoxemia (decreased PaO2) or a rightward-shifted oxy-
hemoglobin dissociation curve (eg, acidemia, hyperthermia,
or hemoglobinopathy). Anemia is an important factor
because O2 concentration is largely the product of hemoglo-
bin concentration and O2 saturation. A decrease in hemoglo-
bin from 12 to 8 g/dL decreases O2 concentration and O2
delivery by 33%—considerably more than most changes in
PaO2 or O2 saturation. Carbon monoxide, because of its high
affinity for hemoglobin, displaces O2 and reduces arterial O2
concentration. In addition, carbon monoxide shifts the oxy-
hemoglobin curve leftward, which, although it tends to
increase O2 concentration at any given PaO2, causes problems
in unloading O2 at the tissue level.
Cardiac output depends on multiple factors, including
adequate systemic venous return, right and left ventricular
function, pulmonary and systemic resistance, and heart rate.
Even in the absence of underlying intrinsic heart disease,
patients with respiratory failure may have impaired or
reduced cardiac output. Hypoxemia and acidosis have
adverse effects on myocardial contractility or may cause
tachycardia, bradycardia, or myocardial infarction. There is
evidence that myocardial depression can be seen in conjunc-
tion with sepsis and septic shock, mediated through products
of microorganisms, patient-produced cytokines, or other
factors. Mechanical ventilation with positive pressure inter-
acts in a number of ways with the heart and circulation.
Although much of the decrease in cardiac output during
positive-pressure ventilation is due to diminished systemic
venous return, left ventricular diastolic compliance is
impaired, pulmonary vascular resistance is increased, and
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right ventricular afterload increases. The degree and signifi-
cance of interaction vary with the type and severity of respi-
ratory failure and the type of mechanical ventilation.
C. Assessment of Oxygen Delivery—The assessment of
adequacy of O2 delivery remains a topic of debate. In normal
subjects, total O2 consumption of the body is independent of
O2 delivery over a wide range. Increasing or decreasing O2
delivery (except at extremely low rates) by changing cardiac
output or hemoglobin does not result in a parallel increase or
decrease in O2 consumption. However, in some patients with
septic shock, ARDS, or other critical illness, O2 consumption
may become functionally dependent on O2 delivery even
when O2 delivery is in the normal range. This finding has
been taken to indicate that adequate O2 delivery in a given
patient cannot be assumed even when O2 delivery is normal;
an increase in O2 consumption in response to increased O2
delivery above normal indicates that the original O2 delivery
was in fact inadequate. To explain this finding, investigators
have proposed that distribution of blood flow in the periph-
eral circulation is poorly matched to O2 requirements of indi-
vidual organs—a form of “distributive shock.” In some
studies, lactic acidosis has been associated with O2 delivery
dependency; this supports the concept of inadequate tissue
oxygenation. In other studies, organ dysfunction is cited as
evidence of hypoxia when O2 consumption is no longer inde-
pendent of O2 delivery. On the other hand, some investigators
believe that these findings are artifacts of measurements or do
not reflect the responses of most patients with these disor-
ders. There have been a few studies suggesting that increasing
O2 delivery has resulted in improved outcome from septic
shock. Several other investigators, however, have been unable
to find any difference in patient survival in critical illness by
empirically increasing O2 delivery. It is highly likely that this
dependence of O2 consumption on O2 delivery is patient-
specific. Therefore, attention should be paid to trying to iden-
tify evidence of inadequate O2 delivery by monitoring renal,
hepatic, cardiac, and other organ system functions.
 Temperature & Blood Gases
The blood gas analyzer maintains the sample of blood at
37°C while PaO2, PaCO2, and pH are determined. For a given
quantity of O2 and CO2 in an aliquot of blood, PaO2 and
PaCO2 will change if the temperature of the blood changes.
When the sample is cooled, PaO2 and PaCO2 decrease; when it
is warmed, PaO2 and PaCO2 increase.
In patients with hypothermia or hyperthermia, some lab-
oratories report “temperature-corrected” blood gases, that is,
what the PaO2 and PaCO2 would be if measured at the
patient’s actual temperature. These corrections are deter-
mined empirically and are derived easily from tables and
nomograms or are displayed automatically by the analyzer.
However, temperature correction of a patient’s blood gas
results may lead to an incorrect clinical interpretation unless
they are compared with temperature-corrected normal blood
gas values. For example, in a normal animal made hypothermic,
temperature-corrected PaO2 and PaCO2 decrease, and because
HCO3
– remains constant, pH increases. If compared with
customary normal values measured at 37°C, interpretation
of temperature-corrected Pao2, PaCO2, and pH would lead to
an erroneous conclusion of hypoxemia and respiratory alka-
losis. One approach to avoiding this problem is to use refer-
ence normal values at each temperature for comparison.
A preferable method is to report all blood gas values at
the 37°C at which the blood is analyzed regardless of the
patient’s actual temperature. These results can then be com-
pared with normal values for PaO2, PaCO2, and pH deter-
mined at 37°C. Interpretation will be correct for both
hypoxemia and acid-base status. Temperature correction of
blood gases is unnecessarily complex and may be misleading
if steps are not taken to provide corrected normal values.
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TREATMENT OF ACUTE RESPIRATORY FAILURE
Respiratory failure is treated by a combination of specific
treatment directed at the underlying compromise of the res-
piratory system plus supportive care of oxygenation and ven-
tilation. The general principles of support are similar
regardless of the type of respiratory system disorder.
 Physiologic Basis Of Treatment
Hypercapnic Respiratory Failure
Because hypercapnia is synonymous with alveolar hypoven-
tilation, supportive care restores alveolar ventilation to nor-
mal until the underlying disorder can be corrected. Alveolar
ventilation sometimes can be improved by establishing an
effective airway—suctioning to remove secretions, stimula-
tion of cough, postural drainage, or chest percussion—or by
establishing an artificial airway with an endotracheal tube or
tracheostomy.
Mechanical assistance may be necessary to maintain the
desired alveolar ventilation until the primary problem is cor-
rected. Although the mechanical ventilator theoretically can
provide any desired amount of ventilation, care should be
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taken to correct hypercapnia judiciously in patients with
chronic hypercapnia. This is because correction of PaCO2 to
normal in these patients can result in severe, life-threatening
alkalemia owing to their elevated plasma bicarbonate levels
as compensation.
Hypoxemia is seen often in patients with hypercapnic res-
piratory failure—especially those with lung disease—and
administration of supplemental oxygen is often necessary. In
some patients with hypercapnia, however, supplemental oxy-
gen may be hazardous if not titrated carefully. This group of
patients with chronic lung disease (either obstructive or
restrictive) or chest wall compromise (eg, kyphoscoliosis)
appears to have particular insensitivity to hypercapnia and
depend on hypoxemia to stimulate ventilation. If sufficient
oxygen is given to overcome hypoxemia, ventilatory drive
may be blunted subsequently, and the patient’s hypercapnia
may worsen.
Patients with hypercapnic respiratory failure owing to
sedative drug overdose or botulism—and most patients with
chest trauma—will improve with time, and treatment is
largely supportive. Some primary diseases associated with
hypercapnia require specific treatment, including myasthe-
nia gravis, electrolyte abnormalities, obstructive lung disease,
obstructive sleep apnea, and myxedema.
Hypoxemic Respiratory Failure
Oxygen supplementation is the most important therapy for
hypoxemic respiratory failure. In severe disorders such as
ARDS, mechanical ventilation, positive end-expiratory pres-
sure (PEEP), and other types of respiratory therapy may be
necessary. Although not a feature of most cases, hypercapnia
may develop because the high work of breathing leads to res-
piratory muscle fatigue. Attention to oxygen transport is
important, and severe anemia should be corrected and ade-
quate cardiac output maintained. The underlying disease
leading to hypoxemic respiratory failure must be addressed,
especially if pneumonia, sepsis, or other cause is identified.
Treatment may include diuretics, antibiotics, and bron-
chodilators as well as other measures.
In some patients with nonuniform lung disease,
dependent positioning of uninvolved or less involved  lung
areas may improve oxygenation. Gravity and the weight of
the lungs increase perfusion and ventilation to dependent
lung regions. Patients with hemoptysis or heavy respiratory
secretions, however, should not be placed in this position
because of the likelihood of aspiration of blood or secre-
tions into uninvolved areas. In ARDS with diffuse noncar-
diogenic pulmonary edema, there has been considerable
interest in placing the patient prone. Prone ARDS patients
appear to have less tendency of dependent lung regions to
collapse as well as smaller areas of the lungs compressed by
the heart or abdominal contents. In some patients,
improvement in arterial hypoxemia is transient after turn-
ing from supine to prone, but in others the effects persist
for at least several hours.
 Airway
When upper airway obstruction is the patient’s only prob-
lem, prompt restoration of an adequate airway is all that is
required to reverse respiratory failure. In all patients, estab-
lishment of the airway is essential for ventilation, oxygena-
tion, and delivery of respiratory medications.
Upper Airway Obstruction
Primary upper airway obstruction should be considered in all
patients with respiratory difficulty—but especially if they
present with any of the following: head and neck trauma, sus-
pected malignancy of the larynx or trachea, acute dyspnea
with wheezing (ie, inspiratory, expiratory, or both), dyspha-
gia, neurologic disease affecting motor or sensory function,
speech difficulty, masses in the neck owing to thyroid enlarge-
ment or lymphadenopathy, or pain, infection, or inflamma-
tion of the pharynx, larynx, or trachea. Patients with asthma
or chronic obstructive pulmonary disease (COPD) also may
have upper airway obstruction from tracheal or subglottic
stenosis if there is a history of recent or remote endotracheal
intubation or tracheostomy. Acute respiratory distress, espe-
cially in the elderly and in children, should arouse suspicion
of a foreign body in the airway. A frequent intermittent cause
of upper airway obstruction is seen in obstructive sleep apnea
syndrome (see below), in which obstruction occurs during
certain stages of sleep. It is important to consider this not
uncommon problem as a complicating factor in patients with
respiratory failure from other causes.
Natural Airway
The normal natural airway permits speech, humidifies
inspired gas, and protects against aspiration and infection;
coughing is effective, and the mucociliary function of the
trachea is maintained. When a decision is made to insert an
artificial airway, the benefits and risks of the endotracheal
tube must outweigh the benefits of the natural airway
(Table 12–3). In patients with severe upper airway obstruc-
tion, the choice is usually easy. In other patients with acute
respiratory failure, the decision rests primarily on whether
oxygen, respiratory medications, and respiratory therapy
via the natural airway will be adequate or whether an arti-
ficial airway would be preferable. A trial of aggressive treat-
ment before intubation often provides useful information.
Guidelines (Table 12–4) for selecting patients who need
endotracheal intubation may be helpful, but clinical assess-
ment of the response to therapy is usually more so.
Noninvasive positive-pressure ventilation does not require
endotracheal intubation and is an important alternative in
patients who meet criteria.
Endotracheal Tubes
Endotracheal tubes are usually made of relatively stiff plastic,
with soft, low-pressure, easily deformable inflatable tracheal
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cuffs. Skilled practitioners should insert these tubes with
attention to prevention of aspiration of gastric contents; ade-
quate oxygenation during the procedure; avoidance of
trauma to the mouth, tongue, nose, epiglottis, and vocal
cords; and selection of an tube of proper size for the patient.
Experience with sedation using opioid analgesics or rapid-
acting sedatives (eg, benzodiazepines such as midazolam)
and muscle relaxants should be available for intubation of
awake patients.
Nasotracheal intubation offers greater patient comfort,
less severe positioning of the head and neck during place-
ment, and better stabilization of the tube. However, the route
of the tube and its smaller size sometimes can complicate
suctioning and weaning from a mechanical ventilator. The
smaller radius of curvature of the nasotracheal route has
been linked to higher tube resistance compared with the
same tube passed orally, but this finding has been ques-
tioned. The nasotracheal route generally is appropriate in
patients who require intubation for reasons unrelated to lung
disease, for example, sedative drug overdose. Otherwise, oro-
tracheal intubation should be used, especially if a larger tube
diameter is needed to facilitate airway suctioning or for
fiberoptic bronchoscopy. Placing an orotracheal tube
requires a laryngoscope for inspection of the vocal cords.
Laryngoscopes with straight or curved blades to hold the
tongue and other structures away are used most often, but
fiberoptic laryngoscopes have proved extremely useful for
difficult intubations or special circumstances.
Smaller-diameter endotracheal tubes impose less risk of
trauma to the vocal cords and may be more comfortable for
the patient. Larger tubes provide better access for tracheal
suctioning, delivery of medications, and fiberoptic bron-
choscopy and generally will create an adequate seal between
the tube and the trachea with lower cuff pressure. Weaning
from mechanical ventilation may be easier with a larger tube
because of lower airflow resistance. Most women can accom-
modate endotracheal tubes of 7.5–8 mm in inner diameter;
men generally will accept tubes of 8.5 or 9 mm in inner
diameter. If fiberoptic bronchoscopy is a consideration, a tube
with at least 8 mm in inner diameter is required, and 8.5 mm
is preferable.
Care of the Artificial Airway
The intubated patient must be suctioned frequently because
both cough and the mucociliary clearance mechanism are
impaired. The frequency of suctioning depends on the
amount and nature of secretions. Although the artificial air-
way becomes rapidly colonized with bacteria, suctioning
should be done using sterile technique to prevent introduc-
tion of additional organisms. A sealed system (ie, suction
catheter contained within a sheath in-line with the endotra-
cheal tube) facilitates frequent suctioning and may minimize
nosocomial contamination. For some patients, disposable
suction catheters are more effective—especially catheters with
bent tips that can be directed into the right or left main
bronchus as desired. It has become common practice to instill
small aliquots of sterile normal saline into the endotracheal
tube to facilitate suctioning of secretions, but this should be
done only if increased amounts of secretions are obtained.
Hypoxemia and tracheal trauma are the most common
complications of suctioning. Minimal negative pressure
should be used, and the suction catheter should be intro-
duced gently. During suctioning, PaO2 may fall rapidly, par-
ticularly if the patient is receiving high concentrations of
inspired O2 and suctioning is performed for more than
10–15 seconds. In patients with focal infiltrates or known
collections of secretions in particular parts of the tracheo-
bronchial tree, selective bronchial suctioning can be tried. By
using bent-tip catheters and by positioning the patient’s
body or head properly, successful suctioning of the left main
bronchus, for example, often can be accomplished.
Risk Benefits
Trauma of insertion 
Oro- or nasopharyngeal trauma
due to chronic pressure
Tracheal damage (erosion,
tracheomalacia)
Impaired cough response   
Increased aspiration risk 
Impaired mucociliary function 
Increased infection risk 
No speech 
Increased resistance and work of 
breathing 
Bypasses upper airway
obstruction 
Route for oxygen and other
medications 
Facilitates positive-pressure
ventilation and PEEP
Route for respiratory medications
Facilitates suctioning of secretions
Fiberoptic bronchoscopy route
Table 12–3. Risks and benefits of the artificial airway.
Table 12–4. Indications for intubation and mechanical
ventilation.∗
Physiologic 
Hypoxemia persists after oxygen administration  
PAco2 >55 mm Hg with pH <7.25  
Vital capacity <15 mL/kg with neuromuscular disease 
Clinical  
Altered mental status with impaired airway protection 
Respiratory distress with hemodynamic instability  
Upper airway obstruction†
High volume of secretions not cleared by patient, requiring
suctioning 
∗These are guidelines that must take into account the patient’s 
clinical status and other factors. 
†Consider need for tracheostomy if obstruction is above trachea.  
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In order to provide positive-pressure ventilation, the
inflated tracheal cuff of the endotracheal tube exerts pressure
on the interior of the trachea to create an effective seal.
Almost all endotracheal and tracheostomy tubes incorporate
low-pressure, high-volume cuffs made of highly compliant
rubber or plastic. These cuffs provide a tracheal tube seal
after inflation to a relatively low pressure. If higher than nor-
mal pressures are needed to achieve a seal, damage to the tra-
chea may occur, including erosion, inflammation, softening
of the cartilage rings with tracheal dilation (tracheomalacia),
and hemorrhage. Endotracheal cuff pressure must be moni-
tored to anticipate these complications and to make certain
that the smallest effective pressure and volume are used. The
best way to do this is to slowly inflate the cuff with air, using
a small syringe, until there is minimal leak around the cuff
with inspiration and adequate tidal volume and ventilation.
The pressure read on a manometer and the amount of air put
into the cuff are recorded. The desired cuff pressure is the
smallest possible that will maintain an adequate seal between
the tube cuff and the trachea, and the pressure is ideally less
than 15 cm H2O. The incidence of tracheal complications
rises when cuff pressures exceed 20–25 cm H2O for pro-
longed periods. An automated system for maintaining opti-
mal cuff pressure is under investigation.
Complications from Endotracheal Tubes
Complications from endotracheal tubes may be classified as
early and late. Early complications are due to the trauma of
tube insertion or to malpositioning of a tube into a main
bronchus or in the esophagus. Confirmation of the tube’s
position by physical examination and chest x-ray are essen-
tial. The tip of the tube should be in the center of the trachea
and 3–5 cm above the carina, but head flexion or extension
can cause 1–5 cm of movement of the endotracheal tube tip
on chest x-ray. If the carina is difficult to see, the position of
the tip of the tube relative to the aortic arch on chest x-ray is
helpful. Analysis of expired CO2 gives reliable assurance of
tracheal rather than esophageal placement; fiberoptic bron-
choscopy also can be valuable for this purpose in selected
patients.
Unplanned extubations are a complication of endotra-
cheal intubation, occurring in 3–10% of placements. The
endotracheal tube should be secured carefully, and the
patient should be educated about the need for and impor-
tance of the tube. Agitation and patient movement are asso-
ciated with extubation, and sedation and physical restraints
should be used as necessary. Several studies have shown that
unplanned extubations led to reintubation in about half of
patients, but some patients can be observed carefully for res-
piratory distress and deterioration of arterial blood gases
rather than immediate reintubation. Factors predictive of a
high likelihood for reintubation include severity of the
underlying disease, a high minute ventilation requirement
during the preceding 24 hours, a high FIO2 requirement, and
altered mental status.
Aspiration of oral secretions or refluxed gastric secretions
is a common problem in intubated patients. Contrary to
common belief, the inflated tracheal cuff does not reliably
protect against aspiration of secretions around the tube.
Endotracheal tubes with a port above the cuff reduce the
incidence of ventilator-associated pneumonia when the port
is connected to continuous suction.
A randomized trial of orotracheal compared with nasotra-
cheal intubation showed that there was a slightly greater fre-
quency of radiographic sinusitis (by CT scan) with
nasotracheal intubation. The incidence was relatively high in
both groups (30% nasotracheal and 22% orotracheal), how-
ever, indicating that this was a frequent complication in all
patients needing endotracheal intubation for more than 7 days.
Most late complications arise from prolonged pressure of
the tube against anatomic structures. The curve of the tube
puts maximum pressure on the side of the mouth, the palate,
and the posterior pharynx (from oral intubation) or the
nasal turbinates and the posterior pharynx (nasal intuba-
tion). The greatest pressure is exerted on the vocal cords, the
narrowest part of the passage. Most late complications are
due to laryngeal trauma, followed by the development of
glottic injury and subglottic stenosis. The incidence of sub-
glottic stenosis is estimated to be less than 5% of patients
intubated for more than 10–14 days. A study of patients with
translaryngeal intubation (orotracheal or nasotracheal)
found that the extent of injury estimated by laryngoscopy
was not predictive of late complications. The duration of
translaryngeal intubation did not influence the ability of the
larynx to heal without future ill effects.
Despite the inability to correlate late complications with
the duration of intubation, early tracheostomy (within 5–7
days) is recommended if prolonged intubation is anticipated.
Translaryngeal intubation for up to 10 days does not usually
cause an appreciable increase in complications, and tra-
cheostomy is preferred if intubation for 21 days or more can
be anticipated. This conclusion is based on a similar inci-
dence of complications from translaryngeal intubation and
tracheostomy. Thus translaryngeal intubation for as long as
21 days may be acceptable unless a longer need for an artifi-
cial airway is expected or whenever there is reason to suspect
greater potential laryngeal trauma (eg, patient movement,
malnutrition, and local or systemic infection). In such cases,
earlier tracheostomy is advised, especially in view of studies
that demonstrate reduced complications when tracheostomy
is performed at 5 days.
Tracheostomy, of course, prevents or avoids laryngeal
injury but does not prevent tracheal injury from the tra-
cheostomy cuff. Attention to cuff pressure and cuff volume
is essential for tracheostomy tubes as well as endotracheal
tubes. Tracheostomy may be contraindicated if the patient
has a bleeding disorder, local infection, or neck mass.
Percutaneous tracheostomy with and without fiberoptic
bronchoscopic assistance potentially reduces complications.
Not only is the timing of tracheostomy controversial,
but so is the role of tracheostomy itself. This is based on
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studies suggesting that the overall outcome of patients
requiring tracheostomy for long-term mechanical ventila-
tion is often poor.
 Oxygen
Supplemental oxygen is required in almost all patients with
respiratory failure. The amount of oxygen needed above that
present in room air depends on the mechanism of hypox-
emia. The type of oxygen delivery device depends on the
amount of oxygen required, patient and physician prefer-
ence, the potential for adverse effects of varying concentra-
tions of oxygen, and the minute ventilation of the patient.
Because high concentrations of oxygen are damaging to the
lungs, efforts should be made to minimize the amount and
duration of oxygen therapy.
PaO2 and P(A–a)O2
For normal subjects, the range for PaO2 during air breathing
at sea level is 75–100 mm Hg, with a decline in PaO2 with age.
One formula for calculating the average PaO2 decline with
age in supine subjects is PaO2 = 109 – 0.43 × age (in years).
Because the PaCO2 in normal subjects does not change appre-
ciably with aging, the usual value for PaCO2 is about 40 mm Hg.
Therefore, PAO2 during room air breathing at sea level is
always about 100 mm Hg. Combining this with the predicted
value for average PO2, the normal range for P(A–a)O2 is 0–30
mm Hg during air breathing, with the high end of the range
seen in normal elderly subjects. P(A–a)O2 increases when
breathing supplemental O2 and can be as much as 100 mm
Hg in normal subjects breathing 100% O2. The increase in
P(A–a)O2 reflects the small amount of physiologic right-to-
left shunt found in normal subjects.
When FIO2 increases, P(A–a)O2 does not remain constant
and cannot be used easily as a measure of the severity of gas
exchange or for predicting the response to a changed FIO2.
Some authors have recommended comparing the ratio of
PaO2 to PAO2 rather than the difference between PAO2 and
PaO2 because the ratio tends to be more constant as FIO2 is
changed in a given patient. The physiologic behavior of PaO2
with respect to PAO2, however, shows that PaO2:PAO2 is often
not sufficiently constant to predict PaO2 when FIO2 is altered.
Therefore, changes in FIO2 must be followed by measurement
of arterial blood gases. In recent years, the ratio of PaO2 to
FIO2 has been used as a marker of the severity of gas exchange
abnormality in hypoxemic respiratory failure and in the def-
inition of refractory hypoxemia as seen in ARDS.
Oxygen Saturation and Oxygen Content
Oxygen saturation and oxygen content increase little when
PaO2 increases above about 60 mm Hg, although there is a
small linear increase in O2 content owing to increased O2 dis-
solved in the plasma (Figure 12–2). Oxygen saturation is
about 92% when PaO2 is 60 mm Hg if the oxyhemoglobin
curve is not shifted rightward or leftward by temperature or
pH changes. The PaO2 at which hemoglobin is 50% saturated
with oxygen (P-50) can be used to indicate the degree of shift
of hemoglobin. With normal unshifted hemoglobin, increas-
ing PaO2 above 60 mm Hg can only increase O2 saturation
from 92–100%. Therefore, for almost all purposes, an
acceptable arterial PO2 is 60 mm Hg or more. Nevertheless,
in most clinical situations, a higher PaO2 is desired (80–100
mm Hg) to anticipate changes in lung gas exchange during
suctioning or changes in the patient’s condition. However,
there is almost never a need for a PaO2 greater than 150 mm
Hg unless the patient is anemic (prior to transfusion) or has
carbon monoxide poisoning—or in some other special
circumstances.
Inspired Oxygen Concentration
The mechanism of hypoxemia determines how much the PaO2
will increase with O2 therapy. Figure 12–3 shows how the PaO2
of patients with pure right-to-left shunts theoretically
responds to increasing concentrations of inspired O2 com-
pared with patients who have 
.
V/
.
Q mismatching. Most
patients with 
.
V/
.
Q mismatching will have a relatively large
increase in PaO2 for a small increase in inspired O2 concen-
tration; increasing FIO2 from 0.21 to about 0.30–0.40 with O2
masks, cannulas, or other devices often will raise PaO2 to
 Figure 12–2. Normal oxyhemoglobin dissociation
curve. At point a, PaO2 = 60 mm Hg results in O2 satura-
tion of about 90%. At point b, the saturation of hemo-
globin is 50% (P-50) at a PaO2 of about 26 mm Hg for
hemoglobin at normal body temperature, pH, and 2,3-
DPG. Increased temperature, decreased pH, and
increased 2,3-DPG shift the curve to the right; decreased
temperature, increased pH, decreased 2,3-DPG, and
carbon monoxide shift the curve leftward.
 CHAPTER 12258
greater than 70–100 mm Hg in these patients. On the other
hand, most patients who are hypoxemic owing to right-to-left
shunting are refractory to O2 therapy, demonstrating only a
small increase in PaO2 when the inspired O2 concentration is
increased from 0.21 to as much as 1.0. These patients often will
require a very high FIO2 (>0.60) to correct hypoxemia. In a
patient with a right-to-left shunt, some venous blood (by def-
inition) always will bypass alveolar spaces and fail to pick up
O2. Because only the blood exposed to the alveolar gas will
pick up O2, we can take advantage of this mechanism of
hypoxemia to further distinguish right-to-left shunt from.
V/
.
Q mismatching. When given 100% O2 (FIO2 = 1.0) and
after the alveolar spaces are completely washed out by O2,
patients with right-to-left shunting always will have some
degree of reduced PaO2, whereas patients with 
.
V/
.
Q mis-
matching will have a PaO2 value close to that of normal sub-
jects breathing 100% O2. For clinical purposes, normal
subjects and patients with 
.
V/
.
Q mismatching will have a PaO2
of greater than 550 mm Hg during 100% O2 breathing; the
PaO2 of patients with right-to-left shunts will be less than
550 mm Hg (see Table 12–2).
Patients with asthma, COPD, mild pneumonia, and pul-
monary embolism usually need only relatively low concen-
trations of supplemental O2 (FIO2 = 0.24–0.40) with a
reasonable expectation that their PaO2 will correct satisfacto-
rily to a safe level. Hypoxemia in these patients, therefore, is
due to 
.
V/
.
Q mismatching. Patients with more severe lung
disease—especially those with pulmonary edema, collapse of
lungs or lobes, severe lobar pneumonia, or ARDS—usually
can be assumed to have right-to-left shunting as the mecha-
nism of hypoxemia. These patients require higher inspired
concentrations of O2 (in the range of 0.50–1.0) to achieve the
same PaO2 goal.
Supplemental Oxygen Delivery Devices
Supplemental oxygen delivery devices are divided into low-
flow and high-flow systems (Table 12–5). Low-flow O2 devices
include nasal cannulas and simple O2 masks patients can use
to draw small supplemental amounts of 100% O2 while the
bulk of the inspired tidal volume is provided by room air
entrainment from around or outside the device. Because the
flow of supplemental O2 is constant, the inspired concentra-
tion of O2 varies inversely with the patient’s minute ventila-
tion. Thus, at a constant flow of 2 L/min into nasal cannulas, a
patient with a low minute ventilation will have a higher FIO2
than another with a high minute ventilation who entrains a
greater amount of room air per minute. For a nasal cannula,
the O2 flow rate should be 0.5–4 L/min; for a simple mask, the
O2 flow should be a minimum of 4 L/min—in order to flush
CO2 out of the mask—and a maximum of 6–8 L/min.
High-flow oxygen delivery devices, including Venturi-
type masks and nonrebreathing masks, generate the total air-
oxygen mixture inhaled by the patient. Venturi-type masks
direct O2 through a constricted tube that increases gas veloc-
ity. The jet of O2 exiting from the constriction generates suf-
ficient negative pressure to draw a much higher volume of air
into the breathing circuit. The relationship between O2 flow,
orifice size, and room air entrainment in Venturi-type masks
is designed to generate a known total flow of gas at a rela-
tively constant concentration of O2. Different FIO2 concen-
trations and different total flow amounts are generated by
using a different-sized orifice or by changing the amount of
air entrainment depending on the design of the system.
Venturi-type masks are ideal when a constant known FIO2 in
the range of 0.24–0.40 is needed. Maximum FIO2 usually is
considered to be about 0.50, and the total gas volume pro-
vided decreases as higher FIO2 values are administered, mak-
ing this type of mask less suitable for patients who have both
minute ventilation requirements greater than 10–12 L/min
and high FIO2 requirements.
Another kind of high-flow device is the nonrebreathing
mask, consisting of a bag reservoir that fills with 100% O2
and one-way valves that permit inspiration only from the
reservoir and prevent room air entrainment. The reservoir
guarantees that even with vigorous inspiratory effort and
high inspiratory flow, patients will inhale essentially 100% O2.
 Figure 12–3. Relationship between PaO2 and FIO2 for
pure right-to-left shunt (
.
Qs/
.
Qt) of 0%, 10%, 20%, and
30%. Line a shows a representative relationship of PaO2
and FIO2 for a patient with mild ventilation-perfusion
(
.
V/
.
Q) mismatching. Line b demonstrates the relationship
for severe 
.
V/
.
Q mismatching. With right-to-left shunt,
PaO2 remains less than 550 mm Hg when breathing
100% O2, but the PaO2 is greater than 550 mm Hg during
100% O2 breathing even with severe 
.
V/
.
Q mismatching.
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The nonrebreathing mask is used primarily for patients
who require very high FIO2 levels (in the range of 0.7–1.0).
Limitations include an inability to provide very high total
gas volumes and patient discomfort. Because this mask is
used in patients with severe hypoxemia requiring high
inspired concentrations of O2, a high percentage of them
may have further deterioration and require other forms of
treatment. Other high-flow oxygen delivery devices usually
generate an oxygen-air mix similar to what is achieved
with the Venturi-type masks but more reliably provide a
larger total flow and higher O2 concentration. They can be
used also to produce cool or warm aerosols along with
high O2 concentrations.
An air-oxygen blender provides oxygen during mechanical
ventilation. The concentration can be varied from 0.21–1.0.
Devices for intermittent positive-pressure breathing, continu-
ous positive airway pressure (CPAP) masks, nasal CPAP, neb-
ulizers for inhaled medications, and others can provide
supplemental O2 as needed in patients with hypoxemia.
Complications of Oxygen Therapy
Complications of oxygen therapy are uncommon. Aside
from increased combustion risk from smoking or open
flames, patients occasionally may have hypoventilation from
loss of hypoxic drive or excessive drying of mucous mem-
branes. On the other hand, more subtle toxic effects of O2
and its metabolites are recognized.
Although O2 itself is relatively nontoxic to biologic tis-
sues, more reactive chemical relatives of O2 resulting from
spontaneous and facilitated conversion have potential for
damage to the lungs. Inflammation and other biologic
processes may increase the generation of more energetic and
toxic oxygen moieties such as hydrogen peroxide, hydroxyl
ion, and superoxide anion. In the presence of myeloperoxi-
dase and hydrogen peroxide, chloride anion is converted to
hypochlorous acid, which has potent biologic effects. The
production of toxic products in a localized region of lung or
other tissues is enhanced when PO2 is increased.
Toxicity from oxygen occurs primarily in the lungs in
adults and is related not to the PaO2 but rather to the
inspired oxygen partial pressure. Subjects at sea level given
100% O2 to breathe have complained of chest pain, dry
cough, and other discomfort after 6 hours. More severe oxy-
gen toxicity has been demonstrated in humans and in exper-
imental animals when 100% O2 is given for 24–48 hours. In
normal lungs, capillary leakage of fluid and protein has been
demonstrated with accompanying increased FIO2. Findings
similar to those of ARDS, with exudative pulmonary edema,
inflammatory changes, and subsequent fibrosis, have been
attributed to oxygen toxicity, but the relationship to under-
lying disease requiring the high oxygen concentration is
unclear.
Because of potential adverse effects, it is advisable to limit
high concentrations of oxygen (FIO2 >0.5) to short duration
(<72 hours) if possible. It is not known whether the presence
and nature of coexisting lung injury enhances or protects
against oxygen toxicity, but there is some evidence that viral
pneumonia increases sensitivity to oxygen toxicity. It is
highly likely that inflammatory cells—such as neutrophils—
that encourage development of toxic oxygen products also
increase the risk of oxygen toxicity. Infection, inflammation
from any cause, and increased inflammatory cell function
Device O2 Flow Rate (L/min) FIO2 Advantages Disadvantages
Low-flow delivery devices
Nasal cannula
Simple mask
2–6
4–8
0.24–0.35
0.24–0.40
Patient comfort
None
FIO2 varies with 
.
VE.
FIO2 varies with 
.
VE.
High-flow delivery devices 
Venturi mask
Nonrebreathing mask 
High-flow O2 blender
‡
2–12∗
6–15
6–20
0.25–0.50
0.70–0.90
0.50–0.90
Constant FIO2 with 
.
VE
High FIO2
High FIO2 at high total flow
Inadequate flow at high FIO2.
Not comfortable; FIO2 not 
adjustable.†
∗The total inspiratory gas flow is the O2 flow plus the amount of room air entrained. See specification for each model. 
†FIO2 can vary with O2 flow rate set; however, the FIO2 is most dependent on the amount of inadvertent room air entrained. In addition,  
total O2 flow may be inadequate in patients with high inspiratory flow demand. 
‡O2 is delivered from various types of “high-flow” O2 blenders with room air entrainment. Different types of masks may be used. 
Table 12–5. Oxygen delivery devices.
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owing to cytokine activation probably will correlate with
potential oxygen-mediated tissue injury. A number of inves-
tigators have suggested that antioxidants (eg, vitamin A,
vitamin E, and acetylcysteine) and scavengers of toxic oxygen
products (eg, superoxide dismutase) may modulate lung
damage from oxygen.
 Bronchodilators
Increased airway resistance is the major feature of asthma
and other chronic obstructive pulmonary diseases.
Resistance increases because of airway smooth muscle con-
traction, excessive secretions, airway inflammation and
edema, and decreased lung elastic recoil. Bronchodilators
affect directly only smooth muscle contraction, although
some may have indirect effects on edema and inflammation.
Bronchodilators are primary treatment for obstructive lung
diseases, but increased airway resistance is a feature of many
other kinds of lung diseases such as pulmonary edema,
ARDS, and pneumonia. Bronchodilator drugs are used often
in these and other respiratory failure settings. The benefits
and risks of adverse effects must be considered when these
drugs are prescribed.
There are five classes of bronchodilators: β-adrenergic
agonists, anticholinergics, methylxanthines, calcium antago-
nists, and a miscellaneous group of agents including magne-
sium sulfate. Calcium antagonists have been used as
bronchodilators experimentally but are not approved for
clinical use. Calcium antagonists are weak bronchodilators,
and their primary value is that they can generally be used
safely to treat hypertension, arrhythmias, and ischemic heart
disease in patients with coexisting obstructive lung disease
and respiratory failure.
Beta-Adrenergic Agonists
These drugs—also called sympathomimetics—are derivatives
of epinephrine, with modifications to improve activity,
specificity, dosing, and pharmacokinetic properties.
Identification of subclasses of adrenergic receptors using
specific antagonists has led to designation of different drugs
as having α-, β1-, or β2-adrenergic agonist activity.
Stimulation of α-adrenergic receptors—present largely on
systemic blood vessels—increases vascular tone and, in the
presence of normal cardiac function, raises blood pressure.
β1-receptor stimulation leads to increased rate and force of
cardiac contraction and peripheral vasodilation, whereas β2-
receptor agonists relax airway smooth muscle. In compari-
son with epinephrine and isoproterenol, albuterol and
terbutaline have increased β2-adrenergic activity with
decreased β1 activity, making these drugs more potent bron-
chodilators with fewer undesired cardiac effects.
A. Route of Administration—These agents are more effec-
tive when given by inhalation rather than when given orally or
parenterally. For a given degree of bronchodilation, side effects
are considerably less for the inhaled route, allowing a larger
and longer-acting dose to be administered. Oral β-adrenergic
agonists are not as useful in acute respiratory failure.
When given by inhalation, the onset of action of the β-
adrenergic agonists is rapid, and newer agents are metabo-
lized slowly enough to allow for relatively long intervals
between doses in most stable patients. Metered-dose inhalers
(MDIs), if used properly, are as effective as gas-driven nebu-
lizers or intermittent positive-pressure breathing for deliver-
ing bronchodilators. Most clinicians now recommend that
patients use an MDI with a spacer device between the MDI
and the mouth to facilitate correct use. For patients receiving
mechanical ventilation, there are a number of devices that
incorporate reservoirs in the ventilator circuit so that MDIs
can be used. However, the comparative effectiveness of MDIs
and gas-driven nebulizers during mechanical ventilation is
unclear. Either type of device can be used, and some objective
measurement should be employed to determine whether
effective bronchodilation is achieved in an individual patient.
MDIs previously used chlorofluorocarbon propellants, but
these are being replaced by hydrofluoroalkanes. The new pro-
pellants are associated with improved distribution of the
bronchodilator and potentially greater clinical effectiveness.
B. Dose and Selection of Drug—Effective therapy may
require two to four times the amount of β-adrenergic ago-
nists than is usually recommended for patients with stable
obstructive lung disease, so increased doses (ie, more puffs
from the MDI or increased quantity in the nebulizer) and
increased frequency of administration (up to every hour or by
continuous nebulization) are often needed. Some protocols
call for increasing amounts of β-adrenergic agonists until a
plateau in improved lung function is reached or until side
effects such as tachycardia or muscle tremors are observed.
Several studies have advocated use of continuous nebuliza-
tion of β-adrenergic agonists rather than frequent intermit-
tent therapy (eg, every hour), but benefit is not conclusive.
Selection of a particular β-adrenergic agonist is based on
potency, efficacy, ease of administration, and limitation of
side effects. Albuterol—the most often used agent—can be
given in a wide range of dosages as needed to treat bron-
chospasm. It has an early onset of action and is available in
MDIs, in solution for nebulization, and in oral form. MDIs
containing albuterol in fixed combination with ipratropium
bromide are used mostly for stable patients with asthma and
COPD. Levalbuterol is the (R)-entantiomer of racemic
albuterol, thought to be the active β-adrenergic agonist
molecule. Some studies have linked increased undesirable
bronchoreactivity to the (S)-isomer, but it is unclear if leval-
buterol has any clinical advantage over the racemic mixture.
Metaproterenol is available for inhalation and orally.
Terbutaline can be given subcutaneously or orally, but there
are no currently available parenteral forms of metapro-
terenol or albuterol.
Epinephrine is a potent β-adrenergic agonist with strong
cardiovascular effects owing to its lack of specificity for β2
receptors. In general, this drug offers no advantages for the
treatment of bronchospasm when compared with more selective
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agents. Salmeterol is a long-acting β-adrenergic agonist useful
for chronic treatment of asthma to prevent rather than treat
bronchospasm. It is not recommended for acute bron-
chospastic attacks. In fact, some asthmatics appear to have
worsening of asthma with use of long-acting β-adrenergic
agonists, including increased risk of death. Fomoterol is a
potent long-acting β-agonist with a short onset of action; its
effects are likely to be similar to that of salmeterol.
Albuterol can be given as two to four puffs from an MDI
every 4–6 hours in stable patients with obstructive lung dis-
ease and bronchospasm. In patients with acute exacerbations
of bronchospasm, the number of puffs can be increased to six
to eight (or more, if tolerated) and the frequency to every 1–2
hours if needed. The response should be objectively meas-
ured, preferably by FEV1 or peak flow, to document the need
for the higher dose; adverse effects should be monitored care-
fully, especially when the doses given exceed usual recom-
mendations. Waiting 3–5 minutes between puffs improves the
effectiveness of a given dose. A nebulized solution of 0.2–0.5 mL
of albuterol (0.5%) or metaproterenol (5%) diluted in 2–3 mL
of normal saline can be given by gas-powered nebulizer or
intermittent positive-pressure breathing every 2–6 hours, but
there is no evidence that this is more effective than adminis-
tration by MDI. Individual patients may have a better
response with certain routes of delivery, and poor response to
one route does not rule out beneficial effects from another.
Patients receiving mechanical ventilation have been
treated by incorporating a nebulizer or aerosol generator in
the ventilator circuit. MDIs have been adapted successfully
for use with ventilators, but the type of adaptor and, most
important, the dose of medication administered greatly
affect the degree of bronchodilation. Patients who do not
have the desired effect using a nebulizer or MDI should be
considered for the alternative form of delivery, or the dose of
β-adrenergic agonist should be adjusted.
C. Adverse Effects—Side effects particularly important in
the ICU and that may limit β-adrenergic agonist use include
tremors, tachycardia, palpitations, arrhythmias, and
hypokalemia. Cardiac effects other than tachycardia may
become important in patients with ischemic heart disease,
but chest pain and ischemia are unusual. Tachycardia is
sometimes more associated with respiratory distress and
hypoxemia than with β-adrenergic agonists and may resolve
after bronchodilator therapy. Hypokalemia is exacerbated by
thiazide diuretics and is caused by shifts of potassium from
extracellular to intracellular compartments in response to β-
adrenergic stimulation.
An uncommon complication of β-adrenergic agonists is
worsening of hypoxemia from exacerbation of ventilation-
perfusion mismatching. This may occur because these drugs
oppose appropriate localized pulmonary artery vasocon-
striction in areas of low ventilation-perfusion ratio;
increased blood flow to these regions increases hypoxemia.
Systemic side effects result largely from absorption
through the mucous membranes of the mouth, and their
incidence may be reduced by spacers or reservoirs that
generate a mix of aerosol particles that more effectively
reaches the intrathoracic airways. Patients should be
instructed to rinse the mouth after each inhalation of the
medication.
Heavy use of β-adrenergic agonist therapy in asthma is
associated with an increased risk of death and exacerbation
of bronchospasm. The mechanism is unknown but may
relate to side effects of the medications or, paradoxically, to
their effectiveness as bronchodilators but not as drugs that
address the underlying cause of asthma. Of particular con-
cern are adverse responses, including death, related to long-
acting β-adrenergic agonists such as salmeterol.
Concomitant corticosteroids are associated with a reduction
in this risk. These findings may or may not be relevant in the
management of status asthmaticus in the ICU.
β-adrenergic blockers are used commonly in ICU
patients for hypertension, ischemic heart disease, and cardiac
arrhythmias. β-adrenergic agonists are less effective when
receptors are blocked, and variable effects on both bron-
chodilation and the underlying cardiovascular condition are
likely to be encountered. Caution should be exercised with β-
adrenergic agonists in patients with cardiac disease,
hypokalemia, or other potential complicating factors.
Anticholinergics
The bronchodilator response to anticholinergic (parasympa-
tholytic) drugs depends on the degree of intrinsic parasym-
pathetic tone. These agents play a somewhat smaller role in
asthma, a disorder in which the mechanism of airway
obstruction is inflammation, than in chronic bronchitis, in
which more parasympathetic tone is present.
Ipratropium bromide is the only anticholinergic agent
used for acute exacerbation. Atropine sulfate should no
longer be given as a bronchodilator because of its systemic
toxicity, including decreased airway and salivary gland secre-
tions, decreased gastrointestinal (GI) motility, tachycardia,
decreased urinary bladder function, pupillary dilation, and
increased intraocular pressure. On the other hand, iprat-
ropium bromide given by inhalation is barely detectable in
the blood and, because it is a quaternary ammonium com-
pound, does not pass easily through lipid membranes,
including the blood-brain barrier. Therefore, ipratropium’s
effects are strongly limited to bronchodilation, and only a
very few complaints of other systemic parasympatholytic
action have been encountered even when large doses are
administered. Tiotropium, a long-acting anticholinergic
inhaled powder, is intended for chronic prevention of bron-
chospasm and has no role in acute exacerbations.
A. Indications—Anticholinergics are recommended prima-
rily for bronchodilation in patients with chronic bronchitis.
Some investigators have recommended ipratropium bromide
as first-line outpatient therapy, but ipratropium always
should be used in combination with β-adrenergic agonists
when treating respiratory failure. Because the effectiveness of
anticholinergics depends on the degree of parasympathetically
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mediated increased smooth muscle contraction, other diseases
in which airway secretions are prominent such as cystic fibro-
sis may respond well. Acute exacerbation of asthma usually
responds better to other agents, but studies support adding
ipratropium to β-adrenergic agonists and corticosteroids.
B. Route and Dose—Ipratropium bromide is available in
MDIs (alone and combined with albuterol) or in solution for
nebulization. Each puff of the MDI provides 18 μg of the drug.
The onset of action appears to be somewhat longer than that
of β-adrenergic agonists—approximately 30 minutes—and
the peak effect occurs at around 60 minutes. The dose of ipra-
tropium bromide recommended has increased with clinical
experience from as few as two inhalations every 6 hours to as
many as four to eight inhalations every 4 hours, with increas-
ing effectiveness at the higher dose range in some cases. For
nebulization of ipratropium, an effective dose appears to be
0.5 mg given every 6–8 hours, and the drug is available in unit-
dose vials containing 0.5 mg ipratropium in 2.5 mL normal
saline. Even at the highest doses, side effects of ipratropium are
minimal, and these doses appear to be safe. As with β-
adrenergic agonists given by MDIs, delivery appears to be
more efficient with the aid of spacers or reservoirs.
C. Adverse Effects—Very few adverse effects are reported—
rarely, tachycardia, palpitations, and urinary retention.
Theophylline
Theophylline is a methylxanthine bronchodilator. It is con-
siderably less potent as a bronchodilator than the β-
adrenergic agonists. The role of this drug is limited, but it
may have effects other than bronchodilation.
A. Mechanism of Action—Theophylline has a long history
of use as a bronchodilator. Although inhibition of phospho-
diesterase was thought to be its mechanism, therapeutic con-
centrations do not inhibit phosphodiesterase strongly, and it
has been difficult to demonstrate a synergistic relationship
with β-adrenergic agonists, which stimulate cyclic AMP pro-
duction. Other proposed mechanisms include effects on
translocation of calcium, antagonism of adenosine, stimula-
tion of β-adrenergic receptors, and anti-inflammatory activ-
ity. Recently, studies of highly specific inhibitors of different
phosphodiesterases have been carried out in patients with
COPD and other disorders.
Theophylline has been relegated by to second-line ther-
apy because of the availability of potent β-adrenergic ago-
nists and other agents.
B. Pharmacokinetics—Theophylline generally is thought to
be effective at a plasma level of 10–20 μg/mL; toxicity is
increasingly likely when levels exceed 20–30 μg/mL, and
severe toxicity is encountered above 40 μg/mL. The dose-
response is curvilinear, with the increase in benefit being
greatest when the theophylline level increases from 5–10
μg/mL and much less when the level increases from 15–20
μg/mL. About 90% of theophylline is metabolized by the
liver to inactive products by the P450 cytochrome system.
This enzyme system is stimulated by tobacco or marijuana
smoking and phenobarbital but is decreased in activity by
cimetidine, erythromycin, oral contraceptives, and many
other drugs. Theophylline metabolism is greatly reduced
with fever, advanced age, cessation of smoking or of a drug
that enhances metabolism, liver disease, and heart failure.
Hepatic failure and heart failure patients often will metabo-
lize theophylline at less than 50% of normal rates.
C. Dose and Route of Administration—In the ICU, theo-
phylline usually is given intravenously. Theophylline is avail-
able premixed in 5% dextrose in water at a concentration of
0.8 mg/mL. To achieve rapid therapeutic levels, intravenous
loading is used, with 5 mg/kg of theophylline given over 20–30
minutes to patients who have not been receiving the drug. If
the patient has been receiving theophylline during the last 24
hours, about 2 mg/kg should be given as the loading dose. This
loading dose and the volume of distribution of theophylline
are intended to achieve a plasma level of about 10 μg/mL.
Most studies have been based on actual rather than ideal body
weight, but it is likely that the volume of distribution does not
increase in proportion to increased body fat. Because metabo-
lism of the drug begins immediately, a constant infusion is
necessary to maintain this level. In the absence of factors that
affect theophylline metabolism, the constant infusion is cho-
sen to be 0.5–0.6 mg/kg per hour, but this should be reduced
to 0.1–0.2 mg/kg per hour in patients with liver disease or
heart failure or those who are taking cimetidine or erythromy-
cin. Elderly patients have decreased clearance of theophylline,
and a constant infusion of 0.2–0.4 mg/kg per hour is recom-
mended. When a steady state is reached after five half-lives
have passed (about 18–36 hours), plasma levels should be
checked to adjust the infusion rate accordingly.
D. Adverse Effects—Tachycardia, nausea, and vomiting
can occur even at therapeutic plasma levels but are more
common at levels over 20 μg/mL. Severe complications
include cardiac arrhythmias, hypokalemia, altered mental
status, and seizures, usually seen when theophylline levels
exceed 35 μg/mL. Many drugs interfere with theophylline
metabolism by hepatic enzymes, causing plasma levels to
rise (eg, erythromycin, cimetidine and ranitidine, and
quinolones), and phenobarbital, rifampin, and smoking
increase the rate of metabolism, sometimes causing plasma
levels to be low.
Magnesium Sulfate
Intravenous magnesium sulfate is a bronchodilator used in
asthma. The mechanism of action appears to be direct airway
smooth muscle relaxation.
A. Indications—Clinical studies, including double-blind,
placebo-controlled trials, have tested this drug in combina-
tion with β-adrenergic agonists or other bronchodilators in
asthmatics.
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B. Route and Dose—Magnesium sulfate is given as 1–2 g
(8–16 meq) intravenously over 10–20 minutes. This dose can
be repeated every 1–2 hours as long as the patient does not
have renal insufficiency and does not develop signs of mag-
nesium toxicity. Plasma magnesium levels may be helpful in
monitoring for toxicity.
C. Adverse Effects—Adverse effects are due to hypermagne-
semia and include loss of deep tendon reflexes, bradycardia,
hypotension, somnolence, muscle weakness, respiratory fail-
ure owing to muscle weakness or paralysis, and cardiac arrest.
 Other Drugs
Corticosteroids
Although both corticosteroids and cromolyn have been used
as anti-inflammatory drugs for respiratory diseases, there is
little or no experience with the latter drug in acute respira-
tory failure in adults. Corticosteroids have been used for
obstructive lung disease, including asthma and chronic bron-
chitis, to decrease airway obstruction from inflammation,
edema, and airway lumen debris, and in ARDS in an effort to
moderate its severity and prevent late fibrotic complications.
Pharmaceutical preparations of corticosteroids have greater
potency than cortisol, fewer mineralocorticoid effects, longer
duration of action, different solubility and degree of systemic
absorption, and different rates of metabolism. The precise
mechanism of anti-inflammatory action of these agents is
unknown, but they have effects on lymphocytes, cytokine
production, interleukin release, macrophage function,
immunoglobulin production, eosinophil activation and pro-
duction, and other immune and allergic responses. The
mechanism of corticosteroids in reducing airway inflamma-
tion is similarly unknown, but changes in inflammatory cell
nature and number have been demonstrated after both sys-
temic and topical administration.
A. Route of Administration—Corticosteroids used in
asthma and COPD can be given orally, intravenously, or by
aerosol. Aerosolized corticosteroids are useful for the treat-
ment of stable mild to moderate asthma. The several available
agents are designed to maintain activity at mucosal surfaces
but have poor systemic absorption. In addition, any amount
swallowed is rapidly and almost completely taken up by the
liver and eliminated. Comparison studies have found few
differences between beclomethasone dipropionate, triamci-
nolone acetonide,and flunisolide.More potent anti-inflammatory
corticosteroids such as budesonide and fluticasone are highly
effective in chronic asthma and have been shown to have some
value in patients with COPD.
Aerosolized corticosteroids are potentially poorly distrib-
uted in acute respiratory failure, and oral or parenteral forms
are almost always used. Prednisone and methylprednisolone
are given orally; methylprednisolone and hydrocortisone are
given intravenously. Some studies have shown little difference
between oral and intravenous administration, but compar-
isons are difficult because of different potencies of the agents
used.
B. Dose—For treatment of obstructive lung disease with acute
exacerbation, most investigators recommend giving large
doses initially and continuing for several days before tapering
and discontinuing, if possible within 7–14 days. Others have
suggested that tapering is not needed to avoid exacerbation of
airway inflammation and that the practice unnecessarily pro-
longs treatment; they suggest that the corticosteroids can be
stopped abruptly. Severe asthma and exacerbation of chronic
bronchitis have been treated with 20–120 mg methylpred-
nisolone intravenously four times a day, usually in the range of
40–60 mg/dose. There is no evidence that higher doses achieve
better outcomes or shorter duration of disease. Almost all
patients can be switched to oral prednisone after 3–5 days of
clinical response, usually in a dosage of 30–60 mg daily. There
is evidence that oral prednisone and intravenous methylpred-
nisolone are equally effective when given acutely to patients
with moderately severe asthma, but the parenteral route is
often preferred. Inhaled corticosteroids are generally withheld
during severe acute exacerbations.
C. Adverse Effects—Side effects of parenteral corticos-
teroids particularly important in the ICU include hyper-
glycemia, hypokalemia, sodium and water retention, acute
steroid myopathy (especially at larger doses), impairment of
the immune system, and psychiatric disorders. An associa-
tion with gastritis and GI bleeding has been suggested but is
debated. Inhaled corticosteroids are relatively free of sys-
temic side effects except for cough, perhaps provocation of
bronchospasm, and oral and pharyngeal candidiasis.
However, the more potent inhaled corticosteroids have
long-term adverse effects on growth, osteoporosis, and
cataract development. Prolonged muscle weakness preclud-
ing weaning from mechanical ventilation has been associ-
ated with simultaneous use of corticosteroids and
nondepolarizing neuromuscular blocking drugs. Patients
for whom corticosteroids are prescribed chronically are at
risk for inhibition of the normal pituitary-adrenal axis; they
may develop acute adrenal insufficiency with withdrawal of
therapeutic corticosteroids.
Systemic corticosteroids should be discontinued as soon
as possible to avoid side effects. However, too early and too
rapid cessation can lead to exacerbation of disease. In most
patients, close monitoring during this phase can identify
potential problems, and selected patients can benefit from a
longer course of corticosteroids. Corticosteroids are often
started by inhalation if persistent airway inflammation is
anticipated and the clinical course warrants continuation of
this mode of therapy. Finally, some patients are unable to tol-
erate discontinuation of systemic corticosteroids; every effort
should be made to reduce the dose to the lowest possible
therapeutic level, and the risks and benefits of this therapy
should be thoroughly reviewed.
 CHAPTER 12264
Leukotriene Antagonists and Inhibitors
Leukotrienes are products of arachidonic acid metabolism
and may have a role in certain kinds of asthma. In chronic
asthma, inhibition of the effect of leukotrienes by leukotriene
receptor antagonists (eg, montelukast or zafirlukast) or inhi-
bition of leukotriene production (eg, zileuton, a 5-lipoxygenase
inhibitor) has beneficial effects on the severity and course of
the disease. There is no role for these agents in acute asthma
exacerbations, but they generally can be continued in
patients who are taking them already.
Expectorants and Nucleonics
There is little evidence that vigorous administration of fluids
improves either the volume or the characteristics of abnor-
mal sputum except perhaps in patients who are volume-
depleted. Oral potassium iodide may have some value in
increasing the volume and thinning tenacious sputum.
Iodinated glycerol has been shown to benefit stable COPD
patients by increasing the force and frequency of coughing
and thus perhaps aiding sputum clearance. The potential
value of this drug in acute exacerbation of asthma or COPD
is unknown. Other expectorants appear to be of little value,
and cough suppressants such as codeine may be contraindi-
cated when removal of secretions by coughing is desired.
Mucolytic agents can be applied directly to airway secre-
tions, especially through endotracheal tubes. Small amounts
(3–5 mL) of normal saline, hypertonic saline, and hypertonic
sodium bicarbonate can be instilled prior to suctioning and
the results judged by the removal of greater amounts of
secretions. Acetylcysteine disrupts disulfide bonds found in
sputum proteins and can be a potent mucolytic agent.
However, aerosolized acetylcysteine is relatively ineffective
and may provoke bronchospasm in asthmatics. Small
aliquots of acetylcysteine have been given by flexible bron-
choscopic lavage into specific airways if necessary.
Respiratory Stimulants
There is no indication for respiratory stimulant drugs. Most
patients with respiratory failure have mechanical and gas
exchange abnormalities that must be corrected, whereas very
few patients solely lack sufficient ventilatory drive. In the
small number of patients who could benefit from stimulation
of the respiratory centers—such as those with CNS depres-
sion from sedative drug overdosage or immediately
postanesthesia—temporary mechanical ventilatory support
is effective and safe.
Sedatives and Muscle Relaxants
In patients not receiving mechanical ventilation, sedative
drugs, including barbiturates and benzodiazepines, and
drugs with respiratory depression potential, such as opioids,
are contraindicated in most forms of respiratory failure.
Attempts to attenuate but not eliminate respiratory drive
with these agents in order to lessen dyspnea have not been
successful. In patients with chest or abdominal pain from
trauma or surgery limiting ventilation, analgesia is very
important; tidal volume and minute ventilation may increase
after treatment.
In patients who are receiving mechanical ventilation, seda-
tion is often necessary, especially shortly after intubation and
initiation of ventilatory support. Benzodiazepines such as
diazepam and lorazepam are often used, and the dosage
should be titrated as necessary. Lorazepam has the advantage
of longer duration of action, which may be beneficial in
patients requiring sedation for several days. All benzodi-
azepines will accumulate in body fat after repeated or pro-
longed use; they are metabolized by the liver, and hepatic
dysfunction also prolongs their effect. Agitation caused by
pain should be treated with analgesics such as morphine sul-
fate rather than increased doses of sedatives. Propofol, which
must be given by continuous intravenous infusion, is an attrac-
tive sedative because awakening of the patient occurs 10–20 min-
utes after the infusion is stopped, unless the drug is used for a
prolonged period of time. Propofol has a rapid onset of action
and generally rapid termination of sedative effect when dis-
continued (unless use is prolonged). Many patients who might
require muscle relaxants to tolerate mechanical ventilation can
be managed successfully using propofol.
In an important randomized, controlled trial, adult
patients receiving mechanical ventilation had sedation inter-
rupted until they were awake every day. They were compared
with a control group who had sedation stopped at the discre-
tion of their physicians. The daily interruption group had a
shorter median duration of mechanical ventilation and sig-
nificantly shorter stays in the ICU. No difference in compli-
cations, including those associated with extubation, was
found. This study suggests that many mechanically ventilated
patients require less sedation than is usually thought to be
necessary.
In a very few patients, muscle relaxants are needed to
facilitate oxygenation or ventilation. Continuous intravenous
infusion of pancuronium or atracurium is used most often.
With these agents, great care is needed to ensure adequate
sedation and maintenance of ventilation. These drugs should
be used only by experienced physicians, and drug dosage
should be titrated carefully using a peripheral nerve stimula-
tor. Because pancuronium has vagolytic effects and is asso-
ciated with histamine release, it should be avoided in patients
with unstable hemodynamics. Atracurium is metabolized in
the plasma, and the duration of action is not affected by renal
or hepatic insufficiency. These agents may cause prolonged
neuromuscular weakness, especially when given in associa-
tion with high dosages of corticosteroids.
 Chest Physiotherapy
Chest physiotherapy is applied to the airways or to the out-
side of the chest. Techniques include incentive spirometry,
intermittent positive-pressure breathing (IPPB), postural
drainage, chest percussion, rotational therapy, and fiberoptic
bronchoscopy.
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Incentive Spirometry
Atelectasis is a common problem in postoperative patients
and those with neuromuscular or chest wall disease.
Incentive spirometers encourage expansion of the lungs as
much as possible above spontaneous breathing; these have
proved to be beneficial in controlled studies. Patients should
be instructed to expand their lungs as much as possible for as
long as they can rather than generate a high negative inspira-
tory pressure for a short time.
Intermittent Positive-Pressure Breathing
The benefit of IPPB has been difficult to demonstrate.
Although sometimes used to deliver bronchodilator medica-
tions, IPPB is usually intended to prevent or treat atelectasis.
In objective studies, patients can improve atelectasis if and
only if IPPB can increase the depth of breathing more than
the patient alone can achieve. IPPB can be tried in patients
with respiratory muscle weakness owing to neuromuscular
disease, those with chest wall abnormalities, and after
abdominal surgery. In general, incentive spirometry should
be tried first and IPPB used only when there is proof that
larger inspired volumes can be reached with this technique.
Postural Drainage and Rotational Therapy
The patient may be placed in various positions to encourage
drainage of airway secretions from specific segments or lobes
of the lungs. This procedure may be particularly important
in patients with lung abscess or bronchiectasis when large
volumes of purulent secretions are present and one or a few
regions of involvement can be identified. The objective
measure of benefit is the increase in volume of expectorated
secretions. It is less clear that patients with pneumonia are
helped by postural drainage, but this measure might be tried
to see if it encourages production of sputum. Patients with
respiratory failure from diffuse airway disease are probably
little benefited by postural drainage, and there is a risk that
worsening of gas exchange may occur in some positions.
Postural drainage and chest percussion should be withheld if
there is no objective evidence that sputum expectoration is
increased after treatment.
There are a number of different kinds of patient care beds
that provide programmed rotation of the patient as well as
vibration therapy or percussion to the chest wall. Of these
modes, rotational therapy may be helpful in preventing or
treating aspiration of secretions and pneumonia.
Chest Percussion
Chest percussion is often added to postural drainage and has
the same indications. It should be discontinued if increased
volume of secretions does not result. Chest percussion can
cause worsening of hypoxemia, rib fractures, and skin abra-
sions. A recent study found that cardiac arrhythmia was a
common complication of chest percussion and postural
drainage, especially in the elderly and those with underlying
heart disease. Patients with atelectasis and no evidence of
increased airway secretions do not improve with chest
percussion.
Fiberoptic Bronchoscopy
Fiberoptic bronchoscopy allows inspection of the airways out
to several generations and provides a means of suctioning air-
way secretions. In respiratory failure, patients with segmental
or lobar collapse owing to mucous plugs who fail to respond
to other forms of treatment may be helped by fiberoptic
bronchoscopy; in these cases, the bronchoscope is essentially
used as a visually directed suction catheter. Occasionally,
unsuspected foreign bodies or airway tumors are found.
Patients with atelectasis who have visible “air bronchograms”
on chest x-rays appear to benefit less from bronchoscopy than
those whose airways leading to the involved region are airless.
The air bronchogram sign indicates that the airway is proba-
bly patent and not obstructed by secretions that can be
removed by fiberoptic bronchoscopy. Because of cost and
potential complications, fiberoptic bronchoscopy should not
be the initial treatment of atelectasis or lobar collapse unless
there is a strong likelihood of endobronchial obstruction.
Likewise, routine fiberoptic bronchoscopy for postoperative
patients should be discouraged.
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 Mechanical Ventilation
Mechanical ventilation in acute respiratory failure has been
viewed as largely supportive, but it is now recognized that
proper management of the patient-ventilator system can
have a positive effect on outcome. The need for and the type
of mechanical ventilatory support depend on the mechanism
of respiratory failure. Potential complications of mechanical
ventilation are also determined to some extent by the sever-
ity and mechanism of disease. The choice of ventilator,
mode, and settings should be made by the critical care physi-
cian in consultation with respiratory care practitioners.
Because changes in ventilator settings affect not only respira-
tory parameters but also hemodynamic and other organ sys-
tem functions, monitoring of the mechanically ventilated
patient can be a complex task. Decisions to initiate and ter-
minate mechanical ventilation require both physiologic
understanding and clinical judgment.
In the past, the goal of mechanical ventilation was to cor-
rect arterial blood gases to normal. It is recognized now that
tidal volume and respiratory rate settings needed to achieve
normal PaCO2 in patients with abnormal lungs may further
damage the lungs. Now, when a low-tidal-volume strategy is
used in ARDS or asthma, for example, hypercapnia may be
“permitted.” As a result, the lungs undergo less damage, and
mortality is decreased.
The Patient-Ventilator System
The normal, spontaneously breathing subject has an intact
ventilatory control system, effective bellows (ie, chest wall
and diaphragm), and efficient gas exchanger (ie, lung
parenchyma and circulation). Feedback from chemorecep-
tors sensing PaO2 and pH (and indirectly PaCO2) and
mechanoreceptors of the lung and chest wall provide input
to a central integrator-controller that generates neural out-
put at an appropriate frequency to signal the inspiratory
effort. The bellows system produces negative intrathoracic
pressure by contraction of the inspiratory muscles, thereby
drawing gas into the lungs. The timing and amount of nega-
tive pressure determine the rate of inspiratory flow. The gas
exchanger (lungs) distributes inspired gas in proportion to
pulmonary blood flow, and O2 and CO2 move into and out
of the circulation by diffusion. Exhalation occurs when the
ventilatory control mechanism signals relaxation of the
inspiratory muscles. Exhalation is complete in the relaxed
subject when passive mechanical forces of the lungs and
chest wall equalize. The lung volume remaining is the func-
tional residual capacity (FRC). The relative amounts of time
spent during inspiration and expiration are determined by
the magnitude of respiratory drive and the interactions
between stimuli received by other receptors.
Mechanical ventilation can be understood by comparing
the parameters chosen by the clinician during controlled-
mode positive-pressure volume-cycled ventilation with a
spontaneously breathing normal person (Table 12–6). In this
mode, the ventilator is set at a specific number of breaths per
minute to be delivered to the patient. There is no negative or
positive feedback from chemoreceptors or other sources that
determine the respiratory rate. The clinician chooses the
tidal volume on the ventilator, and this volume is delivered
each time the ventilator delivers a breath. The rate at which
the tidal volume is delivered to the patient can be adjusted,
and the inspiratory time is determined as the quotient of
tidal volume divided by inspiratory flow rate. The amount of
positive pressure generated by the ventilator depends on the
inspiratory flow, the resistance of the airways, and the com-
pliance of the lungs and chest wall. Passive exhalation begins
Table 12–6. Variables to be set during mechanical
ventilation.∗
Mode How should each breath be initiated? 
Tidal volume What is the volume of each ventilator breath? 
Respiratory rate At what rate should the ventilator deliver
breaths in the event of apnea? 
FIO2 What is the concentration of O2 in the inspired
gas? 
Inspiratory flow How fast should inspiratory flow be delivered? 
PEEP How much end-expiratory pressure is needed? 
Peak pressure At what peak airway pressure should inspiratory
flow be stopped? 
I:E ratio What is the ratio of inspiratory:expiratory time? 
Flow pattern Should inspiratory flow be constant or follow
some other pattern (descending or
sinusoidal)? 
∗For volume preset (volume-cycled) ventilation. 
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immediately after the specified tidal volume has been deliv-
ered and lasts until the next inspiration begins.
Respiratory Mechanics and Mechanical
Ventilation
Lung compliance and airway resistance are the two most
important physiologic concepts in understanding mechani-
cal ventilation. Both are commonly altered from normal in
patients with acute respiratory failure, especially lung com-
pliance in ARDS, chest wall compliance in a variety of disor-
ders, and resistance in asthma and COPD exacerbations.
A. Compliance—When the lungs are expanded, elastic tis-
sues in the lungs and surface tension in the alveoli oppose
expansion. At lung volumes near total lung capacity, the chest
wall also exerts an opposing force. The amount of pressure
needed to overcome these forces, when related to a given
change in lung or chest wall volume, is the respiratory system
compliance (Crs), the ratio of change in volume of the lungs
or chest wall to the change in pressure (ΔV/ΔP). ΔP is the
change in pressure measured between the inside and outside
of the system, in this case alveolar pressure minus chest wall
surface (atmospheric) pressure. Because pressure is needed
to overcome both lung and chest wall elastic recoil, both lung
compliance (Cl) and chest wall compliance (Ccw) are compo-
nents of respiratory system compliance:
The pressure-volume relationship of the respiratory
system is curvilinear (Figure 12–4). The individual
components—lung compliance and chest wall compliance—
can be determined only by measuring intrapleural pressure
using an esophageal balloon. However, most often in the ICU
the respiratory system as a whole is measured, and it is not
partitioned into the two components.
All types of mechanical ventilators measure airway pres-
sure throughout the respiratory cycle, but the following
analysis assumes that a volume-cycled ventilator with a set
tidal volume is being used. If, after the tidal volume is deliv-
ered to the patient by a positive-pressure ventilator, exhala-
tion is delayed briefly and the patient makes no inspiratory
or expiratory efforts, the pressure in the ventilator circuit (ie,
inspiratory plateau pressure) equals the amount of pressure
needed to distend the lungs and chest wall by the tidal vol-
ume delivered (Figure 12–5). Therefore, Crs = tidal
volume/(inspiratory plateau pressure – end-expiratory pressure).
Crs is sometimes called static respiratory system compliance.
Normal Crs is approximately 100 mL/cm H2O in the range of
usual operational lung volume. Thus, for a tidal volume of
800 mL in a mechanically ventilated patient with normal
chest wall and lung compliance, the inspiratory plateau
pressure will be about 8–10 cm H2O.
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 Figure 12–4. Hypothetical respiratory system pressure-
volume curves during positive-pressure breathing. The
normal curve is steeper at low lung volume than the
curve for a patient with less compliant lung or chest wall
(low Crs). Mean respiratory system compliance for the
tidal volume shown is Crs = ΔV/ΔP1 (normal curve) or
Crs = ΔV/(ΔP1 + ΔP2) for the less compliant system.
 Figure 12–5. Airway pressure schematically shown
during respiratory cycle for positive-pressure respiration.
Peak airway pressure, pressure during inspiratory
plateau, and positive end-expiratory pressure (PEEP) are
shown. The difference between peak and inspiratory
plateau pressures provides an indication of airway resist-
ance. The tidal volume/(inspiratory plateau pressure –
PEEP) is an estimate of respiratory system compliance.
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When a patient has a higher than expected inspiratory
plateau pressure for a given tidal volume (decreased Crs),
there must be decreased lung compliance (eg, pulmonary
edema or interstitial fibrosis) or decreased chest wall compli-
ance, such as in obesity, ascites, or kyphoscoliosis. High inspi-
ratory plateau pressures also can be found at extremes of lung
volume. For example, at very low lung volume relative to total
lung capacity, alveolar collapse leads to the tidal volume’s
being distributed over fewer lung units, resulting in a higher
inspiratory plateau pressure. On the other hand, at high lung
volumes relative to total lung capacity, lung units become
overdistended, and the lung is less compliant. Atelectasis, pul-
monary edema, pleural effusions, acute changes in chest wall
compliance, pneumothorax, and potentially dangerous
overdistention of the lung are suggested by a decrease in Crs.
B. Resistance—Gas flows from a region of high pressure to
a region of low pressure. Respiratory resistance arises from
the loss of energy of gas moving through the airways from
friction along the conduit walls. Resistance is a complex
function of gas density and viscosity, velocity, the degree of
turbulence, and the nature of the conduits, but resistance is
always proportionate to the difference in pressure of the gas
between upstream and downstream points. Resistance deter-
mines the rate of gas flow into or out of the lungs at a given
pressure or the necessary pressure for a given flow. In
mechanically ventilated patients, an estimate of relative air-
way resistance during inspiration can be made from the peak
airway pressure during volume-cycled ventilation with con-
stant inspiratory flow. More complex measurements are
needed to determine airway resistance more accurately or
under different circumstances.
In contrast to inspiratory plateau pressure—used earlier
to estimate respiratory compliance—peak airway pressure is
the sum of the pressure needed to expand the lungs and
chest wall plus the pressure needed to push the gas through
the airways. Thus peak pressure always exceeds inspiratory
plateau pressure by the amount needed to overcome airway
resistance. A large difference between peak pressure and
inspiratory plateau pressure (ie, >5–10 cm H2O) indicates
that bronchospasm, airway secretions, or other causes of
increased airway resistance are present. Dynamic respiratory
system compliance is defined as the ratio of tidal volume to
the difference between peak airway pressure and end-
expiratory pressure. This variable reflects both lung compli-
ance and airway resistance and may be useful in
conceptualizing the work of breathing, but it is not strictly a
measure of compliance.
Peak airway pressure is a function of resistance (R) and
Crs, as well as tidal volume (VT), inspiratory flow rate (
.
V), and
positive end-expiratory pressure (PEEP). The inspiratory
plateau pressure is the “static” component of peak airway
pressure, consisting of the quotient of VT and Crs.
C. Mean Airway Pressure—Mean airway pressure is the
time-averaged pressure in the airway during the respiratory
cycle. It reflects both the amount of pressure needed to over-
come resistive and recoil forces during inspiration and any
pressure imposed on the airway during expiration, for exam-
ple, positive end-expiratory pressure. Mean airway pressure
has been suggested as a measure of potential barotrauma to
the lungs, as a predictor of impairment of cardiovascular
function, and as a marker of improved distribution of venti-
lation. However, there is no agreement on how best to inter-
pret this variable.
D. Dynamic Hyperinflation and Intrinsic PEEP—Tidal
volume in patients receiving positive-pressure ventilation is
provided by increasing the pressure in the ventilator circuit,
and gas flows from the ventilator into the patient. In con-
trast, expiration is passive and continues until the lung vol-
ume returns to the functional residual capacity (FRC). At this
point, elastic inward recoil of the lungs and outward recoil of
the chest wall are balanced, and—unless PEEP is set on the
ventilator (see below)—alveolar pressure is equal to atmos-
pheric pressure. By convention, pressure is expressed relative
to atmospheric pressure, so alveolar pressure = 0 cm H2O.
Dynamic hyperinflation occurs when the volume of gas
in the lung at end expiration is greater than the expected
FRC. With mechanical ventilation, dynamic hyperinflation is
most common in patients with obstructive lung disease (eg,
asthma and COPD) who have slow expiratory airflow or in
any patient who requires very large minute ventilation. In the
latter case, large minute ventilation requires high respiratory
rate, high tidal volume, or both. Dynamic hyperinflation
results when there is insufficient time to empty the lungs
such that expiratory tidal volume is smaller than inspiratory
tidal volume. The net increase in lung volume (hyperinfla-
tion) quickly results in a new steady state in which tidal vol-
umes are equal. But now the FRC is increased above normal.
Intrinsic PEEP (PEEPi), sometimes called auto-PEEP,
denotes the difference in pressure between the alveolar space at
end expiration and the pressure in the proximal airway or ven-
tilator circuit. PEEPi is seen in two common situations. First,
PEEPi is associated with dynamic hyperinflation. This is evi-
dent because patients with dynamic hyperinflation continue
to exhale right up to end expiration, indicating a positive alve-
olar pressure relative to proximal airway pressure (hence
PEEPi). Second, any patient who actively contracts expiratory
muscles at end expiration develops positive alveolar pressure
relative to external airway pressure. Note, however, that PEEPi
in this situation is associated with a smaller FRC rather than
hyperinflation. Estimation of PEEPi is described below in the
section on respiratory failure in COPD.
Dynamic hyperinflation has marked consequences for the
pulmonary and systemic circulations, resulting in hypoten-
sion and decreased cardiac output. It also may greatly
increase the work of breathing and may be associated with
barotrauma. Because alveolar pressure is elevated, dynamic
hyperinflation makes it more difficult for patients to trigger
mechanical ventilation in the assist-control or pressure-support
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modes (see below). Dynamic hyperinflation and its marker,
PEEPi, should be suspected in any patient with obstructive
lung disease receiving mechanical ventilation—and in others
with unexplained hypotension or worsening of gas exchange.
Features suggesting dynamic hyperinflation include worsen-
ing of gas exchange with increasing minute ventilation,
hypotension, presence of expiratory flow at end expiration,
high minute ventilation requirements (especially if greater
than 15–20 L/min), and short expiratory time.
Common Methods of Mechanical Ventilation
The most common modes of mechanical ventilation (sum-
marized in Table 12–7) include (1) volume-preset (volume-
cycled), assist-control ventilation, (2) pressure-controlled
ventilation, (3) pressure-support ventilation, (4) intermit-
tent mandatory ventilation, and (5) airway pressure-release
ventilation. Other methods are used less often or are avail-
able only on a limited number of ventilators. New modes are
constantly being introduced, but it is not clear whether any
of these offer useful improvements. Discussions of mechani-
cal ventilation in patients with neuromuscular and chest wall
disorders, ARDS, and obstructive lung diseases are found in
the sections devoted to management of those disorders later
in this chapter.
A. Classification of Mechanical Ventilators—A universally
accepted classification of mechanical ventilators has not been
developed. Historically, successive generations of ventilators
have offered a variety of complex capabilities. First-generation
ventilators were limited to the assist-control mode only.
Second-generation ventilators added intermittent mandatory
ventilation (IMV), PEEP, and improved monitoring capabili-
ties. Later machines used microprocessors to provide a
broader range of options, including pressure-control and
pressure-support modes, time or volume cycling, and various
combinations. Some ventilators incorporate circuits that min-
imize the work of breathing and enhance monitoring capabil-
ities with graphic displays. The newest mechanical ventilators
have modes that allow patients to breathe spontaneously with
pressure-support assistance and can provide additional venti-
lation to meet preset targets. Some newer modes can tailor the
inspiratory flow pattern to limit the rise in airway pressure.
1. Inspiratory phase—The ventilator mode indicates how
the patient-ventilator system initiates inspiration. The start
of inspiration can be completely machine-controlled (con-
trol mode) or chosen by the patient (assist-control mode). A
respiratory rate is set by the clinician, but in the assist-
control mode, if the patient chooses to breathe at a faster
rate, this overrides the set rate.
The changeover from the inspiratory to the expiratory
phase is how the ventilator is cycled. A useful scheme divides
mechanical ventilator methods into those in which the
primary preset independent variable is tidal volume
(volume-preset), airway pressure (pressure-preset), or time.
The ventilator is volume-cycled, time-cycled, or pressure-
cycled depending on whether the inspiratory phase ends
when a preset tidal volume, inspiratory time, or circuit pres-
sure is reached. The inspiratory flow rate and pattern often
can be adjusted to provide an increasing, decreasing, or sinu-
soidal flow pattern during inspiration. Tidal volume, airway
pressure, inspiratory flow rate, and inspiratory time are nec-
essarily interactive. Thus, with different methods of mechan-
ical ventilation, several variables are independent, whereas
the others are dependent.
2. Expiratory phase—Exhalation is passive, occurring
because lung recoil and chest wall recoil create positive pres-
sure in the alveolar space relative to atmospheric pressure. If
the exhalation is stopped before completion, end-expiratory
lung volume rises and end-expiratory pressure is positive rel-
ative to atmosphere. Positive end-expiratory pressure (PEEP)
is often chosen to stabilize alveoli, prevent collapse of lung
units, and improve hypoxemia in certain situations. All
modes of positive-pressure mechanical ventilation described
below can have PEEP added.
B. Volume-Preset Ventilation—Also called the volume-
cycled assist-control mode, this is the most frequently used
method of mechanical ventilatory support and is suitable for
almost all types of respiratory failure. Basically, the ventilator
delivers a preset tidal volume at a constant inspiratory flow at
a respiratory frequency set on the machine.
In the assist-control mode, the physician chooses a respi-
ratory frequency. However, the assist-control mode allows
the patient to initiate a ventilator-delivered breath by making
an inspiratory effort. The ventilator senses this effort as a fall
in ventilator circuit pressure. If the patient makes an inspira-
tory effort sufficient to “trigger” the ventilator at a frequency
greater than the set respiratory frequency, the patient effec-
tively determines the respiratory rate. If no inspiratory
efforts are made or detected, the respiratory rate is equal to
the preset rate. In general, the preset respiratory rate should
be chosen to be slightly less than the patient’s spontaneous
rate, if any. This will guarantee that the patient will receive a
relatively safe amount of ventilation in the event of patient
apnea or hypopnea. The amount of patient effort needed to
trigger the ventilator (sensitivity) can be adjusted on the ven-
tilator. Sensitivity is usually chosen to be 1–2 cm H2O less
than the end-expiratory pressure, although many ventilators
sense “flow” as the triggering event. However, water con-
densed in the ventilator tubing, unavoidable delay in the trig-
gering mechanism, and the presence of PEEPi may make it
more difficult to trigger the ventilator.
Using volume-preset ventilation, recommended tidal
volume has been as much as 10–12 mL/kg of ideal body
weight, but current recommendations of between 6 and
8 mL/kg of ideal weight minimize barotrauma, decrease
lung injury, and improve survival in ARDS. These tidal volumes
should result in an inspiratory plateau pressure of less than
30 cm H2O, although even that pressure is debated. The
actual delivered tidal volume may be smaller or larger than
what is selected. Patients who inspire vigorously along with
the ventilator-delivered breath may draw additional volume
from the ventilator. A smaller than expected tidal volume
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Mode I-E Changeover 
Independent
Parameters 
Dependent
Variables 
Secondary
Modes Advantages Disadvantages Application
Volume-cycled
ventilation (VCV)
(assist-control,
volume-preset) 
Set VT delivered VT.
VI (flow rate)
Backup f  
Peak Paw
I:E ratio 
PEEP; inverse
I:E ratio (IRV) 
Set VT and
backup rate
always
delivered. 
May have high
peak Paw when
set VT is
delivered. 
Primary ventila-
tory mode. 
Pressure-
controlled
ventilation (PCV)
(assist-control
pressure-preset) 
Set inspiratory
time elapsed or
set I:E ratio
reached
Peak Paw, TI, or
I:E ratio 
VT.
VI (flow rate)
PEEP; inverse I:E
ratio (IRV)
Peak Paw
cannot be
exceeded; can
set I:E ratio. Gas
exchange may
improve. 
VT, 
.
VE may vary
and not guaran-
teed; TI and I:E
ratio may
conflict. 
Primary
ventilatory
mode. 
Pressure-support
ventilation (PSV) 
Patient-
determined 
Pressure
support
pressure 
VT
TI
I:E ratio
f 
PEEP Patient-selected
VT, f TI. May be
better tolerated
than other
modes. 
VT, 
.
VE, f not
guaranteed.
Limited data on
improve wean-
ing of difficult
patients. 
Weaning;
primary
ventilatory
mode. 
Intermittent
mandatory
ventilation (IMV) 
Ventilator
breaths: Set VT
delivered
(volume-cycled
VT) 
Mandatory f
and VT
Peak Paw
Spontaneous
VT, f 
PEEP 
PSV
Mandatory
backup VT, f;
spontaneous
breaths
interposed. 
Fixed
mandatory f,
VT, 
.
VE; sponta-
neous breaths
may vary. Some
ventilators have
high work of
breathing. Not
shown to
improve
weaning. 
Weaning;
primary
ventilatory
mode. 
Airway
pressure-
release
ventilation
(APRV)
N/A∗ P[high]
P[low]
Time [high]
Time [low]
VT∗ PEEP
(P[low])
High mean
airway pressure
aids lung
recruitment.
Spontaneous
patient
ventilation.
Spontaneous VT
during P[high]
may exceed
desired volume
limits.
Primary
ventilatory
mode (ARDS).
Key: VT = Tidal volume IRV = Inverse ratio ventilation.
VE = Minute ventilation f = Respiratory rate.
VI = Inspiratory flow rate I:E ratio = Inspiratory:expiratory time ratio
Paw = Airway pressure TI = Inspiratory time
PEEP = Positive end-expiratory pressure
P[high] = high airway pressure
P[low] = low airway pressure
Time [high] = time at high airway pressure
Time [low] = time at low airway pressure
∗The airway pressure change from “high” to “low” (release) is time-cycled, but this is not truly an I-E changeover. VT is determined by
spontaneous patient efforts.
Table 12–7. Ventilator modes.
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can occur if the pressure limit is reached while the inspired
gas is delivered. The pressure limit is set by the operator and
is intended to prevent injury to the patient if the chosen
tidal volume would generate an excessively high pressure.
An inspiratory flow rate of about 1 L/s is set initially for
most patients using volume-cycled ventilation, but higher flow
rates may be essential in patients with status asthmaticus or
COPD or those with high minute ventilation. The flow can be
adjusted according to the respiratory drive of the patient and
the inspiratory time desired. Most volume-cycled ventilators
used in the ICU are capable of constant inspiratory flow. This
means that inspiratory flow will be constant even in patients
with low lung or chest wall compliance or high airway resist-
ance, and inspiratory flow will not decrease when a patient
develops bronchospasm, airway secretions, atelectasis, or other
conditions. Therefore, inspiratory time for a set tidal volume
will remain relatively constant. In special circumstances such
as severe hypoxemic respiratory failure, a decelerating inspira-
tory flow pattern may be helpful, and this pattern has been
described as being similar to pressure-controlled ventilation.
Inspiratory time is usually chosen to be relatively
short compared with expiratory time. An inspiratory
time:expiratory time (I:E) ratio of 1:2–4 is used most often.
An I:E ratio at or near 1:1 may improve oxygenation in
selected patients. Inverse-ratio ventilation may be used with
volume-preset ventilation (see below) in patients with
ARDS. On the other hand, patients with high airway resist-
ance need longer expiratory times to complete exhalation;
they may require an I:E ratio as much as 1:5–10.
Volume-preset, assist-control mechanical ventilation can be
used to ventilate most patients with respiratory failure. The chief
advantage of this mode is that a known tidal volume and—if the
patient does not trigger the machine—a known respiratory fre-
quency are provided. The tidal volume will not vary with
changes in lung and chest wall mechanics. Another advantage is
that clinicians are most often familiar with this mode.
C. Pressure-Controlled Ventilation (PCV)—In pressure-
controlled ventilation (PCV), airway pressure is preset on the
ventilator (rather than tidal volume), and tidal volume
becomes a dependent variable. Although PCV is often
thought of as a way of protecting the lungs from the effects
of excessive airway and alveolar pressure and avoiding baro-
trauma, the major potential advantage of PCV is improved
distribution of inspired gas with improved gas exchange.
PCV might be considered for patients with ARDS, for which
most of the clinical experience has been gathered, although
outcome data are limited. It should not be used for mechan-
ical ventilation of asthmatics or those with COPD.
With PCV, the patient is provided with a preset constant
positive pressure through the ventilator circuit throughout
inspiration. The inspiratory flow pattern is complex and
reflects the decreasing pressure gradient between airway and
alveolar pressure during the inspiratory phase. The duration of
inspiration is determined by setting either the inspiratory time
or the I:E ratio and respiratory rate. Tidal volume is a function
of the inspiratory flow rate and pattern and inspiratory time. PCV
can be used in the assist-control mode, in which the respiratory
rate is chosen either by the patient or, in the absence of suffi-
cient respiratory drive, by the ventilator. Airway pressure must
be chosen carefully with respect to chest wall and lung compli-
ance and airway resistance. In most patients, it is desirable to
limit airway pressure with this mode to 30–40 cm H2O and a
maximum tidal volume of 6–8 mL/kg of ideal weight.
The potential advantages of PCV compared with volume-
preset ventilation include reduced peak airway pressure and
improved distribution of inspired gas. In theory, for the same
tidal volume, peak airway pressure may not differ between
the two modes. In practice, however, as the tidal volume is
delivered during PCV, the difference between airway pressure
and alveolar pressure falls, resulting in a progressive decline
in flow rate—in contrast to constant flow during volume-
preset ventilation. This mechanism is also responsible for the
theoretical improvement in gas distribution. The highest
flow and largest proportion of tidal volume are delivered at
the beginning of the breath, increasing the time available for
gas to move to poorly ventilated lung regions. In several
studies of patients with severe hypoxemia from ARDS,
changing from conventional volume-preset ventilation to
PCV was associated with improved PaO2 and a decrease in
inspiratory oxygen concentration.
PCV has been used frequently with inverse-ratio ventila-
tion (IRV), and some studies have not clearly distinguished
each aspect’s physiologic and clinical effects. IRV is set by
choosing a prolonged inspiratory time (or shortened expira-
tory time) such that the time spent on each breath during
inspiration exceeds expiratory time. That is, the I:E ratio
varies from 1:1 to 4:1 rather than the conventional 1:2–4.
Current understanding of IRV does not attribute any intrin-
sic value to the inverse ratio but views the I:E ratio as a con-
tinuum. Advocates of IRV argue that the shortened
expiratory time increases end-expiratory volume, preventing
or reducing atelectasis, whereas the lengthened inspiratory
time improves inspiratory distribution of gas. However,
increasing the time in which positive pressure is applied to
the lungs should predictably impair cardiac output. IRV
should be restricted to very careful use in selected patients
with ARDS who demonstrate refractory hypoxemia when
managed with other forms of treatment. IRV also can be
used with more conventional volume-preset ventilation. One
disadvantage of IRV is that patients usually require muscle
relaxants or moderately heavy sedation.
D. Pressure-Support Ventilation (PSV)—Pressure-support
ventilation (PSV) is the other major type of pressure-preset ven-
tilation. This mode of ventilation provides a spontaneously
breathing patient with a chosen amount of mechanical assis-
tance during inspiration. Basically, when the patient initiates a
breath, the pressure-support ventilator provides a preset posi-
tive pressure in the ventilator circuit. As long as the patient con-
tinues to inhale, the pressure is maintained at this constant level;
when the patient stops inhaling, the pressure immediately falls to
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baseline. Thus the patient’s inspiratory effort is “supported”
throughout inspiration, thereby unloading the inspiratory mus-
cles. The net driving pressure is equal to the pressure-support
pressure minus the alveolar pressure produced by the patient.
The tidal volume is determined by the net driving pressure and
the patient-selected duration of inspiration.
PSV allows the patient to inspire tidal volumes that might
not be reached using only the patient’s efforts while the
patient and not the ventilator selects the rate and tidal vol-
ume. PSV has been used both during weaning from mechan-
ical ventilation and as a primary mode of ventilation.
Potential advantages during weaning include the possibility
that inspiratory muscles can contract to their accustomed
length, respiratory rate may be slowed (because tidal volume
is maintained), and patients may tolerate pressure support
for prolonged duration. The respiratory muscles experience
less afterload and therefore may be less prone to early fatigue.
PSV can be used as a primary ventilatory mode in suitable
patients who are awake, alert, have adequate ventilatory
drive, and have mild to moderately severe lung disease. The
major advantage is that the patient and ventilator system
often work more in synchrony, and in several studies patients
have noted less discomfort and anxiety when PSV was used.
The level of PSV is chosen with consideration of respira-
tory system compliance, patient effort, desired tidal volume
and minute ventilation, and severity of lung disease.
Pressure-support pressure can be set to 10–15 cm H2O as a
starting point, and the tidal volume and rate measured can
be used to decide on increasing or decreasing the pressure.
Another method is to set pressure support at about two-
thirds of the ventilator pressure needed during conventional
mechanical ventilation to achieve a tidal volume of 6–8 mL/kg.
Pressure-support pressure also may be set to achieve a
selected minute ventilation or to provide enough support to
inhibit accessory respiratory muscle contractions.
E. Intermittent Mandatory Ventilation (IMV)—In this
mode, usually employed for weaning from mechanical venti-
lation but also occasionally for primary support, the ventila-
tor provides tidal volume breaths at a preset fixed rate. In
between ventilator-delivered breaths, the patient is able to
breathe spontaneously at any rate, tidal volume, or pattern.
In newer mechanical ventilators, the spontaneous breaths
can be augmented by increased inspiratory pressure (ie,
PSV) in combination with the ventilator-delivered breaths.
For weaning purposes, the ventilator rate is reduced progres-
sively as the patient’s spontaneous rate and tidal volume are
found to increase. The patient assumes an increasingly
greater role in supplying the minute ventilation. As a primary
support mode, it is believed by some investigators that the
IMV mode is particularly well tolerated by patients who can,
during the spontaneous breaths, adjust their minute ventila-
tion and synchronize their breathing pattern more easily
than with assist-control, volume-cycled mechanical ventila-
tion. The benefit of IMV remains unclear in patients who are
difficult to wean from ventilatory support. There is no study
supporting IMV as superior to other methods of weaning
(see below). In addition, a high work of breathing may be
engendered from the IMV breathing circuit in some
mechanical ventilators that offer this mode.
F. Airway Pressure-Release Ventilation (APRV)—This
mode has features of PCV with a preset airway pressure dur-
ing “inspiration” (P[high]) but with three important differ-
ences. First, P[high], generally chosen to be at the desired
Pplat, is maintained constant much of the time (70–80%).
Second, this pressure is “released” periodically to a lower
pressure or zero, termed P[low]. Third, the ventilator allows
the patient to breathe spontaneously, similar to PSV or IMV,
at both P[high] and P[low]. The intent of APRV is to main-
tain a higher mean airway pressure for lung recruitment,
reduce the number of cycles per minute to avoid stress-
relaxation trauma, and use the pressure-release change in
lung volume plus spontaneous respirations to eliminate CO2.
APRV is time cycled but may be patient-triggered. The clini-
cian sets the P[high] and P[low], as well as the time at
P[high] and P[low].
APRV has been studied mostly in acute lung injury
(ALI)/ARDS. Potential advantages include better lung
recruitment and reduced lung stress, thereby improving oxy-
genation while guarding against volutrauma. However, while
studies indicate that gas exchange and hemodynamics are
acceptable, and the mode appears safe, there are no con-
trolled studies demonstrating improved outcome in patients
with ALI/ARDS.
G. Noninvasive Ventilation—As the name implies, nonin-
vasive ventilatory support devices (ranging from negative-
pressure mechanical ventilators to positive pressure
administered by a nasal or full face mask) have the advantage
of not requiring an endotracheal or tracheostomy tube. As a
result, patients are not subject to the potential complications
associated with intubation, loss of airway defense mecha-
nisms, and inadvertent extubation. On the other hand, non-
invasive modes do not provide the airway protection or
access to respiratory secretions available when ventilation is
delivered via the endotracheal route. Noninvasive positive-
pressure ventilation now clearly has been shown to be useful
in selected patients with acute respiratory failure.
1. Negative-pressure ventilation—Negative-pressure
ventilation may be successful in selected patients for tempo-
rary or long-term management, but this mode generally has
limited use in the ICU. Current devices either use a shell fit-
ted and sealed over the anterior chest (cuirass-type) or a
pneumatic vest–like garment. A mechanical pump provides
negative pressure to the outside of the chest wall. Suitable
patients may be those with neuromuscular weakness who do
not have high airway resistance, low respiratory compliance,
or high ventilatory requirement. Negative-pressure devices
have the disadvantages of reducing patient mobility, causing
skin irritation and breakdown and limiting access to the
chest or back for examination and routine nursing care. In
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addition, negative-pressure mechanical ventilation has been
implicated in the development of upper airway obstruction
during sleep in some patients, presumably owing to a lack of
synchrony between upper airway dilator muscles and
ventilator-initiated breaths.
2. Positive-pressure ventilation—These devices admin-
ister positive pressure to the airway via a nasal or nasal-oral
circuit incorporating a nonrebreathing valve close to the
patient to minimize added dead space. A large number of
delivery circuits—ranging from snug-fitting nasal prongs to
nasal, nasal-oral, and full face masks–are available in several
sizes and shapes to accommodate most patients. Positive-
pressure ventilation (PPV) may be provided by certain con-
ventional mechanical ventilators (those able to tolerate and
compensate for air leaks) or, more commonly, by bilevel
positive-pressure devices specifically designed for noninva-
sive use. Supplemental oxygen may be added using either a
fixed liter-flow rate added to the inspiratory circuit (resulting
in a potentially variable FIO2) or, on newer models, via oxy-
gen blenders capable of providing an FIO2 as high as 1.0.
Early bilevel machines were designed primarily for home use
(for the treatment of obstructive sleep apnea) but quickly
found use in the ICU. Newer devices provide higher pres-
sures (up to 35 cm H2O) and better monitoring and alarm
functions, making them better suited for use in the treatment
of acute respiratory failure.
The success of these devices generally depends on having
a cooperative patient and obtaining a proper fit of the circuit
and attachment headgear (to maximize comfort and mini-
mize potential air leaks). These devices are best used in
patients who do not require continuous or prolonged venti-
latory support because pressure sores can develop even with
properly fitted masks. Other potential complications include
nasal congestion, sinusitis, dry eyes, headaches, and gastric
distention owing to air swallowing. Compared with endotra-
cheal mechanical ventilation, the use of noninvasive methods
increases the level of care provided by nurses and respiratory
therapists during the initiation of therapy (for mask fitting,
monitoring, and ventilator adjustments). Administration of
bronchodilators (or other treatments by inhalation) and eat-
ing generally require temporary removal of the circuit, fur-
ther adding to the level of care required.
Nasal continuous positive airway pressure (nasal CPAP)
is the treatment of first choice for most patients with
obstructive sleep apnea syndrome but also may be useful in
the treatment of other ICU patients. CPAP administered via
a nasal or nasal-oral mask (at pressures of 5–10 cm H2O) can
improve gas exchange in patients with pulmonary edema
and has the added advantage of reducing left ventricular
afterload and improving cardiac output in patients with con-
gestive cardiomyopathies.
While the addition of a low level of CPAP may be helpful
in treating other nonapneic causes of respiratory failure, non-
invasive ventilatory support is usually more successful when
the inspiratory pressure (IPAP) and expiratory pressure (EPAP)
can be adjusted independently, as with bilevel ventilatory sup-
port devices. When operating in the “spontaneous” mode,
these devices can be thought of as being similar to inspiratory
pressure support with PEEP. Airflow into the patient circuit is
adjusted automatically to maintain the preset pressure levels.
As a result, these devices are able to compensate for the air
leaks inevitably seen with mask delivery systems. Patient-
initiated breaths are sensed as a demand for an increase in air-
flow into the patient circuit, which then triggers the switch to
the higher IPAP level. IPAP is maintained until the required
flow returns to a lower level, at which time the pressure
returns to the set EPAP level. The actual tidal volume deliv-
ered during a given breath will depend on the differential
pressure (IPAP – EPAP), the respiratory system compliance,
and the amount of inspiratory effort generated by the patient.
Some devices also offer a “timed” mode (similar to pressure-
controlled IMV) and a “spontaneous or timed” mode (simi-
lar to pressure-controlled IMV plus pressure support).
However, these are generally less useful in treating patients
with acute respiratory failure.
Noninvasive mechanical ventilation is often provided for
obstructive sleep apnea patients unable to tolerate the CPAP
levels required to maintain airway patency or in those with
superimposed central hypoventilation. For these conditions,
EPAP is increased until obstructive apneas are abolished, and
IPAP is titrated upward as necessary to reduce or eliminate
hypopneas, oxygen desaturations, and snoring.
Several randomized, controlled studies in patients with
acute exacerbation of COPD demonstrate that the early
administration of noninvasive ventilatory support improves
gas exchange, vital signs, and dyspnea scores and reduces the
need for invasive mechanical ventilation. Noninvasive
mechanical ventilation may reduce morbidity and mortality
rates as well as the number of both ICU and total hospital
days. The mechanism of benefit is probably related both to
the inspiratory assist provided by IPAP and the low levels of
EPAP (3–6 cm H2O), which reduce the amount of isometric
contraction of inspiratory muscles needed to overcome
PEEPi. Noninvasive ventilation is also helpful in the treat-
ment of acute respiratory failure caused by pneumonia and
acute cardiogenic pulmonary edema, with reduced intuba-
tion rates, fewer ICU days, and a decrease in nosocomial
infections (as compared with endotracheal mechanical ven-
tilation). Finally, noninvasive ventilation can be used to facil-
itate weaning from invasive mechanical ventilation, resulting
in higher overall weaning rates, shorter duration of ventila-
tory support, fewer ICU days, and improved 60-day mortal-
ity compared with routine weaning.
Patients most likely to benefit from noninvasive positive-
pressure ventilation are those with moderate to severe dysp-
nea accompanied by tachypnea, accessory muscle use,
paradoxic breathing, and gas-exchange abnormalities (eg,
PaCO2 >45, pH <7.35, or PaO2/FIO2 <200). Severely ill
patients (eg, those with respiratory arrest, hypotensive shock,
uncontrolled arrhythmias, or ischemia) and those with
excessive secretions or a loss of airway protection are better
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treated with intubation and mechanical ventilation.
Furthermore, patients who are agitated or uncooperative
and those with facial injuries or abnormalities interfering
with mask fit generally are not candidates for noninvasive
ventilation.
After selecting and fitting the mask, recommended initial
settings are IPAP = 8–12 cm H2O and EPAP = 3–5 cm H2O.
The IPAP is increased gradually as tolerated (generally to
10–20 cm H2O) with therapeutic goals of dyspnea relief,
good patient-ventilator synchrony, and improved gas
exchange. The EPAP may be increased if needed for alveolar
recruitment (similar to PEEP changes in standard mechani-
cal ventilation), but in patients with COPD, EPAP should be
kept below the level of PEEPi to avoid worsening hyperinfla-
tion. Supplemental oxygen is added to maintain O2 satura-
tion greater than 90%. Most patients benefit from ongoing
encouragement and reassurance. Occasionally, light sedation
is helpful in anxious and agitated patients; however, these
medications have the potential for compromising airway
patency, so close monitoring is essential.
H. Other Methods of Mechanical Ventilation—Rarely
used methods of mechanical ventilation in critical care
areas include high-frequency ventilation and supplemental
extracorporeal membrane oxygenation or CO2 elimination.
High-frequency ventilation uses very small tidal volume—
sometimes less than anatomic dead space volume—and res-
piratory frequencies greater than 1 breath/s (>1 Hz). The tidal
volume is provided by one of several means, including a high-
velocity air-oxygen jet, a high-frequency inspiratory valve, or
a mechanical or electromagnetic oscillator. The mechanism
of gas movement is not known, although facilitation of gas
diffusion has been postulated. Several years ago there was
considerable interest in these ventilators for severe hypox-
emic respiratory failure, but studies failed to demonstrate
advantages of these devices in adults. A review of high-
frequency ventilation in ARDS and ALI concluded that high-
frequency oscillation (HFO) may be promising but still
should be considered experimental.
Extracorporeal membrane oxygenation and CO2 elimina-
tion have been the subject of several studies of patients with
severe acute respiratory failure, especially ARDS.
Conceptually, membrane oxygenation was used to manage
patients with refractory hypoxemia, but mortality was very
high and unchanged by this treatment. More recently, partial
bypass with focus on CO2 elimination was viewed as a lung-
protective strategy, but data do not support benefit at this
time. These therapies should be viewed as experimental.
Clinical Applications
The mode of mechanical ventilation and the settings to be
used should be chosen in consultation with physicians and
respiratory care practitioners who have experience in the
management of respiratory failure. Some criteria for selec-
tion of modes in different types of respiratory failure are pre-
sented in Table 12–8, and further details are found in
discussions of the various disorders. Proper monitoring of
the patient-ventilator system greatly facilitates patient care,
as shown in Table 12–9.
Respiratory Failure Strategy Tactic 
Neuromuscular or chest wall
disorder 
Avoid barotrauma. Minimize effects on cardiac output. 
Avoid hyperventilation. 
Prevent atelectasis and worsening Pao2. 
VT 6–8 mL/kg; peak Paw <40 cm H2O 
Adjust PaCO2 to pH in presence of elevated HCO3
–
PEEP 3–5 cm H2O 
COPD, asthma Improve gas exchange by avoiding hyperinflation. 
Decrease adverse effects on cardiac output.
Decrease work of breathing. 
Long expiratory time; high 
.
VI (>1 L/s), low f, VT 6–8 mL/kg.
Allow hypoventilation? Use muscle relaxants.
PEEP < intrinsic PEEP? 
ARDS Improve arterial Pao2. Decrease potential for O2
toxicity. 
Meet ventilatory demand.
Reduce potential for barotrauma. Limit adverse effects
on cardiac output and O2 delivery.
PEEP 
PCV or descending flow pattern (VCV)? 
Use FIO2 <0.50 
High 
.
VI, high f 
Low VT (6–8 mL/kg)
Pplat <30 cm H2O 
Key: PCV = pressure-controlled ventilation
PC-IRV = pressure-controlled, inverse-ratio ventilation
PEEP = positive end-expiratory pressure
Pplat = inspiratory plateau pressure
VT = tidal volume.
VI = inspiratory flow rate
f = respiratory rate
Table 12–8. Suggested ventilator strategies and tactics in respiratory failure. 
RESPIRATORY FAILURE 275
Monitoring the Patient on Mechanical
Ventilation
The patient-ventilator system warrants careful monitoring.
The patient’s normal homeostatic and feedback mechanisms
are no longer completely functioning, and extremes of infla-
tion, arterial blood gases, and effects on hemodynamics are
likely without the usual constraints. Some important moni-
toring principles and guidelines are included in Chapter 8.
Monitoring of mechanical ventilation can be divided into
two categories. First, respiratory therapy departments and
ICUs have established monitoring standards for patients on
mechanical ventilation. These usually include hourly—or
more frequent—measurement and documentation of peak
and plateau airway pressure, minute ventilation, oxygen satu-
ration by pulse oximetry, endotracheal tube cuff pressure, and
volume, tidal volume, and respiratory rate. The ventilator set-
tings are charted, including mode, set tidal volume and rate,
inspired concentration of oxygen, PEEP, and alarm settings
and limits. Clinicians should review these data, and the data
should be studied carefully if patients deteriorate, have diffi-
culty with discontinuation of mechanical ventilation, develop
new gas-exchange problems, or show changes on chest x-rays.
A second category of mechanical ventilator monitoring
involves slightly more sophisticated measurements and cal-
culations, and these are recommended for certain clinical sit-
uations. Two simple measurements are PEEPi and
inspiratory plateau pressure. PEEPi (auto-PEEP) can be
measured automatically by some ventilators; in others, expi-
ratory port occlusion (see below) is used. PEEPi determina-
tion is useful in patients with COPD exacerbation and
asthma. Inspiratory plateau pressure should be compared
with peak airway pressure. Respiratory system pressure-
volume (PV) curves have been recommended by some inves-
tigators, especially in Europe, to determine optimal PEEP
settings and in limiting tidal volume in ARDS patients.
Despite important experimental information derived from
PV curves, their clinical use has not become routine for a
variety of technical reasons and problems of interpretation.
Finally, esophageal pressure measurements during mechani-
cal ventilation would provide important information about
PEEPi, chest wall compared with lung compliance changes,
and work of breathing. Once again, these measurements are
not often made in the ICU.
Complications
Some of the complications of mechanical ventilation are
listed in Table 12–10. These can be divided into two cate-
gories: (1) complications and adverse effects of positive-pressure
ventilation and (2) complications of having a mechanical
Variable or Ventilator
Setting Clinical Significance 
Measured 
.
VE Is patient breathing more than set VT and f?
Weaning may be feasible if 
.
VE <12 L/min.
High 
.
VE relative to PaCO2 means  high VD/VT
or increased metabolic rate. 
Peak airway pressure High pressure at a given tidal volume
suggests high airway resistance and/or low
respiratory system compliance. 
Inspiratory plateau
pressure (see text)
High pressure suggests low respiratory sys-
tem compliance. 
FIO2 Combined with PaO2, indicates efficiency of
oxygenation. Use FIO2 to calculate P(A–a)O2 or
PaO2/FIO2 ratio. 
Respiratory rate During IMV, spontaneous rate and tidal vol-
ume indicate contribution of patient to total
minute ventilation. During assisted ventila-
tion, rate higher than set rate indicates
patient has degree of respiratory drive. 
Tidal volume During pressure-support ventilation, compari-
son of VT and support pressure assesses
patient’s contribution to total ventilation. 
Intrinsic PEEP present? See mechanical ventilator management of
patients with respiratory failure from COPD.
Useful in determining if gas exchange is
compromised by dynamic hyperinflation. 
Table 12–9. Monitoring mechanical ventilation. 
Table 12–10. Complications of mechanical ventilation.
Complications of artificial airway 
Complications of positive-pressure ventilation  
Pneumothorax  
Pneumomediastinum  
Parenchymal barotrauma (lung injury) 
Decreased cardiac output  
Increased intracranial pressure 
Impaired ability to monitor or interpret intrathoracic vascular
pressures (pulmonary artery catheter)  
Altered gas exchange (worsening of 
.
V/
.
Q mismatching)  
Complications of artificial ventilation  
Hypoventilation  
Hyperventilation 
Apnea  
Oxygen toxicity  
Mechanical or electrical failure or disconnection of ventilator  
Increased risk of nosocomial pneumonia  
Accidental thermal or chemical burns to airway  
Aspiration and ventilator associated pneumonia  
Psychologic dependence on ventilator 
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substitute for the natural ventilatory system. Because the vast
majority of mechanically ventilated patients have endotra-
cheal tubes or tracheostomy tubes, airway complications also
must be considered under this heading.
A. Barotrauma—Barotrauma is a misnomer because it is
now understood that lung injury occurs because of excessive
and repeated stretching of the lungs regardless of the pres-
sure. Therefore, a patient with very stiff or noncompliant
lungs may require high pressures to ventilate, but because the
lungs are not particularly stretched, barotrauma is uncom-
mon. On the other hand, a patient with very compliant
lungs, such as are seen with bullous emphysema, requires
very low pressures to overstretch the lungs. This type of
patient is at high risk of barotrauma despite low pressure
because of the large volume changes. Barotrauma might
more properly be called volume trauma. Current recommen-
dations to choose smaller tidal volumes when mechanically
ventilating patients with asthma, COPD, and ARDS have
been associated with a reduced incidence of lung injury.
PPV is associated with several forms of barotrauma to the
lungs. Most often appreciated is explosive barotrauma, in
which inspired gas under positive pressure ruptures an area of
lung or airway. Air initially escapes into the interstitial spaces
of the lungs and tracks along bronchovascular bundles
toward the mediastinum. Therefore, at first the patient may
have interstitial emphysema, which may be seen as thin air
density lines against a background of lung consolidation.
Subsequently, the patient may develop evidence of air sur-
rounding mediastinal structures (pneumomediastinum). If
the air separates the lungs and pleura from the inner surface
of the chest wall, an extrapleural pneumothorax can form. A
pneumothorax can evolve another way through rupture of
the lung directly into the space separating the visceral and
parietal pleural surfaces. PPV, especially combined with PEEP,
has been associated with explosive barotrauma, including
interstitial emphysema and pneumothorax, but debate con-
tinues about the relative contributions of underlying lung dis-
ease and PPV. It is likely that both acute lung injury and
chronic lung disease increase the risk of barotrauma.
A more important and more common subtle form of
barotrauma is suggested by evidence that PPV and PEEP are
associated with parenchymal lung injury, leading to more
severe gas-exchange abnormalities and permanent histologic
damage. Mechanical ventilation and PEEP in ARDS may
damage the lungs in somewhat the same way supportive care
for neonatal respiratory distress contributes to bronchopul-
monary dysplasia. These considerations have led to recom-
mendations that airway pressure and tidal volume should be
limited. In experimental animals, both the combination of
low PEEP (0 cm H2O) and high tidal volume (39 mL/kg) and
the combination of high PEEP (15 cm H2O) and low tidal
volume (7 mL/kg) caused pulmonary edema. Other animal
and human data indicate that inflammatory cytokines are
generated and persist when larger tidal volume are used.
Current recommendations to use tidal volumes of between
6 and 8 mL/kg of ideal weight are based on a decreased like-
lihood of barotrauma, decreased lung injury, and improved
patient outcomes.
B. Decreased Cardiac Output—Patients started on
positive-pressure mechanical ventilation not infrequently
become hypotensive, and this is largely because PPV can
reduce cardiac output. In normal subjects, negative pressure
during spontaneous inspiration provides an additional
impetus to systemic venous return by exerting negative pres-
sure on the intrathoracic venae cavae, the right atrium, and
the right ventricle. Pulmonary vascular resistance falls during
inspiration, improved emptying of the right ventricle.
On the other hand, PPV may have several adverse effects
on cardiac output. First, positive pressure (rather than nega-
tive pressure) during inspiration interferes with systemic
venous return. Second, inflation of the lungs with positive
pressure increases pulmonary vascular resistance and
impedes right ventricular emptying. Third, PPV and PEEP
may decrease left ventricular compliance by stiffening the
intraventricular septum because of increased volume of the
right ventricle. There is little evidence, however, for a nega-
tive inotropic effect of PPV. For several reasons, left ventric-
ular afterload decreases during PPV, potentially improving
left ventricular function and ejection fraction. It is important
to distinguish effects on cardiac output from effects on car-
diac function; PPV may improve cardiac function in some
patients while reducing cardiac output in others. Mechanical
ventilation often benefits patients with myocardial dysfunc-
tion, especially of the left ventricle.
Patients who become hypotensive or show evidence of
decreased cardiac output while on PPV should be assessed
for volume depletion, administration of vasoactive drugs
(including opioid analgesics and sedatives), excessively high
tidal volume or airway pressure, and PEEPi, as well as other
systemic causes of hemodynamic compromise. A trial of
intravenous fluids is sometimes warranted while ventilator
adjustments are considered.
C. Other Complications—Inadvertent hypoventilation and
hyperventilation are not uncommon because mechanical
ventilators do not respond automatically to changes in
PaCO2. Appropriate ventilation may not be delivered because
of machine malfunction; disconnection from the patient,
electrical power, O2, or compressed air; operator error; or
obstruction of the ventilator circuit. A rare reported compli-
cation is injury from overheating of the humidifier used to
warm and humidify inspired gas.
Ventilator circuits and humidifiers may become colo-
nized with pathogenic bacteria or fungi. Nosocomial pneu-
monia is an important complication of mechanical
ventilation (ventilator-associated pneumonia [VAP]). In a
study of 264 patients admitted to a medical-surgical ICU
who required mechanical ventilation for more than 48 hours,
22% developed bacterial pneumonia. Gram-negative bacilli
were identified in 63% and Staphylococcus aureus in 23%.
Forty-two percent of those with pneumonia died, compared
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with 37% who did not develop nosocomial pneumonia.
Although this difference in mortality rate was not statistically
significant, VAP did increase the time spent in the ICU. The
diagnosis of VAP is very difficult. Presence or absence of
fever, leukocytosis, or purulent sputum are not sensitive
or specific for VAP. The combination of new infiltrates
plus two of fever, leukocytosis, or purulent sputum has a
likelihood ratio of 2.8. The absence of new infiltrates low-
ers the likelihood of VAP (likelihood ratio = 0.35). Some
investigators have recommended that patients undergo
invasive diagnostic testing using fiberoptic bronchoscopy
(eg, protected brush catheters with quantitative bacterial
cultures); others suggest that these data do not improve
diagnostic accuracy. Decreasing the frequency of ventila-
tor circuit changes is associated with fewer episodes of
nosocomial pneumonia. Attention to careful suctioning,
frequent draining of condensate in the ventilator circuit,
judicious use of antibiotics (including shorter courses),
and avoiding prolonged mechanical ventilation decrease
the risk of VAP.
Discontinuation of Mechanical Ventilation
(“Weaning”)
Mechanical ventilation can be discontinued easily and safely
in the majority of patients, that is, those who do not have
severe lung disease or neuromuscular weakness or who are
electively placed on mechanical ventilation for surgery. In
other patients—especially those with lung disease—mechanical
ventilation usually must be discontinued with careful moni-
toring using a variety of techniques. A gradual reduction in
ventilatory support has led to the use of the term weaning
from the mechanical ventilator as the patient resumes spon-
taneous ventilation, but there is growing evidence that many
patients in the ICU do not need slow withdrawal of
mechanical ventilation. Discontinuation of mechanical ven-
tilation should be distinguished from discontinuation of
endotracheal intubation or tracheostomy. Although the
terms intubation and ventilation are often used synony-
mously, there are some patients in whom intubation is
necessary but mechanical ventilation is not (eg, those with
upper airway obstruction).
In may ICUs, discontinuation of mechanical ventilation is
facilitated by protocols directing physicians, nurses, and res-
piratory therapists. These evidence-based protocols have
been successful in decreasing duration of mechanical venti-
lation and maximizing patient understanding and comfort
during the process. However, not all studies demonstrate that
such protocols are necessary.
A. Physiologic Assessment—For mechanical ventilation to
be discontinued, the patient must have a sustained ventila-
tory capacity that equals or exceeds the ventilatory require-
ment. For most patients who fail, the ventilatory requirement
(ie, how much minute ventilation is needed to maintain
PaCO2) is high relative to ventilatory capacity (how much
minute ventilation the patient is capable of providing
without assistance)(Table 12–11). The ventilatory require-
ment is a function of the metabolic rate (CO2 production),
the set point for PaCO2, and the efficiency of lung gas
exchange (dead space:tidal volume ratio). Ventilatory capac-
ity is determined primarily by the interaction of ventilatory
drive, respiratory system mechanics, and inspiratory muscle
strength and endurance.
Disuse of respiratory muscles leads to atrophy, earlier and
easier fatigue, and possibly discoordination. In patients with
increased airway resistance or decreased lung or chest wall
compliance, respiratory muscles must generate relatively
greater pressure for a given tidal volume. Often these patients
have an increased ventilatory requirement and, therefore, an
increased pressure-time product—an index of muscle work
and potential for fatigue. Factors associated with decreased
muscle strength and endurance include electrolyte abnor-
malities (eg, hypokalemia and hypophosphatemia), critical
illness polymyopathy and polyneuropathy, high-dose corti-
costeroid therapy, malnutrition, and recent use of nondepo-
larizing muscle relaxants.
B. Predicting Successful Weaning—The underlying disease
that caused a need for mechanical ventilation must be cor-
rected first. The patient should have adequate gas exchange, as
evidenced by an only moderate supplemental oxygen require-
ment (PaO2/FIO2 >200), PEEP of less than 5–8 cm H2O, and
VD/VT of less than 0.50. The ventilatory requirement is gen-
erally the minute ventilation (
.
VE) provided during mechani-
cal ventilation. If gas exchange and the metabolic rate do
not change, the patient will have to provide this amount of.
VE to maintain PaCO2 at the preweaning level. Weaning is
usually unsuccessful when the 
.
VE requirement is greater
than 10–12 L/min, or about twice the resting 
.
VE in normal
adults. Adequate ventilatory capacity is encouraged by ensur-
ing normal plasma electrolytes (especially phosphorus,
Increased Ventilatory
Requirement
Decreased Sustained
Ventilatory Capacity
Fever
Infection
Increased ventilatory drive
Metabolic acidosis
Excessive hyperalimentation
(especially with carbohydrate?)
Liver disease 
Respiratory muscle fatigue 
Hypokalemia
Hypophosphatemia 
Decreased ventilatory drive 
Bronchospasm 
Airway secretions 
Decreased lung or chest wall
compliance
Neuromuscular weakness
Malnutrition
Small endotracheal tube
Increased resistance of endotra-
cheal tube or ventilator circuit 
Table 12–11. Factors contributing to difficult weaning:
Increased ventilatory requirement or decreased
ventilatory capacity.
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magnesium, and potassium), discontinuing sedatives, and
minimizing abnormal lung mechanics by treatment with
bronchodilators and suitable patient positioning.
Ventilatory capacity is assessed using a variety of weaning
parameters, some of which are shown in Table 12–12. Vital
capacity, negative inspiratory pressure, spontaneous 
.
VE
measured for 1 minute, and maximum voluntary ventilation
measured for 8–10 seconds estimate short-term ventilatory
capacity. These variables have excellent predictive value in
patients recovering from short-term general anesthesia, but
their predictive value is only marginal in patients with acute
or chronic lung diseases. This is largely because these param-
eters assess only ventilatory capacity and do not take into
account the ventilatory requirement and work of breathing.
In one study in which 58% of patients were weaned success-
fully, the following variables were found to be most closely
correlated with success:days of mechanical ventilation before
the weaning trial, respiratory frequency:tidal volume ratio,
maximal inspiratory pressure, maximal expiratory pressure,
and vital capacity. There were important differences between
groups with COPD, neurologic respiratory failure, and other
causes of respiratory failure; positive predictive values for
successful weaning ranged from 74–94%.
Indices that combine estimates of ventilatory require-
ment, work of breathing, and ventilatory capacity may be
useful. For example, a spontaneous respiratory rate:tidal vol-
ume ratio (f/VT) of less than 100/min/L may predict success-
ful weaning because it is an index of requirement and
capacity. This ratio, termed the rapid shallow breathing index,
proved to have greater sensitivity and specificity than other
variables for prediction of weaning. However, a report of
52 patients undergoing weaning from mechanical ventilation
indicated that 12 of 13 patients with a f/VT of more than
105/min/L were weaned successfully, whereas only one
patient who failed extubation had a ratio that high. One
interpretation is that very low f/VT ratios have a high positive
predictive value for successful weaning, whereas very high
ratios predict unsuccessful weaning well. On the other hand,
ratios of between 70 and 110/min/L are less useful.
Nevertheless, current predictors and clinical judgment of
successful weaning are poor. Because of this, a clinical trial of
patients who have marginal or low likelihoods of successful
weaning may be indicated. In an important study, all patients
using mechanical ventilation had a daily spontaneous
breathing trial unless contraindicated (eg, apnea, hypopnea,
severe hypoxemia, or high oxygen or minute ventilation
requirements). Surprisingly, a number of patients were dis-
continued successfully from mechanical ventilation who
would not have been predicted to do so by their clinicians. In
fact, patients who tolerate a spontaneous breathing trial of
30–120 minutes should be considered for immediate extuba-
tion in the absence of contraindications.
C. Weaning Methods—Patients who are easily weaned from
mechanical ventilation are easily weaned regardless of the
specific method used. Those who are difficult to wean for any
reason are difficult no matter which method is used. An
explanation of the weaning procedure, including descriptions
of possible discomfort and an assurance of close monitoring,
should be provided to the patient before weaning is started.
Once mechanical ventilatory support is being withdrawn,
slowly or rapidly, signs that should lead to restarting
mechanical ventilation or slowing the process include
tachypnea, tachycardia (HR >120 beats/min), hypotension,
severe anxiety, hypoxemia, respiratory acidosis (pH <7.30),
arrhythmias, chest pain, or other signs of hemodynamic
compromise. A study of a small number of patients showed
that a fall in gastric intramural pH, suggesting tissue
ischemia, was found in patients who failed weaning, whereas
those who were successful had no change in gastric intramu-
ral pH. In any patient who has difficulty being weaned from
mechanical ventilation, reassessment of ventilatory require-
ments and ventilatory capacity is indicated.
There are no conclusive studies demonstrating superior-
ity of any weaning method for patients with difficulty having
mechanical ventilation discontinued. Recent studies, how-
ever, suggest that spontaneous breathing trials followed by
extubation in suitable patients reduces length of ICU stay
and duration of mechanical ventilation. Although attractive,
noninvasive PPV in those with postextubated respiratory
distress has not been shown to benefit these patients.
Evidence that intermittent mandatory ventilation helps in
difficult patients is lacking.
1. T tube—The ventilator circuit is disconnected from the
endotracheal tube, and humidified oxygen is supplied by a
tube connected across the endotracheal tube connection
(T tube) while the patient breathes spontaneously. The
patient is observed carefully for signs of respiratory failure,
discomfort, severe dyspnea, or other intolerance.
If the T tube is used for a spontaneous breathing trial and
the patient tolerates the procedure for 30–120 minutes, then
Table 12–12. Some variables used to predict success
during weaning from mechanical ventilation.
Ventilatory capacity  .
VE (on ventilator) <10 L/min and 
.
VE (spontaneous) = 
.
VE
(on ventilator) 
VT >5 mL/kg; VC >10–15 mL/kg 
Spontaneous f <25/min 
Maximum negative inspiratory pressure <–25 cm H2O  
Maximal voluntary ventilation (MVV) >2 x 
.
VE (ventilator) 
Ventilatory requirement 
PaO2 >60 mm Hg with FIO2 <0.50 
VD/VT <0.50 
Combined indices 
<100 breaths/min/L
Successful 30-minute spontaneous breathing trial 
f breaths/min
VT(L)
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the patient can be extubated. Otherwise, the duration of T-
tube sessions is increased depending on the patient’s
response. In between sessions, the patient is reconnected to
the mechanical ventilator in the assist-control mode. In some
patients, a T-tube session may be as short as 5–10 minutes at
first, with very gradual lengthening. The sessions may be
repeated two to four times daily depending on patient toler-
ance. It is important to strike a balance between excessive res-
piratory muscle fatigue during the sessions and adequate time
for the patient to assume some of the work of breathing.
A variation of the T-tube weaning method uses the venti-
lator circuit and ventilator to provide the air-oxygen mixture
during spontaneous breathing rather than a separate T tube.
This method allows for monitoring and warning of low
spontaneous tidal volume. However, some ventilator circuits
during spontaneous ventilation require much more patient
effort than the conventional T tube. Some mechanical venti-
lators provide gas mixtures to spontaneously breathing
patients with minimal work and effort by using continuous
flow or bypass circuits.
2. Intermittent mandatory ventilation (IMV)—This
mode was described earlier. The number of mechanical ven-
tilator breaths each minute is decreased gradually over hours
or days while the patient provides a progressively increasing
share of the breaths taken each minute. The IMV mode in
some mechanical ventilators requires that the patient do
excessive work during the spontaneous breaths, and for this
reason, patients may tire easily. Despite encouraging data
when IMV was first used in the 1970s, there is no evidence
that IMV facilitates weaning in patients with lung disease or
in those who are difficult to wean. IMV has the advantage of
providing good monitoring of the patient during weaning,
with breath-by-breath spontaneous tidal volume and rate
displayed by most ventilators.
3. Pressure-support ventilation—The theoretic advan-
tages of PSV were outlined earlier. During weaning by this
technique, the pressure-support pressure is chosen initially
to achieve a tidal volume of 6–8 mL/kg and a respiratory rate
less than about 20 breaths/min. Pressure-support pressure
then is decreased gradually until the patient’s own tidal vol-
ume without pressure support is adequate. Mechanical ven-
tilation usually can be discontinued when the pressure
support is less than 7–10 cm H2O.
When it is desired to rest the inspiratory muscles tem-
porarily, either pressure-support pressure can be increased
until tidal volume reaches the desired level with little or no
patient effort or using conventional mechanical ventilation.
A few studies comparing PSV to T-tube weaning and IMV
have been completed, and T-tube weaning and PSV are sim-
ilarly more successful than IMV weaning. It is likely that PSV
and T-tube weaning will both be useful depending on patient
selection and clinician preference.
4. Noninvasive positive-pressure ventilation—
Noninvasive positive-pressure ventilation has potential benefits
in the weaning process after the patient is extubated. Some
studies have suggested that patients who are marginal wean-
ing candidates (eg, those with COPD with high ventilatory
requirements or low ventilatory capacity) may be extubated
successfully with the assistance of face-mask noninvasive
positive-pressure ventilation. The advantages might be
decreased duration of intubation, fewer complications, and
shorter hospital stays. Other studies have found that patients
who have failed weaning or extubation might be temporarily
supported using noninvasive positive-pressure ventilation
rather than reintubation. Recent studies have not shown par-
ticular benefit in selected and unselected patients. Further
studies are necessary to determine the precise role and out-
come of noninvasive positive-pressure ventilation in wean-
ing. If used, however, candidates should be selected carefully
and monitored closely.
5. Other methods—Facilities that specialize in manage-
ment and weaning of long-term ventilator-dependent
patients may be a less costly alternative than the ICU in
selected patients. A number of specialized centers have
reported considerable success in weaning patients after very
prolonged mechanical ventilation.
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ACUTE RESPIRATORY FAILURE FROM SPECIFIC
DISORDERS
 Neuromuscular Disorders
ESSENT IALS  OF  D IAGNOS I S
 May present with decreased ventilation owing to respi-
ratory muscle weakness (usually high respiratory rate
with low tidal volume) or decreased ventilatory drive
(low respiratory rate and tidal volume).
 PaCo2 >50 mm Hg.
 VC <55% of predicted or less than 1500 mL may be
associated with hypercapnia.
 Neuromuscular disorders often lead to atelectasis, aspi-
ration, pneumonia, hypoxemia, and poor cough reflex.
 Suspect respiratory muscle weakness in all patients
with neuromuscular weakness; general muscle strength
does not always correlate with respiratory function.
General Considerations
Respiratory failure from neuromuscular diseases results from
respiratory muscle weakness or abnormal control of ventila-
tion. Muscle weakness or paralysis can result from disease in
any part of the nervous system involved with motor activity.
Problems with control of ventilation are seen in diseases that
affect the O2 and CO2 chemoreceptors, their connections to
the CNS, or the integrative and autonomic parts of the brain
stem, primarily the medulla.
In addition to respiratory failure, neuromuscular disease
can be associated with a number of other respiratory mani-
festations (Table 12–13). For critically ill patients, complica-
tions of nonneurologic diseases and treatment may include
neuromuscular weakness (eg, electrolyte abnormalities, cor-
ticosteroid myopathy, hypothyroidism, and peripheral neu-
ropathy) and depressed ventilatory drive (eg, sedatives and
opioid analgesics).
Pathophysiology
Respiratory failure in neuromuscular disease is due to weak-
ness of the intercostal muscles and the diaphragm. However,
other factors contribute to abnormal gas exchange
(Table 12–14). Acute weakness of inspiratory and expiratory
muscles results in a rapidly progressive decrease in vital
capacity and alveolar hypoventilation with hypoxemia. In
most cases, the mechanical properties of the chest wall are
altered, but the lungs are normal unless complications occur.
On the other hand, chronic neuromuscular disease may alter
the lungs and chest wall. Other factors that contribute to dif-
ferences in the presentation of respiratory failure include the
age of the patient at onset of disease, the distribution of mus-
cle weakness, a chronic or relapsing course, and the presence
of underlying lung or heart disease.
A. Normal Respiratory Muscles—Respiratory muscles
include the diaphragm, the intercostal muscles, muscles in the
neck that can generate additional respiratory effort, and mus-
cles of the abdominal wall. Other muscles play a key part in
ventilation, including muscles in the upper airway and the
smooth muscles of the lower airways. Respiratory muscles can
be divided into inspiratory and expiratory muscles, although
some are used during both parts of the respiratory cycle. The
Table 12–13. Respiratory complications of neuromuscular
disease. 
Hypercapnic respiratory failure 
Hypoxemia 
Pneumonia 
Aspiration of gastric contents 
Pulmonary edema 
Abnormal ventilatory pattern 
Upper airway obstruction 
Atelectasis 
Respiratory alkalosis 
Pulmonary embolism 
Table 12–14. Physiologic consequences of neuromuscu-
lar disease. 
Decreased lung volumes  
Alveolar hypoventilation  
Decreased lung compliance  
Increased chest wall compliance (acute weakness) 
Decreased chest wall compliance (chronic spastic paralysis)  
Abnormal abdominal wall mechanics  
Ventilation-perfusion maldistribution  
Atelectasis  
Impaired cough effectiveness 
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diaphragm generates negative intrathoracic pressure during
contraction by pulling downward toward the abdomen.
However, if abdominal wall muscles contract simultaneously
with the diaphragm, the net effect is rather to pull the lower
margins of the rib cage upward and outward, thereby expand-
ing the thoracic volume. Muscles in the neck assist inspiratory
efforts, especially when the work of breathing is increased,
high ventilation is needed, the lungs are hyperinflated, or the
diaphragm becomes fatigued. These accessory muscles include
the sternocleidomastoids and scalenes.
Exhalation is usually passive, but normal subjects can
increase expiratory flow by contracting expiratory muscles
and generating higher positive intrathoracic pressures. Even
passive exhalation depends on respiratory muscles, however,
because passive expiratory flow is proportionate primarily to
airway caliber and lung elastic recoil; both these factors are
maximized at high lung volume, which requires good inspi-
ratory muscle strength to achieve.
B. Lung Volumes in Neuromuscular Disorders—Vital
capacity (VC) and inspiratory capacity (IC) are diminished
because of decreased ability to expand the lungs and chest wall
against passive inward recoil of those structures. While
decreased IC contributes to decreased total lung capacity
(TLC), the other component of TLC is the functional residual
capacity (FRC), often considered to be determined by the pas-
sive balance between inward recoil of the lung and outward
recoil of the chest wall at end expiration. But FRC does change
with the onset of neuromuscular weakness. For example, nor-
mal volunteers given submaximal doses of muscle relaxants
had about a 10% decrease in VC and TLC, but FRC decreased
about 20% as a result of decreased stiffness of the chest wall.
In patients with myasthenia gravis given pyridostigmine, an
increase in FRC correlating with an increase in respiratory
muscle strength was found. A study of stable patients with
moderate respiratory muscle weakness found that VC aver-
aged about 50% of predicted from height and age, TLC about
67% of predicted, and FRC about 79% of predicted.
In chronic neuromuscular disease, both altered chest wall
compliance and reduced lung compliance contribute further
to decreased FRC. Chest wall compliance in patients with
spinal cord injury and spastic paralysis of chest wall muscles
may be only 70% of normal. Small tidal volumes reduce lung
compliance, adversely affecting surfactant distribution and
perhaps stiffening and shortening lung fibrous and elastic
tissues from chronically reduced lung expansion.
C. Inadequate Cough—Inadequate cough, with retention of
secretions and increased tendency to pneumonia and atelec-
tasis, is the most common and important problem seen in
patients with neuromuscular weakness. Coughs are most
effective in removing secretions from airways if large shear
forces are generated by high-velocity gas movement in the
airways. In normal individuals, coughs are initiated at high
lung volumes, depend on vigorous contraction of expiratory
muscles to compress airways and generate high positive
intrathoracic pressures, and are released explosively. The
patient with neuromuscular weakness cannot produce effec-
tive cough if these three components are compromised.
The combination of low lung volume, impaired cough,
and accumulation of secretions leads to atelectasis. At low
lung volumes, alveoli are strongly influenced by surface forces
generated at the interface between the alveolar gas and the
wetted surface of the alveoli. This surface tension increases
the tendency of the alveoli to collapse. Airway secretions also
contribute to atelectasis by obstructing inward airflow and
allowing alveolar gas to be absorbed into the blood.
D. Abnormal Control of Ventilation—As described earlier,
alveolar ventilation in normal individuals is adjusted to regu-
late PaCO2. Hypoxemia also stimulates respiration but does not
play an active role in normal individuals at sea level. Neurologic
disorders that affect the central or peripheral chemoreceptors,
the integrative centers in the brain stem, or the primary outputs
to the respiratory muscles (phrenic nerves) may lead to inap-
propriate ventilation for the metabolic requirements of the
patient. Both hypoventilation and hyperventilation may be
seen depending on the site of the neurologic problem.
Clinical Features
Symptoms, signs, and laboratory findings depend on the
type of neuromuscular disorder leading to respiratory failure
(Table 12–15). Common to all forms of respiratory failure in
neuromuscular diseases are hypoxemia, hypercapnia, atelec-
tasis, poor cough, and risk of development of pneumonia
and other complications. Deep venous thrombosis and pul-
monary embolism are common in immobilized patients.
Occasionally, patients who have difficulty in weaning from
mechanical ventilation are found to have an unsuspected pri-
mary or secondary neuromuscular disorder.
A. Disorders of Ventilatory Control—Impaired ventilatory
control owing to a primary neurologic disorder is a relatively
unusual cause of respiratory failure. Patients present with low
respiratory rate and tidal volume, fluctuating uncoordinated
breathing patterns, or markedly periodic breathing. Diseases
that affect the medullary centers, including poliomyelitis and
cerebrovascular disease, as well as depression by CNS drugs or
hypothyroidism, can suppress the respiratory rhythm and out-
put from the autonomic nervous system. In patients with
impaired ventilatory control, clinical findings are related pri-
marily to the effects of respiratory failure on gas exchange in
addition to the consequences of the underlying disease. If CNS
depression from opioid or sedative drugs is present, patients
often will be lethargic or comatose. Other manifestations of
autonomic dysfunction such as hypertension or hypotension
and bradycardia or tachycardia can be seen in medullary
infarction. Furthermore, infarction or ischemia of the medulla
often results in characteristic effects on other neurologic path-
ways, including motor and sensory long tracts. A largely
reversible disorder of ventilatory control may be seen in
patients who have intermittent and transient hypoxemia, such
as seen in those with severe sleep-disordered breathing or
obstructive sleep apnea syndrome.
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B. Neuromuscular Weakness—Respiratory failure from
neuromuscular diseases that leave ventilatory control mech-
anisms intact usually presents with low tidal volume and,
because of the response to hypoxemia, hypercapnia, and lung
and chest wall mechanoreceptors, increased respiratory fre-
quency. There are some differences between the clinical pic-
tures depending on the particular disorder.
1. Muscle disease—Primary muscle diseases can be con-
genital or acquired. All can result in respiratory failure
when severe, including the congenital muscular dystro-
phies, inflammatory muscle disorders such as polymyositis
and dermatomyositis, drug-induced muscle weakness from
such agents as corticosteroids, and muscle weakness caused
by electrolyte and metabolic disturbances, including
hypokalemia, hypophosphatemia, hypothyroidism, hyper-
thyroidism, and chronic renal failure. Muscle weakness may
not affect all muscle groups equally. Proximal muscles may
be more severely affected in some muscular dystrophies, and
even when respiratory failure is developing, there may be
poor correlation between the strength of the extremity mus-
cles and that of the respiratory muscles. Myotonic dystrophy,
a rare disorder presenting with weakness and myotonic phe-
nomena including impaired muscular relaxation, imposes
the additional burden of a stiff chest wall and increased work
of breathing.
The myopathic effects of corticosteroids can exacerbate
the effects of the underlying disease for which the drug is
administered, and corticosteroid-induced weakness in
patients with asthma or interstitial pneumonitis can con-
tribute substantially to respiratory impairment. A syndrome
associated with use of neuromuscular junction blocking
agents and corticosteroids can cause weakness and failure to
wean from mechanical ventilation. In some of these patients,
both evidence of myopathic changes on muscle biopsy and
neuropathic changes evidenced by nerve conduction studies
have been found. Hypokalemia and hypophosphatemia also
may precipitate respiratory failure in ICU patients.
Myxedema is associated with muscle weakness and elevated
plasma creatine kinase. Muscle weakness seen in thyroid dis-
ease is generally correlated with the severity of thyroid dis-
ease and corrects with treatment.
Patients with a variety of critical illnesses can develop a
syndrome called critical illness myopathy. This disorder has
been associated with critical illness polyneuropathy but may
occur alone. Clinically, these patients develop muscle weak-
ness during treatment for serious illness, although no specific
cause of muscle injury can be identified. Histopathologic
changes may include variation in muscle fiber size, fiber atro-
phy, angulated fibers, fatty degeneration, fibrosis, and single-
fiber necrosis, but there are no inflammatory changes. There
are structural differences between patients who receive corti-
costeroids and those whose muscles are affected by some
combination of cytokines and myotoxic substances.
Common predisposing conditions include ARDS, pneumo-
nia, liver and lung transplantation (possibly related to corti-
costeroids), liver failure, and acidosis. Because of common
predisposing conditions, critical illness polyneuropathy
should be distinguished from this syndrome. Both are asso-
ciated with difficulty in weaning from mechanical ventilation
and sometimes are not suspected until this stage of respira-
tory failure.
Primary muscle disorders often can be distinguished
from peripheral neuropathy by the absence of sensory find-
ings and by electromyography.
2. Peripheral neuropathies—Peripheral nervous system
disorders can be divided into those that affect the neuromus-
cular junction and those that affect the peripheral nerves.
Peripheral neuropathies, although seen in many disorders
such as vasculitis, diabetes mellitus, vitamin deficiencies,
Table 12–15. Neuromuscular diseases associated with
respiratory failure.
Medullary center injury or depression  
Poliomyelitis 
Cerebral vascular disease 
Hypothyroidism 
Narcotic and sedative drug overdosage 
Primary muscle diseases 
Muscular dystrophy 
Myotonic dystrophy 
Polymyositis, dermatomyositis 
Drugs: corticosteroids 
Hypokalemia, hypophosphatemia 
Critical illness myopathy 
Peripheral nerve diseases 
Peripheral neuropathies 
Guillain-Barré syndrome 
Vasculitis  
Diabetes  
Vitamin deficiency 
Toxin exposure  
Infection 
Infiltrative diseases 
Critical illness polyneuropathy 
Neuromuscular junction diseases 
Myasthenia gravis and cholinergic crisis 
Botulism 
Tick paralysis 
Drugs: paralyzing agents, aminoglycosides 
Spinal cord injury and disease 
Trauma 
Poliomyelitis 
Amyotrophic lateral sclerosis  
Malignancy  
Paraspinous or parameningeal abscess  
Diaphragmatic paralysis  
Cerebral cortical diseases  
Stroke 
Extrapyramidal disorders 
Neurogenic pulmonary edema 
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toxin exposure (eg, lead), infections, and infiltrative diseases,
cause respiratory failure only rarely. For ICU patients, the
most important disorders are acute polyradiculoneuritis
(Guillain-Barré syndrome) and critical illness polyneuropa-
thy. Guillain-Barré syndrome is a demyelinating disease that
is seen most often several weeks after nonspecific viral or
other infectious illnesses, although the primary illness may
be asymptomatic or difficult to pinpoint. Some variants have
a strong association with prior Campylobacter jejuni infec-
tion. Clinical findings include ascending paralysis and sen-
sory involvement initially of the lower extremities. In
patients whose disease progresses over the course of about
2–4 weeks, involvement of the respiratory muscles, upper
extremities, and trunk may contribute to respiratory failure.
Autonomic instability may further complicate diagnosis and
management. Variants of Guillain-Barré syndrome may have
different patterns of involvement, making diagnosis more
difficult. About 5% of Guillain-Barré syndrome patients ini-
tially have ataxia, ophthalmoplegia, and aflexia with less
striking extremity weakness (Miller-Fisher variant). Other
variants have purely motor or sensory involvement only.
Critical illness polyneuropathy is associated with sepsis
and multiple-organ failure. Manifestations include muscle
weakness and wasting and findings suggestive of peripheral
neuropathy. Patients have flaccid weakness and loss of deep
tendon reflexes. There is no evidence that metabolic or nutri-
tional factors or inflammation play a major role. The histo-
logic appearance of primary axonal degeneration and
denervation is consistent with widespread primary nerve
injury. It has been speculated that the association with failure
of other organ systems indicates that peripheral neuropathy is
another marker of severe systemic illness. Critical illness
polyneuropathy is associated with respiratory failure and dif-
ficulty in weaning from mechanical ventilation. As many as
70% of patients with sepsis and multiple-organ failure have
primary axonal degeneration of motor and sensory fibers,
and 30% have difficulty in weaning from mechanical ventila-
tion, limb muscle weakness, or diminished muscle reflexes.
Electrophysiologic studies show reduction or absence of mus-
cle and sensory action potentials, but slowing of nerve con-
duction or nerve conduction blocks is absent. Clinically,
patients with critical illness polyneuropathy should be evalu-
ated for botulism, Guillain-Barré syndrome, prolonged effects
of muscle relaxants, and critical illness myopathy. Some inves-
tigators do not make a distinction between critical illness
polyneuropathy and myopathy; the disorders are part of a
continuum of associated complications of critical illness.
3. Neuromuscular junction disorders—Neuromuscular
junction disorders include myasthenia gravis, an immuno-
logic disease caused by antibodies to acetylcholine receptors;
botulism, in which a specific neurotoxin produced by
Clostridium botulinum is ingested; and drug-induced disor-
ders, including pharmacologic blockade of the neuromus-
cular junction by paralyzing agents or inadvertent blockade
by aminoglycosides and other drugs. Myasthenia gravis
occasionally has gone unrecognized until it was severe
enough to present with respiratory failure. Botulism should
be suspected if there is descending paralysis and an appropri-
ate clinical history. On occasion, botulism results from toxin
produced by organisms infecting a wound, often in associa-
tion with parenteral drug abuse. Weakness or difficulty in
weaning in ICU patients should prompt a review of medica-
tions that can affect the neuromuscular junction. Rarely,
these include calcium channel blockers, quinidine, pro-
cainamide, and lithium.
4. Spinal cord disorders—Acute cervical spinal cord
injury resulting in quadriplegia may cause near-total respira-
tory muscle paralysis if above the C3 level, but some function
of neck muscles still may be present. If injury is below C3–4,
diaphragmatic activity may be preserved, but respiratory
failure may develop. In this setting, rib cage movement may
be paradoxical, with inspiratory effort causing the chest wall
to move inward because of flaccid paralysis of intercostal
muscles. The mechanical efficiency of the diaphragm is also
diminished as a result of flaccid paralysis of abdominal wall
muscles, and cough effectiveness is greatly reduced. With
time, the chest wall and abdominal wall become less compli-
ant as muscles become spastic. In some patients, these
changes may allow spontaneous efforts to become sufficient
to maintain ventilation.
Other spinal cord diseases presenting with respiratory
failure include poliomyelitis and amyotrophic lateral sclero-
sis. Poliomyelitis has a variable prognosis, with both weak-
ness and inability to protect the upper airway contributing
to potential respiratory failure. Amyotrophic lateral sclero-
sis is progressive, and respiratory failure is inevitable and
irreversible.
5. Diaphragmatic paralysis—Diaphragmatic paralysis
from bilateral phrenic nerve injury or disease is rare. Vital
capacity is usually less than 50% of predicted and worsens
when supine. The abdominal wall moves paradoxically
inward during inspiration, increasing the work of breathing
and making ventilation particularly inefficient for the other
muscles of inspiration. Unilateral diaphragmatic paralysis is
often well tolerated unless there is underlying lung disease or
a requirement for increased work of breathing or minute
ventilation during illness.
C. Diseases of the Cerebral Cortex—Patients with strokes
have upper motor neuron paralysis but rarely present with
primary respiratory failure. However, respiratory problems
are the most common complications of stroke, including
aspiration and lung infection owing to generalized weakness,
immobility, and aspiration. More recently, the respiratory
complications of extrapyramidal disorders such as
Parkinson’s disease have become appreciated. The increased
stiffness of the chest wall increases the work of breathing,
and there are increased respiratory complications from
immobilization. Isolated closed head injury of any kind
requiring mechanical ventilation is commonly associated
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with pneumonia. In one study, 41% of these patients devel-
oped pneumonia and had a longer ICU stay compared with
those without pneumonia.
A rare complication of cerebral injury is neurogenic pul-
monary edema, seen in association with head injury, stroke,
status epilepticus, and cerebral hypoxia. Although it can be
indistinguishable from other forms of pulmonary edema,
neurogenic pulmonary edema may appear and disappear
rapidly despite causing severe gas-exchange disturbances.
The mechanism of neurogenic pulmonary edema is
unknown but may be related to extreme changes in pul-
monary vascular tone in response to autonomic stimuli.
Both increased lung epithelial permeability and increased
regional lung hydrostatic pressures cause pulmonary edema.
Among critically ill patients, abnormal neurologic status
is a major factor leading to prolonged mechanical ventila-
tion, with reduced level of consciousness the most common
cause. However, the underlying neurologic problem is more
likely a systemic illness (eg, drug toxicity or metabolic
encephalopathy) rather than a primary CNS disease.
D. Laboratory Findings—Hypoxemia is common, and a
PaO2 of less than 70 mm Hg on room air is likely. Hypercapnia
with acute respiratory acidosis is the key marker of respira-
tory failure owing to neuromuscular weakness or decreased
ventilatory drive. Other laboratory findings are not particu-
larly useful, but abnormal plasma electrolytes, including
decreased potassium, magnesium, calcium, and phosphorus,
may contribute to muscle dysfunction. In patients with unex-
plained neuromuscular weakness, elevated plasma creatine
kinase suggests myopathy or myositis. Thyroid function tests
may be useful even if the patient lacks the usual signs of
hypothyroidism or hyperthyroidism. Diagnosis of specific
neuromuscular disorders may be helped by electromyogra-
phy, nerve conduction studies, or nerve biopsy.
E. Imaging Studies—Complications of neuromuscular dis-
eases may be seen on chest x-ray. Atelectasis is a common
finding—either as macroatelectasis, with focal linear,
rounded, or other opacities visible on chest x-ray or evidence
of segmental, lobar, or other collapse, or in some cases with no
chest x-ray findings but only hypoxemia and an increased
P(A–a)O2. In one study, 95% of patients with neuromuscular
disease requiring mechanical ventilation had atelectasis at some
time, most often as lobar atelectasis in the dependent lungs.
Aspiration pneumonia is another common respiratory compli-
cation of neuromuscular diseases. Although dependent areas of
the lungs are involved most often, new alveolar or interstitial
infiltrates anywhere in the lungs suggest pneumonia.
When assessing neurologic disorders associated with res-
piratory failure, CT scanning is not often useful in evaluating
the brain stem and has variable usefulness for spinal cord
abnormalities. MRI is highly effective for imaging these
areas, but patients cannot undergo MRI while being sup-
ported with mechanical ventilation.
F. Assessing Respiratory Muscle Strength—Prediction of
respiratory failure in these disorders involves assessment of
respiratory muscle strength. Adequate respiratory muscle
function requires both inspiratory and expiratory strength,
but neither maximum inspiratory pressure nor expiratory
pressure strongly correlates with general muscle strength. In
patients with polymyositis or other proximal muscle
myopathies presenting with generalized weakness, mean
maximum inspiratory and expiratory airway pressures aver-
aged about 50% of normal in one study, whereas at the same
time the average of maximum inspiratory and maximum
expiratory pressures were less than 70% of predicted in
about two-thirds of patients. PaCO2 was inversely correlated
with both respiratory muscle strength and VC expressed as a
percentage of predicted. Hypercapnia was especially likely
when VC was less than 55% of predicted. In a study of
patients with Guillain-Barré syndrome, one-half of patients
developed respiratory failure. These had a mean VC when
intubation was required of about 15 mL/kg compared with
more than 40 mL/kg for nonintubated patients.
In patients with progressive neuromuscular weakness
who are at risk of respiratory failure, a reasonable approach
is to follow VC daily or more often if necessary. If VC falls
below about 20 mL/kg, is less than 55% of predicted, or
decreases below 1500 mL in an adult, respiratory failure
should be anticipated and arterial blood gases measured.
Intubation and mechanical ventilation (or noninvasive ven-
tilation if rapid reversal is expected) may be necessary if there
is progressive hypercapnia. Although some investigators rec-
ommend using the mean or sum of maximum inspiratory
and expiratory pressures rather than VC measurements, VC
is usually obtained more easily in the ICU.
Treatment
In most cases, treatment of respiratory failure owing to neu-
romuscular disease is supportive, including airway protec-
tion and mechanical ventilation. The exceptions are the few
diseases for which specific treatment is available, including
electrolyte abnormalities, myasthenia gravis, botulism, thy-
roid disease, and corticosteroid myopathy. It is essential to
prevent respiratory complications when possible and to rec-
ognize and treat them promptly when they occur.
A. General Care—Patients with neuromuscular disorders
should have attention to airway protection, including exami-
nation of the swallowing mechanism and gag reflex, alteration
of diet if necessary, careful feeding, and attention to body posi-
tioning. Feeding by mouth or by enteral feeding tubes should
be monitored closely, especially because some neuromuscular
diseases can affect gastric emptying and intestinal motility. In
all neuromuscular disorders—even when stable—respiratory
failure can be precipitated by stress from conditions such as
pulmonary or other infections, concurrent illness such as
heart failure, major surgery, medications, or electrolyte distur-
bances. General measures such as prophylaxis for gastritis and
prevention of deep venous thrombosis should be instituted.
Prevention of atelectasis by mechanical means is contro-
versial. Incentive spirometry is not as helpful in patients with
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neuromuscular weakness as in those with normal strength.
Intermittent positive-pressure breathing (IPPB) seems
attractive as a way of overcoming low lung volume during
tidal breathing. However, results of studies have been mixed.
Continuous positive airway pressure (CPAP) and bilevel
noninvasive positive-pressure ventilation also have been
tried without clear success. Some studies have shown that
rotational therapy using special beds is helpful in decreasing
atelectasis and pneumonia in immobile patients.
B. Treatment of Respiratory Failure—Treatment of respi-
ratory failure in patients with neuromuscular disease
includes airway maintenance, oxygen, bronchodilators if
necessary, and use of incentive spirometry to avoid atelecta-
sis. Respiratory failure is usually of the hypercapnic variety
unless there is atelectasis or consolidation from pneumonia.
Mechanical ventilation is often necessary to perform the
work of breathing in the patient with muscle weakness who
develops hypercapnia.
If respiratory drive is inadequate, the assist-control mode is
used with volume-preset ventilation. There is little rationale
for IMV or pressure-control ventilation, and pressure-support
ventilation cannot be used unless the patient can initiate and
sustain inspiratory efforts. Lung compliance and resistance are
normal in the absence of secondary pulmonary complications.
Unless and until ventilation-perfusion maldistribution devel-
ops, high concentrations of supplemental oxygen are not
needed. As in patients with obstructive or interstitial lung dis-
ease, tidal volumes should be limited to 6–8 mL/kg of ideal
body weight. PEEP may be quite helpful in decreasing atelec-
tasis and for reducing the sense of dyspnea in some patients.
Patients with specific neuromuscular diseases may pres-
ent with different needs. If respiratory muscle weakness is the
primary problem but ventilatory control is intact, pressure-
support ventilation may be suitable. In some disorders, it
may be desirable to rest the respiratory muscles entirely. The
assist mode does not “rest” inspiratory muscles as much as
the control mode—that is, if the patient initiates the breath,
the inspiratory muscles continue to contract throughout
inspiration, whereas if the ventilator initiates the breath,
inspiration is completely passive on the patient’s part.
Pressure-support ventilation, although the inspiratory mus-
cles are not completely rested, may have potential advantages
of allowing some work to be done but with less effort.
In some patients, positive-pressure ventilation is needed
only for some part of the day eg, (at night), and the patient can
breathe well for long periods of time. Tracheostomy may be
necessary to attach the ventilator at night, or noninvasive ven-
tilation may be tried for intermittent use.
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 Thoracic Wall Disorders
ESSENT IALS  OF  D IAGNOS I S
 Chest wall anatomic deformity, chest wall stiffness, or
severe obesity. 
 Massive ascites, late-stage pregnancy, recent abdomi-
nal or thoracic surgery, thoracic and abdominal trauma,
and large abdominal or pelvic masses sometimes may
present with respiratory failure.
 Paco2 >50 mm Hg, usually with hypoxemia.
 Low tidal volume; usually increased respiratory frequency.
 Primary lung disease absent but secondary complications
frequent.
General Considerations
Thoracic wall abnormalities other than those owing to neu-
romuscular disease are relatively rare causes of respiratory
failure. However, acquired and congenital abnormalities may
result in distortion of the chest wall, mechanical disadvan-
tage of the respiratory muscles, increased work of breathing,
or limitation of chest wall expansion. Patients usually have
chronic respiratory failure with hypoxemia, hypercapnia,
and cor pulmonale but also may present with acute deterio-
ration or exacerbations. The most common chronic disor-
ders leading to respiratory failure are severe obesity of the
chest wall and abdomen, kyphoscoliosis and scoliosis, and
ankylosing spondylitis. Massive ascites, late-stage pregnancy,
recent abdominal or thoracic surgery and trauma, and
myotonic dystrophy may cause respiratory failure in a simi-
lar manner.
Pathophysiology
Thoracic cage abnormalities restrict lung expansion. Vital
capacity and total lung capacity are decreased. Functional
residual capacity (FRC) is usually decreased except in most
patients with spondylitis. Because of overall reduction in
lung volumes, FEV1 is also usually low, but the ratio of FEV1
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to VC is normal in the absence of obstructive lung disease.
Respiratory failure results from a combination of increased
work of breathing and ventilation-perfusion maldistribution
owing to restriction of expansion of the lungs and chest wall.
The mechanics of the chest wall and the diaphragm are
altered in ways unique to the type of disorder and the loca-
tion of the abnormalities.
A. Chest Wall Deformity—Scoliosis and kyphosis may be
idiopathic or due to poliomyelitis, tuberculosis, or other iden-
tifiable causes. Patients with scoliosis have an inverse relation-
ship between the severity of scoliotic deformity and the
compliance of the thoracic cage. Those who develop respira-
tory failure have the most severe thoracic deformity and low-
est chest wall compliance. Patients with scoliosis breathe at low
tidal volumes, presumably to minimize the work of breathing.
Kyphosis alone rarely is associated with respiratory failure, but
when seen together with scoliosis, it may contribute to
increased work of breathing and other abnormalities.
Ankylosing spondylitis limits rib cage expansion, and
patients tend to breathe primarily by diaphragmatic move-
ment as the thoracic cage becomes increasingly immobile.
The contribution of thoracic cage expansion to tidal breath-
ing falls as minute ventilation increases. The position of the
thoracic cage at end expiration often becomes fixed at a vol-
ume larger than in normal subjects. The chest wall therefore
exerts a greater than normal outward pull on the lungs, result-
ing in a normal or increased FRC despite low VC and TLC.
A flail chest results from severe blunt trauma outside the
hospital but occasionally from cardiopulmonary resuscita-
tion. The flail is the paradoxical inward movement of the
chest wall during inspiration, making ventilation inefficient
and worsening respiratory mechanics. Chest pain and
underlying lung contusions contribute to respiratory failure.
B. Obesity
1. Severe obesity—Severe obesity—in particular, predomi-
nantly central or truncal obesity—puts a heavy mechanical
burden on the chest wall and the diaphragm during inspira-
tion. Increased weight causes the end-expiratory position of
the chest wall and diaphragm to be more inward than nor-
mal. Thus the amount of gas that can be further expired from
the end-expiratory position (expiratory reserve volume
[ERV]) is reduced. On the other hand, the inspiratory
capacity—the maximal amount of gas that can be inspired
from the resting end-expiratory point—is normal or
increased, at least in young obese adults with no underlying
diseases. The work of breathing is increased, especially when
minute ventilation increases. The larger mass of the chest
wall and abdominal wall must be accelerated at each breath,
and additional energy is expended to move them during tidal
breathing. Small tidal volumes are usually selected by these
patients, and the ability to increase minute ventilation can be
limited and associated with severe dyspnea. It is likely that
obesity associated with more peripheral distribution of
added adipose tissue (eg, buttocks and extremities) has less
effect on respiratory function, but this has not been studied.
Obese patients are more prone to develop obstructive
sleep apnea because of a greater redundant soft tissue in the
upper airway, potentiating airway obstruction during sleep-
associated relaxation of upper airway muscles. A syndrome
of obesity-hypoventilation has been described. The mecha-
nism of this central hypoventilation is unclear but is proba-
bly associated with increased work of breathing, decreased
responsiveness of the respiratory center, and chronic hypox-
emia. These patients have daytime hypercapnia from
depressed chemoresponsiveness, increased work of breath-
ing, and abnormal pulmonary function. Patients with
obesity-hypertension syndrome often have pulmonary
hypertension and cor pulmonale.
C. Limitation of Diaphragmatic Excursion—Patients with
massive ascites, late stage of pregnancy, recent abdominal or
thoracic surgery or trauma, severe hepatomegaly, or large
pelvic or abdominal tumors may present occasionally with
respiratory problems. Most often they have basilar atelecta-
sis, low tidal volumes, and mild hypoxemia. If diaphragmatic
excursion is severely limited, these patients may develop
hypercapnia. The underlying condition may contribute to
additional problems. For example, patients with liver disease,
ascites, or tumors also may have pleural effusions, further
compromising lung function. Those with recent surgery or
trauma may be unable or unwilling to take deep inspirations
because of pain.
D. Gas Exchange and Pulmonary Hypertension—
Patients with all types of chest wall abnormalities may have
ventilation-perfusion maldistribution contributing to
hypoxemia and hypercapnia. In obesity and limited
diaphragmatic excursion, this finding has been attributed
primarily to atelectasis at the bases of the lungs because of
elevation of the diaphragm and low FRC. This is supported
by observations that obese subjects have better gas exchange
when standing than when supine and improvement in
hypoxemia and reduced P(A–a)O2 during exercise. Patients
with ascites and abdominal tumors would be expected to be
similar. In scoliosis and spondylitis, regional differences in
ventilation can be explained by differences in expansion
owing to local chest wall stiffness in spondylitis or asymmet-
ric deformity in scoliosis.
The combination of chronic hypoxemia and respiratory
acidosis along with anatomic deformity of pulmonary vessels
explains the pulmonary hypertension and cor pulmonale
seen in some patients with severe chest wall abnormalities.
For reasons that are not clear, cor pulmonale is seen more
often in chronic respiratory failure from scoliosis, sometimes
in the absence of severe gas-exchange abnormalities; it may
be related to anatomic deformity or arrested development of
pulmonary vessels.
Clinical Features
Some patients with thoracic wall abnormalities have chronic
respiratory failure with chronic hypoxemia and hypercapnia.
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Decompensation leading to acute respiratory failure may be
due to further abrupt worsening of the chest wall disease,
development of a lung complication such as pneumonia or
bronchospasm, or additional metabolic requirements
imposed by surgical stress, infection, or other disease. The
clinical history may reveal the cause of thoracic deformity,
such as prior poliomyelitis or other disease, thoracic wall sur-
gery or injury, tuberculosis of the spine, or surgery for pul-
monary tuberculosis.
A. Symptoms and Signs—Dyspnea at rest and on exertion
are common complaints, but some patients complain only of
fatigue and weakness. Patients present usually with rapid,
shallow tidal breathing unless there is a disorder of ventila-
tory control suggesting central hypoventilation. Physical
examination can show obvious chest wall deformity or
decreased range of motion of the chest wall or diaphragm,
but the degree of abnormality may not be easily determined
from examination alone. Wheezing, rhonchi, or stridor may
be evidence of superimposed obstructive airway disease such
as asthma, but kinking of large central and upper airways in
scoliosis may be the cause. Other signs are due to complica-
tions such as pneumonia, left-sided heart failure, atelectasis,
and pleural effusions. Findings of right-sided heart failure,
such as peripheral edema, elevated central venous pressure,
and hepatic congestion, generally indicate chronic respira-
tory failure.
The likelihood of respiratory failure resulting from obe-
sity is not well correlated with the degree of obesity. Lung
volumes do not decrease routinely in proportion to excess
weight, and no marker of obesity such as weight/height2
(body mass index) predicts respiratory failure. For example,
in otherwise normal subjects who are more than 160% of
ideal weight, lung volumes and flows are usually found to be
normal. Such normal lung function may not persist, how-
ever, as these patients age, and the decline in lung function
with advancing age may be accelerated compared with
nonobese subjects. In addition, obesity is associated with
hypertension and cardiovascular disease, which themselves
may contribute to decreased respiratory function. Central
hypoventilation in obesity (obesity-hypoventilation syn-
drome) further dissociates the degree of obesity from the
severity of hypercapnia, as does the high prevalence of basi-
lar atelectasis causing hypoxemia.
Patients with ascites from liver disease and pregnancy fre-
quently have increased ventilatory drive, probably because of
hormonal changes. The severity of respiratory impairment
from decreased diaphragmatic excursion is highly unpre-
dictable, but most of the patients have some degree of hypox-
emia and only rarely develop hypercapnia.
B. Laboratory Findings—Respiratory failure results from
insufficient minute ventilation to maintain CO2 homeostasis.
With mild thoracic wall disorders, patients often can main-
tain normal PaCO2 and PaO2. As the disorder progresses,
work of breathing increases. Compensation in the form of
increased PaCO2 in exchange for decreased minute ventilation
then occurs, resulting in chronic respiratory acidosis. The
chronicity of respiratory failure can be confirmed by finding
an elevated plasma bicarbonate level.
C. Imaging Studies—The likelihood of respiratory failure
correlates with the severity of the deformity in scoliosis.
Severe thoracic scoliosis is generally considered when the
angle of spinal curvature exceeds 70 degrees, as measured on
an x-ray film. This angle is measured as the angle between
lines drawn perpendicularly to the longitudinal axis of two
vertebral bodies, one above and one below the area of maxi-
mum deformity. The angle is 0 degrees in the absence of sco-
liosis and increases with increasing scoliosis. As many as 50%
of patients with an angle greater than 80 degrees may be con-
sidered at risk for respiratory failure. An angle of 100 degrees
seems to be associated with dyspnea on exertion and an angle
greater than 120 degrees with alveolar hypoventilation.
Treatment
Care of the patient with respiratory failure from thoracic wall
disorders is largely supportive. There is considerable
reported success with noninvasive positive-pressure ventila-
tion (NIPPV) in these patients, but most of these data are in
stable patients requiring ventilation at night and intermit-
tently during the day. There is less experience with acute res-
piratory failure, but NIPPV should be considered in order to
avoid endotracheal intubation. The benefits of NIPPV often
persist, likely because of improvements in respiratory muscle
function and improved respiratory gas exchange. Mechanical
ventilation is initiated if the patient requires additional ven-
tilatory support to overcome increased metabolic require-
ments or during an acute exacerbation owing to infection or
surgery. If concomitant central hypoventilation contributes
to respiratory failure, patients often will respond after several
days of correction of hypoxemia and respiratory acidosis by
demonstrating greatly improved respiratory drive.
Respiratory stimulant drugs such as progesterone and
almitrine are not helpful. Patients with limited diaphrag-
matic excursion are approached according to the type of
problem. Those with severe ascites may benefit from large-
volume paracentesis or other efforts to decrease the volume
of ascites. Pain management is critical in patients following
abdominal or thoracic surgery or trauma.
Treatment of flail chest depends on the severity of injury.
Pain management and monitoring may be adequate. If respi-
ratory failure develops, mechanical ventilation may be neces-
sary until chest wall mechanics recover. Only in rare cases is
surgical repair indicated, including prolonged recovery,
deeper injuries to thoracic structures, and extensive injuries.
Patients with right-sided heart failure from cor pul-
monale may have peripheral edema and hepatic congestion,
but vigorous diuresis is not usually indicated and may be
harmful. Patients with pulmonary hypertension may be sen-
sitive to preload reduction and rapid decrease of intravascu-
lar volume. However, spontaneous diuresis as a response to
improved oxygenation is a good sign. Patients with coexisting
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left-sided heart failure may benefit from diuresis and
decreased pulmonary edema.
The outlook for patients who present with respiratory fail-
ure from chest wall disorders is surprisingly favorable. In many
cases, one or more precipitating factors can be identified and
corrected. Other patients will respond with improved gas
exchange after a short period of supplemental oxygen or
mechanical ventilation. While there is little chance of improv-
ing the underlying pathophysiology in severe scoliosis or
severe ankylosing spondylitis, weight reduction and treatment
of obstructive sleep apnea in obesity can be highly effective.
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 Chronic Obstructive Pulmonary Disease
ESSENT IALS  OF  D IAGNOS I S
 Chronic bronchitis or emphysema.
 Increased dyspnea and cough; decreased exercise
tolerance.
 COPD exacerbation: one or more of increased sputum
volume, increased sputum purulence, and/or worsen-
ing dyspnea.
 Respiratory muscle fatigue.
 Worsening hypoxemia/hypercapnia; new onset or
worsening of hypercapnia.
General Considerations
Chronic obstructive pulmonary disease (COPD) is the most
common respiratory disorder leading to respiratory failure
in adults. Although asthma and cystic fibrosis are chronic
obstructive diseases, COPD is usually considered to include
chronic bronchitis and emphysema. Most patients with
COPD have chronic respiratory failure, many with hypox-
emia (some requiring home oxygen supplementation), a
lesser proportion with chronic hypercapnia. Acute respira-
tory failure in COPD develops both in patients with and
those without chronic respiratory failure. Although precipi-
tated most often by exacerbation of airway obstruction from
infection and increased sputum production, an important
factor leading to acute respiratory failure is inspiratory mus-
cle fatigue. Patients with COPD, because they have limited
ventilatory reserve, may have acute respiratory failure when
they have a nonrespiratory infection, heart failure, or dia-
betes or after major surgery.
COPD patients typically have acute exacerbations several
times per year, but only some require hospitalization and
ICU admission. When admitted to the ICU, however, mortal-
ity is high, and recovery is slow.
A. Definition—Chronic bronchitis and emphysema have in
common limitation of airflow caused by obstruction of
intrathoracic airways, and airway obstruction is more marked
during expiration. Chronic bronchitis is characterized by
increased sputum production, chronic inflammation of the air-
ways, hypertrophy of airway smooth muscles, increased num-
ber and size of airway mucus glands, and thickening of airway
connective tissue. Patients with chronic bronchitis often have a
history of cigarette smoking leading to hypertrophy of mucus
glands. Chronic bacterial infection also plays a role.
Emphysema is characterized by destruction of alveoli and
other tissues beyond terminal bronchioles. Decreased expira-
tory airflow in pure emphysema is not due to primary disease
of the airways but results from decreased elastic recoil of the
destroyed lung parenchyma. During expiration, decreased
lung elastic recoil lowers the distending pressure holding the
airways open and leads to increased airway resistance. The
pathogenesis of emphysema is not known. In a very small
proportion of patients, deficiency of α1-antiprotease has
been identified, and these patients are thought to have
destruction of lung elastic and connective tissue by unop-
posed action of leukocyte elastase. The mechanism of lung
parenchymal destruction in the majority is unknown.
Cigarette smoking, as well as some occupational exposures, is
associated with development of emphysema. Many patients
with emphysema have clinical features of chronic bronchitis.
B. Bacterial Infection and Sputum Changes—Acute res-
piratory failure in COPD occurs with worsening airway
obstruction. Sputum production increases, and the charac-
teristics of the sputum are altered in response to bacterial
infection. Increased sputum and difficulty clearing sputum
may provoke bronchospasm. Bacterial infection also may fol-
low viral or Mycoplasma infection. Some of the evidence for
the role of bacteria in causing exacerbation of COPD comes
from serologic testing, but the most convincing data has been
the demonstration of the beneficial effects of antibiotics in
preventing exacerbation, shortening the course of acute dete-
rioration, and decreasing the need for hospitalization.
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Bacteria colonize the trachea and bronchi of COPD
patients—even when stable—whereas normal subjects do
not have organisms in these sites. The most commonly found
organisms from tracheal aspirates have been Haemophilus
influenzae and Streptococcus pneumoniae, found in 30–60%
of COPD patients, and during acute exacerbations, there
may be an increase in the numbers of these bacteria. Other
bacterial pathogens, including Moraxella catarrhalis, are sus-
pected of being important causes of COPD exacerbation, but
other bacteria capable of causing pneumonia, such as gram-
negative aerobic bacilli, anaerobes, and staphylococci, do not
play a major role in exacerbation of COPD. There is debate
about whether the type and number of bacteria change sig-
nificantly during an exacerbation. A recent study indicates
that bacterial subtypes change during exacerbations even
though the same species are present chronically and during
exacerbation. Since bacteria quantity and quality are only
slightly different, the host’s response is an important feature
of acute exacerbation. The number of inflammatory cells
and the amount of other sputum components change during
acute exacerbation. Sputum becomes thicker, more viscous,
and more adherent to mucosal surfaces. A change from white
to green or yellow reflects increased amounts of myeloperox-
idase in neutrophils. Protein, cellular and bacterial debris,
and cellular DNA are responsible for mechanical changes in
sputum. Disruption and inefficiency of the normal mucocil-
iary clearance mechanisms results, with further worsening of
airway obstruction.
C. Bronchospasm and Respiratory Failure—
Bronchospasm is not a primary cause of airway obstruction
in chronic bronchitis or emphysema as it is in asthma, but
increased bronchomotor tone and airway smooth muscle
contraction are present. In COPD, much of the airway
smooth muscle contraction is mediated through the
parasympathetic nervous system via the vagus nerve. Local
irritation of the tracheobronchial mucosa from sputum, bac-
teria, and other debris stimulates the parasympathetic nerv-
ous system by way of vagal afferent pathways. Vagal efferent
fibers in the vagus nerve stimulate increased airway smooth
muscle contraction and increased airway resistance. Patients
with COPD frequently have a heightened response to metha-
choline inhalation challenge, although not usually as marked
as patients with asthma.
D. Lung Mechanics and Respiratory Muscles—As COPD
patients develop increased airway resistance from secretions
and bronchoconstriction, the work of breathing increases,
and the distribution of ventilation becomes more nonuni-
form. Ventilation requires increased respiratory muscle exer-
tion. Several factors may prevent the patient with COPD
from maintaining adequate ventilation during exacerbation.
First, because of the increase in airway resistance, patients
with severe COPD are unable to maintain expiratory flow. To
keep minute ventilation constant, patients then must either
increase expiratory time by increasing inspiratory flow rate
(shortening inspiratory time) or breath at a relatively higher
lung volume (with respect to TLC). Breathing at higher lung
volumes is helpful because airway resistance is less. Second,
the work of breathing increases. Increased airway resistance
is the major component of increased work, but hyperinfla-
tion displaces the tidal volume to a higher and flatter portion
of the respiratory system’s pressure-volume curve, resulting
in increased elastic work of breathing as well. Third,
although increased resistance is largely expiratory, it is the
inspiratory muscles that compensate by generating faster
inspiratory flow. The inspiratory muscles are disadvantaged
by the decreased lung compliance accompanying hyperinfla-
tion. When the increased force needed exceeds the capacity
of the inspiratory muscles, muscle fatigue ensues, and acute
respiratory failure results from inability to maintain minute
ventilation. Malnutrition, corticosteroids, hypophos-
phatemia, hypokalemia, and other factors predispose
patients to respiratory muscle fatigue.
E. Impaired Lung Gas Exchange—Patients with COPD
have maldistribution of ventilation and perfusion even when
stable, and gas exchange worsens during acute exacerbations
of disease. Hypoxemia generally is responsive to oxygen ther-
apy, but because of the increased VD/VT, hypercapnia may
develop if patients are unable to sustain higher than normal
minute ventilation.
F. Control of Ventilation—There has been considerable
focus on the contribution of reduced ventilatory drive in
acute respiratory failure in COPD, but this is not impor-
tant in most patients, who appear to have normal or
increased ventilatory drive. Chronic hypercapnia is found
in many but not all patients with COPD; it is more com-
mon in chronic bronchitis compared with emphysema.
Severity of COPD is not the major determinant of hyper-
capnia; decreased ventilatory response to CO2 in family
members of hypercapnic COPD patients suggests that
familial factors play a role.
In COPD patients with acute respiratory failure, the com-
bination of severe hypoxemia, high PaCO2, and low pH
depresses central chemoreceptor-mediated ventilatory
drive. Hypoxic stimulation of the carotid bodies is relatively
more preserved as a chemical stimulus for ventilation, and
when arterial hypoxemia is corrected by administration of
supplemental oxygen, ventilatory drive may be suppressed,
and the patient’s minute ventilation falls. This mechanism
has been challenged by evidence suggesting that oxygen
administration does not further depress minute ventilation
acutely. Several studies have shown that breathing pattern
and minute ventilation do not change appreciably after
oxygen is given in the majority of COPD patients with
acute exacerbations. Despite these data, high concentra-
tions of oxygen should be given cautiously to COPD
patients with hypercapnia or suspected hypercapnia (see
below). Furthermore, because ventilation-perfusion mis-
matching is the largest contributor to hypoxemia, COPD
patients generally will achieve adequate PaO2 with only
minimal supplemental oxygen.
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Clinical Features
Features that warrant particular concern are listed in
Table 12–16. These findings suggest impending worsening of
respiratory failure requiring close monitoring and potential
need for endotracheal intubation and mechanical ventila-
tion. Long-term use of corticosteroids, greater PaCO2, and
advanced age are associated with higher mortality during
COPD exacerbation.
A history of chronic sputum production along with
chronic cough, shortness of breath, a history of cigarette
smoking, features of airway obstruction on pulmonary func-
tion tests, and lack of evidence of left-sided heart failure will
identify most patients with chronic bronchitis. The diagnosis
of emphysema is made from an obstructive pattern on pul-
monary function testing, decreased diffusing capacity for
carbon monoxide, hyperinflation and abnormal lucency of
lung fields on chest x-ray, and dyspnea. Cough and sputum
production are not primary features of emphysema, but
these may develop. The initial presentation of COPD is rarely
acute respiratory failure, and it is highly likely that the
patient will have had some symptoms of COPD even if a pre-
vious diagnosis has not been made. These symptoms usually
include exertional dyspnea and chronic cough.
A. Symptoms and Signs—With acute respiratory failure,
COPD patients often will have a variable history of increas-
ing symptoms lasting hours to days; these may include low-
grade fever, malaise, or upper respiratory symptoms leading
to increased dyspnea, cough, inability to clear sputum from
the airways, and decreased exercise tolerance. Some will
report that home oxygen and bronchodilator drugs are less
effective despite increased frequency and intensity of use.
Sleeplessness because of dyspnea, sometimes for days, is a
common complaint, and patients may state that they are
unable to breathe when recumbent. On occasion, COPD
exacerbations may present with evidence of severe right-
sided heart failure manifested by peripheral edema and
ascites. A retrospective case-control study of patients admit-
ted to an ICU with COPD exacerbation found that they had
lower body weight, greater rate of deterioration of lung func-
tion, worse arterial blood gases and plasma bicarbonate, and
larger right ventricular diameter than those not requiring
ICU admission. Numerous studies have confirmed a high
prevalence of malnutrition in COPD patients (40–60%), and
this is more marked in those who required mechanical ven-
tilation for exacerbation of disease (74%) compared with
those who did not need mechanical ventilation (43%).
The amount of sputum increases, but patients may be
unable to cough up the sputum adequately. Sputum may
change from white or clear to green or yellow and usually
becomes thicker, more viscous and adherent, and produces
longer strands. Blood-streaked sputum reflects increased air-
way inflammation, but hemoptysis should raise concern
about other processes as well.
Features of COPD can be found along with signs of acute
respiratory failure. Increased anteroposterior diameter of the
chest gives the appearance of a barrel chest, and on examina-
tion, the hemidiaphragms are low and flat and move little
even when the patient is stable. Clubbing and hypertrophic
osteoarthropathy indicate severe chronic lung disease. Breath
sounds are often difficult to hear, and low-pitched sonorous
rhonchi rather than higher-pitched musical wheezes are more
common than in asthmatics. Especially in emphysema, but
also in any patient with severe obstruction, breath sounds
may be nearly inaudible. Signs of lung consolidation (pneu-
monia), decreased breath sounds with dullness to percussion
(pleural effusions), and decreased breath sounds with hyper-
resonance to percussion (pneumothorax) are important in
searching for contributing causes of acute decompensation.
Especially in patients who have had prior tracheostomy or
endotracheal intubation, acute respiratory failure could be
due to upper airway obstruction. These patients may have
loud stridor heard best over the trachea during inspiratory
efforts. Hypercapnic patients may be somnolent, stuporous,
or comatose. Hypercapnia may be associated with asterixis.
It is essential to look for features on examination suggest-
ing impending worsening of ventilatory function. These
include use of accessory muscles of respiration (sternocleido-
mastoid contraction), intercostal retraction, and paradoxical
abdominal wall motion (inward displacement of the anterior
abdominal wall during inspiration)—all of which indicate
high inspiratory work of breathing or impending inspiratory
muscle fatigue. Patients who are unable to breathe while
supine usually brace their arms on a table or the arms of a
chair to facilitate inspiration using accessory muscles (ie,
“tripoding”). On the other hand, while important, peripheral
edema, hepatomegaly, ascites, a parasternal lift, and other fea-
tures of right ventricular hypertrophy or cor pulmonale are
not reliable predictors of severity of acute respiratory failure.
Table 12–16. Findings suggesting severe exacerbation
of COPD.
Clinical  
Pneumonia  
Pneumothorax
Left ventricular failure  
History of requiring mechanical ventilation  
Nocturnal desaturation or apnea  
Concurrent infection, renal insufficiency  
Poor response to bronchodilators
Poor nutritional status  
Paradoxic abdominal wall movement  
Use of accessory muscles of respiration  
Pulsus paradoxus  
Severe pulmonary hypertension or cor pulmonale  
Physiologic  
pH <7.25 with PcO2 >60 mm Hg  
PaO2 <50 mm Hg  
Respiratory muscle fatigue 
RESPIRATORY FAILURE 291
B. Laboratory Findings—Hypercapnia (PaCO2 >45 mm Hg)
with acute respiratory acidosis is seen often. In those who
have chronically elevated PaCO2, plasma bicarbonate is high,
and the pH may be only mildly reduced. Therefore, the sever-
ity of acute hypercapnic respiratory failure is indicated by
how low the pH is, not the degree of elevation of PaCO2. Any
patient with a pH less than 7.30 should be considered to have
severe acute hypercapnia.
Hypoxemia is due to both hypoventilation and 
.
V/
.
Q mis-
matching. Erythrocytosis, if present, indicates chronic hypox-
emia. Electrolyte abnormalities may include hyponatremia
caused by the syndrome of inappropriate antidiuretic hor-
mone and hypokalemia, especially in those receiving chronic
corticosteroids or aggressive β-adrenergic agonist therapy.
Malnutrition contributing to respiratory failure is observed
commonly, and biochemical markers of decreased nutritional
status such as low plasma albumin, prealbumin, and retinol-
binding protein are present.
Sputum Gram stain and cultures are often obtained, but
the results of these tests rarely guide therapy. On the other
hand, there is considerable interest in “biomarkers” as
predictors of COPD exacerbation and response to therapy. C-
reactive protein may indicate inflammation, and elevated
procalcitonin has been associated with response to antibi-
otics. It remains to be proven if such markers will indicate, for
example, whether a patient should get corticosteroids or
antibiotics.
C. Electrocardiography—The ECG may show right ventric-
ular hypertrophy and low QRS voltages.
D. Imaging Studies—Chest x-ray findings range from
essentially normal with a few increased linear bronchovascu-
lar markings and mild hyperinflation to severe hyperinfla-
tion with localized or diffuse bullae and cysts. The
diaphragm is low and flat, especially as seen on lateral views,
and there are often enlarged retrosternal and retrocardiac
spaces. The chest x-ray should be reviewed carefully, looking
for pneumonia, pneumothorax, pleural effusions, evidence
of pulmonary hypertension, evidence of left-sided heart fail-
ure, and atelectasis. About 16–21% of chest x-rays show sig-
nificant abnormalities in patients with COPD exacerbations.
E. Spirometry—Pulmonary function tests are rarely needed
to diagnose obstructive lung disease during acute exacerba-
tion. Peak flow measurements and FEV1 may be useful, how-
ever, in assessing the response to therapy and prognosis, but
there are few data supporting routine use.
Differential Diagnosis
The differential diagnosis of respiratory failure from COPD
includes asthma with acute exacerbation, upper airway obstruc-
tion, and left ventricular failure. Peripheral edema, weight gain,
hepatomegaly, and other features of fluid overload may be due
to cor pulmonale or left-sided heart failure. Hyperinflation of
the lungs on chest x-ray often makes the heart look smaller;
some clinicians advise that a normal-sized heart be considered a
sign of cardiomegaly in COPD. Pulmonary embolism is seen in
COPD patients with increased frequency.
Treatment
Treatment of acute respiratory failure in COPD is supportive
until the reason for exacerbation of airway obstruction is
eliminated. Oxygen is usually needed for hypoxemia.
Bronchodilators, corticosteroids, and antibiotics address air-
way obstruction and acute infection, but because of the
importance of inspiratory muscle fatigue, the major thera-
peutic decision is when to start mechanical ventilation
because the respiratory muscles are no longer able to main-
tain adequate ventilation.
A. Oxygen—Hypoxemia has several effects in COPD. Aside
from the systemic effects of tissue hypoxia, hypoxemia is a
respiratory stimulant that may be counterproductive. If
patients increase respiratory frequency, expiratory time
shortens, and further adverse hyperinflation ensues.
Increased ventilatory drive generates an increased inspira-
tory flow rate and contributes to respiratory muscle fatigue.
Hypoxemia is due almost entirely to ventilation-
perfusion mismatching. Therefore, small increases in
inspired O2 concentration usually lead to acceptable
increases in PaO2. The target PaO2 is greater than 60 mm Hg
or an O2 saturation of more than 90%. An increase in FIO2 to
0.24–0.35 is usually sufficient, and this can be provided by a
Venturi-type mask or by nasal cannula (1–4 L/min). Oxygen
therapy has been associated with worsening of hypercapnia
and respiratory acidosis in occasional patients, and this has
been attributed to loss of hypoxic drive with administration
of O2. While this particular mechanism has been questioned,
caution in giving excessive O2 is advised. However, caution
must be balanced with the very real danger of hypoxia if arte-
rial O2 saturation remains less than 90%. Patients with
COPD and hypoxemia (PaO2 <55 mm Hg), when they are
ready for discharge, are candidates for home oxygen therapy.
When given for 18–24 hours per day, long-term home oxy-
gen improves prognosis.
B. β-Adrenergic Agonists—Clinical response to these
agents when given by aerosol is almost always achieved,
although not usually as marked a response as in asthmatics.
Because COPD patients are generally older and have more
concurrent medical problems than asthmatics, side effects of
hypokalemia, myocardial stimulation, tremor, effects on
blood pressure, and drug interactions may be more signifi-
cant. Therefore, in COPD patients, the drugs may be given in
lower dosage and less often than in asthma. Oral β-
adrenergic agonists are of lesser value and may limit the
amount of aerosolized drug that can be given. Long-acting β-
adrenergic agonists do not have a role in acute exacerbation.
C. Anticholinergics—Anticholinergic bronchodilators have
become the primary therapy for chronic stable COPD and
are used in conjunction with β-adrenergic agonists during
acute exacerbations despite little data supporting combined
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use. Ipratropium bromide, in well-tolerated doses, is supe-
rior to usual doses of β-adrenergic agents in stable COPD,
and a combination of modest doses of ipratropium, theo-
phylline, and albuterol was better than ipratropium alone.
Surprisingly, there is little evidence comparing the use of
ipratropium with other bronchodilators during acute exacer-
bations. Nevertheless, because of the high level of safety of
ipratropium and its potential as a bronchodilator in COPD,
it should be included in all pharmacologic regimens for
management of COPD exacerbations. Effective doses can be
as much as two or three times the dose usually recom-
mended, but this is so because this drug is very well tolerated
with few, if any, side effects. Ipratropium is available in MDIs
and in a solution for nebulization. Each puff from the MDI
provides 18 μg ipratropium inhaled solution; an effective
starting dosage for stable COPD is two to four puffs every
6 hours. If the solution for nebulization is used, a roughly
equivalent dosage of 500 μg is nebulized for inhalation every
6 hours. Because the effectiveness in acute exacerbation is
not clear, both increased dosage and increased frequency may
be necessary. Response to treatments should be monitored
closely. A fixed-dose MDI containing a combination of
albuterol and ipratropium is available; this is likely more
suitable for chronic stable COPD patients.
D. Methylxanthines—Theophylline has a long history of
use in COPD, but the degree of bronchodilation from theo-
phylline has been called into question. Theophylline
increases the rate and force of contraction of skeletal muscle
and increases the force that can be generated by fatigued res-
piratory muscles. Myocardial effects, including increased
contractility, may be beneficial. Theophylline has other
effects unrelated to bronchodilator action, including evi-
dence for immune modulation, alterations in calcium flux,
diuretic action, and central respiratory stimulation. In acute
exacerbation of COPD, one controlled trial found no further
improvement when aminophylline was added to a standard
treatment regimen that included inhaled β-adrenergic ago-
nists and corticosteroids. These studies, plus the narrow ther-
apeutic range for theophylline coupled with its dangerous
toxic effects, have decreased its use as a primary bronchodila-
tor. Theophylline should be used carefully in COPD patients
and only when maximum therapy with other bronchodila-
tors proves inadequate. Advanced age, heart disease, liver dis-
ease, and concomitant drugs (including some antibiotics
such as erythromycin and fluoroquinolones) decrease theo-
phylline clearance. Severe COPD by itself may be a factor
increasing the incidence of theophylline toxicity. Moderate
therapeutic levels of theophylline should be sought—10–12
μg/mL—in most patients. Theophylline toxicity must be
considered in patients with unexplained tachycardia,
arrhythmias, hypokalemia, or GI or CNS symptoms.
E. Corticosteroids—Corticosteroids have an undisputed role
in management of acute exacerbation of asthma, and data
support their use in COPD patients as well. In one controlled
study during acute exacerbation of COPD, slightly more
rapid improvement was seen in patients given methylpred-
nisolone compared with placebo. Several recent studies of
systemic corticosteroids in acute exacerbation of COPD
found improvement in lung function, decreased symptoms,
and better outcome. Subsequent exacerbations were not
affected, as would be expected.
Severe acute exacerbations of COPD should be treated
with corticosteroids, but it is likely that some subgroups will
benefit more than others. These might include those with
predominant bronchospasm and those with increased num-
bers of blood or sputum eosinophils. The optimal dose and
duration of corticosteroid treatment in COPD exacerbation
are unknown, and complications from these drugs in COPD
patients is high. Therefore, somewhat smaller doses and ear-
lier withdrawal of corticosteroids have been recommended.
However, in the largest controlled trial of COPD patients,
methylprednisolone was given 125 mg every 6 hours for 3 days,
followed by daily oral prednisone 60, 40, and 20 mg for
4 days each. These patients improved more rapidly than with
placebo and were similar to a group that was given an 8-week
course of corticosteroids.
Although there are little data supporting rapid with-
drawal, metabolic complications from corticosteroids (eg,
hyperglycemia and hypokalemia) and corticosteroid myopa-
thy may be avoided.
F. Antibiotics—Antibiotics are given routinely for acute
exacerbations of COPD, although benefit has not been
clearly established in all patients. The goals of treatment are
to shorten the duration of exacerbation and decrease the
degree of severity in those with little pulmonary reserve.
Long-term goals of prolonging time between exacerbations,
slowing progression, and modifying bacterial flora may or
may not be achieved. A large randomized trial found that
patients who had all three of increased volume of sputum,
increased dyspnea, and increased purulence of sputum were
the most likely to improve with antibiotic therapy. Patients
without these changes are statistically more likely to have
viral infection and not improve with antibiotics.
Broad-spectrum drugs are usually used, aimed at H.
influenzae, S. pneumoniae, and other organisms commonly
found in sputum of COPD patients. However, one guideline
has recommended selecting the type of antibiotic based on
age, number of exacerbations, and lung function. Simple
chronic bronchitis (age <65, fewer than four exacerbations
per year, and mild impairment in lung function) should have
therapy directed against H. influenzae, S. pneumoniae, and
M. catarrhalis. Those with complicated chronic bronchitis
(age >65, more exacerbations, and poorer lung function)
may have other gram-negative bacilli involved, and therapy
should be broadened accordingly.
Because of the emergence of β-lactamase-producing
Haemophilus and M. catarrhalis, second-generation
cephalosporins, amoxicillin-clavulanic acid, extended-
spectrum macrolides, and trimethoprim-sulfamethoxazole
are now often prescribed for simple chronic bronchitis
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exacerbation. For complicated exacerbations, second- or
third-generation cephalosporins or fluoroquinolones may be
more efficacious. The clinical significance of penicillin-
resistant S. pneumoniae is unknown in patients with COPD.
Comparison studies often do not clearly support the efficacy
of one agent over another, and cost, availability, and drug
toxicity are important factors. Individual agents all have their
advantages and disadvantages.
Antibiotics previously used may be ineffective.
Erythromycin is not active against Haemophilus, and ampicillin
and amoxicillin are destroyed by β-lactamases and have no
activity against atypical bacteria. Extended-spectrum macrolides
(eg, azithromycin and clarithromycin) are effective against
common organisms in COPD exacerbations, as are fluoro-
quinolones such as levofloxacin. Clinicians at each hospital and
ICU should be aware of local bacterial sensitivities, the fre-
quency of resistance, and local efforts to reduce development of
resistant organisms (eg, restricted use of antibiotics).
In patients with COPD who are found to have pneumo-
nia, antibiotic therapy should be intensified. Use of agents
with particular efficacy against S. pneumoniae, aerobic
gram-negative bacilli, M. pneumoniae, and Legionella pneu-
mophila should be considered, and intravenous antibiotics
probably are indicated at least initially until the patient has
shown clinical response.
G. Mechanical Ventilation—Patients with COPD and acute
respiratory failure who require mechanical ventilation either
have very severe obstruction or encounter fatigue of respira-
tory muscles and inability to maintain adequate minute ven-
tilation. Hypercapnia and respiratory acidosis are the most
common reasons for starting mechanical ventilation; hypox-
emia is not often the primary problem and usually can be
treated satisfactorily by supplemental oxygen alone.
Although mechanical ventilation is frequently administered
to patients with acute exacerbations of COPD, a subset of
patients has been identified that has a poorer prognosis.
These patients are more likely to have pulmonary infiltrates
on chest radiographs, lower plasma albumin, and lower base-
line lung function. In several studies, mortality from acute
exacerbation of COPD requiring mechanical ventilation
ranges from 30–50%.
1. Volume-preset ventilation—The volume-preset
(volume-cycled) mode is used most often in COPD patients
and generally is well tolerated. Because of increased resist-
ance in intrathoracic airways, exhalation of the tidal volume
is prolonged in COPD. Thus sufficient expiratory time dur-
ing mechanical ventilation must be allowed to avoid “air
trapping,” or hyperinflation. Tidal volume generally is lim-
ited to 6–8 mL/kg; inspiratory time is kept relatively short by
choosing high inspiratory flow (at least 1 L/s, often 1.25–1.5
L/s), and expiratory time is kept relatively long by a slow res-
piratory rate. The I:E ratio should be at least 1:3 and prefer-
ably more (1:4–5). If patients have chronic hypoventilation
with compensatory elevation of plasma bicarbonate, minute
ventilation should be chosen to avoid causing acute alkalemia
by not correcting PaCO2 to normal. High concentrations of
supplemental oxygen during mechanical ventilation rarely
are required, and most patients have a satisfactory PaO2 when
the inspired O2 fraction is 0.3–0.5. A need for higher inspired
oxygen concentrations suggests atelectasis or consolidation
rather than airway obstruction alone.
An inspiratory plateau pressure (see above) greater than
30 cm H2O is likely to be associated with barotrauma and
hyperinflation; pressures greater than this should be avoided
by prolonging expiratory time as much as possible. As in
asthmatics, lower tidal volume (6–8 mL/kg) during mechan-
ical ventilation is recommended to decrease barotrauma and
other complications. PaCO2 is allowed to rise, if necessary
(permissive hypercapnia), as long as pH remains above
7.25–7.30. Smaller tidal volume also has a beneficial effect by
reducing intrinsic PEEP.
Increased peak airway pressure (rather than inspira-
tory plateau pressure) should prompt an examination of
the patient for pneumothorax, bronchospasm, or airway
obstruction with mucus or foreign body rather than
hyperinflation.
If patients are able to contribute some efforts to ventila-
tion, the pressure-support mode may be useful. With this
mode, patients can choose the rate and depth of breathing
while having some of the inspiratory work of breathing taken
on by the mechanical ventilator. This mode may be particu-
larly helpful during weaning. The pressure-controlled mode
should not be used in COPD exacerbations because the
inspiratory flow rate, tidal volume, and I:E ratio cannot be
maintained consistently.
2. Intrinsic PEEP—In any situation in which a high venti-
latory requirement or severe airway obstruction is present,
expiration may not be completed by the onset of the next
inspiration. Because expiratory flow persisting up to end
exhalation indicates that there is a positive-pressure gradient
between alveoli and atmosphere at end expiration, alveolar
PEEP must be present. PEEP generated in this way is termed
intrinsic PEEP (PEEPi) or auto-PEEP. The most accurate
method of estimating the magnitude of PEEPi is to use an
esophageal balloon connected to a pressure transducer to
measure intrathoracic pressure. The change in intrathoracic
pressure between end exhalation and the onset of inspiratory
gas flow into the lungs is approximately equal to the PEEPi
(provided that there is minimal or no active expiratory mus-
cle contraction at end exhalation). For clinical purposes,
another method is to occlude the expiratory port of the ven-
tilator circuit just at the end of expiration. An increase in
pressure displayed on the ventilator manometer indicates the
presence and degree of PEEPi (Figure 12–6). This method
may underestimate the degree of PEEPi in patients with
severe obstruction, especially those with heterogeneous dis-
tribution of increased resistance.
High levels of PEEPi adversely affect lung compliance,
work of breathing, and cardiovascular function and domi-
nate gas exchange by affecting distribution of ventilation.
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COPD patients who develop PEEPi while undergoing
mechanical ventilation may have worsening of hypoxemia
and hypercapnia. In this common clinical scenario, PaCO2
can paradoxically worsen when minute ventilation is
increased, leading to rapid deterioration. Lowering respira-
tory frequency and tidal volume instead in this situation
improve gas exchange, reducing PaCO2. Clinicians should be
aware of this potential problem and act accordingly.
Another effect of inadvertent PEEPi is an increase in the
work of breathing when assisted mechanical ventilation is
used. In this mode, the ventilator initiates inspiratory flow
when it senses negative pressure in the circuit, but if alveolar
end-expiratory pressure is positive, inspiratory muscle con-
traction will not immediately generate pressure that is negative
with respect to atmospheric pressure. Thus additional work
of breathing is performed by the patient. Some investigators
have added PEEP (extrinsic PEEP) to the ventilator circuit in
this situation to change the absolute pressure at which the
ventilator initiates inspiratory flow. Ideally, the small amount
of PEEP reduces the work of breathing but does not worsen
hyperinflation. The use of PEEP in this situation is debated,
but the usual recommended amounts of extrinsic PEEP are
small (75–85% of estimated PEEPi) and probably do not
cause adverse effects if monitored carefully.
3. Noninvasive ventilation—In the last several years,
studies have shown a striking benefit of noninvasive positive-
pressure ventilation (NIPPV) for acute respiratory failure in
selected patients with COPD. Theoretically, the use of a face
mask or nasal interface can provide positive-pressure venti-
lation to the patient without endotracheal intubation. In
selected patients, only short-term support may be needed
until the reversible problem leading to exacerbation can be
corrected. A further attraction is obviation of the need for
prolonged weaning after intubation and conventional
mechanical ventilation. Some studies have used NIPPV on a
continuous basis for 24–48 hours or more; in other studies,
patients are placed on NIPPV for 8–20 h/day with inter-
spersed spontaneous breathing periods. Patients who are
poor candidates for NIPPV include those with apnea, con-
current unstable medical problems, swallowing dysfunction,
impaired cough, poor fit of the mask, and upper airway nar-
rowing or those unable to cooperate fully.
For COPD exacerbations, several forms of NIPPV have
been used. First, low levels of continuous positive airway
pressure (CPAP) alone have been given. CPAP theoretically
acts by reducing the work of breathing in patients who have
developed PEEPi and hyperinflation. Other patients have
been administered bilevel positive pressure, with a small
expiratory pressure (3–5 cm H2O) and a time-cycled or
patient-initiated larger inspiratory pressure (8–15 cm H2O).
In this mode, the expiratory pressure acts to overcome
PEEPi, while the inspiratory pressure support provides assis-
tance during inspiration without providing enough pressure
to deliver the entire tidal volume.
Success of NIPPV is measured by rate of subsequent
endotracheal intubation, improvement in arterial blood
gases, and mortality. Success rates of 40–60% have been
reported, but most studies have been on selected patients
who are cooperative, do not have excessive airway secretions,
and who can tolerate a face mask or nasal interface. In a
meta-analysis of NIPPV trials, there was an 11% reduction in
deaths and a 28% reduction in endotracheal intubations.
Surprisingly, NIPPV was most beneficial in the most severe
patients (pH <7.30 or more than 10% mortality in control
group). Decreased respiratory infections is another benefit of
NIPPV compared with endotracheal intubation.
H. Respiratory Stimulants and Depressants—In the past,
acute respiratory failure in COPD was considered to be
partly due to insufficient ventilatory drive, and respiratory
stimulant drugs were administered. Increasing ventilatory
 Figure 12–6. Demonstration of intrinsic PEEP in a
patient with obstructive lung disease. In the top figure,
increased airway resistance slows expiratory airflow so
that the lung is still emptying until the start of the next
inspiration. Alveolar pressure at end expiration is posi-
tive (+10 cm H2O in this example). Because of the high
downstream resistance, a large pressure drop occurs
before the pressure manometer site, and manometer
pressure reads 0 cm H2O despite positive alveolar pres-
sure. If, however—as shown in the bottom figure—at end
expiration, the expiratory port is occluded, stopping flow,
pressure equalizes throughout the system. The manome-
ter now reads a positive pressure that approximates intrin-
sic PEEP. Some mechanical ventilators can make this
measurement automatically. In patients with very hetero-
geneous distribution of airway resistances and compli-
ances, the occlusion method may underestimate the level
of intrinsic PEEP.
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drive makes little sense if respiratory muscle fatigue and
hyperinflation are exacerbated by stimulants, so stimulants
should be used rarely. Acetazolamide, a carbonic anhydrase
inhibitor, is given occasionally to enhance excretion of bicar-
bonate accumulated as compensation for hypercapnia, but
its indications are not clear. It should be considered only in
patients in whom the precipitating factors have been
reversed and there is obvious “metabolic alkalosis” as a con-
sequence of compensation for chronic respiratory acidosis.
Most patients who benefit from acetazolamide will have
known chronic hypercapnia and a known steady-state
plasma bicarbonate target.
Respiratory depressant drugs, including sedatives and
opioids, should be avoided in COPD exacerbations while
patients are breathing spontaneously. These drugs are useful,
however, in patients during mechanical ventilation. On occa-
sion, muscle relaxants are essential to avoid hyperinflation.
I. Other Therapy—A guideline developed following an
extensive critical review of the literature recently concluded
that there was no benefit from chest physiotherapy and
mucolytic medications in patients with COPD exacerbation.
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 Acute Respiratory Distress Syndrome
ESSENT IALS  OF  D IAGNOS I S
 Appropriate clinical situation.
 Refractory hypoxemia (hypoxemia that responds poorly
to increased inspired oxygen concentration).
 Bilateral, diffuse pulmonary infiltrates.
 Absence of clinical evidence of hydrostatic or cardio-
genic pulmonary edema.
General Considerations
Acute respiratory distress syndrome (ARDS) is a disorder of
severe hypoxemic respiratory failure that occurs in associa-
tion with a variety of critical situations including trauma,
aspiration, shock, and pulmonary and extrapulmonary
infection. Other terms used to describe this syndrome are
more descriptive of its pathophysiology, such as noncardio-
genic or exudative pulmonary edema with acute lung injury.
ARDS deserves considerable attention because of its high
mortality rate and the interest it has aroused in the mecha-
nism of acute lung damage from apparently different causes.
Because of superficial similarity to neonatal respiratory dis-
tress syndrome, ARDS formerly had been “adult” respiratory
distress syndrome. However, consistent with the original def-
inition and recommendations of consensus conferences,
ARDS should be understood to mean “acute” respiratory dis-
tress syndrome.
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Although the term ARDS was first used in 1967, it is not
a new disease. Well-documented descriptions of hypoxemic
respiratory failure after severe trauma were reported during
World War II, and there were even earlier reports of pul-
monary edema associated with severe infection. The last
40 years have shown a remarkable increase in recognition of
this syndrome, and there is general agreement that the out-
come from ARDS remains relatively poor. Nevertheless, very
encouraging prognostic information seems to reflect
improved understanding of the pathophysiology and
response to therapy of ARDS.
The major change in the management of ARDS has been
the recognition that a low-tidal-volume strategy (6–8 mL/kg
of ideal weight) decreases mortality. This important finding,
the only proven treatment, has a strong basis in pathophysiol-
ogy and has markedly changed the treatment of this disorder.
Definition
ARDS is a clinical syndrome resulting from the severe end of
the spectrum of acute lung injury (ALI). In ALI, variable
amounts of inflammation, disruption of normal lung archi-
tecture by tissue destruction and repair processes, and
increased lung permeability to capillary fluids are seen. By
definition, ALI does not result from elevated left atrial or
pulmonary capillary pressure (although elevated pressures
may be found coincident to the lung injury). Both the lung
injury and ARDS evolve over hours to days rather than weeks
to months.
ARDS includes clinical features, radiographic findings,
and physiologic derangements, and the association with one
of many clinical situations. Table 12–17 lists criteria for
ARDS. Older criteria required lung compliance measure-
ment to establish increased lung stiffness, pulmonary
artery wedge pressure measurement to exclude cardio-
genic pulmonary edema, and the presence of a known clin-
ical disorder likely to cause lung injury. The North
American–European Consensus Committee statement
requires only refractory hypoxemia (PaO2/FIO2 <200 regard-
less of PEEP), diffuse pulmonary infiltrates on chest
roentgenogram, and absence of clinical features suggestive of
heart failure. These criteria have a very high degree of con-
cordance with other definitions. It should be emphasized
that criteria for ARDS are designed primarily to facilitate
comparison of patients in research studies. On the basis of
appropriate clinical judgment, an individual patient may be
diagnosed as having ARDS and treated accordingly without
meeting all criteria.
ARDS is often distinguished from acute lung injury
(ALI), a somewhat confusing term because it is used fre-
quently to indicate a similar syndrome with less severe
hypoxemia (PaO2/FIO2 >200) for purposes of clinical studies
and prognosis.
Pathophysiology
ARDS results from a combination of ALI, pulmonary edema
from increased permeability of the alveolar epithelium (non-
cardiogenic pulmonary edema), and fibroproliferation with
collagen deposition.
A. Acute Lung Injury—One of the intriguing aspects of
ARDS is the variety of clinical situations associated with ALI,
both direct and indirect. Lungs can be injured directly from
severe bacterial, viral, or other infectious pneumonia; aspira-
tion of gastric contents; near-drowning; inhalation of toxic
gases, such as smoke, chemicals, or poison gas; or blunt
trauma to the lungs. Other disorders cause indirect lung
injury, such as bacterial or fungal sepsis, severe nonthoracic
trauma, fat embolism after orthopedic injury, pancreatitis,
hemodynamic shock, and drugs; these probably damage the
lung through circulating mediators.
ARDS occupies the severe end of a spectrum of lung
injury seen in many clinical contexts, with the histologic hall-
mark of diffuse alveolar damage as the common feature of
inflammatory, toxic, infectious, or other processes that injure
the lung parenchyma. Diffuse alveolar damage consists of
disruption of normal alveolar architecture, replacement of
type I with type II alveolar epithelial cells, damage to pul-
monary capillaries, increased collagen deposition, exudative
pulmonary edema, and a variable amount and variety of
inflammatory cells. Evidence of both ongoing acute and
chronic processes may be found. Diffuse alveolar damage is
seen in other clinical situations, such as cytotoxic drug expo-
sure or as a complication of severe pulmonary infections, or
may be idiopathic.
An approximate time course for diffuse alveolar damage
in ARDS has been proposed. Early in the course (1–7 days),
lung injury is coincident with exudative pulmonary edema,
variable inflammation, platelet-fibrin thrombi, and disap-
pearance of type I alveolar epithelial cells. This is followed by
a proliferative phase (days 7–21) in which there is type II
alveolar cell proliferation and the beginning of organization
and fibrosis (see below). Findings in the later fibrotic phase
may be indistinguishable from the various forms of idio-
pathic interstitial pneumonitis, especially idiopathic pul-
monary fibrosis.
In ARDS, every potential mediator that could lead to dif-
fuse alveolar damage has been implicated, including neutrophils
Table 12–17. Criteria for diagnosis of acute respiratory
distress syndrome. 
Refractory hypoxemia 
Pao2 /FIO2 <200  
Diffuse bilateral pulmonary infiltrates (<7 days old)  
Absence of heart disease  
PA wedge <18 mm Hg or  
No evidence of left ventricular failure 
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and lymphocytes and their cytokines, prostaglandins,
leukotrienes, platelets, coagulation factors, adhesion mole-
cules, and immunoglobulins, as well as exogenous substances
such as endotoxin and other products of bacteria and
fungi. Endogenous cell products have received the most
attention—some as mediators of injury, such as oxygen rad-
icals and proteolytic and elastolytic enzymes, but others as
amplifiers of inflammation and injury, such as interleukins,
platelet-activating factor, complement, and other substances
that are chemotactic, bronchoreactive, or vasoreactive. These
may be active in the early, middle, or late phases of lung
injury. A role for injury from oxygen radicals is supported by
the finding of reduced alveolar fluid glutathione in patients
with ARDS. The coagulation system has been suggested by
some investigators as having a central role in lung injury, per-
haps by linking intravascular events to direct injury to the
endothelium and by activation of inflammatory sequences.
Elevated plasma levels of tumor necrosis factor (TNF) are
found in some patients with ARDS but also in those with
sepsis and other systemic disorders. A potent cytokine, TNF
has a variety of systemic effects, some of which could cause
or potentiate lung damage. The finding of several elevated
cytokines in ARDS suggests the possibility of common regu-
latory factors being involved. One factor, NF-κB, regulates
production of TNF, interleukin 1 (IL-1), IL-6, and IL-8. This
hypothesis is attractive because of the frequent association of
IL-6, TNF, and IL-8 with lung injury. More recently, ARDS
has been linked to toll-like receptors (TLRs), which respond
to a variety of substances to trigger a vast cytokine response.
TLRs are responsible for innate immunity; this could
explain the common finding of ALI in response to the range
of inciting factors.
A key role for polymorphonuclear leukocytes in lung
injury is supported by finding neutrophils in large numbers
in the lungs of ARDS patients. Furthermore, neutrophils are
primed to release potentially toxic substances from their
granules, neutrophil chemotactic factors and activators are
increased, and in some animal models, lung injury is attenu-
ated after neutrophil depletion. For example, neutrophil-
activating protein/interleukin-8 (NAP-1/IL-8) has been
found in high concentrations in alveolar fluid, and there was
a correlation with the number of neutrophils. High concen-
trations of NAP-1/IL-8 also were associated with poor clinical
outcome. On the other hand, neutropenic cancer patients
may develop ARDS indistinguishable from that observed in
nonneutropenic patients, and diffuse alveolar damage in
some animal models does not require the presence of neu-
trophils. Levels of both cytokines and modulators of cytokine
function are highly variable in ARDS, and it is clear that
cytokines taken individually or as patterns of response are not
able to predict development or prognosis of ARDS. In paral-
lel with the diversity of clinical conditions associated with dif-
fuse alveolar damage and ALI, it is highly likely that different
conditions in different patients explain why consistent find-
ings cannot be identified. While this makes a single common
causative mechanism unlikely, this hypothesis helps to
explain why so many conditions can result in very similar his-
tologic and physiologic features. Nevertheless, there is now
ample evidence that persistent elevation of inflammatory
cytokines in blood or alveolar fluid is associated with poor
outcome in ARDS in all forms of this disorder.
Patients may develop secondary bacterial or fungal pneu-
monia during the course of ARDS, further confusing the pic-
ture. Administration of high concentrations of inspired oxygen
contributes to lung injury, and high airway pressure and rela-
tively high tidal volume during mechanical ventilation are
closely linked to worsening pulmonary edema and fibrosis. On
the other hand, higher oxygen requirements and airway pres-
sures may simply indicate more severe underlying disease.
B. Noncardiogenic Pulmonary Edema—Normal lungs are
kept very dry to permit efficient gas exchange, and the struc-
ture and activity of the lungs maintain only a small amount
of fluid in the lungs. Normal lungs have tight junctions
between alveolar epithelial cells, an extensive lymphatic sys-
tem, low hydrostatic pressure in the pulmonary capillaries,
and other mechanisms to avoid pulmonary edema. Thus,
lung injury from any number of insults can promote pul-
monary edema by damaging these mechanisms.
Pulmonary edema is a major clinical manifestation of
ARDS, and the pulmonary edema fluid contains a high con-
centration of protein. This is in marked contrast to pul-
monary edema owing to elevated pulmonary venous
pressure (hydrostatic pulmonary edema) or to decreased
plasma albumin concentration (hypo-oncotic pulmonary
edema), in which the edema fluid is a low-protein transu-
date. ARDS also has been called exudative or noncardiogenic
pulmonary edema, reflecting the increased permeability of
the injured lung to water, solute, and protein. Exudative pul-
monary edema forms in the absence of elevated pulmonary
artery wedge pressure, and the ratio of edema fluid protein to
plasma protein is high. Edema fluid accumulates both in the
pulmonary interstitium and in the alveoli, and because of
potential fluid pathways, lung lymphatics and bronchovascu-
lar spaces (surrounding the bronchioles, bronchi, and pul-
monary arteries) may become engorged. Pulmonary edema
removal by the pulmonary circulation and lymphatics,
including active transport of solute and water, is severely
impaired because of the ALI. In a minority of ARDS patients,
the pulmonary epithelium is able to resolve pulmonary
edema during the first 12 hours. This probably reflects rela-
tively preserved epithelial cells that might increase solute and
water transport in response to β-adrenergic agonists. These
and other drugs are currently being studied.
C. Chronic Lung Injury—Diffuse alveolar damage seen in
ARDS may follow several courses, including resolving
entirely with little or no evidence of chronic damage after
weeks or months. However, other patients develop mild to
severe pulmonary fibrosis. One of the most interesting find-
ings in ARDS is evidence of very early deposition of type III
collagen (procollagen III peptide in alveolar fluid) in the
lung, sometimes within 24 hours of the onset of diffuse
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alveolar damage. Evidence for early fibrosis has been associ-
ated with poor prognosis, stressing the potentially inappro-
priate role of remodeling and repair in late lung injury. These
findings have challenged the time course of ALI, with irre-
versible fibrosis occurring much sooner than in earlier pro-
posed models. Attraction and activation of fibroblasts may
be mediated by various substances such as platelet-activating
factor that are increased in blood and pulmonary edema
fluid. Oxygen toxicity may play a role, especially if patients
require very high inspired oxygen to treat hypoxemia.
Another potential contributor to chronic lung damage is rec-
ognized to be overdistention of the lungs by high tidal vol-
ume, high PEEP, or high airway pressure.
In chronic lung injury, variable amounts of collagen are
laid down into the alveolar and interstitial spaces with distor-
tion and disruption of the normal lung parenchyma, result-
ing in restrictive lung disease, reduced exercise capacity, and
hypoxemia. Histologic findings may be indistinguishable
from idiopathic pulmonary fibrosis. Particularly sensitive
findings are the PaO2 and P(A–a)O2 during exercise. Recent
data show that survivors with more severe early ARDS had
worse late-stage pulmonary function than those with less
severe acute disease. Lung function as assessed by spirometry,
total lung capacity, and diffusing capacity for carbon monox-
ide averaged about 80% of predicted in these survivors.
The greatest degree of improvement was seen in the first
3 months, and there was little additional improvement
between 6 months and 1 year.
The relationship of collagen deposition, severity of lung
injury, and outcome provides some possibilities for interven-
tion. These include potential inhibition of chemotactic or
activating factors for fibroblasts, removal of some forms of
collagen during tissue repair phases, and limitation of lung
injury by controlling inflammation, oxygen toxicity, and
ventilator-induced lung injury.
D. Physiologic Manifestations
1. Refractory hypoxemia—Hypoxemia in ARDS is due to
right-to-left shunt and
.
V/
.
Q mismatching resulting from
atelectasis and filling of alveolar spaces with edema fluid..
V/
.
Q mismatching also may result from nonuniform
changes in airway resistance, decreases in regional lung
compliance, and primary and secondary alterations of
lung blood flow. Hypoxemia usually is severe and not cor-
rected even when the patient is given high concentrations
of inspired O2, termed refractory hypoxemia (Figure 12–7).
As part of the definition of ARDS, the ratio of PaO2 to FIO2
is less than 200.
As shown by CT scanning, the majority of lung in ARDS
is completely airless, with small proportions either normally
inflated or collapsed with potential for recruitment. These
findings suggest that right-to-left shunting plays the major
role in refractory hypoxemia, whereas the use of PEEP walks
a fine line between recruitment of atelectatic lung and
overdistention of normal lung.
2. Altered static lung mechanics—Lung compliance is
severely decreased and airway resistance mildly increased in
ARDS. Decreased lung compliance results from a combina-
tion of interstitial pulmonary edema, collapse of lung units,
airway obstruction, and inactivation of alveolar surfactant.
Ineffective surfactant in ARDS may be due to reduced pool
sizes, alteration in surfactant proteins, altered metabolism,
or inactivation by plasma proteins, oxygen radicals, or
phospholipases exuding into the alveolar spaces. In later
stages, lung compliance is reduced because of accumulation
of collagen.
Studies correlating regional radiographic lung volume
change and inflation pressure show that disease involvement
in ARDS is much less uniform than formerly thought. This
finding has resulted in a major change in understanding of
ARDS. Most lung regions are extensively involved and com-
pletely airless, some participate variably in gas exchange, and
other uninvolved regions accept the bulk of ventilation.
These latter regions have normal specific lung compliance,
indicating that the primary cause of decreased overall lung
 Figure 12–7. Lines showing PaO2 versus FIO2 for vari-
ous constant-shunt fractions (
.
QS/
.
QT) between 0% and
30%. Superimposed are typical responses in patients with
ARDS (lines a and b). Line b shows severe hypoxemia
with a response suggesting severe right-to-left shunt as
the primary mechanism of hypoxemia. Line a demon-
strates severe hypoxemia but with PaO2 increasing more
rapidly with increasing FIO2 than with pure right-to-left
shunt. The mechanism of hypoxemia is probably severe
ventilation-perfusion mismatching.
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compliance is overdistention of these small uninvolved
regions of the lung rather than uniform stiffening of the
entire lung. This finding has major implications for how
patients with ARDS should be mechanically ventilated,
notably the use of a low-tidal-volume strategy.
The pressure-volume (PV) curve of the lungs in ARDS is
shifted downward and rightward (Figure 12–8). The lungs
require greater pressure to inflate, and the work of breathing
is increased. An increase in lung compliance may indicate
improvement of the disease or recruitment of atelectatic
lung, especially with the application of PEEP. Some investiga-
tors have noticed that the respiratory system compliance
curve, which considers both lung and chest wall mechanics,
is altered in ARDS. Patients with nonpulmonary causes of
ARDS (eg, abdominal sepsis, trauma, or postoperative) had
greater response to PEEP, suggesting that the “pulmonary
ARDS” patients (mostly those with pneumonia) had more
severe and less recruitable lung consolidation, whereas the
nonpulmonary ARDS patients had more atelectasis.
The shape of the PV curve has been stressed by some cli-
nicians. The curve has been divided into sections, including
a flat initial increase in volume with increasing pressure, a
lower inflection point after which compliance (slope)
increases, an upper inflection point, and then another region
of low compliance (flat slope). The regions of the PV curve
may have implications for adjusting PEEP (see below) and
limiting tidal volume.
3. Increased airway resistance—Increased airway resist-
ance is described in ARDS patients, probably owing to edema
in the bronchovascular spaces surrounding the bronchi, but
there may be inflammatory mediators that induce bron-
choconstriction. Another cause may be the normal increase
in airway resistance in areas of decreased pulmonary perfu-
sion in response to ventilation-perfusion mismatching. The
increased airway resistance, as much as sixfold compared
with normal individuals, contributes to higher airway pres-
sure and work of breathing. In one study, increased resistance
correlated positively with both peak airway pressure and the
severity of gas-exchange abnormality.
E. Multiple-Organ-System Failure—Although often viewed
as a primary lung disorder, ARDS is clearly associated with
multiple-organ-system dysfunction and failure. Subtle evi-
dence of organ-system dysfunction is very common in both
survivors and nonsurvivors of ARDS, and renal failure, liver
failure, CNS failure, heart failure, thrombocytopenia, and GI
bleeding and malabsorption contribute to mortality and mor-
bidity. In fact, of those who die with ARDS, respiratory failure
has been estimated to be the primary cause in as few as 16%.
Sepsis and nonrespiratory failure accounted for the remainder.
The cause of multiple-organ-system failure in ARDS
remains poorly understood. There are three major theories.
First, some investigators believe that the same systemic
process that damages the lungs injures other organs as well;
ARDS is simply the most obvious and earliest manifestation.
For example, one study found that ARDS patients had
increased urinary myoglobin and β2-microglobulin during
development of pulmonary edema, and there was a correla-
tion between pulmonary edema and the amount of these
proteins in the urine. This mechanism of multiple-organ-
system failure may be particularly likely in patients with sep-
sis and shock. Circulating factors such as endogenous
cytokines or endotoxin are likely mediators of multiple-
organ-system failure in this hypothesis.
Another hypothesis is that hypoxemia and inadequate O2
delivery are the causes of multiple-organ-system failure.
Some studies of ARDS patients suggest that tissue oxygen
consumption depends on systemic oxygen delivery even
when oxygen delivery is normal or elevated. Thus a small
decrease in oxygen delivery can cause oxygen consumption
to fall, resulting in tissue hypoxia and potential organ dam-
age. Studies undertaken to test the hypothesis that increasing
oxygen delivery will raise oxygen consumption, however,
have not shown improved outcomes.
A final consideration in multiple-organ-system failure is
the effects of therapy of ARDS. Positive-pressure ventilation
and PEEP are important parts of the supportive care of
ARDS, but these can have adverse effects on cardiac output
and oxygen delivery. Invasive monitoring, artificial airways,
and other devices increase risk of infection and sepsis. This
theory is attractive because mortality in ARDS, while still
 Figure 12–8. Hypothetical respiratory system pressure-
volume curves for a patient with ARDS showing a flatter
than normal relationship (decreased respiratory system
compliance, Crs = VT/ΔP1). With addition of PEEP, a shift to
a more compliant curve may occur such that Crs = VT/
(ΔP2 − PEEP) increases. The change in compliance may
represent recruitment of poorly ventilated or nonventi-
lated lung units with application of PEEP and may be
correlated with improved oxygenation and gas exchange.
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high, is less often related to respiratory failure than to non-
respiratory organ dysfunction and sepsis. Recent clinical
studies provide circumstantial support for this theory. For
example, use of a low-tidal-volume strategy reduces mortal-
ity in ARDS patients by close to 25%. Because there was no
difference in the degree of obvious barotrauma, a beneficial
effect on nonrespiratory organ system function might be one
explanation.
Clinical Features
A. Predisposing Conditions—More than 100 clinical situa-
tions have been associated with development of ARDS.
Prospective studies have helped to identify the most com-
mon conditions, and 60–80% of cases of ARDS can be
accounted for by sepsis, trauma, diffuse pulmonary infec-
tion, and aspiration of gastric contents, with other condi-
tions being much less frequent (Table 12–18).
The overall attack rate of ARDS is relatively low. In one
study, only 8% of patients at risk with any of the nine most
frequently associated predisposing conditions developed
ARDS, although the incidences ranged from 6–50% for indi-
vidual risks. In those with multiple predisposing conditions,
the incidence of ARDS increases substantially, with an aver-
age incidence of 42% for two or more risks for ARDS com-
pared with 19% for those with a single risk in one
study—although 41% of patients with sepsis alone devel-
oped ARDS.
1. Sepsis—Sepsis is present in as many as 50% of ARDS
patients. In medical patients, sepsis is the most common
ARDS association; in trauma patients, sepsis is the most
common association in ARDS developing 48 hours or more
after admission. A distinction sometimes can be made
between pneumonia leading to ARDS and infection from a
nonlung site leading to ARDS. In severe pneumonia, gas-
exchange abnormalities and chest x-ray features of ARDS are
sometimes seen prior to or in the absence of other character-
istics of systemic infection, suggesting that much of the lung
injury is due to the infectious agent and local response to
infection within the lung. Pathogens include bacteria,
mycobacteria, fungi, viruses, Pneumocystis jerovici, and rick-
ettsiae. On the other hand, a nonpulmonary primary site of
infection is often identified in ARDS patients, including the
GI tract, urinary tract, heart, or soft tissues. Although gram-
negative enteric bacilli are encountered most often, ARDS
can result from systemic infection with any bacterial, viral, or
fungal pathogen. Sepsis is of particular interest because it
appears that circulating mediators, including interleukins
and other responses to infection, are largely responsible for
ARDS, hypotension, and multiple-organ-system failure, in
addition to the microbial organisms themselves. Sepsis com-
plicated by ARDS has a higher mortality, especially if the
source of infection cannot be identified and treated readily.
2. Aspiration of gastric contents—Aspiration of gastric
contents is defined as an observed aspiration during intuba-
tion or witnessed vomiting in a patient with impaired airway
protective mechanisms. Although acidic gastric fluid is
thought to be the primary cause of lung injury and ARDS,
studies support a contributory role for bacteria, partially
digested food particles, gastric enzymes, and other noxious
substances. Neutralization of gastric acid prior to aspiration
does not prevent or moderate ALI. Other syndromes of aspi-
ration, including necrotizing pleuropulmonary infection and
lung abscess, can lead to ARDS if there is severe lung injury
response or sepsis. Aspiration of gastric contents is particu-
larly common in patients of advanced age, those who have
neurologic diseases resulting in paralysis or impaired swal-
lowing, or those who have advanced organ-system failure. In
other ICU patients, including surgical and obstetric patients,
aspiration potential is increased by sedatives, muscle relax-
ants, general anesthesia, and local anesthesia to the pharynx
and larynx; during endotracheal intubation; during enteral
feeding; and in diabetics or others with impaired GI motility.
In a sizable number of patients, aspiration of gastric contents
can only be presumed because predisposing factors are
absent and there is no observed aspiration event.
3. Trauma—Trauma is a common predisposing condition to
ARDS, but the precise mechanism is uncertain. Direct
trauma to the thoracic wall may result in lung contusion,
with hemorrhage into the lung causing abnormal gas
exchange, atelectasis, and further lung injury.
Nonthoracic trauma is also associated with an increased
incidence of ARDS. In some of these patients, lung injury
Table 12–18. Some predisposing conditions associated
with ARDS. 
Infection  
Pneumonia: bacteria, fungi, viruses, Pneumocystis jerovici
Nonpulmonary: Sepsis from gram-negative bacilli, staphylococci,
other gram-positive cocci, Candida
Aspiration of gastric contents  
Trauma  
Thoracic: lung contusion  
Nonthoracic  
Hemorrhagic shock  
Head trauma  
Burns  
Blunt abdominal trauma and pancreatitis  
Orthopedic: fat embolism syndrome, severe fracture  
Other conditions  
Drugs: opiate or salicylate overdose  
Pancreatitis  
Toxic: smoke or gas inhalation  
Amniotic fluid embolism  
Central nervous system pulmonary edema  
Near-drowning  
Multiple transfusions of blood and blood products  
Collagen-vascular disease, including vasculitis and pulmonary
hemorrhage  
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results from fat embolism syndrome, a disorder seen in frac-
tures of long bones, or pancreatitis from blunt or sharp
abdominal trauma. In others, the risk of ARDS correlates
with hypotension and shock and with the amount of blood
and blood products transfused, suggesting that the nature and
extent of trauma may have something to do with the develop-
ment of ARDS. Hypotension and shock release inflammatory
cytokines, and tissue damage liberates a variety of products
that could result in lung injury. Although the number of
blood transfusions administered seems to correlate with the
development of ARDS, the requirement for transfusions is
usually closely tied to the severity of trauma. Any patient,
however, who receives blood products has a risk of lung
injury owing to transfusion-related acute lung injury
(TRALI). While other mechanisms are present, TRALI is pri-
marily thought to be mediated by antibodies in donor plasma
reacting with recipient leukocytes. Blood products from mul-
tiparous donors have an increased risk of causing TRALI.
4. Risk modifiers—Cigarette smoking is associated with
increased likelihood of permeability pulmonary edema and
alveolar hemorrhage. With similar acute risk for ARDS, a
higher proportion of chronic alcoholics will develop ARDS.
Although risk balancing is difficult, elderly patients seem to
be at somewhat higher risk of developing ARDS, and out-
come has been reported to be poorer. Some studies have
shown that ARDS mortality is higher in men.
B. Symptoms and Signs—Patients have severe dyspnea and
respiratory distress. Findings include features of hypoxemia,
such as cyanosis, tachycardia, and tachypnea, but rales and
wheezes are the only features on chest examination, and
these are often surprisingly mild. Although the lungs are
filled with fluid, sputum production is rare, except in those
with bacterial pneumonia. Evidence of the underlying prob-
lem leading to ARDS may be found, including fever,
hypotension, trauma, or findings of organ-system dysfunc-
tion. Features of congestive heart failure are notably absent.
Early in ARDS, symptoms and signs are limited to the lungs.
If multiple-organ-system failure develops, then features of
hepatic, renal, or CNS failure may become evident.
C. Laboratory Findings—A key feature of ARDS is refrac-
tory hypoxemia. PaO2 is severely reduced even when the
patient is given supplemental oxygen. Even 100% O2 may not
raise PaO2 above 60–100 mm Hg. Arterial pH may be high,
normal, or low depending on the success of the patient in
maintaining PaCO2 with severe lung disease and the presence
of hypotension and metabolic acidosis.
Other laboratory findings reflect the clinical condition
leading to ARDS and the multiple-organ-system dysfunction
seen as a consequence of this disorder. Renal and hepatic fail-
ure and electrolyte disturbances are frequent complications.
D. Imaging Studies—At disease onset, the chest x-ray shows
diffuse bilateral infiltrates consistent with pulmonary edema.
The infiltrates range from patchy reticular to dense consoli-
dation. Unless there is coexisting heart disease, cardiomegaly
is absent, and there is a lack of the central perihilar promi-
nence of edema seen in congestive heart failure. In fact, some
have pointed out that ARDS is associated with predomi-
nantly peripheral distribution of infiltrates. Nevertheless,
distinguishing cardiogenic from noncardiogenic pulmonary
edema is never perfect. In patients with severe pneumonia
leading to ARDS, there may be focal densities in addition to
diffuse pulmonary edema. In later stages of ARDS, the origi-
nal dense opacification may change to a pattern of reticular
densities consistent with the proliferative and fibrotic stages
of lung injury. While chest x-rays usually suggest diffuse
involvement, marked nonhomogeneity of lung involvement
is seen on chest CT scans. Chest x-rays are essential in mon-
itoring patients for complications of ARDS, including baro-
trauma. Early evidence of air leaking into the lung
interstitium sometimes may be found as linear low-density
streaks of air surrounding bronchovascular bundles.
Occasionally, this finding is seen as a rounded lucent area
surrounding a pulmonary artery and bronchus. Air subse-
quently may track inward to the mediastinum (pneumome-
diastinum) or into the pleural space (pneumothorax).
Differential Diagnosis
Cardiogenic pulmonary edema is the most important dis-
order to be distinguished from ARDS (Table 12–19)
because treatment is often different. This may be particu-
larly difficult when ARDS is seen in conjunction with fluid
overload or concomitantly with congestive heart failure.
Septic shock may confound this distinction because circu-
lating endotoxin or cytokines may exert myocardial
depressant activity.
Table 12–19. Distinguishing cardiogenic from noncardio-
genic pulmonary edema.
Cardiogenic Noncardiogenic (ARDS)
Prior history of heart disease Absence of heart disease
Third heart sound No third heart sound
Cardiomegaly Normal-sized heart
Central distribution of infiltrates Peripheral distribution of infiltrates
Widening of vascular pedicle
(increased width of mediastinum
at level of azygos vein)
Normal width of vascular pedicle
Elevated pulmonary artery wedge
pressure
Normal or low pulmonary artery
wedge pressure
Positive fluid balance Negative fluid balance
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Treatment
Treatment of ARDS centers on management of severe hypox-
emia, correction of the underlying disease that led to ARDS,
and supportive care to prevent complications. Four major
treatment principles have evolved. First, almost all types of
therapy shown to benefit patients with ARDS—including oxy-
gen, PEEP, and positive-pressure ventilation—have potentially
severe adverse effects. Second, although ARDS is often consid-
ered primarily respiratory failure, multiple nonpulmonary
organ-system failure and infection are the major causes of
death in ARDS. Third, careful management of mechanical
ventilation, especially tidal volume, is associated with fewer
complications and is the only treatment demonstrated to
improve survival. Finally, prognosis is especially poor if the
underlying process is not identified or is poorly treated.
A. Oxygen—Treatment of hypoxemia in ARDS is begun
almost always using 100% oxygen (FIO2 = 1.0), and the con-
centration of O2 is reduced with the goal of maintaining a
PaO2 greater than 60 mm Hg (arterial O2 saturation about
90%). PaO2 increases only slightly with administration of
increasing concentrations of inspired oxygen (refractory
hypoxemia), even when 100% O2 is given, indicating right-
to-left shunt or severe  
.
V/
.
Q mismatching. A very few patients
can be managed using a nonrebreathing oxygen mask, but
most patients will be given oxygen via mechanical ventilation
because they are unable to tolerate the increased work of
breathing without mechanical support. The typical response
to administration of O2 in ARDS is shown in Figure 12–7,
and examining the changes in venous admixture as O2 and
other therapy are given can be helpful. The FIO2 should be
lowered as soon as possible to less than 0.5 to reduce the risk
of lung damage from oxygen toxicity. In most patients, low-
ering FIO2 is helped by using PEEP or other mechanical ven-
tilation methods to improve lung gas exchange. Because both
PEEP and high FIO2 both have the potential for complica-
tions, a compromise between high FIO2 and high PEEP often
must be chosen.
B. Positive End-Expiratory Pressure—PEEP includes both
positive end-expiratory pressure provided with mechanical
ventilation and continuous positive airway pressure (CPAP)
given to spontaneously breathing patients. During exhala-
tion without PEEP, alveolar pressure is higher than atmos-
pheric pressure, providing a pressure gradient, until
equilibrium is reached. When PEEP is applied, a pneumatic
valve terminates exhalation when the pressure in the system
decreases to a value set by the clinician. This PEEP is termed
extrinsic PEEP. The effective PEEP is the sum of extrinsic and
intrinsic PEEP (PEEPi).
1. Mechanism—The mechanism of action of PEEP is not
known, but PEEP probably works by counteracting the ten-
dency of alveoli to collapse in the face of pulmonary edema,
low lung volume, and loss of surfactant. Current understand-
ing of ARDS suggests that a majority of lung (although highly
variable) is completely atelectatic, whereas smaller propor-
tions are normally aerated or partially collapsed. PEEP
“recruits” some proportion of partially collapsed areas,
improving of gas exchange to these areas of low 
.
V/
.
Q matching.
PEEP does not decrease the rate of pulmonary edema forma-
tion nor speed the rate of water reabsorption. It is also unlikely
that PEEP is able to open completely collapsed alveoli. Some
investigators have found that PEEP may affect the distribution
of pulmonary artery blood flow away from poorly ventilated
areas and toward better-ventilated regions, resulting in
improved arterial oxygenation. Finally, some studies have indi-
cated that PEEP may have a beneficial effect on the amount or
nature of lung injury.
If partially collapsed alveoli are recruited by PEEP to par-
ticipate in gas exchange, each tidal volume will be delivered
into a larger number of lung units. Lung compliance should
increase as PEEP as added, and the increase in compliance
should parallel improvement in arterial oxygenation (see
Figure 12–8). On the other hand, if PEEP simply distended
alveoli that are already participating in tidal gas exchange, then
lung compliance would remain constant or, if the lung units
become overdistended, lung compliance would decrease. An
upward shift in the position of the pressure-volume curve
indicates recruitment of lung units; movement along the orig-
inal pressure-volume curve suggests that no recruitment
occurred and that gas exchange will not be improved.
2. PEEP and the PV curve—In patients with early acute-
phase ARDS, the pressure-volume curve (Figure 12–9) is flat
at lung volumes near the end-expiratory volume. In this
region, compliance is abnormally low. As airway pressure is
raised—for example, during a tidal volume breath given with
positive-pressure ventilation—many patients will demon-
strate a region of steeper slope or higher compliance. In the-
ory, this region of higher compliance can only be explained by
recruitment of additional lung units. These units must have
been completely collapsed previously, but open when the air-
way pressure exceeds the units’ critical opening pressures. The
changeover point between low-compliance and higher-
compliance regions on the PV curve has been called the lower
inflection point. In theory, PEEP should be set just above the
lower inflection point to indicate recruitment.
Some investigators also have recommended giving suffi-
cient PEEP to prevent the patient breathing in the region cross-
ing the lower inflection point. At lung volumes near the
end-expiratory volume, alveoli are highly prone to collapse. As
the tidal volume is administered, alveoli are repeatedly exposed
to large shear stress as they change from completely closed to
completely open. This may lead to damage in the small airways
and bronchioles leading to the atelectatic lung units. Lung
injury may be moderated if sufficient PEEP is given to raise the
end-expiratory lung volume high enough to prevent cyclic lung
unit collapse (above the lower inflection point).
On the other hand, selecting an optimal PEEP value using
the lower inflection point remains controversial for several
reasons. First, some patients with ARDS have PV curves that
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have no inflection point and no region of increasing compli-
ance. This has been associated with later stages of ARDS dur-
ing which lung units are poorly or not recruited even at
higher lung volume, and improvement of PaO2 in response
to PEEP is generally poor. Second, some ARDS patients
whose respiratory PV curves have been partitioned into
lung and chest wall PV curves show no inflection point on
the lung PV curve but only on the chest wall PV curve. This
finding challenges the singular notion of lung recruitment
with PEEP. Next, the lower inflection point in ARDS patients
may be as high as 15–18 cm H2O, or considerably higher
than many clinicians believe is necessary. It is likely that a
more modest level of PEEP in conjunction with a low-tidal-
volume strategy will have the most physiologic and clinical
benefit. Finally, some workers have not found that the linear
segment of the PV curve is associated with constant increase in
compliance, implying that the lower inflection point is not
sharply defined.
3. Adverse effects—Adverse effects of PEEP include
reduced cardiac output that, in turn, decreases systemic oxy-
gen delivery. There have been several postulated mechanisms
of decreased cardiac output from PEEP, including, among
others, (1) decreased systemic venous return, (2) impaired
ventricular performance, (3) increased pulmonary vascular
resistance, and (4) decreased left ventricular compliance. It
is important to distinguish between decreased cardiac out-
put and decreased cardiac function, however, because
positive-pressure ventilation and PEEP can support ventric-
ular function, especially in severe pump failure and cardio-
genic shock. Decreased cardiac output lowers systemic
oxygen delivery, the product of cardiac output and arterial
oxygen content.
PEEP has been associated with barotrauma, including
pneumothorax and lung injury, and with exacerbation of
pulmonary edema, interstitial fibrosis, and inflammation.
Debate continues about whether the underlying lung disease
that led to the use of PEEP contributes to barotrauma or
whether barotrauma is solely related to PEEP. It is clear that
the degree of lung distention rather than the level of PEEP or
airway pressure is the important variable. In animal studies,
high end-inspiratory lung volumes were reached using either
low PEEP and high tidal volume or high PEEP and low tidal
volume. Both groups showed evidence of barotrauma. The
relationship of PEEP to barotrauma is clearly linked to tidal
volume, and the low-tidal-volume strategy will influence the
incidence of lung injury from PEEP.
Patients in whom PEEP is poorly tolerated have hypoten-
sion, tachycardia, and decreased cardiac output as the earli-
est manifestations. Hemodynamic intolerance may be signs
of volume depletion, severe pulmonary hypertension, or
ventricular dysfunction. A pulmonary artery catheter may be
helpful, and volume expansion or vasopressor drugs may be
necessary. In other patients, PEEP may improve PaO2 only
slightly, suggesting that they have few recruitable lung units.
PEEP is generally contraindicated in very asymmetric or
localized lung disease with hypoxemia.
PEEP may paradoxically worsen PaO2 in ARDS patients
with a patent foramen ovale. In 39 patients with ARDS given
PEEP of 10 cm H2O, mean P(A–a)O2 improved, and only 7
patients had an increase in shunt fraction, but in 7 patients
with patent foramen ovale, 6 had an increase in shunt frac-
tion and little or no reduction in P(A–a)O2. Failure to
improve oxygenation with PEEP was likely due to increased
right-to-left shunting of blood through the foramen ovale,
owing to an increase in pulmonary vascular resistance medi-
ated by PEEP.
4. Application of PEEP—In patients with ARDS, many cli-
nicians prefer to give oxygen at FIO2 1.0 initially and then to
decrease FIO2 as long as adequate PaO2 and O2 saturation are
maintained. To do this, PEEP is titrated upward starting at 5
cm H2O. One strategy is to use the lowest predetermined
combination of PEEP and FIO2 (Table 12–20), with a clear
target for PaO2 and O2 saturation. Higher PEEP levels have
 Figure 12–9. Hypothetical PV curves shown for normal
individuals and ARDS patients. Regions on the ARDS PV
curve include (1) a region of low compliance at low lung
volume—with a lower inflection point; (2) a region with a
steeper slope showing higher compliance—with an upper
inflection point; and (3) a region with a flatter slope
(poorly compliant). In theory, PEEP might be chosen to be
above the lower inflection point to maximize recruitment
and minimize shear stress on the lungs. Tidal volume
should be adjusted to stay within region (2) to avoid
overdistention. This concept has been challenged because
of evidence that recruitment occurs throughout the PV
curve and is not restricted to the area around the lower
inflection point. See text.
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not shown benefit, although studies of high versus low PEEP
have shown variable results. As described earlier, to avoid the
lowest lung volume range at which additional stress-induced
lung injury may occur, a minimum PEEP of 5 cm H2O prob-
ably should be given, but the minimum PEEP defined by the
lower inflection point may be substantially higher in some
patients. Recently, it has been suggested that the level of
PEEP could best be set by measuring the percentage of
recruitable lung. This avoids excessive PEEP in “nonre-
cruitable” patients but requires CT scanning of the lungs
while inflated to different pressures.
PEEP should be adjusted incrementally, with close moni-
toring of respiratory mechanics (especially inspiratory
plateau pressure), arterial blood gases, and hemodynamic
variables. An initial PEEP of 5 cm H2O is almost always well
tolerated, but blood pressure, heart rate, and pulse oximetry
should be checked immediately before and after the addition.
If the patient is stable, allow 10–20 minutes before arterial
blood gases and cardiac output are determined. If desired
goals are not met, PEEP is increased using selected combina-
tions of PEEP and oxygen concentration. In some patients,
changes in PaO2 may not occur until several hours after PEEP
is changed. These patients cannot be easily identified, but cli-
nicians should be aware that changes in blood gases and
hemodynamics may occur both immediately and long after a
change is made in PEEP.
The goal of PEEP is to facilitate oxygen transfer across the
lungs without impairing systemic oxygen delivery. In most
patients, this is achieved by using the lowest PEEP consistent
with adequate arterial O2 saturation (>90%). For some time,
the concept of “best PEEP” has been promoted, variously
described as the PEEP level applied to an individual patient
with ARDS that results in the best balance between tissue
oxygenation and adverse effects. Most now agree that the
optimal PEEP is the least that achieves predetermined objec-
tives of patient management rather than some theoretically
ideal value. Thus PEEP should be titrated until PaO2, arterial
oxygen content, and oxygen delivery increase to acceptable
levels as long as adverse effects are minimized. In practice,
most clinicians prefer PEEP levels between 5 and 12 cm H2O
and rarely exceed this range because of fear of barotrauma
and decreased cardiac output. Although respiratory system
PV curves can be determined, most clinicians adjust PEEP
using a combination of response of arterial blood gases,
hypothetical maximum and minimum PEEP values, and
hemodynamic response.
C. Mechanical Ventilation
1. Low-tidal-volume strategy—The most important
development in the management of ARDS is that mechan-
ical ventilation with lower tidal volume than previously
used is associated with improved clinical outcome. This
Step 1: Calculate predicted body weight (PBW) in kg. 0.91 x (height, cm – 152.4) + 50 (for men) or 45.5 (for women). 
Step 2: Set ventilatory mode (volume-cycled
assist/control) and tidal volume. 
a. Initial tidal volume = 6 mL/kg PBW (if already set higher, then lower 1 mL/kg/h). 
b. Measure inspiratory plateau pressure (Pplat) with 0.5 s pause every 4 hours and after every
change in PEEP or tidal volume. 
c. Adjust tidal volume based on inspiratory plateau pressure. If Plat >30 cm H2O, decrease
tidal volume to 4–5 mL/kg. If Pplat <25 cm H2O and tidal volume <6 mL/kg,
increase tidal volume by 1 mL/kg. 
Step 3: Adjust respiratory rate. a. Initial respiratory rate to maintain same minute ventilation. 
b. Adjust to keep pH 7.30–7.45. 
c. Do not exceed rate >35/min or increase rate if PaCO2 <25 mm Hg. 
Step 4: Adjust FIO2 and PEEP (cm H2O) to maintain 
PaO2 55–80 mm Hg using only these combinations
Minimize both FIO2 and PEEP 
FIO2 PEEP FIO2 PEEP
0.3–0.4 5 0.7 10, 12, 14
0.4 8 0.8 14
0.5 8, 10 0.9 16, 18
0.6 10 1.0 18, 20, 22, 24
Step 5: Manage acidosis or alkalosis as needed. pH <7.30, increase rate (see Step 3) 
pH <7.30 and rate = 35, consider bicarbonate administration 
pH <7.15, consider increase in tidal volume (even if limited in Step 2) 
pH >7.45 and no patient triggering, decrease rate (keep >6/min) 
Modified from The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal vol-
umes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301–8. 
Table 12–20. Lower tidal volume strategy for ARDS.
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has been termed a low-tidal-volume or lung-protective
strategy. In animals, overdistention of lung regions causes
increased epithelial permeability and a histologic picture
of diffuse alveolar damage. In a multicenter study of
ARDS, mortality decreased from 39% (12 mL/kg of pre-
dicted body weight) to 31% in a group whose tidal volume
was set at 6 mL/kg of predicted body weight. Even smaller
tidal volumes were used if inspiratory plateau pressure
remained greater than 30 cm H2O. A protocol for adjusting
the mechanical ventilation using a low-tidal-volume strat-
egy is summarized in Table 12–20. Reducing tidal volume
is associated with little or no change in the dead space:tidal
volume ratio and may result in improved O2 delivery.
Because lung injury is associated with excessive inspiratory
lung volume, higher levels of PEEP may be safer if tidal
volume is limited. Studies have shown little or no adverse
effects of low tidal volume as long as PEEP is given, but
PaCO2 may increase as minute ventilation is decreased with
the lower tidal volume. Low-tidal-volume ventilation with
elevated PaCO2 has been termed permissive hypercapnia.
Acute respiratory acidosis with permissive hypercapnia
was surprisingly well tolerated in several clinical trials.
However, there may be more subtle effects of respiratory
acidosis on nonpulmonary system function, including
renal and neurologic, that are not yet appreciated.
There is not yet agreement on the mechanism of
improved clinical outcome with a low-tidal-volume strategy.
No differences in pneumothorax (explosive barotrauma) are
reported, but there have been small differences in the rate of
nonpulmonary organ dysfunction. An attractive hypothesis
is that ALI is worsened by lung overdistention, and low tidal
volume moderates this “ventilator-associated lung injury.”
For example, the levels of a variety of proinflammatory
cytokines in blood and alveolar fluid are lower in ARDS
patients treated with low tidal volumes. It is likely that the
severe regional heterogeneity of lung involvement is impor-
tant because overdistention would predominate in the most
compliant portions of the lungs (Figure 12–10).
Interestingly, there are data supporting the hypothesis that
a tidal volume of 6 mL/kg designed to reach a target of a
plateau pressure of less than 30 cm H2O may not be the final
answer. Data suggest that outcome appears to continue to
C. Nonuniform (collapsed
region and normal lung)
 Figure 12–10. Schematic illustrating heterogeneity of lung injury in ARDS and effect on respiratory system compli-
ance for the same tidal volume (ΔV) in all three examples. A. Normal lungs with uniformly normal compliance. A rep-
resentative PV curve is shown with a small ΔP change as the tidal volume is delivered (ΔV). B. Uniformly decreased
compliance of the lungs. The flatter slope of the PV curve results in a larger ΔP required to deliver the same tidal vol-
ume (ΔV). C. ARDS is now recognized to have nonuniform lung involvement, and the decreased respiratory system
compliance arises from collapse of the majority of lung units and overdistention of remaining normal units. The same
tidal volume is delivered to a smaller region of normal lung so that ΔP is large for the same ΔV. The overall compli-
ance shown in C (ΔV/ΔP) is the same as in B.
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improve as tidal volume or targeted plateau pressure
decreases. This likely would mean that some patients would
benefit from a tidal volume of less than 6 mL/kg, although
not all would require this. Further randomized trials are
needed.
2. Volume-preset ventilation—Most ARDS patients are
ventilated using conventional volume-preset (volume-
cycled) positive-pressure ventilators. The major studies using
low tidal volume for ARDS used this mode. Initial tidal vol-
ume is set at 6 mL/kg of ideal body weight, and peak inspira-
tory flow rate is generally at least 1–1.2 L/s owing to the high
demand for inspiratory flow. Adjustments in tidal volume
depend on the level of the inspiratory plateau pressure (Pplat),
as shown in Table 12–20. PEEP is given as necessary for
refractory hypoxemia and in order to lower the FIO2 using a
set of predetermined values for each variable.
Volume-preset ventilation using a high peak flow and a
descending inspiratory flow pattern may have characteristics
similar to those of pressure-controlled ventilation (PCV). In
theory, these settings may improve distribution of ventila-
tion to poorly ventilation lung regions, improving hypox-
emia with smaller increases in PEEP or FIO2.
3. Pressure-controlled ventilation—Pressure-controlled
ventilation (PCV) might seem like a very attractive option in
the management of ARDS, largely because a preset maxi-
mum positive airway pressure cannot be exceeded. However,
this feature does not automatically provide the same benefit
as a low-tidal-volume strategy unless the maximum pressure
is adjusted to also limit tidal volume. On the other hand,
PCV does have the theoretical advantage of providing maxi-
mum inspiratory flow at the beginning of the inspired
breath. In some patients, distribution of ventilation may be
enhanced, especially to the most poorly ventilated lung
regions.
A few studies have shown that PCV compared with con-
ventional volume-preset ventilation results in increased
PaO2, decreased mean and peak airway pressures, and less
impairment of cardiac output. Other studies have shown no
appreciable differences. Careful adjustment of inspiratory
time is needed to optimize tidal volume and minute ventila-
tion. PCV with pressure limited to 30–40 cm H2O might be
considered in ARDS patients with severe hypoxemia unre-
sponsive to PEEP with conventional volume-preset ventila-
tion or in those who require excessively high airway pressures
or PEEP with conventional ventilation.
Similarly, airway pressure-release ventilation (APRV; see
above) has some attractive features for ventilatory support in
ARDS. Lung recruitment might be improved because of the
higher mean airway pressure, and there may be reduced
stress-relaxation lung injury. No studies, however, have
demonstrated improved outcome in ARDS with APRV com-
pared with more conventional modes. For refractory hypox-
emia, a trial of APRV might be useful and could be used in
comparison to IRV, prone ventilation, and maximum-lung-
recruitment strategies.
4. Inverse-ratio ventilation—In ARDS patients with
refractory hypoxemia, inverse-ratio ventilation (IRV) has
been used. In contrast to conventional ventilation, inspira-
tory time is made longer than expiratory time by decreasing
the inspiratory flow rate, holding inspiration for a preset
time before allowing for exhalation, or, if a time-cycled ven-
tilator is used, directly increasing inspiratory time. How IRV
might improve oxygenation is not clear. Inspired gas may be
distributed more evenly because of the longer inspiratory
time. The shortened expiratory time, on the other hand, may
cause dynamic hyperinflation, raising end-expiratory vol-
ume and improving gas exchange in a manner similar to
intrinsic PEEP.
There have been no controlled clinical trials demonstrat-
ing improved outcome with IRV. This method should be
reserved for the rare patient with refractory hypoxemia unre-
sponsive to PEEP and oxygen therapy. Current understand-
ing of IRV suggests that there is nothing intrinsically
different about a I:E ratio greater than 1:1. Rather, the gas-
exchange effects of I:E ratio vary continually.
When initiated, an I:E ratio of 1:1 should be tried, and
blood pressure, heart rate, and pulse oximetry should be
monitored closely. If needed, I:E ratio can be further altered
to 1.5:1, 2:1, or more. It is unusual for I:E ratios of greater
than 3:1 or 4:1 to improve gas exchange.
Increased time spent during inspiration and dynamic
hyperinflation can cause severely reduced cardiac output and
hypotension. Prolonged inspiratory time may be very
uncomfortable to the patient, and sedation or muscle relax-
ants are always needed. Monitoring of IRV is complex
because I:E ratio, peak airway pressure, and PEEP do not
adequately reflect all the essential parameters and because
the pattern of inspiratory pressure and flow in IRV differs
depending on how IRV is produced. Monitoring mean air-
way pressure has been suggested, but this value does not
correlate with gas exchange or hemodynamic compromise
in IRV.
5. Other modes of mechanical ventilation—Lung-
protective strategies are the basis for several other modes of
mechanical ventilation. Carrying low tidal volume to
extreme is extracorporeal membrane oxygenation and CO2
removal, in which the lungs receive no ventilation at all.
Clinical trials have been unable to demonstrate improved
clinical outcomes from this practice. High-frequency oscilla-
tion has been used for more than 20 years. With this method,
very small tidal volumes (1–2 mL/kg or less) at respiratory
rates as high as several hundred per minute are administered
by an oscillating membrane. High-frequency oscillation has
been successful in neonatal respiratory distress, but scaling
up to larger patients has not been uniformly feasible. Gas
exchange often can be maintained or improved, but no dif-
ference in clinical outcome has been demonstrated. Another
lung-protective method is tracheal gas insufflation, in which
a 4–6 L/min flow of fresh gas is provided into a small catheter
placed in the lower trachea. The effect is to reduce the apparent
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dead space and achieve improved gas exchange with lower
tidal volume and pressure. As such, it may be an adjunct to
low-tidal-volume methods.
A more radical method of ventilation is partial liquid
ventilation (PLV), in which the lungs are filled with a per-
fluorocarbon, a substance in which oxygen is highly solu-
ble. Conventional volume-preset ventilation is used, but
gas movement through the lungs is almost entirely by dif-
fusion. PLV has the potential advantages of overcoming
loss of surfactant, recruiting lung units without increased
airway pressure, and avoiding further lung injury. Multiple
randomized trials of PLV have failed to show improved
outcome.
D. Supportive Care—Patients with ARDS often require pro-
longed mechanical ventilation and long duration of stay in
the ICU, putting them at risk for complications of ICU mon-
itoring and therapy, infection, and prolonged bed rest.
Attention must be paid to maintaining nutrition, preventing
deep venous thrombosis and GI bleeding, and preventing
other complications. However, recognizing that deaths in
patients with ARDS often result from infection and nonres-
piratory system failure, supportive care focuses especially on
minimizing cardiovascular compromise and preventing
infection.
E. Treatment and Prevention of Infection—Infection is
a major prognostic factor in ARDS, either as the primary
cause of ARDS or secondarily as a cause of death. In one
study, the mortality rate was 78% in patients who developed
ARDS during bacteremia and 60% in those who develop
nosocomial pneumonia. In another study, infection was
absent in two-thirds of survivors but present in two-thirds
of nonsurvivors. The major infection sites were the lungs or
pleura, the abdomen, soft tissues, and other locations, and
about 5% had multiple sites of infection. Gram-negative
bacilli made up 57% of 177 isolates causing infection in
ARDS in one series, whereas gram-positive cocci were found
in 36% and other organisms in 7%. Among pneumonias,
gram-negative organisms were found in 58% and were
related to endotracheal intubation and prolonged need for
ventilatory support. The finding of gram-negative pathogens
in ARDS patients with pneumonia assumes particular
importance because those patients had only a 12% survival
rate despite appropriate in vitro sensitivity of bacteria to
administered antibiotics, whereas patients with ARDS asso-
ciated with gram-negative bacillary abdominal infections
had a 59% survival rate.
Sepsis or severe pneumonia should be suspected as the
cause of ARDS in all patients unless a highly likely alternative
is present. A primary infection site may be easily identified,
but in doubtful cases, occult lung and abdominal sources
must be investigated. Antibiotics should be selected on the
basis of clinical findings and epidemiologic data. Some
important considerations include the likelihood of gram-
negative bacilli, staphylococci, and candidemia in hospitalized
patients; previous antibiotic use; the possibility of infection
with anaerobic organisms; immunologic competence of the
patient; gastric antacid administration; and other host and
local ICU factors. Ventilator-associated pneumonia is a com-
mon complication of ARDS with prolonged mechanical ven-
tilation. The diagnosis is difficult to confirm, but new or
changing infiltrates, fever, purulent sputum, and worsening
gas exchange are usually to make the diagnosis.
F. Pharmacologic Therapy—There are at present no estab-
lished pharmacologic therapies for ARDS. Many studies have
attempted to intervene in the early stages of ALI by interrup-
tion of cytokine pathways (eg, antagonists and receptor
antagonists), inhibition of endotoxin (eg, monoclonal anti-
bodies), reduction of nonspecific inflammation (eg, corti-
costeroids and prostaglandin and leukotriene inhibitors),
and prevention of oxidant damage (eg, antioxidants such as
acetylcysteine, vitamin C, and superoxide dismutase). None
has proved to be successful.
Nitric oxide is a potent endogenous vasodilator. When
given by inhalation in low concentration, it selectively dilates
pulmonary vessels in well-ventilated regions of the lung, and
it is rapidly inactivated before reaching the systemic circula-
tion. Clinical trials have shown improvement in gas exchange
probably because of improved distribution of pulmonary
perfusion. No large study has concluded that nitric oxide
improves clinical outcome.
Diuretics such as furosemide should be given to ARDS
patients who show evidence of volume overload and are judged
to have adequate systemic intravascular volume. Diuretics
should be used judiciously to avoid volume depletion and com-
promise of right and left ventricular filling. ARDS patients
often have increased airway resistance, so  inhaled β-adrenergic
agonists may be helpful as bronchodilators. These drugs also
stimulate sodium and water transport by alveolar epithelial
cells, perhaps helping to resolve pulmonary edema.
Corticosteroids have been attractive in ARDS because of
potential roles for cytokine- and inflammation-mediated
lung injury, and these drugs are potent anti-inflammatory
agents. However, a large study found no difference in overall
mortality despite some improvement in gas exchange in
patients with ARDS for at least 7 days given large doses of
corticosteroids. The role of nonsteroidal anti-inflammatory
drugs, antioxidants, and other drugs such as ketoconazole
and pentoxifylline remains unclear despite small studies
showing potential benefit. Synthetic surfactants of different
types and components have been the subject of several stud-
ies in ARDS. In most, gas exchange improves, at least tran-
siently, but survival is not improved.
Prognosis
In the first description of the syndrome of ARDS, 12 patients
were described, of whom 7 died. Despite improvement in
care, the mortality rate has changed only slightly.
Nevertheless, recent studies have been encouraging. In one
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study from Seattle, mortality was 50–60% in the mid-1980s
but fell to 30–40% in the late 1990s. The large National
Institutes of Health (NIH)–sponsored trial using low tidal
volumes reported mortality of 30–40%.
A. Respiratory Failure and Outcome—Previously,
patients with ARDS often died early in the course of the dis-
ease from intractable hypoxemic respiratory failure.
Hypoxemia could not be corrected adequately by adminis-
tration of high concentrations of oxygen, and survival was
often less than 3 days after onset. Accordingly, treatment
focused on reversing hypoxemia with positive end-
expiratory pressure, changes in ventilator management, and
extracorporeal membrane oxygenation. Despite signifi-
cantly improved hypoxemia, these measures have had little
or no effect on outcome. One retrospective study found that
unmatched patients who did not receive PEEP had no
higher mortality than those who were given PEEP, although
the PEEP group died later in their course. Other studies
indicate that the severity of respiratory failure at the onset of
ARDS correlates poorly with mortality rate. In another
analysis, the number of neutrophils and lack of acidosis
were associated with survival, whereas the severity of respi-
ratory failure and lung mechanics, response to PEEP, wedge
pressure, blood pressure, and cardiac output were not pre-
dictive. On the other hand, a few studies do find a correla-
tion between outcome and severity of respiratory failure,
but more closely with initial response to therapy. That is,
those patients who have a marked improvement in oxygena-
tion with initial therapy (oxygen and PEEP) at 24 hours do
significantly better than those with a poorer response. More
recently, high dead space:tidal volume ratio has been shown
to correlate with poor outcome in ARDS.
B. Nonrespiratory Organ Failure and Outcome—In one
study, death associated with ARDS was due to irreversible
respiratory failure in only 16%, and most of these died in
the first 3 days. In contrast, of the deaths in this series, most
were due to sepsis, with others resulting from cardiac, CNS,
and hepatic failure. In another study, multiple-organ-
system dysfunction was found in almost all patients with
sepsis and ARDS but much less frequently in those with
ARDS who showed no evidence of infection. The kidneys
were the most commonly affected nonpulmonary organ in
ARDS, with renal failure developing and contributing to
morbidity and mortality data in 30–50%. In a European
multicenter report, the overall ARDS mortality rate was
59%, but death occurred in 38% of cases of ARDS follow-
ing trauma and 68% of those with intraabdominal sepsis.
Probably because of decreased organ-system reserve,
patients over age 70 in this report had a mortality rate of
82%. A study of the importance of multiple-organ-system
failure in ARDS found that nonsurvivors had more severe
thrombocytopenia than survivors, as well as lower blood
pH, more liver dysfunction, and higher plasma creatinine
concentrations.
Current Controversies and Unresolved Issues
A. Fluid Management—Whether intravascular volume
should be reduced in ARDS remains a controversial issue.
Because of increased lung permeability, pulmonary edema is
maintained at pulmonary capillary hydrostatic pressures
that are normal or low. It is argued that resolution of pul-
monary edema would be facilitated by lowering microvascu-
lar hydrostatic pressure with diuretics and fluid restriction.
On the other hand, there is concern about oxygen delivery to
the tissues in the face of intravascular volume depletion.
Positive-pressure ventilation and PEEP reduce cardiac out-
put and oxygen delivery, and cardiac output is maintained
by ensuring adequate intravascular fluid volume. Sepsis and
shock, major factors in ARDS, often require massive fluid
administration because of hypotension and decreased tissue
perfusion. These factors suggest that volume expansion may
be needed and that diuretics and negative fluid balance
should be avoided.
Retrospective evidence indicates that net negative fluid
balance is desirable in ARDS. Reduction of pulmonary
microvascular pressure decreases lung water despite severe
lung injury, and cumulative net negative fluid balance and
weight loss are significantly higher in survivors compared
with nonsurvivors of ARDS. These trials have the problem
of self-selecting patients with better prognoses, but they
nonetheless suggest that fluid balance may be an important
determinant of outcome. In one study, better survival in
ARDS was found in those who had at least a 25% reduction
in pulmonary capillary wedge pressure compared with those
who did not. Survivors of ARDS had lower wedge pressures
and body weights compared with nonsurvivors, and the mean
number of days of mechanical ventilation and days of ICU
care were less in those who gained less than 1 L of fluid over
the first 36 hours. There was no detrimental effect on nonpul-
monary organ system function despite low fluid intake.
Two prospective studies shed light on this problem. In
one, a more “conservative” strategy of fluid replacement was
compared with a more liberal one. Using central venous
pressure (CVP) or pulmonary artery wedge pressure (PAWP)
for guidance, as well as urine output and mean arterial pres-
sure, ALI patients were managed according to protocols.
Over the first 7 days, there was a very small negative cumula-
tive fluid balance for the conservative protocol; the liberal
protocol resulted in a mean positive fluid balance of nearly
7000 mL. There was no difference in 60-day mortality, but
the conservative strategy resulted in shorter duration of
mechanical ventilation and duration of ICU stay. There were
no additional complications.
In the other study, randomization of ALI patients to
insertion and use of a pulmonary artery catheter or central
venous catheter showed no difference in 60-day survival or
organ dysfunction. There were more arrhythmias seen with
the pulmonary artery catheter, but no differences in incidence
of renal failure or use of vasopressors, diuretics, or dialysis.
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B. Periodic Lung Recruitment—The PV curve of the
lungs, both in normal individuals and in those with ARDS,
shows hysteresis, or a different curve during inflation and
deflation. Because the inflation limb requires higher pres-
sures at the same lung volume than the deflation limb, a
relatively high transpulmonary pressure may be needed
initially to “open” lung units. For subsequent breaths, the
pressure needed for inflation is considerably smaller. This
finding has led to the recommendation for periodic
“recruitment maneuvers” superimposed on conventional
ventilatory techniques.
One kind of recruitment maneuver consists of increasing
airway pressure to 30–45 cm H2O and holding pressure con-
stant for 30 seconds or more while ventilator cycling is inhib-
ited. This can be done by using the continuous positive
airway pressure (CPAP) mode, with the patient heavily
sedated or paralyzed. Successful recruitment is marked by a
subsequent increase in lung compliance (lower inspiratory
plateau pressure at the same tidal volume) and lower oxygen
requirements. The frequency, magnitude, safety, and clinical
benefit of aggressive lung recruitment are not established.
These maneuvers might be considered in patients with
refractory hypoxemia, but routine use is not supported by
current evidence.
C. Prone Positioning—A number of investigators have
advocated placing the ARDS patient into the prone position.
Several studies have demonstrated improvement in PaO2 in
50–75% of patients turned from supine to prone, with some
patients having prolonged benefit. The mechanism of prone
positioning appears to be the smaller volume of lung that is
compressed by the abdominal contents and heart in the
prone position and by more uniform lung ventilation.
Hypoxemia is more likely to improve during early-stage
ARDS with pulmonary edema than after significant fibrosis
develops. Because the prone position may allow adequate gas
exchange with lower values of PEEP, tidal volume, and FIO2,
this technique also might be considered a lung-protective
strategy.
Recent studies vary the daily duration of prone position-
ing, use changes in PaCO2 to predict benefit, and compare
prone position with PEEP and recruitment maneuvers.
While there is general agreement that PaO2 increases, current
evidence does not support a survival benefit.
D. Routine Use of PV Curves—PV curves have been recom-
mended for determining optimal PEEP and tidal volume lev-
els to avoid ventilator-associated lung injury. There is no
doubt that careful PV curve analysis has been instrumental in
enhancing our understanding of lung and chest wall mechan-
ics in ARDS, but routine use is not practical for a combina-
tion of technical and clinical reasons. Of interest, some
investigators have shown that current recommendations for
minimal PEEP, optimal tidal volume, and target plateau pres-
sure match very well with data derived from PV curves.
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 Obstructive Sleep Apnea &
Obesity-Hypoventilation Syndrome 
ESSENT IALS  OF  D IAGNOS I S
 Excessive daytime somnolence with evidence of upper
airway obstruction during sleep (obstructive sleep
apnea syndrome).
 Impaired ventilatory response to CO2 and hypoxemia
(obesity-hypoventilation syndrome). 
 May have right-sided heart failure with cor pulmonale,
hypertension, and left ventricular dysfunction. 
General Considerations
The obstructive sleep apnea-hypopnea syndrome is a com-
mon condition affecting 5% of adult men and approximately
half that number of women. This syndrome is closely associ-
ated with snoring and is characterized by repeated episodes
of upper airway collapse during sleep with resulting acute
hypercapnia, hypoxemia, sleep disruption, hemodynamic
alterations, and impairment of daytime functioning. Severely
affected individuals may develop respiratory failure and be
admitted to the ICU with marked hypercapnia, poly-
cythemia, altered mental status, and pulmonary hyperten-
sion with cor pulmonale. Alternatively, obstructive sleep
apnea may be observed in ICU patients admitted for other
indications (eg, unstable angina pectoris or cardiogenic pul-
monary edema); in such cases, the recognition and treatment
of the sleep-disordered breathing may be a critical compo-
nent of the overall ICU therapy. It should be noted, however,
that most patients with obstructive sleep apnea do not have
daytime hypoventilation and therefore do not have respira-
tory failure in the usual sense.
A. Normal Breathing during Sleep—For the purpose of
this chapter, sleep may be separated into two main types,
rapid eye movement (REM) sleep and non–rapid eye move-
ment (NREM) sleep, which differ considerably in their
effects on breathing and on upper airway resistance.
Although REM and NREM sleep stages alternate throughout
the night, the majority of REM sleep is normally concen-
trated during the latter half of the sleep period.
In normal awake individuals, the control of breathing is
influenced not only by chemical and mechanical stimuli but
also by inputs from higher cortical centers. With the transi-
tion to sleep (usually light NREM sleep), volitional influ-
ences are lost, and in addition, the responsiveness of the
central respiratory center to increasing PaCO2 is blunted rel-
ative to the awake state. Upper airway caliber is also reduced
owing to both gravitational effects related to the supine posi-
tion and a decrease in the tonic activity of upper airway dila-
tor muscles, which, during wakefulness, prevent inspiratory
narrowing owing to negative intraairway pressures. The net
effects of these changes in ventilatory drive and airway cal-
iber are a slight increase in inspiratory upper airway resist-
ance and mild hypoventilation (PaCO2 = 42–44 mm Hg at sea
level) relative to the awake state.
During REM sleep, respirations are irregular, and ventila-
tion appears to be, in part, under the control of behavioral
processes activated during this dreaming state. Ventilatory
responsiveness to chemical stimuli is markedly reduced, and
there is a profound suppression of skeletal muscle tone,
including the intercostal muscles and other accessory mus-
cles of respiration, but excluding the diaphragm and extraoc-
ular muscles. Although brief central apneas and hypopneas
can result in transient mild arterial oxygen desaturations,
these are clinically unimportant in normal individuals.
B. Obstructive Sleep Apnea Syndrome—In contrast to
mild narrowing of the upper airway found in normal persons,
an exaggerated response is seen in obstructive sleep apnea
syndrome, with episodic partial (hypopnea) or complete
(apnea) obstruction of the upper airway during sleep. These
events may last from 10–90 seconds and are terminated by an
arousal from sleep, resulting in sleep fragmentation. The site
of obstruction can occur at any point along the airway above
the level of the glottis, and often more than one site is
involved. A strong association of obstructive sleep apnea with
obesity in men suggests that small upper airway caliber is an
important predisposing factor, although obstructive sleep
apnea is found in nonobese individuals as well. Other poten-
tial factors include adenotonsillar hypertrophy or other
anatomic abnormalities, increased collapsibility of the upper
airway, inflammation or edema of these structures, and
abnormal neural reflexes. The degree of respiratory drive
plays a role, as does the amount of nasal airway resistance;
both these factors tend to increase the amount of intralumi-
nal negative pressure and, thereby, the tendency to collapse
the pharyngeal airway during inspiration.
Patients with obstructive sleep apnea syndrome tend to
experience most of their problems during the wake-to-sleep
transition (when ventilatory control is relatively unstable) and
during REM sleep (when respiratory muscle hypotonia and
chemical insensitivity combine to produce frequent and pro-
longed apneas). Because the threshold for arousal is relatively
low during lighter NREM sleep (stages 1 and 2), patients with
obstructive sleep apnea may alternate between these sleep
stages and wakefulness throughout the entire night and never
reach the more restorative deeper NREM stages 3 or 4. For
similar reasons, REM sleep is also typically fragmented and
reduced in quantity. While the severity of daytime sleepiness
generally correlates with the frequency of obstructive breath-
ing events, some patients may have minimal sleepiness despite
severe disruption of breathing during sleep (defined as more
than 30 apneas or hypopneas per hour).
Hemodynamic abnormalities during sleep are common
in patients with obstructive sleep apnea. Hypoxemia and
high levels of circulating catecholamines contribute to both
increased systemic and pulmonary vascular resistance. Blood
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pressure peaks immediately after an arousal occurs after an
obstructive event, when a sudden increase in cardiac output
meets these high vascular resistances. The markedly negative
intrathoracic pressures during obstructed inspiratory efforts
raise the transmural myocardial pressure, further increasing
both right and left ventricular afterload. In addition to
apnea-related fluctuations in blood pressure, obstructive
sleep apnea increases the risk of daytime hypertension. This
effect has been shown to be independent of obesity, age, and
gender and is thought to be related to a “resetting” of the
carotid baroreceptors as a result of repeated hypoxemia and
repetitive bursts of catecholamines with each obstructive
event that remodels vascular tone. Left ventricular hyper-
trophy is common in patients with obstructive sleep apnea,
and left ventricular diastolic dysfunction (more often than
systolic abnormalities) may result in cardiogenic pul-
monary edema in these patients. Increased myocardial oxy-
gen requirements combined with apnea-related hypoxemia
can precipitate myocardial ischemia and present as noctur-
nal angina in patients with underlying coronary artery dis-
ease. Cardiac arrhythmias, including bradycardias and
pauses up to 13 seconds during apneas and ventricular
ectopy associated with severe desaturation, may be seen in
the most severe cases.
Obstructive sleep apnea also has been strongly associated
with coronary artery disease and stroke, although a direct
causal relationship has yet to be definitively demonstrated.
Suggested pathophysiologic mechanisms include the hemo-
dynamic abnormalities described earlier, as well as increases
in platelet activation and plasma fibrinogen that have been
reported in patients with untreated obstructive sleep apnea.
C. Obesity-Hypoventilation Syndrome—Obesity-
hypoventilation syndrome is an uncommon condition in
which usually morbidly obese individuals develop hypercapnic
respiratory failure from a combination of depressed response
to CO2 and hypoxia, increased work of breathing, and possibly
abnormal heart and lung function. Obesity-hypoventilation
syndrome has a variable relationship to obstructive sleep apnea
perhaps because of the association of each with obesity, but
most obesity-hypoventilation syndrome patients have some
degree of obstructive sleep apnea. Obesity-hypoventilation
patients have daytime hypercapnia and decreased responsive-
ness to hypercapnia, in contrast to the majority of obstructive
sleep apnea patients, who, while awake, maintain normal PaCO2
and have a normal ventilatory response to CO2. Patients with
obesity-hypoventilation syndrome often have pulmonary
hypertension leading to cor pulmonale.
Clinical Features 
A. Symptoms and Signs—Patients with obstructive sleep
apnea may complain of daytime hypersomnolence, a history
of heavy snoring, awaking gasping for breath, and unrefresh-
ing sleep. Bed partners, if available, often provide more reli-
able information and will describe repeated periods of apnea
terminated by loud snorts and gasping. Systemic hypertension
is common. These patients may be seen occasionally in the
ICU for severe nocturnal hypoxemia, arrhythmias, cardiac
ischemia, heart failure, or altered mental status. Patients with
obesity-hypoventilation syndrome often have severe right-
and left-sided heart failure with dyspnea and pulmonary and
peripheral edema.
On examination of the obstructive sleep apnea patient,
periodic breathing may be noted during sleep. Unlike the
Cheyne-Stokes breathing pattern seen in severe heart failure,
however, the patient with obstructive sleep apnea will have
little or no airflow despite the increasing respiratory efforts.
After a time varying from seconds to minutes, the patient
arouses, may awaken briefly, and opens the airway to the
accompaniment of snoring and upper respiratory noises.
During the apnea, the patient may demonstrate use of acces-
sory muscles, intercostal retractions and paradoxical inspira-
tory chest wall movements, and movement of the neck
toward the thoracic inlet during inspiratory maneuvers.
These findings are characteristic of obstruction of the upper
airway while respiratory efforts are being made. Pulsus para-
doxus is not uncommon during apneic events.
Those with respiratory failure associated with obstructive
sleep apnea or those with obesity-hypoventilation syndrome
may have acute respiratory acidosis, which may be severe
enough to cause lethargy or coma. Other patients may seek
medical attention primarily for severe peripheral edema and
massive weight gain because of right ventricular failure from
pulmonary hypertension. Dyspnea or wheezing suggests a
component of obstructive lung disease or pulmonary edema.
Most, but not all, patients with severe sleep apnea will show
evidence of daytime hypersomnolence.
B. Laboratory Findings—Most patients with obstructive sleep
apnea have few abnormal laboratory findings when awake.
Erythrocytosis is unusual in obstructive sleep apnea alone and
suggests superimposed obesity-hypoventilation or other causes
of sustained hypoxemia. In patients seen in the ICU who pres-
ent with respiratory failure, hypercapnia and hypoxemia are
seen. Chronic CO2 retention leads to a compensatory elevation
of plasma bicarbonate. Electrocardiography may show evi-
dence of left-sided or biventricular hypertrophy, tachycardia
or bradycardia in association with apneic events, and, rarely,
ventricular ectopy. The chest x-ray may confirm cardiomegaly,
pulmonary edema from left ventricular failure, or enlarged
pulmonary arteries in patients with pulmonary hypertension.
Patients with obesity-hypoventilation syndrome have abnor-
mally low ventilatory response to CO2 and hypoxia.
C. Confirmatory Testing—Traditionally, confirmation of
obstructive sleep apnea has been made by polysomnography.
Measurements made during sleep demonstrate episodic
upper airway obstruction by showing periods of absence of
airflow despite evidence of inspiratory effort. Arterial
hypoxemia or O2 desaturation proves that obstruction is
causing significant gas-exchange abnormalities. In the
sleep laboratory, the number, nature, severity, and duration of
sleep-disordered breathing events (ie, apneas and hypopneas)
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are carefully measured and counted. Other measurements
include electroencephalography and electrocardiography.
Portable cardiorespiratory recorders (four to six channels
including, at a minimum, airflow, respiratory effort, satura-
tion, and heart rate) are better suited for use in the ICU and
generally provide the information needed to guide treat-
ment. In some critically ill patients, diagnostic testing may
not be feasible, and a presumptive diagnosis of obstructive
sleep apnea may have to be made prior to confirmatory test-
ing. In these patients, direct observation of the sleeping
patient and pulse oximetry trends demonstrating an episodic
(sawtooth) pattern of desaturations in the ICU can be used
to initiate and titrate therapy.
Differential Diagnosis 
Obstructive sleep apnea syndrome may coexist with other lung
diseases. Both obstructive sleep apnea and COPD are common
in men, and these diseases complicate each other. Severe car-
diomyopathy and CNS disease may present with periodic
breathing, dyspnea, and hypersomnolence. Obesity is associ-
ated with hypoxemia from atelectasis. Weight gain, edema,
heart failure, and hypoventilation may be seen with hypothy-
roidism. Thyroid function should be determined in all patients
considered to have obesity-hypoventilation syndrome.
Treatment 
A. Mild Obstructive Sleep Apnea—Patients with mild
obstructive sleep apnea are unlikely to be seen in the ICU for
this problem alone, but this syndrome is common and may
be seen in those admitted with other diseases. In these
patients, apneic episodes occur relatively infrequently during
sleep onset and REM sleep, and daytime hypercapnia is not a
problem. Treatment is directed at weight reduction, absti-
nence from alcohol and cigarette use, treatment of nasal dis-
ease (if present), and avoidance of a supine body position
during sleep. Nocturnal nasal CPAP can be used if necessary.
Additional treatment options include mouthpieces that dis-
place the mandible anteriorly during sleep (thereby pulling
the tongue away from the posterior pharyngeal wall), and
rarely, pharyngeal surgery. Successful management should
result in reduced daytime somnolence and improvement of
such neuropsychiatric symptoms.
B. Severe Obstructive Sleep Apnea—Severe obstructive
sleep apnea may require aggressive relief of nocturnal upper
airway obstruction. Tracheostomy is very effective because of
unequivocal reversal of upper airway obstruction, but this is
very rarely required.
1. Nasal CPAP—Nasal continuous positive airway pressure
(CPAP) has become the treatment of choice for this disorder.
By providing positive pressure to the collapsible portion of
the upper airway during sleep, nasal CPAP effectively pre-
vents airway obstruction during inspiration.
Nasal CPAP is generally provided by a blower attached to
flexible tubing leading to a small mask placed over the nose or
small soft nasal prongs. A sufficient continuous flow of air is
blown into the system, and via a controllable vent, continuous
positive pressure of up to 20 cm H2O can be maintained. The
appropriate level of nasal CPAP is best determined during
polysomnography; however, rough approximations may be
made in the ICU by direct observation of the patient during
sleep, with upward titration of pressure until apneas, snoring,
and desaturations are eliminated. Newer “autotitrating”
devices that adjust pressure based on the shape of the inspira-
tory flow profile also can help to identify optimal pressures.
Most patients in whom it is tried, at least for the short term,
tolerate nasal CPAP, but not all patients can be managed suc-
cessfully in this way. For those unable to tolerate the required
continuous pressures, bilevel nasal ventilation may be more
comfortable and effective while allowing a high inspiratory
and a lower expiratory pressure level.
Nasal CPAP has a variable role in patients with obstructive
sleep apnea who present with respiratory failure to the ICU. In
many, nasal CPAP is sufficient to restore and maintain upper
airway patency and normalize gas exchange during sleep.
These patients probably have only mild respiratory center
depression from hypoxemia and hypercapnia. Some patients
are improved by the combination of nasal CPAP and oxygen.
On the other hand, some obstructive sleep apnea patients with
respiratory failure have little immediate response to nasal
CPAP, which suggests that upper airway obstruction is no
longer the only factor. In these patients, nasal CPAP can be
tried, but if satisfactory results are not obtained quickly, more
definitive efforts at restoring ventilation and oxygenation must
be made using mechanical ventilation.
Effective treatment with nasal CPAP is often accompa-
nied by a “rebound” of sleep, which gradually returns to
more normal quantities over several days. A spontaneous
diuresis is also seen commonly and is the result of a reduc-
tion in hypoxia-induced pulmonary vasoconstriction and a
lowering of left ventricular afterload. Hypertension may
improve or even resolve with effective nasal CPAP therapy.
2. Oxygen—Oxygen, alone or given in combination with
noninvasive positive-pressure ventilation, is given to correct
hypoxemia in the setting of respiratory failure with obstruc-
tive sleep apnea. Hypoxemia is a serious complication of this
syndrome, with potential for arrhythmias, altered mental
status, and further deterioration of ventilatory drive.
However, oxygen therapy alone typically prolongs apnea
duration, resulting in worsening hypercapnia and respiratory
acidosis.
In patients with acute respiratory failure, however, hypox-
emia is often very severe and may cause hypoxic inhibition of
central respiratory neural output and marked hypoxia of the
brain, heart, and other organs. The goal is to raise PaO2 to at least
60 mm Hg for at least several days. Oxygen should be given with
careful monitoring of mental status, vital signs, respiratory rate,
and arterial blood gases. Increased hypercapnia indicating
RESPIRATORY FAILURE 313
worsening of respiratory failure with oxygen administration
should suggest the need for initiating or increasing ventilatory
support rather than discontinuing oxygen.
3. Other treatment—Endotracheal intubation or tra-
cheostomy is highly effective. In patients with localized
obstruction owing to adenotonsillar hypertrophy or nasal
polyps, surgical excision may be curative but should not be
done until the patient has been stabilized medically. Other
surgical treatments (including uvulopalatopharyngoplasty
and mandibular osteotomy with hyoid suspension) have
even less of a role in the actual setting because these proce-
dures tend only to reduce the severity of the obstruction, and
the results are difficult to predict. Diuretic administration
may be helpful if elimination of obstructive breathing events
and desaturations is insufficient to induce a spontaneous
diuresis. Pulmonary edema is often the result of left ventric-
ular diastolic dysfunction, and β-blockers may be more effec-
tive than afterload-reducing medications. There is no role for
respiratory stimulants or carbonic anhydrase inhibitors in
the treatment of obstructive sleep apnea syndrome. The use
of sedative-hypnotic agents is contraindicated in these
patients because they suppress the arousal response and
therefore tend to lengthen apneas and cause more severe O2
desaturations.
C. Obesity-Hypoventilation Syndrome—These patients
often benefit from diuresis in response to oxygen and diuret-
ics. Because of coexisting obstructive sleep apnea, mainte-
nance of upper airway patency is essential. Mechanical
ventilation may be necessary. Left ventricular failure is
treated with diuretics with β-blockers or afterload reduction
added as indicated clinically based on estimates or objective
measures of left ventricular function.
Mechanical ventilation should not be withheld until gas
exchange becomes severely abnormal. More often, mechani-
cal ventilation is required as a temporizing measure while
oxygen and other treatment correct the acute physiologic
derangement. Mechanical ventilation is sometimes necessary
so that oxygen can be given safely in patients who have
decreased ventilatory drive. After a few days of improved
PaO2, many patients will have improved ventilatory drive and
marked attenuation of hypercapnia. Patients often will
regain significant ventilatory responsiveness to CO2.
Some patients can be ventilated successfully using nonin-
vasive nasal ventilation with bilevel positive-pressure
ventilation. This procedure requires careful monitoring and
observation because minute ventilation and airway patency
cannot be guaranteed as with conventional mechanical ven-
tilation using an endotracheal tube. Bilevel positive-pressure
ventilation is much like inspiratory pressure-support ventila-
tion, with increased pressure maintained at a preset level
throughout inspiration. Although backup rates can be added
(similar to pressure-controlled IMV), they generally add lit-
tle to spontaneous ventilation in these patients owing to the
limited ability of inspiratory pressure applied noninvasively
to counteract forces produced by the weight of the chest and
abdomen.
Medroxyprogesterone acetate may have a beneficial effect
in patients with chronic obesity-hypoventilation syndrome,
but its usefulness in acute respiratory failure is unclear. In the
long term, weight loss is of substantial benefit because stud-
ies have shown that even a 10% reduction in weight can
improve gas-exchange derangements.
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 Acute Renal Failure
Acute renal failure can be defined as a precipitous impair-
ment of kidney function without regard to etiology or mech-
anism. It can occur as a result of many causes, but clinical
findings, complications, and some forms of treatment are the
same in all cases. The causes can be divided into three main
groups: prerenal, resulting from rapidly reversible renal
hypoperfusion; postrenal, owing to obstruction to urine flow;
and intrinsic, owing to lesions directly involving the renal
parenchyma. In most patients, intrinsic renal failure can be
considered a diagnosis of exclusion once pre- and postrenal
causes are eliminated.
Clinical Features
Investigations useful in determining the cause and severity of
acute renal failure are listed in Table 13–1.
A. History—Noting the time of onset of renal problems
helps to differentiate between acute renal failure and the nat-
ural progression of chronic renal disease. The most com-
mon causes of chronic renal failure are diabetes,
hypertension, chronic glomerulonephritis, and polycystic
kidney disease. The patient’s drug history should seek to
identify medications known to cause renal dysfunction,
including nonsteroidal anti-inflammatory drugs (NSAIDs),
angiotensin-converting enzyme (ACE) inhibitors, and
antibiotics (Table 13–2). Exposure to hydrocarbons (car-
bon tetrachloride), ethylene glycol (antifreeze), or radio-
logic contrast agents also can cause acute renal failure.
B. Symptoms and Signs—Acute renal failure is rarely asso-
ciated with flank pain or dysuria, exceptions being condi-
tions characterized by severe renal inflammation,
crystalluria, acute obstruction, intrarenal hemorrhage, and
arterial embolization. Most of the symptoms associated with
acute renal failure are the result of renal dysfunction. Salt and
water overload, resulting in edema, hypertension, and pul-
monary congestion, is most often the result of inadequate
diuresis. Manifestations associated with acute retention of
uremic toxins include anorexia, nausea, hiccupping, vomit-
ing, hematemesis, impaired hemostasis, neuromuscular irri-
tability, asterixis, lethargy, coma, and seizures. Conditions
seen more often after prolonged uremia include pruritus,
pericarditis, and anemia. Spontaneous bone fractures owing
to secondary hyperparathyroidism and altered vitamin D
metabolism are not associated with acute renal failure, and
their presence argues strongly for chronic uremia as the
cause. Hyperkalemia owing to impaired renal excretion can
cause cardiac arrhythmias. Uremic acidosis may elicit
Kussmaul respirations.
Evaluation of intravascular volume status and degree of
hydration should include measurement of orthostatic blood
pressure and heart rate, assessment of mucosal hydration
and skin turgor, and inspection for the presence or absence
of edema (peripheral and sacral), jugular venous distention,
pulsus paradoxus, cardiac rubs or gallops, pulmonary rales,
or effusions and ascites. Equally informative are signs of
associated morbidity, including those of congestive heart
failure, cirrhosis, or systemic vasculitis.
C. Laboratory Findings—
1. Serum creatinine and glomerular filtration rate—
Creatinine is made in the muscle and released into the circu-
lation at a rate of 15–25 mg/kg per day for a middle-aged
man and 10–20 mg/kg per day for a middle-aged woman.
Under conditions of severe muscle damage (rhabdomyoly-
sis), leakage of creatinine into the serum can exceed the pre-
ceding estimates. Creatinine is excreted primarily by
glomerular filtration, with only a small percentage (10%)
secreted by the tubules and virtually none reabsorbed. The
normal glomerular filtration rate (GFR) must be reduced by
about half before there is a substantial increase in serum cre-
atinine levels (>1 mg/dL). As a result, serum creatinine is not
a reliable guide to modest decreases in renal function. In con-
trast, preexisting increases in serum creatinine support the
diagnosis of chronic renal disease.
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When creatinine levels are relatively stable over several
days, a crude estimate of the prevailing GFR can be made
using the following formula:
The result (in mL/min) is multiplied by 0.85 for a female.
This calculation is useful in providing a quick estimate of
renal function but is potentially misleading if there are sub-
sequent changes in the serum creatinine level. In order to val-
idate the calculation, a 24-hour urine collection for
creatinine is required.
During bouts of severe renal failure, serum creatinine
increases by 1–2 mg/dL per day. More rapid increases in
serum creatinine suggest rhabdomyolysis. Spurious increases
in serum creatinine can occur without declines in GFR when
certain cephalosporins or ketones (acetoacetate) interfere
with the colorimetric reaction used for its identification.
Likewise, cimetidine and trimethoprim-sulfamethoxazole
can compete for tubular secretion and result in increases in
serum creatinine unrelated to decreased GFR.
2. Urea—Urea is the major nitrogen-containing metabolite
of protein catabolism and is excreted primarily by the kid-
neys. Normally, 35–50% of filtered urea is reabsorbed by the
tubules. Under conditions of decreased renal blood flow,
GFR
age][wt (kg)]
Serum creatinine (
=
−
×
[140
72 mg/dL)
Table 13–1. Renal assessment. 
History  
Physical examination  
Serum chemistries  
Urea, creatinine, electrolytes, abnormal serologic tests (see text)  
Urine chemistries  
Na, FENa, urea, FEurea, creatinine  
24-hour clearance: creatinine, urea, protein  
Urinalysis 
Dipstick determinations 
Microscopy  
Sulfosalicylic acid  
Urine culture/Gram stain  
Hemodynamic monitoring  
Ultrasound imaging 
Radiography  
KUB, IVP, tomography, CT scan, MRI  
Invasive radiography  
Renal arteriography (selective, digital subtraction)  
Retrograde pyelography  
Percutaneous antegrade pyelography  
Nuclear scanning  
Split function studies and renal flow (DTPA, MAG-3)  
Gallium scan  
Renal biopsy  
Drug Mechanism of Nephrotoxicity 
Antimicrobial Agents
Abacavir AIN 
Acyclovir Crystalluria
Aminoglycosides ATN; electrolyte-wasting 
Amphotericin B ATN; electrolyte-wasting, renal tubular acidosis 
Cephalosporins AIN, spurious increased creatinine 
Cidofovir ARF 
Ciprofloxacin AIN 
Dapsone ATN 
Foscarnet ATN, electrolyte-wasting, hypocalcemia 
Ganciclovir ARF 
Indinavir Nephrolithiasis, crystalluria, pyuria, obstruction 
Meropenem ARF 
Penicillins AIN 
Pentamidine ATN 
Polymyxin B ATN (may occur when given orally) 
Quinolones AIN? 
Rifampin AIN 
Sulfadiazine ARF, crystalluria 
Sulfamethoxazole AIN, crystals, decreased creatinine secretion 
Sulfisoxazole Crystalluria 
Valacyclovir ARF 
Immunosuppressive Agents
Cisplatin ATN, HUS, Glomerular capillary thrombosis 
Cyclosporine Intrarenal vasoconstriction 
Daclizumab ATN, renal dysfunction? 
Ifosfamide ARF 
Interferon Prerenal azotemia? ATN? 
Interleukin-2 Shock-like syndrome, prerenal azotemia 
Methotrexate Crystalluria (high-dose IV) 
Mitomycin HUS 
Tacrolimus Intrarenal vasoconstriction 
Diuretics
All Prerenal azotemia 
Mannitol Osmotic nephrosis 
Table 13–2. Drugs associated with acute renal failure. 
(continued)
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tubular reabsorption of urea can increase to 90% or more.
Since creatinine is not reabsorbed, serum urea increases
more rapidly than serum creatinine under these conditions,
as seen in prerenal renal failure. In general, when measured
as blood urea nitrogen (BUN) in milligrams per deciliter, the
normal ratio of BUN to serum creatinine is 10:1. If it rises to
levels of 20:1 or more, one should suspect prerenal azotemia.
In addition to variations in renal handling, blood urea con-
centrations are also subject to the state of protein catabolism.
Thus 6 g of protein yields approximately 1 g of urea nitrogen.
Under most clinical conditions, there is a direct relationship
between the amount of protein ingested and urea nitrogen
production. Under conditions of stress, inadequate caloric
intake, or corticosteroid administration, endogenous protein
catabolism results in enhanced urea production. GI hemor-
rhage and the resulting absorption of blood proteins—
approximately 200 g of protein in 1 L of whole blood—also
can increase urea production.
3. Plasma electrolytes—Abnormalities of plasma
sodium, potassium, bicarbonate, calcium, magnesium, and
phosphate are common in acute renal failure, and their
determination and monitoring are an integral part of the
diagnosis and management of acute renal failure.
4. Serologic markers—A search for abnormal serologic
markers, such as various autoantibodies, is part of the basic
workup of immunologically mediated renal disease, includ-
ing glomerulonephritis.
5. Urine electrolytes—Evaluation of random urine sam-
ples provides quick information about the current state of
renal function. The fractional excretion of sodium (FENa) is
the best means of differentiating between prerenal azotemia
and acute tubular necrosis and can be calculated as follows:
In the context of oliguria (urine output <500 mL/day), a
FENa of less than 1% is most commonly associated with pre-
renal azotemia, but it also may be seen with acute glomeru-
lonephritis. Under similar oliguric conditions, a FENa of
greater than 1% is probably related to acute tubular necrosis.
Unfortunately, the potential usefulness of this test is often
lost if diuretics are given prior to collection of the urine sam-
ple.
The fractional excretion of urea (FEurea) also can be use-
ful and is similarly calculated as follows:
Normal values in well-hydrated individuals are between
50% and 65%. Values below 35% are most compatible with
renal hypoperfusion and are not affected by loop diuretics
FE
urine Ur (mg/dL)
urine Cr (mg/dL)
ser
urea
= ×
um Cr (mg/dL)
serum Ur (mg/dL)
FE
urine Na (meq/L)
urine Cr (mg/dL)
serum
Na
= ×
Cr (mg/dL)
serum Na (meq/L)
Drug Mechanism of Nephrotoxicity 
Antihypertensives
ACE inhibitors Hemodynamic compromise (most common
with bilateral renal artery stenosis), AIN 
Angiotensin receptor
blockers 
Hemodynamic compromise (most common
with bilateral renal artery stenosis) 
Anti-Inflammatory Drugs
Celecoxib AIN 
Diclofenac AIN 
Fenoprofen AIN, nephrotic syndrome 
Ibuprofen AIN 
Indomethacin AIN, nephrotic syndrome 
Ketorolac AIN 
Nabumetone AIN 
Naproxen AIN, nephrotic syndrome 
NSAIDs (all) Prerenal azotemia (especially in CHF, cirrho-
sis, nephrosis, chronic renal failure, volume
depletion), ATN 
Rofecoxib AIN 
Sulindac AIN, nephrotic syndrome 
Tolmetin AIN 
Antiplatelet Agents
Clopidogrel HUS 
Ticlopidine Nephrotic syndrome, HUS 
MIscellaneous Agents
Allopurinol AIN 
Cimetidine AIN, decreased creatinine secretion
Disopyramide Obstructive uropathy 
Intravenous immune
globulin
Prerenal azotemia with filtration failure due
to hyperoncotic plasma 
Lithium AIN 
Omeprazole AIN 
Phenindione AIN 
Phenytoin AIN 
Ranitidine AIN 
Radiocontrast Agents 
All ATN (especially with volume depletion or
advanced diabetic nephropathy) 
Key: ACE = angiotension-converting enzyme, AIN = allergic intersti-
tial nephritis, ATN = acute tubular necrosis, CHF = congestive heart
failure, HUS = hemolytic uremic syndrome, NSAID = nonsteriodal
anti-inflammatory drug. (See Table 13–6.) 
Table 13–2. Drugs associated with acute renal failure.
(continued)
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such as furosemide. A markedly diminished FEurea cannot
distinguish between a rapidly reversible prerenal azotemia
and more definitive ischemic damage, such as occurs in acute
tubular necrosis. Nonetheless, values below 35% are very
useful in identifying renal hypoperfusion in patients taking
diuretics, as is most often the case in decompensated conges-
tive heart failure. Osmotic diuresis resulting from adminis-
tration of mannitol or acetazolamide or from diabetic
ketoacidosis increases the fractional excretion of urea despite
the existence of volume depletion.
Twenty-four hour urine collections for determinations of
creatinine, urea, and protein are the most reliable means of
assessing renal function and determining nitrogen balance.
Creatinine or urea clearance can be calculated as follows:
Creatinine clearance (mL/min) 
Urea clearance (mL/min) 
When serum levels of creatinine or urea are increasing
rapidly, the mean of the pre- and postcollection values is
used in the denominator. Timed collections less than 24 hours
are reasonably accurate for creatinine but are less useful for
assessing proteinuria or urea production.
Modest amounts of proteinuria (<1 g/day) are common in
many forms of acute renal failure, but proteinuria in the
nephrotic range (>3.5 g/day) is most often related to glomeru-
lar disease, except when associated with low-molecular-weight
proteins such as Bence Jones protein in multiple myeloma.
Urine protein electrophoresis performed on a 24-hour urine
collection will distinguish between these two disorders.
6. Urinalysis—Routine urinalysis consists of rapid dipstick
tests and microscopic examination. Dipstick determinations
measure pH and can reveal the presence of hemoglobin
(positive for intact red blood cells, free hemoglobin, and
myoglobin), protein, glucose, and ketones. Microscopic
analysis can suggest infection (white blood cells, white blood
cell casts, and bacteria), nephritis (red and white blood cells,
with or without cellular casts), or nephrosis (granular casts
or oval fat bodies). Red blood cell casts are associated most
commonly with glomerulonephritis but may be seen occa-
sionally with other types of acute glomerular injury such as
cholesterol emboli or with malignant hypertension. White
blood cell casts are seen most often with infectious
pyelonephritis, but when associated with sterile urine, they
may be a sign of immunologically mediated interstitial
nephritis. Tubular epithelial cells can be found with intersti-
tial nephritis or acute tubular necrosis. When associated with
muddy-brown casts, acute tubular necrosis is a more likely
diagnosis. Eosinophiluria, demonstrable on smears of urine
sediment stained with Wright’s or Hansel’s stain, can occur
in drug-induced allergic interstitial nephritis.
The urine dipstick test for protein is most sensitive for
albumin, whereas sulfosalicylic acid added to the urine
causes precipitation of all proteins. When the urine dipstick
is negative or only modestly positive for protein and the sul-
fosalicylic acid precipitation is markedly positive, Bence
Jones proteinuria should be suspected.
Urine culture and Gram staining should be performed on
any urine containing white blood cells. Sterile pyuria is often
a sign of drug-induced interstitial nephritis, but renal tuber-
culosis also should be considered.
7. Assessment of intravascular volume—Central
venous pressure monitoring can be accomplished with sub-
clavian, internal jugular, or femoral catheterization. A low
central venous pressure is most compatible with decreased
intravascular volume; elevated central venous pressure may
be secondary to intravascular expansion or pulmonary
hypertension. When the volume status is unclear in the con-
text of dyspnea, elevated levels of B-type natriuretic peptide
(BNP) may help to identify an element of heart failure that
would support a diagnosis of intravascular volume overload.
Pulmonary artery catheterization is the most reliable means
of assessing optimal fluid status by determination of cardiac
output and left ventricular filling pressure but usually is not
necessary.
8. Renal biopsy—Renal biopsy is most often helpful when
inflammatory nephritis (ie, glomerulonephritis, allergic
interstitial nephritis, etc.) is suspected. However, in patients
suspected of having acute tubular necrosis in whom renal
failure fails to resolve in 6–8 weeks, renal biopsy may be indi-
cated to diagnose irreversible causes of renal failure (eg, cho-
lesterol emboli, cortical necrosis, etc.).
D. Imaging Studies—Renal ultrasound provides an accurate
means of measuring renal size (small kidneys are evidence of
chronic renal disease) and determining the existence of
hydronephrosis. Because potentially nephrotoxic contrast
agents are not required, ultrasound has become the first
choice in the evaluation of ureteral obstruction. In  rare
cases, tumor infiltration or retroperitoneal or perirenal
fibrosis may inhibit the expansion of the renal pelvis, thus
yielding a falsely negative result.
The plain abdominal x-ray can demonstrate the presence
of radiopaque kidney stones but is often more valuable in
evaluation of associated disease processes. Intravenous pyel-
ography (IVP) most reliably identifies the site of renal
obstruction, provided that creatinine levels are not exces-
sively elevated (≤4 mg/dL). Retrograde pyelography can image
both the ureters and the bladder. Percutaneous pyelography
can determine the site of renal obstruction when retrograde
pyelography is unsuccessful. CT scanning can evaluate the
site of obstruction (extrinsic versus intrinsic obstruction)
and assess for associated morbidity. Selective renal angiogra-
phy with digital subtraction is the best way to assess the renal
vasculature for stenosis or hemorrhagic leak.
=
×urine Urea (mg/dL) urine volume (mL/min)
serum Urea (mg/dL)
=
×urine Cr (mg/dL) urine volume (mL/min)
serum Cr (mg/dL)
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The potential for radiocontrast nephrotoxicity always
should be considered. Risk factors include volume deple-
tion, low cardiac output, preexisting renal disease, large
contrast load or multiple exposures to contrast agents, a
history of contrast-induced acute renal failure, multiple
myeloma, and most significantly, advanced diabetic
nephropathy. Patients with diabetic nephropathy and crea-
tinine levels above 4 mg/dL have a 90% probability of
developing some degree of renal dysfunction. In some of
these patients, renal failure may be irreversible. Patients at
increased risk should be well hydrated prior to and imme-
diately after exposure to radiocontrast dyes, and every
effort should be made to limit the amount of contrast
material administered. The newer low-osmolality agents
may be preferable. Other means of minimizing the risk of
contrast-induced renal damage include oral administration
of the antioxidant acetylcysteine and infusion of sodium
bicarbonate.
Radionuclide scanning provides the only noninvasive
means of assessing the relative percentage of renal function
from each kidney (split function studies). Renal blood flow
can be assessed with diethylenetriamine pentaacetic acid
(DTPA), which is excreted by glomerular filtration and may
demonstrate renal vascular stenosis. Repeat examination
after administration of captopril increases this test’s sensitiv-
ity. Gallium scans can identify any type of renal inflamma-
tion and are most valuable in assessing unilateral lesions or
identifying a renal origin of pyuria. Gallium scans also may
be positive in patients with nephrosis. Technetium-99m mer-
captoacetyltriglycine (MAG3) is both filtered and secreted
and is the radionuclide imaging agent of choice for patients
with substantial renal failure.
MRI is not yet widely employed in the evaluation of acute
renal failure, but it may be of value in the diagnosis of renal
vein thrombosis. Gadolinium-enhanced magnetic resonance
angiography (MRA) is an accurate means for assessing renal
artery stenosis without the risks of catheterization or the
contrast material used for percutaneous angiography.
Complications
The complications of acute renal failure are listed in
Table 13–3. Cardiovascular problems are most often due to
fluid overload and electrolyte abnormalities. Pericarditis is
probably the result of retained uremic toxins. Insufficient
erythropoietin may cause decreased red blood cell produc-
tion and anemia, but this mechanism is seen more commonly
in patients with chronic renal failure. In contrast, platelet dys-
function, clinically diagnosed on the basis of prolonged
bleeding time, is a common consequence of acute renal fail-
ure. Infections represent an important cause of morbidity
and death in acute renal failure—especially urinary tract
infections, which are particularly difficult to eradicate
because of inadequate urine concentrations of antibiotics.
Electrolyte and acid-base abnormalities are common, the
most serious being hyperkalemia. Hypoglycemia may result
from decreased renal catabolism of exogenously adminis-
tered insulin. Neurologic abnormalities include somnolence,
coma, and convulsions and are often compelling indications
for initiation of dialysis. GI hemorrhage in acute renal failure
is due to the combination of uremic coagulopathy and gas-
tritis, but in chronic renal failure, arteriovenous malforma-
tions are the most common causes.
Briguori C, Marenzi G: Contrast-induced nephropathy:
Pharmacological prophylaxis. Kidney Int Suppl 2006;100:
S30–8. [PMID: 16612399]
Carvounis CP, Nisar S, Guro-Razuman S: Significance of the
fractional excretion of urea in the differential diagnosis of
acute renal failure. Kidney Int 2002;62:2223–9. [PMID:
12427149]
Goldenberg I, Matetsky S: Nephropathy induced by contrast
media: Pathogenesis, risk factors and preventive strategies. Can
Med Assoc J 2005;172:1461–71. [PMID 15911862]
Hilton R: Acute renal failure. Br Med J 2006;333:786–90. [PMID
17038736]
Lameire N et al: Acute renal failure. Lancet 2005;365:417–30.
[PMID 15680458]
Maisel AS et al : Rapid measurement of B-type natriuretic peptide
in the emergency diagnosis of heart failure. N Engl J Med
2002;347:161–7. [PMID: 12124404]
Merten GJ et al: Prevention of contrast-induced nephropathy with
sodium bicarbonate. JAMA 2004;291:2328–34. [PMID:
15150204]
O’Neill WC, Baumgarten DA: Imaging. Am J Kidney Dis
2003;42:601–4. [PMID: 12955693]
Venkataraman R, Kellum JA: Prevention of acute renal failure.
Chest 2007;131:300–8. [PMID: 17218591]
Fluid overload
Pulmonary edema
Anasarca
Pericarditis
Electrolyte disorders
Hyperkalemia
Hyperphosphatemia
Hypocalcemia (rarely, hypercalcemia)
Hypermagnesemia
Metabolic acidosis
Neurologic disorders
Altered sensorium
Peripheral neuropathy
Seizures
Others
Anorexia, nausea, vomiting
Platelet dysfunction
Anemia
Table 13-3. Acute renal failure—Common complications.
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 Prerenal Renal Failure
ESSENT IALS  OF  D IAGNOS I S
 BUN:creatinine ratio >20:1.
 Decreased urine output (unless renal losses are primary).
 FENa <1% and/or FEurea <35%.
 Urine sediment may show a few granular casts but
absence of inflammatory cells and red and white blood
cell casts.
 No evidence of urinary tract obstruction.
General Considerations
Prerenal azotemia is defined as a state of renal hypoperfu-
sion that can be rapidly reversed with proper management.
All causes of renal hypoperfusion stimulate renal autoregu-
latory mechanisms that function to maintain glomerular
filtration despite decreasing renal blood flow. Central in
this response is the balance between vasoconstricting
angiotensin II and vasodilating renal prostaglandins.
Angiotensin II causes vasoconstriction of both the afferent
and the efferent glomerular arterioles, but resistance in the
efferent arteriole rises more. As a result, glomerular hydro-
static pressure increases, filtration fraction rises, and unfil-
trable serum proteins are concentrated. The resulting
increase in efferent arteriolar oncotic pressure stimulates
water and urea reabsorption from the proximal tubule, thus
decreasing the fractional excretion of urea and increasing
the BUN:creatinine ratio. Furthermore, angiotensin II acts
directly on the proximal tubule to stimulate sodium reab-
sorption, thus decreasing the fractional excretion of
sodium.
The causes of prerenal failure can be classified as shown
in Table 13–4. A decrease in cardiac output can be the result
of primary cardiac disease or insufficient end-diastolic fill-
ing pressures. Volume depletion can occur along obvious
routes such as the GI or urinary system, via surgical drains,
or via more occult mechanisms, including diaphoresis and
retroperitoneal hemorrhage. Redistribution of fluid out of
the intravascular space with insufficient circulating vol-
ume can occur with hypoalbuminemia, vasodilatory shock
with capillary leak (sepsis), or intraabdominal accumula-
tion (eg, peritonitis, ascites, and pancreatitis). Crush injury
with massive tissue damage can cause sufficient localized
edema to result in intravascular depletion. Rarely,
overzealous administration of vasodilators decreases effec-
tive circulating volume and can mimic endogenous causes
of vasodilatory shock.
Intrarenal vasoconstriction can be mediated by several
mechanisms, including an imbalance between vasoconstric-
tive angiotensin II and vasodilating prostaglandins (most
often seen when prostaglandin synthetase inhibitors are
given to patients with nephrosis, cirrhosis, congestive heart
failure, preexisting renal disease, or volume depletion). Renal
artery stenosis, preeclampsia, malignant hypertension, scle-
roderma with severe hypertension and renal failure, and
intravenous cyclosporine may be associated with intrarenal
vasoconstriction mediated by angiotensin II or endothelin.
Finally, obstruction to blood flow to or from the kidney can
result from renal artery stenosis or emboli to the renal arter-
ies, related to valvular heart disease, or in patients with atrial
or ventricular mural thrombi; can occur from valvular heart
disease or arrhythmias; or can occur as a complication of
percutaneous renal angioplasty. Renal vein thrombosis in
adults is seen most often in the context of nephrotic syn-
drome and is considered to be the result of its associated
hypercoagulable state.
Table 13–4. Causes of prerenal renal failure.
Decreased cardiac output 
Myocardial infarction 
Cardiomyopathy 
Pericarditis (constrictive or cardiac tamponade) 
Arrhythmias 
Valvular dysfunction 
Pulmonary embolus 
Pulmonary hypertension 
Mechanical ventilation (especially with PEEP) 
Trauma 
Extracellular volume depletion 
Dehydration 
GI losses (vomiting, NG suction, diarrhea, ostomy output) 
Renal losses (diuretics, osmotic diuresis, nonoliguric ATN, adrenal
insufficiency) 
Peritoneal losses (surgical drains) 
Skin losses (burns, diaphoresis) 
Hemorrhage (gastrointestinal, intra- and retroperitoneal) 
Redistribution of fluid 
Hypoalbuminemia (nephrosis, cirrhosis, malnutrition) 
Vasodilatory shock (sepsis, hepatic failure) 
Peritonitis 
Pancreatitis 
Crush injury 
Ascites 
Vasodilators 
Primary intrarenal vasoconstriction 
NSAIDs (prostaglandin inhibition) 
Hepatorenal syndrome 
Preeclampsia 
Malignant hypertension 
Scleroderma 
Cyclosporine 
Renovascular obstruction 
Renal artery (intravascular stenosis, embolus, laceration, thrombus) 
Renal vein (intravascular thrombosis, tumor infiltration, extravascular
compression) 
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Clinical Features
A. Symptoms and Signs—Patients may present with a his-
tory of excessive fluid losses from diarrhea, high urine out-
put, or sweating, and this may be compounded by low fluid
intake. They may complain of lightheadedness or syncope
and may have tachycardia, hypotension, and diaphoresis.
Often, postural decrease in blood pressure and increase in
heart rate are present in patients with significant volume
depletion. Although prerenal azotemia is associated most
commonly with volume depletion, patients with congestive
heart failure, systemic vasodilation, or hypoalbuminemia
may have substantial peripheral edema yet still have insuffi-
cient cardiac output or intravascular volume to maintain
adequate renal perfusion. Conversely, a severely hypoalbu-
minemic patient who appears euvolemic is likely to be
intravascularly depleted.
Thromboembolic diseases, including renal artery
embolization and renal vein thrombosis, decrease renal per-
fusion but are distinct in their symptomatology and diagnos-
tic workup. Renal artery embolization is most often
associated with cardiac valvular disease and can present with
nausea, vomiting, flank pain, and hematuria.
Renal vein thrombosis in adults is most often associated
with nephrotic syndrome, but it also may result from extrin-
sic compression by tumor. Acute thrombosis can present
with flank pain, hematuria, and increased proteinuria and
may be misdiagnosed as a kidney stone. Chronic thrombosis
may be asymptomatic except for an ipsilateral varicocele
when the thrombosis is in the left renal vein.
B. Laboratory Findings—Considering these varying clini-
cal presentations, evaluation of serum and urine
chemistries is required to confirm the diagnosis. Although
both serum creatinine and urea nitrogen increase, low
tubular flow results in increased reabsorption of urea.
Therefore, the serum BUN:creatinine ratio increases usu-
ally to greater than 20:1, and the FEurea is less than 35%.
Because renal tubular function is normal in early prerenal
azotemia, avid sodium reabsorption in the face of volume
depletion causes FENa to be very low, usually less than 1%.
Urinary sediment is usually normal except for the finding
of a few granular casts; white blood cells and red and white
blood cell casts are absent.
C. Imaging Studies—The diagnosis of thromboembolic
disease may be suspected with the demonstration of
decreased function on IVP or absent flow on radionuclide
scan. The definitive diagnosis and a judgment about the
advisability of operation are best arrived at by renal
angiography (the presence of collateral circulation suggests
a better surgical outcome). Renal venography is the most
definitive diagnostic test for renal vein thrombosis but
risks dislodging the thrombus, with resulting pulmonary
embolization. Digital subtraction renal angiography with
evaluation of the venous phase, CT scan, and MRI are safer
alternatives.
Treatment
Prerenal azotemia caused by volume depletion should be
treated by correction of decreased extracellular fluid volume.
Most often, normal saline is given intravenously in an
amount sufficient to replete volume, but in some patients,
blood or colloid solutions are needed. The total volume of
replacement should be estimated in most cases as 10–25% of
extracellular fluid volume (ie, 2–4 L), but the amount actu-
ally given should be carefully titrated by monitoring urine
output, blood pressure, and heart rate. Elderly patients and
those with heart failure should be given fluid cautiously, usu-
ally with central venous pressure or pulmonary artery pres-
sure monitoring. Fluid replacement also should take into
account continued losses from the GI tract and other sources
of fluid loss.
Prerenal azotemia associated with cardiac failure usually
responds to standard drugs and procedures for improving
cardiac output, including loop diuretics, vasodilators,
inotropic agents, and oxygen. Low-dose dopamine (<5 μg/kg
per minute) has become a popular means of initiating diure-
sis in resistant cases. However, its use is unsupported by large
randomized studies. Potential secondary effects include
tachycardia and ischemia. Heart failure and prerenal
azotemia associated with substantial fluid overload also may
respond to infusions of nesiritide, with or without diuretics.
This approach has shown a remarkable success in allowing
for aggressive diuresis without worsening of renal perfusion.
If diuresis is associated with increasing BUN, ACE inhibitors
may be beneficial in decreasing renal resistance. When suc-
cessful, this approach yields an increase in the fractional
excretion of urea, which can be followed on a daily basis and
used as a guide to further treatment. The management of
pericarditis, arrhythmias, pulmonary emboli, and pul-
monary hypertension is discussed elsewhere. One should
note that positive end-expiratory pressure for treatment of
respiratory failure can spuriously elevate pulmonary wedge
pressure, thus making it a misleading measure of intravascu-
lar volume.
Volume repletion should be tailored to the patient’s car-
diopulmonary reserve. The hypoalbuminemic states associ-
ated with cirrhosis or malnutrition can be corrected with
intravenous albumin, but worsening of associated ascites
may occur in a third of patients. In contrast, albumin infu-
sions are futile in patients with ongoing nephrotic syndrome.
Treatment of vasodilatory shock often requires a combi-
nation of fluids and vasoconstrictors. Crush injury repre-
sents a particular case where intravascular volume depletion
combines with the potential nephrotoxicity of myoglobin to
yield a toxic acute tubular necrosis. Proper prevention of
myoglobin nephrotoxicity can be accomplished with aggres-
sive intravascular volume expansion (see below).
Primary intrarenal vasoconstriction by prostaglandin
synthetase inhibitors reverses spontaneously after cessation
of these drugs. Prevention of hepatorenal syndrome involves
restoration of intravascular volume despite increasing ascites
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or edema (see below). Preeclamptic renal failure must be
treated by delivery or termination of pregnancy. Malignant
hypertension and renal crises associated with scleroderma
can be treated successfully with ACE inhibitors. Patients with
refractory hypertension may require nitroprusside, but pro-
longed use of this agent in renal failure may predispose to
thiocyanate toxicity. Intrarenal vasoconstriction resulting
from high doses of intravenous cyclosporine is reversed by
decreasing or discontinuing the drug.
Renal artery stenosis can be treated by percutaneous
angioplasty or surgery. Massive renal artery embolization
resulting from cardiac sources can be managed with anti-
coagulation and thrombolytic therapy but may require
operative management. Renal vein thrombosis is treated
with long-term anticoagulation with heparin and warfarin
but may respond to either intravenous or intraarterial
thrombolytic therapy.
Carvounis CP, Nisar S, Guro-Razuman S: Significance of the frac-
tional excretion of urea in the differential diagnosis of acute
renal failure. Kidney Int 2002;62:2223–9. [PMID: 12427149]
de Denus S, Pharand C, Williamson DR: Brain natriuretic peptide
in the management of heart failure: The versatile neurohor-
mone. Chest 2004;125:652–68. [PMID: 14769750]
Friedrich JO et al: Meta-analysis: Low-dose dopamine increases
urine output but does not prevent renal dysfunction or death.
Ann Intern Med 2005;142:510–24. [PMID 15809463]
Ichai C et al: Comparison of the renal effects of low to high doses
of dopamine and dobutamine in critically ill patients: A single-
blind, randomized study. Crit Care Med 2000;28:921–8. [PMID:
10809260]
Jones D, Bellomo R: Renal-dose dopamine: From hypothesis to
paradigm to dogma to myth and, finally, superstition? J
Intensive Care Med 2005;20:199–211. [PMID: 16061903]
Kaplan AA, Kohn OF: Fractional excretion of urea as a guide to
renal dysfunction. Am J Nephrol 1992;12:49–54. [PMID:
1415365]
 Postrenal Renal Failure
ESSENT IALS  OF  D IAGNOS I S
 Dilated renal pelvis on ultrasound.
 Enlarged, palpable bladder (if obstruction to bladder
outflow).
General Considerations
Demonstrable changes in renal function occur only if both
kidneys are involved or if there is preexisting kidney disease
involving the contralateral kidney. It is important to keep in
mind that obstruction to urine flow decreases tubular sensi-
tivity to antidiuretic hormone, leading to nephrogenic dia-
betes insipidus. Thus the presence of a high urine volume
does not rule out the possibility of partial obstruction.
Obstruction to urine flow can occur anywhere along the
urinary tract and may be secondary to extrinsic compression
or intrinsic blockage (Table 13–5). Causes include tumors,
stones, blood clots, and sloughed renal papillae—the result
of papillary necrosis, a condition known to occur with anal-
gesic abuse, diabetes, recurrent infections, and sickle cell ane-
mia. Although sloughed renal papillae usually cause
unilateral obstruction, blockage of the bladder neck can
cause bilateral obstruction and acute-onset oliguria. In men,
the most common cause of postrenal renal failure is prosta-
tic hypertrophy.
Clinical Features
A. Symptoms and Signs—Obstruction to urine flow result-
ing in renal failure may be accompanied by symptoms and
signs related to unilateral ureteral obstruction or urethral or
bladder obstruction. Occasionally, obstruction is not associ-
ated with any symptoms or signs.
Acute ureteral obstruction may be painful, with the
patient complaining of severe flank and midback pain, espe-
cially when caused by renal stones or blood clots.
Examination may indicate localized tenderness, especially to
percussion. Urethral obstruction, especially in prostatic
hypertrophy, will cause bladder distention and inability to
urinate. Although urine output is very often low or absent,
partial obstruction may cause renal failure without oliguria
or anuria.
B. Laboratory Findings—Elevated serum creatinine and
BUN are indicative of renal insufficiency, and serum elec-
trolytes reflect the severity of renal failure. In patients with
renal stones or blood clots, hematuria without red blood cell
casts is a prominent feature, but ureteral or urethral obstruc-
tion from extrinsic compression such as tumors will not be
associated with abnormal urinary sediment.
Table 13-5. Causes of postrenal renal failure.
Ureteral obstruction (bilateral or unilateral single kidney)  
Extrinsic 
Tumors (endometrial, cervix, lymphoma, metastatic)  
Retroperitoneal fibrosis or hemorrhage  
Accidental surgical ligation  
Intrinsic
Stones, blood clots, sloughed papillae (papillary necrosis), tumors
(transitional cell, etc.)  
Bladder or urethral obstruction  
Prostatic hypertrophy or tumor  
Bladder carcinoma  
Uterine prolapse  
Stones, blood clots, sloughed papillae  
Neurogenic bladder (functional or iatrogenic)  
Obstructed Foley catheter 
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C. Imaging Studies—The existence of postrenal obstruc-
tion, regardless of the site or cause, almost always can be
determined by renal ultrasound examination. In rare cases,
however, tumor infiltration of the renal parenchyma or
perirenal fibrosis may inhibit dilation of the renal pelvis and
yield a falsely negative ultrasound examination. Minimal or
absent caliceal dilation also may occur during the first few
hours after an acute obstruction. Radiologic procedures
requiring potentially nephrotoxic radiocontrast agents are
most helpful in determining the site and nature of the
obstruction. IVP is employed most often in the context of
suspected kidney stone, but imaging is poor if serum creati-
nine levels are elevated. Retrograde pyelography performed
through a cystoscope avoids intravenous contrast adminis-
tration and offers a direct view of the bladder and the possi-
bility of a corrective urologic procedure. Percutaneous
pyelography demonstrates the site of obstruction and offers
rapid relief of obstruction if the catheter is left in situ. CT
scans and MRI are most helpful for determining the extrin-
sic or intrinsic nature of the obstruction. Radionuclide scan-
ning can be valuable in cases of suspected obstruction when
dilation of the renal pelvis can be identified, but the severity
of the blockage is in doubt.
Treatment
Acute ureteral obstruction with a kidney stone or sloughed
papillae is most often managed with aggressive hydration
and control of pain. Treatment of other causes of ureteral
obstruction, such as tumors, depends on the location and
extent of obstruction and may require surgical relief of the
obstruction. Percutaneous nephrostomy is a reasonable
alternative for short-term correction of obstruction of the
kidney. Bladder obstruction or dysfunction can be treated
initially with insertion of a Foley catheter, but in some
patients this may be difficult to perform without special
urologic instruments. An infected, obstructed kidney is a
medical emergency that cannot be managed adequately
with antibiotic therapy alone. Rapid relief of obstruction is
essential.
Klahr S: Urinary tract obstruction. Semin Nephrol 2001;21:
133–45. [PMID: 11245776]
O’Neill WC: B-mode sonography in acute renal failure. Nephron
Clin Pract 2006;103:C19–23. [PMID: 16543751]
 Intrinsic Renal Failure
Intrinsic renal failure is often a diagnosis of exclusion after
prerenal and postrenal causes have been eliminated or
treated. Cases of intrinsic acute renal failure can be catego-
rized as follows (Table 13–6): (1) those involving the
glomeruli (glomerulonephritis), (2) those involving the
interstitium (interstitial nephritis), (3) those leading to
microcapillary or glomerular occlusion, (4) acute tubular
necrosis, and (5) cortical necrosis.
1. Glomerulonephritis
ESSENT IALS  OF  D IAGNOS I S
 Nephritic urine sediment with red blood cells, white
blood cells, and red blood cell casts.
 Proteinuria (variable, sometimes in nephrotic range:
≥ 3.5 g/day).
 Kidney size normal or increased; no evidence of
obstruction.
 Hypertension (variable).
 Evidence for immunologic disease: antinuclear anti-
bodies, antistreptolysin O, cryoglobulins, antineutrophil
cytoplasmic antibodies (ANCAs), anti–glomerular base-
ment membrane (anti-GBM) antibodies, IgA levels,
hepatitis B antigen, hepatitis C antibody, HIV, decreased
C3 and C4.
 Renal biopsy to confirm diagnosis.
Table 13–6. Causes of intrinsic acute renal failure. 
Acute glomerulonephritis  
Postinfectious: streptococcal, bacteria, hepatitis B, HIV, visceral
abscess  
Systemic vasculitides: systemic lupus erythematosus,  
Wegener’s granulomatosis, polyarteritis nodosa, Henoch-Schönlein
purpura, IgA nephritis, Goodpasture’s syndrome  
Membranoproliferative glomerulonephritis 
Idiopathic  
Acute interstitial nephritis  
Drugs: penicillins, NSAIDs, ACE inhibitors, allopurinol, cimetidine, H2
blockers, proton pump inhibitors  
Infectious: streptococcal infections, diphtheria, leptospirosis  
Metabolic: hyperuricemia, nephrocalcinosis  
Poisons: ethylene glycol (calcium oxalate)  
Autoimmune disease: systemic lupus erythematosus, cryoglobulinemia
Microcapillary/glomerular occlusion  
Thrombotic thrombocytopenic purpura, hemolytic uremic syndrome,
disseminated intravascular coagulation, cryoglobulinemia,
cholesterol emboli  
Acute tubular necrosis  
Drugs: aminoglycosides, cisplatin, amphotericin B  
Ischemia  
Septic shock  
Intratubular obstruction: rhabdomyolysis, hemolysis, multiple
myeloma, uric acid, calcium oxalate  
Poisons: radiopaque contrast media, carbon tetrachloride,
ethylene glycol, heavy metals  
Cortical necrosis 
Key: ACE = angiotensin-converting enzyme; NSAID = nonsteroidal
anti-inflammatory drug 
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General Considerations
Table 13–6 lists several glomerulonephritides that are most
commonly associated with acute renal failure. Most—
perhaps all—are immunologically mediated as a result of
recent or ongoing infections, systemic vasculitis, or idiosyn-
cratic autoimmune reactions. Histologic evaluation is most
often positive for immune deposits in varying locations
within the glomerular structures. In pauci-immune
glomerulonephritis, such as is found with Wegener’s granu-
lomatosis or polyarteritis, no immune deposits are found,
but the presence of antineutrophil cytoplasmic antibodies
(ANCAs) may stimulate leukocytes to release their enzymes,
thus mediating an intraglomerular inflammatory reaction.
Clinical Features
A. Symptoms and Signs—Patients with acute glomeru-
lonephritis may present with edema (especially in periorbital
distribution), hypertension, fatigue, and possibly pulmonary
congestion. They may note smoky, rust-colored, or grossly
bloody urine. These findings are common to glomerulonephri-
tis owing to any cause. Other clinical features reflect the under-
lying disease causing glomerulonephritis. Postinfectious
glomerulonephritis presents about 10 days after acute infec-
tion, usually a streptococcal pharyngitis or skin infection.
Symptoms and signs of systemic vasculitis are highly variable
and depend on the distribution of involvement and the size of
the vessels involved. They may include arthralgias and arthritis,
fever, rash, myalgias and muscle tenderness, hypertension,
abdominal pain, nausea, vomiting, diarrhea, headache, and
other features that are manifestations of organ system involve-
ment, including the heart, GI tract, kidneys, CNS, peripheral
nerves, lungs, pleura, and pericardium. In some situations, the
clinical presentation may strongly suggest a given diagnosis,
such as one of the pulmonary-renal syndromes.
B. Laboratory Findings—The most compelling finding sug-
gestive of acute glomerulonephritis is the presence of red
blood cell casts in the urine. These casts are the result of leak-
age of red blood cells past damaged glomeruli into the tubu-
lar lumen, and they must be carefully distinguished from
granular pigmented casts. The absence of red blood cell casts
does not rule out the diagnosis of glomerulonephritis, how-
ever, and they are found occasionally in other disorders such
as acute interstitial nephritis and cholesterol emboli. Other
urinary abnormalities include varying degrees of proteinuria
and pyuria in the absence of urinary infection. A history of
symptoms suggestive of systemic vasculitis can be confirmed
by serologic testing, including antinuclear antibodies, anti-
GBM antibodies, IgA levels, antistreptolysin O antibodies,
cryoglobulins, ANCAs, antibodies and markers for hepatitis
B, hepatitis C, and HIV, and decreased levels of the third and
fourth components of complement (C3 and C4).
Since therapy of glomerulonephritis often entails long-
term risk, renal biopsy usually should be performed to
confirm the diagnosis.
Treatment
Most cases of acute glomerulonephritis are treated with
aggressive immunosuppressive medications, including high-
dose corticosteroids and cyclophosphamide. Recent reports
suggest that mycophenolate mofetil may be an effective alter-
native to cyclophosphamide in some cases. Since therapy is
likely to be prolonged, with the possibility of substantial
morbidity, consultation with a nephrologist is strongly sug-
gested prior to initiation of treatment. On the other hand,
poststreptococcal glomerulonephritis is treated with sup-
portive therapy alone, including prevention of fluid overload
and control of hypertension.
Glomerulonephritis associated with infective endocardi-
tis responds to appropriate antibiotics. Goodpasture’s syn-
drome and cryoglobulinemia often require plasma exchange.
ANCA-positive glomerulonephritis commonly requires
treatment with cyclophosphamide. Patients presenting with
dialysis-requiring renal failure also may benefit from plasma
exchange.
Chadban SJ, Atkins RC: Glomerulonephritis. Lancet
2005;365:1797–806. [PMID 15910953]
Kaplan AA: The use of apheresis in immune renal disorders. Ther
Apher Dial 2003;7:165–72. [PMID: 12918939]
2. Acute Interstitial Nephritis
ESSENT IALS  OF  D IAGNOS I S
Interstitial nephritis:
 History of drug sensitivity, infection, or toxin ingestion.
 Flank pain (occasionally).
 Kidney size normal or increased.
Allergic interstitial nephritis:
 Fever, rash, peripheral blood eosinophilia.
 Sterile pyuria, hematuria, white blood cell casts, tubular
epithelial cells, eosinophiluria. 
 Positive renal gallium scan with prolonged renal uptake.
General Considerations
Several drugs are capable of eliciting an autoimmune attack
on the renal interstitium, resulting in allergic interstitial
nephritis (see Table 13–2). Direct invasion by infection is less
common. Acute urate nephropathy results from the
intratubular precipitation of uric acid and is most often asso-
ciated with the chemotherapeutic treatment of large lym-
phomas or leukemias, with serum levels of uric acid often
above 20 mg/dL. The metabolism of ethylene glycol, ingested
accidentally or deliberately, results in calcium oxalate deposi-
tion within the interstitium and may result in irreversible
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renal damage. Autoimmune diseases such as systemic lupus
erythematosus or cryoglobulinemia may cause a “pure”
interstitial nephritis but more often present with concomi-
tant glomerular disease.
Clinical Features
A. Symptoms and Signs—Drug-induced allergic intersti-
tial nephritis is often associated with a history of drug hyper-
sensitivity and classically presents with a triad of fever, rash,
and peripheral blood eosinophilia. Unfortunately, the triad is
complete in only one-third of patients. The rash is usually
symmetric and widespread, appears suddenly, and is usually
not pruritic. In the case of NSAID toxicity, nephrotic syn-
drome with glomerular involvement may be present in addi-
tion to evidence of interstitial involvement.
B. Laboratory Findings—Further evidence for interstitial
nephritis includes sterile pyuria, white blood cell casts, and
occasionally, eosinophiluria. Hematuria and varying degrees
of proteinuria usually are present as well. Infectious causes of
interstitial nephritis can be identified by blood or urine cul-
tures. Acute urate nephropathy should be anticipated when-
ever aggressive chemotherapy is initiated in a patient with a
large lymphoma or acute leukemia. In these patients, serum
uric acid is often above 20 mg/dL, and urinalysis reveals flat,
rhomboid crystals of uric acid or needle-shaped crystals of
sodium urate. Autoimmune diseases are best identified by
finding serologic evidence of specific diseases.
C. Imaging Studies—A gallium scan positive for prolonged
renal uptake (>72 hours) supports the diagnosis of allergic
interstitial nephritis.
Treatment
Drug-induced acute interstitial nephritis usually reverses
spontaneously after cessation of the offending agent, but
patients may benefit from a course of corticosteroids if renal
failure is severe or prolonged. In anticipation of aggressive
chemotherapy for lymphomas or leukemias, the risks of
acute urate nephropathy can be greatly reduced by pretreat-
ment with allopurinol and forced alkaline diuresis designed
to keep urine pH ≥ 7.0. Alkalinization of the urine can be
accomplished by administration of 5% dextrose in water to
which approximately 100–150 meq/L of sodium bicarbonate
has been added. Acetazolamide may be added to stimulate
bicarbonate excretion.
Infectious causes of interstitial nephritis are treated with
antibiotics selected for urinary tract bacterial pathogens and
adjusted on the basis of urine and blood cultures. Ethylene
glycol-induced renal failure may require hemodialysis.
Baker RJ, Pusey CD: The changing profile of acute tubulointersti-
tial nephritis. Nephrol Dial Transplant 2004;19:8–11. [PMID:
14671029]
Taber SS, Mueller BA: Drug-associated renal dysfunction. Crit
Care Clin 2006;22:357–74. [PMID 16678005]
3. Microcapillary & Glomerular Occlusion
ESSENT IALS  OF  D IAGNOS I S
 Hematuria.
 Proteinuria (variable).
 Thrombotic thrombocytopenic purpura–hemolytic
uremic syndrome and disseminated intravascular
coagulation: thrombocytopenia and microangiopathic
hemolytic anemia.
 Cryoglobulinemia: cryoglobulin present in serum, pur-
pura (variable), and hypertension (variable).
 Cholesterol embolization: hypertension, signs of periph-
eral vascular occlusive disease (claudication), skin discol-
oration (livedo reticularis, purple toes), eosinophilia, and
a history of recent intraaortic catheterization.
General Considerations
These disorders have in common obstruction of the various
parts of the renal circulation or glomerular vascular pole.
Thrombotic thrombocytopenic purpura (TTP), hemolytic
uremic syndrome (HUS), and disseminated intravascular
coagulation (DIC) have the potential to deposit thrombi of
fibrin and platelets in the glomerular capillary lumen.
Cryoglobulins can precipitate in glomerular capillaries but
also may cause an immunologically mediated glomeru-
lonephritis. Microscopic cholesterol emboli may occur spon-
taneously in patients with severe atherosclerotic disease but
are seen most often after catheterization of the aorta for diag-
nostic purposes. Cholesterol emboli are of varying size and
may block intrarenal arteries, preglomerular arterioles, or
the vascular pole of the glomerulus.
Clinical Features
A. TTP and HUS—Thrombotic thrombocytopenic purpura
(TTP) and hemolytic uremic syndrome (HUS) can be sus-
pected when severe thrombocytopenia is associated with
microangiopathic hemolytic anemia in the presence of nor-
mal prothrombin time and partial thromboplastin time.
Symptoms include jaundice, renal disease, and varied neuro-
logic manifestations.
B. DIC—Disseminated intravascular coagulation (DIC) is
often associated with sepsis and is diagnosed by a combina-
tion of thrombocytopenia, increased fibrin split products,
elevated D-dimers, and elevated prothrombin time and par-
tial thromboplastin time. Owing to the ongoing coagulopa-
thy, renal biopsies are performed only rarely in these diseases.
C. Cryoglobulinemia—Cryoglobulinemia is often associ-
ated with purpura and hypertension and is confirmed by
identification of serum cryoglobulins. It has now been
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established that many cases of cryoglobulinemia are associ-
ated with hepatitis C infection.
D. Cholesterol Embolization—A syndrome of microvascu-
lar embolization with livedo reticularis, purple toes, signs of
peripheral vascular disease, and occasionally eosinophilia
will lead to a suspicion of cholesterol embolization. Renal
biopsy, however, is the only confirmatory test.
Treatment
TTP requires aggressive plasma exchange with fresh-frozen
plasma. HUS may respond to intravenous immune globulin
or plasma exchange. DIC is best treated by management of
the inciting cause. Cryoglobulinemia may respond to
immunosuppressive therapy or plasma exchange. If there is
an associated hepatitis C infection, long-term management
may include interferon. Renal failure associated with choles-
terol embolization is irreversible. However, on occasion,
renal failure from cholesterol emboli may be associated with
an element of acute tubular necrosis owing to vascular occlu-
sion. In these patients, some improvement may occur. On
theoretical grounds, anticoagulation is contraindicated
because it may be a precipitating factor.
Fukumoto Y et al: The incidence and risk factors of cholesterol
embolization syndrome, a complication of cardiac catheteriza-
tion: A prospective study. J Am Coll Cardiol 2003;42:211–6.
[PMID: 12875753]
Gallosi A et al: Extrahepatic manifestations of chronic HCV infec-
tion. J Gastrointest Liver Dis 2007;16:65–73. [PMID: 17410291]
George JN: Clinical practice: Thrombotic thrombocytopenic pur-
pura. N Engl J Med 2006;354:1927–35. [PMID: 6672704]
Guillevin L, Pagnoux C: Indications of plasma exchanges for sys-
temic vasculitides. Ther Apher Dial 2003;7:155–60. [PMID:
12918937]
Kamar N et al: Treatment of hepatitis C-virus-related glomeru-
lonephritis. Kidney Int 2006;69:436–9. [PMID: 16514428] 
Meyrier A: Cholesterol crystal embolism: Diagnosis and treatment.
Kidney Int 2006;69:1308–12. [PMID: 16614719]
Rock G: The management of thrombotic thrombocytopenic pur-
pura in 2005. Semin Thromb Hemost 2005;31:709–16. [PMID:
16388422]
4. Acute Tubular Necrosis
ESSENT IALS  OF  D IAGNOS I S
 History of exposure to nephrotoxic drugs or hypotension.
 Oliguria in ischemic ATN but absence of oliguria in toxic
ATN.
 FENa >1%.
 Urinalysis: tubular epithelial cells, red blood cells, and
“muddy brown” casts.
General Considerations
The most common form of hospital-acquired intrinsic acute
renal failure is referred to as acute tubular necrosis (ATN).
This designation is somewhat misleading because in many
cases there is more tubular dysfunction than necrosis. In gen-
eral, the pathogenesis involves direct toxicity to the tubular
epithelium, resulting in inability to reabsorb glomerular fil-
trate properly and massive sodium wasting, intrarenal vaso-
constriction, and tubular blockage with necrotic cellular
debris and proteinaceous material. The most common
causes are ischemia, exogenous toxins including drugs (see
Table 13–2) and radiocontrast agents, and endogenous tox-
ins such as myoglobin, hemoglobin, light chains of
immunoglobulins, or crystals (see Table 13–6). Any cause of
prerenal azotemia (see Table 13–4), if sufficiently severe or
prolonged, can cause ischemic tubular damage and lead to
this disorder. Furthermore, all conditions of renal hypoper-
fusion increase the likelihood of toxicity from exogenous or
endogenous toxins. In many cases, a combination of noxious
stimuli can be identified.
Clinical Features
Ischemic ATN is encountered most often after an identifiable
episode of hemodynamic compromise or after prolonged
ischemia during aortic surgery. The presentation is that of
acute onset of oliguria with an FENa greater than 1% and a
urine rich with cellular and proteinaceous debris, including
red blood cells, white blood cells, tubular epithelial cells, and
“muddy brown” casts. In this setting, correction of identifi-
able prerenal factors and a renal ultrasound examination
excluding obstruction are often sufficient to make the diag-
nosis on clinical grounds, and renal biopsy usually is reserved
for patients in whom renal failure is abnormally prolonged
(6–8 weeks).
ATN from toxic causes is often nonoliguric, and the urine
sediment may be unremarkable. A history of toxin exposure
(eg, aminoglycosides, radiocontrast agents, etc.) and the
exclusion of prerenal and postrenal causes are often suffi-
cient for a clinical diagnosis. Urinalysis with dipstick positive
for blood in the absence of identifiable red blood cells is sug-
gestive of rhabdomyolysis or hemolysis.
Treatment
Although several experimental treatments have been
designed to enhance recovery (eg, antiendothelin antibodies,
ATP, MgCl2, thyroxine, growth factors, etc.), none are cur-
rently applied in clinical practice. Experimentally, infusions
of atrial natriuretic peptide have been shown to increase cre-
atinine clearance and decrease the need for dialysis, but cur-
rently available treatment strategies are limited to prevention
and management. Preventive measures include ensuring ade-
quate hydration when nephrotoxic agents are unavoidable
(eg, radiocontrast agents or necessary nephrotoxic antibi-
otics) and proper dosing of nephrotoxic drugs with special
 CHAPTER 13326
attention to changing renal function and daily measurements
of toxic drug levels. Recent evidence suggests that pretreat-
ment with acetylcysteine or infusions of sodium bicarbonate
may help to prevent contrast-induced nephropathy.
In the early stages of oliguric ATN, a short course of man-
nitol or furosemide may decrease the tendency toward tubu-
lar obstruction. Mannitol has the theoretical advantage of
stimulating an osmotic diuresis originating in the proximal
tubule, with the possibility of increasing tubular flow
throughout the nephron. Unfortunately, when mannitol is
given without resulting diuresis, it may precipitate intravas-
cular volume expansion, which may be poorly tolerated. If
diuresis is not established after 24 hours of treatment with
furosemide or mannitol, further attempts at diuretic therapy
will be futile and potentially harmful.
Birck R et al: Acetylcysteine for prevention of contrast nephropathy:
Meta-analysis. Lancet 2003;362:598–603. [PMID: 12944058]
Gill N et al: Renal failure secondary to acute tubular necrosis:
Epidemiology, diagnosis, and management. Chest
2005;128:2847–63. [PMID: 16236963] 
Merten GJ et al: Prevention of contrast-induced nephropathy with
sodium bicarbonate. JAMA 2004;291:2328–34. [PMID:
15150204]
Weisbord SD, Palevsky PM: Radiocontrast-induced acute renal
failure. J Intensive Care Med 2005;20:63–75. [PMID: 15855219]
5. Cortical Necrosis
Cortical necrosis is the result of severe and prolonged renal
hypoperfusion and has been most often associated with the
hemodynamic catastrophes of pregnancy, including eclamp-
sia, abruptio placentae, and postpartum hemorrhage. The
diagnosis is usually suspected when an episode of acute renal
failure fails to resolve in 6–8 weeks. Renal biopsy is often
required for definitive diagnosis. Renal damage is irre-
versible.
 Common Syndromes Associated with
Acute Renal Failure
1. Pigment Nephropathy: Rhabdomyolysis
& Hemolysis
ESSENT IALS  OF  D IAGNOS I S
 Urine dipstick positive for heme in the absence of red
blood cells.
 Rhabdomyolysis: elevated creatine kinase and aldolase;
decreased BUN:creatinine ratio.
 Hemolysis: elevated serum-free hemoglobin, decreased
haptoglobin, elevated lactate dehydrogenase (LDH). 
General Considerations
Rhabdomyolysis is commonly associated with acute renal
failure, especially in the context of traumatic crush injury.
Hemolysis is usually more insidious and less likely to cause
renal failure except when severe, such as with major transfu-
sion incompatibilities.
In the case of rhabdomyolysis, intravascular volume deple-
tion promotes intratubular precipitation of myoglobin and is
probably the most important comorbid factor in the initiation
of nephrotoxicity. Hemoglobin-related toxicity seems to be
enhanced by the presence of fragmented red blood cell mem-
branes. Several etiologic factors in the development of rhab-
domyolysis and hemolysis are listed in Table 13–7.
Clinical Features
A. Symptoms and Signs—Patients may note dark-colored
red or brown urine. Symptoms and signs in rhabdomyolysis
may be due to crush injury and other associated trauma and
may be focal or diffuse. However, patients with rhabdomyol-
ysis owing to inflammatory muscle disorders such as
polymyositis may complain of muscle pain, tenderness, and
weakness. Patients with hemolysis-induced renal failure will
have symptoms related to severe anemia. Other clinical find-
ings are due to renal failure and associated complications.
Table 13–7. Causes of pigment nephropathy: hemolysis
and rhabdomyolysis.
Rhabdomyolysis 
Physical trauma: crush injury, heat stress, electrocution, exercise,
hypothermia, malignant hyperthermia, neuroleptic malignant syndrome  
Anoxic injury: arterial occlusion, seizures, tetanus, compartment
syndrome 
Metabolic: hypokalemia, hypophosphatemia, diabetic ketoacidosis,
myxedemia, carnitine deficiency, hereditary muscle enzyme
deficiency  
Infections: influenza-like viral infections, gas gangrene, pyomyositis 
Inflammation: polymyositis, dermatomyositis 
Poisons and toxins: ethanol, amphetamine, cocaine, snake and
spider venom. 
Hemolysis 
Transfusion reactions 
Drug toxicities: quinine sulfate, hydralazine, etc. 
Poisons and toxins: benzene, aniline, fava beans, snake and spider
venom, etc. 
Mechanical trauma: valvular prosthesis, extracorporeal circulation,
march hemoglobinuria 
Enzyme deficiencies: glucose-6-phosphate dehydrogenase deficiency
Osmotic stress: intoxication with hypotonic fluids as seen in drowning,
transuretheral prostatectomy, incorrect priming of extracorporeal
circulation 
Infections: malaria
Autoimmune: drugs, systemic lupus erythematosus 
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B. Laboratory Findings—In the absence of detectable red
blood cells in the urine, a urinalysis dipstick positive for
heme is virtually diagnostic of hemoglobinuria or myoglo-
binuria. Similarly, a highly positive heme reaction (3+ or 4+)
in the face of minimal hematuria (3–5 red cells/high-power
field [hpf]) is equally suspicious. Since myoglobin is suffi-
ciently small to be filtered, patients with myoglobinuria have
brown urine, but the serum is clear. In contrast, hemoglobin-
uria also may produce a dark brown urine, but the spun
serum sample is pink because haptoglobin-bound hemoglo-
bin is a complex that is too large to be filtered. Further con-
firmation of the diagnosis is seen in serum chemistry values.
Rhabdomyolysis is associated with elevated creatine kinase
(CK) and other muscle-derived enzymes released into the
circulation, including aspartate aminotransferase (AST), lac-
tate dehydrogenase (LDH), and aldolase. Of these, aldolase is
specific for muscle damage. Occasionally, creatinine released
from damaged muscle leads to an abnormally low BUN:cre-
atinine ratio (<10:1). Severe hemolysis capable of producing
renal failure is usually associated with detectable free hemo-
globin levels above 25 mg/dL and a marked decrease in free
haptoglobin. As with rhabdomyolysis, elevated LDH and
AST may be present; thus these abnormalities do not permit
distinction between the two disorders.
C. Imaging Studies—Imaging studies are not helpful in
diagnosis of pigment nephropathy other than in evaluating
the extent of injury in patients with traumatic rhabdomyol-
ysis. In patients with serious trauma with renal failure, how-
ever, injury to the kidneys, ureters, bladder, or urethra should
be considered, and ultrasound, CT scan, or IVP may be help-
ful in distinguishing direct injury from rhabdomyolysis.
Treatment
The single most important therapeutic maneuver is to
restore circulating volume rapidly and initiate diuresis. If
oliguria is present, a single dose of mannitol, 12.5 g intra-
venously, can be given to promote diuresis. If successful,
mannitol can be continued as a 5% infusion. Alternatively,
furosemide, 40–200 mg intravenously, can be given and
repeated every 6 hours if necessary. Forced diuresis with
aggressive hydration should strive for a urine output of at
least 100 mL/h and should be maintained until levels of cre-
atine kinase or haptoglobin begin to normalize.
Alkalinization of the urine is recommended by some, but
there is no definitive evidence that it is necessary.
Rhabdomyolysis is commonly associated with several
potentially troublesome electrolyte disorders. Hypocalcemia
may be seen early, probably as a consequence of precipitation
of calcium salts owing to associated hyperphosphatemia.
Despite extremely low levels of serum calcium, tetany is
uncommon, perhaps owing to the associated acidosis. Severe
hyperuricemia also may be encountered. Hyperkalemia,
sometimes extremely difficult to control, may be encoun-
tered with both rhabdomyolysis and hemolysis. In contrast,
crush victims who have received early and vigorous fluid
resuscitation and who present with polyuria may develop
hypokalemia. Hypercalcemia during the recovery phase may
be the result of calcium release from healing muscle and an
increase in 1-25 dihydroxyvitamin D.
Better OS, Stein JH: Early management of shock and prophylaxis
of acute renal failure in traumatic rhabdomyolysis. N Engl J
Med 1990;322:825–9. [PMID: 2407958]
Gunal AI et al: Early and vigorous fluid resuscitation prevents
acute renal failure in the crush victims of catastrophic earth-
quakes. J Am Soc Nephrol 2004;15:1862–7. [PMID: 15213274]
Malinoski DJ, Slater MS, Mullins RJ: Crush injury and rhabdomy-
olysis. Crit Care Clin 2004;20:171–92. [PMID: 14979336]
2. Pulmonary Renal Syndromes
Any type of acute renal failure can present with fluid over-
load and pulmonary edema, but there are several conditions
in which simultaneous involvement of both lung and kidneys
is a common presentation or an intrinsic part of the basic
pathogenesis (Table 13–8). Of these, two are of particular
importance because their rapid identification and subse-
quent treatment can be lifesaving: Goodpasture’s syndrome
and paraquat intoxication.
Goodpasture’s Syndrome
Goodpasture’s syndrome is an autoimmune disease charac-
terized by the formation of anti-GBM antibodies that attack
Disease Renal Involvement 
Goodpasture’s syndrome RPGN 
Wegener’s granulomatosis RPGN 
Systemic lupus erythematosus RPGN 
Churg-Strauss syndrome RPGN 
Sarcoidosis Interstitial nephritis 
Scleroderma Hypertensive renal crisis 
Pulmonary embolism Prerenal azotemia 
Pneumonia Prerenal azotemia 
Poisons (paraquat) Actue tubular necrosis 
Congestive heart failure Prerenal azotemia 
Adult respiratory distress
syndrome 
Acute tubular necrosis, prerenal
azotemia 
Key: RPGN = rapidly progressive glomerulonephritis; ATN = acute
tubular necrosis 
Table 13–8. Pulmonary-renal syndromes causing acute
renal failure. 
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both the pulmonary capillary and the glomerulus. The clas-
sic clinical presentation is that of a young male smoker with
signs of acute glomerulonephritis (ie, hematuria, protein-
uria, and red blood cell casts) and hemoptysis associated
with bilateral pulmonary infiltrates. Iron deficiency anemia
is also a frequent finding.
The diagnosis of Goodpasture’s syndrome can be made
by detecting serum levels of anti-GBM antibodies or by lin-
ear immunofluorescence of the GBM on renal biopsy.
Unfortunately, availability of these confirmatory tests may be
delayed, and rapid initiation of treatment often depends on a
high degree of suspicion. Early initiation of treatment is
essential because therapeutic success in reversing renal fail-
ure is rare if the therapy is started after the onset of oliguria.
Aside from smoking, genetic predisposition and hydrocar-
bon exposure have been identified as associated risk factors.
Both life-threatening hemoptysis and rapidly progressive
renal failure can be treated successfully with a combination
of corticosteroids, cyclophosphamide, and 2 weeks of daily
plasma exchange.
Pusey CD: Anti-glomerular basement membrane disease. Kidney
Int 2003;64:1535–50. [PMID: 12969182]
Pusey CD: The continuing challenge of anti-neutrophil cytoplasm
antibody-associated systemic vasculitis and glomerulonephritis.
J Am Soc Nephrol 2006;17:1221–3. [PMID: 16624927]
Paraquat Poisoning
Paraquat is a herbicide used in concentrated solutions.
Ingestion is highly corrosive for the oral and esophageal
mucosa, and net absorption results in pulmonary edema and
anuria. Effective treatment involves gastric lavage and aggres-
sive use of charcoal adsorbents. Daily treatments with char-
coal hemoperfusion or high-efficiency hemodialysis may be
helpful in lowering paraquat levels. There is also reason to
believe that low oxygen tension may limit lung injury.
Consultation with a poison control expert should be sought.
Web site information can be obtained from the national pes-
ticide information network at http://ace.orst.edu/info/nptn/
Van Vleet TR, Schnellmann RG: Toxic nephropathy: Environmental
chemicals. Semin Nephrol 2003;23:500–8. [PMID: 13680539]
3. Hepatorenal Syndrome
Conditions associated with combined hepatic and renal fail-
ure include infections (eg, sepsis, hepatitis, and leptospiro-
sis), drug toxicity (eg, acetaminophen, allopurinol, rifampin,
and methoxyflurane), poisons (eg, rodenticide and carbon
tetrachloride), and autoimmune disorders (eg, systemic
lupus erythematosus, vasculitis, and cryoglobulinemia).
More common, however, is prerenal azotemia associated
with cirrhosis. Patients presenting with this combination
often have signs of advanced liver disease, hypoalbuminemia,
and ascites. Under these conditions, if prerenal azotemia
becomes unresponsive to intravascular volume replacement,
a diagnosis of hepatorenal syndrome becomes appropriate.
This syndrome is a condition of severe renal vasoconstriction
presenting with extremely low urinary sodium (<10 meq/L),
decreased FEurea (<20%), an extremely high urine:plasma
creatinine ratio, and a relatively unimpressive urine sediment
showing bile-pigmented casts.
Until recently, hepatorenal syndrome was considered to
be almost universally fatal, rendering preventive measures as
the most important management option. Most patients with
hepatorenal syndrome develop the problem during hospital-
ization. GI hemorrhage, bacterial peritonitis, and the
overzealous use of diuretics to control ascites all have been
shown to be associated with the precipitation of the hepa-
torenal syndrome. Thus it is crucial that all patients present-
ing with liver disease and prerenal azotemia receive
aggressive volume repletion. In many cases, pulmonary
edema and ascites may be limiting factors in repletion; cen-
tral venous pressure or pulmonary artery catheterization
may be required to adequately judge how much fluid can be
administered safely. With increasing central venous pressure,
there also will be the increased risk of variceal hemorrhage.
In patients with peripheral edema associated with hypoalbu-
minemia, albumin infusions can successfully mobilize fluid
into the intravascular space, but ascites formation increases
in approximately one-third of patients. In the same vein,
high-volume paracentesis should be performed in conjunc-
tion with intravenous albumin infusions to minimize the
tendency for intravascular volume depletion.
Successful reversal of well-established hepatorenal syn-
drome is rare, but several new treatment strategies appear to
offer some success. The combined use of midodrine (an α1-
adrenergic agonist) and octreotide (a somatostatin analogue)
may improve renal hemodynamics and subsequent survival.
The use of vasopressin analogues in conjunction with albu-
min infusions also may improve renal perfusion, but there is
also the risk of ischemia. Interestingly, since the hepatorenal
syndrome is a result of a severe renal vasoconstriction, the
renal parenchyma may remain intact, and liver transplanta-
tion has been associated with return of renal function.
Recently, there have been reports in Europe of successful
treatment of hepatorenal syndrome with albumin-based
dialysis (molecular adsorbent recycling system [MARS]).
Cardenas A, Gines P: Hepatorenal syndrome. Clin Liver Dis
2006;10:371–85. [PMID: 16971267]
Gluud LL et al: Terlipressin for hepatorenal syndrome. Cochrane
Database Syst Rev 2006;4:CD005162. [PMID: 17054242].
Mitzner SR et al: Improvement of hepatorenal syndrome with
extracorporeal albumin dialysis MARS: Results of a prospective,
randomized, controlled clinical trial. Liver Transplant
2000;6:277–86. [PMID: 10827226]
Moreau R, Lebrec D: The use of vasoconstrictors in patients with
cirrhosis: Type 1 HRS and beyond. Hepatology 2006;3:385–94.
[PMID: 16496352]
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Moreau R, Lebrec D: Diagnosis and treatment of acute renal fail-
ure in patients with cirrhosis. Best Pract Res Clin Gastroenterol
2007;21:111–23. [PMID: 17223500]
Wong F, Pantea L, Sniderman K: Midodrine, octreotide, albumin,
and TIPS in selected patients with cirrhosis and type 1 hepatore-
nal syndrome. Hepatology 2004;40:55–64. [PMID: 15239086]
4. Renal Failure in AIDS
Acute renal failure occurs in more than 50% of hospitalized
patients with AIDS. The combination of volume depletion,
nephrotoxic medications, and sepsis accounts for most cases
(Table 13–9), but most AIDS patients presenting with acute
renal failure can recover renal function and be discharged
from the hospital.
Intravascular volume depletion can result from poor fluid
intake, fever, and GI disturbances or may be secondary to
hypoalbuminemia owing to nephrotic syndrome or malnutri-
tion. Enlarged periaortic lymph nodes can obstruct lower
extremity venous return, resulting in severe leg edema but
insufficient central venous pressure. Careful attention to
restoring intravascular volume not only reverses prerenal
azotemia but also will serve to reduce substantially the risk of
nephrotoxicity associated with medications and radiocontrast
agents. In many cases of drug-induced renal failure, renal
function may return rapidly after termination of exposure to
the drug, such as can be seen with NSAIDs and the crystalluria
associated with indinavir and acyclovir. In other cases, a full-
blown syndrome of acute tubular necrosis may develop; this
disorder may require dialytic therapy before recovery.
A renal syndrome that seems to be unique to
patients with AIDS is rapidly progressive focal segmental
glomerulosclerosis. This syndrome is most common in
patients of African descent and is associated with nephrotic-
range proteinuria (>3 g/day), enlarged, hyperechogenic kid-
neys on renal ultrasound, and—in contrast to focal
segmental glomerulosclerosis in the non-AIDS population—
normotension. Progression of this type of renal disease can
be explosive, reaching a stage of irreversible renal failure in
weeks or months. Recent experience, however, suggests that
the new highly active antiretroviral therapy (HAART) regi-
mens can slow the progression of this type of AIDS
nephropathy.
Standard precautions during hemodialysis are employed
to limit transmission of HIV and hepatitis B. In addition,
HIV has been identified in peritoneal dialysate from patients
with AIDS, and this effluent should be handled with appro-
priate precautions.
Hyun G, Lowe FC:. AIDS and the urologist. Urol Clin North Am
2003:30;101–9. [PMID: 12580562]
Khan S, Haraqsim L, Laszik ZG et al: HIV-associated nephropathy.
Adv Chron Kidney Dis 2006;13:307–13. [PMID: 16815235]
Kimmel PL, Barisoni L, Kopp JB: Pathogenesis and treatment of
HIV-associated renal diseases: Lessons from clinical and animal
studies, molecular pathologic correlations, and genetic investi-
gations. Ann Intern Med 2003;139:214–26. [PMID: 12899589]
Wyatt CM, Klotman PE: HIV-associated nephropathy in the era of
antiretroviral therapy. Am J Med 2007;120:488–92. [PMID:
17524746]
5. Renal Failure in the Renal Transplant
Recipient
Acute renal failure in the transplant recipient can be arbitrar-
ily defined as being early (<10 days after transplantation) or
late (>10 days). In the early period, acute renal failure may be
due to ischemic acute tubular necrosis of the transplanted
graft, acute or hyperacute immunologic rejection, or techni-
cal problems related to the surgery (eg, obstruction, leak, or
infection of the renal artery or vein or of the ureter). Acute
drug toxicity from cyclosporine can present as prerenal
azotemia associated with hypertension and is encountered
most often with relatively elevated intravenous dosing.
Acute renal failure in the late period may be the result of
acute rejection, cyclosporine toxicity, ureteral obstruction,
renal artery stenosis, or recurrence of the original renal dis-
ease. Acute rejection may present with fever, graft tenderness,
and swelling where the kidney is implanted into the iliac
fossa, but concurrent immunosuppressive therapy with
steroids or cyclosporine may mask these signs. If the history,
physical examination, and imaging studies (ie, ultrasound
and nuclear flow scans) cannot distinguish the cause of renal
failure, renal biopsy may be required. In any event, prompt
and continued consultations with the patient’s transplant sur-
geon and nephrologist are essential to proper management.
The intensivist is often in a position to identify potential
organ donors. Acceptable donors for renal transplantation
Table 13–9. Causes of acute renal failure associated with
AIDS. 
Prerenal azotemia  
Volume depletion, hypoalbuminemia, NSAIDs  
Acute tubular necrosis  
Pentamidine, amphotericin B, aminoglycosides, foscarnet, acyclovir,
radiocontrast agents, sepsis, shock  
Allergic interstitial nephritis  
Trimethoprim-sulfamethoxazole, phenytoin  
Rapidly progressive focal segmental glomerulosclerosis  
Obstructive uropathy  
Sulfadiazine-related crystalluria, lymphoma, retroperitoneal fibrosis 
Nephrolithiasis  
Indinavir-induced crystalluria  
Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome
Renal edema  
Hypoalbuminemia with massive proteinuria
Multiple myeloma 
Acute glomerulonephritis 
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are aged 6 months to 60 years with no identifiable renal dis-
ease, no active infection, and no malignancy (except brain
tumors). Physicians working in the ICU should familiarize
themselves with local laws and policies regarding the pro-
curement of organs and the criteria for brain death.
Kasiske BL et al: Recommendations for the outpatient surveillance
of renal transplant recipients. American Society of
Transplantation. J Am Soc Nephrol 2000;11:S1–86. [PMID:
11044969]
Silkensen JR: Long-term complications in renal transplantation. J
Am Soc Nephrol 2000;11:582–8. [PMID: 10703683]
Venkat KK, Venkat A: Care of the renal transplant recipient in the
emergency department. Ann Emerg Med 2004;44:330–41.
[PMID: 15459617].
NONDIALYTIC THERAPY FOR ACUTE RENAL
FAILURE
 Fluid Balance
Achieving the appropriate fluid balance in the setting of an
ICU involves two potentially conflicting goals: providing suf-
ficient volume to ensure adequate renal perfusion and avoid-
ing volume overload with resulting pulmonary congestion.
In some patients, when decreased renal perfusion is sus-
pected in the context of pulmonary compromise, only a pul-
monary artery catheter will yield sufficient information to
guide appropriate therapy. Optimal fluid management for
acute renal failure can be divided arbitrarily into three peri-
ods: (1) the prevention phase, during the initial onset of olig-
uria, (2) the oliguric phase, once renal failure is well
established, and (3) the recuperative phase, often heralded by
relative polyuria. Not all episodes of acute renal failure pass
through each of these phases, but a discussion of their man-
agement is a useful guide to overall treatment goals.
Prevention Phase
On initial presentation, the onset of oliguria should call for
prompt evaluation of the type of renal dysfunction. If vol-
ume depletion is suspected, rapid restoration of circulating
volume may prevent ischemic damage. Restoration of ade-
quate circulating volume can be achieved by administration
of crystalloid or colloid. If simple fluid repletion is required,
normal saline usually suffices. In the context of hypoalbu-
minemia and edema, intravenous albumin can serve to draw
excess extravascular fluid into the circulation.
If oliguria persists despite adequate fluid replacement and
acute tubular necrosis is suspected, a short trial of diuretic
therapy may offer some benefit in limiting renal damage. A
single intravenous 12.5-g dose of mannitol may initiate
diuresis and has the theoretical advantage of limiting epithe-
lial cell swelling and intratubular precipitation of cellular
debris. If initially unsuccessful, further mannitol administra-
tion is potentially harmful in that it may lead to poorly
tolerated intravascular expansion. Alternatively, furosemide
may be given intravenously at a dose of 200 mg (1-hour infu-
sions are preferable to more rapid injection) and may be
repeated safely within 6 hours. Dosages above 1 g/day have
been associated with ototoxicity. If, despite the preceding
maneuvers, oliguria persists more than 24 hours, diuretics
should be discontinued, and the physician should be pre-
pared to manage a potentially prolonged period of oliguria.
Oliguric Phase
The oliguric phase of acute renal failure may persist for sev-
eral weeks. During this period, especially in the critical care
setting, the patient may require enormous amounts of intra-
venous fluids, including hyperalimentation, vasopressors,
and antibiotics. Every effort should be made to minimize the
volume of these infusions. Continuous infusions of vaso-
pressors should be maximally concentrated, and antibiotics
should be given in minimum volumes of fluid. When given
in adequate amounts, parenteral hyperalimentation always
requires 1–2 L/day. Thus enteral alimentation is always pre-
ferred when possible.
Proper maintenance of fluid balance requires careful
attention to all avenues of fluid intake and output, including
surgical drains, nasogastric suction, and diarrhea. Normal
insensible losses can equal 1000 mL/day but can increase
substantially in the presence of fever, burns, or exfoliative
dermatitis. Increased minute ventilation enhances water loss
from the lungs even if the inspired gas is humidified. On the
other hand, metabolism of carbohydrate and fat yields
approximately 500 mL/day of metabolically produced water.
Thus, unless insensible losses are increased, an anuric patient
requires only 500 mL/day of water. Finally, despite meticu-
lous monitoring of fluid input and output, there can be no
substitute for daily weight measurements.
Recuperative Phase
In many patients with acute renal failure, the oliguric phase
is followed by a period of relative polyuria, heralding the
beginning of tubular recuperation. During this period,
serum urea nitrogen and creatinine may remain elevated,
and renal dysfunction persists. One must bear in mind that
the urine produced is not appropriately concentrated and
that reabsorption of sodium and other ions is inadequate.
During this phase, it is the goal of management to replace
lost volume and electrolytes. Urinary sodium and potassium
should be measured and replaced in appropriate amounts.
Abnormalities of magnesium, calcium, and phosphate also
should be anticipated.
Monitoring Fluid Balance
In the presence of active pulmonary disease such as pneumo-
nia, acute respiratory distress syndrome (ARDS), or pul-
monary edema and suspected prerenal azotemia, aggressive
fluid replacement may worsen pulmonary gas exchange.
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Furthermore, in patients with vasodilatory shock or hypoal-
buminemia, substantial edema may be present, and still the
patient has insufficient circulating volume. In these settings,
intravascular pressure monitoring becomes invaluable.
Although central venous pressure can be monitored easily
via subclavian, internal jugular, or femoral vein catheteriza-
tion, a more definitive assessment of optimal cardiac filling
pressures can be obtained with pulmonary artery catheteri-
zation. This is because central venous pressure can be
increased by pulmonary hypertension or central venous
thrombosis or occlusion even in a volume-depleted patient.
Similarly, positive-pressure ventilation and, especially, posi-
tive end-expiratory pressure may elevate pulmonary capil-
lary wedge pressure spuriously.
 Acid-Base Balance
Uremic acidosis occurs as a result of the slow accumulation
of phosphates and sulfates and is related to protein catabo-
lism. Approximately 1 meq acid is retained for every gram of
protein catabolism. Thus a 70-g protein diet yields approxi-
mately 70 meq acid, which, when distributed into the total
body water compartment, consumes approximately 2 meq
bicarbonate per liter per day. Replacement of this amount of
bicarbonate is relatively easy and can be in the form of intra-
venous sodium bicarbonate, orally administered sodium or
potassium citrate, or as acetate in hyperalimentation solu-
tion (1 meq acetate converts to 1 meq bicarbonate plus some
energy). The patient’s tolerance for the associated sodium
and potassium load should be considered.
Patients with prolonged uremia may present with a sub-
stantial buffer deficit (serum bicarbonate <15 meq/L),
Kussmaul respirations, and associated hypocalcemia. In this
situation, bicarbonate replacement relieves the dyspnea by
correction of acidosis, but the rapid increase in serum pH
may precipitate tetany. Under these conditions, after deter-
mination of serum calcium and phosphate, it may be pru-
dent to administer 1 ampule of calcium gluconate after the
first 50–100 meq of bicarbonate. However, if phosphate lev-
els are particularly elevated, there is a theoretical risk of
metastatic calcifications with calcium administration.
Lactic acidosis is potentially a more difficult problem. In
the presence of insufficient tissue oxygenation, lactic acid
production can exceed 50 meq/h. This amount of acid low-
ers serum bicarbonate at a rate of 1–2 meq/L per hour. In the
face of oliguria, replacement of this amount of bicarbonate
would risk intravascular fluid overload and hypernatremia
and may require dialytic therapy. Therefore, in lactic acido-
sis, an aggressive effort to restore adequate tissue perfusion is
the mainstay of treatment.
Metabolic alkalosis is an uncommon complication of
acute renal failure, but it may occur as a result of massive
losses from gastric suctioning. Decreasing net acid loss can
be achieved by raising gastric pH with H2 blockers such as
cimetidine or ranitidine or with proton pump inhibitors
such as omeprazole or lansoprazole. If these efforts fail, acid
can be given carefully as arginine hydrochloride or dilute
hydrochloric acid. These treatments can produce severe life-
threatening hyperkalemia and must be given with vigilant
monitoring of potassium levels.
 Electrolytes
Sodium
Sodium balance in acute renal failure is maintained by eval-
uation and matching of sodium losses. Urinary losses are
best measured with 24-hour collections but can be reason-
ably assessed by random sampling and multiplication of
sodium concentration by the day’s total urine volume. After
diuretic administration, urinary sodium will be increased for
several hours and may not reflect a constant excretion rate.
GI losses must be either measured (eg, nasogastric suction)
or estimated (eg, diarrhea)(Table 13–10).
In oliguric renal failure, hyponatremia is the most com-
mon electrolyte abnormality and is almost always the result
of excessive free water administration. Since most fluid losses
are lower in sodium when compared with serum (see Table
13–10), a reasonable initial approach is to add 50 meq
sodium to each liter of infused fluid, most notably the hyper-
alimentation fluid. Daily monitoring of serum sodium
allows for readjustment of water and sodium administered as
necessary.
Potassium
Hyperkalemia is the most serious electrolyte abnormality
associated with acute renal failure. Cardiotoxicity, however,
does not correlate strictly with the measured serum potas-
sium and may be encouraged by acidosis, serum calcium
concentration, and medications. The most rapid and reliable
means for assessing cardiotoxicity is to obtain an ECG, which
may show hyperkalemia in the form of peaked T waves, a
prolonged PR interval, diminished to absent P waves, widen-
ing of the QRS complex, prolongation of the QT interval,
Sodium Content of Intravenous Sodium Content of 
Infusion Fluids Body Fluids 
1 g Na+ = 43 meq Na+ Gastric fluid = 30–90 meq 
1 g NaCl = 17 meq Na+ Na+ per liter 
1 L of 0.9% NaCl =  Diarrhea = 50–110 meq 
154 meq Na+ Na+ per liter 
1 L of 0.45% NaCl =  Small bowel ostomy = 70–150
77 meq Na+ meq Na+ per liter 
1 L of Ringer’s lactate = Biliary drainage = 120–170 meq 
130 meq Na+ Na+ per liter 
50 mL of 7.5% NaHCO3 = Sweat = 20–100 meq Na
+ per liter 
44 meq Na+
Table 13–10. Sodium content: intake and output.
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and ultimately, a sine wave pattern. Immediate management
requires medications designed to stabilize the myocardial
membrane and promote intracellular movement of potas-
sium. Infusion of calcium, bicarbonate, and insulin with glu-
cose temporarily improves the electrocardiographic
abnormalities. Definitive procedures for removing potas-
sium should be initiated as soon as possible.
In oliguric patients unresponsive to diuretic therapy,
exchange resins of sodium polystyrene sulfonate are the most
efficient means of extracorporeal potassium removal.
Administration can be either orally or by retention enema
for at least 30 minutes (orally: 50 g resin in 150 mL 20% sor-
bitol; by enema: 50 g resin in 200 mL tap water to avoid
sorbitol-induced colonic irritation). These doses can be
repeated every hour as necessary. Each potassium ion
removed will be exchanged for a sodium ion—a situation
that may be poorly tolerated in the hypernatremic or fluid-
overloaded patient. In addition, to avoid the possibility of
forming intraluminal concretions, sodium polystyrene sul-
fonate never should be given concurrently with aluminum
hydroxide (used as a phosphate binder or antacid). When
these measures are poorly tolerated because of fluid overload
or hypernatremia—or when the GI tract is not available for
use—dialytic therapy should be considered.
Maintaining potassium balance requires evaluation of
renal and extrarenal losses (Table 13–11). A normal diet con-
tains approximately 70–100 meq potassium per day, and
dietary potassium restriction to 2 g (50 meq) per day is rea-
sonable for patients with oliguric renal failure.
Calcium
Hypocalcemia often accompanies chronic renal failure and is
the result of hyperphosphatemia and altered vitamin D
metabolism. In acute renal failure, hypocalcemia may be
associated with the hyperphosphatemic phase of rhabdomy-
olysis or may occur during administration of the antiviral
agent foscarnet. Hypercalcemia is seen in multiple myeloma
or hyperparathyroidism. Urinary calcium losses are minimal
during acute renal failure. Frank tetany is rare and is usually
the result of overly aggressive correction of acidosis. Since
hypoalbuminemia and acid-base disturbances are common
in the critically ill patient, ionized calcium levels, when avail-
able, are preferred to total serum calcium.
Magnesium
Magnesium excretion is limited during renal failure, and
magnesium-containing antacids such as Maalox and
Mylanta should be avoided. Magnesium wasting may
occur with amphotericin- or cisplatin-induced renal fail-
ure or during the polyuric recuperative phase of acute
tubular necrosis.
Phosphate
Hyperphosphatemia results from insufficient renal excretion
and secondary hyperparathyroidism. Avoiding hyperphos-
phatemia limits the risk of metastatic calcifications and helps
to maintain normal levels of ionized calcium. Diets should
be limited to 800 mg/day of phosphorus, but even at this
level, oral phosphate binders are required to limit GI absorp-
tion. When serum phosphorus exceeds 6 mg/dL, aluminum
hydroxide antacid can be given at a dosage of 30 mL with
each meal and at night. Sevelamer at a dose of 800–1600 mg
with each meal also can be used as an effective phosphate
binder and has the advantage of not presenting the potential
for aluminum toxicity or the constipation associated with
aluminum hydroxide.
When levels are controlled below 6 mg/dL, calcium car-
bonate at  500 mg with each meal or calcium acetate at 667
mg with each meal can be initiated. Intravenous hyperali-
mentation should be prepared without phosphate until levels
are normalized. However, once normal phosphorus levels are
reached, intravenous hyperalimentation solutions should
contain approximately 100–250 mg phosphorus per day
(5–10 meq sodium or potassium phosphate). In the presence
of renal failure, hypophosphatemia is almost always the result
of prolonged parenteral nutrition devoid of phosphate.
 Nutrition
Nitrogen Balance
Several studies have suggested that appropriate nutritional
support can promote renal recovery and improve overall
survival in patients with acute renal failure. Unfortunately,
there is often conflict between giving adequate protein
replacement while at the same time limiting the production
of nitrogenous wastes. Under ideal conditions, an adequate
diet should include 1 g/kg per day of protein and 35–40
kcal/kg per day of carbohydrates and fats. There is no defin-
itive evidence that diets with substantially more than 1.2 g/kg
per day of protein enhance survival rates or reduce morbidity,
Table 13–11. Potassium content: intake and output.
Intake
2 g K+ in diet = 50 meq  
Output
Gastric fluid = 4–12 meq K+/L  
Abdominal drainage = approximately the serum level  
Diarrhea = 10–30 meq K+/L  
Sorbitol-induced diarrhea = 30–40 meq K+/L  
Sodium polystyrene sulfonate (Kayexalate) = 1 meq K+/g of retained
absorbent per hour  
Urine = 5–150 meq K+/L  
Peritoneal dialysis (2 L/h), CAVH (1 L/h) = 5–10 meq K+/h∗
Hemodialysis = 40–60 meq K+/h∗
∗Assuming serum [K+] = 5 meq/L.
Key: CAVH = continuous arteriovenous hemofiltration 
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with the possible exception of the patient with extensive
burns. Overly aggressive protein feeding (>2 g/kg per day) is
unwarranted and can lead to abnormally high amino acid
levels and an unnecessary increase in retained nitrogen
wastes. In the very stable patient with minimal net negative
nitrogen balance (<5 g/day), protein intake can be limited to
0.6 g/kg per day. In the nonoliguric patient, this may reduce
the need for dialysis, but careful attention to nitrogen bal-
ance is required.
Nitrogen balance can be evaluated easily by measuring
the rate of urea production, commonly referred to as the urea
nitrogen appearance (UNA). The daily UNA can be measured
by obtaining a 24-hour urine for urea nitrogen measurement
and evaluating the change in BUN occurring at the begin-
ning and end of the 24-hour collection. The UNA then can
be calculated using the following formula:
where UNA equals the daily urea nitrogen appearance in
grams per day, BUN1 and BUN2 are the levels of blood urea
nitrogen in milligrams per deciliter at the beginning and end
of the 24-hour urine collection, total body water in liters is
estimated as 60% of lean body mass plus the amount of any
extra edema fluid, and UUN is the urine urea nitrogen
expressed as grams per day.
Under conditions of nitrogen balance, UNA depends on
protein ingestion and can be calculated as follows:
It is assumed that every 6.25 g of protein contains 1 g of
nitrogen and that the production of nonurea nitrogen is
30 mg/day per kilogram of lean body mass. The minimum
amount of urea clearance required to remove a given amount
of UNA can be calculated using the following formula:
When the preceding formulas are used, a 70-kg patient
receiving 1 g/kg per day of protein will receive 11 g nitrogen
(70 g ÷ 6.25). On balance, approximately 2 g nitrogen will
become nitrogenous wastes other than urea; the remaining
9 g will form urea.
On the other hand, many patients with acute renal failure
present with a degree of hypercatabolism. Under these con-
ditions, urea production is greatly enhanced owing to the
catabolism of endogenous proteins, and UNA can greatly
exceed that predicted from exogenous protein administra-
tion alone. For example, under conditions of severe stress,
endogenous protein breakdown can generate 30 g or more of
urea nitrogen per day, representing the catabolism of approx-
imately 200 g protein. In addition to enhanced proteolysis
accompanying hypercatabolism, increased urea production
is often the result of GI bleeding, with the ultimate break-
down and absorption of the blood and its proteins. There are
approximately 200 g protein per liter of whole blood.
Treatment of endogenous hypercatabolism and the nega-
tive nitrogen balance that results is controversial. Although
adequate nutrition is essential, it is often not sufficient to
match the ongoing catabolism. Several studies have demon-
strated that increased protein catabolism associated with
stress is mediated by hormones (eg, glucagon, cate-
cholamines, and cortisol) and cytokines (eg, interleukins,
tumor necrosis factor, etc.). For this reason, overly aggressive
protein administration is not only futile but yields unneces-
sary amounts of nitrogenous waste, thereby increasing the
need for dialysis therapy. Until specific therapy for cytokine
neutralization is available, the most successful strategy will
be to administer the majority of needed calories in the form
of carbohydrates, thus allowing for the maximum adminis-
tration of “anticatabolic” insulin.
Calories
Adequate caloric intake is essential to minimize negative
nitrogen balance and to improve overall survival. In the crit-
ically ill patient with acute renal failure, approximately
35 kcal/kg per day is a reasonable goal. Hyperglycemia
resulting from administration of large amounts of carbohydrate
can be managed with insulin.
Vitamins and Trace Elements
There is no evidence that patients with acute renal failure
have unique requirements for either vitamins or trace ele-
ments. Thus daily minimum requirements should be ade-
quate. Once dialysis is initiated, replacement of water-soluble
vitamins should be assured. In most situations, a standard
multivitamin preparation suffices with the possible excep-
tion of folic acid, which should be replaced at a dosage of at
least 1 mg/day.
Fournier A et al: The crossover comparative trial of calcium acetate
versus sevelamer hydrochloride (Renagel) as phosphate binders
in dialysis patients. Am J Kidney Dis 2000;35:1248–50. [PMID:
10877727]
Strejc JM: Considerations in the nutritional management of
patients with acute renal failure. Hemodial Int 2005;9:135–42.
[PMID: 16191061]
Van den Berghe G et al: Outcome benefit of intensive insulin ther-
apy in the critically ill: Insulin dose versus glycemic control. Crit
Care Med 2003;31:359–66. [PMID: 12576937]
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DIALYTIC THERAPY FOR THE CRITICALLY
ILL PATIENT
Renal replacement therapy can provide homeostasis of fluid,
electrolyte, acid-base, and nitrogen balance. Consequently,
the initiation of renal replacement therapy should be consid-
ered whenever any of these factors cannot be controlled with
other therapy. At present, three types of renal replacement
treatment are available for the patient with acute renal fail-
ure: intermittent hemodialysis, peritoneal dialysis, and con-
tinuous renal replacement therapy (CRRT) (Table 13–12).
The particular therapy chosen is often dictated by the
patient’s condition (eg, massive fluid overload, hypercatabo-
lism, or vascular instability) and associated morbid states
(eg, respiratory compromise, hemorrhagic risks, or abdomi-
nal surgery). Aside from these needs, the patient’s baseline
requirements for fluid and solute removal depend on nutri-
tional intake and residual renal function.
Using conventional techniques, machine-driven
hemodialysis is best suited for the hemodynamically stable
patient in whom solute balance is the major concern and
rapid fluid removal is well tolerated. Peritoneal dialysis is pre-
ferred in the patient with significant hemorrhagic risk and in
whom vascular access is difficult to obtain. Continuous
hemofiltration and its related techniques are best for provid-
ing fluid removal in the patient with vascular instability or
massive fluid overload. Despite these generalizations, with
appropriate technical modifications, adequate renal replace-
ment therapy can be provided by any of these methods.
 Indications for Dialytic Therapy
Fluid Overload
Poorly tolerated volume overload is the most evident indica-
tion for initiating renal replacement therapy. In general, the
need to relieve pulmonary vascular congestion is the most
pressing issue. It should be noted that even massive amounts
of peripheral edema may be appropriate for the patient’s
condition (ie. hypoalbuminemia or vasodilatory shock), and
fluid removal may cause intravascular volume depletion,
hampering the return of endogenous renal function. When
hypotension is associated with edema and apparent pul-
monary congestion, pulmonary artery catheter monitoring
can be invaluable in determining the amount of fluid that
can be removed safely.
Time-Averaged 
Urea Clearance Protein Loss
Treatment Prescription mL/min L/day L/week g/day∗
Hemodialysis† 3 × 4 h/week
7 × 4 h/week 
14.3
33.3 
21
48 
144
336 
6
15 
Peritoneal dialysis 2 L/h 26.7 24 168 30 
CAPD 2 L/6 h‡ 6.9 10 70 10 
CAVH 14 L/day 9.7 14 98 15 
CAVHD 1–2 L/h 19–35 29–51 189–357 11 
CVVH 1–3 L/h 17–50 24–72 168–504 18–36 
CVVHD 1–3 L/h 19–52 27–75 189–525 18–36 
∗Includes amino acids and peptides. Published data have been adjusted to account for increased porosity of currently available dialyzers.
†Assumes average urea clearance of 200 mL/min.
‡Assumes 3 L/d net filtrate.
Key: CAPD = chronic ambulatory peritoneal dialysis
CAVH = continuous arteriorvenous hemofiltration
CAVHD = continuous arteriorvenous hemodialysis
CVVH = continuous venovenous hemofiltration
CVVHD = continuous venovenous hemodialysis/hemodiafiltration 
Modified from Kaplan AA: Dialysis and other extracorporeal therapy for acute renal failure. In: Current Therapy in Nephrology and
Hypertension, 4th ed. Glassock RJ (editor). Mosby, 1998. Copyright 1998 Elsevier.
Table 13–12. Renal replacement therapies: urea clearance and protein losses. 
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In the hemodynamically stable patient, intermittent
hemodialysis can provide the most rapid removal of fluid by
easily removing 1–2 L of fluid per hour by ultrafiltration. In
patients with vascular instability, one of the continuous ther-
apies is more appropriate because modest rates of fluid
removal can proceed steadily throughout the day. For exam-
ple, peritoneal dialysis can provide for the gentle removal of
the 2–3 L/day necessitated by intravenous medications and
hyperalimentation. Excessive net fluid removal (>5–10
L/day), however, may lead to hypernatremia because fluid
removed by peritoneal dialysis is hyponatric when compared
with plasma. In patients presenting with massive fluid over-
load, continuous hemofiltration offers the best-tolerated
treatment because the ultrafiltrate is isosmotic. A reasonable
combination of treatments would employ several days of con-
tinuous hemofiltration to achieve normovolemia, followed by
intermittent hemodialysis to provide maintenance therapy.
Electrolyte Abnormalities
Electrocardiographic changes caused by hyperkalemia
should be treated initially with nondialytic therapy (eg, cal-
cium, glucose, and insulin). The only renal replacement ther-
apy capable of rapid potassium removal is machine-driven
hemodialysis, providing clearance rates of 150–250 mL/min
or more (see Table 13–11). Neither continuous hemofiltra-
tion nor peritoneal dialysis can achieve potassium clearance
rates much above 20–40 mL/min, and both these continuous
therapies are best reserved for normalization of modest lev-
els of hyperkalemia or for maintaining potassium balance.
Toxic serum levels of calcium, magnesium, or phosphate
are also most rapidly corrected with machine-driven hemodial-
ysis. Once normal levels are achieved, any of the renal replace-
ment therapies can maintain homeostasis if nutritional intake
is limited and magnesium-containing phosphate binders are
avoided. Renal replacement therapies using dialysate (ie,
hemodialysis, peritoneal dialysis, or continuous hemodialysis)
may contain calcium concentrations of 3.5 meq/L (1.75 mmol/L
of ionized calcium) in the dialysate. Therefore, successful and
rapid treatment of hypercalcemia requires lower dialysate cal-
cium concentrations of 2.5 meq/L (1.25 mmol/L) or less.
Severe hypophosphatemia may complicate all renal replace-
ment therapies, especially in patients being maintained on
intravenous hyperalimentation devoid of phosphate.
Acid-Base Abnormalities
Uremic acidosis rarely generates more than 50–100 mmol
acid per day and can be easily corrected by any of the renal
replacement techniques. Severe uremic acidosis is encoun-
tered most often as a presenting abnormality of unattended
chronic renal failure. Under these conditions, hemodialysis
can provide the most rapid correction of acidosis, but aggres-
sive hemodialysis may precipitate a dysequilibrium syn-
drome. Despite associated hyperkalemia, the dialysate bath
composition should include at least 2 mmol/L potassium
because correction of acidosis causes a substantial lowering
of serum potassium concentration. Consideration also
should be given to a relatively low-calcium bath (2.5 meq/L)
because overly aggressive correction of long-standing
hypocalcemia may precipitate nausea, vomiting, muscle
cramping, and hypertension.
Lactic acid may be produced at rates of up to 50 mmol/h
and usually is associated with severe hemodynamic instabil-
ity. Although daily hemodialysis can provide adequate
replacement of lost bicarbonate, the patient may be left with
rapidly worsening acidosis during the interdialytic period.
Continuous hemofiltration can provide continuous correc-
tion of acidosis and may be best for managing the fluid over-
load often associated with shock and its treatment.
Replacement solutions containing 150 mmol/L bicarbonate
can provide as much as 100 mmol/h of continuous buffer
replacement, but required calcium replacement must be
administered in a separate solution. Peritoneal dialysis, with
exchanges at 2 L/h, can provide approximately 25 mmol
buffer per hour. Dialytic solutions containing lactate should
be avoided because conversion to bicarbonate may be slowed
in patients with circulatory impairment.
Uremia
Although urea is not universally accepted as a uremic toxin,
its levels are used most commonly to judge the degree of ure-
mic toxicity. Several studies suggest that maintaining predial-
ysis BUN at or below 120 mg/dL (43 mmol/L) is beneficial
for overall survival, and it is no longer acceptable to tolerate
excessively high urea levels prior to initiation of renal
replacement therapy. There is good or better evidence to sug-
gest that proper protein-calorie nutrition is also beneficial.
Thus it is inappropriate to withhold adequate nutrition in
order to avoid the associated increase in nitrogen and fluid
intake. On empirical grounds, when pericarditis,
encephalopathy, or hemorrhage is associated with BUN lev-
els above 100 mg/dL, it is hard to argue that such symptoms
are not at least partially the result of retained uremic toxins.
With the preceding considerations in mind, it is reasonable
to initiate renal replacement therapy when BUN is above
100 mg/dL (36 mmol/L). Nonetheless, if rapid return of
renal function is anticipated (eg, in the presence of prerenal
azotemia or obstructive uropathy), levels of 150 mg/dL
(54 mmol/L) or more may be tolerated for a limited period.
Specific indications for dialytic therapy for complications
of uremia include uremic encephalopathy, pericarditis, and
uremic platelet dysfunction. Slowed mentation, somnolence,
and convulsions are part of the uremic syndrome and are
usually associated with other neuromuscular manifestations,
including asterixis, myoclonus, and muscle twitching. In gen-
eral, these symptoms respond within several days after the
start of dialytic therapy.
Despite the existence of massive pericardial effusions,
patients with uremic pericarditis may present with hyper-
tension and pulmonary congestion. The treatment of ure-
mic pericarditis often presents two distinct problems:
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removal of fluid in the face of potentially compromised
hemodynamics and definitive treatment of the pericardial
inflammation. Initial rapid fluid removal with hemodialysis
may be well tolerated, but as volume removal proceeds,
intravascular pressures may become inadequate to maintain
intracardiac filling, and severe hypotension may result. Thus
normovolemia should be achieved with gentle fluid removal
and anticipation of rapid declines in blood pressure.
Although the toxins responsible for uremic pericarditis have
not been identified, it has been shown empirically that
aggressive solute removal can lead to resolution of pericardi-
tis. Hemodialysis performed five times weekly is recom-
mended, but means to limit anticoagulation should be
employed in order to minimize the risk of hemoperi-
cardium. In patients with large pericardial effusions, early
use of pericardiotomy may be recommended because
aggressive hemodialysis may be associated with a high mor-
tality rate. In one retrospective report, peritoneal dialysis
was found to be superior to hemodialysis in avoiding the
need for surgical drainage. Peritoneal dialysis also avoids the
risk of anticoagulation.
Uremic platelet dysfunction is identified most often with
prolongation of the bleeding time. In general, bleeding times
will normalize along with lowering of serum urea. Acutely,
rapid correction of platelet dysfunction can be achieved with
infusions of desmopressin at a single dose of 0.3 μg/kg.
 Drug Dosing During Renal Replacement
Therapy
Many renally excreted medications require dosage modifica-
tion to account for the amount removed by a given renal
replacement therapy. Unfortunately, most of the published
data are of questionable accuracy as a result of variability
between patients and the great differences in clearance rates
achievable with each technique. Four factors govern the
removability of a given drug: molecular weight, degree of
protein binding, volume of distribution, and endogenous
plasma clearance. In general, hemodialysis can offer the
most rapid clearance rates for a low-molecular-weight drug
(<500 kDa). Continuous hemofiltration—but not continu-
ous hemodialysis—will efficiently remove drugs with
molecular weights as high as 10,000 kDa or more. Peritoneal
dialysis will eliminate drugs in the range of MW 500–10,000
kDa. Highly protein-bound medications are not substan-
tially removed by any of the renal replacement techniques,
with the possible exception of peritoneal dialysis. In addi-
tion, modifications of the major techniques may profoundly
alter clearance rates because most of the published data were
obtained with more conventional methodology. For exam-
ple, it has been shown recently that the most modern “high
flux” dialyzers can offer substantial removal of relatively
high-molecular-weight drugs (>1500 kDa), thus greatly
changing their dosing requirements as compared with pre-
vious recommendations.
Aronoff GR et al: Drug Prescribing in Renal Failure: Dosing
Guidelines for Adults, 4th ed. New York: American College of
Physicians, 1999.
 Stopping Dialysis
Owing to the availability of chronic dialysis, irreversibility of
renal failure is not an acceptable indication for stopping
treatment. Instead, the patient’s wishes and overall clinical
status should be the only considerations in discontinuing
therapy. In general, withholding of dialysis may be consid-
ered when there is evidence of irreversible vital organ failure
or severe cerebral damage. Most forms of acute renal failure
reverse within 8 weeks. If renal failure persists beyond this
period, one should initiate plans for maintenance dialysis
therapy.
 Specific Types of Renal Replacement
Therapy in Acute Renal Failure
1. Hemodialysis
Intermittent hemodialysis is the most widely used technique
for acute renal failure. The method of treatment chosen
varies depending on the rate of generation of nitrogenous
wastes and the patient’s tolerance for fluid overload. In gen-
eral, 4-hour treatments performed three times weekly are
sufficient to provide adequate replacement in the oliguric or
anuric patient. Patients with significant residual renal func-
tion may require fewer treatments per week, especially if
renal failure is nonoliguric. Conversely, the patient with
severe hypercatabolism and poorly tolerated fluid overload
may require daily treatments.
The major advantage of hemodialysis is its highly effi-
cient solute removal, thus limiting treatment time and mak-
ing the patient available for other procedures and treatments.
Disadvantages include relatively rapid fluid removal, which
may be poorly tolerated. Other disadvantages of hemodialy-
sis involve the need for large-bore hemoaccess and anticoag-
ulation of the extracorporeal circuit.
Effectiveness of Hemodialysis
Solute clearance and ultrafiltration rates are variable depend-
ing on the blood flows obtained and the dialyzers chosen.
Most modern dialyzers provide 150–250 mL/min of urea
clearance with blood flows between 200 and 300 mL/min.
More rapid solute clearance can be obtained with the newer
more porous filters, especially when operated at blood flows
of up to 400 mL/min or more. Currently available dialyzers
also can produce between 1 and 3 L of ultrafiltrate per hour,
usually limited by the patient’s hemodynamic stability. A rel-
atively gentler type of hemodialysis involves the prolonga-
tion of the treatment in a low-efficiency mode. These slow,
low-efficiency dialysis (SLED) treatments are applied from
8–18 hours at a time and allow for less aggressive fluid
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removal. “High flux” dialyzers provide the most rapid solute
clearance, but their use requires dialysis equipment with vol-
umetric control of fluid removal.
In general, urea removal during hemodialysis follows
first-order kinetics and assumes that urea is distributed
throughout total body water. Under normal operating condi-
tions, a 4-hour dialysis will lower pretreatment urea levels by
approximately 50–70%. Factors that may decrease treatment
efficiency include inadequate blood flow to the dialyzer,
access recirculation, and dialyzer clotting.
Vascular Access
Efficient hemodialysis requires blood flows of at least
200–300 mL/min and a relatively large-bore vascular access.
In the acute setting, the most widely used method is the per-
cutaneous cannulation of either the femoral or subclavian
vein with double-lumen catheters. Regardless of placement
site, the use of double-lumen catheters may allow a certain
percentage of dialyzed blood leaving the efferent lumen to
reenter the afferent lumen. This process is known as recircu-
lation and may reach values of 50% or more, resulting in
extremely inefficient dialysis treatment.
Percutaneous placement of a double-lumen catheter in
the femoral vein is the most widely used method for achiev-
ing rapid access for hemodialysis. Extensive experience has
shown this method to be safe and well tolerated despite the
necessity for repeated punctures. A disadvantage is that the
catheter limits the patient’s mobility, and an unresolved issue
is the length of time a single catheter can be left in place
safely. Ideally, the catheter should be removed after every
procedure; however, this is often impractical or impossible.
In any event, prolonged catheter placement should be
avoided. When alternative access sites are unavailable,
catheters may be replaced over a guidewire, and the removed
catheter tip sent for culture. Careful attention to sterile tech-
nique during placement and meticulous care of the access
site are essential. The most serious complications of femoral
vein access are retroperitoneal hemorrhage and pulmonary
embolism. Retroperitoneal hemorrhage may result from iliac
vein rupture and has been associated with difficult guidewire
placement. Pulmonary emboli are the result of catheter-
related thrombi and are most apt to occur with catheters left
in situ for prolonged periods. Other complications include
hematomas, thrombophlebitis, arteriovenous fistulas, sepsis,
and access-site infection.
Subclavian vein access allows for unhindered patient
mobility, and catheters in the subclavian vein have been left
in place safely for prolonged periods. The major disadvan-
tage is the increased risk of life-threatening complications
during placement. Radiologic evaluation for catheter place-
ment is required prior to the first treatment. Sharp angula-
tions of the distal catheter tip necessitate catheter
repositioning to avoid vessel rupture. Massive hemothorax
and pericardial tamponade are among the most serious com-
plications. These complications can occur even after previously
successful treatments. Cardiac arrhythmias, throm-
bophlebitis, sepsis, air embolism, pneumothorax, and access-
site infection are other complications. It has been
demonstrated that prolonged cannulation can lead to signif-
icant subclavian vein stenosis, thus rendering the ipsilateral
arm incapable of supporting subsequent permanent hemo-
access. Given this risk, use of this access site is to be avoided
in patients for whom there is a high probability of perma-
nent renal failure (eg, diabetic patients with preexisting renal
dysfunction suffering from subsequent acute renal injury).
The right internal jugular vein offers an alternative to
subclavian cannulation. A potential advantage of this
method is that the catheter’s route is relatively straight, thus
avoiding the sharp angulations associated with the subcla-
vian route. Nonetheless, retrograde cannulation of the sub-
clavian vein is possible, and radiologic evaluation of
placement is required. A drawback to this technique is the
relatively awkward placement and the difficulty of access-site
care. “Tunneled” access to the internal jugular is becoming
more popular and allows for much easier access-site care.
Anticoagulation
The need for anticoagulation can be the most significant dis-
advantage associated with hemodialysis. Several methods
have been proposed for reducing hemorrhagic risks.
Regional heparinization is performed by infusing heparin
into the blood before it reaches the filter with continuous
neutralization with protamine into the blood after the filter,
but this procedure has fallen out of favor because of the
“heparin rebound” effect, which may appear up to 10 hours
after treatment.
Low-dose heparin (10–20 units/kg per hour) and bedside
monitoring of coagulation status have been shown to be
superior to regional heparinization in controlling hemor-
rhagic risks. Low-molecular-weight heparin has been pro-
posed because of its limited effect on platelet function.
Unfortunately, these low-molecular-weight fragments have a
prolonged half-life (18 hours) and are not neutralized by
protamine.
Citrate anticoagulation has been used successfully but
requires careful attention to dialysate calcium concentration
and may require substantial amounts of sodium and fluid
infusions.
Because of their short half-life, prostacyclin and its deriv-
atives have been used. Although employed successfully in sta-
ble patients, prostacyclin may be inappropriate for the
critically ill. Aside from a considerable list of potentially
troublesome secondary effects, including flushing, nausea,
headache, and abdominal pain, the antiplatelet action of
prostacyclin is still demonstrable up to 2 hours after cessa-
tion of infusion, and there is no known method for reversing
the effect.
An increasingly popular approach is to completely avoid
anticoagulation by using high blood flows and frequent
saline flushes of the filter (200 mL every 20 minutes). The
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new, more porous dialyzers have ultrafiltration capabilities
that will easily remove the excess fluid administered.
Complications
Although hemodialysis is performed by specially trained
nursing personnel and is directed by a nephrologist, compli-
cations may occur in the ICU setting when the intensivist is
the first physician to evaluate the situation. During treat-
ment, the most commonly encountered complication is
hypotension. Other complications include cardiac arrhyth-
mias, hypoxemia, hemorrhage, air embolism, pyrogenic reac-
tions, and dysequilibrium syndromes.
A. Hypotension—Poorly tolerated fluid removal is the most
obvious cause of hypotension, but several more subtle mech-
anisms may play a role in some patients. Relative intolerance
to acetate can cause hypotension, and bicarbonate-based
dialysates are now used commonly for any patient in whom
vascular instability is considered a potential difficulty. The
relative bioincompatibility of cuprophane- and cellulose-
based membranes can, in rare cases, cause enhanced activa-
tion of complement and the acute onset of severe respiratory
distress and hypotension resistant to volume replacement.
This constellation of symptoms has been called the first-use
syndrome and has been managed with intravenous amino-
phylline or subcutaneous epinephrine. Once a patient’s sus-
ceptibility is established, the syndrome will occur at the
initiation of every treatment with an unused dialyzer, usually
within 15–20 minutes. Definitive management consists of
switching to a more biocompatible membrane.
More recently, a similar anaphylactoid type syndrome has
been described involving the use of polyacrylonitrile dialyzers
(AN-69) in patients treated with angiotensin-converting
enzyme (ACE) inhibitors. Regardless of the cause, sympto-
matic hypotension during dialysis should be treated initially by
lowering the transmembrane pressure, decreasing blood flow,
evaluating for cardiogenic causes, and administering normal
saline, albumin, or hypertonic glucose. If significant wheezing
is present, the first-use syndrome should be suspected.
B. Cardiac Arrhythmias—Several abnormalities increase
the risk of cardiac arrhythmias during dialysis. Of these, the
best-established is digitalis toxicity initiated by the rapid low-
ering of serum potassium levels. Many dialysate baths con-
tain 2 mmol/L of potassium or less; dialysate baths
containing 3.5 mmol/L of potassium have been shown to
reduce the risk of digitalis toxicity. Other causes of arrhyth-
mias include abnormalities of magnesium or calcium,
hypoxia, pericarditis, myocardial infarction, acetate toxicity,
and complications of subclavian catheterization.
C. Hypoxemia—The hemodialysis procedure can induce
hypoxemia by at least two mechanisms. The more benign of
these involves the loss of CO2 through the dialyzer with sub-
sequent decrease in respiratory drive. This complication
occurs with acetate-buffered dialysate solutions, which are
currently being replaced with bicarbonate-based solutions.
When this type of hypoxia does occur, it can be managed eas-
ily with supplemental oxygen. A more ominous cause
involves the first-use syndrome (see above), with rapid acti-
vation of complement leading to leukoagglutination in the
lung and severe bronchospasm. This presentation calls for
termination of treatment and the potential need for amino-
phylline or epinephrine. Subsequent treatments must be per-
formed with a more biocompatible membrane.
D. Hemorrhage—If serious hemorrhage occurs during dial-
ysis, previously administered heparin should be neutralized
with protamine. A rational starting dose would be 1 mg pro-
tamine for every 100 units heparin administered. If possible,
protamine infusions should be limited to no more than 15
mg over 5 minutes to minimize the risk of anaphylactoid
reactions. There is considerable individual variation in prot-
amine requirements, and normalization of the partial
thromboplastin time should be sought. There is also the pos-
sibility of a “heparin rebound” effect occurring up to 10
hours after successful neutralization.
E. Dialysis Dysequilibrium—This syndrome of headache,
nausea, muscle irritability, obtundation, and delirium or
seizures may be associated with rapid correction of severe
uremia. To decrease the risk, short, gentle treatments (blood
flows <200 mL/min) should be prescribed until BUN levels
approach 100 mg/dL (36 mmol/L).
Beathard GA: Catheter management protocol for catheter-related
bacteremia prophylaxis. Semin Dial 2003;16:403–5. [PMID:
12969396]
Brunet P et al: Anaphylactoid reactions during hemodialysis and
hemofiltration: Role of associating AN69 membrane and
angiotensin I converting enzyme inhibitors. Am J Kidney Dis
1992;19:444–7. [PMID: 1585932]
Deshpande KS et al: The incidence of infectious complications of
central venous catheters at the subclavian, internal jugular, and
femoral sites in an intensive care unit population. Crit Care
Med 2005;33:13–20. [PMID: 15644643]
Marshall MR et al: Sustained low-efficiency daily diafiltration
(SLEDD-f) for critically ill patients requiring renal replacement
therapy: Toward an adequate therapy. Nephrol Dial Transplant
2004;19:877–84. [PMID: 15031344]
2. Peritoneal Dialysis
Peritoneal dialysis offers the best method of renal replace-
ment for the patient in whom it is difficult or impossible to
obtain adequate hemoaccess. In contrast, patients with
recent abdominal surgery may be poor candidates owing
to the risks of abdominal wound dehiscence and infection
of recently implanted vascular grafts. In patients with pre-
vious abdominal surgery, intraperitoneal adhesions may
limit dialysate distribution, thus causing decreased ultra-
filtration and decreased solute removal. A major advan-
tage of this technique is that no anticoagulation is
required. Disadvantages include substantial protein loss
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(see Table 13–12), risks of peritonitis, drainage difficulties,
compromised pulmonary function owing to elevated
diaphragms, hydrothorax, glucose and electrolyte abnormal-
ities, and a relatively immobile patient.
Capabilities
Solute removal with this technique depends mostly on
dialysate volume and how long the dialysate is allowed to stay
in the peritoneal space before drainage (dwell time). A rea-
sonably aggressive schedule incorporates 2-L exchanges every
2 hours. Assuming a 50% equilibration between serum and
dialysate urea levels during a 2-hour dwell time, this schedule
provides 12 L of urea clearance per day. A more modest
schedule would be similar to that of chronic ambulatory peri-
toneal dialysis (CAPD), with 2-L exchanges every 4–6 hours.
Assuming a 100% equilibration of urea after a 6-hour dwell
time, four 2-L exchanges yield 8 L of urea clearance per day.
Associated net filtration of approximately 2 L/day will add to
these predicted values. Peritonitis hastens equilibration
between serum and dialysate, thus yielding greater solute
clearance during the more rapid exchange schedules.
Fluid removal depends directly on the concentration of
glucose in the dialysate and the dwell times allowed. With
1.5% dextrose solution, a 2-L exchange performed every
hour can extract 100–200 mL of fluid. A 4.25% solution pro-
vides 500 mL of filtrate per hour. Prolonging dwell times
decreases net filtration rate because of an increasing equili-
bration of dialysate glucose with serum levels, thus decreas-
ing the osmotic drive for fluid removal. The onset of
peritonitis markedly limits ultrafiltration because of rapid
absorption of dialysate glucose.
Access
There are two widely used methods for obtaining access to
the peritoneal cavity. Bedside placement of a stiff Teflon
catheter is the most rapid means of access. Complications
include bowel perforation, bladder perforation, pericatheter
leakage, hemorrhage, and infection. Foley catheter placement
to ensure bladder decompression prior to insertion is
strongly recommended. A major drawback is that the patient
must be bedridden, and drainage problems are not uncom-
mon. Patients with previous abdominal surgery may have
adhesions of bowel to the abdominal wall, thus increasing
the risk of perforation. Bowel perforation sometimes may
be managed successfully by repositioning the catheter and
initiating empirical antibiotic therapy in the dialysate
(Table 13–13). Abdominal wall infection should be consid-
ered a contraindication to catheter placement.
The surgical placement of a pliable Silastic catheter
(Tenckhoff type) is the safest method of obtaining access.
Drawbacks are catheter malposition, abdominal pain, and
delays in catheter placement. When initiating treatment,
low-volume exchanges may limit the risk of suture-line
dehiscence.
Complications
The most common complication of peritoneal dialysis is fail-
ure to drain or insufficient drainage. Identification of the
cause often can be aided by determining if the ability to
infuse fluid through the catheter is maintained. If fluid infu-
sion is obstructed, the catheter may suffer from intrinsic
blockage, and an attempt at declotting may be appropriate
with saline flushes or thrombolysis with urokinase or tissue
plasminogen activator. If declotting is impossible, catheter
replacement is necessary. A catheter that allows unimpeded
fluid infusion but not outflow may be malpositioned or may
be suffering from a “ball valve” effect caused by omentum
wrapped around its pores. Initial management of this prob-
lem consists of having the patient move from side to side or
be placed in the Trendelenburg position. On occasion, an
enema may yield dramatic results. If these initial efforts fail,
catheter position must be determined by radiographic tech-
nique and repositioned, either with an intracatheter
guidewire or by surgical revision.
Organism Initial Dose (per 2 L) Maintenance Dose (per 2 L)∗
Staphylococcus epidermidis Vancomycin 1 g 
Cefazolin 1 g 
1 g every 5 days × 3 
500 mg per exchange x 14 days 
Staphylococcus aureus Vancomycin 1 g 1 g every 5 days × 3 
Escherichia coli Ampicillin 500 mg 100 mg per exchange × 14 days 
Pseudomonas aeruginosa Gentamicin 70–100 mg 15 mg per exchange × 14 days 
∗Dosing appropriate for four exchanges per day.
Modified from Holley JL, Piraino BM: Complications of peritoneal dialysis: Diagnosis and management. Semin
Dialysis 1990;3:245–48, with permission from Blackwell Publishing.
Table 13–13. Intraperitoneal doses of antibiotics for dialysis-related peritonitis. 
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Peritonitis arises most often from contamination during
bag exchanges, although intraperitoneal contamination also
can occur as a result of intraabdominal disease. Clinical signs
of peritonitis include abdominal pain, nausea, cloudy dialysate
effluent, and loss of ultrafiltration (decreased fluid output per
exchange). As opposed to spontaneously occurring peritonitis,
peritoneal infection in the context of peritoneal dialysis may
be managed successfully with intraperitoneal antibiotics (see
Table 13–13). A reasonable diagnostic plan would include
evaluation of white blood cell count in the effluent (with peri-
tonitis, >100 granulocytes/μL) and Gram staining and empir-
ical treatment until the results of culture of the effluent
are reported. Common antibiotic regimens are listed in
Table 13–13. Treatment should be continued for at least 10 days.
Fungal peritonitis most often requires removal of the catheter
and is best treated with cessation of peritoneal dialysis.
In the immediate period after catheter placement, the
dialysate effluent can be blood-tinged. The intraperitoneal
administration of heparin (500–1000 units per 2-L bag) may
limit the formation of fibrin clots but is unlikely to cause sys-
temic anticoagulation. Open drainage systems are associated
with a high rate of peritonitis, and a closed system, with bag-
to-bag connections similar to those used in chronic ambula-
tory peritoneal dialysis, is preferred. Spent dialysate should
be monitored daily for cell count. If granulocyte counts
begin to increase above 100/μL, empirical antibiotic therapy
should be initiated pending culture results. Massive protein
losses are associated with peritonitis but also may occur
without infection (see Table 13–12). These losses should be
measured, and protein intake should be adjusted upward.
Substantial glucose absorption can lead to hyperglycemia
and can be controlled with intraperitoneal insulin. A reason-
able starting dose would be 5–10 units per 2-L dialysate bag.
Goldberg L et al: Initial treatment of peritoneal dialysis peritonitis
without vancomycin with a once-daily cefazolin-based regimen.
Am J Kidney Dis 2001;37:49–55. [PMID: 11136167]
Piraino B et al: ISPD Ad Hoc Advisory Committee: Peritoneal
dialysis-related infections recommendations—2005 update.
Perit Dial Int 2005;25:107–31. [PMID: 15796137]
Gokal R. Dialysis techniques: Peritoneal dialysis. In: Hörl WH et al
(eds), Replacement of Renal Function by Dialysis, 5th ed. Berlin:
Springer, 2004.
3. Continuous Renal Replacement Therapy
(CRRT)
The term continuous renal replacement therapy (CRRT ) has
been applied to a wide array of extracorporeal techniques for
supporting the critically ill patient with acute renal failure.
Originally proposed as a simple method of filtration pow-
ered by arteriovenous circuits and known as continuous arte-
riovenous hemofiltration (CAVH), filtrate outputs provided
by a patient’s unstable blood pressure were found to be inad-
equate for removing the large amounts of nitrogenous wastes
associated with the hypercatabolic patient. In an attempt to
deal with this inadequacy, several technical modifications
have been developed to enhance the efficiency of the treat-
ment. These include the addition of a diffusive component to
solute removal, known as continuous arteriovenous hemodial-
ysis (CAVHD), and the development of specialized machines
for providing continuous pumped filtration—allowing for a
new set of extremely efficient techniques that do not require
arterial access and that no longer depend on the variability of
the patient’s changing blood pressure—continuous venove-
nous hemofiltration (CVVH), continuous venovenous
hemodialysis (CVVHD), and continuous venovenous
hemodiafiltration (CVVHDF).
The continuous therapies have several potential advan-
tages over intermittent dialytic techniques. The most obvious
is that the treatment is continuous, allowing for a constant
readjustment of fluid and electrolyte therapy and the admin-
istration of large amounts of parenteral nutrition without
the risk of interdialytic volume overload. Second among the
advantages—at least for the hemofiltration-based treatments
(ie, CAVH and CVVH)—is its convective mode of solute
transport, known to increase middle-molecule clearance
compared with diffusion-based dialytic techniques. When
compared with peritoneal dialysis, CRRT is not contraindi-
cated in patients with prior abdominal surgery and offers
isovolumetric fluid removal without the risk of peritonitis.
The major drawbacks are the need for continuous anticoag-
ulation and that the patient must remain bedridden during
the treatment.
Issues that arise when considering the application of
CRRT include the amount of solute clearance required, the
type of replacement fluid or dialysate to administer, the type
of anticoagulation to be employed, the amount of nutrition
to be infused, the amount of nutrients lost in the filtrate or
dialysate, and the impact of the treatment on drug dosing,
and the complications likely to be encountered. Each of these
issues may have a substantial impact on outcome. For exam-
ple, a recent study demonstrated that patients receiving fil-
tration rates of 35 mL/kg per hour (approximately 2.5 L/h)
had a significantly increased survival when compared with
patients receiving filtration rates of 20 mL/kg per hour
(approximately 1 L/h). One also must consider who is going
to monitor the treatment and how these personnel are
trained.
The following techniques for continuous renal replace-
ment therapy are available. Each technique has advantages
and disadvantages, and some are more practical or effec-
tive in patients with hypotension, those requiring large
volume of fluid removal, or those needing dialysis as well as
ultrafiltration.
Continuous Arteriovenous Hemofiltration (CAVH)
The standard CAVH circuit allows blood to flow from an
arterial access through a tubing circuit to a low-resistance
hemofilter and back to a venous access. Filtrate, which is rel-
atively protein-free, is produced at a rate of several hundred
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milliliters per hour and is collected into a bag connected to
the ultrafiltrate port of the filter. In the postdilution mode,
the replacement fluid is infused into the venous tubing.
Continuous anticoagulation is administered through a pre-
filter tubing connection.
Management of the circuit and maintenance of its
patency are subject to a variety of procedural choices such as
how often to rinse the system with saline, how often to
change the filters and tubing, and how to achieve hemoac-
cess. These issues often depend on the clinical setting and
the type of system components being employed. Owing to
the need for arterial access and the inconsistent output pro-
vided by blood pressure-driven filtration, the popularity of
CAVH has decreased, and this arteriovenous method is
being replaced with blood pump-driven venovenous sys-
tems (see below).
Slow Continuous Ultrafiltration (SCUF)
Blood pressure-driven filtration is a means of providing con-
tinuous isoosmotic fluid removal for aid in the management
of oliguric patients. The circuit is similar to that of CAVH,
but no replacement fluid is administered. Although insuffi-
cient for adequate solute removal, this technique has been
found useful as a means of maintaining fluid balance in
patients intolerant of aggressive fluid removal and in those
with cardiodynamic instability such as may be seen during
aortic balloon pumping or during open-heart surgery.
Continuous Arteriovenous Hemodialysis
and Hemodiafiltration (CAVHD)
The circuit is essentially the same as that for CAVH but
with the addition of a constant infusion of dialysate pass-
ing through the filtrate compartment of the filter. At the
relatively slow blood flow rates encountered with an arte-
riovenous circuit, complete blood to dialysate equilibrium
of urea is achieved, and clearance rates increase linearly
with dialysate flow rates of up to 33.3 mL/min (2 L/h).
Further increases in dialysate flow up to 4 L/h can yield
urea clearances approaching 50 mL/min. In most clinical
situations, the dialysate flow rate is set at 1 L/h, resulting
in 17 mL/min of urea clearance by diffusion. The major
advantage of this system is the enhanced solute clearance,
which has allowed the technique to be applied to certain
intoxications.
An interesting issue common to all the diffusion-based
CRRT techniques (ie, CAVHD and CVVHD) is the amount
of backfiltration that can occur. About 60% of the dialysates
glucose is absorbed through the membrane. At the common
flow rate of 1 L/h, a standard 1.5% dextrose-containing
dialysate (such as is commonly used for peritoneal dialysis)
produces a net glucose transfer averaging 120 mg/min
(175 g/day), whereas a 4.25% solution yields approximately
415 mg/min (600 g/day). This amount of carbohydrate must
be accounted for when considering the patient’s nutritional
and insulin requirements.
Continuos Venovenous Hemofiltration (CVVH)
This circuit requires a blood pump and an air detector and is
often equipped with arterial and venous pressure monitors.
Equipment especially designed for this treatment is available.
This technique has the clear advantage of avoiding the poten-
tial complications of arterial access and is capable of provid-
ing a substantial amount of convection-based clearance.
Common output rates are between 1 and 2 L/h, replaced
with the appropriate replacement solution. Blood flow rates
between 100 and 150 mL/min allow for a decreased tendency
of filter clotting and limit the dosage requirements for anti-
coagulants.
Continuous Venovenous Hemodialysis
or Hemodiafiltration (CVVHD/F)
The addition of a diffusive component to the CVVH system
allows for the maximum clearance capabilities of any of the
continuous therapies. The basic circuit resembles that of
CVVH but allows a variable amount of dialysate to flow past
the filtrate compartment of the filter as with CAVHD. The
machines used are similar to those employed for CVVH.
Hemoaccess
The blood pressure-driven treatments (ie, CAVH and
CAVHD) require large-bore arterial and venous access. The
most widely used is the combined cannulation of the femoral
artery and vein. Hemoaccess for pump-driven continuous
therapies (ie, CVVH and CVVHD) does not require arterial
catheterization and uses the same access as for machine-
driven hemodialysis (see above).
Femoral artery and femoral vein cannulation is the most
widely used method for obtaining an arteriovenous circuit.
Adequate blood flows are best obtained with large-bore
catheters (0.3-cm luminal diameter) with minimal taper and
no sideholes. Standard hemodialysis catheters are often inad-
equate. Despite the apparent risk of arterial cannulation, the
reported complication rate is low. The successful use of these
catheters may be due to the common practice of restricting
their insertion to the well-trained, experienced operator.
Furthermore, access-site care is enhanced because of the con-
stant monitoring of the filter circuit. Potential complications
include retroperitoneal hemorrhage, vascular occlusion, sep-
sis, access-site infection, and hematomas.
Anticoagulation
The need for continuous anticoagulation is a major draw-
back to all methods of continuous therapy and has led to a
high incidence of hemorrhagic complications. It may be
helpful to use regional heparinization with the slow continu-
ous postfilter infusion of protamine. Starting dosage is usu-
ally 10 units/kg per hour of heparin, with a neutralizing dose
of protamine initially at 1 mg/h for every 100 units/h of
heparin. Dosages should be adjusted to provide partial throm-
boplastin times of 150 seconds or more in the postheparin
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circuit and approximately 50 seconds in the postprotamine
circuit. After establishing required dosing, the partial throm-
boplastin time should be monitored three times daily to
determine the need for further adjustments. In a patient with
a severe preexisting coagulopathy, reasonable filter life may
be achievable without any anticoagulation. The prefilter
infusion of replacement fluid also may help to prolong filter
life. Varying protocols for citrate anticoagulation have been
proposed. These techniques have been shown to provide suffi-
cient and safe anticoagulation, but alkalemia, hypernatremia,
and the risk of systemic hypocalcemia must be addressed for
each of the different protocols. Both prostacyclin and
low-molecular-weight heparin have been tried, but their use
retains the same drawbacks noted for hemodialysis—
notably, prolonged duration of action with no method for
rapid neutralization.
Predilution
The infusion of replacement fluid into the prefilter tubing
segment of the circuit dilutes the intraplasmatic urea concen-
tration and promotes the transfer of intraerythrocytic urea
into the plasma compartment, where it is available for
removal in the filtrate. The predilution technique also limits
the hemoconcentration that occurs at the venous side of the
hemofilter. The potential advantages of the predilution mode
include enhanced urea clearance and the possibility of
increasing filter patency by the prefilter dilution of hemat-
ocrit, clotting factors, and platelets. Disadvantages include the
increased cost of replacement fluid and inability to estimate
plasma electrolyte concentrations from analysis of the filtrate.
Replacement Fluids and Dialysate
All hemofiltration-based techniques (ie, CAVH and CVVH)
require large volumes of sterile, pyrogen-free replacement
fluid. A physiologic and relatively inexpensive formulation
consists of two easily prepared solutions given in alternating
fashion. The first solution is prepared by adding one 10-mL
ampule of 10% calcium gluconate to 1 L of 0.9% NaCl. The
second solution is prepared by adding 50 meq sodium bicar-
bonate to 1 L of 0.45% NaCl. When these two solutions are
given alternately, the net result is an electrolyte solution con-
taining sodium 141 meq/L, chloride 101 meq/L, bicarbonate
25 meq/L, and calcium 4 meq/L. Diffusion-based treatments
(ie, CAVHD and CVVHD) require dialysate solutions with
adequate buffering capacity. Common practice has been to
employ peritoneal dialysis solutions, but several premixed
solutions are now being marketed.
Careful attention to fluid balance is essential and can be
aided by connecting the filtrate output to a volumetric pump
or a balancing scale designed to match inputs and outputs.
Regardless of the CRRT technique employed, volume out-
puts and inputs can easily attain 25–50 L/day or more. Thus
even small percentage errors in fluid balance can lead to sub-
stantial changes in the patient’s volume status. Evaluation
with daily weights is essential.
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CRITICAL ILLNESS IN PATIENTS WITH CHRONIC
RENAL FAILURE
Patients receiving maintenance dialysis often require treat-
ment in the ICU. Cardiac disease, GI hemorrhage, and infec-
tions are the most common comorbid conditions. Standard
treatment options often must be modified for dialysis
patients. Unresponsiveness to standard diuretic regimens
means that fluid removal for pulmonary edema or severe
hypertension calls for ultrafiltration by dialytic means. For
upper GI hemorrhage, magnesium-containing antacids are
best avoided, and H2 blockers may require dosage adjust-
ments. Antibiotic treatment actually may be facilitated in
that antibiotics normally cleared by the kidney may have
more prolonged therapeutic levels, and the nephrotoxicity
of certain medications is no longer a major consideration.
In general, however, management of the patient on dialysis
is similar to that of the patient with acute renal failure, with the
exception of several special considerations as outlined below.
 Nutrition & Fluids
Fluid and Electrolyte Restrictions
Normal fluid restriction for a patient receiving maintenance
hemodialysis (three times weekly) often depends on the
patient’s tolerance for aggressive fluid removal during each
treatment. In general, fluid restriction should be 1–1.5 L/day
and is dictated by the patient’s tendency to develop hyperten-
sion or pulmonary congestion in the interdialysis period. A
certain degree of pedal edema is tolerated as long as hyper-
tension or pulmonary congestion is not present. A patient
maintained on chronic ambulatory peritoneal dialysis often
can tolerate a more liberal fluid restriction because dialysate
glucose concentrations can be adjusted to achieve greater
fluid removal on an ongoing basis. A restriction of 1.5–2 L/day
of fluid intake is often well tolerated, and that amount is
easily removed with the ongoing dialysis.
Nitrogen Balance and Caloric Requirements
Nitrogen balance studies in hemodialysis patients suggest that
protein requirements are between 1 and 1.2 g/kg per day. The
caloric requirement to maintain neutral nitrogen balance is
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37 kcal/kg per day. Patients receiving chronic ambulatory
peritoneal dialysis lose a substantial amount of protein in the
dialysate (approximately 10 g/day), and their protein require-
ments approach 1.4 g/kg per day. Glucose absorption from
the dialysate is substantial but depends on the dialysate glu-
cose concentration and the length of the dialysate dwell time.
A gross estimate of the absorbed glucose can be calculated by
measuring the glucose concentration of the dialysate effluent
and comparing this figure with the infused concentration.
 Vascular Access in Hemodialysis Patients
The hemodialysis patient’s permanent vascular access is the life-
line to adequate treatment, and these surgically implanted
access sites must be treated with care. There are two commonly
used means for creating a subcutaneous arteriovenous connec-
tion: surgical anastomosis of an artery and vein, often in the
wrist (primary arteriovenous fistula), and placement of a poly-
tetrafluoroethylene graft between artery and vein in the
brachial fossa. The primary arteriovenous fistula is more
resistant to infection and thrombosis, but it requires up to
6 weeks to mature, and its placement is surgically impossible
in many patients with inadequate distal vasculature.
Polytetrafluoroethylene grafts are available for use within
1–2 weeks but are more prone to infection and pseudoa-
neurysm formation. A properly functioning graft or fistula will
have a palpable thrill and a bruit audible with a stethoscope.
These findings should be checked daily. In general, the sites
should not be used for routine venipuncture, and blood pres-
sure readings should be taken on the contralateral arm. It is
not uncommon for a prolonged period of hypotension to
result in a thrombosed access. If an access site is found to be
clotted (inaudible bruit), vascular surgical consultation
should be sought immediately. In some cases, thrombolytic
therapy with urokinase or tissue plasminogen activator may
avoid the necessity for surgical revision. Angioplasty by
interventional radiology also may be successful.
Infection of the vascular access route is the most common
infectious complication in the hemodialysis population.
Erythema and tenderness over the site are the most common
signs; however, occult septicemia can result from an appar-
ently unaffected site. Access-site infection should be sus-
pected in all cases of systemic infection. Blood cultures from
the access site are a reasonable first step in diagnosing infec-
tion. As opposed to other infections with implantable grafts,
successful treatment without removal of the graft is possible
with prolonged administration of antibiotics. Most antibi-
otic regimens for access-site infections include vancomycin
because that agent is poorly dialyzable, and a single dose can
maintain adequate serum levels for 3–5 days.
Nassar GM, Ayus JC: Infectious complications of the hemodialysis
access. Kidney Int 2001;60:1–13. [PMID: 11422731]
Venkat A, Kaufmann KR, Venkat K: Care of the end-stage renal dis-
ease patient on dialysis in the ED. Am J Emerg Med
2006;24:847–58. [PMID: 17098110]
 Chronic Ambulatory Peritoneal Dialysis
Patients
Chronic ambulatory peritoneal dialysis (CAPD) commonly
involves four 2-L exchanges per day. Net fluid removal
depends on the rate of exchange and the dialysate glucose
concentration (eg, 1.5%, 2.5%, or 4.25%). Peritoneal dialysis
catheters are surgically placed Silastic tubing with direct con-
nections to the intraperitoneal space. Strict sterility should
be maintained whenever the connection between the
catheter and the dialysate tubing is interrupted. Drainage
problems are not uncommon and may respond to moving
the catheter or turning the patient. On occasion, an enema
may cause sufficient intraabdominal movement to produce
adequate drainage. Standard intraperitoneal antibiotic ther-
apy for peritonitis is outlined in Table 13–13.
 Renal Transplant Patients
The differential diagnosis of acute renal failure in the trans-
planted kidney was discussed earlier. Other commonly
encountered problems in the transplant recipient include
infections, GI complications, and hypertension.
Infections
Renal transplant patients require continuous immunosup-
pressive therapy that may include varying combinations of
corticosteroids, azathioprine, cyclosporine, mycophenolate
mofetil, and tacrolimus. The type of infection likely to occur
as a result of the immunocompromised state has been noted
to be somewhat bimodal in distribution. Whereas common
bacterial pathogens, including streptococci, staphylococci,
and gram-negative bacteria, seem to predominate in the
immediate posttransplant period, common opportunistic
infections with viral, protozoal, or fungal organisms seem to
occur 1 month or more after surgery. It is important to note
that the classic signs of infection, including fever, may be
masked by the anti-inflammatory corticosteroids. In general,
if a life-threatening infection is identified, it is often prudent
to discontinue immunosuppressive medication temporarily
despite the risk of graft rejection. In any event, close consul-
tation with the patient’s nephrologist or transplant surgeon
is essential.
Gastrointestinal Complications
Peptic ulcer disease, colonic perforation, and pancreatitis are
the most common GI complications in the renal transplant
patient. Bleeding or perforation of a peptic ulcer carries a
particularly high morbidity, and prophylactic use of H2
antagonists, proton pump inhibitors, or antacids has been
found to be effective. Colonic perforations are uncommon
but are apt to be lethal if not identified quickly. Pancreatitis
is believed to be a result of long-term use of corticosteroids,
and severe sequelae including hemorrhagic pancreatitis and
pseudocyst formation have been reported.
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Hypertension
Hypertension can complicate up to 50% of all renal trans-
plants. Possible causes include renal artery stenosis of the
native or transplanted kidneys, allograft dysfunction,
cyclosporine, and recurrence of the original renal disease.
Renal artery stenosis of the grafted kidney may be treated
successfully by percutaneous angioplasty. Cyclosporine-
induced hypertension may result from the intrarenal vaso-
constriction associated with endothelin and may respond to
a decrease in dosage. In contrast, allograft dysfunction
related to ongoing infection may require decreased immuno-
suppression.
Kasiske BL et al: Recommendations for the outpatient surveillance
of renal transplant recipients. American Society of
Transplantation. J Am Soc Nephrol 2000;11:S1–86. [PMID:
11044969]
Silkensen JR: Long-term complications in renal transplantation. J
Am Soc Nephrol 2000;11:582–8. [PMID: 10703683]
Venkat KK, Venkat A: Care of the renal transplant recipient in the
emergency department. Ann Emerg Med 2004;44:330–41.
[PMID: 15459617]
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Gastrointestinal Failure
in the ICU
Gideon P. Naudé, MD
This chapter addresses the common causes that fall under the
broad category of gastrointestinal (GI) failure. Pancreatitis,
bowel obstruction, paralytic ileus, diarrhea, and malabsorp-
tion are discussed here. GI hemorrhage and specific GI dis-
eases are presented in other chapters. For an overview of
abdominal pathology, the reader is referred to Chapter 32,
which discusses the acute abdomen.
 Pancreatitis
ESSENT IALS  OF  D IAGNOS I S
 Severe abdominal pain, usually radiating to the back.
 Nausea and vomiting.
 Hemodynamic and respiratory compromise in severe
cases.
 Elevated serum levels of pancreatic enzymes.
 Pancreatic enlargements on CT scan.
General Considerations
Acute inflammation of the pancreas has a wide clinical spec-
trum from mild (eg, acute edematous pancreatitis) to very
severe (eg, necrotizing pancreatitis). Most patients have a
benign course, and recovery is uncomplicated. In approxi-
mately 30% of cases, the inflammatory process is aggressive
and associated with a mortality rate that approaches 50%. In
the latter group, management within the ICU is required.
Aggressive early resuscitation may prevent the onset of lethal
multisystem organ failure.
Acute pancreatitis is frequently precipitated by gallstone
obstruction of the pancreatic duct. Although identification
of a persisting stone within the common bile duct itself
(choledocholithiasis) is unusual, careful straining of stools
identifies a gallstone in up to 90% of patients who have had
an attack of pancreatitis within the preceding 10 days.
Pathogenesis may be related to obstruction of the pancreatic
duct during passage of the stone, which results in ductal
hypertension and causes breakdown of intracellular com-
partmentalization, leading to zymogen activation.
In the United States, alcohol consumption is responsible
for about 40% of cases of pancreatitis. Acute pancreatitis may
occur at any time in the course of ongoing excessive consump-
tion, although commonly the initial attack comes after several
years of alcohol abuse. The initial episode may be followed by
further attacks. The usual pattern is a severe first attack fol-
lowed by subsequent attacks that are less dramatic, presum-
ably because of the loss of active pancreatic tissue. Alcohol is
the etiologic factor most commonly associated with chronic
pancreatitis, and microscopic examination of the gland at first
acute presentation often demonstrates evidence of chronicity,
such as scarring and replacement of acinar elements with
fibrous tissue. This may have implications for pancreatic
endocrine function during subsequent acute attacks.
The mechanism of pancreatic damage by alcohol is
incompletely understood and may be idiosyncratic. Alcohol
has been shown to have ultrastructural effects on acinar cells.
It also may cause spasm of the sphincter of Oddi, producing
ductal hypertension.
Postoperative pancreatitis is seen most commonly follow-
ing operations on the biliary tree. The onset of atypical pain
or unexpected ileus following surgery raises the possibility of
pancreatitis. Because postoperative pancreatitis often lacks
the usual clinical features, early detection may be difficult.
Acute pancreatitis following endoscopic retrograde cholan-
giopancreatography (ERCP) is seen in approximately 2% of
cases and may be severe.
Acute pancreatitis may occur in conjunction with eleva-
tions of serum calcium, including transient hypercalcemic
states that may occur with intravenous infusions. Other
metabolic causes include hyperlipidemia, hypothermia, pro-
tein deficiency, and diabetes.
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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Drugs and toxins probably account for more cases of
pancreatitis than is usually suspected. Common drugs
include furosemide, azathioprine, estrogen-containing con-
traceptives, tetracyclines, and corticosteroids. Scorpion
envenomation is a common cause in tropical environments
such as the Caribbean.
Blunt trauma may be associated with acute pancreatitis,
particularly if there is acute ductal obstruction caused by
hematoma. More commonly, chronic pancreatitis, pseudocyst
formation, or pancreatic fistulas result from blunt injury.
Pancreas divisum, ductal abnormalities, and pancreatic
carcinoma all have been suggested as etiologic factors for
acute pancreatitis. When pancreas divisum is present, the
narrow opening of the minor papilla may obstruct the flow
of pancreatic secretions. Unfortunately, sphincteroplasty of
the minor ampulla has mixed results.
Less common causes of acute pancreatitis include infec-
tious agents such as paramyxovirus (mumps), Epstein-Barr
virus, Mycoplasma species, hepatitis virus, and ascaris, as well
as autoimmune disorders, including systemic lupus erythe-
matosus, necrotizing angiitis, and thrombotic thrombocy-
topenic purpura. Recently, spinal surgery for scoliosis
resulted in a 15% incidence of pancreatitis in children and
young adults. In some patients, the etiologic factor is never
discovered.
Pathophysiology
The pancreas produces a wide variety of digestive enzymes
that have the potential for causing serious cellular and bio-
logic disruption. Proteases such as trypsin, chymotrypsin,
and elastase have been shown to activate proenzymes in the
inflammatory and complement cascades. Lipases such as
phospholipase A2 can liberate phospholipid remnants. These
particles perpetuate the inflammatory response and may
have direct cellular toxicity. Normally, intrapancreatic
enzyme control is achieved by secretion of inactive proen-
zymes (zymogens) and intracellular enzyme inhibitors and
compartmentalization by storage of zymogens and enzyme
activators in separate cytosol granules. Once the integrity of
this protective process is breached, autodigestion initiates an
inflammatory process that is self-sustaining.
Acinar damage quickly disrupts normal organ function,
resulting in almost immediate cessation of exocrine secretion
and alteration of endocrine secretion. For this reason, ongo-
ing formation and leakage of pancreatic enzymes are proba-
bly only a minor factors in the perpetuation of acute
pancreatitis following the initial insult. Factors contributing
to progressive disease with severe inflammation and necrosis
are unknown, but organ ischemia and infection are likely to
be important.
Systemic toxicity and functional impairment of other
organ systems are related to the release of inflammatory
mediators such as interleukin-1 (IL-1), arachidonic acid
metabolites, kinins, and tumor necrosis factor (TNF).
There are profound changes in immune competence and
inappropriate activation of lymphocytes and polymor-
phonuclear neutrophils.
Clinical Features 
Clinical evaluation of acute pancreatitis consists of confir-
mation of the diagnosis, estimation of severity, determina-
tion of prognosis, and identification of pancreatic necrosis.
A. Symptoms and Signs—Pain is the most constant symp-
tom, although its nature and severity are variable. Radiation to
the back is observed in 50% of patients, but no pattern can be
considered typical. The intensity of the pain does not correlate
with the degree of pancreatic inflammation. Occasionally,
other clinical features such as vomiting are dominant. The
diagnosis should be considered in all patients with abdominal
pain of recent onset, especially if associated with physiologic
compromise such as hypotension or hypoxia.
Various clinical signs have been described. Abdominal
distention and tenderness are common, but peritonitis is
rare. Abdominal findings do not indicate the severity of the
retroperitoneal process. If the inflammatory process has
extended beyond the pancreas, erythema around the flanks
may occur. The classic signs of hemorrhagic pancreatitis—
ecchymoses in the flank (Grey Turner’s sign) or umbilicus
(Cullen’s sign)—are not commonly present.
Signs of respiratory compromise may indicate incipient
respiratory failure. Tachypnea greater than 20 breaths/min
and a limited chest expansion on inspiration are important.
Clinical evidence of bilateral pleural effusion is found com-
monly in patients with severe pancreatic inflammation.
B. Laboratory Findings—Elevation of enzyme markers
such as amylase and lipase traditionally was considered diag-
nostic, but the sensitivity and specificity of these tests gener-
ally are inferior to those of CT scan. A normal serum amylase
level does not exclude the diagnosis, and enzyme elevation
may be observed in a number of other conditions, including
perforated or penetrating peptic ulcer, ruptured ectopic
pregnancy, and bowel obstruction or infarction.
Measurement of the renal clearance of amylase does not
enhance the sensitivity of this variable.
C. Imaging Studies—Organ imaging has replaced serum
biochemical analysis as the diagnostic modality of choice in
acute pancreatitis. In all but the mildest cases, imaging the
pancreas by CT scan or ultrasonography should be the initial
investigation. Demonstration of organ enlargement con-
firms the diagnosis. Enzyme levels frequently return to nor-
mal within a few days, whereas pancreatic radiologic
derangement persists for at least a week. Therefore, organ
imaging is also valuable in the retrospective diagnosis of this
condition. Very early in the disease, however, CT scan may be
unhelpful because macroscopic changes may take hours to
develop. During this brief period, measurement of enzyme
markers is preferable.
The value of CT scan versus ultrasonography is debated.
Actually, the procedures are complementary, and both
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should be used. With the interference of bowel gas, examina-
tion of the retroperitoneum by ultrasonography is often lim-
ited initially. However, valuable information concerning the
biliary tree may be obtained. CT scans have low sensitivity
for the detection of gallstones but generally are superior to
ultrasonography for the delineation of retroperitoneal dis-
ease processes.
D. Estimation of Severity and Determination of
Prognosis—Determination of the severity of acute pancreati-
tis based on clinical evaluation alone is accurate in only
35–40% of patients. A number of scoring methods have been
devised for objective assessment of the severity and predic-
tion of morbidity and mortality. These scoring techniques are
useful in ensuring early institution of appropriate manage-
ment and in tracking physiologic progress. However, sickness
scoring systems are of limited use in making management
decisions for individual patients. Their most valuable contri-
bution in acute pancreatitis may be in assessment of new
treatment strategies and evaluation of quality assurance.
Initial scoring systems for acute pancreatitis were developed
prior to the widespread availability of CT scanning and are
based on multiple clinical and biochemical parameters. They
include Ranson’s Early Prognostic Signs, Imrie’s Prognostic
Criteria, Simplified Prognostic Criteria, the Glasgow Criteria,
and the APACHE II (Acute Physiology and Chronic Health
Evaluation) scoring system. These systems have various draw-
backs. Most are complex and difficult to remember, extensive
data collection and computation are required, and lack of data
on all parameters occurs frequently. Completed scores may not
be available during initial management.
Ranson’s method (Table 14–1) is the standard against
which other scoring systems are judged. A score of less than
2 based on Ranson’s criteria indicates mild disease with a
good prognosis. A score greater than 6 correlates with a mor-
tality rate of 20% and a complication rate of 80%. Imrie’s
system is a simplification of the original Ranson criteria and
is popular in the Commonwealth countries. The Simplified
Prognostic Criteria (SPC) with only four parameters is easier
to remember. Two SPC signs are the equivalent of six or more
Ranson signs. As a general guideline, all patients with more
than three of Ranson’s criteria or APACHE II scores greater
than 8 should be managed the ICU.
With the advent of routine organ imaging in acute pan-
creatitis, scoring systems based on the CT appearances of the
primary disease process have been developed. These are at
least as good predictors of severity and outcome as any of the
physiologic scoring systems and have the advantage of
immediate availability. Multiple scans may be necessary to
ensure the accuracy of this technique because the CT appear-
ance may change with time.
Another system, based on the quality and quantity of peri-
toneal fluid that can be recovered by lavage, also has been
described. It has the disadvantage of requiring an invasive pro-
cedure and is not used widely except by clinicians who favor
peritoneal lavage as a treatment measure in acute pancreatitis.
E. Identification of Pancreatic Necrosis—The most seri-
ous local complication of acute pancreatitis is pancreatic
necrosis, which, if infection occurs and treatment is not pro-
vided, carries a 100% mortality rate. Following initial resus-
citation, identification and delineation of this process are the
primary aims of management because timely operation will
reduce the mortality rate significantly.
Clinical signs include increasing pain and abdominal
distention. Progressive physiologic derangement and
increasing systemic toxicity are observed with necrosis.
Physiologic monitoring by repeated objective scoring
assessments may be useful to record progressive deteriora-
tion at this stage.
Identification and assessment of pancreatic necrosis are
based on a combination of clinical appraisal, sickness scor-
ing, measurement of serum factors, organ imaging, and fine-
needle aspiration biopsy of the pancreas. Several serum
factors can be correlated with pancreatic necrosis.
Biochemical parameters include a fall in α2-macroglobulin
and C3 and C4 complement factors and a rise in α2-antipro-
tease, C-reactive protein, and pancreatic ribonuclease. These
parameters lack absolute sensitivity and at best only comple-
ment other methods.
CT scanning is becoming established as the best means of
assessment of pancreatic necrosis. Enhanced physiologic
imaging using high-resolution contrast-enhanced scanning
techniques increases the sensitivity and specificity of this
technique and has been reported to clearly establish the
presence and extent of pancreatic necrosis. The initial CT
scan should be performed for diagnosis and estimation of
disease severity. Repeated scanning is necessary in all but the
mildest cases to monitor local progression of disease.
Subsequent scans may be scheduled after 1 week if the clin-
ical course gradually improves. Patients who fail to respond
Criteria present initially 
Age >55 years 
White blood cell count >16,000/μL 
Blood glucose >200 mg/dL 
Serum LDH >350 IU/L 
AST (SGOT) >250 IU/L 
Criteria developing during first 24 hours 
Hematocrit fall >10% 
BUN rise >8 mg/dL 
Serum Ca2+ <8 mg/dL 
Arterial PO2 <60 mm Hg 
Base deficit >4 meq/L 
Estimated fluid sequestration >6000 mL 
∗Morbidity and mortality rates correlate with the number of criteria
present. Mortality rates correlate as follows: 0–2 criteria present =
2%; 3 or 4 = 15%; 5 or 6 = 40%; 7 or 8 = 100%. 
Table 14–1. Ranson’s criteria of severity of acute
pancreatitis.∗
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after adequate initial resuscitation or show evidence of wors-
ening clinical status require earlier evaluation and are candi-
dates for scanning with dynamic vascular enhancement in an
attempt to establish the presence and extent of the necrosis.
F. Needle Aspiration—Needle aspiration of pancreatic and
peripancreatic collections under CT control is becoming
accepted as a means of identification of superinfection. At
least 40% of necrotic collections are found to be infected at
the time of initial management. The most common organ-
ism is Escherichia coli, but a wide variety of gram-positive
and gram-negative aerobic and anaerobic organisms (as sin-
gle or mixed cultures) has been isolated. Aspiration culture
results may be used as a guide to antibiotic selection.
G. Systemic Considerations—Respiratory failure is com-
mon in patients with moderate to severe acute pancreatitis.
Indium-labeled leukocyte scintiscans demonstrate early
margination of the leukocytes in the lungs. The quantitative
deposition correlates with other prognostic indicators. This
is identical to the pattern seen in sepsis-related acute respira-
tory distress syndrome (ARDS). Assessment of ventilation
and gas exchange should be included in the initial evaluation.
Patients may have clinical evidence of bilateral pleural effu-
sions with or without evidence of underlying atelectasis. It is
often useful to include a few CT images of the lung bases at
the same time as the pancreatic scanning. Such lung sections
clearly demonstrate the pulmonary involvement, which may
be more significant than the chest x-ray suggests. In the more
fulminant cases, the clinical picture is one of typical ARDS. A
marked rise in liver aminotransferase (AST >1000 units/L)
suggests the possibility of ischemic hepatitis. This diagnosis
should be included in the differential in evaluation of a
patient suspected of having gallstone pancreatitis and per-
sistent choledocholithiasis. In its more severe form, ischemic
hepatitis may be associated with other metabolic derange-
ments, including a rise in bilirubin. Gradual recovery usually
can be expected.
A low Glasgow Coma Score may be observed for several
reasons in patients with severe acute pancreatitis. The use of
sedation and opioids for pain relief may modify cerebral
function, and catastrophic illness is often associated with
acute organic brain syndrome. Pancreatic encephalopathy
also has been described as a separate entity. It is attributed to
the release of pancreatic lipases, but the evidence for this
view is inconclusive. MRI demonstrates patchy white matter
abnormalities that resemble the plaques seen in multiple
sclerosis.
Treatment
Critical care of the patient with acute pancreatitis consists
essentially of maintaining adequate perfusion and oxygen
delivery to essential organs during resolution of the primary
disease process. Early and aggressive resuscitation reduces
the mortality rate by reducing the incidence of multisystem
organ failure.
A. Fluid Resuscitation and Physiologic Monitoring—
The degree of intravascular fluid depletion is difficult to
gauge accurately in patients with acute pancreatitis. Tissue
fluid shifts related to systemic release of vasoactive toxins and
severe retroperitoneal losses may be dramatic. As much as
10–20 L of replacement fluid may be required in the first
24 hours. Replacement by crystalloid is the fluid of choice.
Colloid is used only in patients in whom the albumin is dan-
gerously low. Depending on the clinical severity, blood
transfusion should be considered when the hemoglobin is
less than 10 g/dL. The use of fresh-frozen plasma for sys-
temic deactivation of proteases has provided apparent bene-
fit in empirical trials. Controlled studies, however, have failed
to provide objective evidence of an improvement in out-
come, and routine use of fresh-frozen plasma should await
further evaluation.
As in any shock state, adequacy of fluid replacement is
assessed by measurement of central venous or pulmonary
arterial wedge pressure, aiming for values at least 10 mm Hg
above the intrathoracic pressure. In patients in whom positive-
pressure ventilation is being used, the systemic venous
pressure or the pulmonary arterial wedge pressure should
be at least 10 mm Hg higher than the ventilatory positive
end-expiratory pressure.
The adequacy of fluid replacement can be further
assessed by measurement of the response to repeated fluid
challenges with 250–500 mL of balanced salt solution. If cen-
tral filling pressures are sufficient, such challenges will be fol-
lowed by a sustained rise in central venous pressure of 3–5
mm Hg. Once filling pressures are optimized, the increment
in cardiac output in response to further fluid replacement is
minimal, and the patient should be kept stable at this level.
Successful fluid resuscitation should be accompanied by
improved peripheral perfusion, as indicated by limb temper-
ature, peripheral pulse volume, arterial blood pressure, uri-
nary output, and mixed venous oxygen. Low mixed venous
oxygen tension (P–vO2 <40 mm Hg) indicates that the perfu-
sion state is inadequate. If central filling pressures have been
optimized, myocardial dysfunction should be suspected.
B. Inotropic Support—Echocardiographic evaluation is
useful for differentiation of the hypovolemic state from the
hypocontractile state. In the former, heart size is normal or
less than normal, and there is evidence of vigorous wall
motion. In the latter, there is usually discernible chamber
enlargement and segmental or global hypokinesia.
If myocardial hypocontractility is diagnosed, inotropic
support should be instituted. Strict guidelines for choice of
inotropic agents are not available. In general, however, for
patients in whom persistent hypotension dominates, an
incrementally increased infusion of dopamine titrated
against blood pressure is the preferred initial strategy. In sit-
uations where tissue perfusion remains poor despite ade-
quate arterial pressures, inotropic agents without prominent
α-adrenergic effects such as dobutamine may be preferable.
Irrespective of the agent used, the clinical objective is
GASTROINTESTINAL FAILURE IN THE ICU 349
improvement of organ perfusion, and mixed venous oxy-
genation should be specifically evaluated rather than relying
solely on monitoring of arterial blood pressure.
C. Respiratory Support—Patients with significant hypoxia
(PaO2 <60 mm Hg) despite high inspired oxygen or clinical
evidence of compromised ventilation (respiratory rate of >
30 breaths/min or dyskinetic breathing pattern) should be
considered for early intubation and mechanical ventilatory
support. Sedation, analgesia, and mechanical ventilation
improve overall cardiopulmonary performance.
D. Renal Support—Impaired renal function—indicated by
rising serum urea nitrogen and creatinine or oliguria with
frank acute tubular necrosis—is seen often in severe acute
pancreatitis. Early and adequate fluid replacement minimizes
the risk, but renal function may continue to deteriorate
despite adequate hemodynamic resuscitation. Low-dose
dopamine may increase renal blood flow, minimizing the
ischemic insult.
Fortunately, the prognosis for renal function is good, and
in most cases temporary hemodialysis or hemofiltration will
maintain adequate homeostasis until renal function returns.
Once acute tubular necrosis has become established, it is
important to avoid secondary ischemic insults, which may
result in acute cortical necrosis and permanent loss of renal
function.
E. Nutrition—Acute pancreatitis is a hypermetabolic state
similar to sepsis. Retroperitoneal edema may contribute to
prolonged small bowel dysfunction and make enteral nutri-
tional support impossible. This, along with ongoing negative
nitrogen balance, mandates the institution of total parenteral
nutrition. While early institution of total parenteral nutrition
is theoretically desirable, these patients are variably intoler-
ant of the high metabolic loads. The degree of insulin resist-
ance is often extreme, with high-dose insulin infusions required
to stabilize serum glucose levels at less than 150 mg/dL. Early
institution of total parenteral nutrition is not critical, and in
the hemodynamically unstable patient, delayed introduction
is advised.
It has been proposed that hyperlipidemia may in itself
stimulate the pancreas and help perpetuate the inflammatory
process. For this reason, total parenteral nutrition regimens
with reduced fat content have been advocated. There is, how-
ever, no objective evidence that patients with acute pancre-
atitis are adversely affected by customarily used lipid
regimens, and the use of nutritional formulas low in lipids is
a matter of personal choice.
Evidence of the benefit of total parenteral nutrition for
modification of the disease process within the pancreas is not
yet available. Nor is there real evidence to suggest the superi-
ority of any particular regimen for the maintenance of basic
nutrition.
Patients with acute pancreatitis do appear to have a height-
ened susceptibility to intravenous line infections, and meticu-
lous care of catheters is required. Dedicated ports exclusively
for total parenteral nutrition infusions—with meticulous
care during line changes—may help to reduce infection rates.
F. Other Modalities—Little can be done to substantially
modify the inflammatory process within the pancreas.
Various interventions have been proposed, but none has
been shown to have substantial value. Steroids are not indi-
cated. Inhibitors of pancreatic function such as glucagon and
octreotide have been used without demonstrable benefit.
Antiproteases such as aprotinin also have lacked obvious
therapeutic effect and now have been largely abandoned.
The nature and extent of surgery depend on appraisal of
the radiologic appearance of the pancreas and the physio-
logic status of the patient. Peritoneal lavage, manipulation of
the biliary tree, and pancreatic procedures, as well as opera-
tive management of complications, all have a place in the
operative management of severe acute pancreatitis. Optimal
timing of any procedure is critical and is based largely on
clinical judgment.
Once the patient with severe acute pancreatitis is resusci-
tated, efforts must be directed toward the detection and
management of pancreatic necrosis. Dynamic contrast-
enhanced CT scanning is the most accurate method for eval-
uating pancreatic ischemia and also can aid in planning
operative treatment.
1. Peritoneal and retroperitoneal lavage—This rela-
tively noninvasive procedure was first advocated in 1965 and
was widely adopted thereafter. However, subsequent con-
trolled trials and standardization of patient selection showed
no significant difference in overall mortality rates. A more
recent trial of therapeutic peritoneal lavage for 7 days
reported a reduction in both the incidence and mortality rate
of pancreatic sepsis in patients with severe acute pancreatitis.
Some now advocate continuous lavage with 2-L exchanges
performed every hour. A modified balanced salt solution is
usually used.
Retroperitoneal lavage with aggressive irrigation has
avoided surgery and treated sepsis in a significant number of
patients.
2. Biliary procedures—Overwhelming evidence of the
association of choledocholithiasis with gallstone pancreatitis
prompted evaluation of the role of removal of common bile
duct stones in the management of acute pancreatitis. Up to
95% of patients with gallstone pancreatitis pass a gallstone in
the feces during the course of the illness. Choledocholithiasis
can be demonstrated in approximately 70% of these patients
within the first 48 hours of presentation, with the rate of
stone detection falling off rapidly thereafter.
Initial experience with urgent cholecystectomy or chole-
cystostomy with choledochostomy in acute pancreatitis
demonstrated a 72% common duct stone retrieval rate and a
2% mortality rate. However, these results were difficult to
replicate and were reported prior to the general use of scor-
ing systems to standardize illness severity and prognosis in
the management of patients with acute pancreatitis. Early
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definitive surgery in the acute phase of acute pancreatitis car-
ries unacceptable morbidity and mortality rates. However,
results suggest that early ERCP and endoscopic sphinctero-
tomy may have a favorable impact on survival in patients
with severe disease. Patient selection for ERCP and the inher-
ent risks and timing of this procedure in the very sick patient
need to be considered prior to adoption of this policy.
Ascending cholangitis in association with acute pancreatitis
is ideally treated by ERCP and sphincterotomy. Most sur-
geons would advocate semielective cholecystectomy once the
patient has recovered from the acute event—ideally, during
the same hospital admission.
3. Necrosectomy—This operation, involving empirical
debridement of devitalized pancreatic tissue, has gradually
become the treatment of choice in patients with severe
necrotizing pancreatitis. It has replaced formal pancreatic
resection, which carries a persistently high mortality rate.
The nonanatomic basis of this approach makes the outcome
of surgery particularly dependent on optimal timing of oper-
ation. Clinically detectable separation of necrotic and viable
tissue is best seen after 7 days, and patients in whom the ini-
tial operation can be delayed for as long as possible have an
overall lower mortality rate. Minimal debridement should be
planned if earlier operation is mandated by deteriorating
condition of the patient.
In many cases, several operations are required for com-
plete debridement because demarcation progresses over a
period of time. Attempted resection of nondemarcated tissue
to avoid multiple laparotomies is associated with increased
morbidity and mortality rates. The use and placement of
drains and the value of pancreatic bed lavage have lowered
the mortality of this condition. Pancreatic fistulas should be
managed by external drainage in the acute setting.
Management of the abdominal wall in the intervals
between multiple, closely timed laparotomies is also a matter
of choice for the surgeon. Vertical incisions with the use of
zipper closure techniques or horizontal incisions with isola-
tion of the supracolic compartment and an open wound
have been advocated. If the abdomen is left open, paralysis of
the patient is mandatory to prevent evisceration until early
adhesions contain the abdominal contents.
Minimally invasive necrosectomy in the form of aggres-
sive irrigation with fluoroscope-guided removal of tissue
with forceps and snares can buy time as well as be the defin-
itive procedure.
Standard laparoscopy with debridement of the retroperi-
tonium, cholecystectomy and splenectomy, endoscopic
transgastric and transduodenal retroperitoneoscopy and
debridement, and retroperitoneoscopy via either of the
flanks are all being evaluated as procedures that can be per-
formed on patients not fit for standard laparotomy.
4. Enteric fistulas—The massive retroperitoneal inflam-
mation associated with acute pancreatitis may lead to vascu-
lar complications. These include thrombosis and aneurysm
formation, with the former being the most common. The
middle colic vessels supplying the transverse colon are espe-
cially at risk, although gastric, duodenal, and small bowel fis-
tulas also have been described. If necrosectomy is required,
consideration should be given to examination of the trans-
verse colon. If evidence of ischemia is present, elective termi-
nal ileostomy at the time of first laparotomy may be valuable.
Other enteric fistulas are investigated and managed in rou-
tine fashion. One must be alert to this possibility to avoid dan-
gerous delays in diagnosis.
5. Bleeding—Catastrophic bleeding is difficult to manage
surgically because the inflamed pancreatic bed makes delin-
eation of anatomy and accurate dissection hazardous.
Embolization of the bleeding vessel by angiographic tech-
niques is probably the treatment of choice. Bleeding from
erosion into the splenic artery or other vessels may be life-
threatening.
6. Pancreatic abscess—Pancreatic abscess occurs with
delayed infection of limited pancreatic necrotic tissue that
has progressed beyond demarcation to liquefaction and iso-
lation. It is differentiated from infected necrosis by its
delayed presentation (4–6 weeks). Abscesses are best diag-
nosed by CT scan. The value of percutaneous CT-guided
catheter drainage in comparison with laparotomy has not
been established.
7. Pancreatic pseudocyst—Pancreatic pseudocysts form
by one of two mechanisms. Following acute pancreatitis,
extravasation of pancreatic enzymes produces necrosis of
surrounding tissues and forms a sterile collection of fluid
that is not reabsorbed as the inflammatory process subsides.
If the fluid collection becomes infected, a pancreatic abscess
results. If not, the fluid is retained by the surrounding
organs as a pseudocyst. The second mechanism typically fol-
lows trauma and is caused by ductal obstruction that leads
to a retention cyst. Pseudocysts occur in about 2% of all
cases of acute pancreatitis, and over 85% are singular.
Pseudocyst formation presents several weeks after the
episode of acute pancreatitis, making de novo presentation
in the ICU somewhat uncommon. However, patients are fre-
quently readmitted to a critical care facility when increased
epigastric pain, fever, and amylase elevation occur after ini-
tial therapy for pancreatitis. Pain is the most common find-
ing, but a few patients have a palpable mass, jaundice, or
weight loss. A CT scan is the procedure of choice for estab-
lishing the diagnosis, although serial ultrasonography is use-
ful for determining changes in the size of the pseudocyst.
Infection, rupture, and hemorrhage are the major complica-
tions of pancreatic pseudocysts. Many resolve sponta-
neously, although internal drainage via cystoenterostomy
may be required; endoscopic transgastric cystostomy is
being evaluated. Critical care management is similar to that
for acute pancreatitis, with particular requirements for par-
enteral nutritional support and treatment of infectious
complications.
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 Bowel Obstruction
ESSENT IALS  OF  D IAGNOS I S
 Colicky abdominal pain.
 Emesis.
 Dehydration.
 Peristaltic “tinkles and rushes” on abdominal auscultation.
 Air-fluid levels on abdominal x-ray.
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General Considerations
Bowel obstructions are common among critically ill patients
and may be the underlying reason for ICU admission or may
develop as part of another disease process. Obstructions of
the small bowel may be mechanical or paralytic. Mechanical
obstructions occur when a physical impediment to the abo-
ral progress of intestinal contents is present. Paralytic ileus
(ie, functional obstruction) occurs when an underlying dis-
ease process interferes with normal peristalsis. Metabolic
derangements, neurogenic causes, drug effects, and peritoni-
tis are the most common causes of paralytic ileus.
Mechanical obstruction can be divided into simple obstruc-
tions, involving only the bowel lumen, and strangulated
obstructions, which impair blood supply and lead to necro-
sis of the intestinal wall. A simple obstruction takes place at
just one location. When the bowel lumen is occluded in two
or more locations, a closed-loop obstruction is created.
Closed-loop obstructions are often associated with strangu-
lation because blood supply may be compromised.
Adhesions from previous abdominal surgery are the most
common cause of small bowel obstruction. Onset is usually
insidious, with abdominal bloating and crampy abdominal
pain. External hernias through the abdominal wall that
become incarcerated are the second most common cause of
small bowel obstruction. Internal hernias also can occur at
the obturator foramen, through the diaphragm, or at the
foramen epiploicum (Winslow). Defects caused by surgery,
such as those adjacent to stomas, also are potential sites for
the formation of internal hernias.
Neoplasms within or extrinsic to the small bowel may
produce obstruction directly or by mass effect. Such tumors
may serve as the lead point for an intussusception. Although
rare in adults, intussusception may occur without a lesion
serving as a lead point.
Volvulus is produced when mobile bowel rotates around
a fixed point. This is frequently the consequence of congeni-
tal abnormalities or acquired adhesions. Obstruction typi-
cally occurs abruptly and leads to intestinal strangulation if
not relieved quickly. Sigmoid and cecal volvulus of the colon
is significantly more common than small bowel volvulus.
Other less common causes of small bowel obstruction
include gallstone ileus, ingested foreign bodies, inflammatory
bowel disease, stricture owing to radiation therapy, cystic
fibrosis, and posttraumatic hematoma. Gallstone ileus occurs
in patients with cholelithiasis who develop a fistula between
the gallbladder and a loop of small bowel, typically the duo-
denum. As the gallstone progresses distally, it produces a pat-
tern of intermittent small bowel obstruction at different
levels, referred to as “tumbling” obstruction. Air in the biliary
tree on abdominal x-ray is the key to the diagnosis.
When the small bowel is obstructed, distention with gas
and fluid occurs proximally. Swallowed air is the major cause
of distention. This is due to the high nitrogen content in
room air, which is not well absorbed by the mucosa. Bacterial
fermentation produces other gases as well, such as methane.
Inflammation leads to transudation of fluid from the extra-
cellular space into the bowel lumen and peritoneal cavity. As
the proximal lumen distends and fluid accumulates, the bidi-
rectional flow of salt and water is disrupted, and secretion is
enhanced. Other substances such as prostaglandins and
endotoxins released by bacterial proliferation in the static
lumen further the process. Fluid losses may be so severe that
hypotension results and ultimately may lead to cardiovascu-
lar collapse unless recognized and treated expeditiously.
Vomiting usually accompanies small bowel obstruction and
becomes progressively more feculent as the illness progresses.
Peristaltic “rushes” are the auscultatory hallmark of this prob-
lem. Aspiration of vomitus may lead to severe pneumonia and
respiratory distress. Respiration is adversely affected by abdom-
inal distention and impaired diaphragmatic excursion.
Closed-loop obstruction is a feared consequence of com-
plete mechanical obstruction. When it occurs, no outlet for
the accumulated intraluminal contents exists, and perforation
of the bowel may occur. Strangulation rarely results from pro-
gressive distention, although venous outflow becomes signif-
icantly impaired as the bowel and mesentery continue to
distend. This ultimately results in intestinal gangrene and
intraluminal bleeding. Free perforation occurs as a conse-
quence of gangrene, releasing the highly toxic stagnant intra-
luminal mixture of bacterial products, live bacteria, necrotic
tissue, and blood. There are no specific historical, physical, or
laboratory findings that exclude the possibility of strangula-
tion in complete small bowel obstruction, which occurs in
approximately one-third of patients. The early appearance of
shock, gross hematemesis, and profound leukocytosis sug-
gests the presence of a strangulated obstruction.
Clinical Features 
A. Symptoms and Signs—Obstruction of the proximal
small bowel usually presents with vomiting. The extent of
associated abdominal pain is variable and usually is
described as intermittent or colicky with a crescendo-
decrescendo pattern. When the obstruction is located in the
middle or high small bowel (jejunum and proximal ileum),
the pain may be more constant. As the site of involvement
progresses distally, poorly localized crampy pain and abdom-
inal distention become more common (Figure 14–1).
In the early stages of obstruction, vital signs are normal.
As loss of fluid and electrolytes continues, dehydration
occurs, manifested as tachycardia and postural hypotension.
Body temperature is usually normal but may be mildly ele-
vated. Abdominal distention is minimal or absent initially. It
is more pronounced with distal obstruction and when more
proximal lesions have been allowed to progress without
decompression. Dilated loops of small bowel may be visible
beneath the abdominal wall in thin patients. Characteristic
peristaltic rushes, gurgles, and high-pitched tinkles may be
audible and occur in synchrony with cramping pain. Rectal
examination is usually normal. Abdominal wall hernias
should be sought.
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B. Laboratory Findings—Early in the process, laboratory
findings are normal. With progression, there is hemoconcen-
tration, leukocytosis, and electrolyte abnormalities whose
extent and nature depend in part on the level of obstruction
present. Increases in serum amylase are common.
C. Imaging Studies—On plain abdominal films, a ladder-
like pattern of dilated small bowel loops and air-fluid levels
will be noted, particularly in distal obstruction. The colon
may not contain gas. If a gallstone precipitated the event, it
may be noted on the film, or air may be seen in the biliary
tree. When strangulation and necrosis occur, loss of mucosal
regularity, gas within the bowel wall, and “thumbprinting” of
the bowel wall occur. On rare occasions, gas may be seen
within the portal vein. Free air on an upright chest x-ray is
highly suggestive of intestinal perforation.
Contrast studies are usually not required and should not
be performed because of the risk of barium peritonitis if a per-
foration is present. However, in patients with high-grade par-
tial obstructions who are poor surgical risks, administration
of a dilute barium mixture through the nasogastric tube can
be used to determine whether a residual lumen is still pres-
ent for the passage of gas and liquid contents.
Differential Diagnosis
Ileus is a prominent feature of the differential diagnosis. It
can be caused by a number of intraabdominal and retroperi-
toneal processes, including intestinal ischemia, ureteral colic,
pelvic fractures, and back injuries. It may occur after routine
abdominal surgery. If paralytic ileus is present, the pain is
usually not as severe and tends to be more constant.
Obstipation and abdominal distention characterize
obstruction of the large intestine. Vomiting seldom occurs,
and the pain is less colicky. The diagnosis is usually made on
the basis of x-ray findings that show colonic dilation proxi-
mal to the point of obstruction.
Small bowel obstruction can be confused with acute
gastroenteritis, acute appendicitis, and acute pancreati-
tis. Strangulating obstructions may be mimicked by acute
pancreatitis, ischemic enteritis, or mesenteric vascular occlu-
sion owing to venous thrombosis.
High
Frequent vomiting.
No distention. Intermittent
pain but not classic
crescendo type.
Middle
Moderate vomiting.
Moderate distention. Intermittent
pain (crescendo, colicky)
with pain-free intervals.
Low
Vomiting late, feculent.
Marked distention. Variable
pain; may not be classic
crescendo type.
 Figure 14–1. Small bowel obstruction. Variable manifestations of obstruction depend on the level of blockage of
the small bowel. (Reproduced, with permission, from Way LW, Doherty GM (eds), Current Surgical Diagnosis & Treatment,
11th ed. New York: McGraw-Hill, 2002.)
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Paralytic ileus must be differentiated from mechanical
obstruction. Radiographic findings usually show a more dif-
fuse pattern of air-fluid levels without a distinct cutoff point.
These patients may be very ill with other systemic diseases or
may be apparently well with seemingly minor electrolyte
abnormalities. Pseudo-obstruction is particularly common
among patients with diabetes who are recovering from an
episode of ketoacidosis or who have recently undergone
intraabdominal surgery. Treatment of pseudo-obstruction is
directed at the disease process causing the ileus.
Metoclopramide may be helpful once the presence of
mechanical obstruction has been excluded.
Treatment
A. Supportive Measures—Partial small bowel obstructions
may be treated with intravenous hydration and nasogastric
suction if the patient continues to pass stool and flatus. Fluid
and electrolyte losses are corrected with balanced salt solu-
tions. Isotonic solutions should be used to treat hemocon-
centration. The extent of fluid resuscitation is best guided by
urine output, although in elderly patients or those with car-
diopulmonary disease, a pulmonary artery flotation catheter
is advisable. If strangulation is suspected, broad-spectrum
antibiotics should be administered promptly.
B. Surgery—Planning for surgery should be started concur-
rently with fluid and electrolyte therapy because the patient
must be fully resuscitated before operation commences.
Laparoscopy with lysis of the obstructing adhesion if the
obstruction is due to a simple obstructing band or adhesion
may be all that is required, or open surgery may be necessary
if this cannot be performed laparoscopically. When closed-
loop and strangulated obstructions are present, intestinal
resection may be necessary. The major problem at surgery is
distinguishing viable from necrotic bowel. In severe cases,
patients may have to be returned to the operating room
within 24–48 hours for a “second look” procedure to make
certain that all remaining bowel is viable.
Prognosis
The mortality rate for simple obstruction is almost 2%. It
increases to about 8% if strangulation is present and surgery
is performed within 36 hours of presentation—and to 25% if
operation is delayed beyond that point.
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 Obstruction of the Large Bowel
ESSENT IALS  OF  D IAGNOS I S
 Constipation or obstipation.
 Abdominal distention and tenderness.
 Abdominal pain.
 Nausea and vomiting (late).
 Characteristic x-ray findings.
General Considerations
About 15% of intestinal obstructions involve the large bowel.
The sigmoid colon is most commonly involved. When com-
plete obstruction is present, carcinoma usually is the cause.
Other causes include diverticular disease, volvulus, inflam-
matory disorders, benign tumors, and fecal impaction.
Obstructive bands from adhesions and intussusception are
rare causes of large bowel obstruction.
If obstruction occurs at the level of the cecum, the signs
and symptoms will be similar to those of small bowel
obstruction. With more distal colonic obstruction, physical
findings will depend on the competence of the ileocecal
valve. A form of closed-loop obstruction will occur if the
colon cannot decompress itself in retrograde fashion
through the ileocecal valve into the small bowel.
Colonic distention is a progressive process in which intra-
luminal pressures can reach very high levels that can impair
the circulation and lead to gangrene and perforation.
Clinical Features
A. Symptoms and Signs—Patients typically complain of a
deep-seated cramping pain referred to the hypogastrium.
Lesions of fixed portions of the colon (ie, cecum, hepatic
flexure, and splenic flexure) radiate anteriorly. Pain from
obstruction of the sigmoid colon usually radiates to the left
lower quadrant. Severe continuous pain suggests intestinal
ischemia. When a progressive process is responsible, the
obstruction may develop insidiously, although careful ques-
tioning often reveals signs of chronic disease such as a
change in stool caliber, frequency of defecation, and dark or
black feces.
The usual feature of complete obstruction is constipation
or obstipation. Vomiting is a late finding and may not occur if
the ileocecal valve does not allow contents to reflux back into
the small intestine. Feculent vomiting is a late manifestation.
Abdominal distention with peristaltic waves radiating
across the abdominal wall may be observed if the patient is
thin. On auscultation, high-pitched metallic tinkling and
associated rushes and gurgles can be heard. Localized tender-
ness or a nontender palpable mass may indicate a strangu-
lated closed loop. Occult blood on rectal examination may be
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due to carcinoma, whereas fresh blood is characteristic of
diverticular disease and intussusception.
B. Endoscopy—Sigmoidoscopy and colonoscopy are often
beneficial in establishing the diagnosis and may be therapeu-
tic if sigmoid volvulus is present. Care must be exercised
when advancing the endoscope to prevent accidental perfo-
ration of an attenuated colonic wall.
In strictures, dilatation and stenting can be therapeutic or
allow bowel preparation before definitive surgery, making a
diverting colostomy unnecessary. Fulgeration of inoperable
obstructing carcinomas can restore a lumen to palliate an
inoperable lesion.
C. Imaging Studies—Plain abdominal x-rays reveal a dis-
tended colonic segment. With low sigmoid or rectal obstruc-
tions, the entire colon may be dilated. If the ileocecal valve is
incompetent, retrograde decompression will cause distention
of the terminal ileum.
The diagnosis is confirmed by barium enema. Water-
soluble contrast medium should be used if strangulation or
perforation is suspected. Barium is contraindicated in the
presence of suspected colonic perforation.
Differential Diagnosis
It is important to differentiate small bowel obstruction
from colonic obstruction. With the latter, onset is typically
slower, and there is less pain. Vomiting is very unusual with
colonic obstruction despite considerable abdominal dis-
tention. Plain abdominal x-rays are essential to the differ-
ential diagnosis, and adjunctive contrast studies are
sometimes helpful.
Treatment
The primary goal of therapy is decompression of the
obstructed segment and prevention of perforation.
Operation is almost always required in cases of mechanical
obstruction. The surgical procedure depends on the lesion
present, the status of the patient, the extent of colonic dila-
tion, and whether there is evidence of perforation. In general,
proximal diversion (colostomy) is required to decompress
the dilated colon. Simultaneous or subsequent excision of
the obstructing lesion is required before colonic continuity
can be reestablished.
Prognosis
The prognosis depends on the age and general condition of
the patient, as well as on the extent of vascular impairment
of the bowel, the presence or absence of perforation, the
cause of obstruction, and the promptness of surgical man-
agement. Mortality rates are about 20% overall. If the cecum
perforates, a mortality rate of 40% can be expected. In the
case of colonic obstruction secondary to carcinoma, the
prognosis is worse.
Buechter KJ et al: Surgical management of the acutely obstructed
colon: A review of 127 cases. Am J Surg 1988;156:163–8.
[PMID: 3048132]
Gosche JR, Sharpe JN, Larson GM: Colonoscopic decompression
for pseudo-obstruction of the colon. Am Surg 1989;55:111–5.
[PMID: 2916799]
Harig JM et al: Treatment of acute nontoxic megacolon during
colonoscopy: Tube placement versus simple decompression.
Gastrointest Endosc 1988;34:23–7. [PMID: 3350299]
Sloyer AF et al: Ogilvie’s syndrome: Successful management with-
out colonoscopy. Dig Dis Sci 1988;33:1391–6. [PMID: 3180976] 
 Adynamic (Paralytic) Ileus
ESSENT IALS  OF  D IAGNOS I S
 Continuous abdominal pain.
 Vomiting.
 Abdominal distention.
 Obstipation.
 Precipitating factor.
 Radiographic evidence of gas and fluid in the small or
large bowel.
General Considerations
Adynamic ileus is often associated with neurogenic or mus-
cular impairment of small or large bowel function. This may
be due to a variety of causes such as alimentary tract surgery,
a ruptured viscus, hemorrhage, pancreatitis, or peritonitis.
Other causes include anoxic injury, anticholinergic medica-
tions, opioids, vertebral fractures, renal colic, injuries of the
spinal cord, severe infections of either the thoracic or the
abdominal cavity, uremia, diabetic coma, and electrolyte
abnormalities.
Recent abdominal surgery is a principal cause of ady-
namic ileus among critical care patients. In the 24 hours fol-
lowing surgery, motility within the small bowel returns to
normal, whereas gastric function will return after approxi-
mately 24 hours. The colon requires several days to regain
normal motility. The pain associated with ileus is constant
but not severe or colicky, as it is with mechanical obstruction.
Mild abdominal tenderness is noted along with distention. If
this is due to an intraperitoneal inflammatory process, signs
and symptoms of that disorder are usually present. Plain
films of the abdomen are extremely helpful.
Similar to paralytic ileus of the small bowel, pseudo-
obstruction (Ogilvie’s syndrome) of the colon may occur.
This is a severe form of ileus that often arises in bedridden
patients who have serious systemic illnesses. The abdomen is
usually silent, and abdominal cramping is not present.
Tenderness may be noted. Plain films show a dilated colon
that may reach alarming proportions. The entire colon may
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contain gas, but the distention is typically localized to the
right colon with cutoff at the splenic flexure. Contrast stud-
ies may be required to prove the absence of obstruction, but
instillation of radiopaque material must be stopped as soon
as the dilated colon is reached. The risk of cecal perforation
is very high in patients with pseudo-obstruction.
Decompression of the colon should be attempted as quickly
as possible using a fiberoptic colonoscope. Recurrence rates
are as high as 20%. Initial colonoscopic decompression is
successful in 90% of patients. Percutaneous cecostomy is
reserved as an option for decompression if colonoscopy fails.
Clinical Features
A. Symptoms and Signs—Mild to moderate abdominal
pain is usually present. It is continuous rather than colicky
and is often associated with emesis, which may become fecu-
lent. Symptoms of the underlying condition also may be
present, such as prostration from a ruptured viscus.
Dehydration is usually present as a consequence of fluid
translocation into distended loops of bowel. Massive abdom-
inal distention and localized tenderness are common. Bowel
sounds are absent or decreased.
B. Laboratory Findings—Hemoconcentration and elec-
trolyte deficits occur with prolonged vomiting. Elevated
serum amylase levels and leukocytosis are usually present.
C. Imaging Studies—The specific radiographic finding
noted on flat-plate upright abdominal films is gas-filled
loops of intestine. Air even may be present in the rectum.
Air-fluid levels in the distended bowel are common. A con-
trast enema or barium swallow with subsequent small bowel
“follow through” films may be helpful in differentiating ady-
namic ileus from mechanical obstruction.
Differential Diagnosis
Idiopathic pseudo-obstruction is usually seen in teenagers or
young adults and is characterized by symptoms of small
bowel obstruction that recur but never produce evidence of
organic obstruction on x-ray. Treatment is with nasogastric
intubation and suction. Intravenous fluids and parenteral
nutrition are required. Occasionally, colonoscopic decom-
pression or cecostomy is useful. The variant known as chronic
pseudo-obstruction is associated with cramping abdominal
pain, abdominal distention, and vomiting. There may be
involvement of the esophagus, the stomach, the small bowel,
the colon, or the urinary bladder. All or some of these
patients have abnormal motility with sparing of some por-
tions of the alimentary tract. Metoclopramide is often help-
ful. Avoiding narcotic analgesics may prevent an ileus. Use of
thoracic epidural analgesia and postoperative local anes-
thetic wound devices will reduce the need for narcotics.
Treatment
A. Supportive Measures—Most cases of ileus in the post-
operative period respond to restriction of oral intake and
nasogastric suction. Fluid and electrolyte replacement is
essential.
B. Decompression—When colonic dilation is present,
colonoscopy may be valuable. Use of a rectal tube was com-
mon practice at one time but now has been largely abandoned.
C. Surgery—If there is a failure of conservative therapy, sur-
gery may be necessary. Operation is performed to decom-
press the bowel either by enterostomy or by cecostomy and to
exclude mechanical obstruction. Bowel biopsy may be per-
formed to identify neurogenic causes.
Prognosis
The initiating disorder often will dictate the prognosis.
Adynamic ileus may resolve without specific therapy.
Decompression usually helps to return bowel function to
normal.
Current Controversies and Unresolved Issues
Recent studies have reported the use of new agents in the
treatment of adynamic ileus. Itopride has shown some effect
in postoperative ileus. Cisapride has been discontinued
owing to side effects. Erythromycin was studied and showed
no advantage when compared with placebo. Intravenous
lidocaine also has been found to shorten the duration of par-
alytic ileus, presumably by suppressing inhibitory GI reflexes.
Additional trials of all these agents are required before they
can be either recommended or discredited.
Bonacini M et al: Effect of intravenous erythromycin on postoper-
ative ileus. Am J Gastroenterol 1993;88:208–11. [PMID:
8424422]
Dorudi S, Berry AR, Kettlewell MG: Acute colonic pseudo-
obstruction. Br J Surg 1992;79:99–103. [PMID: 1555081]
Gurlich R, Frasco R, Maruna P, Chachkhiani I. Randomized clini-
cal trial of itopride for the treatment of postoperative ileus after
laparoscopic cholecystectomy. Chir Gastroenterol 2004;20:
61–65.
Jetmore AB et al: Ogilvie’s syndrome: Colonoscopic decompres-
sion and analysis of predisposing factors. Dis Colon Rectum
1992;35:1135–42. [PMID: 1473414]
MacColl C et al: Treatment of acute colonic pseudoobstruction
(Ogilvie’s syndrome) with cisapride. Gastroenterology
1990;98:773–6.
Rimback G, Cassuto J, Tollesson PO: Treatment of postoperative
paralytic ileus by intravenous lidocaine infusion. Anesth Analg
1990;70:414–9. [PMID: 2316883]
Vantrappen G: Acute colonic pseudo-obstruction. Lancet
1993;341:152–3. [PMID: 8093750] 
DIARRHEA & MALABSORPTION
Critically ill patients often develop diarrhea from a number of
causes, including overly aggressive enteral feeding, infectious
diarrhea, and malabsorption. After GI resection, short gut
syndromes and exocrine insufficiency may contribute. These
common causes are discussed in the next several sections.
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 Pancreatic Insufficiency
Following pancreatic surgery, pancreatectomy, or pancreati-
tis, pancreatic exocrine insufficiency can develop. Varying
degrees of insufficiency may be present without overt symp-
toms. Following total pancreatectomy, malabsorption of
70% of dietary fat is common. However, in the face of a nor-
mal pancreatic remnant, some resections have little or no
effect on fat absorption.
Patients with pancreatic insufficiency have increased fecal
fat and decreased serum cholesterol. Steatorrhea manifests as
frequent, bulky, light-colored stools. A loss of 90% of pancre-
atic exocrine function is required before such findings
appear. If the patient retains 2–10% of normal pancreatic
function, steatorrhea is mild to moderate. If less than 2% of
normal function remains, steatorrhea is severe.
Pancreatic insufficiency affects fat absorption more than
that of proteins or carbohydrates. Malabsorption secondary
to fat loss or vitamin deficiency is rarely a problem. B vita-
mins, which are water-soluble, are absorbed through the
small intestine. Fat-soluble vitamins depend on bile salt
micelle formation for solubilization and do not require pan-
creatic enzymes for absorption. Vitamin B12 deficiency
occurs rarely but, when present, is an indication for exoge-
nous enzyme replacement.
Diagnosis
A. Secretin or Cholecystokinin Test—The duodenum is
intubated and pancreatic juice recovered after intravenous
injection of synthetic or purified secretin or cholecystokinin.
Optimally, pancreatic fluid bicarbonate should exceed 80
meq/L, and bicarbonate production should be greater than
15 meq every 30 minutes.
B. Pancreolauryl Test—A meal containing fluorescein
dilaurate is ingested, and the subsequent urinary excretion of
fluorescein is measured. Pancreatic esterase is responsible for
the absorption and release of fluorescein. The test is both
specific and sensitive and is the best modality for testing pan-
creatic exocrine function.
C. PABA Excretion (Bentiromide Test)—The synthetic
peptide bentiromide is administered (1 g orally), and the uri-
nary excretion of aromatic amines is measured. Patients with
chronic pancreatitis excrete about 50% of the normal
amount of the amines.
D. Fecal Fat (Balance) Measurement—A diet contain-
ing 75–100 g of fat—measured and given in the same
amount each day—is ingested daily for 5 days. Excretion of
less than 7% of the ingested fat is normal. Fat excretion of
more than 25% of the total daily intake suggests significant
steatorrhea.
Treatment
The diet should provide 3000–6000 kcal daily. Patients with
steatorrhea may not have diarrhea. Dietary fat restriction is
intended primarily to control diarrhea. If a patient does have
diarrhea and is restricted to 50 g fat, the daily allotment of fat
should be increased until the diarrhea reappears.
Pancreatic enzyme replacement can be accomplished
with exogenous extracts. With these formulations,
30,000–50,000 units of lipase can be distributed over several
feedings during the day. If malabsorption does not improve
with enzymes alone, the difficulty is usually due to destruc-
tion of the administered lipase by gastric acid. To alleviate
this problem, an H2-receptor–blocking agent is given and an
enteric-coated lipase formulation provided. When lipase is
administered in this form, the gastric pH is less likely to
affect the enzyme.
Caloric supplementation may be given in the form of
powder or as an oil containing medium-chain triglycerides
(MCTs). The fatty acids are absorbed more readily in this
preparation than when long-chain triglycerides are used. The
MCT oil is associated with bloating, diarrhea, nausea and
vomiting, and very poor patient acceptance.
 Lactase Deficiency
Lactase deficiency is a common problem among critically ill
patients. The symptoms are variable and can range from
minor abdominal bloating to distention, flatulence, and
cramping pain. Some patients, however, have severe diarrhea
in response to only a small amount of lactose. Although a
lactose tolerance test is available, clinical suspicion and rela-
tion of the diarrhea to the time of refeeding usually suggest
the diagnosis. Illnesses such as gastroenteritis may injure the
microvilli and lead to a temporary lactase deficiency. Several
congenital defects of disaccharidase have been described.
Most patients will give a history of dietary problems with
milk products, but the difficulties occasionally surface at
times of physiologic stress. They include sucrose-isomaltose
and glucose-galactose intolerance. Disaccharide deficiency
secondary to short bowel syndrome, celiac disease, giardiasis,
ulcerative colitis, cystic fibrosis, and postgastrectomy prob-
lems may be noted. In all cases, removal of lactose from the
diet and use of a non-lactose-based enteral nutritional sup-
plement usually solve the problem.
Choosing and using a pancreatic enzyme supplement. Drug Ther
Bull 1992;30:37–40. [PMID: 1591984]
Gillanders L et al: Dietary management of the patient with massive
enterectomy. N Z Med J 1990;103:322–3. [PMID: 2115150]
Hammer HF et al: Carbohydrate malabsorption: Its measurement
and its contribution to diarrhea. J Clin Invest 1990;86:1936–44.
[PMID: 2254453]
Nightingale JM et al: Short bowel syndrome. Digestion 1990;45:77–83.
Romano TJ, Dobbins JW: Evaluation of the patient with suspected
malabsorption. Gastroenterol Clin North Am 1989;18:467–83.
[PMID: 2680965] 
 Diarrhea
Diarrhea is defined as an increase in the fluidity, frequency,
or quantity (>200 g/day) of bowel movements. Several
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factors to be considered in the evaluation of diarrhea may
influence the frequency or even the fluidity of bowel move-
ments. Malabsorption or excessive secretion of water usually
results in passage of stools that contain excess water and are
therefore considered as diarrhea. The best index is daily stool
weight. Therefore, one may have small-volume diarrhea,
large-volume diarrhea, and other variants that depend on the
content of blood, mucus, or exudate. The various types of
diarrhea are listed in Table 14–2. Common causes of diarrhea
among patients in an ICU include psychogenic disorders,
drugs (especially antacids, antibiotics, and metoclopramide),
intestinal infections, cholestatic syndromes (eg, hepatitis, bile
duct obstruction, and steatorrhea), malabsorption (eg, short
bowel syndrome and afferent loop syndrome), diabetic neu-
ropathy, hyperthyroidism, and immunodeficiency.
Diagnosis
In general, diarrheal episodes are self-limiting, and diagnos-
tic testing is not necessary. However, in patients with unex-
plained severe or chronic diarrhea, etiologic evaluation may
become necessary. Review of the patient’s chart, evaluation
of drugs being used, and physical examination are often all
that are needed to establish the cause. Examination of stool
for polymorphonuclear cells and parasites and culture for
bacterial pathogens may be required. A sample for culture is
best obtained with the sigmoidoscope. Rectal biopsy may be
helpful and even necessary, especially when Entamoeba his-
tolytica infection is suspected. Assays of stool for Clostridium
difficile toxin are highly accurate and establish the diagnosis
of pseudomembranous enterocolitis.
Treatment
Before specific therapy for diarrhea is begun, it is important
to make certain that fluid losses have been replaced and elec-
trolyte imbalances corrected. Malnutrition should be man-
aged with parenteral nutrition.
Antidiarrheal agents should be used with great caution
and attention to the patient’s critical care history. The
antidiarrheal agent used most commonly is bismuth subsal-
icylate. This can be given in liquid or tablet form. The usual
dose is 30 mL up to eight times a day. Opioid analogs are also
popular; the most frequently prescribed form is diphenoxy-
late with atropine, one tablet three or four times daily as
needed. This drug is contraindicated in patients with jaun-
dice or pseudomembranous or endotoxin colitis and must be
used with caution in patients with advanced liver disease or
those who are addiction-prone. Concurrent use of this med-
ication with monoamine oxidase inhibitors may precipitate a
hypertensive crisis. A secondary drug is loperamide, 4 mg
initially and then 2 mg for each loose stool to a maximum
dose of 16 mg/day. Loperamide is effective in both acute and
chronic diarrhea. Opioids such as paregoric and codeine
phosphate were popular in the past but have little role in crit-
ically ill patients.
Clonidine, when administered as a 1-mg patch, is useful
in patients who have diabetes or cryptosporidiosis.
Octreotide acetate is useful when diarrhea is due to carcinoid
tumors, VIPoma, or AIDS. It is usually started at a dose of
50 μg subcutaneously once or twice daily. For carcinoid
and VIPomas, the required dose may be higher but averages
300 μg/day in two to four divided doses.
Grube BJ, Heimbach DM, Marvin JA: Clostridium difficile diarrhea
in critically ill burned patients. Arch Surg 1987;122:655–61.
[PMID: 3579579]
Pesola GR et al: Hypertonic nasogastric tube feedings: Do they
cause diarrhea? Crit Care Med 1990;18:1378–82. [PMID:
2123143]
Tibibian N: Diarrhea in critically ill patients. Am Fam Phys
1989;40:135–40.
Table 14–2. Classification of diarrhea.
I. Diarrhea secondary to excessive fecal water:  
A. Secretory diarrhea: Produced by excessive secretion by the
mucosal cells of the intestine. Causes: cholera, toxigenic E. coli
infections, Zollinger-Ellison syndrome, and VIPoma.  
B. Osmotic diarrhea: Produced by an excess of water-soluble
molecules in the lumen of the bowel, which cause osmotic reten-
tion of intraluminal water. Causes: Abuse or surreptitious use of
laxatives, administration of magnesium hydroxide, or undigested
disaccharides.  
C. Exudative disease: Produced by intestinal loss of serum proteins,
blood, mucus, or pus due to abnormal mucosal permeability.  
D. Accelerated transport: Impaired contact between intestinal chyme
absorbing surface, which results in rapid transport. Common in
short bowel syndromes.  
E. Motility disturbances: Causes: Amyloidosis, scleroderma, diabetes
mellitus, and bacterial overgrowth.  
II. Diarrhea not secondary to excessive fecal water:  
A. Small, frequent, and painful evacuations caused by partial
obstruction of the left colon or rectum.  
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Infections in the
Critically Ill
Laurie Anne Chu, MD
Mallory D. Witt, MD
The management of infected critically ill patients is a chal-
lenge for ICU physicians and staff. Patients admitted with
symptoms prior to hospitalization are considered to have
community-acquired infections, and those who develop
infection more than 48 hours following admission are con-
sidered to have hospital-acquired, or nosocomial, infections.
Seriously ill patients presenting with fever must be quickly
evaluated for possible infection because most are treatable.
However, drug fever, hypersensitivity reaction, collagen-
vascular disease, neoplastic disease, pulmonary embolism,
trauma, burns, pancreatitis, hypothalamic dysfunction, and
other noninfectious causes of fever must be considered in the
differential diagnosis.
In contrast, some patients may appear to be stable but
nonetheless have serious infections. Elderly patients, uremic
patients, and patients with end-stage liver disease or those
receiving corticosteroids often will fail to mount a signifi-
cant febrile response even to serious infection. In addition,
some infections are notorious for presenting with minimal
symptoms—these include infective endocarditis, sponta-
neous bacterial peritonitis, intraabdominal abscess, endoph-
thalmitis, and meningitis. In the absence of other symptoms
and signs, fever in the asplenic patient, the neutropenic or
immunosuppressed patient, the intravenous drug user or
alcoholic, and the elderly patient requires a rapid and thor-
ough diagnostic evaluation.
The infectious syndromes that may require direct admis-
sion and immediate therapy in the ICU—sepsis, community-
acquired pneumonia, urosepsis, infective endocarditis,
intraabdominal infections, and necrotizing soft tissue
infections—will be described in the following sections.
Special hosts such as patients with diabetes, asplenia or neu-
tropenia patients, and corticosteroid-treated individuals will
be discussed because they often have unique presentations
and complications. Care of the HIV-infected patient is discussed
in Chapter 27.
This chapter also will focus on other nosocomially
acquired infections that are of great concern to the critical
care physician either because of a high mortality rate, diag-
nostic challenge, frequency of occurrence, contagiousness, or
acquisition of antimicrobial resistance. Two unique disease
entities—botulism and tetanus—also will be discussed in
this chapter.
 Sepsis
ESSENT IALS  OF  D IAGNOS I S
 Wide spectrum of clinical findings ranging from fever,
hypothermia, tachycardia, and tachypnea to profound
shock and multiple-organ-system failure.
 Severe or complicated sepsis: lactic acidosis, acute res-
piratory distress syndrome (ARDS), acute renal failure,
disseminated intravascular coagulation (DIC), shock,
CNS dysfunction, or hepatobiliary disease.
 May present with altered mental status, unexplained
hyperventilation, or tachycardia alone.
 Often an identifiable site of infection.
 Predisposing risk factors for infection: organ system fail-
ure, bed rest, invasive procedures, any antibiotic use,
immunocompromised state.
General Considerations
To avoid ambiguity in interpreting the results of clinical tri-
als and to facilitate communication among clinicians, it has
been recommended that specific terminology be used when
referring to sepsis and sepsis syndromes. The systemic inflam-
matory response syndrome (SIRS) is the body’s response to
various insults, both infectious and noninfectious. Patients
with two or more of the following criteria are considered to
have SIRS: (1) temperature greater than 38°C or less than
36°C, (2) heart rate greater than 90 beats/min, (3) respiratory
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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rate greater than 20 breaths/min, and (4) white blood cell
count greater than 12,000 cells/μL, less than 4000 cells/μL, or
more than 10% immature (band) forms. Sepsis is defined as
the SIRS in response to infection. Severe sepsis is defined as
sepsis associated with organ dysfunction. Septic shock is
defined by the additional finding of refractory hypotension
(ie, hypotension despite adequate fluid resuscitation).
Multiple-organ-system dysfunction syndrome is defined as the
presence of altered organ function such that homeostasis
cannot be maintained without intervention. The vague terms
sepsis syndrome and septicemia no longer should be used.
Sepsis, severe sepsis, and septic shock can be considered
points on a continuum describing increasing severity of an
individual patient’s systemic response to infection. A prospec-
tive observational study demonstrated that among hospital-
ized patients meeting the criteria for SIRS, 26% subsequently
developed sepsis, 18% developed severe sepsis, and 4% devel-
oped septic shock. The interval from SIRS to severe sepsis and
septic shock was inversely correlated with the number of SIRS
criteria met. The mortality rates of sepsis, severe sepsis, and
septic shock were 16%, 20%, and 46%, respectively.
Sepsis and septic shock are encountered commonly in
ICUs. Septic shock with multiple-organ-system failure is the
most common cause of death in ICUs. There are currently
over 750,000 new episodes of sepsis each year in the United
States compared with 1979, when approximately 200,000
cases were reported. The greatest rise occurred in persons
over 65 years of age, but increases have been noted in all age
groups. This rising incidence is the result of more aggressive
support of seriously ill patients, the care of more immuno-
compromised patients, use of more mechanical and invasive
devices (eg, bladder catheters, endotracheal tubes, and
intravascular catheters) in ICUs, increased longevity of
patients with susceptibility to infection, and increasing preva-
lence of resistant organisms. Given the expanding use of inva-
sive maneuvers in critically ill patients, it is likely that the
number of cases will continue to rise. The mortality rate from
sepsis ranges from 20–50% in published studies, with over
210,000 patients dying each year. The immediate cause of
death is usually septic shock or multiple-organ-system failure.
Pathophysiology
The complex pathophysiology of sepsis is not completely
understood. Sepsis begins with colonization and proliferation
of microorganisms at a tissue site. Various host characteristics
and organism virulence factors determine both invasiveness
and subsequent intensity of the local inflammatory response.
Replicating microorganisms release numerous exogenous
enzymes and toxins that, in turn, trigger the release of
endogenous mediators, resulting in both local and systemic
inflammatory responses. The exogenous substances differ by
type of microorganism. In the case of gram-negative bacilli,
endotoxin (lipid A) contained in the outer cell membrane is
the chief toxic substance that initiates the cascade of events
clinically recognized as sepsis or septic shock. Endotoxin
activates the complement cascade and Hageman factor,
leading to initiation of both coagulation and fibrinolysis.
Prekallikrein is converted to kallikrein, resulting in the pro-
duction of bradykinin, a mediator of hypotension.
Endotoxin, after binding with and activating macrophages,
also initiates the production of numerous endogenous
cytokines. The biologic effects of these mediators are ampli-
fied, causing host injury by way of endothelial inflammation,
abnormalities in vascular tone, altered regulation of coagula-
tion, and myocardial depression. Many of these endogenous
mediators have been identified. Tumor necrosis factor, platelet-
activating factor, interleukins, interferon, prostaglandins,
thromboxane, leukotrienes, complement components C3a
and C5a, and others factors have been shown to mediate and
trigger the pathophysiologic events.
Tumor necrosis factor (TNF), probably the key endoge-
nous mediator, acts on a variety of cells, stimulating produc-
tion of other cytokines involved with sepsis and septic shock.
Plasma TNF concentrations are elevated in both gram-negative
and gram-positive sepsis. While endotoxin triggers TNF pro-
duction in gram-negative sepsis, the stimulus for release of
TNF in gram-positive sepsis is unknown. However, recent
studies have shown that mediators other than endotoxin can
induce TNF production, including IFN-α, prostaglandin E2,
immune complexes, and colony-stimulating factors.
Pathophysiologic factors in gram-positive bacterial sepsis
are not clearly defined. In the case of Staphylococcus aureus
strains that cause toxic shock syndrome, toxic shock syn-
drome toxin 1 (TSST-1) is the principal exogenous mediator.
Some virulent strains of group A β-hemolytic streptococci
produce similar toxins.
Microbiologic Etiology
Virtually any microorganism can cause sepsis or septic
shock, including bacteria, viruses, protozoa, fungi, spiro-
chetes, and rickettsiae. Bacteria remain the most common
etiologic agent responsible for sepsis.
Gram-negative sepsis cannot be distinguished from gram-
positive sepsis on the basis of clinical characteristics alone.
However, certain epidemiologic, host, and clinical factors
increase the likelihood of particular organisms. For example,
Escherichia coli is the most frequently demonstrated etiologic
agent of sepsis largely because the urinary tract is the most
common source of infection. The incidence of infection
caused by other gram-negative bacteria, staphylococci, strep-
tococci, anaerobes, Candida, and other organisms is largely
determined by epidemiologic and host factors that may be
identified by a thorough history and physical examination.
Clinical Features
A. Symptoms and Signs of Sepsis—Sepsis can present
with a spectrum of clinical features ranging from fever,
tachycardia, and tachypnea to profound shock and multiple-
organ-system (MOS) failure. The challenge to the critical
care specialist is to make the diagnosis early in the course of
the disease to increase the likelihood of a successful outcome.
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Early in its course, the diagnosis of sepsis may not be obvi-
ous. Moreover, debilitated patients may not exhibit signifi-
cant symptomatology at the onset of sepsis.
Implicit in the term sepsis is a documented site of infection
along with systemic signs and symptoms of fever (or
hypothermia), tachycardia, and tachypnea (Table 15–1). In
more severe or complicated sepsis, there is also impaired organ
system function, including lactic acidosis, ARDS, acute renal
failure, DIC, CNS dysfunction, and shock. A systolic blood
pressure of less than 90 mm Hg or a decrease from baseline of
over 40 mm Hg signifies septic shock. Septic shock can be fur-
ther subclassified into responsive and refractory shock states.
Patients who do not respond to aggressive fluid resuscitation
and who require dopamine at a rate of more than 6 μg/kg per
minute (or other vasopressor agents) are considered to be in
refractory shock, which confers a very poor prognosis.
Patients with clinical features of sepsis must be evaluated
carefully, with particular attention paid to their immune sta-
tus, clinical condition, and presence of specific epidemio-
logic factors. The main purpose of the physical examination
in the septic patient is to identify the source of infection and
to note the presence of shock. In particular, a search for a
focus of infection that may require surgical drainage should
be undertaken because these patients are unlikely to respond
to antibiotics alone.
B. Laboratory Findings—Patients suspected of having
sepsis should have relevant cultures obtained to document
the infection and laboratory testing to identify metabolic or
hematologic derangements. No single laboratory test is spe-
cific for sepsis. An elevated white blood cell count is nonspe-
cific and cannot differentiate infection from inflammatory or
other pathologic states. However, an increase in immature
polymorphonuclear white blood cells (bands) strongly sug-
gests infection. Routine serum electrolytes, blood urea nitro-
gen, serum creatinine, and liver function tests may assist in
determining the site of infection as well as identifying com-
plications of sepsis such as acute renal failure or hepatobil-
iary dysfunction. Arterial blood gases, plasma lactate, and
coagulation tests may demonstrate respiratory insufficiency,
metabolic acidosis, and DIC, respectively.
Although most septic patients are intermittently bac-
teremic or fungemic, only 40% have a pathogen identified by
blood cultures. Nevertheless, blood cultures should be
obtained in every patient suspected of having sepsis. The lab-
oratory may use special procedures and blood culture equip-
ment to enhance growth and isolation of fungi, including
Candida. Two sets of blood cultures, as well as urine, respira-
tory secretions, and wound exudates, for Gram staining and
culture should be collected. If indicated by clinical findings,
cerebrospinal fluid, pleural fluid, ascites fluid, and joint fluid
should be analyzed as well.
C. Imaging Studies—A chest radiograph may serve to iden-
tify pneumonia or ARDS; other studies such as ultrasonogra-
phy, CT scan, or MRI may be necessary to identify the site of
infection.
Differential Diagnosis
Many clinical conditions can resemble sepsis, septic shock,
and MOS dysfunction syndrome. Patients with severe burns,
multiple trauma, severe hemorrhagic or necrotizing pancre-
atitis, pulmonary emboli, acute myocardial infarction, and
various metabolic and hematologic abnormalities may have
features that mimic sepsis and its complications.
Treatment
Despite modern therapy, the mortality rate in sepsis is still
unacceptably high. However, the mortality rate can be
reduced by early diagnosis and prompt initiation of appro-
priate therapy. A delay in therapy permits the pathophysio-
logic events in sepsis to proceed, with a concomitant increase
in morbidity and mortality.
A. Supportive Care—Treatment of sepsis begins with oxy-
gen and ventilatory support as needed. The PO2 should be
maintained above 60–65 mm Hg with oxygen delivered by
cannula, mask, or respirator, if necessary.
The administration of intravenous fluids, either crystalloid
or colloid, expands the intravascular volume to correct the
relative deficit resulting from vasodilation owing to bacterial
products or host responses. Administration of several liters
of intravenous fluids is usually required over the first 2–6
hours. If cardiogenic pulmonary edema is a concern, pul-
monary arterial catheterization and monitoring may assist in
guiding appropriate fluid administration. Hypotension may
persist despite fluid replacement because of very low systemic
vascular resistance; in some patients, decreased myocardial
contractility associated with sepsis may contribute. The goal of
Stage Characteristics
I Systemic inflammatory response syndrome (SIRS). Two or
more of the following:
1. Temperature >38°C or <36°C
2. Heart rate >90 per minute
3. Respiratory rate >20 per minute
4. White blood cell count >12,000/μL or <4000/μL or
>10% bands 
II Sepsis
SIRS plus a culture-documented
infection 
III Severe sepsis
Sepsis plus organ dysfunction (lactic acidosis, oliguria,
hypoxemia, or acute alteration in mental status) 
IV Septic shock
Severe sepsis plus hypoperfusion (despite fluid resuscitation)
Table 15–1. Definitions of stages of sepsis. 
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initial resuscitation is to restore and maintain organ perfusion.
Signs of adequate organ perfusion include central venous pres-
sure of 8–12 mm Hg, mean arterial pressure of 65 mm Hg or
greater, urine output of 0.5 mL/kg per hour or more, and cen-
tral venous or mixed venous oxygen saturation of 70% or more.
Vasopressor agents should be used to assist in attaining these
goals. Norepinephrine is generally preferred over dopamine or
other pressors. Patients not responding to norepinephrine may
require the addition of phenylphrine or vasopressin. The use of
vasopressin may allow a reduction in the dose of the other vaso-
pressors, but this is controversial. Vasopressors are not effective
when fluid replacement has been inadequate.
A coordinated approach to early treatment of sepsis is associ-
ated with reduced mortality. This “early goal-directed” therapy,
targeted on the first 6 hours of care in the emergency department
and ICU, focuses on adequate fluid replacement first (to achieve
central venous pressure of 8–12 mm Hg) and then vasopressors
as needed to maintain a mean arterial pressure of greater than
65 mm Hg. Oxygen delivery is assessed using central venous O2
saturation, with a goal of greater than 70%. First, if the patient is
anemic, packed red blood cells are transfused to a target hemo-
globin of at least 10 g/dL. If central venous O2 saturation remains
less than 70%, then dobutamine is given.
B. Antibiotics—The next therapeutic challenge is choosing
appropriate antibiotics. All available clinical, epidemiologic,
and laboratory data should be considered in making this
decision. Rarely is the causative microorganism known at the
time treatment for sepsis is initiated, but if the source can be
determined and/or if a Gram-stained specimen of infected
material (eg, sputum, urine, or purulent drainage) can be
examined, the long list of possible microorganisms often can
be shortened. The following sections will provide a guide to
initial antimicrobial selection depending on the potential
source of infection. Importantly, intravenous antibiotics
must be given without delay and at appropriate doses.
Adjustments for age and renal and hepatic dysfunction are
not required for the starting dose of antibiotics.
C. Surgical Drainage—Significant collections of purulent
material must be drained and necrotic tissue excised in order
to treat sepsis. Surgeons may be reluctant to operate because of
the coexistence of acute renal failure, ARDS, or other organ
system failure, but the pathophysiologic consequences of sep-
sis will tend to continue unless surgical drainage is performed.
D. Adjunctive Therapy—In the last several years, there has
been renewed interest in using corticosteroids for sepsis and
septic shock, with a large French trial showing improved sur-
vival with approximately physiologic replacement with
hydrocortisone and fludrocortisone. The benefit was seen
among patients who failed to increase plasma cortisol levels
by more than 9 μg/mL in response to adrenocorticotropic
hormone (ACTH). This was in contrast to pharmacologic
doses of corticosteroids that, in the past, demonstrated no
difference or an adverse effect. A recent large multicenter
trial, however, demonstrated that physiologic replacement of
corticosteroids did not affect outcome, was associated with
adverse effects, and did not show that the cortisol response to
ACTH was helpful in identifying responders. It is recom-
mended that corticosteroids be given only in severe sepsis if
adrenal suppression is suspected (eg, recent administration
of corticosteroids, etomidate, and other drugs) or if the
patient fails to respond to fluids and vasoactive drugs.
A large trial comparing  recombinant human activated
protein C (drotrecogin-alfa [activated]) with placebo in
patients with sepsis showed a statistically significant
decrease in mortality in the treatment group. A major risk
accompanying use of activated protein C is hemorrhage. In
one study, 3.5% of patients receiving activated protein C
had serious bleeding compared with 2.0% of those receiv-
ing placebo. Adjunctive treatment with activated protein C
should be considered in patients with sepsis with severe
organ compromise and the highest likelihood of death. The
mechanism of action is unknown, but activated protein C
may modulate coagulation and inflammation associated
with severe sepsis.
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 Community-Acquired Pneumonia
ESSENT IALS  OF  D IAGNOS I S
 Patients present with cough, fever, and occasionally
pleuritic chest pain.
 Chest x-ray shows pulmonary infiltrates.
 Most common cause of community-acquired pneumonia
is Streptococcus pneumoniae.
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General Considerations
Community-acquired pneumonia accounts for a large
number of hospitalizations each year and is the sixth lead-
ing cause of death in industrialized communities. Mortality
ranges from 12–40%, the latter number reflecting the death
rate in patients with community-acquired pneumonia
requiring critical care. It is crucial for the physician to rec-
ognize the high-risk patient, to initiate diagnostic proce-
dures, and to begin appropriate and prompt antimicrobial
therapy.
A number of risk factors for community-acquired pneu-
monia have been identified and include increasing age, alco-
holism, diabetes mellitus, malignancy, immunosuppression,
institutionalization, and underlying cardiac, pulmonary,
hepatic, renal, or neurologic disease. A meta-analysis evalu-
ating outcomes of patients with community-acquired pneu-
monia revealed 11 statistically significant factors associated
with mortality: male sex, diabetes mellitus, underlying neu-
rologic or neoplastic disease, pleuritic chest pain, hypother-
mia, tachypnea, hypotension, leukopenia, multilobar
infiltrates, and bacteremia. Increasing age and bacterial etiol-
ogy of the infection were strongly associated with mortality
as well. Patients with infections owing to Pseudomonas aerug-
inosa, S. aureus, and enteric gram-negative rods are at partic-
ularly high risk for increased morbidity and mortality.
Microbiologic Etiology
The most common organisms identified in community-
acquired pneumonia requiring intensive care hospitalization
are S. pneumoniae, Legionella, and Haemophilus influenzae,
with S. aureus included in some series. H. influenzae usually
occurs in persons with chronic obstructive pulmonary dis-
ease. S. aureus can cause severe pneumonia with disease
acquired either by aspiration or by hematogenous spread.
The former is seen in patients with decreased local host
defenses (eg, after influenza, laryngectomy, bronchiectasis, or
cystic fibrosis) or generalized decrease in immunity (eg, mal-
nutrition or immunosuppression). Hematogenous disease
typically is seen in injection drug abusers or patients with
indwelling intravascular catheters. Recently, community-
acquired methicillin-resistant S. aureus (CA-MRSA) has
become an important pathogen. It should be suspected in
any patient with gram-positive cocci in sputum and in
patients with necrotizing pneumonia without suspected
aspiration. Aerobic gram-negative rods such as E. coli and
Klebsiella species are uncommonly implicated as pathogens
in community-acquired pneumonia, but they can cause
severe pulmonary disease in patients of advanced age with
underlying illness who are colonized with these enteric
organisms. Therefore, when enteric organisms are recovered
from sputum samples, it can be difficult to tell if their pres-
ence is pathogenic or simply reflects colonization. P. aerugi-
nosa traditionally has been considered a nosocomial
pathogen, although it can cause severe community-acquired
pneumonia. The physician should consider this organism in
a patient who has structural lung disease such as bronchiec-
tasis, was hospitalized recently, has recently received or is
currently receiving broad-spectrum antibiotics, or resides in
a nursing home.
Atypical pathogens, especially Legionella species, can
cause severe community-acquired pneumonia. More than
half of such cases are caused by L. pneumophila subgroup 1.
Chlamydia pneumoniae and Mycoplasma pneumoniae typi-
cally cause tracheobronchitis or mild pneumonia and only
occasionally severe pneumonia.
Respiratory tract viruses are not commonly thought of as
agents of community-acquired pneumonia. However,
influenza virus, respiratory syncytial virus, adenovirus, and
parainfluenza virus all have been associated with severe
pneumonitis. In the appropriate host, varicella-zoster virus,
cytomegalovirus, hantavirus, and coronavirus (the causative
agent of severe acute respiratory distress syndrome [SARS])
should be considered.
In patients with episodes of altered level of consciousness
caused by seizures, other neurologic diseases, and substance
abuse, an aspiration syndrome should be considered. Aspiration
of gastric contents can cause a chemical pneumonitis—with or
without a polymicrobial pneumonia—that can lead to an
anaerobic lung abscess if left untreated.
Other less common causes of community-acquired
pneumonia include Pneumocystis jiroveci infection in the
patient with risk factors for HIV infection or receiving long-
term steroids or other immunosuppressive therapy. The
physician should maintain a high level of suspicion for
Mycobacterium tuberculosis in the appropriate host. In
patients with a history of travel to the appropriate areas,
endemic mycoses (eg, Histoplasma capsulatum, Blastomyces
dermatitidis, and Coccidioides immitis) should be consid-
ered. Infection with Coxiella burnetii, the etiologic agent
of Q fever, can present with a community-acquired pneu-
monia in a patient with a history of exposure to infected
cattle, sheep, goats, or parturient cats. Chlamydophila
psittaci similarly should be considered if a history of expo-
sure to psittacine birds is elicited. Despite aggressive diag-
nostic efforts, no etiologic agent is identified in over
50–60% of cases of community-acquired pneumonia.
Clinical Features
The diagnosis of community-acquired pneumonia and the
choice of empirical antibiotics depends on results of a
detailed history and physical examination of the patient,
microbiologic analysis of sputum, and review of the chest
radiograph.
A. Symptoms and Signs—Patients with severe community-
acquired pneumonia may report fever, chills, cough (either
dry or productive), dyspnea, and pleuritic chest pain.
Nonspecific symptoms such as diarrhea, headache, myalgias,
or nausea and vomiting are often present. On physical exam-
ination, the typical patient with severe community-acquired
 CHAPTER 15364
pneumonia will have either fever or hypothermia accompa-
nied by tachycardia, tachypnea, abnormal breath sounds, and
possibly egophony or other evidence of lung consolidation. If
a pleural effusion is present, the patient may have decreased
breath sounds with dullness to percussion in the involved
hemithorax. The physical examination may provide clues to
guide empirical therapy. The presence of thrush or oral hairy
leukoplakia may suggest underlying HIV infection. Poor
dentition, caries, and gingival disease are often seen in
patients with aspiration pneumonia. Bullous myringitis is
seen occasionally with M. pneumoniae infection and also
may occur in patients with viral infection. The finding of a
new right-sided heart murmur should raise suspicion of
right-sided endocarditis. The skin should be examined care-
fully for any lesions that suggest one of the endemic mycoses.
B. Laboratory Findings—Routine laboratory studies should
be done, including a complete blood count; serum elec-
trolytes, urea nitrogen, and creatinine determinations; arterial
blood gas determinations; and chest x-ray. Because of their
high degree of specificity, blood cultures should be obtained
on all patients; 25% of patients with pneumococcal pneumo-
nia will be bacteremic. Pleural fluid collections, when present,
should be sampled to differentiate between a parapneumonic
effusion and a complicated effusion or empyema, the latter of
which would require definitive drainage. Pleural fluid should
be submitted for Gram stain, culture, cell count, pH, total
protein, and lactate dehydrogenase (LDH) concentration.
The Gram-stained smear of sputum may be the most
immediately helpful tool in determining empirical antibiotic
therapy. To ensure that an adequate specimen is obtained, the
stain should have 10 or fewer squamous epithelial cells and
more than 25 polymorphonuclear cells per high-power field.
Table 15–2 provides a guide to the probable pathogen based
on the Gram-stained smear of sputum (and other stains)
that can be done in an expeditious fashion. Legionella uri-
nary antigen is 80–95% sensitive for L. pneumophila group 1
and should be performed in appropriate patients.
Other more invasive methods of diagnosis are used in spe-
cial situations or when patients fail to respond despite appro-
priate empirical therapy. Fiberoptic bronchoscopy with
bronchoalveolar lavage may assist in the diagnosis of pneu-
monia caused by P. jiroveci, M. tuberculosis, and certain fungi.
However, routine bacterial culture is not specific for the diag-
nosis of pneumonia caused by bacteria that can colonize the
respiratory tract. The specificity of this procedure can be
increased by quantitative cultures and cytologic examination
of the specimen for intracellular bacteria. The specificity of
bronchoscopy cultures may be increased by use of the
protected brush technique with quantitative cultures.
Bronchoscopy allows for direct inspection of the airways and
sampling from the site of infection. Percutaneous fine-needle
lung aspiration has been performed in some situations. This
procedure is the most sensitive and specific of all diagnostic
maneuvers; however, complications include bleeding and
pneumothorax, which may increase patient morbidity.
Differential Diagnosis
The differential diagnosis of severe community-acquired pneu-
monia is extensive. In addition to the many infectious causes of
pneumonia, diseases that can mimic community-acquired
pneumonia include cardiogenic pulmonary disease, ARDS,
pulmonary emboli with infarction, pulmonary hemorrhage,
and lung cancer. Other less common diseases are pneumonitis
owing to collagen-vascular diseases, radiation or chemical
pneumonitis, hypersensitivity pneumonitis, sarcoidosis, pul-
monary alveolar proteinosis, and occupational lung disease.
Treatment
A. Empirical Antibiotic Therapy—Because it is impossible
to cover all pathogens empirically, the physician must use the
available data to make an informed decision regarding ther-
apy. Table 15–3 provides a guide for treatment of pneumonia
according to pathogen. In most situations involving hospital-
ized patients, when no clues to etiologic agent can be
obtained from history, physical examination, or laboratory
data, empirical antibiotic therapy should consist of a third-
generation cephalosporin in combination with a macrolide
or a quinolone.
Staining Characteristic Potential Pathogen 
Gram-positive diplococci
Gram-positive cocci in clusters
Streptococcus pneumoniae 
Staphylococcus aureus
Gram-negative coccobacilli Haemphilus influenzae 
Moraxella catarrhalis 
Gram-negative bacilli Enteric gram-negative rods
(Escherichia coli, Klebsiella
pneumoniae, Pseudomonas
aeruginosa) 
Mixed bacteria Oral contamination
Mixed aerobes and anaerobes 
No organisms present Viruses 
Mycoplasma penumoniae
Chlamydia pneumoniae
Coxiella burnetii
Legionella species 
Acid-fast stain-positive Mycobacterium pneumoniae
Nocardia species 
KOH/calcofluor white
stain-positive 
Coccidioides immitis
Histoplasma capsulatum 
Blastomyces dermatitidis 
Cryptococcus neoformans
Silver stain-positive Pneumocystis jiroveci
Table 15–2. Sputum-guided potential pathogens for
severe community-acquired pneumonia. 
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B. Resistance Issues and Therapeutic Implications—
S. pneumoniae is the most common cause of community-
acquired pneumonia, and the emergence of penicillin-
resistant strains of this pathogen should be considered when
choosing empirical therapy for critically ill patients. There is
marked geographic variation in the rates of penicillin resist-
ance. Up to 35% of isolates in the United States are not fully
susceptible to penicillin, and up to 22% are highly resistant
to penicillin. However, resistance to third-generation
cephalosporins is less likely. In general, the levels of β-lactam
antibiotics that can be achieved in the lung and bloodstream
with intravenous therapy far exceed the minimum inhibitory
concentration (MIC) for pneumococci with intermediate
and high levels of resistance (as long as the MIC is <4 μg/dL).
Thus, in most cases, in the absence of meningitis, a third-
generation cephalosporin is adequate. Few data are available
regarding pneumococcal infections when the MIC for the
organism is greater than 4 μg/dL. Infection with an organism
with this level of resistance is associated with increased mor-
tality. Some authorities suggest using vancomycin, a car-
bapenem, one of the newer respiratory quinolones, or
possibly linezolid if infection with such a strain is suspected.
Risk factors for drug-resistant S. pneumoniae include
extremes of age, recent antimicrobial therapy, coexisting ill-
nesses, immunodeficiency or HIV-infection, attendance at a
day-care center or family member of a child attending a day-
care center, and institutionalization.
Dremsizov T et al: Severe sepsis in community-acquired pneu-
monia: When does it happen, and do systemic inflammatory
response syndrome criteria help predict course? Chest
2006;129:968–78. [PMID: 16608946]
Mandell LA et al: Infectious Diseases Society of America/American
Thoracic Society consensus guidelines on the management of
community-acquired pneumonia in adults. Clin Infect Dis
2007;44:S27–72. [PMID: 17278083]
Oosterheert JJ et al: Severe community-acquired pneumonia:
What’s in a name? Curr Opin Infect Dis 2003;16:153–9. [PMID:
12734448]
 Urosepsis
ESSENT IALS  OF  D IAGNOS I S
 The patient may be asymptomatic.
 Flank or abdominal pain.
 Pyuria and white blood cell casts.
 Positive urine culture.
Patient Category Most Likely Causative Organisms Empirical Antibiotic Choices1
ICU patient S. pneumoniae
Legionella sp.
M. pneumoniae
Third-generation cephalosporin2 plus either
IV azithromycin or respiratory fluoroquinolone3
ICU patient with increased risk for P. aeruginosa
(recent antibiotic use, hospitalization, or structural
lung disease)
S. pneumoniae
Legionella sp.
H. influenzae
C. pneumoniae
Enteric gram-negative rods
P. aeruginosa
Antipseudomonal, antipneumococcal β-lactam4
plus ciprofloxacin or levofloxacin (750 mg/day).
Or
Antipseudomonal, antipneumococcal β-lactam4 plus
aminoglycoside and azithromycin
Or
Antipseudomonal, antipneumococcal β-lactam4 plus
aminoglycoside and respiratory fluoroquinolone3
ICU patient with increased risk for S. aureus
(gram-positive cocci in clusters in a tracheal
aspirate or in an adequate sputum sample,
end-stage renal disease, injection drug use, prior
influenza, prior antibiotic therapy, necrotizing
pneumonia in absence of risks for aspiration.)
Community-acquired methicillin-resistant
S. aureus (CA-MRSA)
Add vancomycin or linezolid 
1Initial empirical therapy. Changes should be based on results of microbiologic studies and clinical response.
2Third-generation cephalosporin (eg, ceftriaxone or cefotaxime).
3Fluoroquinolone with increased activity against S. pneumoniae (eg, levofloxacin).
4Cefipime, piperacilllin-tazobactam, imipenem, or meropenem.
Table 15–3. Empirical antibiotic therapy for community-acquired pneumonia in patients requiring ICU admission. 
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General Considerations
In the United States, acute pyelonephritis accounts for over
100,000 hospitalizations each year. The physician must be
alert for complications such as underlying immunosuppres-
sion, urinary tract obstruction, and intrarenal or perinephric
abscess formation. When hypotension or other signs of sep-
sis are present, patients should be admitted to the ICU for
appropriate hemodynamic monitoring and management.
Pathophysiology
There are two primary routes by which bacteria invade the
urinary system. In what is by far the most common route of
infection, bacteria gain access to the bladder via the urethra.
Urinary tract infections are common in women because the
relatively short female urethra allows retrograde passage of
bacteria into the bladder. In contrast, urinary tract infection
in men is a rare event in the absence of a urethral catheter or
unless there is obstruction of the urethra (eg, prostatic hyper-
plasia), preventing adequate bladder drainage. Once bacteria
have entered the bladder, they may under some circumstances
ascend the ureters to the renal pelvis and parenchyma. This
process is facilitated by the presence of vesicoureteral reflux.
For example, in the renal transplant patient, the transplanted
kidney is placed in the pelvis with the ureter surgically
implanted in the bladder; as a result, simple cystitis frequently
leads to acute transplant pyelonephritis.
Infection of the urinary tract by hematogenous spread is
a much less common occurrence. Staphylococcal bacteremia
or endocarditis can lead to seeding of renal parenchyma
with subsequent abscess formation. However, experimen-
tally produced gram-negative bacteremia rarely leads to
acute pyelonephritis.
Microbiologic Etiology
The majority (70–95%) of cases of community-acquired
acute urinary tract infections are caused by E. coli, with
Staphylococcus saprophyticus, enterococci, Proteus mirabilis,
Klebsiella species, and Enterobacter species identified in
most of the remaining cases. The list of etiologic agents is
modified by factors such as use of indwelling urinary
catheters, residence in an institutionalized setting, urinary
tract instrumentation, immunosuppression, or recent broad-
spectrum antibiotic administration. In any of these settings,
multidrug-resistant gram-negative bacilli, coagulase-negative
staphylococci, or Candida species may be responsible for
infection.
Clinical Features
A. Symptoms and Signs—Patients with urinary tract infec-
tions as the source of sepsis may present with localizing
symptoms such as flank pain or dysuria. However, many
patients present with nonspecific complaints, such as nausea,
vomiting, abdominal pain, fever, and chills. Physical
examination may detect the presence of flank tenderness. An
indwelling bladder catheter should trigger a prompt evalua-
tion of the urinary tract for the source of sepsis.
B. Laboratory Findings—Routine laboratory tests such as a
complete blood count and chemistry panel should be
obtained. Microscopic evaluation of a urine specimen is the
most important diagnostic test, typically revealing hematuria,
proteinuria, and pyuria (≥10 leukocytes/μL of urine), often
with white blood cell casts. Gram stain of the urine should be
performed; the presence of one organism per oil-immersion
field correlates with 105 bacteria per milliliter of urine or
more, with a sensitivity and specificity approaching 90%. The
presence of 5 or more organisms per oil-immersion field
increases the specificity to 99%. Additionally, determining the
morphology of the infecting bacteria (ie, gram-negative bacil-
lus or gram-positive cocci) may be used to direct empirical
therapy. Identification of the pathogen and the results of
antimicrobial susceptibility testing are usually available
within 48 hours, allowing tailoring of antimicrobial therapy.
Any patient sick enough to warrant hospitalization should
have blood cultures sent. A renal ultrasound examination or an
abdominal CT scan should be obtained in any patient with sus-
pected upper urinary tract obstruction admitted to the ICU.
C. Complications—Possible complications of acute
pyelonephritis include urosepsis, perinephric abscess,
intrarenal abscess, urinary tract obstruction, and emphyse-
matous pyelonephritis. In general, any patient who appears
toxic or has persistent fever or positive blood cultures beyond
the third day of appropriate therapy should undergo investi-
gation for obstruction, abscess, or other complications.
Perinephric abscesses usually are confined to the per-
inephric space by Gerota’s fascia but may extend into the
retroperitoneum. Thirty percent of patients with perinephric
abscess have a normal urinalysis, and up to 40% have a ster-
ile urine culture. Intrarenal abscess is usually a complication
of systemic bacteremia; thus the etiologic agent is often a
Staphylococcus. A plain film of the abdomen may reveal an
abdominal mass, an enlarged indistinct kidney shadow, or
loss of the psoas margin. Rapid diagnosis of perinephric or
intrarenal abscess can be made by renal ultrasound, CT scan,
or MRI. Renal ultrasound can detect an abscess once it
reaches 2–3 cm in size, whereas CT scan and MRI are more
sensitive, detecting abscesses as small as 1 cm in diameter.
Definitive treatment requires drainage of larger abscesses,
either by percutaneous access or open surgical drainage, with
concomitant antimicrobial therapy.
Emphysematous pyelonephritis is a rare complication
of urinary tract infections seen in patients with diabetes,
papillary necrosis, renal obstruction, or renal insufficiency.
The infecting organism is typically E. coli, Klebsiella
species, or Proteus species. Mortality is high, approaching
50% despite appropriate antimicrobial therapy. Diagnosis
is easily made with a plain film or with the more sensitive
CT scan of the abdomen; both will reveal gas in the renal
parenchyma.
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Treatment
In all patients, initial antimicrobial therapy should target the
organism seen on the Gram-stained smear of the urinary
sediment. In the absence of an identified organism on Gram
stain, empirical therapy should consist of a third-generation
cephalosporin, an extended-spectrum penicillin (eg,
piperacillin), a fluoroquinolone, and/or an aminoglycoside
depending on the severity of the infection, the patient’s renal
function and risk for renal insufficiency, and other factors. If
Enterococcus is suspected, ampicillin or piperacillin with or
without an aminoglycoside is appropriate. For emphysema-
tous pyelonephritis, immediate nephrectomy usually is
required.
Hooton TM: The current management strategies for community-
acquired urinary tract infection. Infect Dis Clin North Am
2003;17:303–32. [PMID: 12848472]
Rubenstein JN, Schaeffer AJ: Managing complicated urinary tract
infections: The urologic view. Infect Dis Clin North Am
2003;17:333–52. [PMID: 12848473]
 Infective Endocarditis
ESSENT IALS  OF  D IAGNOS I S
 Clinical presentation varies depending on infecting
organism.
 Patients with S. aureus infective endocarditis typically
present with a short prodrome and a sepsis syndrome.
Clues to the diagnosis of subacute infective endocardi-
tis include a new regurgitant murmur, Roth spots, Osler
nodes, Janeway lesions, splinter hemorrhages, hema-
turia, and splenomegaly.
 Blood cultures are needed for diagnosis.
General Considerations
The incidence of infective endocarditis in the general popu-
lation is estimated to be 1.7–6.2 cases per 100,000 person-
years. Risk factors include underlying valvular abnormalities.
Congenital or rheumatic heart disease, mitral valve prolapse
(particularly when regurgitation or thickened, redundant
valve leaflets are present), calcific valvular heart disease, and
prosthetic valves are implicated in a large percentage of cases.
Another increasingly important risk factor is injection drug
use. Among injection drug users, the presentation of infec-
tive endocarditis is usually acute, reflecting the virulent
nature of S. aureus, the pathogen most commonly associated
with infective endocarditis in this population.
Pathophysiology
The first step in infective endocarditis is the establishment of
bacteremia, which may occur during a dental or other medical
procedure, as a complication of injection drug use, or from
minor trauma. However, in most cases, no initiating event is
identified. The organism attaches to the abnormal endothe-
lial surface of the cardiac valve, and the vegetation propa-
gates with further bacterial proliferation. The complications
that then arise are the result of either (1) direct local invasion
(eg, periannular abscess formation), (2) systemic emboliza-
tion (eg, splenic, renal, or cerebral embolic), or (3) immuno-
logic phenomena (eg, glomerulonephritis or vasculitis).
Microbiologic Etiology
The microbiologic etiology of infective endocarditis has
undergone a shift in the past 3–4 decades. In the 1960s and
1970s, viridans streptococci and enterococci accounted for
up to 80% of cases and staphylococci for approximately 15%.
In more recent series, the viridans streptococci and entero-
cocci still account for 50% of cases, but staphylococci are
now implicated in approximately 50% of cases of acute infec-
tive endocarditis.
The most common bacterial cause of native-valve infective
endocarditis remains the viridans streptococci group. As noted
earlier, S. aureus infective endocarditis usually occurs in injec-
tion drug users and diabetics, who tend to have skin and nasal
colonization with the organism. Other less common pathogens
include S. pneumoniae; groups A, B, C, and G streptococci; and
Listeria monocytogenes, P. aeruginosa, Serratia marcescens, and
rarely, Neisseria gonorrhoeae. In cases of culture-negative endo-
carditis, the HACEK group of microorganisms (Haemophilus
parainfluenzae, H. aphrophilus, Actinobacillus actinomycetem-
comitans, Cardiobacterium hominis, Eikenella corrodens, and
Kingella kingae); nutritionally variant streptococci (now
Abiotrophia species); Brucella, Legionella, and Bartonella
species; C. burnetii; and fungi all should be considered. The
most common reason for culture-negative infective endocardi-
tis is prior antibiotic therapy.
Clinical Features
A. Symptoms and Signs—The clinical presentation of
infective endocarditis varies dramatically depending on the
infecting organism. Patients with S. aureus infective endo-
carditis typically present with a short prodrome and a sepsis
syndrome. Only rarely are the immunologic phenomena
associated with subacute infective endocarditis present.
Among injection drug users, infection usually involves the
tricuspid valve. Thus pulmonary manifestations predomi-
nate, which may manifest as multiple parenchymal infil-
trates, cavities, pleural effusion, or empyema. A murmur may
not be readily appreciated. The less virulent organisms, such
as the viridans streptococci, typically present with the classic
subacute infective endocarditis syndrome. Nonspecific
symptoms such as fatigue, malaise, or back pain usually have
been present for weeks. Clues to the diagnosis of subacute
infective endocarditis include a new regurgitant murmur,
Roth spots, Osler nodes, Janeway lesions, splinter hemor-
rhages, hematuria, and splenomegaly.
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Complications of infective endocarditis, such as conges-
tive heart failure or CNS emboli, may necessitate admission
to an ICU.
B. Laboratory and Radiographic Findings—The first clue
to the diagnosis of infective endocarditis is often a blood cul-
ture yielding growth of an appropriate organism. In the
patient with suspected infective endocarditis who presents
with subacute symptoms, three separate sets of blood cul-
tures should be obtained prior to initiating empirical antimi-
crobial therapy. A complete blood count may reveal only
leukocytosis in a patient with acute S. aureus infective endo-
carditis; however, evidence of anemia of chronic disease may
be present in a patient with subacute infective endocarditis.
Urinalysis may reveal hematuria, proteinuria, or pyuria. A
chemistry panel may demonstrate renal insufficiency (the
result of renal infarction), septic emboli, or immune-
complex glomerulonephritis. Patients may have other non-
specific indicators of acute inflammation, such as an elevated
erythrocyte sedimentation rate or C-reactive protein, hyper-
gammaglobulinemia, or a positive test for rheumatoid factor.
Chest x-ray may reveal multiple pulmonary infiltrates, cavi-
tary lesions, pleural effusion in right-sided disease, or pul-
monary edema in left-sided disease. A 12-lead ECG should be
obtained on all patients to look for intracardiac conduction
delay, manifested as a new first-, second-, or third-degree
heart block, suggesting the presence of an aortic ring abscess.
Any patient with neurologic symptoms should undergo brain
CT scan to look for embolic events or intracranial hemor-
rhage from rupture of an infected (“mycotic”) aneurysm.
Diagnosis of infective endocarditis is aided by use of the
modified Duke criteria (Table 15–4). Echocardiography
should be obtained on all patients in whom the diagnosis is
entertained because it provides both diagnostic and prog-
nostic information. The sensitivity of the transthoracic
echocardiogram for demonstrating valvular vegetations is
only about 60–70%, and for this reason, the procedure can-
not exclude infective endocarditis entirely. On the other
hand, transesophageal echocardiography has a reported sen-
sitivity approaching 95% and is particularly useful in detect-
ing periannular aortic abscess formation.
C. Complications—Because the most seriously ill patients
with infective endocarditis are admitted to the ICU, this pop-
ulation is likely to have a high rate of complications. Thus it
is important for the physician to remain vigilant for these
potential life-threatening events.
Congestive heart failure is the most common complica-
tion of acute infective endocarditis. It may occur acutely as a
result of perforation of a valve leaflet or rupture of a chorda
tendinea, from valvular outlet obstruction owing to large
vegetations, from creation of fistulous tracts leading to high-
output failure, or from prosthetic valve dehiscence.
Congestive heart failure also may present insidiously as a
result of progressive valvular insufficiency or ventricular dys-
function. Congestive heart failure that is refractory to med-
ical management necessitates valve replacement.
Systemic embolization occurs in up to a third of patients
with infective endocarditis. Risk factors for embolic events
include vegetation size greater than 1 cm on the trans-
esophageal echocardiogram, vegetation location on the ante-
rior leaflet of the mitral valve, increasing vegetation size
during appropriate antimicrobial therapy, and infection with
S. aureus, Candida species, one of the HACEK group, or the
Abiotrophia species. There is general agreement that the
occurrence of two or more serious embolic events while on
appropriate antimicrobial therapy is an indication for valve
replacement.
Periannular extension of infection occurs in 10–40% of
cases of native valve infective endocarditis and 55–100% of
cases involving a prosthetic valve. Periannular abscess forma-
tion is more common when the aortic valve is involved. The
infection spreads from the aortic ring and can rupture
through the membranous septum to involve the atrioven-
tricular node; thus the finding of a new intracardiac conduc-
tion delay is often a first clue to this life-threatening
complication. Creation of an intracardiac shunt also can
occur. Periannular extension of infection is best diagnosed by
transesophageal echocardiography, which has a sensitivity of
87% and a specificity of 95%. In most cases, periannular
abscess formation requires valve replacement.
In a patient with infective endocarditis who has persistent
bacteremia, fever, or sepsis in the setting of appropriate
antimicrobial therapy, the possibility of a splenic or renal
abscess should be considered. Splenic infarction occurs in
about 40% of cases of left-sided endocarditis; of these, 5%
progress to abscess formation. Abdominal CT scan or MRI
may be useful for diagnosis. Renal abscesses may require
drainage in conjunction with appropriate antimicrobial
therapy, depending on their size. Splenectomy is the defini-
tive treatment for splenic abscess.
One of the most feared complications of infective endo-
carditis is the development of an infected (“mycotic”)
aneurysm. The most common site of involvement is the
intracranial arteries, followed by the visceral bed and the
upper and lower extremities. The incidence of intracranial
mycotic aneurysms in patients with infective endocarditis is
about 1.2–5%. The overall mortality of this complication is
6–30% without rupture and 80% with rupture. The diag-
nostic method of choice is four-vessel cerebral angiography.
Decisions regarding therapy, including potential surgery,
should be individualized.
Treatment
The spectrum of initial antimicrobial therapy in a critically ill
patient with suspected infective endocarditis should be broad,
directed at the pathogens implicated most commonly in
this disease. Initial therapy should include vancomycin to
cover MRSA, a penicillin with activity against streptococci
and enterococci, and an aminoglycoside for synergy against
these organisms. If infection with S. aureus is highly likely,
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some infectious disease specialists use a semisynthetic peni-
cillin such as nafcillin or oxacillin in conjunction with van-
comycin to optimize coverage of both methicillin-sensitive
and methicillin-resistant strains. When faced with a patient
who has a history of a serious allergic reaction to penicillin,
the physician should use vancomycin in lieu of β-lactams.
Subsequent antibiotic therapy must be tailored once the
infecting organism and its drug susceptibility pattern are
known.
Baddour LM et al: Infective endocarditis: Diagnosis, antimicrobial
therapy, and management of complications. A Statement for
Healthcare Professionals from the Committee on Rheumatic Fever,
Endocarditis, and Kawasaki Disease, Council on Cardiovascular
Disease in the Young, and the Councils on Clinical Cardiology,
Stroke, and Cardiovascular Surgery and Anesthesia, and the
American Heart Association. Circulation 2005;111:e394–434.
[PMID: 15956145]
Beynon RP, Bahl VK, Prendergast BD: Infective endocarditis. Br
Med J 2006;333:334–9. [PMID: 16902214]
Definite infective endocarditis 1. Two major criteria, or
2. One major criterion and three minor criteria, or
3. Five minor criteria
Possible infective endocarditis 1. One major criterion and one minor criterion, or
2. Three minor criteria
Endocarditis rejected 1. Firm alternate diagnosis explaining evidence of infective endocarditis, or
2. Resolution of infective endocarditis syndrome with antibiotic therapy for less than 4 days, or
3. No pathologic evidence of infective endocarditis at surgery or autopsy, with antibiotic therapy for less than
4 days, or
4. Does not meet criteria for possible infective endocarditis, as above
Definitions for modified Duke clinical criteria
Major criteria
1. Blood culture positive for IE a. Typical microorganisms consistent with IE from two separate blood cultures: 
i. Viridans streptococci, Streptococcus bovis, HACEK group, S. aureus, or
ii. Community-acquired enterococci, in the absence of a primary focus, or
b. Microorganisms consistent with IE from persistently positive blood cultures, defined as follows:
i. At least two positive cultures of blood samples drawn 12 hours apart, or
ii. All of three or a majority of more than four separate cultures of blood (with first and last samples drawn at
least 1 hour apart)
iii. Single positive blood culture for C. burnetii or IgG antibody to phase I antigen ≥ 1:800 by IFA
2. Evidence of endocardial
involvement
a. Echocardiogram1 positive for IE, defined as follows:
i. Oscillating intracardiac mass on valve or supporting structures, in the path of regurgitant jets, or on
implanted material in the absence of an alternative anatomic explanation, or
ii. Abscess, or
iii. New partial dehiscence of prosthetic valve
b. New valvular regurgitation (worsening or changing of preexisting murmur not sufficient)
Minor criteria 1. Predisposition, predisposing heart condition or injection drug use
2. Fever, temperature >38ºC
3. Vascular phenomena, major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial
hemorrhage, conjunctival hemorrhages, or Janeway’s lesions
4. Immunologic phenomena: glomerulonephritis, Osler’s nodes, Roth’s spots, and rheumatoid factor
5. Microbiological evidence: positive blood culture but does not meet a major criterion as noted above2 or sero-
logic evidence of active infection with organism consistent with IE
1Transesophageal echocardiogram recommended in patients with prosthetic valves, rated at least “possible IE” by clinical criteria, or compli-
cated IE (paravalvular abscess); otherwise, use transthoracic echocardiogram.
2Excludes single positive cultures for coagulase-negative staphylococci and organisms that do not cause endocarditis.
Table 15–4. Modified Duke clinical criteria for infective endocarditis.
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 Necrotizing Soft Tissue Infections
ESSENT IALS  OF  D IAGNOS I S
 Patients complain of pain out of proportion to physical
findings.
 Essential to differentiate a necrotizing soft tissue infection
from a simple cellulitis.
 Metabolic acidosis, renal insufficiency, and other signs
of organ dysfunction may be present.
General Considerations
Necrotizing fasciitis is an uncommon soft tissue infection
caused by a variety of toxin-producing bacteria. There is fas-
cial necrosis, often with less marked involvement of overly-
ing skin and underlying muscle, and signs of systemic
toxicity. The true incidence of necrotizing soft tissue infec-
tions is difficult to quantify because they are not reportable.
Necrotizing fasciitis can result from a large number of asso-
ciated conditions, including trauma, surgical procedures,
and relatively benign local infections of the skin or soft tis-
sues. The mortality rate ranges between 15% and 52% in
most series. Risk factors for necrotizing soft tissue infections
include diabetes mellitus (the most common preexisting
condition), peripheral vascular disease, alcoholism, injection
drug use, obesity, malnutrition, and immunosuppression,
including HIV infection.
The multitude of terms used to describe soft tissue
infections may be confusing to the reader: hemolytic strep-
tococcal gangrene, progressive synergistic bacterial gangrene,
necrotizing erysipelas, suppurative fasciitis, acute dermal
gangrene, Fournier’s gangrene, and progressive postoperative
bacterial synergistic gangrene all have appeared in the liter-
ature. Distinguishing between the various categories of
necrotizing soft tissue infections is not always necessary
because prognosis and treatment of these conditions are
quite similar.
Pathophysiology
In the pathogenesis of necrotizing soft tissue infections, bac-
teria typically are introduced into the skin or soft tissues by
trauma, either inadvertently or iatrogenically. Inciting events
that have been reported to lead to soft tissue infections
include surgery, blunt or penetrating trauma, insect bites,
varicella infection, injection drug use, perforated viscus, per-
ineal abscess, diverticulitis, percutaneous drainage of
intraabdominal abscess, renal calculi, dental infection or
procedure, pharyngitis, and exposure to sea water.
Hematogenous introduction of the bacteria into soft tissue
has been documented with S. pyogenes and S. aureus (includ-
ing methicillin-resistant S. aureus).
Once bacteria gain entry into the host tissues, bacterial
toxins and endogenous cytokines act synergistically to pro-
duce tissue damage. Both exotoxin A and exotoxin B have
been identified in invasive group A streptococcal infections.
Histopathologic examination of involved tissue typically
reveals widespread necrosis of the fascia and subcutaneous
fat and thrombosis and endarteritis of small vessels.
Occasionally, myonecrosis of underlying skeletal muscle will
be observed.
Microbiologic Etiology
There are three predominant types of necrotizing fasciitis,
with distinctions based on microbiologic etiology. Type 1 is
polymicrobial infection, with a combination of non–group A
streptococci, anaerobes, and facultative anaerobes, usually
Enterobacteriaceae. Among persons developing type 1
necrotizing fasciitis, certain host factors are associated with
infection by specific bacteria. For example, diabetics tend to
become infected with Bacteroides species, S. aureus, and the
Enterobacteriaceae. Immunosuppressed patients may become
infected with P. aeruginosa and other Enterobacteriaceae. Of
note, recent reports describe necrotizing fasciitis owing to
MRSA in patients with underlying HIV infection. Clostridium
species are seen more commonly following trauma. On aver-
age, four different species of bacteria are identified by culture
in patients with type 1 necrotizing fasciitis.
Type 2 necrotizing fasciitis is defined by infection with
group A β-hemolytic streptococci, occurring either alone or
in combination with staphylococci. Type 3 necrotizing fasci-
itis is characterized by infection with marine vibrios follow-
ing exposure to sea water. This group of gram-negative rods
consists of Vibrio vulnificus, V. parahaemolyticus, V. damsela,
and V. alginolyticus; V. vulnificus is considered to be the most
virulent.
Clinical Features
A. Symptoms and Signs—The typical patient presents with
a history of 5–7 days or fewer of localized pain, redness, and
swelling. On physical examination, the patient may be tachy-
cardiac or tachypneic (in compensation for metabolic acido-
sis). Fever is not uniformly present, with up to 50% of
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patients being afebrile. An area of what initially appears to be
simple cellulitis may be noted, with localized warmth, ery-
thema, and tenderness of the skin and soft tissues. An impor-
tant clue to the diagnosis of necrotizing fasciitis is the
presence of pain disproportionate to physical findings. Rapid
progression of soft tissue involvement is typical, with the
evolution of a smooth, tense, and edematous lesion to blister
and bulla formation with an underlying dusky blue hue to
skin surfaces. With progression of soft tissue involvement,
the subcutaneous nerves are destroyed, resulting in anesthe-
sia of overlying skin. However, physical findings may be non-
specific: About 75% of patients present only with pain,
swelling, and cutaneous erythema. Specific findings sugges-
tive of invasive soft tissue involvement, such as crepitus and
blistering, are present in less than 40% of patients.
B. Laboratory Findings—Complete blood count, a chem-
istry panel, and liver enzymes should be obtained on all
patients. Leukocytosis with left shift is typically present;
blood chemistries may reveal metabolic acidosis, renal insuf-
ficiency, and other evidence of organ dysfunction. Creatine
kinase may be elevated, reflecting myonecrosis. One retro-
spective study identified a white blood cell count of greater
than 14,000/μL, a serum sodium of less than 135 mmol/L,
and a serum urea nitrogen of greater than 15 mg/dL as use-
ful in distinguishing patients with necrotizing fasciitis from
patients with cellulitis. Plain films occasionally reveal gas in
the soft tissue, a finding that is specific for necrotizing fasci-
itis. MRI may be a more sensitive tool in differentiating a
necrotizing soft tissue infection from simple cellulitis; how-
ever, this diagnostic modality is not readily available at all
centers. Diagnosis requires surgical exploration of the
involved soft tissue—the hallmark of necrotizing fasciitis is
nonadherence of fascia to underlying muscles on blunt dis-
section. In some cases, a full-thickness biopsy with immedi-
ate frozen section will reveal fascial necrosis. Surgically
debrided tissue should be submitted for aerobic and anaero-
bic bacterial cultures to allow appropriate tailoring of antibi-
otic therapy. Gram stain of an aspirate from the necrotic
center of the lesion has been shown to correlate well with
culture results.
Differential Diagnosis
The differential diagnosis of necrotizing fasciitis includes cel-
lulitis, erysipelas, thrombophlebitis, myositis, and compart-
ment syndrome. In many cases, the differentiation of these
entities from necrotizing fasciitis can be made on clinical
grounds.
Treatment
A. Empirical Antibiotic Therapy—Empirical antimicrobial
treatment of necrotizing fasciitis should include coverage of
aerobic gram-positive cocci, aerobic gram-negative rods, and
anaerobes. Initial antimicrobial choices could include a peni-
cillin or a first-generation cephalosporin along with an
aminoglycoside and either clindamycin or metronidazole.
Given the dramatic increase in rates of community-acquired
MRSA infections, empirical therapy should include clin-
damycin, trimethoprim-sulfamethoxazole, or in some cases,
vancomycin. If S. pyogenes is suspected, the treatment of
choice is high-dose penicillin. In this setting, animal data
support the addition of clindamycin; in the presence of a
high inoculum of organisms in a stationary phase of growth,
penicillin-binding proteins are not fully expressed, reducing
the efficacy of penicillin. Furthermore, clindamycin acts as a
protein synthesis inhibitor at the ribosome, which may sup-
press streptococcal toxin production. If Vibrio infection is
suspected, tetracycline should be added to the regimen.
When clostridial myonecrosis is a consideration, high-dose
penicillin with or without clindamycin should be initiated.
B. Surgery—Because of tissue hypoxia, necrosis, and blood
vessel thrombosis, antibiotics alone never should be consid-
ered definitive therapy for necrotizing fasciitis. Early
debridement of all necrotic tissue is imperative for control of
infection. The goal of surgery is twofold: to render a prompt
diagnosis and to perform definitive debridement. Patients
require frequent reevaluation of the surgical site—at least
every 12 hours. Repeat debridement is often necessary.
C. Adjunctive Therapies—Supportive care is critical, with
appropriate fluid resuscitation and nutritional support to
promote wound healing. The issue of adjunctive hyperbaric
oxygen therapy is controversial; however, the data to support
its use consist of retrospective studies, case reports, and ani-
mal studies. If hyperbaric oxygen is readily available, its use
can be considered. However, it never should be considered an
alternative to adequate surgical debridement.
Prognosis
The mortality rate associated with necrotizing fasciitis is high.
Risk factors for mortality have been identified as age over
60 years, female sex, extent of infection on presentation, delay
in surgical debridement, elevated creatinine, elevated blood
lactate, white blood cell count greater than 30,000/μL, presence
of bacteremia, and degree of organ dysfunction on admission.
The physician should maintain a high level of suspicion when
evaluating patients with soft tissue infections because early
diagnosis with prompt surgical debridement remains the
most important modifiable determinant of prognosis.
Daum RS: Clinical practice: Skin and soft-tissue infections caused
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 Intraabdominal Infections
ESSENT IALS  OF  D IAGNOS I S
 Symptoms may be nonspecific, with patients reporting
vague abdominal pain, anorexia, and fever.
 Abdominal examination may reveal absent or dimin-
ished bowel sounds, with peritoneal signs.
 Laboratory findings are nonspecific in patients with
intraabdominal sepsis.
General Considerations
Intraabdominal infections are a significant cause of mortal-
ity and morbidity in the ICU. The actual incidence of
intraabdominal infections is difficult to quantify because this
category includes a wide range of diagnoses.
Pathophysiology
See Table 15–5.
Microbiologic Etiology
See Table 15–5. The majority of intraabdominal infections
are polymicrobial in nature, caused by Enterobacteriaceae,
anaerobes, or streptococci. The organisms isolated from a
given intraabdominal infection reflect the flora native to the
involved region of the GI tract. The normal flora of the stom-
ach, duodenum, and proximal small bowel consist of small
numbers of viridans streptococci and other microaerophilic
streptococci. The distal small bowel is populated with larger
numbers of Enterobacteriaceae, enterococci, and anaerobes.
The colon is estimated to contain up to 1012 organisms per
Intraabdominal
Infection Pathophysiology Microbiologic Etiology Diagnostic Tests
Empirical Antimicrobial
Therapy
Peritonitis (spontaneous) Translocation of bacteria
across gut lumen in
cirrhosis
E. coli (most frequent),
K. pneumoniae, S. pneumo-
niae, streptococci, enterococci
Paracentesis (neu-
trophils >250/μL,
positive Gram stain
or culture)
Third-generation cephalosporin
(preferably cefotaxime or
ceftriaxone)
Peritonitis (secondary) Perforation of viscus Enterobacteriaceae, anaer-
obes, streptococci, entero-
cocci, Candida species
Paracentesis (polymi-
crobial Gram stain or
culture), plain films
or CT showing free
peritoneal air
β-lactam/β-lactamase inhibitor
or
Third-generation cephalosporin (or
cefepime) + metronidazole 
or
Quinolone + metronidazole
or
Carbapenem 
or
Monobactam + metronidazole
Intraperitoneal abscess Complication of
spontaneous or
secondary
peritonitis
Enterobacteriaceae, anaer-
obes, streptococci, Candida
species
CT scan, ultrasound,
perhaps radionuclide
scan
Pancreatic abscess Complication of pancre-
atitis (biliary, ethanol,
postoperative, or post-
traumatic)
Enterobacteriaceae, anaer-
obes, streptococci, entero-
cocci, Candida species
CT scan or ultrasound
Hepatic abscess Local spread from con-
tiguous infection or
hematogenous seeding
of liver
Mixed facultative and anaero-
bic species (most common),
unless biliary tract source
(enteric gram-negative bacilli
and enterococci); consider
E. histolytica
CT scan or ultrasound
Table 15–5. Intraabdominal infections: Pathophysiology, microbiology, and treatment.
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gram of feces. The predominant flora consists of anaerobes,
Enterobacteriaceae, and enterococci. Candida species colo-
nize the GI tract in approximately 50% of individuals, which
may be an important pathogen in patients with bowel perfo-
ration. The normal microbiologic flora of the GI tract are
altered dramatically by antibiotic therapy, selecting for
increased colonization with Candida species, enterococci,
and other relatively resistant gram-negative bacilli such as
Pseudomonas and Enterobacter species.
Intraabdominal infections may be caused by pathogens
not typically associated with GI flora. In patients with spe-
cific risks (ie, suspected exposure or immunocompromised),
the following organisms should be considered: M. tuberculo-
sis, N. gonorrhoeae, C. trachomatis, C. immitis, Yersinia ente-
rocolitica, and Actinomyces.
Clinical Features
A. Symptoms and Signs—The symptoms and signs of
intraabdominal sepsis not only vary among patients but also
depend on the underlying etiology of the infection.
Symptoms may be nonspecific, with patients reporting vague
abdominal pain, anorexia, or subjective fever. Patients may
be febrile or hypothermic; tachycardia is common, and
tachypnea may be present in compensation for an underly-
ing metabolic acidosis. Abdominal examination may reveal
absent or diminished bowel sounds, with peritoneal signs.
Patients who are morbidly obese, elderly, neutropenic, or
receiving steroids or other immunosuppressive agents are
more likely to have nonspecific complaints, along with rela-
tively benign abdominal findings on physical examination,
even in the presence of severe intraabdominal pathology.
Thus the physician must maintain a high level of suspicion
when evaluating these patient populations.
B. Laboratory Findings—Laboratory findings are nonspe-
cific in patients with intraabdominal sepsis. Peripheral leuko-
cytosis is common, although leukopenia may be seen in some
patients, perhaps owing to intraabdominal sequestration of
white blood cells. Metabolic acidosis may be present and
should prompt consideration of bowel ischemia. Elevation of
liver aminotransferases, although relatively common, is a
nonspecific finding in intraabdominal infection and only
rarely heralds a focal intrahepatic infection. Elevation of
serum alkaline phosphatase and total bilirubin mandates
prompt investigation of the biliary tree to rule out cholecysti-
tis, cholangitis, or an obstructing mass. An elevated serum
amylase or lipase may point to pancreatitis, although an
abnormal serum amylase also may be seen with bowel infarc-
tion or perforation. If ascites is present, a diagnostic paracen-
tesis should be performed, with assessment of cell count,
protein, albumin, Gram stain, and culture of ascitic fluid.
C. Imaging Studies—Supine and upright films of the
abdomen may reveal free air if viscus perforation is present.
Other diagnostic clues may be present on plain radiographs,
such as an elevated hemidiaphragm that may herald an
intraabdominal abscess. Abdominal ultrasound is another
radiographic diagnostic tool that is often readily available
and relatively inexpensive to perform. Abdominal ultra-
sonography is particularly useful in detecting pathology of
the right upper quadrant, retroperitoneum, and pelvis,
where its sensitivity is about 90%. However, ultrasound is less
sensitive in the interloop areas, and the presence of large
amounts of bowel gas may limit the utility of ultrasonography.
CT scan of the abdomen is more sensitive than ultrasound in
the diagnosis of intraabdominal pathology; however, it is more
expensive and requires administration of intravenous and oral
contrast agents. MRI may be a useful diagnostic tool because
it avoids the need for intravenous contrast agent administra-
tion; however, it is costly, not readily available in all centers, and
is not usable in unstable or mechanically ventilated patients.
Treatment
Most intraabdominal infections are caused by polymicrobial
enteric flora; thus empirical therapy should be targeted toward
facultative gram-negative bacilli and anaerobes. In the past,
aminoglycosides were used as first-line therapy against gram-
negative bacilli but are no longer used widely because newer
agents have demonstrated improved penetration and reduced
toxicity. β-lactam/β-lactamase-inhibitor combinations, a car-
bapenem, a third- or fourth-generation cephalosporin, a
quinolone, and a monobactam in conjunction with metron-
idazole are all recommended regimens. None of these regi-
mens has demonstrated consistent superiority over the others.
While metronidazole resistance among B. fragilis is rare,
increasing prevalence of clindamycin-resistant B. fragilis has
rendered this agent less useful for anaerobic coverage. The
combination of metronidazole and aztreonam is not used
widely because of the lack of gram-positive coverage. The
decision to add an antifungal agent should be individualized.
Immediate empirical antifungal therapy is rarely indicated
unless a primary fungal process is suspected. If, during the
course of therapy, Candida is isolated from blood or peritoneal
cultures, or if histopathologic evidence of fungal tissue inva-
sion is obtained, initiation of antifungal therapy with flucona-
zole or other agent is appropriate. In addition to empirical
antimicrobial therapy, surgical consultation should be
obtained for all patients with suspected intraabdominal sepsis.
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 Infections in Special Hosts
Many patients have underlying diseases that render them
susceptible to specific pathogens. Included among these are
 CHAPTER 15374
patients with neutropenia, organ transplant recipients, dia-
betics, asplenic individuals, patients on chronic corticos-
teroid therapy, and HIV-infected patients. Knowledge of an
underlying condition may lead a physician to modify or
broaden empirical antibiotic therapy when such a patient is
admitted to the ICU with infection or suspected infection.
The physician also should keep in mind that relative
immunosuppression may alter or minimize presenting
symptoms and physical findings. Patients with HIV infection
represent a population with specific management issues (see
Chapter 27). In general, immunocompromised patients who
require intensive care for an infectious process should have
an infectious disease consultant involved in their care.
The Neutropenic Patient
Advances in the fields of oncology and hematology have led to
increasing numbers of patients undergoing intensive
chemotherapy for hematologic or solid-organ malignancies,
with significant resulting immunosuppression. One of the
major complications of such therapy—and an important cause
of morbidity and mortality—is supervening infection. At least
50% of febrile neutropenic patients have either established or
occult infection; only 30–50% of these episodes can be docu-
mented microbiologically. Because these patients have a dimin-
ished immune response to infection owing to their
neutropenia, it often happens that no obvious signs of infection
such as purulent drainage, erythema, or edema are present.
Fever is frequently the only sign. Empirical antimicrobial ther-
apy of the febrile neutropenic patient is the standard of care.
Using the Infectious Disease Society of America (IDSA) guide-
lines, neutropenia is defined as fewer than 500 neutrophils/μL
or fewer than 1000 neutrophils/μL with an anticipated decline
to fewer than 500 neutrophils/μL. Fever is defined as a single
oral measurement of 38.3°C or greater or 38°C or greater over
a period of 1 hour. A thorough history and physical examina-
tion should be performed in patients with neutropenia and
fever, with scrutiny of the skin, oropharynx, and perirectal areas
to localize a source of infection. Blood cultures for bacteria and
fungi, a chest x-ray, liver enzymes, a complete blood count, and
a chemistry panel should be obtained. Once such tests have
been performed, empirical antimicrobial therapy should be
initiated without delay. In previous decades, the most common
pathogens identified in febrile neutropenic patients were aero-
bic gram-negative bacilli of enteric origin, including E. coli,
Klebsiella species, and P. aeruginosa. However, an increasing
incidence of bacteremia owing to gram-positive organisms
such as S. epidermidis, S. aureus, β-hemolytic streptococci, and
enterococci has been documented in recent years, thought to be
the result of increased use of indwelling intravenous catheters,
administration of chemotherapeutic regimens that induce
mucositis, induction of profound and prolonged neutropenia,
unrecognized herpetic mucositis, routine use of H2 antagonists,
and use of prophylactic antimicrobial agents with broad gram-
negative coverage (such as trimethoprim-sulfamethoxazole or
ciprofloxacin).
Initial empirical therapy should be targeted against gram-
negative bacilli using an antipseudomonal antibiotic (eg,
piperacillin, ceftazidime, cefepime, meropenem, or
imipenem-cilastin) in conjunction with an aminoglycoside.
Monotherapy with ceftazidime, cefepime, meropenem, or
imipenem-cilastin can be considered. The decision to add
vancomycin to initial empirical therapy should be individu-
alized; if an indwelling catheter is considered a likely source
of infection, if resistant gram-positive infection is considered
likely because of prophylactic administration of antibiotics,
or if significant mucositis, hypotension, or other hemody-
namic instability is present, then vancomycin may be added
to the initial regimen. However, it has been demonstrated
that patients do not suffer increased morbidity or mortality
if vancomycin is withheld until clinical or microbiologic
evidence for such an infection exists.
Once results of blood and other body fluid cultures
become available, antimicrobial therapy may be directed at
specific organisms identified. If, however, the patient remains
febrile after 5–7 days of broad-spectrum antimicrobial ther-
apy and no source of infection has been found, empirical
antifungal therapy should be considered. Amphotericin B
traditionally has been the antifungal agent of choice in this
setting. Acceptable alternatives include lipid formulations of
amphotericin B or echinocandins. Approximately one-third
of neutropenic patients who remain febrile for 1 week or
more on broad-spectrum antimicrobial therapy will be found
to have a systemic fungal infection, usually with Candida or
Aspergillus species. Importantly, isolation of C. glabrata and
C. krusei is more common than C. albicans in some centers,
and affects the choice of empirical antifungal agent.
Organ Transplant Recipients
Organ transplant recipients, because of the nature of their
immunosuppressive therapy, are particularly vulnerable to
infectious complications. Susceptibility to specific infectious
complications in the transplant host varies over time in the
posttransplant setting. A patient’s risk of acquiring a partic-
ular infection is determined by his or her state of immuno-
suppression, as well as individual epidemiologic exposures,
both in the community and in the hospital (eg, M. tubercu-
losis or Legionella). In the first month after transplantation,
90% of infectious complications are typical hospital-
acquired infections, such as transplant wound infection,
pneumonia, urinary tract infection, or catheter-related infec-
tion. Rarely, a systemic infection may be transmitted with
the allograft, or more commonly, an underlying latent infec-
tion in the transplant recipient may recrudesce with
immunosuppression. One to six months following trans-
plantation, organ transplant recipients experience maximal
T-cell immune dysfunction and therefore are particularly
vulnerable to intracellular pathogens (eg, cytomegalovirus,
human herpes virus 7, P. jiroveci, L. monocytogenes, cryptococci,
Toxoplasma, and M. tuberculosis) and endemic mycoses that
may reactivate during this period. In the absence of an
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environmental exposure to a specific pathogen, other oppor-
tunistic infections are rare during this time period. Six
months after transplantation, an individual’s risk of infec-
tion depends on the clinical course and health care status. In
the 80% of patients who have experienced an uneventful
posttransplant course, infectious complications are typically
the same as those of the community at large (eg, influenza
and pneumococcal infection). Another approximately 10%
of patients will develop chronic or progressive viral infec-
tions such as cytomegalovirus, hepatitis B virus, hepatitis C
virus, or Epstein-Barr virus. In the remaining 10% of
patients, chronic or recurrent rejection requires repeated
courses of high-dose immunosuppressive therapy. This pop-
ulation remains at risk for infection with the intracellular
pathogens mentioned earlier, as well as with Aspergillus
species.
Asplenic Patients
The spleen serves a critical function in antibody synthesis,
microbial filtration, and opsonin production. Patients with
asplenia therefore are uniquely susceptible to overwhelming
infection with encapsulated organisms such as S. pneumo-
niae, N. meningitidis, and H. influenzae. Other less common
pathogens seen in the asplenic host include K. pneumoniae,
S. agalactiae, E. coli, Capnocytophaga canimorsus, and S. aureus.
They are also prone to severe infection with intracellular par-
asites such as Babesia and Plasmodium. When attempting to
identify at-risk patients, a history of surgical splenectomy
should be elicited from the patient. When the patient can-
not provide an accurate history, physical examination may
reveal the presence of a surgical splenectomy scar. However,
a functional asplenic state may be overlooked. Conditions
that can lead to functional asplenia include congenital
hyposplenism, sickle cell disease, graft-versus-host disease,
rheumatoid arthritis, systemic lupus erythematosus, amyloi-
dosis, ulcerative colitis, celiac disease, and chronic alcoholism.
A clue to asplenia is the presence of Howell-Jolly bodies on
peripheral blood smear because these inclusions typically are
removed by a functioning spleen. In an asplenic patient with
overwhelming sepsis, high-grade bacteremia is often present;
thus Gram stain of the buffy coat may reveal the infecting
organism. Empirical antimicrobial therapy should include
coverage for the encapsulated organisms, with a third-
generation cephalosporin being a reasonable choice.
Patient on Chronic Corticosteroid Therapy
In one meta-analysis, the rate of infection in patients taking
steroids was 12.7% compared with 8% in patients not on
chronic steroids. The rate of infection was not increased in
patients taking less than 10 mg/day or a cumulative dose of
less than 700 mg prednisone. In addition to increased suscep-
tibility to community-acquired pathogens, patients on
chronic steroid therapy are particularly vulnerable to intra-
cellular pathogens. Examples include Salmonella species,
Legionella species, L. monocytogenes, M. tuberculosis, and
various viruses (eg, herpesviruses). Other organisms that
must be considered when evaluating a steroid-treated patient
with clinical evidence of severe infection include Candida
species, Aspergillus species, C. neoformans, Nocardia species,
Toxoplasma gondii, and P. jiroveci.
Patients with Diabetes Mellitus
Patients with diabetes mellitus often have more severe man-
ifestations of infectious disease than other hosts. In addition,
there are specific disease entities that occur more commonly
in diabetics than in other hosts. For example, rhinocerebral
mucormycosis should be considered in any patient with dia-
betic ketoacidosis and facial pain, ocular complaints, or neuro-
logic symptoms. Physical examination may be unremarkable
or may reveal a black eschar on the hard palate or nasal
mucosa, facial swelling, and/or proptosis late in the course of
the infection. Definitive diagnosis of this life-threatening
infection is made by tissue biopsy to demonstrate fungal
elements invading tissues. Therapy consists of surgical
debridement with adjunctive high doses of liposomal
intravenous amphotericin B. Diabetics are also uniquely
susceptible to urinary tract infections. Serious complications
of urinary tract infections are not uncommon, such as
emphysematous pyelonephritis, which requires surgical ther-
apy along with antimicrobial therapy. Emphysematous chole-
cystitis may develop in the diabetic host, usually the result of
an anaerobic infection with clostridia. Emphysematous
cholecystitis should be suspected when gas is seen on abdom-
inal plain film or CT scan; emergent cholecystectomy is indi-
cated for this condition. Because of impaired vascular
perfusion, patients with diabetes mellitus are prone to more
severe necrotizing soft tissue infections, necessitating a high
degree of vigilance for these life-threatening infections, with
rapid diagnosis and immediate surgical debridement.
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 Principles of Antibiotic Use in the ICU
The choice of antimicrobial agents to be used in established or
strongly suspected bacterial or other infections must be based
on an assessment of what organisms are most likely to be
involved. Initial empirical therapy should be dictated, when
possible, by results of Gram-stained smears of properly col-
lected specimens such as sputum, urine, aspirated purulent
material, or body fluids (eg, blood, cerebrospinal fluid, peri-
toneal fluid, synovial fluid, pleural fluid, or pericardial fluid).
Epidemiologic factors, site of infection, and the clinical
status of the patient also must be considered in selecting
antibiotics. The results of pretreatment cultures can provide
a definitive microbiologic diagnosis, and in vitro antibiotic
susceptibility testing, if appropriate, can be performed.
Interpretation of microbiologic cultures obtained after initi-
ation of antimicrobial therapy is difficult; in this setting, the
presence of sterile cultures may be misleading.
Some general guidelines may be helpful in selecting therapy.
Certain pathogens have a predilection for causing infection at
specific sites, for example, S. pneumoniae (ie, pneumonia or
meningitis) and E. coli (ie, urinary tract infections or bac-
teremia). Certain antimicrobial agents have predictable activity
against specific organisms, for example, penicillins for strepto-
cocci and vancomycin for staphylococci and streptococci,
including methicillin-resistant strains. However, an increasing
number of microorganisms are manifesting resistance to stan-
dard antimicrobials (Table 15–6). Therefore, obtaining cultures
in conjunction with susceptibility testing is imperative.
Despite the availability of numerous antimicrobial
agents, most pathogens are optimally treated with only a few
drugs. Antimicrobial therapy should be as specific, nontoxic,
and inexpensive as confirmatory cultures and susceptibility
tests allow. Used wisely, antimicrobials rarely fail; regimens
should not be changed haphazardly. Any changes should be
based on a complete database, which includes results of stan-
dardized susceptibility testing performed in a reliable labora-
tory. In the ICU patient, the choice of antibiotics may be
dictated by the presence of hepatic or renal dysfunction. In
addition, the doses of some agents must be modified in
patients with impaired excretion of the drugs because of
decreased kidney or liver function.
This section describes some of the newer antimicrobial
agents with the goal of establishing general guidelines for
their use. It is important to keep in mind that the choice of a
specific agent should be based on the nature of the infection
as well as patient factors; the newest antimicrobial drug is
often not the best choice.
Since the development and use of the sulfonamides in the
1930s and penicillin in the 1940s, numerous effective anti-
bacterial and antifungal agents—and, more recently, antivi-
ral agents—have become available. However, there exists a
paucity of new antimicrobial agents under development tar-
geting the increasingly resistant bacteria responsible for
infection, threatening our ability to provide optimal treat-
ment. The similarities of many of existing antibiotics are
more striking than their differences. Nonetheless, many
antibiotics occupy specific niches in the treatment of the
infected patient.
Cephalosporins
Cefepime has been referred to as a fourth-generation
cephalosporin. It has excellent activity against the
Enterobacteriaceae, Enterobacter species, P. aeruginosa, and S.
pneumoniae; moderate activity against S. aureus; and limited
antianaerobe activity.
Carbapenems
Imipenem, meropenem, and ertapenem are the three car-
bapenems currently available for use. The presence of the
carbapenem ring increases the potency and antibacterial
spectrum of these agents. In place of an acylamino side
Organisms With Emerging
Resistance Antibiotics
Streptococcus pneumoniae Beta-lactams, macrolides, quinolones
Staphylococcus aureus Beta-lactams, aminoglycosides,
vancomycin, linezolid quinolones
Enterococcus Aminoglycosides, penicillin,
vancomycin, linezolid, quinupristin-
dalfopristin
Haemophillus influenzae Ampicillin (beta-lactamase-negative),
chloramphenicol 
Pseudomonas aeruginosa
(including other group 1 beta-
lactamase-producing gram-
negative bacilli) 
Aminoglycosides, beta-lactams,
carbapenems, quinolones
Enterobacteriaceae Beta-lactams 
Acinetobacter baumanii Beta-lactams, carbapenems,
quinolones, aminoglycosides
Bacteroides fragilis Clindamycin 
Table 15–6. Emerging resistance to antibiotics.
INFECTIONS IN THE CRITICALLY ILL 377
group off the β-lactam ring—found in the penicillins and
cephalosporins—imipenem has a short hydroxyethyl side
chain that protects the ring from degradation by bacteria-
produced β-lactamases. The carbapenems are active against
most aerobic and anaerobic gram-positive and gram-
negative organisms. Imipenem and meropenem have activity
against P. aeruginosa and Acinetobacter species, whereas
ertapenem does not. Imipenem is available only in combina-
tion with cilastatin sodium; the latter is added to prevent
renal metabolism of the imipenem, which decreases nephro-
toxicity. Imipenem–cilastatin sodium has been associated
with adverse CNS reactions, including seizures. Slight struc-
tural modifications have rendered meropenem resistant to
degradation by the dehydropeptidases of the renal brush
border, conferred slightly greater activity against aerobic
gram-negative bacilli but slightly less activity against aerobic
gram-positive cocci, and decreased the epileptogenic poten-
tial of the drug.
Quinolones
The quinolones are a class of antimicrobial agents that has
expanded significantly in recent years. Quinolones act by
binding to bacterial DNA gyrase and topoisomerase intra-
venous, thus preventing DNA replication. Resistance occurs
via accrual of mutations at the enzyme target or by active
efflux of the drug out of bacterial cells. Ciprofloxaxin, an
early quinolone, has activity primarily against gram-negative
organisms and staphylococci, with limited activity against
streptococci and anaerobes. It is the only fluoroquinolone
with reliable activity against P. aeruginosa. Some newer
agents (eg, levofloxacin, gemifloxacin, and moxifloxacin)
have greater potency against streptococci, particularly S.
pneumoniae, including penicillin-resistant S. pneumoniae.
They also have excellent activity against aerobic gram-
negative bacilli but less activity against P. aeruginosa. All
quinolones have activity against atypical pneumonia
pathogens, including Legionella, C. pneumoniae, M. pneumo-
niae, C. trachomatis, and some mycobacteria. In general, the
quinolones have excellent bioavailability and may be given
either orally or intravenously.
Tigecycline
Tigecycline, a new semisynthetic glycylcycline related to
tetracycline, possesses in vitro antibacterial activity against
many clinically important gram-positive and gram-
negative aerobic and anaerobic bacteria, including some
with resistance to other classes of agents (eg, vancomycin-
resistant enterococci [VRE], MRSA, and multidrug-
resistant Acinetobacter). Tigecycline may be useful in the
treatment of complicated skin and skin-structure infections
and complicated intraabdominal infections. Because of its
limited activity against P. aeruginosa and Proteus species,
tigecycline is not recommended for the treatment of serious
infections caused by these organisms. Tigecycline should be
used carefully to avoid selective pressure leading to the
development of resistance. It is available for parenteral use
only, has a large volume of distribution, and is cleared by
hepatic metabolism and excretion. There is no dose adjust-
ment for renal insufficiency. Nausea and vomiting are the
most frequently reported side effects.
Triazoles
The triazoles are fungistatic drugs that inhibit the fungal
cytochrome P450 enzyme to block the transformation of
lanosterol to ergosterol, the major sterol in the fungal cell
membrane. The result is osmotic instability and loss of
integrity of the fungal cell wall. Fluconazole is available in
both oral and parenteral forms, and essentially equivalent
blood levels are achieved by either route. Fluconazole has a
wide volume of distribution, achieving high levels in urine,
sputum, saliva, peritoneal fluid, vaginal secretions, bile, cere-
brospinal fluid, skin, liver, and prostate. Achievable cere-
brospinal fluid levels are about 60–80% of serum levels.
Fluconazole is 80% excreted unchanged in the urine, and
dose adjustment is required for renal insufficiency.
Fluconazole is active against C. albicans, C. tropicalis, C. para-
psilosis, C. immitis, and C. neoformans. It has been shown to
be effective in the treatment of hematogenous, mucosal, and
end-organ candidal infection. Caution should be used when
treating infection with certain non-albicans species such as
C. krusei and C. glabrata because these organisms are less
sensitive to fluconazole.
Itraconazole is another triazole that is available for
clinical use. A parenteral form is available. Oral formula-
tions have inconsistent absorptions and so should be
avoided in the critically ill patient. Compared with flu-
conazole, itraconazole has greater activity against
Aspergillus, B. dermatitidis, H. capsulatum, and Sporothrix
schenkii.
Voriconazole is available in both parenteral and oral
forms. Voriconazole is active against all Candida species,
including C. krusei and C. glabrata, many Aspergillus species,
B. dermatitidis, C. immitis, H. capsulatum, Scedosporim/
Pseudoallescheria, and Fusarium species. Like fluconazole,
voriconazole has a large volume of distribution and excellent
oral bioavailability. Voriconazole is indicated for the treat-
ment of invasive aspergillosis, Candida esophagitis, and inva-
sive fungal infections caused by Pseudallescheria boydii and
Fusarium species.
Amphotericin B Lipid Formulations
Amphotericin B desoxycholate has long been the standard
for treatment of severe mycoses. It is a fungicidal drug that
binds to ergosterol in the cell wall and causes osmotic insta-
bility and cell death. The major weakness of amphotericin B
desoxycholate is its numerous adverse effects, especially
nephrotoxicity. The new lipid formulations of amphotericin
B are costly but have the advantage of inducing less
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nephrotoxicity. There are currently three formulations avail-
able: amphotericin B lipid complex, amphotericin B colloidal
dispersion, and liposomal amphotericin B. They are
approved for use in patients with invasive fungal infections
who are intolerant of amphotericin B desoxycholate.
Liposomal amphotericin B has an additional indication for
empirical therapy in febrile patients with neutropenia. There
are some data, mostly from retrospective comparisons and a
few prospective trials, suggesting improved response rates
with lipid formulations and a lower incidence of nephrotox-
icity. Owing to the significant cost differential between the
lipid formulations of amphotericin B and amphotericin B
desoxycholate, use of the lipid formulations generally is
reserved for specific subgroups of patients. For example, in
high-risk patients such as bone marrow transplant recipients
with suspected invasive aspergillosis, earlier use of the lipid
formulations may be warranted in an attempt to improve
response rates and to decrease renal toxicity.
Echinocandins
Caspofungin, micafungin, and anidulafungin belong to the
class of antifungal drugs called the echinocandins, which
inhibit β-(1,3) glucan synthesis with resulting damage to fun-
gal cell walls. Caspofungin is available for parenteral use only.
It has activity against Candida and Aspergillus species.
Caspofungin has been demonstrated to be equivalent to
amphotericin B in the treatment of invasive candidiasis and
candidemia. Caspofungin has an indication for empirical
therapy in the febrile neutropenic patient. Anidulafungin is
approved for parenteral treatment of candidemia and candi-
dal peritonitis and intraabdominal abscesses, as well as
esophageal candidiasis. Micafungin is approved for can-
didemia, acute disseminated candidiasis, candida peritonitis,
candidal esophagitis, and antifungal prophylaxis for
hematopoietic stem cell transplant recipients.
Macrolides
The three macrolides available for clinical use in the United
States are erythromycin, clarithromycin, and azithromycin.
In comparison with erythromycin, the latter two have greater
activity against H. influenzae, C. trachomatis, M. avium com-
plex, and other nontuberculous mycobacteria. The role of
these agents in the critically ill patient is limited to treatment of
patients with suspected atypical pneumonias. All three agents
possess good activity against M. pneumoniae, C. pneumoniae,
and Legionella species. Erythromycin and azithromycin are
available in a parenteral formulation, whereas clarithromycin
is available only in an oral form.
Quinupristin-Dalfopristin
Quinupristin-dalfopristin is a formulation of two bacterio-
static antimicrobial agents that, when combined, are bacteri-
cidal. Its antimicrobial activity is the result of inhibition of
protein synthesis at the 50S ribosome. Quinupristin-
dalfopristin is available for intravenous use only. Its spectrum of
activity is similar to that of vancomycin and includes S.
pneumoniae, other streptococci, S. aureus, and coagulase-
negative staphylococci. It is bacteriostatic for Enterococcus
faecium and has no activity against E. faecalis. The niche for
quinupristin-dalfopristin is in the treatment of vancomycin-
resistant E. faecium and possibly glycopeptide-insensitive
S. aureus.
Linezolid
Linezolid belongs to the class of drugs known as oxazolidi-
nones. These drugs block bacterial protein synthesis at the
ribosome at a very early stage. Because of its novel mech-
anism of action, linezolid does not share cross-resistance
with other antimicrobial agents. Linezolid’s spectrum of
activity is essentially identical to that of vancomycin.
Much like quinupristin-dalfopristin, the major indication
for use of this agent is the treatment of vancomycin-
resistant enterococcus and glycopeptide-insensitive S.
aureus infections. Linezolid is approved for treatment of
pneumonia, bacteremia, and skin and soft tissue infec-
tions owing to gram-positive organisms. Linezolid is
available in both oral and parenteral formulations, with
excellent oral bioavailability.
Daptomycin
Daptomycin belongs to a new class of antimicrobial agents; it
is a cyclic lipopeptide antibiotic that is rapidly bactericidal
against S. aureus, streptococci, and enterococci, including
multidrug-resistant strains. It is available for parenteral use
only and is approved for use in complicated skin and soft
tissue infections caused by staphylococci, streptococci, and
E. faecalis.
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 Evaluation of the ICU Patient with New
Fever
The evaluation of new fever in the ICU setting involves con-
sideration of diagnoses much different from those encoun-
tered in patients in a community setting. Many noninfectious
causes of fever must be considered and excluded in order to
avoid missing important diagnoses and perhaps administer-
ing antimicrobial agents unnecessarily.
Clinical Features
A. History and Examination—When eliciting a history, the
physician should pay special attention to changes in quality
and quantity of respiratory secretions, changes in the patient’s
tolerance to oral intake, the condition of the patient’s skin, and
the presence or absence of diarrhea. Because many patients in
an ICU will be unable to provide a history, information should
be elicited from family members and caregivers, and a careful
review of medical records and laboratory data and a thorough
physical examination should be performed.
It is recommended that temperatures be taken using an
electronic probe in the mouth, rectum, or external auditory
canal. Axillary temperature measurements may be spuriously
low and so should not be used. Sinusitis should be consid-
ered in patients with nasotracheal or nasogastric tubes—
which block the sinus ostia, thus predisposing to infection.
Careful auscultatory examination should be performed to
look for new pulmonary findings that may indicate a noso-
comial pneumonia or a new or changing murmur that may
indicate endocarditis. Abdominal examination should be
performed to assess the presence or absence of bowel sounds
and any focal tenderness or masses. All intravascular catheter
sites should be scrutinized for signs of inflammation at the
catheter exit site or along the subcutaneous tunnel. The
patient’s skin requires careful inspection for any lesions that
may indicate hematogenous seeding (either bacterial or fun-
gal), skin eruptions that may indicate a drug reaction, and
decubitus ulcers or surgical wounds that may be infected.
B. Laboratory and Imaging Studies—Laboratory evalua-
tion should include a complete blood count, routine
chemistries with liver enzymes, and urinalysis. Cultures of
blood and urine should be obtained routinely. Other evalua-
tions should be directed by the results of the history and
physical examination. A chest radiograph and sputum sam-
ple for culture should be obtained when nosocomial pneu-
monia is suspected. Stool specimens for C. difficile toxin
should be collected from patients who develop diarrhea
while hospitalized. Routine stool cultures and stool for ova
and parasites are not useful in evaluation of new fever in a
patient in the ICU. Any wounds that appear infected should
be debrided, with cultures performed on any purulent mate-
rial. If the abdominal examination or the liver enzymes sug-
gest an intraabdominal process, a right upper quadrant
ultrasound or CT scan of the abdomen and pelvis may be
requested. If sinusitis is suspected, CT scan or MRI of the
sinuses may be helpful, although impractical in the unstable
or ventilated patient.
Treatment
Empirical therapy will depend on the results of the physical
examination and initial laboratory data.
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 Nosocomial Pneumonia
ESSENT IALS  OF  D IAGNOS I S
 Fever, tachypnea, tachycardia, and abnormal breath
sounds.
 Risk factors include altered mental status, lung disease,
endotracheal tube, or tracheostomy.
 Change in volume or appearance of sputum.
 Infiltrates or other changes on chest x-ray.
 Hypoxemia or worsening arterial blood gases.
General Considerations
It is estimated that at least 5% of hospitalized patients will
develop a nosocomial infection. Pneumonia is the second
most common nosocomial infection after urinary tract
infection and is the leading cause of death owing to hospital-
acquired infection. Although often considered separately,
ventilator-associate pneumonia (VAP) is a very important
subset of nosocomial pneumonia.
Pathophysiology
Pneumonia develops from one of three mechanisms:
(1) inhalation of an aerosol containing infectious microor-
ganisms, (2) hematogenous seeding of microorganisms in
the lung, or (3) aspiration of oropharyngeal flora.
A. Inhalational Pneumonia—Infectious particles less than
3–5 μm in diameter are capable of reaching the terminal
bronchi and alveoli during inhalation. M. tuberculosis,
Legionella, and influenza virus—as well as many fungi—are
known to cause nosocomial pneumonia by this route of
spread. Contaminated respiratory equipment has been rec-
ognized as a source of infected aerosols and a cause of gram-
negative bacillary necrotizing pneumonia. Hospital policies
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and procedures requiring rigorous, frequent changing and
disposal of equipment have markedly decreased the inci-
dence of inhalation pneumonia in the hospital setting.
B. Hematogenous Pneumonia—Pneumonia caused by the
hematogenous seeding of infection is uncommon. Patients
predisposed to hematogenous pneumonia are those with
S. aureus or Candida infections associated with infected
intravenous catheters, septic thrombophlebitis, or endo-
carditis of the right side of the heart. Pneumonia develops as
a consequence of infected thrombi forming within the
intravascular space and traveling through the bloodstream to
reach the pulmonary circulation (septic pulmonary emboli).
C. Aspiration Pneumonia—Aspiration of oropharyngeal
bacterial flora is the most common mechanism responsible
for nosocomial pneumonia. Although all individuals aspirate
microscopic quantities of oropharyngeal secretions, certain
factors increase the risk of pneumonia. Such factors include
(1) high frequency and large volume of secretions aspirated,
(2) aspiration of particularly virulent bacterial species, (3)
the presence of particulate matter in the aspirate, and (4)
abnormalities of the lower airway and alveolar defense mecha-
nisms. Aerobic enteric gram-negative bacilli are not usually
part of the flora colonizing the oropharynx in normal, healthy,
nonhospitalized individuals. However, oropharyngeal colo-
nization by gram-negative bacilli occurs within a days of
admission to the ICU. Patients receiving antibiotics develop
gram-negative colonization more rapidly. Cross-infection and
cross-colonization from patient to patient contribute to the
pathogenesis when infection control measures are substandard.
Prophylaxis of stress ulcers with the use of antacids or
H2-receptor antagonists is considered a risk factor for gram-
negative aspiration pneumonia via gastric acid neutralization,
allowing subsequent overgrowth of enteric gram-negative
bacilli, although this theory remains controversial.
Microbiologic Etiology
The microbiology of pneumonia in hospitalized patients is
significantly different from that of pneumonia acquired
outside the hospital. Early-onset nosocomial pneumonia
(<4–7 days) in patients who have not received prior antibi-
otic therapy is typically caused by Enterobacteriaceae,
Haemophilus species, S. aureus, and pneumococci. Patients
who develop late-onset pneumonia (>4–7 days) and who have
received prior antibiotic therapy are at risk for infection with
P. aeruginosa, A. baumanii, Stenotropomonas maltophilia, and
MRSA. Approximately 20–40% of nosocomial pneumonias
are polymicrobial in etiology. Anaerobic bacteria are not
considered an important pathogen in nosocomial pneumo-
nia. Legionella species have been implicated as the cause of
nosocomial pneumonia in some hospitals.
Clinical Features
The diagnosis of pneumonia depends on physical examina-
tion findings, microbiologic analysis of lower respiratory tract
secretions, and review of the chest x-ray. Although risk factors
for development of pneumonia should be considered in assess-
ing the likelihood of pneumonia, any critically ill patient—
especially one with underlying heart or lung disease—should
be considered at risk for nosocomial pneumonia. Studies have
identified a number of risk factors in the development of
nosocomial pneumonia. Among the most important of these
factors are neurologic impairment, witnessed aspiration,
mechanical ventilation (with increasing risk associated with
prolonged need for mechanical ventilation), underlying
chronic lung disease, the presence of ARDS, increasing age,
use of a nasogastric tube, enteral feeding, endotracheal cuff
pressure, severity of underlying illness, need for tra-
cheostomy, and supine position of the patient.
A. Symptoms and Signs—Patients with suspected nosoco-
mial pneumonia should undergo prompt assessment prior to
initiation of therapy. The clinical features of pneumonia in hos-
pitalized patients are subtle and variable, and in some cases,
there may be no symptoms or examination findings. Use of
clinical and radiographic features alone to diagnose nosoco-
mial pneumonia will lead to the misclassification of many dis-
orders as nosocomial pneumonia. Some diagnostic clues
include altered mental status, fever, tachypnea, tachycardia, and
abnormal breath sounds. Physical findings commonly include
crackles or rales rather than evidence of lung consolidation.
Wheezing may be present, and localized wheezing may suggest
aspiration of a foreign body. The presence of preexisting abnor-
mal lung findings may make the diagnosis difficult. Patients with
a tracheostomy or endotracheal tube may first manifest a lower
respiratory tract infection by a change in gross appearance of the
respiratory secretions or an increase in oxygen requirement. The
physician should query the respiratory therapist or nurse regard-
ing changes in quantity and appearance of these secretions. The
development of purulent sputum or an increase in the quantity
of secretions suggests heavy bacterial colonization or infection,
often prior to the development of a radiographic infiltrate.
B. Laboratory Findings—Most patients in the ICU are too
debilitated to produce an adequate sputum sample; samples
of respiratory secretions may be obtained in such cases by
endotracheal suctioning or fiberoptic bronchoscopy. It is
clear that endotracheal aspirates alone are often inaccurate in
diagnosing the etiologic agent of a nosocomial pneumonia.
Quantitative endotracheal aspirates, a protected specimen
brush, or bronchoalveolar lavage often will provide more
useful information. However, most diagnostic modalities for
nosocomial pneumonia are neither sensitive nor specific.
Respiratory cultures obtained by any means must be inter-
preted with caution because the airways of hospitalized
patients are almost always colonized with various potentially
pathogenic bacteria. A Gram stain of the sputum may help to
identify the etiologic agent and suggest appropriate empiri-
cal therapy. A sputum Gram stain that reveals 10 or fewer
squamous epithelial cells and more than 25 polymorphonu-
clear cells per high-power field can be considered an adequate
specimen. Typically, the Gram stain is more helpful than cul-
ture results in patients already receiving antimicrobial agents
that may inhibit bacterial growth in culture.
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Invasive methods of diagnosis such as bronchoscopy with
or without protected specimen brush should not be used to
determine whether or not to initiate therapy for hospital-
acquired pneumonia, although results of such studies may be
useful in modifying subsequent therapy. Good outcome
remains most closely correlated with correct early antimicro-
bial therapy.
A complete blood count, blood cultures, and a chest x-ray
are essential. The chest x-ray may reveal an infiltrate, but non-
specific findings such as atelectasis may be the only finding.
Patients with prior pulmonary disease often have preexisting
abnormalities on chest x-ray that make it difficult to identify
new infiltrates. Blood cultures, when positive, should be con-
sidered definitive for the etiologic agent; 10–20% of hospital-
acquired pneumonias are associated with a positive blood
culture. Pleural fluid, if present, should be sampled by thora-
centesis for Gram stain, culture for aerobic and anaerobic
organisms, and determination of cell count, pH, total protein,
and LDH concentration. Serologic studies are seldom useful
in determining the cause of nosocomial pneumonia.
Differential Diagnosis
The differential diagnosis of nosocomial pneumonia includes
virtually all processes associated with pulmonary infiltrates.
ARDS, pulmonary emboli with infarction, cardiogenic pul-
monary edema, lung cancer, and atelectasis often are difficult
to differentiate from an infectious lung process. Less common
diseases to be considered include collagen-vascular disease,
pulmonary hemorrhage, radiation pneumonitis, hypersensi-
tivity pneumonitis, sarcoidosis, occupational lung diseases,
and pulmonary alveolar proteinosis.
Treatment
A. Antibiotics—Empirical antimicrobial therapy for nosoco-
mial pneumonia should be based on clinical features, epidemi-
ologic and host factors, and results of an initial sputum Gram
stain. Surveillance data relating to local nosocomial flora
leading to pneumonia in the ICU should be reviewed.
Antibiotic therapy should be administered intravenously and
should target a broad spectrum of bacteria. The possibility of
resistant microorganisms should be considered in the hospi-
talized patient with nosocomial pneumonia. In patients with
early-onset pneumonia, a third-generation non-
antipseudomonal cephalosporin or a β-lactam/β-lactamase
inhibitor (such as piperacillin-tazobactam), or in some cases
a fluoroquinolone should be adequate. In patients with
late-onset pneumonia, cefipime, imipenem, meropenem,
ceftazidime, or a β-lactam/β-lactamase inhibitor in combina-
tion with an aminoglycoside or fluoroquinolone provides the
broadest coverage for infections caused by most
Enterobacteriaceae, P. aeruginosa, and S. aureus. If the
prevalence of MRSA strains is significant, and staphylococ-
cal pneumonia is a consideration, vancomycin should be
included in the initial drug regimen. Quinolones have
excellent activity against most Enterobacteriaceae as well as
H. influenzae but possess less activity against streptococci and
staphylococci (except for levofloxacin and the newer
quinolones) and little to no activity against most anaerobes.
New data suggest that shorter courses of antibiotics (5-8
days) than traditionally used are effective, safe, and result in
less antibiotic resistance.
B. Supportive Care—Patients with pneumonia require suc-
tioning of respiratory secretions, postural drainage, and occa-
sionally, fiberoptic bronchoscopy. Coughing is the most effective
way to clear the large airways of respiratory secretions. In
patients with endotracheal tubes or tracheostomies, use of
appropriate suctioning must substitute for cough. Postural
drainage and chest percussion may be useful in selected
patients, but only if it can be demonstrated that removal of res-
piratory secretions is improved. In certain patients, fiberoptic
bronchoscopy can be helpful in identifying endobronchial
obstruction, and this technique may aid in suctioning secretions
from particular airways. Most patients with pneumonia receive
bronchodilator therapy, but the effectiveness of these agents in
patients without obstructive lung disease is not known.
Prevention
Prevention of nosocomial pneumonia is of utmost impor-
tance in decreasing morbidity and mortality rates and con-
trolling the costs of hospital care. Recognition of the
aspiration-prone patient is essential. Patients with nasogas-
tric tubes for enteral feeding should have the head of the bed
elevated 30–45 degrees during feeding and be monitored for
excess gastric residuals that lead to aspiration. All patients
should be turned frequently whenever possible. Appropriate
disposal, disinfection, or sterilization of respiratory equip-
ment is critical for prevention of contamination and subse-
quent inhalation pneumonias. Nurses, physicians, and
respiratory therapists must use sterile technique for endotra-
cheal suctioning. Meticulous hand washing before and after
patient examination and the wearing of gloves when appro-
priate will help to decrease the overall incidence of nosocomial
infections in the ICU. In intubated patients, subglottic suc-
tioning has been shown to be effective in reducing ventilator-
associated pneumonia. Other interventions that may help in
preventing nosocomial pneumonia include placing patients in
the semirecumbent position, avoidance of prolonged nasal
intubation (which may lead to nosocomial sinusitis), and use
of noninvasive positive-pressure ventilation rather than intu-
bation whenever possible.
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America: Guidelines for the management of adults with hospital-
acquired, ventilator-associated, and healthcare-associated
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 Urinary Catheter–Associated Infections
ESSENT IALS  OF  D IAGNOS I S
 Although the patient may be asymptomatic, suprapubic
tenderness suggests lower tract infection; fever and
flank pain suggest upper tract infection.
 Pyuria and white blood cell casts.
 Positive urine culture.
General Considerations
A urinary (bladder) catheter provides a portal of entry into the
urinary tract for microorganisms. Urinary catheter–associated
infections account for up to 40% of all nosocomial infec-
tions. Fewer than 5% of patients who develop bacteriuria will
become bacteremic; however, the tremendous frequency
of nosocomial bacteriurias accounts for the observation
that urinary catheter–associated infections account for
15% of all nosocomial bacteremias. Early recognition and
appropriate treatment of urinary catheter-associated infec-
tions can reduce morbidity and length of stay in the ICU
significantly.
The urinary catheter allows transit of microorganisms
colonizing the perineum and the urethral meatus to pass
through the urethra and enter the bladder. Most catheter-
associated bacteriuria occurs by extraluminal ascent of bac-
teria via the mucous film coating the outer surface of the
catheter; these organisms colonize the patient’s perineum.
Bacterial also ascend intraluminally through the catheter
because of failure of the closed drainage system or contami-
nation of the collection bag. Bacteriuria occurs in catheter-
ized patients at a rate of 3–10% per catheter-day, with
10–25% of these patient developing symptoms of local infec-
tion and bacteremia and sepsis occurring in 2–4%.
The most common microorganisms causing infection in
short-term catheterized patients in the ICU include
Enterobacteriaciae (such as E. coli, Klebsiella species),
P. aeruginosa, Enterobacter species, enterococci, and Candida
species. Polymicrobial infections occur in up to 15% of
catheterized patients; anaerobic infections are extremely
rare. Candiduria is common in patients receiving corticos-
teroids or broad-spectrum antibiotics and in those with dia-
betes mellitus. Urinary tract infections with Candida species
or S. aureus should raise the question of hematogenous
spread because a urinary tract infection with one of these
organisms can be a marker of disseminated disease.
Risk factors for catheter-associated bacteriuria include
prolonged duration of catheterization, older age, severe
underlying illness, diabetes mellitus, absence of systemic
antibiotic use, female sex, abnormal serum creatinine, errors
in catheter care, and periurethral colonization with potential
uropathogens. Once bacteriuria has occurred, it is difficult to
prevent subsequent infection; thus prevention of the initial
bacteriuria is critical. The only two factors shown to decrease
the risk of nosocomial catheter-associated bacteriuria are
maintenance of a closed catheter system with aseptic inser-
tion of catheter and early removal of the urinary catheter.
Clinical Features
A. Symptoms and Signs—Diagnosis of catheter-related
urinary tract infection is straightforward, although many
patients with catheter-associated urinary tract infections are
asymptomatic. Up to 30% of patients will have fever or other
symptoms of urinary tract infection. Fever or other systemic
signs of infection, as well as pain localized to the flank, sug-
gest upper tract infection.
B. Laboratory Findings—The white blood cell count may
be elevated with serious infection. Definitive diagnosis is
based on urinalysis and results of urine culture. Direct exam-
ination of the urine continues to be valuable for early diag-
nosis of bacterial infections of the genitourinary tract. Pyuria
indicates the presence of urinary infection rather than sim-
ple bacterial colonization of the urine; the presence of white
blood cell casts suggests upper tract disease. The presence
of one or two leukocytes per high-power field (400×) or
bacteria seen under oil immersion (1000×) in unspun urine
has a 95% correlation with the presence of more than
100,000 cfu/mL of urine. Thus microscopy is useful for
identification of urinary tract involvement with a high urine
bacterial count.
The presence of bacteria in a concentration greater than
100,000 cfu/mL with accompanying pyuria is consistent with
infection. In catheterized patients, bacterial counts of more
than 1000 cfu/mL, if untreated, will increase to more than
100,000 cfu/mL within 24–48 hours. Urine culture for bacte-
ria and fungi must be submitted to the laboratory with
prompt processing. Alternatively, specimens may be refriger-
ated at 4°C, where bacterial counts will remain stable for up
to 24 hours. Urine left at room temperature for over 2 hours
after collection will have significantly higher urine bacterial
colony counts, thereby confounding the diagnosis of urinary
tract infection.
Most microbiology laboratories routinely identify and
perform antimicrobial susceptibility tests on microorganisms
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present in numbers of 104 CFU/mL or more. If polymicro-
bial bacteriuria is anticipated (eg, chronic indwelling
catheter or neurogenic bladder), the laboratory should be
alerted to this possibility.
C. Imaging Studies—Seriously ill patients presenting with
a urinary tract infection, whether catheter-related or not,
who have high fever, flank pain, or urosepsis require further
evaluation for upper tract disease. Ultrasonography is use-
ful to assess the anatomy of the genitourinary tract and to
rule out an obstructed ureter. Further studies, including an
intravenous pyelogram, retrograde pyelogram, or CT scan
may be necessary to diagnose renal abscess, perinephric
abscess, or nephrolithiasis.
D. Complications—Complications of bladder and kidney
infections are common and potentially serious. The urinary
tract is the most common site of origin of gram-negative
bacteremia and sepsis. Acute pyelonephritis, chronic
pyelonephritis, emphysematous pyelonephritis, renal
abscess, and urosepsis may complicate an untreated urinary
tract infection.
Differential Diagnosis
Urinary tract infections should be differentiated from
asymptomatic bacteriuria, urethritis, prostatitis, sexually
transmitted diseases, pelvic inflammatory disease, divertic-
ulitis, intraabdominal abscess, and peritonitis.
Treatment
A. Asymptomatic Patient with Bacteriuria—Antibiotic
therapy in the asymptomatic bacteriuric patient with an
indwelling catheter and an unremarkable urinalysis is dis-
couraged because bacteriuria will recur when treatment is
discontinued and selection of antibiotic-resistant organisms
is likely.
B. Patient with Abnormal Urinalysis and Bacteriuria—In
patients with abnormal urinalysis (typically pyuria) and bac-
teriuria, the urinary catheter should be removed and antibi-
otics initiated. If the patient requires an indwelling catheter
for bladder drainage, a new catheter can be reinserted. In gen-
eral, empirical therapy should be directed against nosocomial
gram-negative pathogens; a third-generation cephalosporin,
a quinolone, or an aminoglycoside is usually appropriate ini-
tial antibiotic treatment. Therapy may be discontinued in
uncomplicated cases at 7 days. However, more seriously ill
patients with prolonged fever, suspected upper tract involve-
ment, positive blood cultures, renal insufficiency, or sepsis
require a longer course of intravenous antibiotics and further
evaluation for upper tract disease.
C. Candiduria—Asymptomatic candiduria in immunocom-
promised patients or symptomatic candidal urinary tract
infections in all patients require antifungal treatment. Oral
fluconazole and a short course of intravenous amphotericin B
are both effective for candidal infections confined to the blad-
der. Upper tract infection requires systemic treatment with
oral or intravenous fluconazole or intravenous amphotericin
B; complications such as fungal ball, renal or perirenal
abscess, or hematogenous dissemination should be consid-
ered. In all cases, the catheter should be removed or changed.
Asymptomatic candiduria in most patients without immuno-
compromise usually will clear once the indwelling catheter
has been removed and antimicrobial therapy discontinued.
Current Controversies and Unresolved Issues
The appropriate course of action to take with a hospitalized
patient who develops asymptomatic nosocomial bacteriuria
associated with a urinary catheter remains controversial. The
literature suggests that the treatment of bacteriuria in an
attempt to avoid complications is not useful. One approach
is to remove the catheter as soon as possible after discovery
of bacteriuria, with a repeat urinalysis and urine culture
3–5 days later. If the urinalysis is normal and the urine culture
is sterile, it is likely that the infection has cleared. If bacteri-
uria persists, the patient must be monitored for resolution or
be treated with a short course of antibiotic therapy.
Exceptions to this rule include the presence of bacteriuria
with organisms that have a high predilection for causing sub-
sequent bacteremia (eg, Serratia marcescens) and bacteriuria
in patients at risk for serious complications (eg, neutropenic
or pregnant patients).
Questions about the value of screening tests for bac-
teriuria in patients who have urinary catheters are unre-
solved. Several tests correlate reasonably well with
bacteriuria of 100,000 cfu/mL or more. The leukocyte
esterase–nitrate test has a sensitivity of about 85% in
detecting bacteria at 105 cfu/mL or more. However, the
predictive value of a positive test is much lower (25–50%)
than that of a negative test.
Attempts to decrease the incidence of bacterial coloniza-
tion by use of nitrofurazone- or silver alloy–coated urinary
catheters have been investigated. It appears that such
catheters may decrease the incidence of bacteriuria.
Economic evaluations seem to indicate that these catheters
are cost-effective when used in patients requiring in-dwelling
catheters for short duration.
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bial urinary catheters to prevent catheter-associated urinary
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 Intravenous Catheter–Associated Infections
ESSENT IALS  OF  D IAGNOS I S
 Exit-site infection: erythema, tenderness, induration,
and exudate at cutaneous exit site.
 Tunnel infection: induration, erythema, tenderness at
least 1 cm deep to the skin exit site and without puru-
lent drainage through the exit site.
 Catheter sepsis: fever, tachypnea, and tachycardia with
positive blood cultures and no other site of infection
identified.
General Considerations 
Obtaining short-term central intravenous and arterial access
by means of indwelling catheters is an integral part of the
monitoring and management of patients in the ICU. These
catheters are required for administration of antimicrobial
therapy, blood products, fluid and electrolyte replacement,
and monitoring of hemodynamic status. Short-term catheters
may be metal needles or Teflon or other synthetic catheters
inserted into vessels with only a short distance between the
skin and intravascular space. These include radial, dorsalis
pedis, and femoral artery catheters, intravenous catheters
inserted into superficial veins on the extremities, and large-
bore central venous catheters inserted into subclavian or inter-
nal jugular veins in the neck. The wide-lumen catheters
through which pulmonary artery catheters and temporary
transvenous cardiac pacemakers are placed are also considered
short-term catheters.
Patients requiring long-term central venous catheters,
used primarily for administration of cancer chemotherapy
or for total parenteral nutrition, are often admitted to the
ICU. These long-term catheters have in common a subcuta-
neous tunnel through which the catheter passes after enter-
ing the skin and before entering the vein. The presence of a
Dacron cuff just inside the exit site of the catheter stimulates
growth of the surrounding tissue, thus preventing microor-
ganisms from entering the catheter tract. This permits long-
term use of the catheter with a greatly decreased incidence of
catheter-related infection.
Two relatively recent additions to the armamentarium of
long-term venous access catheters are the midline catheters
and the peripherally inserted central venous catheters
(PICCs). The midline catheter is inserted into the proximal
basilic or cephalic vein or into the distal subclavian vein via
the antecubital fossa. PICCs are inserted into the superior
vena cava via the antecubital fossa as well. These methods of
venous access are associated with fewer mechanical complica-
tions and lower rates of phlebitis and bloodstream infection
and are easier to maintain. It appears that the PICC can be left
in place for a long duration, but the specifics are not yet known.
Pathophysiology
Infection of intravascular catheters typically results from one of
four events. The most common mechanism of infection is
migration of cutaneous colonizing organisms from the inser-
tion site to the catheter tip, frequently seen with short-term
catheters. Inadvertent contamination of the catheter hub by the
physician or nurse at the time of insertion or by frequent device
manipulation also can lead to infection and is an important factor
in long-term catheter infection. Contamination of the infusate
and hematogenous seeding of the intravascular device from
another primary site of infection are less common problems.
Microbiologic Etiology
Gram-positive organisms—most commonly coagulase-
negative staphylococci, followed by S. aureus—and entero-
cocci are implicated in most bloodstream infections owing to
intravenous devices. The incidence of nosocomial infections
owing to Candida species, especially C. albicans, has
increased dramatically in recent years. Approximately
15–20% of bloodstream infection are due to gram-negative
bacilli (eg, E. coli, Klebsiella species, Enterobacter species, and
P. aeruginosa). It is important to remember that virtually any
organism can cause intravenous catheter infection in an
immunocompromised host.
Clinical Features
A. Symptoms and Signs—When evaluating a patient with a
possible catheter-related infection, several syndromes need to
be considered. If an intravascular catheter is removed, growth
of 15 colony-forming units (semiquantitative) or more or 103
organisms (quantitative culture) or more from a distal or prox-
imal segment of the intravascular catheter in the absence of
accompanying clinical symptoms defines bacterial colonization
of the catheter. An exit-site infection is characterized by the
presence of erythema, tenderness, induration, and purulence
within 2 cm of the exit site of the catheter. A tunnel infection is
manifested by erythema, tenderness, and induration in the tis-
sues over the catheter and more than 2 cm from the exit site.
Finally, a catheter-related bloodstream infection is defined as
isolation of the same organism from both the catheter tip and
peripherally drawn blood cultures in the appropriate clinical
setting with no other source of infection identified.
It is important to distinguish patients with severe neu-
tropenia and catheter-related infections from their immuno-
competent cohorts. These patients may not manifest typical
inflammatory changes at the site of infection—especially
notable is the lack of purulent drainage. However, erythema
is still present with infection, and patients may complain of
local tenderness; either finding should alert the physician to
the probability of infection.
Complications that may occur as a result of catheter-
related infections include septic thrombophlebitis and
endocarditis. Associated risk factors for catheter-related
INFECTIONS IN THE CRITICALLY ILL 385
infections include extremes of age, altered host defenses
(especially skin diseases), severity of the underlying disease,
use of a multilumen catheter, and the presence of infections
remote from the catheter site. However, the most important
hospital-related risk factor is the duration of use of a partic-
ular catheter site. Total parenteral nutrition also has been
identified as a risk factor for catheter-related infection, per-
haps because of the length of time the catheter remains in
place, as well as the fact that total parenteral nutrition solu-
tions may act as a culture medium to promote the growth of
various organisms. Location of the central venous catheter
influences the risk of infection. Femoral catheters are most
prone to infection, followed by internal jugular catheters; the
latter is probably the result of contamination with oropha-
ryngeal secretions and difficulty with immobilization.
Subclavian catheters are least prone to infection.
B. Laboratory Findings—Local catheter-related infections
(eg, exit-site or tunnel infections) may be associated with few
or no laboratory abnormalities. Culture of drainage fluid or
exudate associated with the exit site may be helpful in deter-
mining a causative organism.
Bacteremia (positive blood cultures) may be related to
intravascular devices and may occur with or without sepsis.
Device-related bacteremia has been defined using quantitative
blood culture techniques. A device-related bacteremia is defined
as (1) more than a 5–10-fold increase in colony-forming units
of bacteria per milliliter of blood obtained through the device
compared with blood drawn from a distant peripheral vein,
(2) in the absence of positive peripheral blood cultures, more
than 1000 cfu/mL in blood obtained through the device, or
(3) organisms isolated from a catheter tip on removal in the
appropriate clinical setting. When no other clinical source of
infection is evident, resolution of fever on removal of the device
is also suggestive of catheter-related infection.
Differential Diagnosis
Exit-site, catheter-tunnel, or catheter infection must be differ-
entiated from chemical phlebitis, which can cause erythema,
tenderness, and induration of the vessel wall and overlying
skin. Fever also may be present in chemical phlebitis, but sys-
temic symptoms and signs consistent with sepsis are absent,
and exudate cannot be expressed from the exit site.
Thrombophlebitis may complicate catheter-related infection.
Pain, tenderness, and erythema at the infected site, as well as
edema distal to the site, are common presenting signs.
Thrombosis of a central venous catheter can cause edema
proximal to the site of thrombosis, but tenderness, erythema,
and fever are typically absent. Catheter tip sepsis usually pres-
ents with no symptoms or signs of local infection and must be
differentiated from infection from any other source.
Treatment
A. Exit-Site Infections—Short-term catheters suspected of
being infected should be removed. However, there is increasing
interest in maintaining long-term catheters in the presence of
certain infections. Few data are available to assist in developing
recommendations regarding removal or maintenance of an
infected long-term catheter. From the published data that do
exist, it appears that treatment of an infected catheter with
antibiotics alone is successful in about 50% of cases. Thus, in
some settings, it may be reasonable to attempt to eradicate a
long-term catheter exit-site infection with local care plus intra-
venous antibiotics. Empirical therapy should include van-
comycin to cover coagulase-negative staphylococci and S. aureus,
as well as an aminoglycoside or a cephalosporin with activity
against P. aeruginosa and other gram-negative bacilli. Definitive
therapy can be selected using culture results. If there is no
response within a few days, or if the exit-site infection appears to
be progressing to involve the catheter tunnel—or if fungi or
resistant bacteria are isolated—the catheter should be removed.
B. Tunnel Infections—Patients with tunnel infections
require removal of the catheter for definitive therapy. The
tunnel itself may require surgical incision and debridement.
Empirical antibiotic therapy should consist of vancomycin to
treat coagulase-negative staphylococci and S. aureus and a
third-generation cephalosporin or an aminoglycoside to
treat gram-negative bacilli.
C. Catheter-Tip Sepsis—Short-term catheters should be
removed and antibiotics administered. For a long-term
catheter, catheter-tip sepsis may be treated initially with intra-
venous antibiotics while leaving the catheter in place. However,
if the patient is in septic shock, the long-term catheter should
be removed immediately. Vancomycin in conjunction with a
third-generation cephalosporin or aminoglycoside is appropri-
ate initial therapy. Definitive therapy should be guided by the
results of the blood culture. Patients should be treated for a
total of 2–3 weeks. Catheter-tip sepsis in certain patient popu-
lations mandates immediate removal of a long-term catheter.
These include patients with neutropenia, severe immunocom-
promise, persistent bacteremia or sepsis despite appropriate
antibiotics, septic thrombosis, and those whose catheters are
infected with S. aureus, Candida or other fungi, or antibiotic-
resistant bacteria.
Management decisions must be based on the clinical cir-
cumstance. The intravascular device should be removed
immediately in any patient in whom rapid resolution of the
signs of infection does not occur. It should be emphasized
that neutropenic patients may not develop the classic local
signs of infection; therefore, the diagnosis of catheter-
associated infection in these patients may be difficult.
Finally, the risk of catheter-related infection may be signifi-
cantly reduced by appropriate care of the catheter and by
observing strict hand washing, dressing, and glove precautions.
Current Controversies and Unresolved Issues
A. Prevention of Catheter-Related Infection—The
challenge of preventing intravenous catheter infections in
the ICU while providing reliable access for intravenous
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antimicrobial therapy, total parenteral nutrition, hemody-
namic monitoring, or temporary hemodialysis is daunting.
Many recommendations have been put forward for preven-
tion of catheter-related infections, but only a few are sup-
ported by data. The most important are (1) use of full
sterile barrier precautions during insertion; (2) skin decon-
tamination with chlorhexidine; and (3) routine inspection
and care of the catheter site.
Recently, the use of antibiotic-impregnated catheters has
been proposed in an attempt to decrease the incidence of
catheter-site colonization and subsequent bloodstream
infection. A meta-analysis suggested that central venous
catheters impregnated with chlorhexidine–silver sulfadiazine
were effective in decreasing catheter-related bacteremia in
patients at high risk for infection (ie, patients who require
short-term catheters and multilumen catheters). Minocycline-
rifamipin-impregnanted central venous catheters (CVCs)
appear to have a lower rate of catheter-related bacteremia.
Second-generation antiseptic catheters reduced colonization
of bacteria on the catheters at the time of removal. The
impact of these catheters on the development of subsequent
infection  is not as clear.
The cost associated with catheter-tip sepsis has been esti-
mated to be about $6000 per bacteremic episode. Adopting
approaches to decrease catheter infection will reduce mor-
bidity and the overall cost of care.
B. Diagnosis of Catheter-Related Bacteremia—The lab-
oratory diagnosis of catheter-related bacteremia continues to
be difficult. Semiquantitative culture of the external surface
of the catheter tip is the method used most often to detect
catheter colonization and device-related bacteremia.
However, this method may fail to detect significant coloniza-
tion of the internal lumens of catheters. Several quantitative
methods have been described, including time to positivity
and quantitative blood cultures drawn through the catheter
(compared with peripheral blood cultures).
C. Duration of Intravascular Catheter Use—Recent studies
have attempted to clarify the utility of routine change of the
catheter site and the safety of exchanging a central venous
catheter over a guidewire. Pulmonary artery catheters—despite
the need for manipulation of the catheter during measure-
ments—can be left in place unless there is unexplained fever,
positive blood culture, or evidence of skin-site infection.
However, maintenance of a catheter at a given site for a maxi-
mum of 7 days would appear to be a reasonable limit. Central
venous catheters may be left in place without a predetermined
duration of placement; they should be removed in the presence
of a positive blood culture, an infected insertion site, suspicion
of catheter-related infection, or when there is no further need
for the catheter. It does not appear that routine replacement of
central venous catheters is indicated.
Microorganisms most commonly cause catheter-related
infection by migrating along the outer site of the catheter
from the skin surface to the tip. Nevertheless the, exchange of
a central venous or pulmonary artery catheter at the same
site using a guidewire has become accepted practice in many
ICUs if no evidence of catheter infection is present.
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 Clostridium Difficile–Associated Diarrhea
ESSENT IALS  OF  D IAGNOS I S
 Watery diarrhea and low-grade fever.
 Previous or current treatment with antibiotics—but may
occur as long as 6 weeks after antibiotic has been
stopped.
 Presence of C. difficile toxin in stool.
 Sigmoidoscopy may reveal white or yellow plaques of
pseudomembranous colitis.
General Considerations
Diarrhea developing in an ICU patient can be due to infec-
tious or noninfectious causes. The most important infectious
cause of nosocomial diarrhea is infection with C. difficile.
Nosocomial gastroenteritis caused by Salmonella, Shigella, E.
coli, and Campylobacter is exceedingly rare and should be
considered only in outbreak situations.
At least two things must occur for a patient to develop C.
difficile–associated diarrhea: acquisition of or colonization
with C. difficile and administration of an inducing agent. More
than 20% of patients hospitalized for over a week become col-
onized with C. difficile. The risk of acquisition of C. difficile
increases with length of hospital stay, reaching 50% in patients
hospitalized over 1 month. It appears that the administration
of certain antibiotics or chemotherapeutic agents induce the
organisms to elaborate toxins: toxin A is an enterotoxin, and
toxin B is a cytotoxin. The spectrum of disease encountered
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with this disorder ranges from simple diarrhea to pseudomem-
branous colitis, rarely complicated by toxic megacolon, which
can result in colonic perforation and death.
The most common antibiotics implicated in the develop-
ment of C. difficile–associated diarrhea are ampicillin, clin-
damycin, and the cephalosporins. Antibiotics less commonly
associated include trimethoprim-sulfamethoxazole, the
quinolones, aztreonam, the carbapenems, and metronidazole.
Vancomycin, erythromycin, tetracycline, and the aminoglyco-
sides rarely cause C. difficile–associated diarrhea. Although the
disorder is often self-limited, resolving when antibiotics are
stopped and treatment is initiated, severe complications may
occur. Recently, C. difficile strains associated with quinolone
and cephalosporin use have been responsible for several ICU
outbreaks. The presence of this particularly virulent C. difficile
led to increased attributable mortality in these patients.
Clinical Features
A. Symptoms and Signs—C. difficile typically produces
watery diarrhea and low-grade fever with or without abdom-
inal pain. Diarrhea may develop after a single dose of an
antibiotic or may be delayed as long as 6 weeks following the
last dose of the antimicrobial agent. If the patient develops
pseudomembranous colitis, sigmoidoscopy may reveal char-
acteristic white or yellow plaques or pseudomembranes.
Patients may become seriously ill, with fluid and electrolyte
imbalance, toxic megacolon, and colonic perforation.
B. Laboratory Findings—It is recommended that diarrheal
stools of patients who have been hospitalized for more than
72 hours with a history of prior antibiotic use be evaluated
for C. difficile–associated diarrhea. The diagnosis rests on the
identification of C. difficile toxin in the stool. The most sen-
sitive and specific test for this disorder is a tissue culture
assay for toxin B cytotoxicity, with a sensitivity of 94–100%
and a specificity of 99%. However, this test is cumbersome to
perform and takes 1–3 days to complete. Enzyme-linked
immunoassays for identification of toxins A and B have a
sensitivity of 63–99% and a specificity of 75–100%. In 20%
of patients, toxin assays on multiple stool samples may be
required to demonstrate the presence of the toxin.
Identification of fecal leukocytes is neither sensitive nor
specific for C. difficile–associated diarrhea. Nosocomial acqui-
sition of enteric pathogens such as Salmonella, Shigella, and C.
jejuni is extremely rare; thus, performing routine stool cultures
is not cost-effective in hospitalized patients with diarrhea.
Differential Diagnosis
Noninfectious causes of nosocomial diarrhea include various
medications, enteral feeding, inflammatory bowel disease,
ischemic colitis, GI bleeding from a variety of lesions, and
systemic illness. Antimicrobial administration can cause
diarrhea by altering normal bowel flora (eg, ceftriaxone,
tetracycline, and amoxicillin-clavulanic acid) or by bowel
irritation (eg, erythromycin). Infectious causes of nosocomial
diarrhea are rare and include enteric pathogens and
cytomegalovirus colitis in the immunocompromised host.
Treatment
If antibiotic-associated colitis develops in patients receiving
antibiotic therapy, improvement often occurs with discontin-
uation of antibiotics. Specific antimicrobial therapy should be
administered to those with persistent diarrhea or in patients
with severe illness. Asymptomatic carriers of C. difficile
should not be treated because doing so may prolong the car-
rier state. Oral vancomycin and metronidazole are equally
effective for most patients. Metronidazole is less expensive and
does not exert selective pressure for vancomycin-resistant ente-
rococci; for these reasons, it is thus the agent of choice. It should
be given at a dose of 500 mg orally three times a day for 10–14
days. In patients unable to tolerate oral medications, intra-
venous metronidazole at a dose of 500 mg every 8 hours can be
used as initial therapy. Vancomycin is recommended at a dosage
of 125–250 mg orally every 6 hours for 10–14 days in the event
of treatment failure, for persistent symptoms, or probably for
severe cases. As many as 20% of patients will relapse within the
first 2 weeks of completing a course of treatment, although most
will respond to a second course of metronidazole. Risk factors
for relapse include chronic renal failure, multiple previous
episodes of C. difficile–associated diarrhea, continuation of
other antimicrobial therapy, community-acquired C. difficile–
associated diarrhea, and high white blood cell counts.
Patients diagnosed with or suspected of having C. difficile–
associated diarrhea should be managed with enteric precau-
tions. The organism is particularly well suited to survive for
prolonged periods on a variety of surfaces and has been cul-
tured from hospital carpeting, beds, and walls. It is easily trans-
mitted by the hands of hospital personnel from patient to
patient. Therefore, appropriate isolation precautions are essen-
tial when caring for these patients. Note that conventional
handwashing is necessary for hospital personnel because alcohol-
based hand cleansers do not kill C. difficile spores.
It has become clear that C. difficile is a significant nosoco-
mial pathogen; thus prevention and control in the hospital
setting are crucial. C. difficile–associated diarrhea has been
strongly associated with the use of certain antimicrobial
agents, so alteration of patterns of antimicrobial use may be
helpful in reducing its incidence.
Given the high recurrence rate of C. difficile–associated
diarrhea, various non-antimicrobial approaches have been
employed to allow the bowel to reestablish its normal flora,
such as oral administration of Saccharomyces boulardii, lacto-
bacilli, or normal fecal flora. However, these strategies have not
been adequately studied to support formal recommendations.
Bartlett JG, Gerding DN: Clinical recognition and diagnosis of
Clostridium difficile infection. Clin Infect Dis 2008;46 Suppl
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Bouza E, Burillo A, Munoz P: Antimicrobial therapy of Clostridium
difficile–associated diarrhea. Med Clin North Am 2006;90:
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 Hematogenously Disseminated Candidiasis
ESSENT IALS  OF  D IAGNOS I S
 Fever despite broad-spectrum antibacterial therapy and
negative bacterial blood cultures.
 Possible skin manifestations.
 Consider in neutropenic hosts and patients with long-
term vascular access.
General Considerations
Candida species are an increasing cause of nosocomial
bloodstream infections and are associated with high rates of
mortality and morbidity. Patients at increased risk for
hematogenously disseminated candidiasis include those with
extensive burns, indwelling venous catheters, broad-
spectrum antibiotic exposure, immunosuppression (espe-
cially neutropenia), severe mucositis, previous surgical
procedures (particularly GI surgery), total parenteral nutri-
tion, concomitant bacteria or other infections, and mucosal
colonization by Candida species. Mortality from candidemia
is highest among those patients with high APACHE II scores,
severe underlying disease, and persistent candidemia despite
appropriate antifungal therapy.
Microbiologic Etiology
C. albicans is the species most commonly isolated from blood
cultures; however, recent emergence of non-albicans species
has been noted, most notably an increase in the incidence of
C. glabrata. Why non-albicans species are increasingly isolated
is not entirely clear. However, the widespread use of empirical
fluconazole may exert selective pressure leading to the emer-
gence of Candida species that are less sensitive to the triazoles.
Fungemia caused by C. tropicalis usually occurs as a result
of endogenous infection, although cases of nosocomial
transmission also have been documented. Most isolates of
C. tropicalis are sensitive to amphotericin B, flucytosine, and
the triazoles. C. glabrata, a pathogen with decreased suscep-
tibility to fluconazole, is the second most common Candida
species isolated in nosocomial bloodstream infections.
C. parapsilosis infection occurs almost exclusively in the
presence of indwelling venous catheters, prosthetic devices,
or invasive devices and is not usually a member of the
patient’s endogenous flora. This organism is usually suscep-
tible to both amphotericin B and fluconazole. C. krusei is
considered to be resistant to fluconazole and is seen most
commonly in neutropenic patients, especially those receiving
fluconazole for antifungal prophylaxis or empirical therapy.
Clinical Features
A. Symptoms and Signs—Most patients with hematoge-
nously disseminated candidiasis have no systemic symptoms
or signs of infection other than persistent fever in the setting
of broad-spectrum antibiotics. Careful physical examination
should be performed to assess the presence of skin lesions
characteristic of candidemia. Three types of lesions have
been described with hematogenously disseminated candidia-
sis: The classic lesion is macronodular, erythematous, and
0.5–1 cm in diameter. Lesions resembling ecthyma gan-
grenosum and purpura fulminans also have been described.
In all three types of lesions, the organisms are seen readily on
histopathologic examination of punch biopsy specimens.
Any new neurologic symptom should prompt a CT scan or
MRI of the brain because candidal micro- and macroab-
scesses of the CNS have been described in patients with can-
didemia. Patients should undergo daily physical examination
looking for new cardiac murmurs, bone or joint findings,
and hepatosplenomegaly. Endocarditis, osteomyelitis, arthri-
tis, and hepatosplenic candidiasis are all documented com-
plications of candidemia. All patients should have a
thorough ophthalmoscopic examination to rule out candidal
endophthalmitis, typically appearing as white “cotton ball”
lesions that may extend into the vitreous.
B. Laboratory Findings—Laboratory findings in hematoge-
nously disseminated candidiasis are nonspecific. The rate of
premortem diagnosis of disseminated candidemia is typi-
cally low. With the development of new blood culturing tech-
niques such as the BACTEC system, the yield of positive
blood cultures for Candida has increased, although it is still
less than 50%. Thus the diagnosis is made mainly on clinical
grounds. Appropriate imaging studies should be obtained
when there is suspicion of end-organ dissemination; biopsy
of suspicious lesions should be pursued to look for
histopathologic evidence of invasive candidal infection.
Treatment
A. Empirical Antifungal Therapy—The diagnosis of
hematogenously disseminated candidemia typically is
made on clinical grounds, and patients are often treated
empirically based on the presence of multiple risk factors
or evidence for mucosal colonization with Candida
species. A critical intervention in the treatment of can-
didemia is the removal of all potentially infected venous
catheters, especially in neutropenic patients.
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The antifungal agent of choice depends on the clinical
status of the patient and the physician’s knowledge of the
possible infecting Candida species. In the pretriazole era,
amphotericin B was used exclusively in all patients with sus-
pected or documented fungal infection. However, data now
suggest that in a nonneutropenic patient who is hemodynami-
cally stable, fluconazole will provide response rates of 60–100%.
Factors that may prompt the physician to use amphotericin B as
empirical therapy include hemodynamic instability or known
colonization of the patient with non-albicans species, such as
C. glabrata or C. krusei. Caspofungin or micafungin are other
alternatives. There is general agreement that a neutropenic
patient with suspected invasive fungal infection should receive
amphotericin B, micafungin or caspofungin. Flucytosine may
be used in combination with either amphotericin B, micafungin
or fluconazole in severe infections. Itraconazole is available in an
intravenous formulation, but formal studies to support recom-
mendations for its use have not been completed.
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 Antimicrobial Resistance in the ICU
Critically ill patients often receive broad-spectrum antimi-
crobial therapy during their hospitalization; thus the ICU is
fertile ground for the emergence of antimicrobial resistance.
In this section, specific resistance problems encountered in
the ICU will be reviewed, including vancomycin-resistant
enterococci, methicillin-resistant S. aureus, glycopeptide-
insensitive S. aureus, gram-negative bacilli with extended-
spectrum β-lactamases, gram-negative bacilli that produce
group 1 β-lactamases, and Acinetobacter baumanii.
Vancomycin-Resistant Enterococci
A. Incidence—Enterococci are normal inhabitants of the GI
tract and generally are considered to be organisms of low vir-
ulence. Patients with serious nosocomial infections caused
by enterococci have high morbidity and mortality rates owing
to their underlying disease. In the past, most enterococcal
infections were caused by E. faecalis, and only about 5–10% of
infections owing to enterococci were due to E. faecium.
However, the emergence of glycopeptide-resistant E. faecium
has led to a shift in the relative frequency of infection with
this species. The most common site of origin of enterococcal
infection is the urinary tract, followed by intraabdominal
or pelvic infection as part of a polymicrobial process.
Bacteremia usually occurs as a complication of one of the
preceding or may result from infection of an indwelling
venous catheter or prosthetic device.
National nosocomial surveys have demonstrated an
increase in the prevalence of vancomycin-resistant entero-
cocci among enterococcal isolates to levels of 25% or greater.
Case-control studies have identified several risk factors for
acquisition of vancomycin-resistant enterococci. Host factors
include advanced age, severity of underlying disease, hema-
tologic malignancy, neutropenia, cirrhosis, hemodialysis,
recent intraabdominal surgery, prior nosocomial infection,
the presence of pressure sores, prolonged hospitalization,
invasive procedures, contact with another person colonized
or infected with vancomycin-resistant enterococci, and previ-
ous antimicrobial therapy (especially with a third-generation
cephalosporin and vancomycin). Patients in certain health
care settings, including long-term care facilities, outpatient
dialysis units, ICUs, and oncology or transplant wards, have
the highest prevalence of vancomycin-resistant enterococci
carriage.
B. Mechanism of Resistance—Enterococci develop resist-
ance to vancomycin through acquisition of genes conferring
resistance; these genes are specified as vanA or vanB. The
most common phenotype, vanA, is transmitted by a transpo-
son and confers high-level resistance to vancomycin and
teicoplanin. The vanB phenotype is chromosomally based
and confers variable resistance to vancomycin while main-
taining susceptibility to teicoplanin. Both phenotypes are
easily transferable among different enterococci via conjuga-
tion. The mechanism of resistance involves a change in the
cell wall building block, D-alanine-D-alanine, the target site
for vancomycin, to D-alanine-D-lactate.
C. Therapy—Treatment of serious vancomycin-resistant ente-
rococcal infections is difficult. Many strains are resistant to
ampicillin and aminoglycosides, so the remaining options
are few in number, and antienterococcal activity is limited.
Carbapenems, fluoroquinolones, tetracyclines, chlorampheni-
col, rifampin, novobiocin, and nitrofurantoin all have been
used in various combinations in an attempt to treat infection
with vancomycin-resistant enterococci. Quinupristin-
dalfopristin, linezolid, and daptomycin are drugs recently
licensed in the United States that include vancomycin-
resistant enterococci in their spectrum of activity. Urinary
tract infections may be treated successfully with nitrofuran-
toin and removal of the urinary catheter. Mixed infections,
such as intraabdominal abscesses or skin and soft tissue infec-
tions, should undergo aggressive debridement. Indwelling
venous catheters and prosthetic devices should be removed
whenever possible. Treatment of serious vancomycin-
resistant enterococcal infection should include at least two
antimicrobial agents to which the organism is susceptible,
and one of these should be an aminoglycoside unless the
class is contraindicated or resistance is present.
D. Prevention—In the United States, most carriage of van-
comycin-resistant enterococci and outbreaks of infection are
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due to patient-to-patient spread. Thus strict infection con-
trol measures are necessary to prevent spread and persistence
of the organisms. Strict contact isolation should be observed
for any patient infected or colonized with the organism. In
addition, the use of empirical vancomycin for the treatment
of hospitalized patients should be limited to those with clear
indications.
Methicillin-Resistant S. aureus (MRSA)
A. Incidence—The National Nosocomial Infection Surveillance
surveys have demonstrated an increase in the percentage of
MRSA from about 2–3% of all S. aureus isolates in 1975 to
over 50% in the current era. The incidence of community-
acquired MRSA is also increasing. The major route of spread
of MRSA is direct patient-to-patient contact or via the hands
of medical personnel. Common sites of MRSA colonization
include the anterior nares, wounds, burns or other areas of
decreased skin integrity, the perineal area, the upper respira-
tory tract, and the skin adjacent to invasive devices, gastros-
tomy tubes, and tracheostomies. Risk factors for both
colonization and infection with MRSA include previous hos-
pitalization, prolonged hospital stay, hospitalization in a burn
unit or ICU, chronic prior antimicrobial therapy, exposure to
a colonized health care worker or patient, the presence of sur-
gical wounds or burns, and the use of invasive devices.
B. Mechanism of Resistance—Resistance of S. aureus to
methicillin is transmitted chromosomally via the mecA gene.
Acquisition of this gene results in altered penicillin-binding
protein 2A. Presence of the mecA gene is also associated with
resistance to other antibiotics, including all β-lactams,
aminoglycosides, macrolides, tetracycline, rifampin, and flu-
oroquinolones.
C. Therapy—Most strains of MRSA are sensitive to the gly-
copeptide vancomycin. In the United States, vancomycin is
the drug of choice for serious infections with MRSA. There
may be a role for quinupristin-dalfopristin, linezolid, and
daptomycin in the treatment of infections with this organ-
ism. Eradication of MRSA carriage may be attempted with
either topical or systemic antimicrobials or by bathing with
antiseptic soaps. The efficacy of any of these approaches in
eradication is inconsistent and often incomplete. Many
community-acquired strains of MRSA are susceptible to
trimethoprim-sulfamethoxazole, clindamycin, rifampin, and
in some cases macrolides.
Vancomycin-Insensitive S. aureus (VISA) and
Vancomycin-Resistant S. aureus (VRSA)
A. Incidence—The emergence of VISA is probably the most
disturbing development to occur in the antibiotic era.
Vancomycin insensitivity among S. aureus is defined as an
MIC to vancomycin of 8–16 μg/mL. The first reported case
of infection with this organism occurred in Japan in May of
1996. Most patients with VISA were on hemodialysis, and
most had had recurrent MRSA bacteremias that were treated
with prolonged courses of vancomycin. The first case of
vancomycin-resistant S. aureus (MIC to vanomycin of 32
μg/dL or more) was reported in 2002, with only a few addi-
tional cases reported subsequently.
B. Mechanism of Resistance—The mechanism of van-
comycin insensitivity is not clear. Scanning and transmission
electron microscopy of the insensitive organisms show a
thickened bacterial cell wall. A fully vancomycin-resistant
S. aureus strain has been created in vitro, demonstrating a
similarly thickened bacterial cell wall. It is hypothesized that
decreased vancomycin access to the target sites may occur as
a result of sequestration of the drug in the cell wall. Full van-
comycin resistance is mediated via the vanA gene, which con-
fers vancomycin resistance to enterococci.
C. Therapy—Therapy of VISA and VRSA infection is not
standardized; thus antimicrobial therapy should be based on
the organism’s susceptibility profile. Preliminary in vitro data
suggest that as the bacteria become more resistant to van-
comycin, they become more susceptible to oxacillin. Thus
there may be a role for combination therapy with van-
comycin and oxacillin in infections with VISA. A role for
quinupristin-dalfopristin, linezolid, and daptomycin in the
treatment of these infections is a possibility as well.
Gram-Negative Bacilli Producing
Extended-Spectrum β-Lactamases (ESBLs)
A. Incidence—Bacterial strains with ESBLs were first identi-
fied in the mid-1980s. Most are strains of K. pneumoniae or
E. coli. ESBL production has been noted in other species of
Enterobacteriaceae as well but with much lower frequency.
The actual incidence of ESBL-producing strains is difficult to
quantify because surveillance and reporting are incomplete.
Most strains are isolated from hospitalized patients. Risk fac-
tors for acquisition include prolonged hospital stay; severity
of illness; admission to an ICU, oncology unit, or nursing
home; emergency surgical or invasive procedures; central
venous, arterial, or urinary catheterization; and prior
extended-spectrum cephalosporin use. Notably, outbreaks
with ESBL-producing strains have been linked to heavy cef-
tazidime use within a hospital.
B. Mechanism of Resistance—The ESBLs are descendants
of the β-lactamases responsible for ampicillin resistance in
E. coli and penicillin resistance in K. pneumoniae. This plasmid-
mediated gene confers resistance not only to the extended-
spectrum cephalosporins but also to aztreonam. The gene
also may encode resistance to aminoglycosides, tetracyclines,
trimethoprim-sulfamethoxazole, and chloramphenicol. The
plasmids bearing these genes are stable and are easily trans-
missible from bacteria to bacteria.
C. Therapy—On routine susceptibility testing, ESBL-
producing strains may appear to be sensitive to the
extended-spectrum cephalosporins and aztreonam. Clues to
INFECTIONS IN THE CRITICALLY ILL 391
the presence of an ESBL-producing strain are (1) clinical
failure in the setting of “appropriate” antimicrobial therapy,
(2) presence of resistance to certain antibiotics, such as amino-
glycosides, tetracyclines, trimethoprim-sulfamethoxazole, and
chloramphenicol, which are often transmitted on the same
plasmid as the ESBL, and (3) diminished susceptibility to cef-
triaxone, ceftazidime, or aztreonam (if this pattern is seen,
resistance to all extended-spectrum cephalosporins and aztre-
onam should be presumed). ESBL-producing organisms usu-
ally display susceptibility to cephamycins (eg, cefotetan and
cefoxitin) and the carbapenems, with variable susceptibility
to the β-lactam/β-lactamase inhibitor combinations.
Carbapenems are the mainstay of therapy in the seriously ill
patient infected with an ESBL-producing organism because
cases of cephamycin resistance have been reported to emerge
during the course of cephamycin therapy.
Gram-Negative Bacilli Producing Group 1
β-Lactamases
A. Incidence—Group 1 β-lactamases are chromosomally
based β-lactamases. The most commonly encountered organ-
isms with group 1 β-lactamase production are Enterobacter
species, P. aeruginosa, Citrobacter species, S. marcescens, and
some Proteus species. According to the National Nosocomial
Infection Surveillance System, infections owing to these
organisms have been increasing in incidence. This recent
trend is of concern given the resistance of these pathogens to
extended-spectrum cephalosporins, with documented
cephalosporin resistance developing even while on appropri-
ate therapy. Risk factors for acquisition of these pathogens
include prior therapy with ceftizoxime, cefotaxime, or cef-
tazidime and perhaps with extended-spectrum penicillins—
as well as length of previous antimicrobial therapy.
B. Mechanism of Resistance—The mechanism of resist-
ance of group 1 β-lactamase-producing organisms is induc-
tion of a chromosomally based gene that encodes for
production of a group 1 β-lactamase (a cephalosporinase)
that inactivates all cephalosporins.
C. Therapy—Therapy should be based on antimicrobial sus-
ceptibility data for a given strain. These organisms usually
retain their sensitivity to the carbapenems and the fluoro-
quinolones. Emergence of resistance in the setting of ongoing
antimicrobial therapy occurs in approximately 5% of patients
and is more likely to occur with use of a third-generation
cephalosporin rather than an aminoglycoside or an extended-
spectrum penicillin. Whether combination therapy will
decrease the risk of emerging resistance is not yet known. At
this time, it appears that monotherapy with an extended-
spectrum cephalosporin should be avoided when treating
infection caused by group 1 β-lactamase-producing organisms.
Acinetobacter baumanii
A. Incidence—A. baumanii is a gram-negative coccobacillus
that may occur as a normal skin colonizer. It is considered to
be relatively nonvirulent; however, the worldwide emergence
of this organism has been noted increasingly in the nosocomial
setting, sometimes in persistent outbreaks in ICUs. The
treatment challenge with this organism results from its
inherent resistance to a wide array of antimicrobial agents.
Risk factors for infection include underlying illness, prior
broad-spectrum antimicrobial therapy use, length of ICU
stay with use of invasive devices, and prior colonization with
the organism.
B. Mechanism of Resistance—The mechanism of resistance
to the β-lactam drugs is the production of a plasmid-mediated
penicillinase. Resistance to cephalosporins occurs as a result of
overproduction of a chromosomal cephalosporinase.
C. Therapy—As with most multidrug-resistant pathogens,
therapy should be based on available susceptibility data.
However, pending such information, one of the carbapen-
ems can be considered for empirical therapy because these
agents tend to retain their activity against A. baumanii. There
is, however, increasing resistance owing to bacterial produc-
tion of carbapenemases. Other considerations include tige-
cycline and colistin.
Infection Control Concepts
The specter of antimicrobial resistance increasingly threatens
physicians’ ability to treat bacterial infections. To complicate
matters, there is limited development of new antimicrobial
agents targeting resistant bacteria. Numerous studies have
demonstrated a stepwise increase in incidence of drug resist-
ance from the community to the general inpatient ward to the
ICU. Control of antimicrobial resistance is the responsibility
of every critical care physician. This can be broken down into
two critical components: (1) prevention of emergence of new
resistance mechanisms or resistant species and (2) prevention
of spread of organisms from patient to patient.
A. Prevention of Emergence of Resistance—The central
component of prevention is reducing selection pressure for
resistance by judicious use of antimicrobials. Several studies
have demonstrated that while overuse of antibiotics can fos-
ter antimicrobial resistance, changes in antibiotic use can
result in recovery of susceptibility. Judicious antimicrobial
use includes careful consideration of which patients are
appropriate candidates for antimicrobial therapy, when
antimicrobial therapy should be initiated, which antimicro-
bial agents should be administered, and for what duration.
The goal of antimicrobial therapy in the ICU is to expedi-
tiously treat a seriously ill patient with suspected or con-
firmed infection with the appropriate agent(s). The
physician should make every attempt to differentiate
between true bacterial infection and simple colonization.
Moreover, it should be kept in mind that not all fever is the
result of infection; when no source of infection can be iden-
tified, noninfectious causes of fever should be considered
(Table 15–7). Prophylactic use of antimicrobial agents
should be avoided in the absence of a clear indication.
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Much controversy surrounds the empirical use of combi-
nation therapy (eg, a β-lactam plus an aminoglycoside) in
a patient suspected of being infected with an aerobic
gram-negative bacillus. Some in vitro data suggest that com-
bination therapy may decrease the emergence of chromoso-
mally mediated resistance, although it actually may worsen
plasmid-mediated resistance. While it is acceptable to use
broad-spectrum empirical antimicrobial therapy initially,
antibiotics should be tailored once culture data become
available. In addition, focal collections of purulent material
should be drained whenever possible to decrease inoculum
size, thereby improving the outcome of antimicrobial ther-
apy. Prolonged courses or inappropriately broad-spectrum
antibiotics should be avoided.
B. Prevention of Spread of Infection—Prevention of
nosocomial spread of infection involves prompt identifica-
tion of patients colonized or infected with multidrug-resistant
organisms plus rapid institution of appropriate isolation pro-
cedures. Even in wards or ICUs not known to have patients
colonized or infected with multidrug-resistant organisms,
routine hand washing with antiseptic soaps or use of alcohol-
based cleansers by all health care personnel is critical.
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BOTULISM & TETANUS
Patients with botulism and tetanus have primarily neuro-
logic complications that almost always require management
in an ICU. Both disorders are caused by toxins produced by
clostridia. In tetanus, patients have traumatic or surgical
wounds contaminated by C. tetani. Most cases of botulism
are due to ingestion of preformed food-borne toxin; how-
ever, botulism may result from toxin produced by cutaneous
infection with C. botulinum.
 Botulism
ESSENT IALS  OF  D IAGNOS I S
 Nausea, vomiting, dysphagia, diplopia, dilated and
fixed pupils. 
 Sudden weakness in a previously healthy person.
 Cranial nerves affected first (except I and II), followed
by descending symmetric paralysis or weakness.
 Autonomic nervous system involvement: paralytic ileus,
gastric dilation, urinary retention, and orthostatic
hypotension.
 Absence of sensory or mental status changes.
 Botulism toxin isolated from serum, stool, or other body
fluids.
General Considerations 
Botulism is an acute neurologic disorder caused by the pro-
duction of a neurotoxin produced by C. botulinum.
Improperly canned or home-prepared foods are common
sources of the toxin. There are three clinical forms of botu-
lism: food-borne botulism, wound botulism, and infant bot-
ulism. Infant botulism results from the ingestion of botulism
spores, which germinate in the intestine and produce toxin.
Most infants recover with supportive care only. Food-borne
and wound botulism are generally more serious illnesses.
A. C botulinum and Botulism Toxins—C. botulinum is an
anaerobic gram-positive rod that survives in soil and marine
Common causes
Drug fever  
Malignancy  
Deep venous thrombosis  
Posttransfusion  
Postoperative (atelectasis)  
Thrombophlebitis
Chemical aspiration pneumonitis
Less common causes
Hyperthyroidism
Adrenal insufficiency  
Transplant rejection  
Alcohol withdrawal, drug withdrawal  
Pancreatitis  
Pulmonary embolism 
Hematoma 
Table 15–7. Some noninfectious causes of fever
in the ICU.
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sediment by spore formation. Under anaerobic conditions
that permit germination, toxin production occurs. Although
boiling for 10 minutes will kill bacteria and destroy toxins,
spores are heat-resistant and can survive boiling for 3–5 hours.
Food contaminated by botulism toxin may have no detectable
change in appearance or taste.
Botulism toxin is the most potent toxin known on a per-
weight basis. Eight immunologically distinct toxins have
been described: A, B, Cα and Cβ, D, E, F, and G. Each strain
of C. botulinum can produce only a single toxin type. Toxins
A, B, and E have been the most common causes of human
disease. Toxins A and B are the most potent; even small tastes
of food contaminated with these toxins have resulted in full-
blown disease.
Specific C. botulinum toxins appear to be geographically
distributed throughout the world. In the United States, toxin
A is found predominantly west of the Mississippi, whereas
toxin B is found in the eastern states. Toxin E is found in the
Great Lakes region and in Alaska, where one of the highest
rates of botulism worldwide is seen.
Toxins produced by C. botulinum block acetylcholine
release at peripheral neuromuscular and autonomic nerve
junctions, resulting in weakness, flaccid paralysis, and some-
times respiratory failure. Toxin binding is irreversible.
B. Food-Borne Botulism—Botulism toxins are large pro-
teins. In food-borne botulism, ingested preformed toxin is
absorbed in the stomach and upper small intestine. Toxins
are reduced in size by proteolytic enzymes, but their activity
remains unchanged. Pancreatic trypsin actually may
enhance the toxicity of some toxin strains. In addition to
improperly home-canned foods, outbreaks of botulism have
been traced to noncanned foods such as eviscerated dried
fish, yogurt flavored with hazelnut conserve, a garlic-in-oil
product, homemade salsa, cheese sauce, baked potatoes
sealed in aluminum foil, and sautéed onions stored under a
layer of butter.
Botulism toxin has potential as a weapon of bioterrorism,
both from ingestion and by inhalation. Clinical findings
would be identical, but possible features would include a
large outbreak with common environmental exposure, an
unusual toxin type, or multiple simultaneous outbreaks.
C. Wound Botulism—Wound botulism results when C.
botulinum grows and produces toxin in traumatized, devitalized
tissue. The wound may appear insignificant. Toxin produc-
tion is followed by onset of symptoms after an incubation
period of 4–14 days. Many cases of wound botulism have
occurred in teenagers, children, and injection drug users.
Sinus infection with C. botulinum has been reported after
intranasal cocaine use; evidence suggests that botulism toxin
can be inhaled or inoculated through the eye. In recent years,
there has been a dramatic increase in the number of cases of
wound botulism linked to the subcutaneous injection of
impure “black tar” heroin imported from Mexico, perhaps
the result of contamination of the drug during the “cutting”
process with adulterants such as dirt.
D. Adult Infectious Botulism—While most cases of adult
botulism are the result of ingested preformed toxin, there
have been cases of botulism in patients with documented
C. botulinum colonization of the intestinal tract. Risk factors
include abdominal surgery, GI tract abnormalities, and
recent antibiotic administration, all of which presumably
alter the normal GI flora.
Clinical Features
The diagnosis of food-borne botulism should be considered
when an acute illness with GI or neurologic manifestations
affects two or more persons who have shared a meal during
the preceding 72 hours. Wound botulism presents with sim-
ilar neurologic symptoms but without GI complaints.
A. Symptoms and Signs—An initial pentad of signs and
symptoms has been described in botulism, consisting of nau-
sea and vomiting, dysphagia, diplopia, dilated and fixed
pupils, and an extremely dry mouth unrelieved by drinking
fluids. Over 90% of patients have at least three of these signs
or symptoms. Symptoms can occur as early as 2 hours or as
late as 8 days after toxin ingestion but usually occur within
18–36 hours. Onset of symptoms can be abrupt or may
evolve over several days. Abnormalities of cranial nerve
motor functions are followed by descending symmetric
paralysis or weakness. Respiratory muscle weakness may be
subtle or may progress rapidly to respiratory failure. Somatic
musculature is affected last. Patients may develop autonomic
nervous system manifestations, including constipation from
paralytic ileus, gastric dilation, urinary retention, and ortho-
static hypotension.
Notably absent in patients with botulism are sensory dis-
turbances, changes in sensorium, and fever. Cranial nerves I
and II are spared. Deep tendon reflexes may be intact, dimin-
ished, or absent, but pathologic reflexes cannot be demon-
strated. In addition, the heart rate may be normal or slow
unless secondary infection is present.
B. Laboratory Findings—The diagnosis of botulism is con-
firmed by isolating botulism toxin through a mouse neutral-
ization bioassay. Toxin may be identified in samples of
serum, stool, vomitus, gastric aspirate, and suspected foods.
C. botulinum may be grown on selective media from samples
of stool or foods. Specimens for toxin analysis should be
refrigerated, but culture samples for C. botulinum should
not. Because the toxin may enter the bloodstream through
the eye or a small break in the skin, only experienced person-
nel, preferably immunized with botulinum toxoid, should
handle specimens.
Electromyography may be useful in establishing a diagno-
sis of botulism but can be nonspecific and nondiagnostic
even in severe cases. Low-amplitude and short-duration
motor unit action potentials, small M-wave amplitudes, and
posttetanic fasciculation may be seen. A modest increment in
M-wave amplitude with rapid repetitive nerve stimulation
may help to localize the disorder to the neuromuscular
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junction. Single-fiber electromyography may be a more use-
ful and sensitive method for the rapid diagnosis of botulism
intoxication, particularly when signs of general muscular
weakness are absent. Cerebrospinal fluid is normal.
Differential Diagnosis
Differentiating botulism from other diseases is critical to
early implementation of appropriate therapy. Table 15–8 lists
diseases that must be differentiated from botulism.
Treatment
A. Supportive Care—Meticulous supportive care is essential
for patients with all forms of botulism. If respiratory failure
has not already occurred at the time of diagnosis, the patient
should be hospitalized in a monitored setting with serial
measurements of vital capacity. Respiratory failure can occur
with unexpected rapidity. Pulmonary infections are a com-
mon complication of botulism, often the result of aspiration
of oropharyngeal secretions or a complication of atelectasis.
The development of fever should prompt an evaluation of
possible pneumonia. Improvement in ventilatory and upper
airway muscle strength in patients who develop respiratory
failure is most significant over the first 12 weeks, but recov-
ery may not be complete for up to a year.
Wound botulism requires thorough debridement of the
infected wound and administration of penicillin in addition
to antitoxin therapy.
B. Botulism Antitoxin—Botulism antitoxin should be
administered to all patients with food-borne or wound bot-
ulism. Because only equine antitoxin is available, all patients
first must undergo testing for hypersensitivity to equine
serum. Twenty percent of patients will experience some
degree of hypersensitivity, and anaphylaxis also can occur.
Trivalent antitoxin for toxins A, B, and E is distributed
through the Centers for Disease Control and Prevention.
Polyvalent antitoxin for toxins A, B, C, D, E, and F is also
available for specific outbreaks.
Antitoxin should be given as soon as available, but it may
be beneficial even when given several weeks after toxin inges-
tion because circulating toxin can be detected in serum up to
30 days after intoxication. Antitoxin will not neutralize toxin
already bound to neuromuscular junctions, and although it
can slow disease progression, it has no effect on established
neurologic impairment. Two vials of the appropriate anti-
toxin should be given, one intramuscularly and one intra-
venously. This regimen may be repeated after 2–4 hours.
Because of the risk of adverse reactions, prophylactic
antitoxin is not recommended for those who have been
exposed to botulism toxin but have no symptoms. If inges-
tion is recognized early, patients may undergo gastric lavage
or induced vomiting in an attempt to eliminate the toxin
prior to absorption.
Current Controversies and Unresolved Issues
Administration of antibiotics to patients with food-borne
botulism is controversial, although some physicians give
penicillin to eradicate potential bowel carriage of the organ-
ism. The benefit of this approach is uncertain.
Guanidine hydrochloride is thought to increase acetyl-
choline release from terminal nerve endings and is advocated
by some in the treatment of botulism. Reports of its efficacy
are conflicting.
Arnon SS et al: Botulinum toxin as a biological weapon: Medical
and public health management. JAMA 2001;285:1059–70.
[PMID: 11209178]
Cherington M: Botulism: Update and review. Semin Neurol
2004;24:155–63. [PMID: 15257512]
 Tetanus
ESSENT IALS  OF  D IAGNOS I S
 Generalized weakness or stiffness, with trismus (“lock-
jaw”) and severe generalized spasms.
 Opisthotonos and abdominal rigidity.
 Respiratory failure, tachycardia, hypertension, fever,
and diaphoresis may be present.
General Considerations
Although entirely preventable by appropriate vaccination,
tetanus still occurs in developing countries and infrequently
in developed countries. It remains endemic in developing
countries. In the United States, 50–70 cases are reported
annually, typically in patients who have never received a pri-
mary immunization series with tetanus toxoid. Many elderly
patients and patients born or raised in developing countries
have not been vaccinated and are at risk. Elderly women may
be at higher risk than elderly men because many men were
vaccinated during military service. Male gender and black
race are risk factors for tetanus in the United States, perhaps
because of the higher incidence of trauma in these groups.
Myasthenia gravis  
Tick paralysis  
Poliomyelitis  
Guillain-Barré syndrome (Miller-Fisher variant)  
Psychiatric disorder  
Stroke (brain stem)  
Rabies 
Diphtheria 
Eaton-Lambert syndrome 
Table 15–8. Differential diagnosis of botulism.
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Injection drug users, particularly “skin poppers,” are predis-
posed to tetanus. Tetanus is more frequent in warmer cli-
mates and months in part because of the greater frequency of
contaminated wounds. Tetanus is not transmitted from per-
son to person.
A. C. tetani and Tetanospasmin—The clinical syndrome
of tetanus is caused by a potent neurotoxin, tetanospasmin,
released from C. tetani. A slender, motile, gram-positive
nonencapsulated anaerobic rod, C. tetani is a spore-forming
organism that is found commonly in nature. Spores may be
found in soil and dust but are particularly common in areas
contaminated with human or animal excreta. Spores may
remain viable for years and then germinate when they are
introduced into an appropriate anaerobic environment such
as devitalized tissue. The presence of other bacterial organ-
isms appears to enhance the reversion of spores to vegetative
forms and the release of tetanospasmin.
B. Pathophysiology—Tetanospasmin migrates into the
CNS either transsynaptically along peripheral motor nerves
or by hematogenous or lymphatic routes. It binds to the
presynaptic inhibitory neurons and prevents the release of
acetylcholine from nerve terminals in muscle. The functional
loss of inhibitory neurons allows lower motor neurons to
increase muscle tone, producing rigidity and spasm of both
agonist and antagonist muscles. Once tetanospasmin is fixed
to nervous tissue, it cannot be neutralized by antitoxin.
Tetanospasmin also binds to cerebral gangliosides, which
may be the cause of seizures seen in tetanus. Disturbances of
the autonomic nervous system are common, manifested by
sweating, fluctuating blood pressure, tachycardia and cardiac
arrhythmias, and increased production of catecholamines.
Clinical Features
Tetanus may occur in the neonate in the first month of life or
as one of three patterns in adult patients. Generalized tetanus
is the most common adult presentation. Local tetanus and,
even more rarely, cephalic tetanus are manifested by local
muscle spasms in areas contiguous with an infected wound.
Both local and cephalic tetanus may progress to generalized
tetanus. Tetanus is a diagnosis of exclusion. If the diagnosis is
not considered, the opportunity for early treatment will be
lost.
A. Introduction of C. tetani—The wound into which C.
tetani has been introduced may appear insignificant.
However, particularly high-risk wounds include those con-
taminated with dirt, feces, soil, or saliva, as well as any punc-
ture wound, crush wound, burn, decubitus ulcer, or frostbite
injury. Tetanus also has been reported following elective and
emergency surgical procedures, particularly those involving
the GI tract. The postpartum uterus is also susceptible to
C. tetani infection. Thus tetanus should be considered in the
postoperative patient who develops crampy abdominal pain
and abdominal wall rigidity with no history of tetanus vacci-
nation. C. tetani may be harbored in the middle ear (chronic
otitis media) and in wounds of the head, predisposing a
patient to cephalic tetanus.
B. Symptoms and Signs—Tetanus can present 1–54 days
following a puncture or other wound, but an incubation
period shorter than 14 days is most common. Longer incuba-
tion periods generally are related to injury sites farther away
from the CNS. Generalized weakness or stiffness is a frequent
initial symptom, with trismus (“lockjaw”) being the most
common complaint. As symptoms progress over 1–7 days,
severe generalized reflex spasms develop. Opisthotonos, abdom-
inal rigidity, and a grotesque facial expression called risus sar-
donicus are classic signs. Spasms may be precipitated by
minor disturbances such as a draft or noise or by jarring the
bed. In the absence of seizures, the patient’s sensorium is
usually clear. Involvement of the respiratory muscles may
lead to hypoventilation. Autonomic dysfunction may occur,
causing tachycardia, hypotension, fever, and diaphoresis, and
can be difficult to manage.
Tetanus severity scores provide prognostic information.
Extremes of heart rate, high blood pressure, advanced age,
short duration of symptoms, and presence of underlying dis-
eases are associated with worse outcome.
Complications of tetanus include pneumonia, venous
thrombosis, pulmonary embolism, and long bone and spine
fractures from severe sustained muscle contractures. The
mortality rate from tetanus ranges from 21–31% in the
United States and may be as high as 52% in patients over
60 years of age. Poor outcome is associated with autonomic
disturbances such as blood pressure lability, with cardiac
arrhythmias and rate disturbances, and with hyperglycemia,
hyperthermia, and anticoagulation therapy.
Some studies have suggested a poor prognosis when
patients present with short incubation periods and heavily
contaminated wounds. A better prognosis is suggested if
there is no demonstrable focus of infection.
C. Laboratory Findings—The wound in a patient suspected
of having tetanus should be cultured anaerobically for C. tetani.
However, the etiologic confirmation is infrequently made in
this manner, and the diagnosis usually is based on the absence
of detectable tetanus toxoid antibody and the exclusion of
other diseases.
Differential Diagnosis
The differential diagnosis of tetanus includes a list of rather
unusual diseases not commonly encountered in the ICU
(Table 15–9).
Treatment
A. Tetanus Immune Globulin—Patients who present with
tetanus should receive tetanus immune globulin as early as
possible to neutralize unbound toxin. Delay in treatment
may result in a poorer prognosis. The optimal dose of
tetanus immune globulin has not been established, but a
single dose of 3000–6000 units intramuscularly can be given.
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It is advised that some of the dose be injected into the area of
the presumed injury.
B. Supportive Care—Metronidazole is accepted as the drug
of choice. Far more important, wounds should be debrided
properly. In patients with wounds that continue to be
infected, it may be necessary to repeat passive immunization
with tetanus immune globulin after 3–4 weeks because toxin
production may continue, and antibiotic therapy will not
eradicate the spores.
Tracheostomy should be performed in all but very mild
cases to allow for prolonged respiratory assistance with a
ventilator. Problems arising from cardiovascular instability
should be treated appropriately.
Analgesics should be used to relieve pain from muscle
contractions. Benzodiazepines—particularly diazepam—
may be effective in reducing muscle spasms. Inadequate
muscle relaxation or inadequate control of seizure activity
can lead to complications such as long bone and vertebral
fractures. Benzodiazepines may not prevent reflex spasms,
however, and effective respiration may require neuromuscu-
lar blockade.
Patients require nutritional support and meticulous
attention to the prevention of decubiti and flexion contrac-
tures. Consideration should be given to subcutaneous
heparin therapy, particularly in illicit injection drug users
and elderly patients, who appear to be at highest risk for pul-
monary embolism. Constipation is common, and an initial
cleansing enema is helpful. A rectal tube helps to control
abdominal distention. Nosocomial infections may develop
and should be considered if a patient with tetanus develops
more than a moderate elevation in temperature.
C. Immunization—Patients who develop tetanus are not
subsequently immune to the infection. Tetanospasmin is
toxic in such minute quantities that it appears to escape reac-
tion by the immune system, and protective antibody is not
produced. Therefore, active immunization with a primary
immunization series with tetanus toxoid should be adminis-
tered to all patients during the convalescent phase of illness—
usually a period of several weeks.
Current Controversies and Unresolved Issues
Many controversies remain in the management of patients
with tetanus, particularly with respect to cardiovascular
complications. Suggested therapeutic modalities occasionally
are based on single case reports.
Clonidine has been reported to control sympathetic over-
activity in severe tetanus. More recently, the beta-blocker
esmolol was reported to be effective in controlling auto-
nomic instability. Patients with severe tetanus who failed to
respond to beta blockade and low doses of ganglionic block-
ing agents had dramatic suppression of cardiovascular insta-
bility when given continuous spinal anesthesia with
bupivacaine, which provided complete blockade of sympa-
thetic and parasympathetic portions of the autonomic nerv-
ous system.
Another area of interest in the treatment of tetanus is the
control of the severe spasms without sedation and artificial
ventilation. Intrathecal baclofen and intravenous magnesium
sulfate have both been used for control of spasms owing to
tetanus. In patients treated with these modalities, it appears
that less autonomic instability is encountered, and spasms
are controlled while preserving spontaneous ventilation.
Propofol has been used similarly.
Bunch TJ et al: Respiratory failure in tetanus: Case report and
review of a 25-year experience. Chest 2002;122:1488–92.
[PMID: 12377887]
Cook TM, Protheroe RT, Handel JM: Tetanus: A review of the liter-
ature. Br J Anaesth 2001;87:477–87. [PMID: 11517134]
Thwaites CL et al: Predicting the clinical outcome of tetanus: The
tetanus severity score. Trop Med Int Health 2006;11:279–87.
[PMID: 16553907]
Meningoencephalitis (viral, bacterial)  
Phenothiazine overdose  
Peritonsillar abscess  
Hypercalcemic tetany  
Retropharyngeal abscess  
Retroperitoneal hemorrhage  
Dental abscess  
Epilepsy  
Mandibular fracture  
Opioid withdrawal  
Tonsillitis  
Strychnine poisoning  
Diphtheria 
Rabies  
Mumps 
Neuroleptic–malignant syndrome
Trichinosis  
Septicemic spondylitis 
Mandibular osteomyelitis 
Table 15–9. Differential diagnosis of tetanus.
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Surgical Infections
Timothy L. Van Natta, MD∗
General Considerations
Persistent fever in the postoperative patient is always con-
cerning. Potential causes include infection, atelectasis,
deep venous thrombosis, and drug reactions. The surgical
wound and urinary tract are common infections sites.
While management of these problems is relatively straight-
forward, diagnosis and treatment of other inflammatory
and infectious processes can be problematic. It is often dif-
ficult to differentiate between systemic inflammatory
response syndrome (SIRS) and sepsis. Documentation of a
discrete infection is required for diagnosis of the latter.
Infection types and sites not thought of are unlikely to be
identified. An organized diagnostic approach pays divi-
dends, particularly when based on analysis by body region
and through monitoring the presence and duration of
indwelling devices. Early diagnosis of infection portends
optimal outcomes, preempting sepsis and its attendant
complications—provided antimicrobial agents and adjunc-
tive measures are used rationally.
Sepsis may be the reason for ICU admission, or it may
complicate another critical illness. A surgical patient can
present anywhere along a spectrum from SIRS to sepsis to
severe sepsis (ie, sepsis associated with organ dysfunction)
to septic shock to multiple organ dysfunction syndrome
(MODS). A patient’s course often devolves along these
stages despite the physician’s best efforts. However,
prompt application of goal-directed therapy raises the
likelihood of course reversal before irrevocable organ
damage occurs.
Balk RA, Ely EW, Goyette RE: Sepsis Handbook, 2d ed. Nashville,
TN: Thomson Advanced Therapeutics Communications and
Vanderbilt School of Medicine, 2004.
Prevention of Surgical Infections in the ICU
Surgical infections can be prevented through proper use of
prophylactic antibiotics. To be effective, the appropriate antibi-
otic must be administered within 1 hour before the operation
so that tissue levels are high at incision time. Antibiotics with
24-hour dosing are attractive in this regard because no postop-
erative doses are necessary. Prophylactic antibiotics have no
value beyond the first 24 hours following surgery. Their contin-
ued use puts patients at risk for antibiotic-associated
Clostridium difficile colitis, infection by multidrug-resistant
bacteria (eg, methicillin-resistant Staphylococcus aureus,
vancomycin-resistant Enterococcus, and Acinetobacter species),
and fungal infections. No less important, this practice adversely
affects the bacterial ecology in the ICU. Continuing “prophy-
lactic” antibiotics for the duration of drain and chest tube pres-
ence cannot be condoned. Furthermore, antibiotics cannot
compensate for suboptimal surgical conduct.
Invasive procedures in the ICU require strict sterile tech-
nique. This demands that one don a cap, mask, sterile gloves
and gown; generously prepare the area with chlorhexidine;
and meticulously drape the field. Once percutaneous
catheters are in place, making connections and sampling
must be done fastidiously. Chlorhexidine-laden catheter-site
dressings are effective in preventing infections and should be
used routinely. Of course, clinical crises can demand expedi-
tious, nonsterile placement of intravenous and other
catheters. These should be removed as soon as feasible and
never beyond 24 hours from time of placement. When cen-
tral venous access is necessary but central pressure monitor-
ing is not, conversion from a central line to a percutaneously
inserted central catheter (PICC line) lessens infection risk.
When central access is no longer required, a change from
central to peripheral access should be accomplished as soon
as practical. Other devices, such as ventriculostomy drains,
chest tubes, epidural catheters, arterial lines, and urinary
catheters, should be removed as soon as their utility wanes.
The ICU team should take daily stock of all such devices and
think critically about the continued value of each.
∗James A. Murray, MD, and Howard Belzeberg, MD, were the
authors of this chapter in the second edition.
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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Other preventive measures are noteworthy. It has been
established that postoperative hyperglycemia is directly asso-
ciated with increased infection rates. The goal should be to
strive for glucose levels of 80–110 mg/dL and certainly to
prevent levels from exceeding 150 mg/dL. In the ICU, hourly
glucose monitoring and aggressive insulin use are commonly
required to achieve this goal. Insulin drips are frequently
necessary, and there should be no reluctance to use them on
a protocol-driven basis. Judicious use of steroids and other
immunosuppressive medications is an important adjunct as
well. For patients with diseases requiring these agents, the
intensivist must balance their use with the need to prevent
and/or treat infections. The same can be said for transfusion
of blood and blood products. As the immunosuppressive
nature of blood transfusion has become increasingly recog-
nized, the elevated risk of surgical infection must be weighed
against the desire to optimize oxygen delivery.
Malnutrition clearly puts patients at risk for infections, and
nutritional support is a signal feature of intensive care. For
many reasons, including lower infection rates, enteral feeding
is preferred over the intravenous route. However, the latter has
the advantage of prompt delivery of full nutritional support.
There should be no hesitation to initiate parenteral nutrition
should tube feedings be unsuccessful or impractical.
Currently, numerous immune-enhanced formulas are avail-
able. Some of the purported benefits are simply due to their
increased protein content, but additionally, there may be clin-
ically significant benefits to increased provision of certain
amino acids (eg, glutamine, arginine, and glycine), nucleic
acids, and omega-3 fatty acids. This is an area of particularly
intense research activity, and critical care physicians should
follow this work closely.
Furnary AP et al: Continuous insulin infusion reduces mortality in
patients with diabetes undergoing coronary artery bypass graft-
ing. J Thorac Cardiovasc Surg 2003;125:1007–21. [PMID:
12771873]
Hill GE et al: Allogeneic blood transfusion increases the risk of
postoperative bacterial infection: A meta-analysis. J Trauma
2003;54:908-14. [PMID: 12777903]
Diagnosis of Surgical Infection in the ICU
Despite the highly technical atmosphere of the ICU, assiduous
physical examination remains the cornerstone for timely diag-
nosis of surgical infections. The presence of complex devices
and dressings, along with the patient’s relative immobility, can
inhibit thorough physical assessment. Diagnostic delays are
commonly attributable to an intubated patient’s inability to
communicate. Fever and leukocytosis often prompt early eval-
uation by CT scan. Negative or equivocal imaging studies are
not uncommonly followed by a revealing physical evaluation
that could have obviated the trip to radiology.
Clues to presence of infection can be subtle. Examples
include unexplained hyperglycemia and gradual worsening of
hepatic, pulmonary, and/or renal functional indices.
Additionally, stagnant or falling nutritional markers such as
prealbumin may signify infection rather than inadequate pro-
vision of calories and nutrients. Immunosuppressed individ-
uals may not manifest the usual signs of infection, and index
of suspicion should be high if the clinical course is not pro-
ceeding smoothly. For these and other critically ill patients,
both overt and subtle indicators of infection warrant blood,
sputum, and urinary cultures. More sophisticated evaluations
also generally will be necessary. It can be quite difficult to dif-
ferentiate true infection from bacterial or fungal colonization.
It takes experience and discipline to react appropriately when
confronted with culture results in critically ill patients.
Fortunately, there are many tools for diagnosing infec-
tions even when their existence is not forthcoming from
physical examination or culture data. Critical care specialists
are increasingly using bedside ultrasound and echocardiog-
raphy. Pleural, pericardial, peritoneal, and soft tissue fluid
collections can be identified and sampled safely. Diagnostic
peritoneal lavage, though largely supplanted by emergency
department ultrasonography for trauma, still has an occa-
sional role in determining the presence of peritonitis in
patients too unstable for travel to the radiology suite.
Intensivists routinely perform fiberoptic endoscopy of all
sorts. This allows accurate and timely diagnosis of pneumo-
nia and infectious esophagitis and colitis. Diagnostic
laparoscopy and pleuroscopy now can be done at bedside.
Imaging studies play a crucial role in the diagnosis of
infection in the critically ill. Ultrasound, CT, and MRI are
sometimes complementary and sometimes competing. It is
often productive to discuss clinical scenarios in depth with
radiology colleagues before sending the patient for one type
of scan or another. This avoids unnecessary excursions from
the ICU and limits suboptimal studies, redundancy, expense,
and patient risk. Of the three, MRI probably is the least use-
ful in evaluation of the unstable ICU patient. In some cases,
though, particularly when CNS infection is a concern, MRI
may be superior. CT scanning and ultrasound, besides pro-
viding high-quality images, allow therapeutic abscess
drainage. To a large extent, this has replaced surgical explo-
ration for management of abdominal and pelvic infections.
Nuclear medicine studies, when selected appropriately, also
serve an important purpose. For example, indium-labeled
white blood cell scans, though of limited utility early in the
postoperative period, can pinpoint the site of infection later
in a patient’s course when other methods have failed.
Beaulieu Y: Bedside echocardiography in the assessment of the crit-
ically ill. Crit Care Med 2007;35:S235–49. [PMID: 17446784]
Nicolaou S et al: Ultrasound-guided interventional radiology in
critical care. Crit Care Med 2007;35:S186–97. [PMID: 17446778]
Treatment of Surgical Infection in the ICU
Significant progress has been made over the past decade rel-
ative to treatment. Advances are attributable to two major
areas: improvement in use of antimicrobial agents and
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advancement in interventional radiology techniques. A
handful of new antibacterial and antifungal agents have been
introduced recently. While these agents have broadened ther-
apeutic options, multidrug-resistant pathogenic strains con-
tinually threaten the ICU patient. By employing newer agents
rationally and using older agents more effectively, the clini-
cian stands a better chance against problematic organisms.
The change to once-daily dosing of aminoglycosides, for
instance, addresses several issues. Higher doses given over
broader time intervals provide greater peak blood levels. This
enhances bacterial killing, whereas low or undetectable
trough levels limit renal and other toxicity. Renal toxicity is a
largely saturable process. Despite high peak levels, only so
much aminoglycoside can be taken up by renal cells per unit
time. Later in the interval, when renal cells could absorb
more antibiotic, there is little available to produce toxic
effects. Other antibiotics work much better when some con-
tinuous minimum level is maintained. Since there appears to
be no augmentation of bacterial killing by pushing levels
higher, lower doses given more frequently (or even by con-
tinuous infusion) provide a persistent satisfactory level to
achieve optimal bactericidal effect. Penicillins and
cephalosporins exemplify this strategy. As newer agents are
introduced, these principles should be borne in mind.
Newer antibiotics have improved options for treating
surgical infections caused by multidrug-resistant strains.
Examples include linezolid to treat methicillin-resistant S.
aureus (MRSA) and tigecycline to combat difficult gram-
negative rods such as Acinetobacter baumannii. To retain
their efficacy, they must be used with discretion. While
broad agents are often necessary at the onset of infection,
there should be a rapid taper to narrower agents once cul-
ture data are available. Again, it is particularly important to
differentiate between bacterial colonization and true infec-
tion so as not to overuse new agents and diminish their
capabilities.
It is worthwhile at times to also consider alternative
routes of antibiotic administration. These include intrathe-
cal, inhalational, enteral, and intracavitary drug delivery.
Several antimicrobial classes have bioavailability via the
enteral route that rivals that of parenteral delivery.
Examples include quinolones and fluconazole. Once tube
feedings are well tolerated, a switch from parenteral to
enteral delivery can be made confidently, limiting adminis-
trative costs and allowing removal of intravenous catheters
that may, in turn, become infected. Finally, a broader array
of antifungal and antiviral agents has become available in
recent years, enhancing treatment options while in many
cases reducing renal and other toxicity. On occasion, a crit-
ically ill patient whose infection is not responding to mul-
tiple antibiotics must be started presumptively on a
systemic antifungal agent despite lack of supportive culture
data. Close collaboration with infectious disease consult-
ants is necessary in these cases.
Duration of antimicrobial coverage is continually
debated. While there is a trend toward limiting treatment
duration, some infections are particularly hard to treat given
the difficulty of antibiotic penetration into the tissues
involved. Examples include endocarditis, osteomyelitis,
sinusitis, and otitis media. When presence of one of these
infections is certain, prolonged antibiotic courses generally
are necessary and accepted. For most other surgical infec-
tions, however, shorter durations are preferable. It has been
well established that peritonitis following perforated diverti-
culitis or appendicitis (after surgical source control) should
be discontinued once fever, leukocytosis, and ileus have
resolved. If these occur even as early as postoperative day 3,
it is reasonable to stop antibiotics then. Failure to meet these
criteria by days 5, 6, or 7 usually means an abscess has
formed. Continued or additional antibiotics likely will be
ineffective, and one should proceed with an abdominopelvic
CT scan searching for a drainable abscess. In most cases,
abscesses thus identified can be treated definitively by CT- or
ultrasound-guided aspiration via percutaneous, transrectal,
or transvaginal routes. This obviates a return to the operat-
ing room and its attendant morbidity. Occasionally, multiple
abscesses are identified, not all of which are amenable to
image-guided drainage. Options then are limited to continu-
ing conservative (ie, broad antibiotic) treatment versus reop-
eration. This decision hinges on the patient’s status. If
substantial leukocytosis or left shift persists, but the patient is
eating well and lacks marked constitutional symptoms, pro-
longed antibiotic therapy may be successful. This is unusual,
though, and most patients with multiple postoperative
abscesses must be taken back to the operating room.
These concepts involving intraabdominal infection are
not new. Limiting duration of treatment and earlier pursuit
of imaging studies have been applied recently to other infec-
tions, however, such as pneumonia. The common goal is to
get the most out of available agents by preserving their effi-
cacy, limiting toxicity and microbial resistance during ther-
apy, and slowing emergence of resistant strains that might
affect future patients. Every institution and its individual
ICUs have their own unique bacterial ecology. This limits
somewhat the broad applicability of treatment guidelines.
Review of institutional antibiograms on a quarterly basis can
positively influence empirical coverage of apparent pneumo-
nias and bloodstream infections while spotlighting emerging
resistance patterns. Antibiotic “crop rotation” has been
employed as a means to stem development of resistant
strains within ICUs, although this concept remains contro-
versial. What is probably more important is for the inten-
sivist to employ all means at his or her disposal to rapidly
identify the site of infection and its causative organism(s),
allowing the most rapid application of the narrowest effec-
tive agent(s). An organized approach to patient assessment
by body region is helpful.
Bennett KM et al: Implementation of antibiotic rotation protocol
improves antibiotic susceptibility profile in a surgical intensive
care unit. J Trauma 2007;63:307–11. [PMID: 17693828]
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 Evaluation and Management of Infection
by Body Site
Head and Neck
CNS infections, including meningitis, ventriculitis, and
intracerebral abscess, must be considered in patients who
have sustained head injury or have undergone neurosurgical
procedures. Patients with skull base and paranasal fractures
are included in this group. Use of intraparenchymal cerebral
pressure (ICP) monitors and ventriculostomy catheters, while
applied appropriately along guidelines for severe head injury
management, is associated with serious infection risk.
Previously, antibiotic prophylaxis was used for the duration of
ICP monitor presence and for 5–7 days following diagnosis of
skull base or paranasal sinus fractures. It is now recognized
that this exerts pressure toward infection by multidrug-
resistant organisms. Controlled data are lacking as to appro-
priate antibiotic use in these patients, but it is clear that the
indiscriminant use of antibiotics in these settings is associated
with difficult-to-treat secondary infections. With regard to
transcranial pressure monitors, it is hoped that with sterile
technique at placement, fastidious fluid sampling, prudent
antibiotic use, and device removal as early as feasible, occur-
rence of serious infections will diminish.
Another important consideration is infection in and
around the eye. As mentioned earlier, ocular inflammation
often goes unnoticed in the complex ICU patient. Problems
not considered go undiagnosed, and any abnormal ocular
finding should prompt early ophthalmologic consultation as
appropriate. Periorbital cellulitis is of particular concern
because therapeutic delay can result in the catastrophic com-
plication of cavernous sinus thrombosis.
Given the ubiquitous use of nasogastric tubes, paranasal
sinusitis remains a risk. There may or may not be associated
purulent nasal drainage. It is important to remember this not
infrequent but often undiagnosed infection in the febrile
critically ill patient. CT scan is far superior to plain films for
making this diagnosis. Surgical drainage sometimes must
augment antibiotics to clear this infection. It is best to avoid
this condition altogether by choosing the oral over the nasal
route for enteral decompression and feeding in orotracheally
intubated patients. Dental abscess, simple or complicated,
should be considered in the febrile, critically ill patient, par-
ticularly when dentition is poor. These and pharyngeal infec-
tions can evolve into life-threatening necrotizing infections
that can descend transcervically into the chest (ie, acute
necrotizing mediastinitis). The cervical component of this
process is not difficult to recognize given neck edema,
induration, and erythema, but the thoracic component can
have protean manifestations. New and unexplained pleural
fluid noted on chest x-ray is an important early finding.
Central line infections contribute significantly to mor-
bidity and mortality in surgical patients. In the United States,
about 200,000 nosocomial bloodstream infections occur annu-
ally, the majority of which are associated with the presence of
intravascular catheters. Internal jugular and femoral venous
catheters previously carried higher infection rates than those
in the subclavian position, but recent preventive strategies
have perhaps neutralized this difference. Such measures
include perfect sterile technique at placement, chlorhexidine
site preparation, selection of catheters with antibacterial
coatings, use of antiseptic site dressings, and device removal
as early as possible. Application of catheter-site antibiotic
ointments should be avoided because they encourage devel-
opment of infection by resistant bacteria and fungi. Rotation
of catheter sites on a scheduled basis is not helpful, and
catheter changes over a guidewire should be kept to a mini-
mum. In certain situations, vascular access may be exceedingly
difficult. Despite development of fever or leukocytosis, risk-
benefit analysis may favor guidewire exchange over attempting
placement at a new site. However, the removed catheter tip
should be sent for culture. A positive culture mandates
immediate removal of the catheter that replaced the original
one. Infection also can be introduced via the catheter hub,
and those accessing the catheter must maintain strict sterile
technique.
Treatment of head and neck infections is summarized in
Table 16–1.
Gilbert DN et al (eds): The Sanford Guide to Antimicrobial Therapy,
37th ed. Sperryville, VA: Antimicrobial Therapy, Inc., 2007.
Kuminsky RE: Complications of central venous catheterization.
J Am Coll Surg 2007;204:681–96. [PMID: 17382229]
Taylor RW, Palagiri AV: Central venous catheterization. Crit Care
Med 2007;35:1390–6. [PMID: 17414086]
Chest
Ventilator-associated pneumonia (VAP) is the most com-
mon infection in the surgical ICU. VAP is defined as pneu-
monia occurring at least 48–72 hours following
endotracheal intubation. There is debate as to whether or
not VAP independently increases mortality, but it clearly
lengthens ICU stay, increases patient days on the ventilator,
and adds tremendously to health care expenditures.
Antibiotic therapy for VAP is often complex and prolonged,
adversely affecting an ICU’s bacterial ecology. Over recent
years, much effort has been expended to better characterize
the pathophysiology, diagnosis, and proper treatment of
VAP. There is no diagnostic “gold standard,” and treatment
is complicated by undisciplined antibiotic administration
with vague treatment endpoints. The Centers for Disease
Control and Prevention original criteria for pneumonia (ie,
fever, leukocytosis, positive sputum Gram stain, and new or
changing pulmonary infiltrate) have proven insufficient for
diagnosis of VAP in the complicated, critically ill patient. In
patients with a markedly abnormal chest x-ray because of
acute respiratory distress syndrome (ARDS), it is often
impossible to identify a new infiltrate superimposed on the
background of noncardiogenic pulmonary edema.
Although VAP diagnosis and treatment remain problematic,
SURGICAL INFECTIONS 401
its causes have become better understood. Presence of an
endotracheal tube (ETT) allows contaminated oropharyn-
geal secretions to circumvent natural protective barriers.
The endotracheal tube, impaired host immunity, and lurk-
ing environmental pathogens conspire to produce VAP in
the critically ill surgical patient. Negative effects of blood
transfusion, hyperglycemia, and malnutrition, so commonly
seen in the ICU, elevate risks further.
There has been a strong push lately to improve the preven-
tion and management of VAP. Influential multidisciplinary
societies (eg, the American Thoracic Society and the Infectious
Disease Society of America) have promulgated clinical guide-
lines. These ICU “bundles” promote consistency in approach
within and across institutions. Prevention strategies include
head-of-bed elevation 30–45 degrees (or reverse Trendelenburg
position when thoracic spine stability is in question) and
avoidance of gastric distention to minimize aspiration of gas-
tric contents, use of ETTs with suction ports to remove secre-
tions pooling above the ETT cuff, use of sleeved suction
catheters, and improved oral hygiene. Selective gut decontami-
nation has been advocated, but its value is questionable because
enteric organisms generally are not responsible for VAP. The
most common offending organisms are MRSA and species of
the genera Pseudomonas, Acinetobacter, and Stenotrophomonas.
Minimizing transfer of these pathogens from one patient to
another is another key to prevention. Finally, since the inci-
dence of VAP correlates with a patient’s duration of intubation,
any prevention program should include an aggressive strategy
for liberation from the ventilator.
Diagnosis of pneumonia is usually not difficult in the
emergency department. History, physical findings, and
chest x-ray generally suffice. For the intubated ICU patient,
development of fever, leukocytosis, and apparent purulent
sputum raise the question of pneumonia, but establishing a
confident diagnosis may be difficult. Both chest x-ray and
tracheal sputum aspirate analysis lack specificity in these
patients. A normal chest x-ray excludes the diagnosis. When
the chest x-ray is abnormal, the next step is to obtain a reli-
able sputum sample for performance of quantitative analy-
sis. Preferred methods are use of a protected-specimen
brush (PSB) and bronchoalveolar lavage (BAL).
Commonly used thresholds for confirming pneumonia are
103 colony-forming units (cfu)/mL for PSB and 104 cfu/mL
for BAL. These techniques, which require bronchoscopy,
are expensive and time-consuming. However, they more
firmly establish the correct diagnosis and direct appropri-
ate antibiotic therapy. More recently, catheters have been
developed that allow reliable sampling by the respiratory
therapist, eliminating need for bronchoscopy. Both PSBs
and mini-BAL sets are available and are enjoying wider use.
The goals are to distinguish between infection and colo-
nization and, if infection is present, to determine the
offending organism(s) as soon as possible so that treatment
can be tailored specifically.
Diagnosis Organisms Initial Antibiotics Adjunctive Therapy
Meningitis and ventriculitis S. pneumoniae, S. aureus,
coliforms, P. aeruginosa,
Acinetobacter sp.
Vancomycin 500–750 mg IV q6h +
cefepime or ceftazidime 2 g IV q8h or
meropenem 2 g IV q8h + vancomycin
1 g IV q6–12h
Removal of intracerebral
device, intrathecal antibiotic
administration
Periorbital cellulitis S. pneumoniae, Haemophilus
influenzae, Moraxella catarrhalis,
S. aureus, group A
Streptococcus sp. 
Nafcillin-oxacillin 2 g IV q4h (if MRSA,
vancomycin 1 g IV q12h) + ceftriaxone
2 g IV q24h + metronidazole 1 g IV q12h
IV heparin for cavernous sinus
thrombosis if present
Paranasal sinusitis Gram-negative bacilli,
S. aureus
Imipenem 500 mg IV q6h or meropenem
1 g IV q8h or ceftazidime 2 g IV q8h or
cefepime 2 g IV q12h (for possible
MRSA, add vancomycin 1 g IV q12h)
Removal of nasoenteric tube,
aspiration of fluid from sinus
Central line infection S. aureus (MSSA, MRSA),
S. epidermidis, enterococci
Vancomycin 1 g IV or linezolid 600 mg
IV q12h
Removal of catheter, vein
resection if suppurative
thrombophlebitis
Data from Gilbert DN et al (eds): The Sanford Guide to Antimicrobial Therapy, 37th ed. Sperryville, VA: Antimicrobial Therapy, Inc., 2007.
Table 16–1. Summary of head and neck infections in adult surgical patients.
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Aggressive treatment should immediately follow acquisi-
tion of a good sputum sample. Antibiotic selection depends
on the prevailing organisms within an individual ICU.
Offending bacteria change over time, justifying quarterly
analysis of cultures and resistance patterns. In general, initial
therapy should cover MRSA and the difficult gram-negative
rods. It is important to start broadly because delays in appro-
priate coverage may lead to increased mortality. Once reliable
microbiologic data are available, antibiotic coverage should
be tailored immediately to the narrowest bactericidal agent
to which the organism is sensitive. Previously, it was recom-
mended that two antibiotics with different mechanisms of
action should be used to treat the multidrug-resistant gram-
negative rods. This was extrapolated from the neutropenic
cancer patient population and applied to other groups.
Supportive data are lacking for the surgical ICU population,
and single-agent therapy appears to be satisfactory. When
final microbiologic data do not support the diagnosis of VAP,
and the patient is not deteriorating, it is reasonable to stop
antibiotics altogether. If culture results are equivocal and/or
the patient’s condition is worsening, it is appropriate to con-
tinue broad antibiotic coverage, but a firm endpoint of about
7 days should be selected early. In the majority of cases, cul-
ture and sensitivity results will guide selection of the narrow-
est appropriate antibiotic, and duration of therapy can be
determined by the patient’s response.
Antibiotics with high enteral bioavailability often can be
converted safely from intravenous to enteral administration
early in the treatment process. Inhaled administration of
antimicrobials should be considered in some instances.
Pneumonia can be difficult to treat, even with the correctly
chosen and delivered agent, and courses of 10–14 days are
often necessary. Patients with blood and respiratory cultures
growing the same organism have a more serious infection
and generally will need a longer antibiotic course. However,
improvement should be seen within 1 week, and if this has
not occurred, a prolonged antibiotic course is not likely to be
effective. Failure of a timely response should prompt a search
for complications of pneumonia such as pulmonary abscess
or empyema or consideration of an alternative infection
diagnosis. CT scanning is important in this assessment.
Another important surgical infection is empyema, or pus
in the pleural space. Indicative findings on pleural fluid
analysis are pH less than 7.20, organisms present on Gram
stain, and a positive culture. Ultrasound is helpful to guide
safe aspiration of pleural fluid. Surgical patients at risk are
those who have had VAP, blunt or penetrating trauma, tho-
racostomy tube placement, or thoracotomy. CT scan defines
the empyema’s extent. Treatment options include thoracos-
tomy tube placement, instillation of tissue plasminogen acti-
vator (tPA), video-assisted thoracoscopic surgery (VATS) or
open thoracotomy with lung decortication, and open
drainage. Choice of treatment is influenced by the duration
of the process, the pleural fluid distribution, and the patient’s
condition. The three stages of empyema are the early exuda-
tive stage, the intermediate fibrinopurulent stage, and the late
organization stage. A simple empyema in its early stage often
can be well managed with a chest tube and antibiotics.
Beyond antibiotics, the goals are to drain all the infected fluid
and eliminate all free intrapleural space. Generally, the
admonition of “no space, no problem” applies. The chest
tube does not always have to be of large caliber. A single loc-
ulated collection not draining adequately via a well-placed
thoracostomy tube may respond to dissolution by a throm-
bolytic agent. This can be effective, but it is best done in col-
laboration with the surgeon who would operate if
thrombolytics fail because subsequent operative intervention
can be rendered much more difficult.
Multiple loculated fluid collections and more advanced
empyema stages are best dealt with surgically (VATS or tho-
racotomy). For the critically ill or severely debilitated patient,
rib resection and drainage may be the best approach, allow-
ing the space to heal from the inside out as the thoracostomy
tube is slowly withdrawn over weeks to months. A special
empyema subset is that occurring early after pneumonec-
tomy. The majority of these are due to a breakdown of the
bronchial stump. The problem is manifested by a productive
cough, dyspnea, and sepsis. The first maneuver is to place a
thoracostomy tube to drain the infected fluid that will
diminish the septic focus and prevent spread of infection to
the remaining lung. Open thoracostomy with bronchial
repair and muscle or omental flap coverage are required then
to correct the process. Eventually, the chest can be closed over
a pleural space filled with antibiotic solution, with expecta-
tion of success in most cases.
Two other major chest infectious processes are mediastini-
tis and endocarditis. Mediastinitis can occur as a postopera-
tive infection following median sternotomy, as a result of
spontaneous or iatrogenic esophageal perforation, or as a
descending necrotizing process originating from oropharyn-
geal or odontogenic infection. Sternal wound infection after
cardiac surgery can be superficial, responding to antibiotics
and local wound care. Associated life-threatening mediastini-
tis occurs in just over 1% of cardiac surgery patients, with the
incidence in children approximating that in adults. One adult
group at higher risk is diabetic women undergoing bilateral
internal thoracic artery harvest. Fever, leukocytosis, sternal
instability, and wound erythema and drainage warn of this
problem, and a new pleural effusion adds to the probability.
Treatment includes administration of intravenous antibiotics,
surgically evacuating all purulent fluid and necrotic soft tissue
and bone, and either reclosing the sternum over an inflow-
outflow antibiotic delivery system or filling the defect with
pedicled muscle or omental flaps. Esophageal perforation
occurs most commonly now as a complication of endoscopy.
Small tears occasionally can be managed with antibiotics with
or without stent placement, provided that there is no free flow
of diagnostic contrast agent into the mediastinum or pleural
space. Most esophageal perforations require thoracoscopic or
open pleural drainage, mediastinal debridement, and
esophageal repair over a bougie when feasible. Generally, tears
in the upper two-thirds of the esophagus are approached via
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right posterolateral thoracotomy and those in the distal third
by way of left posterolateral thoracotomy.
Acute necrotizing mediastinitis (ANM) is third major
form of mediastinitis. It is a destructive, life-threatening
process usually originating in the oropharyngeal region and
extending transcervically into the mediastinum along con-
tinuous fascial planes. While the cervical component is easy
to recognize, mediastinal involvement is less obvious, caus-
ing significant diagnostic delays. Management includes
prompt institution of broad-spectrum intravenous antimi-
crobials to cover oropharyngeal aerobes and anaerobes,
immediate contrast-enhanced cervicothoracic CT scanning,
and urgent surgical therapy directed at the oropharyngeal,
cervical, and thoracic components. Tracheostomy should be
applied selectively. Occasionally, mediastinal involvement
confined to the upper anterior mediastinal aspect may be
amenable to drainage via the transcervical approach, but the
potential for rapid, diffuse spread deeper into the medi-
astinum must be anticipated and dealt with accordingly.
Minimally invasive approaches have been reported, but gen-
erally they are inadequate to treat this process. A team of sur-
geons including otolaryngologists and thoracic surgeons
(and maxillofacial surgeons in the presence of odontogenic
infection) serves the patient best. At the outset, surgeons
should acknowledge the likely need for multiple operations.
Endocarditis can be seen in surgical patients. This diag-
nosis is particularly likely in the febrile patient with a posi-
tive blood culture and new murmur. Other classic signs of
endocarditis (eg, splinter hemorrhages, Osler’s nodes, and
Janeway’s lesions) are often absent in acute endocarditis.
Risk factors include intravenous drug abuse (IVDA), poor
dental hygiene, long-term hemodialysis, diabetes mellitus,
mitral valve prolapse, and rheumatic heart disease. In the
ICU, endocarditis can occur in patients admitted for other
reasons but who require multiple intravascular catheters.
Enterococci, though overwhelmingly associated with bac-
teremia rather than endocarditis, can be a cause of endo-
carditis in this patient group, and the organisms are
commonly resistant to many antibiotics. Previously, viridans
streptococci led the list of causative bacteria. In most recent
series, S. aureus predominates. Polymicrobial endocarditis is
unusual and generally associated with IVDA. Blood cultures
positive for Streptococcus bovis suggest a colon lesion in
older patients, warranting colonoscopy. Endocarditis
involves native valves 75–93% of the time, with prosthetic
valve infection comprising the remainder. As for the latter,
infections occurring within 2 months of surgery are thought
to be hospital-acquired. If onset exceeds 12 months from
time of surgery, the endocarditis is considered community-
acquired. Between 2 and 12 months, valve infection can be
either origin.
Echocardiography is the primary diagnostic modality
for endocarditis. Transthoracic echocardiography (TTE)
has sensitivity as low as 70% but a specificity approaching
98% for identification of the characteristic vegetations.
When suspicion remains high despite a negative TTE, or
additional detail is required for operative planning, trans-
esophageal echocardiography (TEE) is indicated. TEE sen-
sitivity for endocarditis is around 95%, with a negative
predictive value around 92%. Despite its more invasive
nature, TEE offers a much better view of the cardiac inte-
rior. TEE is particularly valuable for assessment of pros-
thetic valves and evaluation for myocardial abscess. The
latter is associated with conduction system disturbances.
Surgery is indicated urgently to address acute valvular
incompetence, myocardial abscess, or continued septic
embolization despite apparently adequate antibiotic cover-
age. Sometimes multiple cultures are negative in the febrile
patient with a positive echocardiogram. If the laboratory is
alerted to this situation, special culture techniques can be
employed to capture fastidious organisms. For patients
undergoing surgery, the polymerase chain reaction (PCR)
can be run to identify otherwise unculturable organisms
obtained from valve tissue or peripheral emboli.
Treatment of thoracic infections is summarized in
Table 16-2.
American Thoracic Society: Executive summary: Guidelines for
the management of adults with hospital-acquired, ventilator-
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Freeman RK et al: Descending necrotizing mediastinitis: An analy-
sis of the effects of serial surgical debridement on patient mor-
tality. J Thorac Cardiovasc Surg 2000;119:260–7. [PMID:
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Abdomen and Pelvis
This broad class includes infections of the GI mucosa or full
bowel thickness, visceral infarction, abscesses, and diffuse
peritonitis. Infections also occur secondary to mechanical
blockage of the biliary tract (eg, ascending cholangitis and
cholecystitis), urinary tract (eg, pyelonephritis and cystitis),
and female internal genitalia (eg, tubo-ovarian abscess and
pelvic inflammatory disease). Peritonitis occurs in primary,
secondary, and tertiary forms. Primary (spontaneous) bacte-
rial peritonitis truly can be spontaneous (eg, Pneumococcal
peritonitis seen in young girls) or more commonly a compli-
cation in cirrhotic patients with ascites or in those receiving
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peritoneal dialysis. Tuberculous and other granulomatous
forms of peritonitis also are included in this group. In these
instances, there is no leak of organisms from the GI tract.
Secondary peritonitis occurs when there is perforation of a
hollow viscus, such as in duodenal ulcer, anastomotic leak,
appendicitis, or diverticulitis. The further along the GI tract
a perforation occurs, the higher is the bacterial density.
Whereas gastroduodenal perforations are best described as
causing chemical peritonitis complicated by the presence of
bacteria, colonic perforation delivers an enormous load of
bacteria into a peritoneal space that secondarily becomes an
altered, low-pH environment. Sometimes perforations are
contained by surrounding structures such as omentum or
adjacent bowel loops. This produces focal rather than diffuse
peritonitis that is often amenable to antibiotic therapy with
or without percutaneous drainage. Surgical therapy can be
postponed or even avoided altogether. Patients often can be
spared the two-stage emergency procedure with its associ-
ated temporary colostomy. Examples include perforated
appendicitis and diverticulitis with abscess. Diffuse second-
ary peritonitis, on the other hand, requires urgent operative
intervention.
Two phases of secondary peritoneal infections have been
described. Initially, hundreds of bacterial species exit into the
peritoneum on colonic perforation, but within short order
these numbers are reduced to two or three pathogenic
species (simplification). These organisms are predictable
because only a few species can survive in the unusual envi-
ronment of peritonitis: obligate anaerobes such as
Bacteroides fragilis and endotoxin-producing members of the
family Enterobacteriaceae that includes facultative anaerobes
such as Escherichia coli. These bacteria work together (syner-
gism) to produce both abscess formation and systemic sepsis.
Included in this synergistic relationship are Enterococcus
species, at least with regard to abscess formation and wound
infection. However, Enterococcus is of questionable impor-
tance when the other two groups are surgically reduced and
then eliminated by appropriate antibiotics and host defenses.
Diagnosis Organisms Initial Antibiotics Adjunctive Therapy
Ventilator-associated pneumonia (VAP) S. pneumoniae, S. aureus,
P. aeruginosa, Acinetobacter sp.,
Stenotrophomonas maltophilia,
coliforms, anaerobes
Imipenem 500 mg IV q6h or meropenem
1 g IV q8h (+ vancomycin 1 g IV q12h if
ICU MRSA pneumonia rate high) or
cefepime 2 g IV q8h or high-dose
piperacillin-tazobactam + vancomycin
Prevention, quantitative
sputum cultures, ICU
antibiogram
Empyema S. pneumoniae, S. aureus
(consider MRSA), S. pyogenes,
S. milleri, H. influenzae,
Bacteroides sp.,
Enterobacteriaceae
Cefotaxime 1–2 g IV q4–12h or ceftriax-
one 1–2 g IV q24h (+ clindamycin
450–900 mg IV q8h for possible anaer-
obes) or nafcillin-oxacillin 2 g IV q4h
(MSSA) or vancomycin 1 g IV q12h
(MRSA)
Thoracostomy tube,
intrapleural thrombolytics,
VATS, thoracotomy
Mediastinitis after sternotomy S. aureus, possible MRSA Vancomycin 1 g IV q12h Surgical debridement, medi-
astinal inflow-outflow
catheters
Other mediastinitis MRSA/MSSA, coliforms,
Bacteroides sp., and other
anaerobes
Piperacillin-tazobactam 3.375 g IV q6h
(or ceftazidime 2 g IV q8h + metronidazole
15 mg/kg IV q12h or a carbapenem IV)
+ vancomycin 1 g IV q12h
Surgical debridement
Endocarditis S. aureus, S. epidermidis
(prosthetic valve), viridans strep,
S. bovis, enterococci
Vancomycin 1 g IV q12h + gentamicin
1–1.5 mg/kg IV q8h × 14 days or (for
penicillin-sensitive organisms) penicillin
G 18–30 million units in divided doses IV
q4h + gentamicin
Valve repair or replacement,
myocardial debridement
Data from Gilbert DN et al (eds): The Sanford Guide to Antimicrobial Therapy, 37th ed. Sperryville, VA: Antimicrobial Therapy, Inc., 2007.
Table 16–2. Summary of thoracic infections in adult surgical patients.
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Wound infection is largely eliminated by the practice of leav-
ing the cutaneous portion of the surgical wound open to
allow healing by secondary intention. Addition of ampicillin
or other antienterococcal antibiotics (part of the old main-
stay of “triple antibiotic coverage”) is now considered
anachronistic. Since the mid-1990s, appropriate antibiotic
treatment of secondary peritonitis has included metronida-
zole to cover most strains of B. fragilis and a non-
antipseudomonal third-generation cephalosporin to cover
the important Enterobacteriaceae organisms. This remains a
reasonable combination today, although some single-agent
strategies have shown equivalent efficacy. Intraoperative
peritoneal cultures are of little value because the important
pathogens are predictable from the pathophysiology.
Overall, the management goals for secondary peritonitis
as outlined by Wittmann, Schein, and Condon in the mid-
1990s remain true today. Supportive treatment includes pro-
vision of appropriate antibiotics, treatment of hypovolemia
and shock, optimizing tissue oxygenation, nutritional sup-
port, and support of failing organ systems. Surgical measures
include early source control, mechanical cleansing of the peri-
toneal cavity, recognition and avoidance of abdominal com-
partment syndrome, and identification and drainage of
persistent or recurrent infection. As discussed earlier, antibi-
otic treatment is necessary only until there is absence of fever,
normalization of leukocytosis, and resolution of ileus.
Presence of any of these beyond 5–7 days prompts a search for
undrained infection, not addition of extra antibiotics. Culture
of fluid collected with image-guided drainage may be of value
to direct adjunctive antibiotic therapy at this stage.
Tertiary peritonitis is an entity occurring late in the
course of treatment for secondary peritonitis. In patients
with persistent multiple-organ dysfunction after seemingly
appropriate treatment of intestinal perforation, diligent
searches for undrained infection are usually undertaken.
Abdominal or pelvic collections revealed by CT scan are
tapped, only to demonstrate organisms of low pathogenicity.
Unfortunately, the finding of organisms like S. epidermidis,
Candida albicans, and even A. baumannii only confirms the
existence of tertiary peritonitis rather than suggesting defin-
itive antimicrobial treatment. This really only identifies one
more organ that is failing, the peritoneum. Drainage of such
collections and intensifying antibiotic coverage probably
provide little benefit. Optimization of nutritional support
and oxygen delivery are at least as effective as seemingly more
direct measures.
There are a number of other life-threatening intraabdom-
inal infections besides peritonitis. Examples include ascend-
ing cholangitis, gangrenous cholecystitis, and necrotizing
pancreatitis. Acute biliary obstruction in and of itself does not
require urgent intervention. However, when coupled with
fever, leukocytosis, and hemodynamic changes, biliary tract
decompression in needed emergently. Causative bacteria are
predictably enteric organisms, primarily anaerobes and gram-
negative rods, and antibiotic selection is straightforward in
most cases. High blood levels of appropriate antimicrobials
are more helpful than high biliary concentrations. More
important than antibiotic therapy is prompt biliary drainage
via endoscopic retrograde cholangiopancreatography (ERCP).
When ERCP is either unavailable or unsuccessful, percuta-
neous or surgical drainage is required. Gangrenous cholecys-
titis, identified by the presence of air in the gallbladder wall
noted on imaging studies, requires urgent cholecystectomy.
Other forms of cholecystitis, including the acalculous form
complicating critical illness, can be treated by percutaneous
transhepatic cholecystostomy tube placement. The transhep-
atic route prevents spillage of any purulent fluid into the peri-
toneal cavity. Interval cholecystectomy can be performed
when the patient’s condition has improved.
Pancreatic infections can be particularly difficult to sort
out. Severe pancreatitis without sepsis can produce fulminate
SIRS and ARDS that can be confused with sepsis. Presence of
air bubbles within an edematous or necrotic pancreas indi-
cates infection requiring an aggressive surgical approach. In
the absence of this finding, the deteriorating patient with
necrotizing pancreatitis should undergo CT-guided fine-
needle aspiration for Gram stain and culture of the most
prominently involved area. Although this risks introducing
infection to sterile pancreatic necrosis, high mortality can be
expected if true infection is missed and surgery is withheld.
Recently, a number of minimally invasive approaches have
been reported for the surgical management of this problem.
As for other necrotizing infections, however, the need for
multiple surgical interventions should be anticipated. When
infection is not present, the value of pancreatic necrosectomy
in the critically ill is controversial. The value of prophylactic
systemic antibiotics (eg, carbapenems), widely employed
previously, has been debated recently. Other pancreatic infec-
tions, such as infected pseudocyst, often are amenable to per-
cutaneous drainage. Creative combinations of endoscopic
and transcutaneous drainage can eliminate the need for
complex open surgery in many cases.
Other important surgical infections of the abdomen and
pelvis include a variety of abscesses (eg, subdiaphragmatic,
hepatic, splenic, and perinephric), and complications of
blunt and penetrating trauma, gastroenteritis, bowel
ischemia, inflammatory bowel disease (ie, Crohn’s and ulcer-
ative colitis), vasculitis, antibiotic-associated colitis, and sex-
ually transmitted diseases in women. Appropriate treatment
includes attention to the primary causes.
Whether owing to hemorrhage, SIRS, or septic shock, vis-
ceral and peritoneal edema can produce a dangerous rise in
intraabdominal pressure. Physical findings include abdomi-
nal distention, respiratory distress, and measured urinary blad-
der pressures exceeding 30 mm Hg. Patients on mechanical
ventilation manifest progressive elevation of peak inspiratory
pressures and an increasing PCO2. Urine output falls, probably
owing to compression of renal veins. Decompressive laparo-
tomy is indicated to prevent a downhill spiral toward irre-
versible organ dysfunction and death.
Treatment of abdominal and pelvic infections is summa-
rized in Table 16-3.
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dominal infection. Crit Care Med 2003;31:2228–37.
Wittmann DH, Schein M, Condon RE: Management of secondary
peritonitis. Ann Surg 1996;224:10–8. [PMID: 8678610]
Soft Tissues of the Extremities and Torso
Serious soft tissue infection is another common reason for
surgical ICU admission. Cellulitis and soft tissue abscesses
can occur in patients admitted to the ICU for other conditions.
ICU clinicians commonly care for patients with compli-
cated diabetic foot infections either because of the com-
plexity of the infection or for acute management of
advanced cardiovascular disease so frequently seen in these
patients. Necrotizing fasciitis affecting the extremities and
Fournier’s gangrene are two life-threatening infectious
processes often faced by intensivists. Less commonly seen
but equally lethal is suppurative thrombophlebitis. Most of
these infections are caused by multiple organisms working
synergistically to produce tissue destruction, bacteremia,
Diagnosis Organisms Initial Antibiotics Adjunctive Therapy
Primary peritonitis Enterobacteriaceae,
S. pneumoniae, enterococci,
anaerobes, S. aureus,∗ S. epider-
midis,∗ P. aeruginosa∗
Cefotaxime 2 g IV q4–8h or ticarcillin-
clavulanate 3.1 g IV q6h or piperacillin-
tazobactam 3.375 g IV q6h or
ampicillin-sulbactam 3 g IV q6h or
ceftriaxone 2 g IV q24h or ertapenem
1 g IV q24h
Removal of PD catheter as
indicated
Secondary peritonitis Enterobacteriaceae, Bacteroides
sp., enterococci, P. aeruginosa
Ceftriaxone 1–2 g IV q24h + metronida-
zole 1 g IV q12h or imipenem 500 mg IV
q6h or meropenem 1 g IV q8h
Surgical source control, peri-
toneal washout, prevention
and treatment of abdominal
compartment syndrome
Tertiary peritonitis S. epidermidis, Candida sp.,
vancomycin-resistant enterococci
(VRE), Acinetobacter sp.
Antimicrobial agents of questionable
benefit
Supportive care, optimization
of O2 delivery, nutritional
therapy, percutaneous or sur-
gical drainage
Biliary tract infection, including
ascending cholangitis (AC)
Enterobacteriaceae, enterococci,
Bacteroides sp., Clostridium sp.
Ceftriaxone 1–2 g IV q24h + metronida-
zole 1 g IV q12h or piperacillin-
tazobactam 3.375–4.5 g IV q6–8h or
ampicillin-sulbactam 3 g IV q6h or
ticarcillin-clavulanate 3.1 g IV q6h or
carbapenems IV
ERCP with sphincterotomy ±
stent placement, percuta-
neous transhepatic biliary
drainage, or surgical common
bile duct decompression
for AC
Pancreatic infections Enterobacteriaceae, enterococci,
S. aureus, S. epidermidis,
anaerobes, Candida sp.
Same as for biliary tract infection,
guided by fine-needle aspiration results
Prophylactic antimicrobials
controversial for sterile pan-
creatic necrosis, surgical
drainage/debridement, ERCP
with stent PD stent place-
ment, nutritional support
Pelvic inflammatory disease Neisseria gonorrhoeae, Chlamydia
trachomatis, Bacteroides sp.,
Enterobacteriaceae,
Streptococcus sp.
(Cefotetan 2 g IV q12h or cefoxitin 2 g
IV q6h + doxycycline 100 mg IV/PO
q12h) or (clindamycin 900 mg IV q6h +
gentamicin 4.5 mg/kg IV q24h, then
doxycycline 100 mg PO bid × 14 days)
Several alternative antibiotic
regimens available
∗Peritoneal dialysis (PD).
Data from Gilbert DN et al (eds): The Sanford Guide to Antimicrobial Therapy, 37th ed. Sperryville, VA: Antimicrobial Therapy, Inc., 2007.
Table 16–3. Summary of abdominal and pelvic infections in adult surgical patients.
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and sepsis. Suppurative thrombophlebitis and type 2
necrotizing fasciitis are generally monomicrobial. For the
most part, antibiotic treatment is important but secondary
to aggressive surgical debridement.
Cellulitis is an infection of soft tissues that retain their
blood supply and viability. There is edema and erythema, but
appropriate antibiotic therapy will resolve the infection in
most cases. Abscesses and fasciitis are associated with loss of
blood supply, tissue necrosis, and collections of bacteria,
leukocytes, and cellular debris. Surrounding tissues contain
an abscess, whereas fasciitis involves and spreads along facial
planes. Necrotizing fasciitis is a virulent process frequently
associated with septic shock and carries a high mortality.
Diabetic foot infections can present anywhere along this
range from cellulitis to fasciitis, with associated dry or wet
gangrene. Limited infection often responds to antibiotics,
but surgical debridement or amputation is required in the
face of abscesses, wet gangrene, osteomyelitis, or fasciitis.
These infections are associated with the neuropathy and vas-
culopathy of diabetes. In these patients, a distinction should
be made between macrovascular and microvascular disease.
Peripheral pulse assessment and documentation of ankle-
arm indices are essential to the evaluation of these patients,
although the latter can be inaccurate if the arteries are calci-
fied and noncompressible. At any rate, stenoses and occlu-
sions of named arteries may be amenable to percutaneous
and/or surgical amelioration, allowing salvage of tissue and
resolution of infection. Presence of wet gangrene, radi-
ographic evidence of soft tissue emphysema or osteomyelitis,
and signs of sepsis influence urgency of surgical manage-
ment of these infections. Surgeons must strike a balance
between being too radical with tissue resection and avoiding
serial operations that only postpone amputation.
Ultrasound and CT scanning define the character and
extent of soft tissue abscesses. Most abscesses will not resolve
with antimicrobial therapy alone; a combined approach with
image-guided or surgical drainage is usually required. It can
be difficult to distinguish between cellulitis and abscess on
the one hand and life-threatening necrotizing fasciitis on the
other. Classic “hard signs” of fasciitis include skin necrosis
and bulla formation, palpable crepitance and soft tissue gas
on radiography, and hypotension. However, some or all of
these may be absent. Pain out of proportion to clinical find-
ings is also an important clue to the diagnosis. CT scanning,
with its greater sensitivity than plain films, is currently used
widely to help with the diagnosis of these difficult cases.
When available, frozen-section analysis of a musculofascial
biopsy obtained at bedside under local anesthesia can estab-
lish the diagnosis in difficult cases.
There are two major categories of necrotizing fasciitis.
Type 1 is polymicrobial with involvement of at least one
anaerobic species such as C. perfringens. Facultative anaer-
obes from the Enterobacteriaceae family and nontypable
streptococci generally are involved as well. A subclass of type 1
necrotizing fasciitis is Fournier’s gangrene. This fulminate
infection involves the skin and soft tissues of the scrotum,
perineum, and penis. It spreads along the fascial planes and
can involve the thighs and wall of the torso. The majority of
patients with Fournier’s have diabetes mellitus. Type 2 is
monomicrobial, most commonly owing to group A β-hemolytic
streptococci (ie, GAS or Streptococcus pyogenes), the so-called
flesh-eating bacteria. Increasingly, community-acquired
MRSA is producing necrotizing fasciitis, including the pedi-
atric population. Antecedent varicella infection is a risk fac-
tor in about half these patients.
Necrotizing fasciitis has a mortality ranging from
20–60% in developed countries. Risk of death is elevated in
association with immunosuppression, IVDA, streptococcal
toxic shock syndrome, advanced patient age, and presence of
significant comorbidities. Delays in medical and surgical
therapy are deleterious to patient survival. Initial antibiotic
therapy includes high-dose intravenous penicillin, semisynthetic
β-lactam antibiotics, and clindamycin. The latter should
cover most strains of community-acquired MRSA, but van-
comycin should be considered pending final culture and sen-
sitivity results. Whether the fasciitis is type 1 or type 2 cannot
be determined confidently at the outset. Hemodynamically
unstable patients require early, aggressive crystalloid replace-
ment of intravascular volume. In general, central venous
pressure monitoring guides this volume resuscitation and
directs rational addition and titration of vasoactive medica-
tions such as norepinephrine and vasopressin.
The mainstay of treatment for necrotizing fasciitis is
prompt radical debridement of all involved skin, subcuta-
neous tissue, muscle, and fascia. Defining the limits of this
resection is difficult and requires experience, but insufficient
initial debridement can compromise patient survival.
Immediate amputation, even hip disarticulation, may be neces-
sary to effect survival in advanced cases. It is important, when
possible, to have a compassionate but frank discussion with the
patient and family as to the possible extent of surgery before
embarking on an operation for necrotizing fasciitis. General
comprehension of this illness’s severity should not be assumed.
Just as in ANM and necrotizing pancreatitis discussed earlier,
the need for multiple operations should be anticipated.
Adjunctive measures such as hyperbaric oxygen therapy and
intravenous immunoglobulin administration have been
advised for treatment of necrotizing fasciitis, but their use has
not been rigorously verified in controlled studies.
An uncommon but similarly life-threatening infection
seen in burn and other surgical ICUs is suppurative throm-
bophlebitis. Inflammatory superficial thrombophlebitis
occurs quite often after placement of peripheral vein
catheters. Fortunately, its infectious counterpart is unusual. It
should be suspected, though, in the febrile ICU patient whose
site of infection is elusive. All former sites of intravenous
access should be examined carefully for induration, erythema,
tenderness, centrally projecting red streaks, and purulent
drainage. The latter cinches the diagnosis, whereas the other
signs may indicate vein exploration under local anesthesia.
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If the vein is infected, it must be excised urgently in a distal-
to-proximal direction, stopping only when normal, patent
vein is encountered or all infected vein clearly has been
removed. On occasion, infection extends from peripheral
veins into central ones, and thoracotomy with central vein
resection may be a necessary lifesaving measure.
Treatment of soft tissue infections is summarized in
Table 16-4.
Golger A et al: Mortality in patients with necrotizing fasciitis. Plast
Reconstr Surg 2007;119:1803–7. [PMID: 17440360]
Rieger UM et al: Prognostic factors in necrotizing fasciitis and
myositis: Analysis of 16 consecutive cases at a single institution
in Switzerland. Ann Plast Surg 2007;58:523–30.
Table 16–4. Summary of soft tissue infections in adult surgical patients.
Diagnosis Organisms Initial Antibiotics Adjunctive Therapy
Diabetic foot infection S. aureus (assume MRSA), group
A strep (S. pyogenes), group B
strep (S. agalactiae), coliforms,
anaerobes
Vancomycin 1 g IV q12h + β-lactam with
β-lactamase inhibitor or carbapenem IV
Surgical debridement,
vascular surgical evaluation as
indicated
Cellulitis and soft tissue abscess S. pyogenes, group B, C, and G
strep, S. aureus,
Enterobacteriaceae
Penicillin G 1–2 million units IV q6h or
nafcillin-oxacillin 2 g IV q4h; vancomycin
1 g IV q12h for facial cellulitis; for
diabetics, linezolid 600 mg IV q12h or
vancomycin 1 g IV q12h + carbapenem
IV
Consider necrotizing fasciitis
Type 1 necrotizing fasciitis Aerobes, anaerobes including
Clostridium sp.
Penicillin G 24 million units/24 h in
divided IV doses q4–6h + clindamycin
900 mg IV q8h + vancomycin 1 g IV
q12h + ceftriaxone 2 g IV q24h
Goal-directed therapy for
sepsis, prompt and aggressive
surgical debridement
Type 2 necrotizing fasciitis S. pyogenes (GAS), S. aureus
(community-acquired MRSA)
Penicillin G 24 million units/24 h in
divided IV doses q4–6h + clindamycin
900 mg IV q8h
Goal-directed therapy for
sepsis, prompt and aggressive
surgical debridement
Suppurative thrombophlebitis S. aureus, S. pyogenes,
Enterobacteriaceae
Vancomycin 1 g IV q12h (MRSA),
nafcillin-oxacillin 2 g IV q4h (MSSA),
carbapenem IV or extended-spectrum
penicillin (Enterobacteriaceae)
Removal of intravascular
device, excision of entire
involved vein
Data from Gilbert DN et al (eds): The Sanford Guide to Antimicrobial Therapy, 37th ed. Sperryville, VA: Antimicrobial Therapy, Inc., 2007.
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Bleeding & Hemostasis
Elizabeth D. Simmons, MD
Bleeding is a common problem in critically ill patients in the
ICU. A rational approach to diagnosis and treatment of
bleeding requires an understanding of the major elements
of the hemostatic system, currently available laboratory tests
of hemostatic function, and specific disorders of hemostasis.
Bleeding disorders generally are categorized into defects of
coagulation and fibrinolysis, defects of platelets, and defects
of vascular integrity, but critically ill patients who are bleed-
ing may have defects in multiple arms of the hemostatic sys-
tem. Furthermore, defective hemostasis may result in
thrombosis as well as bleeding.
Normal Hemostasis and Laboratory Evaluation
A. Normal Hemostasis—The major elements of hemostasis
are outlined in Table 17–1. A complex interaction of vascular
endothelium, platelets, red blood cells, coagulation factors,
naturally occurring anticoagulants, and fibrinolytic enzymes
results in formation of blood clot at the site of vascular
injury and activation of repair mechanisms to promote heal-
ing of the injured blood vessel. Vascular injury results in
platelet adhesion and aggregation, activation of coagulation
factors ultimately resulting in cleavage of fibrinogen to fib-
rin, and formation of a stable blood clot consisting of cross-
linked fibrin polymers, platelets, and red blood cells.
Simultaneously, naturally occurring anticoagulants and fib-
rinolytic enzymes are activated, a process that limits the
amount of clot formed and degrades clot once the vessel is
repaired. The latter aspects of hemostasis serve to confine
clot formation to the site of vascular injury while permitting
continued blood flow through the affected blood vessel. The
precise factors that regulate the balance between clot forma-
tion and breakdown are not fully understood.
B. Laboratory Tests of Hemostasis (See Table 17–2)—
There are several generally available laboratory tests for eval-
uation of the function of the hemostatic system. Currently
available screening laboratory tests detect clinically signifi-
cant defects (quantitative and qualitative) of most but not all
of the important elements of hemostasis. The history should
dictate the choice of tests to determine the adequacy of hemo-
static function. A highly suggestive history for a bleeding dis-
order calls for sophisticated or specialized laboratory testing,
whereas abnormal test results may not be predictive of future
risk of bleeding in the absence of a significant bleeding history.
1. Tests of coagulation—Calcium and phospholipid are
required for normal coagulation to occur. In the laboratory,
measurement of coagulation times (eg, prothrombin time
and partial thromboplastin time) involves mixing decalcified
plasma (collected in citrate) and a phospholipid substitute
(thromboplastin), adding calcium, and determining the time
for visible clot formation using an automated system.
Different phospholipid reagents activate different parts of
the coagulation cascade, and an activating agent is added for
performance of the activated partial thromboplastin time
(aPTT). Prothrombin time (PT) generally is reported as the
international normalized ratio (INR), which compares
observed results against a reference thromboplastin to mini-
mize interlaboratory variability owing to differing sensitivi-
ties of thromboplastin reagents. The thrombin time (TT) is
performed by adding excess thrombin to decalcified plasma
(phospholipid is not required).
Standard coagulation times are not prolonged until factor
activities drop to less than 20–50% of normal (depending on
the specific factor deficiency). Therefore, a mixture of patient
plasma with normal plasma in equal quantities (1:1 dilution)
should normalize a prolonged coagulation time if due solely
to one or more factor deficiencies. Failure of a prolonged
coagulation time to correct after 1:1 dilution with normal
plasma implies the presence of a circulating inhibitor of
coagulation, including heparin. Detection of some factor
inhibitors may require incubation of the mixture prior to
performing the assay.
In vitro assessment of coagulation depends on the action
of factor XII, high-molecular-weight kininogen, and
prekallikrein (the contact factors), whereas in vivo hemostasis
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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Element Participation in Hemostasis 
Endothelium 
Procoagulant Release of von Willebrand factor (vWF), factor VIII, tissue factor, plasminogen activator inhibitor, and platelet
activating factor in response to injury; maintains tight interendothelial junctions to prevent blood extravasation. 
Anticoagulant Negative charge repels platelets and coagulation factors; produces prostacyclin; releases tissue plasminogen
activator in response to vessel injury; provides thrombomodulin for thrombin-mediated activation of protein
C; provides heparin-like molecules which interact with antithrombin III and accelerate its inactivation of
thrombin and other serine proteases. 
Platelets Adhere to exposed subendothelium via vWF and aggregate in response to activation (via fibrinogen-glycoprotein
IIb/IIIa interaction); secrete agonists which stimulate further platelet aggregation; provide phospholipid for produc-
tion of thromboxane A2 and for coagulation reactions; provide surface on which coagulation reactions are local-
ized; secrete coagulation factors (V, vWF), which increase local concentration; provide contractile machinery for
clot retraction; perhaps maintain interendothelial tight junctions by secretion of metabolically active substances. 
Coagulation factors
Proenzymes In response to vascular injury, sequential activation (VII, IX, X, II) results in generation of thrombin and cleav-
age of fibrinogen to fibrin. 
Thrombin In addition to cleavage of fibrinogen, activates platelets, factors V, VIII, and XIII, and protein C. 
Fibrinogen Cleaved by thrombin to fibrin, which polymerizes to insoluble fibrin clot. 
Factor XIII After activation by thrombin, cross-links fibrin polymers to stabilize clot. 
Cofactors Factors V and VIII, both activated by thrombin, act as cofactors for X and IX, respectively. 
Tissue factor Integral membrane constituent of vascular endothelial cells and stimulated monocytes; acts as receptor for
factor VII; initiates blood coagulation. 
Calcium, phospholipid Necessary for several steps in coagulation. 
Contact factors Factor XII, HMW kininogen, and prekallikrein are important for in vitro hemostasis only. 
Anticoagulants∗
Protein C Vitamin K-dependent anticoagulant, inactivates factors V and VIII after activation by thrombin bound to throm-
bomodulin on endothelial surfaces. 
Protein S Vitamin K-dependent cofactor for protein C. 
Thrombomodulin Receptor for thrombin, initiates activation of protein C pathway. 
Antithrombin (AT) Inactivates thrombin and other serine proteases of the coagulation cascade. 
Tissue factor pathway inhibitor (TFPI) Inhibits tissue factor/factor VIIa complex. 
Fibrinolytic system
Tissue plasminogen activator Cleaves fibrin-bound plasminogen to plasmin. 
Urokinase Plasminogen activator found in urine and in plasma when fibrinolysis is stimulated.
Table 17–1. Normal hemostasis.
Plasminogen Once activated to plasmin, lyses fibrin and fibrinogen. 
Plasminogen activator inhibitor-1 (PAI-1) Prevents activation of plasminogen by tissue plasminogen activator. 
Alpha2-antiplasmin Inactivates circulating plasmin and prevents lysis of fibrin and fibrinogen. 
Blood elements and rheology Laminar flow prevents contact of cellular elements with endothelium; free flow prevents accumulation of factors
at uninjured sites and dilutes concentration of activated factors; dislodges platelet plugs if not firmly attached to
subendothelium; provides inhibitory plasma proteins other than antithrombin to inactivated coagulation factors. 
∗Precise physiologic role in hemostasis not well defined: Other serine proteinase inhibitors (Serpin): alpha2-macroglobulin, alpha1-proteinase
inhibitor, C1 esterase inhibitor, protein C inhibitor, heparin cofactor II.
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appears to occur normally even with complete deficiency of
any of these proteins. Factor XI likewise is essential for in
vitro coagulation, but factor XI deficiency generally is associ-
ated with a very mild bleeding tendency. Specific coagulation
factor deficiencies can be identified using known deficient
plasma in a modification of the 1:1 dilution test when clini-
cally indicated.
Standard screening coagulation tests (ie, PT, aPTT, and
TT) do not detect mild coagulation factor deficiencies, factor
XIII deficiency, defects in fibrinolysis, or abnormalities of
platelets, blood vessels, or supporting connective tissue.
They are not useful for determining deficiencies of the nat-
urally occurring anticoagulants or for evaluating patients
with thrombotic disorders (except for patients with lupus
Test (normal range) Significance of Abnormal Test
Coagulation
Prothrombin time (PT)
(10–13 seconds) expressed as the
international normalized ratio (INR) (1.0)
Deficiencies of or inhibitors to extrinsic and common pathway factors: VII, X, V (<50%), II (<30%),
fibrinogen (<100 mg/dL).
Activated partial thromboplastin time
(aPTT) (25–40 seconds)
Deficiencies of or inhibitors of contact factors, intrinsic and common pathway factors: XII, HMW kininogen,
prekallikrein, XI (<50%), VIII, IX (<20%), X, V, II (<30–50%), fibrinogen (<100 mg/dL). Decreased value
may indicate increased concentration of factor (especially VIII) or hypercoagulable condition.
Thrombin time (TT) (10 seconds) Deficiency or defect of fibrinogen, inhibitors of thrombin action (heparin), or inhibitors of fibrin polymer-
ization (FDP, myeloma proteins).
Reptilase time Deficiency or defect of fibrinogen. Similar to thrombin time but unaffected by heparin.
Stypven time (Russell viper
venom time)
Differentiate factor X from factor VII deficiency (abnormal in factor X deficiency).
Dilute Russell viper venom time Detect lupus anticoagulant; affected by heparin.
1:1 dilution test (corrects to normal) Failure to correct consistent with inhibitors to specific factors or to phospholipid; heparin effect.
Correction to normal consistent with factor deficiency (some inhibitors may require incubation).
Factors assays (60% to >100%) Deficiencies of one or more coagulation factors.
5 M urea clot stability Deficiency of factor XIII.
Platelets
Platelet count (150,000–400,000/μL) Quantitative abnormalities of platelets.
Bleeding time (3–10 minutes) Impaired platelet function, thrombocytopenia, severe anemia, improper technique.
Aggregation (qualitative) Impaired platelet aggregation in response to platelet agonists; can localize defect based on pattern of
abnormal aggregation.
Ristocetin cofactor assay Decreased quantity or function of vWF in patient plasma.
Fibrinolysis
Fibrin(ogen) degradation products
(FDP) (<10 μg/mL)
Accelerated fibrinolysis.
Fibrinogen (150–400 mg/dL) Deficiency of fibrinogen.
Euglobulin lysis time (>2 hours) Accelerated fibrinolysis.
Protamine sulfate test Positive test indicates presence of circulating fibrin monomers.
D-dimer test Positive test indicates presence of cross-linked FDP, formed only if activation of factor XIII has resulted in
cross-linkage of fibrin polymers. Elevated in DIC, fibrinolysis, deep vein thrombosis, and pulmonary
embolism.
Table 17–2. Tests of hemostatic function (average normal values given).
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anticoagulants and contact factor deficiencies). Coagulation
times shorter than normal occur frequently, particularly if
there are higher than normal levels of any of the factors
measured by the test (especially factor VIII), which may
mask deficiencies of other factors.
2. Platelets—The platelet count can be determined by
automated cell counter or by estimation on a peripheral
blood smear (normal, 10–20 platelets/high-power field
[hpf]). The bleeding time is an in vivo test of platelet func-
tion. Bleeding time is affected by platelet number, platelet
function, position and depth of the incision, maintenance of
constant pressure above the site of the incision, medications,
hemoglobin concentration, and renal function. In thrombo-
cytopenic patients, the bleeding time varies as a function of
the cause as well as the degree of thrombocytopenia.
Although the bleeding time is useful in diagnosis of disor-
ders of platelet function, it may not be reliable as a predictor
of clinical bleeding. Other tests of platelet function include
in vitro platelet aggregation in response to various agonists
(eg, thrombin, epinephrine, adenosine diphosphate, and ris-
tocetin) for evaluation of patients suspected of having sig-
nificant disorders of platelet function rather than number.
3. Fibrinolysis—Elevated fibrin and fibrinogen degrada-
tion products and decreased fibrinogen concentration may
reflect excessive intravascular fibrinolysis, but these measure-
ments are not specific. The protamine sulfate test and the D-
dimer test may be useful to confirm the presence of
disseminated intravascular coagulation (DIC) as the cause of
elevated fibrin degradation products. The euglobulin lysis
time, which measures the action of plasminogen activators
and plasmin in blood, may be useful for confirming the pres-
ence of excessive fibrinolysis. Specific assays for elements of
the fibrinolytic system are available if clinically indicated.
 Inherited Coagulation Disorders
ESSENT IALS  OF  D IAGNOS I S
 Personal and family history of bleeding disorder.
 Abnormal screening coagulation tests.
 Abnormal specific factor assays.
General Considerations
Inherited coagulation disorders result from a decrease in
quantity or function of a single coagulation factor, although
there are some cases of familial multiple coagulation factor
deficiencies. The inheritance pattern may be autosomal or X-
linked, dominant or recessive, or may be the result of a new
mutation, so a negative family history does not preclude the
presence of an inherited disorder of coagulation. A personal
history of bleeding may be absent if the defect is mild or if
there has been no prior challenge to the hemostatic system
(eg, major surgery or trauma). In addition, some coagulation
defects are variable over time, with fluctuations both in
bleeding manifestations and in laboratory abnormalities.
Nevertheless, most of the inherited disorders of blood coag-
ulation result in a typical clinical bleeding history accompa-
nied by characteristic reproducible laboratory abnormalities
(Table 17–3).
von Willebrand disease (vWD) is the most common inher-
ited bleeding defect in humans, but prevalence figures vary
widely because of variable expression and penetrance of the
genetic abnormality. The disease results from inheritance of
an autosomal dominant (rarely, autosomal recessive) decrease
in the quantity or function of von Willebrand factor (vWF).
vWF is essential in platelet adhesion and serves as a carrier for
the procoagulant factor VIII protein. Clinical manifestations
typically reflect impaired platelet function, with epistaxis,
easy bruising, menorrhagia, and excessive bleeding after sur-
gery, trauma, or dental procedures. Severe deficiencies (<1%
activity) are rare and may result in bleeding similar to that
seen in hemophilia A. vWD is heterogeneous in severity and
is subject to variability over time and within families. During
pregnancy, vWF levels increase, often sufficiently to permit
adequate hemostasis at childbirth.
Hemophilia A, which accounts for 80% of all hemophil-
ias, results from inheritance of an X-linked recessive muta-
tion in the factor VIII gene, giving rise to severe (<1%
activity), moderate (1–5% activity), or mild (>5% activity)
factor VIII deficiency. The incidence of hemophilia A is
approximately 1 in 5000 men. Hemophilia A does occur in
women, owing either to early X chromosome inactivation of
the normal X in a heterozygous female or to inheritance of
two abnormal X chromosomes (one from an affected father
and one from a carrier mother).
Clinical manifestations depend on the severity of the
deficiency (70% of patients have severe deficiency) but typi-
cally include lifelong spontaneous hemarthroses and soft tis-
sue hematomas, hematuria, and if severe, increased epistaxis,
gum bleeding, and ecchymoses. Postoperative or dental
bleeding is severe and prolonged. CNS hemorrhage occurs in
about 3% of patients and may be fatal. The severity of the
deficiency is generally constant within a family and over time
in an individual, but it varies between families.
Hemophilia B results from inheritance of an X-linked
recessive mutation in the factor IX gene. The pathophysiology
and clinical manifestations are virtually identical with those
of hemophilia A, although severe deficiency is present in only
50%. Hemophilia B is much less common than hemophilia A,
with an estimated incidence of 1 in 50,000 men.
Inherited deficiencies of all the other coagulation factors
have been reported (see Table 17–3), but these are rare. All are
autosomally inherited, usually recessive, and often result from
consanguineous parentage. Clinical severity correlates with
the degree of factor deficiency but is typically milder and
more variable than in hemophilias A and B. Combined defi-
ciencies of multiple coagulation factors are rare. Deficiencies
of factor XII, prekallikrein, and high-molecular-weight
kininogen cause prolongation of the aPTT but are not asso-
ciated with excessive bleeding or thrombosis.
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Table 17–3. Clinical manifestations of inherited coagulation factor deficiencies.
(continued)
Factor Deficiency
vWF VIII IX II V VII X XI XIII Fibrinogen Dysfibrinogenemia 
Combined Factor
V/VIII deficiency
Multiple Vitamin K-
dependent factors
Inheritance AD/AID/
AR 
XR XR AR AR AR AIR AR AR AR AD AR AR
Incidence 1:100 1/10 K 1/40 K Rare Rare Rare Rare Rare∗ Rare Rare Rare Rare Rare
Clinical manifestations
Severity 
(most cases) 
Mild 70%
severe 
50%
severe 
Mild Mild,
variable 
Moderate,
variable 
Moderate Mild Severe Mild Mild Moderate to severe Variable, not well-
described
Easy bruising + (+) (+) (+) + + + (+) + + 
Epistaxis + (+) (+) (+) + + + (+) + + + +
Menorrhagia + (+) + + + (+) + + + +
Soft tissue
hematomas 
+ + (+) (+) + + (+) + (+) +
Hemarthrosis • + + (+) (+) + + + (+) + +
Intracranial 
hemorrhage 
+ + • + + + + •
Gastrointestinal
hemorrhage 
+ + (+) + + + (+)
Bleeding with
trauma, surgery,
or dental
procedures 
+ + + + + (+) (+) (+) + • (+) + +
Umbilical stump
bleeding 
• • + + • (+) 
Spontaneous
abortions 
+ + + +
Male infertility + 
Poor wound
healing 
(+) (+) + + 
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∗Factor XI deficiency much more common in Ashkenazic Jews (5–11% heterozygous).
†Specific factor assays are available for the diagnosis of all the inherited factor deficiencies.
Key: Inheritance: AD, autosomal dominant; AR, autosomal recessive, XR, X-linked recessive; AIR, autosomal incompletely recessive; AID, autosomal incompletely dominant
Frequency of clinical manifestations: + common; (+) occasional; • rare
Thromboembolic
complications 
+ + (with rx) 
Laboratory abnormalities
PT prolonged + + + + + + + +
aPTT prolonged + + + + (+) + + + + + +
Thrombin time
prolonged 
+ +
Bleeding time
prolonged
+ (+) (+) (+)
Other laboratory
tests†
Risto-
cetin
cofactor,
factor
VIII
assay
Stypven
time 
Stypven
time 
5 M urea Reptilase time,
euglobulin lysis,
fibrinogen immuno-
electrophoresis
Low protein C/S
Table 17–3. Clinical manifestations of inherited coagulation factor deficiencies. (continued)
Factor Deficiency 
vWF VIII IX II V VII X XI XIII Fibrinogen Dysfibrinogenemia 
Combined Factor
V/VIII deficiency
Multiple Vitamin K-
dependent factors
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Clinical Features
A. Symptoms and Signs—Bleeding may occur sponta-
neously, but patients sometimes will give a history of bleed-
ing only after surgery, trauma, or dental extractions. In those
with vWD, platelet function is affected, so easy bruising and
menorrhagia may be prominent complaints. On the other
hand, patients with hemophilia often have spontaneous
hemarthroses, soft tissue hematomas, and hematuria. Physical
findings may reflect recent bleeding or may show evidence of
chronic bleeding such as decreased range of joint motion.
B. History—A detailed personal and family history of bleed-
ing often will uncover the nature of the coagulation disorder
and suggest its inheritance pattern. A family history of con-
sanguinity is pertinent for the rare autosomal recessive disor-
ders, and Ashkenazic Jewish ancestry may suggest the
possibility of factor XI deficiency.
C. Laboratory Findings—Laboratory abnormalities may
suggest an underlying hereditary bleeding disorder, but it is
important to remember that not all prolonged coagulation
tests indicate a bleeding diathesis, and some inherited bleed-
ing disorders are associated with normal coagulation tests.
There may be variability over time in some disorders, such as
vWD. The extent of laboratory evaluation for an inherited
coagulation disorder should be determined by the clinical his-
tory. Table 17–3 outlines the typical laboratory features of the
inherited coagulation disorders. Functional assays for factors
II, V, VII, VIII, IX, X, XI, and XII using known deficient
plasma in a modification of the 1:1 dilution test confirm spe-
cific factor deficiencies. Clot stability in 5 M urea with and
without the addition of normal plasma is the screening test of
choice for diagnosis of factor XIII deficiency and can be con-
firmed with a specific factor assay. The diagnosis of vWD is
based on finding low vWF antigen, abnormal ristocetin cofac-
tor activity, and low factor VIII activity (usually <10%).
Quantitative deficiency of vWF can be differentiated from
qualitative defects by electrophoretic analysis of vWF multi-
mers. Determining the subtype of vWD by multimer analy-
sis is important for proper management of bleeding
episodes.
Differential Diagnosis
Bleeding associated with abnormal coagulation tests also
may result from acquired coagulation disturbances, includ-
ing liver disease, vitamin K deficiency, DIC, inhibitors of spe-
cific factors, or therapeutic anticoagulation. Abnormal
coagulation tests may result from a deficiency of one of the
contact factors or from the presence of antiphospholipid
antibodies (lupus anticoagulant), neither of which causes
bleeding but may be associated with thrombosis. Mild coag-
ulation factor deficiencies may be associated with normal
or minimally prolonged clotting times and may result in
bleeding only if major vascular injury occurs. Bleeding in the
presence of normal coagulation times suggests the presence
of an underlying vascular defect, abnormal supporting con-
nective tissue, thrombocytopenia or platelet dysfunction,
excessive fibrinolysis, or factor XIII deficiency. Acquired
inhibitors to coagulation factors may be found in patients
with inherited factor deficiencies as a consequence of
replacement therapy and may be suspected in those who do
not respond adequately to factor replacement. An inhibitor
of coagulation can be confirmed by performing a 1:1 dilu-
tion test with normal plasma (preincubation may be neces-
sary to demonstrate the inhibitor).
Treatment
Factor replacement is appropriate for patients with inherited
coagulation disorders who have active bleeding or who
require surgical or dental procedures. The activity level nec-
essary for adequate hemostasis varies for each factor and
with the type of bleeding or planned procedure. General
guidelines for factor replacement are outlined in Table 17–4.
Aspirin and intramuscular injections should be avoided.
Surgical procedures should be performed only in centers
with adequate blood bank, coagulation laboratory, and
hematology consultation services. Treatment strategies for
patients with inhibitors complicating factor deficiencies
include desmopressin (for minor bleeding), high-dose fac-
tor replacement, use of products that bypass the factor
inhibitor (eg, activated prothrombin complex concentrate
with factor VIII inhibitor bypassing activity, recombinant
factor VIIa, and porcine factor VIII), and techniques to
lower the titer of the inhibitor (eg, plasmapheresis, intra-
venous immune globulin, immunosuppression, and induc-
tion of immune tolerance).
Adjuncts to factor replacement include desmopressin
acetate, antifibrinolytic agents such as aminocaproic acid and
tranexamic acid, and topical hemostatic agents such as fibrin
glue and fibrillar collagen preparations applied directly to
local areas of mucosal bleeding, such as epistaxis.
Desmopressin by intravenous (0.3 μg/kg over 15–30 minutes)
or intranasal (1.5 mg/mL in each nostril) administration
increases circulating levels of vWF and factor VIII by 2 to 5
times baseline within 15–30 minutes by releasing these factors
from endothelial storage sites. Desmopressin is useful for
most patients with vWD and in patients with mild to moder-
ate hemophilia A. Repeated infusions within 1–2 days may be
less effective, however, limiting the usefulness of desmo-
pressin in patients requiring sustained increases in vWF, fac-
tor VIII, or both. On the other hand, use of desmopressin may
completely eliminate the need for blood products in mild
bleeding episodes or during minor dental or surgical proce-
dures and may decrease the amount of blood products
required for major bleeds or surgical procedures. A test dose
of desmopressin should be administered about 1 week before
a planned surgical procedure to determine if a patient with
vWD or hemophilia A is responsive. Severe hemophiliacs and
those with qualitative abnormalities of vWF are rarely respon-
sive to desmopressin. Some subtypes of vWD (eg, type 2B)
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Factor
Deficiency 
t1/2
Hemostatic
Level1
Preferred Sources2 Dose 
Interval Between
Doses 
vWF 12 hours 25–50% a. Desmopressin3
b. Humate-P
c. Cryoprecipitate4
a. 0.3 μg/kg IV/30 minutes or
1.5 mg/mL nasal spray
b. 30 units/kg 
a. 24–48 hours
b. 12 hours for 2 days,
then 24 hours 
VIII 9–18 hours 25–30% a. Purified factor VIII
b. Recombinant factor VIII  
c. Desmopressin5
a. 10–15 units/kg (minor),
30–40 units/kg (major)
b. 10 units/kg (minor); 15–25
units/kg (moderate); 40–50
units/kg, then 20–25 units/kg
(major); 50 units/kg (surgery) 
12 hours (6–12 hours
following major surgery)
IX 20–25 hours 15–30% a. Purified factor IX
b. Recombinant
factor IX
c. Purified prothrombin
complex concentrates (PCC )
a. 10–20 units/kg
b. 100 units/kg, then 7.5
units/kg/h
c. 20–30 units/kg, then 15
units/kg (minor); 40–60
units/kg, then 20–25 units/kg
(major bleeding or surgery) 
24 hours 
II 3 days 20–40% a. Plasma
b. Purified PCC 
a. 15 mL/kg, then 5–10 mL/kg
b. 20 units/kg, then 10 units/kg 
24 hours 
V 36 hours 25–30% FFP, PCC 15–20 mL/kg, then 10 mL/kg 12–24 hours 
VII 4–7 hours 15–20% a. Plasma
b. Purified PCC
c. Recombinant factor VII
d. Factor VII concentrate
a. 20 mL/kg, then 5 mL/kg
b. 30 units/kg, then 10–20
units/kg
c. 15–30 μg/kg
d. 30–40 units/kg
a/b. 4–6 hours
c/d. 12 hours
X 40 hours 10–20% a. Plasma
b. Purified PCC 
a. 15–20 mL/kg, then 10 mL/kg
b. 20–30 units/kg 
24 hours 
XI 80 hours 10–20% Plasma 15–20 mL/kg, then 5 mg/kg 48 hours 
XIII 9–12 days 3–5% a. Plasma
b. Cryoprecipitate
c. Factor XIII concentrate
a. 15–20 mL/kg
b. 1 bag/10 kg
c. 10–20 units/kg 
20–30 days
Fibrinogen 3–4 days a. Plasma
b. Cryoprecipitate
c. Fibrinogen concentrate
a. 15–20 mL/kg
b. 1 bag/10 kg
c. 20–30 mg/kg 
48 hours 
Combined
factors V/VIII
36 hours (V)
9–18 (VIII)
25–30% a. Plasma
b. Desmopressin (as in VIII)
a. 15–20 mL/kg 12 hours
Multiple Vitamin
K-dependent
factors
Varies by factor
(II, VII, IX, X)
Varies by factor a. Plasma
b. PCC
c. Oral Vitamin K
a. 15–20 mL/kg
b. 10–30 units/kg
c. chronic, high dose
Monitor levels
1Estimated level required for normal hemostasis. Higher levels required for major bleeding or surgery (factors VIII and IX: 100%, factor XIII: 25–50%).
2Plasma, fresh frozen (FFP) or fresh (FP), may be used interchangeably except for replacement of factors V and VIII.
3Desmopressin is thrombogenic; use with caution in older patients with vascular disease; may induce fibrinolysis, often used in combination
with antifibrinolytic agents. Must give a test dose to determine efficacy; not effective for vWD type 2b, platelet-type vWD.
4Use only if factor concentrate is unavailable.
5In mild hemophilia A, may reduce or eliminate need for factor VIII replacement for minor surgery, dental work, or acute bleeding episodes.
Same dose as in vWD. 
Table 17–4. General principles of factor replacement for inherited coagulation disorders.
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have been associated with thrombocytopenia following
desmopressin therapy because of increased binding of aber-
rant vWF to platelets. If the response to desmopressin is
unknown and a patient is actively bleeding, factor replace-
ment with blood products is preferable. Desmopressin also
stimulates release of tissue plasminogen activator, so antifib-
rinolytic therapy is often administered simultaneously.
Aminocaproic acid and tranexamic acid are two commer-
cially available antifibrinolytic agents that may be useful for
managing bleeding in patients with a wide variety of bleed-
ing disorders. The use of antifibrinolytics in combination
with desmopressin often eliminates the need for any blood
product administration for patients with vWD or mild
hemophilia A with minor bleeding or after dental proce-
dures. Antifibrinolytic therapy also may be useful as an
adjunct to factor replacement in any inherited coagulation
disorder unless there are contraindications such as hema-
turia, uncontrolled DIC, or use of prothrombin complex
concentrates. For acute bleeding, aminocaproic acid usually
is given as an intravenous infusion at a rate of 1 g/h until
bleeding is controlled (maximum 24 g in 24 hours), followed
by a maintenance dose of 6 g intravenously or orally every 6
hours for 7–10 days. The suggested dose of tranexamic acid
is 10 mg/kg intravenously or 25 mg/kg orally three or four
times a day beginning 1 day before surgery or at the onset of
acute bleeding and to be continued for 2–8 days.
Current Controversies and Unresolved Issues
Current recommendations regarding factor replacement for
inherited coagulation disorders stem primarily from anec-
dotal experience rather than from carefully designed clinical
trials comparing one regimen with another. The optimal
level of factor activity, the precise interval between doses, and
the duration of therapy are somewhat arbitrary and for most
of the rare disorders reflect a lack of clinical experience.
Genetic heterogeneity contributes further to the lack of firm
data to support current recommendations.
Because of the risks of bleeding, infections, and other
transfusion-related complications, elective surgery should be
avoided when possible. There is a body of literature demon-
strating the success of surgery in hemophiliacs and others
with inherited coagulation defects, but clearly, surgery in
such patients poses significant risks and increases the
demand for scarce resources, including blood products.
Current screening for infectious diseases and processing
of factor concentrates to eliminate many (but not all) infec-
tious agents has significantly decreased the risk of transmis-
sion of infectious diseases from plasma-derived products. All
patients with hemophilia and related coagulation disorders
should be vaccinated against hepatitis B. The development of
recombinant factors VIII and IX has contributed to a marked
decrease in virus-associated illnesses in these patients (no
documented cases of HIV and hepatitis B or C since 1985
and 1990, respectively), and human albumin–free products
have been developed to reduce further the possible transmission
of Creutzfeldt-Jakob disease. However, recombinant factors
are two to three times more expensive than plasma-derived
factors, are not always available owing to limited production
capacity, and may be associated with a higher rate of
inhibitor development compared with plasma concentrates.
Hemophilia patients who acquired HIV infection prior to
the widespread availability of screening and purified factors
have been treated successfully with antiretroviral therapy, but
there appears to be an increased risk of spontaneous bleed-
ing in these patients.
The development of inhibitors to factors continues to be
a problem for patients with severe hemophilia; recombinant
factors do not eliminate this risk (estimated at 10–15%).
Recombinant factor VIIa and activated prothrombin com-
plex concentrates (aPCCs) can be used to control hemor-
rhage by bypassing factors VIII and IX in patients with
inhibitors, but both may be associated with thromboem-
bolism. Porcine factor VIII is no longer used owing to con-
tamination with porcine parvovirus. Protein A sepharose
immunoadsorption may transiently lower factor VIII
inhibitors, allowing time for other immunosuppressive ther-
apies to work. Optimal management of inhibitors remains a
challenge in management of severe hemophilia.
Factor IX replacement (recombinant or purified plasma-
derived) can cause anaphylaxis in 5% of patients with severe
hemophilia B. Further replacement therapy in these patients
is risky. Recombinant factor VIIa is the only available thera-
peutic option for these patients.
Research in gene therapy is ongoing for patients with
severe hemophilia A and B. Results from preliminary trials
are promising, but this approach remains experimental.
Gene therapy may not prevent inhibitor development, how-
ever, and patients who are undergoing treatment for HIV
infection or who have hepatitis may not respond to this
approach.
 Acquired Coagulation Disorders
ESSENT IALS  OF  D IAGNOS I S
 Absence of a personal (if newly acquired) or family his-
tory of bleeding disorder.
 Abnormal screening coagulation tests.
 Clinical situation leading to decreased production or
increased destruction of coagulation factors or presence
of an anticoagulant.
General Considerations
Acquired coagulation disorders result from four basic mech-
anisms: vitamin K deficiency, liver disease, consumption of
factors, or inhibition of factor activity or fibrin polymeriza-
tion. Unlike inherited disorders, acquired coagulation disor-
ders are often characterized by multiple factor deficiencies as
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well as platelet defects (quantitative and qualitative). In addi-
tion, many of the clinical symptoms and signs result from the
underlying disease process; the coagulopathy is just one of
many processes contributing to the overall clinical picture.
A. Vitamin K Deficiency—Vitamin K is a cofactor necessary
for the synthesis of functional factors II (ie, prothrombin),
VII, IX, and X and proteins C and S. Vitamin K is found in
dietary sources (green vegetables) and is synthesized by bac-
teria in the intestinal lumen. It is fat-soluble, requiring bile
salts for absorption in the intestine. Vitamin K deficiency is
most likely to occur in patients who have disruption of both
dietary and bacterial sources of vitamin K (eg, patients who
are receiving broad-spectrum antibiotics who are not eating),
who have biliary obstruction or fat malabsorption, or who
are taking warfarin derivatives that inhibit metabolism of
vitamin K in the liver and induce a vitamin K–depleted state.
Vitamin K stores also may be depleted in patients with acute
or chronic liver disease. By unclear mechanisms, certain
antibiotics—particularly certain cephalosporins—and high
doses of aspirin are known to induce a deficiency of vitamin
K–dependent coagulation factors that is reversible with
administration of vitamin K. Cholestyramine, mineral oil,
and other cathartics may interfere with vitamin K absorption
when taken for a prolonged period. Normal newborns have
low levels of vitamin K–dependent factors that fall further
during the first few days of life. Deficiency of vitamin K
results in progressive depletion of all the vitamin K–dependent
factors as they are metabolized. Factor VII has the shortest
biologic half-life and is depleted first, followed by proteins
C and S and then factors IX, X, and II. Bleeding owing to vita-
min K deficiency is uncommon unless the deficiency is severe
(PT >25–30 seconds) or vascular injury is present.
B. Liver Disease—Coagulation disorders associated with
liver disease are complex. With the exception of vWF and
factor VIII, all the coagulation factors and other regulatory
proteins (eg, α2-antiplasmin, proteins C and S, and
antithrombin) are synthesized in hepatocytes. The liver is
also the site of clearance of activated coagulation factors and
degradation products of fibrin and fibrinogen and is respon-
sible for regeneration of vitamin K after it participates in
synthesis of the vitamin K–dependent coagulation factors.
Liver disease from any cause may result in multiple abnor-
malities, including decreased synthesis of all the coagulation
factors (with the exception of factor VIII), abnormal synthe-
sis of factors and proteins (eg, dysfibrinogenemia), abnormal
vitamin K metabolism resulting in functional vitamin K defi-
ciency, impaired fibrin polymerization owing to increased
fibrin degradation products, and accelerated fibrinolysis. In
addition, thrombocytopenia (owing to multiple mecha-
nisms, including inadequate synthesis of thrombopoietin in
the liver and hypersplenism, among others), defective
platelet function, or both may complicate severe liver disease.
Advanced cirrhosis is often associated with abnormalities of
blood vessels (eg, esophageal and gastric varices) and other
defects (eg, gastritis, ulcer disease, and esophageal tears),
which are the major sites of bleeding in patients with liver
disease. Hemostatic abnormalities exacerbate bleeding from
these sites and contribute to epistaxis, ecchymoses, and
increased bleeding with invasive procedures. In general, the
presence of a coagulopathy is a sign of advanced liver disease,
although passive congestion of the liver owing to right-sided
heart failure may be associated with coagulation distur-
bances without irreversible liver dysfunction.
C. Consumption of Coagulation Factors—Consumption
of coagulation factors may result from massive internal or
external blood loss or from DIC. Occasional patients who
have massive blood loss will develop a clinically significant
deficiency of multiple hemostatic factors, but DIC is the
most typical condition associated with consumption of coag-
ulation factors.
DIC occurs as a result of abnormal activation of coagula-
tion because of vascular injury, direct release of procoagulant
materials into the circulation, or both. There also may be
decreased quantity or function of naturally occurring antico-
agulants (ie, thrombomodulin–protein C pathway) in
patients with sepsis-associated DIC or in patients following
resuscitation for cardiac arrest. Consumption of coagulation
factors and platelets is accompanied by secondarily acceler-
ated fibrinolysis and results in a generalized bleeding ten-
dency associated with mucosal bleeding, ecchymoses, and
oozing from sites of vascular trauma, including venipuncture
and surgical sites. Fibrin deposition in the microcirculation
may contribute to some of the clinical sequelae of DIC, such
as tissue hypoxia. Rarely, purpura fulminans complicates
DIC. As a result of widespread arterial and venous thrombo-
sis, patients with purpura fulminans may have skin necrosis
and gangrene of the distal extremities and digits. The condi-
tions in which DIC occurs are complex (Table 17–5), with
multiple pathophysiologic mechanisms contributing to the
overall outcome of patients. DIC itself contributes to
multiple-organ-system failure and death in patients with
severe systemic disorders, particularly sepsis. Localized con-
sumption of coagulation factors and platelets owing to mas-
sive internal bleeding may mimic DIC but is not associated
with intravascular fibrin generation or generalized fibrinoly-
sis. In this situation, depletion of coagulation factors and
platelets may be accompanied by elevated circulating fibrin
degradation products and may result in a serious bleeding
tendency, but it is not associated with microvascular throm-
bus formation. Primary systemic fibrinolysis is extremely
rare and results in rapid destruction of fibrin clots, destruc-
tion of circulating fibrinogen, and consumption of plas-
minogen and its inactivators. Systemic fibrinolysis
accompanies DIC and may contribute significantly to clini-
cal bleeding. Primary fibrinolysis can be confused with DIC
but usually is not associated with thrombocytopenia and
generalized consumption of coagulation factors.
D. Inhibitors of Coagulation—Infrequently, inhibitors of
coagulation develop and may result in a serious bleeding
diathesis. Inhibitors directed against factor VIII are encountered
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most frequently as a complication of treatment for severe
hemophilia A and also may be associated with pregnancy,
collagen vascular diseases, malignancy, or certain drug reac-
tions. Inhibitors may occur as an isolated condition. The
abrupt development of factor V inhibitors following surgical
procedures has been reported and may cause unexpected
severe postoperative bleeding. These inhibitors appear to be
related to the use of topical bovine thrombin preparations con-
taining bovine factor V intraoperatively that may crossreact
with human factor V. Inhibitors to other coagulation factors,
including vWF and factor XIII, have been described. These
inhibitors are immunoglobulins with neutralizing activity
directed against specific factors and result in a clinical picture
consistent with a factor deficiency state. Other types of
inhibitors include substances that inhibit fibrin polymerization
without immunologic specificity for the fibrin molecule (eg,
fibrin degradation products or myeloma proteins). The lupus
anticoagulant typically prolongs the aPTT and therefore may
be confused with factor deficiencies or other inhibitors, but it is
not associated with bleeding. Heparin is a therapeutic inhibitor
of coagulation, accelerating the rate of antithrombin-mediated
inactivation of thrombin and other coagulation factors that act
as serine proteases (ie, factors VII, IX, and X).
Clinical Features
The clinical history, physical examination, and screening lab-
oratory abnormalities are usually sufficient to determine the
nature of the coagulation defect.
A. Symptoms and Signs—Patients with acquired coagula-
tion disorders occasionally may have spontaneous bleeding
but more commonly have excessive bleeding with surgical or
other invasive procedures or exacerbations of bleeding from
GI or other sites. Other clinical features reflect the underly-
ing disorder. Patients with liver disease may have bleeding
from esophageal varices as well as signs of hepatic dysfunc-
tion. In DIC, bleeding is a common finding, but ongoing
coagulation may be manifested as intravascular thrombosis
with skin necrosis and gangrene (ie, purpura fulminans).
Features of the disease causing DIC—particularly sepsis—
may predominate.
B. Laboratory Findings (See Table 17–6)—The PT and
the aPTT may be prolonged in all the acquired coagulation
defects as a result of multiple factor deficiencies. A 1:1 dilu-
tion test that fails to correct the abnormal PT or aPTT indi-
cates the presence of an inhibitor (including heparin and
lupus anticoagulants). Complete correction of the prolonged
PT and aPTT within 24 hours of administration of intra-
venous vitamin K confirms the presence of vitamin K defi-
ciency; vitamin K administration therefore is both diagnostic
and therapeutic. The diagnosis of DIC is based on the pres-
ence of prolonged PT and aPTT, thrombocytopenia, and ele-
vated fibrin degradation products or D-dimer in the
presence of an appropriate underlying condition.
Hypofibrinogenemia may be present in very severe cases,
but—because fibrinogen is an acute-phase reactant—fib-
rinogen levels are often normal. None of these tests is sensi-
tive or specific enough to determine conclusively whether
DIC is present. Circulating fibrin monomers (protamine sul-
fate test) and degradation products of cross-linked fibrin (D-
dimer test) confirm the presence of increased thrombin or
plasmin generation, and both are usually present in DIC;
they also may be positive occasionally in patients with liver
disease. Laboratory findings also vary as the condition of the
patient changes. Despite numerous attempts to standardize
the diagnostic criteria for DIC, DIC remains a clinical diag-
nosis, and assessment of the consequences of DIC is the
most critical aspect of management.
Coagulation defects owing to liver disease may be con-
fused with DIC because of the presence of accelerated fibri-
nolysis, decreased clearance of fibrin and fibrinogen
degradation products, thrombocytopenia, and prolongation
of both the PT and the aPTT. Therefore, differentiating DIC
from the coagulopathy of severe liver disease may be difficult,
and clinical experience is required to interpret the often
complex laboratory abnormalities. Schistocytes may be
found on peripheral blood smear; when present, DIC must
be distinguished from microangiopathic hemolytic anemia.
This disorder, which can be due to thrombotic thrombocy-
topenic purpura–hemolytic uremic syndrome, chemother-
apy, malignant hypertension, and the HELLP (hemolysis,
elevated liver enzymes, low platelets) syndrome, results from
endothelial injury with subsequent platelet activation,
thrombin generation, and fibrinolysis. Thrombocytopenia,
Cause Examples 
Infections Bacterial sepsis (gram-negative and
gram-positive), viremia, rickettsiae,
malaria, tuberculosis
Trauma Massive tissue injury, head trauma, fat
embolism, burns
Malignancy Adenocarcinomas, acute leukemia
Obstetrical complications Abruptio placentae, amniotic fluid
embolism, retained dead fetus, septic
abortion, placenta previa, eclampsia
Vascular disorders and
prosthetic devices 
Giant hemangioma (Kasabach-Merritt
syndrome), aortic aneurysm
Toxins Snake venoms, drugs
Immunologic disorders Severe allergic reaction, hemolytic
transfusion reaction, transplant
rejection
Metabolic disorders Hypotension, hypoxia, hyperthermia,
hypothermia, cardiac arrest
Table 17–5. Causes of disseminated intravascular
coagulation (DIC).
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hemolytic anemia, and fragmented red blood cells are the
hallmarks of microangiopathic hemolytic anemia, without
prolongation of coagulation times in most cases.
Differential Diagnosis
Inherited coagulation defects, thrombocytopenia, platelet
dysfunction, and accelerated fibrinolysis all may result in
bleeding at sites of vascular injury. Prolonged screening
coagulation tests may be abnormal owing to technical error
(including obtaining blood samples through heparinized
lines or inadequate quantity of blood in the tube) because of
inhibitors that do not cause bleeding (eg, lupus anticoagu-
lant) and deficiencies of factors that are not important for in
vivo hemostasis (eg, the contact factors, factor XII, high-
molecular-weight kininogen, and prekallikrein). Finally,
impaired surgical hemostasis, mucosal abnormalities, and
primary vascular abnormalities may result in clinical bleed-
ing regardless of coagulation status.
Treatment
Treatment of the underlying disease state, avoidance of inva-
sive procedures, and replacement of deficient factors during
acute bleeding episodes are the mainstays of treatment.
Vitamin K1 (phytonadione), 1–10 mg orally or subcuta-
neously (not intramuscularly), should be administered to
patients at risk for vitamin K deficiency as both a diagnostic
and therapeutic strategy. The American College of Chest
Physicians recommends different dosing ranges of vitamin K
depending on the elevation of the PT and the bleeding status
or risk of the patient. Weekly administration (10 mg) reduces
the risk of vitamin K deficiency in patients who are poorly
nourished, receiving antibiotics, or who have malabsorption.
Intravenous vitamin K administration works more rapidly
but rarely may cause severe allergic reactions. Larger doses
may be required to reverse massive overdoses of warfarin.
Fresh-frozen plasma administration is necessary to correct
multiple factor deficiencies, but this treatment may be compli-
cated by the large volume required to achieve adequate hemo-
static levels, especially if factors are being consumed rapidly.
The quantity of fresh-frozen plasma administered must be
individualized, but in general, 30–40% of plasma volume (eg,
1000–1200 mL) is required to achieve adequate levels of all the
deficient factors; this amount must be readministered every
6–8 hours to maintain adequate levels of factor VII. Many
patients will not tolerate such a high volume of fresh-frozen
plasma replacement, so only partial correction may be possi-
ble—yet, if increased consumption of factors is present, even
more frequent administration may be needed.
A. Liver Disease—Management of liver disease complicated
by bleeding is difficult owing to the presence of multiple
Laboratory Abnormality 
Vitamin K
Deficiency Liver Disease DIC 
Specific Factor
Inhibitors 
Lupus
Inhibitors 
Primary
Fibrinolysis
PT prolonged + + + +∗ (+)
aPTT prolonged + + + +∗ +
1:1 dilution does not correct +† +
Thrombin time prolonged + + +
Thrombocytopenia + + (+)
FDP elevated + + + +
D-dimers present (+) +
Protein C/S decreased + + (+)
Antithrombin decreased + +
Red blood cells Targets,
macrocytes 
Schistocytes,
microspherocytes
Hypofibrinogenemia (+) (+)
∗Pattern of clotting time prolongation depends on specific factor to which inhibitor is directed.
†May require incubation.
Key: + common; (+) occasional
Table 17–6. Laboratory diagnosis of acquired coagulopathies.
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pathologic processes. Factor replacement with fresh-frozen
plasma, platelet concentrates for thrombocytopenia, and cry-
oprecipitate for severe hypofibrinogenemia is a reasonable
intervention for serious bleeding but must be accompanied
by attempts to correct vascular and mucosal defects that
often are the main reasons for bleeding. The volume of fresh-
frozen plasma required to completely reverse prolonged clot-
ting times is substantial (>1000 mL), which limits its efficacy.
Prothrombin complex concentrate provides essential coagu-
lation factors in a much smaller volume, but because it is
associated with increased thromboembolic complications
and DIC (particularly with severe liver disease owing to
decreased clearance of activated clotting factors present in
the complex), it should be used only in life-threatening
bleeding. Vitamin K1 administration (10–20 mg) may
improve the PT and aPTT in some patients and should be
tried. Desmopressin may shorten the bleeding time in some
patients with platelet dysfunction complicating cirrhosis, but
its efficacy has not been determined for control of bleeding
in liver disease. Treatment with desmopressin may exacer-
bate hyponatremia and hypotension and should be used with
caution. Antifibrinolytic agents have been advocated for
patients with evidence of accelerated fibrinolysis, but their
safety and efficacy in patients with advanced liver disease
have not been proved.
B. Disseminated Intravascular Coagulation—Patients
with DIC have diverse underlying conditions (see Table
17–5) and heterogeneous complications (both hemorrhagic
and thrombotic). Management should be directed primarily
at the underlying disorder. If serious bleeding is present, or if
an invasive procedure is required, factor replacement with
fresh frozen plasma to shorten the PT to within 2–3 seconds
of normal, cryoprecipitate to maintain fibrinogen levels
greater than 100 mg/dL, and platelet concentrates to raise the
platelets to greater than 50,000/μL should be attempted, but
these efforts may be compromised by short survival of the
hemostatic factors. Prophylactic administration of factors
and platelets in the absence of bleeding is not effective, and
coagulation factor concentrates should be avoided because
activated factors present in the concentrate may increase
intravascular coagulation.
Interruption of the primary pathologic coagulation of
DIC with heparin is controversial. DIC complicating acute
leukemia may be associated with marked bleeding owing to
impaired platelet production and may necessitate the use of
low-dose heparin (eg, 5–10 units/kg per hour) to achieve
adequate platelet counts with platelet concentrates, although
controlled studies have demonstrated that heparin adminis-
tration increases platelet transfusion requirements without
decreasing complications associated with DIC. Patients with
solid tumors and chronic DIC are more likely to experience
thrombotic complications than bleeding and may benefit
from long-term administration of heparin. Patients with
overt thromboembolism or purpura fulminans should be
treated with heparin, but because of an increased risk of
adrenal hemorrhage, the initial dose should be relatively low
and adjusted based on clinical response. Although secondary
fibrinolysis often contributes to the bleeding diathesis,
antifibrinolytic agents generally are contraindicated in the
presence of DIC because of the potential for unopposed
intravascular coagulation, which may result in significant
thrombotic complications. If marked symptomatic fibrinol-
ysis is present and there is no evidence of thrombotic com-
plications, however, antifibrinolytic therapy may be
attempted in combination with low-dose heparin to control
bleeding.
C. Circulating Inhibitors—Circulating inhibitors pose sub-
stantial difficulties in management of the bleeding patient.
As in patients with hemophilia A with factor VIII inhibitors,
strategies include high-dose factor replacement, decreasing
the titer of the inhibitor by immunosuppression or plasma-
pheresis, or using factors that bypass the need for the factor
being inhibited (eg, use of activated prothrombin complex
concentrates or recombinant factor VIIa). When high con-
centrations of fibrin and fibrinogen degradation products
are present, treatment of the underlying process (eg, sepsis-
induced DIC) is more useful than specific hemostatic ther-
apy. Myeloma proteins that inhibit fibrin polymerization
should be definitively treated with chemotherapy, but
plasmapheresis may be used as a temporizing measure.
Current Controversies and Unresolved Issues
Despite our understanding of the multiple processes that con-
tribute to bleeding in patients with liver disease, management
of bleeding has not been subject to careful clinical study to
determine optimal treatment strategies. Recombinant factor
VIIa (rFVIIa) has been shown to improve outcome from
acute variceal bleeding in a small preliminary trial, but its pre-
cise role in the management of bleeding in liver disease has
not been defined by clinical studies. The use of thrombopoi-
etin to improve thrombocytopenia is under investigation.
DIC is a syndrome that occurs in diverse clinical condi-
tions and is usually diagnosed on the basis of a combination
of laboratory abnormalities in the appropriate situation.
Several confirmatory laboratory tests have been proposed as
essential for the diagnosis, but the lack of a “gold standard”
combined with lack of standardization for the newer tests has
resulted in conflicting data on their usefulness. Management
of DIC is directed primarily against the underlying condi-
tion, but interventions to interrupt the state of pathologic
coagulation and fibrinolysis seem to be logical because these
processes may contribute significantly to the pathologic
state. Nevertheless, it has been difficult to demonstrate a clear
benefit of anticoagulation or antifibrinolytic therapy in any
situation complicated by DIC above and beyond that of
aggressive supportive care and treatment of the underlying
disease, with the possible exceptions of purpura fulminans
and thromboses associated with solid tumors. The use of
rFVIIa to treat bleeding associated with DIC may increase
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thrombotic sequelae and is not recommended by the manu-
facturer. However, control of refractory bleeding with rFVIIa
without thrombotic complications has been reported in sev-
eral patients with DIC. The use of activated protein C has
been shown to reduce hospital mortality in patients with
severe sepsis; however, this benefit was seen in patients both
with and without DIC. It is not known whether this benefit
is due to its anti-inflammatory properties, profibrinolytic
properties, or antithrombotic properties. Other strategies
aimed at interrupting important steps in the pathogenesis of
DIC such as the use of antithrombin concentrate and
inhibitors of the tissue factor pathway are under investiga-
tion for treatment of DIC. Antifibrinolytic therapy has
proven to be useful in the management of some of the inher-
ited coagulation disorders as an adjunct to factor replace-
ment. Because the acquired coagulation disorders are often
more complex, disruption of fibrinolysis has been attempted
infrequently. Potential complications of such therapy, such as
unmasking an underlying thrombotic diathesis, have limited
its role in the management of acquired coagulation disor-
ders. There is some evidence, however, that patients with
severe liver disease may have excessive fibrinolysis as a major
contributor to bleeding. Future studies to determine the effi-
cacy and safety of antifibrinolytic therapy are necessary
before it can be recommended.
 Inherited Platelet Dysfunction
ESSENT IALS  OF  D IAGNOS I S
 Lifelong history of easy bleeding.
 Prolonged bleeding time out of proportion to platelet
count.
 Normal platelet count or mild thrombocytopenia.
 Normal coagulation times.
General Considerations
Platelets are involved in multiple aspects of normal hemosta-
sis. Defects in platelet membrane constituents, granules,
metabolism, or coagulant function give rise to defective
adhesion, aggregation, secretion, or procoagulant activity
(Table 17–7). These disorders are generally rare, usually fol-
low autosomal recessive inheritance patterns, and result in
varying degrees of bleeding associated with prolongation of
the bleeding time or defective or absent platelet aggregation
in response to platelet agonists. The most severe defects have
onset in the neonatal period or in early childhood with
ecchymoses, epistaxis, and other mucosal bleeding, but
milder defects may be manifest only after surgery or trauma.
Thrombocytopenia is present in some platelet disorders and
may contribute to the bleeding tendency. Other congenital
abnormalities (eg, albinism) also may be present.
Clinical Features
A clinical history of lifelong bleeding, accompanied by a pro-
longed bleeding time in the presence of normal platelet
count (or mild thrombocytopenia), PT, and aPTT, should
suggest the possibility of an inherited platelet disorder. A
peripheral smear made from fresh non-anticoagulated blood
may uncover morphologic platelet abnormalities or absence
of platelet aggregation. Platelet aggregation studies using a
wide variety of platelet agonists (including ristocetin) are
helpful for identifying the specific defect. Confirmation of
the specific diagnosis may require specialized studies avail-
able only in research laboratories.
Differential Diagnosis
A prolonged bleeding time in the absence of a history of clini-
cal bleeding is unreliable as an indicator of platelet dysfunction
or as a predictor of future bleeding. In the presence of bleeding,
a prolonged bleeding time may suggest the diagnosis of vWD
or an acquired disorder of platelet function (eg, uremia, drug
therapy, cardiopulmonary bypass, or myeloproliferative disor-
ders) rather than an inherited defect. Mucosal bleeding, ecchy-
moses, and posttraumatic bleeding may result from severe
coagulation disorders, accelerated fibrinolysis, thrombocytope-
nia, or vascular injury or from multiple hemostatic defects.
Adult onset of a severe bleeding tendency makes the diagnosis
of an inherited disorder of platelet function very unlikely.
Treatment
Serious bleeding usually requires transfusion of normal
platelets. Alloimmunization to HLA antigens and to platelet-
specific antigens may result in refractoriness to platelet trans-
fusions, so efforts to decrease alloimmunization are
Function Disorder
Adhesion Bernard-Soulier syndrome (GP Ib deficiency)
von Willebrand disease.
Aggregation Glanzmann’s thrombasthenia (GP IIb/IIIa deficiency)
Afibrinogenemia∗
Secretion/
signal
transduction
Gray platelet syndrome (alpha granule deficiency)
Storage pool deficiency (delta granule defects)
Arachidonic acid pathway abnormalities
Defective calcium mobilization
Wiskott-Aldrich syndrome (defective cytoskeletal
regulation)
Procoagulant
activity
Decreased platelet factor III activity
Scott syndrome (asymmetry of platelet phospholipids)
∗Defect is extrinsic to platelet but affects platelet function, with
exception of platelet-type von Willebrand disease.
Table 17–7. Inherited disorders of platelet function.
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recommended (eg, limiting transfusions to life-threatening
situations, use of leukocyte-poor platelet preparations, or
administration of HLA-matched platelets). For unclear rea-
sons, some defects respond to therapy with desmopressin.
Antifibrinolytic agents (eg, aminocaproic acid or tranexamic
acid) may be useful for control of minor mucosal bleeding or
as adjuncts to platelet transfusions. Hormonal suppression of
menses is indicated for control of menorrhagia. Antiplatelet
agents are contraindicated, and surgical procedures should
be avoid whenever possible. Antifibrinolytic agents (eg,
epsilon-amino caproic acid and tranexamic acid) may be
helpful for controlling bleeding, as they do in inherited coag-
ulation disorders.
Current Controversies and Unresolved Issues
Optimal therapy of inherited platelet disorders is hampered
by the infectious risk of platelet concentrates and by the risk
of alloimmunization to HLA antigens and platelet-specific
antigens that renders further transfusions ineffective. The
risk of antibody formation is highest in patients with mem-
brane protein defects because of the presence of these pro-
teins on normal platelets. Bone marrow transplantation can
completely correct the bleeding tendency in patients with
inherited platelet disorders but remains experimental
because of potential lethal toxicity. Desmopressin releases
vWF and factor VIII from the endothelium, but it also may
shorten the bleeding time in some patients with a wide vari-
ety of platelet disorders independent of vWF and factor VIII
levels; its mechanism of action in these intrinsic platelet dis-
orders has not been established. Corticosteroid therapy prior
to surgery may improve hemostasis via an effect on vascular
integrity and may be indicated for control of bleeding in
patients with inherited platelet disorders who have no con-
traindications to steroid use.
 Acquired Platelet Dysfunction
ESSENT IALS  OF  D IAGNOS I S
 Mucosal bleeding, ecchymoses, or excessive surgical
bleeding in the absence of thrombocytopenia.
 Abnormal bleeding time.
 Normal coagulation times.
 Clinical condition or medication associated with platelet
dysfunction.
General Considerations
Acquired platelet dysfunction may result from defects in
platelet adhesion, aggregation, secretion, or procoagulant
function. Drugs, liver or renal disease, cardiopulmonary
bypass, antiplatelet antibodies, acquired vWD, dysproteine-
mias, and myeloproliferative or lymphoproliferative disorders
(acute and chronic) may be associated with impairment of
platelet function, as measured by the bleeding time or by
abnormal tests of platelet aggregation. The clinical impor-
tance of the laboratory abnormalities in these diverse clinical
conditions is not always clear. Bleeding depends not only on
the severity of the defect but also on the presence of vascular
injury and other hemostatic defects. Typical manifestations
reflect impaired platelet function with mucocutaneous
bleeding and excessive posttraumatic bleeding. Petechiae are
rare unless thrombocytopenia is also present. Spontaneous
soft tissue hematomas and joint bleeding are rare.
Thromboxane A2 is an important mediator of platelet
secretion and aggregation. Aspirin irreversibly acetylates and
inactivates cyclooxygenase, thus preventing the production of
prostaglandins, including thromboxane A2. Most individuals
who take aspirin will have a slight prolongation of baseline
bleeding time that may persist for several days, but marked
prolongation or clinical bleeding owing to platelet dysfunc-
tion is rare at doses used in most clinical situations, although
chronic use may be accompanied by easy bruising and
mucosal bleeding. Patients with other hemostatic defects,
however, may experience marked prolongation of bleeding
time and clinical bleeding if they take aspirin. Increased GI
tract bleeding is common in patients chronically taking high
doses of aspirin, but this is due to its irritant effect on the
mucosa rather than its effect on platelet function. The effect
of aspirin on bleeding following major surgery or invasive
procedures is controversial. While other nonsteroidal anti-
inflammatory agents reversibly inhibit cyclooxygenase, these
rarely prolong the bleeding time or induce clinical bleeding
even in patients with severe coagulation defects.
Dextran is used occasionally for its antiplatelet effect in
preventing postoperative deep vein thrombosis without
increasing postoperative blood loss. Ticlopidine and clopido-
grel are newer antiplatelet agents that inhibit ADP-induced
platelet aggregation and prolong the bleeding time, and these
occasionally may cause increased mucosal bleeding or bruis-
ing. Both agents appear to have irreversible effects on platelet
function, requiring 7 days for normal platelet function to
appear after withdrawal of the drugs (see Table 39–2).
Platelet glycoprotein IIb/IIIa inhibitors are used for treat-
ment of acute coronary ischemia, usually in combination
with anticoagulants or fibrinolytic agents, and work by pre-
venting fibrinogen-mediated platelet aggregation. β-lactam
antibiotics given at high doses for a prolonged period of time
may affect platelet function and can cause bleeding. However,
most patients with overt bleeding have multiple contributing
problems and can be managed without discontinuing the
antibiotic. Many other drugs have been linked to prolonga-
tion of the bleeding time but rarely result in clinical bleeding.
Renal failure is frequently associated with abnormal
platelet function, as measured by the bleeding time and by
platelet aggregation tests. Impaired platelet function appears
to result from biochemical alteration of intrinsically normal
platelets, although the precise mechanisms have not been
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elucidated. Severe anemia seen with renal failure can con-
tribute to prolongation of the bleeding time. Bleeding mani-
festations attributed to uremia include purpura, epistaxis,
and menorrhagia, but the risk of bleeding does not correlate
well with laboratory assessment of platelet function. With
adequate dialysis and generally improved care of uremic
patients in the past 25 years, bleeding may not be increased
significantly compared with those without renal failure.
Cardiopulmonary bypass induces both thrombocytope-
nia and transient platelet dysfunction. Platelet activation
while the platelets circulate through the bypass circuit results
in a state of functional “refractoriness” that usually reverses
within the first few postoperative hours. Multiple mecha-
nisms appear to be responsible for the observed changes
in platelet membranes, granule content, and functional
activity following bypass. Modest transient coagulation factor
deficiencies—owing mainly to hemodilution coupled with
heparin and protamine use—may result in prolongation of
coagulation times. Bleeding following cardiopulmonary
bypass therefore may result from multiple defects in hemo-
stasis, including inadequate surgical hemostasis.
Acquired hematologic disorders cause platelet dysfunc-
tion through production of intrinsically abnormal platelets
(eg, myeloproliferative disorders, myelodysplastic syn-
dromes, acute leukemias, or hairy cell leukemia), or through
production of abnormal substances that interfere with
platelet function (eg, immunoglobulins in myeloma or
Waldenström’s macroglobulinemia; rarely, immune-
mediated thrombocytopenia), or from abnormalities in vWF
(acquired vWD, seen in aortic stenosis, myeloproliferative
and lymphoproliferative disorders, collagen vascular dis-
eases, and angiodysplasia). Clinical bleeding is more often
the result of associated hemostatic defects or other hemato-
logic abnormalities, such as severe anemia, thrombocytope-
nia, marked leukocytosis, or hyperviscosity. Thrombotic
sequelae also may result from abnormal platelet function,
particularly in the myeloproliferative disorders.
Clinical Features
A. Symptoms and Signs—Mucosal bleeding, ecchymoses, or
excessive posttraumatic or surgical bleeding in the absence of
thrombocytopenia or abnormal coagulation times should sug-
gest the possibility of an acquired defect of platelet function.
B. Laboratory Findings—In most cases, the underlying
condition of the patient and medication use are obvious, and
minimal laboratory evaluation is needed to confirm the pres-
ence of platelet dysfunction. The bleeding time is a readily
available in vivo test of platelet function that will identify
most patients with significantly abnormal platelet function.
In vitro platelet aggregation studies require significant tech-
nical experience for reliable results and should be reserved
for patients with bleeding suggestive of platelet dysfunction
and an unexplained prolongation of the bleeding time—or a
very suggestive history of bleeding without prolongation of
the bleeding time. Bleeding time and platelet aggregation
studies are influenced by multiple factors, and while they are
useful for diagnosis in patients with significant bleeding, they
are not reliable indicators of the risk of future bleeding.
Differential Diagnosis
Inherited disorders of platelet function usually are readily dif-
ferentiated from acquired disorders by the presence of a long
history of bleeding and the absence of underlying conditions
associated with acquired platelet dysfunction. Mucosal bleed-
ing, ecchymoses, or excessive posttraumatic and surgical
bleeding may result from severe coagulation disorders,
thrombocytopenia, excessive fibrinolysis, vascular injury, or
multiple hemostatic defects. Prolongation of the bleeding
time may result from severe anemia, thrombocytopenia,
improper technique, or insignificant platelet dysfunction, and
in the absence of bleeding suggestive of platelet dysfunction,
it is not a reliable indicator of future risk of bleeding.
Treatment
Impaired platelet function in the absence of clinical bleeding
usually requires no specific therapy even when invasive pro-
cedures are performed. If bleeding is present, or if the nature
of an invasive procedure is such that any increased risk of
bleeding is unacceptable, a number of therapeutic options
are available depending on the underlying cause of the
platelet dysfunction. Withdrawal of aspirin or other suspect
drugs is usually adequate for management of drug-induced
platelet dysfunction. Desmopressin may be useful for man-
agement of bleeding in patients with a wide variety of disor-
ders of platelet function, including uremia, cardiopulmonary
bypass, and liver disease. Cryoprecipitate infusions and cor-
rection of severe anemia with red blood cell transfusions or
epoetin alfa (ie, erythropoietin), aggressive dialysis, and con-
jugated estrogens are other strategies for controlling bleeding
in uremic patients with platelet dysfunction. Aprotinin is a
plasmin inhibitor that reduces significant postoperative
bleeding following cardiopulmonary bypass and also may
decrease bleeding after liver transplantation.
Platelet transfusions are indicated in the treatment of
severe bleeding when platelet dysfunction is due to drugs,
cardiopulmonary bypass, or acquired intrinsic abnormalities
of platelets (eg, leukemias, myelodysplasias, and myeloprolif-
erative disorders) but are not helpful for management of
bleeding in uremia. Avoidance of aspirin and other
antiplatelet agents, correction of vascular defects, and treat-
ment of the underlying disease process are the most impor-
tant strategies for prevention and treatment of bleeding
associated with platelet dysfunction.
Current Controversies and Unresolved Issues
The bleeding time has enjoyed widespread use as a screening
test for patients requiring surgical procedures and as a diag-
nostic test in bleeding patients. The bleeding time may be
affected by technique, the site and depth of the incision, the
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presence of anemia, and characteristics of the supporting
connective tissues regardless of the functional status of the
platelets. A recent review of hundreds of studies of bleeding
time produced no convincing evidence that the bleeding
time is a useful predictor of bleeding in any clinical situation.
Its main value is in diagnosing conditions associated with
impaired platelet function, but even when platelet dysfunc-
tion is present, the bleeding time does not correlate well with
clinical bleeding.
Desmopressin acetate has proved to be useful in shorten-
ing the bleeding time in a wide variety of platelet disorders,
and it may decrease clinical bleeding as well. Conflicting
reports on its efficacy and a lack of understanding of its
mechanism of action in diverse diseases have limited its
widespread use. In addition, a few case reports have sug-
gested that desmopressin may contribute to thrombotic
complications, particularly in elderly patients with cardio-
vascular disease. Antifibrinolytic agents may prove to have a
role as adjuncts to other therapies for treatment of acquired
platelet disorders, but the potential for thrombotic complica-
tions must be appreciated when considering their use.
 Thrombocytopenia
ESSENT IALS  OF  D IAGNOS I S
 Mucocutaneous bleeding; petechiae in severe cases.
 Decreased platelet count.
 Absence of other hemostatic defects.
 Associated condition leading to thrombocytopenia.
General Considerations
Thrombocytopenia may result from decreased production,
increased destruction or utilization, or sequestration of
platelets in the spleen (Table 17–8). Decreased production
usually affects all hematopoietic cells and rarely results in
isolated thrombocytopenia. Mechanical destruction of
platelets is often accompanied by evidence of hemolysis with
anemia, reticulocytosis, and red blood cell fragmentation on
peripheral blood smear, as well as clinical manifestations of
the underlying disease process. Immunologic destruction of
platelets may occur as an isolated problem (eg, autoimmune
thrombocytopenic purpura) or may result from drugs, trans-
fusions, or disease states associated with the production of
autoantibodies (eg, chronic lymphocytic leukemia, systemic
lupus erythematosus, or HIV infection). Splenomegaly from
any cause may result in thrombocytopenia and is often
accompanied by anemia and leukopenia.
Clinical Features
The history and physical examination with attention to
bleeding symptoms, medication usage, splenomegaly, and
symptoms and signs of underlying disorders often will reveal
clues to the diagnosis.
A. Symptoms and Signs—Mucocutaneous bleeding is the
most common bleeding manifestation of thrombocytopenia.
Petechiae usually occur only with severe thrombocytopenia
and may reflect the platelet’s essential role in the mainte-
nance of endothelial tight junctions. Spontaneous soft tissue
hematomas and hemarthroses are distinctly unusual. The
risk of serious bleeding depends on the cause and severity of
the thrombocytopenia, the presence of other hemostatic
defects or vascular injury, and the condition of the patient. In
general, patients with thrombocytopenia owing to consump-
tion, destruction, or splenic sequestration are at less risk for
serious bleeding than patients with decreased production of
platelets because decreased platelet survival results in pro-
duction of a younger, more functional population of
platelets. The most feared complication of severe thrombo-
cytopenia is CNS hemorrhage, which is rare unless the
platelet count is less than 10,000/μL and there are other pre-
disposing factors, such as leukemic infiltration, marked
leukocytosis, or other vascular injury. Bleeding manifesta-
tions associated with various degrees of thrombocytopenia
are shown in Table 17–9.
B. Laboratory Findings—Review of the complete blood
count and peripheral blood smear is essential to evaluate asso-
ciated abnormalities in other blood cell lines and to exclude
the possibility of pseudothrombocytopenia owing to in vitro
platelet clumping in the presence of EDTA anticoagulant.
Other instances of artifactual thrombocytopenia may be due
to platelet satellitism around neutrophils or may occur when
many giant platelets are present that may not be counted as
platelets by automated cell counters. Isolated thrombocytope-
nia is most often the result of immunologic destruction of
platelets but may be found in some patients with mild hyper-
splenism, acute alcohol intoxication, or early acute leukemia
and in the rare patient with isolated amegakaryocytic throm-
bocytopenia. The presence of fragmented red blood cells sug-
gests the possibility of intravascular mechanical trauma to
cells, as seen with DIC, thrombotic thrombocytopenic
purpura–hemolytic uremic syndrome, eclampsia (ie, HELLP
syndrome), or mechanical prosthetic heart valves. Abnormal
white blood cells may indicate the presence of leukemia or
lymphoma. The combination of nucleated red blood cells and
immature white blood cells in the peripheral smear, a leuko-
erythroblastic picture, suggests the possibility of bone marrow
infiltration from myelofibrosis or metastatic carcinoma.
Macrocytosis and pancytopenia should suggest the possibility
of vitamin B12 or folate deficiency.
The PT and aPTT  should be determined to detect condi-
tions such as DIC or thrombocytopenia associated with liver
failure. Bone marrow biopsy and aspiration are useful for
evaluation of platelet production and should be performed
when the diagnosis is not certain or if confirmation of a spe-
cific diagnosis (eg, leukemia, aplastic anemia, or metastatic
carcinoma) is essential to proper management.
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Decreased Production Increased Destruction or Utilization
Marrow infiltration or replacement
Leukemia, lymphoma, metastatic carcinoma
Aplastic anemia 
Myelofibrosis
Granulomatous disease 
Toxic or environmental exposures 
Alcohol 
Radiation 
Chemotherapy 
Chemicals 
Thiazide diuretics 
Ineffective hematopoiesis 
Vitamin B12 or folate deficiency 
Myelodysplastic syndromes 
Paroxysmal nocturnal hemoglobinuria
Infections 
Viral: HIV, hepatitis, cytomegalovirus 
Fungal: histoplasmosis 
Acid fast organisms: M tuberculosis,
M avium-intracellulare.
Bacterial sepsis 
Acquired amegakaryocytic thrombocytopenia
Congenital thrombocytopenia
Thrombocytopenia–absent radius syndrome
Wiskott-Aldrich syndrome
May-Hegglin anomaly
Bernard-Soulier syndrome
Alport syndrome
Neonatal rubella or CMV infection
Maternal thiazide use
Mechanical
Abnormal heart valves 
Vascular devices 
Disseminated intravascular coagulation 
Vasculitis 
Cardiopulmonary bypass 
Thrombotic thrombocytopenic purpura 
Hemolytic uremic syndrome 
Renal transplant rejection 
Giant cavernous hemangioma (Kassabach-Merritt syndrome)
Fat embolism
Burns (>10% body surface)
Snake bite (crotalid)
Sequestration (hypersplenism, hypothermia) 
Massive transfusion 
Immunologic 
Drug-induced antibodies or immune complexes 
Systemic lupus erythematosus 
Antiphospholipid antibody syndrome 
Neoplastic diseases (chronic lymphocytic leukemia, 
Hodgkin’s disease) 
Posttransfusion purpura 
Neonatal alloimmune thrombocytopenia 
Viral-associated (HIV, infectious mononucleosis,
cytomegalovirus) 
Pregnancy 
HELLP syndrome (hemolysis, elevated liver enzymes,
low platelets associated with eclampsia) 
Autoimmune thrombocytopenia 
Probably immune 
Malaria 
Bacterial sepsis 
Artifactual thrombocytopenias: Anticoagulant-dependent platelet clumping, pseudothrombocytopenia, platelet
satellitism, giant platelets.
Table 17–8. Causes of thrombocytopenia.
Platelet count (per μL) Clinical manifestations 
>100,000 No increase in bleeding
50,000–100,000 Minimal bleeding even with surgery unless platelet dysfunction is present
30,000–50,000 Increased bleeding with surgery or trauma∗
20,000–30,000 Occasionally associated with easy bruising or other minor spontaneous bleeding∗
10,000–20,000 Epistaxis, petechiae, menorrhagia, gum bleeding
<10,000 Increased gastrointestinal blood loss, spontaneous life-threatening bleeding† (eg, intracranial hemorrhage, hematuria,
melena, hematemesis)
∗Minimal in patients with immune thrombocytopenia or other consumptive disorders.
†Life-threatening hemorrhage ususally occurs only with underlying vascular defect or if a second hemostatic defect is present
(including aspirin ingestion).
Table 17–9. Bleeding manifestations associated with thrombocytopenia.
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Differential Diagnosis
The finding of a normal platelet count in the presence of pal-
pable or nonpalpable purpuric skin lesions (eg, ecchymoses
or petechiae) should suggest the possibility of increased
intravascular pressure, abnormalities or injury to blood ves-
sels (eg, vasculitis), thromboembolic events (including septic
thromboemboli), decreased integrity of the microcirculation
and its supporting structures, or primary cutaneous diseases.
Severe coagulation disorders may result in mucocutaneous
bleeding but are easily distinguished from thrombocytopenia
by the presence of markedly prolonged coagulation times
and quantitatively normal platelets. Impaired platelet func-
tion and vWD should be considered when easy bruising and
mucosal bleeding are present and can be identified in most
cases by prolongation of the bleeding time in the absence of
thrombocytopenia. Abnormalities of coagulation or platelet
function rarely result in petechial skin lesions.
Treatment
The most important aspect of treatment is to reverse the
underlying disease process. Platelet transfusions should be
given only when the risk of bleeding and the probability of
efficacy are sufficient to warrant the potential risks of blood
component therapy. Prophylactic platelet transfusions are
indicated for patients with decreased production of platelets
with counts under 10,000/μL to prevent fatal CNS hemor-
rhage. When life-threatening bleeding is present or invasive pro-
cedures are required, platelet transfusions may be useful if the
platelet count is less than 50,000/μL and no alternative therapies
are available. When decreased platelet survival is present,
platelet transfusions are not likely to effect a sustained rise in
platelet count and should only be given if life-threatening bleed-
ing is present or if an urgent invasive procedure is required.
Platelet transfusions may be harmful in patients with throm-
botic thrombocytopenic purpura–hemolytic uremic syndrome
and heparin-associated thrombocytopenia and should be
avoided unless active, life-threatening hemorrhage is present.
Medications such as aspirin that impair platelet function
should be avoided when thrombocytopenia is present—with
the exception of thrombotic thrombocytopenic purpura, in
which antiplatelet agents may be indicated as part of therapy.
Correction of severe anemia may decrease clinical bleeding in
thrombocytopenic patients. Antifibrinolytic agents such as
aminocaproic acid or tranexamic acid may decrease mucosal
bleeding in chronically thrombocytopenic patients but should
not be used if there is evidence of thrombosis (eg, in DIC) or
hematuria. Alternatives to platelet transfusion for patients
with bleeding owing to thrombocytopenia are outlined in
Table 3–2.
Current Controversies and Unresolved Issues
Intravenous administration of human immunoglobulin
(IVIG) may rapidly increase the platelet count in patients with
immune-mediated thrombocytopenia. Its effect is postulated
to be due to competitive blockade of macrophage receptors
for immunoglobulin, although other mechanisms may be
important. Although it may rapidly increase the platelet
count, its usefulness as therapy for immune thrombocytope-
nia is limited by only transient efficacy combined with its
high cost in the face of a low risk of life-threatening bleeding
in patients with autoimmune idiopathic thrombocytopenia.
It is appropriate for use in patients with serious bleeding
with this disorder as a temporizing measure while other ther-
apies are being administered. Anti-D antibodies (RhoD
immune globulin) also may be useful in the management of
immune-mediated thrombocytopenia in patients who are
Rh-positive, presumably by a similar mechanism (antibody-
coated red blood cells block macrophage receptors). IVIG
has not been proven to be useful in treatment of thrombocy-
topenia owing to platelet alloimmunization.
Alloimmunization to platelet-specific antigen or HLA
antigens is a common sequela of repeated platelet transfu-
sions and limits the response to subsequent platelet transfu-
sions. For patients requiring long-term platelet support,
prevention of alloimmunization is desirable in order to pre-
serve the efficacy of transfusion therapy. Methods to mini-
mize platelet alloimmunization include reducing the total
number of all blood product transfusions, adhering to strict
criteria for transfusing platelets, removing the source of the
HLA sensitization (ie, white blood cells) before transfusion
of any blood product (by filtration or irradiation), and using
HLA-identical donors.
The optimal management of several conditions associ-
ated with thrombocytopenia is under active study. Treatment
of these conditions should be undertaken in consultation
with a hematologist to ensure accurate diagnosis and up-to-
date treatment.
APPROACH TO THE BLEEDING PATIENT
When approaching a patient with a suspected bleeding disor-
der, it is important to assess quickly the prior personal and fam-
ily history of bleeding, the pattern of bleeding, and the pattern
of laboratory abnormalities. If the personal or family history is
suggestive of an inherited bleeding disorder, the apparent
inheritance pattern, bleeding manifestations, and laboratory
abnormalities should suggest the most likely diagnoses. If the
personal and family histories are negative, defective hemostasis
is most likely acquired, although some of the milder inherited
disorders of hemostasis may not be manifested until significant
trauma or surgery occurs later in life. The pattern of bleeding
may suggest the nature of the hemostatic defect (Table 17–10),
and the pattern of laboratory abnormalities (Table 17–11) will
help to localize defects in the hemostatic system.
CURRENT CONTROVERSIES & UNRESOLVED
ISSUES
Gastrointestinal Hemorrhage
For more than a century, critically ill patients have been
observed to have a high rate of GI hemorrhage. Preventive
strategies emerged to decrease this complication, including
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the use of antacids, histamine-2(H2) receptor blockade, pro-
ton pump inhibitors (PPIs), and mucosal protective agents.
However, trials of these therapeutics have yielded conflict-
ing results, with some studies showing a benefit in selected
high-risk patients (eg, patients with mechanical ventila-
tion, hemostatic defects, or prior GI hemorrhage), others
showing an increase in hospital-acquired pneumonia and
complications related to drug interactions, and others
demonstrating no difference in any clinical outcome. Until
this issue is resolved, preventive therapy with mucosal protec-
tant agents (eg, sucralfate), H2 blockade, or PPIs can be con-
sidered for patients identified to be at high risk for bleeding.
Underlying hemostatic defects should be treated according to
the general principles discussed earlier. The use of nons-
teroidal anti-inflammatory drugs (NSAIDs) and low-dose
aspirin increases the risk of GI bleeding independent of their
effects on platelet function. When Helicobacter pylori–associ-
ated ulcer is identified, long-term treatment with omeprazole
or eradication with antibiotics can decrease the risk of recur-
rent bleeding associated with aspirin or NSAIDs.
Gastroesophageal variceal hemorrhage is the most serious
form of GI hemorrhage, with 30% mortality observed with
first episodes. Varices occur in the setting of severe liver disease
so that—in addition to mechanical problems—coagulation
abnormalities, quantitative and qualitative platelet defects, and
excessive fibrinolysis contribute to bleeding. Management of
acute variceal bleeding requires GI specialists who can diag-
nose and treat varices endoscopically (eg, ligation, sclerosis,
or balloon tamponade) but also includes medical therapy
with vasoactive agents such as beta-blockers, nitrates, vaso-
pressin, and somatostatin analogues (eg, octreotide and
vapreotide). When these approaches fail, transjugular or sur-
gical shunting may be required to control bleeding.
Perioperative Bleeding
Preoperative evaluation of hemostasis should include
medical history with attention to adequacy of hemostasis—
spontaneous bleeding or bruising or unexpected bleeding
Pattern of Bleeding Possible Disorders 
Ecchymoses and mucosal
bleeding; petechiae 
Thrombocytopenia or platelet
dysfunction
von Willebrand disease
Severe coagulopathies
Spontaneous hemarthroses, soft
tissue hematomas 
Hemophilia A and B, other severe 
coagulopathies
Posttraumatic or surgical bleeding Thrombocytopenia or platelet
dysfunction
von Willebrand disease
Coagulopathies
Impaired vascular integrity
Inadequate surgical hemostasis
Massive injuries
Generalized oozing from mucosal, 
venipuncture, surgical sites
Consumptive coagulopathies, DIC
Excessive fibrinolyis
Severe thrombocytopenia or 
platelet dysfunction
Table 17–10. Approach to the bleeding patient by pat-
tern of bleeding.
Table 17–11. Approach to the bleeding patient by pattern of screening laboratory abnormalities.
Abnormal Test Possible Defects 
PT only Factor VII deficiency (inherited, vitamin K deficiency, warfarin effect) or inhibitor
aPTT only∗ Factor XII, HMW kininogen, prekallikrein, XI, IX, or VIII deficiency or inhibitors to these factors; lupus anticoagulant
PT and aPTT Deficiency or inhibitor of factor X, V, II (prothrombin), fibrinogen
Multiple factor deficiencies (liver disease, DIC, consumptive coagulopathies, vitamin K deficiency, high dose warfarin effect)
Bleeding time prolonged Platelet dysfunction or thrombocytopenia, improper technique
All screening tests normal Other coagulation abnormalities:
Factor XIII deficiency
Excessive fibrinolyis
Paraproteinemia
Vascular defect (including inadequate surgical hemostasis)
Supporting tissue abnormality
∗Deficiencies of factor XII, HMW kininogen, prekallikrein, and lupus-type inhibitors prolong the aPTT but do not cause bleeding.
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after dental extractions or prior surgical procedures suggests
the presence of an underlying hemostatic defect. Medical ill-
nesses such as liver or renal disease, myeloproliferative disor-
ders, and paraproteinemias predispose patients to excessive
postoperative bleeding. In the absence of symptoms of a
bleeding disorder or such medical illnesses, the value of rou-
tine laboratory screening has been questioned. Most postop-
erative bleeding results from surgical or technical problems
and not from hemostatic defects. The PT and aPTT are not
sensitive enough to detect mild defects and, when abnormal
in a patient with no previous bleeding history, may not accu-
rately predict the risk of bleeding. Whether any laboratory
screening should be done depends also on the type of
planned procedure (ie, minor versus major, use of cardiopul-
monary bypass, neurosurgical procedures, etc.). Table 17–12
outlines suggested laboratory screening prior to surgery. If
abnormalities in screening tests are detected, further evalua-
tion should be done to define the precise abnormality.
Intraoperative hemostasis with ligature, cautery, and top-
ical thrombogenic substances (eg, fibrin glue or topical
bovine thrombin) is essential to prevent postoperative bleed-
ing. In the postoperative period, excessive bleeding may be
due to a hemostatic defect that was not detected by the
screening tests. Mild coagulation factor deficiencies may not
prolong the aPTT, particularly if other factors are elevated
(eg, factor VIII increases in acute inflammatory states and
may mask mild deficiency of other factors). Preoperative use
of aspirin or other antiplatelet drugs may increase postoper-
ative bleeding; if bleeding is severe and the bleeding time is
prolonged, desmopressin or platelet transfusions may be
required for control of bleeding. Surgery on the prostate
gland or uterus may be associated with localized hyperfibri-
nolysis with excessive bleeding. Antifibrinolytic therapy with
aminocaproic acid can be considered for control of bleeding
(5-g loading dose followed by 1 g/h intravenously or orally
until bleeding has stopped), although there is some risk of
thrombi developing in the ureters (following prostate surgery)
that are resistant to lysis. Acute DIC may occur for many rea-
sons following surgery, or decompensation of previously
compensated DIC may develop as a result of tissue factor
release during surgery (Table 17–13).
Acute renal failure owing to hypotension, massive blood
loss, or medications can result in platelet dysfunction, which is
exacerbated by anemia. Posttransfusion purpura with throm-
bocytopenia may occur in previously sensitized individuals.
The use of intraoperative bovine thrombin as a hemostatic
agent may precipitate the development of antibodies to throm-
bin and factor V. There does not appear to be any significance
Bleeding History Type of Surgery Recommended Laboratory Tests
No suggestive history Minor (dental, skin biopsy) None
No suggestive history Major Platelet count, aPTT
Possible bleeding history Major, bypass pump PT, aPTT, platelet count, bleeding time; if normal, factor XIII assay, euglobulin clot lysis time
Positive bleeding history Minor or major Same as above; if negative: thrombin time, factor assays for VIII, IX, XI, alpha2-antiplasmin
assay, post-aspirin bleeding time
Table 17–12. Preoperative laboratory screening.
Sepsis
Hypotension
Acute hepatic necrosis
Release of bone marrow thromboplastins
Liver injury (drugs, hypotension, blunt or penetrating trauma)
Tissue factor release during surgery
Peritoneovenous shunting
Use of cell saver device with excessive suction
Release of tissue factor from placenta
Abruptio placentae
Amniotic fluid embolism
Septic abortion
Placenta previa
Retained dead fetus
Trauma
Fat embolism
Brain injury
Extensive soft tissue injury
Burns
Decompensation of chronic (compensated) DIC
Dissecting aortic aneurysm
Kasabach-Merritt syndrome
Cancer
Infusion of activated clotting factors
Prothrombin complex concentrates
Recombinant activated factor VII
Table 17–13. Causes of postoperative DIC.
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to the antithrombin inhibitor; however, factor V inhibitors
may cause bleeding. Factor VIII inhibitors also may develop
postoperatively; the mechanism for this has not been defined.
Hetastarch, a plasma volume expander, may cause persistent
coagulation abnormalities, particularly in elderly patients,
those with preexisting hemostatic defects, or with prolonged
use. If bleeding is severe, plasmapheresis to remove these large
molecules may be required to control bleeding.
When postoperative bleeding is encountered, immediate
evaluation with history (to uncover preexisting risks and med-
ication use) and laboratory testing (ie, PT, aPTT, and platelet
count) should be done. Medical treatment of hemostatic
defects will depend on the specific abnormalities identified. If
history and screening laboratory tests are unrevealing, consid-
eration should be given to reexploration of the surgical site to
identify adequacy of surgical hemostasis.
Perioperative management of patients with inherited
bleeding disorders requires preoperative collaboration
among the surgeon, anesthesiologist, hematologist, and
blood bank to ensure that optimal hemostasis is achieved
during and after surgery. The details of therapy will depend
on the nature of the specific disorder, the type of surgical
procedure, and whether any additional medical complica-
tions are present.
Posttraumatic Bleeding
In the setting of massive trauma, multiple pathophysiologic
processes contribute to severe bleeding, including multiple
vascular defects, massive transfusion with dilution of coagu-
lation factors and platelets, DIC with acceleration of fibrinol-
ysis, and hypotension. The presence of coagulopathy
following trauma increases the risk of mortality. Severe coag-
ulation disturbances associated with trauma may result in
adrenal hemorrhage, which can further exacerbate hypoten-
sion. Certain types of injuries are particularly associated with
DIC: fat embolism, brain injury, extensive soft tissue injury,
and extensive burns. Pelvic ring fractures are associated with
massive blood loss, often hidden owing to tracking of bleed-
ing up into the retroperitoneal space. Control of bleeding in
such circumstances may be difficult, even with aggressive
blood product support—with fresh-frozen plasma, platelets,
red blood cells, and cryoprecipitate. rFVIIa has been used to
treat massive hemorrhage in trauma patients with some suc-
cess, but evidence supporting its use is primarily anecdotal.
Further studies are necessary to determine which patients are
most likely to benefit from rFVIIa and at what dose it should
be administered.
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Psychiatric Problems
Stuart J. Eisendrath, MD
John R. Chamberlain, MD
ICUs provide the most advanced technology available to
patients with the most serious medical and surgical illnesses.
Perhaps as a consequence, these facilities are often associated
with some of the most stressful psychiatric conditions within
the hospital. Indeed, some physicians have jokingly referred
to the ICU as the “intensive scare unit.” These conditions in
ICUs may affect both patient and staff. This chapter will
describe some of the significant problems.
Most patients entering the ICU will attempt to manage
the stress of their stay with their characteristic coping mech-
anisms. Some regression generally occurs, however, as most
patients experience stressors such as fear of death, enforced
dependency, and potential permanent loss of function.
Separation from family and the loss of autonomy that
accompanies medical treatment in the ICU frequently lead to
further psychologic regression. They may try to cope with
stress by suppressing their feelings, using humor to laugh at
stressful aspects of their situation, or trying to anticipate a
return to good health. If these techniques fail, the individual
may turn to more primitive mechanisms such as projection,
passive-aggressive maneuvers, acting-out behavior, and gross
denial of illness. All this takes place during a time when the
patient must deal with serious and usually multiple medical
problems.
A number of clinical syndromes may develop as a result
of the stressors inherently associated with occupancy of a bed
in the ICU. This discussion will focus on several that may
adversely influence recovery. Delirium, the so-called ICU
psychosis, generally is not due to psychological stress alone
but develops in association with altered brain function.
Anxiety may occur at any time during the patient’s stay in the
ICU—entry, midpoint, or discharge. Depression also may
occur at any point during the patient’s stay but most often
occurs after the immediate threat to life has been dealt with
and the patient must contemplate the subacute prognosis
and ultimate outcome of the disease. Finally, we will discuss
how the ICU environment affects the staff working there.
 Delirium
ESSENT IALS  OF  D IAGNOS I S
 Waxing and waning of consciousness.
 Disorganized thinking.
 Perceptual disturbances such as visual hallucinations.
 Disorientation.
General Considerations
Early reports from ICUs gave rise to the diagnosis of an ICU
syndrome characterized essentially as a delirious state with
psychotic features such as hallucinations. It was believed to
be due to the stress an ill individual felt in a foreboding envi-
ronment with little privacy, lack of sleep, and sensory over-
load. Whether or not this syndrome actually existed as a
specific entity, current research indicates that delirium
occurring in the ICU is most likely due to factors similar to
those patients experience on general medical and surgical
wards—with the difference that ICU patients may have more
severe reactions because of their more severe illnesses.
Stress may play some role in producing delirium, but it is
typically only a contributing one. Other factors that alter
brain function are usually the primary etiologic agents. The
critical care physician should not automatically attribute
delirium to stress. Remembering that delirium is an organic
dysfunction of the CNS will facilitate the search for likely
causes and the provision of appropriate treatment. This
aggressive approach is justified given the serious impact of
delirium on morbidity and mortality in hospitalized
patients. Studies have shown that patients suffering an
episode of delirium have an increased risk of death, a longer
hospital stay, and a greater need for subsequent nursing
home placement. There are at least three broad hypotheses
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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relating to the production of delirium. Any one or any com-
bination of these factors may cause delirium in a particular
patient.
A. Increased Central Noradrenergic Production—Drug
or alcohol withdrawal states are the most common condition
producing delirium in the hospital and probably also the
most common condition responsible for increased nora-
drenergic discharge. Locus ceruleus–controlled production
of brain catecholamines is believed to play a central role in
this type of delirium.
B. Dopamine and Cholinergic Systems—Imbalance of
brain dopamine and cholinergic systems can be recognized
in central anticholinergic syndromes produced by atropinic
agents. These may produce a relative excess of dopaminergic
activity, giving rise to an agitated delirium. This hypothesis
also provides a framework for understanding how
dopamine-blocking agents such as haloperidol may act by
restoring the relative balance between dopaminergic and
cholinergic systems that is disturbed in delirium. Delirium-
producing agents such as the amphetamines, which cause a
shifting of the balance toward the dopaminergic side, also
can be better understood in this framework.
C. Toxic Causes of Delirium—A third framework for
understanding delirium involves the environment brain cells
operate in. Side effects of medications or endotoxins associ-
ated with bacterial infections can affect neuronal function-
ing. Similarly, conditions such as hyperthermia or hypoxia
can disturb functioning throughout the CNS. Many of the
preceding abnormalities are believed to affect the midbrain
particularly; this may, in turn, lead to fluctuations in the
reticular activating system with alterations in level of conscious-
ness and the ability to attend to stimuli in the environment—a
key feature of many cases of delirium.
D. Multifactorial Features—In the ICU there are typically
numerous factors that play a role in producing delirium. A
patient with asthma and pneumonia provides an example—
with fever and hypoxia as well as high levels of circulating
corticosteroids and catecholamines. Although single causes
should be sought diligently, it is unusual to be able to iden-
tify and correct just one causative factor of delirium.
Clinical Features
The clinical criteria for delirium in the ICU setting consists
of a number of signs and symptoms. Typically, the patient
has a waxing and waning of consciousness—may be somno-
lent at one moment and highly alert and agitated a short time
later. The patient’s ability to attend to external stimuli fluctu-
ates over time. Delirious patients usually have disorganized
thinking manifested by rambling or incoherent speech.
Patients frequently have perceptual disturbances such as mis-
perceptions of real objects (illusions) or frank hallucinations.
Patients usually have disorders in normal sleep-wake cycles and
altered psychomotor behavior (either agitation or retardation).
Patients also typically have disorientation to time, place, and
situation. Memory impairment, when present, is generally
global for both recent and remote events. Delirium usually
develops within hours to days. The presence of delirium sig-
nifies primarily organic brain dysfunction and is not a man-
ifestation of psychological distress alone.
The signs and symptoms listed in the preceding para-
graph are useful in making a clear-cut diagnosis.
Unfortunately for that purpose, however, many ICU patients
present only some of the criteria and may require ongoing
vigilance. Indeed, one of the keys to diagnosis in these
patients is repeated observations over time. The waxing and
waning of consciousness so common in delirious patients
requires serial monitoring because a patient may appear
quite lucid at one moment and quite confused a half hour
later. Nursing staff often have the best data on mental status
because of their continuing contact with the patients.
The physician should examine specifically for the presence
of delirium. This involves performing some type of specific
cognitive assessment such as the Folstein Mini Mental Status
Exam. However, intubated patients can be difficult to assess
with this instrument. Newer diagnostic instruments such as
the Cognitive Test for Delirium (CTD) can be very useful in
this setting. This instrument was developed for use in critical
care settings and reliably distinguishes patients with delirium,
dementia, and acute psychiatric illness. This type of examina-
tion tests the patient’s ability to attend to stimuli, concentrate
on a task, comply with simple memory requests, demonstrate
language capabilities through auditory comprehension, and
show orientation to time and situation. More important, this
type of test allows the examiner to detect cognitive deficits
that otherwise would go unrecognized. For example, psychi-
atric consultation may be sought for a patient who is poorly
compliant with the medical regimen. Many of these patients
prove to be suffering from delirium and have significant
memory deficits that make compliance impossible—they
cannot remember instructions for 30 seconds.
The patient may appear quietly confused and in a daze.
This type of delirium may be easily missed because the patient
presents no behavioral problem. Some delirious patients, on
the other hand, present behavioral problems ranging from
pulling out catheters and lines to biting or striking members of
the staff. These patients appear agitated, fearful, and restless.
They may be hallucinating and intensely involved in their psy-
chotic states. One physician described his state of mind during
his stay in the ICU as follows: “I saw a vulture flying over me.
I worried about any drop of blood spilling onto the sheets
because I knew that would bring the vulture down for the
attack.” This physician had been fearfully watching the ceiling
for several days but never told the doctors or nurses because
“they couldn’t do anything, and they’d think I was crazy.”
Many delirious patients resort to primitive psychological
coping mechanisms. They may exhibit massive denial of any
medical problem or externalize their problem as being the
fault of somebody else rather than of their illness. Delirious
patients often project anger about their helplessness onto
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their caregivers. This gives rise to paranoid ideation about
caregivers trying to poison or otherwise harm them. Other
delirious patients—like the doctor in the preceding example—
experience hallucinations that are often threatening. These
hallucinations usually are visual and occur without any exter-
nal stimulus. Many patients will have visual illusions that
involve a misperception of actual external stimuli. For exam-
ple, one patient was convinced that the intravenous standard
in his room was actually a person poised to attack him.
Differential Diagnosis
In the critically ill patient—especially an intubated patient,
for whom communication is most difficult—delirium may
appear to be similar to other conditions.
A. Anxiety—Anxiety occurs quite frequently in the ICU. In
some instances, anxiety may occur in patients who have
delirium. Individuals with cognitive processing impairment
may be quite difficult to reassure. Thus many patients may be
anxious in the ICU, but only some will also have delirium—
although the majority of delirious patients will experience
anxiety and fear. Patients without delirium do not have the
significant cognitive impairment and deficits in reality test-
ing (such as hallucinations) so common in delirium.
B. Underlying Psychosis—ICU patients may have an
underlying psychosis (eg, schizophrenia) that can be confused
with delirium. Schizophrenic patients rarely have visual hal-
lucinations. Visual hallucinations usually are present owing to
an organic cause that requires investigation. Schizophrenic
patients who have paranoid delusions generally have well-
formed ones that are fixed over months and years. Delirious
patients, on the other hand, have rapidly developing delu-
sional beliefs that shift over hours to days. Most schizophrenic
patients have a history of psychiatric treatment and neurolep-
tic medications. Delirious patients generally do not have such
a history. Furthermore, schizophrenic patients typically have
onset of illness by the early to middle twenties, characterized
by a progressive decline in function. In contrast, delirium
often affects older patients and causes a precipitous decline in
mental status and functioning.
C. Neuroleptic Malignant Syndrome—Schizophrenic
patients—or any patient who has received a neuroleptic
medication—are at risk for development of neuroleptic malig-
nant syndrome, characterized by altered mental status, auto-
nomic instability, and extrapyramidal symptoms that are often
severe (eg, lead-pipe rigidity). This syndrome can develop par-
ticularly with high-potency neuroleptic medications when
the individual also suffers from complicating conditions such
as fever and dehydration. Diagnosis in these patients is often
assisted by elevated creatine phosphokinase (CPK) levels,
myoglobinuria, and decreased serum iron levels.
D. Depression—The subdued, quiet delirious patient may be
mistaken for a depressed one. The depressed patient, however,
usually has the depressive view of the world associated with
that disorder along with symptoms such as a sense of worth-
lessness, guilt, and global pessimism. In some instances, small
test doses of dextroamphetamine (eg, 2.5 mg twice daily) may
allow the clinician to differentiate depressive and delirious
patients. The depressed patient may become less depressed
after medication, whereas the delirious patient usually
becomes more agitated. A past psychiatric history of depres-
sive disorder also may help to differentiate the disorders.
E. Personality Disorder—It is not unusual for staff to apply
the pejorative label personality disorder to a patient who fails
to comply with their requests. Whenever such a diagnosis is
contemplated, one should seek confirmation from family or
friends. Personality disorders represent longstanding pat-
terns of maladaptive behavior. They do not develop acutely,
although they may be exacerbated by the stress of illness.
They may emerge in patients after the immediate threat to
life has passed. Psychiatric consultation is often helpful in
confirming this diagnosis.
F. Dementia—One way of conceptualizing the difference
between dementia and delirium is by applying the analogy of
acute and chronic renal failure. Delirium represents acute
cerebral insufficiency, whereas dementia is typically a
chronic condition. Dementia syndromes may represent a
variety of conditions (eg, multi-infarct dementia or
Alzheimer’s disease) characterized by generalized diminu-
tion of intellectual functioning. Most dementias—except for
the subcortical ones, such as in Parkinson’s disease—show
some evidence of cortical dysfunction such as aphasia or
apraxia. Dementia syndromes develop over months or years
rather than hours or days. The patient’s family should be
consulted to clarify baseline mental functioning.
A key finding is that delirious patients typically have a
waxing and waning of consciousness and the ability to attend
to stimuli; deficits in demented patients generally are fixed
throughout the day until nightfall, when “sundowning” may
occur. It is quite common to see dementia patients who have
preserved remote memory, whereas in delirium, all forms of
memory may be impaired. It is unusual for dementia
patients to suffer hallucinations, whereas delirious patients
frequently have hallucinations.
Electroencephalograms may aid in the differentiation of
delirium and dementia. The former often show generalized
slowing, whereas the latter do not.
Treatment
A. Establish the Cause—The key to treatment of delirium
is identification of its cause or causes whenever possible.
Since delirium is usually an acute process, a vigorous investi-
gation of reversible causes should be undertaken, much as
one would investigate the cause of acute renal failure and
attempt to correct it as rapidly as possible. Delirium should
be regarded as an example of acute cerebral failure that is asso-
ciated with significantly increased morbidity and mortality.
There are studies in which patients with delirium had a
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markedly higher mortality rate than other patients (8% ver-
sus 1%; likelihood ratio = 2.3), a higher rate of admission,
and a higher rate of institutionalization. Hospital stays often
are prolonged by an average of 7 days in delirious patients.
There are many causes of delirium. The most common
causes in the ICU are listed in Table 18–1. Withdrawal states
are among the most common causes of delirium in the gen-
eral hospital and always should be considered in assessing the
patient. In some instances, the patient may conceal or be
unable to provide information about drug or alcohol use.
Family and friends will be able to help to establish this his-
tory. In some instances, considerable probing may be neces-
sary. For example, one postoperative vascular surgery patient
denied the use of alcohol or drugs; persistent questioning,
however, revealed that she had increased her usual daily 0.5-mg
alprazolam dosage fourfold in the month prior to surgery
because of anxiety. When she entered the hospital, this med-
ication had been discontinued. Two days later, she had a
florid delirium that responded rapidly to alprazolam. The
benzodiazepines are the prototypical agents for the treat-
ment of alcohol and sedative withdrawal. They are safe in
large doses, prevent seizures, and are well tolerated. An
important feature for ICU use is that they are available in
oral, parenteral, and sublingual formulations.
Medications given in the ICU frequently can produce sig-
nificant psychoactive effects. Table 18–2 lists a number of
drugs that have been established as having these effects.
Switching medications certainly is one of the easiest changes
to make in trying to manage a delirious patient.
Other causes such as hypoxia and hypoperfusion need to be
reversed before improvement from delirium can occur.
Delirium may be the first sign of an infectious process and
should suggest that possibility when no other cause is discov-
ered. For example, a postoperative patient who develops delir-
ium without any identifiable cause may be suffering from a
wound abscess that only becomes apparent several days later.
B. Nonpharmacologic Management—Once one or more
causes are identified, the primary goal of treatment is to
reverse the disorder. In a significant number of cases of delir-
ium, no specific cause can be identified; in others, the identi-
fied cause cannot be reversed easily (eg, an asthmatic on
high-dose corticosteroids). In these instances, symptomatic
treatment may be required. Family may be enlisted to spend
time at the bedside to provide an orienting stimulus. Other
environmental measures may include providing a clock, cal-
endar, and soft music. Staff should attempt to provide ade-
quate day-night orientation and allow the patient to sleep at
night as much as possible. Four-hour periods that allow for
all stages of sleep may be the most beneficial.
C. Pharmacologic Management—For many patients with
delirium, the aforementioned measures will not be enough.
Medications become indicated when behavioral control is
necessary or when distress is severe. For example, a quietly
delirious patient suffering from frightening hallucinations is
a candidate for pharmacotherapy.
1. Management of withdrawal syndromes—A number
of principles must be considered in initiating therapy. If a
withdrawal state is present, the appropriate agent to cover the
withdrawal should be given as soon as possible. Sufficient
medication must be given to abort the withdrawal process
and keep it from reemerging. Alcohol withdrawal is the most
common of these conditions. A frequent mistake is to under-
dose with a benzodiazepine early in the withdrawal process
and then try to catch up with a full-blown delirium later.
Early substantial doses of long-acting agents such as
Drug or alcohol withdrawal or intoxication 
Medication effects (eg, corticosteroids, cimetidine, lidocaine) 
Hypoxia  
Hypoperfusion  
Infections (eg, systemic or central nervous system, HIV) 
Structural lesions (eg, subdural hematomas)  
Metabolic disorders (eg, electrolyte abnormalities, hypercalcemia,
hyperglycemia)  
Ictal or postictal states  
Postoperative states  
Fat emboli  
Dehydration  
Sleep deprivation  
Environmental stress  
Pulmonary embolism 
Table 18–1. Common causes of delirium in the ICU.
Acyclovir Fluoroquinolone antibiotics  
Amiodarone Ganciclovir 
Amphetamines Histamine H2 blockers  
Amphotericin B Interferon alfa 
Anticonvulsants Isoniazid  
Antidepressants Ketamine  
Antihistamines Ketonazole  
Atropine and other Levodopa  
anticholinergics Lidocaine  
Barbiturates Methylphenidate  
Benzodiazepines Metoclopramide  
Beta-adrenergic blockers Metronidazole 
Cimetidine Nonsteroidal anti-inflammatory drugs
Corticosteroids Opioids 
Cycloserine Procaine derivatives
Cyclosporine Propafenone
Digitalis glycosides Quinidine
Dronabinol Trimethoprim-sulfamethoxazole
Epoetin alfa (erythropoietin)
Modified from: Drugs that cause psychiatric symptoms. Med Lett
Drugs Ther 1988;40:21–24. 
Table 18–2. Drugs that may cause delirium in the ICU.
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diazepam may provide timely control. However, lorazepam
may be preferred in patients with liver disease because its
metabolism (via glucuronide conjugation) is less affected in
such individuals.
2. Management of delirium of unknown cause—
a. Benzodiazepines—When the cause of delirium is not
known but withdrawal from sedatives or alcohol is suspected,
one might consider a pharmacologic probe by giving a ben-
zodiazepine such as 1–4 mg lorazepam. If the patient’s condi-
tion worsens, that essentially rules out alcohol and most
benzodiazepine withdrawals. A different course of pharma-
cotherapy then must be pursued. In addition, these agents are
preferred for the agitation present with anticholinergic over-
dose or when there is a need to raise the seizure threshold.
Relatively short-acting agents with no active metabolites, such
as lorazepam, are preferred for this application.
b. Haloperidol alone or with lorazepam—Haloperidol is
often administered intravenously even though the intravenous
form is not approved by the Food and Drug Administration
(FDA). Before initiating haloperidol, some cardiovascular con-
siderations must be addressed (discussed below). Initial dosage
depends on the age and size of the patient. A small elderly
woman may benefit from 0.2 to 0.5 mg haloperidol every
4 hours. A younger 70-kg man may start with 1–2 mg every
2 hours or even higher doses. A more agitated patient should
receive larger doses, and some studies have advocated an initial
infusion of 5–10 mg followed by a continuous infusion at a rate
of 5–10 mg/h. This medication has a mean distribution time of
11 minutes and a half-life of 14–17 hours. If the first dose fails
to produce significant improvement, the dose should be
repeated at 30-minute intervals to allow time for distribution
to occur. The second dose is usually twice the first dose. If
monotherapy fails to produce the desired effect, one may add
0.5–1 mg lorazepam. This combination has been found to
improve symptom control while decreasing the side effects of
treatment. If the patient remains agitated 30 minutes follow-
ing the addition of lorazepam, one may give doses of
haloperidol up to 5 mg and lorazepam 0.5–2 mg at 30-minute
intervals until control is established. In many instances, con-
trol of delirium can be achieved with 5–30 mg haloperidol
and 2–4 mg lorazepam. Some patients may require amounts
substantially above these levels. Doses up to 975 mg haloperi-
dol in a 24-hour period have been reported.
Once control is established, approximately half the first
24-hour total dosage can be given on the following day in
equally divided doses. Each subsequent day’s dosing is
reduced by half until further dosing is no longer necessary.
The goal, once symptom control is achieved, is to taper the
patient to the minimally required dose. Many cases of delir-
ium will clear within a few days, particularly when the cause
has been reversed.
When giving intravenous haloperidol, several points
need to be considered. Generally speaking, intravenous
haloperidol imposes a much lower risk of extrapyramidal
side effects than oral or intramuscular forms. The reason is
not completely clear. It may be that the intravenous route
allows brain receptors to bind with different forms of the drug.
It is possible also that most patients who receive intravenous
haloperidol have some form of central anticholinergic process
by virtue of their delirium that provides a protective effect
against extrapyramidal reactions. Nonetheless, when giving
haloperidol, the clinician should continue to monitor the
patient for adverse reactions, which include dystonias, akathisia,
and neuroleptic malignant syndrome.
The incidence of cardiovascular side effects from
haloperidol is very low. Haloperidol has been found to pro-
long the QT interval and has been linked with rare episodes
of torsade de pointes, ventricular fibrillation, and sudden
death. These effects generally seem to occur with high doses
of the medication and have led to recommendations for
establishing a baseline ECG and subsequent monitoring of
the QT interval. Additional recommendations are to monitor
serum magnesium and potassium. Most cases of hypoten-
sion with haloperidol have been in association with hypov-
olemia. Administering the medication in a slow infusion over
5–10 minutes may be helpful in preventing hypotension, so
intravenous pushes should be avoided.
c. Newer agents—Newer agents such as the atypical
antipsychotics (including risperidone, quetiapine, and olan-
zapine) are receiving increased attention in the treatment of
delirium. They have fewer neurologic side effects (eg,
extrapyramidal symptoms) than the typical antipsychotics
(eg, haloperidol), particularly in elderly and seriously med-
ically ill individuals who are most at risk for delirium. In one
prospective, double-blind trial, haloperidol and risperidone
were equally efficacious in the treatment of delirious
patients. In a small open-label trial, low doses of risperidone
(average maintenance dose of 0.75 mg/day) improved cogni-
tive and behavioral symptoms of delirium. Olanzapine was
compared with haloperidol in a randomized, prospective
trial. While both groups demonstrated similar clinical
improvement and a lessened need for benzodiazepine seda-
tion, 6 of 45 patients treated with haloperidol were found to
have extrapyramidal symptoms, whereas no patients treated
with olanzapine developed extrapyramidal or other side
effects. Quetiapine has been found, in small studies, to be
effective for the treatment of delirium and well tolerated
when used at low doses. One  drawback to atypical neurolep-
tic use is that only olanzapine and ziprasidone are currently
available in immediate-release parenteral formulations.
d. Other pharmacologic interventions—When the combi-
nation of haloperidol (or another antipsychotic) and
lorazepam fails to achieve control, additional interventions
may be necessary, including sedation (with opioids, propo-
fol, barbiturates, or benzodiazepines), pharmacologic paral-
ysis, and mechanical ventilation. These measures, however,
do not enhance the patient’s sense of control, and if sedation
is inadequate, they can be quite terrifying to the patient.
A newer agent for sedation and analgesia in the critical
care patient is dexmedetomidine, an α2-agonist. Reported
advantages of this medication are minimal interference with
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respiration and the ability for patients to be aroused easily. It
is currently approved for infusions up to 24 hours in adults.
D. Social and Psychologic Management—A key consider-
ation in managing delirium involves the psychological
aspects. The patient’s family often has major concerns about
the prognosis for mental recovery. The physician should
reassure both the family and the patient that the condition is
usually reversible and that return to baseline mental func-
tioning can be expected. Empathically telling the patient that
the physician understands the confusion the patient feels
may convey a real sense of hope. Encouraging the patient to
report any strange phenomena such as hallucinations may
make the patient feel more at ease. Similarly, informing the
family that accusations and delusional ideas brought forth
during an episode of delirium have no real meaning is obvi-
ously useful.
Current Controversies and Unresolved Issues
Delirium is such a heterogeneous entity that many issues
remain to be delineated by prospective studies. Molecular
mechanisms for delirium and the role of neurotransmitters
need to be established. We still do not know what the optimal
medications are for controlling delirium, the maximum daily
dosage of haloperidol and other agents, and whether patients
really benefit from large doses of medications or if the prac-
tice helps the staff more than the patient. The use of atypical
antipsychotic medications in the elderly also requires further
study because the available information suggests that use of
at least some of these agents in elderly patients with demen-
tia may be associated with an increased risk of cerebrovascu-
lar adverse events. Other questions relate to possible
preventive measures, whether psychological factors alone can
cause delirium in the absence of organic factors, and a possi-
ble final common pathway for all cases of delirium.
 Depression
ESSENT IALS  OF  D IAGNOS I S
 Depressed mood.
 Feelings of worthlessness and inappropriate guilt.
 Negative thinking.
 Recurrent thoughts or wishes for death or suicide.
General Considerations
Depression occurs in 20–42% of the medically ill. Any
patient with a medical illness severe enough to require
admission to the ICU faces a number of psychological issues,
including real and potential losses. For example, the patient
with myocardial infarction must deal with the threat to life as
well as the potential loss of future health and normal function.
These losses are enough to produce depressive symptoms in
many patients and sad feelings in most patients. An individual
undergoing major surgery must deal with the loss of bodily
integrity and the threat of death. These actual and potential
losses may produce a sense of helplessness in many patients.
Patients are usually placed in unfamiliar surroundings
with little sense of autonomy. These conditions may generate
a depressive view of the world. Cognitive distortions can
develop so that the individual begins to make mistakes in
judgment such as forecasting catastrophe or interpreting
innocuous events negatively. Patients may begin to think of
themselves as worthless and feel they are a burden to family
and friends. Motivation to participate in medical care may be
impaired. In an interesting study, healthy volunteers were
admitted to an ICU to investigate the psychological changes
associated with that environment. Subjects developed
decreased vigor as well as increased confusion and fatigue
that were attributed solely to the ICU environment. The sub-
jects also were found to engage in introspection and to have
a negative view of the hospital environment. In another
study of patients undergoing coronary artery bypass graft-
ing, those with longer stays in the ICU were at risk for greater
levels of depressive symptoms postoperatively.
This depressive picture is often associated with biologic
changes. Neurotransmitter levels and receptor function
change significantly. Serotonin and noradrenergic systems
have substantial alterations. Endocrine dysfunction in both
the pituitary-adrenal and thyroid axes may become dis-
turbed. Even immune function may be altered.
Clinical Features
Patients in the ICU who have clinically significant depression
can by assessed by general criteria for depression. These cri-
teria, however, have only limited usefulness in the ICU
patient because of the context. For example, neurovegetative
symptoms are of limited value; many ICU patients have
appetite and sleep disturbances, but that does not mean they
are depressed.
Nonetheless, some signs and symptoms of depression in
ICU patients can be used to make a diagnosis of depression.
The presence of a depressed or lowered mood is a hallmark.
Irritability, particularly when out of character for an individ-
ual, is another marker of depression. Diminished interest in
activities such as interacting with family or viewing televi-
sion often indicates depression. Pronounced thoughts about
death or wishes for it in the form of suicidal ideation also
indicate depression.
Additional criteria can be used in assessing a patient for
depression. One group of factors involves the depressive view
of the world a depressed patient develops. For example, see-
ing oneself, one’s doctor, and one’s future in negative terms
correlates positively with a diagnosis of depression. Feelings
of guilt, worthlessness, and hopelessness are also common in
depression. Feeling helpless means the individual feels
unable to help himself or herself get better; feeling hopeless
means the individual does not believe anyone else can help
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either. The physician always should ask a depressed patient
about any suicidal ideation. As a practical matter, very few
ICU patients have the means to commit suicide in the unit,
but knowing the patient’s feelings about suicide may help the
physician to gauge the level of depression.
In addition to these cognitive factors, assessing the
patient’s self-esteem often serves as a clue to depression. The
patient who is grieving normally usually feels sad in reaction
to losses sustained or anticipated. The grieving individual
may appear sad but still maintain a proper sense of self-
esteem: “I’m okay, really—I’m still a good person despite my
medical problem.” The depressed individual, on the other
hand, feels worthless and useless: “I’m washed up—a burden
to my family.”
Another way of identifying the depressed individual
engages the physician in using his or her own feelings as an
assessment tool. Depressed patients often generate a feeling
of depression in their physicians; they also may produce a
sense of aversion so that the physician is eager to get away
from the bedside. An appropriately grieving patient, on the
other hand, usually generates a sense of sympathy and sad-
ness in the physician. Thus the physician who is sensitive to
his or her own responses to a patient may be able to confirm
a diagnosis of depression quite readily.
Differential Diagnosis
The key differential diagnosis in a patient who is being con-
sidered for a diagnosis of depression is appropriate grief or
organic mood disturbances. A number of conditions may
produce depressive symptoms. It is completely normal for an
individual to experience sadness and some emotional with-
drawal in response to a loss. Disease often produces a sense
of loss for many individuals, and it may be difficult for the
physician to differentiate appropriate grieving from a clinical
depression. One should consider the degree of dysfunction as
an indicator of depression. Thus, when a patient’s emotional
state is seriously interfering with medical recovery or compli-
ance with medical care, some form of treatment should be
offered. Depression becomes a likely diagnosis when the
patient makes a decision to terminate treatment for a disease
whose prognosis is favorable.
Certain medical conditions frequently produce depressive
symptoms. Examples are Cushing’s disease, hypothyroidism,
and pancreatic carcinoma. Virtually all the organic causes
described in the section on delirium also can produce
depressive states. In fact, a smoldering delirium may be mis-
taken for depression unless cognitive function is assessed.
Some hypoxic individuals, for example, will appear lethargic
and depressed. Medications such as β-blockers, corticos-
teroids, digoxin, cimetidine, levodopa, diazepam, and antihy-
pertensives may produce a depressive picture. Some
dopamine antagonists such as prochlorperazine or metoclo-
pramide produce psychomotor retardation or akathisia that
may mimic depression. A recent study indicated that the
presence of depression at baseline in patients with acute
coronary syndromes predicted failure to return to work and
not feeling better at 1 year. This study provided support for
the assessment of depression in identifying individuals at risk
for poorer outcomes.
Treatment
A key point in the treatment of depression is for the physi-
cian to recognize that depression is a painful and serious
condition that should not be considered “normal.” Just
because a knifing victim might be expected to exsanguinate
and experience a fall in blood pressure, medical treatment is
not withheld; similarly, the identification of depression war-
rants appropriate interventions. In serious cases of depres-
sion, there may be a substantial risk of failing to provide
treatment. A depressed patient is poorly compliant and
poorly motivated to participate in recovery—or may fail to
take adequate nutrition and participate in other aspects of
recovery such as being weaned from a ventilator.
The initial treatment of depression in the ICU should
emphasize psychosocial measures. To the extent possible, the
patient should be permitted to feel some control over what is
happening. Nurses should offer the patient a choice when-
ever possible. For example, the patient can be asked whether
or not pain medication is needed, whether it is time to be
moved, etc. Asking the patient to help plan the day’s bath and
hygiene schedule is very helpful. Encouraging the family to
visit as much as possible also may help to counter depression.
The physician can help to reduce depression by providing
realistic encouragement and support.
If these measures fail to reduce the depression, psychiatric
consultation is indicated followed by pharmacologic treat-
ment. The consultant will inquire about the patient’s psychi-
atric history, particularly to see if some specific antidepressant
medication has been successful in the past. If so, that drug
should be used. If the patient has not had a prior trial of anti-
depressant, a psychostimulant such as dextroamphetamine or
methylphenidate should be considered unless there is a med-
ical contraindication such as tachyarrhythmia. With the usual
starting dextroamphetamine dosage of 2.5 mg at 7 a.m. and
1 p.m., there is little risk of side effects. In an occasional
patient, there may be some increase in blood pressure or
pulse, but these are usually minimal and do not require stop-
ping the trial. If the patient fails to respond to the preceding
dosage, on the next day one can double the dosage to 5 mg
given twice. The maximum dosage is 15 mg twice daily, but
this level is rarely necessary. The medication is given early in
the day so as not to interfere with sleep. Many people have the
misconception that dextroamphetamine may worsen appetite
because it has been used in the past for dieting; in depressed
patients, however, it generally improves appetite.
Dextroamphetamine has the advantage of being essen-
tially free of side effects in most patients; some may have
slight tremor or anxiety. A rare patient may develop persecu-
tory feelings with this drug, but typically only at much higher
doses. The tremendous advantage of dextroamphetamine is
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the rapidity of response when it is successful. The physician
often can observe a beneficial effect 1–2 hours after the first or
second dose. Many patients report improved mood, energy,
appetite, and will to live. The response rate varies in different
studies from 48 to 80% improvement in depressive symptoms.
A number of other agents are effective and well tolerated
for the treatment of depression. An example is fluoxetine,
which was the first serotonin reuptake inhibitor released in
the United States. Although fluoxetine has essentially no
anticholinergic or blood pressure effects, it elevates many
other drug plasma levels by displacing them from their
plasma protein binding sites. This makes fluoxetine an unde-
sirable medication for most ICU patients. Other newer
agents have been developed that appear well suited for use in
ICU patients. Citalopram, sertraline, and venlafaxine are
effective antidepressants that share fluoxetine’s lack of blood
pressure and anticholinergic effects but are associated with
fewer drug interactions. Bupropion has little blood pressure
or anticholinergic effect, but in its immediate-release form it
has been associated with a higher incidence of seizures than
other antidepressants. All these agents have the limitations of
being available only in oral formulations and taking 1–4
weeks to have an effect.
Tricyclic antidepressants can be considered for ICU
patients, but like the newer agents mentioned briefly earlier,
they take 1–4 weeks to show an effect. Their anticholinergic
and quinidine-like side effects also can cause problems.
Tricyclic antidepressants also have the disadvantage of pro-
ducing marked α-adrenergic blockade, which can have trou-
blesome effects on blood pressure. If treatment with a
tricyclic is elected, nortriptyline is the best choice because it
has the least effect on postural hypotension and only modest
anticholinergic effects. It also has a clear therapeutic window
of maximum effectiveness of 50–150 ng/mL.
Current Controversies and Unresolved Issues
Depression may be hard to differentiate at times from normal
grief and sadness, so it would be useful to have a biologic
marker for the condition. Several years ago there was excite-
ment about using the dexamethasone suppression test as a
marker for major depression. Although this was of important
research significance, it has not been useful clinically because
50% of patients will suppress but still have the disorder.
Therefore, the test is of very little significance in trying to
decide on a diagnosis. It will be important for further research
in depression to develop biologic markers the clinician can use.
Another important area for further research involves the
identification of subtypes of depression so that specific phar-
macotherapy can be tailored appropriately. There have been
attempts to differentiate depression by global measures of
neurotransmitter levels. Cerebrospinal fluid and urinary lev-
els of methoxyhydroxyphenylglycol (MHPG) and serotonin
have been used to predict response to serotonergic and nora-
drenergic antidepressants. These efforts have not yet pro-
duced clinically useful applications.
 Anxiety & Fear
ESSENT IALS  OF  D IAGNOS I S
 Overt terror and panic.
 Hypervigilance.
 Fear of being alone.
 Autonomic arousal.
General Considerations
Anxiety is the unpleasant feeling associated with an unknown
internal stimulus and is out of proportion to the threat from
the environment. Fear, on the other hand, is the same feeling
state but derived from a known external stimulus and propor-
tionate to the threat. Obviously, in the ICU these two feelings
are hard to distinguish, and they will be discussed here under
the term fear, which refers to both entities.
Fear is often prominent when the patient first enters the
ICU because of awareness of a substantial threat to his or her
continued existence resulting from the medical or surgical
problem that necessitated the admission. The ICU patient
may be reacting not only to the fear of death but to other
unspoken fears as well. The patient may be anxious about
how the family is responding to the illness and may have con-
cerns about ability to return to work or may harbor unreal-
istic ideas about the nature of the problem and the treatment
required. For example, some patients jump to the conclusion
that they will need open-heart surgery for any type of cardiac
problem. The patient also may associate the illness with a
loved one who had a similar problem. For example, one 59-
year-old man admitted to the coronary care unit feared he
would not survive his heart attack because his father had
died of one at the same age. Asking the patient about whom
he or she knows who had the same medical problem or treat-
ment may reveal a significant factor contributing to the
patient’s fear. A recent study indicated that the risk of devel-
oping posttraumatic stress disorder was linked with anxiety
during the time in the ICU. The study further found that
perceived social support was negatively correlated with
symptoms of posttraumatic stress disorder.
Fear and anxiety may produce significant physiologic
changes. Catecholamine and corticosteroid levels may fluctu-
ate along with anxiety levels. It has been demonstrated that
the perception of physical or emotional stress results in the
activation of several brain regions—serotonergic, cate-
cholaminergic, and perhaps cholinergic nuclei. These path-
ways are apparently then integrated by unknown mechanisms
into the hypothalamus. The end result of this complex
response is the secretion of glucocorticoids. Evidence also has
accumulated for a variety of links between the serotonergic
region and the hypothalamic-pituitary axis that may underlie
the connection between stress and mood. A recent study
found that the risk of cardiocirculatory complications was
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decreased by a factor of 2 in periods of unrestrictive visiting
policies in an ICU. This also was correlated with a greater
reduction in anxiety score and less of an increase in thyroid-
stimulating hormone during the course of admission. A
restrictive visiting policy was associated with a nonsignifi-
cant increase in mortality rate. The authors concluded the
unrestrictive visiting policy might decrease cardiovascular
complications through lessened anxiety and a more desirable
hormonal profile.
Clinical Features
The physician can observe fear in many guises in the ICU.
Patients with a past history of generalized anxiety, panic, or
“nervous” disorders should be expected to have increased
fearfulness in the ICU. Some patients will demonstrate their
terror and panic overtly. Others may appear hypervigilant,
constantly scanning the environment. Others will talk exces-
sively or seek the presence of the nurse so as not to be left
alone. Some patients will fight going to sleep because of fear
of dying while asleep. Blood pressure and heart rate may be
elevated as the autonomic accompaniments of fear ensue.
Some patients may exhibit their fear by major denial of
illness. These individuals may attempt to demonstrate their
good health by exercising in the coronary care unit. Others
will try to sign out of the hospital against medical advice.
Fear is perhaps recognized most easily in the patient being
weaned from the ventilator “before I’m ready.” These patients
often show stark terror as the ventilator settings are reduced.
In such cases, anxiety may grossly interfere with medical
treatment.
Furthermore, anxiety related to experiences in the ICU
does not dissipate at the door on departure from the unit.
Patients may continue to have nightmares and experience
episodes of hypervigilance and panic even after returning to
home care, thus suggesting the diagnosis of posttraumatic
stress disorder (PTSD). Research is still needed to help pre-
dict which individuals are at the greatest risk for develop-
ment of this syndrome. Some studies have linked its
development to adverse experiences in the ICU. One study
found that the presence of delusional memories of events in
the ICU—as opposed to factual memories—indicated an
increased risk for PTSD-related symptoms and panic follow-
ing discharge from the ICU.
Differential Diagnosis
Anxiety and fear can be confused with the agitation of delir-
ium. The delirious patient, however, will have significant cog-
nitive impairment that is usually not present in the anxious
patient. The physician should continuously assess the anxious
patient for organic factors that could contribute to anxiety.
Medications such as corticosteroids, theophylline, and lido-
caine can produce anxiety and fearfulness. Medical conditions
such as hypoxia, pulmonary emboli, pheochromocytoma,
Cushing’s disease, and early drug or alcohol withdrawal may
have anxiety as a major symptom (Table 18–3).
Treatment
The best treatment of anxiety is prevention. Psychologically
preparing a patient for surgery can have a beneficial effect.
These efforts, as well as those offered by the patient’s primary
physician, can be very effective in preventing anxiety. Similarly,
the physician can intervene postoperatively to minimize
patients’ anxiety. One study suggests that playing a brief tape-
recorded message from the surgeon—explaining that surgery
went well, giving an orientation to the ICU, and reassuring the
patient about early recovery—markedly reduces anxiety.
Nonetheless, for many patients, fear and anxiety will
develop in the ICU. The first step in treating the fearful
patient involves exploring precisely what the patient is most
fearful about. This information may be obtained directly
from the patient who is prepared properly and trusts the
physician. The physician can start by saying, “Most people
have some worries or fears in this situation. What are yours?”
This approach normalizes the presence of fears and makes it
easier to talk about them. Whatever the patient brings up as
a concern should be explored.
Pulmonary disorders 
COPD  
Pulmonary embolus  
Asthma  
Hypoxia  
Drugs  
Drug withdrawal  
Drug intoxication (eg, amphetamines, cocaine)  
Infections  
Tuberculosis 
Brucellosis 
Cardiac disorders 
Mitral valve prolapse 
Paroxysmal atrial tachycardia 
Subacute infective endocarditis 
Angina 
Endocrine and metabolic disorders 
Insulinomas 
Carcinoid tumors 
Pheochromocytomas 
Hypoglycemia 
Thyroid disease 
Hypocalcemia 
Porphyria 
Cushing’s disease 
Neurologic disorders 
Multiple sclerosis 
Akathisia 
Temporal lobe epilepsy 
Table 18–3. Medical disorders commonly associated
with anxiety.
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Another valuable technique for helping a patient deal
with fear is reframing the patient’s view of the situation. For
example, one 45-year-old African-American wanted to sign
himself out of the coronary care unit, saying he refused to
believe that he had had a bad heart attack. The doctors
repeatedly tried to warn the patient of the risks of not accept-
ing hospital treatment. The patient responded by doing 10
one-handed push-ups. Finally, psychiatric consultation was
requested. The psychiatrist realized that frightening the
patient only escalated his fear and increased his need to deny
the fear by signing out against advice. The psychiatrist sug-
gested to the patient that it took a strong man to put up with
the bed rest and testing the cardiologists wanted. The con-
sultant suggested that the patient could prove his strength in
this way. In essence, the patient no longer had to equate stay-
ing in the unit as a loss of strength and self-esteem. With this
reframing of his medical care, the patient accepted the
remainder of his treatment without difficulty.
In some ICUs, the psychiatric consultant or liaison nurse
may teach relaxation with the aid of audiotapes. Some
patients may be receptive to learning self-hypnosis. These
techniques may help by restoring the patient’s sense of con-
trol over the environment. These techniques also may be
helpful in the patient being weaned from the ventilator.
If psychosocial interventions do not work or are not
available, medication can be used. Lorazepam is the antianx-
iety drug of choice. Its intermediate half-life (10–20 hours) is
long enough to prevent the withdrawal syndrome that can
occur with shorter-acting agents but not so long that the
drug tends to accumulate. Lorazepam is metabolized in a
one-step conjugation and so can be used in patients with
liver disease. For most patients with mild to moderate anxi-
ety, the dosage of lorazepam is 1–2 mg (depending on age
and weight) every 4–6 hours. For more severe anxiety, one
may double these dosages. Antidepressants such as sertraline
and citalopram also can be useful against anxiety. As with
their use in depression, however, they can take up to 4 weeks
to have a significant effect and must be given orally. When
anxiety is extreme and interfering grossly with the patient’s
care, a shift to antipsychotic medications has been advocated.
Although haloperidol has been advocated for this purpose,
newer agents also should be considered. A recent report
described the use of risperidone for patients with irritability
and hostility. The authors noted that this agent caused fewer
side effects than haloperidol, imposed fewer risks than ben-
zodiazepines, and was effective with a more rapid onset than
antidepressants.
Current Controversies and Unresolved Issues
There is a continuing quest for the anxiolytic agent that gives
relief without clouding the sensorium or producing trouble-
some withdrawal states. For example, triazolam is a popular
sedative benzodiazepine in some regions because it has a
short half-life that makes it unlikely to produce a hangover.
The short half-life, however, has a major disadvantage in
that it may lead to withdrawal syndromes the next day, leav-
ing the patient anxious until the next dose is given. Until the
neurotransmitter systems involving various agents such as
γ-aminobutyric acid are further elucidated, the quest for the
ideal agent will have to continue.
 Staff Issues
The ICU staff considered as a group has many psychological
features similar to those found in individual health
providers. Many doctors and nurses, for example, bring cer-
tain psychological motivations to their work. They may feel a
strong need to save and rescue their patients. They also may
demand perfection from themselves. In some sense, whether
it is consciously realized or not, the ICU staff may make the
same demand as a group. This may be manifested in attempts
to save the unsalvageable patient and reluctance to let any
patient die. On the other hand, many patients have unclear
prognoses, and these may be particularly challenging for the
staff. Research suggests that the most difficult patients for
staff to care for are those with multisystem failure and a poor
prognosis.
A useful equation for conceptualizing a staff ’s self-esteem
is the following:
In this equation, how staff feel about themselves is equal to
what realistic achievement they can accomplish “divided by”
their expectations. The equation represents a shorthand way of
viewing how the relationship between expectations and
achievements influence self-esteem. In instances where the
expectation is one of omnipotence, unless the achievement is
perceived as a perfect performance, the staff will end up feel-
ing like a failure. In this equation, we should note that the real-
istic achievement is relatively fixed within a narrow range
accomplished by most competent staff. The variable that can
be adjusted most easily is the denominator—expectations. If
staff are successful in reducing this value, the staff can feel
much more satisfied with their accomplishments. This issue is
highlighted when staff have to deal with a dying patient. When
staff are able to shift their expectations away from an unrealis-
tic omnipotent fantasy of saving the patient, they can shift to a
more realistic one such as providing a comfortable, dignified
death. Such a goal is much more easily accomplished.
Identifying Staff Problems
Staff issues often can be identified in staff attitudes toward
patients. For example, following a period in which there had
been an unusually high number of deaths in an ICU, an 80-
year-old patient was admitted to the unit with pneumonia.
She required intubation and ventilation. Although her infec-
tion was controlled rapidly, she had difficulty being weaned
from the ventilator. Staff nurses began to voice concerns such
Self-esteem
realistic achievement
expectatio
=
ns
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as, “Why are we putting such effort into an 80-year-old
woman? She won’t make it anyhow.” When those concerns
were raised in a staff meeting, other staff members pointed
out that the patient had been living independently until her
pneumonia developed and that her only current problem
was one of pulmonary mechanics that should clear with
time. This discussion helped the staff to perceive that their
view of the patient had been unfairly pessimistic, probably
related to the several recent deaths that had led to a sense of
inadequacy, helplessness, and group depression. They left the
meeting with a clearer understanding of what they could
accomplish with the patient. She eventually was weaned from
the ventilator and returned to her home.
Interventions
There are various approaches to helping the ICU staff deal
with the stress of working with critically ill patients. Units
emphasizing a culture of cooperation and communication
have a reduced length of stay, increased staff longevity, and a
higher perceived quality of care. These observations reinforce
earlier recommendations to schedule regular staff meetings,
including in the invitation a psychiatrist or social worker
familiar with the unit. Ideally, both physicians and nursing
staff should attend this meeting. Staff should raise any feel-
ings they have about patients or ward situations. These feel-
ings can be clarified, shared, and discussed with others.
Identification of exaggerated expectations or other problems
such as group depression can be investigated and resolved.
Junior staff can gain broader perspectives from more experi-
enced staff. These meetings also can facilitate communica-
tion and humor, which are important ways for a staff to cope.
They can help staff deal with the multisystem patient with a
poor prognosis. Staff can become more comfortable realizing
that they are doing the best job possible with this difficult
population and accepting death if it becomes clear that the
patient will have to die despite the best critical care that could
be offered. Recent studies have found that clinicians perceive
conflict in up to 78% of cases requiring decision making for
critically ill patients. The conflict was perceived to occur with
equal frequency between staff and family members and
within the staff. While the presence of conflict was not always
felt to be detrimental, it can be disruptive and lead to morale
problems. Thus meetings in which such issues can be identi-
fied and discussed will benefit the ICU team.
In addition to staff meetings, there are a host of practical
interventions that can help staff deal with the stress of work-
ing in an ICU. Nursing and physician staff can be encouraged
to take adequate time off for restorative recreation and fam-
ily life. Some institutions schedule fewer but longer shifts in
order to provide longer stretches of time off. House staff
might be given the afternoon off on the day following a night
on call—which is probably the single most important vari-
able in reducing house staff distress. Providing strong med-
ical and nursing directors is extremely helpful for staff
dealing with the ambiguities of complex illnesses. Having the
services of an ethicist and a chaplain available on a regular
basis can be an invaluable support strategy. Another measure
to prevent the development of burnout in ICU staff is creat-
ing a system in which staff rotate between the ICU and other
settings to remove staff from the constant stress of the ICU.
Current Controversies and Unresolved Issues
The difficulty of working in an ICU undoubtedly will persist.
As technological advances allow staff to sustain life in the
face of severe, previously untreatable conditions, the ethical
and philosophical tensions these situations give rise to are
likely to increase. Helping the staff to cope with these stres-
sors will remain an ongoing challenge.
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Care of the Elderly Patient
Shawkat Dhanani, MD, MPH
Dean C. Norman, MD
The elderly are a highly heterogeneous group, and the physi-
cal and medical heterogeneity increases with age. Individuals
over 65 years of age—with or without chronic diseases—vary
widely in their physical, behavioral, and cognitive functions.
Any clinician can relate the “Tale of Two Octogenarians” seen
in practice on the same day: the end-stage patient afflicted
with Alzheimer’s disease seen at the nursing home and the
vigorous retiree seen after his golf game for monitoring of his
historically well-controlled hypertension.
Physiologic rather than chronological age is a better pre-
dictor of the health status of the elderly. An abrupt decline in
physical function or any organ system is almost certainly due to
disease and not due to “normal aging.” Therefore, symptoms in
the geriatric population should not be attributed automatically
to old age, and it is important to look for potentially reversible
causes of symptoms. Moreover, treatable conditions should not
be undertreated for fear of side effects of medication.
Improvement or maintenance of functional status is the
major goal of medical care in the geriatric population.
Functional disability occurs faster and takes longer to correct
in the elderly, necessitating early preventive measures. Active
efforts should be made to maintain functional level even dur-
ing intensive care. Even small changes in function can make
large differences in the quality of life. For example, regaining
the ability to oppose the thumb to other fingers may enable a
geriatric patient to become independent in feeding.
Prevention of iatrogenic diseases is also important. For exam-
ple, close attention should be paid to prevent the develop-
ment of pressure ulcers. A pressure ulcer can develop in just
few hours, and the mortality rate of those who develop the
lesions in the first 2 weeks of intensive care has been reported
to be as high as 73%. Other iatrogenic problems in the ICU
include aspiration pneumonia, sepsis, GI bleeding, delirium,
drug toxicity and interactions, and renal insufficiency.
Multiple concurrent illnesses, cognitive and sensory
impairments, age-related changes in physiology and phar-
macodynamics, increased vulnerability to delirium, and
complications from immobility make management of acute
illness in the elderly a clinical challenge for all physicians and
other health care providers who care for patients in this age
group.
 Physiologic Changes with Age
The Aging Heart
Heart disease is the leading cause of death in people over
75 years of age and the fourth most prevalent chronic disease
in the elderly. Nearly 30% of elderly people have some abnor-
mality affecting the heart. Moreover, occult cardiac disease can
cause marked functional impairments in otherwise apparently
healthy elderly people. Coronary atherosclerosis increases
exponentially with age and, in the elderly, can present as heart
failure, pulmonary edema, arrhythmias, or exercise intoler-
ance rather than as angina or obvious myocardial infarction.
In healthy subjects, the resting heart rate does not change
with age, but the maximum heart rate with exercise decreases
with age (Table 19–1). It can be calculated by the following
formula: 208 – (0.7 × age). Age-related changes in collagen
and elastin contribute to progressive stiffness and loss of
recoil of elastic tissues. In the systemic arteries, this process
contributes to an increase in systolic blood pressure. Systolic
pressure rises approximately 6–7 mm Hg per decade, but
diastolic pressure changes little with age and even may fall
starting in the sixth decade. In addition, the systolic pressure
may be underestimated by the cuff sphygmomanometer in
the elderly. Resistance to blood flow leads to increased left
ventricular wall tension and compensatory left ventricular
hypertrophy. The myocardium is also affected by changes in
collagen and elastin that cause stiffness of the left ventricle
that can result in diastolic dysfunction. The left ventricular
filling rate during early diastole declines markedly with age
(approximately a 50% reduction between age 20 and age 80).
Enhanced active filling in late diastole during atrial contrac-
tion compensates for decreased passive diastolic filling, and
this explains the vulnerability of older persons to congestive
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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heart failure when atrial fibrillation or flutter occurs.
Decreased filling also makes the elderly more vulnerable to
small decreases in venous filling with volume loss or when
given opioids, diuretics, or positive-pressure ventilation. On
the other hand, systolic function is relatively preserved in the
healthy elderly.
Despite these disturbances, cardiac output at rest remains
relatively constant across the life span. During low- and
medium-intensity exercise, increases in stroke volume com-
pensate for the lower heart rates observed in the elderly. This
increase in stroke volume with exercise is the result of an
increase in end-diastolic volume by as much as 30% (Frank-
Starling law). However, with high-intensity exercise, a decline
in cardiac output is observed owing largely to the age-related
decline in maximum heart rate. This hemodynamic profile is
strikingly similar to that observed in younger patients who
exercise in the presence of β-adrenergic blockade. Since
β-adrenergic modulation of pacemaker cells partly explains
the increased heart rate during exercise, this observation led
to the hypothesis—later confirmed—that diminished response
to β-adrenergic modulation is one of the most notable age-
related changes in the cardiovascular system. Chronotropic
and inotropic responses of the aging heart to norepinephrine,
isoproterenol, and dobutamine are diminished. Virtually all
studies show higher mean circulating blood norepinephrine
and epinephrine levels in the elderly than in younger persons.
Both arterial dilation and venous dilation in response to
β-adrenergic stimulation decrease with age. This deficiency
in arterial dilation in addition to any age-related structural
changes within the large vessels may contribute to increased
vascular impedance in advancing age.
The Aging Lung
Cross-sectional population studies consistently show a pro-
gressive age-related decline in pulmonary function. The
decrements in flow rates and lung volumes are not uniform
throughout life but tend to accelerate with age. Given the
large individual differences in the elderly, longitudinal stud-
ies would be preferable for observing the change in pul-
monary function, which is influenced not only by age but
also by environmental factors such as smoking, air pollution,
infections, and other comorbid conditions.
Age-related changes in collagen and elastin produce a
decrease in lung compliance, but this is not physiologically
significant. However, rigidity of the chest wall with aging has
measurably negative mechanical implications resulting in
significantly increased work of breathing. Starting around
age 35 years, there is a decrease in forced vital capacity (FVC)
averaging 14–30 mL per year and a decrease in forced expi-
ratory volume in 1 second (FEV1) averaging 23–32 mL per
year for nonsmoking men. Nonsmoking women show
slightly lesser rates of decline (FVC 15–24 mL per year and
FEV1 19–26 mL per year). All expiratory flow rates decrease
with age and tend to fall faster in men, taller individuals, and
those with increased airway reactivity. The decrease in FVC is
associated with an elevation in functional residual capacity
(FRC) and residual volume (RV). Only minor changes occur
in total lung capacity.
Age-related changes in lung structure and chest wall
mechanics lead to premature closure of terminal airways. This
phenomenon occurs predominantly in the dependent parts of
the lungs that are the best perfused, accounting for increasing
ventilation-perfusion mismatching that results in a progressive
decrease in arterial oxygen tension (PaO2) and an increased
alveolar-arterial oxygen difference—P(A–a)O2—with age. The
following equation predicts PaO2 at sea level in the adult:
PaO2 (mm Hg) = 100 – 0.325 × age (years)
The normal value for the P(A–a)O2 at rest for a given age
can be calculated as follows:
P(A–a)O2 (mm Hg) = (age + 10) × 0.25
Based on this formula, a 90-year-old subject will have a
predicted PaO2 of 71 mm Hg and a maximum normal
P(A–a)O2 of 25 mm Hg at sea level.
Changes in position also influence the PaO2. PaO2 is 6–10
mm Hg lower in the supine position than in the upright posi-
tion in the elderly. Postoperative hypoxemia is especially com-
mon in the elderly, in whom it may persist for several days.
There is no significant change in arterial pH or PCO2 with age.
Ventilatory control is also affected by age and is more
striking compared with the changes in lung volumes and
Table 19–1. Summary of age-related change in cardiac
physiology.
Heart rate At rest: unchanged 
Maximal heart rate with
exercise: decreases 
Stroke volume At rest: unchanged 
With exercise: increases 
Ejection fraction At rest: unchanged
With exercise: fails to increase as
much as in younger subjects 
Cardiac output At rest: unchanged
Low- and medium-intensity exercise:
unchanged 
High-intensity exercise: fails to
increase as much as in younger
subjects 
Early diastolic left ventricular
filling rate 
Decreases 
Late diastolic left ventricular 
filling rate (atrial ”kick”)
Increases
Ventricular compliance Decreases 
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flow rates. The ventilatory response to hypoxemia is reduced
by half in healthy elderly men 64–73 years of age, whereas the
response to hypercapnia is reduced by 40%. Reasons for
these decreased responses are unclear. Suggested explana-
tions include altered central or peripheral chemoreceptor
function as well as reduction in neuromuscular inspiratory
output.
Right atrial, pulmonary artery, and pulmonary capillary
wedge pressures are unchanged in the healthy elderly at rest.
In contrast, the older person’s increases in pulmonary artery
and pulmonary capillary wedge pressures with exercise are
significant, and increases in pulmonary artery resistance are
highly significant with age.
There is a reduction in the effectiveness of cough and
mucociliary clearance with aging and a decline in the cellular
and humoral components of pulmonary immunity. These
changes predispose the older population to pulmonary
infections. Similarly, a diminished gag reflex, dyscoordina-
tion of swallowing, prolonged periods in the supine position,
and sedation contribute to an increased risk of aspiration.
Table 19–2 summarizes these findings.
The Aging Kidney
Many cross-sectional and longitudinal studies of large
human populations have shown a steady decline in creati-
nine clearance with age. As in any other area, the decline in
renal function with age is highly variable among individuals.
In general, changes owing to disease and to aging are in the
same direction and are additive. With aging, there is a loss of
nephrons at a rate of 0.5–1% per year. By the seventh decade
of life, there is a 30–50% loss of functioning glomeruli owing
to age alone. This loss occurs primarily in the renal cortex,
with relative sparing of the medulla. A progressive reduction
in renal plasma flow also has been demonstrated with age. A
50% reduction has been shown between young adulthood
and the eighth decade, averaging 10% per decade.
The major clinically relevant renal functional defect aris-
ing from these histologic and physiologic changes is a pro-
gressive decline, after maturity, in the glomerular filtration
rate (GFR). Age-adjusted normative standards for creatinine
clearance have been established. The rate of decline has been
estimated as 8 mL/min/1.73 m2 per decade after the fourth
decade (or 0.8 mL/min per year). This rather drastic age-
related loss of renal function is not completely reflected in
the serum creatinine because of the proportionate decline in
skeletal muscle mass. Therefore, in order to make an estima-
tion of the glomerular filtration rate in the elderly, the serum
creatinine value should be incorporated in the Cockcroft and
Gault formula that takes into account the age, sex, and
weight of the patient:
Estimated creatinine clearance =
In women, the result should be multiplied by 0.85. For
obese individuals (body mass index [BMI] ≥ 30), ideal rather
than actual body weight should be used.
For the preceding reasons, dosage adjustments of medica-
tions excreted primarily by the kidneys should not be based
on serum creatinine values but rather on measured or esti-
mated creatinine clearance. Drugs that are excreted predom-
inantly through kidneys and have low therapeutic indices
(eg, digoxin, procainamide, and vancomycin) require close
monitoring of serum levels.
Since medullary nephrons, which are relatively spared
compared with cortical nephrons, have reduced concentrat-
ing ability, the elderly tend to excrete more free water. They
release more antidiuretic hormone in response to hyper-
tonicity, yet water retention is less than in younger individu-
als because of reduced end-organ response in older persons.
Older individuals tend to have diminished thirst perception
and diminished awareness of volume contraction. The
response to aldosterone is impaired, and the ability to con-
serve sodium is limited.
The age-related decline in other renal functions such as
urine concentration and dilution, tubular secretion and
reabsorption, and hydrogen ion secretion render the elderly
more susceptible to disorders of fluid, electrolyte, and acid-
base imbalance. Low renin and aldosterone levels can con-
tribute to hyperkalemia and hyponatremia.
 Management of the Elderly Patient
in the ICU
Clinical Presentation of Disease in the Elderly
Elderly patients may present with multiple pathologic
processes in different organ systems. Various studies have
found an average of three to four medical conditions in
ambulatory older patients and five to nine medical diagnoses
among elderly patients in chronic care facilities.
[140 age (years)] body weight (kg)
72 se
− ×
× rum creatinine (mg/dL)
Forced vital capacity (FVC) Decreases 
Forced expiratory volume in 1 second (FEV1) Decreases 
Residual volume Increases
Arterial PO2 Decreases 
Alveolar-arterial oxygen difference Increases 
Arterial PCO2 Unchanged 
Ventilatory response to hypoxia or
hypercapnia 
Decreases 
Mucociliary clearance Decreases 
Table 19–2. Summary of age-related changes in
pulmonary physiology.
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Owing in part to the progressive decrease in physiologic
reserve with age and comorbidity, the elderly may have
unusual presentations of diseases. The onset of a disease in
the elderly generally affects the most vulnerable organ system
first. This explains the frequent apparent lack of relation
between the presenting symptom and the underlying disease.
Thus delirium, functional impairment, frequent falls, incon-
tinence, and syncope could be the presenting manifestations
of a variety of illnesses such as congestive heart failure, pneu-
monia, myocardial infarction, urinary tract infection, or GI
bleeding. Moreover, painless myocardial infarction may
occur in up to 30% of cases. This emphasizes the need for a
thorough evaluation when searching for the cause of non-
specific symptoms.
Drug Therapy
Iatrogenic illness is common and often preventable in the
elderly. The incidence of iatrogenic problems among acutely
hospitalized geriatric patients is close to one in three. By far
the most common iatrogenic disorders in the elderly are
adverse drug reactions. Changes in pharmacokinetics and
pharmacodynamics and polypharmacy predispose geriatric
patients to adverse reactions and drug interactions.
Pharmacokinetics is the study of the time course of
absorption, distribution, metabolism, and excretion of drugs
and their metabolites from the body. Absorption and metab-
olism are minimally affected by aging. Distribution is affected
by changes in body composition. For example, aging is asso-
ciated with an increased percentage of fat (50% increase in
men and 25% increase in women from age 40 to age 80) and
a concomitant decrease of total body water. Thus medications
that distribute in the water space (ie, hydrophilic drugs such
as digoxin and theophylline) have a lower volume of distribu-
tion and tend to reach higher levels in a shorter time in an
older patient. On the other hand, drugs that are lipid-soluble
(ie, lipophilic drugs such as the psychotropics) will have a
larger volume of distribution, resulting in progressive accu-
mulation of these drugs. The net effect of this will be to
increase the half-life of these drugs and prolong the duration
of action. This effect is further compounded by impaired
drug excretion because both renal and, to a lesser extent,
hepatic function tend to decrease with age.
In addition, some plasma protein levels may alter with age.
For example, serum albumin often falls with chronic comor-
bid conditions, resulting in higher free drug levels and a
potential for greater pharmacologic effect at the same dosage
or total serum level for protein bound drugs (eg, phenytoin).
As discussed earlier, renal function tends to decrease with
age, but concurrent changes in muscle mass keep the serum
creatinine constant at approximately 1 mg/dL, often masking
the declining renal function. Thus measurement of creati-
nine clearance or estimation with the Cockcroft and Gault
formula should be used to assess the GFR and make the nec-
essary adjustment  in dosages of drugs excreted by the kid-
neys (see Chapter 4).
Cytochrome P450 enzymatic activity tends to decrease
with age. Warfarin and theophylline are examples of drugs
eliminated by this system. On the other hand, normal aging
does not significantly impair the conjugation capacity of the
liver. There is also a decrease in hepatic blood flow with age.
Compared with renal function, hepatic function is extremely
difficult to quantitate. Only sparse data are available on
hepatic drug metabolism in aging human subjects, and evi-
dence for altered hepatic metabolism in humans is largely
indirect and frequently inconsistent. For example, in studies
with antipyrine (a useful model compound for the study of
drug metabolism), large individual variation frequently
exceeds the effect of age such that only 3% of the variance in
metabolic clearance is explained by age alone.
Pharmacodynamics is the study of the physiologic
response to a drug or combination of drugs and is based on
drug-receptor interactions. For reasons that are not well
understood, the aging process appears to be associated with
an altered sensitivity of receptors for many commonly used
medications. In general, elderly subjects are more sensitive to
some medications, including warfarin, narcotics, sedatives,
and anticholinergic medications, and less sensitive to others,
such as β-adrenergic agonists and antagonists. However,
given the marked heterogeneity of the elderly as a group,
careful individualization should be the general rule when
drawing conclusions about such matters.
Because of multiple diseases and polypharmacy in the eld-
erly, the clinician always should check for possible drug-drug
and drug-disease interactions before prescribing any new
medication. The probability of a significant drug-drug inter-
action is nearly 7% for patients using more than 5 drugs and
24% for those using more than 10 medications. Special atten-
tion should be paid when prescribing medications with long
half-lives or with anticholinergic or potential CNS side effects.
Adverse drug effects can mimic almost any clinical syn-
drome in geriatrics and should be considered in the differen-
tial diagnosis of vague symptoms or deterioration of
function. For example, timolol eye drops—a β-blocker used
for glaucoma treatment—may be absorbed systemically and
can cause cardiac decompensation in a patient with poor
cardiac function.
Hydration and Nutrition
Hydration status is a major concern in the hospitalized eld-
erly. One of the most common reasons for electrolyte abnor-
malities or fluid disturbances in this population is
dehydration. Contributing factors may include laxative or
diuretic use, the presence of fever or infection, decreased
ability to recognize or express thirst, and limited access to
water. There is also an age-related decline in urine concen-
trating ability, which can lead to frequent urination and fluid
loss. Accurate fluid balance assessment is essential in nutri-
tional screening because alterations in hydration state may
contribute to inaccurate anthropometric and biochemical
markers. Because of the high prevalence of congestive heart
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failure in this population, intravenous fluid administration
must be individualized and approached cautiously.
As stated earlier, aging is associated with a change in body
composition with increase in fat content and a concurrent
decrease in muscle mass and total body water. Decrease in
muscle mass and a reduction in physical activity result in a
fall in total energy expenditure with increasing age. Energy
requirements may decrease by about a third between the ages
of 30 and 80 years. However, during periods of stress such as
trauma, surgery, or infection, daily energy requirements may
be more than doubled. In addition to the total energy intake,
attention should be paid to macronutrient and micronutri-
ent requirements.
The elderly are particularly vulnerable to malnutrition.
The reported incidence of malnutrition in elderly hospital-
ized patients varies from 17% to 65%. As the duration of
hospital stay increases, the likelihood of malnutrition rises.
In the elderly, a functional nutritional assessment should
include evaluation of sight, taste, smell, dentition, degree of
cognitive impairment, presence of depression, swallowing
abnormalities, respiratory dysfunction, hand-to-mouth coor-
dination, level of assistance required at meals, and perhaps
drug-appetite and drug-nutrient interactions.
Whenever possible, feeding should be started as soon as
possible in hospitalized or postoperative elderly patients. The
enteral route is greatly preferred, but parenteral nutritional
support can be used, if needed. Increased mortality occurs in
underweight people, but mortality is not clearly increased in
overweight elderly patients.
 Special Considerations
The current disease-oriented model of acute medical care
promotes a sequential approach to diagnosis and treatment
that generally ignores the practice of restorative care until
after the patient is discharged from the hospital. In the frail
elderly, this approach may lead to a decline in functional
abilities despite effective treatment of acute medical illnesses.
The high rate of delirium and psychological decompensa-
tion in the acutely hospitalized elderly may lead to excessive
bed rest with accompanying loss of mobility, muscle atrophy,
contractures, pressure sores, greater tendency to fall, throm-
boembolism, incontinence, anorexia, constipation, and lack
of motivation. This has been called the “cascade of illness and
functional decline.”
Since the physiologic characteristics of the aging popula-
tion include both a decreased functional reserve and large
individual variation, medical management should be indi-
vidualized with the focus on maintenance of functional sta-
tus, protection from the hazards of immobility, and low risk
of complications from treatment.
Delirium
Approximately one-third to one-half of elderly patients will
have a delirious episode during the course of hospitalization
for medical or surgical care. It can be as high as 70% in ICUs.
Delirium is often unrecognized and is associated with pro-
longed hospitalization, greater need for nursing home place-
ment, and increased mortality. The presence of altered level
of consciousness, easy distractibility, rambling conversation,
illogical flow of ideas, unpredictable switching from subject
to subject, perceptual disturbances, and psychomotor agita-
tion or retardation should clue the clinician to the diagnosis
of delirium. Risk factors are listed in Table 19–3. Prior cog-
nitive impairment is the most frequent independent risk
factor for delirium. Other factors that predispose to the
development of delirium include unfamiliar surroundings,
social isolation, structural brain disease, concurrent chronic
illness, sleep deprivation, and alcohol or drug abuse. Delirium
could be the presenting symptom of a variety of illnesses
(Table 19–4). Early diagnosis is important because most
patients can recover if the underlying cause is recognized and
treated. The use of sedatives, psychotropic drugs, or physical
restraints to treat delirium could worsen the existing situa-
tion, placing the patient at higher risk for aspiration pneu-
monia, pressure ulcers, and other immobility-related
complications (cascade effect).
Prior cognitive impairment
Fracture on admission
Age over 80 years
Infection
Male sex
Impaired activities of daily living (ADLs)
Sensory impairment (blindness, deafness)
Polypharmacy (psychoactives, anticholinergics etc.)
Dehydration
Immobility
Bladder catheters
Table 19–3. Risk factors for delirium. 
Decreased cardiac output Fecal impaction
Congestive heart failure Hypothermia and hyperthermia
Acute myocardial infarction Metabolic disorders
Acute blood loss Electrolyte abnormalities
Dehydration Acid-based disturbances
Infections Hypoxia
Fractures Hypercapnia 
Stroke Hypoglycemia and hyperglycemia
Poorly controlled pain Azotemia 
Drugs Transfer to unfamiliar surroundings  
Urinary retention
Table 19–4. Common causes of delirium. 
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The DSM-IV criteria for diagnosis of delirium include
the following: (1) disturbances of consciousness (ie, reduced
clarity of awareness of the environment) in conjunction with
reduced ability to focus, sustain, or shift attention, (2) a
change in cognition (such as memory deficit, disorientation,
or language disturbance) or the development of a perceptual
disturbance that is not better accounted for by a preexisting,
established, or evolving dementia, (3) development of the
disturbance during a brief period (usually hours to days) and
a tendency for fluctuation during the course of the day, and
(4) evidence from the history, physical examination, or labo-
ratory findings that the disturbance is caused by a general
medical condition. The Confusion Assessment Method is a
validated tool to assess delirium. With appropriate training,
it can achieve more than 95% sensitivity and specificity in
the diagnosis of delirium, even in groups with a high preva-
lence of dementia. In contrast with dementia, delirium gen-
erally has an abrupt onset, disturbance of consciousness,
fluctuations during the course of the day, and frequently, an
identifiable and potentially reversible cause.
The decreased attention span seen in delirium can be
assessed by several bedside tests. A simple test is the A test, in
which the interviewer vocalizes letters at a rate of one per
second, and the patient indicates by a sign every time the let-
ter A is mentioned. In the one-tap, two-taps test, the patient is
instructed to tap twice each time the interviewer taps once
and vice versa. More complex tests include spelling the word
world backward or subtracting 7 from 100 each time until 72
is reached (ie, 100, 93, 86, 79, 72). These tests are often abnor-
mal in patients with delirium.
Delirium is indicative of diffuse brain dysfunction and
has been associated with four classes of diseases: (1) primary
cerebral diseases, such as CNS infections, brain tumors, and
stroke, (2) systemic illnesses that secondarily affect brain
function, including cardiac disease, pulmonary failure,
hepatic dysfunction, uremia, deficiency states, anemia,
endocrine disturbances, systemic infections, and inflamma-
tory diseases, (3) intoxication with exogenous substances (eg,
alcohol, illicit drugs, prescribed medications, and industrial
toxins), and (4) withdrawal from dependency-producing
agents (eg, alcohol, barbiturates, and benzodiazepines).
The approach to patients with delirium includes a
focused history and physical examination, review of medica-
tions, and basic laboratory studies such as complete blood
count, serum electrolytes, serum urea nitrogen, glucose, and
urinalysis. Further specialized tests can be done in individual
patients. These include chest radiography, electrocardiogra-
phy, pulse oximetry, selected drug levels, selected cultures,
vitamin B12 level, thyroid function tests, brain imaging, lum-
bar puncture, and electroencephalography.
Treatment of delirium should include identification and
treatment of the underlying cause and review of the medica-
tion regimen. Neuroleptics, opioids, or any medication with
high anticholinergic or sedative side effects should be discon-
tinued or reduced in dosage whenever possible. When avail-
able, constant observation is preferable to restraints. A
well-lighted and predictable environment, use of eyeglasses
and hearing aids, frequent reorientation by family and care-
givers, simple explanations of any procedure or confusing
stimuli, encouragement to stay awake during the daytime, and
nursing routines that permit uninterrupted nighttime sleep
are all valuable in the management of delirium. Finally, it may
be necessary to treat agitated behavior with medication.
Generally, the lowest effective doses of one of the atypical
antipsychotics (eg, risperidone or olanzapine) should be used
because of the low incidence of extrapyramidal side effects.
Complete resolution of symptoms can take days to months.
Communicating with the Elderly Patient
Many elderly patients have hearing and vision problems that
interfere with communication and cause difficulty in orien-
tation and adaptation to a new environment. Being able to
see and hear properly becomes critical when one must cope
with new experiences such as ventilatory support devices and
other invasive interventions.
Communication problems generate great anxiety in the
patient and frustration in the caregiver. There is a risk of mis-
labeling the patient as “confused” and disregarding the patient’s
role as a participant in health care decisions. The elderly patient
who reacts to an unfamiliar situation by becoming “agitated” is
at risk for the use of physical restraints or psychotropic medica-
tions. This causes worsening of the clinical status and may lead
to the cascade effect described earlier. The importance of efforts
to maximize communication with the elderly individual thus is
emphasized, especially in the ICU setting.
Adequate vision makes communication easier, especially
for those who have impaired hearing or comprehension. Eye
contact helps the caregiver to assess the extent to which the
older person hears and understands what is being said. If the
patient wears glasses, they should be clean and within reach
of the patient. The head of the bed should be elevated so that
the patient can see the speaker’s lips and eyes. A glare-free
light source coming from behind the patient helps the
patient to see the face and lips of the speaker. If the patient
has a hearing impairment, background noise should be
reduced by turning the television or radio off, by closing the
door, and by asking others in the area to be quiet. The
speaker should lean forward so that the lips can be seen, but
shouting should be avoided. Most elderly people suffer from
a selective high-frequency hearing loss with decreased ability
to identify high-frequency tones and pitches in the conso-
nants s, f, t, hard g, and j. Increasing the volume of sound is
of little help, and shouting may be misinterpreted as hostility
or anger. The manner of speaking should be natural and not
distorted by exaggerated lip movements. When it is necessary
to repeat a comment or question, it is better to rephrase than
to say the same thing in a louder voice. If the patient has a
hearing aid, it should be properly in place and in good work-
ing condition. Older people are often not aware of their hear-
ing inadequacies, and their perceptions of what they have
heard may not be accurate. Therefore, an attempt should be
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made to determine whether the patient has properly inter-
preted what has been communicated.
Health care personnel and family members should not
whisper or speak together in low tones near a hearing-
impaired older adult. A few words may be heard that will
result in misinterpretation, increasing the possibility of
unwarranted fears, paranoid behavior, or hostility. Glasses
and hearing aids should be worn consistently during the day.
If the patient is able to talk, dentures should be in place to
facilitate clear speech.
Immobility
Elderly patients are particularly vulnerable to the untoward
effects of immobility. Contractures, pressure ulcers, and
deconditioning can develop rapidly. Some of the other con-
sequences of immobility include muscle atrophy, deep
venous thrombosis, increased calcium mobilization from
bone, atelectasis, hypostatic pneumonia, constipation, func-
tional fecal and urinary incontinence, and loss of motivation.
Pressure ulcers are a common and frequent complication
of immobility. Any disease process leading to immobility
(eg, severe congestive heart failure, respiratory failure, delir-
ium, fractures, complicated postoperative course, or spinal
cord injury) places the elderly patient at high risk for devel-
opment of a pressure ulcer. Sites commonly involved are the
sacrum, ischial tuberosities, hip, heel, elbow, knee, ankle, and
occiput. More than 50% of pressure ulcers occur in persons
over age 70. Their prevalence among patients expected to be
confined to a bed or a chair for at least 1 week is as high as
28%. Pressure ulcers generally occur within the first 2 weeks
of hospitalization. Moreover, the development of pressure
sores has prognostic implications; the mortality rate among
those who develop pressure ulcers during the first 2 weeks has
been as high as 73%. Sepsis is the most serious complication
of pressure ulcers. Among bacteremic patients with a pres-
sure ulcer as the probable source of infection, the in-hospital
mortality rate can be as high as 60%.
Frequent repositioning (whether supine or in the sitting
position) has been the primary method of preventing pres-
sure ulcers. The evidence of structural changes in experimen-
tal animal models has led to the recommendation for
repositioning every 2 hours. Repositioning should be per-
formed so that a person at risk is positioned without pressure
on vulnerable bony prominences. This is accomplished in
practice by positioning patients horizontally with the
back resting partially over pillows that maintain the body at
a 30-degree angle to the support surface. Additional pillows
between the legs and supporting the arms will aid in main-
taining optimal positioning. A person with limited ability to
change position who must sit in a chair or have the head of
the bed elevated should not remain in this position for more
than 2 hours at a time. To diminish the shearing forces over
the sacral area, the head of the bed should not be elevated
more than 30 degrees. Particulate matter (eg, food crumbs)
should be removed from the bed. Sheets should be loose, and
tucking of the sheet at the foot of the bed should be avoided
so that movement is not restricted and the feet can assume
their natural position. Heels and elbows should be protected
by raising them with pillows to avoid direct pressure over
bony prominences. Patients should be lifted, not dragged.
The skin should be patted dry, not rubbed. Moisture control
depends on timely skin care. The evaluation and manage-
ment of urinary and fecal incontinence are of crucial impor-
tance in these patients.
In high-risk patients, pressure-relieving devices such as
constant low-pressure supports, alternating-pressure sup-
ports, or pressure-relieving cushions may be needed.
Attention also should be directed toward proper nutrition,
hydration, and pain control.
Educational programs aimed at physicians, nurses, and
other caregivers; family members; and the patients them-
selves have beneficial results. One study found that when
physicians ordered preventive measures for high-risk
patients, the incidence of pressure ulcers was half that for
patients for whom such orders were not written.
Bed rest also results in immobility and loss of weight-
bearing forces on joints. These effects cause changes in peri-
articular and articular structures that result in joint
contractures and changes similar to those of osteoarthritis.
Changes in periarticular tissues occur within days. Muscles
that bridge the immobilized joint shorten. These changes
produce decreased range of motion that can be permanent,
depending on the length of immobilization.
Bed rest is accompanied by progressive cardiovascular
deconditioning with exaggeration of the hemodynamic
changes normally seen with standing, as manifested by
orthostatic intolerance and decreased exercise tolerance.
Although orthostatic hypotension is not always documented,
signs and symptoms of orthostatic intolerance such as tachy-
cardia, nausea, diaphoresis, and syncope are common after
prolonged bed rest. A decrease in coordination, as measured
by pattern tracing and a marked increase in body sway in a
standing position, has been documented after several weeks
of bed rest.
The rate of decrease in muscular strength may be as high
as 5% per day and varies with the degree of immobility. Leg
muscles tend to lose strength about twice as fast as arm mus-
cles. For some elderly patients who normally use 100% of
their quadriceps muscle strength just to stand up, a loss of 5%
per day results in significant loss of function in a short time.
Given the numerous complications resulting from immo-
bility, early mobilization of the elderly patient in the ICU set-
ting should be a high priority. The rate of loss of muscle
strength will slow when active contraction of muscles is
encouraged, particularly if resistance is added. Simple
devices such as elastic fabrics (Theraband) make exercise
against resistance available for patients in beds or chairs.
Active movement in bed and full range-of-motion exercises
should be encouraged in alert patients. For other patients,
passive full range of motion should be done on every nurs-
ing shift.
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Intermittent sitting—and standing when possible—will
reduce the frequency of orthostatic hypotension. The sitting
position also improves oxygenation and diminishes cardiac
work because cardiac output and stroke volume decrease in the
sitting position. Finally, rehabilitation service consultation may
be useful in the management of elderly patients in the ICU.
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Critical Care of the
Oncology Patient∗
Darrell W. Harrington, MD
Darryl Y. Sue, MD
Several complications of cancer may require critical care for
palliative management. These include (1) acute CNS disor-
ders (eg, spinal cord compression and increased intracranial
pressure), (2) severe metabolic disorders (eg, hypercalcemia,
hypocalcemia, tumor lysis syndrome, hyponatremia, hyper-
glycemia, hypoglycemia, and hypokalemia with ectopic
adrenocorticotropic hormone [ACTH] production),
(3) orthopedic disorders (eg, pathologic fracture), (4) uro-
logic disorders (eg, hematuria, hemorrhagic cystitis, and
acute obstructive uropathy), (5) general surgical disorders
(eg, GI bleeding, bowel perforation, bowel obstruction,
extrahepatic biliary obstruction, and intraabdominal abscess
formation), (6) malignant effusions (eg, pericardial effusion
with cardiac tamponade and pleural effusion with lung
compression), (7) complications of chemo- and radiother-
apy, and rarely, (8) superior vena cava syndrome. CNS disor-
ders, metabolic disorders, and superior vena cava syndrome
are addressed in this chapter.
CENTRAL NERVOUS SYSTEM DISORDERS
 Spinal Cord Compression
ESSENT IALS  OF  D IAGNOS I S
 Axial (back) pain that may radiate to arms or legs or
bandlike discomfort around the chest.
 History of malignancy (may be initial presentation of
cancer).
 Neurologic deficits (ie, motor, sensory, or autonomic).
 Abnormal images of spine: MRI (preferred), plain x-rays,
CT scan, CT or planar myelography.
General Considerations
Spinal cord compression from epidural metastases is a
potentially devastating complication in cancer patients. It
occurs in about 5% of cancer deaths and therefore will
develop in about 25,000 of the annual 500,000 cancer deaths.
The most common primary tumors that cause spinal cord
compression are cancers of the lung, breast, and prostate;
lymphomas; and multiple myeloma. Cord compression also
can be seen in patients with leukemia (chloroma) and a wide
range of other solid tumors. It may present as the first and
only manifestation of cancer, but it is postulated that pro-
longed survival from initial diagnosis of cancer will increase
the incidence of spinal cord compression.
Epidural spinal cord compression develops via two mecha-
nisms: (1) by metastatic spread to the vertebral bodies, from
where the tumor expands and erodes into the epidural space,
and (2) by cancerous involvement of the paravertebral region
with extension into the epidural space through the interverte-
bral foramina. Bone scans and spine x-rays may be normal in
the latter cases but usually are abnormal in the former.Vertebral
body metastases account for epidural spinal cord compression
in approximately 85% of patients with solid tumors and 25% of
patients with lymphomas. In the 70% of cancer patients with
metastases at death, metastases to the spine are found in 40%.
Epidural metastases extend from the paravertebral region in the
remainder. In addition to spinal cord compression, sudden irre-
versible spinal dysfunction may occur from vascular compro-
mise, resulting in spinal cord infarction.
The thoracic spine occupies 47% of the total length of the
spine but is the affected area in approximately 70% of
patients, the lumbar spine occupies 30% and is affected in
20%, and the cervical region occupies 22% and is affected in
10% of patients. Spinal cord involvement may occur at mul-
tiple levels in 10–38% of patients. The greater chance of tho-
racic spine involvement may be related to the presence of
physiologic kyphosis and the narrower spinal canal in this
region. Metastases never traverse the intervertebral disks and
rarely traverse the dura.
∗Darrell W. Harrington, MD, and Hassan J. Tabbarah, MD, were the
authors of this chapter in the second edition.
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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Clinical Features
A. Symptoms and Signs—The clinical presentation of
epidural spinal cord compression is well known and depends
on the level of spinal involvement. Axial pain is the most
common presenting symptom (prodromal phase), occurring
in 95% of adults and 80% of children with epidural spinal
cord compression. Therefore, spinal cord compression
should be considered in any patient with cancer and axial
pain. The local pain corresponds to the site of the lesions and
is described as dull and aching. Tenderness over the affected
spinal element is usually readily elicited. Approximately 15%
of patients will develop paraplegia despite a long duration of
painful symptoms (compressive phase), because spinal cord
compression was not anticipated. Pain may persist for several
weeks or months before symptoms of radiculopathy are
manifested. Cervical or lumbar disease usually but not
always presents as unilateral radiculopathy, whereas thoracic
disease produces bilateral symptoms resulting in a bandlike
distribution of pain. Radicular pain may be accompanied by
sensory or motor loss, as determined by the involved nerve
root, and may be easily confused with disk herniation. Pain is
usually worse at night and is aggravated by movement,
coughing, or the Valsalva maneuver. Because midthoracic
back pain is less likely to be due to benign causes, any patient
localizing pain and tenderness to this area regardless of a his-
tory of malignancy should be evaluated carefully.
Neurologic deficits seen in spinal cord compression usu-
ally begin with motor impairment. These are seen more com-
monly in the distal part of the body or the lower extremities
owing to the greater frequency of thoracic and lumbar spine
involvement. Anterior spinal cord compression is more com-
mon than posterior involvement. Accordingly, patients usu-
ally have more motor than sensory disability, at least in the
early stages. Sensory impairment follows, parallels the devel-
opment of motor deficit, and is present in half of patients at
the time of diagnosis of spinal cord compression. Autonomic
dysfunction occurs later and is present in half of cases.
The neurologic deficit is caused either by mechanical
compression by the tumor on the spinal cord or cauda
equina or by destruction of a vertebral body sufficient to
make it collapse and compress the spinal cord. Once spinal
cord compression occurs, progression may be very rapid.
Therefore, the presence of myelopathy is a neurologic emer-
gency. Disease presentation and progression depend on the
level of spinal involvement. For example, high cervical cord
lesions (C3–5) may be life-threatening because both quadri-
plegia and respiratory muscle impairment are common fea-
tures. Involvement of the thoracic cord typically is
characterized by identification of a sensory level on the
trunk. In addition, lower extremity weakness and autonomic
dysfunction may accompany thoracic cord compression. The
specific site of lumbosacral spinal cord compression is less
easily determined by physical examination. Patients may
present with radiculopathy and loss of associated reflexes or
with isolated autonomic dysfunction as seen in the conus
syndrome. It is important that each patient have a complete
neurologic examination, paying close attention to subtle
asymmetries in muscle strength and reflexes. It is important
to note that patellar and ankle reflexes provide information
only about L4 and S1 nerve roots, respectively. Therefore,
normal reflexes of the lower extremity should not be used to
exclude the presence of significant myelopathy.
B. Laboratory Findings—A histologic diagnosis of malig-
nancy is rarely necessary in a patient with a known preexist-
ing malignancy. However, it is prudent to specifically identify
malignancy causing spinal cord compression in an individual
without an underlying history of cancer. This is so because
localized infection causing spinal cord compression may
mimic malignancy. In the presence of complete blockage of
the spinal canal and to avoid worsening of neurologic status,
only a few drops of cerebrospinal fluid (CSF) should be
removed and sent for cytologic examination and protein
determination. Additional studies are sent to exclude infec-
tion. Lumbar puncture otherwise should be reserved for
patients suspected of concomitant leptomeningeal dissemi-
nation of tumor. CSF may have elevated protein, normal or
low glucose, and a lymphocytic pleocytosis.
C. Imaging Studies—MRI is the diagnostic study of choice
to evaluate spinal cord compression, but plain x-rays of the
involved area and planar or CT myelography are potentially
useful or necessary (especially if MRI is unavailable or cannot
be performed). It is critical that imaging should be acquired
as early as possible and should not be delayed more than a few
hours in patients with neurologic symptoms and signs.
The most important attribute of MRI is its ability to eval-
uate directly the full length of the cord, thus making it possi-
ble for multiple levels of compression to be identified and to
determine whether these lesions are related or unrelated to
bony erosion or bone destruction by tumor. At least 35% of
patients who present with focal symptoms have evidence of
subclinical epidural compression at other sites along the
spine. MRI also can determine the number of segments and
vertebrae involved, the location of a compressive mass, if
present (anterior, posterior, or encircling), and perhaps the
percentage loss of bone mass. Imaging of the entire spine is
usually not done because of the length of time needed (as
much as 3 hours), but not taking the time may miss lesions
that cause later neurologic compromise. MRI is comparable
to myelography and CT scanning with contrast material in
detecting leptomeningeal metastasis. However, MRI may be
inadequate in patients who may have had previous spinal
surgery because metal-induced artifacts may be seen or the
patient’s movements cannot be controlled.
Vertebral metastases can be seen on unenhanced T1-
weighted images as foci of low signal intensity (dark) that
contrast with the adjacent high signal intensity (bright) of
normal adult bone marrow. The administration of gadolin-
ium results in normalization of the tumor, making its appear-
ance similar to that of the marrow. Vertebral metastases rarely
cross the disk space, as often seen in infection. However, it
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sometimes may be difficult to distinguish between malig-
nancy and infection with MRI. Diffuse bone marrow
involvement may make interpretation by MRI difficult. This
is also true in younger patients with relatively little fatty mar-
row. MRI is superior to CT scanning with and without
intrathecal contrast material (CT myelogram).
Plain x-rays may be helpful in localizing the anatomic
origin of compression symptoms. Hematologic malignancies
less often are manifested by abnormal plain spine x-rays than
solid tumors. The most common findings include loss of
pedicles, destruction of the vertebral body, and vertebral
body collapse. Plain x-rays will, however, be unsuccessful in
identifying up to 20% of vertebral body lesions and also will
fail to demonstrate paravertebral masses that spare vertebral
body destruction but encroach on the epidural space via the
intervertebral foramina. The overall diagnostic sensitivity of
plain spine films is about 83%.
CT scans can assess the extent of a paravertebral mass,
detect small areas of bone destruction, quantify the extent
and characterize the direction of spinal cord impingement,
and assess response to treatment. CT scans cannot investigate
multiple levels of involvement without extensive scanning
and may miss the area of maximal impingement if CT scan
“cuts” are too widely spaced.
CT myelography remains an important diagnostic
method for epidural spinal cord compression, especially
when MRI is unavailable. Water-soluble contrast media are
preferred. Once a complete block of the spinal canal is
demonstrated by a lumbar myelogram, a C1–2 or suboccipi-
tal myelogram should be done to define the upper level of
block. Myelography may disclose silent epidural metastasis.
Lumbar myelography may cause further deterioration of neu-
rologic findings in approximately 14% of patients even with
the removal of only a small amount of CSF. Myelography has
been associated with complications such as headaches, seizures,
allergic reactions, and deterioration of neurologic status.
The role of radionuclide bone scans is unclear in the set-
ting of suspected epidural spinal cord compression. Bone
scans are less accurate than plain spine x-rays in predicting
epidural involvement. Moreover, bone scans often will suggest
multiple areas of abnormality without identifying the level
associated with pain or neurologic deficit. Bone scans may
not reflect the extent of vertebral involvement. These studies
are reserved for patients with skeletal pain, negative plain x-
rays, and a low suspicion for spinal cord compression.
Differential Diagnosis
The differential diagnosis of spinal cord compression includes
intervertebral disk herniation, vascular disease (eg, hemor-
rhage or infarction), infectious processes such as epidural
abscess, benign neoplasms (eg, meningioma, neurilemoma,
and chordoma), neurologic disorders (eg, multiple sclerosis
and amyotrophic lateral sclerosis), transverse myelitis, lep-
tomeningeal carcinomatosis, and paraneoplastic syndromes
(eg, necrotizing myelopathy and carcinomatous neuropathy).
Treatment
Early recognition, diagnosis, and treatment of epidural
spinal cord compression are of utmost importance. Either
the presence of neurologic symptoms or radiographic evi-
dence of epidural compression is sufficient to justify begin-
ning treatment. Cord compression diagnosed after the onset
of myelopathy has the most profound impact on the patient’s
quality of life. The drastic difference is between 2 and 6
months of ambulatory survival versus 2–6 months of bed or
wheelchair confinement with a urinary catheter, potential
urosepsis, pneumonia, and decubiti—and dependence on
professional care or family members. In one study, 70% of
patients with malignant spinal cord compression had pro-
gression of symptoms from initial symptoms and onset of
treatment. Reasons for delay included lack of recognition by
the patient but also delays in diagnostic evaluation.
Although median survival after treatment for spinal cord
compression is short, two factors appear to predict a good
prognosis for recovery of function: a normal pretreatment
neurologic examination and urgent appropriate treatment.
Other prognostic factors include the rate and onset of pro-
gression of neurologic dysfunction, histologic features of the
primary tumor (eg, myeloma, lymphoma, breast, and
prostate have a better prognosis), the presence of vertebral
collapse, and the location of the compressing lesion (anterior
or posterior). In general, if patients are ambulatory before
the start of treatment, two-thirds will remain ambulatory
after treatment. If patients are paraparetic before treatment,
one-third will be ambulatory after treatment, but if patients
are paraplegic (especially if unresponsive to dexamethasone
therapy), only a few—if any—will become ambulatory after
treatment. The most commonly used treatment regimen
consists of high-dose corticosteroid therapy plus external-
beam radiation. Surgery is used selectively either as initial
treatment or when specifically indicated.
A. Corticosteroids—To reduce edema of the cord adjacent
to the tumor, corticosteroids are used frequently in the treat-
ment of spinal cord compression. These should be started as
soon as the diagnosis is suspected. Delaying therapy while
awaiting formal studies is unnecessary and may lead to fur-
ther progression of the neurologic deficit. These drugs clearly
improve the initial rate of neurologic recovery and often lead
to stabilization of the neurologic deficit. Randomized trials
support the benefit of corticosteroids in those treated subse-
quently with radiotherapy. The optimal dose of corticos-
teroids is not known, but almost all recommendations
support “high doses” in the range of 16–100 mg dexametha-
sone. Some studies have shown both a higher likelihood of
benefit from the highest dosages and more complications of
therapy. One recommendation is to vary the dose with the
degree of neurologic impairment. With pain or radiculopa-
thy alone, dexamethasone, 16 mg intravenously, followed by
4–6 mg intravenously or orally every 6 hours, is adequate.
Patients with rapidly progressive symptoms or significant
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myelopathy should be treated with dexamethasone, 100 mg
intravenously, followed by 24 mg intravenously every 6 hours.
Therapy should be continued until benefit is demon-
strated from definitive therapy (ie, radiation or surgery)
or neurologic deficits are considered irreversible. Tapering of
corticosteroids is accomplished by reducing the dose by
about one-third every 3–4 days over a period of 2–3 weeks.
Corticosteroids should be reinstituted if neurologic deficits
recur. Patients failing to improve after a 7-day trial at 100
mg/day should be rapidly tapered to the lowest dose that will
maintain stable neurologic function. Such steroid regimens
do not appear to be toxic, although vaginal burning may
occur with rapid intravenous administration of dexametha-
sone. Conversely, corticosteroids may result in serious and
fatal complications when used in high doses for more than 40
days or when given to patients with serum albumin concen-
tration of less than 2.5 g/dL.
B. Radiation Therapy—Radiation therapy alone produces
neurologic improvement in 30–50% of patients with epidural
spinal cord compression. Pain relief is obtained in the major-
ity of patients with radiation therapy. Radiation-sensitive
tumors such as hematologic malignancies and seminomas
have the best outcome, breast and prostate cancer have mod-
erately good outcomes, and lung and renal cancer, sarcomas,
and melanoma are radioresistant and have the worst out-
comes. Radiation therapy and surgical therapy appear to be of
equal effectiveness in the treatment of radiosensitive tumors.
The usual dose of radiation is 3000–4000 cGy over a period of
3–4 weeks. There are few differences reported between vari-
ous radiotherapy protocols (ie, dose, number of fractions, and
total duration). Complications of radiation therapy include
radiation myelopathy and impaired wound healing in
patients who undergo subsequent surgery.
C. Surgery—The surgical approach selected—laminectomy,
anterior surgical decompression, or posterolateral surgical
decompression—depends on several variables, including the
specific element of vertebral involvement, cord level, and sta-
bility of the spine. The concept that surgery is not indicated
in the treatment of spinal cord compression is based on ret-
rospective analysis of several surgical series that compared
decompressive laminectomy followed by radiation therapy
with radiation therapy alone. No difference in neurologic
outcome was reported initially. Better understanding of the
pathogenesis of cord compression combined with advances
in operative technique and materials have resulted in
improved outcomes after surgical decompression. For exam-
ple, in 54 patients with cord compression in whom laminec-
tomy or vertebral body resection was performed, all 54
improved, and 23 of 25 patients surviving for 2 years
remained ambulatory. The 30-day mortality rate in this
series was 6%, and the morbidity rate was 15%.
Surgery is a major procedure associated with a significant
rate of complications. Therefore, surgery should be used only
in patients who have less extensive disease and longer life
expectancy. In the absence of medical contraindication,
surgery may be considered (1) when the diagnosis is not
known or is in doubt, (2) when there is spinal instability or
bone deformity, (3) when there is failure to respond to radi-
ation therapy, (4) when there is a history of previous radia-
tion therapy up to cord tolerance, (5) when there is high
cervical spinal cord compression (because of the danger of
respiratory failure), (6) in the presence of a radioresistant
tumor, especially when the onset of signs is rapid and com-
plete block is present, (7) when atlantoaxial compression is
present, (8) when a solitary spinal cord metastasis is present,
and (9) as a form of primary treatment before radiation ther-
apy. When possible, it is recommended that adjuvant
chemotherapy be delayed for 3–6 weeks after surgical ther-
apy to minimize wound complications.
Table 20–1 offers an approach to the patient with known
or suspected malignancy that presents with back pain and
possible spinal cord compression.
Conway R, Graham J, Kidd J, Levack P. Scottish Cord Compression
Group: What happens to people after malignant cord compres-
sion? Survival, function, quality of life, emotional well-being
and place of care 1 month after diagnosis. Clin Oncol (R Coll
Radiol) 2007;19:56–62. [PMID: 17305255]
Graham PH et al: A pilot randomised comparison of dexam-
ethasone 96 mg vs 16 mg per day for malignant spinal-cord
compression treated by radiotherapy: TROG 01.05 Superdex
study. Clin Oncol (R Coll Radiol) 2006;18:70–6. [PMID:
16477923]
Husband DJ, Grant KA, Romaniuk CS: MRI in the diagnosis and
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ment of malignant extradural spinal cord compression: The
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 Increased Intracranial Pressure Due
to Malignancy
ESSENT IALS  OF  D IAGNOS I S
 Mental deterioration, lethargy, somnolence, or confusion.
 Changes in heart rate and blood pressure.
 Pupillary changes.
 Neurologic deficits, focal or nonfocal.
 Abnormal brain CT or MRI diagnostic or suspicious of
intracranial tumor or metastases.
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General Considerations
Increased intracranial pressure (ICP) can cause neurologic
damage either directly or indirectly by way of herniation of
the cerebellar tonsil or uncus or by secondary vascular com-
promise. It is essential that prompt management be insti-
tuted in order to prevent loss of cerebral function or death.
The closed cranium means that any increase in volume of
any intracranial component must result in increased pres-
sure. A tumor increases ICP by adding its bulk or localized
edema to the normal components of brain tissue, CSF, and
vessels within the cranium.
Increased ICP can result from primary or metastatic
tumors. At least one-fourth of patients dying from malig-
nancy will have brain metastases discovered at autopsy.
Hematogenous spread is the most common route of dissem-
ination. Thus most lesions (approximately 80%) are supra-
tentorial. The most common cancers found include lung,
renal, breast, and melanoma. Brain metastases from chorio-
carcinoma, melanoma, and breast cancer more often
undergo hemorrhagic transformation. The metastatic
tumors may be single or multiple and should be distin-
guished from diffuse infiltrative processes that also may
cause increased ICP. Leukemic meningitis and diffuse
leukemic infiltration also can cause increased ICP but with-
out the focal neurologic or radiographic findings usually
seen in primary or metastatic brain tumors. In diffuse
processes, ICP increases without evidence of other concomi-
tant findings (eg, localizing findings from a mass lesion).
Brain edema results from leakage of plasma into the
parenchyma through dysfunctional capillaries (ie, vasogenic
edema). Studies on the formation, speed, and resolution of
brain edema have concluded that increased capillary perme-
ability occurs within the brain tumor itself and not in the
surrounding brain tissue. This increased capillary permeabil-
ity varies depending on the histology of the tumor and its
size. Brain edema occurs preferentially in the cerebral white
matter. Vascular endothelial growth factors may contribute
to dysfunction of tight junctions. It is not clear how brain
edema results in neurologic dysfunction, but it is thought to
be related to ischemia from a mass effect or from metabolic
abnormalities in the surrounding extravascular fluid.
Untreated, metastatic brain tumors ultimately lead to
progressive neurologic dysfunction and death. The median
survival in this setting is 4–6 weeks.
Clinical Features
A. Symptoms and Signs—Headache, nausea, vomiting,
mental deterioration, lethargy, somnolence, and confusion
are key findings in patients with increased ICP. Flexor or
extensor posturing may occur. In addition, decrease in
Other Clinical Findings Diagnostic Studies Treatment
Normal neurologic examination
Normal plain spine x-rays
MRI for high-risk tumors or in the presence
of other metastatic disease. If MRI is not
available, then CT, CT with myelography, or
myelography.
Observe closely for low-risk primary tumors.
Treatment depends on MRI or CT findings.
Normal neurologic examination
Abnormal plain spine films
None.
MRI, or CT with myelography. 
Radiation therapy to symptomatic vertebral metastases
without further imaging. Advantages: No delay in treat-
ment, no further expense. Disadvantages: May miss
other sites of disease that may become symptomatic
later and compromise further radiotherapy because of
overlapping radiation therapy ports. Disadvantages
reduced if x-ray of entire spine is obtained, radiation
port includes two segments above and below lesions, or
bone scan is performed to document that disease is lim-
ited to one area of the spine.
Treatment depends on MRI or CT findings.
Abnormal neurologic examination
Abnormal or normal plain spine x-rays
MRI of symptomatic area to identify adjacent
levels of involvement.
If MRI is unavailable, consider CT with
myelography.
Treatment (radiation therapy) depends on MRI or CT
findings. Consider selective surgery.
Table 20–1. Management of patients with back pain and suspected malignancy.
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heart rate, increase in blood pressure, and abnormal respira-
tory pattern (Cushing’s triad) often can be present but are
late findings. Cerebellar masses may, however, have a
reversed clinical picture. Dilation of one or both pupils sug-
gests rapid and significant increases in ICP. Focal neurologic
deficits and abnormal reflexes may be found. Early diagnosis
is usually based on the timely observation of subtle alter-
ations in the mental status or state of consciousness of the
patient.
B. Laboratory Findings—Lumbar puncture for diagnosis is
to be discouraged because removal of fluid from the
intrathecal sac may result in an acute drop in infratentorial
pressure, thereby precipitating or worsening herniation.
C. Imaging Studies—Head CT scan and MRI are the most
useful diagnostic tests. The size and location of a tumor mass
or masses, the amount of peritumoral edema, shifts in
intracranial structures, and ventricular size can be deter-
mined easily. No test is completely accurate in predicting risk
of herniation. MRI is more sensitive than CT scan for find-
ing tumor, especially when evaluating lesions of the posterior
fossa. However, CT scan may better detect bony involvement
of the skull. Both non-contrast- and contrast-enhanced CT
scans are recommended because the combination not only
may detect hemorrhagic lesions (non-contrast-enhanced)
but also may allow detection of small lesions (contrast-
enhanced).
Differential Diagnosis
The differential diagnosis of increased ICP includes metabolic
encephalopathy (eg, hypo- and hypernatremia, hypercal-
cemia, uremia, hypoxemia, hypoglycemia, and thyroid dys-
function), CNS infection, cerebrovascular disease (especially
intracranial hemorrhage), drug-induced encephalopathy (eg,
sedatives and analgesics), and nutritional deficiencies.
Treatment
A. Medical Treatment—If signs of cerebral herniation are
evident, emergent reduction of ICP is warranted. Emergent
maneuvers include elective intubation and hyperventilation
to maintain PaCO2 between 25 and 30 mm Hg, followed by
administration of mannitol, 1–1.5 g/kg intravenously every
6 hours. Some recommend following serum osmolality as a
guide to dosing mannitol. Use of mannitol should be avoided
when definitive therapy (surgery or radiation) is delayed. In
any case, hypotonic fluids may be harmful and should not be
given. Early corticosteroid (eg, dexamethasone) administra-
tion and fluid restriction appear to be the best means of
achieving a decrease in ICP and brain edema. The specific
mechanism of action of corticosteroids on brain edema is
not known. These agents may either decrease edema produc-
tion or increase edema resorption. Corticosteroids appear to
decrease tumor capillary permeability and alter the exchange
of sodium and water across the endothelial cells and decrease
CSF production at the choroid plexus. Corticosteroid
administration may result in symptomatic improvement
within 4–5 hours, but more commonly such improvement
occurs gradually over several days, with 70% of patients
showing late significant clinical improvement. Dexamethasone
is administered at a dosage of 16 mg/day in four divided
doses, and the dosage may be increased to 100 mg/day. Some
patients must remain on corticosteroids for long periods and
whenever they undergo definitive treatment such as sur-
gery or radiation. Patients are subject to the risks and side
effects of high-dose corticosteroids if administered for long
enough time.
Preemptive antiseizure medications are frequently
administered, but their value is controversial. Because
patients with malignancy have a high risk for venous throm-
boembolism, deep venous thrombosis prophylaxis is recom-
mended despite the theoretical risk of hemorrhage from
primary or metastatic brain tumor.
B. Surgical and Radiation Treatment—Surgery and radi-
ation therapy are important methods of treatment of pri-
mary and metastatic brain tumors either as initial or as
adjunctive therapy. Candidates for surgical resection should
be patients with solitary lesions and limited systemic disease.
Radiation therapy usually involves the whole brain and
requires an average of 3000 cGy. Most recently, radiosurgery
has evolved as a new technique to deliver a single large dose
of radiation to a specific target. Local control rates appear to
be equal to those achieved with surgery. Radiosurgery is
especially useful in patients with multiple or poorly accessi-
ble lesions.
Aoyama H et al: Stereotactic radiosurgery plus whole-brain radia-
tion therapy vs stereotactic radiosurgery alone for treatment of
brain metastases: A randomized, controlled trial. JAMA
2006;295:2483–91. [PMID: 16757720]
Chang JE, Robins HI, Mehta MP: Therapeutic advances in the
treatment of brain metastases. Clin Adv Hematol Oncol
2007;5:54–64. [PMID: 17339829]
Kaal EC, Niel CG, Vecht CJ: Therapeutic management of brain
metastasis. Lancet Neurol 2005;4:289–98. [PMID: 15847842]
Khuntia D et al: Whole-brain radiotherapy in the management of
brain metastasis. J Clin Oncol 2006;24:1295–304. [PMID:
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METABOLIC DISORDERS
 Hypercalcemia of Malignancy
ESSENT IALS  OF  D IAGNOS I S
 Mental status changes, lethargy, confusion, weakness.
 Altered deep tendon reflexes without localized neuro-
logic signs.
 History of malignancy, usually far-advanced.
 Elevated serum calcium, chloride:phosphate ratio, and
(often) parathyroid hormone–related polypeptide
(PTHrP).
General Considerations
Hypercalcemia is the most serious metabolic disorder associ-
ated with cancer. Between 10% and 20% of patients with can-
cer will develop hypercalcemia at some point, and life
expectancy is poor in these patients, even when they are
actively treated. Treatment of hypercalcemia of malignancy is
usually palliative because most of these patients have
advanced disease. However, symptoms are usually improved
with treatment, and many patients may be made well enough
to go home from the hospital. While treatment of hypercal-
cemia may not prolong survival, it clearly improves quality
of life.
Pathogenesis
Serum calcium is regulated by hormones and locally acting
cytokines at three main sites: the gut, the skeletal system, and
the kidneys. Parathyroid hormone (PTH) increases the num-
ber and function of osteoclasts, inhibits osteoblasts, and
increases renal tubular reabsorption of calcium, all of which
increase extracellular calcium levels. The hormone also
increases production of active vitamin D, which increases the
absorption of calcium from the gut.
In all cases of cancer-related hypercalcemia, there is
increased calcium resorption from bones relative to bone
formation (Figure 20–1). Increased bone resorption is
maintained through the destructive action of tumor cells by
increased osteoclast activation mediated through the action
of PTH-related polypeptide (PTHrP) and by locally acting
cytokines. Squamous cell carcinomas originating in the
lung, head and neck, esophagus, uterine cervix, vagina, and
penis—as well as cancers of the breast, lung, and kidney—
produce PTHrP. This hormone shares homology with the
amino-terminal portion of parathyroid-produced PTH
only in 8 of the first 13 amino acids. It has predicted iso-
forms of 139, 141, and 173 amino acids compared with 84
amino acids in PTH. PTHrP, like PTH, can mediate bone
resorption of calcium and renal tubular absorption of
calcium, but unlike PTH, serum calcium levels do not regu-
late its secretion. Recently, an aberrant extracellular calcium-
sensing receptor (CaR) has been associated with a
counterproductive increased release of PTHrP by tumor
cells, as well as potentially stimulating cell growth and
inhibiting apoptosis.
PTH and PTHrP are distinguishable by radioassay, and
for this reason, it is possible to distinguish humoral hypercal-
cemia of malignancy from coexisting primary hyperparathy-
roidism. Despite a high frequency of bony metastases,
prostate, small cell lung cancer, and colorectal carcinoma are
rarely associated with hypercalcemia.
In addition to PTHrP, a number of locally active
cytokines augment resorption of calcium from bone, includ-
ing interleukin 1 (IL-1), IL-3, IL-6, IL-8, and IL-11 and
tumor necrosis factors (TNF-α and TNF-β)—all of which
are components of what was formerly called osteoclast-
activating factor. Furthermore, transforming growth factor
(TGF-α), platelet-derived growth factor, and certain
hematopoietic colony-stimulating factors such as granulocyte-
macrophage colony-stimulating factor (GM-CSF) also can
augment bone resorption. In patients with myeloma,
increased bone resorption from cytokines is the primary
mechanism of hypercalcemia. Prostaglandin E2 also can
increase bone resorption. Two locally acting cytokines also
decrease the amount of calcium from bone: interferon-γ
and transforming growth factor β (TGF-β). Both inhibit
osteoclasts and bone resorption, and TGF-β promotes
osteoblast activity.
Some Hodgkin’s and non-Hodgkin’s lymphomas can 1-
hydroxylate sufficient amount of vitamin D to its more
highly active form. This increases gut absorption of calcium
and, together with the calcium resorption from cytokines
acting locally in bone, may produce hypercalcemia.
Hypercalcemia is a prominent feature of adult T-cell lym-
phomas (45% of cases) and of lymphomas and leukemias
associated with HTLV-1 (90%).
Clinical Features
When hypercalcemia results from malignancy, the cancer is
rarely occult. Patients with severe hypercalcemia (serum cal-
cium >14 mg/dL) are usually symptomatic. These symptoms
are often related to the rapidity of onset of hypercalcemia.
The clinical features of hypercalcemia and, in particular,
its neuromuscular manifestations tend to be much more
prominent in the elderly. Other factors such as the patient’s
performance status, recent chemotherapy, sites of metastasis,
and the presence of hepatic or renal dysfunction may
increase the severity of symptoms. Since calcium is a critical
regulator of cellular function, patients with hypercalcemia
may have a wide range of symptoms affecting different organ
systems. Conversely, the most common symptoms of hyper-
calcemia may be nonspecific and are similar to those seen in
patients with chronic or terminal illnesses, such as nausea,
anorexia, weakness, fatigue, lethargy, and confusion. In late
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stages, patients may be stuporous or comatose, and their
symptoms may mimic a neurologic emergency.
A. Neurologic—The major neurologic manifestations
include weakness, altered mental status, and altered deep
tendon reflexes. Initial manifestations may include subtle
personality changes, impaired concentration, apathy, mild
confusion and irritability, lethargy, hallucinations, and psy-
chosis, with progression to stupor and coma. Focal neuro-
logic signs are usually absent.
B. Gastrointestinal—Because of the depressive action of
hypercalcemia on autonomic nervous tissue, nonspecific
symptoms such as anorexia, nausea, and vomiting may
occur. These often progress to include abdominal pain, con-
stipation, frank obstipation, increased gastric acid secretion,
and acute pancreatitis.
C. Renal—Hypercalcemia causes a reversible tubular defect
in the kidney that limits urinary concentrating ability and
promotes dehydration or hypovolemia. If able, patients will
admit to polyuria, nocturia, and polydipsia. Metabolic alka-
losis is common, and acidosis occurs only when azotemia
supervenes. This contrasts with the effects of PTH, in which
a mild hyperchloremic acidosis is seen. Hypercalcemia also
can lead to precipitation of calcium phosphate crystals in the
 Figure 20–1. Mechanisms of hypercalcemia of malignancy. Osteoclast activity can be stimulated by hormones,
cytokines, and other substances from certain primary tumors distant from bone or by tumor in the bone marrow. In
other patients, local production of cytokines known as osteoclast-activating factors are the primary mediators of
increased calcium mobilization. Both peripheral blood and marrow lymphocytes produce cytokines that affect osteo-
clasts. 1,25(OH)2 vitamin D increases calcium absorption from the small intestine. Other local cytokines have an
inhibitory effect on osteoclast activity. [1,25(OH)2D = vitamin D; PTHrP = parathyroid hormone–related polypeptide;
IL = interleukin; TGF-α and TGF-β = transforming growth factors α and β; TNF-α and TNF-β = tumor necrosis factors α
and β; PDGF = platelet-derived growth factor; GM-CSF = granulocyte-macrophage colony-stimulating factor.]
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kidneys and ureters and the formation of renal calculi. Such
complications, however, are not commonly associated with
hypercalcemia of malignancy, and when they occur, the pos-
sibility of coexisting primary hyperparathyroidism should be
considered.
D. Cardiovascular—Hypercalcemia may cause electrocar-
diographic disturbances such as prolongation of the PR and
QRS intervals and shortening of the QT interval. With severe
hypercalcemia (>16 mg/dL), the T wave widens, increasing
the QT interval. At higher serum calcium concentra-
tions, bradyarrhythmias and bundle branch block may
develop, followed by complete heart block and cardiac arrest
in systole.
E. Bone and Extraskeletal Tissues—Hypercalcemia can
result either from humorally mediated bone resorption or
from osteolytic metastasis. Pain, fractures, and skeletal defor-
mities can occur. Metastatic calcification occurs in long-
standing and very severe hypercalcemia. Extraskeletal
deposition of calcium has been observed with hypercalcemia
in several organs, including the heart, lungs, kidneys, skin,
joints, and conjunctivae.
F. Laboratory Findings—Serum calcium, phosphate, and
albumin levels should be determined in all patients. Ionized
calcium is responsible for clinical manifestations and is
almost half the total serum calcium in normal subjects (the
rest is protein-bound). Measured ionized calcium is the
most accurate predictor of clinical features. A clinical esti-
mate of the “effect” of ionized calcium is the corrected
serum calcium equal to the measured calcium + 0.8 ×
(4 – measured albumin). This calculation is especially
helpful when hypoalbuminemia coexists with hypercal-
cemia. Hypophosphatemia in the presence of hypercal-
cemia strongly suggests the presence of PTHrP or primary
hyperparathyroidism. Elevated alkaline phosphatase is usu-
ally not helpful because it is seen in both primary hyper-
parathyroidism and hypercalcemia of malignancy. Direct
measurement of PTH and PTHrP may be necessary in some
patients.
G. Radiographs—Nephrocalcinosis and nephrolithiasis may
be present in long-standing hypercalcemia and suggest
hyperparathyroidism.
Differential Diagnosis
The differential diagnosis of hypercalcemia of malignancy
includes a wide variety of conditions (Table 20–2). Among
all patients, the two most common causes of hypercalcemia
are malignancy (35%) and primary hyperparathyroidism
(54%). Among hospitalized patients with hypercal-
cemia, 77% have malignancies, 4% have coexistent hyper-
parathyroidism, 2% have vitamin D intoxication, 2%
have tamoxifen-induced hypercalcemia, and 16% are due to
other causes. Table 20–3 lists features that may be used to
differentiate primary hyperparathyroidism from hypercal-
cemia of malignancy.
Treatment
There is no one regimen that should be applied to the acute
management of all cases of hypercalcemia. Moderate hyper-
calcemia with minimal symptoms may be managed with
administration of intravenous 0.9% NaCl. If the hypercal-
cemia is more severe and is symptomatic, furosemide and
calcitonin may be added. Since the effects of calcitonin are
not long-lasting, the use of bisphosphonates early in treat-
ment is indicated. In patients with lymphoma or myeloma
and hypercalcemia, corticosteroids are useful because of the
significant role of cytokines in the hypercalcemia.
Intravenous administration of sodium phosphate can lower
the serum calcium level rapidly, but its use is dangerous
because calcium phosphate complexes will deposit in blood
vessels, lungs, and kidneys with resulting severe organ dam-
age and even fatal hypotension. Therefore, intravenous phos-
phates are not recommended. Oral phosphates are of limited
value because diarrhea often develops with an intake of more
than 2 g/day. Azotemia and hyperphosphatemia are con-
traindications to phosphate therapy.
Table 20–2. Causes of hypercalcemia.
I. Primary hyperparathyroidism (54%)
II. Cancer (35%)
A. Caused by hormones (HHM) (80%)
1. Most common: Lung cancer (especially epidermoid) and renal
cell carcinoma.
2. Less common: Head and neck cancer, ovarian cancer,
hepatoma, pancreatic cancer, bladder cancer, endometrial
cancer, lymphomas, leukemia, multiple myeloma.
3. Isolated case reports: Esophageal cancer, colon cancer, rectal
cancer, cervical cancer, uterine leiomyosarcoma, vulvar cancer,
cancer of the penis, prostate cancer, adrenal cancer, melanoma,
hemangiopericytoma, branchial rest cancer, parotid cancer,
breast cancer, mammary dysplasia.
B. Caused by metastatic destruction of bone (20%). Breast cancer
(most common), multiple myeloma, lymphoma, and leukemia.
III. Others (11%)
A. Nonparathyroid endocrine disorders: Thyrotoxicosis, pheochromo-
cytoma, adrenal insufficiency, vasoactive intestinal polypeptide
hormone-producing tumor.
B. Granulomatous diseases: 1,25-(OH)2 vitamin D excess, sarcoidosis,
tuberculosis, histoplasmosis, coccidioidomycosis, leprosy.
C. Medications: Thiazide diuretics, lithium, estrogens, and antiestrogens.
D. Milk-alkali syndrome.
E. Vitamin A or vitamin D intoxication.
F. Familial hypocalciuric hypercalcemia.
G. Immobilization.
H. Parenteral nutrition.
HHM = humoral hyperglycemia of malignancy.
 CHAPTER 20460
Therapy for hypercalcemia in cancer patients centers on
four main mechanisms: (1) correction of volume depletion,
(2) inhibition of bone resorption of calcium, (3) enhance-
ment of renal calcium excretion, and (4) treatment of the
underlying malignancy. Table 20–4 summarizes the available
drugs and their dosages.
A. Fluid and Electrolytes—Volume and electrolyte reple-
tion are the first priorities. Normal saline (0.9% NaCl), usu-
ally containing potassium chloride (10–20 meq/L), is given at
a rate of 2–3 L/day. Loop diuretics such as furosemide (40–80 mg
intravenously) are used to induce calciuresis and preclude
volume overload once fluid deficits are corrected. Judicious
fluid administration or central venous pressure monitoring
may be appropriate in patients with poor urine output or
congestive heart failure. As a result of calcium-related renal
tubular impairment and the resulting polyuria, urine out-
put may not be a reliable measure of intravascular volume
repletion.
B. Calcitonin—Calcitonin is a useful adjunct in the initial
phase of therapy. It is nontoxic and acts within 4–24 hours.
Calcitonin promotes renal excretion of calcium, inhibits
bone resorption, and inhibits gut absorption of calcium. The
effects of calcitonin, however, are minor and of short dura-
tion. Calcitonin is usually administered over 24 hours as an
intravenous infusion in a dose of 3 units/kg or 100–400 units
subcutaneously every 8–12 hours.
C. Corticosteroids—Corticosteroids decrease intestinal cal-
cium absorption and inhibit bone resorption and in that way
act as vitamin D antagonists. They also inhibit the action of
some of the locally acting cytokines that mediate calcium
mobilization from bone. They are effective primarily in
hematologic malignancies and breast cancer, essentially to
control chronic hypercalcemia.
Primary Hyperparathroidism Hypercalcemia of Malignancy
Symptoms Mild or absent Symptomatic
Serum calcium Mildly increased (<14 mg/dL) Significantly increased (>14 mg/dL)
Serum phosphorus Decreased Variable
Serum potassium Normal Usually decreased
Serum chloride Increased∗ Low or normal
Serum bicarbonate Decreased (hyperchloremic acidosis) Normal or increased 
Urinary calcium Increased Markedly increased
Urinary cAMP Increased Variable
1,25-(OH)2 vitamin D Increased Usually decreased
∗Serum chloride:phosphate ratio is increased.
Table 20–3. Features used to differentiate primary hyperparathyroidism from malignancy-
related hypercalcemia.
Table 20–4. Treatment of hypercalcemia of malignancy.
1. IV fluid replacement with 3–6 L of 0.9% NaCl with 40–80 mg of
potassium chloride per liter over 24 hours.
2. Furosemide, 40–160 mg IV over 24 hours.
3. Bisphosphonates:
Pamidronate, 60–90 mg in 1 L 0.9% NaCl over 4–24 hours.
Etidronate, 7.5 mg/kg in 300 mL 0.9% NaCl over 3 hours for
3–5 days.
4. Calcitonin: Extremely useful in patients with life-threatening
hypercalcemia. It has the most rapid action: 2–4 hours.
600 IU in 1 L 0.9% NaCl over 6 hours.
6–8 IU/kg IM every 6–8 hours for 2–3 days.
5. Corticosteroids: 200–300 mg of hydrocortisone per day or equivalent.
6. Gallium nitrate: 200 mg/m2 in 1 L 5% dextrose over 24 hours for
5 days.
7. Plicamycin: 25 μg/kg for total dose of 1.5–2 mg IV administered
in brief infusion or over 12 hours. No benefit from prolonged
infusion.
8. Phosphates: Oral phosphates, 0.5–3 g/d diluted in water.
IV phosphates should not be given.
Formula to correct serum calcium for changes in serum albumin
concentration: Corrected serum calcium = measured total calcium
value (mg/dL) − serum albumin valve (g/dL) + 4.
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D. Bisphosphonates—Bisphosphonates are used routinely
because of their efficacy and low toxicity. They are potent
inhibitors of osteoclasts and bind to hydroxyapatite in bone
to inhibit dissolution. A single dose of pamidronate (60–90 mg
in 1 L of normal saline over 4–24 hours) by intravenous infu-
sion is safe and effective. Significant reductions in serum cal-
cium usually occur in 1–2 days and persist for several weeks.
Zoledronic acid is a more potent bisphosphonate that has
been associated with a higher proportion of correction of
hypercalcemia and more rapid normalization than
pamidronate. It is given intravenously as 4 mg over not less
than 15 minutes. The dose must be adjusted for renal insuffi-
ciency. Rare complications of bisphosphonates include acute
systemic inflammatory reaction, eye inflammation, renal fail-
ure, nephrotic syndrome, and hypocalcemia. Jaw osteonecro-
sis is seen primarily with long term use of bisphosphonates.
E. Dialysis—Hemodialysis is very effective in the treatment
of hypercalcemia but is usually reserved for management in
the setting of renal failure or life-threatening manifestations.
F. Other Therapies—Plicamycin and gallium nitrate decrease
bone resorption. Prostaglandin synthetase inhibitors and
other investigational drugs such as amifostine (WR-2721)
have been used. Amifostine inhibits PTH secretion and bone
resorption and facilitates urinary excretion of calcium.
All patients should be encouraged to avoid immobilization
and ambulate. In addition, liberal fluid intake and avoidance
of large amounts of foods rich in calcium are also suggested.
Halfdanarson TR, Hogan WJ, Moynihan TJ: Oncologic emergen-
cies: Diagnosis and treatment. Mayo Clin Proc 2006;81:835–48.
[PMID: 16770986]
Horwitz MJ, Stewart AF: Humoral hypercalcemia of malignancy.
In Favus MJ (ed), Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism, 5th ed. Philadelphia:
Lippincott Williams & Wilkins, 2003, pp. 246–50.
Spinazze S, Schrijvers D: Metabolic emergencies. Crit Rev Oncol
Hematol 2006;58:79–89. [PMID: 16337807]
 Hypocalcemia in Malignant Disease
ESSENT IALS  OF  D IAGNOS I S
 Tetany; paresthesias of the face, hands, and feet.
 Positive Chvostek and Trousseau signs.
 Muscle cramps, laryngeal spasm, headache, lethargy.
 Low serum calcium (corrected) or low ionized calcium.
 Osteoblastic metastases (breast or prostate cancer) or
tumor lysis syndrome with elevated serum phosphorus.
General Considerations
Hypocalcemia is a rare complication of cancer resulting from
osteoblastic metastasis secondary either to rapid bone healing
in patients with prostate or breast cancer receiving hormonal
therapy or to hyperphosphatemia in patients with tumor
lysis syndrome. The most common neoplasm associated with
hypocalcemia is prostate cancer, and 31% of patients with
prostate cancer and extensive osteoblastic bone metastasis
develop hypocalcemia. The skeleton in these patients has
been described as a “calcium sink.” Hypocalcemia secondary
to tumor lysis syndrome may be severe and appears to
result from a rise in the serum calcium × phosphorus prod-
uct, leading to precipitation of calcium in soft tissues,
including the kidneys, and the development of secondary
hyperparathyroidism.
Hypocalcemia also may occur secondarily in patients with
low circulating 1,25(OH)2 vitamin D and calcifying chon-
drosarcoma. Magnesium deficiency results in hypocalcemia
in patients with prolonged nasogastric drainage, parenteral
hyperalimentation without magnesium supplementation,
cisplatin therapy, long-term diuretic therapy, chronic diar-
rhea, and chronic alcoholism and does not respond to cal-
cium replacement alone. Treatment of hypercalcemia with
plicamycin, bisphosphonates, or intravenous phosphate also
may cause hypocalcemia.
Clinical Features
The diagnosis of hypocalcemia is made with ease in patients
who develop tetany. Paresthesias of the face, hands, and feet
associated with muscle cramps, laryngeal spasm, diarrhea,
headache, lethargy, irritability, or seizures are the common
clinical manifestations. Chvostek’s and Trousseau’s signs are
usually present. The ECG usually shows a prolonged QT
interval. In long-standing cases, dry skin, papilledema, and
cataracts may develop.
Differential Diagnosis
The differential diagnosis of hypocalcemia should include
severe alkalosis secondary to vomiting, nasogastric suction,
or hyperventilation and severe muscle cramps resulting from
vincristine or procarbazine therapy.
Treatment
Treatment of acute severe hypocalcemia (serum calcium < 6
mg/dL) consists of intravenous administration of calcium
gluconate or calcium chloride, 1 g every 15–20 minutes until
tetany disappears, and magnesium sulfate, 1 g intravenously
or intramuscularly every 8–12 hours if the serum magne-
sium level is less than 1.5 mg/dL or is unknown. In patients
with moderate hypocalcemia (serum calcium >7 mg/dL),
calcium and magnesium may be replaced more slowly.
Carmeliet G et al: Disorders of calcium homeostasis. Best Pract Res
Clin Endocrinol Metab 2003;17:529–46. [PMID: 14687587]
Maalouf NM et al: Bisphosphonate-induced hypocalcemia: Report
of 3 cases and review of literature. Endocr Pract 2006;12:48–53.
[PMID: 16524863]
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 Tumor Lysis Syndrome
ESSENT IALS  OF  D IAGNOS I S
 Lethargy, tetany, muscle cramps, convulsions.
 Administration of chemotherapy to patient with rapidly
proliferating malignancy.
 Elevated serum uric acid, potassium, phosphate, and
urea nitrogen.
General Considerations
When given to a patient with a highly responsive (usually
rapidly growing) malignancy, chemotherapy may trigger
release of massive amounts of potassium, phosphate, uric
acid, and other breakdown products of dying tumor cells
into the bloodstream. Hypocalcemia owing to hyperphos-
phatemia may occur. This syndrome of tumor lysis occurs
most commonly in patients with rapidly proliferating and
chemotherapy-sensitive malignancies, such as acute
leukemia and Burkitt’s lymphoma and, on rare occasions,
following treatment of solid tumors and chronic lympho-
cytic leukemia (CLL). Tumor lysis syndrome has been
reported after chemotherapy, radiotherapy, monoclonal
antibody treatment, corticosteroids, and rarely sponta-
neously. Life-threatening complications may occur, including
renal failure from hyperuricemia and cardiac arrhythmias
induced by hyperkalemia or hypocalcemia.
Diagnosis
Diagnosis of tumor lysis syndrome is made most often from
laboratory studies. However, lethargy, tetany, muscle cramps,
and convulsions occurring in a patient with an appropriate
tumor who has just received chemotherapy should prompt
evaluation. Hyperkalemia, hyperphosphatemia, azotemia,
and oliguria usually are present.
Treatment
Early recognition of risk is the key to prevention and treat-
ment of this complication of cancer therapy. Despite appro-
priate treatment, renal insufficiency still may occur.
However, prognosis is good, and recovery to baseline renal
function is expected.
A. Hyperkalemia—Immediate treatment of hyperkalemia
consists of administration of 50–100 mL of 50% dextrose in
water and 10 units of regular insulin. Removal of potassium
can be achieved with oral sodium polystyrene sulfonate,
20–30 g every 6 hours. Hemodialysis may be necessary for
the management of refractory hyperkalemia.
B. Hyperphosphatemia—Hyperphosphatemia is typically
severe, with serum levels ranging from 6 up to as much as
35 mg/dL resulting from tumor cell lysis and subsequent
renal failure. Patients should be given 20% dextrose in water
and insulin until the serum phosphate level falls below 7
mg/dL. Aluminum hydroxide, 30–60 mL orally every 2–6
hours, is used to bind phosphate in the intestines. Oral fluids
are given at the rate of 2–4 L every 24 hours. Dialysis may be
necessary for patients with renal failure. Hyperphosphatemia
may be accompanied by hypocalcemia as well.
C. Hyperuricemia and Hyperuricosuria—Increased uri-
nary uric acid excretion may occur in untreated patients with
rapidly growing malignancies or during their treatment with
chemotherapy or radiation therapy. Uric acid nephropathy
secondary to the precipitation of uric acid crystals in the kid-
neys may result. Nephrolithiasis with urate stones or urate
interstitial nephritis also may occur. When massive doses of
allopurinol are used to prevent uric acid production, renal
oxypurinol stones may form occasionally.
Prevention of anticipated hyperuricemia is the corner-
stone of management. Allopurinol should be given to
patients with myeloproliferative disorders and hematologic
malignancies at least 12 hours before starting chemotherapy.
Rasburicase, a recombinant urate oxidase, does not cause
xanthine and hypoxanthine to accumulate but rather con-
verts urate to allantoin, a much more soluble product.
Rasburicase is much more effective and rapid in lowering
plasma uric acid levels. However, rasburicase is highly
immunogenic, with development of antirasburicase anti-
bodies occurring in the majority of patients exposed. This
limits the use of this agent to those with severe and poorly
responsive hyperuricemia.
D. Hydration—Vigorous hydration and alkalinization of the
urine decrease the risks of urinary tract precipitation of uric
acid and may decrease hyperkalemia. Urine flow should be
maintained at a rate of more than 100 mL/h, and urine pH
should be between 7.0 and 7.5. Sodium bicarbonate or aceta-
zolamide is given to alkalinize the urine. The ideal choice of
intravenous fluid is not clear, but usually dextrose 5% in
0.45% NaCl is given with 50–100 meq of NaHCO3 added per
liter starting 24–48 hours before treatment, if possible. A rare
complication of urinary alkalinization is precipitation of
calcium phosphate stones.
Coiffier B, Riouffol C: Management of tumor lysis syndrome in
adults. Exp Rev Anticancer Ther 2007;7:233–9. [PMID:
17288532]
Del Toro G, Morris E, Cairo MS: Tumor lysis syndrome:
Pathophysiology, definition, and alternative treatment
approaches. Clin Adv Hematol Oncol 2005;3:54–61. [PMID:
16166968]
Rampello E, Fricia T, Malaguarnera M: The management of tumor
lysis syndrome. Nat Clin Pract Oncol 2006;3:438–47. [PMID:
16894389]
Tiu RV et al: Tumor lysis syndrome. Semin Thromb Hemost
2007;33:397–407. [PMID: 17525897]
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 Hyponatremia in Malignancy
ESSENT IALS  OF  D IAGNOS I S
 Nausea, anorexia, lethargy, confusion, weakness, con-
vulsions, coma.
 Low plasma sodium with persistent excretion of con-
centrated urine.
 Normal renal function with low serum urea nitrogen,
absence of fluid retention, and absence of intravascular
volume contraction.
 History of malignancy, most frequently associated with
small cell carcinoma of the lung.
General Considerations
Hyponatremia in malignant disease is most often associated
with the syndrome of inappropriate antidiuretic hormone
secretion (SIADH), resulting from secretion of ADH by the
tumor. SIADH causes an increase in total body water with
moderate expansion of plasma volume, hyponatremia,
plasma hypo-osmolality, and inability to excrete maximally
diluted urine. It may occur with any malignancy but is most
frequently associated with small cell carcinoma of the lung
and mesothelioma. Other causes of SIADH are the admin-
istration of thiazide diuretics, vincristine, cyclophos-
phamide, chlorpropamide, tolbutamide, carbamazepine,
intravenous opioids, and psychotropic drugs (eg, amitripty-
line and thioridazine) in the setting of treatment of the can-
cer patient.
Clinical Features
A. Symptoms and Signs—Lethargy, nausea, anorexia, and
generalized weakness are the most common symptoms. Such
symptoms, however, are nonspecific and may be caused by
the primary cancer rather than hyponatremia. Confusion,
convulsions, coma, and death may occur if hyponatremia is
severe or of rapid onset.
B. Laboratory Findings—Plasma sodium concentration is
less than 135 meq/L, and there is persistent excretion of
urinary sodium. Renal function tests are normal, and
edema and intravascular volume contraction do not occur.
Blood urea nitrogen (BUN) concentration is characteristi-
cally low.
Diagnostic criteria for SIADH include hyponatremia
with low serum urea nitrogen (<10 mg/dL), absence of
intravascular volume contraction, persistent urinary excre-
tion of sodium (>30 meq/L), absence of fluid retention such
as peripheral edema or ascites, normal renal function, and
plasma hypotonicity in the presence of urine that is not
maximally dilute (urine osmolarity >100–150 mOsm/L with
plasma osmolarity <260 mOsm/L).
Differential Diagnosis
The differential diagnosis of low plasma sodium consists of
a long list that includes edematous states (eg, heart failure,
nephrotic syndrome, and cirrhosis), myxedema, salt-wasting
states (eg, mineralocorticoid deficiency, glucocorticoid
deficiency, and chronic renal failure), GI electrolyte losses
with hypotonic fluid replacement, compulsive water drink-
ing, and hypothalamic disorders. Pseudohyponatremia
secondary to hyperglycemia, mannitol administration,
and paraproteinemia should be excluded.
Treatment
Treatment of hyponatremia is discussed in Chapter 2. The
management of severe hyponatremia (plasma sodium < 110
meq/L) should be aggressive in a patient who is comatose or
convulsing, with the goal of raising plasma sodium above
120 meq/L but no higher than 130 meq/L. In other patients,
a maximum increase in plasma sodium of 8 meq/L in 24 hours
should be the target because of the complication of osmotic
demyelination syndrome.
Patients with plasma sodium levels of 125 meq/L or less
should be restricted to 500–700 mL of fluid a day. Patients
with higher plasma sodium concentrations are restricted to
1000 mL/day. Severe hyponatremia or symptomatic hypona-
tremia of any severity may require other treatment.
Administration of 0.9% NaCl will not correct hyponatremia
in patients with SIADH who have a urine osmolality of more
than 308 mOsm/L. In these patients, hypertonic saline (3%
NaCl, 1000 mL over 6–8 hours) and furosemide (40–80 mg
every 6–8 hours as needed) may be necessary. Central venous
pressure monitoring can reduce the risk of the precipitous
development of pulmonary edema. Plasma sodium and potas-
sium concentrations should be monitored hourly. Furosemide
and hypertonic saline are discontinued when plasma sodium
exceeds 110 meq/L and fluid restriction is started.
Direct antagonism of inappropriately secreted arginine
vasopressin should facilitate water elimination. Conivaptan,
a new vasopressin antagonist approved for euvolemic
hyponatremia, is given with an intravenous loading dose of
20 mg, followed by 20 mg administered as a continuous
intravenous infusion over 24 hours.
For chronic hyponatremia, demeclocycline, 150–300 mg
orally four times daily, may be given to patients who cannot
tolerate chronic fluid restriction or do not improve with fluid
restriction. Demeclocycline induces nephrotoxic diabetes
insipidus and may cause azotemia.
Adler SM, Verbalis JG: Disorders of body water homeostasis in
critical illness. Endocrinol Metab Clin North Am
2006;35:873–94. [PMID: 17127152]
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 Hypokalemia & Ectopic ACTH Secretion
A number of tumors secrete ACTH, stimulate adrenal pro-
duction of corticosteroids, and result in Cushing’s syndrome.
These tumors include small cell lung cancer; carcinoid
tumors of the bronchi, pancreas, thymus, and ovary; islet cell
tumors; and cancers of the ovary, thyroid, and prostate, as
well as pheochromocytoma, hematologic malignancies,
and sarcomas. Unfortunately, most malignant causes of
ectopic ACTH production are rapidly fatal. Patients typically
present with weakness, cachexia, and hypertension. Typical
features of nonmalignant chronic Cushing’s syndrome are
often absent.
The differential diagnosis of hypokalemia includes GI
losses associated with alkalosis, vomiting, prolonged nasogas-
tric suction, villous adenoma of the colon, Zollinger-Ellison
syndrome, and chronic laxative abuse. Hyperaldosteronism,
hypercortisolism, hypercalcemia, and licorice ingestion also
may cause hypokalemia.
The most effective treatment of hypokalemia is control of
the underlying tumor. Carcinoid, thyroid tumors, pheochro-
mocytoma, and islet cell tumors are treated surgically if they
are resectable. If the tumors are nonresectable, chemotherapy
may be used (eg, mitotane, metyrapone, ketoconazole, and
aminoglutethimide). Potassium replacement should be
accomplished as early as possible. Spironolactone, 100–400 mg
daily, is helpful.
 Hypophosphatemia in Malignancy
Hypophosphatemia (serum phosphorus <3 mg/dL) is occa-
sionally associated with rapidly growing tumors (eg, acute
leukemia) and marked nutritional deprivation and cachexia.
Symptoms may include generalized weakness, respiratory
muscle weakness causing respiratory failure, decreased
myocardial function, platelet dysfunction, and leukocyte dys-
function. Hemolysis and rhabdomyolysis may occur with
serum phosphorus levels of less than 1 mg/dL. The manage-
ment of severe hypophosphatemia (serum phosphorus <1
mg/dL) consists of intravenous administration of a solution
of 30–40 mmol/L of neutral sodium phosphate or potassium
phosphate at the rate of 50–100 mL/h. Intravenous adminis-
tration of phosphates should be monitored very carefully.
Patients with mild hypophosphatemia (serum phosphorus
1–2 mg/dL) can be given inorganic phosphate supplements
orally unless severely symptomatic.
 Hyperglycemia in Malignancy
Hyperglycemia not due to insulin deficiency is present in
many patients with cancer. It occurs in patients with
glucagonoma, somatostatinoma, pheochromocytoma, and
ACTH-secreting tumors. Nonketotic hyperglycemia with
hyperosmolar coma may occur as a complication of treat-
ment with cyclophosphamide, vincristine, or prednisone in
patients with mild diabetes mellitus and in patients who are
receiving hyperalimentation.
Hyperglycemia caused by a tumor may respond to treat-
ment of the primary tumor with surgical resection, radiation
therapy, or chemotherapy. Hyperosmolar coma is treated
with replacement of fluid losses (intravenous NaCl solu-
tions) and insulin administration.
 Hypoglycemia in Malignancy
Hypoglycemia may be secondary to inappropriate secretion
of insulin (insulinoma) or to nonsuppressible insulin-like
substances that are produced by some tumors. Large
retroperitoneal fibrosarcomas, mesotheliomas, and renal,
adrenal, and primary hepatocellular carcinomas are the most
common tumors associated with hypoglycemia. Patients
with extensive hepatic metastases may develop severe hypo-
glycemia secondary to depletion of glycogen and impaired
gluconeogenesis. Other causes of hypoglycemia include
administration of drugs such as insulin, oral hypoglycemic
agents, alcohol, and salicylates. Starvation, chronic liver dis-
ease, hypoadrenalism, hypopituitarism, and myxedema also
may cause hypoglycemia. Pseudohypoglycemia may occur in
patients with marked granulocytosis, especially in the setting
of myeloproliferative disorders.
Tumor-associated hypoglycemia produces changes that
are characteristic of hypoglycemia in the fasting state, such as
fatigue, convulsions, or coma. On the other hand, tremors,
sweating, tachycardia, and hunger are symptoms more char-
acteristic of reactive hypoglycemia in the postprandial state.
Intravenous glucose is the treatment of choice and should
be given to all patients with blood glucose levels below 40
mg/dL and symptomatic patients with glucose levels below
60 mg/dL. Continuous infusion of 10–20% dextrose in
water should be given at a rate to maintain a blood glu-
cose level above 60 mg/dL. If blood glucose levels cannot
be increased to a safe level, prednisone, diazoxide, or
glucagon may be considered.
 Lactic Acidosis
Lactic acidosis is seen in the ICU most often because of
severe hypoperfusion from septic or cardiogenic shock.
Rarely, patients with leukemia or lymphoma without obvi-
ous shock appear to have tumor overproduction of lactic
acid, possibly related to increased anaerobic metabolism
from lack of perfusion to tumor. There may be associated
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hypoglycemia. Treatment of the underlying tumor may help,
but lactic acidosis in cancer patients has a poor prognosis.
Spinazze S, Schrijvers D: Metabolic emergencies. Crit Rev Oncol
Hematol 2006;58:79–89. [PMID: 16337807]
SUPERIOR VENA CAVA SYNDROME
ESSENT IALS  OF  D IAGNOS I S
 Distention of neck and anterior chest wall veins.
 Edema of the face; cyanosis and edema of upper
extremities.
 Clinical evidence of intrathoracic malignancy.
General Considerations
There are no clinical or experimental data to support the
concept that superior vena cava obstruction is an oncologic
emergency, except perhaps on very rare occasions when the
patient presents with symptoms caused by tracheal obstruc-
tion or severe cerebral edema.
Superior vena cava syndrome was first described in 1751.
Malignant tumors are the most common cause (60%), but
recently, benign causes have increased in proportion to the
number of intravascular devices placed in the large systemic
veins in the thorax. Bronchogenic carcinoma is the leading
cause of superior vena cava syndrome and is responsible for
nearly 80% of all malignant causes. Approximately 5% of all
patients with bronchogenic carcinoma develop superior vena
cava syndrome during their lifetime, but the frequency of
this syndrome in small cell cancer is much higher. Malignant
lymphomas are responsible for approximately 15% of malig-
nant cases. Other causes (<5%) include metastatic disease to
the mediastinal lymph nodes (from primary breast and tes-
ticular cancer and, rarely, sarcomas). Benign causes are now
most commonly from complications of intravascular devices
(eg, catheters and pacemakers), with mediastinal fibrosis sec-
ondary to histoplasmosis, tuberculosis, pyogenic infection,
and radiation therapy to the mediastinum much less com-
mon. Very rarely, superior vena cava syndrome may be
caused by benign mediastinal tumors such as dermoids, ter-
atomas, thymomas, retrosternal goiters, sarcoidosis, and
aneurysms of the ascending thoracic aorta.
Malignant obstruction of the superior vena cava may be
caused by the tumor compressing its thin wall or invading it.
Thrombosis with clot formation is usually present. Collateral
circulation develops gradually. The collateral circulation
involves the internal mammary, intercostal, azygos, hemiazy-
gos, superior epigastric, and inferior epigastric veins. It
should be noted that in rapidly growing tumors, engorge-
ment of the venous collateral circulation may be absent.
Incompetence of the valves of internal jugular veins may
result only rarely in severe cerebral edema. Obstruction of
the trachea by mediastinal tumors is a serious associated
complication.
Clinical Features
The most common physical findings in superior vena cava
syndrome are neck and anterior chest wall vein distention
(60%), tachypnea (50%), edema of the face (50%), and
cyanosis and edema of the upper extremities (15%). The
diagnosis of superior vena cava syndrome is made on clinical
grounds in almost all patients. Superior vena cavography
may be used to verify the diagnosis and localize the site of
obstruction. Chest radiographs, CT scans, and MRI demon-
strate, evaluate, and define the extent of the mediastinal
lesion. Chest radiographs readily demonstrate a mass in
more than 90% of patients. MRI has no specific advantage
over CT scan in this disorder.
Although the symptoms of superior vena cava syndrome
are quite distressing to the patient, attempts to obtain a defi-
nite histopathologic diagnosis should be pursued vigorously
at the earliest opportunity. More than 60% of these patients
have small cell lung cancer or lymphomas that are appropri-
ately treated with chemotherapy, and early treatment with
radiation therapy or corticosteroids before making a definite
histopathologic diagnosis may make subsequent diagnosis
difficult or impossible. The diagnosis may be established by
sputum cytology, bone marrow biopsy, bronchoscopy, lymph
node biopsy, mediastinotomy, and anterior thoracotomy.
Mediastinoscopy with biopsy is not recommended owing to
the high incidence of severe hemorrhage, increasing neck
edema, and failure of wound healing. Adequate tissue biopsy
and a touch-preparation for pathologic examination should
be done when the diagnosis of lymphoma is suspected.
Ample data support the safety of invasive diagnostic proce-
dures in patients with superior vena cava syndrome except
those with tracheal obstruction or laryngeal edema.
Treatment
Supportive therapy should be instituted as soon as the
patient is admitted to the hospital. Upper airway obstruction
from tracheal compression with resulting hypoxia must be
addressed promptly. Corticosteroids may reduce associated
brain and possibly tracheal edema and lessen secondary
inflammatory reaction. Endotracheal intubation should be
avoided if possible in patients with tracheal obstruction to
prevent further edema. Frequently, the tracheal obstruction
is present in the more distal part of the trachea and cannot
be bypassed with endotracheal intubation. Tracheostomy is
rarely indicated for the same reasons. Placement of a self-
expanding metal endoprosthesis stent provides rapid relief
and is successful in over 90% of patients.
Chemotherapy is the treatment of choice for patients
with small cell lung cancer, lymphomas, and germ cell
tumors—more than 60% of patients with superior vena cava
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syndrome. Radiation therapy is the only treatment available
for other cancers. Spiral saphenous vein bypass grafting also
may be useful in selected patients. Anticoagulants and
antifibrinolytic agents are of no value and may be harmful.
Diuretics are of little help.
Overall, it has been observed that improvement in symp-
toms occurs in 50–70% of patients over a period of 1–2
weeks of treatment rather than within the first few days. It is
suggested that such improvement may be due to the develop-
ment of collateral circulation rather than to relief of the vena
caval obstruction. Studies have shown that in patients with
complete clinical symptomatic relief, the superior vena cava
lumen remained completely obstructed in 46% on venogra-
phy and in 76% at autopsy. Individual mortality is related to
the underlying malignancy rather than to the presence of
superior vena caval obstruction.
Rice TW, Rodriguez RM, Light RW: The superior vena cava syn-
drome: Clinical characteristics and evolving etiology. Medicine
(Baltimore) 2006;85:37–42. [PMID: 16523051]
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Cardiac Problems
in Critical Care
Shelley Shapiro, MD, PhD
Malcolm M. Bersohn, MD, PhD
Critically ill patients can present challenging cardiac prob-
lems for both diagnosis and management. Many critically ill
patients develop cardiac problems secondary to the metabolic
and hemodynamic consequences of their underlying illness.
Others have preexisting cardiac conditions that are either well
compensated or asymptomatic prior to presentation to the
ICU and become clinically relevant during their ICU course.
A final group of patients is treated in the ICU for known car-
diac conditions or has their heart condition diagnosed during
their ICU admission. In all of these patients, the interplay of
the cardiac illness with other medical problems critically
influences the patient’s outcome. Therefore, defining the type
and severity of the underlying cardiac problem, considering
their relationship to other medical problems, and treating the
heart disease are important considerations. As always, the key
factor in the management of cardiac problems is a high
degree of suspicion and early diagnosis. Methods for identify-
ing and diagnosing cardiac disease in critically ill ICU
patients will be emphasized throughout this chapter.
 Congestive Heart Failure
ESSENT IALS  OF  D IAGNOS I S
 Cardiomegaly, decreased ventricular ejection fraction or
abnormal ventricular wall motion, elevated pulmonary
artery wedge pressure, low cardiac output.
 May have a previously known cause such as valvular heart
disease or cardiomyopathy but also may present as a result
of ischemia or secondary to severe systemic hypertension.
 Acute pulmonary edema: dyspnea, orthopnea, rales,
and wheezing; abnormal chest x-ray with perihilar con-
gestion; hypoxemia.
 Cardiogenic shock: hypotension; abnormal renal,
hepatic, and CNS function due to decreased perfusion;
lactic acidosis.
General Considerations
Congestive heart failure is a major therapeutic and diagnos-
tic challenge because of the number of its possible causes, the
number of patients who have heart failure, and the associ-
ated disability. Congestive heart failure is the most frequent
diagnostic category coded in Medicare patients. Determining
the cause and severity of congestive heart failure is extremely
important for effective treatment. Although coronary artery
disease is a frequent cause of congestive heart failure, partic-
ularly in the elderly, there are many other causes. For exam-
ple, congestive heart failure with pulmonary edema
secondary to mitral stenosis is managed quite differently
from that due to dilated cardiomyopathy. Therapy effective
in treating congestive heart failure in a patient with severe
mitral regurgitation could be lethal in a patient with critical
aortic stenosis. With the ability to perform valve replace-
ment and repair, coronary bypass grafting and angioplasty,
and the possibility of cardiac transplantation, a specific car-
diac diagnosis has implications for interventional manage-
ment as well as drug therapy.
The causes of chronic congestive heart failure may be very
different from the causes of acute failure. Acute congestive
heart failure in critically ill patients is due to myocardial
ischemia or infarction, acute valvular insufficiency (eg, mitral
or aortic regurgitation), worsening aortic stenosis or mitral
stenosis, acute myocarditis (rare), cardiotoxic drugs, alcohol,
and sepsis. Often, volume overload (owing to fluid volume
administered in the ICU for treatment of hypotension or as
part of administration of therapy for other disease processes)
precipitates heart failure in the ICU setting. This may be com-
pounded by anemia and/or by reduced renal function result-
ing in additional fluid retention and volume expansion. The
role of excessive fluid resuscitation and accumulating vol-
ume overload in ICU patients cannot be too highly empha-
sized. Hypoalbuminemia also can add to the picture by
allowing fluid to transudate at lower oncotic pressures.
Recently, a new acute form of heart failure has been
described in patients suffering acute severe stress resulting in
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
CHAPTER 21
acute severe myocardial dysfunction (mimicking myocardial
infarction or acute cardiomyopathy). This syndrome, more
common in females, appears to be reversible but presents as
life-threatening heart failure. Chronic congestive heart fail-
ure is often idiopathic, although in many cases it is associated
with ischemic heart disease, chronic valvular heart disease,
and hypertension. The additional stress of the ICU and asso-
ciated critical illness may worsen preexisting myocardial dys-
function and heart failure in a previously stable patient.
A high degree of suspicion of congestive heart failure is
required to identify subtle cases or patients with coexisting
heart failure. Patients in the ICU with dyspnea and hypox-
emia often have combined heart and lung disease, and
patients with known pulmonary disease can develop cardiac
disease as a result of the increased stress of sepsis, hypoxia, or
deterioration of pulmonary function. Any patient with unex-
plained hypoxemia, hypotension, or a worsening clinical
state requires assessment of cardiac function.
A. Cardiac Function in the Normal Heart—Cardiac out-
put is the product of stroke volume and heart rate. Stroke
volume is determined by three factors: preload, afterload,
and contractility. In the intact heart, preload is the end-
diastolic tension or wall stress and is ultimately determined
by the resting length of the muscle or the degree of stretch of
the muscle fibers. Preload is directly related to the compli-
ance of the ventricle and the end-diastolic pressure.
Although preload is a measure of force, in conceptual terms
it can be thought of as being most closely related to the end-
diastolic volume of the ventricle. As the ventricular volume
and pressure increase, so does the preload. Pulmonary capil-
lary wedge pressure is often used when clinically describing a
patient’s preload.
Afterload is the resistance against which the ventricle
ejects blood. Afterload or tension on the left ventricle can be
described by the formula ΔP × r/h, where ΔP is the trans-
mural pressure during ejection, r is the radius of the left ven-
tricular chamber, and h is the thickness of the ventricular
wall. Stroke volume is inversely proportional to afterload.
Contractility is the inherent ability of the muscle to con-
tract and is independent of the loading conditions on the heart
(ie, preload and afterload). Circulating catecholamines and
increased sympathetic efferent activity increase contractility.
Cardiac performance can be improved for a given level of
myocardial contractility by changing the loading conditions.
B. Cardiac Function in Congestive Heart Failure—
Congestive heart failure develops when cardiac function is
inadequate to maintain sufficient cardiac output to supply
the metabolic needs of the body at normal filling pressures
and heart rate. In mild heart failure, cardiac function may
be adequate at rest. However, exercise or illness can
increase metabolic demands that may not be met when
cardiac reserve is inadequate. Thus congestive heart failure
may be precipitated by critical illness with attendant fever,
anemia, and vasodilation. In heart failure owing to
decreased left ventricular function with reduced stroke vol-
ume, cardiac output may be transiently maintained by
increased heart rate or by increased preload with ventricu-
lar dilation and increased volume. The increasing use of
beta-blockers in the treatment of chronic congestive heart
failure, ischemia, and chronic coronary artery disease may
blunt the sympathetic response and tachycardia necessary
to maintain cardiac output. Acutely, however, cardiac out-
put may be insufficient, and signs and symptoms of hypop-
erfusion including hypotension, cyanosis, and peripheral
vasoconstriction, may be present (forward failure).
Inadequate ventricular emptying (low forward flow) results
in elevated left atrial and left ventricular end-diastolic vol-
ume and pressure that are transmitted back into the lungs
and the pulmonary venous system with transudation of
fluid. Clinically, this is manifested by rales, hypoxemia, and
dyspnea (backward failure).
A number of neurally and hormonally mediated
responses develop in an attempt to compensate for inade-
quate cardiac performance. These compensatory responses
include renal-mediated fluid retention and peripheral vaso-
constriction, tachycardia, and ventricular dilation which
attempt to maintain systemic blood pressure and cardiac out-
put. However, these compensations frequently are counter-
productive and worsen hemodynamic status. For example,
vasoconstriction, while maintaining systemic blood pressure,
increases ventricular afterload, ultimately decreasing stroke
volume and cardiac output; fluid retention increases preload
(improving stroke volume), but it also raises pulmonary
venous pressure and is detrimental to oxygenation and gas
exchange. Tachycardia increases cardiac output but also
increases myocardial oxygen demand which is particularly
devastating in the setting of myocardial ischemia and
decreases diastolic time needed for optimal ventricular fill-
ing, which is particularly problematic in patients with dias-
tolic dysfunction (problems with ventricular stiffness).
It is now well recognized that vasoconstriction and tachy-
cardia, previously considered compensatory and useful to
the patient, play important roles in the progression of con-
gestive heart failure. This is why afterload-reduction therapy
with angiotensin-converting enzyme (ACE) inhibitors or
other vasodilating agents and aggressive diuretic therapy have
greatly improved survival in this disorder. Beta-adrenergic
blockade in stable patients with compensated heart failure is
useful and prolongs life by decreasing the disadvantageous
effects of adrenergic stimulation. The benefit of beta-blockers
must be weighed against worseing heart failure and should
be withheld until heart failure is well controlled.
Clinical Features
A. Symptoms and Signs—Patients with congestive heart
failure may develop symptoms slowly or acutely. They may
complain of peripheral edema or of congestive symptoms
such as dyspnea, orthopnea, or paroxysmal nocturnal dysp-
nea. Symptoms consistent with decreased cardiac output
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include fatigue and exercise intolerance. Chest pain may be a
feature of acute-onset congestive heart failure associated
with myocardial ischemia, infarction, or severe hypertension.
Because of sedation and decreased activity in the critical care
setting, ICU patients may not complain of any symptoms at
all. An increasing heart rate, decreasing oxygen saturation, or
increasing oxygen requirement may be the only clues.
Patients who present with acute pulmonary edema may
have pink frothy sputum, rales, expiratory wheezes, and cen-
tral along with peripheral cyanosis. Tachycardia and
hypotension are manifestations of decreased cardiac output;
in these patients, low output may be accompanied by periph-
eral vasoconstriction, with peripheral cyanosis, cold extrem-
ities, and diaphoresis. In patients in whom severe systemic
hypertension is causally related to congestive heart failure,
blood pressure may be high despite low cardiac output. In
patients with cardiogenic shock, hypotension is accompa-
nied by evidence of very poor peripheral perfusion. On
examination, patients with dilated cardiomyopathy may have
an S3 gallop, a murmur consistent with mitral regurgitation,
and elevated jugular venous pressure. Other findings depend
on the specific cause and may include murmurs consistent
with valvular heart disease and an S4 gallop. However, in an
ICU setting, many of the findings may be blunted or difficult
to appreciate. Patients with long-standing chronic heart fail-
ure may have high filling pressures and severe heart failure
without the development of rales or an S3 owing to the devel-
opment of chronic pulmonary hypertension and other com-
pensatory mechanisms. They are in heart failure nevertheless
and respond to appropriate therapy once the diagnosis is
established.
B. Laboratory Findings—Patients may present with hypox-
emia, metabolic acidosis from lactic acidosis, and hypona-
tremia. In patients with hypotension or shock, renal and
hepatic function tests may be abnormal.
C. Electrocardiography—The ECG should be examined for
evidence of myocardial ischemia or infarction, atrial hyper-
trophy, and ventricular hypertrophy. Rhythm disturbances
(eg, atrial fibrillation or flutter) may be a cause or an effect
of congestive heart failure. Patients with dilated cardiomy-
opathy or severe left ventricular hypertrophy owing to
hypertension or hypertrophic processes may have conduc-
tion or voltage abnormalities consistent with left ventricular
hypertrophy. Tachycardia may indicate poor hemodynamic
performance.
D. Imaging Studies—
1. Chest x-ray—Chest x-ray may show cardiomegaly in
patients with dilated or hypertrophic cardiomyopathy.
However, patients with valvular heart disease may have only
a mild increase in heart size or isolated chamber enlarge-
ment. Ventricular dilatation may not be present in acutely
developing heart failure and therefore not seen on x-ray.
Cardiogenic pulmonary edema is usually marked by central
or perihilar infiltrates, increased size of vessels serving the
upper portions of the lungs in the upright position, and
increased prominence of interlobular septa—usually bilat-
eral and symmetric. Pleural effusions are common. Chest
x-rays are very important to exclude pulmonary disease that
may mimic heart failure, in particular acute respiratory
distress syndrome (ARDS) and severe pneumonia.
2. Echocardiography—Noninvasive testing, particularly
in a critically ill patient, may be difficult but gratifying if suc-
cessful in identifying a treatable cause of congestive heart
failure. Echocardiography, because of its portability, repro-
ducibility, and ability to evaluate myocardial and valvular
function, is a valuable tool in the assessment of ICU
patients. Hemodynamic data, including an estimate of right
ventricular pressure, left atrial pressure, valve areas, left ven-
tricular ejection fraction, and ventricular volumes, can be
obtained at the bedside if image quality is adequate. Cardiac
output can be estimated with echo Doppler using the conti-
nuity equation. Myocardial ischemia can be inferred by
identification of segmental wall motion abnormalities at
rest or during special interventions designed to bring out
abnormalities in ischemic regions. Dobutamine or adeno-
sine infusion can be performed with echocardiography and
ECG monitoring to obtain a bedside stress test. Pericardial
effusions can be diagnosed and measured and their hemo-
dynamic impact evaluated. Echocardiography is a sensitive
technique for diagnosing cardiac tamponade. Assessment of
valvular regurgitation and monitoring the response to ther-
apy are other uses for echocardiography.
Echocardiography is technically difficult in about 10% of
patients overall. Although echo-enhancing contrast agents can
improve image quality, ICU patients, because they are often
mechanically ventilated and have multiple intravenous or cen-
tral lines in place, are difficult to position ideally and often are
more difficult to image properly with echocardiography.
Transesophageal technology has increased the value of echocar-
diography by providing images of good quality in patients who
have had inadequate transthoracic studies. With trans-
esophageal echocardiography, the heart is imaged via a trans-
ducer inserted into the esophagus through the mouth. The close
proximity of the esophagus to the left atrium provides an excel-
lent acoustic window resulting in better images. Views unob-
tainable with conventional transthoracic echocardiography are
possible with this technique. The pulmonary veins, both atrial
appendages, and the ascending and descending aorta can be well
imaged in addition to the ventricles and valves.
3. Radionuclide angiography—Radionuclide angiogra-
phy can measure right and left ventricular ejection fractions
and evaluate wall motion. Myocardial uptake of technetium
pyrophosphate at times can be useful to identify myocardial
infarction or cardiac contusions. A number of radionuclide
techniques are used to assess coronary artery disease. These
studies are not performed at bedside and are of no utility in
ICU patients.
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4. CT scan—In patients who can be moved to the scanner,
CT scanning provides high-resolution tomographic imaging
of the heart and great vessels and can assess right and left
ventricular size. CT scans also can assess lung parenchyma to
rule out a primary pulmonary process and differentiate con-
gestive heart failure from other lung diseases. With the use of
contrast material, pulmonary thromboembolism or proxi-
mal pulmonary artery thrombosis can be seen with spiral CT
scanning (CT angiogram).
5. Cardiac catheterization/pulmonary artery
catheterization—When noninvasive studies cannot
fully answer questions about cardiac function, bedside
balloon-tipped flow-directed (Swan-Ganz catheter) pul-
monary artery catheterization is performed. The catheter is
used to measure a variety of hemodynamic parameters,
including left ventricular end-diastolic pressure (pul-
monary artery wedge pressure) and thermodilution cardiac
output. Newer modified catheters can continuously meas-
ure cardiac output and oxygen saturation. The catheter is
placed transvenously into the pulmonary artery by way of
the right atrium and right ventricle, usually without fluoro-
scopic guidance. The catheter is often of critical importance
in defining cardiac function and differentiating cardiac
from pulmonary disease in patients with pulmonary infil-
trates and dyspnea. The pulmonary artery catheter is par-
ticularly useful for monitoring the effect of intravenous
drugs on hemodynamics when cardiac output is low. In
patients with acute severe congestive heart failure, the goal
is to maximize cardiac output while lowering wedge pres-
sure in order to relieve pulmonary edema.
In selected patients, left-sided heart catheterization allows
direct measurement of left ventricular pressures and func-
tion, imaging of the coronary arteries to rule out critical
obstruction, and angiographic measurement of cardiac out-
put and left ventricular ejection fraction. Left-sided heart
catheterization requires fluoroscopy and cannot be done in
most ICUs.
Differential Diagnosis
Patients with clinical features of congestive heart failure pre-
senting with dyspnea, orthopnea, rales, and wheezing instead
may have pneumonia, ARDS, fluid overload, or exacerbation
of chronic obstructive pulmonary disease (COPD) or
asthma. Cardiomegaly may be due to ventricular hypertro-
phy, right ventricular dilatation, or pericardial effusion
rather than an enlarged left ventricle itself. In patients who
present with symptoms and signs of primarily right-sided
heart failure—such as elevated jugular venous pressure,
ascites, edema, and evidence of right ventricular hypertrophy—
lung disease resulting in cor pulmonale, or pulmonary arte-
rial hypertension (eg, pulmonary arteriopathy, idiopathic or
secondary pulmonary arterial hypertension, or pulmonary
emboli) should be considered. Patients with hypotension
from cardiac failure should be distinguished from those with
volume depletion, sepsis, and pulmonary embolism.
Treatment
A. General Measures—After determining the underlying
cause of congestive heart failure, treatment in the ICU con-
sists of quickly reversing the hemodynamic problem without
adding further ones. In very ill patients, initial management
of congestive heart failure should use intravenous medica-
tions. In this form, medications can be titrated rapidly and
stopped quickly if necessary. Intravenous administration of
drugs guarantees absorption, particularly in patients with
bowel edema and decreased bowel motility. Although some
intravenous agents have long half-lives and slow onsets of
action, nitroprusside, nitroglycerin, nesiritide, dopamine,
dobutamine, and milrinone act quickly and are easily reversed.
Cardiogenic shock may require the initial or concomitant
use of vasopressor drugs such as dopamine and inotropic
drugs such as dobutamine or milrinone to allow the institu-
tion of afterload-reduction therapy. Nitroprusside is a potent
reducer of left ventricular afterload and is particularly valu-
able in treating severe congestive heart failure. Disadvantages
include toxicity in patients with renal insufficiency who are
given nitroprusside over a prolonged period of time.
Intravenous preparations of ACE inhibitors are effective and
have longer durations of action. Digoxin and diuretics are still
important despite development of newer classes of drugs.
Because of negative inotropic effects, calcium channel block-
ers and beta-blockers are used with extreme caution, if at all,
in patients with acute congestive heart failure. Occasionally,
however, congestive heart failure may be secondary to tach-
yarrhythmias, left ventricular diastolic dysfunction, or severe
transient ischemia, and these drugs then play an important
role. Close hemodynamic monitoring, usually with a pul-
monary artery catheter, allows the physician to titrate multi-
ple drugs optimally. In cases of severe cardiogenic shock with
low cardiac output, use of mechanical devices including
intraaortic balloon pump or left ventricular assist devices is a
consideration. The use of these devices involves decisions
regarding long-term treatment options, prognosis, and
underlying disease etiologies. The decision to intervene at this
level requires consultation with a cardiac catheterization team
and the heart transplant team or heart failure specialists.
General treatment of congestive heart failure in critically
ill patients includes oxygen, bed rest, and reduction of meta-
bolic derangements that increase myocardial oxygen demand
(eg, fever and anemia). Endotracheal intubation and
mechanical ventilation usually are not necessary, except in
severe cardiogenic pulmonary edema.
B. Specific Treatment of Congestive Heart Failure—
Patients with congestive heart failure can be subdivided into
several groups for which specific treatments can be described
as follows:
1. Systolic dysfunction without hypotension—These
patients have low stroke volumes and ejection fractions and
usually have tachycardia. Pulmonary edema may accompany
systolic dysfunction. Digoxin, diuretics, and ACE inhibitors are
the mainstays of therapy. Several studies have shown that ACE
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inhibitors prolong life in patients with chronic congestive heart
failure owing to left ventricular dysfunction and in patients
with myocardial infarction associated with reduced left ventric-
ular function. If the patient is felt to be stable enough to toler-
ate oral therapy, small doses of an ACE inhibitor and digoxin
can be initiated. Hypotension may accompany ACE inhibitor
therapy if cardiac output fails to increase after vasodilation, and
inotropic drug support of blood pressure may be required.
Withholding or reducing the dosage of diuretics when ACE
inhibitors are added often can prevent the development of
hypotension. Serum creatinine and potassium levels must be
observed carefully because of the effect of ACE inhibitors on
renal function (particularly in patients with renal artery steno-
sis) and on the renin-aldosterone system.
Diuretics are useful in reducing volume overload, partic-
ularly when signs of right-sided failure such as peripheral
edema, elevated jugular venous pressure, and liver engorge-
ment are present. Intravenous furosemide can be given in a
dose of 10–80 mg (more in patients with poor response) and
repeated as needed. Continuous infusion of furosemide at a
rate of 5–10 mg/h is also effective. Metolazone or
hydrochlorothiazide can augment the effectiveness of
furosemide by further inhibiting reabsorption of sodium.
Sustained diuresis with any of these agents is associated with
significant loss of potassium and magnesium. Nesiritide  is a
recombinant human B-type natriuretic peptide that is indi-
cated for intravenous treatment of acutely decompensated
congestive heart failure. It is given as an initial bolus of 2 μg/kg,
followed by continuous infusion of 0.01 μg/kg per minute
for less than 48 hours. Hypotension is a known side effect.
Spironolactone has been shown to decrease mortality in
chronic congestive heart failure and can be added to help
spare potassium loss in the acute situation. Finally, patients
in severe congestive heart failure with renal dysfunction may
be unable to excrete large amounts of sodium and water, so
ultrafiltration may be needed to correct volume overload.
Newer devices allow removal of fluid at rates up to 400 mL/h
using specially designed 18-gauge peripheral lines and there-
fore eliminate the need for a large-bore vascular catheters.
However, if electrolyte abnormalities and renal dysfunction
compound the volume overload, dialysis may be required.
Noninvasive positive-pressure ventilation using tight-fitting
masks can be useful in acute pulmonary edema. A significant
reduction in the need for mechanical ventilatory support has
been demonstrated in patients present with acutely decompen-
sated congestive heart failure with the use of this noninvasive
form of ventilation compared to standard therapy. It appears
that the positive-pressure breathing lowers preload and left
ventricular afterload, improves oxygenation, and provides time
for pharmacologic therapy to work.
The effect of various drugs on filling pressures and cardiac
output can be demonstrated on the Frank-Starling curve
(Figure 21–1). Both digoxin and afterload-reducing agents
improve the patient’s cardiac output or stroke volume for a
given filling pressure (move the patient to a more effective
curve). In contrast, diuretics lower the left ventricular filling
pressure, relieving symptoms of dyspnea, but they also may
reduce cardiac output. The patient moves down along the
same function curve. Optimal treatment, therefore, should use
agents that move the patient to a better function curve, and
diuretics are employed to help lower filling pressures—if
they remain elevated—and to expedite symptomatic improve-
ment. In some patients with mild to moderate congestive heart
failure, bed rest alone will result in significant diuresis. In addi-
tion, improvement of cardiac output with afterload-reducing
agents and digoxin ultimately will result in diuresis. On the
other hand, both preload- and afterload-reducing agents can
result in venodilation and thus fluid retention, so diuretics
may be needed to counteract this unwanted side effect.
Although major emphasis has been placed on ACE
inhibitors in the treatment of chronic congestive heart fail-
ure, other drugs are effective, including preload-lowering
agents such as nitrates and afterload-reducing agents such as
hydralazine. For example, the combination of hydralazine
and nitrates has been shown to prolong life in patients with
chronic congestive heart failure.
2. Severe congestive heart failure with hypotension
(cardiogenic shock)—Patients with severe congestive
heart failure associated with hypotension, pulmonary
edema, and metabolic acidosis require aggressive and immediate
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 Figure 21–1. Curves demonstrating the relationship
between stroke volume and left ventricular end-diastolic
pressure (preload) and showing the normal range for each
variable. End-diastolic pressures greater than 25 mm Hg
are associated with pulmonary edema. Curve 1 represents
severely depressed left ventricular function, with normal
stroke volume being achieved only at substantially ele-
vated preload (high left ventricular end-diastolic pressure).
Curve 2 demonstrates a normal relationship between
stroke volume and preload. Curve 3 represents a condition
of increased inotropy. Treatment with afterload-reducing
agents or inotropic drugs can improve stroke volume by
moving an individual from curve 1 to curve 2 (solid
arrow). Diuretics can lower filling pressure by moving a
patient along his or her own curve (dashed arrow).
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intervention. These patients often have some reason for acute
deterioration such as ischemia, myocardial infarction, new or
worsening valvular insufficiency, poor adherence to medical
therapy, volume overload, or concomitant medical problems.
Even before invasive hemodynamic monitoring is instituted,
hemodynamic support can be started using intravenous
agents. With severe hypotension, blood pressure support is
required—intravenous dopamine should be administered in
dosages titrated to achieve a systolic blood pressure of approx-
imately 90 mm Hg or greater. An exception to this precept
would be a patient with cardiomyopathy whose known systolic
blood pressure is chronically 80 mm Hg. In such cases, clinical
markers of hypoperfusion such as decreased mental status or
acidosis should help to determine the appropriate blood pres-
sure goal. The inotropic drugs dobutamine and milrinone can
be used in conjunction with or as an alternative to dopamine to
increase cardiac output. Dobutamine has the further advantage
of peripheral vasodilation with reduction in left ventricular
afterload.
In patients with either adequate blood pressure (systolic
blood pressure >100 mm Hg) or even marginal pressure (sys-
tolic pressure 90–100 mm Hg), nitroprusside can be started at
small dosages (0.01–0.1 μg/kg per minute) and titrated upward
every 3–5 minutes while blood pressure is observed closely.
Although these are low starting doses, they may avoid the signif-
icant and rapid hypotension that sometimes occurs with larger
doses, and rapid dose adjustments make it possible to reach the
effective dose in a relatively short period. The goal of reducing
left ventricular afterload with nitroprusside is to increase cardiac
output. However, if peripheral resistance drops in response to
nitroprusside without an increase in cardiac output, hypoten-
sion will occur. The drop in blood pressure following nitroprus-
side administration can be dealt with by immediately
discontinuing the drug and providing inotropic support if
needed. The extremely short half-life of intravenous nitroprus-
side makes this a safe and valuable agent to try even before inva-
sive hemodynamic monitoring can be started.
Loop diuretics are also extremely valuable in this setting if
marked volume overload (pulmonary edema) is evident, as
furosemide causes a lowering of preload even before diuresis
occurs. Intravenous furosemide can be given in a dose of 10
to 40 mg (more in patients with poor response) and can be
repeated as needed. Continuous infusion of furosemide at a
rate of 5–10 mg/h is also very effective. Intravenous nitroglyc-
erin has preload-reducing as well as some afterload-reducing
properties and can be used alone or in conjunction with
intravenous nitroprusside to improve cardiac output and
reduce left-sided pressures. Nesiritide must be used with cau-
tion in cardiogenic shock to avoid worsening of hypotension.
Intraaortic balloon pumps and left ventricular assist
devices have been used to treat patients with extreme cardio-
genic shock. They are used acutely to allow time to explore
opportunities for additional interventions including angio-
plasty, cardiac surgery, or heart transplantation. This level of
tertiary management is undertaken in referral centers with
appropriate equipment, resources, and surgical staff and in
selected patients with potential for good outcomes.
Echocardiography assists in the management of patients
with cardiogenic shock in several ways: (1) by identifying surgi-
cally correctable valvular abnormalities such as severe aortic or
mitral valvular disease that may be contributing to failure, (2) by
identifying segmental wall motion abnormalities suggestive of
ischemia, and (3) by establishing baseline left ventricular func-
tion in patients with new onset congestive heart failure.
A pulmonary artery catheter will enable the physician to
adjust medications more carefully, with the goal of maximizing
cardiac output at acceptably high end-diastolic filling pressures.
The pulmonary artery catheter is strongly recommended to
help guide the management of congestive heart failure patients
who have hypotension and congestive symptoms. Using a pul-
monary artery catheter, a cardiac index (cardiac output divided
by body surface area) of less than 2 L/min/m2 is considered car-
diogenic shock and is incompatible with prolonged survival.
Heart rate and cardiac output need to be considered in optimiz-
ing hemodynamics, particularly in patients with congestive
heart failure and myocardial ischemia. If an adequate cardiac
index is maintained by an increased heart rate rather than
improved stroke volume, ultimate outcome will be poor.
Conversely, patients with bradycardia in the setting of conges-
tive heart failure may have dramatically improved cardiac out-
put with a pacemaker or the use of pharmacologic agents that
increase the heart rate.
Calculation of stroke volume to assess therapy is very use-
ful. The mixed venous oxygen (O2) saturation (S
–vO2) is another
way of assessing severity of disease and response to therapy. It
reflects delivery and utilization of O2 and the effectiveness of
cardiac output. Some pulmonary artery catheters have an
oximeter probe at their tips to continuously monitor S–vO2 in
addition to pulmonary artery pressures. A decrease in S–vO2 can
be an early marker of decreased cardiac output and function. A
desirable goal of therapy in treating cardiogenic shock is to
attain a mixed venous O2 saturation of greater than 70%.
After optimizing hemodynamic variables with intravenous
medications and attaining a period of stability, a gradual change
to oral medication is appropriate. Oral afterload-reducing agents
(eg,ACE inhibitors, angiotensin-receptor blockers, or hydralazine)
should be added while reducing the dosages of intravenous
agents. An intravenous ACE inhibitor such as enalaprilat given
every 6 hours is an alternative to oral ACE inhibitors.
3. Congestive heart failure with severe systemic
hypertension—Treatment is directed at the pathophysio-
logic mechanisms of congestive heart failure in severe hyper-
tension, including reduction of systemic blood pressure and
intravascular volume. In these patients, left ventricular sys-
tolic function may be normal, whereas left ventricular dias-
tolic dysfunction is a major problem resulting in congestion
and pulmonary edema. Systolic dysfunction, if present, may
improve significantly following afterload reduction.
Control of blood pressure with reduction of left ventric-
ular afterload is the major focus of initial therapy. If systolic
function is unknown, an intravenous agent such as nitro-
prusside or nitroglycerin is recommended to lower systemic
pressures and to improve filling pressures acutely. Intravenous
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enalaprilat also can be considered (see the section “Hypertensive
Crisis”). For continued treatment of hypertension, β-adrenergic
blockers or calcium channel blockers can be added after conges-
tive heart failure has improved and acceptable left ventricular
systolic function has been documented. However, these agents
should be used with caution in patients with high filling pres-
sures and severe hypertension because they may depress
myocardial function without adequately reducing the afterload.
The net result may be worsening congestive heart failure or
hemodynamic collapse. Pulmonary artery catheterization may
be helpful when considering the use of β-adrenergic blockers or
calcium channel blockers in these patients, but catheterization is
not needed to initiate therapy with nitroprusside unless
hypotension develops early in treatment, raising the possibility
of complicating cardiac or pulmonary problems.
4. High-output or volume-overload congestive heart
failure—These patients present with congestive symptoms
and signs (eg, pulmonary edema and peripheral edema), but
systolic cardiac function is normal, and cardiac output may be
elevated. Treatment should be directed at the cause of the high
cardiac output (eg, anemia, thiamine deficiency, sepsis, and
hyperthyroidism) or volume overload state (eg, renal failure,
iatrogenic volume overload, and excessive sodium intake).
Rapid lowering of intravascular volume by ultrafiltration may
improve blood pressure, hypoxemia, and edema, especially in
patients who do not respond well to diuretic therapy. In the
ICU patient, volume overload may be due to obligate fluid
intake from hyperalimentation, blood product replacement, or
antibiotic therapy.
5. Congestive heart failure with diastolic dysfunc-
tion—Diastolic dysfunction means that ventricular filling is
impaired, and left ventricular end-diastolic pressures may be
elevated. Diastolic dysfunction is the most difficult form of
heart failure to treat. Systolic function is preserved, but ven-
tricular relaxation and filling are inadequate. Diastolic dys-
function is seen commonly in patients who have
hypertension with left ventricular hypertrophy and/or
ischemia. Patients with hypertrophic cardiomyopathy also
can have significant diastolic heart failure with preserved sys-
tolic function. Elderly patients can have undiagnosed diastolic
heart failure with or without systemic hypertension. Patients
with amyloidosis also have low ventricular compliance
resulting in diastolic dysfunction, but systolic dysfunction
often accompanies this clinical picture. Patients with dias-
tolic dysfunction have congestive symptoms (eg, shortness
of breath and pulmonary edema) despite normal ejection
fraction and normal systolic wall motion. Diuretics usually
are required to reduce preload and symptoms related to
elevated left atrial pressure. Beta-adrenergic blockade to
slow the heart rate, allowing more time for diastolic filling,
can be helpful. On occasion, too aggressive diuretic therapy
becomes counterproductive in patients with diastolic dys-
function by reducing stroke volume, systemic blood pres-
sure, and cardiac output. Because cardiac output is the
product of heart rate and stroke volume, excessive bradycardia
from beta-blockers or calcium channel blockers also can
worsen the clinical situation by causing an inadequate cardiac
output.
6. Isolated right-sided heart failure with pulmonary
hypertension—Patients may have isolated right-sided heart
failure secondary to pulmonary arterial hypertension (PAH).
Pulmonary hypertension may be related to congenital heart
disease, lung disease , medications, liver disease (eg, portopul-
monary hypertension), HIV infection, and collagen vascular
diseases (eg, scleroderma and mixed connective tissue disease)
or may be idiopathic. PAH owing to pulmonary emboli or
proximal pulmonary arterial thrombus need to be considered
and excluded with appropriate diagnostic tests before conclud-
ing that pulmonary hypertension is due to a pulmonary arteri-
opathy. Pulmonary venous hypertension also must be excluded
(ie, left-sided heart disease). In PAH, the pathophysiologic
mechanism of the dyspnea and orthopnea is not entirely clear,
although gas exchange in the lungs is inefficient because of
maldistribution of perfusion. Compression of the left ventricle
with abnormal septal motion and relative left ventricular filling
difficulties because of right ventricular encroachment into the
pericardial space is another possible mechanism.
Diuretics are used to reduce right atrial pressure and
right ventricular and right atrial volume. Oxygen may
reduce pulmonary hypertension in patients with PAH or
lung diseases. As oxygenation improves, liver engorgement,
abdominal distention, and lung mechanics improve. One
goal is to reduce right atrial pressure to less than 10 mm Hg.
Finally, digoxin may be helpful by increasing right ventricu-
lar function. Reduction of pulmonary artery pressures and
right ventricular afterload with nitric oxide or intravenous
prostacyclin should be considered when a clear diagnosis of
PAH is made (in the absence of left-sided heart failure). In
the last 3 to 4 years, there have been dramatic advances in the
treatment of PAH in terms of chronic management, includ-
ing the use of endothelin-receptor blockers (eg, bosentan),
phosphodiesterase-5 inhibitors (PDE-5) including sildenafil,
and prostacyclins (eg, epoprostenol, treprostinol, and ilo-
prost). Acute treatment with inhaled nitric oxide can restore
oxygenation and stabilize a patient until long-term treat-
ment issues can be addressed. This is in the realm of tertiary
care at institutions able to administer such therapy.
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 Valvular Heart Disease
ESSENT IALS  OF  D IAGNOS I S
Valvular insufficiency:
 Dyspnea, pulmonary edema, new murmur.
 Echocardiogram with Doppler demonstrating regurgitation.
Valvular stenosis:
 Dyspnea, pulmonary edema, murmur, syncope,
hypotension; decreased carotid pulses (aortic stenosis).
 Atrial fibrillation (mitral stenosis), left ventricular
hypertrophy (aortic stenosis).
 Echocardiogram documenting decreased valve area.
Prosthetic valve dysfunction:
 New onset of symptoms of congestive heart failure,
syncope; change in examination (new murmur,
change in intensity of valve sounds).
 Echocardiographic evidence of increased valve pres-
sure gradient, thrombosis, or other dysfunction.
Infective endocarditis:
 May or may not have history of valvular heart dis-
ease or prosthetic valve.
 New onset of heart failure with valvular insufficiency
or unexplained fever and pathologic heart murmur.
 Echocardiographic evidence of valvular disease, pos-
itive blood cultures.
General Considerations
As with congestive heart failure, treating valvular heart dis-
ease in the ICU setting involves considering the possibility
and proceeding to assess its severity. Few ICUs can afford the
luxury of a quiet place to auscultate the heart, but with
patience and perseverance, the experienced clinician can
detect important murmurs. The acoustic qualities of the
murmurs are affected by cardiac output. Patients in shock
with low-output states and febrile or anemic patients with
high-output states may present with misleading physical
findings that under- or overestimate the severity of their
valvular heart disease. At the bedside, echocardiography
affords the physician a convenient window on the heart and
a way to quantitate valve dysfunction and clarify the relation-
ship between valve function and myocardial function.
Acute valvular insufficiency with regurgitation may be
due to endocarditis, trauma, papillary muscle dysfunction
(mitral valve), or ischemia. Patients may present with wors-
ening of chronic valvular disease from myxomatous degener-
ation or prolapse with and without connective tissue
disorders or rheumatic heart disease. Isolated aortic valve
insufficiency may be due to aortic diseases such as aortic dis-
section, cystic medial necrosis, and syphilitic aortitis. Most
commonly, however, chronic aortic regurgitation results
from a congenital bicuspid aortic valve. Mitral stenosis is
almost always due to rheumatic heart disease. Aortic stenosis
is occasionally due to rheumatic heart disease but more often
is due to progressive valvular calcification in the elderly,
either of a normal valve or of a congenital bicuspid valve.
Patients with previous valve surgery with prosthetic or
bioprosthetic valves represent a special circumstance. These
valves are subject to a variety of chronic and acute complica-
tions, including infective endocarditis, calcification with
simultaneous stenosis and incompetence, thrombosis with
valve dysfunction, and peripheral embolic events such as
strokes, valve dehiscence, and paravalvular leaks. Valve
repairs also can be subject to some of the same problems,
including endocarditis, recurrent valve dysfunction, and rel-
ative valve stenosis, after repair of valvular regurgitation.
Clinical Features
A. Symptoms and Signs—Specific findings depend on
which valve is abnormal. Patients with aortic or mitral valvu-
lar stenosis or insufficiency may present with congestive heart
failure, including pulmonary edema and evidence of
decreased cardiac output. Physical findings include rales, S3
gallop, wheezing, peripheral vasoconstriction, tachycardia,
and murmurs. Other important findings to be sought include
the character of arterial pulses, intensity of the heart sounds,
and changes in the quality of murmurs with different maneu-
vers such as the Valsalva maneuver. Chest pain is a frequent
accompanying symptom in patients with significant aortic
stenosis or aortic regurgitation. Atrial arrhythmias frequently
accompany mitral valve disease with left atrial enlargement.
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B. Electrocardiography—The ECG may suggest features of
specific valvular as heart diseases—for example, left ventric-
ular hypertrophy as seen in aortic stenosis and regurgitation,
and left atrial enlargement and right ventricular hypertrophy
as seen in mitral stenosis.
C. Imaging Studies—The chest x-ray may show cardiomegaly
with specific chamber enlargement. Echocardiography is
extremely useful in assessing valvular heart disease. It can
provide evidence of leaflet abnormalities, including vegeta-
tions and decreased motion of valve leaflets, as well as esti-
mates of valve cross-sectional area in valvular stenosis. The
size of the atria and ventricles can be determined and wall
motion and ejection fraction estimated. With Doppler tech-
niques, one can quantitatively estimate regurgitant blood
flow across an abnormal valve, measure valve pressure gradi-
ents and calculate valve areas.
D. Additional Studies—Pulmonary artery catheters directly
measure pulmonary artery pressures and cardiac output and
provide an estimate of left atrial pressure (pulmonary artery
wedge pressure). Cardiac catheterization is usually required
to assess valve function prior to surgery and to identify coex-
istent coronary artery disease.
Treatment: Native Valves
A. Valvular Regurgitation—The management of left-sided
valvular regurgitation is determined by the severity of the
regurgitation, the specific cause, and the degree of left ven-
tricular dysfunction. The severity of regurgitation can be
estimated echocardiographically using color-flow and
continuous-wave Doppler and calculating left ventricular
and left atrial pressures noninvasively. Echocardiography
also will help to define operability and determine the cause
of the valve dysfunction. Mild to moderate aortic or mitral
regurgitation without symptoms requires no treatment. In
patients with more severe left-sided valvular regurgitation,
associated congestive heart failure (pulmonary edema) can
be treated with diuretics and digoxin. However, the most
important therapy is the use of unloading agents such as
ACE inhibitors, hydralazine, and, if needed, nitroglycerin
and nitroprusside. These drugs work by decreasing down-
stream resistance and increasing downstream compliance.
Forward blood flow increases while regurgitant flow
decreases, so ventricular filling pressures decline while car-
diac output improves. The management of congestive heart
failure owing to aortic or mitral regurgitation is quite similar
to the management of congestive heart failure owing to sys-
tolic ventricular dysfunction.
In patients with such severe valvular regurgitation that
cardiac output is very low and there is hypotension (cardio-
genic shock), emergent valve surgery may be necessary.
Invasive hemodynamic monitoring with a pulmonary artery
catheter is essential, and maximal unloading of the left ventri-
cle with intravenous nitroprusside should be started immedi-
ately. Inotropic drugs such as dopamine may be required to
maintain adequate systemic blood pressure even though—by
increasing afterload—valvular regurgitation may be tran-
siently worsened. Mitral regurgitation associated with car-
diogenic shock may benefit from an intraaortic balloon
pump, but this therapy is contraindicated in those with aor-
tic valve regurgitation.
B. Valvular Stenosis—Aortic stenosis is treated with sur-
gery when it results in congestive heart failure. Choices for
medical management are limited, but possible pharmaco-
logic interventions include mild diuresis and the use of
digoxin. Systemic vasodilators, useful in other forms of heart
failure, may cause severe hypotension in patients with aortic
stenosis. In selected patients with combined stenosis and
ventricular dysfunction, judiciously used intravenous
unloading therapy has been employed with hemodynamic
monitoring. This type of hemodynamic manipulation is per-
formed in the catheterization laboratory or under the guid-
ance of a cardiologist and is not the standard of care.
Dopamine can be tried if shock develops, but by this time,
surgery is essential. A rapid and limited search for confound-
ing problems can be undertaken to try to find ways to
improve the patient acutely. Atrial fibrillation, for example,
because it results in a decrease in left ventricular filling in the
patient with severe aortic stenosis, should be treated aggres-
sively with the goal of returning the patient to sinus rhythm.
Successful cardioversion of atrial fibrillation may result in
acute improvement in cardiac output.
Severe mitral stenosis is also a surgical problem, although
it is somewhat more amenable to pharmacologic therapy. The
most important goal is to decrease the heart rate, thereby pro-
longing diastolic filling time and allowing the left atrium to
empty. Left atrial pressure and, therefore, pulmonary venous
pressure are determined by the degree of left atrial emptying.
In patients with mitral stenosis, left atrial emptying is limited
by decreased mitral orifice size, and the smaller the valve area,
the longer it takes for the atrium to empty. Inadequate time
for emptying leads to increased left atrial pressure and vol-
ume and worsening pulmonary congestion. Thus, by slowing
the heart rate and lengthening diastole, the left atrium has
more time in which to empty. Therefore, if left ventricular
function is preserved and there is only mild to moderate
mitral regurgitation, heart rate control using beta-blockers or
calcium channel blockers (or digoxin, if the patient has atrial
fibrillation) often will greatly improve symptoms.
Treatment: Prosthetic Valves
A. Transvalvular Dysfunction of Prosthetic Valves—This
entity can be a true medical emergency resulting in rapid
deterioration of a stable patient and can lead to death if not
recognized and treated promptly. Bioprosthetic valves tend
to calcify and become both stenotic and incompetent over
time. Once the valve becomes dysfunctional, further progres-
sion can be rapid, with a rigid leaflet suddenly becoming
severely incompetent and producing fulminant congestive
 CHAPTER 21476
heart failure. Mechanical prosthetic valves are more durable,
with, for example, Starr-Edwards valves (ball-cage valves)
functioning for more than 30 years. However, ingrowth of
tissue (pannus formation) or thrombosis secondary to inad-
equate anticoagulation can result in the development of valve
dysfunction with either obstruction, regurgitation, or both
depending on where the tissue ingrowth or clot develops.
Progressive thrombosis, particularly on a single-leaflet
mechanical valve, can result in death because the valve may
stick in the closed position. The St. Jude valve, because it is a
bileaflet device, usually develops both insufficiency and
stenosis. Other less frequent problems have resulted from
mechanical damage to the valve, such as strut fracture with
Björk-Shiley-type valves and loss of poppets owing to ball
variance and fractures in the older Starr-Edwards valves. In
evaluating patients with suspected prosthetic valve dysfunc-
tion, physical examination may show evidence of congestive
heart failure. The murmurs that accompany the prosthetic
valve may be fainter than usual because of low cardiac out-
put or high filling pressures. The key to the diagnosis of pros-
thetic valve dysfunction is a high degree of clinical suspicion
and noninvasive assessment of valvular function. Patients
with prosthetic valves who present with worsening heart fail-
ure should undergo Doppler evaluation of the valves to
assess  gradients across the valves and to estimate valve area.
Transesophageal echocardiography is extremely useful in this
setting and can confirm valve obstruction by demonstrating
the presence of a clot and reduced prosthetic leaflet motion.
A large pressure gradient across the valve or the presence of
substantial transvalvular regurgitation is suggestive of valve
thrombosis. Cinefluoroscopy can be used to assess opening
angles of the mechanical prosthetic valves by measuring the
angle on still frames. The angle of opening for specific valve
models is known. If the valve does not open to the expected
amount, valve dysfunction and thrombosis can be suspected.
Treatment includes immediate heparinization if throm-
bosis is suspected, hemodynamic monitoring, and surgical
evaluation for urgent valve replacement. Valve replacement is
critical and can be lifesaving. Patients who present with
severe heart failure in this setting sometimes can be helped
dramatically by use of thrombolytic agents, including
alteplase or streptokinase. Risks of thrombolytic therapy
include embolization of lysed clots and CNS hemorrhage,
but the risks may have to be accepted when cardiogenic
shock occurs secondary to valve thrombosis and surgery is
considered too hazardous. Results with alteplase can be seen
within 90 minutes. Heparinization must be continued after
thrombolytic therapy to prevent immediate thrombosis.
B. Emboli—Thrombi forming on prosthetic valves are a
source of thromboemboli, which can cause complications
based on where the emboli lodge, including strokes, renal
infarction, ischemic limbs, pulmonary emboli, and coronary
artery occlusion. Emboli occur uncommonly in anticoagu-
lated patients; however, inadequate anticoagulation or discon-
tinuation of anticoagulation—particularly with mechanical
valves—can result in embolic events. Treatment is supportive
with use of intravenous anticoagulation for treatment of
peripheral embolization and prevention of further emboli.
Surgical removal of emboli can be performed if they are in
accessible locations, such as in limb vessels. In patients who are
already adequately anticoagulated with warfarin, the addition
of aspirin or dipyridamole has been shown to decrease the fre-
quency of recurrent embolization.
In patients with cerebral emboli, the decision to anticoag-
ulate may be difficult because of the risk of conversion of a
bland embolic stroke to a hemorrhagic one. Most neurolo-
gists recommend waiting 48–72 hours before anticoagulating
such patients unless the concern for recurrent emboli is felt
to outweigh these risks. Finally, surgical replacement of a
partially thrombosed valve in a patient with stroke is associ-
ated with a very high risk of perioperative intracerebral hem-
orrhage owing the combination of low cerebral perfusion
and the need for heparin during the procedure.
C. Paravalvular Leaks and Valve Dehiscence—Valve dehis-
cence is another form of valve dysfunction seen with both bio-
prosthetic and mechanical valves. The artificial valve is attached
to the myocardium or to the annulus where the native valve
previously resided. Paravalvular leaks can be a result of techni-
cal problems occurring at the time of surgery or may develop
years later as a result of prosthesis infection (endocarditis).
Paravalvular leaks are a result of space developing between the
sewing ring of the valve and the annulus or cardiac tissue.
Small, hemodynamically insignificant leaks are often seen as a
result of minor surgical imperfections and can remain stable
for years. Paravalvular leaks secondary to infective endocarditis
often are associated with valve dehiscence, and these paravalvu-
lar leaks tend to progress—often rapidly. This results in severe
hemodynamic dysfunction, further dehiscence of the valve,
instability of the valve, and frequently, hemolysis owing to
mechanical destruction of red blood cells as they pass through
the disordered valve. However, paravalvular leaks can develop
over time even in the absence of infection.
Development of a paravalvular leak in the setting of
endocarditis is a surgical emergency. Complications include
progressive uncontrollable congestive heart failure, sepsis,
and complete dehiscence of the valve resulting in death.
Echocardiography—particularly transesophageal—or car-
diac catheterization is required to define the severity of the
valve lesions, assess overall cardiac function, and guide valve
replacement. In the absence of infection, the decision with
regard to valve replacement is determined by the degree of
regurgitation and associated heart failure. Paravalvular leaks
that increase over time suggest instability of the valve and
necessitate valve replacement.
Treatment: Infective Endocarditis (Prosthetic
or Native Valve)
Infective endocarditis is a pleomorphic disease that can be
rapidly progressive when caused by invasive organisms or
can be slowly progressive and debilitating resulting in
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chronic congestive heart failure and wasting. Diagnosis and
identification of the organism are essential for proper man-
agement. Clinical features of endocarditis, including fever,
heart murmur, unexplained anemia, and peripheral or
immunologic stigmata, should alert the physician. In partic-
ular, endocarditis needs to be considered in any febrile
patient with a known history of valvular heart disease, a
pathologic murmur, or a prosthetic valve. Patients with
community-acquired Staphylococcus aureus or Streptococcus
viridans bacteremia have a high incidence of endocarditis
(20% and 80%, respectively) and should be considered to
have endocarditis until proven otherwise.
The diagnosis of endocarditis is made on clinical grounds
(see Chapter 15). Positive blood cultures are found in as
many as 90% of patients, but the frequency of this finding
depends on the type of organism and the number of blood
cultures obtained. Therefore, one should obtain an adequate
number of samples of blood for culture before starting
antibiotic therapy or specify laboratory techniques to mini-
mize the effect of antibiotics on the culture results.
Obtaining cultures for fungi, anaerobic bacteria, and fastidi-
ous or slow-growing organisms may increase the likelihood
of an etiologic diagnosis in susceptible patients.
Echocardiography, especially using the transesophageal
approach, is extremely useful in detecting valvular vegeta-
tions in endocarditis and for assessing the degree of valvular
incompetence, if any (Figure 21–2).
Effective antibiotic therapy requires selection of bacterici-
dal or fungicidal drugs to which the organism is sensitive and
then delivering intravenous antibiotics in adequate quanti-
ties for a prolonged period. Fungal endocarditis is almost
never eradicated using pharmacotherapy. The duration of
therapy, in part, depends on the organism. Prosthetic valve
endocarditis often necessitates valve replacement because
antibiotics fail to eliminate the infection or because of valve
dysfunction, valve dehiscence, or ring abscess.
The outcome of both native and prosthetic valve endo-
carditis depends on cardiac function. Patients developing
congestive heart failure do quite poorly without valve
replacement. Valve replacement, even while the patient is still
 Figure 21–2. Transesophageal echocardiogram demonstrating mitral valve endocarditis with a prolapsing and partial
flail mitral valve leaflet (arrow). A vegetation can be seen as well. The left ventricle and left atrium are indicated by
LV and LA, respectively. At surgery, the valve was found to be necrotic. The mitral valve was incompetent, with severe
mitral regurgitation, as seen on color-flow Doppler, but this is not shown in this still-frame image.
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infected or septic, can be lifesaving after congestive heart fail-
ure has developed. When to operate in cases of native valve
endocarditis depends in part on the hemodynamic conse-
quences of the infection (eg, severe valvular regurgitation,
intracardiac shunts, or congestive heart failure). Surgery is
required if antibiotic therapy fails to clear the infection, if
there are persistent fevers or a valve ring abscess, or if cul-
tures have identified a fastidious organism known to be dif-
ficult to eradicate medically. Patients who have more than
one major embolic episode with left-sided endocarditis
almost always undergo valve replacement. Larger vegeta-
tions, particularly on the left side of the heart, are associated
with higher complication rates and poorer outcomes.
In patients suspected of having infective endocarditis,
echocardiography should be performed to identify valvular
vegetations or valve destruction and to qualitatively assess the
degree of valvular regurgitation present. Echocardiography
then can be used to monitor therapy. Increase in vegetation
size, worsening of regurgitation, or the development of
mycotic aneurysms, intramyocardial abscesses, or a fistula
suggests treatment failure and the need for further interven-
tion. In patients with left-sided endocarditis, aortic valve ring
abscess, left-to-right shunts, valvular incompetence, and large
vegetations have important implications for outcome and the
need for valve surgery. Transesophageal echocardiography has
superior sensitivity for identifying valvular vegetations, valve
ring abscesses, and intracardiac shunts. It is particularly valu-
able for visualizing lesions in patients with prosthetic valve
endocarditis. For these reasons, transesophageal echocardiog-
raphy is recommended for all patients suspected of having
left-sided endocarditis, aortic valve endocarditis, or suspected
prosthetic valve endocarditis and for patients with endocardi-
tis who are hemodynamically unstable or deteriorating. The
transesophageal echocardiogram also should be used in the
preoperative and intraoperative management of these
patients to identify unsuspected pathologic findings, includ-
ing aortic-to-atrial fistulas and valve ring infection, and to
verify the adequacy of surgical repair.
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 Cardiac Tamponade
ESSENT IALS  OF  D IAGNOS I S
 Evidence of elevated pericardial pressure manifested as
elevated systemic venous pressure, decreased cardiac
output and hypotension; evidence of decreased periph-
eral perfusion.
 Echocardiography: diastolic collapse of right ventricle, sys-
tolic collapse of right atrium, large pericardial effusion.
 Pulmonary artery catheter monitoring: equalization of
right atrial, left atrial, and left ventricular end-diastolic
pressures.
General Considerations
Pericardial effusions occur in a variety of patients seen in the
ICU, including those with malignancy, tuberculosis, fungal
infections, myocardial infarction, trauma, acute and chronic
renal failure, thyroid disease, autoimmune conditions, and
more rarely, those with endocarditis or aortic dissection.
Patients after cardiac surgery can develop pericarditis and
pericardial effusions for several reasons. The size of the effu-
sion and the rapidity with which it develops are the major
determinants of its hemodynamic effects. Cardiac tamponade
ensues when adequate ventricular and atrial filling are pre-
vented by increased intrapericardial pressure owing to the
presence of a pericardial effusion. Left atrial, right atrial, left
ventricular end-diastolic, and right ventricular end-diastolic
pressures increase and equalize. Stroke volume, cardiac out-
put, and systemic blood pressure fall greatly, and patients may
develop shock with evidence of end-organ hypoperfusion.
Clinical Features
A. Symptoms and Signs—Symptoms and signs may reflect
the underlying cause of the pericardial effusion, especially if
there is inflammation of the pericardium with acute peri-
carditis. Chest pain that is pleuritic and positional suggests
this diagnosis. However, patients with tamponade need not
have chest pain, especially if tamponade is due to other
causes such as malignancy or uremia. When cardiac tampon-
ade develops, patients may have associated dyspnea and
orthopnea.
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Physical findings in cardiac tamponade include distended
neck veins, tachycardia, hypotension, and pulsus paradoxus.
Elevated pericardial pressure will cause distended neck veins
(which should be looked for in the upright position because
the meniscus may not be visible in a semisupine patient
when the pressures are markedly elevated), pulsus paradoxus
(ie, augmented respiratory variation in the pulse pressure,
usually >10 mm Hg), and usually hypotension. Although in
general the blood pressure is reduced, normal or elevated
blood pressure can be seen with tamponade in patients with
previous hypertension. Tachycardia, tachypnea, and orthop-
nea are important supporting signs suggesting elevated pres-
sures affecting the left side of the heart. Heart sounds as well
as the left ventricular impulse may be muted because the
heart is surrounded by fluid and farther away from the chest
wall. Hepatomegaly and peripheral edema may be present.
Patients rarely may present with “low pressure” cardiac tam-
ponade, in which classic signs may be absent but there is evi-
dence of reduced cardiac output. These patients have decreased
intravascular pressures relative to pericardial pressures, but the
diagnosis usually can be made by echocardiogram.
B. Laboratory Findings—Laboratory abnormalities may
identify a specific cause of pericardial effusion. If a diagnos-
tic pericardiocentesis is performed, a specific diagnosis may
be made from bacterial, fungal, or mycobacterial cultures;
cytologic examination; and other studies.
C. Electrocardiography—Electrocardiography may show
decreased voltage. Acute pericarditis may present with dif-
fusely elevated ST segments or PR depression on ECG.
Electrical alternans is an important clue supporting the
diagnosis of cardiac tamponade but is neither sensitive nor
specific.
D. Imaging Studies—The chest x-ray may show car-
diomegaly with a characteristic “water bottle” shape, but if
the development of pericardial effusion  is rapid, heart size
may be only slightly increased. At the bedside, echocardio-
graphy can rapidly and accurately determine if pericar-
dial fluid is present and estimate ventricular function
(Figure 21–3). In addition, there are several echocardio-
graphic criteria for the diagnosis of tamponade in patients
with pericardial effusions. These findings include the
 Figure 21–3. Two-dimensional echocardiogram taken from the subcostal window demonstrating a large pericardial
effusion with cardiac tamponade. PEF locates the pericardial effusion surrounding the heart. R and L indicate the right
and left ventricles, respectively. Note that the chambers are quite small because of the massive pericardial effusion.
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“swinging heart,” right ventricular diastolic or right atrial
systolic collapse, respiratory variation in the left ventricular
and the right ventricular chamber sizes, and right atrial
indentation. Although helpful, these signs are neither sensi-
tive nor specific. Therefore, after identifying a moderate to
large pericardial effusion by echocardiography in a sympto-
matic patient, a bedside pulmonary artery catheter should be
placed to confirm the hemodynamic findings of tamponade.
Treatment
Initial treatment of cardiac tamponade consists of rapid
intravenous fluid loading and dopamine. The goal is to
increase intravascular pressures enough to overcome the
increased pericardial pressure as well as maintain adequate
systemic blood pressure. Although these agents may improve
the hemodynamic status for a short time, pericardiocentesis
when tamponade is present is essential to avoid hemody-
namic collapse and death. This procedure should be per-
formed rapidly to relieve the hemodynamic compromise and
to determine the cause of the effusion.
An intrapericardial catheter can be placed through a sub-
xiphoid approach using a wire placed through a thin-walled
needle (Seldinger technique). Positioning is done using elec-
trocardiographic guidance, echocardiographic guidance, or
fluoroscopy. The catheter should remain in place to permit
repeated aspirations of fluid. Fluid should be sent for cul-
ture, cytologic examination, and serologic testing. Patients
with moderate to large effusions and elevated filling pres-
sures but not satisfying the criteria for cardiac tamponade
should have hemodynamic measurements made before and
after pericardiocentesis to verify hemodynamic benefit as
well as to obtain fluid for diagnosis. Cardiac tamponade sec-
ondary to renal failure may benefit from injection of a non-
absorbable corticosteroid into the pericardial space after
drainage of the fluid.
In patients with malignant pericardial effusion and car-
diac tamponade, drainage followed by sclerotherapy using
bleomycin or fluorouracil may decrease the recurrence of
tamponade. Alternatively, balloon pericardiotomy may allow
drainage of fluid into the pleural or mediastinal space—thus
preventing reaccumulation of fluid, which would result in
tamponade. However, in patients whose life expectancy is
greater than 6 months (a small number of patients with
malignant pericardial effusions and tamponade) and in
those whose effusion cannot be controlled with sclerosis of
the pericardial space, pericardiectomy should be considered.
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 Hypertensive Crisis & Malignant
Hypertension
ESSENT IALS  OF  D IAGNOS I S
 Hypertensive crisis: systemic blood pressure >240/130
mm Hg without symptoms or elevated blood pressure
with chest pain, headache, or heart failure; may have
intracranial hemorrhage, aortic dissection, pulmonary
edema, myocardial infarction, or unstable angina.
 Malignant hypertension: severe hypertension associated
with encephalopathy, renal failure, or eye findings
including retinal hemorrhage, exudates, or papilledema.
General Considerations
Hypertension in adults is usually a chronic condition that, if
untreated, is a significant risk factor for the long-term devel-
opment of coronary, cerebral, and peripheral vascular disease.
Mild to moderate hypertension usually poses no immediate
danger to the patient if the pressure is below 170/110 mm Hg.
Patients with mild to moderate hypertension are often
asymptomatic, and control of their blood pressure can be
achieved using oral medications and modification of diet.
Antihypertensive treatment usually is begun on an outpatient
basis after documentation of persistent hypertension and
evaluation for potentially reversible causes.
A subset of patients present with or develop severe life-
threatening hypertension or have other coexisting medical
problems requiring urgent control of blood pressure; these
patients are defined as having a hypertensive crisis (some-
times called a hypertensive emergency). For example, patients
with acute myocardial infarction or unstable angina benefit
greatly from reduction of elevated blood pressure and lower-
ing of left ventricular afterload. Blood pressure represents a
major factor in myocardial oxygen demand. When conges-
tive heart failure owing to left ventricular dysfunction or aor-
tic or mitral regurgitation is associated with severe
hypertension, rapid lowering of blood pressure will acceler-
ate treatment of the hemodynamic dysfunction. Patients
with acute aortic dissection and elevated blood pressure have
greatly increased stress on the aorta, and urgent control of
blood pressure is mandatory. Patients with intracranial
hemorrhage—intracerebral or subarachnoid—also require
control of blood pressure and may become acutely hyperten-
sive as a result of the CNS event. Severe hypertension results
in local and systemic effects that start a cascade of events that
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further elevates blood pressure. Dilation of cerebral blood
vessels results in hypertensive encephalopathy, and damage
to the blood vessel wall can increase permeability, resulting
in edema or bleeding.
Malignant hypertension is defined by some as severe
hypertension associated with specific end-organ damage,
namely encephalopathy, nephropathy, or eye findings,
including retinal hemorrhages, exudates, or papilledema.
Treatment of malignant hypertension is important because
rapid and effective lowering of blood pressure is essential for
reversal of complications.
Any of the causes of hypertension can be associated with
hypertensive crisis, including essential, renovascular, or
endocrine-mediated (eg, pheochromocytoma) forms of
hypertension. Most patients who present with hypertensive
crises have preexisting hypertension.
Clinical Features
A. Symptoms and Signs—Patients with severely elevated
blood pressure are frequently asymptomatic, but most will pres-
ent with headache, confusion, stupor, seizure, or coma depend-
ing on the severity of the hypertension and the degree of
end-organ involvement. Chest pain may be due to angina pec-
toris, unstable angina, or myocardial infarction associated with
hypertension, but chest pain also should raise the possibility of
aortic dissection. In malignant hypertension, papilledema, reti-
nal hemorrhages, or exudates are present by definition and may
be accompanied by encephalopathy. Acute oliguric renal failure
as well as signs and symptoms of congestive heart failure may be
seen. The blood pressure is usually quite elevated, with diastolic
blood pressure exceeding 130 mm Hg. Ophthalmoscopic exam-
ination may demonstrate retinal hemorrhages and exudates as
well as papilledema. Patients may have evidence of congestive
heart failure. Neurologic findings owing to severe hypertension
may include focal motor or sensory abnormalities as well as
altered mental status. However, other causes of acute neurologic
impairment with hypertension must be excluded, including pri-
mary CNS events such as strokes, tumors, head injury,
encephalitis, and collagen vascular disease.
B. Laboratory Findings—Serum creatinine and urea nitro-
gen may be elevated. In those with acute hypertensive
nephropathy, urinalysis shows red blood cells, red blood cell
casts and proteinuria.
C. Electrocardiography—Electrocardiography may show left
ventricular hypertrophy, particularly with chronic hyperten-
sion. Acute ST-segment and T-wave changes may be second-
ary to hypertension but also may represent acute ischemia.
D. Imaging Studies—The chest x-ray may show car-
diomegaly and pulmonary edema. Aortic dissection should
be considered when reviewing the film. Imaging of specific
organs depends on symptoms and signs and may include
head CT scan (eg, strokes and focal neurologic findings),
renal ultrasound (eg, acute renal insufficiency), and
echocardiography (eg, aortic dissection).
Treatment
The most important consideration in patients with hyper-
tensive crisis is rapid reduction of blood pressure with a
short-acting, easily titratable agent. The goal is to prevent
permanent vascular and neurologic damage and to avoid
worsening the heart failure or causing uncontrollable
hypotension. Blood pressure should be controlled aggres-
sively in these patients, and therapy should be instituted even
while etiologic investigation is still under way. Of particular
concern, patients with strokes or other types of neurologic
dysfunction may sustain further neurologic damage if blood
pressure is lowered too abruptly or excessively. Therefore,
the initial goal of antihypertensive therapy within the first
6 hours is to lower the blood pressure by 25% of the starting
blood pressure value or to no less than 150/110 mm Hg.
Further lowering should take place more gradually.
A. Nitroprusside—Intravenous nitroprusside, which acts as
a peripheral arteriodilator, is the drug of choice in hyperten-
sive crises because it can be titrated rapidly and safely.
Excessive hypotension can be avoided by careful blood pres-
sure monitoring, usually with an arterial catheter, but a non-
invasive automated cuff manometer is usually satisfactory. If
hypotension occurs with nitroprusside therapy, discontinu-
ation of the drug results in rapid restoration of blood pres-
sure. Nitroprusside is given intravenously at a rate of
0.25–10 μg/kg per minute. Usually one begins at a low infu-
sion rate and adjusts the rate as needed every 5 minutes over
a period of 1–2 hours. Thiocyanate toxicity can occur, par-
ticularly in patients with renal failure. However, over the
first 24 hours, when control of blood pressure is essential,
this is not a major concern. After blood pressure is lowered
to a satisfactory level, institution of oral antihypertensive
drugs is begun with the goal of discontinuing nitroprusside
within 24–48 hours.
B. Other Antihypertensive Agents—Other parenteral
agents that can be used in patients with severe hypertension
include esmolol, hydralazine, labetalol, nitroglycerin (usually
a mild blood pressure–lowering agent), and enalaprilat, an
ACE inhibitor. Esmolol is a short-acting β-adrenergic blocker
indicated for short-term use. It should be avoided in patients
with bronchospasm, severe heart failure, heart block, or
bradycardia. Hydralazine is a peripheral vasodilator that can be
given orally or intravenously. Reflex tachycardia is common, and
β-adrenergic blockers are almost always given simultaneously.
Labetalol has both α- and β-adrenergic blocking effects.
Nitroglycerin has primarily venodilator effects. The degree of
lowering of blood pressure with intravenous nitroglycerin varies
from patient to patient, and there is some risk of lowering car-
diac output excessively with this drug. On the other hand, nitro-
glycerin has the advantage of being a coronary artery
vasodilator and therefore is useful in patients with hypertension
and myocardial ischemia. Enalaprilat is the only intravenous
ACE inhibitor available. It is converted to the active drug
enalapril after infusion. It has modest antihypertensive effects
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at the dosages recommended (starting dose 0.625 mg). Side
effects include worsening of renal failure and hyperkalemia.
Oral calcium channel blockers, including amlodipine and
diltiazem, are useful in less severe hypertension. In patients
with severe hypertension and heart failure, calcium channel
blockers and beta-blockers may result in unacceptable depres-
sion of ventricular function, in some cases worsening conges-
tive heart failure. However, β-adrenergic blockers must be
used in patients with dissecting aortic aneurysms before sys-
temic vasodilators (eg, hydralazine and nitroprusside) are
given to prevent an increase in shear stress on the aortic wall.
Diuretics may be needed in addition to the antihypertensive
medication to help relieve the volume overload associated
with treatment with many of the vasodilator drugs.
Stable patients with severe hypertension without
encephalopathy may be managed with oral agents, including
beta-blockers, calcium channel blockers, clonidine,
hydralazine, and ACE inhibitors. Combinations of drugs are
often necessary to maximize effects and minimize side effects
and toxicities.
Aggarwal M, Khan IA: Hypertensive crisis: Hypertensive emergen-
cies and urgencies. Cardiol Clin 2006;24:135–46. [PMID:
16326263]
Chobanian AV et al: The seventh report of the Joint National
Committee on prevention, detection, evaluation, and treatment
of high blood pressure: The JNC 7 report. JAMA
2003;289:2560–72. [PMID: 12748199]
Feldstein C: Management of hypertensive crises. Am J Ther 2007;14:
135–9. [PMID 17414580]
Marik PE, Varon J: Hypertensive crises. Chest 2007;131:1949–62.
[PMID: 17565029]
 Complications of Cardiac Catheterization
ESSENT IALS  OF  D IAGNOS I S
 Bleeding or thrombosis at vascular access site.
 Peripheral arterial emboli from clot at access site.
 CNS complications from cerebrovascular emboli.
 Arrhythmias, myocardial infarction, cardiac tamponade
from myocardial perforation, aortic dissection.
General Considerations
Patients may be admitted to the ICU after cardiac catheteri-
zation for monitoring or because of complications from the
procedure. Complications may result from the underlying
cardiac problem, but complications from the cardiac
catheterization procedure itself should be anticipated.
Complications can be grouped into problems related to the
vascular access site, the aorta, and the heart.
A. Vascular Access Complications—Vascular access, partic-
ularly in an atherosclerotic vessel, can result in the development
of dissection or occlusion at the vascular site or may provide
a nidus for thrombus with or without peripheral emboliza-
tion. In addition, large hematomas may develop at the entry
site if adequate hemostasis is not achieved or if vascular
damage with a pseudoaneurysm or intimal tear has
occurred. The use of heparin, clopidogrel, aspirin, and glyco-
protein IIb/IIIa receptor inhibitors for treatment of unstable
angina and prolonged catheter placement after catheteriza-
tion have increased the risk of bleeding and the need to pay
close attention to local hemostasis. Several kinds of devices
have been developed to close arterial catheter puncture sites
when catheterization is completed, including those with
arterial sutures and devices that provide internal compres-
sion with a collagen plug. These devices have reduced the risk
of bleeding significantly.
In patients with bleeding at the access site, the hematoma
should be measured, outlined with a marker, and then
observed for any increase in size. An enlarging hematoma or
swelling at the access site indicates a need for rapid evalua-
tion to exclude or control significant bleeding. Distal periph-
eral pulses, leg temperature, and the arterial site should be
checked and findings recorded frequently. Doppler studies
are indicated if changes occur or pain develops in the distal
portion of the extremity or if a pseudoaneurysm or dissec-
tion is suspected. Patients undergoing percutaneous translu-
minal coronary angioplasty (PTCA) and stent placement
may have the arterial sheath left in place for 12–24 hours or
may undergo repeat catheterizations to treat multiple
lesions. These repeat and prolonged interventions may
increase the risk of complications and require diligent anti-
coagulation to avoid arterial thrombosis. Newer coated stents
have improved outcomes dramatically with angioplasty and
higher patency rates but require prolonged treatment with a
combination of clopidogrel and aspirin. Discontinuation of
these agents, in particular clopidogrel, can result in acute
stent thrombosis and abrupt myocardial infarction. This
complicates the management of bleeding complications after
catheterization and also poses problems for ICU patients
requiring surgical noncardiac interventions where postoper-
ative bleeding may be an issue.
B. CNS Complications—Strokes can occur during and after
cardiac catheterization because of embolization of intracar-
diac thrombi, aortic intimal plaque disruption, catheter
thrombosis and embolization, and more rarely, dissection of
carotid arteries or air injected inadvertently during catheter-
ization. Strokes owing to catheterization are not infrequent
occurrences. A careful neurologic evaluation prior to cardiac
catheterization makes evaluation after catheterization more
useful. Interpretation of neurologic findings can be compli-
cated by the use of sedation for catheterization; however, a
localizing finding such as hemiplegia or aphasia is highly
suggestive of postcatheterization embolization. A CT scan or
MRI of the head or cerebral arteriography should be per-
formed immediately to help determine whether the event is
associated with hemorrhage. In the absence of hemorrhage,
intervention with thrombolysis is an option to lyse the clot.
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This can be done by localized infusion during cerebral
angiography or with systemic thrombolytic agents.
Prolonged use of heparin or use of other anticoagulants dur-
ing catheterization may preclude the use of systemic throm-
bolysis, and decisions are made on an individual basis with
the help of a stroke team.
C. Other Complications—Cardiac complications related to
catheterization include myocardial infarction, arrhythmias,
cardiac tamponade, and aortic dissection. Echocardiography
should be performed with little hesitation in patients com-
plaining of dyspnea or chest pain after catheterization, and
this technique can be useful to look for new cardiac wall
motion abnormalities, aortic dissection, or the development
of a pericardial effusion.
Pericardial effusions developing after catheterization are
relatively rare but require close observation for develop-
ment of tamponade, particularly in patients who have had
interventions (eg, angioplasty) or are receiving platelet
inhibitors or anticoagulation. Tamponade with hemody-
namic collapse can develop rapidly in these situations.
Acute shortness of breath with chest pain may be due to
acute ischemia, and this must be differentiated from acute
cardiac tamponade.
Radiologic contrast medium–related problems include
histamine-mediated reactions (eg, urticaria, angioedema,
and hypotension), volume depletion and hypotension sec-
ondary to the osmotic diuresis, and acute renal failure. Close
monitoring of patients after cardiac catheterization requires
attention to electrolyte and fluid balance. Patients with dia-
betes and preexisting renal disease are at increased risk of
acute renal failure. Urticaria and other histamine reactions
can be reduced by pretreatment with antihistamines and H2-
blockers one hour before the procedure. Patients with known
allergic reactions to contrast media also should be pretreated
with corticosteroids 8–12 hours before the procedure.
Hydration before and after contrast administration is the
best way to prevent renal failure. Patients with renal insuffi-
ciency or preexisting diabetes may have a reduced risk of fur-
ther deterioration if given acetylcysteine prior to the
administration of contrast material.
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 Aortic Dissection
ESSENT IALS  OF  D IAGNOS I S
 Severe chest pain without features of ischemic heart
disease in the presence of hypertension.
 Widened mediastinum on chest x-ray.
 Aortic dissection identified by echocardiogram, CT scan,
or MRI.
General Considerations
Acute aortic dissection is seen in patients with underlying
atherosclerotic vascular disease, hypertension, and connec-
tive tissue abnormalities such as Marfan’s syndrome. Aortic
dissection is the acute development of a tear in the intima of
the aorta. Arterial blood under high pressure enters the
intima, extending the tear and causing progressive destruc-
tion of the aortic media. This process is potentially cata-
strophic. The path the dissection takes is quite variable,
spiraling superiorly and retrograde to the aortic valve and
the coronary arteries, antegrade to the abdominal aorta, or
both. The hemodynamic manifestations and clinical findings
will depend on the path the dissection takes.
Dissections occur most frequently in the ascending aorta
near the aortic valve or in the proximal descending aorta beyond
the takeoff of the left subclavian artery. There are several classifi-
cation systems for describing the location of aortic dissection.
The easiest to understand and most relevant in terms of clinical
decision making divides aortic dissections into two types. The
proximal or ascending (type A) dissection involves the proximal
aorta but may extend beyond the aortic arch. This type is analo-
gous to the DeBakey type I and type II classification of aortic dis-
sections. Descending or distal (type B) dissection involves only
the descending portion of the aorta, similar to DeBakey type
III. Type A dissections are often lethal, causing acute aortic insuf-
ficiency, congestive heart failure, pericardial effusions, often with
tamponade, and acute myocardial infarctions. Treatment is
almost always surgical. Type B dissections are initially treated
medically but may require surgery after stabilization.
Clinical Features
A. Symptoms and Signs—The most common clinical pres-
entation of patients with aortic dissections is the abrupt onset
of severe chest or back pain. The pain is at maximum intensity
at onset. The pain tracks the progression or pathway of the dis-
section and often is described as tearing or ripping in quality.
The severity of the pain may precipitate vagal reflexes, includ-
ing hypotension and bradycardia. If the aortic valve or coro-
nary arteries are involved, congestive heart failure or myocardial
ischemia can develop acutely. Cardiac tamponade may occur
if the tear extends into the proximal aortic root, allowing blood
to enter the pericardial space. Physical findings include dimin-
ished or unequal peripheral pulses and blood pressures.
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A murmur of aortic regurgitation may be heard along with
findings consistent with acute pulmonary edema or tamponade.
In this age of thrombolytic therapy and anticoagulation
for acute myocardial infarction, it is critically important to
distinguish aortic dissection from myocardial ischemia.
Although both present with chest pain, the pattern of pain—
quality, location, duration, and onset—should help to distin-
guish between the two. Pain from aortic dissection is more
abrupt in onset, more often reaches maximum intensity
immediately, and is often described as tearing in quality.
Location is more often in the back than substernal. Unlike
myocardial pain, the pain of aortic dissection usually does not
respond to nitrates or beta-blockers acutely but may do so if
a reduction in blood pressure decreases the stress on the
aorta. Also unlike myocardial ischemia, aortic dissection pain
usually is unrelated to activity. In contrast, ischemic pain usu-
ally begins slowly and increases in intensity. It radiates to the
neck, jaw, and arm but never below the umbilicus. Beta-
adrenergic blockers and nitrates usually relieve ischemic pain,
although not necessarily the pain of myocardial infarction.
Ischemia and infarction often have electrocardiographic find-
ings of ST-segment and T-wave changes. On examination, the
presence of a new aortic diastolic murmur, unequal peripheral
pulses, and absence of rales in a patient with chest pain
should raise the question of aortic dissection.
If aortic dissection is a consideration, diagnostic tests
should be undertaken expeditiously because the treatment—
lowering the blood pressure, decreasing myocardial contractil-
ity with beta-blockers, and surgical repair—must be adminis-
tered urgently. Anticoagulation and thrombolytic therapy are
clearly contraindicated. Unfortunately, because aortic dissec-
tion can cause acute myocardial infarction by involving coro-
nary arteries in the dissection, the distinction between aortic
dissection and myocardial ischemia is not always clear.
B. Imaging Studies—Initial evaluation with chest x-ray may
identify a widened mediastinum, but more definitive infor-
mation can be obtained using transthoracic echocardiogra-
phy. Although the sensitivity for identifying aortic dissection
is relatively low with transthoracic echocardiography, this test
provides other useful additional information on cardiac func-
tion, ventricular wall motion, and valvular abnormalities and
can identify the presence of pericardial effusion. In addition,
the echocardiogram can be used to measure the aortic root
size, and Doppler echocardiography can determine the degree
of aortic valvular regurgitation (Figure 21–4).
 Figure 21–4. Aortic dissection and aneurysm with an intimal flap demonstrated by transesophageal echocardiogra-
phy. The aneurysm of the ascending aorta is at A. The aortic valve is at V. The arrow points to the intimal flap approxi-
mately 2 cm above the aortic valve in the proximal ascending aorta.
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Transesophageal echocardiography, MRI, and CT scan are
80–100% sensitive and specific for the diagnosis of aortic dissec-
tion. MRI is probably the most sensitive and specific procedure,
but the availability of transesophageal echocardiography and
the ability to monitor the patient more closely during echocar-
diography than during MRI or CT scanning are important con-
siderations. Monitoring patients during MRI scanning can be
difficult, and unstable or hypotensive patients should undergo
transesophageal echocardiography at the bedside instead. One
of these tests should make the diagnosis rapidly (Figure 21–5).
If the imaging technique identifies aortic dissection, therapy is
based on the location of the dissection and the extent of aortic
involvement. Further studies may be indicated to assess coro-
nary anatomy and aortic valve function. Cardiac catheterization
may be needed to help guide the surgical intervention.
Treatment
In general, type A aortic dissections require surgery because
medical management alone for proximal ascending aortic
dissection has a high short-term and 1-year mortality rate.
Type B aortic dissections that involve the descending portion
of the thoracic aorta only are managed medically unless there
is compromise of the renal or mesenteric circulations.
Complicated dissections involving the arch and arch vessels
have high surgical and medical mortality rates, making ther-
apeutic decisions more difficult.
Immediate management of all aortic dissections
requires aggressive medical and pharmacologic therapy to
reduce systolic blood pressure and to decrease the peak
systolic velocity of aortic blood flow and thereby reduce
sheer forces on the aortic wall. The goals of therapy
include control of pain, reduction of systolic blood pres-
sure to 100–120 mm Hg (as long as renal, myocardial, and
cerebral perfusion is maintained), and stabilization of the
patient’s hemodynamic variables to permit a thorough
diagnostic evaluation. Beta-adrenergic blockers are used
aggressively to decrease the force of ventricular contrac-
tion. Heart rate is used as a guide to the degree of beta-
blockade, and enough β-adrenergic blockade should be
given to lower the heart rate to 55–65 beats/min.
Nitroprusside is used to control blood pressure initially
and is adjusted as required when beta-blockade is
achieved. Calcium channel blockers, because of their neg-
ative inotropic and antihypertensive properties, are ideal
alternatives in patients who are unable to tolerate beta-
blockers. Hydralazine and other direct vasodilators should
not be given to control blood pressure in the absence of β-
adrenergic blockade. Although blood pressure will fall, the
force of aortic blood flow may increase, further increasing
stress on the damaged aortic wall.
Survival rates approach 80–90% when appropriate ther-
apy is instituted rapidly in both type A and type B aortic dis-
sections. Outcome is determined in part by the degree of
damage to vital organs (eg, kidneys, brain, heart, and bowel),
the underlying condition of the aorta, and the extent of the
repair needed.
 Figure 21–5. Aortic dissection and aneurysm with an intimal flap as demonstrated by ultrafast CT scan in the same
patient as shown by transesophageal echocardiography in Figure 21–4. The arrows point to the intimal flap. The
aneurysm is marked by an A.
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ATRIAL ARRHYTHMIAS
Critically ill patients—particularly those with pulmonary
disease and respiratory failure—are at high risk for develop-
ing atrial arrhythmias. Atrial distention, electrolyte imbal-
ances, hypoxemia, and high catecholamine levels all
contribute to electrical instability and increased atrial auto-
maticity. Identifying the type of supraventricular arrhythmia
is essential in choosing the correct treatment. A 12-lead ECG
permits more careful evaluation of P-wave morphology and
axis than a single-lead ECG from the bedside monitor or
“rhythm strip.” The morphology of the ST segments and T
waves should be examined for evidence of ischemia. The PR
interval and initial activation of the QRS segment can iden-
tify the presence of an atrioventricular (AV) nodal bypass
tract and show evidence of preexcitation.
Treatment is directed primarily toward eliminating or
reversing the precipitating or exacerbating causes.
Correction of alkalosis, hypokalemia, hypomagnesemia, or
hypoxemia will increase the likelihood of rate control and
eventual conversion to sinus rhythm. The major goal of acute
treatment is to slow the ventricular rate so as to improve car-
diac output and blood pressure. In the setting of hemody-
namic compromise (eg, hypotension, syncope, chest pain, or
electrocardiographic evidence of ischemia), rapid treatment
using electrical cardioversion may be indicated. This treat-
ment also should be performed immediately if the ventricu-
lar rate is extremely rapid or the patient will not tolerate
prolonged tachycardia because of other conditions such as
aortic or mitral stenosis, hypertrophic cardiomyopathy, or
unstable angina. The high likelihood of recurrence of these
arrhythmias makes rhythm identification and appropriate
pharmacologic treatment important even if initially cor-
rected by electrical cardioversion.
 AV Nodal or Reentrant Tachycardia
AV nodal reentrant (circus movement) tachycardias are
rhythm disturbances that depend on the properties of the AV
node for initiation and propagation. The arrhythmia results
from an endless circle of electrical impulses conducted down
one pathway and up another with slow and fast pathways
cooperating to facilitate and maintain the circuit. Alteration of
refractoriness or conduction velocities in either pathway in the
AV node can stop the arrhythmia immediately. The arrhyth-
mia can be prevented by altering the electrical properties of
the involved pathways or by decreasing the frequency of the
premature atrial contractions that often initiate the cycle.
AV nodal reentrant tachycardias usually have ventricular
rates of 140–220 beats/min, and AV conduction is usually 1:1
but rarely 2:1. The P wave may not be obvious if atrial and
ventricular depolarization occur simultaneously, although a
retrograde P wave may be seen. The differential diagnosis
includes sinus tachycardia, atrial tachycardia, atrial flutter, and
orthodromic AV reentry using an accessory pathway. If the
diagnosis is unclear, adenosine (6–12 mg intravenously) usu-
ally will stop either AV nodal reentry or AV reentry causing the
ventricular rate to fall all at once to the underlying sinus rate
and rhythm. A brief intervening period of sinus bradycardia or
complete heart block may occur. Sinus tachycardia will slow
gradually in response to adenosine and then return to the pre-
treatment rate. If the rhythm is atrial tachycardia, atrial flutter,
or atrial fibrillation, increasing AV block with adenosine usu-
ally will make the diagnosis apparent.
AV nodal reentrant tachycardias are treated effectively
with adenosine (6–12 mg IV bolus), verapamil (5 mg IV
bolus), diltiazem (0.25 mg/kg infusion given over 2 minutes),
or β-adrenergic blockers (eg, metoprolol, 5 mg intravenously
up to a total of three doses given every 5 minutes if needed).
These drugs alter conduction velocity through the AV node.
Because of adenosine’s extremely short half-life (measured in
seconds), it is the drug of choice for acute treatment of narrow-
complex tachyarrhythmias, but it is not useful in preventing
recurrences. Therefore, if the risk of recurrence is great in
patients with an underlying predisposing medical condition,
one of the other drugs can be administered to decrease the
likelihood of recurrence and can be tried if adenosine fails to
convert the patient to sinus rhythm. In patients with com-
promised ventricular function, digoxin may be a more
appropriate long-term drug than either calcium channel
blockers or β-adrenergic blockers, both of which are myocar-
dial depressants.
Procainamide is effective in treating atrial arrhythmias by
preventing premature atrial beats and decreasing atrial auto-
maticity. When the AV reentry tachycardia uses concealed
retrograde conduction through a bypass tract, procainamide
also may help by slowing conduction through the bypass
tract. A bypass tract may be suspected when the ventricular
rate exceeds 200 beats/min in an adult or when a baseline
ECG demonstrates a short PR interval and evidence of pre-
excitation. Digoxin, β-adrenergic blockers, and calcium
channel blockers can be dangerous in patients with bypass
tracts who have atrial fibrillation because these drugs block
AV nodal conduction and thereby facilitate conduction
through the bypass tract. The ventricle is bombarded by an
increased number of impulses from the atria, resulting in a
very rapid ventricular rate. Ventricular fibrillation may
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follow. Class Ic and class III antiarrhythmic agents such as
flecainide and amiodarone also can be helpful for medical
management of patients with bypass tracts. The develop-
ment of transvenous radiofrequency ablation of bypass
tracts obviates the need for long-term pharmacologic ther-
apy for most patients and has largely replaced surgical abla-
tion. AV nodal reentry arrhythmias without bypass tracts
and atrial flutter are also treated effectively with transvenous
ablation techniques.
 Atrial Tachycardia
Atrial tachycardia is an automatic rhythm (repetitive single
focus) and does not depend on the AV node and reentry to
continue. Atrial tachycardia is less common than AV nodal
reentrant rhythms and usually has a regular ventricular rate
of 140–220 beats/min, although AV block may cause the ven-
tricular rate to be considerably slower. The P waves have uni-
form morphology and relationship to the QRS complex.
Although calcium channel blockers, beta-blockers, and
digoxin usually will not terminate these atrial arrhythmias,
they will decrease the ventricular response rate by slowing AV
nodal conduction and therefore can effectively improve
hemodynamics. Slowing of the ventricular rate may be help-
ful in identifying underlying atrial activity on the ECG so
that a distinction can be made between atrial tachycardia, AV
nodal reentry, atrial flutter, and atrial fibrillation. After the
ventricular rate is controlled, conversion to sinus rhythm can
be attempted with class Ia, Ic, or III antiarrhythmic agents or
electrical cardioversion. Radiofrequency ablation can be con-
sidered in selected patients when the focus of the arrhythmia
can be localized and the arrhythmia occurs frequently.
 Atrial Flutter
Atrial flutter is a macroreentrant arrhythmia and in many
ways behaves like atrial tachycardia. Atrial flutter always
should be considered when a patient presents with supraven-
tricular tachycardia with a rate of approximately 150
beats/min. The atrial flutter rate usually is approximately 300
beats/min, but because of normal delays in conduction
through the AV node, the ventricular response rate is slower
than the atrial rate, with only every other (2:1 AV block) or
every third (3:1 AV block) beat effectively conducted to the
ventricle. Increasing the degree of AV nodal block with drugs
(adenosine) or by carotid massage brings out the underlying
flutter waves on the ECG and establishes the diagnosis.
Drugs that increase AV nodal block usually—though not
always—can control the ventricular rate at rest, but conver-
sion to sinus rhythm usually requires either antiarrhythmic
drugs or, more commonly, electrical cardioversion. Ibutilide,
sotalol, or amiodarone can be tried. In general, atrial flutter
is more resistant to pharmacologic conversion than AV nodal
reentrant tachycardia. However, unlike atrial fibrillation and
atrial tachycardia, atrial flutter can be converted using fairly
small amounts of electrical energy, usually less than 50 J.
Atrial flutter also can be converted to sinus rhythm with
overdrive pacing using a transvenous right atrial pacemaker
electrode or an esophageal pacemaker electrode. Atrial flutter
is a rhythm that is amenable to radiofrequency ablation, with
success rates approaching those for other supraventricular
tachycardias. Given the difficulty of treating atrial flutter and
converting it with medical therapy, ablation provides effec-
tive long-term treatment.
A subset of patients with atrial tachyarrhythmia may
develop bradycardia after electrical cardioversion or drug
therapy. Patients with tachy-brady syndrome pose a particu-
lar problem in designing therapy and may require temporary
pacing if cardioversion is attempted. They also may require a
permanent pacemaker to generate an adequate ventricular
rate when receiving necessary drug therapy to control the
tachyarrhythmias.
 Atrial Fibrillation
Atrial fibrillation is a chaotic arrhythmia probably owing to
multiple reentry circuits within the atria that results in loss
of atrial contraction and an irregular, often rapid ventricu-
lar rate. Because of the rapid but unpredictable bombard-
ment of the AV node by the atrial fibrillatory impulses and
variable penetration of the impulses through the AV node to
the ventricle, the ventricular rate is highly variable. An irreg-
ularly irregular ventricular rate with the absence of P waves
is the hallmark of atrial fibrillation and makes it easily dis-
tinguishable from the other more organized and regular
atrial arrhythmias. Patients with acute atrial fibrillation may
develop hypotension, myocardial ischemia, decreased perfu-
sion of vital organs, and acute congestive heart failure.
Those with chronic atrial fibrillation have an increased risk
of atrial mural thrombus formation, usually in the left atrial
appendage, with the risk of subsequent systemic emboliza-
tion. Atrial fibrillation is very common in patients with
mitral stenosis, lung disease, sepsis, and hyperthyroidism, as
well as in any form of heart disease or after cardiac surgery.
Therapy is directed at slowing the ventricular rate initially,
followed, in appropriate patients, by conversion of atrial fibril-
lation to sinus rhythm. Slowing of the ventricular rate can be
achieved with β-adrenergic blockers, calcium channel block-
ers, or digoxin, all of which increase the AV nodal refractory
period. Control of the ventricular rate is particularly impor-
tant in patients with ischemia and chest pain, congestive heart
failure, mitral stenosis, and hypotension. Intravenous diltiazem
can be given at a dose of 5–10 mg followed by a continuous infu-
sion. Alternatively, intravenous digoxin is effective when given at
a dosage of 0.125–0.25 mg every 4–6 hours until the desired rate
is achieved or until 1–1.5 mg has been given. In some patients,
combinations of these drugs are necessary, but excessive AV
nodal blockade should be avoided. The goal of rate control is to
lower the ventricular rate to about 80–100 beats/min.
Ibutilide, an intravenous short-acting class III antiar-
rhythmic agent, can be used to convert atrial fibrillation to
normal sinus rhythm. When given before direct current (DC)
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cardioversion, it increases the likelihood of success. It has
proarrhythmic effects, including torsade de pointes, that
necessitate close monitoring during its infusion and for sev-
eral hours thereafter. Intravenous magnesium is given fre-
quently prior to ibutilide to reduce this risk. Combined use
with amiodarone may increase heart block or arrhythmias.
Sotalol, a class III antiarrhythmic with β-adrenergic blocking
properties, also can be used. These agents can be continued to
help maintain normal sinus rhythm. Long-term use of sotalol
and amiodarone, however, may result in bradycardia, which
may be prolonged with amiodarone because of the 32-day
half-life.
Today, conversion to sinus rhythm is only rarely
attempted using class Ia antiarrhythmic drugs such as
quinidine or procainamide. Before administering class Ia
drugs, the ventricular response rate must be well controlled
because acceleration of the ventricular rate may occur when
these drugs are given. This problem is also seen with atrial
flutter and atrial tachycardia. It also should be noted that
the administration of quinidine may result in nearly a dou-
bling of the serum digoxin level. Thus, a patient with atrial
fibrillation whose ventricular rate is controlled with
digoxin and who has no evidence of digoxin toxicity may
develop digoxin toxicity when quinidine is given.
Procainamide therefore may be a better short-term choice
in the critically ill patient receiving digoxin. Neither quini-
dine nor procainamide is well tolerated as a long-term oral
medication, and both also have significant proarrhythmic
effects. They are being replaced by the newer class  agents
Ic agents flecainide and propafenone, which can be used
safely in patients without coronary disease, left ventricular
hypertrophy, or left ventricular dysfunction, and by the
class III agent dofetilide. The latter is safe in patients with
left ventricular dysfunction but does require initial in-
patient monitoring for excessive QT-interval prolongation.
Sotalol is also effective, but it too carries a risk of QT-
interval prolongation and torsades de pointes, necessitating
initial monitoring for safest administration. Amiodarone is
probably the most effective medication for maintaining
sinus rhythm, but its myriad of potentially dangerous side
effects indicate the need for caution in using it to treat an
arrhythmia that is not lethal.
Electrical cardioversion of atrial fibrillation to sinus
rhythm is effective at least acutely but generally requires higher
amounts of electrical energy than other atrial arrhythmias,
often more than 200 J. Newer biphasic defibrillators have a
higher success rate and require less energy. In a hemodynam-
ically unstable patient with rapid atrial fibrillation, electrical
cardioversion is the appropriate first treatment. Patients with
acute myocardial infarction, hypertrophic cardiomyopathy,
severe systolic left ventricular dysfunction, critical aortic
stenosis, or recent major surgery are patients who would
benefit from rapid restoration of normal sinus rhythm but
who might not tolerate the hypotensive episode or further
hypotension caused by the antiarrhythmic agents used to
chemically treat the atrial fibrillation.
Atrial fibrillation poses a risk of embolization because the
noncontracting atria are potential sites for thrombus forma-
tion, and the risk of embolization increases with cardiover-
sion. The greatest risk of embolization is associated with
atrial enlargement and atrial fibrillation of long duration.
Therefore, patients who have had atrial fibrillation for more
than 2–3 days should be anticoagulated for 3–4 weeks before
conversion is attempted. Alternatively, it has been shown to
be safe to undertake cardioversion if a transesophageal
echocardiogram performed while the patient is on anticoag-
ulation demonstrates no atrial thrombi and anticoagulation
is continued for 4 weeks after cardioversion. This approach
allows fairly prompt cardioversion of patients in whom the
duration of atrial fibrillation is unknown and avoids leaving
the patient in atrial fibrillation for several additional weeks.
Patients without mitral stenosis who develop acute atrial fib-
rillation can be cardioverted within the first few days without
anticoagulation.
Patients with atrial fibrillation who cannot be converted
to sinus rhythm are managed by controlling their ventricular
rates. Anticoagulation with warfarin should be considered
in patients with chronic atrial fibrillation because of the
increased frequency of embolic strokes even in the absence
of intrinsic heart disease. Patients at higher risk for embolic
events include the elderly; those with ischemic, valvular, or
hypertensive heart disease; diabetics; and patients with a
history of stroke or TIA. Aspirin may be an alternative in
otherwise healthy younger patients with lone atrial fibrilla-
tion or in those with contraindications to anticoagulation
with warfarin.
 Multifocal Atrial Tachycardia 
Multifocal atrial tachycardia is an atrial arrhythmia that can
be confused with atrial fibrillation, but it is managed quite
differently. This arrhythmia generally is seen in patients with
severe lung disease and respiratory failure. The hallmark of
this atrial tachycardia is an irregular ventricular rate but with
multiple atrial foci (P waves with different morphologic
appearances). Atrial fibrillation also has an irregular ventric-
ular response, but P waves are absent.
Treatment of the underlying lung disease and respiratory
failure usually corrects the arrhythmia. Once the precipitat-
ing pulmonary process resolves, sinus rhythm often returns.
Multifocal atrial tachycardia responds poorly to digoxin,
with neither slowing of the ventricular rate nor conversion to
sinus rhythm. Verapamil may be effective sometimes in slow-
ing ventricular rate and decreasing the frequency of ectopic
atrial beats.
VENTRICULAR ARRHYTHMIAS
Management of ventricular arrhythmias in the ICU is often
more complicated than management of atrial arrhythmias
because the treatment is sometimes worse than the disease,
and because these arrhythmias may be poorly tolerated by
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critically ill patients. Rapid ventricular arrhythmias (eg, ven-
tricular tachycardia) require immediate treatment, particu-
larly in patients who have severe underlying cardiac disease.
Almost all antiarrhythmic agents used for the treatment of
ventricular arrhythmias may facilitate arrhythmias (proar-
rhythmic effect) and have a variety of other unpleasant or
life-threatening side effects. Therefore, treatment of ventric-
ular arrhythmias should be limited to those known to cause
hemodynamic compromise or those that occur in the setting
of underlying myocardial disease. In general, the more malig-
nant the arrhythmia appears—that is, the more rapid the
rate, the longer the duration of the arrhythmia, the more fre-
quent the occurrence, and the greater the hemodynamic
compromise (eg, hypotension or syncope)—the more
important it is to treat. In addition, the presence of ventricu-
lar tachycardia always should raise the question of ischemia
with underlying coronary artery disease.
The nuances of evaluation and management of sudden
cardiac death and nonsustained and sustained ventricular
tachycardia in the presence or absence of ventricular dys-
function are beyond the scope of this text. However, develop-
ment of significant ventricular arrhythmia justifies and
necessitates consultation with an electrophysiologist to
determine whether medical therapy is indicated, to assess
drug efficacy, and to consider more definitive treatment,
including implantable defibrillators and transvenous abla-
tion. The development of sudden cardiac death and sus-
tained ventricular tachycardia in patients without known
cardiac disease should result in a careful search for cardiac
disease, particularly ischemia. Cardiac catheterization with
coronary arteriography may be indicated.
 Ventricular Ectopy (Premature Ventricular
Contractions)
Treatment of asymptomatic ventricular ectopy (ie, premature
ventricular contractions [PVCs]) is usually not indicated, par-
ticularly in light of many studies demonstrating both the lack
of efficacy and potential catastrophic side effects resulting
from treatment of non-life-threatening ventricular arrhyth-
mias in certain populations. Ventricular ectopy is often benign
and requires no treatment. However, development of PVCs
may be a clue to the presence of digoxin toxicity or electrolyte
or other metabolic imbalance—particularly hypokalemia but
also hypomagnesemia, alkalosis, hyperkalemia, hypoxemia,
and ischemia. Correcting these abnormalities often eliminates
the PVCs. High catecholamine states, including treatment in
an ICU, recent surgery, and prolonged pain, can result in
PVCs. Beta-adrenergic blockade may help to reduce the fre-
quency of PVCs in these patients.
Unifocal PVCs, bigeminy, and couplets (paired PVCs)
usually do not require treatment even in a patient with
myocardial ischemia. Antiarrhythmic therapy should be
reserved for patients with sustained or nonsustained ventric-
ular tachycardia accompanied by hemodynamic compro-
mise. However, the indications for short-term therapy of
PVCs are less rigorous than the indications for long-term
antiarrhythmic treatment, and short-term therapy to sup-
press PVCs may be appropriate while a patient is medically
unstable in the ICU. In patients with congestive heart failure
and ventricular ectopy, PVCs may not generate an adequate
stroke volume, and frequent PVCs may result in a reduced
cardiac output. Suppression of the ectopy therefore may be
indicated to increase cardiac output. This goal often can be
achieved with administration of intravenous lidocaine.
Procainamide and quinidine are alternatives that are essen-
tially no longer used. Their long- and short-term toxicity
generally outweighs any perceived benefit.
Lidocaine toxicity is seen most often in elderly patients
and those with decreased liver function or congestive heart
failure, and the proarrhythmic effects of lidocaine are mini-
mal. Both quinidine and procainamide can cause torsade de
pointes and worsening of ventricular arrhythmias; use of
these agents calls for close monitoring and careful consider-
ation of indications for therapy. The use of beta-blockers,
particularly in a patient who has evidence of a high-
catecholamine state (eg, tachycardia, agitation, and hyper-
tension), may result in a reduction in PVCs, heart rate, and
blood pressure.
 Ventricular Tachycardia
Ventricular tachycardia is defined as  three or more consecu-
tive ventricular beats and is most commonly a reentrant type
of tachycardia. Nonsustained ventricular tachycardia lasts for
less than 30 seconds and terminates spontaneously, in con-
trast to sustained ventricular tachycardia. Myocardial
ischemia is the most common situation in which ventricular
tachycardia is seen, but valvular heart disease, myocarditis,
and other forms of heart disease also predispose to this
arrhythmia. Patients with prolonged QT intervals with or
without administration of quinidine or another drug that
prolongs the QT interval (such as a tricyclic antidepressant)
may have a form of ventricular tachycardia known as torsade
de pointes. This arrhythmia presents as ventricular tachycar-
dia marked by a pattern of multiform ventricular beats with
the axis shifting with each beat, yielding an undulating QRS
pattern (Figure 21–6). Rapid ventricular tachycardia often
deteriorates into ventricular fibrillation.
In the presence of underlying cardiac disease, ventricular
tachycardia often deserves therapy. Nonsustained ventricular
tachycardia in the setting of acute ischemia or infarction
justifies antiarrhythmic suppression at least over the first
24–48 hours. A similar arrhythmia in a healthy 20-year-old
postoperative patient might be observed without therapy, or
the patient might be given a β-adrenergic blocker to decrease
the effects of excess catecholamines. Electrolyte imbalances
(particularly hypokalemia, hypomagnesemia, and alkalosis)
and hypoxemia increase ventricular irritability and therefore
may predispose to ventricular arrhythmias. In addition,
there is evidence that magnesium administration may
decrease or prevent ventricular arrhythmias even in the
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 Figure 21–6. Four-channel ECG demonstrating torsade de pointes. This multiform ventricular tachycardia changes its axis with changing height and
direction of the QRS complex shifting over the episode. The arrhythmia was initiated by a premature ventricular contraction during a period of high-
degree heart block. Note that not all the P waves are conducted to the ventricle and that the ventricular rate is quite slow.
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absence of hypomagnesemia. Digoxin toxicity, alcohol with-
drawal, and ischemia also must be considered in ICU
patients who develop ventricular arrhythmias.
As a general rule, patients with sustained ventricular
tachycardia that produces hemodynamic instability with
syncope, obtundation, hypotension, congestive heart failure,
or chest pain should be electrically cardioverted immediately
using 100–200 J. Persistent myocardial ischemia or hypoten-
sion that occurs while trying various pharmacologic agents
puts the patient at risk of further deterioration and ventric-
ular fibrillation. As the ventricle becomes more ischemic, sta-
bilization becomes more difficult, and intractable ventricular
fibrillation and death may ensue.
Pharmacologic conversion of ventricular tachycardia can
be used in patients with ventricular tachycardia who are tol-
erating this rhythm without chest pain, hypotension, or con-
gestive heart failure. Initial therapy is lidocaine administered
by an intravenous bolus of 1–2 mg/kg, followed by an intra-
venous infusion of 1–4 mg/min. Procainamide can be given
intravenously as a loading dose (500–1000 mg given at a rate of
50 mg/min), followed by an intravenous infusion (2–4 mg/min)
as an alternative if lidocaine fails. Intravenous amiodarone is an
effective alternative that is being used more frequently, and it is
now recommended as the initial antiarrhythmic medication for
refractory ventricular arrhythmia in Advanced Cardiac Life
Support (ACLS). Amiodarone has a fairly complicated load-
ing schedule: 150 mg is given over 10 minutes followed by 1
mg/min for 6 hours and then 0.5 mg/min for 18 hours.
Loading of amiodarone can be repeated if ventricular tachy-
cardia recurs. Bretylium, another class III antiarrhythmic
agent, is no longer available. Overdrive pacing to suppress
ventricular arrhythmias is helpful in occasional patients.
Patients with torsade de pointes or polymorphic ventricu-
lar tachycardia with a long QT interval are treated differently.
Antiarrhythmic drugs that prolong the QT interval should
not be given including class Ia (eg, quinidine or pro-
cainamide), class Ic (eg, flecainide or propafenone), and some
class III agents (eg, amiodarone or sotalol). These drugs
should be stopped if the arrhythmia occurs during their use.
Isoproterenol or ventricular overdrive pacing may be helpful
in suppressing the initiating ectopic beats and shortening the
QT interval; this is unlike other ventricular arrhythmias in
which β-adrenergic agonists may exacerbate the arrhythmia.
Indications for implantable defibrillators in the treatment
of ventricular arrhythmias are changing rapidly. They are not
generally placed in the acute setting for the management of
ICU-related ventricular arrhythmias. Patients with reduced
left ventricular function after myocardial infarction or owing
to cardiomyopathy, patients with complex ventricular
arrhythmias and depressed left ventricular function, and
patients at high risk for sudden arrhythmic death owing to
underlying heart disease are appropriate candidates. The
presence of an implantable cardiac defibrillator in an ICU
patient can complicate management of the arrhythmias,
including pacemaker-mediated tachycardia; inappropriate
shocks in an ICU setting in the presence of a variety of atrial
tachycardias could lead to inappropriate therapies. In an
emergency when there are incessant inappropriate
implantable cardiac defibrillator shocks, placement of a mag-
net over the implantable cardiac defibrillator usually will
inhibit the defibrillator from delivering therapy. Patients
with implantable cardiac defibrillators and increasing
arrhythmias in the ICU should have their device interrogated
by an electrophysiologist to determine the extent and type of
arrhythmia and to potentially modify the programming of
the device to better control the rhythm.
HEART BLOCK
Heart block occurs when one or more segments of the car-
diac conduction system transmit impulses at an inadequate
rate. Heart block can be divided into (1) sinus node prob-
lems including sinus arrest, sinus node Wenckebach, and
some forms of sinus bradycardia; (2) AV nodal block includ-
ing first-degree AV block, and second-degree Mobitz type I
block (Wenckebach); and (3) infranodal block including
bundle branch block, Mobitz type II AV block, and third-
degree heart block. Both Mobitz type II block and third-
degree heart block also can occur in the AV node, but they
are more commonly manifestations of infranodal disease. In
addition to degeneration caused by aging of the conduction
system, heart block can be induced iatrogenically with med-
ications or may be due to myocardial ischemia or infarction;
metabolic abnormalities; enhanced vagal tone from tracheal
irritation, suction, or intubation; abdominal distention; or
severe vomiting. Heart block sometimes can be confused
with other cardiac dysrhythmias.
It is important to determine whether the arrhythmia is
due to an inadequate impulse formation or poor conduction
from the atrium to the ventricles (default) or to a fast nodal
or ventricular rate relative to the atrial rate (usurpation).
Accelerated idioventricular rhythms, junctional tachycardia,
and isorhythmic dissociation are not due to heart block but
rather result from an acceleration of AV nodal or infranodal
pacemakers. Since there is no heart block, speeding of the
atrial rate will entrain the ventricles normally.
Heart block is managed differently depending on whether
the ventricular rate is adequate or there is clinically significant
bradycardia. Treatment of heart block should focus on several
issues: (1) identification of reversible causes, (2) the hemody-
namic consequences of the arrhythmia, (3) the potential to
progress or recur, and (4) the patient’s underlying medical
condition. For example, the management of patients with
second-degree heart block secondary to the combined use of
a calcium blocker and a β-adrenergic blocker for hyperten-
sion is different from management of a similar degree of heart
block owing to intrinsic conduction system disease. Time, cal-
cium, and perhaps isoproterenol may obviate the need for
even temporary pacing support in the former, but permanent
pacing probably will be required for the latter.
External cardiac pacing may be used for short periods of
time, permitting stabilization with adequate ventricular rates
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and decreasing the urgency of the need for temporary trans-
venous pacing. Temporary transvenous pacing should be
used in patients who are hemodynamically compromised by
heart block. Indications for both temporary and permanent
pacing in coronary artery disease are discussed in Chapter 22.
 Heart Block & Conduction Disturbances
Sinus Bradyarrhythmias
The name sick sinus syndrome has been given to a variety of
bradyarrhythmias arising in the sinus node including sinus
arrest and symptomatic sinus bradycardia. When seen in
association with alternating bradycardia and supraventricu-
lar tachycardia, the term tachy-brady syndrome is sometimes
used. Many patients with sinus bradyarrhythmias have
intrinsic heart disease, but digoxin, beta-blockers, calcium
channel blockers, and other drugs may precipitate bradycar-
dia with syncope, hypotension, and heart failure. In patients
with drug-related bradyarrhythmias, discontinuation of the
drug is necessary; in others with symptomatic bradycardia, a
pacemaker may be necessary. As described earlier, treatment
of supraventricular tachycardia associated with alternating
bradycardia may require drug treatment of the tachycardia
(eg, digoxin and beta-blockers) and a pacemaker (because of
drug-induced bradycardia).
AV Block
Temporary or permanent alteration of conduction through
the AV node or bundle of His is classified as AV block.
Patients with prolonged PR intervals (>210 ms) have first-
degree AV block; this can be due to intrinsic conduction sys-
tem disease, increased vagal tone, or more commonly,
cardiac medications or ischemia. First-degree AV block is
usually benign. Second-degree AV block is diagnosed when
atrial impulses are conducted intermittently through to the
ventricles. In Mobitz type I second-degree AV block
(Wenckebach block), the PR interval lengthens on successive
beats prior to a nonconducted atrial beat (P wave without a
following QRS complex). The electrocardiographic pattern
that emerges is grouped beating in which the number of ven-
tricular complexes is equal to the number of P waves
minus 1. This rhythm is usually due to increased vagal tone
and is seen often in conjunction with reversible ischemia of
the AV node. Treatment of symptomatic or severe bradycar-
dia with Mobitz type I block is begun with atropine.
Isoproterenol and dopamine may be tried; a temporary pace-
maker is necessary occasionally if the ventricular response is
inadequate and prolonged.
Mobitz type II second-degree AV block is usually due to
disease in the infranodal conduction system. The PR interval
is constant in conducted beats. The QRS interval is usually
mildly prolonged secondary to the infranodal conducting
system disease. In the nonconducted or blocked beats, a P
wave is seen without a QRS interval. This form of block may
occur in a pattern or may occur randomly. Several P waves
without accompanying ventricular beats may be seen (3:1 or
4:1 block). A temporary pacemaker is often necessary with
this type of block because of the higher likelihood of pro-
gression to complete AV block, and the escape pacemaker
with type II block, which originates in the ventricle, may not
generate an adequate ventricular rate.
During complete heart block (ie, third-degree AV block),
no atrial impulses are conducted to the ventricles because of
usually infranodal or severe AV nodal conduction system dis-
ease. There is no relationship between P waves and the QRS
interval (AV dissociation). The prolonged QRS interval indi-
cates that ventricular activation is initiated by a ventricular
pacemaker (automatic focus). Ventricular rates of 25–40
beats/min are seen with these ventricular escape rhythms
and usually are inadequate to maintain acceptable cardiac
output and blood pressure. Temporary and often permanent
pacing is required in adults with type II second-degree heart
and third-degree heart block.
 Malfunction of Permanent Artificial
Pacemakers
Permanent pacemakers are used to support cardiac electrical
activity and maintain adequate heart rate by providing elec-
trical stimulation to the cardiac chambers. Pacemaker leads
are placed transvenously, although occasionally they may be
placed epicardially in association with other cardiac surgery.
Pacemakers have become increasingly more complex and
sophisticated in the last 10–15 years. In addition to the famil-
iar single-lead pacemakers, which sense and pace in the ven-
tricular chamber, pacemakers now are often dual-chamber,
sensing and pacing in both the atrium and the ventricle, and
sometimes they have an additional left ventricular lead for
cardiac resynchronization to treat congestive heart failure.
Pacemakers can be programmed to interrupt arrhythmias by
overdrive pacing or by administering ectopic beats.
Pacemakers can have rate-responsive features that allow the
heart rate to increase in response to increased physiologic
demand. When the pacemaker’s rate-responsive sensor is
minute ventilation (measured by transthoracic impedance),
inappropriate tachycardia may be observed during mechani-
cal ventilation.
Because of these added features, assessing pacemaker
function has become extremely complex and requires knowl-
edge of the type of pacemaker, understanding of the algo-
rithms the pacemaker uses, and information about the mode
in which the pacemaker is functioning. For example, for a
rate-responsive pacemaker, knowing the rate at which the
pacemaker should be inhibited involves not only knowing its
backup settings but the ramp used to adjust the pacing rate
and the stimulus to which it is responding.
In a critically ill patient, the major concerns about perma-
nent pacemaker function are (1) that the electrical impulse
from the pacemaker results in stimulation and electrical acti-
vation in the heart, (2) that the pacemaker is providing an
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adequate heart rate to meet the patient’s needs, and (3) that
the pacemaker is sensing the intrinsic cardiac activity and
not competing with it. A properly functioning pacemaker is
able to sense the intrinsic electrical activity of the heart so
that the pacemaker-generated rhythm and intrinsic rhythm
are not competing with each other. Failure to sense the
intrinsic rhythm raises the possibility of pacemaker-induced
arrhythmia; for example, ventricular tachycardia may result
from a pacemaker-triggered QRS interval occurring on a T
wave from the intrinsic rhythm.
In general, in the absence of battery failure, pacemaker
failure is almost always due either to lead malfunction from
wire fracture, loss of insulation, or fibrosis at the endocardial
contact site or to dislodgment in the cardiac chamber or dis-
connection at the connection between the pacemaker and
the pacemaker lead. Lead malfunctions produce problems
with both sensing and capturing, but often the malfunction
is intermittent, occurring when the lead is moved in a partic-
ular way, making detection difficult. Interrogation of the
pacemaker using the programming device provided by the
manufacturer will produce information about the pace-
maker’s settings as well as lead impedance, thresholds, ampli-
tude of sensed electrical activity, and strength of the battery.
This information often can differentiate lead malfunction
from component malfunction. Unfortunately, the older the
pacemaker, the less information can be derived from the pro-
grammer, and the older the pacemaker, the more likely it is
that malfunction will occur.
Programmability of the pacemaker, the ability to change
the rate of pacing or the relationship of ventricular to atrial
activation, allows manipulation of the patient’s hemodynam-
ics. For example, in a febrile or septic patient or one with
heart failure, increasing the ventricular rate may be needed to
increase cardiac output. In patients who develop atrial tach-
yarrhythmias, changing the pacemaker function to ignore the
atrial activity sometimes can allow much better rate control.
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CARDIAC PROBLEMS DURING PREGNANCY
Pregnant patients with cardiac disorders may pose difficult
management problems. One always must consider the
impact of therapy on both the patient and the fetus. It is
often possible to pick a medication that will achieve the
desired clinical effect without injuring the fetus. However,
when the issue of fetal injury secondary to medication arises,
the risks need to be defined and the patient advised.
Knowledge of which medications cross the placenta and have
known teratogenic effects is mandatory. Ultimately, it is the
patient and physician who need to make the decision about
fetal risks to be accepted or avoided.
Common cardiac problems that occur in pregnant
women and may lead to admission to the ICU include valvu-
lar heart disease, arrhythmias, congestive heart failure, and
pulmonary hypertension.
 Valvular Heart Disease During Pregnancy
Valvular heart disease may be unsuspected in a woman of
childbearing age who has been previously healthy.
Rheumatic heart disease resulting in mitral stenosis is seen
with increased frequency in regions that have large Hispanic
and Asian populations.
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Clinical Features
Women with mitral stenosis often are asymptomatic until the
normal increase in blood volume and cardiac output occurring
during pregnancy leads to elevated left atrial pressures and pul-
monary venous hypertension. Tachycardia or atrial fibrillation
is seen often in the acute presentation. These patients present
with signs and symptoms mimicking asthma and, if heart dis-
ease is unsuspected, become progressively worse owing to
drug-induced tachycardia from treatment with β-adrenergic
agonists. Atrial fibrillation also may result in atrial thrombus
formation, so the initial presentation may be a stroke.
The rapid heart rate does not allow time for atrial emptying,
and left atrial pressures therefore rise, resulting in pulmonary
edema. The presence of a diastolic murmur and opening snap
consistent with mitral stenosis and an echocardiogram showing
decreased mitral valve area and increased right ventricular pres-
sure should lead to appropriate management.
Treatment
When mitral stenosis is the dominant cardiac lesion, β-
adrenergic blockers should be used to slow the heart rate and
allow more time for ventricular filling. In general, cardiose-
lective β-adrenergic blockers such as atenolol are preferred
because they cross the placental barrier less effectively than
noncardioselective beta-blockers such as propranolol. If
atrial fibrillation rather than sinus tachycardia is present,
digoxin also can be used to slow the ventricular rate.
Although calcium channel blockers such as diltiazem and
verapamil also will slow heart rate, their effects on the fetus
need to be considered. In pregnant patients with tight mitral
stenosis and especially those with atrial fibrillation, anticoag-
ulation is important to reduce the risk of a stroke. Depending
on the stage of pregnancy, unfractionated heparin or low-
molecular-weight heparin may be most appropriate.
Returning the patient to normal sinus rhythm may
improve cardiac function by allowing better rate control, and
restored atrial contraction will aid in left ventricular filling.
Cardioversion must be done with the patient fully anticoag-
ulated—with plans to continue anticoagulation—and it is
necessary to demonstrate that atrial thrombi are not present
by transesophageal echocardiography. Finally, in patients
with severe mitral stenosis who continue to have severe con-
gestive heart failure symptoms despite medical therapy, per-
cutaneous valvuloplasty can be considered. Patients should
be chosen based on appropriate valve morphology and the
absence of significant mitral regurgitation. Fetal age and via-
bility should be considered in the timing of the intervention,
and neonatologists and obstetricians should be involved in
weighing the risk and benefit to the fetus.
In patients with other types of valvular heart disease,
management is directed toward maximizing the patient’s
cardiac output. However, some of the unloading agents used
to treat left ventricular dysfunction and left-sided valvular
regurgitation may decrease blood supply to the placenta and
therefore to the fetus. Thus the risks of treatment must be
weighed carefully. Fetal monitoring can be used to help assess
the impact of therapy.
 Arrhythmias During Pregnancy
Atrial and ventricular arrhythmias are often benign.
However, sustained rapid atrial or ventricular tachycardia
has the potential to impair uterine blood flow resulting in
compromised fetal oxygenation. Late in pregnancy, when
systemic venous return is limited by compression of the infe-
rior vena cava by the enlarged uterus, a tachyarrhythmia may
result in profound hypotension and syncope. Therefore,
pregnant women who complain of dizziness or syncope must
be evaluated and monitored carefully, usually in an inpatient
setting. Because of toxic side effects and potential effects on
the fetus, antiarrhythmic drugs should be used only for doc-
umented sustained arrhythmias, with drugs and dosages
chosen to minimize effects on the fetus. Beta-blockers and
digoxin generally are safe in pregnancy.
 Congenital Heart Disease and Pulmonary
Hypertension During Pregnancy
Pregnancy in patients with cyanotic congenital heart disease
is associated with a high incidence of fetal loss as well as
maternal death. Pulmonary hypertension, atrial tach-
yarrhythmias, inability to increase cardiac output with
increased demand, and hypoxemia all result in inadequate
cardiac output to the mother and the fetus. Postpartum,
acute exacerbation of pulmonary hypertension and sudden
death occur frequently. Treatment during the pregnancy is
supportive, including restricting activity, avoiding volume
overload, and treating polycythemia. A controlled elective
delivery using an epidural block or cesarean section to mini-
mize myocardial demand should be considered. Inhaled nitric
oxide or intravenous prostacyclin can be used to help manage
the worsening pulmonary hypertension seen after delivery in
patients with Eisenmenger’s syndrome with cyanosis.
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Elkayam U et al: Pregnancy-associated cardiomyopathy: Clinical
characteristics and a comparison between early and late presen-
tation. Circulation 2005;111:2050–5. [PMID: 15851613]
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TOXIC EFFECTS OF CARDIAC DRUGS
Cardiac medications have changed the treatment of patients
with heart disease dramatically, improving the quality and
duration of life, but these drugs have side effects both major
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and minor. Some of the toxic effects are extensions of a
drug’s therapeutic effects, whereas others are idiopathic or
autoimmune in nature. In some patients, toxicity may
develop only when metabolic changes occur that result in
decreased clearance of the drug, but reactions may occur
unpredictably even when drugs levels are in the therapeutic
range. Thus drug levels that produce a desirable drug effect in
one patient may produce a life-threatening side effect in
another. Toxicity also may develop when several drugs inter-
act. Both the toxic and the therapeutic effects of drugs, their
interaction with other drugs, and drug metabolism should be
understood and considered in making treatment decisions
and in evaluating patients receiving cardiac medications.
Discussed below are some of the more common and
important side effects of frequently used cardiac medica-
tions. The key to treating critically ill patients with cardiac
drugs is always to consider the possible or likely side effects
and interactions of the drugs, especially when the patient has
unexplained problems.
 Digoxin
Pharmacology
Digoxin is a glycoside that inhibits Na+-K+ ATPase and
thereby changes the intracellular Na+ concentration. By alter-
ing the amount of Na+ available for the Na+-Ca2+ exchanger,
the net effect of digoxin is to increase the intracellular cal-
cium. Similarly, the effect of digoxin on Na+-K+ ATPase also
alters the transmembrane potential of other cells and there-
fore affects cell excitability, conduction velocity, and refrac-
tory periods. Various cell types are affected differently; this
accounts for the differing effects of digoxin on atrial, AV
nodal, and ventricular tissue. Digoxin, like other cardiac gly-
cosides, also has neurally mediated effects that alter auto-
nomic balance and sympathetic output.
In appropriate doses, digoxin functions as an inotropic
agent, increasing contractility. Its clinically important elec-
trophysiologic effect is to block the AV node, thereby
decreasing the ventricular response rate in atrial fibrillation
and inhibiting reentrant supraventricular tachycardia.
Digoxin has a fairly long half-life of 36–48 hours. It also has
a relatively narrow therapeutic range. Digoxin is cleared pri-
marily by the kidneys with, perhaps, some clearance through
the GI tract.
In critically ill patients, rapidly changing renal function
and the requirement for multiple other drugs make the
development of digoxin toxicity more frequent. Electrolyte
abnormalities such as hypokalemia, hypomagnesemia, and
hypercalcemia enhance digoxin toxicity. Serum levels of
digoxin are affected by a variety of drugs. Quinidine alters
the renal clearance and volume of distribution of digoxin.
Therapeutic levels of quinidine double digoxin serum con-
centrations. Therefore, the dose of digoxin should be
reduced by half when instituting quinidine therapy.
Amiodarone, verapamil, and propafenone have similar
effects on renal clearance of digoxin and digoxin serum level,
although the magnitude of the effect is smaller. Periodic
determination of drug levels with appropriate dose reduc-
tion or cessation can avoid the worse complications.
Toxicity
Digoxin serum levels generally are considered therapeutic in
the range of 0.8–2 ng/mL, which, unfortunately, overlaps with
the range in which toxicity may be seen. Toxicity is rare in
patients with serum levels under 1.4 ng/mL but is seen with
increased frequency when serum levels exceed 2 ng/mL. The
positive inotropic effect of digoxin increases in a dose-related
manner, and this effect persists even in the face of high drug
levels. The toxic effects of digoxin can be broken down into
systemic and electrolyte effects and mild and severe arrhyth-
mias. With mild toxicity, the patient may develop nausea,
visual disturbances, and decreased appetite. At higher serum
levels of digoxin, as the Na+-K+ ATPase is poisoned, hyper-
kalemia develops that may lead to cardiac arrest. Arrhythmias
seen at low levels of toxicity reflect the effect of digoxin on
automaticity, resulting in paroxysmal atrial tachycardia, junc-
tional tachycardia, and ventricular ectopy (particularly
bigeminy). Because digoxin increases AV nodal block, the
atrial tachycardias are associated with heart block.
Treatment
Treatment depends on the severity of toxic manifestations.
Withholding digoxin and correcting hypoxemia, hypokalemia,
and the acid-base disturbances that exacerbate digoxin toxi-
city usually correct arrhythmias over time. Marked bradycar-
dia in the setting of atrial fibrillation can be treated with
atropine in mild cases and temporary pacing in more severe
situations. Lidocaine or phenytoin often can control the less
serious ventricular arrhythmias. Electrical cardioversion may
be necessary acutely to treat sustained ventricular tachycar-
dia from digoxin toxicity when drugs and other measures
have failed, but there is an increased risk of arrhythmic com-
plications because of increased ventricular automaticity
caused by digoxin. Using less electrical energy (fewer joules)
may decrease the risk.
In cases of severe digoxin toxicity that include the devel-
opment of hyperkalemia, severe bradyarrhythmia, recurrent
ventricular tachycardia, or ventricular fibrillation, digoxin
immune Fab (ovine) can be lifesaving. This preparation is a
sheep antibody fragment that has a high affinity for digoxin,
rapidly binding to the drug and reversing its effect. The Fab
fragments have a lower molecular weight than complete anti-
bodies and thus have a greater rate and volume of distribu-
tion. The Fab-digoxin complexes are excreted in the urine,
thus enhancing renal clearance of the drug. Digoxin anti-
body is indicated in the setting of life-threatening digoxin
toxicity or when the ingestion of large amounts of digoxin
makes the development of toxic side effects likely. The dosage
of digoxin immune Fab depends on the digoxin level and the
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estimated volume of distribution. However, if the desired
effect is not achieved with the calculated dose, treatment
with the maximum dose is indicated in life-threatening situ-
ations. Side effects from digoxin immune Fab are minimal.
The drug is expensive, and its use therefore is reserved for
patients with severe life-threatening digoxin toxicity. In most
patients, prevention of digoxin toxicity is preferable and
achievable with forethought. For example, for elderly
patients or critically ill patients in the ICU with acute renal
failure or cardiogenic shock, digoxin should not be given as a
standing order for more than 1 day without careful review
and adjustment if necessary.
 Antiarrhythmic Drugs
Lidocaine
Because lidocaine is metabolized by the liver, hypotension,
right-sided heart failure, and liver failure may result in
decreased clearance of this drug. Lidocaine has minimal
proarrhythmic and myocardial depressant effects. Its side
effects are primarily neurologic consisting of acute onset of
agitation, tremulousness, psychosis, and seizures.
Withdrawal of the drug and time are the treatments. If indi-
cated, another antiarrhythmic agent can be used when lido-
caine is discontinued.
Procainamide and Quinidine
Procainamide, used for treatment of both atrial and ventric-
ular arrhythmias, is cleared by the kidneys. Both the drug
and its by-product, N-acetyl procainamide (NAPA), accu-
mulate in patients with renal failure. Procainamide is a
myocardial depressant and can cause hypotension. It also can
cause QT-interval prolongation with the development of
polymorphic ventricular tachycardia similar to the effects of
quinidine. Unlike quinidine, procainamide does not alter
serum digoxin levels. A number of noncardiac side effects are
caused by procainamide, the most important being agranu-
locytosis and the development of a lupus-like syndrome.
Agranulocytosis is reversible, but the patient may present
with sepsis. The lupus-like syndrome is generally a late devel-
opment in the course of prolonged administration with man-
ifestations such as fever, pleuropericarditis, and arthralgias.
There are serum antihistone antibodies associated with this
drug-induced syndrome as well. This side effect may be seen
more frequently in patients who metabolize the drug slowly
(slow acetylators). The syndrome is reversible with discontin-
uation of the drug.
Quinidine should not be used as a routine drug in the
ICU and virtually never should be started as a new agent.
Quinidine, a class Ia agent whose indications are similar to
those of procainamide, has less myocardial depressant effects
but is only available orally. Its proarrhythmic effects are well
known, with QT-interval prolongation resulting in ventricu-
lar tachycardia and syncope. GI side effects are frequent, and
the development of nausea and diarrhea often limits its use.
Neurologic side effects include tinnitus, hearing loss, and
confusion. Autoimmune thrombocytopenia or hemolytic
anemia occasionally develops unexpectedly, resulting in
hemorrhage or death. Quinidine-induced thrombocytopenia
is treated as autoimmune thrombocytopenia.
If polymorphic ventricular tachycardia (torsade de
pointes) develops during treatment with quinidine or pro-
cainamide, the drug should be stopped, and other class Ia and
Ic agents should be avoided. Beta-adrenergic agonists such as
isoproterenol can be used to speed up the heart rate and
shorten the QT interval. Overdrive pacing with a transvenous
pacing wire also can be used in patients with recurrent ven-
tricular tachycardia until the offending drug is cleared or
metabolized. When monitoring the QT interval during
administration of quinidine or procainamide, the drug
should be discontinued if the QT interval exceeds 500 ms.
Flecainide
Flecainide is a class Ic antiarrhythmic agent that is well toler-
ated, with minimal noncardiac side effects. It is proarrhyth-
mic, however, and can cause significant and sustained
ventricular tachycardia that is resistant to other antiarrhyth-
mic agents. Flecainide slows conduction throughout the con-
ducting system, which can result in bradycardia as well as
heart block. It is poorly tolerated by patients with depressed
left ventricular function and should not be used for those
patients.
Amiodarone
Amiodarone is a powerful antiarrhythmic agent with mini-
mal proarrhythmic effects. However, it has a number of car-
diac and noncardiac side effects that are magnified by its long
half-life. Resulting toxicities can last from days to months
depending on the duration of therapy and the dose.
Amiodarone slows conduction throughout the heart, result-
ing in bradycardia and heart block, which may require per-
manent pacing. GI side effects include nausea and decreased
appetite resulting in weight loss and necessitating dose
reduction or termination of therapy. Either hypo- or hyper-
thyroidism can result from amiodarone’s effect on iodine
metabolism. Deposits in the skin can result in darkening of
skin especially in sun-exposed areas. Intracytoplasmic lamel-
lar deposits can occur in several parts of the eyes, most com-
monly causing corneal epithelial opacities in more than 70%
of patients and lens opacities in 50–60%. Neither impairs
visual acuity, and amiodarone treatment can be continued.
Pulmonary fibrosis is a frightening and potentially life-
threatening complication that can further compromise
patients who already have significant cardiac impairment.
Baseline and follow-up pulmonary function tests are manda-
tory to monitor the development of pulmonary involvement.
Amiodarone interacts with and changes the metabolism of a
myriad of drugs. Its interactions with digoxin, β-adrenergic
blockers, calcium channel blockers, and warfarin should be
monitored carefully.
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Sotalol
Sotalol is a class II (β-adrenergic blocker) and class III antiar-
rhythmic drug that is excreted renally and therefore must be
monitored carefully in patients with changing renal function.
It is an effective agent for atrial and ventricular arrhythmias,
but—like most antiarrhythmic agents—it has proarrhythmic
effects, occurring particularly while therapy is being initiated.
It can cause significant bradycardia and heart block when used
in conjunction with digoxin or calcium channel blockers.
 Calcium Channel Blockers
These drugs can be categorized into three subclasses:
verapamil-like drugs, diltiazem-like drugs, and nifedipine-like
drugs. Some of the toxic effects are the logical result of their
therapeutic mechanisms and may be beneficial in certain set-
tings. For example, slowing of the heart rate in patients with
ischemia is a desirable effect of some of the calcium channel
blockers. However, verapamil and diltiazem also can slow AV
nodal and sinus node conduction excessively, resulting in
bradyarrhythmias and hypotension. Because they are myocar-
dial depressants, these drugs may precipitate or exacerbate
congestive heart failure. The bradycardiac effects of diltiazem
and verapamil can be augmented by concomitant use of β-
adrenergic blockers or digoxin. In contrast, nifedipine and
other drugs in its dihydropyridene class of calcium channel
blockers have no effect on the AV node but can cause reflex
tachycardia and hypotension from vasodilation. Calcium
administered intravenously may reverse some of the toxic
effects of the calcium channel blockers, at least temporarily.
 Beta-Adrenergic Blockers
Beta-adrenergic blockers are extremely useful drugs for con-
trolling hypertension, treating atrial arrhythmias, and allevi-
ating myocardial ischemia. In a patient with myocardial
dysfunction, β-adrenergic blockers can precipitate profound
heart failure and block the normal tachycardiac response to
hypotension and low cardiac output. Despite this, however,
these drugs have been shown to improve long-term survival
in patients with chronic congestive heart failure, including in
patients with class III to IV heart failure.
These drugs are myocardial depressants, block the AV
node, and by blocking the action of catecholamines,
decrease the sinus nodal rate. In patients with conduction
system disease, β-adrenergic blockers may cause profound
bradycardia. The effects of Beta-adrenergic blockers and cal-
cium channel blockers on the myocardium, the sinus node,
and the AV node can be additive, resulting in severe
hypotension and heart block. Beta-adrenergic agonists may
be used to counteract the excessive depressant effects of β-
adrenergic blockers.
 ACE Inhibitors
ACE inhibitors (eg, captopril, enalapril, benazepril, lisinopril)
are commonly used vasodilators valuable in the treatment of
congestive heart failure and hypertension. These drugs can
cause hyperkalemia even in patients without overt renal dis-
ease. Therefore, potassium levels must be observed carefully
when initiating or maintaining therapy with ACE inhibitors.
Rapidly developing renal failure may occur in patients with
renal artery stenosis when ACE inhibitors are started.
Angioedema is a significant and concerning side effect that
should result in terminating this entire class of drug from the
patient’s medical regimen. Cough is another side effect that
patient’s may find bothersome with this class of medica-
tions. In fact, the cough may be confused with the cough
owing to heart failure but responds fairly quickly to removal
of the drug. Angiotensin-receptor blockers have effects simi-
lar to those of ACE inhibitors and may be substituted for
management of the cough complaint. As with other antihy-
pertensive agents, profound hypotension may develop when
starting ACE inhibitors, particularly in patients who are
hypovolemic. In critically ill patients, the benefits and side
effects of these drugs need to be considered carefully.
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Atherosclerotic coronary artery disease is the leading cause of
death in the United States. Each year approximately 1.5 million
patients experience a myocardial infarction. Approximately
20% of these individuals die before they reach the hospital,
and an additional 7–15% die during hospitalization. This
chapter will consider the major coronary artery disease
syndromes: angina pectoris, acute coronary syndromes
(unstable angina and non-ST-segment-elevation myocar-
dial infarction), and acute ST-segment-elevation myocardial
infarction.
 Physiologic Considerations
Coronary Anatomy
The right and left coronary arteries arise from ostia in the
right and left sinuses of Valsalva. Their function is to deliver
oxygen and nutrients and to remove toxic metabolites. The
origin of the left coronary artery is called the left main coro-
nary artery and divides into the left anterior descending coro-
nary artery, which feeds the anterior wall of the left ventricle
and the left ventricular septum, and the left circumflex artery,
which supplies the lateral and posterior walls of the left ven-
tricle. The right coronary artery supplies the right ventricular
free wall and in 90% of cases gives off the posterior descending
artery, which, in turn, provides the blood supply for the pos-
terior right ventricle as well as the inferior left ventricular wall
and septum. The coronary artery that gives rise to the poste-
rior descending artery is referred to as dominant. Thus 90% of
people have a right-dominant circulation. The remaining 10%
have a posterior descending artery that originates from the
left circumflex coronary artery. Coronary collateral vessels
span the area between the right and left coronary artery terri-
tories. These vessels are very small and difficult to demon-
strate even during cardiac catheterization. However, as
coronary stenoses develop in the major epicardial coronary
arteries, collateral vessels may increase in size and number
and provide a protective effect by allowing increased blood
supply from the opposite coronary circulation.
Coronary Blood Flow
Coronary blood flow at rest is ordinarily 70–100 mL/min per
100 g of heart tissue. Approximately 80% of the coronary flow
occurs during diastole. As a consequence, coronary blood
flow is highly dependent on diastolic blood pressure and
resistance to coronary flow within the coronary circulation.
In the absence of disease and with a constant myocardial
oxygen requirement (MVO2), coronary blood flow is kept con-
stant by autoregulation of the coronary vasculature by both
myogenic and metabolic factors. Diastolic perfusion pressure
provides the driving pressure for coronary blood flow.
Metabolic factors, particularly adenosine, affect regional
myocardial blood flow. As tissue oxygen decreases, ADP is
converted to AMP and then to adenosine by the enzyme 5′-
nucleotidase. Adenosine then diffuses out of the cell and
causes relaxation of local vascular smooth muscle. This action
of adenosine is terminated by its deamination to inosine.
Myocardial Oxygen Consumption
Over 90% of the heart’s energy is derived from aerobic
metabolism, primarily from oxidation of fatty acids. The
absence of oxygen forces a transition to anaerobic metabo-
lism of glucose and glycogen. Myocardial O2 requirements
are multiple: 20% of the MVO2 is used to support the basal
metabolism of the heart, less than 5% is used to support elec-
trical activity, and approximately 15% is used to move cal-
cium into the sarcoplasmic reticulum. The most important
determinant of MVO2 is myocardial contractility, accounting
for 60% of MVO2.
A. Heart Rate and Systolic Blood Pressure—An impor-
tant concept about coronary artery disease is the relation of
MVO2 to the heart rate (HR) and systolic blood pressure
(SBP). HR × SBP is commonly referred to as the double prod-
uct. The double product is proportional to MVO2 and can be
used as a measure of myocardial work and thus myocardial
O2 consumption. The inotropic state of the myocardium is
another important determinant of MVO2 and myocardial
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work. However, it is somewhat difficult to measure clinically;
fortunately, the heart rate and systolic blood pressure usually
provide sufficient information for clinical decision making.
B. Balance of Oxygen Demand and Supply—Myocardial
ischemia represents an imbalance between myocardial oxy-
gen demand and myocardial blood supply. A fixed coronary
artery stenosis will limit coronary blood supply. In this cir-
cumstance, demand for coronary blood flow may increase,
but the stenosis will limit the available blood flow. Hence
demand will exceed supply, and myocardial ischemia will
result. The ability of the coronary artery to respond to sym-
pathetic stimulation and other local factors also can result in
an inadequate blood supply through coronary artery spasm.
However, coronary artery spasm (ie, variant angina and
Prinzmetal’s angina) is seldom the sole cause of inadequate
coronary blood flow. More often, fixed coronary artery
stenoses exist in combination with some degree of coronary
spasm or vasoconstriction to cause a myocardial O2 demand-
supply imbalance.
 Myocardial Ischemia (Angina Pectoris)
ESSENT IALS  OF  D IAGNOS I S
 Complaint of heavy, pressure-like or viselike discomfort;
sometimes choking, a constricting feeling in the throat,
or a sensation of strangling; discomfort located diffusely
in substernal region, left arm, jaw, or neck—rarely local-
ized to a single point.
 Discomfort lasts 30 seconds to 15 minutes.
 May be provoked by exertion, emotional distress, eat-
ing, and cold.
 Should decrease with rest and may be relieved in 1–2
minutes after sublingual nitroglycerin.
General Considerations
Resistance to blood flow in the coronary arteries becomes
significant when there is sufficient narrowing of the coronary
artery diameter by atherosclerotic plaques (diameter
decreased by more than 50%). The physiologic consequence
is that coronary artery blood flow becomes fixed at some
value rather than increasing to meet increased myocardial
demands. Coronary blood flow may be adequate to supply
the myocardium at rest but becomes insufficient during
exertion when the myocardial oxygen demand increases.
This explains why, in patients with stable angina pectoris,
symptoms are seen with exercise and disappear with rest.
Clinical Features
The diagnosis of angina pectoris is typically a clinical one.
Pain with the qualities described below should be considered
the primary diagnostic criterion—that is, the history is the
most important diagnostic clue to ischemic heart disease and
myocardial ischemia (angina pectoris).
A. Symptoms—There are six major features of the clinical
manifestations of myocardial ischemia (angina pectoris): the
quality of the discomfort (patients do not always complain of
“pain”), the location, the duration, provoking factors,
sources of relief, and actions taken by the patient during the
episode.
1. Quality of discomfort—Patients with myocardial
ischemia frequently describe the discomfort as a heavy,
pressure-like, or viselike sensation. They may describe chok-
ing or a constricting feeling in the throat. Indigestion or a sen-
sation of strangling is also frequently described. The patient
should be asked about “discomfort” because many patients do
not perceive angina or myocardial ischemia as “pain.”
2. Location of discomfort—The discomfort of myocar-
dial ischemia usually is located in the substernal region but
also may be located in the arms (the left more often than the
right), the jaw, the neck, the left interscapular region, or
occasionally, the epigastrium. It is often useful to ask the
patient to define the extent of the pain with one finger. The
pain of myocardial ischemia is not likely to be localized to a
single point.
3. Duration of discomfort—Angina pectoris usually lasts
30 seconds to 15 minutes. Longer episodes of ischemic pain
are associated with unstable angina or myocardial infarction.
4. Provocation of discomfort—Exertion, emotional dis-
tress, eating, cold weather, and sexual activity are frequent
initiating events.
5. Relief of discomfort—Pain from myocardial ischemia
should decrease with rest or a reduction in exertion.
Sublingual nitroglycerin should relieve angina within 1–2
minutes, and this feature can be used both for diagnosis and
for treatment.
6. Actions taken by the patient—Angina pectoris is not
relieved by inspiration or movement of the upper extremities
or torso nor by antacids or food. Pain relief achieved in this
way should make one think of other disorders.
B. Physical Findings—During an episode of angina, an S3
gallop, pulmonary rales, or the murmur of mitral regurgita-
tion may appear. However, these findings are more likely to
be noted during stress testing, when the patient’s chest pain
is provoked with a physician present.
C. Electrocardiography—
1. Resting ECG—If ST-segment and T-wave changes (ie, ST-
segment depression, T-wave inversion, or both) are present
during an episode of pain and return to normal with spon-
taneous relief of pain or after administration of nitroglyc-
erin, the diagnosis of myocardial ischemia is confirmed.
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2. Exercise stress ECG—The resting ECG frequently is
normal in patients with myocardial ischemia owing to coro-
nary artery disease or coronary artery spasm because the
pain usually has subsided by the time the patient reaches
medical attention. For this reason, stress testing during bicy-
cle or treadmill exercise is frequently employed to reproduce
the supply and demand imbalance that triggers myocardial
ischemia. The patient is asked to walk on a treadmill or pedal
on a bicycle as the work load is increased progressively.
Continuous electrocardiographic monitoring permits detec-
tion of ST-segment depression. Exercise causes an increase in
heart rate and blood pressure (an increase in the double
product); thus patients with a fixed (and inadequate)
myocardial blood supply owing to coronary artery disease
frequently will experience angina with ST-segment depres-
sion as myocardial work exceeds a fixed O2 supply.
D. Imaging Studies
1. Stress testing—Specialized forms of exercise stress test-
ing, including thallium scintigraphy and stress ventriculog-
raphy, have been introduced to diagnose myocardial
ischemia in patients who have resting ECGs that would make
the diagnosis of myocardial ischemia difficult on the basis of
exercise electrocardiography. For example, patients with rest-
ing ST-segment and T-wave abnormalities owing to left ven-
tricular hypertrophy, from administration of digitalis
glycosides, or from prior myocardial infarction may have a
stress ECG that is difficult or impossible to interpret with
precision. In these circumstances, the use of myocardial per-
fusion scanning with thallium-201 or technetium-99m ses-
tamibi may be useful. These perfusion agents are taken up by
viable myocardium in proportion to coronary blood flow. As
coronary blood flow requirements increase (such as during
exercise), myocardium supplied by normal coronary vessels
will have a normal uptake of the tracer. Conversely, areas of
myocardium served by stenotic coronary arteries will have
reduced coronary blood flow during exercise. As a conse-
quence, the reduced uptake of the perfusion agent will
appear as a “cold spot.”
Exercise ventriculography using echocardiography, cine-
CT scanning, or radionuclide angiography can identify the
presence of myocardial ischemia by the development of a
new or worsened wall motion abnormality during stress. As
myocardial O2 requirements outstrip the available supply,
regional wall motion abnormalities will develop as nutrient
flow to the myocardium remains fixed in the face of an
increasing metabolic demand. Initially, a localized wall
motion abnormality will appear or will worsen (if a previous
infarction is present). Next, the global left ventricular ejec-
tion fraction will fall. Although these tests are substantially
more expensive than the standard electrocardiographic stress
test, they may provide a definitive noninvasive means of
diagnosing myocardial ischemia.
2. Coronary angiography—Anatomic diagnosis of coro-
nary atherosclerosis is made by injection of radiopaque
contrast material directly into the coronary arteries. Patients
are taken to the catheterization laboratory, where careful
hemodynamic monitoring can be performed. Significant
atherosclerotic lesions are seen as a reduction in the diame-
ter of the coronary artery, and the anatomic information can
be used to decide whether medical therapy or interventional
procedures such as coronary angioplasty or coronary artery
bypass surgery might be useful.
Differential Diagnosis
Other causes of chest pain that may have features suggestive
of angina pectoris include pericarditis (pain is often posi-
tional and related to respiration); esophageal spasm (related
to meals and swallowing); chest wall pain (often reproduced
by applying pressure to the chest wall); aortic dissection
(classically “tearing” in quality and radiating to the back;
pulses in the arms may be unequal); GI pain from esophagi-
tis, gastritis, cholecystitis, and cholelithiasis (often associated
with meals and, for esophagitis and gastritis, relieved by
antacids); and hyperventilation.
Treatment
The treatment of myocardial ischemia is directed at both
reducing myocardial O2 consumption (myocardial O2
demand and double product) and increasing myocardial
blood supply. Initially, medical therapy is used in an attempt
to reduce myocardial O2 consumption (eg, use of beta block-
ade to reduce heart rate and blood pressure) or to increase
myocardial O2 supply by using coronary vasodilators such as
calcium channel blocking agents or either short-acting (sub-
lingual nitroglycerin) or long-acting nitrates (isosorbide
dinitrate).
More aggressive therapy, such as percutaneous translumi-
nal coronary angioplasty and coronary artery bypass surgery,
increase coronary blood supply directly. While effective in
reaching this goal, as well as in relieving angina, these strate-
gies are invasive and cause a variable degree of morbidity. To
date, with the exception of patients with left main coronary
artery disease or three-vessel coronary artery disease in the
presence of left ventricular dysfunction, neither coronary
angioplasty nor coronary bypass surgery will reduce the
mortality rate from coronary artery disease. The high cost
and stress on the health care network of these procedures
would suggest that the management of myocardial ischemia
with medical therapy is a reasonable first step.
A. Long-Acting Nitrates—Nitrates are the oldest form of
anti-ischemic therapy. Their continued use is a testament to
their efficacy as well as their safety. Therapy with long-acting
nitrates aims to improve coronary blood flow. Twenty mil-
ligrams of isosorbide dinitrate three times a day is a typical
starting dose. Although lower doses may be used, they usu-
ally have little more than a placebo effect in patients with
coronary artery disease. After initial dosing with 20 mg three
times daily for 3–5 days, the dose can be increased to either
40 or 60 mg three times daily. A target dose of at least 40 mg
three times daily would be a reasonable therapeutic goal,
assuming that the patient does not suffer from headaches or
symptoms of hypotension. Alternatively, extended-release
isosorbide mononitrate in a dose of 30–120 mg once or twice
daily may enhance compliance.
“Nitrate headaches” occur frequently during the first few
days of therapy with isosorbide dinitrate. The patient should
be encouraged to continue the medication (perhaps with
administration of acetaminophen) because the headaches fre-
quently subside with time and the antianginal efficacy of the
long-acting nitrates persists. Doses of isosorbide dinitrate
larger than 60 mg three times daily generally are not necessary
for therapy of angina pectoris and produce a smaller incre-
mental improvement in symptoms compared with the
increase from 20 to 40 or 60 mg three times daily. However, in
the treatment of unstable angina or for patients who have
severe angina pectoris that is not amenable to revasculariza-
tion, such high doses of long-acting nitrates may be useful in
providing an asymptomatic or moderately symptomatic state.
B. Beta-Adrenergic Blockade—β-adrenergic blockers are
particularly effective in the treatment of patients who have
coexisting angina and hypertension. Likewise, the combina-
tion of β-blocker therapy with a long-acting nitrate may be
hemodynamically desirable because the long-acting nitrates
tend to produce a modest reflex tachycardia that can be
blunted or eliminated by beta blockade. In the treatment of
exertional angina, beta blockade can be particularly advanta-
geous because it will block catecholamine-induced increases
(from exercise or emotional stress) in heart rate and blood
pressure.
Initial therapy with β-blockers can commence with meto-
prolol, 50 mg twice daily (or 50–100 mg of sustained-release
metoprolol daily); atenolol, 50 mg once daily; or betaxolol,
10 mg once daily. In the elderly patient, these initial doses
should be reduced at the initiation of therapy. Titration of
the dose upward can commence after four to five half-lives
have elapsed, that is, 2–3 days for metoprolol, 3–4 days for
atenolol, and 5–7 days for betaxolol or extended-release
metoprolol (eg, Toprol XL). Upward titration of the dose of
β-blocker should be considered if the resting heart rate or
blood pressure are not affected by the initial dose of therapy.
As a general rule, patients who may be operating machin-
ery or driving automobiles should be warned of the possibil-
ity of drowsiness or lethargy when taking β-blockers.
Frequently, the administration of longer-acting agents such
as extended-release forms of metoprolol or betaxolol at bed-
time can be useful in reducing symptoms of fatigue and
reduced attentiveness during the daytime.
Concern is frequently raised about the use of beta block-
ade in patients with diabetes. However, if the patient does not
suffer from episodes of hypoglycemia, judicious therapy with
beta blockade is often rewarded by substantial reduction in
angina pectoris. In addition, β-blocker use in diabetic
patients with coronary artery disease is associated with a
reduction in mortality. The major concern regarding the
coadministration of beta blockade with hypoglycemic agents
is blunting of the symptoms of hypoglycemia. However, this
effect is related primarily to a reduction of tachycardia;
diaphoresis and hunger are not blunted by β-blocker ther-
apy. Of course, β-blockers should be avoided in the brittle
type 1 diabetic or in diabetics with a history of ketoacidosis.
C. Calcium Channel Blocking Agents—
1. Dihydropyridines—This class of calcium antagonists is
characterized by both a systemic and coronary vasodilator
effect. The dihydropyridines have no effect on sinoatrial (SA)
or atrioventricular (AV) nodal function. Therefore, coad-
ministration of a dihydropyridine with β-blockers for the
combined therapy of angina and hypertension is fre-
quently highly effective. Both agents tend to lower blood
pressure, and the bradycardic effect of beta blockade will
prevent any reflex tachycardia that may be engendered by the
dihydropyridine.
Nifedipine, the first-generation dihydropyridine, had a
relatively short half-life and frequently caused symptoms of
vasodilation, including flushing, headaches, and peripheral
edema. Sustained-release nifedipine is still used for refrac-
tory hypertension in doses of 30–90 mg/day or more.
However, for the treatment of coronary artery disease,
nifedipine and the second-generation dihydropyridines have
been superseded.
Amlodipine and felodipine are “long acting” dihydropyri-
dine calcium channel antagonists. Amlodipine has an inher-
ently long half-life of over 30 hours, whereas felodipine gains
its once-a-day dosing from an enteric coating that results in
the gradual release of the agent. Amlodipine is approved for
both angina and hypertension; felodipine is approved for
hypertension only.
Amlodipine is the only calcium channel blocking agent
that can be used safely in patients with impaired left ventric-
ular function. Hence the agent can be used for antianginal
treatment in addition to nitrates and β-blockers, particularly
when coexisting hypertension is present. The starting dose
for amlodipine is 2.5–5 mg/day with a recommended maxi-
mum of 10 mg/day. Higher doses of amlodipine may afford
additional antianginal and antihypertensive effects, but side
effects such as peripheral edema become more pronounced.
Given the long half-life of amlodipine, the dose of this agent
should not be increased more than once weekly.
2. Verapamil—Verapamil is a vasodilating calcium channel
blocking agent that, in addition to causing coronary artery
vasodilation, has a negative chronotropic effect. Conduction
through both the SA node and the AV node can be slowed by
this agent. Verapamil has a side-effect profile similar to that
of nifedipine. In addition, verapamil causes constipation,
and the patient’s bowel habits should be evaluated carefully.
Many clinicians will start patients on stool softeners or pro-
phylactic milk of magnesia when commencing therapy with
verapamil.
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Verapamil is a fairly potent peripheral vasodilator and
therefore is an effective antihypertensive agent. Additionally,
with its bradycardic effect, it may be particularly useful in
patients with ischemic heart disease who are intolerant of
β-blockers, such as those with asthma or type 1 diabetes. It
should be recalled that, on balance, verapamil exerts the
greatest negative inotropic effect of the currently available
calcium channel blockers and should be avoided in patients
with a history of congestive heart failure or a known reduc-
tion in ejection fraction. Short-acting verapamil typically is
administered in a dosage of 80–120 mg every 8 hours.
However, the long-acting verapamil preparations generally
are preferred for the sake of compliance and convenience.
Long-acting verapamil should be initiated at a dosage of
180 mg once daily with upward titration to 240 mg/day.
Titration can occur at weekly intervals for symptoms of
angina or control of hypertension. Patients should be
warned to avoid chewing or crushing the long-acting
preparations of verapamil because the entire daily dose may
be released rapidly. Long-acting verapamil should be initi-
ated at a dosage of 120 mg/day in the elderly or in under-
weight patients.
3. Diltiazem—Diltiazem has a modest effect on heart rate
and blood pressure in normotensive patients. Like all cal-
cium channel blocking agents, it exerts a coronary vasodi-
lating effect. Diltiazem’s antianginal properties are the
result of both coronary vasodilation and a reduction in the
product of heart rate and systolic blood pressure.
Diltiazem has a favorable side-effect profile characterized
by minor occurrences of dyspepsia, rash, and edema.
Because diltiazem depresses SA and AV nodal function, con-
comitant administration of β-blockers warrants careful
attention to the heart rate.
Starting dosages for diltiazem are 60 mg every 8 hours,
and this can be increased to 120 mg every 6–8 hours. Long-
acting preparations of diltiazem have been introduced.
Therapy with these sustained-release preparations can be
initiated at a dosage determined by therapy with the short-
acting preparation (eg, patients who tolerate 60 mg every
8 hours can be converted directly to 180 mg/day of the long-
acting preparation). Frequently, clinicians initiate therapy
with 180 mg of the sustained-release compound and
increase the dose weekly up to 360 mg/day. For elderly and
underweight patients, a starting dose of 120 mg/day may be
preferable.
Like all calcium channel blocking agents currently mar-
keted (with the exception of amlodipine), diltiazem should
be avoided in patients with reduced left ventricular func-
tion. A large multicenter trial demonstrated that the
administration of diltiazem to patients with left ventric-
ular ejection fractions of less than 0.40 or with pul-
monary congestion after acute myocardial infarction is
associated with an approximately 1.4-fold increase in car-
diovascular death. Similar results have been seen in trials
with verapamil.
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 Acute Coronary Syndromes: Unstable
Angina and Non-ST-Segment-Elevation
Myocardial Infarction 
ESSENT IALS  OF  D IAGNOS I S
 Increase in the frequency, severity, or duration of stable
angina or angina occurring at a lower threshold (unsta-
ble angina with low-risk characteristics).
 Prolonged (>20 minutes) angina at rest now resolved,
plus diabetes, age over 65, deep T-wave inversions in
more than three leads, angina on walking one to two
blocks on the level or climbing one flight of stairs at a
normal pace in the past 2 weeks, nocturnal angina, or
pathologic Q waves (unstable angina with intermediate-
risk characteristics).
 Ongoing (>20 minutes) chest pain, ST-segment depression
= 1 mm or more, angina plus heart failure, or angina plus
hypotension (unstable angina with high-risk characteristics).
 Any of the preceding plus cardiac enzyme markers of
myocardial necrosis (troponin I, troponin T, or CK-MB)
(non-ST-segment-elevation myocardial infarction).
General Considerations
Patients with non-ST-segment-elevation (non-Q-wave)
myocardial infarctions represent the severe end of the spec-
trum of the pathology associated with unstable angina.
Fissuring or rupture of an atherosclerotic plaque precedes
unstable angina. If the plaque disruption can be stabilized
spontaneously or through medical intervention, unstable
angina develops. If not, then non-ST-segment-elevation
myocardial infarction may occur.
The American College of Cardiology/American Heart
Association (ACC/AHA) has issued guidelines for the manage-
ment of unstable angina pectoris and non-ST-segment-
elevation myocardial infarction (non-STEMI). The intensity
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of medical therapy and interventional procedures, as well as
the urgency of starting treatment, should be guided by both
symptoms and objective findings.
Clinical Features
A. Symptoms and Signs—The signs and symptoms of
unstable angina and non-STEMI are the same as those of sta-
ble angina pectoris. The distinction between stable angina
and unstable angina or non-STEMI is in the longer duration
of the pain episodes, the reduced amount of exertion
required to produce angina (including pain at rest), and the
increased frequency of chest discomfort.
B. Diagnostic Testing—As in stable angina, patients with
unstable angina frequently have normal ECGs. However, the
presence of new ST-segment depression, T-wave inversion,
or both that resolve spontaneously or with the administra-
tion of sublingual nitroglycerin identifies a category of
patients at high risk for subsequent cardiac events, including
myocardial infarction or death. Chest pain with ST-segment
depression now can be managed by specific therapy defined
by large randomized clinical trials.
A non-STEMI is diagnosed when markers of myocardial
necrosis (ie, elevated levels of troponins or CK-MB) are pres-
ent in the absence of ST-segment elevation on the ECG.
C. Evaluation of the Stabilized Patient—In patients
whose symptoms become well controlled on antianginal
therapy after an episode of unstable angina pectoris, three
approaches may be followed: (1) Perform coronary arteriog-
raphy with the anticipation of elective coronary artery angio-
plasty or coronary artery bypass surgery. If catheterization
and revascularization can be accomplished within 48 hours
of presentation, this approach can reduce morbidity and
mortality in patients with troponin-positive non-STEMIs
and in patients with unstable angina with 1 mm or more of
labile ST-segment depression on presentation. (2) Treat the
patient conservatively with increased doses of antianginal
medications. (3) Perform a functional test to select patients
most likely to benefit from more invasive therapies.
A “low level” stress test can be used in ACC/AHA low-
and intermediate-risk unstable angina patients to identify
those who are at high or low risk for development of subse-
quent myocardial infarction, further unstable angina, and
death after an initial episode of unstable angina. These exer-
cise stress tests, which are limited either by workload (5–7
mets [ie, five to seven times the resting metabolic rate]) or
heart rate (<120 beats/min or less than 65% of predicted
maximum heart rate), are used to determine whether
ischemia is present at levels of exercise likely to be encoun-
tered in ordinary daily activities. Safety is the primary reason
for limiting the test to a lower target workload or heart rate
than might be the goal for diagnosis of angina in a patient
with chest pain. Furthermore, it makes little sense intuitively
to challenge with a conventional stress test a patient who has
recently had symptoms with minimal exertion.
A negative low-level stress test is associated with a rela-
tively good outcome, with over 70% of patients with a nega-
tive study having no or mild angina pectoris in the ensuing
6 months to 1 year. Conversely, a positive low-level stress test,
with development of ST-segment depression or chest pain, is
associated with a greater than 80% incidence of subsequent
undesirable outcomes (eg, recurrent unstable angina,
myocardial infarction, or death). Thus the low-level stress
test can be used to identify patients at high risk and therefore
more likely to benefit from early aggressive management of
ischemic heart disease.
Treatment
Patients who experience an increase in the frequency or
duration of angina pectoris or a marked decline in the
amount of exertion required to provoke chest pain are can-
didates for hospitalization. This will both reduce the work of
the heart (hospitalization itself) and initiate or intensify
pharmacologic therapy for ischemic heart disease.
A. Aspirin—Over two decades ago, two major studies
attested to the importance of aspirin in the therapy of unsta-
ble angina pectoris. Both the Veterans Administration and
the Canadian Cooperative trials demonstrated a 50% reduc-
tion in deaths and myocardial infarctions in patients with
unstable angina who take one to four 325-mg aspirin tablets
a day. The observation that patients with unstable angina or
non-STEMI have large amounts of thrombus in patent but
atherosclerotic coronary arteries at the time of coronary
angioscopy or coronary arteriography provides the patho-
physiologic basis for this remarkably successful and inexpen-
sive form of therapy. Patients with true allergies to aspirin
can substitute clopidogrel, 75 mg/day.
B. Beta-Blockers—The prevention of the ischemia that
underlies unstable angina pectoris and non-STEMI is accom-
plished most easily by reducing the work of the heart. By low-
ering both the heart rate and blood pressure, β-blockers
perform this task efficiently and inexpensively. In patients with
high-risk characteristics of unstable angina or evidence of a
non-STEMI, intravenous administration of β-blocking agents
followed by oral β-blockers is appropriate and desirable.
Metoprolol should be administered intravenously in 5-mg
increments more than 2 minutes apart to a total dose of 15 mg
(or more if better control of the heart rate is desired). Following
intravenous loading of β-blockers, oral metoprolol, 50 mg twice
daily, or oral atenolol, 50 mg once daily, should be initiated.
For patients with contraindications to beta blockade (eg,
bronchospastic lung disease), calcium channel blocking
agents may be substituted. Calcium channel blockers,
angiotensin-converting enzyme (ACE) inhibitors, or
angiotensin II receptor blockers may be added to beta block-
ade if additional antihypertensive therapy is required.
C. Nitrates—Oral nitrates may be initiated as 20-mg isosor-
bide dinitrate three times per day with a target dose of 40–60 mg
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three times per day. Long-acting isosorbide mononitrate can
be initiated at a dosage of 20 mg/day with a target dosage of
60–120 mg/day. These agents usually are administered to
low- and intermediate-risk patients who need additional
anti-ischemic therapy after β-blockers.
Intravenous nitrate therapy may be particularly useful in
the patient with high-risk unstable angina pectoris who has
ongoing pain or the non-STEMI patient with hypertension
that is difficult to control. Patients receiving intravenous
nitroglycerin should be monitored closely, and the rate of
infusion should be titrated to relieve pain as well as to meet
blood pressure goals while avoiding hypotension.
D. Thrombolytic Therapy—There is no role for throm-
bolytic therapy in unstable angina or non-STEMI. Trials
designed to test the efficacy of thrombolytic therapy in these
settings are negative (thrombolytics increased morbidity and
mortality).
E. Clopidogrel—The thienopyridine clopidogrel is an
antiplatelet agent that inhibits platelet aggregation induced by
adenosine diphosphate (ADP), whereas aspirin blocks the
thromboxane-mediated payway. The CURE trial randomized
12,562 patients with acute coronary syndromes to clopidogrel
75 mg/day (after a 300-mg oral loading dose) or a placebo.
Clopidogrel therapy was associated with a substantial reduc-
tion in the composite endpoint of death from cardiovascular
causes, nonfatal myocardial infarction, or stroke. Although
approved for all forms of acute coronary syndromes, the ben-
efit of this agent was demonstrated only in patients with
unstable angina and ST-segment depression and patients with
non-STEMIs.
F. Anticoagulation—The ESSENCE and TIMI 11B trials
have provided convincing evidence supporting the use of the
low-molecular-weight heparin enoxaparin in high-risk
unstable angina pectoris and non-STEMI patients. While
also approved for use in intermediate-risk unstable angina, a
close look at the data suggests that the greatest benefit from
this agent occurs in patients with pain at rest and 1 mm or
more of ST-segment depression or who have elevated tro-
ponins or CK-MB. The dose of enoxaparin is 1 mg/kg subcu-
taneously every 12 hours for 48–72 hours.
Intravenous unfractionated heparin can be given for non-
STEMI as well as for intermediate- and high-risk unstable
angina. However, given the advantages of low-molecular-
weight heparin, unfractionated heparin seems most useful as
an adjunct to the glycoprotein IIb/IIIa inhibitors or in renal
failure, where enoxaparin is not desired because it is cleared
by the kidneys.
Recently, the synthetic pentasaccharide fondaparinux,
which also binds to activated factor Xa, has been shown to
reduce ischemic events in acute coronary syndromes much
the same as enoxaparin. Fewer bleeding events were observed.
G. Glycoprotein IIb/IIIa Receptor Inhibitors—This class
of drugs blocks the affinity of the glycoprotein IIb/IIIa recep-
tor for fibrinogen on platelets activated by products released
from plaque rupture. In this manner, platelet plugging and
clot formation in atherosclerotic lesions are retarded or
inhibited.
Like enoxaparin, the glycoprotein IIb/IIIa receptor
antagonists (ie, eptifibatide and tirofiban) are indicated for
the treatment of intermediate- and high-risk unstable
angina and for non-STEMI patients. Eptifibatide is
approved for use in preventing complications of percuta-
neous revascularization. Both agents are administered with
unfractionated heparin at a dose titrated to result in a
twofold increase in the partial thromboplastin time.
Eptifibatide is initiated with an intravenous bolus of 180
μg/kg, followed by an infusion of 2 μg/kg per minute for
72–96 hours. Tirofiban is given as an intravenous loading
dose of 0.4 μg/kg per minute for 30 minutes, followed by an
infusion of 0.1 μg/kg per minute for 48–96 hours.
Both glycoprotein IIb/IIIa receptor antagonists reduce the
combined endpoint of death or myocardial infarction or the
need for urgent revascularization. Like enoxaparin, the great-
est benefit from these agents appears to be conferred on the
more ill patients (ie, those with prolonged chest pain, 1 mm
or more of ST-segment depression, or elevated troponins or
cardiac enzymes). The decision to use these costly agents may
hinge on the likelihood of side effects of bleeding.
H. Coronary Angioplasty and Coronary Artery Bypass
Grafting—Debate continues regarding the advantages of
conservative compared with aggressive management of
these patients. The clinician may elect to initiate or enhance
the therapy of patients with low-risk unstable angina and
simply follow the patient symptomatically with or without
hospitalization. This option is based on the observation
that low-risk patients have a risk of serious events (eg,
death and myocardial infarction) that is similar to that
borne by patients with stable angina. Even intermediate-
risk unstable angina pectoris patients who stabilize their
symptoms on medical therapy are at risk only for an
increased rate of recurrent unstable angina during the
ensuing year. Hence, for stabilized patients, watchful wait-
ing appears to carry little risk and may avoid unneeded
revascularization procedures.
Recurrent ischemic pain despite adequate medical ther-
apy should prompt urgent coronary angiography in anticipa-
tion of coronary bypass grafting or coronary angioplasty.
This recommendation also applies to patients with recurrent
pain during treatment of non-STEMI.
Data from TACTICS and TIMI 18 suggest that patients
with rest pain plus ST-segment depression or those who have
a non-STEMI may benefit from an early (but not emergent)
cardiac catheterization in anticipation of expeditious coro-
nary revascularization.
Table 22–1 outlines basic evidence-based treatment
strategies for acute coronary syndromes. The terms low,
intermediate, and high risk refer to ACC/AHA guideline esti-
mates of risk for adverse outcome (eg, recurrent unstable
angina, myocardial infarction, and death).
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 Acute Myocardial Infarction with ST-
Segment Elevation
ESSENT IALS  OF  D IAGNOS I S
 Precordial chest pain with or without radiation to the
left arm, shoulder, or jaw.
 Pain may be identical in quality and description to that
of angina pectoris but may last from 10 minutes to sev-
eral hours.
 Greater than 1 mm ST-segment elevation in two con-
tiguous leads with or without Q-wave formation.
 Confirmation by serial changes in ECGs plus elevation of
cardiac enzymes (ie, CK-MB, troponin I, or troponin T).
 Complications may include arrhythmias, pulmonary
edema, hypotension and shock, ventricular rupture, and
pericarditis.
Non-STEMI
(Elevated Troponin)
High-Risk UAP (Chest
Pain and ≥ 1 mm ST-
Segment Depression
High-Risk UAP (<1 mm
ST-Segment Depression)
Intermediate-
Risk UAP
Low-Risk UAP
Aspirin + + + + +
β-Adrenergic blockers + + + + +
Clopidogrel +∗ +∗
Low-molecular-weight
heparin (enoxaparin)
+†,‡ +†,‡
IIb-IIIa inhibitor and
unfractionated heparin
+§ +§
Consider cardiac catheteri-
zation and revasculariza-
tion within 48 hours
+ +
Note: Recurrent chest pain in the hospital is an indication for expeditious catheterization and intervention. 
∗For 30 days.
†Avoid if creatinine ≥ 2.5 mg/dL.
‡Substitute IIb-IIIa inhibitor + unfractionated heparin if urgent catheterization is planned.
§Avoid if creatinine ≥ 4 mg/dL; adjust dose if creatinine ≥ 2.
Table 22-1. Treatment of unstable angina pectoris (UAP) or non-ST-segment-elevation myocardial infarction (non-STEMI) 
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General Considerations
Coronary thrombosis is the immediate cause of acute
myocardial infarction in over 90% of patients with this syn-
drome of acute myocardial infarction with ST-segment ele-
vation (STEMI). Although early autopsy investigations
suggested a variety of other causes of acute myocardial
infarction—including coronary vasospasm and emboli—
over 86% of those with acute myocardial infarction had
coronary artery thrombi when coronary angiography was
performed within 4 hours of the onset of symptoms.
Current concepts of acute myocardial infarction support
the view that the nidus for thrombosis is an atherosclerotic
plaque in a coronary artery. The plaque itself may or may not
result in stenosis of the artery severe enough to cause symp-
toms, although more severe atherosclerotic stenoses may be
associated with exertional angina. The pathophysiologic
sequence of events then probably includes plaque rupture
with exposure of the subintimal components of the plaque to
coronary blood flow. Platelet activation occurs as the con-
tents of the atherosclerotic plaque (including cholesterol and
calcium) interact with circulating blood components.
Platelet activation releases thromboxane A2, a vasoconstric-
tive substance that may lead to localized vasospasm, which
further impedes coronary artery blood flow. The net result of
these events is interruption of coronary blood flow by
thrombus formation followed by myocardial necrosis if ther-
apy is not effective.
New information regarding the treatment of unstable
angina and non-STEMI appears almost weekly. The thera-
pies of unstable angina, non-STEMI, and STEMI are now
driven by large clinical trials that define current pharmaco-
logic and revascularization strategies.
Clinical Features
A. Symptoms—Acute myocardial infarction is classically
associated with precordial chest pain with or without radia-
tion to the left arm, shoulder, or jaw. The pain is identical to
that described in the section on angina pectoris but often
more severe. The only deviation is duration. The chest pain
of myocardial infarction lasts from 10–15 minutes to several
hours. The pain is poorly responsive to nitroglycerin and
may require morphine for relief. Diaphoresis, syncope, and
lightheadedness may be present. Dyspnea and orthopnea
may be associated with acute congestive heart failure and
pulmonary edema.
B. Signs—During myocardial infarction, an S3 gallop, pul-
monary rales, or the murmur of mitral regurgitation may
appear. Myocardial infarction may be associated with
decreased intensity of S1 and S2. Patients should be examined
carefully for murmurs of mitral regurgitation and for the pres-
ence of pericardial friction rubs. Rales and wheezes may indi-
cate acute pulmonary edema from congestive heart failure.
C. Laboratory Findings—Venous blood should be obtained
routinely to measure the cardiac-specific CK-MB and
troponin I or troponin T on admission to hospital and every
6–8 hours thereafter for the first 24 hours. Daily CK-MB and
troponin levels may be useful during the balance of the
patient’s hospital stay to detect silent recurrent myocardial
necrosis. A partial thromboplastin time should be obtained
on admission and repeated if unfractionated heparin therapy
is indicated. Arterial blood gases should be measured if
hypoxemia is suspected from physical findings, chest x-ray,
or pulse oximetry.
D. Electrocardiography—By definition, acute STEMI is
associated with specific electrocardiographic findings.
However, with modern management, the classic electrocar-
diographic changes of ST-segment elevation followed by T-
wave inversion with development of Q waves may be
retarded or even abolished. A substantial proportion of
patients with myocardial infarction will not develop Q waves
after initial ST-segment elevation and may demonstrate only
T-wave changes or no changes in their ECGs. The develop-
ment of Q waves portends a worse prognosis.
E. Imaging Studies—Imaging studies should not delay
prompt management of acute myocardial infarction.
1. Chest x-ray—The chest x-ray should be reviewed for car-
diomegaly, pulmonary edema, and pleural effusions. In
upright chest x-rays, fullness and congestion of vessels lead-
ing to the upper lung fields sometimes is taken as evidence of
mild pulmonary edema from heart failure.
2. Echocardiography—Echocardiography is useful in
defining coexisting heart disease—especially valvular or con-
genital disease—identifying pericardial effusion, evaluating
unexplained tachycardia, and assessing ventricular function.
Patients with acute myocardial infarction should have an
echocardiogram if there is hypotension or shock. Other indi-
cations for echocardiography include suspicion of ventricu-
lar septal rupture or severe mitral regurgitation (both
potentially requiring surgery), a large myocardial infarction
as judged from CK-MB or troponin elevation, suspected
pericardial effusion, or left ventricular dysfunction that may
be worsened by β-adrenergic blockade or calcium channel
antagonists.
An evaluation of left ventricular function by echocardio-
graphy or radionuclide ventriculography should be per-
formed in almost all patients after an acute myocardial
infarction to help define prognosis and guide appropriate
prophylactic therapy. ACE inhibitors given after myocardial
infarction will prolong survival, and the greater the degree
of reduction in ejection fraction or severity of heart failure
as defined by New York Heart Association (NYHA) func-
tional class, the greater is the benefit from the routine use of
these agents. Similar statements can be made for the β-
blocker carvedilol in patients with NYHA class II and class III
symptoms.
3. Pulmonary artery catheterization (right-sided
heart catheterization)—Right-sided heart catheteriza-
tion allows the determination of right atrial, right ventricular,
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pulmonary artery, and pulmonary capillary wedge pressures.
Since the latter value is a rough estimate of the left ventricu-
lar end-diastolic pressure, pulmonary capillary wedge pres-
sure can provide valuable information regarding the
necessity for volume expansion or diuresis. The right-sided
heart catheters are equipped with a temperature-measuring
thermistor that allows determination of cardiac output by
thermodilution.
Right-sided heart catheterization should be considered at
any point during the course of an acute myocardial infarc-
tion when a question exists regarding fluid volume status.
For example, a patient with acute myocardial infarction and
possible pneumonia may have a lung examination that could
represent pulmonary edema, pneumonia, or both. On the
other hand, treatment of hypotension in the presence of sus-
pected right ventricular infarction usually can commence
without right-sided heart catheter guidance. Patients with an
acute inferior infarction who experience hypotension and
have clear lungs and no S3 gallop should receive 500–1000
mL normal saline to see if volume expansion will increase the
blood pressure without causing rales. However, should fur-
ther volume supplementation seem necessary or should
incipient left-sided heart failure be present or suspected,
right-sided heart catheterization would be invaluable in
determining the true volume status of the patient.
For patients in whom hypotension persists for more than
an hour despite use of vasopressors, right-sided heart
catheterization is strongly advised.
4. Cardiac catheterization—Cardiac catheterization
after acute STEMI generally is reserved for patients who
develop instability. The routine use of cardiac catheterization
after acute myocardial infarction for the purpose of elective
angioplasty or bypass surgery has not found justification in
randomized trials of elective revascularization after acute
STEMI. Rather, patients who have an uncomplicated
myocardial infarction (no recurrent chest pain) can safely
undergo stress testing (usually with a low-level exercise pro-
tocol) prior to hospital discharge to identify those at high
risk for reinfarction or death who should undergo further
study.
Cardiac catheterization before hospital discharge is indi-
cated in two classes of patients: (1) patients who develop
chest pain after acute myocardial infarction, which is thought
to be ischemic in nature, and (2) patients who have chest
pain or evidence of ischemia on electrocardiography or
myocardial perfusion scintigraphy during low-level exercise
stress testing. These patients have “failed” medical therapy by
virtue of having chest pain in the hospital (presumably while
on adequate medication) and are likely to be best served by
undergoing coronary angioplasty or coronary bypass graft-
ing if their anatomy is found to be suitable by angiography.
Differential Diagnosis
The differential diagnosis of myocardial infarction is essen-
tially the same as that of angina pectoris (see above).
Treatment
Treatment may be divided into immediate and later phases.
Immediate therapy is empirical and is initiated after obtain-
ing the history, performing a physical examination, and
examining the ECG.
A. Initial Outpatient Treatment—Sublingual nitroglycerin
tablets or nitroglycerin spray should be self-administered if
the patient has either drug. Otherwise, sublingual nitroglyc-
erin should be administered by paramedics or by personnel
in the emergency department. A sublingual nitroglycerin
tablet (usually 0.3 mg) can be administered every 3–5 min-
utes (if pain persists) for an initial total of three to five
tablets. Repeat doses of nitroglycerin can be administered
once blood pressure monitoring is available and the patient
has no significant side effects such as dizziness or severe
headaches.
B. Immediate Hospital Therapy—Initial therapy of a
patient in the hospital suspected of having myocardial
infarction consists of nitroglycerin as indicated earlier.
Oxygen therapy, usually 2 L/min by nasal cannula, is fre-
quently begun empirically and adjusted based on pulse
oximetry. One aspirin tablet (325 mg) should be chewed and
swallowed by the patient to reduce subsequent morbidity
and improve chances for survival. For aspirin-allergic
patients or patients already taking prophylactic aspirin, oral
clopidogrel, 75 mg, may be substituted.
1. Reperfusion—All patients with STEMI must be consid-
ered for an early strategy for reperfusion at the time of initial
contact. The choice of strategy depends on duration of
symptoms, availability of resources, and relative risks of the
patient and the treatments.
Fibinolysis (ie, thrombolytic therapy) and an invasive
strategy (eg, angioplasty with stent) are the two options.
There is no preference for either strategy if presentation time
is less than 3 hours and there is no delay for an invasive strat-
egy. Otherwise, an invasive strategy generally is preferred if
the procedure can be performed within 60–90 minutes, the
patient is at high risk of complications from STEMI (eg, car-
diogenic shock or pulmonary edema), thrombolysis is con-
traindicated because of increased bleeding risk, or STEMI
diagnosis is in doubt. Thrombolytic therapy is preferred if an
invasive strategy is not an option or there is a potential delay
of angioplasty of more than 1 hour from hospital arrival to
onset of the procedure.
a. Thrombolytic therapy—If the patient has a classic his-
tory for acute myocardial infarction and has more than 1
mm of ST-segment elevation in two contiguous leads [eg, in
two inferior leads (II, III, or aVF), or in leads I and aVL, or in
two contiguous chest or V leads], thrombolytic therapy
should be an option. The presence of a left bundle branch
block not known to be old is also an indication for throm-
bolytic therapy.
Tenecteplase, intravenous streptokinase, or anisoylated
plasminogen streptokinase activator complex (anistreplase;
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APSAC) can be administered if the patient does not have one
or more of the following contraindications: active internal
bleeding; history of stroke; intracranial or intraspinal surgery
or trauma within 2 months; intracranial neoplasm, arteri-
ovenous malformation, or aneurysm; known bleeding
diathesis; or severe uncontrolled hypertension. Age over 75
has been used as a contraindication to thrombolytic therapy,
but this remains controversial.
Following thrombolysis, patients receive heparin, either
unfractionated heparin titrated to the activated partial thrombo-
plastin time or, preferably, low-molecular-weight heparin
(LMWH). In comparison trials, LMWH was associated with
improved survival and a lower rate of recurrent myocardial
infarction and restenosis compared with unfractionated heparin.
b. Primary angioplasty—Facilities with an available
catheterization laboratory may opt for urgent coronary
angiography and percutaneous angioplasty (usually with
stenting). If the patient can be brought to the angiographic
laboratory in an expeditious manner, the angiographer may
initiate a glycoprotein IIb/IIIa inhibitor, which binds to the
platelet glycoprotein IIb/IIIa receptor and inhibits platelet
aggregation, to reduce the incidence of subsequent myocar-
dial infarction and death.
Whether angioplasty or thrombolytic treatment is chosen
as the therapy for acute STEMI, the administration of aspirin
and intravenous beta blockade should not be delayed.
2. Beta-adrenergic blockade—β-adrenergic blockade with
intravenous metoprolol should be accomplished as soon as
possible after the diagnosis of acute myocardial infarction has
been established by history and electrocardiography.
Intravenous beta blockade can be initiated provided the patient
has an initial heart rate over 50 beats/min, a systolic blood pres-
sure over 90 mm Hg, rales less than one-third the way up the
back, a PR interval less than 0.28 s, and no other contraindica-
tions (eg, asthma). Metoprolol should be administered intra-
venously in 5-mg increments more than 2 minutes apart to a
total dose of 15 mg (or more if greater control of the heart rate
is desired). Following intravenous loading of β-blockers, oral
metoprolol, 50 mg twice daily, or oral atenolol, 50 mg once
daily, should be initiated.
3. Intravenous nitroglycerin—Intravenous nitroglycerin
frequently was administered to all patients with known or
suspected myocardial infarction in the hope of reducing mor-
bidity and mortality. Large trials of patients with STEMI have
failed to justify the enthusiasm for the routine use of this
agent in asymptomatic patients with acute myocardial infarc-
tion. Current recommendations for intravenous nitroglycerin
include relief of ischemic pain and reduction of systolic
blood pressure. A dose of 0.5 μg/kg per minute (35 μg/min
for an average-sized patient) can be initiated and the rate of
administration increased until pain relief or a reduction in
systolic blood pressure to less than 90–100 mm Hg is seen.
The rate of administration should not be increased further if
the patient develops dizziness or other evidence of decreased
organ perfusion. If long-term nitrate therapy is desired, long-
acting nitrates such as isosorbide dinitrate or isosorbide
mononitrate should be started within 24 hours. The continu-
ous administration of intravenous nitroglycerin can rapidly
lead to “nitrate tolerance” and loss of anti-ischemic effect.
4. Morphine sulfate—Morphine beginning with 2 mg
intravenously should be administered if nitroglycerin does
not provide prompt relief of pain. Incremental doses of mor-
phine can be administered to a total that is usually less than
20 mg. Much lower doses may be effective. As morphine
doses exceed 10–15 mg, the possibility of respiratory depres-
sion must be considered.
5. Antiarrhythmic therapy—Patients with acute myocar-
dial infarction who have hemodynamically unstable ventricu-
lar arrhythmias (eg, ventricular fibrillation or ventricular
tachycardia) lasting for more than 30 seconds or causing
hemodynamic collapse or hypotension should be electrically
cardioverted. Sustained monomorphic ventricular tachycardia
not associated with symptoms or hypotension (blood pressure
< 90 mm Hg) should be treated with one of the following.
a. Lidocaine—An intravenous bolus of lidocaine
(1–1.5 mg/kg) is given, followed by supplemental boluses of
0.5–0.75 mg/kg every 5–10 minutes to a maximum loading
dose of 3 mg/kg. Loading is followed by an intravenous infu-
sion of lidocaine at a rate of 2–4 mg/min. Nursing staff must
be alert to changes in the patient’s mental status (eg, somno-
lence, disorientation, or dysesthesias) that may signal lido-
caine toxicity. The elderly are particularly susceptible.
b. Amiodarone—Give 150 mg intravenously over 10 min-
utes, followed by an infusion of 1 mg/min for 6 hours and
then a maintenance infusion of 0.5 mg/min.
c. Procainamide—Give a loading dose by intravenous
infusion of 12–17 mg/kg at a rate of 20–30 mg/min, followed
by an infusion of 1–4 mg/min.
The acute administration of antiarrhythmics allows time
to diagnose and correct electrolyte abnormalities such as
hypokalemia and hypomagnesemia, correct hypoxemia, and
allow anti-ischemic therapy (beta blockade) to be intensified.
6. Sedation—Sedatives such as intravenous or oral benzodi-
azepines may be useful in reducing the level of anxiety
engendered by the ICU setting.
C. Additional Care in the ICU—
1. General measures—The patient should be placed at
complete bed rest during the first 24 hours. Thereafter, in sta-
ble uncomplicated patients, the patient should be encouraged
to sit up in bed, dangling the legs over the side several times a
day, and then spend increasing amounts of time sitting in a
chair or ambulating with assistance. The patient should be
provided with a clear-liquid diet for the first 8–12 hours of
hospitalization for acute myocardial infarction. Stool soften-
ers are useful to prevent straining during defecation.
Subcutaneous heparin, 5000 units twice daily, should be
considered—if no contraindication exists—to prevent deep
venous thrombosis and pulmonary embolism. Additional
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supportive measures for patients in the coronary care unit
include daily monitoring of serum electrolytes (including
serum Mg2+) for at least 72 hours. In patients with normal
renal function, potassium supplements should be adminis-
tered to keep the serum K+ greater than 4.5 meq/L, and mag-
nesium should be given intravenously to maintain serum
Mg2+ levels at greater than 2.0 mg/dL. These maneuvers will
reduce the incidence of ventricular arrhythmias in a safe and
physiologic manner. While prophylactic Mg2+ administra-
tion does not reduce mortality overall, there is some sugges-
tion that high-risk groups (nonreperfused patients) may
benefit. Magnesium sulfate [10 g (40 mmol) in 100–200 mL
D5W administered over 2–3 hours] usually will increase the
steady-state serum levels of Mg2+ about 0.3–0.4 mg/dL in
patients with normal renal function. Hyperglycemia is a risk
factor for poor outcome in acute myocardial infarction; tight
glycemic control may decrease complications.
2. Aspirin—One aspirin tablet per day (eg, enteric-coated
aspirin, 160–325 mg) should be administered to all patients
after myocardial infarction unless there are contraindications.
Regardless of whether thrombolytic therapy has been given or
not, prophylactic aspirin therapy has reduced the
post–myocardial infarction mortality rate by 23%. For aspirin-
allergic patients, clopidogrel, 75 mg/day, can be substituted.
3. Beta-adrenergic blockade—Any of the following—
propranolol, 180 mg daily in divided doses; timolol, 10 mg
twice daily; metoprolol, 100 mg twice daily; or atenolol, 100 mg
once daily—should be administered after acute myocardial
infarction to prevent sudden death in patients who can toler-
ate this class of drugs. The criteria used to define patients eli-
gible for prophylactic β-adrenergic blockade are similar to
those applicable in the immediate post–myocardial infarc-
tion period: systolic blood pressure greater than 90–100 mm
Hg, heart rate greater than 50 beats/min, no rales, PR inter-
val less than 0.28 s, and no contraindications (eg, asthma or
“brittle” diabetes).
Randomized trials of over 50,000 patients in the United
States and Europe have consistently demonstrated a 25–35%
decrease in post–myocardial infarction sudden death with the
prophylactic use of beta blockade. Of particular interest is the
observation that if a patient can tolerate beta blockade after
acute myocardial infarction, the greatest benefit accrues to
those in whom some of the most serious concerns against beta
blockade are raised. Specifically, a patient who has had heart
block, sudden death (eg, ventricular fibrillation or ventricular
tachycardia), or heart failure after myocardial infarction and
can tolerate beta blockade subsequently (ie, if heart failure
clears with one or two doses of diuretics) gains the greatest
cardioprotective effect from beta blockade. For example,
assuming a pool of patients with prior congestive heart failure
who subsequently stabilize, it is estimated that prophylactic
treatment with β-blockers of only 26 patients is required to
save one life. Carvedilol, a nonselective β- and α-blocker has
been approved by the Food and Drug Administration (FDA)
for post-MI patients with LV dysfunction.
4. Antihypertensive agents—Patients with hypertension
have an obvious need for lowering systolic blood pressure. A
goal for systolic blood pressure of approximately 120 mm Hg
or less would be desirable, although any evidence of cerebral
hypoperfusion may frustrate this goal in some patients.
While most antihypertensive drugs are potentially suitable
for treatment of hypertension in patients with acute myocar-
dial infarction, preference should be given to agents likely to
treat both hypertension and the underlying coronary artery
disease. For example, β-blockers would seem an ideal antihy-
pertensive choice because they reduce the work of the heart
(by lowering both heart rate and blood pressure) as well as
providing a cardioprotective effect that reduces the incidence
of sudden death following acute myocardial infarction.
ACE inhibitors may be useful for the treatment of hyper-
tension and should be strongly considered if the patient has
any element of congestive heart failure (eg, rales, car-
diomegaly, or known reduction of ejection fraction) in con-
junction with an acute myocardial infarction. Survival
benefit in the post–myocardial infarction setting has been
demonstrated for a host of ACE inhibitors, with greater
improvement in survival being observed in the patients with
the greatest reductions in ejection fraction. For patients
intolerant of ACE inhibitors, the angiotensin II receptor
blocking agents (eg, losartan, valsartan, candesartan, and
others) are suitable alternatives.
The calcium channel blockers diltiazem and verapamil are
reasonable alternatives to β-adrenergic blockade in patients
with brittle diabetes or bronchospastic lung disease. Both
agents have a modest bradycardic effect in addition to their
antihypertensive effects. It should be remembered that these
agents should be reserved for patients with preserved left ven-
tricular function because these drugs increase mortality sub-
stantially in patients with ejection fractions under 0.40.
5. Diltiazem—In patients with acute myocardial infarction
who do not develop Q waves on the ECG (acute non-Q-wave
myocardial infarction or subendocardial myocardial infarc-
tion), strong consideration should be given to administering
diltiazem in a dose of 60 mg four times daily or 90 mg every
8 hours. At these doses, this agent has been shown to prevent
reinfarction in the month following an acute non-Q-wave
myocardial infarction.
Complications
A. Arrhythmias—
1. Atrial fibrillation—This disorder, characterized by a
narrow QRS complex and an irregular rhythm, is frequently
associated with extensive damage to the myocardium. If
rapid atrial fibrillation is associated with symptomatic
hypotension or with chest pain, conservative measures
should be abandoned, and synchronized electrical cardiover-
sion should be performed immediately.
Typically, initial therapy would consist of digoxin given
intravenously in a dose of 0.25–0.5 mg to slow the ventricular
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response and improve left ventricular function. Subsequent
doses of 0.125–0.25 mg of intravenous digoxin can be given
up to a total of 1–1.5 mg over the initial 24 hours after
myocardial infarction. Oral digoxin, usually 0.125–0.25
mg/day, is administered for maintenance therapy. The goal of
digoxin therapy is to reduce the ventricular rate to less than
90–100 beats/min.
Concomitant therapy with either β-adrenergic blockers
or the calcium channel blocking agent diltiazem will achieve
acceptable heart rate control in a shorter period of time than
with digoxin alone. For example, 5 mg intravenous metopro-
lol can be administered every 5 minutes to achieve prompt
control of rapid atrial fibrillation while digoxin therapy is
being initiated. An oral maintenance dose of metoprolol, 50
mg twice daily, can be initiated once the resting heart rate is
controlled with the intravenous preparation. Intravenous dilti-
azem, a loading dose of 20 mg (or 0.25 mg/kg) over 2 minutes,
can be given and repeated in 15 minutes. A maintenance infu-
sion of 10–15 mg/h can be prescribed for 24 hours if necessary.
Heparin should be given in the absence of contraindications.
2. Ventricular premature beats—Prophylactic aboli-
tion of asymptomatic ventricular ectopy after myocardial
infarction results in a marked increase in mortality rate. The
results of the Cardiac Arrhythmia Suppression Trial (CAST)
have documented conclusively that routine use of antiar-
rhythmic therapy for asymptomatic ventricular ectopy is
contraindicated. It is worth noting, however, that the pro-
phylactic use of β-adrenergic blockade has been associated
with a decrease in the frequency of ventricular ectopy. Since
β-blockers prolong survival after a myocardial infarction,
they should be considered the primary form of nonspecific
antiectopy therapy.
Isolated ventricular premature beats need not be treated,
but repetitive forms of ventricular ectopy such as couplets
and ventricular tachycardia (ie, more than three ventricular
premature beats in a row) are indications for prophylactic
lidocaine if they are associated with hypotension (see above).
If longer-term antiarrhythmic therapy is believed necessary,
intravenous procainamide (2–4 mg/min) or oral sustained-
release procainamide (750 mg every 6 hours) would be
potentially beneficial. Alternative agents include quinidine
sulfate (200 mg every 6 hours) and sustained-release quini-
dine gluconate (324 mg every 8 hours), as well as tocainide,
mexiletine, and amiodarone.
B. Heart Failure—Heart failure complicating acute
myocardial infarction will increase the mortality rate from
2–3% to as high as 50% per year. A primary goal of ther-
apy for acute myocardial infarction is to prevent the pro-
gression of uncomplicated myocardial infarction to
reinfarction with development of heart failure. The admin-
istration of intravenous, cutaneous, or oral nitrates, as well
as β-adrenergic blockade therapy and thrombolytic therapy,
is directed toward this goal.
If congestive heart failure develops after myocardial
infarction, initial therapy may include the following.
1. Diuretics—Rales and S3 gallop sometimes are eradicated
by a single intravenous dose of furosemide (20–40 mg intra-
venously in patients who have not previously received this
agent). Larger doses of intravenous furosemide may be used
as the initial diuretic dose if the patient is known to have
been receiving diuretic therapy in the past.
2. Vasodilators—ACE inhibitors are first-line therapy for
the treatment of congestive heart failure in acute myocardial
infarction. In addition to their beneficial hemodynamic
effects, these agents improve survival by altering favorably
the “remodeling” of the left ventricle that occurs with
myocardial infarction. Captopril can be initiated in dosages
of 12.5 mg every 8 hours and then increased to 100 mg every
8 hours. Dose escalation can occur daily (or more frequently)
if no orthostatic symptoms are noted. Corresponding doses
of enalapril range from 2.5–10 mg twice daily—and for
lisinopril, 5 mg once daily initially, titrated upward to 10–20
mg/day. Ramipril is another ACE inhibitor with proof of effi-
cacy and survival benefit in the treatment of congestive heart
failure complicating acute myocardial infarction.
Cough and elevation of the serum creatinine can limit
the use of ACE inhibitors. Some clinicians have substituted
angiotensin II receptor antagonists such as losartan and
valsartan for ACE inhibitors. Clinical trials in chronic heart
failure would support this practice, although the ACE
inhibitors remain the vasodilators of choice for prolonga-
tion of life with heart failure and depressed left ventricular
function. Another alternative therapy for heart failure with
proven survival benefits is the combination of the
vasodilator hydralazine with isosorbide dinitrate.
Hydralazine can be started at 25 mg orally with the dose
increased every 3–6 hours to a target of 100 mg every 8 hours.
Isosorbide dinitrate can be initiated at 20 mg three times
daily and increased with each dose to a target of 60 mg
three times daily.
A serum sodium level of less than 135 meq/L developing
during the course of acute myocardial infarction or chronic
congestive heart failure suggests that the patient’s blood pres-
sure is critically dependent on various compensatory mech-
anisms designed to support blood pressure, such as
production of antidiuretic hormone and angiotensin. In
such patients, heart failure therapy with ACE inhibitors may
result in substantial or profound hypotension.
3. Digoxin—Digoxin is frequently administered to patients
with heart failure who do not respond to one or two doses of
intravenous furosemide. Since digoxin may increase myocar-
dial O2 consumption and may aggravate ventricular arrhyth-
mias, it should be given orally at a dose of 0.125–0.25 mg
daily. The administration of a “loading dose” of digoxin is
unnecessary unless rapid atrial fibrillation coexists with
heart failure and rapid control of ventricular rate is desired.
C. Cardiogenic Shock—The mortality rate for cardiogenic
shock complicating acute myocardial infarction still remains
over 50%. Treatment may include the following.
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1. Increase intravascular fluid volume—Volume
expansion with 250–500 mL of normal saline may be used as
the first treatment for cardiogenic shock if no evidence of left
ventricular failure is present (ie, no rales and absent S3 gal-
lop). If no clear response is seen (ie, blood pressure does not
increase), more fluid may be administered, but consideration
of pressor agents or right-sided heart catheterization (or
both) should be high on the list of subsequent priorities.
2. Vasoactive and inotropic agents—Intravenous
dopamine in the range of 5–25 μg/kg per minute may be given
to raise the systolic blood pressure to more than 90 mm Hg or
to otherwise maintain organ perfusion. Intravenous dobuta-
mine given in doses of 2.5–25 μg/kg per minute is frequently
helpful in cardiogenic shock. This agent is particularly useful
because it is both a vasodilator and an inotropic agent. Despite
its vasodilator properties, in patients with a markedly reduced
cardiac output, dobutamine infusions frequently result in an
increase in blood pressure as a result of increased cardiac
output.
If either of these agents is required for more than a few
minutes to an hour, placement of a pulmonary artery
catheter is warranted so that the dose of each agent can be
adjusted to meet hemodynamic goals. The simultaneous
administration of dopamine (6–7 μg/kg per minute initially)
and dobutamine (3–4 μg/kg per minute initially) may be
useful in increasing both the blood pressure and the cardiac
output in patients with acute myocardial infarction and
severely compromised hemodynamics. These dosages are an
empirical starting point. A right-sided heart catheter is
required for rational adjustment of these two pressor agents.
Milrinone has a hemodynamic profile similar to that of
dobutamine, but it is much more costly. This phosphodi-
esterase inhibitor does not demonstrate the rapid tachyphy-
laxis seen with β-adrenergic agonists. If long-term high-dose
catecholamine support is required to maintain cardiac out-
put, milrinone may be a suitable alternative.
3. Intraaortic balloon pump—The intraaortic balloon
pump should be considered if acute ischemia is suspected as
the primary cause of cardiogenic shock. If a patient has con-
tinued chest pain after myocardial infarction and develops
cardiogenic shock, intraaortic balloon pumping may provide
a bridge to surgical therapy of shock. The intraaortic balloon
is inflated in the descending aorta during diastole, thereby
increasing coronary perfusion pressure. By deflating during
systole, it “unloads” the left ventricle.
D. Heart Block
1. Inferior myocardial infarction and heart block—
Heart block frequently occurs along with acute inferior wall
myocardial infarction during which the blood supply to the
AV node has been compromised either by ischemia or by
infarction. However, temporary pacing is not necessarily
indicated if the heart block is Mobitz I (Wenckebach) and the
patient’s blood pressure and clinical status are stable.
Atropine is very useful for increasing the heart rate in
patients with symptomatic bradycardia. An increase in heart
rate and blood pressure is seen frequently after a 1-mg intra-
venous bolus of atropine sulfate. Atropine can be repeated
once or twice if necessary. However, serious side effects (eg,
dry mouth, blurred vision, and even psychosis) preclude its
continued use. Therefore, the development of heart block
with hemodynamic compromise (ie, fall in blood pressure,
decrease in mentation, or other evidence of peripheral
hypoperfusion) should lead to serious consideration of a
transvenous temporary pacemaker.
2. Temporary transcutaneous pacing—Transcutaneous
pacing may be very helpful as a temporary expedient. The
technique is very painful to the patient and should be
replaced by transvenous pacemaker placement in high-risk
patients likely to require pacing. Transcutaneous pacing is
indicated for symptomatic bradycardia (heart rate < 50
beats/min) or bradycardia with hypotension (systolic blood
pressure < 80 mm Hg) unresponsive to drug therapy, Mobitz
type II second-degree AV block, third-degree heart block and
bilateral bundle branch block (BBB)(ie, alternating BBB),
new BBB or fascicular block, and right or left BBB with first
degree AV block.
3. Temporary transvenous pacing—Temporary transve-
nous pacing in the acute myocardial infarction patient is
indicated for the following conditions: asystole, symptomatic
bradycardia unresponsive to medications and type I second-
degree AV block, bilateral BBB, a new BBB or fascicular block
and first-degree AV block, and Mobitz type II second-degree
AV block.
4. Permanent pacing after acute myocardial infarc-
tion—Consideration for permanent pacemaker implanta-
tion should take place in the presence of persistent Mobitz
type II second-degree AV block or complete heart block after
myocardial infarction, transient second- or third-degree AV
block plus BBB, and symptomatic AV block at any level.
E. Right Ventricular Infarction—Right ventricular myocar-
dial infarction complicates roughly one-third of all acute
inferior wall myocardial infarctions. The right ventricle is a
very thin-walled structure that is poorly adapted to acute
demands of either pressure or volume. The diagnosis of
this entity can be made through echocardiography,
radionuclide ventriculography, cardiac catheterization, or
electrocardiography.
1. Diagnosis—ST-segment elevation in the right-sided elec-
trocardiographic chest leads is the most sensitive test for
detecting an acute right ventricular infarction. Lead V4R is
the most sensitive and most specific lead. However, all elec-
trocardiographic criteria begin to dissipate within hours of
an acute right ventricular infarction, and the hemodynamic
consequences may be more apparent than changes on the
ECG. Right ventricular infarction should be suspected in all
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patients with acute inferior wall myocardial infarction with
hypotension, especially if there is evidence that left ventricular
function is preserved. The hallmarks of a hemodynamically
significant right ventricular infarction include the presence
of elevated neck veins with clear lungs but evidence of poor
cardiac output.
2. Treatment
Since right ventricular infarction is a common complication
in patients with acute inferior wall myocardial infarction,
initial doses of nitroglycerin should be given cautiously to
these patients. This is so because right ventricular output
may decrease markedly in response to systemic venodilation
by nitroglycerin. These patients also may be particularly sen-
sitive to diuretics such as furosemide.
To increase blood pressure and cardiac output in the face
of a known or suspected acute right ventricular myocardial
infarction, initial therapy should consist of intravenous flu-
ids, provided there is no evidence of pulmonary congestion
or a left ventricular S3 gallop. Patients who fail to respond to
fluid infusion with an increase in blood pressure and
improved systemic perfusion should be treated next with
intravenous dobutamine, preferably with a pulmonary artery
catheter to help guide therapy.
F. Other Complications
1. Pericarditis—Pericarditis is a common complication of
myocardial infarction. If the infarction process involves the
epicardium of the left ventricle, irritation of the pericardium
may occur. The patient typically complains of chest pain
exacerbated by respiration and supine posture; the patient
frequently feels more comfortable sitting upright. The
appearance of a three-component friction rub representing
the left ventricular epicardium rubbing against an inflamed
pericardium confirms the diagnosis.
Treatment is generally straightforward. An asymptomatic
friction rub heard on routine daily examinations need not be
treated. Symptomatic episodes of pericarditis can be treated
with either aspirin, 325 mg every 4–6 hours, or nonsteroidal
anti-inflammatory agents. Rarely, corticosteroids are required
to control post–myocardial infarction pericarditis pain.
Most episodes of pericarditis are self-limited and require
no more than symptomatic therapy. If a question regarding a
patient’s symptoms arises, an echocardiogram that demon-
strates an increase in pericardial fluid may be helpful in
establishing the diagnosis of pericarditis.
Thrombolytic therapy and heparin (except for subcuta-
neous heparin for prevention of deep venous thrombosis)
should be terminated if pericarditis is suspected or diag-
nosed after myocardial infarction. Rarely, post–myocardial
infarction pericarditis leads to a pericardial effusion sizable
enough to cause hemodynamic compromise. The hallmarks
of a significant pericardial effusion include an increase in
heart rate, an increase in the magnitude of paradoxic pulses,
a decrease in the systolic pressure, a decrease in the systemic
pulse pressure, elevated neck veins, and, in advanced stages,
evidence of low cardiac output (eg, cool extremities,
decreased mentation, and decreased urine output). Should a
hemodynamically significant pericardial effusion be sus-
pected, urgent echocardiography should be performed to
confirm the diagnosis and to localize the effusion. While the
echocardiogram is being performed, cardiac catheterization
laboratory personnel should be preparing to perform peri-
cardiocentesis if necessary.
2. Papillary muscle rupture and ventricular septal
rupture—These are rare but life-threatening complications
of acute myocardial infarction. A murmur consistent with
acute mitral regurgitation may be heard in up to 50% of
patients with acute myocardial infarction during the first
24–48 hours after the event. However, these mitral regurgi-
tant murmurs usually represent transient papillary muscle
ischemia and disappear with time or remain hemodynami-
cally unimportant.
Papillary muscle rupture or an acute ventricular septal
rupture should be suspected in patients who develop sudden
hypotension or evidence of severe heart failure. The hallmark
of both lesions is a loud systolic murmur, often with a thrill
palpable over the left chest. The diagnosis of these lesions can
be confirmed by echocardiography. Alternatively, since these
lesions are usually associated with heart failure and a low car-
diac output, a pulmonary artery catheter should be placed to
help guide subsequent management. The presence of high
(near systemic) O2 saturation in a right atrial blood sample
confirms the diagnosis of ventricular septal rupture (with
left-to-right shunting of blood). The presence of a large v
wave in the pulmonary capillary wedge pressure tracing may
lend support to the diagnosis of left ventricular papillary
muscle rupture.
Both these conditions are acute emergencies. Conservative
measures usually are insufficient to allow survival.
Consideration should be given to urgent cardiac catheteriza-
tion with anticipation of emergent open-heart surgery.
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Primary cardiovascular disease is the most common single
indication for ICU care and monitoring. Many patients with
other diseases requiring intensive care develop secondary
cardiovascular complications. Moreover, cardiac surgery
patients remain the most common group of surgical patients
requiring intensive care and monitoring. Many of the ICU
concerns relevant to cardiac surgical patients are covered in
other sections of this text, but certain aspects are unique to
this common subset of patients. The following sections cover
these unique problems and include aneurysm and dissection
of the great vessels, postoperative arrhythmias, perioperative
coagulopathy, complications of artificial circulation, and
postoperative low-output states.
ANEURYSMS, DISSECTIONS, & TRANSECTIONS
OF THE GREAT VESSELS
ESSENT IALS  OF  D IAGNOS I S
 Chest pain.
 Differential peripheral pulses.
 Aortic insufficiency.
 Widened mediastinum on chest x-ray.
 Cardiovascular collapse.
 End-organ ischemic symptoms.
General Considerations
Disease of the great vessels often presents dramatically and
is often lethal if not managed expeditiously. Timely surgical
correction or, when appropriate, medical therapy may be
lifesaving. However, despite considerable progress in surgi-
cal approaches and medical therapies, a minority of patients
still faces the specter of complications: potential paraplegia,
pre- or postoperative mortality, end-organ injury, delayed
recovery from surgical incisions, or subsequent surgery from
disease progression after initial medical or surgical therapy.
Terminology is frequently confusing owing, in part, to the
nature of the pathology and because of various classification
schemes. Aortic dissections, transections, and aneurysms are
related but distinct entities. Aortic dissections and transec-
tions predispose to false (pseudo) aneurysms, and
aneurysms predispose to dissections, but because of thera-
peutic and prognostic considerations, it is desirable and
usually possible to determine which came first. These three
entities frequently present simultaneously as a combined
lesion, but the relative contribution of each component of
the disease should be considered separately—while appreci-
ating their interrelationships.
Aneurysms of the great vessels (ie, aorta, innominate
artery, carotid artery, ductus arteriosus, and subclavian
artery) are pathologically either true aneurysms composed of
all three layers of the vascular wall or false aneurysms con-
taining only adventitia and periaortic fibrous tissue. True
aneurysms result from transmural degeneration of the struc-
tural components of the vessel (eg, Marfan’s syndrome,
residual ductus arteriosus tissue, ectatic vein grafts, and aor-
tic disease associated with obstructive lung disease) or from
a localized degeneration of vascular layers (eg, atherosclero-
sis and vasculitis). False aneurysms usually are due to prior
dissection, trauma, prior great vessel surgery, or rarely,
tumor. Descriptively, both true and false aneurysms are
either saccular or fusiform (Figure 23–1). Classification of
great vessel aneurysms based on location and extent is help-
ful for diagnosis, prognosis, and therapy. Aneurysms that
involve the arch are more technically complex than those iso-
lated to the ascending or descending aorta. Because they usu-
ally require circulatory arrest for repair, they have an
increased potential for neurologic injury. Repair of
aneurysms that traverse the diaphragm are more prone to
cause paraplegia because of their proximity to the arterial
supply of the anterior spinal artery. Aneurysms that involve
the aortic root are likely to require coronary reimplantation
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and valve resuspension or replacement. Hence they have
increased risk for myocardial ischemia and the potential
complications associated with valvular surgery. Extensive
aneurysms of the entire aorta may require a staged approach
with initial replacement of the ascending aorta, followed by
the arch, and subsequently by the descending thoracic and
abdominal portions.
Aneurysms presumably cause symptoms by expansion,
compression of local structures, distal embolism of con-
tained material, secondary dissection, and either contained
or free rupture. The frequency of these complications
increases exponentially with aneurysm size.
Etiology
A. Aortic Transection—Aortic transection occurs most
commonly after significant blunt trauma and generally
occurs at points of relative aortic fixation—in descending
order of frequency, near the ligamentum arteriosus, at the
diaphragmatic hiatus, at the ascending aorta, and at the
abdominal aorta. Shearing stress from rapid deceleration has
been regarded as the primary biomechanism of this injury,
but recent evidence suggests that lateral-impact collision
forces with simultaneous acceleration of the victim and
increased hydrostatic pressure within the aorta also may be
important mechanisms. In survivable cases, tenuous vascular
integrity is maintained by the adventitia. Early symptomatic
presentation usually is exsanguinating rupture or distal dis-
section, whereas late presentation is in the form of a
pseudoaneurysm. Aortic transection occasionally is due to
penetrating violent injury or to iatrogenic trauma during
cardiac or other surgery.
B. Aortic Dissection—Aortic and other great vessel dissec-
tions represent pathologic separation of the vessel layers,
thereby creating a true lumen and a false one. Since aortic tis-
sue is intrinsically stable, there is usually associated pathology
such as disease of the intima or media (eg, atherosclerosis,
cystic medial necrosis, or Marfan’s syndrome), increased wall
tension (eg, preexisting aneurysm or hypertension), or
trauma (blunt or sharp). Indeed, the two conditions most
frequently associated with aortic dissection are hypertension
(about 80%) and Marfan’s syndrome. Mechanistically, rup-
ture of the vasa vasorum is probably the most important
inciting event. It is not clear whether spontaneous bleeding
into the aortic wall (ie, intramural hematoma) may cause
aortic dissection. Dissections are usually complex anatomi-
cally and dynamic in presentation. Once the intimal tear
occurs, there is progressive separation of the adventitia and
the intima. This separation typically propagates distally but
occasionally may extend proximally. As the separation
extends, branch vessels may be themselves dissected,
occluded, or completely unaffected depending on the loca-
tion and extent of the aortic dissection. Ultimately, the dis-
section reaches an equilibrium between the vessel’s intrinsic
resistance and shear forces that promote propagation. The
dissection then either reenters the true lumen via a second or
third tear in the intima or creates a blind pouch. These
“neostructures” then may remain permanently patent
because of continued flow down the false channel, or they
may thrombose owing to stasis. These dynamics of aortic
dissection are a function of the balance between tissue
strength and continued shear forces. Shear forces, in turn, are
determined by blood pressure, change in blood pressure with
time (dP/dT), size and location of the intimal tear, and blood
vessel diameter.
Two classification schemes are used commonly, based on
the location and extent of dissection—the Stanford and
DeBakey classifications. A Stanford type A dissection begins
in the ascending or transverse aorta with variable amounts of
aortic involvement. Type B dissections begin distal to the
takeoff of the last great vessel, usually the left subclavian
artery. By comparison, a type I DeBakey lesion is analogous
to an extensive Stanford type A dissection. Both begin in the
ascending aorta and extend across the arch and down the
descending aorta. A DeBakey type II dissection involves only
the ascending aorta, whereas a type III DeBakey lesion is
analogous to a Stanford type B dissection.
These classification schemes are vital to management and
prognosis, with particular emphasis on identifying involve-
ment of the ascending aorta. Type A dissections have an 80%
mortality within 48 hours without surgical treatment,
whereas selected type B dissections frequently can be man-
aged medically with only a 10% mortality at 30 days. These
vastly different outcomes are based primarily on the proxim-
ity of type A dissections to vital structures, including the
heart, coronary arteries, aortic valve, and carotid vessels.
Myocardial infarction, acute aortic insufficiency, intrapericar-
dial rupture causing tamponade, and stroke are all frequent
consequences of proximal dissections. In addition, progres-
sion of a type A dissection may result in all the complications
normally associated with a type B dissection such as intratho-
racic rupture, paraplegia, visceral ischemia, extremity ischemia,
 Figure 23–1. Types of thoracic aortic aneurysms.
A. Fusiform. B. Saccular. (Reproduced, with permission,
from Way LW (ed), Current Surgical Diagnosis & Treatment,
10th ed. Originally published by Appleton & Lange.
Copyright © 1991 by The McGraw-Hill Companies, Inc.)
A B
 CHAPTER 23516
and intraabdominal rupture. Fortunately, many of the struc-
tures affected by type B dissections are either paired
(eg, renal), tolerate ischemia for long periods of time (eg,
extremities), or have collateral pathways (eg, GI tract) for
blood supply.
Other changes related to the dissection process include
(1) lability of the blood pressure to fluid shifts, cardiac
decompensation, baroreceptor involvement, and underlying
etiology, (2) coagulopathy from massive blood exposure to
tissue, (3) metabolic derangements from hypoperfusion,
(4) respiratory compromise from systemic inflammation
and local airway compression, (5) any variety of neurologic,
renal, GI, cardiac, and extremity complications, and (6) pro-
gression to chronic pseudoaneurysm or, rarely, stenosis or
obstruction of the aortic lumen. The surgical risks and
adverse effects of therapy multiply with extent and acuity of
the disease process.
Clinical Features
A. Symptoms and Signs—Any patient with significant
chest pain should be assumed to have an aortic catastrophe
until another cause is established. Discrepancies in periph-
eral pulses and blood pressures occur frequently, particularly
in the presence of aortic valve insufficiency. Changes in pulse
contour or distribution may help to localize the extent of a
dissection or transection. Patients with recent or remote
trauma, a family history of Marfan’s syndrome, hyperten-
sion, or prior surgery of the aorta are at increased risk.
Dissections in particular—and sometimes aneurysms—
have myriad presentations, making them a diagnostic chal-
lenge. By far the most common symptom accompanying
aneurysms, transections, and dissections is chest pain, usu-
ally sharp and, less frequently, tearing or ripping, with radia-
tion to the back or abdomen.
Aneurysms may present with pressure symptoms related
to the recurrent laryngeal nerve, great veins, trachea, esoph-
agus, or chest wall. Significantly, aneurysms may be asymp-
tomatic until they rupture and present with circulatory
collapse.
Any number of end organs may become ischemic tem-
porarily or permanently with their own characteristic symp-
toms. Temporary neurologic findings are particularly
common, but any vascular organ can present with initial or
subsequent ischemia.
B. Electrocardiography—Because primary coronary artery
disease is more common than significant aortic disease, a
normal ECG with normal cardiac enzymes should heighten
the suspicion of dissection or aneurysm as a cause of chest
pain. However, if a type A dissection extends into a coronary
(more commonly the right coronary) artery, an ECG cannot
make this distinction. Moreover, electrocardiographic find-
ings occur in about 70% of dissection patients, including
nonspecific ST-segment–T-wave changes, left ventricular
hypertrophy, ischemia, myocardial infarction with old Q
waves, or myocardial infarction with new Q waves.
C. Imaging Studies—A normal chest x-ray is helpful but does
not exclude disease. Overlying structures may compromise
aortic visibility. Tortuosity of the aorta may falsely suggest
enlargement. Aortic transections and dissections may be pres-
ent in an aorta of normal caliber. However, the majority of
cases will show mediastinal widening that mandates further
investigation. To evaluate mediastinal widening, a posteroan-
terior chest x-ray should be obtained because anteroposterior
views are frequently misleading. If available, prior films should
be examined. Other radiographic findings, in decreasing order
of frequency, are abnormal aortic or cardiac contour, displace-
ment or calcification of the aorta, and pleural effusion.
Many patients will have more than one special imaging
study to determine the presence and extent of disease. All the
examinations mentioned below have sensitivities and speci-
ficities greater than 90% when performed and interpreted
properly. Probably the most important consideration is to
establish in advance which approach will be used based on
resources and expertise because diagnosis must be rapid.
In the past, angiography was standard for evaluating aor-
tic disease, and it still has many advantages over other tech-
niques. Angiography has sensitivity and specificity similar to
those of other examinations, provides an assessment of flow
to vessels from both the true and false lumens, permits coro-
nary angiography to be obtained simultaneously in selected
patients, allows evaluation of aortic insufficiency, and fre-
quently establishes the etiology of the disease. Disadvantages
include its invasive nature, the possibility of iatrogenic
catheter injury, peripheral access problems secondary to dis-
sections or underlying obstructive disease, contrast load,
occasional inadequate visualization of a nonperfused false
channel, and nonvisualization of surrounding structures.
Furthermore, angiography is more time-consuming than
other diagnostic techniques (see below), and delay in diagno-
sis may contribute to further morbidity and mortality. With
these considerations, echocardiography and CT scanning are
the diagnostic tests of choice.
CT scanning and MRI provide similar views. CT scanning
is more widely available than MRI and usually can be
obtained rapidly, but it requires contrast material adminis-
tration. The sensitivity and specificity of these modalities are
excellent, and both provide information about surrounding
structures.
Echocardiography—particularly transesophageal echo-
cardiography—has emerged as a valuable technique in the
diagnosis of aortic disease and is considered by many to be
the preferred diagnostic modality. For adequate visualiza-
tion, a biplane transesophageal probe is required. Expertise
in evaluating the images is crucial. The technique is limited
by the presence of intervening structures, particularly those
containing air, and distance of the probe from the vessel.
Differential Diagnosis
Pericarditis, myocardial infarction, and primary aortic insuf-
ficiency are common cardiac diseases that can have similar
presentations. Similarly, pain from esophageal diseases such
as spasm, rupture, tumor, achalasia, and reflux can be con-
fused with aortic symptomatology. Tortuosity and athero-
sclerosis of the aorta may have a similar appearance on chest
x-ray. Tumors may widen the mediastinal silhouette, and
pulmonary diseases such as pleural effusions and pulmonary
emboli can cause densities on radiographs that may be diffi-
cult to differentiate from aortic disease. When this occurs,
CT scanning or MRI can be of value. Minor ruptures of the
aortic vasa vasorum can widen the aortic shadow without
actually producing aortic disruption.
Treatment
A. General Measures—The disease extent and, if applicable,
the site of intimal injury should be determined based on clin-
ical examination and studies already available. Patients who
are exsanguinating may require immediate operation based
on chest x-ray findings alone. Others should be evaluated rap-
idly and, if ascending aortic disease or aortic transection is
confirmed, repaired immediately. Many elderly patients with
type B dissections or asymptomatic small (<5 cm) aneurysms
may best be managed initially with medical therapy.
Regardless of disease type, patient age, or initial treat-
ment, vigorous continuous medical control of shear forces
with antihypertensives and negative inotropes is essential if
there is residual abnormal aorta. Patients with aortic transec-
tions and localized aneurysms frequently have curative sur-
gery with no remaining diseased aorta. Commonly, when an
aortic dissection is present, only a portion of the aorta is
repaired, and residual disease requires vigorous treatment
and long-term follow-up.
Since diseases of the thoracic aorta can cause morbidity
and mortality owing to complex disease, significant comor-
bidities, and acuteness of presentation, they provide a logical
potential application for newer catheter-based therapies that
have proliferated in the past decade for the treatment of car-
diovascular disorders. Indeed, endovascular stent grafts have
been used in both elective and emergent settings for thoracic
aortic dissection, aneurysmal disease, and blunt injury to the
thoracic aorta. Furthermore, percutaneous fenestration of
the intimal flap has been performed successfully to restore
perfusion to end organs when ischemia results from dissec-
tion. As long-term results of these therapies become available
and as new technology develops, the indications for the use
of percutaneous-based therapies in diseases of the thoracic
aorta will become clearer.
B. Blood Pressure Control—Rapid, continuous control of
blood pressure and pulse pressure should be pursued aggres-
sively immediately following diagnosis. Systolic blood pres-
sure should be kept below 110 mm Hg systolic. The force of
left ventricular contraction (dP/dt) should be minimized by
administering negative inotropes.
An intraarterial monitoring line is vital during the early
phases of treatment because of the potential for rapid alter-
ations in blood pressure. The arterial line should be used
until documented continuous blood pressure control is
accomplished.
Central venous pressures should be monitored and fluid
status optimized. Patients with severe blood loss, intraperi-
cardial blood and tamponade, or end-organ ischemia may
require volume replacement. Cardiovascular function is fre-
quently labile, and inotropes and vasopressors may be
required while definitive diagnosis is established.
A single, ideal drug applicable to every situation does not
exist, but several aspects of the many available antihyperten-
sives are useful. The rapidity of onset, half-life, potency, dis-
tribution, metabolism, degradation products, side effects, and
physiologic effects all should be considered. Use of a short-
acting vasodilator (eg, IV nitroprusside) in combination with
a negative inotropic agent (eg, IV esmolol) effectively reduces
both blood pressure and the force of blood ejection.
Vasodilators commonly used include nitroprusside,
hydralazine, and nitroglycerin. Nitroprusside is well toler-
ated, extremely potent, rapid-acting, and has a short half-life.
Its disadvantages include an increase in dP/dT when used
alone, elevation of pulmonary shunt, and creation of a toxic
metabolite (cyanide) with prolonged high-dose use.
Hydralazine is longer-acting and available orally, making it a
suitable agent for long-term use. Nitroglycerin decreases car-
diac output and blood pressure through direct venodilation
but has little effect on arterial relaxation. Thus its usefulness
for disorders of the thoracic aorta is limited, and it should
not be regarded as a first-line agent.
β-Blockers are available in short-acting (eg, esmolol) and
long-acting (eg, atenolol) forms. As such, they are usually a
part of both short- and long-term management. Of the many
β-blockers available, esmolol offers the advantage of an
extremely short half-life, allowing precise and frequent dos-
ing adjustments toward optimal blood pressure. Labetalol is
also an efficacious agent because of its blockade of both
β-adrenergic and β-adrenergic receptors. With this said, for
acute blood pressure control, β-blocker therapy combined
with sodium nitroprusside, as needed, is regarded as the
therapy of choice.
Calcium blockers produce both decreased blood pressure
and decreased contractility. They are of greatest benefit in
long-term management. Their relatively long half-life limits
use acutely during unstable periods.
Central sympatholytics include trimethaphan, clonidine,
methyldopa, and reserpine. They are used less commonly but
do have a role in acute and chronic care as adjuncts to stan-
dard drug regimens.
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 Postoperative Arrhythmias
ESSENT IALS  OF  D IAGNOS I S
 Variable heart rate.
 Regular or irregular rhythm.
 Electrocardiographic abnormalities.
 Altered peripheral perfusion.
General Considerations
Significant cardiac dysrhythmias occur in up to one-third of
postoperative cardiac surgical patients. Age is the most con-
sistently identified predictor of postoperative arrhythmias,
although many other risk factors exist, including valvular
disease, cardiomyopathy, ischemia, reperfusion, adequacy of
myocardial protection, metabolic derangements, adrenergic
states, medications, temperature, and mechanical irritants.
Arrhythmias should be classified first by ventricular rate.
The rhythm then is subclassified according to its origin—
supraventricular or ventricular—by establishing the rate of
the atrium and evaluating the status of the atrioventricular
(AV) conduction system. Bradycardias include sinus brady-
cardia, heart block, sinus arrest, and slow junctional
rhythms. Tachycardias include (1) supraventricular arrhyth-
mias (eg, atrial fibrillation, atrial flutter, premature atrial
contractions, paroxysmal atrial tachycardia, and fast junc-
tional rhythms) and (2) ventricular tachycardia, flutter, fib-
rillation, and premature ventricular contractions.
Conduction defects include heart block, bundle branch
block, and preexcitation. Sometimes, the origin of a rapid
arrhythmia is indeterminate and should be referred to as a
nonspecific wide complex tachycardia.
Etiology
The etiology of perioperative arrhythmias is multifactorial.
Mechanistically, they can be separated into ectopic foci and
reentrant circuits. Both originate either from abnormal car-
diac tissue affected by ischemia, hypertrophy, dilation, car-
diomyopathy, and scar or from normal cardiac tissue
induced by inotropes, endogenous catecholamines, auto-
nomic stimulation, and metabolic derangements.
A. Intrinsic Factors—Age is associated with supraventricu-
lar arrhythmias and heart block in both cardiac and other
thoracic surgical patients. The etiology of this association is
unclear, but the incidence in patients over 65 years of age is
high enough to warrant prophylactic therapy in many cases.
To this end, β-blockers (eg, sotalol) and amiodarone are
commonly used agents. Although routine preoperative pro-
phylaxis against postoperative arrhythmias (particularly
atrial fibrillation) remains controversial, it is increasingly
supported by emerging data. Intrinsic cardiac disease,
including cardiomyopathy, acute coronary insufficiency,
valvular heart disease, congenital lesions, pulmonary hyper-
tension, ventricular outflow obstruction, and ventricular
failure, also increases the incidence and severity of arrhyth-
mias in both the preoperative and postoperative periods.
Cardiomyopathy, both ischemic and nonischemic, as well
as dilated and nondilated, frequently causes both atrial and
ventricular rhythm irregularity and is one of the more com-
mon presenting complaints. Surgical therapy (excluding
aneurysm resection and endocardial ablation) frequently
does not eliminate the cause. Atrial arrhythmias can result
from primary involvement of atrial muscle or secondary
dilation of atrial chambers by ventricular failure. Ectopic foci
and reentrant circuits are the primary underlying causes, but
the metabolic complications of diuresis and inotropes fre-
quently contribute. Ventricular rhythm disturbances develop
by these same mechanisms and are often life-threatening.
Acute coronary arterial insufficiency frequently presents
with severe arrhythmias (particularly ventricular) or heart
block. They can recur or present postoperatively from resid-
ual or recurrent ischemia and reperfusion injury.
Valvular heart disease frequently has residua that predis-
pose to arrhythmias despite correction of the valvular lesion.
The conduction system is anatomically close to valvular
structures and is easily interrupted.
Endocarditis is particularly likely to be associated with
heart block pre- and postoperatively. Aortic disease leads to
left ventricular hypertrophy or ventricular dilatation, both of
which predispose to reentrant circuits or arrhythmic foci.
Mitral and tricuspid valve disease most commonly causes
atrial arrhythmias, primarily fibrillation. These should be
expected to recur with almost 100% certainty in the postop-
erative period.
Congenital lesions frequently are associated with abnor-
malities of the location and function of the conduction sys-
tem and with chamber enlargement or hypertrophy. All these
factors contribute to ectopic foci and reentry. Wolff-
Parkinson-White syndrome is a common congenital lesion
of the conduction system predisposing to reentrant AV
rhythms. Gross anatomic disease is also occasionally associ-
ated with specific rhythm changes. In particular, Ebstein’s
anomaly may be complicated by Wolff-Parkinson-White
syndrome, tetralogy of Fallot is associated with right ventric-
ular arrhythmic foci, and certain types of transposition result
in abnormal conduction anatomy and an increased incidence
of perioperative heart block. Pulmonary and pulmonary
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vascular abnormalities are superimposed on all these lesions
and result in right ventricular enlargement and hypertrophy,
tricuspid regurgitation, and secondary atrial arrhythmias.
B. Extrinsic Factors—Mechanical irritants (eg, chest tubes,
central catheters, blood, and tamponade), metabolic
derangements (eg, hypo- or hypermagnesemia, -kalemia,
-phosphatemia, and -calcemia), adrenergic or vagotonic
states, and cardiovascular drugs are frequent in the postoper-
ative period and can induce and aggravate arrhythmias.
Clinical Features
The approach to the diagnosis of rhythm disturbances in the
postoperative period is similar to that presented elsewhere.
However, because of the unique perioperative factors that
contribute to arrhythmias, an organized, rapid, and complete
evaluation is crucial.
A. Symptoms and Signs—Patients with cardiac arrhyth-
mias in the perioperative period have findings identical to
those seen in nonsurgical patients. They may have more pro-
found and acute circulatory compromise owing to residual
anesthetic agents, cardiopulmonary bypass effects, ongoing
hemorrhage, metabolic derangements, volume shifts,
hypothermia, and residual cardiac disease.
B. Electrocardiography—Unique to cardiac surgical
patients is the frequent presence of ventricular or atrial pac-
ing wires, which can provide valuable information and man-
agement options. Twelve-lead surface electrocardiographic
tracings should be compared with preoperative and earlier
postoperative examinations for evidence of ischemia, rhyth-
micity, conduction abnormalities, QRS-complex and ST-
segment abnormalities, and QT-interval prolongation.
If the rhythm cannot be diagnosed conclusively, an atrial
ECG should be obtained by attaching one or more of the
atrial pacing wires (if not in use for pacing) to the electrocar-
diographic machine or bedside monitor. A predetermined
configuration on the 12-lead machine is usually used, and
the tracings based on the atrial wires will emphasize the atrial
portion of the rhythm despite its small muscle mass.
Signal-averaged ECGs and programmed electrical stimu-
lation are beyond the scope of this text but should be pur-
sued on an individual basis to establish a diagnosis, stratify
risk, and evaluate the effects of treatment.
C. Laboratory Findings—Arterial blood gases and elec-
trolytes should be obtained to exclude acidosis, alkalosis, and
electrolyte abnormalities. Serum potassium and calcium lev-
els merit particular attention.
Invasive Hemodynamic Monitoring
Invasive hemodynamic monitoring with arterial lines and
flow-directed pulmonary artery catheters typically is per-
formed to assist with management after cardiac surgery.
Analysis of these data is invaluable in the diagnosis and man-
agement of postoperative arrhythmias. Furthermore,
confirmation of appropriate waveforms (eg, pulmonary cap-
illary wedge pressure and pulmonary artery pressure) with
the pulmonary artery catheter may decrease the suspicion of
mechanical irritation from the catheter, significantly con-
tributing to the arrhythmias.
Differential Diagnosis
Problems peculiar to postoperative cardiac surgical patients
that may lead to arrhythmias include hypovolemia, bleeding,
pericardial tamponade, tension pneumothorax, thrombosis
or dehiscence of a prosthetic valve, coronary ischemia, and
hypoxia. Care must be exerted to ensure that the bedside
monitor is working correctly and that observed rhythms are
not due to electrical interference.
Treatment
A. Antiarrhythmics—Arrhythmias are frequent postopera-
tively, and prophylaxis with a variety of agents appears effec-
tive. In particular, β-blockers reduce the incidence and
severity of atrial arrhythmias and probably prevent some
ventricular arrhythmias. Although there is conflicting evi-
dence, magnesium appears to have some antiarrhythmic
effects and may reduce the incidence of atrial fibrillation,
atrial flutter, and ventricular arrhythmias as well. Calcium
channel blockers may have similar benefits, but these agents
are less well studied in the postoperative context.
Amiodorone, a class III agent, has been shown recently, albeit
in a very small study, to reduce the incidence of postopera-
tive arrhythmias when administered perioperatively. Further
discussion of the medical treatment of arrhythmias is found
in detail in Chapter 22.
B. Cardioversion—In addition to pharmacologic measures,
preparation should be made for rapid cardioversion in
patients at high risk for severe ventricular arrhythmias.
Patients who have had ventricular fibrillation perioperatively
may require immediate cardioversion. Equipment should be
ready at the bedside and attached to the patient. Much of the
morbidity of severe ventricular arrhythmias can be avoided
by immediate cardioversion.
The rhythm type and chamber of origin—atrial, junc-
tional, or ventricular—should be established. If the atrial
arrhythmia is fast and poorly tolerated (ie, symptomatic),
immediate electrical conversion is warranted. To convert
atrial fibrillation or flutter, high-energy shock usually is
required and always should be synchronized. Overdrive atrial
pacing may be performed at the bedside using the atrial epi-
cardial pacing wires. This is most effective for supraventricu-
lar tachyarrhythmias such as atrial flutter and paroxysmal
atrial or AV junctional reentrant circuits. Rapid atrial pacing
also can interrupt a reentrant circuit such as atrial fibrilla-
tion, thereby restoring sinus rhythm, although less effec-
tively. When performing overdrive pacing, great vigilance
must be exercised to ensure that the atrial leads—rather than
the ventricular leads—are attached to the generator.
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Ventricular tachycardia frequently can be terminated
with low-energy synchronized cardioversion. Ventricular fib-
rillation should be treated immediately with high-energy
defibrillation, usually unsynchronized. Both defibrillation
and cardioversion can worsen the existing rhythm, so one
must be prepared to increase electrical output rapidly and
defibrillate again. If the rhythm is bradycardiac or becomes
so following electrical or chemical conversion, ventricular
pacing should be instituted immediately. After an adequate
heart rate is obtained with ventricular pacing, the patient can
be converted to atrial or AV sequential pacing if wires are
available. If wires are not available or do not function, tem-
porary transvenous pacing (eg, balloon-guided or pacing
pulmonary artery catheter wires) can be attempted.
C. Supportive Measures—If prophylaxis has been unsuc-
cessful, the first objective is to maintain adequate oxygen
delivery and pH control with optimal ventilation.
Circulatory support with cardiopulmonary resuscitation
(CPR) may be necessary while preparations are made for
electrical cardioversion. CPR procedures in cardiac surgery
patients are similar to those followed under other circum-
stances. Closed chest compressions are effective in cardiac
surgery patients and should be used when indicated, as in
any other resuscitation effort. If a pulse is obtained with
CPR, continued efforts at external electrical conversion can
be pursued, but if perfusion is inadequate or external electri-
cal conversion is unsuccessful, open cardiac massage and
internal paddle defibrillation should be considered.
After initial control with electrical conversion in unstable
patients—and primarily in stable patients—the rhythm
should be evaluated for type and probable causes. Many
rhythms are caused by temporary derangements and are best
treated by eliminating the primary cause. Almost all antiar-
rhythmic drugs have adverse side effects even when used
appropriately, and many (perhaps all) are proarrhythmic.
Careful consideration of the risks and benefits of drug ther-
apy is vital because the complications of therapy sometimes
are worse than the underlying arrhythmia. The safest thera-
pies are to optimize electrolytes, decrease sympathetic stim-
ulation, remove mechanical causes, treat ischemia, and allow
some temporary arrhythmias (owing to reperfusion) to
resolve spontaneously with careful monitoring.
Atrial arrhythmias are particularly common and usually
cannot be allowed to persist because they are accompanied by
symptomatic tachycardia. The rate of conduction of atrial fib-
rillation and flutter through the AV node can be blocked with
digoxin, β-blockers, and calcium channel blockers singly or in
combination. After adequate rate control is established, con-
version of the arrhythmia can be accomplished with a class Ia
antiarrhythmic agent (eg, procainamide or quinidine). The
risk of treating relatively benign atrial arrhythmias with class
I agents should be appreciated because there is a chance of
inducing ventricular arrhythmias.
Ventricular arrhythmias in the postoperative period
require individual evaluation of the circumstances, prior
therapy, and risks of drug treatment. Unless a specific cause
is found and removed, most arrhythmias will recur, requir-
ing drug or device therapy to block the effects. For this rea-
son, symptomatic ventricular arrhythmias (eg, tachycardia
or fibrillation) almost always should be corrected.
Kerstein J et al: Giving IV and oral amiodarone perioperatively for
the prevention of postoperative atrial fibrillation in patients
undergoing coronary artery bypass surgery: The GAP study.
Chest 2004;126:716–24.
Knotzer H et al: Postbypass arrhythmias: Pathophysiology, prevention,
and therapy. Curr Opin Crit Care 2004;10:330–5. [PMID: 15385747]
Mathew JP et al: A multicenter risk index for atrial fibrillation after
cardiac surgery. Investigators of the Ischemia Research and
Education Foundation, Multicenter Study of Perioperative
Ischemia Research Group. JAMA 2004;291:1720–9. [PMID:
15082699]
Palin CA, Kailasam R, Hogue CW Jr: Atrial fibrillation after cardiac
surgery: Pathophysiology and treatment. Semin Cardiothorac
Vasc Anesth 2004;8:175–83. [PMID: 15375479]
Piotrowski AA, Kalus JS: Magnesium for the treatment and pre-
vention of atrial tachyarrhythmias. Pharmacotherapy 2004;24:
879–95. [PMID: 15303452]
 Bleeding, Coagulopathy, & Blood 
Product Utilization
ESSENT IALS  OF  D IAGNOS I S
 Excessive chest tube output.
 Hypovolemia.
 Bleeding from needle puncture sites.
 GI or endotracheal tube bleeding.
 Rash, hematuria.
 Abdominal or groin distention.
 Respiratory compromise.
 Neurologic event.
 Evidence of tamponade.
General Considerations
Hypocoagulable and hypercoagulable states are known com-
plications of all major surgery but are particularly common
following cardiovascular surgery. Both may adversely affect
outcome. Factors contributing to a hypocoagulable state
include the underlying pathology and anatomy of the heart
or great vessel disease itself and a variety of intrinsic coagu-
lation abnormalities owing to hepatic failure, uremia, drugs,
and cardiopulmonary bypass. Hypercoagulability results
from intravascular stasis, endothelial injury, implanted for-
eign bodies, and derangement of the normal anticoagulant
factors by blood loss, surgical complications, cardiopul-
monary bypass, and drugs.
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Etiology
A number of causes combine to make both bleeding and
excessive coagulation two of the most common complica-
tions of cardiovascular surgery. Both are reviewed here
because of the delicate balance between normal coagulation
and pathologic bleeding or clotting. Factors favoring coagu-
lation and decreased bleeding are complicated by the seque-
lae of excessive thrombosis: myocardial infarction, stroke, or
peripheral embolus.
A. Hypocoagulability—The frequency of blood product
administration varies widely among institutions, but the
incidence of blood and coagulation factor loss in cardiotho-
racic surgery patients is significant at all centers. The major-
ity of coronary, valvular, congenital, and ascending aortic or
arch aortic surgeries performed by current techniques use
total cardiopulmonary bypass and systemic anticoagulation
with heparin, with or without hypothermia. This remains
true even with the recent increased popularity of minimally
invasive techniques (“keyhole” surgery) and “beating heart”
(ie, off-pump) surgery. Descending thoracic aortic surgery is
performed frequently using partial bypass or the “clamp and
sew” technique, both of which eliminate or reduce the need
for anticoagulation with heparin. Total cardiopulmonary
bypass circuits consist of priming solutions, pumps, cannu-
las, tubing, reservoirs, filters, and oxygenators. Each of these
components causes a variety of coagulation changes, includ-
ing dilution of all blood components by priming solution,
consumption and impairment of clotting factors and
platelets by contact with component surfaces, release of
cytokines and complement, blood and factor injury by direct
air contact in the operative field, and injury by turbulence
and mechanical stress. Additionally, many operations use
hypothermia, which further decreases the activity of existing
clotting factors. The length of cardiopulmonary bypass and
the degree of hypothermia employed are related to the sever-
ity of these changes.
In addition to these deleterious changes are the effects
produced by heparin. High-dose heparin (100 units/kg) is
necessary for current bypass circuits to prevent circuit
thrombosis. With the use of heparin-bonded bypass circuits,
lower-dose heparin may be as efficacious, although this is
currently the focus of active investigation. The majority of
heparin’s effects are counteracted by protamine administra-
tion after weaning from cardiopulmonary bypass.
Protamine, however, is itself a weak anticoagulant, and the
heparin-protamine complex thus formed impairs platelet
and factor function until cleared from the bloodstream by
the reticuloendothelial system. Occasionally, heparin-
induced antibodies or protamine intolerance complicates the
perioperative course and requires specific therapy as out-
lined below. The development of bypass circuits with
improved biocompatibility (eg, heparin-bonded circuits)
may decrease the heparin—and thus the protamine—
requirements. Further, there is ongoing investigation of
heparin alternatives, particularly direct thrombin inhibitors
(eg, bivalirudin), for use in cardiac surgery. Partial bypass
circuits and shunts that do not require an oxygenator (eg, left
atrial to femoral or descending aorta) can be accomplished
with little or no heparin in many instances. This is particu-
larly important in traumatic aortic injuries, where anticoag-
ulation is usually contraindicated.
Numerous risk factors identify patients more likely to
have hemorrhagic complications and require transfusion
therapy. Platelet inhibitors commonly used for treatment
and prevention of cardiovascular disorders include newer
agents such as the platelet glycoprotein IIb/IIIa receptor
inhibitors (eg, abciximab), although aspirin remains the
most commonly used medication. Platelet function is
reduced dramatically by aspirin for up to 10 days following a
single dose. Nonsteroidal anti-inflammatory agents have
similar effects but usually are more transient. Heparin ther-
apy preoperatively can result in heparin-antibody-platelet
complexes with subsequent thrombocytopenia or occasional
thrombotic complications. Warfarin therapy preoperatively
typically is reversed by withholding warfarin for several days
until measured coagulation tests are normal. Thrombolytics
usually are combined with both heparin and antiplatelet
therapy and have the additional effect of depleting fibrino-
gen levels. Antibiotics occasionally result in vitamin
K–dependent factor loss. High-dose penicillin-like antibi-
otics can cause profound platelet dysfunction.
A number of systemic diseases cause specific defects.
Uremia primarily affects platelet function, and hepatic failure
(primary or secondary to alcohol or congestive heart failure)
results in decreased levels and delayed restoration of clotting
factors. Cyanotic disease is believed to cause factor and
platelet dysfunction. Thrombocytopenia and factor defi-
ciency frequently occur with septicemia associated with endo-
carditis. Von Willebrand’s disease and other inherited platelet
and factor abnormalities usually can be identified by a careful
preoperative history. Poor tissues are associated with malnu-
trition, age, organ failure, advanced endocarditis, and connec-
tive tissue disease. Transfusion reactions are sometimes
difficult to detect but can cause severe coagulopathies.
Reoperations and procedures requiring multiple suture
lines, work on abnormal tissue, and extensive operative dis-
sections increase the risk for bleeding. These include all reop-
erations, aortic dissections and aneurysms, multiple-valve
and combined procedures, complex congenital heart disease,
and patients who require ventricular support.
Prolonged cardiopulmonary bypass, hypothermia, circu-
latory arrest, a history of massive intraoperative blood loss,
and perioperative cardiovascular collapse all decrease the
level and function of platelets and clotting factors. A history
of heparin resistance or a protamine reaction frequently her-
alds a fibrinolytic state, intravascular coagulation, or severe
platelet or factor deficiency.
Recent efforts to modify the bypass circuit with heparin
bonding or to improve surgical techniques (eg, by minimally
invasive or “beating heart” surgery) appear to ameliorate the
inflammation and coagulation abnormalities after cardiac
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surgery. However, even with these advances, current tech-
niques are only partially effective; thus coagulation abnor-
malities continue to be a major cause of morbidity after
cardiac surgery.
B. Hypercoagulable States—Hypercoagulable states are
classically explained by Virchow’s triad of stasis, endothelial
injury, and systemic hypercoagulability. Stasis is present dur-
ing low-flow states, periods of immobility, during certain
arrhythmias, and intraoperatively during vessel or chamber
cannulation or clamping. The risk of major arterial thrombo-
sis and deep venous thrombosis appears to be low in patients
who have undergone full anticoagulation. In procedures such
as descending aortic replacement with heparinless shunts or
without bypass, the risk is similar to that of other thoraco-
tomy and vascular surgery patients. Endothelial injury (ie,
abnormal endothelium) is ubiquitous in cardiovascular sur-
gery and includes coronary anastomotic sites, vascular clamp
sites, tears in aortic dissection patients, conduits, valves,
intravascular or cardiac patches, and numerous arterial and
venous catheters. Systemic hypercoagulability occurs after all
types of major surgery presumably owing to coagulation fac-
tor activation and derangements of factor levels. Naturally
occurring anticoagulants, including proteins A, C, and S and
antithrombin III, are also frequently depleted, particularly in
patients receiving heparin, warfarin, or thrombolytics. In
addition to coagulation abnormalities caused by the disease
process and its treatment, both inherited and acquired hyper-
coagulable states (eg, activated protein C resistance), which
are being recognized increasingly, also may coexist and con-
tribute to a perioperative hypercoagulable state.
Hypercoagulability is less common than hypocoagulabil-
ity but has dramatic consequences. Liver disease, either pri-
mary or secondary (eg, congestive hepatopathy), also may
result in anticoagulant factor depletion. Antifibrinolytics (eg,
aprotinin) and desmopressin can result in a hypercoagulable
state, and their use should be evaluated critically. Heparin-
induced thrombocytopenia (HIT) is an increasingly recog-
nized phenomenon in cardiac surgery and may be a
significant contributor to associated morbidity and mortal-
ity. HIT can result in thromboembolic complications with
significant associated morbidity and mortality. Patients with
prior deep venous thrombosis, pulmonary embolism, or
thrombophlebitis are especially prone to recurrent thrombo-
sis, and early anticoagulation should be considered. Patients
undergoing coronary endarterectomy appear to have an
increased risk of graft thrombosis and usually are started on
antiplatelet agents immediately after surgery. Areas of stasis
are always at risk for thrombosis. These include the deep
veins in immobile patients and the left atrium in those with
atrial fibrillation or akinetic endocardium after a myocardial
infarction. The presence of intravascular foreign bodies may
increase the risk of thrombosis. Catheters, patches, valves,
conduits, balloon pumps, and ventricular assist devices may
cause thrombosis and embolism.
In summary, hemostatic and coagulation abnormalities
are very common in cardiac surgical patients and clearly
contribute to associated morbidity and mortality. The etiol-
ogy often is complicated, involving myriad interrelating fac-
tors. Nonetheless, appreciation of these causative factors is
important to optimize care of the cardiac surgical patient.
Clinical Features
A. Chest Tube Output—Chest tube output varies widely
among patients and over time in individuals. It should be
considered in the context of chest x-ray findings, hemody-
namics, previous outputs, surgical findings, and the patient’s
history. Chest tube output is frequently miscalculated as a
result of autotransfusion, multiple tubes and containers, and
in unrecorded intervals such as during patient transport.
These possible errors should be considered, and a repro-
ducible technique of recording and reporting outputs should
be established. Many valid definitions of excessive chest tube
output exist; in the descriptions that follow, output greater
than 200 mL/h for 2 hours is considered significant, whereas
output greater than 400 mL/h for 2 hours is considered
severe. Chest tube output during the first 2 hours following
operation is extremely variable owing to retained blood in
the pleural space and lack of drainage during transport.
Increased drainage can be expected during this period.
Greater than 200 mL/h of drainage after the initial period
may indicate the need for reexploration. The average chest
tube output over 24 hours is approximately 1200 mL in pri-
mary low-risk coronary artery bypass graft patients, but it
may be significantly higher after more complex procedures.
If chest tubes are clotted or do not communicate with the
bleeding site, cardiovascular instability consistent with hypo-
volemia frequently will be the presenting sign. Inadequate
resuscitation of prior or ongoing severe bleeding presents in
a similar fashion.
Patients with excessive drainage from chest tubes
should be thoroughly examined for diffuse oozing from
other sites such as needle punctures, wounds, and nasogas-
tric tubes. A generalized rash and hematuria should alert
one to the possibility of hemolysis owing to a transfusion
reaction. Other findings suggestive of bleeding include
abdominal or groin distention, respiratory compromise
owing to intrapleural blood, low cardiac output owing to
tamponade, and neurologic changes from hypoperfusion
or intracranial hemorrhage.
B. Thrombosis—An uncommon result of a relative hyperco-
agulable state is prosthetic valve thrombosis. Although most
common in patients not adequately anticoagulated chroni-
cally, valve thrombosis can occur at any time in the hospital
course and requires immediate diagnosis. A new murmur
suggesting outflow or inflow obstruction or valvular insuffi-
ciency should be investigated immediately with echocardio-
graphy. Hemodynamic changes may be severe.
Arterial occlusions owing to primary thrombosis or sec-
ondary to embolus may be subtle or dramatic and are quite
common. The arteries at highest risk for primary thrombosis
are recent coronary or peripheral grafts, peripheral cannula-
tion sites, and arteries with preexisting stenosis. An arterial
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embolus will have a similar presentation, but multiple emboli
commonly occur with combined neurologic, coronary, GI,
and peripheral findings. Subtle neurologic changes are sensi-
tive indicators of arterial thrombi or emboli. Findings associ-
ated with arterial occlusion under normal circumstances may
be blurred by perioperative low-flow states, systemic
hypothermia, and preexisting arterial disease.
Venous thrombosis or venous embolism (ie, pulmonary
embolism) is not seen commonly following cardiac surgery
presumably because of systemic anticoagulation during car-
diopulmonary bypass. Since lower extremity edema follow-
ing cardiac surgery is common, owing to increased
extravascular water and venectomy incisions, lower extrem-
ity venous duplex ultrasound examination is critical for diag-
nosis when deep venous thrombosis is suspected. In
congenital disease, systemic and pulmonary venous patches
and conduits are potential sites for thrombosis.
C. Imaging Studies—The routine postoperative chest x-ray
should be reviewed in any patient with suspected bleeding.
Changes in mediastinal width (corrected for technique),
pleural accumulations, and other lesions causing hemody-
namic compromise can be diagnosed rapidly.
D. Laboratory Findings—Activated clotting times (ACTs)
are obtained routinely to determine the adequacy of antico-
agulation during bypass and to assess its reversal by prota-
mine. A normal ACT is between 100 and 120 seconds.
Anticoagulation during bypass increases it to over 400 seconds.
Limited anticoagulation usually falls in the range of
150–250 seconds.
Thromboelastography gives a rapid assessment of the
adequacy of the coagulation cascade and can help to predict
the subgroup of patients whose bleeding is due to an under-
lying disorder. Thromboelastography also can identify
unsuspected hypercoagulable patients. Five parameters are
measured (Figure 23–2). The specific cause of an abnormal
thromboelastogram can be further investigated by routine
coagulation tests (described below).
Platelet counts should be obtained in patients with long
or complex bypass runs and those with excessive bleeding.
However, platelet dysfunction is common perioperatively
despite adequate platelet numbers and is probably the most
common cause of excessive bleeding. Unfortunately, no sim-
ple reproducible test of in vivo platelet function is currently
available. Template bleeding time can provide some infor-
mation but is not recommended on a routine basis. It
should be obtained in patients with a history of bleeding or
refractory postoperative blood loss. A very prolonged tem-
plate bleeding time (>8 minutes) is suggestive of significant
platelet dysfunction.
Routine coagulation tests—international normalized
ratio (INR),∗ partial thromboplastin time (PTT), thrombin
time (TT), fibrinogen level, and fibrinogen degradation
products (FDPs)—should be obtained in any patient with
severe bleeding who will be receiving factor replacement. The
INR is frequently mildly elevated early postoperatively in all
patients, but an INR greater than 1.7 in a patient with exces-
sive bleeding should be corrected. TT is extremely sensitive
to the presence of heparin, whereas PTT accurately reflects
the level of heparin activity. Fibrinogen deficiency and elevated
FDPs usually indicate excessive fibrinolysis consistent with
consumption coagulopathy. Using the preceding guidelines,
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 Figure 23–2. Quantification of thrombelastograph vari-
ables: r = reaction time (time from sample placement in
the curette until thrombelastograph tracing amplitude
reaches 2 mm [normal range 6–8 min]). This represents
the rate of initial fibrin formation and is related function-
ally to plasma clotting factor and circulating inhibitor
activity (intrinsic coagulation). Prolongation of the r time
may be a result of coagulation factor deficiencies, antico-
agulation (heparin), or severe hypofibrinogenemia.
A small r value may be present in hypercoagulability syn-
dromes. K = clot formation time (normal range 3–6 min),
measured from r time to the point where the amplitude
of the tracing reaches 20 mm. The coagulation time rep-
resents the time taken for a fixed degree of viscoelastic-
ity to be achieved by the forming clot as a result of fibrin
buildup and cross-linking. It is affected by the activity of
the intrinsic clotting factors, fibrinogen, and platelets.
Alpha angle (α°; normal range 50–60°) = angle formed
by the slope of the thrombelastograph tracing from the
r to the K value. It denotes the speed at which solid clot
forms. Decreased values may occur with hypofibrinogene-
mia and thrombocytopenia. Maximum amplitude
(MA; normal range 50–60 mm) = greatest amplitude on
the thrombelastograph trace and is a reflection of the
absolute strength of the fibrin clot. It is a direct function
of the maximum dynamic properties of fibrin and
platelets. Platelet abnormalities, whether qualitative or
quantitative, substantially disturb the MA. A80 (normal
range = MA – 5 min) = amplitude of the tracing 60 min-
utes after MA is achieved. It is a measure of clot lysis or
retraction. The clot lysis index (CLI; normal range >85%)
is derived as A80/MA × 100 (%). It measures the ampli-
tude as a function of time and reflects loss of clot
integrity as a result of lysis. (Reprinted, with permission,
from Mallett SV, Cox DJA: Thromboelastography. Br J
Anaesth 1992;69:307–13.)
∗The INR is the equivalent of the prothrombin time (PT) corrected
for the wide interlaboratory variation in reagents and PT results.
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the results of routine coagulation tests are used to direct
therapy at the specific defects outlined below.
To monitor the proper perioperative anticoagulation in
patients with artificial valves and other indications for sys-
temic anticoagulation, the INR is obtained on a daily basis
before and after beginning warfarin therapy. The INR is
superior to the PT because it minimizes interlaboratory
reagent variation. Appropriate levels for given circumstances
are outlined below. In occasional patients at high risk for
thrombosis or those who may need further invasive proce-
dures postoperatively, heparin is started when deemed safe,
and anticoagulation is maintained at a level appropriate for
the relative risks using PTT assays or the ACT. When HIT is
suspected based on clinicopathologic findings, antibodies to
heparin–platelet factor 4 complex should be sought (ie, HIT
antibody test), and heparin administration is stopped
immediately.
Differential Diagnosis
Bleeding is usually easy to diagnose while chest tubes are in
place if they are not clotted and if they communicate with the
bleeding site. If the patient is hypothermic on arrival to the
ICU owing to surgical techniques, then core rewarming over
the first 1–2 hours can be associated with progressive vasodi-
lation, hemodynamic changes, and a fluid requirement that
can be mistaken for ongoing bleeding. Pleural accumulations
of blood or serous fluid are common, and their drainage can
be alarming but benign, as can mediastinal collections.
Hemolysis is rarely confused with significant bleeding but
should be considered. Intrinsic cardiac dysfunction and con-
gestive heart failure may present with hypotension, hemodi-
lution, and congestion similar to hypovolemia or tamponade,
as can any other cause of shock and hypotension.
Arterial thromboembolic complications easily can be
confused with poor perfusion owing to low-output states
and vasoactive drugs. Vascular spasm is particularly common
with mammary artery grafts and can mimic occlusion.
Spasm of peripheral vessels may be observed. Cholesterol
emboli from an atherosclerotic aortic wall are probably
much more common than thromboemboli owing to dissem-
inated clotting. Cholesterol emboli usually present immedi-
ately postoperatively and are frequently multiple.
Treatment
A. Bleeding—If postoperative bleeding is apparent, one
must immediately ensure the availability of adequate sup-
plies of blood products. Careful fluid balances are crucial and
should be reported in a reproducible fashion at appropriate
intervals. Patients should be rapidly stratified according to
the level of bleeding. Bleeding less than 200 mL/h frequently
stops without additional therapy as the effects of cardiopul-
monary bypass and anticoagulation resolve. Bleeding greater
than 300 mL/h only rarely resolves spontaneously. Severe
bleeding (>400 mL/h) frequently requires operation. If the
patient is hemodynamically stable, evaluation for a nonsurgical
cause of bleeding may be undertaken provided that prepara-
tion for mediastinal exploration is begun and sufficient
blood products are available.
If patients can be stabilized and bleeding is less than mas-
sive, a check for residual heparin can be performed with an
ACT in a few minutes. Protamine then should be adminis-
tered if the ACT is elevated above baseline. A platelet count
should be checked, although an adequate number does not
equate with adequate function. Thromboelastography can
provide an overview of the level of coagulation, and if it is
normal, one should suspect a surgical cause for the bleeding.
Routine coagulation tests can be obtained to guide specific
factor therapy and to rule out ongoing fibrinolysis.
B. Transfusion—Transfusion therapy is guided by the
hemostatic laboratory profile, which should be easily and
rapidly obtained. Usually, platelets are the initial therapy
because they augment platelet function, supply fresh-
frozen plasma, and provide a source of fibrinogen with the
same number of donor exposures. If platelet concentrate
fails to correct the deficit or severe factor deficiencies are
documented, an elevated INR is usually treated with fresh-
frozen plasma, and a diminished fibrinogen is treated with
cryoprecipitate.
C. Other Agents—Antifibrinolytics such as aminocaproic
acid (4–5 g in 250 mL of diluent over 1 hour intravenously,
followed by 1 g/h as a continuous infusion) can be added if
fibrinolysis is significant; however, most agents should be
given preoperatively for full effect. Patients felt to be at high
risk for bleeding should be treated prophylactically.
Desmopressin acetate (0.3 μg/kg intravenously over 15–30
minutes) is particularly effective in the treatment of patients
with platelet deficiency owing to uremia or von Willebrand’s
disease, but it may cause increased graft thrombosis.
Conjugated estrogens and serine protease inhibitors also may
be helpful in treatment of uremic bleeding, although consid-
eration always must be given to the risks and benefits of these
pharmacologic therapies. Recently, recombinant factor V11a
has become available to assist with hemorrhagic complica-
tions following cardiac surgery. Although it has been used
with success in both the adult and the pediatric population,
an evidence-based approach guiding its use is not yet avail-
able. Similar to published reports, we have found it useful in
the setting of continuing hemorrhage and coagulopathy
despite ongoing transfusion of usual products in the absence
of surgical bleeding.
If correction of the clotting mechanism does not stop the
hemorrhage, immediate surgical exploration is mandatory
irrespective of the patient’s hemodynamic status.
D. Thrombosis—Clinical (eg, chest pain and hemodynamic
changes) and electrocardiographic (eg, ST-segment changes)
evidence for coronary graft thrombosis is not infrequently
due to graft spasm, particularly with arterial conduits (mam-
mary arteries). In unresolved cases, echocardiography should
be obtained to evaluate wall motion in the suspect arterial
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territory. Antispasmodics should be instituted (eg, calcium
channel blocking agents, nitroglycerin, or phosphodiesterase
inhibitors) while diagnostic evaluation continues. Many cen-
ters give antispasmodics (eg, calcium channel blockers) pro-
phylactically in an attempt to avoid spasm. If wall motion
abnormalities are documented and persist with antispas-
modics, angiography may be indicated to confirm graft
patency. Reexploration of grafts then is considered on an
individual basis.
Peripheral thromboembolism is not uncommon in open-
heart surgery and occurs in the presence of a left ventricular
thrombus, preexisting vascular disease, and injuries from
prior angiography. Additionally, peripheral emboli and
thrombosis are frequent in patients with intravascular pros-
theses or devices, particularly intraaortic balloon pumps and
prosthetic valves. All unnecessary foreign bodies should be
removed as soon as possible. Patients should be stratified
according to risk of thrombosis, and those who subsequently
have a thromboembolism despite one level of anticoagulation
should be increased to the next level of anticoagulation, and a
thorough evaluation of why they failed should be undertaken.
Patients with a high risk of thrombosis, delayed onset of long-
acting anticoagulants (eg, warfarin), or evidence of current
thromboembolism should be treated with rapid-onset anti-
coagulants (eg, heparin) with appropriate consideration of
the risk of bleeding in the perioperative period.
All patients with unexplained or recurrent thrombotic
episodes should be evaluated for acquired or inherited
thrombophilias, including (at least) resistance to activated
protein C (eg, factor V Leiden or HR2 haplotype), heterozy-
gosity or homozygosity for factor V Leiden or G20210A
prothrombin mutation, hyperhomocysteinemia, factor VIII
levels, and the presence of lupus anticoagulant. If HIT is
suspected, all heparin should be eliminated. If ongoing
anticoagulation is needed, then direct thrombin inhibitors
or platelet inhibitors can be used until warfarin levels are
adequate. Antithrombin III deficiency can be treated tem-
porarily with fresh-frozen plasma and long term with war-
farin. The treatment of protein A, C, or S deficiency is
approached on an individual basis. Hyperhomocysteinemia
is treated indefinitely with folic acid, supplemented with
vitamins B6 and B12 if homocysteine levels do not normal-
ize on folic acid alone.
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 Cardiopulmonary Bypass, Hypothermia,
Circulatory Arrest, & Ventricular Assistance
ESSENT IALS  OF  D IAGNOS I S
 Decreased peripheral perfusion.
 Altered end-organ function.
 Hypothermia.
 Coagulopathy.
 Hemolysis.
 Edema, localized or generalized.
General Considerations
More than 30 years ago, the introduction of cardiopul-
monary bypass—and therefore the ability to interrupt and
alter the circulation locally and systemically—revolutionized
the approach to cardiothoracic and other major surgery of
vascular structures. Continued advances in technique have
made cardiopulmonary bypass well tolerated, but untoward
effects still occur, particularly at the extremes of age. Despite
the recent popularity of minimally invasive and off-pump
techniques in cardiac surgery, full cardiopulmonary bypass is
still used for the majority of cardiac surgical procedures in
the United States. An understanding of the pitfalls of car-
diopulmonary bypass are crucial to realizing its benefits.
Both total and partial bypass circuits are used on a rou-
tine basis and are primed with crystalloid, colloid, or blood if
estimated hemodilution will be severe. Total cardiopul-
monary bypass begins with drainage of systemic venous
blood into a reservoir via a venous cannula. A separate
pump-driven cardiotomy suction device can be added to
return shed blood from the operative field to the same reser-
voir. Blood then is actively pumped through an
oxygenator/heat exchanger and back to the systemic circula-
tion via the arterial cannula. A number of additional special-
ized circuits deliver cardioplegia, provide pulmonary venous
and collateral drainage (vents), or perfuse localized areas.
Arterial and venous cannulas are usually placed in the
ascending aorta and right atrium, but a number of locations
are used on an individual basis (Figure 23–3). Partial bypass
circuits include venovenous bypass (usually with oxygenator),
left atrioarterial or right atriopulmonary bypass or ventric-
ular assist (usually without oxygenator), and simple arte-
rioarterial and venovenous shunts, with or without pumps
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or oxygenators. Severe adverse effects of cardiopulmonary
bypass strictly owing to the circuit itself are rare but include
massive air embolism, aortic dissection from cannulas or
clamps, general or localized venous congestion from kinked
or misplaced return lines; severe hypoxia from oxygenator
dysfunction; and a number of unusual but significant events.
One or more lesser effects of the cardiopulmonary bypass cir-
cuit are nearly universal. Microscopic air, platelet, and cho-
lesterol emboli; direct blood cell trauma; and endothelial
injury may occur secondary to mechanical pump or cannu-
lation injury.
Blood contact with the artificial surfaces of the circuit
causes a variety of undesirable effects, including systemic
inflammation (ie, elaboration of cytokines and leukocyte
activation), complement activation, coagulation abnormali-
ties, and endothelial cell activation. Indeed, these changes
contribute to the morbidity and mortality of cardiac sur-
gery. Full anticoagulation with heparin (300 units/kg) is
required in all circuits to prevent widespread coagulation,
although lower anticoagulation protocols may prove equally
efficacious as the biocompatibility of the circuits improves
(ie, heparin bonding). Partial-bypass circuits—and some
full-bypass circuits with heparin-bonded components—
frequently can be maintained with little or no systemic anti-
coagulation depending on flow, component surfaces, and
the effects of the pump, filters, and special devices. Circuit
priming solutions and added fluids cause hemodilution,
which is frequently helpful in diminishing blood cell loss
but may be excessive in patients with low blood volumes. In
selected patients with generous prebypass blood cell vol-
umes, whole blood or blood components may be removed
prior to bypass for retransfusion postoperatively. This
restores coagulation factor activity and reduces homologous
blood product utilization.
Perfusion during total cardiopulmonary bypass is almost
always nonpulsatile, and flow is maintained at a level to
ensure adequate end-organ perfusion based on metabolic
demands. Perfusion during partial bypass or ventricular sup-
port may be pulsatile or nonpulsatile depending on the cir-
cuit and device. Flows in these local circuits are determined
by arterial resistances in the native perfused and mechani-
cally perfused beds, left- and right-sided pressures during
ventricular support, inflow limitations, technical considera-
tions, and device capabilities. Measured pump flows are
felt to be more crucial than blood pressure in patients
without vascular stenoses. Typical flows at normothermia
 Figure 23–3. Cannulation sites used commonly in connecting the extracorporeal circuit. Venous blood is drained
through tubes introduced into both venae cavae. Oxygenated blood is returned to the arterial system through a tube in
the aorta. (Reproduced, with permission, from Way LW (ed), Current Surgical Diagnosis & Treatment, 10th ed. Originally
published by Appleton & Lange. Copyright © 1991 by The McGraw-Hill Companies, Inc.)
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are 2.4 L/min/m2, which sustains systemic blood pressure at
greater than 40 mm Hg.
Determinants of tissue metabolic demand include tissue
activity (primarily skeletal and cardiac muscle), temperature,
tissue mass, and preexisting metabolic debt. Certain organs are
intrinsically more susceptible to inadequate flows. Brain and
spinal cord, heart, liver, kidneys, GI tract, skeletal muscle, and
skin tolerate warm ischemia for periods varying between a few
minutes and many hours. Metabolic activity of cardiac muscle
can be markedly decreased with hyperkalemic or other forms of
arrest. Skeletal muscle relaxants vastly decrease the metabolic
demands of skeletal muscle. Barbiturates may decrease CNS
metabolic demands. In addition to minimizing contraction of
cardiac and skeletal muscle, hypothermia is often added to
extend the period of safe hypoperfusion. Systemic hypothermia
further attenuates metabolic demands and may be used during
certain cardiac surgical procedures (eg, coronary artery bypass
grafting) to minimize the sequelae of bypass or circulation
arrest. The routine use of systemic hypothermia during cardiac
surgery remains controversial. The length of time that decreased
or arrested circulation is tolerated varies inversely with temper-
ature, with CNS protection being the limiting factor. At core
temperatures near or below 18°C, circulatory arrest may be well
tolerated for periods exceeding 1 hour in extreme circum-
stances. However, the safety of the CNS is not guaranteed owing
to temperature variations and undesirable metabolic activity.
Following cardiopulmonary bypass, patients usually are
anemic because they have gained significant extracellular and
intracellular fluid. The combined effects of anesthesia, sur-
gery, and cardiopulmonary bypass produce hypothermia and
coagulopathy. The latter is caused by factor loss and activa-
tion, hemodilution, and residual heparin and protamine.
Ongoing effects are due to reperfusion of tissues inadequately
protected or congested during cardiopulmonary bypass. In
addition, a number of drugs, anesthetics, blood products, and
ongoing insults from cardiac instability make the period
immediately following cardiopulmonary bypass unique.
All organs are potential sites of dysfunction, and each
should be examined as it becomes accessible to evaluation.
Cardiovascular and renal complications are evident almost
immediately. Neurologic function frequently is slow to return
secondary to anesthetics, particularly in the elderly, but is
probably the most sensitive measure of the adverse effects of
cardiopulmonary bypass. Indeed, much of the impetus for
off-pump techniques was directed toward minimizing the
neurologic sequelae that occur frequently after bypass. Short-
term memory loss, focal defects, choreoathetoid motions,
paraplegia, confusion, worsening of previous neurologic
deficits, seizures, and visual changes occur frequently and are
presumably due to edema, microemboli, hypoperfusion,
residual anesthetics, and drugs and the systemic effects of car-
diopulmonary bypass. GI function usually returns within
24 hours, and persistent GI complaints are rare. The extrem-
ities may be hypoperfused individually or in concert and
occasionally are sufficiently ischemic to result in tissue
(usually muscle) loss.
A. Circuit-Related Complications—Circuit-related compli-
cations are infrequent following cardiac surgery but are seri-
ous when they occur. Full knowledge of the type, location,
and variations of the cannulas used during bypass or ventric-
ular support is essential to evaluate subsequent problems.
Complications include aortic dissection from ascending aor-
tic cannulation; arterial occlusion from peripheral cannula-
tion; congestion of the upper body, lower body, or both from
venous cannulation mishaps; and obstruction, leakage, and
cavitation of indwelling cannulas owing to kinking, disrupted
connections, or excessive pump flows. Monitoring lines are
frequently placed in unusual locations, particularly in
patients with congenital disease and in those with ventricular
assist devices. Familiarity with their care and use is essential.
Certain bypass components are related more frequently
than others to adverse effects. Oxygenators are either of the
membrane or bubble type, with a trend nowadays toward
membrane oxygenators because of a perception that they are
associated with fewer deleterious effects because a “mem-
brane” separates blood from air. Roller pumps or centrifugal
pumps are used for total cardiopulmonary bypass.
Centrifugal pumps are used more commonly because there
is less blood component trauma and less chance of massive
air embolism. Care providers of patients with ventricular
assist devices should familiarize themselves with the
anatomy, connections, components, and monitoring associ-
ated with individual patient situations. The complications in
these patients secondary to circuit failure are characteristi-
cally immediate and severe. A familiarity with typical oper-
ative circuits also provides excellent background for
diagnosis of related problems.
B. Coagulation Parameters—Profound heparin anticoagu-
lation is required for cardiopulmonary bypass. Protamine is
used intraoperatively to reverse the heparin effect.
Inadequate anticoagulation results in consumption coagu-
lopathy; with inadequate protamine, rebound heparinization
may occur. Significant protamine reactions are infrequent
but may result in hypotension, coagulopathy, pulmonary
hypertension, and massive pulmonary edema.
C. Crossclamp Time and Hypothermia—Crossclamp time
primarily applies to cardiac procedures, but any organ that
was isolated from systemic cardiopulmonary bypass support
should be considered at special risk. With current organ pro-
tection techniques, crossclamp time does not always repre-
sent ischemia and may in fact be beneficial, but the
circumstances and length of altered organ perfusion should
be considered.
The degree of hypothermia and the length of decreased
or absent systemic perfusion should be established to raise
the index of suspicion for complications of these interven-
tions. At the extremes of age, systemic effects are common, as
outlined below. The extent of rewarming is variable, and
ongoing temperature changes have significant effects.
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D. Fluid and Drug Administration—To monitor the course
of the operation and to assist with postoperative fluid
management, both perfusion and anesthesia records
should be evaluated. Intake and output fluids—including
blood loss, hemoconcentrators, urine output, red blood
cell scavenger, acute blood donations, cardioplegia, chest
tube autotransfusion, rapid infusers, and priming solu-
tions—should be considered carefully.
Inotropes, pressors, vasodilators, inhaled and intravenous
anesthetics, paralyzing agents, antiarrhythmics, anticoagu-
lants, and antibiotics are a routine part of cardiopulmonary
bypass and have altered effects, kinetics, and distribution vol-
umes in the bypass circuit itself and in cold, artificially per-
fused organs. As in all critically ill patients, effects of current
and past drugs should be considered as the cause of a variety
of complications.
E. Surgical Details—The specifics of the operative proce-
dure, particularly in unusual cases, are essential to under-
standing ongoing problems. Complex aortic procedures,
congenital disease, valvular disease, and noncardiac surgery
requiring cardiopulmonary bypass frequently have unique
complications secondary to old and new anatomy and
physiology.
Diagnosis
A. Peripheral Perfusion—Alterations in generalized or local
perfusion can result from prior cardiopulmonary bypass or
ongoing cardiac support with assist devices. Peripheral
pulses should be examined immediately following operation
or device placement so that the severity of subsequent
changes can be appreciated fully. Peripheral perfusion is fre-
quently decreased immediately following cardiopulmonary
bypass owing to vasoconstriction from hypothermia but
should return to normal when normothermia is reached.
A general evaluation of all major tissue beds should be
performed early. Examination of the circulation, including
peripheral pulses, ankle/brachial pressure indices, duplex
examinations of vascular beds with abnormal perfusion,
ophthalmologic examination, and angiography, should be
pursued early when localized changes are noted.
Cardiovascular parameters, including filling pressures, out-
puts, vascular resistances, and oxygen saturations, should be
reviewed. Pulmonary function may change dramatically with
reperfusion, and blood gases—particularly PaCO2 levels—
increase rapidly with rewarming and inactivation of muscle
relaxants. Renal function is normally quite brisk owing to
excess fluid and mannitol administration surrounding the
period of cardiopulmonary bypass. Low urine output may
indicate renal hypoperfusion. Neurologic dysfunction is
present in almost all patients to a mild degree when evalu-
ated by psychometric testing. Single and multifocal CNS
defects result most commonly from thromboembolism and
hemorrhage. Watershed defects frequently are due to inade-
quate local or generalized flows. More severe psychometric
defects, seizures, blindness, and choreoathetoid movements
may result from air embolus, microparticulate emboli,
hypoxia, profound anemia, or hypoperfusion. Paraplegia
from regional hypoperfusion, aortic dissection, or embolism
is rarely seen with full cardiopulmonary bypass but may
occur in up to 40% of patients with complex thoracoabdom-
inal procedures with or without artificial support. GI and
hepatic symptoms, including abdominal pain, ileus, ascites,
and GI bleeding, may represent prior or ongoing venous
congestion or arterial hypoperfusion.
B. Hypothermia—Numerous local temperatures are meas-
ured during bypass. Core temperature should be evaluated
postoperatively, and other localized temperatures (ie, axillary
and rectal) should be correlated.
C. Coagulopathy—Coagulopathy and hemolysis usually are
most evident during or immediately after cardiopulmonary
bypass, respectively, and both may herald a complicated
post–cardiopulmonary bypass course. Examine for diffuse
bleeding, blood-tinged urine, evidence of abnormal throm-
bosis, or abnormal laboratory values.
D. Edema—Differential edema and severe generalized
edema should be noted and potential reversible mechanical
causes (venous obstruction) evaluated. Accurate pre- and
postoperative weights are essential for evaluating fluid accu-
mulations and losses, which may represent 10–20 L in
extreme cases.
E. Laboratory Studies—Coagulation studies, free hemoglo-
bin, amylase, liver function tests, and arterial blood gases
may delineate secondary adverse effects of cardiopulmonary
bypass on tissue beds.
F. Imaging Studies—A chest x-ray should be examined
postoperatively for retained foreign bodies, catheter position,
ventricular support cannula positions, chest tubes, valves,
pulmonary parenchymal and pleural abnormalities, medi-
astinal contour, aortic calcification and evidence of displace-
ment, endotracheal tube position, and if applicable,
intraaortic balloon pump placement.
G. Mechanical Problems—In patients with ongoing ven-
tricular support, erratic pump flows or increased tubing
motion may herald cannula obstruction or pump failure. Air
in the circuit is always an emergency, and although rare, it
should be excluded. Left- and right-sided chamber pressures
are vitally interdependent in patients being maintained on
ventricular assist devices because the normal physiologic
homeostatic mechanisms do not apply. Filling, arterial, and
line pressures require constant vigilance.
Differential Diagnosis
Secondary organ changes owing to congenital, valvular, and
coronary disease are frequently superimposed on—and
magnified by—the effects of cardiopulmonary bypass. An
appreciation of the preexisting and subsequent anatomy and
physiology is essential. Sepsis, either preexisting or new,
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mimics almost all the inflammatory, organ failure, and
embolic effects of cardiopulmonary bypass, as do many ana-
phylactic or cardiovascular drug reactions and hemolysis.
Superimposed myocardial infarction during cardiopul-
monary bypass may have profound systemic effects.
Treatment
A. Minimize Support Period—Decreasing the level and
time of artificial circulation is the most direct treatment but
is rarely feasible. Changing the type of support device will be
possible occasionally, and many available pulsatile support
devices are tolerated for long periods of time. As mentioned
earlier, improvements in the biocompatibility of the bypass
circuit blunt the systemic coagulation and inflammation
abnormalities and may improve clinical endpoints. Despite
these “equipment” improvements, they are only partially
effective, and optimal therapy in the future probably will
combine multiple strategies for optimal outcomes.
B. Restore Perfusion—Organs with documented inade-
quate flow should have perfusion restored by moving cannu-
las, administering vasodilators locally, performing peripheral
bypass grafts where appropriate, or performing thromboem-
bolectomy.
C. Correct Hypothermia—Correction of hypothermia should
be ongoing with warmed intravenous fluids, radiant heat,
and heated ventilatory gases. However, the efficacy of all
these maneuvers is very limited, and in cases of extreme
hypothermia, consideration should be given to direct blood
rewarming with a partial bypass circuit and heat exchanger.
During rewarming, fluid requirements may be substan-
tial secondary to vasodilation and ongoing losses. The sig-
nificant cellular and extracellular edema that accumulates
demands vigorous diuresis as soon as feasible to prevent the
increased cardiovascular burden of increasing preload as
fluid is mobilized. Robust urine output of 300–500 mL/h
may be necessary to keep pace with fluid administration and
mobilization.
D. Correct Coagulopathies—Coagulopathies frequently cor-
rect spontaneously with rewarming, but the occasional
patient with ongoing fibrinolysis, significant factor deficits,
or ongoing bleeding needs specific therapy as outlined in the
section on coagulation.
E. Organ Dysfunction—Patients who develop myocardial
dysfunction, neurologic or ophthalmologic deficits, acute
respiratory distress syndrome (ARDS), pancreatitis, general-
ized inflammatory states, renal failure, and extremity
ischemia temporally related to cardiopulmonary bypass are
treated in fashion similar to what is available for these mal-
adies caused by other insults. Cardiopulmonary bypass
should not be assumed to be the cause of these deficits until
other primary causes are excluded.
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 Postoperative Low-Output States
ESSENT IALS  OF  D IAGNOS I S
 Diaphoresis.
 Cyanosis or pallor.
 Poor peripheral perfusion.
 Thready pulse; tachycardia or bradycardia.
 Tachypnea.
 Venous congestion.
 Pulmonary rales.
 New or increased murmurs.
 Mental status changes.
 Anxiety.
 Low urine output.
General Considerations
Cardiac insufficiency may complicate the course of postop-
erative cardiac surgical patients. Intrinsic myocardial dys-
function, valvular disease, and congenital anomalies
frequently coexist with extrinsic cardiac factors and compli-
cate the diagnosis and therapy of shock in this group of
patients. Rapid diagnosis and reversal of decreased cardiac
output are essential to avoid secondary organ damage.
Etiology
A. Intrinsic Factors—The preoperative cardiac and vascular
anatomy, rhythm, ventricular function (diastolic and sys-
tolic), vascular resistances, valvular gradients and insufficien-
cies, coronary anatomy, and prior interventions should be
reviewed and correlated. This cannot be overemphasized,
particularly in patients with cardiomyopathy, acute coronary
insufficiency, valvular heart disease, congenital cardiac
lesions, pulmonary hypertension, ventricular outflow
obstruction, or ventricular failure.
B. Cardiomyopathy—Cardiomyopathy is conveniently clas-
sified by etiology as ischemic or nonischemic and by type as
dilated or nondilated. Dilated cardiomyopathy is character-
ized by loss of muscle mass or function that is compensated
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for by moving residual myocardial function farther along the
Starling curve, that is, by increasing myofibril length. Resting
cardiac output is preserved, but systolic reserve is limited,
and compliance is decreased. These cardiomyopathies fre-
quently are associated with ventricular dilatation, areas of
dyskinesis, mitral incompetence, cardiac rhythm distur-
bances, pulmonary hypertension, and secondary right ven-
tricular failure. Hypertrophic disease usually is nondilated
and causes decreased diastolic function with small chamber
size, increased left ventricular mass, functional outflow
obstruction, and elevated filling pressures. Many patients
with cardiomyopathy undergo revascularization, arrhythmia
surgery, valvular replacement, or eventual transplant.
C. Acute Coronary Insufficiency—Preoperative acute coro-
nary insufficiency frequently necessitates emergent revascu-
larization. This may be complicated by reperfusion injury,
residual ischemia, and myocardial infarction with secondary
mitral regurgitation, ventricular rupture, or ventricular sep-
tal defect. Reperfusion injury results in decreased ventricular
compliance, decreased systolic and diastolic function, and
rhythm disturbances (eg, atrial fibrillation and flutter, pre-
mature atrial contractions, ventricular fibrillation, ventricu-
lar tachycardia, and heart block). Residual ischemia causes
similar derangements that may fluctuate with the level of
ischemia. Acute papillary muscle rupture with severe mitral
regurgitation, ventricular free wall rupture, and ischemic
ventricular septal defects can occur pre- or postoperatively.
These events usually are associated with large transmural
infarcts and usually present acutely with severe compromise.
D. Valvular Heart Disease—Valvular heart diseases fre-
quently leave residua that predispose to poor cardiac func-
tion despite correction of the valvular lesion. Aortic stenosis
leads to left ventricular hypertrophy and severely reduced
ventricular compliance early in its course. Ventricular dilata-
tion and reduced systolic function are frequent late conse-
quences. Associated coronary artery disease or left
ventricular outflow tract obstruction also may contribute to
poor hemodynamics in patients with aortic stenosis. Aortic
insufficiency classically evolves into a dilated, hypokinetic
left ventricle with decreased compliance. Aortic valve disease
of both types is often complicated by pulmonary hyperten-
sion and right-sided heart failure. With mitral valve disease,
left ventricular dynamics may be near normal (eg, rheumatic
mitral stenosis) or severely depressed (eg, ischemic mitral
regurgitation). Mitral stenosis frequently coexists with a nor-
mally functioning ventricle preoperatively; however, with
relief of inflow obstruction, ventricular overload may occur.
Mitral regurgitation is often associated with decreased left
ventricular function and dilatation preoperatively. Function
may worsen in the early postoperative period because of an
acute increase in afterload and anatomic changes. Left ven-
tricular function is usually less compromised following
mitral valve commissurotomy or repair, but prosthetic
mitral valve replacement changes ventricular dynamics sig-
nificantly and in many cases severely impairs left ventricular
function. Other confounding factors include left ventricular
outflow obstruction following mitral valve repair or replace-
ment, pulmonary hypertension, right ventricular failure, and
tricuspid regurgitation.
E. Congenital Lesions—Congenital lesions are beyond the
scope of this discussion, but an assessment of preoperative
and postoperative anatomy and function is essential to treat-
ment. Specifically, both the systemic status and the pul-
monary (if present) ventricle’s functional state should be
assessed, preoperative and residual shunts quantitated, vas-
cular resistances determined, outflow and inflow obstruc-
tions documented, and associated pulmonary and vascular
changes considered. Ventricular function may be compro-
mised for a variety of reasons. Patients with a right ventricle
as a systemic chamber have minimal reserve function and are
a subset of the cardiomyopathies mentioned earlier.
Congenital lesions may be associated with coronary compro-
mise and secondary loss of ventricular function (eg, tricus-
pid atresia with intact ventricular septum). In patients
without a pulmonary ventricle (eg, postoperative Fontan
patients), supranormal systemic ventricular function, low
systemic-sided filling pressures, and low pulmonary vascular
resistance all must be maintained to promote passive pul-
monary flow. Patients with left ventricular outflow obstruc-
tion (eg, coarctation or aortic stenosis) frequently have
significant left ventricular hypertrophy and dysfunction.
Shunts at multiple levels are also common. Residual shunts
following correction of congenital anomalies may be benefi-
cial by permitting decompression of high filling pressures and
maintenance of cardiac output (eg, following Fontan repair)
or may cause significant compromise owing to ventricular
overload or arterial desaturation. In view of these complexi-
ties and their interrelationships, a detailed understanding of
the function of each ventricle, the volume load presented to
each chamber, and the configuration of outflow and inflow is
essential to proper management.
F. Arrhythmias—Arrhythmias may complicate the postop-
erative course and produce low-output states.
Supraventricular rhythms, including atrial fibrillation and
flutter, occur in up to 30% of open-heart surgery patients
and are particularly detrimental in the presence of decreased
ventricular compliance or marginal functional reserve.
Metabolic derangements, atrial ischemia, atrial dilatation,
and sympathetic activity all contribute to supraventricular
arrhythmias. Similarly, ventricular arrhythmias are com-
mon, particularly in dilated cardiomyopathies, hypertrophic
disease, and ischemia. Finally, bradycardias and conduction
disturbances are common, particularly at the extremes of age.
G. Pulmonary Disease—Pulmonary and pulmonary vascu-
lar disease may be superimposed on any of the preceding
lesions. Chronic left ventricular failure compromises lung
compliance, airflow, and oxygenation. Pulmonary vascular
resistance is frequently elevated and may or may not be
reversible. Vascular rings and slings may directly compromise
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pulmonary blood flow or gas exchange. Additionally, some
conditions may be associated with decreased lung parenchyma
or vasculature (eg, endocardial cushion defects, tetralogy of
Fallot, and pulmonary atresia).
H. Extrinsic Factors—Pericardial tamponade, tension pneu-
mothorax, inadequate or excessive resuscitation, and circu-
lating myocardial depressants all should be considered
during evaluation of inadequate cardiac output.
Resuscitation is frequently inadequate during the early post-
operative course. Patients with ongoing blood loss, decreased
ventricular compliance, perioperative infarcts, significant
organ damage, or complicated cardiopulmonary bypass
courses have particularly high fluid requirements, as do those
who are rewarming following hypothermic bypass or circu-
latory arrest. Overzealous fluid administration also can result
in acute cardiac insufficiency, especially in patients with
exceptionally low ejection fractions. This delicate balance
between inadequate and excessive fluid administration pro-
vides the basis for invasive hemodynamic monitoring in
patients with complex problems.
1. Tamponade—Tamponade may result from both early
bleeding and late pericardial fluid accumulation. Localized
collections can result in atypical but equally dangerous pre-
sentations. The causes of tamponade are reviewed in the sec-
tions on postoperative hemorrhage and postpericardiotomy
syndrome.
2. Tension pneumothorax—Tension pneumothorax
should be excluded in any patient with hemodynamic com-
promise. Myocardial depressants are frequently active peri-
operatively. Calcium channel blockers, β-blockers,
antiarrhythmics, and anesthetic agents all contribute to
decreased myocardial performance. Endogenous substances
such as interleukin 6 (IL-6) also may play a role in patients
with long cardiopulmonary bypass runs or systemic injury
from prolonged hypoperfusion.
Clinical Features
A. Symptoms and Signs—Invasive hemodynamic moni-
toring with pulmonary artery catheters is valuable to assess
cardiopulmonary physiology and guide therapy.
Confounding problems specific to cardiac surgery patients
are due to the frequent presence of endotracheal tubes, resid-
ual anesthetic agents, and continued “normal” residual
effects of cardiopulmonary bypass. Ongoing hemorrhage,
pulmonary insufficiency, metabolic derangements, volume
shifts, and temperature changes all contribute to variable
cardiac performance.
B. Imaging Studies—Chest radiographs should be
obtained early and evaluated for evidence of enlarging car-
diac silhouette (eg, tamponade), pulmonary venous conges-
tion (eg, congestive heart failure and tamponade), pleural
fluid (eg, ongoing bleeding), mediastinal shift, and extrapul-
monary air (eg, tension pneumothorax). Chest radiographs
need to be evaluated in comparison with previously obtained
films to highlight changes and permit correlation with a
changing clinical course.
C. Echocardiography—Surface or transesophageal echocar-
diography can be invaluable in specific clinical circumstances.
Surface echo is usually performed initially. If necessary, trans-
esophageal studies can be added to provide additional infor-
mation about posterior structures, particularly the mitral
valve and thoracic aorta. Echocardiography is useful in the
evaluation of tamponade because it can display diffuse or
localized fluid collections as well as shift and paradoxical
motion of the ventricular septum, which suggest hemody-
namic compromise. In addition, echo can confirm poor ven-
tricular function, which occurs with cardiomyopathy or global
ischemia. It visualizes localized wall motion abnormalities
owing to new or recurrent local ischemia. Ventricular filling
and insufficient or excess volume resuscitation also can be
evaluated. Echo is also helpful in evaluating left ventricular
outflow obstruction, seen frequently present in patients with
hypertrophic cardiomyopathies and after mitral or aortic valve
repair or replacement. New or residual valvular disease, dissec-
tion of the aorta, and septal defects also can be visualized.
D. Electrocardiography—Electrocardiographic tracings
should be compared with preoperative and earlier postoper-
ative examinations for evidence of ischemia, rhythm and rate
disturbances, or diffuse changes sometimes seen with peri-
cardial hematoma and pericarditis.
E. Hemodynamic Monitoring—Cardiac output, central
venous pressure, and pulmonary artery and pulmonary wedge
pressures, as determined with a thermodilution pulmonary
artery catheter, are invaluable for assessment of cardiovascular
status at the bedside. Indeed, these data are often the earliest
and easiest to obtain, further underscoring their importance.
A cardiac index of less than 2.0 L/min/m2 always requires
prompt evaluation and correction. Even higher indices may be
inadequate in specific situations. Inaccurate output measure-
ments can occur if incorrect calibration constants are used or
tricuspid regurgitation is present. If measured values appear
inappropriate to the clinical situation, their validity should be
confirmed by venous O2 saturation measurement or echocar-
diography (see below). Central pressures should be evaluated
early in the course of low-output states.
F. Oxyhemoglobin Saturation—Venous oxyhemoglobin
saturation can be measured intermittently by transcatheter
aspiration or continuously by fiberoptic pulmonary artery
catheters. Central venous (right atrial) oxygen saturations
typically are measured, and resting values are usually 75%.
Assuming a 100% arterial saturation, this represents unload-
ing of one-fourth of the available oxygen. Venous desatura-
tion usually indicates inadequate tissue perfusion whether or
not the cardiac index is depressed. Oxygen content calcula-
tions from specific chambers also can be used to determine
intracardiac shunts and flows.
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Differential Diagnosis
Intravascular volume changes, including hypovolemia,
ongoing bleeding, and overload with impaired right or left
ventricular function, all can result in acute cardiovascular
insufficiency. Extrinsic factors (eg, pericardial tamponade,
tension pneumothorax, or hemothorax) and intrinsic cardiac
compromise (eg, ventricular free wall rupture, acute ventric-
ular septal defect, papillary muscle rupture, prosthetic valve
dehiscence or thrombosis, coronary ischemia, and arrhyth-
mias) also can be confused with low-output syndromes.
Systemic hypoxia, hypocalcemia, acidosis, sepsis, and organ
ischemia occasionally can present initially as a low-output
state in the postoperative period. Malfunctioning arterial
catheters and electronic monitors occasionally prompt a
search for the cause of hypotension in a normal patient.
Treatment
A. Supportive Measures—As with any critically ill patient,
the first objective is to maintain adequate oxygen delivery
and pH control by optimizing ventilation. If the cause of the
low-output state is not easily identifiable and remedied, then
early reintubation, while the patient is still hemodynamically
resuscitatable, is preferable to subsequent emergent interven-
tion. If an endotracheal tube is already in place, its function
and position should be confirmed rapidly by assessing breath
sounds, ventilatory settings and pressures, and inspired O2.
Pulse oximetry and blood gas analysis should be obtained as
quickly as possible, as well as electrolytes and hematocrit.
Reversible causes (eg, respiratory disorders and electrolyte
imbalance) should be corrected promptly.
During evaluation for specific causes, the circulation should
be supported aggressively, and this is best accomplished by a
systematic approach to appraisal of the hemodynamic status of
the patient. As mentioned earlier, adequate oxygenation and
ventilation must be ensured. Preload then should be optimized.
The virtues of prompt administration of fluids, when appro-
priate, cannot be overemphasized. Inadequate volume admin-
istration is common in patients who are rewarming following
a period of hypothermia, who are being treated with vasodila-
tors, or who have poor left or right ventricular compliance. In
these circumstances, prompt fluid administration is all that is
required for full restoration of cardiovascular stability. In addi-
tion, patients with tamponade frequently respond to fluids
while preparations for definitive therapy are being made.
Conversely, in the patient who has gradually become volume-
overloaded, with subsequent impairment of ventricular per-
formance, it is important to treat with inotropes and afterload
reduction instead of with additional volume. Patients with very
poor ventricular function are prone to both hyper- and hypo-
volemia. Occasionally, some of the classic signs of hypov-
olemia, such as increased creatinine and decreased cardiac
output, are the result of excessive fluid administration and sub-
sequent ventricular impairment.
Heart rate and rhythm disturbances then should be
assessed and treated as outlined in Chapter 22. Contractility
may be enhanced with inotropic agents, with particular atten-
tion to right ventricular status. Lastly, afterload may be reduced
with vasodilators to further improve cardiac output and sys-
temic perfusion. Although most inotropes are described else-
where in the text, a few warrant further comment.
There are a number of inotropic drugs that are used com-
monly to support the failing heart—including dopamine,
dobutamine, epinephrine, and phosphodiesterase inhibitors
(eg, milrinone). While these agents are all effective for improv-
ing the contractile state of the myocardium and have variable
effects on heart rate and afterload, their effects are exerted pri-
marily on the left ventricle. More recently, the importance of
adequate right ventricular function to cardiovascular success
has been appreciated, as well as the sensitivity of the right ven-
tricle to increased afterload, which is manifested as cardiovas-
cular failure. Accordingly, pharmacologic agents that provide
physiologic benefit to the right ventricle—in the context of
perioperative low cardiac output syndrome—including phos-
phodiesterase III inhibitors (eg, amrinone and milrinone),
inhaled nitric oxide (NO), and the increasingly used agent
recombinent human B-type natriuretic peptide (BNP, ie,
nesiritide [Natrecor]) have received attention.
The phosphodiesterase III inhibitors have been termed
inodilators because of their ability to improve myocardial
contractility while simultaneously causing vascular smooth
muscle relaxation. As a result, these agents have consistently
been shown to improve cardiac index and decrease systemic
vascular resistance (SVR) and pulmonary vascular resistance
(PVR). Furthermore, they cause little or no increase in
myocardial oxygen consumption and have almost no effect
on systemic blood pressure and heart rate. Moreover, these
agents may act synergistically with β1-adrenergic agonists
(eg, epinephrine). Amrinone and its newer derivative, milri-
none, are the most common drugs used in this class. As a
result of these beneficial effects on the myocardium and the
pulmonary and systemic vasculature, these agents are playing
an increasing role in the management of perioperative low
cardiac output syndrome.
Nitric oxide (NO), formerly known as endothelium-derived
relaxing factor (EDRF), has emerged as a critical regulator of
vascular tone and reactivity in both normal and pathologic
processes. Exogenous (ie, inhaled) NO retains the biologic
properties of endogenous NO and is the only known agent that
specifically dilates the pulmonary vasculature. Accordingly, it
has been used with success when pulmonary hypertension is
the primary physiologic disturbance When it is used, continu-
ous monitoring of its lethal by-product (nitrogen dioxide) is
necessary. Furthermore, therapy with inhaled NO mandates
mechanical ventilation and is very expensive—thus it is infre-
quently a first-line agent. The role of NO in the treatment of
perioperative low cardiac output syndrome is limited at this
time, but NO offers specific physiologic benefits that may pro-
vide the basis for increased use of NO in this setting.
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BNP, or nesiritide, is a promising new agent in cardiovas-
cular medicine. It has been approved for use in heart failure
but may assist with management of cardiac surgery patients.
Like endogenous BNP, nesiritide has widespread favorable
effects, including vasodilatation (thus reducing peripheral
and pulmonary vascular resistance), natriuresis, increased
glomerular filtration rate, symphathoinhibition, and inhibi-
tion of the renin-aldosterone system. Although there is lim-
ited experience published to date, these pharmacologic
properties make it an attractive adjunct to postoperative
management of cardiac surgery patients, particularly, per-
haps, those with current congestive heart failure, renal insuf-
ficiency, or pulmonary hypertension.
In patients who continue to have low-output states
despite these strategies, intraaortic balloon counterpulsation
should be added. In appropriate patients who fail to respond
to intraaortic balloon counterpulsation, more extensive ven-
tricular support should be considered.
B. Correction of Arrhythmias—Most patients will have
continuous electrocardiographic monitoring, and the rate
and rhythm should be established and corrected as appropri-
ate. Rate abnormalities may have profound hemodynamic
consequences, and a rate of 80–100 beats/min should be the
goal. Temporary atrial, ventricular, and ground wires are fre-
quently available and can be used to correct bradycardias
with atrial, ventricular, or sequential AV pacing. In emergent
settings, simple single-chamber ventricular pacing should be
instituted first to restore cardiac function immediately. Then,
if atrial wires are available, sequential AV pacing can be insti-
tuted to optimize cardiac function. Electrical cardioversion
of hemodynamically significant arrhythmias is preferable to
long periods of low cardiac output and is performed easily,
particularly in intubated and ventilated patients. In extu-
bated patients, brief intravenous anesthesia is sometimes
appropriate for cardioversion of atrial fibrillation, atrial flut-
ter, or sustained slow ventricular tachycardia. This is not
indicated in patients who are significantly compromised.
C. Surgical Evaluation of Pericardial Tamponade—
Ventilation, rhythm, blood pressure, and fluid status should
be established within the first few minutes of evaluation.
Classically, cardiac tamponade is suggested by hemodynamic
instability in a patient with significant bleeding that recently
decreased or stopped. Further evidence includes elevated
filling pressures (possibly left-right equilibration), mediasti-
nal widening on serial chest radiographs, and increasing
tachycardia (compensatory). If not diagnosed rapidly, pulse-
less electrical activity may result. Despite full evaluation,
tamponade frequently cannot be excluded conclusively, and
mediastinal exploration, either in the ICU or in the operat-
ing room, is required. If time permits, echocardiography may
be performed at the bedside to determine the presence or
absence of pericardial tamponade. Any patient with cardio-
vascular collapse in the early period following cardiac sur-
gery should be considered to have tamponade and should be
explored surgically if they are not responding to appropriate
therapy—even if other examinations are inconclusive or are
negative. Tension pneumothorax can occur in any critically
ill patient and should be treated on the basis of ventilator
pressure changes, physical examination, and chest x-ray.
D. Other Modalities—Occasional patients will be incom-
pletely revascularized or may have vein or arterial conduit
spasm. If serial ECGs are suggestive of ischemia, vascular
antispasmodics (ideally calcium channel blockers) should be
administered and consideration given to echocardiography
to document localized wall motion abnormalities, angiogra-
phy to definitively establish localized vascular lesions, or
early reoperation to treat acute graft occlusion.
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 Status Asthmaticus
ESSENT IALS  OF  D IAGNOS I S
 Usually unremitting asthma, rapidly increasing in severity,
but may present with sudden and severe obstruction
without warning.
 Poor and decreasing response to β-adrenergic agonist
therapy.
 May develop hypercapnic respiratory failure.
 Severe hyperinflation.
 Evidence of respiratory (inspiratory) muscle fatigue.
General Considerations
Status asthmaticus is very severe asthma that is unremitting
and poorly responsive to usual therapy. Studies have empha-
sized the differences between chronic stable asthma and sta-
tus asthmaticus in terms of pathophysiology, prognosis,
management, and response to treatment. Importantly, there
has been increased awareness of mortality and morbidity
from severe asthma, recognition of the key role of inflamma-
tion in the mechanism of severe asthma, changes in the mode
of delivery of agents for treating asthma, and revised concepts
in management of patients requiring mechanical ventilation.
Many patients with asthma will have episodic attacks that
are treated easily and rapidly. These mild exacerbations call
for changes in management because even episodic asthma is
undesirable, but the important feature of such cases is that
the patient responds and returns to baseline in a short time.
These attacks are distinguished from status asthmaticus,
which is characterized by slow and inadequate response to
treatment and a poor outlook for resolution of attacks. The
recognition of severe acute asthma in some cases may be dif-
ficult when the patient is assessed against a background of
chronic but stable asthma.
Pathophysiology and Pathogenesis
Asthma prevalence is increasing throughout the world, and
asthma mortality is a matter of great concern. Airway
obstruction is the major feature of this disorder, and
asthma is both an acute reversible obstructive disease and a
chronic pulmonary disease leading to permanent airway
obstruction. Failure to control asthma symptoms is associ-
ated with a more rapidly progressive decline in lung func-
tion and loss of reversibility. This is the basis for consensus
recommendations for chronic asthma management, which
can be summarized as follows: (1) There is a key role for anti-
inflammatory therapy (eg, corticosteroids), (2) regular
β-adrenergic agonist use as the sole therapy for asthma is
ineffective and potentially harmful, and (3) the goal of
asthma treatment is to keep the patient completely
symptom-free at all times. Despite widespread dissemination
of these recommendations, optimal management of asthma
is far from an achieved objective, and many asthmatics have
moderate to severe exacerbations requiring hospitaliza-
tion—with some requiring ICU management.
Airway obstruction in asthma results from three mecha-
nisms: enhanced bronchial smooth muscle contraction
(increased tone and response to stimuli), bronchial mucosal
inflammation and edema, and plugging of the bronchi by
secretions and inflammatory debris. The response to therapy
depends on the relative contributions of each of these mech-
anisms. For example, bronchodilators relax bronchial
smooth muscles but have little or no effect on reducing air-
way obstruction caused by inflammation or debris.
Corticosteroids have no direct effect on bronchial smooth
muscle but reduce inflammation in the bronchial walls.
The baseline amount of inflammation and airway nar-
rowing is a major determinant of the severity of exacerba-
tions once an asthma exacerbation is triggered.
Exacerbations may be triggered by allergens in susceptible
individuals, by cold air or irritants such as dust, by aspirin, or
by respiratory infections, especially viral infections. These
insults cause release of mast cell products such as histamine,
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inflammatory mediators (eg, leukotrienes and prostaglandins),
and substances that attract and activate leukocytes, especially
eosinophils. An identifiable precipitating cause for an exacer-
bation often cannot be identified. Bronchial smooth muscle
contraction and bronchospasm usually occur early, with
mucosal edema, increased mucous gland secretions, and
inflammatory cell infiltration following rapidly. The propor-
tion of airway obstruction owing to bronchospasm and that
owing to edema, inflammation, and mucus plugging is
highly variable between patients.
Eosinophilic infiltration of the bronchial mucosa in
asthma plays a key role, but neutrophils and T-lymphocytes
also have been implicated. Eosinophils may be attracted by
platelet-activating factor produced by a variety of cells, and
there is increased local production of interleukin 5 (IL-5), an
activator of eosinophils.
A number of studies have suggested an association
between regular use of β-adrenergic agonists and fatal or
near-fatal asthma events. Proposed mechanisms are (1) pro-
motion of airway hyperresponsiveness by these drugs
because they are so effective that the patients are more apt
to undergo prolonged exposure to allergens or irritants,
(2) heavy use of β-adrenergic agonists results in
hypokalemia and cardiac arrhythmias, and (3) some other
effects of β-agonists that remain undetermined. Recent stud-
ies have linked long-acting β-adrenergic agonists to worsening
asthma and increased mortality, yet there are very clear data
demonstrating benefits of these agents. Some studies have
shown that concomitant inhaled corticosteroids may protect
against adverse effects of long-acting β-agonists, but this has
not been settled. Furthermore, it is likely that some patients
are more susceptible to adverse effects of β-agonists poten-
tially because of polymorphisms of the β-adrenergic receptor
resulting in greater downregulation with repeated stimuli.
Status asthmaticus is characterized by poor responsive-
ness to bronchodilator therapy; a rapid, unremitting, and
often progressive course; and slow recovery to a baseline.
Patients who die with status asthmaticus are often found to
have severe mucus impaction of airways and marked inflam-
matory infiltration of the bronchial walls, suggesting a
greater role of airway mucosal inflammation over bronchial
smooth muscle contraction. In some patients with status
asthmaticus, hypoxemia persists much longer than airway
narrowing (as measured by peak flow or forced expiratory
capacity in 1 second [FEV1]), suggesting that persistent
blockage of small airways with mucus prolongs ventilation-
perfusion mismatching. It is not known why an asthmatic
with exacerbation sometimes may develop a self-terminated
bronchoconstrictor response and at other times generate a
persistent unremitting response (status asthmaticus) with
airway edema and inflammation.
A small number of patients with fatal or near-fatal asthma
appear to have rapid onset of symptoms with little airway
inflammation. These patients experience very severe bron-
chospasm that may lead to death within minute or hours.
Identification of such patients before they have a fatal or
near-fatal episode is difficult, but evidence suggests that
these patients may have reduced perception of increased
airway resistance combined with decreased hypoxic ventila-
tory drive.
Most patients with asthma exacerbations can be treated
successfully before they develop severe respiratory failure.
Respiratory failure in status asthmaticus comes about from
two major mechanisms. First, the diffuse and variable
bronchial obstruction causes ventilation-perfusion mismatch-
ing with resulting hypoxemia and, if the patient fails to
increase alveolar ventilation appropriately, hypercapnia.
Second is respiratory muscle fatigue, which somewhat para-
doxically is more marked for the inspiratory than for the expi-
ratory muscles. Because airway obstruction in asthmatics is
intrathoracic, airway narrowing is more marked during the
expiratory phase, increasing expiratory work of breathing and
lengthening the time needed for adequate exhalation.
However, because respiratory drive is increased in asthma as a
result of hypoxemia, hypercapnia, and other factors, the respi-
ratory rate increases and expiratory time shortens. This com-
bination of greater expiratory airway obstruction and
shorter expiratory time results in hyperinflation (air trap-
ping). Hyperinflation puts an additional burden on the
inspiratory muscles because these muscles are shorter than
normal prior to contraction and thus are unable to generate
as much tension for as long a time. Respiratory failure devel-
ops because the patient becomes unable to compensate for
the pathophysiologic changes. The result is fatigue of inspira-
tory muscles, worsening hypercapnia and respiratory acidosis,
and usually a need for intubation and mechanical ventilation.
Clinical Features
A. Symptoms and Signs—The severity of an asthma exac-
erbation should be judged in order to make decisions about
management. Early (30–60 minutes) response to therapy is
the key piece of information, but other information may be
helpful including prolonged duration of attacks, history of
hospitalization for asthma, prior or current use of systemic
corticosteroids, poor response to bronchodilators, increas-
ingly more frequent or increased dosages of medications,
recent or repeated emergency room or office visits for acute
asthma, and a history of requiring mechanical ventilation for
asthma. Increasing severity of asthma may be manifested by
less diurnal variation in asthma severity, diminished peak
flow both before and after bronchodilators, and inability to
sleep. A minority of asthmatics present with status asthmati-
cus after very short duration of symptoms. Some investiga-
tors have suggested that these patients presenting with a
hyperacute attack may have a variety of asthma marked by
sudden severe airway closure, perhaps from a neural mecha-
nism rather than from airway inflammation. Because preg-
nancy has a variable effect on women with stable chronic
asthma, including causing marked worsening in some indi-
viduals, pregnancy in women with childbearing potential
should be considered as a factor for asthma worsening.
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The physical examination is helpful for identifying signs
of severe airway obstruction (eg, absence of wheezing, use of
accessory muscles of respiration, intercostal retractions, and
pulsus paradoxus) or signs of impending respiratory muscle
fatigue (eg, paradoxical abdominal wall movement), but
these signs are insensitive or unreliable when used by them-
selves to assess severity. A number of studies have attempted
to assess the value of other signs, such as tachycardia, tachyp-
nea, cyanosis, and hypotension, singly or in combination, but
these have not proved to be of discriminating value. A key
role of physical examination is to exclude other acute respi-
ratory problems that may be mistaken for asthma, such as
pulmonary edema, pulmonary embolism, anaphylaxis or
angioedema, pneumothorax, pneumonia, and upper or cen-
tral airway obstruction owing to tumor, foreign body, or
epiglottitis.
B. Laboratory Findings—Ninety percent of patients with
acute asthma will have hypoxemia of mild to moderate
degree, and hypoxemia is not a particularly discriminating
variable for asthma severity. Most asthmatics (80%) present-
ing with an acute episode have mild respiratory alkalosis.
Only a small proportion have normal or elevated PCO2, and
there is an association between severe airway obstruction and
hypercapnia in asthma. Nonetheless, although hypercapnia is
of concern in status asthmaticus, hypercapnia is not consis-
tently linked with prolonged severe asthma or the need for
mechanical ventilation. Metabolic acidosis owing to an
increase in blood lactate in patients presenting with acute
asthma, especially in association with hypoxemia, may be
seen. Although pulse oximetry gives an estimate of arterial
oxygenation, an arterial blood gas determination of pH and
PCO2 is mandatory for any asthmatic admitted from the
emergency department or being considered for admission to
the ICU.
Serum sodium and potassium should be measured
because of the association of hyponatremia with pulmonary
diseases and respiratory failure and the observation that
aggressive β-adrenergic agonist use can result in severe
hypokalemia. Although magnesium has been used as a bron-
chodilator and hypokalemia and hypomagnesemia are
closely related, hypomagnesemia has not been associated
with asthma exacerbations.
C. Imaging Studies—Chest radiographs during acute
asthma almost always show hyperinflation, with low, flat
hemidiaphragms and an increased anteroposterior diameter.
They are not helpful in assessment of the severity of asthma,
precipitating factors, or complications. However, some inves-
tigators have claimed that chest radiographs provide impor-
tant diagnostic information in asthmatics who are admitted
to the hospital in that the choice of therapy is altered by the
findings on the radiograph. Features to be sought include the
presence of pneumothorax, infiltrates suggestive of bacterial
or viral pneumonia, findings suggestive of allergic bron-
chopulmonary aspergillosis (eg, fleeting infiltrates or cylin-
dric bronchiectasis), and lobar or segmental atelectasis
suggesting mucous impaction of large airways. Because pul-
monary edema may present with acute onset of dyspnea and
wheezing, cardiomegaly and features of congestive heart fail-
ure should be excluded.
D. Spirometry—Spirometry can be very helpful in the assess-
ment of status asthmaticus both initially and in following
treatment. The objective response to therapy after the first
1–2 hours provides much meaningful information. Peak flow
or FEV1 should be measured on initial presentation to the
emergency room and then hourly with treatment until a deci-
sion is made to hospitalize. The frequency of spirometry
thereafter depends on clinical assessment, but the response to
additional treatment with bronchodilators and, after suffi-
cient time has elapsed, to corticosteroids may be of additional
value in planning treatment and observation. The FEV1 or
peak flow may be compared with predicted values for the
patient’s age, sex, and size, but improvement in the measured
values over time is the most helpful indicator. In one study,
good response to treatment at 30 minutes was the single vari-
able most highly correlated with favorable patient outcome.
Differential Diagnosis
Features suggesting status asthmaticus, including acute onset
of shortness of breath, cough, wheezing, and progression to
respiratory failure, may be seen to varying degrees in conges-
tive heart failure, upper airway obstruction, exacerbation of
chronic bronchitis or emphysema, spontaneous pneumotho-
rax, anaphylaxis, acute pulmonary embolism, and foreign-
body aspiration. Upper airway obstruction is characterized
by inspiratory wheezing or stridor, sometimes loudest over
the trachea in the neck. Asthmatics who had prior endotra-
cheal intubation—especially for long duration—or tra-
cheostomy should be suspected of having extrathoracic
airway obstruction. A small but significant number of
patients mistakenly diagnosed as having asthma instead have
vocal cord dysfunction syndrome. In this syndrome, the
vocal cords adduct inappropriately during exhalation,
increasing expiratory resistance and causing expiratory
wheezing and hyperinflation. Vocal cord dysfunction may go
unidentified for years until direct visualization of the vocal
cords during the respiratory cycle makes the diagnosis. On
some occasions, patients who are intubated for severe asthma
have sudden and complete relief of obstruction and wheez-
ing, and these patients should be suspected of vocal cord dys-
function syndrome.
Treatment
Status asthmaticus is treated with bronchodilators (titrated to
patient response), corticosteroids, and oxygen, with endotra-
cheal intubation and mechanical ventilation if necessary. The
aim of treatment is to relieve the airway obstruction by relax-
ing bronchial smooth muscles and reversing inflammation
while supporting respiratory function. Support of respira-
tory function depends on the severity of the asthma and the
ability of the patient to sustain inspiratory and expiratory
muscle work. An important concept in the treatment of sta-
tus asthmaticus is that the airway obstruction should not be
expected to reverse as quickly or completely as in mild asthma
exacerbations. Current management focuses on supporting
the patient’s gas exchange without causing further harm while
waiting for anti-inflammatory treatment to take effect.
A. Oxygen—Ninety percent of patients presenting with an asth-
matic attack are hypoxemic to some degree. Hypoxemia
increases respiratory drive and tachypnea, contributing to
increased hyperinflation and possible inspiratory muscle fatigue.
In addition to correcting hypoxemia, oxygen may be helpful in
attenuating some respiratory drive and prolonging expiratory
time, thereby decreasing hyperinflation. Because hypoxemia is
usually due to ventilation-perfusion mismatching, hypoxemia in
most asthmatics can be treated with low concentrations
(30–50%) of supplemental oxygen in sufficient amounts to raise
PaO2 to 80–100 mm Hg. In nonintubated patients, oxygen can be
given by nasal cannula or Venturi-type masks.
B. Bronchodilators—Bronchodilators of all types have been
used in status asthmaticus, including β-adrenergic agonists
(sympathomimetics), methylxanthines (theophylline), anti-
cholinergics, and others (see Chapter 12). β-Adrenergic ago-
nists are the most effective bronchodilator agents in acute
asthma exacerbations. Those that are modified to have greater
specificity for β2 receptors, such as albuterol, are preferred
because of their decreased effect on heart rate. Aerosolized
formulations are much more potent and better tolerated than
the same drugs given orally, subcutaneously, or intravenously,
having a greater bronchodilator effect and causing less tachy-
cardia and less hypokalemia even in patients who have severe
bronchial obstruction. In moderately severe to severe asthma,
aerosolized β-adrenergic agonists can be given with equal
effectiveness with either a metered-dose inhaler (MDI) with
spacer or hand-held nebulizer. Finally, the effective dose of
β-adrenergic agonists is often higher than was formerly rec-
ommended; the doses should be titrated in individual patients
to tolerance, often using clinical response, tachycardia, tremor,
or other observations as guides to dosage. Beta-adrenergic
agonists may be given in conventional doses as often as hourly
or even by continuous nebulization. Continuous nebulization
has been found to be variably effective. Hypokalemia as a con-
sequence of β-adrenergic agonist therapy—causing increased
transport of potassium into cells—is a known complication
when these drugs are given in large doses.
Subcutaneous epinephrine has a long history of effective
use in acute asthma, but inhalation of selective β-adrenergic
agonists is more effective. The side effects of epinephrine
include tachycardia, increased myocardial oxygen require-
ment, and hypertension. Salmeterol is a long-acting β-
adrenergic agonist that is structurally similar to albuterol but
has a longer side chain that anchors it near the β2-receptor
site. This drug has no value in acute severe asthma, and sal-
meterol should be reserved for use only after resolution of
the acute attack.
In severe asthma, aerosolized albuterol is recommended. If
given by MDI, a spacer or reservoir is necessary. A starting
dosage is 2–4 puffs every 1–2 hours, and the number of puffs
can be increased to 6–8 or more, if tolerated. Alternatively, a
nebulized solution of 0.5 mL albuterol (0.5%) diluted in 2.5
mL normal saline can be given by gas-powered nebulizer or
intermittent positive-pressure breathing every 2–6 hours, but
there is no evidence that this is more effective than administra-
tion by MDI. The response to bronchodilators should be meas-
ured objectively, preferably by peak flow. Tachycardia, tremors,
and changes in blood pressure should be monitored carefully,
especially when doses given exceed usual recommendations.
Anticholinergic drugs are generally considered more
effective in chronic bronchitis than in asthma. Studies sup-
port their use in severe asthma in conjunction with opti-
mized β-adrenergic agonist use. The quaternary anticholinergic
drug ipratropium bromide is given via MDI or by nebuliza-
tion. Effective doses of ipratropium bromide may be consid-
erably higher than currently recommended, but its minimal
side effects allow it to be well tolerated. Ipratropium should
be given to asthmatics with severe exacerbations along with
maximal β-adrenergic agonist therapy. By MDI, the starting
dosage should be 2–4 puffs every 4–6 hours. For nebuliza-
tion, an effective dose is 0.5 mg given every 6–8 hours. Even
at the highest doses, side effects of ipratropium are minimal,
and these doses appear to be safe.
The addition of theophylline to optimized regimens of
β-adrenergic agonist therapy confers little or no additional
benefit and increased toxicity and side effects. Some of the
side effects of theophylline are identical to those of β-adrenergic
agonists, and this may limit use of the more beneficial agent.
Theophylline should be considered a third-line bronchodila-
tor drug in status asthmaticus, but it might warrant consid-
eration in selected patients who are not responding to other
therapy. Theophylline is tolerated only when the serum con-
centrations are carefully maintained in the therapeutic range,
and in some patients toxicity occurs even then.
Intravenous magnesium sulfate (MgSO4) has been shown to
be an effective bronchodilator in some studies of asthma exac-
erbation. Doses administered have been in the range of 0.5–1
mmol/min over 20 minutes, corresponding to about 3–5 grams
of MgSO4. Comparison with β-adrenergic agonists has not been
carried out in the ideal manner for evaluating the precise role of
magnesium sulfate in combination with other drugs. There
have been trials of inhaled magnesium sulfate as well.
C. Corticosteroids—Corticosteroids are a key component
of treatment of status asthmaticus, but the ideal dosage
remains undetermined. In one study, 15 mg methylpred-
nisolone given intravenously every 6 hours did not appear to be
as effective as larger doses such as 40 or 125 mg every 6 hours,
and most clinicians agree that a dose of 10–15 mg/kg per day
of hydrocortisone or equivalent is effective. Larger doses have
not resulted in improved outcome or more rapid resolution.
These recommendations translate into quite large doses,
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such as 120–240 mg prednisone or methylprednisolone per
day in divided doses for average-sized adults. Oral adminis-
tration has been shown to be as effective as intravenous infu-
sion with no difference in time of onset of effect, but
intravenous administration is chosen more commonly.
For status asthmaticus, intravenous methylprednisolone
at 40–60 mg every 6 hours, or similar dosage of oral pred-
nisone or methylprednisolone is recommended. The dose
should be continued, in the absence of acute severe side
effects, for several days even if the patient improves. The rate
of tapering of systemic corticosteroids depends on clinical
response as well as the patient’s recent history of asthma
severity and previous dosage of corticosteroids.
The beneficial effect of corticosteroids is not clinically
apparent until at least 6 hours after administration.
Therefore, if corticosteroids are to be optimally effective, they
should be given early, as soon as a diagnosis of status asth-
maticus is made. Corticosteroids should be continued ini-
tially for at least 36–48 hours and then reduced by
approximately 25–50% depending on clinical response.
Further reduction generally can take place over about a 2-
week period. Most investigators do not believe there is a role
for aerosolized corticosteroids in status asthmaticus because
of concern about delivery to the airways during acute airway
obstruction. However, these agents are quite beneficial as the
systemic corticosteroids are tapered, and relatively soon
(within a few days), highly potent inhaled corticosteroids are
effective.
The major concern of corticosteroid therapy is the side
effects. The usual side effects of high-dose corticosteroids in
critically ill patients include hyperglycemia, altered mental
status, metabolic alkalosis, and hypokalemia. In asthmatics,
acute myopathy has been reported in association with corti-
costeroids. Three mechanisms have been proposed to explain
this phenomenon. First, hypokalemia may develop, especially
with high-dose β-adrenergic agonist use and high-dose corti-
costeroids. Second, acute steroid myopathy has been reported
at the dosages used in status asthmaticus. Finally, there is an
association with prolonged muscle weakness when high-dose
corticosteroids are given in combination therapy with nonde-
polarizing muscle relaxants. In the latter syndrome, tempo-
rary pharmacologic denervation of muscles appears to
potentiate the acute myopathic effects of corticosteroids. This
syndrome, seen in asthmatics and others requiring muscle
relaxants to help them accept mechanical ventilation, may
prolong the need for mechanical ventilation.
Because of the central role of inflammation in status
asthmaticus, other agents that interfere with the inflamma-
tory response have been proposed. Although methotrexate
has been used in stable steroid-dependent asthmatics, there
are no studies of this antimetabolite in status asthmaticus.
Leukotriene antagonists and inhibitors of leukotriene syn-
thesis are effective in modifying asthma and perhaps reduc-
ing exacerbations. They do not appear to have a role in
acute asthma exacerbations but have been used in clinical
trials.
D. Asthma in Pregnancy—Asthma is the most commonly
encountered pulmonary problem in pregnant women, and
asthma may worsen, improve, or remain unchanged in sever-
ity (roughly one-third in each group) during pregnancy. Fetal
outcome is adversely influenced if the mother’s asthma is
poorly controlled, and improvement in asthma control is
rewarded by a better outcome. Guidelines for treatment
developed by the National Asthma Education and Prevention
Program emphasize recommendations similar to those for
nonpregnant patients. These include close monitoring of lung
function, early administration of inhaled corticosteroids or
other anti-inflammatory agents, and rapid therapeutic inter-
vention during acute exacerbations to avoid hypoxemia.
Clinicians may be reluctant to give medications to pregnant
women because of risks to the fetus. Beta-adrenergic agonists
are considered safe, as are inhaled corticosteroids, and sys-
temic corticosteroids should not be withheld if needed during
acute exacerbations. A more complete discussion of this topic
is included in Chapter 39.
E. Mechanical Ventilation—Patients with status asthmati-
cus who require intubation and mechanical ventilation are
identified either by the extreme severity of the airway
obstruction or by anticipating failure of the patient to main-
tain adequate alveolar ventilation. Although most patients
who require intubation and mechanical ventilation develop
altered mental status, acute CO2 retention, or both, a poor
response to treatment or evidence of impending inspiratory
muscle failure implies a high likelihood of a need for ventila-
tory support.
1. Dynamic hyperinflation and complications from
mechanical ventilation—Mechanical ventilation in sta-
tus asthmaticus was at one time associated with a dispropor-
tionate complication rate and high mortality. Barotrauma
(eg, pneumothorax) and other complications of positive-
pressure ventilation and endotracheal intubation were much
higher in asthmatics than in patients with other forms of res-
piratory failure requiring mechanical ventilation. Possible
reasons for this include failure to recognize the severity and
slow reversibility of status asthmaticus, insufficient attention
to the high airway pressure and progressive hyperinflation
seen during mechanical ventilation of asthmatics, and failure
to understand the importance of hyperinflation or air trap-
ping as a cause of gas-exchange failure. Identified risk factors
for barotrauma in one study included significantly higher
minute ventilation and degree of estimated hyperinflation
compared with those who escaped complications.
Current recommendations for mechanical ventilation
reduce complications and mortality in this disorder to rates
comparable with other causes of acute respiratory failure.
The most important recommendation is limiting the degree
of dynamic hyperinflation. Dynamic hyperinflation occurs
when end-expiratory lung volume increases because there is
insufficient time for the patient to exhale. This increases the
risk of barotrauma because the lung is highly stretched at
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end expiration and end inspiration. It also results in very
inefficient gas exchange with a large increase in the ratio of
dead space to tidal volume and in hypercapnia. Finally,
because of the high air space pressures it engenders during
both inspiration and expiration, dynamic hyperinflation
may compromise the circulation.
Dynamic hyperinflation results from a combination of
factors. First, expiratory airway resistance is high, and the
tidal volume requires more time to be exhaled. Second,
patients with asthma may have high ventilatory drive owing
to hypoxemia, hypercapnia, or both. High ventilatory drive
increases respiratory rate and decreases the time available for
exhalation. Third, because of the hypercapnia, clinicians may
try to increase minute ventilation by raising tidal volume and
increasing respiratory rate during mechanical ventilation.
High tidal volume and high respiratory rate during status
asthmaticus are predictably associated with high peak airway
pressures, high inspiratory plateau pressures, short expira-
tory times, auto PEEP, and hyperinflation. The magnitude of
dynamic hyperinflation can be remarkable. In one study,
estimates of the volume of “trapped gas” were as much as
12–20 mL/kg above normal end-expiratory volume.
2. Ventilator settings—All asthmatics who are receiving
mechanical ventilation potentially can have severe dynamic
hyperinflation, and a trial of reduced tidal volume, respira-
tory frequency, or both should be initiated with careful mon-
itoring of arterial pH and PCO2. Dynamic hyperinflation is
especially likely to occur if hypercapnia is worsening in the
face of recent increases in tidal volume or respiratory fre-
quency. One key adjustment is to minimize dynamic hyper-
inflation by maximizing inspiratory flow rate (if
volume-cycled ventilation is used). This adjustment shortens
inspiratory time and lengthens expiratory time, providing a
greater opportunity to exhale the tidal volume. Inspiratory
flow should be at least 80–100 L/min (1.3–1.6 L/s). The
resulting I:E ratio should be 1:4 or higher.
A second important strategy is to constrain tidal volume
and respiratory rate during volume-cycled positive-pressure
ventilation to keep inspiratory plateau pressure 30 cm H2O
or less. Tidal volume should be 6–7 mL/kg of ideal body
weight, and respiratory rate should be adjusted to minimize
estimated auto PEEP (<5 cm H2O) and inspiratory plateau
pressure (<30 cm H2O). Patients may require sedation but
almost never muscle relaxants to achieve these goals.
Dynamic hyperinflation plays a dominant role in deter-
mining effective gas exchange. Therefore, although seemingly
paradoxical, decreasing tidal volume or respiratory rate (lower
minute ventilation) may result in a lower PaCO2. However, a
more likely consequence of such changes is worsening hyper-
capnia. Current practice is to allow moderate hypercapnia
(pH >7.25) to avoid the consequences of dynamic hyperinfla-
tion, a far worse complication. Thus “permissive hypercapnia”
is often seen in the management of status asthmaticus.
The decision to increase minute ventilation and reverse
hypercapnia generally is made as peak airway pressure and
auto PEEP decline as the patient’s high airway resistance falls
with treatment. In one study, a 40–60 seconds apnea period
was set for asthmatic patients who were sedated and given
muscle relaxants. The total exhaled gas volume was measured;
this consisted of the previous tidal volume plus any amount
of “trapped gas” that could be exhaled during the prolonged
exhalation period. Patients whose total exhaled gas volumes
exceeded 20 mL/kg had their respiratory frequency reduced
regardless of the measured PCO2. However, the respiratory
frequency was increased in the other patients as much as pos-
sible without exceeding 20 mL/kg total exhaled volume, and
these patients did not have worsening of hypercapnia or evi-
dence of barotrauma. Patients were discontinued from
mechanical ventilation when a PCO2 of 40 mm Hg could be
obtained and exhaled gas volume was less than 20 mL/kg.
There is limited published experience with administra-
tion of intravenous sodium bicarbonate to compensate for
the increased PCO2, and this treatment should be used judi-
ciously in selected patients. In one study, no complications of
bicarbonate therapy were identified, but there is concern for
development of paradoxical cerebrospinal fluid acidosis,
hypernatremia, and intravascular volume overload. The use
of other buffers that do not produce additional CO2 when
they react with acids has been proposed.
Current Controversies and Unresolved Issues
A. General Anesthesia for Refractory Asthma—In
patients undergoing mechanical ventilation, halothane and
ketamine anesthesia has been used in status asthmaticus that
is refractory to conventional management, but this manage-
ment has not been compared with other forms of therapy.
Both agents have bronchodilator properties, but this remains
an unproved and potentially risky therapy. Such treatment is
used very rarely.
B. Mucolytic Administration by Fiberoptic Bronchoscopy—
Recognition that severe refractory airway obstruction in sta-
tus asthmaticus is often due to plugging of small airways
with inspissated mucus led to the use of mucolytic agents
such as acetylcysteine. However, aerosolization of this agent
sometimes led to bronchospasm, and its effectiveness in the
dose and manner administered has been questioned.
Bronchoalveolar lavage with acetylcysteine and saline has
been performed using the fiberoptic bronchoscope. Because
of compromise of the airway with the bronchoscope, this
must be done only during mechanical ventilation with seda-
tion, muscle relaxants, or general anesthesia. The usefulness
of this technique has not been proved, and because of the
high risks to the patient, it should be considered only if other
more conventional treatment has failed. Using a strategy to
reduce dynamic hyperinflation and waiting for resolution of
the underlying asthma in response to corticosteroids is
almost always a better option.
C. Helium-Oxygen Inhalation—Helium-oxygen mixtures
(21–40% oxygen, balance helium) have less density than
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nitrogen-oxygen mixtures. Because a less dense gas is more
likely to move through airways under conditions resulting in
laminar rather than turbulent flow, helium-oxygen mixtures
may improve distribution of ventilation and reduce airway
pressures needed for effective ventilation. Helium-oxygen has
been used in spontaneously breathing asthmatics to unload
the work of the inspiratory and expiratory muscles. This may
allow enough time for anti-inflammatory therapy to take
effect and avoid intubation and mechanical ventilation.
Mechanical ventilation with 60% helium and 40% oxygen
mixtures has been used with improved arterial blood gases
and markedly decreased airway pressures compared with a
nitrogen-oxygen mixture. Although there have been no con-
trolled studies of helium-oxygen mixtures in status asthmati-
cus, it is reasonable to suppose that this form of treatment
may be beneficial in some refractory asthmatics. The prob-
lems include obtaining the appropriate gas, adapting the ven-
tilator to use the gas mixture, monitoring tidal volume, and
ensuring the adequacy of oxygen in the inspired gas mixture.
D. Noninvasive Ventilation—Non-invasive positive-
pressure ventilation (NiPPV) successfully reduces endotra-
cheal intubation and mechanical ventilation in patients with
chronic obstructive pulmonary disease (COPD) exacerba-
tion and acute pulmonary edema. Surprisingly, there are
numerous studies but limited data supporting its use in sta-
tus asthmaticus, although it would appear that temporary
support by NiPPV of fatiguing inspiratory muscles would be
helpful. NiPPV is a potentially useful adjunct but may be
successful only in carefully selected patients. One danger is
that some patients with status asthmaticus regain lung func-
tion very slowly, and NiPPV may not be tolerated long
enough to preclude intubation.
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 Life-Threatening Hemoptysis
ESSENT IALS  OF  D IAGNOS I S
 Expectoration of blood or blood-tinged sputum in suffi-
cient quantity to compromise lung function.
 Either a large volume of hemoptysis in a healthy
patient (>600 mL in 24 hours) or a smaller volume
(<200 mL in 24 hours) in a patient with preexisting lung
or heart disease who is unable to protect their airway,
maintain adequate gas exchange, or has altered level
of consciousness.
General Considerations
Hemoptysis can be caused by a wide variety of lung condi-
tions. Expectoration of blood sufficient to be acutely life-
threatening is not common, occurring in 5–15% of
hemoptysis patients. Acute hemoptysis was formerly classi-
fied as massive or nonmassive, and the major decision about
whether to perform surgical intervention was based on the
estimated amount of bleeding. There is now recognition that
even large volumes of hemoptysis can be tolerated if the
patient is relatively healthy. Conversely, small amounts of
bleeding can cause severe complications in patients who have
limited cardiopulmonary reserve from COPD, previous lung
resection, tuberculosis, or heart disease. Mortality from
severe hemoptysis does correlate with the estimated amount
of hemoptysis. However, with additional approaches to diag-
nosis and management now available, one considers both the
severity of bleeding and the patient’s ability to tolerate accu-
mulation of blood in the lungs and airways.
Pathophysiology and Pathogenesis
A. Mechanisms of Hemoptysis—Bleeding in the airways
and lungs can result from several different mechanisms and
two major sources, the bronchial arteries (systemic pressure)
and the pulmonary arteries (low pressure system). Disorders
associated with hemoptysis are listed in Table 24–1. The most
common are bronchiectasis, lung cancer, and tuberculosis
(including mycetoma).
1. Inflammation of the bronchi—Inflammation of the
tracheobronchial mucosa is the most common cause of
hemoptysis but is rarely associated with severe bleeding. In
chronic bronchitis, the mucosa develops increased vascular-
ity with engorged and hypertrophied bronchial arteries that
readily bleed in the face of increased inflammation or acute
viral or bacterial infection.
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2. Infection—Worldwide, tuberculosis remains an impor-
tant cause of hemoptysis both during active infection and as
a consequence of the scarring and cavitation seen with
chronic disease. Active disease may result in hemoptysis from
lung necrosis, often with a cavity visible on chest x-ray.
Tuberculous cavities may cause hemoptysis whether or not
viable mycobacteria are present. Bleeding arises from dilated
vessels in the wall of the cavity, most often fed by an elabo-
rately developed network of vessels arising from bronchial
arteries with interconnections between these and pulmonary
arteries. An important cause of bleeding from tuberculous
cavities is the development of a mycetoma, or fungus ball,
usually formed by Aspergillus species, that seems to further
stimulate bronchial artery hypertrophy and blood flow.
Rarely, aneurysmal dilation of a vessel in the wall of the cav-
ity has been known to be the cause of severe hemoptysis. In
tuberculosis patients without cavities, bleeding can be
caused by broncholiths (ie, calcified lymph nodes) adjacent
to airways that erode through the bronchial wall and by
chronic bronchiectatic changes of the airways. Patients with
other forms of bronchiectasis (eg, previous viral infections,
bronchopulmonary aspergillosis syndrome, or idiopathic
cases), bacterial lung abscess, and fungal infections with cav-
itation may present with hemoptysis, and on occasion these
patients may have a bout of severe and life-threatening
hemoptysis. Bacterial pneumonia sometimes can present
with blood-tinged sputum (eg, “rusty” sputum seen with
Streptococcus pneumoniae or “currant jelly” sputum seen with
Klebsiella pneumoniae), but significant bleeding is rare.
3. Noninfectious causes—Infarction of the pulmonary
parenchyma can result in hemoptysis by causing death of
lung tissue, but most patients with pulmonary embolism do
not have pulmonary infarction. Inflammation of lung owing
to involvement by Wegener’s granulomatosis may be associ-
ated with hemoptysis, occasionally severe. Two autoimmune
diseases for which hemoptysis is a characteristic feature,
Goodpasture’s syndrome and idiopathic pulmonary hemo-
siderosis, are not associated with inflammatory changes in
the lung. In the former, bleeding arises from involvement of
the alveolar-capillary interface by anti-glomerular basement
membrane antibodies. Less frequent causes of hemoptysis
include left ventricular failure and mitral stenosis, with
bleeding resulting from increased pulmonary venous and
capillary pressures. Hemoptysis may be seen with vascular
malformations occurring as isolated abnormalities of the
pulmonary circulation or in association with hereditary
hemorrhagic telangiectasia syndrome (HHT), including
Osler-Weber-Rendu syndrome.
Bronchogenic carcinoma and benign tumors of the tra-
cheobronchial tree are other important causes of hemopty-
sis, with bleeding coming from hypertrophied bronchial
arteries supplying the tumor. Finally, thoracic trauma may
result in hemoptysis owing to rupture of pulmonary vessels,
resulting in bleeding into the lung parenchyma (lung contu-
sion) or laceration of a major airway.
4. Hemoptysis in ICU patients—In ICU patients who
develop hemoptysis unrelated to their primary problems,
some unique mechanisms must be considered. The most
common source of hemoptysis is upper airway bleeding,
which may result from tracheobronchitis owing to infec-
tion or suction catheter trauma. However, other airway
problems should be considered, such as trauma from the
tip of the endotracheal tube or tracheostomy tube or necro-
sis of the tracheal mucosa by the tube cuff. Rarely, bleeding
can arise from pressure necrosis and erosion of the tube
into an innominate or carotid artery or even into the aortic
arch. A recognized cause of severe hemoptysis is rupture of
a pulmonary artery by a pulmonary artery catheter because
of overdistention of the catheter balloon tip, perforation of
the vessel by the tip of the catheter, or eccentric balloon
placement causing rupture during balloon inflation.
Mortality rates with these types of catheter complications
are very high.
Regardless of the cause of hemoptysis, bleeding can be
made worse in patients with coagulopathy, qualitative platelet
dysfunction from uremia or drugs, or thrombocytopenia.
Patients with severe thrombocytopenia may have sponta-
neous alveolar hemorrhage.
Table 24–1. Common causes of hemoptysis.∗
Airway  
Tracheobronchitis 
Chronic bronchitis 
Bronchogenic carcinoma 
Benign tracheobronchial tumors 
Bronchiectasis
Cystic fibrosis 
Suctioning or bronchoscopic trauma 
Post-transbronchial or endobronchial biopsy 
Transthoracic needle aspiration or biopsy 
Trauma
Lung parenchyma 
Pulmonary infarction (pulmonary embolism) 
Invasive pulmonary infection (Aspergillus, bacteria) 
Necrotizing bacterial or fungal pneumonia 
Lung abscess 
Tuberculosis with or without cavity
Pulmonary vasculitis 
Goodpasture’s syndrome
Idiopathic pulmonary hemosiderosis
Trauma 
Thrombocytopenia 
Cardiovascular 
Left-ventricular failure 
Mitral stenosis
Pulmonary artery rupture (PA catheter balloon) 
Pulmonary artery aneurysm 
Aortic aneurysm 
Hereditary hemorrhagic telangiectasia 
∗Items in italics are those associated most often with massive
hemoptysis. 
 CHAPTER 24542
B. Massive Hemoptysis—A large volume of hemoptysis,
often called massive hemoptysis, usually results from a
smaller number of common disorders causing hemoptysis
(see Table 24–1). The mechanisms are often due to chronic
and severe development of enhanced bronchial blood flow
(eg, tuberculosis, lung abscess, bronchiectasis, and malig-
nancy), necrosis and destruction of lung parenchyma (eg,
abscess, tuberculous cavity, and fungal pneumonia in
immunocompromised host), or disruption of a pulmonary
artery (eg, trauma, rupture by pulmonary artery catheter
balloon). In major series of patients with massive hemopty-
sis, tuberculosis and bronchiectasis are found in a large
majority of patients, whereas bronchogenic carcinoma is
quite unusual as a cause of massive hemoptysis.
Clinical Features
A. Symptoms—Patients, especially those with chronic spu-
tum production (eg, chronic bronchitis or bronchiectasis),
may complain of coughing up blood-tinged sputum. Others
will note expectoration of bright or dark red material only.
The degree of coughing is highly variable, with some patients
having intractable coughing and others noting only that the
blood wells up into the mouth with little stimulation of
cough. Occasionally, patients actually can describe the
approximate location of the intrathoracic source by pointing
to the area of the sensation within their chest. The relation-
ship of prior hemoptysis to massive or life-threatening
hemoptysis is also highly variable. Some patients have pro-
longed minor hemoptysis, whereas others have no premoni-
tory blood in the sputum prior to a life-threatening event.
The degree of dyspnea accompanying hemoptysis is
determined by the volume of blood expectorated and by
the patient’s underlying cardiopulmonary reserve. Patients
with moderate to severe obstructive lung disease, those with
extensive lung destruction from tuberculosis, and those with
other heart or lung disorders will be most likely to have res-
piratory compromise. Fever, night sweats, and weight loss
suggest active tuberculosis, but other infections also should
be considered. A history of cigarette smoking or other risks
for bronchogenic carcinoma should be sought.
An important part of the medical history is to estimate
the amount of bleeding. While this cannot always be meas-
ured accurately, the patient should be asked to provide an
estimate in cups, tablespoons, or other convenient measures
and over as precise a time frame as possible. If admitted to
the hospital, they should be given a cup to collect all their
expectorated sputum over a 24-hour period for a more accu-
rate determination of the amount of bleeding.
B. Signs—Physical examination may not be helpful in eval-
uating the severity of hemoptysis. The upper airway, includ-
ing the  nasopharynx and upper larynx, should be carefully
examined to exclude these sites as the source of bleeding.
Localization to the right or left lower respiratory tract by
physical examination alone is often inaccurate. The presence
of blood in the airways may lead to generalized or focal
wheezing, crackles, and dullness to percussion if there is suf-
ficient bleeding to fill a portion of the lungs. In patients with
chest trauma, rib fractures, superficial injury, and other find-
ings may be helpful in assessing the likelihood of lung contu-
sion, but these indicators are insensitive and nonspecific.
Features of heart failure, such as a third heart sound, rales,
and lower extremity edema, may be helpful in the differential
diagnosis, as well as a diastolic murmur suggesting mitral
stenosis. Osler-Weber-Rendu syndrome is suggested by find-
ing single or multiple telangiectases on the skin or mucosal
membranes. The physical examination is most useful in
determining the severity of respiratory and nonrespiratory
diseases that contribute to mortality and complications from
hemoptysis.
C. Laboratory Findings—Sputum should be examined by
acid-fast stain for mycobacteria, by Gram stain for bacteria,
and by cytology for malignant cells. The presence of a large
number of red blood cells often makes these examinations
difficult. Cultures should be obtained from sputum and
blood if bacterial pneumonia is suspected. Coagulation
times, bleeding time, platelet count, and hematocrit should
be determined. Blood for transfusion should be arranged for
but often is not needed to correct a low hematocrit until
operative treatment is indicated. The presence of a coagu-
lopathy or thrombocytopenia, however, should trigger the
administration of replacement of coagulation factors or
platelets to help to control the bleeding process. Arterial
blood gases are helpful in evaluating the adequacy of gas
exchange and the ability to tolerate further aspiration of
blood into the lungs.
The presence of renal insufficiency changes the differen-
tial diagnosis of hemoptysis to include pulmonary-renal syn-
dromes including Goodpasture’s syndrome and Wegener’s
granulomatosis. Therefore, it is important to evaluate the
urine for the presence of hematuria and to determine renal
function. Unfortunately, despite a rigorous evaluation, the
investigators in one study were unable to identify a cause of
hemoptysis in 41% of patients with a serum creatinine level
greater than 1.5 mg/dL and hemoptysis, and the yield of
fiberoptic bronchoscopy was very low.
D. Imaging Studies—Usual procedures such as chest x-rays
and CT scans may show an infiltrate, cavity, atelectasis, or
other features that suggest a lesion from which bleeding is
arising. These findings should be interpreted with caution,
however, because another unsuspected source may be pres-
ent. For example, aspirated blood may cause atelectasis and
infiltrates remote from the actual bleeding site. Lung cavities
are often multiple, bilateral, and involve several lobes, but the
cavity from which blood is coming may not be readily iden-
tified. Cavitary lung disease, especially in the upper lung
zones, may suggest tuberculosis, but active tuberculosis can-
not be diagnosed accurately from imaging studies.
Furthermore, cavities are seen in fungal infection, sarcoido-
sis, necrotizing pneumonia, and other diseases. A mycetoma
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within a cavity may be identified on chest x-rays or CT
scan—especially if taken with the patient in several positions.
High-resolution CT scans without intravascular contrast
agents are helpful in establishing the cause and location of
hemoptysis. Localization of bleeding, however, may require
bronchial or, rarely, pulmonary angiography (see below).
Treatment
In life-threatening hemoptysis, maintenance of the airway
and removal of blood from the airway take precedence.
Diagnostic measures must be deferred until it is established
that the patient can maintain adequate gas exchange with or
without an artificial airway, oxygen, and other measures to
reverse coagulopathies or other bleeding tendencies. After
the patient is stabilized, efforts are directed toward determin-
ing the site of bleeding as rapidly as possible so that defini-
tive control of the bleeding site can be achieved.
The outcome of patients with large-volume hemoptysis is
said to be poor, and this has strongly influenced recom-
mended treatment options. However, much of these data
comes from older studies in which tuberculosis caused the
hemoptysis from severe chronic destruction of the lung
parenchyma. For example, a series of patients from the 1950s
and 1960s demonstrated that patients who coughed up more
than 600 mL of blood within 16 hours had a 75% mortality
rate, whereas those who produced less than 600 mL over
16–48 hours had a mortality rate of only 5%. About three-
fourths of these patients had active or inactive tuberculosis,
with the remainder having lung abscess, bronchiectasis, or
bronchogenic cancer. Another study of patients who expec-
torated more than 600 mL of blood within 24 hours reported
a 22% overall mortality rate.
The term life-threatening hemoptysis is preferred over
massive hemoptysis. Although the volume of expectorated
blood does relate to outcome, asphyxiation rather than
exsanguination is the most common cause of death.
Therefore, the most important risk factors for mortality are
the rapidity of blood loss and the severity of preexisting car-
diopulmonary disease. Other prognostic signs are listed in
Table 24–2, and most reflect the ability to control blood loss,
maintain a patent airway, and provide for adequate gas
exchange. Some studies have pointed out that spontaneous
cessation of bleeding in those who have had massive hemop-
tysis does not necessarily predict a good short- or long-term
outcome. Rebleeding is very common without definitive
treatment and may occur soon after the patient has been
judged to be stable or greatly improved.
A. Localization of Bleeding—Severe hemoptysis occasion-
ally may be misidentified as upper GI bleeding or bleeding
from the nose, nasopharynx, mouth, or upper airway, but the
history and examination should confirm or absolve these
structures as possible sites of bleeding. The evaluation of the
bloody material produced by the patient occasionally can
be helpful in distinguishing between a GI source and a lung
source. The presence of alveolar macrophages or an alkalotic
pH in the absence of acid-suppressing medications is more
likely to represent a respiratory tract specimen, whereas food
particles or an acidic pH is more suggestive of a stomach
source. Once the lungs are suspected, the next step is to
establish whether bleeding is from the trachea or the right or
left lung. Although it is tempting to conclude that an infil-
trate or cavity on chest x-ray or chest CT scan indicates the
site of bleeding, bilateral disease in tuberculosis, infection,
and inflammatory disorders is common. The infiltrate also
may represent a collection of blood brought up from the
contralateral side or from a different lobe or segment.
Bronchoscopy is the procedure of choice for identification
of a bleeding site in the tracheobronchial tree, and flexible
fiberoptic bronchoscopy generally is preferred over rigid
bronchoscopy. Bronchoscopy performed early in the course
of massive hemoptysis increases the likelihood of localization.
The advantages of fiberoptic bronchoscopy are patient com-
fort and the ability to explore further generations of bronchi.
The fiberoptic bronchoscope may be of limited use in severe
hemoptysis because the view is easily obscured by small
amounts of blood, and its suctioning ability is limited by the
small-diameter channel. Although the fiberoptic broncho-
scope can be passed through a large enough endotracheal
tube (usually >8 mm), maintenance of a patent airway may
be very difficult if the patient is actively bleeding. The fiberop-
tic bronchoscope provides limited treatment options, includ-
ing lavage, suctioning, and balloon tamponade. New
techniques have shown value, including direct application of
thrombin or thrombin-fibrinogen. Bronchoscopy-guided
topical hemostatic tamponade therapy (THT) using an oxi-
dized regenerated cellulose (ORC) mesh recently has been
shown to be helpful. On the other hand, the rigid broncho-
scope can be used even during large-volume hemoptysis
because of its better ability to suction blood, maintain the air-
way, and provide adequate ventilation. In general, if hemopt-
ysis subsides and the patient is stable, bronchoscopy can be
delayed for several days so that the fiberoptic instrument can
be used for careful inspection of the tracheobronchial tree. In
more emergent situations, rigid bronchoscopy is the preferred
bronchoscopic technique. Isolation of a bleeding lobe or
segment by endobronchial balloon tamponade using the
Table 24–2. Factors contributing to life-threatening
hemoptysis.
Massive hemoptysis (estimated >600 mL blood over 24 hours)  
Decreased pulmonary function (obstructive or restrictive disease)  
Altered mental status or level of consciousness 
Poor cough due to advanced age, sedation, neuromuscular weakness 
Coagulopathy or thrombocytopenia 
Mechanism of hemoptysis  
Underlying disease 
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fiberoptic or rigid bronchoscope and lavage of the bleeding
site with iced saline or vasoconstrictor agents such as epi-
nephrine should be regarded as minor adjuncts to control of
hemoptysis. Lastly, these procedures may be difficult to per-
form in the face of severe hemoptysis.
Bronchial arteriography may be useful for localization
of bleeding, and bronchial artery embolization (see below)
is used widely for control of severe hemoptysis. The angio-
graphic characteristics of potentially involved bronchial
arteries include hypervascularity, hypertrophy, aneurysms,
and bronchopulmonary anastomoses. Occasionally, no
abnormalities are identified. In tuberculosis and other dis-
orders, these changes may be seen in several locations,
including bilaterally, suggesting that findings do not estab-
lish the site of bleeding with complete confidence. Because
extravasation of contrast material injected into a bronchial
artery is rarely, if ever, seen except with rapid blood loss,
exact localization of a bleeding site is often not confirmed
until after successful embolization. If there is no evidence
of potential bronchial artery abnormalities, some investi-
gators suggest that pulmonary arteriography should be
performed to examine the pulmonary circulation as a
source of bleeding.
B. Medical Treatment—Supportive care consists of main-
taining an adequate airway and introducing measures to
control bleeding. Patients should be at bed rest with the
suspected or known side of bleeding dependent to protect
less involved parts of the lungs from filling with blood.
Cough suppressants such as codeine and sedative drugs
should be used cautiously, with a balance between decreas-
ing irritation of the airway from coughing and losing the
effectiveness of cough in keeping the airways clear. Vitamin
K, fresh-frozen plasma, and platelet transfusions should be
given if coagulopathy or thrombocytopenia is present.
Significant anemia is not usually due to acute hemoptysis,
so erythrocyte transfusions are needed only if the patient
has symptomatic anemia or other sources of blood loss.
Oxygen generally is administered to all hospitalized
patients. Antibiotics are often given to decrease any inflam-
matory component owing to acute bacterial bronchitis. If
active tuberculosis is suspected, antituberculosis therapy
should be instituted.
The best means of maintaining an adequate airway is the
patient’s own cough. The decision to place an endotracheal
tube implies that the rate and volume of hemoptysis exceed
the patient’s ability to cough up blood to keep the airway
clear. A cuffed endotracheal tube can be introduced into the
trachea and the patient suctioned to see if this treatment is
adequate to keep the airway clear. A sufficiently large endo-
tracheal tube—preferably at least 8 mm—is usually needed.
If extensive bleeding continues, selective endobronchial
intubation of the nonbleeding lung for ventilation can be
performed by advancing the endotracheal tube into a main
bronchus to protect the nonbleeding lung. For uncontrolled
right-sided bleeding, the endotracheal tube should be
inserted into the left main bronchus under fluoroscopic or
bronchoscopic guidance. The left lung is selectively venti-
lated, and blood is allowed to come up the trachea around
the tube. For left-sided bleeding, however, the endotracheal
tube cuff should be placed in the trachea, and a balloon-
tipped catheter (eg, Fogarty-type 14F balloon) is used to
seal the left main bronchus while the right lung is selectively
ventilated. This method permits ventilation of the entire
right lung, including the right upper lobe, because its open-
ing is usually close to the carina and is frequently blocked
by the insertion of an endotracheal tube into the right
mainstem bronchus. Placement of the balloon-tipped
catheter may be difficult while there is active bleeding.
Although the use of double-lumen endobronchial tubes
for split lung ventilation during thoracic surgery has been
advocated to separate the bleeding lung from the nonbleeding
lung, these tubes are not placed easily by inexperienced per-
sons and are subject to displacement even if situated properly.
In addition, the two lumens are small, which limits the
amount of blood that can be suctioned. Both Carlens-type
double-lumen tubes and newer plastic double-lumen tubes
with soft low-pressure tracheal and bronchial cuffs have been
used to achieve lung separation in hemoptysis, but only expe-
rienced personnel familiar with these devices should be asked
to insert them. To maintain the position of these tubes,
patients generally require heavy sedation and sometimes even
paralysis.
C. Bronchial Artery Embolization—Bronchial arteriogra-
phy and selective bronchial artery embolization with artifi-
cial material (eg, polyvinyl alcohol, steel coils, and gelatin
sponge) have greatly changed the management of severe
hemoptysis. Control of bleeding is achieved with a high
degree of success in patients with a variety of causes of
hemoptysis. Bronchial artery embolization is performed by
identifying bronchial arteries leading to the affected side, the
usual patterns consisting of one or two bronchial arteries on
each side arising from the aorta between the fifth and sixth
thoracic vertebrae. Branches of these arteries also may supply
anterior spinal arteries and intercostal arteries.
Complications of this procedure include distal arterial
embolization if the catheter is not placed far enough into the
selected artery and spinal cord damage if embolization is
performed into a branch supplying both the bronchial artery
and the spinal cord. If performed with proper care, this pro-
cedure is highly effective and may lead to long-term resolu-
tion of hemoptysis as well as short-term control prior to
definitive therapy. Estimates of immediate control of bleed-
ing by bronchial arterial embolization range as high as 90%
of patients. Recurrent bleeding after successful embolization
may suggest the need for repeat embolization in the same or
other areas. In some patients with chronic inflammatory
lung disease, identification of collateral arterial vessels may
be important. In one study, lasting control of hemoptysis was
achieved in 82% of patients during follow-up for as long as
24 months. Recurrent bleeding was seen with significantly
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greater frequency in patients with residual pulmonary dis-
ease and mycetomas.
D. Surgical Treatment—Surgical resection of the bleeding
lobe or segment in patients who can tolerate the procedure
removes the threat of recurrent bleeding. Earlier reports of
mortality rates higher than 30% from resectional surgery in
massive hemoptysis are now considered to be due to ongoing
bleeding, poor pulmonary function, and failure of preopera-
tive localization of the bleeding site. Local control of bleed-
ing by airway management or bronchial artery embolization
allows surgery to be performed under more controlled con-
ditions, and emergency surgery is now quite rare, with a cor-
responding decrease in surgical deaths.
On the other hand, many patients with severe hemopty-
sis will not be surgical candidates because of extensive bilat-
eral lung disease and severe reduction of lung function. Of
the remainder, medical management is usually adequate to
control bleeding, and early surgical therapy is reserved for
those with progressive aspiration of blood or inability to
control bleeding.
There is debate about prophylactic surgical resection after
severe hemoptysis has resolved. Recurrent bleeding is com-
mon after medical management in some series (25–40%),
and death from hemoptysis has occurred during the initial
bout of hemoptysis without warning or during a recurrent
bout after bleeding had apparently ceased. This risk of recur-
rent life-threatening hemoptysis has prompted some to per-
form elective resectional surgery in all patients with
hemoptysis in whom surgery is deemed tolerable. However,
while there is nearly universal agreement that surgery is indi-
cated for recurrent hemoptysis from a tuberculous or other
cavity in which a mycetoma is identified, prophylactic sur-
gery is not universally recommended. Potential candidates
for resection include those with well-localized disease, ade-
quate pulmonary function, minimal pleuropulmonary adhe-
sions, and a high likelihood of recurrence. Results of surgical
resection should be compared with the increasingly long-
term experience with arterial embolization (nonsurgical
management) for hemoptysis.
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 Deep Venous Thrombosis & Pulmonary
Thromboembolism
ESSENT IALS  OF  D IAGNOS I S
Deep venous thrombosis:
 Risk factors include a chronic or acute illness, immobi-
lization, recent surgery or orthopedic injury, hypercoag-
ulable state.
 Asymmetric calf or thigh pain or tenderness but may be
asymptomatic.
 Confirmation by contrast venography or duplex com-
pression ultrasonography.
Pulmonary thromboembolism:
 Dyspnea, tachycardia, pleuritic chest pain, and tachyp-
nea; if severe, hypotension, syncope, cyanosis, or shock.
 May have evidence of deep venous thrombosis.
 Mild to moderate hypoxemia, increased P(A–a)O2, and
mildly reduced PacO2.
 Suggested by a clinical syndrome consistent with pul-
monary embolism in the presence of a confirmed deep
vein thrombosis
 Confirmation by ventilation-perfusion radionuclide
scan, pulmonary angiogram, or CT angiography (helical
CT scan).
General Considerations
Venous thromboembolism is a disease thought to affect
approximately 1 in every 1000 hospitalized patients in the
United States and Europe. Some studies suggest that this
process accounts for or contributes to over 200,000 deaths
annually in the United States. Because of the difficulty in rec-
ognizing and diagnosing this syndrome, this figure may be
an underestimate of its true prevalence.
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Deep venous thrombosis and pulmonary thromboem-
bolism present three primary problems in the ICU. First,
patients with pulmonary thromboembolism may present
with severe respiratory failure or hemodynamic instability.
Second, critically ill patients with a variety of medical and
surgical disorders can develop pulmonary thromboem-
bolism complicating their underlying conditions. The diag-
nosis of venous thromboembolism in these ICU patients is
often especially difficult to make or confirm. The usual
method of treatment with anticoagulation is hazardous and
may be contraindicated in some of these patients. Finally,
there is increased emphasis on the prevention of deep venous
thrombosis and pulmonary thromboembolism in ICU
patients given that they tend to have multiple risk factors for
this disease. The causative relationship between the two dis-
orders means that the diagnosis, treatment, and prevention
of both must be considered together.
Pathophysiology and Pathogenesis
A. Deep Venous Thrombosis—The pathophysiology of
deep venous thrombosis centers around Virchow’s triad of
stasis of blood flow, intimal vascular injury, and a hypercoag-
ulable state. It is often the failure of mechanisms that prevent
the normally circulating blood from clotting in the intravas-
cular space, which leads to clot formation. A systemic hyper-
coagulable state can be either inherited or acquired and is
identified in only a small fraction of patients with venous
thromboembolism. In general, these thrombophilic states do
not cause a clinical thrombotic event without the presence of
a second acquired risk factor or precipitating circumstance.
Factor V Leiden or activated protein C resistance has been
identified in up to 5% of the Caucasian population in the
United States. Other hypercoagulable states include congen-
ital or acquired deficiency of circulating anticoagulants (eg,
deficiency of protein C, protein S, or antithrombin III), pro-
thrombin gene mutation (ie, G20210A), abnormalities in fib-
rinolysis, the presence of a lupus-associated anticoagulant,
and increased procoagulant activity such as occurs in some
malignant diseases and severe generalized trauma.
Assessment for the presence of one of these thrombophilic
states can only in part be performed at the time of the acute
thromboembolic event because the clotting process itself can
contribute to low of protein C and S levels. These low protein
C or S levels during the acute phase may not represent a true
deficiency of these factors, but may actually represent con-
sumption of these factors. Factor V Leiden and anticardi-
olipin, and antiphospholipid antibodies, on the other hand,
are not affected by the acute clotting process. More often,
however, patients with deep venous thrombosis have a com-
bination of venous stasis plus local damage to the venous
endothelium, exposing subendothelial procoagulant tissue
factor to the blood. Obstruction of venous flow leads to
edema and pain in the area drained by the affected veins.
On occasion, the intravenous clot is palpable on examina-
tion as a cord. Destruction of venous valves and persistent
venous occlusion by this process may lead to venous
insufficiency or permanent localized discomfort, edema, and
pain known as the postphlebitic syndrome.
Risk factors for deep venous thrombosis include pro-
longed immobilization, trauma to the extremity or pelvis,
generalized trauma, preexisting venous insufficiency, periph-
eral arterial disease, recent surgery, pregnancy or recent deliv-
ery, obesity, nephrotic syndrome, congestive heart failure,
acute myocardial infarction, malignancy, estrogen therapy,
and advanced age. Another important risk group consists of
patients with neurologic diseases leading to immobility
including strokes and spinal cord injury with subsequent
paralysis. Severe acute illness necessitating hospital admission
is also associated with an increased incidence of deep venous
thrombosis. Lastly, the increasing use of central venous
catheters in the ICU setting has led to an increasing incidence
of upper as well as lower extremity deep venous thromboses.
Deep venous thrombosis develops most frequently in the
posterior tibial vein, the popliteal vein just above the knee,
and the common femoral vein in the thigh. A smaller number
of patients with deep venous thrombosis have thrombi in the
pelvic veins. While the calf vein is probably the most common
site of deep venous thrombosis, only about 15–20% of these
lesions will extend proximally into deep veins above the knee.
In addition, it appears that upper extremity deep venous
thrombosis may occur more frequently than previously spec-
ulated owing to the use of short- and long-term central
venous catheters inserted into the internal jugular or subcla-
vian veins in ICU patients. Thrombi also may be found in the
right atrium in patients with chronic atrial fibrillation and in
the ventricles of patients with dilated cardiomyopathy or ven-
tricular aneurysms. Hypercoagulable states may cause clots to
form in the superior and inferior vena cava, the renal veins
(especially in nephrotic syndrome), and the hepatic veins (in
Budd-Chiari syndrome).
B. Pulmonary Thromboembolism—As many as 90% of
patients with pulmonary thromboembolism have blood clots
arising from proximal veins of the lower extremities (deep
femoral veins), with the remainder having thrombi coming
predominantly from pelvic veins. In a study of patients with
deep venous thrombosis, perfusion lung scans were uni-
formly negative in those with thrombosis limited to calf
veins only. This emphasizes the importance of identifying
high-risk thrombi located in popliteal and thigh veins or
extension of clot from calf to proximal veins. Thrombosis of
superficial veins is rarely associated with significant pul-
monary embolism. With increasing use of central venous
catheters and transvenous pacemakers, there has been a
reported rise in venous thrombosis and subsequent pul-
monary thromboembolism from the upper extremity. A
7–20% risk of embolization has been cited in patients with
symptomatic upper extremity thromboses.
The finding of lower extremity proximal deep venous
thrombosis has become part of several algorithms for the diag-
nosis of pulmonary embolism because of the association
between proximal leg deep venous thrombosis and pulmonary
embolism. These data are obtained from the overall population
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of patients with pulmonary embolism but may not reflect
findings in patients already in the ICU. Nevertheless, deep
venous thrombosis of the proximal leg veins remains the most
frequent source of pulmonary thromboemboli.
The clinical manifestations of pulmonary thromboem-
bolism reflect two pathologic processes: obstruction of the
pulmonary circulation resulting in hemodynamic compro-
mise and gas-exchange abnormalities. The degree of circula-
tory compromise depends on the size and number of
thromboemboli and the preembolic state of the right side
of the heart and pulmonary circulation. Some authors have
used the term massive pulmonary embolism to describe the
angiographic occlusion of two or more lobar pulmonary
arteries or greater than 50% of the pulmonary circulation,
while others reserve this label for patients who have hemody-
namic instability directly related to the embolic event. The use
of this radiographic description of a “massive pulmonary
embolism” has started to fall out of favor as these large or
multiple emboli may or may not be associated with circula-
tory collapse and shock. Patients with a previously normal
pulmonary circulation and right ventricular function gener-
ally can tolerate occlusion of even a large pulmonary artery
with maintenance of sufficient cardiac output to avoid shock.
However, acute pulmonary thromboembolism in a patient
with preexisting pulmonary hypertension or heart failure
with minimal reserve may lead to acute right-sided heart fail-
ure and subsequent circulatory collapse. The same may hap-
pen to a previously normal patient in whom a very large
embolus lodges in the main pulmonary artery or who has
multiple moderately sized emboli in several major branches.
Occlusion of pulmonary arteries results in decreased
regional perfusion of the lungs. If ventilation to these areas is
maintained, then high 
.
V/
.
Q areas contribute to increased dead
space ventilation. Minute ventilation requirements increase to
maintain PaCO2 within normal range. Arterial hypoxemia is
much more common. Although the mechanism of hypoxemia
is not completely understood, it probably results from a com-
bination of ventilation-perfusion mismatching from atelecta-
sis, redistribution of pulmonary blood flow, and increased
blood transit time. Occasionally, acute pulmonary hyperten-
sion leads to the opening of a patent foramen ovale with intraa-
trial right-to-left shunting and severe refractory hypoxemia.
The manifestations of pulmonary thromboembolism
often appear to be greater than can be explained by the degree
of vascular occlusion by thrombi. Although this is often due
to a lack of cardiopulmonary reserve in patients with chronic
illness, it is probable that vasoactive and bronchoactive sub-
stances play a role as well as normal compensatory processes
within the lung circulation and parenchyma. Among poten-
tial candidates for participation in this response are products
released by platelets and endothelial cells. In addition, occlu-
sion of a pulmonary artery is associated with a decreased
amount and effectiveness of surfactant in the region of lung
supplied by that vessel contributing to atelectasis.
Pulmonary infarction is another potential manifestation
of pulmonary thromboembolism. However, this diagnosis
does not seem to alter outcome or management other than
causing different abnormalities on chest x-ray and somewhat
different clinical manifestations. Pulmonary infarction is
uncommon in pulmonary embolism because of the dual sys-
temic and pulmonary artery blood supply to the lung.
Patients who present with pulmonary infarction are more
frequently those with congestive heart failure, in whom both
pulmonary venous congestion and systemic perfusion may
be compromised at baseline.
Because the lungs receive the total cardiac output, a
number of other emboli can make their way into the pul-
monary arterial circulation. These include pieces of tumor,
including adenocarcinomas that have eroded into the sys-
temic veins; foreign bodies such as broken intravenous
catheters or particulate matter accidentally or deliberately
injected into veins; fat and tissue emboli from orthopedic
injury, operative procedures, or bone marrow infarction as
seen in acute chest syndrome in patients with sickle cell dis-
ease; air introduced through intravenous lines, lung rupture,
or decompression during ascent from underwater diving;
and amniotic fluid introduced into the systemic circulation
during a tumultuous obstetric delivery. The pathophysio-
logic consequences of these emboli depend somewhat on
the clinical situation, the size and number of emboli, and
concomitant medical problems. Of note, fat emboli may
result in a distinct syndrome with systemic manifestations as
a result of the breakdown of free fatty acids within the
microcirculation.
Clinical Features
The clinical features of deep venous thrombosis and pul-
monary thromboembolism are intertwined, and both can
present diagnostic difficulties. Deep venous thrombosis
causes nonspecific clinical findings and is sometimes found
in patients with pulmonary embolism in whom thrombosis
was previously unsuspected. The diagnosis of pulmonary
thromboembolism can be difficult because it too presents
with nonspecific symptoms, signs, and laboratory tests that
suggest other acute lung and heart diseases. In the critically
ill patient with preexisting cardiac or respiratory failure,
pneumonia, atelectasis, pleural effusion, or infection, diag-
nosing superimposed pulmonary thromboembolism may be
even more difficult. It is often suspected when a critically ill
patient undergoes acute deterioration from previous baseline
findings manifested by tachypnea, tachycardia, and impaired
gas exchange.
A. Deep Venous Thrombosis—
1. Symptoms and signs—Obstruction of the deep venous
system of the leg may result in edema of the lower part or the
entire leg, pain, tenderness, redness, and other nonspecific
features. Findings are notoriously unreliable and insensitive,
with as many as 50% of patients with deep venous thrombo-
sis being asymptomatic or lacking abnormal physical find-
ings. Clinically significant venous thrombi may not
completely occlude the vascular lumen, or collateral veins
and lymphatics may prevent swelling. Most blood clots do
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not elicit an inflammatory response unless there is additional
vascular injury, so redness and warmth are most often not
present in uncomplicated deep venous thrombosis.
Importantly, patients with proximal deep venous thrombosis
may have a somewhat greater tendency to have silent disease
compared with those who have calf vein involvement.
However, swelling above or below the knee, recent immobil-
ity, cancer, and fever were found to have diagnostic value
in proximal acute deep venous thrombosis. Only 5% of
95 patients had none of these five findings, whereas 42% had
between two and five of these features.
The differential diagnosis of deep venous thrombosis in
symptomatic patients includes cellulitis and other soft tissue
infections, popliteal cysts with below-the-knee swelling,
septic or inflammatory arthritis, lymphatic obstruction or
inflammation, external compression of deep veins, trauma,
and hematomas. The finding of unilateral leg swelling does
not rule out primary disease in pelvic iliac veins.
2. Diagnostic workup—Imaging studies for deep venous
thrombosis include contrast venography, duplex compres-
sion ultrasonography, impedance plethysmography, radio-
fibrinogen uptake scans, CT venography, and MRI. Contrast
venography uses injection of radiocontrast material into
peripheral veins of the legs to identify obstructing thrombi
in the deep venous system. Between 20% and 50% of proxi-
mal venous thrombi usually can be identified as intralumi-
nal filling defects. Costs and complications make this test less
desirable.
Duplex ultrasound uses a combination of real-time ultra-
sound imaging to demonstrate normal venous collapse with
direct compression and Doppler venous flow assessment.
Because collapse with compression is the most important
feature, a more accurate name for this technique is compres-
sion ultrasonography. Failure to collapse or demonstration of
intraluminal echoes is indirect evidence of deep venous
thrombosis. Compression ultrasonography is practical for
the popliteal vein, the common femoral vein, and often the
superficial femoral vein. It is generally regarded as having as
high as 89–98% sensitivity for proximal deep venous throm-
bosis and comparable specificity. It is less reliable in imaging
the venous plexus in the calf, and it cannot detect thrombi
limited to iliac or pelvic veins. As discussed below, compres-
sion ultrasonography has been incorporated into numerous
diagnostic algorithms for the diagnosis of pulmonary
thromboembolism.
Impedance plethysmography uses the change in electrical
impedance of the lower extremity when blood flows out of
the leg venous system after release of a pressure cuff. Failure
to change impedance is presumptive evidence of proximal
deep venous thrombosis. This test has been reported to be
highly accurate for diagnosing proximal deep venous throm-
bosis, although other forms of venous obstruction and con-
gestive heart failure can give false-positive results. In
addition, the accuracy of the test is likely to be hospital-
dependent or operator-dependent. It has been recommended
that each facility establish the accuracy of impedance
plethysmography compared with contrast venography.
Impedance plethysmography must be performed with the leg
held immobile and cannot be used if there is a plaster cast on
the suspected leg. In a comparison trial of compression ultra-
sonography and impedance plethysmography, the predictive
value of compression ultrasonography was significantly
higher in symptomatic outpatients.
Radiofibrinogen leg scans demonstrate the inclusion of
radiolabeled fibrinogen into actively forming thrombi. This
test is useful primarily for identifying calf and lower-thigh
deep venous thrombosis. Only clots that are actively forming
can be located with this method. It is poor in detecting prox-
imal deep venous thrombosis. This test is used rarely today
except in research protocols.
MRI and CT pulmonary angiography accompanied by
venography are currently being investigated for their role in
the workup of thromboembolic disease. The advantage of
these studies would be evaluation of the pulmonary vascular
system for emboli combined with evaluation of the pelvis
and lower extremity venous system for their source  in a sin-
gle study.
Owing to its invasive nature, contrast venography is obvi-
ously not appropriate for screening patients at risk for deep
venous thrombosis. Both impedance plethysmography and
compression ultrasonography can be used effectively for this
purpose. In patients at high risk for deep venous thrombosis,
such as those with pelvic or hip trauma and those with criti-
cal medical illness, compression ultrasonography is probably
most sensitive and specific for proximal vein thrombosis,
even though there has been greater experience with imped-
ance plethysmography. In patients with deep venous throm-
bosis limited to the calf, serial compression ultrasonography
of patients is needed to identify  the 15–20% of patients who
extend their thrombi into the proximal veins. Most clots have
been found to extend proximally within the first 7 days. Thus
studies have recommended follow-up examinations within
2–3 days and again in 7–10 days if clinical suspicion for deep
venous thrombosis remains high.
B. Pulmonary Embolism
1. Symptoms and signs—The clinical features of pul-
monary embolism have been accurately described, and
review of these findings demonstrates their nonspecificity.
Table 24–3 summarizes data from a series of 500 patients
comparing the clinical signs and symptoms in patients with
proven pulmonary emboli by pulmonary angiography (202
patients) versus those without pulmonary embolism.
Dyspnea and chest pain were the most common complaints;
tachycardia, tachypnea, rales, and an increased intensity of
the pulmonic component of the second heart sound were the
most frequent findings on physical examination. The classic
findings of hemoptysis, chest pain, and dyspnea were
uncommon as a triad. Fewer than one-third of the total
group had symptoms or signs suggesting deep venous
thrombosis. While it is correct that these clinical findings do
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not distinguish patients with pulmonary embolism from
those with other severe heart and lung diseases, patients sus-
pected of pulmonary embolism who have cyanosis, hypoten-
sion, shock, or syncope deserve particular consideration.
Symptoms and signs can establish meaningful probabili-
ties for pulmonary embolism. Several clinical models for esti-
mating probability have been developed and validated.
Patients suspected of pulmonary embolism were stratified
into low, moderate, and high probability, and these classifica-
tions were confirmed by subsequent testing (Table 24–4).
This clinical estimate of pulmonary embolism likelihood is
the first step in diagnosis, followed by laboratory and imaging
studies. Objectively derived clinical prediction rules should be
used for judging “pretest” probability of pulmonary
embolism. These have been derived for nonhospitalized
patients suspected of pulmonary embolism and may not be
valid in hospitalized or ICU patients.
2. Laboratory findings—Arterial blood gases most often
show mild to moderate hypoxemia, increased P(A–a)O2, and
mildly reduced PaCO2. Almost all patients with pulmonary
embolism have a PaO2 of less than 80 mm Hg, but no
absolute level of PaO2 can be used to exclude the diagnosis.
Diagnostic accuracy may be improved somewhat by using
the P(A–a)O2 difference rather than the PaO2, but again, a
clear distinction between those with and those without pul-
monary embolism cannot always be made. In the Prospective
Investigation of Pulmonary Embolism Diagnosis (PIOPED)
study, 7% of patients with angiographically documented
pulmonary emboli had completely normal arterial blood gas
measurements. Conversely, another study found that
patients suspected of having a venous thromboembolic event
who had a normal P(A–a)O2 had only a 1.8% chance of hav-
ing a pulmonary embolism. Severe hypoxemia refractory to
oxygen administration may indicate the opening of a patent
foramen ovale. Hypercapnia is unusual and suggests the
presence of underlying lung disease.
PE Present
(n = 202) 
PE Absent 
(n = 298) 
Symptoms 
Dyspnea
Sudden onset 
Gradual onset 
78% 
6%
29%
20%
Chest pain 
Pleuritic
Nonpleuritic 
44%
16% 
30%
10% 
Orthopnea 1% 9% 
Fainting 26% 13% 
Hemoptysis 9% 5% 
Cough 11% 15% 
Palpitations 18% 15% 
Signs 
Tachycardia
HR >100 beats/min 
24% 23% 
Cyanosis 16% 15% 
Hypotension (SBP <90 mm Hg) 3% 2% 
Neck vein distention 12% 9% 
Unilateral leg swelling 17% 9% 
Fever >38°C 7% 21% 
Crackles 18% 26% 
Wheezes 4% 13% 
Pleural friction rub 4% 4% 
Data from Miniati M et al: Accuracy of clinical assessment in the
diagnosis of pulmonary embolism. Am J Respir Crit Care Med
1999;159:864–71. 
Table 24–3. Symptoms and signs in 500 patients with
suspected pulmonary embolism (PE).
Table 24-4. Estimating clinical probability of pulmonary
embolism (PE).
Points
Risk factors
Age >65 years 1
Previous DVT or PE 3
Surgery under general anesthesia or fracture 2
of the lower limb within 1 month
Active malignant condition (solid or hematologic 2
malignant condition, currently active or
considered cured <1 year)
Symptoms
Unilateral lower limb pain 3
Hemoptysis 2
Clinical signs
Heart rate 75–94 beats/min 3
Heart rate ≥95 beats/min 5
Pain on lower limb deep venous palpation and 4
unilateral edema
Clinical probability of pulmonary embolism
Low (8%) Total = 0–3 
Intermediate (28%) Total = 4–10
High (74%) Total ≥11 
Modified from Le Gal G et al: Prediction of pulmonary embolism in
the emergency department: The revised Geneva score. Ann Intern
Med 2006;144:165–71.
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Sinus tachycardia is a frequent and nonspecific finding in
acute pulmonary embolism. Supraventricular tachycardia
and atrial fibrillation are sometimes present. Features
suggesting acute right-sided heart strain on the ECG occur
relatively infrequently; these include acute right-axis devia-
tion, P pulmonale, right bundle branch block, and
inverted T waves and ST-segment changes in right-sided
leads. Electrocardiographic patterns such as an S wave in lead
I, a Q wave in lead III, and an inverted T wave in lead III
(“S1Q3T3”) and S waves in leads I, II, and III (“S1S2S3”)
were considered highly predictive of pulmonary embolism.
These observations were found in fewer than 12% of patients
with pulmonary emboli. In the differential diagnosis of pul-
monary embolism, the ECG is particularly useful to assess
the presence of myocardial ischemia and infarction.
D-dimer, a fibrin degradation product, is found in the
plasma of patients with deep venous thrombosis and pul-
monary embolism. D-dimer is the result of plasmin action
(thrombolysis) on fibrin monomers that have undergone
cross-linking by factor XIII to form fibrin polymers. Various
methodologies are available to measure D-dimer levels. ELISA
D-dimer assays have a higher sensitivity and negative predictive
value (91–100%) when compared with latex agglutination
techniques. However, the older ELISAs were more labor-
intensive, required skilled personnel, and took hours to com-
plete, making them less useful clinically in an emergent
situation, whereas the semiquantitative latex agglutination
studies can be performed at the bedside. A D-dimer level of less
than 500 μg/L by ELISA is considered the cutoff for excluding
venous thromboemboli. Newer latex whole blood agglutina-
tion techniques have demonstrated consistently high negative
predictive values in patients with low pretest probability of dis-
ease. Current recommendations are to combine this laboratory
finding with the pretest clinical probability as well as some
other noninvasive evaluation to guide decision making for
diagnosis and management. The one exception would be in the
face of a low clinical pretest probability, when the finding of a
low D-dimer may be enough to exclude venous thromboem-
bolic disease. Lastly, D-dimer is of limited use in a number of
clinical scenarios, which are associated with elevated D-dimer
levels as part of the disease state including surgery or trauma in
the past 3 months, underlying malignancy, sepsis with or with-
out disseminated intravascular coagulation (DIC), inflamma-
tory states, pregnancy, or abnormal liver function.
Elevation in cardiac troponins in the setting of an acute
pulmonary embolism has been described. In patients with
either a moderate or large pulmonary embolism, troponin T
(TnT) levels greater than 0.1 ng/mL were seen in 32% of
patients in one trial. None of the patients with small emboli
had an elevation of this cardiac marker. In another study,
tropoinin I (TnI) levels greater than 0.4 ng/mL were seen in
21% of patients with pulmonary embolism, with levels
exceeding 2.3 ng/mL in 4% of patients. It is thought that the
strain on the right ventricle from the increased pulmonary
arterial resistance in the face of an acute embolism leads to
the right ventricular myocardial ischemia in these patients
and is associated with a poorer prognosis.
3. Imaging studies—Radiographic studies include nonspe-
cific tests such as chest x-rays, examinations of the pul-
monary circulation such as perfusion lung scans, CT
pulmonary angiography (spiral or helical CT scans), MRI,
and pulmonary angiograms, as well as studies directed at
finding deep venous thrombosis.
a. Chest x-ray—The chest x-ray is most useful in identi-
fying coexisting problems such as pneumonia, lung mass,
lymphadenopathy, pulmonary edema, atelectasis, or pleural
effusion. The most common findings in pulmonary
embolism without coexisting disease are nonspecific, includ-
ing no visible abnormality, enlarged cardiac silhouette, ele-
vated hemidiaphragm, atelectasis, or small pleural effusion.
A normal chest x-ray in a patient with shortness of breath
and hypoxemia should prompt a further evaluation for pul-
monary embolism. Findings suggestive of pulmonary vascu-
lar occlusion, such as an apparent cutoff of a segmental or
lobar pulmonary artery, regional hyperlucency of the lung
parenchyma or oligemia (Westermark’s sign), or a wedge-
shaped density consistent with pulmonary infarction
(Hampton’s hump if located in the periphery), may suggest
pulmonary embolism but are insensitive and lack specificity.
b. Radionuclide ventilation-perfusion scan—The venti-
lation-perfusion lung scan was previously the test used most
frequently to diagnose pulmonary embolism. Newer imaging
studies have replaced this nuclear medicine study in many
centers. In addition, scan results must be considered carefully
because these tests do not have perfect diagnostic accuracy,
and over 70% of patients undergoing this radiographic eval-
uation have indeterminate results. To perform the perfusion
scan, radionuclide-labeled macroaggregated albumin is
injected into a peripheral vein, after which the labeled parti-
cles become trapped in the pulmonary capillary bed.
Uniform distribution of the radionuclide throughout the
lung fields implies the absence of significant localized pul-
monary arterial obstruction, whereas a pulmonary
embolism occluding a pulmonary artery will result in a per-
fusion defect. Unfortunately, perfusion defects commonly
result from other causes, including focal vasoconstriction
accompanying atelectasis, pneumonia, or bronchospasm.
To improve diagnostic value, uniformity of ventilation is
assessed using a ventilation scan, performed by inhalation of
either radioactive Xenon or an aerosol containing a radiola-
beled solute. The perfusion and ventilation scans are then
compared. A sufficiently large perfusion defect without a cor-
responding ventilation defect in the same area (ie, mis-
matched defect) generally is considered supportive of the
diagnosis of pulmonary embolism. On the other hand, a
matched ventilation-perfusion defect generally is considered
indeterminate and not helpful in making the diagnosis of
pulmonary embolism or other kinds of heart or lung disease
such as pneumonia or bronchospasm.
By convention, ventilation-perfusion lung scans are inter-
preted as normal (no perfusion defects), low or high proba-
bility for pulmonary embolism, or intermediate probability
(sometimes called indeterminate) for pulmonary embolism.
Prospective studies have led to accepted diagnostic strategies
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for pulmonary embolism. The PIOPED multicenter study
compared lung scan results with pulmonary angiography in
patients with suspected pulmonary embolism. Table 24–5 is
a modified summary of lung scan categories and criteria
used in 931 patients included in this study.
Of patients with suspected pulmonary embolism, lung
scans indicated a high probability of pulmonary embolism in
13% and were normal or nearly normal in 14%. Intermediate
or low probability was the conclusion in 73%. The sensitiv-
ity, specificity, and likelihood ratios of lung scan interpreta-
tions for angiographically diagnosed pulmonary emboli are
shown in Table 24–6. The likelihood of pulmonary embolism
parallels the interpretation of the lung scans, especially when
used in conjunction with the pretest clinical likelihood of
pulmonary embolism. A reading of any probability (low,
intermediate, or high) of pulmonary embolism on lung scan
resulted in 98% sensitivity but low specificity. Unfortunately,
only 41% of cases of pulmonary embolism had high-
probability lung scans, whereas 42% had intermediate-
probability scans and 17% had low-probability scans. It is
emphasized that patients with low-probability lung scans are
found to have pulmonary emboli about 15–30% of the time.
These and other data show that ventilation-perfusion lung
scans are of greatest utility when they show high probability for
pulmonary embolism (87% likelihood of pulmonary embolism
in all patients suspected of pulmonary embolism; 96% if clinical
suspicion is high) or when they are normal (nil to 4% likelihood
of pulmonary embolism during long-term follow-up even if clin-
ical suspicion was high). Thus high-probability lung scans effec-
tively predict pulmonary embolism, whereas a normal scan (no
perfusion defects) effectively excludes pulmonary embolism.
Treatment or withholding therapy can be guided by this rule with
considerable confidence. Unfortunately, the majority of patients
suspected of having pulmonary embolism fall into intermediate
or low probability, and substantial numbers within each
Table 24–5. PIOPED lung scan interpretation criteria
(modified).
High probability 
≥ 2 large (>75% of the segment), OR 
≥ 2 moderate (25–75% of the segment) plus one large, OR 
≥ 4 moderate mismatched perfusion lung scan defects 
Low probability 
Nonsegmental perfusion defects only, OR 
One moderate mismatched segmental perfusion defect with normal
chest x-ray, OR
Any perfusion defect with a larger chest x-ray abnormality, OR 
Limited number of large or moderate perfusion defects with
matching ventilation defects (with normal or mildly abnormal
chest x-ray) 
Intermediate probability 
Not falling into normal, low-, or high-probability categories 
Borderline high or borderline low 
Difficult to categorize as high or low 
Normal 
No perfusion defects, OR 
Perfusion outlines exactly the shape of lungs seen on chest x-ray
(chest x-ray or ventilation lung scan may be abnormal) 
Table 24-6. Sensitivity, specificity, likelihood ratios, and posttest probabilities of ventilation-perfusion radionuclide
lung scans and CT pulmonary angiograms for pulmonary embolism.
For a patient with suspected pulmonary embolism, estimate pretest probability (clinical information or clinical information plus results of prior tests).
Look up posttest probability at intersection of pretest probability (column) and test result (row).
Pretest Probability∗
8% 28% 50% 74%
Ventilation-Perfusion Radionuclide Scan 
Scan Result Sensitivity Specificity Likelihood Ratio Posttest Probability
High probability 41% 97% 17.1 60% 87% 94% 98%
Indeterminate 41% 62% 1.1 9% 30% 52% 76%
Low probability 16% 60% 0.4 3% 13% 29% 53%
Near-normal or normal 2% 81% 0–0.1 0–1% 0–4% 0–9% 0–22%
CT Pulmonary Angiogram
Positive 78–97% 53–100% 3.5–32 23–74% 58–93% 78–97% 91–99%
Negative 0.05–0.48 0–4% 2–16% 5–32% 12–58%
∗Using the revised Geneva Score (see Table 24–4).
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category will or will not actually have the disease. It should be
emphasized that these studies have characterized mostly patients
who were not critically ill, in whom the appropriate studies could
be performed and compared. The predictive value of lung scans
may not be comparable in patients in the ICU.
c. Combination imaging—Multiple approaches for
improving diagnostic accuracy when lung ventilation-
perfusion scanning is nondiagnostic have been described
(Figure 24–1). The traditionally used strategy is to perform
pulmonary angiography for all suspected patients in whom
intermediate probability lung scans are found (pulmonary
embolism present by angiography in 16–66% depending on
clinical suspicion) or in whom a low-probability lung scan is
associated with high or uncertain clinical suspicion (pul-
monary embolism found in 16–40%). A normal pulmonary
angiogram is quite accurate in excluding pulmonary
embolism, with fewer than 1% of patients with negative pul-
monary angiograms subsequently proving to have pulmonary
embolism without treatment during long-term follow-up or
at autopsy. This approach would be ideal if it were not for
problems encountered with obtaining pulmonary angiogra-
phy, including limited availability, uncertain reliability in all
hospitals, and risks of vascular catheterization and radi-
ographic contrast agents. Small amounts of contrast material,
selective pulmonary angiography, nonionic contrast material,
and careful preinjection measurement of pulmonary artery
pressure reduce the frequency of complications from pul-
monary angiography. Pulmonary hypertension is a relative
contraindication because of reported morbidity and mortal-
ity from injecting additional volume into a system already
under high pressure. Other complications, including death,
respiratory distress leading to intubation, renal failure, and
hematoma requiring transfusion, are reported to occur in
up to 4% of critically ill patients undergoing pulmonary
angiography. Pulmonary angiography used to be per-
formed in all patients being considered for thrombolytic
 Figure 24–1. One suggested approach to a patient with suspected pulmonary embolism. After estimation of clinical
probability (see Table 24–4), most patients should have CT pulmonary angiogram performed unless a contraindication exists.
If the cumulative probability of clinical estimation plus CT angiogram results is sufficient to begin or withhold treatment,
diagnostic studies are completed. If not, further studies are required (eg, compression ultrasonography or pulmonary
angiography) until a decision can be reached. Any decision to begin or withhold treatment must take into account the risk
of treatment compared with the potential benefits of treatment.
Suspected pulmonary embolism
Estimate clinical probability
Low (8%) Moderate (28%) High (78%)
D-dimer (ELISA)
No treatment DVT studies Treat
CT angiogram1
High
Positive
Positive
Positive
Low Negative
Negative
Negative
Pulmonary
angiogram
1If CT is contraindicated due to iodine allergy or creatinine clearance is prohibitive, consider
starting with V/Q scan or compression ultrasonography 
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therapy, but this recommendation is being questioned
because of the subsequent risk of bleeding (as high as 20%).
The major disadvantage of this approach is that a large num-
ber of patients would require pulmonary angiography
because of abnormal but nondiagnostic lung scans. In some
studies, patients making up this group comprise 40–60% of
the total enrolled.
A second approach recognizes the close relationship
between pulmonary thromboembolism and deep venous
thrombosis. Proximal vein deep venous thrombosis is found
on initial testing in about 50% of patients with pulmonary
embolism. In patients with low- or intermediate-probability
ventilation-perfusion lung scans but with high or uncertain
clinical probability of pulmonary embolism, compression
ultrasonography or impedance plethysmography may be
performed. A combination of high or uncertain clinical sus-
picion, abnormal (but not high-probability) lung scan, and
positive noninvasive test for deep venous thrombosis
strongly supports the diagnosis of pulmonary embolism.
Treatment should be initiated on the basis of this result. The
absence of evidence of deep venous thrombosis, however,
should not rule out pulmonary embolism because the false-
negative rate of a single noninvasive test for deep venous
thrombosis ranges from as low as 3% to as high as 30%.
Therefore, these patients must undergo pulmonary angiog-
raphy or serial duplex ultrasonography if the initial ultra-
sound is negative (see below). The combination of lung scan
and noninvasive deep venous thrombosis studies decreases
the number of pulmonary angiograms needed in these
patients from about 72% to 33%. Completely noninvasive
strategies for selected patients also have been proposed. In
patients suspected of pulmonary embolism who have abnor-
mal but nondiagnostic lung scans (ie, low or intermediate
probability) and adequate cardiopulmonary reserve (eg, lack
of respiratory failure, hypotension, severe underlying lung
disease, and severe tachycardia), serial noninvasive tests for
proximal lower extremity deep venous thrombosis are per-
formed (eg, impedance plethysmography or compression
ultrasonography). If evidence of deep venous thrombosis is
found initially or subsequently, treatment is started.
However, if no evidence of deep venous thrombosis is found,
anticoagulation is withheld while noninvasive deep venous
thrombosis studies are repeated at least twice over the next
10–14 days. In a study of 627 untreated patients with sus-
pected pulmonary embolism with nondiagnostic lung scans
and negative serial impedance plethysmographic studies over
2 weeks, pulmonary thromboembolism occurred in only
1.9% over the next 3 months. Treatment therefore can be
withheld in this group of patients with acceptable results. In
fact, this approach clarifies the natural history of pulmonary
thromboembolism in that extension of the pulmonary
embolus itself rarely occurs without treatment, and treat-
ment is directed solely at prevention of extension of the
venous thrombus. This noninvasive approach can be used to
avoid pulmonary angiography in some patients with nondi-
agnostic lung scans. For critically ill patients, however, this
strategy may not be feasible because of concomitant heart
and lung disease and lack of cardiopulmonary reserve. In
addition, patients being considered for therapy other than
anticoagulation, such as thrombolytic therapy, cannot be
evaluated appropriately using this method.
Another completely noninvasive strategy included the com-
bined use of CT angiography, a ventilation-perfusion scan,
plasma D-dimer measurements, and in some patients compres-
sion ultrasonography of the lower extremities. In 247 patients
evaluated using this strategy, the 3-month risk of developing an
embolic event without therapy if none of these studies revealed
venous thromboembolism was only 1.7%. In general, the diag-
nostic protocols that combine these noninvasive studies either
have obtained all studies during the initial assessment and made
treatment decisions based on all study results altogether or have
obtained a single study at a time and continue to obtain addi-
tional diagnostic data if the results are not conclusive until a
definitive diagnosis is obtained or excluded.
d. CT pulmonary angiography—Imaging studies that
attempt to assess the pulmonary vasculature bed directly have
been evaluated for their role in the diagnostic workup of pul-
monary thromboembolism. The development of helical
(spiral) and electron-beam CT pulmonary angiography has
nearly replaced the ventilation-perfusion scan in many cen-
ters with its reported sensitivities in most studies of greater
than 80% and specificities of greater than 90% for diagnosing
pulmonary emboli in the main, lobar, and segmental pul-
monary arteries. The lower sensitivity of this imaging study
results in part from the poor performance in the diagnosis of
subsegmental emboli. The clinical impact of emboli in these
subsegmental arteries is unclear, and they may not pose the
same morbidity and mortality risks as emboli in larger seg-
ments. However, in patients with a limited cardiopulmonary
reserve, emboli in subsegmental arteries potentially could be
devastating. Newer imaging techniques that are available
today, including thin collimation (1–3-mm instead of 5-mm
slices) and faster acquisition timing have improved the evalu-
ation of these subsegmental vessels. An additional advantage
of these imaging studies is their ability to provide additional
information with regard to other disease processes within the
thorax that may be responsible for the patient’s clinical pres-
entation, such as pneumonic infiltrates, pleural disease, medi-
astinal lymphadenopathy, or parenchymal masses. CT
imaging requires the administration of intravenous contrast
material and a degree of patient cooperation with the ability to
lie still and breath-hold for approximately 25 seconds in some
protocols to obtain good-quality pictures of the vasculature.
In a small but important proportion of studies, the results are
not acceptable because of movement artifacts or inadequate
concentration of contrast material in the pulmonary arteries.
The exact role of these CT imaging techniques with the
diagnosis of pulmonary thromboembolic disease is continu-
ing to evolve, and these techniques are included in a number
of combined-strategy models. In fact, some investigators
have adopted CT imaging as the key starting diagnostic test
for all patients considered likely to have a pulmonary
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embolism. A meta-analysis evaluated the 3-month clinical
outcome in patients with suspected pulmonary embolism
managed solely based on the results of CT pulmonary
angiography. The rate of subsequent venous thromboem-
bolism after a negative CT result in untreated patients was
1.4%, which is similar to the rate seen in previous studies
with negative pulmonary angiograms. Because concern still
exists among many physicians about the overall sensitivity of
CT imaging but with acceptable specificity, the helical CT
can be used to diagnose pulmonary thromboembolism if a
thrombus is seen but may not be able to exclude significant
pulmonary artery thrombi if clots are not visualized in
patients with a high pretest probability of having this disease
state. Nevertheless, a diagnostic strategy based on clinical
probability, D-dimer, and CT pulmonary angiography
proved highly effective. In those in whom pulmonary
embolism was “excluded,” only 1.3% of untreated patients
had recurrent venous thromboembolism.
CT pulmonary angiography combined with CT venogra-
phy of the pelvis and lower extremities to evaluate the venous
system for the source of the embolus during the same study
(ie, CTA-CTV) was investigated in the PIOPED II trial. While
the addition of venography increased the sensitivity of this
combined CT imaging study, the authors concluded that
both CT angiography alone or combined with CT venogra-
phy had high predictive values when concordant with the
pretest probability of disease. However, when these imaging
studies were discordant with the pretest probability, addi-
tional studies were needed before excluding venous throm-
boembolic disease from the differential diagnosis for the
patient’s clinical signs and symptoms. Therefore, the addi-
tion of CT venography to diagnostic algorithms has not been
strongly recommended based on the little it adds to predic-
tive value of CT angiography and clinical probability. MRI of
both the pulmonary vasculature and the venous system of
the pelvis and lower extremity also may have a future role in
the workup of this disease. The advantage MRI studies of the
vasculature would be the avoidance of iodine-based contrast
material and its associated risks, including anaphylactic reac-
tions and renal impairment.
4. Diagnostic approach to pulmonary thromboem-
bolism—Many algorithms optimizing diagnostic strategies
have been proposed. A logical approach is to assess clinical
pretest probability based on symptoms and signs and then
apply tests that increase or decrease the probability of disease
(posttest probability). In this way, the likelihood of pul-
monary embolism can be estimated and the risks of treat-
ment compared. Table 24–5 assigns low, moderate, and high
clinical estimates for disease based on clinical findings for
patients evaluated in an emergency department setting.
Validation of these data confirmed that these groups had 8%,
28%, and 74% likelihood of pulmonary embolism.
The clinician must decide whether these probabilities are
a sufficient basis for decisions about whether or not to treat
a patient. If a more certain diagnosis is warranted—and this
is almost always the case with clinical information alone—
another diagnostic test is applied. The first diagnostic study
in many algorithms in the past was the ventilation-perfusion
radionuclide scan, but this has now been replaced in many
centers by CT pulmonary angiography, especially in patients
with preexisting obstructive or parenchymal lung disease
likely to result in uninterpretable scans. Table 24–6 compares
posttest probability using typical sensitivity and specificity
values for various imaging results for selected clinical pretest
probabilities. If posttest probability is sufficiently high to jus-
tify starting treatment or sufficiently low to justify withhold-
ing treatment, further diagnostic tests are not indicated. If
more diagnostic certainty is desired, then noninvasive stud-
ies—compression ultrasonography or pulmonary angiogra-
phy—can be performed. For decision-making purposes, the
pulmonary angiogram is assumed to have 100% specificity;
that is, a negative study excludes pulmonary embolism. The
probabilities of pulmonary embolism when assessed by com-
pression ultrasonography, D-dimer, and other diagnostic
tests are shown in Table 24–7. These tests can be applied
sequentially to support the diagnosis or to exclude the diag-
nosis; although to be certain, these estimates are derived
from a number of studies of different populations. While
they are not strictly independent estimates, the combined
probabilities are still likely to have value. Any decision to
begin or withhold treatment must take into account the risk
of treatment compared with its potential benefit especially in
the ICU patient population.
Treatment
A. Anticoagulation—Anticoagulation is the major therapy
for deep venous thrombosis and pulmonary embolism.
Heparin, either unfractionated heparin (UFH) or low-
molecular-weight heparin (LMWH), is most often given for
4–5 days, overlapping with oral anticoagulant therapy begin-
ning on day 1. Oral anticoagulant agents, mainly in the form
of vitamin K antagonists such as warfarin, are given for a
minimum of 3 months. There are a number of other treat-
ment schedules depending on the underlying cause of the
event, the history of previous thromboembolic events, and
the patient’s underlying medical history. Heparin therapy
should be started immediately before any definitive tests are
performed if there is a strong clinical suspicion and no con-
traindications exist. Heparin also should be started once a
diagnosis of deep venous thrombosis or pulmonary
embolism is confirmed, if not started prior to the diagnosis.
Anticoagulants do not directly affect existing thrombi, but if
given in sufficient amounts, they can prevent further clot
propagation until the patient’s inherent fibrinolytic system
can begin to break down the thrombus or embolism.
In the absence of contraindications, initial treatment
should be with heparin in the form of continuous intra-
venous infusion of UFH or subcutaneous LMWH. To begin
therapy with continuous UFH, an infusion of heparin is
given at a dose that achieves and maintains a stable activated
partial thromboplastin time (aPTT) of 1.5–2.5 times control
when measured at 6-hour intervals. The aPTT then can be
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measured at approximately daily intervals once this goal
range has been achieved. Failure to achieve an aPTT at least
in the lower level of this range within the first 24 hours of
therapy has been associated with recurrent venous throm-
boembolism in patients with deep venous thrombosis.
Standard heparin dose-adjustment protocols or nomo-
grams for deep venous thrombosis and pulmonary
thromboembolism are highly desirable and have been
shown to increase therapeutic efficacy and reduce bleeding
complications. One weight-based nomogram is shown in
Table 24–8. A bolus of UFH at 80 units/kg of body weight is
given, followed by 18 units/kg per hour. For a 60-kg adult, this
corresponds to 4800 units as a bolus followed by 1080 units/h
or about 26,000 units/day. Concern has been expressed that
Table 24-7. Sensitivity, specificity, likelihood ratios, and posttest probabilities of pulmonary embolism from selected
studies of compression ultrasonography and D-dimer.
Instructions: For a patient with suspected pulmonary embolism, estimate pretest probability and find posttest probability at intersection of pretest probability
(columns) and test results (rows).
aPTT (s) 
Rate Change
(units/kg/h) 
Additional Action Next aPTT 
<35 (<1.2 × normal) +4 Rebolus with 80 units/kg 6 hours 
35–45 (1.2–1.5 × normal) +2 Rebolus with 40 units/kg 6 hours 
46–70 (1.5–2.3 × normal) 0 None 6 hours 
71–90 (2.3–3.0 × normal) –2 None 6 hours 
>80 (>3 × normal) –3 Stop infusion for 1 hour 6 hours 
∗During the first 24 hours, repeat aPTT every 6 hours. Thereafter, obtain aPTT every morning unless it is outside the
therapeutic range. 
Modified from Hyers TM: Venous thromboembolism. Am J Respir Crit Care Med 1999;159:1–14.
Table 24–8. Body weight-based dosing of intravenous unfractionated heparin. 
Initial dosing
Loading: 80 units/kg
Maintenance infusion: 18 units/kg/h using 25,000 units in 250 mL D5W (100 units/mL)
Obtain aPTT before and 6 hours after starting heparin
Subsequent dose adjustments based on aPTT measured at 6-hour intervals∗
Pretest Probability
8% 28% 50% 78%
Compression Ultrasonography (for Patients with Symptoms of DVT)
Sensitivity Specificity Test Result Likelihood Ratio Posttest Probability
95% 95% Positive 19.00 62% 88% 95% 98%
Negative 0.05 0.40% 2% 5% 12%
Compression Ultrasonography (for Patients without Symptoms of DVT)
62% 97% Positive 21.00 65% 89% 95% 98%
Negative 0.39 3% 13% 28% 53%
D-Dimer
85–100% 45–68% Positive 1.6–2.7 12–19% 38–51% 62–73% 82–88%
Negative 0.09–0.22 0–1.80% 3–8% 8–18% 20–39%
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the maintenance dose of heparin is frequently underesti-
mated, resulting in recurrent deep venous thrombosis or pul-
monary thromboemboli. The mean heparin requirement in
several studies was approximately 1300 units/h (about 31,000
units/24 h) compared with older studies suggesting that
1000 units/h usually was adequate. The dose is adjusted
upward or downward as needed based on the aPTT.
Although this nomogram should be strictly used only when
the same reagent is employed as in the development of the
nomogram, it should prove useful as a guide in all hospitals.
LMWH differs from standard UFH in its pharmacoki-
netics, bioavailability, and anticoagulant activity and has
found a role in the treatment of both deep venous throm-
bosis and pulmonary embolism. These heparin fractions
have greater bioavailability when given subcutaneously,
longer duration of action, allowing for once- or twice-daily
dosing, and predictable anti-factor Xa activity. The antico-
agulation effects of LMWH can be correlated with body
weight for dosing purposes, and this diminishes the need
for following laboratory parameters to ensure adequate
anticoagulation. In direct comparisons, LMWH has been
associated with fewer major bleeding complications, less
thrombocytopenia, and a lower incidence of osteoporosis
than UFH. All LMWH formulations crossreact with UFHs
and cannot be used as an alternative form of anticoagulation
in patients with heparin-induced thrombocytopenia syn-
drome. Dosage adjustments may be necessary in patients
with morbid obesity and renal insufficiency. Each LMWH
formulation has its own distinct pharmacokinetic profile,
so data on one form cannot be readily extrapolated to
another form in the same class. In the treatment of deep
venous thrombosis and pulmonary thromboembolism, the
2004 American College of Chest Physicians (ACCP) con-
sensus recommendations are as follows: LMWH treatment
administered subcutaneously in doses adjusted to body
weight or dose-titrated intravenous UFH for at least the
first 5 days of therapy; LMWH is preferred over UFH in
patients with “nonmassive” pulmonary emboli, whereas
UFH is preferred in patients with severe renal impairment.
In addition to heparin, warfarin can be started on day 1
unless there are contraindications to its use. Warfarin, an oral
anticoagulant that inhibits synthesis of vitamin K–dependent
coagulation factors, becomes an effective anticoagulant only
after disappearance of previously synthesized circulating
coagulation factors. Thus several days are needed for war-
farin to have an antithrombotic effect, whereas its anticoag-
ulant effect occurs sooner. In the past, concern has been
raised about a potential hypercoagulable state induced by
warfarin because synthesis of proteins C and S, naturally
occurring anticoagulants, is also inhibited by this agent. This
problem is encountered very rarely.
Almost all patients can be started with a single oral dose
of warfarin at 5 mg/day. The goal is to achieve an interna-
tional normalized ratio (INR) of 2.5 (range 2.0–3.0). This
corresponds roughly to a prolongation of the prothrom-
bin time to 1.3–1.5 times normal (using the usual tissue
thromboplastin assay employed in laboratories in North
America). Nomograms for warfarin dosing suggest that the
INR measured at least 15 hours after the first dose is helpful
in deciding on subsequent doses. If the first INR is greater
than 1.5, a very low maintenance dose (1 mg) is probably suf-
ficient; an INR of between 1.2 and 1.3 calls for a dose of 2–3
mg/day. All other patients should receive a second oral dose
of 5 mg and should be monitored by continued daily INR
measurements. Heparin can be discontinued after 4–5 days if
the INR is greater than 2.0 for two consecutive days.
The dose of warfarin should be adjusted according to the
prothrombin time. Initially, the prothrombin time should
be measured daily until a stable INR is achieved. Thereafter,
twice-weekly measurements followed by weekly measure-
ments should be adequate. A number of drugs interact with
warfarin, both increasing and decreasing its effectiveness.
Antibiotics in particular may decrease bacterial flora of the
gut that are responsible for a significant amount of vitamin
K synthesis. In the ICU, other drugs that may prolong the
prothrombin time by potentiating the action of warfarin
include aspirin, nonsteroidal anti-inflammatory drugs
(NSAIDs), omeprazole, and amiodarone, as well as antimi-
crobial agents such as most cephalosporins, erythromycin,
fluconazole, and metronidazole. On the other hand, barbi-
turates, rifampin, and carbamazepine may reduce the effect
of warfarin on the prothrombin time by increasing the rate
of its metabolism in the liver. Warfarin and other oral vita-
min K antagonists are contraindicated during pregnancy
because of the potential for abnormal fetal development.
The optimal duration of anticoagulation therapy for deep
venous thrombosis and pulmonary embolism has not been
determined for all clinical situations and depends on under-
lying predisposing risk factors. Studies have shown that
heparin followed by 3 months of warfarin results in an
acceptably low (<5%) frequency of recurrent deep venous
thrombosis in patients who have a transient and identifiable
risk factor. This applies to patients with a first event whose
predisposing risk factor, such as immobilization from a bro-
ken bone, surgery, or trauma, has resolved. For patients with
a first episode of idiopathic venous thromboembolism (no
identifiable risk factor), at least 6 months of anticoagulation
therapy is recommended. On the other hand, patients in
whom risk factors are long term and poorly reversible, such
as those with chronic congestive heart failure or hypercoagu-
lable states, should receive a longer period of anticoagulation
therapy on the order of 12 months or even indefinitely. In
patients with a hypercoagulable state associated with malig-
nancy, the effectiveness of anticoagulation is highly variable.
Patients unable to receive warfarin should be given either
subcutaneous UFH at a dosage sufficient to prolong the
aPTT more than 1.5 times control (adjusted-dose subcuta-
neous heparin) or daily LMWH.
The major complication of UFH therapy is bleeding,
occurring in approximately 5% of patients (ranges from 1% in
those with low risk for bleeding to 10% in those with high risk).
LMWH has imposed a lower risk of major bleeding events
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when used in the setting of venous thromboembolism.
Bleeding is usually not spontaneous but due to some underly-
ing cause. Heparin-induced thrombocytopenia may con-
tribute to bleeding, as may simultaneous administration of
antiplatelet agents such as aspirin or dextran. Warfarin and
other oral anticoagulant agents are also associated with bleed-
ing complications. Bleeding has been demonstrated to be less
common when excessively prolonged coagulation times are
avoided.
The effect of UFH can be quickly counteracted by discon-
tinuing its infusion and administering protamine sulfate.
Approximately 1 mg of protamine will neutralize 100 units of
circulating heparin. The reversal of subcutaneously adminis-
tered UFH may require a prolonged infusion of protamine.
Patients who use a protamine-based insulin preparation, have
undergone a vasectomy, or have known hypersensitivity to fish
are at increased risk of developing adverse allergic reactions to
protamine, including anaphylaxis. The effects of LMWH are
only in part reversed by the administration of protamine.
Nonbleeding patients on warfarin with an elevated INR but
in the less than 5.0 range can safely have warfarin withheld
until the INR falls into the therapeutic range. For INR values
between 5.0 and 9.0, low-dose vitamin K (<5 mg oral phy-
tonadione) is indicated if there is bleeding, high risk of bleed-
ing, or need for performing an invasive procedure. If the INR
is greater than 9.0 and associated with bleeding, oral vitamin
K in larger doses (5–10 mg) is necessary. For serious bleeding
at any elevation of INR, treatment is a 10 mg slow intra-
venous infusion of vitamin K supplemented with factor
replacement (eg, fresh-frozen plasma or prothrombin com-
plex concentrate). Restoration of the desired anticoagulated
state may be difficult and prolonged if too much vitamin K is
administered. Reversal of the effects of warfarin with oral or
intravenous vitamin K can take several hours to correct the
INR, whereas fresh-frozen plasma, which contains the vitamin
K–dependent factors inhibited by warfarin, can be given to
reverse the prothrombin time relatively quickly.
An important complication of heparin use is heparin-
induced thrombocytopenia syndrome, an immune-mediated
disease that is associated with both bleeding and venous and
arterial thrombotic complications. This syndrome should be
suspected when the platelet count falls precipitously in a
patient receiving any form of heparin. It is seen in approxi-
mately 3–4% of patients receiving UFH and fewer patients
receiving LMWH. Treatment of this syndrome includes
immediate discontinuation of all forms of heparin adminis-
tration, including intravenous flushes. If anticoagulation is
still necessary for the patient’s primary disease process, direct
thrombin inhibitors (eg, lepirudin, bivalirudin, and arga-
troban) or heparinoids (eg, danaparoid) can be used. Case
reports of using fondaparinux, a synthetic pentasaccharide
anticoagulant, in cases of heparin-induced thrombocytope-
nia are also in the literature. However, this drug is not currently
FDA approved for this indication, but may play a role in the
future as more evidence becomes available. Warfarin should
not be used alone.
B. Thrombolytic Therapy—Thrombolytic agents currently
approved for use in venous thromboembolic disease in the
United States are urokinase, streptokinase, and alteplase (ie,
recombinant tissue plasminogen activator [tPA]). Deep
venous thrombosis, especially in patients with extensive
iliofemoral thrombosis with limb threat owing to vascular
occlusion, is an approved indication for the use of throm-
bolytic agents according to the 2004 American College of
Chest Physician guidelines. In studies in which thrombolytic
therapy was given for pulmonary embolism the associated
deep vein thrombosis resolved more rapidly, and there was
evidence that destruction of venous valves was lessened,
decreasing the pain, swelling, and potential for postphlebitic
venous insufficiency. However, thrombolytic therapy should
be individualized and is not currently recommended as rou-
tine therapy for deep vein thrombosis.
In short-term studies of pulmonary embolism, throm-
bolytic therapy was associated with faster clot lysis than
heparin, decreased pulmonary hypertension, improved pul-
monary perfusion, and subsequent higher pulmonary capil-
lary blood volume, as assessed by carbon monoxide diffusing
capacity. A trend toward lower death rates in patients with pul-
monary embolism treated with urokinase followed by heparin
compared with those given heparin alone was seen in one trial;
in the first 2 weeks of treatment, 7% died in the urokinase
group compared with 9% in the heparin group. Lower num-
bers of recurrent pulmonary emboli in the urokinase-treated
group also were found. Despite these results, many physicians
believe that the benefits of thrombolytic therapy over antico-
agulation alone are not clear for patients with pulmonary
embolism. Thus the vast majority of patients are treated with
heparin and oral anticoagulation alone.
Thrombolytic therapy has been considered most often in
the setting of “massive”pulmonary embolism, described in ear-
lier studies based on the radiographic finding of a clot occupy-
ing over 50% of the pulmonary vascular bed. Occlusion of
much smaller amount of the pulmonary vascular bed may be
considered “massive” in a patient with significant underlying
cardiopulmonary disease. Rather than the size of the radio-
graphic occlusion itself defining a massive pulmonary
embolism, this syndrome is now defined by the presence of
severe hemodynamic compromise with hypotension, shock,
syncope, or severe gas-exchange abnormalities. Several small
clinical trials of patients with severe large pulmonary emboli
have shown faster lysis of clot in the pulmonary circulation,
reduction of pulmonary artery pressure, and improved cardiac
output with the combination of thrombolytic agent and
heparin compared with heparin alone. However, a survival
benefit has not been clearly established with this therapy and
the risk of bleeding is higher than when heparin is used alone.
At present, thrombolytic therapy should be considered in
patients with acute massive embolism who are hemodynami-
cally unstable and who appear to be able to tolerate throm-
bolysis. It may also be a consideration in patients with
“submassive” embolism who show evidence of right ventric-
ular (RV) dysfunction, but this area remains controversial.
 CHAPTER 24558
RV dysfunction appears to identify normotensive patients
who have a significantly higher risk of recurrent pulmonary
embolism and death, and therefore, thrombolysis may bene-
fit this subgroup of patients. Mortality rates between 4.3%
and 12.8% have been seen in patients with an acute pul-
monary embolism with evidence of RV dysfunction as com-
pared with rates between 0% and 0.9% in patients with
normal right-sided heart function. Echocardiography has
become a key tool used to evaluate right-sided heart function
in these patients. Echocardiographic findings suggestive of
RV dysfunction acutely related to a pulmonary embolism
include qualitative findings such as RV hypokinesis and
quantitative finding such as enlarged RV to LV end-diastolic
diameter greater than 1 mm, RV end-diastolic diameter
greater than 30 mm, and pulmonary artery systolic pressure
greater than 30 mm Hg. Another echocardiographic finding
that has been found to have a high specificity in the diagnosis
of an acute pulmonary embolism is the McConnell sign in
which the RV fee wall is hypokinetic in the face of preserved
contractility of the apical segment.
Most investigators previously recommended that pul-
monary angiography be used to confirm the diagnosis of
pulmonary embolism prior to the administration of throm-
bolytic therapy. However, one analysis found that the fre-
quency of major bleeding averaged 14% in patients who
received tissue plasminogen activator after pulmonary
angiography, whereas it was estimated from thrombolytic
trials in acute myocardial infarction patients that a noninva-
sive diagnosis of pulmonary embolism would be associated
with only a 4.2% risk of bleeding. These authors suggested
that it would be safer to avoid pulmonary angiography for
patients chosen to receive thrombolytics who have positive
findings on a CT pulmonary angiogram, a high-probability
lung scan, an intermediate-probability scan plus high clinical
suspicion, or evidence of significant RV dysfunction by
echocardiography. A comparison of relative risks may prove
useful in making decisions about pulmonary angiography
and thrombolytic therapy.
Contraindications to thrombolytic therapy include sur-
gery in the past 10 days, recent puncture or invasion of non-
compressible vessels, recent intracerebral hemorrhage or
stroke, uncontrolled hypertension, recent trauma, preg-
nancy, hemorrhagic retinopathy, other sites of potential
bleeding, and infective endocarditis. In addition, streptoki-
nase has been associated with allergic reactions given its anti-
genic properties and cannot be administered more than once
in a 6-month period. Customary invasive vascular proce-
dures such as arterial blood gas measurements and catheter-
ization sites where bleeding cannot be easily controlled
should be avoided. Pulmonary angiography, if done, should
be approached from the brachial vein rather than from the
femoral vein. Heparin should be discontinued before starting
thrombolytic agents; antiplatelet agents should not be given
simultaneously.
Streptokinase, urokinase, and alteplase have been used
in pulmonary embolism. Urokinase and streptokinase are
given as a loading dose (streptokinase: 250,000 units over
30 minutes; urokinase: 4400 units/kg over 10 minutes), followed
by continuous infusion (streptokinase: 100,000 units/h for
24 hours; urokinase: 4400 units/kg per hour for 12–24
hours). Alteplase usually has been administered as a contin-
uous peripheral infusion of 100 mg over 2 hours.
After completion of thrombolytic therapy with any of
these agents, the continuous infusion of heparin is reinsti-
tuted once the measured aPTT is less than 2.5 times control.
Streptokinase and urokinase activate plasminogen bound to
both fibrinogen and fibrin, but alteplase or tissue plasmino-
gen activator, a genetic recombinant product, is somewhat
more specific for activation of plasminogen bound to fibrin.
This difference suggestes that alteplase may be associated
with fewer bleeding complications than urokinase or strep-
tokinase, but clinical bleeding so far has been found to be
similar for all three agents.
C. Inferior Vena Cava Interruption—There are no data
supporting the routine use of inferior vena cava (IVC) inter-
ruption with a filter in patients with deep venous thrombosis
or pulmonary emboli. A study comparing anticoagulation
with anticoagulation plus placement of an IVC filter demon-
strated a slight reduction in early symptomatic or asympto-
matic pulmonary embolism. There was no effect on
mortality. After 3 years, a significant increase in recurrent
deep venous thrombosis was found in the IVC filter group.
These data, however, support the effectiveness of IVC
interruption in reducing early embolization. Therefore, three
main indications have evolved for interruption of the infe-
rior vena cava in patients with deep venous thrombosis and
pulmonary embolism. First, patients who are at high risk for
pulmonary embolism (proximal deep venous thrombosis) in
whom heparin is contraindicated should be strongly consid-
ered for the procedure. The contraindication may be a strong
likelihood of bleeding prior to anticoagulation or moderate
to severe bleeding during heparin therapy. For example, in
trauma patients admitted to the ICU who were treated for
deep venous thrombosis or pulmonary embolism with
heparin, 36% developed complications requiring termina-
tion of the drug, whereas no serious complications or deaths
were reported in 34 other patients who underwent place-
ment of an IVC filter. A second indication is failure of anti-
coagulation to prevent recurrent pulmonary embolism
despite an adequate dose and duration of therapy. However,
early embolism after initiation of heparin generally should
not be considered as necessitating IVC interruption because
poorly organized thrombi may detach themselves from the
venous wall or from other parts of the clot regardless of
heparin therapy. Finally, a clinical indication for IVC inter-
ruption is identified in the rare patient whose cardiac and
pulmonary reserves are so low that even a single small pul-
monary thromboembolus may be life-threatening.
The decision to proceed with interruption of the IVC
should be based on evidence that the thromboemboli are
coming from deep veins that flow into that vessel. The right
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atrium and ventricle and the upper extremities should be
excluded as sources. If an upper extremity is identified as the
continued source of emboli, some centers are capable of
placing superior vena cava filters. Contrast venography or
other proof of existing clot below the site of planned inter-
ruption should be obtained.
The Greenfield filter or other types of intravenous
devices is used most often, while surgical ligation of the IVC
is rarely needed. The filter can be placed via percutaneous
venous access under fluoroscopic guidance either from an
internal jugular vein or from a femoral vein. The filter usu-
ally is positioned below the level of the renal veins, but there
are reports of its being placed above the renal veins in
patients with IVC and renal vein thrombosis. If the filter is
placed because of recurrent pulmonary emboli during anti-
coagulation, anticoagulation usually is continued to prevent
additional thrombi from forming on the filter and else-
where. If the filter is placed because of a contraindication
for or adverse reaction to anticoagulation, anticoagulation
therapy is not given. The risk of recurrent pulmonary
emboli after interruption of the vena cava with this device
is low (2–3%). Other reported problems include procedural
complications, filter malposition and migration, caval
occlusion, and sepsis owing to device infection.
D. Other Treatment—In some centers, emergent pul-
monary embolectomy can be performed in selected patients.
Mortality is high (up to 30% in some series), and special
experience and expertise are needed. Other modalities cur-
rently being investigated include local instillation of throm-
bolytics directly into the embolus; intravascular catheter
disruption systems, including fragmentation, rotor devices,
and rheolytic therapy that break the clot into smaller pieces
that then can be removed; suction catheter removal of the
clot; and balloon angioplasty of the embolus.
E. Supportive Care—Abnormal pulmonary gas exchange
may require supplemental oxygen. Severe respiratory dis-
tress, because of involvement of large portions of the lungs
or because of underlying heart or lung disease, may necessi-
tate mechanical ventilatory support. Some patients may have
bronchospasm that benefits from bronchodilators.
Hemodynamic compromise in pulmonary embolism usually
indicates severe obstruction of the pulmonary circulation
with failure of the right ventricle. Volume loading of the right
ventricle may be helpful. However, volume overexpansion
can lead to increasing right ventricular myocardial oxygen
consumption and subsequent ischemia and deterioration of
function. Inotropic and vasoactive drugs generally are of
little value in severe hemodynamic compromise, but
dopamine, dobutamine, and norepinephrine may be tried.
Prevention
Prevention of deep venous thrombosis and thereby of pul-
monary embolism has become a major goal in the manage-
ment of critically ill patients who are at high risk of
development of deep venous thrombosis as a consequence of
bed rest, immobility, central venous catheterization, critical
illness, or trauma. It has been pointed out, however, that
many ICU patients are not receiving thromboembolism pro-
phylaxis despite this high risk.
The risk of developing a deep vein thrombosis varies with
the clinical scenario and the patient’s underlying medical
condition. Patients with hip fracture, total hip replacement,
or total knee replacement have a 40–70% chance of develop-
ing deep venous thrombosis. Other surgical and medical
patients have approximately a 15–50% risk. It is estimated
that patients with myocardial infarction have about a 24%
overall incidence of deep venous thrombosis, and patients
with stroke may have up to a 55% risk.
Prevention of deep venous thrombosis depends on rever-
sal of predisposing conditions (eg, the local hypercoagulable
state and venous stasis). Antithrombotic therapy can interfere
with thrombus formation either by preventing the platelet
nidus from forming or by preventing activation of the coagu-
lation cascade. The type of preventive therapy is closely linked
to the underlying condition and the bleeding risk. For exam-
ple, patients at moderate risk (eg, minor surgery with additional
risk factors or aged 40 to 60 years with no additional risks)
will benefit from low-dose UFH, LMWH, or intermittent
pneumatic compression of the legs. On the other hand, high-
risk patients including hip fracture or total knee replacement
patients must be treated with LMWH, fondapariunux (2.5
mg started 6–8 hours after surgery), or adjusted-dose war-
farin with a target INR of 2.5. A summary of recommenda-
tions is presented in Table 24–9.
Low-dose UFH, 5000–7500 units subcutaneously every
8–12 hours, has been shown to be effective and safe in several
groups of patients, including those immediately postopera-
tive from general or gynecologic surgery and medical
patients with heart failure, myocardial infarction, respiratory
failure, and stroke. At these doses, the aPTT is not usually
prolonged, and there is little increased risk of bleeding.
LMWH also has been shown to have reliably favorable dose-
response properties and turns out to be superior for prophy-
laxis of deep venous thrombosis in a number of clinical
settings. Warfarin is effective in certain clinical situations
and, for example, is one of the choices for prophylactic treat-
ment for patients with hip fractures as well as elective hip
and knee replacement surgeries. Fondaparinux, a synthetic
pentasaccharide that selectively inhibits factor Xa activity,
has been shown to be highly efficacious in the prevention of
deep vein thrombosis primarily in large orthopedic surgical
trials. Finally, mechanical methods of prophylaxis with grad-
uated compression stockings or external compression of the
legs can be provided by rhythmic intermittent pneumatic
compression devices and have been shown to have compara-
ble effectiveness in preventing deep venous thrombosis with
no risk of hemorrhage. These devices can be combined with
pharmacologic means of prophylaxis in very high-risk
patients or used alone in patients at risk of bleeding compli-
cations from medical therapy.
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Medical Conditions
Critically ill patients with high bleeding risk
Critically ill patients without high bleeding risk
Mechanical prophylaxis (ES or IPC) until risk diminishes
LDUH or LMWH with or without mechanical prophylaxis
General Surgery
Low risk (minor procedure, age <40, no risk factors)
Moderate risk (40–60 years, major procedure and <40 years
with no risk factors)
High risk (not low or moderate risk) and highest risk (multiple
risk factors)
High risk of bleeding
Early and persistent ambulation
LDUH, 5000 units bid or LMWH <3400 units once/day
LDUH, 5000 units tid or LMWH >3400 units once/day or LMWH with
mechanical prophylaxis (higher risk)
Mechanical prophylaxis (ES or IPC) until risk diminishes
Vascular Surgery
Low-risk procedure
High-risk procedure
No routine prophylaxis
LDUH or LMWH
Gynecologic Surgery
Procedure <30 min for benign disease
Laparoscopic procedure, risk factors present
Major surgery for benign disease
Extensive surgery for malignancy
Early and persistent ambulation
LDUH, LMWH, and/or mechanical prophylaxis
LDUH, 5000 units bid; LDUH, 5000 units tid if VTE risk factors; continue
until discharge; if age >60, continue for 2–4 weeks after discharge
LDUH 5000 units tid or LMWH >3400 units/day; continue for 2–4 weeks
after discharge
Urologic Surgery
Minor, transurethral procedure
Major open procedure
Bleeding or high risk of bleeding
Early and persistent ambulation
LDUH twice or three times daily; with multiple risk factors, add
mechanical prophylaxis
Mechanical prophylaxis (ES or IPC) until risk diminishes
Laparoscopic Surgery
Laparoscopic surgery Early and persistent ambulation, unless risk factors present, then LDUH, 
LWMH, and/or mechanical prophylaxis
Orthopedic Surgery
Elective total hip replacement
Elective total knee replacement
Hip fracture surgery
LMWH at high-risk dose, 12 h before surgery or 12–24 h after surgery, or
4–6 h after surgery at half the high-risk dose; increase to high-risk dose
the next day 
or fondaparinux 2.5 mg beginning 6–8 h after surgery 
or adjusted-dose warfarin started the evening after surgery (INR target 2.5)
Continue prophylaxis for 28–35 days after surgery
LMWH at high-risk dose, fondaparinux, or adjusted-dose warfarin (INR
target 2.5)
Fondaparinux, LMWH at high-risk dose, adjusted-dose warfarin (INR target 
2.5), or LDUH; continue for 28–35 days after surgery
Table 24–9. Prophylaxis of deep vein thrombosis and pulmonary embolism for patients.
Neurosurgery, Trauma, Spinal Cord Injury
Elective spine procedure (elderly, malignancy, neurologic deficit, prior 
to VTE, or anterior surgical approach)
Trauma, identifiable risk factor
Acute spinal cord injury
Postoperative LDUH, LMWH, or IPC alone; if multiple risk factors, combine
LDUH or LMWH with mechanical prophylaxis
LMWH, when safe; mechanical prophylaxis if LMWH is delayed or
contraindicated because of high bleeding risk; consider screening with
ultrasound for those at highest risk; continue LMWH or warfarin (INR
target 2.5) after discharge if impaired mobility
Mechanical prophylaxis; add LDUH or LWMH started when safe (hemostasis
achieved)
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However, in patients with trauma—especially to the brain
or spinal cord—or those undergoing surgical procedures of
the eye, brain, or spinal cord, even low-dose heparin may be
contraindicated because of the increased risk of bleeding at
these operative sites. External pneumatic compression of the
legs is effective in these patients. Neurosurgical patients and
patients with heparin-induced thrombocytopenia also
should be considered for prevention of deep venous throm-
bosis by pneumatic compression devices. This therapy gener-
ally is well tolerated, but patients may require sedation owing
to discomfort from the cyclic compression or heat generated
by the apparatus.
Hip fractures, major orthopedic surgery, and some types
of urologic surgery enhance the thrombogenic state, prob-
ably by increased contact with and release of tissue throm-
boplastin. While low-dose UFH does decrease the risk of
deep venous thrombosis in some of these patients, it is less
effective than LMWH and the newer anticoagulant fonda-
parinux. Current guidelines recommend the use of LMWH,
fondaparinux, or adjusted-dose warfarin (goal INR 2.5) in
these high-risk orthopedic patients. Adjunctive prophylaxis
with mechanical devices such as elastic stockings and inter-
mittent pneumatic compression devices can add additional
benefit with little risk. The duration of prophylaxis, espe-
cially in this orthopedic patient population, is being inves-
tigated. There is some evidence that extending the period of
prophylaxis to 28–35 days postoperatively has reduced the
incidence of deep venous thrombosis and subsequent pul-
monary embolism. The 2004 ACCP consensus guidelines
recommend extending prophylaxis into the outpatient set-
ting with LMWH, fondaparinux, or warfarin for a total of
4–5 weeks after surgery for these high-risk postoperative
patients.
IVC filters also have been studied for their use in the pre-
vention of complications from deep venous thrombosis, pri-
marily in the surgical population. Four studies evaluating
high-risk surgical patients without current evidence of deep
venous thrombosis using historical controls found a decreased
incidence of pulmonary emboli in the following patients who
had an IVC filter placed: those with high injury severity scores,
head or spinal cord trauma, pelvic or lower extremity frac-
tures, prolonged immobility, and mechanical ventilatory sup-
port. This means of prophylaxis has not been studied in direct
comparison with heparin or mechanical devices. Other patient
populations that may benefit from prophylactic filter place-
ment include patients with advanced malignancy, orthopedic
surgical patients, and patients with limited cardiopulmonary
reserve such as those with severe COPD. The use of these fil-
ters as prophylaxis remains controversial and requires larger
studies to determine their exact role.
Current Controversies and Unresolved Issues
The diagnosis of pulmonary embolism in the critically ill
patient with multiple preexisting diseases can be very difficult.
The incidence of pulmonary embolism complicating critical
illness is unknown, but 5–10% of deaths may be associated
with unsuspected pulmonary emboli. In a study of patients
with COPD exacerbation, 25% of those without obvious pre-
cipitating cause had pulmonary embolism. Risk was associ-
ated with malignancy, prior venous thromboembolic disease,
and decrease in PaCO2 of at least 5 mm Hg. Abnormal pul-
monary gas exchange and hemodynamic compromise result-
ing from new pulmonary emboli may not be identified in
patients who already have underlying lung or heart disease.
Defects on perfusion lung scans may or may not represent
pulmonary emboli in patients with abnormal chest x-rays,
and ventilation scans cannot be performed without special
arrangements for patients receiving mechanical ventilation.
The helical or spiral CT scan requires administration of con-
trast material and a degree of patient cooperation and breath-
holding to achieve adequate imaging. Again, this may be
difficult for critically ill patients to perform. Finally, treatment
issues are complex, with some patients having relative con-
traindications to anticoagulation and others having diseases
in which adequate anticoagulation is difficult to achieve.
Patients with worsening hypoxemia or increased physio-
logic dead space, increased pulmonary artery pressure (in the
absence of other causes), unexplained tachycardia or
hypotension, or other features of unclear cardiopulmonary
insufficiency should be suspected of having pulmonary
thromboembolic disease until proven otherwise. The use of
end-tidal CO2 monitors in the ICU may be a noninvasive
means for detecting an acute change in dead space ventila-
tion that may be an early clue for pulmonary embolism.
Ventilation-perfusion scans in patients with COPD gen-
erally are considered to be of limited value because airway
obstruction causes falsely positive perfusion defects. A study
of such patients suspected of having a pulmonary embolism
found that high-probability scans were rare but had a high
predictive value for pulmonary embolism; similarly, a nor-
mal perfusion scan was highly predictive of a normal pul-
monary angiogram. However, 90% of the group had
intermediate-probability (60%) or low-probability (30%)
scans, of which only 17% had pulmonary embolism con-
firmed by angiography. The authors of the study concluded
that ventilation-perfusion lung scans were helpful only if
they were high-probability or normal. In all others, they con-
cluded, sufficient clinical suspicion should lead to pul-
monary angiography.
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 Anaphylaxis
ESSENT IALS  OF  D IAGNOS I S
 Follows reexposure to foreign antigens such as food,
drug, nonhuman protein, or other substances.
 Respiratory tract: rhinitis, edema, laryngeal edema,
asthma.
 Hypotension, lightheadedness, collapse.
 Generalized erythema, pruritus, and urticarial skin
lesions with or without angioedema.
General Considerations
Anaphylaxis is a severe allergic reaction that occurs after reex-
posure to a foreign substance such as food, a drug, serum, ven-
oms, or nonhuman proteins but also occurs occasionally after
exercise. Approximately 72 hours after initial exposure to a
foreign antigen, IgE antibody synthesis begins. Reexposure to
the antigen promotes cross-linking of mast cell and basophil-
bound IgE molecules and causes the subsequent release of
stored mediators of anaphylaxis such as histamine and other
substances. These factors cause increases in capillary perme-
ability, mucosal edema, and smooth muscle contraction; acti-
vate the classic complement pathway and components of the
clotting cascade; and cause the release of other mediators.
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Anaphylactoid (ie, anaphylaxis-like) reactions are clini-
cally similar to anaphylaxis but are not mediated by
antigen-antibody interactions. Many of the same mediators
are involved, so treatment is identical to that for anaphy-
laxis. Mechanisms include (1) activation of the comple-
ment cascade by immune complexes or other substances
that cause release of anaphylatoxins (eg, C3a and C5a),
resulting in mediator release from mast cells and
basophils, and (2) direct activation by certain agents of
mast cells and basophils resulting in mediator release (eg,
effect of hyperosmolar solutions such as mannitol and
radiocontrast media).
Patients with anaphylaxis may be admitted to the ICU
because of severe respiratory or cardiovascular compromise,
or they may develop anaphylaxis in the ICU from exposure
to blood products or drugs.
Clinical Features
The onset of a systemic anaphylactic reaction, which may
develop over minutes to 1–2 hours, depends on the sensitiv-
ity of the person as well as the route, rate, and quantity of the
precipitating agent. The clinical signs and symptoms can dif-
fer greatly depending on the severity of the anaphylactic
reaction, and clinical findings may be present in various
combinations. Severe systemic reactions are characterized by
respiratory failure and cardiovascular collapse. Recurrence of
symptoms can occur 2–24 hours after onset despite initial
stabilization and treatment.
A. History—A history of recent use of medication, ingestion
of new or unusual foods (notably peanuts and other nuts and
shellfish), and exposure to toxic products such as venoms or
insect bites should be sought, but treatment should be initi-
ated immediately if necessary. An increasingly recognized
cause of allergy and anaphylaxis is exposure to latex rubber.
About half of patients will have a history of atopy, and only
about 70% of patients who develop anaphylaxis outside
the hospital will have an identifiable precipitating cause. In
the ICU, intravenous contrast agents, antibiotics, NSAIDs,
aspirin, and other drugs are the most likely causes.
B. Symptoms and Signs—Anaphylaxis is often associated
with severe anxiety and apprehension. Patients may experi-
ence any combination of the following symptoms: itching of
skin and mucosal surfaces, swelling of the lips and tongue,
hoarseness, coughing, shortness of breath, wheezing, vomit-
ing, abdominal cramps, diarrhea, and palpitations.
Physical findings in severe systemic reactions include
hypotension, upper airway obstruction resulting in stridor,
and bronchospasm with impaired gas exchange, hypercap-
nia, and wheezing. Loss of consciousness may result from
poor cerebral perfusion. Urticaria may be present, and there
may be evidence of angioedema.
Allergens injected systemically—for example, insect
stings, intravenous drugs, blood products, and allergy desen-
sitization treatments—often cause a predominantly
cardiovascular reaction with hypotension. Food and inhaled
allergens may cause more facial and respiratory edema, asso-
ciated with respiratory problems.
Differential Diagnosis
Anaphylaxis may be confused with syncopal episodes associ-
ated with metabolic or vascular disturbances, acute respira-
tory failure secondary to epiglottitis, status asthmaticus,
obstruction owing to foreign-body aspiration, and pulmonary
embolism. Similar disorders with cutaneous and respiratory
manifestations—for example, mastocytosis, carcinoid syn-
drome, hereditary angioedema, and other specific adverse
pharmacologic (allergic and nonallergic) reactions to
drugs—should be considered if appropriate.
Treatment
Treatment is based on early recognition of features of ana-
phylaxis combined with a history of exposure to an inciting
agent. The suspected agent should be discontinued if possi-
ble (eg, a drug, blood products, or contact with latex rubber),
the extent and severity of the reaction should be assessed,
and treatment should be initiated as soon as anaphylaxis is
suspected.
A. General Measures—The patient should be positioned
supine or head down with the feet elevated. The airway must
be maintained by proper positioning. If necessary, endotra-
cheal intubation, tracheostomy, or cricothyroidotomy
should be performed. Because of the need for intravenous
fluid infusion and medications, a large-bore intravenous
catheter should be inserted.
B. Initial Treatment—Epinephrine should be given first in
a dosage of 0.3–0.5 mL of 1:1000 dilution (0.3–0.5 mg)
intramuscularly deep into the thigh every 10–20 minutes as
needed. The subcutaneous route is no longer recom-
mended. In severe anaphylaxis with suspicion of poor per-
fusion, slow intravenous injection (5 mL of 1:10,000
dilution) should be considered. Other initial treatment
includes oxygen, inhaled β-adrenergic agonists for bron-
chospasm, and airway management.
C. Other Medications—Medications are directed toward
blocking further mediator action on target organs, preventing
further release of mediators, reversing the physiologic effects
of the mediators, and supporting vital functions.
Antihistamines (histamine H1-antagonists) such as
diphenhydramine hydrochloride, 25–50 mg intra-
venously every 6 hours, are useful. Some studies show
additional benefit of histamine H2-receptor antagonists, so
cimetidine or ranitidine may be given as well. Excessive
antihistamine dosages may cause impaired CNS function,
anticholinergic symptoms (eg, dry mouth or urinary reten-
tion), and drowsiness, especially in elderly patients.
Hydrocortisone, 100 mg intravenously every 8 hours for
 CHAPTER 24564
several doses, is recommended, especially if there is bron-
chospasm or airway compromise. Patients who are receiving
β-blockers may have a poor response to treatment directed at
hypotension. These patients may have some response to
glucagon, which has both inotropic and chronotropic effects
on the heart.
D. Intravenous Fluids—Adults should receive 0.9% NaCl
solution, 0.5–1 L intravenously over 30 minutes, if hypoten-
sive. Additional fluid therapy depends on blood pressure,
heart rate, urine output, and clinical response.
E. Prevention of Anaphylaxis—The patient should be
instructed to avoid the offending agent in future, if possible.
For patients who have a likelihood of reexposure to an
identified antigen, a kit containing epinephrine for self-
administration should be considered.
 Angioedema
ESSENT IALS  OF  D IAGNOS I S
 Subcutaneous swelling of skin or mucous membranes,
possibly with laryngeal or lower airway compromise.
 May present with urticaria.
 Acute angioedema: may have history of ACE inhibitor,
aspirin, or NSAID therapy or a history of allergies.
 History of recurrent transient episodes of swelling may
be present in allergic or hereditary forms.
General Considerations
Angioedema is produced by mechanisms similar to those
that cause anaphylaxis and anaphylactoid reactions. In addi-
tion, these mechanisms can be triggered by various physical
forces, exercise, and other medical conditions such as
endocrine disorders, infections, malignancies, allergic phe-
nomena, and collagen vascular diseases. Severe angioedema
involving the upper or lower airways is a medical emergency
similar to anaphylaxis.
Acute angioedema, which may occur once or on multiple
occasions, is often idiopathic or associated with allergic phe-
nomena. Among identified causes, the most common are
related to ACE inhibitor therapy, aspirin, and NSAIDs.
Hereditary angioedema is caused by an autosomal domi-
nant inherited deficiency or functional abnormality of C1
esterase inhibitor. Without this inhibitor, the complement
cascade is activated, and a kinin-like fragment and other
mediators are released that produce the angioedema.
Acquired C1 esterase inhibitor deficiency is very rare and
seen in adults with autoimmune or lymphoproliferative
disorders. Patients have unexplained recurrent angioedema,
and the diagnosis is confirmed by low levels of C1q and low
C1 esterase inhibitor activity.
Clinical Features
A. Symptoms and Signs—Angioedema is characterized by
the presence of nonpruritic subcutaneous swelling of the skin
and mucous membranes. Lesions of the skin are poorly
demarcated and reddish. These may occur in conjunction with
urticarial lesions. Involvement of the upper airway can result
in hoarseness, stridor, shortness of breath, and even death.
Likewise, GI involvement is associated with abdominal pain,
nausea, and diarrhea. Patients may or may not have associated
urticaria, characterized by evanescent pruritic lesions.
Because of widespread use of ACE inhibitors for hyperten-
sion, diabetic proteinuria, and congestive heart failure, these
agents are a common cause of acute angioedema. This disor-
der may present after recent initiation of ACE inhibitor ther-
apy but may occur even after prolonged use. It is said that
urticaria is unusual in ACE inhibitor–induced angioedema.
Angiotensin-receptor blockers, sometimes given to patients
instead of or in addition to an ACE inhibitor, rarely have
been associated with angioedema, but some experts have
cautioned against use of these agents in patients with ACE
inhibitor–induced angioedema. Hereditary or acquired
angioedema has been precipitated by ACE inhibitors.
In hereditary angioedema, episodes can be precipitated
by trauma, emotional upset, infections, and exposure to sud-
den temperature changes. The disorder usually is apparent in
childhood, and attacks tend to be recurrent and usually are of
2–4 days duration. The physical findings are similar to those
described earlier. Similar features are present in acquired
forms of angioedema.
B. Laboratory Findings—In patients with angioedema or
urticaria, investigation should include a complete blood
count, erythrocyte sedimentation rate, and urinalysis. Other
laboratory tests should be ordered depending on the under-
lying medical condition. In patients with abdominal symp-
toms, edema of the bowel wall may be seen on CT scan.
When hereditary angioedema is suspected, C4, C3, CH50
or total complement, and C1 esterase inhibitor (by immuno-
chemical and functional assay) should be measured. Levels of
C4 and C2 are always low, and CH50 is usually diminished or
absent during an attack. C1 esterase will be reduced but may
be normal in persons with a functional abnormality.
Acquired angioedema (acquired C1 inhibitor deficiency) is
due to increased catabolism of C1 esterase inhibitor and C1q.
Laboratory findings in allergic angioedema and that induced
by ACE inhibitors and NSAIDs are rarely specific or helpful.
Treatment
Patients may require long-term treatment and should avoid
precipitating conditions and situations. In some patients, the
underlying cause may not be identifiable.
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A. General Measures—Acute angioedema is treated ini-
tially much the same way as anaphylaxis. The underlying
cause should be treated or removed, especially if ACE
inhibitors have been implicated. Hypotension and shock
should be treated with intravenous fluids. The airway
should be protected, and endotracheal intubation may
become necessary. If there is severe upper airway obstruction,
tracheostomy should be considered.
B. Specific Treatment
1. Epinephrine—Epinephrine is indicated for patients with
severe acute urticaria or angioedema with airway involve-
ment. It can be given subcutaneously or intravenously. One
recommendation is to give 0.3–0.5 mL of 1:1000 solution
subcutaneously and repeat every 10–20 minutes as necessary.
Epinephrine may be lifesaving in angioedema, but it should
be noted that many patients with ACE inhibitor–induced
angioedema are elderly or have heart disease or hyperten-
sion. Epinephrine may cause excessive tachycardia, may
increase myocardial oxygen demand, may provoke myocar-
dial ischemia, and may raise blood pressure excessively.
2. Antihistamines—Antihistamines usually are effective
against urticaria and can be helpful for some forms of
angioedema. H1-blockers such as diphenhydramine, 50 mg
orally or intravenously every 6 hours, are helpful for an acute
episode of urticaria. Patients may have dry mouth, drowsi-
ness, and excessive sedation with these agents. In patients
with angioedema, in addition to H1-blockers, an H2-blocker
such as ranitidine, 50 mg intravenously two or three times
daily or 150 mg orally twice daily, or cimetidine, 300 mg
orally or intravenously every 6 hours, may be helpful.
3. Corticosteroids—Corticosteroids usually are not nec-
essary for acute urticaria alone but can be very helpful in
refractory acute urticaria or chronic urticaria. A recom-
mended initial dosage is prednisone, 2 mg/kg per day
orally, or methylprednisolone, 60 mg intravenously every
6 hours.
C. Hereditary Angioedema—Clinical trials of recombinant
C1 inhibitor concentrate for acute hereditary angioedema
are under way. C1 inhibitor concentrates from pooled
plasma are available in Europe but not in the United States.
Fresh frozen plasma may be given (2 units) as treatment to
prevent angioedema or in preparation for surgery. Long-
term preventive treatment of angioedema can be tried using
androgen derivatives such as danazol, 200 mg orally three
times daily, or stanozolol, 2–4 mg/day.
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Several endocrine problems may require management in the
ICU, including severe thyroid disease, acute adrenal insuffi-
ciency, and diabetic ketoacidosis. While these problems usu-
ally are encountered in patients in whom a diagnosis of
endocrine dysfunction has already been made, they are occa-
sionally the presenting manifestation in an undiagnosed
patient. If these endocrine disorders are not identified, spe-
cific treatment such as endocrine replacement therapy may be
delayed, and significant complications or death may ensue.
In this chapter, severe thyrotoxicosis (eg, thyroid storm or
decompensated hyperthyroidism), severe hypothyroidism
(eg, myxedema coma), and acute and chronic adrenal insuffi-
ciency are discussed. Diabetic ketoacidosis and other manifes-
tations of severe diabetes mellitus are covered in Chapter 26.
In this chapter we also discuss the problem of assessing thy-
roid function in severe nonthyroidal illness (ie, sick euthyroid
syndrome).
 Thyroid Storm
ESSENT IALS  OF  D IAGNOS I S
 Long-standing hyperthyroidism, uncontrolled or poorly
controlled.
 Breakdown of the body’s thermoregulatory mechanisms,
resulting in hyperpyrexia.
 Altered mental status.
 Precipitating illnesses or events such as thyroid sur-
gery, infection, trauma, acute abdominal problems, or
anesthesia.
 Signs and symptoms of severe hyperthyroidism—usually
marked wasting.
General Considerations
Thyroid storm—or thyrotoxic crisis—results from the even-
tual failure of the body’s compensatory mechanisms in
severe hyperthyroidism. Clinically, thyroid storm has been
defined as “a life-threatening augmentation of the manifesta-
tions of hyperthyroidism.” There are no pathognomonic lab-
oratory markers of thyroid storm. However, because of its
high mortality rate, one should be vigilant for its diagnosis
and provide aggressive and prompt management. This is
especially true because the features of thyroid storm are com-
mon findings in other critically ill patients.
A. Incidence—The incidence of thyroid storm has decreased
markedly since the advent of antithyroid drugs. Some studies
suggest that the incidence is 2–8% of all patients admitted to
the hospital for management of hyperthyroidism. However, a
recent evaluation at a major teaching hospital revealed that
severe complicated thyrotoxicosis is a rare syndrome,
accounting for only 0.01% of hospital admissions over a
14-year period. Thyroid storm occurs nine to ten times more
commonly in women than in men, probably a reflection of
the higher incidence of thyroid diseases in women in general.
No race- or age-related differences in incidence have been
reported. An association between thyroid storm and med-
ically underserved, socially disadvantaged populations has
been suggested. In one study, patients admitted because of
complicated thyrotoxicosis were more likely to be uninsured,
poorer, unmarried, and African-American than uncompli-
cated thyrotoxic controls. One explanation is that control of
chronic hyperthyroidism with antithyroid drugs is very effec-
tive in preventing decompensation, but poorer populations
may be less likely to receive adequate treatment.
Pathophysiology 
The pathophysiology of thyrotoxic crisis is not well under-
stood. Indices of thyroid gland overactivity (levels of total
and free thyroxine or triiodothyronine) are not significantly
higher than in usual cases of hyperthyroidism.
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Although the signs and symptoms of hyperthyroidism
suggest sympathetic overactivity, plasma levels and secretion
rates of epinephrine and norepinephrine are actually normal
in patients with thyroid storm. Because of this, increased
sensitivity to catecholamines has been suggested, and ele-
vated cAMP levels in these patients have been cited as evi-
dence of increased adrenergic activity.
The mechanisms that lead to the decompensated state
characteristic of thyroid storm have not been well studied.
Higher levels of cytokines and immune dysregulation have
been implicated, but without conclusive data. The basal
metabolic rate and thermogenesis are increased, and there is
a net degradation of proteins. Although both protein synthe-
sis and degradation are increased, hyperthyroidism results in
negative nitrogen balance, muscle wasting, and reduced
albumin concentrations. Although cortisol clearance is
increased, its production rates are also increased, so the cor-
tisol levels remain essentially unchanged. Thyroid hormones
have direct cardiostimulatory effects, resulting in tachycardia
and increased contractility. Increased thermogenesis results
in vasodilatation as part of the compensatory response to
increased body temperature.
Clinical Features
Thyroid storm is usually seen in patients with known hyper-
thyroidism but may be the presenting feature in a patient with
previously undiagnosed thyrotoxicosis. Thyroid storm is seen
often in association with one of a long list of precipitating
conditions, but the two most common conditions are surgical
procedures of any kind—but particularly thyroid surgery in
an uncontrolled or poorly prepared hyperthyroid patient—
and infections. Thyroid storm is now quite uncommon fol-
lowing thyroid surgery because of preoperative preparation
and control of hyperthyroidism with antithyroid drugs.
Other potential precipitating factors include cardiovascu-
lar disease (including acute myocardial infarction), systemic
illness, trauma, diabetic ketoacidosis, vigorous palpation of
an untreated hyperthyroid gland, administration of iodi-
nated contrast material, stroke, and preeclampsia or eclamp-
sia. Rare cases of thyroid storm have been seen after
amiodarone administration. Exacerbation of hyperthy-
roidism may occur following radioactive iodine treatment of
Graves’ disease, but thyroid storm is unusual because most
hyperthyroid patients are well controlled by antithyroid drug
therapy. In contrast, thyroid storm may occur in hyperthy-
roid patients who discontinue antithyroid medications pre-
maturely or inadvertently. Patients who accidentally or
deliberately ingest an excessive amount of thyroid hormone
may present with severe hyperthyroidism but usually with-
out the complete picture seen in thyroid storm.
A. Symptoms and Signs—Thyroid storm is characterized
by clinical features of severe thyrotoxicosis with fever and
altered mental status. In one series of patients hospitalized
for complicated thyrotoxicosis, cardiovascular complications
and neuropsychiatric syndromes were the two most frequent
indications for admission. Mental status changes may
include confusion, agitation, overt psychosis, and in extreme
cases, even coma. Common cardiovascular manifestations
include tachycardia that is out of proportion to fever, cardiac
arrhythmias (sinus or supraventricular tachycardia, includ-
ing atrial fibrillation), and congestive heart failure. Patients
presenting with congestive heart failure are usually elderly
and have an underlying history of heart disease. However, it
is well documented that hyperthyroidism can cause conges-
tive heart failure even in the absence of underlying heart dis-
ease. Hypotension and shock may be late manifestations. GI
manifestations include nausea, vomiting, diarrhea, and
abdominal pain. Weight loss and cachexia are common.
Goiter is almost always present and may be diffuse or
multinodular. Since many of these patients have Graves’ dis-
ease, the goiter is more often diffuse and nontender. Patients
often have marked muscle weakness owing to proximal
myopathy and generalized cachexia. Tremor is present. The
skin is warm, moist, flushed, soft, and “velvety.” The reflexes
may be brisk. Graves’ disease patients also may have ophthal-
mopathy and dermopathy. Burch and Wartofsky have pro-
posed a point scale to facilitate the diagnosis of thyroid
storm, assigning points based on the severity of thermoregu-
latory dysfunction (temperature), cardiovascular dysfunc-
tion, CNS effects, GI-hepatic dysfunction, and precipitating
factors. That is, thyrotoxic patients with fever and dysfunc-
tion of one or more organ systems, particularly cardiovascu-
lar and CNS, are more likely to have severe thyrotoxicosis and
need hospitalization for aggressive treatment.
B. Laboratory Findings—Elevated aminotransferases,
hyperbilirubinemia, and hepatomegaly are common.
Alkaline phosphatase levels are also increased, but this usu-
ally represents an increase in the bone fraction rather than
the liver fraction. Serum calcium may be elevated as a reflec-
tion of increased bone resorption. Other laboratory abnor-
malities observed in patients hospitalized for complicated
thyrotoxicosis include hypo- or hypernatremia, hyper-
glycemia, and anemia.
The diagnosis of thyroid storm is essentially a clinical
one. The presence of high fever and altered mental status in
a severely ill patient with hyperthyroidism should warrant
aggressive treatment for thyrotoxic crisis. Laboratory tests of
thyroid function confirm the presence of hyperthyroidism,
that is, high total and free thyroxine (T4) and triiodothyro-
nine (T3) and a reduced and nearly undetectable thyrotropin
(TSH) level. However, T3 and T4 levels may be decreased by
concurrent nonthyroidal illness. Therefore, levels of T4 and
T3 may not correlate with the patient’s clinical picture.
Treatment
The management of thyroid storm can be discussed under
three broad categories: (1) control of hyperthyroidism,
(2) treatment of the precipitating illness, and (3) other
supportive measures. Treatment is summarized in Table 25–1.
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A. Control of Hyperthyroidism—Several therapeutic
agents that act by different mechanisms to block the synthe-
sis, secretion, activation, or action of thyroid hormones can
be used together for rapid control of hyperthyroidism.
1. Thioureas—Propylthiouracil, methimazole, and car-
bimazole inhibit thyroid hormone synthesis primarily by
inhibiting reactions catalyzed by the thyroid peroxidase
enzyme. These reactions include oxidation, organification,
and iodotyrosine coupling. Propylthiouracil is also a weak
inhibitor of peripheral conversion of T4 to T3. Methimazole is
generally considered to be more potent than propylthiouracil.
In comatose patients with thyroid storm, propylthiouracil or
methimazole may be given through a nasogastric tube because
these drugs are not available in parenteral formulations.
There is no agreement about the optimal dosage of
antithyroid drugs. One regimen is to start propylthiouracil at
an initial dose of 600–1200 mg/day in four divided doses.
Alternatively, 60–120 mg/day methimazole can be given in
four divided doses. Should the patient be unable to take med-
ication orally, these medications can be administered rectally.
Others have advocated giving a loading dose of 600–1200 mg
propylthiouracil followed by 200–300 mg every 8 hours.
However, some investigators have questioned whether addi-
tional inhibition of thyroperoxidase is achievable at dosages
of propylthiouracil in excess of 300 mg daily. Methimazole
is given at one-tenth the preceding dosage. The serum half-
life of propylthiouracil is 75 minutes; of methimazole,
240–360 minutes. However, the intrathyroidal residence time
of methimazole is 20 hours, and its duration of action is
believed to be as long as 40 hours. These data have been used to
support once-daily administration of methimazole. However,
in the life-threatening situation of thyroid storm, it may be
preferable to give methimazole three or four times daily.
Propylthiouracil is also a weak inhibitor of 5′-deiodinase, the
enzyme that converts T4 to T3, and this may be a minor advan-
tage over methimazole—although the two drugs have never
been compared directly. Propylthiouracil has been rarely asso-
ciated with pulmonary capillaritis and alveolar hemorrhage.
Resistance to the effects of antithyroid drugs is extremely
uncommon. Most cases of apparent resistance turn out to be
problems of noncompliance. Acute side effects of these drugs
are uncommon, but allergic reactions, leukopenia, and hepa-
totoxicity may occur.
2. Ipodate sodium—Ipodate sodium is an iodine-
containing radiocontrast agent used for gallbladder imaging.
It is one of the most potent inhibitors of 5′-deiodinase.
Clinical studies with ipodate in hyperthyroidism have shown
that the drug has an extremely rapid onset of action, result-
ing in marked lowering of serum T3 levels within 4–6 hours
and normalization of serum T3 levels within 24–48 hours.
The mechanism of antithyroid effect of ipodate is complex.
Besides inhibiting conversion of T4 to T3, ipodate also lowers
serum T4 levels, albeit to a lesser degree, indicating additional
direct effects on thyroid hormone synthesis. Reverse T3 levels
are higher in ipodate-treated patients, an observation consis-
tent with drug-induced inhibition of 5′-deiodinase.
Although ipodate is an iodine-containing contrast agent,
radioiodine uptake studies in patients with Graves’ disease
treated with ipodate for more than a year revealed normal
uptake a week after discontinuation of ipodate therapy.
Ipodate sodium is administered orally as capsules con-
taining 500 mg. Recommended dosages range from 1–3
g/day. In obtunded patients, ipodate can be administered via
Mechanism of Action Treatment
Measures to reduce thyroid
hormone synthesis or
peripheral conversion of
T4 to T3
Propylthiouracil,∗ 200–300 mg orally
or through a nasogastric tube every
6 hours.
or
Propylthiouracil, 600 mg loading dose
orally, followed by 200–300 mg
every 8 hours.
or
Methimazole, 20–30 mg orally or
through a nasogastric tube every
6 hours.
plus
Ipodate,† 1–1.5 g/d for the first
24 hours, then 500 mg twice daily.
Measures to inhibit the
release of thyroid hormones
Lugol’s solution, 5–10 drops three
times daily, or saturated solution of
sodium iodide, 3 drops three times
daily, after antithyroid therapy
(above) has been instituted.
Lithium carbonate, 300 mg every
8 hours, may be used in patients
with iodine allergy.
Sympathetic blockade Propranolol, 0.5–1 mg IV slowly over
5–10 minutes. Repeat every 3–4 hours 
as indicated.
Contraindicated in COPD and asthma;
should be very carefully administered
in patients with congestive heart
failure.
Glucocorticoids Dexamethasone, 2–4 mg IV every
6–8 hours.
Supportive measures Identify and treat the precipitating
event.
Provide fluid and electrolyte replace-
ment as needed.
Hyperpyrexia: Cooling blankets, ice, or
cool sponges as necessary. Other
supportive measures.
∗Both propylthiouracil and methimazole may be administered rectally.
†If the patient is allergic to iodine, lithium may be used: lithium
carbonate, 300–400 mg every 8 hours. Serum lithium levels to be
maintained at approximately 1 meq/L. 
Table 25–1. Treatment of thyroid storm.
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the intragastric route. It has been recommended that propy-
lthiouracil or methimazole be given prior to administration
of iodine-containing medications to prevent an iodide-
mediated exacerbation of hyperthyroidism.
3. Lithium—Lithium can be used in patients unable to tol-
erate iodine. Lithium is concentrated by the thyroid and
inhibits iodine uptake by the thyroid. It also inhibits thyroid
hormone release. A dosage of 300–400 mg every 8 hours can
be used temporarily to control the thyrotoxic patient who is
allergic to iodine. The dose should be adjusted as necessary
to maintain a serum lithium level of approximately 1 meq/L.
4. Iodide—Iodide blocks the release of thyroid hormones
from the gland. Iodide also has an inhibitory effect on thy-
roid hormone synthesis. High doses of inorganic iodide
decrease the yield of organic iodine within the thyroid
gland—a phenomenon referred to as the Wolff-Chaikoff
effect. However, this inhibitory effect on thyroid hormone
synthesis is transient, and in most patients, an escape from
this inhibition occurs with time.
Iodide should be administered only after synthesis of thy-
roid hormones has been inhibited by prior administration of
thioureas. Intravenous sodium iodide can be administered at
a dosage of 0.25 g every 6 hours. Alternatively, if the patient is
able to take medication orally, Lugol’s solution at a dosage of
5–10 drops three times a day or saturated potassium iodide
solution at a dose of 3 drops three times daily can be used.
Administration of a large dose of inorganic iodide pre-
dictably will reduce radioiodine uptake by the thyroid gland
for several weeks. Therefore, prior administration of inor-
ganic iodide will preclude subsequent treatment with
radioactive iodine for several weeks.
5. Propranolol—β-adrenergic blockers attenuate many of
the peripheral manifestations of hyperthyroidism. Thus
these agents can reverse the thyroid hormone-induced
increases in heart rate, cardiac output, and tremor. However,
weight loss is not affected by β-blockers. Propranolol, in
addition to its antiadrenergic properties, is a weak inhibitor
of 5′-deiodinase and thus lowers T3 levels. The advantage of
the 5′-deiodinase inhibition property of propranolol is
unclear given the similar action of propylthiouracil and ipo-
date sodium. Other β-adrenergic blocking agents such as
esmolol and labetalol also have been used successfully.
The response to propranolol varies from patient to
patient, and dosages should be titrated to the clinical
response. The initial dose usually is 0.5–1 mg intravenously
given slowly over 5–10 minutes for a total of up to 10 mg.
This can be followed by 40–60 mg orally every 6 hours. If the
patient is unable to take medication orally, propranolol can
be administered intravenously in doses of 1–2 mg every 3–4
hours. These dosage recommendations are only general
guidelines to be used initially. Subsequent dosage adjust-
ments should be dictated by the clinical response.
Propranolol blood levels in the range of 50–100 μg/mL have
been shown to provide effective beta blockade. However,
blood levels of propranolol have not been used extensively in
clinical practice; it is much simpler to follow the heart rate
and blood pressure responses. Side effects of β-adrenergic
blockade in patients with thyroid storm include heart failure,
bradycardia, hypotension, and increased airway resistance.
6. Glucocorticoids—The older literature warned that
adrenal insufficiency might ensue in patients with thyroid
storm because of accelerated cortisol degradation. However,
this hypothesis has never been validated, and the routine use
of glucocorticoid replacement has declined. Glucocorticoids
do, however, have several salutary effects on thyroid function
in thyroid storm. In patients receiving thyroxine replace-
ment, glucocorticoids lower serum T3 concentrations, prob-
ably by inhibition of peripheral 5′-deiodinase. In addition,
glucocorticoids lower serum T4 levels in patients with
Graves’ disease. Finally, glucocorticoids in pharmacologic
doses inhibit TSH secretion. One recommended regimen is
2–4 mg dexamethasone every 6 hours intravenously. Patients
suspected of having adrenal insufficiency should be treated
accordingly with higher doses of hydrocortisone (see below).
7. Extracorporeal therapy—Exchange transfusion and
plasmapheresis have been advocated as ways of removing
large amounts of thyroid hormones from the circulation.
Experience with these techniques is limited. Furthermore,
with the availability of potent antithyroid drugs, they are not
likely to be needed.
B. General Supportive Measures—General measures
include fluid and electrolyte replacement and control of
hyperpyrexia. The latter may require the use of cooling blan-
kets. Salicylates should be avoided because these drugs can
inhibit T4 and T3 binding to the binding proteins and
increase the concentrations of the free T4 and T3. In addition,
specific measures for prompt treatment of the precipitating
illness, cardiac arrhythmias, and congestive heart failure
should be initiated if indicated.
Prognosis
Most data on mortality statistics in thyroid storm are old, and
there are no recent series. Survival figures vary from 24–66%
in older series. The precipitating illness is clearly an important
determinant of prognosis. Many of these patients may require
admission to the ICU, and most require an extended hospital
stay; in one study, the median hospital stay was 12 days.
Basaria S, Cooper DS: Amiodarone and the thyroid. Am J Med
2005;118:706–14. [PMID: 15989900]
Cardenas GA, Cabral JM, Leslie CA: Amiodarone-induced thyro-
toxicosis: Diagnostic and therapeutic strategies. Cleve Clin J Med
2003;70:624–6. [PMID: 12882384]
Cooper DS: Antithyroid drugs. N Engl J Med 2005;352:905–17.
[PMID: 15745981]
Goldberg PA, Inzucchi SE: Critical issues in endocrinology. Clin
Chest Med 2003;24:583–606. [PMID: 14710692]
Nayak B, Burman K: Thyrotoxicosis and thyroid storm.
Endocrinol Metab Clin North Am 2006;3:663–86. [PMID:
17127140]
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 Myxedema Coma
ESSENT IALS  OF  D IAGNOS I S
 Features of severe hypothyroidism (myxedema): dry,
rough, cold skin, nonpitting doughy edema, loss of eye-
brows and scalp hair, and delayed relaxation phase of
deep tendon reflexes.
 Hypothermia.
 Altered mental status or coma.
 Hypercapnic respiratory failure.
General Considerations
Myxedema coma represents a breakdown of the body’s com-
pensatory mechanisms during the course of long-standing
severe hypothyroidism. Development of an intercurrent illness
such as an infection on top of the underlying severe hypothy-
roidism usually leads to this decompensation. Myxedema
coma is primarily a clinical diagnosis. While laboratory tests
confirm hypothyroidism, the diagnosis is based on the con-
stellation of clinical findings of myxedema, altered mental sta-
tus, and hypothermia. The physician must remain alert for the
possibility of myxedema coma because the consequences of
missing the diagnosis can be devastating. In addition, the usual
clinical signs of infection such as fever and leukocytosis may
be masked in patients with severe hypothyroidism. Therefore,
one also must actively search for infection or other precipitat-
ing factors and treat these illnesses aggressively.
Pathophysiology
Hypothyroidism is a common endocrinopathy, but
myxedema coma is encountered much less commonly
because of thyroid hormone replacement therapy.
Myxedema coma is associated with poor outcome. Patients
with myxedema most often have a history of hypothy-
roidism, but the precipitating condition is almost always a
combination of failure to take an adequate amount of thy-
roid replacement therapy and the presence of some comor-
bid condition. Because the serum half-life of T4 is quite long,
hypothyroidism is a subacute condition characterized by
decreased metabolic rate, accumulation of edema fluid, dete-
rioration of cardiac function from structural and physiologic
changes, hyperlipidemia, and inability to manifest an appro-
priate response to hypothermia. Ventilatory drive is dimin-
ished from central mechanisms and, because of respiratory
muscle weakness and pleural effusions and ascites, can result
in hypercapnia. Hyponatremia is common and results from
the inability to dilute urine maximally.
Clinical Features
Myxedema coma almost always occurs in patients with
known hypothyroidism but rarely can present as the initial
finding in hypothyroidism. A precipitating event usually can
be identified along with absent or inadequate thyroid replace-
ment therapy. The majority of cases of myxedema coma are
reported in winter months in regions with cold climates. Thus
cold exposure appears to be an important antecedent factor.
Other precipitating factors include sedative or anesthetic
drugs, congestive heart failure, cerebrovascular accidents,
trauma, infections, and a variety of other illnesses.
A. Symptoms and Signs—Most patients with myxedema
are elderly women. The classic signs of myxedema are pres-
ent, including puffy, expressionless face; dry, rough, and cold
skin; nonpitting, doughy edema; loss of eyebrows and scalp
hair; delayed relaxation phase of the tendon reflexes; and
enlarged tongue. Hypothermia is a hallmark of myxedema
coma, with core body temperatures as low as 21°C but more
often in the range of 32–35°C. Severe hypothermia (temper-
ature <32°C) is associated with a poor prognosis. However,
hypothermia can be easily overlooked if a thermometer that
can register temperatures below the usual range is not used.
Blood pressure may be normal, high, or low. The heart rate is
classically slow. Respirations may be slow and shallow
depending on the level of ventilatory drive and respiratory
muscle weakness. Mental status changes may include confu-
sion, somnolence, hallucinations, or coma. The thyroid gland
may not be palpable because of idiopathic atrophy, prior
radiation, or surgery.
Drug metabolism is significantly reduced in hypothy-
roidism, and administration of the usual doses of sedatives
may depress ventilation significantly and compromise men-
tal status. In critically ill patients, the diagnosis of hypothy-
roidism sometimes may be hard to make on clinical grounds.
B. Laboratory Findings—Hyponatremia is often present.
Arterial blood gases may reveal respiratory acidosis, hypercap-
nia, and hypoxemia. Hypoglycemia may occur, particularly if
there is deficiency of pituitary hormones as well. Chest x-ray
may reveal an enlarged cardiac silhouette and pleural and peri-
cardial effusions. The ECG may demonstrate low voltage,
sinus bradycardia, diffuse T-wave depression, nonspecific
ST-segment changes, and prolonged QT and PR intervals.
There may be conduction blocks as well. Cerebrospinal fluid
(CSF) pressure and protein concentrations may be increased.
Although myxedema coma is a clinical diagnosis, thyroid
function tests reveal low thyroxine (T4), low T3 resin uptake,
and a high thyrotropin (TSH) level. It may be difficult at times
to distinguish sick euthyroid syndrome from primary hypothy-
roidism by thyroid function tests. Very high serum TSH levels
(>20 μU/mL) favor the diagnosis of primary hypothyroidism.
Moderately elevated TSH levels (up to 20 μU/mL) may be seen
occasionally in the course of sick euthyroid syndrome. Severe
nonthyroidal illness decreases the TSH response, and inappro-
priately low TSH is seen in secondary hypothyroidism owing
to hypothalamic or pituitary disorders.
C. Adrenal Insufficiency—In patients with hypothyroidism,
the manifestations of adrenal insufficiency may be masked.
This is important because adrenal insufficiency can coexist
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with hypothyroidism in two clinical situations. First, in
patients with autoimmune thyroid disease, there is a higher
incidence of autoimmune adrenalitis and adrenal insufficiency
than in the general population. Second, patients with panhy-
popituitarism may have absence of both TSH and adrenocor-
ticotropin (ACTH). These patients with secondary adrenal
insufficiency lack the skin and mucosal hyperpigmentation
that is characteristic of primary adrenal insufficiency. For
these reasons, it is easy to miss adrenal insufficiency in this set-
ting, and the clinician must keep alert to the possibility of con-
comitant adrenal insufficiency. A rapid ACTH stimulation test
should be performed in patients with myxedema. However, it
should be recognized that the cortisol response to ACTH may
be attenuated by hypothyroidism.
Treatment
Treatment consists of thyroid hormone replacement,
replacement of other necessary hormones, and supportive
measures (Table 25–2), including treatment of hypothermia
and of the precipitating illness.
A. Thyroid Hormone Replacement—While all commenta-
tors assert the need for prompt thyroid hormone replacement
in myxedema coma, there is disagreement about what consti-
tutes an optimal regimen. The major controversy relates
to which regimen of thyroid hormone replacement to use:
T4 alone, T3 alone, or a combination of T4 and T3. The use of
T3 alone has been advocated by some on physiologic grounds.
This is so because the activity of 5′-deiodinase is diminished
in hypothyroidism, and the conversion of T4 to T3 may be
limited. On the other hand, a rapid increase in T3 may be
detrimental to the patient because of cardiac arrhythmias and
too rapid an increase in myocardial oxygen demand. Large
doses of T3 (>75 μg) have been associated with increased
mortality. Because of its potential adverse effects, the use of
this regimen has been discouraged by some.
Intravenous administration of T4 is considered safe and has
been the standard for the past three decades. One traditional
regimen consists of 500 μg of levothyroxine (T4) given slowly
intravenously, followed by 100–150 μg every 24 hours. The
rationale for the large initial dose is that it restores the total thy-
roxine pool. However, it is not clear if this regimen is any bet-
ter than 150 μg given intravenously daily. The rate of fall in
serum TSH levels is not significantly different between the two
regimens. In fact, a dose of 100–150 μg levothyroxine given
intravenously daily would correct the thermoregulatory, respi-
ratory, cardiac, and mental status changes over 24–48 hours.
A third regimen consists of a combination of both T4 and
T3. It is suggested that 200–300 μg T4 be given simultane-
ously with 25 μg T3 intravenously. This is followed by admin-
istration of another 25 μg T3 12 hours later and 100 μg T4 at
24 hours. Starting the third day, 100 μg T4 is given daily until
the patient regains consciousness.
Recent literature has witnessed conflicting reports on the
effectiveness of combined regimens of levothyroxine and
triiodothyronine. The rates of conversion of thyroxine to
triiodothyronine do vary in different tissues; animal studies
suggest that T3 concentrations in some tissues of thyroidec-
tomized rats replaced with levothyroxine alone are lower
than those observed in euthyroid animals. Similarly, circulat-
ing levels of T3 in hypothyroid patients treated with levothy-
roxine alone are lower than those in euthyroid individuals.
Objective differences between thyroxine replacement com-
pared with combined thyroxine plus triiodothyronine
replacement have not been found.
There is no strong basis for advocating any one regimen.
The rapid restoration of thyroid hormone levels is desirable.
Most authorities agree that expeditious thyroid hormone
replacement is a more important objective than the exact
regimen of thyroid hormone replacement and that high-dose
levothyroxine administered intravenously is a reasonable and
safe choice.
B. Glucocorticoids—As discussed earlier, signs of adrenal
insufficiency may be masked in hypothyroid patients. On the
other hand, initiation of levothyroxine therapy without con-
comitant glucocorticoid replacement may precipitate adre-
nal crisis if the patient has adrenal insufficiency. Therefore,
one must be on guard against the possibility of adrenal insuf-
ficiency in appropriate patients. If in doubt, it is better to err
on the side of treatment with corticosteroids (see “Adrenal
Insufficiency” next) because the consequences of delayed or
no replacement can be serious.
C. Supportive Measures—Patients with myxedema coma
may need transient endotracheal intubation and mechanical
ventilation for hypercapnic respiratory failure. Intravenous
Mechanism of Action Treatment 
Thyroid hormone replacement Levothyroxine (T4), 500 μg by slow
intravenous infusion, followed by
100–150 μg every 24 hours. 
or
T4, 200–300 μg, and triiodothyronine
(T3), 25 μg IV; 25 μg of T3 12 hours 
later; and 100 μg of T4 at
24 hours.
Glucocorticoid Hydrocortisone, 100 mg IV every
8 hours.
Supportive measures Maintain adequate ventilation.
Institute endoctracheal intubation
and mechanical ventilation if
necessary.
Identify and treat the precipitating
event.
Provide fluid and electrolyte
replacement as needed.
Correct core body temperature. 
Table 25–2. Treatment of myxedema coma.
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fluids, electrolytes, and vasopressors may be needed to maintain
blood pressure. Rapid rewarming through the use of heating
blankets is not generally recommended because it may provoke
or worsen peripheral vasodilation and hypotension. However,
in patients with severe hypothermia, thermogenic shivering
mechanisms may become impaired, and these patients may not
be able to raise their body temperatures. Therefore, gradual but
active rewarming may be required in some patients. In most
patients with mild hypothermia, wrapping the patient in blan-
kets in a warm room is sufficient to restore body temperature,
provided that thyroid replacement therapy has been initiated.
Treatment of hypothermia is discussed in Chapter 38. A search
for infection or other precipitating factors should be mounted.
In many instances, empirical antibiotic therapy may be justified.
Because of decreased metabolic rate, many drugs are cleared
more slowly in patients with severe hypothyroidism.
Prognosis
Myxedema coma may be fatal if unrecognized and left
untreated. Poor prognostic indicators include severe hyper-
capnia and hypothermia. If infection or other precipitating
illness is present, outcome depends on treatment and
response to these problems. Complications of thyroxine (T4)
and triiodothyronine (T3) replacement therapy may include
serious cardiac morbidities, such as acute coronary syn-
drome and cardiac arrhythmias.
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 Acute Adrenal Insufficiency
ESSENT IALS  OF  D IAGNOS I S
 Hypotension, volume depletion, hypovolemic shock.
 Hyperkalemia, hyponatremia.
 Weakness, abdominal pain, nausea, vomiting, fever.
 Acute infectious illness or trauma, recent cessation of
corticosteroid therapy, or inadequate replacement in
chronic adrenal insufficiency.
 Abnormal ACTH stimulation test.
General Considerations
Critical illness, whether from sepsis, trauma, surgery, or any
condition associated with hemodynamic compromise, stim-
ulates the hypothalamic-pituitary-adrenal axis causing an
increased production of cortisol. This hormone, synthesized
in the adrenal cortex under the influence of ACTH, main-
tains vascular integrity and tone, stimulates neoglucogenesis
and free water clearance, and influences fluid and electrolyte
balance. Lack of aldosterone—a mineralocorticoid—is asso-
ciated with inability to conserve sodium in the face of hypo-
volemia and hyperkalemia. Deficiency of cortisol—a
glucocorticoid—on the other hand, is associated with inabil-
ity to clear free water and with hemodynamic compromise
mimicking hypovolemic or septic shock. Hyponatremia, a
hallmark of adrenal insufficiency, is typically due to the
inability of these patients to clear free water owing to corti-
sol deficiency and dysregulated antidiuretic hormone (ADH)
secretion. Patients with adrenal insufficiency become
hypotensive owing to a combination of factors, including
hypovolemia and impaired vascular response to cate-
cholamines and also to loss of a direct inotropic effect of cor-
tisol. Cortisol stimulates hepatic neoglucogenesis, and it is
therefore not surprising that patients with adrenal insuffi-
ciency may present with hypoglycemia. Serum cortisol levels
in acutely ill patients are usually increased.
Acute adrenal insufficiency is the result of inadequate
cortisol production with life-threatening cardiovascular col-
lapse and potentially severe electrolyte and fluid abnormali-
ties. Acute insufficiency can occur as a result of an acute
insult to the adrenal glands from infection or trauma or may
be seen in a patient with chronic adrenal insufficiency who
develops critical illness. Patients who receive corticosteroids
for treatment of inflammatory diseases will have chronic
suppression of pituitary-adrenal function, and abrupt cessa-
tion of therapy may precipitate acute adrenal insufficiency,
especially if there is intercurrent illness. A high index of sus-
picion for the diagnosis of adrenal crisis is the key. Because
delay in instituting treatment can be fatal, acute adrenal
insufficiency should be suspected in any patient presenting
with hypotension, fever, abdominal pain, hyponatremia, or
hyperkalemia, especially if hyperpigmentation is present. In
many clinical situations, empirical therapy may be appropri-
ate, even before a definitive diagnosis has been made.
Pathophysiology
Idiopathic or autoimmune adrenalitis accounts for about
80% of cases of chronic adrenal insufficiency in outpatients.
Tuberculosis used to be a major cause of adrenal insuffi-
ciency, but that disease is relatively uncommon now in devel-
oped countries. Other less common causes include adrenal
hemorrhage; fungal infections such as histoplasmosis, coc-
cidioidomycosis, blastomycosis, and candidiasis; hemochro-
matosis; irradiation; surgical removal of the adrenal glands;
drug toxicity; and congenital disorders such as synthetic
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enzyme deficiencies. Patients with HIV infection often have
abnormalities in the adrenal glands at autopsy but appear to
have only a slightly increased incidence of adrenal insuffi-
ciency (about 5–10%). The impaired immune status result-
ing from HIV infection increases the likelihood of adrenal
involvement with cytomegalovirus (the most common find-
ing), fungi (eg, Cryptococcus and Histoplasma), or mycobac-
teria (both tuberculous and nontuberculous). HIV, however,
directly affects the adrenal glands only in a small number of
patients. Secondary adrenal insufficiency can occur in HIV-
infected patients because of direct involvement of the hypo-
thalamus or the pituitary gland, opportunistic infections
(eg, tuberculoma or histoplasmosis), or lymphoma.
Other causes of adrenal insufficiency include metastatic
cancer and hemorrhage. Although metastases to the adrenal
gland are relatively common, adrenal insufficiency as a result
of metastatic disease is uncommon. Adrenal hemorrhage may
occur during the course of sepsis, excessive anticoagulation,
trauma, pregnancy, or surgery. Adrenal infarction may occur
as a result of thrombosis, embolism, or arteritis. Infiltrative
disorders include amyloidosis, sarcoidosis, and hemochro-
matosis. Congenital disorders leading to adrenal insufficiency
include congenital adrenal hyperplasia. This is due to a genetic
defect in one of the steroidogenic enzymes or hypoplasia.
A number of drugs directly inhibit the enzymes involved in
steroidogenesis. Etomidate is frequently used during endotra-
cheal intubation; it suppresses adrenocortical function for up
to 24 hours. Metyrapone inhibits β-hydroxylase, aminog-
lutethimide inhibits side-chain cleavage enzymes, ketoconazole
inhibits a number of cytochrome P450-linked steroidogenic
enzymes, and mitotane is an adrenolytic cytotoxic agent.
Fluconazole also has been implicated. Relatively common med-
ications such as rifampin and seizure medications (eg, pheny-
toin and carbamazepine) increase hepatic cytochrome P450
activity, thus increasing cortisol metabolism. These medica-
tions should be used with caution in patients with limited adre-
nal reserve.
In patients with autoimmune adrenalitis, there is an
increased incidence of other endocrinopathies. For example,
Hashimoto’s thyroiditis, Graves’ disease, pernicious anemia,
hypoparathyroidism, premature ovarian or testicular failure,
and type 1 diabetes occur with a greater frequency than in
the general population. It is now clear that multiple
endocrine organs may be affected by organ-specific autoim-
mune disease. These polyendocrine autoimmune syndromes
are classified into two major groups: type I and type II. Type
I patients usually present in early childhood with
hypoparathyroidism and mucocutaneous candidiasis; adre-
nal insufficiency may develop later. Disease is usually limited
to one generation of siblings. Genetic analyses of families are
consistent with an autosomal recessive inheritance in a single
gene. Mutations in an autoimmune regulator gene (AIRE)
have been described in association with polyendocrine
autoimmune syndrome type I. In contrast, type II patients
usually present with adrenal insufficiency in the third or
fourth decade. Type 1 diabetes mellitus occurs in almost
half of patients. There is a strong association with HLA-DR3
or -DR4 haplotypes. Hyperthyroidism (Graves’ disease),
Hashimoto’s thyroiditis, primary ovarian failure, myasthenia
gravis, celiac disease, and pernicious anemia occur much more
commonly in patients with type II polyendocrine autoimmune
syndrome than in the general population. Multiple generations
in the same family are usually affected. The genetic analyses of
families suggest that it is a polygenic disorder with autosomal
dominant inheritance. Autoantibodies against at least three
cytochrome P450 enzymes that are involved in cortisol synthe-
sis have been reported in association with Addison’s disease
as part of both type I and type II syndromes.
Acute Adrenal Crisis
Acute adrenal crisis refers to the collapse and shock syndrome
that occurs in a patient with inadequate adrenal cortical
function. This can occur in chronic adrenal insufficiency
because of stress imposed by a serious illness such as infec-
tion, trauma, or surgery without adequate replacement. In
other patients, acute bilateral adrenal hemorrhage (ie,
Waterhouse-Friderichsen syndrome), originally described in
association with meningococcemia, is the cause of acute adre-
nal insufficiency. Acute adrenal hemorrhage can complicate the
course of systemic sepsis from other pathogens as well. In fact,
Pseudomonas aeruginosa is a common organism in children
dying with sepsis and adrenal hemorrhage. Other common
acute antecedent factors include anticoagulant therapy, dissem-
inated intravascular coagulation, and the perioperative state.
Clinical Features
The clinical manifestations of adrenal insufficiency depend
(1) on whether the patient has primary or secondary adrenal
failure, (2) on the presence or absence of other endocrinopathies
(eg, coexistence of hypothyroidism may significantly attenu-
ate the manifestations of adrenal insufficiency), and (3) on the
presence of superimposed nonendocrinologic illness or stress.
In the ICU, symptoms and signs of the acute illness may
overshadow the features of concomitant adrenal insuffi-
ciency, making clinical suspicion the key to diagnosis.
A. Symptoms and Signs—Patients with chronic adrenal
insufficiency may not come to medical attention for some
time because of the nonspecific nature of symptoms, such as
fatigue, anorexia, weight loss, nausea, and vomiting. Other
manifestations include weakness, salt craving, and postural
dizziness. Patients with primary adrenal insufficiency usually
have hyperpigmentation of the skin and mucous membranes
because of increased ACTH production by the pituitary.
Patients often develop a “tan” in both sun-exposed and non-
exposed parts, especially in areas that suffer chronic friction
and trauma, such as elbows, knees, knuckles, and the belt-
line. The buccal mucosa may show hyperpigmentation,
especially along sites of dental occlusion. The “tan” appear-
ance of these patients often conveys a misleading impression
of good health. Scars acquired during the course of adrenal
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insufficiency also become hyperpigmented, whereas those
acquired before or after remain unpigmented.
The hallmarks of acute adrenal insufficiency (ie, adrenal
crisis) include severe hypotension and vascular collapse, nau-
sea, vomiting, abdominal pain, and fever. Hypotension is due
largely to volume depletion, and there may be other evidence
of volume depletion. Abdominal symptoms may lead to an
erroneous diagnosis of acute abdomen, resulting in unwar-
ranted and potentially catastrophic surgical exploration.
Confusion and altered mental status also may occur.
Petechiae may be found if meningococcemia is the cause of
acute adrenal hemorrhage. Hyperpigmentation, if present,
indicates chronic primary adrenal insufficiency. Infection,
surgical stress, and trauma may precipitate acute adrenal cri-
sis in patients with chronic adrenal insufficiency. Patients
should be questioned about receiving chronic corticosteroid
therapy, especially if they have a history of asthma, interstitial
lung disease, rheumatologic diseases such as systemic lupus
erythematosus, or lymphoproliferative disorders. Patients
with HIV infection and autoimmune endocrinopathies
should be suspected of adrenal insufficiency if they present
with intractable hypotension and hyponatremia.
A degree of clinical suspicion may be necessary in evalu-
ating critically ill patients who may present in atypical fash-
ion. Patients with hemodynamic instability that cannot be
explained easily—in association with fever with no identified
source and alteration in mental status—should be consid-
ered for adrenal insufficiency. These patients may benefit
from empirical adrenal replacement therapy.
B. Laboratory Findings—Laboratory data may reveal
hyponatremia, hyperkalemia, and azotemia. Hypoglycemia
occurs more often in children but may be seen in adults as
well, especially in those who have been vomiting.
Corticosteroids play an important role in regulating gluco-
neogenesis and have potent anti-insulin actions.
Hypercalcemia and eosinophilia also may be found.
Hyponatremia is usually multifactorial. Patients with pri-
mary adrenal insufficiency are unable to conserve sodium
because of mineralocorticoid deficiency. However, these
patients become hyponatremic even in the face of positive
sodium balance. This is so mainly because of inability to
clear free water due to glucocorticoid deficiency. The exact
pathophysiology of the defect in free water clearance in pri-
mary adrenal insufficiency is not known, but there is lack of
adequate suppression of ADH levels in the face of hypona-
tremia. In addition, glucocorticoids also exert a permissive
effect of ADH directly at the kidney level. In the evaluation
of volume depletion and hyponatremia, low urinary sodium
and fractional excretion of sodium usually reflect volume
depletion; in adrenal insufficiency, however, both urinary
indices may be elevated because of the inability of the kid-
neys to conserve sodium maximally in the absence of cortisol
and aldosterone.
C. Adrenal Function Tests—A patient in whom acute adre-
nal insufficiency is suspected should be treated immediately.
However, diagnosis can be made rapidly and reliably by an
ACTH stimulation test. In addition, a random serum cortisol
level greater than 20 μg/dL makes the diagnosis of adrenal
insufficiency unlikely.
The traditional protocol for the rapid ACTH stimulation
test is as follows: 250 μg cosyntropin (containing amino acids
1–24 of ACTH) is administered intravenously, and plasma
samples are obtained at 0, 30, and 60 minutes for measure-
ment of cortisol. In addition, it is helpful to save contingency
samples for plasma aldosterone measurement. Earlier stud-
ies had suggested that an increment of more than 7 μg/dL
after cosyntropin administration or peak levels greater than
17 μg/dL would exclude adrenal insufficiency. However,
other data indicate that any cortisol value greater than or
equal to 20 μg/dL before or after the cosyntropin test is con-
sistent with normal adrenal function. A normal response
excludes primary adrenal insufficiency. Concern about adre-
nal insufficiency should be raised if any of these criteria are
not met. A small incremental increase in plasma cortisol
after cosyntropin despite a baseline value in the normal
range may be associated with a poor outcome and increased
mortality.
Some studies have suggested that the supraphysiologic
dose of corticotropin used may cause false-negative readings
in patients with partial or secondary adrenal insufficiency.
This is so because patients with adrenal insufficiency may
have some reserves left, and using the relatively large dose of
corticotropin might lead to a normal response. Some have
advocated using instead a low-dose ACTH stimulation test
with 1 μg corticotropin. A normal response is a rise in corti-
sol level to 20 μg/dL or more at 30 or 60 minutes.
If the cortisol response to cosyntropin is subnormal, the
contingency samples can be used to measure aldosterone and
endogenous ACTH to distinguish primary from secondary
adrenal insufficiency. Aldosterone responses to cosyntropin
are impaired in primary adrenal insufficiency but are pre-
served in secondary adrenal insufficiency (due to decreased
endogenous ACTH secretion). ACTH is elevated in primary
adrenal insufficiency and low normal or below normal in
secondary adrenal insufficiency. Certain clinical features also
can be useful in distinguishing primary from secondary
adrenal insufficiency. For example, hyperpigmentation and
hyperkalemia are observed in primary but not in secondary
adrenal insufficiency. The presence of other endocrine hor-
mone deficiencies does not necessarily indicate panhypopi-
tuitarism because these also could be a consequence of
autoimmune polyendocrinopathy.
Treatment
Once the diagnosis of adrenal insufficiency has been made,
treatment is relatively straightforward (Table 25–3).
A. Corticosteroid Replacement—Promptness in institut-
ing corticosteroid therapy is very important. Corticosteroid
replacement can be given as hydrocortisone sodium succinate,
75–100 mg intravenously every 6–8 hours. If the patient is
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hypotensive, performance of the diagnostic ACTH stimula-
tion test may unduly delay institution of therapy. Under
these circumstances, an equivalent dose of dexamethasone
(3–4 mg every 6–8 hours) can be given intravenously con-
temporaneously with ACTH administration. Dexamethasone
does not crossreact in the cortisol assay, and the diagnostic
procedure therefore can be done without concern about the
delay in instituting replacement therapy. The dose of hydro-
cortisone sodium succinate can be reduced to the replace-
ment level (10–20 mg in the morning and 5–10 mg in the
evening) as the patient’s condition improves.
Some studies cast doubt on the need for large pharmaco-
logic doses of corticosteroids during surgery. Studies in
adrenalectomized monkeys suggest that physiologic replace-
ment doses of corticosteroids are sufficient in this primate
model to tolerate the stress of surgical laparotomy.
Supraphysiologic doses of corticosteroids conferred no sur-
vival advantage on these adrenalectomized monkeys over
physiologic replacement doses during the period of surgical
stress. Other studies have shown that patients receiving
steroids prior to undergoing surgery did not require addi-
tional glucocorticoids during the perioperative period.
Empirical recommendations for glucocorticoid adminis-
tration in surgical patients are to estimate the degree of stress
and give 25 mg/day of hydrocortisone for mild stress, 50–75
mg/day for 2–3 days for moderate stress, and 100–150
mg/day for 2–3 days for severe stress. After recovery from
acute illness, patients with adrenal insufficiency should be
placed on chronic replacement therapy with hydrocortisone.
Traditionally, a dose of 30 mg hydrocortisone administered
in two divided doses—20 mg in the morning and 10 mg in
the evening—has been used widely. However, recent assess-
ments using more accurate isotope dilution and mass spec-
trometric methods suggest that daily cortisol production
rates are 5–6 mg/m2 of body surface area rather than the
12–15 mg/m2 of body surface area, as was thought previously.
Therefore, the traditional regimen of 30 mg hydrocortisone
daily possibly represents excessive glucocorticoid replace-
ment and may increase the risk of osteoporosis. A more
appropriate regimen may be 15 mg hydrocortisone adminis-
tered in two divided doses: 10 mg in the morning and 5 mg
in the afternoon. Although hydrocortisone traditionally has
been administered in a twice-daily regimen, some authors
have suggested that a thrice-daily regimen (10, 5, and 5 mg)
might provide more physiologic cortisol levels.
B. Mineralocorticoid Replacement—Most patients with
primary adrenal insufficiency require mineralocorticoid
replacement. In chronic adrenal insufficiency, this can be
administered as fludrocortisone acetate. The usual starting
dosage is 0.05–0.1 mg by mouth daily. Some patients may
develop leg edema on initiation of therapy. This usually will
abate if the dose is reduced. Hydrocortisone by itself has
some mineralocorticoid activity, so when patients are receiv-
ing more than 50–60 mg/day of hydrocortisone, no addi-
tional mineralocorticoid replacement is necessary. However,
if dexamethasone, which has little or no mineralocorticoid
activity, is used instead of hydrocortisone, a mineralocorti-
coid should be added.
C. Fluid and Electrolytes—Patients with adrenal insuffi-
ciency often have an enormous salt and water deficit. It is
important to correct these deficits aggressively by adminis-
tration of 0.9% NaCl solution intravenously. However,
patients with adrenal insufficiency may continue to be
hypotensive even after adequate fluid and electrolyte
replacement. Blood pressure may be restored only by cor-
ticosteroid administration. It is often not recognized that
corticosteroids have an inotropic effect on the myocardium.
Patients with adrenal insufficiency may present with
hyperkalemia; therefore, routine potassium replacement
should be postponed until serum potassium measure-
ments are obtained.
Diagnostic testing If you are considering a diagnosis of acute adrenal insufficiency, perform a rapid ACTH test (see text) immediately and initiate
treatment pending return of laboratory results. If a patient is highly likely to have adrenal insufficiency, give dexamethasone
immediately while the ACTH test is being conducted.
Glucocorticoid Hydrocortisone sodium succinate, 75–100 mg IV immediately and then every 6–8 hours.
or
Dexamethasone, 3–4 mg IV every 6–8 hours.
Mineralocorticoid Not required when large doses of hydrocortisone (>50–60 mg/d) are used. Consider adding fludrocortisone acetate, 0.05–0.1 mg
orally daily if dexamethasone is used.
Supportive measures Identify and treat the precipitating illness. 
Correct fluid and electrolyte abnormalities. Intravenous NaCl 0.9% is usually given initially.
Monitor blood glucose and electrolytes and administer glucose if necessary.
Table 25–3. Management of acute adrenal insufficiency (adrenal crisis).
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D. Glucose—Corticosteroids are important regulators of
gluconeogenesis. Although in adults, unlike children, hypo-
glycemia is not a common manifestation of adrenal insuffi-
ciency, patients who have been vomiting for a few days may
present with hypoglycemia or develop hypoglycemia during
the course of evaluation or treatment. Therefore, plasma glu-
cose levels should be monitored and glucose given intra-
venously to correct or prevent hypoglycemia.
E. Other Treatment—It is crucial to identify and treat the
antecedent illness precipitating acute adrenal insufficiency.
This may include administration of antibiotics to treat an
infection. Many patients with adrenal insufficiency have one
or more endocrinopathies. It is important to recognize and
treat these when identified.
Current Controversies and Unresolved Issues
Serum cortisol is measured as the total rather than free cor-
tisol, and more than 90% of cortisol is protein-bound. In
critically ill patients, low serum albumin and serum proteins
may cause lower serum total cortisol but normal free corti-
sol. Therefore, some patients might be labeled incorrectly as
having cortisol deficiency. In a recently published study,
baseline and postcosyntropin total cortisol were lower in
patients with serum albumin levels of less than 2.5 g/dL com-
pared with those with higher serum albumin levels. Despite
this finding, baseline and postcosyntropin free cortisol meas-
urements were often not different. Thus, in this study, almost
40% of patients with low serum albumin levels had low total
cortisol levels, but all had normal adrenal function. Because
free cortisol measurements are not widely available, it is not
clear how to interpret low serum total cortisol in the face of
hypoproteinemia. The safest course would be to continue to
give these patients glucocorticoid replacement but recognize
that some of the patients may be treated unnecessarily.
Another controversial issue has been the use of corticos-
teroids in patients with septic shock. Some studies suggest
that hydrocortisone at dosages similar to replacement for
adrenal insufficiency improves outcome in septic shock.
Benefit was seen almost exclusively in those with an increase
in serum cortisol level of less than 9 μg/dL in response to cor-
ticotropin, despite some patients having supraphysiologic
baseline serum cortisol levels. A cytokine-induced “relative”
adrenal insufficiency has been postulated, but it is not clear
that patients with high cortisol levels require replacement.
However, a recent study did not find that corticosteroids
benefit septic shock patients, and one recommendation is to
use corticosteroids only if baseline cortisol levels are very low
or if etomidate had been given within 24 hours.
Alonso N et al: Evaluation of two replacement regimens in primary
adrenal insufficiency patients: Effects on clinical symptoms,
health-related quality of life and biochemical parameters.
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 Sick Euthyroid Syndrome
ESSENT IALS  OF  D IAGNOS I S
 Low T3 and/or low total T4 suggestive of hypothy-
roidism in a patient with acute or chronic nonthyroidal
illness.
 But patient is euthyroid, as shown by clinical appear-
ance, normal TSH, usually normal TSH response to
thyrotropin-releasing hormone (TRH), and normal free
T4 by equilibrium dialysis.
 In extremely ill patients, free T4 may fall to subnormal
levels.
General Considerations
Alterations in thyroid function occurring with nonthyroidal
illness are usually associated with changes in other hormonal
systems and can be thought of as part of a complex and mul-
tifaceted response of the endocrine system to illness. A num-
ber of nonthyroidal illnesses produce alterations in thyroid
function in patients in whom no intrinsic thyroid disease is
present and the patient is judged to be euthyroid. These low
T3 and low T3-T4 syndromes seen with nonthyroidal illness
represent a continuum probably reflecting severity of the dis-
ease process rather than discrete conditions. The syndromes
must be distinguished from hypothyroidism because their
treatment requires correction of the underlying disorder
rather than thyroid hormone replacement.
Pathophysiology
The sick euthyroid syndrome is essentially a laboratory diag-
nosis (Table 25–4). Patients are clinically euthyroid, but
because they have acute or chronic nonthyroidal illness, the
underlying disease may make assessment of thyroid status
difficult or unclear. The syndrome may be divided into three
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patterns: low T3, low T3 and T4, and low thyroid-stimulating
hormone (TSH).
A. Low T3—This is the most common presentation. In the
early stages of nonthyroidal illness, serum T3 (bound and
free) decreases, and reverse T3 (rT3) is increased. T4 and TSH
levels are within the normal range. The low T3 state results in
part from decreased conversion of T4 to T3 because of the
inhibition of peripheral tissue 5′-monodeiodinase activity
and reduced T3 production. Contrary to earlier belief that
the elevated rT3 resulted from increased conversion of T4 to
rT3, the elevated rT3 results from decreased rT3 clearance sec-
ondary to decreased 5′-monodeiodinase activity. Circulating
T3 levels can fall below normal within 24 hours of onset of
any systemic illness, major trauma, surgery, or caloric depri-
vation, and T3 concentrations generally become normal as
the underlying illness resolves. It has been postulated that
decreased T3 may be a protective mechanism during acute ill-
ness because it is associated with decreased urine urea nitro-
gen excretion and decreased protein breakdown. Tissue T3 levels
fall proportionate to serum levels.
In the early recovery phases from illness, there may be a
transient increase in serum TSH concentrations to levels seen
in patients with primary hypothyroidism. Although these
levels rarely exceed 20 μU/L, there have been several case
reports of sick euthyroid patients having TSH values
exceeding this commonly used cutoff value. This elevation
of TSH has been proposed to stimulate the thyroid gland to
increase its secretion of T4. Nonetheless, a TSH level greater
than 20 μU/mL is suggestive of primary hypothyroidism.
In one study of unselected ICU patients, 44% had low
free T3 levels on admission, indicating nonthyroidal ill-
ness, 24% of these had normal TSH and 21% had low TSH
levels.
B. Low T3 and T4—Free T4 (FT4) is almost always normal
early in the course of nonthyroidal illness. In more severe ill-
ness of longer duration, the decreased serum T3 levels are
accompanied by a reduction in serum T4. This portends a
poor prognosis: The greater the reduction in T4, the worse
is the outcome. This condition may occur in 25–50% of
medical patients admitted to an ICU. In patients with T4 con-
centrations less than 3 μg/dL, the mortality rate may reach
80%. The fall in FT4 to subnormal levels is multifactorial;
decreased TSH resulting in decreased T4 secretion from the
thyroid, alterations in T4 binding to plasma proteins, and
alterations in binding protein concentrations all contribute
to low T4 concentrations. Despite the finding of very low T4,
these patients are not considered as having hypothyroidism,
and replacement of thyroid hormone does not improve
outcome.
C. Low TSH—Low T3 or low T3 and T4 are also seen in
hypothyroidism, but a euthyroid state in these patients with
nonthyroidal illness is suggested by the clinical appearance, the
normal TSH concentration, and the normal free T4 level by
equilibrium dialysis. Also, the TSH response may be blunted
to thyrotropin-releasing hormone (TRH) stimulation.
Not uncommonly, low TSH values (<0.1 μU/mL) rather
than normal TSH values are encountered in euthyroid hospi-
talized patients, although most patients will have only mar-
ginally depressed values of more than 0.1 μU/mL. The
availability of more sensitive third-generation TSH assays
has made it possible to distinguish between marginally
depressed TSH concentrations in euthyroid patients and the
highly suppressed levels seen with hyperthyroidism (<0.01
μU/mL). If necessary, a TRH stimulation test can be used to
confirm the result. Euthyroid patients with nonthyroidal ill-
ness and depressed TSH will show detectable responses of
TSH (>0.1 μU/mL) to TRH stimulation, whereas hyperthy-
roid patients will show the expected absence of response to
TRH stimulation.
Diagnosis
A. Laboratory Findings—When assessing thyroid dysfunc-
tion in the critically ill, perhaps the best initial screening tests
are total T4, T3 resin uptake, T3, and sensitive TSH levels. Low
T3 is always seen in sick euthyroid syndrome and can fall
from normal values within 24 hours of onset of acute illness.
The rT3 level may be increased. The euthyroid state is con-
firmed if total T4 and T3 resin uptake are normal or if free T4
by equilibrium dialysis is normal, along with normal TSH
values.
As described earlier, a more difficult situation arises when
both T3 and total T4 are reduced in more severe or prolonged
illness. Free T4 by equilibrium dialysis is often normal but
may be misleadingly low despite the patient being clinically
euthyroid. A normal or low TSH generally confirms the find-
ing of a euthyroid state, whereas TSH greater than 20 μU/L
makes hypothyroidism a strong possibility. If there is any
doubt about the TSH response, then evaluation of pituitary
function may be helpful.
B. Disorders Associated with Altered Thyroid Function
Tests—A number of conditions can produce alterations in
thyroid function tests suggesting thyroid hormone deficiency
(Table 25–5).
Table 25–4. Profile of thyroid hormone indices during
different phases of acute illness.
Phases of Illness T3 T4 FT4 rT3 TSH
Mild, early D N N I N
Moderate D N, D N I N
Severe D D D I N, D
Early recovery D D, N D, N I N, I
D = decreased; I = increased; N = normal.
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1. Malnutrition or caloric deprivation—Caloric dep-
rivation such as that seen during fasting can produce a signif-
icant fall in serum T3 concentrations and a rise in serum rT3
within 24 hours. Hypocaloric diets containing as few as 600
kcal/day can produce these same changes. T4 concentrations
are usually normal, but the TSH response to TRH is blunted.
Free T4 may rise transiently and then stabilize. It has been
suggested that caloric deprivation causes the starving body to
conserve energy by reducing the amount of metabolically
active T3. Administering T3 to starving subjects induces
greater muscle catabolism. Refeeding with as little as 50 g
carbohydrate (200 kcal) normalizes serum T3 and rT3.
However, the TSH response to TRH may remain reduced,
suggesting a difference in recovery time between peripheral
5′-monodeiodination and pituitary responsiveness.
2. Chronic liver disease—Liver disease may have pro-
found effects on thyroid function. The liver is the main organ
for thyroid hormone metabolism and the major site for
extrathyroidal (peripheral) conversion of T4 to T3. Serum T3
levels are low, rT3 is elevated, and TSH is normal in patients
with liver disease. The serum T4 is usually normal, although
low levels are found in the most severely ill. Very low T3 pre-
dicts a poor outcome.
3. Renal disease—Patients with chronic renal failure tend to
have multiple factors that may affect thyroid function tests.
These include poor nutrition, metabolic disturbances, medica-
tions, and hemodialysis. A reduced serum T3 is found in many
patients, and T3 does not increase with thyroxine replacement.
However, rT3 is normal rather than elevated because of
increased uptake in tissues. Secondary hyperparathyroidism,
which often accompanies renal failure, also may be partly
responsible for this pattern of thyroid function tests because a
low T3 and normal rT3 also are seen in states of elevated parathy-
roid hormone. Free T4 may be elevated transiently during
hemodialysis, probably representing a heparin effect. TSH levels
are usually normal. Extensive metabolic studies of patients with
renal failure and low serum T3 concentrations indicate that they
are euthyroid.
Patients with nephrotic syndrome may lose significant
amounts of thyroxine-binding globulin (TBG) from urinary
protein losses, resulting in decreased serum T4 levels. The T3
resin uptake is increased in proportion to the lowered TBG
levels, and the free T4 index is usually normal. A number of
other conditions are associated with increased and decreased
TBG levels (Table 25–6).
4. Diabetes mellitus—Diabetes and thyroid disorders
are linked at several levels. The association of autoimmune
thyroid disease with type 1 diabetes mellitus as part of the
autoimmune polyendocrinopathy syndrome is well recog-
nized. Diabetic ketoacidosis produces a similar pattern of
altered thyroid function tests seen in other severe ill-
nesses. With treatment, most patients normalize thyroid
function tests within a few days. Insulin deficiency mim-
ics a fasting state because carbohydrate is not used prop-
erly. Poorly controlled diabetes causes a marked reduction
in conversion of T4 to T3; T3 levels increase with improved
glycemic control.
5. Infection—Infection also produces changes in thyroid
hormone parameters similar to those seen in sick euthyroid
patients. These alterations are corrected by successful treat-
ment of the infection. Because malnutrition often accompa-
nies severe infection, it is thought to play a role in the
changes observed. Fever alone also may be a factor in altering
thyroid function tests. A negative correlation between tem-
perature and serum T3 has been observed.
6. Acute myocardial infarction—A consistent pattern of
thyroid function abnormalities has been observed in acute
myocardial infarction. Serum T3 concentrations fall after an
Table 25–5. Conditions that produce thyroid function
test patterns suggesting thyroid hormone deficiency
(sick euthyroid syndrome).
Malnutrition, caloric deprivation
Chronic liver disease
Renal disease
Diabetes mellitus
Infection
Acute myocardial infarction
Cancer
Surgery
Medications
AIDS
Increased TBG Decreased TBG
Physiologic conditions
Pregnancy
Newborns
Nonthyroidal illness
Acute hepatitis
Chronic liver disease
Acute intermittent porphyria
Hydatidiform mole
Lymphosarcoma 
Estrogen-producing tumor
Drugs
Estrogens
Heroin and methadone
Clofibrate
Fluorouracil
Familial disorders
Nonthyroidal illness
Nephrotic syndrome
Chronic liver disease, Cirrhosis
Acromegaly
Cushing’s syndrome
Drugs
Androgens
Anabolic steroids
Glucocorticoids
Familial disorders
Table 25–6. Conditions associated with altered thyroxine
binding globulin (TBG) concentrations.
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acute myocardial infarction, reaching a nadir at 1–3 days with
a reciprocal increase in rT3. Serum TSH levels increase at day
4–5, followed by a rise in T4. The severity and size of the
infarct are correlated with the degree of fall in T3 and increase
in rT3. The same pattern is seen with unstable angina. Low T3
is a powerful prognostic marker of death in all forms of car-
diac disease, including congestive heart failure.
7. Cancer—Most cancer patients show a pattern of thyroid
studies similar to other nonthyroidal illness. Malnutrition
and cachexia are contributing factors. Some antitumor
chemotherapeutic agents such as fluorouracil and asparagi-
nase alter TBG levels.
8. Surgery—Elective and emergency surgeries typically
cause significant changes in thyroid hormone levels. Serum
T3 concentrations fall during surgery and may take up to a
week to recover. This is accompanied by a reciprocal rise in
rT3. Serum T4 levels usually remain stable unless there is a
prolonged recovery period. TSH may be unchanged or
reduced intraoperatively but returns to normal within a cou-
ple of days.
9. Medications—The patient in the ICU is commonly tak-
ing multiple medications, some of which may have profound
effects on thyroid function parameters. Some common drugs
and their effects are listed in Table 25–7. Patients in the ICU
commonly receive dopamine for blood pressure support or
high-dose corticosteroids for various reasons. These drugs
suppress TSH secretion, but not usually to the levels seen in
hyperthyroidism. However, in patients with primary
hypothyroidism, dopamine may suppress an elevated TSH
into the normal range, confounding diagnosis.
Other drugs likely to be encountered in the ICU that may
confuse interpretation of thyroid function tests include
octreotide, amiodarone, and β-adrenergic antagonists.
Octreotide decreases TSH secretion at high doses.
Amiodarone, an antiarrhythmic drug containing iodide, may
induce hypothyroidism or hyperthyroidism but more com-
monly results in low serum T3 and normal or high T4.
Amiodarone inhibits 5′-deiodinase. Large doses of propra-
nolol, atenolol, and metoprolol decrease serum T3 levels but
do not result in hypothyroidism.
10. AIDS—In patients with AIDS, direct infection of the thy-
roid gland by opportunistic organisms such as
cytomegalovirus, Cryptococcus, and Pneumocystis jerovici may
occur rarely in addition to infiltration by Kaposi’s sarcoma.
Patients with P. jerovici thyroiditis may have hypo- or hyper-
thyroidism depending on the degree of involvement and dis-
ruption of the gland. Cytomegalovirus thyroiditis usually is
associated with sick euthyroid syndrome rather than
hypothyroidism. Some of the medications used for treating
patients with AIDS may alter thyroid function. For example,
rifampin increases T4 clearance by hepatic microsomal
enzyme induction. Hypothyroidism has been reported after
ketoconazole treatment. One would expect to see a sick
euthyroid pattern with AIDS, but this occurs infrequently
and usually at later stages of HIV infection owing to
decreased extrathyroidal conversion to T3.
A unique pattern of thyroid function tests in AIDS has
been observed that includes a progressive elevation in TBG,
decreased rT3, and normal T3 levels. These alterations are felt
to be part of the abnormal immunoregulation in HIV-
infected individuals and may be mediated by tumor necrosis
factor or other cytokines. The normal T3 level is felt to be a
failure of the normal adaptive response to illness, but
whether this causes the cachexia associated with AIDS
remains to be proved. The prevalence of hypothyroidism,
both clinical and subclinical, in AIDS is higher than in the
general population and has been correlated with CD4 cell
count.
Treatment
It is important to distinguish the sick euthyroid state from
intrinsic thyroid disease because the former does not require
thyroid hormone replacement therapy. Studies show that
treating patients with the low T3-T4 syndromes with T4 was
not beneficial and had no effect on mortality rates. In fact,
there was no increase in T3 levels, suggesting that peripheral
conversion was not enhanced. To exclude inhibition of
peripheral conversion as a factor in nonthyroidal illness,
TSH suppression
Dopamine
Glucocorticoids
Bromocriptine
Apomorphine
Pyridoxine
Octreotide
Impaired thyroid hormone production or secretion
Thionamides (propylthiouracil, methimazole, carbimazole)
Lithium
Iodide
Amiodarone
Impaired T4 to T3 conversion
Propylthiouracil
Glucocorticoids
Propranolol
Ipodate sodium
Iopanoic acid
Amiodarone
Increased hepatic uptake and metabolism of T4
Phenobarbital
Phenytoin
Carbamazepine
Rifampin
Impaired protein binding
Salicylates
Phenytoin
Table 25–7. Effect of drugs on thyroid function.
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some investigators have administered T3, but once again
these studies have not demonstrated a beneficial effect on
outcome. Supportive measures such as adequate nutrition
and specific and successful treatment of the underlying ill-
ness should result in eventual normalization of the thyroid
function alterations.
Current Controversies and Unresolved Issues
Two major issues related to sick euthyroid syndrome are the
subject of some controversy. First, the pathogenesis of the
syndrome remains unclear. The only thing that appears cer-
tain is that the mechanisms are complex, multifactorial, and
involve changes at multiple levels of the thyroid loop,
including changes in TSH and thyroid hormone secretion,
5′-deiodinase, and thyroid hormone binding to proteins
owing to a variety of inhibitors.
Second, the physiologic significance of these changes in the
thyroid function tests remains unclear. We do not know
whether these abnormalities signal a functionally hypothyroid
state or are part of the body’s adaptation to the stress of acute
illness. The answer to this question will determine whether
these patients should receive thyroid hormone replacement
therapy. Unfortunately, there are no clinically practical mark-
ers that reflect the biologic action of thyroid hormones in tis-
sues rather than their levels in the blood. Several studies in
small numbers of patients have failed to reveal any benefit of
thyroid hormone replacement therapy. On the contrary, in
patients with burns, T3 replacement increased urinary nitro-
gen excretion. Furthermore, thyroid hormone replacement
therapy may inhibit TSH secretion and thereby delay recovery
of thyroid function as the acute underlying illness abates. Only
a large prospective study randomizing administration of thy-
roid hormone can answer this question.
Low T3 levels are found in the vast majority of heart
donors, in potential heart transplant recipients, and in
patients who have undergone cardiopulmonary bypass.
Because cardiac dysfunction is a major problem after
transplantation, T3 supplementation has been proposed for
both donor and recipient. There are limited data demon-
strating that T3 supplementation in brain-dead donors
decreases both the amount and duration of inotropic
support. Recently, combined administration of growth
hormone–releasing peptide 2 (GHRP-2), TRH, and
gonadotropin-releasing hormone (GnRH) was shown to
reactivate the growth hormone, TSH, and luteinizing hor-
mone (LH) axes in men with prolonged critical illness.
Combined administration of these secretagogues evoked
beneficial metabolic effects, including reduction in urea pro-
duction and an increase in osteocalcin levels, which were not
observed with GHRP-2 infusion alone. The clinical efficacy
of such an approach should be further tested.
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Diabetes Mellitus,
Hyperglycemia, & the
Critically Ill Patient∗
Eli Ipp, MD
Chuck Huang, MD
Patients with diabetes mellitus are seen frequently in the ICU
because of complications of poorly controlled disease,
including diabetic ketoacidosis, hyperglycemic hyperosmolar
nonketotic diabetic coma, and hypoglycemia. In addition,
diabetic patients with critical illness often will exhibit insta-
bility and poor control of blood glucose, including hyper-
and hypoglycemia. Recent studies have demonstrated that
hyperglycemia in nondiabetic patients in the ICU also can
have a significant impact on morbidity and mortality. This
chapter also will cover new approaches to management of
hyperglycemia in the ICU.
 Diabetic Ketoacidosis
ESSENT IALS  OF  D IAGNOS I S
 Acute illness in a patient with known type 1 (insulin-
dependent) diabetes mellitus, especially if the patient
is vomiting.
 Evidence of precipitating illness, including infection.
 Clinical symptoms and signs of volume depletion.
 Clinical features of metabolic acidosis.
 Laboratory features: hyperglycemia, anion gap acidosis,
ketonemia, and acidemia.
General Considerations
Diabetic ketoacidosis is the most serious metabolic compli-
cation of type 1 (insulin-dependent) and, to a smaller
extent, type 2 (non-insulin-dependent) diabetes mellitus.
There has been little change in the mortality rate associated
with diabetic ketoacidosis in recent decades despite great
improvements in our understanding of its pathophysiology
and treatment. The most effective means of reducing deaths
owing to diabetic ketoacidosis consists of teaching patients to
recognize its early signs. Close clinical and biochemical obser-
vation of every patient during treatment of diabetic ketoaci-
dosis remains the cornerstone of effective management.
A. Pathophysiology—The pathophysiology of diabetic
ketoacidosis is based primarily on an abnormal hormonal
setting: insulin deficiency combined with an excess of hor-
mones that increase the blood glucose level. This situation is
similar to the physiologic state seen during normal fasting
and is probably best considered as an abnormal and extreme
expression of the fasting state. During the fed state, insulin is
the predominant hormone, required for disposal and storage
of ingested nutrients. During fasting, the body converts to a
state in which endogenous sources of fuels need to be tapped
for ongoing support of metabolism in the brain and in mus-
cle tissue, and the hormonal milieu therefore begins to
change. Plasma insulin concentrations fall, and glucagon
concentrations rise. This change in the insulin:glucagon ratio
permits the liver to become the major source for glucose dur-
ing fasting. At the same time, decreased insulin concentra-
tions lead to lipolysis in fat depots, providing a source of free
fatty acids as a fuel for muscle and thus sparing glucose for
use by the brain. Furthermore, free fatty acids are converted
by the liver to ketones under the influence of glucagon.
Ketones constitute another alternative (nonglucose) energy
source for brain and muscle tissues. Glycerol released by
lipolysis and alanine from protein catabolism in muscle pro-
vide substrates for gluconeogenesis in the liver.
In diabetic ketoacidosis, this picture is greatly exaggerated
because of severe insulin deficiency. This is typical of patients
with type 1 diabetes, all of whom have sustained autoim-
mune beta cell destruction. However, insulin deficiency is
now also recognized as the major contributor to ketoacidosis
in type 2 diabetes, an increasingly reported entity, once
thought to be exceedingly rare. The effectiveness of circulat-
ing insulin is also reduced because patients with diabetic
∗Eli Ipp, MD, and Tricia L. Westhoff, MD, were the authors of this
chapter in the second edition.
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ketoacidosis also have considerable insulin resistance.
Historically, this resistance to insulin action was thought to
require massive doses of insulin during treatment of diabetic
ketoacidosis. Although since the 1970s “low dose” continu-
ous insulin infusion has replaced the large intermittent doses
used previously, a high level of resistance to insulin action
remains an important feature of diabetic ketoacidosis. Some
of the known causes of insulin resistance in diabetic ketoaci-
dosis are listed in Table 26–1.
In contrast to the low levels of insulin, glucagon concen-
tration is markedly elevated, with a high glucagon:insulin
ratio more striking than that seen during fasting. In addition,
diabetic ketoacidosis is characterized by large increases in the
levels of stress hormones, including the glucose counterreg-
ulatory hormones cortisol, growth hormone, and cate-
cholamines. These hormones help to define diabetic
ketoacidosis and are responsible for its two major features:
hyperglycemia and ketonemia. Glucagon has its predomi-
nant effects on the liver, enhancing long-chain fatty acid
transport into mitochondria by decreasing levels of malonyl-
CoA and increasing activity of carnitine acyltransferase I.
Cortisol enhances gluconeogenesis by increasing delivery of
gluconeogenic substrates to and transamination in the liver.
Prolonged hypersecretion of cortisol also decreases sensitiv-
ity to insulin. Catecholamines enhance lipolysis, providing
substrate for ketogenesis, and accelerate glycogenolysis and
gluconeogenesis. Finally, growth hormone also contributes
to increased lipolysis and insulin resistance.
Ketoacidosis in a pregnant diabetic is a rare example that
highlights these pathophysiologic components. This serious
complication is caused by insulin deficiency in a setting of
three factors unique to all pregnancies: accelerated starva-
tion, severe insulin resistance, and net lowered buffering
capacity owing to increased renal excretion of bicarbonate, a
consequence of increased minute ventilation and respiratory
alkalosis in pregnancy.
B. Hyperglycemia—Hyperglycemia in diabetic ketoacidosis
results from several mechanisms involving a variety of hor-
mones as well as their different target organs. Using glucose
turnover studies, it has been shown that the major physio-
logic aberration that results from the combination of mech-
anisms just described is excessive hepatic glucose
production. This, in turn, is responsible primarily for hyper-
glycemia in patients with diabetic ketoacidosis. Glucose
clearance by insulin-sensitive tissues is also reduced,
although some increase in glucose utilization is associated
with the mass-action effect of high blood glucose levels. An
important factor that determines the degree of hyper-
glycemia in diabetic ketoacidosis is the extent of renal glu-
cose losses. As long as the kidneys are well perfused, they act
as a continuing source of glucose leak from the extracellular
space and thereby prevent severe hyperglycemia.
Figure 26–1 illustrates mechanisms for hyperglycemia,
with emphasis on a quantitative estimate of their contribu-
tions in diabetic ketoacidosis. The numbers presented in this
diagram are drawn from mean values reported in patients
with diabetic ketoacidosis. Insulin deficiency associated with
glucose counterregulatory hormone excess gives rise to
highly exaggerated hepatic glucose production. Although
some increase in glucose utilization owing to severe hyper-
glycemia may occur, glucose clearance remains low, and uti-
lization is insufficient to match the rise in glucose
production by the liver. In an average 70-kg patient in dia-
betic ketoacidosis with a hypothetical stable glucose concen-
tration of 450 mg/dL, hepatic glucose production is
approximately 18 g/h. Average glucose utilization is estimated
 Figure 26–1. Mechanisms contributing to hyperglycemia
in a 70-kg patient with a plasma glucose level of 450
mg/dL. Values are from mean values obtained in
patients with diabetic ketoacidosis. The box represents
the extracellular glucose compartment. Lack of insulin
and increased counterregulatory hormones result in
decreased glucose utilization (7 g/h) and increased
hepatic glucose production (18 g/h). Renal glucose
losses may delay development of severe hyperglycemia.
Elevated counterregulatory hormones  
Acidemia  
Hypertonicity  
Phosphate depletion  
Elevated plasma free fatty acids  
Hyperaminoacidemia  
Glucose toxicity
Table 26–1. Mechanisms of insulin resistance in diabetic
ketoacidosis. 
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to be about 7 g/h. The square in the diagram represents the
extracellular space, in which there is a total of 81 g glucose
at this time. Considering that the input into the system
(hepatic glucose production) exceeds the output (glucose
utilization), stable glucose concentrations can persist only if
there is another source of glucose loss. Thus renal losses of
glucose are an important component of the protection from
severe hyperglycemia afforded patients with developing dia-
betic ketoacidosis. The average amount of glucose lost
through the kidneys in this example is estimated to be
approximately 11 g/h.
If, without any increase in hepatic glucose production, the
leak of glucose in the urine were diminished by only one-
fifth—for example, as a result of diminished perfusion of the
kidney owing to volume depletion—considerable net accu-
mulation of glucose would occur rapidly in the extracellular
space. In this example, a reduction of about 2 g/h of urinary
glucose losses would result in a further accumulation of about
50 g glucose added to the 81 g in the extracellular space over
24 hours. If the rate of glucose utilization were unchanged—
and with contraction of the extracellular space owing to fluid
losses—this could result in a doubling of serum glucose con-
centrations within a 24-hour period. The features of this dia-
gram accentuate the important role of the kidneys and the
liver in the generation of hyperglycemia in diabetic ketoaci-
dosis. Although not demonstrated in this diagram, these fac-
tors will be discussed later as an important mechanism for
reduction of hyperglycemia once treatment begins.
The degree of volume depletion has an important effect
on the development of hyperglycemia. In a study of insulin
withdrawal in type 1 diabetes, volume depletion (>3% of
weight) increased plasma glucose concentrations compared
with control subjects. Glucose production and disposal were
increased during the volume-depletion study compared with
the control study. Although the study did not evaluate renal
perfusion, a likely explanation of the increased glycemia is a
reduction of glucose excreted owing to reduced glomerular
filtration during volume depletion. Much of the variability of
glycemia in ketoacidosis may be the result of lack of fluid or
energy intake prior to or during metabolic decompensation.
Given the common occurrence of volume depletion in
patients who present with diabetic ketoacidosis, it is proba-
ble that the variability in severity of this factor—as well as the
severity of insulin deficiency and underlying illness—
explains much of the glycemic variability observed in dia-
betic ketoacidosis.
C. Ketosis and Metabolic Acidosis—Ketosis is the second
major manifestation of diabetic ketoacidosis and results
from the accumulation of keto acids generated by the liver.
Ketosis is predominantly a disorder of increased synthesis
of ketones, although inability of peripheral tissues to use
the excess ketones probably plays a small role. The keto
acid measured in the blood during diabetic ketoacidosis is
predominantly β-hydroxybutyrate rather than acetoacetate.
This reflects an altered redox state in the liver.
The increase in keto acids results in an increase in the
serum anion gap that develops because of buffering by bicar-
bonate of hydrogen ion. If the acidosis in diabetic ketoacido-
sis is due only to ketosis, the fall in serum bicarbonate is
equal to the increase in anion gap. It is evident, however, that
acidosis in diabetic ketoacidosis may have additional mecha-
nisms. Many patients have a reduction in serum bicarbonate
concentration that is greater than the increase in anion gap,
indicating, in addition, the presence of a non-anion gap
hyperchloremic acidosis. Previously, hyperchloremic acidosis
was recognized as a common manifestation of the later treat-
ment stages in diabetic ketoacidosis. It is now appreciated
that it also may be present at initial presentation, where it
appears to occur in patients who are less severely volume-
depleted. Recognition of hyperchloremic acidosis is impor-
tant because hyperchloremic acidosis takes longer to resolve
during treatment than ketoacidosis. This is so because keto
acids are metabolized to generate bicarbonate in equimolar
amounts, whereas hyperchloremic acidosis depends for its
correction on regeneration of bicarbonate by the kidneys.
Another cause of acidosis in diabetic ketoacidosis is lactic
acidosis. Lactic acidosis also contributes to the increase in the
anion gap, with a corresponding further decrease in serum
bicarbonate.
D. Fluid and Electrolyte Imbalance—Extensive losses of
fluids and electrolytes comprise the third important feature
of diabetic ketoacidosis and are a consequence of the forego-
ing abnormalities. Fluid and electrolytes are lost in the
osmotic diuresis caused by glycosuria that occurs as a result
of marked hyperglycemia in diabetic ketoacidosis. Fluid
losses are generally about 5–8 L in a 70-kg person, and deple-
tion of sodium, potassium, and chloride may be 300–500
mmol or more at presentation (Table 26–2). Magnesium and
phosphate are also lost, but in smaller quantities. While water
losses are usually easily appreciated clinically, serum elec-
trolyte concentrations do not generally reflect the large losses
that occur in these patients. This is especially true for potas-
sium because, despite large urinary losses, normal or even
high serum levels are seen at presentation as a result of a shift
of potassium from the intracellular to the extracellular
fluid—a consequence of acidosis and the loss of water from
Water 5–8 L
Sodium 400–700 mmol
Chloride 300–500 mmol
Potassium 300–1000 mmol
Calcium 100 mmol
Magnesium 50 mmol
Phosphate 50 mmol
Bicarbonate 350–400 mmol
Table 26–2. Approximate fluid and electrolyte deficits in
patients with diabetic ketoacidosis.
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the extracellular space. The water shift is in response to the
hyperosmolar extracellular space brought on by hyper-
glycemia; intracellular potassium accompanies the water
shift. This fluid shift also plays a role in determining serum
sodium concentration. Because osmotic diuresis is associated
with greater water loss than sodium or chloride, hyperna-
tremia might be expected to occur, but this is not seen com-
monly because of the fluid shift from the intracellular space.
This mechanism explains the mild hyponatremia often
found at diagnosis. In contrast, normal serum chloride con-
centrations are the rule, for the reason that chloride losses are
less than sodium losses. This is so because sodium is also lost
as the cation accompanying ketones excreted in the urine.
E. Altered Mental Status—The altered state of conscious-
ness observed in diabetic ketoacidosis has not been
explained. The closest correlation with impaired conscious-
ness is the serum osmolality. There appears to be an almost
linear relationship between the degree of mental obtunda-
tion and the level of serum osmolality, and most patients
with mental impairment have been found to have serum
osmolality greater than 350 mOsm/Kg (Figure 26–2). If a
patient has altered consciousness in association with a serum
osmolality of less than 340 mOsm/Kg, another cause for the
neurologic problems should be considered.
F. Precipitating Disease—Although diabetic ketoacidosis
can occur in the absence of any coexisting disease, in all
patients with diabetic ketoacidosis (or even milder metabolic
decompensation in diabetes mellitus), a precipitating factor
should be looked for. The most commonly identified pre-
cipitating factors are withdrawal of insulin, infection, and
undiagnosed diabetes during the initial presentation of the
disease. Intercurrent illnesses increase the requirements for
insulin by increasing insulin resistance, a consequence of the
hormonal mechanisms outlined earlier. In the absence of an
appropriate increase in the dose of insulin, patients become
acutely insulin-deficient; the effects of stress increase the
counterregulatory hormones; and the stage is set for the
development of diabetic ketoacidosis.
Clinical Features
A. Symptoms and Signs—Most patients present with a his-
tory of polyuria and polydipsia, weakness, and weight loss.
Duration is often as short as 24 hours, but the history usually
extends over several days, and in newly diagnosed diabetes,
symptoms often go on for weeks. Patients are usually
anorexic and may have vomiting and abdominal pain.
Abdominal pain associated with ketosis is most common
in children, although it may occur in adults as well, and
occasionally has features of an acute abdomen. Fatigue and
muscle cramps are also presenting features of diabetic
ketoacidosis.
Signs of volume depletion are characteristic. Decreased
skin turgor, dry mucous membranes, sunken eyeballs, tachy-
cardia, orthostatic hypotension, and even supine hypoten-
sion may be present. If severe acidosis is present, deep and
slow Kussmaul respirations may be noted as well as the char-
acteristic odor of ketones on the breath. Additional findings
include alteration in CNS function ranging from drowsiness
to coma. Only about 10% of patients who present with dia-
betic ketoacidosis are actually in coma, and about 20% have
clear mentation. The rest have various degrees of altered con-
sciousness. Abdominal tenderness may be noted.
Hypothermia may be present, but fever is not associated with
diabetic ketoacidosis alone. The features of an associated pre-
cipitating illness often dominate the clinical picture.
Precipitating factors for diabetic ketoacidosis are listed in
Table 26–3. The most commonly recognized causes fall
into three groups: (1) undiagnosed type 1 diabetes mellitus,
(2) reduction of insulin dose in association with intercurrent
illness (particularly patients who have anorexia and vomiting
and reduce the insulin dose for fear of hypoglycemia) or non-
compliance (in recent times, interruption of nonconven-
tional, nondepot insulin delivery—for example, insulin
infusion pumps—also may be responsible for an unintended
reduction in insulin dose), and (3) infection, where two
important and potentially confounding features of diabetic
ketoacidosis should be recognized: Fever is not caused by dia-
betic ketoacidosis alone and therefore suggests the presence of
infection, and a white blood cell count of 15,000–40,000/μL
may be seen in the absence of any infection. In some patients,
precipitating factors cannot be identified.
Unusual presentations of patients with diabetic ketoaci-
dosis must be recognized in order to make the correct
diagnosis and provide appropriate therapy (Table 26–4).
Diabetic ketoacidosis should be considered in any patient
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 Figure 26–2. Relationship between serum osmolality
and level of consciousness in patients with diabetic
ketoacidosis. (Reproduced, with permission, from Kitabchi
AE, Wall B: Diabetic ketoacidosis. Med Clin North Am
1995;79:10–37.)
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with type 1 diabetes who develops an acute illness. The need
to rule out diabetic ketoacidosis in a patient with type 1 dia-
betes who is becoming ill applies equally in the outpatient or
inpatient setting. When patients are at home, ketosis can be
tested easily by checking urine ketones. The possibility of
developing diabetic ketoacidosis provides a rationale for
teaching patients to test their urine for glucose and ketones
even though urine glucose measurement  is no longer used to
monitor glycemic control. In inpatients, urine or serum
ketones will help to exclude diabetic ketoacidosis as the cause
of a change in a patient’s condition. Effective bedside meth-
ods for measurement of serum β-hydroxybutyrate now have
been developed, and this should contribute to more rapid
diagnosis of ketosis in hospitalized patients.
B. Laboratory Findings (See Table 26–5)—
1. Hyperglycemia—Serum glucose usually ranges from
500–800 mg/dL in patients with diabetic ketoacidosis.
Although it is often the blood glucose measurement that
alerts the staff to the possibility of diabetic ketoacidosis in an
undiagnosed patient, it is important to keep in mind that
severe hyperglycemia does not always occur. The diagnosis
should be suspected even if serum glucose levels are not
greatly elevated. This is particularly important in patients
who are fasting and may have imbibed alcohol recently
(which inhibits gluconeogenesis) or in pregnant women,
whose serum glucose levels can be normal or only slightly
elevated during severe diabetic ketoacidosis.
2. Metabolic acidosis—Total keto acids average 10–20
mmol/L; lactate is often elevated. As shown in Table 26–5,
however, less severe acidosis may be seen, based on the bicar-
bonate and pH measurements, at initial presentation. This
may be a result in part of possible earlier access to medical
care, but it also may be due to a shift in the strictness of the
criteria used to classify acute metabolic decompensation in
diabetes.
Absence of acidemia or only mild acidemia in diabetic
ketoacidosis may occur if the patient has had vomiting severe
enough to result in a mixed metabolic alkalosis and acidosis.
Absence of ketones in a patient with acidosis, hyperglycemia,
and volume depletion should make one suspect a predomi-
nance of the β-hydroxybutyrate component of the serum
ketones. With an altered redox state—in particular, in the
presence lactic acidosis—acetoacetate is converted to β-
hydroxybutyrate. The nitroprusside reagent that is used to
measure ketones semiquantitatively in most laboratories
recognizes only acetoacetate. A predominantly β-
hydroxybutyrate acidosis therefore may be missed because it
will not be picked up by this method. Use of bedside
methodology for β-hydroxybutyrate measurement should
help to eliminate this factor as a source of confusion in the
diagnosis of diabetic ketoacidosis.
3. Serum electrolytes—Table 26–6 summarizes electrolyte
abnormalities seen at the time of presentation in diabetic
1. New-onset type 1 
2. Reduction of insulin dosage 
Anorexia and vomiting 
Nonadherence
Failure of nondepot insulin delivery 
3. Infection 
4. Acute disease 
Trauma 
Pancreatitis 
Myocardial infarction 
Cerebrovascular accident 
5. Treatment 
Corticosteroids
Pentamidine 
Peritoneal dialysis 
6. Endocrine disorders 
Hyperthyroidism 
Pheochromocytoma 
Somatostatinoma 
Table 26–3. Precipitating factors in patients with
diabetic ketoacidosis.
Typical Exceptions 
Acute illness in a patient with
(suspected) type 1 diabetes 
Diagnosis of diabetic ketoacidosis
may be delayed in older patients
with new-onset type 2 diabetes. 
Clinical symptoms and signs of
volume depletion 
Absence of volume depletion in
patient with diabetic ketoacidosis
and oliguric renal failure. 
Laboratory features 
Hyperglycemia Less severe hyperglycemia in
pregnancy or after alcohol intake. 
Increased anion gap Hypertriglyceridemia may mask
increase in anion gap by interfer-
ing with serum Cl– and HCO3
–
measurements. 
Metabolic acidemia Vomiting may cause concurrent
metabolic alkalosis, decreasing
severity of metabolic acidosis. 
Ketonemia Beta-hydroxybutyrate is not
detected by nitroprusside reaction.
If this ketone predominates,
ketonemia may be underesti-
mated or absent. 
Table 26–4. Typical and atypical features of diabetic
ketoacidosis. 
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ketoacidosis. Mild hyponatremia is the most common abnor-
mal finding and is due to a shift of water from the intracellular
compartment into the hypertonic extracellular fluid. In addi-
tion, a total sodium deficit occurs as a result of the osmotic
diuresis and the obligate cations accompanying ketones
excreted in the urine. Hypochloremia is less common because
chloride is not lost with urinary ketones and because of the
high incidence of hyperchloremic acidosis mentioned earlier.
Despite total body losses of other electrolytes, serum chloride
concentrations usually are normal or low normal at presenta-
tion. Most patients have normokalemia or hyperkalemia at
presentation, but it is important to recognize that up to 20%
will be hypokalemic at that time. Ten percent of patients have
hypophosphatemia at diagnosis, and less than 10% of patients
present with hypomagnesemia. Hypocalcemia occurs in almost
30% of patients. Serum osmolality is rarely measured directly
but instead is calculated from the electrolytes. Hyperosmolality
of varying degrees is a typical feature.
4. Interference with other laboratory tests—
Abnormalities observed in diabetic ketoacidosis may contribute
to artifactual interference with other laboratory tests.
Foster and McGarry∗ Kitabchi† Ipp and Linfoot‡
Glucose (mg/dL) 476 616 542 
Sodium (meq/L) 132 134 132 
Potassium (meq/L) 4.8 4.5 4.9 
Bicarbonate (meq/L) <10 9.4 16 
Anion gap (meq/L) — — 20 
Blood urea nitrogen (mg/dL) 25 32 25 
Acetoacetate (mmol/L) 4.8 — —
Beta-hydroxybutyrate (mmol/L) 13.7 9.1 9.1
Lactate (mmol/L) 4.6 — 2.0 
Blood pH — 7.12 7.26 
∗Data from Foster DW, McGarry JD: The metabolic derangements and treatment of diabetic ketoacidosis. N Engl
J Med 1983;309:159–69.
†Data from Kitabchi AE et al: Diabetes Care 2001;24:131–53.
‡Unpublished results.
Table 26–5. Mean laboratory values in patients with diabetic ketoacidosis on admission
to hospital.
Low Normal High Comment 
Sodium 67 26 7 Body stores depleted; serum [Na+] depends on
[glucose] and relative water loss. 
Chloride 33 45 22 
Potassium 18 43 39 Body stores depleted. 
Magnesium 7 25 68 
Phosphate 11 18 71 Decreases with insulin treatment. 
Calcium 28 68 4 
Table 26–6. Serum electrolyte concentrations in patients with diabetic ketoacidosis at presentation
(% of patients). 
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Acetoacetate crossreacts in some automated methods for
measuring creatinine and thus may artificially elevate creati-
nine concentrations; if owing to this mechanism, elevated
serum creatinine concentrations diminish rapidly as acetoac-
etate levels are cleared with therapy.
Hypertriglyceridemia occurs quite frequently in diabetic
ketoacidosis. This is of importance not only because of the
clinical manifestations of hypertriglyceridemia (eg, acute
pancreatitis) but also because high triglyceride levels inter-
fere with accurate measurement of sodium, chloride, and
bicarbonate. When hypertriglyceridemia is present, pseudo-
hyponatremia may be seen (serum is composed of a sodium-
containing water phase and a large lipid-triglyceride phase
that contributes non-sodium-containing volume). What is
less well recognized is that hypertriglyceridemia can interfere
with the colorimetric measurement of chloride and bicar-
bonate, although there is no interference with more com-
monly used ion-specific electrode assays. The effect is to
report falsely high serum chloride and bicarbonate concen-
trations that may mask the increase in anion gap expected in
ketoacidosis and lead to incorrect evaluation of the patient.
This possibility should be considered whenever the anion
gap is not elevated in an otherwise typical clinical situation
suggestive of diabetic ketoacidosis.
Differential Diagnosis
Clinical manifestations of diabetic ketoacidosis, such as dys-
pnea, nausea, vomiting, or abdominal pain, may mimic non-
diabetic acute disease. In known diabetic patients with coma
or altered mental status, ketoacidosis must be distinguished
from hypoglycemia. This is usually not difficult clinically
because the circumstances and clinical findings are usually
quite different. The patient with diabetic ketoacidosis is
volume-depleted and may be acidotic, whereas the hypo-
glycemic patient is usually cold and clammy. In either case,
bedside diagnosis of these conditions by direct measurement
of blood glucose can be made quickly, so clinical differentiation
is less relevant. In comatose patients with diabetic ketoacidosis
in whom serum osmolality is less than 340 mOsm/Kg, another
cause of coma should be considered.
A common difficulty arises when differentiating alcoholic
ketosis from diabetic ketoacidosis in a patient with diabetes
who has ingested alcohol. In such situations, whatever the
cause of ketosis, the management is that of diabetic ketoacido-
sis. Severe abdominal pain from diabetic ketoacidosis, often
accompanied by vomiting, may mimic an acute abdomen.
Acute pancreatitis is often in the differential diagnosis, and its
diagnosis is complicated by the fact that serum amylase levels
are often elevated in diabetic ketoacidosis as a result of an
increase in serum amylase from the salivary isoenzymes.
Treatment
The principles of management of diabetic ketoacidosis are to
replace losses of water and electrolytes, give sufficient insulin
(ie, stop ketogenesis, lipolysis, and gluconeogenesis), correct
blood pH, closely monitor the patient through all stages of
management, and eliminate or treat precipitating causes.
Rapid initial evaluation takes place in the emergency room in
most patients with diabetic ketoacidosis, although at times
diabetic ketoacidosis does develop in the hospital. Table 26–7
sets forth the initial steps in management when diabetic
ketoacidosis is suspected. Figure 26-3 provides an overview
of management.
A. Monitoring—Close monitoring is the key to successful
management of diabetic ketoacidosis. Most management
decisions are fairly straightforward if the data are available
in timely fashion. Errors in management occur most often
when there is a lapse in monitoring so that a “catch-up” sit-
uation develops or the effects of overtreatment need to be
corrected.
Blood glucose should be monitored hourly at the bedside.
This provides information about whether the insulin dose is
adequate to cause a fall in blood glucose at the expected rate
of about 100 mg/dL per hour. Later, glucose measurement
prevents overshooting the target serum glucose level of
250–300 mg/dL, at which time infusion of dextrose should
be started. Serum electrolytes and ketones should be moni-
tored every 2 hours, and this should include measurement of
serum phosphorus as well. Arterial blood gases should be
repeated as necessary if progress in the clearing of acidosis is
slow or if there are associated pulmonary problems. If phosphate
therapy is used, serum calcium should be measured at least
once (after an initial measurement) during the first 12 hours
to detect any large decrease in serum calcium. All the data
obtained, including fluid balance measurements, should be
maintained on a flowchart for easy review and evaluation.
1. Correction of hyperglycemia—Correction of hyper-
glycemia occurs by four different mechanisms (Table 26–8).
First, the concentration of the extracellular glucose is diluted
by fluid replacement, expanding the extracellular space. The
second is by continuing—and usually increased—urinary
Rapid clinical examination. 
Bedside blood glucose and urine ketone determinations. 
Obtain blood for laboratory determination of glucose, ketones, electrolytes, 
urea nitrogen, creatinine, phosphorus, magnesium. 
Obtain arterial blood for blood gases. 
Chest x-ray. 
ECG (also to monitor K+ levels). 
Search for precipitating factor. 
Monitoring: Hourly bedside glucose and two-hourly measurement of
anion gap, serum electrolytes, serum ketones, serum phosphorus. 
Obtain arterial blood gases as needed. 
Table 26–7. Initial diagnosis and management of diabetic
ketoacidosis.
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loss of glucose that occurs with improved renal perfusion
following expansion of the intravascular space. Third is the
effect of insulin to diminish the hepatic glucose production
rate. Considering that this is one of the important pathophys-
iologic mechanisms producing hyperglycemia in diabetic
ketoacidosis, inhibition of this process must be one of the
management goals. Indeed, it has been demonstrated that
insulin infused at the routine doses is very effective in reduc-
ing glucose production by the liver during recovery from dia-
betic ketoacidosis. Increased glucose utilization is the fourth
mechanism and is also an insulin-dependent process.
2. Correction of ketosis—Ketosis is corrected more
slowly than hyperglycemia, so while serum glucose levels
usually will reach 250–300 mg/dL within an average of 6–8
hours, it can take up to 12 hours or more for ketosis to clear.
It is particularly important to continue insulin infusion dur-
ing this period despite the fact that one major goal of ther-
apy (reduction of hyperglycemia) has been attained.
Intravenous insulin therefore should be stopped only when
ketosis has cleared.
It is not always easy to decide when a patient is no longer
in a state of ketoacidosis. Serum ketone measurements do
not provide the entire answer because they can remain posi-
tive for many hours after the acidosis is resolved, probably
because acetone is cleared much more slowly than the two
keto acids. Acetone, however, is also measured by the nitro-
prusside reaction and can give rise to persistently positive
serum ketone measurements even though it does not alter
acid-base balance. For this reason, monitoring the anion gap
is a better way of determining when ketosis has cleared.
Serum bicarbonate concentrations are useful for monitoring
progress of therapy but less useful when used alone to determine
 Figure 26–3. Management of adult patients with diabetic ketoacidosis. [Na]c = corrected serum sodium concentra-
tion (for each 100 mg/dL glucose >100 mg/dL, add 1.6 meq/L to measured serum sodium.) (Modified from American
Diabetes Association. Hyperglycemic crises in diabetes. Diabetes Care 2004;27:S94–102.)
Dilution by expansion of extracellular volume
Urinary losses  
Diminished glucose production rates 
Increased glucose utilization 
Table 26–8. Correction of hyperglycemia: Mechanisms.
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that ketoacidosis has cleared because bicarbonate is slow to
normalize completely. This is so because hyperchloremic aci-
dosis accompanies saline therapy in almost all patients and
because hyperventilation persists after the patient is no
longer acidotic. Arterial blood pH measurement can be use-
ful when it is difficult to decide whether ketosis has cleared—
particularly if the anion gap has normalized and
hyperglycemia is resolved, yet the patient still appears to be
ill. The overall clinical picture is useful—in a patient whose
appetite has returned and is able to eat and retain a meal, this
generally signals resolution of ketoacidosis.
B. Fluid Replacement—Fluid losses in an adult with dia-
betic ketoacidosis average 5–7 L and may be as much as
10–15% of body weight. Fluid replacement should be initi-
ated immediately after diagnosis to prevent further deterio-
ration of hemodynamic status. Fluid therapy is begun with
intravenous 0.9% NaCl solution. A rough guide to volume
replacement is as follows: (1) 2 L can be given over the first 2
hours, (2) this can be followed by 2 L over the next 4 hours
using 0.9% or 0.45% NaCl solution, and (3) over the next 8
hours, another 2 L can be given using either 0.9% or 0.45%
NaCl. This schedule should be modified according to ongoing
assessment of volume replacement needs and serum sodium
levels. In hemodynamically compromised patients and the
elderly, close monitoring of volume status may be necessary,
and consideration should be given to use of a central venous
pressure or pulmonary artery catheter. If severe hypotension
is present, maintaining intravascular volume with albumin or
other plasma expanders also should be considered.
When the plasma glucose concentration reaches 250–300
mg/dL, 5% dextrose solution should be started with an
appropriate amount of NaCl according to the needs of the
patient at that time.
There is disagreement about the best approach when
serum sodium exceeds 150 meq/L at presentation. When
0.45% NaCl is given at the outset, some patients have devel-
oped hypotension during treatment. This is likely due to the
insulin effect to drive glucose intracellularly; water follows,
and the intravascular space is depleted. When hypotonic
saline is used, there is less addition of solute that will remain
in the intravascular and extracellular spaces. Therefore, a
greater proportion of the infused fluid will be ineffective in
expanding the intravascular volume.
Administering 0.9% NaCl solution provides a greater
osmotic load, and thus it is more likely to protect intravascu-
lar volume in the face of fluid shifts in diabetic ketoacidosis
patients who are strikingly volume-depleted. The concern
with infusing 0.9% NaCl (normal saline) is that hyperosmo-
lality will not be corrected. However, this approach conforms
to the physiologic principle that during states of severe vol-
ume depletion, volume maintenance takes precedence over
maintaining normal serum osmolality. Thus 0.9% NaCl is
recommended as the volume replacement fluid of first choice
even when the patient is initially hypernatremic: 0.9% NaCl
is hypo-osmolar relative to serum when serum osmolality is
greater than 308 mOsm/Kg. Once volume depletion has been
corrected, administration of 0.45% NaCl or 5% dextrose in
water to correct hypernatremia is indicated.
Fluid replacement has been given without insulin therapy
to test its effects in the absence of insulin. In a few studies
there has been considerable improvement in hyperglycemia
but with no consistent effect on serum ketones. The
improvement in serum glucose concentrations in the
absence of insulin is probably the result of increased renal
glucose losses and a dilution effect (see Table 26–8).
C. Insulin
1. Initial therapy—Insulin is started at the time of diagno-
sis at a rate of 0.1 unit/kg per hour by continuous intravenous
infusion. A bolus dose of 0.15 unit/kg may be administered
initially. Blood glucose levels should be checked at hourly
intervals using bedside (glucometer) measurements, and lab-
oratory serum glucose determinations can be obtained every
2 hours, along with serum electrolytes, to provide confirma-
tion of the glucometer measurements.
In most patients, the recommended starting dose is suffi-
cient to treat diabetic ketoacidosis because the serum-free
insulin levels achieved with this infusion rate are 7 to 10
times normal basal concentrations. However, some patients
do require even faster infusion rates. Therefore, if serum glu-
cose concentrations have not begun to fall after the first hour,
the rate of insulin infusion should be doubled—and doubled
once again if the same should happen during continuing ther-
apy. The insulin infusion should cause blood glucose to fall at
a rate of about 75 mg/dL per hour. The rate of insulin infusion
should be continued—if glucose is falling appropriately—
until serum glucose has reached 230–300 mg/dL. At that
time, a 5% dextrose infusion should be started, but the
insulin infusion must continue until ketosis clears. Because
considerable insulin resistance remains even though some of
the factors described in Table 26–1 have normalized, insulin
infusion should be maintained at the same rate and 10%
dextrose infused, if necessary, to maintain serum glucose lev-
els while awaiting clearance of ketones. Decreasing insulin
infusion rates at this time may result in slower resolution of
ketosis. Clearing of ketosis should be monitored using a
combination of the anion gap, bicarbonate, and serum
ketone measurements and, if necessary, arterial blood gas pH
measurement.
2. After resolution of ketosis—Once ketosis has
cleared—and if the patient is eating—a subcutaneous insulin
regimen can be started. The patient should be given a subcu-
taneous injection of regular insulin about 30 minutes before
stopping the insulin infusion. This allows some of the subcu-
taneously injected insulin to be absorbed before the insulin
infusion is halted. Because intravenous insulin has a half-life
of only 5–6 minutes, stopping the intravenous insulin prior
to giving subcutaneous insulin can result in temporarily
inadequate serum insulin concentrations. Low serum insulin
levels, in turn, can cause a rebound into diabetic ketoacidosis,
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particularly if there is significant delay in delivering the sub-
cutaneous regular insulin injection. Subcutaneous rapid-
acting (regular or analogue) insulin is also best injected
before a meal, and the insulin infusion can be halted once the
meal begins. The bolus of regular insulin thus will be deliv-
ered at a physiologically appropriate time, and the meal will
help to compensate for any error of excess in estimating the
regular insulin dosage at that time.
Split-dose insulin therapy with a combination of regular
and NPH insulin before breakfast and dinner can be started
as soon as the diabetic ketoacidosis has resolved and the
patient is able to eat. The total daily dose can be similar to pre-
hospital doses in patients with known diabetes; in newly diag-
nosed patients, regular insulin can be given before meals and
at 12 midnight using a sliding scale for 24 hours. The total
dose required then can be used to calculate split-dose therapy,
giving two-thirds of the total dose in the morning and one-
third in the evening. NPH insulin usually constitutes two-
thirds of the morning dose and three-fourths of the evening
dose, with the remainder in each case being regular insulin.
D. Potassium Replacement—Usual potassium deficits in
diabetic ketoacidosis have been estimated to be approxi-
mately 300 meq, but the deficit may be as much as 1000 meq.
This total body potassium deficit is the result of combined
renal losses owing to osmotic diuresis and potassium shifts
from intracellular to extracellular fluid that lead to further
loss through the kidneys.
If the patient is normokalemic or hypokalemic at presen-
tation, potassium replacement should be started when
insulin therapy is initiated. If the serum potassium level is
high, potassium therapy should be started only after insulin
therapy is begun and with the second liter of fluid replace-
ment. If treatment is necessary before the serum potassium
level is reported, epidemiologic data provide a basis for
determining the frequency of serum potassium abnormali-
ties (see Tables 26–5 and 26–6). Most patients initially have
either normal or high serum potassium levels; however, up to
20% of patients will have hypokalemia at the outset. In this
last group of patients, insulin infusion alone (without potas-
sium replacement) will exacerbate the hypokalemia, with
potentially severe consequences. In contrast, the fear of giv-
ing potassium to normokalemic or hyperkalemic patients is
mitigated by the effects of the concomitant insulin infusion,
intracellular rehydration, and rise in pH. Thus, if the serum
potassium concentration is unknown, the ECG does not
demonstrate hyperkalemic changes, and the patient is pro-
ducing adequate amounts of urine, potassium infusion
should be started at the same time insulin therapy is begun.
Potassium replacement is started by the addition of
potassium chloride 20–40 meq/L to the fluid replacement
solution. Potassium phosphate also may be given (alternating
with potassium chloride) if phosphate repletion is necessary.
Subsequent potassium replacement depends on the results of
serum potassium determinations, which should be done at
2-hour intervals throughout the period of management of
diabetic ketoacidosis. In addition, electrocardiographic
follow-up with single-lead measurement is a useful way of
monitoring serum potassium for gross hyperkalemia or
hypokalemia so that emergency treatment can be initiated if
necessary. It should be kept in mind that even while replace-
ment of potassium is taking place, continuing potassium
losses occur in the kidney throughout the period of manage-
ment of diabetic ketoacidosis. For this reason, serum potas-
sium measurements also should be obtained daily once the
patient is no longer ketotic. A total body deficit of potassium
may persist despite initial correction of serum potassium,
and oral potassium replacement therapy should be given to
patients who continue to be hypokalemic.
E. Bicarbonate—Acidosis generally resolves with insulin ther-
apy and metabolism of keto acids. In most cases of diabetic
ketoacidosis, it is not necessary to treat acidemia with bicar-
bonate. Recent studies have demonstrated that bicarbonate
therapy does not alter the eventual outcome of diabetic
ketoacidosis, nor does it increase the rate at which pH is cor-
rected. In fact, some have found a counterproductive effect of
sodium bicarbonate in the treatment of diabetic ketoacidosis.
Clinical and animal studies have shown that bicarbonate
administration actually may increase ketone production.
Recent data suggest also that in children with diabetic ketoaci-
dosis, the mean duration of hospitalization for those receiving
bicarbonate was 23% longer than that of children who did not
receive bicarbonate. Lastly, a multicenter retrospective study of
the risk factors associated with cerebral edema in children with
diabetic ketoacidosis found that the relative risk of cerebral
edema was 4.2 in children treated with bicarbonate compared
with a matched control group that did not receive bicarbonate.
Bicarbonate therapy also has been associated with hypocal-
cemic tetany, decreased tissue oxygen delivery, a paradoxical
fall in pH of the cerebrospinal fluid, rebound alkalosis, greater
potassium needs, and sodium overload.
However, when pH values are extremely low, concern
about the hazards of acidemia begin to outweigh the con-
cerns with alkali therapy. Therefore, at a pH of less than 7.0,
particularly in a patient who is very ill, many clinicians will
administer bicarbonate. The effects of low pH are a negative
inotropic effect on the heart, vasodilatation, cerebral depres-
sion, insulin resistance, and depression of enzyme activity. If
treatment with bicarbonate is begun, the American Diabetes
Association (ADA) recommends that 100 mmol of sodium
bicarbonate should be added to 400 mL of sterile water and
given at a rate of 200 mL/h in severe acidosis (pH <6.9). In
patients with a pH of 6.9–7.0, 50 mmol of sodium bicarbon-
ate should be diluted in 200 mL of sterile water and infused
at a rate of 200 mL/h.
In general, taking into account the hazards of treatment,
the hazards of acidemia, and the probable benefits of bicar-
bonate administration, it is not necessary to treat routinely
with bicarbonate.
F. Phosphate Replacement—The routine administration of
phosphate in the management of diabetic ketoacidosis remains
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controversial. Although there are theoretical reasons for replac-
ing phosphate during treatment, most studies have not demon-
strated any beneficial effect. Despite depletion of erythrocyte
2,3-diphosphoglycerate and the concern about decreased oxy-
gen delivery to the tissues resulting from a leftward shift in the
oxyhemoglobin dissociation curve, there are no deleterious
clinical consequences of a mildly low serum phosphorus con-
centration. For most patients with diabetic ketoacidosis, routine
administration of phosphate is unnecessary.
However, it is important to separate out one group of
patients in whom phosphate therapy is essential—those with
low serum phosphorus levels at presentation, which includes
about 10% of patients (see Table 26–6). Serum phosphorus
decreases in all patients, sometimes dramatically, after insti-
tution of insulin therapy. If the initial serum phosphorus
concentration is 1.5 mg/dL, however, it may fall with treat-
ment into the range of concentrations that are associated
with the hypophosphatemia syndrome (Table 26–9). This
syndrome may include decreased myocardial contractility,
respiratory muscle weakness and respiratory failure, hemol-
ysis, and rhabdomyolysis. It is important to note that none of
the studies evaluating the efficacy of phosphate therapy in
diabetic ketoacidosis included patients with severely
depressed serum levels at presentation, so the conventional
wisdom that phosphate therapy is unnecessary should not be
extended to include the group with low serum phosphate
levels at diagnosis.
Severe hypophosphatemia may not be recognized unless
frequent serum phosphorus measurements are made. These
should be obtained every 2 hours during treatment of dia-
betic ketoacidosis in all patients whose serum phosphorus
level is less than 2.5 mg/dL at presentation. Patients with
hypophosphatemia should be given supplemental phospho-
rus in the form of potassium phosphate.
Potassium phosphate can be added to the fluid replacement
solution, alternating with potassium chloride. Hypopho-
sphatemic patients generally will require 500–1000 mg
elemental phosphorus given over 12–24 hours depending on
the severity of phosphorus depletion. This is equivalent to
about 15–30 mmol of phosphate, or a total of 5–10 mL of
potassium phosphate solution (3 mmol/mL) to be added to
the fluid replacement solutions (1–4 mL potassium phos-
phate solution per liter of replacement fluid). A concern
about phosphate administration in patients with diabetic
ketoacidosis is hypocalcemic tetany, which has been
described in some patients who receive phosphate therapy. It
should be kept in mind that calcium levels may fall during
the management of diabetic ketoacidosis. Small decreases in
serum calcium therefore may not be a contraindication to
continued phosphate repletion in patients who are
phosphorus-depleted, but they do require more frequent
monitoring of serum calcium to prevent hypocalcemia.
Patients with normal or high serum phosphorus levels
at diagnosis will have a decrease in serum phosphorus
during therapy, but only to levels that do not usually
require treatment.
Complications of Diabetic Ketoacidosis
A number of complications of diabetic ketoacidosis may
occur during treatment. Hypocalcemia, hypokalemia or
hyperkalemia, hypophosphatemia, and hypoglycemia need
to be watched for during continuous monitoring of patients
with diabetic ketoacidosis (Table 26–10). Another recognized
complication is thromboembolism that occurs as a result of
Table 26–9. Hazards of hypophosphatemia and
phosphorus repletion in diabetic ketoacidosis.
Hypophosphatemia
Decreased red cell 2,3-diphosphoglycerate with decreased
O2 delivery
Muscle weakness
Hypophosphatemia syndrome ([P] <1.0 mg/dL) with respiratory
insufficiency, decreased myocardial contractility, rhabdomyolysis,
hemolysis
Phosphorus administration
Hypocalcemia and tetany
Complication Possible Mechanism
Hypokalemia Bicarbonate therapy, inadequate replacement, 
insulin
Hyperkalemia Anuria, excessive replacement
Hypophosphatemia Insulin therapy (if [P] starts out
<1.5 mg/dL)
Hypoglycemia Inadequate glucose infusion with insulin
therapy
Other
Thromboembolism 
Aspiration 
ARDS 
Cerebral edema 
Mucormycosis 
Increased platelet adhesiveness, hypervis-
cosity, poor perfusion
Gastric stasis, vomiting; lack of nasogastric
suction
Use of hypotonic replacement fluids or
excess crystalloid infusion or increased
pulmonary epithelial permeability
Excessive correction of hyperglycemia
Use of hypotonic replacement fluids(?) 
Acidemia 
Table 26–10. Complications of diabetic ketoacidosis. 
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increased platelet adhesiveness and hyperviscosity.
Aspiration of gastric contents is associated with gastroparesis
and vomiting. Nasogastric suction should be initiated in all
patients who have altered consciousness to prevent this com-
plication. Cerebral edema and acute respiratory distress syn-
drome are other complications that will be discussed below.
One of the rare but significant conditions that should be
kept in mind in the management of diabetic ketoacidosis is
mucormycosis. This rare condition associated with ketoaci-
dosis is a treatable yet severe infection by the fungus
Rhizopus. Early diagnosis is essential so that therapy can be
instituted to prevent the severe morbidity associated with
this rapidly invasive infectious process. The hallmark of
mucormycosis is the finding of black necrotic debris in the
area of the eye, nose, or nasal cavity and histologic evidence
of vascular thrombosis or tissue infarction on biopsy. These
findings result from the propensity for invasion by
mucormycosis into the vascular system. This diagnosis is
considered to be a medical emergency that requires urgent
surgical and antifungal therapy.
Current Controversies and Unresolved Issues
A. Fluid Replacement—Fluid replacement remains a con-
troversial issue from two different points of view. The first is
volume replacement. A study comparing the effects of pro-
viding 3 L of volume replacement over the first 8-hour
period of treatment versus giving 6 L over the same period of
time showed very little difference in outcomes in the two
groups of patients. The conclusion is that smaller volumes of
fluid may be administered safely to some patients with dia-
betic ketoacidosis. It needs to be emphasized that patients
with severe volume deficits were excluded from this study,
but patients with moderate fluid deficits may do well with
slower replacement of their losses. One approach provides a
more flexible regimen for fluid replacement that recognizes
the unique requirements of each patient but consequently
requires careful monitoring. Fluid is replaced at a rate of
15–20 mL/kg per hour for 1 hour and then at 4–14 mL/kg
per hour thereafter according to need, as determined by care-
ful monitoring of fluid balance.
The type of fluid replacement also has been an issue of
controversy. Some investigators feel that colloid therapy is
better than crystalloid infusion in the management of dia-
betic ketoacidosis. Their concern is that insufficient fluid is
maintained in the intravascular space during therapy and
that much of the fluid, when given as crystalloid, finds its way
into the interstitial space, where edema is the result. It has
been suggested that the syndromes of cerebral edema and
pulmonary edema may be a consequence in part of the
sequestration of fluid outside the intravascular space.
However, no controlled studies of colloid infusion have been
performed. Colloid solutions should be considered in the
management of hypotension in patients who present with
diabetic ketoacidosis, but at this time, crystalloid infusion
remains the management of choice.
B. Cerebral Edema—This serious complication is fortu-
nately quite rare. Cerebral edema manifests as a deteriorating
level of consciousness at a time when other parameters of dia-
betic ketoacidosis are improving in response to treatment.
Clinical evidence for this complication generally appears
early in the course of treatment; almost two-thirds of
patients who develop neurologic deterioration begin to do
so within 12 hours of initiation of therapy. Cerebral edema
occurs mainly in children and young adults and is associ-
ated with a greater than 90% mortality. However, despite its
rarity, this complication has influenced one of the basic
aspects in our management of diabetic ketoacidosis because
of its catastrophic consequences. As mentioned earlier, it is
accepted practice to start glucose infusion to prevent serum
glucose concentrations from falling below 250–300 mg/dL.
This recommendation derives from studies of experimentally
induced cerebral edema in diabetic dogs that demonstrated
an association of cerebral edema with greater decrements in
plasma glucose concentrations during treatment.
In an observational study of children who developed cere-
bral edema with ketoacidosis, only treatment with bicarbon-
ate was associated with cerebral edema. Neither the initial
serum glucose concentration nor the rate of change in the
serum glucose concentration during therapy was associated
with the development of cerebral edema. Symptomatic cere-
bral edema has developed in a few children with diabetic
ketoacidosis before the initiation of therapy, suggesting that it
may not necessarily be caused by therapy. Children with dia-
betic ketoacidosis who have low partial pressures of arterial
carbon dioxide (relative risk 2.7 per decrease of 7.8 mm Hg)
and high serum urea nitrogen concentrations (relative risk 1.8
per increase of 9 mg/dL) at presentation were at increased risk
for cerebral edema. This supports the hypothesis that cerebral
edema in children with diabetic ketoacidosis is related to
decreased perfusion of the brain. Both hypocapnia, which
causes cerebral vasoconstriction, and extreme dehydration
would be expected to decrease brain perfusion. Furthermore,
because the developing brains of children are more sensitive
to hypoxia, this may explain the greater incidence of cerebral
edema in children than in adults.
Subclinical cerebral edema appears to be quite common
in patients with diabetic ketoacidosis because compression of
the subarachnoid and ventricular spaces during treatment
has been observed by CT scan without any obvious clinical
manifestations. The high frequency of subclinical edema has
raised questions about the rate and composition of fluid
replacement discussed earlier in this section. Mannitol is
used in therapy of symptomatic cerebral edema.
C. Acute Respiratory Distress Syndrome (ARDS)—
Another unusual but serious complication of ketoacidosis is
ARDS. Patients present with progressive dyspnea and hypox-
emia; the earliest sign appears to be an increased P(A–a)O2,
and pulmonary edema is found on chest x-ray. ARDS in dia-
betic ketoacidosis tends to occur most often in patients
under 50 years of age, and the mortality rate associated with
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this syndrome is extremely high. The pathogenesis of ARDS
in diabetic ketoacidosis is unknown, but it also has been sug-
gested that the syndrome may be associated with crystalloid
infusion and perhaps with excess volume replacement. It is
unlikely that either of these factors is the sole cause of ARDS
because it is too unusual a complication of diabetic ketoaci-
dosis to be simply fluid-dependent given the wide range of
replacement regimens used. However, it is possible that there
is an association with excessive fluid replacement in patients
who have some underlying pulmonary disease process asso-
ciated with increased pulmonary epithelial permeability.
Glaser NS et al: Mechanism of cerebral edema in children with dia-
betic ketoacidosis. J Pediatr 2004;145:164–71. [PMID: 15289761]
Kamalakannan D et al: Diabetic ketoacidosis in pregnancy.
Postgrad Med J 2003;79:454–7. [PMID: 12954957]
Kitabchi AE et al: Hyperglycemic crises in adult patients with
diabetes: A consensus statement from the American Diabetes
Association. Diabetes Care 2006;29:2739–48. [PMID:
17130218]
Linfoot P, Bergstrom C, Ipp E: Pathophysiology of ketoacidosis in
type 2 diabetes mellitus. Diabet Med 2005;22:1414–9. [PMID:
16176205]
 Hyperglycemic Hyperosmolar Nonketotic
Coma
This disorder is probably not a distinct entity but rather a
variant of the diabetic ketoacidosis syndrome because a large
overlap exists in the clinical presentation and pathogenesis of
diabetic ketoacidosis and nonketotic coma. Management of
the two conditions is essentially identical. However, there are
clearly major differences in clinical presentation between
typical patients with nonketotic coma and diabetic ketoaci-
dosis, who probably represent opposite extremes of this
metabolic syndrome.
The patient with nonketotic coma typically is an elderly
person who presents with diabetes for the first time, is
severely dehydrated, is more often in coma, and has severe
associated diseases and a poor outcome. In contrast, the
common first presentation of diabetic ketoacidosis is in a
teenager who is otherwise healthy, not often in coma, and has
an excellent chance of recovery. Biochemically, the typical
patient with hyperglycemic hyperosmolar nonketotic coma
has more severe hyperglycemia (eg, serum glucose often >
1000 mg/dL) and hyperosmolarity, more pronounced elec-
trolyte abnormalities, and no ketosis. Between these two
extremes are a large number of patients in whom the clinical
syndromes overlap, so some degree of ketosis is often present
in a patient who otherwise would be classified as having typ-
ical nonketotic coma; on the other hand, hyperosmolarity
and severe hyperglycemia occur in what otherwise appears to
be typical diabetic ketoacidosis.
The pathogenesis of hyperglycemic hyperosmolar nonke-
totic coma is not well understood. The severity of the hyper-
osmolarity can be ascribed to a greater degree of volume
depletion. Indeed, severe volume depletion is the most
important common feature and can best be explained by the
degree of hyperglycemia. Figure 26–1 provides an explana-
tion for this severe hyperglycemia. Since volume depletion is
a characteristic feature, renal blood flow and the glomerular
filtration rate are reduced, thus diminishing the urinary
escape of glucose. However, the hormonal setting ensures a
continuing high rate of hepatic glucose production (see
above for further discussion of Figure 26–1), and this has the
capacity to rapidly increase blood glucose levels. If this
sequence of events is not halted, severe hyperglycemia and
hyperosmolarity ensue.
The other major feature of nonketotic coma—the rela-
tively low level of serum keto acids—also may play an impor-
tant role in the development of severe hyperglycemia.
Ketoacidosis makes the patients feel more ill and thus pre-
vents the syndrome from going undiagnosed for prolonged
periods. The lack of ketosis in hyperglycemic hyperosmolar
nonketotic coma may delay presentation, resulting in ongo-
ing osmotic diuresis that results in more severe volume
depletion. The mechanism for the lower levels of ketosis is
unexplained. The hormonal picture at presentation is not
helpful because concentrations of circulating counterregula-
tory hormones do not appear to be different from those seen
in diabetic ketoacidosis, nor do insulin levels seem to differ.
Nevertheless, it is thought that a restraining effect on lipoly-
sis by small increases of circulating insulin—and, as a result,
less availability of substrate for ketogenesis—may explain
low ketone concentrations in this syndrome. It also appears
that hyperosmolarity may itself play a role in diminishing
ketosis; this is based on in vitro studies in which hyperosmo-
larity was shown to suppress lipolysis.
Management is not different from that of diabetic
ketoacidosis. Plasma glucose concentrations should be
allowed to decrease at a rate of about 100 mg/dL per hour,
and fluid replacement should begin with normal saline as
discussed earlier. Early aggressive volume replacement is
important to prevent hypotension that may result from
fluid shifts that accompany insulin-mediated glucose
transport into the intracellular compartment. Many of
these patients are elderly, and monitoring fluid balance
with central venous catheters therefore is advised. Because
of the massive osmotic diuresis that precedes presentation
in these patients, electrolyte losses may be severe. It is par-
ticularly important to monitor serum potassium concen-
tration carefully during early management and in
subsequent days so as to provide potassium supplements if
they become necessary. The mortality rate is high, with
deaths often due to concurrent illnesses or thrombotic and
infectious complications.
Kitabchi AE et al: Hyperglycemic crises in adult patients with
diabetes: A consensus statement from the American Diabetes
Association. Diabetes Care 2006;29:2739–48. [PMID:
17130218]
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MANAGEMENT OF THE ACUTELY ILL PATIENT
WITH HYPERGLYCEMIA OR DIABETES MELLITUS
Management of patients in the ICU setting has undergone a
strategic change in a matter of a few years since the publica-
tion of a landmark work known as the Leuven study in 2001.
This study demonstrated unequivocally that management of
hyperglycemia is of fundamental importance in critically ill
patients and has changed the way in which hyperglycemia
and diabetes are managed in the ICU.
For many years it was thought that moderate control of
blood glucose in inpatients and the critically ill was appro-
priate care. This was a result of the prevailing interpretation
of the hyperglycemia of injury as a benign adaptive process
that contributes to survival. Mild or moderate hyperglycemia
is common in critically ill patients, even in those not previ-
ously known to have diabetes. Hyperglycemia is due to a
combination of physiologic changes including insulin resist-
ance and increased hepatic glucose production despite
increased secretion of insulin and was seen as necessary to
provide glucose as fuel during severe injury. The Leuven
study challenged these concepts after demonstrating that
tight glucose control (<110 mg/dL) improved mortality and
morbidity in critically ill patients and thereby changed not
only the practice of medicine in the ICU but also how we
think about glucose regulation in acute illness.
 Hyperglycemia
Pathophysiology
The most frequent pathophysiologic abnormality of glucose
metabolism induced by acute illness is an increase in insulin
resistance. The molecular mechanisms are not well under-
stood, but a number of associated abnormalities contribute to
the development of insulin resistance. Increased secretion of
glucose counterregulatory hormones occurs in the acutely ill
patient. Increased concentrations of cortisol, catecholamines,
growth hormone, and glucagon lead to increased hepatic glu-
cose production by gluconeogenesis and glycogenolysis, as well
as insulin resistance at the level of muscle and adipose tissue.
Although insulin secretion increases in response to rising glu-
cose concentrations, it is insufficient to prevent hyperglycemia,
which is usually mild in nondiabetic patients. Catecholamines
may play a role in restraining an adequate insulin secretory
response by their action to suppress beta cell function.
The ability to continue to secrete increasing (although
inadequate) amounts of insulin in response to elevated serum
glucose is probably what prevents the development of ketoaci-
dosis in most patients with type 2 diabetes when acute illness
supervenes, although insufficient to prevent hyperglycemia.
The presence of even low levels of insulin may be sufficient to
inhibit lipolysis in adipose tissue and thereby suppress ketoge-
nesis in the liver. Indeed, it is unusual for patients with type 2
diabetes to develop diabetic ketoacidosis even though they
have the same pattern of glucose counter-regulatory hormone
release. If diabetic ketoacidosis occurs in type 2 diabetes, it is
due to more severe insulin deficiency than in equally ill type
2 patients without ketosis.
Clinical Benefits of Intensive Insulin Therapy
in the Critically Ill
A brief outline of the Leuven study will be provided to illustrate
the benefits of the use of insulin-mediated tight glycemic con-
trol in the ICU. Critically ill patients, almost all post–cardiac
surgery and most not previously known to have diabetes, were
studied with the intention of testing the role of maintaining
strict normoglycemia (<110 mg/dL) in the ICU. Those patients
randomized to the control group also were treated with insulin
if the blood glucose level exceeded 200 mg/dL, so average blood
glucose concentrations were 150–160 mg/dL, previously
thought to be adequate glycemic control in this setting.
Mortality was reduced dramatically in the intensive insulin ther-
apy group, especially among patients with prolonged critical ill-
ness in the ICU. In those requiring intensive care for more than
5 days, mortality was reduced from 20% to about 10%. Time in
the ICU was decreased significantly. Morbidity also was reduced
significantly, including prevention of severe complications such
as acute renal failure, nosocomial infections, liver dysfunction,
critical illness neuropathy, muscle weakness, and anemia. Other
recent reports confirm the findings in this landmark study,
including medical ICU patients, although less strikingly in this
population. Carefully monitored intravenous insulin titration
regimens are recommended to induce normoglycemia without
the risk of significant hypoglycemia.
This approach is also applied to patients with diabetes,
although in known diabetic patients hyperglycemia may be
more severe to begin with. Patients who have inadequate
insulin secretory reserve but who are not frankly diabetic are
at great risk for severe metabolic decompensation owing to
intercurrent disease. These patients are unable to respond to
increasing insulin needs, but unlike in previously diagnosed
diabetes, they may not necessarily recognize the symptom
complex associated with hyperglycemia. This can be exacer-
bated if large quantities of glucose are infused or ingested.
For example, in patients who ingest a large amount of
sucrose from sugar-containing soft drinks because of
extreme thirst induced by diuresis or diarrhea, ensuing
osmotic diuresis can make this a self-perpetuating disorder.
Similarly, peritoneal dialysis using solutions with high glu-
cose concentrations, used in an attempt to remove excess
extracellular fluid, may be associated with hyperglycemia and
even hyperosmolar diabetic coma.
An example of how control of diabetes influences the
management of another disorder is when diabetes insipidus
and diabetes mellitus coexist. In diabetes insipidus, large
volumes of free water are lost in the urine because of an
inability to concentrate urine. During treatment, equally
large quantities of electrolyte-poor solutions—usually 5%
dextrose—are infused to match urine output. If the urine
output is large, 6–10 L of 5% dextrose may be given within a
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24-hour period, representing a load of 300–500 g of glucose
into the extracellular pool (compared with about 20 g in the
extracellular pool in a patient with normal serum glucose
concentration; see Figure 26–1). Nondiabetic subjects handle
this glucose load by increasing the secretion of insulin.
However, in patients who have underlying or overt diabetes
and a poor insulin secretory response, serum glucose
increases, and glycosuria and an osmotic diuresis develop
unresponsive to the effect of vasopressin. Continuing urine
volume losses result in the administration of even larger vol-
umes of dextrose, perpetuating a vicious circle. Proper man-
agement consists of preventing glycosuria by tightly
controlling blood glucose concentration. This can be achieved
using an intravenous insulin infusion in the ICU while simul-
taneously treating the diabetes insipidus with vasopressin.
 Hypoglycemia
Some diabetic patients appear to have decreased insulin
requirements or a decreasing need for oral hypoglycemic
agents when acute illness supervenes. A decrease in insulin
requirements may result from a number of different
mechanisms.
Pathophysiology
A. Decreased Insulin Resistance—Weight loss may occur
prior to or during the acute illness. It is well known that
weight loss reduces insulin resistance in diabetes mellitus,
and small decreases in weight often are sufficient to produce
a substantially decreased requirement for insulin or other
hypoglycemic agents. Another cause of decreased insulin
resistance is a deficiency of one of the glucose counterregu-
latory hormones. Adrenal or pituitary insufficiency may
occur as part of an intercurrent disease process. Decreased
growth hormone or cortisol can diminish the need for hypo-
glycemic agents by enhancing peripheral insulin sensitivity
and decreasing gluconeogenesis.
B. Decreased Clearance of Insulin or Oral Hypoglycemic
Agents—Because the liver and the kidneys are the primary
organs involved in metabolism of insulin and the sulfony-
lurea drugs, development of renal or hepatic failure may
delay drug clearance and result in hypoglycemia. In the case
of the sulfonylureas, this may be associated with severe, pro-
longed hypoglycemia and coma. Concomitant use of other
drugs also may influence the metabolism of sulfonylurea
agents (Table 26–11). A relatively common cause of unex-
pected hypoglycemia occurs during acute episodes of con-
gestive heart failure in insulin-treated patients. As a result of
liver congestion and possibly decreased insulin clearance
with reduced hepatic blood flow, insulin requirements are
transiently diminished. If the insulin dose is not reduced,
hypoglycemia may occur.
C. Drug Interactions—Drug interactions are of particular
importance with the first generation of oral hypoglycemic
agents that are tightly protein-bound and may be displaced
by other protein-bound drugs. Table 26–11 summarizes pos-
sible interactions between drugs used in management of dia-
betes and therapeutic agents that may affect glucose control.
Because multiple drugs are used often in acutely ill patients,
particularly the elderly, the possibility of drug interactions
giving rise to hypoglycemia always needs to be considered.
Clinical Features
Hypoglycemia in hospitalized patients occurs most com-
monly in patients with diabetes, and this is usually due to a
decrease in caloric intake related to illness or hospital routine
with continued administration of hypoglycemic drugs. Some
of the causes of hypoglycemia observed in hospitalized
patients with diabetes are presented in Table 26–12.
Concomitant diseases play an important role in increasing
the risk of hypoglycemia in patients with diabetes, for exam-
ple, renal insufficiency, malnutrition, and sepsis—three dis-
orders known to be associated with hypoglycemia even in
nondiabetic hospitalized patients—as well as alcohol inges-
tion, liver disease, shock, pregnancy, and malignancy. A high
mortality rate has been reported in nondiabetic critically ill
patients who develop hypoglycemia, and in some, this may
represent a terminal phenomenon associated with malnutri-
tion or kidney and liver disease.
Pentamidine, used for treatment for Pneumocystis carinii
infection, is associated with hypoglycemia probably owing to
destruction of pancreatic beta cells with acute insulin release.
Treatment
Several factors determine appropriate management for
patients with diabetes mellitus and acute illness to avoid the
consequences of hyperglycemia and hypoglycemia.
Interaction Drug
Displacement of sulfonylureas
from plasma proteins
Clofibrate, phenylbutazone,
salicylates, sulfonamides
Reduced hepatic sulfonylurea
metabolism
Dicumarol, chloramphenicol,
monoamine oxidase inhibitors,
phenylbutazone
Decreased urinary excretion of
sulfonylureas or metabolites
Allopurinol, probenecid, phenylbu-
tazone, salicylates, sulfonamides
Intrinsic hypoglycemic activity Insulin, alcohol, beta-adrenergic
agonists, salicylates, guanethidine,
monoamine oxidase inhibitors
Table 26–11. Pharmacokinetic and pharmacodynamic
interactions that augment the hypoglycemic actions of
sulfonylurea drugs.
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A. Goal for Serum Glucose—Based on the data of the
Leuven study, target glucose concentrations in acutely ill
patients have been changed to attempt to achieve normo-
glycemia, defined as concentrations of less than 110 mg/dL.
In medical patients, a target of 130–140 mg/dL may be more
appropriate. This is best achieved using continuous intra-
venous insulin infusion with a titration algorithm. Once
patients are out of the critical care setting, other regimens
may be appropriate.
B. Fasting Patients—Patients who for any reason are not
being fed do not need bolus injections of rapid-acting insulin
to maintain glucose homeostasis postprandially; a continu-
ous intravenous insulin infusion is more appropriate.
Intravenous insulin is given routinely if a patient is receiving
total parenteral nutrition because of the large load of calories
given to patients during this therapy. However, even in the
absence of an exogenous source of glucose, such as total par-
enteral nutrition, it is important to recognize that hyper-
glycemia in patients with diabetes is the result of a
continuous delivery of large amounts of glucose from an
endogenous source, that is, the liver. It is logical, therefore,
that serum glucose concentration be controlled by continu-
ous levels of insulin, and this can be done with intravenous
insulin infusion. The response should be evaluated by moni-
toring blood glucose level at the bedside at 2–3-hour intervals.
An alternative to the use of intravenous infusion of insulin for
patients who are no longer critical is the use of long-acting sub-
cutaneous insulin (eg, glargine insulin or insulin-detemir).
These insulins analogues provide the equivalent of a basal
infusion rate, but because they do not provide the possibility
of hour-to-hour titration, they are unsuitable for anyone but
very stable patients, in whom day-to-day titration of insulin
is often sufficient.
C. Patients with Intermittent Food Intake—Patients who
are acutely ill, are vomiting, or have decreased food intake
can be managed somewhat differently. Under these circum-
stances, longer-acting insulins may be inappropriate because
it is difficult to predict insulin needs for more than a few
hours in advance. Thus, even if NPH insulin were adminis-
tered in an appropriate dose, inability to eat a meal hours
later could put the patient at risk for hypoglycemia. Rapid-
acting insulin given before each meal and at midnight is
preferable.
Rapid-acting insulin can be given to patients four times a
day using a variable insulin dosage (2–10 units) based on the
bedside blood glucose determination (sliding scale). Glucose
is measured preprandially, immediately before each insulin
dose is to be administered, and at midnight. This provides
insulin coverage for the expected glucose excursion with each
meal, and the dose can be reduced if the patient is not going
to eat the next meal. As soon as the patient begins to stabilize
and is able to eat consistently, an attempt should be made to
convert the patient to morning and evening split-dose
insulin injections using a combination of NPH and regular
insulin or multiple-dose insulin using a combination of pre-
meal rapid-acting analogues and a basal insulin (eg, glargine
or detemir).
D. Patients Eating Regularly—Patients who are eating
meals or receiving feeding in bolus fashion in reasonably
consistent manner can be treated with a split-dose regimen
of NPH and rapid-acting insulin. Alternatively, basal insulin
(eg, glargine or detimir) with premeal rapid-acting ana-
logues can be used. If necessary, a sliding scale of supplemen-
tary preprandial rapid-acting insulin doses can be added to
provide good glycemic control. There is no need for pro-
longed use of sliding scales in this situation because with the
sliding-scale approach the doses of insulin are variable from
day to day, and more stable patients will do better if managed
with a more constant regimen.
Once patients have stabilized, in addition to preprandial
glucose measurements, which are the basis for the sliding
scale, blood glucose measurements also should be performed
2 hours after meals to evaluate whether the dose of rapid-
acting insulin given prior to those meals is appropriate for
adequate glucose control. These 2-hour postprandial glucose
measurements are most useful for determining the required
dose of rapid-acting insulin. Rapid-acting insulin dosages
can be increased or decreased depending on the change in
glucose concentration from that obtained immediately prior
to the meal (keeping in mind that there is a normal rise in
blood glucose levels of about 40–50 mg/dL after a meal).
Table 26–12. Proximate causes of hypoglycemia in 42
diabetic patients receiving insulin (60 episodes) or oral
hypoglycemia drugs (four episodes).
Cause % Episodes
Decreased intake of calories
Nausea, vomiting, anorexia, lethargy
NPO because of diagnostic test or surgical
procedures
Enteral tube feedings held for measurement
of residual
Meals not delivered 
Adjustment of insulin dosage
Treatment of diabetic ketoacidosis or nonketotic
coma
Attempt at tighter metabolic control
Sliding scale insulin doses too high for patient with
renal insufficiency
Failure to reduce insulin dose after one hypoglycemia 
episode
Less insulin needed as infection resolved
Incorrect dose of insulin given 
No cause identified
45
23
14
5
3
39
17
9
6
5
2
8
8
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 Other Complications of Diabetes Mellitus
In addition to disordered glucose control, it is important to
consider the interaction between the complications of diabetes
and unrelated acute illness. Some of the complications are clin-
ically obvious, such as renal failure or nephrotic syndrome with
hypoalbuminemia. Others are less obvious, such as defects in
vision (short of total blindness), which may make it difficult for
the patient to be totally compliant with management.
Renal and retinal complications should be looked for
routinely if the patient is known to have diabetes. However,
the consequences of autonomic neuropathy often are not
addressed in clinical evaluation. In patients with long-
standing diabetes, there may be devastating effects. For
example, orthostatic hypotension is usually not symptomatic
in most patients with autonomic neuropathy yet may
become dramatically important when other causes of
hypotension are present, such as volume depletion, cardiac
disease, or drug-related causes. Another overlooked problem
that can interfere with management is gastroparesis, which
should be considered in patients who are vomiting or have
diabetes that is difficult to control. With this disorder, poor
glucose control results from a lack of coordination between
insulin injection and absorption of meals owing to delay in
food exiting the stomach. Recurrent urinary tract infections
may result from a neurogenic bladder. Lastly, patients with
symptomatic autonomic neuropathy are also at increased
risk for sudden death from cardiorespiratory arrest.
Another not uncommon phenomenon that can cause an
acute problem in patients with long-standing diabetes is the
syndrome of hyporeninemic hypoaldosteronism. This disor-
der is seen commonly in older patients with type 2 diabetes
and mild renal insufficiency. With administration of ACE
inhibitors or in the presence of other acute illness, severe
hyperkalemia may be seen. Hyperkalemia may occur in
patients whose serum potassium concentration may be only
mildly elevated or at the upper limit of normal under usual
circumstances owing to hyporeninemic hypoaldosteronism.
Hermans G et al: Impact of intensive insulin therapy on neuro-
muscular complications and ventilator dependency in the med-
ical intensive care unit. Am J Respir Crit Care Med
2007;175:480–9. [PMID: 17138955].
Van den Berghe G et al: Intensive insulin therapy in the medical
ICU. N Engl J Med 2006;354:449–61. [PMID: 16452557]
Van den Berghe G et al: Outcome benefit of intensive insulin dose
versus glycemic control. Crit Care Med 2003;31:359–66. [PMID:
12576937]
Van den Berghe G et al: Intensive insulin therapy in the critically ill
patients. N Engl J Med 2001;345:1359–67. [PMID: 11794168]
Vanhorebeek I, Langouche L, Van den Berghe G: Tight blood glu-
cose control with insulin in the ICU: Facts and controversies.
Chest 2007;132:268–78. [PMID: 17625087]
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Since acquired immunodeficiency syndrome (AIDS) was
first described in 1981, much has been learned about the
spectrum of diseases associated with the progressive
immunosuppression caused by the human immune defi-
ciency virus (HIV). Malignancies and opportunistic infec-
tions are common sequelae of advanced HIV disease, but
HIV also can directly and indirectly affect the pulmonary
circulation, kidneys, heart, brain, and adrenal glands. Sepsis,
respiratory failure, and neurologic complications are com-
mon problems that often require management in the ICU.
The advent of highly active antiretroviral therapy (HAART)
and the success of prophylaxis strategies against several
common opportunistic infections have led to prolonged
survival and improved quality of life of patients with HIV
infection. In turn, the characteristics of patients with HIV
who are admitted to the ICU are changing, with concomi-
tant reconsideration of the benefits of ICU care. However,
widespread use of HAART has led to new problems and
complications of treatment, some of which are serious
enough to warrant ICU admission. The benefits of ICU care
for HIV-infected patients were questioned early in the epi-
demic because of studies reporting poor outcomes for
patients with respiratory failure owing to Pneumocystis
pneumonia (PCP). In the early stages of the HIV epidemic,
respiratory failure owing to PCP was responsible for up to
one-half of ICU admissions for patients with HIV infection,
with a mortality approaching 80–90%. By the mid-1990s,
the incidence of PCP with respiratory failure declined sig-
nificantly, accounting for only 18% of ICU admissions, and
mortality rates were considerably lower (50–60%). A recent
study at a single institution documented improved survival
of HIV-infected patients admitted to the ICU in the current
era, with an overall survival rate to hospital discharge of
71% compared with 31% in the pre-HAART era. However,
other institutions report survival rates in the range of
44–61%. Differences in patient populations, ICU admission
standards, and clinical practices may limit our ability to
draw comparisons across institutions.
With the decline in ICU admissions owing to PCP, the
most common present-day indications for admission of
patients with HIV infection are respiratory failure (42%,
including PCP), sepsis (12%), cardiac causes (10%), and neu-
rologic disease (12%), followed by smaller percentages of
patients requiring postoperative care and those with GI bleed-
ing, metabolic derangements, trauma, and drug overdoses.
End-stage liver disease is an increasingly common cause of
death in HIV-infected patients as deaths from opportunistic
infections decline and the complications of chronic hepatitis C
and B coinfection are seen. Patients may present with compli-
cations of HAART, such as lactic acidosis, impaired glucose
tolerance, hyperlipidemia, adverse drug reactions, and non-
salutory drug interactions leading to toxicities. Thus patients
with HIV infection are admitted to the ICU for a number of
reasons. Below we review the most common conditions neces-
sitating ICU hospitalization among HIV-infected patients.
COMPLICATIONS OF HIV DISEASE: AN
OVERVIEW 
The primary cause of immunosuppression in HIV disease is
a progressive decline in the number and percentage of CD4
lymphocytes, resulting in decreased cellular immunity as
well as impairment of B-lymphocyte function. Increased
likelihood of infections caused by bacterial, protozoal,
mycobacterial, fungal, and viral pathogens can occur
throughout the entire course of HIV infection. However,
opportunistic infections and malignancies, certain neuro-
logic disorders, and severe wasting are associated with
advanced HIV infection.
The use of HAART has greatly modified the course of
HIV disease, with substantial declines in HIV-associated
morbidity and mortality. However, HAART regimens are
often complex, consisting of multiple drugs from up to four
different classes of antiretroviral agents; their success
depends on strict compliance with regimens, careful atten-
tion to the effects of food on absorption of antiretroviral
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drugs, the presence of resistant virus, drug interactions, and
patients’ ability to tolerate adverse effects of the medications.
Side effects and toxicities of HAART drugs are relatively
common, and changes in doses and/or components of regi-
mens may be necessary. As described below, a number of
antiretroviral agents preclude prescription of other com-
monly used medications, and certain drug-drug interactions
necessitate dose modifications of either or both drugs.
Although the presentation of HIV infection can be highly
variable, a number of general principles can be applied to all
patients. First, the level of immunosuppression must be consid-
ered when evaluating any disorder in an HIV-infected patient.
The likelihood of opportunistic infections and malignancies
increases as the number of CD4+ T-lymphocytes decreases.
In the presence of waning cellular and humoral immu-
nity, reactivation of latent infections may occur. For example,
in the absence of appropriate prophylaxis, one-third of HIV-
infected patients with prior exposure to Toxoplasma (ie, a
positive serum titer of IgG antibody to Toxoplasma) may
develop cerebral toxoplasmosis if they reach a sufficient level
of immunosuppression. In the absence of appropriate anti-
tuberculous prophylaxis, an HIV-infected individual with a
positive tuberculin skin test has a 7–10% chance per year of
developing active tuberculosis compared with an individual
without HIV infection with a positive skin test, who has less
than a 10% lifetime risk. Endemic fungal infections such as
histoplasmosis and coccidioidomycosis may reactivate with
declining immune status, presenting as disseminated infec-
tion. However, the most common infectious agents encoun-
tered in patients with HIV are traditional bacterial
pathogens, leading to pneumonia, bacteremia, and sepsis.
Patients with severe immunosuppression marked by
low CD4 T-lymphocyte counts benefit substantially
from prophylaxis against infections with P. jiroveci and
Mycobacterium avium complex (MAC). Appropriate prophy-
laxis should be given to selected patients, including those
with positive purified protein derivative (PPD) skin tests for
tuberculosis and those with antitoxoplasma antibodies.
Bica I et al: Increasing mortality due to end-stage liver disease in
patients with human immunodeficiency virus infection. Clin
Infect Dis 2001;32:492–7. [PMID: 11170959]
Davaro RE, Thirumalai M: Life-threatening complications of HIV
infection. J Intensive Care Med 2007;22:73–81. [PMID: 17456727]
Huang L et al: Intensive care of patients with HIV infection. N Engl
J Med 2006;355:173–81. [PMID: 16837681]
Khouli H et al: Outcome of critically ill human immunodeficiency
virus-infected patients in the era of highly active antiretroviral
therapy. J Intensive Care Med 2005;20:327–33. [PMID:
16280405]
Morris A et al: Improved survival with highly active antiretroviral
therapy in HIV-infected patients with severe Pneumocystis
carinii pneumonia. AIDS 2003;17:73–80. [PMID: 12478071]
Morris A et al: Current issues in critical care of the human immun-
odeficiency virus–infected patient. Crit Care Med 2006;34:42–9.
[PMID: 16374154]
Mrus JM et al: Impact of HIV/AIDS on care and outcomes of
severe sepsis. Crit Care 2005;9:R623–30. [PMID: 16280060]
Rosen MJ, Narashimhan M: Critical care of immunocompromised
patients: Human immunodeficiency virus. Crit Care Med 2006;34:
S245–50. [PMID: 16917430]
Tedaldi EM et al: Influence of coinfection with hepatitis C virus on
morbidity and mortality due to human immunodeficiency
virus infection in the era of highly active antiretroviral therapy.
Clin Infec Dis 2003;36:363–7. [PMID: 12539079]
Vincent B et al: Characteristics and outcomes of HIV-infected
patients in the ICU: Impact of the highly active antiretroviral
treatment era. Intensive Care Med 2004;30:859–66. [PMID:
14767592]
 Severe Complications of Antiretroviral
Therapy
Beginning with zidovudine (azidothymidine [AZT]), anti-
retroviral therapy has been used to slow the progression of
HIV infection. In the mid-1990s, protease inhibitors in com-
bination with other antiretroviral therapy demonstrated
potent effects on HIV, termed highly active antiretroviral
therapy (HAART). Increased availability of new HIV thera-
pies has led to an attendant increase in drug-drug interac-
tions as well as adverse effects of these therapies. Below we
review the serious complications of antiretroviral therapy
that, in some cases, may necessitate ICU admission.
Antiretroviral therapy can be divided into four drug classes:
nucleoside analogue reverse-transcriptase inhibitors (NRTIs),
nonnucleoside reverse-transcriptase inhibitors (NNRTIs),
protease inhibitors (PIs), and fusion inhibitors. These
drugs demonstrate both class and individual adverse drug
reactions as well as important interactions with each other
and with other drugs used to treat heart failure, anxiety,
infection, depression, and hyperlipidemia. Patients admitted
to the ICU with underlying HIV disease may be receiving
antiretroviral therapy that can complicate current manage-
ment or may present with unique adverse reactions to the
medications.
Lactic Acidosis and Hepatic Steatosis
Hyperlactatemia is an uncommon complication of NRTI use
and can be associated with fatal lactic acidosis. Its presenta-
tion may mimic septic or cardiogenic shock, hepatitis, or
drug-induced liver failure. Clinical features include
hepatomegaly, abnormal liver function tests, pancreatitis,
mild to severe lactic acidosis, and evidence of fatty liver on
ultrasound or CT scanning. Many NRTIs have been associ-
ated with this disorder, although stavudine and didanosine,
alone or in combination, are implicated most commonly.
The likely mechanism is inhibition of mitochondrial DNA
synthesis leading to impaired oxidative phosphorylation
with ensuing lactic acidosis and evidence of dysfunction in
the liver as well as other organs.
 CHAPTER 27600
Hyperglycemia and Other Metabolic
Complications
Glucose intolerance, including hyperglycemia, frank dia-
betes, and even ketoacidosis may occur in some patients,
necessitating ICU admissions. Glucose dysregulation has
been associated with PI use and resulting insulin resistance
after a median of 60 days from initiation of therapy. In some
cases, substitution of an alternative antiretroviral agent leads
to resolution of hyperglycemia.
Lipid disorders are a growing concern in the setting of
HAART, with elevations in triglycerides, low-density
lipoprotein (LDL), and total cholesterol described. While
hyperlipidemia itself rarely leads to ICU admission, the
potential for accelerated atherosclerosis and coronary artery
disease associated with these lipid disorders is of concern. The
increased risk of cardiovascular disease in HAART-associated
hyperlipidemia is small but measurable. A recent report from
the Data Collection on Adverse Events of Anti-HIV Drugs
study indicated that the incidence of myocardial infarction
increased by an average of 26% per year of exposure to
HAART. A subsequent analysis revealed that over a period of
36,145 person-years of follow-up, 207 patients experienced at
least one cardio- or cerebrovascular event (CCVE). The inci-
dence of the first CCVE was 5.7 per 1000 person-years, with a
relative risk of 1.26 per year of exposure to HAART. The
impact of HAART on atherosclerotic disease is less than that
of hypertension, smoking, and other traditional risk factors;
emphasis on modification of risk factors remains paramount
in patients with HIV disease on HAART.
Pancreatitis can occur in the setting of HIV infection as a
result of antiretroviral and other HIV-related medications and
sometimes can be severe enough to necessitate ICU admission.
Didanosine, stavudine, or a combination of didanosine, stavu-
dine, and hydroxyrea have been implicated most commonly,
but lamivudine, ritonavir, isoniazid, lopinavir/ritonavir,
trimethoprim-sulfamethoxasole, sulfonamides, corticos-
teroids, and pentamidine rarely have been associated with
pancreatitis. Alcohol use as well as gallstones must be consid-
ered in the HIV-infected person presenting with pancreatitis.
Bartlett JG, Gallant JE: 2005–2006 Medical Management of HIV
Infection. Baltimore: Johns Hopkins Medicine, Health
Publishing Business Group, 2005.
Falco V et al: Severe nucleoside-associated lactic acidosis in human
immunodeficiency virus–infected patients: A report of 12 cases
and review of the literature. Clin Infect Dis 2002;34:838–46.
[PMID: 11850865]
Monier PL, Wilcox R: Metabolic complications with the use of
highly active antiretroviral therapy in HIV-1-infected adults.
Am J Med Sci 2004;328:48–56. [PMID: 15254441]
 Pulmonary Complications of HIV Infection 
The most common cause of respiratory failure in the pres-
ence of HIV infection is P. jiroveci pneumonia, discussed
below. Other infectious etiologies that may present with
respiratory failure include bacterial pneumonia, endemic
fungal infections such as coccidioidomycosis and histoplas-
mosis, and sepsis.
The likelihood of specific pathogens being responsible for
pulmonary infection depends on several factors, including
the degree of immunosuppression, relevant exposure history,
and receipt of appropriate prophylaxis. For example, pneu-
mococcal pneumonia and tuberculosis may infect patients
irrespective of CD4 count, whereas P. jiroveci is uncommon
with a CD4 count above 200/μL. Second, prophylaxis with
trimethoprim-sulfamethoxazole significantly decreases the
likelihood of PCP as well as cerebral toxoplasmosis. Third, a
history of prior or latent infection may be important, such as
the presence of a positive tuberculin skin test, a history of
exposure to endemic fungi, or prior bacterial pneumonia.
Finally, the pattern on the chest x-ray may provide important
clues, including evidence of localized infection or findings
consistent with disseminated infection.
A. Symptoms and Signs—Important clues to the underly-
ing cause of respiratory failure include the duration of symp-
toms; the quantity and quality of sputum; the presence of
hemoptysis, dyspnea, and cyanosis; recent travel; geographic
place of residence; history of tuberculin skin testing results;
and recent adherence to prophylaxis.
B. Laboratory and Imaging Studies—Evaluation should
include chest x-ray, sputum Gram stain, sputum acid-fast
stain, complete blood count, blood cultures for bacteria,
liver function tests, serum lactate dehydrogenase (LDH),
creatinine, and arterial blood gases. In some cases, addi-
tional studies may be warranted, including serum crypto-
coccal antigen, fungal and mycobacterial blood cultures, and
CD4 count (if not known). Chest CT scan may be helpful to
identify additional foci of infection, verify the presence or
absence of hilar or mediatstinal adenopathy or parenchymal
cavitary lesions, or demonstrate a miliary pattern suggestive
of disseminated tuberculosis or coccidioidomycosis.
Urinary Histoplasma antigen should be measured in patients
from endemic areas or with known or potential exposure. In
the appropriate geographic area or with known or suspected
prior exposure, the presence of antibody to Coccidioides
immitis should be determined, but antibody is absent in up
to 25% of patients with advanced HIV infection and dis-
seminated coccidioidomycosis.
C. Fiberoptic Bronchoscopy—For patients with PCP (see
next), fiberoptic bronchoscopy with bronchoalveolar
lavage is diagnostic, and lavage may be useful for the diag-
nosis of tuberculosis and nontuberculous mycobacterial
infections.
D. Empirical Therapy—If the patient is critically ill, empiri-
cal therapy is indicated before results of laboratory studies
are available. Because bacterial pneumonia caused by
Streptococcus pneumoniae is the most common infection
leading to focal or diffuse infiltrates, antibacterial antibiotics
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should be initiated. For ICU patients, recommended treat-
ment includes a third-generation cephalosporin plus a
macrolide such as azithromycin. Antipseudomonal therapy
should be initiated in the at-risk patient.
The decision to start empirical treatment for PCP depends
on clinical suspicion. Patients likely to have PCP have more
severe hypoxemia, may have diffuse lung disease (although
x-ray abnormalities vary widely), often have elevated serum
LDH, and have a CD4 lymphocyte count under 200/μL.
Treatment should consist of trimethoprim-sulfamethoxazole
unless contraindicated; high-dose corticosteroids are indi-
cated if severe hypoxemia is present (see below).
 P. Jiroveci Pneumonia 
ESSENT IALS  OF  D IAGNOS I S
 Nonproductive cough, fever, anorexia, progressive
dyspnea.
 Hypoxemia with increased P(A–a)o2.
 Focal, diffuse, or patchy infiltrates on chest x-ray; on
occasion, the chest x-ray appears normal.
 Finding of P. jiroveci on bronchoalveolar lavage.
General Considerations
Despite the widespread use of primary and secondary pro-
phylaxis, PCP remains the most common pulmonary infec-
tion associated with respiratory failure in persons with AIDS,
usually occurring in patients with previously undiagnosed
HIV infection or in patients who are nonadherent to prophy-
laxis and HAART. Early recognition and treatment, as well as
the use of adjunctive corticosteroid therapy, have resulted in
improved survival and less morbidity for patients with mod-
erate to severe disease.
Decreased survival of patients with PCP and respiratory
failure has been associated with severity of illness at hospi-
tal admission and prior use of PCP prophylaxis. The para-
dox of decreased survival in the setting of PCP prophylaxis
has been attributed to more severe immunosuppression
leading to failure of prophylaxis or potential resistance to
antibiotics.
Clinical Features
A. Symptoms and Signs—Common symptoms include
nonproductive cough, fever, anorexia, and progressive dysp-
nea. Physical examination may reveal fever, tachypnea,
cyanosis, and oral thrush, with rales and decreased basilar
breath sounds on lung examination.
B. Laboratory Findings—The white blood cell count is typ-
ically low or normal. The CD4 lymphocyte count is typically
less than 200/μL. Patients have moderate to severe hypoxemia
with increased P(A–a)O2. Serum LDH is elevated in nearly all
patients.
C. Imaging Studies—The chest radiograph typically
demonstrates bilateral interstitial or alveolar infiltrates,
although virtually every radiographic pattern has been
described. Pleural effusions and mediastinal or hilar
adenopathy typically are absent unless a second pulmonary
process is present.
D. Fiberoptic Bronchoscopy with Bronchoalveolar
Lavage—The diagnosis is confirmed by identifying the
organism using modified Giemsa or methenamine silver
stains or immunofluorescent antibody. In most patients, the
diagnosis is made by bronchoalveolar lavage using fiberoptic
bronchoscopy, which has a sensitivity of 95–98% Some
patients may be too hypoxemic to undergo fiberoptic bron-
choscopy; in such cases, sputum obtained by suctioning from
the endotracheal tube or by expectoration may be stained
and examined for P. jiroveci, but the sensitivity is consider-
ably lower.
Differential Diagnosis
In a patient with known or suspected HIV infection and res-
piratory failure with pulmonary infiltrates consistent with
PCP, the differential diagnosis includes bacterial and viral
pneumonia, tuberculosis, other opportunistic infections
(including fungal pneumonia), congestive heart failure with
pulmonary edema, and acute respiratory distress syndrome
(ARDS).
Treatment
Patients with hypoxemic respiratory failure from PCP gener-
ally are managed in the same way as patients with ARDS.
Patients will require oxygen supplementation and may
require endotracheal intubation and mechanical ventilation.
A. Antipneumocystis Therapy—
1. Trimethoprim-sulfamethoxazole (TMP-SMX)—This
agent remains the treatment of choice for patients with PCP.
It is given as a fixed combination that delivers 15 mg/kg per
day of trimethoprim in divided doses every 8 hours intra-
venously or orally for 21 days. Side effects include fever, a
spectrum of exfoliative skin eruptions, eosinophilia,
leukopenia, thrombocytopenia, nausea, vomiting, and hepa-
titis. The dose must be decreased if the creatinine clearance is
less than 40 mL/min.
2. Pentamidine isethionate—This drug may be given to
patients with moderate to severe PCP who are unable to take
TMP-SMX because of serious allergic reactions. It is
administered a dose of 4 mg/kg per day intravenously for
21 days. However, serious side effects including renal insuf-
ficiency, pancreatitis, and orthostatic hypotension limit its
utility. Hypoglycemia may occur during or after treatment
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and is exacerbated by renal insufficiency. Serum glucose
should be monitored at least every 8 hours. In some
patients, hypoglycemia may be followed by protracted
hyperglycemia requiring insulin. If any of these side effects
occur, an alternative treatment must be chosen.
3. Clindamycin and primaquine—Clindamycin, 600 mg
intravenously or 300–450 mg orally every 6 hours, can be
given with primaquine, 30 mg base orally once daily, for 21
days. Side effects include pseudomembranous (Clostridium
difficile) colitis, rash, hemolytic anemia in persons deficient
in glucose-6-phosphate dehydrogenase, liver function test
abnormalities, and methemoglobinemia.
4. Dapsone and trimethoprim—Dapsone is given in a
dosage of 100 mg orally once daily along with trimethoprim,
15 mg/kg per day in three or four divided doses, for 21 days.
Side effects include hemolytic anemia in patients with
glucose-6-phosphate dehydrogenase deficiency, methemo-
globinemia, liver function test abnormalities, rash, fever,
leukopenia, and thrombocytopenia.
5. Atovaquone—Atovaquone may be administered in
patients allergic to or unable to tolerate the preceding regi-
mens. It is given as a suspension of 750 mg twice daily by oral
administration for 21 days.
B. Corticosteroids—In patients with PCP who present with
respiratory failure of moderate to severe degree, adjunctive
therapy with corticosteroids is indicated. Corticosteroids
reduce the incidence of severe respiratory failure and
decrease mortality in patients with severe hypoxemia.
Candidates for corticosteroids have a P(A–a)O2 greater than
35 mm Hg or a PaO2 less than 70 mm Hg. Such patients
should be given prednisone, 40 mg orally twice daily for
5 days, 40 mg orally once daily for 5 days, and then 20 mg
orally once daily for the remainder of the 21-day course of
treatment. To achieve maximum benefit, prednisone should
be started within 72 hours of beginning therapy. In patients
unable to take oral medications, intravenous methylpred-
nisolone can be substituted using the same dosage regimen.
C. Follow-up Care—Response to therapy typically occurs
within 2–7 days, marked by improvement in gas exchange
and decrease in fever. For patients who initially respond to
therapy and then develop fever, a search for another source
of infection should be undertaken. Drug fever, often
caused by TMP-SMX, should be considered when no other
pathogens are recovered and the patient is improving
clinically.
Twenty-one days of antipneumocystis therapy should be
followed by secondary prophylaxis with TMP-SMX, one
tablet (double-strength) orally three times per week. In
patients unable to tolerate TMP-SMZ, acceptable alternative
prophylactic regimens include dapsone, atovaquone, and
other agents.
 Pulmonary Infection with Mycobacterium
Tuberculosis
ESSENT IALS  OF  D IAGNOS I S
 Fever, night sweats, weight loss, cough, hemoptysis.
 Chest radiograph showing focal infiltrates with cavita-
tion (CD4 lymphocytes >500/μL); focal or generalized
infiltrates (CD4 lymphocytes <500/μL); hilar and medi-
astinal lymphadenopathy.
 Positive sputum for acid-fast bacilli or positive culture
for M. tuberculosis. Positive acid-fast stain or culture
from nonpulmonary site.
General Considerations
Tuberculosis (TB) is common in HIV-infected individuals
and in some cases may be associated with respiratory failure
or multiorgan dysfunction severe enough to warrant ICU
admission. TB occurs at all stages of HIV disease, even when
cell-mediated immunity is relatively intact, as measured by
CD4 count. Both primary infection and reactivation occur
with great frequency in this highly susceptible population.
The clinical presentation of tuberculosis in the presence of
underlying HIV infection may be atypical. Rather than the
cavitary lesions or upper lobe and apical disease usually seen
in immunocompetent, HIV-negative hosts, chest x-ray find-
ings may include infiltrates located in the middle and lower
lung zones, interstitial infiltrates, and hilar adenopathy; up to
25% of patients may have a normal chest x-ray. Disseminated
tuberculosis with lymphatic, bone marrow, and liver involve-
ment is significantly more common in persons with HIV
infection than in those with normal immune function.
Mycobacterial blood cultures are positive much more fre-
quently in HIV-infected patients. The tuberculin skin test
(PPD) is unreliable as a marker of tuberculous infection
because of its low sensitivity in HIV-infected patients.
Clinical Features
A. Symptoms and Signs—Patients with tuberculosis and
HIV infection may present with fever, productive cough,
shortness of breath, night sweats, lymphadenopathy, and
weight loss similar to that observed in non-HIV-infected
patients. Alternatively, symptoms may be minimal. Physical
examination findings include fever, loss of lean body mass,
and abnormal lung findings; some patients may have lym-
phadenopathy and/or hepatosplenomegaly.
B. Laboratory Findings—Liver function tests may be
abnormal in patients with tuberculosis, especially with dis-
seminated disease; elevated alkaline phosphatase, LDH, and
γ-glutamyl transpeptidase suggest granulomatous hepatitis.
Anemia is frequently present, and pancytopenia may be
present if there is bone marrow involvement.
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Smears for acid-fast bacilli from sputum and culture of
sputum for mycobacteria are the key to diagnosis. Three or
more sputum samples should be submitted for stain and cul-
ture. If the patient is unable to produce adequate sputum for
sampling, sputum can be induced by administering
aerosolized hypertonic saline. Negative acid-fast smears do
not exclude tuberculosis; in select patients, empirical treat-
ment should be continued until cultures are negative. In
patients undergoing fiberoptic bronchoscopy with bron-
choalveolar lavage for diagnosis of PCP, fluid also should be
sent for acid-fast staining and mycobacterial culture, even if
prior sputum specimens have been negative. Urine cultures
and blood isolators for mycobacteria may be positive. Drug
susceptibility studies should be done on all M. tuberculosis
isolates because drug-resistant strains are not uncommon in
many areas.
In patients suspected of having disseminated tuberculo-
sis, bone marrow or liver biopsy, punch biopsy of suspicious
skin lesions, and in some cases lumbar puncture may assist in
making the diagnosis.
C. Imaging Studies—Virtually any chest x-ray pattern can
be seen in tuberculosis with HIV infection, from classic api-
cal fibronodular infiltrates with cavitation to normal lung
parenchyma. A radiographic pattern consistent with primary
tuberculous infection is seen more often with HIV infection,
consisting of middle to lower lung field infiltrates, sometimes
with hilar adenopathy. Disseminated tuberculous infection
may be accompanied by a miliary pattern on chest x-ray.
Treatment
Patients with HIV infection and tuberculosis with suscepti-
ble strains of M. tuberculosis usually are treated successfully
with conventional antituberculous drug regimens. The ideal
duration of therapy is not known. The initial use of rifampin,
isoniazid, ethambutol, and pyrazinamide is recommended if
organisms are likely to be sensitive. If multidrug-resistant
tuberculosis is suspected, five- and six-drug regimens should
be considered. Absorption of antituberculous drugs may be
impaired in critically ill patients, and administration of par-
enteral agents may be necessary. Liver aminotransferase lev-
els should be monitored because isoniazid, rifampin, and
pyrazinamide are hepatotoxic. Tuberculosis and HIV coin-
fection is an indication for instituting directly observed ther-
apy (DOT) of tuberculosis.
A. Isoniazid, Rifampin, Pyrazinamide, and Ethambutol—
This combination of drugs is highly effective against suscep-
tible tuberculous organisms. The duration of treatment in
the HIV patient consists of 2 months of all four drugs fol-
lowed by 18 weeks of isoniazid and rifampin. Isoniazid is
given in a dosage of 300 mg orally or intramuscularly daily.
Common side effects include hepatitis, peripheral neuropa-
thy from pyridoxine deficiency, alteration in sensorium,
fever, and rash. Patients receiving isoniazid should be given
pyridoxine, 50 mg daily.
The usual dose of rifampin is 600 mg/day orally or intra-
venously. Side effects include hepatitis, discoloration of
urine, rash, fever, and alteration in other drug levels (eg, oral
contraceptives, warfarin, corticosteroids, digoxin, and
methadone). Pyrazinamide is given as 15 mg/kg orally daily.
Elevation of aminotransferases, hepatitis, hyperuricemia,
and arthralgias may be seen as side effects of this drug.
Ethambutol is given orally at a dosage of 15 mg/kg per day.
Ethambutol is generally well tolerated, but loss of color
vision or visual acuity may occur.
Rifampin is contraindicated in patients receiving PIs, such
as indinavir and ritonavir, and some NNRTIs, such as nevi-
rapine and delavirdine, because of significant drug interac-
tions. Rifabutin may be substituted for rifampin to minimize
drug interactions with PIs and NNRTIs. Dose modifications
of antiretrovirals and rifabutin may be needed.
B. Other Antituberculous Drugs—Patients in the ICU who
cannot tolerate or absorb oral medications may be given
intravenous isoniazid and rifampin; intravenous amikacin
and a fluoroquinolone should be added to optimize antimy-
cobacterial therapy. The usual dose for amikacin is 7.5 mg/kg
every 12 hours intravenously or intramuscularly. Serum lev-
els should be monitored to avoid nephrotoxicity. Side effects
may include renal failure, ototoxicity, and rarely, neuromus-
cular blockade. Dose adjustment for impaired renal function
is necessary. Fluoroquinolone dosing varies depending on
which agent is selected. Common side effects include GI
intolerance, rash, and altered sensorium. The dose is
decreased in patients with renal function abnormalities.
 Bacterial Pneumonia
At all stages of HIV disease, bacterial pathogens are the most
common cause of community-acquired pneumonia. In fact,
bacterial pneumonia occurs approximately 25-fold more fre-
quently among HIV-infected adults than in the general com-
munity, with an inverse relationship between CD4 counts
and incidence. Among the bacterial pathogens, the pneumo-
coccus is particularly important: Infection with S. pneumo-
niae occurs approximately 100 times more frequently than in
the HIV-uninfected host, with increased incidence in the set-
ting of smoking and low CD4 counts. Recurrence rates for
pneumococcal pneumonia are high, ranging from 6–24%.
The presentation of pneumococcal pneumonia in the HIV-
infected patient is similar to that in the immunocompetent
host, with abrupt onset fever, chills, cough and pleuritic
chest pain. S. pneumoniae bacteremia in the setting of HIV
infection occurs in up to 90% of patients and may be the key
to diagnosing a community-acquired pneumonia because
the sensitivity of sputum Gram stain and culture is 50% or
less. Radiographic findings of pneumococcal pneumonia
consist of the characteristic lobar or bronchopneumonia.
Haemophilus influenzae, Legionella pneumophila, and
Mycoplasma pneumoniae are also seen in the setting of HIV
infection. Hospitalized or neutropenic patients are at
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increased risk for infection with Staphylococcus aureus,
including methicillin-resistant S. aureus (MRSA), and gram-
negative aerobic bacilli, including Pseudomonas aeruginosa,
especially in the ICU setting. Bacterial infections may occur
alone or, less commonly, may complicate an opportunistic
infectious process such as PCP. Unusual bacteria may be
responsible for pneumonia, including Rhodococcus equi, an
aerobic intracellular gram-positive coccobacillus causing
cavitary lung disease.
For patients admitted to the ICU with community-
acquired pneumonia, recommended initial therapy includes
a third-generation cephalosporin (eg, ceftriaxone, 2 g intra-
venously once daily) plus azithromycin, 500 mg intra-
venously once daily, unless there is suspicion of Pseudomonas
infection (substitute a β-lactam with antipseudomonal effi-
cacy such as ceftazidime or piperacillin-tazobactam).
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immunodeficiency virus/acquired immune deficiency syn-
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America: Treatment of tuberculosis. Am J Respir Crit Care Med
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OTHER INFECTIOUS CAUSES OF PNEUMONIA
AND RESPIRATORY FAILURE
 Fungal Pneumonia
Fungal pneumonias should be considered in patients with
pulmonary infiltrates, negative cultures and smears for
mycobacteria, negative stains and cultures for bacteria, and
clinical progression with antibacterial treatment. Fungal
infection also may present as a disseminated process with
multiorgan involvement. Tissue biopsies and serologic tests
are most helpful because growth of fungal pathogens in cul-
ture is slow, sometimes on the order of weeks.
A. Cryptococcal Pneumonia—Since advanced HIV disease
is the primary risk factor for cryptococcal infections in most
of the world, the incidence of cryptococcal infections has
declined significantly in countries with access to HAART. The
lung is the most common portal of entry for the organism,
after which asymptomatic colonization or life-threatening
pneumonia can occur. In the presence of an advanced
immunocompromised state, cryptococcal pneumonia may
progress rapidly, with dissemination from the lung to blood-
stream, skin, and/or meninges. Most patients with AIDS and
cryptococcal pneumonia are symptomatic, with fever,
malaise, cough, dyspnea, and weight loss. Radiographic find-
ings include diffuse interstitial opacities, focal infiltrates, alve-
olar infiltrates, pleural effusions, and cavitary lesions.
Diagnosis is made by isolation of Cryptococcus neoformans
from sputum, bronchoalveolar lavage fluid, or pleural fluid or
by the presence of a positive cryptococcal antigen in bron-
choalveolar lavage fluid. Lumbar puncture must be per-
formed to rule out CNS cryptococcal infection even if
patients are asymptomatic because concomitant CNS
involvement is present in approximately 90% of patients with
AIDS and cryptococcal pneumonia. The serum cryptococcal
antigen is an insensitive test in the absence of disseminated
disease and may be negative in the patient with isolated cryp-
tococcal pneumonia. Patients with respiratory failure attrib-
uted to cryptococcal pneumonia should undergo evaluation
for PCP as well; in some cases, both pathogens may be pres-
ent. Mortality for those with respiratory failure from crypto-
coccal pneumonia is very high despite aggressive treatment.
Although mild to moderate cryptococcal pneumonia
alone can be treated with fluconazole, HIV-infected patients
with severe cryptococcal pneumonia admitted to the ICU
should receive amphotericin B, 0.7–1 mg/kg per day intra-
venously, with or without flucytosine, 100 mg/kg daily, until
symptoms are controlled, followed by fluconazole, 200–400
mg/day indefinitely or until immune restoration with
HAART has been well established. This regimen is optimal
for CNS disease as well, except that amphotericin B and
flucytosine are given for at least 2 weeks.
B. Other Fungal Pneumonias—Endemic mycoses caused
by such fungi as Histoplasma capsulatum and Coccidioides
immitis usually present in patients with advanced immunod-
eficiency as a disseminated process of which pulmonary dis-
ease is one component. Fever, cough, and progressive
dyspnea are common and may be accompanied by signs and
symptoms of sepsis or other organ system involvement.
Chronic or subacute pneumonia caused by C. immitis can
occur in up to 10% of AIDS patients living in endemic areas
such as Arizona and the San Joaquin Valley of California.
However, use of HAART has been associated with a decline in
the incidence of HIV-associated coccidioidomycosis. Any radi-
ographic findings may be present on chest x-ray, including
cavities, interstitial or lobar infiltrates, nodules, and pleural
effusions. Disseminated coccidioidomycosis is associated with
advanced immunosuppression. Sputum, bronchoalveolar
lavage fluid, and/or bronchial washings should be sent for fun-
gal stains and culture. Complement fixation titers greater than
1:16 are diagnostic of disseminated coccidioidomycosis but
may be insensitive in HIV-infected patients; up to 25% of
patients will have no detectable anticoccidioidal antibodies.
Intravenous amphotericin B, 0.5–1 mg/kg per day, should be
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used for initial treatment of pulmonary disease to a total
dose of 30–40 mg/kg, followed by fluconazole at 200
mg/day orally. Patients with suspected dissemination
should undergo lumbar puncture to look for meningitis
because high-dose fluconazole is the preferred treatment
for meningitis caused by C. immitis.
Pneumonia owing to Histoplasma was seen in up to 15%
of AIDS patients living in endemic areas in the pre-HAART
era, although it is significantly less common today.
Dissemination occurs in patients with advanced disease and
low CD4 lymphocyte counts. Chest x-ray findings are non-
specific, with diffuse infiltrates, nodules, focal infiltrates, cav-
ities, and hilar adenopathy noted. Urine Histoplasma
polysaccharide antigen assay is moderately sensitive
(50–70%) in cases of pneumonia, with a sensitivity of 90% in
the setting of disseminated disease. Histoplasma serum and
bronchoalveolar lavage antigen, serologic studies, the pres-
ence of intracellular organisms on peripheral blood smear
(30% sensitivity for disseminated Histoplasma infection),
and tissue biopsy may be helpful in diagnosis. Cultures of
blood, respiratory tract secretions, bone marrow, or
biopsy specimens are positive in 85% of patients but require
2–4 weeks to grow. In severe or disseminated disease for
patients in the ICU, intravenous amphotericin B should be
given initially (for 3–14 days depending on response), fol-
lowed by itraconazole, 200 mg orally twice daily indefinitely.
Invasive and obstructing aspergillosis has been described
rarely in patients with HIV infection and advanced immun-
odeficiency. Factors predisposing to Aspergillus infection
include corticosteroid use, neutropenia, pneumonia caused
by other pathogens, marijuana smoking, and use of broad-
spectrum antibiotics. Chest x-ray abnormalities may include
focal infiltrates, cavities, pleural-based densities, or diffuse
infiltrates. Because Aspergillus organisms may colonize
patients without causing infection, sputum culture and
staining may be unreliable. A tissue biopsy showing
Aspergillus in tissue or invading blood vessels is the most reli-
able diagnostic test. Voriconazole is the treatment of choice
for invasive aspergillosis, at a dose of 6 mg/kg intravenous
every 12 hours × 2 doses, followed by 4 mg/kg intravenous
every 12 hours for at least 1 week, then 200 mg bid.
Alternative agents include intravenous amphotericin B, as
well as itraconazole for prolonged treatment in milder cases if
there has been a good clinical response to initial treatment.
 Kaposi Sarcoma 
The incidence of Kaposi sarcoma (KS) has declined dramat-
ically in the HAART era, with a concomitant decline in the
incidence of pulmonary KS. Studies from the pre- and early
HAART era described an incidence of pulmonary involve-
ment in approximately 35% of patients with HIV-associated
KS, with a higher proportion found at autopsy. Clinically
symptomatic pulmonary KS is seen most often with
advanced HIV disease and can progress to respiratory failure.
Most but not all pulmonary KS occurs in the presence of
concomitant mucocutaneous lesions. Patients typically pres-
ent with nonproductive cough, dyspnea, and sometimes
fever, with chest pain and hemoptysis less commonly
reported. Chest x-ray abnormalities typically include bilat-
eral middle-lower lung opacities with a central or perihilar
distribution; infiltrates may be interstitial or nodular or may
appear as linear perihilar densities. Kerley B lines, intratho-
racic adenopathy, and pleural effusions are seen less com-
monly. Abnormal gas exchange, hemoptysis, and
superinfection with bacteria may occur. The diagnosis of
pulmonary KS is usually established by fiberoptic bron-
choscopy. Bronchoalveolar lavage should be performed to
rule out other opportunistic pathogens because pulmonary
KS is often seen in conjunction with PCP or other oppor-
tunistic infections. Response of KS to chemotherapy or radi-
ation therapy generally was poor in the pre-HAART era;
however, potent antiretroviral therapy in conjunction with
daunorubicin, liposomal doxorubicin, or paclitaxel may
arrest or even reverse the course of pulmonary KS.
Chiller TM, Galgiani JN, Stevens DA: Coccidioidomycosis. Infect
Dis Clin North Am 2003;17:41–57. [PMID: 12751260]
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patients with HIV, 1994–2003. Cancer 2004;100:2644–54.
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 Sepsis In HIV-Infected Patients
ESSENT IALS  OF  D IAGNOS I S
 Fever or hypothermia, hypotension, hyperventilation,
change in mental status.
 Complications of organ failure, such as alteration in gas
exchange, renal insufficiency or failure, lactic acidosis,
disseminated intravascular coagulation, or liver failure.
 Bacteremia, fungemia, or features arousing a high clin-
ical suspicion of infection.
 Previous evidence or suspicion of bacterial, fungal, or
mycobacterial infection may be helpful in differential
diagnosis.
General Considerations
Sepsis was discussed in Chapter 15. Important considerations
in patients with HIV infection include the potential for oppor-
tunistic and/or unusual microbial organisms to be involved
and differences in diagnostic strategy and empirical therapy.
Because HIV infection is associated with disruption of
both cellular and humoral immunity, disseminated infection
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occurs in a substantial proportion of patients, with the rate
of dissemination proportionate to the degree of immuno-
suppression. Furthermore, phagocytic cell dysfunction and
skin and mucosal membrane disruption increase the likeli-
hood of organism translocation. Compared with age-
matched cohorts, bacteremia is more commonly seen in
HIV-infected patients with an identified focal bacterial infec-
tion. In addition, M. tuberculosis is more likely to disseminate
to multiple organs and causes active disease more often in
patients with HIV infection and immunosuppression.
Treatment with various medications used to treat HIV and
its complications, including zidovudine, trimethoprim-
sulfamethoxazole, pyrimethamine, and valganciclovir—and
even HIV itself—may cause neutropenia.
A. Bacterial Sepsis—Most of these infections are associated
with an identifiable source, such as the lungs, GI tract, uri-
nary tract, CNS, or an intravascular catheter. Clinically silent
sites of bacterial infection include the sinuses, prostate, bil-
iary tract, skin and soft tissues, endocardium, and GI tract.
The most common gram-positive organism responsible for
bacteremia is S. pneumoniae, whereas Escherichia coli is the
most common gram-negative organism found in blood, sug-
gesting that common infections such as pneumonia and uri-
nary tract infection are still the most likely sources of
bacterial infection. Neutropenia should alert one to the pos-
sible presence of P. aeruginosa and staphylococci, both com-
munity- and hospital-acquired. In particular, P. aeruginosa
infection is reported to be increasing in incidence, with risk
factors including neutropenia, antibiotic use, corticosteroid
use, and low CD4 lymphocyte count.
Infection with MRSA is increasingly common among
patients with HIV infection, typically causing multiple skin
and soft tissue abscesses but sometimes with accompanying
bacteremia and/or sepsis. Community-acquired strains of
MRSA are more susceptible to antibiotics than their nosoco-
mial counterparts, with sensitivity to vancomycin, TMP-
SMX, and in some cases clindamycin. Sepsis may be caused
by enteric diarrhea-associated pathogens and Listeria.
B. Disseminated Mycobacterial Infections—A subacute
course of fever, weight loss, night sweats, cough, headache, or
lymphadenopathy suggests a fungal or mycobacterial
pathogen. The initial symptoms are often nonspecific and
the clinical picture benign, but patients may present late,
with a clinical picture consistent with sepsis. Findings sug-
gestive of disseminated fungal or mycobacterial infections
include hepatosplenomegaly, lymphadenopathy, and the
presence of skin or oral lesions. There may be laboratory
findings of pancytopenia (bone marrow infiltration) and ele-
vated LDH and alkaline phosphatase levels.
Tuberculosis can present as a widely disseminated
process. The clinical picture is characterized by weight loss,
anorexia, and fever and sometimes by cough, dyspnea, and
night sweats. Disseminated tuberculosis may be associated
with tuberculous meningitis, necessitating a lumbar puncture
if clinical suspicion of meningeal involvement exists.
Disseminated MAC infection is a late sequela of HIV infec-
tion and is seen in patients with CD4 lymphocyte counts of
less than 50/μL. The clinical picture is similar to that of late-
stage tuberculosis and is also associated with severe diarrhea.
The course is protracted, and the diagnosis is often made by
demonstration of the organisms in the blood using the lysis-
centrifugation method or on tissue biopsy. MAC grows in
approximately 3–6 weeks and can be identified using a DNA-
specific probe.
C. Disseminated Fungal Infections—C. neoformans, C.
immitis, and H. capsulatum are primarily acquired through
the respiratory tract and are hematogenously disseminated
to multiple organs. Because of impaired cellular immunity,
infections with these organisms may progress rapidly in
HIV-infected persons. Progressive disseminated histoplas-
mosis is characterized by an initial mild course with minimal
symptoms of 4–5 weeks’ duration, followed by a syndrome of
hypotension, disseminated intravascular coagulation, renal
insufficiency, severe pancytopenia, abnormal liver function
tests (especially LDH), and respiratory failure. CNS involve-
ment is common. Intracellular organisms may be seen on the
peripheral blood smear. Early initiation of amphotericin B
therapy is critical while awaiting diagnostic studies.
Disseminated coccidioides infection presents in a similar
manner. Diagnosis and treatment of coccidioidomycosis are
discussed in the section on pulmonary infection in HIV-
infected patients.
Although oral and esophageal candidiasis occurs with
great frequency in patients with symptomatic HIV infection,
disseminated candidiasis is rare except in the usual settings of
intravascular catheters, broad-spectrum antibiotics, or intra-
venous hyperalimentation.
Clinical Features
A. Symptoms and Signs—In addition to features that may
localize the primary site of infection, additional information
useful for planning empirical therapy include the travel his-
tory, tuberculin skin test status, history of exposure to or pre-
vious infection with mycobacteria or endemic fungi, and
recent use of antibiotics. Besides the primary infection site,
examination should focus on potential sites of dissemina-
tion, including a careful funduscopic examination, inspec-
tion of skin and mucous membranes, and a search for
lymphadenopathy and hepatosplenomegaly.
B. Laboratory and Imaging Studies—This should include
initially a complete blood count, peripheral blood smear
(intracellular Histoplasma organisms may be seen occasion-
ally), blood cultures (two sets each for aerobic and anaerobic
bacteria); liver function tests: LDH; urinalysis; chest x-ray;
and creatine kinase.
Any potential site of infection should be cultured for
suspected pathogens. Special culture techniques, such as
urine culture after prostatic massage or aspiration of skin
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or soft tissue fluid collections, may be indicated. Imaging of
specific sites may include CT scan, ultrasonography, MRI,
or x-rays.
Septic patients with HIV infection and no obvious site of
infection require more generalized investigation. Urine cul-
ture for fungi and mycobacteria, blood cultures using the
lysis-centrifugation method for mycobacteria and fungi,
serum antigen for C. neoformans, sputum for acid-fast smear
and mycobacterial culture, and urine Histoplasma antigen
tests should be considered in patients with relevant exposure
histories. Patients with sepsis may have subtle CNS, pul-
monary, abdominal, soft tissue, or mucosal sources of infec-
tion. In these patients, CT scan of the head, abdomen, and
pelvis may be indicated. Lumbar puncture should be per-
formed in any HIV patient with unexplained sepsis or fever
with or without alteration in mental status or abnormal neu-
rologic findings. Cryptococcal meningitis and fungal and
mycobacterial infections of the CNS may be associated with
minimal symptoms and physical findings.
Biopsy of suspicious skin or mucosal lesions, lymph
nodes, spleen, liver, or bone marrow should be performed
expeditiously if results of other studies are unrevealing.
Special stains for microorganisms are necessary along with
traditional histologic examinations. Cultures from biopsy
specimens for many potential organisms may take 4–6 weeks
to yield results.
Treatment
Patients with sepsis accompanied by hypotension, altered
mental status, severe localized infection, or any organ system
dysfunction should receive immediate antimicrobial therapy
after appropriate cultures have been obtained. Empirical
antibiotic treatment should be directed at possible bacterial
pathogens; suspicion of fungal or mycobacterial dissemina-
tion should prompt initiation of appropriate targeted ther-
apy. The likelihood of bacterial infection is increased in
patients with either leukocytosis or neutropenia, those with
acute onset of chills and fever, those who have an identifiable
site of infection, and those who have higher CD4 lymphocyte
counts. Patients with very low CD4 lymphocyte counts are
susceptible to a wide variety of infections, including bacteria,
fungi, and mycobacteria. In such patients, antifungal and
antimycobacterial agents should be considered early; in addi-
tion, these antimicrobial regimens also should be considered
in any patient who is deteriorating clinically on antibacterial
therapy alone. Filgrastim (G-CSF) is indicated in patients
with significant neutropenia (<500–750 cells/μL).
Patients with disseminated tuberculosis can be treated
initially with regimens used for pulmonary tuberculosis (see
above). Treatment of MAC requires administration of a
macrolide such as clarithromycin (500 mg orally twice daily)
in conjunction with ethambutol (15 mg/kg per day orally)
with or without rifampin or rifabutin (600 or 300 mg/day,
respectively). If intravenous therapy is necessary, azithromycin
plus amikacin or ciprofloxacin should be considered.
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 CNS Disorders In HIV-Infected Patients
HIV is a neurotropic virus; as a result, infection of the cen-
tral and peripheral nervous systems is likely to occur very
early in the disease course. However, severe CNS manifesta-
tions occur late in the course of HIV disease, when CD4
counts are very low. Neurologic disorders may result from
autoimmune phenomena (eg, vasculitis and demyelinating
inflammatory polyneuropathy), immunosuppression (eg,
opportunistic infections and CNS lymphoma), and direct
effects of HIV (eg, meningitis and dementia). In the ICU
patient with HIV disease, neurologic problems are the third
most common reason for admission. Severe CNS problems
leading to ICU admission include delirium and coma,
intracranial mass lesions from primary CNS lymphoma or
toxoplasmosis, meningitis (eg, bacterial, cryptococcal, tuber-
culous, aseptic, or viral), status epilepticus, and respiratory
failure owing to severe neuropathy or myopathy.
Focal CNS disorders include cerebral toxoplasmosis, pri-
mary CNS lymphoma (PCNS-L), and progressive multifo-
cal leukoencephalopathy (PML). Mass lesions can present
in a variety of ways, including symptomatic neurologic
deficits, altered mental status, or change in personality. In
conjunction with the clinical presentation, imaging studies
sometimes may be able to distinguish infection, malig-
nancy, or an inflammatory process. If a lumbar puncture
can be performed safely, CSF should be submitted for
cytology, Epstein-Barr virus (EBV) polymerase chain reac-
tion (PCR), and JC virus PCR, which may assist in the
diagnosis of PCNS-L and PML. Empirical therapy for tox-
oplasmosis should be initiated in critically ill patients with
focal ring-enhancing brain lesions pending results of serum
Toxoplasma titers. Patients with mass lesions and increased
intracranial pressure may require endotracheal intubation,
ventilatory support, corticosteroids to decrease cerebral
edema, antiseizure prophylaxis, and frequent neurologic
evaluation.
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 Cryptococcal Meningitis in HIV-Infected
Patients
Meningitis caused by C. neoformans is unusual in immuno-
competent patients but may occur in the presence of
advanced immunosuppression caused by HIV. Patients often
present with fever and headache, sometimes in conjunction
with nonspecific neurologic findings, including weakness,
fatigue, dizziness, lack of alertness, visual changes, and
seizures. Importantly, HIV patients with cryptococcal
meningitis have little or no meningeal irritation, and
meningismus is rare. Thus a lumbar puncture is warranted in
the patient with advanced HIV disease and any clinical suspi-
cion of a CNS process. CSF may be completely normal or may
reveal slightly elevated protein, decreased glucose, and/or a
mild lymphocytic response (up to 100/μL). In contrast to
these mild abnormalities, India ink preparations are positive
in 40–70%; positive cultures are the “gold standard” of diag-
nosis. CSF cryptococcal antigen is 95–98% sensitive and spe-
cific. Opening pressure always should be measured because it
has important prognostic significance. For example, elevated
opening pressure of the cerebrospinal fluid (>250 mm H2O)
correlates with high cryptococcal polysaccharide antigen,
poor clinical response, and decreased short-term survival.
With treatment, failure of CSF opening pressure to fall has
been associated with poor outcome. Patients with cryptococ-
cal meningitis should be treated with amphotericin B,
0.7–1 mg/kg per day intravenously, with flucytosine, 100 mg/kg
daily orally for 2 weeks, followed by fluconazole 400 mg/day
orally for 8–10 weeks, and then 200 mg/day as suppressive
therapy. Elevated opening pressure should be managed with
serial (daily) lumbar punctures to reduce pressure to less
than 200 mm H2O, or 50% of opening pressure.
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Dermatologic Problems
in the Intensive Care Unit
Kory J. Zipperstein, MD
The skin plays an important role in maintaining homeosta-
sis. Thermoregulation, containment of body fluids, and pro-
tection of internal organs and structures from environmental
insults are some of the vital functions performed by the skin.
The skin is readily available for examination, so inspection
often provides important clues to underlying diseases. This
chapter focuses on the following categories of cutaneous dis-
orders in the critically ill patient: common skin disorders,
drug eruptions, purpura, life-threatening dermatoses, and
cutaneous manifestations of infections.
COMMON SKIN DISORDERS
Contact dermatitis, miliaria (heat rash), and candidiasis are
common in the critically ill patient as well as in the general
population. These conditions, as well as graft-versus-host
disease, are discussed in this section.
 Contact Dermatitis
ESSENT IALS  OF  D IAGNOS I S
 Circumscribed vesiculobullous eruptions on a base of
erythema, confined to the area of the contact. 
 Linear or sharply angulated pattern suggesting external
contact.
 Pruritus may be a prominent symptom.
 History of exposure or contact in involved areas.
General Considerations
Contact dermatitis is an eczematous eruption caused by
allergens or irritants coming in contact with the skin. The
latter type is more common and results from exposure to
irritating substances. Allergic contact dermatitis is a delayed
hypersensitivity reaction that affects individuals previously
exposed to the antigen. Any substance applied to the skin,
including tape, cleansing agents, and topical medications,
may be the offender. Even some topical steroids contain sen-
sitizing chemicals. An eruption that appears to improve but
subsequently becomes worse may be due to a contact der-
matitis from an applied medication. Occasionally, Candida
or bacteria are a secondary invader.
Clinical Features
The morphology and distribution of the lesions, as well as
the history of exposure, are diagnostic. Clinically, a circum-
scribed vesiculobullous eruption on a base of erythema, con-
fined to the area of the contact, is the hallmark of contact
dermatitis. Pruritus may be prominent. Contact dermatitis
often has a characteristic configuration—for example, linear
or sharply angulated patterns—that suggests that the erup-
tion is caused by external rather than internal stimuli.
Marked erythema, often with an eroded surface, suggests an
irritant contact dermatitis. Constant exposure to moisture,
urine, or fecal matter in areas such as the groin, perineum,
the backs of bedridden patients, and around a colostomy site
may produce such an eruption. The differential diagnosis of
contact dermatitis includes other eczematous eruptions,
impetigo, and candidiasis.
Treatment
The suspected irritant or allergen should be removed, and
cool tap water compresses can be applied to alleviate discom-
fort and remove crusts. Apply a high-potency topical steroid
such as fluocinonide cream twice daily to the affected area.
Eruptions on the face or intertriginous areas should be
treated with low- to medium-potency topical steroids.
Antihistamines may be administered to control itching. The
involved area should be observed for the development of sec-
ondary infection.
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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 Miliaria (Heat Rash)
ESSENT IALS  OF  D IAGNOS I S
 Seen in bedridden patients with fever.
 Miliaria crystallina: small, superficial, sweat-filled vesi-
cles without surrounding inflammation, giving the
appearance of clear dewdrops. The vesicles rupture
with the slightest frictional trauma.
 Miliaria rubra (prickly heat): discrete, pruritic, erythe-
matous papules and vesiculopustules, especially on the
back, the antecubital and popliteal fossae, the chest,
and other regions prone to sweating and occlusion.
General Considerations
Miliaria is a common disorder characterized by retention of
sweat. It is seen in individuals exposed to warm or humid cli-
mates and in bedridden patients with fever and increased sweat-
ing. Increased moisture causes swelling of the stratum corneum,
with resulting occlusion of eccrine sweat ducts and pores and
eventual disruption of the sweat gland or duct. Leakage of sweat
into the surrounding tissue produces the lesions of miliaria.
Clinical Features
Two forms of miliaria may be seen in the febrile patient. In
miliaria crystallina, the sweat duct is occluded at the skin sur-
face, producing small and very superficial sweat-filled vesi-
cles without surrounding inflammation, giving the
appearance of clear dewdrops. The vesicles rupture with the
slightest frictional trauma. The eruption is asymptomatic
and self-limited.
A second form, miliaria rubra (prickly heat), is due to occlu-
sion of the intraepidermal portion of the sweat duct. The erup-
tion consists of discrete, pruritic, erythematous papules and
vesiculopustules. The erythema may be broad and diffuse
depending on the degree of inflammation. Areas such as the
backs of patients lying in bed, the antecubital and popliteal fos-
sae, the chest, and other regions prone to sweating and occlu-
sions are the sites of predilection; the palms and soles are spared.
Miliaria crystallina is clinically distinct. However, miliaria
rubra may resemble folliculitis, which usually can be
distinguished by its follicular papulopustules with penetrat-
ing hair shafts. A Gram stain or culture of the pustular con-
tents may help in distinguishing the two conditions.
Treatment
The patient should be kept cool and dry. The pruritus asso-
ciated with miliaria rubra may respond to oral antihista-
mines, such as hydroxyzine; medium-potency topical
steroids, such as triamcinolone acetonide 0.1%; or a topical
antipruritic lotion containing phenol and menthol (eg,
Sarna) or pramoxine hydrochloride.
Haas N, Martens F, Henz BM: Miliaria crystallina in an intensive
care setting. Clin Exp Dermatol 2004;29:32–4. [PMID:
14723716]
 Candidiasis (Moniliasis)
ESSENT IALS  OF  D IAGNOS I S
 Oral candidiasis: white curdlike plaques on the oral
mucosa, including the tongue, with a red, macerated
base and painful erosions.
 Easily ruptured pustules commonly found in the groin,
between the buttocks, under overhanging abdominal
folds or pendulous breasts, and in the umbilicus. If rup-
tured, a bright red base with a fringe of moist scale at
the border and satellite pustules. Intense pruritus, irri-
tation, and burning are common.
 In systemic candidiasis, may have acneiform pustules or
petechiae that may progress to necrotic ulcerative
lesions on the trunk and extremities.
General Considerations
The yeastlike fungus Candida albicans may cause infections
limited to the skin and mucous membranes in addition to
severe disseminated disease. Superficial candidiasis affects
warm, moist areas such as the vagina (vulvovaginitis), the
mouth (thrush), the uncircumcised penis (balanitis), the
intertriginous areas, and sites around fistulas and artificial
openings. Other predisposing factors include endocrine
abnormalities (especially diabetes), malignancies, and
immune-impaired states. Broad-spectrum antibiotics, preg-
nancy, incontinence, and skin maceration also may allow the
yeast to become pathogenic.
Clinical Features
A. Symptoms and Signs—Oral candidiasis, or thrush, com-
monly consists of white curdlike plaques on the oral mucosa,
including the tongue. The base of these plaques is red and
macerated, and painful erosions also may be seen.
Frequently, the infection will spread to the angles of the
mouth (ie, angular cheilitis or perlèche), resulting in macer-
ation and fissuring of the oral commissures.
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Candidiasis also tends to develop in intertriginous
regions, including the groin, between the buttocks, under
overhanging abdominal folds or pendulous breasts, and in
the umbilicus. In these areas, pustules form but are easily
ruptured by the friction of opposing surfaces, leaving a
bright red base with a fringe of moist scale at the border.
Coalescence of individual lesions results in spreading of the
erythema with satellite pustules at the edges. Intense pruri-
tus, irritation, and burning are common.
Oral candidiasis may spread to the esophagus or lungs.
Candidal proctitis may develop with or without concurrent
perianal infection. Systemic candidiasis is an opportunistic
infection that tends to occur in patients with AIDS (rarely),
hematologic malignancies, indwelling intravenous catheters,
or malnutrition. Widespread dissemination may produce
fever and proximal muscle tenderness, but any organ may be
affected. Skin findings occur in about 10% of patients with
candidal sepsis and consist of acneiform pustules or
petechiae that may progress to necrotic ulcerative lesions on
the trunk and extremities. Ophthalmoscopy may be helpful
to look for candidal endophthalmitis. Concurrent superficial
candidiasis may not be present and, by itself, is not helpful in
establishing the diagnosis of systemic infection.
Superficial candidiasis is usually distinctive, but it may be
confused with eczematous eruptions, dermatophytosis, and
pus-producing bacterial skin infections (ie, pyodermas).
Systemic candidiasis must be distinguished from other
septicemias.
B. Laboratory Findings—For superficial candidiasis, a
potassium hydroxide preparation demonstrating budding
yeast or spores and pseudohyphae establishes the diagnosis.
Culture on Sabouraud’s agar shows growth in 3–4 days. The
diagnosis of systemic candidiasis is made by discovery of
microorganisms in cutaneous biopsy or a positive culture
from fluids (eg, blood or cerebrospinal fluid) or tissues nor-
mally sterile for candida in a patient in whom clinical find-
ings are compatible.
Treatment
A. Superficial Candidiasis—Moist areas should be kept
clean and dry. If the skin is weeping, a wet compress should
be applied for 10–20 minutes twice daily. Topical anticandi-
dal creams (eg, clotrimazole) applied twice daily are effective.
Adding a low-potency topical steroid to the anticandidal
agent may reduce the inflammatory component and speed
healing. Creams should be rubbed into the area gently but
thoroughly. This should be followed with an anticandidal
powder (eg, miconazole).
The patient should be evaluated for predisposing factors
such as diabetes, fecal and urinary incontinence, and
immunosuppression.
B. Systemic Candidiasis—Systemic candidiasis requires
more aggressive therapy with systemic agents such as ampho-
tericin B, fluconazole, itraconazole, or an echinocandin.
Mays SR, Bogle MA, Bodey GP: Cutaneous fungal infections in the
oncology patient: Recognition and management. Am J Clin
Dermatol 2006;7:31–43. [PMID: 16489841]
Sobel JD, Vazquez J: Candidiasis in the intensive care unit. Semin
Respir Crit Care Med 2003;24:99–112. [PMID: 16088529]
 Graft-Versus-Host Disease
ESSENT IALS  OF  D IAGNOS I S
 Prior allogeneic transplant containing immunologically
competent cells, particularly bone marrow.
 Acute (days to weeks after transplant): pruritic macular
and papular erythema, frequently progressing to a gen-
eralized erythroderma with bullae in severe cases.
 Chronic (50–100 days after transplant): widespread
scaly plaques and desquamation. Cicatricial alopecia
and dystrophic nails. In severe forms, sclerodermatous
changes supervene.
General Considerations
Graft-versus-host disease occurs when tissues containing
immunologically competent cells (eg, blood products, bone
marrow, and solid organs) are introduced into an antigeni-
cally foreign person who is incapable of mounting an effec-
tive response to destroy the transplanted cells. It is the chief
complication of allogeneic transplantation. Two forms are
recognized: an acute form that can occur within days or as
late as 1–2 months after transplantation and a chronic form
that typically presents from 50–100 days or more after trans-
plantation. Both forms are associated with significant mor-
bidity and a high mortality rate.
Clinical Features
A. Symptoms and Signs—In acute graft-versus-host dis-
ease, the skin is the most commonly affected organ. The
cutaneous eruption is characterized by a pruritic macular
and papular erythema, often on the palms, soles, ears, and
upper trunk, frequently progressing to a generalized erythro-
derma. In severe cases, bullae may develop, resembling the
lesions of toxic epidermal necrolysis. The intestines, liver,
and immune system are the other principally involved organs
in acute graft-versus-host disease, with manifestations of
diarrhea, hepatitis, and delayed immunologic recovery usu-
ally appearing after the skin eruption. The incidence of acute
graft-versus-host disease ranges from 10–80%.
Chronic graft-versus-host disease may occur with or
without preceding acute disease. However, any manifestation
of acute graft-versus-host disease increases the chance of
developing the chronic form. The incidence ranges from
30–60%. Cutaneous abnormalities occur in about 80% of
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patients with chronic graft-versus-host disease and usually
resemble lichen planus, with widespread scaly plaques and
desquamation. Destruction of skin appendages leads to cica-
tricial alopecia and dystrophic nails. In severe forms, sclero-
dermatous changes supervene. This may remain localized
but more often is generalized, producing induration, dyspig-
mentation, atrophy, telangiectases, and chronic skin ulcers.
Vitiligo also may occur. Other target organs include the
mucosal surfaces, the eyes, the hematopoietic and immune
systems, the liver, and the lungs.
B. Laboratory Findings—Skin biopsy may be useful for
confirming the diagnosis and grading the severity of acute
cutaneous graft-versus-host disease but does not help in dif-
ferentiating acute graft-versus-host disease from drug erup-
tions. Laboratory studies are not specific but are important
for monitoring other organ system involvement, the severity
of illness, and the response to treatment. Key values are total
bilirubin and stool output, which, when evaluated with the
extent of rash and stage of disease, are prognostic for early
acute graft-versus-host disease. Circulating autoantibodies
and elevated immunoglobulins may be present in chronic
graft-versus-host disease.
Differential Diagnosis
The skin abnormalities in acute graft-versus-host disease may
be confused with toxic epidermal necrolysis, drug-induced
eruptions, infectious exanthems, and other causes of palmar
erythema—including cirrhosis, pregnancy, and other hypere-
strogen states—and chemotherapy-related acral erythema. Of
these, drug eruptions may be the most difficult to exclude.
The skin in chronic graft-versus-host disease may have the
appearance of collagen-vascular diseases such as scleroderma,
lupus erythematosus, and dermatomyositis. The diagnosis is
suspected when a characteristic skin eruption occurs in the
presence of typical involvement in other organs.
Treatment
Over the past several years, major efforts have been focused
on prophylaxis against graft-versus-host disease using corti-
costeroids, cyclosporine, tacrolimus, mycophenolate mofetil,
and methotrexate. Posttransfusion graft-versus-host disease
can be prevented by irradiating blood products prior to
transfusion. The immunosuppressive agents used for pre-
venting graft-versus-host disease are also useful in treating
established acute disease. Antithymocyte globulins (ATGs),
monoclonal antibodies such as anti-interleukin 2 receptor
(anti-IL2R), extracorporeal photopheresis, and psoralen
with ultraviolet A (PUVA) may be useful in refractory cases.
Patients with localized chronic graft-versus-host disease
do well without intervention. In generalized chronic dis-
ease, immunosuppressive agents are the mainstays of treat-
ment. In addition, thalidomide, etretinate, extracorporeal
photopheresis, PUVA, and hydroxychloroquine are some-
times used.
Bolanos-Meade J et al : Acute graft-versus-host disease. Clin Adv
Hematol Oncol 2004;2:672–82. [PMID: 16163254]
Gilman AL, Serody J: Diagnosis and treatment of chronic graft-
versus-host disease. Semin Hematol 2006;43:70–80. [PMID:
16412791]
Hymes SR et al: Cutaneous manifestations of chronic graft-versus-
host disease. Biol Blood Marrow Transplant 2006;12:1101–13.
[PMID: 17085303]
Marra D et al: Tissue eosinophils and the perils of using skin
biopsy specimens to distinguish between drug hypersensitivity
and cutaneous graft-versus-host disease. J Am Acad Dermatol
2004;51:543–6. [PMID: 15389188]
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ment of cutaneous graft versus host disease. Am J Clin
Dermatol 2004;5:403–16. [PMID: 15663337]
Vargas-Diez E et al: Life-threatening graft-vs-host disease. Clin
Dermatol 2005;23:285–300. [PMID: 15896544]
DRUG REACTIONS
A drug reaction is defined as any adverse response temporally
related to the administration of a drug. Unwanted drug reac-
tions have been estimated to occur in 15–30% of hospitalized
patients. Cutaneous eruptions are among the most common
adverse reactions to drugs, affecting 2–3% of hospitalized
patients. Patients receiving many different drugs, such as the
critically ill, are more likely to develop a drug eruption. The
cutaneous manifestations vary in severity from mild and
transient to the occasional development of severe systemic
disease and even death, and often mimic other dermatoses,
both clinically and histologically. In this section, drug erup-
tions with distinctive morphologic characteristics will be dis-
cussed, with emphasis on some common or life-threatening
conditions encountered in critically ill patients. Special
forms of drug reactions are also discussed in the sections on
contact dermatitis, vasculitis, anticoagulant necrosis, and
exfoliative erythroderma.
 Morbilliform, Urticarial, & Bullous Drug
Eruptions
ESSENT IALS  OF  D IAGNOS I S
 Exposure to drugs commonly associated with drug
eruptions, especially antibiotics, anticonvulsants, and
blood products—but may be due to any medication.
 Onset of rash temporally related to drug administration,
most often 5–10 days after exposure to a new drug or
1–2 days as a reaction to a drug to which the patient
has been previously sensitized.
 Eruptions are usually symmetric and widespread,
appear suddenly, and are not associated with systemic
symptoms other than pruritus and mild fever.
 Improvement with cessation of drug supports diagnosis.
General Considerations
Adverse reactions that involve immune mechanisms, such as
IgE-mediated urticaria and anaphylaxis, and cell-mediated con-
tact reactions are true drug allergies. Reactions involving sus-
pected immune mechanisms of unknown or mixed
pathogenesis include the erythematous maculopapular or mor-
billiform rashes, bullous eruptions, erythema multiforme and
Stevens-Johnson syndrome, and exfoliative erythrodermas.
Nonimmune mechanisms and idiosyncratic reactions may lead
to skin abnormalities via activation of effector pathways,
direct toxicity, drug interactions, and overdosage. Drug-
induced urticaria can be produced by several mechanisms:
IgE-mediated anaphylactic hypersensitivity, immune
complex–induced urticaria associated with serum sickness–like
reactions (eg, urticaria, fever, hematuria, and arthralgias), non-
immunologic release of mast cell mediators, and direct stimula-
tion of the complement cascade. Unfortunately, the pathogenic
mechanisms in the majority of drug eruptions remain unknown.
Clinical Features
A. History of Medications—When a drug eruption is sus-
pected, it is important to document each medication cur-
rently being given or recently discontinued, the duration of
its use, and the timing of drug exposure in relation to onset
of the rash. As a rule, a recently started medication is more
apt to be responsible for a drug eruption. Rarely will a med-
ication that has been taken regularly for months to years
stimulate the immune system to produce an eruption. It typ-
ically takes 5–10 days following exposure to a new drug—or
1–2 days after previous sensitization—for a drug eruption to
appear. However, the rash may appear suddenly, as seen in
urticaria and anaphylaxis. Prior history of an adverse reac-
tion is the only clinically helpful risk factor.
B. Symptoms and Signs—The morphology of the rash and
the reported frequency of adverse cutaneous reactions to a
given drug may assist in identifying the offending agent.
Some drugs are rarely associated with skin eruptions
(Table 28–1). In the ICU setting, the most frequently impli-
cated medications are antibiotics (eg, ampicillin, semisyn-
thetic penicillins, and trimethoprim-sulfamethoxazole),
anticonvulsants, and blood products. Certain drugs are more
commonly associated with specific morphologic patterns,
thus helping to identify the causative agent when multiple
drug exposures have occurred (Table 28–2).
Morbilliform eruptions, or toxic erythemas, are the most
common type of drug-induced rashes. These eruptions are
usually symmetric, widespread, and consist of erythematous
macules or papules that often become confluent. The rash
typically begins on the trunk or in dependent areas; involve-
ment of the palms and soles is variable. Pruritus and mild
fever may accompany the reaction. Signs and symptoms usu-
ally regress within a few days after treatment is stopped.
Exceptionally, the eruption fades despite continued intake of
the drug.
Urticaria represents the second most common type of
drug eruption. Urticaria is a vascular reaction of the skin
characterized by wheals, which are pinkish, edematous, pru-
ritic lesions that vary in size and shape. Individual lesions are
transient, rarely lasting longer than 24 hours. Angioedema
refers to urticarial swelling of deep dermal and subcutaneous
tissues. Angioedema may involve the mucous membranes
and may be life-threatening. Urticaria may occur alone or in
conjunction with angioedema or anaphylaxis. The reaction is
usually self-limited, lasting a few days to a few weeks.
Blisters may accompany a variety of drug-induced erup-
tions, including fixed-drug eruptions, erythema multiforme,
Stevens-Johnson syndrome, toxic epidermal necrolysis, vas-
culitis, and anticoagulant necrosis. Some drugs can produce
blistering eruptions that are indistinguishable from primary
bullous dermatoses such as bullous pemphigoid and por-
phyria cutanea tarda. Coma bullae—blisters over pressure
areas—are seen in patients in coma from various causes,
including narcotics, barbiturates, and carbon monoxide poi-
soning. Some bullous drug eruptions do not fit into any of
these diagnostic classes.
C. Laboratory Findings—Laboratory tests are rarely helpful
in diagnosis. Morbilliform reactions are occasionally associ-
ated with eosinophilia, antinuclear antibody titers are posi-
tive in drug-induced lupus, and there may be evidence of
liver, kidney, and hematologic abnormalities in the pheny-
toin hypersensitivity syndrome (see next). Skin biopsy find-
ings are usually nonspecific. Tissue eosinophils may help to
differentiate drug eruptions from the dermatoses they
mimic. However, a few specific eruptions, including coma
bullae, fixed drug eruptions, erythema multiforme, toxic epi-
dermal necrolysis, and vasculitis, may show distinctive
histopathologic changes.
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Acetaminophen Isosorbide dinitrate 
Aminophylline Laxatives 
Antacid Lidocaine 
Atropine Meperidine 
Chloral hydrate Morphine 
Chloramphenicol Multivitamins 
Chlorpromazine Nitroglycerin 
Dexamethasone Potassium iodide 
Digoxin Prednisolone 
Diphenhydramine Prednisone 
Ferrous sulfate Promethazine 
Flurazepam Propranolol 
Folic acid Spironolactone 
Hydrochlorothiazide Tetracycline 
Hydroxyzine Theophylline 
Insulin Thyroid hormones 
Table 28–1. Drugs infrequently associated with adverse
skin reactions. 
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Differential Diagnosis
Drug eruptions sometimes may be distinguished clinically
from the dermatoses they simulate by their sudden appear-
ance, symmetry, widespread distribution, and paucity of
associated systemic symptoms. Medication history and
improvement of the skin after the medication is stopped may
support the diagnosis.
The principal causes of morbilliform eruptions are drug
reactions and infections, especially viral exanthems.
Occasionally, a morbilliform drug rash may be confused with
a bacterial or rickettsial infection or collagen-vascular dis-
ease. Although the diagnosis of urticaria is usually apparent
because of the presence of evanescent wheals, the cause may
be difficult to discern. In addition to drugs, other common
causes of urticaria include food allergies, insect bites and
stings, and parasitic infections. If the urticarial lesions persist
longer than 24–36 hours, are tender, or have a purpuric com-
ponent, an urticarial vasculitis or serum sickness–like reac-
tion should be considered. Bullous drug eruptions may
resemble primary blistering dermatoses.
Treatment
The challenges to the clinician faced with a suspected drug
rash are to consider alternative explanations for the rash,
identify the offending drug, predict progression to serious or
life-threatening eruptions, and decide whether or not to
intervene.
A. Review Medications—When feasible, discontinue likely
causative agents and substitute chemically unrelated drugs. If
the medication is not essential, it may be stopped without
substitution. If the eruption is mild and relatively asympto-
matic and a particular drug is necessary, the drug may be
continued with cautious observation. However, urticaria,
erythema multiforme, vasculitis, or generalized erythema
(erythroderma) requires a search for alternative therapy.
B. General Measures—Treatment of drug eruptions is usu-
ally supportive and symptomatic because most eruptions
resolve within 2–5 days of stopping the offending drug.
Pruritus can be treated with oral antihistamines, such as
hydroxyzine, and a topical antipruritic lotion (eg, Sarna or
Pramosone). Treatment of severe urticarial reactions associ-
ated with angioedema or anaphylaxis consists of supportive
measures to maintain vital functions, epinephrine, antihista-
mines, and if all else fails, systemic corticosteroids. Blistering
eruptions may require decompression of large bullae, topical
antibiotics to denuded areas, and baths or wet compresses to
remove exudate or crusts. Drug-induced erythroderma may
require systemic corticosteroid therapy.
Callen JP: Newly recognized cutaneous drug eruptions. Dermatol
Clin 2007;25:255–61. [PMID: 17430762]
Greenberger PA: Drug allergy. J Allergy Clin Immunol
2006;117:S464–70. [PMID: 16455348]
Maculopapular eruptions Toxic epidermal necrolysis and
Oral hypoglycemic agents Stevens-Johnson syndrome
Thiazides Allopurinol
Enalapril Penicillins
Allopurinol Chlormezanine
Ampicillin Corticosteroids
Barbiturates Felbamate
Blood products Lamotrigine
Captopril Phenylbutazone
Gentamicin Valporic acid
Isoniazid Barbiturates
Phenytoin Carbamazepine
Sulfonamides Dapsone
Urticaria Phenytoin
Azole antifungals Sulfonamides
Cephalosporins Allopurinol 
Proton pump inhibitors Purpura
Oral hypoglycemic agents Thrombocytopenic
Aminoglycosides Carbamazepine
Barbiturates NSAIDs
Blood products Vasculitis
Chlorpromazine Allopurinol 
Hydralazine Barbiturates 
Morphine Clindamycin 
NSAIDs Furosemide 
Penicillins Hydralazine 
Phenytoin Penicillins 
Radiographic contrast Phenytoin 
Salicylates Salicylates 
Sulfonamides Sulfonamides 
Bullous eruptions Miscellaneous
Barbiturates (coma bullae) Corticosteroids 
Captopril Heparin 
Heparin Warfarin 
Pencillamine (pemphigus- Serum sickness
like) Antithymocyte globulin
Piroxicam Blood products
Phenytoin Beta-blockers
Sulfonamides Bupropion
Warfarin Minocycline
Erythema multiforme major Cephalosporins
Barbiturates Penicillins 
NSAIDs Phenytoin 
Penicillins Radiographic contrast 
Phenytoin Sulfonamides 
Rifampin Exfoliative erythroderma
Sulfonamides Barbiturates 
Sulfonylureas Captopril 
Carbamazepine 
Cefoxitin 
Cimetidine 
Furosemide 
Isoniazid 
Phenytoin 
Salicylates 
Sulfonamides 
Sulfonylureas 
Table 28–2. Some morphologic patterns of drug
eruptions and commonly incriminated agents. 
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Knowles SR, Shear NH: Recognition and management of severe
cutaneous drug reactions. Dermatol Clin 2007;25:245–53.
[PMID: 17430761]
Litt JZ: Drug Eruption Reference Manual, 10th ed. New York: Taylor
and Francis Group, 2004.
 Erythema Multiforme 
ESSENT IALS  OF  D IAGNOS I S
 Erythema multiforme minor: prodrome of low-grade
fever, malaise, and upper respiratory symptoms, fol-
lowed by a nonspecific symmetric eruption of erythe-
matous macules, papules, and urticarial plaques.
 Evolves into concentric rings of erythema with papular,
dusky, necrotic, or bullous centers (target lesions) over
1–2 days but also may be annular, polycyclic, or pur-
puric (multiforme).
 Erythema multiforme with mucous membrane involve-
ment: high fever, headache, myalgias, and sore throat,
with more than one mucosal surface affected. Stomatitis
is conspicuous, beginning with vesicles on the lips,
tongue, and buccal mucosa. The vesicles rapidly evolve
into erosions and ulcers covered by hemorrhagic crusts.
General Considerations
Historically, erythema multiforme (EM), Stevens-Johnson
syndrome (SJS), and toxic epidermal necrolysis (TEN) were
lumped into the same diagnostic group erythema multi-
forme because they shared clinical and histologic features.
In recent years, a new classification scheme has been pro-
posed that distinguishes EM from SJS and TEN. This new
scheme is based on the observation that EM is triggered by
herpes simplex virus (HSV) infection in nearly all cases,
and SJS and TEN are adverse reactions to medications. EM
may present with a wide range of severity. Patients with
herpes simplex–associated EM (HAEM) and mild or no
mucosal involvement are classified as having EM minor.
Some patients with EM have more severe disease called
erythema multiforme with mucous membrane involvement
(also called EM major). EM major is caused by HSV in
about half the cases. There is a long list of other suspected
etiologic triggers that have been reported to trigger EM
major (Table 28-3), but only Mycoplasma pneumoniae and
radiation therapy have been reproducibly documented
associations.
EM minor is an acute, self-limited, recurrent inflamma-
tory disease of the skin or mucous membranes. EM major is
a severe and occasionally fatal form characterized by marked
oral and ocular mucosal involvement. Erythema multiforme
occurs in all age groups.
The pathogenesis of erythema multiforme is not fully
understood. According to one hypothesis, foreign antigens
are sequestered in the epithelium, leading to immune-
mediated apoptosis and epithelial damage. Polymerase chain
reaction (PCR) studies have demonstrated HSV DNA in the
skin lesions of many patients, even in patients with no obvi-
ous clinical association with HSV.
Clinical Features
A. Symptoms and Signs—Both EM minor and EM major
have similar skin lesions that characteristically appear 1–3
weeks after an HSV infection, although some episodes will
not be preceded by an obvious outbreak of herpes. In EM
minor, a prodrome of low-grade fever, malaise, and upper
respiratory symptoms may develop. In EM major, high fever,
headache, myalgias, and sore throat develop abruptly, often
associated with coryza, vomiting, diarrhea, and joint pains.
This is followed by a nonspecific symmetric eruption of ery-
thematous macules, papules, and urticarial plaques that
evolve into target lesions over a 1–2-day period. The classic
target or iris lesions are concentric rings of erythema with
papular, dusky, necrotic, or bullous centers. The lesions also
may be annular, polycyclic, or purpuric, demonstrating the
polymorphous (multiforme) nature of the eruption. The
extensor surfaces of the forearms, the face, the neck, the legs,
and the palms and soles are the most commonly involved
sites. The lesions appear in crops over 1–2 weeks and usually
resolve within 4 weeks, often with residual hyperpigmenta-
tion. The mucous membranes commonly reveal hemor-
rhagic crusting of the lips, painful oral erosions, and
purulent conjunctivitis.
In EM major, patients appear extremely ill and may have
tachycardia and tachypnea. More than one mucosal surface is
Drugs: See Table 28–2.
Infection 
Herpes simplex 
M. pneumoniae
Streptococcus 
Yersinia 
Tuberculosis 
Histoplasmosis 
Other conditions 
Irradiation of tumors 
Sarcoidosis 
Pregnancy 
Carcinomas 
Leukemias 
Collagen-vascular diseases 
Inflammatory bowel disease
Idiopathic 
Table 28–3. Common causes of erythema multiforme
major.
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affected. Stomatitis is conspicuous, beginning with vesicles
on the lips, tongue, and buccal mucosa. The vesicles evolve
rapidly into erosions and ulcers, covered by hemorrhagic
crusts. Bilateral catarrhal conjunctivitis, corneal ulcers, ero-
sive rhinitis, balanitis, and vulvovaginitis may develop. The
urethra, larynx, esophagus, trachea, and bronchi also may be
involved. Occasionally, the skin is spared, but in most
instances a vesiculobullous or erythematous eruption
appears on the face and distal extremities. Complications
include dehydration resulting from the ulcerative stomatitis
and blindness resulting from the corneal ulcers. In patients
with extensive disease, the mortality rate approaches 5%,
with deaths usually a result of sepsis.
B. Laboratory Findings—There are no specific laboratory
abnormalities. Leukocytosis, elevated erythrocyte sedi-
mentation rate, abnormal liver function tests, proteinuria,
and occasionally, hematuria are seen. The diagnosis is
based on characteristic clinical features with histopatho-
logic confirmation.
Underlying causative factors should be sought.
Evaluation of the patient with EM major should include the
following: complete blood count, erythrocyte sedimentation
rate, urinalysis, and a purified protein derivative (PPD) test.
Other tests may include cold agglutinin titers; chest, sinus,
and dental x-rays; hepatitis B serologic tests; cultures for bac-
teria, viruses, and fungi; and antinuclear antibody (ANA)
and rheumatoid factor determinations. Other tests for the
evaluation of diseases such as sarcoidosis or occult malignan-
cies also should be considered.
Differential Diagnosis
EM may resemble many other skin disorders, especially when
the classic target lesions are absent. The presence of target
lesions and characteristic histopathologic features helps to
distinguish EM from urticaria, viral exanthems, and vasculi-
tis, as well as from other mucocutaneous disorders such as
Reiter’s syndrome, Behçet’s syndrome, herpes gingivostom-
atitis, and Kawasaki’s disease. When blisters are present, EM
must be differentiated from bullous impetigo, bullous pem-
phigoid, pemphigus vulgaris, SJS, and TEN. The skin lesions
in SJS are characteristically purpuric macules and atypical
target lesions on the torso, face, and extremities, involving
less than 10% of the body surface 
Treatment
If the specific cause is identified, treatment directed at that
cause is indicated. In most cases, therapy is supportive and
symptomatic. The patient should be monitored closely for
potential progression to secondary infection and sepsis. Cool
compresses, followed by the application of mupirocin oint-
ment, are useful for crusting and secondary infection.
For patients with compromised oral intake or extensive
erosions, proper attention must be paid to fluids, electrolytes,
and nutrition. An antiseptic mouthwash or hydrogen peroxide
should be used to keep the oral cavity clean. Viscous lidocaine
or a mixture of equal parts of diphenhydramine hydrochloride
and an oral antacid may alleviate pain on swallowing.
Eye involvement should be managed in consultation with
an ophthalmologist. Avoid sulfonamide-containing eye
drops because they can cause or exacerbate sulfonamide-
induced reactions. Topical or systemic steroids have not been
proved to prevent ocular sequelae or progression of cuta-
neous disease, and they may be harmful. However, some
authorities advocate systemic steroids early in the course of
the reaction (within 48 hours).
Auquier-Dunant A et al: Correlations between clinical patterns
and causes of erythema multiforme majus, Stevens-Johnson
syndrome, and toxic epidermal necrolysis: Results of an
International Prospective Study. Arch Dermatol
2002;138:1019–24. [PMID: 12164739]
 Stevens-Johnson Syndrome & Toxic
Epidermal Necrolysis
ESSENT IALS  OF  D IAGNOS I S
 Severe, acute blistering diseases associated with signif-
icant morbidity and mortality.
 Often a recent history of drug ingestion.
 Prodrome of fever, nausea, vomiting, diarrhea, malaise,
headache, cough, sore throat, myalgia, and arthralgia
1–14 days before the skin eruption.
 SJS: widespread red or purpuric macules or flat atypical
target lesions with subepidermal detachment over less
than 10% of body surface at worse; mucosal erosions
frequent; no correlation between extent of mucosal
involvement and extent of epidermal detachment;
subepidermal separation of skin (Nikolsky’s sign).
 TEN: variant of same process with epidermal detach-
ment greater than 30% of surface; features of SJS:
stomatitis, blotchy eruption with target lesions.
General Considerations
SJS and TEN are acute, severe blistering diseases of the skin
and mucous membranes caused by drugs or infections. The
mortality rate of SJS approaches 5%, but the mortality rate of
TEN may be closer to 30%. TEN is a rare, life-threatening
syndrome characterized by skin tenderness, erythema, and
exfoliation of the epidermis and mucous membranes remi-
niscent of a scald injury. The pathophysiology is not known,
but these disorders are believed to be immunologically medi-
ated. Most cases are drug-induced by such agents as
antiepileptics (eg, phenytoin, phenobarbital, and carba-
mazepine), sulfonamides, sulfones, nonsteroidal anti-
inflammatory drugs (especially pyrazolone derivatives),
allopurinol, and ampicillin. Identification of the causative
drug is often difficult because many patients are treated with
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multiple medications. In general, the interval between initial
dose of the drug and onset of the disease is 1–3 weeks, except
for phenytoin-induced cases, which may occur as late as 8
weeks following the start of therapy. If the patient has a his-
tory of SJS or TEN from previous exposure to a drug, the
time period may be reduced to 24–48 hours. Patients with
AIDS appear to have an increased risk for TEN.
Clinical Features
A. Symptoms and Signs—Fever, nausea, vomiting, diar-
rhea, malaise, headache, upper respiratory symptoms, chest
pain, myalgia and arthralgia, and conjunctivitis usually pre-
cede the skin and mucous membrane lesions by 1–14 days.
Cutaneous involvement appears acutely as tender, discrete,
symmetric erythematous or purpuric macules and urticarial
plaques with atypical target lesions with dusky centers on the
face and upper trunk. Coalescence and extension to the
entire body rapidly ensue. Subsequently, large flaccid bullae
develop within the areas of erythema, and the necrotic epi-
dermis sloughs in sheets. Pressure applied directly over an
intact blister produces lateral spread of the lesion. Gentle
rubbing of erythematous areas induces separation of the epi-
dermis (Nikolsky’s sign). In SJS, the extent of epidermal
detachment is less than 10% of the body surface area. In
TEN, coalescence and extension to the entire body ensue rap-
idly, with detachment of the epidermis exceeding 30% of the
body surface area. The palms and soles may be involved, but
the hairy part of the scalp characteristically is spared.
Mucous membrane involvement is extensive, with erosions
or ulcers of the conjunctiva, lips, oropharynx, trachea,
esophagus, and anogenital area.
The extent of epidermal separation is a major prognostic
factor. Sepsis is the most frequent cause of death and may be
heralded by a sudden drop in temperature. Pulmonary
embolism, pulmonary edema, and GI bleeding are other
important causes of death. Pneumonia superimposed on
sloughing of the tracheobronchial mucosa may require ven-
tilatory assistance. Fluid loss, thermoregulatory impairment,
and increased energy expenditure result from extensive skin
loss, as in burn victims. The mortality rate ranges from
25–75% and is higher in elderly patients. Disabling ocular
sequelae affect up to 50% of survivors. Cutaneous reepithe-
lialization requires 2–3 weeks, whereas the mucous mem-
brane lesions persist longer.
B. Laboratory Findings—Routine laboratory studies
reflect the extent and severity of the disease but are not
specific. There may be evidence of electrolyte depletion
and dehydration. Serum creatinine may be elevated owing
to prerenal azotemia or acute tubular necrosis. Serum
aminotransferase levels often are slightly increased. In vir-
tually all patients, anemia is present; lymphopenia, neu-
tropenia, and thrombocytopenia sometimes are seen and
may indicate a poor prognosis. Biopsy of involved skin
may be very helpful, revealing full-thickness epithelial
necrosis.
Differential Diagnosis
Clinically, TEN and staphylococcal scalded skin syndrome
are quite similar. The latter disorder is caused by an epider-
molytic toxin produced by Staphylococcus aureus. The toxin
produces superficial (subcorneal) skin separation. Nikolsky’s
sign is present, but skin tenderness and mucous membrane
lesions usually are absent. Staphylococcal scalded skin syn-
drome more frequently affects neonates and toddlers, is rare
in adults, and has a much better prognosis than TEN.
Historically, SJS and EM major were considered part of
the same disease group. EM major can be differentiated from
SJS by the presence typical target lesions localized in a sym-
metric acral distribution, low or no fever, and frequent asso-
ciation with HSV infection.
Other differential diagnostic considerations include pem-
phigus vulgaris and other blistering diseases, toxic shock syn-
drome, chemical or thermal burns, and Kawasaki’s disease.
TEN shares many features with—and is considered by some
to be a severe form of—SJS.
Treatment
The principles of therapy are similar to those for major
second-degree burn victims. Ideally, patients should be man-
aged in a burn unit.
A. General Measures—Discontinue the most likely offend-
ing medication, provide pain control as necessary, and attend
to fluids, electrolytes, and nutrition. Aggressive nutritional
support should be started early; nasogastric feeding is pre-
ferred to parenteral nutrition.
B. Infection Control—Prophylactic antibiotics may pro-
mote the emergence of resistant strains of bacteria or
Candida and should be avoided. Obtain blood, urine, and
skin cultures frequently, and start empirical broad-spectrum
antibiotics at the earliest sign of infection. Consider acyclovir
in HIV-infected patients because secondary HSV infection
may be clinically undetectable.
C. Skin and Mucous Membrane Care—Ophthalmologic
consultation is essential to prevent blindness and other ocu-
lar sequelae. Oral hygiene and antisepsis are important.
Intact bullae should be left in place because they provide a
natural dressing. Nonviable, necrotic, and loosely attached
areas of epidermis should be débrided. Apply biologic dress-
ings, such as porcine xenografts and cryopreserved cadaveric
allografts, or synthetic coverings, such as hydrogel dressing
or paraffin gauze, to denuded areas. Silver sulfadiazine must
be avoided in patients suspected of sulfonamide sensitivity.
Current Controversies and Unresolved Issues
Toxic epidermal necrolysis has been considered by some to
be at the most severe end of the spectrum of EM and SJS, but
the two disorders instead may be distinct reactional states
with clinicopathologic similarities. Supporting the latter
view is the observation that the three do not have the same
etiologic spectrum.
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Although corticosteroids have been used for decades,
recent studies suggest that systemic steroid therapy is more
detrimental than useful in TEN. Claims for a reduction of
morbidity and mortality in response to a large dose of sys-
temic steroids in the first 24–48 hours have not been substan-
tiated, and most authors now suggest that corticosteroids
should not be used. Plasmapheresis, cyclophosphamide,
intravenous immunoglobulin, cyclosporine, and infliximab
likewise have been claimed to be beneficial on the basis of case
reports and uncontrolled studies, but again, there is no proof.
Auquier-Dunant A et al: Correlations between clinical patterns
and causes of erythema multiforme majus, Stevens-Johnson
syndrome, and toxic epidermal necrolysis: Results of an
International Prospective Study. Arch Dermatol
2002;138:1019–24. [PMID: 12164739]
Heymann WR: Toxic epidermal necrolysis 2006. J Am Acad
Dermatol 2006;55:867–9. [PMID: 17052494]
Mittmann N et al: Intravenous immunoglobulin use in patients
with toxic epidermal necrolysis and Stevens-Johnson syndrome.
Am J Clin Dermatol 2006;7:359–68. [PMID: 17173470]
Pereira FA, Mudgil AV, Rosmarin DM: Toxic epidermal necrolysis.
J Am Acad Dermatol 2007;56:181–200. [PMID: 17224365]
Prins C et al: Treatment of toxic epidermal necrolysis with high-
dose intravenous immunoglobulins: Multicenter retrospective
analysis of 48 consecutive cases. Arch Dermatol 2003;139:
26–32. [PMID: 12533160]
Trent J et al: Use of SCORTEN to accurately predict mortality in
patients with toxic epidermal necrolysis in the United States.
Arch Dermatol 2004;140:890–2. [PMID: 15262712]
 Phenytoin Hypersensitivity Syndrome
ESSENT IALS  OF  D IAGNOS I S
 High spiking fever, malaise, and rash 2–3 weeks after
starting phenytoin therapy—or sooner if prior exposure
to drug.
 Patchy erythematous rash evolving into extensive pru-
ritic maculopapular rash, occasionally with follicular
papules and pustules.
 Exfoliative erythroderma, EM, SJS, or TEN may develop,
especially in those with prior adverse reactions to
phenytoin; edema of palms, soles, and face.
 Tender localized or generalized lymphadenopathy; mild
to severe hepatic injury; sometimes conjunctivitis,
pharyngitis, diarrhea, myositis, reversible acute renal
failure, and eosinophilia.
General Considerations
A number of adverse skin reactions, ranging from morbilli-
form eruptions to vasculitis, exfoliative erythroderma, EM,
SJS, and TEN, occur in up to 3–15% of patients receiving
phenytoin. In a small percentage of these patients, a distinc-
tive syndrome occurs, characterized by an extensive rash,
fever, eosinophilia, and hepatic injury. The disorder is
believed to be immune-mediated. All age groups are affected.
The incidence is highest in blacks.
Clinical Features
A. Symptoms and Signs—Onset is usually 2–3 weeks after
initiation of therapy—or within days if prior exposure has
occurred—heralded by high spiking fevers, malaise, and a
rash. The cutaneous eruption is variable. It often begins as
patchy erythema that evolves into an extensive pruritic mac-
ulopapular rash. Some patients have follicular papules and
pustules. The rash may generalize into an exfoliative erythro-
derma. EM, SJS, and TEN may occur, especially in patients
with previous adverse reactions to the drug and in those who
continue to receive the drug after developing signs of hyper-
sensitivity. Erythema and edema of the palms and soles and
prominent facial edema are common. The eruption usually
resolves with desquamation.
Tender localized or generalized lymphadenopathy is a
consistent finding. Virtually all patients with this syndrome
have hepatic injury, which varies from mild and transient to
severe and fulminant, resulting in massive hepatic necrosis.
Hepatosplenomegaly is found in most patients. Other fea-
tures of the syndrome, not uniformly present, are conjunc-
tivitis, pharyngitis, diarrhea, myositis, and reversible acute
renal failure. In general, the signs and symptoms resolve rap-
idly once the medication is discontinued; however, multior-
gan abnormalities may progress even after the phenytoin has
been stopped. Some patients endure a prolonged and com-
plicated course of exacerbations and remissions. The mortal-
ity rate approaches 20% in patients with severe liver damage.
B. Laboratory Findings—Laboratory studies are important
for monitoring the severity and progression of the reaction.
Leukocytosis with eosinophilia (5–50%) is common.
Coombs-negative hemolytic anemia and atypical circulating
lymphocytes may be seen. The degree of elevation in serum
aminotransferases and alkaline phosphatase levels reflects
the severity of liver injury, and renal function may be abnor-
mal. It is of note that the erythrocyte sedimentation rate and
serum complement levels are normal in this disorder.
Differential Diagnosis
Other anticonvulsant medications, particularly phenobarbi-
tal, may cause reactions indistinguishable from phenytoin
hypersensitivity disorder. Infectious mononucleosis may
resemble this syndrome.
Treatment
The medication must be discontinued. Data regarding cross-
reactivity among the anticonvulsants is scanty, but if anti-
convulsant therapy is still necessary, valproic acid or
carbamazepine may be safer alternatives.
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General supportive care is vital because of the multisys-
tem involvement. Systemic corticosteroids are sometimes
used, but their effectiveness has not been documented.
Arif H et al: Comparison and predictors of rash associated with 15
antiepileptic drugs. Neurology 2007;68:1701–9. [PMID:
17502552]
Gogtay NJ, Bavdekar SB, Kshirsagar NA: Anticonvulsant hypersen-
sitivity syndrome: A review. Expert Opin Drug Saf 2005;4:
571–81. [PMID: 15934861]
Kaminsky A et al. Anticonvulsant hypersensitivity syndrome. Int J
Dermatol 2005;44:594–8. [PMID: 15985033]
Seitz CS et al: Anticonvulsant hypersensitivity syndrome: Cross-
reactivity with tricyclic antidepressant agents. Ann Allergy
Asthma Immunol 2006;97:698–702. [PMID: 17165282]
PURPURA
Purpura results from hemorrhage into the skin or mucous
membranes. Incomplete blanching on pressure is characteris-
tic. Purpuric lesions may be a clue to acutely life-threatening
diseases but are seen in benign conditions as well. An impor-
tant step in evaluating the patient with purpura is to determine
whether the lesions are macular (flat) or palpable.
Nonpalpable purpura, the result of bleeding into the skin
without inflammation, is due to disorders of hemostasis and
vessel wall integrity. In these cases, small petechial hemor-
rhages (<3 mm) occur. Common causative factors are throm-
bocytopenia and disorders of platelet function. Petechiae also
may be a clue to diseases that affect the integrity of blood ves-
sels, for example, scurvy or amyloidosis. In contrast, disorders
of coagulation cause bleeding from larger vessels, producing
ecchymoses (ie, hemorrhagic macules >3 mm). Palpable pur-
pura, the expression of inflammatory damage to the vascula-
ture and consequent extravasation of blood, is the hallmark of
small vessel vasculitis but also may be seen with septic emboli.
Purpura develops occasionally as a secondary manifesta-
tion in an inflammatory dermatosis. For example, macular
drug eruptions or exanthematous infectious diseases such as
measles and scarlet fever can become purpuric as a result of
increased permeability of the blood vessels and extravasation
of red cells into the surrounding tissue. Causes of purpura
are classified arbitrarily in Table 28–4. In this section, leuko-
cytoclastic vasculitis, disseminated intravascular coagulation,
and purpura fulminans are discussed.
Table 28–4. Causes of purpura.
Vascular Disorders Abnormal distribution 
Inflammatory disorders Diseases associated with splenomegaly
Palpable purpura Kasabach-Merritt syndrome
Vasculitis Purpura with normal platelet counts
Septic emboli Platelet function defects
Nonpalpable purpura Drugs (eg, salicylates, NSAIDs)
Viral infections Uremia
Rickettsial infections Coagulopathies
Drugs and chemicals Purpura with high platelet counts
Pigmented purpuric dermatoses Myeloproliferative syndromes
Noninflammatory disorders Postsplenectomy
Trauma Various neoplasms and inflammatory diseases
Amyloidosis Disorders of Coagulation
Scurvy Acquired
Dysproteinemic states Vitamin K deficiency
Solar purpura Disseminated intravascular coagulation
Abnormalities of Platelet Number and Function Parenchymal liver disease
Thrombocytopenic purpuras Cardiopulmonary bypass surgery
Increased platelet destruction Lupus anticoagulant syndrome
Microangiopathic diseases Inherited
Infections Classic hemophilia
Immunologic disorders von Willebrand’s disease
Idiopathic thrombocytopenic purpura (ITP) Thrombotic disorders
Drug-induced thrombocytopenia Protein C and S deficiency
Autoimmune diseases (eg, SLE) Antithrombin III deficiency
Decreased platelet production Drugs (eg, aminocaproic acid, estrogen compounds)
Neoplastic replacement of bone marrow Nephrotic syndrome 
Myelosuppressive disorders Anticoagulant necrosis 
Radiation 
Chemotherapy 
Infections 
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 Leukocytoclastic Vasculitis
ESSENT IALS  OF  D IAGNOS I S
 Palpable purpura; hemorrhagic bullae, purpuric
plaques, vesicles, pustules on a purpuric base, and
urticaria-like papules may be present.
 Systemic symptoms occur in 40–50%, including fever,
myalgias, and arthralgias; abdominal pain, GI bleeding,
and pulmonary disease (eg, pneumonitis, pleuritis, or
hemoptysis) occur less frequently.
 Biopsy of involved skin shows necrotizing vasculitis
with prominent neutrophilic infiltrates in and around
the vessel walls, extravasated red blood cells, and dep-
osition of fibrin.
General Considerations
Vasculitis is defined as inflammation and subsequent necro-
sis of the vessel wall. Various clinical syndromes share vas-
culitis as a feature and may be classified according to the size
and type of involved vessels (eg, postcapillary venule, arteri-
ole, vein, or artery), the type of inflammatory infiltrate (eg,
necrotizing or granulomatous), and the organs affected
(Table 28–5). Some forms of vasculitis are confined to the
skin, whereas others involve internal organs and may cause
severe and potentially fatal disease. When the small vessels of
the skin are involved, the most common finding is palpable
purpura. Involvement of larger vessels produces subcuta-
neous nodules, stellate-shaped purpura, or necrosis.
Pathophysiology
Most of the vasculitic diseases are immunologically mediated
and probably are due to immune complex deposition. The evi-
dence for immune complex–mediated damage is most com-
pelling for small-vessel, or “leukocytoclastic,” vasculitis. The
pathologic process involves the following sequence of events:
deposition of circulating soluble antigen-antibody complexes
in postcapillary venule walls, activation of the complement
cascade, chemotaxis of neutrophils to the sites of immune
complex deposition, and release of lysosomal enzymes and
other products from neutrophils, resulting in necrosis of the
vessel wall. Hemorrhage, thrombosis, and surrounding tissue
necrosis follow. The inflammatory cell infiltrate and edema in
and around the vessels cause the lesions to become palpable. In
some situations, vasculitis may result from direct invasion of
vessels by infectious agents. Cell-mediated immune damage
may be involved in granulomatous vasculitis.
Clinical Features
A. Symptoms and Signs—As noted earlier, the classic cuta-
neous finding in leukocytoclastic vasculitis is palpable pur-
pura (although the palpability may be subtle). However,
hemorrhagic bullae, purpuric plaques, vesicles, pustules on a
purpuric base, and urticaria-like papules may be present.
Affected patients also may have ulcerative, infarcted, or retic-
ulated lesions. The lesions arise in crops, predominantly on
the lower extremities and in dependent areas. Edema of the
lower legs is common. About 40–50% of patients with leuko-
cytoclastic vasculitis have systemic symptoms. Fever, myal-
gias, and arthralgias may accompany the cutaneous
manifestations. Kidney involvement may be transient, with
hematuria or proteinuria, or may lead to glomerulonephritis
or renal failure. Abdominal pain, GI bleeding, and pul-
monary disease (eg, pneumonitis, pleuritis, or hemoptysis)
occur less often. Peripheral neuropathies occur infrequently
and portend a poor prognosis.
B. Laboratory Findings—The definitive diagnosis of cuta-
neous vasculitis depends on compatible cutaneous lesions
plus histopathologic confirmation of blood vessel damage.
Necrotizing vasculitis is characterized by a prominent neu-
trophilic infiltrate in and around the vessel wall associated
with nuclear fragments (“nuclear dust”), extravasated red
blood cells, and deposition of fibrin. Furthermore, granulo-
matous vasculitis shows fibrinoid necrosis of the blood vessels
associated with intravascular and extravascular granulomas.
Evaluation of lesions by direct immunofluorescence for
the presence of immunoglobulins and complement may help
to confirm the diagnosis. However, negative results are com-
mon, and this test is often of little clinical value.
Leukocytoclastic (hypersensitivity) vasculitis 
Systemic-cutaneous vasculitis 
Variants of leukocytoclastic vasculitis 
Urticarial (hypocomplementemic) vasculitis 
Serum sickness 
Henoch-Schönlein purpura 
Rheumatic vasculitis 
Systemic lupus erythematosus 
Rheumatoid vasculitis 
Sjögren’s syndrome 
Scleroderma and dermatomyositis 
Polyarteritis nodosa 
Cutaneous type 
Systemic type 
Granulomatous vasculitis 
Churg-Strauss syndrome (allergic granulomatosis) 
Wegener’s granulomatosis 
Giant cell arteritis 
Temporal arteritis 
Takayasu’s arteritis 
Miscellaneous 
Degos’ disease (malignant atrophic papulosis) 
Kawasaki’s disease 
Lucio phenomenon 
Table 28–5. Classification of vasculitis.
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Once the diagnosis of cutaneous vasculitis is established, a
comprehensive evaluation is necessary to determine the pres-
ence and extent of internal involvement and to identify poten-
tial underlying causes (Table 28–6). Some recommended
screening studies include the following: complete blood count
and erythrocyte sedimentation rate; chemistry profile; serum
protein electrophoresis and cryoglobulin titer; hepatitis B and
C screens; antinuclear antibody titer, anti-Ro and anti-La titers,
C3, C4, total hemolytic complement, and VDRL; urinalysis and
stool occult blood; throat culture and antistreptolysin O titer;
and chest x-ray. Depending on the clinical situation, other tests
may include antineutrophilic cytoplasmic antibody titers, anti-
cardiolipin antibodies, direct immunofluorescence, biopsy of
affected organs, radiographic studies (including angiograms)
of affected organs, malignancy screening tests, echocardiogra-
phy, visceral angiography, and nerve conduction studies.
Differential Diagnosis
Palpable purpura occurs in both vasculitis and septicemia.
Certain clinical patterns favor the diagnosis of sepsis and
sometimes can provide clues to the causative organism. The
skin lesions associated with staphylococcal sepsis are acrally
located, asymmetric, and fewer in number than those associ-
ated with vasculitis. The characteristic lesions of gonococcal
bacteremia are discrete, tender pustules on a hemorrhagic
base, often accompanied by polyarthralgias, tenosynovitis, or
septic arthritis. The well-known skin findings in infective
endocarditis are painful nodules on the volar surfaces of the
fingers and toes (Osler’s nodes), nontender hemorrhagic mac-
ules on the palms and soles (Janeway’s lesions), and subungual
splinter hemorrhages. Petechiae, ecchymoses, hemorrhagic
vesicles and pustules, and ulcerated nodules all may be seen
with sepsis. The diagnosis is confirmed by a positive blood cul-
ture or a positive culture or Gram stain from the skin lesions.
Palpable purpura also can occur in nonseptic embolic disor-
ders such as atheromatous emboli or left atrial myxoma.
Treatment
The therapy of vasculitis is based on the extent and severity of
the disease. Any associated disease, infection, chemical, or drug
should be treated or removed. For vasculitis limited to the skin,
conservative therapy is appropriate because most cases are acute
and self-limited. Bed rest, antihistamines, and nonsteroidal anti-
inflammatory drugs may suppress or control cutaneous lesions
effectively. For necrotic or highly symptomatic eruptions,
colchicine, dapsone, or prednisone may be useful.
For systemic vasculitis, therapy with immunosuppressive
and/or cytotoxic agents such as corticosteroids, azathioprine,
cyclosporine, methotrexate, and mycophenolate mofetil is
usually necessary. Plasmapheresis may be tried in patients
refractory to other therapeutic modalities. Monoclonal anti-
body therapy with infliximab may be of value.
Cutaneous ulcers or bullae are treated with debridement,
tap water soaks, topical antibiotics, and vapor-permeable
membranes.
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2004;6:195–202. [PMID: 15134598]
Gonzalez-Gay MA, Garcia-Porrua C, Pujol RM: Clinical approach
to cutaneous vasculitis. Curr Opin Rheumatol 2005;17:56–61.
[PMID: 15604905]
Hayat S, Berney SM: Cutaneous vasculitis. Curr Rheumatol Rep
2005;7:276–80. [PMID: 16045830]
Langford CA: Vasculitis in the geriatric population. Rheum Dis
Clin North Am 2007;33:177–95. [PMID: 17367699]
Mang R, Ruzicka T, Stege H: Therapy for severe necrotizing vas-
culitis with infliximab. J Am Acad Dermatol 2004;51:331–2.
[PMID: 15280860]
Marder W, McCune WJ: Advances in immunosuppressive drug
therapy for use in autoimmune disease and systemic vasculitis.
Semin Respir Crit Care Med 2004;25:581–94. [PMID:
16088501]
Russell JP, Gibson LE: Primary cutaneous small vessel vasculitis:
Approach to diagnosis and treatment. Int J Dermatol
2006;45:3–13. [PMID: 16426368]
Suresh E: Diagnostic approach to patients with suspected vasculi-
tis. Postgrad Med J 2006;82:483–8. [PMID: 16891436]
Drugs: See Table 28–2. 
Chemical
Insecticides
Petroleum products
Weed killers
Foreign proteins
Heterologous serum
Snake antivenin
Hyposensitization antigens
Infections
Group A beta-hemolytic streptococci
Hepatitis B
Mycobacterial diseases
Influenza
Abnormal immunoglobulins
Multiple myeloma
Cryoglobulinemia
Macroglobulinemia
Rheumatic diseases
Rheumatoid arthritis
Systemic lupus erythematosus
Dermatomyositis
Sjögren’s syndrome
Miscellaneous diseases
Ulcerative colitis
Lymphomas and leukemias
Malignant tumors
Idiopathic 
Table 28–6. Causes of vasculitis.
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 Disseminated Intravascular Coagulation
& Purpura Fulminans
ESSENT IALS  OF  D IAGNOS I S
 Extensive skin necrosis, fever, and hypotension associ-
ated with evidence of disseminated intravascular coag-
ulation.
 Sudden appearance of large, irregular areas of purpura,
especially over the extremities.
 Skin lesions are tender, enlarge rapidly, and may evolve
into hemorrhagic bullae with subsequent necrosis and
black eschar formation; necrosis of an entire extremity
may develop.
 May be associated with pulmonary, hepatic, or renal
failure; GI bleeding; and hemorrhagic adrenal infarction.
General Considerations
Disseminated intravascular coagulation (DIC) is a dynamic
process associated with a variety of underlying diseases and
is the result of uncontrolled activation of coagulation and
fibrinolysis. Purpura fulminans is an acute, severe, often rap-
idly fatal syndrome characterized by extensive necrosis of the
skin associated with fever and hypotension. Purpura fulmi-
nans represents the extreme end of the spectrum of DIC.
Pathophysiology
The central pathogenic events in DIC are excessive generation
of thrombin and formation of intravascular fibrin clots, sec-
ondary activation of the fibrinolytic system, and consump-
tion of platelets and coagulation factors. Abnormalities of the
endogenous anticoagulants protein C and protein S may be
directly related to the pathogenesis of purpura fulminans by
contributing to the thrombotic tendency in patients with
DIC. Neonates with homozygous protein C deficiency present
with massive thrombosis of skin capillaries and veins, result-
ing in cutaneous necrosis, secondary sepsis, and death (pur-
pura fulminans neonatalis). Acquired deficiencies of proteins
C and S have been reported in liver disease and sepsis.
Purpura fulminans occurs most commonly in children and
often follows an infectious process such as scarlet fever or
streptococcal pharyngitis, meningococcemia, varicella, rube-
ola, or Rocky Mountain spotted fever. Purpura fulminans also
has been associated directly with S. aureus strains that pro-
duce high levels of toxic shock syndrome toxin 1 or staphylo-
coccal enterotoxins. Adults also may be affected, and the
syndrome may occur without a preceding illness.
Clinical Features
A. Symptoms and Signs—Cutaneous findings of DIC may
range from insignificant bruising and oozing from venipuncture
sites to massive hemorrhage and necrosis of skin and vital
organs. Purpura fulminans is characterized by the sudden
appearance of large, irregular areas of purpura, especially
over the extremities. The lesions are tender, enlarge rapidly,
and may evolve into hemorrhagic bullae with subsequent
necrosis and black eschar formation. The trunk, ears, and
nose may be involved. Necrosis of an entire extremity may
develop. Fever, chills, and hypotension almost always accom-
pany the disorder. Complications may include pulmonary,
hepatic, and renal failure, as well as GI bleeding and hemor-
rhagic adrenal infarction (Waterhouse-Friderichsen syn-
drome). Mortality rates range from 20–40%. The differential
diagnosis of purpura fulminans encompasses the entire spec-
trum of purpuric conditions.
B. Laboratory Findings—Because of the dynamic balance
between intravascular clot deposition and dissolution, serial
laboratory studies may be required to diagnose and monitor
DIC. The blood count usually shows thrombocytopenia, and
anemia may result from bleeding or microangiopathic
hemolysis. Consumption of coagulation factors and fibrino-
gen causes prolongation of the prothrombin time and partial
thromboplastin time. There is hypofibrinogenemia, and
increased fibrin degradation products (fibrin split products)
are present. More specific tests, such as measurement of the
D-dimer fragment, a breakdown product of cross-linked fib-
rin, may be helpful.
Treatment
Immediate attention must be directed toward stabilizing the
patient and treating the underlying cause. Heparin may pre-
vent further clot formation but should be avoided in patients
with suspected or documented intracranial bleeding. Plasma
or platelet replacement therapy may be indicated in patients
with active bleeding, but efficacy has not been proved in ran-
domized, controlled trials. Recombinant human activated
protein C should be considered in sepsis-related DIC.
Surgical debridement of necrotic eschars, grafting, and even
amputation are sometimes necessary.
Betrosian AP, Berlet T, Agarwal B: Purpura fulminans in sepsis. Am
J Med Sci 2006;332:339–45. [PMID: 17170624]
Fourrier F: Recombinant human activated protein C in the treat-
ment of severe sepsis: An evidence-based review. Crit Care Med
2004;32:S534–41. [PMID: 15542961]
Franchini M, Manzato F: Update on the treatment of disseminated
intravascular coagulation. Hematology 2004;9:81–5. [PMID:
15203862]
Kravitz GR et al: Purpura fulminans due to Staphylococcus aureus.
Clin Infect Dis 2005;40:941–7. [PMID: 15824983]
Levi M, de Jonge E, van der Poll T: Plasma and plasma components
in the management of disseminated intravascular coagulation.
Best Pract Res Clin Haematol 2006;19:127–42. [PMID:
16377546]
Zeerleder S, Hack CE, Wuillemin WA: Disseminated intravascular
coagulation in sepsis. Chest 2005;128:2864–75. [PMID:
16236964]
DERMATOLOGIC PROBLEMS IN THE INTENSIVE CARE UNIT 623
LIFE-THREATENING DERMATOSES
 Pemphigus Vulgaris
ESSENT IALS  OF  D IAGNOS I S
 Flaccid, easily ruptured blisters on noninflamed skin;
after rupture, nonhealing crusted erosions remain.
 Superficial detachment of the skin after pressure or
trauma variably present (Nikolsky’s sign).
 Skin biopsy shows characteristic intraepidermal cleft
just above the basal cell layer, with separation of ker-
atinocytes from one another (acantholysis).
 Direct immunofluorescence of normal-appearing skin
shows intercellular IgG and complement deposition
throughout the epithelium.
General Considerations
Pemphigus vulgaris is a rare life-threatening autoimmune dis-
ease characterized by intraepithelial vesicles and bullae.
Stratified squamous epithelium of both skin and mucosal sur-
faces is involved. The pathogenic process involves circulating
IgG autoantibodies directed against the intercellular substance
of the epidermis. The mean age at onset is the sixth decade.
Clinical Features
A. Symptoms and Signs—Nonhealing oropharyngeal ero-
sions are common and often precede the skin findings by
weeks or months. The primary cutaneous lesion is a flaccid
blister on noninflamed skin. These blisters rupture easily,
leaving nonhealing erosions that ultimately develop crusts. A
positive Nikolsky sign (tractional pressure adjacent to a
lesion causes skin separation) is characteristic but not
pathognomonic. With treatment, the lesions generally heal
without scarring. The sites of predilection are the scalp, face,
axillae, and oral cavity. The conjunctival, vaginal, and
esophageal mucosa and the vermilion border of the lips also
may be involved. The process may become generalized.
Oropharyngeal involvement causes difficulty in swallowing,
and laryngeal involvement produces hoarseness. Prior to the
availability of corticosteroids, the mortality rate of pemphi-
gus approached 60–90% owing primarily to protein, fluid,
and electrolyte losses or to sepsis. More recently, the mortal-
ity rate has dropped to the range of 5–15%; the most com-
mon causes of death today are infection and complications
of treatment.
B. Laboratory Findings—The diagnosis is based on patho-
logic findings, including skin biopsy showing a characteristic
intraepidermal cleft just above the basal cell layer, with sepa-
ration of keratinocytes from one another (acantholysis). The
acantholytic cells line the vesicle and also lie free within the
cavity. A Tzanck smear from the base of a bulla may show
acantholytic epidermal cells. Direct immunofluorescence of
normal-appearing skin near a lesion shows intercellular IgG
and complement deposition throughout the epithelium.
Indirect immunofluorescence of the patient’s serum demon-
strates circulating intercellular autoantibodies in about
80–90% of patients specific for desmoglein-3 alone when
lesions are limited to the mouth and for both desmoglein-3
and -1 when skin lesions are present in addition to oral lesions.
However, titers of the circulating autoantibodies do not corre-
late with disease severity but often parallel disease activity.
Fluid, electrolyte, and nutritional disturbances may occur
but are less pronounced than in disorders involving loss of
the entire thickness of the epidermis (eg, TEN).
Differential Diagnosis
Histopathologic examination, immunofluorescent microscopy,
and bacterial cultures permit differentiation from EM, SJS,
TEN, bullous drug eruptions, and bullous impetigo, as well
as from other primary blistering diseases such as bullous
pemphigoid and dermatitis herpetiformis.
Treatment
Discontinue drugs known to cause pemphigus (eg, penicil-
lamine and captopril).
A. Specific Treatment—Prednisone, 60–120 mg/day, in com-
bination with azathioprine, 100–150 mg/day, is usually effective.
Prior to initiation of therapy, the patient should be evaluated for
contraindications to systemic steroids. Patients with a history of
tuberculosis or a positive skin test for tuberculosis need con-
comitant isoniazid while receiving immunosuppressive therapy.
When control of the blistering is achieved, prednisone is
reduced gradually as tolerated. Methotrexate, cyclophos-
phamide, mycophenolate mofetil, cyclosporine, intravenous
high-dose immunoglobulins, gold, chlorambucil, and plasma-
pheresis are alternative modalities, as is pulse corticosteroid
therapy. Monoclonal antibodies may be of value in the future.
B. Topical Therapy—Silver sulfadiazine or mupirocin oint-
ment may reduce secondary infection. Whirlpool treatments
are helpful in removing crusts from lesions. Oral mucosal
erosions may benefit from topical steroids, antiseptics, vis-
cous lidocaine, and attention to oral hygiene.
Akerman L, Mimouni D, David M: Intravenous immunoglobulin
for treatment of pemphigus. Clin Rev Allergy Immunol
2005;29:289–94. [PMID: 16391404]
Berookhim B et al: Treatment of recalcitrant pemphigus vulgaris
with the tumor necrosis factor alpha antagonist etanercept.
Cutis 2004;74:245–7. [PMID: 15551718]
Bystryn JC, Rudolph JL: Pemphigus. Lancet 2005;366:61–73.
[PMID: 15993235]
El Tal AK et al: Rituximab: A monoclonal antibody to CD20 used
in the treatment of pemphigus vulgaris. J Am Acad Dermatol
2006;55:449–59. [PMID: 16908351]
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Mutasim D: Management of autoimmune bullous diseases:
Pharmacology and therapeutics. J Am Acad Dermatol
2004;51:859–77. [PMID: 15583576]
Ruocco E et al: Life-threatening bullous dermatoses: Pemphigus
vulgaris. Clin Dermatol 2005;23:223–6. [PMID: 15896536]
Stanley JR, Amagai M: Pemphigus, bullous impetigo, and the
staphylococcal scalded-skin syndrome. N Engl J Med 2006;355:
1800–10. [PMID: 17065642]
 Generalized Pustular Psoriasis
ESSENT IALS  OF  D IAGNOS I S
 Acute onset of widespread sterile pustules arising on ten-
der, warm, erythematous skin that coalesce into lakes of
pus; the tongue and mouth are commonly involved.
 Recurrent waves of pustulation and remissions occur;
fever and leukocytosis are often present; bacterial
infections and sepsis may be complications.
 Arthritis and pericholangitis are sometimes present;
rarely, there is associated hypotension, high-output
heart failure, and renal failure; a history of psoriasis
may or may not be present.
 Characteristic subcorneal pustules are seen on histologic
examination.
General Considerations
In addition to the exfoliative erythrodermic form of psoriasis,
another serious and sometimes fatal type is generalized pus-
tular psoriasis. It is characterized by the acute onset of wide-
spread erythematous areas studded with many sterile pustules
and associated with fever, chills, and leukocytosis. The disease
may develop either de novo or in individuals with a history of
psoriasis. The exact pathogenesis is unclear; however, precip-
itating events include topical and systemic corticosteroid
therapy and its subsequent withdrawal, other medications
(eg, sulfonamide drugs, penicillin, lithium, and pyrazolones),
infections, pregnancy, and hypocalcemia. Pustular psoriasis
tends to occur in patients over 40 years of age.
Clinical Features
A. Symptoms and Signs—The primary lesions are sterile
pustules that arise on tender, warm, erythematous skin and
coalesce into lakes of pus. Lesions typical of psoriasis vulgaris
may coexist. The tongue and mouth are commonly involved,
with geographic tongue and superficial erosions. These
patients appear ill and complain of itching and burning. The
course is punctuated by recurrent waves of pustulation and
remissions. Arthritis and pericholangitis sometimes occur.
Circulatory shunting through the skin may lead to significant
edema and, rarely, hypotension, high-output heart failure,
and renal failure. Superimposed bacterial infections or sepsis
can complicate the clinical picture.
B. Laboratory Findings—Laboratory data are nonspecific
but may be helpful. Leukocytosis, hypoalbuminemia, and
hypocalcemia are seen often during flares of this disorder,
although Gram stains and bacterial cultures of lesions are
negative. HIV serology should be checked because severe
exacerbations of psoriasis can be seen in HIV-infected indi-
viduals. Histologic examination of a lesion shows a charac-
teristic subcorneal pustule.
Differential Diagnosis
The diagnosis of pustular psoriasis is generally clear-cut on
clinical and histologic grounds. Other diagnostic consider-
ations include miliaria rubra, acneiform secondary syphilis,
pustular drug eruptions, and folliculitis. Cellulitis may be
suggested by the marked edema and erythema of the legs.
Treatment
A. Specific Treatment—The drugs of choice in this severe
form of psoriasis are the retinoids acitretin and isotretinoin.
These drugs should not be used in patients with lipid abnor-
malities or active hepatitis, and effective contraception must
be ensured during and for at least 3 years after treatment in
women of childbearing potential. Most patients show signif-
icant improvement in 5–7 days. Precipitating causes, includ-
ing lithium, antimalarials, diltiazem, propranolol, and
irritating topical medications, must be identified and
removed. Withdrawal from systemic corticosteroids is the
most common trigger. Oral acitretin works rapidly; but in
women of childbearing age, isotretinoin may be a better
choice because it has a shorter period of teratogenicity.
Methotrexate and cyclosporine are alternatives in carefully
selected patients; methotrexate is absolutely contraindicated
in HIV-infected patients. Hydroxyurea, mycophenolate
mofetil, and azathioprine have been used in some patients.
Recent case reports suggest that monoclonal antibodies to
tumor necrosis factor-α may be very helpful in patients with
pustular psoriasis. Systemic steroids should be avoided.
B. General Measures—A medium-potency topical steroid
applied twice daily to affected areas, emollient creams, cool
compresses, and baths alleviate discomfort. Attention must
be paid to fluid and electrolyte imbalances. The patient
should be monitored for secondary infection and sepsis.
Aaronson D, Lebwohl M: Review of therapy of psoriasis: The pre-
biologic armamentarium. Dermatol Clin 2004;22:379–88.
[PMID: 15450334]
Benoit S et al: Treatment of recalcitrant pustular psoriasis with
infliximab: Effective reduction of chemokine expression. Br J
Dermatol 2004:150:1009–12. [PMID: 15149518]
de Gannes GC et al: Psoriasis and pustular dermatitis triggered by
TNF-α inhibitors in patients with rheumatologic conditions.
Arch Dermatol 2007;143:223–31. [PMID: 17310002]
Mengesha YM, Bennett ML: Pustular skin disorders: Diagnosis and
treatment. Am J Clin Dermatol 2002;3:389–400. [PMID:
12113648]
DERMATOLOGIC PROBLEMS IN THE INTENSIVE CARE UNIT 625
 Exfoliative Erythroderma 
ESSENT IALS  OF  D IAGNOS I S
 Generalized or nearly generalized diffuse erythema
with desquamation.
 Pruritus, malaise, fever, chills, and weight loss may be
present.
 There may be a history of primary dermatologic dis-
ease, or the erythroderma may be a sign of malignancy
(T-cell lymphoma); the cause in many cases remains
undetermined.
General Considerations
Exfoliative erythroderma is a clinical syndrome characterized
by generalized or nearly total diffuse erythema of the skin
accompanied by variable degrees of desquamation.
Exfoliative erythroderma is a nonspecific endpoint of skin
reactivity; multiple conditions can lead to it (Table 28–7).
Approximately half of all cases are due to exacerbation of a
primary dermatologic condition. Underlying skin diseases
such as psoriasis and various forms of eczema may become
generalized through neglect, the abrupt discontinuation of
therapy, or intercurrent cutaneous or systemic infection (eg,
HIV-infected individuals are at risk of development of ery-
throdermic psoriasis). Less commonly, exfoliative erythro-
derma is the initial manifestation of a dermatosis. The
remaining cases are nearly equally divided among undeter-
mined causes, drug reactions, and underlying malignancies,
most commonly cutaneous T-cell lymphoma.
Clinical Features
A. History—A careful history with attention to preexisting der-
matoses, family history of skin conditions, medication history,
and clues to occult malignancy may suggest a specific cause.
B. Symptoms and Signs—Most patients complain of pru-
ritus. The entire skin surface is red, scaly, and indurated.
Excoriations, peripheral edema, and moderate symmetric
lymph node enlargement are common; massive or asym-
metric lymphadenopathy and splenomegaly are suggestive
of an underlying lymphoma. The mucous membranes usu-
ally are spared. There may be symptoms of orthostatic
hypotension owing to increased insensible water loss.
Congestive heart failure owing to marked circulatory
shunting through the skin may develop in patients with
preexisting cardiac disease.
Thermoregulatory dysfunction can result in relative
hypothermia and chills, thereby concealing the fever of sep-
sis. Nevertheless, patients with erythroderma owing to
drugs or lymphoma—or patients with secondary infections—
often present with fever. Secondary bacterial infection
manifests as purulent exudate or crusting. Sepsis, pneumo-
nia, and complications of malignancy are the leading causes
of death.
C. Laboratory Findings—Laboratory studies are usually of
limited value in establishing the underlying cause but are
necessary for assessing response to the skin disease.
Leukocytosis and anemia are common, whereas eosinophilia
suggests a drug offender. Atypical circulating lymphocytes
(Sézary cells), if present in sufficiently high numbers, sug-
gest Sézary’s syndrome, the leukemic phase of cutaneous T-
cell lymphoma. Hypoalbuminemia and negative nitrogen
balance result from protein loss by desquamation and an
elevated metabolic rate. Serologic testing for HIV is recom-
mended for patients with erythrodermic psoriasis.
Other tests should include urinalysis and stool occult
blood, chest x-ray, and ECG. Skin biopsy results usually are
nonspecific but may be diagnostic in leukemia, cutaneous T-
cell lymphoma, or Norwegian crusted scabies. Routine
biopsy of superficial lymph nodes is even less helpful because
the pathologic findings are usually reactive (dermatopathic
lymphadenopathy). However, biopsy of unusually promi-
nent or asymmetric lymph nodes may yield a diagnosis of
lymphoreticular malignancy.
Differential Diagnosis
Exfoliative erythroderma should be differentiated from other
conditions associated with diffuse erythema, such as com-
mon morbilliform drug eruptions, various viral and bacter-
ial exanthems, early phases of TEN, toxic shock syndrome,
and graft-versus-host disease.
Treatment
Irrespective of the underlying cause, all exfoliative erythro-
dermas may be treated initially in a similar manner. The
Underlying dermatosis  
Eczematous conditions
Contact dermatitis
Atopic dermatitis
Seborrheic dermatitis
Psoriasis
Pityriasis rubra pilaris
Pemphigus foliaceus
Norwegian scabies
Others
Drugs: See Table 28–2.
Malignancies
Cutaneous T cell lymphoma
Hodgkin’s disease
Miscellaneous lymphomas and leukemias
Idiopathic
Table 28–7. Causes of exfoliative erythroderma. 
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goals of therapy are relief of symptoms and reduction of
cutaneous inflammation.
A. Specific Treatment—Once the cause is established, spe-
cific treatment may be initiated. Systemic steroids should be
avoided unless indicated as specific therapy for the underly-
ing disease.
B. General Measures—Patients must be monitored closely
for complications of erythroderma, including anemia, elec-
trolyte imbalances, high-output heart failure, hypothermia,
pneumonia, and sepsis. Administer systemic antibiotics to
patients with cutaneous or systemic infection. Adequate
nutrition is essential. One should stop any potentially
offending medications and keep the patient warm. Daily
whirlpool treatments aid in removing scale and decreasing
bacterial colonization. Baths and wet compresses also may be
used. After each whirlpool treatment, apply a medium-
potency topical steroid such as fluocinolone acetonide
0.025% and bland emollient such as petrolatum to the entire
body; frequent applications of the emollient each day help to
partially restore skin barrier function. Topical medium-
potency steroids such as fluoninolone acetonide 0.025%
ointment may be used 2–3 times daily. Antihistamines are
helpful in controlling pruritus.
Inspect the skin regularly for morphologic changes that
may be diagnostic of an underlying dermatitis as the ery-
throderma subsides.
Akhyani M et al: Erythroderma: A clinical study of 97 cases. BMC
Dermatol 2005;5:5. [PMID: 15882451]
Rothe MJ, Bernstein ML, Grant-Kels JM: Life-threatening erythro-
derma: Diagnosing and treating the “red man.” Clin Dermatol
2005;23:206–17. [PMID: 15802214]
Sigurdsson V et al: Erythroderma: A clinical and follow-up study
of 102 patients, with special emphasis on survival. J Am Acad
Dermatol 1996;35:53–7. [PMID: 8682964]
CUTANEOUS MANIFESTATIONS OF INFECTION
The febrile patient with a rash often presents a clinical
dilemma in that both noninfectious and infectious causes
must be considered. Among the noninfectious causes already
discussed are drug eruptions, vasculitis, and exfoliative ery-
throderma. In addition, systemic lupus erythematosus, juve-
nile rheumatoid arthritis, and Kawasaki’s disease may be
manifested as eruptions associated with fever.
Systemic viral, bacterial, rickettsial, and fungal diseases
may involve the skin, producing a multiplicity of cuta-
neous reactions that, in general, are not pathognomonic
either for infection or for a specific organism. The follow-
ing discussion focuses on life-threatening infections with
sufficiently distinctive skin findings to facilitate early diag-
nosis. Cutaneous manifestations of sepsis were addressed
earlier.
 Varicella-Zoster
ESSENT IALS  OF  D IAGNOS I S
Primary infection—varicella
 After a prodromal period of 1–3 days, small erythema-
tous macules appear and evolve into clear vesicles; pru-
ritus is intense; new crops appear at 3–5-day intervals.
 Vesicles form crusted erosions; oropharyngeal vesicles
rupture quickly to form superficial mucosal ulcers.
 In normal adults as well as immunosuppressed indi-
viduals, varicella may be complicated by life-
threatening pneumonia, hepatitis, myocarditis,
encephalitis, and DIC. 
Reactivation infection—herpes zoster
 Acute, usually painful unilateral eruption in dermatomal
distribution, with clusters of vesicles occurring on a
background of erythema; in persons with compromised
immune systems, the lesions may become severe and
necrotic.
General Considerations
Varicella-zoster virus (VZV) is a herpesvirus that typically
causes a self-limited infection but is capable of producing
life-threatening illness. Primary infection produces varicella;
reactivation of latent virus in sensory ganglia results in her-
pes zoster (shingles). Varicella is spread by direct person-to-
person contact or inhalation of infected droplets. Contact
with the lesions of herpes zoster may produce varicella in a
person not previously infected with VZV.
Clinical Features
A. Symptoms and Signs—After primary exposure to VZV,
the incubation period ranges from 11–21 days but may be
shorter in immunocompromised persons. The prodromal
symptoms in children are minimal and consist of low-grade
fever and malaise. In adults, the symptoms are more severe
and include prolonged fever, malaise, and arthralgias. One to
a few days after onset of illness, small erythematous macules
appear on the trunk, face, and proximal extremities. The pri-
mary lesion evolves rapidly into a clear vesicle that, if left
undisturbed, becomes cloudy. The vesicles eventually rup-
ture to form crusted erosions. New crops appear at irregular
intervals over the next 3–5 days, giving the characteristic
finding of lesions in various stages of development. Pruritus
is often intense. Healing with scarring is not uncommon,
particularly in excoriated or secondarily infected lesions.
Oropharyngeal vesicles rupture quickly to form superficial
mucosal ulcers. In normal adults as well as immunosup-
pressed individuals, varicella may be especially severe and
complicated by life-threatening pneumonia. Hepatitis,
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myocarditis, encephalitis, and DIC also may occur along with
extensive hemorrhagic skin lesions.
In the normal host, herpes zoster is an acute, self-limited,
usually painful unilateral eruption in a dermatomal distribu-
tion. Characteristically, clusters of vesicles occur on a back-
ground of erythema. Occasionally—especially in persons
with compromised immune systems—herpes zoster may
become severe and necrotic. Wide dissemination of multiple,
small, varicella-like vesicles may develop. In such patients,
secondary bacterial infection is an added risk.
B. Laboratory Findings—A Tzanck smear demonstrates
diagnostic multinucleated epithelial giant cells. This test is
performed by scraping the base of a vesicular lesion with a
scalpel blade, transferring the material to a glass slide, and
staining with Giemsa’s or Wright’s stain. The Tzanck smear is
also positive in HSV infections. Culture of a lesion may con-
firm the diagnosis but requires approximately 10 days of
growth. An immunofluorescent antibody test using materials
from a lesion is also available. Acute and convalescent sera
may be helpful.
Differential Diagnosis
Varicella may be confused with widespread impetigo, dis-
seminated herpes zoster, disseminated herpes simplex,
eczema herpeticum, and smallpox. Eczema herpeticum is a
widespread cutaneous infection with HSV occurring in
patients with preexisting skin disorders such as atopic der-
matitis. The lesions in smallpox begin as red macules and
evolve in synchrony through vesicular and pustular stages,
and they predominately affect the face and extremities.
Treatment
Systemic acyclovir in the doses listed is recommended in the
following situations: (1) All VZV infections in immunocom-
promised individuals (10 mg/kg intravenously every 8 hours
for 7–10 days), (2) varicella in teenage and adult patients
(800 mg orally five times a day for 5–7 days), and (3) elderly
patients and patients with severe, painful, or destructive
zoster when seen within 48–72 hours after onset (800 mg
orally five times a day for 7 days). Alternative drugs for acute
herpes zoster are famciclovir, 500 mg three time daily for
7 days, and valacyclovir, 1 g three times daily for 7 days.
Secondary bacterial infection should be treated aggres-
sively. Cool compresses and antihistamines may help to
remove crusts and alleviate pruritus. Analgesics should be
provided as necessary.
Dworkin RH et al: Recommendations for the management of her-
pes zoster. Clin Infect Dis 2007;44:S1–26. [PMID: 17143845]
Gardella C, Brown ZA: Managing varicella zoster infection in preg-
nancy. Cleve Clin J Med 2007;74:290–6. [PMID: 17438678]
Heininger U, Seward JF: Varicella. Lancet 2006;368:1365–76.
[PMID: 17046469]
 Rubeola (Measles)
ESSENT IALS  OF  D IAGNOS I S
 Incubation period of 7–14 days, followed by high
fever, malaise, cough, coryza, and conjunctivitis with
photophobia.
 Three to 5 days later, discrete erythematous macules
and thin papules appear on the forehead and behind
the ears, spreading to the trunk and extremities, with
coalescence and increased redness.
 Koplik’s spots usually appear on buccal mucosa 1–2
days before exanthem.
 Complications include secondary bacterial infection, oti-
tis media, pneumonia, viral myocarditis, liver function
abnormalities, and thrombocytopenia.
General Considerations
Rubeola is an acute epidemic disease characterized by
marked upper respiratory symptoms and a widespread ery-
thematous maculopapular rash. It is caused by a paramyx-
ovirus transmitted by inhalation of infected droplets. The
severity of the illness varies with the age and immunologic
status of the patient.
Clinical Features
A. Symptoms and Signs—After an incubation period of
7–14 days, a prodrome of high fever develops, associated
with malaise, cough, coryza, and conjunctivitis with photo-
phobia. In 3–5 days, discrete erythematous macules and thin
papules appear on the forehead and behind the ears. Over the
next few days, the lesions spread to the trunk and extremities
(including the palms and soles), coalesce on the face and
upper trunk, and intensify in color to a deeper red. The erup-
tion fades after 5–10 days in the order of its appearance, often
with fine desquamation and postinflammatory hyperpig-
mentation. Koplik’s spots—blue-white pinpoint macules
with a red halo—usually appear on the buccal mucosa 1–2
days before the exanthem and remain for several days. Up to
40% of immunocompromised patients with measles have no
rash; the remainder have either typical or unusual skin find-
ings, including urticarial plaques, petechiae, and palpable
purpura. Rubeola must be distinguished from cutaneous
drug reactions as well as other viral exanthems.
Complications may arise from viral dissemination, sec-
ondary bacterial infection, or hypersensitivity phenomena.
Otitis media, sinusitis, pneumonia, and liver function abnor-
malities are common. Viral myocarditis and thrombocy-
topenic purpura (owing to immune-mediated platelet
destruction) may occur. Death, resulting from pneumonitis
or encephalitis, occurs in about 0.1% of patients in the
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United States. The complication and case-fatality rates for
the very young, the elderly, the malnourished, and patients
with malignancies or HIV infection are significantly higher.
The clinical presentation in immunocompromised patients
is frequently atypical. One-third of such patients present
with no rash.
B. Laboratory Findings—Serologic studies of paired speci-
mens are the most practical method of confirming the diag-
nosis. Measles virus may be isolated from the blood, urine,
nasopharyngeal washings, and throat or from conjunctival
secretions.
Treatment
Therapy is supportive because no proven antiviral agent is
available. Aerosolized ribavirin may be beneficial for the treat-
ment of measles pneumonitis, but its effectiveness has not yet
been proved. Intravenous immunoglobulin and interferon
are other treatment options for measles pneumonitis and
encephalitis. Isolation precautions must be observed.
Garly ML et al: Prophylactic antibiotics to prevent pneumonia and
other complications after measles: Community-based ran-
domised, double-blind, placebo-controlled trial in Guinea-
Bissau. Br Med J 2006;333:1245. [PMID: 17060336]
Greenaway C et al: Susceptibility to measles, mumps, and rubella
in newly arrived adult immigrants and refugees. Ann Intern
Med 2007;146:20–4. [PMID: 17200218]
Perry RT, Halsey NA: The clinical significance of measles: A review.
J Infect Dis 2004;189:S4–16. [PMID: 15106083]
 Meningococcemia
ESSENT IALS  OF  D IAGNOS I S
 Petechial (or, less commonly, urticarial or morbilliform)
rash on the trunk and lower extremities; also on the
palms, soles, and mucous membranes; petechiae are
frequently palpable, with gun-metal gray centers and
irregular borders.
 If complicated by purpura fulminans, extensive hemor-
rhagic bullae and areas of necrosis.
 Other features of meningococcal meningitis or dissemi-
nated meningococcemia, including meningeal signs,
arthritis, myocarditis, pericarditis, and acute adrenal
infarction; hypotension and shock are often present.
 Confirmation of Neisseria meningitidis by culture, Gram
stain, or immunologic tests.
General Considerations
N. meningitidis is a gram-negative diplococcus responsible
for a spectrum of illnesses ranging from a mild upper
respiratory infection to fulminant septicemia. Disease occurs
most often in children under age 15, with the attack rate
highest in infants 6–12 months of age. Peak incidence of
infection is in the winter and spring. Asymptomatic colo-
nization of the nasopharynx is common and provides a
source of person-to-person transmission through infected
droplets. People with deficiencies of the terminal compo-
nents of the complement cascade (C5–9) are particularly
susceptible to invasive and recurrent meningococcal disease.
The cutaneous lesions are a consequence of damage to small
dermal blood vessels both by direct bacterial involvement of
skin vessels and by lipopolysaccharide endotoxins.
Clinical Features 
A. Symptoms and Signs—Invasive meningococcal disease
usually results in meningitis or meningococcemia. The incu-
bation period varies from 2–10 days. The onset may be
insidious, following a flulike illness, or abrupt, with fever,
chills, malaise, signs of meningeal irritation, prostration,
and shock. A rash that is characteristically petechial or, less
commonly, urticarial or morbilliform is often among the
earliest signs of generalized infection. The petechiae typi-
cally appear on the trunk and lower extremities but also can
be found on the palms, soles, and mucous membranes. They
are frequently palpable, with gun-metal-gray centers and
irregular borders.
Extensive hemorrhagic bullae and areas of necrosis
develop in patients with meningococcemia whose disease
is complicated by purpura fulminans. Obtundation,
hypotension, and death may ensue within hours despite
appropriate antimicrobial therapy. Absence of meningeal
signs is a feature of this acute fulminant form of meningo-
coccal disease. Children under age 2 have the highest mor-
tality rate, perhaps as a consequence of immaturity of the
protein C system.
Other complications of invasive meningococcal disease
are arthritis, myocarditis, pericarditis, cervicitis, and
Waterhouse-Friderichsen syndrome. More rare meningo-
coccal diseases include occult bacteremia and chronic
meningococcemia.
B. Laboratory Findings—Confirmation of the diagnosis
depends on demonstration of the organism. This
may be by culture, Gram stain, or immunologic tests.
Blood and cerebrospinal fluid cultures are indicated in
all patients suspected of having invasive disease. Naso-
pharyngeal and synovial cultures are positive in some cases.
Counterimmunoelectrophoresis or latex agglutination with
group-specific antisera of cerebrospinal fluid, urine, or tears
can facilitate rapid diagnosis. A Gram stain of material from
purpuric lesions may reveal the organism. Other laboratory
studies are otherwise nonspecific but should be performed
as indicated to assess and monitor the illness, including eval-
uation for DIC.
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Differential Diagnosis
Meningococcal infection must be considered in patients
with the combination of fever and a petechial rash, espe-
cially in association with meningitis. Depending on the
clinical presentation, other infections, such as gram-negative
septicemia, Rocky Mountain spotted fever, echovirus and
coxsackievirus infections, and atypical measles, must be
excluded. Vasculitis and other causes of purpura also are
diagnostic possibilities.
Treatment
Intravenous penicillin G or ampicillin is the therapy of choice.
Ceftriaxone is an acceptable alternative (see Chapter 15).
Hemodynamic and other supportive measures must be pro-
vided as necessary to maintain organ system function.
Respiratory isolation is mandatory. Close contacts of patients
with meningococcal disease should be given rifampin pro-
phylaxis and monitored closely.
Ramos-e-Silva M, Pereira AL: Life-threatening eruptions due to
infectious agents. Clin Dermatol 2005;23:148–56. [PMID:
15802208]
 Rocky Mountain Spotted Fever
ESSENT IALS  OF  D IAGNOS I S
 Potential exposure to ticks in endemic area.
 After incubation period of 1–14 days, sudden onset of
fever, headache, myalgia, and nausea or vomiting.
 Appearance on days 2–4 of blanchable pinkish red mac-
ular rash over ankles, wrists, and forearms, spreading to
involve the soles, palms, extremities, trunk, and face
within hours; bilaterally symmetric petechiae of the
palms and soles are a major finding.
 May be complicated by CNS, cardiac, pulmonary, renal,
or other organ involvement; DIC and shock leading to
death may occur.
 Diagnosis can be confirmed by serologic tests, but these
are not reliable before the second week of illness.
General Considerations
Rocky Mountain spotted fever is an acute systemic illness
characterized by fever and a purpuric eruption. The disease
is transmitted to humans by the bite of a tick infected with
the causative organism Rickettsia rickettsii. Transmission
reflects the tick season in a particular geographic area, with
highest incidence in spring and summer. The disease is wide-
spread in the United States and Canada; most cases are from
the southeastern and Rocky Mountain states. All age groups
are affected, but most are between 5 and 9 years old.
Clinical Features
The incubation period is usually about 1 week, ranging from
1–14 days.
A. Symptoms and Signs—Sudden onset of fever, headache,
myalgia, and nausea or vomiting are initial features. On the sec-
ond to fourth days of illness, a blanchable pinkish red macular
rash appears over the ankles, wrists, and forearms, spreading to
involve the soles, palms, extremities, trunk, and face within
hours. Over the next 1–2 days, the eruption becomes papular
and nonblanchable (purpuric) and may evolve into gangrene
of the digits, nose, earlobes, scrotum, or vulva. Bilaterally sym-
metric petechiae of the palms and soles is a major finding. The
illness can persist up to 3 weeks and may be complicated by
CNS, cardiac, pulmonary, renal, or other organ involvement.
DIC and shock leading to death may occur.
B. Laboratory Findings—The diagnosis of Rocky Mountain
spotted fever can be established retrospectively by one of
many serologic techniques, including complement fixation,
latex agglutination, or microagglutination tests. However,
these tests are not reliably positive before the second week of
the illness.
Skin biopsy reveals a necrotizing vasculitis. A Giemsa-
stained smear of tissue sections occasionally may demon-
strate the organism. Immunofluorescent microscopic
examination of skin biopsy specimens may confirm the diag-
nosis as early as the fourth day of illness.
Differential Diagnosis
Rocky Mountain spotted fever must be differentiated from
other serious febrile illnesses such as viral and bacterial
meningitis, meningococcemia, measles, vasculitis, and
thrombotic thrombocytopenic purpura.
Treatment
Treatment should be initiated as soon as the diagnosis is sus-
pected. Doxycycline is the drug of choice for patients with
Rocky Mountain spotted fever. Gangrene of the earlobes,
digits, nose, etc. requires additional antibiotics if secondarily
infected.
Chapman AS et al: Diagnosis and management of tickborne
rickettsial diseases: Rocky Mountain spotted fever, ehrli-
chioses, and anaplasmosis—United States: A practical
guide for physicians and other health-care and public
health professionals. MMWR Recomm Rep 2006;55:1–27.
[PMID: 16572105]
Cunha BA. Clinical features of Rocky Mountain spotted fever.
Lancet Infect Dis 2008;8:143–4. [PMID: 18291332]
Dantas-Torres F. Rocky Mountain spotted fever. Lancet Infect Dis
2007;7:724–32. [PMID: 17961858]
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 Necrotizing Fasciitis
ESSENT IALS  OF  D IAGNOS I S
 Typically occurs following surgery or penetrating
trauma; diabetes may be a predisposing condition.
 Erythema, edema, and pain develop 1–2 days following
surgery or trauma with central areas of dusky gray-blue
discoloration, occasionally in association with serosan-
guineous blisters.
 Involved areas become gangrenous within a few days;
culture frequently grows multiple aerobic and anaero-
bic bacteria.
 Severe systemic toxicity is usually present.
General Considerations
Necrotizing fasciitis is a rare, life-threatening soft tissue
infection characterized by acute and widespread fascial
necrosis. It typically occurs following surgery or penetrating
trauma. Diabetes may be a predisposing condition. The
pathogenesis involves the introduction of organisms into the
subcutis with subsequent spread through fascial planes.
Many different virulent bacteria have been isolated in associ-
ation with necrotizing fasciitis, including β-hemolytic strep-
tococci, staphylococci, coliforms, enterococci, Pseudomonas,
and Bacteroides. Rhizopus and C. albicans have been cultured
from tissue. The process is often fatal unless diagnosed
quickly and treated aggressively.
Clinical Features
A. Symptoms and Signs—Erythema, edema, and pain
develop 1–2 days following introduction of the organism into
the subcutis. The infection spreads rapidly and deeply, result-
ing in local tissue ischemia. Clinically, there are central areas of
dusky gray-blue discoloration, occasionally in association with
serosanguineous blisters. Crepitus is usually absent in necro-
tizing fasciitis. Within a few days, these areas become gan-
grenous; liberation of toxins and organisms into the
bloodstream leads to severe systemic toxicity. The extremities
are the most commonly affected site, but the trunk, perineum,
and abdomen also may be affected. Fournier’s gangrene is
necrotizing fasciitis of the perineum, scrotum, or penis that
spreads rapidly to the anterior abdominal wall. Necrotizing
fasciitis may be confused with cellulitis, angioedema,
eosinophilic fasciitis, and clostridial myonecrosis.
B. Laboratory Findings—Incisional biopsy of both the
advancing edge and the involved tissue should be performed
early, looking for necrotic fascia and the causative organism.
Tissue cultures frequently grow multiple aerobic and anaer-
obic bacteria as well as fungi. Radiographs of soft tissue
rarely may reveal tissue gas.
Treatment
Radical surgical debridement, intravenous broad-spectrum
antibiotics, and general supportive care are the mainstays of
therapy. The major indication for operative treatment is fasciitis
spreading despite empirical antibiotics in an acutely ill patient.
Anaya DA, Dellinger EP: Necrotizing soft-tissue infection:
Diagnosis and management. Clin Infect Dis 2007;44:705–10.
[PMID: 17278065]
Gabillot-Carre M, Roujeau JC: Acute bacterial skin infections and
cellulitis. Curr Opin Infect Dis 2007;20:118–23. [PMID:
17496568]
Lopez FA, Lartchenko S: Skin and soft tissue infections. Infect Dis
Clin North Am 2006;20:759–72. [PMID: 17118289]
Mehta S et al: Morbidity and mortality of patients with invasive
group A streptococcal infections admitted to the ICU. Chest
2006;130:1679–86. [PMID: 17166982]
Miller LG et al: Necrotizing fasciitis caused by community-
associated methicillin-resistant Staphylococcus aureus in Los
Angeles. N Engl J Med 2005;352:1445–53. [PMID: 15814880]
 Toxic Shock Syndrome (TSS)
ESSENT IALS  OF  D IAGNOS I S
 Highest incidence in menstruating women, persons
with focal staphylococcal infection or colonization, and
women using a diaphragm or contraceptive sponge—
but may occur in others.
 Rapid onset of fever, vomiting, watery diarrhea, sore
throat, and profound myalgias, with hypotension.
 Diffuse, blanching erythema appears early, predomi-
nantly truncal, with accentuation in the axillary and
inguinal folds and spreading to the extremities; desqua-
mation of the involved skin and of the palms and soles
seen during the second or third week.
 Acute renal failure, acute respiratory distress syndrome
(ARDS) , refractory shock, ventricular arrhythmias, and DIC
may occur.
General Considerations
Toxic shock syndrome is a multisystem illness characterized
by the acute onset of high fever associated with myalgias,
vomiting, diarrhea, headache, pharyngitis, and hypotension.
Mucocutaneous findings are prominent. Staphylococcal pyo-
genic toxin superantigens (TSST-1) and enterotoxins B and
C are involved in the pathogenesis. Streptococcal toxic shock
syndrome is caused mainly by toxin-producing group A
strains but also by strains of groups B, C, F, and G. In the
1980s, most cases occurred in menstruating women using
superabsorbent tampons. Currently, most cases are caused
by nonmenstrual S. aureus infection—postoperative,
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influenza-associated, or recalcitrant erythematous desqua-
mating syndrome—or by colonization of contraceptive
diaphragms or sponges. Streptococcal toxic shock syn-
drome may or may not be associated with necrotizing fasci-
itis or myositis.
Clinical Features
The Centers for Disease Control and Prevention (CDC) case
definition of toxic shock syndrome is based on six major
criteria—high fever, rash, desquamation, hypotension,
involvement of three or more organ systems (eg, GI, muscu-
lar, mucous membrane, renal, hepatic, hematologic, and
CNS)—and exclusion of other causes.
A. Symptoms and Signs—Patients usually present with
rapid onset of fever, vomiting, watery diarrhea, sore throat,
and profound myalgias. Significant hypotension develops
during the first 48–72 hours of illness. Multisystem organ
involvement probably results both from poor tissue perfu-
sion and from toxin-induced damage. Potentially devastating
complications include acute renal failure, ARDS with pul-
monary edema, refractory shock, ventricular arrhythmia,
and DIC. Some patients have relatively mild episodes.
The cutaneous and mucous membrane findings are
prominent but not diagnostic. A diffuse, blanching erythema
(scarlatiniform exanthem) appears early. The rash is pre-
dominantly truncal, with accentuation in the axillary and
inguinal folds and spreading to the extremities. Erythema
and edema of the palms and soles may develop. Generalized
nonpitting edema is also common. Intense hyperemia of the
conjunctival, oropharyngeal, and vaginal surfaces is a fre-
quent finding. Desquamation of the involved skin and of the
palms and soles is seen during the second or third week of ill-
ness. Toxic shock syndrome recurs in approximately 30% of
untreated patients. Mortality is higher (12%) in patients with
nonmenstrual causation.
B. Laboratory Findings—Laboratory studies are useful for
assessing and monitoring the severity and progression of the
illness. Patients often have leukocytosis with a left shift and
thrombocytopenia. If DIC is suspected, coagulation studies
should be obtained. Serum electrolytes, calcium, phospho-
rus, creatine kinase, renal function and liver function tests,
albumin, total serum protein, and amylase may be abnormal.
Urinalysis may show proteinuria and pyuria.
Chest x-ray, arterial blood gas determinations, and
echocardiography may provide useful information. Cultures
of blood, soft tissue sites of infection, and all mucosal surfaces
(including the trachea if intubation is performed) should be
obtained. Serologic tests should be ordered for Rocky
Mountain spotted fever, leptospirosis, or measles, as indicated
in individual patients, to exclude alternative diagnoses.
Differential Diagnosis
Toxic shock syndrome is a clinical diagnosis. Appropriate
laboratory tests help to distinguish it from several serious
and potentially life-threatening exanthematous diseases,
including streptococcal toxic shock–like disease, scarlet fever,
Kawasaki’s disease, Rocky Mountain spotted fever, SJS, drug
eruptions, bacterial sepsis, measles, and leptospirosis.
Treatment
Tampons or other contraceptive devices must be removed
immediately, followed by irrigation of the vagina. Any surgi-
cal packings also should be removed. Soft tissue abscesses,
empyema, and other sites of infection require surgical
drainage and irrigation.
An antistaphylococcal antibiotic should be administered
intravenously based on a presumptive diagnosis, although its
effect on the outcome of the acute episode is unclear.
Antibiotics do reduce the recurrence of menses-related toxic
shock syndrome. Treatment of group A streptococcal toxic
shock syndrome includes penicillin or ceftriaxone plus clin-
damycin or erythromycin.
Supportive care, including management of organ system
failure and treatment of hypotension, is the mainstay of ther-
apy. Systemic corticosteroids, if given within 3–4 days of dis-
ease, reduce its severity and shorten the duration of fever.
Andrews MM et al: Recurrent nonmenstrual toxic shock syn-
drome: Clinical manifestations, diagnosis, and treatment. Clin
Infect Dis 2001;32:1470–9. [PMID: 11317249]
Kain KC, Schulzer M, Chow AW: Clinical spectrum of nonmen-
strual toxic shock syndrome (TSS): Comparison with menstrual
TSS by multivariate discriminant analyses. Clin Infect Dis
1993;16:100–6. [PMID: 8448283]
Ramos-e-Silva M, Pereira AL: Life-threatening eruptions due to
infectious agents. Clin Dermatol 2005;23:148–56. [PMID:
15802208]
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The critical care of patient with peripheral vascular disease
requires considerable diagnostic skill and clinical acumen.
Associated medical comorbidities—diabetes, renal insuffi-
ciency, coronary artery disease, and many others—necessitate
admission to an ICU for preoperative optimization and post-
operative observation. Acute arterial occlusion, pulmonary
embolism, and—with the advent of endovascular interven-
tions—pseudoaneurysm formation are among the more
common vascular-related complications encountered in the
otherwise routine care of medical and surgical patients.
This chapter addresses acute vascular emergencies in criti-
cally ill patients and discusses the management of complica-
tions following both elective and emergency vascular surgical
procedures.
VASCULAR EMERGENCIES IN THE ICU
 Acute Arterial Insufficiency
ESSENT IALS  OF  D IAGNOS I S
 The “six Ps”: pain, paralysis, paresthesia, pallor, pulse-
lessness, and poikilothermia.
 Loss of light touch and position sense followed by
paralysis.
 Absence of previously palpable distal pulses and slow
capillary refill.
 Cool extremity with skin mottling, often with a detectable
line of demarcation.
 Collapse of the superficial venous system and develop-
ment of venous thrombosis and rigid muscular com-
partments in prolonged ischemia.
General Considerations
The management of acute limb ischemia continues to chal-
lenge today’s critical care specialist. Patients often present in a
severely compromised state with unclear symptomatology and
may have multiple associated medical illnesses. Despite
improved therapeutic options in recent years, outcome
remains poor. In a review of 35 reported series, a mortality rate
of 26% and an amputation rate of 37% were documented.
Decreased arterial inflow in a previously normal limb
may be due to embolization from a remote origin (owing to
in situ thrombosis from preexisting occlusive disease) or may
occur in association with a low-flow state. Although throm-
bosis occurs more frequently than embolic occlusion in the
general population, progression to complete occlusion of an
atherosclerotic thrombus is an unusual cause of acute arterial
insufficiency in a critically ill patient admitted for other rea-
sons. Depending on the artery affected and the adequacy of
collateral circulation, clinical presentation may be along a
continuum from subtle to overt limb threat.
The most common site of origin of an embolus is the
heart, with atherosclerotic disease the predominant under-
lying factor. Other sources include aortic and peripheral
aneurysms, atherosclerotic debris from ulcerating plaques,
and less commonly, paradoxical embolus through a cardiac
anomaly, arteritis, or vascular trauma. Atrial fibrillation,
often seen in the postoperative setting, is currently associ-
ated with two-thirds to three-quarters of peripheral emboli.
Acute arterial insufficiency in the ICU is most commonly
caused by intrinsic obstruction produced by the emboliza-
tion of clot from distant sites. Atherosclerotic cardiac vascu-
lar disease accounts for 60–70% of all arterial emboli. Most
arise in patients with atrial fibrillation and stasis in the left
atrial appendage. Those who have sustained a recent myocar-
dial infarction also may develop mural thrombi, most com-
monly at the cardiac apex or in a trabeculation of the left
ventricle. No clear temporal relationship exists between the
time of the myocardial infarction and when embolization
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occurs. When congestive heart failure or cardiomyopathy is
present, dyskinetic segments again result in areas of relative
stasis that lead to the formation of thrombi. After separation
from its site of origin, an embolus may be swept into the
innominate or left subclavian artery and travel distally in an
upper extremity until the arterial tree narrows sufficiently to
trap it. If it is carried into either of the internal carotid or ver-
tebral arteries, a bland (dry) stroke results. Distal emboli typ-
ically lodge where vessels taper or branch and consequently
are seen in the superior mesenteric artery, resulting in vis-
ceral ischemia, or in the iliac, femoral, or popliteal arteries.
Peripheral emboli travel to the lower extremities 10 times
more often than to the upper extremities. Commonly
involved arterial segments are listed in Table 29-1.
Other intrinsic sources of arterial emboli are atheroscle-
rotic debris from aneurysms, fibrin plugs, or collections of
platelets. It is unusual for atherosclerotic emboli to present
de novo in a patient admitted to the ICU for another reason.
The exception to this is the blue toe syndrome, which results
from occlusion of digital vessels by atherosclerotic emboli.
However, when the possibility of an expanding aneurysm or
symptomatic chronic aortic dissection was the reason for
admission, acute limb ischemia should arouse concern that
the atherosclerotic plaque or the grumous clot lining the
aneurysm has embolized.
Patients with atherosclerotic microemboli frequently
have transient focal ischemia associated with minor tissue
loss. The clinical distinction between arterial embolism and
arterial thrombosis is often difficult to make, although an
effort should be made to confirm the diagnosis because of
the differences in therapeutic approach and outcome
(Table 29–2). Fibrin plugs and platelet emboli occur most
commonly in patients with disseminated intravascular coag-
ulation (DIC) or in those anticoagulated with heparin who
develop antiheparin antibodies.
Extrinsic emboli are produced when foreign material
such as catheter tips, balloon fragments, and endovascular
Characterisitics of Occlusion Embolus Thrombosis 
Onset of symptons Rapid or immediate Slower or insidious 
Prior symptoms: claudication Rare Frequent 
Length of time to presentation Acute Chronic 
Identifiable source Recent cardiac disease (eg, atrial fibrillation,
myocardial infarction) 
None 
Physical findings Normal contralateral extremity Bilateral peripheral vascular disease 
Angiography Multiple sharp cutoffs, “reversed meniscus,” scant
collaterals
Diffuse peripheral vascular disease, irregular cutoff,
many collaterals 
Goal of immediate therapy Eliminate embolus Correct disease 
Long-term pharmacologic treatment Anticoagulation Platelet inhibition 
Results of thromboembolectomy Good Poor 
Amputation risk Lower Higher 
Causes of mortality Cardiac disease Limb ischemia 
Adapted from Young JR et al (eds): Peripheral Vascular Disease. St Louis: Mosby–Year Book, 1991; and from Rutherford RB (ed): Vascular
Surgery. Philadelphia: Saunders, 2000.
Table 29–2. Differentiation of emoblism from thrombosis.
Table 29–1. Sites of peripheral arterial emboli.
Segment Incidence (%)
Femoral 36 
Aortoiliac 22 
Popliteal-tibial 15 
Upper extremity 14  
Visceral 7 
Other 6 
Data complied from 1303 embolic events at the Massachusetts
General Hospital and Stanford University. Adapted from Rutherford RB
(editor): Vascular Surgery. Philadelphia: Saunders, 2000. 
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occluding devices migrate to distant sites. Bullet emboli
should be remembered as a possible cause of acute arterial
insufficiency in a trauma victim in whom the missile was not
recovered or was unreachable at the time of surgery. Other
penetrating injuries, such as stab wounds, may partially dis-
rupt the vascular intima and begin the process of dissection
and thrombotic occlusion.
Once arterial flow is halted, three pathophysiologic events
occur, each worsening the overall ischemic insult. Initially,
propagation of thrombus can occlude potential collateral
vessel orifices and lend to the no-reflow phenomenon once
large vessel revascularization is established. Second, cellular
swelling owing to local hypoxia may cause red blood cell
trapping and effectively increase the ischemic period even
after adequate inflow is restored. The cause of cellular
swelling is debated but may consist of failure of the sodium
pump. This inability to reperfuse after ischemic intervals is
termed the no-reflow or low-reflow phenomenon. As fluid
leaves the interstitium and enters the cellular matrix, the
effective viscosity of the blood increases, raising the pressure
required to overcome the blood’s inertia (yield stress) and
causing significant narrowing and occlusion of the arterioles,
capillaries, and venules. The more protracted the ischemic
period, the greater is the fluid loss and the higher is the yield
stress. Muscle damage produced by ischemia and reperfusion
is more related to “reflow” than to the absolute period of
ischemia. Animal models have shown that graded return of
inflow over a period of time did result in improved postis-
chemic muscle function and less edema. The mediators of
capillary endothelial injury are highly active oxygen metabo-
lites such as superoxide (O2
–) and hydroxyl (-OH) radicals.
On reperfusion, the lactic acid, potassium, myoglobin, and
cardiodepressants such as thromboxane that have accumu-
lated in the ischemic limb are systemically released. The
resulting metabolic acidosis and biochemical insult can have
profound consequences in an already fragile patient.
Peripheral nerve fibers that mediate light touch and posi-
tion sense are much more vulnerable than skin and subcuta-
neous tissue. Thus deficits in these areas, although subtle,
present an illusion of surface viability while masking the
presence of complete functional loss.
Clinical Features
A. Symptoms and Signs—Acute ischemia is often mani-
fested by some or all of the six cardinal signs known as the
“six P’s.” Ischemic pain is profound, and most patients
require large doses of opioid analgesics before they obtain
relief. The diagnosis of acute arterial ischemia is usually
entertained because of the localized nature of the pain. The
level of the obstruction is typically in the artery lying one
joint above the area of discomfort (Table 29–3). Emboli to
the axillary artery, which has excellent collateral flow, are
either asymptomatic, detected primarily by a pulse deficit,
or noted only with physical activity. Conversely, emboli to
the common femoral or popliteal arteries typically produce
profound ischemia, and symptoms appear rapidly. On exam-
ination, the extremity is pallid and cool. Unlike venous
thrombosis, arterial ischemia produces a white rather than a
violaceous limb. Occasionally, the sensorial perception of
numbness and paresthesias predominates and may mask the
primary component of pain. A late sign, paralysis is the result
of motor nerve ischemia followed by muscle necrosis. Distal
pulses are usually absent, although profound ischemia may
occur in the presence of a normal pulse when the embolus is
lodged distally in the small arteries of the hand or foot. In
some patients—especially those with chronic disease and
generalized edema or anasarca—pulses may be difficult or
impossible to detect. The extremity may be firm because of
muscle swelling. A compartment syndrome occurs when
muscle swelling limits venous outflow from within a fascial
compartment. An indurated and hard compartment is an
indication for release of the pressure by fasciotomy.
Although indicative of arterial insufficiency, these symp-
toms are in essence nonspecific. They serve to alert the clini-
cian to the presence of ischemia but do not lend themselves
to grading or quantification. It is of paramount importance
to assess the degree of ischemia, which is stratified into three
categories based on the physical findings: viable, threatened,
and irreversible. Symptoms depend on the location of the
embolus and the adequacy of the collateral circulation. The
Joint Council of the Society for Vascular Surgery and the
North American Chapter of the International Society for
Cardiovascular Surgery has developed a consensus that
divides severity of limb ischemia into three categories
(Table 29–4). Category I (viable) limbs usually present as an
acute on chronic process. Patients in this category have abun-
dant collaterals and develop an acute femoral artery throm-
bosis overlying a chronic stenosis. The prognosis of category
II patients is dictated by the time interval between diagnosis
and revascularization. Prompt versus immediate intervention
Site of Occlusion Line of Demarcation 
Infrarenal aorta Mid abdomen 
Aortic bifurcation and common
iliac arteries 
Groin/pelvis 
External iliac arteries Proximal thigh 
Common femoral artery Lower third of thigh 
Superficial femoral artery Upper third of calf 
Popliteal artery Lower third of calf 
Adapted from Way LW (editor): Current Surgical Diagnosis and
Treatment, 10th ed. Originally published by Appleton & Lange.
Copyright © 1994 by The McGraw-Hill Companies, Inc. 
Table 29–3. Demarcation of physical findings in relation
to site of arterial occlusion.
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is dictated by the severity of presentation. Amputation is the
only recourse in category III patients.
B. Noninvasive Diagnostic Studies
1. Doppler examination—A Doppler flow probe is useful
in patients who are edematous or in whom a pulse may
not be detectable for other reasons. Evidence of flow by
Doppler examination indicates only that obstruction is not
complete—it does not mean that flow is adequate. One should
guard against grading “Doppler pulses” because they are
influenced by several factors, including the angle of
insonation, the gain of the system, and the flow in the artery.
The more superficial the vessel under consideration, the
higher is the frequency of the probe that should be used.
2. Ankle-brachial index (ABI)—Although used primarily
in patients with chronic arterial disease, the ABI may be use-
ful in patients who complain of subtle changes in their
extremities. The ABI is also useful in postoperative vascular
patients for monitoring graft patency. The index is calculated
by placing a blood pressure cuff at the high calf position, just
below the knee, where it will occlude the tibial arteries. A
Doppler probe is placed over either the posterior tibial or the
dorsalis pedis artery, and the cuff is then deflated. The pres-
sure at which flow resumes is documented to obtain an
opening pressure. The brachial artery pressure is measured in
a similar manner, taking the arm with the higher systolic
pressure. The ankle-brachial index then is calculated (by
dividing ankle Doppler pressure by brachial Doppler pres-
sure). An index greater than 1.0 is normal, and an index less
than 0.4 signifies a threat to the limb. Of greatest value are
changes in the index from previous values or a discrepancy
between the two extremities.
3. Duplex scanning—In equivocal cases or when angiogra-
phy is not available, noninvasive color-flow duplex ultra-
sonography has been a major advance in the diagnosis and
treatment of vascular diseases. It has several components. A
two-dimensional real-time image is projected in the B mode,
which can locate vessels in soft tissues, measure vessel
diameters, and reveal irregularities within the lumen. This
may be helpful in locating the position of the embolus.
Pulsed-wave Doppler technology determines the velocity of
blood flow at a specified location that is superimposed on the
B-mode image. Turbulent flow is seen with a mosaic pattern,
whereas a color-flow void signifies occlusion. Although
duplex scanning can be performed conveniently at the bed-
side, it has the disadvantage of being highly operator-
dependent. Duplex scanning can provide essentially the same
information as arteriography with respect to localization of
arterial segments with either stenosis or total occlusion.
4. Air plethysmography—Although it is seldom used, air
plethysmography remains a valuable noninvasive diagnostic
technique. Several types are available, but all measure the
same physiologic parameter: change in volume. A blood
pressure cuff is placed around the affected extremity and
inflated to 65 mm Hg. A pressure waveform tracing is then
recorded, and occlusive disease is graded based on pulse con-
tour. An advantage of this application is that the recording
obtained is not affected by vessel wall stiffness. In conjunc-
tion with segmental pressure measurements, an accurate
assessment in patients with peripheral occlusive disease can
be made. However, in the setting of acute limb ischemia,
other more specific modalities are necessary.
C. Angiography—Radiographic studies are best obtained in
consultation with a vascular surgeon to avoid unnecessary
delays. Arteriography remains the standard and is extremely
useful in the planning of operative procedures and is recom-
mended in all but the most straightforward cases. Only when
the location of the occlusion is apparent (eg, femoral embolus)
and coupled with an acutely ischemic limb is preoperative
angiography required. However, when symptoms are atypi-
cal in a threatened limb, arteriography is helpful in deter-
mining the surgical strategy or in the institution of
catheter-directed thrombolytic therapy. The major disadvan-
tage of radiologic studies in this setting is the time required
to obtain them. Delayed can lead to irreversible soft tissue
ischemic injury.
Category Description Sensory Loss Muscle Weakness Arterial Doppler Venous Doppler 
I. Viable
II.  Threatened
Marginal
Immediate
III. Irreversible 
No immediate threat
Salvage with prompt treatment 
Salvage with immediate treatment
Permanent tissue loss  
None 
Minimal 
Rest pain 
Anesthetic 
None 
None 
Mild to moderate 
Paralysis 
+
– 
–
–
+ 
+
+
–
Adapted from Rutherford RB et al: Recommended standards for reports dealing with lower extremity ischemia: Revised version.
J Vasc Surg 1997;26:517. 
Table 29–4. Clinical categories of acute limb ischemia.
 CHAPTER 29636
Differential Diagnosis
Acute arterial insufficiency owing to an embolus may be
mimicked by low-flow states produced by congestive heart
failure and hypovolemic shock. In the latter conditions, how-
ever, global ischemia is present, and the localizing symptoms
associated with an embolus are lacking. Acute stroke or tran-
sient ischemic attacks may produce muscle weakness but are
seldom associated with pain. Aneurysmal disease or aortic
dissection not only may be the source of emboli but also may
result in rupture. If a dissection extends distally, it may
become thrombotic, producing acute ischemia of the organs
that receive blood from its false channel. Diabetic neuropa-
thy and neuritis may produce hypesthesias in the extremities
but seldom are a diagnostic dilemma.
Treatment
Prompt restoration of inflow is the most important manage-
ment priority. In general, the extent of tissue necrosis and the
resulting disability are directly proportional to the duration
of ischemia. Tolerance of ischemia varies widely among dif-
ferent tissues, extremities, and individuals. Thus a safe upper
limit for arterial compromise cannot be established,
although most authorities cite 4–6 hours as the usual time
limit beyond which irreversible injury of muscles and nerves
may have occurred, even though the overlying skin still may
be viable. For this reason, once a threat to limb survival has
been recognized, prompt treatment is paramount.
A. Anticoagulation—Systemic anticoagulation with heparin
is used unless life-threatening contraindications such as active
GI or cerebral bleeding is present. Heparin prevents the distal
propagation of thrombus, protects the distal vascular bed,
and preserves the extremity’s outflow. The usual dose of
heparin is 100 units/kg given as a bolus, followed by 10–20
units/kg per hour. Before heparin is started, one should
record a baseline partial thromboplastin time (aPTT), pro-
thrombin time (PT), and platelet count. Heparin is cleared
when bound to receptors on endothelial cells and macrophages,
where it is depolymerized. Consequently, its half-life depends
on the initial bolus. The half-life increases from approximately
30 minutes following an intravenous bolus of 25 units/kg to
60 minutes with a bolus of 100 units/kg and to 150 minutes
with a bolus of 400 units/kg. Based on the standard dosage,
most authors recommend titrating a continuous heparin drip
to lengthen the aPTT to twice baseline. Heparin should be
started before any diagnostic maneuvers and may be contin-
ued through to the time of surgery. Titration of the heparin
dosage should not substitute for or delay appropriate surgical
management. The use of heparin should be followed by oral
anticoagulation to prevent recurrent embolism in patients
undergoing thromboembolectomy.
Some surgeons recommend nonoperative management
for acute arterial ischemia, in which case heparin in “high”
doses (20,000 units as an IV bolus followed by 4000 units/h)
is used as the sole form of treatment. Extreme caution must
be exercised in recommending such therapy, however, and
only patients without signs of limb threat should be treated
with anticoagulation alone. This therapy is best reserved for
upper extremity lesions in which collateral flow is good—or
in lower extremity cases in patients whose neural function is
not diminished or in whom it improves quickly after institu-
tion of therapy.
B. Rheologic Agents—The increase in blood viscosity asso-
ciated with acute ischemia has led some vascular surgeons to
recommend the use of either mannitol or low-molecular-
weight dextran (dextran 40; MW 40,000) to reduce cellular
swelling. An additional benefit of these agents is that they
produce an osmotic diuresis and may help to prevent renal
failure owing to myoglobin released from ischemic and
necrotic muscle. Mannitol is started with an intravenous
bolus dose of 25–50 g. Care must be exercised in patients
with congestive heart failure because the increased intravas-
cular volume may worsen cardiac symptoms.
C. Platelet-Active Agents—Aspirin, the agent prescribed
most commonly for this purpose, has been thoroughly eval-
uated and found to prevent vascular death by approxi-
mately 15% and nonfatal vascular events by about 30% in a
meta-analysis of over 50 secondary prevention trials in var-
ious groups of patients. The role of aspirin in acute limb
ischemia is more restricted to postoperative adjunctive
cardiac prophylaxis.
Integrin glycoprotein IIb/IIIa receptor antagonists (eg,
abciximab) inhibit the final common pathway of platelet
aggregation. Their development objective was to prevent
restenosis in patients undergoing percutaneous coronary
intervention. Three large randomized trials involving
approximately 27,000 patients resulted in a higher mortality
and excessive bleeding complications when compared with
aspirin. The role of this class of medications is evolving.
Thienopyridines such as clopidogrel inhibit ADP-induced
platelet aggregation with no direct effects on arachidonic acid
metabolism. Use of this agent in the acute setting has not been
studied; however, in a comparison trial with aspirin involving
a subset of 6400 patients, virtually all the benefit associated
with clopidogrel was observed in the group with symptomatic
peripheral vascular disease. As a group, these patients had
fewer myocardial infarctions and fewer vascular-related
deaths than did the aspirin-treated group. The main disad-
vantage is the permanent platelet defect encountered, which
can be replaced only with platelet turnover.
D. Thrombin Inhibitors—Direct thrombin inhibitors (eg,
lepirudin, desirudin, bivalirudin, and argatroban) have been
used successfully to treat arterial and venous thrombotic com-
plications of heparin-induced thrombocytopenia. Despite
producing a more predictable anticoagulant response than
heparin, direct thrombin inhibitors have yet to find a place in
the treatment of acute arterial thrombosis. Potential disadvan-
tages include the irreversible nature of this complex, because
no antidote is available if bleeding occurs, and its narrow
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therapeutic window when combined with thrombolytic ther-
apy. Table 29–5 details the currently available thrombin
inhibitors. Lepirudin and argatroban are approved for the
treatment of thrombosis in patients with heparin-induced
thrombocytopenia. There are no currently agents available for
reversing the effects of the direct thrombin inhibitors.
E. Thrombolytic Agents—Thrombolytic agents such as
urokinase, streptokinase, and recombinant tissue plasmino-
gen activator (rt-PA; alteplase) have been evaluated in
numerous clinical trials for safety and efficacy and in com-
parison with operative management. Initially, an intense
thrombolytic state was induced with systemic therapy sus-
tained by constant intravenous infusion. In 10 uncontrolled
studies involving 1800 patients, best results were obtained
within 72 hours of onset of symptoms. Lysis was observed in
40%, with no difference in success rates between embolic or
thrombotic occlusions. Unfortunately, serious hemorrhagic
complications occurred in one-third of patients.
Regional or intraarterial thrombolysis has become an alter-
native to systemic therapy. The rate of successful reperfusion
(50–85%) appears to be higher than what is reported with sys-
temic infusion. Local infusion coupled with arteriography
conferred an additional advantage in delineating the cause of
the arterial occlusion (thrombosis versus embolus). Vessel wall
morphologic characteristics that may lead to early recurrent
thrombosis also were unmasked and further directed appro-
priate management (surgery versus angioplasty). Prolonged
arterial catheterization (hours to days) resulting in major
bleeding (6–20%) remains the main disadvantage of this
approach. Current thrombolytic agents include streptokinase,
urokinase, alteplase, reteplase, and tenecteplase.
Urokinase, a relatively inexpensive trypsin-like protease,
converts plasminogen directly to plasmin. Initially, the main
advantages of urokinase over streptokinase were its direct
action on plasminogen and its nonantigenicity. However,
pyretic reactions have been observed and attributed to inter-
leukins present during the manufacturing process. As a result,
urokinase is currently not available in the United States.
Alteplase is now the only thrombolytic agent available for
peripheral arterial thrombolysis. A naturally occurring acti-
vator of plasminogen, it is produced and released by the
endothelium. Manufactured through recombinant DNA
techniques, it is nonantigenic, has a half-life of 3.5–4 min-
utes, and has a high affinity for fibrin, which enhances lysis at
the thrombus level. Similar to urokinase, the primary route
of metabolism is hepatic.
Reteplase is a new plasminogen activator approved for
treatment of acute myocardial infarction and is used anecdo-
tally in the peripheral vasculature. Designed for use as bolus
therapy through recombinant DNA technology, experience
with reteplase in arterial and venous thromboembolic dis-
ease is limited.
An inert zymogen activated by the presence of fibrin clot,
prourokinase is converted to an active two-chain urokinase
that is highly fibrin-specific. Availability of this agent is also
limited.
Tenecteplase, a genetically engineered variant of alteplase,
has a prolonged half-life, increased fibrin specificity, and
higher resistance to inhibition by circulating plasminogen
activator inhibitor-1. A three-amino-acid substitution
resulted in a 14–19-minute half-life and more specific fibri-
nolysis in comparison with alteplase. Pending approval by
the Food and Drug Administration (FDA) for treatment of
acute myocardial infarction, the role of tenecteplase in the
management of peripheral arterial and venous thrombotic
occlusion has yet to be explored.
Because of the lack of evidence demonstrating the bene-
fits of improved limb salvage, lower mortality, or cost-
effectiveness, thrombolytic therapy cannot be regarded as
Drug Dose∗ Duration Notes
Lepirudin Load: 0.4 mg/kg IV then
0.15 mg/kg/hr
2–10 days Keep aPTT between 1.5 and 2.5 times normal.
Indicated for use in patients with HIT.
Bivalirudin Load: 1.0 mg/kg IV, followed
by 2.5 mg/kg/h for 4 h, then
0.2 mg/kg/h
20 h Has only been studied with concomitant aspirin
treatment.
Argatroban Initial dose 2 μg/kg/min IV Indicated as an anticoagulant in heparin-induced
thrombocytopenias. Monitor aPTT beginning 2 h
after start of infusion—steady state should be
1.5–3 times initial baseline.
∗Check current prescribing information. Doses may need to be adjusted in the presence of comorbidites such as hepatic and/or renal failure.
Table 29–5. Currently available thrombin inhibitors.
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first-line treatment in the management of acute limb
ischemia. However, it remains a reasonable alternative in a
select group of patients, especially those with distal throm-
boembolic occlusions in surgically inaccessible small arteries
of the hands and feet and in patients who are at high risk for
surgery (Table 29–6).
F. Surgery—Operation is the best treatment of acute extrem-
ity ischemia, achieving both life and limb salvage. Adequate
preoperative support is essential. In the presence of active
cardiac risk, use of local anesthesia must be considered and
adequate intravenous hydration provided to minimize renal
insufficiency. At the time of surgery, placement of the inci-
sion is guided by the cause of occlusion, the presence of a
palpable pulse, and a history of previous revascularization.
In patients with embolic occlusion, exploration of the
femoral artery is considered in the presence of femoral and
distal pulses. A below-the-knee approach is preferred in
patients presenting with a palpable popliteal pulse and dis-
tal embolization. Patients with acute ischemia and a previ-
ous bypass graft usually are explored through the distal
anastomosis.
A transverse incision is often sufficient for passage of a
Fogarty catheter. Longitudinal arteriotomy is considered if
the cause is not known for certain or if bypass is necessary.
Removal of the entire embolic material is essential, and suc-
cess is confirmed through an intraoperative arteriogram to
ensure patency of the arterial runoff distal to the embolus.
Approximately 35–40% of completion angiograms will iden-
tify residual thrombus.
Although highly successful in embolic occlusion, blind
thromboembolectomy in patients with acute on chronic
thrombosis is highly dangerous and risks further intimal dis-
ruption to an already diseased vessel. Often these patients
require further surgical revascularization (eg, bypass or
endarterectomy) or endovascular management (eg, thrombol-
ysis, angioplasty, or stent placement in debilitated patients).
Intraoperative lytic therapy has been reported in several
series for the following indications: residual thrombus on
angiography, slow flow despite the absence of an angiographic
defect, prolonged ischemia with evidence of thickened blood
on retrograde bleeding, and persistent ischemia despite
restoration of sufficient proximal inflow. In a series of 78
patients, limb salvage was achieved in 73% of the 67%
treated successfully.
A new approach to intraoperative thrombolysis undergo-
ing recent investigation is high-dose isolated limb perfusion.
Surgical cutdowns of the femoral vessels are performed, with
intraarterial insertion of standard infusion pumps. A tourni-
quet is applied proximal to the exposed vessels, and venous
effluent is drained by gravity or through the use of extracor-
poreal pump support with concomitant dialysis.
Fasciotomy should be considered in all patients following
successful revascularization in the setting of prolonged
ischemia. Common clinical indications are pain out of pro-
portion to findings, pain on passive stretch, tense muscular
compartments with elevated pressures, and compartmental
hypesthesia and paralysis.
G. Supportive Care—Perioperative care of the patient fol-
lowing revascularization of an acutely ischemic limb can
vary from simple to extremely complex. Reperfusion of an
ischemic extremity can lead to the release of toxic cellular
products, the generation of oxygen-free radicals, hyper-
kalemia, increased intracellular calcium overload, myoglo-
binuria, and altered arachidonic acid metabolism. Critical
care therefore is directed toward ameliorating the damage
done by cellular breakdown.
Appropriate hemodynamic monitoring is essential.
Correction of electrolyte abnormalities and prompt treat-
ment of hyperkalemia through brisk diuresis and adminis-
tration of insulin and glucose can prevent fatal cardiac
arrhythmias. Adequate fluid volume and the administration
of mannitol—a free-radical scavenger and osmotic
diuretic—is the best strategy to correct acidosis and to pre-
vent acute renal failure caused by myoglobin precipitates.
Local mechanical factors are also important to prevent
skin and soft tissue breakdown. The extremity should be kept
warm but must not be heated in an effort to restore flow
because this will increase the metabolic rate, further the lac-
tic acidosis, and contribute to tissue destruction. Similarly,
cooling is inappropriate. Care must be taken to prevent
Drug Half-Life Intravenous Dose Intraarterial Dose
Altepase (t-PA) 3.5 min 50 mg over 2 h, followed by 0.05–0.1 unit/kg/h
Reteplase 14 min 10 units over 2 min, then 10 0.25–1 unit/h
Tenectplase 15 min 0.5 mg/kg Unknown
Data from Schmittling ZC, Hodgson KJ: Thrombolysis and mechanical thrombectomy for arterial disease. Surg Clin North Am 2004;84:1237–66.
Table 29–6. Thrombolytic agents.
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pressure on an ischemic extremity. Heel pads and cushions
should be used as needed. Other vascular precautions
include keeping linens suspended with a bed cradle and posi-
tioning the patient in reverse Trendelenburg.
In patients who have not undergone fasciotomy, fre-
quent and careful assessment of the lower extremities is
warranted. In the event that a compartment syndrome is
diagnosed, prompt decompression is required to preserve
tissue viability.
Pain control typically requires high doses of an opioid
such as morphine. Analgesia must not be increased to the
point that symptoms are masked and a reliable neurologic
examination cannot be obtained. Short-acting intravenous
agents such as fentanyl have been used with success, pro-
vided that the dose is regulated so as not to obscure worsen-
ing of symptoms.
Prognosis
Despite recent advances in perioperative critical care, the
mortality rate after acute leg ischemia remains relatively
high. Both the mortality rate and the need for amputation
are directly related to the duration of ischemia. A recent
study found that no amputations were required when sur-
gery was undertaken within 2 hours compared with a 44%
amputation rate when operation was delayed up to 7 days.
The mortality rate was 10% in patients with symptoms pres-
ent for less than 2 hours and 32% in those whose symptoms
were present for up to 8 hours. Coexisting cardiopulmonary
complications were the underlying cause of most fatalities,
especially in patients with acute arterial thrombosis in con-
trast to peripheral embolism.
Current Controversies and Unresolved Issues
The cause of ischemic injury remains unclear. While it is
logical to assume that hypoxia is the culprit, investigations
have shown that most of the tissue damage actually occurs
during the time of reperfusion. Even short periods of
ischemia followed by reperfusion can cause cell damage. A
recent canine study found that 3 hours of partial ischemia
resulted in more tissue damage than the same period of
complete ischemia. Furthermore, the extent of postreperfu-
sion damage can be decreased by graded reflow. These inves-
tigations suggest that scavengers of free radicals may be
useful in the treatment of acute vascular insufficiency.
Although numerous investigations have been under-
taken, little improvement has been made over the last 2
decades in morbidity and mortality associated with surgical
thrombectomy in this fragile patient group. The advantage of
surgery stems from rapid restoration of blood flow. On the
contrary, pharmacologic thrombolysis is much less invasive.
The main disadvantage is the time lag involved for revascu-
larization. What is needed is an ideal therapeutic option that
achieves rapid blood flow and is minimally invasive. The
advent of endovascular surgery has spurred the development
of percutaneous mechanical thrombectomy devices to
answer this need. Current devices in various stages of clinical
trials include rheolytic, clot aspiration, and microfragmenta-
tion catheters.
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 Deep Venous Thrombosis
ESSENT IALS  OF  D IAGNOS I S
 Multiple risk factors.
 Aching pain exaggerated by motion.
 Calf and thigh swelling.
 Tenderness to palpation and dorsiflexion.
 Erythema, cyanosis, or venous distention.
General Considerations
Three factors (Virchow’s triad) contribute to the develop-
ment of venous thrombosis: stasis, increased coagulabil-
ity, and vessel wall damage. Contrary to former belief,
low flow alone is not sufficient to cause thrombosis.
Thrombophlebitis is venous thrombosis that follows inflam-
mation of the vessel wall. Because of underlying intimal
irregularities, the clot adheres firmly and is unlikely to
become dislodged. Phlebothrombosis occurs without vessel
wall injury and results in minimal clot adherence.
Patients at risk for the development of deep venous
thrombosis may be divided into three groups: (1) Low-risk
patients are under 40 years of age and are free of systemic
disease. Surgery lasts less than 60 minutes and is uncompli-
cated. Overall risk for the development of deep venous
thrombosis is less than 2%, and the chance of proximal pro-
gression is less than 1%. (2) Moderate-risk patients are over
age 40 and have undergone general anesthesia for more than
60 minutes. They also may have risk factors such as cancer,
obesity, varicose veins, bed rest, or cardiac failure. If prophy-
laxis is not given, the risk for development of deep venous
thrombosis is between 10% and 40% and that of proximal
propagation is between 2% and 8%. The risk of fatal pul-
monary embolism is almost 1%. (3) High-risk patients have
a history of deep venous thrombosis or of pulmonary
embolism. They undergo extensive abdominal or pelvic pro-
cedures for advanced disease or for some orthopedic indica-
tion. The risk of calf vein thrombosis is between 40% and
80% without prophylaxis. Proximal extension occurs in
10–20%, leading to fatal pulmonary embolism in up to 5%.
Risk factors for the development of venous thrombi and rec-
ommended prophylaxis are listed in Table 29–7. Most deep
venous thrombi are initiated by platelet adhesion either to
endothelial tissue or to exposed collagen of damaged vascular
Low Risk Moderate Risk High Risk 
Event or condition
General surgery Age <40 years or time <60 minutes Age >40 years or time >60 minutes Age >40 years or time >60 minutes
plus risk factor 
Orthopedic surgery — — Elective hip or knee surgery 
Trauma — — Extensive soft tissue injury; major
fractures; multiple trauma 
Medical conditions Pregnancy Myocardial infarction postpartum,
especially with previous deep
venous thrombosis; estrogen use;
varicose veins 
Stroke, paraplegia, spine fracture,
prolonged bed rest, burns, hyperco-
agulable state, obesity 
Incidence of thromboembolism without prophylaxis (%)
Distal calf veins 2 10–40 40–80 
Proximal veins (pelvis, thigh,
popliteal veins) 
0.4 2–8 10–20 
Symptomatic pulmonary embolism 0.2 1–8 5–10 
Fatal pulmonary embolism 0.002 0.1–0.4 1–5 
Recommended prophylaxis Graduated compression stockings;
early ambulation 
Heparin (5000 units SC twice daily),
LMWH, external or pneumatic
compression 
Heparin (5000 units SC three times
daily), LMWH, external pneumatic
compression, inferior vena caval
filter, warfarin 
Adapted from Colman RW et al (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott, 1994.
Table 29–7. Risk stratification for venous thrombosis and recommended prophylaxis.
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walls. As platelet aggregation continues, the clot becomes
organized and begins to trap circulating white and red blood
cells. Deposition of fibrin organizes the clot and allows it to
build a stable matrix.
Activation of either the intrinsic or the extrinsic clotting
system contributes to thrombus formation. Adhesion of fac-
tor XII to exposed endothelium results in progressive activa-
tion of factor X. Activated factor X (Xa), along with factor V,
converts prothrombin to thrombin and fibrinogen to fibrin,
producing an insoluble clot. Platelets accumulate within the
matrix and provide a surface for further fibrin deposition.
Thromboxane A2, produced and released by platelets, aids
the process by contributing to vasoconstriction and further
platelet aggregation. Prostacyclin, which is produced by vas-
cular intima, limits the process by causing vascular dilation
and by inhibiting platelet aggregation. Antithrombin III
inhibits the action of factors IX, X, XI, and XII. Proteins C
and S, produced by the liver, inhibit coagulation by destroy-
ing factors V and VII and provide negative feedback to con-
trol the generation of thrombin (Figure 29–1).
The velocity of blood flow is inversely proportional to the
propensity for intravascular clotting. However, the threshold
for thrombus formation is decreased in the face of vascular
endothelial injury. Such injury may be caused by catheters,
infection, or external influences. In normal veins, the
endothelium is well supplied with prostacyclin and plas-
minogen, which prevent thrombus formation even at low
flow rates. However, when intimal damage is present—or in
the face of a hypercoagulable state—thrombus accumulates
rapidly. Red clots predominate in the venous system and
consist of platelets, red blood cells, and fibrin. White
thrombi, which contain chiefly platelets, are usually found in
the arterial system.
Hypercoagulable states are common in postoperative
critical care patients. The plasma concentration of clotting
factors rises after surgery. Maximum procoagulant activity
corresponds temporally with the peak incidence of throm-
boembolism. Detection of hypercoagulability remains diffi-
cult except in certain pathologic conditions such as
decreased concentrations of antithrombin III, protein C, and
 Figure 29–1. Factors involved in arrest of hemorrhage. Injury to the blood vessel wall initiates a series of reactions
that arrest hemorrhage. The exposed subendothelial collagen initiates formation of the platelet plug (primary hemo-
stasis). The coagulation system is activated, leading to production of fibrin, which interacts with the platelet aggregate
to form a hemostatic seal. These relationships are also involved in spontaneous thrombus formation, although the
inciting event is usually not identifiable. (Reproduced, with permission, from Way LW (ed), Current Surgical Diagnosis &
Treatment, 10th ed. Originally published by Appleton & Lange. Copyright © 1993 by The McGraw-Hill Companies, Inc.)
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protein S. Use of some medications, such as oral contracep-
tives, is known to increase the risk of thromboembolic dis-
ease. Ill-defined alterations in the clotting mechanism that
predispose to clotting accompany some severe systemic dis-
eases such as cancer and sepsis.
Most deep venous thrombi begin in the veins of the calf.
When limited to this location, they are usually asymptomatic
except for mild calf pain and minimal swelling. Extension
into the deep venous system of the thigh produces more
swelling, pain, and purpura. Proximal propagation involves
the veins of the pelvis (iliofemoral thrombosis). As outflow is
restricted, the lower extremity swells and causes obstruction
of lymphatic channels, producing a blanched “milk leg”
(phlegmasia alba dolens). If patency is not restored, cyanosis
and venous gangrene result. This condition, known as phleg-
masia cerulea dolens (“blue leg”), is more common in the left
lower extremity than in the right from compression of the left
iliac vein as it passes under the right iliac artery. Phlegmasia
cerulea dolens is usually associated with disseminated malig-
nancies or sepsis. It is accompanied by hypotension and
hypovolemia, which result from venous pooling in the leg.
Thrombosis of the deep veins of the thigh and pelvis dra-
matically increases the risk of pulmonary embolism.
Approximately 85% of clinically significant pulmonary
emboli arise from the thighs and pelvis. Eighty percent of
deep venous thrombi remain confined to the calf, whereas
20% extend proximally. In the latter group, 40–50% will
result in pulmonary embolism if not treated appropriately.
Unfortunately, only 30% of those with confirmed pul-
monary embolism have objective signs consistent with deep
venous thrombosis.
Venous thrombosis of the upper extremities is becoming
increasingly prevalent in the ICU as a result of chronic
indwelling central venous catheters. Patients being main-
tained on long-term parenteral nutrition, hemodialysis,
antibiotics, or chemotherapy or those with poor peripheral
access are some of those at risk. Other predisposing factors
include exertion, thoracic outlet syndrome, congenital mal-
formations, and trauma (Table 29–8). Approximately 3–6%
of all pulmonary emboli and 1–2% of fatal pulmonary
emboli have been reported to originate from clots in the deep
veins of the upper extremity.
Superficial venous thrombi typically present as a small
lump or cord. These are usually of no systemic significance
except in the saphenous vein of the thigh, where they can
propagate through the saphenofemoral junction and gain
access to the deep iliofemoral system. When such proximal
extension is noted, ligation of the saphenous vein just distal
to its origin is warranted.
Clinical Features
A. Symptoms and Signs—Patients may complain of a
vague aching sensation or tightness in the calf or thigh. This
is worsened by active motion of the calf or foot. When super-
ficial thrombosis is present, localized tenderness is usually
also present.
Physical examination is notoriously unreliable for deep
venous thrombosis and accurately detects only 50% of cases.
Areas with increased tenderness to palpation include the
sole, the region deep to Achilles’ tendon, the groove between
the tibia and fibula, the regions over the soleus and gastroc-
nemius muscles, in the popliteal fossa, over the adductor
muscles of the thigh, and at the femoral vein near the
inguinal ligament. Tenderness induced by compression of
the calf muscles anteriorly against the interosseous mem-
brane or with passive dorsiflexion of the ankle (Homans’
sign) is present in less than 30% of patients. Inflation of a
sphygmomanometer cuff (40 mm Hg) placed above the knee
may provoke pain at the site of the thrombosis. A difference
of 1.5 cm in diameter between the swollen and the contralat-
eral leg supports the diagnosis.
Deep venous thrombosis of the axillary and subclavian
veins of the upper extremity results in swelling of the entire
arm. Pitting edema is usually absent. Percussion over the
clavicle and the course of the axillary vein often elicits
tenderness.
B. Noninvasive Diagnostic Techniques—Hand-held
continuous-wave Doppler devices test for continuity
between the deep system of the leg and the intrathoracic vena
cava. The probe is placed initially at the popliteal fossa and
subsequently over the femoral vein. The patient is instructed
to inspire, at which time an augmentation of flow should be
heard. The increased flow is due to transmission of the neg-
ative intrathoracic pressure to the deep system. This is a use-
ful screening test that can be performed at the bedside, but it
has a sensitivity of only about 75% when compared with
venography. Duplex scans and color-coded Doppler exami-
nations have accuracy rates between 90% and 100% for
detecting large thrombi of the femoral veins in symptomatic
patients. The sensitivity decreases to 59%, although the sen-
sitivity remains at 98%, in asymptomatic patients. Accuracy
also diminishes when examining the distal veins of the calf
owing to poor visualization. Isolated instances of iliac vein
thrombosis are also not detectable by ultrasound imaging
but may be diagnosed by simple Doppler examination.
Source Incidence (%) 
Catheter-associated 
Spontaneous (effort-induced) 
Miscellaneous 
Intravenous drug use 
Thoracic tumors 
Trauma 
Radiation 
30–40
20–30
30–40 
Table 29–8. Etiology of upper extremity venous
thrombosis.
CRITICAL CARE OF VASCULAR DISEASE & EMERGENCIES 643
Multiple studies have shown that repeat duplex scanning has
an improved negative predictive value in patients suspected
of deep vein thrombosis but who have negative initial scans.
Pressure on the underlying vein by the ultrasound probe
helps to establish the age of the clot because fresh thrombi
are poorly organized and easily compressible. This is the
diagnostic test of choice for most patients, although it
requires an experienced technician to perform and interpret.
Impedance plethysmography relies on changes in electri-
cal resistance associated with alteration in limb volume. Deep
venous thrombosis impedes venous outflow and causes a
slower change in impedance when a proximally occluding
cuff is deflated. This technique is very accurate in ambulatory
patients but should be interpreted cautiously in those with
congestive heart failure or hypervolemia. It is more sensitive
for iliac and femoral vein thrombosis than for calf thrombi
and generally cannot be used in patients with fractures or
bandages that prevent proper electrode positioning. A posi-
tive test correctly indicates the presence of thrombosis in 90%
of patients. Recently, however, the sensitivity for plethysmog-
raphy in symptomatic patients was found to be much less
than earlier studies reported. In asymptomatic patients, the
specificity also falls. Impedance plethysmography can over-
look sizable thrombi that are not totally occlusive and can
interpret any pelvic venous outflow obstruction (eg, enlarged
nodes or pregnancy) as a venous thrombus. It also may be
falsely negative in patients with well-developed collaterals.
CT scanning and MR venography have successfully
diagnosed thrombi in the proximal veins and have proved
to be superior to conventional phlebography in visualizing
the great veins, identifying intraluminal thrombi, distin-
guishing new thrombi, and delineating adjacent abnormal-
ities. Ongoing prospective trials are confirming these initial
findings.
C. Invasive Diagnostic Studies—Contrast venography is
the “gold standard” with which all noninvasive modalities are
compared. It is the most reliable technique for detecting
thrombi in any location. Positive findings on venography
include constant filling defects, abrupt termination of the
dye column, nonfilling of the entire deep venous system or
portions thereof, and diversion of flow through collaterals.
The venogram catheter may be exchanged for one capable of
delivering thrombolytic agents if that therapeutic route is
chosen. Overall accuracy is better than 90%. A negative study
virtually eliminates the possibility of venous thrombosis.
Complications include foot pain at the site of injection and a
2–3% incidence of thrombosis owing to contrast
material–induced endothelial cell injury. Not routinely used
for primary diagnosis, phlebography has been advocated in
the diagnosis of symptomatic recurrent venous thrombosis
and after hip operations in suspected patients in whom non-
invasive means lack sensitivity.
D. Laboratory Findings—Several blood tests are available
that detect activation of the clotting cascade, including meas-
urement of fibrinopeptide A, fibrin monomers, and fibrin
degradation products. Plasma D-dimer, a degradation prod-
uct of plasmin digestion of mature cross-linked fibrin, is ele-
vated in patients with venous thrombosis. The sensitivity
measured by enzyme-linked immunosorbent assay
approaches 97%. Although highly accurate, confirmation of
venous thrombosis with an elevated D-dimer concentration
is necessary with objective imaging tests.
Differential Diagnosis
See Table 29–9.
Prevention
All critically ill patients should be considered for throm-
boembolic prophylaxis. Particular attention should be paid
to those with preexisting risk factors (see Table 29–7).
A. Physical Measures—Early ambulation or exercise of the
lower extremity muscles is probably the best and most cost-
effective prophylactic measure for preventing subsequent
venous thrombosis. Lower extremity elevation and active
flexion-extension exercises of the ankle will prevent stasis.
Prolonged standing in one position should be discouraged
because it promotes venous pooling. Use of thigh-high
antiembolism stockings is encouraged when they are fitted
properly. Casual application of stockings that extend only to
the knee are unlikely to be of value.
Of the compression techniques available, intermittent
compression garments are best. Garments with single com-
partments for the calves or multiple sequential compart-
ments are available. Maximum benefit is realized when they
are applied prior to surgery. Direct sequential compression
promotes blood flow and also stimulates systemic fibri-
nolytic activity. Therefore, benefit still accrues even with only
unilateral application can be achieved because of bandages
or casts. Studies have shown a reduction in the incidence of
thrombosis from 23–7% in patients so treated.
B. Anticoagulation—When used properly, preoperative
anticoagulation decreases the incidence of postoperative deep
venous thrombosis and secondary pulmonary embolism.
Lymphatic obstruction 
Cellulitis 
Baker’s cyst 
Traumatic contusion 
Tendon rupture 
Congestive heart failure 
Nephrosis 
Arterial occlusion 
Table 29–9. Differential diagnosis of deep venous
thrombosis.
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1. Warfarin—Coumarin derivatives act by suppressing the
formation of vitamin K–dependent clotting factors (II,VII, IX,
and X). When these agents are initiated before and continued
after operation, they are safe and effective. Coumarins require
several days to reach full effect because of the time interval
required for clearance of normal coagulation factors. These
agents are usually started after the patient has already been sys-
temically anticoagulated with unfractionated heparin.
Initiation of therapy with warfarin alone can have deleterious
effects. Protein C and protein S—natural anticoagulants—are
similarly reduced (especially protein C) with factor VII,
thereby shifting the hemostatic balance toward coagulation. In
patients with underlying protein C and protein S deficiency,
warfarin-induced skin necrosis can occur from thrombotic
occlusion of small vessels in the subcutaneous tissue. This
effect is manifested within 3–8 days of administration of the
initial dose. Patients with protein C and protein S deficiency
should not receive a loading dose of warfarin, and heparin
should be continued until the international normalization
ratio (INR) is therapeutic for 2 consecutive days.
Several drug interactions are known to occur with war-
farin. Of particular importance are those that increase
hepatic degradation (eg, barbiturates) and those that dis-
place warfarin from albumin (eg, aspirin and nonsteroidal
anti-inflammatory agents). Coumarins are also teratogenic
and should not be given to pregnant patients.
2. Heparin—Unfractionated heparin binds with antithrom-
bin III to prevent the conversion of prothrombin to throm-
bin. A “low dose” unfractionated heparin (LDUH) regimen is
used customarily prior to surgery and in the postoperative
period while the patient is still at risk. The postulated mech-
anism of action is enhancement of antithrombin III. The
usual regimen consists of 5000 units given subcutaneously
2 hours before surgery and every 8–12 hours during the
postoperative period. No changes in the usual coagulation
parameters can be detected at this dosing level. Increased
bleeding at the time of surgery generally does not occur.
Heparin prophylaxis is unlikely to be effective when started
in the postoperative period. It is not effective for patients
undergoing hip surgery and should not be used in those with
bleeding disorders or for scheduled intracerebral procedures.
An adjusted-dose heparin regimen has been described for
patients undergoing total hip replacement. Two days prior to
surgery, the patient receives 3500 units of heparin subcuta-
neously every 8 hours, with the dose adjusted to elevate the
aPTT to the high-normal range. This regimen has been
shown to reduce the incidence of deep venous thrombosis in
hip replacement patients from 39–13%.
3. Low-molecular-weight heparin (LMWH)—LMWHs
are produced by depolymerization of unfractionated
heparin. They have a more uniform molecular weight, longer
half-life, and more predictable pharmacokinetics. Significantly,
when compared with unfractionated heparin, they have a
higher ration of anti–factor Xa activity to anti–factor IIa
activity and are less likely to lead to heparin-induced
thrombocytopenia. LMWH has several clinical advantages
over unfractionated heparin. First evaluated in the 1980s in
high-risk surgical patients, one daily dose administered sub-
cutaneously is as effective as two or three doses of unfrac-
tionated heparin for deep vein thrombosis prophylaxis. It has
become the anticoagulant of choice for preventing deep vein
thrombosis in most orthopedic procedures. Its long half-life
precludes the need for laboratory monitoring, and it is more
effective than unfractionated heparin in preventing recur-
rence of venous thrombosis. Inpatient and outpatient uses of
LMWH have equivalent safety and efficacy. LMWH and
LDUH appear to be equally effective in reducing the inci-
dence of deep vein thrombosis in general surgical patients.
Studies have reported contradictory results with regard to
the incidence of wound hematomas and bleeding complica-
tions when comparing LMWH and LDUH likely because of
the doses used. Higher doses of LMWH are associated with
more bleeding, whereas lower doses are equivalent to LDUH
in preventing venous thromboembolism in moderate-risk
patients and have a lower rate of bleeding complications.
Currently, two LMWH preparations are approved in the
United States for the prevention of deep venous thrombosis
(Table 29–11). Enoxaparin is approved for use in patients
undergoing abdominal surgery as well as hip and knee sur-
gery. It is also approved for use in medical patients who are
at risk owing to severely restricted mobility during acute ill-
ness. The usual dose of enoxaparin in abdominal surgical
patients is 40 mg by subcutaneous injection given once daily.
The first dose should be administered 2 hours prior to sur-
gery, and the drug should be continued for 7–12 days after
surgery. The same dosing regimen applies to medical patients
with the exception that the drug should be started at the time
of immobilization. Dalteparin is approved for use in patients
undergoing hip replacement surgery and those undergoing
abdominal surgery who are at risk for thromboembolic com-
plications. The dose for abdominal surgical patients is 2500
IU given by subcutaneous injection starting 1–2 hours prior
to surgery, and then the drug is given once daily for 5–10
days. Neither of the LMWH preparations requires routine
monitoring of coagulation parameters during its use. Careful
monitoring for bleeding complications is mandatory. The
dose of LMWH may need to be reduced in older patients and
in those with renal and/or hepatic impairment.
4. Low-molecular-weight dextran—Dextran 40 acts by
coating platelet surfaces to reduce adhesion. It also increases
plasma volume and decreases the viscosity of blood. An
important mechanism of action may be the prevention of
platelet adhesion to venous valve cusps. The usual dose of
dextran 40 is 100–200 mL as an intravenous bolus (intra-
operatively), followed by 30–40 mL/h for 2–3 days after
surgery. Because dextran 40 is a volume expander, patients
with congestive heart failure or respiratory distress should
be monitored carefully for hypervolemia. Dextran potenti-
ates the effects of heparin, reducing the dosing requirements
of the latter by up to 50%.
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5. Factor Xa Inhibitors—Fondaparinux is a synthetic
molecule that is an indirect inhibitor of factor Xa. It acts by
potentiating the anti–factor Xa activity of antithrombin.
Fondaparinux has no platelet effect, nor does it modulate
primary hemostasis. It is currently approved in the United
States for deep vein thrombosis prophylaxis in patients
undergoing hip fracture or replacement surgery and knee
replacement surgery. Fondaparinux has no effect on routine
coagulation studies, and monitoring is not necessary. The
usual dose is 2.5 mg given subcutaneously starting 6–8 hours
after surgery. Administration either prior to surgery or soon
after surgery is associated with an increased risk of major
bleeding.
Management of Deep Vein Thrombosis
The objectives of treatment are to limit further accumulation
of thrombus, prevent embolization, and minimize injury to
venous valves.
A. Supportive Therapy—Treatment of calf vein thrombi
remains largely controversial, with most centers recommend-
ing supportive care. In several large trials, anticoagulation was
withheld safely in patients with suspected deep vein thrombo-
sis and normal results on serial examinations with compres-
sion ultrasonography. Only supportive therapy is required,
consisting of bed rest, leg elevation, and mild analgesics.
Although some advocate the use of warm soaks, this measure
can macerate the overlying skin and promote infection. Early
ambulation should be encouraged, with elastic stockings as
required. Anticoagulation is indicated in patients with symp-
tomatic deep vein thrombosis identified by duplex scanning
and those with recurrent venous thrombosis.
B. Anticoagulation—Thrombi of the proximal veins (ie,
popliteal vein, femoral vein, and iliac veins) or of the axillary
and subclavian veins requires anticoagulation. Heparin,
either unfractionated or low-molecular weight, is the agent of
choice because it limits further propagation of the thrombus.
A recent consensus conference found that there is no differ-
ence between them regarding their efficacy or safety.
However, because of the advantages of convenient dosing,
facilitation of outpatient therapy, and a potentially lower risk
for recurrent deep vein thrombosis, some prefer the use of
LMWH over unfractionated heparin (UFH). Additionally,
there may be a survival advantage favoring the use of LMWH
in venous thromboembolic disease associated with malig-
nancy. For most patients, an initial bolus dose of 100 units/kg
(UFH) followed by a continuous infusion of 10 units/kg per
hour is adequate. Larger doses (200 units/kg as bolus injec-
tion) may be given if the clot extends into the iliac or femoral
system, if there is profound edema of the leg, or if imaging
studies indicate the presence of a long tail extending proxi-
mally. Anticoagulation should be assessed by monitoring
either the aPTT or the activated clotting time (ACT). The
heparin infusion should be titrated to keep the aPTT
between 1.5 and 2.5 times normal. Failure to achieve a
therapeutic level of anticoagulation within 24 hours carries a
25% risk of recurrent deep venous thrombosis. Bleeding
complications are reduced if dosage is regulated by monitor-
ing of anticoagulation and if the heparin is given by continu-
ous infusion rather than by intermittent bolus administration.
Five days of intravenous heparin therapy followed by oral
warfarin is usually effective and generally is regarded as con-
ventional therapy.
Although warfarin therapy can be started concomitantly
with heparin, most prefer to wait several days before starting
oral anticoagulation. Titration of the dose to achieve an INR
of 2.0–3.0 is adequate. Oral anticoagulation is continued for
3–6 months following discharge from the hospital based on
risk factors (Table 29–10).
Platelet counts should be obtained initially and every
other day to detect the development of heparin-induced
antiplatelet antibodies. Immune heparin-induced thrombo-
cytopenia (HIT) is suspected when the platelet count falls
below 100,000/μL or less than 50% of the baseline value. This
IgG-mediated platelet deficiency is seen in 3% of patients
and occurs 5–15 days after heparin therapy is initiated.
Management of patients with persistent thrombosis and HIT
can be difficult. Two agents, argatroban and lepirudin, have
been approved for patients with HIT needing anticoagulant
therapy. Argatroban is begun with a continuous intravenous
infusion at 2 μg/kg per minute and titrated to keep the
aPTT 1.5–3 times the initial baseline. Lepirudin (recombi-
nant hirudin) achieves rapid anticoagulation with a loading
dose of 0.4 mg/kg followed by an infusion of 0.15 mg/kg per
hour. It is adjusted to maintain an aPTT 1.5–3 times normal.
Oral warfarin then is instituted for the appropriate duration.
Approximately 3% of patients receiving oral anticoagula-
tion will present with recurrent deep venous thrombosis.
These patients should be assessed for a deficiency in
antithrombin III and proteins C and S. Bleeding is the major
complication of anticoagulation and occurs in 5–10% of
patients. This often presents as oozing from wounds, melena,
or a heme-positive gastric aspirate. If bleeding continues
despite discontinuation of heparin, protamine sulfate, a
heparin inhibitor, may be required. Infusion of fresh-frozen
plasma and vitamin K can counteract the effects of warfarin.
When LMWH is employed, the dose used depends on the
preparation (Table 29-11). Meta-analysis has failed to find a
clear advantage of one LMWH over the others with regard to
both safety and efficacy. Once-daily administration appears
as safe and effective as twice-daily use. Although anticoagu-
lation monitoring generally is unnecessary, anti–factor Xa
levels may be followed for 4 hours after injection, with a
desirable therapeutic range of 0.6–1.0 units/mL for twice-
daily administration and 1.0–2.0 units/mL for once-daily
administration. Monitoring is recommended for patients
with renal impairment because of the risk of accumulation
of anti–factor Xa activity.
C. Thrombolytic Therapy—There are currently two throm-
bolytic agents available for use in venous thrombosis.
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Multiple investigations have determined that streptokinase
and recombinant tissue plasminogen activator (rt-PA;
alteplase) are superior to intravenous heparin in preserving
venous patency and valvular function. Approximately 50% of
patients treated with thrombolytic agents retain valve func-
tion compared with 7% of those treated with heparin alone.
If complete thrombolysis is achieved, the incidence of post-
phlebitic syndrome is reduced. However, owing to the vari-
able nature of this syndrome, further investigation is
warranted to confirm these early findings.
Thrombolytic agents followed by heparin result in more
rapid resolution of lower extremity and pulmonary emboli,
restoring hemodynamic homeostasis. The main disadvantage
is the additional 1–2% risk of intracranial hemorrhage.
Because the incidence and mortality of pulmonary embolism
are the same in the two treatment modalities, systemic throm-
bolysis is reserved for acute massive pulmonary embolus in an
unstable patient with no bleeding dyscrasias. Young patients
with massive ileofemoral venous thrombosis (eg, phlegmasia
cerulea dolens) also may benefit from thrombolysis.
Neither streptokinase nor alteplase directly dissolves the
clot but rather requires activation of the fibrinolytic system.
Absolute contraindications to the use of lytic therapy include
active bleeding, recent (<2 months) cerebrovascular acci-
dent, or intracranial disease. Major contraindications include
recent surgery and evidence of GI hemorrhage. Prior to insti-
tution of therapy, the fibrinogen level, thrombin time, PT
and aPTT, platelet count, and hematocrit should be deter-
mined. Heparin administration should be discontinued.
Dosing regimens vary widely, but common doses are as fol-
lows: (1) streptokinase, 250,000 units over 30 minutes, fol-
lowed by an infusion of 100,000 units/h up to 72 hours, or
(2) alteplase, 100 mg infused over 2 hours. Within 4 hours of
commencing therapy, thrombin time, fibrinogen level, and
fibrin degradation products should be assessed. A lytic state
is documented by an elevated thrombin time and the pres-
ence of fibrin degradation products. Hematocrit should be
assessed every 6 hours. Elevation of fibrin degradation
products is anticipated. Infusion for more than 24 hours sel-
dom produces additional results. Lytic therapy should be
Patient Characteristic Recommendation 
Calf vein thrombosis Up to 3 months of anticoagulant therapy 
Proximal venous thrombosis or pulmonary embolus without previous
episode 
a. Transient clinical risk factor—major orthopedic surgery or trauma 
b. Metastatic cancer 
c. Hypercoagulable risk factors∗
or
Idiopathic thromboembolism 
Anticoagulant therapy for 4–6 weeks or until risk factor is resolved and
patient is mobile, whichever is later. 
Long-term anticoagulation (indefinite) 
Either 3–6 months of therapy 
or
Lifelong anticoagulation 
Recurrent venous thromboembolism 1 year or lifelong anticoagulation 
Any venous thromboembolism during pregnancy Unfractionated intravenous heparin for 5 days, followed by adjusted-dose
subcutaneous heparin every 12 hours† or low-molecular-weight heparin
until delivery followed by oral warfarin for 4–6 weeks. 
∗Hypercoagulable risk factors include protein C and S, antithrombin III, plasminogen deficiencies; resistance to activated protein C; hyper-
homocystinemia, and antiphospholipid antibodies.
†aPTT should be checked 6 hours after initial subcutaneous dosing.
Adapted from Ginsberg JS: Management of venous thromboembolism. N Engl J Med 1996;335:1816.
Table 29–10. Recommendations for long-term management of venous thromboembolism.
Drug Name
Subcutaneous Dose for Treatment of
Venous Thromboembolism
Enoxaparin 100 anti-Xa units/kg every 12 h*,† or 150
anti-Xa units/kg every 24 h‡
Dalteparin 100 anti-Xa units/kg twice daily‡ or 200
anti-Xa units/kg once daily‡
Tinzaparin 175 anti-Xa U/kg once daily†
∗For enoxaparin, 100 anti-Xa units/kg corresponds to a dose of
100 mg/kg.
†FDA approved for this indication.
‡FDA approved for this indication.
Data from McRae SJ, Ginsberg JS: Initial treatment of venous throm-
boembolism. Circulation 2004;110;I3–I9.
Table 29–11. Low-molecular weight heparins.
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instituted as early as possible because thrombi older than 3–5
days are less likely to respond. Bleeding, both superficial and
internal, is the most common complication. When a severe
coagulopathy develops, transfusion with fresh-frozen plasma
may be necessary to correct the deficit.
The use of thrombolytic agents in the treatment of
venous thromboembolism continues to be highly individual-
ized. In general, patients with hemodynamically unstable
pulmonary embolus or massive iliofemoral thrombosis, who
are at low risk to bleed, are the most appropriate candidates.
Endovascular placement of stents for residual iliac stenosis
after venous thrombolysis also has been reported. In a small
group of patients, patency was shown to be superior than
with conventional heparin and warfarin. Survival rates on
Kaplan-Meier life-table analysis, however, were equivalent.
D. Vena Caval Interruption—Historically, ligation of the
vena cava was performed to prevent thrombi arising in the
lower extremities and pelvis from reaching the pulmonary
bed. Plication with a clip also has been attempted. Avoidance
of complete occlusion maintained circulatory stability and
resulted in a lower frequency of recurrent pulmonary emboli
than complete ligation. In the latter, dilation of collateral ves-
sels in the retroperitoneum became a potential route for pul-
monary emboli.
Placement of a stainless steel filter, such as the Greenfield
filter, is now the preferred procedure. Absolute indications
for filter placement include recurrent thromboembolism
despite adequate anticoagulation and deep venous thrombo-
sis in patients at risk for hemorrhage. Relative indications
include the presence of a propagating iliac or femoral vein
thrombus despite adequate anticoagulation and a high-risk
patient with a large, free-floating iliac or femoral vein throm-
bus demonstrated on venography. Sepsis is not a contraindi-
cation to filter placement.
Filters usually are placed percutaneously through the
uninvolved femoral vein or through a jugular vein and posi-
tioned below the renal veins. The long-term patency rate of
the device is 98%, with a recurrent embolism rate of 4%. Up
to 80% of the filter may become filled with thrombus before
it loses its efficacy. Recurrent embolism is an indication for
inferior venacavography to evaluate the filter for the presence
of proximal thrombus. The most common complication is
displacement, which occurs in 7% of patients.
E. Operative Embolectomy—Operative removal of a deep
venous thrombus is usually reserved for cases of phlegmasia
cerulea dolens with limb threat. The highest success rate is
achieved when the procedure is performed within 24 hours
after onset of symptoms. Although early postoperative
results may be encouraging, subsequent venograms usually
show rethrombosis. This is often due to incomplete throm-
bus removal and injury to the venous endothelium.
Reocclusion is often well tolerated as long as it occurs after
the formation of sufficient venous collaterals. Mechanical
thrombectomy with creation of a temporary arteriovenous
fistula can improve early patency and allow collaterals to
develop. A recent study that examined long-term results after
embolectomy found fewer instances of venous hypertension,
valvular incompetency, and restrictions in activity among
patients who had embolectomy performed for deep venous
thrombosis of less than 3 days duration.
Postthrombotic Syndrome
Venous thrombosis is often accompanied by symptoms of
pain, swelling, and skin ulceration occurring immediately or
years after an episode of deep venous thrombosis. It is pres-
ent in over 50% of patients with proximal thrombosis and
has been reported in a third of patients with calf thrombosis.
The symptoms are thought to stem from the development of
venous hypertension caused by valvular dysfunction.
Residual venous obstruction also may contribute to the syn-
drome to a lesser extent. Thrombolytic therapy preserves
valvular function and potentially can reduce the incidence of
this phenomenon. Early results are promising. Standard
treatment involves the use of graduated compression stock-
ings and sequential compression devices.
Venous Thromboembolism in Pregnancy
Care of the pregnant patient focuses on avoiding teratogenic
injury to the fetus. Patients can be treated with continuous
UFH and gradually switched over to multiple daily subcuta-
neous doses of LMWH until delivery. Warfarin, reportedly
safe for infants of nursing mothers, is continued for 4–6
weeks postpartum. Supplemental calcium should be given in
cases of prolonged heparinization (>1 month) to prevent
heparin-induced osteoporosis. In the event of a bleeding con-
traindication or a documented pulmonary embolus, a vena
caval filter can be placed. The procedure should be performed
in the third trimester through an internal jugular approach.
The site of deployment—contrary to what is done for a non-
pregnant patient—is above the renal veins. This avoids kink-
ing and displacement of the device by a gravid uterus.
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 Acute Mesenteric Ischemia
ESSENT IALS  OF  D IAGNOS I S
 Severe acute abdominal pain out of proportion to the
physical examination.
 GI symptoms: nausea, emesis, forceful evacuation.
 Abdominal distention and GI hemorrhage.
 Leukocytosis, acidosis, and hyperamylasemia.
 Mesenteric arterial occlusion with minimal collateraliza-
tion on angiography.
General Considerations
Acute mesenteric ischemia of the bowel is an uncommon but
dramatic occurrence among ICU patients, with an estimated
overall incidence of 0.1% of all hospital admissions.
Predisposing factors include age, cardiovascular disease, ath-
erosclerosis, systemic disorders (eg, collagen-vascular dis-
ease), hypercoagulable states, malignancy, portal
hypertension, inflammation, and trauma. Semiacute and
chronic syndromes have been described, but they are rare
among ICU patients admitted for other reasons.
The consequences of vascular occlusion depend on the
vessel involved, the extent of collateral flow, and the time
period over which the occlusion took place. Acute occlusion
of vascular inflow or outflow quickly causes ischemia and
leads to transmural necrosis within 6–12 hours. The sero-
muscular layer is particularly sensitive and begins to slough
within 4 hours. Xanthine oxidase, found in high concentra-
tions within the villi, is responsible for the production of
superoxides that mediate many of the toxic reactions.
Ulceration and bacterial overgrowth follow ischemic slough-
ing. Bacterial proliferation leads to increased edema and fur-
ther thrombosis of small vessels. Increased capillary
permeability and the absorption of toxic products across the
compromised mucosa cause remote complications such as
respiratory distress syndrome. Continued ischemia leads to
intraluminal sequestration of fluid, which ultimately results
in hypovolemia and hypotension. Four general categories of
acute mesenteric ischemia are recognized.
A. Acute Embolic Occlusion—Emboli to the superior
mesenteric artery account for 40–50% of all cases. Because
these are almost always mural thrombi of cardiac origin, up to
20% of patients have synchronous emboli to other arteries. In
the majority of cases, the embolus lodges just distal to the ori-
gin of the superior mesenteric artery. Occasionally, the emboli
fracture and travel into the distal arcades of the artery before
they become lodged. Initially, collateral flow is adequate to
maintain viability of the intestine. However, after a period of
partial occlusion, vasoconstriction develops both proximal
and distal to the embolus and produces profound ischemia.
B. Mesenteric Thrombosis—Progressive atherosclerotic
narrowing of the origin of the superior mesenteric artery is
responsible for mesenteric thrombosis. Conditions that com-
promise flow through the stenotic orifice can lead to throm-
botic occlusion. Between 20% and 50% of patients with
mesenteric thrombosis will give a history of postprandial
pain and weight loss within the 6 months prior to admission.
Many have severe and diffuse atherosclerosis, with a history
of coronary, cardiac, or peripheral vascular arterial insuffi-
ciency. Mesenteric thrombosis occurs in 10–15% of all cases
of acute mesenteric ischemia.
C. Venous Thrombosis—Once thought to be the major
cause of acute mesenteric ischemia, venous thrombosis is
diagnosed in 8–10% of patients. Hypercoagulable states
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including neoplasms, cirrhosis and portal hypertension, pan-
creatitis, peritonitis, diverticular disease, trauma, and
splenectomy are precipitating factors. Presentation can be
either acute or protracted, developing over a period of sev-
eral weeks. Up to 60% of patients have a history of deep
venous thrombosis in an extremity.
D. Nonocclusive Intestinal Ischemia—Hypoperfusion or a
low-flow state is the inciting event of acute mesenteric
ischemia in 25% of cases. Coexisting conditions—predomi-
nantly cardiac pump failure—lead to prolonged visceral arte-
rial spasm and subsequent tissue infarct. Shunting of arterial
blood away from the seromuscular layer and villi causes acti-
vation of toxic intermediates. The vasoconstriction may per-
sist long after the inciting cause or agent has been removed.
Pharmacologic agents such as ergotamine derivatives, digi-
talis, cocaine, and peripheral vasocontrictors administered for
sepsis or after cardiovascular surgery are also associated with
acute mesenteric ischemia. In 4% of patients undergoing
repair of an aortic coarctation, postoperative hypertension
may lead to a necrotizing vasculitis from reperfusion injury.
Clinical Features
A. Symptoms and Signs—Acute abdominal pain is the
most common finding. Peritoneal signs are often absent on
physical examination despite the complaint of sharp excruci-
ating pain—thus the sine qua non of “pain out of propor-
tion.” Shortly thereafter, many patients experience rapid and
forceful evacuation of the bowels. Nausea and vomiting—
seen in 50% of patients—hematochezia, hematemesis,
abdominal distention, back pain, and shock are late signs
that usually accompany progression of intestinal necrosis.
The presence of peritoneal signs often heralds the onset of
systemic toxicity. Up to 30% of elderly patients develop men-
tal confusion. The duration of symptoms, however, does not
correlate with the reversibility of injury. A history of weight
loss and an acute exacerbation of chronic abdominal pain are
suggestive of acute thrombosis owing to underlying chronic
occlusive disease.
Mesenteric venous thrombosis also presents with pain as
the initial finding, but only two-thirds of patients manifest
clear signs of peritonitis. Occult blood is often present,
although frank hematochezia or hematemesis is found in
15% of patients, usually from bleeding esophageal varices.
The most common findings are abdominal pain (90%),
vomiting (77%), nausea (54%), diarrhea (36%), and consti-
pation (14%). Most patients have temperatures higher than
38°C. Hemorrhage resulting from gastric varices owing to
isolated splenic vein thrombosis is termed sinistral portal
hypertension. In this case, intestinal ischemia is not expected.
A variant of splanchnic venous disease has been described
recently. Mesenteric inflammatory veno-occlusive disease
results in unexplained acute mesenteric ischemia. Diagnosis
is based on the presence of venulitis or phlebitis with a lym-
phocytic, necrotizing, granulomatous mural infiltrate on
pathologic specimen examination.
B. Laboratory Findings—A marked leukocytosis, often
greater than 15,000/mm3, is usually present, although 10% of
patients have a normal white blood cell count. The smooth
muscle fraction (BB) of creatine kinase (CK) is elevated in
the presence of intestinal infarction. Elevations of lactate
dehydrogenase (LDH) also may be seen. Serum inorganic
phosphate is often elevated owing to either spillage from
phosphate-rich intestinal cells or degradation of intracellular
ATP. Approximately 80% of patients with intestinal infarc-
tion have high serum levels of inorganic phosphate, and 50%
demonstrate hyperamylasemia. Fluid sequestration results in
hemoconcentration and oliguria. Increased base deficit may
occur but was found in only 18 of 43 patients in a retrospec-
tive study. Peritoneal fluid analysis typically reveals leukocy-
tosis and bacteria proportionate to the extent of necrosis. It
may not be helpful in the early stages.
C. Imaging Studies—Plain films of the abdomen should be
obtained as an initial screening procedure. Nonspecific find-
ings consistent with the diagnosis include air-fluid levels,
dilated and thickened bowel wall, blunted plicae circulares,
and distention of the bowel to the level of the splenic flexure.
Specific findings of bowel necrosis include transmural air,
pneumatosis intestinalis, or gas in the portal system. Barium
contrast studies may reveal decreased motility and
thumbprinting owing to necrosis.
Angiography is the mainstay of the diagnosis and should
be individualized. The presence of peritoneal signs and sys-
temic toxicity requires immediate operative treatment to
remove devitalized tissue. Mesenteric angiography can be per-
formed early in hemodynamically stable patients suspected of
having the disease with a sole complaint of abdominal pain.
Radiographic findings will vary depending on the cause.
When an embolus is present, early truncation of the superior
mesenteric artery is observed. With acute thrombosis, com-
plete obliteration of the trunk of the artery is common. The
findings of nonocclusive ischemia are (1) tapered narrowing
of the origins of multiple branches of the superior mesenteric
artery, (2) segmental irregularities of the intestinal branches,
(3) spasm of the arcades, and (4) impaired filling of the intra-
mural branches. Findings consistent with mesenteric venous
thrombosis include (1) demonstration of a thrombus in the
superior mesenteric vein with partial or complete occlusion,
(2) failure to visualize the superior mesenteric vein or portal
vein, (3) slow or absent filling of the mesenteric veins, (4) arterial
spasm, (5) failure of the arterial arcades to empty, (6) reflux of
contrast material into the artery, and (7) a prolonged blush
phase. Abdominal CT scanning can establish the diagnosis in
more than 90% of patients with venous occlusion. Thrombus
with enhanced venous wall opacification is a highly indicative
finding. Hypodensity of the superior mesenteric vein, thick-
ening of the bowel wall, and the presence of peritoneal fluid
are a diagnostic triad seen on CT suggesting probable bowel
infarction. Scintiangiography with 99mTc sulfur colloid–labeled
leukocytes has been described but is too unreliable for general
use. Recently, the use of duplex scanning has been proposed
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as a bedside screening test, although the technique is limited
by intestinal gas overlying the vessels of interest and the
need for a skilled technician.
D. Special Studies—Laparoscopy can be useful in diagnosis,
although complete exploration of the abdomen with the
laparoscope is difficult. Furthermore, abdominal insufflation
to more than 20 mm Hg reduces mesenteric blood flow and
may exacerbate the condition. Preliminary evidence indicates
that if CO2 is used for insufflation at lower pressures, it may
provide some mesenteric vasodilation. Colonoscopy may be
useful if the large intestine is involved, although nonspecific
colitis may be the only finding. Esophagograstroduodenoscopy
can be used to detect and sclerose bleeding varices but does not
treat the underlying venous thrombosis. Both modalities avail
little in small bowel ischemia, the most common location of
acute mesenteric ischemia. Bowel tonometry using an inflat-
able balloon to provide information about intramucosal pH
(pHi) may be helpful, although decreased motility may prevent
proper peroral placement.
Differential Diagnosis
Other conditions associated with abdominal pain in the ICU
such as a perforated ulcer, pancreatitis, acalculous cholecys-
titis, appendicitis, and gynecologic pathology in women
must be investigated. These often can be identified by ultra-
sound and specific serum tests. Renal calculi produce colicky
pain radiating to the groin. Aortic dissection and rupture of
an abdominal aortic aneurysm are rare occurrences in
patients admitted to the ICU for other reasons.
Treatment
Optimal outcome depends on rapid recognition and treat-
ment. Initial therapy consists of fluid resuscitation, correction
of electrolyte and acid-base abnormalities, and management
of cardiac arrhythmias. Systemic heparinization is instituted
in patients with suspected superior mesenteric artery throm-
bosis or venous occlusion. If time permits, demonstration of
the offending lesion by angiography is ideal. When arterial
spasm is present, 25 mg tolazoline may be injected, followed
by repeat angiography. If an embolus is the cause, an infusion
of papaverine into the superior mesenteric artery orifice
should be instituted immediately. The dose customarily used
is 30–60 mg/h. Some also use papaverine in the face of mesen-
teric thrombosis, although catheter placement is difficult
owing to the occluded arterial orifice. Papaverine infusion
should be continued while the patient is readied for surgery.
Because arterial spasm and the hypercoagulable state may
persist even after successful surgery, papaverine and heparin
infusions should be continued following operation. Broad-
spectrum antibiotics are indicated both before and after sur-
gery. Nonoperative therapy is appropriate (1) if there are
significant contraindications to surgery, (2) if there are no
peritoneal signs, and (3) if there is adequate perfusion of the
vascular beds distal to the site of partial obstruction.
Infusion of thrombolytic agents has been successful anecdo-
tally in both venous and arterial thromboses. Gastroesophageal
varices—once thought to be a contraindication to this prac-
tice—were seen to resolve with successful venous clot lysis.
Problems with access to the splanchnic venous system have lim-
ited this approach. In arterial thrombosis, lytic therapy should
be instituted only in the most stable patients because of the time
required for clot lysis. When patients are treated without opera-
tion, repeat angiography at 6–8-hour intervals is required to
monitor the progress of therapy. Any worsening in the patient’s
condition is an indication for immediate operation.
Surgical management is aimed at restoration of flow and
resection of nonviable bowel. Arterial inflow may be restored
either by bypass, endarterectomy, or embolectomy.When venous
thrombosis is present, extensive bowel resections may be
required. Assessment of intestinal viability is often difficult, and
adjuncts such as Doppler flow probes and tissue fluorescence are
often used, although no method is always reliable in separating
viable from ischemic bowel. A wide resection is usually under-
taken as long as more than 6 feet of normal bowel remains. Sixty
percent of recurrent infarcts occur in the area adjacent to the
anastomosis. If the majority of the intestine is compromised,
resection is more conservative, and “second look” procedure to
determine the viability of unresected bowel commonly is per-
formed within 12–24 hours of the initial procedure.
Nonocclusive ischemia is best managed through treat-
ment of the underlying disorder causing the low-flow state.
Resuscitation and optimization of the patient’s hemodynamic
status are essential. Vasopressors should be discontinued if
possible. An alternative to digoxin should be sought, espe-
cially in patients with portal hypertension. Digitalis deriva-
tives promote mesenteric vasoconstriction in patients with
hepatic congestion from congestive heart failure. Ergotamine
poisoning is treated with selective infusion of vasodilators
(eg, papaverine), sympatholytics, and anticoagulants.
Angiotensin-converting enzyme (ACE) inhibitors (eg, capto-
pril) also serve to assuage the vasoconstrictive effects of the
renin-angiotensinogen axis in hypovolemic patients. Surgery
is reserved for resection of nonviable intestine. In addition to
careful hemodynamic support, perioperative anticoagulation
has been shown to improve survival in patients with mesen-
teric venous thrombosis. In one study, half of patients receiv-
ing no postoperative anticoagulation died. Without
anticoagulation, one-third of patients also will experience a
recurrence. Most centers recommend continuing anticoagu-
lation indefinitely unless there is a contraindication or the
factor responsible for the venous thrombosis has been cor-
rected. Recently, intravenous glucagon administered during
the early phase of reperfusion of ischemic intestinal segments
has been shown experimentally to improve mucosal recovery,
suggesting possible adjunctive use in the clinical setting.
Prognosis
Acute mesenteric ischemia carries a high mortality rate—in
some series approaching 70%. When more than half the small
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bowel must be resected, the death rate increases to as high as
85%. The cause of death in most cases is irreversible shock or
advanced intestinal necrosis. Reconstruction is attempted in
less than 10% of patients because findings at laparotomy often
show advanced disease. Patients diagnosed with superior
mesenteric artery thrombosis have an overall worse prognosis
than those in whom distal embolization has occurred. Acute
venous thrombosis has a 30% mortality rate, whereas nonoc-
clusive intestinal ischemia has been associated with death rates
as high as 90%. Early recognition of low-flow states, resuscita-
tion, and aggressive therapy have lowered mortality.
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CRITICAL CARE OF THE VASCULAR SURGERY
PATIENT
Atherosclerosis affects one in four Americans and constitutes
a major international health problem. There are over
600,000 episodes of stroke and 1.5 million myocardial
infarctions each year in the United States alone. Medical care
of these patients is complicated by advanced age and addi-
tional medical comorbidities that create a challenge in pre-
and postoperative management. This section will address
specific problems encountered when caring for vascular
surgery patients.
 Respiratory Management
Vascular surgery patients often have an extensive smoking
history. Chronic obstructive pulmonary disease (COPD),
bronchitis, and asthma therefore are not unexpected. A
room-air arterial gas measurement often determines
whether more extensive pulmonary workup is necessary.
Formal pulmonary function tests are useful to determine
the nature and extent of respiratory compromise.
Encouragement in cessation of smoking for a minimum of
2 weeks prior to elective surgery and maximization of pul-
monary reserve with adequate pharmacologic support for
patients with obstructive or restrictive airway disease are
ideal. Instruction in the use of incentive spirometry and
deep breathing exercises is also helpful in restoring postop-
erative lung function. Mechanical ventilator support is the
rule in patients undergoing intracavitary aortic operations.
An aggressive attempt at weaning should be instituted once
the patient is sufficiently awake to cooperate and maintain
airway patency. This should be followed by aggressive incen-
tive spirometry, adequate pain control, and early ambula-
tion. The details of ventilator management are presented in
Chapter 12.
 Nutritional Management
Nutritional support is a mandatory but frequently neglected
aspect of postoperative care. The catabolic response follow-
ing aortic surgery is pronounced. Because most vascular sur-
gery patients are well nourished prior to surgery, immediate
institution of nutritional support is not necessary. However,
if resumption of oral intake is not anticipated within
5–7 days after surgery, enteral nutrition should be started
through a nasoenteric feeding tube. Extensive manipulation
of the small bowel may cause mechanical ileus, although
absorptive capacity is maintained. Transient pancreatitis
also can be encountered in aortic surgery from retractor
blade pancreatic irritation. Feeding with an elemental for-
mula can be instituted at low rates (30 mL/h) and increased
in volume as tolerated. Enteral feedings reduce the risk of
septicemia associated with hyperalimentation catheters. This
is of particular importance in vascular disease patients who
have unincorporated graft surfaces exposed to the circulation.
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If nutritional support is required for more than 1 week, a
nitrogen balance study should be completed to ensure that
protein needs are being met.
 Management of Ischemic Heart Disease
Atherosclerosis is a systemic disease that affects both the
peripheral vasculature and the coronary arteries. An analysis
of pooled data from 50 studies with more than 10,000
patients demonstrated the presence of coronary artery dis-
ease in 50% of patients who had operations for aortic
aneurysms, carotid artery disease, and lower extremity
ischemia. In another series of patients with known coronary
artery disease undergoing vascular surgery, 63% were found
to have ischemic cardiac events. In the Cleveland Clinic
series, fatal myocardial infarction accounted for a 3.3% mor-
tality rate after lower extremity procedures and a 6% mortal-
ity rate after aortic aneurysm resection. A study from the
same institution using routine coronary angiography before
aortic surgery found that 85% of patients had some degree of
coronary artery disease, whereas 31% had severe disease con-
sisting of either two- or three-vessel involvement or stenosis
of the left anterior descending artery. In a study of 1000
patients undergoing routine coronary angiography, 14–22%
of patients without any prior clinical history of coronary
artery disease had severe coronary artery disease on angiog-
raphy. It should be remembered, however, that demonstra-
tion of an anatomic lesion does not necessarily equate with
physiologic compromise.
The pathophysiology of acute perioperative infarction is
not completely understood, although multiple factors are
certainly involved. These include catechol release, increased
myocardial sensitivity to catechols, fluid sequestration, alter-
ations in oxygen transport, hypercoagulable states, and
tachycardia. Because elevations in heart rate and blood pres-
sure increase the tension-time index, they result in increased
oxygen consumption. Tachycardia further limits oxygen
delivery by decreasing the diastolic filling time, during which
the myocardium receives its perfusion.
Valvular heart disease also increases morbidity after vas-
cular procedures. In the presence of aortic stenosis, up to
20% mortality may be expected for abdominal or thoracic
operations and up to 10% for peripheral procedures.
Preoperative Assessment of Risk Owing
to Coronary Artery Disease
The high incidence of cardiac ischemia after vascular surgery
frequently occasions preoperative admission of these
patients to the ICU for hemodynamic evaluation and
optimization of cardiac status. Several scales have been
devised to predict surgical risk based on clinical assessment.
The American Association of Anesthesiologists score is based
on assessment of overall health and chronic disease. While
generally useful, it is not sufficiently specific for use in
patients with critical illnesses. An evaluation developed by
Goldman employs nine variables to predict cardiac risk.
Unfortunately, it underestimates cardiac complications in
vascular patients and is able to predict cardiac mortality in
only 50% of cases. An alternative scale includes a history of
previous myocardial infarction, congestive heart failure,
unstable angina, diabetes, and age over 70. Patients classified
as intermediate or high risk were expected to have an event
rate of 10–15%. Those in the low-risk group had a less than
5% incidence of cardiac ischemia.
A. Ambulatory Electrocardiographic (Holter) Monitoring—
Continuous ambulatory monitoring of the ECG is used to
detect clinically silent ischemia. A positive finding consists of
six or more episodes in a 24-hour period of ST-segment
depression of more than 2 mm. A significantly greater inci-
dence of perioperative cardiac morbidity and mortality
occurs in those with abnormal results. A recent study found
that 38% of patients with preoperative ischemia had postop-
erative cardiac events, whereas fewer than 1% of patients
without ischemia suffered cardiac morbidity. Continuous
preoperative monitoring identifies patients with clinically
silent ischemia who might benefit from therapy. Although
this method is simple, noninvasive, and inexpensive, it suf-
fers from low sensitivity and has a positive predictive value of
only 38%.
B. Exercise Electrocardiographic Testing—Exercise stress–
induced alterations in the ECG have been used extensively
to assess cardiac risk. Because they typically require walk-
ing or running, they are not suitable for use in dysvascu-
lar patients whose exercise tolerance is limited by
claudication. Submaximal effort may yield false-negative
results.
C. Dipyridamole-Thallium Scintigraphy—In this test, a phar-
macologic agent is substituted for exercise to increase coro-
nary artery blood flow. Intravenously administered
dipyridamole promotes coronary artery blood flow without
increasing myocardial oxygen consumption by increasing the
intracellular concentration of adenosine. Blood flow
increases through normal arteries that dilate maximally.
Stenotic arteries do not respond because of fixed anatomic
lesions. Prior to administration of dipyridamole, thallium-
201 is injected to demonstrate areas of myocardial ischemia.
Because thallium-201 is preferentially taken up by the nor-
mal myocardium, areas of hypoperfusion appear as “cold”
spots. If homogeneity improves after dipyridamole is given,
thallium redistribution is said to have occurred, and the scan
is considered positive. Redistributed areas consist of viable
but ischemic myocardium that are at risk for infarction.
Areas that fail to improve after dipyridamole infusion
probably consist of previously infarcted muscle that is not at
risk for a future ischemic event. Thallium redistribution is
associated with a 30–50% risk of some postoperative cardiac
event. The positive predictive value of the test is only 22%.
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A negative scan indicates a low likelihood of perioperative
infarction, but a positive scan is of ambiguous import. The
specificity of thallium scans can be increased by combining
them with other risk factors for myocardial ischemia, includ-
ing age, a history of angina, the presence of Q waves on ECG,
the presence of type 1 diabetes, and a history of therapy-
dependent ventricular ectopy. The risk of a cardiac event in
intermediate-risk patients (one or two predictors) is as high
as 30%. This finding has since been challenged by reports
from several centers finding little use for dipyridamole-
thallium scanning in moderate-risk patients and suggesting
that a new procedure be investigated.
D. Radionuclide Ventriculography—Multiple-gated acquisi-
tion (MUGA) blood pool scans provide quantitative infor-
mation about the left ventricular ejection fraction (LVEF)
and ventricular wall motion. The normal LVEF is 55% or
greater. Those with a normal LVEF are at low risk for postop-
erative cardiac events. Those with LVEF values between 36%
and 55% are at intermediate risk, with a perioperative infarc-
tion risk of 20%. High-risk patients have LVEF values of less
than 35% and had an 80% risk of myocardial infarction.
Unfortunately, the test has a low sensitivity (44%), which
means that a negative study does not necessarily eliminate
the risk of myocardial infarction.
E. Dobutamine Stress Echocardiography—Dobutamine
stimulates myocardial contractility and increases heart
rate through β1 activity. Administration of this pharmaco-
logic agent results in higher oxygen demand. Two-
dimensional echocardiography then is used to visualize
regional wall dysfunction from myocardial ischemia.
Compared with dipyridamole-thallium scanning, this test
also was initially more successful in predicting periopera-
tive cardiac events. However, ensuing studies reported
inconsistent results with a sensitivity ranging from
54–96% and specificity in the range of 57–95% in com-
parison with cardiac catheterization.
F. Coronary Angiography—Coronary angiography should
be used only in selected patients whose noninvasive studies
place them at high risk for coronary events. The results of
angiography can be used to plan further procedures such as
angioplasty or coronary artery bypass.
Postoperative Cardiac Management
Postoperative cardiac ischemia and myocardial infarction are
caused by an increased myocardial oxygen requirement in
the face of inadequate supply. Myocardial oxygen consump-
tion is related to the tension-time index, which is the prod-
uct of systolic blood pressure and heart rate. Animal studies
have shown that cardiac work and myocardial oxygen con-
sumption both increase when the heart pumps against
elevated diastolic pressures. Prolonged work against
increased afterload results in myocardial hypertrophy, which
also increases oxygen consumption. Tachycardia has two
adverse effects on myocardial oxygen balance. First, it
directly increases oxygen demand by increasing the time-
tension index, and second, it reduces the diastolic filling
time, thereby limiting the period during which myocardial
blood flow occurs. Pharmacologic management is frequently
necessary to improve myocardial oxygenation by decreasing
the heart rate and lowering blood pressure.
Antihypertensive Therapy
Postoperative hypertension occurs in up to 50% of patients
after aortic or carotid surgery. Pain is one of the most com-
mon causes and should be addressed initially. Small intra-
venous doses of morphine sulfate should be titrated to effect.
Hypotension and respiratory depression are the major com-
plications of opioid administration. Opioids should be
given to carotid surgery patients only after they have recov-
ered from their anesthetic and a postoperative neurologic
examination has been completed. Lorazepam is a relatively
short-acting benzodiazepine that provides sedation. It may
be used as an adjunct to the analgesic effect of morphine.
Lorazepam is particularly useful in aortic surgery patients
who require mechanical ventilation after operation. The initial
intravenous dose is usually 2–3 mg titrated to effect at inter-
vals of 4–6 hours.
Excessive intraoperative volume administration may
cause postoperative hypertension. This is particularly true
among patients who have received epidural anesthetics that
cause vasodilation. Resolution of the block and return of
normal vascular tone may result in hypertension.
Hypervolemia also may follow mannitol administration and
excessive volume loading instituted prior to removal of the
aortic cross-clamp. Postoperative volume status should be
evaluated and optimized with the aid of a pulmonary artery
flotation catheter. Careful administration of diuretics is
required to avoid inadvertent iatrogenic hypervolemia.
Once remediable causes of hypertension have been elimi-
nated, persistent hypertension should be treated to reduce
myocardial oxygen demand owing to increased wall stress.
The threshold for treatment will vary with the patient, the
type of procedure performed, the duration of hypertension,
and preoperative risk factors. Elevation of systolic blood pres-
sure above 120% of baseline is a reasonable point at which
therapy should be instituted. Agents with shorter half-lives
allow more precise titration of blood pressure, whereas
longer-acting agents have the advantage of decreased dosing
requirements. Nitroprusside and nitroglycerin are both fast-
acting agents that can be given intravenously. Nitroprusside
has a balanced effect because it dilates both arterioles and
veins. As an arterial vasodilator, it lowers blood pressure by
decreasing arteriolar vascular resistance without increasing
venous capacity. The decreased afterload reflexively
increases cardiac sympathetic stimulation that may result in
undesirable tachycardia. Nitroglycerin is preferred because
it produces coronary artery vasodilation in addition to
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decreasing preload. Because nitroglycerin can precipitously
decrease filling pressures, it is imperative to ensure normal
pulmonary capillary wedge pressure (PCWP) prior to the
institution of therapy. Intravenous doses are started near 5 μg/min
and increased by this amount every 5–10 minutes until the
desired effect is reached. The normal vasodilatory dose is
between 50 and 100 μg/min, although some patients require
doses as high as 400 μg/min. High doses can be tolerated for
several days, although methemoglobin concentration should
be monitored.
Agents that provide β-adrenergic blockade also may be
used to treat postoperative hypertension. Labetalol is partic-
ularly useful because it provides not only nonspecific beta
blockade but prevents reflex increases in vasoconstriction by
its α-adrenergic blocking activity. Labetalol has a relatively
long half-life of 6–8 hours and should be used with caution
in patients with hepatic and renal insufficiency because of its
route of elimination. The initial intravenous dose is 10–25 mg,
supplemented every half-hour to desired effect. ACE
inhibitors, initially used to decrease afterload in heart failure,
were demonstrated recently to significantly reduce mortality,
myocardial infarction, stroke, cardiac arrest, and heart fail-
ure. The Heart Outcomes Prevention Evaluation Study inves-
tigators found that treating 1000 patients with ramipril
(a long-acting ACE inhibitor) for 4 years prevented approxi-
mately 150 events in 70 patients.
Tachycardia
Fever, pain, and hypovolemia are the most common causes of
tachycardia (heart rate >100 beats/min) in postoperative
patients. Hypovolemia may be caused by inadequate volume
replacement or by continued volume loss such as hemorrhage
or osmotic diuresis. Unrecognized causes of obligatory
osmotic diuresis include hyperglycemia and intravenous
contrast material administered prior to or during surgery.
Pulmonary artery flotation catheters facilitate the evaluation
of tachycardia by providing information on relative volume
status. After inciting causes have been addressed, primary
tachycardia should be treated if the heart rate remains ele-
vated. Esmolol is an agent that is relatively β1-selective and has
a half-life of only 9–10 minutes. A loading dose of 500 μg/kg is
administered over 1 minute, followed by a continuous infu-
sion of 50 μg/kg per minute. The infusion rate is decreased as
tachycardia resolves.
Renal Failure
The incidence and prognosis of acute renal failure occurring
after vascular surgery depend on the overall preoperative sta-
tus of the patient, the nature of the surgery performed, and
associated complications such as cardiac failure or sepsis.
The reported incidence of acute renal failure after elective
aortic surgery ranges from 1–15%. Following surgery for
ruptured aortic aneurysms, it is between 21% and 100%,
with associated mortality rates between 50% and 95%.
Despite improved intra- and postoperative management, the
incidence of acute renal failure after vascular surgery has not
changed appreciably in the past 20 years. Several factors con-
tribute to the development of renal failure, including
suprarenal aortic cross-clamping, renal artery occlusion,
declamping hypotension, and embolization of atheroscle-
rotic debris to the kidneys. Autopsy studies of patients with
postischemic acute renal failure have found minimal alter-
ations of glomerular architecture in the face of profound dis-
ruption of tubular morphology. Acute tubular necrosis or
luminal obstruction caused by sloughing of tubular cells is
thought to be the inciting event.
Intraoperative maneuvers aimed at protecting renal func-
tion are directed mainly at reducing the severity and dura-
tion of renal ischemia. Circulating blood volume and cardiac
output should be optimized prior to interruption of renal
blood flow. The intravenous infusion of 12.5–25 g mannitol
prior to aortic occlusion is common practice. Mannitol offers
a protective effect by (1) expanding circulating blood vol-
ume, (2) acting as an osmotic diuretic to promote urine flow
and prevent stasis, (3) attenuating the reduction in cortical
blood flow, and (4) serving as a free-radical scavenger.
Intraoperative contrast angiography produces a postopera-
tive osmotic diuresis and makes absolute urine output an
unreliable indicator of renal perfusion. When dye has been
used, sufficient fluid should be administered to reduce urine
specific gravity below 1.015. In the postoperative period,
maintenance of adequate blood volume and cardiac output
are the best defenses against renal failure. A pulmonary
artery catheter should be used to assess venous return and
cardiac function in patients who have had intraabdominal
surgery. Sufficient maintenance and replacement fluid must
be given to ensure adequate cardiac preload. Inotropic agents
such as dopamine or dobutamine also may be required.
Dopamine in doses below 5 μg/kg per minute promotes
diuresis by dilating renal afferent arterioles. Recently, the
administration of oral acetylcysteine along with hydration
has been shown to prevent the reduction in renal function
caused by low-osmolarity contrast agents in patients with
chronic renal insufficiency. Its vasodilatory and antioxidant
properties are speculated to be the mechanisms of action.
Acetylcysteine is given in a dosage of 600 mg twice on the day
prior to and on the day of contrast material administration.
Reperfusion of severely ischemic muscle beds may cause
the release of myoglobin into the circulation. A positive dip-
stick reaction for urine hemoglobin without the presence of
red blood cells on microscopic analysis is evidence of myo-
globinuria. Sodium bicarbonate (100 meq/L) admixed with
maintenance intravenous solutions should be administered
to alkalinize the urine. Urine volume must be maintained
above 1–2 mL/kg per hour. The myonephrotic syndrome of
renal failure in the face of progressive rhabdomyolysis carries
a mortality rate of more than 50%.
Other causes of oliguria include aminoglycoside toxicity
and postrenal obstruction. The latter may be caused by a
kinked urinary catheter or by inadvertent intraoperative
ureteral ligation. After other causes of oliguria have been
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excluded, radionuclide imaging is reasonable to assess renal
blood flow and urinary excretion. If concern about postrenal
obstruction exists, bedside ultrasound can be used to identify
hydronephrosis.
 Complications of Vascular Surgery
Infection
Prosthetic graft infection is a devastating complication that
occurs in 1–6% of patients depending on comorbid factors,
location, and type of graft. The organism usually responsi-
ble is Staphylococcus aureus, although others, including
yeasts, anaerobic bacteria, and mycobacteria, have been
identified. Most graft infections are diagnosed after discharge
(>4 months) rather than in the early postoperative period.
Perioperative antibiotic prophylaxis usually consists of a
first-generation cephalosporin with good activity against
S. aureus and S. epidermidis. It should be noted that compa-
rable rates of graft infection have been reported both with
and without the use of perioperative antibiotics.
Antibiotic administration should be continued until all
indwelling intravenous and urinary catheters have been
removed. Patients who have undergone reconstruction fol-
lowing vascular trauma should be observed closely for evi-
dence of necrosis at wound sites. Devitalized tissue is an
excellent culture source for bacteria. Early debridement and
sufficient autologous coverage can prevent the late sequelae
of graft infections—namely, thrombosis, rupture, and the
development of paraanastomotic pseudoaneurysms.
Gastrointestinal Complications
Ischemic colitis and mesenteric ischemia are feared compli-
cations following resection of an abdominal aortic
aneurysm. Interruption of the blood supply to the left colon
following ligation of the inferior mesenteric artery is the
usual cause, especially after repair of a ruptured aneurysm. In
patients with severe chronic occlusive disease or those who
have had previous abdominal procedures, interruption of
vital visceral collaterals also can contribute to bowel
ischemia. Early nonspecific harbingers of this complication
include an acute fever spike with increased white blood cell
count, lactic acidosis, and bloody diarrhea. Antibiotics, intra-
venous fluid administration, and immediate sigmoidoscopy
and colonoscopy are undertaken. Once the diagnosis is veri-
fied, a transmural infarct requires operative resection.
Expectant management is justified in patients in whom
ischemia does not involve the full thickness of the bowel wall.
Acalculous cholecystitis occurs in 1% of all patients
undergoing aortic surgery. Right upper quadrant abdominal
pain, fever, leukocytosis, and hyperbilirubinemia are com-
mon. Bedside ultrasonography is preferred over 99mTc-HIDA
scanning to establish the diagnosis. Immediate cholecystec-
tomy or cholecystostomy is usually required. Ischemic
pancreatitis may be confused with cholecystitis. Elevations of
the serum amylase and lipase allow separation of the two. A
mild pancreatitis is caused by exposure of the aorta and
retractor injury. It is usually self-limiting.
 Complications of Common Vascular
Procedures
Carotid Endarterectomy
Either hypotension or hypertension may occur early in the
postoperative course. Hypertension may lead to the forma-
tion of neck hematomas and hemorrhagic stroke.
Hypotension can lower the cerebral perfusion pressure that a
hypertensive patient is normally accustomed to and thus
results in cerebral infarct. Judicious use of fast-acting
vasodilators (eg, nitroglycerin or nitroprusside), β-blockers
(eg, esmolol), or vasoconstrictors (eg, dopamine) in the
immediate perioperative period to maintain a constant and
stable blood pressure is a sound management stratagem.
Effective weaning from these agents is accomplished once
sufficient volume is infused.
The incidence of postoperative strokes ranges from
1–3%. Although the majority result from intraoperative
embolization or cerebral ischemia, up to 19% may be due to
acute thrombosis of the carotid artery. Transient ischemic
attacks within the first week have been reported to be as high
as 8%. When a patient is first noted to have a neurologic
deficit, determining internal carotid artery patency is impor-
tant because prospects for neurologic recovery are directly
related to the speed with which flow is restored. If no intra-
operative completion studies were performed, initial diag-
nostic evaluation should be via noninvasive bedside imaging
such as Doppler ultrasound or duplex scanning. Patients
with abnormal or equivocal findings require immediate
reexploration. If noninvasive studies are normal, emergency
carotid angiography is indicated to identify small defects that
can be repaired. If the patient had a normal intraoperative
completion arteriogram or duplex scan, the source of deficit
is embolic, and reoperation offers little benefit.
Headaches after carotid surgery are not uncommon.
Severe headaches in the face of hypertension should be mon-
itored carefully and the blood pressure expeditiously con-
trolled. A CT scan of the brain is obtained, and a diagnosis of
cerebral hyperperfusion syndrome is then entertained. This
can happen in patients undergoing endarterectomy for
chronic severe occlusive disease or in patients with an acute
cerebrovascular accident. The common denominator is reac-
tive hyperemia or cerebral reperfusion injury. Lesser forms of
this condition result in symptoms consistent with mild cere-
bral edema, headache, and seizures. A more severe presenta-
tion results in catastrophic intracerebral hemorrhage from
vessel rupture. Prompt recognition and treatment with anti-
hypertensives, osmotic diuretics, and anticonvulsants can be
lifesaving. If intracerebral hemorrhage has occurred, the
prognosis is poor.
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Aortic Operations
Abdominal aortic aneurysm repair in the elective setting
has a mortality rate of 1–3%. Repaired emergently, mortal-
ity is often greater than 50%. Predictors that herald poor
survival include the duration and severity of perioperative
shock, hypothermia, and cardiac reserve. Postoperatively,
myocardial infarction, coagulopathy, renal failure, respira-
tory insufficiency, ischemic bowel, poor nutrition, and
infection often contribute to morbidity. Meticulous ICU
monitoring with a pulmonary catheter and aggressive treat-
ment are mandatory. Adequate intravascular volume
replacement is necessary to maintain organ perfusion.
Patients often require a significant amount of volume for
the first 24–48 hours owing to shifts of intravascular fluid
into the interstitium. On the third or fourth day, reentry
into the vascular system occurs, and a brisk diuresis ensues.
At this stage, electrolytes are replaced carefully and urine
output maintained, with diuretics if necessary. Prolonged
mechanical ventilation is required for respiratory failure
and hemodialysis for renal compromise. Mesenteric
ischemia and ischemic colitis may result, and the first sign
is often an uncorrectable metabolic acidosis, fever, and
rapid leukocytosis. Melena and hematochezia are late signs
and portend bowel necrosis. Prolonged shock and ischemia
of the spinal cord result in paraplegia in 2% of patients.
Corticosteroids may be used once other causes of spinal
shock have been eliminated.
Peripheral Operations
The most common cause of morbidity in lower extremity
bypass operations is cardiac insufficiency. Preoperative opti-
mization and dosing with β-blockers have been shown to
decrease postoperative events. Prolonged hypotension or
hypovolemia may lead not only to myocardial ischemia but
also to thrombosis of the bypass graft. Careful hemodynamic
monitoring and support can prevent these complications. If
a palpable pulse is present distal to the graft, it should be
monitored regularly for any change in strength or character.
An abrupt decline in or absence of the pulse is highly sugges-
tive of graft occlusion. In patients who are admitted to the
ICU without palpable pulses, a Doppler probe or piezoelec-
tric pulse monitor can be used to evaluate graft patency.
A pulse oximeter probe placed on a finger or toe distal to the
bypass site is another convenient technique for monitoring
graft patency. Revascularization for traumatic injury or
chronic ischemia may cause limb swelling that resolves with
elevation. The development of a compartment syndrome
should be recognized immediately and treated promptly
with fasciotomies. In patients with prolonged ischemia, myo-
globinuria may occur after revascularization and may lead to
renal failure unless recognized and treated with adequate
hydration and diuresis.
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Alterations of consciousness including coma, seizures, and
neuromuscular disorders account for many of the neurologic
problems in patients admitted to ICUs. Therefore, this chap-
ter emphasizes encephalopathy and coma, seizures and status
epilepticus, and problems associated with neuromuscular
disorders. A comprehensive review of cerebrovascular disease
and stroke syndromes is beyond the scope of this book, but
since the critical care physician undoubtedly will have to deal
with cerebrovascular diseases, some fundamental aspects of
these disorders are described. In addition, certain aspects and
complications of CNS infectious diseases are included.
ENCEPHALOPATHY & COMA
 Coma
The brain controls the individual’s ability to breathe, obtain
food and water, and avoid noxious stimuli in the environment.
When the individual slips into coma, the ability to perform
these functions is lost, and the patient will not survive unless
coma is reversed. In this sense, coma represents a global failure
of brain function. There are many causes of coma, some of
them reversible. The first responsibility of the physician caring
for a patient in coma is to ensure that breathing, circulation,
and nutrition are maintained. The cause of coma then must be
determined and reversible causes treated appropriately.
Normal consciousness has two main components: con-
tent and arousal. They have different anatomic substrates,
with the former localized largely in the cerebral cortex and
the latter depending on the brain stem reticular activating
system. Injury to the dominant cortical hemisphere leads to
impairment or loss of language function, but bilateral corti-
cal injury is required for complete loss of consciousness.
Furthermore, the cortex is responsible for interpreting
incoming signals. This includes encoding and assigning
“meaning” to emotional and sensory inputs. When the cor-
tex is diffusely injured, the ability to reflect on and interpret
experience is lost, and for this reason, the content of con-
sciousness is lost as well.
The major role of the brain stem reticular activating sys-
tem is to arouse and alert the cortex so that the organism can
reflect on and react to stimuli from the environment. A
patient can lose consciousness by two different mechanisms:
diffuse dysfunction of the cerebral cortex or injury to the
reticular activating system. Coma often develops as a result of
injury to both areas. However, cortical neurons are extremely
sensitive to a variety of metabolic and toxic injuries, includ-
ing hypoxia, hypercapnia, hyponatremia, hypernatremia,
hypoglycemia, hyperglycemia, and many drugs, whereas the
brain stem is more resistant to these injuries. Thus toxic and
metabolic injuries first cause dysfunction in cortical neu-
rons, and only with increasing severity influence the brain
stem. In contrast, coma owing to primary brain injury affects
the reticular activating system. These major anatomic differ-
ences allow the clinician to distinguish metabolic from struc-
tural causes of coma.
Neuroimaging techniques suggest that there may be a
fundamental pathophysiologic basis for many of the meta-
bolic causes of coma, perhaps explaining why so many
patients with different causes present with such similar clin-
ical profiles. In comas owing to metabolic encephalopathy, a
profound and diffuse decrease in cerebral glucose metabo-
lism has been shown using positron-emission tomography.
Similarly, severe and diffuse cerebral hypoperfusion as meas-
ured with 133Xe appears in patients in coma owing to sepsis,
hepatic encephalopathy, hypoxia, head trauma, and cocaine
intoxication. Studies in comatose patients using 31P magnetic
resonance spectroscopy have shown dramatic decreases in
the brain’s energy-containing phosphorus compounds,
including ATP and phosphocreatine. This work suggests that
any process that compromises cortical neuronal energy pro-
duction may lead to a comatose state.
Clinical Features
One key issue in the evaluation of any unconscious patient
is whether the unconscious state is due to metabolic,
toxic, or structural brain injury. Because there are only
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minor differences in the clinical characteristics of comatose
states owing to varying types of metabolic and toxic insults,
the clinical examination cannot definitively distinguish one
metabolic cause from another; thus the cause must be sought
or confirmed with laboratory investigations. In contrast, if
the clinical examination suggests structural brain injury,
emergency imaging tests must be performed to determine
the cause so that appropriate treatment can be initiated.
Simultaneously with the assessment of the neurologic
examination, it is critical that the physician obtain an accu-
rate history. Although a comatose patient cannot give a his-
tory, relatives, housemates, and others often describe the
onset of coma and provide information regarding medica-
tions and preexisting illnesses. Even when information from
these sources is not available, paramedics usually can provide
details about the circumstances in which the patient was
found. In all cases, a check of the patient’s pockets and purse
or wallet may help to elicit important medical data, and some
patients wear medical bracelets or necklaces, which will alert
the examiner to potential causes of coma.
Rapidity of onset is an important clue to the cause of
coma. Certain metabolic insults such as hypoxia, ischemia, or
hypoglycemia may come on suddenly, whereas others such as
hyponatremia, hypernatremia, and hyperglycemia develop
subacutely. Similarly, subarachnoid hemorrhage or brain
stem ischemic stroke can lead to sudden coma, whereas coma
related to chronic subdural hematoma, cortical ischemic
stroke, or brain tumor usually develops slowly.
The five main areas that need to be assessed in the evalu-
ation of a patient in coma are (1) level of consciousness,
(2) pupillary responses and ophthalmoscopic examination,
(3) oculomotor system, (4) motor system, and (5) respira-
tory and circulatory systems.
Based on the findings in these domains, usually it is pos-
sible to localize accurately the specific regions in the brain
that are impaired. Table 30–1 lists changes that occur with
injury in different anatomic areas of the brain. A precise
anatomic localization of the area of dysfunction in the brain
often helps to elucidate the cause of coma. Although coma
scales are helpful in assessing prognosis, they are not a sub-
stitute for neurologic examination because they neither
localize the area of dysfunction nor help in determination of
the cause.
A. Level of Consciousness—Many terms such as stuporous,
lethargic, drowsy, and semicomatose have been used to char-
acterize degrees of altered consciousness. However, it is bet-
ter to describe the patient’s spontaneous activity, response to
verbal stimuli, and reaction to painful stimuli in precise
terms that do not have different meanings to different
observers. A carefully recorded description of the patient’s
level of consciousness on entry into the hospital will be
invaluable in following the progression of the comatose state.
With herniation from a large unilateral cerebral hemisphere
mass, drowsiness occurs when the reticular activating system
in the thalamus is compressed; coma ensues when injury to
the reticular activating system reaches the midbrain.
The best places to apply painful stimuli to determine
arousability are over the sternum or the nail beds; these
maneuvers also help to determine whether the patient
responds with evidence of focality, for example, if there is no
movement of one side while the other hand attempts to
remove the painful stimulus.
B. Pupillary and Ophthalmoscopic Evaluation—Perhaps
no component of the neurologic examination is as valuable
for differentiating metabolic or toxic coma from coma owing
to structural brain disease as inspection of the pupils.
Pupillary size is determined by the relative contributions of
the parasympathetic and sympathetic autonomic fibers.
Coma associated with brain injury usually exhibits changes
in the pupillary response. These changes occur because most
structural comas are associated with injury to the reticular
activating system in the brain stem where the Edinger-
Westphal and sympathetic autonomic fibers are located.
Anatomic Level Mental Status Pupillary Size and Position Eye Movement Motor Responses 
Respiration and
Circulation 
Diencephalon Drowsy Small (1–2 mm) Normal Abnormalities of flexion Cheyne-Stokes 
Midbrain Coma Fixed in mid position Dysconjugate Abnormalities of
extension 
Hyperventilation 
Pons Coma 1 mm in primary pontine
injury; fixed and 4–5 mm
with prior midbrain injury 
Complete paralysis Abnormalities of
extension 
Hyperventilation 
Medulla Variable Variable Variable Flaccid Apnea, circulatory
collapse 
Table 30–1. Localization of brain lesions in a comatose patient. 
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With acute injury to the midbrain, the pupils become fixed
in midposition as a result of simultaneous injury of sympa-
thetic and parasympathetic fibers. In contrast, injury to the
pons often is associated with pinpoint, minimally reactive
pupils. Lateral tentorial herniation of the temporal lobe may
result in compression of the third cranial nerve and the
parasympathetic fibers traveling with it, causing dilation of
the pupil on the side of the herniation. In some lateral herni-
ations there will be compression of the contralateral third
nerve against the edge of the tentorium.
A major characteristic of coma owing to metabolic dis-
eases is sparing of the pupillary response. This occurs
because metabolic coma causes selective dysfunction of the
cortex, whereas the centers in the brain stem that control the
pupils are spared. Many comas owing to drugs spare the
pupils, although some commonly used drugs do influence
the pupillary response (Table 30–2).
The ophthalmoscopic examination can provide valuable
information. Papilledema usually implies increased intracra-
nial pressure, whereas subhyaloid hemorrhage, which
appears as a fresh, red flame-shaped hemorrhage between
the retina and vitreous, is virtually pathognomonic of sub-
arachnoid hemorrhage.
Despite the importance of the ophthalmoscopic evalua-
tion, under no circumstances should the pupil be dilated in a
comatose patient because changes in the pupils are often the
most reliable clinical indication of deterioration following
brain injury.
C. Oculomotor System—As with pupillary responses,
changes in the oculomotor system often occur with primary
neurologic injury. The system responsible for moving the
eyes is located between the sixth nerve in the pons and the
third nerve in the midbrain. Closely adjacent to the sixth
nerve is a gaze center known as the pontine paramedian retic-
ular formation (PPRF). Just prior to moving one of the eyes
laterally, which is accomplished with the sixth nerve, there is
rapid firing in the PPRF. The contralateral eye will deviate
medially via fibers that travel from the PPRF, cross in the
pons, and travel medially to the contralateral third nerve
nucleus in the medial longitudinal fasciculus.
The simplest way to test the viability of this system is the
oculocephalic (“doll’s eye”) reflex. For this test, the patient is
positioned with 30-degree neck extension, and the head is
moved from side to side. If the brain stem PPRF and the
vestibular system are intact, the eyes should move smoothly
in the direction opposite to that in which the head is moved.
A more precise test is the caloric oculovestibular response.
For this test, the comatose patient is elevated to a 30-degree
angle, and one tympanic membrane is irrigated with ice-cold
water. Ten milliliters usually is sufficient to produce a
response. Within 1–2 minutes, both eyes should deviate lat-
erally toward the side where the cold water was instilled. In
metabolic or toxic coma this system is spared, whereas in
many structural comas the oculovestibular system is
impaired; in brain death, it is absent. In the normal, awake
patient, slow deviation toward the side of the stimulus is lost,
and nystagmus in the contralateral direction is observed.
D. Motor Systems—Primary brain lesions often are associ-
ated with focal motor deficits, but in metabolic or toxic
states, focal motor findings are normally absent. With lateral
cortical or internal capsular injury, the examination shows
contralateral motor deficit. Posturing in flexion (decorticate
posturing) supervenes when diffuse dysfunction of the dien-
cephalon occurs. Injury of the brain stem motor systems
between the red nucleus in the midbrain and the vestibu-
lospinal nuclei in the medulla leads to an abnormal extensor
response in the arms with flaccid or extensor response in the
legs (decerebrate posturing). Injury to motor systems at or
below the level of the vestibulospinal nuclei results in flaccid-
ity. With progressive neurologic injury, moving from higher
to lower centers, one sees a progression from paralysis to
flexor posturing to extensor posturing to flaccidity.
E. Respiratory and Circulatory Changes—With injury at
the level of the pons, abnormal respirations may occur. Once
the medulla is injured, there is loss of respiratory function,
and apnea ensues. Similarly, in the beginning stages of
medullary compression, abnormalities in blood pressure—
usually hypertension—can present. As the medullary injury
progresses, hypotension intervenes.
The first manifestation of a compressive lesion of the
medulla often is respiratory or circulatory collapse. Severe
hypertension is sometimes the first or main manifestation
of posterior fossa lesions. For these reasons, posterior fossa
lesions are difficult to diagnose and can be catastrophic
when missed.
Drug Type 
Pupillary
Response Other Changes 
Opioids Pinpoint None 
Barbiturates and
benzodiazepines 
Reactive None 
Anticholinergics
(scopolamine, etc.) 
Pupils dilated Tachycardia, seizures 
Anticholinesterases
(organophosphates) 
Pupils constricted Bradycardia, sweating,
salivation 
Cocaine and
amphetamine 
Pupils dilated Tachycardia, hypertension,
hypotension, arrhythmia 
Neuroleptics Pupils variable Motor rigidity,
hypotension, hyperthermia
Antidepressants Pupils dilated Rarely seizure 
Table 30–2. Physical findings in drug-induced comas.
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Differential Diagnosis
The major group of diseases that cause coma include meta-
bolic, toxic, and primary neurologic injury. The cause usually
can be determined by neurologic examination.
A. Metabolic Coma—In any patient with unexplained coma
suggesting metabolic dysfunction, it is important to measure
serum sodium, glucose, urea nitrogen, and creatinine; to
determine PaO2 and PaCO2; and to perform liver and thyroid
function tests. A toxicology screen also is mandatory. Sepsis
can lead to coma, and evidence for infection should be sought
in any delirious or comatose patient. The physician should
have a low threshold for obtaining lumbar puncture for cere-
brospinal fluid (CSF) analysis in a patient with unexplained
coma. Comas owing to various metabolic factors have more
similarities than differences. Table 30–3 lists the major meta-
bolic causes of coma and comments on subtle differences in
coma owing to these various metabolic abnormalities.
Elderly people are particularly vulnerable to the effects of
metabolic insults and poorly tolerant of mild fluctuations in
metabolic status. Therefore, it is common to observe an eld-
erly patient in coma owing to relatively mild metabolic
abnormalities, whereas this same combination of metabolic
changes might not lead to coma in a young, otherwise
healthy individual. One typical example is the elderly patient
who develops delirium or even coma associated with a
pulmonary or urinary tract infection. In fact, elderly
patients’ changes in mental status sometimes are the first
manifestation of sepsis. Many patients with primary brain
injury, however, demonstrate mild metabolic abnormalities,
and one should not automatically assume that subtle meta-
bolic changes explain why a patient is in coma.
B. Toxic Coma—Coma secondary to drugs often resembles
coma from other metabolic processes. However, respiratory
suppression may be more common in patients with drug-
induced coma. Similarly, some groups of drugs have specific
effects on the pupils. The drugs that can cause coma are too
numerous to list in this chapter. Table 30–2 lists some com-
monly abused drugs and emphasizes the characteristics of
coma associated with drug overdose.
C. Primary Brain Injury—CNS infection, trauma, and
stroke can lead to coma. Massive rises in intracranial pressure
such as those seen with severe head injury, subarachnoid
hemorrhage, or blockage of CSF flow by a ventricular mass
cause sudden coma. Coma also occurs with acute injury to
the reticular activating system in the brain stem owing to
basilar artery thrombosis or pontine hemorrhage. In any
patient with altered consciousness and focal motor findings,
it should be assumed that a focal brain lesion is present.
Once it has been determined that a primary neurologic
event is a possible cause of the coma, emergency scan of the
brain is required. CT generally can be done quickly, is very
sensitive for acute hemorrhage, and demonstrates most focal
injuries. However, many patients with coma secondary to
ischemic brain injury, isodense subdural hematomas,
encephalitis, and meningitis will not show changes on CT
unless contrast material is used. If readily available, MRI is a
Disease Coma Mechanisms and Features Treatment 
Hyponatremia Acutely: <120 meq/L
Chronically: <110 meq/L 
Leads to true cytotoxic edema.
Skin can be doughy. 
Hypertonic saline. Overly rapid correction
may lead to central pontine myelinolysis. 
Hypernatremia >155 meq/L Loss in brain water. Seizures common. Slow rehydration. 
Hypoglycemia <30 meq/dL Deprivation of brain glucose for energy
metabolism. Seizures are common. 
Needs urgent glucose replacement. 
Hyperglycemia Ketotic or nonketotic Changes in brain water and pH contribute 
to both. Nonketotic coma often has
focal findings. 
Slow correction. 
Hypoxia PaO2 usually <40 mm Hg Loss of brain O2 for aerobic
metabolism. 
Needs urgent correction. 
Renal failure Variable Brain acidosis is a factor. Renal dialysis. 
Hepatic failure Variable. Often precipitated by medications
or gastrointestinal bleeding 
Brain ammonia and changes in glutamine 
or dopamine hypothesized as causes.
Hyperventilation and decerebrate
posturing. 
Treat precipitating factor.
Lactulose administration. 
Hypothyroidism Chronic low levels Clinical findings of myxedema. Slow thyroid hormone replacement. 
Table 30–3. Metabolic comas: mechanisms and treatment.
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good choice, although the imaging process takes longer than
CT scanning and is more expensive. Cerebral blood flow
imaging, single-photon-emission computed tomography
(SPECT), and diffusion MRI also may be helpful in the eval-
uation and management of patients with acute brain injury.
D. Brain Death—The diagnosis of brain death is an
unavoidable issue in the practice of critical care medicine
and must be approached with sensitivity to the patients’ close
associates and an awareness of the possibility of organ dona-
tion. When brain death appears likely, a frank discussion
with family members usually is indicated. It should be recog-
nized that spinal reflexes and even myoclonus may persist in
the brain-dead patient and can be misunderstood both by
medical personnel and by family members. Declaration of
brain death requires the demonstration of irreversible loss of
both brain stem and cerebral function and should be done in
consultation with a neurologist. Permanent loss of cerebral
function with preservation of brain stem function is termed
the chronic vegetative state, and current practice requires that
such patients be given appropriate supportive care.
Treatment
The first step in the management of a patient in coma is to
secure the airway and ensure adequate oxygenation. This
may require intubation. Furthermore, intubation should be
considered when control of PaCO2 is necessary. Hypercapnia
causes cerebral vasodilation, and hypocapnia causes vaso-
constriction; the former can increase intracranial pressure,
and the latter can reduce it. In addition, aspiration is a com-
mon problem in the patient with altered consciousness and
another reason to consider intubation.
Just as important in the management of coma is the quick
assessment and control of the circulatory system. Even in
patients with initially normal blood pressures, sudden loss of
systemic perfusion can occur and can lead to irreversible brain
injury. Therefore, a large-bore intravenous catheter should be
placed in all comatose patients so that circulatory access is
assured. Following this and when dealing with an unknown
cause, 100 mg thiamine and then a bolus of dextrose should be
administered as treatment for potential cases of Wernicke’s
encephalopathy or hypoglycemia. In many patients with brain
lesions and increased intracranial pressure, reflex systemic
hypertension occurs. In the case of cerebellar or ventricular
mass lesions, focal findings may be subtle or even absent and
can lead to the incorrect assumption that the coma is due to
hypertension and the primary problem ignored. Unexpected
herniation can occur in such patients. Irrespective of the cause
of increased intracranial pressure, lowering of systemic blood
pressure could result in loss of cerebral perfusion.
Once respiration and circulation are maintained, the
focus is on treatment appropriate to the diagnosis. The next
chapter outlines the management of coma owing to
increased intracranial pressure. Many metabolic causes of
coma such as hypernatremia, hyponatremia, hyperglycemia,
and hepatic encephalopathy have protocols that demand
meticulously organized treatments that often require days.
Similarly, drug-induced comas may require specific treat-
ment. In coma owing to barbiturate or benzodiazepine tox-
icity, simply maintaining respiratory and circulatory
support until the drug is cleared will be sufficient, whereas
other poisons may require administration of specific anti-
dotes (see Chapter 37).
SEIZURES
All physicians in critical care medicine on occasion will have
to manage seizures, which may be seen as the patient’s pri-
mary problem or as a problem complicating other illnesses.
Prompt recognition and treatment of seizures are important
because prolonged or frequently repeated generalized
seizures may lead to permanent brain injury.
The basic functional property of neurons is electrochem-
ical, and the basic disturbance of this property that underlies
all seizures is termed the paroxysmal depolarization shift. The
various lesions that produce seizures result in a paroxysmal
production of synaptic potentials, which brings neurons
above their threshold and causes repetitive action potentials.
Thus the electrochemical disturbance is propagated, and
clinical seizures result.
Seizures may occur as a result of substrate deprivation,
synaptic dysfunction, or brain injury or as a manifestation of
primary generalized epilepsy. The brain depends on two
major substrates—oxygen and glucose—and deprivation of
either may result in seizures. Similarly, sodium is required to
maintain the electrochemical property of neurons, and
extreme changes in sodium concentration also can lead to
seizures. In general, the magnitude of hypoglycemia,
hypoxia, and hyponatremia must be great enough to result in
alteration of consciousness, following which seizures occur.
Similarly, various toxic insults can result in seizures by alter-
ing synaptic function.
Direct brain injury may cause seizures, both acutely and in
delayed fashion. In acute head injury, mechanical factors
probably disturb membrane function, and the resulting
seizures are seen within minutes to hours following the
trauma. These seizures may be limited and do not typically
recur. Brain injury from laceration in open head wounds or
direct tissue damage in closed head injury may result in post-
traumatic seizures. Pathologically, this occurs after healing
and gliosis have taken place at the injured site. Typically, these
seizures begin a few months to a year following trauma. The
precise nature of this “ripening” process is unclear, but den-
dritic abnormalities have been observed on surviving neurons
in the areas of gliosis. Direct electric shock also can cause
seizures and is a classic method for testing the effectiveness of
proposed anticonvulsant medications in animal models.
Finally, a common cause of seizures is primary generalized
epilepsy. The precise pathophysiologic mechanisms are
unknown, but most investigators believe the disturbance
probably is related to ion channel, neurotransmitter, and
CRITICAL CARE OF NEUROLOGIC DISEASE 663
synaptic dysfunction. Potential insights into the pathophysiol-
ogy of primary generalized epilepsy are provided by the pro-
posed mechanism of action of anticonvulsant medications.
For example, phenytoin and carbamazepine are thought to act
at sodium channels, whereas valproic acid is thought to act at
sodium and calcium channels. In addition, a great deal of
investigation with valproic acid concerns its action on γ-
aminobutyric acid (GABA) receptors. Phenobarbital has been
found to block posttetanic potentiation produced by elec-
troshock and also may act at calcium and chloride channels.
Classification of Seizures
Recognition and understanding of the seizure type is the first
step in the evaluation process and serves as a guide for
workup and management. The types of seizures are summa-
rized in Table 30–4.
A. Partial Seizures—Partial seizures are those that arise
from a focal area of the cortex. The clinical nature of the
seizure is dictated by the functional specialization of the cor-
tical area from which it arises. Focal motor seizures are a
good example. Note that a seizure is an activation of function
and not a loss of function, as occurs in a transient ischemic
attack. Partial seizures that are limited and not associated
with alteration of consciousness are termed simple partial
seizures. Impairment of consciousness coupled with a partial
seizure is called a complex partial seizure.
Complex partial seizures generally arise from the tempo-
ral lobe or other limbic structures. At the onset of this type
of seizure, the patient commonly experiences some auto-
nomic or emotional symptoms, such as a feeling of fear, asso-
ciated with a rising or breathless sensation within the chest
or a sense of being startled. Abdominal sensations are
reported commonly. The patient may experience other phe-
nomena such as déjà vu or may experience visual or olfactory
hallucinations. These altered perceptions tend to be stereo-
typed from seizure to seizure in any given patient and are
usually brief in duration. Following this type of onset, the
patient has an alteration of consciousness and usually has lit-
tle memory of what occurs until the seizure is completed.
To an observer, the onset of a complex partial seizure may
appear only as a motionless stare. After the onset, the patient
may develop some type of automatic and repetitive move-
ments. Examples are lip smacking or movements of one or
both extremities or repetitive picking at some part of the
body or a piece of clothing. During this time, the patient is
poorly responsive to the environment but still may have
some limited interaction. The patient then seems to recover
but remains confused for variable periods, usually only a few
minutes. Most seizures last from a few minutes to about
15 minutes. In repetitive, frequent complex partial seizures,
the patient seems to be in a twilight state, awake yet poorly
responsive to the examiner and the environment.
B. Generalized Tonic-Clonic Seizures—These were at one
time called grand mal seizures. Such seizures are sometimes
preceded by a cry. They are always accompanied by loss of
consciousness, but the tonic and clonic phases are variable.
The tonic phase usually precedes the clonic phase, and all the
extremities are involved in both phases. During the tonic
phase, there is expression of extensor motor dysfunction,
whereas throughout the rhythmic clonic phase, there is flexor
motor predominance. The duration of a single generalized
seizure is measured in minutes, and there always will be a
period of postictal confusion that is likewise usually brief.
Generalized tonic-clonic seizures may develop as a conse-
quence of spread from a partial seizure; in this instance, it
would be designated as secondarily generalized. Tonic-clonic
seizures, generalized at onset, may be caused by metabolic
abnormalities, drug withdrawals, poisons, or other patho-
logic states that affect overall brain function. Primary gener-
alized epilepsy is a major cause of generalized tonic-clonic
seizures. However, the essential pathogenesis of primary gen-
eralized epilepsy is poorly understood. In general, the pri-
mary generalized epilepsies (both generalized and absence)
have their onset in childhood.
C. Absence Seizures—Typical absence seizures were for-
merly called petit mal seizures. They are due to another type
of primary generalized epilepsy and always begin abruptly
with the patient losing cognitive contact. There may be some
fluttering of the eyelids, but body tone is maintained, and the
patient does not fall. Typically, after a few moments (occa-
sionally up to 1 minute or longer), the patient abruptly
regains awareness and will continue the interrupted activity.
Some patients recognize that the period of absence has
occurred, but others do not. This type of seizure is not asso-
ciated with a postictal state. The EEG shows generalized three
per second spike-and-wave discharges during the seizure.
Characteristically, the discharges are provoked by hyperven-
tilation. Absence seizures can be very frequent and pro-
longed—a condition referred to as absence status.
D. Status Epilepticus—Status epilepticus exists whenever
seizures are persistent or there is incomplete recovery
between seizures. Generalized tonic-clonic status epilepticus
is a medical emergency. The consequences of status can
Simple partial (focal seizure with preservation of consciousness) 
Complex partial (focal seizure with alteration of consciousness) 
Secondarily generalized tonic-clonic 
Primarily generalized tonic-clonic (grand mal) 
Absence (petit mal) 
Status epilepticus 
Convulsive tonic-clonic 
Nonconvulsive 
Absence 
Partial (epilepsia partialis continua) 
Table 30–4. Classification of seizures. 
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include aspiration pneumonia, hypoxia, hypotension, hyper-
thermia, autonomic instability with cardiac arrhythmias,
hyperkalemia, lactic acidosis, myoglobinuria, decreased
cerebral perfusion, and death. Furthermore, prolonged gen-
eralized tonic-clonic seizures can result in permanent neu-
ronal injury, particularly in the hippocampus, cerebellum,
and neocortex.
In nonconvulsive status, the patient has impairment or
loss of consciousness without generalized motor seizures.
Nonconvulsive status can be quite subtle and difficult to rec-
ognize in the critical care setting. The patient may show an
occasional twitch of an extremity or a facial twitch.
Sometimes the only evidence for seizure activity involves eye
movements, which can be observed only by lifting the eye-
lids. Nonconvulsive status of this type often is associated
with significant metabolic encephalopathy and sometimes
with underlying structural brain disease. Electroence-
phalography is required for diagnosis.
Another type of generalized nonconvulsive status is
absence status, also called spike-wave status. Absence status
most often occurs in children who have generalized epilepsy.
In adults it is rare, but it may occur suddenly in elderly
patients and present as a confusional state with minor
automatisms such as eye blinking or facial twitching.
Status epilepticus also can occur with partial seizures.
This has been called epilepsia partialis continua, and focal
motor seizures are the type most apt to be seen by the criti-
cal care physician. Complex partial status presents with a
patient in a confusional state, often with various automa-
tisms as described previously.
Clinical Features
A. History and Examination—The history is critical in the
diagnosis of seizures, and a comprehensive review of the his-
tory and the hospital course is required. Patients may
describe their symptoms, particularly in the case of complex
partial seizures; however, many patients are unaware of activ-
ity during the episode because consciousness has been
impaired. In fact, patients are sometimes even unaware that
they have had a lapse of consciousness. Thus it is important
to obtain a history from the patient and from witnesses such
as nurses, other patients in the room, family members, or
other attending physicians. Neurologic examination should
be directed toward signs of metabolic encephalopathy,
increased intracranial pressure, and lateralized findings
indicative of focal brain disease. An EEG may help to clarify
the nature of the seizure, particularly if it is obtained during
or soon after the seizure activity. Unless an obvious cause for
a seizure is known (eg, medication noncompliance in a
patient who has a known and previously evaluated seizure
disorder), brain imaging is necessary to see if structural brain
disease is present. If an infectious cause is suspected and there
is no contraindication owing to intracranial mass effect, lum-
bar puncture should be performed to obtain CSF for exami-
nation. If mass effect is present, neurosurgical consultation
should be obtained.
With new-onset seizures in the critical care setting, a use-
ful approach is to consider reversible causes first. In most
instances, these seizures will be generalized, tonic-clonic in
nature. Hypoxic-ischemic events are a common cause of
such seizures. The magnitude and duration of brain oxygen
deprivation will determine the severity of the seizure, as well
as the ultimate outcome. A brief seizure or several brief
seizures with rapid resolution may require no anticonvulsant
therapy. If the hypoxia-ischemia is severe, the seizures may be
prolonged and difficult to treat, and hypoxia-ischemia also
may be a cause of nonconvulsive status epilepticus.
The most common causes of drug-withdrawal seizures are
ethanol, barbiturates, and opioids. Ethanol-withdrawal seizures
usually occur after 24–72 hours of abstinence and rarely lead to
status epilepticus unless there are other underlying diseases.
Theophylline is probably the most common pharmacologic
cause of seizures in the ICU. Lithium toxicity may cause an
encephalopathy that may include seizures. Penicillin toxicity
causes seizures but is a rare occurrence usually associated with
kidney failure. A more common metabolic cause of seizures is
hyponatremia, which often is associated with inappropriate
antiduretic hormone secretion, and/or fluid overload.
Seizures occurring with acute neurologic disease often are
partial, or partial with secondary generalization, and the par-
tial onset may not be clinically apparent. Herpes simplex
encephalitis tends to be focal, whereas encephalitis from
other causes is more generalized. Electroencephalography
and imaging studies are helpful in the differential diagnosis.
Seizures usually do not occur with uncomplicated meningi-
tis. If they occur in bacterial meningitis, one should suspect
a complicating cortical venous thrombosis. Brain abscesses
commonly cause seizures.
The EEG is very useful in critical care neurology. To obtain
the maximum information from the EEG, the clinician
should provide the electroencephalographer with a brief his-
tory that includes the patient’s age, a description of the level
of consciousness, and a list of the medications being admin-
istered. One syndrome that can be defined with the EEG is
called periodic lateralized epileptiform discharges (PLEDs).
Affected patients are stuporous or comatose, may have occa-
sional epileptiform twitching movements of one side of the
face, and show the characteristic lateralized epileptiform dis-
charges. PLEDs usually are associated with some underlying
structural brain disease, such as an old infarct, and a superim-
posed metabolic encephalopathy. In general, the prognosis is
hopeful with correction of the metabolic disturbance and,
usually, administration of anticonvulsant medication.
In the case of seizures, the EEG can be diagnostic if
obtained during the seizure, but also it may show interictal
discharges and abnormalities supportive of the diagnosis and
indicate any focal aspect. Sometimes it is helpful to employ
closed-circuit TV, together with an electroencephalographic
monitoring system, to fully evaluate the seizure as well as the
progress of therapy. The EEG also is helpful in establishing
the diagnosis of a generalized toxic-metabolic encephalopathy
whether or not seizures are present.
CRITICAL CARE OF NEUROLOGIC DISEASE 665
Differential Diagnosis
Seizures may be associated with many different pathologic
states, including structural disease owing to neoplasms, vas-
cular anomalies, old strokes, and past trauma, or metabolic
encephalopathies. Other common problems leading to
seizures include poisoning, drug withdrawal, infections such
as viral encephalitis, and primary generalized epilepsies. Poor
compliance with the anticonvulsant regimen is a common
reason for a patient with epilepsy to develop status epilepti-
cus as well as to have poor seizure control. Drug level moni-
toring in these patients is essential.
Partial seizures of any type imply an underlying struc-
tural brain disease. Likewise, a postictal paresis (Todd’s pare-
sis) implies underlying focal disease.
Treatment
The management of seizures in critical care practice requires
first the removal or correction of precipitating causes and sec-
ond the administration of anticonvulsant medication. Often
it will seem prudent to administer anticonvulsant medication
on a temporary basis while causative conditions are resolving.
Whether anticonvulsants are administered orally or intra-
venously, it is critical to monitor serum concentrations to
ensure a therapeutic range. Phenytoin (fosphenytoin IV
preparation fully converted to phenytoin after injection),
phenobarbital, and valproate can be administered either
intravenously or orally. Lorazepam and diazepam are useful
anticonvulsants only when given intravenously.
Table 30–5 lists the doses and average half-lives of these
anticonvulsant medicines administered intravenously. Since
these half-lives are variable, the information provides an
approximation of the duration of action.
The major limiting factor for diazepam is that it peaks
into the therapeutic range for only a brief time; seizures may
recur 15–20 minutes after it is given. On the other hand, it is
rapidly effective. There may be some risk of apnea when
diazepam and phenobarbital are given together. Lorazepam
also is rapidly effective and has a longer duration of action.
The dose of lorazepam is usually 2–10 mg, or 0.1 mg/kg. It
can be administered in 2-mg increments at intervals of a few
minutes until the seizures are controlled or the maximum
dose is reached.
Both fosphenytoin or phenytoin and phenobarbital are
effective anticonvulsants, although their onset of action may
be slower than that of the benzodiazepines. Phenytoin, phe-
nobarbital, and valproate can be continued orally. Phenytoin
must be administered at a rate no faster than 50 mg/min
because of the risk of cardiac arrhythmia. Electrocardiographic
monitoring is advised while phenytoin is given. Phenytoin
should not be mixed in a dextrose solution because it will pre-
cipitate. The initial intravenous dose is 18–20 mg/kg of body
weight; the maximum dose is 30 mg/kg. Fosphenytoin is
dosed in phenytoin equivalents (PEs); it can be mixed in nor-
mal saline or a 5% dextrose solution and infused at a rate up
to 150 mg PE per minute. Extravasated phenytoin solution
often is harmful to surrounding tissues, whereas extravasated
fosphenytoin usually results in no tissue damage.
The intravenous dose of phenobarbital is 300–1000 mg
(or 15–20 mg/kg) for seizure control. Usually it is supplied
in 60-mg units, so an initial dose of 300 mg is convenient and
can be repeated every 10–20 minutes until seizure control
occurs or the maximum dose is reached.
Valproate sodium injection is a broad-spectrum anticon-
vulsant; it has complete bioequivalence with oral valproate and
may be mixed in normal saline or 5% dextrose solution. The
recommended infusion rate is up to 20 mg/min. Valproate is
the drug of choice for absence seizures. Intravenous valproate,
lorazepam, and diazepam are effective in absence status.
Levetiracetam also is available as an intravenous solution
as well as an oral preparation. It is approved as adjunctive ther-
apy in the treatment of partial-onset seizures in adults when
oral administration is not feasible. The intravenous dose is
equivalent to the oral dose (1000–3000 mg/day given twice daily)
and is supplied in 500-mg/5-mL vials. It should be diluted in
100 mL normal saline and infused over 15 minutes.
Levetiracetam is 66% excreted unchanged in the urine and has
no metabolism involving hepatic cytochrome P450 isoenzymes.
Seizures from metabolic encephalopathies, nonconvul-
sive status, and PLEDs often do not respond fully and quickly
to anticonvulsive medications. In this circumstance, it is best
to maintain therapeutic anticonvulsant blood concentrations
while pursuing therapy of underlying diseases. Partial
seizures or partial status likewise may be resistant to treat-
ment. In such cases, two anticonvulsant drugs can be tried,
but it is best to maintain them in the usual therapeutic range
and determine if with time there is greater benefit.
Generalized tonic-clonic status epilepticus does consti-
tute an emergency and must be controlled. Ventilation and
cardiac function must be supported. If hypoglycemia is a
consideration, 50 mL of a 50% dextrose solution should be
Drug Average Half-Life Dose∗
Diazepam 1 hour 10–30 mg 
Lorazepam 3 hours 2–10 mg 
Phenytoin 12 hours 18–20 mg/kg 
Fosphenytoin 12 hours† 20 mg phenytoin
equivalents (PE)/kg 
Phenobarbital 99 hours 15–20 mg/kg 
Valproate sodium
injection‡
10 hours 250–500 mg 
∗Status epilepticus or loading.
†Converted to phenytoin in 10–15 minutes.
‡TMAX = 1 hour. 
Table 30–5. Intravenous anticonvulsants. 
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administered promptly. If there is any possibility that the
patient is an alcoholic, dextrose should be preceded by
100 mg thiamine to prevent Wernicke’s encephalopathy.
Anticonvulsant medication for status epilepticus always
must be administered intravenously and be given in full
loading doses. A common mistake is to give inadequate
amounts of several different drugs.
If generalized tonic-clonic seizures persist despite the
patient’s being given intravenous anticonvulsants, pentobar-
bital anesthesia is recommended. This should be accomplished
with neurologic consultation and under electroencephalo-
graphic control. Pentobarbital is given in a dosage of 5 mg/kg
for induction of anesthesia and 0.5–2 mg/kg per hour for
maintenance. The drug is administered so as to titrate the EEG
to a burst-suppression pattern. When it is judged that an
appropriate interval of time has lapsed (about 24–48 hours),
the pentobarbital dose may be reduced to test for seizure
recurrence. If the seizures are controlled, the pentobarbital
may be withdrawn, but therapeutic levels of an anticonvulsant
such as phenytoin must be present and maintained.
Current Controversies and Unresolved Issues
Resistant partial or lateralized seizures and nonconvulsive
generalized status epilepticus remain problems in manage-
ment, and there is some uncertainty about how vigorous the
physician should be in the administration of medications.
No absolute indication exists for the choice of first med-
ication to treat generalized tonic-clonic status; rather, it is a
matter of common practice and personal choice.
In the past few years, the number of oral antiepileptic drugs
available has increased dramatically, and experience with them
in daily practice is accumulating but is not yet great. Use of
these drugs, as well as other treatments, including surgical and
vagus nerve stimulation, and the management of chronic
seizure disorders are mostly beyond the scope of critical care
practice. Neurology consultation is recommended when newly
prescribing or switching oral antiepileptic medicine.
NEUROMUSCULAR DISORDERS
Respiratory failure and cardiac failure are the most serious
potential complications of neuromuscular diseases and can
lead to death if not treated appropriately. Diseases directly
affecting respiration include Guillain-Barré syndrome,
myasthenia gravis, amyotrophic lateral sclerosis, and
Duchenne’s muscular dystrophy. Less commonly, botulism,
tetanus, porphyria, and diphtheritic polyneuropathy cause
neuromuscular failure. Similarly, a number of neuronal poi-
sons can lead to severe weakness and even respiratory fail-
ure. Chronic neuromuscular diseases can lead to secondary
pulmonary problems, including phrenic nerve injury,
kyphoscoliosis, pulmonary emboli, atelectasis, and most fre-
quently, aspiration pneumonia. Another potential problem
associated with neuromuscular diseases involves cardiac
complications such as arrhythmias, as seen in Guillain-Barré
syndrome, or conduction blocks with sudden death, as seen
in myotonic dystrophy. Advances in the ICU treatment of
these patients have decreased morbidity and mortality rates,
avoiding sudden death in some instances.
Pathophysiology 
Progressive weakness may result from disorders anywhere
along the motor tract (Figure 30–1). Lesions in the brain,
particularly the upper motor neuron pathways (site A) or
 Figure 30–1. Localization of lesions causing neuro-
muscular diseases. A. Cortex (upper motor neuron).
B. Spinal cord. C. Anterior horn cell. D. Peripheral nerve
(axon or myelin). E. Neuromuscular junction. F. Muscle.
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brain stem (site B), may lead to progressive weakness.
Likewise, disorders at the level of the spinal cord or the lower
motor neurons (site C), either at the anterior horn cell bod-
ies, motor axons, or myelin (site D) or at the pre- or postsy-
naptic terminals (site E), may lead to weakness. Furthermore,
many of the muscle diseases (site F) can directly impair effec-
tive ventilation. Table 30–6 lists some examples of diseases
that can occur at each site.
One general rule associated with respiratory failure sec-
ondary to neuromuscular disorders is that unlike primary
pulmonary illnesses, where dysfunction in gas exchange
often results predominantly in hypoxemia, respiratory failure
secondary to neuromuscular dysfunction usually leads to
hypoventilation. Arterial blood gases often demonstrate CO2
retention, or hypercapnia, with relatively mild hypoxemia.
By the time PaCO2 begins to increase, hypoventilation has
gone beyond the safe limit. Decrease in vital capacity is asso-
ciated with predictable signs of pulmonary dysfunction
(Figure 30–2). Therefore, the single most important param-
eter to measure in patients with neuromuscular diseases is
the vital capacity.
In order to make an etiologic diagnosis of neuromuscu-
lar disease leading to weakness and respiratory failure, spe-
cific clinical symptoms and signs as well as laboratory
diagnostic studies are used to localize the lesions.
Measurements of vital capacity and cardiac monitoring are
essential in patients admitted to the ICU owing to exacer-
bation of neuromuscular diseases because respiratory
compromise and cardiac arrhythmias can develop rapidly.
The clinical presentation of the illness depends on the site
of the lesion.
 Spinal Cord Compression
ESSENT IALS  OF  D IAGNOS I S
 Back pain, limb paresis, and spasticity.
 Sensory loss below the level of the spinal cord lesion.
 Bowel or bladder incontinence.
 Neuroimaging studies of the clinically suspected spinal
levels.
 Blood cultures and purified protein derivative (PPD) test
if an abscess is suspected.
 Biopsies to evaluate tumors and abscesses.
General Considerations
Back pain can be caused by a variety of diseases, such as local
structural disorders, retroperitoneal disease, trauma, infec-
tion, and neoplasms. However, tumors, abscesses, or disk
fragments in the spinal canal may produce an acute syn-
drome of spinal cord compression. This is a neurologic
emergency that may lead to permanent paralysis if not
treated rapidly. Diagnostic signs or symptoms vary depend-
ing on the spinal level of the compression.
Intra- and extramedullary spinal cord malignancies, as
well as various infections with parasitic (eg, cysticercosis),
bacterial (eg, anaerobes, tuberculomas, and gummas), or
viral (eg, varicella-zoster or poliomyelitis) organisms, may
produce direct or compressive lesions to the spinal cord.
Most abscesses are in the thoracic or lumbar areas, and the
agent is usually Staphylococcus aureus. Tuberculosis also may
infect the vertebral column (Pott’s disease), causing kyphosis,
Motor cortex and pyramidal tract 
Amyotrophic lateral sclerosis 
Brain stem 
Progressive bulbar palsy 
Spinal cord and lower motor neuron 
Spinal muscular atrophies 
Amyotrophic lateral sclerosis  
Poliomyelitis 
Toxins: mercury 
Infections: tetanus, spinal cord and epidural abscesses 
Peripheral neuropathies 
Axonal types (including critical illness polyneuropathy) 
Diabetes 
Alcohol-related 
Uremia 
Hypothyroidism 
Sarcoidosis 
Collagen-vascular diseases  
Paraproteinemias 
Drugs 
Heavy metals 
Industrial toxins 
Amyloidosis 
Carcinoma (remote effect) 
Tick paralysis 
Demyelinating neuropathies 
Guillain-Barré syndrome 
Diphtheria 
Porphyria 
Hereditary: Charcot-Marie-Tooth disease 
Neuromuscular junction disorders 
Myasthenia gravis 
Botulism 
Eaton-Lambert syndrome 
Pseudocholinesterase deficiency 
Organophosphate intoxication 
Other drugs and toxins: neomycin, penicillamine  
Disease of muscles  
Muscular dystrophies  
Inflammatory myopathies  
Endocrine and metabolic myopathies  
Toxic myopathies: alcohol, carbon monoxide  
Inherited metabolic myopathies: periodic paralysis; glycogen or lipid
enzymatic defect
Neuroleptic malignant syndrome, malignant hyperthermia 
Table 30–6. Neuromuscular diseases affecting respiration. 
 CHAPTER 30668
which then may cause cord compression or respiratory
difficulties.
Clinical Features
A. Symptoms and Signs—Diagnosis of a spinal cord
lesion depends on clinical examination and neuroimaging
studies. Limb weakness and the presence of a sensory level
(particularly to pinprick and vibratory senses) are useful in
approximating the level of involvement. Tendon reflexes
below the level of the lesion may be increased, and
Babinski signs may be present. Fever associated with back
pain and myelophthisic signs should arouse suspicion of
epidural abscess.
B. Laboratory Findings—When an infectious cause is sus-
pected, blood cultures and a tuberculin test will help to direct
specific antibiotic therapies. Biopsy examination is indicated
for suspected tumor or abscess.
C. Imaging Studies—MRI or CT scan is necessary to accu-
rately localize the lesion.
Treatment
Early recognition and treatment can prevent irreversible
neurologic damage. Tumors generally respond to surgical
removal or radiotherapy. High-dose corticosteroid therapy
also may be indicated. Selection of antibiotic therapy for
epidural abscess depends on biopsy or culture results.
 Guillain-Barré Syndrome
ESSENT IALS  OF  D IAGNOS I S
 Antecedent flulike illness.
 Acute or subacute ascending flaccid paralysis.
 Early loss of tendon reflexes.
 Subjective distal paresthesias and pain.
 Occasional cranial nerve deficits.
 Elevated protein in CSF with no cells.
General Considerations
Guillain-Barré syndrome is an acute or subacute prima-
rily motor polyneuropathy that is usually idiopathic,
although a number of etiologic factors, including
Mycoplasma pneumoniae and hepatitis B, have been
implicated in rare cases. In more than 50% of patients
with Guillain-Barré syndrome, an antecedent flulike ill-
ness or vaccination occurred within 4 weeks prior to the
neurologic symptoms.
Acute or subacute ascending muscle weakness develops
over 2–4 weeks, followed by gradual recovery over a few
weeks to many months. Eighty-five percent of patients will
have complete functional recovery.
 Figure 30–2. Effects of decreasing vital capacities secondary to weakness from neuromuscular diseases.
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Clinical Features
A. Symptoms and Signs—Cranial nerve deficits, especially
of those controlling eye movements and facial muscles, can be
present either alone or associated with limb weakness. Deep
tendon reflexes are absent, whereas pupils and eyelids often
are spared. Miller-Fisher syndrome is a variant of Guillain-
Barré syndrome characterized by absent reflexes, gait ataxia,
and ophthalmoparesis. The prognosis for complete recovery
of this form of Guillain-Barré syndrome is excellent.
B. Laboratory Findings—Lumbar puncture can be diagnostic
by the second week, when CSF shows an elevated protein con-
centration without pleocytosis (albuminocytologic dissociation).
C. Nerve Conduction Studies—Nerve conduction studies
show segmental demyelination and reduction of velocity in
85–90% of patients by the second week. Up to 40% of
patients develop respiratory muscle weakness and/or auto-
nomic instability. Therefore, ICU admission is best for most
patients, and frequent vital capacity measurements and car-
diac monitoring are necessary for timely detection of these
complications.
Treatment
A. Respiratory Care—Respiratory weakness requiring ven-
tilatory support develops in 40% of patients and may be rap-
idly progressive in the early phases. Intubation may be
required. Bulbar muscle weakness can lead to aspiration
pneumonia, which is potentially preventable by placement of
a nasogastric tube, as well as by intubation.
B. Cardiac Care—In up to 40% of patients with Guillain-
Barré syndrome, autonomic dysfunction may occur and
accounts for much of the morbidity and most of the deaths
in this group of patients. The cardiac abnormalities fre-
quently include sinus tachycardia, and asystole can occur.
Therefore, it is essential to maintain cardiac monitoring and
to administer antiarrhythmic drugs as necessary.
C. Other Treatment—When the weakness is progressive and
severe, plasmapheresis or intravenous immune globulin
(IGIV) is recommended. Because most of these patients expe-
rience a significant amount of pain (which may be difficult to
recognize when the patient is intubated), use of opioids as
needed is indicated.
 Critical Illness Polyneuropathy
ESSENT IALS  OF  D IAGNOS I S
 Associated with multiorgan failure, often with sepsis.
 Difficulty weaning from respirator owing to weakness.
 Distal limb weakness with diminished or absent reflexes.
 EMG nerve conduction studies characteristic.
General Considerations
Critical illness polyneuropathy has been recognized in asso-
ciation with sepsis and multiorgan failure in the ICU setting.
Sometimes it is first identified because of difficulty weaning
a patient from the ventilator owing to respiratory muscle
weakness. It is an axonal sensorimotor polyneuropathy of
obscure origin; there is no inflammation or demyelination of
the nerves.
Clinical Features
A. Symptoms and Signs—The typical findings on exami-
nation are distal limb weakness with flaccidity and hypore-
flexia or areflexia as well as respiratory muscle weakness or
even quadriplegia in severe cases. Mild facial weakness some-
times occurs, but ophthalmoparesis is uncommon. Distal
sensory loss may be expected, but under the usual circum-
stances of this condition, sensory deficits are difficult or
impossible to assess accurately. Superimposed entrapment or
compression neuropathies, because of positioning problems,
should be considered in the differential diagnosis. Also to be
differentiated is critical illness myopathy, which is a syndrome
of weakness that develops in some critically ill patients after
the use of corticosteroids, often in combination with neuro-
muscular blocking agents. Creatine kinase usually is elevated,
many times to very high levels, and can be associated with
rhabdomyolysis and myoglobinuria. Another condition to be
differentiated is prolonged neuromuscular blockade, which
may occur in critically ill patients after neuromuscular block-
ing agents have been discontinued; the duration can range
from hours to days.
B. Laboratory Findings—Electromyographic and nerve
conduction studies show reduced motor and sensory ampli-
tudes but preserved conduction velocities and distal laten-
cies. This is distinguished from Guillain-Barré syndrome, in
which conduction block and segmental slowing are found.
The CSF protein is normal in critical illness polyneuropathy.
Treatment
Treatment consists of correction and management of under-
lying illnesses. The neuropathy often improves after weeks or
months as sepsis and organ failure resolve. Patients who have
mild or moderate neuropathy may have complete recovery,
whereas those severely affected probably will have residual
and permanent weakness. It is prudent to minimize the use
of neuromuscular blocking agents, especially in patients who
are receiving corticosteroids.
 Toxic Neuropathies
There are three anatomic locations where toxins can affect
the peripheral nerve: the cell body, the nerve sheath myelin,
and the axon. Diphtheria toxin, tetanus toxoid, and antibiotic
treatments may lead to acute sensory neuropathy secondary
to myelin loss, whereas the most common toxic neuropathies
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result in axonal injuries. Many drugs and industrial chemi-
cals can be neurotoxic. Examples of such drugs are isoniazid,
chloramphenicol, metronidazole, disulfiram, amiodarone,
gold, cisplatin, vincristine, lithium, nitrofurantoin, nitrous
oxide, and pyridoxine.
Exposure to industrial chemicals such as arsenic, acry-
lamide, carbon disulfide, mercury, the organophosphate
parathion, and vinyl chloride can cause distal axonal neu-
ropathy. The clinical course depends on the concentration of
the offending agent. Chronic exposure to these agents leads
to an insidious onset of paresthesia in glove-stocking distri-
bution. With more acute exposure, patients develop other
systemic signs along with a more rapid onset of neuropathy.
Two important ubiquitous toxins, lead and arsenic, both
have characteristic clinical presentations.
Lead Poisoning
Lead poisoning can occur via the GI tract, lungs, or skin and
is associated with abdominal cramps and encephalopathy
(particularly in infants). Blood smears show basophilic stip-
pling in the erythrocytes. The elevated lead level can be
measured in serum. Although other nerves may be affected,
lead has a peculiar predilection for radial nerves, resulting in
weakness of wrist and finger extension. Sensory symptoms
are unusual.
Arsenic Poisoning
Arsenic poisoning often results from accidental ingestion of
rat poisons or industrial sprays, although intentional poison-
ings do occur. These patients often develop an acute
polyneuropathy several weeks after exposure. The nail beds
show pale bands called Mees’s lines. After exposure, urine,
hair, and nails all may contain arsenic. With higher exposure,
a painful sensory neuropathy may evolve to a flaccid paraly-
sis beginning in the lower extremity but eventually affecting
the respiratory muscles and upper extremities.
Urine and serum for a heavy metal screen, along with a
careful drug and toxin exposure history, are mandatory in
any patient presenting with an acute neuropathy. Finally,
nerve conduction studies will help to differentiate demyeli-
nating versus axonal types of neuropathy.
 Myasthenia Gravis
ESSENT IALS  OF  D IAGNOS I S
 History of fluctuating weakness and fatigability.
 Positive edrophonium (Tensilon) test.
 Decremental responses on nerve conduction studies.
 Positive serologic tests for acetylcholine receptor
antibodies.
 Chest CT scan or MRI may show thymoma.
General Considerations
Myasthenia gravis appears to be an autoimmune disease, pri-
marily a disorder of the postsynaptic neuromuscular junction.
Acetylcholine receptor antibodies are found in 85–90% of
patients. Other immunologic diseases such as thyroid disease,
polymyositis, rheumatoid arthritis, and systemic lupus erythe-
matosus all have been associated with myasthenia gravis.
Repetitive stimulation of a motor nerve at 3 Hz shows a
decremental response of electromyographic motor units in
up to 85% of patients with myasthenia gravis, whereas dis-
eases affecting the presynaptic nerve terminal such as
Lambert-Eaton syndrome or botulism demonstrate an incre-
mental response at a higher rate of stimulation.
Clinical Features
A. Symptoms and Signs—Myasthenia gravis is character-
ized by variable weakness and easy fatigability. The motor
weakness worsens with exercise and improves after rest.
Diplopia often is an early symptom, and over 90% of patients
develop ocular muscle involvement. Patients feel strongest in
the morning and weakest at night because their muscles tire
during the day.
B. Laboratory Findings—The edrophonium test demon-
strates that an increase in peripheral acetylcholine improves
motor function. It is performed as follows: (1) Stop other anti-
cholinesterase medications 24 hours prior to the test if possible.
(2) Atropine sulfate, 0.4 mg (1 mL), which blocks muscarinic
“side effects” of edrophonium but not the nicotinic effect at the
neuromuscular junction, and normal saline (1 mL) are used
first as control injections. (3) Edrophonium should elicit a
response in 30–60 seconds that should last for 10–30 minutes.
Draw up 10 mg and give 2 mg for the first dose; if there is no
response, follow with 8 mg. (4) Assess strength of affected mus-
cles 1–2 minutes after each intravenous dose.
The absence of acetylcholine receptor antibodies does not
exclude the diagnosis, but their presence is confirmatory.
Antistriational antibodies are found in 90% of myasthenic
patients with thymoma.
C. Imaging Studies—Approximately 10% of patients
develop thymoma, and 70% will have thymic hyperplasia.
Therefore, chest CT scan or MRI is performed to search for
mass lesions.
Treatment
A. Oral Therapy—Pyridostigmine often is successful first-
line therapy. The usual initial dose is 30 or 60 mg. The inter-
val of dosing can be adjusted in individual patients
depending on observed duration of action but is usually on
the order of 4 hours. Prednisone and other immunosuppres-
sive drugs also are used in difficult cases.
B. Intravenous Therapy—Plasmapheresis, 2–3 L per
exchange three times a week over 2 weeks, has been successful
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in some patients who do not respond to anticholinesterase
medications. Intravenous immune globulin (IGIV) is an
alternative to plasmapheresis, and both are useful in prepar-
ing patients for thymectomy.
C. Thymectomy—Thymectomy improves long-term out-
come in patients with myasthenia gravis, and all patients
undergoing thymectomy should be monitored carefully pre-
and postoperatively in the ICU under the supervision of a
neurologist. Postoperatively, immunosuppression with high-
dose prednisone is helpful in many patients.
D. Exacerbations—When a myasthenic patient presents
with increased weakness, it is important to differentiate
between myasthenic versus cholinergic crisis. A myasthenic
crisis requires treatment with additional anticholinesterase
medications, whereas weakness owing to cholinergic crisis
only improves if the medication is withheld. An edropho-
nium test may be helpful in differentiating the two. In myas-
thenic crisis, look for causes such as infection (especially
aspiration pneumonia), drugs with a potential for blocking
neuromuscular transmission, and excessive use of sedative
drugs. In general, if vital capacity is less than 1 L, it is best to
intubate and stop all myasthenic medication until the cause
of the exacerbation is determined.
 Botulism
ESSENT IALS  OF  D IAGNOS I S
 GI symptoms with dry mouth.
 Blurred vision, dilated pupils, and diplopia.
 Respiratory distress.
 Incremental response with repetitive nerve conduction
studies.
 Stool examination positive for Clostridium botulinum
and its exotoxin.
General Considerations
Unlike myasthenia gravis, the neuromuscular junction defect
in botulism results primarily from presynaptic cholinergic
conduction blockade. It is an acute poisoning resulting from
ingestion of C. botulinum exotoxin. The organism is found in
inadequately cooked or defectively canned food. Also, it may
be found in clostridial wound infections, which is a source of
the disease in people injecting illicit drugs. In infants
between the ages of 1 and 38 weeks, the toxin may be found
in the GI tract.
Clinical Features
A. Symptoms and Signs—Symptoms begin within 5–50
hours of eating the contaminated food or exposure to the
toxin. Dry mouth and GI symptoms such as cramps, nausea,
vomiting, and diarrhea or constipation, as well as malaise
and headache, are noted initially. Extraocular muscle weak-
ness and dilated, sluggishly reactive pupils cause diplopia and
blurred vision. These patients may rapidly develop dysphagia
and respiratory distress. Respiratory failure and aspiration
pneumonia may be the principal causes of death from botu-
lism. The nervous system is involved in descending fashion,
beginning with muscles innervated by the cranial nerves.
Consciousness and sensation remain intact, however.
B. Laboratory Findings—Botulinus toxin can be isolated
from infected serum, stool, or contaminated food. Since cul-
tures of the organism or evaluation for the toxin may take
several days, repetitive nerve stimulation should be per-
formed as soon as possible in patients suspected of having
botulism. CSF is normal.
C. Nerve Conduction Studies—Diagnostic studies with
high-rate (40 Hz) repetitive nerve stimulation demonstrate
incremental responses of the compound action potentials in
the motor nerves.
Treatment
A. Antitoxin—Type E antitoxin has the greatest clinical effi-
cacy and should be administered as quickly as possible. The
dose may be repeated in 4 hours if the condition worsens.
Skin testing to exclude hypersensitivity should precede
administration of the antitoxin. One vial of antitoxin should
be given orally and one intravenously.
B. Antibiotics—When botulism occurs from a wound infec-
tion, antibiotic therapy with penicillin, 300,000 units/kg per
day intravenously, is preferred. Other useful drugs are clin-
damycin (30 mg/kg per day intravenously) and chloram-
phenicol (50 mg/kg per day intravenously); guanidine
hydrochloride (50 mg/kg per day orally) may improve mus-
cle function.
 Inflammatory Myopathies
Most inflammatory myopathies result from autoimmune
processes, although some result from infections. Typical
examples include dermatomyositis, polymyositis, secondary
involvement with lupus erythematosus, and viral myositis. In
20% of older patients (>50 years), polymyositis and der-
matomyositis may be associated with an occult malignancy.
Myalgia and proximal muscle weakness are the most com-
mon complaints in patients with inflammatory myopathies.
Most forms are self-limited, lasting 2–3 weeks. However, ful-
minant myositis may lead to rhabdomyolysis, which can be
fatal. Occasionally, when the swallowing muscles are involved,
the patient requires nasogastric tube feedings.
Laboratory studies often reveal an elevated creatine
kinase and sedimentation rate. Electromyography shows signs
of muscular irritability with fibrillation potentials and small
polyphasic waveforms—all characteristic of inflammatory
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myopathies. Perivascular infiltrates and perifascicular atro-
phy are seen in muscle biopsy specimens, and this informa-
tion may be necessary for definitive diagnosis.
 Neuroleptic Malignant Syndrome
ESSENT IALS  OF  D IAGNOS I S
 Encephalopathy.
 Markedly elevated core temperature.
 Autonomic dysfunction.
 “Lead pipe” muscular rigidity with elevated creatine kinase
General Considerations
Neuroleptic malignant syndrome is a life-threatening idio-
syncratic reaction to neuroleptic agents. The drugs that pro-
duce this syndrome typically include phenothiazines,
butyrophenones, and other postsynaptic dopamine blocking
agents. Failure to recognize the syndrome may lead to a rap-
idly fatal course over hours to several days. Even brief expo-
sure to the drug may produce the syndrome.
Clinical Features
A. Symptoms and Signs—The clinical presentation may
be variable but frequently consists of encephalopathy,
markedly elevated core temperature, and muscular rigidity.
Fever and increased muscle activity are the main features.
Mental status changes may vary from confusion or agitation
to coma. Involuntary movements such as tremor or dyskine-
sia occasionally accompany muscular rigidity—so-called
lead pipe rigidity. When severe rigidity occurs, rhabdomyol-
ysis may result and in turn lead to myoglobinuria and acute
renal failure.
B. Laboratory Findings—There is no unequivocal diagnos-
tic test or criterion for neuroleptic malignant syndrome.
Creatine kinase elevations may range from several hundred
to over 10,000 units per liter.
Differential Diagnosis
Many nonneuroleptic drugs can produce similar disorders.
Examples include cocaine, amphetamines, reserpine, meto-
clopramide, and tricyclic antidepressants in combination
with lithium or monoamine oxidase inhibitors. The differen-
tial diagnosis also includes many causes of encephalopathy
and fever, catatonia, and malignant hyperthermia.
Malignant hyperthermia is a genetically determined
hypermetabolic state with onset shortly after the use of cer-
tain anesthetics. Although it is similar to neuroleptic malig-
nant syndrome in the markedly elevated temperature and
creatine kinase concentrations, it can be distinguished by
the lack of encephalopathy or autonomic dysfunction.
Furthermore, the generation of fever is most likely peripheral
in malignant hyperthermia and central in neuroleptic malig-
nant syndrome. The genetic trait for malignant hyperther-
mia does not appear to impose any risks for development of
neuroleptic malignant syndrome.
Treatment
A. General Measures—Effective treatment requires early
recognition and critical care monitoring of possible
multiple-organ failure. Fever must be controlled, and vigor-
ous intravenous hydration is necessary to lower the body
temperature and minimize the effects of possible rhab-
domyolysis. Blood pressure and urinary output must be
monitored carefully. Most important, dopamine-blocking
agents must be discontinued.
B. Drug Therapy—Centrally acting bromocriptine,
7.5–100 mg/day, has been used to control the high tempera-
ture and rigidity; effects may be seen within hours.
Dantrolene, a peripherally acting muscle relaxant, also is
highly effective. It can be given intravenously at a dosage of
0.25 mg/kg twice daily and increased as needed to control the
rigidity. When the patient is able to take oral medications,
25–600 mg/day may be effective.
 Muscular Dystrophies
ESSENT IALS  OF  D IAGNOS I S
 Proximal extremity weakness.
 Pseudohypertrophy of the gastrocnemius muscles.
 Muscle fiber necrosis and minor regeneration on biopsy.
General Considerations
There are a number of inherited muscular diseases that may
have respiratory or cardiac complications that ultimately
require management in the ICU. Duchenne’s muscular dys-
trophy and myotonic dystrophy are the most common dis-
eases of this type.
Muscular dystrophy patients have an increased rate of
adverse reactions to many anesthetics and frequently have
respiratory complications and prolonged postoperative
courses if they undergo general anesthesia. When possible,
surgery or general anesthesia should be avoided in these
patients. In general, sedatives also are contraindicated
because of their adverse effects on weakened muscles.
Clinical Features
A. Symptoms and Signs—Diagnosis of Duchenne’s mus-
cular dystrophy can be made by the family history (X-linked
recessive, but one-third can be spontaneous mutations),
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clinical examination showing characteristic proximal
extremity weakness, and pseudohypertrophy of the gastroc-
nemius muscles by age 3–4.
B. Laboratory Findings—Muscle biopsies demonstrate pro-
gressive muscle fiber necrosis and minor degrees of regenera-
tion. These patients pursue a steady downhill course and
develop lumbar lordosis and scoliosis. Laboratory studies will
show markedly elevated (10–50 times normal) serum creatine
kinase and characteristic abnormalities on electrocardiography,
electromyography, and muscle biopsies. New findings from
molecular genetic studies show absent dystrophin protein in
muscles of patients with Duchenne’s muscular dystrophy,
whereas patients with the Becker variant (clinically similar but
a later age at onset) have a slightly lower than normal level or
an altered protein. Genetic linkage analysis, although inaccu-
rate, usually provides a carrier status or prenatal diagnosis as a
“percentage risk” rather than a definite yes or no.
Treatment
A. Respiratory Care—Elective intubation is recommended
when vital capacity falls below 15–20 mL/kg. Ventilator set-
tings should be monitored along with arterial blood gases.
Baseline blood gases can be obtained after 20 minutes of FIO2
at 100%, after which inspired oxygen concentration can be
decreased to maintain the PaO2 between 75 and 85 mm Hg.
Positive end-expiratory pressure (PEEP) should be set at
3–5 cm H2O and tidal volume at 6–8 mL/kg. The intermittent
mandatory ventilation (IMV) rate should be approximately
12/min with 30–40 L/min inspiratory flow. If the patient
requires prolonged intubation—more than 2–3 weeks—a tra-
cheostomy should be performed to maintain a stable airway.
Criteria for weaning a neuromuscular patient from a ven-
tilator include several parameters, the most important of
which is the vital capacity, which should be greater than
15 mL/kg. Inspiratory pressure should be greater than –25 cm
H2O and expiratory pressure greater than 40 cm H2O. PaO2
should be greater than 80 mm Hg and PaCO2 less than 42 mm
Hg at FIO2 of .40. Spontaneous respiration should be less
than 20/min, and there should be no other adverse medical
conditions such as fulminant pneumonia or serious cardiac
problems.
All patients presenting with weakness should be followed
carefully for respiratory status. Good pulmonary toilet is
mandatory. It is helpful to have an accurate diagnosis so that
special precautions can be taken to anticipate or prevent the
progression of symptoms. A superimposed infection may
exacerbate the weakness of many neuromuscular diseases,
and temporary life support will enable the patient to return
to baseline strength. Therefore, it is imperative to exclude the
possibility of a reversible cardiopulmonary complication.
B. Cardiac Care—Between 70% and 90% of patients with
Duchenne’s muscular dystrophy will develop electrocardio-
graphic abnormalities consisting of tall right precordial R
waves and precordial Q waves. Arrhythmias and persistent
tachycardia are noted frequently in Duchenne’s muscular
dystrophy. Patients with myotonic dystrophy also develop
cardiac arrhythmias secondary to conduction abnormalities
and can present with sudden death if not detected early.
Differential Diagnosis
There are many CNS disorders that can mimic neuromuscu-
lar diseases. For example, a brain stem lesion may produce
diplopia that may be mistaken for myasthenia gravis or bul-
bar symptoms that may be mistaken for amyotrophic lateral
sclerosis. Neuroleptic malignant syndrome often is difficult
to differentiate from other causes of fever and encephalopa-
thy. Blood cultures, drug screens, and brain imaging may be
necessary to exclude systemic infections, drug exposures, or
disorders producing changes in autonomic control and tem-
perature such as injury to the hypothalamic region.
A careful history (including family history) and physical
examination generally will distinguish the major groups of
illnesses. However, electrophysiologic studies or laboratory
evaluations sometimes are necessary to differentiate the spe-
cific types of diseases. Nerve conduction studies with repeti-
tive stimulation will help to differentiate presynaptic from
postsynaptic diseases, and serum creatine kinase will help to
distinguish a primary myopathy from neurogenic weakness.
 Current Controversies and Unresolved
Issues
A particularly difficult problem is whether to intubate a
patient who has an irreversible advanced neuromuscular dis-
ease. If possible, the issue of code status should be discussed
with the patient and the family prior to clinical deterioration.
Perhaps the patient already has a living will or a family mem-
ber has power of attorney to help with the decision-making
process.
CEREBROVASCULAR DISEASES
ESSENT IALS  OF  D IAGNOS I S
 Stepwise impairment usually produced by occlusive dis-
ease.
 Emboli produce sudden deficits.
 Intracerebral hemorrhage causes rapid onset of symp-
toms, often with increased intracranial pressure.
General Considerations
Brain stem and cerebral infarctions occur as a result of either
progressive occlusive vascular disease, usually hypertensive
and atherosclerotic, or embolism. In occlusive disease,
infarcts are bland, and in embolic disease, infarcts are hem-
orrhagic if the embolus fragments and the vascular territory
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is reperfused. A hemorrhagic infarct implies embolism.
Spontaneous intracerebral hemorrhage occurs as a result of
hypertensive vascular disease, but in elderly people it also can
be caused by amyloid angiopathy.
Clinical Features
A. Symptoms and Signs—Stroke owing to occlusive vascu-
lar disease, or thrombosis, tends to have its onset in a stepwise
or progressive fashion. It occurs commonly while the patient
is sleeping. An embolic stroke is sudden in onset and produces
maximum neurologic deficit at the outset. Transient ischemic
attacks can precede either thrombotic or embolic infarction
but probably are more frequent in association with throm-
botic disease. An intracerebral hemorrhage also is sudden in
onset and may cause an acute rise in intracranial pressure
owing to mass effect. The location of a stroke is clinically
helpful; for example, a small lacunar infarct in the internal
capsule is almost certainly due to intracranial, small vessel, or
occlusive disease. The first step in localizing the lesion is a
careful neurologic examination.
B. Imaging Studies—Brain imaging will confirm the loca-
tion of the infarct and determine whether hemorrhage has
occurred. This information is required before anticoagulation
therapy can be started. Typically, a bland infarct will not show
on CT scan in the first few hours up to about 24 hours after
onset. CT imaging, however, is very sensitive for the detection
of fresh bleeding. MRI, especially with diffusion studies, is
sensitive for acute infarction. MR angiography can demon-
strate occluded or stenotic large- and medium-sized arteries.
Differential Diagnosis
A history of hypertension, diabetes mellitus, or tobacco
smoking and a family history of stroke or myocardial infarc-
tion are common in occlusive disease. A history of hyperten-
sion is common in intracerebral hemorrhage. If an embolic
infarction is present, a source should be found; this may be
clots arising in the heart or clots from the periphery reach-
ing the brain as a result of right-to-left cardiac shunting, as
may occur with a patent foramen ovale. Artery-to-artery
embolization, usually from an internal carotid artery, also
may be considered. Strokes secondary to cocaine abuse cur-
rently are a problem not to be overlooked. Also occasionally
encountered are strokes caused by carotid artery or vertebral
artery dissection. These are traumatic in origin, and symp-
tomatic onset usually is 24–72 hours following trauma.
Often a history of neck extension is obtained. An intimal
tear and flap are demonstrated by either endovascular or
MR angiography. A brain CT scan is very sensitive for
demonstrating intracerebral hemorrhage or hemorrhagic
infarction, but an acute bland infarct does not show until
density of the infarcted tissue has decreased and edema
occurs. MRI is sensitive in all cases. Occlusion of large ves-
sels supplying the brain can be demonstrated with Doppler
ultrasound, MR angiography, and CT angiography. Selective
contrast angiography is indicated when the diagnosis is in
doubt and a surgically treatable vascular lesion could be
present. The workup for an embolic source should include
electrocardiography and, if a rhythm disturbance such as
atrial fibrillation is not found, echocardiography. An
embolic source sometimes can be demonstrated only on the
transesophageal echocardiogram.
Rarer causes of stroke include polycythemia, sickle cell
disease, collagen-vascular diseases, lupus anticoagulant, and
hypercoagulable states. Infrequent causes of stroke also are
moyamoya disease, fibromuscular hyperplasia, Takayasu’s
disease, and tuberculous or other arterites. Infarction caused
by arterial spasm associated with ruptured berry aneurysm
and subarachnoid hemorrhage is well known in neurosurgi-
cal practice.
Treatment
In general, the management of an acute stroke consists of
supportive care and control of blood pressure. In this cir-
cumstance, autoregulation of cerebral blood flow is impaired
or lost, and regional brain perfusion is passive and essentially
dependent on systemic blood pressure. Therefore, hypoten-
sion is to be avoided. Edema characteristically develops
24–72 hours following infarction and can lead to complica-
tions owing to mass effect; this is especially critical in the
posterior fossa, where obstruction of CSF flow and second-
ary hydrocephalus can result (Figure 30–3). Fluid balance in
acute stroke patients therefore should be watched carefully
and kept on the “dry side” to minimize the risk of hypona-
tremia and further brain swelling. Inappropriate antidiuretic
hormone secretion sometimes can complicate this problem.
When progressive mass effect with secondary hydrocephalus
occurs, management is as described in Chapter 29, and will
require consultation with a neurosurgeon. Since many stroke
patients develop dysphagia or have poor mental status, aspi-
ration precautions should be taken, and a nasogastric tube
should be placed. Swallowing evaluations often are necessary
before allowing oral intake.
Anticoagulation is clearly indicated in embolic disease
but usually must be delayed in the presence of a significant
hemorrhagic infarct because of the risk of further bleeding.
However, this factor must be weighed against what one
judges to be the risk for repeated embolization. Common
practice is to delay for about 10–14 days. The efficacy of anti-
coagulation in occlusive vascular disease is less clear, but it is
common practice at this time to anticoagulate patients with
strokes in progression or frequently repeated transient
ischemic attacks. In the critical care situation, initial antico-
agulation for cerebrovascular disease is accomplished with
intravenous heparin.
Antiplatelet therapy has been shown to reduce the inci-
dence of future stroke in patients at risk, including those with
present or prior stroke, and it can be initiated in the acute
phase of a new stroke. The available agents are aspirin or
enteric-coated aspirin, 81–325 mg/day; clopidogrel bisulfate,
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 Figure 30–3. A, B. Hypodense lesion in the right cerebellar hemisphere with swelling and mass effect resulting in obliter-
ation of the fourth ventricle and cisterns surrounding the brain stem and secondary enlargement of the third ventricle and the
temporal and lateral ventricles. Approximately 21/2 hours after this CT scan was obtained, the patient became comatose and
lost brain stem function owing to progressive obstructive hydrocephalus and brain stem compression. Also, intracranial pres-
sure may exceed cerebral perfusion pressure in this circumstance. Timely neurosurgical intervention can prevent this sequence
of events and thus be lifesaving. C, D. Normal studies for comparison. 1 and 5, cistern; 3, fourth ventricle; 2 and 6, temporal
ventricle; 4, lateral ventricle. Third ventricle unlabeled.
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75 mg/day; or aspirin and extended-release dipyridamole,
one 25/200-mg capsule twice daily. Ticlopidine, 250 mg twice
daily, also is available but is associated with a higher inci-
dence of adverse reactions than the others.
Treatment of acute ischemic stroke with intravenous
recombinant tissue plasminogen activator (rt-PA; alteplase)
has been shown to be beneficial but only if initiated within 3
hours of stroke onset; thus a clear history of time of onset and
prompt transportation to a treatment facility are crucial. The
benefit realized is reduction in long-term disability; improve-
ment taking place in the acute phase is not clearly attributa-
ble to the treatment. Nevertheless, many specialists in this
area believe that within the 3-hour time window, the sooner
the better is the rt-PA treatment. The major adverse event
of this treatment is intracerebral hemorrhage, but even so,
the long-term outcome may be improved if the patient sur-
vives. Overall, the most frequently reported hemorrhage
rate is in the 3–6% or more range. It is essential that the
treating institution establish a system for immediate patient
evaluation and have a protocol in place. Table 30–7 lists the
inclusion and exclusion criteria adopted by the authors’
institution, and Table 30–8 gives the protocol for evaluation
and treatment.
Current Controversies and Unresolved Issues
Carotid endarterectomy generally is recommended to reduce
the risk of future stroke when 70–80% or more of stenosis is
present in a symptomatic artery (it is contraindicated in an
occluded artery). Some data exist indicating that endarterec-
tomy on an asymptomatic, high-grade stenotic carotid artery
is beneficial, but this remains controversial.
Work is in progress to better assess outcome of patients
treated with intravenous rt-PA and to refine selection criteria
for identifying those more or less likely to respond. Also, pro-
tocols are in place to define the role of intraarterial r-tPA and
a device for clot removal in acute cerebrovascular occlusion.
 Complications of Central Nervous System
Infections
ESSENT IALS  OF  D IAGNOS I S
 History: neurologic symptoms, exposures.
 Examination: level of consciousness, neck stiffness,
focal neurologic findings, seizures.
 Brain imaging with and without contrast material.
 CSF analysis.
Inclusion criteria  
Age 18 or older  
Clearly defined time of onset (very important!)  
Ability to initiate rt-PA within 180 minutes from time of onset  
Exclusion criteria  
Minor stroke or rapidly improving symptoms  
Hemorrhage or edema on noncontrast head CT  
Suspected subarachnoid hemorrhage  
Stroke or serious head trauma within 3 months prior to current stroke  
Major surgery or trauma within 14 days prior to current stroke  
History of intracranial hemorrhage  
Systolic blood pressure >185 mm Hg or diastolic blood pressure
>110 mm Hg  
Gastrointestinal or urinary tract hemorrhage within 21 days prior to
current stroke  
Arterial puncture at a noncompressible site within 7 days prior to
current stroke  
Acute myocardial infarction or pericarditis  
Patient taking anticoagulants or has received heparin within the
48 hours preceding the onset of stroke and has elevated aPTT  
Platelet count <100,000/μL  
PT >15 seconds (INR >1.7) or aPTT >34 seconds  
Glucose <50 mg/dL or >400 mg/dL  
Seizure at onset of stroke  
Known or suspected pregnancy or lactating woman  
Aggressive treatment required to maintain blood pressure below 
indicated parameters  
Lumbar puncture within 7 days prior to current stroke  
Occult blood in urine or stool  
Table 30–7. rt-PA (alteplase) criteria. 
1. When notified of a possible rt-PA candidate, call designated medical
personnel immediately.
2. Get the time of onset, a medication list, and complete neurologic
examination. Patient needs a monitored bed in the emergency
room.
3. Obtain stat head CT scan (noncontrast) to rule out hemorrhage;
stat labs: CBC, PT/aPTT/glucose; stat ECG.
4. Go through all exclusion criteria (Table 30–7) and put sheet on chart.
5. Dose: Alteplase (Activase) 0.9 mg/kg (maximum 90 mg total
dose) IV. Give 10% as bolus over 1 minute, remainder by continu-
ous infusion over 60 minutes.
6. If patient recieves rt-PA, needs ICU bed.
7. Order vital signs and neurologic checks (specify what you want
checked):
• Every 15 minutes for 2 hours
• Every 30 minutes for 6 hours
• Every 1 hour for 16 hours
8. Strict blood pressure control (185/95 mm Hg or less). Use IV
labetalol or nitroprusside drip.
9. Urgent: No anticoagulants and no antiplatelet agents whatsoever
for 24 hours after rt-PA given.
10. If there is any worsening on neurologic or mental status examina-
tion, stop rt-PA if still being infused and order stat head CT
(noncontrast) to rule out hemorrhage.
Table 30–8. rt-PA (alteplase) protocol.
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General Considerations
The initial patient examination should lead to an etiologic
diagnosis and selection of appropriate therapy. Infectious
disease consultation may be necessary in the process. Beyond
this, the critical care physician should be alert to certain
aspects and complications of CNS infections. Viral, granulo-
matous, parasitic, and bacterial infections each have special
features requiring consideration, and all have some common
features.
Clinical Features
A. Viral Infections—Meninges and neurons are the site of
most CNS viral infections; human immunodeficiency virus
(HIV), which infects microglia and leads to the formation of
multinucleated cells in the brain, is a notable exception. Viral
meningitis usually runs a self-limited course with supportive
therapy only, and the specific virus usually is not identified,
no more than headache, fever, neck stiffness, and abnormal
CSF findings are expected clinical features. On the other
hand, viral encephalitis reflects neuronal dysfunction. Altered
mental status, seizures, and even focal neurologic signs are
common. Early recognition is especially important in herpes
simplex type I (HSV) encephalitis because early and prompt
treatment with acyclovir improves outcome. This virus has a
predilection for temporal lobes; thus presenting features
commonly are confusion, change of usual behavior patterns,
memory disturbance, and complex partial seizures, which
may secondarily generalized (see section on seizures).
Inflammation, sometimes with a hemorrhagic component,
and edema may be enough to affect nearby cortex, giving rise
to additional focal features such as hemiparesis, sensory
deficit, or language disturbance. If HSV encephalitis is sus-
pected, acyclovir should be started immediately and not
postponed awaiting confirmatory workup.
HIV infection of the CNS may result in mental and motor
slowing (AIDS dementia complex) by mechanisms not yet
understood, but aside from the acute phase of infection, the
occurrence of seizures, focal neurologic symptoms, and find-
ings or symptoms and signs of meningitis indicate a super-
imposed complication such as infection with Toxoplasma,
Cryptococcus, fungus, or mycobacteria or an intracerebral
lymphoma.
B. Parasitic Infections—Cysticercosis is the most common
parasitic CNS infection encountered in the United States. It
is most common in states bordering Mexico and is seen
most often in Mexican immigrants. It is a major public
health problem in other parts of the world as well. It is
acquired by ingestion of eggs of the tapeworm Taenia, which
are shed in the feces of human carriers. Three forms of the
disease exist. The most common site of infection is the
parenchyma of the cerebral hemispheres, and the natural
course of this form of the disease is eventual death of the
organisms and subsequent calcification of the lesion, which
is readily identified as punctate calcifications on CT scans.
This process often is entirely asymptomatic, but sometimes
the tissue reaction and associated edema caused by the
organisms’ death produce focal neurologic symptoms and
signs, and imaging studies may not clearly distinguish such
a lesion from a primary or metastatic neoplasm. In this
instance, neurologic consultation is indicated. The charac-
teristic locus of parenchymal cysticercosis is at the gray-
white junction, and the usual clinical manifestation is a
seizure disorder, which sometimes is limited in time and
sometimes chronic. The seizures are partial, often with sec-
ondary generalization, which may be so rapid that the par-
tial onset is unrecognizable. Treatment with antiepileptic
medication is indicated.
Another form of this disease is intraventricular cysticer-
cosis, in which the organism remains cystic and is located
within the ventricular system. It is asymptomatic unless it
causes obstructive hydrocephalus with headaches as the ini-
tial symptom. This is a very dangerous situation because the
cysts often are free to move within a ventricle and thus can
cause acute hydrocephalus and relatively sudden and unex-
pected death of the patient. A high degree of suspicion is nec-
essary and should lead to brain imaging studies, which could
include CT brain scan, intraventricular positive-contrast CT
brain scan to outline a cyst, and MRI of the brain.
Neurosurgical intervention for shunting of CSF or cyst
removal is required.
Finally, the organism may reside in the subarachnoid
space, where it exists in the racemose form and can cause
meningeal inflammation. This is an indolent and chronic
form, and racemose membrane formation with cystic locula-
tions usually is slowly progressive. If this occurs around the
base of the brain, it also may result in obstructive hydro-
cephalus and require placement of a CSF shunt. Nonsteroidal
anti-inflammatory medication is indicated for relief of
headache owing to the meningeal reaction and may decrease
the inflammatory response.
Praziquantel or albendazole will kill the organism in the
parenchymal form and perhaps the racemose form, but no
controlled evidence exists that treatment with these agents
changes the natural outcome of the disease. Furthermore, the
increased rate of organism death and the subsequent brain
tissue reaction have increased patient morbidity and in some
instances, particularly when the disease was present in the
posterior fossa and around the brain stem, have contributed
to death of the patient.
Amebic meningoencephalitis occurs but is rare in the
United States. Usually it is acquired from swimming or
bathing in infected fresh warm water springs. Fever,
headache, and seizures are the presenting signs. Amphotericin
B has been recommended for treatment.
Toxoplasmosis—infection with Toxoplasma gondii, an
obligate intracellular parasite—is one of the most frequent
opportunistic infections in patients with AIDS and as a con-
sequence is encountered much more frequently than it used
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to be. Symptoms are those of meningoencephalitis and often
include headache, confusion, delirium, obtundation, and less
often, seizure. Brain imaging studies and CSF examination,
including serum Toxoplasma IgG antibody titer, are useful in
diagnosis, but sometimes a favorable response to treatment
with pyrimethamine and sulfadiazine (usually judged by
reduction of lesions seen on imaging studies) is necessary for
diagnostic confirmation. Brain biopsy will be diagnostic if
response to treatment is uncertain or fails.
C. Granulomatous Infections—Among fungi and yeast
infections, coccidioidomycosis and cryptococcosis are
encountered most frequently. While their infectious agents
and mycobacteria may form parenchymal lesions, a chronic
progressive meningitis is the rule, and it has a predilection
for meninges at the base of the brain. A common complica-
tion is the development of hydrocephalus owing to blockage
of CSF flow from the foramina of Luschka and Magendie. It
is usually a relatively slow and progressive process, occurring
in the middle to later stages of these diseases, and it often
requires placement of a CSF shunt. Brain CT scan or MRI
will show the presence and progression of hydrocephalus.
With contrast material, those studies also show the presence
of the inflammatory basilar meningitis. Other complications
are cranial nerve deficits and infarctions caused by inflam-
mation and constriction from the proliferative meningitis
around arteries. Fluconazole and intravenous amphotericin B
are the primary drugs for treatment of coccidioidomycosis
and cryptococcosis, but sometimes the response is insuffi-
cient, and intrathecal administration of amphotericin B is
necessary. One must be aware that if the drug is delivered
into a lateral ventricle in the presence of hydrocephalus and
a shunt, it will not reach the site of infection but rather be
diverted away. Under these circumstances, placement of a
reservoir for delivery into the foramen magnum or lumbar
subarachnoid space may be possible. This will require neuro-
surgical consultation.
D. Bacterial Infections—CNS infection with Listeria mono-
cytogenes is singled out here because it is unusual in that it
can cause a rhombencephalitis with prominent brain stem
findings, and it also may cause meningitis. Persons with
chronic illness are predisposed to this disease. In general,
prompt diagnosis and appropriate therapy of bacterial infec-
tions can prevent or reduce complications.
When seizures or focal neurologic deficits occur in the
course of bacterial meningitis, one should suspect cortical
vein thrombosis, which can be demonstrated by brain imag-
ing studies. In the case of seizures, an antiepileptic drug such
as phenytoin or phenobarbital should be administered and
probably will have to be given intravenously (see section on
seizures). Acute sagittal sinus thrombosis is a life-threatening
complication because of brain swelling and bleeding into the
parenchyma; neurologic findings can include obtundation
and signs of increased intracranial pressure, seizures, and
perhaps focal neurologic deficits—typically paresis of the
legs because of the functional localization of the area of brain
drained by the sinus. CT scan or MRI will confirm the diag-
nosis. Administration of an anticoagulant may diminish
clotting but may serve to increase bleeding from veins feed-
ing the sinus. Seizures should be treated with an antiepilep-
tic drug. As prompt a resolution as possible of the underlying
infection will improve outcome.
Hydrocephalus can be an early or late complication of
bacterial meningitis. Impairment of CSF absorption at the
arachnoid granulations caused by purulent accumulation,
inflammation, and adhesions is a significant factor in this
case. CSF shunting may be necessary.
Neurologic features of bacterial brain abscesses characteris-
tically are focal neurologic findings and seizures. These
abscesses often develop because of cardiac or pulmonary right-
to-left shunting or extension of a sinus infection. In addition to
antibiotic therapy, neurosurgical drainage and excision may be
necessary. The dreaded complication is rupture of an abscess
into the ventricles; this results in an acute ventriculitis, which
almost always is fatal. Because of postinfectious scarring and
gliosis, a chronic seizure disorder can develop.
Lastly, it is notable that a partially treated bacterial
meningitis can mimic viral meningitis.
E. Laboratory Findings—The EEG should be normal in
viral meningitis, but it is highly likely to be abnormal in viral
encephalitis, showing generalized slowing and, sometimes,
epileptiform events. Characteristic of herpes encephalitis are
periodic seizure discharges, predominant over the affected
temporal area; absence of this finding does not rule out her-
pes encephalitis. Hydrocephalus, especially from disease in
the posterior fossa, can show background disorganization
and slowing with intermittent runs of high-voltage slow
waves. Any focal brain disease may result in focal slow activ-
ity in the EEG, and often it is especially prominent in brain
abscesses. The presence of epileptiform discharges will con-
firm the diagnosis of seizures and, if focal, indicate the site of
the epileptogenic process.
The CSF examination will show an increased cellular con-
tent in all active meningeal infections, although rarely the
specimen may be obtained just preceding the cellular
response; in this case, another specimen after a day or so
should show increased cells. In general, bacterial infections
will show polymorphonuclear leukocytes (PMNs) and the
other infections predominantly mononuclear cells. Some
viral infections, notably herpes simplex, may show a signifi-
cant proportion of PMNs early in the course of the disease.
It is typical in herpes encephalitis for the CSF to contain red
blood cells, but their absence does not rule it out. Partially
treated bacterial meningitis can show predominantly
mononuclear cells. Eosinophils are found occasionally in
cases of cysticercosis. The organism can be demonstrated by
India ink preparation in cryptococcosis and by wet prepara-
tion in amebic infection, but not finding them does not rule
out either one. The Gram stain may find bacteria and the
acid-fast stain mycobacteria. Low CSF glucose results from
infections interfering with its transport into the CSF, and it is
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characteristically quite low in bacterial, fungal, and tubercu-
lous meningitis. It is usually little altered in viral meningitis.
Since the CSF glucose level is normally close to half the blood
glucose level, significantly high or low blood glucose can
confuse the issue. CSF glucose concentration lags behind
blood glucose 1–2 hours, but a blood glucose measured near
the time of obtaining the CSF specimen is usually satisfac-
tory for judging the CSF level. In viral infections, the CSF
protein content, like the glucose, is little altered, whereas it is
elevated in the other infections. If the protein content is very
high, blockage and impairment of CSF flow should be sus-
pected. Culture of CSF can provide a definitive diagnosis in
most infections other than viral, in which it is unusual to
recover the agent. Anaerobic organisms are common in brain
abscesses. Frequently the best management is to initiate
appropriate therapy while awaiting the results of culture.
Serologic tests of CSF include latex agglutination or other
techniques for detection of bacteria-specific antigens (usu-
ally available as a panel), measurement of cryptococcal anti-
gen, and assay of coccidioidal antibody titer—the latter two
are useful to follow as an index of response to treatment.
False-negative immunologic tests frequently are encountered
in neurocysticercosis, and a positive test may be found in
extraneural cysticercosis, so the practical value of such test-
ing is limited. Serum-specific HSV antibody titers rising over
the course of the illness can confirm the diagnosis, but usu-
ally in retrospect. Polymerase chain reaction (PCR) testing
for CSF herpes simplex antigen has rarely been helpful in the
authors’ experience. Toxoplasma IgM titer is helpful if posi-
tive; a negative result does not exclude the disease in AIDS.
HIV infection of the CNS can be accurately followed by
assaying the CSF viral load.
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Neurosurgical critical care covers a wide array of disorders
with varying pathophysiologic features. These conditions
also may be associated with unique complications that must
be recognized and treated promptly. Physicians involved in
the ICU management of neurosurgical patients therefore
must be familiar with the clinical features, complications,
and treatment of CSN disorders.
This chapter focuses on the management of patients with
head injury, aneurysmal subarachnoid hemorrhage, brain
tumor, and cervical spinal cord injury. These disorders com-
prise the majority of neurosurgical ICU admissions.
Following injury, the CNS is vulnerable to a variety of sec-
ondary insults that can occur minutes, hours, or days following
the primary injury. Systemic conditions such as hypoxia,
hypotension, and electrolyte disorders may result in morbidity in
severely injured patients. Cerebral complications such as elevated
intracranial pressure, seizure, hemorrhage, and ischemia also
have the potential to cause neurologic impairment. The main
focus of current intensive care is to avoid or quickly reverse con-
ditions that can lead to secondary injury. Therefore, meticulous
management of all aspects of critical care is required to prevent
increased neurologic damage and improve patient outcome.
 Head Injuries
ESSENT IALS  OF  D IAGNOS I S
 Signs depend on severity and anatomic location.
 Concussion: transient loss of consciousness, memory
loss, headache, autonomic dysfunction.
 Herniation: depressed level of consciousness, anisocoria,
abnormal motor findings.
General Considerations
Injuries to the brain remain the most common cause of
trauma-related death and disability. More than 500,000 peo-
ple suffer some degree of head trauma annually in the United
States. In the past, patients with traumatic brain injuries were
viewed with pessimism because both surgical and medical
therapeutic resources were limited. However, with recent
advances, including prompt, intensive management of head-
injured patients, the outcome has improved. One of the
major reasons for the better results has been improved criti-
cal care management, particularly the recognition and pre-
vention of disorders that cause secondary brain injury.
Classification
A. Primary Injuries—By definition, primary traumatic brain
injury occurs at the time of impact. This may lead to irre-
versible damage from cell disruption depending on the mech-
anism and severity of the inciting event. Head trauma may
cause damage to the scalp, skull, and underlying brain. Scalp
lacerations can cause significant hemorrhage, but in most
cases hemostasis can be achieved easily. Fractures are classi-
fied as linear, depressed, compound, or involving the skull
base. Linear or simple skull fractures require no specific treat-
ment. Depressed skull fracture occurs when the outer table of
the skull is depressed below the inner table and may result in
tearing of the dura or laceration of the brain. Operative repair
may be required, especially if the depressed fracture involves
the posterior wall of the frontal sinus or is associated with
intracranial hematoma. Compound depressed fractures are
defined as those associated with laceration of the overlying
scalp and are treated by surgical wound debridement and
fracture elevation, if severe. Basal skull fractures, which may
be diagnosed by the clinical findings of periorbital ecchymo-
sis (“raccoon eyes”), ecchymosis of the postauricular area
(Battle’s sign), hemotympanum, or cerebrospinal fluid (CSF)
leak, may be complicated by meningitis or brain abscess.
Patients suffering from skull fractures have an increased risk
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of delayed intracranial hematoma and should be observed for
12–24 hours after the initial injury.
Brain injury can occur directly under the injury site (coup
injury), but because the brain may move relative to the skull
and dura, compression of the brain remote from the site of
impact also can occur. This explains why brain injury can occur
in intracranial regions opposite the point of impact (contrecoup
injury). Craniocerebral trauma can cause concussion, cerebral
contusion, intracranial hemorrhage, or diffuse axonal injury.
1. Concussion—Concussion is an episode of transient loss
of consciousness following craniocerebral trauma. There is
no evidence of pathologic brain damage. Patients may suffer
from variable degrees of memory loss, autonomic dysfunc-
tion, headaches, tinnitus, and irritability.
2. Cerebral contusions—Cerebral contusions are hetero-
geneous areas of hemorrhage into the brain parenchyma and
may produce neurologic deficits depending on their anatomic
location. The anterior portions of the frontal and temporal
lobes are particularly vulnerable because of the rough contour
of the skull in these regions. Contusions are often associated
with disruption of the blood-brain barrier and may be com-
plicated by extension of the hemorrhage, edema formation, or
seizure. Large contusions can cause a mass effect resulting in
elevation of intracranial pressure or brain herniation.
3. Intracranial hematomas—Head injury may cause hem-
orrhage into the epidural, subdural, or subarachnoid spaces.
This bleeding, which may require surgical evacuation depend-
ing on its size and location, is usually diagnosed prior to admis-
sion to the ICU. However, delayed intracranial hematomas or
postoperative hematomas are not uncommon following cran-
iocerebral trauma and can develop and progress during ICU
observation. Intracranial bleeding may result in mass effect that
can cause intracranial pressure elevation (see below) and brain
herniation with compression of vital cerebral structures.
a. Epidural hematoma—This lesion is typically associated
with skull fracture and laceration of a meningeal vessel, most
commonly the posterior branch of the middle meningeal
artery. This may occur following low-velocity impact
injuries. Because the dura is firmly tethered to the inner table
of the skull, the hematoma usually takes on a homogeneous
lentiform configuration (Figure 31–1A).
b. Subdural hematoma—Subdural hematoma can be sec-
ondary to tearing of the cortical vessels, such as the bridging
veins that drain from the cortex to the dura and superior sagittal
sinus. It is commonly associated with other injuries such as cere-
bral contusions and has a worse prognosis than epidural
hematoma. Because it is not contained by dural attachments, the
hemorrhage often spreads diffusely across the cortical surface
resulting in a crescent-shaped image on CT scan (Figure 31–1B).
A B
 Figure 31–1. A. Left temporoparietal epidural hematoma with obliteration of the left lateral ventricle and midline
shift. B. Right frontoparietal and interhemispheric subdural hematoma with massive right-to-left midline shift.
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c. Subarachnoid hemorrhage—Subarachnoid hemor-
rhage is caused most commonly by craniocerebral trauma.
The subarachnoid bleeding itself does not usually cause neu-
rologic damage, but hydrocephalus and cerebral vasospasm,
which are delayed complications, can lead to neurologic
impairment. Subarachnoid hemorrhage as a result of a rup-
tured intracranial aneurysm always should be considered as
a possible causative factor in trauma and needs to be ruled
out with an angiogram if there is reasonable concern.
4. Diffuse axonal injury—Diffuse axonal injury is shear-
ing of brain tissue with disruption of neuronal axon projec-
tions in the cerebral white matter resulting from rotational
deceleration of the brain. This diffuse injury to axons occurs
microscopically and can result in severe neurologic impair-
ment. Evidence of diffuse axonal injury is often not demonstra-
ble on CT scan. However, macroscopic hemorrhagic lesions
can be seen in deep brain structures such as the corpus callo-
sum or brain stem in association with diffuse axonal injury.
B. Secondary Injuries—Many studies have observed that
cerebral autoregulation is impaired after traumatic brain
injury. This causes patients with head injuries to be unusu-
ally vulnerable to secondary ischemic insults such as
hypotension, intracranial hypertension, and hypoxia.
Further ischemic damage often can be prevented with an
understanding of the pathophysiology of these secondary
insults and an aggressive targeted management protocol.
These conditions can be conveniently divided into intracra-
nial and systemic disorders (Table 31–1). Following traumatic
brain injury, some cells are directly and irreversibly damaged.
However, other cells may be functionally compromised and
not mechanically disrupted. These may recover if provided
with an optimal environment for survival. Compromised
cells are vulnerable to the pathophysiologic challenges
imposed by secondary insults. Prevention or rapid recogni-
tion and treatment of secondary insults is the primary focus
of modern critical care management of head-injured patients.
1. Secondary intracranial insults (raised intracra-
nial pressure)—Intracranial hypertension following cran-
iocerebral trauma may be caused by intracranial hematomas,
cerebral edema, or cerebral hyperemia. The Monro-Kellie
doctrine proposes that small increments in intracranial vol-
ume ultimately may cause intracranial pressure (ICP) to rise
because of the rigid and inelastic properties of the skull.
Under normal circumstances, intracranial volume is com-
posed of roughly 80% brain tissue, 10% CSF, and 10% blood.
An increase in volume of one of these compartments—or the
addition of a new pathologic compartment (eg, intracranial
hematoma)—must be compensated for by a reduction in the
volume of another compartment to maintain pressure.
Compensatory mechanisms that buffer such volume changes
include increased CSF absorption, redistribution of CSF
from the intracranial cavity into the spinal subarachnoid
space, and a reduction in cerebral blood volume. Cerebral
compliance relates the change in intracranial volume to the
resulting change in ICP (Figure 31–2). High compliance
signifies a system that can use buffering mechanisms to keep
ICP stable with changes in intracranial volume. However,
when the buffering becomes saturated, large pressure eleva-
tions result from small volume changes (poor compliance;
arrow in Figure 31–2). Therefore, although ICP may lie
within a relatively normal range (up to 20 mm Hg), a low-
compliance state may exist, and rapid elevations in ICP may
result from small increases in intracranial volume.
The falx cerebri, tentorium cerebelli, and foramen mag-
num are relatively rigid structures that compartmentalize
regions of the brain. Because many pathologic processes are
focal, pressure gradients can be generated between the
intracranial compartments. Elevated ICP may exert its delete-
rious effect by causing pressure gradients between different
brain compartments. If this pressure gradient is of sufficient
magnitude, shifting or herniation of brain tissue occurs and
can result in compression of vital structures. For example,
transtentorial herniation occurs when increased supratentorial
volume and pressure are sufficient to shift the uncus and the
medial portion of the temporal lobe through the tentorial
notch, causing compression and dysfunction of the midbrain
and oculomotor nerve. Compression of the medulla occurs
Table 31–1. Secondary insults. 
Intracranial 
Raised intracranial pressure 
Delayed intracerebral hematoma 
Edema 
Hyperemia 
Carotid artery dissection 
Seizures 
Vasospasm 
Systemic 
Hypoxia 
Respiratory arrest 
Airway obstruction 
ARDS 
Aspiration pneumonia 
Pneumonia and hemothorax 
Pulmonary contusion 
Hypotension 
Shock 
Excessive bleeding 
Myocardial infarction 
Cardiac contusion or tamponade 
Spinal cord injury 
Tension pneumothorax  
Electrolyte imbalance  
Diabetes insipidus  
SIADH  
Others  
Anemia  
Hyperthermia  
Hypercapnia  
Hypoglycemia  
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when ICP is elevated and the cerebellar tonsils herniate through
the foramen magnum. This condition, known as tonsillar herni-
ation, can prove fatal because of the location of vital respiratory
and vasomotor centers in this area of the brain stem.
Alternatively, since cerebral perfusion pressure (CPP) is
inversely related to ICP,∗ elevations in pressure may cause
impaired cerebral perfusion. If CPP is greatly reduced
(<40–50 mm Hg), cerebral ischemia or infarction can occur.
Therefore, maintenance of systemic blood pressure is of
paramount importance when ICP is elevated.
2. Secondary systemic insults—Of the various systemic
secondary insults, hypoxia and hypotension are the most
significant. Prospective clinical studies have demonstrated
that these two variables independently have a deleterious
influence on the outcome in severe head injury. Hypotension
alone is associated with a 150% increase in mortality rate. In
patients with significant head injuries, hypoxemia may be due
to upper airway obstruction, pneumothorax, hemothorax,
pulmonary edema, or hypoventilation. Whatever the cause,
hypoxemia must be corrected rapidly to avoid potential
damage to neural tissues. Hypotension reduces cerebral
perfusion, which promotes cerebral ischemia and infarc-
tion. This is particularly harmful in the face of elevated ICP.
In addition, impaired cerebral autoregulation can occur
after brain injury. With normal autoregulation, cerebral
blood flow remains constant despite fluctuation in mean
arterial pressure between 60 and 180 mm Hg (Figure 31–3).
Rapid arteriolar constriction or dilation occurs in response
to pressure changes. However, when this normal response is
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 Figure 31–2. Intracranial pressure (ICP) remains normal with increased volume until the point of decompensation is
reached. Above this critical volume, ICP increases quickly.
 Figure 31–3. Cerebral blood flow (CBF) remains normal over a wide range of cerebral perfusion pressures in nor-
mal patients. Under pathologic conditions, CBF varies directly with cerebral perfusion pressure (CPP).
CCP (mm Hg)
CB
F 
(p
erc
en
t)
∗Cranial perfusion pressure (CPP) = Mean arterial pressure (MAP) – Intracranial pressure (ICP)
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impaired, cerebral blood flow becomes directly related to
systemic arterial pressure. Thus, if hypotension occurs,
reduced tissue perfusion and ischemia may result. Elective
surgery for extracranial injuries should be delayed as long as
possible because of this issue. Surgery-related hypotensive
episodes can have correspondingly negative impact on brain
perfusion and ultimately the quality of overall outcome.
Other treatable or preventable systemic causes of secondary
brain injury include electrolyte disturbances, anemia, hypo-
glycemia, hyperthermia, coagulopathies, and seizures.
Clinical Features
A. Symptoms and Signs—Clinical examination remains
the best method for rapidly identifying neurologic deteriora-
tion. The Glasgow Coma Scale, which is based on eye open-
ing as well as verbal and motor responses, is used widely to
assess head injury patients (Table 31–2). Other important
components of the initial neurologic examination include
assessment of brain stem function, including level of con-
sciousness, respiratory pattern, pupillary size and reactivity,
as well as oculocephalic, oculovestibular, and gag reflexes. Eye
movements, extremity motor and sensory function, and lan-
guage and speech also should be evaluated. Following this
initial brief examination, a more thorough neurologic assess-
ment can be performed.
Transtentorial herniation, usually secondary to an
expanding supratentorial mass, produces a classic triad of
clinical signs: (1) depressed level of consciousness owing to
compression of the midbrain reticular activating system,
(2) anisocoria and loss of the pupillary light reflex owing to
ipsilateral third nerve compression, and (3) abnormal motor
findings from compression of the midbrain. In the early
stages of herniation, the ipsilateral third nerve is compressed;
however, if pressure on the brain stem increases, both pupils
may become dilated and unreactive. Contralateral hemipare-
sis owing to direct compression of the ipsilateral cerebral
peduncle is the most frequent abnormal motor response.
However, in about 25% of patients, hemiparesis may occur
on the same side as the mass lesion because the brain stem is
displaced away from the mass, compressing the opposite
cerebral peduncle against the free edge of the tentorium
(Kernohan’s notch phenomenon). The posterior cerebral
artery can be occluded during transtentorial herniation and
result in infarction of the occipital lobe it supplies.
Signs of tonsillar herniation include respiratory irregular-
ities, Cushing’s response (ie, elevated blood pressure associ-
ated with bradycardia), nuchal rigidity, and abnormal gag
and cough reflexes owing to medullary compression. During
early herniation, the patient’s level of consciousness may be
normal because the upper brain stem and reticular activating
system remain intact.
Neurologic deterioration in the ICU warrants immediate
and thorough evaluation in an effort to elucidate the cause.
Vital signs, serum electrolytes, O2 saturation, and arterial
blood gas values should be determined if the deterioration is
global in nature. However, if the examination suggests a focal
lesion, an intracranial hematoma, elevated intracranial pres-
sure with a herniation syndrome, cerebral edema, or cerebral
ischemia is probably present. Studies validate that aggressive
medical management can reverse herniation and improve
outcome.
B. Imaging Studies—
1. CT scan—CT scanning is significantly more accurate than
conventional radiographs and has replaced them in the eval-
uation of head injuries. CT scanning can delineate parenchy-
mal hemorrhages and contusions, epidural and subdural
hematomas, cerebral edema, hydrocephalus, and cerebral
infarction. An intracranial lesion is said to exert a “mass
effect” on the brain when there is CT evidence of effacement
of the cerebral ventricles, subarachnoid cisterns, or cortical
sulci signifying redistribution of CSF. Further CT evidence of
a mass effect includes a shift of midline structures away from
the lesion and herniation of tissues. The outlet of the con-
tralateral ventricle can become “trapped” as a result of mid-
line shifting, and this can further increase ICP. Because MRI
is slower and generally not available emergently, especially in
intubated patients, it is not used commonly to assess acute
neurologic deteriorations. The availability of portable CT
scanners enables the diagnostic study to be performed with-
out transporting an unstable patient and risking harmful res-
piratory or cardiovascular events.
2. Cerebral angiography—Prior to the advent of CT
scanning, angiography was the primary diagnostic study for
evaluating head-injured patients because it detects the mass
effect from intracranial lesions. Currently, however, the main
role for angiography is the assessment of vascular disorders
Table 31–2. Glasgow Coma Scale. 
Eye opening (E) 
Spontaneous 4 
To voice 3 
To pain 2 
None 1 
Motor responses (M) 
Obeys commands 6 
Localizes pain 5 
Withdraws 4 
Abnormal flexion 3 
Abnormal extension 2 
None 1 
Verbal responses (V) 
Oriented 5 
Confused 4 
Inappropriate words 3 
Incomprehensible sounds 2  
None 1  
TOTAL SCORE (3 to 15)  
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such as dissection or traumatic pseudoaneurysm of the
internal carotid or vertebral arteries and cerebral vasospasm.
Both MRI- and CT-based noncatheter angiography have sup-
planted invasive techniques for most emergency indications.
3. Transcranial Doppler ultrasonography—Transcranial
Doppler ultrasonography is a noninvasive technique that
measures blood flow velocity in the basal cerebral arteries.
It can be performed serially at the bedside in the ICU and
can reliably detect arterial narrowing owing to vasospasm,
which causes increased flow velocity. It also can aid in the
confirmation of absent blood flow owing to brain death.
C. Monitoring of Intracranial Pressure—Measurement of
ICP through an open catheter placed in the lateral ventricle
(ventriculostomy) is the standard with which all other meth-
ods of ICP measurement must be compared. Additionally,
CSF may be drained via the ventriculostomy to treat elevated
pressures, if present. Ventricular catheters may be placed in
the operating room during surgery or can be inserted at the
bedside in the emergency room or ICU. Because of the risk
of infection, patients with ventriculostomies should be given
prophylactic antibiotics with gram-positive coverage such as
cefazolin or vancomycin, and the catheters must be changed
periodically. Measurement of ICP also can be done using a
fiberoptic or strain-gauge device. These monitors are usually
more expensive, have a tendency to drift, and are unable to
drain CSF.
D. Lumbar Puncture—Lumbar puncture should not be per-
formed in the initial evaluation of head trauma patients
because of the risk of tonsillar herniation. The only role for
lumbar puncture is to examine CSF in patients who may
have meningitis. In such cases, ICP must be thought to lie
within the normal range prior to the procedure, or patients
should receive mannitol to induce diuresis prior to a small-
volume tap with a thin (eg, 22-gauge) spinal needle.
Treatment
A. Surgery—Patients who show neurologic deterioration
require rapid intervention to prevent irreversible tissue dam-
age. Cerebral contusions, intracranial hematomas, and for-
eign bodies may require emergent evacuation depending on
their size and location.
B. Reduction of Intracranial Pressure—Raised ICP should
be treated using the following measures:
1. Removal of CSF by ventricular drainage.
2. The use of mannitol prior to ICP monitoring should be
reserved for signs of transtentorial herniation or progres-
sive neurologic deterioration not attributable to systemic
extracranial explanations. Serum osmolarity should be
maintained below 320 mOsm/L to avoid renal failure, and
volume should be replaced with colloid agents or blood if
necessary to avoid hypotension or reduced cerebral per-
fusion. A Foley catheter is essential.
3. Hyperventilation results in cerebral vasoconstriction and
can help to reduce ICP for brief and specific periods. The
vasoconstrictive effects assist in the management of an
intracranial hypertensive crisis; however, the long-term
influence can produce permanent injury by reducing
blood flow below critical levels in an already injured
brain. Therefore, in the absence of high ICP, chronic
hyperventilation (PaCO2 <25 mm Hg) should be avoided
in the first 24 hours after traumatic brain injury. In addi-
tion, the use of prophylactic hyperventilation (PaCO2 <
35 mm Hg) during the first 24 hours should be limited
because it can compromise cerebral perfusion during a
time of reduced cerebral blood flow (CBF).
4. Head elevation should be maintained to promote cerebral
venous drainage. The head should be kept straight, and
tape from the endotracheal tube should not cross the
jugular area.
5. Sedation and neuromuscular paralysis are recommended
in intubated patients. Noxious stimuli may increase ICP,
which can be alleviated by sedation. Narcotics are useful
because they can be reversed rapidly. Neuromuscular
paralysis can reduce ICP in intubated patients by prevent-
ing increases in venous pressure associated with the Valsalva
maneuver during ventilatory support. Benzodiazepines and
propofol can be used as first-line agents for the sedation
of head-injured patients.
6. Anticonvulsant therapy (eg, IV keppra or phenytoin) can
be used to prevent or control seizure activity that
increases cerebral blood flow and subsequently ICP.
Available evidence does not indicate that the prevention
of early posttraumatic seizures improves outcome follow-
ing head injury, so these agents should be used with dis-
cretion. Bedside electroencephalography should be
obtained in patients with suspicious movements, pos-
tures, or eye movements and in those with unexplained
depression of consciousness. One week of prophylactic
anticonvulsant medication generally is sufficient in a
patient without evidence of seizure activity.
7. Fever increases ICP and should be prevented when possi-
ble. Chilled intravenous fluids or cooling blankets are
helpful for the management of refractory temperature
elevations.
8. Barbiturate (eg, pentobarbital) coma is useful if all other
medical therapies fail because it reduces ICP by decreas-
ing cerebral metabolism and therefore cerebral blood
flow. Care must be taken to prevent hypotension.
9. In selected patients in whom maximum medical therapy has
failed to reduce ICP, bony decompression or temporal lobec-
tomy can be performed surgically. Hemicraniectomy with
duraplasty can be performed in severe, refractory cases.
C. Electrolytes—Cerebral salt wasting is a recognized phe-
nomenon following brain injury and is caused by release of
cerebral natriuretic factors. It is defined as renal loss of
 CHAPTER 31686
sodium during intracranial disease leading to hyponatremia
and a decrease in extracellular fluid volume. Hyponatremia
produces increased brain swelling, and the volume depletion
that accompanies cerebral salt wasting must be treated
aggressively to avoid hypotension and reduced cerebral per-
fusion. Therefore, cerebral salt wasting should be recognized
promptly and treated with hypertonic saline solutions.
Traumatic brain injury also can result in a number of
other electrolyte disturbances requiring treatment, including
hypomagnesemia, hypophosphotemia, and hypokalemia.
Becker DP, Gudeman SK (eds): Textbook of Head Injury.
Philadelphia: Saunders, 1989.
Chesnut RM, Marshall LF: Treatment of abnormal intracranial
pressure. Neurosurg Clin North Am 1991;2:267–84.
Cooper PR: Delayed brain injury: Secondary insults. In Becker DP,
Povlishock JT (eds), Central Nervous System Trauma Status
Report—1985. Prepared for the National Institute of
Neurological and Communicative Disorders and Stroke.
Washington: National Institutes of Health, 1986.
Guidelines for the Management of Severe Head Injury, 2d ed.
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Seelig JM et al: Traumatic acute subdural hematoma: Major mor-
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 Aneurysmal Subarachnoid Hemorrhage
ESSENT IALS  OF  D IAGNOS I S
 Headache.
 Nausea and vomiting.
 Photophobia.
 Nuchal rigidity.
 Depressed level of consciousness.
 Cranial nerve palsies, motor abnormalities.
General Considerations
Rupture of an intracranial aneurysm is a devastating event
because roughly half of these patients die. Of the remainder,
almost half are left with significant neurologic deficits as a
result of their initial hemorrhage or owing to delayed com-
plications such as rebleeding, vasospasm, or hydrocephalus.
In order to optimize outcome following subarachnoid hem-
orrhage, successful surgical or radiologic intervention and
meticulous ICU care are required.
Intracranial aneurysms typically occur at bifurcation sites
of major arteries at the base of the brain and usually point in
the direction of blood flow. It is believed that a defect in the
medial elastic lamina is present that predisposes to aneurysm
formation. Aneurysms are associated with a variety of condi-
tions, including hypertension, polycystic kidney disease,
coarctation of the aorta, Ehlers-Danlos syndrome, pseudoxan-
thoma elasticum, and cerebral arteriovenous malformations.
Approximately 85% are located in the anterior circulation,
with the most common sites being the junction of the anterior
cerebral and anterior communicating arteries, the junction of
the internal carotid and posterior communicating arteries, the
bifurcation or trifurcation of the middle cerebral artery, and
the bifurcation of the internal carotid artery. Fifteen percent of
aneurysms lie within the posterior circulation; the basilar
artery apex is the most common site. Multiple aneurysms can
be identified in 15–20% of patients. Since the cerebral arteries
course within the subarachnoid space, rupture typically pro-
duces subarachnoid hemorrhage. However, intraparenchymal
and intraventricular bleeding may occur depending on the
location of the aneurysm and the extent of bleeding.
The three major complications following aneurysmal sub-
arachnoid hemorrhage are rebleeding, vasospasm, and hydro-
cephalus. Rebleeding from a ruptured intracranial aneurysm
occurs in 20% of patients during the first 2 weeks after the
initial hemorrhage if the aneurysm is untreated. The highest
risk is in the first 24 hours, and occlusive treatment with sur-
gery or interventional embolization is required. Cerebral
vasospasm is a common delayed complication of subarach-
noid hemorrhage and is related to the amount of blood
located within the subarachnoid space. Vasospasm typically
occurs between 3 and 14 days postbleed. Arterial narrowing is
thought to result from degradation of subarachnoid blood,
which produces breakdown products that cause smooth mus-
cle constriction. If this smooth muscle constriction is pro-
longed, morphologic alterations such as fibrosis can occur in
the vessel wall, further enhancing arterial narrowing.
Communicating hydrocephalus is another complication that
can occur after subarachnoid hemorrhage and is secondary to
blockage of CSF reabsorption by platelets, erythrocytes, and
their breakdown products. Hydrocephalus may present in an
acute, subacute, or delayed fashion.
In addition to the previously described neurologic com-
plications, several systemic medical disorders can occur fol-
lowing subarachnoid hemorrhage. Cardiac arrhythmias and
myocardial ischemia are observed often. Respiratory compli-
cations such as pulmonary edema, acute respiratory distress
syndrome (ARDS), and pneumonia are common. Other dis-
orders such as anemia, GI bleeding, deep vein thrombosis,
and hyponatremia occur with varying frequency.
Clinical Features
A. Symptoms and Signs—Subarachnoid hemorrhage is
described most often as the sudden onset of the worst
headache of the patient’s life. Other symptoms such as nausea
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and vomiting, photophobia, nuchal rigidity, depressed level
of consciousness (eg, somnolence, obtundation, or coma),
cranial nerve palsies, and motor abnormalities can occur.
The severity of symptoms is related to the site and extent of
the bleeding. Following aneurysmal subarachnoid hemor-
rhage, the patient is categorized by grade using the Hunt and
Hess classification system (Table 31–3). This system has been
widely accepted and is the equivalent of the Glasgow Coma
Score in trauma patients.
B. Imaging Studies—
1. CT scanning—Ninety percent of patients with subarach-
noid hemorrhage have evidence of subarachnoid blood on
initial CT scans obtained within the first 48 hours after rup-
ture. Scanning also detects intraparenchymal and intraven-
tricular bleeding. The extent and location of subarachnoid
hemorrhage can help to determine the location of the
aneurysm and identify patients at highest risk for developing
cerebral vasospasm. Rebleeding, hydrocephalus, and cerebral
infarction also can be verified using this technique.
2. Angiography—Once the diagnosis of subarachnoid hem-
orrhage has been established, a form of cerebral angiography
should be performed unless a surgical lesion such as a signif-
icant intraparenchymal hematoma is present and requires
emergent lifesaving evacuation. Angiography is required
prior to aneurysm surgery to localize the aneurysm, define its
anatomy, and identify areas of cerebral vasospasm that may
require postponement of surgery. All cerebral vessels should
be imaged because of the occurrence of multiple aneurysms
in 15–20% of patients.
3. Transcranial Doppler ultrasonography—Transcranial
Doppler ultrasonography has become a useful technique for
monitoring patients at risk for developing vasospasm. With
progressive arterial narrowing, blood flow velocity increases
through the constricted segment and can be detected by this
procedure. Since this technique is noninvasive and portable,
it can be performed at the bedside in the ICU. It can detect
arterial narrowing prior to the development of ischemic
symptoms so that therapy aimed at improving cerebral blood
flow can be instituted.
C. Lumbar Puncture—In patients in whom no subarachnoid
hemorrhage is present on CT and the history is suggestive of
rupture of an intracranial aneurysm, lumbar puncture should
be performed. Bloody or xanthochromic fluid is the most
sensitive indicator of subarachnoid hemorrhage. CSF cultures
must be sent to rule out meningitis. However, lumbar punc-
ture never should be performed prior to CT scanning because
patients with elevated ICP are at risk for herniation following
removal of fluid from the spinal subarachnoid space.
D. Laboratory Findings—Coagulation parameters, includ-
ing a platelet count, bleeding time, and prothrombin and
partial thromboplastin times, should be obtained. If abnor-
mal clotting parameters are present, they should be corrected
rapidly because of the increased risk of rebleeding.
E. Electrocardiography—The ECG is abnormal in many
cases of subarachnoid hemorrhage and may identify cardiac
arrhythmias or ischemia that may require treatment.
Treatment
A. Surgery or Embolization—Most centers advocate early
intervention (within 24 hours of rupture) with either surgery
or embolization. Early treatment of the aneurysm has the
advantage of preventing rebleeding and allowing aggressive
therapy for vasospasm should it develop. Because of the risk
of exacerbating ischemia by brain retraction, surgery may be
delayed in patients who are medically unstable or who have
severe vasospasm.
B. Preoperative ICU Therapy—Prior to surgery, treatment
is aimed at reducing the risk of rebleeding and preventing
ischemic complications related to vasospasm. Patients
should remain at bed rest in a quiet setting. Mild analgesics
(not aspirin because of its antiplatelet properties) are used if
headache or neck pain is severe. Stool softeners are useful to
prevent straining, which can increase ICP and promote
rerupture.
C. Blood Pressure Control—Systolic blood pressure should
be maintained below 150 mm Hg; however, hypotension
must be avoided so that cerebral perfusion pressure is not
reduced to ischemic levels. Intravenous administration of
sodium nitroprusside has the advantage of being rapidly
reversible. Mild intravascular fluid augmentation using intra-
venous colloid infusion (5% albumin, 250 mL every 6–8
hours) helps to maintain adequate cerebral perfusion.
D. Reduction of Ischemic Deficits Owing to Vasospasm—
Vasospasm is the most frequent cause of morbidity and mor-
tality in patients admitted after subarachnoid hemorrhage
and occurs in 22–44% of patients. Arterial narrowing may
lead to diminished perfusion and cause infarction.
Vasospasm is induced by products of erythrocyte break-
down, and the risk of developing this complication is related
Grade 1 Asymptomatic, or minimal headache and slight nuchal
rigidity.  
Grade 2 Moderate to severe headache, nuchal rigidity, no
neurologic deficit other than a cranial nerve palsy. 
Grade 3 Drowsiness, confusion, or mild focal deficit. 
Grade 4 Stupor, moderate to severe hemiparesis, early decere-
brate rigidity, and vegetative disturbances. 
Grade 5 Deep coma, decerebrate rigidity, moribund rigidity. 
Table 31–3. Hunt and Hess grades for the assessment
of patients with subarachnoid hemorrhage. 
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to the quantity of blood in the subarachnoid space. There is
a peak incidence 4–12 days after subarachnoid hemorrhage,
and vasospasm then resolves gradually. Prophylactic therapy
using calcium channel blockers and mild volume expansion
are only partially effective. Once vasospasm has been diag-
nosed by transcranial Doppler ultrasonography or angiogra-
phy, more intense therapy is warranted. If ischemic
neurologic symptoms are evident, aggressive treatment
should be instituted immediately.
Induced hypervolemia, hemodilution, and hypertension
(triple-H therapy) may augment cerebral blood flow and
prevent ischemic cellular damage. Because cerebral autoreg-
ulation can be impaired after subarachnoid hemorrhage,
hypertension and hypervolemia may increase cerebral blood
flow directly. Decreased blood viscosity by induced hemodi-
lution can improve cerebral blood flow in regions of hypop-
erfusion. The optimal hematocrit is between 31% and 33%.
Oxygen-carrying capacity of the blood is not significantly
reduced in this range. Since aggressive therapy is often
required, placement of an indwelling pulmonary artery
catheter is recommended to monitor hemodynamics.
Therapy should be titrated to ameliorate ischemic symp-
toms. In addition, cerebral blood flow measurements may
aid in documenting adequate perfusion following treatment.
A poor outcome may occur despite triple-H therapy in most
patients with a low Glasgow Coma Score and evidence of
hydrocephalus at the onset of vasospasm.
Oral administration of the calcium channel antagonist
nimodipine (60 mg orally every 4 hours for 21 days) has been
shown to reduce ischemic neurologic deficits attributable to
vasospasm following aneurysmal subarachnoid hemorrhage.
E. Prevention of Seizures—Patients who have sustained
aneurysmal subarachnoid hemorrhage are at risk for seizures
and should receive anticonvulsants (eg, phenytoin, 18 mg/kg
intravenously initially, followed by 300–400 mg daily)
because of the risk of seizure-induced arterial hypertension,
ICP alterations, and local increased cerebral blood flow
requirements.
F. Respiratory Management—Intubation and mechanical
ventilation are required in comatose patients and those with
respiratory compromise. Mild hyperventilation can be useful
to control elevations of ICP.
G. Correction of Electrolyte Disturbances—Hyponatremia
is common following subarachnoid hemorrhage and can
lead to harmful cellular volume changes in the CNS. (Please
refer to the preceding discussion of cerebral salt wasting.)
Correction of hyponatremia should be accomplished care-
fully so that abrupt sodium changes do not occur.
Administration of hypertonic saline (3%) is often necessary
to improve the sodium level and volume depletion.
H. Intracranial Pressure Monitoring—Placement of a ven-
tricular catheter is necessary to monitor ICP in comatose
patients and to treat hydrocephalus if present. This also helps
clear erythrocyte breakdown products, which are associated
with the development of hydrocephalus. Care should be taken
to avoid rapid overdrainage of CSF because abrupt reduction
in ICP may induce aneurysm rebleeding. Many patients even-
tually will require a permanent ventriculoperitoneal shunt.
I. Antifibrinolytic Therapy—Agents such as aminocaproic
acid that inhibit dissolution of the fibrin clot have been shown
to reduce the incidence of rebleeding. However, this positive
effect is offset by an increased risk of permanent ischemic
sequelae and systemic venous thrombosis. Treatment with
antifibrinolytic agents does not improve clinical outcome fol-
lowing aneurysmal hemorrhage and should not be used.
J. Angioplasty—Even though treatment using hypervolemic
hemodilution and induced arterial hypertension is effective,
a significant number of patients do not respond to these
techniques. Balloon dilation angioplasty can mechanically
increase vessel diameter and has been shown to improve
cerebral blood flow and relieve symptoms dramatically.
Cerebral angioplasty is a new technique and is indicated,
where available, in subjects who do not respond to medical
therapy. Intraoperative vasodilating agents such as papaver-
ine also can be infused during catheter angiography.
Adams HP et al: Predicting cerebral ischemia after aneurysmal
subarachnoid hemorrhage: Influences of clinical condition, CT
results, and antifibrinolytic therapy. A report of the Cooperative
Aneurysm Study. Neurology 1987;37:1586–90.
Barker FG, Heros RC: Clinical aspects of vasospasm. Neurosurg
Clin North Am 1990;1:277–88.
Kassell NF et al: Treatment of ischemic deficits from vasospasm
with intravascular volume expansion and induced arterial
hypertension. Neurosurgery 1982;11:337–43.
Newell DW et al: Angioplasty for the treatment of symptomatic
vasospasm following subarachnoid hemorrhage. Neurosurgery
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Cerebrovascular Disease. Baltimore: Williams & Wilkins, 1988.
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 Tumors of the Central Nervous System
ESSENT IALS  OF  D IAGNOS I S
 Generalized signs of mass effect.
 Aphasia.
 Memory disturbance.
 Hemiparesis.
 Sensory impairment.
 Seizure may be the presenting sign.
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General Considerations
The critical care of patients harboring brain tumors requires
an understanding of intracranial mass effect, cerebral edema
and the blood-brain barrier, progression of neurologic
symptoms, seizures, and serum electrolyte abnormalities.
Careful serial neurologic examination and physiologic mon-
itoring can result in optimal care for the patient with a brain
tumor.
The signs of either a primary or metastatic brain tumor
are the result of the tumor’s location, mass effect, and rate of
growth and of metabolic disturbances. The Monro-Kellie
doctrine describes the relationship between intracranial vol-
ume (composed of brain, CSF, and blood) and ICP. The brain
can accommodate enlarging mass lesions until a critical vol-
ume is reached. The actual volume tolerated is increased if
growth is gradual. At this point, the ICP increases dramati-
cally (Figure 31–2). Normally, the endothelial tight junctions
of cerebral vessels (blood-brain barrier) prevent the leakage
of large solutes and water into the brain. Vessels in cerebral
tumors tend to have less constant tight junctions and may
lack certain enzymes that degrade vasoactive substances in
the brain such as leukotrienes. Reactive edema fluid thus
accumulates in the extracellular space adjacent to the tumor.
Edema can cause neurologic deterioration by increasing ICP
and causing a midline shift of brain structures. Hyponatremia
can occur in patients with CNS neoplasms and may cause
cytotoxic edema and seizures. This can occur secondary to
cerebral salt wasting, as described earlier. Conversely, hyper-
natremia can result from hypothalamic dysfunction and lack
of antidiuretic hormone response and is referred to as dia-
betes insipidus. These patients lose excessive amounts of free
water. Any serum sodium abnormality can result in altered
mental status and eventually coma and neuronal cell death.
Clinical Features
A. Symptoms and Signs—In contrast to the generalized
symptoms of mass effect, edema, and sodium imbalance,
which include headache, nausea and vomiting, and mental
status changes, the precise location of a tumor can cause spe-
cific neurologic deficits. These deficits include aphasia, mem-
ory or personality disturbances, hemiparesis, and visual or
sensory impairment. In many patients, no neurologic deficit
is present on initial presentation, and a seizure is the first
indication of a CNS neoplasm. In the awake patient, the his-
tory should be taken carefully to determine the exact initial
symptoms and the rate at which the problems have
advanced. This information can indicate the approximate
location in the nervous system and serves as a clue to the rate
of tumor growth. Neurologic examination in the ICU should
include ophthalmoscopy for papilledema, detailed mental
status and language assessment, cranial nerve tests, motor,
sensory, and reflex tests, and testing of cerebellar function.
B. Imaging Studies—A chest x-ray should be performed to
evaluate whether a metastatic source of CNS disease is likely.
The study of choice for a suspected CNS mass lesion is CT
scan or MRI. The latter technique gives finer detail and sub-
tracts the image of cortical bone. It is particularly helpful in
evaluating the posterior fossa and skull base. SPECT-
thallium scans are useful in differentiating high-grade versus
low-grade gliomas.
C. Electroencephalography—Electroencephalography can
localize dysfunctional cortex and epileptogenic foci related to
neoplastic growths.
Differential Diagnosis
Several disease processes should be considered when evaluat-
ing a patient who presents with confusion, headache, dys-
phasia, motor or sensory deficits, seizures, hyponatremia, or
any combination of these findings. Stroke usually presents
with a sudden onset of fixed neurologic signs and differs
from the progressive course of a CNS neoplasm. The gradual
progression of a neurodegenerative disease can result in
symptoms similar to those caused by a mass lesion, but pre-
liminary CT scanning or MRI can rule out this lesion.
Infections such as meningitis, encephalitis, and especially
cerebral abscess can result in global or focal neurologic dys-
function and seizures but frequently are accompanied by
fever, leukocytosis, and (in the case of cerebral abscess) char-
acteristic findings on CT scan or MRI. An important distinc-
tion to be made is whether the mass represents a primary or
metastatic lesion. In the latter, a general physical examination
with radiologic studies and metastatic evaluation is required.
Treatment
A. Immediate ICU Intervention—Treatment of the patient
with altered mental status and findings of papilledema
should begin with protection of the airway and elevation of
the head. The neck should not be flexed nor the head turned
so that optimal venous drainage of the brain via the jugular
veins can be ensured. Hyperventilation, systemic arterial
hypertension, and bradycardia are signs of Cushing’s
response (to raised ICP) and identify a patient in great dan-
ger. Mannitol, 1 g/kg, should be infused rapidly via an intra-
venous catheter. This can be followed by 0.25–0.5 g/kg
every 4 hours accompanied by frequent testing of serum
osmolarity. If seizure activity has been observed or is sus-
pected, a loading dose of phenytoin (18 mg/kg) should be
infused intravenously at a rate not to exceed 50 mg/min. A
daily dose of 300–400 mg can be started the next day. An
immediate CT scan or MRI scan should be obtained. If a
tumor is diagnosed and significant mass effect is present,
placement of a ventricular catheter can be considered in
patients at risk of critical elevation in ICP. Ventricular
catheters allow continuous ICP monitoring and drainage of
CSF. If a neurologic deficit or significant cerebral edema is
present, dexamethasone should be administered. The initial
dose can be as high as 20–24 mg intravenously, followed by
10 mg every 6 hours. This steroid can stabilize endothelial
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cell membranes and reduce the accumulation of cerebral
edema. For the severely ill or deteriorating patient, endotra-
cheal intubation should be performed with hyperventilation
to achieve a PaCO2 of 30–35 mm Hg. Lowering the PaCO2 con-
stricts cerebral arterioles and reduces the volume of blood in
the brain, thereby alleviating one component of intracranial
volume and increased ICP.
B. Nonoperative Therapy—For patients in poor medical
condition, with multiple metastatic lesions, or with a solitary
tumor in an inaccessible location, stereotactic or CT-guided
biopsy followed by radiation or chemotherapy (or both)
should be instituted. Patients should be weaned from venti-
lator support and ventricular drainage whenever possible.
This may be difficult in a deteriorating patient because of
ethical and family considerations.
C. Surgery—The goals of surgery are to obtain a tissue diag-
nosis and decrease the mass effect by safely removing as
much of the lesion as possible. Craniotomy (removal of a
replaceable bone flap) or craniectomy (removal of sections of
the base of the skull that are not replaced) with microscope-
assisted removal of the tumor can be accomplished with very
satisfactory morbidity and mortality results. Bipolar coagu-
lation forceps, suction and irrigation, ultrasonic aspirators,
and (less frequently) lasers can be used to precisely remove
tumor while limiting damage to surrounding brain. For
tumors in the sellar region, a transnasal, transsphenoidal
approach is most useful. The risks of operation include
increased neurologic deficit, bleeding, deep vein thrombosis,
pulmonary embolism, and death. Mortality rates in most
large centers for patients undergoing removal of intracranial
tumors are under 5%.
Current Controversies and Unresolved Issues
Several aspects of the care of critically ill patients harboring
brain tumors remain controversial. It is still unclear what the
roles of surgery and radiation are in the patient with a low-
grade primary brain tumor. The risk of slow progression of
tumor growth over many years may not outweigh the ill
effects of operation or postirradiation angiopathy and neu-
ronal death (ie, radiation necrosis). Another debatable aspect
of care is the role of chemotherapy for high-grade primary
tumors. Prolongation of survival of 3–6 months with
chemotherapy (beyond the 6–12-month survival of surgery
and radiation alone) may not outweigh the short-term mor-
bidity associated with intravenous antineoplastic therapy.
Deep vein thrombosis and pulmonary embolism repre-
sent a considerable risk to the patient with a brain tumor
who is less mobile or bedridden, yet the role of perioperative
anticoagulation remains an unresolved issue. The duration
of prophylactic anticonvulsant therapy following craniotomy
remains debatable. The range in practice is between 1 month
and 12 months.
Future issues that are likely to make a major impact on the
therapy for critically ill patients with brain tumors include
advances in stereotactic radiation, manipulation of the
blood-brain barrier for selective delivery of antineoplastic
agents to the tumor, and molecular engineering to selectively
transfect tumor cells with gene fragments capable of inducing
differentiation and stopping cellular proliferation. At the pres-
ent time, however, surgical reduction of the total malignant
cell mass and radiation remain standard therapy for malignant
brain tumors. Frameless image-guided neurosurgery has
improved intraoperative visualization of these tumors and
provides hope for improved outcomes in the future.
Brennan RW: Differential diagnosis of altered states of conscious-
ness. In Youmans JR (ed), Neurological Surgery: A
Comprehensive Reference Guide to the Diagnosis and
Management of Neurosurgical Problems, Vol. 1. Philadelphia:
Saunders, 1990.
Plum F, Posner JB: The Diagnosis of Stupor and Coma, 3d ed. San
Francisco: Davis, 1985.
Wilkinson HK: Intracranial pressure. In Youmans JR (ed),
Neurological Surgery: A Comprehensive Reference Guide to the
Diagnosis and Management of Neurosurgical Problems, Vol. 2.
Philadelphia: Saunders, 1990.
 Cervical Spinal Cord Injuries
ESSENT IALS  OF  D IAGNOS I S
 Neck pain.
 Motor or sensory deficits.
 Hypoventilation.
 Neurogenic shock.
 Priapism.
General Considerations
Approximately 10,000 new cervical and thoracic spinal cord
injuries occur each year in the United States. Most result
from motor vehicle accidents, falls, gunshot wounds, and
sporting accidents. Improved acute management has permit-
ted many patients to survive the initial injury and to have a
near-normal life expectancy. Adolescents and young adults
suffer the highest incidence of spinal cord injuries, with the
majority occurring in young males. Although the loss of
motor and sensory function imposes a catastrophic physical
and emotional handicap, many spinal cord injury patients
are able to return to a nondependent functional state.
Most spinal cord injuries occur in the mobile cervical
region. The cervical cord contains lower motor neurons as
well as long tracts conveying motor and sensory fibers that, if
damaged, can result in variable neurologic dysfunction. In
addition, the cervical cord also conducts vital respiratory and
sympathetic functions that can be damaged following
trauma, leading to devastating respiratory or circulatory
collapse. Secondary events such as hypotension, hypoxia, and
reinjury of the cord can cause further neurologic deterioration.
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Because of these unique features, all patients with cervical
cord injuries should be admitted to an ICU staffed by per-
sonnel experienced with the complex care of spinal cord
injuries.
Pathophysiology
There are a number of anatomic, chemical, and vascular
changes that occur in response to blunt injury of the spinal
cord. From immediately following and up to 3–5 hours after
injury, there is focal swelling of the cord owing to disruption
of blood vessels and their endothelial tight junctions. This
leads to localized bleeding and leakage of albumin, neuro-
transmitters, extracellular calcium, lactate, and prostaglandins.
There is a decrease in local blood flow beginning in the cen-
tral regions of the cord and spreading to the surrounding
white matter (centripetal decrease in blood flow). This leads
to worsening edema over the first 2–3 days and central cavi-
tary necrosis over the ensuing week. The level of injury may
rise as much as two vertebral levels in response to these sec-
ondary events. Diminished swelling followed by cord atro-
phy becomes evident after the first week after injury.
Experimental and clinical treatment strategies are aimed at
blocking this cascade of secondary events following spinal
cord contusion. Calcium channel blockers, diuretics, corti-
costeroids, and other free-radical scavengers may be helpful,
although their true efficacy is debated.
Clinical Features
A. History—The key to the initial diagnosis of cervical spine
injury is maintaining a high level of suspicion for an under-
lying bony or ligamentous injury. This is especially true in
patients involved in motor vehicle accidents or significant
falls, particularly if they have other associated injuries such as
head trauma or extremity fractures.
Many trauma patients are conscious and may complain
of neck pain, numbness, or weakness suggestive of spinal
cord injury. In trauma patients with altered mental status, it
is best to assume that an unstable cervical spine injury is
present until proved otherwise by radiography.
B. Symptoms and Signs—Several complications of cervical
cord injury may require immediate attention and therefore
must be diagnosed promptly. Hypoventilation and respira-
tory compromise secondary to injury of cord segments sup-
plying the phrenic nerve (C3–5) usually can be diagnosed
easily and require immediate assisted ventilation. Although
respiratory dysfunction may not be apparent immediately
after a high cervical injury, respiratory status may deteriorate
during the first few days in the ICU. This can be secondary to
primary muscle fatigue or “ascending” cord involvement
from edema or ischemia. Neurogenic shock may be encoun-
tered following cervical cord injury. This results from inter-
ruption of sympathetic fibers that are descending to the
T1–L2 spinal cord segments and can lead to hypotension,
bradycardia, and hypothermia. Priapism also may occur in
males owing to unopposed parasympathetic impulses.
Although neurogenic shock patients do not appear to be
hypovolemic (eg, the skin is warm and the pulse is slow),
their hypotension responds to rapid administration of
intravascular colloid and crystalloid solutions, and use of
vasopressors such as dopamine or dobutamine is often indi-
cated to maintain arterial pressure and perfusion. Central
venous pressure and cardiac monitoring may be required
along with the frequent assessment of temperature.
After initial resuscitation, meticulous neurologic assess-
ment should be performed to determine the level and sever-
ity of spinal cord damage. Evaluation should include
assessment of motor strength; sensory testing; assessment of
reflexes, including abdominal cutaneous, cremasteric, and
bulbocavernosus reflexes; rectal and perirectal examination;
and palpation of the entire spine while the patient is carefully
log-rolled to maintain spinal alignment.
A complete spinal cord lesion is defined as total loss of
motor and sensory function below the level of injury. One
must not be confused by spinal mass reflexes such as reflex
withdrawal of an extremity in response to pain, which is not
representative of true motor function and may mistakenly
lead to classification of the injury as incomplete. Figure 31–4
portrays the motor and sensory levels of the spinal cord, and
Table 31–4 lists the important motor findings associated with
injuries at different cervical levels.
Patients with complete cervical cord lesions present ini-
tially in a state known as spinal shock, defined as a total loss of
motor and sensory function associated with an areflexic, flac-
cid trunk and extremities below the level of the lesion. In a
complete lesion, spinal shock occurs immediately after the
injury and may persist for 1–2 weeks, after which time upper
motor neuron findings develop with increased deep tendon
reflexes and increased muscular tone associated with spastic-
ity. However, abdominal cutaneous reflexes remain absent.
The mass reflex may occur and is characterized by exagger-
ated involuntary extremity movement owing to loss of
descending cortical inhibition. Interruption of autonomic
fibers results in bladder paralysis, urinary retention, poor gas-
tric emptying, and intestinal ileus with abdominal distention.
An incomplete lesion is characterized by evidence of any
motor or sensory function below the level of the lesion. In
severe incomplete injuries, spinal shock may be present ini-
tially but begins to wear off within 24 hours. Patients with
incomplete cervical cord injuries generally show some degree
of neurologic recovery (up to 40% may make a functional
recovery), whereas patients with true complete injuries
demonstrate no significant neurologic recovery. Rectal
examination is an essential part of the complete neurologic
assessment because any evidence of sacral sparing, such as
voluntary sphincter contraction or sensation in the perianal
region, classifies the injury as incomplete and implies the
possibility of some functional recovery. Important incom-
plete spinal cord injury syndromes include the following:
1. Anterior cord syndrome—This syndrome is associated
most often with cervical flexion injuries and results in loss of
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Labia
Perineum (S1, 2)
Bladder (S3, 4)
Rectum (S4, 5)
Anus (S5, C1)
Gluteal region (T12, L1)
Inguinal region (L1, 2)
MOTOR LEVELS
Facial muscles VII
Pharyngeal, palatine muscles X
Laryngeal muscles XI
Tongue muscles XII
Esophagus X
Sternocleidomastoid XI (C1, 2, 3)
Neck muscles (C1, 2, 3)
Trapezius (C3, 4)
Rhomboids (C4, 5)
Diaphragm (C3, 4, 5)
Supra-, infraspinatus (C4, 5, 6)
Deltoid, brachioradialis, and
   biceps (C5, 6)
Serratus anterior (C5, 6, 7)
Pectoralis major (C5, 6, 7, 8)
Teres minor (C4, 5)
Pronators (C6, 7, 8, T1)
Triceps (C6, 7, 8)
Long extensors of carpi and
   digits (C6, 7, 8)
Latissimus dorsi, teres major
   (C5, 6, 7, 8)
Long flexors (C7, 8, T1)
Thumb extensors (C7, 8)
Interossei, lumbricales, thenar,
   hypothenar (C8, T1)
Iliopsoas (L1, 2, 3)
Sartorius (L2, 3)
Quadriceps femoris (L2, 3, 4)
Gluteal muscles (L4, 5, S1)
Tensor fasciae latae (L4, 5)
Adductors of femur (L2, 3, 4)
Abductors of femur (L4, 5, S1)
Tibialis anterior (L5)
Gastrocnemius, soleus (L5, S1, 2)
Biceps, semitendinosus,
   semimembranosus (L4, 5, S1)
Obturator, piriformis, quadratus
   femoris (L4, 5, S1)
Flexors of the foot, extensors
   of toes (L5, S1)
Peronei (L5, S1)
Flexors of toes (L5, S1, 2)
Interossei (S1, 2)
Perineal muscles (S3, 4)
Vesicular muscles (S4, 5)
Rectal muscles (S4, 5, C1)
 Figure 31–4. Motor and sensory levels of the spinal cord. (Reproduced, with permission, from Waxman SG: Correlative
Neuroanatomy, 20th ed. New York: McGraw-Hill, 2000.)
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motor function and pain and temperature perception (ie,
corticospinal and spinothalamic tracts), with preservation of
proprioception and perception of vibration and light touch
(dorsal columns) below the level of the lesion. This is
thought to result either from direct anterior trauma or from
injury to the anterior spinal artery, which supplies the ante-
rior two-thirds of the spinal cord. The paired posterior spinal
arteries supply the dorsal columns and the posterior one-
third of the cord.
2. Central cord syndrome—This is most commonly due
to a hyperextension injury in an older patient with preexist-
ing cervical spondylosis or stenosis. The motor and sensory
deficits are greater in the upper extremities (more pro-
nounced distally) than in the lower extremities. Hemorrhagic
necrosis in the central portions (eg, gray matter) of the cer-
vical cord results in upper extremity weakness. Since the
lumbar leg and sacral tracts are peripheral in the cervical
cord, they are relatively spared.
3. Brown-Séquard’s syndrome—This syndrome occurs
with hemisection of the spinal cord, usually from penetrat-
ing injuries such as stab or gunshot wounds. The result is
ipsilateral loss of motor and dorsal column function (ie,
vibration, proprioception, and discriminatory touch)
immediately below the level of injury associated with con-
tralateral loss of pain and temperature sensation one or two
levels below the injury (spinothalamic tracts decussate
within one to two levels of their entry).
4. Posterior spinal cord syndrome—This rare syndrome
results from disruption of the posterior columns, causing
loss of vibration, proprioception, and discriminatory sense
below the level of the lesion.
C. Imaging Studies—Radiographs are essential for the eval-
uation and diagnosis of cervical spine injuries. These should
include a cervical spine series with lateral, anteroposterior,
and odontoid (open mouth) views. Radiographs are
inspected for the presence of prevertebral soft tissue swelling,
alignment of the anterior and posterior aspects of the verte-
bral bodies, angulation of the bony spinal canal, and the pres-
ence of fractures. The odontoid view is essential to diagnose
axis (C2) fractures or Jefferson fractures of the ring of the
atlas (displacement of the lateral masses of C1). Ligamentous
damage should be suspected in patients with minimal sublux-
ation or persistent neck pain without evidence of a fracture.
Dynamic flexion and extension cervical radiographs, which
should only be considered in awake and cooperative patients,
are useful to detect instability secondary to ligamentous
injury. These x-rays may be performed several days after the
initial injury so that muscle spasms, which can mask instabil-
ity by limiting subluxation, may subside.
CT scanning is excellent for visualizing the bony struc-
tures of the spinal canal and is the next step in evaluating a
fracture or subluxation. In patients with neurologic symp-
toms or signs and no radiographic evidence of bony abnor-
malities, MRI should be obtained. MRI demonstrates the
cord and soft tissue structures with outstanding clarity and
can identify intraaxial contusions and cord compression
from a herniated disk or hematoma. However, MRI does not
demonstrate bony structures very well.
The role of myelography in spinal cord injury is contro-
versial. Myelography should be performed if there is a signif-
icant incomplete neurologic deficit that cannot be explained
by bony abnormalities and if an MRI cannot be obtained.
D. Other Studies—Somatosensory evoked potentials are
occasionally useful to confirm or dispute the diagnosis of
complete spinal cord injury. This is especially true in patients
who are difficult to examine, such as those with altered men-
tal status.
Treatment
Optimal treatment of spinal cord injuries must be initiated at
the scene of the accident. The spinal cord is susceptible to
reinjury after the primary insult, making prevention of sec-
ondary injury one of the most important aims of therapy.
This includes immediate spinal immobilization with sand-
bags or a hard collar and rapid correction of hypoxia,
hypotension, shock, or hypothermia, if present. Early place-
ment of a nasogastric tube and an indwelling urinary
catheter are necessary because an atonic bladder and GI tract
commonly accompany cervical cord injuries.
Segment Important Characteristics 
C1 to C3 No arm motor function. Absent respiratory muscle
contractions. If C3 is spared, patient can support neck. 
C4 If the C4 segment is functional, patients may only
require initial ventilatory support and then, after
strengthening, may self-ventilate.
C5 Useful movements of the deltoid, biceps, and usually
the brachialis muscles are present, permitting shoulder
shrug, elbow flexion, and forearm pronation. 
C6 Allows wrist extension. 
C7 Functional upper extremity movements with maintained
innervation of the triceps (elbow extension), extensor
digitorum (finger extension), and flexor carpi ulnaris
(wrist extension). Weak finger flexors with poor grasp. 
C8 Improved hand function due to innervation of most
hand intrinsic muscles. 
T1 Complete hand strength maintained because of innerva-
tion of all hand intrinsic muscles. 
Table 31–4. Important motor characteristics associated
with injuries at different cervical levels and T1. 
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Serial neurologic examinations are important to detect
signs of deterioration so that corrective measures can be
taken expeditiously. The patient must be maintained in opti-
mal physiologic condition to maximize the chances of neu-
rologic repair and recovery.
A. Respiratory Care—Patients with cervical cord injuries
frequently develop worsening of their respiratory status in
the ICU. This may be secondary to diaphragm fatigue or
ascending neurologic damage from edema or ischemia and
may require prompt respiratory support. Intubation in
patients with unstable cervical injuries should be performed
using fiberoptic nasotracheal intubation (see below for selec-
tion of neuromuscular blocking agents). Hypoventilation,
particularly during sleep, is not uncommon in the early stages
following high cervical cord injury and may require nighttime
ventilation. This is probably due to an impaired respiratory
drive to CO2 or diaphragm fatigue. A high index of suspicion
for this disorder, which usually resolves in 1–2 weeks, must be
maintained in the early phases of ICU care.
Aggressive pulmonary toilet and aerosol bronchodilators
should be used to avoid atelectasis, mucus plugs, and pneu-
monia. Prophylactic antibiotics should not be used to pre-
vent pulmonary infections.
B. Hemodynamic Support—During spinal shock, decreased
sympathetic outflow may be manifested by bradycardia or
hypotension. However, one must not overlook a source of
hemorrhage (eg, liver laceration or pelvic fracture) because
such patients will not complain of pain. Hypotension from
spinal shock usually responds well to intravenous infusions
of crystalloid and colloid solutions. Vasopressors such as
dopamine may be required. Atropine, although short-acting,
may rapidly reverse hypotension associated with bradycardia.
Placement of a temporary cardiac pacemaker may be required
for severe bradycardia. Following recovery from spinal shock,
reflex hypertension, sweating, pilomotor erection, and rarely,
bradycardia or cardiac arrest (autonomic dysreflexia) may
occur. This is usually precipitated by painful stimuli such as
bladder catheterization, respiratory suctioning, or colorectal
manipulation. Hypertensive crises, which can be life-
threatening, should be treated by elimination of the precipi-
tating stimulus and administration of rapid-acting
intravenous antihypertensive agents. In recurrent severe
attacks, prophylaxis with phenoxybenzamine may be useful.
C. Cervical Immobilization—Unstable malaligned cervical
spine subluxations or fractures should be managed initially
with external immobilization. This can be achieved by
attaching tongs or a halo ring to the patient’s skull and apply-
ing distraction force through a pulley system attached to
weights. One must exclude the presence of atlanto-occipital
dislocation because traction in this condition can result in
overdistraction and serious injury. Gentle application of
5–10 lb is used initially, gradually increasing by up to 5 lb per
cervical level (eg, 20 lb for C4 and 30 lb for C6). More weight
may be required for reduction, but no more than 10 lb per
level should be administered. After each weight increase, the
lateral x-ray should be repeated to determine if realignment
has been achieved. It is often necessary to administer muscle
relaxants such as diazepam (5–10 mg intravenously every
8 hours) during skeletal traction to reduce muscle contrac-
tions or spasms that can hinder spinal realignment.
Application of a halo vest orthosis may be the proper choice
for certain bony injuries of the cervical spine.
D. Surgery—The principal goal in the management of cervi-
cal spine injuries is prevention of secondary neurologic
injury and provision of an optimal environment for recov-
ery. Securing a stable cervical spine (ie, bones, muscles, and
ligaments) will prevent further neurologic injury and reduce
the chance for persistent cervical pain resulting from insta-
bility. In general, bony lesions heal well if immobilized prop-
erly, whereas ligamentous injuries typically do not heal. The
indications for operation are decompression of incompletely
injured neural tissue and reduction and stabilization of
malaligned or unstable cervical segments. Some of the basic
features and treatment modalities for several common cervi-
cal injuries are outlined below.
1. Atlanto-occipital dislocation—These injuries, which
are seen most commonly in children owing to immature
craniovertebral articulations, are often fatal. They involve
extensive ligamentous disruption and can cause injury to the
brain stem, cervical cord, nerve roots, or vertebral artery.
Traction should not be used because it can increase the
distraction and cause further CNS damage. These injuries
are highly unstable and require operative bony fusion.
2. Jefferson fracture of the atlas—This is a burst frac-
ture of the ring of the atlas resulting from an axial force and
is usually asymptomatic. If combined displacement of the
left and right lateral masses on open mouth x-ray is more
than 6.9 mm, immobilization with a halo vest is suggested;
otherwise, a hard cervical collar is sufficient.
3. Axis fractures—A type 1 odontoid fracture involves
only the tip of the odontoid and can be treated with hard cer-
vical collar immobilization. Fractures through the odontoid
base are classified as type 2 and have a high incidence of
nonunion. Current treatment recommendations are for sur-
gical fusion if the fracture is displaced more than 6 mm or
halo vest immobilization for fractures displaced less than
6 mm. Anterior odontoid screw fixation or posterior
atlantoaxial fixation may be performed. Type 3 odontoid
fractures involve the base of the odontoid with extension into
the vertebral body and require only halo vest immobilization
for fusion. Hangman fractures are bilateral fractures of the
C2 pedicles with anterior displacement of C2 onto C3. They
are usually due to hyperextension injuries such as automo-
bile accidents in which the head hits the windshield.
Hangman fractures may be unstable and require traction ini-
tially if malalignment is present, followed by immobilization
in a halo vest. Isolated laminar or spinous process fractures
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of the axis usually can be treated with a hard cervical collar.
Treatment for combined atlas and axis fractures is usually
based on the type of axis fracture present.
4. Wedge compression fracture—This results from a
hyperflexion force causing compression of one vertebra
against an adjacent vertebra. The optimal management of
these injuries is controversial. Simple wedge fractures with-
out associated ligamentous injury or significant subluxation
heal well in a hard cervical collar. If the kyphotic angulation
is significant, or if instability is present, early surgical fusion
or closed realignment with skeletal traction followed by halo
vest application may be warranted. Persistent instability may
be present in 15% of patients treated by immobilization only
and requires subsequent operative surgical fusion. Care must
be taken in patients with neurologic deficits to exclude a
compressive lesion such as an extruded cervical disk that may
require early operation.
5. Flexion teardrop fracture—This is secondary to severe
hyperflexion with disruption of the intervertebral disk associ-
ated with ligamentous damage and a fracture through the
anteroinferior vertebral body. This is a highly unstable injury
often associated with devastating neurologic damage and
requires early realignment by traction. Management after initial
stabilization is controversial and may include halo vest immobi-
lization or surgical fusion. Care must be taken to exclude any
compressive lesions, such as bone or disk material, that may
contribute to neurologic dysfunction and require removal.
6. Facet dislocation—Bilateral facet dislocation occurs
when the inferior articular facet of the upper vertebra slides
forward over the superior articular facet of the lower verte-
bra. This is due to severe hyperflexion injury and is unstable.
Lateral cervical x-rays show anterior subluxation of the
superior vertebra by over 50% of the length of the vertebral
body. Anteroposterior views demonstrate alignment of the
spinous processes. Immediate closed reduction using skele-
tal traction should be attempted; if this fails, open surgical
reduction may be necessary. Surgical fusion is required in
either case. Unilateral facet dislocation results from simulta-
neous flexion and rotation injuries. The lateral cervical
spine x-ray shows anterior subluxation of the superior ver-
tebra, but this is only 30% or less of the length of the verte-
bral body. The spinous processes on anteroposterior views
are rotated and do not align. Although the unilateral locked
facet is a stable injury, it is commonly associated with nerve
root injury and chronic pain. In these patients, closed or
open reduction may be beneficial.
E. Corticosteroids—Although previous versions of this chap-
ter have advocated use of intravenous methylprednisolone
acutely after spinal cord injury, this therapy is now consid-
ered an option rather than a recommendation. Critical
analysis of the original data as well as the clinical experiences
over the past several years have not come out with significant
efficacy of this medication regime. Some clinicians may wish
to use the steroid in the hope that local nerve root improve-
ment may be hastened, but the decision needs to be weighed
against potential complications.
F. Pulmonary Embolism Prophylaxis—Pulmonary embolism
is a constant threat to patients with weak limbs and should
be combated using subcutaneous heparin (5000 units twice
daily), pneumatic compression stockings, or both.
Intravascular insertion of a vena cava filter is highly recom-
mended for patients with lower limb paralysis.
G. Gastrointestinal Considerations—Atony and paralytic ileus
may occur for days to weeks following spinal cord injury.
Early nasogastric decompression is required to reduce
abdominal distention. Serum electrolytes should be evalu-
ated regularly. Because these patients are in a catabolic state
after injury, they often require early nutritional support.
Reflex evacuation of the rectum occurs following the acute
phase of spinal cord injury and can be aided by a regular reg-
imen of laxative agents.
H. Urinary Care—Bladder atonia and sphincter paralysis result
in urinary retention after spinal cord injury. Initial placement
of an indwelling bladder catheter is required, but the catheter
should not be left in place for longer than 2–3 weeks. After this
time, reflex emptying of the neurogenic bladder can occur
spontaneously or in response to stimuli such as suprapubic
compression. Many patients require intermittent bladder
catheterization, and this can be self-administered using metic-
ulous technique. Urologic consultation is frequently helpful to
determine individual bladder care programs.
I. Skin Care—Prevention of decubitus ulcers is a primary con-
cern in spinal injury patients. Patients should be turned at
least every 2 hours, pressure points should be padded, and
kinetic therapy beds should be used if available.
J. Avoidance of Depolarizing Neuromuscular Blocking
Agents—Denervated muscles are hypersensitive to depolar-
ization, and administration of a depolarizing agent (eg, suc-
cinylcholine) can result in rapid hyperkalemia that may be
complicated by ventricular fibrillation.
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Handbook of Central Nervous System Trauma. New York: Marcel
Dekker, 1993.
Ogilvy CS, Heros RC: Spinal cord compression. In Ropper AH,
Kennedy SF (eds), Neurological and Neurosurgical Intensive
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Sonntag VKH, Hadley MN: Management of upper cervical insta-
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The term acute abdomen denotes an abdominal pathologic
condition that, if left undiscovered and untreated, would
have a deleterious effect on the patient’s health status.
Numerous factors make the diagnosis and treatment of
abdominal conditions more difficult in ICU patients.
Physiologic Considerations
The peritoneum is a complex mesothelium-lined organ that
invests the intraabdominal viscera (visceral peritoneum) and
the abdominal cavity (parietal peritoneum). The peritoneum
functions to maintain the integrity of the intraabdominal
organs and provides lubrication by peritoneal fluid (nor-
mally <50 mL). For free movement of the viscera, the nondi-
aphragmatic peritoneal surface behaves as a passive
semipermeable membrane that allows bidirectional
exchange of water and electrolytes. The diaphragmatic sur-
face is highly specialized, with numerous gaps in the peri-
toneal lining that serve as entrances to a plexus of lymphatic
channels that drain via substernal lymph nodes into the tho-
racic duct. This diaphragmatic absorptive pathway is
enhanced by respiratory excursion and normally accounts
for at least 30% of the total lymphatic drainage of the
abdomen, helping to maintain the balance between visceral
parietal transudation and parietal peritoneal fluid uptake.
The omentum participates in absorption of peritoneal
fluid and particulate material up to 10 μm in diameter. The
omentum is highly mobile and can act to seal off a perforated
viscus or contain a bacterial inoculum.
Pain from intraabdominal disease is transmitted via
somatic sensory and visceral autonomic pathways. Visceral
pain, primarily elicited by distention, is referred in a logical
fashion in the same order as embryologic development; the
nerves accompany the major splanchnic vessels. Foregut
sources (eg, esophagus, stomach, liver, pancreas, biliary tract,
duodenum, and spleen) elicit upper epigastric pain, midgut
lesions (eg, jejunum, ileum, appendix, and right colon) elicit
periumbilical pain, and hindgut lesions (eg left colon and rec-
tum) radiate to the hypogastrium. This visceral pain is typically
colicky in nature and somewhat vague in location—in con-
trast to somatic pain, which is usually constant and well local-
ized to the site of direct parietal peritoneal irritation.
Intraabdominal disease also can cause pain to be referred
to other areas through neural pathways or other anatomic
constraints. Examples of referred pain include shoulder pain
from splenic or hepatic hemorrhage, causing phrenic nerve
irritation, and hip or thigh pain from a psoas abscess.
 Pathophysiology
Critical care patients are susceptible to common causes of
abdominal disease such as appendicitis, diverticulitis, and
calculous cholecystitis with approximately the same fre-
quency as the general population. More important, they are
prone to develop more complex and unusual abdominal
processes resulting from a variety of predisposing condi-
tions. For example, recent surgery, especially involving
enteric anastomoses, may lead to intraabdominal abscess or
small bowel obstruction.
Shock with associated low flow states leads to an
increased risk of mesenteric ischemia, acalculous cholecysti-
tis, and possibly gut translocation of bacteria. Present or pre-
vious antimicrobial therapy also may contribute to illness
with overgrowth of resistant organisms, including Clostridium
difficile (pseudomembranous) colitis. The fasting state of
many critically ill patients may contribute to the develop-
ment of acalculous cholecystitis or, along with opioid use,
lead to a colonic pseudo-obstruction (Ogilvie’s syndrome;
see below).
Iatrogenic complications are common in patients under-
going multiple procedures and receiving several medications.
Inadvertent visceral injury may occur during paracentesis or
thoracentesis. Missed intraabdominal disease in traumatized
patients should be strongly considered in any patient not
recovering as expected. The problem of stress gastritis and
stress ulcers has been diminished with aggressive pH moni-
toring and pharmacologic prophylaxis but still presents a
formidable challenge.
32
Acute Abdomen
Allen P. Kong, MD
Michael J. Stamos, MD
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
ACUTE ABDOMEN 697
Clinical Features
A. Symptoms—While many patients in the ICU are unable
to give a history because of intubation or altered mental sta-
tus, a detailed review of recent symptomatology should be
obtained whenever possible. Family members and friends
should be interviewed. Patients may have been transferred
from a hospital ward or may have had recent contact with
the hospital or emergency room. However obtained, the his-
tory should describe any preexisting medical conditions,
previous surgery, present medications, prior abdominal
complaints, changes in eating or bowel habits, and recent
weight loss. Exposure to toxic substances (including alco-
hol) and recent trauma should be noted. The obstetric and
gynecologic history should include data about menses and
sexual contacts.
Events leading to hospitalization need to be reviewed,
and if pain is part of the symptomatology, a history of its
presentation and progression is helpful. Despite efforts to
elicit a detailed history, this is often not possible in critically
ill patients.
1. Location of the pain—The location of pain can give
valuable information about its cause. Even more important is
an account of its progression and changes in location
(Table 32–1). Knowing where the pain began occasionally
means more than determining where it is at presentation. A
perforated ulcer may cause lower abdominal pain from intes-
tinal contents collecting in the pelvis owing to gravitational
effects or even owing to a pelvic abscess, whereas a detailed
history may reveal days or weeks of epigastric or right upper
quadrant pain. Pain radiating to some other area of the body
also may give valuable information. For example, epigastric
pain that radiates through to the back is more likely to be due
to pancreatitis than to reflux esophagitis.
2. Nature of the pain—Episodic or crampy pain is usually
due to blockage or obstruction of a hollow viscus during
contraction or attempted peristalsis such as in bowel
obstruction or during an attack of acute cholecystitis.
Questioning and observation often will determine what fac-
tors increase or relieve the pain. Patients with direct peri-
toneal inflammation will resist movement, whereas patients
with renal colic will writhe about with no apparent exacerba-
tion from the movement itself.
3. Progression of the pain—Since virtually all patients
subjected to abdominal operations have postoperative pain,
progression of the pain gives important information about
its source. Incisional pain usually begins to subside after the
first 72 hours, whereas pain owing to other causes such as an
intraabdominal abscess or bowel obstruction often will begin
after 72 hours and become progressively worse.
B. Physical Examination—A comprehensive physical
examination of the ICU patient can be difficult and frustrat-
ing, especially just after an operation. Nevertheless, a com-
plete examination is essential on admission to the unit,
starting with measurement of routine vital signs. Body
temperatures should be obtained from a reliable site—rectal,
bladder, or core measurements from a Swan-Ganz catheter
probe will suffice. Oral and axillary temperatures are often
unreliable. Fever with or without hypotension arouses sus-
picion of abdominal disease, and the presence of both often
will suggest an acute abdomen. Examination to exclude an
extraabdominal source of sepsis should include inspection
of old and existing intravenous sites, chest auscultation
and percussion, inspection of all wounds (traumatic and
surgical), and gross evaluation of urine, especially in
catheterized patients.
1. Observation—Abdominal examination should begin
with careful observation of not only the abdomen but also
the patient’s body position and general demeanor. Is the
patient resting comfortably or in significant distress, with
guarding of the abdominal area? Any distention, ecchymoses,
Table 32–1. Locations of common etiologies of acute
abdomen. 
Epigastrium Suprapubic and Pelvic
Esophageal disease Cystitis
Peptic ulcer disease Diverticulitis 
Pancreatitis (including  Proctitis 
pseudocyst) Pelvic abscess
Cardiac disease Renal colic
Hiatal hernia (including  Left Upper Quadrant 
paraesophageal) Pancreatitis (including pseudocyst)
Right Upper Quadrant Splenic disease
Cholecystitis Hiatal hernia (including
Cholangitis paraesophageal)
Pancreatitis (including  Renal colic
pseudocyst) Left lower lobe pneumonia
Peptic ulcer disease Colitis (especially ischemic)
Renal colic Subphrenic abscess
Hepatitis Periumbilical
Appendicitis Umbilical hernia
Cecal volvulus Early appendicitis
Hepatic abscess Small bowel obstruction
Subphrenic abscess Mesenteric ischemia
Right lower lobe pneumonia Aortic aneurysm
Right Lower Quadrant Left Lower Quadrant
Appendicitis Diverticulitis
Diverticulitis Sigmoid volvulus
Crohn’s disease Colitis (especially ischemic)
Colonic obstruction Renal colic
Psoas abscess Inguinal hernia
Pelvic inflammatory disease Pelvic inflammatory disease
Ovarian cyst or torsion Ovarian cyst or torsion
Ectopic pregnancy  Ectopic pregnancy
Inguinal hernia  Epididymitis
Epididymitis  Pelvic abscess
Pelvic abscess  Psoas abscess 
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and old surgical scars should be noted. Some abdominal dis-
tention is normal in the postoperative abdominal surgical
patient, but any increase in distention postoperatively may
signify problems such as a nonfunctioning nasogastric tube,
prolonged ileus, small bowel obstruction, or development of
ascites. Recent incisions should be inspected, and any ery-
thema, edema, or fluid discharge should alert the examiner
to a potential wound or intraabdominal infection.
2. Auscultation—Auscultation is difficult in a noisy ICU
environment and therefore frequently neglected. Absent
bowel sounds may be normal in recent postoperative patients
but in others may be viewed appropriately with suspicion.
Hyperactive, high-pitched rushes may signify bowel obstruc-
tion. Abdominal bruits indicate the presence of aneurysms,
arteriovenous fistulas, or severe atherosclerotic disease.
3. Percussion—Gentle percussion with close attention to
grimacing or other movement by the patient can give sub-
tle information about localized peritoneal irritation. The
presence of a tympanic area in the right upper quadrant
overlying the liver suggests pneumoperitoneum. Percussion
also can help to detect bowel obstruction (calling for naso-
gastric intubation) or ascites or may disclose a distended
bladder owing to a nonfunctioning or nonexistent Foley
catheter.
4. Palpation—Palpation may reveal hepatomegaly or
splenomegaly, an abdominal wall hernia, a distended gall-
bladder, an intraabdominal tumor or abscess, or an aortic
aneurysm. Rebound tenderness is intended to elicit peri-
toneal irritation. Gentle percussion is a good test for local-
ized peritonitis. Gently bumping the patient or the bed or
having the patient cough will cause enough peritoneal move-
ment to exacerbate pain from peritoneal inflammation.
Careful observation of the patient’s facial expression and
body position will be revealing. Deep palpation of the
abdominal wall and sudden release to elicit rebound tender-
ness is often misleading and in the presence of peritonitis
often will increase guarding and make subsequent examina-
tions more difficult.
When cholecystitis is in the differential diagnosis, right
upper quadrant palpation may reveal tenderness or even a
positive Murphy sign (ie, arrested inspiration during palpa-
tion of the right upper quadrant). Although the retroperi-
toneum and pelvis are less accessible to direct palpation,
indirect evidence of inflammation can be elicited. Pain on
hyperextension of the hip, on stretching the iliopsoas muscle
(psoas sign), and on flexion and internal rotation of the hip,
stretching the obturator muscle (obturator sign), can indi-
cate an adjacent inflammatory process. Gentle palpation or
percussion of the posterior costovertebral angles should
diagnose or exclude pyelonephritis.
5. Rectal and pelvic examination—Genitourinary and
rectal examinations are essential to evaluate for incarcerated
hernias, pelvic or rectal masses, cervical motion tenderness,
prostatic or scrotal disease, and bloody stools. Stool may be
guaiac-tested to confirm a clinical suspicion, but—at least in
the ICU patient population—this test is too insensitive and
nonspecific to be useful in making clinical decisions.
C. Laboratory Findings—A white blood cell count is non-
specific and relatively insensitive—its absolute level is less
useful than its trend. A differential count indicating a left
shift increases the sensitivity of this test. The hematocrit is
helpful or even essential in diagnosing intraabdominal or GI
bleeding.
Urinalysis should be performed with attention to the
presence of white blood cells or white blood cell casts indica-
tive of urinary tract infection. Urine specific gravity can give
information useful in fluid resuscitation efforts, and the
presence of glucose or ketones is of diagnostic and therapeu-
tic importance.
Elevated liver enzymes (eg, AST, ALT, and alkaline phos-
phatase) direct attention to the liver (eg, hepatitis) and bil-
iary system (eg, cholangitis or cholecystitis). Bilirubin
elevation is seen in hepatobiliary disease but also can be asso-
ciated with sepsis, hemolysis, and cholestasis owing to par-
enteral nutrition.
Serum amylase is neither sensitive nor specific, although
markedly elevated values usually indicate pancreatitis.
Elevated serum amylase is also seen with perforated ulcer,
mesenteric ischemia, facial trauma, parotitis, and ruptured
ectopic pregnancy. Lipase or Pankrin values may improve
specificity in the diagnosis of pancreatitis. Arterial blood gas
measurements may demonstrate acidosis or hypoxia. Acidosis
may reflect severe sepsis or ischemia, whereas hypoxia may
reflect acute respiratory distress syndrome (ARDS) owing to
uncontrolled sepsis. Additionally, arterial lactate levels may be
more specific in identifying worsening acidosis, especially in
the setting of preexisting acidosis such as renal failure.
D. Imaging Studies—Although bedside studies are rela-
tively risk free, CT scans, MRI, arteriography, and nuclear
medicine scans usually require patient transport. In this
select group of critically ill patients, transfer to other areas of
the hospital carries significant risks.
1. Bedside films—Radiographs of the chest can evaluate for
pulmonary infections as well as free air when performed
with the patient in a sitting position. Pleural effusions, espe-
cially when asymmetric, may signify an intraabdominal
process. Abdominal radiographs may show a colonic volvu-
lus or obstructed bowel gas pattern, biliary or renal calculi, or
(rarely) pneumobilia. Ultrasound can be useful as a diagnos-
tic and therapeutic tool—intraabdominal abscesses can be
identified with this procedure and percutaneous drainage
facilitated. Cholecystitis (calculous or acalculous) can be
diagnosed and even treated (percutaneous cholecystostomy).
In questionable cases, percutaneous aspiration with analysis
of gallbladder contents (ie, Gram stain and culture) can be
invaluable.
2. Radiology department studies—CT scans have
assumed a primary position in the diagnosis of acute
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abdomen. They should not be used indiscriminately, how-
ever, and are of little value in the first week after abdominal
surgery, when normal postoperative findings (ie, blood, air,
and seromas) make identification of an abscess difficult. In
the critically ill patient with multiple-organ-system failure,
transport to the radiology department may carry a greater
risk than the potential benefit. These patients perhaps
should be considered for early laparotomy. CT scanning for
intraabdominal abscesses has an accuracy rate greater than
95%. Studies that have looked specifically at critically ill sur-
gical patients, however, are not so promising, with sensitiv-
ity rates as low as 50% and with only 25% of the scans
actually providing beneficial information that perhaps
altered the outcome of therapy. CT scans should be per-
formed only when the information obtained is expected to
have that result.
GI contrast studies can be useful occasionally in patients
with recent anastomoses or in those with possible missed
injuries (especially esophageal injuries). In general, water-
soluble agents (eg, Gastrografin) should be used.
Angiography is useful in patients with suspected mesenteric
ischemia and should be performed early after initial resusci-
tation. In addition to securing the diagnosis, intraarterial
vasodilators (eg, papaverine) can be used as primary therapy
or to demarcate and salvage marginally viable intestine.
Angiography also plays a diagnostic role in selected patients
with GI bleeding, aiding in localization of the bleeding site,
and it has therapeutic applications in the delivery of intraar-
terial vasopressin or embolization. Blood loss of at least
0.5 mL/min is required before it can be detected by angiog-
raphy. 99mTc-tagged red blood cell scans have a reported sen-
sitivity of 0.05–0.1 mL/min and may play a role in screening
patients for the more invasive angiographic approach.
Gallium- or indium-tagged white blood cell scans are
useful occasionally in relatively stable patients. The poor
specificity of the tests, especially in the postoperative patient,
and the 24–48-hour time period for completion limit their
usefulness.
E. Peritoneal Lavage—Extensively used in abdominal
trauma, diagnostic peritoneal lavage also may be quite useful
in selected ICU patients. The same factors that make assess-
ment of critically ill patients difficult (eg, altered mental sta-
tus, intubation, etc.) make lavage an attractive alternative.
Numerous studies have shown its utility in selected patients
with white blood cell counts greater than 500/μL or red
blood cell counts greater than 50,000–100,000/μL. Lavage
has limited if any usefulness in the recent postoperative
patient. In this setting, CT- or ultrasound-guided percuta-
neous aspiration is safer and more reliable.
F. Endoscopy—In the presence of active upper GI bleeding,
esophagogastroduodenoscopy is of proved diagnostic and
therapeutic benefit. Flexible sigmoidoscopy and colonoscopy
also may be of diagnostic value in the patient with possible
ischemic colitis or pseudomembranous colitis. Up to a third
of patients with pseudomembranous colitis have negative
C. difficile toxin assays; visualization and biopsy will increase
the diagnostic accuracy to over 95%. Ischemic colitis can
occur as a result of embolic disease, shock (low-flow state),
or—not uncommonly in the ICU setting—after aortic sur-
gery. Endoscopy can confirm the diagnosis and can allow
observation of the progression of disease in selected patients.
Endoscopic retrograde cholangiopancreatography has a
proven therapeutic role in septic patients with cholangitis,
allowing stone extraction or stenting.
Evaluation of the Postoperative Abdomen
Postoperatively, a number of potential intraabdominal com-
plications can occur in the ICU patient. These include such
diverse problems as intraperitoneal bleeding, anastomotic
dehiscence, early small bowel obstruction, and fascial dehis-
cence. Early recognition and aggressive corrective action are
required.
To identify a failure to recover on schedule after laparo-
tomy, one must understand the normal course following
major abdominal surgery. Third-space fluid sequestration
occurs in approximate proportion to the magnitude of the
surgery. Mild to moderate abdominal distention and olig-
uria—frequently seen in the first 24–72 hours after sur-
gery—can make identification of postoperative hemorrhage
difficult. Not infrequently, a declining hematocrit is attrib-
uted to dilutional effects or to equilibration. The accompany-
ing tachycardia may be falsely attributed to pain. Alert
watchfulness for possible postoperative bleeding can avert a
disastrous outcome.
Fever is the most commonly observed postoperative
physiologic abnormality. The presence of fever suggests
infection, but the approach to evaluation must be methodi-
cal. A single febrile episode in most patients should call for
nothing more than a review of the history and a physical
examination. Intermittent spikes of recurrent fever may war-
rant a more thorough investigation—again directed by a
thorough physical examination. The goal should be to iden-
tify a complication early while intervention still may improve
the outcome.
Other than missed injuries to hollow viscera (traumatic
or iatrogenic), intraabdominal sepsis—including abscess and
anastomotic leaks or dehiscences—typically is manifested
between 5 and 10 days after surgery. Early recognition and
treatment are critical. Subtle signs may aid in early diagnosis.
Third spacing should resolve within 48–96 hours, and obser-
vation of a vigorous postoperative diuresis during this period
is a reliable sign of improvement. Leukocytosis following
major surgery is frequently regarded as a normal finding
(largely owing to demargination), whereas failure of the
white blood cell count to return to normal or an increase
from a declining value should suggest the possibility of
intraabdominal sepsis. Other findings include glucose intol-
erance, continued tachycardia, worsening acidosis, pro-
longed ileus, or persistent diarrhea on return of bowel
function (owing to adjacent pelvic abscess).
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Treatment
Following the initial evaluation of an ICU patient for consid-
eration of an acute abdomen, the primary decision is
whether urgent surgery is required. Resuscitation with intra-
venous fluids is usually necessary to correct third-space
losses or bleeding. A bladder catheter should be inserted to
monitor urine output and, unless contraindicated, a naso-
gastric tube to decompress the stomach. Both H2 blockers
and antacids are effective, with greatest efficacy achieved by
maintaining the gastric pH higher than 5.0. An arterial and a
pulmonary artery flotation catheter may be necessary in some
patients to monitor hemodynamic function and intravascular
volume. Antibiotics should be given as indicated. Caution
should be exercised in giving antibiotics to patients with
undiagnosed but suspected sepsis because of concerns about
obfuscating the clinical picture and frustrating further evalu-
ation. Antibiotic therapy is largely adjunctive, although small
abscesses or phlegmonous processes owing to contained
enteric leaks often will resolve with their use.
SPECIFIC PATHOLOGIC ENTITIES
 Bowel Obstruction
The diagnosis of early postoperative small bowel obstruc-
tion frequently is delayed primarily because of the differen-
tial consideration of persistent adynamic ileus. The
characteristic symptoms of obstruction include abdominal
distention, obstipation, and vomiting. These symptoms also
characterize adynamic ileus, and the first step in differentia-
tion is consideration of the diagnosis. Further confusing the
clinical picture is the side effect of opioid analgesics on
decreasing GI motility.
The clinical history and physical examination are often
nondiagnostic, although the patient who has brief return of
GI function followed by its cessation probably has an adhe-
sive obstruction. Plain radiographs likewise are frequently
nondiagnostic in this setting.
A nasogastric tube should be inserted. Hypovolemia
should be corrected and electrolytes checked, with special
attention to hypokalemia and hypocalcemia. If there is a pos-
sibility of intraabdominal abscess or sepsis, CT scan or ultra-
sonography is indicated. If the diagnosis is still in doubt, a
water-soluble contrast study (eg, Gastrografin) can be diag-
nostic as well as therapeutic because of the cathartic effect of
the hyperosmolar solution. Drainage of an abscess may
relieve the localized ileus or obstruction. Patients who are
receiving adrenal corticosteroids may develop adynamic ileus
if the drug is withdrawn too quickly. High doses (300 mg
hydrocortisone daily or equivalent) intravenously will give
prompt resolution.
Complete obstruction warrants reoperation as soon as
resuscitation is complete. Partial obstruction often will resolve
with conservative management.
 Enteric Fistula
Risk factors for enteric fistula include previous radiation,
inflammatory bowel disease, and chronic corticosteroid
administration. After initial resuscitation, the first maneuver
is to determine the need for early operation. A controlled fis-
tula is present when enteric contents are captured by a drain
or when rapid egress from a wound results in little or no
peritoneal contamination or irritation—such cases can be
expected to resolve with nonoperative therapy. Percutaneous
drainage of an associated abscess found by ultrasound or CT
scan may allow closure of the fistula and improve the
patient’s physiologic status prior to definitive management.
Complicating conditions include radiation damage, malig-
nancy, inflammatory bowel disease, the presence of a foreign
body, and distal intestinal obstruction. Water-soluble con-
trast studies are occasionally helpful to visualize the site of
fistula, evaluate the adequacy of drainage, and rule out distal
obstruction. Once a decision to attempt conservative man-
agement is made, useful therapeutic maneuvers may include
restriction of oral intake, parenteral nutrition, octreotide
acetate (50–200 μg subcutaneously twice to three times
daily), and nasogastric suction. Elemental diets may be sub-
stituted for parenteral nutrition in selected patients—especially
those with distal fistulas or with fistulas not in continuity
(eg, duodenal stump and pancreatic).
Conversely, an anastomotic leak or dehiscence that results
in free peritoneal spillage requires emergent operation for
patient survival. The clinical setting and physical examina-
tion usually will allow an accurate assessment. Oliguria and
hypovolemia often portend extensive peritoneal contamina-
tion and third spacing, whereas diffuse peritoneal irritation
manifested by a rigid abdomen on examination offers no real
dilemma. The patient with localized peritoneal signs, mild to
moderate leukocytosis, and perhaps minimal additional fluid
requirements presents a more difficult decision.
 Intraabdominal Abscess
Intraabdominal abscess is usually the result of contamination at
the time of surgery or leakage of enteric contents. The process
has been contained by the patient’s immune system and
defense mechanisms, including the omentum. Antibiotics—
especially with smaller collections—may resolve the process.
Larger abscesses—especially those with continued enteric
communication—may require percutaneous or open drainage
or even intestinal resection to control the process. The exact
role and limitations of percutaneous drainage seem to depend
more on the availability of an experienced interventional radi-
ologist than on any absolute criteria, although multiloculated
and interloop abscesses may be less amenable to this tech-
nique. Success rates range from 25–100%. Infected pancreatic
necrosis and other phlegmonous processes are not amenable
to the percutaneous approach. Of particular importance is
appropriate attention to ensure continued success, including
catheter irrigations, frequent rescanning, and contrast studies.
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 Cholecystitis
Patients in the ICU may develop calculous or acalculous
cholecystitis as well as cholangitis or biliary pancreatitis. The
diagnosis may already be known or suspected, as in the
patient admitted for observation of acute pancreatitis, or
may be a confounding factor, as in the recent cardiac surgical
patient developing acalculous cholecystitis.
The typical findings of right upper quadrant pain, fever,
and Murphy’s sign may not be present even in an awake,
responsive patient. Elevated liver enzymes or unexplained
fever often prompt consideration of biliary disease. Well-
recognized risk factors for cholecystitis (ie, NPO, parenteral
nutrition, recent surgery, and shock) should arouse suspi-
cion. Perhaps the main difficulty is the lack of a reliable diag-
nostic examination in a critically ill patient, especially one
with acalculous disease. The findings of sludge in the gall-
bladder by ultrasound and nonvisualization on 99mTc-HIDA
scan are nonspecific and even expected in patients being
maintained on long-term parenteral nutrition. The tech-
nique of percutaneous cholecystostomy (transhepatic) or
aspiration of gallbladder contents with analysis (eg, Gram
stain and culture) can be useful and deserves consideration
in the most unstable patients. The diagnosis remains largely
a clinical one, and exploration is often required for confirma-
tion and treatment. Surgical exploration frequently is based
on clinical suspicion and nonexclusionary test results.
 Colonic Pseudo-Obstruction (Ogilvie’s
Syndrome)
Typical findings include abdominal distention, abdominal
pain, and obstruction. Plain abdominal radiographs are usu-
ally diagnostic, although contrast studies or endoscopy may
be necessary to exclude volvulus and distal colonic obstruc-
tion. Predisposing factors include bed rest, spinal fractures
and cord injuries, and prolonged opioid use. Treatment is
required when the cecal diameter exceeds 10 cm on a plain
film of the abdomen. Therapy should include correction of
electrolyte disturbances (especially hypokalemia), cessation
of narcotics, and nasogastric decompression to prevent fur-
ther gaseous distention. Neostigmine has emerged as the
treatment of choice. If the cecal diameter exceeds 12 cm, and
if there is no improvement with the preceding measures,
colonoscopic decompression is usually effective, with
15–20% of patients requiring repeated procedures. Operative
treatment (eg, tube cecostomy or right colectomy) is reserved
for patients with signs of present or impending perforation
or a situation in which a skilled endoscopist is not available.
 Abdominal Compartment Syndrome
The concept of elevated intraabdominal pressure having
detrimental clinical sequelae was enunciated over two
decades ago. Initially, renal “toxicity” was focused on, and
oliguria remains one of the earlier clinical signs. Other
sequelae include pulmonary compromise and mesenteric
ischemia. The important factors to keep in mind are to have
a high index of suspicion (especially in patients with signifi-
cant abdominopelvic trauma), to use bladder pressure meas-
urements as a reflection of intraabdominal pressure, and to
consider or perform decompressive laparotomy early if indi-
cated. Control of the open abdomen may be accomplished by
superficially securing an opened 3-L intravenous fluid bag.
Also, the application of an external vacuum-assisted closure
(VAC) device can be applied in this setting.
CURRENT CONTROVERSIES & UNRESOLVED
ISSUES
Bacterial Translocation and Enteral Feedings
The clinical picture of a critically ill patient succumbing to
sepsis and multiple-organ-system failure without any appar-
ent septic focus is a not infrequent clinical problem. A large
volume of data—largely experimental or anecdotal—points
to bacterial translocation across a dysfunctional GI barrier as
the cause. Attempts at correction or prevention have
included selective gut decontamination, maintenance of
intravascular volume, and enteral feedings. Adequate enteral
feedings initiated early appear to maintain adequate GI bar-
rier function. Crucial to this effect seems to be the amino
acid glutamine, a specific nutrient that supports intestinal
mucosal cell growth and replication. Glutamine-containing
enteral nutrition may prevent or at least lessen the severity of
multisystem organ failure induced by bacterial translocation
and bypass the difficulties inherent in enteral feedings in this
group of patients. Additionally, the concept of “immune
enhancing” diets rich in arginine, nucleotides, and fish oil is
being investigated.
Activated Protein C and Corticosteroids in Sepsis
Despite recent advances in critical care, patients continue to
succumb to septic states. This may occur as a result of
delayed recognition or presentation, diminished immune
responses, or overwhelming insults.
Sepsis is associated with widespread inflammation and
intravascular coagulation. Activated protein C is an anticoag-
ulant currently being evaluated in the setting of sepsis, dif-
fuse systemic inflammation, and multiple-organ-system
dysfunction. A recent study has shown a statistically signifi-
cant decrease in 28-day mortality associated with use of acti-
vated protein C. Downsides to use of this drug include its
cost and the associated risk of coagulopathy.
The use of corticosteroids in septic patients is widely con-
troversial. One recent study revealed that small-dose hydro-
cortisone and fludrocortisone in very select patients
conferred a slight decrease in mortality. However, the routine
use of corticosteroids in all patients with sepsis is not justi-
fied. Further research is needed on this topic.
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Monoclonal Antibodies
Numerous monoclonal antibodies have been tested and
show promise. These agents are targeted against mediators of
sepsis and in no way obviate standard identification and
treatment of the septic source. They include antibodies
against gram-negative endotoxin as well as tumor necrosis
factor and interleukin-1. Of these, monoclonal antibodies
against tumor necrosis factor are the only ones with proven
efficacy in human trials, albeit with a modest benefit
(3.5–4% increase in survival). Appropriate selection of
patients and timing of therapy are among the ongoing clini-
cal issues. Additionally, their widespread use may be limited
by the expected prohibitive costs.
Laparoscopy
The laparoscope has become a common tool of the general
surgeon in the last 20 years, and it is only natural that its role
in critical care patients has been explored. The laparoscope is
likely to be mainly a diagnostic instrument for the near
future because of the untoward cardiovascular and respira-
tory side effects of prolonged abdominal insufflation, espe-
cially in this group of high-risk patients. If anecdotal results
are supported by further prospective investigations,
laparoscopy may supplant peritoneal lavage for the bedside
diagnosis of peritonitis or visceral perforation.
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Overt gastrointestinal (GI) bleeding is a quintessential gas-
troenterologic emergency. Appropriate and timely patient
resuscitation and treatment are crucial. GI bleeding carries
considerable morbidity, and 7–10% mortality rates have
been reported. Mortality is up to 30% in patients with in-
hospital onset of GI bleeding. GI bleeding is common, with
incidence of 20–100 per 100,000 adults.
Management of GI bleeding presents unique challenges
owing to the wide spectrum of etiologies, clinical presenta-
tions, and diagnostic and treatment modalities. Furthermore,
treatment approaches to GI bleeding have changed signifi-
cantly over the past decade.
This chapter discusses major causes of severe GI bleeding,
focusing on management aspects pertinent to critical care
medicine. We consider bleeding as severe when hemoglobin
falls acutely by more than 2 g/dL, requiring patient hospital-
ization and consideration of blood transfusion. Occult GI
bleeding is not discussed in this chapter.
 Upper Gastrointestinal Bleeding
ESSENT IALS  OF  D IAGNOS I S
 Hematemesis and melena: hematochezia is almost
always lower GI bleeding but may be seen with severe
upper GI bleeding.
 Ulcers/erosions and varices are responsible for the
majority of upper GI bleeding.
 Lifelong risk of variceal bleeding is about 50% in cir-
rhotic patients.
 Hemodynamic status and comorbid illnesses are key in
the initial assessment of a bleeding patient. Age, syn-
cope or orthostatic change in blood pressure, fresh blood
in the emesis or nasogastric aspirate, or presence of car-
diopulmonary or liver disease portend poor prognosis
and need for urgent endoscopy.
General Considerations
Upper gastrointestinal (UGI) bleeding is defined by the loca-
tion of bleeding lesion proximal to the ligament of Treitz.
UGI bleeding is five to six times more common than lower
GI bleeding. It is found twice as frequently in men than in
women. Despite recent advances in management and treat-
ment, UGI bleeding mortality and medical costs remain
high. In the United States, UGI bleeding accounts for more
than 300,000 hospital admissions annually with an estimated
cost of $750 million.
Clinical Presentation
Hematemesis (vomiting of blood) is the hallmark of UGI
bleeding. Bright red blood in the emesis or in nasogastric
(NG) aspirate is indicative of recent active bleeding, whereas
“coffee grounds” indicate older blood that has had time to be
reduced by acid in the stomach. Melena, another frequent
complaint, is black tarry stools with a foul odor caused by
degradation of blood in the small intestine and colon.
The distinction between upper and lower GI bleeding
based on stool color is not always reliable. Hematochezia
(bright red blood or maroon color stools with clots), typical
of lower GI bleeding, also can occur in severe UGI bleeding.
Hematochezia in UGI bleeding is a sign of massive hemor-
rhage, and patients are usually orthostatic. In a recent series
of 80 patients with hematochezia, UGI bleeding was found in
11% of patients.
Initial Evaluation
Initial evaluation of a patient with overt GI bleeding starts
with hemodynamic status assessment, critical for proper
Gastrointestinal Bleeding∗
∗Tracey D. Arnell, MD, was the author of this chapter in the second
edition.
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patient triage and timely resuscitation. Syncope or lighthead-
edness, when associated with GI bleeding, are classic signs of
hemodynamic compromise. Unstable vital signs or postural
hypotension indicates significant blood volume loss (>10%),
pointing to possibly massive bleeding (Table 33-1).
Following hemodynamic assessment, a focused history
and physical examination should be performed. Timing,
amount, and color of the blood; potential risk factors for GI
bleeding; and confounding comorbidities are the main
points to be elicited.
Repeated bleeding episodes or passage of bright red blood
or large blood clots indicates clinically significant bleeding.
In trying to identify potential risk factors, a detailed medica-
tion history is particularly important. Aspirin and non-
steroidal anti-inflammatory drugs (NSAIDs) are the most
common causes of UGI bleeding. The risk appears to be
dose-related, but even patients taking low-dose (75 mg)
aspirin are at increased risk for bleeding. The risk is further
amplified when NSAIDs are taken along with corticosteroids
or bisphosphonates. Although data are limited, bleeding risk
also appears to be increased with clopidogrel. Chronic anti-
coagulation itself does not increase the risk for GI bleeding
but is thought to unmask preexisting causes of bleeding.
Particular attention should be paid to associated comor-
bidities. Confounding medical problems, in particular coro-
nary artery disease (CAD), chronic obstructive pulmonary
disease (COPD), and liver disease, affect subsequent resusci-
tative and treatment decisions. Moreover, with recent
advances in GI bleeding management, mortality mostly
results from decompensation of associated illnesses caused
by bleeding rather than from the bleeding itself.
Physical examination of a patient with GI bleeding should
focus on signs of hemodynamic instability and volume loss.
Rectal examination should be performed with attention to
stool color and presence of frank blood or melena. Stool
occult blood testing is not helpful in the acute setting.
Another important goal of the examination is to assess
the severity of comorbid medical conditions. For example,
ascites, spider angiomas, and abdominal wall collateral veins
indicate significant liver disease. Respiratory status should be
checked in all patients, particularly those with in COPD, to
determine sedation risk and the need for endotracheal intu-
bation prior to therapeutic interventions.
After initial resuscitation, physical examination usually is
followed by NG aspiration. Presence of blood in NG aspi-
rates confirms an upper GI source of bleeding, but a 10–15%
false-negative rate of NG aspiration has been reported, mostly
in patients with postpyloric bleeding lesions. Some experts
consider NG aspiration redundant if endoscopy is planned
within a few hours. However, finding of bright red blood in the
aspirate has been shown to correlate strongly with GI bleeding
mortality and is an independent predictor of rebleeding. NG
lavage also helps to clear blood and blood clots from the stom-
ach prior to endoscopy, improving diagnostic yield. To clear
the stomach prior to endoscopy, some experts also recom-
mend administration of a promotility agent such as erythro-
mycin (3 mg/kg intravenously). Cold water or saline lavage is
no longer recommended because it does not facilitate hemo-
stasis. Testing of NG aspirate for occult blood is notoriously
unreliable and should be discouraged.
The initial evaluation concludes with focused laboratory
tests, including hemoglobin, prothrombin time (PT) or inter-
national normalization ratio (INR), platelet count, and assess-
ment of renal and liver function. In patients with CAD (or high
risk for CAD), an ECG should be obtained. If chest pain or sig-
nificant ECG changes are present, cardiac biomarkers need to
be checked. Initial hemoglobin values often underestimate the
extent of blood loss because hemodilution can take up to
72 hours to occur. Thus initial hemoglobin can be misleading
in risk stratification decisions. A blood urea nitrogen
(BUN):creatinine (Cr) ratio of more than 36 may be seen in
UGI bleeding. Blood proteins are degraded by bacteria in the
upper intestinal tract and are absorbed as urea, thus increasing
BUN. The sensitivity of a BUN:Cr ratio of more than 36 for
UGI bleeding is about 90%, but specificity is quite low (~30%).
The results of the initial evaluation should provide answers
to two main questions: (1) Is bleeding moderate or massive,
based on the degree of hemodynamic compromise, and (2) is
there exacerbation of a comorbid illnesses by the bleeding?
Resuscitation
Resuscitation has a dual goal: (1) aggressively restore intravas-
cular volume and (2) optimize comorbid conditions in order
to decrease bleeding and minimize treatment-related compli-
cations. The degree of hemodynamic instability and associated
illnesses determines the extent of resuscitative measures and
monitoring. Older patients and patients with significant car-
diopulmonary disease or hemodynamic compromise should
be monitored in the ICU. For these patients, endoscopy should
be performed at the bedside in the ICU to optimize monitor-
ing. Patients with altered mental status or massive bleeding
should be electively intubated for airway protection. All
patients need two large (at least 18 gauge) intravenous
catheters placed or central venous access obtained.
Initial volume resuscitation should be done with normal
saline or lactated Ringer’s. Colloids can be given. In patients
Finding % Blood Loss
Shock 20–25%
Postural hypotension 10–20%
Normal <10%
Modified from Feldman M et al: Sleisenger and Fordtran’s
Gastrointestinal and Liver Disease. Philadelphia: Saunders, 2003,
p. 212.
Table 33–1. Gastrointestinal bleeding: vital signs and
blood loss.
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with cardiopulmonary, renal, or liver disease, central venous
monitoring can be helpful to monitor volume status closely.
Concurrently with intravascular volume resuscitation,
any hemostatic abnormalities need to be corrected. A target
level for INR of less than 1.5 and platelet count greater than
50,000/μL should be sought when active GI bleeding is
occurring. Appropriate clotting factors, usually in the form
of fresh-frozen plasma, are given to achieve rapid reversal of
coagulopathy. Even if deficient, vitamin K typically does not
correct a coagulopathy fast enough and should be used only
as an adjunct to clotting factors.
Transfusion of packed red blood cells is usually consid-
ered when hemoglobin is less 10 g/dL, especially in patients
with cardiopulmonary disease. Clinical data supporting this
threshold value are limited. However, maintaining the hemo-
globin level above 10 g/dL showed a trend toward improved
survival in critically ill patients with CAD. Aiming at a hemo-
globin level of greater than 8 g/dL appears to be safe for
young, healthy patients without comorbidities.
Risk Stratification
Initial evaluation and the patient’s response to resuscitation
determine patient risk, and patients can be stratified into high-
or low-risk categories for rebleeding and mortality. Indeed,
80% of patients with UGI bleeding stop bleeding without
treatment. It is crucial to identify the remaining 20% who are
at increased risk for continued bleeding and mortality.
Multiple scoring systems have been proposed based on both
clinical and endoscopic criteria. Because physicians typically
determine risk prior to endoscopy, risk stratification schemes
based on clinical parameters alone are most practical.
Predictors of rebleeding and mortality are age greater
than 65 years, shock, comorbid illnesses, bright red blood per
rectum or in the emesis, low initial hemoglobin, and high
transfusion requirements. For example, a scoring system that
has been prospectively validated recently includes initial vital
signs, presence of syncope or melena, hemoglobin, BUN, and
presence of hepatic or cardiac disease. This system correctly
identified up to 99% of patients with serious bleeding and
more than 20% of low-risk patients who were further man-
aged as outpatients. However, because such risk stratification
schemes mostly come from cohort studies, concerns remain
about their prospective validity.
We use a simple risk stratification system based on
patient age, orthostatic changes in blood pressure or heart
rate or syncope, history of cardiopulmonary or liver disease,
and fresh blood in emesis or NG aspirate. Patients with these
clinical predictors are considered to be at high risk for con-
tinued bleeding and mortality. Such patients require ICU
monitoring and endoscopy in the ICU immediately after
resuscitation is completed (Figure 33–1). In life-threatening
hemorrhage, when patients fail initial resuscitation, we per-
form endoscopy in the operating room with surgical service
backup rather than delaying endoscopy with repeated resus-
citation attempts.
Non-variceal
bleeding
Endoscopic
therapy
Endoscopic
therapy
Gastric
PPI IV
H. pylori
Inpatient
48–72 h
PPI PO
H. pylori
Early discharge
Hematemesis
Melena
Coffee-ground emesis
Older age SyncopeOrthostatic hypotension
Fresh blood in
NG aspirate
Liver disease
CAD
No endoscopic
therapy
TIPS
IV octreotide, 3–5 days
antibiotics
IV PPI
Repeat EGD in 2–3 weeks
Variceal
bleeding
IV fluids, blood
IV PPI
± Octreotide/FFP
Urgent
endoscopy
Esophageal
 Figure 33–1. Management of upper gastrointestinal bleeding.
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Causes of UGI Bleeding
Causes of acute UGI bleeding can be grouped into six main
categories based on anatomic and pathophysiologic parame-
ters: ulcers or erosions, portal hypertension, vascular lesions,
trauma, tumors, and miscellaneous (Table 33–2). For
decades, peptic ulcer disease has been the most common
cause of UGI bleeding, followed by esophageal varices.
Recently, the trends have changed (Table 33–3). The latest
review of the Clinical Outcomes Research Initiative (CORI)
database showed that peptic ulcer disease accounts for fewer
than 21% of UGI bleeding episodes. Nowadays, the most
common cause is nonspecific mucosal abnormalities (such
as erosions), responsible for 42% of UGI bleedings. This
changing dynamic is most likely brought about by wide-
spread use of NSAIDs and by increased recognition and treat-
ment of Helicobacter pylori infection.
A. Peptic Ulcer Disease—Peptic ulcer disease can be a
result of H. pylori infection, NSAID use, stress, or excess gas-
tric acid exposure. H. pylori is a spiral gram-negative bac-
terium found in 90% of duodenal ulcers and 70% of gastric
ulcers. It is thought to be transmitted via the fecal-oral route
and is commonly acquired in early childhood. H. pylori does
not typically invade mucosa but makes mucosa more suscep-
tible to gastric acid damage. It also stimulates host immune
response, resulting in chronic inflammation (gastritis) and
further mucosal damage. Most infected individuals are
asymptomatic, but in some, chronic inflammation and
increased gastric acid secretion lead to ulcer formation.
NSAIDs are another common cause of gastroduodenal
ulceration. Aspirin and NSAIDs are prescribed very often,
and their use is particularly widespread in the elderly because
of aspirin’s cardioprotective effects and the role of NSAIDs in
osteoarthritis management. Until recently, NSAID-related
injury was thought to be limited primarily to the stomach
and duodenum. Later reports showed that NSAIDs are also a
common cause of distal small bowel and even colonic ulcer-
ation. NSAID-induced mucosal injury results from both
direct topical and systemic effects of prostaglandin inhibi-
tion. NSAIDs also can be a contributing factor to nonhealing
ulcers from other causes. Although erosions and small ulcer-
ations are found frequently in NSAID users, most patients
are asymptomatic. The risk of clinically significant ulceration
and bleeding with chronic NSAID treatment is about 1%.
Peptic ulceration also commonly occurs with severe
stress, including major trauma, burns, sepsis, and multiorgan
system failure. The injury is likely the result of impaired
mucosal defense mechanisms secondary to decreased
mucosal blood flow. Over the past decade, the incidence of
stress-induced ulcer bleeding has been declining, with the
recently reported rate in critically ill patients only 1.5%. The
Cause Relative Frequency
Mucosal abnormalities 37%
Peptic ulcer disease 21%
Esophagitis 15%
Varices 12%
AVM 6%
Mallory-Weiss tear 5%
Tumors 4%
Table 33–3. Common causes of upper gastrointestinal
bleeding.
Table 33–2. Causes of upper gastrointestinal bleeding.
Ulcerative
erosive
Peptic ulcer disease
Infectious (H. pylori, CMV)
NSAIDs, ASA
Stress-induced
Zollinger-Ellison syndrome
Esophagitis
Peptic
Infectious (Candida, HSV, CMV)
Pill-induced (alendronate, ASA, NSAIDs, tetracycline)
Portal
hypertension
Varices
Esophageal
Gastric
Portal hypertensive gastropathy
Vascular
malformation
Arteriovenous malformations
Idiopathic angiomas
Osler-Weber-Rendu syndrome
Dieulafoy’s lesion
Radiation-induced telangiectasia
Gastric antral vascular ectasia 
Traumatic,
postoperative
Mallory-Weiss tear
Foreign body
Aortoenteric fistula
Tumors Benign
Leiomyoma
Gastrointestinal stromal tumors
Lipoma
Polyps (adematous, inflammatory)
Malignant
Adenocarcinoma
GI stromal tumor
Sarcomas
Lymphoma
Carcinoid
Melanoma
Kaposi’s sarcoma
Miscellaneous Hemobilia
Hemosuccus pancreaticus
Meckel’s diverticulum
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decrease in incidence is probably due to wide use of stress-
ulceration prophylaxis in ICU patients.
B. Portal Hypertension—Varices are a hallmark of portal
hypertension, most commonly caused by liver cirrhosis. The
lifelong risk of variceal bleeding is about 50% in cirrhotic
patients. For patients with variceal bleeding, prognosis is
poor. Without treatment, the risk of rebleeding is 70%. Each
episode of variceal bleeding carries 30% mortality rate.
The size, location, and endoscopic appearance of varices
and the Child-Pugh score are the most important independent
predictors of variceal bleeding. Varices that are larger than 6
mm or that occupy more than a third of the lumen portend
the highest risk of bleeding. Esophageal varices are responsible
for most cases of variceal bleedings, whereas gastric varices
account for fewer than 30%. Usually, gastric varices are found
in combination with esophageal varices, but isolated gastric
varices should prompt evaluation for splenic vein thrombosis.
If isolated splenic vein thrombosis is present, splenectomy is
the therapy of choice. Gastric varices, and in particular, iso-
lated fundic varices, tend to produce severe and difficult-to-
control bleeding. Endoscopic appearance of varices is also a
bleeding risk predictor. Red streaks or “cherry” or cystic spots
(“blood blisters”) are high bleeding risk endoscopic stigmata.
Development of varices parallels the progression of liver
disease. Thus patients with higher Child-Pugh scores are more
likely to have varices and are at higher risk for variceal bleed-
ing. As an example of these factors put together, a Child’s C
cirrhotic patient with large varices and endoscopic red streaks
has a 76% yearly risk of variceal bleeding, whereas the risk
drops to 10% for a Child’s A patient without other risk factors.
UGI Bleeding Diagnosis and Treatment 
Over the past decade, significant advances have been made in
the diagnosis and treatment of UGI bleeding. Endoscopy has
evolved from a merely diagnostic technique into a com-
monly used therapeutic modality. Endoscopic therapy
decreases mortality and the need for surgery and reduces
rebleeding rates, length of hospital stay, and transfusion
requirements. Endoscopy also plays an important role in
patient risk stratification, allowing for significant cost savings.
The armamentarium of available diagnostic techniques has
further expanded with the invention of capsule endoscopy. A
small camera/capsule is swallowed by the patient and trans-
mits 360-degree pictures throughout the UGI tract. In par-
ticular, capsule endoscopy significantly improves localization
of small bowel bleeding lesions. Another new endoscopic
technique is double-balloon enteroscopy, which allows for
endoscopic examination of the entire small bowel. It is still
under development and has limited availability.
A combination of endoscopic and pharmacologic therapies
is successful in great majority of UGI bleeding patients.
Currently, 95% of UGI bleeding patients respond to combined
endoscopic and pharmacologic therapy. Therefore, surgery and
interventional radiology techniques are reserved for patients
who fail endoscopic management. Below we focus on endo-
scopic and pharmacologic approaches to the two main types of
UGI bleeding: peptic ulcer and variceal bleeding.
Peptic Ulcer Disease
A. Endoscopic Diagnosis and Treatment of Peptic Ulcer
Bleeding—Endoscopic findings determine the need for endo-
scopic therapy and guide further decisions on hospitalization
and the extent of follow up (Table 33–4). Active bleeding, a vis-
ible vessel, and adherent clot are considered high-risk endo-
scopic signs. Endoscopic therapy is recommended for such
patients, and they need to be monitored closely for signs of
rebleeding. Indeed, without endoscopic therapy, an ulcer
found to be actively bleeding during the endoscopy has a 90%
rebleeding rate after bleeding stops spontaneously. On the
other hand, no endoscopic therapy is indicated for clean base
ulcers (low-risk finding). Such patients can be discharged
safely after endoscopy with close outpatient follow-up.
Endoscopic Stigmata Prevalence
Rebleeding Risk without
Endoscopic Therapy
Rebleeding Risk after
Endoscopic Therapy
High risk Active arterial bleeding 10% 90% 18%
Nonbleeding visible vessel 25% 40–50% 10–15%
Adherent clot 10–14% 25–35% 0–5%
Oozing without visible vessel 10% 10–20% <1%
Low risk Flat spot 10% 7% N/A
Clean-base ulcer 35% 3–5% N/A
Modified from Katschinski B et al: Dig Dis Sci 1994;39:706; and from Center for Ulcer Research and Education: Digestive Disease Research
Center, Hemostasis Research Group, UCLA School of Medicine and the West Los Angeles VA Medical Center.
Table 33–4. UGI bleeding: endoscopic stigmata and risk of rebleeding without and with endoscopic therapy.
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Modern endoscopic therapeutic techniques include injec-
tion of vasoconstrictive agents, thermal therapy, and use of
mechanical devices. Injection therapy employs a needle with
retractable tip, with epinephrine the most commonly used
agent. Injections are frequently combined with thermal ther-
apy. A bipolar coagulation or heater probe is physically com-
pressed against the bleeding vessel, and thermal energy then
seals the vessel wall. More recently, mechanical devices, in
particular endoscopic clips, are being used increasingly in
ulcer hemostasis. A number of studies have shown signifi-
cantly decreased rebleeding rates with the combination of
endoscopic clips and injection therapy compared with injec-
tion therapy alone. However, clips are difficult to place in a
scarred-down ulcer, and they also are more likely to fall off in
this situation. Overall, clip application is more operator- and
position-dependent than other modalities.
B. Pharmacologic Therapy for Peptic Ulcer Bleeding—
Pharmacologic therapy by acid suppression is the cornerstone
of peptic ulcer bleeding management. Indeed, clot lysis occurs
at pH less than 6, and platelet aggregation is enhanced at pH
greater than 6. Proton pump inhibitors (PPIs) are the main
acid suppressive agents. A high-dose PPI bolus followed by
continuous infusion is particularly efficacious after endo-
scopic therapy. A recent large double-blind, randomized trial
showed 6.7% versus 22.5% rebleeding rates in patients on con-
tinuous intravenous PPIs after endoscopic therapy compared
with placebo. PPIs also decreased rebleeding and surgery rates
compared with histamine-2 (H2) blockers. Data also support
the use of empirical high-dose PPI therapy prior to endoscopy.
H. pylori eradication is important in peptic ulcer bleeding
management, in particular for prevention of ulcer recur-
rence. H. pylori serology and antral biopsy are the preferred
tests in acute bleeding. H. pylori eradication should be con-
firmed after treatment with a urea breath test.
Intravenous octreotide has been studied in nonvariceal acute
UGI bleeding, but its effectiveness remains undetermined.
C. Recurrent Peptic Ulcer Bleeding and Endoscopic
Therapy Failures—Effective hemostasis is attained endo-
scopically in more than 95% of ulcers that are actively bleed-
ing or have high-risk endoscopic stigmata. However,
high-risk ulcers have a 15% risk of rebleeding, usually in the
first 72 hours after index bleed. Active spurting of blood and
large (>2 cm) ulcers were independent risk factors for endo-
scopic therapy failure in a recent prospective study.
Therefore, a “second look” endoscopy is usually indicated in
case of rebleeding, with a 73% rate of long-term hemostasis.
Failure of the second endoscopic therapy attempt should
initiate consideration for alternative treatments, in particular
surgery (Figure 33–2). According to a recent large registry of
UGI bleeding cases, 6.5% of patients with bleeding peptic
ulcers underwent surgery for continued bleeding or rebleed-
ing. With the effective medical therapies available, the goal of
surgery is no longer ulcer cure but control of hemorrhage in
these patients. The choice of surgical procedure includes
simple oversewing of the ulcer (with or without vessel liga-
tion), ulcer excision, or radical surgery (ie, depending on
ulcer location, vagotomy with antrectomy or gastrectomy).
In a recent review of surgical options, conservative therapy
Continued bleeding
or early recurrence
Failed
repeat endoscopy
TIPS1
Splenectomy2 Shunt surgery Surgery Angiography
Variceal bleeding Nonvaricealbleeding
Balloon
tamponade
1Treatement of choice for gastric varices
2Treatment of choice for isolated splenic vein thrombosis & gastric varices
 Figure 33–2. Upper gastrointestinal bleeding: failures of endoscopic therapy.
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with oversewing of the ulcer had rates of morbidity and mor-
tality comparable with those of more radical surgery.
However, rebleeding rate was somewhat higher. Current rec-
ommendations are for ulcer excision in patients with a bleed-
ing gastric ulcer, but gastric resection should be performed
for a large penetrating ulcer. Duodenal ulcers should be over-
sewn and vessel ligation performed.
Patients who are not surgical candidates can be considered
for a third endoscopic therapy attempt or for therapeutic
angiography. The latter showed a 50–90% success rate in
management of large gastroduodenal ulcers. Intraarterial
vasopressin infusion and embolization with microcoils, gela-
tin, or polyvinyl alcohol particles are the main angiographic
techniques in ulcer hemostasis. With selective catheterization,
complications of embolization such as bowel ischemia, perfo-
ration, abscess formation, and hepatic infarction are rare.
Variceal Bleeding
A. Endoscopic Diagnosis and Treatment of Variceal
Bleeding—Endoscopy is critical in all aspects of variceal
bleeding management: to identify the patients at risk, to pre-
vent a first bleed, to treat active bleeding, and to decrease the
risk of rebleeding. Both esophageal and gastric (near the car-
dia) varices can be treated endoscopically, with overall suc-
cess rates of about 90% (see Figure 33-1). However, gastric
varices often require additional treatment modalities to pre-
vent rebleeding.
Two endoscopic techniques are applied most often for
variceal bleeding hemostasis: sclerotherapy, which has been
in use for 60 years, and more recently, band ligation. In scle-
rotherapy, a sclerosant (routinely 5% ethanolamine) is
injected via a retractable-tip needle into the varix and/or sur-
rounding tissues, leading to coagulation necrosis and variceal
thrombosis. Repeated sclerotherapy can be performed until
there is complete eradication of esophageal varices. However,
sclerotherapy has been associated with 2–5% mortality and
up to a 20% major complication rate. Major complications
include deep ulcerations, stricture formation, esophageal
perforation, and mediastinitis. Transient bacteremia is com-
mon during sclerotherapy, and antibiotics should be given to
at-risk patients prior to sclerotherapy.
In recent years, band ligation has replaced sclerotherapy
as the primary endoscopic treatment of variceal bleeding,
and it is equally efficacious but much safer. In this procedure,
a rubber band is placed on the varix via a device attached to
the endoscope. The band effectively strangulates the varix,
resulting in varix thrombosis. Multiple bands can be
deployed in one setting. The effect of the band is local, and
systemic complications are rare. In several studies, band lig-
ation was compared with sclerotherapy for the prevention of
esophageal varices recurrence. Rebleeding rate and number
of sessions needed for variceal obliteration were significantly
lower with band ligation (6% and four sessions compared
with 21% and five sessions for sclerotherapy). On the other
hand, recurrence of varices at 1 year was less with sclerotherapy
(8% versus 29% for band ligation). Some experts recom-
mend combining band ligation and sclerotherapy at the final
therapy session to improve long-term eradication of varices.
B. Pharmacologic Therapy of Variceal Bleeding—
Pharmacologic therapy is a necessary component of variceal
bleeding management. Octreotide, a long-acting analogue of
somatostatin, is used most commonly owing to its safety and
ease of administration. Octreotide is thought to work, at least
in part, by decreasing splanchnic blood flow. Octreotide typ-
ically is given as a bolus followed by continuous infusion.
Optimal duration of therapy is not well defined, but 3–5 days
of administration after the bleeding episode is typically rec-
ommended. Octreotide, used in combination with endo-
scopic therapy, has been shown to significantly improve
short-term hemostasis rate (66% versus 55% for band liga-
tion alone).
Prophylactic use of antibiotics in cirrhotic patients with
UGI bleeding is another important aspect of variceal bleed-
ing management. Indeed, bacterial infections are found in up
to 20% of cirrhotic patients with UGI bleeding. Antibiotic
prophylaxis not only reduces infectious complications but
also has shown a trend toward improved mortality. The
choice of antibiotic and duration of therapy are not well
established. An oral quinolone is used commonly for 7–10
days after the bleeding episode.
Several uncontrolled studies suggest that acid suppres-
sion (ie, with a PPI) might be another useful addition to
endoscopic therapy, in particular in healing of postscle-
rotherapy or post–band ligation ulcers. Nonselective β-
blockers and nitrates have a limited role in acute variceal
bleeding setting and should be reserved for outpatient
rebleeding prevention.
C. Recurrent Variceal Bleeding and Endoscopic Therapy
Failures—In 10–20% of patients, combined endoscopic and
pharmacologic therapy fails to achieve long-term hemosta-
sis. The highest risk for rebleeding is in the first 48 hours, as
well as up to 6 weeks after the index bleed. Generally, repeat
endoscopy is recommended in early hemostasis failure.
Alternative endoscopic therapeutic modality should be
applied in these cases, such as sclerotherapy if initial band
ligation was unsuccessful.
Surgery and transjugular intrahepatic portosystemic
shunting (TIPS) are the two main treatment options for patients
who have failed endoscopic therapy (see Figure 33-2).
Balloon tamponade usually is attempted to address acute
severe bleeding until one of these options is chosen. The
Sengstaken-Blakemore tube, with both esophageal and gastric
balloons, is used most commonly for tamponade. Short-term
hemostasis rates vary from 30–90%, and rebleeding usually
occurs after balloon deflation. Balloon tamponade is associ-
ated with a number of significant complications, in particular
esophageal rupture and aspiration. To prevent these compli-
cations, the esophageal balloon should not be inflated for
more than 24 hours, and tamponade should be performed
only in patients with an endotracheal tube in place.
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Surgery is effective in variceal bleeding. Unfortunately,
most variceal bleeding patients present with decompensated
cirrhosis, making them poor surgical candidates. Nowadays,
both nonselective (ie, portocaval) and selective (ie, splenore-
nal) shunts are used for variceal bleeding control.
Nonshunting operations, such as gastroesophageal devascu-
larization (Sugiura procedure), are performed rarely.
Perioperative morbidity and mortality are quite high for
emergent shunt operations, and management is further com-
plicated by a 40–50% incidence of encephalopathy. Surgical
shunting also significantly alters vascular anatomy, making
future liver transplantation more challenging.
In recent years, TIPS has emerged as a safer and easier-
to-perform alternative to surgical shunting. TIPS is done
by an interventional radiologist and requires only local
anesthesia or light sedation. The stent is passed via the
transjugular route and connects the hepatic vein with an
intrahepatic portion of the portal vein, thus creating a por-
tosystemic shunt. TIPS is effective in more than 90% of
variceal bleeds. It is the treatment of choice for gastric
variceal bleeding because endoscopic therapy usually does
not prevent rebleeding of gastric varices. As with surgical
shunts, post-TIPS encephalopathy is common (~30% inci-
dence). Another limitation of TIPS is frequent stent
restenosis or thrombosis leading to multiple revisions and
restenting.
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 Lower Gastrointestinal Bleeding
ESSENT IALS  OF  D IAGNOS I S
 Hematochezia (bright red or maroon stools).
 Initial evaluation is similar for lower and upper GI
bleeding patients.
 Patients younger than 50 years of age with self-limited
mild lower intestinal bleeding (most likely owing to
internal hemorrhoids) can be further evaluated with
colonoscopy or flexible sigmoidoscopy as outpatients.
 Urgent colonoscopy is indicated in the presence of
unstable vital signs, continued bleeding, or more than
two comorbid conditions. 
 Life-threatening lower intestinal bleeding require con-
sideration of emergent angiography or surgery without
delaying for bowel preparation/colonoscopy.
General Considerations
Lower intestinal bleeding is characterized by a lesion location
distal to ligament of Treitz. Most often the source of bleeding
is colonic. Hematochezia (ie, bright red or maroon colored
stools) is the classic clinical presentation. Although severe
lower intestinal bleeding is less common than UGI bleeding,
it is a frequent GI emergency. On average, a full-time gas-
troenterologist sees more than 10 severe lower intestinal
bleeding cases per year.
Initial Approach, Resuscitation, and Risk
Stratification
The main principles of initial evaluation and resuscitation of
UGI bleeding apply equally to lower intestinal bleeding. The
goals are the same: to assess bleeding severity based on the
degree of hemodynamic compromise, to evaluate comorbid
illnesses, and to optimize the patient’s condition prior to
treatment. Syncope or postural hypotension is indicative of
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potentially massive bleeding. In such cases, NG aspiration
should be performed to exclude an upper bleeding source. In
hematochezia without hemodynamic compromise, severe
UGI bleeding is unlikely, and NG tube placement might not
be necessary. After assessing bleeding severity, attention
should be paid to exacerbation of comorbid illnesses. In par-
ticular, evaluation for cardiac ischemia is important because
lower intestinal bleeding is frequent in elderly patients.
Resuscitation of lower and upper GI bleeding patients
involves similar approaches. As described earlier for UGI
bleeding, resuscitation aims to quickly restore intravascular
volume with crystalloids, colloids, and blood and to correct
hemostatic abnormalities, if present. Patients with severe
bleeding should be admitted to an ICU, and surgical consulta-
tion should be obtained early in the course of hospitalization.
In most patients, lower intestinal bleeding stops sponta-
neously. Thus it is crucial to identify patients who are at high
risk for continued bleeding. Commonly reported clinical
predictors are hypotension and tachycardia, continued rectal
bleeding during the first 4 hours of hospitalization, absence
of abdominal pain, use of aspirin, and presence of at least
two comorbid conditions. Prospective validation of this risk
stratification scheme showed 0% rebleeding in a low-risk
group compared with 77% in a high-risk group.
 Causes of Lower Intestinal Bleeding
Diverticulosis, colitis (ie, ischemic, infectious, or postradia-
tion), cancer, and angiodysplasia are the main causes of
severe lower intestinal bleeding (Table 33–5). Hemorrhoids
are a frequent cause of rectal bleeding, especially in patients
younger than 50 years. However, hemorrhoidal bleeding is
rarely severe.
Diverticulosis is responsible for more than 30% of lower
intestinal bleeding. Colonic diverticula are mucosal and sub-
mucosal herniations through the muscle layer, thought to
develop owing to increased intraluminal pressure or
decreased colonic wall muscle tone. They are found in half the
adult population in the Western hemisphere, and the inci-
dence increases with age. Bleeding occurs in only 5–15% of
patients with diverticular disease. However, lower GI bleeding
can be massive in a third of those patients. Painless hema-
tochezia is the classic clinical presentation of diverticular
bleeding. In 75%, diverticular bleeding stops spontaneously,
but the risk of rebleeding is 25–38% in the following 4 years.
Colitis (inflammation of the colon) is another common
cause of severe lower intestinal bleeding. Of note, mortality
rates as high as 20–50% have been reported in hospitalized
patients with ischemic colitis bleeding. Hematochezia in
ischemic colitis is typically accompanied by mild abdominal
pain, differentiating it from painless diverticular bleeding.
The mechanism of mucosal ischemia is thought to be hypo-
perfusion of small intramural vessels rather than large vessel
occlusion. Ischemic colitis can occur throughout the colon,
but watershed areas such as at the splenic flexure or rectosig-
moid junction are affected most frequently. Ischemic colitis
sometimes occurs after extensive surgical procedures or as a
result of systemic hypotension.
Infectious and inflammatory colitis rarely cause severe
lower intestinal bleeding. However, infectious colitis, in par-
ticular secondary to Clostridium difficile, can mimic ischemic
colitis and should be excluded as part of the workup for
hematochezia and colitis.
Angiodysplasias (arteriovenous malformations) account
for about 8% of severe lower intestinal bleeding, but its inci-
dence has been decreasing in recent years. Angiodysplasia is
associated with renal failure and hereditary hemorrhagic
telangiectasia syndrome (Osler-Weber-Rendu syndrome).
An association with aortic stenosis is less clear.
Colon cancer typically presents with occult blood loss
rather than overt hematochezia. Severe lower intestinal
bleeding usually is caused by cancer ulceration, signifying an
advanced stage.
Diagnosis of Lower Intestinal Bleeding
Colonoscopy is typically the first step in evaluation of
lower intestinal bleeding (Figure 33–3). Its main advantage
is that both diagnosis and treatment can be accomplished
in one procedure. However, downsides are the requirement
for bowel preparation and the small, albeit identifiable,
risk of sedation. Notably, management of severe life-
threatening lower intestinal bleeding (ie, angiography or
surgery) should not be delayed for bowel preparation/
colonoscopy. Some gastroenterologists perform colonoscopy
on unprepared bowel because blood is cathartic.
Table 33–5. Severe lower gastrointestinal bleeding: causes.
Relative Frequency
Anatomic Diverticulosis 33%
Vascular
malformations
Arteriovenous malformations
Idiopathic angiomas
Osler-Weber-Rendu syndrome
Radiation-induced 
telangiectasia
Angiodysplasia, 8%
Inflammatory Ischemic colitis
Infectious colitis
Inflammatory bowel disease
Radiation colitis
18%
Neoplasm Polyps
Carcinoma
19%
Other Hemorrhoids
Ulcer
Postbiopsy, postpolypectomy
18%
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Occasionally, flexible sigmoidoscopy on unprepared bowel
is sufficient, in particular as a quick check for ischemic or
infectious colitis. In most cases, we recommend urgent
bowel purge with polyethylene glycol (4–6 L) over 3–5
hours via NG tube or orally. Metoclopramide can be used
in conjunction with the purge to improve gastric emptying
and decrease nausea. Sodium phosphate preparations
should not be used in the acute setting because of high
phosphate and sodium loads. Radiographic studies should
be obtained prior to the bowel preparation to rule out per-
foration or intestinal obstruction.
The overall diagnostic yield of colonoscopy in lower intes-
tinal bleeding is between 48% and 90% (mean 68%). There
are conflicting data on the optimal timing for colonoscopy.
One recent report suggests that diagnostic yield improves with
urgent colonoscopy. We usually perform colonoscopy for
severe lower intestinal bleeding within 6–12 hours of hospital-
ization, after resuscitation and bowel preparation.
Treatment of Lower Intestinal Bleeding 
Although surgery is the most common treatment modality
for lower intestinal bleeding, endoscopic therapeutic options
have been expanding in recent years. In particular, bipolar
coagulation is used successfully for angiodysplasia bleeding.
In diverticular hemorrhage, a visible bleeding vessel or clot
(high-risk stigmata) can be treated with sclerotherapy and
bipolar coagulation similar to peptic ulcer bleeding. Use of
endoscopic clips in diverticular bleeding is currently under
investigation. Significantly decreased short- and long-term
rebleeding rates have been reported for endoscopic therapy
of diverticular bleeding. However, urgent colonoscopy and
experience in advanced endoscopic techniques are needed to
achieve high hemostasis success rates.
Failure of Endoscopic Diagnosis and Treatment
Radionuclide imaging typically is the next step in the local-
ization of a bleeding site after unsuccessful colonoscopy
(Figure 33–4). Radiolabeled red blood cells are injected
intravenously, and focal collections of radiolabeled material
are detected by scintigraphy. A 78% accuracy rate has been
reported, and bleeding as slow as 0.1–0.5 mL/min can be
identified. However, confirmatory colonoscopy is recom-
mended in the case of a positive radionuclide test owing to
rather high false-positive rates, typically a result of blood
from a UGI source collecting in the right colon.
Angiography is another diagnostic and therapeutic
modality used in case of colonoscopic failure. Angiography is
highly specific, but its sensitivity is significantly lower than
that of radionuclide imaging or colonoscopy. For angiogra-
phy to be positive, bleeding must be brisk, at a rate of more
than 1–1.5 mL/min. Since most lower GI bleeding stops
spontaneously, the timing of the angiography procedure is
particularly important. The overall diagnostic yield varies
widely from 12–69%. Some experts recommend radionu-
clide imaging prior to angiography to increase sensitivity.
However, this would further delay angiography and poten-
tially decrease its diagnostic yield.
After the bleeding site is identified angiographically, vaso-
pressin can be infused or a vessel can be selectively embolized
to stop the bleeding. Hemostasis rates of 91% have been
reported after intraarterial vasopressin in diverticular and
angiodysplasia bleeding. However, the rebleeding rate can be
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threatening
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 Figure 33–3. Management of lower gastrointestinal bleeding.
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as high as 50%. Angiography also has a fairly significant (up
to 9%) rate of major complications, including intestinal
ischemia, contrast-induced renal failure, femoral artery
thrombosis, and transient ischemic attack.
Surgical Treatment
Surgery is recommended for continued bleeding (~10% of
all patients presenting with lower intestinal bleeding; see
Figure 33-4). If bleeding has been localized preoperatively,
segmental resection is performed with or without a stoma.
Reported surgical mortality is about 10%, mostly because of
comorbid conditions.
In the case of bleeding that cannot be localized, enteroscopy
and, if available, capsule endoscopy should be performed as a
final attempt to identify the bleeding site. If the bleeding lesion
is still not identified, a thorough surgical exploration is per-
formed, with examination and palpation of the entire small
intestine. If there is a significant amount of blood in the small
intestine, intraoperative endoscopy can be performed.
Exploratory laparotomy leads to localization of the bleeding
site in 78% of patients without preoperative diagnosis.
In the absence of an identified source of bleeding, subto-
tal colectomy is undertaken with ileorectal anastomosis or
ileostomy with Hartmann’s pouch. Emergent subtotal colec-
tomy carries significant morbidity (37%) and mortality
(11%). However, segmental colectomy without a definitive
source of bleeding is associated with an unacceptably high
30% rebleeding rate.
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 Figure 33–4. Lower gastrointestinal bleeding: failures of endoscopic diagnosis.
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Hepatobiliary Disease
Hernan I. Vargas, MD
Liver disease is the ninth leading cause of death in the United
States, resulting in approximately 30,000 deaths each year.
Cirrhosis represents the final common pathway for a wide
variety of chronic liver diseases. Cirrhosis is defined as a dif-
fuse fibrotic process in the liver. Grossly abnormal nodules
replace the normally smooth hepatic parenchyma.
Patients with cirrhosis often develop complications from
their underlying liver disease such as upper GI bleeding,
renal insufficiency, ascites, or encephalopathy and require
critical care. In other circumstances, cirrhotic patients may
require critical care owing to unrelated problems such as
trauma, cancer, or major surgery. The physician caring for
patients in the ICU therefore should be knowledgeable about
disorders of liver function.
 Acute Hepatic Failure
ESSENT IALS  OF  D IAGNOS I S
 Acute onset.
 Jaundice.
 Encephalopathy.
General Considerations
Acute hepatic failure is a rapid-onset, severe impairment of
liver function. The natural history is that of progressive dete-
rioration with multiple-system organ failure. Prior to the
availability of liver transplantation, the mortality was as high
as 80%.
The interval between the development of jaundice and
the onset of encephalopathy has been used to classify hepatic
failure as hyperacute (0–7 days), acute (8–28 days), and sub-
acute (28 days–12 weeks).
Acute viral hepatitis (ie, hepatitis B [HVB], and hepatitis A
[HVA]) and acetaminophen toxicity are the most common
causes of acute hepatic failure in the United States. Other
causes are as listed in Table 34–1.
Clinical Features
A. Symptoms and Signs—The onset of symptoms is usu-
ally abrupt, characterized by malaise, fatigue, and loss of
appetite. Less frequently, patients complain of abdominal
pain and fever. The physical examination is significant for the
presence of jaundice, hepatomegaly, and right upper quad-
rant tenderness.
Signs of developing encephalopathy range from mild per-
sonality change to confusion and deep coma. The presence of
encephalopathy is a precondition for a diagnosis of acute
hepatic failure. The severity of encephalopathy is measured
in four stages (Table 34–2).
Patients with encephalopathy stage III or stage IV com-
monly suffer from cerebral edema and increased intracra-
nial pressure. Cerebral edema is a common finding in
patients who die from acute hepatic failure. The pathogene-
sis of cerebral edema has not been clearly elucidated.
However, investigators have proposed a breakdown of the
blood-brain barrier as an important mechanism. Sodium
accumulation in the brain cells secondary to inhibition of
Na+,K+-ATPase also has been proposed. Cerebral edema
causes an acute rise in the intracranial pressure that
decreases perfusion pressure and cerebral blood flow.
Autoregulation of cerebral blood flow is lost.
Oliguria and generalized edema occur commonly and
are associated with higher mortality. They are typically
caused by hypovolemia, acute tubular necrosis, or hepatore-
nal syndrome.
Late in the course, patients may develop upper GI bleed-
ing and blood loss from the airways, puncture sites, and soft
tissues.
The clinical course of acute hepatic failure is frequently
complicated by bacterial and fungal infections. Infectious
complications are a major contributor to increased morbid-
ity and are the immediate cause of death in nearly half of
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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fatal cases. The immune system is impaired by decreased
function of the reticuloendothelial system and complement
deficiency.
Coagulopathy may occur as a consequence of decreased
production of coagulation factors by the liver, as a conse-
quence of increased fibrinolysis, and from consumption, as in
disseminated intravascular coagulation. Thrombocytopenia
and platelet dysfunction are common.
Predictors of poor outcome are summarized in the King’s
College criteria (Table 34–3).
Treatment
Acute liver failure constitutes a medical emergency given the
high incidence of multisystem organ failure and the high
mortality. Patients with mild hepatic injury require mainte-
nance therapy with adequate hydration, euglycemia, and
electrolyte balance. Because the condition of patients with
more severe liver damage may deteriorate rapidly, respira-
tory support is often needed—particularly when cerebral
edema ensues.
A. Support Measures—
1. Encephalopathy and intracranial hypertension—
Cerebral herniation is a major cause of death if cerebral
edema and hypertension are untreated. Intracranial pressure
measurement is used for diagnosis of intracranial hyperten-
sion and monitoring of intracranial pressure dynamics. The
techniques for intracranial pressure monitoring are dis-
cussed in Chapter 31. Other monitoring techniques are
measurements of cerebral blood flow (with xenon) and cere-
bral oxygen consumption (by calculating the arterial-jugular
venous oxygen content difference).
The head of the bed is typically elevated 20–30 degrees to
reduce intracranial pressure, although the cerebral perfusion
pressure should be monitored to avoid an adverse impact
from a decrease in systemic pressure. Patients being main-
tained on ventilatory support are subjected to mild hyper-
ventilation to decrease cerebral hyperemia. Patient
stimulation must be minimized by premedication prior to
suctioning or postural changes in patients with severe
intracranial hypertension. A number of other measures may
decrease cerebral edema, such as mannitol (1 g/kg). Serum
osmolarity should be monitored. Mannitol is contraindi-
cated if the serum osmolarity is greater than 320 mOsm/L.
The use of barbiturates has been proposed as a means of
lowering intracranial pressure in combination with hypother-
mia. Barbiturates decrease cerebral metabolism and further
Table 34–1. Causes of acute hepatic failure.
Most common causes in USA
Acute viral hepatitis (HBV, HAV, HC)
Acetaminophen toxicity
Less common causes
Hepatitis D and E
Herpes simplex virus
Epstein-Barr virus
Drug toxicity
Antimicrobials (eg, ampicillin-clavulanate, ciprofloxacin, 
erythromycin, isoniazid, tetracycline)
Sodium valproate
Lovastatin
Phenytoin
Tricyclic antidepressants
Halothane
Other toxins
Ecstasy (methylenedioxymethamphetamine)
Amanita phalloides (mushrooms)
Organic solvents
Herbal medicines (eg, ginseng, pennyroyal oil, Teucrium polium).
Miscellaneous causes
Acute fatty liver of pregnancy
Autoimmune hepatitis
Budd-Chiari syndrome
Reye’s syndrome
Wilson’s disease
Indeterminate
Stage Mental Status Tremor Electroencephalography 
I Euphoria, occasionally depression; fluctuating mild confu-
sion; slowness of mentation and affect; slurred speech;
disorder in sleep rhythm 
Slight Normal
II Drowsiness; inappropriate behavior. Present Generalized slowing
III Sleeps most of the time but is arousable, confused;
incoherent speech. 
Present Abnormal
IV Unarousable Absent Abnormal
Table 34–2. Stages of encephalopathy. 
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decrease cerebral blood flow and pressure. They also prevent
seizures. Barbiturate use is controversial, however, because of
their delayed metabolism owing to liver insufficiency.
2. Cardiovascular support—Patients with acute liver
insufficiency experience arteriovenous shunting and vasodi-
lation that causes tachycardia and hypotension. The
decreased clearance of vasoactive metabolites causes
decreased systemic vascular resistance and increased cardiac
output. Therefore, volume resuscitation and vasoactive drugs
may be necessary as support measures. With this hemody-
namic profile, an important differential diagnosis is sepsis.
3. Coagulopathy—Transfusion therapy is in general
reserved for patients with active bleeding. It is indicated also
prior to invasive procedures such as the placement of
intracranial pressure monitoring.
4. Renal failure—Renal failure is common in patients with
acute liver insufficiency. Maintenance of euvolemia is critical.
Avoidance of nephrotoxic drugs (ie, aminoglycosides) is
important. If renal azotemia ensues, dialysis may be needed.
Continuous venovenous dialysis or arteriovenous dialysis
methods are preferred to avoid hemodynamic changes and
hypotension associated with standard hemodialysis.
5. Respiratory failure—Airway intubation and mechani-
cal ventilation are frequently used as the encephalopathy
progresses to stage III. Acute respiratory distress syndrome
(ARDS) occurs in one-third of patients, causing hypoxemia.
B. Liver Transplantation—The mortality of severe acute
liver insufficiency in the absence of liver transplantation
approaches 80%. Survival after orthotopic liver transplanta-
tion has improved in recent years from 50% to more than
80% in selected series. Unfortunately, only 40–60% of
patients actually undergo transplantation owing to the short-
age of available organ donors.
Contraindications to liver transplantation are malig-
nancy, extrahepatic sepsis, irreversible brain injury from
intracranial hemorrhage, and unresponsive cerebral edema.
Bioartificial liver support is being investigated in selected
centers as a bridge to transplantation. Reports of hemoperfu-
sion, plasmapheresis, and extracorporeal perfusion exist, but
there has been limited success. Most recently, the develop-
ment of hybrid bioartificial support systems using hepato-
cytes from human or xenogeneic sources has shown some
promise.
 Acute Gastrointestinal Bleeding
from Portal Hypertension
ESSENT IALS  OF  D IAGNOS I S
 Hematemesis, melena.
 Stigmata of chronic liver disease.
 Endoscopic evidence of bleeding varices.
General Considerations
Esophagogastric varices occur in 90% of patients with cir-
rhosis. Approximately one-third of these patients will experi-
ence GI bleeding, and between 30% and 50% of them will die
during each episode. It is not unexpected that bleeding from
esophagogastric varices accounts for one-third of all deaths
in patients with cirrhosis.
Esophagogastric varices are dilated intramural veins asso-
ciated with an extensive and tortuous capillary network.
They are alternative pathways of venous flow around the
increased vascular resistance in the intrahepatic and portal
system. They occur as a consequence of portal hypertension.
The development of varices is facilitated by systemic vasodi-
lation and decreased vascular resistance present in cirrhotics.
Clinical Features
A. Symptoms and Signs—Patients with acute bleeding
present with hematemesis. Patients with more chronic
bleeding present with melena and symptoms of anemia,
such as fatigue and weakness. Anemia may cause pallor and
tachycardia.
B. Laboratory Findings—Anemia occurs frequently.
Decreases in hemoglobin levels may not be detectable in an
early assessment of the bleeding. Evidence of chronic hepatic
dysfunction such as elevated serum aminotransferases,
bilirubin, and alkaline phosphatase is commonly present.
Differential Diagnosis
Patients with cirrhosis may experience an upper GI bleed
from other causes such as gastritis, peptic ulcer disease,
esophageal ulceration, or mucosal tears (Mallory-Weiss syn-
drome). Endoscopy is essential for diagnosis.
Table 34–3. Predictors of poor outcome in patients with
acute hepatic failure (King’s College criteria).
Acetaminophen toxic patients  
Blood pH <7.30 (irrespective of grade of encephalopathy) or–
A combination of: encephalopathy stage III or IV, prothrombin time
>100 s (INR >6.5), and serum creatinine >3.4 mg/dL 
Nonacetaminophen toxic patients 
Prothrombin time >100 s (INR >6.5) (irrespective of stage of 
encephalopathy) or–
Any three of the following five variables (irrespective of stage of 
encephalopathy): 
1. Age <10 years or >40 years 
2. Etiology: hepatitis C, halothane hepatitis, idiosyncratic drug 
reactions 
3. Duration of jaundice before onset of encephalopathy of >7 days 
4. Prothrombin time >50 s (INR >3.5) 
5. Serum bilirubin level of >17.5 mg/dL 
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Treatment
Initial management is based on restoring blood volume
through intravenous hydration and transfusion. Coagulopathy
should be corrected as appropriate with fresh-frozen plasma.
In patients with significant bleeding or with altered senso-
rium, endotracheal intubation for protection of the airway
may be necessary.
A. Medical Treatment—Vasoactive drugs may be started as
soon as the diagnosis is suspected. These drugs have proven
value in nonesophageal sites of bleeding, such as portal
hypertensive gastropathy and gastric varices. Vasoconstrictors
decrease portal flow and pressure by decreasing splanchnic
arterial flow. Vasodilators decrease hepatic vascular resist-
ance and cause peripheral vasodilation, resulting in reflex
splanchnic vasoconstriction.
Vasopressin’s main role is as a temporizing measure. An
infusion of 0.2–0.4 units/min successfully controls acute
variceal bleeding in half of patients. It is often used for 48–72
hours. However, recurrent episodes of bleeding are common
(approximately 50%). By decreasing the rate of bleeding, it
facilitates initial resuscitation and the performance of
endoscopy for local definitive therapy of the bleeding varices.
Secondary effects are significant vasoconstriction with
hypertension, bradycardia, and risk of myocardial infarction.
Vasopressin generally is used in conjunction with nitroglyc-
erin. The combination, which reduces cardiac ischemia, is
superior to vasopressin alone in controlling acute variceal
bleeding. Nitroglycerin is also delivered via continuous infu-
sion at a dose of 0.2 μg/kg per minute.
Somatostatin is an effective hormone in the control of
acute variceal bleeding. An intravenous infusion of 25–50 μg/h
has been found to be as effective as vasopressin, balloon tam-
ponade, and sclerotherapy in prospective randomized trials.
Octreotide, the longer-acting form of somatostatin, is the
agent of choice in the initial management of acute variceal
bleeding because it is at least as effective as vasopressin but
has fewer side effects. Octreotide has been found to be as
effective as balloon tamponade of the esophagus in a clinical
trial.
B. Endoscopic Management—Sclerotherapy is the treat-
ment of choice in the management of acute variceal bleeding.
Sclerotherapy is successful in 60–90% of patients during ini-
tial management and is superior to vasopressin and balloon
tamponade. Complications of sclerotherapy are esophageal
ulceration, bleeding, perforation, bacteremia, and mediastini-
tis. Complications can occur in 10–30% of patients.
Variceal ligation is an alternative to sclerotherapy. The
efficacy is high and comparable with that of sclerotherapy.
There seems to be a trend toward fewer complications with
ligation.
Balloon tamponade is used less frequently as a temporiz-
ing measure, showing an efficacy of approximately 60–70%,
comparable with that of vasopressin and sclerotherapy but
associated with a high complication rate. In a Sengstaken-
Blakemore tube, the gastric balloon is passed into the stomach
and inflated; the esophageal balloon is inflated only if bleed-
ing is not controlled by the gastric balloon to 35–50 mm Hg
of pressure using manometer control. The lowest pressure
possible that will control hemorrhage should be used.
Serious complications, with a 5% mortality, include aspira-
tion pneumonia, esophageal rupture, and mucosal ulcera-
tion. The risk of complications increases with prolonged use.
However, use of a Blakemore-Sengstaken tube or a Linton
tube can be a lifesaving maneuver if medical and endoscopic
measures fail to stop bleeding.
C. Nonsurgical Shunts (Transjugular Portosystemic
Shunt [TIPS])—This technique is used widely in the setting
of acute variceal bleeding because it offers a rapid decom-
pressive shunt that does not require laparotomy. It is used as
primary treatment for patients with bleeding gastric varices
and for patients with hypertensive portal gastropathy—
mainly because of the difficulty and poor results with endo-
scopic management.
D. Surgical Treatment—Surgery plays a role in the manage-
ment of patients who fail medical, endoscopic, and TIPS
management of acute variceal bleeding. The surgical options
are either shunt or nonshunt operations.
Shunt procedures are either total (eg, portacaval shunt,
mesocaval shunt, and central splenorenal shunt) or selective
(eg, distal splenorenal shunt). These procedures are so
named because they theoretically divert all (total) or only
part (selective) of the portal blood flow. The most commonly
used operation in the emergency setting is a portacaval
shunt. It is very effective in controlling acute bleeding and
preventing rebleeding, but the mortality rate is as high as
50%. All surgical procedures have some undesirable side
effects, including encephalopathy and/or ascites. The selec-
tive procedures loose their selective nature over time and also
have undesirable side effects.
Gastroesophageal devascularization (Sugiura operation)
is a nonshunt operation. It has fallen into disfavor because
the recurrence rate of bleeding is high, but it is indicated in a
selected subset of patients with portal vein thrombosis or
segmental portal hypertension with an acute bleeding
episode.
 Ascites
ESSENT IALS  OF  D IAGNOS I S
 History: abdominal distention.
 Physical examination: fluid wave, shifting dullness, and
dullness to percussion.
 Abdominal ultrasound may detect up to 100 mL of
ascitic fluid; ultrasound is useful in the diagnosis of
patients with minimal ascites.
 Paracentesis; serum ascites albumin gradient >1.1 g/dL.
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General Considerations
A typical circulatory dysfunction characterized by arterial
vasodilation and high cardiac output coupled with increased
sinusoidal pressure and hepatic insufficiency is the cause of
ascites in cirrhotic patients. In addition, there is renal sodium
and water retention caused by stimulation of the renin-
angiotensin-aldosterone axis and activation of antidiuretic
hormone (ADH) secretion by the relative underfilling of the
arterial vascular compartment.
Over 50% of patients with cirrhosis will develop ascites. It
is therefore one of the most common complications of cir-
rhosis. Once ascites develops, the median survival is approx-
imately 1 year.
Clinical Features
A. Symptoms and Signs—Patients with large-volume
ascites complain of increasing abdominal girth and abdomi-
nal pressure. Some patients complain of anorexia, early sati-
ety, and nausea or flank pain. Clinical findings of abdominal
distention and shifting dullness and demonstration of a fluid
wave support the diagnosis of ascites. Other stigmata of liver
disease that aid in diagnosis are jaundice, spider angiomas,
and large periumbilical collateral veins in the abdominal wall
(caput medusae).
B. Laboratory Findings—Diagnostic paracentesis is essen-
tial in the evaluation and management of patients with
ascites. Inspection of the fluid in patients with portal
hypertension reveals clear, straw-colored fluid. Laboratory
evaluation includes cell count, cytologic examination, albu-
min and protein concentrations, and bacteriologic analysis.
The serum-to-ascites albumin gradient, calculated by sub-
tracting the ascitic fluid albumin level from the serum albu-
min level, has been shown to be effective in differentiating
portal hypertensive from nonportal hypertensive ascites.
Patients with a gradient of more than 1.1 g/dL can be diag-
nosed as having portal hypertension with a reliability of
97%. A gradient of less than 1.1 g/dL suggests nonportal
hypertensive etiology. Further differentiation of the ascitic
fluid as a transudate or exudate provides insight into the
origin of ascites.
C. Imaging Studies—Ultrasonography may be helpful in
the detection of small volumes of ascitic fluid. Duplex
ultrasound of the portal and hepatic venous system is indi-
cated if portal vein thrombosis or hepatic vein thrombosis
is suspected. CT scanning is also helpful in the detection of
small volumes of ascites, usually as an incidental finding
when x-rays are requested for evaluation of intraabdominal
pathology.
Differential Diagnosis
Cirrhosis and chronic liver disease are the most common
causes of ascites (approximately 70–80% of patients). The
differential diagnosis of ascites is set forth in Table 34–4.
Spontaneous bacterial peritonitis is a frequent complica-
tion of cirrhotic patients with ascites. It has a 1-year mortal-
ity of 40% despite treatment with antibiotics. Because its
inception can be subclinical, bacteriologic analysis should be
done on every patient with new-onset ascites. Culture of
ascitic fluid in blood culture bottles is more reliable and is
successful in approximately 80% of patients.
Treatment
The treatment of ascites is directed at the underlying
pathogenesis.
A. Medical Treatment—Patients with mild ascites may be
managed with fluid (1.5 L/day) and sodium restriction (88
meq/day). Addition of an inhibitor of aldosterone (eg,
spironolactone) provides a slow sodium loss with preserva-
tion of potassium. Initial doses are 100 mg/day but may be
elevated progressively up to 400 mg/day. Monitoring of
weight and electrolytes is important so that adjustments can
be made to the initial therapy.
Patients with moderate ascites should, in addition, receive
loop diuretics (eg, furosemide). An initial dose of 40 mg/day
generally is well tolerated and may be increased up to
160 mg/day in adults. Careful monitoring of weight, elec-
trolytes, and serum creatinine may prevent complications
from diuretic therapy. Any rise in serum creatinine or urea
nitrogen warrants reduction of the diuretic dosage. An initial
daily weight loss of 500 g/day is acceptable in patients with
moderate ascites. If patients have peripheral edema, a weight
loss of approximately 1 kg/day is acceptable.
Patients with tense ascites in addition should be treated
with paracentesis. Up to 4–5 L may be removed safely.
Organ System Cause 
Hepatic Cirrhosis
Veno-occlusive disease
Cardiac Right ventricular failure
Constrictive pericarditis
Renal Nephrotic syndrome
Renal failure 
Malignancy Ovarian
Gastric
Colorectal
Pancreatic 
Immunologic Tuberculosis 
Pancreas Pancreatitis 
Lymphatic Congenital anomaly
Trauma 
Digestive Malnutrition 
Endocrine Myxedema 
Table 34–4. Differential diagnosis of ascites. 
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Attention to salt and water restriction is also a critical com-
ponent of management. Patients who require large-volume
paracentesis may develop rapid contraction of the intravascu-
lar space after fluid shifting. Clinical trials have documented a
better outcome after large-volume paracentesis with the
simultaneous infusion of intravenous albumin. Intravenous
salt-poor albumin should be used routinely in patients under-
going large-volume paracentesis. As a rule of thumb, salt-poor
albumin (~10 g/L of ascitic fluid) is infused concomitantly
intravenously. Spontaneous bacterial peritonitis must be sus-
pected in patients with known liver disease who present with
fever, leukocytosis, and abdominal pain. Cell count of the
ascitic fluid is diagnostic if the polymorphonuclear neutrophil
count is 250 in the absence of a visceral source of infection.
Treatment should be initiated empirically on diagnosis. A
third-generation cephalosporin such as ceftriaxone or cefo-
taxime generally is the first-line therapy until a specific organ-
ism has been selected on the basis of ascitic fluid culture. A
5-day course generally is therapeutic. Most common organ-
isms are Escherichia coli, Klebsiella, and Streptococcus pneumo-
niae. Other organisms are Enterococcus, Bacteroides, and
Enterobacter. Antibiotics with a nephrotoxic profile, such as
aminoglycosides, should be avoided if at all possible.
B. Surgical Treatment—Ten percent of patients develop
intractable ascites. Refractory ascites may be treated by the
placement of a transjugular intrahepatic portosystemic
shunt. Transjugular intrahepatic portosystemic shunt inser-
tion lowers the rate of ascites recurrence and the risk of
developing hepatorenal syndrome compared with paracente-
sis plus albumin administration in patients with refractory
ascites. However, a recent meta-analysis documented
increased encephalopathy and absence of improvement in
survival. Transjugular intrahepatic portosystemic shunt
insertion is also recommended in the treatment of patients
with severe ascites and imminent rupture of umbilical/ven-
tral hernia or hepatic hydrothorax.
Operative therapy with placement of a peritoneovenous
shunt may be considered in patients with mild, stable liver
dysfunction who are otherwise refractory to less invasive
therapies. Although shunting is a simple surgical procedure,
the incidence of postoperative complications is high, related
to infection, coagulopathy, congestive heart failure, and early
shunt occlusion.
Patients with severe or rapidly deteriorating liver dys-
function should be considered for liver transplantation.
 Hepatorenal Syndrome
ESSENT IALS  OF  D IAGNOS I S
 Chronic liver disease.
 Renal failure.
 Circulatory abnormalities (low systemic vascular resist-
ance and blood pressure).
General Considerations
Hepatorenal syndrome is a clinical condition that occurs in
patients with chronic liver disease, advanced hepatic failure,
and portal hypertension characterized by impaired renal
function. The prevalence of hepatorenal syndrome in patients
with end-stage cirrhosis ranges between 7% and 15%. It is
associated with marked abnormalities in the arterial circula-
tion and activity of the endogenous vasoactive system. Severe
renal vasoconstriction causes a low glomerular filtration rate
(GFR), whereas in the extrarenal circulation there is predom-
inance of arterial vasodilation, which results in reduction of
total systemic vascular resistance and arterial hypotension.
Hepatorenal syndrome is caused by severe vasoconstric-
tion of the renal circulation. A number of vasoactive media-
tors are implicated in the development of vasoconstriction,
such as angiotensin II, norepinephrine, neuropeptide Y,
endothelin, adenosine, and cysteine leukotrienes. The most
commonly accepted explanation is the arterial vasodilation
theory, which proposes that renal hypoperfusion represents
the extreme manifestation of underfilling of the arterial cir-
culation secondary to massive vasodilation of the splanchnic
circulation. Splanchnic vasodilation is caused by nitric oxide,
prostaglandins, and vasodilator peptides. In the early phase,
urine output and renal function are maintained by renal
vasodilator factors. Hepatorenal syndrome develops later,
when vasoconstriction ensues from relative hypovolemia.
Hepatorenal syndrome may be precipitated by concomi-
tant illnesses or may occur spontaneously. Spontaneous bac-
terial peritonitis is the most common precipitating factor of
hepatorenal syndrome in patients with cirrhosis.
Clinical Features
A. Symptoms and Signs—Hepatorenal syndrome occurs as
a complication of cirrhosis, more commonly in patients with
ascites. Two types are recognized. Type I is characterized by
rapid and progressive impairment of renal function.
Dominant features are marked renal failure, oliguria or
anuria, and high levels of urea and creatinine. Most patients
have hyperbilirubinemia, coagulopathy, and encephalopathy.
The median survival is only 2 weeks. Type II consists of mild
and stable reduction in renal function. These patients typi-
cally present with diuretic-resistant ascites.
Four major criteria must be present to establish the diag-
nosis of hepatorenal syndrome: (1) low GFR (creatinine
clearance <40 mL/min or serum creatinine >1.5 mg/dL),
(2) absence of shock with ongoing bacterial infection, fluid
loss, and current treatment with nephrotoxic drugs, (3) no
improvement in renal function after withdrawal of diuretics,
and (4) no evidence of obstructive uropathy and absence of
proteinuria (<500 mg/day).
B. Laboratory Findings—Laboratory findings in hepatorenal
syndrome include a creatinine clearance of less than 40 mL/min
or a serum creatinine concentration of more than 1.5 mg/dL,
a urine sodium concentration of less than 10 meq/L, a urine
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osmolality that is greater than plasma osmolarity, urine red
blood cells fewer than 50/hpf, and a serum sodium concen-
tration of less than 130 meq/L.
Differential Diagnosis
Other causes of renal failure that must be excluded prior to
making a diagnosis of hepatorenal syndrome include hypov-
olemia causing prerenal failure (eg, use of diuretics or bleed-
ing), acute tubular necrosis (eg, following hypotension or
sepsis), drug-induced nephrotoxicity (eg, NSAIDs or amino-
glycosides), and glomerulonephritis (commonly associated
with proteinuria) secondary to autoimmune disease.
Treatment
Initial management requires volume replacement and reach-
ing a euvolemic state. Once hepatorenal syndrome is sus-
pected, medical management is difficult and more often than
not unsuccessful. Basic management requires monitoring of
urine output, patient weight, blood pressure, evaluation and
replacement of electrolytes, and possibly dialysis.
Intravenous clonidine has been shown to lower renal vas-
cular resistance and increase the GFR by as much as 25%.
Dopamine has been proposed as a selective vasodilator of the
renal circulation in selected reports, but the literature sug-
gests that there is only a very mild effect in increasing GFR.
Liver transplantation causes a dramatic improvement in
renal function. Recovery of renal function typically is seen
within 48–72 hours of transplantation. Long-term survival
after transplantation is very good—approximately 60% after
3 years. The perioperative phase may be more complicated
owing to a 30% requirement of temporary hemodialysis and
the higher incidence of morbidity and mortality than in
patients transplanted without hepatorenal syndrome.
 Preoperative Assessment & Perioperative
Management of Patients With Cirrhosis
There is high perioperative morbidity and a high mortality
risk in patients with cirrhosis undergoing abdominal surgery
for any indication. Liver function may deteriorate from general
anesthesia. Anesthesia reduces cardiac output, induces
splanchnic vasodilation, and causes a 30–50% reduction in
hepatic blood flow.
The 30-day mortality for patients with cirrhosis undergo-
ing celiotomy is 30%. A 60% major complication rate also
was reported. The risk depends on a number of factors.
A. Physiologic Status—The Child-Turcotte-Pugh classifi-
cation of surgical risk is summarized in Table 34–5. This clas-
sification was first proposed (by Child) as a means of
predicting the operative mortality associated with portacaval
shunt surgery. The presence of ascites, encephalopathy, and
coagulopathy predicts mortality. There is a 10% mortality
rate for patients with Child class A cirrhosis, 30% for Child
class B, and 75% for Child class C.
Another model predictive of outcomes in patients with cir-
rhosis is the Model for End-Stage Liver Disease (MELD),
which is a numerical scale based on the etiology of cirrhosis,
bilirubin, creatinine, and international normalization ratio
(INR). Scores range from 6 (less ill) to 40 (gravely ill), and the
model is used for liver transplant candidates aged 12 and older.
B. Type of Surgery—The overall hospital mortality rate was
estimated at 21% for biliary surgery, 35% for peptic ulcer
disease, and 55% for colectomy. Newer techniques such as
laparoscopy and better patient selection have contributed to
a reduced mortality rate in recent reports of laparoscopic
cholecystectomy and appendectomy.
C. Other Factors—Active infection, a higher number of
blood transfusions, pulmonary complications, GI bleeding,
and the need for emergency surgery have a negative impact
on the outcome of surgery in patients with cirrhosis.
 Liver Resection in Patients
with Cirrhosis
Hepatectomy is a major operation that induces a severe cata-
bolic response and immunosuppression. Cirrhotic patients
already suffer from underlying catabolism and immunosup-
pression. Liver resection in patients with underlying liver
Clinical Variable 1 Point 2 Points 3 Points 
Encephalopathy None Stage 1–2 Stage 3–4 
Ascites Absent Slight Moderate 
Bilirubin (mg/dL) <2 2–3 >3 
Albumin (g/dL) 3.5 2.8–3.5 <2.8 
Prothrombin time 
(seconds prolonged or INR) 
<4 s or
INR <1.7 
4–6 s or
INR 1.7–2.3 
>6 s or
INR >2.3 
Interpretation: Child class A = 5–6 points, Child class B = 7–9 points, Child class C = 10–15 points. 
Table 34–5. Child-Turcotte-Pugh estimate of surgical risk.
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insufficiency carries the risk of postoperative liver failure. In
experienced hands, the mortality rate after hepatectomy
ranges from 5–50%.
Other postoperative complications are common, such as
the development of ascites (5%), encephalopathy (20%),
renal failure (15%), and upper GI bleeding (5%). Factors
that contribute to this great variability are the extent of resec-
tion and the patient’s underlying physiologic status.
Preoperative patient selection and perioperative manage-
ment are critical to successful outcome after liver resection in
patients with cirrhosis.
Preoperative Evaluation
Prior to operation, attention is directed to identification of
patients in whom the complication rate or mortality risk
is prohibitive. Numerous methods of identification have been
proposed. The clinical classification of patients according to
their Child score is a time-tested approach and is used most
commonly. Patients with Child A liver function have a hospi-
tal mortality risk for major hepatectomy of 3–15%. Patients
with Child B or C liver function tolerate liver resection poorly,
and that procedure should be withheld except in highly
selected individuals who require minimal surgery. Others have
proposed the use of the indocyanine green clearance test, the
lidocaine clearance test, and measuring the degree of fibrosis
in the unaffected liver as predictors of morbidity and mortal-
ity. Another factor that must be considered in selection of
patients is the volume of remaining liver estimated by CT scan.
As before any other major surgery, a good clinical history
and examination should alert the clinician to the presence of
any significant pulmonary, cardiac, hematologic, or renal
disorders. Screening of hematologic, biochemical, renal, pul-
monary, and cardiac function is essential.
Operative Management
Metabolic and hematologic derangements must be corrected
prior to surgery. Intraoperative monitoring of blood loss,
hemodynamics, and urine output is crucial. Patients with
hepatic dysfunction suffer from peripheral vasodilation and
are less responsive to catecholamines. It is therefore impor-
tant to maintain the circulatory volume. Maintaining liver
perfusion during surgery is critical to the prevention of any
further impairment of hepatic function. Therefore, anes-
thetic agents that do not impair hepatic perfusion and oxy-
genation should be selected.
Liver transection must be performed with two issues in
mind, minimizing blood loss and having adequate hemostasis
and securing biliary radicles to avoid postoperative biliary leak-
age, which is a cause of postoperative morbidity and sepsis.
Postoperative Care
Postoperative monitoring should include hemodynamics,
oxygen saturation, vital signs, fluid balance, electrolytes, and
blood glucose. Postoperative pain must be controlled to
avoid cardiopulmonary complications. Careful fluid man-
agement is a critical component of postoperative care.
Maintaining euvolemia is a priority. Owing to alterations in
the renin-angiotensin-aldosterone axis, cirrhotic patients
have a propensity for salt retention and third spacing of
extracellular water. This, in turn, manifests as ascites. When
salt restriction is required, 0.25% saline solution should be
used instead of 0.5%.
Parenteral nutritional support is provided in the form of
branched-chain amino acids because they reduce the cata-
bolic response and promote hepatic protein synthesis and
liver regeneration in cirrhosis. Adequate calories and fatty
acids are also provided. Perioperative nutritional support
reduces overall postoperative morbidity by decreasing septic
complications, the incidence of ascites, and deterioration of
liver function.
Potassium phosphate is used in the parenteral solution to
avoid hypophosphatemia, which occurs commonly after
hepatectomy. Phosphate is necessary for production of ATP
in the liver.
At least one study supports the use of salt-poor albumin
in septic cirrhotic patients as a means of reducing renal com-
plications and mortality.
Hyperbilirubinemia occurs commonly and generally is
transient, but progressive hyperbilirubinemia is an ominous
sign. Decreased sensorium, hypoglycemia, and acidosis are
present in severe hepatic failure and portend a poor prognosis.
Hepatic failure is complicated by a noncorrectable coagulopa-
thy and sepsis. Use of the bioartificial liver is potentially a life-
saving measure, but this resource is not yet widely available.
Liver transplantation is the only option (see Chapter 35).
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Burns represent particularly challenging and difficult man-
agement problems. This chapter addresses the most common
causes, including thermal, electrical, and chemical burns.
Because of the far-reaching implications for care, additional
aspects of electrical injuries such as lightning strikes and
electrocution are discussed further with environmental
injuries in Chapter 37.
I. THERMAL BURN INJURY
Approximately 1.25 million burn injuries occur each year
in the United States. House and structure fires account for
81% of the 3600 burn- and fire-related deaths that occur
each year. Flame injury following a house fire or ignition of
clothing is the most common burn injury in patients
admitted to burn centers. Scald burns, the most common
burn injury in children, are responsible for about 30% of
patients requiring hospitalization for burns. Most burn
injuries are treated adequately on an outpatient basis; how-
ever, approximately 60,000 patients per year require hospi-
tal care because of the extent of their injury, the presence of
comorbid factors, or extremes of age. Approximately 20,000
patients have injuries of such significance that care is best
undertaken in a designated burn care facility. The American
Burn Association has developed criteria to identify patients
who require treatment in a burn center. These criteria assess
the severity of injury and the need for specialized burn cen-
ter treatment based on the age of the patient; the extent,
depth, and location of the burn; the type of injury; and the
presence of preexisting comorbid factors or associated
injuries (Table 35–1).
Thermal burn injury initiates a deleterious pathophys-
iologic response in every organ system, with the extent
and duration of organ dysfunction proportionate to the
size of the burn. Direct cellular damage is manifested by
coagulation necrosis, with the magnitude of tissue destruc-
tion determined by the temperature to which the tissue is
exposed and the duration of contact.
 Histopathologic Characteristics of Burned
Tissue
Following thermal injury, the region of the burn in which
protein coagulation and cell death has occurred has been
referred to as the zone of necrosis. In full-thickness injury, all
dermal elements are destroyed, whereas partial-thickness
burns are characterized by a variable and incomplete dermal
necrosis. Extending radially from the zone of necrosis are
areas of cellular damage referred to as the zones of stasis and
hyperemia. The zone of stasis is characterized by a decreased
microvascular blood flow, which may be restored to normal
with successful resuscitation or converted to necrosis follow-
ing inadequate perfusion, desiccation, or infection. Minimal
thermal injury induces a zone of hyperemia characterized by
an immediate inflammatory response and increased
microvascular blood flow. These early histopathologic
changes are depicted as concentric tissue zones about the
point of thermal contact. Coagulation necrosis of the skin
and skin appendages results in loss of normal skin functions;
the antimicrobial barrier is destroyed, control of water evap-
oration is lost, and regulation of body temperature is
impaired.
 Mechanisms of Edema Formation
Following thermal injury, edema formation in the burn
wound and in unburned tissues is greatest in the first 6 hours
following injury and continues to a lesser extent for the first
24 hours postburn. Postcapillary venular constriction results
in a marked increase in capillary hydrostatic pressure and
the production of interstitial edema in the early postinjury
phase. In an animal model of burn injury, a strongly nega-
tive interstitial fluid hydrostatic pressure has been shown
to occur within 30 minutes of injury. The duration and
∗The views of the authors do not purport to reflect the position of
the Department of the Army and the Department of Defense.
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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magnitude of the negative hydrostatic pressure change were
proportional to the size of the burn. An early increase in the
interstitial fluid colloid osmotic pressure following burn
injury resulting in a reversal of the transcapillary osmotic
pressure gradient also has been reported. Following initial
changes in the physical characteristics of burn tissue, subse-
quent edema formation generally has been attributed to an
increase in microvascular permeability owing to the effects of
humoral factors liberated from burned tissue and cytokines
produced by activated leukocytes. The plasma concentration
of histamine, a potent regulator of vascular permeability
present in abundance in mast cells, rises in proportion to
burn size immediately following injury. Many inflammatory
mediators, including activated proteases, prostaglandins,
leukotrienes, fibrin degradation products, and substance P,
have been reported to increase microvascular permeability
following burn injury. Specific antagonists to these agents
have been shown to decrease but not eliminate edema forma-
tion when administered prior to burn injury. The efficacy of
inflammatory mediator antagonists in decreasing microvas-
cular permeability when administered following burn injury
has not been demonstrated conclusively.
Leukocyte activation results in the production of
cytokines and other factors capable of increasing microvas-
cular permeability. Lysosomal enzymes, increased xanthine
oxidase activity, products of complement activation, and
oxygen radicals are generated following thermal injury and
are capable of increasing microvascular permeability and
burn wound edema. Interleukin 2 (IL-2)–activated human
killer lymphocytes have been shown to increase albumin flux
across monolayers of cultured endothelial cells in vitro. Even
though neutrophil depletion has been reported to protect
against postburn lung injury, it did not reduce burn wound
edema formation. The response of the leukocyte appears to
depend on the agent of injury, the proximity to the site of
injury, and exposure to humoral mediators.
Edema formation also occurs in unburned tissues follow-
ing a major burn. Conflicting reports exist concerning the
mechanism of this edema formation. In animal studies, an
increase in the ratio of lymph to plasma protein measured in
uninjured extremities following burn injury, as well as an
increase in extravasation of radiolabeled albumin into unin-
jured tissue, has been described. Others were unable to
demonstrate a change in ratios of lymph to serum protein
from an uninjured sheep extremity following burn injury,
implying that no change in vascular permeability in the
uninjured extremity had occurred. Edema accumulation
may be massive in unburned tissue following thermal injury,
and despite the conflicting reports, it is most likely due to
changes in oncotic pressure and the dilutional effects result-
ing from the infusion of large volumes of crystalloid fluid
required for burn resuscitation. Edema formation is charac-
terized by a shift of fluid and protein from the intravascular
into the extravascular compartment. Volume shifts occur in
proportion to the extent of burn, resulting in decreased
blood volume and decreased cardiac output, which, if
untreated, progress to hypovolemic shock.
 Organ System Responses to Burn Injury
The magnitude and duration of the prototype organ
response to thermal injury of early hypofunction and later
hyperfunction depend on the extent of injury.
Cardiovascular System
During the resuscitative phase, the initial cardiovascular
response to thermal injury is manifested by decreased cardiac
output and increased peripheral vascular resistance followed
by a progressive increase in cardiac output and decrease in
peripheral vascular resistance during the hypermetabolic
flow phase. The fall in cardiac output is proportional to the
size of the burn and attributable to the loss of fluid and pro-
tein from the intravascular into the extravascular compart-
ment. There is a corresponding reflex increase in peripheral
vascular resistance as a consequence of the neurohumoral
response to hypovolemia. A myocardial depressive factor has
been implicated as the cause of initial impaired myocardial
performance; however, this factor has not been identified.
Clinical studies have demonstrated that in the absence of
heart disease, the ventricular ejection fraction and velocity of
myocardial fiber shortening were increased following thermal
injury and that hypovolemia, as measured by decreased left
ventricular end-diastolic volume, was the cause of depressed
cardiac output. Fluid resuscitation following burn injury
improves cardiac performance as hypovolemia is corrected.
Table 35–1. American Burn Association burn center
referral guidelines.
Partial-thickness burns greater than 10% total body surface area
Burns that involve the face, hands, feet, genitalia, perineum, or major
joints
Third-degree burns in any age group
Electrical burns, including lightning injury
Chemical burns 
Inhalation injury
Burn injury in patients with preexisting medical disorders that could
complicate management, prolong recovery, or affect mortality
Any patients with burns and concomitant trauma (such as fractures) in 
which the burn injury poses the greatest risk of morbidity or
mortality. In such cases, if the trauma poses the greater immediate
risk, the patient may be initially stabilized in a trauma center before
being transferred to a burn unit. Physician judgment will be neces-
sary in such situations and should be in concert with the regional
medical control plan and triage protocols.
Burned children in hospitals without qualified personnel or equipment
for the care of children
Burn injury in patients who will require special social, emotional, or 
long-term rehabilitative intervention
TBSA=total surface area.
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As microvascular permeability decreases, the plasma volume
deficit is replenished in the second 24 hours, and cardiac out-
put increases to supranormal levels. Peripheral vascular
resistance decreases below normal, and the postburn hyper-
metabolic state, which peaks in the second postburn week
and slowly recedes thereafter, is established. Studies have
demonstrated that the postresuscitation increase in cardiac
output is directed primarily toward the burn wound; that is,
the blood flow to a burned extremity is significantly
increased compared with an unburned extremity in the same
patient, and the increase is proportional to the extent of burn
on the involved extremity. As a consequence, a decrease in
cardiac output secondary to hypovolemia or pharmacologic
intervention may reduce the flow of oxygen and nutrients to
the wound and impair wound healing.
Lungs
Following thermal injury, even in the absence of associated
smoke inhalation, physiologic changes in pulmonary func-
tion occur. Immediately postburn, minute ventilation is
unchanged or slightly increased as a result of anxiety- and
pain-induced hyperventilation. With the initiation of fluid
resuscitation, respiratory rate and tidal volume increase pro-
gressively, resulting in a minute ventilation that may be two
to two and one-half times normal. The magnitude of this
increase is proportional to the extent of burn and is consid-
ered to reflect postinjury hypermetabolism. In patients with
circumferential burns of the thorax, the unyielding eschar
and underlying edema may restrict ventilation to the point of
requiring escharotomy incisions to relieve the restrictive ven-
tilatory defect.
Pulmonary vascular resistance increases immediately fol-
lowing thermal injury, and the increase is more prolonged
than the increase in peripheral vascular resistance. The
release of vasoactive amines and other mediators following
thermal injury may be responsible for the increased pul-
monary vascular resistance, and this process may exert a pro-
tective effect during fluid resuscitation by decreasing
pulmonary capillary hydrostatic pressure and thus prevent
pulmonary edema. Lung lymph flow studies have demon-
strated no change in pulmonary capillary permeability fol-
lowing cutaneous thermal injury. Complement activation
and generation of the chemotactic peptide C5A have been
shown to be temporally related to neutropenia, aggregation
of leukocytes in pulmonary capillaries, and intraalveolar
hemorrhages. In other laboratory studies, preburn depletion
of complement, neutrophils, and platelets was protective of
postinjury lung dysfunction. Preinjury treatment with cata-
lase and superoxide dismutase also improve postburn pul-
monary function, implicating toxic oxygen products
produced by activated neutrophils as mediators of the post-
burn pulmonary dysfunction.
Whether or not the infusion of large volumes of crystal-
loid solution associated with burn resuscitation causes post-
burn pulmonary changes remains controversial. The
accumulation of chest wall edema, exacerbated by infusion
of large volumes of resuscitation fluid, decreases total lung
compliance and promotes atelectasis and hypoxemia.
Furthermore, overzealous initial fluid resuscitation may
result in florid pulmonary edema as the edema fluid is
resorbed during the third to fifth postburn days. Consequently,
the smallest volume of resuscitation fluid that maintains ade-
quate organ perfusion should be administered to avoid
secondary pulmonary complications.
Kidneys
The renal response following thermal injury parallels the car-
diovascular response. In the immediate postburn period, renal
blood flow and the glomerular filtration rate are reduced in
proportion to the size of the burn and the magnitude of the
intravascular volume deficit. Delayed or inadequate fluid
resuscitation may cause inadequate renal perfusion and lead to
acute tubular necrosis and renal failure. Following a successful
resuscitation phase, cardiac output and renal blood flow are
increased as edema fluid is resorbed. A diuretic response is
observed during the period of edema resorption; however, this
response may be modified by a large evaporative loss of fluids
through the wound surface and slow rates of edema resorption
in patients with large-surface-area burns. Despite the
markedly increased cardiac output and renal plasma flow seen
in the flow phase of burn injury, the blood volume of patients
measured by 51Cr red blood cell labeling was only 81% of pre-
dicted values. Plasma renin activity and antidiuretic hormone
levels are elevated, as predicted by the decreased blood vol-
ume, despite the findings of increased blood flow to the kid-
ney. This may explain in part the propensity for sodium
retention to occur during the course of treatment for thermal
injury. As in other organ systems, the duration of changes in
renal physiology is related to the timing of wound closure by
primary healing or autografting. Owing to the increased renal
blood flow, drugs excreted by the kidneys tend to have
markedly shortened half-lives, and appropriate dosing adjust-
ments of these drugs are necessary.
Gastrointestinal Tract and Liver
GI and hepatic dysfunction are also related to the magnitude
of thermal injury. In patients with burns of more than 25% of
the total body surface, ileus, resulting from the combined
effects of hypovolemia and neurohumoral changes, is a
prominent feature. Nasogastric intubation for gastric decom-
pression is usually required. Following resuscitation, normal
GI motility commonly returns by the third to fifth postburn
day. Focal ischemic mucosal lesions of the stomach and duo-
denum may be observed as early as 3–5 hours following burn
injury, and in the absence of stress ulcer prophylaxis, these
early lesions may progress to frank ulceration. Intestinal bac-
terial translocation following thermal injury has been studied
extensively in the laboratory, and increased intestinal perme-
ability to low-molecular-weight sugars has been identified as
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a prodrome to the onset of infection in thermally injured
patients. However, the clinical significance and therapeutic
implications of these findings are yet to be fully elucidated.
As the magnitude of a burn increases, so does the likeli-
hood of early postburn hepatic dysfunction. An initial
increase in hepatic aminotransferase is common following
burns of more than 50% of the body surface area. This is most
likely due to the acute reduction in cardiac output, increased
blood viscosity, and associated splanchnic vasoconstriction
that occur immediately following thermal injury. Following
successful fluid resuscitation, the hepatic enzymes promptly
return to normal in most patients. The magnitude of initial
enzyme derangements has not been predictive of outcome;
however, the early onset of jaundice following thermal injury
is associated with a poor prognosis, probably indicating
preinjury hepatic dysfunction or severely compromised
hepatic perfusion during the resuscitative phase. The onset of
hepatic dysfunction later in the postburn period usually is
manifested by hyperbilirubinemia and elevation of liver
enzymes in a cholestatic pattern. These changes are most
often associated with sepsis or multiple-organ failure.
Nervous System
Nonspecific neurologic changes such as increased anxiety
and disorientation are observed commonly in patients with
extensive thermal injury and are most likely due to the neu-
rohumoral stress response and ICU isolation. Specific neuro-
logic changes are observed more commonly in patients with
high-voltage electrical injury or mechanical trauma.
Changing neurologic symptoms and signs, manifested by
increasing disorientation, obtundation, or seizures, may be
the earliest indications of hypoxemia, electrolyte or fluid
imbalance, sepsis, or the toxic effects of medications.
Changes in neurologic findings require prompt intervention
to identify and correct such abnormalities.
Endocrine System
The metabolic response to thermal injury is also proportion-
ate to the extent of burn and follows the typical biphasic
response documented in other organ systems. Immediately
following burn injury, during the period of hypovolemia, the
metabolic rate decreases; however, as resuscitation pro-
gresses, a catabolic or hypermetabolic hormonal pattern
emerges. Serum levels of catecholamines, glucagon, and
cortisol increase, whereas insulin and triiodothyronine lev-
els are decreased. There is an increase in net glucose flow,
with relative peripheral insulin resistance and a markedly
negative nitrogen balance. As the burn wounds heal or are
closed by autografting, the catabolic hormone response
dissipates, an anabolic state is eventually attained, and
restoration of lean body mass ensues. Septic complications
superimposed on thermal injury initially exaggerate the
hypermetabolic response, but if the septic state persists,
progressive deterioration and multisystem organ failure,
characterized by hypometabolism, may occur.
Hematopoietic System
Destruction of red blood cells following thermal injury
occurs to an extent proportional to the size and depth of
burn. In areas of full-thickness burn, red blood cells are
immediately coagulated in the involved microvasculature.
There is a continuing red blood cell loss in patients with
extensive burns of 8–12% of the red blood cell mass per day
caused by the continued lysis of cells damaged by heat,
microvascular thrombosis in zones of ischemia that subse-
quently become necrotic, and repeated blood sampling. In
the early postburn period, platelet number and fibrinogen
levels are depressed, with a corresponding rise in fibrin split
products. Following resuscitation, platelets and serum levels
of fibrinogen and factors V and VIII rapidly increase to
supranormal levels. Erythropoietin levels are increased coin-
cident with the anemia following thermal injury. Recent
studies have suggested that the rate of erythropoiesis may be
further increased by the administration of recombinant ery-
thropoietin and iron. However, a decrease in transfusion
requirements has yet to be demonstrated.
Immunologic Response
Infection remains the major cause of death among burn
patients. Following injury, dysfunction of the cellular and
humoral immune response occurs that is related to the
extent of injury. Destruction of the normal skin barrier
results in loss of mechanical protection from microbial pro-
liferation and allows microbial invasion into normal tissues.
Modern burn care—with emphasis on effective topical
antimicrobial agents, infection control policies, and timely
excision with autograft closure of burn wounds—has signif-
icantly decreased the incidence of burn wound infection.
Other infectious complications, principally pneumonia,
remain the major source of morbidity and mortality, and
treatment may be made difficult by the generalized immune
system dysfunction following thermal injury.
During the first postburn week, the total white blood cell
count is elevated, although peripheral blood lymphocyte
counts are reduced. Burn injury also causes apoptosis of lym-
phocytes in various solid organs following burn injury. This
process is glucocorticoid-mediated and can be blocked
experimentally by the administration of glucocorticoid
receptor antagonists. This process is not TNF-α– or Fas
ligand–dependent and may represent a counterregulatory
mechanism to reduce inflammatory stimuli. Delayed hyper-
sensitivity reactions and peripheral blood lymphocyte prolif-
eration in the mixed lymphocyte reaction are both inhibited
following thermal injury. Alterations in lymphocyte subpop-
ulations have been described that normalize over the second
postburn week in patients whose course is uncomplicated.
Further alterations occur prior to and during the onset of
septic complications. Alterations in IL-2 production and
IL-2 receptor expression by lymphocytes have been measured
following burn injury, and direct correlation has been estab-
lished between the extent of burn and the decrease in IL-2
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production by peripheral blood lymphocytes. Septic compli-
cations result in a further decrement in IL-2 production.
Serum IgG levels are decreased following burn injury and
gradually return to normal over 2–4 weeks as the patient
recovers. Restoration of IgG levels to normal by exogenous
administration has not been shown to affect morbidity or
mortality. Many investigators, using a number of experimen-
tal approaches, have demonstrated immunosuppressive fac-
tors present in the serum of thermally injured patients.
Similar immunosuppressive properties have been detected in
burn blister fluid. Immunosuppressive polypeptides have
been the most commonly invoked agents; however, other fac-
tors, including complement degradation products,
immunoglobulin fragments, prostaglandins, and endocrine
secretions, occur in the serum following thermal injury.
Alterations in granulocyte chemotaxis, degranulation,
adherence, oxygen free-radical production, and complement
receptor expression have been observed following thermal
injury. Granulocytes from burned patients exhibit an
increase in cytosolic oxidase activity, suggesting in vivo acti-
vation. They also exhibit greater than normal oxidase activ-
ity after in vitro stimulation. This increase suggests that
neutrophils from burned patients have an increased oxida-
tive burst potential that, if activated, could cause increased
tissue and organ injury. A marked and sustained increase in
neutrophil expression of the complement opsonin receptors
CRT and CR3 has been described following burn injury. The
increase in receptor expression correlated with decreased
chemotaxis in response to zymosan-activated serum, sug-
gesting that C5A was responsible for inducing systemic neu-
trophil activation. Recent investigations have demonstrated
significant elevation of F-actin content and decreased ability
to polymerize and depolymerize F-actin in the granulocytes
of burn patients when compared with controls. These alter-
ations may be partly responsible for the observed changes in
chemotaxis and migration following thermal injury.
Almost every aspect of immunoregulation is affected fol-
lowing burn injury. At present, no effective immunomodula-
tory treatment has been identified; however, the development
of new immunomodulatory drugs and recombinant lym-
phokines and their antagonists may prove beneficial in cor-
recting immune dysfunction following burn injury.
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INITIAL CARE OF THE BURN PATIENT
Prehospital Treatment
The primary concern at the accident scene is to stop the
burning process. Burning and smoldering clothing should be
extinguished. Patients with electrical injury should be sepa-
rated from points of electric contact, taking all necessary care
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to avoid injuring oneself. If the burn was caused by a chemi-
cal agent, all contaminated clothing should be removed and
copious water lavage initiated.
As with all trauma patients, the primary concern during
initial assessment is maintenance of cardiopulmonary func-
tion. Airway patency and adequacy of ventilation must be
maintained and supplemental oxygen administered as neces-
sary. In the absence of associated mechanical trauma or need
for cardiopulmonary resuscitation, placement of an intra-
venous cannula is not necessary if transport to a treatment
facility can be accomplished in less than 45 minutes. The
application of ice or cold water soaks will relieve pain in areas
of second-degree burn. If the cold therapy is initiated within
10 minutes of burning, tissue heat content is also reduced,
and the depth of thermal injury may be lessened. If cold ther-
apy is used, care must be taken to avoid causing hypother-
mia. Cold soaks or ice should only be used on patients with
burns of less than 10% of the body surface and only for the
time required to produce analgesia. After the ice or cold soak
is removed, the patient should be covered with a clean sheet
and blanket to conserve body heat and minimize contamina-
tion of the burn wounds during transport to the hospital.
 Emergency Management
On arrival at the hospital, the patency of the airway and ade-
quacy of breathing should be reassessed and endotracheal
intubation performed if necessary. Intravenous fluid resusci-
tation is initiated by infusing a physiologic salt solution, for
example, lactated Ringer’s solution, through a large-bore
intravenous cannula. The order of preference for the site of
intravenous cannulation is a peripheral vein underlying
unburned skin, a peripheral vein underlying burned skin,
and lastly, a central vein.
A history should be obtained, paying special attention to
the circumstances of the injury, the presence of preexisting
disease, allergies and medications, and the use of illicit drugs
or alcohol prior to injury. A complete physical examination
should be performed and associated injuries identified.
Baseline laboratory data should include an arterial blood gas
and pH analysis, serum electrolytes, urea nitrogen, creati-
nine, and glucose, and a complete blood count. If available,
continuous transcutaneous pulse oximetry determination of
oxygen saturation should be initiated in patients with sus-
pected inhalation injury or extensive burns.
Since all currently used resuscitation formulas are based on
body weight and the percentage of total body surface area
burned (TBSB), the patient should be weighed and the depth
and extent of burn estimated. The extent of body surface area
burned can be estimated easily using the “rule of nines,” which
recognizes that specific anatomic regions represent 9% or 18%
of the total body surface area (Figure 35–1). Since the area of
one surface of the patient’s hand (palm and digits) represents
1% of that person’s total body surface, one can use that rela-
tionship in estimating the extent of irregularly distributed
burns. Infants and children have a different body surface area
distribution, with relatively larger heads and smaller lower
extremities. When estimating the body surface burn area for
children under age 10, the Lund and Browder burn diagram
(Figure 35–2) or other similar diagram should be used to deter-
mine the body surface area burned with greater precision.
The depth of burn is classified as partial- or full-thickness
with respect to the extent of dermal destruction by coagula-
tion necrosis (Figure 35–3). First- and second-degree burns
are considered partial-thickness injuries and third-degree
burns full-thickness injuries. Superficial partial-thickness
burns heal spontaneously by epithelial migration from pre-
served dermal appendages. Full-thickness injuries have com-
plete destruction of all epithelial elements and require skin
grafting for wound closure. Deep partial-thickness burns
may heal over a long period of time, but grafting is frequently
performed to decrease time to wound closure, reduce scar
formation, improve functional outcome, and shorten the
hospital stay. The clinical criteria in Table 35–2 permit initial
differentiation among the different depths of burn injury.
Only the total percentage of skin surface area involved in
second- and third-degree burns is calculated or estimated for
resuscitation purposes. First-degree burns do not cause sig-
nificant edema formation or metabolic alteration and are not
considered in the calculation of burn size for estimation of
resuscitation requirements. Differentiation between second-
and third-degree burns is more important in the later post-
burn course because it has implications for the duration of
hypermetabolism, the need for autograft closure of the burn
wound, and the anticipated functional result.
ADULT
“Rule of Nines”
 Figure 35–1. Rule of nines showing distribution of
body surface area (BSA) by anatomic parts in the adult.
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The presence of associated mechanical trauma may affect
the resuscitation requirements of the thermally injured
patient. Soft tissue trauma and bleeding from any injury will
increase the fluid required to establish adequate urine out-
put. The presence of thermal injury should not delay or alter
the evaluation and subsequent treatment, including opera-
tive intervention, of mechanical trauma. An indwelling
urethral catheter should be inserted in all patients requiring
intravenous fluid therapy, and the urinary output should be
measured and recorded hourly. Vital signs and the patient’s
general condition should be monitored and recorded fre-
quently on a flowsheet. The rectal temperature should be
measured hourly, providing a guide for maintenance of core
temperature. In patients with high-voltage electrical injury,
 Figure 35–2. The use of a burn diagram permits a more exact estimation of the extent of burn. Note that the sur-
face areas of the head and lower extremities change significantly with age.
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electrocardiographic monitoring should be initiated in the
emergency department.
The tetanus immunization status of the patient should be
determined in the emergency department. The burn patient
who has been immunized against tetanus previously should
be given a booster dose of tetanus toxoid if the last dose was
administered more than 5 years previously. Patients with no
history of active immunization should receive tetanus
immune globulin in addition to an initial dose of tetanus
toxoid. Active immunization is completed subsequently
according to the routine dosage schedule.
PRINCIPLES OF BURN TREATMENT
 Fluid Resuscitation
Fluid resuscitation should be started as soon as possible fol-
lowing thermal injury. Generally, burns involving more than
25% of the body surface area require intravenous fluid resus-
citation because ileus precludes oral resuscitation. Patients
with smaller burns in whom ileus does not develop should
have liberal access to electrolyte-containing fluids such as
fruit juices or milk, but excessive intake of electrolyte-free
water should be avoided to prevent hyponatremia. Many for-
mulas have been proposed for calculation of intravenous
fluid resuscitation of thermally injured patients (Table 35–3).
The central theme is that the volume of fluid required
depends on the patient’s weight and the extent of burn. Most
often it is recommended that half the calculated requirement
be infused over the first 8 hours following injury, that is, at
the time of maximal vascular permeability; the remainder of
the first 24-hour resuscitation volume is delivered over
the next 16 hours. Certain subgroups of patients require a
significantly greater resuscitation volume than that estimated
by the formulas. A delay in starting fluid resuscitation,
inhalation injury, and ethanol intoxication frequently are
associated with greater than predicted fluid requirements.
Patients with high-voltage electrical injuries frequently
require more resuscitation fluid than that predicted based on
the extent of cutaneous injury. One must recognize that any
resuscitation formula serves only to guide the initiation of
fluid therapy. The actual amount of resuscitation fluid is tai-
lored to each patient’s physiologic responses, with frequent
reassessment and adjustment of infusion rates as needed to
preserve vital organ perfusion.
The various burn formulas in Table 35–3 differ consider-
ably with respect to the volume and composition of the
resuscitation fluids; however, each formula has been found to
be clinically effective. The general use of burn formulas has
decreased the frequency of burn-induced hypovolemic shock
and organ dysfunction, which were secondary to inadequate
 Figure 35–3. Diagram of the skin and subcutaneous
tissues demonstrating the depth of burn and relationship
to the location of the cutaneous adnexa. First- and sec-
ond-degree burns are considered partial-thickness.
Preservation of the hair follicles and sweat glands per-
mits spontaneous healing by epithelial cell migration.
Full-thickness (third-degree) burns will not reepithelialize
and require skin grafting for closure.
First-Degree Second-Degree Third-Degree
Cause Exposure to sunlight, very brief expo-
sure to hot liquid, flash, flame, or
chemical agent. 
Limited exposure to hot liquid, flash,
flame, or chemical agent. 
Prolonged exposure to flame, hot object, or chem-
ical agent. Contact with high-voltage electricity.
Color Red Pink or mottled red Pearly white, charred, translucent, or parchment-
like. Thrombosed vessels may be visible.
Surface Dry or very small blisters Bullae or moist, weeping surface Dry and inelastic
Sensation Painful Painful Insensate surface
Table 35–2. Characteristics of first-, second-, and third-degree burns.
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resuscitation. Failure to reevaluate the patient’s response to
resuscitation frequently on a scheduled basis may lead to
over- or underresuscitation. This is frequently observed
when the volume of fluid administered is based solely on the
initial estimate. With overzealous administration of intra-
venous fluids, pulmonary, cerebral, and excessive burn
wound edema may result. These complications are most evi-
dent from the third to sixth postburn days, when vascular
permeability has returned to “normal,” vascular resistance
has decreased, and burn wound edema is being resorbed.
Laboratory and clinical studies evaluating transcapillary
fluid movement and the physiologic response to resuscita-
tion have failed to demonstrate a benefit from the use of col-
loid-containing solutions during the first 24 hours of
resuscitation. Extravascular lung water has been shown to
remain essentially unchanged during the first postburn week
in patients who received only crystalloid-containing fluids in
the first 24 hours following injury. However, extravascular
lung water increased progressively in patients who received
colloid-containing fluids as part of the initial resuscitation.
During the latter half of the first week following injury, cap-
illary permeability normalizes and fluid requirements
decrease. As this occurs, the use of colloid-containing fluids
repletes the intravascular volume deficit more efficiently and
with a lesser volume than with crystalloid fluids alone.
The use of hypertonic saline has been proposed as a
means of reducing resuscitation fluid volume requirements.
Although the initial volume of fluid administered when
using hypertonic fluid is clearly less, the proposed benefits of
a decreased need for escharotomy, decreased incidence and
duration of ileus, and decreased fractional sodium retention
have not been found in all studies. Potential problems with
hypertonic saline resuscitation include hypernatremia,
which, if of sufficient magnitude to require infusion of hypo-
tonic fluid, negates the potential benefits of this resuscitation
strategy. The cellular dehydration induced by hypertonic
saline infusion of sufficient magnitude (15%) may cause cel-
lular and organ dysfunction necessitating correction with
hypotonic fluid administration. Subsequent evaporative
water loss from the burn wound may worsen the expected
hypernatremia from hypertonic saline resuscitation, requir-
ing additional hypotonic fluid infusion. Occasionally, some
patients with markedly reduced cardiac reserve may benefit
from resuscitation protocols employing hypertonic saline;
however, isotonic fluid resuscitation formulas provide ade-
quate resuscitation in most patients. Caution should be
Formula Electrolyte-Containing Solution Colloid-Containing Solution 5% Glucose in Water
First 24 Hours Postburn 
Parkland Lactated Ringer’s, 4 mL/kg per % burn. 
Hypertonic sodium
resuscitation 
Volume of fluid containing 250 meq of
sodium/L to maintain hourly urinary
output of 30 mL. 
Modified Brooke Lactated Ringer’s, 2 mL/kg per % burn. 
Consensus∗ Lactated Ringer’s, 2–4 mL/kg per %
burn. 
Second 24 Hours Postburn
Parkland 20–60% of calculated plasma volume. As necessary to maintain urinary
output.
Hypertonic sodium
resuscitation 
33% isotonic salt solution up to
3500 mL limit. 
Modified Brooke 0.3–0.5 mL/kg per % burn† As necessary to maintain urinary
output.
Consensus∗ 0.3–0.5 mL/kg per % burn† As necessary to maintain urinary
output.
∗American Burn Association: Advanced Burn Life Support Course. 
†Administered as a plasma equivalent (eg, 5% albumin in 0.9% sodium chloride solution.) 
Table 35–3. Commonly used resuscitation formulas.
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observed when implementing hypertonic saline resuscitation
because increases in early acute renal failure and mortality
have been reported.
Adjuvant administration of high-dose ascorbic acid dur-
ing the first 24 hours after thermal injury has been shown to
reduce the resuscitation fluid volume required significantly
during this period in burn patients. Wound edema and body
weight gain also were decreased. Infusion of ascorbic acid has
been shown to attenuate postburn lipid peroxidation as a
known antioxidant. It is uncertain as to the exact mechanism
by which vitamin C seems to confer these benefits during
burn resuscitation. Additional study of this treatment should
be performed.
The modified Brooke formula (see Table 35–3), which is
recommended by the authors, employs a physiologic salt
solution during the first 24 hours without the addition of
colloid or electrolyte-free crystalloid solutions. Lactated
Ringer’s is the preferred solution because of its more nearly
physiologic concentration of chloride ions than normal
saline. Fluid needs are estimated as 3 mL (children) or 2 mL
(adults) per kilogram body weight per percent TBSA of lac-
tated Ringer’s solution. Children have a greater body surface
area per unit of body mass and require more resuscitation
fluid than adults. One-half the calculated estimate is admin-
istered in the first 8 hours and the second half over the sub-
sequent 16 hours postburn. If initiation of fluid resuscitation
is delayed, that amount of fluid calculated to be administered
in the first 8 hours should be infused at a rate such that half
the estimated 24-hour fluid requirement will be delivered by
8 hours postburn.
In the second 24 hours following burn injury, 5% albumin
solution in physiologic saline is administered in an amount
proportional to body weight and the extent of burn to aid in
correction of the plasma volume deficit (Table 35–4). During
the second 24 hours, lactated Ringer’s infusion is stopped,
and 5% dextrose and water is delivered to maintain adequate
urine output.
Monitoring Resuscitation
The objective of fluid resuscitation following thermal injury
is maintenance of organ perfusion and function. The ade-
quacy of resuscitation may be assessed by the hemodynamic
response, the status of mental function, indicating the ade-
quacy of cerebral perfusion, and the volume of urine output,
indicating effective renal perfusion.
Patient disorientation, anxiety, and restlessness may be
early signs of hypovolemia or hypoxemia that require imme-
diate assessment and correction. Sphygmomanometric mon-
itoring of blood pressure in patients with extensive burns can
be misleading. In a burned limb—or in an unburned
extremity in which massive edema develops—Korotkoff
sounds may be progressively attenuated, falsely implying
hypoperfusion. Blood pressure measurements, even when
obtained by use of an indwelling peripheral arterial cannula,
may not reflect true hydration status because markedly ele-
vated circulating levels of catecholamines and other vasoac-
tive materials may cause severe vasospasm. A resting
tachycardia between 100 and 120 beats/min is common fol-
lowing thermal injury. Rates above this level may reflect
inadequate pain control or inadequate fluid resuscitation. A
more objective indication of the adequacy of resuscitation is
the rate of production of urine, which reflects the adequacy
of renal perfusion. In the absence of osmotically driven
diuresis, a urinary output of 30–50 mL/h indicates adequate
resuscitation in most adult patients, and 1 mL/kg per hour
indicates adequate resuscitation in patients weighing less
than 30 kg.
Routine use of flow-directed pulmonary artery catheters
during burn resuscitation is unnecessary. Even with extensive
injury, healthy young adults usually respond to fluid resusci-
tation in a predictable manner. The previously discussed
indicators of adequacy of resuscitation may be used to guide
fluid infusion rates. Fluid infusion rates should be adjusted if
the hourly urine output is below or above the desired urinary
output by more than 33% for 2 consecutive hours. Only
patients who do not respond to fluid resuscitation as
expected—or whose fluid administration in the first 6 hours
exceeds that volume which will result in a 6 mL/kg per
percent burn resuscitation—should be monitored with a
flow-directed pulmonary artery catheter. If the pulmonary
artery occlusion pressure or measurements of right ventricu-
lar end-diastolic volume indicate an adequate intravascular
volume, this type of patient may benefit from the use of a
cardiac inotropic agent to augment cardiac output.
Occasionally, patients manifest a diminished cardiac out-
put with a markedly elevated systemic vascular resistance
when pulmonary artery wedge pressures indicate adequate
fluid resuscitation. In these patients, administration of a
short-acting afterload-reducing agent may result in a
decrease in the systemic vascular resistance and an increase
in the hourly urinary output. Administration of small doses
of hydralazine (0.5 mg/kg) has been shown to be effective
when used in this manner. In animal models of burn injury,
sodium nitroprusside and verapamil administered during
the resuscitation period reduced peripheral vascular resist-
ance and increased cardiac output. This therapy should be
administered cautiously and only to patients who have
received adequate fluid loading. If used inappropriately, the
resulting vasodilation will exacerbate the hypovolemia and
further depress cardiac output and organ perfusion.
Table 35–4. Estimation of colloid replacement during
second 24 hours postburn.
30–50% burn: 0.3 mL/kg body weight per % burn
50–70% burn: 0.4 mL/kg body weight per % burn
>70% burn: 0.5 mL/kg body weight per % burn
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Excessive fluid administration during resuscitation may
result in pulmonary edema, increased need for escharotomy,
and even the need for fasciotomy in unburned limbs.
Recently, the occurrence of intraabdominal compartment
syndrome has been recognized as a complication of excessive
fluid resuscitation. An increase in intraabdominal pressure to
greater than 25 mm Hg may impair venous return and
decrease cardiac output. This is often associated with elevated
peak and mean airway pressures and high pulmonary artery
wedge and central venous pressures. It is prudent to monitor
intraabdominal pressure routinely using an indwelling blad-
der catheter in patients with extensive burns who receive fluid
volumes of more than 25% of preburn total body weight dur-
ing the resuscitation phase. More important, strict attention
to the rate of fluid administration and reduction of excessive
resuscitation fluid volumes should be emphasized.
Continuous monitoring of arterial blood pressure with
indwelling arterial cannulas is not required in uncomplicated
burn resuscitations. In patients with inhalation injury or
those who do not respond as expected to fluid resuscitation,
frequent monitoring of arterial blood gases should be per-
formed, and a distal extremity artery should be cannulated to
decrease the risk of complications associated with repetitive
arterial puncture. Femoral arterial cannulation also has a low
complication rate and may be employed if distal arterial can-
nulation is not possible.
Other measures of perfusion such as serum lactate, base
deficit, and intramucosal pH, commonly followed during
resuscitation of various shock states, may be difficult to
interpret when used to monitor burn resuscitation. An eleva-
tion of plasma lactate concentration is observed frequently in
severely burned patients and may in part reflect increased
circulating levels of catecholamines. Glucose administration
increases the rate of glucose oxidation with a subsequent
increase in plasma lactate and pyruvate concentrations fol-
lowing thermal injury. Thus caution must be used in inter-
preting elevated serum lactate levels as related to the
adequacy of burn resuscitation and systemic oxygen delivery.
Similarly, measurement of the arterial base deficit during
burn resuscitation often will yield values as low as –6 even
though other measures of resuscitation, such as urinary out-
put, are at normal levels. This may reflect a relative deficit in
systemic oxygen delivery; however, the excessive fluid admin-
istration required to reverse the base deficit will result in
complications of overresuscitation. Measurement of gastric
intramucosal PCO2 changes using a gastric tonometer may be
used to detect intestinal ischemia during burn resuscitation.
Patients with significant gastric acidosis have a mortality rate
twice that of patients without acidosis. The deaths in this
group were predominantly from multiple-organ dysfunction
occurring several weeks after injury. This suggests that intes-
tinal ischemia still may occur in some patients despite appar-
ently adequate fluid resuscitation after thermal injury,
inflicting persistent deleterious effects on distant organ func-
tion. Conversely, Venkatesh and colleagues have reported
depression of gastric mucosal pH in the presence of “nor-
mal” indices of systemic circulation and attributed this dis-
parity to selective GI vasoconstriction and the development
of tissue edema.
At the beginning of the second postburn day, when col-
loid replacement is initiated and infusion of lactated Ringer’s
solution is discontinued, the volume of 5% dextrose in water
infused per hour should be equal to 25–50% of the preced-
ing hour’s volume of lactated Ringer’s solution. If the urinary
output remains greater than 30 mL/h, that infusion rate
should be maintained for the next 3 hours, at which time the
rate of infusion of 5% dextrose in water should be further
reduced in a similar manner.
Pulmonary function must be reassessed continually
throughout the resuscitative phase. Tachypnea may indicate
metabolic acidosis from underresuscitation, hypoxemia, or
restriction of chest wall motion owing to circumferential
burns or massive edema. Evaluation must include ausculta-
tion, chest x-rays, and arterial blood gas analyses if a signifi-
cant tachypnea occurs. Thermally injured patients in the ICU
should be monitored with a pulse oximeter. In most patients,
hemoglobin saturation by arterial blood gas analysis matches
that obtained by pulse oximetry; however, patients with
severely burned digits may be difficult to monitor using this
method. In addition, a decrease in intensity of the pulsed sig-
nal detected in an extremity monitored by pulse oximetry
may reflect inadequate distal perfusion from underresuscita-
tion, constricting circumferential burn wounds, or arterial
spasm owing to high levels of circulating catecholamines.
Low oxygen saturation, as measured by pulse oximetry, also
may indicate circulating levels of carboxyhemoglobin or
methemoglobin as a consequence of the inhalation of carbon
monoxide or cyanide, respectively.
In thermally injured patients requiring endotracheal
intubation and mechanical ventilation, end-tidal CO2 moni-
toring should be used to detect early changes in ventilation
owing to inhalation injury or restriction of chest wall
motion. This method of monitoring is particularly useful in
pressure-controlled modes of mechanical ventilation. Chest
radiographs should be obtained at least daily during resusci-
tation and the period of edema absorption. Subsequent x-
rays are ordered as clinically indicated.
Serum chemistry profiles, complete blood count, arterial
blood gases, and other baseline blood studies are obtained on
admission, with further tests depending on the clinical situa-
tion. The patient’s weight should be measured on admission
and followed daily as an indicator of fluid balance.
Evaporative water loss from the wound typically peaks on
the third postburn day and persists until the burn wound is
healed or grafted. Insensible water losses may be estimated
according to the following formula:
Insensible water loss (mL/h) = (25% + % BSA
burned) × total BSA (m2)
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This formula, like the initial resuscitation formulas, is
only an estimate, and replacement of evaporative water loss
should be guided by assessing the adequacy of hydration by
monitoring the patient’s weight, serum osmolality, and
serum sodium concentrations. Following elimination of the
resuscitation-related salt and water load, salt-containing flu-
ids should be administered in the amount needed to main-
tain a normal serum sodium concentration.
Goodwin CW et al: Randomized trial of efficacy of crystalloid and
colloid resuscitation on hemodynamic response and lung water
following thermal injury. Ann Surg 1983;197:520–31. [PMID:
6342554]
Gore DC et al: Influence of glucose kinetics on plasma lactate con-
centrations and energy expenditure in severely burned patients.
J Trauma Inj Infect Crit Care 2000;49:673–8.
Gunn ML et al: Prospective randomized trial of hypertonic sodium
lactate versus lactated Ringer’s solution for burn shock resusci-
tation. J Trauma 1989;29:1261–7. [PMID: 2671402]
Huang PP et al: Hypertonic sodium resuscitation is associated with
renal failure and death. Ann Surg 1995;221:543–54. [PMID:
7748036]
Ivy ME et al: Intra-abdominal hypertension and abdominal com-
partment syndrome in burn patients. J Trauma Inj Infect Crit
Care 2000;49:387–91.
Lorente JA et al: Systemic hemodynamics, gastric intramucosal
PCO2 changes and outcome in critically ill burn patients. Crit
Care Med 2000;28:1728–35. [PMID: 10890610]
Onarheim H et al: Effectiveness of hypertonic saline–dextran 70
for initial fluid resuscitation of major burns. J Trauma
1990;30:597–603.
Pruitt BA Jr, Mason AD Jr, Moncrief JA: Hemodynamic changes in
the early postburn patient: The influence of fluid administra-
tion and of a vasodilator (hydralazine). J Trauma 1971;11:
36–46. [PMID: 5099912]
Pruitt BA Jr: Discussion of Caldwell FT and Bowser BH: Critical
evaluation of hypertonic and hypotonic solutions to resuscitate
severely burned children: A prospective study. Ann Surg
1979;189:551–2.
Tanaka H et al: Reduction of resuscitation fluid volumes in severely
burned patients using ascorbic acid administration: A random-
ized, prospective study. Arch Surg 2000;135:326–31. [PMID:
10722036]
Venkatesh B et al: Monitoring tissue oxygenation during resuscita-
tion of major burns. J Trauma 2001;50:485–94.
 Escharotomy & Fasciotomy
Edema formation beneath the inelastic eschar of circumfer-
ential full-thickness burns of the extremities may impair the
circulation to the distal and underlying tissues. To prevent
secondary ischemic necrosis of those tissues, an escharotomy
may be necessary to reduce the elevated tissue pressure. To
identify the need for escharotomy, the adequacy of circula-
tion must be assessed at no less than hourly intervals. The
most reliable determination is made with a Doppler flowme-
ter to detect pulsatile blood flow in the palmar arch, digital
vessels in the upper limbs, and pedal vessels in the lower
limbs. Absence or progressive decrease of pulsatile flow on
sequential examination is an indication for escharotomy.
Clinical indicators of impaired extremity perfusion, includ-
ing distal cyanosis, impaired capillary refilling, neurologic
deficits, and deep tissue pain, are less precise in determining
true impairment of blood flow and should be used only as
indications for escharotomy when a Doppler flowmeter is
unavailable. Fascial compartment pressure monitoring also
has been described following thermal injury. Fascial com-
partment pressures often exceed 30 mm Hg following cir-
cumferential extremity burns, and escharotomy based on
compartment pressures has been proposed. A greater sensi-
tivity of direct compartment pressure measurements in
detecting critically low-flow states and preserving threatened
tissues has not been confirmed by direct comparison with
Doppler flowmeter assessments. This technique is associated
with a risk of infection arising in the pressure cannula tract,
but the magnitude of the risk is undefined.
The escharotomy procedure may be performed in the
ICU without the use of general or local anesthesia. Since only
insensate, full-thickness burn is incised, the use of anesthetic
agents is unnecessary. The first escharotomy incision is
placed in the midlateral line of the involved extremity. If this
does not improve distal blood flow, a second escharotomy
incision is made in the mid-medial line of that limb
(Figure 35–4). The escharotomy incision should be per-
formed along the entire length of the full-thickness burn to
 Figure 35–4. The dashed lines show the preferred
sites for escharotomy incisions. The solid segments of
the lines demonstrate the importance of extending the
incisions across joints with full-thickness burns.
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ensure adequate release of vascular and neural compression.
The incision must cross involved joints because the relative
lack of subcutaneous tissue in these areas permits ready com-
pression of vessels and nerves. The escharotomy incision
should only penetrate the eschar and immediately subjacent
thin connective tissue to permit expansion of the edematous
subcutis. When performed at this level, loss of blood from
the escharotomy incision is minimal and readily controlled
by electrocoagulation or application of pressure. When inci-
sions are carried into the subcutaneous tissues, excessive
bleeding often occurs. The consumptive coagulopathy that
may occur in the early postburn period may contribute to
excessive blood loss when escharotomy incisions are made
too deep.
Fasciotomy is rarely required to restore circulation in a
thermally injured limb. However, in patients with high-
voltage electrical injury, fasciotomy is often necessary.
Patients with very deep burns involving fascia and muscle or
patients with associated traumatic injuries may require
fasciotomies to restore adequate limb circulation.
Escharotomies also may be required in patients with cir-
cumferential truncal burns to relieve restriction of chest wall
movement by the unyielding eschar and restore more effec-
tive ventilation. The escharotomy incision is made in the
anterior axillary line in the area of full-thickness burn. An
incision along the lower margin of the rib cage may be nec-
essary in patients with deep burns extending onto the upper
abdominal wall (see Figure 35–4). Patients may become rest-
less, agitated, and tachypneic despite having an adequate air-
way, indicating the need for chest escharotomy. In
mechanically ventilated patients, the need for escharotomy is
manifested by a progressive increase in peak inspiratory pres-
sure, decreased tidal volumes in pressure-controlled ventila-
tion, and an increase in the end-tidal CO2 fraction. Once
chest escharotomy is performed, these changes promptly
revert toward normal.
Saffle JR, Zeluff GR, Warden GD: Intramuscular pressure in the
burned arm: Measurement and response to escharotomy. Am J
Surg 1980;140:825–31. [PMID: 7457708]
CARE OF THE BURN WOUND
 Debridement
Only after respiratory and hemodynamic stability have been
achieved should care of the burn wound be addressed.
During transport of the patient from the accident scene or
from the initial care facility to a burn center, the burns
should be covered with clean sheets or blankets and no
attempt made to debride or dress them. In the absence of
gross contamination, burn wounds may be managed safely
without topical antimicrobial agents for the first 24–48
hours. When the patient arrives at the definitive care facility,
general anesthesia is not necessary for initial burn wound
debridement; intravenous analgesia is sufficient for pain
control during this procedure. The burns are gently cleansed
with a surgical soap solution, and nonviable epidermis is
debrided. Bullae are excised, and body hair is shaved from
the area of thermal injury beyond the margin of normal skin.
The patient is placed in a clean bed, and bulky dressings may
be placed beneath the burned parts to absorb the serous exu-
date. These dressings should be changed as they become sat-
urated. Patients should be turned frequently to prevent
maceration of burned and unburned skin.
 Topical Antimicrobial Therapy
The development and clinical use of effective topical antimi-
crobial agents has decreased the incidence of invasive burn
wound infection and subsequent sepsis significantly. This has
been associated with improved survival of burn patients and
nearly eliminated invasive bacterial burn wound infection as
a cause of death. Mafenide (Sulfamylon), silver sulfadiazine
(Silvadene), and silver nitrate are the three topical antimicro-
bial agents employed most commonly for burn wound care.
Each agent has specific advantages and limitations with
which the physician must be familiar to ensure optimal ben-
efit and patient safety. Mafenide acetate and silver sulfadi-
azine are available as topical creams to be applied directly to
the burn wound. Silver nitrate is applied as a 0.5% solution
in occlusive dressings.
Mafenide burn cream is an 8.5% by weight suspension of
mafenide acetate in a water-soluble base. Mafenide is very
water-soluble and diffuses freely into the eschar. Mafenide is
the preferred agent if the patient has heavily contaminated
burn wounds or has had burn wound care delayed by several
days. Mafenide has the added advantage of being highly
effective against gram-negative organisms. The limitations of
mafenide burn cream include hypersensitivity reactions in
7% of patients, pain or discomfort of 20–30 minutes’ dura-
tion when applied to partial-thickness burns, and carbonic
anhydrase inhibition. The latter may produce an early bicar-
bonate diuresis and increase postburn hyperventilation.
This metabolic acidosis may develop into significant
acidemia if respiratory complications occur and the com-
pensatory hyperventilation is impaired. Carbonic anhydrase
inhibition rarely persists for more than 7–10 days, and the
severity of acidosis can be minimized if mafenide is applied
once per day followed by an application of silver sulfadiazine
cream 12 hours later.
Silver sulfadiazine burn cream is a 1% suspension of sil-
ver sulfadiazine in a water-miscible base. Unlike mafenide
acetate, silver sulfadiazine has limited solubility in water and
thus limited penetration into the eschar. The agent is most
effective when applied to burns immediately after injury to
minimize bacterial proliferation on the wound’s surface. This
agent has the advantage of being painless on application and
has no effect on serum electrolytes or acid-base balance.
Silver sulfadiazine burn cream may induce neutropenia,
which usually subsides after discontinuation of the agent.
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Hypersensitivity is uncommon and is manifested by an ery-
thematous maculopapular rash on unburned skin. The sulfa-
diazine component of silver sulfadiazine is ineffective against
certain strains of Pseudomonas and virtually all Enterobacter
species; however, the sensitivity of microorganisms coloniz-
ing burn wounds to the silver ion of this compound main-
tains its effectiveness as a topical antimicrobial agent.
Either cream is applied in an 1/8-inch layer to the entire
burn wound in an aseptic manner following initial debride-
ment and is reapplied at 12-hour intervals to ensure contin-
uous topical chemotherapy. Once each day, all the topical
agent should be cleansed from the patient using a surgical
detergent or disinfectant solution and the wounds inspected
by the attending physician.
Silver nitrate solution (0.5%) delivered in multilayered
occlusive gauze dressings may provide an effective antimicro-
bial barrier to the burn wound surface. This agent is employed
most commonly when a history of allergy to sulfonamide
drugs is elicited or when the patient develops a hypersensitiv-
ity reaction to one of the burn creams. The dressings are
changed two or three times daily and moistened every 2 hours
to prevent evaporation from increasing the silver nitrate con-
centration to cytotoxic levels within the dressings. Transeschar
leaching of sodium, potassium, chloride, and calcium should
be anticipated and replaced appropriately. Because silver
nitrate precipitates on contact with the proteinaceous exudate
of the burn wound and does not penetrate the eschar, it is not
effective for treatment of burn wound infection or for prophy-
lactic treatment of heavily contaminated wounds. A common
use of silver nitrate is for topical antimicrobial prophylaxis in
patients with toxic epidermal necrolysis syndrome, a disorder
caused by idiosyncratic drug reactions resulting in significant
epidermal sloughing. Hypersensitivity to silver nitrate has not
been described.
Acticoat is a new burn wound dressing. It consists of a
urethane film onto which nanocrystalline elemental silver is
deposited. When moistened, application of this dressing to
the wound results in a sustained release of elemental silver,
which is bactericidal and fungicidal. The mechanism of
action is probably much like that of silver nitrate dressings;
however, Acticoat does not cause transeschar leaching of
electrolytes. The silver does not penetrate the eschar, limiting
its use on infected or heavily contaminated wounds.
Transient mild pain may be noted occasionally after applica-
tion. The use of Acticoat is currently limited to partial-thick-
ness burns.
Aquacel Ag hydrofiber (ConvaTec, a Bristol-Myers Squibb
Company, Skillman, NJ) is another dressing containing ele-
mental silver, although at a much lower concentration. When
compared with silver sulfadiazine on partial-thickness burns,
this dressing was associated with an increased rate of reep-
ithelization and was a slightly more cost-effective. This study
was limited owing to sample size; however, the replacement
of burn cream pharmaceuticals with silver-containing bar-
rier dressings is occurring in certain settings, namely, those
of superficial burns.
All these agents are effective in the prevention of inva-
sive burn wound infection. However, because of their lack
of eschar penetration, silver nitrate soaks and silver sulfa-
diazine burn cream are most effective in the treatment of
full-thickness burns when applied immediately following
burn injury.
 Burn Wound Infection (See Figure 35–5)
ESSENT IALS  OF  D IAGNOS I S
 Hypo- or hyperthermia.
 Tachycardia and tachypnea.
 Glucose intolerance.
 Disorientation.
 Ileus.
 Change in appearance of the burn wound.
General Considerations
Inherent characteristics of the microorganisms and the burn
wound they colonize influence the rate of microbial penetra-
tion of and proliferation in the eschar. The moist, protein-
rich, avascular eschar serves as an excellent culture medium
from which white blood cells and systemically administered
antibiotics are excluded. The density of bacterial coloniza-
tion of the eschar influences the likelihood of burn wound
infection. Bacterial invasion is uncommon unless the num-
ber of microorganisms exceeds 105 per gram of tissue.
Bacterial strain–specific factors such as enzyme production
 Figure 35–5. The frequency of infection by site
expressed as a percentage of all infections complicating
thermal injury.
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(eg, collagenase, protease, etc.), bacterial motility, and antibi-
otic resistance may be important in the pathogenesis of
eschar penetration and invasion of viable tissues.
Although the use of topical chemotherapeutic agents and
the timely excision and grafting of the burn wound have
decreased the incidence of invasive burn wound infection in
most U.S. burn centers, this problem has not been eliminated
entirely. Invasive burn wound infection is uncommon in sec-
ond-degree burns and in patients with burns of less than
30% of the body surface. Extremes of age and increasing size
of burn strongly influence the risk of developing invasive
burn wound infection.
Clinical Features
A. Symptoms and Signs—Clinical signs of invasive burn
wound infection are often indistinguishable from those
observed in uninfected hypermetabolic burn patients or
burn patients with other sources of sepsis and include
hyper- or hypothermia, tachycardia, tachypnea, ileus, glu-
cose intolerance, and disorientation. Tinctorial and physical
changes in the appearance of the burn wound are more reli-
able signs of invasive burn wound infection (Table 35–5).
The development of clinical signs and symptoms of sepsis in
the thermally injured patient should prompt a thorough
examination of the burn wound to identify areas suspicious
for invasive infection.
B. Laboratory Findings—Surface cultures of the eschar can-
not distinguish colonization from invasive infection.
Quantitative bacteriologic cultures of burn wound tissue
correlate poorly with the presence of invasive burn wound
infection. Quantitative bacteriologic counts less than 105 per
gram of biopsy tissue correlate with absence of invasive burn
wound infection; however, even when quantitative counts
exceed 105 organisms per gram of biopsy tissue, histologic
examination confirms invasive infection in less than half of
biopsy specimens.
Histologic examination of a biopsy of the burn wound
and underlying viable tissue is the most rapid and reliable
method for differentiating microbial colonization of nonvi-
able eschar from microbial invasion of viable subeschar tis-
sue. The latter defines invasive burn wound infection. A burn
wound biopsy is performed as an ICU procedure. A 500-mg
elliptical biopsy (0.5 × 1.0 cm) including subjacent unburned
tissue is obtained by scalpel dissection from the area of the
burn wound identified as suspicious for infection. Hemostasis
is achieved by application of direct pressure or by electroco-
agulation. Half the specimen is cultured for organism identi-
fication and antibiotic sensitivities, and the other half is
submitted for histologic analysis. The presence of microor-
ganisms in viable tissue confirms the diagnosis of invasive
burn wound infection. The histologic staging scheme for
burn wound colonization and infection is presented in
Table 35–6. If only colonization (stage 1A to stage 1C) is pres-
ent, no specific change in antimicrobial therapy is indicated
unless serially obtained specimens document a progression of
colonization stage. If stage 2 (invasion) is reported, prompt
treatment for invasive burn wound infection should begin.
Treatment
When the diagnosis of invasive burn wound infection is
made, local and systemic antimicrobial therapy is initiated.
In the case of bacterial burn wound invasion, topical
chemotherapy should be in the form of twice-daily applica-
tions of mafenide acetate because of its superior eschar pen-
etration. Systemic antibiotic therapy is initiated based on
prior surface cultures or burn center organism prevalence.
Further refinements in therapy are based on biopsy, culture,
and sensitivity results. Customary critical care supportive
measures are employed to maintain hemodynamic and res-
piratory stability. Subeschar antibiotic clysis of the infected
area with a broad-spectrum penicillin is recommended at
12 hours and immediately prior to operation to minimize
the risk of hematogenous seeding and florid septic shock at
the time of eschar excision. Half the daily dose of a broad-
spectrum penicillin (eg, piperacillin or ticarcillin) delivered
in 1 L of normal saline is infused into the subeschar tissues
by means of a no. 20 spinal needle. Excision of the burn
wound to the level of the investing fascia is employed to
ensure removal of all nonviable tissue. The wound is usually
treated with moist dressings of 5% mafenide acetate, 0.5%
silver nitrate, or a biologic dressing. The patient is returned
to the operating room in 24–48 hours for wound inspection
and redebridement or split-thickness skin grafting as needed.
Stage I: Colonization
A. Superficial: Sparse microbial population on burn wound surface.
B. Penetration: Microorganisms present in variable thickness of eschar.
C. Proliferation: Dense population of microorganisms at interface of
nonviable and viable tissue.
Stage II: Invasion
A. Microinvasion: Microscopic foci of microorganisms in viable tissue
immediately subjacent to subeschar space.
B. Generalized: Widespread penetration of microorganisms deep into
viable subcutaneous tissues.
C. Microvascular: Involvement of lymphatics and microvasculature.
Table 35–6. Histologic staging of burn wound infection.
Table 35–5. Clinical signs of burn wound infection.
Conversion of second-degree burn to full-thickness necrosis
Focal dark brown or black discoloration of wound
Degeneration of wound with “neoeschar” formation
Unexpectedly rapid eschar separation
Hemorrhagic discoloration of subeschar fat
Erythematous or violaceous, edematous wound margin
Metastatic septic lesions in unburned tissue
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In addition to bacteria, fungi and yeasts also cause inva-
sive burn wound infection and have become the predomi-
nant organisms causing burn wound infection because
topical therapy and early excision have reduced the incidence
of bacterial infection. Candida species commonly colonize
wounds but rarely cause invasive burn wound infection.
Aspergillus, the most common filamentous fungus that
causes invasive burn wound infection, usually remains con-
fined to subcutaneous tissues and seldom transverses fascial
planes. Wounds colonized by Candida or Aspergillus can be
treated with topical application of clotrimazole, but histo-
logic evidence of invasion requires surgical burn wound exci-
sion and initiation of systemic amphotericin B therapy. The
Phycomycetes often behave in a manner similar to
Aspergillus; however, these organisms may spread rapidly
along tissue plains, invade blood vessels, and penetrate fascia.
Aggressive wide debridement, including amputation, may be
necessary to control these infections.
Becker WK et al: Fungal burn wound infection: A 10-year experi-
ence. Arch Surg 1991;126:44–8. [PMID: 1985634]
McManus AT: Pseudomonas aeruginosa: A controlled burn
pathogen? Antibiot Chemother 1989;42:103–8. [PMID: 2512832]
McManus WF, Goodwin CW Jr, Pruitt BA Jr: Subeschar treatment
of burn-wound infection. Arch Surg 1983;118:291–4. [PMID:
6824429]
Pruitt BA Jr: The diagnosis and treatment of infection in the burn
patient. Burns Incl Ther Inj 1984;11:79–91. [PMID: 6525539]
Waymack J, Pruitt BA Jr: Burn wound care. Adv Surg 1990;23:
261–89. [PMID: 2403460] 
 Burn Wound Excision & Grafting
Technique
The current operative management of burns employs tan-
gential excision of eschar to viable dermis or fat and scalpel
excision to the level of the investing fascia for burn wound
removal. Burn wound excision may be performed early in
the postburn course once the patient is hemodynamically
stable and resuscitation is complete.
The operative procedure should be limited to excision of
20% of the body surface area, an area of excision producing
a blood loss equal to the patient’s blood volume, or 2 hours
of operative time. Careful anesthetic management is impera-
tive to avoid hypotension and hypothermia. Hypotension
may impair blood flow to areas of second-degree burn,
resulting in ischemia of the wound and conversion to full-
thickness injury. The depth of excision in tangential and
sequential burn wound removal is governed by the appear-
ance of healthy tissue and punctate bleeding from dermal
beds. Scalpel excision of burns involves removal of the
wound and underlying subcutaneous tissue to the level of the
investing muscle fascia. This may be accomplished more rap-
idly and with significantly less blood loss than tangential or
sequential wound excisions. Once a viable wound surface is
obtained, wound coverage is accomplished with autograft or
biologic dressings.
Conventional skin grafting is achieved with cutaneous
autografts 0.008–0.012 inches thick. These grafts may be
employed as a sheet graft or meshed to provide expansion
ratios ranging from 1.5:1 to 9:1. Expansion ratios of 4:1 or
greater require a prolonged time for interstitial closure, have a
greater propensity for scar formation, and are used only in
patients with massive burns and limited donor sites. Following
grafting, occlusive dressings moistened with topical antibiotic
agents are applied. The wounds are kept moist to prevent des-
iccation until the interstices of the graft have epithelialized.
Skin Substitutes and Biologic Dressings
In massively burned patients, the disparity between donor-
site area and burn-wound area requires the use of temporary
skin substitutes or biologic dressings to effect wound closure
while awaiting donor-site availability. Biologic dressings pre-
vent desiccation of the wound bed, decrease protein and
fluid losses, promote angiogenesis of granulation tissue, and
reduce pain. Viable cadaver allograft currently provides the
best temporary wound coverage. Allograft becomes vascular-
ized from the underlying wound bed and usually remains
adherent until surgically excised or immunologically rejected
by the patient. As a result of the immunosuppression associ-
ated with thermal injury, the allograft may remain intact,
vascularized, and viable for several weeks following applica-
tion. The same theoretical risks of disease transmission (eg,
hepatitis, HIV infection, etc.) associated with organ donation
apply to the use of cadaveric allografts. Appropriate tissue
banking measures are imperative. In addition to fresh
cadaver allograft, frozen and lyophilized allograft is available
from many sources.
Porcine xenograft is also available as a fresh, frozen, or
lyophilized preparation. Advantages include an abundant
supply and lower cost. This biologic dressing, however, does
not become vascularized and adheres to the wound bed by
fibrin bonding. The underside of the graft is nourished by
the plasma circulation, and desiccation and necrosis of the
outer surface usually occur within 1 week. Application of
porcine cutaneous xenografts to superficial partial-thickness
wounds facilitates healing and decreases pain. Porcine
xenografts are of limited usefulness in the coverage of excised
wounds because of their lack of vascularization and the lim-
ited time until desiccation and necrosis occur.
Several synthetic skin substitutes have been developed in
an attempt to avoid the problems of disease transmission and
storage requirements common to biologic dressings. The
most successful materials have been of a bilaminated config-
uration with an outer layer mimicking epidermis that allows
water vapor transmission and prevents bacterial contamina-
tion. The inner dermal layer is designed to promote adher-
ence and fibrovascular ingrowth from the wound bed.
Biobrane is currently the most commonly used synthetic skin
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substitute. The epidermal layer is composed of pliable Silastic,
and the dermal component is derived from porcine collagen.
This product is available with a variety of pore sizes, and its
elastic nature allows freedom of motion and is well adapted to
body contours. Biobrane promotes healing of second-degree
burns and usually provides adequate short-term coverage for
excised wounds, although submembrane suppuration and
lack of adherence cause difficulties. Integra is a synthetic der-
mal substitute that is unique in that a neodermis is formed by
fibrovascular ingrowth into a glycosaminoglycan matrix der-
mal analogue. The epidermal component is Silastic and is
removed once the dermal analogue is vascularized, allowing
definitive closure of the wound with ultrathin split-thickness
autografts. This permits more rapid healing of donor sites for
repeated autograft harvesting. Incomplete adherence, sub-
membrane suppuration, and technical problems with the
application of ultrathin autografts have been observed.
TransCyte is a bilaminated biosynthetic skin substitute
used as a temporary dressing on second-degree burns or
excised full-thickness burns. This product is composed of
Biobrane on which human foreskin-derived neonatal dermal
fibroblasts are seeded and grown to confluence in culture.
The fibroblasts secrete matrix proteins and growth factors
that remain active after the product is frozen. Application of
TransCyte to the wound surface is similar to that of
Biobrane. It also carries the same limitations.
The availability of commercial laboratories capable of
carrying out skin culture techniques has led to the recent
evaluation of cultured autologous keratinocytes for coverage
of wounds in massively burned patients. Current culture
techniques require 3 or more weeks of preparation for a
product six to eight epidermal cells in thickness. These grafts
are quite fragile and susceptible to bacterial colonization of
the recipient wound bed and minimal shear forces. The use
of cultured autologous keratinocytes to effect wound closure
in massively burned patients was studied recently. In a series
of 16 patients with an average burn size greater than 60% of
BSA, definitive final engraftment covered only 4.7% of the
body surface area at a cost of over $9000 per percent of BSA
closed. Wound bed microbial colonization, lack of dermal
elements, and patient age may be significant factors relating
to the failure of culture-derived cells as a definitive form of
burn wound coverage. This technology has the potential for
providing timely coverage of large surface areas but is
presently limited by the aforementioned problems.
Caruso DM et al: Randomized clinical study of Hydrofiber dressing
with silver or silver sulfadiazine in the management of partial-
thickness burns. Burn Care Res 2006;27:298–309. [PMID:
16679897]
Hansbrough JF: Current status of skin replacements for coverage
of extensive burn wounds. J Trauma 1990;30:S155–60. [PMID:
2254975]
Hansbrough JF et al: Burn wound closure with cultured autolo-
gous keratinocytes and fibroblasts attached to a collagen-
glycosaminoglycan substrate. JAMA 1989;262:2125–30.
Heimbach D et al: Artificial dermis for major burns: A multicenter
randomized clinical trial. Ann Surg 1988;208:313–20.
Pruitt BA Jr, Levine NS: Characteristics and uses of biologic dress-
ings and skin substitutes. Arch Surg 1984;119:312–22. [PMID:
6365034]
Pruitt BA Jr, McManus WF, McDougal WS: Surgical management
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 Inhalation Injury
ESSENT IALS  OF  D IAGNOS I S
 Facial burns.
 Intraoral burns or carbonaceous sputum.
 Edema, erythema, mucosal ulcerations on laryngoscopy.
 Increased 133Xe retention.
 Decreased Pao2 and expiratory flow rates.
General Considerations
Pulmonary injury from smoke inhalation is frequently
observed in patients with thermal injury who require admis-
sion to a burn center. In a recent series, 33% of patients had
concomitant inhalation injury. The injury caused by the
inhalation of smoke or toxic gases may include chemical
damage to the respiratory system, carbon monoxide toxicity,
and infrequently, direct thermal injury to the tracheo-
bronchial tree. Patients most likely to have inhalation injury
are those with burns sustained in a closed space and those
who were burned during a period of depressed conscious-
ness secondary to head trauma or drug intoxication.
Direct thermal injury to the airway is encountered rarely
in patients who survive a fire and are hospitalized for treat-
ment. However, autopsy series of patients dying at the scene
of a fire frequently reveal devastating direct thermal injury to
the airways. The effective cooling capabilities of the
nasopharynx and oropharynx prevent significant heat expo-
sure of the lower respiratory system; however, direct thermal
injury to the supraglottic airway does occur and may lead to
upper airway obstruction. An exception is burns caused by
exposure to steam because water has a heat-carrying capac-
ity 4000 times greater than that of air.
Smoke inhalation—particularly when the injury occurred
in a closed space—may be associated with carbon monoxide
poisoning, which may impair tissue oxygenation. The pres-
ence of carboxyhemoglobin or the chemical alteration of the
cytochrome system by carbon monoxide does not affect the
amount of dissolved oxygen in the blood; thus the PaO2 will
remain normal. However, saturation of hemoglobin by oxy-
gen may be markedly reduced, impairing oxygen delivery.
The inhalation of smoke (incomplete products of combus-
tion) is manifest by deleterious effects on both the airway and
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the pulmonary vasculature. The anatomic location of pul-
monary injury depends on the size of the inhaled particle.
When the particle diameter is less than 0.05 μm, the larger,
endoscopically visible airways may appear normal in the pres-
ence of severe alveolar and terminal bronchiolar inflammatory
damage. Alternatively, the larger airways may be severely
inflamed, leading to mucosal ulceration or necrosis in the pres-
ence of relatively normal gas exchange and alveolar function.
In various animal models of inhalation injury, increased
pulmonary microvascular permeability and peribronchial
edema have been reproduced. Thromboxane A2 levels have
been found to increase within 5 minutes of inhalation injury,
with levels correlating with increases in lung lymph flow and
extravascular lung water. The role of the neutrophil in the
pathophysiology of smoke inhalation is currently under
investigation. Both the preinjury induction of a neutropenic
state by administration of mechlorethamine and postinjury
treatment with pentoxifylline have been reported to attenu-
ate pulmonary artery hypertension, reduce pulmonary vas-
cular resistance, and decrease the severity of pulmonary
insufficiency following smoke exposure in animals. Although
alterations in surfactant function have been described fol-
lowing smoke inhalation, surfactant replacement has not
been shown to improve pulmonary function in animal mod-
els of inhalation injury.
Clinical Features
A. Symptoms and Signs—Smoke inhalation should be sus-
pected in patients with facial burns, singed facial hair and
nasal fibrissae, intraoral burns or carbonaceous deposits in the
oropharynx, or a history of being burned in a closed space.
B. Bronchoscopy—The diagnosis of inhalation injury is
made by examination of the upper airway and tracheo-
bronchial tree by fiberoptic bronchoscopy. Direct laryn-
goscopy also may be used to visualize the upper airway. The
presence of carbonaceous material, edema, erythema, or
mucosal ulcerations below the vocal cords confirms the diag-
nosis. An endotracheal tube of appropriate size should be
placed over the fiberoptic bronchoscope before the examina-
tion so that intubation may be readily achieved if the appear-
ance of upper airway edema threatens airway patency.
False-negative bronchoscopic examinations occur occasion-
ally and usually are secondary to the failure to observe
inflammation and erythema in the hypovolemic patient with
impaired tracheal mucosa perfusion.
C. Radionuclide Studies—133Xe ventilation-perfusion lung
scans may be performed in patients in whom the clinical sus-
picion of inhalation injury is high yet the bronchoscopic
examination appears relatively normal. After intravenous
injection of 10 μCi of 133Xe, serial chest scintigraphs are
obtained. Retention of the gas in the lungs for over 90 seconds
following injection or an unequal distribution of radiation
density is considered diagnostic of inhalation injury. The false-
negative and false-positive rates from this study are 5% and 8%,
respectively. False-negatives result from marked hyperventila-
tion and false-positives from preexisting chronic obstructive
pulmonary disease (COPD), bronchitis, or atelectasis.
D. Respiratory Function Studies—Measurements of pul-
monary function also may be helpful in establishing the
diagnosis of inhalation injury. Burn patients with inhalation
injury may have a decreased PaCO2 and peak expiratory flow
and an increased ventilation-perfusion gradient, airway
resistance, and nitrogen washout slope. Static and dynamic
compliance tends to be normal in the early phase of inhala-
tion injury. The complexity of some pulmonary function
tests and the requirement for full patient cooperation often
limit their clinical usefulness as aids to the early diagnosis of
inhalation injury.
The diagnosis of inhalation injury can be made with 96%
accuracy when the results of fiberoptic bronchoscopy, venti-
lation-perfusion scanning, and pulmonary function testing
are combined. Overdiagnosis of inhalation injury accounts
for the 4% error.
Treatment
A. General Measures—The current treatment of inhalation
injury is primarily supportive because no specific agent has
been identified that minimizes the severity of the insult. The
aim of treatment, therefore, is to correct the underlying pul-
monary insufficiency while minimizing further iatrogenic
pulmonary insults. The amount of intervention required is
guided by the severity of pulmonary insufficiency.
B. Respiratory Support—Patients with mild disease require
only administration of humidified oxygen-enriched air (usu-
ally 40%) and noninvasive pulmonary physiotherapy. Severe
injury may require maximal mechanical ventilatory support
and frequent flexible fiberoptic or rigid bronchoscopy to
clear the airways of sloughed mucosal debris and secretions.
Small-airways disease may produce significant atelectasis
requiring increased oxygen administration and institution of
positive end-expiratory pressure. Systemic administration of
steroids has not decreased morbidity or mortality rates in
patients with inhalation injury, and such treatment has been
reported to increase infectious complications.
A recent clinical trial of the prophylactic use of high-fre-
quency percussive ventilation in patients with inhalation
injury demonstrated significant improvements in morbid-
ity and mortality rates compared with conventional volume
ventilation. Fifty-four burn patients with documented
inhalation injury were managed by this type of ventilation
within 24 hours of intubation. Fourteen patients (25.9%)
developed pneumonia, compared with a predicted histori-
cal frequency of 45.8%. The observed mortality rate was
18.5% compared with a historical frequency of 35%. Only
4 of the 10 deaths were attributable to pulmonary failure.
Although the exact mechanism by which high-frequency
percussive ventilation improves outcome is not known, the
ability to maintain ventilation and oxygenation at lower peak
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airway pressures and inspired oxygen concentrations may
reduce the iatrogenic injury associated with the use of
volume-controlled ventilators. The high frequency percussive
breaths also improve clearance of secretions—similar to results
obtained with high-frequency oscillators and jet ventilators.
C. Antimicrobial Therapy—Bronchopneumonia is the most
common cause of morbidity and death in patients with
inhalation injury. The daily chest roentgenograph should be
examined carefully. Appropriate antimicrobial therapy is ini-
tiated based on the presence of pulmonary infiltrates and
sputum leukocytosis. Pneumonia occurring after inhalation
injury usually is caused by gram-positive organisms. Gram-
negative pneumonias, which now occur infrequently, usually
develop later in the hospital course. Therapy is initiated
based on the results of the sputum Gram stain, with refine-
ments of antibiotic choice depending on endobronchial cul-
ture and microbial sensitivity testing.
Prognosis
Smoke inhalation, in the absence of cutaneous thermal
injury, is almost always treated successfully by supportive
measures. The tracheobronchial mucosa typically heals com-
pletely in 2–3 weeks. However, when smoke inhalation
occurs in the presence of moderate to severe cutaneous burn,
mortality rates are increased by as much as 20% over those
predicted by the age of the patient and the extent of injury.
When pneumonia complicates inhalation, the mortality rate
may rise to 60% above the predicted level.
Cioffi WG et al: High-frequency percussive ventilation in patients
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tilation in patients with inhalation injury. Ann Surg
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Huang Y, Li A, Yang Z: Effect of smoke inhalation injury on throm-
boxane levels and platelet counts. Burns Incl Therm Inj
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POSTRESUSCITATION PERIOD
 Prevention & Treatment of Complications
1. Infection Control
Infectious complications always have been the predominant
determinant of outcome in thermally injured patients.
Improved care of critically ill patients and the control of
burn wound sepsis through effective topical antimicrobial
agents and timely excision and grafting have resulted in the
salvage of more burn patients who previously would have
died in the early postburn period. The hospital course of
nonsurvivors also has been prolonged. Since infection con-
tinues as the leading cause of morbidity and death in burn
patients, prolonged hospitalization increases the risk of col-
onization and infection by nosocomial organisms that are
predominantly true fungi, yeasts, and multiply-antibiotic-
resistant bacteria.
A strict infection control program can minimize the clin-
ical impact of exposure to nosocomial pathogens during a
prolonged hospital stay in an immunocompromised patient.
Such a program might employ scheduled microbial surveil-
lance, an actively functioning infection control committee,
environmental monitoring procedures, biopsy monitoring of
the burn wound, and cohort patient care as deemed neces-
sary. The surveillance program includes thrice-weekly cul-
tures of sputum and the burn wound surface and
twice-weekly culturing of urine and stool. Multiple antibiotic
sensitivities are determined for all staphylococci as well as all
Pseudomonas species and other gram-negative organisms
recovered from routine cultures. Reports are provided on a
daily basis, enabling initial empirical selection of antibiotics
to be made more precisely should an infection be diagnosed.
Cohort patient care is initiated if a patient is admitted
and found to be colonized or infected with an organism of
broad antibiotic resistance or if this resistance pattern devel-
ops during broad-spectrum antibiotic therapy.
Cross-contamination is minimized by strict enforce-
ment of hand washing, gowning, and gloving policies. The
establishment of patient care teams to provide care for
only one specific patient or a limited number of patients
and restriction of the traffic of convalescing patients (often
colonized with resistant organisms) are imperative in
reducing cross-contamination and eradicating endemic
microorganisms.
The infection control committee monitors infections
occurring in the burn unit to identify changes in microbial
prevalence, the incidence of infection, and evidence of cross-
contamination. Strict criteria for the definition and identifi-
cation of infections that occur in burn patients are necessary
to avoid unnecessary and inappropriate antibiotic adminis-
tration. Antibiotics are used only for specific indications to
minimize the emergence of microbial resistance. Effective
infection control policies require continual reevaluation of
surveillance culture results and correlation with the sites and
treatment of infections.
2. Infectious Complications: Prevention,
Diagnosis, & Treatment
With the decrease in fatal burn wound sepsis and improved
survival of patients with massive burns, infections in other
sites have shown a relative increase as principal causes of
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death. Dense bacterial colonization of the burn wound and
the presence of immunosuppression associated with burn
injury increase the likelihood of development of infectious
complications.
Pneumonia
Pneumonia is the most frequent septic complication follow-
ing thermal injury. As the occurrence of invasive burn
wound infection has decreased, bronchopneumonia has
surpassed hematogenous pneumonia as the predominant
form. The increase in airborne pneumonia also may be
attributable to improved survival in patients with severe
inhalation injury. Atelectasis is often present prior to the
development of infection. The appearance of an ill-defined
irregular infiltrate on chest x-ray mandates Gram stain, cul-
ture, and sensitivity testing of endobronchial secretions.
Empirical antibiotic treatment is begun as determined by
microbiologic surveillance and Gram stain of the secretions.
Subsequent antibiotic therapy is adjusted on the basis of
sensitivity testing.
Compared with bronchopneumonia, hematogenous
pneumonia usually occurs later in the hospital course.
Remote septic foci such as invasive wound infection,
endocarditis, and suppurative thrombophlebitis are com-
mon causes. The radiographic hallmark is a solitary nodu-
lar pulmonary infiltrate, but progression to multiple
nodular infiltrates throughout the lungs may occur. All
possible sites of infection must be evaluated if a character-
istic nodular pulmonary infiltrate appears. The primary
infection must be identified and treated. The pneumonic
process is treated by systemic administration of antibi-
otics directed against the causative organism and ventila-
tory support as needed. Aggressive pulmonary toilet
to prevent atelectasis may help to decrease the occurrence
of pneumonia, although most routine measures have little
proved benefit.
Suppurative Thrombophlebitis
The loss of skin integrity, the presence of dense bacterial col-
onization of the burn wound, and the frequent need for
long-term venous access increase the likelihood that suppu-
rative thrombophlebitis will develop in burn patients.
Limiting the duration of cannulation of a vein to 3 days or
less in patients with thermal injury has reduced the inci-
dence of this complication from 4.3% to less than 1.4% in
recent years. Local signs of thrombophlebitis are present in
less than half of patients with this complication because of
the presence of the overlying burn wound and the systemic
immunosuppression accompanying burn injury. With the
increased use of central venous cannulation, these patients
are also at risk for development of central vein suppurative
thrombophlebitis.
The diagnosis of peripheral vein suppurative throm-
bophlebitis is made by operative exploration, excision, histologic
analysis, and culture of the suspected phlebitic vein.
Identification of bacteria within the vein necessitates excision
of the entire length of involved vein to a level of patent normal
vein and the administration of systemic antibiotics to which
the causative microorganism is sensitive. The diagnosis of cen-
tral venous thrombophlebitis is more difficult. Indium-
111–labeled leukocyte scanning, CT scanning, and contrast
venography may help to establish the diagnosis. This rare com-
plication is treated with systemic antibiotics directed against
the organism isolated by blood culture and anticoagulation
with heparin. The efficacy of thrombolytic therapy in the treat-
ment of central venous thrombosis is unclear. The failure of
antibiotics and anticoagulation to eradicate the infectious focus
mandates surgical exploration and vein excision.
The true incidence of intravascular catheter–related bac-
teremia in thermally injured patients is unknown. Vascular
access through a densely colonized wound in those with
extensive surface area burns limits the use and effectiveness
of standard catheter care policies employed for other criti-
cally ill patients. Presumably, as a result of contamination by
removal through colonized eschar and skin, catheter tip cul-
tures frequently are positive even in the absence of sepsis or
bacteremia. Exchanging catheters over guidewires, an
accepted practice in most ICUs, is discouraged because the
catheters and guidewires often transverse heavily contami-
nated open wounds or intact eschar. Consequently, central
venous and pulmonary artery catheters are removed and a
new catheter inserted at a different site every 3 days. This pol-
icy has resulted in a low incidence of bacteremia and sepsis
clinically attributable to catheter-related infections.
Endocarditis
Acute infective endocarditis is an infrequent but consistent
source of morbidity and mortality in burn patients (1.3%)
owing to the bacteremias associated with wound manipula-
tion, prolonged intravenous cannulation, and septic throm-
bophlebitis. Preventive measures include effective topical
antimicrobial therapy, timely excision and closure of the
burn wound, and early discontinuation or frequent replace-
ment of intravenous cannulas.
Staphylococcus aureus is the most common causative
organism, and the right side of the heart is affected most fre-
quently. Recurrent staphylococcal bacteremia in a burn
patient with sepsis and no other apparent identifiable source
of infection should suggest the diagnosis. Heart murmurs
are difficult to detect in hyperdynamic, tachycardiac
patients. Transesophageal echocardiography is the pre-
ferred examination to detect valvular lesions, but small veg-
etations may remain undetected. On occasion, cardiac
catheterization—to identify valvular vegetations or valvular
incompetence—may be required for definitive diagnosis if
echocardiographic findings are equivocal. Systemic maximal-
dose antibiotic therapy is directed against the causative
organism. Antibiotic therapy is continued for 6 weeks after
the last positive blood culture.
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Sinusitis
The true incidence of sinusitis in burn patients is unclear, but
patients requiring prolonged transnasal intubation of both
the airway and stomach are at increased risk. One study
reported an incidence of 36% in transnasally intubated ICU
burn patients. Sinusitis is most often clinically undetectable
and requires radiographic examination by plain films or CT
scanning to establish the diagnosis. These studies help to
direct sinus aspiration to differentiate between congestion
and infection. Treatment involves topical mucosal vasocon-
strictors to improve patency of the sinus ostia and removal of
transnasal tubes. Appropriate systemic antibiotic therapy
should be initiated. Surgical drainage is required in cases not
responsive to these procedures. Tracheostomy or gastros-
tomy may be necessary if prolonged ventilatory support and
enteral nutrition are required.
Other Complications
A. Ocular—Thermal injury of the ocular adnexa is common
in patients sustaining facial burns, but actual injury to the
cornea and globe is uncommon because of the ble-
pharospasm induced by heat, noxious gases, and smoke.
Exceptions occur in patients with altered sensoria at the
time of burning and incomplete protection of the globe.
Shortly after admission, fluorescein staining of the cornea
and examination with a Wood’s lamp should be performed
to detect loss of epithelial integrity. If epithelial defects are
noted, prophylactic topical antibiotic therapy, for example,
bacitracin zinc–neomycin sulfate–polymyxin B sulfate oph-
thalmic ointment, should be initiated. Ophthalmologic con-
sultation should be obtained and the defects examined daily
to document resolution or progression of the epithelial
defects, the major hazard of which is bacterial infection.
Minor corneal abrasions that become infected may progress
rapidly to corneal ulceration and globe perforation.
Infections caused by Pseudomonas species are particularly
prone to this complication.
Frequent ocular examination, adequate eye lubrication,
prophylactic and therapeutic use of topical antibiotics, and
timely performance of eyelid releases are paramount in the
prevention of ocular complications. With severe burns of the
eyelids, ectropion or loss of lid margin may occur. If the
cornea is no longer protected, operation is indicated in the
form of an eyelid release with split-thickness skin grafting.
Release of one or both lids may be required, and in severe
cases, repeated release of the same lid may be made necessary
by progressive skin graft contracture. A temporary tarsorrha-
phy is sometimes useful to protect the cornea from exposure,
but severe ectropion or loss of the lid margin limits the use-
fulness of this technique.
B. Gastrointestinal—Many GI complications have been
documented following thermal injury and include pancreati-
tis, acalculous cholecystitis, gastroduodenal stress ulceration,
and Ogilvie’s syndrome. Stress ulceration of the upper GI
tract has been controlled effectively by prophylactic antacid
or H2-receptor antagonist therapy. Hemorrhage or perfora-
tion requiring operative management occurred in only five
patients (0.1%) during a 14-year series. In a recent study, the
prophylactic administration of sucralfate has been found
equally effective in stress ulcer prevention. Gastric colonization
with gram-negative organisms occurred later among patients
receiving sucralfate than among those receiving antacids, but
this did not change the incidence or type of pneumonia
occurring following burn injury.
Superior mesenteric artery syndrome may occur in
patients who sustain profound weight loss during their hos-
pital course. This condition results in compression and
obstruction of the transverse duodenum by the superior
mesenteric artery from weight loss–induced changes in the
anatomic position of this vessel. Current nutritional prac-
tices have nearly eliminated this complication. If diagnosed,
initial management should be directed toward nutritional
repletion and nasogastric decompression. Nasoenteral feed-
ing tubes may be guided past the obstruction under fluoro-
scopic guidance and are preferred over parenteral alimentation.
Operation is rarely necessary.
The management of GI complications in thermally
injured patients is the same as in other critically ill patients.
If operation is required, retention sutures should be used in
closing any abdominal incision in burn patients owing to the
increased risk of postoperative wound infection and fascial
dehiscence.
Bowers BL, Purdue GF, Hunt JL: Paranasal sinusitis in burn
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NUTRITION
 Postburn Hypermetabolism
Extensive thermal injury may cause metabolic rates to rise
to levels one and one-half to two times normal, far exceed-
ing the hypermetabolism observed in other critically ill
patients. The hypermetabolic response is linearly related to
the extent of burn, and the actual physiologic response is
influenced by environmental temperature, the patient’s age,
physical activity, pain and anxiety, and the presence of
infection. The hypermetabolic response to burn injury,
common to other forms of critical illness and trauma, is
partially driven by the neurohumoral milieu produced by
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the hypothalamic-pituitary and autonomic nervous system
responses. Activation of the former results in increased release
of antidiuretic hormone, adrenocorticotropic hormone
(ACTH), and β-endorphins, whereas stimulation of the latter
results in the release of catecholamines, glucagon, and corti-
sol. Postburn hypermetabolism is manifested by increased
oxygen consumption, a hyperdynamic circulation, increased
core temperature, wasting of lean body mass, and increased
urinary nitrogen excretion. An increase in CO2 production
follows that parallels oxygen consumption. Hypermetabolism
is temperature-sensitive in patients with burns involving over
50% of the BSA, and a 10% decrease in metabolic rate may be
achieved by maintaining ambient temperatures above 30°C.
Blood flow to the burn wound is markedly increased com-
pared with the blood flow to other organs and tissues. This
explains to some extent the relationship of extent of burn to
hypermetabolism.
 Substrate Utilization
Glucose metabolism is altered following thermal injury.
Hepatic gluconeogenesis and total glucose flow increase.
However, owing to relative insulin insensitivity, glucose uptake
by insulin-dependent tissues is decreased. An exaggerated frac-
tion of nutrient flow is directed to the burn wound. Through
anaerobic, insulin-independent means, large quantities of glu-
cose are required to support the immune cellular functions of
necrotic tissue removal and microbial containment and
destruction. Cellular proliferation and wound healing are also
glucose-dependent. The predominance of anaerobic metabo-
lism in the burn wound results in increased lactate production
with subsequent hepatic conversion of lactate to glucose via
the Cori cycle.
Marked catabolism resulting in muscle protein breakdown
and loss of lean body mass is observed following thermal
injury. Catabolism of muscle protein provides amino acid glu-
coneogenic precursors (converted to glucose by liver and gut)
and supplies amino acid substrates for synthesis of acute-phase
proteins. Significant nitrogen loss occurs, with 80–90%
excreted as urea. The metabolism of glutamine, a preferred
substrate for gut metabolism and a precursor for renal ammo-
nia production, is also increased during the hypermetabolic
phase. Glutamine is converted by the gut into alanine, which
subsequently enters the gluconeogenic pathway.
The ability to oxidize fat as a source of nonprotein calo-
ries depends on the extent of injury and the degree of
hypermetabolism. In patients with relatively small burns,
carbohydrate and fat may be used interchangeably as effec-
tive nonprotein calorie sources. In patients with larger
burns, carbohydrate is more effective than fat in maintain-
ing body protein stores when each is used as a sole energy
source.
 Estimation of Caloric Needs
Many formulas exist for the estimation of caloric needs in
thermally injured patients. Some of the more common ones
based on body size, age, and sex are presented in Table 35–7.
The increase in calories required to support the metabolic
demand following burn injury is computed by either adding
predetermined stress or injury factors to standard formulas or
by incorporating the measured extent of burn into those for-
mulas specifically derived for burn patients. The use of for-
mulas to predict caloric requirements in individual patients
may result in overestimation or underestimation of caloric
needs. Since most formulas are derived by patient measure-
ments in the resting state, activity factors are customarily
applied and range from 10–50%. Serial measurements by
indirect calorimetry provide the most accurate determination
of energy requirements for patients with major burns; how-
ever, there is no current consensus regarding the most appro-
priate formula to use when requirements must be estimated.
The best method to calculate the protein requirements of
thermally injured patients remains controversial; however,
supplying 12–18 g of nitrogen per square meter of body sur-
face area or 1.5–2 g of protein per kilogram of body weight
Based on Harris-Benedict equation Basal metabolic rate × Activity factor × Injury factor
BMR male = 66.47 + 13.75 (kg BW) + 5.00 (cm ht) – 6.76 (age yr)
BMR female = 65.51 + 9.56 (kg BW) + 1.85 (cm ht) – 4.68 (age yr)
Activity factor = 1.2 bed rest, 1.3 out of bed
Injury factor = 2.1 for severe burn
Curreri (25 kcal × kg BW) + 40 kcal × % burn
Shriner’s (Galveston) 1800 kcal/m2 BSA + 2200 kcal/m2 of burn
USAISR Basal in kcal/m2 BSA per hour x Factor
Factor = 2.33764 – (1.33764[–0.0286 × % burn])
USAISR = U.S. Army Institute of Surgical Research.
Table 35–7. Formulas for estimating energy requirements in thermally injured patients.
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has been recommended. Nonprotein kilocalorie-to-nitrogen
ratios of 100:1 to 150:1 are acceptable. Only enough fat to
prevent essential fatty acid deficiency is required. Some burn
patients may tolerate up to 9 mg/kg per minute of carbohy-
drate administration. However, carbohydrate delivery
exceeding 5 mg/kg per minute occasionally results in hepatic
fat deposition and excessive CO2 production. This may cause
CO2 retention in patients unable to compensate by increas-
ing minute ventilation.
Once the optimal delivery rate of carbohydrates is deter-
mined, balancing the remainder of the caloric requirements
with fat may be achieved safely if the fraction of calories
delivered as fat does not exceed one-third of the total.
Triglyceride clearance usually is increased following thermal
injury, but triglyceride levels should be followed weekly in
patients whose nutritional regimens contain a significant
percentage of calories supplied as fat. Hypertriglyceridemia,
usually from parenteral infusion of fat emulsions, may result
in coagulation abnormalities, hepatic dysfunction, and
altered pulmonary diffusion capacity. Triglyceride levels
above 200 mg/dL should prompt a decrease in lipid admin-
istration. The combination of medium- and long-chain
triglycerides provided in most enteral formulas is the pre-
ferred form of dietary fat supplementation and rarely results
in hypertriglyceridemia.
 Delivery of Nutritional Support
Administration of nutrition by the enteral route is pre-
ferred to preserve enterohepatic delivery of substrates and
maintain mucosal function and integrity. Enteral intake
may be initiated safely when the ileus associated with ther-
mal injury has resolved. Patients with burns exceeding
30–40% of BSA may not be capable of meeting nutritional
goals by oral intake alone, and supplementation with any of
the commercially available enteral formulas with an appro-
priate calorie-to-nitrogen ratio may be used. Nasogastric
and nasojejunal feedings are commonly employed based on
institutional preference. Nasojejunal feedings have the
added advantage of providing continuous nutrition
throughout the perioperative and intraoperative periods
with a low risk of aspiration.
Parenteral nutrition is reserved for patients with pro-
longed ileus or conditions prohibiting effective GI motility
or absorption. Glucose intolerance is a more common com-
plication of parenteral nutrition and necessitates frequent
monitoring of blood glucose levels.
 Monitoring Nutritional Therapy
Careful monitoring of nutritional therapy is imperative if the
high metabolic demand associated with thermal injury is to
be met and adequate nutrition maintained throughout the
hospital course. Useful indices include body weights, calo-
rie counts, nitrogen balance studies, and measurement of
respiratory quotients. In other critically ill patients, measure-
ment of serum albumin, transferrin, prealbumin, and
retinol-binding protein are commonly employed to monitor
the adequacy of nutritional support; however, these bio-
chemical markers have been shown to be poor predictors of
temporal changes in nitrogen balance in thermally injured
patients, and their use is not recommended. Nitrogen bal-
ance calculations based on urinary urea nitrogen (UUN)
excretion measurements should be modified to include
wound losses and other nonurea protein losses. Wound
losses, in grams per day, may be estimated as 0.1 × BSA in m2
× percent BSA of unhealed burn wound. Total urinary nitro-
gen excretion exceeds UUN in thermally injured patients.
Increasing the measured 24-hour UUN by 25% will provide
an accurate estimate of total urinary nitrogen losses. The
daily nitrogen loss is increased by adding 2 g to account for
stool and normal integumentary losses. The formula derived
for daily nitrogen loss following thermal injury is as follows:
Total nitrogen loss (g/day) = 24-hour UUN
× 1.25 + [0.1 × BSA (m2)] + 2
If indirect calorimetric measurements are available, mon-
itoring the respiratory quotient (RQ) provides useful infor-
mation regarding substrate utilization. An RQ of greater than
1.0 indicates carbohydrate oxidation and overfeeding, which
may result in hepatic fat deposition. An RQ of less than 0.7
indicates fat oxidation and is consistent with the delivery of
insufficient carbohydrate calories. Routine serum chemistries,
liver function tests, and serum calcium, phosphorus, magne-
sium, and triglyceride determinations should be monitored
once or twice a week during nutritional therapy. Most meta-
bolic complications can be avoided by appropriate adjust-
ment of the elemental and nutrient composition of the
formula administered.
 Complications
The mechanical, septic, and metabolic complications associ-
ated with enteral and parenteral nutrition in thermally
injured patients are the same as those common to all critically
ill patients. However, the quantity and duration of nutritional
supplementation required in thermally injured patients are
such that strict attention to the amount, composition, and
safe delivery of nutrition is required to avoid complications.
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Current Controversies & Unresolved Issues
Postburn Hemodynamics
Resuscitation of patients to provide supranormal levels of
oxygen delivery in states of severe illness or injury has been
popularized recently. At present, this goal is impractical in
the acute resuscitation of thermally injured patients. Even
though large volumes of fluid may be required to maintain
urine output, burned patients have decreased oxygen deliv-
ery and consumption during the initial phase of resuscita-
tion. Attempts to improve oxygen delivery would result in
massive fluid administration leading to excessive edema for-
mation and subsequent morbidity. The goal of fluid resusci-
tation in thermally injured patients is to maintain vital organ
function at the lowest physiologic cost. A more physiologic
restoration of intravascular volume and oxygen delivery
would seem beneficial.
Several approaches to reduction of edema formation and
restoration of circulatory integrity are under investigation.
Early intervention to block production of or to scavenge
superoxide and oxygen free radicals has been shown to
decrease edema formation. Administration of a soluble com-
plement receptor that blocks the classic and alternative com-
plement pathways has attenuated postburn edema formation
in animals. Fluid resuscitation with deferoxamine has been
shown to diminish the systemic effects of burn-induced oxi-
dant injury, and an inositol phosphate derivative, 1,2,6-D-
myoinositol triphosphate, has been shown to decrease burn
wound edema and resuscitation fluid requirements by an
unknown mechanism. Vitamin C, which has been shown in
various animal models to reduce burn wound edema and
resuscitation volume, was administered to burn patients in a
prospective, randomized, controlled manner. The patients
were resuscitated according to the Parkland formula. The 24-
hour total fluid infusion volumes were 5.5 mL/kg per percent
burn in the control group and 3.0 mL/kg per percent burn in
the vitamin C group. The vitamin C group had an initial
weight gain of 9.2% of pretreatment weight compared with a
17.8% weight increase in controls. The results of this initial
small study are encouraging. Urinary outputs were main-
tained between 0.5 and 1.0 mL/kg per hour during the first
24 hours postburn, and total 24-hour urine volumes were
not different between groups. Inhibition of lipid peroxida-
tion accomplished by antioxidant administration may be an
important adjunct in limiting fluid resuscitation volume and
edema formation following burn injury.
The inclusion of osmotically active macromolecules,
such as pentafraction, that have a decreased propensity for
transcapillary leakage during resuscitation also could improve
early circulatory integrity. Until mechanisms of edema forma-
tion are better understood and means of limiting transvascu-
lar fluid loss are developed, “supranormal” resuscitation is
neither appropriate nor feasible for burn patients.
Inhalation Injury
The mechanism by which inhalation of smoke and products of
incomplete combustion injure the tracheobronchial mucosa,
distal airways, and lung parenchyma is not completely under-
stood. In part, injury is governed by particle size, which deter-
mines the anatomic region where injury will occur. Toxicities
of noxious gases produced by combustion of synthetic and
natural materials also contribute to the tissue injury of
smoke inhalation but are at present impossible to quantify in
patients following exposure. Most animal models used to
study the effects of smoke inhalation fail to reproduce the
clinical and histologic changes associated with inhalation
injury in humans. Problems with smoke composition, car-
bon monoxide poisoning, and smoke delivery systems are
common. In a recent study of smoke inhalation injury in non-
human primates, high-frequency percussive ventilation was
found to be superior to conventional volume ventilation and
high-frequency oscillatory ventilation in decreasing baro-
trauma and the histopathologic severity of injury.
Pharmacologic intervention to modulate the response to
smoke inhalation may prove beneficial in decreasing pul-
monary vascular changes and improving lung aeration.
Recent studies in sheep have shown improved alveolar venti-
lation and diminished inflammatory response to smoke
inhalation following postexposure treatment with pentoxi-
fylline. The use of inhaled nitric oxide—which does not alter
the normal inflammatory response—to ameliorate pul-
monary artery hypertension following smoke inhalation is
also being studied. Other treatments, including complement
depletion and antioxidant therapy, are being investigated and
may prove beneficial. Any attempt to modulate the host
response to inhalation injury must proceed with caution to
avoid impairing the normal mechanisms of cellular repair
and immunologic defense.
A nebulized cocktail of heparin and a mucolytic agent,
N-acetylcystine, has been shown to reduce pulmonary failure
and ameliorate airway cast formation in both an animal
model and a case-controlled human study in 47 children. A
blinded, randomized study or studies in adults have not
been reported; however, decreases in reintubation rates
and mortality rates for patients treated with this regimen
were noted when compared with historical controls.
Further information is also needed in this arena; however,
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this may represent a potentially beneficial active interven-
tion as opposed to supportive care and good pulmonary
toilet that represents the mainstay of current care of smoke
inhalation injury.
Infection
The immune dysfunction following burns, for which a specific
cause is unknown, also may be a potential site of pharmaco-
logic intervention. Granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF; sargramostim), in addition to
stimulating proliferation of granulocyte and macrophage pro-
genitor cells, increases macrophage phagocytic and cytocidal
activity, granulocyte RNA and protein synthesis, granulocyte
oxidative metabolism, and antibody-dependent cytotoxic
killing in mature cells in vitro. In a small cohort of burn
patients, sargramostim therapy increased granulocyte counts
by 50%. Administration of sargramostim reduced granulocyte
cytosolic oxidative function and myeloperoxidase activity to
control levels without changing superoxide production.
However, following cessation of treatment, superoxide activity
was subsequently increased compared with untreated burn
patients. These findings caution against clinical extrapolation
of in vitro results. A reduction in myeloperoxidase activity
actually may be detrimental because bactericidal capability
may be compromised. Increased superoxide production could
potentiate endothelial cell damage leading to increased capil-
lary permeability. The inability of immunomodulatory drugs
to significantly alter the postburn changes in immune func-
tion simply may represent the inability of single agents to alter
the complex cascade of pathophysiologic events occurring in
extensively burned patients.
The concept that the gut plays a central role in mainte-
nance of a persistent catabolic state in severely injured
patients has gained substantial popularity. Many animal stud-
ies support this hypothesis; however, the lack of clinically sig-
nificant bacteremia and endotoxemia in humans makes the
meaning of these findings unclear. Intestinal permeability is
increased preceding and during episodes of sepsis in burn
patients. Whether alterations in intestinal permeability result
in infection or represent only an epiphenomenon remains to
be proved. In a recent clinical study, the administration of
prophylactic enteral polymyxin B to burn patients resulted in
a decrease in endotoxemia; however, no correlation with ill-
ness severity score or outcome was observed.
Wound Closure
Excision of the burn wound with subsequent split-thickness
skin grafting is now common practice in most institutions.
Some clinicians advocate complete excision of the burn
wound within the first several days of hospitalization. The
postulated benefits of this treatment include decreasing the
extent and duration of hypermetabolism and immunosup-
pression, shortening the length of the hospital stay, and
improving survival. Prompt excision and closure of the burn
wound has been shown to ameliorate the hypermetabolic
response in laboratory animals, provided that the entirety of
the excised wound is closed by grafting. Similar reversal of
the immunosuppressive effects of burning also has been
documented. Such findings have yet to be observed in
humans probably because the entirety of the full-thickness
wound is seldom removed, partial-thickness wounds are not
excised, and definitive closure of large wounds cannot be
accomplished in a single operation. In several reports dealing
exclusively with early wound excision in burned children, the
duration of hospital stay was clearly shortened, intraopera-
tive blood loss was decreased, and survival was reported to be
improved. The duration of hospitalization has decreased for
adult burn patients in many centers because excisional ther-
apy is employed routinely, but a favorable impact of early
complete excision of the burn wound on pathophysiologic
changes and outcome has not been documented. Moreover,
the deleterious hemodynamic and pulmonary effects of gen-
eral anesthesia during the early postburn period speak for
cautious use of such procedures during the resuscitation
period in the severely burned patient. Such excisions should
be performed on carefully selected patients and only by expe-
rienced operating teams and anesthesiologists.
The identification and availability of various growth fac-
tors have stimulated interest in the potential for accelerating
the healing of burns, skin grafts, and skin graft donor sites.
An effective agent could produce more rapid healing of
burns (hastening return to work), permit more frequent har-
vesting of donor sites in massive burns, and shorten healing
time of skin grafts (reducing periods of immobility). The
topical application of epidermal growth factor has been
shown to enhance healing of split-thickness skin graft donor
sites by reducing the time to complete healing by 1.5 days.
Although the decrease in healing time was statistically signif-
icant, the clinical benefit would be minimal. A 50% reduc-
tion in skin graft donor-site healing time would be required
to be clinically effective. The systemic administration of
human growth hormone also has been reported to decrease
the time of skin graft donor-site healing in children, but the
same effect was not observed routinely in adult patients. The
ability of growth factors to improve healing in burn patients
continues to be an area of active research and debate.
Hypermetabolism
The hypermetabolic response to thermal injury is well
described, and in addition to the classic hormonal mediators,
cytokines may play an important role in maintenance of the
hyperdynamic state. Circulating levels of tumor necrosis fac-
tor, IL-1, and IL-6 are increased at various times following
thermal injury and sepsis; however, the effect of pharmaco-
logic or immunologic blockade of these cytokines is not
clearly established following burn injury. In a series of exten-
sively burned patients, blood levels of TNF-α, IL-1, and IL-6,
although frequently elevated, had no correlation with the
patients’ clinical courses.
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The hypermetabolic response to thermal injury can be
attenuated by β-adrenergic blockade. Administration of pro-
pranolol has been effective in decreasing metabolic rate and
cardiac work in burned children and adults; however,
increased nitrogen loss was induced presumably from periph-
eral β-receptor blockade. Cardioselective β-adrenergic block-
ers are currently being studied that may circumvent the
nitrogen-wasting effects of nonselective agents. Attempts to
decrease catabolism and protein wasting also have been stud-
ied. The selective β2-adrenergic agonist clenbuterol increased
resting energy expenditure and normalized muscle protein
content, muscle mass, and body weight gain in burned rats.
Administration of insulin-like growth factor 1 (IGF-1) to
burn patients, decreased protein oxidation and protein break-
down only in patients in whom an insulin-like effect also
occurred. Similar responses in burn patients were demon-
strated with the administration of low-dose exogenous
insulin and glucose. Testosterone analogues also have been
used to reduce postinjury catabolism. Oxandrolone, a weakly
androgenic testosterone analogue, has been shown recently to
decrease net daily nitrogen loss and weight loss in seriously
burned patients. This study also described a decrease in heal-
ing time of standarized donor sites from 13 ± 3 days to 9 ± 2
days. Complications were similar between groups, and no side
effects directly attributed to the drug were identified.
Herndon and colleagues evaluated the effect of β-adrenergic
blockade using orally administered propranolol on resting
energy expenditure and muscle-protein catabolism in
severely burned children. After 2 weeks of treatment, a dose
sufficient to decrease the resting heart rate by 20% resulted in
a 24% decrease in resting energy expenditure in the propra-
nolol group compared with a 5% increase in a matched con-
trol group. The net muscle-protein balance increased by 82%
over baseline values in the propranolol group, whereas it
decreased by 27% in the control group.
Further studies are required to determine if the apparent
benefits of blockade of the hypermetabolic response result in
decreased morbidity and mortality for the severely burned
patient or whether they merely reflect short-term changes in
protein metabolism.
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II. CHEMICAL BURN INJURY
The severity of injury caused by chemical exposure is related
to the amount and concentration of the agent and the dura-
tion of contact with the tissues. Strong alkalis and acids
found in common household cleaners are responsible for
the majority of minor chemical injuries. More extensive
injuries often result from industrial and laboratory acci-
dents or from assaults. The amount of tissue damage
incurred also depends on the nature of the specific agent.
Strong alkalis react with tissues to produce saponification
and liquefaction necrosis. Acids are water-soluble and pene-
trate easily into subcutaneous tissue and cause coagulation
necrosis soon after contact. The exothermic reaction pro-
duced by contact with strong acids or bases also contributes
to the depth of injury. Organic solvents and petroleum
products, which are highly lipid-soluble, injure tissues by
delipidation. Cutaneous absorption of certain chemical
agents may cause systemic toxicity, which complicates sub-
sequent therapy and makes identification of the causative
agent imperative.
 Initial Care of Chemical Burns
Chemical injuries, unlike other thermal injuries, require
immediate care of the burn wound. The caustic agent must
be washed from the skin surface as soon as possible. All
clothing, including shoes and gloves, must be removed and
the wounds copiously irrigated with water. If possible,
lavage of chemical injuries should continue for at least 30
minutes. In the case of alkali burns, this treatment should
continue for a minimum of 1 hour. If ocular injury is sus-
pected, prompt and prolonged irrigation with saline or
water should begin. A search for specific antidotes is unnec-
essary and may only delay the initiation of adequate water
lavage. Assessing the depth of injury in chemical burns is
difficult because many agents may produce a tanned or
bronzed appearance of the skin, which remains pliable to
the touch but may represent extensive full-thickness tissue
necrosis. With the exception of the initial attention given to
the burn wound, the resuscitation and later treatment of
skin injury follow that of thermal burns.
 Specific Chemical Agents & Systemic
Toxicities
In general, the use of antidotes for specific chemicals is con-
demned, and copious water lavage is considered the appro-
priate form of initial therapy. However, several specific
chemical agents exist for which treatment with a specific
antidote has proved beneficial. Injury owing to hydrofluo-
ric acid exposure is an occupational hazard of petroleum
refinery workers, etchers, and those employed in the clean-
ing of air-conditioning equipment. Following contact with
this agent, there is usually a pain-free interval followed by
pallor in the area of contact in association with severe tis-
sue pain. Fluoride ion continues to penetrate the tissues
until inactivated by calcium salt formation. Immediately
after exposure, the area should be copiously irrigated with
water. Topical treatment with a calcium gluconate gel
should be instituted, and if the pain does not subside, local
injection of 10% calcium gluconate into the damaged tissue
may provide prompt pain relief. Intraarterial infusion of
calcium gluconate also has been used to limit tissue damage
and relieve pain, but surgical excision of the damaged tissue
may be necessary for complete pain control. Hypocalcemia
may occur following extensive hydrofluoric acid burns.
Phenol
Phenol is an aromatic acid alcohol with high lipid solubility.
Initial treatment consists of copious water lavage; however,
owing to the poor water solubility of phenol, a lipophilic sol-
vent such as polyethylene glycol (50% solution in water) may
be more effective at removing the residual agent. Sufficient
systemic absorption of phenol produces CNS depression,
hypothermia, hemolysis, renal failure, and hypotension.
Maximal ICU support may be required. No specific antidote
is available.
Hydrocarbons
Cutaneous injury from immersion in gasoline and other
hydrocarbons is often overlooked in victims of motor vehicle
accidents who sustain prolonged exposure during extrica-
tion. Skin necrosis results from lipid dissolution. Partial- and
full-thickness injuries have been described, and systemic tox-
icity, similar to that produced by ingestion or inhalation, may
occur. The pulmonary excretion of hydrocarbons may pro-
duce chemical pneumonitis and bronchitis. Systemic lead
poisoning from cutaneous absorption of leaded gasoline also
has been described.
Inhalation of Aerosolized Chemicals
Inhalation of aerosolized chemicals may produce pulmonary
injury and systemic toxicity, thus requiring accurate diagno-
sis and aggressive treatment. Varying degrees of pulmonary
insufficiency may be agent-specific and manifested by severe
airway edema formation, mucosal sloughing, and bron-
chospasm. Systemic toxicity through pulmonary absorption
may occur; thus the causative agents must be clearly identi-
fied to ensure appropriate diagnostic and treatment strate-
gies. The degree of pulmonary support required is
determined by the severity of pulmonary insufficiency.
Ocular Injury
If chemical eye injury is suspected, prompt and prolonged
irrigation of the eye with water or saline should ensue. A spe-
cially designed scleral contact lens with an irrigating sidearm
 CHAPTER 35750
is useful when prolonged irrigation is necessary. Epithelial
defects may be identified by fluorescein stain.
Ophthalmology consultation should be obtained on all sus-
pected chemical eye injuries.
Mozingo DW et al: Chemical burns. J Trauma 1988;28:642–7.
[PMID: 3367407]
III. ELECTRICAL BURN INJURY
Tissue damage from electrical injury results from heat gener-
ated by the passage of electric current through the body as
well as direct thermal injury caused by the ignition of cloth-
ing. The severity of the injury depends on the voltage, the
type of current (alternating or direct), the path of the current
through the body, and the duration of contact. High- and
low-voltage injuries are arbitrarily defined as those above
and below 1000 V.
Tissue damage from electrical injury may be obvious at
the cutaneous contact site or sites but also may involve
underlying tissues and organs along the path of the current.
The amount of heat generated is proportionate to tissue
resistance; however, the differences in tissue resistance (eg,
bone, fat, nerve, etc.) are so small that the body acts as a
volume conductor. Current density then predominates as
the main determinant of tissue damage, with severity of
injury being inversely proportional to the cross-sectional
area traversed by current. Thus severe injuries to the
extremities are often encountered, and significant injuries
to the torso are rare. Superficial tissues in a limb may be
normal, whereas tissues near bone may be nonviable owing
to longer duration of heating because of the slower heat
dissipation from bone. Alternating current injuries may ini-
tiate ventricular fibrillation, whereas high-voltage injury
and lightning injury are associated with asystolic cardiopul-
monary arrest.
Treatment
Cardiac arrest often occurs following an electrical contact
and requires immediate cardiopulmonary resuscitation.
Patients with electric injury are more likely to have associ-
ated injuries owing to falls or tetanic skeletal muscle con-
tractions from the electric current; therefore, the patient’s
spine should be immobilized until cervical, thoracic, and
lumbar radiographs exclude the presence of spinal frac-
tures. In patients not sustaining an initial cardiac arrest,
cardiac dysrhythmias occur in a small percentage of
patients. All patients should have continuous electrocar-
diographic monitoring for at least 24 hours, and function-
ally significant dysrhythmias should be treated promptly if
they occur.
The estimation of resuscitation fluid requirements in
patients sustaining electrical injury is difficult owing to
extensive subcutaneous or deep tissue involvement with only
limited areas of cutaneous injury. This “iceberg” effect may
require the performance of fasciotomy—rather than
escharotomy—to ensure adequate perfusion of the distal
extremity and to evaluate the viability of the underlying sub-
cutaneous tissue and muscle. With extensive muscle necrosis,
hemochromogens may be liberated, resulting in the appear-
ance of those pigments in the urine. Intravenous fluids are
administered to achieve a urine output of 100 mL/h in
adults. If the hemochromogenuria does not clear with an
adequate urine output, 50 meq sodium bicarbonate should
be added to each liter of intravenous fluid to promote alkalin-
ization of the urine and prevent pigment precipitation in the
renal tubules. If after aggressive fluid resuscitation the renal
output does not reach 100 mL/h, an osmotic diuretic such as
mannitol also may be administered (a bolus dose of 25 g with
12.5 g added to each liter of IV fluid until pigment clearing
occurs) to force an increased urine output. When urine pro-
duction is increased by the use of diuretics, invasive hemody-
namic monitoring with a pulmonary artery catheter should
be considered because urine output is no longer a reliable
measure of intravascular volume and organ perfusion.
Complications
Associated injuries are more common in patients sustaining
electrical injury than those injured by thermal burns. Owing
to the titanic contractions of the paraspinal musculature
induced by the electric current, compression fractures of the
lumbar and thoracic spine may occur. Furthermore, many
electrical injuries involve workers who fall from heights.
Blunt traumatic injuries should be suspected and appropri-
ate diagnostic measures initiated.
A complete neurologic examination must be performed
on admission and at scheduled intervals in all patients sus-
taining electrical injury. Neurologic changes may be of early
or late onset. Immediate peripheral deficits owing to the
damaging effects of electric current may be irreversible; how-
ever, early deficits in a distribution where there is no clear tis-
sue damage are likely to resolve. Neurologic symptoms of
delayed onset, often mimicking upper motor neuron disease,
tend to be progressive and permanent. Progressive thrombo-
sis of nutrient vessels of the spinal cord or nerve trunks may
play a role in the pathogenesis of the late-occurring upper
motor neuron deficits.
Direct electrical injury to the viscera is rare; however, liver
necrosis, intestinal perforation, focal pancreatic necrosis, and
gallbladder necrosis have been reported in patients with
high-voltage electric injury and truncal contact points. An
increased occurrence of cholelithiasis has been reported in
convalescent patients following electric injury.
Delayed hemorrhage from moderate-sized to large blood
vessels has been described following electrical injury and
attributed by some to an “arteritis” produced by the electric
current. The actual mechanism of this complication is unclear,
but inadequate initial wound debridement and subsequent
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exposure and desiccation of the involved vessel appear to be
causative factors.
In patients in whom the electrical contact point involved
the head or neck, the development of cataracts up to 3 years
or more following injury has been described.
Ophthalmologic slit-lamp examination should document
the presence or absence of cataracts during the initial hospi-
talization. Additional information on electrical injuries is
presented in Chapter 37.
Grube BJ et al: Neurologic consequences of electrical burns. J
Trauma 1990;30:254–8.
Pruitt BA Jr, Mason AD: Lightning and electric shock. In
Weatherall DJ, Ledinghan JGG, Warrell DA (eds), Oxford
Textbook of Medicine, 2nd ed. New York: Oxford University
Press, 1987.
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An integral part of the practice of critical care is treating the
patient who either intentionally or inadvertently ingests or is
exposed to a potentially toxic substance. The magnitude of this
problem is staggering. In 2002, the American Association of
Poison Control Centers documented 2,112,774 episodes of
toxin exposure resulting in poison center notification. This
number actually underrepresents the true number of poison-
ings because 70% are never reported to poison control centers.
Treating these patients requires a working understanding
of the principles of stabilization and supportive care, decon-
tamination, drug elimination, use of antidotes, and the
pathophysiologic features specific to the poisons or toxins
involved. This chapter will cover the general principles
involved in caring for these patients and will discuss the
details of treating the specific poisons typically encountered
in the practice of critical care.
EVALUATION OF POISONING IN THE ACUTE
CARE SETTING OR ICU
The pathophysiologic consequences following an exposure
are poison-specific, and adequate treatment requires an
understanding of these individual differences. However, there
are several general guidelines for the evaluation and treat-
ment of a patient with a potential ingestion or toxic exposure.
 Diagnosis of Poisoning
History
Obtaining a history from a patient with a potential ingestion
or toxic exposure may be difficult if the patient is too young
to communicate, is obtunded, or is reluctant to cooperate. It
may be helpful to question the patient’s relatives, friends, or
coworkers to obtain additional historical information in
these cases. When getting the patient’s history, several points
require particular attention: the drugs or toxins involved, the
route of exposure (ie, oral, dermal, inhalation, etc.), and the
time of the exposure or ingestion. It is important to remem-
ber, however, that the history may be unreliable in patients
who intentionally ingest toxins. Careful physical examina-
tion is key, and laboratory evaluation and close observation
are frequently required.
Symptoms and Signs
The physical examination can provide a wealth of informa-
tion, even in patients unable to provide a useful history. An
abbreviated physical examination, which could be called the
toxidrome-oriented physical examination, focuses on the phys-
ical findings observed in patients exposed to particular types
of poisons and offers rapid assessment and guides testing and
treatment. This physical examination should include vital
signs, a brief neurologic examination emphasizing level of
consciousness and pupillary and motor responses, palpa-
tion of the skin for moisture and inspection for cyanosis
and rashes, auscultation and percussion of the lungs, and
auscultation of bowel sounds (Table 36–1). Table 36–2 sum-
marizes the physical findings associated with the major
groups of poisons and lists several examples of each.
Laboratory Studies
A rapid bedside serum glucose concentration should be checked
in all patients with altered mental status, and if it is found to be
low, intravenous glucose should be administered. Serum elec-
trolytes, blood urea nitrogen (BUN), serum creatinine, arterial
blood gas, serum osmolality, calculated osmolar gap, and a uri-
nalysis (ie, crystals, myoglobinuria or hemoglobinuria) are the
basic laboratory tests in the evaluation of patients with over-
doses (Table 36–3). Other tests (eg, drug levels, methemoglobin
level, and carboxyhemoglobin level) may be helpful in specific
patients and will be discussed later in this chapter.
As a general rule, toxicology screens are of limited value
in evaluation of these patients and are expensive and
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time-consuming. In some specific situations, however,
screening may be helpful. These tests can be useful in nar-
rowing the differential diagnosis in patients who present
with altered mental status or abnormal vital signs; in such
cases, a directed toxicology screen should be ordered that
tests for agents consistent with the patient’s presentation and
physical findings. A toxicology screen also may be helpful in
patients with mixed-drug ingestions or those who present
with signs of major toxicity. Finally, a sample of blood may
be saved for future toxicology evaluation in patients in whom
the diagnosis is unclear.
Serum concentrations of some drugs are helpful in guid-
ing management decisions (Table 36–4). Salicylate, aceta-
minophen, barbiturates, digoxin, ethanol, iron, lithium, and
theophylline serum levels are available in most hospital lab-
oratories on an urgent basis. (Methanol and ethylene glycol
levels often need to be sent out; positive tests are often used
to confirm a suspected case, but management must begin
before levels are available.) Salicylate serum drug levels are
not necessary in all ingestion cases, an acetaminophen level
should be sent in virtually all cases. This drug is found in
many prescription and over-the-counter medications, and
patients may ingest potentially lethal amounts but show
minimal or nonspecific signs of toxicity.
Physical Examination Sedative– Hypnotic Cholinergic Anticholinergic Sympathomimetic Sympatholytic 
Temperature  N/– N N/+ N/+/++ N/– 
Respiratory rate N/–/– – +/– N/– +/– – 
Heart rate N/– + or – +/++ ++ N/– 
Blood pressure N/– + N/+ ++ N/– 
Level of consciousness Normal
Obtunded
Comatose 
Normal
Confusion
Coma 
Delirium
Coma 
Normal
Agitated
Paranoid, delusional 
Normal
Lethargy, coma 
Pupillary examination Miosis Miosis Mydriasis Mydriasis N or miosis 
Motor responses N/– Weakness
Paralysis
Fasciculations 
N N N 
Skin, moisture N ++
Diaphoresis 
Dry, hot Diaphoresis Dry 
Lung examination N Bronchospasm
Bronchorrhea 
N N N 
Bowel sounds N/– ++
(SLUD) 
–– N/– N/– 
Examples Opioids
Benzodiazepines
Alcohols
Barbiturates 
Organophosphates
Carbamates
Physostigmine
Edrophonium
Some mushrooms 
Tricyclics
Phenothiazines
Antihistamines
Scopolamine
Amantadine 
Cocaine
Amphetamine
Methamphetamines
Phenylpropanolamine
Ephedrine
Caffeine 
Theophylline
Phencyclidine 
Clonidine 
SLUD = salivation, lacrimation, urination, defecation; N = no effect; + = increased; ++ = markedly increased; – = decreased; – – = markedly decreased.
Vital signs 
Temperature 
Blood pressure 
Respiratory rate 
Heart rate 
Brief neurologic examination 
Level of consciousness 
Pupillary examination 
Motor responses 
Skin examination: moisture, rash, cyanosis 
Lung examination 
Auscultation for bowel sounds 
Table 36–1. The toxidrome-oriented physical examination. 
Table 36–2. Toxidromes.
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Electrocardiography
An ECG should be ordered in all patients with potential drug
ingestions. The heart rate, evidence of dysrhythmias, vector
axes, and interval measurements are helpful in determining
the presence or severity of several ingestions, and serial elec-
trocardiographic evaluation can, in some cases, help to fol-
low the progression of toxicity.
Imaging Studies
A plain abdominal film may be helpful in patients who ingest
radiopaque medications such as iron tablets or some enteric-
coated medications. These films also may be helpful in visu-
alizing drug packets in “body packers”—individuals who
ingest wrapped packets of illicit drugs to transport them.
Although the packages themselves are often not radiopaque,
they still may be visualized by the changes caused in bowel
gas patterns by their presence.
 Differential Diagnosis of Poisoning
The differential diagnosis of the toxin-exposed patient is
extensive and varies with the agent involved. In general, how-
ever, infectious processes (eg, meningitis, encephalitis, and sep-
sis), metabolic disorders (eg, hypo- or hyperthyroidism, hypo-
or hyperglycemia, hypo- or hypercalcemia, and hypo- or
hypernatremia), and environmental disorders (eg, heat
stroke) are the most common other causes of the clinical
syndromes found in toxic exposures. Head trauma or hypox-
emia also may cause findings similar to those observed fol-
lowing toxin exposure.
Erickson TB et al: The approach to the patient with an unknown
overdose. Emerg Med Clin North Am 2007;25:249–81. [PMID:
17482020]
Mokhlesi B et al: Adult toxicology in critical care: I. General
approach to the intoxicated patient. Chest 2003;123:577–92.
[PMID: 12576382]
Lai MW et al: 2005 Annual Report of the American Association of
Poison Control Centers’ national poisoning and exposure data-
base. Clin Toxicol (Phila) 2006;44:803–932. [PMID: 17015284]
TREATMENT OF POISONING IN THE ICU
General Measures
The first priority in treating any patient with a toxic exposure
is resuscitation and stabilization; assessing the patient’s air-
way, breathing, and circulation are the initial goals. This may
require establishing an airway, ventilating and oxygenating
the patient, and supporting circulation by normalizing and
maintaining an adequate heart rate and blood pressure. These
measures should be taken regardless of the toxin involved;
more specific interventions can be made after stabilization is
completed. All overdose or toxin-exposed patients should be
placed on a cardiac monitor and given supplemental oxygen
if hypoxic. Intravenous access should be established.
Airway Management
Endotracheal or nasotracheal intubation is indicated in all
patients who are inadequately ventilating, those who have
significant hypoxemia, those who cannot protect their airway
because of obtundation or a poor gag reflex, or those with an
anticipated clinical course of deterioration. Intubation for
airway protection also should be considered in patients who
need gastric lavage, although this once frequently used prac-
tice is now indicated in only rare instances.
There are two potential situations where an obtunded
patient may not need intubation. Altered patients whose
rapid blood glucose is low may respond sufficiently to intra-
venous dextrose to obviate the need for intubation. (In
patients with suspected alcohol abuse or those who appear
significantly malnourished, administration of dextrose
should be preceded by a 100-mg dose of thiamine intra-
venously or intramuscularly.) Obtunded patients taking nar-
cotics or benzodiazepines may respond to administration of
naloxone or flumazenil (see “Antidotes” below).
Hemodynamic Support
Abnormal blood pressure, heart rate, and temperature should
be managed in the usual fashion; more specific interventions
Electrolytes 
Serum glucose and rapid bedside glucose level 
Blood urea nitrogen 
Serum creatinine 
Arterial blood gases 
Serum osmolality 
Calculated osmolal gap 
Urinalysis 
Electrocardiogram 
Acetaminophen level 
Other laboratory test (methemoglobin level, carboxyhemoglobin
level, etc) as indicated 
Specific drug levels (as indicated) 
Abdominal x-ray (as indicated) 
Table 36–3. Screening evaluation of the poison-exposed
patient. 
Salicylates Ethylene glycol  
Acetaminophen Iron  
Barbiturates Isopropyl alcohol
Digoxin Lithium 
Ethanol Theophylline 
Methanol 
Table 36–4. Drug levels helpful in guiding management. 
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or modifications of treatment can be addressed when more
information regarding the toxin involved is available.
Control of Seizures
Benzodiazepines should be used initially for the manage-
ment of seizures; phenytoin or barbiturates may be needed if
benzodiazepines are not effective. In cases of refractory
seizures, general anesthesia or the use of paralytic agents may
be required; in this case, electroencephalographic monitor-
ing should be instituted to determine if the patient continues
to have electrical seizure activity. It is important to note that
normalization of vital signs and control of seizures may
require interventions specific to the toxin involved (eg, pyri-
doxine for treating isoniazid ingestion).
Opioid and Benzodiazepine Antagonists
Comatose patients should receive naloxone, particularly if
they are hypoventilating and have miotic pupils. The usual
dose is 0.8 mg intravenously in both adults and children; if
there is a suspicion that the patient may be narcotic-
addicted, the dose should be titrated in increments of
0.2–0.4 mg to prevent abrupt withdrawal symptoms. Certain
opioid ingestions, particularly propoxyphene, may require
larger doses of naloxone to be effective. If this ingestion is
suspected, 2 mg naloxone should be administered.
Flumazenil—a benzodiazepine antagonist—may be indi-
cated in patients who present with obtundation or coma sus-
pected to be due to benzodiazepine ingestion. Since use of
this agent in the benzodiazepine-dependent patient may pre-
cipitate withdrawal seizures, this agent should be used with
extreme care in these patients if it is used at all. The initial
dose of flumazenil is 0.2 mg intravenously given over
30 seconds; if, after observation for 30 seconds, the patient
does not respond, an additional dose of 0.3 mg should be
given over 30 seconds. If additional doses are needed, 0.5 mg
should be given over 30 seconds at 1-minute intervals to a
total dose of 3–5 mg; if the patient does not respond to this
maximum dose, the primary cause of altered mental status is
unlikely to be due to benzodiazepines. Because the half-life of
flumazenil is approximately 1 hour (shorter than the half-life
of all currently available benzodiazepines), resedation occurs
in 50–65% of patients with benzodiazepine overdose. When
it occurs, the resedation is usually within 1–3 hours of
flumazenil administration; this necessitates close observation
of these patients.
Decontamination
After stabilization and initial basic therapeutic interventions
have been completed, decontamination should be addressed.
A. External Exposures—Patients who have dermal expo-
sure to a toxin should be undressed and copiously irrigated
with tepid water. Health care personnel must take appropri-
ate measures to ensure that they are not exposed to the agent
while caring for the patient. Irrigation also should be used in
patients with eye contamination, particularly with alkali or
acid substances.
B. Ingestions—Since the vast majority of poisonings occur
by ingestion, gastric emptying and gut decontamination have
been a mainstay of management. Studies have shown, how-
ever, that these interventions are of little benefit in most cases.
1. Syrup of ipecac—In the past, syrup of ipecac was used
extensively to induce gastric emptying in patients with toxic
ingestions, particularly children, but studies question the role
of ipecac in these situations. Ipecac is no longer recom-
mended for the treatment of most ingestions (see “Current
Controversies and Unresolved Issues” below).
2. Gastric lavage—Gastric lavage is a relatively effective
means of accomplishing gastric emptying, decreasing drug
absorption by as much as 50%. Studies of its impact on clin-
ical outcome in poisoned patients, however, have reported
conflicting results. Gastric lavage should not be used routinely
in all poisoned patients but may have a role in specific clini-
cal situations. Gastric lavage should be considered in patients
who present within 1 hour of ingesting a potentially lethal
amount of a toxin. Another possible indication is in poison-
ings with agents that decrease gastric motility (eg, anticholin-
ergic agents), although utility in these cases is questionable.
Gastric lavage may be useful when patients ingest agents that
bind poorly to activated charcoal and in life-threatening poi-
sonings with agents such as theophylline, tricyclic antidepres-
sants, and cyanide. Table 36–5 summarizes these indications.
When gastric lavage is performed, the patient should be
placed in the head-down lateral position. Owing to the risk
of aspiration, gastric lavage never should be performed with
the patient supine, particularly if the patient is in restraints
and cannot be turned quickly if emesis occurs. Suction
equipment should be available at all times. A large-bore gav-
age tube (ie, 36–42F in adults and 16–32F in children) should
be used to remove large pill fragments and whole pills. Some
authors recommend that extra holes be cut along the sides of
the distal end of the tube to facilitate pill removal. Since these
tubes are large, they should not be passed through the nose;
oral passage is better tolerated and has fewer complications.
Once gastric tube position is confirmed, aspiration of the
stomach should be performed to remove as much of the
Recent ingestion (<1 hour) of a potentially life-threatening poison 
Ingestion of a substance that slows gastric emptying (eg, anticholinergic
medications) 
Ingestion of a poison that is slowly absorbed from the gastrointestinal
tract 
Ingestion of a substance that does not bind well to activated charcoal
(eg, iron, lithium) 
Ingestion of specific life-threatening poisons (eg, tricyclic antidepres-
sants, theophylline, cyanide) 
Table 36–5. Indications for gastric lavage.
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poison as possible before irrigation is instituted. Once aspi-
ration is complete, tepid tap water should be used for gastric
lavage. In patients under age 5, normal saline should be used
to prevent electrolyte disturbances. Using 150–300-mL
aliquots (50–150 mL in children), the fluid should be alter-
natively instilled down the tube and then allowed to efflux
from the stomach by gravity; amounts in excess of 300 mL
increase the risk of emesis and aspiration. Lavage should be
continued until the effluent fluid is clear of pill fragments. If
activated charcoal and a cathartic is to be used, it can be
placed down the lavage tube before it is withdrawn.
Several complications are associated with gastric lavage.
Aspiration and subsequent pneumonitis can occur; there-
fore, it is critical that patients who cannot protect their air-
ways be intubated prior to gastric lavage. Esophageal
perforation has been reported, as has inadvertent tracheal
tube placement (with subsequent instillation of lavage fluid
into the lungs). Children under the age of 5 years may
develop electrolyte imbalances if normal saline is not used as
the lavage fluid. Laryngospasm and cardiac dysrhythmias
also have been described.
Gastric lavage has only one absolute contraindication—it
should not be used in caustic ingestions because it may cause
the patient to vomit, leading to more extensive esophageal
and oral burns.
3. Charcoal—Activated charcoal is an odorless, tasteless
powder that is beneficial in many types of ingestions and is
the cornerstone of therapy for most cases. In the gut, it binds
the toxin and prevents its absorption. Although it binds
many compounds, there are several potentially life-
threatening poisons that do not bind well to charcoal
(Table 36–6). When used in repeated doses, activated char-
coal can both interrupt enterohepatic circulation and
enhance the elimination of some drugs that have already
been absorbed from the GI tract (Table 36–7); this is referred
to as gastrointestinal dialysis. When used in this fashion, the
dose of activated charcoal should be 25–50 g orally every 2–4
hours; in children, it is 0.25–1 g/kg every 2–4 hours.
Activated charcoal is administered as a slurry of water
and charcoal. Although the initial dose is 50–100 g orally in
adults and 1–2 g/kg in children, when the amount of ingested
agent is known, the optimal dosing of activated charcoal is in
a ratio of 10:1, charcoal to ingested agent.
The only relative contraindication to giving charcoal is in
patients with caustic ingestions; the charcoal accumulates in
burned areas of the GI tract and interferes with endoscopy.
The most common complication of charcoal administration
is constipation. This problem can be addressed by adding a
cathartic to the charcoal. If repeat-dose activated charcoal
therapy is to be used, the cathartic should be added only to
the first dose of charcoal because the every 2–4-hour dosing
of the repeat-dose activated charcoal regimen can lead to
excessive cathartic administration and possible electrolyte
imbalances from the resulting diarrhea. In addition, some
children have become hypermagnesemic when magnesium
citrate was used as the cathartic. The most common cathartics
used in this situation are 70% sorbitol (1 g/kg), magnesium
citrate (4 mL/kg), and 10% magnesium sulfate (250 mg/kg).
4. Bowel irrigation—Whole bowel irrigation is a method
of removing ingested toxins from the gut by forcing the toxin
rapidly through the GI tract. Indications for whole bowel
irrigation are limited; the most common use of this tech-
nique is in patients who intentionally ingest packets of illicit
compounds such as cocaine or heroin in order to transport
them without detection. The other indication for this ther-
apy is in patients who ingest potentially lethal toxins that are
difficult to remove from the stomach and do not bind well to
charcoal (eg, iron).
The technique for whole bowel irrigation involves admin-
istration of 1–2 L of polyethylene glycol electrolyte solution
per hour, either orally or via a nasogastric tube. In children
under the age of 5 years, the solution should be given at a rate
of 150–500 mL/h. The goal is to produce a rectal discharge
with the same appearance as the administered oral solution,
which indicates complete cleansing of the gut. Effective
whole bowel irrigation usually takes 6–12 hours. The patient
must be able to cooperate and sit either on a toilet or a bed-
side commode during the procedure.
The only contraindications to this procedure are the pres-
ence of ileus, GI perforation, and bleeding. It should not be
used in patients who are uncooperative or combative or in
those with CNS depression or respiratory distress. The compli-
cations associated with whole bowel irrigation are abdominal
Bromides 
Caustics 
Cyanide 
Ethylene glycol 
Heavy metals 
Iron 
Isopropyl alcohol 
Lithium 
Methanol 
Table 36–6. Poisons not well bound by activated charcoal.
Carbamazepine 
Diazepam 
Digitalis 
Phenobarbital 
Phenytoin 
Salicylates 
Theophylline 
Tricyclic antidepressants 
Table 36–7. Some drugs amenable to repeat-dose
activated charcoal therapy.
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cramping and vomiting. Emesis can be treated with
antiemetics and a slowed administration rate of the solution.
Hyperchloremia has been reported and requires repeated
serum chloride determinations during the procedure. It is
also important to note that activated charcoal, if indicated,
should be given before the initiation of whole bowel irriga-
tion. Repeat-dose activated charcoal is not effective when
given during whole bowel irrigation.
5. Ion trapping—Once a drug has been absorbed from the
GI tract, gut decontamination measures become relatively
ineffective. Ion trapping is a method to enhance elimination
of an already absorbed drug by “trapping” it in the urine.
Drugs that acidify urine (eg, salicylates) ionize in alkaline
urine and then cannot be reabsorbed by the kidney and are
therefore excreted. This treatment is most helpful in salicy-
late and phenobarbital ingestions.
The simplest method for ion trapping uses 1 L of 0.45%
saline solution to which 2 ampules of sodium bicarbonate
have been added. The solution is infused intravenously at a
rate of 150–250 mL/h. Urine pH is monitored, with the goal
being a pH of 7.0–8.0. Potassium deficits need to be replaced
because alkalinization of the urine is difficult to achieve in
the hypokalemic patient. Complications of urinary alkalin-
ization are volume overload and hypokalemia.
6. Hemodialysis and hemoperfusion—In some situa-
tions, hemodialysis or hemoperfusion may be required to
eliminate the toxin. Indications include patients refractory to
supportive care alone, those who have a potentially toxic
drug level or highly toxic dose of the ingestant, and those in
whom other routes of elimination are impaired (eg, by renal
failure). Few toxins are amenable to this type of therapy;
cases in which hemodialysis or hemoperfusion may be useful
are listed in Table 36–8.
 Current Controversies & Unresolved Issues
Administration of activated charcoal has become the pri-
mary means for decontamination of the gut in most cases of
toxic ingestion. Gastric lavage was once a mainstay for
decontamination of the gut and removal of the ingested
agent. Recent studies, however, have shown little change in
outcome for most patients who undergo gastric lavage. In
addition, this method has the potential for causing serious
side effects such as aspiration. Gastric lavage should be lim-
ited to patients who ingest a potentially lethal amount of an
agent poorly adsorbed to charcoal or those who present less
than 1 hour after ingesting a potentially significant amount
of a toxic agent—and it should be done with care.
Ipecac, a central- and peripheral-acting agent used to
induce vomiting in patients with toxic ingestions, was once a
common method of gastric decontamination. However, this
agent is no more effective than gastric lavage, and vomiting
after ipecac can persist for several hours, precluding the use
of oral activated charcoal. Its use is contraindicated in caus-
tic and hydrocarbon ingestions and in infants under 6
months of age. At this point, syrup of ipecac has little, if any,
role in the management of toxic ingestions.
In the past, forced diuresis was recommended in the treat-
ment of several drug ingestions. Studies have shown that forced
diuresis does not enhance elimination significantly and that the
relatively large volumes of intravenous crystalloid needed can
lead to pulmonary edema, particularly in patients with cardiac
dysfunction. Forced diuresis is therefore no longer recom-
mended as a modality in treating drug ingestions.
Bateman DN: Gastric decontamination: A view for the millen-
nium. J Accid Emerg Med 1999;16:84–6. [PMID: 10191436]
Bond GR: The role of activated charcoal and gastric emptying in
gastrointestinal decontamination: A state-of-the-art review.
Ann Emerg Med. 2002;39:273–86. [PMID: 11867980]
Krenzelok EP, McGuigan M, Lheur P: Position statement: Ipecac
syrup. American Academy of Clinical Toxicology, European
Association of Poisons Centre and Clinical Toxicologists. J Toxicol
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MANAGEMENT OF SPECIFIC POISONINGS
 Sedative-Hypnotic Overdose
ESSENT IALS  OF  D IAGNOS I S
 Dysarthria.
 Ataxia.
 Emotional lability.
 Altered sensorium.
 Horizontal and vertical nystagmus.
 Respiratory, cardiovascular, and renal failure.
Table 36–8. Poisons amenable to hemoperfusion or
hemodialysis. 
Hemoperfusion Hemodialysis
Digitalis
Carbamazepine
Paraquat
Phenobarbital
Theophylline
Ethylene glycol
Methanol
Lithium
Salicylate
Theophylline
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General Considerations
Sedative-hypnotic abuse is common, particularly among
patients who began using the drugs therapeutically for
sleep or as anxiolytics. Other patients may use these drugs
orally or intravenously because of the disinhibition and
euphoria they produce. In the past, short-acting barbitu-
rates such as amobarbital, pentobarbital, and secobarbital
were used commonly; these agents are used much less fre-
quently because benzodiazepines are now prescribed more
commonly. Their use is frequently combined with other
drugs or with alcohol.
Continued abuse of sedative-hypnotics is more likely to
cause mental and physical impairment when compared
with narcotics. When administered intravenously, the alka-
line barbiturate solutions cause sclerosis of the veins and
may result in profound ischemia if intraarterial injection
occurs.
Withdrawal from sedative-hypnotics produces a charac-
teristic syndrome that may be fatal. Although a period of ini-
tial improvement may occur after 8–16 hours of abstinence,
rapid deterioration with agitation, altered mental status, and
seizures frequently follows. ICU admission is mandatory for
any patient suspected of having barbiturate withdrawal
symptoms.
Clinical Features
A. Symptoms and Signs—An overdose of these drugs results
in findings similar to those of intoxication with alcohol: ataxia,
altered sensorium, and dysarthria. Both horizontal and vertical
nystagmus may be present. When intoxication is severe, respira-
tory and cardiovascular compromise may occur. Ventilation is
usually slow and shallow, and pulmonary edema or pneumoni-
tis may develop. Centrally mediated vasomotor depression
results in a decrease in blood pressure. If perfusion is not main-
tained, renal failure may follow. Tissue hypoxia may develop as
a result of decreased respiratory function, and pupillary dilation
may be seen. Deep tendon reflexes also may be depressed.
B. Laboratory Findings—Routine laboratory studies should
include electrolytes and an arterial blood gas determination.
A sample of blood should be obtained and sent for barbitu-
rate concentration determination. Lethal levels vary widely
depending on patient factors and the presence of coinges-
tants. An acetaminophen level should be determined in case
this agent was coingested.
C. Imaging Studies—A chest x-ray is advisable to evaluate
the extent of atelectasis and pneumonitis present at the time
of admission.
Differential Diagnosis
Ingestions of nonbarbiturate sedatives such as chloral
hydrate, ethchlorvynol, glutethimide, methyprylon, and
methaqualone are the considerations when treating a barbi-
turate overdose. Coingestion of alcohol, benzodiazepines, or
opioids also must be considered.
Treatment
A. General Measures—When cardiovascular and respira-
tory parameters are normal and stable, supportive care gener-
ally is all that is required. However, when intoxication is
severe, hypoventilation and depressed cough and gag reflexes
are indications for intubation to protect the airway, prevent
aspiration, and allow for mechanical ventilation as needed.
B. Decontamination—Lavage generally should be consid-
ered if ingestion has been within the preceding 45 minutes.
Food in the stomach decreases absorption and may prolong
the time during which lavage is useful; however, if obtunda-
tion is a concern, the risks of lavage may not outweigh any
potential benefits of this procedure.
C. Diuresis—Although believed to be useful in the past,
forced diuresis is no longer felt to be useful. Sodium bicar-
bonate to alkalinize the urine prevents tubular reabsorption
of phenobarbital and supplemental potassium chloride
should be given to ensure alkalinization of the urine. Careful
serum electrolyte monitoring is mandatory.
D. Cardiovascular Support—Hypotension usually responds
to the administration of balanced salt solutions such as nor-
mal saline or lactated Ringer’s solution, although vasopres-
sors may be required. If large amounts of fluid are necessary
for resuscitation, fluid administration should be guided by
central venous or pulmonary artery catheter monitoring to
prevent pulmonary edema.
E. Hemodialysis—When renal failure occurs, hemodialysis
may be necessary. Most of the barbiturates are dialyzable,
although the short-acting forms have the lowest percentage
of removal.
Withdrawal
Withdrawal from sedative-hypnotics may be fatal. Symptoms
of withdrawal typically occur after 8–16 hours of abstinence
and include anxiety, tremulousness, weakness, and insomnia.
GI symptoms include abdominal cramping, anorexia, nau-
sea, and vomiting. As withdrawal progresses, neurologic
findings become predominant and are characterized by
twitching, coarse tremors, increased startle response, and
hyperactive deep tendon reflexes. After 2–3 days, grand mal
seizures may occur. As the seizures subside, improvement usu-
ally is noted, although some patients develop organic brain
syndrome with disorientation, visual and auditory hallucina-
tions, and delusions. Hyperthermia may lead to cardiovascular
collapse and death.
When withdrawal is suspected, the patient should be given
an intravenous dose of pentobarbital or phenobarbital based on
an estimate of the most recent consumption. This dose then can
be reduced by about 10% per day until the patient is drug-free.
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 Opioids
ESSENT IALS  OF  D IAGNOS I S
 Decreased level of consciousness.
 Depressed respiration.
 Miosis.
 Pulmonary edema.
General Considerations
Narcotic abuse is a major problem worldwide. Although the
drugs of choice traditionally have been morphine and
heroin, the shorter-acting agents such as fentanyl have come
into vogue, especially among health care workers. Most nar-
cotics are administered intravenously because of the rapid
euphoria they produce. Methadone, a long-acting oral agent,
is used commonly in narcotic addiction treatment/mainte-
nance programs. Pentazocine is a synthetic analgesic with
both agonist and antagonist properties. When given to a
narcotic-dependent patient, pentazocine may cause with-
drawal symptoms. In high doses, it can cause visual halluci-
nations and dysphoria.
Immediate care of the narcotic overdose or withdrawal
patient focuses on resuscitation, stabilization, and use of
antidotes. Critical care of patients suffering from narcotic
overdose and withdrawal may include the treatment of con-
ditions caused by narcotic use and the sharing of injection
needles. These include pulmonary hypertension (presum-
ably from cotton fiber emboli), endocarditis (from bacterial
contamination), necrotizing fasciitis, and tetanus. Other
reported complications include hepatitis, AIDS, cutaneous
abscesses, and Guillain-Barré syndrome. Many patients will
use other intoxicants concurrently, such as alcohol or
cocaine, which complicates their care.
Clinical Features
A. Symptoms and Signs—Patients with opioid overdoses
present most commonly with decreased level of conscious-
ness, depressed respiration, and miotic pupils. In severe
cases, such as cases of attempted suicide, respiratory depres-
sion may be pronounced. Pulmonary edema may be seen,
particularly in heroin overdose. Other common findings
include hypo- or hyperthermia, emesis, hypoxia, hypoten-
sion, and depression of deep tendon reflexes.
B. Laboratory Findings—A blood sample should be sent for
toxicology screen and alcohol level and to check for other
CNS depressants. Routine electrolytes, a complete blood
count, and liver function tests should be obtained. In cases of
pulmonary edema, pulse oximetry and/or an arterial blood
gas analysis will help to assess severity. In patients with oral
opioid ingestions, an acetaminophen level should be deter-
mined. If the patient is febrile and uses opioids by injection
blood cultures should be sent.
C. Imaging Studies—A chest x-ray should be obtained in
patients suspected to have pulmonary edema or other indi-
cations of pulmonary compromise. A head CT scan may be
useful in patients with depressed level of consciousness who
do not respond appropriately to naloxone to exclude the
presence of a mass lesion or intracranial bleed.
Treatment
A. General Measures—Most patients transferred to the
ICU will already have been stabilized and intravenous access
established. Patients should be reassessed on arrival to the
ICU because those with significant narcotic overdose are at
high risk for respiratory depression and airway compromise.
If indicated by either a low blood glucose determination or
in the obtunded patient in whom this measurement cannot
be made, 50 mL of 50% dextrose should be given intra-
venously along with 100 mg thiamine.
Mechanical ventilation may be required both for
decreased respiratory drive and for management of pul-
monary edema. Hypotension usually responds to volume
infusion and correction of hypoxia. Pulmonary edema
caused by narcotic overdose usually does not respond to the
customary regimen of diuretics and preload and afterload
reduction, and intubation is often required.
B. Decontamination—If the use of coingestants is sus-
pected, administration of activated charcoal is advisable; this
can be done either orally or via an nasogastric (NG) tube. If
there is a risk of aspiration, however, charcoal should be used
only if it has a high likelihood of improving the patient’s
outcome.
C. Narcotic Antagonists—Several narcotic antagonists have
been used—naloxone, naltrexone, nalmefine, nalorphine, and
levallorphan; the latter two also have agonist properties.
Although naltrexone is longer-acting than naloxone, its use in
the acute setting has been disappointing, and naloxone is the
drug of choice in this situation. An initial dose of 0.2–0.8 mg
should be administered intravenously for heroin and mor-
phine overdoses, titrating to response. When the abused drug
is codeine, pentazocine, or propoxyphene, an initial dose of
up to 2 mg naloxone may be required. When effective, an
improvement in respiration and mental status typically
occurs in less than 2 minutes, often in seconds. If no response
to a total dose of 2 mg is seen, the diagnosis of narcotic
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overdose should be questioned. Because the half-life of nalox-
one is substantially shorter than that of most narcotic agents,
repeat dosing may be required to prevent recurrence of respi-
ratory and mental status depression. Continuous administra-
tion of naloxone intravenously may be required in some cases
to prevent relapse of respiratory depression.
D. Other Modalities—Because of the complications associ-
ated with narcotic abuse, additional therapy in the ICU may
be required for pulmonary edema, pneumonitis, cardiac
valvular compromise, or infectious complications. Overdosage
with meperidine may cause hyperactive reflexes and convul-
sions. Rhabdomyolysis may occur, particularly in patients
who have been obtunded for a significant amount of time; if
not treated, patients may develop renal failure from the myo-
globinuria seen in this condition.
Withdrawal
Withdrawal from narcotics produces autonomic distur-
bances, hyperexcitability, and personality changes character-
ized by drug-seeking behavior. Within the first 8 hours of
withdrawal, lacrimation, rhinorrhea, diaphoresis, and sneez-
ing are common. This is followed by nausea and vomiting,
diarrhea, and abdominal cramping. Patients may exhibit
tremors and twitching in association with myalgias.
Pilomotor erection produces the “cold turkey” appearance of
the skin. All the symptoms are relieved by the administration
of narcotic.
Clark NC, Lintzeris N, Muhleisen PJ: Severe opiate withdrawal in a
heroin user precipitated by a massive buprenorphine dose. Med
J Aust 2002;176:166–7. [PMID: 11913917]
Compton WM, Volkow ND: Major increases in opioid analgesic
abuse in the United States: Concerns and strategies. Drug
Alcohol Depend 2006;81:103–7. [PMID: 16023304]
Joranson DE, Ryan KM, Gilson AM, Dahl JL: Trends in medical use
and abuse of opioid analgesics. JAMA 2000;283:1710–4. [PMID:
10755497]
Paulozzi LJ: Opioid analgesic involvement in drug abuse deaths in
American metropolitan areas. Am J Public Health
2006;96:1755–7. [PMID: 17008568]
Sachdeva DK, Jolly BT: Tramadol overdose requiring prolonged
opioid antagonism. Am J Emerg Med 1997;15:217–8. [PMID:
9115538]
 Sympathomimetics
ESSENT IALS  OF  D IAGNOS I S
 Agitation, anxiety, hallucinations, psychosis.
 Seizures.
 Coma, stroke, encephalopathy.
 Hypertension, tachycardia.
General Considerations
Sympathomimetics are a category of drugs that induce a
physiologic state similar to that caused by catecholamine
release. Many different prescription, over-the-counter, and
recreational or abuse drugs fall into this category.
Examples include amphetamine and its derivatives, over-
the-counter products for appetite control, cold remedies, and
stimulants (eg, phenylpropanolamine, caffeine, ephedrine, and
pseudoephedrine).
Overuse of sympathomimetics causes toxicity by induc-
ing excessive release of neurotransmitters, including epi-
nephrine and norepinephrine, and the subsequent α- and
β-adrenergic effects they produce. α-Adrenergic effects are
primarily vasoconstriction, diaphoresis, and dilated pupils;
β1-adrenergic effects lead to tachycardia, and β2-adrenergic
effects cause bronchodilation and vasodilation. The clini-
cal effects that result from any specific sympathomimetic
drug depend on the relative α- or β-adrenergic actions of
that drug (eg, phenylpropanolamine is an α-selective drug
that causes hypertension, diaphoresis, and mydriasis).
Duration of toxicity is usually limited; however, patients
may demonstrate prolonged toxicity if they ingest bags con-
taining the drug for illicit transport or if they use “Ice,” a
long-acting, smokable form of methamphetamine.
Clinical Features
A. Symptoms and Signs—Sympathomimetic toxicity
causes a toxic syndrome that includes primarily CNS and
cardiovascular effects (see Table 36–2). Both illicit drug users
and those who use excessive amounts of over-the-counter
medications (eg, diet aids, stimulants, and cold medications)
may present with sympathomimetic poisoning.
CNS toxicity is manifested as agitation, anxiety, delusions,
hallucinations, paranoia, and seizures. Sympathomimetics
may cause a psychotic state indistinguishable from that seen
in schizophrenia; although almost always temporary, this
psychosis may take weeks to months to resolve. Less common
but more severe effects include coma, strokes (ischemic and
hemorrhagic), hypertensive encephalopathy, and focal neu-
rologic deficits.
Cardiovascular effects include hypertension and sinus
tachycardia. Hypertension may be of rapid onset and severe.
Because these patients often do not have underlying hyper-
tension, they have no CNS autoregulation at these exces-
sively high blood pressures. As a result, they are much more
likely to suffer serious CNS sequelae such as hemorrhagic
strokes or encephalopathy from acute hypertension. Sinus
bradycardia or atrioventricular block occurs mainly after
ingestion of drugs with primarily α-agonist properties.
Patients may suffer tachydysrhythmias, cardiac ischemia,
and rarely, infarction.
Other findings include rhabdomyolysis with or without
renal failure, diarrhea, intestinal cramping, and hyperther-
mia. Pupils typically are dilated if the patient ingests an agent
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with α-adrenergic properties; by the same mechanism, these
patients also may be diaphoretic.
B. Laboratory Findings—Laboratory abnormalities are
variable and not diagnostic. Toxicology screening may be
positive for sympathomimetic drugs, but it is by no means
comprehensive of the wide array of available agents; there-
fore, a negative screen does not exclude sympathomimetic
toxicity. Leukocytosis is common as a result of demargina-
tion caused by catecholamine stimulation. Patients should
have a creatine kinase (CK) determination to evaluate for
rhabdomyolysis. Serum electrolytes (especially potassium)
and blood pH should be tested.
C. Imaging Studies—CT scanning is indicated in patients
with altered mental status or seizures.
Differential Diagnosis
Thyrotoxicosis may present in a manner identical to sympa-
thomimetic overdose. A history of thyroid disease is sugges-
tive of the diagnosis, as is the presence of goiter or physical
findings suggestive of hyperthyroidism. CNS infections may
cause similar clinical findings. Drug withdrawal (eg, ethanol
and benzodiazepines) also presents with agitation and car-
diovascular abnormalities. Similar clinical findings result
from toxic effects of theophylline, tricyclic and SSRI antide-
pressants, anticholinergics, isoniazid, phencyclidine, and
salicylates, and from interaction between monoamine oxi-
dase inhibitors and other drugs. The agitation and paranoia
seen in these patients may mimic psychiatric disorders such
as schizophrenia.
Treatment
A. General Measures—After initial assessment and stabi-
lization, treatment should be individualized to the drug
involved and the toxic clinical effects manifest. If the drug
was ingested, gastric lavage should be considered if presenta-
tion is within 1 hour of ingestion or if the patient is trans-
porting the drugs as a body packer. Care must be taken to
protect the airway because these patients may seize as a result
of their ingestion. Activated charcoal should be administered
to all patients with an oral ingestion. Repeat-dose activated
charcoal is helpful in enhancing caffeine elimination. Forced
diuresis, hemodialysis, and hemoperfusion are not helpful in
these poisonings.
B. Hypertension—Hypertension is a medical emergency in
these patients because of the risk of hemorrhage or
encephalopathy. Patients with evidence of end-organ dys-
function from hypertension (eg, headache, renal compro-
mise, cardiac ischemia, and heart failure) should be treated
with antihypertensive agents. Nitroprusside is a good choice
because it is easily titratable and doses can be adjusted rap-
idly. Phentolamine may be used in patients who overdose on
pure α-agonists such as phenylpropanolamine. Although
nifedipine is a potent antihypertensive agent, it is not easily
titrated, and cases of prolonged hypotension from its use
have been reported. Labetalol may be a good choice in
patients with significant tachycardia.
C. Arrhythmias—Sinus tachycardia rarely requires interven-
tion. Supraventricular tachycardia is usually benign; how-
ever, when the patient suffers compromise from the rapid
ventricular response, verapamil or adenosine may be used to
control the rhythm. Esmolol may be used to treat both
supraventricular tachycardia and ventricular dysrhythmias.
Esmolol and other β-adrenergic blockers may worsen hyper-
tension because of unopposed α-adrenergic activity.
D. Seizures—Seizures and agitation should be treated with
benzodiazepines. Status epilepticus may develop and may
require treatment with phenobarbital and phenytoin. If these
medications are ineffective, paralysis may be required to pre-
vent rhabdomyolysis, acidosis, and hyperthermia.
Continuous electroencephalographic monitoring is required
in these patients because they may continue to have electri-
cal seizure activity despite chemical paralysis.
E. Psychosis—Benzodiazepines may be used to treat psy-
chosis associated with sympathomimetic overdoses.
Although neuroleptics have been used in the past, they can
lower the seizure threshold and alter thermoregulation; their
use probably should be avoided in this situation.
F. Myocardial Ischemia—Although actual myocardial
infarction is rare, patients with angina pectoris should be
managed with aspirin, nitrates, and heart rate control.
Patients usually respond to this treatment and should be
monitored for elevation of cardiac enzymes or changes in the
ECG consistent with myocardial infarction.
G. Hyperthermia—Hyperthermia can be severe and life-
threatening. When present, aggressive treatment is war-
ranted. Patients with agitation or seizures should receive
benzodiazepines. Antipyretics are rarely helpful. All clothing
should be removed and patients sprayed with a mist of water
or covered with damp sheets to increase evaporation, and a
fan is helpful. Those with excessive agitation or seizures who
do not respond to benzodiazepines may need paralysis to
control heat production.
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 Phencyclidine 
ESSENT IALS  OF  D IAGNOS I S
 Nystagmus.
 Hypertension.
 Tachycardia.
 Agitation, psychosis, violent behavior.
 Seizures.
General Considerations
Phencyclidine (PCP), pharmacologically related to ketamine,
is an illicit hallucinogen used as a recreational drug. The
usual method of consumption is by smoking cigarettes that
have been soaked in a solution of PCP. PCP also can be used
via the intranasal route or by ingestion. Some patients have
become intoxicated from percutaneous exposure by han-
dling the drug. Absorption is rapid by any route; effects are
seen within a few minutes to half an hour. The drug is highly
lipid-soluble, and inconstant release from adipose tissue may
lead to waxing and waning findings that are predominantly
due to CNS effects. Metabolism is primarily in the liver. The
half-life varies from 7 hours to over 3 days.
Clinical Features
The clinical presentation of PCP intoxication is extremely
variable, ranging from confusion to agitation. Alterations in
mental status are erratic, and violent behavior often occa-
sions transport to a hospital. Concurrent use of other drugs
of abuse is common, and the treating physician must be
aware of this possibility when evaluating these patients. In
addition, phencyclidine is an analgesic agent. These patients
may suffer significant traumatic injuries with minimal find-
ings on examination.
A. Symptoms and Signs—The most common findings
(>50% of patients) are nystagmus (horizontal, vertical, or
rotatory) and hypertension. Although hypertension is com-
mon, medical complications are rare. Tachycardia is also
common, but rates over 130 beats/min are unusual. The level
of consciousness may vary from comatose to agitated to fully
alert. Mental status may wax and wane, and unpredictable
and precipitous violent outbursts may occur. These patients
may require physical and chemical restraints to prevent them
from hurting themselves or the medical personnel caring for
them. Hallucinations, frank psychosis, and seizures are com-
mon. Most symptoms resolve spontaneously within hours;
however, some patients may remain symptomatic for several
days or even a week. The psychosis may last months, and in
these cases, recovery may be gradual. Rhabdomyolysis is a
relatively common complication of PCP intoxication and
may lead to renal failure in up to 2.5% of cases.
B. Laboratory Findings—Urine for PCP level may be sent to
confirm the diagnosis. Quantitative levels are not necessary
and do not correlate with clinical effects. If patients who
appear to be PCP-intoxicated have negative urine results,
they need to be evaluated for other causes of their symptoms
(see “Differential Diagnosis” below).
Elevated creatine kinase levels are found in up to 70% of
cases and can occur even in the absence of excessive muscle
activity. Although usually positive for blood, initial urine
dipstick may be negative despite a significant elevation in
CK, so all patients with PCP intoxication should have a
serum sample sent for CK measurement.
C. Concealed Injuries—Because PCP has anesthetic proper-
ties, patients may suffer significant trauma in the prehospital
setting that may not be manifested in the usual fashion. All
patients should undergo a thorough physical evaluation for
trauma and be reevaluated several times during the hospital
stay, particularly as their mental status improves.
Differential Diagnosis
Lethargic patients may have consumed other intoxicants,
including sedative-hypnotic drugs or barbiturates. Patients
who are agitated or violent must be evaluated for possible
sympathomimetic use or a withdrawal syndrome. Other
causes include head trauma, infection (eg, meningitis or
encephalitis), metabolic derangements, and psychiatric
disorders.
Treatment
A. Decontamination—Gastric lavage is rarely indicated
because PCP is typically inhaled. If patients ingest the agent,
activated charcoal should be used.
B. Supportive Measures—Most patients respond to mini-
mal measures such as being placed in a quiet, darkened room
with minimal stimulation. Benzodiazepines may be useful to
decrease agitation. In some cases, however, specific treatment
measures may be necessary.
Patients with hypertension or tachycardia rarely need
intervention for these problems; end-organ dysfunction
should be managed in the usual manner. Hyperthermia
requires treatment with antipyretics and cooling measures as
necessary. Seizures should be treated with benzodiazepines.
If the patient develops refractory seizures, phenytoin may be
used, but neuromuscular blockade may be required to pre-
vent acidosis, hyperkalemia, and rhabdomyolysis.
Continuous electroencephalographic monitoring is required
in this situation.
In the past, urinary acidification was advocated to cause
urinary ion trapping of the drug and enhance elimination.
Because only a small amount of the drug is excreted
unchanged in the urine, and because induction of aciduria is
difficult to achieve and may lead to renal dysfunction owing
to rhabdomyolysis, this treatment is no longer recommended.
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C. Hydration—If serum CK is elevated, vigorous hydration is
required, and intravenous crystalloid is the mainstay of ther-
apy. Normal saline should be used until the patient is
volume-repleted and has a good urine outflow; the goal is a
urine output of 150 mL/h. Adequate urine output is the
mainstay of therapy, but additional therapy with intravenous
mannitol and bicarbonate also may be used. Follow serial CK
levels to ensure that levels decrease. BUN and creatinine lev-
els should be measured to monitor renal function, and potas-
sium levels and blood gases should be followed to evaluate
hyperkalemia and acidosis.
D. Restraints and Sedation—Patients who are agitated or
violent may require physical or chemical restraints. The use
of physical restraints alone may exacerbate rhabdomyolysis
as the patient fights against the restraints. Restrained patients
should be placed in a quiet room to avoid stimulation.
Benzodiazepines or haloperidol may be used for sedation.
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 Cocaine
ESSENT IALS  OF  D IAGNOS I S
 Hypertension.
 Tachycardia and other dysrhythmias.
 Headache.
 Myocardial infarction.
 Transient ischemic attacks, stroke.
 Seizures.
General Considerations
Cocaine is available as cocaine hydrochloride, a water-soluble
crystalline salt that can be used intranasally or dissolved and
injected intravenously. Cocaine is also available in an alkaloid
form that is not water-soluble and can be smoked in a free-
base form or mixed with baking soda and water and smoked
as the “crack” form. Absorption from all sites is rapid. The
half-life varies with the route of administration; intravenous
use or smoking leads to a half-life of 60–90 minutes, whereas
intranasal or oral use has a half-life of several hours.
Cocaine has several effects. It causes CNS release of neu-
rotransmitters, including dopamine; acts as a local anes-
thetic; blocks neuronal catecholamine reuptake; and inhibits
serotonin reuptake. The end result of these mechanisms is a
spectrum of clinical findings primarily involving the central
nervous and cardiovascular systems. Respiratory and meta-
bolic effects also may be noted.
Clinical Features
A. Symptoms and Signs—Hypertension occurs frequently
and can be severe. It can lead to intracranial bleeding, aortic
dissection, and cardiac ischemia. Tachycardia is also com-
mon, as are dysrhythmias, including atrial fibrillation, atrial
tachycardia, ventricular tachycardia, and rarely, asystole.
Cocaine is a potent vasoconstrictor that may result in
organ ischemia. Myocardial infarction, bowel ischemia, renal
infarction, and limb ischemia all have been reported. A com-
bination of vasospasm, enhanced platelet aggregation, and
enhanced workload caused by an excessive demand for oxy-
gen produces end-organ dysfunction. In addition to organ
ischemia, cocaine can cause a myocarditis manifested by ele-
vated CK-MB enzymes and diffuse ST-segment elevations or
T-wave inversions on ECG.
There are many CNS manifestations of cocaine toxicity.
Headache is common in chronic abusers. In patients who
develop CNS complications owing to cocaine, cerebral
infarction occurs in about one-fourth, subarachnoid hemor-
rhage in another one-fourth, and intraparenchymal hemor-
rhage in the remainder.
Patients who abuse cocaine also may present with
depressed mental status or frank coma, a condition known as
cocaine abstinence syndrome. This phenomenon is likely due
to CNS depletion of neurotransmitters. These patients char-
acteristically have been using large amounts of cocaine for
over a week and present either after a seizure or when they
are found obtunded. They may be frankly comatose or
extremely difficult to arouse, often prompting extensive
medical evaluation of their altered mental status. Typically,
they awaken completely within 24 hours.
Seizures occur in up to 2% of cocaine abusers, and
although they usually occur soon after cocaine use, they may
not present until several hours later. Transient ischemic
attacks have been described and may lead to stroke; cocaine
use should be considered in the differential diagnosis of a
young patient with a stroke. Strokes are independent of the
route of administration and may occur as late as 24 hours
after use. They can present in first-time users but are more
common in chronic abusers.
Pulmonary complications include pneumothorax and
pneumomediastinum in patients who smoke or snort
cocaine. Pulmonary edema is rare in most cases of cocaine
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toxicity but is a common finding in patients who die of
cocaine intoxication.
Rhabdomyolysis may occur with excess muscle activity
and hyperthermia. Hyperthermia, when present, is often
severe.
B. Laboratory Findings—Laboratory evaluation of patients
with serious intoxication should include an ECG and meas-
urements of serum electrolytes, total CK levels, and a urine
test for myoglobin. Blood for cardiac markers may be indi-
cated by the patient’s clinical presentation. Toxicology
screens for cocaine may focus the diagnosis.
C. Imaging Studies—CT head scanning should be per-
formed in any patient with a concerning headache or in
those with neurologic findings or altered mental status. Plain
films of the abdomen may reveal packets in the intestines of
patients who swallow containers of the drug for the purpose
of transport (“body packers”).
Differential Diagnosis
Other stimulants, including sympathomimetics, SSRIs, theo-
phylline, phencyclidine, and anticholinergic drugs, can cause
a similar clinical picture. Withdrawal from ethanol or benzo-
diazepines may present similarly, as can thyrotoxicosis and
CNS infection. Psychiatric disorders are also in the differen-
tial diagnosis.
Treatment
A. Supportive Measures—Basic supportive measures such
as intravenous access, fluid administration, and supplemen-
tal oxygen should be initiated as indicated by the clinical sit-
uation. Gastric decontamination is not indicated in most
cases; however, patients who have ingested packets of the
drug are candidates for whole bowel irrigation.
B. Hyperthermia—When hyperthermia is present, the
patient should be undressed completely and sprayed with a
cool mist or draped with a wet sheet. A fan can be used to
facilitate evaporation. Ice packs should be placed at the neck,
axillae, and groin. Care should be taken not to overcool the
patient. Antipyretic agents are not effective.
C. Seizures—Initial treatment of agitation and seizures
should be with benzodiazepines. Neuroleptics may be effec-
tive, but since they lower the seizure threshold, their use is
discouraged. Seizures refractory to benzodiazepines can be
treated with phenobarbital or phenytoin. Status epilepticus
unresponsive to this therapy should be treated with pharma-
cologic paralysis and mechanical ventilation; continuous
EEG monitoring is necessary in these cases to ensure that the
paralyzed patient is not seizing.
D. Hypertension—Mild hypertension usually does not require
intervention. Severe hypertension or labile hypertension
should be treated with intravenous nitroprusside. Labetalol is
another alternative, especially in the tachycardiac patient.
Tachydysrhythmias that require treatment may respond to β-
blockers such as esmolol or metoprolol, but the patient must
be observed carefully for the development of worsening hyper-
tension from the unopposed α-adrenergic stimulation and β-
adrenergic blockade. Concurrent use of nitroprusside with
β-blockers is often necessary. Patients suspected of having a
myocardial infarction should receive standard therapy, but may
or may not have classic arteriosclerotic coronary artery disease.
E. Rhabdomyolysis—Rhabdomyolysis should be treated
with isotonic fluids to ensure a urine output of over 150 mL/h.
The addition of mannitol or alkalinization also may be
useful.
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Feldman JA et al: Acute cardiac ischemia in patients with cocaine-
associated complaints: Results of a multicenter trial. Ann Emerg
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 Tricyclic Antidepressants
ESSENT IALS  OF  D IAGNOS I S
 Tachycardia, arrhythmias.
 Seizures.
 Sensorium may range from awake and alert to comatose.
 Mydriasis.
 Dry skin.
 Ileus.
 Urinary retention.
General Considerations
Tricyclic antidepressants (TCAs) such as amitriptyline, doxepin,
and trimipramine work therapeutically by blocking reuptake
of norepinephrine into adrenergic nerves, but they also have
significant toxic effects related to their anticholinergic
and α-adrenergic blocking properties. When ingested, they
are absorbed rapidly; in overdose situations, owing to the slowed
intestinal motility from the anticholinergic effects, absorption
may be prolonged, increasing the half-life to as much as 3–4 days.
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Clinical Features
A. Signs and Symptoms—Patients with TCA overdose may
deteriorate rapidly, progressing from awake with normal
vital signs to having seizures or cardiac arrest within less than
an hour of significant ingestion. Mental status may range
from awake and alert to having seizures to frankly comatose.
Patients with suspected TCA ingestion need immediate
medical evaluation and close observation. Evaluation often
reveals both central and peripheral anticholinergic effects:
tachycardia, mydriasis, dry skin, urinary retention, ileus, ele-
vated temperature (usually mild), altered mental status (eg, agi-
tation, anxiety, delirium, and coma), seizures, and occasionally,
respiratory depression. Cardiovascular effects are usually the
cause of death and can include sinus tachycardia, dysrhyth-
mias, atrioventricular blockade, and hypotension (decreased
contractility and α-adrenergic blockade). This ingestion
should be suspected in any patient who presents with seizures,
anticholinergic signs (including coma), and cardiovascular
abnormalities, particularly if the ECG is abnormal.
B. Electrocardiography—The single most valuable initial test
in patients suspected of having a TCA overdose is the ECG.
Common findings include sinus tachycardia, PR-interval and
QT-segment prolongation, and nonspecific ST-segment
changes. QRS complex prolongation suggests a serious over-
dose. Rightward and superior terminal QRS forces (a wide,
prominent S wave in leads I, aVF, and V6, with a prominent R
wave in aVR) are very suggestive of TCA overdose.
C. Laboratory Findings—General laboratory evaluation is
rarely helpful. Drug levels correlate poorly with toxic effects
and can vary widely in an individual patient.
D. Imaging Studies—Since some TCAs are radiopaque, a
plain film of the abdomen may show tablets in the stomach
or intestines.
Differential Diagnosis
The combination of altered mental status, seizures, and car-
diovascular abnormalities suggests several diagnoses.
Toxicologic causes include phenothiazines, anticholinergics,
and theophylline; less commonly, β-blockers, calcium chan-
nel blockers, and local anesthetic drug overdose (eg, lido-
caine) can cause these findings. Nontoxicologic causes
include meningitis, sepsis, hypoglycemia (severe), anaphy-
laxis, and head trauma.
Treatment
A. Initial Management—General measures aimed at stabi-
lization, monitoring, and intravenous access should be insti-
tuted rapidly. A urinary catheter should be placed to monitor
urine output and provide easy determination of urine pH.
Syrup of ipecac should be avoided because these patients may
deteriorate rapidly and become obtunded before vomiting
begins, placing them at risk for aspiration. Gastric lavage should
be considered in patients presenting within 1 hour of ingestion
of a large amount of TCAs. If gastric lavage is performed,
suction and airway management equipment must be readily
available in the event the patient develops seizures. Activated
charcoal, 100 g, should be placed down the lavage tube (if
used) or given to the patient via NG tube. There is some evi-
dence that a repeated-dose activated charcoal regimen (every
2–4 hours) may be helpful in significant ingestions.
TCA overdose patients need to be admitted to the ICU if
they have any of the following: persistent tachycardia (>120
beats/min); dysrhythmias, including premature ventricular
contractions; QRS >100 ms; hypotension; or evidence of
CNS toxicity. Patients admitted should be monitored until
they are free of toxicity for 24 hours. Patients who present
with none of the preceding and do not develop any of the
listed admission criteria after 6 hours of observation may be
discharged; a psychiatric evaluation before discharge is pru-
dent and is mandatory in cases of attempted suicide.
B. Bicarbonate Therapy—Alkalinization of the blood is a
mainstay in the therapy of TCA ingestion. It effectively treats
most of the major adverse effects of the drug, including
hypotension, cardiac conduction abnormalities, and dys-
rhythmias. Alkalinization has varying efficacy in the treat-
ment of seizures and coma. Optimal blood pH is 7.50, and
the urine pH should be over 7.0. Alkalinization is achieved by
intravenous sodium bicarbonate therapy; in intubated
patients, transient hyperventilation will alkalinize the blood
until intravenous therapy can be initiated.
Supportive care and alkalinization therapy usually are ade-
quate to manage patients with TCA overdose. In some cases,
additional measures will be needed to stabilize the patient.
Those with severe agitation, delirium, or seizures may require
benzodiazepines or barbiturates for control. Dysrhythmias
refractory to alkalinization can be treated with lidocaine or
cardioversion. Class Ia antiarrhythmic agents should be
avoided in this patient population because they can exacerbate
dysrhythmias. Hypotension that does not respond to alkalin-
ization can be managed with fluid boluses or with vasopres-
sors; since the hypotension is often due to α-adrenergic
blockade, α-adrenergic agonists (eg, phenylephrine or
methoxamine) are a good choice. Dopamine may be ineffec-
tive or may exacerbate hypotension owing to its β-agonist
effects (peripheral β2-adrenergic stimulation produces vasodi-
lation). Hemodialysis and hemoperfusion are relatively inef-
fective in these patients because the TCAs are highly
protein-bound and not easily removed by these measures.
Current Controversies and Unresolved Issues
In the past, physostigmine was recommended for treatment
of TCA overdose. As an acetylcholinesterase inhibitor,
physostigmine increases acetylcholine availability at receptor
sites and reverses central and peripheral anticholinergic
effects. It has not been proven to be effective in treating
hypotension, ventricular dysrhythmias, and conduction dis-
turbances, which are the major causes of fatal toxicity in TCA
overdoses. Significant adverse effects such as atrioventricular
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blockade, bradycardia, and asystole may occur with
physostigmine. Therefore, use of physostigmine is not rec-
ommended in the treatment of TCA overdose.
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 Serotonin Syndrome
ESSENT IALS  OF  D IAGNOS I S
 Coma, somnolence, confusion, agitation, or seizures.
 Autonomic instability, including fever, diaphoresis,
tachycardia, hyper- or hypotension, mydriasis.
 Clonus (may be spontaneous), especially ocular clonus,
rigidity, hyperreflexia.
 History of use of serotonin-based antidepressants or
other drugs associated with serotonin release.
General Considerations
The serotonin syndrome historically has been associated with
cocaine, amphetamines, and other drugs that cause increased
release of serotonin, such as a drug of abuse, 3,4–methylene-
dioxymethamphetamine (MDMA or “ecstasy”), or dex-
tromethorphan, bromocriptine, and linezolid. With the
increased use of selective serotonin reuptake inhibitors
(SSRIs) as antidepressants, overdose of these agents is respon-
sible for a number of cases of serotonin syndrome.
Clinical Features
A. Symptoms and Signs—The serotonin syndrome shares
many symptoms and signs with overdose of sympath-
omimetics (eg, tachycardia and mydriasis) and with the
neuroleptic malignant syndrome (eg, rigidity, hyperthermia,
and alterations of mental status). In fact, distinguishing sero-
tonin syndrome from these may be difficult. Most cases of
serotonin syndrome are mild and self-limited, but severe
complications can include diaphroresis with severe fluid loss,
rhabodomyolysis, marked hyperthermia, and death.
Diagnostic criteria have been proposed, but these are some-
what nonspecific.
B. Laboratory Findings—Laboratory evaluation in patients
with serious intoxication should include an ECG and meas-
urements of serum electrolytes, total CK levels, and urinary
myoglobin. There are no specific tests for this syndrome,
although toxicology studies may demonstrate the presence of
concomitant cocaine, amphetamines, or other drugs.
Differential Diagnosis
The differential diagnosis includes sympathomimetic over-
dose, including amphetamines and cocaine, both of which
also can trigger the serotonin syndrome. A more confusing
clinical picture is the neuroleptic malignant syndrome, in
which muscular rigidity, altered mental status, and hyper-
thermia are key features. Some authors have suggested that
dilated pupils with clonus and hyperreflexia rather than
severe muscle rigidity make it more likely to be the serotonin
syndrome. A key differential feature is evidence of an over-
dose of an SSRI or other drug. While neuroleptic malignant
syndrome may occur at any time after a neuroleptic is pre-
scribed, it is not more likely after an overdose. Other possible
syndromes include thyroid storm and withdrawal from ben-
zodiazepines or ethanol.
Treatment
A. Supportive Measures—Basic supportive measures such
as intravenous fluid administration and supplemental oxy-
gen should be initiated as indicated by the clinical situation.
When hyperthermia is present, the patient should be
undressed completely and sprayed with a cool mist or draped
with a wet sheet. A fan can be used to facilitate evaporation.
Ice packs should be placed at the neck, axillae, and groin.
Care should be taken not to overcool the patient. Antipyretic
agents are not effective.
B. Specific Treatment—Potential drugs precipitating the
serotonin syndrome should be discontinued. Benzodiazepines
generally are considered useful for the serotonin syndrome.
They are anticonvulsants, are not associated with serotonin
release, and are anxiolytic and sedating. Dantrolene uncou-
ples excitation-contract in skeletal muscles and has been
used in malignant hyperthermia, neuroleptic malignant
syndrome, and serotonin syndrome. There are case reports
of benefit from dantrolene in serotonin syndrome but no
controlled trials.
C. Current Controversies—A number of authors have com-
mented on the approach when it is not clear whether a
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patient has severe serotonin syndrome or neuroleptic malig-
nant syndrome. Cyproheptadine and chlorpromazine poten-
tially antagonize serotonin in the CNS, but there are no
controlled trials of these agents. However, chlorpromazine
may be contraindicated in neuroleptic malignant syndrome
because of its antidopaminergic properties. On the other
hand, bromocriptine, a central dopaminergic agonist thought
to be useful in neuroleptic malignant syndrome, may cause
the serotonin syndrome and therefore is contraindicated.
One approach is to treat with benzodiazepines as neces-
sary while carefully supporting the patient and considering
the need for dantrolene and cyproheptadine. When the clin-
ical picture becomes clearer, then other treatment may be
added.
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 Antihypertensives
ESSENT IALS  OF  D IAGNOS I S
β-Blockers:
 Bradycardia.
 Conduction blocks.
 Hypotension.
 Cardiogenic shock.
 Depressed mental status.
Calcium channel blockers:
 Bradycardia.
 Hypotension.
 Heart block.
 Drowsiness.
General Considerations
Acute overdose of β-blockers and calcium channel blockers
can be potentially life-threatening and poses significant
treatment challenges for the intensivist. Clinical manifesta-
tions of β-blocker overdose are due to the effects of systemic
β-adrenergic blockade. Toxic effects involve mainly the car-
diovascular system, but CNS effects are seen as well. β-
Blockers are absorbed rapidly from the GI tract, and clinical
effects may appear as rapidly as 20–60 minutes after inges-
tion. Half-life depends on the specific drug but ranges from
2–12 hours; excessive overdose may prolong this half-life.
Clinical effects of calcium channel blocker overdose are
caused by actions on the myocardium and on the smooth
muscle of blood vessels. This produces vasodilation and neg-
ative inotropic, dromotropic, and chronotropic activity. The
most commonly used calcium channel blockers are vera-
pamil, diltiazem, and nifedipine, and each has slightly differ-
ent effects. All are well absorbed from the GI tract, but
diltiazem and verapamil both undergo a significant hepatic
first-pass effect. Metabolism is primarily in the liver.
Clinical Features
Although toxicity is seen most frequently with oral ingestion,
significant β-blocker toxicity also can be seen in patients
being treating with β-blocker eyedrops for conditions such as
glaucoma. Patients with significant β-blockade toxicity pres-
ent with bradycardia, conduction blocks, hypotension,
decreased cardiac output, and cardiogenic shock; depressed
mental status also may be seen. Bradycardia can be severe
and appears to be more common with ingestions of propra-
nolol than with other drugs. Overdose with atenolol, nadolol,
carvedilol, and metoprolol tend to present with hypotension
and a heart rate that may be within normal limits. Pindolol
and practolol overdoses may present with tachycardia owing
to their partial agonist activity. First-degree atrioventricular
block is common with propranolol overdoses, and junctional
rhythms, bundle branch block, complete atrioventricular
block, and asystole all have been observed with β-blocker
ingestions. Hypotension is common and may be profound.
Depressed mental status is also seen frequently and is more
common in patients with significant hypotension. Seizures
are uncommon but do occur with propranolol ingestion.
Significant bronchospasm is surprisingly rare.
Significant calcium channel blocker overdose commonly
presents with bradycardia, hypotension, and significant heart
block (including third-degree heart block), which can be life-
threatening. Hypotension is due to both decreased cardiac
output and peripheral vasodilation. These patients also may
be somewhat drowsy, although markedly altered mental sta-
tus is rare.
Differential Diagnosis
β-Blocker overdoses present with bradycardia and hypoten-
sion; these findings also can occur with barbiturate intoxica-
tion and in cases of ingestion of some antiarrhythmics such
as mexiletine.
Treatment
A. Decontamination—In both β-blocker and calcium
channel blocker overdoses, patients who present soon after
ingestion of a significant amount of the drug should be con-
sidered for gastric lavage. Activated charcoal should be given;
repeat doses may be helpful. Patients who are initially stable
and who remain so need only be observed and monitored for
12–24 hours.
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B. Specific Therapy—
1. β-Blocker overdose—
a. Glucagon—Glucagon has been used with significant
success in patients with symptomatic overdoses of β-blockers
and is considered to be the drug of choice. It is effective
because its effects are independent of β-receptors, and it has
both inotropic and chronotropic effects. The dose used is
higher than that used for stimulating gluconeogenesis. The
recommended initial dose is 0.05 mg/kg intravenously, fol-
lowed by an infusion of up to 0.07 mg/kg per hour as needed.
It is important to be certain that the preparation used for
these doses does not contain phenol as a diluent because even
small amounts of phenol may be toxic. The most common
side effects of this dose of glucagon are nausea and vomiting.
b. β-Agonists—β-Adrenergic agonists have been used to
treat β-blocker overdoses with varying success. Since use of
these agents requires quantities sufficient to overcome the
competitive blockade at the receptor, the necessary doses
may be prohibitively high. Agonists may be tried empirically,
but if excessive doses are used with minimal effect, the drug
should be discontinued.
c. Atropine—Atropine, the agent usually first used to treat
symptomatic bradycardia, may have little effect in cases of β-
blocker toxicity because these rhythms are not vagally medi-
ated. When used, a dose of not more than 1 mg intravenously
should be administered. Use of external or transvenous pac-
ing has been reported, but the heart is often refractory to
normal pacing potentials, and the pacemaker may not cap-
ture despite the use of high voltage settings.
2. Calcium channel blocker overdose—
a. Calcium—Calcium channel blocker overdoses have
been treated with a variety of medications with varying suc-
cess. Calcium intuitively would seem to be appropriate ther-
apy, but its use has been disappointing. This result is not
surprising, however, because the calcium channels are
blocked, and this effect is not easily overcome with additional
calcium. Calcium is relatively nontoxic, however, and admin-
istration of calcium chloride, 5–10 mL of a 10% solution, is
probably indicated in most cases of symptomatic calcium
channel blocker toxicity.
b. Glucagon—As with β-blocker overdoses, glucagon is
useful in managing patients with calcium channel blocker
ingestion, although results have been less impressive. Dosing
is the same as that used in treating β-blocker toxicity.
c. Atropine—Atropine has been used to treat bradydys-
rhythmias and heart block but has proved to be relatively
ineffective. If the patient does not respond to 1 mg intra-
venously, use of atropine should be discontinued.
Transvenous pacing may be necessary and may require high
voltage settings outputs for capture.
d. Pressors—Dobutamine and dopamine infusions have
been used in these ingestions with varying results. These
agents may be tried in patients whose hypotension does not
respond to fluid administration and use of glucagon.
Norepinephrine also may be used.
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 Digoxin
ESSENT IALS  OF  D IAGNOS I S
 Weakness, fatigue.
 Palpitations.
 Nausea, anorexia.
 Visual complaints.
General Considerations
Digitalis is found in commercially prepared medications and
is also naturally occurring in plants such as oleander; toxic-
ity may be seen in patients exposed to medications or with
plant toxicity.
Digitalis preparations (eg, digoxin and digitoxin) have
two therapeutic effects. The first is to increase vagal tone,
which leads to conduction blockade at the atrioventricular
node and results in decreased chronotropy. The second is to
inhibit the myocardial Na+,K+-ATPase pump, which nor-
mally pumps calcium and sodium out of the cell and potas-
sium into it. Inhibition causes the intracellular calcium
concentration to rise, resulting in increased contractile force
(ie, positive inotropic effect). In the patient suffering from
digitalis toxicity, inhibition of the pump leads to excessive
extracellular potassium and intracellular sodium and cal-
cium, causing exaggerations of the therapeutic effects of the
drug. Toxicity is manifested by cardiac, GI, neurologic, and
electrolyte abnormalities.
Many of the symptoms of digitalis toxicity are nonspe-
cific. Patients may develop digitalis toxicity even when they
have normal blood levels of the drug if they have an under-
lying condition that sensitizes them to its effects (eg,
hypokalemia). Conversely, patients with elevated levels may
show no evidence of toxicity. The diagnosis of digitalis toxi-
city, therefore, often requires that the treating physician
know the patient groups at risk and suspect the diagnosis in
the appropriate setting. Table 36–9 summarizes the factors
that predispose to the development of digitalis toxicity.
Patients with any of these factors who are also taking digitalis
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should be evaluated for possible digitalis toxicity when the
clinical setting is suggestive.
Clinical Features
A. Symptoms and Signs—Over 80% of patients with digi-
talis toxicity will complain of weakness, nausea, anorexia,
fatigue, and visual complaints. The visual complaints may be
a clue to making this diagnosis. The patient may complain of
yellow or green vision or of halos around objects—in addi-
tion to other visual disturbances such as photophobia or
transient amblyopia. Other complaints include vomiting,
headache, diarrhea, and dizziness.
B. Electrocardiography—Patients with significant cardiac
toxicity may not manifest either GI or neurologic effects.
Cardiac toxicity is due both to the increased vagal effects of
the drug and to the effects on the Na+,K+-ATPase pump. In
general, cardiac toxicity results from depression of impulse
formation or conduction (vagally mediated) and from
enhancement of automaticity (caused by blocking the
Na+,K+-ATPase pump). Virtually any rhythm disturbance
can be observed in digitalis-toxic patients.
Effects on the sinus node lead to bradycardia, sinoatrial
block, and sinus arrest. Increased irritability and automatic-
ity in the atria cause atrial tachycardia and can produce
atrial fibrillation or flutter. The ventricular rate is often nor-
mal or slow as a result of the conduction block caused by
the drug. Digitalis effect in the atrioventricular node can
cause atrioventricular block or junctional rhythm. In fact,
patients with digitalis toxicity may show “regularized”
atrial fibrillation—that is, a regular junctional rhythm with
a background of atrial fibrillation owing to the high degree
of atrioventricular block. The effect in the ventricles may
cause premature ventricular contractions (the most common
digitalis toxic rhythm), ventricular tachycardia, and ventricular
fibrillation.
C. Laboratory Findings—Hyperkalemia may be observed in
acute ingestions owing to the effect of digitalis on the
Na+,K+-ATPase pump and the resulting shift of potassium to
the extracellular space. This effect is not prominent in
patients who are maintained on digitalis on a chronic basis
and develop toxicity.
Evaluation of the patient with suspected digitalis toxicity
includes a serum digitalis level, serum electrolytes (including
magnesium and calcium), BUN, and serum creatinine. An
arterial blood gas analysis or pulse oximetry should be per-
formed to ensure that the patient is not hypoxic. An ECG
also should be obtained.
Differential Diagnosis
Symptoms of digitalis intoxication are nonspecific and are
not infrequently misdiagnosed as gastroenteritis or a viral
syndrome. The bradydysrhythmias may be associated with
other medications, including β-blockers and calcium chan-
nel blockers. The observed ectopy also can occur with elec-
trolyte disorders, particularly hypokalemia, and in patients
who are hypoxic or in those with cardiac ischemia.
Treatment
A. Decontamination—In the patient with suspected digitalis
toxicity, it is crucial to determine whether the toxicity is acute,
chronic, or acute on chronic. Although the same general care
principles apply to all three situations, patients with an acute
overdose may need several additional measures such as gastric
emptying, which should be considered if the patient presents
within 1 hour of the ingestion. If performed, lavage should be
done carefully because all gastric emptying techniques cause
increased vagal tone and may lead to worsening of any brady-
dysrhythmias or blocks. Pretreatment with atropine may have
minimal effect owing to digoxin’s blocking effect on the atri-
oventricular node. Whether lavage is performed or not, char-
coal, 50–100 g orally, should be given to adsorb any digitalis
remaining in the GI tract. Repeat-dose activated charcoal may
be effective in enhancing elimination of the drug.
Cholestyramine, which binds digitalis in the gut, also has
been used for this purpose in doses of 4–8 g orally, but it has
no particular advantage over charcoal. Drug levels should not
be drawn until at least 6 hours after the acute ingestion
because it takes that long for the drug level to equilibrate, and
levels obtained sooner may be misleadingly high.
In most cases of chronic toxicity, withdrawal of the drug
and a period of observation are all that are required for treat-
ment. In cases of both acute and chronic toxicity, forced
diuresis, hemoperfusion, and hemodialysis have been shown
to be ineffective in removing digitalis owing to its high
degree of protein binding.
B. Management of Electrolyte Abnormalities—Patients
who develop hyperkalemia should be treated with the
standard treatment regimen. It is important to note, how-
ever, that some of these measures may be ineffective in the
presence of digitalis toxicity. Use of bicarbonate and the
Table 36–9. Predisposing factors in digitalis toxicity.
Increased Sensitivity Increased Drug Level
Electrolyte disturbances 
Hypokalemia 
Hypernatremia 
Hypercalcemia 
Hypomagnesemia  
Cardiac abnormalities 
Ischemia 
Cardiomyopathy 
Conduction abnormalities 
Hypoxemia 
Drugs 
Verapamil 
β-blockers 
Diuretics 
Renal disease
Drugs
Quinidine
Verapamil
Amiodarone
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administration of glucose and insulin intravenously require
an intact Na+,K+-ATPase pump to reduce the elevated potas-
sium and may not produce the desired effect of lowering the
potassium level. Intravenous calcium is contraindicated
because it sensitizes the patient further to the toxic effects of
the digitalis. Sodium-potassium exchange resins are effective
and probably constitute the first choice in treating hyper-
kalemia from digitalis toxicity (polystyrene sulfonate, 15 g in
20–100 mL of syrup orally one to four times daily or 30–50
g in 100 mL of water per rectum every 6 hours). Dialysis is
also effective and can be used if hyperkalemia is life-
threatening or refractory to exchange-resin treatment.
Digitalis antibodies (see below) are also effective in
treating hyperkalemia. A serum potassium level over 5
meq/L in the setting of an acute overdose is an indication for
treatment with antidigitalis antibodies.
C. Treatment of Arrhythmias—The major and most life-
threatening toxicity associated with digitalis is cardiotoxicity.
Bradydysrhythmias, owing to the increased vagal tone,
should be treated with atropine starting with doses of 0.5 mg
intravenously. Doses can be repeated at 5-minute intervals as
necessary to a total dose of about 2 mg (0.3 mg/kg). If the
bradydysrhythmias are refractory to atropine, electrical pac-
ing may be necessary.
Tachydysrhythmias or rhythms resulting from increased
automaticity should be treated in a stepwise approach. First,
if the patient is hypokalemic (serum potassium <3.5 meq/L),
particularly if the patient is suffering from chronic toxicity,
potassium should be gently replenished, with frequent moni-
toring of the serum potassium level. Magnesium should be
given to virtually all patients with tachydysrhythmias except
those with elevated magnesium levels or those with renal fail-
ure. The optimal dose is unknown, but 2 g of magnesium sul-
fate intravenously over 20–30 minutes appears effective. In
patients whose tachydysrhythmia does not respond to elec-
trolyte replacement or who have contraindications to elec-
trolyte replacement, lidocaine should be used. If the patient’s
tachydysrhythmias persist despite adequate lidocaine dosing,
phenytoin poses an effective alternative, aiming for a thera-
peutic level of 10–20 μg/mL. Cardioversion is safe when used
in patients who have normal digitalis levels and no evidence
of toxicity. However, cardioversion in patients with digitalis
toxicity can lead to refractory ventricular tachycardia, ventric-
ular fibrillation, or asystole. It should be avoided if possible in
this group of patients, and all attempts should be made to
treat dysrhythmias medically. However, in some cases, car-
dioversion may be necessary to regain a perfusing rhythm. If
needed, it is critical that the lowest possible energy level be
used to achieve cardioversion. If possible, pretreatment with
lidocaine may be prudent.
D. Antibodies—Digoxin-specific antibodies (digoxin immune
Fab [ovine]) are a vital addition to the armamentarium for
treating digitalis toxicity, but their use should be limited to very
specific situations. These antibodies are sheep serum Fab frag-
ments that have a high affinity for digoxin—higher than the
affinity of digoxin for Na+,K+-ATPase. They circulate in the
intravascular space and diffuse into the extracellular space,
where they bind to free digoxin. The complex formed has no
biologic activity and is excreted in the urine. The intracellular-
to-extracellular gradient produced by the binding of extracel-
lular free digoxin causes intracellular digoxin to diffuse from
within the cells to be bound to the antibody and subsequently
excreted. Indications for use of these antibodies are listed in
Table 36–10. In general, digitalis-specific antibody should be
used when there are life-threatening dysrhythmias that do not
respond to conventional therapy, in patients with an initial
potassium level of greater than 5 meq/L (particularly in acute
ingestions), in patients who have ingested more than 10 mg of
digoxin (4 mg in children), and in those who have a steady-
state digoxin level of greater than 10 ng/mL.
Dosing of digoxin antibodies is based on the fact that
each vial contains 40 mg antibody and will bind 0.6 mg
digoxin or digitoxin. The formula for calculating the dose of
antibody in a particular patient is shown below:
Life-threatening dysrhythmias 
Serum potassium >5 meq/L 
Acute ingestion of >10 mg of digoxin (>4 mg in children) 
Steady-state digoxin level >10 ng/mL 
Table 36–10. Indications for therapy with digoxin
antibodies.
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In patients with life-threatening complications who have
ingested an unknown amount, or if the blood level is
unavailable, a dose of 20 vials (800 mg) should be given.
Dysrhythmias are treated successfully with these antibod-
ies in about 70% of patients. The rhythms usually respond
within 20–60 minutes of administration of the antibody. Side
effects are generally mild. Up to 15% of patients may develop
minor allergic reactions, and some patients with preexisting
congestive heart failure may have an exacerbation owing to
the volume of fluid used to infuse the antibodies. It is impor-
tant to note that measuring digoxin levels after giving anti-
bodies is unreliable for up to 7 days after their
administration. Levels tend to rise to alarming levels because
so much of the drug ends up in the circulation bound as the
inactive antibody complex.
Current Controversies and Unresolved Issues
The treating physician must understand the indications for
digoxin antibodies and use them appropriately. Patients who
have minor manifestations of digitalis toxicity such as GI
complaints or visual changes and those with evidence of car-
diac toxicity that does not need intervention or responds to
conventional therapy do not need this treatment. In addition,
patients with elevated digitalis levels but without evidence
of toxicity do not need treatment unless their levels are over
10 ng/mL at steady state. The levels should be measured at least
6–8 hours after the ingestion or the last dose of the medication.
Critchley JA, Critchley LA: Digoxin toxicity in chronic renal fail-
ure: Treatment by multiple dose activated charcoal intestinal
dialysis. Hum Exp Toxicol 1997;16:733–5. [PMID: 9429088]
Dawson AH, Whyte IM: Therapeutic drug monitoring in drug
overdose. Br J Clin Pharmacol 2001;52:97–102S. [PMID:
11564057]
Eddleston M et al: Anti-digoxin Fab fragments in cardiotoxicity
induced by ingestion of yellow oleander: A randomised, con-
trolled trial. Lancet 2000;355:967–72. [PMID: 10768435]
Van Deusen SK, Birkhahn RH, Gaeta TJ: Treatment of hyper-
kalemia in a patient with unrecognized digitalis toxicity. J Toxicol
Clin Toxicol 2003;41:373–6. [PMID: 12870880]
 Acetaminophen
ESSENT IALS  OF  D IAGNOS I S
 Nausea and vomiting.
 Jaundice.
 Right upper quadrant pain.
 Asterixis.
 Lethargy and coma.
 Bleeding.
 Hypoglycemia.
General Considerations
Acetaminophen is an antipyretic and analgesic medication
available over the counter generically and in several brand-
name preparations. It is also used commonly in many com-
bination medications, both over the counter and available by
prescription. Overdose may occur inadvertently or inten-
tionally. Patients may ingest excessive doses of acetamino-
phen in an attempt to treat their own pain, being unaware of
the potential for toxicity. In the intentional overdose, treating
physicians must be aware that many medications contain
acetaminophen as a component of a combination prepara-
tion, and what might otherwise be a relatively benign inges-
tion from the other active ingredients in the medication
becomes a potentially lethal one in light of the amount of
acetaminophen consumed.
Acetaminophen is normally metabolized by the liver to
non-toxic compounds. If these pathways are saturated, a
toxic intermediate (N-acetyl-p-benzoquinoneimine) is
formed that is detoxified by glutathione. Excessive amounts
of acetaminophen deplete glutathione stores, leading to
accumulation of high levels of these toxic metabolites. The
major toxicity is hepatotoxicity, with hepatocyte necrosis
and, in severe cases, frank liver failure. N-Acetylcysteine, the
antidote for this toxicity, acts by enhancing glutathione stores
and providing a glutathione substitute to allow for detoxifi-
cation of the toxic metabolites.
Susceptibility to toxicity is variable. Patients with liver
disease or severe malnutrition are more sensitive, whereas
children under 9–12 years of age are more resistant than their
adult counterparts. Toxic doses vary; in adults, doses of less
than 125 mg/kg are rarely toxic unless the patient has preex-
isting liver disease or malnutrition. Doses of 125–250 mg/kg
produce variable toxicity, with some patients developing sig-
nificant liver damage at these levels. Doses over 250 mg/kg
commonly place the patient at risk to develop massive
hepatic necrosis and liver failure. Patients with severe hepa-
totoxicity eventually die from massive liver failure 4–18 days
after ingestion. Among patients who recover, liver enzymes
begin to normalize 5 days after ingestion, and full recovery
occurs within 3 months. Chronic liver disease after aceta-
minophen ingestion is extremely rare in patients who were
healthy prior to ingestion.
Clinical Features
A. History—The treating physician must be aware of the
potential for acetaminophen toxicity in virtually all patients
with intentional overdoses because of the widespread avail-
ability of this compound in combination preparations. In
addition, patients may unintentionally take excessive
amounts of acetaminophen to treat themselves for painful
conditions, not knowing that this drug may be toxic.
B. Symptoms and Signs—Despite ingesting potentially
lethal amounts of the agent, patients with acetaminophen
overdose often are asymptomatic or minimally symptomatic
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in the first 24 hours. GI complaints such as nausea and
vomiting are common in large overdoses but may not be
seen in all serious overdoses. Patients also may be somewhat
lethargic and diaphoretic. Twenty-four to forty-eight hours
after ingestion, the patient feels well; however, hepatotoxicity
begins during this time, and levels of hepatic enzymes begin
to rise. Three to four days after significant ingestion, the
patient presents with progressive hepatic damage, nausea,
vomiting, jaundice, right upper quadrant pain, asterixis,
lethargy, coma, and bleeding, and hypoglycemia may develop.
C. Laboratory Findings—The single most important labo-
ratory test in patients who present after acetaminophen
ingestion is the acetaminophen level. A serum sample
should be drawn at least 4 hours after an acute single inges-
tion; levels drawn before this 4-hour time delay are unreli-
able in predicting toxicity. The acetaminophen treatment
protocol nomogram (Figure 36–1) is used to ascertain
patient risk. In general, patients who have a 4-hour level of
over 150 μg/mL should be regarded as toxic and treated
accordingly.
Patients with significant ingestions should have their liver
enzymes and coagulation studies checked at least once every
12–24 hours and should be monitored closely for hypo-
glycemia, which is common among those with hepatotoxicity.
Differential Diagnosis
Liver failure may be caused by a number of other toxins, most
commonly chronic ethanol abuse. Acute ingestions such as
cyclopeptide toxicity following mushroom ingestion also
cause liver damage. Shock liver and massive hepatic necrosis
from hepatitis also may produce a similar clinical picture.
Treatment
A. Decontamination—All patients who present within 1 hour
of ingesting a potentially lethal amount of acetaminophen-
containing medications should be considered for gastric
emptying. Use of activated charcoal is somewhat controver-
sial because activated charcoal binds and prevents the
absorption of both acetaminophen and its antidote, acetyl-
cysteine (N-acetylcysteine). The charcoal may bind up to
40% of the acetylcysteine. However, increasing the acetylcys-
teine dose can provide adequate absorption despite the use of
charcoal. Therefore, if charcoal is used, the acetylcysteine dose
should be adjusted accordingly.
Patients who present more than 4–6 hours after inges-
tion already have absorbed the acetaminophen, making
gastric decontamination and charcoal administration rela-
tively ineffective. It should be noted, however, that patients
may have ingested other medications along with the aceta-
minophen that may respond to repeated-dose charcoal
treatment if the ingested agent is one that can be recovered
in this way.
B. Acetylcysteine—To date, there are no reliably effective
methods for enhancing the elimination of acetaminophen
already absorbed from the gut. Therefore, antidote therapy
is the mainstay of treatment for patients with potentially
toxic ingestions. Acetylcysteine is indicated in patients who
have toxic levels, as determined by the treatment nomo-
gram, and in those who may have ingested toxic amounts
of acetaminophen and present 8 hours or more after inges-
tion (see Figure 36–1). Acetylcysteine is most effective
when given within the first 8 hours after ingestion; after
that time, efficacy decreases with increasing delay. There is
no benefit to giving acetylcysteine in the first 4 hours after
ingestion, so treating the patient with acetylcysteine can
wait until the acetaminophen level is known if this infor-
mation will be available within 8 hours of ingestion. If the
result will be delayed beyond the 8-hour window and the
patient ingested a significant amount of acetaminophen,
acetylcysteine therapy should be started empirically and
can be discontinued if the level obtained falls in the non-
toxic range.
Acetylcysteine usually is given orally. The loading dose is
140 mg/kg, and subsequent doses of 70 mg/kg then are given
every 4 hours, typically for a total of 17 doses. A 2-day regi-
men also has been used successfully in selected patients.
Patients with acetaminophen toxicity may have significant
nausea and vomiting, which may make oral administration
of acetylcysteine difficult. As a rule, patients who vomit
 Figure 36–1. Acetaminophen treatment protocol.
(Adapted from Rumack BH et al: Acetaminophen overdose:
662 cases with evaluation of oral acetylcysteine treatment.
Arch Intern Med 1981;141:382 [PMID: 7469629].)
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within 1 hour of receiving their oral acetylcysteine dose
should have that dose repeated. In addition, several measures
can be taken to minimize this difficulty. Antiemetics (eg,
prochlorperazine, metaclopramide, or ondansetron) should
be used. If they prove inadequate, the acetylcysteine may be
administered via an NG tube.
Some patients with toxic acetaminophen levels may have
persistent vomiting despite the preceding measures, preclud-
ing enteric administration of acetylcysteine. In this situation,
intravenous acetylcysteine is indicated and can be lifesaving.
Recently, an intravenous formulation of N-acetylcysteine was
approved for use in the United States. Dosing is the same as
for the oral route.
Common complications of intravenous acetylcysteine
treatment are rashes and urticaria. Serious reactions are rare.
Complications are minimized when acetylcysteine is deliv-
ered in at least 250 mL of diluent and infused over 1 hour.
C. Other Measures—Supportive care, including administra-
tion of vitamin K and lactulose, is indicated in patients with
coagulopathy or encephalopathy, respectively. In severe cases
refractory to supportive care, liver transplantation may be
necessary.
Current Controversies and Unresolved Issues
Administration of acetylcysteine beyond 24 hours after acet-
aminophen ingestion has been shown to have little effect.
Despite this information, and because there are few treat-
ment options other than supportive care and liver transplan-
tation in severely toxic cases, acetylcysteine probably should
be used in these situations. The duration of treatment is also
controversial. Currently, a 72-hour course is considered the
standard of care, but studies have shown that a 48-hour
course may be just as effective.
American College of Emergency Physicians Clinical Policies
Subcommittee (Writing Committee) on Critical Issues in the
Management of Patients Presenting to the Emergency
Department with Acetaminophen Overdose, Wolf SJ et al:
Clinical policy: critical issues in the management of patients pre-
senting to the emergency department with acetaminophen over-
dose. Ann Emerg Med 2007;50:292–313. [PMID: 17709050]
Broughan TA, Soloway RD: Acetaminophen hematoxicity. Dig Dis
Sci 2000;45:1553–8. [PMID: 11007105]
Dart RC et al. Acetaminophen poisoning: An evidence-based con-
sensus guideline for out-of-hospital management. Clin Toxicol
(Phila) 2006;44:1–18. [PMID: 16496488]
Dawson AH, Whyte IM: Therapeutic drug monitoring in drug over-
dose. Br J Clin Pharmacol 2001;52:97–102S. [PMID: 11564057]
Gunn VL et al: Toxicity of over-the-counter cough and cold med-
ications. Pediatrics 2001;108:E52. [PMID: 11533370]
Gyamlani GG, Parikh CR: Acetaminophen toxicity: suicidal vs
accidental. Crit Care 2002;6:155–9. [PMID: 11983042]
Larson AM et al. Acetaminophen-induced acute liver failure:
Results of a United States multicenter, prospective study.
Hepatology 2005;42:1364–72. [PMID: 16317692]
 Salicylates
ESSENT IALS  OF  D IAGNOS I S
 Nausea and vomiting.
 Tinnitus.
 Diaphoresis.
 Hyperventilation.
 Confusion and lethargy.
 Convulsions and coma.
 Cardiovascular failure.
General Considerations
Salicylates are used widely as antipyretics, analgesics,
antiplatelet agents, and anti-inflammatories; salicylates are
also found in topical preparations used to treat sore joints
and muscles. Not only are they available as aspirin preparations,
but they also constitute a common component of other com-
bination medications readily available over the counter.
Another source of salicylates is oil of wintergreen; this for-
mulation contains very large amounts of the drug, with con-
centrations as high as 7 g per teaspoon (compared with
325–650 mg per tablet in most aspirin preparations).
When taken orally, salicylates are absorbed rapidly from
both the stomach and the small bowel. Peak blood levels
occur 2 hours after ingestion of a normal dose. In therapeu-
tic doses, salicylates undergo hepatic metabolism and renal
excretion with a half-life of 4–6 hours. In the event of an
overdose, the hepatic enzymes become saturated, and metab-
olism changes from first-order (concentration-dependent)
to zero-order (concentration-independent) kinetics. Under
these circumstances, the drug’s half-life increases dramati-
cally to 18–36 hours. In the event of an overdose, renal excre-
tion of the unchanged salicylate becomes the major pathway
of drug elimination.
Salicylates produce respiratory alkalosis by directly stim-
ulating the CNS respiratory center and by increasing its sen-
sitivity to changes in CO2 and oxygen concentrations.
Salicylates also uncouple oxidative phosphorylation, which
leads to an increased metabolic rate with a resulting increase
in glucose utilization, oxygen consumption, and heat pro-
duction. Clinical effects of this uncoupling include hypo-
glycemia and fever. Inhibition of enzymatic components of
the Krebs cycle occurs, leading to an increase in pyruvate and
lactate that causes a elevated anion gap metabolic acidosis. As
a result of their stimulatory effects on lipid metabolism, sal-
icylates increase ketone formation.
Clinically, it is important to divide patients with salicylate
toxicity into two groups: those who take the medication on a
chronic basis and those who have taken an acute overdose.
Patients who use aspirin chronically, such as the elderly or
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patients with arthritis, may present with unintentional over-
dose, and because they may have subtle clinical findings,
these patients are often misdiagnosed. As a result of this mis-
diagnosis, serious sequelae may develop, such as pulmonary
and CNS complications, with a mortality rate that
approaches 25%. The acute overdose group, on the other
hand, ingests this drug intentionally, and the acutely elevated
levels cause these patients to be more symptomatic and
therefore easier to diagnose. Acute ingestions of over 150
mg/kg are commonly associated with symptoms of toxicity.
Pulmonary and neurologic complications are less common
in this group, and the mortality rate is only 2%.
Clinical Features
A. Symptoms and Signs—Patients with mild to moderate sal-
icylate toxicity present with nausea, vomiting, tinnitus,
diaphoresis, and hyperventilation (eg, hyperpnea or tachypnea),
confusion, and lethargy. In cases of severe poisoning, convul-
sions, coma, and respiratory or cardiovascular failure may
occur. These symptoms of coma, seizures, hyperventilation, and
dehydration are more common in patients with chronic poison-
ing and are observed at lower salicylate levels (35–50 mg/dL).
Pulmonary edema, cerebral edema, gastritis with hematemesis,
and hyperpyrexia are observed occasionally.
B. Laboratory Findings—Salicylate levels are important in
the management of these patients. Peak levels after overdose
occur 4–6 hours after ingestion. This peak may be delayed or
prolonged if the patient ingested enteric-coated preparations
or if the patient develops gastric concretions of aspirin after
a massive ingestion. The Done nomogram (Figure 36–2)
estimates the severity of acute salicylate toxicity; it does not
apply in the patient with chronic toxicity. Levels obtained
6 hours or more after an acute ingestion can be plotted on the
nomogram and extrapolated to obtain the level of severity.
Common laboratory findings in a patient suffering from
salicylism are an elevated anion gap metabolic acidosis and
respiratory alkalosis. Other laboratory abnormalities may
include a prolonged prothrombin time, thrombocytosis,
hypernatremia, hyper- or hypoglycemia, ketonemia, lactic
acidemia, hypokalemia, and elevated liver transaminases. A
urine Phenistix test is usually positive, as is the ferric chloride
test (5–10 drops of 10% ferric chloride solution added to
urine that has been boiled for 1–2 minutes will turn the solu-
tion a burgundy color). Because coingestions are common,
an acetaminophen level should be obtained.
Differential Diagnosis
Because salicylism often presents with altered mental status
and an increased metabolic state, other entities that cause
this combination should be considered in the differential
diagnosis. Stimulants are the primary toxicologic cause, and
meningitis, sepsis, or encephalitis are possible infectious
sources. Pneumonia, renal failure, diabetic ketoacidosis, and
alcoholic ketoacidosis also should be considered.
Treatment
A. Decontamination—Gastric lavage should be performed
in any patient with an ingestion of over 100 mg/kg within
1 hour before presentation. Gastric lavage also should be
considered in patients who have ingested massive amounts of
salicylates because they are prone to develop intragastric or
intraintestinal concretions; lavage may be helpful as late as
12–24 hours after ingestion in these cases. Activated charcoal
should be given to all patients with salicylate ingestion.
Repeated-dose activated charcoal administration should be
considered in patients with a significant exposure.
B. Alkaline Therapy—Alkalinization is the mainstay of
therapy for salicylate poisoning. It is indicated for patients
with significant acidemia and for those with blood salicylate
levels of over 35 mg/dL. In an alkaline environment, salicy-
lates remain in an ionized form and do not easily diffuse into
tissues. Alkalinization of the urine leads to trapping of the
salicylates in the renal tubules and facilitates excretion. The
goal of treatment is to achieve and maintain the urine pH at
8.0 or above. An adequate serum potassium level is required
before urinary alkalinization can be achieved, and patients
Asynotinatuc
Moderate
 Figure 36–2. Nomogram for determining severity of
salicylate intoxication. Absorption kinetics assume acute
(one-time) ingestion of non-enteric-coated preparation.
(Redrawn and reproduced, with permission, from Done AK:
Salicylate intoxication: Significance of measurement of sali-
cylate in blood in cases of acute ingestion. Pediatrics
1960;26:800 [PMID: 13723722].)
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may require potassium supplementation to ensure adequate
blood levels. Patients receiving bicarbonate therapy should
be evaluated serially for the possible development of cerebral
or pulmonary edema.
C. Hemoperfusion and Hemodialysis—Hemoperfusion
and hemodialysis effectively remove salicylates from the
blood (Table 36–11). Hemodialysis may be preferable
because it also can be used to manage fluid and electrolyte
imbalances. Hemodialysis is specifically indicated for
patients who are deteriorating despite supportive and con-
ventional therapy, those with acute levels over 120 mg/dL if
drawn less than 6 hours after ingestion or 100 mg/dL if
drawn at 6 hours after ingestion despite the clinical presenta-
tion, those with chronic toxicity and levels of 60–70 mg/dL,
those with rising salicylate levels despite attempts at elimina-
tion, those with significant CNS effects, and those with pul-
monary edema or renal or hepatic failure.
D. Other Measures—Patients who develop seizures should
be treated with benzodiazepines or phenobarbital.
Hypotension should be treated with fluids and vasopressors.
Pulmonary edema may develop as a result of capillary dam-
age from salicylates and can be exacerbated by aggressive fluid
therapy. Development of pulmonary edema may require
intubation and mechanical ventilation with positive end-
expiratory pressures. Hemodialysis is frequently required in
these instances.
Chyka PA et al: Salicylate poisoning: An evidence-based consensus
guideline for out-of-hospital management. Clin Toxicol (Phila)
2007;45:95–131. [PMID: 17364628]
Hofman M, Diaz JE, Martella C: Oil of wintergreen overdose. Ann
Emerg Med 1998;31:793–4. [PMID: 9624330]
O’Malley GF: Emergency department management of the
salicylate-poisoned patient. Emerg Med Clin North Am
2007;25:333–46. [PMID: 17482023]
Skelton H et al: Drug screening of patients who deliberately harm
themselves admitted to the emergency department. Ther Drug
Monit 1998;20:98–103. [PMID: 9485563]
 Theophylline
ESSENT IALS  OF  D IAGNOS I S
 Nausea and vomiting.
 Tachycardia with atrial or ventricular dysrhythmias.
 Hypotension.
 Agitation, hyperreflexia, seizures.
 Hypokalemia.
General Considerations
Although inhalational agents are now the first-line therapy
for reactive airways disease, theophylline is a phosphodiesterase
inhibitor that is still used for the treatment of this disorder.
It comes in several forms, including an elixir and tablets that
are absorbed rapidly. Drug levels usually peak 2–4 hours after
ingestion. Theophylline is also available as a sustained-
release preparation whose serum level peaks anywhere from
6–24 hours after ingestion.
As a phosphodiesterase inhibitor, theophylline produces
an increase in intracellular cAMP, a mediator of β-adrenergic
effects. In addition, at toxic levels, theophylline causes cate-
cholamine release from the adrenal medulla. Therefore, the
result of toxic levels of theophylline is excessive β-stimulation,
and most of the toxic effects are a result of this excessive cat-
echolamine activity. Theophylline toxicity also causes CNS
effects, the mechanism of which is unclear.
Theophylline toxicity, like that of salicylates, causes two
distinct clinical entities depending on whether the toxicity
results from acute ingestion or chronic intake. Acute toxicity
usually results from an intentional overdose in a patient not
already taking the medication. Chronic toxicity is usually an
inadvertent overmedication in a patient already maintained
on this drug. Patients with acute intoxications more com-
monly have metabolic abnormalities and tolerate higher lev-
els of the drug, often not demonstrating serious toxic effects
until the levels reach 80–100 mg/L. Patients with chronic tox-
icity, on the other hand, often do not demonstrate metabolic
abnormalities but may manifest serious toxicity at levels as
low as 40 mg/L. It is also important to note that in the patient
with chronic toxicity, the serum levels often do not correlate
with the severity of toxicity—that is, the patient with what
may appear to be a mildly elevated drug level may have life-
threatening toxic effects. This is particularly true in elderly
patients with chronic theophylline toxicity.
Clinical Features
A. Symptoms and Signs—Theophylline toxicity causes GI,
cardiovascular, CNS, and metabolic abnormalities. As a result
of local gastric irritation and central effects, patients often
complain of nausea and vomiting. This is not universal,
Acute ingestion with levels over 120 mg/dL if drawn <6 hours after
ingestion, or over 100 mg/dL if drawn ≥6 hours after ingestion 
Chronic toxicity with a salicylate level of 60–70 mg/dL 
Deterioration despite conventional therapy 
Significant central nervous system toxicity 
Renal failure 
Hepatic failure 
Pulmonary edema 
Rising salicylate levels despite attempts at decontamination
and elimination 
Table 36–11. Indications for hemodialysis in salicylate
therapy. 
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however, and patients may have other life-threatening toxic
effects without GI complaints.
Owing to the excessive β-stimulation, patients are often
tachycardic and prone to ventricular tachydysrhythmias.
Atrial dysrhythmias, including atrial fibrillation and multifo-
cal atrial tachycardia, are also seen. As a result of the stimula-
tion of peripheral β2-adrenergic receptors and vasodilation,
these patients may develop hypotension. Decreased diastolic
pressure may be a warning sign that severe vasodilation is
developing.
Patients with theophylline toxicity demonstrate agitation,
hyperreflexia, and tremulousness. Seizures may develop and
are often the first CNS sign of toxicity; this is frequently the
case in patients with chronic toxicity. Seizures may be focal or
generalized and are often prolonged; status epilepticus is not
uncommon. Seizures may be refractory to anticonvulsant
therapy and can result in permanent brain damage or death.
B. Laboratory Findings—Hypokalemia is common with
acute ingestions; it occurs as a result of a theophylline-
induced intracellular shift of potassium. Theophylline toxic-
ity also causes hyperglycemia, metabolic acidosis, respiratory
alkalosis, and leukocytosis.
Differential Diagnosis
In addition to theophylline, toxic causes of altered mental
status, seizures, and cardiovascular abnormalities include tri-
cyclic antidepressants, anticholinergic agents, and phenoth-
iazines. Rarely, calcium channel blockers, β-blockers, and
overdoses of local anesthetic agents cause these findings.
Nontoxic causes include meningitis, sepsis, anaphylaxis, head
trauma, and hypoglycemia.
Treatment
A. General Measures—Basic supportive measures such as
intravenous access, hemodynamic monitoring, oxygen
administration, and airway management (as needed) should
be the first priority.
B. Correction of Hypotension—Hypotension should be
treated initially with infusion of crystalloid as a bolus of
250–500 mL over several minutes, repeated as necessary. If
infusions of balanced salt solution do not correct the
hypotension, or if the patient cannot tolerate the volume,
pressors may be necessary. Pure α-agonists such as phenyle-
phrine are preferable to pressors with beta-effects that may
exacerbate theophylline toxicity. Propranolol also may be
used to treat the hypotension in patients who do not have
contraindications to using this drug. The mechanism for the
efficacy of propranolol lies in the fact that it blocks the
peripheral β2-adrenergic receptors that participate in the
peripheral vasodilation of theophylline toxicity.
C. Antiarrhythmics—Patients who have severe supraven-
tricular dysrhythmias from theophylline toxicity (eg, severe
sinus tachycardia, supraventricular tachycardia, or multifocal
atrial tachycardia) may be treated with verapamil or β-
blockers if there are no contraindications to using these
drugs. Ventricular dysrhythmias should be treated by cor-
recting hypokalemia and administering lidocaine.
D. Anticonvulsants—Seizures should be treated with ben-
zodiazepines, phenobarbital, or phenytoin singly or in com-
bination. Seizures accompanying theophylline toxicity are
frequently refractory to treatment. It may be necessary to
either place the patient under general anesthesia or use neu-
romuscular blockade to prevent acidosis and rhabdomyoly-
sis and to facilitate ventilation. Patients still may have
electrical seizure activity despite being anesthetized or para-
lyzed. Electroencephalographic monitoring should be used
to make this determination.
E. Decontamination—Once the patient is stabilized hemo-
dynamically, prevention of further absorption of the drug is
the next goal. Patients who present within the first hour after
ingestion should be considered for gastric lavage; because
seizures may be precipitous, intubation is often indicated
before lavage if the patient manifests signs of significant tox-
icity. If the patient ingested a sustained-release form of theo-
phylline, lavage should be considered as long as 3–4 hours
after ingestion.
Charcoal administration is pivotal in treating patients
with theophylline toxicity. All patients, regardless of the time
since ingestion, should receive activated charcoal, in a dose of
either 1–2 g/kg or 10 g of charcoal for every gram of theo-
phylline ingested. This can be given orally or via the lavage
tube. For patients who cannot drink the charcoal slurry, an
NG tube should be placed and the charcoal delivered directly
into the stomach. Serial charcoal dosing is a mainstay in the
treatment of theophylline toxicity. Charcoal avidly binds
theophylline, making this treatment akin to “gastrointestinal
dialysis.” Doses of 0.5–1 g/kg of charcoal every 2 hours dra-
matically decrease the half-life of theophylline. To prevent GI
fluid and electrolyte losses, it is essential not to give cathartics
with each dose of the charcoal. Cathartics should be given
with the first dose of charcoal only, and subsequent doses
should be a slurry of the charcoal only. If the serial charcoal
needs to be continued for more than 24 hours, cathartics can
be given once or twice daily as needed. If the patient has per-
sistent vomiting that precludes charcoal administration,
metoclopramide or ondansetron can be given intravenously.
In these patients, the charcoal may be better tolerated when
given as a continuous administration of 0.25–0.5 g/kg per
hour via an NG tube.
Despite appropriate treatment, some patients with theo-
phylline toxicity continue to have dysrhythmias, hypoten-
sion, and seizures. Following an acute ingestion, serum levels
of more than 90–100 mg/L are associated with more serious
toxic effects. After chronic intoxication, this toxic level is
approximately 60 mg/L. When drug concentrations reach
these levels, hemoperfusion or hemodialysis may be indi-
cated. Table 36–12 lists the major indications for initiating
hemodialysis or hemoperfusion therapy in patients with
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theophylline toxicity. Of the two procedures, hemoperfusion
is the method of choice. It is important to initiate these pro-
cedures early because if hemodynamic instability develops,
hemodialysis may not be possible.
Cantrell FL: Treatment of theophylline overdose. Am J Emerg Med
1997;15:547. [PMID: 9270403]
Charytan D, Jansen K: Severe metabolic complications from theo-
phylline intoxication. Nephrology (Carlton) 2003;8:239–42.
[PMID: 15012710]
Chyka PA et al: Prophylaxis of seizures after theophylline overdose.
Pharmacotherapy 1997;17:1044–5. [PMID: 9324199]
Shannon M: Life-threatening events after theophylline overdose: A
10-year prospective analysis. Arch Intern Med 1999;159:989–94.
[PMID: 10326941]
Shannon MW: Comparative efficacy of hemodialysis and hemop-
erfusion in severe theophylline intoxication. Acad Emerg Med
1997;4:674–8. [PMID: 9223689]
 Methanol & Ethylene Glycol
ESSENT IALS  OF  D IAGNOS I S
Methanol:
 Visual disturbances.
 Nausea, vomiting, abdominal pain.
 Lethargy and confusion.
 Seizures and coma.
 Abdominal tenderness.
Ethylene glycol:
 Stage I: intoxication, slurred speech, ataxia, stupor, hal-
lucinations, seizures, coma.
 Stage II: hypertension, tachycardia, high-output renal
failure, myositis.
 Stage III: costovertebral angle tenderness; oliguria or
anuria.
General Considerations
Methanol and ethylene glycol are CNS depressants that are
found most commonly in antifreeze and deicing products.
Ingestions of these compounds occur sporadically in alco-
holic patients seeking an ethanol substitute, as an accidental
ingestion, or epidemically in groups of patients seeking CNS
effects. Both methanol and ethylene glycol are absorbed rap-
idly from the GI tract. Methanol blood levels peak 30–90
minutes after ingestion, whereas ethylene glycol levels peak
1–4 hours after ingestion. Although the parent compounds
are relatively benign, both are metabolized in the liver by
alcohol dehydrogenase to toxic metabolites. Formic acid is
the major toxic metabolite of methanol; glycolic acid and
oxalic acid are the predominant metabolites of ethylene gly-
col. The half-lives of methanol and ethylene glycol are 14–18
and 3–8 hours, respectively. When ethanol is ingested at the
same time as either compound, the half-life can more than
double because alcohol dehydrogenase preferentially metab-
olizes ethanol. Ingestions as small as 30–60 mL of these com-
pounds have been fatal in adults. Even very small amounts
may cause significant morbidity.
Clinical Features
A. Symptoms and Signs—If presentation is soon after
ingestion, apparent intoxication may be the only finding.
Because toxicity is from metabolites rather than from the
parent compound, specific toxic clinical effects may not be
noted for many hours after ingestion. The delay is increased
when ethanol is ingested at the same time.
1. Methanol—The latent period from ingestion of
methanol to manifestations of toxicity is 12–24 hours. At that
time, about half of patients will complain of visual distur-
bances, which include cloudy, blurred, or misty vision.
Scotomas are common. The patient typically appears intoxi-
cated and often complains of a headache. Nausea, vomiting,
and abdominal pain are common. Ophthalmologic examina-
tion may reveal multiple eye abnormalities, including dilated
and fixed pupils, constricted visual fields, retinal edema, and
hyperemia of the optic disk. However, some patients may
have a completely normal eye examination despite having
subjective visual complaints. Patients may be lethargic or
confused. Seizures and coma may occur. Abdominal tender-
ness is common. Death may follow abrupt respiratory arrest
without warning, so careful monitoring is mandatory.
2. Ethylene glycol—Ethylene glycol ingestion presents in
three stages. Stage I, known as the CNS stage, occurs 30 minutes
to 12 hours after ingestion. It is characterized by intoxication,
slurred speech, ataxia, stupor, hallucinations, seizures, and
coma. The patient may complain of nausea and vomiting and
may be mildly hypertensive and tachycardic. Stage II, the
cardiopulmonary stage, manifests 12–24 hours after inges-
tion. Patients become significantly hypertensive and tachy-
cardic and may develop high-output cardiac failure. Some
patients also develop diffuse myositis with muscle tenderness.
Refractory dysrhythmias, hypotension, or seizures 
Acute ingestion with level >90–100 mg/L 
Chronic ingestion with— 
Level 60–90 mg/L 
Level 40–60 mg/L and—
Age <6 months or >60 years 
Congestive heart failure 
Liver disease 
Unable to tolerate oral charcoal 
Patient not tolerating current level 
Table 36–12. Indications for hemoperfusion or
hemodialysis in theophylline toxicity. 
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Stage III, the renal stage, occurs 24–72 hours after ingestion.
Patients complain of flank pain and costovertebral angle ten-
derness. Oliguria, frank renal failure, and anuria develop.
B. Laboratory Findings—Laboratory evaluation of these
patients is notable for an elevated osmolal gap (Table 36–13).
Most patients with ethylene glycol ingestion have crystalluria at
presentation. The crystals can be either envelope-shaped cal-
cium oxalate crystals or needle-shaped calcium oxalate mono-
hydrate crystals. Leukocytosis and hypocalcemia occur in up to
85% of patients who ingest ethylene glycol. Metabolic acidosis
with an increased anion gap is sometimes the first clue to
ingestion of these toxic alcohols.
Treatment
A. General Measures—Supportive care should be initiated
as described rapidly. Gastric lavage is rarely effective after
ingestion of these compounds.
B. Specific Treatment—Specific treatment of these intoxi-
cations is the mainstay of therapy and is similar for both
methanol and ethylene glycol.
Any patient with a history, clinical presentation, or labo-
ratory findings suggestive of methanol or ethylene glycol
ingestion should be treated. There are three major goals:
(1) to correct the metabolic acidosis, (2) to block the produc-
tion of metabolites, and (3) to remove the parent compound
and toxic metabolites.
1. Acidosis—Acidosis is treated with intravenous sodium
bicarbonate. Bicarbonate therapy should be initiated when
the pH drops below 7.2, with therapy directed at maintaining
the pH above that level. Massive doses of bicarbonate may be
required because the toxic metabolites are inorganic acids
that are being produced continuously. Blood pH should be
measured frequently. Iatrogenic hypernatremia may develop
if large doses of bicarbonate are needed.
2. Metabolites—Production of toxic metabolites can be
blocked by administering either ethanol or fomepizole, both
of which alter metabolism of the parent compounds to toxic
metabolites by alcohol dehydrogenase. Ethanol can be
administered either orally or intravenously. The loading dose
of ethanol for an average adult is 0.6 g/kg (1.2 mL/kg of 50%
ethanol orally or 6 mL/kg of 10% ethanol intravenously over
30 minutes). Intravenous solutions should be at concentra-
tions of 10% or less to decrease toxicity. Infusion should
provide blood ethanol levels of 100–150 mg/dL to ensure
Molecular Weight Toxic Concentration 
Approximate
Corresponding ΔGosm (mosm/kg) 
Ethanol 46 300 65 
Methanol 32 50 16 
Ethylene glycol 62 100 16 
Isopropanol 60 150 25 
Note: Most laboratories use the freezing point method for calculating osmolality. If the vaporization point method is used, alcohols are 
driven off and their contribution to osmolality is lost. 
Note: A normal osmolar gap may be present in the face of a potentially lethal methanol or ethylene glycol ingestion.
Modified from Saunders CE, Ho MT (editors): Current Emergency Diagnosis & Treatment, 4th ed. Originally published by Appleton & Lange.
Copyright © 1992 by The McGraw-Hill Companies, Inc. 
Table 36–13. Use of the osmolal gap in toxicology.
The osmolal gap (Δosm) is determined by subtracting the calculated serum osmolality from the measured serum osmolality. 
Δosm = Measured osmolality – Calculated osmolality 
Serum osmolality may be increased by contributions of circulating alcohols and other low-molecular-weight substances. Since these substances are not
included in the calculated osmolality, there will be a gap proportionate to their serum concentration and inversely proportionate to their molecular weight:
Serum concentration
(mg/dL)
osm
Molecul
= ×Δ ar weight
10
Calculated
osmolality
(mosm/kg)
Na meq/L= +2[ ( )] +
Glucose
(mg/dL)
18
+
BUN
(mg/dL)
2.8
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preferential metabolism of ethanol over the toxic alcohol.
Since alcohol dehydrogenase has a higher affinity for ethanol
and will preferentially metabolize ethanol rather than the
toxic alcohols, the goal is to maintain a blood ethanol level of
100–150 mg/dL, which saturates the enzyme (Table 36–14).
Fomepizole (4-methylprazole) may be preferred over
ethanol for the treatment of methanol and ethylene glycol
ingestions. This agent blocks the metabolism of the toxic
alcohols by alcohol dehydrogenase. It offers the benefit of not
needing to maintain a blood level as with ethanol treatment,
but it is expensive. Fomepizole is extremely effective, but
dialysis remains necessary to definitively remove the alcohols
and their metabolites.
3. Decontamination—Once bicarbonate and ethanol or
fomepizole therapy have been instituted, hemodialysis is begun
to remove the parent compound and toxic metabolites. This
has the additional benefit of correcting severe acidosis refrac-
tory to intravenous bicarbonate therapy. However, hemodialy-
sis also removes ethanol. Patients with methanol ingestion also
should receive folic acid, 50 mg intravenously every 4 hours.
Those with ethylene glycol ingestion should be given thiamine,
100 mg intramuscularly, and pyridoxine, 100 mg orally.
Barceloux DG et al: American Academy of Clinical Toxicology
practice guidelines on the treatment of ethylene glycol poison-
ing. J Toxicol Clin Toxicol 1999;37:537–60. [PMID: 10497633]
Green R. The management of severe toxic alcohol ingestions at a
tertiary care center after the introduction of fomepizole. Am J
Emerg Med 2007;25:799–803. [PMID: 17870485]
Hovda KE et al: Fomepizole may change indication for hemodial-
ysis in methanol poisoning: Prospective study in seven cases.
Clin Nephrol 2005;64:190–7. [PMID: 16175943]
Megarbane B, Borron SW, Baud FJ: Current recommendations for
treatment of severe toxic alcohol poisonings. Intensive Care
Med. 2005;31:189–95. [PMID: 15627163]
 Isopropyl Alcohol
ESSENT IALS  OF  D IAGNOS I S
 Headache, dizziness, confusion.
 Intoxication with poor coordination.
 Abdominal pain, nausea, vomiting.
 Tachycardia.
 Miosis and nystagmus.
General Considerations
Isopropyl alcohol is a clear and colorless liquid found in rub-
bing alcohol, skin and hair products, and antifreeze. It is
ingested occasionally as a substitute for ethanol. Up to 80%
of the volume ingested is absorbed from the GI tract within
30 minutes. Half the isopropyl alcohol is excreted
unchanged by the kidney, with the remainder metabolized
in the liver to acetone. Both isopropyl alcohol and acetone
are CNS depressants. Isopropyl alcohol ingestion is usually
relatively benign, with patients surviving after ingestions of
up to 1 L. Some patients develop serious toxicity with doses
as low as 2–4 mL/kg. Although uncommon, dermal exposure
can cause toxicity.
Loading Dose 
Infusion Rate During
Dialysis 
Infusion Rate After
Dialysis 
Total Over 36 Hours  
Amount of ethanol Chronic drinker
Nondrinker 
42 g
42 g 
18.0 g/h
11.8 g/h 
10.8 g/h
4.6 g/h 
474 g
251 g  
Volume of IV 10%
ethanol 
Chronic drinker
Nondrinker 
530 mL
530 mL 
228 mL/h
149 mL/h 
137 mL/h
58 mL/h 
6010 mL
3010 mL 
Volume of oral 43%
ethanol 
Chronic drinker
Nondrinker 
125 mL
125 mL 
54 mL/h
35 mL/h 
32 mL/h
14 mL/h 
1410 mL
749 mL 
Volume of oral 90%
ethanol 
Chronic drinker
Nondrinker 
60 mL
60 mL 
26 mL/h
17 mL/h 
15 mL/h
7 mL/h 
666 mL
359 mL 
∗Calculated to achieve and maintain blood ethanol concentration of 100 mg/dL, assuming ethanol dialysance of 120 mL/min and a 6-hour
dialysis period.
From McCoy HG et al: Severe methanol poisoning: An application of a pharmacokinetic model for ethanol therapy and hemodialysis. Am J Med
1979;67:806.
Table 36–14. Ethanol doses∗ for treatment of methanol poisoning in a 70-kg adult. 
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Clinical Features
A. Symptoms and Signs—GI and CNS effects predomi-
nate. Patients often complain of headache, dizziness, confu-
sion, intoxication, and poor coordination. Abdominal pain,
nausea, and vomiting are also common. Because isopropyl
alcohol is a gastric irritant, it may cause gastritis, which can
result in hematemesis. Massive upper GI bleeding from hem-
orrhagic gastritis is a rare but potentially fatal complication
of this ingestion.
Examination of these patients is usually normal except
for evidence of intoxication. Mild sinus tachycardia may be
seen. Hypotension can occur following severe ingestions.
Patients may have miosis, nystagmus, and decreased deep
tendon reflexes.
B. Laboratory Findings—Serum ketosis without acidosis is
the hallmark of isopropyl alcohol ingestion. The metabolism
of isopropyl alcohol produces acetone, which is a ketone
without acidic properties. Since isopropyl alcohol increases
serum osmolality, an osmolal gap also may be present. For
every 1 mg/dL of isopropyl alcohol in the blood, there is a
rise in serum osmolality of 0.18 mOsm/kg. Hypoglycemia is
frequently present.
Differential Diagnosis
Patients who appear intoxicated may have ingested ethanol,
methanol, ethylene glycol, or isopropanol. All these alcohols
can cause an elevated osmolal gap, but ethylene glycol and
methanol also cause a metabolic acidosis not observed with
isopropyl alcohol ingestions. Other causes of metabolic
abnormalities such as hyperglycemia, hyperosmolar states,
infections (eg, sepsis and meningitis), and head trauma also
should be considered.
Treatment
A. General Measures—Intravenous fluid resuscitation, oxy-
gen administration, and hemodynamic monitoring should be
initiated. If the patient presents more than 30 minutes after
ingestion, gastric decontamination is not effective. Activated
charcoal does not bind alcohols well and should only be given
if coingestion of another substance is suspected.
Patients with hematemesis should have blood sent for
typing in case bleeding becomes clinically significant and the
patient requires transfusion. Hypotension should be man-
aged with crystalloid infusion; if necessary, vasopressors may
be added.
B. Glucose Supplementation—Since hypoglycemia is
common with significant isopropyl alcohol ingestion, fre-
quent evaluation of the blood glucose with administration of
supplemental intravenous glucose as needed is mandatory.
Hourly rapid glucose determinations should be followed
with more frequent monitoring if patients have symptoms
typical of hypoglycemia.
C. Dialysis—Dialysis is rarely necessary following isopropyl
alcohol ingestion. The only indication for hemodialysis is in
the patient who remains hypotensive despite crystalloid and
vasopressor administration.
Zaman F, Pervez A, Abreo K: Isopropyl alcohol intoxication: A
diagnostic challenge. Am J Kidney Dis 2002;40:E12. [PMID:
12200829]
 Mushroom Poisoning
ESSENT IALS  OF  D IAGNOS I S :
CYC LOPEPT IDES
Early:
 Colicky abdominal pain.
 Watery diarrhea, nausea, vomiting.
Late:
 Right upper quadrant pain.
 Hepatomegaly, asterixis, jaundice, encephalopathy,
liver failure.
E SS ENT IALS  OF  D IAGNOS I S :
GYROMITR IN
Early:
 Dizziness, bloating, nausea, vomiting.
 Headache.
Late:
 Hepatic failure.
 Seizures and coma.
E SSENT IALS  OF  D IAGNOS I S :
OTHERS
 Findings related to specific ingestion.
General Considerations
Severe mushroom poisoning is rare in the United States, with
only 200–350 cases and 50 deaths reported each year.
Children account for half of these ingestions, which occur
most commonly in the spring, summer, and fall. Of the 500
species of mushrooms in the United States, 100 are toxic, and
only 10 are potentially fatal when ingested. The toxicity of
any particular mushroom is variable and depends on the cli-
mate, the amount of rainfall, and the maturity of the plant.
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Toxic mushrooms are divided into eight categories
grouped by the effects of the toxin and the time to manifes-
tation of effects. Table 36–15 summarizes these categories.
Half the reported mushroom ingestions and 95% of the fatal
cases result from the cyclopeptide group. Mushrooms har-
boring this toxin are found chiefly along the northwest
Pacific Coast region of North America, including California.
Ingestions occur most commonly in the summer and fall.
Toxicity is due to GI irritation and hepatic failure. Mortality
rates are as high as 50%, with death often owing to hepatore-
nal syndrome, which occurs 6–16 days after ingestion.
The remainder of the fatal ingestions result from con-
sumption of mushrooms in the gyromitrin group, also known
as false morels. Found in California woodlands, these poison-
ings occur most commonly in the early spring. Gyromitrins
are hydrolyzed in the liver to monomethylhydrazine, which
causes toxicity by inactivating pyridoxal phosphate.
Both cyclopeptide and gyromitrin toxins have delayed
symptom onset from time of ingestion; this characteristic
serves as an important clue that the patient may have
ingested a potentially lethal mushroom.
Mushrooms that contain toxins that affect the autonomic
nervous system are found virtually everywhere, often growing
alongside other nontoxic mushrooms. Two types of auto-
nomic syndromes occur in this category. Ingestion of mush-
rooms that contain significant amounts of muscarine
produces stimulation of postganglionic parasympathetic mus-
carinic effectors, causing a cholinergic toxidrome. Ingestion of
the coprine group of mushrooms (“inky caps”) is usually non-
toxic, and these mushrooms often are considered a delicacy.
Coingestion of ethanol with these mushrooms, however, leads
to a disulfiram-like reaction probably owing to blocking of
aldehyde dehydrogenase in the liver. If the ethanol is ingested
before or concurrently with the mushrooms, this toxicity does
not occur. Instead, sensitivity to ethanol begins 2 hours after
ingestion of the mushrooms and lasts up to 5 days.
Ingestion of mushrooms that affect the CNS often consti-
tutes a form of recreational drug use. Inadvertent consumption
Poison Symptoms Onset Examples 
Rapid-Onset Toxicity
Poisons affecting the autonomic nervous system 
Muscarine Cholinergic toxidrome 1–2 hours Clitocybe species 
Coprine “Nature’s disulfiram”: flushing, nausea,
vomiting, diaphoresis 
30 minutes after ethanol Coprinus species 
Poisons affecting the central nervous system 
Ibotenic acid, muscimol Dizziness, incoordination, myotonic
jerks, spasms, hallucinations 
30 minutes to 2 hours Amanita muscaria
Psilocybin, psilocin Euphoria or dysphoria, lethargy, deep
sleep, hallucinations (visual) 
30 minutes to 1 hour Psilocybe species 
Poisons affecting the gastrointestinal system 
Multiple Nausea, vomiting, diarrhea, abdominal
pain 
30 minutes to 2 hours ”Little brown mushrooms,”
widespread 
Delayed-Onset Toxicity
Poisons causing cellular destruction 
Cyclopeptides Abdominal pain, nausea, vomiting, diar-
rhea, delayed jaundice, coma 
6–24 hours Amanita phalloides, Galerina marginata
Gyromitrin, monomethylhydrazine Nausea, vomiting, diarrhea, incoordina-
tion, seizures, coma 
6–12 hours Gyromitra species 
Poisons affecting the renal system 
Orelline, orellanine Gastritis, delayed renal failure 3–14 days Cortinarius species (especially Japan,
Europe) 
Table 36–15. Classification of mushroom toxicity.
 CHAPTER 36782
of mushrooms in this category also occurs because they are
often found along the Pacific Coast in the spring, summer,
and fall. Although these mushrooms rarely produce serious
toxicity in adults, children may develop lethal complications.
Clinical Features
A. History—Mushroom toxicity presents with a wide array
of symptoms depending on the type of mushroom ingested.
Patients who present with mushroom toxicity may or may
not relate a history of ingestion. They may not connect their
consumption of the mushrooms with their illness, or if they
are using mushrooms for recreational purposes, they may be
hesitant to give medical personnel this information. In clini-
cal settings suggestive of mushroom ingestion, clinicians
should ask specifically about this possibility.
One of the most important historical pieces of information
that should be sought from the patient is the time from inges-
tion to the onset of symptoms; mushrooms that are potentially
lethal (those containing cyclopeptides and gyromitrins) have a
time delay of at least 4–6 hours from ingestion to symptoms, a
very important clinical clue in determining the potential for
serious toxicity. Any patient who presents with symptoms that
occur more than 6 hours after ingesting a potentially toxic
mushroom should be considered to have a possibly fatal inges-
tion. It should be kept in mind, however, that patients may
coingest several different types of toxic mushrooms, and a
rapid onset of symptoms does not exclude concurrent inges-
tion of a potentially lethal one.
B. Symptoms and Signs—Cyclopeptides, the most com-
monly lethal mushroom toxin, cause a three-phase illness.
The GI phase begins abruptly 6–12 hours after ingestion and
is characterized by severe colicky abdominal pain, profuse
watery diarrhea, nausea, and vomiting. These symptoms last
up to 24 hours and then resolve. The patient feels well during
a latent phase of 3–5 days, but hepatic toxicity is occurring. At
the end of this phase, the patient presents with findings typi-
cal of liver failure, including right upper quadrant pain,
hepatomegaly, asterixis, jaundice, or frank encephalopathy.
Gyromitrin-containing mushrooms (false morels) cause
gastritis with an onset 6–12 hours after ingestion. The patient
complains of dizziness, bloating, nausea, vomiting, and
severe headache. Hepatic failure may occur in severe cases,
usually 3–4 days after ingestion. Seizures and coma are also
described.
The Cortinarius species of mushrooms, found most com-
monly in Japan and Europe, contains orelline, which results in
a delayed presentation 24–36 hours after ingestion with a self-
limited gastritis-like illness. Three to fourteen days after inges-
tion, the patient presents with night sweats, anorexia, headache,
chills, and a severe burning thirst. Oliguria and flank pain also
may be present. These patients may develop renal failure.
The remainder of the toxic mushrooms cause symptoms
soon after ingestion. Toxins that affect the autonomic nervous
system include muscarine and coprine. Fifteen minutes to 1 hour
after ingestion of muscarine-containing mushrooms, the
patients will complain of headache, nausea, vomiting, and
abdominal pain and may develop cholinergic symptoms of
salivation, lacrimation, urination, defecation, and diaphoresis.
In severe cases, bronchospasm, bronchorrhea, bradycardia, and
shock may occur. In most cases, however, symptoms are usually
mild and resolve in 2–6 hours. Coprine-containing mush-
rooms alone do not cause toxicity; however, when ethanol is
ingested 2 hours to 5 days after ingestion of these mushrooms,
the patient may develop a disulfiram-like syndrome. Fifteen to
twenty minutes after drinking ethanol, the patient complains of
a severe headache, facial flushing, paresthesias, lightheadedness,
orthostatic hypotension, vomiting, palpitations, and tachycar-
dia. Although the patient feels ill, these symptoms rarely cause
significant compromise and abate after several hours.
Mushrooms that affect the CNS contain one of several
toxins, including ibotenic acid, muscimol, and psilocybin.
Symptoms usually begin 30 minutes to 4 hours after inges-
tion. Patients complain of drowsiness, incoordination, wax-
ing and waning mental status, and formed or unformed
visual hallucinations. Psilocybins are renowned for causing
alterations in perceptions of shapes, sounds, and colors.
Ibotenic acid and muscimol may cause anticholinergic
effects that are rarely severe except in children; these effects
are seizures, coma, tachycardia, and hypertension. Most of
these patients resolve their symptoms within several hours
without sequelae.
The final group of toxic mushrooms are those known as
“little brown mushrooms” and cause primarily a self-limited
GI illness characterized by rapid onset of malaise, nausea,
vomiting, and diarrhea within 1–3 hours of ingestion. These
symptoms usually resolve within 24–48 hours.
C. Laboratory Findings—Laboratory results are related
specifically to the type of ingestion.
1. Cyclopeptides—Laboratory evaluation may reveal hypo-
glycemia, elevated aminotransferases, metabolic acidosis,
and coagulopathy.
2. Gyromitirin—Laboratory evaluation may show elevated
liver function tests and coagulopathy; these patients also may
have methemoglobinemia.
3. Orelline—Laboratory evaluation may reveal red blood
cell casts, elevated BUN, serum creatinine, proteinuria, and
hematuria.
Differential Diagnosis
Owing to the wide range of symptoms caused by toxic mush-
rooms, the differential diagnosis depends on the type of mush-
room ingested. Most of the toxic mushrooms cause a GI
syndrome that may be confused with gastroenteritis, infectious
diarrhea, or other GI diseases. Liver failure (associated with the
cyclopeptides and gyromitrins) can be caused by other toxins,
particularly acetaminophen, as well as entities such shock liver,
severe hepatitis, and alcoholism. CNS effects of mushroom
toxicity also can be observed in patients who ingest anticholin-
ergics, LSD, peyote, and other hallucinogens. The cholinergic
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syndrome that occurs with muscarine-containing mushrooms
is also found in organophosphate poisoning.
Treatment
Treatment of patients with toxic mushroom ingestions
depends on the type of mushroom ingested and the symp-
toms. If there is any possibility that the patient may have
ingested a potentially lethal mushroom—even if it cannot be
confirmed—the patient should be treated aggressively.
A. Decontamination—In general, all patients who may
have ingested potentially lethal mushrooms should have
gastric emptying if they present as long as 4 hours after
ingestion. Repeated-dose activated charcoal should be given
to these patients and those presenting after this 4-hour time
period.
B. Antidotes—Although several potential antidotes have
been used to treat patients who may have ingested
cyclopeptide-containing mushrooms, none have been
proved to be effective. These patients need supportive care
and ultimately may need liver transplantation if liver failure
becomes severe.
C. Renal Dialysis—Cortinarius mushroom toxicity that
results in renal failure should be managed with dialysis as
needed. These patients may need dialysis for weeks to
months but usually will recover renal function eventually.
D. Other Measures—If significant methemoglobinemia
(metHb >30% or symptomatic hypoxia or ischemia and a
metHb <30%) develops in a patient who ingests gyromitrin-
containing mushrooms, one should give methylene blue,
0.1–0.2 mL/kg of a 1% solution intravenously over 5 minutes.
Such patients who develop intractable seizures refractory to
standard therapy may respond to pyridoxine, 25 mg/kg
intravenously given over 25–30 minutes.
Patients with cholinergic symptoms from muscarine-
containing mushrooms usually need observation only.
However, if they develop bronchospasm, bronchorrhea,
bradycardia, or shock, they should be treated with atropine,
0.5–1 mg intravenously, repeated as needed for recurrence of
symptoms. This dose should be repeated every 10–20 minutes
until the symptoms resolve.
Patients who ingest hallucinogenic mushrooms do not
need specific medical interventions. They should be placed
in a dark, quiet room and observed until the effects subside.
If patients manifest significant anticholinergic signs, they
should be monitored closely and receive specific treatment
for anticholinergic toxicity if indicated.
Current Controversies and Unresolved Issues
Several antidotes have been used to treat cyclopeptide toxic-
ity. Thioctic acid, a coenzyme in the Krebs cycle, has been
used in a dose of 50–150 mg intravenously every 6 hours with
variable results. Its only major side effect is hypoglycemia,
which requires close monitoring. Since this poisoning can be
life-threatening, use of thioctic acid should be considered
with the understanding that its effects have not been validated.
Other treatments, including high-dose penicillin, silibinin,
high-dose steroids, hyperbaric oxygenation, and pyridoxine,
have been used with inconclusive results.
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 Organophosphates
ESSENT IALS  OF  D IAGNOS I S
Muscarinic effects:
 Bronchospasm, bronchorrhea.
 Salivation, lacrimation, urination, defecation, gastric
emesis (SLUDGE) syndrome.
 Blurred vision.
Nicotinic effects:
 Muscle fasciculations, weakness, paralysis.
 Ataxia.
CNS effects:
 Headache.
 Slurred speech.
 Confusion.
 Seizures, coma.
 Depression of the respiratory center.
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General Considerations
Organophosphates are found most commonly in herbicides
and insecticides and are in the form of organophosphates or
carbamates. They also can be used in chemical warfare or ter-
rorism events. They act by causing irreversible inactivation of
acetylcholinesterase, resulting in an accumulation of acetyl-
choline at cholinergic receptors. The toxicity results from
excessive muscarinic, nicotinic, and CNS effects of the excess
acetylcholine. Toxicity may develop after oral or dermal
exposure.
Patients with organophosphate toxicity may be exposed
accidentally at work, often by dermal exposure. Alternatively,
patients may accidentally or intentionally ingest these com-
pounds. The diagnosis often is made clinically because there
are no laboratory tests immediately available to detect these
compounds.
Clinical Features
A. Symptoms and Signs—Patients present with a myriad of
symptoms. Peripheral muscarinic effects include bron-
chospasm, bronchorrhea, nausea, vomiting, diarrhea, miosis,
blurred vision, urinary incontinence, salivation, diaphoresis,
and lacrimation. The combination of salivation, lacrimation,
urination, defecation, and gastric emesis is known as the
SLUDGE syndrome and is very suggestive of organophos-
phate poisoning. Nicotinic effects consist primarily of skele-
tal muscle symptoms, particularly muscle fasciculations,
weakness, ataxia, and frank paralysis. Blood pressure and
heart rate effects vary depending on whether muscarinic or
nicotinic effects predominate. Patients may be tachycardic or
bradycardic and hypertensive or hypotensive. Elevated CNS
acetylcholine concentrations cause headache, slurred speech,
confusion, seizures, and coma, as well as depression of the
respiratory centers. Respiratory failure is the usual cause of
death, often owing to a combination of central respiratory
depression, respiratory muscle weakness, bronchospasm, and
increased bronchial secretions.
B. Laboratory Findings—There are no laboratory tests
immediately available that characterize this ingestion, and
the diagnosis is often made on the basis of a potential for
exposure to the toxin combined with a suggestive clinical
presentation. Laboratory testing for cholinesterase activity
will show decreased activity of this enzyme and often con-
firms the diagnosis. However, this test is usually not per-
formed on an emergent basis, and several days may pass
before results become available. Definitive diagnosis is made
by appropriate response to treatment (eg, atropine or prali-
doxime) and decreased cholinesterase activity in the blood.
Differential Diagnosis
The combination of salivation, lacrimation, urination, and
defecation strongly suggests organophosphate poisoning.
This diagnosis is of particular importance if the patient is
diaphoretic and has bronchospasm, with excessive pul-
monary secretions and muscle weakness. Patients with myas-
thenia gravis in cholinergic crisis present with a similar
clinical picture.
Treatment
A. Decontamination—Medical personnel should wear
gowns and gloves when treating patients with organophos-
phate poisoning because they may become contaminated
and symptomatic from either the patient’s clothing or secre-
tions and body fluids. Patients with dermal exposure need
copious irrigation in a protected area. Gastric lavage should
be attempted if the ingestion was less than 1 hour before
presentation and the patient is not already vomiting. After
lavage, activated charcoal should be given through the NG
tube before it is removed. Intubation and ventilatory support
should be considered early.
B. Atropine—Atropine antagonizes the peripheral mus-
carinic effects of the excess acetylcholine and may moderate
some of the CNS effects, but it does nothing to alter the
skeletal muscle nicotinic effects, nor does it restore acetyl-
cholinesterase to an active state. Indications for the use of
atropine are suspected organophosphate poisoning in a
patient who has muscarinic symptoms and signs. The drug
can be used both diagnostically and therapeutically.
Diagnostically, a dose of 1 mg (or 0.015 mg/kg) intra-
venously should dilate the pupils and increase the heart rate
within 10 minutes. If there is no response to this dose,
cholinergic toxicity is suggested. At that point, 2–4 mg (or
0.02–0.05 mg/kg) of atropine should be given intravenously
every 10–15 minutes, with the endpoint being a drying of
secretions, particularly bronchial secretions. Pupillary dila-
tion and tachycardia should not be used as endpoints
because these effects may be seen before drying of bronchial
secretions is achieved. Massive doses of atropine may be
needed to achieve full effect.
C. Pralidoxime—Pralidoxime reverses phosphorylation of
acetylcholinesterase and therefore restores its activity. This
drug will reverse the nicotinic effects of muscle weakness and
also reverses some of the CNS effects of the poison. Because
pralidoxime is more effective in reversing the nicotinic than
the muscarinic effects, it should be used in conjunction with
atropine. Indications for pralidoxime include the nicotinic
effects of organophosphate poisoning (eg, fasciculations and
weakness) or CNS effects (eg, altered mental status). Blood
should be drawn and sent for cholinesterase activity before
the drug is administered. The dose is 1–2 g (or 25–50 mg/kg)
intravenously over 5–15 minutes. End-organ effects are seen
in 15–45 minutes and are manifested by increased muscle
strength. Dosing can be repeated in 1–2 hours if weakness
and fasciculations persist. Pralidoxime can be repeated every
4–12 hours as needed. Its side effects (eg, nausea, headache,
and tachycardia) are rare and usually result from too rapid
injection.
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In moderate to severe poisoning, atropine and prali-
doxime should be continued for at least 24 hours; in severe
poisonings, therapy may need to be continued for days to
weeks. Treatment with antidotes can be discontinued when
clinical response indicates that they are no longer needed—
that is, when there is an absence of clinical improvement
with therapy and a lack of recurrence of signs and symptoms
of toxicity when the antidotes are withheld.
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Patients with injuries owing to environmental hazards and
toxic exposure may require admission to an ICU for resuscita-
tion, stabilization, and definitive treatment. This chapter
reviews the essentials of diagnosis and treatment of heat
stroke, hypothermia, frostbite, near-drowning, envenomation,
electric shock (and lightning injury), and radiation injury.
 Heat Stroke
ESSENT IALS  OF  D IAGNOS I S
 Core body temperature approaching 41°C.
 Confusion, stupor, coma.
 Hypotension and tachycardia.
 Muscle stiffness.
 Hot, dry skin.
 Elevated hematocrit and hyperkalemia.
General Considerations
The three major manifestations of heat illness are heat
cramps, heat exhaustion, and heat stroke. The syndromes
usually occur in warm, humid environments after strenu-
ous physical exertion. However, elderly persons with med-
ical problems or infants may be affected under less severe
conditions.
Heat cramps and heat exhaustion result from the deple-
tion of fluid and electrolytes. Complete recovery occurs after
removal of the patient from the stressful environment and
the institution of replacement therapy. Heat stroke results
from the failure of thermoregulatory mechanisms. It is a
medical emergency, and prompt reduction of body tempera-
ture is necessary to prevent morbidity and mortality.
To maintain a constant body temperature, heat loss must
equal heat production. Cutaneous vasodilation allows for heat
loss through the processes of radiation, conduction, and con-
vection. Evaporative heat loss occurs from sweating and to a
lesser extent from the airway. When the environmental tem-
perature exceeds body temperature, the only effective means
of heat loss is through sweating. Although significant amounts
of heat can be dissipated through this mechanism, sweating
becomes less efficient under conditions of high humidity.
Heat stress syndromes develop as a result of processes
that attempt to maintain normal body temperature. Heat
stroke results from failure of thermoregulatory mechanisms.
Heat cramps and heat exhaustion commonly occur after
excessive sweating in a hot environment. Heat cramps are
painful spasms of voluntary muscles that occur as a result of
electrolyte depletion. Depletion of fluid and electrolytes con-
tributes to the weakness and mental status changes associ-
ated with heat exhaustion.
Heat stroke occurs when the core body temperature
exceeds 41°C. Heat stroke may occur in otherwise healthy
people after extreme exertion in a hot climate, particularly in
unacclimatized individuals. In this setting, heat production
exceeds heat loss, resulting in failure of thermoregulatory
mechanisms. Once these mechanisms have failed, body tem-
perature may rise quite rapidly. Signs and symptoms can
develop suddenly. A rise in core body temperature above
42°C is associated with protein denaturation and cellular
lipid membrane dissolution. Hypovolemia owing to dehy-
dration may exacerbate the direct organ injury.
Nonexertional heat stroke is often called classic heat stroke
and commonly affects elderly or debilitated individuals with
impaired thermoregulation owing to disease or medications.
The volume status of a patient with nonexertional heat
stroke is unpredictable. In both exertional and nonexertional
heat stroke, myocardial dysfunction may occur as a result of
direct damage to the myocytes.
The neurologic abnormalities associated with heat
stroke range from confusion and stupor to coma and seizure
disorders. Cerebral and cerebellar neurons may be destroyed
by the increased temperature. Intracerebral hemorrhage and
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cerebral edema can occur in severe cases. Although many
patients recover without neurologic sequelae, residual cere-
bellar symptoms, quadriparesis, hemiparesis, and memory
loss may be present.
Hypovolemia results from dehydration, intracellular vol-
ume shifts, decreased peripheral vascular resistance, or poor
myocardial function. Myocardial depression follows heat-
induced myocardial necrosis.
Disseminated intravascular coagulation can result from
heat stroke. Denaturation of the proteins involved in the
coagulation cascade may produce prolongation of the pro-
thrombin time and partial thromboplastin time. Direct ther-
mal injury may result in platelet dysfunction. Megakaryocytes
in the bone marrow also may show thermal damage.
Coagulation abnormalities cause hemorrhage within the CNS
resulting in secondary neurologic deterioration.
Thermal injury results in direct muscle damage and
necrosis. It may occur in nonexertional heat stroke as well as
in heat stroke associated with exertion. Rhabdomyolysis
results in the release of large amounts of myoglobin and
muscle enzymes.
Renal failure may result from direct thermal damage to
the tubules. Hypoperfusion of the kidneys results in acute
tubular necrosis. Myoglobinuria may exacerbate renal failure
owing to direct toxic effects.
Death in heat stroke can occur from direct heat injury to
the brain. Other causes of death and morbidity include cere-
bral hemorrhage, aspiration pneumonia, cardiac failure,
renal failure, and hepatic failure.
Clinical Features of Heat Stroke
A. Symptoms and Signs—Heat stroke can develop sud-
denly, with loss of consciousness, and need not be preceded
by prodromal symptoms such as headache, dizziness, muscle
cramps, nausea, and fainting. Although hot, flushed skin is
associated with heat stroke, about half of patients exhibit
sweating. Depression of neurologic status is present in nearly
all cases, and most patients are unconscious at presentation.
Signs of cerebellar dysfunction and seizures also may occur.
Sinus tachycardia and hypotension are common in patients
with heat stroke. Hypovolemia with dehydration causes these
changes in most cases, but cardiac dysfunction also may
occur as a result of direct injury or acidosis. In the later stages
of heat stroke, acute respiratory failure, renal failure, and
severe coagulation disorders may develop.
B. Laboratory Findings—Serum concentrations of sodium,
potassium, phosphate, calcium, and magnesium are usually
low during the early stages of heat stroke. Hematocrit is usu-
ally elevated as a result of hemoconcentration. In the later
stages of heat stroke, hyperkalemia may develop as a result of
rhabdomyolysis. This also results in serum enzyme eleva-
tions of creatine kinase (CK), lactate dehydrogenase (LDH),
and aspartate aminotransferase (AST). Coagulation studies
may be abnormal in the later stages of the syndrome.
Elevation of fibrin split products suggests disseminated
intravascular coagulation and is associated with a poor prog-
nosis. Arterial blood gases usually reveal a mixed disorder,
with respiratory alkalosis owing to hyperventilation and a
profound metabolic acidosis. Arterial blood gases should
be interpreted without temperature correction to avoid
misinterpretation.
Differential Diagnosis
The diagnosis of exertional heat stroke is usually straightfor-
ward and based on a history of strenuous physical activity in
a hot environment. In the elderly patient presenting with
fever, hypotension, tachycardia, and mental status changes,
sepsis must be considered. A thorough physical examination
should be performed and appropriate cultures obtained to
exclude this possibility. Heat stroke also must be differenti-
ated from neuroleptic malignant syndrome. In this syndrome,
hyperthermia is triggered by major antipsychotic medications
such as phenothiazines, thioxanthenes, and the butyrophe-
nones. Neuroleptic malignant syndrome occurs in as many as
1% of patients receiving these medications, and its recogni-
tion is important because effective treatment is available with
the nondepolarizing muscle relaxants and dantrolene.
It is important to differentiate between fever and the
hyperthermia of heat stroke. In the febrile patient, the regu-
latory set point is increased owing to endogenous or exoge-
nous pyrogens, and body temperature is balanced at a new
set point. Heat stroke represents a failure of thermoregula-
tory mechanisms. Therefore, antipyretics are ineffective in
patients with heat stroke, and the peripheral cooling used to
lower body temperature in these patients generally is not
effective in treating patients with fever.
Treatment of Heat Stroke
A. Prompt Lowering of Body Temperature—The patient
should be placed in a cool environment. If the patient is
unconscious, endotracheal intubation should be performed
and mechanical ventilation with supplemental oxygen insti-
tuted to maintain adequate gas exchange. Fluid resuscitation
is required to reverse hypovolemia. In almost all cases, cen-
tral venous pressure monitoring will be necessary to evaluate
fluid status. In the elderly patient with evidence of cardiac
dysfunction, pulmonary artery catheterization may be
required. After rapid resuscitation, the rapid reduction of
body temperature is the major priority. The optimal method
for cooling the patient remains controversial. Immediate
treatment usually consists of surface cooling with immersion
in ice water or cold water or the use of cooling blankets. Cold
water immersion has been shown to be as effective as ice
water immersion and may be less uncomfortable for the
patient. The disadvantages of ice water immersion include
peripheral vasoconstriction and shivering. Shivering is unde-
sirable because of increased heat production and metabolic
demand. In this setting, shivering can be abolished by the
administration of nondepolarizing muscle relaxants. The use
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of phenothiazines should be avoided because of the risk of
toxicity and the possibility of a decrease in the seizure
threshold. Other techniques for cooling include cold intra-
venous fluids, cold water gastric or rectal lavage, peritoneal
dialysis with cold fluids, and the use of external cooling with
circulatory bypass. Once the temperature has been reduced
to 39°C, cooling efforts should be discontinued to prevent
the development of hypothermia. The use of antipyretics
such as aspirin or acetaminophen is ineffective for the rea-
sons previously stated, and their use is contraindicated
because they may worsen an existing coagulopathy or exac-
erbate hepatic injury. The use of alcohol sponge baths is also
contraindicated because of the risk of systemic absorption
and resulting toxicity.
B. Physiologic Monitoring—Continued monitoring in the
ICU is essential because many of the complications of hyper-
thermia, such as pulmonary failure, renal failure, and coagu-
lopathy, may take 24–48 hours to develop. Electrolytes
should be monitored frequently to detect life-threatening
electrolyte disorders. If rhabdomyolysis develops, osmotic
diuresis and alkalinization of the urine may help to prevent
renal damage from myoglobinuria. Organ system dysfunc-
tion may necessitate continued mechanical ventilation or
hemodialysis.
Current Controversies and Unresolved Issues
Investigations continue to focus on the relationship between
heat stroke and malignant hyperthermia and the role of
inflammatory mediators in the pathogenesis of heat stroke.
Clinical heat stroke may be associated with an underlying
inherited abnormality of skeletal muscle similar to that of
malignant hyperthermia. Skeletal muscle biopsies performed
in patients who developed heat stroke have shown abnormal
responses similar to those seen in malignant hyperthermia.
Such an association might suggest that certain patients are
more susceptible to heat stroke than others. Several authors
have suggested that dantrolene may be effective in the treat-
ment of heat stroke patients. However, the scant data avail-
able are still inconclusive.
There is evidence that inflammatory mediators may have
a role in the pathogenesis of heat stroke and subsequent
organ-system dysfunction. Patients with heat stroke have
been found to have elevated levels of tumor necrosis factor
and interleukin-1α. These elevated levels persisted even after
cooling was completed. Heat stroke also has been associated
with excessive nitric oxide (NO) production, the magnitude
of which is proportional to the severity of illness. It has been
suggested that NO may be an important mediator and inte-
gral part of the pathophysiologic processes resulting in heat
stroke and may be a central factor linking the observed neu-
rologic and cardiovascular abnormalities. If a role is estab-
lished for these mediators, new management strategies may
be possible by modulation of the inflammatory response or
specific blocking agents.
Lugo-Amador NM et al: Heat-related illness. Emerg Med Clin
North Am 2004;22:315–27. [PMID: 15163570]
Rav-Acha M et al: Fatal exertional heat stroke: A case series. Am J
Med Sci 2004;328:84–7. [PMID: 15311166]
 Hypothermia
ESSENT IALS  OF  D IAGNOS I S
 History of events.
 Early hypothermia (35–37°C): shivering, cool cyanotic
extremities, tachycardia.
 Mild hypothermia (32.2–35°C): confusion, disorienta-
tion, hyperventilation.
 Moderate hypothermia (28–32.2°C): amnesia, lethargy,
J-wave on ECG, atrial fibrillation.
 Severe hypothermia (<28°C): coma, dilated pupils and
absent tendon reflexes, absence of shivering, ventricu-
lar fibrillation, asystole, apnea.
General Considerations
Hypothermia is defined as an unintentional decline in the
core body temperature. Below 35°C, the systems responsible
for thermoregulation begin to fail because the compensatory
physiologic responses to minimize heat loss are ineffective.
Hypothermia may occur as a result of environmental expo-
sure or during prolonged surgical procedures. Prompt diag-
nosis and treatment are necessary in severe cases to reverse
organ dysfunction and to prevent death. Frostbite results
from local cold injury and threatens mainly function. Cold
injuries are being encountered with increasing frequency in
the elderly, in the homeless, and in individuals participating
in winter sports without proper protective clothing.
Hypothermia develops because of an imbalance between
body heat generation and environmental losses. Body heat is
generated as a by-product of metabolic processes and as a
result of muscular contraction. Heat is lost from the body by
radiation, convection, conduction, and evaporation.
Immersion injuries result in rapid conductive heat loss to the
cold water. Radiation and evaporation are the mechanisms by
which heat is lost during prolonged open-cavity surgical pro-
cedures. Hypothermia may occur in individuals with normal
thermoregulation following prolonged exposure to extreme
cold. Neurologic disorders, drug intoxication, myxedema, and
malnutrition may cause thermoregulatory malfunction, and
hypothermia may occur after only mild to moderate cold
exposure in individuals with these conditions. Hypothermia
may be classified as acute if the patient has been hypothermic
for less than 6 hours and chronic if for more than 6 hours.
Dehydration and electrolyte imbalance are more likely to
occur in patients with chronic hypothermia.
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When the core body temperature falls below 36°C,
increased sympathetic activity, shivering, and peripheral
vasoconstriction develop. These mechanisms have the effect
of increasing heat production and preventing further heat
loss. Shivering may result in a profound increase in meta-
bolic rate with a sixfold increase in oxygen consumption.
The principal defense against cold is peripheral vasocon-
striction. Cold-induced vasoconstriction may lead to an initial
rise in central venous pressure from redistribution of blood to
the central circulation. Patients with severely compromised
cardiac function may develop pulmonary edema as a result of
this central circulatory overload. Limb ischemia may develop,
and the resulting anaerobic metabolism may contribute to
metabolic acidosis. As the core body temperature falls below
35°C, many patients no longer complain of being cold. When
the core body temperature falls below 32°C, shivering ceases.
The metabolic rate falls rapidly, and the muscles become rigid.
With profound hypothermia, the metabolic rate is reduced to
less than 50% of the basal level. Amnesia and lethargy develop,
progressing to coma. Bradycardia is prominent, and cardiac
output falls. The respiratory rate decreases, but a relative alka-
losis is maintained. This alkalosis may be protective of protein
and enzyme function, myocardial function, and cerebral
autoregulation. The cerebral ischemic tolerance during
hypothermia is considerably increased compared with the
normothermic state. This may, in some cases, contribute to
full neurologic recovery. For this reason, most patients with
hypothermia should be rewarmed and reevaluated before a
diagnosis of brain death is made. An additional consequence
of the altered level of consciousness is that normal protective
airway reflexes are abolished. This probably accounts for the
high incidence of aspiration pneumonia in hypothermic
patients. Atrial fibrillation, heart block, ventricular fibrillation,
or asystole may develop when the core body temperature falls
below 28°C. Ventricular fibrillation may occur spontaneously
or may be induced by line placement or other therapeutic
maneuvers. When ventricular fibrillation develops in this set-
ting, it is difficult to convert by countershock or pharmaco-
logic agents without further rewarming.
As the core body temperature falls below 26°C, hypoten-
sion and decreased systemic vascular resistance develop. An
additional factor contributing to hypotension may be the
hypovolemia that is commonly observed in accidental
hypothermia victims. The hypovolemia is frequently related
to a preexisting medical condition and may be exacerbated
by hypothermia-induced diuresis. Although renal blood flow
and the glomerular filtration rate decrease with hypother-
mia, cold diuresis usually results from the redistribution of
blood to the central circulation and from a decreased
response of the renal tubule to antidiuretic hormone. With
profound hypothermia, severe oliguria develops as a result of
generalized hypoperfusion and also may be related to acute
tubular necrosis secondary to rhabdomyolysis.
Hypothermia has profound effects on the hematologic
and coagulation systems. The hematocrit and the viscosity of
the blood increase owing to hemoconcentration, and viscosity
is further increased by the fall in temperature. Coagulation is
impaired as a result of platelet dysfunction and decreased
enzymatic protein activity. These coagulation disorders are
usually reversed on rewarming.
Hypothermia may result in severe GI complications,
including ileus, pancreatitis, and gastric stress ulcers. Depressed
hepatic function may result in alterations in the pharmacoki-
netics of many drugs and reduced clearance of toxins.
As core body temperature falls below 26°C, spontaneous
respirations cease, asystole develops, and electrocerebral
silence occurs.
Clinical Features
A. Symptoms and Signs—The history of the events prior to
presentation is essential for the diagnosis of hypothermia. In
cases such as cold water immersion or prolonged exposure to
winter temperatures, the diagnosis will be obvious. The diag-
nosis may be less obvious in a patient with associated injuries
or in the elderly patient with multiple medical problems.
Suspicion of hypothermia is particularly relevant when the
history suggests that an injury or disease has resulted in a
prolonged period of immobility with or without the associa-
tion of a cold environment.
Patients experiencing early hypothermia (35–37°C) usu-
ally present with shivering. The extremities are cool and
cyanotic as a result of reflex vasoconstriction. Tachycardia
results from increased sympathetic activity. In patients with
mild hypothermia (33–35°C), confusion and disorientation
are common. Hyperventilation may develop in response to
increased metabolic activity. Patients with moderate
hypothermia (30–33°C) are amnesic, obtunded, and often
progress to coma. When the core temperature falls below
32°C, shivering ceases and bradycardia develops. Terminal
additions to the QRS complex known as Osborne waves or
J waves develop in the ECG, and the PR and QT intervals may
be prolonged. Atrioventricular block or atrial fibrillation can
develop. Patients with severe hypothermia (<30°C) present
with coma, dilated pupils, and absent tendon reflexes. Life-
threatening cardiac arrhythmias or asystole may be present.
B. Temperature Monitoring—Body temperatures should
be accurately measured in all patients suspected of being
hypothermic. Standard clinical thermometers have a low
temperature limit of 32–33°C and should not be used.
Electronic temperature-sensing systems accurate down to
25°C are desirable, and many of these systems provide for
continuous temperature monitoring. If electronic equip-
ment is not available, standard glass laboratory thermome-
ters can be used to monitor temperature. In addition to
sublingual, axillary, and rectal sites, specialized electronic
systems allow for temperature monitoring in the esophagus,
pulmonary artery, bladder, and tympanic membrane.
Monitoring temperature at the tympanic membrane may
offer some advantage because this area is warmed by cerebral
blood flow, but temperature always should be recorded at
several sites to ensure accuracy.
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C. Laboratory Findings—A complete blood count, arterial
blood gas measurements, and blood cultures should be
obtained in all patients with hypothermia. The arterial blood
gas should be interpreted with and without temperature cor-
rection to avoid misinterpretation. Coagulation studies are
not usually of benefit because the blood sample is heated to
physiologic temperature prior to testing, and the results thus
do not correlate with the clinical situation.
D. Electrocardiography—Continuous electrocardiographic
monitoring should be established immediately. In cases of
moderate hypothermia, a complete ECG should be obtained
to determine intervals and to check for the presence of J waves.
Differential Diagnosis
The signs and symptoms of early hypothermia are nonspe-
cific. Accurate temperature determination is essential to
establish or exclude the diagnosis. Hypothermia may compli-
cate other disorders, including drug or alcohol intoxication
and endocrinopathies—that is, hypoglycemia, hyperosmolar
coma, diabetic ketoacidosis, and myxedema. Hypothermia
also may occur as a complication of sepsis. Patients with
severe trauma or burns are particularly at risk for the devel-
opment of hypothermia.
Treatment
A. Airway—Orotracheal intubation is indicated for all
hypothermic patients with altered mental status.
Nasotracheal intubation should be avoided because nasal
bleeding can be a significant problem in the patient with a
coagulation disorder. Cricothyroid pressure should be main-
tained during intubation attempts to prevent aspiration. It
should be recognized that even a cuffed endotracheal tube
will not offer complete protection against aspiration, and an
orogastric tube should be passed and placed on continuous
suction to evacuate the stomach contents. During the
rewarming process, endotracheal tube cuff pressures must be
monitored frequently to avoid tracheal injury because the
volume and pressure in the cuff will increase.
B. Breathing—Patients with moderate to severe hypothermia
require mechanical ventilation. Warm humidified gases should
be used to prevent further heat loss, but they will not play a
major role in rewarming owing to the small amount of heat
they convey. Adjustment of mechanical ventilation should be
guided by non-temperature-corrected blood gas values for pH
and PaCO2. However, temperature correction is required for
accurate determination of PaO2 and hemoglobin saturation.
C. Circulation—Most patients with moderate to severe
hypothermia also will be hypovolemic. These patients may
require as many as 10 L of crystalloid during rewarming.
Ideally, all intravenous fluids should be warmed to 39°C. This
can be accomplished in a number of ways, including use of
microwave ovens, but care must be taken to avoid overheat-
ing, which can lead to hemolysis. Heating units allow for
rapid fluid administration with precise temperature control
and should be used if available. Central venous pressure or
pulmonary artery pressure monitoring may be necessary in
patients who do not respond to aggressive volume adminis-
tration. Inotropic and vasoconstrictive agents such as
dopamine should be avoided because they are usually inef-
fective and may result in cardiac arrhythmias.
D. Rewarming—The faster the patient is warmed, the better
is the prognosis. Once the diagnosis of hypothermia is sus-
pected, all efforts should be directed toward reducing further
heat loss and rewarming the patient. In addition to the use of
warm intravenous fluids and heated respiratory gases, warm
blankets should be applied to prevent radiant heat loss during
resuscitation and evaluation. There are three options for
rewarming: (1) passive rewarming, (2) active external rewarm-
ing, and (3) active internal rewarming. The overall condition
of the patient will determine the most appropriate method.
Most patients with mild to moderate hypothermia will be
able to rewarm themselves, and passive external measures to
prevent further heat loss will be all that are necessary. Active
external rewarming, achieved by conductive surface warming
with methods such as warm water immersion or heating blan-
kets, is often ineffective in adults because of the low body-
surface-to-body-volume ratio. The vasodilation resulting from
these methods also may worsen hypotension. In addition, the
reestablishment of flow in peripheral circulatory beds may
lead to increased transport of colder peripheral blood to the
central core, resulting in a paradoxical decrease in core tem-
perature. To effect external rewarming, air circulating systems
may prove to be more effective because they provide for addi-
tional heat exchange by convection. These devices are usually
readily available in the operating room or recovery area. To
minimize adverse circulatory effects, these systems can be
applied initially only to the trunk. In most cases of moderate
to severe hypothermia, active external rewarming will need to
be combined with active internal rewarming.
Active internal rewarming is achieved by gastric, colonic, or
bladder lavage with heated saline, pleural lavage, peritoneal
lavage, and cardiopulmonary bypass. Gastric, colonic, and
bladder lavage can be performed easily without specialized
equipment or facilities. Although rewarming is relatively slow
by these methods because of limited surface area, it may be
enough to make the difference in cases of moderate hypother-
mia. Lavage fluid temperatures should not exceed 40.5°C to
avoid mucosal injury. With gastric lavage, care should be taken
to minimize the risk of aspiration. Gastric lavage should not be
performed on a patient receiving chest compressions for car-
diopulmonary resuscitation. Although more invasive, peri-
toneal lavage will result in more rapid warming. Lavage fluid up
to 43°C can be used, and the placement of two catheters will
provide for a continuous flow rate of up to 6 L/h. An intact car-
diovascular status is necessary to provide adequate perfusion so
that heat exchange can take place. If the patient has severe
hypothermia and cardiac arrest, open cardiac massage and
mediastinal and pleural lavage with warm saline is indicated.
The methods available for extracorporeal blood rewarm-
ing include hemodialysis, arteriovenous rewarming, venovenous
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rewarming, and cardiopulmonary bypass. Hemodialysis
offers the advantage of requiring only a single venous cannu-
lation with a two-way flow catheter. The femoral approach is
preferred to avoid cardiac irritation. Hemodialysis may offer
additional advantages in patients with renal failure and drug
or other toxicity.
In addition to providing circulatory support for the patient
with cardiac arrest or arrhythmia, cardiopulmonary bypass
will allow for rapid rewarming. A major drawback of car-
diopulmonary bypass is that systemic heparinization is
required. Therefore, the technique may be contraindicated in
patients who have sustained severe trauma. The use of systems
with heparin-bonded tubing may overcome some of these
problems. Standard cannulation techniques may be used in
the patient with a thoracotomy for open cardiac massage.
Alternatively, femoral venoarterial bypass can be instituted by
cutdown or by percutaneously placed catheters in the patient
with intact cardiovascular function. Portable systems using
percutaneous access may allow the institution of bypass
warming in the ICU. The long-term outcome of patients with
severe hypothermia treated with cardiopulmonary bypass has
been favorable.
Prognosis
The outcome depends on a number of factors, including the
severity and duration of hypothermia and the presence of
coexisting medical conditions. Aggressive treatment is indi-
cated because any hypothermic patient has the potential for
full recovery despite severely depressed cardiac or respiratory
function. Successful resuscitation with full recovery has been
reported after documented ice water submersion for as long
as 66 minutes in a small child. Success such as this probably
depends on rapid symmetric cooling of the entire body,
including the brain.
Current Controversies and Unresolved Issues
Techniques such as the use of very high temperature intra-
venous fluids are being explored for the treatment of moder-
ate to severe hypothermia. Intravenous fluids heated to 65°C
have been used in animal studies and have resulted in rewarm-
ing rates of 2.9–3.7°C per hour with minimal intimal injuries.
Diathermy involves the conversion of energy waves into
heat. Ultrasound or low-frequency microwave radiation
can deliver large amounts of heat to deep tissues. Although
animal studies have yielded some promising results, further
investigation is needed to determine the optimal clinical
use of diathermy. There is controversy about when and
when not to resuscitate the victim of hypothermia. The
techniques necessary to reverse severe hypothermia require
a major allocation of personnel and resources. Although it
has been stated that no person is dead until “warm and
dead,” in many cases additional information will establish a
definitive diagnosis. Severe hyperkalemia (>10 meq/L) sug-
gests that the patient died prior to the development of
hypothermia because the potassium level is usually normal
or low in patients with hypothermia. Of course, other
causes of hyperkalemia such as renal failure or crush injury
must be ruled out.
Once instituted, resuscitation should proceed until a core
temperature of 30°C is achieved. At this temperature, some
signs of life should be evident, and successful cardioversion is
usually possible.
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hypothermia: A review. Aviat Space Environ Med 2000;71:
733–52. [PMID: 10902937]
Kempainen RR et al: The evaluation and management of acciden-
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 Frostbite
ESSENT IALS  OF  D IAGNOS I S
 First degree: hyperemia and edema after rewarming;
no blister formation.
 Second degree: hyperemia, edema, and serous blister
formation; severe pain during rewarming.
 Third degree: full-thickness skin injury resulting in skin
necrosis, black eschars, and hemorrhagic blister formation.
 Fourth degree: complete necrosis of soft tissue, muscle,
and bone; after rewarming, the tissue is cyanotic and
ischemic; mummification with minimal edema.
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General Considerations
Local injuries owing to cold include chilblains, immersion
foot, and frostbite. Chilblains and immersion foot result
from prolonged exposure of the extremities in wet condi-
tions to temperatures above freezing. Severe neurovascular
damage may result, and ulcerations with chronic infections
may be incapacitating.
Frostbite occurs when the tissues are actually frozen.
Edema and blister formation develop after thawing or partial
thawing. These areas may progress to gangrene.
There are two phases of injury that occur with frostbite:
Phase 1: direct cellular cryotoxicity—As ice crystals
form within the affected area, cell death occurs as a result of
both dehydration and mechanical disruption owing to
expanding ice crystals. The most severe injuries occur after
partial thawing and refreezing of tissues.
Phase 2: progressive vascular thrombosis—Cold
exposure results in reflex arterial vasoconstriction and freez-
ing of the tissues that result in capillary injuries. In addition,
cold increases blood viscosity. When thawing occurs, the cir-
culatory stasis and tissue swelling result in intravascular
thrombosis. Tissue necrosis will occur when reperfusion can-
not be sustained following rewarming.
Clinical Features
Freezing begins distally and progresses centrally. Therefore,
the fingers and toes are most susceptible to severe injury.
There is usually a line of demarcation between the frozen and
unfrozen areas. However, the severity of injury and the extent
of nonviable tissue will not become apparent until several
days after thawing. In classifying frostbite, it is most impor-
tant to differentiate between superficial frostbite with skin
injury only and deep frostbite with injury to deeper struc-
tures of the extremities. Frostbite traditionally has been clas-
sified in somewhat the same way as burns.
Frostbitten extremities are painless, numb, and have a
blanched, waxy appearance. Superficial frostbite involves
only the skin and subcutaneous tissues. Deep frostbite
extends deeper and produces a woody consistency. However,
a wide range of frostbite injuries may appear similar at the
time of the initial evaluation. Therefore, classification of
frostbite should be applied after rewarming.
Treatment
The injury associated with freezing is progressive, and expo-
sure should be limited as soon as possible. However, thawing
should be avoided if refreezing is likely because this will
increase the severity of injury.
A. Rapid Rewarming—Extremities can be rewarmed most
effectively by immersion in a warm water bath with a mild
antibacterial agent such as povidone-iodine at a temperature
between 40 and 42°C. Lower temperatures may compromise
tissue survival. Higher temperatures should be avoided
because of the risk of thermal injury. Thawing should con-
tinue until all the blanched tissues of the injured extremity are
perfused with blood. A red to purple color and pliability of the
tissues will indicate that warming is complete. Active motion
during thawing may be beneficial, but it is important to avoid
rubbing the affected area because this may worsen the injury.
Severe pain is likely to develop during the warming process,
and opioid analgesics are usually required. Unfortunately, the
high opioid doses often required lead to side effects such as
heavy sedation, respiratory depression, and nausea that may
become a serious problem. In cases of frostbite injury of the
lower extremities, epidural blockade has been demonstrated to
provide good pain relief with fewer of these complications.
B. Postthaw Care—The affected area must be carefully pro-
tected after rewarming. White blisters should be debrided
and hemorrhagic ones left intact. Aloe vera (available in
generic preparations), a topical inhibitor of thromboxane,
should be applied to the injured tissue every 6 hours. The
extremity can be splinted in a position of function with ele-
vation, for both protection and comfort. Tetanus prophylaxis
should be administered if required. The use of ibuprofen as
a systemic antithromboxane agent is preferable to aspirin
because aspirin has been shown to inhibit prostaglandins
beneficial to wound healing. Ibuprofen 400 mg should be
given orally every 6 hours. Penicillin, with excellent coverage
of Streptococcus, is the antibiotic of choice for prophylaxis
and is usually continued for 48–72 hours. Daily hydrother-
apy at 40°C for 30–45 minutes aids debridement of devital-
ized tissue. Range-of-motion exercises are essential for
preservation of function. Adequate analgesia is necessary to
permit effective physical therapy.
C. Avoid Early or Inappropriately High Amputation—
Amputation should not be performed until the degree of tis-
sue loss is clearly determined. This may not be possible until
weeks or months after injury. In most cases, skin necrosis will
not be associated with deep tissue loss. Occasionally, digital
escharotomy or fasciotomy is necessary because a compart-
ment syndrome develops or because the range of motion
becomes severely limited. Imaging studies such as tech-
netium scanning and MRI may allow for precise determina-
tion of viable tissue and earlier debridement and
reconstruction with no loss in stump length. In some cases,
the survival of deeper structures may be improved by cover-
age with vascularized tissue.
Prognosis
Patients who sustain superficial frostbite usually achieve
complete recovery with minimal loss of tissue and no loss of
function. Complete recovery is unlikely for patients with
more severe degrees of frostbite injury. Amputation may
result in loss of function and severe cosmetic defects. Patients
may be incapacitated by the development of reflex sympathetic
dystrophy. Numbness, hypertrophic skin changes, chronic
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pain, hyperhidrosis, stiffness, and cold intolerance are all
potential sequelae of frostbite. Regional sympathectomy may
improve some of the symptoms of vasospasticity related to
sympathetic hyperactivity.
Children exposed to extreme cold may develop early epi-
physial closure as a result of injury to the growth plate. This
injury results in shortened phalanges. Hand function usually
remains excellent, and reconstructive surgery is rarely required.
Current Controversies and Unresolved Issues
Current interest in frostbite management centers around
heparin anticoagulation, low-molecular-weight dextran
administration, and the role of early sympathectomy.
Frostbite necrosis develops when reperfusion cannot be sus-
tained following rewarming. This has led to the development
of experimental treatments designed to maintain blood flow
in the microcirculation during the period of reperfusion.
However, none of these treatments has been proved to be
effective in controlled trials. Low-molecular-weight dextran
may improve circulation by decreasing blood viscosity and
red blood cell clumping. Animal experiments have demon-
strated a decrease in tissue loss, but this has yet to be estab-
lished in a clinical trial. Clinical studies on the use of heparin
anticoagulation have been inconclusive. Thrombolytic
agents have resulted in significant improvement in tissue sur-
vival in animal models of frostbite. These studies have yet to
be validated in human trials.
Murphy JV et al: Frostbite: pathogenesis and treatment. J Trauma
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ment of hypothermia and cold injury. Emerg Med Clin North
Am 2003;21:1165–78. [PMID: 14708823]
Wittmers LE Jr: Pathophysiology of cold exposure. Minn Med
2001;84:31–6. [PMID: 11816961]
 Near-Drowning
ESSENT IALS  OF  D IAGNOS I S
 History.
 Hypoxemia.
 Metabolic or mixed acidosis.
 Hypovolemia.
 Profound electrolyte abnormalities.
 Hypothermia.
 Associated injuries.
General Considerations
Drowning is death from asphyxia while submerged. The
near-drowning victim, having survived the acute episode, is
at major risk of developing severe organ dysfunction and of
subsequent mortality.
Pathogenic mechanisms of near-drowning are related to
hypoxemia and aspiration. The physiologic effects of aspira-
tion differ depending on whether the drowning medium is
fresh or salt water. Compared with plasma, these fluids are
hypo- and hypertonic, respectively. Although it is possible for
a drowning victim to die of hypoxemia without aspiration,
this rarely occurs. When fresh water is aspirated, the fluid is
rapidly absorbed from the alveoli, producing intravascular
hypervolemia, hypotonicity, dilution of serum electrolytes,
and intravascular hemolysis. Saltwater aspiration produces
the opposite effects as water is drawn into the alveoli from the
vascular space, producing hypovolemia, hemoconcentration,
and hypertonicity. Hemolysis is not a major problem after
saltwater drowning.
The initial contact of water with the upper respiratory
tract usually stimulates severe laryngospasm. This occasion-
ally results in hypoxia without significant aspiration of water.
Aspiration of water into the trachea and bronchi can result in
airway obstruction. Additional effects of water aspiration
include bronchoconstriction, loss of surfactant, damage to
alveolar and capillary endothelium, and direct alveolar
flooding. Aspiration of gastric contents is common in near-
drowning victims and dramatically increases the severity of
the direct injury.
Hypoxemia occurs most often as a result of intrapul-
monary shunting. Approximately 50% of near-drowning
victims develop acute respiratory distress syndrome (ARDS),
in most cases reversible.
The pathophysiology of brain injury is directly related
to hypoxia and diffuse neuronal damage. The resulting
brain edema may increase intracranial pressure, which may
further compromise cerebral perfusion. In children, the
diving reflex may play a protective role in cases of cold
water submersion. Owing to a high surface-to-volume
ratio, prompt hypothermia results in decreased cerebral
metabolism, with shunting of the circulation to the cerebral
and coronary systems.
Atrial and ventricular arrhythmias occur in the near-
drowning victim owing to hypoxia, metabolic and respira-
tory acidosis, and catecholamine excess. Vagally mediated
cardiac arrhythmias can develop as well. Electrolyte distur-
bances contribute to the generation of cardiac arrhythmias.
Acute tubular necrosis in the drowning victim develops as
a result of hypotension and hypoxemia. Renal failure is exac-
erbated by rhabdomyolysis and hemolysis associated with
disseminated intravascular coagulation.
Clinical Features
The diagnosis of near-drowning is necessarily based on the
history. In the surviving victim, the severity of injury is
determined by evaluation of the level of pulmonary and neu-
rologic function, metabolic and respiratory acidosis, elec-
trolyte abnormalities, and hypovolemia. Victims should be
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examined carefully to exclude associated injuries that may
require additional management decisions.
Differential Diagnosis
When a history of diving with compressed gas is obtained,
several additional diagnoses must be considered. Pulmonary
barotrauma occurs when expanding gases are unable to
escape from the alveoli during ascent from a dive.
Pneumothorax with arterial gas embolization then may
occur. Arterial gas embolization may result in neurologic
dysfunction and cardiovascular collapse. These diagnoses
should be suspected in any case of near-drowning associated
with compressed air diving.
The use of compressed air while diving may cause other
problems owing to the release of excess gas from tissues on
ascent. Severe pain is the usual clinical manifestation of
decompression sickness and is due to the presence of gas
bubbles in body tissues. Gas bubble formation also may
result in spinal cord injury or CNS dysfunction. In some
cases, this may have precipitated the drowning episode.
A blood alcohol level and a drug screen should be
obtained in all adolescent and adult victims of near-
drowning because intoxication is a factor in more than half
the cases.
Treatment
A. Airway—Since a successful outcome in the near-
drowning victim depends on early correction of hypoxia,
endotracheal intubation should be performed early if there is
any evidence of pulmonary dysfunction. Prior to intubation,
it is important to clear the airway of vomitus or debris.
Cervical spine precautions should be maintained in any vic-
tim who suffers a near-drowning episode after diving.
B. Breathing—The arterial oxygen saturation should be
maintained at a level greater than 90%. If this level cannot be
maintained with high concentrations of inspired oxygen or
with continuous positive airway pressure, mechanical ventila-
tion with positive end-expiratory pressure should be insti-
tuted. Alveolar flooding, with loss of surfactant and direct
capillary injury, results in atelectasis and pulmonary edema.
Aspiration injury may result from vomiting and aspiration of
gastric contents. Aspiration of polluted water and foreign
materials can result in additional lung injury. Early chest radi-
ographs may be normal, with pulmonary infiltrates becoming
evident 48–72 hours after injury. Delayed pulmonary compli-
cations include ARDS and aspiration pneumonia.
C. Circulation—The hypotensive near-drowning victim
requires vigorous fluid resuscitation. Central venous pressure
monitoring is instituted in patients who do not respond to
volume resuscitation and in those with hypoperfusion
despite fluid challenges.
D. Acid-Base Status—Metabolic acidosis is best managed
by optimization of fluid status. In most cases, bicarbonate
should not be administered. Mechanical hyperventilation
may be used to establish a compensatory respiratory alkalo-
sis in victims with severe metabolic acidosis.
E. Correction of Electrolyte Abnormalities—Electrolyte
abnormalities are usually not significant in victims of fresh-
water near-drowning. In the case of saltwater victims, critical
elevations of sodium and chloride may occur. Treatment
requires aggressive diuresis, adjustment of intravenous flu-
ids, and in some cases hemodialysis. Hypermagnesemia and
hypercalcemia also may develop in victims of saltwater
drowning and require hemodialysis.
The kidney may be adversely affected if significant
intravascular hemolysis has occurred. Hemoglobinuria is
treated initially by establishing an osmotic diuresis and by
alkalinization of the urine. Despite these measures, acute
tubular necrosis can develop and require dialysis.
Prognosis
The outcome depends on a number of factors, including the
length of submersion, water temperature, time to first
breath, initial pH, and the initial neurologic evaluation. A
recent review reported 58% survival, with no neurologic
deficit, in a group of pediatric victims of near-drowning. The
major factors that improved outcome were the presence of a
detectable heartbeat and hypothermia on admission to the
hospital. Neurologic outcome in adults is also improved in
cases of cold water near-drowning.
Current Controversies and Unresolved Issues
Emergency cardiopulmonary bypass may have a role in the
resuscitation of the profoundly hypothermic near-drowning
victim. Survival with subsequent normal neurologic func-
tion has been reported in victims with severe hypothermia
and no vital signs on admission. An obvious limitation of
this technique is the necessity for immediate availability of
equipment and personnel to institute bypass and the need
for systemic anticoagulation. However, it is unlikely that any
other method of resuscitation would prove successful in this
select group of patients.
Concern regarding the sequelae of cerebral edema in the
near-drowning victim has prompted the consideration of
various therapeutic interventions to prevent cerebral injury.
Unfortunately, the use of steroids, intracerebral monitoring,
hypothermia, and controlled hyperventilation have not
resulted in improved outcomes in controlled clinical trials.
The potential benefits of calcium channel blockers,
prostaglandin inhibitors, free-radical inhibition, and hemod-
ilution to decrease tissue injury remain unproved.
Gheen KM: Near-drowning and cold water submersion. Semin
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Giesbrecht GG: Cold stress, near drowning and accidental
hypothermia: A review. Aviat Space Environ Med 2000;71:
733–52. [PMID: 10902937]
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 Envenomation
1. Snakebite
ESSENT IALS  OF  D IAGNOS I S
Crotalidae:
 Swelling, erythema, ecchymosis.
 Coagulopathy.
 Metallic taste, perioral paresthesias.
 Hypotension.
 Tachypnea.
 Respiratory compromise.
Elapidae:
 Respiratory compromise, generalized paralysis.
General Considerations
It is estimated that 1500 snakebites are inflicted annually in
the United States by 19 species of venomous snakes.
Depending on the degree of envenomation, significant mor-
bidity and potential mortality can result. Ninety-five percent
of poisonous snakebites in the United States are caused by pit
vipers (Crotalidae), which include rattlesnakes, cotton-
mouths and copperheads; only 4–5% of bites are inflicted by
coral snakes (Elapidae).
The main functions of crotalid venom are immobiliza-
tion, death, and digestion of prey. These venoms are complex
mixtures of enzymes and toxic proteins. Other components
include metalloproteins, glycoproteins, lipids, and biogenic
amines. Crotalid venom causes local tissue injury, coagulopa-
thy, and systemic manifestations. The local injury is due to a
combination of direct toxic damage to tissue as well as to
ischemic damage owing to elevated compartment pressure
resulting from local tissue edema. The coagulopathy is
caused by procoagulant esterases that act on fibrinogen and
split off fibrinopeptides. This results in depletion of fibrino-
gen and elevation of the prothrombin and partial thrombo-
plastin times. The platelet count usually remains normal.
Bradykinin is released by the action of arginine ester hydrox-
ylase on plasma kininogen and may cause vasodilation and
pooling of blood in the pulmonary and splanchnic beds,
resulting in decreased venous return, hypotension, and
shock. Interstitial loss of intravascular fluid further worsens
the hypotension. Myocardial ischemia and depression of
contractility also have been associated with pit viper venom.
Renal failure probably results from hypotension, from the
direct effects of the venom, and from myoglobinuria.
Disseminated intravascular coagulation further contributes
to the development of renal failure.
The Mojave rattlesnake has a different type of venom
containing a toxin that immobilizes prey by neuromuscular
blockade. This toxin is present to some extent in other cro-
talid species, but in Mojave rattlesnake venom the higher
concentration significantly increases the risk of airway and
breathing complications. For these reasons, Mojave rat-
tlesnake venom has the lowest median lethal dose level of any
North American crotalid venom.
Venom from the Elapidae causes symptoms that are pri-
marily neurologic in nature, with little or no local tissue tox-
icity. The neurotoxic elements are polypeptides that bind
postsynaptically and effect nondepolarizing blockade of the
acetylcholine receptors. Generalized paralysis, bulbar paraly-
sis, and respiratory arrest may occur. The neurotoxic effects
of these venoms are severe and in some cases irreversible.
The signs and symptoms of envenomation can be delayed for
more than 12 hours and often occur precipitously.
Clinical Features
A. Signs and Symptoms—The symptoms in each individ-
ual case of snakebite vary depending on the degree of enven-
omation. It is estimated that approximately 3% of
snakebites are “dry,” with no evidence of venom injection.
In the case of crotalid bites, the degree of envenomation can
be estimated by the presence and progression of signs and
symptoms. The bites of elapid snakes usually cause minimal
early symptoms—it is only after 1–12 hours that severe
systemic symptoms suddenly appear.
Minimal envenomation is characterized by the presence
of local findings with slow progression and the absence of
systemic signs and symptoms. In the case of severe enveno-
mation, local findings will progress rapidly, and systemic
complications appear early and are particularly severe.
B. Laboratory Findings—Determination of coagulation
parameters helps to evaluate the degree of envenomation in cro-
talid bites. Prothrombin time, partial thromboplastin time,
platelet count, fibrinogen levels, and fibrin degradation prod-
ucts should be determined initially and repeated at regular
intervals to estimate the severity and monitor the progression of
coagulopathy. Serial red blood cell counts should be obtained to
evaluate for the development of hemoconcentration caused by
third spacing of fluid or to detect anemia owing to bleeding or
hemolysis. Urinary myoglobin indicates myonecrosis.
Laboratory data should be obtained on admission, again after
the administration of antivenin, and then every 4 hours until
the data have returned to near-normal levels.
Differential Diagnosis
Identification of the type of snake is necessary to secure the
appropriate antivenin. In cases where the snake has not been
identified, the diagnosis of venomous snakebite often can be
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made by examination of the fang marks. Crotalid bites are char-
acterized by two such marks. Remember that elapid bites may
not result in local signs or symptoms despite envenomation.
Treatment
A. Resuscitation—The adequacy of the airway and ventila-
tion should be verified. The primary survey and resuscitation
should follow standard protocols available from the
American College of Surgeons Advanced Trauma Life
Support Course. The airway should be secured promptly in
patients with envenomation to the head or neck. Subsequent
swelling could make endotracheal intubation difficult or
impossible. Hypotension is best treated with rapid crystal-
loid infusion. Fluid resuscitation should be aggressive to pre-
serve organ function. Prophylactic antibiotics are not
recommended.
B. Antivenin—In the patient with major systemic signs and
symptoms owing to severe envenomation, antivenin should
be administered as quickly as possible. Antivenin is recom-
mended for moderate to severe envenomation and for any
envenomation with symptoms of progression—particularly
worsening local injury, progressive coagulopathy, and hemol-
ysis. A skin test is performed with the antivenin prior to
administration in an attempt to predict the likelihood of an
allergic reaction. The test is performed by intradermal injec-
tion of 0.2 mL of antivenin diluted 1:10 with normal saline.
Erythema and a wheal reaction within 30 minutes is a posi-
tive reaction indicating the need for treatment. Antivenin
should be given only by slow intravenous infusion. The use
of antivenin should be considered early because it may have
to be obtained from a distance. The time required to prepare
the antivenin will result in an additional delay. Patients may
require additional doses of antivenin if their symptoms
progress after the initial administration.
Moderate to severe antivenin reactions occur in 15–20%
of patients who receive antivenin. Mild reactions can be
treated with intravenous diphenhydramine and epinephrine;
severe reactions require increased doses.
In cases of severe envenomation, further antivenin ther-
apy should be strongly considered after treatment of a reac-
tion. In less severe cases, antivenin should be withheld if
possible after a reaction because there have been cases of
death owing to anaphylaxis. Antivenin information can be
obtained from local poison control centers or from a
national service by calling 1-800-222-1222.
Exotic envenomations may occur occasionally in the United
States from foreign snakes or lizards kept in zoos or private col-
lections. The principles of management are the same: support-
ive care and administration of appropriate antivenin. Most
exotic antivenins are available at the institutions that maintain
the snakes. The availability of these antivenins also can be
determined through the Antivenin Index.
C. Local Treatment—Local therapy consists of elevation and
immobilization of the affected area until swelling recedes.
Extremities should be observed for the development of
compartment syndrome. If muscle compartments become
firm, or if pain increases, the compartment pressure should
be measured. In some cases, fasciotomy may be required to
prevent ischemic necrosis. Cruciate incisions should not be
performed in an attempt to extract venom.
D. Tetanus Prophylaxis—Tetanus prophylaxis should be
administered if the patient’s immunization status is not cur-
rent or is unknown.
Current Controversies and Unresolved Issues
Immediate excision of the bite down to fascia and including
damaged fascia and muscle has been advocated to reduce the
incidence of local necrosis and to reduce systemic symptoms.
This therapy can be effective only in cases of recent enveno-
mation and in the absence of local diffusion of venom or sys-
temic symptoms. Surgical excision of the envenomation site
cannot be recommended for a number of reasons: Most vic-
tims of snakebite do not reach medical care for several hours
and are therefore beyond the point where local excision
would be expected to have any benefit. In addition, wide
local excision can increase morbidity in cases of minimal
envenomation without offering any benefit.
A polyvalent antivenin, CroTAb, has been approved for
clinical use. This antivenin is produced by immunizing sheep
with venom from the eastern and western diamondback rat-
tlesnakes, the Mojave rattlesnake, and the eastern cottonmouth.
In a randomized trial in the United States, CroTAb was demon-
strated to effectively terminate venom effects. In another study,
CroTAb was successful in immediately and completely revers-
ing neurotoxicity resulting from Mojave rattlesnake envenoma-
tion. Conventional polyvalent antivenin is often ineffective in
the treatment of venom-induced neurotoxicity.
2. Spider & Scorpion Bites
ESSENT IALS  OF  D IAGNOS I S
Black widow spider:
 Numbing pain at the site of the bite.
 Muscle cramps and low back pain.
 Severe abdominal pain.
 Respiratory insufficiency.
 Cardiac conduction abnormalities.
Brown recluse spider:
 Pain beginning 1–4 hours after bite.
 Erythema, central pustule, bull’s-eye lesion.
 Fever, malaise, arthralgias, rash, hemolysis.
Scorpions:
 Pain with little erythema or swelling.
 Generalized reactions within 1 hour.
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General Considerations
Spider and scorpion bites are particularly common in the
western United States. Only the female black widow spider
(Latrodectus mactans) is dangerous. Its venom contains a
potent neurotoxin that induces neurotransmitter release fol-
lowing interaction with a specific cell surface receptor. This
action affects mainly the neuromuscular junction and results
in unrestrained muscle contraction and severe cramping.
The local reaction at the site of envenomation is usually mild.
Venom from the brown recluse spider (Loxosceles reclusa)
contains sphingomyelinase D. It is primarily cytotoxic and
causes local tissue destruction. Hemolysis is the principal
systemic effect, and it is usually minor.
Most scorpion stings are harmless and produce only local
reactions. However, venom from Centruroides exilicauda con-
tains a neurotoxin that may cause severe systemic reactions.
Clinical Features
A. Symptoms and Signs—Initially, a black widow spider
bite is painless. Symptoms begin within 10–60 minutes and
include severe pain and muscle spasms of the abdomen and
trunk. Headache, nausea, vomiting, and hyperactive deep
tendon reflexes may be present. Spasms give way to agoniz-
ing pain. Rigidity of the abdominal wall may be confused
with an intraabdominal catastrophe. Hypertension with or
without seizures develops uncommonly. Symptoms are
maximum at 2–3 hours after the bite and may persist for up
to 24 hours.
Brown recluse spider bites produce pain after 1–4 hours.
Initially, an erythematous area with a central pustule or hem-
orrhagic area appears. A bull’s-eye appearance of the lesion
may be noted because of an ischemic halo surrounded by
extravasated blood. Over several days, an ulcer may form,
which, if extensive, requires excision and skin grafting.
Systemic reactions are infrequent but may occur 1–2 days
after the bite and include massive hemolysis, hemoglobin-
uria, jaundice, renal failure, pulmonary edema, and dissemi-
nated intravascular coagulation.
Scorpion stings are extremely painful but often exhibit no
erythema or swelling. Light palpation of the area causes
extreme pain. Generalized reactions are not common but
may develop within 60 minutes: restlessness, jerking, nystag-
mus, hypertension, diplopia, confusion, and rarely seizures.
Death is uncommon.
Differential Diagnosis
The signs and symptoms of black widow spider envenomation
can be easily confused with other common conditions, partic-
ularly those cases with minimal bite-related symptoms. In
some cases, the abdominal pain may mimic an acute
abdomen. Black widow spider envenomation should be con-
sidered in patients presenting with the acute onset of severe
pain and muscle cramps, particularly if the history is consis-
tent with spider bite.
Brown recluse spider bites are occasionally confused with
those of other insects. It should be remembered that spiders
usually bite only once, whereas other insects produce multi-
ple bites.
Treatment
A. Black Widow Spider Bites—The most effective treat-
ment options include specific antivenin alone or with a com-
bination of intravenous opioids and muscle relaxants.
Although calcium gluconate administration has been recom-
mended, it has not been shown to be effective. Intravenous
morphine and benzodiazepines are helpful in achieving relief
of symptoms. Antivenin should be considered in moderate to
severe cases but should be used with caution because it has
been associated with fatal reactions. Advanced life support
measures may be required for patients who develop cardio-
vascular collapse or respiratory failure.
B. Brown Recluse Spider Bites—Most patients can be
treated with supportive measures. Ice may be beneficial.
Exercise of the limb or application of heat will potentiate the
actions of the venom. Patients requiring admission to the
ICU are usually older, with systemic symptoms. Dapsone,
50–100 mg orally twice daily for 10 days, has been used in
patients who do not have glucose-6-phosphate dehydroge-
nase deficiency. Some authorities use oral erythromycin,
250 mg four times daily for 10 days, to control skin infection.
C. Scorpion Stings—Children and older adults must be
admitted to the ICU for observation. The affected part
should be immobilized and ice applied. A tourniquet must
not be used. Respiratory depression may result from the use
of tranquilizers. Opioid analgesics are particularly dangerous
because they seem to potentiate the toxicity of the venom.
Seizures, when present, usually can be controlled with intra-
venous diazepam or phenobarbital. Hypertension may
require the use of sympatholytic agents.
3. Marine Life Envenomations
ESSENT IALS  OF  D IAGNOS I S
 Pain at the site of envenomation.
 Systemic symptoms subsequently.
 Multiple wounds may be present.
General Considerations
Marine life envenomations are caused most commonly by
stingrays, jellyfish (Portuguese man-of-wars), scorpion
fish, and sea urchins. Although many victims can be
treated in the emergency department and released, critical
care may be required for hemodynamic and respiratory
complications.
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Clinical Features
A. Stingray—Multiple sites may be present, with pain and
swelling occurring immediately. Local hemorrhage also may
be present. Systemic symptoms, when present, include nau-
sea, vomiting, weakness, vertigo, tachycardia, and muscle
cramps. Syncope, paralysis, hypotension, and tachycardia
may occur with extensive envenomations.
B. Scorpion Fish—Central radiation of pain from the
wound may cause extreme discomfort requiring ICU admis-
sion for control. Systemic symptoms are manifest within the
first few hours after envenomation and include vomiting,
weakness, diarrhea, paresthesias, seizures, fever, hyperten-
sion, cardiac arrhythmias, and respiratory failure.
C. Sea Urchins—Sea urchin venoms contain several toxins,
including cholinergic compounds and neurotoxins. Multiple
spines usually are present in the skin and indicate the nature
of the contact. Systemic reactions include nausea and vomit-
ing, intense pain, paralysis, aphonia, and respiratory distress.
Treatment
A. Stingray—Wounds can be treated with local measures,
including warm soaks and lidocaine. Ice should not be applied.
Operative debridement may be required. Supportive therapy is
usually all that is required. Infection prophylaxis should be
instituted with trimethoprim-sulfamethoxazole or tetracycline.
B. Scorpion Fish—Care is similar to that outlined for
stingray contact. Infection prophylaxis should be instituted
in a similar fashion. Seizures can be treated with phenobar-
bital, phenytoin, or diazepam.
C. Sea Urchins—Although pain can subside within a few
hours, paralysis may last for 6–8 hours and require intuba-
tion and mechanical ventilation until the patient has
regained sufficient strength.
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 Electric Shock & Lightning Injury
ESSENT IALS  OF  D IAGNOS I S
 Momentary or prolonged unconsciousness.
 Cardiac arrhythmias.
 Muscular pain, fatigue, headache.
 Rhabdomyolysis and renal failure.
General Considerations
Electrical injuries account for more than 500 fatalities each
year in the United States. One-fifth of these deaths are due to
lightning. The number of nonfatal injuries may be three or
four times this number. Patients who have sustained electri-
cal injury or a lightning strike exhibit a number of signs
depending on the energy of the current conducted. Most
household electrical injuries are produced by alternating
current (50–60 Hz) in the 110–220-volt range. Direct current
usually produces less severe injuries for the same amount of
voltage. Electricity can cause partial- or full-thickness burns
with injury to the deeper tissues of the body. In some cases,
the burn injury at the entry and exit points may correlate
directly with the extent of underlying muscle injury, but
extensive deep injuries may be present with only minimal
superficial findings. Myonecrosis and rhabdomyolysis are
frequently present with higher-energy exposures.
Rhabdomyolysis may lead to renal failure if not recognized
and treated promptly. Compartment syndrome can occur in
extremities with resulting circulatory compromise.
Ventricular fibrillation may be present if the current pathway
has included the heart.
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A potential difference of more than 440 V is considered
high voltage. At greater than 1000 V, severe tissue destruction
occurs as a result of electrical energy being converted to heat.
Electrocution may be accompanied by arc and flash burns
(see Chapter 35). Associated injuries are a result of falls
owing to tetany of the major muscles.
Lightning strikes impart huge amounts of energy to their
victims. Cardiac and respiratory failure are responsible for
immediate deaths. Those surviving the immediate period are at
risk for delayed neurologic, visual, and otologic as well as mus-
culoskeletal complications. Although neurologic sequelae pre-
viously were thought to be transient, recent investigations have
demonstrated permanent injury in one-half of the victims.
Clinical Features
A. Electric Shock—Shock from household current commonly
produces transient loss of consciousness, although this may be
prolonged. Patients frequently have regained normal function
by the time they arrive in the emergency room, at which time
they complain of headache, muscle cramps, and fatigue.
Nervous irritability and a sensation of anxiety are other com-
mon findings. Patients with prolonged unconsciousness
should undergo CT scanning to rule out an associated cerebral
injury from a fall or direct injury. Cardiac arrhythmias typi-
cally are tachyarrhythmias, with atrial and ventricular fibrilla-
tion being the most common. Difficulty in breathing with
varying degrees of respiratory paresis or complete paralysis
requires immediate attention. Damage to skeletal muscles may
produce a spurious rise in the CK-MB fraction, leading to the
erroneous diagnosis of myocardial infarction.
Burn wounds often accompany electrocution victims.
These injuries are of three types: (1) direct burn, (2) arc
injury, or (3) flame burn from an associated ignition source.
Burn wounds are more common with higher-voltage injuries.
All patients with burn wounds should receive tetanus prophy-
laxis. Patients with more severe burns should be considered
for transfer after stabilization to a specialized burn center.
Additional management is discussed in Chapter 35.
B. Lightning Strike—Patients who require critical care after a
lightning strike usually are admitted for complications or sim-
ply for cardiac monitoring. Lightning victims may present with
paraplegia or quadriplegia that resolves over several hours. This
may be accompanied by autonomic instability. In cases of pro-
longed paresis, imaging studies should be obtained to rule out
a spinal injury. Electrocardiographic changes include nonspe-
cific ST-T-segment changes that may be accompanied by eleva-
tion of cardiac enzymes. Initial hypertension usually resolves
spontaneously and does not require treatment.
Lightning victims may have a number of associated find-
ings related to blunt trauma sustained at the time of impact.
Rib and long bone fractures in the extremities are particu-
larly common. Burns may be present but are superficial in
most patients and often require only superficial wound care.
Unlike those who have sustained electrical injuries, patients
with lightning injuries rarely develop myoglobinuria.
Treatment: Electric Shock
Patients suffering from electrical injuries should be admitted
to the ICU when the conditions outlined in Table 37–1 are
present.
A. General Measures—Most electrocution patients admit-
ted to the ICU already will have had the airway secured (if
necessary) and large-bore intravenous catheters inserted for
resuscitation and fluid management. Adequate urine output
must be ensured to prevent renal failure from myoglobin-
uria. The goal is to maintain a urine output of 75–100 mL/h.
Mannitol may be give as a bolus (1 g/kg) and then as an infu-
sion to maintain an osmotic diuresis as long as the urine con-
tains myoglobin (positive hemoglobin nitrotoluidine test).
Sodium bicarbonate may be added to alkalinize the urine
and prevent the precipitation of acid hematin. The calculated
fluid requirement is approximately 1.7 times the standard
fluid calculation based on the total body surface area burned.
Electrolytes should be monitored frequently during the
resuscitation period.
B. Arrhythmias—After initial stabilization, the most imme-
diate risk is from cardiac arrhythmia, particularly when the
electric current has passed through the thorax.
Antiarrhythmics and inotropic support should be instituted
when appropriate. However, most arrhythmias are self-
limited and infrequently cause hemodynamic abnormalities.
Atrial fibrillation occurs occasionally and usually will con-
vert without treatment. Electrocardiographic changes are
present in 10–30% of patients. The most common abnor-
mality is nonspecific ST-T-wave changes. Myocardial infarc-
tion is unusual, but patients with high-voltage injuries may
sustain direct myocardial damage. In these patients, close
monitoring of fluid therapy may be necessary to prevent pul-
monary edema.
C. Neurologic Sequelae—More than half of patients with
severe electrical injury develop loss of consciousness, but full
recovery usually ensues. Neurologic sequelae sometimes are
delayed and may develop days to years after the injury.
Deterioration of neurologic status may be of three types:
(1) ascending paralysis, (2) amyotrophic lateral sclerosis, or
High-voltage electrocution  
Burns >20% of BSA  
Evidence of entrance and exit burns  
Cardiac arrhythmias  
Unconsciousness  
Respiratory or motor paralysis  
Multiple associated injuries  
Prior medical compromise  
Table 37–1. Criteria for ICU admission following electrical
injury. 
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(3) transverse myelitis. Peripheral nerve injuries and motor
neuropathies result from demyelinization, vacuolization,
gliosis, and perivascular hemorrhage. The prognosis for
recovery of useful function is poor.
D. Burns—Most critical care required by victims of electri-
cal injury relates to burns. This subject is discussed in
Chapter 35.
Treatment: Lightning Strikes
The most severe complication of lightning injury is respira-
tory arrest caused by depression of the respiratory control
center. This can result in secondary cardiac arrest in an oth-
erwise salvageable patient. Surviving victims of lightning
strikes tend to have fewer complications than patients with
electrical injury. Early emergency resuscitation usually stabi-
lizes these patients to the point that only observation is nec-
essary. The need for cardiac monitoring for more than 24
hours is debatable. Most patients will be confused and have
anterograde amnesia covering a period of several days after
the incident. If neurologic deterioration is noted, CT scan-
ning or MRI should be obtained to exclude the possibility of
intracranial hemorrhage or other injury. In most cases, long-
term sequelae from lightning injuries are rare.
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 Radiation Injury
ESSENT IALS  OF  D IAGNOS I S
 Nausea and vomiting, diarrhea.
 Weakness, dehydration.
 Bone marrow depression.
 Sepsis.
 Severe neurologic changes.
 Cardiovascular collapse.
General Considerations
Acute radiation syndrome consists of characteristic clinical
manifestations following accidental or therapeutic exposure
to ionizing radiation. In cases of unknown level of exposure,
knowledge of the manifestations enables the clinician to
estimate the exposure dose and determine appropriate
treatment.
Ionizing radiation can be either electromagnetic (eg, x-
rays and gamma rays) or particulate (eg, electrons, protons,
and neutrons). The power of penetration of these particles
is determined by the energy they carry. High-energy parti-
cles can travel deep into the body and cause severe damage
to tissues.
The principal lethal effect of radiation appears to be the
production of chemically active free radicals within cells that
damage essential macromolecules such as DNA. Very high
radiation doses will disrupt cell metabolism and result in
rapid cell death. Moderate radiation doses produce breaks in
double-stranded DNA. No visible effects occur until the cell
attempts mitosis. At that time, cell division may be arrested,
or the daughter cells may lack essential genetic material and
become nonfunctional. Small doses of radiation can produce
gene mutations. This may result in no observable effect or in
subsequent malignant transformation.
Individual tissues vary greatly in their sensitivity to radi-
ation damage. The most sensitive tissues are those that
require continued cellular proliferation for proper function,
such as the GI and hematopoietic systems. Acute radiation
syndrome is most pronounced in these systems. With very
high levels of exposure, dysfunction of the cardiovascular
and central nervous systems is also observed, most likely
resulting from direct organ injury.
Radiation Dosimetry
The rad is the unit of absorbed radiation dose. It is defined
as that quantity of radiation that deposits 100 ergs of energy
per gram of tissue. Clinically, a dose of radiation is often pre-
scribed in grays (Gy) (1 Gy = 100 rads; 1 rad = 1 cGy).
Clinical Features
Radiation injury is characterized by an acute phase, referred
to as the prodromal phase, and a subacute phase, character-
ized by bone marrow and GI dysfunction. The phases are
separated by a latent period of 1–3 weeks, during which time
the patient may be completely asymptomatic. The severity of
acute radiation injury is determined by the dose and the time
over which the exposure occurs. After exposure to less than
150 cGy, most patients have minimal or no prodromal symp-
toms. Slight depression of platelets and granulocytes may be
observed after a latent period of 30 days. Lymphocytes are
most sensitive to radiation and may be decreased.
Patients exposed to 150–400 cGy develop transient nau-
sea and vomiting 1–4 hours following exposure. After a latent
period of 1–3 weeks, GI symptoms occur: nausea, vomiting,
and bloody diarrhea. Bone marrow depression is manifest by
anemia, coagulopathy, and depressed immune function.
Susceptibility to infection is increased significantly.
An acute whole body exposure of 600–1000 cGy results in
an accelerated version of the acute radiation syndrome. GI
complications predominate in the early phase of the illness
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and may be life-threatening. Severe hematologic complica-
tions can be expected to develop in survivors.
A fulminating course is seen in patients sustaining acute
whole body exposure to higher doses. Vomiting occurs
shortly after exposure and is rapidly followed by diarrhea,
tenesmus, dehydration, and circulatory collapse. CNS mani-
festations may include ataxia, incoordination, weakness, con-
fusion, seizures, and coma. Death occurs within 48 hours.
Pericarditis with effusions and constriction are delayed
manifestations that develop several months after exposure.
Myocarditis can occur but is less common. If injury is mild,
full recovery is the rule.
Treatment
In cases of moderate radiation exposure, initial treatment is
supportive and uncomplicated. Immediate aggressive ther-
apy is not indicated because the prodromal symptoms usu-
ally are not severe and are self-limited. It is after the latent
period of 1–3 weeks that the more severe clinical manifesta-
tions of the syndrome develop. In cases in which severe
symptoms develop without a latent period, death is
inevitable, and only symptomatic care should be provided.
Patients with moderate to severe radiation exposure
should be admitted to the hospital and isolated. Care should
be exercised to limit patient and personnel movement
through the hospital in order to contain the radiation. Many
radioactive materials are in particulate form and will not
pass through the skin and are removed by washing. To this
end, clothes should be removed and stored in specially
labeled plastic bags. Showering or washing skin surfaces
removes most of the contamination. A Geiger counter
should be used to assess the adequacy of decontamination.
The process can be aided by hair removal. Undiluted house-
hold bleach (5% sodium hypochlorite) can be used after
soap and water. A dilute solution (1 part bleach to 5 parts
water) should be used around the face and wounds. Wounds
should be thoroughly debrided and irrigated to remove
radioactive material.
Fluid loss should be corrected with intensive intravenous
replacement. The blood count should be monitored care-
fully. Reverse isolation is required when the white blood cell
count falls below 1000/μL. Whole blood and platelet transfu-
sions are nearly always required because of anemia and bleed-
ing. When immunosuppression is apparent, blood products
should be irradiated with 5000 cGy before transfusion to
decrease the possibility of a graft-versus-host reaction.
Intestinal microorganisms are a major source of infection,
and prophylactic antibiotics directed against gram-negative
organisms should be administered. The appearance of clinical
signs of infection should prompt a thorough evaluation.
Broad-spectrum antibiotics should be administered until
culture results are obtained.
The use of chlorpromazine or promethazine in an
attempt to control radiation-induced vomiting should be
avoided. These medications depress gastric emptying and
may increase the risk of aspiration and subsequent pul-
monary infection.
Current Controversies and Unresolved Issues
Antidopaminergic agents appear to prevent radiation-
induced vomiting without causing gastroplegia. Clinical tri-
als suggest that domperidone may be effective, but more
controlled studies need to be completed.
In most cases of moderate to severe acute radiation
injury, exposure of the bone marrow is not uniform, and a
return of function can be anticipated. In cases of lethal expo-
sures, the use of bone marrow transplantation as a form of
therapy has been suggested. However, based on current expe-
rience, the likelihood of success cannot be adequately
ensured. Numerous problems exist in the potential applica-
tion of this type of therapy. It could not be used in a mass-
casualty situation because of the extensive resources required
for the treatment of individual patients. Additional problems
can be anticipated in securing suitable HLA-compatible
donors and in controlling graft-versus-host disease. This
treatment was attempted in 13 victims of the Chernobyl acci-
dent. Eleven of these patients died. It is not clear whether the
other two patients would have survived with conventional
supportive therapy.
A newer mode of treatment of pancytopenia is the stim-
ulation of hematopoietic tissue through the use of cytokines
and colony-stimulating factors. This has been demonstrated
to decrease the period of leukocyte count depression and to
elevate the nadir. Additional studies are required to establish
efficacy and optimal dosing regimens.
GI pathogen suppression may be accomplished by the
deliberate inoculation of the gut with nonpathogenic bacte-
ria such as lactobacilli. The theory is that this will result in
normalization of the intestinal flora that had been altered by
antibiotic therapy. Prolonged survival has been demon-
strated in animal models, but studies in humans are lacking.
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PHYSIOLOGIC ADAPTATION TO PREGNANCY
The average duration of gestation is 40 weeks from the first
day of the last menses, with term defined as being between
37 and 42 weeks. The mother’s basic physiology is altered in
a number of ways during normal pregnancy. Some of these
may alter her baseline state and response to critical illness,
but others may predispose to injuries and conditions that
require critical care.
 Cardiovascular System
Pregnancy causes changes in the appearance and function of
the heart and great vessels. Elevation of the hemidiaphragms,
which accompanies advancing pregnancy, causes the heart to
assume a more horizontal position in the chest, and this
results in lateral deviation of the cardiac apex, with a larger
cardiac silhouette on chest x-ray and a shift in the electrical
axis. The heart does increase in size in pregnancy, but only by
about 12%. Cardiac output increases by 30–50%, with most
of the increase occurring in the first trimester. Both stroke
volume and heart rate increase. The heart rate increases by
about 17%, with the maximum reached by the middle of the
third trimester (32 weeks). Stroke volume increases by 32%,
with the maximum reached by midgestation. After 20 weeks,
cardiac output may decrease significantly (25–30%) when the
patient lies in the supine position as compared with the left
lateral position. This is apparently due to compression of the
inferior vena cava by the pregnant uterus with resulting
decreased venous return. The distribution of cardiac output is
altered as well. At term, 17% of the cardiac output is directed
to the uterus and its contents, and an additional 2% goes to
the breasts. The skin and kidneys also receive additional blood
flow compared with the nonpregnant state. Blood flow to the
brain and liver may increase. Perfusion of other organs such
as the skeletal muscle and gut is unchanged.
Peripheral vascular resistance decreases during preg-
nancy. A concomitant decrease in systemic blood pressure
reaches its nadir at about 24 weeks of gestation. Blood pressure
then rises gradually until term but should not exceed non-
pregnant levels at any time during pregnancy. Central hemo-
dynamic studies of normal pregnant women demonstrate a
significant decrease in both systemic and pulmonary vascu-
lar resistance. Mean arterial pressure, pulmonary capillary
wedge pressure, central venous pressure, and left ventricular
stroke work index are unchanged. Colloid osmotic pressure
is decreased.
Labor and delivery are associated with cardiac stress
beyond that of late pregnancy. Cardiac output may increase
by as much as 40% in patients not receiving adequate pain
relief, although those with adequate anesthesia experience
much smaller rises. The rise in cardiac output is progressive
over the different stages of labor, and there is a further rise
of approximately 15% during each uterine contraction
resulting from the expression of 300–500 mL of blood from
the uterus back into the mother’s circulation. Delivery of
the fetus is associated with as much as a 59% increase in
cardiac output, presumably as a result of autotransfusion of
blood contained in the uterus. This increase may be blunted
by the blood loss at delivery. In patients with clinically sig-
nificant mitral stenosis, delivery may be associated with an
increase in the pulmonary capillary wedge pressure of up to
16 mm Hg.
 Respiratory System
During pregnancy, the subcostal angle increases from about
68 degrees to about 103 degrees, with a concomitant increase
in the transthoracic diameter. The resting level of the
diaphragm is 4 cm higher at term than in the nongravid
state. Many authors state that this elevation is a result of pres-
sure from the expanding uterus. However, diaphragmatic
excursions are increased by 1–2 cm over nonpregnant values,
suggesting that uterine pressure is not the sole cause of the
elevation.
Several aspects of pulmonary function change during
pregnancy (Figure 38–1). Tidal volume increases by about
40%, and residual volume decreases by about 20%. These
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changes may make the lung appear denser on x-ray because
it is more collapsed during expiration. Data on vital capacity
in pregnancy are contradictory, with older studies suggesting
that there is no change and some newer ones suggesting that
there is a marked increase. During pregnancy, expiratory
reserve volume decreases by about 200 mL, and inspiratory
reserve volume increases by about 300 mL. Forced expiratory
volume appears to be unchanged.
Total body oxygen uptake at rest increases by about
30–40 mL/min in pregnancy, or about 12–20%. Most of the
oxygen is needed to meet maternal metabolic alterations.
The increased oxygen need is met by increased tidal vol-
ume alone because the pulmonary diffusing capacity
appears to be decreased in pregnancy, and the respiratory
rate does not significantly increase. There is a total increase
in minute ventilation of 48% at term, which exceeds the
need for increased oxygen delivery. This “hyperventilation
of pregnancy” appears to be hormonally mediated and
results in a decrease in PaCO2 to below 30 mm Hg in normal
women. Maternal pH does not change because there is a
reciprocal decline in bicarbonate concentration. The net
result of these acid-base alterations is facilitation of fetal-
maternal CO2 exchange.
 Hematologic System
Both the volume and the composition of the blood change
during pregnancy. Plasma volume increases by 40–60%, the
bulk of the increase occurring before the beginning of the
third trimester. The red blood cell mass also expands, with a
total increase of 25% at term. This percentage can be maxi-
mized (to about 30%) by iron supplementation. An increase
in red blood cell mass occurs throughout pregnancy, but the
early—and in some patients disproportionate—increase in
plasma volume leads to a dilutional anemia. Normal preg-
nant women who are not iron-supplemented have hemoglo-
bin concentrations of approximately 11 g/dL at 24 weeks of
gestation, with little change until term. Those supplemented
with iron have similar hemoglobin concentrations at 24 weeks
but manifest an increase in hemoglobin to near-normal at
term.
The white blood cell count increases to about 10,000/μL at
term. The platelet count may decrease slightly to a mean value
of 260,000/μL at 35 weeks of gestation. Platelet levels above
120,000/μL generally are regarded as normal in pregnancy.
Biochemical characteristics of the blood also change.
Serum osmolarity decreases by about 10 mOsm/L early in
pregnancy and remains constant thereafter. Sodium, potas-
sium, calcium, magnesium, and zinc all demonstrate minor
decreases in their serum levels. Chloride does not change,
although bicarbonate decreases markedly. Serum creatinine
decreases early, with a mean creatinine of 0.66 mg/dL at
12 weeks, and this decrease is maintained at least until 32 weeks
of gestation. The creatinine clearance in pregnancy is
approximately 50% higher than in the nonpregnant state.
The plasma concentrations of albumin and total protein
decrease in proportion to the plasma volume expansion.
Most of the commonly tested serum enzymes do not change
in pregnancy, but alkaline phosphatase does increase as a
result of the production of a placental form of this enzyme.
Creatine kinase decreases in early pregnancy, although the
serum levels return to normal by term. Serum lipids increase
toward term, with the levels of cholesterol and triglycerides
doubling during pregnancy.
The levels of many coagulation factors are altered.
Fibrinogen increases to levels as high as 600 mg/dL at term,
with levels below 400 mg/dL generally being regarded as
unusual. The presence of fibrin degradation products in trace
amounts is also not unusual at term and depends on the sensi-
tivity of the test being used. Coagulation and bleeding times are
not increased. The risk of thromboembolism increases, with a
relative risk of 1.8 in gestation and 5.5 during the puerperium.
The increased risk of thromboembolism also may be due to the
increased incidence of venous stasis and vessel wall injury.
 Immune System
Pregnant women appear to be at increased risk of certain
infections, probably owing to the same immune alterations
that allow tolerance of the antigenically foreign placenta. For
 Figure 38–1. The components of lung volume in late
pregnancy compared with those in nonpregnant women.
(Reproduced, with permission, from Hytten FE, Leitch I: The
Physiology of Human Pregnancy. Boston: Blackwell, 1964.)
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this reason, reactivation of viral diseases and tuberculosis are
more common during pregnancy. Severe complications of
common disorders such as varicella and pyelonephritis are
also more frequent. Measurable indices of immune function
such as white blood cell counts and immunoglobulin levels
do not explain the maternal immune dysfunction. Various
theories have been offered to explain these observations, but
none has achieved general acceptance.
Granger JP: Maternal and fetal adaptations during pregnancy: Lessons
in regulatory and integrative physiology. Am J Physiol Regul Integr
Comp Physiol 2002;283:R1289–92. [PMID: 12429557]
Yeomans ER, Gilstrap LC 3rd: Physiologic changes in pregnancy
and their impact on critical care. Crit Care Med 2005;33:
S256–8. [PMID: 16215345]
GENERAL CONSIDERATIONS IN THE CARE
OF THE PREGNANT PATIENT IN THE ICU
The care of the pregnant patient is necessarily the care of two
patients. Although care of the mother is the primary concern
in most circumstances, attention also must be paid to fetal
health and well-being.
Position
As discussed earlier, a pregnant woman may experience a
decrease in cardiac output with associated hypotension when
lying in the supine position. For this reason, the pregnant
woman who is beyond the twentieth week of gestation
should avoid lying supine. In the ICU, this means that preg-
nant women who are bedridden and unable to move by
themselves should be positioned with the right hip elevated,
usually with an obstetric wedge, to about 4 in above the plane
of the bed. Alternatively, the patient may be positioned in the
right lateral decubitus position, taking care that she is tilted
adequately to prevent caval compression. This is not neces-
sary in a patient who is in Fowler’s position, that is, with the
head of the bed elevated. Because of the increased risk of
thromboembolism in pregnancy or immediately postpar-
tum, these patients also should receive measures to prevent
deep venous thrombosis. Venous compression stockings may
be of some benefit, but—especially in the recently delivered
patient—heparin in doses adequate to achieve a partial
thromboplastin time (PTT) of 65–85 s or low molecular
weight heparin sufficient to achieve anti–factor Xa levels of
0.05–0.2 units/mL is considered necessary to avoid pelvic or
lower extremity venous thrombosis.
Monitoring
When caring for a critically ill pregnant patient, the question
of how to monitor the fetus arises frequently. Monitoring by
auscultation of fetal heart tones is considered one of the vital
signs in any hospitalized pregnant women. However, contin-
uous fetal heart rate monitoring with an electronic monitor
may be indicated in the viable or near-viable fetus (23 weeks
and beyond), especially if the maternal condition affects pul-
monary or hemodynamic function. Use of the continuous
fetal monitor requires personnel skilled in its interpretation.
Fetal monitoring may be especially helpful during special
procedures or surgery when maternal position, hypotension,
or anesthesia can lead to fetal compromise that could be
reversed with changes in position or fluid resuscitation. Fetal
heart rate monitoring according to a predetermined schedule
(nonstress testing) also may be useful in gauging fetal
response to the mother’s illness and in determining when
fetal compromise may necessitate early delivery. This strategy
(as opposed to continuous fetal heart rate monitoring)
should be reserved for the stable patient whose underlying
condition might result in decreased uteroplacental perfusion
or altered placental function. Additional biophysical testing
might be deemed necessary by the consulting obstetrician,
but that subject is beyond the scope of this chapter.
Teratogenesis and Drugs Used During Pregnancy
Critical care of a pregnant patient necessarily involves the use
of drugs and physical agents that may have an effect on the
developing fetus. The first concern of the physician is properly
with the life and long-term health of the mother. In cases in
which alternative therapies or diagnostic modalities are avail-
able, the physician must consider their possible fetal effects.
Information regarding the potential risk to the fetus of
various agents is available from a number of published
sources and from the manufacturers’ package inserts. In
addition, many areas are served by teratogen “hotline” serv-
ices. The Food and Drug Administration (FDA) requires all
drug manufacturers to rate their drugs for risk in pregnancy
(Table 38–1). Most drugs are not studied in pregnancy dur-
ing the FDA approval period, so most new drugs will be
placed in category C. For this reason, many drugs used rou-
tinely during pregnancy are older ones, with an established
record of safe use.
The overriding principle in choice of a therapeutic agent
is that the anticipated benefit should outweigh any theoretic
risks. Consequently, a potentially teratogenic—but life-
sustaining—pharmacologic intervention for which there is
no good alternative would be acceptable, whereas one with
less proven risk but prescribed as a comfort measure only
might not be.
Imaging Studies
Ionizing radiation is known to be a human teratogen, and the
use of x-ray is appropriately limited in pregnant women.
Persons exposed to high levels of ionizing radiation in utero
may exhibit microcephaly, mental retardation, retarded
growth, and various structural abnormalities. Some reports
also have suggested an increased risk of childhood cancer fol-
lowing prenatal x-ray exposure. Data from atomic bomb sur-
vivors suggest that the most vulnerable period for the fetus is
from 8–15 weeks of gestation. Fetuses in this gestational age
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range appear to have a linear increase in mental retardation
with increasing x-ray exposure, with an incidence of 0.4% per
rad of exposure, although a definite fetal effect may not be
seen below 5 cGy. Fetuses older than 16 weeks were less sensi-
tive to x-rays. In one study, the risk of childhood leukemia was
estimated to be 1.7 times that of controls in patients exposed
to radiation in utero. The risk for childhood cancers also
appeared to be higher in fetuses exposed to x-rays in the sec-
ond as compared with the third trimester. The fetal exposure
for different radiologic studies has been calculated and is pre-
sented in Table 38–2. As will be apparent, many studies, such
as chest films and head and neck studies, entail only slight
exposure of the fetus, although the fetal exposure owing to
abdominopelvic CT studies is appreciable. Nevertheless, the
uterus and its contents should be shielded whenever possible.
Iodinated contrast media are not contraindicated in preg-
nancy and may be used as in nonpregnant patients. These
media may be rated in category D owing to the risk of fetal
goiter when these agents are injected into the amniotic fluid.
Radionuclide scans should be used with caution in preg-
nancy. Iodine is concentrated in the fetal thyroid after 10 weeks
of gestation, and radioactive iodine may cause harm to the fetal
thyroid. Other radionuclides may be associated with an
increased risk of fetal mutagenesis or teratogenesis if they cross
the placenta in large amounts. Agents bound to large protein
aggregates do not cross the placenta and probably represent a
negligible risk to the fetus. In particular, the performance of
pulmonary ventilation-perfusion scanning for pulmonary
emboli has been calculated to result in a fetal dose of only
50 mrem, and this is largely from fetal exposure to the agent in
the maternal bladder during urinary excretion of the agent.
Ultrasonography is used extensively in obstetrics.
Controlled studies are not available regarding its safety, but
numerous observational studies have lead to the conclusion
that diagnostic ultrasound is safe for use in pregnancy.
However, fetal damage has been demonstrated in animal
models using ultrasound power levels sufficient to cause tis-
sue heating. For this reason, the use of therapeutic ultra-
sound in pregnancy is contraindicated. Few studies are
available concerning the safety of MRI in pregnancy. There is
a theoretical concern that the strong magnetic field may
affect fetal cell migration in the first trimester, and the use of
MRI has been discouraged early in pregnancy, although there
are no reports of adverse human fetal effects.
Total Parenteral Nutrition
As a consequence of depletion of maternal glucose by the
fetoplacental unit, pregnant patients are more sensitive than
Category A Controlled studies in women fail to demonstrate a
risk to the fetus in the first trimester (and there is no
evidence of risk in later trimesters), and the possibil-
ity of fetal harm appears remote. 
Category B Either animal-reproduction studies have not demon-
strated a fetal risk but there are no controlled studies
in pregnant women, or animal-reproduction studies
have shown an adverse effect (other than a decrease
in fertility) that was not confirmed in controlled
studies in women in the first trimester (and there is
no evidence of a risk in later trimesters). 
Category C Either studies in animals have revealed adverse
effects on the fetus (teratogenic or embryocidal or
other) and there are no controlled studies in women,
or studies in women and animals are not available.
Drugs should be given only if the potential benefit
justifies the potential risk to the fetus. 
Category D There is positive evidence of human fetal risk, but the
benefits from use in pregnant women may be accept-
able despite the risk (eg, if the drug is needed in a
life-threatening situation or for a serious disease for
which safer drugs cannot be used or are ineffective). 
Category X Studies in animals or human beings have demon-
strated fetal abnormalities, or there is evidence of
fetal risk based on human experience, or both, and
the risk of the drug in pregnant women clearly out-
weighs any possible benefit. The drug is contraindi-
cated in women who are or may become pregnant. 
Federal Register 1980;44:31434–67.
Table 38–1. Risk factors for drug use in pregnancy.
Absorbed Dose
Examination Mrad mGy
Upper GI series 100 1
Cholecystography 100 1
Lumbar spine radiography 400 4
Pelvic radiography 200 2
Hip and femur radiography 300 3
Retrograde pyelography 600 6
Barium enema study 1000 10
Abdominal (KUB) radiography 250 2.5
Hysterosalpingography 150 10
CT scan, head ~0 ~0
CT scan, chest 16 0.16
CT scan, abdomen 3000 30
Data from Parry RA, Glaze SA, Archer BR: The AAPM/RSNA Physics
Tutorial for Residents. RadioGraphics 1999;19:1289–1302.
Table 38–2. Estimated doses to the uterus from diagnostic
procedures.
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nonpregnant ones to starvation. Blood glucose is lower by
15–20 mg/dL in a pregnant woman after a 12-hour fast, and
starvation ketosis is exaggerated. Undernutrition has been
associated with increased infant mortality and decreased
birth weight. These facts suggest that nutrition should be
addressed early in the course of critical care. Total parenteral
nutrition has been used in pregnancy with good fetal out-
comes in patients with intractable nausea and vomiting of
pregnancy as well as in patients with other chronic diseases.
Total parenteral nutrition should be considered in any preg-
nant patient who is expected to be without oral intake for
more than 7 days and in whom enteral (tube) feedings are
contraindicated. In patients in whom shorter durations of
starvation are expected, peripheral nutritional supplementa-
tion is essential. At a minimum, when the patient is denied
oral intake, enough intravenous glucose should be adminis-
tered to avoid ketonemia.
Patient Counseling
The fetal organs are essentially fully formed by the end of the
first trimester. This is important when considering the ter-
atogenic potential of medications given to the mother.
Teratogenic effects are most likely to occur early, when preg-
nancy may not yet be diagnosed. CNS growth and develop-
ment, body growth, and sexual organ development occur in
the second trimester, with CNS development and body
growth continuing during the third trimester. Drugs given
during the last trimester may affect neurologic development
but will not cause significant structural abnormalities other
than impaired fetal growth. A woman in the ICU who is
found to be pregnant should be given complete information
on the timing and dosages of the drugs and diagnostic agents
used in her care. It may be helpful to refer such a patient and
her family to a medical geneticist or prenatal diagnostic cen-
ter for counseling and possible diagnostic procedures. As a
medicolegal issue, it also may be advisable to obtain an
obstetric ultrasound examination as early as possible during
the pregnant patient’s stay in the ICU. Fetal abnormalities
apparent at that time are probably preexisting conditions
and not the result of medications given in the unit.
Furthermore, this will document gestational age and estab-
lish a baseline from which to assess fetal growth.
ACOG Committee on Obstetric Practice: ACOG Committee
Opinion. Number 299, September 2004. Guidelines for diagnos-
tic imaging during pregnancy. Obstet Gynecol 2004;104: 647–51.
[PMID: 15339791]
Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and
Lactation: A Reference Guide to Fetal and Neonatal Risk, 7th ed.
Philadelphia: Lippincott Williams & Wilkins, 2005.
De Santis M et al: Ionizing radiations in pregnancy and teratogen-
esis: A review of literature. Reprod Toxicol 2005;20:323–9. [PMID:
15925481]
Fattibene P et al: Prenatal exposure to ionizing radiation: Sources,
effects and regulatory aspects. Acta Pediatr 1999;88:693–702.
[PMID: 10447122]
McNally RJ, Parker L: Environmental factors and childhood acute
leukemias and lymphomas. Leuk Lymphoma 2006;47:583–98.
[PMID: 16690516]
Shepard TH, Lemore RJ: Catalog of Teratogenic Agents, 11th ed.
Baltimore: Johns Hopkins University Press, 2004.
Soubra SH, Guntupalli KK: Critical illness in pregnancy: An
overview. Crit Care Med 2005;33:S248–55. [PMID: 16215344]
Vasquez DN et al: Clinical characteristics and outcomes of obstet-
ric patients requiring ICU admission. Chest 2007;131:718–24.
[PMID: 17356085]
Cardiopulmonary Resuscitation (CPR)
in the Pregnant Woman
The American Heart Association has recommended that
when cardiac arrest occurs in a pregnant woman, standard
resuscitative measures and procedures can and should be
taken without modification. In particular, they endorse the
use of closed-chest compression, defibrillation, and vaso-
pressors as indicated and emphasize the need to displace the
uterus from the abdominal vessels by a right hip wedge or by
manual pressure on the fundus. Finally, they endorse the per-
formance of a perimortem cesarean section promptly if rou-
tine ACLS protocols are ineffective in restoring circulation
(see below).
Labor and Delivery in the ICU
The presence of a pregnant woman in the ICU necessitates a
plan for delivery of the pregnancy, if necessary. On occasion,
spontaneous labor may occur in a patient too unstable to be
transferred to the delivery room. In this case, labor and deliv-
ery must be undertaken in the ICU. Fetal heart rate monitor-
ing may be useful in advising the pediatrician about the fetal
condition even if cesarean section is not an option. Attention
should be paid to achieving adequate maternal analgesia
because of the significant maternal cardiac demands
imposed by unmedicated labor. In the case of any fetus of
22 weeks or more of gestational age or expected to weigh
more than 500 g, a neonatal resuscitation team should be in
attendance at delivery. The delivery should be conducted by
experienced personnel in an atraumatic manner.
Rarely, it may be necessary to perform perimortem
cesarean section in the ICU if the mother has died and an
attempt is being made to salvage the fetus. For this reason, in
any critically ill hospitalized pregnant patient, a determina-
tion should be made as early as possible about the potential
viability of the fetus. If perimortem cesarean section is a pos-
sibility, necessary instruments should be kept at or near the
bedside. In a large series of such procedures, normal infant
survival was associated with delivery within 5 minutes of
maternal death (from cardiac arrest). Fewer than 15% of
infants survived when delivery was performed more than
15 minutes after maternal demise, although fetal survival
after a much longer delay has been reported. Given this infor-
mation and data suggesting that the effectiveness of CPR in
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the mother may improve with evacuation of the uterus, some
authorities, including the American Heart Association, sug-
gest that cesarean section should be started within 4–5 minutes
of initiation of CPR.
Several reports have described mothers who met elec-
troencephalographic criteria for death who were maintained
for prolonged periods on life support in order to allow
growth and maturation of the fetus. In a number of these
cases, apparently healthy infants have been delivered,
although the outcome of the infant in such cases cannot be
guaranteed.
Atta E, Gardner M. Cardiopulmonary resuscitation in pregnancy.
Obstet Gynecol Clin North Am 2007;34:585–97, xiii. [PMID:
17921016]
Mallampalli A, Guy E: Cardiac arrest in pregnancy and somatic
support after brain death. Crit Care Med 2005;33:S325–31.
[PMID: 16215355]
Soar J et al: European Resuscitation Council. European Resuscitation
Council guidelines for resuscitation 2005, Section 7: Cardiac
arrest in special circumstances. Resuscitation 2005;67:S135–70.
[PMID: 16321711]
MANAGEMENT OF CRITICAL COMPLICATIONS
OF PREGNANCY
 Preeclampsia-Eclampsia
ESSENT IALS  OF  D IAGNOS I S
 Hypertension.
 Proteinuria.
 Seizures (eclampsia).
General Considerations
Preeclampsia is a common disorder with an incidence of
14–20% in women undergoing their first pregnancy and
about 6% in multigravidas. It is one of the leading causes of
maternal death in the United States. Most preeclamptic
patients will be managed in the delivery suite and will not
require critical care. Patients with severe disease, however,
may have significant complications warranting ICU care.
Preeclampsia appears to be associated with defects in pla-
centation; it therefore originates in events early in pregnancy.
Although the mechanisms of preeclampsia are not com-
pletely understood, potential etiologies include abnormal
trophoblast invasion, immunologic intolerance between
mother and fetus, abnormalities of immune function, vita-
min deficiencies, and genetic abnormalities. Preeclamptic
women demonstrate an increased vascular smooth muscle
response to pressor agents, particularly angiotensin II, that
predates the development of overt hypertension. The resulting
vasospasm leads to hypertension and contraction of
intravascular volume. In more severe cases, this is accompa-
nied by endothelial cell injury with activation of the coagu-
lation system and multi-organ-system damage.
Preeclampsia may occur in previously normotensive
patients or in patients with preexisting chronic hypertension,
who are then said to have superimposed preeclampsia.
Indeed, preeclamptic patients with chronic hypertension or
with underlying renal or collagen-vascular disease may have
more severe disease and a more complicated course.
Preeclampsia generally occurs only after the twentieth week
of gestation but rarely may develop earlier in the woman
with multiple fetuses or with hydatidiform mole.
Clinical Features
A. Symptoms and Signs—Preeclampsia is classically
defined by the triad of hypertension, proteinuria, and
edema. However, because of the frequent occurrence of
edema in pregnancy without preeclampsia, edema has been
omitted as a diagnostic criterion for preeclampsia.
Nevertheless, a sudden and dramatic weight gain in late
pregnancy often presages the development of overt
preeclampsia. For this reason, all patients receiving prenatal
care have regular determinations made of their weight,
urine protein content, and blood pressure. According to the
National High Blood Pressure Education Working Group
Report on High Blood Pressure in Pregnancy, the minimum
criteria for the diagnosis of preeclampsia are (1) sustained
blood pressure elevation of 140 mm Hg systolic or 90 mm
Hg diastolic in a previously normotensive woman after 20
weeks of gestation and (2) proteinuria—at least 300 mg of
urinary protein in a 24-hour period or at least 30 mg/dL
(1+) in a random urine sample.
Preeclampsia is classified as mild or severe. Severe
preeclampsia is characterized by at least one of the following
additional criteria: (1) blood pressure of 160 mm Hg or
greater systolic or 110 mm Hg or greater diastolic, (2) pro-
teinuria of 5 g or more in 24 hours, (3) elevated serum crea-
tinine, (4) pulmonary edema, (5) oliguria (<500 mL/24 h),
(6) microangiopathic hemolytic anemia, (7) thrombocy-
topenia, (8) hepatocellular dysfunction (abnormally elevated
AST or ALT), (9) fetal growth restriction, (10) symptoms
suggestive of end-organ involvement (eg, headache, visual
disturbances, epigastric or right upper quadrant pain), or
(11) eclampsia, defined by the presence of seizures in a preg-
nant patient without other known cause.
B. Laboratory Findings—Preeclampsia is diagnosed prima-
rily by clinical criteria. The major role of the laboratory is
identifying and following the course of complications. These
include involvement of the renal, hepatic, or hematologic
systems. In the care of a severely preeclamptic patient, serial
determinations of platelet count, fibrinogen and fibrin
degradation products, hemoglobin, liver function tests, and
serum creatinine are essential.
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Differential Diagnosis
In addition to preeclampsia, the differential diagnosis of
hypertension in late gestation includes chronic hypertension,
gestational hypertension (ie, pregnancy-induced hyperten-
sion without proteinuria), and acute fatty liver of pregnancy.
Acute fatty liver, amniotic fluid embolism, and placental
abruption also may be associated with coagulopathy.
Proteinuria may result from urinary tract infection or from
chronic renal disease. Edema is common in pregnancy and
not necessarily a sign of preeclampsia, but nondependent
edema is more commonly associated with preeclampsia.
Management
A. Delivery—The only definitive treatment for preeclampsia
is delivery of the fetus. In the case of severe preeclampsia, this
should be undertaken without delay, except in rare cases
when the mother is stable and the fetus very immature. Such
a delay in delivery in the patient with severe preeclampsia—
while antihypertensive therapy is given—remains controver-
sial and should be permitted only when the anticipated
benefits to the fetus outweigh the potential risks to both
mother and the fetus.
B. Seizure Prophylaxis—Seizure prophylaxis should be
employed in all severely preeclamptic patients. This is
usually begun as soon as the diagnosis is made and is con-
tinued until the patient is either delivered or the patient is
deemed stable enough to be followed expectantly.
Treatment greatly reduces the likelihood of eclamptic
seizures that might occur during a patient’s initial hospital
evaluation. Once the decision is made to proceed with
delivery of the patient with preeclampsia, seizure prophy-
laxis should be initiated and continued throughout labor
and delivery and until 24 hours postpartum. The routine
use of magnesium sulfate prophylaxis in patients with mild
preeclampsia is controversial.
In the United States, magnesium sulfate is the most com-
monly employed seizure prophylaxis. It is usually adminis-
tered intravenously, although the intramuscular route also
can be employed. The usual regimen includes an intravenous
loading dose of 4–6 g given over 20–30 minutes, followed by
a continuous infusion of 2 g/h. The infusion rate should be
adjusted to achieve serum magnesium levels in the therapeu-
tic range of 4.8–8.4 mg/dL.
C. Control of Hypertension—In general, blood pressures
over 180 mm Hg systolic or 110 mm Hg diastolic should be
treated acutely with antihypertensives. Hydralazine, 5–20 mg
intravenously, according to patient response, is used com-
monly. An acceptable alternative is labetalol 20 mg, also given
by intravenous bolus. If an adequate response is not obtained,
the dose should be doubled and repeated at 10-minute intervals
up to a maximum single bolus dose of 80 mg and a total max-
imum dose of 220 mg. Oral or sublingual nifedipine also has
been suggested for this situation, but concurrent use of
nifedipine and magnesium sulfate may result in profound
hypotension. Nitroglycerin and sodium nitroprusside may
be used if severe hypertension is unresponsive to the preced-
ing agents, but intra-arterial pressure monitoring is recom-
mended. Owing to the potential for fetal cyanide toxicity,
the duration of nitroprusside treatment should be limited.
One should exercise caution in administering any vasodila-
tors to patients with preeclampsia because intravascular vol-
ume contraction is often present, making them susceptible to
dramatic falls in blood pressure. Excessive and rapid decreases
in blood pressure—even to above-normal levels—may be
associated with fetal distress secondary to decreased uteropla-
cental perfusion and therefore should be avoided.
D. Hemodynamic Monitoring—A pulmonary artery
catheter may be indicated in the presence of oliguria unre-
sponsive to initial fluid boluses, pulmonary edema that does
not respond to furosemide diuresis and positioning, or
severe hypertension unresponsive to hydralazine or labetalol.
Untreated preeclamptic patients without pulmonary edema
have been found to have greater systemic vascular resistance,
increased cardiac index, and hyperdynamic left ventricular
function when compared with normal controls. Treatment
may modify these findings. The pulmonary artery catheter is
essential in differentiating these mechanisms because central
venous pressures have been found not to reliably reflect pul-
monary artery pressures in preeclampsia.
E. Pulmonary Edema—Pulmonary edema may be due to
left ventricular dysfunction secondary to high systemic vas-
cular resistance, iatrogenic volume overload in the face of
contracted intravascular space, decreased plasma colloid
oncotic pressure (occurs in normal pregnancy and is exag-
gerated in preeclampsia), or pulmonary capillary membrane
injury. Colloid oncotic pressure may decrease further follow-
ing intravenous fluid replacement with crystalloids and as a
result of rapid intravascular mobilization of edema fluid
after delivery. Nevertheless, pulmonary edema remains an
uncommon complication of preeclampsia, with an incidence
of 2.9% in severe preeclampsia, usually occurring postpar-
tum. Management consists of diuretics and oxygen, with dig-
italis glycosides reserved for the rare patient with evidence of
left ventricular dysfunction.
F. Oliguria—Oliguria—defined as less than 30 mL of urine
output per hour for 2 hours—in severe preeclampsia seldom
progresses to frank renal failure. Oliguria associated with
preeclampsia can be due to (l) intravascular volume deple-
tion (most common), (2) oliguria accompanied by normal
cardiac function and systemic vascular resistance, probably
owing to isolated renal arteriolar spasm and perhaps respon-
sive to low-dose dopamine, l–5 μg/kg per minute, and (3) rel-
ative volume overload with depressed left ventricular
function secondary to high systemic vascular resistance,
managed with fluid restriction and afterload reduction.
Echocardiograpic assessment of cardiac function may assist
in differentiating these scenarios.
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G. HELLP Syndrome—Preeclampsia may be complicated by
the hemolysis, elevated liver enzymes, and low platelets
(HELLP) syndrome. There is controversy over whether the
HELLP syndrome represents a separate clinical entity or is part
of the spectrum of preeclampsia. Patients with the HELLP syn-
drome are older and more frequently multiparous than other
preeclamptic women. The hemolysis observed in these patients
is consistent with a microangiopathic hemolytic process and
seldom requires specific treatment (other than fetal delivery).
Severe thrombocytopenia (platelet count <30,000/μL) occurs
in fewer than 10% of patients. Treatment with platelet transfu-
sion is usually necessary only for cesarean section or other
major surgery. The elevated liver enzymes result from hepato-
cellular injury secondary to vasospasm and may be associated
with hepatic infarction, intrahepatic hemorrhage, and subcap-
sular hematomas. Rarely, a subcapsular hematoma may rup-
ture, precipitating hemodynamic instability. In the absence of
liver rupture, treatment of HELLP syndrome is usually sup-
portive, although the laboratory derangements associated with
the syndrome may be transiently reversed with steroid treat-
ment. Dexamethasone, 10 mg intravenously every 12 hours,
has been shown to result in clinical improvement and reversal
of laboratory abnormalities in HELLP syndrome. Treatment
may allow some delay in delivery in the extremely preterm
pregnancy. This regimen has the added advantage of promot-
ing fetal lung maturation. Abnormalities recur promptly if
steroids are discontinued. In addition, a meta-analysis of
steroid treatment confirmed an increase in platelet count but
failed to demonstrate any improvement in maternal or fetal
outcome. The maternal mortality rate associated with HELLP
syndrome has been estimated to be 1–2%.
H. Eclampsia—Eclampsia is defined as the occurrence of
grand mal seizures in a woman with preeclampsia in whom
the seizures cannot be attributed to some other cause.
Eclampsia carries a maternal mortality rate of 1–2% and a
fetal mortality rate of approximately 10%. Onset of seizures
is often preceded by a severe, unrelenting headache.
Management of eclampsia consists of control of seizures,
pharmacologic control of severe hypertension, and delivery.
Seizures can be controlled with a 4–6-g intravenous bolus of
magnesium sulfate (8 g in 50 mL of 0.9% NaCl) given at a
rate no more rapid than 1 g/min, followed by a continuous
infusion of 2 g/h, with monitoring as described earlier. A 2-g
bolus is employed if the patient is already receiving magne-
sium sulfate prophylaxis or if there is a recurrent seizure after
the initial bolus. Magnesium sulfate is the treatment of
choice because studies have demonstrated its superiority to
either phenytoin or diazepam and because it has less sedating
effect on the fetus. In addition, levels of magnesium are easy
to monitor, and magnesium sulfate has a long record of safe
use. Once seizures are controlled and the patient is consid-
ered stable, efforts should be directed toward accomplishing
delivery. In many cases, labor can be induced safely and vagi-
nal delivery achieved. Seizure prophylaxis with magnesium
sulfate should be continued until 24 hours postpartum.
I. Other Complications—Disseminated intravascular coag-
ulation, cerebral edema, cerebral bleeding, transient cortical
blindness, retinal detachments, placental abruption, fetal
growth restriction, and fetal distress rarely may complicate
preeclampsia and eclampsia.
ACOG Practice Bulletin Number 33: Diagnosis and management
of preeclampsia and eclampsia. Obstet Gynecol 2002;99:
159–67. [PMID: 16175681]
Chang J et al: Pregnancy-related mortality surveillance—United
States, 1991–1999. MMWR Surveill Summ 2003;52:1–8.
[PMID: 12825542]
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 Acute Fatty Liver of Pregnancy
ESSENT IALS  OF  D IAGNOS I S
 Hepatic dysfunction.
 Microvesicular fatty infiltration of hepatocytes.
General Considerations
Acute fatty liver of pregnancy is a rare but potentially cata-
strophic complication of pregnancy with an incidence of
between 1:7,000 and 1:16,000 deliveries. It presents as hepatic
dysfunction associated with microvesicular fatty infiltration of
hepatocytes occurring during the last trimester of pregnancy
or immediately postpartum. Hypertension is commonly pres-
ent, and some consider the disorder to be a variant of
preeclampsia. Indeed, there is an increased incidence of both
conditions in first pregnancies and with twin gestations.
Although in the past fetal and maternal mortality rates exceed-
ing 70% were reported, data suggest that fetal and maternal
mortality is closer to 20%. This discrepancy is most likely the
result of earlier diagnosis and improved management as well
as recognition that milder forms of this disorder exist.
The etiology of acute fatty liver of pregnancy remains
unknown. In many, but not all, cases, mother or fetus has
been found to have a genetic defect of fatty acid beta oxida-
tion. This association is strong enough that infants of
affected mothers should be screened.
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Clinical Features
A. Symptoms and Signs—Typically, patients present with a
history of nausea, vomiting, anorexia, and malaise for 1–2
weeks. Epigastric or right upper quadrant pain also may be
present, as may jaundice of varying degrees. Hypertension
with or without proteinuria and edema is frequently present,
and transient diabetes insipidus is a common association. In
severe acute fatty liver of pregnancy, ascites and progressive
hepatic encephalopathy develop along with hypoglycemia,
consumptive coagulopathy, metabolic acidosis, and renal
failure. Pancreatitis and GI bleeding also may occur.
Improvement usually follows delivery of the fetus. If delivery
has not been performed, fetal death often results, presumably
from uteroplacental insufficiency or hypoglycemia.
B. Laboratory Findings—The white blood cell count is usu-
ally elevated, often to greater than 20,000/μL. There may be
normochromic, normocytic anemia with fragmented red
blood cells consistent with disseminated intravascular coag-
ulation (DIC) or microangiopathic hemolysis. Prothrombin
time and partial thromboplastin time are usually prolonged,
and there are decreased fibrinogen and platelets and elevated
fibrin degradation products, all indicative of consumptive
coagulopathy. Decreased coagulation factors also can result
from decreased hepatic synthesis.
AST and ALT are elevated, but seldom more than 2000
IU/L. Alkaline phosphatase and bilirubin are also elevated,
and serum albumin is decreased. Hypoglycemia is often pres-
ent and may be severe. Uric acid is usually high, and blood
urea nitrogen (BUN) and creatinine are elevated if renal
impairment is present. Hypernatremia may be present if
there is diabetes insipidus, and elevated serum lipase and
amylase indicate the presence of pancreatitis.
Diagnosis of acute fatty liver of pregnancy can be made
with reasonable certainty from the clinical presentation and
the laboratory findings, but confirmation requires the
demonstration of microvesicular fat within the hepatocytes
on liver biopsy. This is done with either staining a frozen tis-
sue section with oil red O stain or by electron microscopy.
Percutaneous liver biopsy should not be attempted if there
are significant coagulation abnormalities. Increased
echogenicity of the liver on ultrasound examination and
decreased attenuation over the liver on CT scan or MRI have
been described in patients with this disorder, but these find-
ings are not always present.
Treatment
Management of acute fatty liver of pregnancy can be divided
into four categories: monitoring, stabilization, delivery, and
support. Monitoring should apply to both the patient and
her fetus. Because the fetal condition can deteriorate rapidly,
continuous monitoring of the fetal heart rate should be per-
formed until delivery can be accomplished. Fetal biophysical
profiles sometimes can aid in the diagnosis of fetal compro-
mise. In severe acute fatty liver of pregnancy, the patient
should be managed in the ICU and may require invasive
hemodynamic monitoring. Laboratory parameters should be
followed at frequent intervals.
Stabilization involves maintenance of a patent airway and
adequate ventilation if mental obtundation exists, normaliza-
tion of intravascular volume, correction of electrolyte distur-
bances, treatment of hypoglycemia with intravenous glucose,
and correction of hematologic and coagulation abnormalities
with transfusions of red blood cells, platelets, and fresh-
frozen plasma. Intravenous magnesium sulfate and, less fre-
quently, hydralazine may be required if there is concomitant
preeclampsia. Maintenance magnesium sulfate dosage should
be decreased if there is significant renal impairment.
Once the patient has been stabilized, delivery should be
accomplished as soon as possible, for this is what will ulti-
mately lead to improvement. Delivery is often by cesarean
section because this is often the most expeditious method
and permits correction of coagulation defects just prior to
surgery. However, if the cervix is favorable for labor induc-
tion and there is no evidence of fetal compromise, vaginal
delivery can be attempted. This avoids the risks of abdominal
surgery in the face of coagulopathy and ascites and decreases
the need for anesthesia. The choice of anesthetic for cesarean
section is controversial. Conduction anesthesia can be used if
coagulation abnormalities are corrected. General anesthesia
is used otherwise, with care taken to avoid agents that are
hepatotoxic or that require metabolism in the liver.
Following delivery, the patient will require supportive
management until she recovers from her multiple-organ-
system failure. Protein intake should be limited, and nutri-
tional maintenance should be primarily in the form of
glucose to decrease the load of nitrogenous waste until
hepatic function improves. This can be administered intra-
venously or by nasogastric tube, and blood glucose should be
monitored every 1–2 hours to prevent hypoglycemia. To
decrease production of ammonia by intestinal bacteria, oral
lactulose, 20–30 g (30–45 mL) every 1–2 hours to induce diar-
rhea and then enough to produce two to four soft stools per
day, can be administered. Alternatively, oral neomycin, 0.5–1
g every 6 hours, can be used. Although poorly absorbed, small
amounts of neomycin may reach the bloodstream, and care
should be taken to avoid levels that might cause nephrotoxic-
ity. Magnesium citrate administered orally will decrease intes-
tinal transit time, further decreasing ammonia absorption.
Optimal fluid and electrolyte management is critical, par-
ticularly if there is significant renal impairment, diabetes
insipidus, or ascites. Diabetes insipidus can be managed with
desmopressin acetate until this phase of the disease resolves.
Vitamin K should be administered to aid restoration of coag-
ulation, and further transfusions of fresh-frozen plasma or
platelets should be necessary only in the face of clinical
bleeding or if a surgical procedure is anticipated. Care should
be taken to avoid nosocomial infection in this already com-
promised patient. Some patients have been treated success-
fully with liver transplantation after delivery for acute fatty
liver of pregnancy.
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 Amniotic Fluid Embolism 
ESSENT IALS  OF  D IAGNOS I S
 Hypotension, hypoxia, coagulopathy.
 Frequently seizures, pulmonary edema, cardiac arrest.
General Considerations
Amniotic fluid embolism is a rare but catastrophic complica-
tion of pregnancy. Its incidence is unknown but is thought to
be between 1:80,000 and 1:8000 pregnancies. It is classically
thought to be triggered by the release of amniotic fluid, con-
taining fetal squamous cells, into the maternal pulmonary
circulation, causing severe pulmonary vasoconstriction with
subsequent hemodynamic and cardiorespiratory collapse
and coagulopathy. Cardiac arrest is common, with 26–80%
of cases ending in maternal demise. There is significant con-
troversy about the pathophysiology of the condition, and
treatment therefore is empirical and supportive.
Amniotic fluid embolism has been reported as a compli-
cation of first- and second-trimester pregnancy termination
and during otherwise normal pregnancy and the puer-
perium. The time of greatest risk is during labor. Placental
abruption and fetal death are common antecedents to amni-
otic fluid embolism. Although links with hypertonic uterine
contractions, augmented labor, and meconium-stained
amniotic fluid also have been reported, a national registry of
amniotic fluid embolism did not confirm these associations.
Clinical Features
A. Symptoms and Signs—The patient with amniotic fluid
embolism presents with dyspnea and hypotension, which may
rapidly deteriorate to cardiac arrest. Half of all patients will die
within an hour of developing symptoms. An alternative pres-
entation is as a severe coagulopathy. Up to one-third of patients
have seizures, and nearly 75% exhibit pulmonary edema.
Although animal studies demonstrate a rise in pulmonary
artery pressure at the time of embolism, with resolution
within 30 minutes, no patient has had an amniotic fluid
embolism with a pulmonary artery catheter in place. Reports
of patients who have had a pulmonary artery catheter placed
hours to days after the acute event show no clear pattern of
pulmonary artery pressures. Patients surviving the initial
phase of the disorder may exhibit left-sided heart failure with
elevated pulmonary capillary wedge pressures and decreased
systemic vascular resistance. Acute respiratory distress syn-
drome is common, and 40–50% may have DIC with hemor-
rhage. The bleeding picture may be further complicated by
uterine atony, which appears also to be a result of the amni-
otic fluid embolism.
B. Laboratory Findings—The classic laboratory finding of
amniotic fluid embolism has been fetal squamous cells in the
maternal pulmonary circulation at autopsy. Some authors
have reported finding such cells in blood from a pulmonary
artery catheter in patients suspected of having the diagnosis,
but these appear to come from the maternal skin as an artifact
from insertion of the catheter. The presence of squamous cells
in the pulmonary circulation is of uncertain significance.
Treatment
Amniotic fluid embolism is a rare and unpredictable disor-
der. Few practitioners have seen more than a handful of
cases, and published data are subject to arguable interpreta-
tion. Treatment is supportive. The most common manifesta-
tion of the disorder in the ICU is acute respiratory distress
syndrome (ARDS), which should be managed in the same
way as for other patients. The severe uterine atony associated
with amniotic fluid embolism may necessitate hysterectomy
to control uterine bleeding.
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 Pyelonephritis in Pregnancy
ESSENT IALS  OF  D IAGNOS I S
 Fever, flank pain. 
 Dysuria, pyuria.
General Considerations
Pyelonephritis occurs in 1–2% of pregnancies. In pregnancy,
progesterone mediates ureteral relaxation, predisposing to
urinary stasis. In addition, compression of the ureters by the
gravid uterus and engorged pelvic vessels is implicated. In
this context, bacteria from lower urinary tract infections can
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ascend more easily to the kidney. Obstetricians aggressively
treat even asymptomatic lower tract infections because,
untreated, 25% of such patients will progress to pyelonephri-
tis. The most frequent etiologic organism in pregnant
women is Escherichia coli. Pregnant women with
pyelonephritis usually are treated as inpatients because of the
greater incidence of severe complications of this disease in
pregnancy. In one series, 17% of pregnant women with
pyelonephritis developed septic shock, and 7% of these
patients developed respiratory insufficiency, which can occur
24–48 hours after starting antibiotic therapy and is presum-
ably due to release of bacterial endotoxin.
Clinical Features
A. Symptoms and Signs—The typical patient presents with
flank pain and fever of recent origin, often with rigors or
chills. There may be a history of lower urinary tract infec-
tion, and many patients complain of concurrent lower tract
symptoms such as dysuria and frequency. Some patients also
have nausea and vomiting and anorexia. On physical exami-
nation, flank tenderness is usually present, more frequently
on the right. There is usually fever, occasionally higher than
40°C. Tachycardia of both mother and fetus may be present
owing to fever and volume depletion. Uterine contractions
also may be present. The presence of hypotension, tachyp-
nea, extremely high fever, or marked tachycardia is ominous.
B. Laboratory Findings—The urine nearly always contains
white blood cells and bacteria, and red blood cells and casts are
also seen frequently. The urine should be sent for culture to
confirm the diagnosis and to check for antibiotic resistance.
Differential Diagnosis
In any febrile pregnant patient it is critical to exclude the
diagnosis of intraamniotic infection. If any doubt exists, con-
sideration should be given to performing amniocentesis to
exclude this possibility. Amniocentesis usually is performed
after the administration of antibiotics in order to avoid
injecting bacteria into a sterile uterus. Amniotic fluid should
be sent for cell count, glucose, Gram stain, and cultures. A
leukocyte count of more than 30/μL (especially polymor-
phonuclear cells [PMNs]) or a glucose concentration of less
than 18 mg/dL should be considered suspicious for infection.
Similarly, a Gram stain showing increased PMNs—even in
the absence of organisms—suggests bacterial infection. Any
organisms seen on Gram stain should be considered signifi-
cant and probably are an indication for delivery.
The pregnant patient also may have a renal stone, and one
should be sought, especially in patients in whom the febrile
course does not respond to antibiotics. This diagnosis can be
made by ultrasound in most cases, although an intravenous
urogram (single film to minimize radiation exposure) is
sometimes still necessary.
Also included in the differential are appendicitis, chole-
cystitis, and viral gastroenteritis. Appendicitis in the pregnant
patient often presents with tenderness higher in the
abdomen than at McBurney’s point, and in many cases there
are less remarkable peritoneal signs.
Treatment
The mainstay of treatment is intravenous antibiotics, with an
antimicrobial agent chosen empirically to cover the majority
of community-acquired urinary pathogens. Since nausea and
vomiting and anorexia frequently accompany pyelonephritis,
volume depletion and dehydration are common and should
be corrected promptly with intravenous crystalloid. The fever
and dehydration of pyelonephritis frequently lead to prema-
ture uterine contractions. In addition, high maternal fevers
have been shown to be associated with fetal neurologic harm.
For this reason, fever should be brought down below 38.3°C
with acetaminophen or a cooling blanket. Because of the high
risk of pulmonary damage in these patients, fluid overload
should be avoided, and tocolytic drugs should be reserved for
patients who demonstrate clear cervical changes.
Even with adequate treatment, the patient with
pyelonephritis may demonstrate a hectic fever course,
although uncomplicated patients become afebrile after 48 hours.
Effective treatment of pyelonephritis often results in the lib-
eration of bacterial endotoxins that may be associated with
hypotension, hypothermia, pulmonary infiltrates, and rarely,
ARDS. Patients who develop pulmonary edema or respira-
tory distress syndrome typically do so 24–48 hours after hos-
pital admission. Transient impairment of renal function is
also common. One group found that essentially all patients
with pyelonephritis demonstrated evidence of hemolysis,
sometimes leading to anemia and associated with bacterial
endotoxins. Finally, the number of uterine contractions
increases after the initiation of antibiotic therapy in some
patients; this effect also has been attributed to the release of
bacterial endotoxins. Treatment for endotoxin-mediated
complications is symptomatic and supportive while antibi-
otics are continued. Pyelonephritis-induced ARDS has been
treated with the fetus in utero with subsequent good fetal
outcome.
The possibility of endotoxin-mediated complications
mandates close observation of pregnant patients with
pyelonephritis even after antibiotics have been begun. This
routinely should include continuous fetal heart rate moni-
toring in all pregnancies beyond 22 weeks of gestation. Even
prior to this gestational age, maternal hypotension and
hypoxemia should be detected and corrected before fetal
injury results.
Pregnant patients with pyelonephritis typically are treated
for 10–14 days with antibiotics. These antibiotics can be
administered orally on an outpatient basis after the patient
becomes afebrile. After an episode of pyelonephritis, the preg-
nant patient is at increased risk for a recurrence. Often these
patients are given antibiotic prophylaxis for the duration of
the pregnancy and for 6 weeks postpartum. Serial urine cul-
tures are also an acceptable management scheme.
CRITICAL CARE ISSUES IN PREGNANCY 813
Hill JB et al: Acute pyelonephritis in pregnancy. Obstet Gynecol
2005;105:18–23. [PMID: 15625136]
Sheffield JS, Cunningham FG: Urinary tract infection in women.
Obstet Gynecol 2005;106:1085–92. [PMID: 16260529]
 Septic Abortion
ESSENT IALS  OF  D IAGNOS I S
 Fever.
 Uterine or pelvic tenderness.
 Recent history of uterine instrumentation with pregnancy.
General Considerations
Septic abortion is defined as sepsis in association with a
recent pregnancy termination (spontaneous or induced).
This complication was much more common when abortion
was illegal. Abortion-induced sepsis can progress rapidly to
septic shock with an incidence of 2–10%. Data from the
1960s suggests that 300 of 100,000 illegal abortion proce-
dures resulted in death of the mother. The current maternal
mortality related to legal abortion in the United States is 0.7
per 100,000 procedures, with infection and hemorrhage each
accounting for about one-quarter of those deaths. The likeli-
hood of complications increases in patients who have later
abortions and in those having dilatation and evacuation pro-
cedures. Clostridial infection was a feared complication of
illegal abortions and remains a factor in septic abortions
today. Several recent cases of fatal maternal sepsis following
medically induced abortion using mifepristone were due to
Clostridium sordellii.
Clinical Features
A. Symptoms and Signs—Patients will present with pelvic
pain and a serosanguineous to purulent discharge. Some
patients will complain more of vaginal bleeding, whereas
others will emphasize crampy pain. All describe a history of
recent (within a week) pregnancy termination, spontaneous
or induced, or other intrauterine instrumentation in preg-
nancy. Hematuria and shock may develop rapidly.
B. Laboratory Findings—Blood, urine, and cervical speci-
mens should be obtained for culture. Gram stain of poten-
tially infected material is useful for initial therapy. The
diagnosis of clostridial infection (C. perfringens) is sug-
gested by the presence of large gram-positive rods on Gram
stain of the cervical secretions or tissue obtained by curet-
ting. The white blood count is usually elevated but may be
low in patients with severe disease. Studies of renal and
coagulation function and blood gas analyses may be helpful
to predict the more severe complications of the infection.
Abdominal x-rays may be helpful in the diagnosis of uterine
or bowel perforation (which can be a complication of the
original procedure) or in the diagnosis of clostridial infec-
tion. The presence of gas in the myometrium is consistent
with clostridial infection and is a grave prognostic sign.
Finally, ultrasound may be helpful in assessing the presence
of retained products of conception and in detecting possible
pelvic abscesses.
Treatment
Sepsis after spontaneous or induced abortion is treated with
high-dose antibiotics followed promptly by uterine evacua-
tion. In clostridial infections, which are more than superfi-
cial, prompt hysterectomy may be lifesaving. Pelvic surgery
also may be required to drain hematomas or abscesses. These
also may be approached by guided needle aspiration. Other
aspects of septic shock, including hypotension, anemia, and
ARDS, are treated supportively.
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 Pulmonary Edema
ESSENT IALS  OF  D IAGNOS I S
 Dyspnea, hypoxemia, cough.
 Chest x-ray showing pulmonary edema with usually
bilateral diffuse interstitial and alveolar infiltrates and
perihilar congestion.
General Considerations
Women without known predisposing conditions may
develop pulmonary edema during the course of pregnancy,
especially at the time of delivery. Common obstetric condi-
tions responsible for this complication are (1) hypertensive
disorders of pregnancy, (2) undiagnosed underlying heart
disease, especially mitral stenosis, (3) use of tocolytic
drugs, especially β-adrenergic agonists, (4) iatrogenic fluid
overload, (5) systemic infection, especially pyelonephritis
or chorioamnionitis, and more rarely, (6) peripartum
cardiomyopathy.
Hypertensive disorders of pregnancy were discussed earlier.
These patients are particularly disposed to pulmonary edema
because of increased systemic vascular resistance and
decreased plasma oncotic pressure. Pulmonary edema also
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may supervene in these patients if left ventricular function is
compromised or in cases of pulmonary capillary or epithelial
injury. In other patients, the rapid mobilization of edema fluid
that follows delivery may result in transient pulmonary edema.
Patients with flow-restricting cardiac lesions (eg, mitral
stenosis) may be intolerant of the increased vascular volume
of pregnancy and especially of the autotransfusion that
accompanies delivery. In some women, the first symptom of
cardiac disease is pulmonary edema after delivery.
Pulmonary edema associated with the use of β-adrenergic
agonists appears to be unique to pregnancy. There is no asso-
ciation of pulmonary edema with these drugs in nonpregnant
patients despite considerable clinical experience. The inci-
dence of pulmonary edema as a complication of tocolytic
therapy with these drugs has been estimated to be between
0.15% and 4% in different studies. This risk may be increased
to more than 20% in the face of intraamniotic infection.
Intravenous β-adrenergic agonists are currently rarely used in
pregnancy owing to the number and severity of complica-
tions experienced with these agents. Pulmonary edema also
can complicate subcutaneous use of β-adrenergic agonists,
but the risk appears to be much less. Pulmonary edema also
has been described with other tocolytic agents, with an inci-
dence of 1:300 in one study of magnesium sulfate.
Patients in labor typically receive large volumes of intra-
venous crystalloid fluids. It is common practice to give labor-
ing women a 1000-mL bolus before administering epidural
anesthesia, and most women receive a maintenance rate of
crystalloid infusion at all other times. Most laboring patients
tolerate this regimen well. In some patients with pyelonephri-
tis or in those who are undergoing tocolysis, however, careful
fluid management can make the difference in developing
pulmonary edema.
Peripartum cardiomyopathy is a rare complication of preg-
nancy, occurring in about 1:2200 to 1:3200 pregnancies in the
United States, with one study showing an increase in recent
years. It is characterized by a dilated cardiomyopathy and fre-
quently is associated with systemic and pulmonary emboli.
About half of patients with peripartum cardiomyopathy have
complete resolution after delivery, with return of normal heart
size and cardiac function. The remainder have continued car-
diac dilatation. These patients tolerate future pregnancies
poorly, and some have required cardiac transplantation. The
cause of this condition is unknown, but at least some of the
affected patients have evidence of viral myocarditis.
The mechanism for the increased susceptibility to pul-
monary edema in pregnancy is not clear. Fluid overload has
been suggested as a cause because of the known increase in
extracellular fluid volume during pregnancy, decreased
excretion of sodium and water in pregnant patients when
supine, and concomitant administration of large amounts
of intravenous fluids in many cases. However, there is no
convincing evidence of increased pulmonary artery wedge
pressure to identify either fluid overload or left ventricular
failure as the cause of pulmonary edema in many cases.
The finding of a low pulmonary artery wedge pressure in
the face of pulmonary edema normally would be indicative
of increased capillary permeability pulmonary edema, but
evidence against this mechanism is the usually rapid resolu-
tion of edema with treatment in the case of tocolytic use or
in many cases of preeclampsia. Hypoalbuminemia and
decreased plasma oncotic pressure of pregnancy also may
play a role in the etiology of pulmonary edema.
Clinical Features
A. Symptoms and Signs—Patients present with dyspnea,
cough, chest discomfort, and frothy sputum. Findings
include bilateral rales, but most patients lack other signs of
heart failure, such as a third heart sound. Review of the hos-
pital records frequently documents administration of large
amounts of intravenous fluids, sometimes for treatment of
tachycardia or mild hypotension. Patients may have fever or
other symptoms of infection.
B. Laboratory Findings—The chest x-ray shows bilateral
interstitial or alveolar infiltrates consistent with pulmonary
edema. Occasionally, findings are unilateral. The cardiac size
may not be greatly enlarged, but it has been pointed out that
there is an apparent increase in heart size during normal
pregnancy. Pleural effusions are rare. Arterial blood gases
show hypoxemia with respiratory alkalosis in most patients.
Fetal heart monitoring may reveal late decelerations and loss
of variability of the fetal heart rate consistent with fetal
hypoxia and acidemia.
Ventilation-perfusion lung scans may be useful in exclud-
ing pulmonary thromboembolism in selected patients.
Echocardiography should be considered to exclude car-
diomyopathy or valvular heart disease.
Differential Diagnosis
Acute onset of dyspnea during late pregnancy may be due to
pulmonary embolism, amniotic fluid embolism, or asthma.
Patients with known underlying heart or lung disease also
should be suspected of having an exacerbation of these prob-
lems if symptoms occur.
Prevention
Patients who have severe underlying heart diseases should not
receive β-adrenergic agonists as tocolytic therapy because of
the risk of inducing pulmonary edema. Magnesium sulfate, if
necessary, may be considered. There is no place for tocolytic
therapy in preeclampsia. Any patient at increased risk of pul-
monary edema requires careful attention to fluid status. The
presence of an intraamniotic infection mandates delivery in
the great majority of cases, and patients with other infections
must be monitored closely while undergoing therapy.
Treatment
Discontinuation of tocolytic agents and administration of
intravenous furosemide (20–40 mg as needed) and oxygen are
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generally associated with rapid reversal of symptoms and
resolution of pulmonary edema in the absence of structural
heart disease or sepsis. Patients with associated infection
should be treated with appropriate antibiotics. Continuous
fetal heart rate monitoring is essential until normal maternal
pulmonary function is restored and hypoxemia corrected.
In patients with slow resolution of pulmonary edema,
structural abnormalities should be considered. A pulmonary
artery catheter may be helpful in identifying the cause of pul-
monary edema and guiding therapy. A normal echocardio-
gram often predicts rapid resolution, but in patients with
abnormal findings, long-term treatment is usually needed.
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 Status Asthmaticus in Pregnancy
Asthma is the most common respiratory disease occurring in
conjunction with pregnancy. In general, the influence of
pregnancy on lung volumes, tidal volume, minute ventila-
tion, and arterial blood gases has little effect on asthma.
About 30–40% of asthmatics who become pregnant have
worsening of their asthma; 35–40% have no change in the
frequency and duration of symptoms; and 20–30% show an
improvement in symptoms. In most patients, the course of
asthma during pregnancy is similar in subsequent pregnan-
cies. This constancy of asthmatic outcome may be altered
with newer methods of asthma control.
Asthma can have adverse effects on pregnancy, especially
when maternal hypoxemia affects oxygenation of the fetus.
Premature labor and low birth weight are well-known com-
plications of maternal asthma, and patients with hypoxemia
owing to asthma are also at increased risk of fetal death. Thus
the central theme in managing the pregnant asthmatic is pre-
vention of maternal asthma exacerbation and hypoxemia.
There is no known association of pregnancy with status
asthmaticus (ie, asthma unresponsive to treatment and usu-
ally requiring hospitalization) or with severe asthma (ie,
daily wheezing and need for medication). On the other hand,
pregnant women with asthma may have worsening of
asthma or may be reluctant to use prescribed asthma medica-
tions, thus increasing the risk of these complications. Patients
with a history of asthma requiring hospitalization, mechani-
cal ventilation, and prolonged use of systemic corticosteroids
or of asthma complicated by pneumothorax should be mon-
itored carefully. These patients should be instructed to report
any asthmatic exacerbations, upper respiratory infections,
increased cough, or other respiratory symptoms. Anemia,
because it can adversely affect maternal oxygen transport,
should be assessed and treated.
Clinical Features
A. Symptoms and Signs—Pregnant asthmatics present no
differently than other patients with asthma. Patients with sta-
tus asthmaticus complain of dyspnea, wheezing, cough, and
failure of response to inhaled bronchodilator drugs. They
may note inability to sleep because of dyspnea or cough, and
they may report a frank upper airway infection. The time
from onset of the attack should be noted because a pro-
longed duration may be predictive of poor response to treat-
ment. Physical findings include wheezing, use of accessory
muscles of respiration, a prolonged expiratory phase, tachyp-
nea, tachycardia, and cyanosis. Patients presenting with acute
severe asthma usually have a history of asthma; rarely,
asthma will present initially during pregnancy.
B. Laboratory Findings—Arterial blood gases should be
interpreted in the light of changes seen in pregnancy. In nor-
mal pregnancy, serum bicarbonate is decreased, and PaCO2 is
approximately 30 mm Hg. Development of hypercapnia
therefore may be subtle, and only a slight elevation of PaCO2
above 40 mm Hg may be indicative of impending respira-
tory failure in the pregnant woman. Severe hypoxemia in
status asthmaticus is due to ventilation-perfusion mis-
matching resulting from bronchospasm and plugging of air-
ways with mucus. As in nonpregnant asthmatics, spirometry
is useful for assessing severity of asthma and following the
response to therapy, especially because the peak expiratory
flow rate does not change in pregnancy. Strong considera-
tion should be given to obtaining a chest x-ray in those with
unexplained fever, persistent bronchospasm, heavy sputum
production, asymmetry on chest examination, severe
hypoxemia, or suspicion of heart disease, pleural effusion, or
pneumothorax.
Differential Diagnosis
Dyspnea during pregnancy is common, with most patients
complaining of some subjective shortness of breath during
the last trimester. Patients with acute onset of shortness of
breath may have congestive heart failure, pulmonary edema,
pulmonary thromboembolism, amniotic fluid embolism,
pneumothorax, or sepsis. Valvular heart disease should be
considered—especially previously undiagnosed mitral
stenosis, mitral valve prolapse, aortic regurgitation, and aor-
tic stenosis. A rare but important problem that should be
considered in young women is primary pulmonary hyper-
tension; this disorder can present with new onset of dyspnea
and other symptoms in response to the increased cardiac
output that occurs with pregnancy.
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Treatment
Treatment of status asthmaticus in the pregnant asthmatic
should be aggressive and rapid. Fetal oxygenation is highly
dependent on adequate maternal arterial blood oxygen con-
tent, and delay in treatment is hazardous to the fetus. As with
all conditions adversely affecting maternal respiratory func-
tion, fetal heart rate should be monitored continuously in
potentially viable fetuses. Bronchodilator and anti-
inflammatory therapy are directed at reversing airway obstruc-
tion; oxygen is given to treat hypoxemia. Pharmacologic
therapy of asthma in pregnancy is based on administering
drugs with a long history of use with good outcome rather than
drugs that have been tested specifically during pregnancy.
A. Bronchodilators—β-Adrenergic agonists have been used
extensively in pregnancy, but there are no controlled experi-
mental studies in pregnant women for any of these agents.
Terbutaline, albuterol, and metaproterenol have been adminis-
tered to pregnant asthmatics with good results. Inhaled terbu-
taline is an FDA category B drug, whereas metaproterenol and
albuterol are category C drugs. Several clinical studies following
pregnant asthmatics have not found any differences in compli-
cations of pregnancy or fetal outcome among asthmatics
receiving bronchodilators and nonasthmatics who did not
receive these drugs. In general, the newer more selective β2-
adrenergic agonist drugs are used more commonly than other
agents. Administration of β-agonists by metered-dose inhalers,
as in nonpregnant asthmatics, is  preferred to nebulizers. The
dose and frequency of inhaled bronchodilators should be
titrated to the clinical response (see Chapter 24).
B. Corticosteroids—These drugs play a major role in reversing
airway obstruction. Systemic corticosteroids—for example,
intravenous methylprednisolone and oral prednisone—are
well tolerated in pregnant women and are essential in the man-
agement of status asthmaticus. The optimal dose of corticos-
teroids in status asthmaticus is not known in the nonpregnant
patient, but 40–60 mg methylprednisolone every 6 hours is
usually given, and the dose in pregnancy should be similar. Use
of corticosteroids should be aimed at achieving control of
asthma, followed by rapid tapering and discontinuation over
approximately 2 weeks, if possible. In some patients, continued
administration of oral prednisone, 15–30 mg/day, is necessary
for prevention of asthma attacks. Inhaled corticosteroids also
may be used in the treatment of chronic asthma in the preg-
nant patient.
C. Cromolyn Sodium—Cromolyn sodium in inhaled or
nasal spray form has not been associated with any fetal effect
in observational studies. In chronic asthma, inhaled cro-
molyn may be a valuable agent, but cromolyn has no role in
status asthmaticus.
D. Oxygen and Other Therapy—Supplemental oxygen
should be provided to maintain PaO2 at 85–100 mm Hg at all
times to ensure fetal oxygenation.
Antibiotics generally are not warranted in status asthmati-
cus because infection, when present as a triggering or exacer-
bating factor, is usually of viral origin. If there is evidence of
bacterial infection, broad-spectrum antibiotics can be given.
Ampicillin, cephalosporins, and erythromycin (but not eryth-
romycin estolate) generally are considered safe for use during
pregnancy. Sulfonamides should not be given—especially
during the third trimester—owing to a theoretical risk of ker-
nicterus in the newborn. Erythromycin estolate, tetracycline,
chloramphenicol, and quinolones should be avoided.
E. Intubation and Mechanical Ventilation—If the patient
fails to respond to the foregoing measures and exhibits a nor-
mal or increased PaCO2, she should be admitted to an ICU. If
the fetus is potentially viable, fetal monitoring should be
instituted. Intubation and mechanical ventilation are indi-
cated for a PaO2 of 70 mm Hg or less, significant mental sta-
tus changes, respiratory acidosis, cardiac arrhythmias, or
evidence of myocardial ischemia. If mechanical ventilation
does not correct the hypoxemia and the fetus is potentially
viable, delivery by cesarean section should be considered for
fetal reasons.
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and American College of Allergy, Asthma and Immunology
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 Postpartum Hemorrhage
ESSENT IALS  OF  D IAGNOS I S
 Rapid loss of 500–1000 mL or more of blood after
delivery.
General Considerations
Postpartum hemorrhage has been defined classically as an
estimated blood loss of more than 500 mL after delivery.
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Investigations have shown, however, that the average blood
loss after vaginal delivery is near 500 mL, whereas that fol-
lowing cesarean section is in excess of 1 L. The working
definition of postpartum hemorrhage therefore is relative.
Most would acknowledge the presence of postpartum hem-
orrhage when blood loss exceeds 1 L, when there is a 10%
change in the hematocrit between admission and postpar-
tum determinations, or when transfusion is necessary.
The most common causes of early postpartum hemorrhage
(<24 hours after delivery) are uterine atony, lower genital tract
lacerations, and retained products of conception. Less common
causes include placenta accreta, uterine rupture, inversion of
the uterus, and coagulopathies. Uterine atony is by far the most
common and may be associated with the antepartum use of
oxytocin or with uterine overdistention from multiple gesta-
tion or polyhydramnios. Other factors thought to be associated
with uterine atony include high parity, prolonged labor,
cesarean section, precipitous labor, chorioamnionitis, and the
use of tocolytic agents (especially magnesium sulfate).
Lower genital tract lacerations occur frequently and usu-
ally present with vaginal bleeding immediately after delivery.
Uterine lacerations can bleed into the peritoneal cavity or
retroperitoneal space and therefore do not always present
with vaginal hemorrhage. Factors associated with lower gen-
ital tract lacerations are forceps or vacuum delivery, fetal
macrosomia or malpresentation, and precipitate delivery.
Failure of the placenta to completely separate is a risk fac-
tor for the development of both uterine atony and postpar-
tum hemorrhage presumably owing to the placental
fragments interfering with the normal contraction of the
uterus that is necessary for hemostasis. Retention of a suc-
centuriate lobe (accessory lobe of the placenta) may present
with postpartum hemorrhage in the early postpartum
period. Placenta accreta also may cause life-threatening hem-
orrhage owing to the inability of the placenta to completely
separate from the uterine wall. Risk factors for placenta acc-
reta include previous puerperal curettage or previous uterine
surgery, including cesarean section, and placenta previa.
Uterine rupture is an uncommon but catastrophic cause
of postpartum hemorrhage. Because uterine artery blood
flow is between 500 and 600 mL/min, hemorrhage from this
cause can result in rapid maternal exsanguination. Conditions
thought to predispose to uterine rupture include previous
uterine surgery, breech extraction, obstructed labor, abnor-
mal fetal position, and high parity.
Uterine inversion is also a rare complication of delivery,
although it may recur in a patient’s subsequent pregnancies.
Uterine inversion is most remarkable for the development of
shock out of proportion to the amount of blood lost.
Coagulopathies frequently are associated with postpar-
tum hemorrhage. They often occur in association with other
complications of pregnancy such as abruptio placentae,
retained dead fetus, and amniotic fluid embolism. In addi-
tion, preexisting chronic coagulation disorders are signifi-
cant contributors to postpartum hemorrhage.
Delayed postpartum hemorrhage occurring between
24 hours and 6 weeks after delivery may require admission to
the ICU for resuscitation, observation, and perioperative
care. Common causes include infection, placental site subin-
volution, and retained products of conception, as well as
underlying coagulopathy.
Clinical Features
Although the initial management of postpartum hemorrhage
will be accomplished in the delivery room, the ICU physician
should be familiar with the basic principles of diagnosis and
early management. The first priority is to establish the cause.
The relationship between the onset of hemorrhage and the
time of delivery is critical in establishing the diagnosis.
Bleeding prior to delivery of the placenta often indicates a
genital tract laceration, a coagulopathy, or a partial separation
of the placenta. When bleeding begins after the placenta is
delivered, uterine atony, uterine inversion, retained fragments
of the placenta, or placenta accreta may be responsible. The
placenta should be inspected to ensure that torn vessels are
not present, which might indicate the presence of an acces-
sory lobe; that appropriate contour is observed; and that por-
tions are not missing (suggesting placenta accreta).
Uterine atony requires fundal massage and the adminis-
tration of ecbolic drugs (see next). Lacerations should be
sutured in a manner that allows closure of the wound and
compression of the underlying vessels. Hematomas may
form as the result of lacerations. Hematomas below the
pelvic diaphragm usually are accompanied by severe pain
and a palpable mass. Sudden onset of shock without signifi-
cant apparent blood loss suggests that the bleeding point is
above the pelvic diaphragm.
A coagulopathy is suggested by the presence of bleeding
from remote locations such as intravenous insertion sites.
The diagnosis of coagulopathy may be made rapidly by
observing a tube of the patient’s blood for clot formation. If
a firm clot forms within 5 minutes, it is unlikely that clini-
cally significant hypofibrinogenemia is present.
Treatment
A. General Measures—Postpartum hemorrhage represents
a special cause of hemorrhagic (hypovolemic) shock. A sta-
ble airway and adequate intravenous access must be ensured.
Initial resuscitation should be with balanced salt solutions,
although blood replacement will be required early if hemor-
rhage cannot be arrested. Packed red blood cells are usually
used. In the event of severe hemorrhage, replacement of clot-
ting factors also may be needed via the use of fresh-frozen
plasma. Fresh-frozen plasma should be given only if labora-
tory testing shows that the patient has developed a coagu-
lopathy. Blood should be warmed to prevent hypothermia.
Arterial blood gas and hemoglobin determinations should
be performed regularly during resuscitation and after control
of bleeding. Measurements of blood pressure, pulse rate, and
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urine output will help to assess volume status. Pulmonary
artery catheters are seldom required, although a central
venous catheter may be helpful in actively bleeding patients
who require ongoing resuscitation and transfusion.
B. Ecbolic Agents—Hemorrhage from uterine atony should
be managed with fundal massage plus an intravenous infusion
of oxytocin (10–40 units/L of normal saline). If oxytocin does
not arrest the hemorrhage, treatment with either methyler-
gonovine (0.2 mg intramuscularly) or carboprost
tromethamine (15-methylprostaglandin F2α), 0.25 mg intra-
muscularly, may be used. Misoprostol (800 mg per vagina or
rectum) also may be effective. Methylergonovine may be asso-
ciated with an increase in maternal blood pressure and should
not be used in the patient with hypertension. Prostaglandin
agents may provoke bronchospasm and should be not be
used in patients with significant asthma.
C. Surgery—When postpartum hemorrhage cannot be con-
trolled by massage and ecbolic agents, emergent surgery usu-
ally is required. In many cases, these procedures will have
been performed before the patient is transferred to the ICU.
Occasionally, however, a previously stable patient will require
exploration for hemorrhage after it has been controlled.
Common surgical procedures include evacuation of
hematomas caused by lacerations (combined with suturing
of the injury and control of the bleeding vessel), ligation of
pelvic arterial vessels, packing, and hysterectomy. Recent
reviews of cesarean hysterectomy reveal that the average
blood loss for this procedure when done emergently was
3000 mL, and the most common antecedent complications
were uterine rupture, placenta accreta and uterine atony.
D. Angiographic Embolization—When bleeding continues
from an identifiable localized area, embolization via a radi-
ographically placed catheter may be extremely helpful. Some
authors have described the placement of embolization
catheters prophylactically in patients at highest risk of post-
partum hemorrhage.
E. Delayed Postpartum Hemorrhage—Fewer than 1% of
patients with postpartum hemorrhage present more than 24
hours after delivery. Infection and retained products of concep-
tion are the most common causes, with subinvolution of the
placental site also being a consideration. Uterine curettage
should be performed only when retained products of concep-
tion are suspected because of the risk of intrauterine adhesions.
Pelvic and uterine ultrasonography may be helpful in determin-
ing whether retained products are present, although all postpar-
tum uteri contain some clot and debris. Even when there is not
retained placental tissue, evacuation of intrauterine clots allows
more efficient uterine contraction and often results in hemosta-
sis. Estrogens may be used to improve endometrial regrowth
after curettage and to avoid intrauterine adhesions. Ecbolic
agents and antibiotics may be given if retained products of con-
ception are not present. If hemorrhage persists more than 12–24
hours, the patient should undergo curettage for presumed
retained products, even in the absence of a definite diagnosis.
Jansen AJ et al: Postpartum hemorrhage and transfusion of blood
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 Trauma During Pregnancy
Accidental injury occurs in approximately 1 in 12 pregnancies.
While many of these incidents are minor, one should bear in
mind that two patients are at risk. Serious injuries during preg-
nancy do not result in a higher maternal mortality rate than do
similar injuries in a nongravid patient. Fetal death, however, is
common, with fetal loss rates of up to 61% reported in studies
of severe trauma. Eighty-five percent of all maternal deaths
from trauma are due to closed head injuries and hemorrhagic
shock, whereas fetal deaths result from abruptio placentae as
well as maternal death and fetal hypoxia. Because of this com-
bined risk, and because of the risk of preterm labor, pregnant
patients often require inpatient observation.
The physiologic changes of pregnancy make the patient
both more and less susceptible to the effects of trauma. The
increased plasma volume and decreased hematocrit further
the potential for diminished oxygen delivery following
blood loss. Fluid resuscitation requirements after hemor-
rhage are greater because of the 50% increase in maternal
intravascular volume. Conversely, the increased blood vol-
ume makes the mother more tolerant of blood loss without
change in her vital signs. The increase in maternal heart rate
(15–20 beats/min) and the decrease in both systolic and
diastolic blood pressures (10–15 mm Hg) may confound
attempts to evaluate volume replacement. Furthermore, an
elevation of coagulation factors during pregnancy increases
the risk for thrombogenesis with surgery or prolonged
immobilization.
As pregnancy progresses into the second trimester, fetal
growth distends the uterus upward into the abdomen, where
it becomes more susceptible to direct injury. The bladder also
becomes more prone to injury, especially after the twelfth
week of gestation. Because blood flow to the uterus is abun-
dant (as much as 600 mL/min), direct injury to the uterus
may cause rapid exsanguination. Uterine blood vessels lack
autoregulation, so maternal shock causes a substantial
decrease in fetal oxygen delivery. Uterine blood flow may fall
before maternal shock becomes manifest and may result in
fetal hypoxia in the face of normal maternal vital signs. Fetal
responses to decreased perfusion and hypoxia include alter-
ations in heart rate (bradycardia or tachycardia), loss of heart
rate variability, and repetitive late decelerations.
Motor vehicle accidents are the principal cause of acci-
dental injuries during pregnancy and account for about 50%
of all cases of blunt abdominal trauma, but 82% of injuries
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resulting in fetal death. Three-point-restraint seat belts are
preferable for pregnant passengers because the incidence of
body flexion and uterine compression is less than that
induced by lap belts alone. Placental abruption is the most
common cause of fetal demise after blunt abdominal trauma.
Abruption is caused by deformation of the elastic uterus
around the inelastic placenta. The shearing force thus pro-
duced tears the decidua basalis. Current evidence indicates
that the position of the placenta does not influence the devel-
opment of abruption. Uterine rupture is uncommon and
probably occurs in less than 0.6% of all traumatic injuries
during pregnancy. It carries a maternal death rate of less than
10%, but a fetal death rate of nearly 100%. Maternal pelvic
fractures occur frequently but do not necessarily preclude
subsequent vaginal delivery. Such fractures are of concern
when they are comminuted and badly displaced because they
carry the potential to injure the uterus and fetus. Placental
abruption and pelvic fractures are highly correlated.
Gunshot wounds are the most common type of penetrat-
ing injury sustained by pregnant patients. Regrettably, inci-
dents occur in which there was clear intent to harm the fetus.
When compared with nonpregnant victims, pregnant
patients actually have a lower mortality rate after abdominal
gunshot wounds, perhaps because the enlarged uterus and its
contents protect the patient by absorbing and dissipating the
missile’s kinetic energy. Upper abdominal gunshot and stab
wounds, however, cause a higher incidence of intestinal
injury because of cephalad displacement of the viscera by the
uterus. Direct injury of the fetus by a bullet occurs in 70% of
cases, with a 65% intrauterine fetal death rate. Maternal
death is much less common.
Burns, electrocution, and suicide attempts are less com-
mon causes of injury. Unless a burn covers more than 30% of
the patient’s body surface area, it generally will not affect the
pregnancy. Fetal outcome is probably related to gestational age
at the time of the burn. The highest mortality rate is recorded
during the first trimester. Topical iodine solutions should be
avoided because large amounts may be absorbed through
the burn wound. House current electrical injuries occur
uncommonly but may be associated with a high fetal mor-
tality rate because of the path of the current through the
patient’s body. Pregnant victims of electrocution may report
a reduction in fetal movements immediately after the incident.
Fetal demise or intrauterine growth retardation may follow.
Oligohydramnios has been reported at the time of delivery.
Management
A. General Principles—Pregnant patients who require ICU
admission following injury commonly will be resuscitated
and stabilized in the emergency department. Initial treat-
ment in the ICU may be advisable, however, because of the
availability of invasive monitoring.
On arrival, initial concern must be directed toward the
mother, with attention paid to establishment of an adequate
airway, breathing, and circulation. The patient should lie in
the left lateral position, if possible, to prevent compression of
the vena cava by the gravid uterus. Both maternal hypoten-
sion and fetal hypoxia may result from caval compression. If
concern about the cervical spine precludes the decubitus
position, an assistant should displace the uterus by hand to
the left in an attempt to decompress the vena cava.
Alternatively, the entire bed or support board can be tilted.
Supplemental oxygen should be given to increase oxygen
delivery to the fetus. Upper extremity intravenous catheters
should be placed to ensure adequate intravenous access. A
nasogastric tube should be inserted during the early stages of
resuscitation to allow gastric decompression and prevent
aspiration. In the presence of a viable fetus, continuous fetal
heart rate monitoring should be instituted as soon as possible.
Blood is preferred as the initial fluid for resuscitation of
hypotensive trauma patients. Particular attention must be
paid to Rh compatibility. If Rh-incompatible blood is inad-
vertently given to an Rh-negative woman, anti-D antibody
should be given in a dose of 300 mg for every 30 mL of whole
blood or 15 mL of packed red blood cells transfused.
Pregnant patients require more volume replacement than do
nonpregnant patients because of their physiologically
expanded intravascular space.
A bladder catheter should be placed as soon as possible
both to measure the urine output and to help establish the
integrity of the urethra and bladder. Urine so obtained
should be inspected for gross blood and tested for micro-
scopic hematuria.
Normal physical signs of abdominal injury such as pain
and loss of bowel sounds may be masked by the pregnant
uterus. Conversely, all these findings may be produced by the
pregnancy itself. Vaginal bleeding generally is considered an
ominous sign because it may signal placental abruption or
severe pelvic injury.
B. Laboratory Studies—Studies should include hemoglo-
bin serum electrolytes, coagulation profile, amylase, and
blood crossmatch. Routine arterial blood gases are advisable.
When placental separation is suspected because of a pelvic
fracture, fetal distress, uterine tetany, or vaginal bleeding,
measurements of blood fibrinogen concentration, fibrin
degradation products, and platelet count are of particular
importance. Additionally, a tube of blood should be obtained
and observed for clot formation. Noncoagulable blood indi-
cates probable placental abruption and mandates immediate
replacement of fibrinogen with fresh-frozen plasma or cryo-
precipitate, followed by evacuation of the uterus. The possi-
bility of fetomaternal hemorrhage should be evaluated with
a Kleihauer-Betke study. Fetomaternal hemorrhage is most
common when the placenta is located anteriorly, when pelvic
tenderness is present, and following motor vehicle accidents.
If severe, it can result in fetal anemia or fetal death.
C. Imaging Studies—Critical radiographic studies should
not be withheld in an attempt to avoid fetal x-ray exposure.
The fetal risks from various doses of x-ray and the expected
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doses from various procedures were discussed previously.
The need for chest and abdominal x-rays should be guided
by the nature and severity of the injury. Free air under the
diaphragm on an upright chest x-ray is an indication for
immediate laparotomy. Traumatic separation of the pubic
symphysis in or after the second trimester is difficult to
detect on x-ray because of the normal ligamentous laxity that
accompanies pregnancy. Maternal and fetal complications
are more common after pelvic fractures, and their presence
must be identified.
Obstetric ultrasound should be performed in all cases of
trauma during pregnancy. It is helpful in diagnosing a retro-
placental clot, although absence of a visible clot on ultra-
sound cannot rule out placental abruption. Additionally,
ultrasound can aid in estimating gestational age when a his-
tory cannot be obtained.
D. Peritoneal Lavage—Open peritoneal lavage through a
supraumbilical incision is an excellent technique for diag-
nosing abdominal injuries. Approximately 1 L of lavage fluid
is instilled through the small incision and allowed to return
passively to the container. Criteria that constitute a positive
lavage include (1) a red blood cell count of more than
100,000/μL, (2) a white blood cell count of more than
500/μL, (3) the presence of GI contents, bile, or bacteria, and
(4) increased amylase.
E. Fetal Monitoring—Immediately on patient arrival in the
ICU, fetal heart monitoring should be instituted. Such mon-
itoring provides information about both the fetus and the
mother. The fetus may be compromised by hypoxia before
the mother becomes hypotensive. Bradycardia, tachycardia,
and loss of beat-to-beat variability are ominous signs.
Monitoring in gestations beyond 18–20 weeks may be able to
predict abruptio placentae. Although intermittent ausculta-
tion is possible, it should not substitute for electronic surveil-
lance. The gestational age at which monitoring is mandatory
is controversial, but all authorities would monitor potentially
viable fetuses (>22–23 weeks). Monitoring necessitates the
presence in the ICU of personnel experienced in the inter-
pretation of fetal heart rate patterns.
F. Tocodynamometry (Uterine Contraction Monitoring)—
Tocodynamometry is of significant importance in predicting
early placental abruption. The incidence of abruption
increases with frequent uterine activity (more than eight
uterine contractions per hour), and about 25% of trauma
patients with at least three uterine contractions in a 20-
minute period suffered either abruptio placentae or preterm
labor. Another study found that these complications did not
occur in patients who were without contractions for the first
4 hours. Monitoring during the first 4–6 hours after admis-
sion therefore has been proposed, with additional monitor-
ing only in patients with contractions on initial monitoring
or with a change in maternal condition.
G. Surgery
1. Trauma—Certain kinds of trauma must be managed
operatively. Bowel injuries must be repaired, fractures
reduced, and wounds closed. Pregnancy should not delay or
contraindicate surgical exploration.
2. Abruptio placentae—Evacuation of the uterus is indi-
cated for placental abruption. If gestation has continued for
more than 30 weeks, immediate cesarean section may save
both the fetus and the mother. In cases of intrauterine fetal
demise, labor and spontaneous vaginal delivery may occur.
Caution must be exercised to detect DIC, which is more
common after extensive abruption. If both the platelet count
and the fibrinogen concentration decline, fresh-frozen
plasma or cryoprecipitate should be given and a hysterotomy
performed if delivery is not imminent. The coagulopathy
usually ceases when the placenta is removed.
3. Uterine rupture—Shock, severe abdominal pain, and
lack of fetal heart tones suggest uterine rupture. It may be
difficult to localize the fundus of the uterus, and fetal parts
may be easily palpable through the abdominal wall. An
abdominal x-ray usually shows that the fetal skeleton is in an
unusually high location in the abdomen. Peritoneal lavage is
always positive for blood and returns more fluid than was
instilled (amniotic fluid). At surgery, massive bleeding may
have to be controlled with bilateral internal iliac artery liga-
tion. Supracervical hysterectomy may be required.
4. Cesarean section—Adequate exposure of abdominal
injuries usually can be achieved with careful mobilization of
the uterus. Cesarean section may be required, however, when
the gravid uterus prevents access to deep pelvic injuries.
Patients with undisplaced pelvic fractures usually do not
require cesarean section.
Premature separation of the placenta and fetal head
injuries both may be consequences of maternal trauma dur-
ing pregnancy. Placental separation coexisting with a living
fetus often mandates an emergent cesarean section. In the
case of a live fetus undergoing labor after maternal trauma,
consideration should be given to fetal ultrasound for evi-
dence of fetal head injury. If such evidence exists, this fetus
also may benefit from cesarean delivery.
Cusick SS, Tibbles CD. Trauma in pregnancy. Emerg Med Clin
North Am 2007;25:861–72, xi. [PMID: 17826221]
El-Kady D et al: Trauma during pregnancy: An analysis of mater-
nal and fetal outcomes in a large population. Am J Obstet
Gynecol 2004;190:1661–8. [PMID: 15284764]
Mattox KL, Goetzl L: Trauma in pregnancy. Crit Care Med
2005;33:S385–9. [PMID: 16215362]
Muench MV, Canterino JC. Trauma in pregnancy. Obstet Gynecol
Clin North Am 2007;34:555–83, xiii. [PMID: 17921015]
Weiss HB, Songer TJ, Fabio A: Fetal deaths related to maternal
injury. JAMA 2001;286:1863–8. [PMID: 11597288]
 821
0039
Antithrombotic Therapy
Elizabeth D. Simmons, MD
Pathologic blood clot formation within blood vessels
(thrombosis) and embolization of clots to distant sites result
from complex interactions among platelets and coagulation
proteins, the fibrinolytic system, and the blood vessel itself.
Thrombi are composed of red blood cells, platelets, and fib-
rin in varying proportions depending on the conditions
present at the site of thrombus formation. Very diverse clini-
cal conditions are associated with increased risks of such
pathologic thrombosis and embolization (Table 39–1).
Thromboembolic disease is a major cause of morbidity and
mortality; 30–40% of all deaths in the United States are
attributed to thrombotic events, and nonfatal events occur in
hundreds of thousands of people each year.
Antithrombotic therapy consists of strategies (both phar-
macologic and physical) to prevent pathologic blood clot
formation or to treat established thromboses in order to
limit the clinical consequences of such clots. The decision to
use antithrombotic therapy in clinical practice is often com-
plicated because of the diversity of the clinical conditions
affecting patients, difficulties in establishing accurate diag-
noses of thromboembolism, and our still incomplete under-
standing of the risks and benefits of antithrombotic therapy
in the prevention and treatment of thromboembolic disease.
Numerous new pharmacologic agents have been developed
or are under development, and various combinations of
antithrombotic agents are being used in diverse settings.
 Physical Measures
Venous stasis and damage to blood vessels are the two most
important risk factors for the development of venous throm-
boembolism (VTE). Physical measures to decrease venous
stasis are quite important in preventing venous clots, particu-
larly in hospitalized patients. Limiting bed rest as much as
possible for most medical patients and early mobilization
after surgery can decrease the period of risk for venous throm-
bosis. Intermittent pneumatic compression devices (IPCs) and
the venous foot pump (VFP) reduce venous stasis, increase
venous flow, and reduce the risk of deep vein thrombosis
(DVT) in lower-risk patients but have not been demonstrated
to reduce the risk of pulmonary embolism (PE). These devices
are used primarily in patients with high bleeding risk or in
combination with pharmacologic agents for prevention of
VTE. IPCs should not be used in the presence of established
thrombosis, severe peripheral vascular disease, skin ulcers, or
after leg trauma if there is compromised tissue viability.
Graduated compression stockings may help to control leg
edema but are not highly effective for the prevention of VTE.
They are not recommended as an isolated measure for preven-
tion of VTE in patients at moderate to high risk.
Interruption of the inferior vena cava using a fluoroscop-
ically placed filter is indicated for treatment of patients with
lower extremity venous thrombosis who have a major con-
traindication to anticoagulant therapy or for patients with
recurrent thromboembolism despite adequate anticoagula-
tion. Inferior vena cava filter placement reduces the risk of PE
but does not prevent recurrence or extension of lower
extremity thromboses. Therefore, unless contraindicated, ini-
tiation of anticoagulation as soon as possible after filter place-
ment is advised.
Surgical or transvenous embolectomy is performed occa-
sionally in selected patients with life-threatening thromboem-
bolic disease, particularly in patients with contraindications to
anticoagulation or thrombolysis.
 Antiplatelet Agents
Antiplatelet therapy (alone or in combination with anticoag-
ulants) is most beneficial in prevention or treatment of arte-
rial thrombosis. Arterial thrombi usually develop in
abnormal blood vessels and are associated with activation of
both blood coagulation and platelets; however, arterial
thrombi are composed primarily of platelets held together by
fibrin strands. Antiplatelet agents inhibit platelet function
through several biochemical pathways or by exerting effects
on the platelet membrane.
Copyright © 2008 by The McGraw-Hill Companies, Inc. Click here for terms of use. 
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Antiplatelet agents are useful in the management of
patients with unstable angina; suspected acute myocardial
infarction; a history of myocardial infarction, nonfatal stroke,
transient ischemic attacks, or peripheral vascular disease; and
those undergoing vascular procedures. Antiplatelet agents are
not as useful as other measures for prevention of VTE, such as
anticoagulation, particularly in high-risk surgical patients or
for stroke prevention in patients with atrial fibrillation.
Inhibitors of Cyclooxygenase (Aspirin,
Nonsteroidal Anti-inflammatory Agents)
Cyclooxygenase (COX) is a key enzyme in the prostaglandin
pathway within platelets and endothelial cells. The final prod-
uct of this pathway differs in platelets and endothelial cells.
Thromboxane A2 (TXA 2), a potent inducer of platelet aggre-
gation, is produced in platelets, whereas prostacyclin, an
inhibitor of platelet aggregation, is produced in endothelial
cells. Aspirin irreversibly inhibits COX (COX-1 more so than
COX-2), which cannot be resynthesized by platelets because
they have no nucleus. Vascular prostacyclin production is
affected to a much lesser extent by aspirin because endothelial
cells can resynthesize cyclooxygenase, and because prostacy-
clin is also COX-2–derived, which is much less sensitive to
inhibition by aspirin. Thus aspirin is an ideal pharmacologic
agent for the treatment and prevention of thromboembolic
disease. Several of the nonsteroidal anti-inflammatory drugs
(NSAIDs) also inhibit platelet COX, but inhibition is
reversible. NSAIDs may cause clinical bleeding in patients
with underlying hemostatic defects or after invasive proce-
dures, but they are generally not used therapeutically for treat-
ment or prevention of thromboembolic disorders. COX-2
inhibitors do not inhibit production of platelet TXA 2 and do
not have antithrombotic properties; these agents actually may
increase the risk of thromboembolism.
Three reversible COX inhibitors (ie, indobufen, flur-
biprofen, and triflusal) that may have beneficial effects simi-
lar to those of aspirin have been investigated as alternatives
to aspirin; none are currently approved for use in the United
States, and it is unclear whether they will prove to have any
advantage over currently available treatments.
Aspirin is rapidly and completely absorbed from the GI
tract, metabolized to salicylate, and circulates as salicylate
bound primarily to albumin. Salicylate is metabolized in the
liver and excreted in the urine. The serum half-life of salicy-
late is 15–20 minutes. The effect of aspirin on platelet func-
tion begins within 1 hour of ingestion (3–4 hours for
enteric-coated preparations) and lasts the life of the platelet
(8–10 days). Enteric-coated tablets should be chewed if rapid
antiplatelet effect is necessary. Gastric irritation may be
reduced with enteric-coated and timed-release forms of
aspirin, but absorption may be reduced or delayed.
Ingestion of aspirin in doses commonly used in clinical
practice prolongs the bleeding time in normal subjects some-
what variably, typically by 1–3 minutes, and out of the normal
range only in about half of subjects. Aspirin inhibits platelet
aggregation in vitro, but these laboratory effects do not corre-
late well with in vivo hemostasis. In patients with underlying
hemostatic defects (eg, hemophilia, von Willebrand disease,
uremia, mild preexisting disorders of platelet function, and
thrombocytopenia), aspirin may markedly prolong the bleed-
ing time and cause serious bleeding.
Stasis Immobilization
Congestive heart failure
Surgery
Advanced age
Obesity 
Atrial fibrillation
Blood vessel abnormalities Trauma, coronary artery disease, peripheral 
vascular disease, varicosities, vasculitis,
artificial surfaces (vascular grafts, heart
valves, indwelling catheters), diabetes
mellitus
Homozygous homocystinuria
Previous thrombosis 
Abnormalities of
physiologic
antithrombotic
mechanisms 
Antithrombin deficiency 
Protein C or S deficiency 
Hereditary resistance to activated protein C
(factor V Leiden and prothrombin gene
mutation G20210A) 
Methylenetetrahydrofolate reductase
(MTHFR) gene mutation C677T 
Defective or deficient plasminogen 
Plasminogen activator deficiency 
Abnormalities of
coagulation and
fibrinolysis 
Malignancy 
Pregnancy 
Oral contraceptives 
Hormone replacement therapy
Tamoxifen
Nephrotic syndrome 
Lupus anticoagulant/antiphospholipid
antibody syndrome
Prothrombin complex concentrate solution
Dysfibrinogenemia 
Factor VIII >150%  
Abnormalities of platelets Myeloproliferative disorders 
Paroxysmal nocturnal hemoglobinuria
Hyperlipidemia
Diabetes mellitus 
Heparin-associated thrombocytopenia
Thrombotic thrombocytopenic purpura 
Hyperviscosity Polycythemia
Leukemia 
Sickle cell disease 
Leukoagglutinin
Hypergammaglobulinemia 
Table 39–1. Conditions associated with pathologic
thromboembolism. 
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The clinical benefits of aspirin have been established by
large trials of patients with various thromboembolic phenom-
ena, with endpoints including development of thrombosis,
death from thrombosis, and bleeding complications.
Laboratory tests of platelet function are not useful for monitor-
ing such patients in clinical practice. The measurable
antiplatelet effects of aspirin are equivalent over a wide range of
daily aspirin dosage (300–3600 mg/day), and the therapeutic
benefits have been demonstrated with as little as 75 mg/day (or,
in one study, 30 mg/day). The minimum effective dose varies for
different disorders, but for most situations, a daily dose between
50 and 100 mg is effective and minimizes toxicity with long-
term use. In acute myocardial infarction and acute ischemic
stroke, a dose of 160 mg/day reduces early mortality and recur-
rent events. Higher-dose aspirin (eg, 650–1500 mg/day) does
not improve outcome and actually may be detrimental.
Currently available data support the use of aspirin in car-
diovascular disease prevention, stable and unstable angina,
acute myocardial infarction, transient ischemic attacks and
incomplete stroke, severe carotid stenosis, stroke following
carotid artery surgery, and in patients with prosthetic heart
valves (in combination with oral anticoagulation). The ben-
efits of aspirin following vascular or valve surgery, arterial
procedures, or creation of fistulas or shunts are less certain
but appear to include a reduction in risk of arterial occlusion
compared with no therapy. Aspirin, although more effective
than placebo, is less effective than anticoagulation in pre-
venting recurrent stroke associated with nonvalvular atrial
fibrillation. Aspirin has not been shown to be effective for
treatment of established VTE and is inferior to other meas-
ures for prevention of VTE, especially in high-risk patients.
Although one large trial showed a benefit of aspirin—alone
or in combination with anticoagulation—for patients under-
going hip surgery, it is less effective than anticoagulation.
The safety and efficacy of aspirin in combination with
anticoagulants have not been clearly established.
Aspirin resistance resulting in treatment failure has been
observed in some patients receiving aspirin for the treatment of
ischemic vascular disease. The mechanisms underlying resist-
ance are not known, and there is currently no reliable platelet
function test to predict which patients are unlikely to benefit
from aspirin. Concomitant therapy with other NSAIDs can
reduce the antiplatelet effect of aspirin because of competition
for binding sites in the platelet and may be one important
mechanism of aspirin treatment failure because of widespread
use of these over-the-counter medications. Patients who
develop recurrent ischemic events despite aspirin are candi-
dates for alternative antiplatelet therapy or anticoagulation.
Adverse effects of aspirin include dose-dependent GI irrita-
tion (eg, dyspepsia, nausea and vomiting, occult blood loss, and
gastric ulceration), hypersensitivity reactions, abnormal liver
function tests (rare), nephrotoxicity (rare), and at high doses,
tinnitus and hearing loss. Enteric-coated aspirin does not
reduce the risk of GI bleeding compared with regular aspirin.
Concomitant use of NSAIDs may increase the risk of GI bleed-
ing.Omeprazole is effective at treating and preventing GI ulceration
and bleeding associated with NSAIDs and may permit chronic
use of aspirin in patients at high risk for cardiovascular events
who have had this complication. Overdosage of aspirin (salicy-
late intoxication) may be life-threatening and is manifest by
metabolic acidosis and respiratory alkalosis, dehydration, fevers,
sweating, vomiting, and severe neurologic symptoms. Reye’s
syndrome in infants and children appears to be associated with
aspirin usage. In patients at risk for major bleeding, the
antithrombotic effects of aspirin may result in serious bleeding.
High doses of aspirin may result in interference with prothrom-
bin synthesis, prolongation of the prothrombin time, and signif-
icant hemorrhagic sequelae. Subarachnoid hemorrhage may
occur with the use of more than 15 aspirin per week, particu-
larly in older or hypertensive women.
Inhibitors of ADP-Mediated Platelet Aggregation
(Ticlopidine, Clopidogrel)
Ticlopidine and clopidogrel are structurally related
thienopyridines that inhibit platelet function. Repeated daily
dosing results in cumulative inhibition of ADP-induced
platelet aggregation and slow recovery of platelet function
after stopping the drug. The major properties of ticlopidine
and clopidogrel are compared in Table 39–2.
Ticlopidine is well absorbed (80–90%) from the GI tract.
It is rapidly metabolized with one active metabolite. Steady
state levels are achieved with 250 mg twice daily after 14 days.
The onset of antiplatelet effect is delayed (up to 2 weeks), so
ticlopidine should not be used when a rapid antiplatelet
effect is needed. Ticlopidine was introduced as a potential
alternative to aspirin, but its high cost, toxicity, and only
marginally better efficacy have limited its use in current
practice. Ticlopidine is approved for stroke prevention when
aspirin has failed or in patients who cannot tolerate aspirin.
Ticlopidine may cause neutropenia (2.4%), thrombocy-
topenia, or pancytopenia (0.04–0.08%), particularly in the
first 3 months of therapy, so monitoring of blood counts
must be done during that time. Thrombotic thrombocy-
topenic purpura (TTP) has been reported with ticlopidine
therapy (0.02–0.04%), but ticlopidine also has been used
successfully in management of TTP. Other adverse effects
include diarrhea (20%), skin rash (2–15%), increase in total
cholesterol levels (mean increase of 9%), and reversible liver
function test abnormalities (rare).
Clopidogrel is rapidly absorbed and metabolized to active
metabolites (the main one being SR 26334, a carboxylic acid
derivative). The onset of inhibition of platelet aggregation is
dose-dependent, occurring 2 hours after a single dose
(400 mg) but after 2–7 days with lower daily dosing (50–100
mg daily). Platelet function returns to normal 7 days after
stopping the drug, consistent with irreversible inhibition of
platelet function. A loading dose of 300 mg followed by 75 mg
daily will result in a rapid and sustained antiplatelet effect; a
loading dose of 600 mg is used in patients undergoing percu-
taneous coronary intervention, but the optimal loading dose
has not been determined. Clopidogrel appears to have
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approximately the same antiplatelet effects as ticlopidine, but
because of its better safety profile, it has replaced ticlopidine
for most clinical situations. Its therapeutic efficacy appears to
be equivalent to aspirin in most settings except for sympto-
matic peripheral artery disease, in which it may be superior.
It is currently approved for use in patients with recent stroke
or myocardial infarction and in those who have peripheral
arterial vascular disease. Clopidogrel combined with aspirin
decreases the rate of cardiovascular events following acute
coronary syndromes compared with aspirin monotherapy
and is the standard regimen following placement of coronary
stents (for at least 1 month; longer duration may be better).
Combination therapy is associated with more bleeding than
with aspirin alone, but only with higher doses of aspirin
(>100 mg/day). The most common side effects of clopido-
grel are rash and diarrhea. GI bleeding occurs less often than
with aspirin (2%); however, in one study in patients who had
bleeding ulcers while taking aspirin, clopidogrel was associ-
ated with a higher rate of recurrent bleeding than aspirin
when each was combined with a proton-pump inhibitor.
Neutropenia has been reported less often than with ticlopi-
dine (0.8%), as has TTP (reported occurrence 1:250,000 per-
sons, about the same as the general population), usually
occurs within the first 2 weeks of treatment.
Integrin αIIbβ3 (Platelet Glycoprotein IIb/IIIa)
Receptor Inhibitors
Platelet glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors block
the binding of fibrinogen to its receptor on the platelet
membrane, preventing platelet aggregation. There are three
GP IIb/IIIa inhibitors currently approved for use in the
United States: abciximab (recombinant humanized mono-
clonal antibody), eptifibatide (synthetic heptapeptide similar
to that found in snake venom from Sistrurus m barbouri), and
tirofiban (a nonpeptide mimetic), all of which are given intra-
venously. Prolongation of bleeding time and decreased
platelet aggregation in vitro are seen with all these agents, but
in contrast to aspirin, ticlopidine, and clopidogrel, these
effects are rapidly reversible after discontinuation of the drug.
Results of six large studies have shown that these agents, in
combination with aspirin and heparin, are effective for pre-
venting ischemic complications associated with percutaneous
coronary artery interventions. The benefits of these agents are
less certain for management of patients with acute coronary
syndromes who are not undergoing percutaneous interven-
tion; studies have yielded conflicting results in terms of bene-
fits, whereas in all studies there is a higher risk of bleeding
compared with standard therapy. Only diabetes have consis-
tently benefited from addition of one of these agents to stan-
dard therapy. Although coronary flow and reinfarction rates
are improved by adding GP IIb/IIIa blockade to throm-
bolytic therapy in acute myocardial infarction, there does not
appear to be any mortality benefit for combined therapy, and
bleeding is increased by the combination. Four orally active
agents have been tested and are not more effective when
combined with aspirin or when given in place of aspirin for
patients with acute coronary syndromes and may increase
mortality. The observed increase in mortality may be due to
increased bleeding and a possible paradoxical prothrombotic
Ticlopidine Clopidogrel 
Absorption (oral) 90% Rapid 
Half-life 24–36 hours (single dose); 96 hours (after 14 days
or therapy) 
Active metabolite SR 26334: 8 hours 
Active metabolities Yes Requires metabolism to active inhibitor: SR 26334 
Onset of antithrombotic action Delayed up to 2 weeks 2 hours (single 400 mg dose); 1 day (50–100 daily dose) 
Recovery of platelet function after
discontinuing drug 
7 days 7 days 
Recommended dose 250 mg orally twice daily 300 mg loading dose; 75 mg orally daily 
Clinical use Cerebral ischemia with aspirin failure or intolerance Peripheral vascular disease, prevention of recurrent
stroke, myocardial infarction. Combined with aspirin
after coronary artery stent placement. 
Side effects Neutropenia (2.4%), thrombocytopenia, TTP
(0.2%–0.04%), aplastic anemia, rash, diarrhea 
Rash, diarrhea, TTP (1/1,000,000), neutropenia
(0.8%), gastrointestinal bleeding (2%) 
Expense About $2–3/pill About $3/pill 
TTP = thrombotic thrombocytopenic purpura.
Table 39–2. Comparison of ticlopidine and clopidogrel.
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effect owing to activation of platelets. GP IIb/IIIa inhibitors
can cause bleeding similar to that seen with fibrinolytic ther-
apy. They are contraindicated in patients with platelet counts
of less than 100,000/μL.
Abciximab binds rapidly to the platelet receptors, fol-
lowed by dose-dependent inhibition of platelet aggregation,
accompanied by prolongation of the bleeding time. Bleeding
time returns gradually to normal by 12 hours after a bolus
injection, and platelet aggregation normalizes within 48 hours.
A bolus dose of 0.25 mg/kg followed by a 10 μg/min contin-
uous infusion results in sustaining of the antiplatelet effect.
This regimen has been used to prevent ischemic events in
patients undergoing percutaneous transthoracic coronary
angioplasty (PTCA). Major bleeding, especially in combi-
nation with full-dose heparin, can occur with abciximab.
Reversible thrombocytopenia may occur (1–2%) as soon as
2 hours after starting therapy. Antibodies develop in about
6%. The antiplatelet effects of abciximab may be responsi-
ble for its therapeutic benefits, but it also inhibits throm-
bin formation, which may contribute to its antithrombotic
properties.
Eptifibatide may cause less bleeding time prolongation
than other GP IIb/IIIa inhibitors while causing equivalent
inhibition of platelet aggregation, although this effect may
have been related to methods of measurement. Like abcix-
imab, eptifibatide can inhibit thrombin generation. Several
dosing regimens have been used for eptifibatide, ranging
from a 90–180 μg/kg bolus followed by continuous infusion
rates between 0.5 and 2 μg/kg per minute for 18–24 hours.
Bleeding time returns to normal 1 hour after stopping the
infusion, whereas inhibition of platelet aggregation may last
4 hours or more. Eptifibatide does not appear to increase the
overall rate of thrombocytopenia, but it may cause severe
thrombocytopenia in a small number of patients.
Tirofiban is a nonpeptide inhibitor of the GP IIb/IIIa
receptor that increases bleeding time and inhibits platelet
aggregation. Its effects are augmented by simultaneous
administration of aspirin. Onset of platelet inhibition is
rapid (5 minutes) and returns to normal within 1.5–4 hours
after discontinuation. Reported studies use bolus doses of
5–15 μg/kg followed by infusions of 0.05–0.15 μg/kg per
minute. Severe reversible thrombocytopenia may complicate
treatment with tirofiban.
Dextran
Dextran (available in high- and low-molecular-weight formu-
lations) interferes with platelet function and fibrin polymer-
ization and enhances plasmin-mediated fibrinolysis. Although
dextran is a volume expander, hemodilution induced by dex-
tran does not appear to influence its antithrombotic effects.
Dextran is less effective than other agents for  prevention of
VTE. Dextran has been used primarily during carotid
endarterectomy and microvascular procedures, but because
there are few data from controlled clinical trials, firm recom-
mendations about its role cannot be made. Dextran is not
effective in the treatment of active thromboembolic disease.
Because of its volume-expanding properties, dextran should
be avoided in patients at risk for volume overload. Dextran
occasionally may cause hypersensitivity reactions.
Phosphodiesterase Inhibitors
Dipyridamole is the only phosphodiesterase inhibitor cur-
rently in use in the United States. Dipyridamole does not affect
platelet aggregation but prolongs platelet survival time in
patients with arterial thrombosis or prosthetic heart valves.
Dipyridamole does not appear to be a particularly effective
antithrombotic agent on its own, in part, owing to limited
bioavailability. A new preparation with improved bioavailabil-
ity combined with aspirin is available (200 mg dipyri-
damole/25 mg aspirin) and has demonstrated a significant
reduction in recurrent stroke or death in patients with prior
strokes or transient ischemic attacks (TIAs). The most com-
mon side effect of dipyridamole is headache; it does not
appear to increase the risk of bleeding compared with placebo.
 Anticoagulants
The commonly used anticoagulants interfere with blood clot
formation and extension by inhibiting coagulation factors
(eg, unfractionated and low-molecular-weight heparin) or
blocking the synthesis of biologically active coagulation fac-
tors (eg, vitamin K antagonists). These anticoagulants have
demonstrated efficacy in a wide range of thromboembolic
conditions, both venous and arterial. Indications for use of
anticoagulants are expanding. The development of several
new anticoagulants, including several direct thrombin
inhibitors (DTIs), with different mechanisms of action and
more favorable therapeutic indices has expanded the use of
anticoagulant therapy and increased the therapeutic options
for patients with complicated medical conditions.
Unfractionated Heparin (UFH)
UFH is derived from porcine intestine or bovine lung and is
a mixture of molecules of heterogeneous size (MW
3000–33,000). Heparin binds to antithrombin (AT; also
known as antithrombin III) and accelerates antithrombin’s
inhibition of activated thrombin and other coagulation fac-
tors (particularly activated factor X). Only about a third of
administered UFH contains the specific pentasaccharide
sequence that is necessary for binding to AT, and only those
molecules have anticoagulant activity. An additional
sequence of 13 saccharides is required for the AT-heparin
complex to bind with thrombin; however, only the pentasac-
charide sequence is required for inactivation of activated fac-
tor X. This heparin-AT interaction is the major mechanism
for heparin’s anticoagulant effect. At high concentrations,
heparin also can bind directly to heparin cofactor II and
inactivate thrombin. Heparin, particularly the high-
molecular-weight fractions, also inhibits platelet function. In
addition to its anticoagulant properties, heparin can increase
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vascular permeability, inhibit vascular smooth muscle cell
proliferation, and interfere with normal bone homeostasis.
Heparin is not well absorbed from the GI tract, so it must
be administered parenterally (subcutaneously or intra-
venously). Subcutaneous UFH has lower bioavailability and
should be accompanied by an intravenous bolus injection if
immediate anticoagulation is required and a higher initial
dose (about 10% greater than for IV administration).
The pharmacology of heparin is complex. It circulates
bound to plasma proteins, binds to endothelial cells, where it
is neutralized by platelet factor 4, and is taken up by
macrophages and desulfated. There is a nonlinear dose-
response relation and a dose-dependent biologic half-life.
The route of elimination of heparin is not certain; plasma
clearance is accelerated by the presence of acute thromboem-
bolism. The rate of clearance of heparin depends on the size
of the molecules; larger molecules are cleared more rapidly
than low-molecular-weight molecules.
Although there is a relationship between the dose of
UFH and its efficacy (as well as safety), the variability of
response to UFH requires monitoring and adjustment of
dose. Monitoring of UFH activity is based on its biologic
effect on in vitro coagulation. UFH prolongs three impor-
tant in vitro coagulation parameters: the thrombin time
(TT), the prothrombin time (PT), and the activated partial
thromboplastin time (aPTT). The TT is the most sensitive
indicator of heparin’s effect and may be used to detect even
small amounts of heparin. The TT is useful to differentiate
heparin’s effect from that of circulating inhibitors of coag-
ulation, which are phospholipid-dependent and therefore
will result in a prolonged aPTT but normal TT. The PT is
the least sensitive measure of heparin’s effect and is usu-
ally normal unless the patient is also receiving oral antico-
agulant treatment or is overanticoagulated. The aPTT is
intermediate in sensitivity and is the most commonly used
test for monitoring UFH. However, recent clinical studies
have found that the aPTT does not always reliably predict
response to therapy. In addition, commercial reagents
used in the aPTT assay have variable sensitivity to
heparin, which makes monitoring UFH therapy of uncer-
tain accuracy. Nevertheless, the aPTT is still the most
commonly used method for monitoring response to UFH.
In most clinical situations, the desired aPTT while receiv-
ing UFH is one and one-half to two times the control
time. Suggested adjustment of UFH dose based on aPTT
results is outlined in Table 39–3 and ideally should be
based on calibration of the aPTT reagent to correspond to
therapeutic heparin levels (0.3–0.7 IU/mL). Dose modifi-
cations should be made when UFH is used in combination
with thrombolytic therapy or platelet GP IIb/IIIa antago-
nists. When UFH is given subcutaneously, peak plasma
levels are reached after 3 hours.
A. Initial Dose
Indication Loading Dose by IV Bolus Initial Maintenance Infusion∗
Venous thromboembolism 80 units/kg 18 units/kg/h
Unstable angina or acute myocardial
infarction
60–70 units/kg to maximum of
5000 units
12–15 units/kg/h (maximum
1000 units/h)
Concomitant alteplase for acute STEMI 60 units/kg to maximum of
4000 units
12 units/kg/h (maximum
1000 units/h)
Table 39–3. Unfractionated heparin, dosing and adjustment.
B. Subsequent Dose Adjustments Based on aPTT (First aPTT Obtained 6 hours after Starting
Unfractionated Heparin)
aPTT (s)
Rate Change
(units/kg/h) Additional Action Obtain Next aPTT
<35 +4 Rebolus 80 units/kg 6 h
35–45 +2 Rebolus 40 units/kg 6 h
46–70† 0 None Following morning
71–90 –2 None 6 h
>90 –3 Hold infusion 60 min 6 h
∗Unfractionated heparin, 25,000 units in 250 mL D5W (100 units/mL).
†The therapeutic range for aPTT should be standardize to correspond to therapeutic anti–factor Xa levels
(0.3–0.7 IU/mL).
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UFH is effective for prevention and treatment of VTE
(DVT and PE; Table 39-4), mural thrombus after myocardial
infarction, unstable angina, and acute myocardial infarction.
UFH is usually combined with antiplatelet agents (eg,
aspirin, clopidogrel, and more recently, GP IIb/IIIa receptor
inhibitors) in the treatment of acute ischemic heart disease.
UFH has been used in conjunction with thrombolysis for
coronary artery occlusion; however, recent studies have sug-
gested that UFH may increase the risk of bleeding with little
added benefit over thrombolysis, particularly in patients
receiving aspirin. UFH is used alone or in combination with
GP IIb/IIIa inhibitors during percutaneous coronary inter-
vention (PCI). UFH is not effective for prevention of
restenosis after coronary angioplasty, and prolonged infusion
of UFH after completion of PCI increases bleeding without
reducing ischemic events. Guidelines for use of UFH in coro-
nary artery disease have been proposed (see Table 39–4);
however, ongoing trials probably will result in modification
of these guidelines as results of studies using newer agents
and combinations of agents are reported. UFH is also used
during extracorporeal circulation of blood (in cardiovascular
surgery and hemodialysis), prior to cardioversion in atrial
fibrillation (if no mural thrombus is detected by trans-
esophageal echocardiography), in some cases of dissemi-
nated intravascular coagulation, and to treat fetal growth
retardation in pregnant women. Heparin (UFH or low-
molecular-weight heparin) is generally the anticoagulant of
choice during pregnancy because it does not cross the pla-
centa and is not teratogenic. Heparin is also used when
chronic oral anticoagulation (eg, in patients with heart
valves, atrial fibrillation, and recurrent thromboembolic dis-
ease) is interrupted for invasive procedures or when recur-
rent thromboembolism occurs despite adequate oral
anticoagulation.
Multiple factors modify the anticoagulant effects of UFH
(Table 39–5), so the precise dose of UFH in a given patient
cannot be predicted in advance. When immediate anticoag-
ulation is required, an intravenous bolus is given followed by
continuous intravenous infusion or intermittent subcuta-
neous UFH (see Table 39–3). Continuous infusion is used
more often because of its lower risk of hemorrhage, but inter-
mittent subcutaneous UFH may be used in selected situations
(eg, thromboprophylaxis). Long-term use of subcutaneous
UFH during pregnancy or other conditions requiring long-
term outpatient heparin therapy has been replaced with sub-
cutaneous low-molecular-weight heparin. Careful monitoring
of the aPTT is essential for patients maintained on UFH to
ensure adequate anticoagulant effect without undue risk of
hemorrhage (see Table 39–3). Larger doses of UFH are
required to treat established thromboembolic disease than for
prevention of VTE possibly because thrombin bound to fibrin is
much less sensitive to inhibition by UFH than circulating throm-
bin and because of increased plasma reactive proteins, which
bind and neutralize UFH. Heparin resistance (requirement of
Table 39–4. Indications and administration of anticoagulants in selected settings.∗
Prevention of venous thromboembolism Low risk (patients <40 with no risk factors undergoing minor surgery): early mobilization.
Moderate risk (<40 with risk factors for VTE or patients age 40–60): UFH every 12 hours, LMWH
(<3400 units/day), IPC.
High risk (patient >60, 40–60 with risk factors): UFH every 8 hours, LMWH (>3400 units/day), or IPC.
Highest risk (multiple risk factors, hip or knee arthroplasty, hip fracture surgery, major trauma,
spinal cord injury): LMWH (>3400 units/day), fondaparinux, oral anticoagulant (INR 2–3), or
IPC combined with UFH every 12 hours or LMWH daily. 
Treatment of acute venous thromboembolism Adjusted-dose UFH. Monitor and adjust according to Table 39–3; OR full-dose LMWH (dose varies
by preparation). Begin oral anticoagulation on day 1. Continue UFH or LMWH until fully
anticoagulated with oral agent (overlap with oral anticoagulant in therapeutic range at least
2 days, usually 4–5 days total heparin).
Coronary artery disease (if no contraindication to
anticoagulation)
Non-ST-segment acute coronary syndrome (NSTEMI). Use UFH in combination with antiplatelet
therapy. Dose as in Table 39-3, target aPTT between 50 and 75 seconds† or LMWH (dose varies
with preparation.
Acute MI with ST-segment elevation (STEMI) or new left bundle branch. Use UFH in combination with
fibrinolytic: Dose as in Table 39–3, target aPTT between 50 and 75 seconds, administer for 48
hours (longer in patients at high risk for systemic or venous thromboembolism—anterior MI,
pump failure, atrial fibrillation, left ventricular thrombus, previous thromboembolism) or LMWH
(dose varies with preparation).
Chronic outpatient use (pregnancy,
warfarin failure)∗
UFH at 12,000 units SC twice daily. Monitor aPTT 6 hours after injection and adjust subsequent
dose to maintain aPTT 50–85 seconds if LMWH is unavailable.
∗Choice of specific regimen should take into account individual patient characteristics, including risk of thrombosis, risk of bleeding with
anticoagulation and renal function.
†7th ACCP Conference Guidelines
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very large doses of heparin to prolong the aPTT) may occur
owing to the presence of elevated factor VIII or fibrinogen
levels, increased heparin-binding proteins, increased
heparin clearance, or AT deficiency. Measuring anti–factor
Xa levels may be a better alternative for monitoring heparin
therapy in these patients. It is not necessary to cause prolon-
gation of the aPTT for prevention of VTE in moderate-risk
patients, although in very high-risk patients—for example,
those undergoing orthopedic surgery—prolongation of the
aPTT to the upper end of normal is required to prevent
thrombosis.
Hemorrhage is the most common complication of
heparin therapy. Hemorrhage occurs more frequently with
high-dose heparin therapy and when the aPTT is prolonged
beyond the therapeutic range. Intermittent bolus UFH
results in a higher rate of hemorrhage than continuous-
infusion UFH, which may be due to the higher total daily
dose required to maintain a therapeutic aPTT with intermit-
tent administration. Concomitant use of aspirin or other
antiplatelet drugs increases the risk of hemorrhage, but in
patients with coronary thrombosis, the risk is felt to be
acceptable. The presence of other hemostatic defects, chronic
alcoholism, and the overall general condition of the patient
also influence the risk of hemorrhage with heparin therapy.
Management of hemorrhage associated with UFH varies
depending on the severity of the bleeding and the degree of
the anticoagulant effect, as measured by the aPTT. If the indi-
cation for anticoagulation is strong, continuation of UFH
with close monitoring of the aPTT and blood counts may be
acceptable for patients with trivial bleeding. If minor bleed-
ing is associated with an aPTT that is markedly prolonged
above the therapeutic range, withholding UFH until the
aPTT falls into the desired range (usually within a few hours)
is recommended if the patient is stable, with clinical evalua-
tion of the patient before resuming UFH for evidence of con-
tinued hemorrhage. Serious bleeding requires cessation of
UFH therapy, whereas truly life-threatening bleeding (eg,
intracranial hemorrhage or hemorrhage associated with
hemodynamic instability) may require immediate reversal of
UFH with protamine sulfate. One milligram of protamine
sulfate per 100 units of UFH (50 mg protamine sulfate for a
5000-unit dose of UFH), given intravenously over 10 minutes
(to avoid hypotension), will neutralize UFH given 30 minutes
earlier. The dose of protamine sulfate should be reduced
depending on the time interval from UFH administration
(eg, give 50% of the dose if 60 minutes have elapsed and 25%
if 2 hours have elapsed), and for reversal of continuous-
infusion UFH, the dose of protamine sulfate should be esti-
mated based on the UFH infused in the preceding 2–3 hours.
Since protamine sulfate has a shorter half-life than UFH,
the dose may need to be repeated. Side effects of prota-
mine sulfate include hypotension with rapid administra-
tion and prolongation of the aPTT (with possible bleeding)
if excess protamine is given. Recombinant platelet factor
4 (2.5–5 mg/kg) has been reported to be effective for reversal
of UFH as well but is not available everywhere.
Heparin-induced thrombocytopenia (HIT) occurs com-
monly (5–15%) with therapeutic UFH administration, less
commonly with prophylactic UFH, and appears to be more
common with UFH derived from bovine lung than that from
porcine intestine. The onset of thrombocytopenia is usually
between 3 and 15 days after initiation of treatment with UFH
(median 10 days) but may be as short as a few hours in a pre-
viously sensitized individual, particularly if the prior treat-
ment with UFH was within 3 months of reexposure.
Resolution of thrombocytopenia occurs within 4–5 days of
discontinuation of UFH.
Thrombocytopenia in this disorder is immunologically
mediated. Heparin molecules greater than MW 4000 bind to
platelet factor 4 and form complexes to which heparin-
induced antibodies bind. Platelets are activated, resulting in
increased thrombin generation. Thrombosis, usually associ-
ated with very severe thrombocytopenia, occurs in about
0.4% of patients.
Diagnosis is usually made on clinical grounds, but sero-
logic tests are available to confirm the presence of HIT anti-
bodies. Although these tests are sensitive for the presence of
HIT antibodies, they are less specific and therefore must be
interpreted with caution. Prevention of this disorder by
shortening the duration of UFH administration is impor-
tant. Initiation of oral anticoagulants simultaneously with
UFH in patients who will require long-term anticoagulation
will permit a shorter course of UFH and is highly recom-
mended for patients requiring long-term anticoagulation.
Frequent (every 1–2 days) monitoring of the platelet count is
important for identification of patients before thrombosis
occurs. The use of low-molecular-weight heparin (or hepari-
noids) appears to be associated with a lower risk of heparin-
induced thrombocytopenia as well.
Management of HIT is outlined in Table 39–6. Stopping
UFH is the most common intervention, but there appears to
be a marked risk in clinically significant thrombosis in the
Table 39–5. Endogenous factors modifying the
anticoagulant effect of heparin.
Factor Mechanism 
Platelets Bind and protect factor Xa from heparin. 
Produce platelet factor 4 and neutralizes
heparin. 
Fibrin Binds thrombin and protects if from heparin.
Endothelial surfaces Bind thrombin and protects it from heparin. 
Bind and neutralize heparin via displaced 
platelet factor 4.
Plasma proteins Bind and neutralize heparin. 
Antithrombin 
(antithrombin III)
Hereditary or acquired deficiency state results
in heparin resistance. 
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week after cessation of UFH. Warfarin may aggravate throm-
bosis and should be delayed until the platelet count is over
100,000/μL. There are two anticoagulants currently approved
in the United States for use in HIT—lepirudin (a recombi-
nant hirudin) and argatroban (a selective direct thrombin
inhibitor)—that should be considered even without overt
thrombosis. Bivalirudin (another hirudin analogue), which
is approved in the United States as an alternative to heparin
in patients undergoing percutaneous coronary interventions,
appears to be promising, and because it has only minor renal
excretion, it may be preferable to lepirudin in patients with
significant renal impairment. Anticoagulation with the alter-
native agent should be continued until the platelet count has
returned to normal. Ancrod also has been used for treatment
of HIT but is not available in the United States.
If anticoagulant therapy is necessary in a patient with a
suspected history of HIT (without complicating thrombo-
sis), heparin-dependent antibodies (platelet activation assay
or antigen assay) may help to determine the risk of reexpo-
sure to heparin. If negative, short-term treatment with UFH
with careful monitoring may be acceptable. Patients with a
history of HIT-associated thrombosis should be considered
for treatment with anticoagulants other than heparin.
Other adverse effects of UFH include transient elevation of
liver function tests (particularly ALT and AST), hyperkalemia,
osteoporosis (owing to heparin binding to osteoblasts that
release factors that stimulate osteoclasts; clinically significant
with long-term UFH administration), skin necrosis, alopecia,
hypersensitivity reactions, and hypoaldosteronism.
Low-Molecular-Weight Heparins (LMWHs)
LMWHs are prepared by depolymerization of UFH by
chemical or enzymatic means. Like UFH, LMWH accelerates
antithrombin-mediated inactivation of factor Xa, but unlike
UFH, LMWH does not inactivate thrombin because it lacks
the additional 13 saccharides required for heparin to form a
complex with AT. Because it binds less strongly to plasma
proteins, cells, and thrombin, LMWH has greater bioavail-
ability at low doses, a longer half-life, and a more predictable
anticoagulant response than UFH. LMWH can be adminis-
tered subcutaneously at a fixed dose (adjusted for weight)
1. Monitor platelet counts during heparin therapy every 1–2 days.
2. Exclude other causes of acute thrombocytopenia (other drugs, sepsis, DIC, pseudothrombocytopenia).
3. Evaluate for thrombotic complications (iliofemoral artery occlusion, cerebral infarction, and myocardial infarctions are the most common; other
arterial thromboses and venous thromboses occur less commonly).
4. Do not administer platelet tranfusions (increased risk of thrombosis). 
5. Discontinue heparin (including heparin flushes) for platelet count below 100,000/uL. 
6. Administered alternative anticoagulant until the platelet count has recovered and oral anticoagulation has taken effect, if long-term anticoagulation
is required. Overlap alternative anticoagulant with warfarin for a minimum of 5 days.∗
7. Consider lower extremity ultrasound to assess for subclinical thrombosis.
Anticoagulant Dose/Monitoring 
Lepirudin (a recombinant hirudin
derivative) 
0.4 mg/kg (up to 44 mg) IV bolus followed by 0.15 mg/kg/h. Adjust dose to maintain aPTT 1.5–2.5 times
normal range. May omit bolus in patients with renal failure.
Danaparoid (a heparinoid, available
outside the United States)
2250 units IV bolus followed by 400 units/h for 4 hours, then 300 units/h for 4 hours, then 150–250
units/h. Monitor anti-factor Xa activity (if available), maintain at 0.5–0.8 anti-factor Xa units/mL 
Argatroban (a selective direct thrombin
inhibitor) 
2 μg/kg/min. Adjust dose to maintain aPTT 1.5–3 times control (but <100 seconds) 
Bivalirudin† (an analog of hirudin) 0.2 mg/kg/h. Adjust dose to maintain aPTT 1.5–2.5 times baseline.
Fondaparinux (a synthetic
pentasaccharide)
Not approved for HIT but may be useful as an alternative to heparin in patients with preexisting thrombocy-
topenia to avoid the development of HIT.
∗Do not administer warfarin in patients with heparin-induced thrombocytopenia and deep venous thrombosis until platelet count is
>100,000 (potential risk for venous-limb gangrene). If anticoagulant therapy is necessary in a patient with a suspected history of heparin-
induced thrombocytopenia without complicating thrombosis, laboratory assessment for heparin-dependent antibodies (platelet activation
assay or antigen assay) may help determine risk of reexposure. If negative, short-term treatment with heparin along with careful monitoring
may be acceptable. Patients with a history of hepain-induced thrombocytopenia-associated thrombosis should be considered for alternative
anticoagulants.
†FDA-approved for other indications (angioplasty).
Table 39–6. Management of heparin-induced thrombocytopenia. 
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once or twice daily (dosing depends on specific preparation)
and does not require laboratory monitoring using the aPTT.
These two factors make outpatient use of LMWH possible in
selected situations. LMWH preparations are excreted
renally, and the biologic half-life is prolonged in patients
with renal failure. The incidence of HIT appears to be less
with LMWH than with UFH. LMWH has been used in some
patients with HIT, but thrombocytopenia may persist.
Several LMWH preparations are now approved for use in
the United States: enoxaparin, dalteparin, and tinzaparin.
Selection of one preparation over another is difficult at pres-
ent because few studies comparing different preparations and
dosing regimens have been performed. Cost ultimately may
be as important as any other factor for choosing which
LMWH to use. The major advantage of LMWHs compared
with UFH relates to their convenience of administration, pre-
dictable anticoagulant response at a weight-adjusted fixed
dose, and lack of need for laboratory monitoring. Exceptions
include renal failure and obesity, in which cases monitoring
may be useful. In patients with creatinine clearances of less
than 30 mL/min, anti–factor Xa activity accumulates with
repeated dosing, although this varies among the different
LMWHs. Use of UFH may be preferable in these patients, but
when LMWH is needed, decreasing the dose and monitoring
anti–factor Xa activity should be performed to prevent over-
anticoagulation. Few studies have addressed dosing in very
obese patients. There does not appear to be an increased risk
of bleeding during therapeutic anticoagulation with LMWH
in obese patients, but most studies have included very few
markedly obese patients. Measuring anti–factor Xa activity 4
hours after subcutaneous administration may provide useful
information for dose reduction. Conversely, since obesity is
an independent risk factor for thromboembolism, weight-
based dosing or a 25% increase in fixed-dose LMWH may be
preferable for thromboprophylaxis in very obese patients. A
comparison of UFH and LMWH is presented in Table 39–7.
LMWH is effective for prevention of VTE in patients
undergoing major orthopedic procedures (eg, hip fracture or
replacement or knee replacement) or neurosurgery, after
major trauma (in patients eligible for anticoagulation), and
Unfractionated Heparin (UFH) Low-Molecular-Weight Heparin (LMWH)
Plasma half-life Dose-dependent; range 1–2.5 hours Increased; range 2–6 hours; prolonged in renal failure 
Bioavailability Lower Better 
Molecular weight: range 
(Mean) 
3000–30,000 
(15,000) 
100–10,000 
(4500–5000) 
Binding properties: proteins, cells (macrophages,
endothelium, osteoblasts) 
High Low 
Relative inactivation: Xa/IIa Lower Higher (five to six times compared with
unfractionated heparin)
aPTT Prolonged Not prolonged 
Efficacy Equivalent Equivalent (most situations) 
Major bleeding Approximately equivalent: 0–7% higher
(fatal, 0–2%), higher in acute stroke 
Approximately equivalent: 0–3% (fatal, 0–0.8%),
higher in acute stroke 
Heparin-induced thrombocytopenia 2.5–6% Decreased 
Osteoporosis 30%: decreased bone density; 
15%: vertebral fractures 
2–3%: vertebral fractures in pregnancy 
Decreased 
2.5%: vertebral fractures 
Cost $15/d, full dose >$100/d, full dose 
Reversibility with protamine sulfate (PS) Good: 1 mg PS/100 units UFH (bolus dose);
estimate for infusion based on total amount
in preceeding 2–3 hours.
Fair, not reliable: <8 hours since LMWH at 1 mg/100
anti-factor Xa units (1 mg enoxaparin = 100 units)
>8 hours: smaller dose.
Repeat with 50% of original dose if persistent
bleeding.
Table 39–7. Comparison of  unfractionated heparin and low-molecular-weight heparin.
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in high-risk medical patients (see Table 39-4). LMWH is as
effective as UFH in the treatment of DVT and PE. It can be
administered to outpatients with acute DVT, but treatment
of PE may require hospitalization. LMWH is equivalent in
efficacy to warfarin for prevention of recurrent DVT follow-
ing acute DVT, with a lower incidence of minor bleeding, but
it is much more expensive. There also may be a higher rate of
rebound thromboembolism after discontinuation of the
drug than with warfarin.
The role of LMWH in coronary artery disease continues
to evolve as studies in various clinical syndromes are com-
pleted. LMWH is more effective than UFH in combination
with aspirin in the acute treatment of unstable angina and
non-ST-segment-elevation myocardial infarction. LMWH in
combination with thrombolytic therapy for acute myocardial
infarction has not been studied as extensively as UFH and
cannot be recommended until adequate studies demonstrate
efficacy and safety. LMWH may be used as an alternative to
UFH in patients undergoing PCI but is more difficult to
monitor and adjust than UFH. LMWH is not effective for
prevention of restenosis after coronary angioplasty and does
not reduce post-PCI ischemic events when administered fol-
lowing PCI. The use of LMWH is not recommended for
thromboprophylaxis in patients with prosthetic heart valves
but may be used as bridging therapy for these patients when
oral anticoagulation is temporarily interrupted.
Complications of therapy with LMWH are similar to
those seen with UFH heparin, with the exceptions of throm-
bocytopenia and osteoporosis, which occur less often with
LMWH. There may be less major bleeding in patients treated
for DVT with LMWH, but in most other situations the risk
is approximately equivalent to that seen with UFH. The use
of LMWH and heparinoids in the setting of spinal or
epidural anesthesia—or with spinal puncture—may cause
bleeding in the spinal column with subsequent prolonged or
permanent paralysis. If excessive bleeding does occur, labora-
tory assessment with a anti–factor Xa heparin assay can be
performed. The usual therapeutic range is between 0.5 and
1.0 unit/mL. When heparin anti–factor Xa is greater than
1.0 unit/mL, the aPTT also may be prolonged. Protamine
sulfate is much less effective for reversing the effect of
LMWH than UFH, but if serious bleeding occurs, protamine
sulfate, 1 mg per 100 anti–factor Xa units of LMWH (1 mg
of enoxaparin = 100 anti–factor Xa units), may be given, and
a smaller (50% of the original dose) dose may be given if
bleeding continues. Activated factor VII therapy recently has
been reported to reverse bleeding owing to LMWH, but has
not been adequately evaluated.
 New Anticoagulants
Direct Thrombin Inhibitors
Lepirudin (a recombinant hirudin derivative), bivalirudin
(an analogue of hirudin), and argatroban are direct throm-
bin inhibitors that do not depend on antithrombin to exert
their anticoagulant effects. Unlike heparin, these agents bind
to free and clot-bound thrombin, do not bind to plasma pro-
teins, and are not neutralized by platelet factor 4. Hirudin
and argatroban are approved for use in HIT; bivalirudin is
approved for use as an alternative to heparin in patients
undergoing PCI (see Table 39–6). Studies of these agents in
other clinical settings have not shown clear advantages over
heparin, and there are no antidotes available to reverse the
anticoagulant effects of these drugs should bleeding occur.
Therefore, use of these agents has been restricted to the spe-
cific indications listed earlier. Lepirudin is cleared extensively
by the kidneys, requiring significant dose reduction and care-
ful monitoring in patients with renal impairment.
Bivalirudin has minor renal excretion and may be useful for
patients with impaired renal function as an alternative to lep-
irudin. Argatroban is a carboxylic acid derivative that inter-
feres with thrombin by binding to its active site. Several other
agents in this class are under investigation, some of them well
absorbed from the GI tract (eg, ximelagatran) with a pre-
dictable anticoagulant response, making laboratory moni-
toring unnecessary.
Indirect Thrombin Inhibitors
A. Pentasaccharide Analogues—These are synthetic ana-
logues of the pentasaccharide sequence responsible for bind-
ing heparin to antithrombin. They form a complex with
antithrombin that binds to and inhibits factor Xa; the pen-
tasaccharide is then released and can be reused. Fondaparinux
is the only agent in this class approved for use in the United
States for thromboprophylaxis following major orthopedic
surgery. It is administered subcutaneously once a day, is
excreted renally, and cannot be given to patients with creati-
nine clearances of less than 30 mL/min. Because it does not
bind to platelet factor 4, it should not cause thrombocytope-
nia. Fondaparinux is more effective than enoxaparin for pre-
vention of thromboembolism following major orthopedic
surgery. The rate of major bleeding may be higher than with
enoxaparin but appears to be similar if the first dose is given
6–8 hours after surgery. Fondaparinux is as effective as UFH or
LMWH in the initial treatment of VTE and is under investiga-
tion for patients with acute coronary syndromes. There is no
antidote for fondiparinux, but severe, uncontrolled bleeding is
potentially treatable with recombinant factor VIIa. However,
this extremely expensive agent is not available everywhere.
B. Heparinoids—Heparinoids are low-molecular-weight
glycosaminoglycuronans derived from porcine intestinal
mucosa. Danaparoid is available only outside the United
States for treatment of HIT and is a mixture of heparan sul-
fate, dermatan sulfate, and chondroitin sulfate. The small
heparan sulfate portion of this drug (4% of the total) has a
high affinity for antithrombin and is responsible for the major
anticoagulant effect of danaparoid. Dermatan sulfate also
mediates development of heparin cofactor II–thrombin com-
plexes and contributes to the anticoagulant effect. Danaparoid
has a higher ratio of anti–factor Xa activity compared with
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anti–factor IIa activity (20:1) than UFH (1:1) and LMWH
(2–4:1) and has fewer effects on platelet function than UFH.
It is similar to LMWH in its anticoagulant effects and has
minimal effect on coagulation parameters (ie, aPTT, PT, and
thrombin time), but it has certain structural differences (eg,
contains galactosamine, absent in LMWH) that distinguish it
from LMWH. A functional anti–factor Xa assay using dana-
paroid as the standard can be used to monitor the anticoag-
ulant effect of danaparoid when the agent is given for more
than 3 days. Danaparoid is as effective as lepirudin in the
treatment of HIT with less major bleeding. Danaparoid does
not cross the placenta, so it should be safe for treatment of
HIT during pregnancy.
 Defibrinating Agents
Ancrod, an enzyme derived from the Malayan pit viper, is an
anticoagulant that cleaves fibrinogen and causes hypofib-
rinogenemia. Ancrod is licensed for use in Canada. Ancrod is
an effective anticoagulant that apparently causes minimal
excess bleeding. It is not associated with the development of
thrombocytopenia, is an excellent alternative anticoagulant
for patients with HIT, and has shown some promise in the
treatment of acute ischemic stroke. An initial dose of 1 unit/kg
is infused intravenously over 8–12 hours, followed by daily
maintenance doses adjusted for the level of fibrinogen
(see Table 39–7). Neutralizing antibodies develop with
long-term use, thus limiting its usefulness to situations in
which only short-term anticoagulation is required. An
antivenom is available to reverse its effect, and cryoprecipi-
tate also may be required for fibrinogen replacement if
excessive bleeding occurs.
 Oral Anticoagulants
Warfarin
Warfarin (a 4-hydroxycoumarin compound) is the most
commonly used oral anticoagulant in North America.
Warfarin interferes with the metabolism of vitamin K,
inhibiting reduction of vitamin K to its active form, vitamin
KH2, in a two-step process in the liver. Vitamin KH2 is essen-
tial for posttranslational modification (γ-carboxylation) of
the vitamin K–dependent coagulation factors and natural
anticoagulants (eg, factors II, VII, IX, and X and proteins C
and S). Decreased carboxylation of these important proteins
impairs their biologic function by impeding calcium-
binding capability and induces an anticoagulant effect.
Reduced protein C and S levels have the potential for causing
thrombosis, but in most situations, the anticoagulant effect
predominates.
Warfarin is absorbed rapidly from the GI tract, reaching
peak plasma levels in 90 minutes, circulates bound to plasma
proteins (97% albumin-bound), is metabolized in the liver,
and is excreted in urine and bile. The anticoagulant effect of
warfarin is not immediate. Until carboxylated coagulation
factors are adequately depleted, blood coagulation is normal.
The vitamin K–dependent proteins have plasma half-lives
ranging from 6 hours (factor VII) to 72 hours (prothrombin
and factor II). Proteins C and S have relatively short half-lives
(~8 hours). Because levels of factor VII, protein C, and pro-
tein S fall at about the same time—and 1–3 days before
depletion of the other coagulation factors—a relative hyper-
coagulable state may exist in the first 1–2 days after initiation
of warfarin. Although an observable anticoagulant effect
usually occurs after 2 days, the full antithromboic effect is
delayed for 4–5 days. The delayed effect may be of impor-
tance for patients with HIT and those with inherited or
acquired deficiency of protein C or protein S, who may be
particularly susceptible to warfarin-induced skin necrosis.
Whenever rapid anticoagulation is needed or in patients
with known thrombophilic states (eg, protein C or S defi-
ciency), heparin (UFH or LMWH) should be given for at
least 4 days at the start of warfarin therapy until the interna-
tional normalization ration (INR) is in the therapeutic
range. A loading dose of warfarin should not be given. The
initial dose should be between 5 and 10 mg for most patients
(lower for patients at high risk of bleeding or elderly
patients), with subsequent dosing based on results of the
INR. The average dose required to achieve a therapeutic level
by 4–5 days is 5 mg daily.
The anticoagulant effect of warfarin is assessed by in vitro
coagulation tests, the PT and aPTT. The therapeutic range
for warfarin depends on the indication for which it is used,
but at usual doses, the aPTT is normal or minimally pro-
longed, whereas the PT is maintained at 1.3 (low intensity) to
2.5 (high intensity) times control (PT ratio). Because of
marked interlaboratory variability in the sensitivity of the
thromboplastin reagents used in the PT assay, a standardized
approach has been adopted. This approach requires calibra-
tion of the thromboplastin to a reference preparation using
the international sensitivity index (ISI). Results then are
reported as the INR based on a formula comparing the PT
ratio obtained with the laboratory thromboplastin with that
with the reference thromboplastin. The therapeutic range of
warfarin for most indications ranges from an INR of 2–3
(low intensity) to an INR of 2.5–3.5 (high intensity). If the
thromboplastin reagent used by a clinical laboratory remains
constant, the PT and INR will be predictably related to each
other. Substitution of a reagent with either more or less sen-
sitivity, however, may dramatically alter the relationship of
the PT and INR. The INR is more reliable than the PT and is
the preferred method of reporting for warfarin monitoring.
It is important to fill the collection tube adequately when
measuring the INR because the concentration of the citrate
anticoagulant in the test sample affects the INR. Underfilling
the tube may lead to erroneously high INR results.
Although there is a direct dose-response relation, there is
marked variation in anticoagulant response to warfarin
among patients. There is also significant variability of antico-
agulant response during long-term therapy in individual
patients. This variability results from many factors, including
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endogenous stores of vitamin K, changes in dietary intake or
recent therapeutic administration of vitamin K, genetically
determined differences in warfarin sensitivity, use of antibi-
otics (which may impair synthesis of vitamin K by intestinal
flora) or other drugs (which may increase or decrease war-
farin effect), the presence of liver disease, fat malabsorption
(including obstructive jaundice), hypermetabolic states,
pregnancy, poor patient compliance, and laboratory inaccu-
racy. In addition, elderly patients appear to be more sensitive
to warfarin, possibly owing to decreased clearance of war-
farin with age. Because of this marked variability, continued
monitoring is required, and most patients require dosage
adjustments periodically. Initial monitoring should be per-
formed daily until therapeutic and then two or three times
weekly until the INR is stable. When the PT or INR is stable,
monitoring every 4 weeks is usually adequate, although more
frequent monitoring may increase the amount of time the
PT or INR is in the therapeutic range (time in therapeutic
range [TTR]). Intensity of therapy and TTR are important
determinants of therapeutic efficacy of warfarin. More fre-
quent monitoring is advisable for elderly patients, those who
take multiple medications, or those who are at higher risk for
bleeding.
Although patients taking warfarin are commonly
instructed to limit their intake of vitamin K–rich vegetables,
it is preferable to suggest that the intake of these vegetables
remain relatively constant in the diet because the nutritional
benefits of these foods unrelated to vitamin K may be impor-
tant. Numerous drugs influence the anticoagulant effect of
warfarin through multiple mechanisms, and bleeding unre-
lated to the anticoagulant effect of warfarin may result from
effects on other hemostatic pathways (eg, aspirin and other
antiplatelet drugs and heparin), as well as effects on intestinal
mucosa (eg, aspirin). Before beginning warfarin therapy—or
before adding new medications when a patient is taking
warfarin—a review of potential interactions should be
undertaken (readily available in pharmaceutical handbooks
such as the Physicians’ Desk Reference or other drug com-
pendiums). The frequency of monitoring should be
increased in patients taking warfarin whenever new medica-
tions are started to allow proper dose adjustments.
The decision to use long-term oral anticoagulation is
based on an assessment of the risk to the patient of bleeding
compared with the potential benefits related to its anticoag-
ulant effect. Warfarin is effective for management of multiple
thromboembolic conditions and is used when long-term
anticoagulation is required. Candidates for long-term anti-
coagulation include those with artificial heart valves, chronic
atrial fibrillation, left ventricular mural thrombus, recurrent
cerebrovascular ischemia, and antiphospholipid antibody
syndrome.
The role of warfarin is well established and accepted in
the prevention and treatment of VTE. Long-term use is effec-
tive for prevention of recurrent VTE. Treatment for 3–6
months reduces the risk of recurrent VTE compared with
shorter durations of treatment. Patients with temporary or
reversible risk factors for VTE, such as surgery or trauma,
have a lower risk of recurrence and can be managed with
3 months of warfarin. For patients with idiopathic VTE,
extended treatment duration beyond 6 months reduces the
risk of recurrence but carries an increased risk of serious
bleeding, and when discontinued, the risk of recurrence
increases. Therefore, treatment duration for patients with
idiopathic VTE must take into consideration individual
patient characteristics and preferences. Two years of warfarin
therapy has been shown to reduce the risk of recurrent VTE
significantly (from 8.6–2.2%) in the subset of patients with
factor V Leiden or prothrombin 20210A mutation compared
with 6 months. Patients with antiphospholipid antibodies
have an increased risk of recurrent VTE and mortality (29%
and 15%, respectively) and should be considered for
extended duration of treatment with warfarin. Patients with
cancer have a higher risk of recurrent VTE and also should be
considered for longer term treatment with warfarin. Following
a second VTE, indefinite anticoagulation with warfarin
reduces the risk of recurrence compared with 6 months of
therapy from 20.7–2.6% but is associated with a threefold
increase in the risk of major bleeding. Careful patient
selection and monitoring are needed to balance the benefits
of longer-duration anticoagulation with its risks.
Warfarin is effective for prevention of systemic or cere-
bral emboli in patients with atrial fibrillation, artificial heart
valves, left ventricular mural thrombus, or very low left ven-
tricular ejection fractions. It is also effective for long-term
treatment of patients with peripheral arterial embolism and
may prevent thrombosis of peripheral arterial bypass grafts
in high-risk patients. Antiplatelet agents are preferred over
warfarin for the prevention of acute myocardial infarction in
patients with peripheral arterial disease; for prevention of
stroke, recurrent infarction, or death in patients with acute
myocardial infarction; and for prevention of myocardial
infarction in men at high risk, but cardiac mortality is
reduced in the highest-risk patients by combining low-
intensity warfarin with aspirin. This combination carries a
risk of cerebral hemorrhage if blood pressure is not moni-
tored and controlled. Warfarin is not better than aspirin for
prevention of recurrent stroke, even in patients taking
aspirin at the time of the stroke, but is still recommended by
some neurologists for patients with recent noncardiac
embolic strokes or TIAs. Low-dose warfarin (0.5–1 mg/day)
is often used to prevent thrombosis of vascular access
catheters in cancer patients and to prevent thrombosis asso-
ciated with thalidomide therapy, but efficacy has not been
established for these situations.
The target INR for most indications is 2–3. A higher INR
(2.5–3.5) is recommended for patients with certain pros-
thetic heart valves (eg, tilting-disk and bileaflet mitral valves
and caged-ball or disk valves). Higher-intensity warfarin
may be considered for patients with recurrent VTE occur-
ring on therapeutic doses of warfarin or thrombosis associ-
ated with antiphospholipid antibodies (although this
remains controversial). Lower-intensity warfarin treatment
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(INR 1.5) is recommended when it is combined with aspirin
for prevention of fatal coronary events in patients at very
high risk.
Bleeding is the most common complication of warfarin
and is related to the intensity of the anticoagulation (espe-
cially in patients over 75 years of age), concomitant use of
aspirin, coexisting hemostatic defects (including renal fail-
ure), age over 75 years, history of GI bleeding, cancer, pres-
ence of anemia, and history of stroke or atrial fibrillation. If
GI bleeding or hematuria occurs when the INR is less than
3.0, an underlying GI or renal lesion should be suspected,
although spontaneous bleeding may occur when the INR is
in the high-intensity range or above. Prolonged use (lifelong)
also may increase the cumulative risk of bleeding. Patients
who consume excess alcohol or those who suffer from fre-
quent falls have a much higher risk of serious bleeding. There
are rare patients who have been identified to have mutations
in factor IX that cause an unusual susceptibility to bleeding
without prolongation of the INR.
Overdosage of warfarin (accidental or intentional) may
lead to serious bleeding. Management of hemorrhage associ-
ated with warfarin is similar to that encountered with
heparin in terms of using clinical criteria to determine the
urgency of the situation. Mild excess prolongation of the INR
(<5.0) without hemorrhage should be managed expectantly
by withholding warfarin until the INR returns to the desired
range and then resuming at a lower dose. Serious bleeding
may require immediate reversal with fresh-frozen plasma
(2–3 units) to provide functional vitamin K–dependent fac-
tors. Because vitamin K is a fat-soluble vitamin that is stored
in the liver, reversal of warfarin effects with vitamin K may
result in resistance to subsequent warfarin therapy. Low-dose
oral vitamin K1 (phytonadione, 1–2.5 mg) will lower the INR
to less than 5 in patients with INR values between 5 and 9,
and 5 mg will correct INR values of greater than 9 in the
majority of patients within 24 hours without inducing war-
farin resistance. Intravenous vitamin K1 should be reserved
for patients with an urgent need to reverse anticoagulation—
particularly patients with life-threatening hemorrhage not
controlled by fresh frozen plasma who will not require sub-
sequent warfarin therapy.
Patients receiving chronic warfarin therapy undergoing
invasive procedures likely to cause bleeding may require
interruption of warfarin. Depending on the patient’s risk for
perioperative thromboembolism, coverage with UFH or
LMWH may be necessary until the patient resumes warfarin.
Dental procedures may not require interruption of warfarin;
local hemostasis can be achieved with the use of topical
agents, such as tranexamic acid or aminocaproic acid
mouthwashes. Tables 39–8 and 39–9 summarize guidelines
proposed by the American College of Chest Physicians for
warfarin therapy (ie, dose, monitoring, adjustment, and peri-
operative management). Included in Table 39-9 are sug-
gested strategies for reversal of warfarin when time does not
permit withholding warfarin for several days (eg, for urgent
or emergent surgery).
Warfarin skin necrosis is a rare but serious complication
of warfarin, usually occurring 2–7 days after initiation of
warfarin therapy. Extensive thrombosis of venules and cap-
illaries of subcutaneous fat, particularly in the lower extrem-
ities, buttocks, or breast, appears to be most common in
patients who have an inherited or acquired deficiency of
Initial dose: 5 mg/d (lower in patients who are elderly, on multiple medications, malnourished, or have liver disease).
Check INR daily until therapeutic, then two or three times per week until stable, then every 4 weeks. 
INR Intervention 
Subtherapeutic Increase dose. Continue frequent monitoring until therapeutic. 
Therapeutic (range based on underlying condition
requiring anticoagulation) 
Continue current dose. 
Between therapeutic range and 5 Omit dose. Resume at a lower dose when INR is therapeutic. 
5.0–9.0, no bleeding Omit 1 or 2 doses. Resume at a lower dose when INR is therapeutic
OR give vitamin K1, 1–2.5 mg orally. Resume warfarin at reduced dose
when therapeutic. 
>9.0, no bleeding Hold warfarin, give vitamin K1, 3–5 mg orally. Resume warfarin at
reduced dose when therapeutic. 
>20.0 or serious bleeding Hold warfarin. Give vitamin K1, 10 mg by slow intravenous infusion.
Supplement with fresh frozen plasma or prothrombin complex concen-
trate if needed. 
Table 39–8. Administration and monitoring of warfarin. 
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protein C or protein S. Patients who are known to be defi-
cient in protein C or protein S should receive warfarin only
with simultaneous administration of heparin for at least
5 days to allow for depletion of all the vitamin K–dependent
coagulation proteins to prevent skin necrosis.
Warfarin is teratogenic, resulting in a fetal embryopathy
associated with multiple anomalies when is administered
during the first trimester of pregnancy (estimated incidence
7–28%). Warfarin crosses the placenta and may result in fetal
bleeding. Because of these negative fetal effects, warfarin is
contraindicated between weeks 6 and 12 of pregnancy, and
because it may cause fetal bleeding, it should be avoided near
term. Women of reproductive age who are taking warfarin
should be advised of the teratogenic effects of the drug, and
if pregnancy is contemplated, UFH or LMWH should be
substituted prior to pregnancy (except for women with
mechanical heart valves; see “Antithrombotic Therapy in
Pregnancy”). Warfarin does not cause anticoagulation in
infants who are breastfed by mothers taking warfarin.
Other infrequent side effects of warfarin include alopecia,
GI discomfort, rash, and liver dysfunction. In patients with
underlying arterial vascular disease, warfarin therapy has
been associated rarely with the development of atheroem-
bolic complications, including ischemic toes, livedo reticularis,
gangrene, abdominal pain, and renal and other visceral
infarctions owing to cholesterol emboli. Early reports sug-
gested that chronic warfarin therapy may increase the risk of
bone fractures and osteoporosis, but a meta-analysis of avail-
able studies failed to show a definite association.
Anisindione
Patients who cannot tolerate warfarin may be treated with
anisindione, an oral anticoagulant that is structurally unre-
lated to warfarin but works by a similar mechanism, namely,
inhibition of γ-carboxylation of the vitamin K–dependent
coagulation factors. The drug is well absorbed from the GI
tract, is highly protein-bound, and is metabolized to inactive
metabolites that are excreted in the urine. These metabolites
may cause a red-orange discoloration of the urine. The anti-
coagulant response of anisindione occurs within 20–72
hours, and it is cleared slowly from circulation with a half-life
of 3–5 days. Like warfarin, its anticoagulant effect can be
reversed by vitamin K and fresh-frozen plasma. Anisindione
crosses the placenta and causes fetal malformations and fetal
bleeding, so it should be avoided during pregnancy.
Anisindione is FDA approved for use in myocardial
infarction and venous thrombosis, but there is a lack of good
Low risk for thromboembolism (VTE >3 months ago or atrial
fibrillation without stroke risk factors) 
Stop warfarin 4 days before surgery. Give heparin (UFH or LMWH) briefly at prophylactic
doses and resume warfarin simultaneously in the postoperative period. 
Intermediate risk for thromboembolism Stop warfarin 4 days before surgery. Use low-dose UFH or prophylactic dose of LMWH
starting 2 days before surgery. After surgery, resume warfarin and continue heparin
until INR therapeutic. 
High risk for thromboembolism (VTE <3 months ago; multiple
VTE; mechanical mitral valve; ball-and-cage prosthetic heart
valve) 
Stop warfarin 4 days before surgery. Start full-dose intravenous or subcutaneous
heparin or LMWH when INR falls (usually about 2 days before surgery). Stop heparin before
surgery (5 hours for intravenous or 12 hours for subcutaneous UFH or LMWH). Resume
warfarin and continue heparin postoperatively until INR therapeutic. 
Low risk of bleeding Continue warfarin at lowered dose (INR 1.3–1.5) for 4–5 days before surgery. 
Resume full dose postoperatively. Use prophylactic dose of heparin until INR
therapeutic. 
Dental procedures with low risk of bleeding Continue warfarin at usual dose and INR.  
Dental procedures with higher risk of bleeding Continue warfarin at usual dose and INR. Use tranexamic acid or aminocaproic acid
mouthwash to control bleeding. 
Urgent/emergent surgery (1–8 hours) Vitamin K 10 mg IV over 30 minutes and fresh frozen plasma (2–4 units depending
on INR < or >2.5).
Urgent/emergent surgery (8–12 hours) Vitamin K 10 mg IV over 30 minutes and fresh frozen plasma (2 units if INR >2).
Urgent/emergent surgery (12–24 hours) Vitamin K 10 mg IV or SC; UFH if high risk for thromboembolism until 6 hours before
surgery.
Urgent/emergent surgery (24+ hours) Vitamin K 10 mg SC if INR >2; UFH if high risk for thromboembolism until 6 hours
before surgery.
VTE = venous thromboembolism.  
Table 39–9. Management of warfarin during invasive procedures. 
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clinical studies to support its use as a substitute for warfarin
except for patients who are truly intolerant of warfarin. In
those patients, a loading dose of 300 mg on day one, 200 mg
on day two, and 100 mg on day three is followed by daily
maintenance of 50–250 mg, adjusted according to the INR.
Anisindione may cause myelosuppression, dermatitis, jaun-
dice, and renal insufficiency, which have limited its use.
 Thrombolytic Therapy
Thrombolytic (fibrinolytic) agents differ from other
antithrombotic agents in that they actually dissolve estab-
lished clots rather than interfering with initiation and prop-
agation of thrombosis. The mechanism of action of these
agents is complex and involves many components of the nat-
urally occurring fibrinolytic system. Activation of plasmino-
gen to plasmin (the major fibrinolytic enzyme) is enhanced
by these drugs, accompanied by increased consumption of its
inhibitor (α2-antiplasmin). The net effect is an increase in
free plasmin, which results in degradation of fibrin and other
coagulation factors.
All the available agents cause varying degrees of systemic
activation of the fibrinolytic mechanism and therefore induce
generalized fibrinolysis and fibrinogenolysis and some degree
of platelet dysfunction owing to proteolysis of key membrane
receptors by plasmin, although some are more specific for
plasmin bound to clot (fibrin-specific). These drugs work best
when given soon after onset of symptoms (eg, within 3–4
hours in acute arterial thrombosis, 48 hours for pulmonary
thromboembolism, and 7 days for DVT), before thrombi are
highly cross linked and more resistant to thrombolysis.
Five thrombolytic agents are approved for use in the
United States. Selected features of these agents are outlined in
Table 39–10. Thrombolytic therapy may be used in the treat-
ment of acute arterial thrombosis, including myocardial
infarction and peripheral arterial occlusion, and in the treat-
ment of severe VTE (eg, massive pulmonary thromboem-
bolism with hemodynamic compromise, massive DVT, or
phlegmasia cerulea dolens). Thrombolysis can improve neu-
rologic function in patients with acute nonhemorrhagic stroke
if patients at high risk for bleeding are excluded and if
Drug t1⁄2 (min) 
Fibrin-
Specific 
Indications
(FDA-Approved) 
Neutralizing
Antibodies∗ Typical Dose† Estimated Cost 
Alteplase 5 Yes 
(2+)
Myocardial infarction, acute
cardiovascular accident, pul-
monary thromboembolism 
No Myocardial infarction: 100 mg
infusion over 90 minutes to
3 hours; cerebrovascular
accident: 0.9 mg/kg (maxi-
mum 90 mg) infused over
60 minutes with 10% of total
dose given as an initial bolus 
$2200
Tenecteplase 18–20 Yes 
(3+)
Myocardial infarction. No Single bolus, 30–50 mg
depending on weight in kg
$2200
Reteplase 13–16 Yes
(1+) 
Myocardial infarction No Two bolus injections, 10 units
each given 30 minutes apart 
$2200
Streptokinase 20 No Myocardial infarction (intra-
venous or intracoronary),
deep vein thrombosis, pul-
monary thromboembolism,
catheter thrombosis, periph-
eral arterial occlusion 
Yes 1.5 million units infused over
30–60 minutes intravenously
OR
20,000 units by intracoronary
bolus followed by 2000 to 4000
units/min for 30 to 90 minutes
$300
Urokinase 20 No Myocardial infarction (intra-
coronary), pulmonary
thromboembolism, catheter
thrombosis 
No 6000 units/min infused intra-
coronary for up to 2 hours
OR 
4400 units/kg infused over
10 minutes followed by 4400
units/kg/hr for 12 hours
OR
5000 units for catheter
thrombosis
$4000–$6000 (myocar-
dial infarction, pul-
monary embolus) $60
(catheter thrombosis) 
∗Presence of neutralizing antibodies precludes repeat use within 6–24 months, possibly longer, because of allergic reactions and decreased
effectiveness of the agent.
†Doses may vary depending upon clinical situation.
Table 39–10. Comparison of selected fibrinolytic agents.
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administered within 3 hours of onset of symptoms.
Thrombolytic agents are also used to reestablish patency of
clotted indwelling venous catheters and vascular grafts.
Indications, timing of administration, use of adjunctive
antithrombotic agents, and choice of specific agent for throm-
bolytic therapy are evolving. Thrombolysis reduces mortality
from acute myocardial infarction by about 20–50%. In
patients not undergoing percutaneous transthoracic coronary
angioplasty for acute myocardial infarction, alteplase may be
more effective than streptokinase. Bolus fibrinolytic agents,
reteplase and tenecteplase, are potentially advantageous
because they can be given quickly and could be available in the
prehospital setting. Reteplase appears to be equivalent in safety
and efficacy to alteplase, whereas tenecteplase has a somewhat
lower rate of major bleeding. Any available fibrinolytic agent
may be used with acute myocardial infarction. Although the
newer agents are much more expensive than streptokinase, the
contribution of drug costs to the overall cost of care—particu-
larly for acute myocardial infarction—has not been shown to
be significant. When cost-effective analyses have been done,
streptokinase appears to be marginally more cost-effective than
the other agents but should not be given to patients previously
treated with streptokinase owing to its antigenicity. Urokinase
is used primarily for dissolution of catheter thromboses.
The principal goal of fibrinolytic therapy is to reestablish
patency of an occluded blood vessel (or indwelling catheter).
Fibrinolytic therapy for myocardial infarction results in
angiographically confirmed patency about 50% of the time.
Additional antithrombotic therapy may be required to
improve reperfusion. The role of heparin combined with fib-
rinolytics for patients with acute myocardial infarction is
controversial, and the combination appears to be associated
with a high rate of major bleeding. Ongoing studies are
required to define the optimal use of heparin (UFH or
LMWH) or other anticoagulants such as the hirudin deriva-
tives and heparinoids in combination with fibrinolytic ther-
apy. Antiplatelet agents have been shown to be very
important as an adjunct to fibrinolytic therapy. Platelets play
a key role in the development of coronary thrombosis.
Aspirin and platelet GP IIb/IIIa inhibitors potentiate fibri-
nolysis and improve coronary artery patency rates, although
bleeding complications also may be increased when streptok-
inase is combined with GP IIb/IIIa inhibitors. Large trials
recently completed will provide additional information
about the safety and efficacy of various combinations of
antiplatelet agents and fibrinolytics in the treatment of acute
myocardial infarction. In addition, the combination of
reduced-dose fibrinolytic therapy with invasive coronary
interventions (eg, angioplasty) may improve outcomes.
Further study in this area is needed to define optimal dosing
to enhance coronary artery patency while maintaining an
acceptable rate of hemorrhage.
Alteplase is approved for use in acute nonhemorrhagic
stroke and is effective when administered intravenously
within 3 hours of the onset of symptoms. The risk of intra-
cerebral hemorrhage is 3%, but because it can lead to improved
neurologic function, this may be an acceptable risk. Only an
estimated 2% of all stroke patients are able to receive
alteplase within the 3-hour time frame, limiting its potential
impact on outcomes from stroke. Streptokinase increases
early mortality and intracerebral hemorrhage when used in
the treatment of acute stroke and is not recommended.
Recently, MRI to locate arterial occlusions, followed by
superselective intraarterial thrombolysis, has been suggested
as a potentially beneficial approach for patients with acute
stroke who are more than 3 hours from the onset of symp-
toms. This approach has an even higher risk of hemorrhage
(10% overall), but in centers equipped with a stroke unit and
all necessary personnel and technologic support quickly
available, it may prove to increase the number of patients
who could benefit from thrombolysis for acute stroke.
Fibrinolytic therapy is of limited value in the treatment of
massive PE. Hemodynamic instability and radiographic
changes improve more rapidly than with anticoagulation
only, but there does not appear to be any significant
improvement in overall outcome compared with anticoagu-
lation alone. Fibrinolytic therapy of PE should be considered
for patients with hemodynamic instability, severe gas-
exchange abnormalities, or significant impairment in right
ventricular function. Echocardiography to assess right ven-
tricular function plays a key role in determining the potential
benefit of fibrinolytic therapy or other means of reducing
clot burden (eg, thromboembolectomy). Fibrinolytic therapy
for DVT has not improved outcome over anticoagulation in
most patients, with the possible exception of patients with
severe venous occlusion and threatened gangrene of the
limb. Despite a high rate of clot lysis, there is no good evi-
dence that thrombolytic therapy reduces the rate of post-
phlebitic syndrome following DVT. Furthermore,
hemorrhagic complications are much higher than with stan-
dard anticoagulation in the treatment of VTE.
Fibrinolytic therapy is effective in the treatment of acute
arterial thrombus in medium and large peripheral arteries. A
fibrinolytic agent administered through a catheter proximal
to the clot dissolves it completely about 75% of the time.
Catheter-directed intraarterial administration appears to be
superior to intravenous administration. Thrombolysis
should be considered prior to revascularization surgery as
long as the affected limb is still salvageable. Surgery can be
avoided in 35% of these patients, and overall mortality
appears to be somewhat better than with immediate surgery.
Urokinase, 5000 units, may be instilled into an occluded
venous catheter without excessive pressure, which could dis-
lodge the clot or rupture the catheter. Because venous
catheters may be occluded by substances other than clots (eg,
drug precipitate), urokinase is not always effective.
The most common complication of thrombolytic therapy
is hemorrhage (3–40%). Hemorrhagic complications can be
minimized if patients are selected properly and monitored
carefully. The use of other antithrombotic agents—particularly
heparin—increases the risk of bleeding. Contraindications to
thrombolytic therapy include major ischemic changes or
 CHAPTER 39838
signs of intracranial hypertension on CT scan, seizure at the
onset of a stroke, previous stroke or serious head injury
within the preceding 3 months, active or recent visceral
bleeding, aortic dissection, major surgery, trauma, arterial or
lumbar puncture in the preceeding 2 weeks, severe uncon-
trolled hypertension (>180/110 mm Hg), significant throm-
bocytopenia (platelet count <100,000/μL), signs of
pericarditis, pregnancy, recent retinal laser surgery, cardio-
genic shock (except when owing to massive PE), and the use
of heparin with a prolonged aPTT or oral anticoagulants
resulting in an INR greater than 1.5. Thrombolytic therapy
results in decreased plasma fibrinogen concentration and
increased fibrin degradation products, but these tests are not
predictive of efficacy or clinical bleeding. The bleeding time,
if prolonged, may correlate with minor bleeding but is not
usually monitored.
The thrombin time is the best laboratory test for moni-
toring the status of the fibrinolytic system. When the throm-
bin time is prolonged more than five to seven times normal,
the incidence of bleeding complications increases signifi-
cantly. Intracerebral hemorrhage is more common in patients
who are elderly or underweight, who have prior neurologic
disease, or who are receiving antithrombotic drugs. Women
appear to have a higher risk of intracerebral hemorrhage. If
major bleeding occurs with thrombolytic therapy, the drug
should be stopped immediately. Hypofibrinogenemia can
be reversed with cryoprecipitate, and aminocaproic acid
can be given to inhibit plasmin activity. If the patient is
receiving heparin, protamine sulfate can be used to reverse
its effect.
Other potential adverse reactions to certain thrombolytic
agents (eg, streptokinase and anistreplase) include allergic
reactions and the development of neutralizing antibodies
that preclude repeated usage for 6–24 months and perhaps
longer. Cholesterol emboli rarely may complicate throm-
bolytic therapy, resulting in the “purple toe syndrome” and
multiorgan failure. Arrhythmias may accompany reperfusion
of an ischemic myocardium.
 Antithrombotic Therapy in Pregnancy
Pregnancy and the postpartum period pose special chal-
lenges in the management of thromboembolic disorders. In
addition to the apparent increased risk of venous thrombo-
embolic events, certain pregnancy complications (eg, fetal
loss, preeclampsia, abruption, fetal growth retardation, and
intrauterine death) are associated with maternal throm-
bophilias (eg, antiphospholipid antibodies, factor V Leiden,
prothrombin gene mutation, antithrombin deficiency, and
hyperhomocysteinemia). In addition, women who are taking
warfarin for preexisting conditions (eg, venous thromboem-
bolism or mechanical heart valves) require continued
antithrombotic therapy during this higher-risk period.
Warfarin is contraindicated between 6 and 12 weeks of preg-
nancy because of its teratogenicity and because it may
increase the risk of fetal bleeding. UFH does not cross the
placenta and appears to be safe and effective during preg-
nancy. LMWH and danaparoid have a lower risk of osteo-
porosis and thrombocytopenia than UFH. Dosing may be
adjusted for increasing weight, or anti–factor Xa levels
(drawn 4 hours after morning dose) can be monitored (tar-
get range 0.5–1.2 units/mL). Because these agents do not
cross the placenta, fetal bleeding is not a complication; how-
ever, there have been recent reports of congenital anomalies
with some of the LMWH preparations (eg, enoxaparin and
tinzaparin), and there has been insufficient clinical experi-
ence with danaparoid during pregnancy to determine its ter-
atogenicity. Maternal bleeding occurs with the same
frequency as in other situations requiring anticoagulation
(major bleeding, about 2%). Bleeding can complicate deliv-
ery. The aPTT may not adequately reflect the anticoagula-
tion effect of UFH because of increased factor VIII and
fibrinogen that occurs during pregnancy. When possible,
UFH or LMWH should be discontinued 24 hours before
labor (eg, when electively induced). UFH and LMWH are
not secreted in breast milk, and warfarin does not appear to
cause an anticoagulant effect in babies who are breastfed by
mothers taking warfarin. Guidelines for the management of
antithrombotic agents during pregnancy are outlined in
Table 39-11.
The use of heparin (UFH and LMWH) during pregnancy
appears to be effective for prophylaxis and treatment of VTE.
In women with mechanical heart valves, heparin is not be as
effective as warfarin for prevention of thromboembolic com-
plications, particularly if the aPTT is only moderately ele-
vated. Choices for anticoagulation in these women include
using warfarin (target INR 3.0), except for weeks 6–12 and
near delivery, when UFH can be substituted, to prevent fetal
embryopathy or bleeding, or to use UFH throughout preg-
nancy. If UFH is used, it is imperative that high doses be used
and that the aPTT (6 hours after subcutaneous injection) is
monitored closely. The addition of low-dose aspirin (81–162
mg/day) may reduce the risk of thrombosis but also increases
the risk of bleeding. Maternal and fetal deaths from throm-
botic complications have been reported when enoxaparin
was used for thromboprophylaxis in pregnant women with
prosthetic heart valves; however, the incidence of this com-
plication is not known. The optimal approach for manage-
ment of anticoagulation for women with mechanical valves
during pregnancy is not clear owing to a lack of sufficient
clinical trials.
Low-dose aspirin appears to be safe when administered in
the second and third trimesters to modestly reduce the risk
of preeclampsia and intrauterine growth retardation in high-
risk women and appears to be safe for both mother and fetus.
Additional studies are required to determine the optimal
selection of patients, timing, and dose of aspirin therapy.
Low-dose aspirin combined with heparin reduces the risk of
miscarriage in women with the antiphospholipid antibody
syndrome and recurrent miscarriage, but it is uncertain
whether this strategy is effective in women with other throm-
bophilic conditions.
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Women at high risk for thromboses during pregnancy,
such as those with prior VTE, inherited thrombophilic disor-
ders, and antiphospholipid antibody syndrome (without
prior thrombosis or miscarriage), should be considered for
prophylactic anticoagulation with UFH or LMWH during
pregnancy and the postpartum period. Determining the
optimal management strategy for these patients is difficult
because there are inadequate data available to support spe-
cific recommendations. A discussion of the potential risks
and benefits, known and uncertain, with each patient must
be undertaken at the onset of pregnancy.
 Antiphospholipid Antibody Syndrome
Significant thrombotic events in the presence of the
antiphospholipid antibody syndrome (APLA) pose special
therapeutic challenges. Acute management with heparin may
be complicated by baseline elevation in the aPTT. If baseline
aPTT is prolonged, monitoring should be performed using a
specific heparin assay that depends on factor Xa inhibition
(therapeutic range 0.3–0.7). LMWH can be used without the
need for laboratory monitoring. The optimal intensity and
duration of warfarin therapy (following initial therapy with
UFH or LMWH) for these patients is unclear, but higher-
intensity warfarin (INR at least 3) is probably superior to
lower-intensity warfarin, and longer-duration therapy (2–4
years) offers a lower rate of recurrence than 6 months of
anticoagulation. Low-dose aspirin (81 mg daily) should be
added to oral anticoagulation for arterial thrombosis or for
recurrent VTE despite adequate oral anticoagulation.
Heparin therapy (UFH or LMWH) has been advocated by
some for patients with APLA syndrome, but there is no direct
evidence that it is superior if INR is monitored and adjusted
carefully. Some patients also have hypoprothrombinemia,
with baseline prolongation of the PT, which makes monitor-
ing with INR unreliable. Coagulation tests that are insensi-
tive to the lupus anticoagulant may be required in these
patients (eg, prothrombin-proconvertin test or chromogenic
factor X level). Corticosteroids and immunosuppressive
agents may improve coagulation abnormalities, but the ben-
efits are usually short-lived. If patients have multisystem
involvement, corticosteroids, immunosuppressives, and
plasmapheresis may be beneficial; however, ongoing treat-
ment of the thrombotic diathesis with anticoagulation is
advisable. Management of APLA syndrome during preg-
nancy was discussed earlier.
Table 39–11. Antithrombotic therapy during pregnancy.
Clinical Situation Recommendation
Women on long-term anticoagulation who wish to become pregnant Frequent pregnancy tests; convert to LMWH or adjusted-dose UFH once
pregnant
VTE during pregnancy LMWH or adjusted-dose UFH throughout pregnancy and for at least
6 weeks postpartum
Prior VTE with transient risk factors∗ Close surveillance during pregnancy; postpartum anticoagulation†
Prior VTE with thrombophilia or family history∗ Low- to moderate-dose UFH or LMWH throughout pregnancy; postpartum
anticoagulation
Multiple prior VTE∗ LMWH or adjusted-dose UFH throughout pregnancy; resume long-term
anticoagulation postpartum
Thrombophilia without history of VTE No clinical data to support specific recommendation; consider prophylaxis
for patients with AT deficiency, factor V Leiden or prothrombin G20210A
heterozygotes, homozygous factor V Leiden or prothrombin G20210A
mutation
Mechanical heart valve Options:
1. LMWH, monitor anti-Xa activity
2. Adjusted-dose UFH
3. LMWH or adjusted-dose UFH until week 13; warfarin until mid-third
trimester, resume LMWH or UFH until term
4. Consider adding aspirin, 75–162 mg/day for high-risk women
∗Recommendations should be individualized; very low recurrence of VTE in small study of these patients.
†All pregnant women with history of VTE should consider use of graduated compression stockings throughout pregnancy and postpartum.
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Immunologically mediated thrombocytopenia is com-
mon in APLA syndrome but generally is mild and does not
require treatment. When severe thrombocytopenia
(<20,000/μL) is present, increased bleeding during anticoag-
ulation may occur. Treatment as for other immune thrombo-
cytopenias should be given to achieve a reasonable platelet
count (ie, >50,000/μL) to decrease the risk of serious hemor-
rhage with concomitant anticoagulation. Catastrophic APLA
syndrome (eg, multiorgan and bowel thrombosis, gangrene,
livedo reticularis, and stroke) requires aggressive therapy
with anticoagulation, plasmapheresis, and immunosuppres-
sive agents but is associated with a high rate of mortality
despite these measures.
 Thrombosis in Cancer Patients
The risk of thrombosis in patients with cancer is significant
and is due to several factors, many of which may be present
simultaneously: activation of coagulation by tumors, throm-
bocytosis, tumor angiogenesis, trapping of cancer cells in the
microcirculation of organs, treatment (ie, chemotherapy and
hormonal therapy), indwelling vascular catheters, obstruc-
tion of venous and lymphatic channels, surgical procedures,
and limited mobility. Postoperative VTE is much higher in
patients undergoing cancer surgery, and recurrence of VTE
after completion of anticoagulation is more common in
patients with cancer. Patients undergoing major cancer sur-
gery, especially when associated with prolonged immobility,
should be considered for thromboprophylaxis with LMWH
postoperatively. Extending the duration of prophylaxis from
8–10 days to 4 weeks reduces the risk of VTE from 12–4.8%.
LMWH may be superior to warfarin for the treatment of
established VTE in cancer patients, reducing the rate of treat-
ment failure and improving survival. Studies have shown
conflicting results with LMWH therapy for patients with
advanced malignancy without established VTE. There may
be a small survival advantage for selected patients with bet-
ter initial prognosis, but the risks of bleeding, cost, and
inconvenience to the patient must be considered before initi-
ating therapy. Prevention of catheter-associated thrombosis
has not been studied adequately, but low-dose warfarin ther-
apy may be considered for patients at high risk of clotting.
Patients receiving therapy associated with an increased rate
of thrombosis should be educated about symptoms of VTE
and monitored closely. Prophylactic dose LMWH may be
useful for the prevention of thrombosis associated with thali-
dodmide therapy for multiple myeloma, whereas low-dose
warfarin, although used frequently, has not yet been shown
to be effective.
 Future Directions
There are several exciting active areas of research in the
field of antithrombotic therapy. Many new agents are in
various stages of development. Modifications of existing
antithrombotic agents may serve to increase the predictabil-
ity of anticoagulant effect, improve bioavailability and con-
venience, and decrease complications. Combinations of
various antithrombotic agents are under investigation in an
attempt to improve efficacy while maintaining an acceptable
risk for hemorrhage.
Several classes of anticoagulants are under active inves-
tigation: inhibitors of the factor VIIa–tissue factor pathway,
factor Xa inhibitors, and direct thrombin inhibitors. One of
the most promising agents had been an orally active throm-
bin inhibitor, ximelegatran. The development of an orally
active agent with a more predictable anticoagulant response
would be a major advance over warfarin for the outpatient
management of thromboembolic disease. Ximelegatran is
metabolized to melagatran (the active agent), has a pre-
dictable anticoagulant response at a fixed dose, and does
not require monitoring. It had been shown to be effective
and safe for postoperative thromboprophylaxis and treat-
ment of VTE, atrial fibrillation, and acute coronary syn-
dromes (combined with aspirin). Unfortunately, liver
toxicity led to this drug being withdrawn from the market
worldwide in 2006.
In addition to new anticoagulants, attempts to augment
the naturally occurring anticoagulant pathway of protein C
and the fibrinolytic system may prove useful. Recombinant
activated protein C has been tested in patients with sepsis
and has been shown to decrease mortality; however, it may
increase the risk of bleeding. New antiplatelet agents, includ-
ing additional platelet GP IIb/IIIa receptor inhibitors, are
also being studied.
While endeavoring to improve the benefit-risk ratio of
antithrombotic therapy, cost-effectiveness holds major
importance in the future of antithrombotic therapy. The
indications for antithrombotic therapy are continuously
expanding, and the cost of many new agents is very high.
It is important that any new antithrombotic drug be com-
pared with older, established therapies, with demonstra-
tion of definite advantage, before changing the standard
of care for patients with or at risk for thromboembolic
disease.
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drug-induced, 95
heart block, 491–492
in hemodialysis, 338
in hyperkalemia, 40
in hypokalemia, 36
in hypomagnesemia, 49
postoperative, 518–520, 530, 533
during pregnancy, 494
with pulmonary artery catheter placement,
198–199
sinus bradyarrhythmias, 492
ventricular. See Ventricular arrhythmias
Arsenic poisoning, 670
Arterial insufficiency. See Acute arterial insufficiency
Arterial oxygen content (CaO2), 223–224
Arteriography, bronchial, 544
Artificial airway. See Endotracheal intubation
Ascending cholangitis, 405, 406t
Ascites, 20, 718–719, 718t
Aspergillus/aspergillosis, 605, 738
Aspiration, 97, 300
Aspiration pneumonia, 149–150, 150f, 380. See also
Nosocomial pneumonia
Aspirin
for acute arterial insufficiency, 636
adverse effects, 124t
antiplatelet effects, 823
clinical benefits, 823
nutrient deficiencies caused by, 124t
pharmacology, 822
in pregnancy, 838
resistance to, 823
for ST-segment elevation myocardial infarction,
507, 509
for stroke, 674, 676
for unstable angina or non-STEMI, 503, 505t
Asplenia, 375
Asthma, 152, 534, 538. See also Status asthmaticus
Atelectasis, 145–146, 145f
Atenolol
for myocardial ischemia, 501
for ST-segment elevation myocardial infarction, 509
for unstable angina or non-STEMI, 503
Atlanto-occipital dislocation, 694. See also Cervical spinal 
cord injuries
Atovaquone, 602
Atracurium, 107t, 108, 264
Atrial arrhythmias
in acute myocardial infarction, 509–510
atrial fibrillation, 487–488
atrial flutter, 487
atrial tachycardia, 487
AV nodal or reentrant tachycardia, 486–487
general considerations, 486
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Balloon tamponade, 717
Band ligation, 709, 717
Barbiturates, 111. See also specific drugs
Barium enema, 355
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for beta-blocker overdose, 768
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Beta-adrenergic blockers
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Bismuth subsalicylate, 358
Bisphosphonates, 56, 459, 460t, 461
Bivalirudin
for acute arterial insufficiency, 636–637, 637t
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mechanisms of action, 831
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postoperative
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general considerations, 520
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treatment, 524
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coagulation disorders, 417–420, 420t
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Blood components. See Transfusion therapy
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Bromocriptine, for neuroleptic malignant syndrome, 672
Bronchial arteriography, 544
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infection
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fungal, 738
general considerations, 736–737, 736f
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treatment, 737–738
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escharotomy and fasciotomy, 106, 734–735,
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topical antimicrobial therapy, 735–736
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Calcium, 51–52, 123t. See also Hypercalcemia; Hypocalcemia
Calcium channel blockers
after acute myocardial infarction, 509
in aortic dissection, 485
for heart failure, 473
in hypertensive crisis, 482
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antithrombotic therapy in, 840
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hypoglycemia, 464
hypokalemia, 464
hyponatremia, 463
hypophosphatemia, 464
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lactic acidosis, 464–465
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superior vena cava syndrome, 465–466
tumor lysis syndrome, 46, 462
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Candida albicans, 388, 610
Candida glabrata, 388
Candida krusei, 388
Candida parapsilosis, 388
Candida tropicalis, 388
Candidiasis, 388–389
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Candiduria, 383
CAPD (chronic ambulatory peritoneal dialysis),
334t, 343
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Captopril, 510
Carbapenems, 376–377
Carbon dioxide output (VCO2), 206
Carboprost tromethamine, for postpartum hemorrhage, 818
Cardiac catheterization
for acute myocardial infarction, 507
complications, 482–483
in heart failure, 470
Cardiac compressive shock, 227t, 245–246
Cardiac index, 201t
Cardiac output
during fluid resuscitation for burn 
injury, 732
general considerations, 199–200
in heart failure, 468
measurement methods, 200–201, 201t
during mechanical ventilation, 276
in normal heart, 468
in respiratory failure, 252
Cardiac pacemakers. See Pacemakers
Cardiac tamponade
clinical features, 478–479
essentials of diagnosis, 478
general considerations, 478
imaging studies, 479–480, 479f
postoperative, 531
pulmonary capillary wedge pressure in, 198
surgical evaluation, 533
treatment, 480
Cardiac troponins, in pulmonary embolism, 550
Cardiogenic shock
after acute myocardial infarction, 510–511
causes, 242t
clinical features, 242–243
differential diagnosis, 227t, 243
essentials of diagnosis, 242
general considerations, 242
prognosis, 245
stages, 242
treatment, 243–245, 470, 471–472, 511
Cardiomyopathy, peripartum, 814
Cardiopulmonary bypass
adverse effects, 528–529
circuit-related complications, 527
coagulation parameters, 527
cross-clamp time and hypothermia, 527
fluid and drug administration during, 417
general considerations, 525–527, 526f
platelet dysfunction and, 424
Cardiopulmonary resuscitation, in pregnancy, 806
Cardiothoracic surgery. See also Cardiopulmonary bypass
arrhythmias after, 518–520
bleeding after. See Bleeding, postoperative
cardiac insufficiency after, 529–533
hypercoagulability after, 522–525
Cardiovascular system
age-related changes, 443–444, 444t
in pregnancy, 802
thermal burn injury response, 724–725
Cardioversion, 106, 519–520
Carotid endarterectomy, 655, 676
Caspofungin, 378
Catheter–associated infections
intravenous. See Intravenous catheter–associated infections
urinary. See Urinary catheter–associated infections
CAVD (continuous arteriovenous hemodialysis and 
hemodiafiltration), 334t, 341
CAVH (continuous arteriovenous hemofiltration), 334t,
340–341
Cavitary pneumonia, 147, 148f
Cecal volvulus, 173f
Cefazolin, 339t
Cefepime, 376
Ceftriaxone, 89t
Celecoxib, 316t
Cellulitis, 407, 408t
Central cord syndrome, 693
Central nervous system
dysfunction indicators, 234t
head injury. See Head injury
infections, 677–679
spinal cord, 692f
compression. See Spinal cord compression
disorders/trauma, 132, 283. See also Cervical spinal cord
injuries
thermal burn injury response, 726
tumors, 688–690
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Central venous catheters
clinical applications, 193–195, 194f, 195f
complications, 140–141, 140f, 195. See also Intravenous
catheter–associated infections
for contrast injection, 139
imaging studies, 140–141, 140f
positioning, 140
for potassium administration, 38
Central venous pressure (CVP), 193–195, 194f, 195f
Cephalosporins, 315t, 376
Cerebral contusion, 681
Cerebral edema, 592, 714
Cerebrospinal fluid (CSF), 678–679
Cervical spinal cord injuries
clinical features, 691–693, 692f, 693t
essentials of diagnosis, 690
general considerations, 690–691
imaging studies, 693
pathophysiology, 691
treatment, 693–695
Cesarean section, 806–807, 820
Chagas’ disease, transfusion-associated, 82t
Charcoal, for poisonings, 756, 756t
Chemical burn injury
hydrocarbons, 749
hydrofluoric acid, 749
inhalation of aerosolized chemicals, 749
initial care, 749
ocular injury, 749–750
pathophysiology, 749
phenol, 749
Chest percussion, 265
Chest physiotherapy, 264–265
Chest radiographs, 137
in acute myocardial infarction, 506
in aortic dissection, 516
in ARDS, 160–161, 161f, 301
in aspiration pneumonia, 150, 150f
in asthma, 152
in atelectasis, 145–146, 145f, 146f
in cardiac compressive shock, 245–246
of cardiac pacemakers, 143
in cardiac tamponade, 479
in cardiogenic shock, 243
of central venous catheters, 140, 140f
in COPD, 151, 151f, 291
of endotracheal tubes, 139–140, 256
in heart failure, 469
in infective endocarditis, 368
of nasogastric tubes, 143, 143f
in neuromuscular disease with respiratory failure, 284
in pleural effusions, 162–163
in Pneumocystis pneumonia, 601
in pneumonia, 147–148, 148f
in pneumothorax, 165–166, 165f, 166f
of pulmonary artery catheters, 141, 142f, 196–197
in pulmonary edema, 158–159, 158f
in pulmonary embolism, 153, 154, 550
routine daily, 144
in status asthmaticus, 536
in tuberculosis, 603
Chest tube output, postoperative, 522
Chest wall compliance, 205, 267, 267f
Chest wall disorders. See Thoracic wall disorders
Child-Turcotte-Pugh classification, surgical risk in cirrhosis, 720, 720t
Chlordiazepoxide, 89t
Chloride, 123t, 125t
Cholecystectomy, 349–350
Cholecystitis
acalculous, 182–184, 183f, 655
calculous, 181–182, 182f
clinical features, 701
diagnosis, 701
emphysematous, 375
risk factors, 701
treatment, 183–184
Cholesterol embolization, 325
Cholestyramine, 124t, 769
Cholinergics. poisoning/overdose, 753t
Chromium, 123t
Chronic ambulatory peritoneal dialysis (CAPD), 334t, 343
Chronic anemia, 71–72
Chronic bronchitis, 288. See also Chronic obstructive 
pulmonary disease
Chronic obstructive pulmonary disease (COPD)
acute respiratory failure in
clinical features, 290–291, 290t
differential diagnosis, 291
essentials of diagnosis, 288
general considerations, 5t, 288–289
noninvasive ventilatory support for, 273
pathophysiology, 289
treatment
antibiotics, 292–293
anticholinergics, 291–292
beta-adrenergic agonists, 291
corticosteroids, 292
mechanical ventilation, 274t, 293–294, 294f
oxygen, 291
reminders, 5t
respiratory stimulants and depressants, 294–295
theophylline, 292
definition, 288
imaging studies, 150–152, 151f, 291
nutritional support in, 130
Churg-Strauss syndrome, 327t
Cidofovir, 315t
Cimetidine
adverse effects, 240
for angioedema, 565
drug interactions, 93t
nephrotoxicity, 316t
Ciprofloxacin, 315t, 377
Circulation, Respiration, Abdomen, Motor, Speech (CRAMS) Scale,
11–12, 12t
Cirrhosis
ascites in, 717–719
definition, 714
hepatorenal syndrome in, 719–720
liver resection in, 720–721
preoperative assessment and perioperative management, 720, 720t
variceal bleeding in. See Variceal bleeding
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Cisatracurium, 107t, 108
Cisplatin, 124t, 315t
Citrate, 337
Clarithromycin, 378
Clindamycin
for Pneumocystis pneumonia, 602
protein binding, 89t
resistance to, 376t
Clonidine, 358, 720
Clopidogrel
for acute arterial insufficiency, 636
antiplatelet effects, 824
nephrotoxicity, 316t
pharmacology, 823–824
side effects, 824
vs. ticlopidine, 824t
for unstable angina or non-STEMI, 503, 504, 505t
Clostridium botulinum, 392. See also Botulism
Clostridium difficile–associated diarrhea, 386–387
Coagulation
acquired disorders
clinical features, 419–420, 420t
differential diagnosis, 420
essentials of diagnosis, 417
general considerations, 417–418
pathophysiology, 418–419
treatment, 420–421
inherited disorders
clinical features, 413–414t, 415
controversies and unresolved issues, 417
differential diagnosis, 415
essentials of diagnosis, 412
general considerations, 412
treatment, 415–417, 416t
laboratory tests, 409, 411–412, 411t
Coagulation factors, 410t, 418
Cocaine abstinence syndrome, 763
Cocaine toxicity, 763–764
Coccidioidomycosis, 678
Coccoides immitis, 604–605
Cockroft-Gault equation, 90
Cofactors, 410t
Cognitive Test for Delirium, 432
Colitis, 175–176, 176f, 711
Colloid solutions
for hypovolemia, 18, 18t
for hypovolemic shock, 229, 230
for septic shock, 236
Colonoscopy, 711–712
Coma
brain death in, 662
clinical features
history, 658–659
level of consciousness, 659
localization of brain lesions, 659, 659t
motor systems, 660
oculomotor system, 660
pupillary and ophthalmoscopic evaluation, 659–660, 660t
respiratory and circulatory changes, 660
differential diagnosis, 661–662
drug-induced, 660t
general considerations, 658
hyperglycemic hyperosmolar nonketotic, 593
metabolic, 661, 661t
pathophysiology, 658
in primary brain injury, 661–662
toxic, 661
treatment, 662
Common-mode voltage, 188
Community-acquired pneumonia. See also Pneumonia
clinical features, 363–364, 364t
differential diagnosis, 364
essentials of diagnosis, 362
general considerations, 363
microbiologic etiology, 363, 364t
treatment, 364–365, 365t
Compartment syndrome
abdominal, 701
intraabdominal, 733
Compassion fatigue, 220
Complement activation, 232
Complex partial seizure, 663, 663t. See also Seizures
Compression ultrasonography, 548, 555t
Computed tomography (CT), 138
in acalculous cholecystitis, 183
in acute calculous cholecystitis, 182, 182f
in acute mesenteric ischemia, 174–175, 175f, 649
in acute pancreatitis, 180, 180f, 181f, 346–347
in acute renal failure, 317
in acute respiratory distress syndrome, 161, 164f
in aortic dissection, 485, 485f
in ascites, 718
in asthma, 153
in back pain with suspected malignancy, 455t
in bowel obstruction, 170, 172f
in cervical spine injuries, 693
in chronic obstructive pulmonary disease, 152
in colitis, 176, 176f
in head trauma, 684
in heart failure, 159, 470
in increased intracranial pressure due to malignancy,
456
in intraabdominal abscess, 178, 178f, 373
in obstructive uropathy, 184, 185f
in pancreatic necrosis, 347–348
in pleural effusion, 164, 164f
in pneumonia, 148–149, 149f
in pneumoperitoneum, 168, 169f
in pulmonary embolism, 153, 155, 155f, 553–554
in renal colic, 185, 185f
in septic pulmonary emboli, 157, 157f
in spinal cord compression, 453
in stroke, 674, 675f
in subarachnoid hemorrhage, 687
in surgical infections, 398
in urinary tract infection, 185
Concussion, 681
Confidentiality, in interfacility transport, 210–211
Congenital heart disease, 494, 530
Congestive heart failure. See Heart failure
Conivaptan, 29, 463
Contact dermatitis, 609
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Continuous arteriovenous hemodialysis and hemodiafiltration
(CAVD), 334t, 341
Continuous arteriovenous hemofiltration (CAVH), 334t,
340–341
Continuous positive airway pressure (CPAP)
for ARDS, 302–304, 303f
nasal, 273, 312
for obstructive sleep apnea, 312
Continuous renal replacement therapy (CRRT)
advantages, 340
anticoagulation for, 341–342
continuous arteriovenous hemodialysis and hemodiafiltration, 341
continuous arteriovenous hemofiltration, 340–341
continuous venovenous hemodialysis or hemofiltration, 341
continuous venovenous hemofiltration, 341
disadvantages, 340
hemoaccess, 341
predilution, 342
replacement fluids and dialysate, 342
slow continuous ultrafiltration, 341
types, 340
urea clearance and protein losses, 334t
Continuous venovenous hemodialysis or hemofiltration
(CVVHD/F), 334t, 341
Continuous venovenous hemofiltration (CVVH), 334t, 341
Contrast agents. See Iodinated contrast agents
Contrast nephropathy, 139, 316t, 318, 483
Contrast venography, 643
Contrecoup injury, 681
COPD. See Chronic obstructive pulmonary disease
Copper, 123t, 125
Coprine, 781, 781t, 782
Cor pulmonale, 21
Corneal injury, after thermal burn injury, 743
Coronary angiography, 500, 505t
Coronary angioplasty, 504, 508
Coronary artery bypass grafting (CABG), 504, 505t
Coronary heart disease
anticoagulant therapy in, 827t
myocardial ischemia, 499–502
physiologic considerations, 498–499
postoperative management, 653–654
preoperative risk assessment, 652–653
Cortical necrosis, 326. See also Renal failure, acute
Cortical vein thrombosis, 678
Corticosteroids
for acute adrenal insufficiency, 574–575, 575t
for acute respiratory failure, 263, 292, 307
adverse effects, 28, 263, 538
for angioedema, 565
for hypercalcemia, 56
for hypercalcemia of malignancy, 459, 460, 460t
for increased intracranial pressure due to malignancy, 456
indications, 76t
infections in patients on chronic therapy, 375
muscle weakness and, 282
for myxedema coma, 571, 571t
nutrient deficiencies caused by, 124t
for pemphigus vulgaris, 623
as platelet transfusion alternative, 76t
for Pneumocystis pneumonia, 602
in pregnancy, 816
in sepsis, 362, 701
for septic shock, 237
for spinal cord compression, 453–454
for status asthmaticus, 537–538, 816
for thyroid storm, 568t, 569
Cortisol, 224
Cortrosyn stimulation test, 237
Cough
in hemoptysis, 544
inadequate, in neuromuscular disorders, 281
Coup injury, 681
CPAP. See Continuous positive airway pressure
CRAMS (Circulation, Respiration, Abdomen, Motor, Speech) Scale,
11–12, 12t
Creatinine, 314–315
Creatinine clearance, 317, 445
Critical care. See also Intensive care unit
early identification of problems, 1–2
limits of, 78
recent developments, 2t
scoring systems, 10–12, 11t, 12t
Critical illness myopathy, 282, 669
Critical illness polyneuropathy, 282, 669
Crotalidae, 795–796
CRRT. See Continuous renal replacement therapy
Cryoglobulinemia in, 324–325
Cryoprecipitate, 77–78, 416t, 424
Cryptococcosis, 678
cryptococcal meningitis, in HIV disease, 608
cryptococcal pneumonia, in HIV disease, 604
Crystalloid solutions
excessive administration, 228
for hypovolemia, 17–18, 18t
for hypovolemic shock, 227–229, 228t, 230
for septic shock, 236
CT. See Computed tomography
Cullen’s sign, 346
Cushing’s syndrome, 464
Cutaneous disorders
candidiasis, 610–611
contact dermatitis, 609
drug reactions
erythema multiforme, 615–616, 615t
morbilliform, urticarial, and bullous, 612–614, 613t, 614t
phenytoin hypersensitivity syndrome, 618–619
Stevens-Johnson syndrome, 616–618
toxic epidermal necrolysis, 616–618
exfoliative erythroderma, 614t, 625–626, 625t
generalized pustular psoriasis, 624
graft-versus-host disease, 611–612
miliaria (heat rash), 610
pemphigus vulgaris, 623
purpura
causes, 614t, 619, 619t
in disseminated vascular coagulation, 622. See also
Disseminated intravascular coagulation
general considerations, 619
in leukocytoclastic vasculitis, 620–621, 620t, 621t
CVP (central venous pressure), 193–195, 194f, 195f
CVVH (continuous venovenous hemofiltration), 334t, 341
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CVVHD/F (continuous venovenous hemodialysis or 
hemofiltration), 334t, 341
Cyclodextrin, 110
Cyclooxygenase inhibitors, 822–823. See also Aspirin
Cyclooxygenase pathway, 231–232, 231f
Cyclopeptide (mushroom) poisoning, 780, 781, 781t
Cyclosporine, 93t, 315t
Cysticercosis, 677
Cytochrome P450 (CYP), 82t, 93–94, 446
Cytokines, 231, 297
Cytomegalovirus, 81t
D
Daclizumab, 315t
Dalteparin, 644, 645t. See also Low-molecular-weight heparin
Damping coefficient, 190–192, 191f
Danaparoid, 829t, 831–832
Dantrolene, 116, 672
Dapsone, 315t, 602
Daptomycin, 378
D-dimer test, 411t, 550, 555t
Dead space:tidal volume ratio (VD/VT), 248, 249f
DeBakey classification, aortic dissection, 515
Debridement, of burn wounds, 735
Decision making, in intensive care unit
assessment of patient capacity, 216
health care professional’s role, 219–220
medicolegal aspects, 217
shared, 217
surrogates for, 216–217
withholding and withdrawing treatment,
218–219
Deep venous thrombosis
in cancer patients, 840
clinical features, 547–548, 642–643
controversies and unresolved issues, 561
diagnostic approach, 548
differential diagnosis, 643t
essentials of diagnosis, 545, 640
general considerations, 545–546, 640–641
imaging studies, 548, 643
pathophysiology and pathogenesis, 546, 641–642, 641f
postthrombotic syndrome, 647
in pregnancy, 647, 804
prevention, 559–561, 560t, 640t, 643–645. See also
Antithrombotic therapy
risk factors, 822t
risk stratification, 640, 640t
treatment
anticoagulation, 554–557, 555t, 645
inferior vena cava interruption, 558–559, 647
operative embolectomy, 647
supportive care, 559, 645
thrombolytic therapy, 557–558, 645–647
upper extremity, 642, 642t
Defibrinating agents, 832
Delirium
causes, 433–434, 434t, 447t
clinical features, 432–433
controversies and unresolved issues, 436
differential diagnosis, 433
drug-induced, 434t
in elderly patients, 447–448, 447t
essentials of diagnosis, 431
general considerations, 431
pathophysiology, 431–432
risk factors, 447t
treatment, 434–436
Delta agent, transfusion-associated, 81t
Demeclocycline, for hyponatremia, 463
Dementia, 433
Depression, 433, 436–438
Dermatologic problems. See Cutaneous disorders
Desmopressin (DDAVP)
for acquired coagulation disorders, 421
indications, 76t
for inherited coagulation disorders,
415, 416t
for platelet dysfunction, 423, 424, 425
for postoperative bleeding, 524
Dexamethasone, 568t. See also Corticosteroids
Dexmedetomidine, 435–436
Dextrans 
for acute arterial insufficiency, 636
for deep venous thrombosis prophylaxis, 644
for hypovolemic shock, 229
platelet function and, 423, 825
Dextroamphetamine, 437–438
Dextrose, in total parenteral nutrition, 129
Diabetes insipidus
brain tumor and, 689
central, 30, 30t
clinical features, 32
diagnosis, 31f, 32
nephrogenic, 30t
treatment, 33
Diabetes mellitus
complications in acute illness
diabetic ketoacidosis. See Diabetic ketoacidosis
gastroparesis, 597
hyperglycemia, 594–595
hyperglycemic hyperosmolar nonketotic coma, 593
hypoglycemia, 595–596, 595t, 596t
hyporeninemic hypoaldosteronism, 597
retinal, 597
infections in, 375
new-onset in ICU patients, 134–135
nutritional support in, 133–134
thyroid function in, 578
Diabetic foot infections, 407, 408t
Diabetic ketoacidosis
clinical features, 584–587, 585t, 586t
complications, 591–592, 591t
controversies and unresolved issues
acute respiratory distress syndrome, 591–592
cerebral edema, 591
fluid replacement, 591
differential diagnosis, 587
essentials of diagnosis, 581
general considerations, 5t, 581
hypophosphatemia during treatment, 43
metabolic acidosis in, 61, 61t
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Diabetic ketoacidosis (Cont.):
pathophysiology, 581–584, 582f, 582t, 583t
potassium supplementation in, 39
precipitating factors, 584, 585t
treatment
algorithm, 588f
bicarbonate, 590
correction of hyperglycemia, 587–588, 588t
correction of ketosis, 588–589
fluid replacement, 589
initial, 587t
insulin, 589–590
monitoring, 587
phosphate replacement, 590–591, 591t
potassium replacement, 590
reminders, 5t
Dialysis. See also Continuous renal replacement therapy;
Hemodialysis; Peritoneal dialysis
drug dosing during, 336
indications, 334–336
stopping, 336
types, 334t
Diaphragm, 100, 283
Diarrhea
classification, 358, 358t
Clostridium difficile–associated, 386–387
definition, 357
diagnosis, 358
pathophysiology, 358
treatment, 358
Diazepam
as anticonvulsant, 665, 665t
pharmacology, 110, 110t
protein binding, 89t
side effects, 110
uses, 110
Diclofenac, 316t
Diffuse axonal injury, 682
Digoxin
for atrial fibrillation, 487, 509–510
for cardiogenic shock, 244
for heart failure after acute myocardial infarction, 510
pharmacology, 495
therapeutic ranges, 92t
toxicity, 495–496
clinical features, 769
controversies and unresolved issues, 771
differential diagnosis, 769
essentials of diagnosis, 768
general considerations, 768–769
predisposing factors, 769t
treatment, 769–771, 770t
Digoxin immune Fab, 495–496, 770–771, 770t
Dihydropyridines, 501
Diltiazem
after acute myocardial infarction, 509
for atrial fibrillation, 487, 510
for AV nodal reentrant tachycardias, 486
contraindications, 502
for myocardial ischemia, 502
Dilute Russell viper venom time, 411t
Diphenhydramine, 240, 563, 565
Diphenoxylate with atropine, 358
Dipyridamole, 652–653, 825
Disopyramide, 316t
Disseminated intravascular coagulation (DIC)
acute renal failure in, 324, 325
causes, 418, 419t
clinical features, 622
coagulation factor consumption in, 418
controversies and unresolved issues, 421–422
essentials of diagnosis, 622
in heat stroke, 787
pathophysiology, 622
postoperative, 429, 429t
treatment, 421, 622
Distributive shock. See Anaphylactic shock; Neurogenic shock;
Septic shock
Diuretics
in ARDS, 307
for ascites, 718
for heart failure, 471, 472, 473, 510
in hypercalcemia, 55
for hypernatremia, 33
for hypervolemia, 21–22
hypocalcemia and, 53
hypokalemia and, 36, 39
metabolic alkalosis and, 64
nephrotoxicity, 315t
nutrient deficiencies caused by, 124t, 131
Diverticulosis, 711
Do not resuscitate/do not attempt resuscitation (DNR/DNAR)
orders, 218
Dobutamine
for calcium channel blocker overdose, 768
for cardiogenic shock, 243–244, 511
for septic shock, 236–237
Dobutamine stress echocardiography, 653
“Doll’s eye” reflex, 660
Dopamine
for anaphylactic shock, 240
for calcium channel blocker overdose, 768
for cardiogenic shock, 244, 472, 511
for septic shock, 236
Doppler ultrasound
in acute arterial insufficiency, 635t
for blood pressure monitoring, 190
for cardiac output measurement, 200
in deep venous thrombosis, 642–643
transcranial, 685, 687
Double product, 498
Doxacurium, 107t, 109
Drotrecogin alfa, 237–238, 362, 701
Drug(s). See also specific drugs
adverse effects
cardiac toxicity, 95
cutaneous reactions
erythema multiforme, 615–616, 615t
morbilliform, urticarial, and bullous, 612–614, 613t, 614t
phenytoin hypersensitivity syndrome, 618–619
Stevens-Johnson syndrome, 616–618
toxic epidermal necrolysis, 616–618
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delirium, 434t
in elderly patients, 446
electrolyte abnormalities, 95
hepatotoxicity, 94–95, 95t
nephrotoxicity, 94, 94t, 315–316t
thyroid dysfunction, 579, 579t
clearance
hepatic dysfunction and, 91, 91t
renal dysfunction and, 90–91, 90t
distribution, 89–90, 89t
in elderly patients, 446
errors, 95–96
interactions
pharmaceutical, 93
pharmacodynamic, 92–93
pharmacokinetics, 93–94, 93t
in pregnancy, 804, 805t
therapeutic ranges, 92, 92t
withdrawal. See Withdrawal
Duchenne’s muscular dystrophy, 672–673
Duke criteria, infective endocarditis, 368, 369t
Dynamic hyperinflation, 268–269, 538–539
Dysfibrinogenemia, 413–414t
E
Echinocandins, 378
Echocardiography
in acute myocardial infarction, 506
in aortic dissection, 484–485, 484f, 516
in cardiac tamponade, 479–480, 479f
in cardiogenic shock, 243, 472
in heart failure, 469
in infective endocarditis, 368, 403, 477–478, 477f
Eclampsia, 809. See also Preeclampsia-eclampsia
Edema
in hypervolemia, 20
pulmonary. See Pulmonary edema
in thermal burn injury, 723–724
Edrophonium test, 670
Effective arterial volume, 15
Elapidae, 795–796
Elderly patients
clinical presentation of disease, 445–446
communication problems, 448–449
delirium, 447–448, 447t
drug therapy, 446
hydration and nutrition, 446–447
immobility, 449–450
physiologic changes
cardiac, 443–444, 444t
pulmonary, 444–445, 445t
renal, 445
Electric shock injury, 798–800, 799t
Electrical burn injury, 750–751, 799
Electrocardiography (ECG), 187–188, 188f
in acute myocardial infarction, 506
ambulatory, for preoperative risk assessment, 652
in cardiac tamponade, 479
in COPD, 291
in digitalis toxicity, 769
in heart failure, 469
in infective endocarditis, 368
in myocardial ischemia, 499–500
in pulmonary embolism, 550
Electroencephalography (EEG), 664, 678
Elimination half-life (t
1/2), 88
Embolic stroke, 674. See also Stroke
Embolism
in acute mesenteric ischemia, 648
air, 141, 195, 199
amniotic fluid, 811
arterial. See Acute arterial insufficiency
pulmonary. See Pulmonary embolism
Embolization
in atrial fibrillation, 488
in infective endocarditis, 368
from prosthetic heart valves, 476
Emergency medical technician (EMT), 213
Emergency Treatment and Active Labor Act (EMTALA), 210
Emesis. See Vomiting
Emphysema, 288. See also Chronic obstructive pulmonary disease
Empyema, 147, 148–149, 149f, 402, 404t
Enalaprilat, 481
Encephalitis, viral, 677
Encephalopathy
hepatic, 131, 715–716
hyponatremic, 25, 27
End-tidal CO2 monitoring, 203–204
End-tidal PCO2, 203
Endocarditis 
after thermal burn injury, 742
clinical features, 367–368, 369t, 476–477
complications, 368
essentials of diagnosis, 367, 474
general considerations, 367, 403
imaging studies, 477, 477f
microbiologic etiology, 367, 403
modified Duke clinical criteria, 369t
pathophysiology, 367
in surgical patients, 403
treatment, 368–369, 404t, 477–478
Endocrine problems
acute adrenal insufficiency. See Adrenal insufficiency, acute
diabetes mellitus. See Diabetes mellitus
sick euthyroid syndrome. See Sick euthyroid syndrome
in thermal burn injury, 726
thyroid storm. See Thyroid storm
Endorphins, 224
Endoscopy
for lower gastrointestinal bleeding, 712
for peptic ulcer bleeding, 707–708, 707t
for variceal bleeding, 709
Endothelium, in hemostasis, 410t
Endotoxin, 360
Endotracheal intubation
air leakage, 103
airway care, 255–256
complications, 256–257
general considerations, 102
imaging studies, 139–140
indications, 255t
nasotracheal vs. orotracheal, 255, 256
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Endotracheal intubation (Cont.):
neuromuscular blocking agents in, 102
risks and benefits, 254–255, 255t
time factors, 102
tube positioning, 103, 139–140, 256
tube size, 102
Enoxaparin. See also Low-molecular-weight heparin
for deep venous thrombosis prophylaxis, 644
for deep venous thrombosis treatment, 645t
for unstable angina or non-STEMI, 504, 505t
Enteral nutrition. See also Nasogastric tubes
after thermal burn injury, 745
feeding tube position, 127
formulas for, 127
lipids, 127
protein, 127
vs. total parenteral nutrition, 126–127
Enteric fistulas. See Gastrointestinal tract, fistulas
Enterobacteriaceae, 376t
Enterococcal infections, 376t, 389–390
Envenomation
marine life, 797–798
snakebite, 795–796
spider and scorpion bites/stings, 796–797
Environmental injuries
chemical burn injury, 749–750
electric shock and lightning injury, 750–751,
798–800
envenomation
marine life, 797–798
snakebite, 795–796
spider and scorpion bites, 796–797
frostbite, 791–793
heat stroke, 786–788
hypothermia. See Hypothermia
near-drowning, 793–794
radiation injury, 800–801
thermal burns. See Thermal burn injury
Epidural hematoma, 681, 681f
Epiglottitis, 153
Epinephrine
for anaphylactic shock, 240
for anaphylaxis, 563
for angioedema, 565
in hypovolemic shock, 224
for status asthmaticus, 537
Epstein-Barr virus, transfusion-associated, 81t
Eptifibatide, 504, 825
Erythema multiforme, 614t, 615–616, 615t
Erythromycin, 89t, 93t, 378
Erythropoietin, 76t, 85
Escharotomy, 106, 734–735, 734f
Escherichia coli
in dialysis-related peritonitis, 339t
in pancreatic necrosis, 348
in pyelonephritis in pregnancy, 812
Esmolol, 481, 517
Esophageal perforation, 402
Esophagogastric varices, 707, 716. See also Variceal bleeding
Estrogens, 76t, 124t
Ethacrynic acid, 89t
Ethambutol, 603
Ethanol, 778–779, 779t
Ethics
conflicts in, 216
in decision making, 216–217
institutional policies, 220, 220t
organ donation, 219
principles, 215–216
in withholding and withdrawing treatment, 218–219
Ethylene glycol poisoning, 61t, 62, 777–779, 778t
Etidocaine, 106t
Euglobulin lysis time, 411t
Exchange transfusion, 73
Exercise stress ECG, 500, 652
Exfoliative erythroderma, 614t, 625–626, 625t
Expectorants, 265
Expiratory airway pressure, 205
Extended-spectrum β-lactamases, 390–391
Extracellular space, 15
Extracorporeal membrane oxygenation, 274
Exudative diarrhea, 358t
Exudative pulmonary edema. See Acute respiratory 
distress syndrome
F
Facet dislocation, 695. See also Cervical spinal cord injuries
Factor II deficiency, 413–414t, 416t
Factor IX concentrates, 76t
Factor V deficiency, 413–414t, 416t
Factor VII concentrate, 76t
Factor VII deficiency, 413–414t, 416t
Factor VIII deficiency, 412, 413–414t, 416t
Factor IX deficiency, 412, 413–414t, 416t
Factor X deficiency, 413–414t, 416t
Factor XI
concentrate, 76t, 416t
deficiency, 413–414t, 416t
Factor XIII
concentrate, 76t
deficiency, 413–414t, 416t
in hemostasis, 410t
Famciclovir, for herpes zoster, 627
Fasciotomy, 735
Fear. See Anxiety and fear
Febrile-associated transfusion reaction (FATR), 83t
Feeding tubes. See Nasogastric tubes
Felodipine, 501
Fenoprofen, 316t
Fentanyl, 104–105, 111t, 112–113
Fetus
monitoring in pregnant ICU patient, 804, 820
radiation exposure, 804–805, 805t
traumatic injury, 818–820
Fever
new, in ICU patient, 379
noninfectious causes, 392t
recurrent or persistent, 7t
Fiberoptic bronchoscopy, 265. See also Bronchoscopy
Fibrin degradation products, 411t
Fibrin glue, 76t
Fibrinogen, 410t, 411t
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Fibrinogen concentrate, 76t, 416t
Fibrinogen deficiency, 413–414t, 416t
Fibrinolysis, 410t, 411t, 412
Fibrinolytic therapy. See Thrombolytic therapy
Fick method, cardiac output measurement, 200–201
First-degree burns, 728, 730t. See also Thermal burn injury
Flail chest, 286, 287
Flecainide, 487, 496
Flexion teardrop fractures, 695. See also Cervical 
spinal cord injuries
Fluconazole, 377, 389, 604
Fluid flux, 223
Fluid management
in acute renal failure, 320, 330–331
in ARDS, 308
in elderly patients, 446–447
in hypercalcemia of malignancy, 460
in tumor lysis syndrome, 462
Fluid replacement
for acute adrenal insufficiency, 575
for diabetic ketoacidosis, 589, 592
for hypernatremia, 32–33
for hypovolemia, 17–19, 18t, 19t
Fluid resuscitation
in acute pancreatitis, 348
in cardiac compressive shock, 246
in cardiogenic shock, 243, 511
in electrical burn injury, 750
in hypovolemic shock, 227–229, 228t
in lower gastrointestinal bleeding, 710–711
in neurogenic shock, 241
in sepsis, 361–362
in septic shock, 235–236, 238
in thermal burn injury, 730–734, 731t, 732t
in upper gastrointestinal bleeding, 704–705
Fluid volume, 14. See also Hypervolemia; Hypovolemia
Flumazenil, 755
Fluoroquinolones, 93t
Fluoxetine, 438
Focal segmental glomerulosclerosis, 329
Folate, 122
Folic acid, 122t
Fomepizole, 779
Fondaparinux, 831
in coronary heart disease, 504
for deep venous thrombosis prophylaxis, 559, 560t, 645
for heparin-induced thrombocytopenia, 829t
Foscarnet, 315t
Fosphenytoin, 665, 665t
Fournier’s gangrene, 407
Fractional excretion of sodium (FE
Na), 316
Fractional excretion of urea (FEUr), 316
Frank-Starling curve, 471, 471f
Frostbite, 791–793
Functional residual capacity, 99
Fungal pneumonia, in HIV disease, 604–605
Furosemide
for ascites, 718
for heart failure, 471, 472, 510
for hypercalcemia, 56
for hypercalcemia of malignancy, 460t
for hypervolemia, 21
for hyponatremia, 28
for oliguria, 330
protein binding, 89t
for pulmonary edema in pregnancy, 814–815
G
Gallium nitrate, 56, 460t
Gallstone ileus, 352
Ganciclovir, 315t
Gastric lavage, 755–756, 755t, 757
Gastrointestinal dialysis, 756
Gastrointestinal tract
bleeding
lower
causes, 711, 711t
diagnosis, 711–712
essentials of diagnosis, 710
general considerations, 710
initial approach, resuscitation, and risk stratification,
710–711
treatment, 712–713, 712f, 713f
upper
causes, 705–706, 705t
clinical features, 703, 716
differential diagnosis, 716
essentials of diagnosis, 703, 716
general considerations, 6t, 703, 716
initial evaluation, 6t, 703–704, 704t
preventive treatment, 3, 427–428
resuscitation, 704–705
risk stratification, 705
treatment
after failed endoscopic therapy, 708–709, 708f, 709–710
algorithm, 705f
peptic ulcer disease, 707–709, 707t
reminders, 6t
variceal bleeding, 709–710, 717
complications
in renal transplant recipients, 343
in thermal burn injury, 743
dysfunction indicators, 234t
fistulas
in acute pancreatitis, 350
nutritional support in, 131
risk factors, 700
treatment, 700
ileus. See Ileus
obstructions. See Large bowel obstruction; Small bowel 
obstruction
perforation. See Pneumoperitoneum
thermal burn injury response, 725–726
Gastroparesis, 597
Gentamicin, 92t, 339t
Gitelman’s syndrome, 36, 49, 65
Glasgow Coma Scale (GCS), 11, 11t, 684, 684t
Glomerular filtration rate (GFR), 314–315
Glomerulonephritis, 94t, 322t
postinfectious, 323
Glucagon, 244, 768
Glucocorticoids. See Corticosteroids
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Glucose, 123t, 576. See also Hyperglycemia; Hypoglycemia
Glycoprotein IIb/IIIa receptor inhibitors
for acute arterial insufficiency, 636
benefits, 824
characteristics, 825
for unstable angina or non-STEMI, 504, 505t
Goiter, 567
Goodpasture’s syndrome, 327–328, 541
Graft-versus-host disease, 83t, 85, 611–612
Granulocyte transfusion, 72t, 78
Grey Turner’s sign, 346
Growth hormone, for burn injuries in children, 135
Guillain-Barré syndrome, 283, 668–669
H
HAART (highly active retroviral therapy), 599–600
Haemophilus influenzae, 376t
Haloperidol, 89t, 114, 435
Head and neck infections, 400, 401t
Head injury
clinical features, 684–685, 684t
essentials of diagnosis, 680
general considerations, 680
ICU monitoring, 684–685
imaging studies, 681f
nutritional support in, 132
primary injuries, 680–682, 681f
secondary injuries, 682–684, 682t, 683f
treatment, 685–686
Health care agent, 217
Heart block, 491–492, 511
Heart failure
acute renal failure in, 319, 320, 327t
after acute myocardial infarction, 510
causes, 467–468
clinical features, 468–469
differential diagnosis, 470
electrocardiography, 469
essentials of diagnosis, 467
general considerations, 467–468
hepatic dysfunction in, 91
hyperkalemia in, 40
hyperthyroidism and, 567
hypervolemia treatment in, 22
imaging studies, 469–470
indicators, 234t
in infective endocarditis, 368
nutritional support in, 130–131
pulmonary edema in, 158–159, 158f
treatment, 470–473
Heat cramps, 786
Heat exhaustion, 786
Heat rash (miliaria), 610
Heat stroke, 786–788
Helicobacter pylori, 706, 708
Helicopter transport, 209t, 210
Helium-oxygen inhalation, 539–540
HELLP syndrome, 809
Hematemesis, 703. See also Gastrointestinal tract, bleeding
Hematochezia, 703, 710. See also Gastrointestinal tract, bleeding
Hematogenous pneumonia, 380. See also Nosocomial pneumonia
Hematologic system
dysfunction indicators, 234t
in pregnancy, 803
thermal burn injury response, 726
Hematoma
after cardiac catheterization, 482
intracranial, 681, 681f
mediastinal, 140f
Hemodialysis
advantages, 336
anticoagulation for, 337
complications, 338
disadvantages, 336
drug dosing during, 336
drugs removed by, 91, 91t
effectiveness, 336–337
for hyperkalemia, 42
indications, 334–336
for poisoning
principles, 757, 757t
salicylates, 775, 775t
theophylline, 777t
serum albumin in, 120, 121f
stopping, 336
urea clearance and protein losses, 334t
vascular access, 337, 343
Hemodynamic calculations, 201t
Hemoglobin saturation (%Sat Hb), 198
Hemolysis, 326–327, 326t
Hemolytic anemia, 73
Hemolytic transfusion reactions, 79–80
Hemolytic uremic syndrome, 324, 325
Hemoperfusion, 757, 757t, 777, 777t
Hemophilia A, 412
Hemophilia B, 412
Hemoptysis
clinical features, 542
essentials of diagnosis, 540
general considerations, 540
imaging studies, 542–543
pathophysiology and pathogenesis, 540–542, 541t
prognostic signs, 534t
treatment, 543–545
Hemorrhage
in acute pancreatitis, 350
gastrointestinal, 427–428. See also Gastrointestinal tract,
bleeding
in hemodialysis, 338
in heparin therapy, 828
postpartum, 816–818
in thrombolytic therapy, 837–838
in warfarin therapy, 834
Hemostasis
laboratory tests, 409, 411–412, 411t
normal, 409, 410t
preoperative evaluation, 428–429, 429t
Henderson-Hasselbalch equation, 57
Heparin. See Low-molecular-weight heparin; Unfractionated
heparin
Heparin-induced thrombocytopenia, 522, 557, 645, 828–829, 829t
Heparinoids, 829t, 831–832
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Hepatic abscess, 372t
Hepatic encephalopathy, 131, 715–716
Hepatic failure
causes, 714, 715t
clinical features, 714–715, 715t
coma in, 661t
drug clearance in, 91, 91t
drug-induced, 94–95, 95t
essentials of diagnosis, 714
general considerations, 714
indicators, 234t
predictors of poor outcome, 716t
in thermal burn injury, 726
treatment, 715–716
Hepatic steatosis, 599
Hepatitis
A, 81t
alcoholic, 131
B, 81t
C, 81t
G, 81t
Hepatorenal syndrome, 328, 719–720
Hereditary angioedema, 564, 565
Herpes zoster, 626–627
Hetastarch, 229
Highly active retroviral therapy (HAART), 599–600
Histamine H2 antagonists, 240, 563, 565
Histoplasma capsulatum, 604–605
Hospital-acquired pneumonia. See Nosocomial pneumonia
Howell-Jolly bodies, 375
HTLV-1, 81t
HTLV-2, 81t
Human immunodeficiency virus (HIV) disease
acute renal failure in, 329, 329t
CNS disorders, 607
complications of antiretroviral therapy
hyperglycemia and other metabolic disorders, 600
lactic acidosis and hepatic steatosis, 599
cryptococcal meningitis in, 408
overview, 598–599
pulmonary complications
bacterial pneumonia, 603–604
fungal pneumonia, 604–605
Kaposi sarcoma, 605
Pneumocystis pneumonia, 598, 601–602
respiratory failure, 600–601
tuberculosis, 602–603
sepsis in, 605–607
thyroid function in, 579
transfusion-associated, 81t
Hunt and Hess grades, subarachnoid hemorrhage, 687, 687t
Hydralazine
for aortic dissection, 485, 517
for heart failure after acute myocardial infarction, 510
for hypertensive crisis, 481
nutrient deficiencies caused by, 124t
for preeclampsia, 808
protein binding, 89t
Hydrocarbons, cutaneous injury from, 749
Hydrocephalus, 678
Hydrochloric acid, 66
Hydrochlorothiazide, 471
Hydrocortisone
for anaphylaxis, 563
for biphasic anaphylaxis prevention, 240
for myxedema coma, 571, 571t
in total parenteral nutrition solution, 128
Hydrofluoric acid, 749
Hydronephrosis, 184–185, 185f
Hyperbaric oxygen therapy, 371
Hyperbilirubinemia, after liver resection, 721
Hypercalcemia
in acute renal failure, 332
clinical features, 55
essentials of diagnosis, 54
general considerations, 54
of malignancy
clinical features, 457–459
differential diagnosis, 459, 460t
essentials of diagnosis, 457
pathogenesis, 457, 458f, 459t
treatment, 459–461, 460t
pathophysiology, 54–55
risk factors, 54t
treatment, 55–56
Hypercapnia, 249, 249t. See also Acute respiratory failure,
hypercapnic
Hyperchloremic metabolic acidosis, 60
Hyperemia, 723
Hyperglycemia
antiretroviral therapy-related, 599
coma in, 661t
in critical illness, 133–135, 398, 594–595
in diabetic ketoacidosis, 582–583, 582f, 585, 587–588, 661t
hyponatremia and, 25
in malignancy, 464
postoperative, 398
in septic shock, 235, 237
Hyperglycemic hyperosmolar nonketotic coma, 593
Hyperkalemia
in acute renal failure, 314, 331–332
clinical features, 40, 41f
in diabetic ketoacidosis, 591t
drug-induced, 95
essentials of diagnosis, 39, 41f
general considerations, 39
pathophysiology, 39–40
in rhabdomyolysis, 327
transfusion-related, 83t
treatment, 41–42
in tumor lysis syndrome, 462
Hypermagnesemia
clinical features, 51
essentials of diagnosis, 50
general considerations, 50
pathophysiology, 50–51
treatment, 51
Hypermetabolism, after thermal burn injury, 743–744,
747–748
Hypernatremia
clinical features, 30–32, 31f
coma in, 661t
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Hypernatremia (Cont.):
in diabetes insipidus. See Diabetes insipidus
essentials of diagnosis, 29, 31f
general considerations, 6t, 29
pathophysiology, 29–30, 30t
with polyuria, 32
treatment, 6t, 32–33
without polyuria, 32
Hyperparathyroidism, 459, 459t, 460t
Hyperphosphatemia
in acute renal failure, 332
clinical features, 46–47, 46t
essentials of diagnosis, 45
general considerations, 46
treatment, 47
in tumor lysis syndrome, 462
Hypertension
in cocaine intoxication, 764
intracranial. See Intracranial hypertension
in pregnancy. See Preeclampsia-eclampsia
in renal transplant recipients, 344
in sympathomimetic poisoning/overdose, 761
Hypertensive crisis, 480–482
Hyperthermia
in cocaine intoxication, 764
in heat stroke, 787
in sympathomimetic poisoning/overdose, 761
Hyperthyroidism. See Thyroid storm
Hypertonic saline
for fluid resuscitation in burn injury, 731–732, 731t
for hyponatremia, 28
for hypovolemic shock, 228–229
Hypertriglyceridemia, 587, 745
Hyperuricemia, in tumor lysis syndrome, 462
Hyperuricosuria, in tumor lysis syndrome, 462
Hypervolemia
clinical features, 20
essentials of diagnosis, 19
general considerations, 14
with hyponatremia, 28
pathophysiology, 19–20, 20t
treatment, 20–22
Hypoalbuminemia, 76t, 119–121,
120t, 121f
Hypocalcemia
in acute renal failure, 332
clinical features, 53
essentials of diagnosis, 52
general considerations, 52–53
with hyperphosphatemia, 47
with hypomagnesemia, 49, 50, 53
in malignant disease, 461
pathophysiology, 53
in rhabdomyolysis, 53, 327
risk factors, 52t
transfusion-related, 83t
treatment, 53–54
Hypoglycemia
coma in, 661t
in diabetic patients with acute illness, 595–596, 595t, 596t
in malignancy, 464
Hypokalemia
clinical features, 36–38, 37f
in diabetic ketoacidosis, 590, 591t
differential diagnosis, 464
drug-induced, 95, 124t
essentials of diagnosis, 35, 37f
general considerations, 35
in malignancy, 464
pathophysiology, 35–36
treatment, 38–39, 50
Hypomagnesemia
acute myocardial infarction and, 49
clinical features, 49
drug-induced, 124t
general considerations, 48
hypocalcemia and, 49, 53
hypokalemia and, 36, 49
pathophysiology, 48–49, 48t
in total parenteral nutrition, 124
treatment, 49–50
Hyponatremia
in acute adrenal insufficiency, 572
in acute renal failure, 331
clinical features, 25–26, 26f
coma in, 661t
differential diagnosis, 463
drug-induced, 95, 124t
essentials of diagnosis, 24, 26f
general considerations, 6t, 24
in malignancy, 463
pathophysiology, 24–25, 24t
treatment, 6t, 27–29, 463
Hyponatremic encephalopathy,
25, 27
Hypoparathyroidism, 53
Hypophosphatemia
clinical features, 44–45, 44t
in diabetic ketoacidosis, 590–591, 591t
drug-induced, 124, 124t
essentials of diagnosis, 43
general considerations, 43
in malignancy, 464
pathophysiology, 43–44
physiologic effects, 44, 124
in total parenteral nutrition, 124
treatment, 45, 124–125
Hyporeninemic hypoaldosteronism, 597
Hypotension
general considerations, 6t
in hemodialysis, 338
in theophylline poisoning, 776
treatment, 6t
Hypothermia
anesthesia and, 100–101
blood gases in, 253, 790
with cardiopulmonary bypass,
527–529
clinical features, 787–790
controversies and unresolved issues, 791
differential diagnosis, 790
essentials of diagnosis, 788
INDEX 861
general considerations, 788–789
prognosis, 791
transfusion-related, 83t
treatment, 790–791
Hypothyroidism. See Myxedema coma
Hypovolemia. See also Hypovolemic shock
clinical features, 16–17, 223t
with decreased extracellular volume, 15, 15t
definition, 14, 15
in diabetic ketoacidosis, 583–584, 583t
differential diagnosis, 17
essentials of diagnosis, 15
ICU monitoring, 17
with increased or normal extracellular volume, 15t, 16
pathophysiology, 15–16, 15t, 223t
treatment, 17–19, 18t, 19t
Hypovolemic shock
cardiovascular effects, 222–223
cellular and immunologic effects, 224–225
clinical features, 223t, 225–226
controversies and unresolved issues, 230
differential diagnosis, 226, 227t
essentials of diagnosis, 222
gastrointestinal effects, 225
general considerations, 222
hematologic and thrombotic effects, 225
metabolic effects, 223–224
neuroendocrine effects, 224
neurologic effects, 225
pathophysiology, 223t
renal effects, 225
treatment
blood transfusion, 230
colloids, 229
crystalloids, 227–229, 228t
general principles, 226–227
Hypoxemia, 250, 250t. See also Acute respiratory failure,
hypoxemic
in hemodialysis, 338
refractory, 298, 298f
Hypoxia, 250, 661t
I
Ibotenic acid, 781t
Ibuprofen, 316t
Ibutilide, 487
Ifosfamide, 315t
IgG, 76t
Ileus
clinical features, 356
colonic/pseudo-obstruction (Ogilvie’s syndrome), 172,
355–356, 701
controversies and unresolved issues, 356
differential diagnosis, 354, 356
essentials of diagnosis, 355
gallstone, 352
general considerations, 355–356
imaging studies, 170, 172, 174f, 356
pathophysiology, 172
prognosis, 356
treatment, 356
Imaging studies. See also specific conditions
for central venous catheters, 140–141, 140f
chest radiographs. See Chest radiographs
computed tomography. See Computed tomography
contrast agents for, 138–139
for endotracheal and tracheostomy tubes, 139–140
in intraaortic balloon counterpulsation, 141–142
magnetic resonance imaging. See Magnetic 
resonance imaging
for nasogastric tubes, 143–144, 143f
nuclear scintigraphy. See Nuclear scintigraphy
for pulmonary artery catheters, 141, 142f
for thoracostomy tubes, 144
ultrasound. See Ultrasound
Imipenem, 376–377
Immobility, 449–450
Immune-enhancing diet, 134
Immune serum globulin, 76t
Immunologic system
dysfunction indicators, 234t
thermal burn injury response, 726–727
Immunosuppressive agents
for acute glomerulonephritis, 323
nephrotoxicity, 315t
Impedance plethysmography, 548, 643
Incentive spirometry, 265
Indinavir, 315t
Indomethacin, 316t
Infection(s). See also Sepsis
in ARDS, 307
in asplenic patients, 375
botulism. See Botulism
candidiasis. See Candidiasis
central nervous system, 676–679
Clostridium difficile–associated diarrhea, 386–387
endocarditis. See Infective endocarditis
intraabdominal. See Intraabdominal infections/abscess
intravenous catheter–associated. See Intravenous 
catheter–associated infections
meningococcemia, 628–629
in neutropenic patient, 374
in organ transplant recipients, 343, 374–375
in patients on chronic corticosteroid therapy, 375
in patients with diabetes mellitus, 375
pneumonia. See Pneumonia
Rocky Mountain spotted fever, 629
rubeola, 627–628
soft tissue. See Necrotizing fasciitis
surgical. See Surgical infections
tetanus. See Tetanus
thyroid function in, 578
toxic shock syndrome, 630–631
transfusion-associated, 81t
urinary catheter–associated. See Urinary catheter–associated
infections
urinary tract. See Urinary tract infections
varicella-zoster virus, 626–627
vascular graft, 655
Infection control, 9, 391–392, 741
Inflammatory response, 225
Informed consent, 79
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Inhalation injury
clinical features, 740
controversies and unresolved issues, 746–747
essentials of diagnosis, 739
general considerations, 739–740
prognosis, 741
treatment, 740–741
Inhalational pneumonia, 379–380. See also Nosocomial pneumonia
Injury Severity Score (ISS), 12
Inspiratory airway pressure, 205
Inspiratory capacity, 281
Insulin
for diabetic ketoacidosis, 589–590
for hyperkalemia, 42
hypophosphatemia following administration, 43, 45
management in diabetic patients with acute illness, 595–596
for tight glycemic control in ICU patients, 133–135, 398,
594–595
Insulin resistance
after severe injury, 117–118
decrease during acute illness, 595
in diabetic ketoacidosis, 581–582, 582t
metabolic stress syndrome and, 135–136
Integra, 739
Intensive care unit (ICU). See also Critical care
data display, 3
decision making in
assessment of patient capacity, 216
health care professional’s role, 219–220
medicolegal aspects, 217
shared, 217
surrogates for, 216–217
withholding and withdrawing treatment, 218–219
infection control, 9
monitoring techniques, 3
airway CO
2, 203–204
blood pressure. See Blood pressure monitoring
cardiac output. See Cardiac output
central venous catheters. See Central venous catheters
electrocardiography. See Electrocardiography
pulmonary artery catheters. See Pulmonary artery catheters
pulse oximetry, 201–202
respiratory mechanics, 204–205
respired gas analysis, 206–207
transcutaneous blood gases, 204
outcomes and alternatives, 10
patient care recommendations, 2t, 4–7t
problem-oriented medical record in, 2–3
protocols, practice guidelines, and order sets, 8–9
psychosocial needs of patients, 7
quality assurance, 9
staff issues
burnout, 10
communication, 10
controversies and unresolved issues, 441
education and errors, 9–10
intervention, 441
problem identification, 440–441
self-esteem, 440
supportive and preventive care, 3
Interfacility transport. See Transport, interfacility
Interferon, 315t
Interleukin-2, 315t
Intermittent mandatory ventilation (IMV), 270t, 272, 279. See also
Mechanical ventilation
Intermittent positive-pressure breathing, 265
International normalized ratio (INR), 409
Interstitial nephritis, 94t, 322t, 323–324. See also Renal failure, acute
Interstitial pneumonia, 147
Intestinal ischemia. See Acute mesenteric ischemia
Intestinal pseudo-obstruction. See Ileus, colonic ileus/pseudo-obstruction
Intraabdominal compartment syndrome, 733
Intraabdominal infections/abscess
clinical features, 373
essentials of diagnosis, 372
general considerations, 372
imaging studies, 177–179, 178f, 373
microbiologic etiology, 372–373, 372t
pathophysiology, 372t, 403–405, 700
postoperative, 699, 700
treatment, 373, 399, 405
types, 403–404
Intraaortic balloon counterpulsation, 11, 141–142
Intracellular space, 14
Intracranial hematoma, 681, 681f
Intracranial hypertension
in acute hepatic failure, 715–716
due to malignancy
clinical features, 455–456
differential diagnosis, 456
essentials of diagnosis, 454
general considerations, 455
imaging studies, 456
treatment, 456
in head injury
pathophysiology, 682–683, 683f
treatment, 685
Intraperitoneal abscess, 372t
Intrathoracic pressure, 205
Intravenous catheter–associated infections
in central venous catheters, 195
clinical features, 384–385
controversies and unresolved issues, 385–386
differential diagnosis, 385
essentials of diagnosis, 384
general considerations, 384
microbiologic etiology, 384
pathophysiology, 384
prevention, 385–386, 400
in total parenteral nutrition, 129
treatment, 385, 401t
Intravenous immunoglobulin (IVIG), 76t, 316t, 427
Intravenous pyelography, 317, 322
Intrinsic PEEP, 268, 293–294
Inverse-ratio ventilation (IRV), 271
Iodide, for thyroid storm, 569
Iodinated contrast agents
adverse reactions, 138–139
central venous catheters for injection, 139
histamine-mediated reactions, 483
nephrotoxicity, 189, 316t, 318, 483
Iodinated glycerol, 265
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Ion trapping, 757
Ipecac, 755, 757
Ipodate sodium, for thyroid storm, 568–569, 568t
Ipratropium bromide, 261–262, 292, 537
Iris lesions, 615
Iron, 83t, 125
Iron deficiency anemia, 132
Isoniazid, 124t, 603
Isopropyl alcohol poisoning, 62, 779–780
Isoproterenol, 244
Isosorbide dinitrate
for heart failure after acute myocardial infarction, 510
for myocardial ischemia, 500–501
for unstable angina or non-STEMI, 503–504
Isotretinoin, 624
ISS (Injury Severity Score), 12
Itraconazole, 377
J
Jefferson fracture of the atlas, 694. See also
Cervical spinal cord injuries
Justice, 215
K
Kaposi sarcoma, 605
Kerley lines, 158, 158f
Kernohan’s notch phenomenon, 684
Ketamine, 106, 114
Ketorolac, 316t
Ketorolac tromethamine, 106
Ketosis, in diabetic ketoacidosis, 583, 588–589
Kidney, 445, 725
failure. See Renal failure, acute
transplantation. See Renal transplant recipient
King’s College Criteria, outcome in acute hepatic failure, 716t
Koplik’s spots, 627
Kussmaul’s sign, 245
Kyphosis, 286
L
Labetalol
for aortic dissection, 517
for hypertensive crisis, 481
for postoperative hypertension, 654
for preeclampsia, 808
Labor and delivery, 802, 806–807. See also Pregnancy
Lactase deficiency, 357
Lactic acidosis, 61–62, 61t, 464–465, 599
Large bowel obstruction, 169, 170, 173f, 354–355
Laryngeal mask airway (LMA), 102
Laryngoedema, 97
Laryngospasm, 97
Laxatives, nutrient deficiencies caused by, 124t
Lead poisoning, 670
Left ventricular end-diastolic pressure (LVEDP), 198
Legal issues, in interfacility transport, 210
Legionella, 363
Lepirudin
for acute arterial insufficiency, 636–637, 637t
for heparin-induced thrombocytopenia, 645, 829t
mechanisms of action, 831
Leukocytoclastic vasculitis, 620–621, 620t
Leukotriene inhibitors, 264
Leukotriene receptor antagonists, 264
Leuven study, 594
Levalbuterol, 260
Levetiracetam, 665
Levothyroxine (T
4), for myxedema coma, 571, 571t
Lidocaine
in acute myocardial infarction, 508
adverse effects, 489, 496
for pain management, 105
pharmacology, 105, 106t, 496
for premature ventricular contractions, 489
therapeutic ranges, 92t
for ventricular tachycardia, 491
Life support, withholding and withdrawing,
218–219
Life-threatening hemoptysis, 543, 543t. See also Hemoptysis
Lightning injury, 798–800
Limb ischemia. See Acute arterial insufficiency
Linezolid, 376t, 378
Lipids, 123t, 127, 129
Listeria monocytogenes, 678
Lithium, 316t, 568t, 569
Liver disease. See also Hepatic failure
coagulation disorders in, 418
thyroid function in, 578
treatment of bleeding in, 420–421
Liver resection, 720–721
Liver transplantation, 716, 720
Living will, 217
Local anesthetics, 98, 105–106, 106t. See also specific drugs
Loperamide, 358
Lorazepam
as anticonvulsant, 665, 665t
for anxiety, 440
pharmacology, 110–111, 110t
protein binding, 89t
side effects, 111
uses, 110
for withdrawal syndromes, 435
Low-molecular-weight heparin (LMWH)
advantages, 830
complications, 831
for deep venous thrombosis/pulmonary embolism
prophylaxis, 559–561, 560t, 644
treatment, 556, 645, 646t
in hemodialysis, 337
indications, 830–831
mechanisms of action, 829–830
in pregnancy, 838, 839t
vs. unfractionated heparin, 830t
for unstable angina or non-STEMI, 504, 505t
Lugol’s solution, for thyroid storm, 568t, 569
Lung abscess, 147–148, 148f
Lung cancer, 541
Lung compliance
anesthesia and, 99
in ARDS, 298–299, 299f
in mechanical ventilation, 267–268, 267f
monitoring, 205
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Lung-protective strategy, mechanical ventilation, 304–306, 304t, 305f
Lyme disease, transfusion-associated, 81t
M
Macrolides, 376t, 378
Mafenide burn cream, 735, 737
Magnesium
in acute renal failure, 332
in body fluids, 125t
daily requirements, 123t
distribution, 47, 125t
excretion, 47–48
functions, 47, 48
imbalances. See Hypermagnesemia; Hypomagnesemia
intake, 47
losses, 124
normal levels, 124
replacement therapy, 50
Magnesium sulfate
for acute myocardial infarction, 509
for acute respiratory failure, 262–263
adverse effects, 263
for seizure prophylaxis/treatment in preeclampsia-eclampsia,
808, 809
for status asthmaticus, 537
Magnetic resonance imaging (MRI), 138
in back pain with suspected malignancy, 455t
in increased intracranial pressure due to malignancy, 456
in spinal cord compression, 452–453
Malaria, transfusion-associated, 82t
Malignant hypertension, 480–482
Malignant hyperthermia, 115–116, 116t
Malnutrition. See also Nutrition
delayed hypersensitivity in, 121
drug-induced nutrient deficiencies, 124t
in elderly patients, 447
infection risk and, 398
laboratory findings, 121
lean body mass loss in, 121–122
new treatment strategies
albumin, 135
anabolic steroids, 135
beta-adrenergic blockade, 135–136
growth hormone, 135
insulin, 134–135
nutritional support in, 130
symptoms and signs, 121
thyroid function in, 578
treatment in specific diseases
acute hepatic porphyria, 134
burns, 133
cancer, 132
cardiopulmonary disorders, 130–131
diabetes mellitus, 133–134
gastrointestinal disorders, 131
hematologic disorders, 132
hypoalbuminemia, 130
immune-enhancing diet, 134
renal disorders, 132
sepsis and multiple organ failure syndrome, 133
stroke, 133
trauma, 132–133
wound dehiscence and healing, 133
vitamins and minerals, 123–125. See also specific vitamins 
and minerals
Manganese, 123t
Mannitol
for acute arterial insufficiency, 636
for increased intracranial pressure in brain tumor, 689
nephrotoxicity, 315t
for oliguria, 330
for pigment nephropathy, 327
Massive hemoptysis, 542. See also Hemoptysis
Massive pulmonary embolism, 547. See also Pulmonary embolism
Maximum expiratory airway pressure, 205
Maximum inspiratory airway pressure, 205
Mean airway pressure, 268
Mean arterial pressure (MAP), 189
Measles (rubeola), 627–628
Mechanical ventilation
airway pressure-release, 270t, 272
for ARDS, 304–307, 304t, 305f
central venous pressure in, 195f
complications, 275–277, 275t
for COPD exacerbations, 274t, 293–294, 294f
expiratory phase, 269
in inhalation injury, 740–741
inspiratory phase, 269
during interfacility transport, 212
methods
airway pressure-release ventilation, 272
comparison, 270t
extracorporeal membrane oxygenation, 274
high-frequency ventilation, 274
intermittent mandatory ventilation, 272
noninvasive negative-pressure, 272–273
noninvasive positive-pressure. See Noninvasive 
positive-pressure ventilation
pressure-controlled ventilation, 271
pressure-support ventilation, 271–272
volume-present ventilation, 269–271
monitoring, 275, 275t
in muscular dystrophy, 673
neuromuscular blockade in, 107
in neuromuscular disease, 274t, 285
patient-ventilator system, 266
respiratory alkalosis and, 69–70
respiratory mechanics in, 267–269, 267f
in septic shock, 236
for status asthmaticus, 274t, 538–539
tidal volume monitoring, 204–205
variables in, 266t
ventilator capabilities, 269
weaning
methods, 278–279
physiologic assessment, 277, 277t
predictors of success, 277–278, 278t
Mediastinal hematoma, 140f
Mediastinitis, 402–403, 404t
acute necrotizing, 403
Medical director, intensive care unit, 8–10
Medical futility, 216
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Medication errors, 95–96
Medroxyprogesterone acetate, 313
Mee’s lines, 670
Melena, 703. See also Upper gastrointestinal bleeding
Mendelson’s syndrome, 150
Meningitis, 400, 401t, 608
viral, 677
Meningococcemia, 628–629
Meperidine, 111t, 112
Mepivacaine, 106t
Meropenem, 315t, 376–377
Metabolic acidosis
clinical features, 62
controversies and unresolved issues, 63–64
definition, 58
in diabetic ketoacidosis, 583, 585
differential diagnosis, 62–63
elevated anion gap, 61–62, 61t, 778, 778t
essentials of diagnosis, 60
expected response, 59t
general considerations, 60
normal anion gap, 60–61
relationship between pH and HCO3
–, 59t
in septic shock, 235
treatment, 63
Metabolic alkalosis
clinical features, 65–66
definition, 58
differential diagnosis, 66
essentials of diagnosis, 64
expected response, 59t
general considerations, 64
pathophysiology, 64–65, 65t
relationship between pH and HCO3
–, 59t
treatment, 66–67
Metabolism
changes during critical illness
acute-phase response, 117
catabolism and urine urea nitrogen, 118, 126
energy expenditure, 126
hormonal, 117–118
dysfunction indicators, 234t
in hypovolemic shock, 223–224
in septic shock, 233
Metaproterenol, 260
Methadone, 112
Methanol poisoning, 61t, 777–779, 778t, 779t
Methicillin-resistant Staphylococcus aureus (MRSA),
363, 390
Methimazole, for thyroid storm, 568, 568t
Methohexital, 106
Methotrexate, 315t
Methylergonovine, for postpartum hemorrhage, 818
Methylphenidate, 437
Methylprednisolone, 537–538, 565
Metoclopramide, 354, 356
Metolazone, 21, 471
Metoprolol
for myocardial ischemia, 501
for ST-segment elevation myocardial infarction, 508, 509
for unstable angina or non-STEMI, 503
Metronidazole, 387
Micafungin, 378
Midazolam, 89t, 110t, 111
Midline catheter, 384
Miliaria (heat rash), 610
Milk-alkali syndrome, 55, 64
Miller-Fisher syndrome, 669
Milrinone, for cardiogenic shock, 511
Mineralocorticoids, 575, 575t
Minute ventilation, 203, 248, 249f
Mitomycin, 315t
Mitral regurgitation, 198, 475
Mitral stenosis, 198, 475, 494
Mivacurium, 107t, 108–109
Mixed expired PCO2, 203
Mixed venous oxygen saturation (S–VO2), 195, 198
Modified Brooke formula, 731t, 732
Modified fluid gelatin (MFG), 229
Mojave rattlesnake, 795
Molybdenum, 123t
Monitoring
in intensive care unit. See Intensive care unit, monitoring
during interfacility transport, 212
Monoclonal antibodies, 702
Monomethylhydrazine, 781t
Morbilliform eruptions, 612–614, 614t
Morphine
in acute myocardial infarction, 508
epidural, 104, 105
in patient-controlled analgesia, 104
pharmacology, 111t, 112
side effects, 98, 112
uses, 112
MRSA. See Methicillin-resistant Staphylococcus aureus
Mucolytics, 539
Mucormycosis, 591t, 592
rhinocerebral, 375
Multifocal atrial tachycardia, 488
Multiple organ system failure (multiple organ system 
dysfunction syndrome)
in ARDS, 299–300
assessment, 234t
definition, 360
nutritional support in, 133
in septic shock, 233
Murphy sign, 698
Muscarine, 781t, 782
Muscimol, 781t
Muscle relaxants. See Neuromuscular blockade
Muscular dystrophies, 672–673
Mushroom poisoning, 780–783, 781t
Myasthenia gravis, 283, 670–671
Mycobacterium tuberculosis. See Tuberculosis
Mycotic aneurysm, 368
Myocardial depressant factor (MDF), 232–233
Myocardial infarction. See Acute myocardial
infarction
Myocardial ischemia (angina pectoris), 499–502
Myopathies, inflammatory, 671, 672
Myotonic dystrophy, 672–673
Myxedema coma, 570–572, 571t, 661t
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N
Nabumetone, 316t
Nafcillin, 89t
Naloxone, 113–114, 755
Naproxen, 316t
Narcotic analgesia/anesthesia. See Opioid(s)
Nasal continuous positive airway pressure (nasal CPAP), 273, 312
Nasogastric tubes, 143–144, 143f. See also Enteral nutrition
Near-drowning, 793–794
Necrosectomy, pancreatic, 350
Necrosis, pancreatic, 347–348
Necrotizing fasciitis
categories, 407
clinical features, 370–371, 630
differential diagnosis, 371
essentials of diagnosis, 370, 630
general considerations, 370, 630
microbiologic etiology, 370
pathophysiology, 370
prognosis, 371, 407
treatment, 371, 407, 408t, 630
Needle aspiration, pancreas, 348
Neisseria meningitidis, 628
Neostigmine, 701
Nephropathy, contrast-related, 139, 318, 483
Nesiritide, 471, 533
Neurogenic pulmonary edema, 284
Neurogenic shock, 227t, 241–242
Neuroleptic malignant syndrome, 433, 672
Neuromuscular blockade
in anesthesia, 101
commonly used agents, 107t, 108–109. See also specific drugs
complications, 108, 109
in endotracheal intubation, 102
indications, 106–107
in mechanical ventilation, 107, 264
monitoring, 109
respiratory effects, 101
reversal, 110
Neuromuscular disorders
botulism. See Botulism
controversies and unresolved issues, 673
critical illness myopathy, 282, 669
critical illness polyneuropathy, 282, 669
differential diagnosis, 673
Guillain-Barré syndrome, 283, 668–669
inflammatory myopathies, 671–672
muscular dystrophies, 672–673
myasthenia gravis, 283, 670–671
neuroleptic malignant syndrome, 433, 672
pathophysiology, 666–667, 666f
respiratory failure in, 274t
clinical features, 281–284, 282t
diseases causing, 667t
essentials of diagnosis, 280
general considerations, 280, 280t
pathophysiology, 280–281, 280t, 667, 668f
treatment, 284–285
spinal cord compression. See Spinal
cord compression
toxic neuropathies, 669–670
Neuropathy, toxic, 669–670
Neutropenia, 374
Niacin. See Vitamin B
3
Nifedipine, 89t, 501, 808
Nikolsky’s sign, 617, 623
Nitrates, 500–501, 503–504
Nitric oxide
for ARDS, 307
in heat stroke, 788
for perioperative low cardiac output, 532
for pulmonary hypertension, 473
in septic shock, 232
Nitrogen balance, in acute renal failure, 332–333
Nitrogen loss, after thermal burn injury, 745
Nitroglycerin
for acute myocardial infarction, 507, 508
for aortic dissection, 517
for cardiogenic shock, 243, 245, 472
for hypertensive crisis, 481
for variceal bleeding, 717
Nitroprusside
for aortic dissection, 485, 517
for cardiogenic shock, 244, 470, 472
for hypertensive crisis, 481
for septic shock, 237
toxicity, 244
No-reflow phenomenon, 634
Non-ST-segment-elevation myocardial infarction (non-STEMI),
502–504, 505t
Noncardiogenic pulmonary edema, 297. See also Acute respiratory
distress syndrome
Noninvasive positive-pressure ventilation (NiPPV), 273–274
after weaning from mechanical ventilation, 279
negative-pressure, 272–273
for acute respiratory failure in thoracic wall disorders, 287
for COPD exacerbations, 294
for heart failure, 471
for status asthmaticus, 540
negative-pressure, 272–273
positive-pressure, 273–274 
Nonmaleficence, 215
Nonrebreathing mask, 258, 259t
Nonsteroidal anti-inflammatory drugs (NSAIDs)
antiplatelet effects, 822
gastroduodenal ulceration and, 706
nephrotoxicity, 316t
for pain management, 106
Norepinephrine
for anaphylactic shock, 240
for cardiogenic shock, 244
for neurogenic shock, 241
for septic shock, 237
Nortriptyline, 438
Nosocomial pneumonia 
aspiration, 149–150, 150f, 380
clinical features, 380–381
definition, 146
differential diagnosis, 381
essentials of diagnosis, 379
general considerations, 379
hematogenous, 380
INDEX 867
imaging studies, 148
inhalational, 379–380
microbiologic etiology, 380
pathophysiology, 379–380
prevention, 381
treatment, 381
Nuclear scintigraphy, 138
in acalculous cholecystitis, 183, 183f
in acute calculous cholecystitis, 182
in acute renal failure, 184, 318
in intraabdominal abscess, 178
Nutrition. See also Malnutrition
in acute pancreatitis, 349
in acute renal failure, 332–333
after thermal burn injury. See Thermal burn injury,
nutritional support
assessment of needs, 4t, 126
changes during critical illness, 117–118
enteral. See Enteral nutrition
general considerations, 4t
macronutrients, 123t
micronutrients, 123t
outcome predictors, 119–121, 120t, 121f
status indicators, 118–119
total parenteral nutrition (TPN)
after thermal burn injury, 745
catheter placement, 128–129
catheter-related infection in, 129
central route, 128
in diabetes, 134
vs. enteral nutrition, 126–127
formulas for, 128t, 129
hyperphosphatemia in, 46
indications, 127t
lean body mass loss during, 118
ordering, 129–130
peripheral route, 128, 130
in pregnancy, 805–806
in vascular surgery patients, 651–652
vitamins and minerals, 122–125, 122t. See also specific
vitamins and minerals
O
Obesity, 89, 286, 287
Obesity-hypoventilation syndrome, 311, 313
Obstruction, bowel
large, 169, 170, 173f, 354–355
small
clinical features, 352–353, 353f
differential diagnosis, 353–354
essentials of diagnosis, 351
general considerations, 352
imaging studies, 169–170, 171f,
172f, 353
pathophysiology, 169, 352
postoperative, 700
treatment, 354
Obstructive sleep apnea, 273, 310–313
Obstructive uropathy, 184–185, 185f
Obturator sign, 698
Octreotide
for diarrhea in carcinoid tumors, 358
for enteric fistulas, 700
for variceal bleeding, 709, 717
Ocular injury
chemical, 749–750
thermal, 743
Oculocephalic reflex, 660
Ogilvie’s syndrome (colonic ileus), 172,
355–356
Oil of wintergreen, 773
Olanzapine, 435
Omega-3 fatty acids, 127
Omeprazole, 316t
Oncology patient. See Cancer
Opioid(s)
in cardiogenic shock, 243
cardiovascular effects, 98
commonly used, 111t, 112–113. See also specific drugs
epidural and intrathecal, 104–105
intravenous, 104
pharmacology, 111t, 112–113
poisoning/overdose, 759–760
respiratory effects, 100
uses, 112–113
withdrawal, 760
Opioid agonist-antagonists, 113
Opioid antagonists, 113–114
Orellanien, 781t
Orelline, 781t, 782
Organ donation, 219
Organ transplant recipient, 343, 374–375. See also
Renal transplant recipient
Organic osmolytes, 32
Organophosphate poisoning, 783–785
Oscillometry, for blood pressure monitoring,
190
Osler-Weber-Rendu syndrome, 542
Osmolality, 22
Osmolar gap, 778t
Osmotic demyelination syndrome, 27
Osmotic diarrhea, 358t
Osteoclast-activating factor, 457
Overdose. See Poisoning/overdose
Oxacillin, 89t
Oxandrolone, 135, 748
Oxygen delivery, 252–253
Oxygen therapy
for ARDS, 302
complications, 259–260
for COPD exacerbation, 291
delivery devices, 258–259, 259t
inspired oxygen concentration, 257–258,
258f
for obstructive sleep apnea, 312–313
oxygen saturation and oxygen content,
257, 257f
PaO2 and P(A-a)O2, 257
for status asthmaticus, 537
Oxygen uptake (VO2), 206, 224
Oxyhemoglobin dissociation curve, 257f
Oxytocin, for postpartum hemorrhage, 818
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P
Pacemakers, cardiac
after acute myocardial infarction, 511
imaging studies, 143
malfunction, 492–493
PaCO2
age-related changes, 445t
in respiratory failure, 247, 250–251
Pain, 103–104
Pain management
for burn excision and wound debridement, 106
for cardioversion, 106
opioids for. See Opioid(s)
Pamidronate, 56, 461
Pancreatic abscess, 179, 180, 372t
Pancreatic infections/necrosis, 347, 405
Pancreatic insufficiency, 357
Pancreatitis, acute
alcohol consumption and, 345
clinical features, 346–348, 347t
complications, 350
essentials of diagnosis, 345
general considerations, 345–346
in HIV disease, 600
hypocalcemia in, 53
imaging studies, 179–181, 180f, 181f, 346–347
nutritional support in, 131
pathophysiology, 179, 346
postoperative, 345
treatment, 181, 348–350 
Pancuronium, 107t, 108, 264
Pancytopenia (post-chemotherapy), 7t
Pantothenic acid, 122t
PaO2
age-related changes, 444
in oxygen therapy, 257, 257f
in respiratory failure, 247
Papillary muscle rupture, 512
Paracentesis, 22, 718–719
Paralytic ileus. See Ileus
Paranasal sinusitis, 400, 401t
Paraquat poisoning, 327t, 328
Parasitic infections, 82t, 677–678
Parathyroid hormone (PTH), 52, 54, 457, 458f
Parathyroid hormone–related peptide (PTHrP),
55, 457
Parenteral nutrition. See Nutrition
Parkinson’s disease, 283
Parkland formula, 731t
Paroxysmal depolarization shift, 662
Partial seizures, 663, 663t. See also Seizures
Parvovirus B19, 81t
Patient-controlled analgesia (PCA), 104
Patient’s bill of rights, 215, 216t
PCWP (pulmonary capillary wedge pressure), 197–198, 236
Peak airway pressure, 268
PEEP (positive end-expiratory pressure), 302–304, 303f
Pelvic inflammatory disease, 406t
Pemphigus vulgaris, 623
Penicillamine, 124t
Penicillins, 315t, 376t
Pentamidine, 315t, 595, 601–602
Pentasaccharide analogues. See Fondaparinux
Pentobarbital, 666, 685
Peptic ulcer disease, 706–709. See also Upper gastrointestinal bleeding
Percutaneous pyelography, 317
Pericardial effusions, 478. See also Cardiac tamponade
Pericardial tamponade. See Cardiac tamponade
Pericarditis, 512
Periodic lung recruitment, 309
Periorbital cellulitis, 400, 401t
Peripheral nerve stimulator, 109
Peripherally inserted central venous catheter (PICC), 384
Peritoneal dialysis
access, 339
advantages, 338
capabilities, 339
complications, 339–340, 339t
disadvantages, 338–339
urea clearance and protein losses, 334t
Peritoneal lavage
in acute abdomen, 699
in acute pancreatitis, 349
in pregnancy, 820
Peritonitis
dialysis-related, 339t, 340
primary/spontaneous, 372t, 403–404, 406t
secondary, 372t, 405, 406t
tertiary, 405, 406t
Permissive hypercapnia, 305
Personality disorders, 433
PGD
2, 232t
PGE2, 232t
PGF2, 232t
Pharmacodynamics, 88
Pharmacokinetics, 88
absorption, 88
distribution, 89–90
drug clearance, 90–91, 90t, 91t
in elderly patients, 446
parameters, 88
Pharmacotherapy. See Drug(s); specific drugs
Phencyclidine (PCP) intoxication, 762–763
Phenindione, 316t
Phenobarbital
as anticonvulsant, 665, 665t
drug interactions, 93t
nutrient deficiencies caused by, 124t
therapeutic ranges, 92t
Phenol, 749
Phenothiazines, 124t
Phenylephrine, 241
Phenytoin
as anticonvulsant, 665, 665t, 688
drug interactions, 93t
hypersensitivity syndrome, 618–619
nephrotoxicity, 316t
nutrient deficiencies caused by, 124t
protein binding, 89, 89t
therapeutic ranges, 92, 92t
Phlebostatic axis, 193, 193f
Phlegmasia alba dolens, 642
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Phlegmasia cerulea dolens, 642
Phosphodiesterase III inhibitors, 532, 825
Phosphorus
daily requirements, 123t
factors affecting balance, 43
functions, 42
imbalances. See Hyperphosphatemia; Hypophosphatemia
laboratory studies, 43
replacement therapy, 45, 124–125
after liver resection, 721
for diabetic ketoacidosis, 590–591, 591t
for hypercalcemia of malignancy, 460t
Pigment nephropathy, 326–327, 326t
PIOPED (Prospective Investigation of Pulmonary Embolism
Diagnosis), 549, 551t
Pipecuronium, 107t, 109
Placenta, 817, 819
Plasma exchange therapy, 77
Plasma osmolality, 22
Plasma transfusion. See also Transfusion therapy
indications, 72t, 77, 416t
products available, 72t, 75–76, 76t
requirements, 77
Plasminogen, 410t
Plasminogen activator inhibitor, 410t
Platelet(s)
acquired dysfunction, 423–424
in hemostasis, 410t
inherited dysfunction, 422–423, 422t
inhibitors. See Antiplatelet agents
laboratory tests, 411t, 412
in pregnancy, 803
transfusion, 72t, 74–75, 76t, 424. See also Transfusion therapy
Plethysmography, 190, 635, 643
Pleural effusions, 161–164, 164f
Plicamycin, 56, 460t
Pneumocystis pneumonia (PCP), in HIV disease, 598, 601–602
Pneumomediastinum, 166–167
Pneumonectomy, 402
Pneumonia
acute renal failure in, 327t
after thermal burn injury, 742
community-acquired
clinical features, 363–364, 364t
differential diagnosis, 364
essentials of diagnosis, 362
general considerations, 363
microbiologic etiology, 363, 364t
treatment, 364–365, 365t
in HIV disease
bacterial, 603–604
fungal, 604–605
Pneumocystis, 598, 601–602
imaging studies, 146–149, 148f, 149f
nosocomial. See Nosocomial pneumonia
nutritional support in, 130
ventilator-associated. See Ventilator-associated pneumonia
Pneumoperitoneum, 167–168, 168f, 169f
Pneumothorax
with central venous catheter placement, 141
iatrogenic, 165
imaging studies, 164–166, 165f, 166f
with pulmonary artery catheter placement, 198
tension, 165–166, 166f
P(A-a)O2, 257
Poisoning/overdose
diagnosis, 752–754, 753t, 754t
differential diagnosis, 754
serotonin syndrome in, 766–767
specific agents
acetaminophen, 771–773, 772f
antihypertensives, 767–768
arsenic, 670
cocaine, 763–764
digoxin. See Digoxin, toxicity
ethylene glycol, 61t, 62, 777–779, 778t
isopropyl alcohol, 62, 779–780
lead, 670
methanol, 61t, 777–779, 778t, 779t
mushrooms, 780–783, 781t
opioids, 759–760
organophosphates, 783–785
phencyclidine, 762–763
salicylates, 61t, 773–775, 774f, 775t
sedative-hypnotics, 753t, 757–758
sympathomimetics, 753t, 760–761
theophylline, 775–777, 777t
tricyclic antidepressants, 764–766
treatment
airway management, 754
control of seizures, 755
decontamination, 755–757, 755t, 756t
general measures, 754
hemodynamic support, 754–755
opioid and benzodiazepine antagonists, 755
Poliomyelitis, 283
Polymorphonuclear leukocytes, 297
Polymyxin B, 315t
Polyuria, in hypernatremia, 32
Pontine paramedian reticular formation, 660
Porphyria, acute hepatic, 134
Portal hypertension, 707. See also Variceal bleeding
Positive end-expiratory pressure (PEEP), 302–304, 303f
Posterior spinal cord syndrome, 693
Postphlebitic syndrome, 546
Postrenal renal failure, 321–322, 321t. See also
Renal failure, acute
Postthrombotic syndrome, 647
Posttransfusion purpura, 83t
Posttraumatic stress disorder (PTSD), 439
Potassium
in body fluids, 125t
daily requirements, 123t
extracellular-intracellular distribution, 34–35, 35t
imbalances. See Hyperkalemia; Hypokalemia
intake and output, 332t
plasma levels, 34
renal excretion, 34, 35t
replacement therapy, 38–39
supplementation in acute myocardial infarction, 509
total body, 34
Pralidoxime, for organophosphate poisoning, 784
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Praziquantel, for cysticercosis, 677
Prednisone. See also Corticosteroids
for angioedema, 565
for pemphigus vulgaris, 623
for status asthmaticus, 538
Preeclampsia-eclampsia, 807–809
Pregnancy
acute fatty liver of, 809–810
amniotic fluid embolism in, 811
anticoagulant therapy in, 827t, 838–839, 839t
asthma in, 538
cardiac arrhythmias during, 494
congenital heart disease during, 494
deep venous thrombosis in, 647, 804
diabetic ketoacidosis in, 582
general considerations for care in the ICU
cardiopulmonary resuscitation, 806
drugs, 804, 805t
imaging studies, 804–805, 805t
labor and delivery, 806–807
monitoring, 804
patient counseling, 806
position, 804
total parenteral nutrition, 805–806
HELLP syndrome in, 809
physiologic adaptation to
cardiovascular, 802
hematologic, 803
immune, 803–804
respiratory, 802–803, 803f
postpartum hemorrhage, 816–818
preeclampsia-eclampsia in, 807–809
pulmonary edema in, 813–815
pyelonephritis in, 811–812
septic abortion in, 813
status asthmaticus in, 815–816
trauma during, 818–820
valvular heart disease during, 493–494
warfarin use during, 835
Premature ventricular contractions (PVCs), 489
Prerenal renal failure, 319–321, 319t. See also Renal failure, acute
Pressure-controlled ventilation (PCV), 270t, 271. See also
Mechanical ventilation
Pressure-support ventilation (PSV), 270t, 271–272, 279. See also
Mechanical ventilation
Pressure ulcers (decubitus), prevention, 449–450
Pressure-volume (PV) curve
in ARDS, 299, 299f, 302–303, 303f, 309
positive end-expiratory pressure and, 302–303, 303f
Primaquine, 602
Problem-oriented medical record, 2–3
Procainamide
in acute myocardial infarction, 508
for atrial arrhythmias, 486
for atrial fibrillation, 487
therapeutic ranges, 92t
toxicity, 489, 496
for ventricular tachycardia, 491, 510
Procaine, 106t
Prochlorperazine, 89t
Procoagulant, 410t
Proenzymes, 410t
Progesterone, 124t
Prone positioning, in ARDS, 309
Propafenone, 487
Propofol, 114, 264
Proportionality, 216
Propranolol
for atrial fibrillation, 510
in burn injuries, 135–136
for ST-segment elevation myocardial infarction, 509
for thyroid storm, 568t, 569
Propylthiouracil, for thyroid storm, 568, 568t
Prospective Investigation of Pulmonary Embolism Diagnosis
(PIOPED), 549, 551t
Prostacyclin (PGI
2), 232t, 337
Prosthetic heart valves, 475–476, 522–523
Protamine sulfate, 557, 828
Protamine sulfate test, 411t
Protein
daily requirements, 123t
in enteral nutrition, 127
requirements in thermal burn injury, 744–745
in total parenteral nutrition, 129
Protein binding, 89, 89t
Protein C, 410t
Protein S, 410t
Proteinuria, 317
Prothrombin time (PT), 409, 411t
Proton pump inhibitors, 708
Prourokinase, 637
Pseudo-obstruction, colonic, 172, 355–356, 701, See also Ileus
Pseudoaneurysm, pulmonary artery, 141
Pseudocysts, pancreatic, 179, 181, 350
Pseudomembranous colitis, 175
Pseudomonas aeruginosa
in community-acquired pneumonia, 363
in dialysis-related peritonitis, 339t
resistance issues, 376t
Psilocin, 781t
Psilocybin, 781t
Psoas sign, 698
Psoriasis, generalized pustular, 624
Psychiatric problems
anxiety and fear, 438–440
delirium, 431–436, 434t
depression, 436–438
Psychosis, vs. delirium, 433
PTH (parathyroid hormone), 52, 54, 457, 458f
PTHrP (parathyroid hormone–related peptide), 55, 457
Pulmonary angiography, 153, 156, 553–554
Pulmonary artery catheters
clinical applications
in acute myocardial infarction, 506–507
in heart failure, 470, 472
mixed venous oxygen saturation, 198
pressure measurements, 197–198
complications, 141, 142f, 198–199
general considerations, 6t, 196–197, 196f
imaging studies, 141, 142f
positioning, 196, 197f
Pulmonary artery pseudoaneurysm, 141
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Pulmonary artery rupture, 141, 199
Pulmonary capillary wedge pressure (PCWP), 197–198, 236
Pulmonary edema
cardiogenic vs. noncardiogenic, 159, 159f, 301, 301t. See also
Heart failure
in hypervolemia, 20
hypooncotic, nutritional support in, 130
imaging studies, 157–160, 158f, 159f
neurogenic, 285
noncardiogenic, 297. See also Acute respiratory distress syndrome
pathophysiology, 157–158
in preeclampsia, 808
in pregnancy, 813–815
Pulmonary embolism
acute renal failure in, 327t
clinical features, 548–550, 549t
diagnostic approach, 552f, 554
essentials of diagnosis, 545
general considerations, 545–546
imaging studies, 153–156, 155f, 550–554, 551t
pathophysiology and pathogenesis, 546–547
prevention, 559–561, 560t
septic, 156–157, 157f
treatment
anticoagulation, 554–557, 555t
inferior vena cava interruption, 558–559
pulmonary embolectomy, 559
supportive care, 559
thrombolytic therapy, 557–558, 837
Pulmonary function
age-related changes, 444–445
during fluid resuscitation for burn injury, 733
in pregnancy, 802–803, 803f
Pulmonary gas exchange, anesthetic effects, 100
Pulmonary hypertension, 473
Pulmonary infarction, 142f, 547
Pulmonary interstitial emphysema, 166–167
Pulmonary renal syndromes, 327–328, 327t
Pulmonary vascular resistance, 201t
Pulse oximetry, 201–202
Pulse pressure, 189
Pulse waveform analysis, 201
Pupillary response, in coma, 659–660, 660t
Purpura
causes, 614t, 619, 619t
in disseminated vascular coagulation, 622. See also Disseminated
intravascular coagulation
general considerations, 619
in leukocytoclastic vasculitis, 620–621, 620t, 621t
Purpura fulminans, 622
Pyelonephritis. See also Urinary tract infections
emphysematous, 366
Pyrazinamide, 603
Pyridostigmine, 670
Pyridoxine. See Vitamin B
6
Q
Quality assurance, 9
Quinidine, 489, 496
Quinolones, 315t, 376t, 377
Quinupristin-dalfopristin, 376t, 378
R
Radiation injury, 800–801
Radiation therapy, 454, 456
Radiocontrast agents. See Iodinated contrast agents
Radiofibrinogen leg scans, 548
Radiographs, abdominal, 137–138
in acute calculous cholecystitis, 182
in acute pancreatitis, 179–180, 180f
in acute renal failure, 317
in bowel obstruction, 169–170, 171f, 173f, 353, 355
in colitis, 176f
in ileus, 172, 174f
in intestinal ischemia, 174
in intraabdominal abscess, 177, 373
in pneumoperitoneum, 167–168, 168f, 169f
in toxic megacolon, 177, 177f
Radionuclide angiography, 469
Radionuclide scintigraphy. See Nuclear scintigraphy
Radionuclide ventriculography, 653
Radiosurgery, 456
Ramipril, 510
Ranitidine, 240, 316t, 563, 565
Ranson’s criteria, severity of acute pancreatitis, 347, 347t
Rapid shallow breathing index, 278
Recombinant tissue plasminogen activator (r-tPA). See Alteplase;
Thrombolytic therapy
Red blood cell casts, 317, 323
Red blood cells (RBCs)
preparation, 71
transfusion. See also Transfusion therapy
complications, 79–84, 81–82t, 83t
indications, 71–74, 72t
in pregnancy, 73
products available, 72t
requirements, 74
Refractory hypoxemia, 298, 298f
Regional analgesia, 105
Remifentanil, 111t, 113
Renal angiography, 317, 320
Renal biopsy, 317
Renal failure
acute
in acute hepatic failure, 716
in acute pancreatitis, 349
after vascular surgery, 654–655
causes, 314
clinical features, 4t, 314–317, 315t
complications, 318, 318t
definition, 314
drug elimination in, 90–91
drug-induced, 94, 94t, 315–316t
in heat stroke, 787
in HIV/AIDS, 329
hyperkalemia in, 39–40
imaging studies, 184–185, 317–318
indicators, 234t
intrinsic
acute interstitial nephritis, 323–324
acute tubular necrosis, 94t, 325–326
causes, 4t, 322t
cortical necrosis, 326
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Renal failure, acute, intrinsic (Cont.):
glomerulonephritis, 94t, 322–323
microcapillary and glomerular occlusion, 324–325
platelet dysfunction in, 423–424
postrenal, 321–322, 321t
prerenal, 319–321, 319t
in renal transplant recipient, 329–330
syndromes associated with
Goodpasture’s syndrome, 327–328
hepatorenal syndrome, 328
paraquat poisoning, 328
pigment nephropathy, 326–327, 326t
pulmonary renal syndromes, 327–328, 327t
treatment
dialytic therapy, 334–336, 334t. See also Continuous renal
replacement therapy; Hemodialysis; Peritoneal dialysis
nondialytic therapy
acid-base balance, 331
electrolytes, 331–332, 331t, 332t
fluid balance, 330–332
nutritional support, 132, 332–333
reminders, 4t
chronic
drug elimination in, 90–91
fluid and electrolyte restrictions, 342
nutritional support in, 132, 342–343
thyroid function in, 578
Renal transplant recipient
acute renal failure in, 329–330
gastrointestinal complications in, 343
hypertension in, 344
infections in, 343
Renal tubular acidosis (RTA), 61
Renal vein thrombosis, 319–320
Reptilase time, 411t
Respiratory acidosis
clinical features, 67–68
controversies and unresolved issues, 68
definition, 58
essentials of diagnosis, 67
expected response, 59t
general considerations, 67
pathophysiology, 67, 67t
relationship between pH and HCO
3
–, 59t
treatment, 68
Respiratory alkalosis
clinical features, 69
definition, 58
differential diagnosis, 69
essentials of diagnosis, 68
expected response, 59t
general considerations, 68–69
hypophosphatemia in, 43
relationship between pH and HCO3
–, 59t
treatment, 69–70
Respiratory failure, 247–248. See also Acute
respiratory failure
Respiratory system
dysfunction indicators, 234t
effectiveness and efficiency, 247
muscles, 280–281
in pregnancy, 802–803, 803f
thermal burn injury response, 725
Respiratory system compliance (Crs), 267
Respired gas analysis, 206–207
Resting energy expenditure (REE), 126
Reteplase, 637, 638t, 836t. See also Thrombolytic therapy
Retinol. See Vitamin A
Retrograde pyelography, 322
Retrograde pyelography failure, 317
Retroperitoneal lavage, 349
Reverse T3, 118
Revised Trauma Score (RTS), 11, 12t
Rewarming
in frostbite, 792
in hypothermia, 790–791
Rhabdomyolysis
acute renal failure in, 326–327
causes, 326t
in cocaine intoxication, 764
hyperkalemia in, 327
hyperphosphatemia and, 46
hypocalcemia in, 53, 327
Rhinocerebral mucormycosis, 375
Riboflavin. See Vitamin B2
Rickettsia rickettsii, 629
Rifabutin, 93t
Rifampin
contraindications, 603
drug interactions, 93t
nephrotoxicity, 315t
protein binding, 89t
for tuberculosis, 603
Right internal jugular vein, for hemodialysis
access, 337
Right-to-left shunt, 251
Right ventricular infarction, 511–512
Rigler’s sign, 168, 168f
Risperidone, 435, 440
Ristocetin cofactor assay, 411t
Risus sardonicus, 395
Riva-Rocci method, blood pressure monitoring, 189–190
Rocky Mountain spotted fever, 629
Rocuronium, 107t, 109
Rofecoxib, 316t
Ropivacaine, 106, 106t
Rotational therapy, 265
r-tPA (recombinant tissue plasminogen activator). See Alteplase;
Thrombolytic therapy
RTS (Revised Trauma Score), 11, 12t
Rubeola (measles), 627–628
Rule of nines, 728, 728f
Russell viper venom time (Stypven time), 411t
S
Sagittal sinus thrombosis, 678
Salicylates
poisoning/overdose
clinical features, 774, 774f
differential diagnosis, 774
essentials of diagnosis, 773
general considerations, 773–774
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metabolic acidosis in, 61t
treatment, 61t, 774–775, 775t
therapeutic ranges, 92t
Salmeterol, for status asthmaticus, 537
Sarcoidosis, 327t
Scleroderma, 327t
Sclerotherapy, for variceal bleeding, 709, 717
Scoliosis, 286
Scorpion fish envenomation, 797–798
Scorpion stings, 796–797
Sea urchin envenomation, 797–798
Second-degree burns, 728, 730t.
See also Thermal burn injury
Secretory diarrhea, 358t
Sedative-hypnotics
barbiturates, 111
benzodiazepines. See Benzodiazepines
in mechanical ventilation, 264
opioid. See Opioid(s)
poisoning/overdose, 753t, 757–758
uses, 110
withdrawal, 758
Seizures
classification, 663–664, 663t
clinical features, 664
controversies and unresolved issues, 666
differential diagnosis, 665
in drug withdrawal, 664
general considerations, 662
generalized tonic-clonic, 663, 663t
pathophysiology, 662–663
in preeclampsia-eclampsia, 808, 809
in sympathomimetic poisoning/overdose, 761
treatment, 665–666, 665t
Seldinger technique, 480
Selenium, 123t
Self-esteem, ICU staff, 440
Sentinel loop, 172, 180f
Sepsis
ARDS and, 300
clinical features, 360–361
definition, 360
differential diagnosis, 361
essentials of diagnosis, 359
general considerations, 359–360
in HIV disease, 605–607
microbiologic etiology, 360
nutritional support in, 133
pathophysiology, 360
stages, 361t
treatment, 361–362
Septic abortion, 813
Septic shock
clinical features, 233, 235
controversies and unresolved issues, 238
definition, 360, 361t
differential diagnosis, 227t, 235
essentials of diagnosis, 230
general considerations, 230–231
hemodynamic effects, 232–233
metabolic effects, 233
multiple organ failure in, 233, 234t
pathogenesis, 231–232, 231f
treatment
antimicrobial agents, 237
corticosteroids, 237
drotrecogin alfa, 237–238
early goal-directed, 235, 235f
fluid resuscitation, 235–236, 238
glycemic control, 237
pharmacologic support, 236–237
respiratory support, 236
transfusion, 238
Serotonin syndrome, 766–767
Serum albumin, 119–121, 120t, 121f
Serum creatinine, 314–315
Serum sickness, 614t
Severe sepsis, 360, 361t
Shock
anaphylactic. See Anaphylactic shock
cardiac compressive. See Cardiac compressive shock
cardiogenic. See Cardiogenic shock
hypovolemic. See Hypovolemic shock
neurogenic. See Neurogenic shock
septic. See Septic shock
SIADH. See Syndrome of inappropriate secretion of ADH
Sick euthyroid syndrome
controversies and unresolved issues, 580
disorders associated with, 577–579, 578t
drugs causing, 579, 579t
essentials of diagnosis, 576
general considerations, 576
pathophysiology, 576–577
treatment, 579–580
Sick sinus syndrome, 492
Sickle cell anemia, 73
Silvadene. See Silver sulfadiazine burn cream
Silver nitrate solution, 736
Silver sulfadiazine burn cream, 735
Sinistral portal hypertension, 649
Sinus bradyarrhythmias, 492
Sinusitis, after thermal burn injury, 743
Skin disorders. See Cutaneous disorders
Skin grafting, 738
Skin substitutes, 738–739
Sleep, 310. See also Obstructive sleep apnea
Slow continuous ultrafiltration (SCUF), 341
SLUDGE syndrome, 784
Small bowel obstruction. See also Bowel; Obstruction
clinical features, 352–353, 353f
differential diagnosis, 353–354
essentials of diagnosis, 351
general considerations, 352
imaging studies, 169–170, 171f, 172f, 353
pathophysiology, 169, 352
postoperative, 700
treatment, 354
Smoke inhalation. See Inhalation injury
Snakebite, 795–796
Sodium
in acute renal failure, 331, 331t
in body fluids, 125t
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Sodium (Cont.):
daily requirements, 123t
excretion, 15
factors affecting balance of, 15t
imbalances. See Hypernatremia; Hyponatremia
intake and output, 331t
restriction, in hypervolemia, 21
Sodium bicarbonate
for diabetic ketoacidosis, 590
for hyperkalemia, 42
for metabolic acidosis, 63
for TCA poisoning/overdose, 765
Soft tissue infections
necrotizing. See Necrotizing fasciitis
surgical, 406–407, 408t
Soluble cell adhesion molecules (SCAMs), 225
Somatostatin, 717
Sotalol, 488, 497
Spike-wave status, 664
Spinal cord, 692f
Spinal cord compression
clinical features, 452–453, 668
differential diagnosis, 453
essentials of diagnosis, 451, 667
general considerations, 451, 667
imaging studies, 452–453
pathophysiology, 451
treatment, 453–454, 668
Spinal cord disorders/trauma. See also Cervical 
spinal cord injuries
nutritional support in, 132
respiratory failure in, 283
Spinal shock, 691
Spirometry, in status asthmaticus, 536
Spironolactone
for ascites, 718
for heart failure, 471
hyperkalemia and, 40
for hypervolemia, 21
Splenectomy, 76t
Sputum, Gram-stained smears, 364, 364t
ST-segment elevation myocardial infarction (STEMI)
clinical features, 506–507
complications, 509–512. See also Cardiogenic shock
differential diagnosis, 507
general considerations, 506
imaging studies, 506–507
treatment, 507–509
Stanford classification, aortic dissection, 515
Staphylococcus aureus
in dialysis-related peritonitis, 339t
in infective endocarditis, 367–368
methicillin-resistant. See Methicillin-resistant 
Staphylococcus aureus
resistance issues, 376t
vancomycin-insensitive, 390
vancomycin-resistant, 390
Staphylococcus epidermidis, 339t
Starling’s law, 23
Starvation, ketoacidosis in, 62
Static respiratory system compliance, 267
Status asthmaticus
atelectasis in, 145f
clinical features, 535–536
controversies and unresolved issues
general anesthesia, 539
helium-oxygen inhalation, 539–540
mucolytic administration by fiberoptic bronchoscopy, 539
noninvasive ventilation, 540
differential diagnosis, 536
essentials of diagnosis, 534
general considerations, 5t, 534
imaging studies, 536
pathophysiology and pathogenesis, 534–535
in pregnancy, 815–816
spirometry, 536
treatment
bronchodilators, 537
corticosteroids, 537–538
mechanical ventilation, 274t, 538–539
oxygen, 537
principles, 5t, 536–537
Status epilepticus, 663–664, 663t. See also Seizures
Stevens-Johnson syndrome, 614t, 616–618
Stewart-Hamilton indicator dilution equation, 199
Stingray envenomation, 797–798
Streptococcus pneumoniae, 365, 365t, 376t, 377
Streptokinase, 558, 646, 836t. See also Thrombolytic therapy
Stress ventriculography, 500
String of pearls sign, 171f
Stroke
after cardiac catheterization, 482–483
after carotid endarterectomy, 655
clinical features, 674
controversies and unresolved issues, 676
differential diagnosis, 674
essentials of diagnosis, 673
general considerations, 673–674
imaging studies, 674, 675f
nutritional support in, 133
respiratory complications, 283
treatment, 675–676, 676t, 837
Stroke volume, 201t
Stroke volume index, 201t
Stypven time (Russell viper venom time), 411t
Subarachnoid hemorrhage
aneurysmal, 686–688, 687t
humate: P, 76t, 416t
traumatic, 682
Subclavian vein, for hemodialysis access, 337
Subdural hematoma, 681, 681f
Succinylcholine, 107t, 108
Sufentanil, 111t, 113
Sulfadiazine, 315t
Sulfamethoxazole, 315t
Sulfamylon. See Mafenide burn cream
Sulfisoxazole, 315t
Sulfosalicylic acid, 317
Sulindac, 316t
Superior mesenteric artery syndrome, 743
Superior vena cava syndrome, 465–466
Suppurative thrombophlebitis, 407, 408t, 742
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Surgical infections
abdominal, 403–405, 406t. See also Intraabdominal
infections/abscess
diagnosis, 398
general considerations, 397
head and neck, 400, 401t
prevention, 397–398
soft tissue, 406–408, 408t
thoracic, 400–403, 404t
treatment, 398–399, 401t, 404t, 406t, 408t
Surrogate decision makers, 216–217
Swan-Ganz catheters, 6t. See also Pulmonary artery catheters
Sympatholytic poisoning/overdose, 753t
Sympathomimetic poisoning/overdose, 753t, 760–761
Syndrome of inappropriate secretion of ADH (SIADH)
causes, 463
hyponatremia in, 25
laboratory findings, 27
in malignancy, 463
treatment, 28
Syphilis, transfusion-associated, 81t
Syrup of ipecac, 755, 757
Systemic inflammatory response syndrome (SIRS), 359–360, 361t
Systemic lupus erythematosus, 327t
Systemic oxygen delivery (DO2), 224
Systemic vascular resistance (SVR), 189, 201t
Systemic vasculitis, 323
T
T tube, 278–279
Tachy-brady syndrome, 492
Tachycardia
AV nodal or reentrant, 486–487
postoperative, 654
TACO (transfusion-associated circulatory overload), 83t
Tacrolimus, 315t
Target lesions, 615
TBW (total body water), 22–23
Tenecteplase, 637, 638t, 836t. See also Thrombolytic therapy
Tension pneumothorax, 165–166, 166f, 246, 531
Teratogens, 804, 805t
Terbutaline, 260
Tetanus, 394–396, 396t, 730
Tetracycline, 124t
Thallium scintigraphy, 500, 652–653
Theophylline
for acute respiratory failure, 262, 292
adverse effects, 262
drug interactions, 93t
hypokalemia and, 36
poisoning/overdose, 775–777, 777t
for status asthmaticus, 537
therapeutic ranges, 92t
Therapeutic drug monitoring, 92, 92t
Thermal burn injury
beta-blockers in, 135–136
burn center referral guidelines, 723, 724t
in children, growth hormone for, 135
classification, 728, 730f, 730t
complications, 742–743
controversies and unresolved issues
hypermetabolism, 746–747
infection, 746
inhalation injury, 746–747
postburn hemodynamics, 746
wound closure, 746
edema formation in, 723–724
histopathologic characteristics, 723
incidence, 723
inhalation injury in. See Inhalation injury
nutritional support, 133, 743–745, 744t
organ system responses, 724–726
total body surface area estimate, 728, 728f, 729f
treatment. See also Burn wound
emergency management, 728–730, 728f, 729f
fluid resuscitation
formulas, 730–732, 731t, 732t
monitoring, 732–734
principles, 730
infection control, 741
prehospital treatment, 727–728
Thiamine. See Vitamin B
1
Thiopental, 111
Thioureas, 568
Third-degree burns, 728, 730t. See also Thermal burn injury
Thoracic aortic aneurysms, 515f. See also Aneurysms, great vessels
Thoracic bioimpedance, 200
Thoracic wall disorders, acute respiratory failure in, 274t, 285–288
Thoracostomy tubes, 144
Thrombin, 410t
Thrombin inhibitors, 636
Thrombin time (TT), 409, 411t
Thrombocytopenia
clinical features, 425, 426t
controversies and unresolved issues, 427
differential diagnosis, 427
essentials of diagnosis, 425
general considerations, 425
heparin-induced, 522, 557, 645, 828–829, 829t
nutritional support in, 132
pathophysiology, 425, 426t
treatment, 427
Thromboelastography, 523, 523f
Thrombolytic therapy
for acute arterial insufficiency, 637–638, 638t
for acute myocardial infarction, 507–508
comparison of agents for, 836t, 837
complications, 837–838
for deep venous thrombosis/pulmonary embolism, 557–558,
645–647
indications, 836–837
monitoring, 838
principles, 836
for prosthetic valve dysfunction, 476
for stroke, 676, 676t
Thrombomodulin, 410t
Thrombophlebitis, 407, 408t, 742. See also
Acute arterial insufficiency
Thrombosis
in acute mesenteric ischemia, 648–649
in cancer patients, 840
cerebrovascular, 674. See also Stroke
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Thrombosis (Cont.):
coronary graft, 523, 524–525
prosthetic valve, 522
Thrombotic thrombocytopenic purpura, 324, 325
Thromboxane A2, 232t, 423
Thrombus, 633t
Thrush (oral candidiasis), 610–611
THT (topical hemostatic tamponade therapy), 543
Thumb sign, 153
Thymectomy, for myasthenia gravis, 671
Thyroid hormones, 118, 571, 571t. See also Sick 
euthyroid syndrome
Thyroid storm, 566–569, 568t
Thyrotoxic crisis. See Thyroid storm
Ticlopidine, 316t, 823–824, 824t
Tigecycline, 377
Timolol, 446, 509
Tinzaparin, 646t. See also Low-molecular-weight heparin
Tirofiban, 504, 825
Tissue factor, 410t
Tissue factor pathway inhibitor, 410t
Tissue plasminogen activator, 410t
Tobramycin, 92t
Tocodynamometry, 820
Tolmetin, 316t
Tonsillar herniation, 684
Topical hemostatic tamponade therapy (THT), 543
Torsade de pointes
characteristics, 489, 490f
drug-induced, 95, 496
treatment, 491
Total body water (TBW), 22–23
Toxic epidermal necrolysis, 614t, 616–618
Toxic megacolon, 176–177, 177f
Toxic shock syndrome, 630–631
Toxidromes, 752t. See also Poisoning/overdose
Toxoplasmosis, 82t, 677–678
Tracheal stenosis, 140
Tracheostomy, 140, 256
Tranexamic acid, 417
Transcutaneous blood gases, 204
Transcutaneous pacing, 511
TransCyte, 739
Transfusion-associated circulatory overload (TACO), 83t
Transfusion-related acute lung injury (TRALI), 82, 83t
Transfusion therapy
administration, 79
blood component preparation, 79
blood resource conservation, 86–87
complications
infectious, 80–82, 81t
nonhemolytic, noninfectious, 82, 83t
red cell antibody-mediated reactions, 79–80
cryoprecipitate, 77–78
directed donations in, 84
in emergency situations, 86
emerging technologies, 86
granulocytes, 72t, 78
for hypovolemic shock, 230
indications, 72t
informed consent, 79
during interfacility transport, 212
massive, 85–86
patient identification, 79
perioperative, 82–84
plasma, 72t, 75–77, 76t
platelets, 72t, 74–75, 76t
postoperative, 524
pretransplant, 86
products available, 72t
red blood cells. See Red blood cells, transfusion
refusal of, 85
safety considerations, 84–85
for septic shock, 238
Transient ischemic attacks, 674
Transjugular intrahepatic portosystemic shunt
for ascites, 719
for variceal bleeding, 709–710, 717
Transport, interfacility
controversies and unresolved issues, 214
crew composition, 208–209, 212
crew qualifications, 213
equipment monitoring, 211–212
liability and legal issues, 210–211
modes, 209–210, 209t
outcome, 211
physician duties in, 212–213
reimbursement, 213–214
standards, 213
Transtentorial herniation, 684
Transtubular potassium gradient 
(TTKG), 38
Transvenous pacing, 511
Trauma
ARDS and, 300–301
cervical spinal cord. See Cervical spinal cord injuries
head. See Head injury
nutritional support in, 132–133
during pregnancy, 818–820
Trauma Score, 11, 11t
Triazolam, 440
Triazoles, 377
Tricyclic antidepressants, 124t, 438, 764–766
Triiodothyronine (T3), for myxedema coma, 571, 571t
Trimethoprim-sulfamethoxazole, 40, 601
Trismus, 395
Tuberculosis, 541, 602–603
Tumor lysis syndrome, 46, 462
Tumor necrosis factor (TNF), 297, 360
Typhlitis, 176
U
Ultrafiltration, for heart failure, 471
Ultrasound examination, 138. See also Doppler ultrasound
in acalculous cholecystitis, 183, 183f
in acute arterial insufficiency, 635
in acute calculous cholecystitis, 182, 182f
in acute pancreatitis, 346
in acute renal failure, 317
in ascites, 718
in deep venous thrombosis, 548, 642–643
in hydronephrosis, 184
INDEX 877
in intraabdominal abscess, 177–178, 373
in pregnancy, 805
in pulmonary embolism, 555t
in surgical infections, 398
in urinary obstruction, 322
in urinary tract infection, 185, 383
Unfractionated heparin (UFH). See also Low-molecular-
weight heparin
for acute arterial insufficiency, 636
complications, 556–557, 828–829, 829t
for deep venous thrombosis/pulmonary embolism
prophylaxis, 559–561, 560t, 644, 827t
treatment, 554–557, 645, 827t
for disseminated intravascular coagulation,
421, 622
dosing and adjustment, 826, 826t
factors modifying effects, 827–828, 828t
in hemodialysis, 337
hyperkalemia and, 40
indications and administration, 827, 827t
intravenous, weight-based dosing, 555t
vs. low-molecular-weight heparin, 830t
mechanisms of action, 825–826
in peritoneal dialysis, 340
pharmacology, 826
postoperative hypocoagulability and, 521
in pregnancy, 827t, 838, 839t
protein binding, 89t
renal clearance, 90
for ST-segment elevation myocardial infarction, 509
in total parenteral nutrition solution, 128
for unstable angina or non-STEMI, 504, 505t
Unstable angina pectoris (USA), 502–504, 505t
Upper airway obstruction, 254
Urea, in acute renal failure, 315–316
Urea-bridged gelatin, 229
Urea clearance, 317, 333
Urea nitrogen appearance (UNA), 333
Uremia, 61t, 62
Ureteral obstruction, 321–322
Urinalysis, in acute renal failure, 317
Urinary catheter–associated infections, 382–383
Urinary obstruction, 321–322
Urinary tract infections
clinical features, 366
complications, 366
in diabetes, 375
essentials of diagnosis, 365
general considerations, 366
imaging studies, 185–186
microbiologic etiology, 366
pathophysiology, 366
in pregnancy, 811–812
treatment, 367
Urine concentration, 23
Urokinase, 410t, 558, 637, 836t.
See also Thrombolytic therapy
Urticaria, drug-related, 613, 614t
Uterine atony, 818
Uterine inversion, 817
Uterine rupture, 817, 820
V
Valacyclovir, 315t, 627
Valproate sodium, 665, 665t
Valvular heart disease
aortic regurgitation, 198, 475
aortic stenosis, 475
cardiac sufficiency following surgery for, 530
clinical features, 474–475
emboli, 476
essentials of diagnosis, 474
general considerations, 474
imaging studies, 475
infective endocarditis. See Endocarditis
mitral senosis, 198, 475, 494
native valve regurgitation, 475
native valve stenosis, 475
paravalvular leaks and valve dehiscence, 476
during pregnancy, 493–494
prosthetic valve dysfunction, 475–476
Vancomycin
for C. difficile–associated diarrhea, 387
for dialysis-related peritonitis, 339t
resistance to, 376t, 389
therapeutic ranges, 92t
Vancomycin-insensitive Staphylococcus aureus (VISA), 390
Variant-Creutzfeldt-Jakob disease,
transfusion-associated, 82t
Variceal bleeding
clinical features, 707, 716
differential diagnosis, 716
essentials of diagnosis, 716
general considerations, 707, 716
treatment, 428, 709–710, 717
Varicella-zoster virus, 626–627
Vascular surgery patient
complications, 655–656
nutritional management, 651–652
postoperative care, 653–654
preoperative risk assessment, 652–653
renal failure in, 653–654
respiratory management, 651
Vasculitis, 620–621, 620t, 621t
Vasodilators, 237, 244–245
Vasopressin. See also Antidiuretic hormone
for diabetes insipidus, 33
in hypovolemic shock, 224
for septic shock, 237
for variceal bleeding, 717
Vecuronium, 89t, 107t, 109
Vena cava filters
inferior, 558, 561, 647, 821
Venography, 643
Venous air embolism, 141
Venous thromboembolism. See Deep venous thrombosis;
Pulmonary embolism
Ventilation-perfusion index (V/QI), 198
Ventilation-perfusion (V/Q) mismatch, 251
Ventilation-perfusion (V/Q) scan, 153, 154, 550–552, 551t
Ventilator-associated pneumonia (VAP)
in ARDS, 307
diagnosis, 277, 400–401
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Ventilator-associated pneumonia (VAP) (Cont.):
morbidity and mortality, 276–277
prevention, 277, 401
treatment, 402, 404t
Ventricular arrhythmias. See also Arrhythmias
after acute myocardial infarction, 510
cardioversion for, 520
general considerations, 488–489
postoperative, 520
ventricular ectopy (premature ventricular contractions),
489
ventricular tachycardia, 489–491, 490f
Ventricular septal defect (VSD), 512
Ventriculitis, 400, 401t
Venturi mask, 258, 259t
Verapamil, 89t, 486, 501–502
Viral meningitis, 677
Virchow’s triad, 546, 640
Vital capacity, 99–100, 281
Vitamin A, 55, 122t, 123–124
Vitamin B1 (thiamine), 122t, 131
Vitamin B2 (riboflavin), 122t, 124t
Vitamin B3 (niacin), 122t, 124t
Vitamin B6 (pyridoxine), 122t, 124t
Vitamin B12, 122t
Vitamin C, 122t, 123, 124t
Vitamin D, 52, 55, 122t, 124t
Vitamin E, 122t
Vitamin K
daily requirements, 122t
deficiency
coagulation disorders and, 413–414t,
416t, 418
drug-induced, 124t, 418
dosing in coagulation disorders, 420
sources, 122t
Vocal cord dysfunction syndrome, 536
Volume-control ventilation (VCV), 269–271, 270t.
See also Mechanical ventilation
Volume of electrically participating tissue 
(VEPT), 200
Volume trauma. See Barotrauma
Volvulus, 352
Sigmoid, 173f
Vomiting
metabolic alkalosis and, 64
in small bowel obstruction, 352, 353f
von Willebrand disease, 412, 413–414t,
416t
Voriconazole, 377
W
Warfarin
administration and monitoring, 832, 834t
adverse effects, 834–835
for deep venous thrombosis/pulmonary embolism,
556, 644, 645
indications, 833
interactions, 93t, 833
management during invasive procedures, 834, 835t
nutrient deficiencies caused by, 124t
pharmacology, 832
in pregnancy, 835, 838
variations in response, 832–833
Water balance, 22–24, 23t. See also
Hypernatremia; Hyponatremia
Water deprivation test, 32
Water excretion, 23t, 24
Watercraft, for critical care transport, 210
Waterhouse-Friderichsen syndrome, 573
Weaning, mechanical ventilation. See Mechanical
ventilation, weaning
Wedge compression fractures, 695. See also Cervical
spinal cord injuries
Wegener’s granulomatosis, 327t, 541
West Nile virus, transfusion-associated, 81t
Westermark’s sign, 154
White blood cell casts, 317
Withdrawal
delirium in, 434
from opioids, 760
from sedative-hypnotics, 758
seizures in, 664
Wolff-Chaikoff effect, 569
Work of breathing, 205–206
Wound botulism, 393
Wound dehiscence, abdominal, 133
Wound healing, 133, 234t
X
Ximelagatran, 840 
Z
Zinc
in body fluids, 125t
daily requirements, 123t
drug-induced deficiency, 124t
supplementation, 125
Zoledronic acid, 461
Zone of necrosis, 723
Zone of stasis, 723
